0	Facial	_	_	B-Claim
1	hirsutism	_	_	I-Claim
2	is	_	_	I-Claim
3	one	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	characteristic	_	_	I-Claim
7	features	_	_	I-Claim
8	of	_	_	I-Claim
9	polycystic	_	_	I-Claim
10	ovary	_	_	I-Claim
11	syndrome	_	_	I-Claim
12	(	_	_	I-Claim
13	PCOS	_	_	I-Claim
14	)	_	_	I-Claim
15	,	_	_	I-Claim
16	and	_	_	I-Claim
17	this	_	_	I-Claim
18	can	_	_	I-Claim
19	lead	_	_	I-Claim
20	to	_	_	I-Claim
21	high	_	_	I-Claim
22	levels	_	_	I-Claim
23	of	_	_	I-Claim
24	depression	_	_	I-Claim
25	and	_	_	I-Claim
26	anxiety	_	_	I-Claim
27	.	_	_	I-Claim

28	To	_	_	O
29	evaluate	_	_	O
30	the	_	_	O
31	impact	_	_	O
32	of	_	_	O
33	laser	_	_	O
34	treatment	_	_	O
35	on	_	_	O
36	the	_	_	O
37	severity	_	_	O
38	of	_	_	O
39	facial	_	_	O
40	hirsutism	_	_	O
41	and	_	_	O
42	on	_	_	O
43	psychological	_	_	O
44	morbidity	_	_	O
45	in	_	_	O
46	women	_	_	O
47	with	_	_	O
48	PCOS	_	_	O
49	.	_	_	O

50	A	_	_	O
51	randomized	_	_	O
52	controlled	_	_	O
53	trial	_	_	O
54	of	_	_	O
55	five	_	_	O
56	high-fluence	_	_	O
57	treatments	_	_	O
58	(	_	_	O
59	intervention	_	_	O
60	)	_	_	O
61	vs.	_	_	O
62	five	_	_	O
63	low-fluence	_	_	O
64	treatments	_	_	O
65	(	_	_	O
66	control	_	_	O
67	)	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	over	_	_	O
71	6	_	_	O
72	months	_	_	O
73	in	_	_	O
74	a	_	_	O
75	National	_	_	O
76	Health	_	_	O
77	Service	_	_	O
78	teaching	_	_	O
79	hospital	_	_	O
80	.	_	_	O

81	Subjects	_	_	O
82	were	_	_	O
83	88	_	_	O
84	women	_	_	O
85	with	_	_	O
86	facial	_	_	O
87	hirsutism	_	_	O
88	due	_	_	O
89	to	_	_	O
90	PCOS	_	_	O
91	recruited	_	_	O
92	from	_	_	O
93	hospital	_	_	O
94	outpatient	_	_	O
95	clinics	_	_	O
96	and	_	_	O
97	a	_	_	O
98	patient	_	_	O
99	support	_	_	O
100	group	_	_	O
101	in	_	_	O
102	2001-2002	_	_	O
103	.	_	_	O

104	The	_	_	O
105	main	_	_	O
106	outcomes	_	_	O
107	were	_	_	O
108	self-reported	_	_	O
109	severity	_	_	O
110	of	_	_	O
111	facial	_	_	O
112	hair	_	_	O
113	(	_	_	O
114	measured	_	_	O
115	on	_	_	O
116	a	_	_	O
117	scale	_	_	O
118	of	_	_	O
119	1-10	_	_	O
120	)	_	_	O
121	,	_	_	O
122	depression	_	_	O
123	,	_	_	O
124	anxiety	_	_	O
125	(	_	_	O
126	measured	_	_	O
127	on	_	_	O
128	the	_	_	O
129	Hospital	_	_	O
130	Anxiety	_	_	O
131	and	_	_	O
132	Depression	_	_	O
133	Scale	_	_	O
134	)	_	_	O
135	and	_	_	O
136	quality	_	_	O
137	of	_	_	O
138	life	_	_	O
139	(	_	_	O
140	measured	_	_	O
141	on	_	_	O
142	the	_	_	O
143	WHOQOL-BREF	_	_	O
144	)	_	_	O
145	.	_	_	O

146	Self-reported	_	_	B-Premise
147	severity	_	_	I-Premise
148	of	_	_	I-Premise
149	facial	_	_	I-Premise
150	hair	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	intervention	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	n	_	_	I-Premise
157	=	_	_	I-Premise
158	51	_	_	I-Premise
159	)	_	_	I-Premise
160	fell	_	_	I-Premise
161	from	_	_	I-Premise
162	7.3	_	_	I-Premise
163	to	_	_	I-Premise
164	3.6	_	_	I-Premise
165	over	_	_	I-Premise
166	the	_	_	I-Premise
167	6-month	_	_	I-Premise
168	study	_	_	I-Premise
169	period	_	_	I-Premise
170	;	_	_	I-Premise
171	for	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	(	_	_	I-Premise
176	n	_	_	I-Premise
177	=	_	_	I-Premise
178	37	_	_	I-Premise
179	)	_	_	I-Premise
180	the	_	_	I-Premise
181	corresponding	_	_	I-Premise
182	scores	_	_	I-Premise
183	were	_	_	I-Premise
184	7.1	_	_	I-Premise
185	and	_	_	I-Premise
186	6.1	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	change	_	_	I-Premise
190	was	_	_	I-Premise
191	significantly	_	_	I-Premise
192	greater	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	intervention	_	_	I-Premise
196	group	_	_	I-Premise
197	[	_	_	I-Premise
198	ancova	_	_	I-Premise
199	F	_	_	I-Premise
200	(	_	_	I-Premise
201	(	_	_	I-Premise
202	1,83	_	_	I-Premise
203	)	_	_	I-Premise
204	)	_	_	I-Premise
205	=	_	_	I-Premise
206	24.5	_	_	I-Premise
207	,	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0.05	_	_	I-Premise
211	]	_	_	I-Premise
212	.	_	_	I-Premise

213	Self-reported	_	_	B-Premise
214	time	_	_	I-Premise
215	spent	_	_	I-Premise
216	on	_	_	I-Premise
217	hair	_	_	I-Premise
218	removal	_	_	I-Premise
219	declined	_	_	I-Premise
220	from	_	_	I-Premise
221	112	_	_	I-Premise
222	to	_	_	I-Premise
223	21	_	_	I-Premise
224	min	_	_	I-Premise
225	per	_	_	I-Premise
226	week	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	intervention	_	_	I-Premise
230	group	_	_	I-Premise
231	and	_	_	I-Premise
232	from	_	_	I-Premise
233	92	_	_	I-Premise
234	to	_	_	I-Premise
235	56	_	_	I-Premise
236	min	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	control	_	_	I-Premise
240	group	_	_	I-Premise
241	[	_	_	I-Premise
242	F	_	_	I-Premise
243	(	_	_	I-Premise
244	(	_	_	I-Premise
245	1,80	_	_	I-Premise
246	)	_	_	I-Premise
247	)	_	_	I-Premise
248	=	_	_	I-Premise
249	10.2	_	_	I-Premise
250	,	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	/=	_	_	I-Premise
254	0.05	_	_	I-Premise
255	]	_	_	I-Premise
256	.	_	_	I-Premise

257	Mean	_	_	B-Premise
258	depression	_	_	I-Premise
259	scores	_	_	I-Premise
260	fell	_	_	I-Premise
261	from	_	_	I-Premise
262	6.7	_	_	I-Premise
263	to	_	_	I-Premise
264	3.6	_	_	I-Premise
265	in	_	_	I-Premise
266	the	_	_	I-Premise
267	intervention	_	_	I-Premise
268	group	_	_	I-Premise
269	,	_	_	I-Premise
270	compared	_	_	I-Premise
271	with	_	_	I-Premise
272	6.1	_	_	I-Premise
273	to	_	_	I-Premise
274	5.4	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	control	_	_	I-Premise
278	group	_	_	I-Premise
279	[	_	_	I-Premise
280	F	_	_	I-Premise
281	(	_	_	I-Premise
282	(	_	_	I-Premise
283	1,83	_	_	I-Premise
284	)	_	_	I-Premise
285	)	_	_	I-Premise
286	=	_	_	I-Premise
287	14.7	_	_	I-Premise
288	,	_	_	I-Premise
289	P	_	_	I-Premise
290	<	_	_	I-Premise
291	0.05	_	_	I-Premise
292	]	_	_	I-Premise
293	.	_	_	I-Premise

294	A	_	_	B-Premise
295	similar	_	_	I-Premise
296	change	_	_	I-Premise
297	was	_	_	I-Premise
298	seen	_	_	I-Premise
299	for	_	_	I-Premise
300	mean	_	_	I-Premise
301	anxiety	_	_	I-Premise
302	scores	_	_	I-Premise
303	:	_	_	I-Premise
304	intervention	_	_	I-Premise
305	11.1	_	_	I-Premise
306	to	_	_	I-Premise
307	8.2	_	_	I-Premise
308	,	_	_	I-Premise
309	control	_	_	I-Premise
310	9.6	_	_	I-Premise
311	to	_	_	I-Premise
312	9.3	_	_	I-Premise
313	[	_	_	I-Premise
314	F	_	_	I-Premise
315	(	_	_	I-Premise
316	(	_	_	I-Premise
317	1,84	_	_	I-Premise
318	)	_	_	I-Premise
319	)	_	_	I-Premise
320	=	_	_	I-Premise
321	17.8	_	_	I-Premise
322	,	_	_	I-Premise
323	P	_	_	I-Premise
324	<	_	_	I-Premise
325	0.05	_	_	I-Premise
326	]	_	_	I-Premise
327	.	_	_	I-Premise

328	Psychological	_	_	B-Premise
329	quality	_	_	I-Premise
330	of	_	_	I-Premise
331	life	_	_	I-Premise
332	also	_	_	I-Premise
333	improved	_	_	I-Premise
334	more	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	intervention	_	_	I-Premise
338	group	_	_	I-Premise
339	,	_	_	I-Premise
340	from	_	_	I-Premise
341	49.6	_	_	I-Premise
342	to	_	_	I-Premise
343	61.2	_	_	I-Premise
344	vs.	_	_	I-Premise
345	50.1	_	_	I-Premise
346	to	_	_	I-Premise
347	51.5	_	_	I-Premise
348	in	_	_	I-Premise
349	the	_	_	I-Premise
350	control	_	_	I-Premise
351	group	_	_	I-Premise
352	[	_	_	I-Premise
353	F	_	_	I-Premise
354	(	_	_	I-Premise
355	(	_	_	I-Premise
356	1,84	_	_	I-Premise
357	)	_	_	I-Premise
358	)	_	_	I-Premise
359	=	_	_	I-Premise
360	10.9	_	_	I-Premise
361	,	_	_	I-Premise
362	P	_	_	I-Premise
363	<	_	_	I-Premise
364	0.05	_	_	I-Premise
365	]	_	_	I-Premise
366	.	_	_	I-Premise

367	Laser	_	_	B-Claim
368	treatment	_	_	I-Claim
369	appeared	_	_	I-Claim
370	to	_	_	I-Claim
371	reduce	_	_	I-Claim
372	the	_	_	I-Claim
373	severity	_	_	I-Claim
374	of	_	_	I-Claim
375	facial	_	_	I-Claim
376	hair	_	_	I-Claim
377	and	_	_	I-Claim
378	time	_	_	I-Claim
379	spent	_	_	I-Claim
380	on	_	_	I-Claim
381	hair	_	_	I-Claim
382	removal	_	_	I-Claim
383	as	_	_	I-Claim
384	well	_	_	I-Claim
385	as	_	_	I-Claim
386	alleviating	_	_	I-Claim
387	depression	_	_	I-Claim
388	and	_	_	I-Claim
389	anxiety	_	_	I-Claim
390	in	_	_	I-Claim
391	women	_	_	I-Claim
392	with	_	_	I-Claim
393	PCOS	_	_	I-Claim
394	.	_	_	I-Claim

395	These	_	_	B-Claim
396	findings	_	_	I-Claim
397	suggest	_	_	I-Claim
398	that	_	_	I-Claim
399	ways	_	_	I-Claim
400	of	_	_	I-Claim
401	making	_	_	I-Claim
402	this	_	_	I-Claim
403	method	_	_	I-Claim
404	of	_	_	I-Claim
405	hair	_	_	I-Claim
406	removal	_	_	I-Claim
407	more	_	_	I-Claim
408	widely	_	_	I-Claim
409	available	_	_	I-Claim
410	to	_	_	I-Claim
411	women	_	_	I-Claim
412	with	_	_	I-Claim
413	facial	_	_	I-Claim
414	hirsutism	_	_	I-Claim
415	should	_	_	I-Claim
416	be	_	_	I-Claim
417	considered	_	_	I-Claim
418	.	_	_	I-Claim


0	Despite	_	_	B-Claim
1	considerable	_	_	I-Claim
2	improvement	_	_	I-Claim
3	in	_	_	I-Claim
4	the	_	_	I-Claim
5	treatment	_	_	I-Claim
6	of	_	_	I-Claim
7	advanced	_	_	I-Claim
8	ovarian	_	_	I-Claim
9	cancer	_	_	I-Claim
10	,	_	_	I-Claim
11	the	_	_	I-Claim
12	optimization	_	_	I-Claim
13	of	_	_	I-Claim
14	efficacy	_	_	I-Claim
15	and	_	_	I-Claim
16	tolerability	_	_	I-Claim
17	remains	_	_	I-Claim
18	an	_	_	I-Claim
19	important	_	_	I-Claim
20	issue	_	_	I-Claim
21	.	_	_	I-Claim

22	Therefore	_	_	O
23	,	_	_	O
24	we	_	_	O
25	performed	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	,	_	_	O
29	phase	_	_	O
30	III	_	_	O
31	non-inferiority	_	_	O
32	trial	_	_	O
33	comparing	_	_	O
34	paclitaxel	_	_	O
35	plus	_	_	O
36	cisplatin	_	_	O
37	(	_	_	O
38	PT	_	_	O
39	)	_	_	O
40	with	_	_	O
41	paclitaxel	_	_	O
42	plus	_	_	O
43	carboplatin	_	_	O
44	(	_	_	O
45	TC	_	_	O
46	)	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	advanced	_	_	O
51	ovarian	_	_	O
52	cancer	_	_	O
53	.	_	_	O

54	A	_	_	O
55	total	_	_	O
56	of	_	_	O
57	798	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	International	_	_	O
61	Federation	_	_	O
62	of	_	_	O
63	Gynecology	_	_	O
64	and	_	_	O
65	Obstetrics	_	_	O
66	stage	_	_	O
67	IIB-IV	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	six	_	_	O
74	courses	_	_	O
75	of	_	_	O
76	either	_	_	O
77	PT	_	_	O
78	or	_	_	O
79	TC	_	_	O
80	at	_	_	O
81	3-week	_	_	O
82	intervals	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	endpoint	_	_	O
87	was	_	_	O
88	the	_	_	O
89	proportion	_	_	O
90	of	_	_	O
91	patients	_	_	O
92	without	_	_	O
93	progression	_	_	O
94	at	_	_	O
95	2	_	_	O
96	years	_	_	O
97	.	_	_	O

98	Secondary	_	_	O
99	endpoints	_	_	O
100	included	_	_	O
101	toxicity	_	_	O
102	,	_	_	O
103	response	_	_	O
104	to	_	_	O
105	treatment	_	_	O
106	,	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	,	_	_	O
111	and	_	_	O
112	overall	_	_	O
113	and	_	_	O
114	progression-free	_	_	O
115	survival	_	_	O
116	time	_	_	O
117	.	_	_	O

118	Quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	using	_	_	O
124	the	_	_	O
125	European	_	_	O
126	Organization	_	_	O
127	for	_	_	O
128	Research	_	_	O
129	and	_	_	O
130	Treatment	_	_	O
131	of	_	_	O
132	Cancer	_	_	O
133	quality-of-life	_	_	O
134	questionnaire	_	_	O
135	(	_	_	O
136	QLQ	_	_	O
137	)	_	_	O
138	-C30	_	_	O
139	,	_	_	O
140	version	_	_	O
141	2.0	_	_	O
142	.	_	_	O

143	Survival	_	_	O
144	curves	_	_	O
145	were	_	_	O
146	calculated	_	_	O
147	using	_	_	O
148	the	_	_	O
149	Kaplan-Meier	_	_	O
150	method	_	_	O
151	,	_	_	O
152	and	_	_	O
153	hazard	_	_	O
154	ratios	_	_	O
155	were	_	_	O
156	estimated	_	_	O
157	using	_	_	O
158	the	_	_	O
159	Cox	_	_	O
160	proportional	_	_	O
161	hazards	_	_	O
162	model	_	_	O
163	.	_	_	O

164	The	_	_	B-Premise
165	proportion	_	_	I-Premise
166	of	_	_	I-Premise
167	patients	_	_	I-Premise
168	without	_	_	I-Premise
169	progression	_	_	I-Premise
170	at	_	_	I-Premise
171	2	_	_	I-Premise
172	years	_	_	I-Premise
173	was	_	_	I-Premise
174	not	_	_	I-Premise
175	statistically	_	_	I-Premise
176	significantly	_	_	I-Premise
177	different	_	_	I-Premise
178	between	_	_	I-Premise
179	the	_	_	I-Premise
180	two	_	_	I-Premise
181	treatment	_	_	I-Premise
182	arms	_	_	I-Premise
183	(	_	_	I-Premise
184	40.0	_	_	I-Premise
185	%	_	_	I-Premise
186	for	_	_	I-Premise
187	PT	_	_	I-Premise
188	versus	_	_	I-Premise
189	37.5	_	_	I-Premise
190	%	_	_	I-Premise
191	for	_	_	I-Premise
192	TC	_	_	I-Premise
193	,	_	_	I-Premise
194	difference	_	_	I-Premise
195	=	_	_	I-Premise
196	2.5	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	one-sided	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	confidence	_	_	I-Premise
203	interval	_	_	I-Premise
204	[	_	_	I-Premise
205	CI	_	_	I-Premise
206	]	_	_	I-Premise
207	=	_	_	I-Premise
208	-	_	_	I-Premise
209	infinity	_	_	I-Premise
210	to	_	_	I-Premise
211	8.2	_	_	I-Premise
212	%	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Median	_	_	B-Premise
216	progression-free	_	_	I-Premise
217	survival	_	_	I-Premise
218	time	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	TC	_	_	I-Premise
222	arm	_	_	I-Premise
223	(	_	_	I-Premise
224	17.2	_	_	I-Premise
225	months	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	15.2	_	_	I-Premise
232	to	_	_	I-Premise
233	19.3	_	_	I-Premise
234	months	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	the	_	_	I-Premise
238	PT	_	_	I-Premise
239	arm	_	_	I-Premise
240	(	_	_	I-Premise
241	19.1	_	_	I-Premise
242	months	_	_	I-Premise
243	,	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	=	_	_	I-Premise
248	16.7	_	_	I-Premise
249	to	_	_	I-Premise
250	21.5	_	_	I-Premise
251	months	_	_	I-Premise
252	)	_	_	I-Premise
253	were	_	_	I-Premise
254	also	_	_	I-Premise
255	not	_	_	I-Premise
256	statistically	_	_	I-Premise
257	significantly	_	_	I-Premise
258	different	_	_	I-Premise
259	;	_	_	I-Premise
260	the	_	_	B-Premise
261	same	_	_	I-Premise
262	was	_	_	I-Premise
263	true	_	_	I-Premise
264	of	_	_	I-Premise
265	median	_	_	I-Premise
266	overall	_	_	I-Premise
267	survival	_	_	I-Premise
268	time	_	_	I-Premise
269	(	_	_	I-Premise
270	43.3	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	=	_	_	I-Premise
277	37.2	_	_	I-Premise
278	to	_	_	I-Premise
279	47.8	_	_	I-Premise
280	months	_	_	I-Premise
281	versus	_	_	I-Premise
282	44.1	_	_	I-Premise
283	months	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	40.2	_	_	I-Premise
290	to	_	_	I-Premise
291	49.4	_	_	I-Premise
292	months	_	_	I-Premise
293	,	_	_	I-Premise
294	for	_	_	I-Premise
295	the	_	_	I-Premise
296	TC	_	_	I-Premise
297	and	_	_	I-Premise
298	PT	_	_	I-Premise
299	arms	_	_	I-Premise
300	,	_	_	I-Premise
301	respectively	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Premise
305	TC	_	_	I-Premise
306	regimen	_	_	I-Premise
307	was	_	_	I-Premise
308	associated	_	_	I-Premise
309	with	_	_	I-Premise
310	a	_	_	I-Premise
311	higher	_	_	I-Premise
312	frequency	_	_	I-Premise
313	of	_	_	I-Premise
314	hematologic	_	_	I-Premise
315	toxicity	_	_	I-Premise
316	,	_	_	I-Premise
317	but	_	_	B-Premise
318	a	_	_	I-Premise
319	lower	_	_	I-Premise
320	frequency	_	_	I-Premise
321	of	_	_	I-Premise
322	gastrointestinal	_	_	I-Premise
323	and	_	_	I-Premise
324	neurologic	_	_	I-Premise
325	toxicity	_	_	I-Premise
326	,	_	_	I-Premise
327	than	_	_	I-Premise
328	the	_	_	I-Premise
329	PT	_	_	I-Premise
330	regimen	_	_	I-Premise
331	.	_	_	I-Premise

332	Mean	_	_	B-Premise
333	global	_	_	I-Premise
334	quality-of-life	_	_	I-Premise
335	scores	_	_	I-Premise
336	at	_	_	I-Premise
337	the	_	_	I-Premise
338	end	_	_	I-Premise
339	of	_	_	I-Premise
340	treatment	_	_	I-Premise
341	were	_	_	I-Premise
342	statistically	_	_	I-Premise
343	significantly	_	_	I-Premise
344	better	_	_	I-Premise
345	in	_	_	I-Premise
346	the	_	_	I-Premise
347	TC	_	_	I-Premise
348	arm	_	_	I-Premise
349	than	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	PT	_	_	I-Premise
353	arm	_	_	I-Premise
354	(	_	_	I-Premise
355	65.25	_	_	I-Premise
356	versus	_	_	I-Premise
357	51.97	_	_	I-Premise
358	,	_	_	I-Premise
359	respectively	_	_	I-Premise
360	;	_	_	I-Premise
361	difference	_	_	I-Premise
362	=	_	_	I-Premise
363	-13.28	_	_	I-Premise
364	,	_	_	I-Premise
365	95	_	_	I-Premise
366	%	_	_	I-Premise
367	CI	_	_	I-Premise
368	=	_	_	I-Premise
369	-18.88	_	_	I-Premise
370	to	_	_	I-Premise
371	-7.68	_	_	I-Premise
372	)	_	_	I-Premise
373	.	_	_	I-Premise

374	The	_	_	B-Claim
375	TC	_	_	I-Claim
376	regimen	_	_	I-Claim
377	achieved	_	_	I-Claim
378	comparable	_	_	I-Claim
379	efficacy	_	_	I-Claim
380	to	_	_	I-Claim
381	the	_	_	I-Claim
382	PT	_	_	I-Claim
383	regimen	_	_	I-Claim
384	but	_	_	I-Claim
385	was	_	_	I-Claim
386	associated	_	_	I-Claim
387	with	_	_	I-Claim
388	better	_	_	I-Claim
389	tolerability	_	_	I-Claim
390	and	_	_	I-Claim
391	quality	_	_	I-Claim
392	of	_	_	I-Claim
393	life	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	should	_	_	I-Claim
397	,	_	_	I-Claim
398	therefore	_	_	I-Claim
399	,	_	_	I-Claim
400	be	_	_	I-Claim
401	considered	_	_	I-Claim
402	as	_	_	I-Claim
403	an	_	_	I-Claim
404	important	_	_	I-Claim
405	alternative	_	_	I-Claim
406	for	_	_	I-Claim
407	standard	_	_	I-Claim
408	first-line	_	_	I-Claim
409	chemotherapy	_	_	I-Claim
410	in	_	_	I-Claim
411	patients	_	_	I-Claim
412	with	_	_	I-Claim
413	advanced	_	_	I-Claim
414	ovarian	_	_	I-Claim
415	cancer	_	_	I-Claim
416	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	2-year	_	_	O
10	functional	_	_	O
11	performance	_	_	O
12	and	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	in	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	operable	_	_	O
20	squamous	_	_	O
21	cell	_	_	O
22	carcinoma	_	_	O
23	of	_	_	O
24	the	_	_	O
25	esophagus	_	_	O
26	,	_	_	O
27	who	_	_	O
28	have	_	_	O
29	received	_	_	O
30	either	_	_	O
31	surgery	_	_	O
32	or	_	_	O
33	definitive	_	_	O
34	chemoradiation	_	_	O
35	(	_	_	O
36	CRT	_	_	O
37	)	_	_	O
38	.	_	_	O

39	The	_	_	O
40	functional	_	_	O
41	outcomes	_	_	O
42	and	_	_	O
43	quality	_	_	O
44	of	_	_	O
45	life	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	receiving	_	_	O
49	esophagectomy	_	_	O
50	or	_	_	O
51	definitive	_	_	O
52	CRT	_	_	O
53	is	_	_	O
54	uncertain	_	_	O
55	.	_	_	O

56	Data	_	_	O
57	were	_	_	O
58	extracted	_	_	O
59	from	_	_	O
60	the	_	_	O
61	database	_	_	O
62	of	_	_	O
63	a	_	_	O
64	prospective	_	_	O
65	randomized	_	_	O
66	controlled	_	_	O
67	trial	_	_	O
68	that	_	_	O
69	included	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	resectable	_	_	O
73	mid	_	_	O
74	or	_	_	O
75	lower	_	_	O
76	thoracic	_	_	O
77	esophageal	_	_	O
78	cancers	_	_	O
79	.	_	_	O

80	The	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	either	_	_	O
86	standard	_	_	O
87	esophagectomy	_	_	O
88	or	_	_	O
89	definitive	_	_	O
90	CRT	_	_	O
91	.	_	_	O

92	Quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	assessments	_	_	O
96	were	_	_	O
97	performed	_	_	O
98	using	_	_	O
99	the	_	_	O
100	EORTC	_	_	O
101	QLQ-C30	_	_	O
102	and	_	_	O
103	QLQ-OES24	_	_	O
104	modules	_	_	O
105	.	_	_	O

106	Other	_	_	O
107	functional	_	_	O
108	assessments	_	_	O
109	included	_	_	O
110	pulmonary	_	_	O
111	and	_	_	O
112	eating	_	_	O
113	functions	_	_	O
114	.	_	_	O

115	From	_	_	O
116	July	_	_	O
117	2000	_	_	O
118	to	_	_	O
119	December	_	_	O
120	2004	_	_	O
121	,	_	_	O
122	a	_	_	O
123	total	_	_	O
124	of	_	_	O
125	81	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	enrolled	_	_	O
129	into	_	_	O
130	the	_	_	O
131	study	_	_	O
132	.	_	_	O

133	No	_	_	B-Premise
134	significant	_	_	I-Premise
135	longitudinal	_	_	I-Premise
136	changes	_	_	I-Premise
137	were	_	_	I-Premise
138	detected	_	_	I-Premise
139	in	_	_	I-Premise
140	the	_	_	I-Premise
141	global	_	_	I-Premise
142	health	_	_	I-Premise
143	status	_	_	I-Premise
144	in	_	_	I-Premise
145	both	_	_	I-Premise
146	groups	_	_	I-Premise
147	upon	_	_	I-Premise
148	available	_	_	I-Premise
149	follow-up	_	_	I-Premise
150	.	_	_	I-Premise

151	Surgery	_	_	B-Premise
152	was	_	_	I-Premise
153	associated	_	_	I-Premise
154	with	_	_	I-Premise
155	worsened	_	_	I-Premise
156	physical	_	_	I-Premise
157	functioning	_	_	I-Premise
158	and	_	_	I-Premise
159	fatigue	_	_	I-Premise
160	symptoms	_	_	I-Premise
161	up	_	_	I-Premise
162	to	_	_	I-Premise
163	6	_	_	I-Premise
164	months	_	_	I-Premise
165	after	_	_	I-Premise
166	treatment	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	0.001	_	_	I-Premise
171	and	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	0.021	_	_	I-Premise
175	,	_	_	I-Premise
176	respectively	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	these	_	_	I-Premise
180	scales	_	_	I-Premise
181	improved	_	_	I-Premise
182	at	_	_	I-Premise
183	2	_	_	I-Premise
184	years	_	_	I-Premise
185	.	_	_	I-Premise

186	In	_	_	B-Premise
187	terms	_	_	I-Premise
188	of	_	_	I-Premise
189	pulmonary	_	_	I-Premise
190	function	_	_	I-Premise
191	,	_	_	I-Premise
192	dyspnoic	_	_	I-Premise
193	and	_	_	I-Premise
194	coughing	_	_	I-Premise
195	symptoms	_	_	I-Premise
196	were	_	_	I-Premise
197	significantly	_	_	I-Premise
198	worsened	_	_	I-Premise
199	3	_	_	I-Premise
200	months	_	_	I-Premise
201	after	_	_	I-Premise
202	surgery	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.024	_	_	I-Premise
207	and	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	0.036	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	)	_	_	I-Premise
214	whereas	_	_	I-Premise
215	symptoms	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	CRT	_	_	I-Premise
219	group	_	_	I-Premise
220	progressively	_	_	I-Premise
221	deteriorated	_	_	I-Premise
222	over	_	_	I-Premise
223	time	_	_	I-Premise
224	.	_	_	I-Premise

225	Concerning	_	_	B-Premise
226	the	_	_	I-Premise
227	eating	_	_	I-Premise
228	function	_	_	I-Premise
229	,	_	_	I-Premise
230	both	_	_	I-Premise
231	groups	_	_	I-Premise
232	had	_	_	I-Premise
233	improvements	_	_	I-Premise
234	in	_	_	I-Premise
235	dysphagia	_	_	I-Premise
236	but	_	_	I-Premise
237	there	_	_	I-Premise
238	were	_	_	I-Premise
239	frequent	_	_	I-Premise
240	need	_	_	I-Premise
241	for	_	_	I-Premise
242	endoscopic	_	_	I-Premise
243	intervention	_	_	I-Premise
244	.	_	_	I-Premise

245	Neither	_	_	B-Premise
246	surgery	_	_	I-Premise
247	nor	_	_	I-Premise
248	definitive	_	_	I-Premise
249	CRT	_	_	I-Premise
250	significantly	_	_	I-Premise
251	impaired	_	_	I-Premise
252	the	_	_	I-Premise
253	global	_	_	I-Premise
254	health	_	_	I-Premise
255	status	_	_	I-Premise
256	of	_	_	I-Premise
257	patients	_	_	I-Premise
258	.	_	_	I-Premise

259	Surgery	_	_	B-Claim
260	was	_	_	I-Claim
261	associated	_	_	I-Claim
262	with	_	_	I-Claim
263	a	_	_	I-Claim
264	short-term	_	_	I-Claim
265	negative	_	_	I-Claim
266	impact	_	_	I-Claim
267	in	_	_	I-Claim
268	some	_	_	I-Claim
269	aspects	_	_	I-Claim
270	of	_	_	I-Claim
271	health	_	_	I-Claim
272	related	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	assessments	_	_	I-Claim
277	but	_	_	B-Claim
278	these	_	_	I-Claim
279	changes	_	_	I-Claim
280	became	_	_	I-Claim
281	insignificant	_	_	I-Claim
282	2	_	_	I-Claim
283	years	_	_	I-Claim
284	after	_	_	I-Claim
285	treatment	_	_	I-Claim
286	.	_	_	I-Claim

287	However	_	_	O
288	,	_	_	O
289	CRT	_	_	B-Claim
290	was	_	_	I-Claim
291	associated	_	_	I-Claim
292	with	_	_	I-Claim
293	progressive	_	_	I-Claim
294	deteriorations	_	_	I-Claim
295	in	_	_	I-Claim
296	pulmonary	_	_	I-Claim
297	function	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	longer	_	_	I-Claim
301	term	_	_	I-Claim
302	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	TCM	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	removing	_	_	O
9	toxic	_	_	O
10	substance	_	_	O
11	and	_	_	O
12	unblocking	_	_	O
13	meridians	_	_	O
14	on	_	_	O
15	post-radiation	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QOF	_	_	O
21	)	_	_	O
22	in	_	_	O
23	55	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	lung	_	_	O
27	cancer	_	_	O
28	.	_	_	O

29	All	_	_	O
30	patients	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	two	_	_	O
36	groups	_	_	O
37	,	_	_	O
38	the	_	_	O
39	55	_	_	O
40	patients	_	_	O
41	in	_	_	O
42	the	_	_	O
43	treated	_	_	O
44	group	_	_	O
45	were	_	_	O
46	treated	_	_	O
47	with	_	_	O
48	radiotherapy	_	_	O
49	combined	_	_	O
50	with	_	_	O
51	the	_	_	O
52	TCM	_	_	O
53	therapy	_	_	O
54	,	_	_	O
55	and	_	_	O
56	the	_	_	O
57	53	_	_	O
58	in	_	_	O
59	the	_	_	O
60	control	_	_	O
61	group	_	_	O
62	were	_	_	O
63	given	_	_	O
64	radiotherapy	_	_	O
65	alone	_	_	O
66	.	_	_	O

67	The	_	_	O
68	clinical	_	_	O
69	efficacy	_	_	O
70	was	_	_	O
71	evaluated	_	_	O
72	by	_	_	O
73	indexes	_	_	O
74	including	_	_	O
75	KPS	_	_	O
76	scores	_	_	O
77	,	_	_	O
78	QLQ-C30	_	_	O
79	questionnaire	_	_	O
80	,	_	_	O
81	LC13	_	_	O
82	specific	_	_	O
83	scale	_	_	O
84	for	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	,	_	_	O
88	evaluation	_	_	O
89	criteria	_	_	O
90	for	_	_	O
91	TCM	_	_	O
92	efficacy	_	_	O
93	,	_	_	O
94	the	_	_	O
95	6-min	_	_	O
96	walking	_	_	O
97	distance	_	_	O
98	,	_	_	O
99	and	_	_	O
100	body	_	_	O
101	weight	_	_	O
102	,	_	_	O
103	etc	_	_	O
104	.	_	_	O

105	The	_	_	B-Premise
106	KPS	_	_	I-Premise
107	score	_	_	I-Premise
108	in	_	_	I-Premise
109	the	_	_	I-Premise
110	treated	_	_	I-Premise
111	group	_	_	I-Premise
112	after	_	_	I-Premise
113	treatment	_	_	I-Premise
114	was	_	_	I-Premise
115	improved	_	_	I-Premise
116	in	_	_	I-Premise
117	13	_	_	I-Premise
118	patients	_	_	I-Premise
119	(	_	_	I-Premise
120	23.6	_	_	I-Premise
121	%	_	_	I-Premise
122	)	_	_	I-Premise
123	,	_	_	I-Premise
124	stabilized	_	_	I-Premise
125	in	_	_	I-Premise
126	27	_	_	I-Premise
127	(	_	_	I-Premise
128	49.6	_	_	I-Premise
129	%	_	_	I-Premise
130	)	_	_	I-Premise
131	and	_	_	I-Premise
132	declined	_	_	I-Premise
133	in	_	_	I-Premise
134	15	_	_	I-Premise
135	(	_	_	I-Premise
136	27.3	_	_	I-Premise
137	%	_	_	I-Premise
138	)	_	_	I-Premise
139	,	_	_	I-Premise
140	while	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	control	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	it	_	_	I-Premise
147	was	_	_	I-Premise
148	improved	_	_	I-Premise
149	in	_	_	I-Premise
150	7	_	_	I-Premise
151	(	_	_	I-Premise
152	13.2	_	_	I-Premise
153	%	_	_	I-Premise
154	)	_	_	I-Premise
155	,	_	_	I-Premise
156	stabilized	_	_	I-Premise
157	in	_	_	I-Premise
158	21	_	_	I-Premise
159	(	_	_	I-Premise
160	39.6	_	_	I-Premise
161	%	_	_	I-Premise
162	)	_	_	I-Premise
163	and	_	_	I-Premise
164	declined	_	_	I-Premise
165	in	_	_	I-Premise
166	25	_	_	I-Premise
167	(	_	_	I-Premise
168	47.2	_	_	I-Premise
169	%	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	the	_	_	I-Premise
173	difference	_	_	I-Premise
174	between	_	_	I-Premise
175	the	_	_	I-Premise
176	two	_	_	I-Premise
177	groups	_	_	I-Premise
178	was	_	_	I-Premise
179	significant	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	<	_	_	I-Premise
183	0.05	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	results	_	_	I-Premise
188	from	_	_	I-Premise
189	evaluation	_	_	I-Premise
190	with	_	_	I-Premise
191	QLQ-C30	_	_	I-Premise
192	questionnaire	_	_	I-Premise
193	and	_	_	I-Premise
194	LC30	_	_	I-Premise
195	scale	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	treated	_	_	I-Premise
199	group	_	_	I-Premise
200	was	_	_	I-Premise
201	also	_	_	I-Premise
202	superior	_	_	I-Premise
203	to	_	_	I-Premise
204	those	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	control	_	_	I-Premise
208	group	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.05	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	respectively	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	scores	_	_	I-Premise
219	of	_	_	I-Premise
220	TCM	_	_	I-Premise
221	efficacy	_	_	I-Premise
222	(	_	_	I-Premise
223	24.52	_	_	I-Premise
224	+/-	_	_	I-Premise
225	8.98	_	_	I-Premise
226	vs	_	_	I-Premise
227	29.76	_	_	I-Premise
228	+/-	_	_	I-Premise
229	7.09	_	_	I-Premise
230	,	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.05	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	the	_	_	I-Premise
237	6-min	_	_	I-Premise
238	walking	_	_	I-Premise
239	distance	_	_	I-Premise
240	(	_	_	I-Premise
241	233.4	_	_	I-Premise
242	+/-	_	_	I-Premise
243	29.2	_	_	I-Premise
244	m	_	_	I-Premise
245	vs	_	_	I-Premise
246	205.8	_	_	I-Premise
247	+/-	_	_	I-Premise
248	31.9	_	_	I-Premise
249	m	_	_	I-Premise
250	,	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	0.05	_	_	I-Premise
254	)	_	_	I-Premise
255	were	_	_	I-Premise
256	better	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	treated	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	After	_	_	B-Premise
263	treatment	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	treated	_	_	I-Premise
267	group	_	_	I-Premise
268	,	_	_	I-Premise
269	the	_	_	I-Premise
270	body	_	_	I-Premise
271	weight	_	_	I-Premise
272	was	_	_	I-Premise
273	increased	_	_	I-Premise
274	in	_	_	I-Premise
275	11	_	_	I-Premise
276	patients	_	_	I-Premise
277	(	_	_	I-Premise
278	20.0	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	,	_	_	I-Premise
282	stabilized	_	_	I-Premise
283	in	_	_	I-Premise
284	28	_	_	I-Premise
285	(	_	_	I-Premise
286	50.9	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	decreased	_	_	I-Premise
291	in	_	_	I-Premise
292	16	_	_	I-Premise
293	(	_	_	I-Premise
294	29.1	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	while	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	control	_	_	I-Premise
302	group	_	_	I-Premise
303	it	_	_	I-Premise
304	was	_	_	I-Premise
305	increased	_	_	I-Premise
306	in	_	_	I-Premise
307	5	_	_	I-Premise
308	(	_	_	I-Premise
309	9.4	_	_	I-Premise
310	%	_	_	I-Premise
311	)	_	_	I-Premise
312	,	_	_	I-Premise
313	stabilized	_	_	I-Premise
314	in	_	_	I-Premise
315	26	_	_	I-Premise
316	(	_	_	I-Premise
317	49.1	_	_	I-Premise
318	%	_	_	I-Premise
319	)	_	_	I-Premise
320	and	_	_	I-Premise
321	decreased	_	_	I-Premise
322	in	_	_	I-Premise
323	22	_	_	I-Premise
324	(	_	_	I-Premise
325	41.5	_	_	I-Premise
326	%	_	_	I-Premise
327	)	_	_	I-Premise
328	,	_	_	I-Premise
329	difference	_	_	I-Premise
330	between	_	_	I-Premise
331	the	_	_	I-Premise
332	two	_	_	I-Premise
333	groups	_	_	I-Premise
334	was	_	_	I-Premise
335	significant	_	_	I-Premise
336	,	_	_	I-Premise
337	too	_	_	I-Premise
338	(	_	_	I-Premise
339	P	_	_	I-Premise
340	<	_	_	I-Premise
341	0.05	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	TCM	_	_	B-Claim
345	therapy	_	_	I-Claim
346	for	_	_	I-Claim
347	removing	_	_	I-Claim
348	toxic	_	_	I-Claim
349	substance	_	_	I-Claim
350	and	_	_	I-Claim
351	unblocking	_	_	I-Claim
352	meridians	_	_	I-Claim
353	can	_	_	I-Claim
354	improve	_	_	I-Claim
355	the	_	_	I-Claim
356	post-radiation	_	_	I-Claim
357	QOL	_	_	I-Claim
358	of	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	lung	_	_	I-Claim
362	cancer	_	_	I-Claim
363	to	_	_	I-Claim
364	some	_	_	I-Claim
365	extent	_	_	I-Claim
366	.	_	_	I-Claim


0	The	_	_	O
1	AVEREL	_	_	O
2	trial	_	_	O
3	[	_	_	O
4	A	_	_	O
5	Study	_	_	O
6	of	_	_	O
7	Avastin	_	_	O
8	(	_	_	O
9	Bevacizumab	_	_	O
10	)	_	_	O
11	in	_	_	O
12	Combination	_	_	O
13	With	_	_	O
14	Herceptin	_	_	O
15	(	_	_	O
16	Trastuzumab	_	_	O
17	)	_	_	O
18	/Docetaxel	_	_	O
19	in	_	_	O
20	Patients	_	_	O
21	With	_	_	O
22	HER2-Positive	_	_	O
23	Metastatic	_	_	O
24	Breast	_	_	O
25	Cancer	_	_	O
26	]	_	_	O
27	evaluated	_	_	O
28	first-line	_	_	O
29	bevacizumab-containing	_	_	O
30	therapy	_	_	O
31	for	_	_	O
32	human	_	_	O
33	epidermal	_	_	O
34	growth	_	_	O
35	factor	_	_	O
36	receptor	_	_	O
37	2	_	_	O
38	(	_	_	O
39	HER2	_	_	O
40	)	_	_	O
41	-positive	_	_	O
42	locally	_	_	O
43	recurrent/metastatic	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	LR/MBC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	measurable/evaluable	_	_	O
53	HER2-positive	_	_	O
54	LR/MBC	_	_	O
55	who	_	_	O
56	had	_	_	O
57	not	_	_	O
58	received	_	_	O
59	trastuzumab	_	_	O
60	or	_	_	O
61	chemotherapy	_	_	O
62	for	_	_	O
63	LR/MBC	_	_	O
64	were	_	_	O
65	stratified	_	_	O
66	by	_	_	O
67	prior	_	_	O
68	adjuvant	_	_	O
69	trastuzumab	_	_	O
70	,	_	_	O
71	prior	_	_	O
72	(	_	_	O
73	neo	_	_	O
74	)	_	_	O
75	adjuvant	_	_	O
76	taxane	_	_	O
77	,	_	_	O
78	hormone	_	_	O
79	receptor	_	_	O
80	status	_	_	O
81	,	_	_	O
82	and	_	_	O
83	measurable	_	_	O
84	disease	_	_	O
85	and	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	docetaxel	_	_	O
92	100	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	plus	_	_	O
98	trastuzumab	_	_	O
99	8	_	_	O
100	mg/kg	_	_	O
101	loading	_	_	O
102	dose	_	_	O
103	followed	_	_	O
104	by	_	_	O
105	6	_	_	O
106	mg/kg	_	_	O
107	either	_	_	O
108	with	_	_	O
109	bevacizumab	_	_	O
110	15	_	_	O
111	mg/kg	_	_	O
112	or	_	_	O
113	without	_	_	O
114	bevacizumab	_	_	O
115	,	_	_	O
116	all	_	_	O
117	administered	_	_	O
118	every	_	_	O
119	3	_	_	O
120	weeks	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	was	_	_	O
127	progression-free	_	_	O
128	survival	_	_	O
129	(	_	_	O
130	PFS	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Additional	_	_	O
134	end	_	_	O
135	points	_	_	O
136	included	_	_	O
137	overall	_	_	O
138	survival	_	_	O
139	,	_	_	O
140	response	_	_	O
141	rate	_	_	O
142	(	_	_	O
143	RR	_	_	O
144	)	_	_	O
145	,	_	_	O
146	safety	_	_	O
147	,	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	,	_	_	O
152	and	_	_	O
153	translational	_	_	O
154	research	_	_	O
155	.	_	_	O

156	Results	_	_	O
157	Baseline	_	_	O
158	characteristics	_	_	O
159	of	_	_	O
160	the	_	_	O
161	424	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	balanced	_	_	O
165	between	_	_	O
166	treatment	_	_	O
167	arms	_	_	O
168	.	_	_	O

169	Most	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	visceral	_	_	O
173	metastases	_	_	O
174	,	_	_	O
175	43	_	_	O
176	%	_	_	O
177	had	_	_	O
178	a	_	_	O
179	disease-free	_	_	O
180	interval	_	_	O
181	less	_	_	O
182	than	_	_	O
183	12	_	_	O
184	months	_	_	O
185	,	_	_	O
186	and	_	_	O
187	85	_	_	O
188	%	_	_	O
189	had	_	_	O
190	measurable	_	_	O
191	disease	_	_	O
192	.	_	_	O

193	Median	_	_	O
194	follow-up	_	_	O
195	was	_	_	O
196	26	_	_	O
197	months	_	_	O
198	.	_	_	O

199	The	_	_	B-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	for	_	_	I-Premise
203	investigator-assessed	_	_	I-Premise
204	PFS	_	_	I-Premise
205	was	_	_	I-Premise
206	0.82	_	_	I-Premise
207	(	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	0.65	_	_	I-Premise
213	to	_	_	I-Premise
214	1.02	_	_	I-Premise
215	;	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.0775	_	_	I-Premise
219	;	_	_	I-Premise
220	median	_	_	I-Premise
221	PFS	_	_	I-Premise
222	,	_	_	I-Premise
223	13.7	_	_	I-Premise
224	v	_	_	I-Premise
225	16.5	_	_	I-Premise
226	months	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	non-bevacizumab	_	_	I-Premise
230	and	_	_	I-Premise
231	bevacizumab	_	_	I-Premise
232	arms	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	;	_	_	I-Premise
236	PFS	_	_	I-Premise
237	events	_	_	I-Premise
238	in	_	_	I-Premise
239	72	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	Independent	_	_	I-Premise
245	Review	_	_	I-Premise
246	Committee-assessed	_	_	I-Premise
247	PFS	_	_	I-Premise
248	hazard	_	_	I-Premise
249	ratio	_	_	I-Premise
250	was	_	_	I-Premise
251	0.72	_	_	I-Premise
252	(	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	CI	_	_	I-Premise
256	,	_	_	I-Premise
257	0.54	_	_	I-Premise
258	to	_	_	I-Premise
259	0.94	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.0162	_	_	I-Premise
264	;	_	_	I-Premise
265	median	_	_	I-Premise
266	PFS	_	_	I-Premise
267	,	_	_	I-Premise
268	13.9	_	_	I-Premise
269	v	_	_	I-Premise
270	16.8	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	respectively	_	_	I-Premise
274	;	_	_	I-Premise
275	PFS	_	_	I-Premise
276	events	_	_	I-Premise
277	in	_	_	I-Premise
278	53	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	The	_	_	B-Premise
283	RR	_	_	I-Premise
284	was	_	_	I-Premise
285	70	_	_	I-Premise
286	%	_	_	I-Premise
287	versus	_	_	I-Premise
288	74	_	_	I-Premise
289	%	_	_	I-Premise
290	,	_	_	I-Premise
291	respectively	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.3492	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Grade	_	_	B-Claim
299	â‰¥	_	_	I-Claim
300	3	_	_	I-Claim
301	febrile	_	_	I-Claim
302	neutropenia	_	_	I-Claim
303	and	_	_	I-Claim
304	hypertension	_	_	I-Claim
305	were	_	_	I-Claim
306	more	_	_	I-Claim
307	common	_	_	I-Claim
308	with	_	_	I-Claim
309	bevacizumab-containing	_	_	I-Claim
310	therapy	_	_	I-Claim
311	.	_	_	I-Claim

312	High	_	_	B-Premise
313	baseline	_	_	I-Premise
314	plasma	_	_	I-Premise
315	vascular	_	_	I-Premise
316	endothelial	_	_	I-Premise
317	growth	_	_	I-Premise
318	factor	_	_	I-Premise
319	A	_	_	I-Premise
320	(	_	_	I-Premise
321	VEGF-A	_	_	I-Premise
322	)	_	_	I-Premise
323	concentrations	_	_	I-Premise
324	were	_	_	I-Premise
325	associated	_	_	I-Premise
326	with	_	_	I-Premise
327	greater	_	_	I-Premise
328	bevacizumab	_	_	I-Premise
329	benefit	_	_	I-Premise
330	(	_	_	I-Premise
331	not	_	_	I-Premise
332	statistically	_	_	I-Premise
333	significant	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Combining	_	_	B-Claim
337	bevacizumab	_	_	I-Claim
338	with	_	_	I-Claim
339	docetaxel	_	_	I-Claim
340	and	_	_	I-Claim
341	trastuzumab	_	_	I-Claim
342	did	_	_	I-Claim
343	not	_	_	I-Claim
344	significantly	_	_	I-Claim
345	improve	_	_	I-Claim
346	investigator-assessed	_	_	I-Claim
347	PFS	_	_	I-Claim
348	.	_	_	I-Claim

349	The	_	_	O
350	potential	_	_	O
351	predictive	_	_	O
352	value	_	_	O
353	of	_	_	O
354	plasma	_	_	O
355	VEGF-A	_	_	O
356	is	_	_	O
357	consistent	_	_	O
358	with	_	_	O
359	findings	_	_	O
360	in	_	_	O
361	HER2-negative	_	_	O
362	LR/MBC	_	_	O
363	,	_	_	O
364	warranting	_	_	O
365	prospective	_	_	O
366	evaluation	_	_	O
367	.	_	_	O


0	Vinorelbine	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	in	_	_	I-Claim
9	elderly	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	advanced	_	_	I-Claim
13	non-small-cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	.	_	_	I-Claim

20	Some	_	_	B-Claim
21	studies	_	_	I-Claim
22	have	_	_	I-Claim
23	also	_	_	I-Claim
24	suggested	_	_	I-Claim
25	that	_	_	I-Claim
26	gemcitabine	_	_	I-Claim
27	is	_	_	I-Claim
28	well	_	_	I-Claim
29	tolerated	_	_	I-Claim
30	and	_	_	I-Claim
31	effective	_	_	I-Claim
32	in	_	_	I-Claim
33	such	_	_	I-Claim
34	patients	_	_	I-Claim
35	.	_	_	I-Claim

36	We	_	_	O
37	compared	_	_	O
38	the	_	_	O
39	effectiveness	_	_	O
40	and	_	_	O
41	toxicity	_	_	O
42	of	_	_	O
43	the	_	_	O
44	combination	_	_	O
45	of	_	_	O
46	vinorelbine	_	_	O
47	plus	_	_	O
48	gemcitabine	_	_	O
49	with	_	_	O
50	those	_	_	O
51	of	_	_	O
52	each	_	_	O
53	drug	_	_	O
54	given	_	_	O
55	alone	_	_	O
56	in	_	_	O
57	an	_	_	O
58	open-label	_	_	O
59	,	_	_	O
60	randomized	_	_	O
61	phase	_	_	O
62	III	_	_	O
63	trial	_	_	O
64	in	_	_	O
65	elderly	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	advanced	_	_	O
69	NSCLC	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	aged	_	_	O
73	70	_	_	O
74	years	_	_	O
75	and	_	_	O
76	older	_	_	O
77	,	_	_	O
78	enrolled	_	_	O
79	between	_	_	O
80	December	_	_	O
81	1997	_	_	O
82	and	_	_	O
83	November	_	_	O
84	2000	_	_	O
85	,	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	intravenous	_	_	O
92	vinorelbine	_	_	O
93	(	_	_	O
94	30	_	_	O
95	mg/m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	of	_	_	O
100	body	_	_	O
101	surface	_	_	O
102	area	_	_	O
103	)	_	_	O
104	,	_	_	O
105	gemcitabine	_	_	O
106	(	_	_	O
107	1200	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	)	_	_	O
113	,	_	_	O
114	or	_	_	O
115	vinorelbine	_	_	O
116	(	_	_	O
117	25	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	)	_	_	O
123	plus	_	_	O
124	gemcitabine	_	_	O
125	(	_	_	O
126	1000	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	)	_	_	O
132	.	_	_	O

133	All	_	_	O
134	treatments	_	_	O
135	were	_	_	O
136	delivered	_	_	O
137	on	_	_	O
138	days	_	_	O
139	1	_	_	O
140	and	_	_	O
141	8	_	_	O
142	every	_	_	O
143	3	_	_	O
144	weeks	_	_	O
145	for	_	_	O
146	a	_	_	O
147	maximum	_	_	O
148	of	_	_	O
149	six	_	_	O
150	cycles	_	_	O
151	.	_	_	O

152	The	_	_	O
153	primary	_	_	O
154	endpoint	_	_	O
155	was	_	_	O
156	survival	_	_	O
157	.	_	_	O

158	Survival	_	_	O
159	curves	_	_	O
160	were	_	_	O
161	drawn	_	_	O
162	using	_	_	O
163	the	_	_	O
164	Kaplan-Meier	_	_	O
165	method	_	_	O
166	and	_	_	O
167	analyzed	_	_	O
168	by	_	_	O
169	the	_	_	O
170	Mantel-Haenszel	_	_	O
171	test	_	_	O
172	.	_	_	O

173	Secondary	_	_	O
174	endpoints	_	_	O
175	were	_	_	O
176	quality	_	_	O
177	of	_	_	O
178	life	_	_	O
179	and	_	_	O
180	toxicity	_	_	O
181	.	_	_	O

182	Of	_	_	O
183	698	_	_	O
184	patients	_	_	O
185	available	_	_	O
186	for	_	_	O
187	intention-to-treat	_	_	O
188	analysis	_	_	O
189	,	_	_	O
190	233	_	_	O
191	were	_	_	O
192	assigned	_	_	O
193	to	_	_	O
194	receive	_	_	O
195	vinorelbine	_	_	O
196	,	_	_	O
197	233	_	_	O
198	to	_	_	O
199	gemcitabine	_	_	O
200	,	_	_	O
201	and	_	_	O
202	232	_	_	O
203	to	_	_	O
204	vinorelbine	_	_	O
205	plus	_	_	O
206	gemcitabine	_	_	O
207	.	_	_	O

208	Compared	_	_	B-Premise
209	with	_	_	I-Premise
210	each	_	_	I-Premise
211	single	_	_	I-Premise
212	drug	_	_	I-Premise
213	,	_	_	I-Premise
214	the	_	_	I-Premise
215	combination	_	_	I-Premise
216	treatment	_	_	I-Premise
217	did	_	_	I-Premise
218	not	_	_	I-Premise
219	improve	_	_	I-Premise
220	survival	_	_	I-Premise
221	.	_	_	I-Premise

222	The	_	_	B-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	of	_	_	I-Premise
226	death	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	receiving	_	_	I-Premise
230	the	_	_	I-Premise
231	combination	_	_	I-Premise
232	treatment	_	_	I-Premise
233	was	_	_	I-Premise
234	1.17	_	_	I-Premise
235	(	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	confidence	_	_	I-Premise
239	interval	_	_	I-Premise
240	[	_	_	I-Premise
241	CI	_	_	I-Premise
242	]	_	_	I-Premise
243	=	_	_	I-Premise
244	0.95	_	_	I-Premise
245	to	_	_	I-Premise
246	1.44	_	_	I-Premise
247	)	_	_	I-Premise
248	that	_	_	I-Premise
249	of	_	_	I-Premise
250	patients	_	_	I-Premise
251	receiving	_	_	I-Premise
252	vinorelbine	_	_	I-Premise
253	and	_	_	I-Premise
254	1.06	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	=	_	_	I-Premise
260	0.86	_	_	I-Premise
261	to	_	_	I-Premise
262	1.29	_	_	I-Premise
263	)	_	_	I-Premise
264	that	_	_	I-Premise
265	of	_	_	I-Premise
266	patients	_	_	I-Premise
267	receiving	_	_	I-Premise
268	gemcitabine	_	_	I-Premise
269	.	_	_	I-Premise

270	Although	_	_	B-Premise
271	quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	was	_	_	I-Premise
275	similar	_	_	I-Premise
276	across	_	_	I-Premise
277	the	_	_	I-Premise
278	three	_	_	I-Premise
279	treatment	_	_	I-Premise
280	arms	_	_	I-Premise
281	,	_	_	I-Premise
282	the	_	_	B-Premise
283	combination	_	_	I-Premise
284	treatment	_	_	I-Premise
285	was	_	_	I-Premise
286	more	_	_	I-Premise
287	toxic	_	_	I-Premise
288	than	_	_	I-Premise
289	the	_	_	I-Premise
290	two	_	_	I-Premise
291	drugs	_	_	I-Premise
292	given	_	_	I-Premise
293	singly	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	combination	_	_	I-Claim
297	of	_	_	I-Claim
298	vinorelbine	_	_	I-Claim
299	plus	_	_	I-Claim
300	gemcitabine	_	_	I-Claim
301	is	_	_	I-Claim
302	not	_	_	I-Claim
303	more	_	_	I-Claim
304	effective	_	_	I-Claim
305	than	_	_	I-Claim
306	single-agent	_	_	I-Claim
307	vinorelbine	_	_	I-Claim
308	or	_	_	I-Claim
309	gemcitabine	_	_	I-Claim
310	in	_	_	I-Claim
311	the	_	_	I-Claim
312	treatment	_	_	I-Claim
313	of	_	_	I-Claim
314	elderly	_	_	I-Claim
315	patients	_	_	I-Claim
316	with	_	_	I-Claim
317	advanced	_	_	I-Claim
318	NSCLC	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	psychoeducational	_	_	O
7	intervention	_	_	O
8	in	_	_	O
9	improving	_	_	O
10	cancer-related	_	_	O
11	fatigue	_	_	O
12	.	_	_	O

13	This	_	_	O
14	randomized	_	_	O
15	controlled	_	_	O
16	trial	_	_	O
17	involved	_	_	O
18	109	_	_	O
19	women	_	_	O
20	commencing	_	_	O
21	adjuvant	_	_	O
22	chemotherapy	_	_	O
23	for	_	_	O
24	stage	_	_	O
25	I	_	_	O
26	or	_	_	O
27	II	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	in	_	_	O
31	five	_	_	O
32	chemotherapy	_	_	O
33	treatment	_	_	O
34	centers	_	_	O
35	.	_	_	O

36	Intervention	_	_	O
37	group	_	_	O
38	patients	_	_	O
39	received	_	_	O
40	an	_	_	O
41	individualized	_	_	O
42	fatigue	_	_	O
43	education	_	_	O
44	and	_	_	O
45	support	_	_	O
46	program	_	_	O
47	delivered	_	_	O
48	in	_	_	O
49	the	_	_	O
50	clinic	_	_	O
51	and	_	_	O
52	by	_	_	O
53	phone	_	_	O
54	over	_	_	O
55	three	_	_	O
56	10-	_	_	O
57	to	_	_	O
58	20-minute	_	_	O
59	sessions	_	_	O
60	1	_	_	O
61	week	_	_	O
62	apart	_	_	O
63	.	_	_	O

64	Instruments	_	_	O
65	included	_	_	O
66	a	_	_	O
67	numeric	_	_	O
68	rating	_	_	O
69	scale	_	_	O
70	assessing	_	_	O
71	confidence	_	_	O
72	with	_	_	O
73	managing	_	_	O
74	fatigue	_	_	O
75	;	_	_	O
76	11-point	_	_	O
77	numeric	_	_	O
78	rating	_	_	O
79	scales	_	_	O
80	measuring	_	_	O
81	fatigue	_	_	O
82	at	_	_	O
83	worst	_	_	O
84	,	_	_	O
85	average	_	_	O
86	,	_	_	O
87	and	_	_	O
88	best	_	_	O
89	;	_	_	O
90	the	_	_	O
91	Functional	_	_	O
92	Assessment	_	_	O
93	of	_	_	O
94	Cancer	_	_	O
95	Therapy-Fatigue	_	_	O
96	and	_	_	O
97	Piper	_	_	O
98	Fatigue	_	_	O
99	Scales	_	_	O
100	;	_	_	O
101	the	_	_	O
102	Cancer	_	_	O
103	Self-Efficacy	_	_	O
104	Scale	_	_	O
105	;	_	_	O
106	the	_	_	O
107	European	_	_	O
108	Organisation	_	_	O
109	for	_	_	O
110	Research	_	_	O
111	and	_	_	O
112	Treatment	_	_	O
113	of	_	_	O
114	Cancer	_	_	O
115	Quality	_	_	O
116	of	_	_	O
117	Life	_	_	O
118	Questionnaire	_	_	O
119	C30	_	_	O
120	;	_	_	O
121	and	_	_	O
122	the	_	_	O
123	Hospital	_	_	O
124	Anxiety	_	_	O
125	and	_	_	O
126	Depression	_	_	O
127	Scale	_	_	O
128	.	_	_	O

129	For	_	_	O
130	each	_	_	O
131	outcome	_	_	O
132	,	_	_	O
133	separate	_	_	O
134	analyses	_	_	O
135	of	_	_	O
136	covariance	_	_	O
137	of	_	_	O
138	change	_	_	O
139	scores	_	_	O
140	between	_	_	O
141	baseline	_	_	O
142	(	_	_	O
143	T1	_	_	O
144	)	_	_	O
145	and	_	_	O
146	the	_	_	O
147	three	_	_	O
148	follow-up	_	_	O
149	time	_	_	O
150	points	_	_	O
151	(	_	_	O
152	T2	_	_	O
153	,	_	_	O
154	T3	_	_	O
155	,	_	_	O
156	and	_	_	O
157	T4	_	_	O
158	)	_	_	O
159	were	_	_	O
160	conducted	_	_	O
161	,	_	_	O
162	controlling	_	_	O
163	for	_	_	O
164	the	_	_	O
165	variable	_	_	O
166	's	_	_	O
167	corresponding	_	_	O
168	baseline	_	_	O
169	value	_	_	O
170	.	_	_	O

171	Compared	_	_	B-Premise
172	with	_	_	I-Premise
173	the	_	_	I-Premise
174	intervention	_	_	I-Premise
175	group	_	_	I-Premise
176	,	_	_	I-Premise
177	mean	_	_	I-Premise
178	difference	_	_	I-Premise
179	scores	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	baseline	_	_	I-Premise
183	(	_	_	I-Premise
184	T1	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	immediate	_	_	I-Premise
188	after	_	_	I-Premise
189	the	_	_	I-Premise
190	test	_	_	I-Premise
191	(	_	_	I-Premise
192	T2	_	_	I-Premise
193	)	_	_	I-Premise
194	assessments	_	_	I-Premise
195	increased	_	_	I-Premise
196	significantly	_	_	I-Premise
197	more	_	_	I-Premise
198	for	_	_	I-Premise
199	the	_	_	I-Premise
200	control	_	_	I-Premise
201	group	_	_	I-Premise
202	for	_	_	I-Premise
203	worst	_	_	I-Premise
204	and	_	_	I-Premise
205	average	_	_	I-Premise
206	fatigue	_	_	I-Premise
207	,	_	_	I-Premise
208	Functional	_	_	I-Premise
209	Assessment	_	_	I-Premise
210	of	_	_	I-Premise
211	Cancer	_	_	I-Premise
212	Therapy-Fatigue	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	Piper	_	_	I-Premise
216	fatigue	_	_	I-Premise
217	severity	_	_	I-Premise
218	and	_	_	I-Premise
219	interference	_	_	I-Premise
220	measures	_	_	I-Premise
221	.	_	_	I-Premise

222	These	_	_	B-Premise
223	differences	_	_	I-Premise
224	were	_	_	I-Premise
225	not	_	_	I-Premise
226	observed	_	_	I-Premise
227	between	_	_	I-Premise
228	baseline	_	_	I-Premise
229	and	_	_	I-Premise
230	T3	_	_	I-Premise
231	and	_	_	I-Premise
232	T4	_	_	I-Premise
233	assessments	_	_	I-Premise
234	.	_	_	I-Premise

235	No	_	_	B-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	were	_	_	I-Premise
239	identified	_	_	I-Premise
240	for	_	_	I-Premise
241	any	_	_	I-Premise
242	pre-	_	_	I-Premise
243	or	_	_	I-Premise
244	post-test	_	_	I-Premise
245	change	_	_	I-Premise
246	scores	_	_	I-Premise
247	for	_	_	I-Premise
248	confidence	_	_	I-Premise
249	with	_	_	I-Premise
250	managing	_	_	I-Premise
251	fatigue	_	_	I-Premise
252	,	_	_	I-Premise
253	cancer	_	_	I-Premise
254	self-efficacy	_	_	I-Premise
255	,	_	_	I-Premise
256	anxiety	_	_	I-Premise
257	,	_	_	I-Premise
258	depression	_	_	I-Premise
259	,	_	_	I-Premise
260	or	_	_	I-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	.	_	_	I-Premise

265	Preparatory	_	_	B-Claim
266	education	_	_	I-Claim
267	and	_	_	I-Claim
268	support	_	_	I-Claim
269	has	_	_	I-Claim
270	the	_	_	I-Claim
271	potential	_	_	I-Claim
272	to	_	_	I-Claim
273	assist	_	_	I-Claim
274	women	_	_	I-Claim
275	to	_	_	I-Claim
276	cope	_	_	I-Claim
277	with	_	_	I-Claim
278	cancer-related	_	_	I-Claim
279	fatigue	_	_	I-Claim
280	in	_	_	I-Claim
281	the	_	_	I-Claim
282	short	_	_	I-Claim
283	term	_	_	I-Claim
284	.	_	_	I-Claim

285	However	_	_	B-Claim
286	,	_	_	I-Claim
287	further	_	_	I-Claim
288	research	_	_	I-Claim
289	is	_	_	I-Claim
290	needed	_	_	I-Claim
291	to	_	_	I-Claim
292	identify	_	_	I-Claim
293	ways	_	_	I-Claim
294	to	_	_	I-Claim
295	improve	_	_	I-Claim
296	the	_	_	I-Claim
297	potency	_	_	I-Claim
298	and	_	_	I-Claim
299	sustainability	_	_	I-Claim
300	of	_	_	I-Claim
301	psychoeducational	_	_	I-Claim
302	interventions	_	_	I-Claim
303	for	_	_	I-Claim
304	managing	_	_	I-Claim
305	cancer-related	_	_	I-Claim
306	fatigue	_	_	I-Claim
307	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	incidence	_	_	O
4	and	_	_	O
5	temporal	_	_	O
6	resolution	_	_	O
7	of	_	_	O
8	dysuria	_	_	O
9	after	_	_	O
10	permanent	_	_	O
11	prostate	_	_	O
12	brachytherapy	_	_	O
13	,	_	_	O
14	and	_	_	O
15	to	_	_	O
16	identify	_	_	O
17	predictors	_	_	O
18	of	_	_	O
19	brachytherapy-related	_	_	O
20	dysuria	_	_	O
21	.	_	_	O

22	The	_	_	O
23	study	_	_	O
24	included	_	_	O
25	130	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	no	_	_	O
29	history	_	_	O
30	of	_	_	O
31	transurethral	_	_	O
32	resection	_	_	O
33	of	_	_	O
34	the	_	_	O
35	prostate	_	_	O
36	before	_	_	O
37	treatment	_	_	O
38	,	_	_	O
39	who	_	_	O
40	had	_	_	O
41	brachytherapy	_	_	O
42	on	_	_	O
43	one	_	_	O
44	of	_	_	O
45	two	_	_	O
46	prospective	_	_	O
47	randomized	_	_	O
48	trials	_	_	O
49	,	_	_	O
50	with	_	_	O
51	explicitly	_	_	O
52	planned	_	_	O
53	and	_	_	O
54	executed	_	_	O
55	urethral-sparing	_	_	O
56	techniques	_	_	O
57	(	_	_	O
58	100-150	_	_	O
59	%	_	_	O
60	minimum	_	_	O
61	peripheral	_	_	O
62	dose	_	_	O
63	)	_	_	O
64	using	_	_	O
65	either	_	_	O
66	103Pd	_	_	O
67	or	_	_	O
68	125I	_	_	O
69	for	_	_	O
70	clinical	_	_	O
71	T1c-T2c	_	_	O
72	prostate	_	_	O
73	cancer	_	_	O
74	.	_	_	O

75	The	_	_	O
76	median	_	_	O
77	follow-up	_	_	O
78	was	_	_	O
79	22.6	_	_	O
80	months	_	_	O
81	.	_	_	O

82	An	_	_	O
83	alpha-blocker	_	_	O
84	was	_	_	O
85	initiated	_	_	O
86	either	_	_	O
87	prophylactically	_	_	O
88	2	_	_	O
89	weeks	_	_	O
90	before	_	_	O
91	implantation	_	_	O
92	and	_	_	O
93	continued	_	_	O
94	at	_	_	O
95	least	_	_	O
96	until	_	_	O
97	the	_	_	O
98	International	_	_	O
99	Prostate	_	_	O
100	Symptom	_	_	O
101	Score	_	_	O
102	(	_	_	O
103	IPSS	_	_	O
104	)	_	_	O
105	returned	_	_	O
106	to	_	_	O
107	normal	_	_	O
108	,	_	_	O
109	or	_	_	O
110	withheld	_	_	O
111	until	_	_	O
112	the	_	_	O
113	onset	_	_	O
114	of	_	_	O
115	significant	_	_	O
116	brachytherapy-related	_	_	O
117	urinary	_	_	O
118	morbidity	_	_	O
119	.	_	_	O

120	Dysuria	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	on	_	_	O
124	a	_	_	O
125	0-10	_	_	O
126	scale	_	_	O
127	,	_	_	O
128	before	_	_	O
129	brachytherapy	_	_	O
130	and	_	_	O
131	then	_	_	O
132	at	_	_	O
133	1	_	_	O
134	,	_	_	O
135	3	_	_	O
136	,	_	_	O
137	6	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	afterward	_	_	O
142	,	_	_	O
143	with	_	_	O
144	a	_	_	O
145	median	_	_	O
146	of	_	_	O
147	four	_	_	O
148	dysuria	_	_	O
149	questionnaires	_	_	O
150	per	_	_	O
151	patient	_	_	O
152	.	_	_	O

153	Clinical	_	_	O
154	,	_	_	O
155	treatment	_	_	O
156	and	_	_	O
157	dosimetric	_	_	O
158	variables	_	_	O
159	evaluated	_	_	O
160	included	_	_	O
161	alpha-blocker	_	_	O
162	,	_	_	O
163	age	_	_	O
164	,	_	_	O
165	IPSS	_	_	O
166	before	_	_	O
167	and	_	_	O
168	the	_	_	O
169	maximum	_	_	O
170	after	_	_	O
171	treatment	_	_	O
172	,	_	_	O
173	prostate	_	_	O
174	volume	_	_	O
175	on	_	_	O
176	ultrasonography	_	_	O
177	,	_	_	O
178	hormonal	_	_	O
179	status	_	_	O
180	,	_	_	O
181	supplemental	_	_	O
182	radiotherapy	_	_	O
183	,	_	_	O
184	isotope	_	_	O
185	,	_	_	O
186	urethral	_	_	O
187	dose	_	_	O
188	,	_	_	O
189	V	_	_	O
190	(	_	_	O
191	100/200	_	_	O
192	)	_	_	O
193	,	_	_	O
194	D90	_	_	O
195	,	_	_	O
196	and	_	_	O
197	time	_	_	O
198	to	_	_	O
199	obtaining	_	_	O
200	a	_	_	O
201	normal	_	_	O
202	IPSS	_	_	O
203	.	_	_	O

204	The	_	_	O
205	maximum	_	_	O
206	incidence	_	_	O
207	of	_	_	O
208	dysuria	_	_	O
209	was	_	_	O
210	85	_	_	O
211	%	_	_	O
212	at	_	_	O
213	1	_	_	O
214	month	_	_	O
215	after	_	_	O
216	brachytherapy	_	_	O
217	,	_	_	O
218	with	_	_	O
219	subsequent	_	_	O
220	resolution	_	_	O
221	over	_	_	O
222	time	_	_	O
223	.	_	_	O

224	The	_	_	B-Premise
225	use	_	_	I-Premise
226	of	_	_	I-Premise
227	prophylactic	_	_	I-Premise
228	tamsulosin	_	_	I-Premise
229	resulted	_	_	I-Premise
230	in	_	_	I-Premise
231	a	_	_	I-Premise
232	statistically	_	_	I-Premise
233	lower	_	_	I-Premise
234	dysuria	_	_	I-Premise
235	severity	_	_	I-Premise
236	score	_	_	I-Premise
237	(	_	_	I-Premise
238	difference	_	_	I-Premise
239	of	_	_	I-Premise
240	2.7	_	_	I-Premise
241	vs	_	_	I-Premise
242	4.2	_	_	I-Premise
243	,	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.005	_	_	I-Premise
247	)	_	_	I-Premise
248	at	_	_	I-Premise
249	1	_	_	I-Premise
250	month	_	_	I-Premise
251	,	_	_	I-Premise
252	with	_	_	I-Premise
253	no	_	_	I-Premise
254	discernible	_	_	I-Premise
255	differences	_	_	I-Premise
256	at	_	_	I-Premise
257	3	_	_	I-Premise
258	,	_	_	I-Premise
259	6	_	_	I-Premise
260	,	_	_	I-Premise
261	12	_	_	I-Premise
262	and	_	_	I-Premise
263	18	_	_	I-Premise
264	months	_	_	I-Premise
265	.	_	_	I-Premise

266	Patients	_	_	B-Premise
267	with	_	_	I-Premise
268	dysuria	_	_	I-Premise
269	had	_	_	I-Premise
270	a	_	_	I-Premise
271	statistically	_	_	I-Premise
272	higher	_	_	I-Premise
273	IPSS	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Premise
276	dysuria	_	_	I-Premise
277	resolved	_	_	I-Premise
278	faster	_	_	I-Premise
279	in	_	_	I-Premise
280	patients	_	_	I-Premise
281	implanted	_	_	I-Premise
282	with	_	_	I-Premise
283	103Pd	_	_	I-Premise
284	but	_	_	B-Premise
285	was	_	_	I-Premise
286	unaffected	_	_	I-Premise
287	by	_	_	I-Premise
288	the	_	_	I-Premise
289	use	_	_	I-Premise
290	of	_	_	I-Premise
291	supplemental	_	_	I-Premise
292	radiotherapy	_	_	I-Premise
293	and/or	_	_	I-Premise
294	androgen	_	_	I-Premise
295	deprivation	_	_	I-Premise
296	therapy	_	_	I-Premise
297	.	_	_	I-Premise

298	In	_	_	B-Premise
299	multivariate	_	_	I-Premise
300	analysis	_	_	I-Premise
301	,	_	_	I-Premise
302	prophylactic	_	_	I-Premise
303	alpha-blockers	_	_	I-Premise
304	resulted	_	_	I-Premise
305	in	_	_	I-Premise
306	statistically	_	_	I-Premise
307	lower	_	_	I-Premise
308	maximum	_	_	I-Premise
309	dysuria	_	_	I-Premise
310	scores	_	_	I-Premise
311	,	_	_	I-Premise
312	while	_	_	B-Premise
313	the	_	_	I-Premise
314	maximum	_	_	I-Premise
315	IPSS	_	_	I-Premise
316	after	_	_	I-Premise
317	implantation	_	_	I-Premise
318	and	_	_	I-Premise
319	isotope	_	_	I-Premise
320	type	_	_	I-Premise
321	(	_	_	I-Premise
322	but	_	_	I-Premise
323	only	_	_	I-Premise
324	at	_	_	I-Premise
325	6	_	_	I-Premise
326	months	_	_	I-Premise
327	)	_	_	I-Premise
328	were	_	_	I-Premise
329	the	_	_	I-Premise
330	best	_	_	I-Premise
331	predictors	_	_	I-Premise
332	of	_	_	I-Premise
333	the	_	_	I-Premise
334	resolution	_	_	I-Premise
335	of	_	_	I-Premise
336	dysuria	_	_	I-Premise
337	.	_	_	I-Premise

338	Dysuria	_	_	B-Claim
339	is	_	_	I-Claim
340	common	_	_	I-Claim
341	after	_	_	I-Claim
342	brachytherapy	_	_	I-Claim
343	but	_	_	I-Claim
344	is	_	_	I-Claim
345	typically	_	_	I-Claim
346	mild	_	_	I-Claim
347	.	_	_	I-Claim

348	Prophylactic	_	_	B-Claim
349	alpha-blockers	_	_	I-Claim
350	gave	_	_	I-Claim
351	significantly	_	_	I-Claim
352	lower	_	_	I-Claim
353	maximum	_	_	I-Claim
354	dysuria	_	_	I-Claim
355	scores	_	_	I-Claim
356	but	_	_	B-Claim
357	did	_	_	I-Claim
358	not	_	_	I-Claim
359	affect	_	_	I-Claim
360	the	_	_	I-Claim
361	time	_	_	I-Claim
362	to	_	_	I-Claim
363	the	_	_	I-Claim
364	resolution	_	_	I-Claim
365	of	_	_	I-Claim
366	dysuria	_	_	I-Claim
367	.	_	_	I-Claim

368	The	_	_	B-Claim
369	maximum	_	_	I-Claim
370	IPSS	_	_	I-Claim
371	after	_	_	I-Claim
372	the	_	_	I-Claim
373	implant	_	_	I-Claim
374	was	_	_	I-Claim
375	the	_	_	I-Claim
376	best	_	_	I-Claim
377	predictor	_	_	I-Claim
378	of	_	_	I-Claim
379	the	_	_	I-Claim
380	resolution	_	_	I-Claim
381	of	_	_	I-Claim
382	dysuria	_	_	I-Claim
383	.	_	_	I-Claim


0	The	_	_	B-Claim
1	addition	_	_	I-Claim
2	of	_	_	I-Claim
3	bevacizumab	_	_	I-Claim
4	to	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	improved	_	_	I-Claim
7	progression-free	_	_	I-Claim
8	survival	_	_	I-Claim
9	(	_	_	I-Claim
10	PFS	_	_	I-Claim
11	)	_	_	I-Claim
12	of	_	_	I-Claim
13	patients	_	_	I-Claim
14	with	_	_	I-Claim
15	metastatic	_	_	I-Claim
16	breast	_	_	I-Claim
17	cancer	_	_	I-Claim
18	(	_	_	I-Claim
19	MBC	_	_	I-Claim
20	)	_	_	I-Claim
21	.	_	_	I-Claim

22	We	_	_	O
23	examined	_	_	O
24	the	_	_	O
25	efficacy	_	_	O
26	and	_	_	O
27	safety	_	_	O
28	of	_	_	O
29	adding	_	_	O
30	gemcitabine	_	_	O
31	to	_	_	O
32	paclitaxel/bevacizumab	_	_	O
33	(	_	_	O
34	PB	_	_	O
35	)	_	_	O
36	.	_	_	O

37	In	_	_	O
38	this	_	_	O
39	multicenter	_	_	O
40	,	_	_	O
41	open-label	_	_	O
42	,	_	_	O
43	randomized	_	_	O
44	phase	_	_	O
45	II	_	_	O
46	trial	_	_	O
47	,	_	_	O
48	women	_	_	O
49	with	_	_	O
50	locally	_	_	O
51	advanced	_	_	O
52	or	_	_	O
53	MBC	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	paclitaxel	_	_	O
60	90	_	_	O
61	mg/m	_	_	O
62	(	_	_	O
63	2	_	_	O
64	)	_	_	O
65	(	_	_	O
66	days	_	_	O
67	1	_	_	O
68	,	_	_	O
69	8	_	_	O
70	,	_	_	O
71	15	_	_	O
72	)	_	_	O
73	and	_	_	O
74	bevacizumab	_	_	O
75	10	_	_	O
76	mg/kg	_	_	O
77	(	_	_	O
78	days	_	_	O
79	1	_	_	O
80	,	_	_	O
81	15	_	_	O
82	)	_	_	O
83	with	_	_	O
84	or	_	_	O
85	without	_	_	O
86	gemcitabine	_	_	O
87	1500	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	(	_	_	O
93	days	_	_	O
94	1	_	_	O
95	,	_	_	O
96	15	_	_	O
97	)	_	_	O
98	in	_	_	O
99	28-day	_	_	O
100	cycles	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	with	_	_	O
104	prior	_	_	O
105	cytotoxic	_	_	O
106	therapy	_	_	O
107	for	_	_	O
108	MBC	_	_	O
109	were	_	_	O
110	ineligible	_	_	O
111	.	_	_	O

112	The	_	_	O
113	primary	_	_	O
114	endpoint	_	_	O
115	was	_	_	O
116	investigator-assessed	_	_	O
117	overall	_	_	O
118	response	_	_	O
119	rate	_	_	O
120	(	_	_	O
121	ORR	_	_	O
122	)	_	_	O
123	;	_	_	O
124	secondary	_	_	O
125	endpoints	_	_	O
126	were	_	_	O
127	PFS	_	_	O
128	,	_	_	O
129	overall	_	_	O
130	survival	_	_	O
131	(	_	_	O
132	OS	_	_	O
133	)	_	_	O
134	,	_	_	O
135	safety	_	_	O
136	,	_	_	O
137	and	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	.	_	_	O

142	Ninety-four	_	_	O
143	patients	_	_	O
144	received	_	_	O
145	PB	_	_	O
146	,	_	_	O
147	and	_	_	O
148	93	_	_	O
149	received	_	_	O
150	paclitaxel/bevacizumab/gemcitabine	_	_	O
151	(	_	_	O
152	PB+G	_	_	O
153	)	_	_	O
154	.	_	_	O

155	The	_	_	B-Premise
156	ORRs	_	_	I-Premise
157	were	_	_	I-Premise
158	48.9	_	_	I-Premise
159	%	_	_	I-Premise
160	(	_	_	I-Premise
161	95	_	_	I-Premise
162	%	_	_	I-Premise
163	confidence	_	_	I-Premise
164	interval	_	_	I-Premise
165	[	_	_	I-Premise
166	CI	_	_	I-Premise
167	]	_	_	I-Premise
168	,	_	_	I-Premise
169	38.5	_	_	I-Premise
170	%	_	_	I-Premise
171	-59.5	_	_	I-Premise
172	%	_	_	I-Premise
173	)	_	_	I-Premise
174	and	_	_	I-Premise
175	58.7	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	,	_	_	I-Premise
182	47.9	_	_	I-Premise
183	%	_	_	I-Premise
184	-68.9	_	_	I-Premise
185	%	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.117	_	_	I-Premise
190	)	_	_	I-Premise
191	with	_	_	I-Premise
192	PB	_	_	I-Premise
193	and	_	_	I-Premise
194	PB+G	_	_	I-Premise
195	,	_	_	I-Premise
196	respectively	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Premise
199	median	_	_	I-Premise
200	PFS	_	_	I-Premise
201	was	_	_	I-Premise
202	8.8	_	_	I-Premise
203	months	_	_	I-Premise
204	(	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	8.1-10.4	_	_	I-Premise
210	months	_	_	I-Premise
211	)	_	_	I-Premise
212	and	_	_	I-Premise
213	11.3	_	_	I-Premise
214	months	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	9.7-12.7	_	_	I-Premise
221	months	_	_	I-Premise
222	;	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.247	_	_	I-Premise
226	;	_	_	I-Premise
227	hazard	_	_	I-Premise
228	ratio	_	_	I-Premise
229	,	_	_	I-Premise
230	0.82	_	_	I-Premise
231	)	_	_	I-Premise
232	;	_	_	I-Premise
233	the	_	_	I-Premise
234	median	_	_	I-Premise
235	OS	_	_	I-Premise
236	was	_	_	I-Premise
237	25.0	_	_	I-Premise
238	months	_	_	I-Premise
239	(	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	,	_	_	I-Premise
244	18.8-not	_	_	I-Premise
245	assessable	_	_	I-Premise
246	[	_	_	I-Premise
247	N/A	_	_	I-Premise
248	]	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	24.3	_	_	I-Premise
253	months	_	_	I-Premise
254	(	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	,	_	_	I-Premise
259	20.3-N/A	_	_	I-Premise
260	months	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.475	_	_	I-Premise
265	;	_	_	I-Premise
266	hazard	_	_	I-Premise
267	ratio	_	_	I-Premise
268	,	_	_	I-Premise
269	0.84	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	with	_	_	I-Premise
273	PB	_	_	I-Premise
274	and	_	_	I-Premise
275	PB+G	_	_	I-Premise
276	,	_	_	I-Premise
277	respectively	_	_	I-Premise
278	.	_	_	I-Premise

279	There	_	_	B-Premise
280	was	_	_	I-Premise
281	significantly	_	_	I-Premise
282	more	_	_	I-Premise
283	grade	_	_	I-Premise
284	3-4	_	_	I-Premise
285	neutropenia	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.001	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	dyspnea	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.014	_	_	I-Premise
297	)	_	_	I-Premise
298	with	_	_	I-Premise
299	PB+G	_	_	I-Premise
300	.	_	_	I-Premise

301	Patients	_	_	B-Premise
302	treated	_	_	I-Premise
303	with	_	_	I-Premise
304	PB	_	_	I-Premise
305	experienced	_	_	I-Premise
306	more	_	_	I-Premise
307	improvement	_	_	I-Premise
308	in	_	_	I-Premise
309	total	_	_	I-Premise
310	FACT-B	_	_	I-Premise
311	(	_	_	I-Premise
312	Functional	_	_	I-Premise
313	Assessment	_	_	I-Premise
314	of	_	_	I-Premise
315	Cancer	_	_	I-Premise
316	Therapy-Breast	_	_	I-Premise
317	)	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	=	_	_	I-Premise
321	.021	_	_	I-Premise
322	)	_	_	I-Premise
323	,	_	_	I-Premise
324	FACT-B	_	_	I-Premise
325	Social/Family	_	_	I-Premise
326	Well-being	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	=	_	_	I-Premise
330	.041	_	_	I-Premise
331	)	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	Breast	_	_	I-Premise
335	Cancer-Additional	_	_	I-Premise
336	Concerns	_	_	I-Premise
337	(	_	_	I-Premise
338	P	_	_	I-Premise
339	=	_	_	I-Premise
340	.008	_	_	I-Premise
341	)	_	_	I-Premise
342	scores	_	_	I-Premise
343	than	_	_	I-Premise
344	patients	_	_	I-Premise
345	treated	_	_	I-Premise
346	with	_	_	I-Premise
347	PB+G	_	_	I-Premise
348	.	_	_	I-Premise

349	The	_	_	B-Claim
350	addition	_	_	I-Claim
351	of	_	_	I-Claim
352	gemcitabine	_	_	I-Claim
353	to	_	_	I-Claim
354	PB	_	_	I-Claim
355	was	_	_	I-Claim
356	not	_	_	I-Claim
357	associated	_	_	I-Claim
358	with	_	_	I-Claim
359	a	_	_	I-Claim
360	statistically	_	_	I-Claim
361	significant	_	_	I-Claim
362	improvement	_	_	I-Claim
363	in	_	_	I-Claim
364	ORR	_	_	I-Claim
365	.	_	_	I-Claim

366	Treatment	_	_	B-Claim
367	with	_	_	I-Claim
368	PB+G	_	_	I-Claim
369	increased	_	_	I-Claim
370	the	_	_	I-Claim
371	incidence	_	_	I-Claim
372	of	_	_	I-Claim
373	severe	_	_	I-Claim
374	neutropenia	_	_	I-Claim
375	and	_	_	I-Claim
376	dyspnea	_	_	I-Claim
377	,	_	_	I-Claim
378	although	_	_	B-Claim
379	the	_	_	I-Claim
380	regimen	_	_	I-Claim
381	generally	_	_	I-Claim
382	was	_	_	I-Claim
383	well	_	_	I-Claim
384	tolerated	_	_	I-Claim
385	.	_	_	I-Claim


0	Maintenance	_	_	O
1	therapy	_	_	O
2	,	_	_	O
3	commenced	_	_	O
4	immediately	_	_	O
5	after	_	_	O
6	the	_	_	O
7	completion	_	_	O
8	of	_	_	O
9	first-line	_	_	O
10	chemotherapy	_	_	O
11	,	_	_	O
12	is	_	_	O
13	a	_	_	O
14	promising	_	_	O
15	strategy	_	_	O
16	for	_	_	O
17	improving	_	_	O
18	treatment	_	_	O
19	outcomes	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	non-small-cell	_	_	O
24	lung	_	_	O
25	cancer	_	_	O
26	(	_	_	O
27	NSCLC	_	_	O
28	)	_	_	O
29	.	_	_	O

30	The	_	_	O
31	global	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	SequentiAl	_	_	O
35	Tarceva	_	_	O
36	in	_	_	O
37	UnResectable	_	_	O
38	NSCLC	_	_	O
39	(	_	_	O
40	SATURN	_	_	O
41	)	_	_	O
42	study	_	_	O
43	evaluated	_	_	O
44	the	_	_	O
45	efficacy	_	_	O
46	and	_	_	O
47	safety	_	_	O
48	of	_	_	O
49	the	_	_	O
50	epidermal	_	_	O
51	growth	_	_	O
52	factor	_	_	O
53	receptor	_	_	O
54	(	_	_	O
55	EGFR	_	_	O
56	)	_	_	O
57	tyrosine-kinase	_	_	O
58	inhibitor	_	_	O
59	erlotinib	_	_	O
60	as	_	_	O
61	maintenance	_	_	O
62	treatment	_	_	O
63	in	_	_	O
64	NSCLC	_	_	O
65	patients	_	_	O
66	without	_	_	O
67	progression	_	_	O
68	after	_	_	O
69	first-line	_	_	O
70	chemotherapy	_	_	O
71	.	_	_	O

72	We	_	_	O
73	report	_	_	O
74	a	_	_	O
75	retrospective	_	_	O
76	subanalysis	_	_	O
77	of	_	_	O
78	Asian	_	_	O
79	patients	_	_	O
80	enrolled	_	_	O
81	in	_	_	O
82	SATURN	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	with	_	_	O
86	advanced	_	_	O
87	NSCLC	_	_	O
88	with	_	_	O
89	no	_	_	O
90	evidence	_	_	O
91	of	_	_	O
92	progression	_	_	O
93	after	_	_	O
94	four	_	_	O
95	cycles	_	_	O
96	of	_	_	O
97	chemotherapy	_	_	O
98	were	_	_	O
99	randomized	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	erlotinib	_	_	O
103	150	_	_	O
104	mg/day	_	_	O
105	or	_	_	O
106	placebo	_	_	O
107	,	_	_	O
108	until	_	_	O
109	progressive	_	_	O
110	disease	_	_	O
111	or	_	_	O
112	limiting	_	_	O
113	toxicity	_	_	O
114	.	_	_	O

115	The	_	_	O
116	co-primary	_	_	O
117	endpoints	_	_	O
118	of	_	_	O
119	SATURN	_	_	O
120	were	_	_	O
121	progression-free	_	_	O
122	survival	_	_	O
123	(	_	_	O
124	PFS	_	_	O
125	)	_	_	O
126	in	_	_	O
127	all	_	_	O
128	patients	_	_	O
129	and	_	_	O
130	in	_	_	O
131	those	_	_	O
132	with	_	_	O
133	positive	_	_	O
134	EGFR	_	_	O
135	immunohistochemistry	_	_	O
136	(	_	_	O
137	IHC	_	_	O
138	)	_	_	O
139	status	_	_	O
140	.	_	_	O

141	Secondary	_	_	O
142	endpoints	_	_	O
143	included	_	_	O
144	overall	_	_	O
145	survival	_	_	O
146	(	_	_	O
147	OS	_	_	O
148	)	_	_	O
149	,	_	_	O
150	disease	_	_	O
151	control	_	_	O
152	rate	_	_	O
153	,	_	_	O
154	safety	_	_	O
155	,	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	(	_	_	O
160	QoL	_	_	O
161	)	_	_	O
162	and	_	_	O
163	biomarker	_	_	O
164	analyses	_	_	O
165	.	_	_	O

166	In	_	_	O
167	total	_	_	O
168	,	_	_	O
169	126	_	_	O
170	patients	_	_	O
171	from	_	_	O
172	East	_	_	O
173	and	_	_	O
174	South-East	_	_	O
175	Asian	_	_	O
176	centers	_	_	O
177	were	_	_	O
178	randomized	_	_	O
179	(	_	_	O
180	14	_	_	O
181	%	_	_	O
182	of	_	_	O
183	the	_	_	O
184	intent-to-treat	_	_	O
185	population	_	_	O
186	)	_	_	O
187	:	_	_	O
188	88	_	_	O
189	from	_	_	O
190	Korea	_	_	O
191	,	_	_	O
192	28	_	_	O
193	from	_	_	O
194	China	_	_	O
195	and	_	_	O
196	10	_	_	O
197	from	_	_	O
198	Malaysia	_	_	O
199	;	_	_	O
200	one	_	_	O
201	patient	_	_	O
202	was	_	_	O
203	excluded	_	_	O
204	from	_	_	O
205	this	_	_	O
206	analysis	_	_	O
207	due	_	_	O
208	to	_	_	O
209	Indian	_	_	O
210	ethnicity	_	_	O
211	.	_	_	O

212	PFS	_	_	B-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	prolonged	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	erlotinib	_	_	I-Premise
219	treatment	_	_	I-Premise
220	arm	_	_	I-Premise
221	,	_	_	I-Premise
222	both	_	_	I-Premise
223	overall	_	_	I-Premise
224	(	_	_	I-Premise
225	hazard	_	_	I-Premise
226	ratio	_	_	I-Premise
227	[	_	_	I-Premise
228	HR	_	_	I-Premise
229	]	_	_	I-Premise
230	:	_	_	I-Premise
231	0.57	_	_	I-Premise
232	;	_	_	I-Premise
233	p=0.0067	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	in	_	_	I-Premise
237	patients	_	_	I-Premise
238	with	_	_	I-Premise
239	EGFR	_	_	I-Premise
240	IHC-positive	_	_	I-Premise
241	disease	_	_	I-Premise
242	(	_	_	I-Premise
243	HR=0.50	_	_	I-Premise
244	;	_	_	I-Premise
245	p=0.0057	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	There	_	_	B-Premise
249	was	_	_	I-Premise
250	a	_	_	I-Premise
251	trend	_	_	I-Premise
252	towards	_	_	I-Premise
253	an	_	_	I-Premise
254	increase	_	_	I-Premise
255	in	_	_	I-Premise
256	OS	_	_	I-Premise
257	,	_	_	I-Premise
258	which	_	_	I-Premise
259	reached	_	_	I-Premise
260	statistical	_	_	I-Premise
261	significance	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	EGFR	_	_	I-Premise
265	IHC-positive	_	_	I-Premise
266	subgroup	_	_	I-Premise
267	(	_	_	I-Premise
268	p=0.0233	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Premise
272	overall	_	_	I-Premise
273	response	_	_	I-Premise
274	rate	_	_	I-Premise
275	was	_	_	I-Premise
276	significantly	_	_	I-Premise
277	higher	_	_	I-Premise
278	with	_	_	I-Premise
279	erlotinib	_	_	I-Premise
280	compared	_	_	I-Premise
281	with	_	_	I-Premise
282	placebo	_	_	I-Premise
283	(	_	_	I-Premise
284	24	_	_	I-Premise
285	%	_	_	I-Premise
286	versus	_	_	I-Premise
287	5	_	_	I-Premise
288	%	_	_	I-Premise
289	;	_	_	I-Premise
290	p=0.0025	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Erlotinib	_	_	B-Claim
294	was	_	_	I-Claim
295	generally	_	_	I-Claim
296	well	_	_	I-Claim
297	tolerated	_	_	I-Claim
298	and	_	_	I-Claim
299	had	_	_	I-Claim
300	no	_	_	I-Claim
301	negative	_	_	I-Claim
302	impact	_	_	I-Claim
303	on	_	_	I-Claim
304	QoL	_	_	I-Claim
305	in	_	_	I-Claim
306	this	_	_	I-Claim
307	subpopulation	_	_	I-Claim
308	.	_	_	I-Claim

309	The	_	_	B-Premise
310	most	_	_	I-Premise
311	common	_	_	I-Premise
312	treatment-related	_	_	I-Premise
313	adverse	_	_	I-Premise
314	events	_	_	I-Premise
315	were	_	_	I-Premise
316	rash	_	_	I-Premise
317	,	_	_	I-Premise
318	diarrhea	_	_	I-Premise
319	and	_	_	I-Premise
320	pruritus	_	_	I-Premise
321	.	_	_	I-Premise

322	Erlotinib	_	_	B-Claim
323	was	_	_	I-Claim
324	effective	_	_	I-Claim
325	and	_	_	I-Claim
326	well	_	_	I-Claim
327	tolerated	_	_	I-Claim
328	in	_	_	I-Claim
329	Asian	_	_	I-Claim
330	patients	_	_	I-Claim
331	,	_	_	I-Claim
332	producing	_	_	I-Claim
333	benefits	_	_	I-Claim
334	consistent	_	_	I-Claim
335	with	_	_	I-Claim
336	those	_	_	I-Claim
337	observed	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	overall	_	_	I-Claim
341	SATURN	_	_	I-Claim
342	population	_	_	I-Claim
343	.	_	_	I-Claim

344	Maintenance	_	_	B-Claim
345	treatment	_	_	I-Claim
346	with	_	_	I-Claim
347	erlotinib	_	_	I-Claim
348	appears	_	_	I-Claim
349	to	_	_	I-Claim
350	be	_	_	I-Claim
351	a	_	_	I-Claim
352	useful	_	_	I-Claim
353	option	_	_	I-Claim
354	for	_	_	I-Claim
355	the	_	_	I-Claim
356	management	_	_	I-Claim
357	of	_	_	I-Claim
358	Asian	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	advanced	_	_	I-Claim
362	NSCLC	_	_	I-Claim
363	without	_	_	I-Claim
364	progression	_	_	I-Claim
365	after	_	_	I-Claim
366	first-line	_	_	I-Claim
367	chemotherapy	_	_	I-Claim
368	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	abatacept	_	_	O
8	during	_	_	O
9	2	_	_	O
10	years	_	_	O
11	of	_	_	O
12	the	_	_	O
13	ATTAIN	_	_	O
14	(	_	_	O
15	Abatacept	_	_	O
16	Trial	_	_	O
17	in	_	_	O
18	Treatment	_	_	O
19	of	_	_	O
20	Anti-TNF	_	_	O
21	INadequate	_	_	O
22	responders	_	_	O
23	)	_	_	O
24	trial	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	rheumatoid	_	_	O
29	arthritis	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	completing	_	_	O
33	the	_	_	O
34	6-month	_	_	O
35	,	_	_	O
36	double-blind	_	_	O
37	period	_	_	O
38	were	_	_	O
39	eligible	_	_	O
40	to	_	_	O
41	enter	_	_	O
42	the	_	_	O
43	long-term	_	_	O
44	extension	_	_	O
45	;	_	_	O
46	patients	_	_	O
47	received	_	_	O
48	abatacept	_	_	O
49	approximately	_	_	O
50	10	_	_	O
51	mg/kg	_	_	O
52	,	_	_	O
53	plus	_	_	O
54	disease-modifying	_	_	O
55	antirheumatic	_	_	O
56	drugs	_	_	O
57	.	_	_	O

58	Safety	_	_	O
59	and	_	_	O
60	efficacy	_	_	O
61	(	_	_	O
62	American	_	_	O
63	College	_	_	O
64	of	_	_	O
65	Rheumatology	_	_	O
66	(	_	_	O
67	ACR	_	_	O
68	)	_	_	O
69	criteria	_	_	O
70	responses	_	_	O
71	,	_	_	O
72	DAS28	_	_	O
73	(	_	_	O
74	C-reactive	_	_	O
75	protein	_	_	O
76	)	_	_	O
77	,	_	_	O
78	HAQ-DI	_	_	O
79	,	_	_	O
80	SF-36	_	_	O
81	,	_	_	O
82	Medical	_	_	O
83	Outcomes	_	_	O
84	Study	_	_	O
85	Sleep	_	_	O
86	Problems	_	_	O
87	Index	_	_	O
88	,	_	_	O
89	fatigue	_	_	O
90	VAS	_	_	O
91	)	_	_	O
92	were	_	_	O
93	assessed	_	_	O
94	through	_	_	O
95	2	_	_	O
96	years	_	_	O
97	.	_	_	O

98	317	_	_	O
99	patients	_	_	O
100	(	_	_	O
101	218	_	_	O
102	from	_	_	O
103	the	_	_	O
104	abatacept	_	_	O
105	and	_	_	O
106	99	_	_	O
107	from	_	_	O
108	the	_	_	O
109	placebo	_	_	O
110	group	_	_	O
111	)	_	_	O
112	entered	_	_	O
113	and	_	_	O
114	222	_	_	O
115	(	_	_	O
116	70	_	_	O
117	%	_	_	O
118	)	_	_	O
119	completed	_	_	O
120	18	_	_	O
121	months	_	_	O
122	of	_	_	O
123	long-term	_	_	O
124	extension	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	The	_	_	B-Premise
128	incidence	_	_	I-Premise
129	and	_	_	I-Premise
130	type	_	_	I-Premise
131	of	_	_	I-Premise
132	adverse	_	_	I-Premise
133	events	_	_	I-Premise
134	were	_	_	I-Premise
135	consistent	_	_	I-Premise
136	between	_	_	I-Premise
137	the	_	_	I-Premise
138	double-blind	_	_	I-Premise
139	and	_	_	I-Premise
140	cumulative	_	_	I-Premise
141	(	_	_	I-Premise
142	double-blind	_	_	I-Premise
143	plus	_	_	I-Premise
144	long-term	_	_	I-Premise
145	extension	_	_	I-Premise
146	)	_	_	I-Premise
147	periods	_	_	I-Premise
148	.	_	_	I-Premise

149	Rates	_	_	B-Premise
150	of	_	_	I-Premise
151	serious	_	_	I-Premise
152	adverse	_	_	I-Premise
153	events	_	_	I-Premise
154	were	_	_	I-Premise
155	25.6	_	_	I-Premise
156	and	_	_	I-Premise
157	23.4	_	_	I-Premise
158	per	_	_	I-Premise
159	100	_	_	I-Premise
160	patient-years	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	double-blind	_	_	I-Premise
164	versus	_	_	I-Premise
165	cumulative	_	_	I-Premise
166	period	_	_	I-Premise
167	.	_	_	I-Premise

168	At	_	_	B-Premise
169	6	_	_	I-Premise
170	months	_	_	I-Premise
171	and	_	_	I-Premise
172	2	_	_	I-Premise
173	years	_	_	I-Premise
174	,	_	_	I-Premise
175	using	_	_	I-Premise
176	non-responder	_	_	I-Premise
177	analyses	_	_	I-Premise
178	,	_	_	I-Premise
179	ACR	_	_	I-Premise
180	responses	_	_	I-Premise
181	in	_	_	I-Premise
182	abatacept-treated	_	_	I-Premise
183	patients	_	_	I-Premise
184	were	_	_	I-Premise
185	:	_	_	I-Premise
186	ACR	_	_	I-Premise
187	20	_	_	I-Premise
188	,	_	_	I-Premise
189	59.4	_	_	I-Premise
190	%	_	_	I-Premise
191	and	_	_	I-Premise
192	56.2	_	_	I-Premise
193	%	_	_	I-Premise
194	;	_	_	I-Premise
195	ACR	_	_	I-Premise
196	50	_	_	I-Premise
197	,	_	_	I-Premise
198	23.5	_	_	I-Premise
199	%	_	_	I-Premise
200	and	_	_	I-Premise
201	33.2	_	_	I-Premise
202	%	_	_	I-Premise
203	;	_	_	I-Premise
204	ACR	_	_	I-Premise
205	70	_	_	I-Premise
206	,	_	_	I-Premise
207	11.5	_	_	I-Premise
208	%	_	_	I-Premise
209	and	_	_	I-Premise
210	16.1	_	_	I-Premise
211	%	_	_	I-Premise
212	;	_	_	I-Premise
213	HAQ-DI	_	_	I-Premise
214	responses	_	_	I-Premise
215	were	_	_	I-Premise
216	54.4	_	_	I-Premise
217	%	_	_	I-Premise
218	and	_	_	I-Premise
219	47.9	_	_	I-Premise
220	%	_	_	I-Premise
221	.	_	_	I-Premise

222	At	_	_	B-Premise
223	6	_	_	I-Premise
224	months	_	_	I-Premise
225	and	_	_	I-Premise
226	2	_	_	I-Premise
227	years	_	_	I-Premise
228	,	_	_	I-Premise
229	using	_	_	I-Premise
230	post-hoc	_	_	I-Premise
231	as-observed	_	_	I-Premise
232	analyses	_	_	I-Premise
233	,	_	_	I-Premise
234	the	_	_	I-Premise
235	percentage	_	_	I-Premise
236	of	_	_	I-Premise
237	patients	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	confidence	_	_	I-Premise
242	interval	_	_	I-Premise
243	)	_	_	I-Premise
244	achieving	_	_	I-Premise
245	DAS28	_	_	I-Premise
246	(	_	_	I-Premise
247	C-reactive	_	_	I-Premise
248	protein	_	_	I-Premise
249	)	_	_	I-Premise
250	low	_	_	I-Premise
251	disease	_	_	I-Premise
252	activity	_	_	I-Premise
253	score	_	_	I-Premise
254	(	_	_	I-Premise
255	<	_	_	I-Premise
256	or	_	_	I-Premise
257	=	_	_	I-Premise
258	3.2	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	DAS28	_	_	I-Premise
262	(	_	_	I-Premise
263	C-reactive	_	_	I-Premise
264	protein	_	_	I-Premise
265	)	_	_	I-Premise
266	-defined	_	_	I-Premise
267	remission	_	_	I-Premise
268	(	_	_	I-Premise
269	<	_	_	I-Premise
270	2.6	_	_	I-Premise
271	)	_	_	I-Premise
272	increased	_	_	I-Premise
273	from	_	_	I-Premise
274	18.3	_	_	I-Premise
275	%	_	_	I-Premise
276	(	_	_	I-Premise
277	13.0	_	_	I-Premise
278	,	_	_	I-Premise
279	23.5	_	_	I-Premise
280	)	_	_	I-Premise
281	to	_	_	I-Premise
282	32.0	_	_	I-Premise
283	%	_	_	I-Premise
284	(	_	_	I-Premise
285	24.6	_	_	I-Premise
286	,	_	_	I-Premise
287	39.4	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	11.1	_	_	I-Premise
291	%	_	_	I-Premise
292	(	_	_	I-Premise
293	6.8	_	_	I-Premise
294	,	_	_	I-Premise
295	15.3	_	_	I-Premise
296	)	_	_	I-Premise
297	to	_	_	I-Premise
298	20.3	_	_	I-Premise
299	%	_	_	I-Premise
300	(	_	_	I-Premise
301	13.9	_	_	I-Premise
302	,	_	_	I-Premise
303	26.6	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Clinically	_	_	B-Premise
307	meaningful	_	_	I-Premise
308	improvements	_	_	I-Premise
309	in	_	_	I-Premise
310	SF-36	_	_	I-Premise
311	,	_	_	I-Premise
312	pain	_	_	I-Premise
313	,	_	_	I-Premise
314	fatigue	_	_	I-Premise
315	and	_	_	I-Premise
316	sleep	_	_	I-Premise
317	problems	_	_	I-Premise
318	were	_	_	I-Premise
319	also	_	_	I-Premise
320	maintained	_	_	I-Premise
321	throughout	_	_	I-Premise
322	the	_	_	I-Premise
323	2	_	_	I-Premise
324	years	_	_	I-Premise
325	of	_	_	I-Premise
326	abatacept	_	_	I-Premise
327	treatment	_	_	I-Premise
328	.	_	_	I-Premise

329	No	_	_	B-Premise
330	unique	_	_	I-Premise
331	safety	_	_	I-Premise
332	observations	_	_	I-Premise
333	were	_	_	I-Premise
334	reported	_	_	I-Premise
335	during	_	_	I-Premise
336	open-label	_	_	I-Premise
337	exposure	_	_	I-Premise
338	.	_	_	I-Premise

339	Improvements	_	_	B-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	signs	_	_	I-Premise
343	and	_	_	I-Premise
344	symptoms	_	_	I-Premise
345	of	_	_	I-Premise
346	rheumatoid	_	_	I-Premise
347	arthritis	_	_	I-Premise
348	,	_	_	I-Premise
349	physical	_	_	I-Premise
350	function	_	_	I-Premise
351	and	_	_	I-Premise
352	health-related	_	_	I-Premise
353	quality	_	_	I-Premise
354	of	_	_	I-Premise
355	life	_	_	I-Premise
356	observed	_	_	I-Premise
357	after	_	_	I-Premise
358	6	_	_	I-Premise
359	months	_	_	I-Premise
360	,	_	_	I-Premise
361	were	_	_	I-Premise
362	maintained	_	_	I-Premise
363	throughout	_	_	I-Premise
364	the	_	_	I-Premise
365	2	_	_	I-Premise
366	years	_	_	I-Premise
367	in	_	_	I-Premise
368	this	_	_	I-Premise
369	population	_	_	I-Premise
370	with	_	_	I-Premise
371	difficult-to-treat	_	_	I-Premise
372	disease	_	_	I-Premise
373	.	_	_	I-Premise


0	Gemcitabine	_	_	O
1	for	_	_	O
2	advanced	_	_	O
3	pancreatic	_	_	O
4	cancer	_	_	O
5	(	_	_	O
6	APC	_	_	O
7	)	_	_	O
8	is	_	_	O
9	palliative	_	_	O
10	and	_	_	O
11	the	_	_	O
12	prognosis	_	_	O
13	is	_	_	O
14	poor	_	_	O
15	,	_	_	O
16	making	_	_	O
17	health-related	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	HRQOL	_	_	O
23	)	_	_	O
24	particularly	_	_	O
25	important	_	_	O
26	.	_	_	O

27	We	_	_	O
28	evaluated	_	_	O
29	HRQOL	_	_	O
30	with	_	_	O
31	the	_	_	O
32	EuroQol	_	_	O
33	(	_	_	O
34	EQ-5Dâ„¢	_	_	O
35	)	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	APC	_	_	O
40	participating	_	_	O
41	in	_	_	O
42	Cancer	_	_	O
43	and	_	_	O
44	Leukemia	_	_	O
45	Group	_	_	O
46	B	_	_	O
47	80303	_	_	O
48	,	_	_	O
49	a	_	_	O
50	multicenter	_	_	O
51	,	_	_	O
52	double-blind	_	_	O
53	,	_	_	O
54	randomized	_	_	O
55	trial	_	_	O
56	comparing	_	_	O
57	overall	_	_	O
58	survival	_	_	O
59	(	_	_	O
60	OS	_	_	O
61	)	_	_	O
62	between	_	_	O
63	two	_	_	O
64	treatment	_	_	O
65	arms	_	_	O
66	:	_	_	O
67	gemcitabine	_	_	O
68	with	_	_	O
69	bevacizumab	_	_	O
70	or	_	_	O
71	gemcitabine	_	_	O
72	with	_	_	O
73	placebo	_	_	O
74	.	_	_	O

75	A	_	_	O
76	consecutive	_	_	O
77	subsample	_	_	O
78	of	_	_	O
79	patients	_	_	O
80	was	_	_	O
81	invited	_	_	O
82	to	_	_	O
83	complete	_	_	O
84	the	_	_	O
85	EQ-5D	_	_	O
86	surveys	_	_	O
87	.	_	_	O

88	Because	_	_	O
89	neither	_	_	O
90	clinical	_	_	O
91	nor	_	_	O
92	HRQOL	_	_	O
93	outcomes	_	_	O
94	differed	_	_	O
95	based	_	_	O
96	on	_	_	O
97	the	_	_	O
98	study	_	_	O
99	arm	_	_	O
100	,	_	_	O
101	analyses	_	_	O
102	were	_	_	O
103	pooled	_	_	O
104	.	_	_	O

105	Changes	_	_	O
106	in	_	_	O
107	mean	_	_	O
108	scores	_	_	O
109	from	_	_	O
110	baseline	_	_	O
111	to	_	_	O
112	eight	_	_	O
113	weeks	_	_	O
114	and	_	_	O
115	the	_	_	O
116	prognostic	_	_	O
117	value	_	_	O
118	of	_	_	O
119	the	_	_	O
120	EQ-5D	_	_	O
121	were	_	_	O
122	evaluated	_	_	O
123	.	_	_	O

124	Mean	_	_	B-Premise
125	index	_	_	I-Premise
126	scores	_	_	I-Premise
127	remained	_	_	I-Premise
128	stable	_	_	I-Premise
129	(	_	_	I-Premise
130	0.78	_	_	I-Premise
131	at	_	_	I-Premise
132	baseline	_	_	I-Premise
133	[	_	_	I-Premise
134	n=267	_	_	I-Premise
135	]	_	_	I-Premise
136	,	_	_	I-Premise
137	0.79	_	_	I-Premise
138	at	_	_	I-Premise
139	eight	_	_	I-Premise
140	weeks	_	_	I-Premise
141	[	_	_	I-Premise
142	n=186	_	_	I-Premise
143	]	_	_	I-Premise
144	,	_	_	I-Premise
145	P=0.34	_	_	I-Premise
146	,	_	_	I-Premise
147	Wilcoxon	_	_	I-Premise
148	signed	_	_	I-Premise
149	rank	_	_	I-Premise
150	test	_	_	I-Premise
151	)	_	_	I-Premise
152	,	_	_	I-Premise
153	attributable	_	_	I-Premise
154	to	_	_	I-Premise
155	a	_	_	I-Premise
156	modest	_	_	I-Premise
157	deterioration	_	_	I-Premise
158	of	_	_	I-Premise
159	physical	_	_	I-Premise
160	function	_	_	I-Premise
161	domain	_	_	I-Premise
162	scores	_	_	I-Premise
163	coincident	_	_	I-Premise
164	with	_	_	I-Premise
165	small	_	_	I-Premise
166	improvements	_	_	I-Premise
167	in	_	_	I-Premise
168	pain	_	_	I-Premise
169	and	_	_	I-Premise
170	anxiety/depression	_	_	I-Premise
171	scores	_	_	I-Premise
172	.	_	_	I-Premise

173	A	_	_	B-Premise
174	small	_	_	I-Premise
175	decline	_	_	I-Premise
176	in	_	_	I-Premise
177	visual	_	_	I-Premise
178	analogue	_	_	I-Premise
179	scale	_	_	I-Premise
180	scores	_	_	I-Premise
181	was	_	_	I-Premise
182	observed	_	_	I-Premise
183	(	_	_	I-Premise
184	70.7	_	_	I-Premise
185	vs.	_	_	I-Premise
186	68.2	_	_	I-Premise
187	,	_	_	I-Premise
188	P=0.026	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	HRQOL	_	_	B-Premise
192	changes	_	_	I-Premise
193	within	_	_	I-Premise
194	chemotherapy	_	_	I-Premise
195	response	_	_	I-Premise
196	strata	_	_	I-Premise
197	revealed	_	_	I-Premise
198	stable	_	_	I-Premise
199	index	_	_	I-Premise
200	scores	_	_	I-Premise
201	but	_	_	B-Premise
202	a	_	_	I-Premise
203	trend	_	_	I-Premise
204	of	_	_	I-Premise
205	worsened	_	_	I-Premise
206	physical	_	_	I-Premise
207	function	_	_	I-Premise
208	among	_	_	I-Premise
209	patients	_	_	I-Premise
210	with	_	_	I-Premise
211	disease	_	_	I-Premise
212	progression	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	those	_	_	I-Premise
216	with	_	_	I-Premise
217	stable	_	_	I-Premise
218	or	_	_	I-Premise
219	improved	_	_	I-Premise
220	disease	_	_	I-Premise
221	.	_	_	I-Premise

222	Visual	_	_	B-Premise
223	analogue	_	_	I-Premise
224	scale	_	_	I-Premise
225	scores	_	_	I-Premise
226	trended	_	_	I-Premise
227	downward	_	_	I-Premise
228	over	_	_	I-Premise
229	time	_	_	I-Premise
230	irrespective	_	_	I-Premise
231	of	_	_	I-Premise
232	chemotherapy	_	_	I-Premise
233	response	_	_	I-Premise
234	status	_	_	I-Premise
235	,	_	_	I-Premise
236	with	_	_	I-Premise
237	a	_	_	I-Premise
238	statistically	_	_	I-Premise
239	meaningful	_	_	I-Premise
240	deterioration	_	_	I-Premise
241	in	_	_	I-Premise
242	patients	_	_	I-Premise
243	who	_	_	I-Premise
244	progressed	_	_	I-Premise
245	(	_	_	I-Premise
246	68.9	_	_	I-Premise
247	vs.	_	_	I-Premise
248	64.4	_	_	I-Premise
249	,	_	_	I-Premise
250	P=0.029	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Baseline	_	_	O
254	scores	_	_	O
255	from	_	_	O
256	both	_	_	O
257	EQ-5D	_	_	O
258	scales	_	_	O
259	were	_	_	O
260	significant	_	_	O
261	predictors	_	_	O
262	of	_	_	O
263	OS	_	_	O
264	in	_	_	O
265	Cox	_	_	O
266	proportional	_	_	O
267	hazard	_	_	O
268	models	_	_	O
269	.	_	_	O

270	Response	_	_	B-Claim
271	to	_	_	I-Claim
272	gemcitabine	_	_	I-Claim
273	treatment	_	_	I-Claim
274	in	_	_	I-Claim
275	APC	_	_	I-Claim
276	is	_	_	I-Claim
277	not	_	_	I-Claim
278	associated	_	_	I-Claim
279	with	_	_	I-Claim
280	appreciable	_	_	I-Claim
281	improvement	_	_	I-Claim
282	of	_	_	I-Claim
283	global	_	_	I-Claim
284	HRQOL	_	_	I-Claim
285	.	_	_	I-Claim

286	Small	_	_	O
287	improvements	_	_	O
288	in	_	_	O
289	pain	_	_	O
290	and	_	_	O
291	mood	_	_	O
292	are	_	_	O
293	observed	_	_	O
294	despite	_	_	O
295	progressive	_	_	O
296	functional	_	_	O
297	decline	_	_	O
298	.	_	_	O

299	Those	_	_	B-Claim
300	who	_	_	I-Claim
301	respond	_	_	I-Claim
302	to	_	_	I-Claim
303	gemcitabine	_	_	I-Claim
304	may	_	_	I-Claim
305	experience	_	_	I-Claim
306	a	_	_	I-Claim
307	slight	_	_	I-Claim
308	slowing	_	_	I-Claim
309	of	_	_	I-Claim
310	functional	_	_	I-Claim
311	deterioration	_	_	I-Claim
312	.	_	_	I-Claim


0	Bone-cancer	_	_	O
1	pain	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	and	_	_	O
6	refractory	_	_	O
7	cancer	_	_	O
8	pain	_	_	O
9	.	_	_	O

10	Opioids	_	_	O
11	,	_	_	O
12	on	_	_	O
13	their	_	_	O
14	own	_	_	O
15	,	_	_	O
16	do	_	_	O
17	not	_	_	O
18	control	_	_	O
19	this	_	_	O
20	type	_	_	O
21	of	_	_	O
22	pain	_	_	O
23	well	_	_	O
24	enough	_	_	O
25	,	_	_	O
26	and	_	_	O
27	co-analgesics	_	_	O
28	are	_	_	O
29	necessary	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	with	_	_	O
33	bone	_	_	O
34	metastasis-related	_	_	O
35	pain	_	_	O
36	at	_	_	O
37	Numeric	_	_	O
38	Rating	_	_	O
39	Scale	_	_	O
40	â‰¥4	_	_	O
41	were	_	_	O
42	enrolled	_	_	O
43	to	_	_	O
44	this	_	_	O
45	randomized	_	_	O
46	placebo-controlled	_	_	O
47	trial	_	_	O
48	.	_	_	O

49	They	_	_	O
50	had	_	_	O
51	also	_	_	O
52	received	_	_	O
53	morphine	_	_	O
54	or	_	_	O
55	transdermal	_	_	O
56	fentanyl	_	_	O
57	patches	_	_	O
58	for	_	_	O
59	at	_	_	O
60	least	_	_	O
61	1	_	_	O
62	week	_	_	O
63	.	_	_	O

64	During	_	_	O
65	the	_	_	O
66	3-day	_	_	O
67	efficacy	_	_	O
68	phase	_	_	O
69	,	_	_	O
70	patients	_	_	O
71	received	_	_	O
72	placebo	_	_	O
73	or	_	_	O
74	1-3	_	_	O
75	tablets	_	_	O
76	of	_	_	O
77	oxycodone/paracetamol	_	_	O
78	(	_	_	O
79	5/325	_	_	O
80	mg	_	_	O
81	)	_	_	O
82	,	_	_	O
83	four	_	_	O
84	times	_	_	O
85	daily	_	_	O
86	for	_	_	O
87	3	_	_	O
88	days	_	_	O
89	.	_	_	O

90	All	_	_	O
91	patients	_	_	O
92	kept	_	_	O
93	a	_	_	O
94	daily	_	_	O
95	pain	_	_	O
96	diary	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	endpoint	_	_	O
101	was	_	_	O
102	the	_	_	O
103	Pain	_	_	O
104	Intensity	_	_	O
105	Difference	_	_	O
106	(	_	_	O
107	PID	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	endpoints	_	_	O
112	were	_	_	O
113	cases	_	_	O
114	of	_	_	O
115	breakthrough	_	_	O
116	pain	_	_	O
117	and	_	_	O
118	rescue	_	_	O
119	morphine	_	_	O
120	consumption	_	_	O
121	.	_	_	O

122	Additional	_	_	O
123	analyses	_	_	O
124	included	_	_	O
125	the	_	_	O
126	Short	_	_	O
127	Form-6	_	_	O
128	Dimensions	_	_	O
129	(	_	_	O
130	SF-6D	_	_	O
131	)	_	_	O
132	quality-of-life	_	_	O
133	scale	_	_	O
134	and	_	_	O
135	a	_	_	O
136	general	_	_	O
137	impression	_	_	O
138	(	_	_	O
139	GI	_	_	O
140	)	_	_	O
141	of	_	_	O
142	patient	_	_	O
143	satisfaction	_	_	O
144	with	_	_	O
145	treatment	_	_	O
146	at	_	_	O
147	the	_	_	O
148	end	_	_	O
149	of	_	_	O
150	the	_	_	O
151	phase	_	_	O
152	.	_	_	O

153	Of	_	_	O
154	the	_	_	O
155	246	_	_	O
156	patients	_	_	O
157	in	_	_	O
158	the	_	_	O
159	intent-to-treat	_	_	O
160	set	_	_	O
161	,	_	_	O
162	89Â·4	_	_	O
163	%	_	_	O
164	completed	_	_	O
165	the	_	_	O
166	3-day	_	_	O
167	efficacy	_	_	O
168	phase	_	_	O
169	.	_	_	O

170	PIDs	_	_	B-Premise
171	were	_	_	I-Premise
172	0Â·9	_	_	I-Premise
173	and	_	_	I-Premise
174	0Â·3	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	oxycodone/paracetamol	_	_	I-Premise
178	and	_	_	I-Premise
179	placebo	_	_	I-Premise
180	groups	_	_	I-Premise
181	respectively	_	_	I-Premise
182	,	_	_	I-Premise
183	on	_	_	I-Premise
184	day	_	_	I-Premise
185	1	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0Â·001	_	_	I-Premise
190	)	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	1Â·5	_	_	I-Premise
194	and	_	_	I-Premise
195	0Â·3	_	_	I-Premise
196	respectively	_	_	I-Premise
197	on	_	_	I-Premise
198	day	_	_	I-Premise
199	3	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0Â·001	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Thirty-eight	_	_	B-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	treatment	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	58	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	placebo	_	_	I-Premise
218	group	_	_	I-Premise
219	,	_	_	I-Premise
220	suffered	_	_	I-Premise
221	breakthrough	_	_	I-Premise
222	pain	_	_	I-Premise
223	on	_	_	I-Premise
224	day	_	_	I-Premise
225	3	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0Â·001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	SF-6D	_	_	I-Premise
234	score	_	_	I-Premise
235	decreased	_	_	I-Premise
236	to	_	_	I-Premise
237	21Â·2	_	_	I-Premise
238	Â±	_	_	I-Premise
239	2Â·5	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	oxycodone/paracetamol	_	_	I-Premise
243	group	_	_	I-Premise
244	at	_	_	I-Premise
245	the	_	_	I-Premise
246	end	_	_	I-Premise
247	of	_	_	I-Premise
248	the	_	_	I-Premise
249	phase	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0Â·001	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	the	_	_	I-Premise
258	oxycodone/paracetamol	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	67	_	_	I-Premise
262	%	_	_	I-Premise
263	rated	_	_	I-Premise
264	GI	_	_	I-Premise
265	as	_	_	I-Premise
266	good	_	_	I-Premise
267	,	_	_	I-Premise
268	very	_	_	I-Premise
269	good	_	_	I-Premise
270	,	_	_	I-Premise
271	or	_	_	I-Premise
272	excellent	_	_	I-Premise
273	.	_	_	I-Premise

274	Patients	_	_	B-Claim
275	with	_	_	I-Claim
276	bone-cancer	_	_	I-Claim
277	pain	_	_	I-Claim
278	,	_	_	I-Claim
279	already	_	_	I-Claim
280	on	_	_	I-Claim
281	opioids	_	_	I-Claim
282	,	_	_	I-Claim
283	obtain	_	_	I-Claim
284	clinically	_	_	I-Claim
285	important	_	_	I-Claim
286	,	_	_	I-Claim
287	additional	_	_	I-Claim
288	pain-control	_	_	I-Claim
289	,	_	_	I-Claim
290	with	_	_	I-Claim
291	regular	_	_	I-Claim
292	oxycodone/paracetamol	_	_	I-Claim
293	dosing	_	_	I-Claim
294	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	seated	_	_	O
7	exercise	_	_	O
8	program	_	_	O
9	on	_	_	O
10	fatigue	_	_	O
11	and	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	QOL	_	_	O
17	)	_	_	O
18	in	_	_	O
19	women	_	_	O
20	with	_	_	O
21	metastatic	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	controlled	_	_	O
28	,	_	_	O
29	longitudinal	_	_	O
30	trial	_	_	O
31	.	_	_	O

32	Outpatient	_	_	O
33	clinic	_	_	O
34	of	_	_	O
35	a	_	_	O
36	comprehensive	_	_	O
37	cancer	_	_	O
38	center	_	_	O
39	.	_	_	O

40	Convenience	_	_	O
41	sample	_	_	O
42	of	_	_	O
43	38	_	_	O
44	women	_	_	O
45	who	_	_	O
46	were	_	_	O
47	beginning	_	_	O
48	outpatient	_	_	O
49	chemotherapy	_	_	O
50	.	_	_	O

51	Subjects	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	a	_	_	O
56	control	_	_	O
57	or	_	_	O
58	intervention	_	_	O
59	group	_	_	O
60	;	_	_	O
61	the	_	_	O
62	intervention	_	_	O
63	was	_	_	O
64	performance	_	_	O
65	of	_	_	O
66	a	_	_	O
67	seated	_	_	O
68	exercise	_	_	O
69	program	_	_	O
70	using	_	_	O
71	home	_	_	O
72	videotape	_	_	O
73	three	_	_	O
74	times	_	_	O
75	per	_	_	O
76	week	_	_	O
77	for	_	_	O
78	four	_	_	O
79	cycles	_	_	O
80	of	_	_	O
81	chemotherapy	_	_	O
82	.	_	_	O

83	All	_	_	O
84	subjects	_	_	O
85	completed	_	_	O
86	the	_	_	O
87	Functional	_	_	O
88	Assessment	_	_	O
89	of	_	_	O
90	Chronic	_	_	O
91	Illness	_	_	O
92	Therapy	_	_	O
93	Fatigue	_	_	O
94	Version	_	_	O
95	IV	_	_	O
96	(	_	_	O
97	FACIT	_	_	O
98	F	_	_	O
99	)	_	_	O
100	at	_	_	O
101	baseline	_	_	O
102	and	_	_	O
103	at	_	_	O
104	the	_	_	O
105	time	_	_	O
106	of	_	_	O
107	the	_	_	O
108	next	_	_	O
109	three	_	_	O
110	cycles	_	_	O
111	.	_	_	O

112	Subjects	_	_	O
113	were	_	_	O
114	asked	_	_	O
115	to	_	_	O
116	document	_	_	O
117	the	_	_	O
118	frequency	_	_	O
119	,	_	_	O
120	duration	_	_	O
121	,	_	_	O
122	and	_	_	O
123	intensity	_	_	O
124	of	_	_	O
125	all	_	_	O
126	exercise	_	_	O
127	participation	_	_	O
128	on	_	_	O
129	monthly	_	_	O
130	calendars	_	_	O
131	.	_	_	O

132	Exercise	_	_	O
133	,	_	_	O
134	fatigue	_	_	O
135	,	_	_	O
136	and	_	_	O
137	QOL	_	_	O
138	.	_	_	O

139	32	_	_	O
140	subjects	_	_	O
141	,	_	_	O
142	16	_	_	O
143	per	_	_	O
144	group	_	_	O
145	,	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	study	_	_	O
149	follow-up	_	_	O
150	.	_	_	O

151	With	_	_	B-Premise
152	a	_	_	I-Premise
153	mixed	_	_	I-Premise
154	modeling	_	_	I-Premise
155	approach	_	_	I-Premise
156	,	_	_	I-Premise
157	total	_	_	I-Premise
158	FACIT	_	_	I-Premise
159	F	_	_	I-Premise
160	scores	_	_	I-Premise
161	for	_	_	I-Premise
162	the	_	_	I-Premise
163	entire	_	_	I-Premise
164	sample	_	_	I-Premise
165	declined	_	_	I-Premise
166	at	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	rate	_	_	I-Premise
170	(	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.003	_	_	I-Premise
174	)	_	_	I-Premise
175	beginning	_	_	I-Premise
176	with	_	_	I-Premise
177	cycle	_	_	I-Premise
178	3	_	_	I-Premise
179	but	_	_	B-Premise
180	at	_	_	I-Premise
181	a	_	_	I-Premise
182	slower	_	_	I-Premise
183	rate	_	_	I-Premise
184	for	_	_	I-Premise
185	the	_	_	I-Premise
186	experimental	_	_	I-Premise
187	group	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.02	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Fatigue	_	_	B-Premise
195	scores	_	_	I-Premise
196	indicated	_	_	I-Premise
197	less	_	_	I-Premise
198	increase	_	_	I-Premise
199	and	_	_	I-Premise
200	physical	_	_	I-Premise
201	well-being	_	_	I-Premise
202	subscale	_	_	I-Premise
203	scores	_	_	I-Premise
204	showed	_	_	I-Premise
205	less	_	_	I-Premise
206	decline	_	_	I-Premise
207	for	_	_	I-Premise
208	the	_	_	I-Premise
209	experimental	_	_	I-Premise
210	group	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.008	_	_	I-Premise
215	and	_	_	I-Premise
216	p	_	_	I-Premise
217	=	_	_	I-Premise
218	0.02	_	_	I-Premise
219	,	_	_	I-Premise
220	respectively	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	Women	_	_	B-Premise
224	with	_	_	I-Premise
225	advanced	_	_	I-Premise
226	breast	_	_	I-Premise
227	cancer	_	_	I-Premise
228	randomized	_	_	I-Premise
229	to	_	_	I-Premise
230	the	_	_	I-Premise
231	seated	_	_	I-Premise
232	exercise	_	_	I-Premise
233	intervention	_	_	I-Premise
234	had	_	_	I-Premise
235	a	_	_	I-Premise
236	slower	_	_	I-Premise
237	decline	_	_	I-Premise
238	in	_	_	I-Premise
239	total	_	_	I-Premise
240	and	_	_	I-Premise
241	physical	_	_	I-Premise
242	well-being	_	_	I-Premise
243	and	_	_	I-Premise
244	less	_	_	I-Premise
245	increase	_	_	I-Premise
246	in	_	_	I-Premise
247	fatigue	_	_	I-Premise
248	scores	_	_	I-Premise
249	starting	_	_	I-Premise
250	with	_	_	I-Premise
251	the	_	_	I-Premise
252	third	_	_	I-Premise
253	cycle	_	_	I-Premise
254	of	_	_	I-Premise
255	chemotherapy	_	_	I-Premise
256	.	_	_	I-Premise

257	Seated	_	_	B-Claim
258	exercise	_	_	I-Claim
259	may	_	_	I-Claim
260	be	_	_	I-Claim
261	a	_	_	I-Claim
262	feasible	_	_	I-Claim
263	exercise	_	_	I-Claim
264	program	_	_	I-Claim
265	for	_	_	I-Claim
266	women	_	_	I-Claim
267	with	_	_	I-Claim
268	advanced	_	_	I-Claim
269	cancer	_	_	I-Claim
270	for	_	_	I-Claim
271	controlling	_	_	I-Claim
272	fatigue	_	_	I-Claim
273	and	_	_	I-Claim
274	improving	_	_	I-Claim
275	physical	_	_	I-Claim
276	well-being	_	_	I-Claim
277	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	programs	_	_	O
3	assist	_	_	O
4	patients	_	_	O
5	and	_	_	O
6	their	_	_	O
7	family	_	_	O
8	caregivers	_	_	O
9	to	_	_	O
10	manage	_	_	O
11	advanced	_	_	O
12	cancer	_	_	O
13	and	_	_	O
14	maintain	_	_	O
15	their	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QOL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	This	_	_	O
24	study	_	_	O
25	examined	_	_	O
26	(	_	_	O
27	i	_	_	O
28	)	_	_	O
29	whether	_	_	O
30	patient-caregiver	_	_	O
31	dyads	_	_	O
32	(	_	_	O
33	i.e.	_	_	O
34	,	_	_	O
35	pairs	_	_	O
36	)	_	_	O
37	randomly	_	_	O
38	assigned	_	_	O
39	to	_	_	O
40	a	_	_	O
41	brief	_	_	O
42	or	_	_	O
43	extensive	_	_	O
44	dyadic	_	_	O
45	intervention	_	_	O
46	(	_	_	O
47	the	_	_	O
48	FOCUS	_	_	O
49	Program	_	_	O
50	)	_	_	O
51	had	_	_	O
52	better	_	_	O
53	outcomes	_	_	O
54	than	_	_	O
55	dyads	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	to	_	_	O
59	usual	_	_	O
60	care	_	_	O
61	and	_	_	O
62	(	_	_	O
63	ii	_	_	O
64	)	_	_	O
65	whether	_	_	O
66	patients	_	_	O
67	'	_	_	O
68	risk	_	_	O
69	for	_	_	O
70	distress	_	_	O
71	and	_	_	O
72	other	_	_	O
73	factors	_	_	O
74	moderated	_	_	O
75	the	_	_	O
76	effect	_	_	O
77	of	_	_	O
78	the	_	_	O
79	brief	_	_	O
80	or	_	_	O
81	extensive	_	_	O
82	program	_	_	O
83	on	_	_	O
84	outcomes	_	_	O
85	.	_	_	O

86	Advanced	_	_	O
87	cancer	_	_	O
88	patients	_	_	O
89	and	_	_	O
90	their	_	_	O
91	caregivers	_	_	O
92	(	_	_	O
93	N	_	_	O
94	=	_	_	O
95	484	_	_	O
96	dyads	_	_	O
97	)	_	_	O
98	were	_	_	O
99	stratified	_	_	O
100	by	_	_	O
101	patients	_	_	O
102	'	_	_	O
103	baseline	_	_	O
104	risk	_	_	O
105	for	_	_	O
106	distress	_	_	O
107	(	_	_	O
108	high	_	_	O
109	versus	_	_	O
110	low	_	_	O
111	)	_	_	O
112	,	_	_	O
113	cancer	_	_	O
114	type	_	_	O
115	(	_	_	O
116	lung	_	_	O
117	,	_	_	O
118	colorectal	_	_	O
119	,	_	_	O
120	breast	_	_	O
121	,	_	_	O
122	or	_	_	O
123	prostate	_	_	O
124	)	_	_	O
125	,	_	_	O
126	and	_	_	O
127	research	_	_	O
128	site	_	_	O
129	and	_	_	O
130	then	_	_	O
131	randomly	_	_	O
132	assigned	_	_	O
133	to	_	_	O
134	a	_	_	O
135	brief	_	_	O
136	(	_	_	O
137	three-session	_	_	O
138	)	_	_	O
139	or	_	_	O
140	extensive	_	_	O
141	(	_	_	O
142	six-session	_	_	O
143	)	_	_	O
144	intervention	_	_	O
145	or	_	_	O
146	control	_	_	O
147	.	_	_	O

148	The	_	_	O
149	interventions	_	_	O
150	offered	_	_	O
151	dyads	_	_	O
152	information	_	_	O
153	and	_	_	O
154	support	_	_	O
155	.	_	_	O

156	Intermediary	_	_	O
157	outcomes	_	_	O
158	were	_	_	O
159	appraisals	_	_	O
160	(	_	_	O
161	i.e.	_	_	O
162	,	_	_	O
163	appraisal	_	_	O
164	of	_	_	O
165	illness/caregiving	_	_	O
166	,	_	_	O
167	uncertainty	_	_	O
168	,	_	_	O
169	and	_	_	O
170	hopelessness	_	_	O
171	)	_	_	O
172	and	_	_	O
173	resources	_	_	O
174	(	_	_	O
175	i.e.	_	_	O
176	,	_	_	O
177	coping	_	_	O
178	,	_	_	O
179	interpersonal	_	_	O
180	relationships	_	_	O
181	,	_	_	O
182	and	_	_	O
183	self-efficacy	_	_	O
184	)	_	_	O
185	.	_	_	O

186	The	_	_	O
187	primary	_	_	O
188	outcome	_	_	O
189	was	_	_	O
190	QOL	_	_	O
191	.	_	_	O

192	Data	_	_	O
193	were	_	_	O
194	collected	_	_	O
195	prior	_	_	O
196	to	_	_	O
197	intervention	_	_	O
198	and	_	_	O
199	post-intervention	_	_	O
200	(	_	_	O
201	3	_	_	O
202	and	_	_	O
203	6	_	_	O
204	months	_	_	O
205	from	_	_	O
206	baseline	_	_	O
207	)	_	_	O
208	.	_	_	O

209	The	_	_	O
210	final	_	_	O
211	sample	_	_	O
212	was	_	_	O
213	302	_	_	O
214	dyads	_	_	O
215	.	_	_	O

216	Repeated	_	_	O
217	measures	_	_	O
218	MANCOVA	_	_	O
219	was	_	_	O
220	used	_	_	O
221	to	_	_	O
222	evaluate	_	_	O
223	outcomes	_	_	O
224	.	_	_	O

225	Significant	_	_	B-Premise
226	group	_	_	I-Premise
227	by	_	_	I-Premise
228	time	_	_	I-Premise
229	interactions	_	_	I-Premise
230	showed	_	_	I-Premise
231	that	_	_	I-Premise
232	there	_	_	I-Premise
233	was	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	dyads	_	_	I-Premise
238	'	_	_	I-Premise
239	coping	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	<	_	_	I-Premise
243	0.05	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	self-efficacy	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	<	_	_	I-Premise
250	0.05	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	and	_	_	I-Premise
254	social	_	_	I-Premise
255	QOL	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.01	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	in	_	_	I-Premise
263	caregivers	_	_	I-Premise
264	'	_	_	I-Premise
265	emotional	_	_	I-Premise
266	QOL	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	<	_	_	I-Premise
270	0.05	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Effects	_	_	O
274	varied	_	_	O
275	by	_	_	O
276	intervention	_	_	O
277	dose	_	_	O
278	.	_	_	O

279	Most	_	_	O
280	effects	_	_	O
281	were	_	_	O
282	found	_	_	O
283	at	_	_	O
284	3	_	_	O
285	months	_	_	O
286	only	_	_	O
287	.	_	_	O

288	Risk	_	_	B-Premise
289	for	_	_	I-Premise
290	distress	_	_	I-Premise
291	accounted	_	_	I-Premise
292	for	_	_	I-Premise
293	very	_	_	I-Premise
294	few	_	_	I-Premise
295	moderation	_	_	I-Premise
296	effects	_	_	I-Premise
297	.	_	_	I-Premise

298	Both	_	_	B-Premise
299	brief	_	_	I-Premise
300	and	_	_	I-Premise
301	extensive	_	_	I-Premise
302	programs	_	_	I-Premise
303	had	_	_	I-Premise
304	positive	_	_	I-Premise
305	outcomes	_	_	I-Premise
306	for	_	_	I-Premise
307	patient-caregiver	_	_	I-Premise
308	dyads	_	_	I-Premise
309	,	_	_	I-Premise
310	but	_	_	B-Premise
311	few	_	_	I-Premise
312	sustained	_	_	I-Premise
313	effects	_	_	I-Premise
314	.	_	_	I-Premise

315	Patient-caregiver	_	_	B-Claim
316	dyads	_	_	I-Claim
317	benefit	_	_	I-Claim
318	when	_	_	I-Claim
319	viewed	_	_	I-Claim
320	as	_	_	I-Claim
321	the	_	_	I-Claim
322	'unit	_	_	I-Claim
323	of	_	_	I-Claim
324	care	_	_	I-Claim
325	'	_	_	I-Claim
326	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	efficacy	_	_	O
5	of	_	_	O
6	Shenqi	_	_	O
7	Fuzheng	_	_	O
8	Injection	_	_	O
9	(	_	_	O
10	SFI	_	_	O
11	)	_	_	O
12	combined	_	_	O
13	with	_	_	O
14	chemotherapy	_	_	O
15	in	_	_	O
16	treating	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	advanced	_	_	O
20	breast	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	Sixty	_	_	O
24	patients	_	_	O
25	were	_	_	O
26	randomly	_	_	O
27	assigned	_	_	O
28	to	_	_	O
29	two	_	_	O
30	groups	_	_	O
31	by	_	_	O
32	digital	_	_	O
33	table	_	_	O
34	,	_	_	O
35	the	_	_	O
36	control	_	_	O
37	group	_	_	O
38	and	_	_	O
39	the	_	_	O
40	treatment	_	_	O
41	group	_	_	O
42	,	_	_	O
43	30	_	_	O
44	in	_	_	O
45	each	_	_	O
46	group	_	_	O
47	.	_	_	O

48	All	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	treated	_	_	O
52	with	_	_	O
53	the	_	_	O
54	same	_	_	O
55	CTF	_	_	O
56	regimen	_	_	O
57	of	_	_	O
58	chemotherapy	_	_	O
59	for	_	_	O
60	21	_	_	O
61	days	_	_	O
62	as	_	_	O
63	one	_	_	O
64	therapeutic	_	_	O
65	cycle	_	_	O
66	,	_	_	O
67	while	_	_	O
68	those	_	_	O
69	in	_	_	O
70	the	_	_	O
71	treatment	_	_	O
72	group	_	_	O
73	were	_	_	O
74	given	_	_	O
75	SFI	_	_	O
76	additionally	_	_	O
77	in	_	_	O
78	the	_	_	O
79	meanwhite	_	_	O
80	.	_	_	O

81	The	_	_	O
82	therapeutic	_	_	O
83	efficacy	_	_	O
84	was	_	_	O
85	evaluated	_	_	O
86	after	_	_	O
87	2	_	_	O
88	cycles	_	_	O
89	of	_	_	O
90	treatment	_	_	O
91	by	_	_	O
92	observing	_	_	O
93	the	_	_	O
94	changes	_	_	O
95	of	_	_	O
96	short-term	_	_	O
97	efficacy	_	_	O
98	,	_	_	O
99	TCM	_	_	O
100	syndrome	_	_	O
101	,	_	_	O
102	quality	_	_	O
103	of	_	_	O
104	life	_	_	O
105	and	_	_	O
106	immune	_	_	O
107	function	_	_	O
108	,	_	_	O
109	as	_	_	O
110	well	_	_	O
111	as	_	_	O
112	the	_	_	O
113	adverse	_	_	O
114	reaction	_	_	O
115	.	_	_	O

116	The	_	_	B-Premise
117	total	_	_	I-Premise
118	short-term	_	_	I-Premise
119	remission	_	_	I-Premise
120	rate	_	_	I-Premise
121	,	_	_	I-Premise
122	the	_	_	I-Premise
123	improvement	_	_	I-Premise
124	rate	_	_	I-Premise
125	of	_	_	I-Premise
126	clinical	_	_	I-Premise
127	syndrome	_	_	I-Premise
128	and	_	_	I-Premise
129	quality	_	_	I-Premise
130	of	_	_	I-Premise
131	life	_	_	I-Premise
132	was	_	_	I-Premise
133	50.0	_	_	I-Premise
134	%	_	_	I-Premise
135	,	_	_	I-Premise
136	70.0	_	_	I-Premise
137	%	_	_	I-Premise
138	and	_	_	I-Premise
139	76.7	_	_	I-Premise
140	%	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	treatment	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	43.3	_	_	I-Premise
148	%	_	_	I-Premise
149	,	_	_	I-Premise
150	46.7	_	_	I-Premise
151	%	_	_	I-Premise
152	and	_	_	I-Premise
153	50.0	_	_	I-Premise
154	%	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	control	_	_	I-Premise
158	group	_	_	I-Premise
159	,	_	_	I-Premise
160	respectively	_	_	I-Premise
161	,	_	_	I-Premise
162	showing	_	_	I-Premise
163	significant	_	_	I-Premise
164	difference	_	_	I-Premise
165	between	_	_	I-Premise
166	the	_	_	I-Premise
167	two	_	_	I-Premise
168	groups	_	_	I-Premise
169	(	_	_	I-Premise
170	all	_	_	I-Premise
171	P	_	_	I-Premise
172	<	_	_	I-Premise
173	0.05	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	The	_	_	B-Premise
177	occurrence	_	_	I-Premise
178	of	_	_	I-Premise
179	adverse	_	_	I-Premise
180	reaction	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	was	_	_	I-Premise
186	lower	_	_	I-Premise
187	than	_	_	I-Premise
188	that	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	0.05	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	level	_	_	I-Premise
201	of	_	_	I-Premise
202	CD3+	_	_	I-Premise
203	CD4+	_	_	I-Premise
204	and	_	_	I-Premise
205	CD4+/CD8+	_	_	I-Premise
206	ratio	_	_	I-Premise
207	increased	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	0.05	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	CD8+	_	_	I-Premise
215	decreased	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	treatment	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	,	_	_	I-Premise
226	while	_	_	I-Premise
227	they	_	_	I-Premise
228	showed	_	_	I-Premise
229	insignificant	_	_	I-Premise
230	change	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	.	_	_	I-Premise

236	For	_	_	B-Claim
237	treatment	_	_	I-Claim
238	of	_	_	I-Claim
239	advanced	_	_	I-Claim
240	breast	_	_	I-Claim
241	cancer	_	_	I-Claim
242	,	_	_	I-Claim
243	SFI	_	_	I-Claim
244	can	_	_	I-Claim
245	alleviate	_	_	I-Claim
246	the	_	_	I-Claim
247	bone	_	_	I-Claim
248	marrow	_	_	I-Claim
249	inhibition	_	_	I-Claim
250	caused	_	_	I-Claim
251	by	_	_	I-Claim
252	chemotherapy	_	_	I-Claim
253	,	_	_	I-Claim
254	improve	_	_	I-Claim
255	clinical	_	_	I-Claim
256	symptoms	_	_	I-Claim
257	and	_	_	I-Claim
258	quality	_	_	I-Claim
259	of	_	_	I-Claim
260	life	_	_	I-Claim
261	and	_	_	I-Claim
262	prolong	_	_	I-Claim
263	the	_	_	I-Claim
264	survival	_	_	I-Claim
265	period	_	_	I-Claim
266	by	_	_	I-Claim
267	regulating	_	_	I-Claim
268	cellular	_	_	I-Claim
269	immune	_	_	I-Claim
270	function	_	_	I-Claim
271	of	_	_	I-Claim
272	patients	_	_	I-Claim
273	,	_	_	I-Claim
274	so	_	_	I-Claim
275	as	_	_	I-Claim
276	to	_	_	I-Claim
277	enhance	_	_	I-Claim
278	the	_	_	I-Claim
279	therapeutic	_	_	I-Claim
280	effect	_	_	I-Claim
281	of	_	_	I-Claim
282	chemotherapy	_	_	I-Claim
283	.	_	_	I-Claim


0	The	_	_	O
1	American	_	_	O
2	College	_	_	O
3	of	_	_	O
4	Surgeons	_	_	O
5	Oncology	_	_	O
6	Group	_	_	O
7	phase	_	_	O
8	III	_	_	O
9	Surgical	_	_	O
10	Prostatectomy	_	_	O
11	Versus	_	_	O
12	Interstitial	_	_	O
13	Radiation	_	_	O
14	Intervention	_	_	O
15	Trial	_	_	O
16	comparing	_	_	O
17	radical	_	_	O
18	prostatectomy	_	_	O
19	(	_	_	O
20	RP	_	_	O
21	)	_	_	O
22	and	_	_	O
23	brachytherapy	_	_	O
24	(	_	_	O
25	BT	_	_	O
26	)	_	_	O
27	closed	_	_	O
28	after	_	_	O
29	2	_	_	O
30	years	_	_	O
31	due	_	_	O
32	to	_	_	O
33	poor	_	_	O
34	accrual	_	_	O
35	.	_	_	O

36	We	_	_	O
37	report	_	_	O
38	health-related	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	(	_	_	O
43	HRQOL	_	_	O
44	)	_	_	O
45	at	_	_	O
46	a	_	_	O
47	mean	_	_	O
48	of	_	_	O
49	5.3	_	_	O
50	years	_	_	O
51	for	_	_	O
52	168	_	_	O
53	trial-eligible	_	_	O
54	men	_	_	O
55	who	_	_	O
56	either	_	_	O
57	chose	_	_	O
58	or	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	RP	_	_	O
64	or	_	_	O
65	BT	_	_	O
66	following	_	_	O
67	a	_	_	O
68	multidisciplinary	_	_	O
69	educational	_	_	O
70	session	_	_	O
71	.	_	_	O

72	After	_	_	O
73	initial	_	_	O
74	lack	_	_	O
75	of	_	_	O
76	accrual	_	_	O
77	,	_	_	O
78	a	_	_	O
79	multidisciplinary	_	_	O
80	educational	_	_	O
81	session	_	_	O
82	was	_	_	O
83	introduced	_	_	O
84	for	_	_	O
85	eligible	_	_	O
86	patients	_	_	O
87	.	_	_	O

88	In	_	_	O
89	all	_	_	O
90	,	_	_	O
91	263	_	_	O
92	men	_	_	O
93	attended	_	_	O
94	47	_	_	O
95	sessions	_	_	O
96	.	_	_	O

97	Of	_	_	O
98	those	_	_	O
99	,	_	_	O
100	34	_	_	O
101	consented	_	_	O
102	to	_	_	O
103	random	_	_	O
104	assignment	_	_	O
105	,	_	_	O
106	62	_	_	O
107	chose	_	_	O
108	RP	_	_	O
109	,	_	_	O
110	and	_	_	O
111	94	_	_	O
112	chose	_	_	O
113	BT	_	_	O
114	.	_	_	O

115	Five	_	_	O
116	years	_	_	O
117	later	_	_	O
118	,	_	_	O
119	these	_	_	O
120	190	_	_	O
121	men	_	_	O
122	underwent	_	_	O
123	HRQOL	_	_	O
124	evaluation	_	_	O
125	by	_	_	O
126	using	_	_	O
127	the	_	_	O
128	cancer-specific	_	_	O
129	50-item	_	_	O
130	Expanded	_	_	O
131	Prostate	_	_	O
132	Cancer	_	_	O
133	Index	_	_	O
134	Composite	_	_	O
135	,	_	_	O
136	the	_	_	O
137	Short	_	_	O
138	Form	_	_	O
139	12	_	_	O
140	Physical	_	_	O
141	Component	_	_	O
142	Score	_	_	O
143	,	_	_	O
144	and	_	_	O
145	Short	_	_	O
146	Form	_	_	O
147	12	_	_	O
148	Mental	_	_	O
149	Component	_	_	O
150	Score	_	_	O
151	.	_	_	O

152	Response	_	_	O
153	rate	_	_	O
154	was	_	_	O
155	88.4	_	_	O
156	%	_	_	O
157	.	_	_	O

158	The	_	_	O
159	Wilcoxon	_	_	O
160	rank	_	_	O
161	sum	_	_	O
162	test	_	_	O
163	was	_	_	O
164	used	_	_	O
165	to	_	_	O
166	compare	_	_	O
167	summary	_	_	O
168	scores	_	_	O
169	between	_	_	O
170	the	_	_	O
171	two	_	_	O
172	interventions	_	_	O
173	.	_	_	O

174	Of	_	_	O
175	168	_	_	O
176	survey	_	_	O
177	responders	_	_	O
178	,	_	_	O
179	60.7	_	_	O
180	%	_	_	O
181	had	_	_	O
182	BT	_	_	O
183	(	_	_	O
184	9.5	_	_	O
185	%	_	_	O
186	randomly	_	_	O
187	assigned	_	_	O
188	)	_	_	O
189	and	_	_	O
190	39.3	_	_	O
191	%	_	_	O
192	had	_	_	O
193	RP	_	_	O
194	(	_	_	O
195	9.5	_	_	O
196	%	_	_	O
197	randomly	_	_	O
198	assigned	_	_	O
199	)	_	_	O
200	.	_	_	O

201	Median	_	_	O
202	age	_	_	O
203	was	_	_	O
204	61.4	_	_	O
205	years	_	_	O
206	for	_	_	O
207	BT	_	_	O
208	and	_	_	O
209	59.4	_	_	O
210	for	_	_	O
211	RP	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	.05	_	_	O
216	)	_	_	O
217	.	_	_	O

218	Median	_	_	O
219	follow-up	_	_	O
220	was	_	_	O
221	5.2	_	_	O
222	years	_	_	O
223	(	_	_	O
224	range	_	_	O
225	,	_	_	O
226	3.2	_	_	O
227	to	_	_	O
228	6.5	_	_	O
229	years	_	_	O
230	)	_	_	O
231	.	_	_	O

232	For	_	_	B-Premise
233	BT	_	_	I-Premise
234	versus	_	_	I-Premise
235	RP	_	_	I-Premise
236	,	_	_	I-Premise
237	there	_	_	I-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	bowel	_	_	I-Premise
243	or	_	_	I-Premise
244	hormonal	_	_	I-Premise
245	domains	_	_	I-Premise
246	,	_	_	I-Premise
247	but	_	_	O
248	men	_	_	B-Premise
249	treated	_	_	I-Premise
250	with	_	_	I-Premise
251	BT	_	_	I-Premise
252	scored	_	_	I-Premise
253	better	_	_	I-Premise
254	in	_	_	I-Premise
255	urinary	_	_	I-Premise
256	(	_	_	I-Premise
257	91.8	_	_	I-Premise
258	v	_	_	I-Premise
259	88.1	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.02	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	sexual	_	_	I-Premise
267	(	_	_	I-Premise
268	52.5	_	_	I-Premise
269	v	_	_	I-Premise
270	39.2	_	_	I-Premise
271	;	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.001	_	_	I-Premise
275	)	_	_	I-Premise
276	domains	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	in	_	_	I-Premise
280	patient	_	_	I-Premise
281	satisfaction	_	_	I-Premise
282	(	_	_	I-Premise
283	93.6	_	_	I-Premise
284	v	_	_	I-Premise
285	76.9	_	_	I-Premise
286	;	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	.001	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Although	_	_	O
293	treatment	_	_	O
294	allocation	_	_	O
295	was	_	_	O
296	random	_	_	O
297	in	_	_	O
298	only	_	_	O
299	19	_	_	O
300	%	_	_	O
301	,	_	_	O
302	all	_	_	O
303	patients	_	_	O
304	received	_	_	O
305	identical	_	_	O
306	information	_	_	O
307	in	_	_	O
308	a	_	_	O
309	multidisciplinary	_	_	O
310	setting	_	_	O
311	before	_	_	O
312	selecting	_	_	O
313	RP	_	_	O
314	,	_	_	O
315	BT	_	_	O
316	,	_	_	O
317	or	_	_	O
318	random	_	_	O
319	assignment	_	_	O
320	.	_	_	O

321	HRQOL	_	_	B-Claim
322	evaluated	_	_	I-Claim
323	3.2	_	_	I-Claim
324	to	_	_	I-Claim
325	6.5	_	_	I-Claim
326	years	_	_	I-Claim
327	after	_	_	I-Claim
328	treatment	_	_	I-Claim
329	showed	_	_	I-Claim
330	an	_	_	I-Claim
331	advantage	_	_	I-Claim
332	for	_	_	I-Claim
333	BT	_	_	I-Claim
334	in	_	_	I-Claim
335	urinary	_	_	I-Claim
336	and	_	_	I-Claim
337	sexual	_	_	I-Claim
338	domains	_	_	I-Claim
339	and	_	_	I-Claim
340	in	_	_	I-Claim
341	patient	_	_	I-Claim
342	satisfaction	_	_	I-Claim
343	.	_	_	I-Claim


0	A	_	_	O
1	multidimensional	_	_	O
2	rehabilitation	_	_	O
3	program	_	_	O
4	for	_	_	O
5	cancer	_	_	O
6	survivors	_	_	O
7	was	_	_	O
8	developed	_	_	O
9	to	_	_	O
10	overcome	_	_	O
11	cancer-related	_	_	O
12	problems	_	_	O
13	and	_	_	O
14	to	_	_	O
15	improve	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	.	_	_	O

20	The	_	_	O
21	two	_	_	O
22	purposes	_	_	O
23	of	_	_	O
24	the	_	_	O
25	study	_	_	O
26	were	_	_	O
27	to	_	_	O
28	describe	_	_	O
29	the	_	_	O
30	effectiveness	_	_	O
31	of	_	_	O
32	the	_	_	O
33	program	_	_	O
34	and	_	_	O
35	to	_	_	O
36	obtain	_	_	O
37	information	_	_	O
38	about	_	_	O
39	patient	_	_	O
40	preferences	_	_	O
41	for	_	_	O
42	multi	_	_	O
43	or	_	_	O
44	mono	_	_	O
45	dimensional	_	_	O
46	rehabilitation	_	_	O
47	programs	_	_	O
48	.	_	_	O

49	cancer	_	_	O
50	survivors	_	_	O
51	with	_	_	O
52	different	_	_	O
53	diagnoses	_	_	O
54	,	_	_	O
55	and	_	_	O
56	cancer-related	_	_	O
57	physical	_	_	O
58	and	_	_	O
59	psychosocial	_	_	O
60	problems	_	_	O
61	.	_	_	O

62	a	_	_	O
63	15-week	_	_	O
64	rehabilitation	_	_	O
65	program	_	_	O
66	including	_	_	O
67	individual	_	_	O
68	exercise	_	_	O
69	,	_	_	O
70	sports	_	_	O
71	,	_	_	O
72	psycho-education	_	_	O
73	,	_	_	O
74	and	_	_	O
75	information	_	_	O
76	.	_	_	O

77	Group-wise	_	_	O
78	randomization	_	_	O
79	was	_	_	O
80	implemented	_	_	O
81	by	_	_	O
82	assigning	_	_	O
83	one	_	_	O
84	half	_	_	O
85	of	_	_	O
86	the	_	_	O
87	patients	_	_	O
88	to	_	_	O
89	the	_	_	O
90	complete	_	_	O
91	program	_	_	O
92	while	_	_	O
93	the	_	_	O
94	other	_	_	O
95	half	_	_	O
96	were	_	_	O
97	allowed	_	_	O
98	to	_	_	O
99	choose	_	_	O
100	which	_	_	O
101	program	_	_	O
102	components	_	_	O
103	they	_	_	O
104	considered	_	_	O
105	relevant	_	_	O
106	.	_	_	O

107	Health-Related	_	_	O
108	Quality	_	_	O
109	of	_	_	O
110	Life	_	_	O
111	[	_	_	O
112	RAND-36	_	_	O
113	and	_	_	O
114	Rotterdam	_	_	O
115	Symptom	_	_	O
116	Check	_	_	O
117	List	_	_	O
118	(	_	_	O
119	RSCL	_	_	O
120	)	_	_	O
121	]	_	_	O
122	,	_	_	O
123	exercise	_	_	O
124	capacity	_	_	O
125	(	_	_	O
126	symptom	_	_	O
127	limited	_	_	O
128	bicycle	_	_	O
129	ergometry	_	_	O
130	)	_	_	O
131	,	_	_	O
132	muscle	_	_	O
133	force	_	_	O
134	(	_	_	O
135	hand-held	_	_	O
136	dynamometry	_	_	O
137	)	_	_	O
138	,	_	_	O
139	and	_	_	O
140	patient	_	_	O
141	preferences	_	_	O
142	.	_	_	O

143	Measurements	_	_	O
144	were	_	_	O
145	performed	_	_	O
146	before	_	_	O
147	(	_	_	O
148	T0	_	_	O
149	)	_	_	O
150	and	_	_	O
151	after	_	_	O
152	the	_	_	O
153	rehabilitation	_	_	O
154	program	_	_	O
155	(	_	_	O
156	T1	_	_	O
157	)	_	_	O
158	,	_	_	O
159	and	_	_	O
160	at	_	_	O
161	a	_	_	O
162	3-month	_	_	O
163	follow-up	_	_	O
164	(	_	_	O
165	T2	_	_	O
166	)	_	_	O
167	.	_	_	O

168	After	_	_	B-Premise
169	the	_	_	I-Premise
170	rehabilitation	_	_	I-Premise
171	program	_	_	I-Premise
172	,	_	_	I-Premise
173	cancer	_	_	I-Premise
174	survivors	_	_	I-Premise
175	(	_	_	I-Premise
176	n=63	_	_	I-Premise
177	)	_	_	I-Premise
178	displayed	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	improvements	_	_	I-Premise
182	on	_	_	I-Premise
183	health-related	_	_	I-Premise
184	quality	_	_	I-Premise
185	of	_	_	I-Premise
186	life	_	_	I-Premise
187	with	_	_	I-Premise
188	effect	_	_	I-Premise
189	sizes	_	_	I-Premise
190	(	_	_	I-Premise
191	ES	_	_	I-Premise
192	)	_	_	I-Premise
193	varying	_	_	I-Premise
194	from	_	_	I-Premise
195	0.38	_	_	I-Premise
196	to	_	_	I-Premise
197	0.99	_	_	I-Premise
198	(	_	_	I-Premise
199	RAND-36	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	from	_	_	I-Premise
203	-0.34	_	_	I-Premise
204	to	_	_	I-Premise
205	-0.57	_	_	I-Premise
206	(	_	_	I-Premise
207	RSCL	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	most	_	_	I-Premise
211	persistent	_	_	I-Premise
212	at	_	_	I-Premise
213	3-month	_	_	I-Premise
214	follow-up	_	_	I-Premise
215	.	_	_	I-Premise

216	Furthermore	_	_	B-Premise
217	,	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significant	_	_	I-Premise
220	improvements	_	_	I-Premise
221	in	_	_	I-Premise
222	exercise	_	_	I-Premise
223	capacity	_	_	I-Premise
224	and	_	_	I-Premise
225	muscle	_	_	I-Premise
226	force	_	_	I-Premise
227	of	_	_	I-Premise
228	upper	_	_	I-Premise
229	and	_	_	I-Premise
230	lower	_	_	I-Premise
231	extremities	_	_	I-Premise
232	were	_	_	I-Premise
233	displayed	_	_	I-Premise
234	after	_	_	I-Premise
235	rehabilitation	_	_	I-Premise
236	.	_	_	I-Premise

237	If	_	_	B-Premise
238	offered	_	_	I-Premise
239	a	_	_	I-Premise
240	choice	_	_	I-Premise
241	,	_	_	I-Premise
242	80	_	_	I-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	patients	_	_	I-Premise
247	prior	_	_	I-Premise
248	to	_	_	I-Premise
249	start	_	_	I-Premise
250	and	_	_	I-Premise
251	58	_	_	I-Premise
252	%	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	patients	_	_	I-Premise
256	after	_	_	I-Premise
257	completion	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	program	_	_	I-Premise
261	indicated	_	_	I-Premise
262	that	_	_	I-Premise
263	they	_	_	I-Premise
264	preferred	_	_	I-Premise
265	the	_	_	I-Premise
266	entire	_	_	I-Premise
267	multidimensional	_	_	I-Premise
268	program	_	_	I-Premise
269	.	_	_	I-Premise

270	A	_	_	B-Claim
271	multidimensional	_	_	I-Claim
272	rehabilitation	_	_	I-Claim
273	program	_	_	I-Claim
274	has	_	_	I-Claim
275	statistically	_	_	I-Claim
276	and	_	_	I-Claim
277	clinically	_	_	I-Claim
278	relevant	_	_	I-Claim
279	beneficial	_	_	I-Claim
280	effects	_	_	I-Claim
281	on	_	_	I-Claim
282	health-related	_	_	I-Claim
283	quality	_	_	I-Claim
284	of	_	_	I-Claim
285	life	_	_	I-Claim
286	,	_	_	I-Claim
287	exercise	_	_	I-Claim
288	capacity	_	_	I-Claim
289	,	_	_	I-Claim
290	and	_	_	I-Claim
291	muscle	_	_	I-Claim
292	force	_	_	I-Claim
293	in	_	_	I-Claim
294	cancer	_	_	I-Claim
295	patients	_	_	I-Claim
296	with	_	_	I-Claim
297	different	_	_	I-Claim
298	diagnoses	_	_	I-Claim
299	.	_	_	I-Claim

300	Furthermore	_	_	O
301	,	_	_	O
302	if	_	_	B-Claim
303	offered	_	_	I-Claim
304	the	_	_	I-Claim
305	choice	_	_	I-Claim
306	,	_	_	I-Claim
307	the	_	_	I-Claim
308	majority	_	_	I-Claim
309	of	_	_	I-Claim
310	cancer	_	_	I-Claim
311	survivors	_	_	I-Claim
312	seem	_	_	I-Claim
313	to	_	_	I-Claim
314	prefer	_	_	I-Claim
315	multidimensional	_	_	I-Claim
316	programs	_	_	I-Claim
317	to	_	_	I-Claim
318	programs	_	_	I-Claim
319	with	_	_	I-Claim
320	only	_	_	I-Claim
321	one	_	_	I-Claim
322	component	_	_	I-Claim
323	.	_	_	I-Claim


0	Surgery	_	_	O
1	and	_	_	O
2	radiotherapy	_	_	O
3	commonly	_	_	O
4	cause	_	_	O
5	adverse	_	_	O
6	musculoskeletal	_	_	O
7	problems	_	_	O
8	,	_	_	O
9	particularly	_	_	O
10	loss	_	_	O
11	of	_	_	O
12	strength	_	_	O
13	and	_	_	O
14	range	_	_	O
15	of	_	_	O
16	motion	_	_	O
17	,	_	_	O
18	in	_	_	O
19	the	_	_	O
20	upper	_	_	O
21	quadrant	_	_	O
22	of	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	Few	_	_	O
28	well-designed	_	_	O
29	studies	_	_	O
30	have	_	_	O
31	investigated	_	_	O
32	whether	_	_	O
33	these	_	_	O
34	impairments	_	_	O
35	can	_	_	O
36	be	_	_	O
37	prevented	_	_	O
38	.	_	_	O

39	Stretching	_	_	B-Claim
40	is	_	_	I-Claim
41	an	_	_	I-Claim
42	effective	_	_	I-Claim
43	technique	_	_	I-Claim
44	for	_	_	I-Claim
45	increasing	_	_	I-Claim
46	range	_	_	I-Claim
47	of	_	_	I-Claim
48	motion	_	_	I-Claim
49	,	_	_	I-Claim
50	hence	_	_	O
51	the	_	_	O
52	aim	_	_	O
53	of	_	_	O
54	this	_	_	O
55	study	_	_	O
56	was	_	_	O
57	to	_	_	O
58	investigate	_	_	O
59	whether	_	_	O
60	a	_	_	O
61	stretching	_	_	O
62	program	_	_	O
63	reduced	_	_	O
64	acute	_	_	O
65	musculoskeletal	_	_	O
66	impairments	_	_	O
67	in	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	radiotherapy	_	_	O
71	for	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	.	_	_	O

75	Sixty-four	_	_	O
76	women	_	_	O
77	were	_	_	O
78	recruited	_	_	O
79	prior	_	_	O
80	to	_	_	O
81	commencement	_	_	O
82	of	_	_	O
83	radiotherapy	_	_	O
84	following	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	surgery	_	_	O
88	.	_	_	O

89	Participants	_	_	O
90	were	_	_	O
91	randomised	_	_	O
92	to	_	_	O
93	either	_	_	O
94	a	_	_	O
95	control	_	_	O
96	or	_	_	O
97	stretch	_	_	O
98	group	_	_	O
99	.	_	_	O

100	Participants	_	_	O
101	in	_	_	O
102	both	_	_	O
103	groups	_	_	O
104	were	_	_	O
105	reviewed	_	_	O
106	by	_	_	O
107	the	_	_	O
108	physical	_	_	O
109	therapist	_	_	O
110	on	_	_	O
111	a	_	_	O
112	weekly	_	_	O
113	basis	_	_	O
114	for	_	_	O
115	approximately	_	_	O
116	6	_	_	O
117	weeks	_	_	O
118	,	_	_	O
119	and	_	_	O
120	were	_	_	O
121	given	_	_	O
122	general	_	_	O
123	information	_	_	O
124	about	_	_	O
125	skin	_	_	O
126	care	_	_	O
127	and	_	_	O
128	lymphedema	_	_	O
129	.	_	_	O

130	The	_	_	O
131	control	_	_	O
132	group	_	_	O
133	received	_	_	O
134	no	_	_	O
135	advice	_	_	O
136	about	_	_	O
137	exercise	_	_	O
138	.	_	_	O

139	The	_	_	O
140	stretch	_	_	O
141	group	_	_	O
142	received	_	_	O
143	instruction	_	_	O
144	on	_	_	O
145	low-load	_	_	O
146	,	_	_	O
147	prolonged	_	_	O
148	pectoral	_	_	O
149	stretches	_	_	O
150	,	_	_	O
151	which	_	_	O
152	were	_	_	O
153	to	_	_	O
154	be	_	_	O
155	performed	_	_	O
156	daily	_	_	O
157	and	_	_	O
158	were	_	_	O
159	checked	_	_	O
160	at	_	_	O
161	weekly	_	_	O
162	visits	_	_	O
163	.	_	_	O

164	Shoulder	_	_	O
165	range	_	_	O
166	of	_	_	O
167	motion	_	_	O
168	,	_	_	O
169	strength	_	_	O
170	,	_	_	O
171	arm	_	_	O
172	circumference	_	_	O
173	,	_	_	O
174	and	_	_	O
175	quality	_	_	O
176	of	_	_	O
177	life	_	_	O
178	measurements	_	_	O
179	were	_	_	O
180	taken	_	_	O
181	prior	_	_	O
182	to	_	_	O
183	,	_	_	O
184	and	_	_	O
185	at	_	_	O
186	completion	_	_	O
187	of	_	_	O
188	radiotherapy	_	_	O
189	,	_	_	O
190	and	_	_	O
191	at	_	_	O
192	7	_	_	O
193	months	_	_	O
194	after	_	_	O
195	radiotherapy	_	_	O
196	.	_	_	O

197	There	_	_	B-Premise
198	was	_	_	I-Premise
199	no	_	_	I-Premise
200	difference	_	_	I-Premise
201	in	_	_	I-Premise
202	any	_	_	I-Premise
203	outcome	_	_	I-Premise
204	between	_	_	I-Premise
205	groups	_	_	I-Premise
206	.	_	_	I-Premise

207	Breast	_	_	B-Premise
208	symptoms	_	_	I-Premise
209	increased	_	_	I-Premise
210	for	_	_	I-Premise
211	both	_	_	I-Premise
212	groups	_	_	I-Premise
213	during	_	_	I-Premise
214	radiotherapy	_	_	I-Premise
215	,	_	_	I-Premise
216	without	_	_	I-Premise
217	loss	_	_	I-Premise
218	of	_	_	I-Premise
219	strength	_	_	I-Premise
220	or	_	_	I-Premise
221	range	_	_	I-Premise
222	of	_	_	I-Premise
223	movement	_	_	I-Premise
224	.	_	_	I-Premise

225	The	_	_	B-Premise
226	incidence	_	_	I-Premise
227	of	_	_	I-Premise
228	lymphedema	_	_	I-Premise
229	during	_	_	I-Premise
230	the	_	_	I-Premise
231	study	_	_	I-Premise
232	was	_	_	I-Premise
233	low	_	_	I-Premise
234	for	_	_	I-Premise
235	both	_	_	I-Premise
236	groups	_	_	I-Premise
237	and	_	_	I-Premise
238	did	_	_	I-Premise
239	not	_	_	I-Premise
240	differ	_	_	I-Premise
241	between	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	pectoral	_	_	I-Premise
246	stretching	_	_	I-Premise
247	program	_	_	I-Premise
248	did	_	_	I-Premise
249	not	_	_	I-Premise
250	influence	_	_	I-Premise
251	the	_	_	I-Premise
252	outcomes	_	_	I-Premise
253	measured	_	_	I-Premise
254	because	_	_	I-Premise
255	the	_	_	I-Premise
256	symptoms	_	_	I-Premise
257	reported	_	_	I-Premise
258	by	_	_	I-Premise
259	patients	_	_	I-Premise
260	were	_	_	I-Premise
261	not	_	_	I-Premise
262	a	_	_	I-Premise
263	consequence	_	_	I-Premise
264	of	_	_	I-Premise
265	contracture	_	_	I-Premise
266	.	_	_	I-Premise


0	Postoperative	_	_	B-Claim
1	outcomes	_	_	I-Claim
2	of	_	_	I-Claim
3	patients	_	_	I-Claim
4	undergoing	_	_	I-Claim
5	laparoscopic-assisted	_	_	I-Claim
6	colectomy	_	_	I-Claim
7	(	_	_	I-Claim
8	LAC	_	_	I-Claim
9	)	_	_	I-Claim
10	have	_	_	I-Claim
11	shown	_	_	I-Claim
12	modest	_	_	I-Claim
13	improvements	_	_	I-Claim
14	in	_	_	I-Claim
15	recovery	_	_	I-Claim
16	but	_	_	I-Claim
17	only	_	_	I-Claim
18	minimal	_	_	I-Claim
19	differences	_	_	I-Claim
20	in	_	_	I-Claim
21	quality	_	_	I-Claim
22	of	_	_	I-Claim
23	life	_	_	I-Claim
24	(	_	_	I-Claim
25	QOL	_	_	I-Claim
26	)	_	_	I-Claim
27	compared	_	_	I-Claim
28	with	_	_	I-Claim
29	open	_	_	I-Claim
30	colectomy	_	_	I-Claim
31	.	_	_	I-Claim

32	We	_	_	O
33	therefore	_	_	O
34	sought	_	_	O
35	to	_	_	O
36	assess	_	_	O
37	the	_	_	O
38	effect	_	_	O
39	of	_	_	O
40	LAC	_	_	O
41	on	_	_	O
42	QOL	_	_	O
43	in	_	_	O
44	the	_	_	O
45	short	_	_	O
46	and	_	_	O
47	long	_	_	O
48	term	_	_	O
49	,	_	_	O
50	using	_	_	O
51	individual	_	_	O
52	item	_	_	O
53	analysis	_	_	O
54	of	_	_	O
55	multi-item	_	_	O
56	QOL	_	_	O
57	assessments	_	_	O
58	.	_	_	O

59	QOL	_	_	O
60	variables	_	_	O
61	were	_	_	O
62	analyzed	_	_	O
63	in	_	_	O
64	449	_	_	O
65	randomized	_	_	O
66	patients	_	_	O
67	from	_	_	O
68	the	_	_	O
69	COST	_	_	O
70	trial	_	_	O
71	93-46-53	_	_	O
72	(	_	_	O
73	INT	_	_	O
74	0146	_	_	O
75	)	_	_	O
76	.	_	_	O

77	Both	_	_	O
78	cross-sectional	_	_	O
79	single-time	_	_	O
80	and	_	_	O
81	change	_	_	O
82	from	_	_	O
83	baseline	_	_	O
84	assessments	_	_	O
85	were	_	_	O
86	run	_	_	O
87	at	_	_	O
88	day	_	_	O
89	2	_	_	O
90	,	_	_	O
91	week	_	_	O
92	2	_	_	O
93	,	_	_	O
94	month	_	_	O
95	2	_	_	O
96	,	_	_	O
97	and	_	_	O
98	month	_	_	O
99	18	_	_	O
100	postoperatively	_	_	O
101	in	_	_	O
102	an	_	_	O
103	intention-to-treat	_	_	O
104	analysis	_	_	O
105	using	_	_	O
106	Wilcoxon	_	_	O
107	rank-sum	_	_	O
108	tests	_	_	O
109	.	_	_	O

110	Stepwise	_	_	O
111	regression	_	_	O
112	models	_	_	O
113	were	_	_	O
114	used	_	_	O
115	to	_	_	O
116	determine	_	_	O
117	predictors	_	_	O
118	of	_	_	O
119	QOL	_	_	O
120	.	_	_	O

121	Of	_	_	O
122	449	_	_	O
123	colon	_	_	O
124	cancer	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	230	_	_	O
128	underwent	_	_	O
129	LAC	_	_	O
130	and	_	_	O
131	219	_	_	O
132	underwent	_	_	O
133	open	_	_	O
134	colectomy	_	_	O
135	.	_	_	O

136	Subdomain	_	_	B-Premise
137	analysis	_	_	I-Premise
138	revealed	_	_	I-Premise
139	a	_	_	I-Premise
140	clinically	_	_	I-Premise
141	moderate	_	_	I-Premise
142	improvement	_	_	I-Premise
143	from	_	_	I-Premise
144	baseline	_	_	I-Premise
145	for	_	_	I-Premise
146	LAC	_	_	I-Premise
147	in	_	_	I-Premise
148	total	_	_	I-Premise
149	QOL	_	_	I-Premise
150	index	_	_	I-Premise
151	at	_	_	I-Premise
152	18	_	_	I-Premise
153	months	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.02	_	_	I-Premise
158	)	_	_	I-Premise
159	as	_	_	I-Premise
160	well	_	_	I-Premise
161	as	_	_	I-Premise
162	other	_	_	I-Premise
163	small	_	_	I-Premise
164	symptomatic	_	_	I-Premise
165	improvements	_	_	I-Premise
166	.	_	_	I-Premise

167	Poor	_	_	O
168	preoperative	_	_	O
169	QOL	_	_	O
170	as	_	_	O
171	indicated	_	_	O
172	by	_	_	O
173	a	_	_	O
174	rating	_	_	O
175	scale	_	_	O
176	of	_	_	O
177	â‰¤	_	_	O
178	50	_	_	O
179	was	_	_	O
180	an	_	_	O
181	independent	_	_	O
182	predictor	_	_	O
183	of	_	_	O
184	poor	_	_	O
185	QOL	_	_	O
186	at	_	_	O
187	2	_	_	O
188	months	_	_	O
189	postoperatively	_	_	O
190	.	_	_	O

191	QOL	_	_	O
192	variables	_	_	O
193	related	_	_	O
194	to	_	_	O
195	survival	_	_	O
196	were	_	_	O
197	baseline	_	_	O
198	support	_	_	O
199	(	_	_	O
200	P	_	_	O
201	=	_	_	O
202	0.001	_	_	O
203	)	_	_	O
204	and	_	_	O
205	baseline	_	_	O
206	outlook	_	_	O
207	(	_	_	O
208	P	_	_	O
209	=	_	_	O
210	0.01	_	_	O
211	)	_	_	O
212	.	_	_	O

213	Eighteen	_	_	B-Premise
214	months	_	_	I-Premise
215	after	_	_	I-Premise
216	surgery	_	_	I-Premise
217	,	_	_	I-Premise
218	any	_	_	I-Premise
219	differences	_	_	I-Premise
220	in	_	_	I-Premise
221	quality	_	_	I-Premise
222	of	_	_	I-Premise
223	life	_	_	I-Premise
224	between	_	_	I-Premise
225	patients	_	_	I-Premise
226	randomized	_	_	I-Premise
227	to	_	_	I-Premise
228	LAC	_	_	I-Premise
229	or	_	_	I-Premise
230	open	_	_	I-Premise
231	colectomy	_	_	I-Premise
232	favored	_	_	I-Premise
233	LAC	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	B-Premise
236	,	_	_	I-Premise
237	the	_	_	I-Premise
238	magnitude	_	_	I-Premise
239	of	_	_	I-Premise
240	the	_	_	I-Premise
241	benefits	_	_	I-Premise
242	was	_	_	I-Premise
243	small	_	_	I-Premise
244	.	_	_	I-Premise

245	Patients	_	_	B-Claim
246	with	_	_	I-Claim
247	poor	_	_	I-Claim
248	preoperative	_	_	I-Claim
249	QOL	_	_	I-Claim
250	appear	_	_	I-Claim
251	to	_	_	I-Claim
252	be	_	_	I-Claim
253	at	_	_	I-Claim
254	higher	_	_	I-Claim
255	risk	_	_	I-Claim
256	for	_	_	I-Claim
257	difficult	_	_	I-Claim
258	postoperative	_	_	I-Claim
259	courses	_	_	I-Claim
260	,	_	_	I-Claim
261	and	_	_	I-Claim
262	may	_	_	I-Claim
263	be	_	_	I-Claim
264	candidates	_	_	I-Claim
265	for	_	_	I-Claim
266	enhanced	_	_	I-Claim
267	ancillary	_	_	I-Claim
268	services	_	_	I-Claim
269	to	_	_	I-Claim
270	address	_	_	I-Claim
271	their	_	_	I-Claim
272	particular	_	_	I-Claim
273	needs	_	_	I-Claim
274	.	_	_	I-Claim


0	The	_	_	O
1	goal	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	neuronavigation	_	_	O
12	on	_	_	O
13	the	_	_	O
14	cytoreductive	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	solitary	_	_	O
18	contrast-enhancing	_	_	O
19	intracerebral	_	_	O
20	tumors	_	_	O
21	and	_	_	O
22	outcomes	_	_	O
23	of	_	_	O
24	this	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	cases	_	_	O
28	in	_	_	O
29	which	_	_	O
30	neuronavigation	_	_	O
31	was	_	_	O
32	preoperatively	_	_	O
33	judged	_	_	O
34	to	_	_	O
35	be	_	_	O
36	redundant	_	_	O
37	.	_	_	O

38	The	_	_	O
39	authors	_	_	O
40	conducted	_	_	O
41	a	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	study	_	_	O
45	in	_	_	O
46	which	_	_	O
47	45	_	_	O
48	patients	_	_	O
49	,	_	_	O
50	each	_	_	O
51	harboring	_	_	O
52	a	_	_	O
53	solitary	_	_	O
54	contrast-enhancing	_	_	O
55	intracerebral	_	_	O
56	tumor	_	_	O
57	,	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	for	_	_	O
61	surgery	_	_	O
62	with	_	_	O
63	or	_	_	O
64	without	_	_	O
65	neuronavigation	_	_	O
66	.	_	_	O

67	Peri-	_	_	O
68	and	_	_	O
69	postoperative	_	_	O
70	parameters	_	_	O
71	under	_	_	O
72	investigation	_	_	O
73	included	_	_	O
74	the	_	_	O
75	following	_	_	O
76	:	_	_	O
77	duration	_	_	O
78	of	_	_	O
79	the	_	_	O
80	procedure	_	_	O
81	;	_	_	O
82	surgeon	_	_	O
83	's	_	_	O
84	estimate	_	_	O
85	of	_	_	O
86	the	_	_	O
87	usefulness	_	_	O
88	of	_	_	O
89	neuronavigation	_	_	O
90	;	_	_	O
91	quantification	_	_	O
92	of	_	_	O
93	the	_	_	O
94	extent	_	_	O
95	of	_	_	O
96	resection	_	_	O
97	,	_	_	O
98	determined	_	_	O
99	using	_	_	O
100	magnetic	_	_	O
101	resonance	_	_	O
102	imaging	_	_	O
103	;	_	_	O
104	and	_	_	O
105	the	_	_	O
106	postoperative	_	_	O
107	course	_	_	O
108	,	_	_	O
109	as	_	_	O
110	evaluated	_	_	O
111	by	_	_	O
112	neurological	_	_	O
113	examinations	_	_	O
114	,	_	_	O
115	the	_	_	O
116	patient	_	_	O
117	's	_	_	O
118	quality-of-life	_	_	O
119	self-assessment	_	_	O
120	,	_	_	O
121	application	_	_	O
122	of	_	_	O
123	the	_	_	O
124	Barthel	_	_	O
125	index	_	_	O
126	and	_	_	O
127	the	_	_	O
128	Karnofsky	_	_	O
129	Performance	_	_	O
130	Scale	_	_	O
131	score	_	_	O
132	,	_	_	O
133	and	_	_	O
134	the	_	_	O
135	patient	_	_	O
136	's	_	_	O
137	time	_	_	O
138	of	_	_	O
139	death	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	mean	_	_	I-Premise
143	amount	_	_	I-Premise
144	of	_	_	I-Premise
145	residual	_	_	I-Premise
146	tumor	_	_	I-Premise
147	tissue	_	_	I-Premise
148	was	_	_	I-Premise
149	28.9	_	_	I-Premise
150	%	_	_	I-Premise
151	for	_	_	I-Premise
152	standard	_	_	I-Premise
153	surgery	_	_	I-Premise
154	(	_	_	I-Premise
155	SS	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	13.8	_	_	I-Premise
159	%	_	_	I-Premise
160	for	_	_	I-Premise
161	surgery	_	_	I-Premise
162	involving	_	_	I-Premise
163	neuronavigation	_	_	I-Premise
164	(	_	_	I-Premise
165	SN	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	The	_	_	B-Premise
169	corresponding	_	_	I-Premise
170	mean	_	_	I-Premise
171	amounts	_	_	I-Premise
172	of	_	_	I-Premise
173	residual	_	_	I-Premise
174	contrast-enhancing	_	_	I-Premise
175	tumor	_	_	I-Premise
176	tissue	_	_	I-Premise
177	were	_	_	I-Premise
178	29.2	_	_	I-Premise
179	and	_	_	I-Premise
180	24.4	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	.	_	_	I-Premise

185	These	_	_	B-Premise
186	differences	_	_	I-Premise
187	were	_	_	I-Premise
188	not	_	_	I-Premise
189	significant	_	_	I-Premise
190	.	_	_	I-Premise

191	Gross-total	_	_	B-Premise
192	removal	_	_	I-Premise
193	(	_	_	I-Premise
194	GTR	_	_	I-Premise
195	)	_	_	I-Premise
196	was	_	_	I-Premise
197	achieved	_	_	I-Premise
198	in	_	_	I-Premise
199	five	_	_	I-Premise
200	patients	_	_	I-Premise
201	who	_	_	I-Premise
202	underwent	_	_	I-Premise
203	SS	_	_	I-Premise
204	and	_	_	I-Premise
205	in	_	_	I-Premise
206	three	_	_	I-Premise
207	who	_	_	I-Premise
208	underwent	_	_	I-Premise
209	SN	_	_	I-Premise
210	.	_	_	I-Premise

211	Median	_	_	B-Premise
212	survival	_	_	I-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	shorter	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	SN	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	5.6	_	_	I-Premise
222	months	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	9	_	_	I-Premise
226	months	_	_	I-Premise
227	,	_	_	I-Premise
228	unadjusted	_	_	I-Premise
229	hazard	_	_	I-Premise
230	ratio	_	_	I-Premise
231	=	_	_	I-Premise
232	1.6	_	_	I-Premise
233	)	_	_	I-Premise
234	;	_	_	I-Premise
235	however	_	_	B-Premise
236	,	_	_	I-Premise
237	this	_	_	I-Premise
238	difference	_	_	I-Premise
239	may	_	_	I-Premise
240	be	_	_	I-Premise
241	attributable	_	_	I-Premise
242	to	_	_	I-Premise
243	the	_	_	I-Premise
244	coincidental	_	_	I-Premise
245	early	_	_	I-Premise
246	death	_	_	I-Premise
247	of	_	_	I-Premise
248	three	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	SN	_	_	I-Premise
253	group	_	_	I-Premise
254	.	_	_	I-Premise

255	No	_	_	B-Premise
256	discernible	_	_	I-Premise
257	important	_	_	I-Premise
258	effect	_	_	I-Premise
259	on	_	_	I-Premise
260	the	_	_	I-Premise
261	patients	_	_	I-Premise
262	'	_	_	I-Premise
263	3-month	_	_	I-Premise
264	postoperative	_	_	I-Premise
265	course	_	_	I-Premise
266	was	_	_	I-Premise
267	identified	_	_	I-Premise
268	.	_	_	I-Premise

269	There	_	_	B-Claim
270	is	_	_	I-Claim
271	no	_	_	I-Claim
272	rationale	_	_	I-Claim
273	for	_	_	I-Claim
274	the	_	_	I-Claim
275	routine	_	_	I-Claim
276	use	_	_	I-Claim
277	of	_	_	I-Claim
278	neuronavigation	_	_	I-Claim
279	to	_	_	I-Claim
280	improve	_	_	I-Claim
281	the	_	_	I-Claim
282	extent	_	_	I-Claim
283	of	_	_	I-Claim
284	tumor	_	_	I-Claim
285	resection	_	_	I-Claim
286	and	_	_	I-Claim
287	prognosis	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	harboring	_	_	I-Claim
291	a	_	_	I-Claim
292	solitary	_	_	I-Claim
293	enhancing	_	_	I-Claim
294	intracerebral	_	_	I-Claim
295	lesion	_	_	I-Claim
296	when	_	_	I-Claim
297	neuronavigation	_	_	I-Claim
298	is	_	_	I-Claim
299	not	_	_	I-Claim
300	already	_	_	I-Claim
301	deemed	_	_	I-Claim
302	advantageous	_	_	I-Claim
303	because	_	_	I-Claim
304	of	_	_	I-Claim
305	the	_	_	I-Claim
306	size	_	_	I-Claim
307	or	_	_	I-Claim
308	location	_	_	I-Claim
309	of	_	_	I-Claim
310	the	_	_	I-Claim
311	lesion	_	_	I-Claim
312	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	ability	_	_	O
4	of	_	_	O
5	the	_	_	O
6	cytoprotectant	_	_	O
7	,	_	_	O
8	amifostine	_	_	O
9	,	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	chemoradiotherapy-induced	_	_	O
13	esophagitis	_	_	O
14	and	_	_	O
15	evaluate	_	_	O
16	its	_	_	O
17	influence	_	_	O
18	on	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	and	_	_	O
26	swallowing	_	_	O
27	symptoms	_	_	O
28	.	_	_	O

29	A	_	_	O
30	total	_	_	O
31	of	_	_	O
32	243	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	stage	_	_	O
36	II	_	_	O
37	to	_	_	O
38	IIIA/B	_	_	O
39	non-small-cell	_	_	O
40	lung	_	_	O
41	cancer	_	_	O
42	received	_	_	O
43	induction	_	_	O
44	paclitaxel	_	_	O
45	225	_	_	O
46	mg/m	_	_	O
47	(	_	_	O
48	2	_	_	O
49	)	_	_	O
50	intravenously	_	_	O
51	(	_	_	O
52	IV	_	_	O
53	)	_	_	O
54	days	_	_	O
55	1	_	_	O
56	and	_	_	O
57	22	_	_	O
58	and	_	_	O
59	carboplatin	_	_	O
60	area	_	_	O
61	under	_	_	O
62	the	_	_	O
63	curve	_	_	O
64	(	_	_	O
65	AUC	_	_	O
66	)	_	_	O
67	days	_	_	O
68	1	_	_	O
69	and	_	_	O
70	22	_	_	O
71	,	_	_	O
72	followed	_	_	O
73	by	_	_	O
74	concurrent	_	_	O
75	weekly	_	_	O
76	paclitaxel	_	_	O
77	(	_	_	O
78	50	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	IV	_	_	O
84	)	_	_	O
85	and	_	_	O
86	carboplatin	_	_	O
87	(	_	_	O
88	AUC	_	_	O
89	2	_	_	O
90	)	_	_	O
91	,	_	_	O
92	and	_	_	O
93	hyperfractionated	_	_	O
94	radiation	_	_	O
95	therapy	_	_	O
96	(	_	_	O
97	69.6	_	_	O
98	Gy	_	_	O
99	at	_	_	O
100	1.2	_	_	O
101	Gy	_	_	O
102	bid	_	_	O
103	)	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	were	_	_	O
107	randomly	_	_	O
108	assigned	_	_	O
109	at	_	_	O
110	registration	_	_	O
111	to	_	_	O
112	amifostine	_	_	O
113	(	_	_	O
114	AM	_	_	O
115	)	_	_	O
116	500	_	_	O
117	mg	_	_	O
118	IV	_	_	O
119	four	_	_	O
120	times	_	_	O
121	per	_	_	O
122	week	_	_	O
123	or	_	_	O
124	no	_	_	O
125	AM	_	_	O
126	during	_	_	O
127	chemoradiotherapy	_	_	O
128	.	_	_	O

129	Beyond	_	_	O
130	standard	_	_	O
131	toxicity	_	_	O
132	end	_	_	O
133	points	_	_	O
134	,	_	_	O
135	physician	_	_	O
136	dysphagia	_	_	O
137	logs	_	_	O
138	(	_	_	O
139	PDLs	_	_	O
140	)	_	_	O
141	,	_	_	O
142	daily	_	_	O
143	patient	_	_	O
144	swallowing	_	_	O
145	diaries	_	_	O
146	,	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	(	_	_	O
150	EORTC	_	_	O
151	QLQ-C30/LC-13	_	_	O
152	)	_	_	O
153	were	_	_	O
154	also	_	_	O
155	collected	_	_	O
156	.	_	_	O

157	Swallowing	_	_	O
158	AUC	_	_	O
159	analyses	_	_	O
160	were	_	_	O
161	calculated	_	_	O
162	from	_	_	O
163	patient	_	_	O
164	diaries	_	_	O
165	and	_	_	O
166	PDLs	_	_	O
167	.	_	_	O

168	A	_	_	O
169	total	_	_	O
170	of	_	_	O
171	120	_	_	O
172	patients	_	_	O
173	were	_	_	O
174	randomly	_	_	O
175	assigned	_	_	O
176	to	_	_	O
177	receive	_	_	O
178	AM	_	_	O
179	,	_	_	O
180	and	_	_	O
181	122	_	_	O
182	,	_	_	O
183	to	_	_	O
184	receive	_	_	O
185	no	_	_	O
186	AM	_	_	O
187	(	_	_	O
188	one	_	_	O
189	patient	_	_	O
190	was	_	_	O
191	ineligible	_	_	O
192	)	_	_	O
193	;	_	_	O
194	72	_	_	O
195	%	_	_	O
196	received	_	_	O
197	AM	_	_	O
198	per	_	_	O
199	protocol	_	_	O
200	or	_	_	O
201	with	_	_	O
202	a	_	_	O
203	minor	_	_	O
204	deviation	_	_	O
205	.	_	_	O

206	AM	_	_	B-Premise
207	was	_	_	I-Premise
208	associated	_	_	I-Premise
209	with	_	_	I-Premise
210	higher	_	_	I-Premise
211	rates	_	_	I-Premise
212	of	_	_	I-Premise
213	acute	_	_	I-Premise
214	nausea	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.03	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	vomiting	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.007	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	cardiovascular	_	_	I-Premise
229	toxicity	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.0001	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	infection	_	_	I-Premise
238	or	_	_	I-Premise
239	febrile	_	_	I-Premise
240	neutropenia	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.03	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	rate	_	_	I-Premise
249	of	_	_	I-Premise
250	>	_	_	I-Premise
251	/=	_	_	I-Premise
252	grade	_	_	I-Premise
253	3	_	_	I-Premise
254	esophagitis	_	_	I-Premise
255	was	_	_	I-Premise
256	30	_	_	I-Premise
257	%	_	_	I-Premise
258	with	_	_	I-Premise
259	AM	_	_	I-Premise
260	versus	_	_	I-Premise
261	34	_	_	I-Premise
262	%	_	_	I-Premise
263	without	_	_	I-Premise
264	AM	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.9	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Patient	_	_	B-Premise
272	diaries	_	_	I-Premise
273	demonstrated	_	_	I-Premise
274	lower	_	_	I-Premise
275	swallowing	_	_	I-Premise
276	dysfunction	_	_	I-Premise
277	AUC	_	_	I-Premise
278	with	_	_	I-Premise
279	amifostine	_	_	I-Premise
280	(	_	_	I-Premise
281	z	_	_	I-Premise
282	test	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.025	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	QOL	_	_	B-Premise
289	was	_	_	I-Premise
290	not	_	_	I-Premise
291	significantly	_	_	I-Premise
292	different	_	_	I-Premise
293	between	_	_	I-Premise
294	the	_	_	I-Premise
295	two	_	_	I-Premise
296	arms	_	_	I-Premise
297	,	_	_	I-Premise
298	except	_	_	I-Premise
299	for	_	_	I-Premise
300	pain	_	_	I-Premise
301	,	_	_	I-Premise
302	which	_	_	I-Premise
303	showed	_	_	I-Premise
304	more	_	_	I-Premise
305	clinically	_	_	I-Premise
306	meaningful	_	_	I-Premise
307	improvement	_	_	I-Premise
308	and	_	_	I-Premise
309	less	_	_	I-Premise
310	deterioration	_	_	I-Premise
311	at	_	_	I-Premise
312	6	_	_	I-Premise
313	weeks	_	_	I-Premise
314	follow-up	_	_	I-Premise
315	(	_	_	I-Premise
316	v	_	_	I-Premise
317	pretreatment	_	_	I-Premise
318	)	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	AM	_	_	I-Premise
322	arm	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	.003	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Premise
330	median	_	_	I-Premise
331	survival	_	_	I-Premise
332	rates	_	_	I-Premise
333	for	_	_	I-Premise
334	both	_	_	I-Premise
335	arms	_	_	I-Premise
336	were	_	_	I-Premise
337	comparable	_	_	I-Premise
338	(	_	_	I-Premise
339	AM	_	_	I-Premise
340	,	_	_	I-Premise
341	17.3	_	_	I-Premise
342	v	_	_	I-Premise
343	no	_	_	I-Premise
344	AM	_	_	I-Premise
345	,	_	_	I-Premise
346	17.9	_	_	I-Premise
347	months	_	_	I-Premise
348	;	_	_	I-Premise
349	P	_	_	I-Premise
350	=	_	_	I-Premise
351	.87	_	_	I-Premise
352	)	_	_	I-Premise
353	.	_	_	I-Premise

354	AM	_	_	B-Claim
355	did	_	_	I-Claim
356	not	_	_	I-Claim
357	significantly	_	_	I-Claim
358	reduce	_	_	I-Claim
359	esophagitis	_	_	I-Claim
360	>	_	_	I-Claim
361	/=	_	_	I-Claim
362	grade	_	_	I-Claim
363	3	_	_	I-Claim
364	in	_	_	I-Claim
365	patients	_	_	I-Claim
366	receiving	_	_	I-Claim
367	hyperfractionated	_	_	I-Claim
368	radiation	_	_	I-Claim
369	and	_	_	I-Claim
370	chemotherapy	_	_	I-Claim
371	.	_	_	I-Claim

372	However	_	_	B-Claim
373	,	_	_	I-Claim
374	patient	_	_	I-Claim
375	self-assessments	_	_	I-Claim
376	suggested	_	_	I-Claim
377	a	_	_	I-Claim
378	possible	_	_	I-Claim
379	advantage	_	_	I-Claim
380	to	_	_	I-Claim
381	AM	_	_	I-Claim
382	that	_	_	I-Claim
383	is	_	_	I-Claim
384	being	_	_	I-Claim
385	explored	_	_	I-Claim
386	with	_	_	I-Claim
387	modified	_	_	I-Claim
388	dosing	_	_	I-Claim
389	route	_	_	I-Claim
390	strategies	_	_	I-Claim
391	.	_	_	I-Claim


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	the	_	_	O
4	side	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	megestrol	_	_	O
8	acetate	_	_	O
9	on	_	_	O
10	the	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	noncachectic	_	_	O
16	women	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	was	_	_	O
22	studied	_	_	O
23	in	_	_	O
24	a	_	_	O
25	dose-response	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	of	_	_	O
29	the	_	_	O
30	Cancer	_	_	O
31	and	_	_	O
32	Leukemia	_	_	O
33	Group	_	_	O
34	B	_	_	O
35	(	_	_	O
36	CALGB	_	_	O
37	8741	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Side	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	appetite	_	_	O
44	increase	_	_	O
45	and	_	_	O
46	weight	_	_	O
47	gain	_	_	O
48	at	_	_	O
49	higher	_	_	O
50	doses	_	_	O
51	were	_	_	O
52	predicted	_	_	O
53	to	_	_	O
54	have	_	_	O
55	a	_	_	O
56	negative	_	_	O
57	effect	_	_	O
58	on	_	_	O
59	quality	_	_	O
60	of	_	_	O
61	life	_	_	O
62	.	_	_	O

63	Stage	_	_	O
64	IV	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	randomized	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	either	_	_	O
73	160	_	_	O
74	,	_	_	O
75	800	_	_	O
76	,	_	_	O
77	or	_	_	O
78	1,600	_	_	O
79	mg/d	_	_	O
80	of	_	_	O
81	megestrol	_	_	O
82	acetate	_	_	O
83	.	_	_	O

84	Quality	_	_	O
85	of	_	_	O
86	life	_	_	O
87	was	_	_	O
88	assessed	_	_	O
89	in	_	_	O
90	131	_	_	O
91	patients	_	_	O
92	at	_	_	O
93	trial	_	_	O
94	entry	_	_	O
95	and	_	_	O
96	at	_	_	O
97	1	_	_	O
98	and	_	_	O
99	3	_	_	O
100	months	_	_	O
101	while	_	_	O
102	on	_	_	O
103	treatment	_	_	O
104	,	_	_	O
105	by	_	_	O
106	telephone	_	_	O
107	interview	_	_	O
108	,	_	_	O
109	using	_	_	O
110	the	_	_	O
111	following	_	_	O
112	measures	_	_	O
113	:	_	_	O
114	the	_	_	O
115	Functional	_	_	O
116	Living	_	_	O
117	Index-Cancer	_	_	O
118	(	_	_	O
119	FLIC	_	_	O
120	)	_	_	O
121	,	_	_	O
122	Rand	_	_	O
123	Functional	_	_	O
124	Limitations	_	_	O
125	Scale	_	_	O
126	,	_	_	O
127	Rand	_	_	O
128	Mental	_	_	O
129	Health	_	_	O
130	Inventory	_	_	O
131	(	_	_	O
132	MHI	_	_	O
133	)	_	_	O
134	,	_	_	O
135	the	_	_	O
136	Body	_	_	O
137	Image	_	_	O
138	Subscale	_	_	O
139	,	_	_	O
140	and	_	_	O
141	linear	_	_	O
142	analog	_	_	O
143	scales	_	_	O
144	of	_	_	O
145	drug	_	_	O
146	side	_	_	O
147	effects	_	_	O
148	.	_	_	O

149	At	_	_	B-Premise
150	3	_	_	I-Premise
151	months	_	_	I-Premise
152	,	_	_	I-Premise
153	women	_	_	I-Premise
154	treated	_	_	I-Premise
155	with	_	_	I-Premise
156	160	_	_	I-Premise
157	mg/d	_	_	I-Premise
158	reported	_	_	I-Premise
159	less	_	_	I-Premise
160	severe	_	_	I-Premise
161	side	_	_	I-Premise
162	effects	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	.0005	_	_	I-Premise
167	)	_	_	I-Premise
168	,	_	_	I-Premise
169	better	_	_	I-Premise
170	physical	_	_	I-Premise
171	functioning	_	_	I-Premise
172	(	_	_	I-Premise
173	FLS	_	_	I-Premise
174	,	_	_	I-Premise
175	P	_	_	I-Premise
176	<	_	_	I-Premise
177	.0005	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	less	_	_	I-Premise
181	psychologic	_	_	I-Premise
182	distress	_	_	I-Premise
183	(	_	_	I-Premise
184	MHI	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.008	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	an	_	_	I-Premise
193	improvement	_	_	I-Premise
194	in	_	_	I-Premise
195	overall	_	_	I-Premise
196	quality	_	_	I-Premise
197	of	_	_	I-Premise
198	life	_	_	I-Premise
199	(	_	_	I-Premise
200	FLIC	_	_	I-Premise
201	,	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.003	_	_	I-Premise
205	)	_	_	I-Premise
206	from	_	_	I-Premise
207	the	_	_	I-Premise
208	time	_	_	I-Premise
209	of	_	_	I-Premise
210	study	_	_	I-Premise
211	entry	_	_	I-Premise
212	as	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	those	_	_	I-Premise
216	treated	_	_	I-Premise
217	with	_	_	I-Premise
218	1,600	_	_	I-Premise
219	mg/d	_	_	I-Premise
220	.	_	_	I-Premise

221	Patients	_	_	B-Premise
222	who	_	_	I-Premise
223	received	_	_	I-Premise
224	the	_	_	I-Premise
225	800-mg/d	_	_	I-Premise
226	dose	_	_	I-Premise
227	fell	_	_	I-Premise
228	between	_	_	I-Premise
229	the	_	_	I-Premise
230	low-	_	_	I-Premise
231	and	_	_	I-Premise
232	high-dose	_	_	I-Premise
233	arms	_	_	I-Premise
234	in	_	_	I-Premise
235	reported	_	_	I-Premise
236	intensity	_	_	I-Premise
237	of	_	_	I-Premise
238	drug	_	_	I-Premise
239	side	_	_	I-Premise
240	effects	_	_	I-Premise
241	,	_	_	I-Premise
242	but	_	_	B-Premise
243	responded	_	_	I-Premise
244	similarly	_	_	I-Premise
245	to	_	_	I-Premise
246	those	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	160-mg/d	_	_	I-Premise
250	group	_	_	I-Premise
251	in	_	_	I-Premise
252	terms	_	_	I-Premise
253	of	_	_	I-Premise
254	physical	_	_	I-Premise
255	functioning	_	_	I-Premise
256	,	_	_	I-Premise
257	psychologic	_	_	I-Premise
258	distress	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	overall	_	_	I-Premise
262	quality	_	_	I-Premise
263	of	_	_	I-Premise
264	life	_	_	I-Premise
265	.	_	_	I-Premise

266	Unless	_	_	B-Claim
267	additional	_	_	I-Claim
268	follow-up	_	_	I-Claim
269	data	_	_	I-Claim
270	demonstrate	_	_	I-Claim
271	a	_	_	I-Claim
272	survival	_	_	I-Claim
273	advantage	_	_	I-Claim
274	at	_	_	I-Claim
275	higher	_	_	I-Claim
276	doses	_	_	I-Claim
277	,	_	_	I-Claim
278	the	_	_	I-Claim
279	160-mg/d	_	_	I-Claim
280	dose	_	_	I-Claim
281	is	_	_	I-Claim
282	optimal	_	_	I-Claim
283	,	_	_	I-Claim
284	achieving	_	_	I-Claim
285	maximal	_	_	I-Claim
286	treatment	_	_	I-Claim
287	effect	_	_	I-Claim
288	with	_	_	I-Claim
289	the	_	_	I-Claim
290	fewest	_	_	I-Claim
291	side	_	_	I-Claim
292	effects	_	_	I-Claim
293	and	_	_	I-Claim
294	better	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	.	_	_	I-Claim


0	Study	_	_	O
1	Type	_	_	O
2	--	_	_	O
3	Therapy	_	_	O
4	(	_	_	O
5	RCT	_	_	O
6	)	_	_	O
7	Level	_	_	O
8	of	_	_	O
9	Evidence	_	_	O
10	1b	_	_	O
11	.	_	_	O

12	What	_	_	O
13	's	_	_	O
14	known	_	_	O
15	on	_	_	O
16	the	_	_	O
17	subject	_	_	O
18	?	_	_	O

19	and	_	_	O
20	What	_	_	O
21	does	_	_	O
22	the	_	_	O
23	study	_	_	O
24	add	_	_	O
25	?	_	_	O

26	Androgen	_	_	O
27	deprivation	_	_	O
28	therapy	_	_	O
29	(	_	_	O
30	ADT	_	_	O
31	)	_	_	O
32	is	_	_	O
33	commonly	_	_	O
34	used	_	_	O
35	as	_	_	O
36	a	_	_	O
37	primary	_	_	O
38	treatment	_	_	O
39	for	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	prostate	_	_	O
43	cancer	_	_	O
44	(	_	_	O
45	PCa	_	_	O
46	)	_	_	O
47	who	_	_	O
48	are	_	_	O
49	not	_	_	O
50	eligible	_	_	O
51	for	_	_	O
52	radical	_	_	O
53	treatment	_	_	O
54	options	_	_	O
55	.	_	_	O

56	ADT	_	_	O
57	is	_	_	O
58	also	_	_	O
59	used	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	PCa	_	_	O
64	as	_	_	O
65	neo-adjuvant	_	_	O
66	hormone	_	_	O
67	therapy	_	_	O
68	to	_	_	O
69	reduce	_	_	O
70	prostate	_	_	O
71	volume	_	_	O
72	and	_	_	O
73	down-stage	_	_	O
74	the	_	_	O
75	disease	_	_	O
76	before	_	_	O
77	radiotherapy	_	_	O
78	with	_	_	O
79	curative	_	_	O
80	intent	_	_	O
81	.	_	_	O

82	The	_	_	O
83	present	_	_	O
84	study	_	_	O
85	showed	_	_	O
86	that	_	_	O
87	ADT	_	_	O
88	with	_	_	O
89	the	_	_	O
90	gonadotropin	_	_	O
91	hormone-releasing	_	_	O
92	hormone	_	_	O
93	(	_	_	O
94	GhRH	_	_	O
95	)	_	_	O
96	antagonist	_	_	O
97	degarelix	_	_	O
98	is	_	_	O
99	non-inferior	_	_	O
100	to	_	_	O
101	combined	_	_	O
102	treatment	_	_	O
103	with	_	_	O
104	the	_	_	O
105	LHRH	_	_	O
106	agonist	_	_	O
107	goserelin	_	_	O
108	and	_	_	O
109	bicalutamide	_	_	O
110	in	_	_	O
111	terms	_	_	O
112	of	_	_	O
113	reducing	_	_	O
114	prostate	_	_	O
115	volume	_	_	O
116	during	_	_	O
117	the	_	_	O
118	treatment	_	_	O
119	period	_	_	O
120	of	_	_	O
121	3	_	_	O
122	months	_	_	O
123	.	_	_	O

124	Degarelix	_	_	O
125	treatment	_	_	O
126	evokes	_	_	O
127	,	_	_	O
128	however	_	_	O
129	,	_	_	O
130	significantly	_	_	O
131	better	_	_	O
132	relief	_	_	O
133	of	_	_	O
134	lower	_	_	O
135	urinary	_	_	O
136	tract	_	_	O
137	symptoms	_	_	O
138	in	_	_	O
139	patients	_	_	O
140	having	_	_	O
141	moderate	_	_	O
142	and	_	_	O
143	severe	_	_	O
144	voiding	_	_	O
145	problems	_	_	O
146	.	_	_	O

147	To	_	_	O
148	assess	_	_	O
149	the	_	_	O
150	efficacy	_	_	O
151	of	_	_	O
152	monthly	_	_	O
153	degarelix	_	_	O
154	treatment	_	_	O
155	for	_	_	O
156	reduction	_	_	O
157	of	_	_	O
158	total	_	_	O
159	prostate	_	_	O
160	volume	_	_	O
161	(	_	_	O
162	TPV	_	_	O
163	)	_	_	O
164	,	_	_	O
165	relief	_	_	O
166	of	_	_	O
167	lower	_	_	O
168	urinary	_	_	O
169	tract	_	_	O
170	symptoms	_	_	O
171	(	_	_	O
172	LUTS	_	_	O
173	)	_	_	O
174	and	_	_	O
175	improvement	_	_	O
176	of	_	_	O
177	quality	_	_	O
178	of	_	_	O
179	life	_	_	O
180	(	_	_	O
181	QoL	_	_	O
182	)	_	_	O
183	in	_	_	O
184	patients	_	_	O
185	with	_	_	O
186	prostate	_	_	O
187	cancer	_	_	O
188	(	_	_	O
189	PCa	_	_	O
190	)	_	_	O
191	using	_	_	O
192	monthly	_	_	O
193	goserelin	_	_	O
194	as	_	_	O
195	active	_	_	O
196	control	_	_	O
197	.	_	_	O

198	This	_	_	O
199	was	_	_	O
200	a	_	_	O
201	randomized	_	_	O
202	,	_	_	O
203	parallel-arm	_	_	O
204	,	_	_	O
205	active-controlled	_	_	O
206	,	_	_	O
207	open-label	_	_	O
208	,	_	_	O
209	multicentre	_	_	O
210	trial	_	_	O
211	on	_	_	O
212	182	_	_	O
213	patients	_	_	O
214	treated	_	_	O
215	with	_	_	O
216	either	_	_	O
217	monthly	_	_	O
218	degarelix	_	_	O
219	(	_	_	O
220	240/80	_	_	O
221	mg	_	_	O
222	)	_	_	O
223	or	_	_	O
224	goserelin	_	_	O
225	(	_	_	O
226	3.6	_	_	O
227	mg	_	_	O
228	)	_	_	O
229	for	_	_	O
230	12	_	_	O
231	weeks	_	_	O
232	.	_	_	O

233	For	_	_	O
234	flare	_	_	O
235	protection	_	_	O
236	,	_	_	O
237	goserelin-treated	_	_	O
238	patients	_	_	O
239	also	_	_	O
240	received	_	_	O
241	daily	_	_	O
242	bicalutamide	_	_	O
243	(	_	_	O
244	50	_	_	O
245	mg	_	_	O
246	)	_	_	O
247	during	_	_	O
248	the	_	_	O
249	initial	_	_	O
250	28	_	_	O
251	days	_	_	O
252	.	_	_	O

253	Key	_	_	O
254	trial	_	_	O
255	variables	_	_	O
256	monitored	_	_	O
257	monthly	_	_	O
258	were	_	_	O
259	TPV	_	_	O
260	(	_	_	O
261	primary	_	_	O
262	endpoint	_	_	O
263	)	_	_	O
264	,	_	_	O
265	serum	_	_	O
266	testosterone	_	_	O
267	,	_	_	O
268	prostate-specific	_	_	O
269	antigen	_	_	O
270	(	_	_	O
271	PSA	_	_	O
272	)	_	_	O
273	,	_	_	O
274	the	_	_	O
275	International	_	_	O
276	Prostate	_	_	O
277	Symptom	_	_	O
278	Score	_	_	O
279	(	_	_	O
280	IPSS	_	_	O
281	)	_	_	O
282	and	_	_	O
283	the	_	_	O
284	Benign	_	_	O
285	Prostate	_	_	O
286	Hyperplasia	_	_	O
287	Impact	_	_	O
288	Index	_	_	O
289	.	_	_	O

290	In	_	_	O
291	all	_	_	O
292	,	_	_	O
293	175	_	_	O
294	patients	_	_	O
295	completed	_	_	O
296	the	_	_	O
297	trial	_	_	O
298	(	_	_	O
299	96.1	_	_	O
300	%	_	_	O
301	)	_	_	O
302	.	_	_	O

303	At	_	_	B-Premise
304	week	_	_	I-Premise
305	12	_	_	I-Premise
306	,	_	_	I-Premise
307	changes	_	_	I-Premise
308	in	_	_	I-Premise
309	TPV	_	_	I-Premise
310	for	_	_	I-Premise
311	degarelix	_	_	I-Premise
312	and	_	_	I-Premise
313	goserelin	_	_	I-Premise
314	were	_	_	I-Premise
315	similar	_	_	I-Premise
316	(	_	_	I-Premise
317	-37.2	_	_	I-Premise
318	%	_	_	I-Premise
319	vs	_	_	I-Premise
320	-39.0	_	_	I-Premise
321	%	_	_	I-Premise
322	)	_	_	I-Premise
323	and	_	_	I-Premise
324	met	_	_	I-Premise
325	the	_	_	I-Premise
326	predefined	_	_	I-Premise
327	non-inferiority	_	_	I-Premise
328	criterion	_	_	I-Premise
329	.	_	_	I-Premise

330	Decreases	_	_	B-Premise
331	in	_	_	I-Premise
332	IPSS	_	_	I-Premise
333	were	_	_	I-Premise
334	greater	_	_	I-Premise
335	in	_	_	I-Premise
336	degarelix	_	_	I-Premise
337	than	_	_	I-Premise
338	in	_	_	I-Premise
339	goserelin-treated	_	_	I-Premise
340	patients	_	_	I-Premise
341	,	_	_	I-Premise
342	differences	_	_	I-Premise
343	being	_	_	I-Premise
344	statistically	_	_	I-Premise
345	significant	_	_	I-Premise
346	in	_	_	I-Premise
347	patients	_	_	I-Premise
348	with	_	_	I-Premise
349	baseline	_	_	I-Premise
350	IPSS	_	_	I-Premise
351	>	_	_	I-Premise
352	13	_	_	I-Premise
353	(	_	_	I-Premise
354	-6.7	_	_	I-Premise
355	Â±	_	_	I-Premise
356	1.8	_	_	I-Premise
357	vs	_	_	I-Premise
358	-4.0	_	_	I-Premise
359	Â±	_	_	I-Premise
360	1.0	_	_	I-Premise
361	;	_	_	I-Premise
362	P	_	_	I-Premise
363	=	_	_	I-Premise
364	0.02	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	The	_	_	B-Premise
368	number	_	_	I-Premise
369	of	_	_	I-Premise
370	patients	_	_	I-Premise
371	with	_	_	I-Premise
372	an	_	_	I-Premise
373	IPSS	_	_	I-Premise
374	change	_	_	I-Premise
375	of	_	_	I-Premise
376	â‰¥	_	_	I-Premise
377	3	_	_	I-Premise
378	over	_	_	I-Premise
379	baseline	_	_	I-Premise
380	was	_	_	I-Premise
381	also	_	_	I-Premise
382	significantly	_	_	I-Premise
383	higher	_	_	I-Premise
384	in	_	_	I-Premise
385	patients	_	_	I-Premise
386	treated	_	_	I-Premise
387	with	_	_	I-Premise
388	degarelix	_	_	I-Premise
389	(	_	_	I-Premise
390	61.0	_	_	I-Premise
391	vs	_	_	I-Premise
392	44.3	_	_	I-Premise
393	%	_	_	I-Premise
394	,	_	_	I-Premise
395	P	_	_	I-Premise
396	=	_	_	I-Premise
397	0.02	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	Both	_	_	B-Claim
401	treatments	_	_	I-Claim
402	were	_	_	I-Claim
403	safe	_	_	I-Claim
404	and	_	_	I-Claim
405	well	_	_	I-Claim
406	tolerated	_	_	I-Claim
407	.	_	_	I-Claim

408	Medical	_	_	B-Claim
409	castration	_	_	I-Claim
410	reduces	_	_	I-Claim
411	TPV	_	_	I-Claim
412	and	_	_	I-Claim
413	could	_	_	I-Claim
414	also	_	_	I-Claim
415	improve	_	_	I-Claim
416	LUTS	_	_	I-Claim
417	in	_	_	I-Claim
418	patients	_	_	I-Claim
419	with	_	_	I-Claim
420	PCa	_	_	I-Claim
421	.	_	_	I-Claim

422	While	_	_	O
423	the	_	_	B-Claim
424	short-term	_	_	I-Claim
425	efficacy	_	_	I-Claim
426	of	_	_	I-Claim
427	degarelix	_	_	I-Claim
428	and	_	_	I-Claim
429	goserelin	_	_	I-Claim
430	+	_	_	I-Claim
431	bicalutamide	_	_	I-Claim
432	was	_	_	I-Claim
433	the	_	_	I-Claim
434	same	_	_	I-Claim
435	in	_	_	I-Claim
436	terms	_	_	I-Claim
437	of	_	_	I-Claim
438	TPV	_	_	I-Claim
439	reduction	_	_	I-Claim
440	,	_	_	I-Claim
441	degarelix	_	_	B-Claim
442	showed	_	_	I-Claim
443	superiority	_	_	I-Claim
444	in	_	_	I-Claim
445	LUTS	_	_	I-Claim
446	relief	_	_	I-Claim
447	in	_	_	I-Claim
448	symptomatic	_	_	I-Claim
449	patients	_	_	I-Claim
450	,	_	_	I-Claim
451	which	_	_	I-Claim
452	could	_	_	I-Claim
453	highlight	_	_	I-Claim
454	the	_	_	I-Claim
455	different	_	_	I-Claim
456	actions	_	_	I-Claim
457	of	_	_	I-Claim
458	these	_	_	I-Claim
459	drugs	_	_	I-Claim
460	on	_	_	I-Claim
461	extrapituitary	_	_	I-Claim
462	gonadotrophin-releasing	_	_	I-Claim
463	hormone	_	_	I-Claim
464	(	_	_	I-Claim
465	GnRH	_	_	I-Claim
466	)	_	_	I-Claim
467	receptors	_	_	I-Claim
468	in	_	_	I-Claim
469	the	_	_	I-Claim
470	bladder	_	_	I-Claim
471	and/or	_	_	I-Claim
472	the	_	_	I-Claim
473	prostate	_	_	I-Claim
474	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	postoperative	_	_	O
6	radiotherapy	_	_	O
7	in	_	_	O
8	women	_	_	O
9	with	_	_	O
10	'low-risk	_	_	O
11	'	_	_	O
12	axillary	_	_	O
13	node	_	_	O
14	negative	_	_	O
15	breast	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	T0-2	_	_	O
19	)	_	_	O
20	treated	_	_	O
21	by	_	_	O
22	breast-conserving	_	_	O
23	surgery	_	_	O
24	and	_	_	O
25	endocrine	_	_	O
26	therapy	_	_	O
27	improves	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	and	_	_	O
32	is	_	_	O
33	more	_	_	O
34	cost-effective	_	_	O
35	.	_	_	O

36	A	_	_	O
37	randomised	_	_	O
38	controlled	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	,	_	_	O
42	using	_	_	O
43	a	_	_	O
44	method	_	_	O
45	of	_	_	O
46	minimisation	_	_	O
47	balanced	_	_	O
48	by	_	_	O
49	centre	_	_	O
50	,	_	_	O
51	grade	_	_	O
52	of	_	_	O
53	cancer	_	_	O
54	,	_	_	O
55	age	_	_	O
56	,	_	_	O
57	lymphatic/vascular	_	_	O
58	invasion	_	_	O
59	and	_	_	O
60	preoperative	_	_	O
61	endocrine	_	_	O
62	therapy	_	_	O
63	,	_	_	O
64	was	_	_	O
65	performed	_	_	O
66	.	_	_	O

67	A	_	_	O
68	non-randomised	_	_	O
69	cohort	_	_	O
70	was	_	_	O
71	also	_	_	O
72	recruited	_	_	O
73	,	_	_	O
74	in	_	_	O
75	order	_	_	O
76	to	_	_	O
77	complete	_	_	O
78	a	_	_	O
79	comprehensive	_	_	O
80	cohort	_	_	O
81	study	_	_	O
82	.	_	_	O

83	The	_	_	O
84	setting	_	_	O
85	was	_	_	O
86	breast	_	_	O
87	cancer	_	_	O
88	clinics	_	_	O
89	in	_	_	O
90	cancer	_	_	O
91	centres	_	_	O
92	in	_	_	O
93	the	_	_	O
94	UK	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	aged	_	_	O
98	65	_	_	O
99	years	_	_	O
100	or	_	_	O
101	more	_	_	O
102	were	_	_	O
103	eligible	_	_	O
104	provided	_	_	O
105	that	_	_	O
106	their	_	_	O
107	cancers	_	_	O
108	were	_	_	O
109	considered	_	_	O
110	to	_	_	O
111	be	_	_	O
112	at	_	_	O
113	low	_	_	O
114	risk	_	_	O
115	of	_	_	O
116	local	_	_	O
117	recurrence	_	_	O
118	,	_	_	O
119	were	_	_	O
120	suitable	_	_	O
121	for	_	_	O
122	breast-conservation	_	_	O
123	surgery	_	_	O
124	,	_	_	O
125	were	_	_	O
126	receiving	_	_	O
127	endocrine	_	_	O
128	therapy	_	_	O
129	and	_	_	O
130	were	_	_	O
131	able	_	_	O
132	and	_	_	O
133	willing	_	_	O
134	to	_	_	O
135	give	_	_	O
136	informed	_	_	O
137	consent	_	_	O
138	.	_	_	O

139	The	_	_	O
140	standard	_	_	O
141	treatment	_	_	O
142	of	_	_	O
143	postoperative	_	_	O
144	breast	_	_	O
145	irradiation	_	_	O
146	or	_	_	O
147	the	_	_	O
148	omission	_	_	O
149	of	_	_	O
150	radiotherapy	_	_	O
151	.	_	_	O

152	Quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	was	_	_	O
156	the	_	_	O
157	primary	_	_	O
158	outcome	_	_	O
159	measure	_	_	O
160	,	_	_	O
161	together	_	_	O
162	with	_	_	O
163	anxiety	_	_	O
164	and	_	_	O
165	depression	_	_	O
166	and	_	_	O
167	cost-effectiveness	_	_	O
168	.	_	_	O

169	Secondary	_	_	O
170	outcome	_	_	O
171	measures	_	_	O
172	were	_	_	O
173	recurrence	_	_	O
174	rates	_	_	O
175	,	_	_	O
176	functional	_	_	O
177	status	_	_	O
178	,	_	_	O
179	treatment-related	_	_	O
180	morbidity	_	_	O
181	and	_	_	O
182	cosmesis	_	_	O
183	.	_	_	O

184	The	_	_	O
185	principal	_	_	O
186	method	_	_	O
187	of	_	_	O
188	data	_	_	O
189	collection	_	_	O
190	was	_	_	O
191	by	_	_	O
192	questionnaire	_	_	O
193	,	_	_	O
194	completed	_	_	O
195	at	_	_	O
196	home	_	_	O
197	with	_	_	O
198	a	_	_	O
199	research	_	_	O
200	nurse	_	_	O
201	at	_	_	O
202	four	_	_	O
203	times	_	_	O
204	over	_	_	O
205	15	_	_	O
206	months	_	_	O
207	.	_	_	O

208	The	_	_	B-Claim
209	hypothesised	_	_	I-Claim
210	improvement	_	_	I-Claim
211	in	_	_	I-Claim
212	overall	_	_	I-Claim
213	quality	_	_	I-Claim
214	of	_	_	I-Claim
215	life	_	_	I-Claim
216	with	_	_	I-Claim
217	the	_	_	I-Claim
218	omission	_	_	I-Claim
219	of	_	_	I-Claim
220	radiotherapy	_	_	I-Claim
221	was	_	_	I-Claim
222	not	_	_	I-Claim
223	seen	_	_	I-Claim
224	in	_	_	I-Claim
225	the	_	_	I-Claim
226	EuroQol	_	_	I-Claim
227	assessment	_	_	I-Claim
228	or	_	_	I-Claim
229	in	_	_	I-Claim
230	the	_	_	I-Claim
231	functionality	_	_	I-Claim
232	and	_	_	I-Claim
233	symptoms	_	_	I-Claim
234	summary	_	_	I-Claim
235	domains	_	_	I-Claim
236	of	_	_	I-Claim
237	the	_	_	I-Claim
238	European	_	_	I-Claim
239	Organisation	_	_	I-Claim
240	for	_	_	I-Claim
241	Research	_	_	I-Claim
242	in	_	_	I-Claim
243	the	_	_	I-Claim
244	Treatment	_	_	I-Claim
245	of	_	_	I-Claim
246	Cancer	_	_	I-Claim
247	(	_	_	I-Claim
248	EORTC	_	_	I-Claim
249	)	_	_	I-Claim
250	scales	_	_	I-Claim
251	.	_	_	I-Claim

252	Some	_	_	O
253	differences	_	_	O
254	were	_	_	O
255	apparent	_	_	O
256	within	_	_	O
257	subscales	_	_	O
258	of	_	_	O
259	the	_	_	O
260	EORTC	_	_	O
261	questionnaires	_	_	O
262	,	_	_	O
263	and	_	_	O
264	insights	_	_	O
265	into	_	_	O
266	the	_	_	O
267	impact	_	_	O
268	of	_	_	O
269	treatment	_	_	O
270	were	_	_	O
271	also	_	_	O
272	provided	_	_	O
273	by	_	_	O
274	the	_	_	O
275	qualitative	_	_	O
276	data	_	_	O
277	obtained	_	_	O
278	by	_	_	O
279	open-ended	_	_	O
280	questions	_	_	O
281	.	_	_	O

282	Differences	_	_	B-Premise
283	were	_	_	I-Premise
284	most	_	_	I-Premise
285	apparent	_	_	I-Premise
286	shortly	_	_	I-Premise
287	after	_	_	I-Premise
288	the	_	_	I-Premise
289	time	_	_	I-Premise
290	of	_	_	I-Premise
291	completion	_	_	I-Premise
292	of	_	_	I-Premise
293	radiotherapy	_	_	I-Premise
294	.	_	_	I-Premise

295	Radiotherapy	_	_	B-Claim
296	was	_	_	I-Claim
297	then	_	_	I-Claim
298	associated	_	_	I-Claim
299	with	_	_	I-Claim
300	increased	_	_	I-Claim
301	breast	_	_	I-Claim
302	symptoms	_	_	I-Claim
303	and	_	_	I-Claim
304	with	_	_	I-Claim
305	greater	_	_	I-Claim
306	fatigue	_	_	I-Claim
307	but	_	_	I-Claim
308	with	_	_	I-Claim
309	less	_	_	I-Claim
310	insomnia	_	_	I-Claim
311	and	_	_	I-Claim
312	endocrine	_	_	I-Claim
313	side-effects	_	_	I-Claim
314	.	_	_	I-Claim

315	Patients	_	_	B-Premise
316	had	_	_	I-Premise
317	significant	_	_	I-Premise
318	concerns	_	_	I-Premise
319	about	_	_	I-Premise
320	the	_	_	I-Premise
321	delivery	_	_	I-Premise
322	of	_	_	I-Premise
323	radiotherapy	_	_	I-Premise
324	services	_	_	I-Premise
325	,	_	_	I-Premise
326	such	_	_	I-Premise
327	as	_	_	I-Premise
328	transport	_	_	I-Premise
329	,	_	_	I-Premise
330	accommodation	_	_	I-Premise
331	and	_	_	I-Premise
332	travel	_	_	I-Premise
333	costs	_	_	I-Premise
334	associated	_	_	I-Premise
335	with	_	_	I-Premise
336	receiving	_	_	I-Premise
337	radiotherapy	_	_	I-Premise
338	.	_	_	I-Premise

339	By	_	_	B-Premise
340	the	_	_	I-Premise
341	end	_	_	I-Premise
342	of	_	_	I-Premise
343	follow-up	_	_	I-Premise
344	,	_	_	I-Premise
345	patients	_	_	I-Premise
346	receiving	_	_	I-Premise
347	radiotherapy	_	_	I-Premise
348	were	_	_	I-Premise
349	expressing	_	_	I-Premise
350	less	_	_	I-Premise
351	anxiety	_	_	I-Premise
352	about	_	_	I-Premise
353	recurrence	_	_	I-Premise
354	than	_	_	I-Premise
355	those	_	_	I-Premise
356	who	_	_	I-Premise
357	had	_	_	I-Premise
358	not	_	_	I-Premise
359	received	_	_	I-Premise
360	radiotherapy	_	_	I-Premise
361	.	_	_	I-Premise

362	Functionality	_	_	B-Premise
363	was	_	_	I-Premise
364	not	_	_	I-Premise
365	greatly	_	_	I-Premise
366	affected	_	_	I-Premise
367	by	_	_	I-Premise
368	treatment	_	_	I-Premise
369	.	_	_	I-Premise

370	Within	_	_	B-Premise
371	the	_	_	I-Premise
372	randomised	_	_	I-Premise
373	controlled	_	_	I-Premise
374	trial	_	_	I-Premise
375	,	_	_	I-Premise
376	the	_	_	I-Premise
377	Barthel	_	_	I-Premise
378	Index	_	_	I-Premise
379	demonstrated	_	_	I-Premise
380	a	_	_	I-Premise
381	small	_	_	I-Premise
382	but	_	_	I-Premise
383	significant	_	_	I-Premise
384	fall	_	_	I-Premise
385	in	_	_	I-Premise
386	functionality	_	_	I-Premise
387	with	_	_	I-Premise
388	radiotherapy	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	the	_	_	I-Premise
392	no	_	_	I-Premise
393	radiotherapy	_	_	I-Premise
394	arm	_	_	I-Premise
395	of	_	_	I-Premise
396	the	_	_	I-Premise
397	trial	_	_	I-Premise
398	.	_	_	I-Premise

399	Results	_	_	B-Premise
400	from	_	_	I-Premise
401	the	_	_	I-Premise
402	non-randomised	_	_	I-Premise
403	patients	_	_	I-Premise
404	did	_	_	I-Premise
405	not	_	_	I-Premise
406	confirm	_	_	I-Premise
407	this	_	_	I-Premise
408	effect	_	_	I-Premise
409	,	_	_	I-Premise
410	however	_	_	I-Premise
411	.	_	_	I-Premise

412	Cosmetic	_	_	B-Premise
413	results	_	_	I-Premise
414	were	_	_	I-Premise
415	better	_	_	I-Premise
416	in	_	_	I-Premise
417	those	_	_	I-Premise
418	not	_	_	I-Premise
419	receiving	_	_	I-Premise
420	radiotherapy	_	_	I-Premise
421	but	_	_	B-Premise
422	this	_	_	I-Premise
423	did	_	_	I-Premise
424	not	_	_	I-Premise
425	appear	_	_	I-Premise
426	to	_	_	I-Premise
427	be	_	_	I-Premise
428	an	_	_	I-Premise
429	important	_	_	I-Premise
430	issue	_	_	I-Premise
431	to	_	_	I-Premise
432	the	_	_	I-Premise
433	patients	_	_	I-Premise
434	.	_	_	I-Premise

435	The	_	_	B-Claim
436	use	_	_	I-Claim
437	of	_	_	I-Claim
438	home-based	_	_	I-Claim
439	assessments	_	_	I-Claim
440	by	_	_	I-Claim
441	a	_	_	I-Claim
442	research	_	_	I-Claim
443	nurse	_	_	I-Claim
444	proved	_	_	I-Claim
445	to	_	_	I-Claim
446	be	_	_	I-Claim
447	an	_	_	I-Claim
448	effective	_	_	I-Claim
449	way	_	_	I-Claim
450	of	_	_	I-Claim
451	obtaining	_	_	I-Claim
452	high-quality	_	_	I-Claim
453	data	_	_	I-Claim
454	.	_	_	I-Claim

455	Costs	_	_	O
456	to	_	_	O
457	the	_	_	O
458	NHS	_	_	O
459	associated	_	_	O
460	with	_	_	O
461	postoperative	_	_	O
462	radiotherapy	_	_	O
463	were	_	_	O
464	calculated	_	_	O
465	to	_	_	O
466	be	_	_	O
467	of	_	_	O
468	the	_	_	O
469	order	_	_	O
470	of	_	_	O
471	2000	_	_	O
472	pounds	_	_	O
473	per	_	_	O
474	patient	_	_	O
475	.	_	_	O

476	In	_	_	B-Premise
477	the	_	_	I-Premise
478	follow-up	_	_	I-Premise
479	in	_	_	I-Premise
480	this	_	_	I-Premise
481	study	_	_	I-Premise
482	,	_	_	I-Premise
483	there	_	_	I-Premise
484	were	_	_	I-Premise
485	no	_	_	I-Premise
486	recurrences	_	_	I-Premise
487	,	_	_	I-Premise
488	and	_	_	I-Premise
489	the	_	_	I-Premise
490	quality	_	_	I-Premise
491	of	_	_	I-Premise
492	life	_	_	I-Premise
493	utilities	_	_	I-Premise
494	from	_	_	I-Premise
495	EuroQol	_	_	I-Premise
496	were	_	_	I-Premise
497	almost	_	_	I-Premise
498	identical	_	_	I-Premise
499	.	_	_	I-Premise

500	Although	_	_	B-Premise
501	there	_	_	I-Premise
502	are	_	_	I-Premise
503	no	_	_	I-Premise
504	differences	_	_	I-Premise
505	in	_	_	I-Premise
506	overall	_	_	I-Premise
507	quality	_	_	I-Premise
508	of	_	_	I-Premise
509	life	_	_	I-Premise
510	scores	_	_	I-Premise
511	between	_	_	I-Premise
512	the	_	_	I-Premise
513	patients	_	_	I-Premise
514	treated	_	_	I-Premise
515	with	_	_	I-Premise
516	and	_	_	I-Premise
517	without	_	_	I-Premise
518	radiotherapy	_	_	I-Premise
519	,	_	_	I-Premise
520	there	_	_	I-Premise
521	are	_	_	I-Premise
522	several	_	_	I-Premise
523	dimensions	_	_	I-Premise
524	that	_	_	I-Premise
525	exhibit	_	_	I-Premise
526	significant	_	_	I-Premise
527	advantage	_	_	I-Premise
528	to	_	_	I-Premise
529	the	_	_	I-Premise
530	omission	_	_	I-Premise
531	of	_	_	I-Premise
532	irradiation	_	_	I-Premise
533	.	_	_	I-Premise

534	Over	_	_	B-Premise
535	the	_	_	I-Premise
536	first	_	_	I-Premise
537	15	_	_	I-Premise
538	months	_	_	I-Premise
539	,	_	_	I-Premise
540	radiotherapy	_	_	I-Premise
541	for	_	_	I-Premise
542	this	_	_	I-Premise
543	population	_	_	I-Premise
544	is	_	_	I-Premise
545	not	_	_	I-Premise
546	a	_	_	I-Premise
547	cost-effective	_	_	I-Premise
548	treatment	_	_	I-Premise
549	.	_	_	I-Premise

550	However	_	_	O
551	,	_	_	O
552	the	_	_	O
553	early	_	_	B-Claim
554	postoperative	_	_	I-Claim
555	outcome	_	_	I-Claim
556	does	_	_	I-Claim
557	not	_	_	I-Claim
558	give	_	_	I-Claim
559	a	_	_	I-Claim
560	complete	_	_	I-Claim
561	answer	_	_	I-Claim
562	and	_	_	O
563	the	_	_	B-Claim
564	eventual	_	_	I-Claim
565	cost-effectiveness	_	_	I-Claim
566	will	_	_	I-Claim
567	only	_	_	I-Claim
568	become	_	_	I-Claim
569	clear	_	_	I-Claim
570	after	_	_	I-Claim
571	long-term	_	_	I-Claim
572	follow-up	_	_	I-Claim
573	.	_	_	I-Claim

574	Extrapolations	_	_	B-Claim
575	from	_	_	I-Claim
576	these	_	_	I-Claim
577	data	_	_	I-Claim
578	suggest	_	_	I-Claim
579	that	_	_	I-Claim
580	radiotherapy	_	_	I-Claim
581	may	_	_	I-Claim
582	not	_	_	I-Claim
583	be	_	_	I-Claim
584	a	_	_	I-Claim
585	cost-effective	_	_	I-Claim
586	treatment	_	_	I-Claim
587	unless	_	_	I-Claim
588	it	_	_	I-Claim
589	results	_	_	I-Claim
590	in	_	_	I-Claim
591	a	_	_	I-Claim
592	recurrence	_	_	I-Claim
593	rate	_	_	I-Claim
594	that	_	_	I-Claim
595	is	_	_	I-Claim
596	at	_	_	I-Claim
597	least	_	_	I-Claim
598	5	_	_	I-Claim
599	%	_	_	I-Claim
600	lower	_	_	I-Claim
601	in	_	_	I-Claim
602	absolute	_	_	I-Claim
603	terms	_	_	I-Claim
604	than	_	_	I-Claim
605	those	_	_	I-Claim
606	treated	_	_	I-Claim
607	without	_	_	I-Claim
608	radiotherapy	_	_	I-Claim
609	.	_	_	I-Claim

610	Further	_	_	B-Claim
611	research	_	_	I-Claim
612	is	_	_	I-Claim
613	needed	_	_	I-Claim
614	into	_	_	I-Claim
615	a	_	_	I-Claim
616	number	_	_	I-Claim
617	of	_	_	I-Claim
618	areas	_	_	I-Claim
619	including	_	_	I-Claim
620	the	_	_	I-Claim
621	long-term	_	_	I-Claim
622	aspects	_	_	I-Claim
623	of	_	_	I-Claim
624	quality	_	_	I-Claim
625	of	_	_	I-Claim
626	life	_	_	I-Claim
627	,	_	_	I-Claim
628	clinical	_	_	I-Claim
629	outcomes	_	_	I-Claim
630	,	_	_	I-Claim
631	costs	_	_	I-Claim
632	and	_	_	I-Claim
633	consequences	_	_	I-Claim
634	of	_	_	I-Claim
635	omitting	_	_	I-Claim
636	radiotherapy	_	_	I-Claim
637	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	outcome	_	_	O
10	of	_	_	O
11	early	_	_	O
12	oral	_	_	O
13	postoperative	_	_	O
14	feeding	_	_	O
15	(	_	_	O
16	EOF	_	_	O
17	)	_	_	O
18	compared	_	_	O
19	with	_	_	O
20	traditional	_	_	O
21	oral	_	_	O
22	feeding	_	_	O
23	(	_	_	O
24	TOF	_	_	O
25	)	_	_	O
26	in	_	_	O
27	gynecologic	_	_	O
28	oncology	_	_	O
29	patients	_	_	O
30	undergoing	_	_	O
31	a	_	_	O
32	complex	_	_	O
33	laparotomy	_	_	O
34	,	_	_	O
35	including	_	_	O
36	upper	_	_	O
37	abdominal	_	_	O
38	surgery	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	aged	_	_	O
42	18-75	_	_	O
43	years	_	_	O
44	,	_	_	O
45	undergoing	_	_	O
46	an	_	_	O
47	elective	_	_	O
48	laparotomy	_	_	O
49	and	_	_	O
50	with	_	_	O
51	a	_	_	O
52	preoperative	_	_	O
53	suspicion	_	_	O
54	of	_	_	O
55	gynecologic	_	_	O
56	malignancy	_	_	O
57	,	_	_	O
58	were	_	_	O
59	eligible	_	_	O
60	.	_	_	O

61	Exclusion	_	_	O
62	criteria	_	_	O
63	included	_	_	O
64	infectious	_	_	O
65	conditions	_	_	O
66	,	_	_	O
67	intestinal	_	_	O
68	obstruction	_	_	O
69	,	_	_	O
70	severe	_	_	O
71	malnutrition	_	_	O
72	,	_	_	O
73	American	_	_	O
74	Society	_	_	O
75	of	_	_	O
76	Anesthesiologists	_	_	O
77	score	_	_	O
78	C4	_	_	O
79	,	_	_	O
80	intestinal	_	_	O
81	resection	_	_	O
82	,	_	_	O
83	and	_	_	O
84	postoperative	_	_	O
85	stay	_	_	O
86	in	_	_	O
87	the	_	_	O
88	intensive	_	_	O
89	care	_	_	O
90	unit	_	_	O
91	lasting	_	_	O
92	24	_	_	O
93	h.	_	_	O
94	Patients	_	_	O
95	allocated	_	_	O
96	to	_	_	O
97	EOF	_	_	O
98	received	_	_	O
99	liquid	_	_	O
100	diet	_	_	O
101	in	_	_	O
102	the	_	_	O
103	first	_	_	O
104	postoperative	_	_	O
105	day	_	_	O
106	and	_	_	O
107	then	_	_	O
108	regular	_	_	O
109	diet	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	received	_	_	O
113	traditional	_	_	O
114	feeding	_	_	O
115	scheme	_	_	O
116	until	_	_	O
117	resolution	_	_	O
118	of	_	_	O
119	postoperative	_	_	O
120	ileus	_	_	O
121	to	_	_	O
122	start	_	_	O
123	liquid	_	_	O
124	diet	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	end-point	_	_	O
129	of	_	_	O
130	the	_	_	O
131	trial	_	_	O
132	was	_	_	O
133	length	_	_	O
134	of	_	_	O
135	hospital	_	_	O
136	stay	_	_	O
137	.	_	_	O

138	Between	_	_	O
139	January	_	_	O
140	1	_	_	O
141	,	_	_	O
142	2007	_	_	O
143	,	_	_	O
144	and	_	_	O
145	November	_	_	O
146	17	_	_	O
147	,	_	_	O
148	2007	_	_	O
149	,	_	_	O
150	a	_	_	O
151	total	_	_	O
152	of	_	_	O
153	143	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	receive	_	_	O
159	either	_	_	O
160	EOF	_	_	O
161	or	_	_	O
162	TOF	_	_	O
163	.	_	_	O

164	Hospital	_	_	B-Premise
165	stay	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	who	_	_	I-Premise
169	received	_	_	I-Premise
170	EOF	_	_	I-Premise
171	(	_	_	I-Premise
172	n=71	_	_	I-Premise
173	)	_	_	I-Premise
174	was	_	_	I-Premise
175	4.7	_	_	I-Premise
176	vs.	_	_	I-Premise
177	5.8	_	_	I-Premise
178	days	_	_	I-Premise
179	for	_	_	I-Premise
180	the	_	_	I-Premise
181	TOF	_	_	I-Premise
182	group	_	_	I-Premise
183	(	_	_	I-Premise
184	n=72	_	_	I-Premise
185	)	_	_	I-Premise
186	(	_	_	I-Premise
187	P=0.006	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	mean	_	_	I-Premise
192	level	_	_	I-Premise
193	of	_	_	I-Premise
194	postoperative	_	_	I-Premise
195	satisfaction	_	_	I-Premise
196	was	_	_	I-Premise
197	significantly	_	_	I-Premise
198	higher	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	EOF	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	82.8	_	_	I-Premise
205	vs.	_	_	I-Premise
206	71.7	_	_	I-Premise
207	mm	_	_	I-Premise
208	,	_	_	I-Premise
209	P	_	_	I-Premise
210	B	_	_	I-Premise
211	0.001	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	Patients	_	_	B-Premise
215	who	_	_	I-Premise
216	received	_	_	I-Premise
217	the	_	_	I-Premise
218	TOF	_	_	I-Premise
219	scheme	_	_	I-Premise
220	had	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	overall	_	_	I-Premise
224	postoperative	_	_	I-Premise
225	complications	_	_	I-Premise
226	(	_	_	I-Premise
227	39	_	_	I-Premise
228	vs.	_	_	I-Premise
229	17	_	_	I-Premise
230	%	_	_	I-Premise
231	in	_	_	I-Premise
232	EOF	_	_	I-Premise
233	group	_	_	I-Premise
234	,	_	_	I-Premise
235	P=0.003	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	infective	_	_	I-Premise
239	complications	_	_	I-Premise
240	(	_	_	I-Premise
241	14	_	_	I-Premise
242	%	_	_	I-Premise
243	in	_	_	I-Premise
244	TOF	_	_	I-Premise
245	group	_	_	I-Premise
246	vs.	_	_	I-Premise
247	3	_	_	I-Premise
248	%	_	_	I-Premise
249	in	_	_	I-Premise
250	EOF	_	_	I-Premise
251	group	_	_	I-Premise
252	,	_	_	I-Premise
253	P=0.017	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Variables	_	_	B-Premise
257	such	_	_	I-Premise
258	as	_	_	I-Premise
259	nausea	_	_	I-Premise
260	and	_	_	I-Premise
261	vomiting	_	_	I-Premise
262	,	_	_	I-Premise
263	analgesic	_	_	I-Premise
264	and	_	_	I-Premise
265	antiemetic	_	_	I-Premise
266	requirement	_	_	I-Premise
267	as	_	_	I-Premise
268	well	_	_	I-Premise
269	as	_	_	I-Premise
270	level	_	_	I-Premise
271	of	_	_	I-Premise
272	pain	_	_	I-Premise
273	and	_	_	I-Premise
274	quality	_	_	I-Premise
275	of	_	_	I-Premise
276	life	_	_	I-Premise
277	were	_	_	I-Premise
278	not	_	_	I-Premise
279	different	_	_	I-Premise
280	between	_	_	I-Premise
281	groups	_	_	I-Premise
282	.	_	_	I-Premise

283	On	_	_	B-Claim
284	the	_	_	I-Claim
285	basis	_	_	I-Claim
286	of	_	_	I-Claim
287	these	_	_	I-Claim
288	findings	_	_	I-Claim
289	,	_	_	I-Claim
290	the	_	_	I-Claim
291	policy	_	_	I-Claim
292	of	_	_	I-Claim
293	EOF	_	_	I-Claim
294	should	_	_	I-Claim
295	be	_	_	I-Claim
296	used	_	_	I-Claim
297	after	_	_	I-Claim
298	a	_	_	I-Claim
299	complex	_	_	I-Claim
300	gynecologic	_	_	I-Claim
301	oncologic	_	_	I-Claim
302	laparotomy	_	_	I-Claim
303	.	_	_	I-Claim


0	Insomnia	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	common	_	_	I-Claim
4	complaint	_	_	I-Claim
5	among	_	_	I-Claim
6	cancer	_	_	I-Claim
7	survivors	_	_	I-Claim
8	.	_	_	I-Claim

9	Fortunately	_	_	O
10	,	_	_	O
11	cognitive-behavioral	_	_	O
12	therapy	_	_	O
13	for	_	_	O
14	insomnia	_	_	O
15	(	_	_	O
16	CBT-I	_	_	O
17	)	_	_	O
18	has	_	_	O
19	been	_	_	O
20	shown	_	_	O
21	to	_	_	O
22	be	_	_	O
23	an	_	_	O
24	effective	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	this	_	_	O
28	population	_	_	O
29	.	_	_	O

30	However	_	_	O
31	,	_	_	O
32	it	_	_	O
33	is	_	_	O
34	rarely	_	_	O
35	implemented	_	_	O
36	given	_	_	O
37	its	_	_	O
38	limited	_	_	O
39	availability	_	_	O
40	.	_	_	O

41	To	_	_	O
42	address	_	_	O
43	this	_	_	O
44	barrier	_	_	O
45	,	_	_	O
46	we	_	_	O
47	examined	_	_	O
48	the	_	_	O
49	ability	_	_	O
50	of	_	_	O
51	an	_	_	O
52	easily	_	_	O
53	accessible	_	_	O
54	online	_	_	O
55	CBT-I	_	_	O
56	program	_	_	O
57	to	_	_	O
58	improve	_	_	O
59	insomnia	_	_	O
60	symptoms	_	_	O
61	in	_	_	O
62	cancer	_	_	O
63	survivors	_	_	O
64	.	_	_	O

65	Twenty-eight	_	_	O
66	cancer	_	_	O
67	survivors	_	_	O
68	with	_	_	O
69	insomnia	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	either	_	_	O
75	an	_	_	O
76	Internet	_	_	O
77	insomnia	_	_	O
78	intervention	_	_	O
79	(	_	_	O
80	n	_	_	O
81	=	_	_	O
82	14	_	_	O
83	)	_	_	O
84	or	_	_	O
85	to	_	_	O
86	a	_	_	O
87	waitlist	_	_	O
88	control	_	_	O
89	group	_	_	O
90	(	_	_	O
91	n	_	_	O
92	=	_	_	O
93	14	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	online	_	_	O
98	program	_	_	O
99	,	_	_	O
100	Sleep	_	_	O
101	Healthy	_	_	O
102	Using	_	_	O
103	The	_	_	O
104	Internet	_	_	O
105	,	_	_	O
106	delivers	_	_	O
107	the	_	_	O
108	primary	_	_	O
109	components	_	_	O
110	of	_	_	O
111	CBT-I	_	_	O
112	(	_	_	O
113	sleep	_	_	O
114	restriction	_	_	O
115	,	_	_	O
116	stimulus	_	_	O
117	control	_	_	O
118	,	_	_	O
119	cognitive	_	_	O
120	restructuring	_	_	O
121	,	_	_	O
122	sleep	_	_	O
123	hygiene	_	_	O
124	,	_	_	O
125	and	_	_	O
126	relapse	_	_	O
127	prevention	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Pre-	_	_	O
131	and	_	_	O
132	post-assessment	_	_	O
133	data	_	_	O
134	were	_	_	O
135	collected	_	_	O
136	via	_	_	O
137	online	_	_	O
138	questionnaires	_	_	O
139	and	_	_	O
140	daily	_	_	O
141	sleep	_	_	O
142	diaries	_	_	O
143	.	_	_	O

144	Participants	_	_	B-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	Internet	_	_	I-Premise
148	group	_	_	I-Premise
149	showed	_	_	I-Premise
150	significant	_	_	I-Premise
151	improvements	_	_	I-Premise
152	at	_	_	I-Premise
153	post-assessment	_	_	I-Premise
154	compared	_	_	I-Premise
155	with	_	_	I-Premise
156	those	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	control	_	_	I-Premise
160	group	_	_	I-Premise
161	in	_	_	I-Premise
162	overall	_	_	I-Premise
163	insomnia	_	_	I-Premise
164	severity	_	_	I-Premise
165	(	_	_	I-Premise
166	F	_	_	I-Premise
167	(	_	_	I-Premise
168	1,26	_	_	I-Premise
169	)	_	_	I-Premise
170	=	_	_	I-Premise
171	22.8	_	_	I-Premise
172	;	_	_	I-Premise
173	p	_	_	I-Premise
174	<	_	_	I-Premise
175	0.001	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	sleep	_	_	I-Premise
179	efficiency	_	_	I-Premise
180	(	_	_	I-Premise
181	F	_	_	I-Premise
182	(	_	_	I-Premise
183	1,24	_	_	I-Premise
184	)	_	_	I-Premise
185	=	_	_	I-Premise
186	11.45	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	0.002	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	sleep	_	_	I-Premise
194	onset	_	_	I-Premise
195	latency	_	_	I-Premise
196	(	_	_	I-Premise
197	F	_	_	I-Premise
198	(	_	_	I-Premise
199	1,24	_	_	I-Premise
200	)	_	_	I-Premise
201	=	_	_	I-Premise
202	5.18	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.03	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	soundness	_	_	I-Premise
210	of	_	_	I-Premise
211	sleep	_	_	I-Premise
212	(	_	_	I-Premise
213	F	_	_	I-Premise
214	(	_	_	I-Premise
215	1,24	_	_	I-Premise
216	)	_	_	I-Premise
217	=	_	_	I-Premise
218	9.34	_	_	I-Premise
219	;	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0.005	_	_	I-Premise
223	)	_	_	I-Premise
224	,	_	_	I-Premise
225	restored	_	_	I-Premise
226	feeling	_	_	I-Premise
227	upon	_	_	I-Premise
228	awakening	_	_	I-Premise
229	(	_	_	I-Premise
230	F	_	_	I-Premise
231	(	_	_	I-Premise
232	1,24	_	_	I-Premise
233	)	_	_	I-Premise
234	=	_	_	I-Premise
235	11.95	_	_	I-Premise
236	;	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	0.002	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	general	_	_	I-Premise
244	fatigue	_	_	I-Premise
245	(	_	_	I-Premise
246	F	_	_	I-Premise
247	(	_	_	I-Premise
248	1,26	_	_	I-Premise
249	)	_	_	I-Premise
250	=	_	_	I-Premise
251	13.88	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Although	_	_	B-Premise
259	other	_	_	I-Premise
260	group	_	_	I-Premise
261	Ã—	_	_	I-Premise
262	time	_	_	I-Premise
263	interactions	_	_	I-Premise
264	were	_	_	I-Premise
265	not	_	_	I-Premise
266	significant	_	_	I-Premise
267	,	_	_	I-Premise
268	overall	_	_	I-Premise
269	adjusted	_	_	I-Premise
270	effect	_	_	I-Premise
271	sizes	_	_	I-Premise
272	for	_	_	I-Premise
273	all	_	_	I-Premise
274	sleep	_	_	I-Premise
275	variables	_	_	I-Premise
276	as	_	_	I-Premise
277	well	_	_	I-Premise
278	as	_	_	I-Premise
279	for	_	_	I-Premise
280	fatigue	_	_	I-Premise
281	,	_	_	I-Premise
282	depression	_	_	I-Premise
283	,	_	_	I-Premise
284	anxiety	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	I-Premise
287	quality	_	_	I-Premise
288	of	_	_	I-Premise
289	life	_	_	I-Premise
290	ranged	_	_	I-Premise
291	from	_	_	I-Premise
292	small	_	_	I-Premise
293	to	_	_	I-Premise
294	large	_	_	I-Premise
295	.	_	_	I-Premise

296	CBT-I	_	_	B-Claim
297	delivered	_	_	I-Claim
298	through	_	_	I-Claim
299	an	_	_	I-Claim
300	interactive	_	_	I-Claim
301	,	_	_	I-Claim
302	individually	_	_	I-Claim
303	tailored	_	_	I-Claim
304	Internet	_	_	I-Claim
305	intervention	_	_	I-Claim
306	may	_	_	I-Claim
307	be	_	_	I-Claim
308	a	_	_	I-Claim
309	viable	_	_	I-Claim
310	treatment	_	_	I-Claim
311	option	_	_	I-Claim
312	for	_	_	I-Claim
313	cancer	_	_	I-Claim
314	survivors	_	_	I-Claim
315	experiencing	_	_	I-Claim
316	insomnia	_	_	I-Claim
317	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	gemcitabine	_	_	O
8	plus	_	_	O
9	cisplatin	_	_	O
10	with	_	_	O
11	single-agent	_	_	O
12	gemcitabine	_	_	O
13	as	_	_	O
14	first-line	_	_	O
15	chemotherapy	_	_	O
16	for	_	_	O
17	locally	_	_	O
18	advanced	_	_	O
19	or	_	_	O
20	metastatic	_	_	O
21	pancreatic	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	Patients	_	_	O
25	with	_	_	O
26	advanced	_	_	O
27	adenocarcinoma	_	_	O
28	of	_	_	O
29	the	_	_	O
30	pancreas	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	receive	_	_	O
36	either	_	_	O
37	gemcitabine	_	_	O
38	1,000	_	_	O
39	mg/m2	_	_	O
40	and	_	_	O
41	cisplatin	_	_	O
42	50	_	_	O
43	mg/m2	_	_	O
44	given	_	_	O
45	on	_	_	O
46	days	_	_	O
47	1	_	_	O
48	and	_	_	O
49	15	_	_	O
50	of	_	_	O
51	a	_	_	O
52	4-week	_	_	O
53	cycle	_	_	O
54	(	_	_	O
55	GemCis	_	_	O
56	arm	_	_	O
57	)	_	_	O
58	or	_	_	O
59	gemcitabine	_	_	O
60	alone	_	_	O
61	at	_	_	O
62	a	_	_	O
63	dose	_	_	O
64	of	_	_	O
65	1,000	_	_	O
66	mg/m2	_	_	O
67	on	_	_	O
68	days	_	_	O
69	1	_	_	O
70	,	_	_	O
71	8	_	_	O
72	,	_	_	O
73	and	_	_	O
74	15	_	_	O
75	of	_	_	O
76	a	_	_	O
77	4-week	_	_	O
78	regimen	_	_	O
79	(	_	_	O
80	Gem	_	_	O
81	arm	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	end	_	_	O
87	point	_	_	O
88	was	_	_	O
89	overall	_	_	O
90	survival	_	_	O
91	;	_	_	O
92	secondary	_	_	O
93	end	_	_	O
94	points	_	_	O
95	were	_	_	O
96	progression-free	_	_	O
97	survival	_	_	O
98	,	_	_	O
99	response	_	_	O
100	rate	_	_	O
101	,	_	_	O
102	safety	_	_	O
103	,	_	_	O
104	and	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	.	_	_	O

109	One	_	_	O
110	hundred	_	_	O
111	ninety-five	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	enrolled	_	_	O
115	and	_	_	O
116	showed	_	_	O
117	baseline	_	_	O
118	characteristics	_	_	O
119	well	_	_	O
120	balanced	_	_	O
121	between	_	_	O
122	treatment	_	_	O
123	arms	_	_	O
124	.	_	_	O

125	Combination	_	_	B-Premise
126	treatment	_	_	I-Premise
127	in	_	_	I-Premise
128	the	_	_	I-Premise
129	GemCis	_	_	I-Premise
130	arm	_	_	I-Premise
131	was	_	_	I-Premise
132	associated	_	_	I-Premise
133	with	_	_	I-Premise
134	a	_	_	I-Premise
135	prolonged	_	_	I-Premise
136	median	_	_	I-Premise
137	progression-free	_	_	I-Premise
138	survival	_	_	I-Premise
139	(	_	_	I-Premise
140	5.3	_	_	I-Premise
141	months	_	_	I-Premise
142	v	_	_	I-Premise
143	3.1	_	_	I-Premise
144	months	_	_	I-Premise
145	;	_	_	I-Premise
146	hazard	_	_	I-Premise
147	ratio	_	_	I-Premise
148	[	_	_	I-Premise
149	HR	_	_	I-Premise
150	]	_	_	I-Premise
151	=	_	_	I-Premise
152	0.75	_	_	I-Premise
153	;	_	_	I-Premise
154	P	_	_	I-Premise
155	=	_	_	I-Premise
156	.053	_	_	I-Premise
157	)	_	_	I-Premise
158	.	_	_	I-Premise

159	Also	_	_	B-Premise
160	,	_	_	I-Premise
161	median	_	_	I-Premise
162	overall	_	_	I-Premise
163	survival	_	_	I-Premise
164	was	_	_	I-Premise
165	superior	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	treated	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	GemCis	_	_	I-Premise
172	arm	_	_	I-Premise
173	as	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	the	_	_	I-Premise
177	Gem	_	_	I-Premise
178	arm	_	_	I-Premise
179	(	_	_	I-Premise
180	7.5	_	_	I-Premise
181	v	_	_	I-Premise
182	6.0	_	_	I-Premise
183	months	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	an	_	_	B-Premise
187	advantage	_	_	I-Premise
188	which	_	_	I-Premise
189	did	_	_	I-Premise
190	not	_	_	I-Premise
191	,	_	_	I-Premise
192	however	_	_	I-Premise
193	,	_	_	I-Premise
194	reach	_	_	I-Premise
195	statistical	_	_	I-Premise
196	significance	_	_	I-Premise
197	(	_	_	I-Premise
198	HR	_	_	I-Premise
199	=	_	_	I-Premise
200	0.80	_	_	I-Premise
201	;	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.15	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Tumor	_	_	B-Premise
208	response	_	_	I-Premise
209	rates	_	_	I-Premise
210	were	_	_	I-Premise
211	comparable	_	_	I-Premise
212	between	_	_	I-Premise
213	treatment	_	_	I-Premise
214	arms	_	_	I-Premise
215	(	_	_	I-Premise
216	10.2	_	_	I-Premise
217	%	_	_	I-Premise
218	v	_	_	I-Premise
219	8.2	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	rate	_	_	I-Premise
225	of	_	_	I-Premise
226	stable	_	_	I-Premise
227	disease	_	_	I-Premise
228	was	_	_	I-Premise
229	,	_	_	I-Premise
230	however	_	_	I-Premise
231	,	_	_	I-Premise
232	greater	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	combination	_	_	I-Premise
236	arm	_	_	I-Premise
237	(	_	_	I-Premise
238	60.2	_	_	I-Premise
239	%	_	_	I-Premise
240	v	_	_	I-Premise
241	40.2	_	_	I-Premise
242	%	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	O

249	Grade	_	_	B-Premise
250	3	_	_	I-Premise
251	to	_	_	I-Premise
252	4	_	_	I-Premise
253	hematologic	_	_	I-Premise
254	toxicity	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	exceed	_	_	I-Premise
258	15	_	_	I-Premise
259	%	_	_	I-Premise
260	in	_	_	I-Premise
261	both	_	_	I-Premise
262	treatment	_	_	I-Premise
263	arms	_	_	I-Premise
264	.	_	_	I-Premise

265	These	_	_	B-Claim
266	results	_	_	I-Claim
267	support	_	_	I-Claim
268	the	_	_	I-Claim
269	efficacy	_	_	I-Claim
270	and	_	_	I-Claim
271	safety	_	_	I-Claim
272	of	_	_	I-Claim
273	an	_	_	I-Claim
274	every-2-weeks	_	_	I-Claim
275	treatment	_	_	I-Claim
276	with	_	_	I-Claim
277	gemcitabine	_	_	I-Claim
278	plus	_	_	I-Claim
279	cisplatin	_	_	I-Claim
280	.	_	_	I-Claim

281	Median	_	_	B-Claim
282	overall	_	_	I-Claim
283	survival	_	_	I-Claim
284	and	_	_	I-Claim
285	progression-free	_	_	I-Claim
286	survival	_	_	I-Claim
287	were	_	_	I-Claim
288	more	_	_	I-Claim
289	favorable	_	_	I-Claim
290	in	_	_	I-Claim
291	the	_	_	I-Claim
292	combination	_	_	I-Claim
293	arm	_	_	I-Claim
294	as	_	_	I-Claim
295	compared	_	_	I-Claim
296	with	_	_	I-Claim
297	gemcitabine	_	_	I-Claim
298	alone	_	_	I-Claim
299	,	_	_	I-Claim
300	although	_	_	B-Premise
301	the	_	_	I-Premise
302	difference	_	_	I-Premise
303	did	_	_	I-Premise
304	not	_	_	I-Premise
305	attain	_	_	I-Premise
306	statistical	_	_	I-Premise
307	significance	_	_	I-Premise
308	.	_	_	I-Premise


0	Extracellular	_	_	O
1	adenosine	_	_	O
2	5'-triphosphate	_	_	O
3	(	_	_	O
4	ATP	_	_	O
5	)	_	_	O
6	is	_	_	O
7	involved	_	_	O
8	in	_	_	O
9	the	_	_	O
10	regulation	_	_	O
11	of	_	_	O
12	a	_	_	O
13	variety	_	_	O
14	of	_	_	O
15	biologic	_	_	O
16	processes	_	_	O
17	,	_	_	O
18	including	_	_	O
19	neurotransmission	_	_	O
20	,	_	_	O
21	muscle	_	_	O
22	contraction	_	_	O
23	,	_	_	O
24	and	_	_	O
25	liver	_	_	O
26	glucose	_	_	O
27	metabolism	_	_	O
28	,	_	_	O
29	via	_	_	O
30	purinergic	_	_	O
31	receptors	_	_	O
32	.	_	_	O

33	In	_	_	B-Claim
34	nonrandomized	_	_	I-Claim
35	studies	_	_	I-Claim
36	involving	_	_	I-Claim
37	patients	_	_	I-Claim
38	with	_	_	I-Claim
39	different	_	_	I-Claim
40	tumor	_	_	I-Claim
41	types	_	_	I-Claim
42	including	_	_	I-Claim
43	non-small-cell	_	_	I-Claim
44	lung	_	_	I-Claim
45	cancer	_	_	I-Claim
46	(	_	_	I-Claim
47	NSCLC	_	_	I-Claim
48	)	_	_	I-Claim
49	,	_	_	I-Claim
50	ATP	_	_	I-Claim
51	infusion	_	_	I-Claim
52	appeared	_	_	I-Claim
53	to	_	_	I-Claim
54	inhibit	_	_	I-Claim
55	loss	_	_	I-Claim
56	of	_	_	I-Claim
57	weight	_	_	I-Claim
58	and	_	_	I-Claim
59	deterioration	_	_	I-Claim
60	of	_	_	I-Claim
61	quality	_	_	I-Claim
62	of	_	_	I-Claim
63	life	_	_	I-Claim
64	(	_	_	I-Claim
65	QOL	_	_	I-Claim
66	)	_	_	I-Claim
67	and	_	_	I-Claim
68	performance	_	_	I-Claim
69	status	_	_	I-Claim
70	.	_	_	I-Claim

71	We	_	_	O
72	conducted	_	_	O
73	a	_	_	O
74	randomized	_	_	O
75	clinical	_	_	O
76	trial	_	_	O
77	to	_	_	O
78	evaluate	_	_	O
79	the	_	_	O
80	effects	_	_	O
81	of	_	_	O
82	ATP	_	_	O
83	in	_	_	O
84	patients	_	_	O
85	with	_	_	O
86	advanced	_	_	O
87	NSCLC	_	_	O
88	(	_	_	O
89	stage	_	_	O
90	IIIB	_	_	O
91	or	_	_	O
92	IV	_	_	O
93	)	_	_	O
94	.	_	_	O

95	Fifty-eight	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	10	_	_	O
104	intravenous	_	_	O
105	30-hour	_	_	O
106	ATP	_	_	O
107	infusions	_	_	O
108	,	_	_	O
109	with	_	_	O
110	the	_	_	O
111	infusions	_	_	O
112	given	_	_	O
113	at	_	_	O
114	2-	_	_	O
115	to	_	_	O
116	4-week	_	_	O
117	intervals	_	_	O
118	,	_	_	O
119	or	_	_	O
120	no	_	_	O
121	ATP	_	_	O
122	.	_	_	O

123	Outcome	_	_	O
124	parameters	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	every	_	_	O
128	4	_	_	O
129	weeks	_	_	O
130	until	_	_	O
131	28	_	_	O
132	weeks	_	_	O
133	.	_	_	O

134	Between-group	_	_	O
135	differences	_	_	O
136	were	_	_	O
137	tested	_	_	O
138	for	_	_	O
139	statistical	_	_	O
140	significance	_	_	O
141	by	_	_	O
142	use	_	_	O
143	of	_	_	O
144	repeated-measures	_	_	O
145	analysis	_	_	O
146	,	_	_	O
147	and	_	_	O
148	reported	_	_	O
149	P	_	_	O
150	values	_	_	O
151	are	_	_	O
152	two-sided	_	_	O
153	.	_	_	O

154	Twenty-eight	_	_	O
155	patients	_	_	O
156	were	_	_	O
157	allocated	_	_	O
158	to	_	_	O
159	receive	_	_	O
160	ATP	_	_	O
161	treatment	_	_	O
162	and	_	_	O
163	30	_	_	O
164	received	_	_	O
165	no	_	_	O
166	ATP	_	_	O
167	.	_	_	O

168	Mean	_	_	B-Premise
169	weight	_	_	I-Premise
170	changes	_	_	I-Premise
171	per	_	_	I-Premise
172	4-week	_	_	I-Premise
173	period	_	_	I-Premise
174	were	_	_	I-Premise
175	-1.0	_	_	I-Premise
176	kg	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	confidence	_	_	I-Premise
181	interval	_	_	I-Premise
182	[	_	_	I-Premise
183	CI	_	_	I-Premise
184	]	_	_	I-Premise
185	=	_	_	I-Premise
186	-1.5	_	_	I-Premise
187	to	_	_	I-Premise
188	-0.5	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	control	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	0.2	_	_	I-Premise
196	kg	_	_	I-Premise
197	(	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	=	_	_	I-Premise
202	-0.2	_	_	I-Premise
203	to	_	_	I-Premise
204	+0.6	_	_	I-Premise
205	)	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	ATP	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=.002	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Serum	_	_	B-Premise
216	albumin	_	_	I-Premise
217	concentration	_	_	I-Premise
218	declined	_	_	I-Premise
219	by	_	_	I-Premise
220	-1.2	_	_	I-Premise
221	g/L	_	_	I-Premise
222	(	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI=	_	_	I-Premise
226	-2.0	_	_	I-Premise
227	to	_	_	I-Premise
228	-0.4	_	_	I-Premise
229	)	_	_	I-Premise
230	per	_	_	I-Premise
231	4	_	_	I-Premise
232	weeks	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	control	_	_	I-Premise
236	group	_	_	I-Premise
237	but	_	_	I-Premise
238	remained	_	_	I-Premise
239	stable	_	_	I-Premise
240	(	_	_	I-Premise
241	0.0	_	_	I-Premise
242	g/L	_	_	I-Premise
243	;	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	=	_	_	I-Premise
248	-0.3	_	_	I-Premise
249	to	_	_	I-Premise
250	+0.3	_	_	I-Premise
251	)	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	ATP	_	_	I-Premise
255	group	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	=.006	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Elbow	_	_	B-Premise
262	flexor	_	_	I-Premise
263	muscle	_	_	I-Premise
264	strength	_	_	I-Premise
265	declined	_	_	I-Premise
266	by	_	_	I-Premise
267	-5.5	_	_	I-Premise
268	%	_	_	I-Premise
269	(	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	=	_	_	I-Premise
274	-9.6	_	_	I-Premise
275	%	_	_	I-Premise
276	to	_	_	I-Premise
277	-1	_	_	I-Premise
278	.	_	_	I-Premise

279	4	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	per	_	_	I-Premise
283	4	_	_	I-Premise
284	weeks	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	control	_	_	I-Premise
288	group	_	_	I-Premise
289	but	_	_	I-Premise
290	remained	_	_	I-Premise
291	stable	_	_	I-Premise
292	(	_	_	I-Premise
293	0.0	_	_	I-Premise
294	%	_	_	I-Premise
295	;	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	CI=	_	_	I-Premise
299	-1.4	_	_	I-Premise
300	%	_	_	I-Premise
301	to	_	_	I-Premise
302	+1.4	_	_	I-Premise
303	%	_	_	I-Premise
304	)	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	ATP	_	_	I-Premise
308	group	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=.01	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	A	_	_	B-Premise
315	similar	_	_	I-Premise
316	pattern	_	_	I-Premise
317	was	_	_	I-Premise
318	observed	_	_	I-Premise
319	for	_	_	I-Premise
320	knee	_	_	I-Premise
321	extensor	_	_	I-Premise
322	muscles	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	=.02	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	The	_	_	B-Premise
329	effects	_	_	I-Premise
330	of	_	_	I-Premise
331	ATP	_	_	I-Premise
332	on	_	_	I-Premise
333	body	_	_	I-Premise
334	weight	_	_	I-Premise
335	,	_	_	I-Premise
336	muscle	_	_	I-Premise
337	strength	_	_	I-Premise
338	,	_	_	I-Premise
339	and	_	_	I-Premise
340	albumin	_	_	I-Premise
341	concentration	_	_	I-Premise
342	were	_	_	I-Premise
343	especially	_	_	I-Premise
344	marked	_	_	I-Premise
345	in	_	_	I-Premise
346	cachectic	_	_	I-Premise
347	patients	_	_	I-Premise
348	(	_	_	I-Premise
349	P	_	_	I-Premise
350	=.0002	_	_	I-Premise
351	,	_	_	I-Premise
352	P	_	_	I-Premise
353	=.0001	_	_	I-Premise
354	,	_	_	I-Premise
355	and	_	_	I-Premise
356	P	_	_	I-Premise
357	=	_	_	I-Premise
358	.	_	_	I-Premise

359	0001	_	_	I-Premise
360	,	_	_	I-Premise
361	respectively	_	_	I-Premise
362	,	_	_	I-Premise
363	for	_	_	I-Premise
364	ATP	_	_	I-Premise
365	versus	_	_	I-Premise
366	no	_	_	I-Premise
367	ATP	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	QOL	_	_	B-Premise
371	score	_	_	I-Premise
372	changes	_	_	I-Premise
373	per	_	_	I-Premise
374	4-week	_	_	I-Premise
375	period	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	ATP	_	_	I-Premise
379	group	_	_	I-Premise
380	showed	_	_	I-Premise
381	overall	_	_	I-Premise
382	less	_	_	I-Premise
383	deterioration	_	_	I-Premise
384	than	_	_	I-Premise
385	in	_	_	I-Premise
386	the	_	_	I-Premise
387	control	_	_	I-Premise
388	group-physical	_	_	I-Premise
389	scores	_	_	I-Premise
390	(	_	_	I-Premise
391	-0.2	_	_	I-Premise
392	%	_	_	I-Premise
393	versus	_	_	I-Premise
394	-2.4	_	_	I-Premise
395	%	_	_	I-Premise
396	;	_	_	I-Premise
397	P	_	_	I-Premise
398	=	_	_	I-Premise
399	.	_	_	I-Premise

400	0002	_	_	I-Premise
401	)	_	_	I-Premise
402	;	_	_	I-Premise
403	functional	_	_	I-Premise
404	scores	_	_	I-Premise
405	(	_	_	I-Premise
406	+0.4	_	_	I-Premise
407	%	_	_	I-Premise
408	versus	_	_	I-Premise
409	-5.5	_	_	I-Premise
410	%	_	_	I-Premise
411	;	_	_	I-Premise
412	P	_	_	I-Premise
413	=.02	_	_	I-Premise
414	)	_	_	I-Premise
415	;	_	_	I-Premise
416	psychologic	_	_	I-Premise
417	scores	_	_	I-Premise
418	(	_	_	I-Premise
419	-0.7	_	_	I-Premise
420	%	_	_	I-Premise
421	versus	_	_	I-Premise
422	-2.4	_	_	I-Premise
423	%	_	_	I-Premise
424	;	_	_	I-Premise
425	P	_	_	I-Premise
426	=.11	_	_	I-Premise
427	)	_	_	I-Premise
428	;	_	_	I-Premise
429	overall	_	_	I-Premise
430	QOL	_	_	I-Premise
431	score	_	_	I-Premise
432	(	_	_	I-Premise
433	+0.1	_	_	I-Premise
434	%	_	_	I-Premise
435	versus	_	_	I-Premise
436	-3.5	_	_	I-Premise
437	%	_	_	I-Premise
438	;	_	_	I-Premise
439	P	_	_	I-Premise
440	=.0001	_	_	I-Premise
441	)	_	_	I-Premise
442	.	_	_	I-Premise

443	This	_	_	O
444	randomized	_	_	O
445	trial	_	_	O
446	demonstrates	_	_	O
447	that	_	_	O
448	ATP	_	_	B-Claim
449	has	_	_	I-Claim
450	beneficial	_	_	I-Claim
451	effects	_	_	I-Claim
452	on	_	_	I-Claim
453	weight	_	_	I-Claim
454	,	_	_	I-Claim
455	muscle	_	_	I-Claim
456	strength	_	_	I-Claim
457	,	_	_	I-Claim
458	and	_	_	I-Claim
459	QOL	_	_	I-Claim
460	in	_	_	I-Claim
461	patients	_	_	I-Claim
462	with	_	_	I-Claim
463	advanced	_	_	I-Claim
464	NSCLC	_	_	I-Claim
465	.	_	_	I-Claim


0	Abiraterone	_	_	B-Claim
1	acetate	_	_	I-Claim
2	plus	_	_	I-Claim
3	prednisone	_	_	I-Claim
4	significantly	_	_	I-Claim
5	improves	_	_	I-Claim
6	radiographic	_	_	I-Claim
7	progression-free	_	_	I-Claim
8	survival	_	_	I-Claim
9	in	_	_	I-Claim
10	asymptomatic	_	_	I-Claim
11	or	_	_	I-Claim
12	mildly	_	_	I-Claim
13	symptomatic	_	_	I-Claim
14	,	_	_	I-Claim
15	chemotherapy-naive	_	_	I-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	metastatic	_	_	I-Claim
19	castration-resistant	_	_	I-Claim
20	prostate	_	_	I-Claim
21	cancer	_	_	I-Claim
22	compared	_	_	I-Claim
23	with	_	_	I-Claim
24	prednisone	_	_	I-Claim
25	alone	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	describe	_	_	O
29	analyses	_	_	O
30	of	_	_	O
31	data	_	_	O
32	for	_	_	O
33	patient-reported	_	_	O
34	pain	_	_	O
35	and	_	_	O
36	functional	_	_	O
37	status	_	_	O
38	in	_	_	O
39	a	_	_	O
40	preplanned	_	_	O
41	interim	_	_	O
42	analysis	_	_	O
43	of	_	_	O
44	a	_	_	O
45	phase	_	_	O
46	3	_	_	O
47	trial	_	_	O
48	.	_	_	O

49	Between	_	_	O
50	April	_	_	O
51	28	_	_	O
52	,	_	_	O
53	2009	_	_	O
54	,	_	_	O
55	and	_	_	O
56	June	_	_	O
57	23	_	_	O
58	,	_	_	O
59	2010	_	_	O
60	,	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	progressive	_	_	O
64	,	_	_	O
65	metastatic	_	_	O
66	castration-resistant	_	_	O
67	prostate	_	_	O
68	cancer	_	_	O
69	were	_	_	O
70	enrolled	_	_	O
71	into	_	_	O
72	a	_	_	O
73	multinational	_	_	O
74	,	_	_	O
75	double-blind	_	_	O
76	,	_	_	O
77	placebo-controlled	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	were	_	_	O
82	eligible	_	_	O
83	if	_	_	O
84	they	_	_	O
85	were	_	_	O
86	asymptomatic	_	_	O
87	(	_	_	O
88	score	_	_	O
89	of	_	_	O
90	0	_	_	O
91	or	_	_	O
92	1	_	_	O
93	on	_	_	O
94	item	_	_	O
95	three	_	_	O
96	of	_	_	O
97	the	_	_	O
98	Brief	_	_	O
99	Pain	_	_	O
100	Inventory	_	_	O
101	Short	_	_	O
102	Form	_	_	O
103	[	_	_	O
104	BPI-SF	_	_	O
105	]	_	_	O
106	questionnaire	_	_	O
107	)	_	_	O
108	or	_	_	O
109	mildly	_	_	O
110	symptomatic	_	_	O
111	(	_	_	O
112	score	_	_	O
113	of	_	_	O
114	2	_	_	O
115	or	_	_	O
116	3	_	_	O
117	)	_	_	O
118	and	_	_	O
119	had	_	_	O
120	not	_	_	O
121	previously	_	_	O
122	received	_	_	O
123	chemotherapy	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	were	_	_	O
127	randomly	_	_	O
128	assigned	_	_	O
129	(	_	_	O
130	1:1	_	_	O
131	)	_	_	O
132	to	_	_	O
133	receive	_	_	O
134	oral	_	_	O
135	abiraterone	_	_	O
136	(	_	_	O
137	1	_	_	O
138	g	_	_	O
139	daily	_	_	O
140	)	_	_	O
141	plus	_	_	O
142	prednisone	_	_	O
143	(	_	_	O
144	5	_	_	O
145	mg	_	_	O
146	twice	_	_	O
147	daily	_	_	O
148	)	_	_	O
149	or	_	_	O
150	placebo	_	_	O
151	plus	_	_	O
152	prednisone	_	_	O
153	in	_	_	O
154	continuous	_	_	O
155	4-week	_	_	O
156	cycles	_	_	O
157	.	_	_	O

158	Pain	_	_	O
159	was	_	_	O
160	assessed	_	_	O
161	with	_	_	O
162	the	_	_	O
163	BPI-SF	_	_	O
164	questionnaire	_	_	O
165	,	_	_	O
166	and	_	_	O
167	health-related	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	(	_	_	O
172	HRQoL	_	_	O
173	)	_	_	O
174	with	_	_	O
175	the	_	_	O
176	Functional	_	_	O
177	Assessment	_	_	O
178	of	_	_	O
179	Cancer	_	_	O
180	Therapy-Prostate	_	_	O
181	(	_	_	O
182	FACT-P	_	_	O
183	)	_	_	O
184	questionnaire	_	_	O
185	.	_	_	O

186	We	_	_	O
187	analysed	_	_	O
188	data	_	_	O
189	with	_	_	O
190	prespecified	_	_	O
191	criteria	_	_	O
192	for	_	_	O
193	clinically	_	_	O
194	meaningful	_	_	O
195	pain	_	_	O
196	progression	_	_	O
197	and	_	_	O
198	deterioration	_	_	O
199	in	_	_	O
200	HRQoL	_	_	O
201	.	_	_	O

202	All	_	_	O
203	patients	_	_	O
204	who	_	_	O
205	underwent	_	_	O
206	randomisation	_	_	O
207	were	_	_	O
208	included	_	_	O
209	in	_	_	O
210	analyses	_	_	O
211	.	_	_	O

212	1088	_	_	O
213	patients	_	_	O
214	underwent	_	_	O
215	randomisation	_	_	O
216	:	_	_	O
217	546	_	_	O
218	were	_	_	O
219	assigned	_	_	O
220	to	_	_	O
221	abiraterone	_	_	O
222	plus	_	_	O
223	prednisone	_	_	O
224	and	_	_	O
225	542	_	_	O
226	to	_	_	O
227	placebo	_	_	O
228	plus	_	_	O
229	prednisone	_	_	O
230	.	_	_	O

231	At	_	_	O
232	the	_	_	O
233	time	_	_	O
234	of	_	_	O
235	the	_	_	O
236	second	_	_	O
237	prespecified	_	_	O
238	interim	_	_	O
239	analysis	_	_	O
240	,	_	_	O
241	median	_	_	O
242	follow-up	_	_	O
243	was	_	_	O
244	22Â·2	_	_	O
245	months	_	_	O
246	(	_	_	O
247	IQR	_	_	O
248	20Â·2-24Â·8	_	_	O
249	)	_	_	O
250	.	_	_	O

251	Median	_	_	B-Premise
252	time	_	_	I-Premise
253	to	_	_	I-Premise
254	progression	_	_	I-Premise
255	of	_	_	I-Premise
256	mean	_	_	I-Premise
257	pain	_	_	I-Premise
258	intensity	_	_	I-Premise
259	was	_	_	I-Premise
260	longer	_	_	I-Premise
261	in	_	_	I-Premise
262	patients	_	_	I-Premise
263	assigned	_	_	I-Premise
264	to	_	_	I-Premise
265	abiraterone	_	_	I-Premise
266	plus	_	_	I-Premise
267	prednisone	_	_	I-Premise
268	(	_	_	I-Premise
269	26Â·7	_	_	I-Premise
270	months	_	_	I-Premise
271	[	_	_	I-Premise
272	95	_	_	I-Premise
273	%	_	_	I-Premise
274	CI	_	_	I-Premise
275	19Â·3-not	_	_	I-Premise
276	estimable	_	_	I-Premise
277	]	_	_	I-Premise
278	)	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	those	_	_	I-Premise
282	assigned	_	_	I-Premise
283	to	_	_	I-Premise
284	placebo	_	_	I-Premise
285	plus	_	_	I-Premise
286	prednisone	_	_	I-Premise
287	(	_	_	I-Premise
288	18Â·4	_	_	I-Premise
289	months	_	_	I-Premise
290	[	_	_	I-Premise
291	14Â·9-not	_	_	I-Premise
292	estimable	_	_	I-Premise
293	]	_	_	I-Premise
294	;	_	_	I-Premise
295	hazard	_	_	I-Premise
296	ratio	_	_	I-Premise
297	[	_	_	I-Premise
298	HR	_	_	I-Premise
299	]	_	_	I-Premise
300	0Â·82	_	_	I-Premise
301	,	_	_	I-Premise
302	95	_	_	I-Premise
303	%	_	_	I-Premise
304	CI	_	_	I-Premise
305	0Â·67-1Â·00	_	_	I-Premise
306	;	_	_	I-Premise
307	p=0Â·0490	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	as	_	_	I-Premise
311	was	_	_	I-Premise
312	median	_	_	I-Premise
313	time	_	_	I-Premise
314	to	_	_	I-Premise
315	progression	_	_	I-Premise
316	of	_	_	I-Premise
317	pain	_	_	I-Premise
318	interference	_	_	I-Premise
319	with	_	_	I-Premise
320	daily	_	_	I-Premise
321	activities	_	_	I-Premise
322	(	_	_	I-Premise
323	10Â·3	_	_	I-Premise
324	months	_	_	I-Premise
325	[	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	9Â·3-13Â·0	_	_	I-Premise
330	]	_	_	I-Premise
331	vs	_	_	I-Premise
332	7Â·4	_	_	I-Premise
333	months	_	_	I-Premise
334	[	_	_	I-Premise
335	6Â·4-8Â·6	_	_	I-Premise
336	]	_	_	I-Premise
337	;	_	_	I-Premise
338	HR	_	_	I-Premise
339	0Â·79	_	_	I-Premise
340	,	_	_	I-Premise
341	95	_	_	I-Premise
342	%	_	_	I-Premise
343	CI	_	_	I-Premise
344	0Â·67-0Â·93	_	_	I-Premise
345	;	_	_	I-Premise
346	p=0Â·005	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	Median	_	_	B-Premise
350	time	_	_	I-Premise
351	to	_	_	I-Premise
352	progression	_	_	I-Premise
353	of	_	_	I-Premise
354	worst	_	_	I-Premise
355	pain	_	_	I-Premise
356	was	_	_	I-Premise
357	also	_	_	I-Premise
358	longer	_	_	I-Premise
359	with	_	_	I-Premise
360	abiraterone	_	_	I-Premise
361	plus	_	_	I-Premise
362	prednisone	_	_	I-Premise
363	(	_	_	I-Premise
364	26Â·7	_	_	I-Premise
365	months	_	_	I-Premise
366	[	_	_	I-Premise
367	95	_	_	I-Premise
368	%	_	_	I-Premise
369	CI	_	_	I-Premise
370	19Â·4-not	_	_	I-Premise
371	estimable	_	_	I-Premise
372	]	_	_	I-Premise
373	)	_	_	I-Premise
374	than	_	_	I-Premise
375	with	_	_	I-Premise
376	placebo	_	_	I-Premise
377	plus	_	_	I-Premise
378	prednisone	_	_	I-Premise
379	(	_	_	I-Premise
380	19Â·4	_	_	I-Premise
381	months	_	_	I-Premise
382	[	_	_	I-Premise
383	16Â·6-not	_	_	I-Premise
384	estimable	_	_	I-Premise
385	]	_	_	I-Premise
386	)	_	_	I-Premise
387	,	_	_	I-Premise
388	but	_	_	I-Premise
389	the	_	_	I-Premise
390	difference	_	_	I-Premise
391	was	_	_	I-Premise
392	not	_	_	I-Premise
393	significant	_	_	I-Premise
394	(	_	_	I-Premise
395	HR	_	_	I-Premise
396	0Â·85	_	_	I-Premise
397	,	_	_	I-Premise
398	95	_	_	I-Premise
399	%	_	_	I-Premise
400	CI	_	_	I-Premise
401	0Â·69-1Â·04	_	_	I-Premise
402	;	_	_	I-Premise
403	p=0Â·109	_	_	I-Premise
404	)	_	_	I-Premise
405	.	_	_	I-Premise

406	Median	_	_	B-Premise
407	time	_	_	I-Premise
408	to	_	_	I-Premise
409	HRQoL	_	_	I-Premise
410	deterioration	_	_	I-Premise
411	was	_	_	I-Premise
412	longer	_	_	I-Premise
413	in	_	_	I-Premise
414	patients	_	_	I-Premise
415	assigned	_	_	I-Premise
416	to	_	_	I-Premise
417	abiraterone	_	_	I-Premise
418	plus	_	_	I-Premise
419	prednisone	_	_	I-Premise
420	than	_	_	I-Premise
421	in	_	_	I-Premise
422	those	_	_	I-Premise
423	assigned	_	_	I-Premise
424	to	_	_	I-Premise
425	placebo	_	_	I-Premise
426	plus	_	_	I-Premise
427	prednisone	_	_	I-Premise
428	as	_	_	I-Premise
429	assessed	_	_	I-Premise
430	by	_	_	I-Premise
431	the	_	_	I-Premise
432	FACT-P	_	_	I-Premise
433	total	_	_	I-Premise
434	score	_	_	I-Premise
435	(	_	_	I-Premise
436	12Â·7	_	_	I-Premise
437	months	_	_	I-Premise
438	[	_	_	I-Premise
439	95	_	_	I-Premise
440	%	_	_	I-Premise
441	CI	_	_	I-Premise
442	11Â·1-14Â·0	_	_	I-Premise
443	]	_	_	I-Premise
444	vs	_	_	I-Premise
445	8Â·3	_	_	I-Premise
446	months	_	_	I-Premise
447	[	_	_	I-Premise
448	7Â·4-10Â·6	_	_	I-Premise
449	]	_	_	I-Premise
450	;	_	_	I-Premise
451	HR	_	_	I-Premise
452	0Â·78	_	_	I-Premise
453	,	_	_	I-Premise
454	95	_	_	I-Premise
455	%	_	_	I-Premise
456	CI	_	_	I-Premise
457	0Â·66-0Â·92	_	_	I-Premise
458	;	_	_	I-Premise
459	p=0Â·003	_	_	I-Premise
460	)	_	_	I-Premise
461	and	_	_	I-Premise
462	by	_	_	I-Premise
463	the	_	_	I-Premise
464	score	_	_	I-Premise
465	on	_	_	I-Premise
466	its	_	_	I-Premise
467	prostate-cancer-specific	_	_	I-Premise
468	subscale	_	_	I-Premise
469	(	_	_	I-Premise
470	11Â·1	_	_	I-Premise
471	months	_	_	I-Premise
472	[	_	_	I-Premise
473	8Â·6-13Â·8	_	_	I-Premise
474	]	_	_	I-Premise
475	vs	_	_	I-Premise
476	5Â·8	_	_	I-Premise
477	months	_	_	I-Premise
478	[	_	_	I-Premise
479	5Â·5-8Â·3	_	_	I-Premise
480	]	_	_	I-Premise
481	;	_	_	I-Premise
482	HR	_	_	I-Premise
483	0Â·70	_	_	I-Premise
484	,	_	_	I-Premise
485	95	_	_	I-Premise
486	%	_	_	I-Premise
487	CI	_	_	I-Premise
488	0Â·60-0Â·83	_	_	I-Premise
489	;	_	_	I-Premise
490	p	_	_	I-Premise
491	<	_	_	I-Premise
492	0Â·0001	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	Abiraterone	_	_	B-Claim
496	plus	_	_	I-Claim
497	prednisone	_	_	I-Claim
498	delays	_	_	I-Claim
499	patient-reported	_	_	I-Claim
500	pain	_	_	I-Claim
501	progression	_	_	I-Claim
502	and	_	_	I-Claim
503	HRQoL	_	_	I-Claim
504	deterioration	_	_	I-Claim
505	in	_	_	I-Claim
506	chemotherapy-naive	_	_	I-Claim
507	patients	_	_	I-Claim
508	with	_	_	I-Claim
509	metastatic	_	_	I-Claim
510	castration-resistant	_	_	I-Claim
511	prostate	_	_	I-Claim
512	cancer	_	_	I-Claim
513	.	_	_	I-Claim

514	These	_	_	B-Claim
515	results	_	_	I-Claim
516	provide	_	_	I-Claim
517	further	_	_	I-Claim
518	support	_	_	I-Claim
519	for	_	_	I-Claim
520	the	_	_	I-Claim
521	efficacy	_	_	I-Claim
522	of	_	_	I-Claim
523	abiraterone	_	_	I-Claim
524	in	_	_	I-Claim
525	this	_	_	I-Claim
526	population	_	_	I-Claim
527	.	_	_	I-Claim


0	Postoperative	_	_	B-Claim
1	adjuvant	_	_	I-Claim
2	chemoradiation	_	_	I-Claim
3	treatment	_	_	I-Claim
4	after	_	_	I-Claim
5	curative	_	_	I-Claim
6	resection	_	_	I-Claim
7	for	_	_	I-Claim
8	rectal	_	_	I-Claim
9	cancer	_	_	I-Claim
10	was	_	_	I-Claim
11	needed	_	_	I-Claim
12	to	_	_	I-Claim
13	reduce	_	_	I-Claim
14	recurrence	_	_	I-Claim
15	and	_	_	I-Claim
16	improve	_	_	I-Claim
17	a	_	_	I-Claim
18	survival	_	_	I-Claim
19	rate	_	_	I-Claim
20	.	_	_	I-Claim

21	Intravenous	_	_	B-Claim
22	5-fluorouracil	_	_	I-Claim
23	(	_	_	I-Claim
24	5-FU	_	_	I-Claim
25	)	_	_	I-Claim
26	and	_	_	I-Claim
27	leucovorin	_	_	I-Claim
28	has	_	_	I-Claim
29	been	_	_	I-Claim
30	a	_	_	I-Claim
31	mainstay	_	_	I-Claim
32	of	_	_	I-Claim
33	chemotherapy	_	_	I-Claim
34	,	_	_	I-Claim
35	but	_	_	O
36	oral	_	_	B-Claim
37	5-FU	_	_	I-Claim
38	derivatives	_	_	I-Claim
39	have	_	_	I-Claim
40	been	_	_	I-Claim
41	shown	_	_	I-Claim
42	a	_	_	I-Claim
43	comparable	_	_	I-Claim
44	antitumor	_	_	I-Claim
45	activity	_	_	I-Claim
46	.	_	_	I-Claim

47	Intravenous	_	_	O
48	5-FU	_	_	O
49	and	_	_	O
50	oral	_	_	O
51	doxifluridine	_	_	O
52	were	_	_	O
53	compared	_	_	O
54	with	_	_	O
55	respect	_	_	O
56	to	_	_	O
57	therapeutic	_	_	O
58	efficacy	_	_	O
59	,	_	_	O
60	drug	_	_	O
61	toxicity	_	_	O
62	,	_	_	O
63	and	_	_	O
64	quality	_	_	O
65	of	_	_	O
66	life	_	_	O
67	.	_	_	O

68	A	_	_	O
69	total	_	_	O
70	of	_	_	O
71	166	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	to	_	_	O
76	receive	_	_	O
77	intravenous	_	_	O
78	5-FU	_	_	O
79	(	_	_	O
80	450	_	_	O
81	mg/m2/day	_	_	O
82	)	_	_	O
83	or	_	_	O
84	oral	_	_	O
85	doxifluridine	_	_	O
86	(	_	_	O
87	900	_	_	O
88	mg/m2/day	_	_	O
89	)	_	_	O
90	in	_	_	O
91	combination	_	_	O
92	with	_	_	O
93	leucovorin	_	_	O
94	(	_	_	O
95	20	_	_	O
96	mg/m2/day	_	_	O
97	)	_	_	O
98	for	_	_	O
99	depth	_	_	O
100	of	_	_	O
101	invasion	_	_	O
102	,	_	_	O
103	nodal	_	_	O
104	status	_	_	O
105	,	_	_	O
106	metastasis	_	_	O
107	(	_	_	O
108	TNM	_	_	O
109	)	_	_	O
110	stage	_	_	O
111	II	_	_	O
112	and	_	_	O
113	III	_	_	O
114	patients	_	_	O
115	between	_	_	O
116	October	_	_	O
117	1997	_	_	O
118	and	_	_	O
119	February	_	_	O
120	1999	_	_	O
121	.	_	_	O

122	Consecutive	_	_	O
123	daily	_	_	O
124	intravenous	_	_	O
125	infusion	_	_	O
126	for	_	_	O
127	5	_	_	O
128	days	_	_	O
129	per	_	_	O
130	every	_	_	O
131	month	_	_	O
132	for	_	_	O
133	a	_	_	O
134	total	_	_	O
135	of	_	_	O
136	12	_	_	O
137	cycles	_	_	O
138	(	_	_	O
139	IV	_	_	O
140	arm	_	_	O
141	,	_	_	O
142	n	_	_	O
143	=	_	_	O
144	74	_	_	O
145	)	_	_	O
146	and	_	_	O
147	oral	_	_	O
148	doxifluridine	_	_	O
149	daily	_	_	O
150	for	_	_	O
151	3	_	_	O
152	weeks	_	_	O
153	and	_	_	O
154	1	_	_	O
155	week	_	_	O
156	rest	_	_	O
157	for	_	_	O
158	a	_	_	O
159	total	_	_	O
160	of	_	_	O
161	12	_	_	O
162	cycles	_	_	O
163	(	_	_	O
164	oral	_	_	O
165	arm	_	_	O
166	,	_	_	O
167	n	_	_	O
168	=	_	_	O
169	92	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Drug	_	_	O
173	toxicity	_	_	O
174	and	_	_	O
175	quality	_	_	O
176	of	_	_	O
177	life	_	_	O
178	were	_	_	O
179	observed	_	_	O
180	.	_	_	O

181	Quality	_	_	O
182	of	_	_	O
183	life	_	_	O
184	was	_	_	O
185	scored	_	_	O
186	according	_	_	O
187	to	_	_	O
188	22	_	_	O
189	daily	_	_	O
190	activity	_	_	O
191	items	_	_	O
192	(	_	_	O
193	good	_	_	O
194	,	_	_	O
195	>	_	_	O
196	or	_	_	O
197	=71	_	_	O
198	;	_	_	O
199	fair	_	_	O
200	,	_	_	O
201	<	_	_	O
202	70	_	_	O
203	;	_	_	O
204	poor	_	_	O
205	,	_	_	O
206	<	_	_	O
207	52	_	_	O
208	)	_	_	O
209	.	_	_	O

210	There	_	_	O
211	was	_	_	O
212	no	_	_	O
213	difference	_	_	O
214	of	_	_	O
215	sex	_	_	O
216	between	_	_	O
217	two	_	_	O
218	groups	_	_	O
219	(	_	_	O
220	IV	_	_	O
221	arm	_	_	O
222	:	_	_	O
223	male/female	_	_	O
224	=	_	_	O
225	45/29	_	_	O
226	,	_	_	O
227	oral	_	_	O
228	arm	_	_	O
229	:	_	_	O
230	male/female	_	_	O
231	=	_	_	O
232	59/33	_	_	O
233	)	_	_	O
234	.	_	_	O

235	The	_	_	O
236	mean	_	_	O
237	age	_	_	O
238	was	_	_	O
239	52.3	_	_	O
240	vs.	_	_	O
241	59.5	_	_	O
242	,	_	_	O
243	respectively	_	_	O
244	.	_	_	O

245	There	_	_	O
246	was	_	_	O
247	also	_	_	O
248	no	_	_	O
249	difference	_	_	O
250	of	_	_	O
251	TNM	_	_	O
252	stage	_	_	O
253	distribution	_	_	O
254	and	_	_	O
255	type	_	_	O
256	of	_	_	O
257	operation	_	_	O
258	between	_	_	O
259	groups	_	_	O
260	(	_	_	O
261	P	_	_	O
262	>	_	_	O
263	.05	_	_	O
264	)	_	_	O
265	.	_	_	O

266	Mean	_	_	B-Premise
267	numbers	_	_	I-Premise
268	of	_	_	I-Premise
269	chemotherapy	_	_	I-Premise
270	cycles	_	_	I-Premise
271	were	_	_	I-Premise
272	6.5+/-3.7	_	_	I-Premise
273	(	_	_	I-Premise
274	IV	_	_	I-Premise
275	arm	_	_	I-Premise
276	)	_	_	I-Premise
277	vs.	_	_	I-Premise
278	7.2+/-4.3	_	_	I-Premise
279	(	_	_	I-Premise
280	oral	_	_	I-Premise
281	arm	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	respectively	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	rate	_	_	I-Premise
288	of	_	_	I-Premise
289	recurrence	_	_	I-Premise
290	was	_	_	I-Premise
291	9/74	_	_	I-Premise
292	(	_	_	I-Premise
293	12.1	_	_	I-Premise
294	%	_	_	I-Premise
295	)	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	IV	_	_	I-Premise
299	arm	_	_	I-Premise
300	and	_	_	I-Premise
301	6/92	_	_	I-Premise
302	(	_	_	I-Premise
303	6.5	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	oral	_	_	I-Premise
309	arm	_	_	I-Premise
310	,	_	_	I-Premise
311	respectively	_	_	I-Premise
312	(	_	_	I-Premise
313	P	_	_	I-Premise
314	=	_	_	I-Premise
315	.937	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	Local	_	_	B-Premise
319	recurrence	_	_	I-Premise
320	was	_	_	I-Premise
321	2/74	_	_	I-Premise
322	(	_	_	I-Premise
323	stage	_	_	I-Premise
324	III	_	_	I-Premise
325	;	_	_	I-Premise
326	2.7	_	_	I-Premise
327	%	_	_	I-Premise
328	)	_	_	I-Premise
329	in	_	_	I-Premise
330	the	_	_	I-Premise
331	IV	_	_	I-Premise
332	arm	_	_	I-Premise
333	and	_	_	I-Premise
334	1/92	_	_	I-Premise
335	(	_	_	I-Premise
336	stage	_	_	I-Premise
337	II	_	_	I-Premise
338	;	_	_	I-Premise
339	1.1	_	_	I-Premise
340	%	_	_	I-Premise
341	)	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	oral	_	_	I-Premise
345	arm	_	_	I-Premise
346	,	_	_	I-Premise
347	respectively	_	_	I-Premise
348	.	_	_	I-Premise

349	Systemic	_	_	B-Premise
350	recurrence	_	_	I-Premise
351	was	_	_	I-Premise
352	7/74	_	_	I-Premise
353	(	_	_	I-Premise
354	stage	_	_	I-Premise
355	III	_	_	I-Premise
356	;	_	_	I-Premise
357	9.4	_	_	I-Premise
358	%	_	_	I-Premise
359	)	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	IV	_	_	I-Premise
363	arm	_	_	I-Premise
364	and	_	_	I-Premise
365	5/92	_	_	I-Premise
366	(	_	_	I-Premise
367	stage	_	_	I-Premise
368	III	_	_	I-Premise
369	;	_	_	I-Premise
370	5.4	_	_	I-Premise
371	%	_	_	I-Premise
372	)	_	_	I-Premise
373	in	_	_	I-Premise
374	the	_	_	I-Premise
375	oral	_	_	I-Premise
376	arm	_	_	I-Premise
377	,	_	_	I-Premise
378	respectively	_	_	I-Premise
379	.	_	_	I-Premise

380	The	_	_	B-Premise
381	most	_	_	I-Premise
382	common	_	_	I-Premise
383	site	_	_	I-Premise
384	of	_	_	I-Premise
385	systemic	_	_	I-Premise
386	recurrence	_	_	I-Premise
387	was	_	_	I-Premise
388	the	_	_	I-Premise
389	liver	_	_	I-Premise
390	.	_	_	I-Premise

391	Toxicity	_	_	B-Premise
392	profile	_	_	I-Premise
393	was	_	_	I-Premise
394	as	_	_	I-Premise
395	follows	_	_	I-Premise
396	:	_	_	I-Premise
397	leukopenia	_	_	I-Premise
398	(	_	_	I-Premise
399	30/74	_	_	I-Premise
400	vs.	_	_	I-Premise
401	17/92	_	_	I-Premise
402	)	_	_	I-Premise
403	and	_	_	I-Premise
404	alopecia	_	_	I-Premise
405	(	_	_	I-Premise
406	21/74	_	_	I-Premise
407	vs.	_	_	I-Premise
408	13/92	_	_	I-Premise
409	)	_	_	I-Premise
410	were	_	_	I-Premise
411	statistically	_	_	I-Premise
412	more	_	_	I-Premise
413	common	_	_	I-Premise
414	in	_	_	I-Premise
415	the	_	_	I-Premise
416	IV	_	_	I-Premise
417	arm	_	_	I-Premise
418	.	_	_	I-Premise

419	Diarrhea	_	_	B-Premise
420	was	_	_	I-Premise
421	more	_	_	I-Premise
422	common	_	_	I-Premise
423	in	_	_	I-Premise
424	the	_	_	I-Premise
425	oral	_	_	I-Premise
426	arm	_	_	I-Premise
427	.	_	_	I-Premise

428	Poor	_	_	B-Premise
429	quality	_	_	I-Premise
430	of	_	_	I-Premise
431	life	_	_	I-Premise
432	score	_	_	I-Premise
433	between	_	_	I-Premise
434	two	_	_	I-Premise
435	groups	_	_	I-Premise
436	was	_	_	I-Premise
437	observed	_	_	I-Premise
438	at	_	_	I-Premise
439	1	_	_	I-Premise
440	month	_	_	I-Premise
441	(	_	_	I-Premise
442	23.9	_	_	I-Premise
443	%	_	_	I-Premise
444	vs.	_	_	I-Premise
445	13	_	_	I-Premise
446	%	_	_	I-Premise
447	)	_	_	I-Premise
448	and	_	_	I-Premise
449	2	_	_	I-Premise
450	months	_	_	I-Premise
451	(	_	_	I-Premise
452	15.8	_	_	I-Premise
453	%	_	_	I-Premise
454	vs.	_	_	I-Premise
455	3.7	_	_	I-Premise
456	%	_	_	I-Premise
457	)	_	_	I-Premise
458	after	_	_	I-Premise
459	chemotherapy	_	_	I-Premise
460	.	_	_	I-Premise

461	Good	_	_	B-Premise
462	quality	_	_	I-Premise
463	of	_	_	I-Premise
464	life	_	_	I-Premise
465	score	_	_	I-Premise
466	was	_	_	I-Premise
467	observed	_	_	I-Premise
468	at	_	_	I-Premise
469	1	_	_	I-Premise
470	month	_	_	I-Premise
471	(	_	_	I-Premise
472	19.5	_	_	I-Premise
473	%	_	_	I-Premise
474	vs.	_	_	I-Premise
475	49	_	_	I-Premise
476	%	_	_	I-Premise
477	)	_	_	I-Premise
478	and	_	_	I-Premise
479	2	_	_	I-Premise
480	months	_	_	I-Premise
481	(	_	_	I-Premise
482	47	_	_	I-Premise
483	%	_	_	I-Premise
484	vs.	_	_	I-Premise
485	72	_	_	I-Premise
486	%	_	_	I-Premise
487	)	_	_	I-Premise
488	,	_	_	I-Premise
489	respectively	_	_	I-Premise
490	(	_	_	I-Premise
491	P	_	_	I-Premise
492	<	_	_	I-Premise
493	.05	_	_	I-Premise
494	)	_	_	I-Premise
495	.	_	_	I-Premise

496	Oral	_	_	B-Claim
497	doxifluridine	_	_	I-Claim
498	with	_	_	I-Claim
499	leucovorin	_	_	I-Claim
500	shows	_	_	I-Claim
501	a	_	_	I-Claim
502	comparable	_	_	I-Claim
503	therapeutic	_	_	I-Claim
504	efficacy	_	_	I-Claim
505	to	_	_	I-Claim
506	intravenous	_	_	I-Claim
507	5-FU	_	_	I-Claim
508	regimen	_	_	I-Claim
509	with	_	_	I-Claim
510	high	_	_	I-Claim
511	quality	_	_	I-Claim
512	of	_	_	I-Claim
513	life	_	_	I-Claim
514	as	_	_	I-Claim
515	postoperative	_	_	I-Claim
516	adjuvant	_	_	I-Claim
517	therapy	_	_	I-Claim
518	.	_	_	I-Claim

519	The	_	_	B-Claim
520	oral	_	_	I-Claim
521	regimen	_	_	I-Claim
522	also	_	_	I-Claim
523	can	_	_	I-Claim
524	be	_	_	I-Claim
525	safely	_	_	I-Claim
526	given	_	_	I-Claim
527	with	_	_	I-Claim
528	appropriate	_	_	I-Claim
529	toxicity	_	_	I-Claim
530	and	_	_	I-Claim
531	tolerability	_	_	I-Claim
532	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	chemotherapy	_	_	O
8	regimens	_	_	O
9	,	_	_	O
10	gemcitabine	_	_	O
11	plus	_	_	O
12	carboplatin	_	_	O
13	and	_	_	O
14	mitomycin	_	_	O
15	,	_	_	O
16	ifosfamide	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cisplatin	_	_	O
20	,	_	_	O
21	in	_	_	O
22	chemotherapy-naive	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	advanced	_	_	O
26	non-small-cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	(	_	_	O
30	NSCLC	_	_	O
31	)	_	_	O
32	.	_	_	O

33	The	_	_	O
34	regimens	_	_	O
35	were	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	regard	_	_	O
39	to	_	_	O
40	effects	_	_	O
41	on	_	_	O
42	survival	_	_	O
43	,	_	_	O
44	response	_	_	O
45	rates	_	_	O
46	,	_	_	O
47	toxicity	_	_	O
48	,	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	.	_	_	O

54	Eligible	_	_	O
55	patients	_	_	O
56	had	_	_	O
57	previously	_	_	O
58	untreated	_	_	O
59	stage	_	_	O
60	IIIB	_	_	O
61	or	_	_	O
62	IV	_	_	O
63	NSCLC	_	_	O
64	suitable	_	_	O
65	for	_	_	O
66	cisplatin-based	_	_	O
67	chemotherapy	_	_	O
68	.	_	_	O

69	Randomly	_	_	O
70	assigned	_	_	O
71	patients	_	_	O
72	were	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	four	_	_	O
76	cycles	_	_	O
77	,	_	_	O
78	each	_	_	O
79	at	_	_	O
80	3-week	_	_	O
81	intervals	_	_	O
82	,	_	_	O
83	of	_	_	O
84	carboplatin	_	_	O
85	area	_	_	O
86	under	_	_	O
87	the	_	_	O
88	curve	_	_	O
89	of	_	_	O
90	5	_	_	O
91	on	_	_	O
92	day	_	_	O
93	1	_	_	O
94	plus	_	_	O
95	gemcitabine	_	_	O
96	1,200	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	(	_	_	O
107	GCa	_	_	O
108	)	_	_	O
109	or	_	_	O
110	mitomycin	_	_	O
111	6	_	_	O
112	mg/m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	,	_	_	O
117	ifosfamide	_	_	O
118	3g/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	,	_	_	O
123	and	_	_	O
124	cisplatin	_	_	O
125	50	_	_	O
126	mg/m	_	_	O
127	(	_	_	O
128	2	_	_	O
129	)	_	_	O
130	on	_	_	O
131	day	_	_	O
132	1	_	_	O
133	(	_	_	O
134	MIC	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Between	_	_	O
138	February	_	_	O
139	1999	_	_	O
140	and	_	_	O
141	August	_	_	O
142	2001	_	_	O
143	,	_	_	O
144	422	_	_	O
145	patients	_	_	O
146	(	_	_	O
147	GCa	_	_	O
148	,	_	_	O
149	n	_	_	O
150	=	_	_	O
151	212	_	_	O
152	;	_	_	O
153	MIC	_	_	O
154	,	_	_	O
155	n	_	_	O
156	=	_	_	O
157	210	_	_	O
158	)	_	_	O
159	were	_	_	O
160	randomly	_	_	O
161	assigned	_	_	O
162	in	_	_	O
163	the	_	_	O
164	United	_	_	O
165	Kingdom	_	_	O
166	.	_	_	O

167	The	_	_	O
168	majority	_	_	O
169	of	_	_	O
170	patients	_	_	O
171	received	_	_	O
172	the	_	_	O
173	intended	_	_	O
174	four	_	_	O
175	cycles	_	_	O
176	(	_	_	O
177	GCa	_	_	O
178	,	_	_	O
179	64	_	_	O
180	%	_	_	O
181	;	_	_	O
182	MIC	_	_	O
183	,	_	_	O
184	61	_	_	O
185	%	_	_	O
186	)	_	_	O
187	.	_	_	O

188	There	_	_	B-Premise
189	was	_	_	I-Premise
190	a	_	_	I-Premise
191	significant	_	_	I-Premise
192	survival	_	_	I-Premise
193	advantage	_	_	I-Premise
194	for	_	_	I-Premise
195	GCa	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	MIC	_	_	I-Premise
199	(	_	_	I-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	,	_	_	I-Premise
203	0.76	_	_	I-Premise
204	;	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	0.61	_	_	I-Premise
210	to	_	_	I-Premise
211	0	_	_	I-Premise
212	.	_	_	I-Premise

213	93	_	_	I-Premise
214	;	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.008	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Median	_	_	B-Premise
221	survival	_	_	I-Premise
222	was	_	_	I-Premise
223	10	_	_	I-Premise
224	months	_	_	I-Premise
225	with	_	_	I-Premise
226	GCa	_	_	I-Premise
227	and	_	_	I-Premise
228	7.6	_	_	I-Premise
229	months	_	_	I-Premise
230	with	_	_	I-Premise
231	MIC	_	_	I-Premise
232	(	_	_	I-Premise
233	difference	_	_	I-Premise
234	,	_	_	I-Premise
235	2.4	_	_	I-Premise
236	months	_	_	I-Premise
237	;	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	,	_	_	I-Premise
242	1.0	_	_	I-Premise
243	to	_	_	I-Premise
244	4.0	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	1-year	_	_	I-Premise
249	survival	_	_	I-Premise
250	was	_	_	I-Premise
251	40	_	_	I-Premise
252	%	_	_	I-Premise
253	with	_	_	I-Premise
254	GCa	_	_	I-Premise
255	and	_	_	I-Premise
256	30	_	_	I-Premise
257	%	_	_	I-Premise
258	with	_	_	I-Premise
259	MIC	_	_	I-Premise
260	(	_	_	I-Premise
261	difference	_	_	I-Premise
262	,	_	_	I-Premise
263	10	_	_	I-Premise
264	%	_	_	I-Premise
265	;	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	,	_	_	I-Premise
270	3	_	_	I-Premise
271	%	_	_	I-Premise
272	to	_	_	I-Premise
273	18	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Overall	_	_	B-Premise
278	response	_	_	I-Premise
279	rates	_	_	I-Premise
280	were	_	_	I-Premise
281	similar	_	_	I-Premise
282	(	_	_	I-Premise
283	42	_	_	I-Premise
284	%	_	_	I-Premise
285	for	_	_	I-Premise
286	GCa	_	_	I-Premise
287	v	_	_	I-Premise
288	41	_	_	I-Premise
289	%	_	_	I-Premise
290	for	_	_	I-Premise
291	MIC	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.84	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	More	_	_	B-Premise
299	thrombocytopenia	_	_	I-Premise
300	occurred	_	_	I-Premise
301	with	_	_	I-Premise
302	GCa	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.03	_	_	I-Premise
307	)	_	_	I-Premise
308	,	_	_	I-Premise
309	but	_	_	B-Premise
310	this	_	_	I-Premise
311	was	_	_	I-Premise
312	not	_	_	I-Premise
313	associated	_	_	I-Premise
314	with	_	_	I-Premise
315	increased	_	_	I-Premise
316	hospital	_	_	I-Premise
317	admission	_	_	I-Premise
318	or	_	_	I-Premise
319	fatality	_	_	I-Premise
320	.	_	_	I-Premise

321	GCa	_	_	B-Premise
322	caused	_	_	I-Premise
323	less	_	_	I-Premise
324	nausea	_	_	I-Premise
325	,	_	_	I-Premise
326	vomiting	_	_	I-Premise
327	,	_	_	I-Premise
328	constipation	_	_	I-Premise
329	,	_	_	I-Premise
330	and	_	_	I-Premise
331	alopecia	_	_	I-Premise
332	and	_	_	I-Premise
333	was	_	_	I-Premise
334	associated	_	_	I-Premise
335	with	_	_	I-Premise
336	fewer	_	_	I-Premise
337	admissions	_	_	I-Premise
338	for	_	_	I-Premise
339	administration	_	_	I-Premise
340	and	_	_	I-Premise
341	better	_	_	I-Premise
342	quality	_	_	I-Premise
343	of	_	_	I-Premise
344	life	_	_	I-Premise
345	.	_	_	I-Premise

346	In	_	_	B-Claim
347	patients	_	_	I-Claim
348	with	_	_	I-Claim
349	advanced	_	_	I-Claim
350	NSCLC	_	_	I-Claim
351	,	_	_	I-Claim
352	GCa	_	_	I-Claim
353	chemotherapy	_	_	I-Claim
354	was	_	_	I-Claim
355	shown	_	_	I-Claim
356	to	_	_	I-Claim
357	be	_	_	I-Claim
358	a	_	_	I-Claim
359	better-tolerated	_	_	I-Claim
360	treatment	_	_	I-Claim
361	that	_	_	I-Claim
362	conferred	_	_	I-Claim
363	a	_	_	I-Claim
364	survival	_	_	I-Claim
365	advantage	_	_	I-Claim
366	over	_	_	I-Claim
367	MIC	_	_	I-Claim
368	.	_	_	I-Claim


0	To	_	_	O
1	perform	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	70	_	_	O
7	and	_	_	O
8	80	_	_	O
9	Gy	_	_	O
10	radiotherapy	_	_	O
11	for	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	A	_	_	O
16	total	_	_	O
17	of	_	_	O
18	306	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	localized	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	were	_	_	O
25	randomized	_	_	O
26	.	_	_	O

27	No	_	_	O
28	androgen	_	_	O
29	deprivation	_	_	O
30	was	_	_	O
31	allowed	_	_	O
32	.	_	_	O

33	The	_	_	O
34	primary	_	_	O
35	endpoint	_	_	O
36	was	_	_	O
37	biochemical	_	_	O
38	relapse	_	_	O
39	according	_	_	O
40	to	_	_	O
41	the	_	_	O
42	modified	_	_	O
43	1997-American	_	_	O
44	Society	_	_	O
45	for	_	_	O
46	Therapeutic	_	_	O
47	Radiology	_	_	O
48	and	_	_	O
49	Oncology	_	_	O
50	and	_	_	O
51	Phoenix	_	_	O
52	definitions	_	_	O
53	.	_	_	O

54	Toxicity	_	_	O
55	was	_	_	O
56	graded	_	_	O
57	using	_	_	O
58	the	_	_	O
59	Radiation	_	_	O
60	Therapy	_	_	O
61	Oncology	_	_	O
62	Group	_	_	O
63	1991	_	_	O
64	criteria	_	_	O
65	and	_	_	O
66	the	_	_	O
67	late	_	_	O
68	effects	_	_	O
69	on	_	_	O
70	normal	_	_	O
71	tissues-subjective	_	_	O
72	,	_	_	O
73	objective	_	_	O
74	,	_	_	O
75	management	_	_	O
76	,	_	_	O
77	analytic	_	_	O
78	scales	_	_	O
79	(	_	_	O
80	LENT-SOMA	_	_	O
81	)	_	_	O
82	scales	_	_	O
83	.	_	_	O

84	The	_	_	O
85	patients	_	_	O
86	'	_	_	O
87	quality	_	_	O
88	of	_	_	O
89	life	_	_	O
90	was	_	_	O
91	scored	_	_	O
92	using	_	_	O
93	the	_	_	O
94	European	_	_	O
95	Organization	_	_	O
96	for	_	_	O
97	Research	_	_	O
98	and	_	_	O
99	Treatment	_	_	O
100	of	_	_	O
101	Cancer	_	_	O
102	Quality	_	_	O
103	of	_	_	O
104	Life	_	_	O
105	Questionnaire	_	_	O
106	30-item	_	_	O
107	cancer-specific	_	_	O
108	and	_	_	O
109	25-item	_	_	O
110	prostate-specific	_	_	O
111	modules	_	_	O
112	.	_	_	O

113	The	_	_	O
114	median	_	_	O
115	follow-up	_	_	O
116	was	_	_	O
117	61	_	_	O
118	months	_	_	O
119	.	_	_	O

120	According	_	_	O
121	to	_	_	O
122	the	_	_	O
123	1997-American	_	_	O
124	Society	_	_	O
125	for	_	_	O
126	Therapeutic	_	_	O
127	Radiology	_	_	O
128	and	_	_	O
129	Oncology	_	_	O
130	definition	_	_	O
131	,	_	_	O
132	the	_	_	O
133	5-year	_	_	O
134	biochemical	_	_	O
135	relapse	_	_	O
136	rate	_	_	O
137	was	_	_	O
138	39	_	_	O
139	%	_	_	O
140	and	_	_	O
141	28	_	_	O
142	%	_	_	O
143	in	_	_	O
144	the	_	_	O
145	70-	_	_	O
146	and	_	_	O
147	80-Gy	_	_	O
148	arms	_	_	O
149	,	_	_	O
150	respectively	_	_	O
151	(	_	_	O
152	p	_	_	O
153	=	_	_	O
154	.036	_	_	O
155	)	_	_	O
156	.	_	_	O

157	Using	_	_	O
158	the	_	_	O
159	Phoenix	_	_	O
160	definition	_	_	O
161	,	_	_	O
162	the	_	_	O
163	5-year	_	_	O
164	biochemical	_	_	O
165	relapse	_	_	O
166	rate	_	_	O
167	was	_	_	O
168	32	_	_	O
169	%	_	_	O
170	and	_	_	O
171	23.5	_	_	O
172	%	_	_	O
173	,	_	_	O
174	respectively	_	_	O
175	(	_	_	O
176	p	_	_	O
177	=	_	_	O
178	.09	_	_	O
179	)	_	_	O
180	.	_	_	O

181	The	_	_	O
182	subgroup	_	_	O
183	analysis	_	_	O
184	showed	_	_	O
185	a	_	_	O
186	better	_	_	O
187	biochemical	_	_	O
188	outcome	_	_	O
189	for	_	_	O
190	the	_	_	O
191	higher	_	_	O
192	dose	_	_	O
193	group	_	_	O
194	with	_	_	O
195	an	_	_	O
196	initial	_	_	O
197	prostate-specific	_	_	O
198	antigen	_	_	O
199	level	_	_	O
200	>	_	_	O
201	15	_	_	O
202	ng/mL	_	_	O
203	.	_	_	O

204	At	_	_	O
205	the	_	_	O
206	last	_	_	O
207	follow-up	_	_	O
208	date	_	_	O
209	,	_	_	O
210	26	_	_	O
211	patients	_	_	O
212	had	_	_	O
213	died	_	_	O
214	,	_	_	O
215	10	_	_	O
216	of	_	_	O
217	their	_	_	O
218	disease	_	_	O
219	and	_	_	O
220	none	_	_	O
221	of	_	_	O
222	toxicity	_	_	O
223	,	_	_	O
224	with	_	_	O
225	no	_	_	O
226	differences	_	_	O
227	between	_	_	O
228	the	_	_	O
229	two	_	_	O
230	arms	_	_	O
231	.	_	_	O

232	According	_	_	B-Premise
233	to	_	_	I-Premise
234	the	_	_	I-Premise
235	Radiation	_	_	I-Premise
236	Therapy	_	_	I-Premise
237	Oncology	_	_	I-Premise
238	Group	_	_	I-Premise
239	scale	_	_	I-Premise
240	,	_	_	I-Premise
241	the	_	_	I-Premise
242	Grade	_	_	I-Premise
243	2	_	_	I-Premise
244	or	_	_	I-Premise
245	greater	_	_	I-Premise
246	rectal	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	rate	_	_	I-Premise
249	was	_	_	I-Premise
250	14	_	_	I-Premise
251	%	_	_	I-Premise
252	and	_	_	I-Premise
253	19.5	_	_	I-Premise
254	%	_	_	I-Premise
255	for	_	_	I-Premise
256	the	_	_	I-Premise
257	70-	_	_	I-Premise
258	and	_	_	I-Premise
259	80-Gy	_	_	I-Premise
260	arms	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	.22	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	B-Premise
270	Grade	_	_	I-Premise
271	2	_	_	I-Premise
272	or	_	_	I-Premise
273	greater	_	_	I-Premise
274	urinary	_	_	I-Premise
275	toxicity	_	_	I-Premise
276	was	_	_	I-Premise
277	10	_	_	I-Premise
278	%	_	_	I-Premise
279	at	_	_	I-Premise
280	70	_	_	I-Premise
281	Gy	_	_	I-Premise
282	and	_	_	I-Premise
283	17.5	_	_	I-Premise
284	%	_	_	I-Premise
285	at	_	_	I-Premise
286	80	_	_	I-Premise
287	Gy	_	_	I-Premise
288	(	_	_	I-Premise
289	p	_	_	I-Premise
290	=	_	_	I-Premise
291	.046	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Similar	_	_	B-Premise
295	results	_	_	I-Premise
296	were	_	_	I-Premise
297	observed	_	_	I-Premise
298	using	_	_	I-Premise
299	the	_	_	I-Premise
300	LENT-SOMA	_	_	I-Premise
301	scale	_	_	I-Premise
302	.	_	_	I-Premise

303	Bladder	_	_	B-Premise
304	toxicity	_	_	I-Premise
305	was	_	_	I-Premise
306	more	_	_	I-Premise
307	frequent	_	_	I-Premise
308	at	_	_	I-Premise
309	80	_	_	I-Premise
310	Gy	_	_	I-Premise
311	than	_	_	I-Premise
312	at	_	_	I-Premise
313	70	_	_	I-Premise
314	Gy	_	_	I-Premise
315	(	_	_	I-Premise
316	p	_	_	I-Premise
317	=	_	_	I-Premise
318	.039	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	The	_	_	B-Premise
322	quality-of-life	_	_	I-Premise
323	questionnaire	_	_	I-Premise
324	results	_	_	I-Premise
325	before	_	_	I-Premise
326	and	_	_	I-Premise
327	5	_	_	I-Premise
328	years	_	_	I-Premise
329	after	_	_	I-Premise
330	treatment	_	_	I-Premise
331	were	_	_	I-Premise
332	available	_	_	I-Premise
333	for	_	_	I-Premise
334	103	_	_	I-Premise
335	patients	_	_	I-Premise
336	with	_	_	I-Premise
337	no	_	_	I-Premise
338	differences	_	_	I-Premise
339	found	_	_	I-Premise
340	between	_	_	I-Premise
341	the	_	_	I-Premise
342	70-	_	_	I-Premise
343	and	_	_	I-Premise
344	80-Gy	_	_	I-Premise
345	arms	_	_	I-Premise
346	.	_	_	I-Premise

347	High-dose	_	_	B-Claim
348	radiotherapy	_	_	I-Claim
349	provided	_	_	I-Claim
350	a	_	_	I-Claim
351	better	_	_	I-Claim
352	5-year	_	_	I-Claim
353	biochemical	_	_	I-Claim
354	outcome	_	_	I-Claim
355	with	_	_	I-Claim
356	slightly	_	_	I-Claim
357	greater	_	_	I-Claim
358	toxicity	_	_	I-Claim
359	.	_	_	I-Claim


0	Several	_	_	O
1	multicomponent	_	_	O
2	regimens	_	_	O
3	have	_	_	O
4	been	_	_	O
5	reported	_	_	O
6	to	_	_	O
7	be	_	_	O
8	useful	_	_	O
9	in	_	_	O
10	advanced	_	_	O
11	androgen-independent	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	We	_	_	O
16	used	_	_	O
17	a	_	_	O
18	randomized	_	_	O
19	phase	_	_	O
20	II	_	_	O
21	design	_	_	O
22	to	_	_	O
23	evaluate	_	_	O
24	and	_	_	O
25	compare	_	_	O
26	two	_	_	O
27	such	_	_	O
28	regimens	_	_	O
29	.	_	_	O

30	Patients	_	_	O
31	were	_	_	O
32	accrued	_	_	O
33	primarily	_	_	O
34	in	_	_	O
35	the	_	_	O
36	community	_	_	O
37	setting	_	_	O
38	.	_	_	O

39	Patients	_	_	O
40	with	_	_	O
41	progressive	_	_	O
42	,	_	_	O
43	androgen-independent	_	_	O
44	prostate	_	_	O
45	cancer	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	one	_	_	O
51	of	_	_	O
52	two	_	_	O
53	treatments	_	_	O
54	:	_	_	O
55	either	_	_	O
56	ketoconazole/doxorubicin	_	_	O
57	alternating	_	_	O
58	with	_	_	O
59	vinblastine/estramustine	_	_	O
60	(	_	_	O
61	KA/VE	_	_	O
62	)	_	_	O
63	or	_	_	O
64	paclitaxel	_	_	O
65	,	_	_	O
66	estramustine	_	_	O
67	,	_	_	O
68	and	_	_	O
69	oral	_	_	O
70	etoposide	_	_	O
71	(	_	_	O
72	TEE	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	prospectively	_	_	O
78	stratified	_	_	O
79	on	_	_	O
80	the	_	_	O
81	basis	_	_	O
82	of	_	_	O
83	disease	_	_	O
84	volume	_	_	O
85	.	_	_	O

86	The	_	_	O
87	primary	_	_	O
88	end	_	_	O
89	points	_	_	O
90	were	_	_	O
91	response	_	_	O
92	and	_	_	O
93	overall	_	_	O
94	survival	_	_	O
95	time	_	_	O
96	.	_	_	O

97	A	_	_	O
98	total	_	_	O
99	of	_	_	O
100	75	_	_	O
101	patients	_	_	O
102	were	_	_	O
103	registered	_	_	O
104	;	_	_	O
105	71	_	_	O
106	are	_	_	O
107	included	_	_	O
108	in	_	_	O
109	the	_	_	O
110	analysis	_	_	O
111	.	_	_	O

112	By	_	_	O
113	the	_	_	O
114	criterion	_	_	O
115	of	_	_	O
116	an	_	_	O
117	80	_	_	O
118	%	_	_	O
119	prostate-specific	_	_	O
120	antigen	_	_	O
121	reduction	_	_	O
122	maintained	_	_	O
123	for	_	_	O
124	at	_	_	O
125	least	_	_	O
126	8	_	_	O
127	weeks	_	_	O
128	,	_	_	O
129	11	_	_	O
130	(	_	_	O
131	30	_	_	O
132	%	_	_	O
133	)	_	_	O
134	of	_	_	O
135	37	_	_	O
136	patients	_	_	O
137	in	_	_	O
138	the	_	_	O
139	TEE	_	_	O
140	arm	_	_	O
141	responded	_	_	O
142	,	_	_	O
143	whereas	_	_	O
144	11	_	_	O
145	(	_	_	O
146	32	_	_	O
147	%	_	_	O
148	)	_	_	O
149	of	_	_	O
150	34	_	_	O
151	assigned	_	_	O
152	to	_	_	O
153	KA/VE	_	_	O
154	responded	_	_	O
155	.	_	_	O

156	Median	_	_	B-Premise
157	survival	_	_	I-Premise
158	was	_	_	I-Premise
159	16.9	_	_	I-Premise
160	months	_	_	I-Premise
161	(	_	_	I-Premise
162	95	_	_	I-Premise
163	%	_	_	I-Premise
164	confidence	_	_	I-Premise
165	interval	_	_	I-Premise
166	[	_	_	I-Premise
167	CI	_	_	I-Premise
168	]	_	_	I-Premise
169	,	_	_	I-Premise
170	10.5	_	_	I-Premise
171	to	_	_	I-Premise
172	21.2	_	_	I-Premise
173	months	_	_	I-Premise
174	)	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	TEE	_	_	I-Premise
178	arm	_	_	I-Premise
179	and	_	_	I-Premise
180	23.4	_	_	I-Premise
181	months	_	_	I-Premise
182	(	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	,	_	_	I-Premise
187	12.9	_	_	I-Premise
188	to	_	_	I-Premise
189	30.6	_	_	I-Premise
190	months	_	_	I-Premise
191	)	_	_	I-Premise
192	for	_	_	I-Premise
193	patients	_	_	I-Premise
194	treated	_	_	I-Premise
195	with	_	_	I-Premise
196	KA/VE	_	_	I-Premise
197	.	_	_	I-Premise

198	Many	_	_	B-Premise
199	patients	_	_	I-Premise
200	(	_	_	I-Premise
201	24	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	failed	_	_	I-Premise
205	to	_	_	I-Premise
206	complete	_	_	I-Premise
207	at	_	_	I-Premise
208	least	_	_	I-Premise
209	6	_	_	I-Premise
210	weeks	_	_	I-Premise
211	of	_	_	I-Premise
212	therapy	_	_	I-Premise
213	,	_	_	I-Premise
214	including	_	_	I-Premise
215	five	_	_	I-Premise
216	(	_	_	I-Premise
217	8	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	treatment-related	_	_	I-Premise
221	early	_	_	I-Premise
222	deaths	_	_	I-Premise
223	.	_	_	I-Premise

224	Each	_	_	B-Claim
225	of	_	_	I-Claim
226	these	_	_	I-Claim
227	regimens	_	_	I-Claim
228	produced	_	_	I-Claim
229	clinically	_	_	I-Claim
230	significant	_	_	I-Claim
231	responses	_	_	I-Claim
232	,	_	_	I-Claim
233	and	_	_	O
234	the	_	_	B-Claim
235	observed	_	_	I-Claim
236	median	_	_	I-Claim
237	survival	_	_	I-Claim
238	(	_	_	I-Claim
239	18.9	_	_	I-Claim
240	months	_	_	I-Claim
241	for	_	_	I-Claim
242	all	_	_	I-Claim
243	71	_	_	I-Claim
244	patients	_	_	I-Claim
245	)	_	_	I-Claim
246	compares	_	_	I-Claim
247	favorably	_	_	I-Claim
248	with	_	_	I-Claim
249	previously	_	_	I-Claim
250	published	_	_	I-Claim
251	results	_	_	I-Claim
252	,	_	_	I-Claim
253	especially	_	_	I-Claim
254	in	_	_	I-Claim
255	the	_	_	I-Claim
256	community	_	_	I-Claim
257	setting	_	_	I-Claim
258	.	_	_	I-Claim

259	Nonetheless	_	_	B-Claim
260	,	_	_	I-Claim
261	it	_	_	I-Claim
262	is	_	_	I-Claim
263	apparent	_	_	I-Claim
264	that	_	_	I-Claim
265	these	_	_	I-Claim
266	first-generation	_	_	I-Claim
267	regimens	_	_	I-Claim
268	must	_	_	I-Claim
269	be	_	_	I-Claim
270	applied	_	_	I-Claim
271	judiciously	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	O
274	thus	_	_	B-Claim
275	we	_	_	I-Claim
276	view	_	_	I-Claim
277	efforts	_	_	I-Claim
278	at	_	_	I-Claim
279	better	_	_	I-Claim
280	patient	_	_	I-Claim
281	selection	_	_	I-Claim
282	and	_	_	I-Claim
283	the	_	_	I-Claim
284	development	_	_	I-Claim
285	of	_	_	I-Claim
286	more	_	_	I-Claim
287	tolerable	_	_	I-Claim
288	therapies	_	_	I-Claim
289	as	_	_	I-Claim
290	higher	_	_	I-Claim
291	priorities	_	_	I-Claim
292	than	_	_	I-Claim
293	carrying	_	_	I-Claim
294	either	_	_	I-Claim
295	of	_	_	I-Claim
296	these	_	_	I-Claim
297	regimens	_	_	I-Claim
298	to	_	_	I-Claim
299	phase	_	_	I-Claim
300	III	_	_	I-Claim
301	evaluation	_	_	I-Claim
302	in	_	_	I-Claim
303	the	_	_	I-Claim
304	cooperative	_	_	I-Claim
305	group	_	_	I-Claim
306	setting	_	_	I-Claim
307	.	_	_	I-Claim


0	Systematic	_	_	B-Claim
1	assessment	_	_	I-Claim
2	is	_	_	I-Claim
3	vital	_	_	I-Claim
4	to	_	_	I-Claim
5	palliative	_	_	I-Claim
6	care	_	_	I-Claim
7	,	_	_	O
8	but	_	_	O
9	documentation	_	_	O
10	confirming	_	_	O
11	completion	_	_	O
12	of	_	_	O
13	systematic	_	_	O
14	assessment	_	_	O
15	in	_	_	O
16	hospice	_	_	O
17	settings	_	_	O
18	is	_	_	O
19	often	_	_	O
20	inadequate	_	_	O
21	or	_	_	O
22	absent	_	_	O
23	.	_	_	O

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	the	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	determine	_	_	O
32	the	_	_	O
33	efficacy	_	_	O
34	of	_	_	O
35	systematic	_	_	O
36	feedback	_	_	O
37	from	_	_	O
38	standardized	_	_	O
39	assessment	_	_	O
40	tools	_	_	O
41	for	_	_	O
42	hospice	_	_	O
43	patient-caregiver	_	_	O
44	dyads	_	_	O
45	in	_	_	O
46	improving	_	_	O
47	hospice	_	_	O
48	outcomes	_	_	O
49	compared	_	_	O
50	with	_	_	O
51	the	_	_	O
52	usual	_	_	O
53	clinical	_	_	O
54	practice	_	_	O
55	.	_	_	O

56	The	_	_	O
57	sample	_	_	O
58	of	_	_	O
59	patients	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	709	_	_	O
64	)	_	_	O
65	newly	_	_	O
66	admitted	_	_	O
67	to	_	_	O
68	hospice	_	_	O
69	home	_	_	O
70	care	_	_	O
71	in	_	_	O
72	2	_	_	O
73	hospices	_	_	O
74	had	_	_	O
75	designated	_	_	O
76	family	_	_	O
77	caregivers	_	_	O
78	.	_	_	O

79	The	_	_	O
80	interdisciplinary	_	_	O
81	teams	_	_	O
82	(	_	_	O
83	IDTs	_	_	O
84	)	_	_	O
85	caring	_	_	O
86	for	_	_	O
87	these	_	_	O
88	dyads	_	_	O
89	were	_	_	O
90	randomly	_	_	O
91	assigned	_	_	O
92	to	_	_	O
93	either	_	_	O
94	experimental	_	_	O
95	(	_	_	O
96	n	_	_	O
97	=	_	_	O
98	338	_	_	O
99	)	_	_	O
100	or	_	_	O
101	control	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	371	_	_	O
106	)	_	_	O
107	conditions	_	_	O
108	.	_	_	O

109	Data	_	_	O
110	were	_	_	O
111	collected	_	_	O
112	from	_	_	O
113	both	_	_	O
114	groups	_	_	O
115	of	_	_	O
116	dyads	_	_	O
117	using	_	_	O
118	standardized	_	_	O
119	assessments	_	_	O
120	on	_	_	O
121	admission	_	_	O
122	and	_	_	O
123	1	_	_	O
124	week	_	_	O
125	after	_	_	O
126	each	_	_	O
127	of	_	_	O
128	the	_	_	O
129	first	_	_	O
130	2	_	_	O
131	IDT	_	_	O
132	meetings	_	_	O
133	in	_	_	O
134	which	_	_	O
135	these	_	_	O
136	dyads	_	_	O
137	were	_	_	O
138	discussed	_	_	O
139	.	_	_	O

140	The	_	_	O
141	experimental	_	_	O
142	intervention	_	_	O
143	consisted	_	_	O
144	of	_	_	O
145	reporting	_	_	O
146	data	_	_	O
147	from	_	_	O
148	the	_	_	O
149	standardized	_	_	O
150	assessments	_	_	O
151	to	_	_	O
152	the	_	_	O
153	IDTs	_	_	O
154	.	_	_	O

155	Results	_	_	B-Premise
156	showed	_	_	I-Premise
157	improved	_	_	I-Premise
158	patient	_	_	I-Premise
159	depression	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	<	_	_	I-Premise
163	.001	_	_	I-Premise
164	)	_	_	I-Premise
165	as	_	_	I-Premise
166	a	_	_	I-Premise
167	result	_	_	I-Premise
168	of	_	_	I-Premise
169	the	_	_	I-Premise
170	intervention	_	_	I-Premise
171	and	_	_	I-Premise
172	improvement	_	_	I-Premise
173	in	_	_	I-Premise
174	both	_	_	I-Premise
175	groups	_	_	I-Premise
176	in	_	_	I-Premise
177	patients	_	_	I-Premise
178	'	_	_	I-Premise
179	quality	_	_	I-Premise
180	of	_	_	I-Premise
181	life	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	.001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	No	_	_	B-Premise
189	other	_	_	I-Premise
190	patient	_	_	I-Premise
191	outcomes	_	_	I-Premise
192	(	_	_	I-Premise
193	symptom	_	_	I-Premise
194	distress	_	_	I-Premise
195	,	_	_	I-Premise
196	spiritual	_	_	I-Premise
197	needs	_	_	I-Premise
198	)	_	_	I-Premise
199	or	_	_	I-Premise
200	caregiver	_	_	I-Premise
201	outcomes	_	_	I-Premise
202	(	_	_	I-Premise
203	depression	_	_	I-Premise
204	,	_	_	I-Premise
205	support	_	_	I-Premise
206	,	_	_	I-Premise
207	spiritual	_	_	I-Premise
208	needs	_	_	I-Premise
209	)	_	_	I-Premise
210	were	_	_	I-Premise
211	significantly	_	_	I-Premise
212	different	_	_	I-Premise
213	.	_	_	I-Premise

214	Assessment	_	_	O
215	of	_	_	O
216	depression	_	_	O
217	added	_	_	O
218	to	_	_	O
219	usual	_	_	O
220	care	_	_	O
221	probably	_	_	O
222	had	_	_	O
223	an	_	_	O
224	effect	_	_	O
225	because	_	_	O
226	it	_	_	O
227	is	_	_	O
228	not	_	_	O
229	normally	_	_	O
230	a	_	_	O
231	focus	_	_	O
232	of	_	_	O
233	hospice	_	_	O
234	staff	_	_	O
235	.	_	_	O

236	Hospice	_	_	B-Premise
237	care	_	_	I-Premise
238	was	_	_	I-Premise
239	so	_	_	I-Premise
240	good	_	_	I-Premise
241	during	_	_	I-Premise
242	the	_	_	I-Premise
243	study	_	_	I-Premise
244	that	_	_	I-Premise
245	overall	_	_	I-Premise
246	quality	_	_	I-Premise
247	of	_	_	I-Premise
248	life	_	_	I-Premise
249	improved	_	_	I-Premise
250	as	_	_	I-Premise
251	a	_	_	I-Premise
252	result	_	_	I-Premise
253	of	_	_	I-Premise
254	standard	_	_	I-Premise
255	care	_	_	I-Premise
256	and	_	_	I-Premise
257	left	_	_	I-Premise
258	little	_	_	I-Premise
259	room	_	_	I-Premise
260	for	_	_	I-Premise
261	improvement	_	_	I-Premise
262	in	_	_	I-Premise
263	other	_	_	I-Premise
264	variables	_	_	I-Premise
265	.	_	_	I-Premise

266	Systematic	_	_	B-Claim
267	assessment	_	_	I-Claim
268	of	_	_	I-Claim
269	depression	_	_	I-Claim
270	is	_	_	I-Claim
271	needed	_	_	I-Claim
272	in	_	_	I-Claim
273	hospice	_	_	I-Claim
274	patients	_	_	I-Claim
275	.	_	_	I-Claim

276	No	_	_	O
277	caregiver	_	_	O
278	variables	_	_	O
279	changed	_	_	O
280	,	_	_	O
281	which	_	_	O
282	may	_	_	O
283	indicate	_	_	O
284	a	_	_	O
285	need	_	_	O
286	for	_	_	O
287	a	_	_	O
288	focus	_	_	O
289	on	_	_	O
290	caregivers	_	_	O
291	.	_	_	O


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	examine	_	_	O
5	the	_	_	O
6	effectiveness	_	_	O
7	of	_	_	O
8	a	_	_	O
9	self-management	_	_	O
10	multimodal	_	_	O
11	comprehensive	_	_	O
12	coping	_	_	O
13	strategy	_	_	O
14	program	_	_	O
15	(	_	_	O
16	CCSP	_	_	O
17	)	_	_	O
18	on	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	among	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	patients	_	_	O
29	1	_	_	O
30	year	_	_	O
31	after	_	_	O
32	treatment	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	110	_	_	O
39	)	_	_	O
40	with	_	_	O
41	stage	_	_	O
42	II	_	_	O
43	,	_	_	O
44	III	_	_	O
45	,	_	_	O
46	or	_	_	O
47	IV	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	scheduled	_	_	O
51	to	_	_	O
52	receive	_	_	O
53	high	_	_	O
54	dose	_	_	O
55	chemotherapy	_	_	O
56	and	_	_	O
57	autologous	_	_	O
58	hematopoietic	_	_	O
59	stem	_	_	O
60	cell	_	_	O
61	transplantation	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	either	_	_	O
66	CCSP	_	_	O
67	treatment	_	_	O
68	or	_	_	O
69	control	_	_	O
70	group	_	_	O
71	.	_	_	O

72	The	_	_	O
73	CCSP	_	_	O
74	intervention	_	_	O
75	was	_	_	O
76	taught	_	_	O
77	2	_	_	O
78	week	_	_	O
79	before	_	_	O
80	hospital	_	_	O
81	admission	_	_	O
82	with	_	_	O
83	reinforcement	_	_	O
84	at	_	_	O
85	specified	_	_	O
86	times	_	_	O
87	during	_	_	O
88	treatment	_	_	O
89	and	_	_	O
90	3	_	_	O
91	months	_	_	O
92	after	_	_	O
93	discharge	_	_	O
94	.	_	_	O

95	The	_	_	O
96	CCSP	_	_	O
97	components	_	_	O
98	included	_	_	O
99	educational	_	_	O
100	information	_	_	O
101	,	_	_	O
102	cognitive	_	_	O
103	restructuring	_	_	O
104	,	_	_	O
105	coping	_	_	O
106	skills	_	_	O
107	enhancement	_	_	O
108	,	_	_	O
109	and	_	_	O
110	relaxation	_	_	O
111	with	_	_	O
112	guided	_	_	O
113	imagery	_	_	O
114	.	_	_	O

115	Instruments	_	_	O
116	administered	_	_	O
117	at	_	_	O
118	baseline	_	_	O
119	included	_	_	O
120	the	_	_	O
121	following	_	_	O
122	:	_	_	O
123	Quality	_	_	O
124	of	_	_	O
125	Life	_	_	O
126	Index-Cancer	_	_	O
127	Version	_	_	O
128	(	_	_	O
129	QOLI-CV	_	_	O
130	)	_	_	O
131	,	_	_	O
132	State-Trait	_	_	O
133	Anxiety	_	_	O
134	Inventory	_	_	O
135	,	_	_	O
136	Beck	_	_	O
137	Depression	_	_	O
138	Inventory	_	_	O
139	,	_	_	O
140	and	_	_	O
141	Coping	_	_	O
142	Strategies	_	_	O
143	Questionnaire	_	_	O
144	.	_	_	O

145	At	_	_	O
146	1-year	_	_	O
147	follow-up	_	_	O
148	,	_	_	O
149	patients	_	_	O
150	(	_	_	O
151	n	_	_	O
152	=	_	_	O
153	73	_	_	O
154	)	_	_	O
155	completed	_	_	O
156	and	_	_	O
157	returned	_	_	O
158	the	_	_	O
159	follow-up	_	_	O
160	QOLI-CV	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	were	_	_	O
164	mainly	_	_	O
165	â‰¥	_	_	O
166	40	_	_	O
167	years	_	_	O
168	of	_	_	O
169	age	_	_	O
170	,	_	_	O
171	married	_	_	O
172	,	_	_	O
173	Caucasian	_	_	O
174	,	_	_	O
175	and	_	_	O
176	diagnosed	_	_	O
177	with	_	_	O
178	advanced	_	_	O
179	breast	_	_	O
180	cancer	_	_	O
181	.	_	_	O

182	A	_	_	B-Premise
183	model	_	_	I-Premise
184	measuring	_	_	I-Premise
185	effectiveness	_	_	I-Premise
186	of	_	_	I-Premise
187	CCSP	_	_	I-Premise
188	on	_	_	I-Premise
189	QOL	_	_	I-Premise
190	(	_	_	I-Premise
191	total	_	_	I-Premise
192	and	_	_	I-Premise
193	subscale	_	_	I-Premise
194	)	_	_	I-Premise
195	at	_	_	I-Premise
196	1-year	_	_	I-Premise
197	follow-up	_	_	I-Premise
198	showed	_	_	I-Premise
199	that	_	_	I-Premise
200	the	_	_	I-Premise
201	CCSP	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	n	_	_	I-Premise
205	=	_	_	I-Premise
206	38	_	_	I-Premise
207	)	_	_	I-Premise
208	had	_	_	I-Premise
209	significant	_	_	I-Premise
210	improvement	_	_	I-Premise
211	in	_	_	I-Premise
212	overall	_	_	I-Premise
213	QOL	_	_	I-Premise
214	(	_	_	I-Premise
215	p	_	_	I-Premise
216	<	_	_	I-Premise
217	0.01	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	health	_	_	I-Premise
221	and	_	_	I-Premise
222	functioning	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	<	_	_	I-Premise
226	0.05	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	socioeconomic	_	_	I-Premise
231	(	_	_	I-Premise
232	p	_	_	I-Premise
233	<	_	_	I-Premise
234	0.05	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	psychological/spiritual	_	_	I-Premise
238	well-being	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	(	_	_	I-Premise
250	n	_	_	I-Premise
251	=	_	_	I-Premise
252	35	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	CCSP	_	_	I-Premise
257	patients	_	_	I-Premise
258	frequently	_	_	I-Premise
259	used	_	_	I-Premise
260	the	_	_	I-Premise
261	CCSP	_	_	I-Premise
262	to	_	_	I-Premise
263	manage	_	_	I-Premise
264	psychological	_	_	I-Premise
265	(	_	_	I-Premise
266	51	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	sleep	_	_	I-Premise
271	problems	_	_	I-Premise
272	(	_	_	I-Premise
273	60	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Premise
278	CCSP	_	_	I-Premise
279	improved	_	_	I-Premise
280	QOL	_	_	I-Premise
281	for	_	_	I-Premise
282	patients	_	_	I-Premise
283	at	_	_	I-Premise
284	1-year	_	_	I-Premise
285	follow-up	_	_	I-Premise
286	.	_	_	I-Premise

287	Patients	_	_	B-Premise
288	overwhelmingly	_	_	I-Premise
289	reported	_	_	I-Premise
290	that	_	_	I-Premise
291	CCSP	_	_	I-Premise
292	was	_	_	I-Premise
293	beneficial	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	CCSP	_	_	I-Claim
297	as	_	_	I-Claim
298	an	_	_	I-Claim
299	effective	_	_	I-Claim
300	coping	_	_	I-Claim
301	intervention	_	_	I-Claim
302	has	_	_	I-Claim
303	potential	_	_	I-Claim
304	as	_	_	I-Claim
305	a	_	_	I-Claim
306	self-management	_	_	I-Claim
307	program	_	_	I-Claim
308	for	_	_	I-Claim
309	breast	_	_	I-Claim
310	cancer	_	_	I-Claim
311	survivors	_	_	I-Claim
312	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	etoposide	_	_	I-Claim
4	plus	_	_	I-Claim
5	cisplatin	_	_	I-Claim
6	(	_	_	I-Claim
7	EP	_	_	I-Claim
8	)	_	_	I-Claim
9	is	_	_	I-Claim
10	considered	_	_	I-Claim
11	to	_	_	I-Claim
12	be	_	_	I-Claim
13	standard	_	_	I-Claim
14	therapy	_	_	I-Claim
15	for	_	_	I-Claim
16	small-cell	_	_	I-Claim
17	lung	_	_	I-Claim
18	cancer	_	_	I-Claim
19	(	_	_	I-Claim
20	SCLC	_	_	I-Claim
21	)	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	determine	_	_	O
25	whether	_	_	O
26	drug	_	_	O
27	intensification	_	_	O
28	improves	_	_	O
29	survival	_	_	O
30	of	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	extensive	_	_	O
34	SCLC	_	_	O
35	,	_	_	O
36	we	_	_	O
37	compared	_	_	O
38	this	_	_	O
39	treatment	_	_	O
40	with	_	_	O
41	a	_	_	O
42	four-drug	_	_	O
43	regimen	_	_	O
44	containing	_	_	O
45	EP	_	_	O
46	plus	_	_	O
47	cyclophosphamide	_	_	O
48	and	_	_	O
49	4'-epidoxorubicin	_	_	O
50	(	_	_	O
51	PCDE	_	_	O
52	)	_	_	O
53	.	_	_	O

54	In	_	_	O
55	a	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	clinical	_	_	O
59	trial	_	_	O
60	organized	_	_	O
61	by	_	_	O
62	the	_	_	O
63	French	_	_	O
64	Federation	_	_	O
65	of	_	_	O
66	Cancer	_	_	O
67	Institutes	_	_	O
68	,	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	either	_	_	O
76	EP	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	109	_	_	O
81	;	_	_	O
82	etoposide	_	_	O
83	at	_	_	O
84	a	_	_	O
85	dose	_	_	O
86	of	_	_	O
87	100	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	days	_	_	O
94	1-3	_	_	O
95	plus	_	_	O
96	cisplatin	_	_	O
97	at	_	_	O
98	100	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	2	_	_	O
106	)	_	_	O
107	or	_	_	O
108	PCDE	_	_	O
109	(	_	_	O
110	n	_	_	O
111	=	_	_	O
112	117	_	_	O
113	;	_	_	O
114	etoposide	_	_	O
115	and	_	_	O
116	cisplatin	_	_	O
117	given	_	_	O
118	as	_	_	O
119	in	_	_	O
120	EP	_	_	O
121	plus	_	_	O
122	cyclophosphamide	_	_	O
123	at	_	_	O
124	400	_	_	O
125	mg/m	_	_	O
126	(	_	_	O
127	2	_	_	O
128	)	_	_	O
129	on	_	_	O
130	days	_	_	O
131	1-3	_	_	O
132	and	_	_	O
133	4'-epidoxorubicin	_	_	O
134	at	_	_	O
135	40	_	_	O
136	mg/m	_	_	O
137	(	_	_	O
138	2	_	_	O
139	)	_	_	O
140	on	_	_	O
141	day	_	_	O
142	1	_	_	O
143	)	_	_	O
144	every	_	_	O
145	4	_	_	O
146	weeks	_	_	O
147	.	_	_	O

148	Both	_	_	O
149	groups	_	_	O
150	received	_	_	O
151	a	_	_	O
152	total	_	_	O
153	of	_	_	O
154	six	_	_	O
155	cycles	_	_	O
156	.	_	_	O

157	Survival	_	_	O
158	differences	_	_	O
159	were	_	_	O
160	analyzed	_	_	O
161	by	_	_	O
162	Wilcoxon	_	_	O
163	and	_	_	O
164	log-rank	_	_	O
165	tests	_	_	O
166	.	_	_	O

167	Associations	_	_	O
168	of	_	_	O
169	treatment	_	_	O
170	group	_	_	O
171	and	_	_	O
172	putative	_	_	O
173	prognostic	_	_	O
174	variables	_	_	O
175	with	_	_	O
176	survival	_	_	O
177	were	_	_	O
178	tested	_	_	O
179	in	_	_	O
180	the	_	_	O
181	Cox	_	_	O
182	proportional	_	_	O
183	hazards	_	_	O
184	model	_	_	O
185	.	_	_	O

186	Quality	_	_	O
187	of	_	_	O
188	life	_	_	O
189	was	_	_	O
190	assessed	_	_	O
191	from	_	_	O
192	the	_	_	O
193	responses	_	_	O
194	to	_	_	O
195	the	_	_	O
196	European	_	_	O
197	Organization	_	_	O
198	for	_	_	O
199	Research	_	_	O
200	and	_	_	O
201	Treatment	_	_	O
202	of	_	_	O
203	Cancer	_	_	O
204	quality-of-life	_	_	O
205	questionnaire	_	_	O
206	(	_	_	O
207	C30	_	_	O
208	,	_	_	O
209	health	_	_	O
210	status	_	_	O
211	and	_	_	O
212	lung	_	_	O
213	cancer	_	_	O
214	module	_	_	O
215	13	_	_	O
216	)	_	_	O
217	.	_	_	O

218	All	_	_	O
219	statistical	_	_	O
220	tests	_	_	O
221	were	_	_	O
222	two-sided	_	_	O
223	.	_	_	O

224	Patients	_	_	B-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	PCDE	_	_	I-Premise
228	arm	_	_	I-Premise
229	had	_	_	I-Premise
230	a	_	_	I-Premise
231	statistically	_	_	I-Premise
232	significant	_	_	I-Premise
233	higher	_	_	I-Premise
234	frequency	_	_	I-Premise
235	of	_	_	I-Premise
236	combined	_	_	I-Premise
237	complete	_	_	I-Premise
238	plus	_	_	I-Premise
239	partial	_	_	I-Premise
240	responses	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	those	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	EP	_	_	I-Premise
247	arm	_	_	I-Premise
248	(	_	_	I-Premise
249	21	_	_	I-Premise
250	%	_	_	I-Premise
251	plus	_	_	I-Premise
252	55	_	_	I-Premise
253	%	_	_	I-Premise
254	versus	_	_	I-Premise
255	13	_	_	I-Premise
256	%	_	_	I-Premise
257	plus	_	_	I-Premise
258	48	_	_	I-Premise
259	%	_	_	I-Premise
260	,	_	_	I-Premise
261	respectively	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.02	_	_	I-Premise
265	for	_	_	I-Premise
266	difference	_	_	I-Premise
267	in	_	_	I-Premise
268	combined	_	_	I-Premise
269	objective	_	_	I-Premise
270	responses	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Patients	_	_	B-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	PCDE	_	_	I-Premise
277	arm	_	_	I-Premise
278	survived	_	_	I-Premise
279	longer	_	_	I-Premise
280	than	_	_	I-Premise
281	those	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	EP	_	_	I-Premise
285	arm	_	_	I-Premise
286	(	_	_	I-Premise
287	1-year	_	_	I-Premise
288	survival	_	_	I-Premise
289	rate	_	_	I-Premise
290	:	_	_	I-Premise
291	40	_	_	I-Premise
292	%	_	_	I-Premise
293	and	_	_	I-Premise
294	29	_	_	I-Premise
295	%	_	_	I-Premise
296	,	_	_	I-Premise
297	respectively	_	_	I-Premise
298	;	_	_	I-Premise
299	median	_	_	I-Premise
300	survival	_	_	I-Premise
301	:	_	_	I-Premise
302	10.5	_	_	I-Premise
303	and	_	_	I-Premise
304	9.3	_	_	I-Premise
305	months	_	_	I-Premise
306	,	_	_	I-Premise
307	respectively	_	_	I-Premise
308	;	_	_	I-Premise
309	log-rank	_	_	I-Premise
310	P	_	_	I-Premise
311	=.0067	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	In	_	_	B-Premise
315	the	_	_	I-Premise
316	Cox	_	_	I-Premise
317	model	_	_	I-Premise
318	,	_	_	I-Premise
319	the	_	_	I-Premise
320	relative	_	_	I-Premise
321	risk	_	_	I-Premise
322	of	_	_	I-Premise
323	death	_	_	I-Premise
324	for	_	_	I-Premise
325	patients	_	_	I-Premise
326	in	_	_	I-Premise
327	the	_	_	I-Premise
328	PCDE	_	_	I-Premise
329	arm	_	_	I-Premise
330	compared	_	_	I-Premise
331	with	_	_	I-Premise
332	those	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	EP	_	_	I-Premise
336	arm	_	_	I-Premise
337	was	_	_	I-Premise
338	0.70	_	_	I-Premise
339	(	_	_	I-Premise
340	95	_	_	I-Premise
341	%	_	_	I-Premise
342	confidence	_	_	I-Premise
343	interval	_	_	I-Premise
344	=	_	_	I-Premise
345	0.51	_	_	I-Premise
346	to	_	_	I-Premise
347	0.95	_	_	I-Premise
348	)	_	_	I-Premise
349	;	_	_	I-Premise
350	the	_	_	B-Premise
351	disease	_	_	I-Premise
352	also	_	_	I-Premise
353	progressed	_	_	I-Premise
354	more	_	_	I-Premise
355	slowly	_	_	I-Premise
356	in	_	_	I-Premise
357	patients	_	_	I-Premise
358	in	_	_	I-Premise
359	the	_	_	I-Premise
360	PCDE	_	_	I-Premise
361	arm	_	_	I-Premise
362	.	_	_	I-Premise

363	Hematologic	_	_	B-Premise
364	toxicity	_	_	I-Premise
365	was	_	_	I-Premise
366	higher	_	_	I-Premise
367	in	_	_	I-Premise
368	the	_	_	I-Premise
369	PCDE	_	_	I-Premise
370	arm	_	_	I-Premise
371	(	_	_	I-Premise
372	22	_	_	I-Premise
373	%	_	_	I-Premise
374	with	_	_	I-Premise
375	documented	_	_	I-Premise
376	infections	_	_	I-Premise
377	compared	_	_	I-Premise
378	with	_	_	I-Premise
379	8	_	_	I-Premise
380	%	_	_	I-Premise
381	in	_	_	I-Premise
382	the	_	_	I-Premise
383	EP	_	_	I-Premise
384	arm	_	_	I-Premise
385	;	_	_	I-Premise
386	P	_	_	I-Premise
387	=.0038	_	_	I-Premise
388	)	_	_	I-Premise
389	,	_	_	I-Premise
390	and	_	_	O
391	the	_	_	B-Premise
392	toxicity-related	_	_	I-Premise
393	death	_	_	I-Premise
394	rate	_	_	I-Premise
395	was	_	_	I-Premise
396	9	_	_	I-Premise
397	%	_	_	I-Premise
398	in	_	_	I-Premise
399	the	_	_	I-Premise
400	PCDE	_	_	I-Premise
401	arm	_	_	I-Premise
402	versus	_	_	I-Premise
403	5.5	_	_	I-Premise
404	%	_	_	I-Premise
405	in	_	_	I-Premise
406	the	_	_	I-Premise
407	EP	_	_	I-Premise
408	arm	_	_	I-Premise
409	(	_	_	I-Premise
410	P	_	_	I-Premise
411	=.22	_	_	I-Premise
412	)	_	_	I-Premise
413	.	_	_	I-Premise

414	The	_	_	B-Claim
415	global	_	_	I-Claim
416	health	_	_	I-Claim
417	status	_	_	I-Claim
418	showed	_	_	I-Claim
419	similar	_	_	I-Claim
420	improvement	_	_	I-Claim
421	in	_	_	I-Claim
422	both	_	_	I-Claim
423	arms	_	_	I-Claim
424	during	_	_	I-Claim
425	treatment	_	_	I-Claim
426	.	_	_	I-Claim

427	Compared	_	_	B-Claim
428	with	_	_	I-Claim
429	the	_	_	I-Claim
430	EP	_	_	I-Claim
431	regimen	_	_	I-Claim
432	,	_	_	I-Claim
433	the	_	_	I-Claim
434	PCDE	_	_	I-Claim
435	regimen	_	_	I-Claim
436	yielded	_	_	I-Claim
437	higher	_	_	I-Claim
438	response	_	_	I-Claim
439	rates	_	_	I-Claim
440	and	_	_	I-Claim
441	better	_	_	I-Claim
442	survival	_	_	I-Claim
443	rates	_	_	I-Claim
444	in	_	_	I-Claim
445	patients	_	_	I-Claim
446	with	_	_	I-Claim
447	extensive	_	_	I-Claim
448	SCLC	_	_	I-Claim
449	without	_	_	I-Claim
450	affecting	_	_	I-Claim
451	the	_	_	I-Claim
452	quality	_	_	I-Claim
453	of	_	_	I-Claim
454	life	_	_	I-Claim
455	of	_	_	I-Claim
456	the	_	_	I-Claim
457	patients	_	_	I-Claim
458	during	_	_	I-Claim
459	chemotherapy	_	_	I-Claim
460	.	_	_	I-Claim


0	Although	_	_	O
1	many	_	_	O
2	drug	_	_	O
3	combination	_	_	O
4	therapies	_	_	O
5	have	_	_	O
6	been	_	_	O
7	proposed	_	_	O
8	,	_	_	O
9	there	_	_	B-Claim
10	is	_	_	I-Claim
11	no	_	_	I-Claim
12	standard	_	_	I-Claim
13	therapy	_	_	I-Claim
14	for	_	_	I-Claim
15	patients	_	_	I-Claim
16	with	_	_	I-Claim
17	advanced	_	_	I-Claim
18	gastric	_	_	I-Claim
19	carcinoma	_	_	I-Claim
20	.	_	_	I-Claim

21	The	_	_	B-Claim
22	superiority	_	_	I-Claim
23	of	_	_	I-Claim
24	combination	_	_	I-Claim
25	therapy	_	_	I-Claim
26	over	_	_	I-Claim
27	monochemotherapy	_	_	I-Claim
28	has	_	_	I-Claim
29	not	_	_	I-Claim
30	been	_	_	I-Claim
31	demonstrated	_	_	I-Claim
32	convincingly	_	_	I-Claim
33	.	_	_	I-Claim

34	To	_	_	O
35	explore	_	_	O
36	the	_	_	O
37	role	_	_	O
38	of	_	_	O
39	monochemotherapy	_	_	O
40	,	_	_	O
41	the	_	_	O
42	authors	_	_	O
43	evaluated	_	_	O
44	5-fluorouracil	_	_	O
45	(	_	_	O
46	5-FU	_	_	O
47	)	_	_	O
48	,	_	_	O
49	modulated	_	_	O
50	by	_	_	O
51	6S-leucovorin	_	_	O
52	(	_	_	O
53	6S-LV	_	_	O
54	)	_	_	O
55	and	_	_	O
56	a	_	_	O
57	cisplatin-containing	_	_	O
58	regimen	_	_	O
59	,	_	_	O
60	which	_	_	O
61	was	_	_	O
62	comprised	_	_	O
63	of	_	_	O
64	epirubicin	_	_	O
65	,	_	_	O
66	etoposide	_	_	O
67	,	_	_	O
68	and	_	_	O
69	cisplatin	_	_	O
70	with	_	_	O
71	the	_	_	O
72	addition	_	_	O
73	of	_	_	O
74	the	_	_	O
75	reversal	_	_	O
76	agent	_	_	O
77	lonidamine	_	_	O
78	(	_	_	O
79	EEP-L	_	_	O
80	)	_	_	O
81	.	_	_	O

82	After	_	_	O
83	stratification	_	_	O
84	according	_	_	O
85	to	_	_	O
86	performance	_	_	O
87	status	_	_	O
88	(	_	_	O
89	PS	_	_	O
90	)	_	_	O
91	and	_	_	O
92	resection	_	_	O
93	of	_	_	O
94	the	_	_	O
95	primary	_	_	O
96	tumor	_	_	O
97	,	_	_	O
98	72	_	_	O
99	patients	_	_	O
100	with	_	_	O
101	advanced	_	_	O
102	gastric	_	_	O
103	carcinoma	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	2	_	_	O
108	parallel	_	_	O
109	Phase	_	_	O
110	II	_	_	O
111	trials	_	_	O
112	with	_	_	O
113	5-FU/6S-LV	_	_	O
114	and	_	_	O
115	EEP-L	_	_	O
116	,	_	_	O
117	respectively	_	_	O
118	.	_	_	O

119	Thirty-six	_	_	O
120	patients	_	_	O
121	in	_	_	O
122	Study	_	_	O
123	A	_	_	O
124	received	_	_	O
125	bolus	_	_	O
126	6S-LV	_	_	O
127	,	_	_	O
128	100	_	_	O
129	mg/m2	_	_	O
130	,	_	_	O
131	followed	_	_	O
132	by	_	_	O
133	bolus	_	_	O
134	5-FU	_	_	O
135	,	_	_	O
136	370	_	_	O
137	mg/m2	_	_	O
138	,	_	_	O
139	on	_	_	O
140	Days	_	_	O
141	1-5	_	_	O
142	and	_	_	O
143	36	_	_	O
144	others	_	_	O
145	in	_	_	O
146	Study	_	_	O
147	B	_	_	O
148	received	_	_	O
149	epirubicin	_	_	O
150	,	_	_	O
151	30	_	_	O
152	mg/m2	_	_	O
153	,	_	_	O
154	on	_	_	O
155	Days	_	_	O
156	1	_	_	O
157	and	_	_	O
158	5	_	_	O
159	;	_	_	O
160	etoposide	_	_	O
161	,	_	_	O
162	100	_	_	O
163	mg/m2	_	_	O
164	,	_	_	O
165	on	_	_	O
166	Days	_	_	O
167	1	_	_	O
168	,	_	_	O
169	3	_	_	O
170	,	_	_	O
171	and	_	_	O
172	5	_	_	O
173	;	_	_	O
174	cisplatin	_	_	O
175	,	_	_	O
176	30	_	_	O
177	mg/m2	_	_	O
178	,	_	_	O
179	on	_	_	O
180	Days	_	_	O
181	2	_	_	O
182	and	_	_	O
183	4	_	_	O
184	;	_	_	O
185	and	_	_	O
186	lonidamine	_	_	O
187	,	_	_	O
188	150	_	_	O
189	mg/day	_	_	O
190	.	_	_	O

191	There	_	_	O
192	were	_	_	O
193	6	_	_	O
194	partial	_	_	O
195	responses	_	_	O
196	(	_	_	O
197	18.2	_	_	O
198	%	_	_	O
199	)	_	_	O
200	(	_	_	O
201	95	_	_	O
202	%	_	_	O
203	confidence	_	_	O
204	interval	_	_	O
205	[	_	_	O
206	CI	_	_	O
207	]	_	_	O
208	+/-	_	_	O
209	13.2	_	_	O
210	)	_	_	O
211	in	_	_	O
212	Study	_	_	O
213	A	_	_	O
214	and	_	_	O
215	7	_	_	O
216	partial	_	_	O
217	responses	_	_	O
218	(	_	_	O
219	21.9	_	_	O
220	%	_	_	O
221	)	_	_	O
222	(	_	_	O
223	95	_	_	O
224	%	_	_	O
225	CI	_	_	O
226	+/-	_	_	O
227	14.3	_	_	O
228	)	_	_	O
229	in	_	_	O
230	Study	_	_	O
231	B	_	_	O
232	.	_	_	O

233	Partial	_	_	O
234	responses	_	_	O
235	were	_	_	O
236	more	_	_	O
237	frequent	_	_	O
238	in	_	_	O
239	patients	_	_	O
240	with	_	_	O
241	resected	_	_	O
242	tumors	_	_	O
243	or	_	_	O
244	with	_	_	O
245	an	_	_	O
246	Eastern	_	_	O
247	Cooperative	_	_	O
248	Oncology	_	_	O
249	Group	_	_	O
250	PS	_	_	O
251	of	_	_	O
252	0-1	_	_	O
253	.	_	_	O

254	The	_	_	B-Premise
255	median	_	_	I-Premise
256	duration	_	_	I-Premise
257	of	_	_	I-Premise
258	response	_	_	I-Premise
259	was	_	_	I-Premise
260	8.8	_	_	I-Premise
261	and	_	_	I-Premise
262	8.3	_	_	I-Premise
263	months	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	,	_	_	I-Premise
267	in	_	_	I-Premise
268	Study	_	_	I-Premise
269	A	_	_	I-Premise
270	and	_	_	I-Premise
271	Study	_	_	I-Premise
272	B	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	median	_	_	I-Premise
276	survival	_	_	I-Premise
277	reached	_	_	I-Premise
278	8	_	_	I-Premise
279	months	_	_	I-Premise
280	in	_	_	I-Premise
281	Study	_	_	I-Premise
282	A	_	_	I-Premise
283	and	_	_	I-Premise
284	9	_	_	I-Premise
285	months	_	_	I-Premise
286	in	_	_	I-Premise
287	Study	_	_	I-Premise
288	B	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Premise
291	the	_	_	I-Premise
292	whole	_	_	I-Premise
293	population	_	_	I-Premise
294	of	_	_	I-Premise
295	patients	_	_	I-Premise
296	survival	_	_	I-Premise
297	was	_	_	I-Premise
298	significantly	_	_	I-Premise
299	higher	_	_	I-Premise
300	in	_	_	I-Premise
301	patients	_	_	I-Premise
302	with	_	_	I-Premise
303	a	_	_	I-Premise
304	PS	_	_	I-Premise
305	of	_	_	I-Premise
306	0-1	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	0.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Patients	_	_	B-Premise
314	with	_	_	I-Premise
315	a	_	_	I-Premise
316	PS	_	_	I-Premise
317	of	_	_	I-Premise
318	0-1	_	_	I-Premise
319	and	_	_	I-Premise
320	a	_	_	I-Premise
321	resected	_	_	I-Premise
322	tumor	_	_	I-Premise
323	had	_	_	I-Premise
324	the	_	_	I-Premise
325	significantly	_	_	I-Premise
326	longest	_	_	I-Premise
327	survival	_	_	I-Premise
328	both	_	_	I-Premise
329	in	_	_	I-Premise
330	EEP-L	_	_	I-Premise
331	treated	_	_	I-Premise
332	patients	_	_	I-Premise
333	and	_	_	I-Premise
334	in	_	_	I-Premise
335	all	_	_	I-Premise
336	evaluable	_	_	I-Premise
337	patients	_	_	I-Premise
338	in	_	_	I-Premise
339	the	_	_	I-Premise
340	two	_	_	I-Premise
341	studies	_	_	I-Premise
342	.	_	_	I-Premise

343	The	_	_	B-Premise
344	most	_	_	I-Premise
345	frequent	_	_	I-Premise
346	World	_	_	I-Premise
347	Health	_	_	I-Premise
348	Organization	_	_	I-Premise
349	Grade	_	_	I-Premise
350	3-4	_	_	I-Premise
351	toxic	_	_	I-Premise
352	effects	_	_	I-Premise
353	were	_	_	I-Premise
354	gastrointestinal	_	_	I-Premise
355	in	_	_	I-Premise
356	Study	_	_	I-Premise
357	A	_	_	I-Premise
358	and	_	_	I-Premise
359	hematologic	_	_	I-Premise
360	in	_	_	I-Premise
361	Study	_	_	I-Premise
362	B	_	_	I-Premise
363	.	_	_	I-Premise

364	No	_	_	B-Premise
365	treatment-related	_	_	I-Premise
366	death	_	_	I-Premise
367	was	_	_	I-Premise
368	observed	_	_	I-Premise
369	.	_	_	I-Premise

370	The	_	_	B-Claim
371	efficacy	_	_	I-Claim
372	of	_	_	I-Claim
373	5-FU	_	_	I-Claim
374	,	_	_	I-Claim
375	modulated	_	_	I-Claim
376	with	_	_	I-Claim
377	6S-LV	_	_	I-Claim
378	,	_	_	I-Claim
379	is	_	_	I-Claim
380	moderate	_	_	I-Claim
381	in	_	_	I-Claim
382	patients	_	_	I-Claim
383	with	_	_	I-Claim
384	advanced	_	_	I-Claim
385	gastric	_	_	I-Claim
386	carcinoma	_	_	I-Claim
387	,	_	_	I-Claim
388	similar	_	_	I-Claim
389	to	_	_	I-Claim
390	cisplatin-containing	_	_	I-Claim
391	regimens	_	_	I-Claim
392	.	_	_	I-Claim

393	PS	_	_	B-Claim
394	and	_	_	I-Claim
395	other	_	_	I-Claim
396	prognostic	_	_	I-Claim
397	factors	_	_	I-Claim
398	could	_	_	I-Claim
399	influence	_	_	I-Claim
400	the	_	_	I-Claim
401	response	_	_	I-Claim
402	rate	_	_	I-Claim
403	,	_	_	I-Claim
404	which	_	_	I-Claim
405	does	_	_	I-Claim
406	not	_	_	I-Claim
407	appear	_	_	I-Claim
408	to	_	_	I-Claim
409	be	_	_	I-Claim
410	a	_	_	I-Claim
411	reliable	_	_	I-Claim
412	parameter	_	_	I-Claim
413	for	_	_	I-Claim
414	evaluating	_	_	I-Claim
415	the	_	_	I-Claim
416	outcome	_	_	I-Claim
417	of	_	_	I-Claim
418	chemotherapy	_	_	I-Claim
419	trials	_	_	I-Claim
420	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	an	_	_	O
6	expressive	_	_	O
7	writing	_	_	O
8	(	_	_	O
9	EW	_	_	O
10	)	_	_	O
11	intervention	_	_	O
12	on	_	_	O
13	perceptions	_	_	O
14	of	_	_	O
15	emotional	_	_	O
16	support	_	_	O
17	in	_	_	O
18	women	_	_	O
19	completing	_	_	O
20	treatment	_	_	O
21	for	_	_	O
22	early	_	_	O
23	stage	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Women	_	_	O
28	were	_	_	O
29	recruited	_	_	O
30	to	_	_	O
31	the	_	_	O
32	study	_	_	O
33	during	_	_	O
34	their	_	_	O
35	final	_	_	O
36	week	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	.	_	_	O

40	Of	_	_	O
41	260	_	_	O
42	eligible	_	_	O
43	patients	_	_	O
44	,	_	_	O
45	104	_	_	O
46	(	_	_	O
47	40	_	_	O
48	%	_	_	O
49	)	_	_	O
50	agreed	_	_	O
51	to	_	_	O
52	participate	_	_	O
53	,	_	_	O
54	and	_	_	O
55	93	_	_	O
56	were	_	_	O
57	randomised	_	_	O
58	.	_	_	O

59	Women	_	_	O
60	in	_	_	O
61	the	_	_	O
62	writing	_	_	O
63	group	_	_	O
64	wrote	_	_	O
65	for	_	_	O
66	20	_	_	O
67	min	_	_	O
68	on	_	_	O
69	four	_	_	O
70	consecutive	_	_	O
71	days	_	_	O
72	.	_	_	O

73	The	_	_	O
74	control	_	_	O
75	group	_	_	O
76	received	_	_	O
77	normal	_	_	O
78	care	_	_	O
79	.	_	_	O

80	Women	_	_	O
81	's	_	_	O
82	perceptions	_	_	O
83	of	_	_	O
84	emotional	_	_	O
85	support	_	_	O
86	,	_	_	O
87	quality	_	_	O
88	of	_	_	O
89	life	_	_	O
90	(	_	_	O
91	QOL	_	_	O
92	)	_	_	O
93	,	_	_	O
94	mood	_	_	O
95	,	_	_	O
96	and	_	_	O
97	healthcare	_	_	O
98	utilisation	_	_	O
99	were	_	_	O
100	assessed	_	_	O
101	at	_	_	O
102	baseline	_	_	O
103	,	_	_	O
104	1	_	_	O
105	month	_	_	O
106	,	_	_	O
107	3	_	_	O
108	months	_	_	O
109	and	_	_	O
110	6	_	_	O
111	months	_	_	O
112	.	_	_	O

113	Interviews	_	_	O
114	were	_	_	O
115	conducted	_	_	O
116	to	_	_	O
117	explore	_	_	O
118	women	_	_	O
119	's	_	_	O
120	experience	_	_	O
121	of	_	_	O
122	writing	_	_	O
123	.	_	_	O

124	Eighty	_	_	O
125	participants	_	_	O
126	completed	_	_	O
127	all	_	_	O
128	follow-ups	_	_	O
129	.	_	_	O

130	There	_	_	B-Premise
131	was	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	effect	_	_	I-Premise
135	of	_	_	I-Premise
136	group	_	_	I-Premise
137	on	_	_	I-Premise
138	women	_	_	I-Premise
139	's	_	_	I-Premise
140	perceptions	_	_	I-Premise
141	of	_	_	I-Premise
142	social	_	_	I-Premise
143	support	_	_	I-Premise
144	with	_	_	I-Premise
145	those	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	intervention	_	_	I-Premise
149	group	_	_	I-Premise
150	being	_	_	I-Premise
151	more	_	_	I-Premise
152	satisfied	_	_	I-Premise
153	with	_	_	I-Premise
154	the	_	_	I-Premise
155	emotional	_	_	I-Premise
156	support	_	_	I-Premise
157	they	_	_	I-Premise
158	received	_	_	I-Premise
159	(	_	_	I-Premise
160	p	_	_	I-Premise
161	<	_	_	I-Premise
162	0.05	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Satisfaction	_	_	B-Premise
166	with	_	_	I-Premise
167	emotional	_	_	I-Premise
168	support	_	_	I-Premise
169	was	_	_	I-Premise
170	negatively	_	_	I-Premise
171	correlated	_	_	I-Premise
172	with	_	_	I-Premise
173	depression/dejection	_	_	I-Premise
174	(	_	_	I-Premise
175	p	_	_	I-Premise
176	<	_	_	I-Premise
177	0.05	_	_	I-Premise
178	)	_	_	I-Premise
179	and	_	_	I-Premise
180	anger/hostility	_	_	I-Premise
181	(	_	_	I-Premise
182	p	_	_	I-Premise
183	<	_	_	I-Premise
184	0.05	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	positively	_	_	I-Premise
188	correlated	_	_	I-Premise
189	with	_	_	I-Premise
190	social	_	_	I-Premise
191	and	_	_	I-Premise
192	family	_	_	I-Premise
193	well-being	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	<	_	_	I-Premise
197	0.001	_	_	I-Premise
198	)	_	_	I-Premise
199	6	_	_	I-Premise
200	months	_	_	I-Premise
201	post	_	_	I-Premise
202	intervention	_	_	I-Premise
203	.	_	_	I-Premise

204	There	_	_	B-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	significant	_	_	I-Premise
208	effects	_	_	I-Premise
209	of	_	_	I-Premise
210	the	_	_	I-Premise
211	intervention	_	_	I-Premise
212	on	_	_	I-Premise
213	mood	_	_	I-Premise
214	,	_	_	I-Premise
215	QOL	_	_	I-Premise
216	or	_	_	I-Premise
217	healthcare	_	_	I-Premise
218	utilisation	_	_	I-Premise
219	.	_	_	I-Premise

220	Most	_	_	B-Premise
221	participants	_	_	I-Premise
222	found	_	_	I-Premise
223	writing	_	_	I-Premise
224	valuable	_	_	I-Premise
225	and	_	_	I-Premise
226	did	_	_	I-Premise
227	not	_	_	I-Premise
228	report	_	_	I-Premise
229	any	_	_	I-Premise
230	long-term	_	_	I-Premise
231	negative	_	_	I-Premise
232	effects	_	_	I-Premise
233	.	_	_	I-Premise

234	EW	_	_	B-Claim
235	was	_	_	I-Claim
236	associated	_	_	I-Claim
237	with	_	_	I-Claim
238	a	_	_	I-Claim
239	higher	_	_	I-Claim
240	level	_	_	I-Claim
241	of	_	_	I-Claim
242	satisfaction	_	_	I-Claim
243	with	_	_	I-Claim
244	emotional	_	_	I-Claim
245	support	_	_	I-Claim
246	compared	_	_	I-Claim
247	with	_	_	I-Claim
248	controls	_	_	I-Claim
249	.	_	_	I-Claim

250	Given	_	_	O
251	the	_	_	O
252	existing	_	_	O
253	evidence	_	_	O
254	supporting	_	_	O
255	the	_	_	O
256	importance	_	_	O
257	of	_	_	O
258	social	_	_	O
259	support	_	_	O
260	in	_	_	O
261	adjustment	_	_	O
262	to	_	_	O
263	breast	_	_	O
264	cancer	_	_	O
265	,	_	_	O
266	it	_	_	B-Claim
267	seems	_	_	I-Claim
268	feasible	_	_	I-Claim
269	to	_	_	I-Claim
270	suggest	_	_	I-Claim
271	that	_	_	I-Claim
272	EW	_	_	I-Claim
273	may	_	_	I-Claim
274	be	_	_	I-Claim
275	a	_	_	I-Claim
276	cost	_	_	I-Claim
277	effective	_	_	I-Claim
278	accessible	_	_	I-Claim
279	treatment	_	_	I-Claim
280	that	_	_	I-Claim
281	could	_	_	I-Claim
282	be	_	_	I-Claim
283	incorporated	_	_	I-Claim
284	into	_	_	I-Claim
285	the	_	_	I-Claim
286	ongoing	_	_	I-Claim
287	care	_	_	I-Claim
288	of	_	_	I-Claim
289	women	_	_	I-Claim
290	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	tested	_	_	O
3	hyperbaric	_	_	O
4	oxygen	_	_	O
5	(	_	_	O
6	HBO	_	_	O
7	)	_	_	O
8	as	_	_	O
9	an	_	_	O
10	adjunct	_	_	O
11	to	_	_	O
12	surgery	_	_	O
13	and	_	_	O
14	antibiotics	_	_	O
15	in	_	_	O
16	the	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	bisphosphonate-related	_	_	O
20	osteonecrosis	_	_	O
21	of	_	_	O
22	the	_	_	O
23	jaw	_	_	O
24	(	_	_	O
25	ONJ	_	_	O
26	)	_	_	O
27	and	_	_	O
28	evaluated	_	_	O
29	its	_	_	O
30	effects	_	_	O
31	on	_	_	O
32	gingival	_	_	O
33	healing	_	_	O
34	,	_	_	O
35	pain	_	_	O
36	,	_	_	O
37	and	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	.	_	_	O

42	The	_	_	O
43	investigators	_	_	O
44	implemented	_	_	O
45	a	_	_	O
46	randomized	_	_	O
47	controlled	_	_	O
48	trial	_	_	O
49	and	_	_	O
50	enrolled	_	_	O
51	a	_	_	O
52	sample	_	_	O
53	composed	_	_	O
54	of	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	ONJ	_	_	O
58	,	_	_	O
59	where	_	_	O
60	the	_	_	O
61	predictor	_	_	O
62	variable	_	_	O
63	was	_	_	O
64	HBO	_	_	O
65	administered	_	_	O
66	at	_	_	O
67	2	_	_	O
68	atm	_	_	O
69	twice	_	_	O
70	a	_	_	O
71	day	_	_	O
72	for	_	_	O
73	40	_	_	O
74	treatments	_	_	O
75	as	_	_	O
76	an	_	_	O
77	adjunct	_	_	O
78	to	_	_	O
79	conventional	_	_	O
80	therapy	_	_	O
81	of	_	_	O
82	surgery	_	_	O
83	and	_	_	O
84	antibiotics	_	_	O
85	versus	_	_	O
86	conventional	_	_	O
87	therapy	_	_	O
88	alone	_	_	O
89	.	_	_	O

90	Over	_	_	O
91	the	_	_	O
92	next	_	_	O
93	24	_	_	O
94	months	_	_	O
95	,	_	_	O
96	oral	_	_	O
97	lesion	_	_	O
98	size	_	_	O
99	and	_	_	O
100	number	_	_	O
101	,	_	_	O
102	pain	_	_	O
103	,	_	_	O
104	and	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	were	_	_	O
109	assessed	_	_	O
110	.	_	_	O

111	Forty-six	_	_	O
112	patients	_	_	O
113	(	_	_	O
114	mean	_	_	O
115	age	_	_	O
116	,	_	_	O
117	66	_	_	O
118	yrs	_	_	O
119	;	_	_	O
120	57	_	_	O
121	%	_	_	O
122	women	_	_	O
123	)	_	_	O
124	contributed	_	_	O
125	data	_	_	O
126	to	_	_	O
127	the	_	_	O
128	trial	_	_	O
129	.	_	_	O

130	There	_	_	O
131	were	_	_	O
132	no	_	_	O
133	statistically	_	_	O
134	significant	_	_	O
135	differences	_	_	O
136	in	_	_	O
137	the	_	_	O
138	distribution	_	_	O
139	of	_	_	O
140	variables	_	_	O
141	used	_	_	O
142	to	_	_	O
143	assess	_	_	O
144	randomization	_	_	O
145	success	_	_	O
146	between	_	_	O
147	the	_	_	O
148	HBO	_	_	O
149	and	_	_	O
150	standard	_	_	O
151	treatment	_	_	O
152	groups	_	_	O
153	.	_	_	O

154	Seventeen	_	_	B-Premise
155	of	_	_	I-Premise
156	25	_	_	I-Premise
157	HBO-treated	_	_	I-Premise
158	patients	_	_	I-Premise
159	(	_	_	I-Premise
160	68	_	_	I-Premise
161	%	_	_	I-Premise
162	)	_	_	I-Premise
163	improved	_	_	I-Premise
164	versus	_	_	I-Premise
165	8	_	_	I-Premise
166	of	_	_	I-Premise
167	21	_	_	I-Premise
168	controls	_	_	I-Premise
169	(	_	_	I-Premise
170	38.1	_	_	I-Premise
171	%	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.043	_	_	I-Premise
176	,	_	_	I-Premise
177	Ï‡	_	_	I-Premise
178	(	_	_	I-Premise
179	2	_	_	I-Premise
180	)	_	_	I-Premise
181	test	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Mean	_	_	B-Premise
185	time	_	_	I-Premise
186	to	_	_	I-Premise
187	improvement	_	_	I-Premise
188	was	_	_	I-Premise
189	39.7	_	_	I-Premise
190	weeks	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	confidence	_	_	I-Premise
195	interval	_	_	I-Premise
196	[	_	_	I-Premise
197	CI	_	_	I-Premise
198	]	_	_	I-Premise
199	,	_	_	I-Premise
200	22.4	_	_	I-Premise
201	to	_	_	I-Premise
202	57.0	_	_	I-Premise
203	weeks	_	_	I-Premise
204	)	_	_	I-Premise
205	for	_	_	I-Premise
206	HBO-treated	_	_	I-Premise
207	patients	_	_	I-Premise
208	versus	_	_	I-Premise
209	67.9	_	_	I-Premise
210	weeks	_	_	I-Premise
211	(	_	_	I-Premise
212	95	_	_	I-Premise
213	CI	_	_	I-Premise
214	,	_	_	I-Premise
215	48.4	_	_	I-Premise
216	to	_	_	I-Premise
217	87.5	_	_	I-Premise
218	weeks	_	_	I-Premise
219	)	_	_	I-Premise
220	for	_	_	I-Premise
221	controls	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.03	_	_	I-Premise
226	,	_	_	I-Premise
227	log-rank	_	_	I-Premise
228	test	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	However	_	_	B-Premise
232	,	_	_	I-Premise
233	complete	_	_	I-Premise
234	gingival	_	_	I-Premise
235	healing	_	_	I-Premise
236	occurred	_	_	I-Premise
237	in	_	_	I-Premise
238	only	_	_	I-Premise
239	14	_	_	I-Premise
240	of	_	_	I-Premise
241	25	_	_	I-Premise
242	HBO-treated	_	_	I-Premise
243	patients	_	_	I-Premise
244	(	_	_	I-Premise
245	52	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	versus	_	_	I-Premise
249	7	_	_	I-Premise
250	of	_	_	I-Premise
251	21	_	_	I-Premise
252	controls	_	_	I-Premise
253	(	_	_	I-Premise
254	33.3	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.203	_	_	I-Premise
260	,	_	_	I-Premise
261	Ï‡	_	_	I-Premise
262	(	_	_	I-Premise
263	2	_	_	I-Premise
264	)	_	_	I-Premise
265	test	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	time	_	_	I-Premise
270	to	_	_	I-Premise
271	healing	_	_	I-Premise
272	was	_	_	I-Premise
273	59	_	_	I-Premise
274	weeks	_	_	I-Premise
275	(	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	,	_	_	I-Premise
280	42.8	_	_	I-Premise
281	%	_	_	I-Premise
282	to	_	_	I-Premise
283	75.8	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	for	_	_	I-Premise
287	HBO-treated	_	_	I-Premise
288	patients	_	_	I-Premise
289	versus	_	_	I-Premise
290	70	_	_	I-Premise
291	weeks	_	_	I-Premise
292	(	_	_	I-Premise
293	95	_	_	I-Premise
294	CI	_	_	I-Premise
295	,	_	_	I-Premise
296	52.2	_	_	I-Premise
297	%	_	_	I-Premise
298	to	_	_	I-Premise
299	88.36	_	_	I-Premise
300	%	_	_	I-Premise
301	)	_	_	I-Premise
302	for	_	_	I-Premise
303	controls	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	.32	_	_	I-Premise
308	,	_	_	I-Premise
309	log-rank	_	_	I-Premise
310	test	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Pain	_	_	B-Premise
314	decreased	_	_	I-Premise
315	faster	_	_	I-Premise
316	for	_	_	I-Premise
317	HBO-treated	_	_	I-Premise
318	subjects	_	_	I-Premise
319	(	_	_	I-Premise
320	P	_	_	I-Premise
321	<	_	_	I-Premise
322	.01	_	_	I-Premise
323	,	_	_	I-Premise
324	linear	_	_	I-Premise
325	regression	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Quality-of-life	_	_	B-Premise
329	scores	_	_	I-Premise
330	for	_	_	I-Premise
331	physical	_	_	I-Premise
332	health	_	_	I-Premise
333	(	_	_	I-Premise
334	P	_	_	I-Premise
335	=	_	_	I-Premise
336	.002	_	_	I-Premise
337	)	_	_	I-Premise
338	and	_	_	I-Premise
339	perceived	_	_	I-Premise
340	health	_	_	I-Premise
341	(	_	_	I-Premise
342	P	_	_	I-Premise
343	=	_	_	I-Premise
344	.043	_	_	I-Premise
345	)	_	_	I-Premise
346	decreased	_	_	I-Premise
347	at	_	_	I-Premise
348	6	_	_	I-Premise
349	months	_	_	I-Premise
350	for	_	_	I-Premise
351	control	_	_	I-Premise
352	group	_	_	I-Premise
353	but	_	_	I-Premise
354	for	_	_	I-Premise
355	not	_	_	I-Premise
356	the	_	_	I-Premise
357	HBO	_	_	I-Premise
358	group	_	_	I-Premise
359	.	_	_	I-Premise

360	ONJ	_	_	B-Claim
361	is	_	_	I-Claim
362	multifactorial	_	_	I-Claim
363	and	_	_	I-Claim
364	no	_	_	I-Claim
365	single	_	_	I-Claim
366	treatment	_	_	I-Claim
367	modality	_	_	I-Claim
368	is	_	_	I-Claim
369	likely	_	_	I-Claim
370	to	_	_	I-Claim
371	reverse	_	_	I-Claim
372	it	_	_	I-Claim
373	;	_	_	I-Claim
374	however	_	_	B-Claim
375	,	_	_	I-Claim
376	it	_	_	I-Claim
377	is	_	_	I-Claim
378	treatable	_	_	I-Claim
379	and	_	_	I-Claim
380	even	_	_	I-Claim
381	advanced	_	_	I-Claim
382	presentations	_	_	I-Claim
383	can	_	_	I-Claim
384	improve	_	_	I-Claim
385	with	_	_	I-Claim
386	intensive	_	_	I-Claim
387	multimodal	_	_	I-Claim
388	therapy	_	_	I-Claim
389	.	_	_	I-Claim

390	Clinically	_	_	B-Claim
391	,	_	_	I-Claim
392	HBO	_	_	I-Claim
393	appears	_	_	I-Claim
394	to	_	_	I-Claim
395	be	_	_	I-Claim
396	a	_	_	I-Claim
397	useful	_	_	I-Claim
398	adjunct	_	_	I-Claim
399	to	_	_	I-Claim
400	ONJ	_	_	I-Claim
401	treatment	_	_	I-Claim
402	,	_	_	I-Claim
403	particularly	_	_	I-Claim
404	for	_	_	I-Claim
405	more	_	_	I-Claim
406	severe	_	_	I-Claim
407	cases	_	_	I-Claim
408	,	_	_	I-Claim
409	although	_	_	I-Claim
410	this	_	_	I-Claim
411	study	_	_	I-Claim
412	was	_	_	I-Claim
413	underpowered	_	_	I-Claim
414	to	_	_	I-Claim
415	fully	_	_	I-Claim
416	support	_	_	I-Claim
417	this	_	_	I-Claim
418	claim	_	_	I-Claim
419	.	_	_	I-Claim


0	Therapy	_	_	O
1	for	_	_	O
2	polycystic	_	_	O
3	liver	_	_	O
4	is	_	_	O
5	invasive	_	_	O
6	,	_	_	O
7	expensive	_	_	O
8	,	_	_	O
9	and	_	_	O
10	has	_	_	O
11	disappointing	_	_	O
12	long-term	_	_	O
13	results	_	_	O
14	.	_	_	O

15	Treatment	_	_	O
16	with	_	_	O
17	somatostatin	_	_	O
18	analogues	_	_	O
19	slowed	_	_	O
20	kidney	_	_	O
21	growth	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	polycystic	_	_	O
26	kidney	_	_	O
27	disease	_	_	O
28	(	_	_	O
29	PKD	_	_	O
30	)	_	_	O
31	and	_	_	O
32	reduced	_	_	O
33	liver	_	_	O
34	and	_	_	O
35	kidney	_	_	O
36	volume	_	_	O
37	in	_	_	O
38	a	_	_	O
39	PKD	_	_	O
40	rodent	_	_	O
41	model	_	_	O
42	.	_	_	O

43	We	_	_	O
44	evaluated	_	_	O
45	the	_	_	O
46	effects	_	_	O
47	of	_	_	O
48	lanreotide	_	_	O
49	,	_	_	O
50	a	_	_	O
51	somatostatin	_	_	O
52	analogue	_	_	O
53	,	_	_	O
54	in	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	polycystic	_	_	O
58	liver	_	_	O
59	because	_	_	O
60	of	_	_	O
61	autosomal-dominant	_	_	O
62	(	_	_	O
63	AD	_	_	O
64	)	_	_	O
65	PKD	_	_	O
66	or	_	_	O
67	autosomal-dominant	_	_	O
68	polycystic	_	_	O
69	liver	_	_	O
70	disease	_	_	O
71	(	_	_	O
72	PCLD	_	_	O
73	)	_	_	O
74	.	_	_	O

75	We	_	_	O
76	performed	_	_	O
77	a	_	_	O
78	randomized	_	_	O
79	,	_	_	O
80	double-blind	_	_	O
81	,	_	_	O
82	placebo-controlled	_	_	O
83	trial	_	_	O
84	in	_	_	O
85	2	_	_	O
86	tertiary	_	_	O
87	referral	_	_	O
88	centers	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	with	_	_	O
92	polycystic	_	_	O
93	liver	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	54	_	_	O
98	)	_	_	O
99	were	_	_	O
100	randomly	_	_	O
101	assigned	_	_	O
102	to	_	_	O
103	groups	_	_	O
104	given	_	_	O
105	lanreotide	_	_	O
106	(	_	_	O
107	120	_	_	O
108	mg	_	_	O
109	)	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	,	_	_	O
113	administered	_	_	O
114	every	_	_	O
115	28	_	_	O
116	days	_	_	O
117	for	_	_	O
118	24	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	The	_	_	O
122	primary	_	_	O
123	end	_	_	O
124	point	_	_	O
125	was	_	_	O
126	the	_	_	O
127	difference	_	_	O
128	in	_	_	O
129	total	_	_	O
130	liver	_	_	O
131	volume	_	_	O
132	,	_	_	O
133	measured	_	_	O
134	by	_	_	O
135	computerized	_	_	O
136	tomography	_	_	O
137	at	_	_	O
138	weeks	_	_	O
139	0	_	_	O
140	and	_	_	O
141	24	_	_	O
142	.	_	_	O

143	Analyses	_	_	O
144	were	_	_	O
145	performed	_	_	O
146	on	_	_	O
147	an	_	_	O
148	intention-to-treat	_	_	O
149	basis	_	_	O
150	.	_	_	O

151	Baseline	_	_	B-Premise
152	characteristics	_	_	I-Premise
153	were	_	_	I-Premise
154	comparable	_	_	I-Premise
155	for	_	_	I-Premise
156	both	_	_	I-Premise
157	groups	_	_	I-Premise
158	,	_	_	I-Premise
159	except	_	_	B-Premise
160	that	_	_	I-Premise
161	more	_	_	I-Premise
162	patients	_	_	I-Premise
163	with	_	_	I-Premise
164	ADPKD	_	_	I-Premise
165	were	_	_	I-Premise
166	assigned	_	_	I-Premise
167	to	_	_	I-Premise
168	the	_	_	I-Premise
169	placebo	_	_	I-Premise
170	group	_	_	I-Premise
171	(	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.03	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	mean	_	_	I-Premise
179	liver	_	_	I-Premise
180	volume	_	_	I-Premise
181	decreased	_	_	I-Premise
182	2.9	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	from	_	_	I-Premise
186	4606	_	_	I-Premise
187	mL	_	_	I-Premise
188	(	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	confidence	_	_	I-Premise
192	interval	_	_	I-Premise
193	(	_	_	I-Premise
194	CI	_	_	I-Premise
195	)	_	_	I-Premise
196	:	_	_	I-Premise
197	547-8665	_	_	I-Premise
198	)	_	_	I-Premise
199	to	_	_	I-Premise
200	4471	_	_	I-Premise
201	mL	_	_	I-Premise
202	(	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	CI	_	_	I-Premise
206	:	_	_	I-Premise
207	542-8401	_	_	I-Premise
208	mL	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	given	_	_	I-Premise
214	lanreotide	_	_	I-Premise
215	.	_	_	I-Premise

216	In	_	_	B-Premise
217	the	_	_	I-Premise
218	placebo	_	_	I-Premise
219	group	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	mean	_	_	I-Premise
223	liver	_	_	I-Premise
224	volume	_	_	I-Premise
225	increased	_	_	I-Premise
226	1.6	_	_	I-Premise
227	%	_	_	I-Premise
228	,	_	_	I-Premise
229	from	_	_	I-Premise
230	4689	_	_	I-Premise
231	mL	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	:	_	_	I-Premise
237	613-8765	_	_	I-Premise
238	mL	_	_	I-Premise
239	)	_	_	I-Premise
240	to	_	_	I-Premise
241	4895	_	_	I-Premise
242	mL	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	:	_	_	I-Premise
248	739-9053	_	_	I-Premise
249	mL	_	_	I-Premise
250	)	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.01	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Post	_	_	B-Premise
258	hoc	_	_	I-Premise
259	stratification	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	with	_	_	I-Premise
263	ADPKD	_	_	I-Premise
264	or	_	_	I-Premise
265	PCLD	_	_	I-Premise
266	revealed	_	_	I-Premise
267	similar	_	_	I-Premise
268	changes	_	_	I-Premise
269	in	_	_	I-Premise
270	liver	_	_	I-Premise
271	volume	_	_	I-Premise
272	,	_	_	I-Premise
273	with	_	_	I-Premise
274	statistically	_	_	I-Premise
275	significant	_	_	I-Premise
276	differences	_	_	I-Premise
277	in	_	_	I-Premise
278	patients	_	_	I-Premise
279	given	_	_	I-Premise
280	lanreotide	_	_	I-Premise
281	(	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.01	_	_	I-Premise
285	for	_	_	I-Premise
286	both	_	_	I-Premise
287	diseases	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Claim
291	patients	_	_	I-Claim
292	with	_	_	I-Claim
293	polycystic	_	_	I-Claim
294	liver	_	_	I-Claim
295	,	_	_	I-Claim
296	6	_	_	I-Claim
297	months	_	_	I-Claim
298	of	_	_	I-Claim
299	treatment	_	_	I-Claim
300	with	_	_	I-Claim
301	lanreotide	_	_	I-Claim
302	reduces	_	_	I-Claim
303	liver	_	_	I-Claim
304	volume	_	_	I-Claim
305	.	_	_	I-Claim


0	A	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	mitoxantrone	_	_	I-Claim
4	plus	_	_	I-Claim
5	prednisone	_	_	I-Claim
6	is	_	_	I-Claim
7	preferable	_	_	I-Claim
8	to	_	_	I-Claim
9	prednisone	_	_	I-Claim
10	alone	_	_	I-Claim
11	for	_	_	I-Claim
12	reduction	_	_	I-Claim
13	of	_	_	I-Claim
14	pain	_	_	I-Claim
15	in	_	_	I-Claim
16	men	_	_	I-Claim
17	with	_	_	I-Claim
18	metastatic	_	_	I-Claim
19	,	_	_	I-Claim
20	hormone-resistant	_	_	I-Claim
21	,	_	_	I-Claim
22	prostate	_	_	I-Claim
23	cancer	_	_	I-Claim
24	.	_	_	I-Claim

25	The	_	_	O
26	purpose	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	was	_	_	O
31	to	_	_	O
32	assess	_	_	O
33	the	_	_	O
34	effects	_	_	O
35	of	_	_	O
36	these	_	_	O
37	treatments	_	_	O
38	on	_	_	O
39	health-related	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	HQL	_	_	O
45	)	_	_	O
46	.	_	_	O

47	Men	_	_	O
48	with	_	_	O
49	metastatic	_	_	O
50	prostate	_	_	O
51	cancer	_	_	O
52	(	_	_	O
53	n	_	_	O
54	=	_	_	O
55	161	_	_	O
56	)	_	_	O
57	were	_	_	O
58	randomized	_	_	O
59	to	_	_	O
60	receive	_	_	O
61	either	_	_	O
62	daily	_	_	O
63	prednisone	_	_	O
64	alone	_	_	O
65	or	_	_	O
66	mitoxantrone	_	_	O
67	(	_	_	O
68	every	_	_	O
69	3	_	_	O
70	weeks	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	prednisone	_	_	O
74	.	_	_	O

75	Those	_	_	O
76	who	_	_	O
77	received	_	_	O
78	prednisone	_	_	O
79	alone	_	_	O
80	could	_	_	O
81	have	_	_	O
82	mitoxantrone	_	_	O
83	added	_	_	O
84	after	_	_	O
85	6	_	_	O
86	weeks	_	_	O
87	if	_	_	O
88	there	_	_	O
89	was	_	_	O
90	no	_	_	O
91	improvement	_	_	O
92	in	_	_	O
93	pain	_	_	O
94	.	_	_	O

95	HQL	_	_	O
96	was	_	_	O
97	assessed	_	_	O
98	before	_	_	O
99	treatment	_	_	O
100	initiation	_	_	O
101	and	_	_	O
102	then	_	_	O
103	every	_	_	O
104	3	_	_	O
105	weeks	_	_	O
106	using	_	_	O
107	the	_	_	O
108	European	_	_	O
109	Organization	_	_	O
110	for	_	_	O
111	Research	_	_	O
112	and	_	_	O
113	Treatment	_	_	O
114	of	_	_	O
115	Cancer	_	_	O
116	Quality-of-Life	_	_	O
117	Questionnaire	_	_	O
118	C30	_	_	O
119	(	_	_	O
120	EORTC	_	_	O
121	QLQ-C30	_	_	O
122	)	_	_	O
123	and	_	_	O
124	the	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Module-Prostate	_	_	O
129	14	_	_	O
130	(	_	_	O
131	QOLM-P14	_	_	O
132	)	_	_	O
133	,	_	_	O
134	a	_	_	O
135	trial-specific	_	_	O
136	module	_	_	O
137	developed	_	_	O
138	for	_	_	O
139	this	_	_	O
140	study	_	_	O
141	.	_	_	O

142	An	_	_	O
143	intent-to-treat	_	_	O
144	analysis	_	_	O
145	was	_	_	O
146	used	_	_	O
147	to	_	_	O
148	determine	_	_	O
149	the	_	_	O
150	mean	_	_	O
151	duration	_	_	O
152	of	_	_	O
153	HQL	_	_	O
154	improvement	_	_	O
155	and	_	_	O
156	differences	_	_	O
157	in	_	_	O
158	improvement	_	_	O
159	duration	_	_	O
160	between	_	_	O
161	groups	_	_	O
162	of	_	_	O
163	patients	_	_	O
164	.	_	_	O

165	At	_	_	B-Premise
166	6	_	_	I-Premise
167	weeks	_	_	I-Premise
168	,	_	_	I-Premise
169	both	_	_	I-Premise
170	groups	_	_	I-Premise
171	showed	_	_	I-Premise
172	improvement	_	_	I-Premise
173	in	_	_	I-Premise
174	several	_	_	I-Premise
175	HQL	_	_	I-Premise
176	domains	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	O
179	only	_	_	B-Premise
180	physical	_	_	I-Premise
181	functioning	_	_	I-Premise
182	and	_	_	I-Premise
183	pain	_	_	I-Premise
184	were	_	_	I-Premise
185	better	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	mitoxantrone-plus-prednisone	_	_	I-Premise
189	group	_	_	I-Premise
190	than	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	prednisone-alone	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	After	_	_	B-Premise
197	6	_	_	I-Premise
198	weeks	_	_	I-Premise
199	,	_	_	I-Premise
200	patients	_	_	I-Premise
201	taking	_	_	I-Premise
202	prednisone	_	_	I-Premise
203	showed	_	_	I-Premise
204	no	_	_	I-Premise
205	improvement	_	_	I-Premise
206	in	_	_	I-Premise
207	HQL	_	_	I-Premise
208	scores	_	_	I-Premise
209	,	_	_	I-Premise
210	whereas	_	_	I-Premise
211	those	_	_	I-Premise
212	taking	_	_	I-Premise
213	mitoxantrone	_	_	I-Premise
214	plus	_	_	I-Premise
215	prednisone	_	_	I-Premise
216	showed	_	_	I-Premise
217	significant	_	_	I-Premise
218	improvements	_	_	I-Premise
219	in	_	_	I-Premise
220	global	_	_	I-Premise
221	quality	_	_	I-Premise
222	of	_	_	I-Premise
223	life	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=.009	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	four	_	_	I-Premise
230	functioning	_	_	I-Premise
231	domains	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	nine	_	_	I-Premise
235	symptoms	_	_	I-Premise
236	(	_	_	I-Premise
237	.001	_	_	I-Premise
238	<	_	_	I-Premise
239	P	_	_	I-Premise
240	<	_	_	I-Premise
241	.	_	_	I-Premise

242	01	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	O
246	the	_	_	B-Premise
247	improvement	_	_	I-Premise
248	(	_	_	I-Premise
249	>	_	_	I-Premise
250	10	_	_	I-Premise
251	units	_	_	I-Premise
252	on	_	_	I-Premise
253	a	_	_	I-Premise
254	scale	_	_	I-Premise
255	of	_	_	I-Premise
256	0	_	_	I-Premise
257	to100	_	_	I-Premise
258	)	_	_	I-Premise
259	lasted	_	_	I-Premise
260	longer	_	_	I-Premise
261	than	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	prednisone-alone	_	_	I-Premise
265	group	_	_	I-Premise
266	(	_	_	I-Premise
267	.004	_	_	I-Premise
268	<	_	_	I-Premise
269	P	_	_	I-Premise
270	<	_	_	I-Premise
271	.05	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	addition	_	_	I-Premise
276	of	_	_	I-Premise
277	mitoxantrone	_	_	I-Premise
278	to	_	_	I-Premise
279	prednisone	_	_	I-Premise
280	after	_	_	I-Premise
281	failure	_	_	I-Premise
282	of	_	_	I-Premise
283	prednisone	_	_	I-Premise
284	alone	_	_	I-Premise
285	was	_	_	I-Premise
286	associated	_	_	I-Premise
287	with	_	_	I-Premise
288	improvements	_	_	I-Premise
289	in	_	_	I-Premise
290	pain	_	_	I-Premise
291	,	_	_	I-Premise
292	pain	_	_	I-Premise
293	impact	_	_	I-Premise
294	,	_	_	I-Premise
295	pain	_	_	I-Premise
296	relief	_	_	I-Premise
297	,	_	_	I-Premise
298	insomnia	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	global	_	_	I-Premise
302	quality	_	_	I-Premise
303	of	_	_	I-Premise
304	life	_	_	I-Premise
305	(	_	_	I-Premise
306	.001	_	_	I-Premise
307	<	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.003	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Treatment	_	_	B-Claim
314	with	_	_	I-Claim
315	mitoxantrone	_	_	I-Claim
316	plus	_	_	I-Claim
317	prednisone	_	_	I-Claim
318	was	_	_	I-Claim
319	associated	_	_	I-Claim
320	with	_	_	I-Claim
321	greater	_	_	I-Claim
322	and	_	_	I-Claim
323	longer-lasting	_	_	I-Claim
324	improvement	_	_	I-Claim
325	in	_	_	I-Claim
326	several	_	_	I-Claim
327	HQL	_	_	I-Claim
328	domains	_	_	I-Claim
329	and	_	_	I-Claim
330	symptoms	_	_	I-Claim
331	than	_	_	I-Claim
332	treatment	_	_	I-Claim
333	with	_	_	I-Claim
334	prednisone	_	_	I-Claim
335	alone	_	_	I-Claim
336	.	_	_	I-Claim


0	Studies	_	_	O
1	on	_	_	O
2	quality	_	_	O
3	of	_	_	O
4	life	_	_	O
5	(	_	_	O
6	QOL	_	_	O
7	)	_	_	O
8	among	_	_	O
9	women	_	_	O
10	with	_	_	O
11	endometrial	_	_	O
12	cancer	_	_	O
13	have	_	_	O
14	shown	_	_	O
15	that	_	_	O
16	patients	_	_	O
17	who	_	_	O
18	undergo	_	_	O
19	pelvic	_	_	O
20	radiotherapy	_	_	O
21	report	_	_	O
22	lower	_	_	O
23	role	_	_	O
24	functioning	_	_	O
25	and	_	_	O
26	more	_	_	O
27	diarrhea	_	_	O
28	and	_	_	O
29	fatigue	_	_	O
30	.	_	_	O

31	In	_	_	O
32	the	_	_	O
33	Post	_	_	O
34	Operative	_	_	O
35	Radiation	_	_	O
36	Therapy	_	_	O
37	in	_	_	O
38	Endometrial	_	_	O
39	Cancer	_	_	O
40	(	_	_	O
41	PORTEC	_	_	O
42	)	_	_	O
43	trial	_	_	O
44	,	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	endometrial	_	_	O
48	carcinoma	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	external-beam	_	_	O
55	radiotherapy	_	_	O
56	(	_	_	O
57	EBRT	_	_	O
58	)	_	_	O
59	or	_	_	O
60	vaginal	_	_	O
61	brachytherapy	_	_	O
62	(	_	_	O
63	VBT	_	_	O
64	)	_	_	O
65	.	_	_	O

66	QOL	_	_	O
67	was	_	_	O
68	evaluated	_	_	O
69	by	_	_	O
70	using	_	_	O
71	the	_	_	O
72	European	_	_	O
73	Organisation	_	_	O
74	for	_	_	O
75	Research	_	_	O
76	and	_	_	O
77	Treatment	_	_	O
78	of	_	_	O
79	Cancer	_	_	O
80	Quality	_	_	O
81	of	_	_	O
82	Life	_	_	O
83	Questionnaire	_	_	O
84	C30	_	_	O
85	and	_	_	O
86	subscales	_	_	O
87	from	_	_	O
88	the	_	_	O
89	prostate	_	_	O
90	cancer	_	_	O
91	module	_	_	O
92	,	_	_	O
93	PR-25	_	_	O
94	,	_	_	O
95	and	_	_	O
96	the	_	_	O
97	ovarian	_	_	O
98	cancer	_	_	O
99	module	_	_	O
100	,	_	_	O
101	OV-28	_	_	O
102	.	_	_	O

103	PORTEC-2	_	_	O
104	accrued	_	_	O
105	427	_	_	O
106	patients	_	_	O
107	between	_	_	O
108	2002	_	_	O
109	and	_	_	O
110	2006	_	_	O
111	,	_	_	O
112	of	_	_	O
113	whom	_	_	O
114	214	_	_	O
115	were	_	_	O
116	randomly	_	_	O
117	assigned	_	_	O
118	to	_	_	O
119	EBRT	_	_	O
120	,	_	_	O
121	and	_	_	O
122	213	_	_	O
123	were	_	_	O
124	randomly	_	_	O
125	assigned	_	_	O
126	to	_	_	O
127	VBT	_	_	O
128	.	_	_	O

129	Three-hundred	_	_	O
130	forty-eight	_	_	O
131	patients	_	_	O
132	(	_	_	O
133	81	_	_	O
134	%	_	_	O
135	)	_	_	O
136	were	_	_	O
137	evaluable	_	_	O
138	for	_	_	O
139	QOL	_	_	O
140	.	_	_	O

141	QOL	_	_	O
142	outcomes	_	_	O
143	were	_	_	O
144	analyzed	_	_	O
145	at	_	_	O
146	a	_	_	O
147	median	_	_	O
148	follow-up	_	_	O
149	of	_	_	O
150	2	_	_	O
151	years	_	_	O
152	.	_	_	O

153	At	_	_	O
154	baseline	_	_	O
155	after	_	_	O
156	surgery	_	_	O
157	,	_	_	O
158	patient	_	_	O
159	functioning	_	_	O
160	was	_	_	O
161	at	_	_	O
162	the	_	_	O
163	lowest	_	_	O
164	level	_	_	O
165	,	_	_	O
166	and	_	_	O
167	it	_	_	O
168	increased	_	_	O
169	during	_	_	O
170	and	_	_	O
171	after	_	_	O
172	radiotherapy	_	_	O
173	to	_	_	O
174	reach	_	_	O
175	a	_	_	O
176	plateau	_	_	O
177	after	_	_	O
178	12	_	_	O
179	months	_	_	O
180	.	_	_	O

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	VBT	_	_	I-Premise
185	group	_	_	I-Premise
186	reported	_	_	I-Premise
187	better	_	_	I-Premise
188	social	_	_	I-Premise
189	functioning	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.002	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	lower	_	_	I-Premise
197	symptom	_	_	I-Premise
198	scores	_	_	I-Premise
199	for	_	_	I-Premise
200	diarrhea	_	_	I-Premise
201	,	_	_	I-Premise
202	fecal	_	_	I-Premise
203	leakage	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	need	_	_	I-Premise
207	to	_	_	I-Premise
208	stay	_	_	I-Premise
209	close	_	_	I-Premise
210	to	_	_	I-Premise
211	the	_	_	I-Premise
212	toilet	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	limitation	_	_	I-Premise
216	in	_	_	I-Premise
217	daily	_	_	I-Premise
218	activities	_	_	I-Premise
219	because	_	_	I-Premise
220	of	_	_	I-Premise
221	bowel	_	_	I-Premise
222	symptoms	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	At	_	_	O
230	baseline	_	_	O
231	,	_	_	O
232	15	_	_	O
233	%	_	_	O
234	of	_	_	O
235	patients	_	_	O
236	were	_	_	O
237	sexually	_	_	O
238	active	_	_	O
239	;	_	_	O
240	this	_	_	O
241	increased	_	_	O
242	significantly	_	_	O
243	to	_	_	O
244	39	_	_	O
245	%	_	_	O
246	during	_	_	O
247	the	_	_	O
248	first	_	_	O
249	year	_	_	O
250	(	_	_	O
251	P	_	_	O
252	<	_	_	O
253	.001	_	_	O
254	)	_	_	O
255	.	_	_	O

256	Sexual	_	_	B-Premise
257	functioning	_	_	I-Premise
258	and	_	_	I-Premise
259	symptoms	_	_	I-Premise
260	did	_	_	I-Premise
261	not	_	_	I-Premise
262	differ	_	_	I-Premise
263	between	_	_	I-Premise
264	the	_	_	I-Premise
265	treatment	_	_	I-Premise
266	groups	_	_	I-Premise
267	.	_	_	I-Premise

268	Patients	_	_	B-Premise
269	who	_	_	I-Premise
270	received	_	_	I-Premise
271	EBRT	_	_	I-Premise
272	reported	_	_	I-Premise
273	significantly	_	_	I-Premise
274	higher	_	_	I-Premise
275	levels	_	_	I-Premise
276	of	_	_	I-Premise
277	diarrhea	_	_	I-Premise
278	and	_	_	I-Premise
279	bowel	_	_	I-Premise
280	symptoms	_	_	I-Premise
281	.	_	_	I-Premise

282	This	_	_	O
283	resulted	_	_	O
284	in	_	_	O
285	a	_	_	O
286	higher	_	_	O
287	need	_	_	O
288	to	_	_	O
289	remain	_	_	O
290	close	_	_	O
291	to	_	_	O
292	a	_	_	O
293	toilet	_	_	O
294	and	_	_	O
295	,	_	_	O
296	as	_	_	O
297	a	_	_	O
298	consequence	_	_	O
299	,	_	_	O
300	more	_	_	O
301	limitation	_	_	O
302	of	_	_	O
303	daily	_	_	O
304	activities	_	_	O
305	because	_	_	O
306	of	_	_	O
307	bowel	_	_	O
308	symptoms	_	_	O
309	and	_	_	O
310	decreased	_	_	O
311	social	_	_	O
312	functioning	_	_	O
313	.	_	_	O

314	Vaginal	_	_	B-Claim
315	brachytherapy	_	_	I-Claim
316	provides	_	_	I-Claim
317	a	_	_	I-Claim
318	better	_	_	I-Claim
319	QOL	_	_	I-Claim
320	,	_	_	I-Claim
321	and	_	_	I-Claim
322	should	_	_	I-Claim
323	be	_	_	I-Claim
324	the	_	_	I-Claim
325	preferred	_	_	I-Claim
326	treatment	_	_	I-Claim
327	from	_	_	I-Claim
328	a	_	_	I-Claim
329	QOL	_	_	I-Claim
330	perspective	_	_	I-Claim
331	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	health-related	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	life	_	_	O
9	(	_	_	O
10	HRQOL	_	_	O
11	)	_	_	O
12	of	_	_	O
13	continuous	_	_	O
14	combined	_	_	O
15	hormone	_	_	O
16	replacement	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	ccHRT	_	_	O
20	)	_	_	O
21	with	_	_	O
22	estradiol	_	_	O
23	valerate/medroxyprogesterone	_	_	O
24	acetate	_	_	O
25	(	_	_	O
26	E	_	_	O
27	(	_	_	O
28	2	_	_	O
29	)	_	_	O
30	V/MPA	_	_	O
31	)	_	_	O
32	over	_	_	O
33	nine	_	_	O
34	years	_	_	O
35	and	_	_	O
36	at	_	_	O
37	follow-up	_	_	O
38	one	_	_	O
39	year	_	_	O
40	after	_	_	O
41	discontinuation	_	_	O
42	.	_	_	O

43	A	_	_	O
44	total	_	_	O
45	of	_	_	O
46	419	_	_	O
47	women	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	to	_	_	O
51	one	_	_	O
52	of	_	_	O
53	four	_	_	O
54	treatments	_	_	O
55	:	_	_	O
56	once-daily	_	_	O
57	1	_	_	O
58	mg	_	_	O
59	E2V/2.5	_	_	O
60	mg	_	_	O
61	MPA	_	_	O
62	(	_	_	O
63	1	_	_	O
64	+	_	_	O
65	2.5	_	_	O
66	group	_	_	O
67	)	_	_	O
68	;	_	_	O
69	1	_	_	O
70	mg	_	_	O
71	E2V/5	_	_	O
72	mg	_	_	O
73	MPA	_	_	O
74	daily	_	_	O
75	(	_	_	O
76	1	_	_	O
77	+	_	_	O
78	5	_	_	O
79	group	_	_	O
80	)	_	_	O
81	;	_	_	O
82	2	_	_	O
83	mg	_	_	O
84	E2V/2.5	_	_	O
85	mg	_	_	O
86	MPA	_	_	O
87	daily	_	_	O
88	(	_	_	O
89	2	_	_	O
90	+	_	_	O
91	2.5	_	_	O
92	group	_	_	O
93	)	_	_	O
94	;	_	_	O
95	2	_	_	O
96	mg	_	_	O
97	E2V/5	_	_	O
98	mg	_	_	O
99	MPA	_	_	O
100	daily	_	_	O
101	(	_	_	O
102	2	_	_	O
103	+	_	_	O
104	5	_	_	O
105	group	_	_	O
106	)	_	_	O
107	(	_	_	O
108	Indivina	_	_	O
109	,	_	_	O
110	Orion	_	_	O
111	Pharma	_	_	O
112	)	_	_	O
113	.	_	_	O

114	For	_	_	O
115	the	_	_	O
116	last	_	_	O
117	six	_	_	O
118	months	_	_	O
119	,	_	_	O
120	all	_	_	O
121	received	_	_	O
122	the	_	_	O
123	1	_	_	O
124	+	_	_	O
125	2.5	_	_	O
126	dosage	_	_	O
127	.	_	_	O

128	The	_	_	O
129	2	_	_	O
130	+	_	_	O
131	2.5	_	_	O
132	dosage	_	_	O
133	was	_	_	O
134	discontinued	_	_	O
135	at	_	_	O
136	the	_	_	O
137	end	_	_	O
138	of	_	_	O
139	year	_	_	O
140	7	_	_	O
141	.	_	_	O

142	A	_	_	O
143	total	_	_	O
144	of	_	_	O
145	198	_	_	O
146	women	_	_	O
147	continued	_	_	O
148	after	_	_	O
149	year	_	_	O
150	7	_	_	O
151	.	_	_	O

152	Annualized	_	_	O
153	percentage	_	_	O
154	rates	_	_	O
155	for	_	_	O
156	cardiovascular	_	_	O
157	events	_	_	O
158	[	_	_	O
159	corrected	_	_	O
160	]	_	_	O
161	and	_	_	O
162	endometrial	_	_	O
163	cancers	_	_	O
164	[	_	_	O
165	corrected	_	_	O
166	]	_	_	O
167	were	_	_	O
168	below	_	_	O
169	national	_	_	O
170	rates	_	_	O
171	for	_	_	O
172	Finland	_	_	O
173	and	_	_	O
174	those	_	_	O
175	reported	_	_	O
176	for	_	_	O
177	the	_	_	O
178	Women	_	_	O
179	's	_	_	O
180	Health	_	_	O
181	Initiative	_	_	O
182	.	_	_	O

183	There	_	_	B-Premise
184	were	_	_	I-Premise
185	no	_	_	I-Premise
186	serious	_	_	I-Premise
187	events	_	_	I-Premise
188	with	_	_	I-Premise
189	the	_	_	I-Premise
190	1	_	_	I-Premise
191	+	_	_	I-Premise
192	2.5	_	_	I-Premise
193	dosage	_	_	I-Premise
194	or	_	_	I-Premise
195	after	_	_	I-Premise
196	ccHRT	_	_	I-Premise
197	discontinuation	_	_	I-Premise
198	.	_	_	I-Premise

199	Climacteric	_	_	B-Premise
200	symptoms	_	_	I-Premise
201	remained	_	_	I-Premise
202	significantly	_	_	I-Premise
203	below	_	_	I-Premise
204	baseline	_	_	I-Premise
205	values	_	_	I-Premise
206	after	_	_	I-Premise
207	dosage	_	_	I-Premise
208	reduction	_	_	I-Premise
209	;	_	_	I-Premise
210	some	_	_	B-Premise
211	symptoms	_	_	I-Premise
212	recurred	_	_	I-Premise
213	after	_	_	I-Premise
214	discontinuation	_	_	I-Premise
215	of	_	_	I-Premise
216	ccHRT	_	_	I-Premise
217	.	_	_	I-Premise

218	HRQOL	_	_	B-Premise
219	ratings	_	_	I-Premise
220	improved	_	_	I-Premise
221	with	_	_	I-Premise
222	ccHRT	_	_	I-Premise
223	,	_	_	I-Premise
224	irrespective	_	_	I-Premise
225	of	_	_	I-Premise
226	dosage	_	_	I-Premise
227	,	_	_	I-Premise
228	including	_	_	I-Premise
229	depressed	_	_	I-Premise
230	mood	_	_	I-Premise
231	,	_	_	I-Premise
232	anxiety	_	_	I-Premise
233	,	_	_	I-Premise
234	health	_	_	I-Premise
235	perception	_	_	I-Premise
236	and	_	_	I-Premise
237	sexual	_	_	I-Premise
238	interest	_	_	I-Premise
239	.	_	_	I-Premise

240	Scores	_	_	B-Premise
241	on	_	_	I-Premise
242	a	_	_	I-Premise
243	scale	_	_	I-Premise
244	assessing	_	_	I-Premise
245	daily	_	_	I-Premise
246	functioning	_	_	I-Premise
247	and	_	_	I-Premise
248	enjoyment	_	_	I-Premise
249	(	_	_	I-Premise
250	Q-LES-Q	_	_	I-Premise
251	)	_	_	I-Premise
252	improved	_	_	I-Premise
253	from	_	_	I-Premise
254	year	_	_	I-Premise
255	7	_	_	I-Premise
256	to	_	_	I-Premise
257	year	_	_	I-Premise
258	9	_	_	I-Premise
259	.	_	_	I-Premise

260	They	_	_	B-Premise
261	deteriorated	_	_	I-Premise
262	during	_	_	I-Premise
263	follow-up	_	_	I-Premise
264	in	_	_	I-Premise
265	women	_	_	I-Premise
266	not	_	_	I-Premise
267	continuing	_	_	I-Premise
268	ccHRT	_	_	I-Premise
269	.	_	_	I-Premise

270	Lower	_	_	B-Claim
271	dosages	_	_	I-Claim
272	of	_	_	I-Claim
273	HRT	_	_	I-Claim
274	were	_	_	I-Claim
275	as	_	_	I-Claim
276	effective	_	_	I-Claim
277	as	_	_	I-Claim
278	higher	_	_	I-Claim
279	doses	_	_	I-Claim
280	in	_	_	I-Claim
281	improving	_	_	I-Claim
282	climacteric	_	_	I-Claim
283	symptoms	_	_	I-Claim
284	and	_	_	I-Claim
285	HRQOL	_	_	I-Claim
286	ratings	_	_	I-Claim
287	and	_	_	I-Claim
288	had	_	_	I-Claim
289	fewer	_	_	I-Claim
290	safety	_	_	I-Claim
291	concerns	_	_	I-Claim
292	.	_	_	I-Claim

293	Following	_	_	B-Premise
294	discontinuation	_	_	I-Premise
295	of	_	_	I-Premise
296	ccHRT	_	_	I-Premise
297	,	_	_	I-Premise
298	patient	_	_	I-Premise
299	satisfaction	_	_	I-Premise
300	was	_	_	I-Premise
301	variable	_	_	I-Premise
302	,	_	_	I-Premise
303	with	_	_	I-Premise
304	15	_	_	I-Premise
305	%	_	_	I-Premise
306	electing	_	_	I-Premise
307	to	_	_	I-Premise
308	continue	_	_	I-Premise
309	or	_	_	I-Premise
310	restart	_	_	I-Premise
311	HRT	_	_	I-Premise
312	and	_	_	I-Premise
313	7	_	_	I-Premise
314	%	_	_	I-Premise
315	resuming	_	_	I-Premise
316	at	_	_	I-Premise
317	follow-up	_	_	I-Premise
318	.	_	_	I-Premise

319	This	_	_	B-Claim
320	supports	_	_	I-Claim
321	the	_	_	I-Claim
322	need	_	_	I-Claim
323	for	_	_	I-Claim
324	an	_	_	I-Claim
325	individualized	_	_	I-Claim
326	approach	_	_	I-Claim
327	to	_	_	I-Claim
328	therapy	_	_	I-Claim
329	recommendations	_	_	I-Claim
330	.	_	_	I-Claim


0	Few	_	_	O
1	randomized	_	_	O
2	trials	_	_	O
3	have	_	_	O
4	compared	_	_	O
5	the	_	_	O
6	survival	_	_	O
7	benefit	_	_	O
8	of	_	_	O
9	interferon-alfa	_	_	O
10	over	_	_	O
11	controls	_	_	O
12	in	_	_	O
13	metastatic	_	_	O
14	renal	_	_	O
15	cell	_	_	O
16	carcinoma	_	_	O
17	,	_	_	O
18	and	_	_	O
19	none	_	_	O
20	has	_	_	O
21	been	_	_	O
22	performed	_	_	O
23	using	_	_	O
24	interleukin-2	_	_	O
25	.	_	_	O

26	The	_	_	O
27	Programme	_	_	O
28	Etude	_	_	O
29	Rein	_	_	O
30	Cytokines	_	_	O
31	(	_	_	O
32	PERCY	_	_	O
33	)	_	_	O
34	Quattro	_	_	O
35	trial	_	_	O
36	was	_	_	O
37	designed	_	_	O
38	to	_	_	O
39	evaluate	_	_	O
40	both	_	_	O
41	cytokines	_	_	O
42	for	_	_	O
43	their	_	_	O
44	survival	_	_	O
45	benefit	_	_	O
46	to	_	_	O
47	intermediate	_	_	O
48	prognosis	_	_	O
49	patients	_	_	O
50	,	_	_	O
51	who	_	_	O
52	represent	_	_	O
53	the	_	_	O
54	majority	_	_	O
55	of	_	_	O
56	candidates	_	_	O
57	for	_	_	O
58	these	_	_	O
59	treatments	_	_	O
60	.	_	_	O

61	Patients	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	in	_	_	O
65	a	_	_	O
66	2-by-2	_	_	O
67	factorial	_	_	O
68	design	_	_	O
69	to	_	_	O
70	medroxyprogesterone	_	_	O
71	acetate	_	_	O
72	200	_	_	O
73	mg	_	_	O
74	daily	_	_	O
75	,	_	_	O
76	interferon-alfa	_	_	O
77	9	_	_	O
78	million	_	_	O
79	IU	_	_	O
80	3	_	_	O
81	times	_	_	O
82	a	_	_	O
83	week	_	_	O
84	,	_	_	O
85	subcutaneous	_	_	O
86	interleukin-2	_	_	O
87	9	_	_	O
88	million	_	_	O
89	IU	_	_	O
90	daily	_	_	O
91	,	_	_	O
92	or	_	_	O
93	a	_	_	O
94	combination	_	_	O
95	of	_	_	O
96	both	_	_	O
97	cytokines	_	_	O
98	.	_	_	O

99	Tumor	_	_	O
100	response	_	_	O
101	was	_	_	O
102	evaluated	_	_	O
103	at	_	_	O
104	Week	_	_	O
105	12	_	_	O
106	and	_	_	O
107	Month	_	_	O
108	6	_	_	O
109	;	_	_	O
110	progression-free	_	_	O
111	patients	_	_	O
112	received	_	_	O
113	further	_	_	O
114	identical	_	_	O
115	treatment	_	_	O
116	for	_	_	O
117	a	_	_	O
118	maximum	_	_	O
119	of	_	_	O
120	3	_	_	O
121	additional	_	_	O
122	months	_	_	O
123	.	_	_	O

124	Primary	_	_	O
125	endpoint	_	_	O
126	was	_	_	O
127	overall	_	_	O
128	survival	_	_	O
129	;	_	_	O
130	secondary	_	_	O
131	endpoints	_	_	O
132	were	_	_	O
133	disease-free	_	_	O
134	survival	_	_	O
135	,	_	_	O
136	response	_	_	O
137	rate	_	_	O
138	,	_	_	O
139	toxicity	_	_	O
140	,	_	_	O
141	and	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	.	_	_	O

146	Survival	_	_	O
147	was	_	_	O
148	analyzed	_	_	O
149	on	_	_	O
150	an	_	_	O
151	intent-to-treat	_	_	O
152	basis	_	_	O
153	.	_	_	O

154	From	_	_	O
155	January	_	_	O
156	2000	_	_	O
157	to	_	_	O
158	July	_	_	O
159	2004	_	_	O
160	,	_	_	O
161	492	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	enrolled	_	_	O
165	.	_	_	O

166	Analysis	_	_	O
167	was	_	_	O
168	performed	_	_	O
169	after	_	_	O
170	a	_	_	O
171	29.2-month	_	_	O
172	median	_	_	O
173	follow-up	_	_	O
174	(	_	_	O
175	range	_	_	O
176	,	_	_	O
177	0	_	_	O
178	months	_	_	O
179	to	_	_	O
180	54.6	_	_	O
181	months	_	_	O
182	)	_	_	O
183	.	_	_	O

184	There	_	_	B-Premise
185	were	_	_	I-Premise
186	no	_	_	I-Premise
187	significant	_	_	I-Premise
188	survival	_	_	I-Premise
189	differences	_	_	I-Premise
190	between	_	_	I-Premise
191	the	_	_	I-Premise
192	244	_	_	I-Premise
193	interferon-alfa-treated	_	_	I-Premise
194	patients	_	_	I-Premise
195	and	_	_	I-Premise
196	248	_	_	I-Premise
197	noninterferon-alfa	_	_	I-Premise
198	patients	_	_	I-Premise
199	(	_	_	I-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	,	_	_	I-Premise
203	1.00	_	_	I-Premise
204	;	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	0.81-1.24	_	_	I-Premise
210	)	_	_	I-Premise
211	or	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	247	_	_	I-Premise
215	interleukin-2	_	_	I-Premise
216	and	_	_	I-Premise
217	245	_	_	I-Premise
218	noninterleukin-2-treated	_	_	I-Premise
219	patients	_	_	I-Premise
220	(	_	_	I-Premise
221	hazard	_	_	I-Premise
222	ratio	_	_	I-Premise
223	,	_	_	I-Premise
224	1.07	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	,	_	_	I-Premise
230	0.87-1.33	_	_	I-Premise
231	;	_	_	I-Premise
232	log	_	_	I-Premise
233	rank	_	_	I-Premise
234	,	_	_	I-Premise
235	0.99	_	_	I-Premise
236	and	_	_	I-Premise
237	0.52	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Grade	_	_	B-Premise
243	3-4	_	_	I-Premise
244	toxicities	_	_	I-Premise
245	were	_	_	I-Premise
246	significantly	_	_	I-Premise
247	more	_	_	I-Premise
248	frequent	_	_	I-Premise
249	in	_	_	I-Premise
250	cytokine-treated	_	_	I-Premise
251	patients	_	_	I-Premise
252	than	_	_	I-Premise
253	in	_	_	I-Premise
254	medroxyprogesterone-treated	_	_	I-Premise
255	patients	_	_	I-Premise
256	.	_	_	I-Premise

257	Subcutaneous	_	_	B-Claim
258	interleukin-2	_	_	I-Claim
259	and/or	_	_	I-Claim
260	interferon-alfa	_	_	I-Claim
261	provide	_	_	I-Claim
262	no	_	_	I-Claim
263	survival	_	_	I-Claim
264	benefit	_	_	I-Claim
265	in	_	_	I-Claim
266	metastatic	_	_	I-Claim
267	renal	_	_	I-Claim
268	cancers	_	_	I-Claim
269	of	_	_	I-Claim
270	intermediate	_	_	I-Claim
271	prognosis	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	I-Claim
274	they	_	_	I-Claim
275	induce	_	_	I-Claim
276	a	_	_	I-Claim
277	significant	_	_	I-Claim
278	risk	_	_	I-Claim
279	of	_	_	I-Claim
280	toxicity	_	_	I-Claim
281	.	_	_	I-Claim

282	Newly	_	_	B-Claim
283	available	_	_	I-Claim
284	angiogenesis	_	_	I-Claim
285	inhibitors	_	_	I-Claim
286	should	_	_	I-Claim
287	be	_	_	I-Claim
288	preferred	_	_	I-Claim
289	for	_	_	I-Claim
290	these	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	hypofractionated	_	_	O
7	thoracic	_	_	O
8	radiotherapy	_	_	O
9	(	_	_	O
10	TRT	_	_	O
11	)	_	_	O
12	is	_	_	O
13	comparable	_	_	O
14	to	_	_	O
15	more	_	_	O
16	standard	_	_	O
17	fractionated	_	_	O
18	radiotherapy	_	_	O
19	(	_	_	O
20	RT	_	_	O
21	)	_	_	O
22	in	_	_	O
23	advanced	_	_	O
24	non-small-cell	_	_	O
25	lung	_	_	O
26	cancer	_	_	O
27	(	_	_	O
28	NSCLC	_	_	O
29	)	_	_	O
30	.	_	_	O

31	A	_	_	O
32	total	_	_	O
33	of	_	_	O
34	421	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	locally	_	_	O
38	advanced	_	_	O
39	stage	_	_	O
40	III	_	_	O
41	or	_	_	O
42	stage	_	_	O
43	IV	_	_	O
44	NSCLC	_	_	O
45	tumors	_	_	O
46	were	_	_	O
47	included	_	_	O
48	.	_	_	O

49	Inclusion	_	_	O
50	criteria	_	_	O
51	were	_	_	O
52	inoperable	_	_	O
53	,	_	_	O
54	disease	_	_	O
55	too	_	_	O
56	advanced	_	_	O
57	for	_	_	O
58	curative	_	_	O
59	radiotherapy	_	_	O
60	,	_	_	O
61	and	_	_	O
62	chest	_	_	O
63	symptoms	_	_	O
64	or	_	_	O
65	central	_	_	O
66	tumor	_	_	O
67	threatening	_	_	O
68	the	_	_	O
69	airways	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	three	_	_	O
77	arms	_	_	O
78	:	_	_	O
79	A	_	_	O
80	,	_	_	O
81	17	_	_	O
82	Gy	_	_	O
83	per	_	_	O
84	two	_	_	O
85	fractions	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	146	_	_	O
90	)	_	_	O
91	;	_	_	O
92	B	_	_	O
93	,	_	_	O
94	42	_	_	O
95	Gy	_	_	O
96	per	_	_	O
97	15	_	_	O
98	fractions	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	145	_	_	O
103	)	_	_	O
104	;	_	_	O
105	and	_	_	O
106	C	_	_	O
107	,	_	_	O
108	50	_	_	O
109	Gy	_	_	O
110	per	_	_	O
111	25	_	_	O
112	fractions	_	_	O
113	(	_	_	O
114	n	_	_	O
115	=	_	_	O
116	130	_	_	O
117	)	_	_	O
118	.	_	_	O

119	Four	_	_	O
120	hundred	_	_	O
121	seven	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	eligible	_	_	O
125	for	_	_	O
126	the	_	_	O
127	study	_	_	O
128	;	_	_	O
129	395	_	_	O
130	patients	_	_	O
131	(	_	_	O
132	97	_	_	O
133	%	_	_	O
134	)	_	_	O
135	participated	_	_	O
136	in	_	_	O
137	the	_	_	O
138	health-related	_	_	O
139	quality-of-life	_	_	O
140	(	_	_	O
141	HRQOL	_	_	O
142	)	_	_	O
143	study	_	_	O
144	.	_	_	O

145	The	_	_	O
146	European	_	_	O
147	Organization	_	_	O
148	for	_	_	O
149	Research	_	_	O
150	and	_	_	O
151	Treatment	_	_	O
152	of	_	_	O
153	Cancer	_	_	O
154	(	_	_	O
155	EORTC	_	_	O
156	)	_	_	O
157	Quality	_	_	O
158	of	_	_	O
159	Life	_	_	O
160	Questionnaire	_	_	O
161	(	_	_	O
162	QLQ	_	_	O
163	)	_	_	O
164	-C30	_	_	O
165	and	_	_	O
166	EORTC	_	_	O
167	QLQ-lung	_	_	O
168	cancer-specific	_	_	O
169	module	_	_	O
170	(	_	_	O
171	LC13	_	_	O
172	)	_	_	O
173	were	_	_	O
174	used	_	_	O
175	to	_	_	O
176	investigate	_	_	O
177	airway	_	_	O
178	symptom	_	_	O
179	relief	_	_	O
180	and	_	_	O
181	changes	_	_	O
182	in	_	_	O
183	HRQOL	_	_	O
184	.	_	_	O

185	Assessments	_	_	O
186	were	_	_	O
187	performed	_	_	O
188	before	_	_	O
189	TRT	_	_	O
190	and	_	_	O
191	until	_	_	O
192	week	_	_	O
193	54	_	_	O
194	.	_	_	O

195	Clinicians	_	_	O
196	'	_	_	O
197	assessments	_	_	O
198	of	_	_	O
199	symptom	_	_	O
200	improvement	_	_	O
201	were	_	_	O
202	at	_	_	O
203	2	_	_	O
204	,	_	_	O
205	6	_	_	O
206	,	_	_	O
207	and	_	_	O
208	14	_	_	O
209	weeks	_	_	O
210	after	_	_	O
211	completion	_	_	O
212	of	_	_	O
213	TRT	_	_	O
214	.	_	_	O

215	The	_	_	O
216	patients	_	_	O
217	were	_	_	O
218	observed	_	_	O
219	for	_	_	O
220	a	_	_	O
221	minimum	_	_	O
222	of	_	_	O
223	3	_	_	O
224	years	_	_	O
225	.	_	_	O

226	Results	_	_	O
227	Baseline	_	_	O
228	prognostic	_	_	O
229	data	_	_	O
230	were	_	_	O
231	equally	_	_	O
232	distributed	_	_	O
233	in	_	_	O
234	the	_	_	O
235	treatment	_	_	O
236	groups	_	_	O
237	.	_	_	O

238	Patient	_	_	O
239	compliance	_	_	O
240	with	_	_	O
241	respect	_	_	O
242	to	_	_	O
243	the	_	_	O
244	HRQOL	_	_	O
245	investigation	_	_	O
246	was	_	_	O
247	minimum	_	_	O
248	74	_	_	O
249	%	_	_	O
250	.	_	_	O

251	HRQOL	_	_	B-Premise
252	and	_	_	I-Premise
253	symptom	_	_	I-Premise
254	relief	_	_	I-Premise
255	were	_	_	I-Premise
256	equivalent	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	treatment	_	_	I-Premise
260	arms	_	_	I-Premise
261	.	_	_	I-Premise

262	No	_	_	B-Premise
263	significant	_	_	I-Premise
264	difference	_	_	I-Premise
265	in	_	_	I-Premise
266	survival	_	_	I-Premise
267	among	_	_	I-Premise
268	arms	_	_	I-Premise
269	A	_	_	I-Premise
270	,	_	_	I-Premise
271	B	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	C	_	_	I-Premise
275	was	_	_	I-Premise
276	found	_	_	I-Premise
277	,	_	_	I-Premise
278	with	_	_	I-Premise
279	median	_	_	I-Premise
280	survival	_	_	I-Premise
281	8.2	_	_	I-Premise
282	,	_	_	I-Premise
283	7.0	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	6.8	_	_	I-Premise
287	months	_	_	I-Premise
288	,	_	_	I-Premise
289	respectively	_	_	I-Premise
290	.	_	_	I-Premise

291	Our	_	_	B-Claim
292	data	_	_	I-Claim
293	indicate	_	_	I-Claim
294	that	_	_	I-Claim
295	protracted	_	_	I-Claim
296	palliative	_	_	I-Claim
297	TRT	_	_	I-Claim
298	renders	_	_	I-Claim
299	no	_	_	I-Claim
300	improvement	_	_	I-Claim
301	in	_	_	I-Claim
302	symptom	_	_	I-Claim
303	relief	_	_	I-Claim
304	,	_	_	I-Claim
305	HRQOL	_	_	I-Claim
306	,	_	_	I-Claim
307	or	_	_	I-Claim
308	survival	_	_	I-Claim
309	when	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	short-term	_	_	I-Claim
313	hypofractionated	_	_	I-Claim
314	treatment	_	_	I-Claim
315	in	_	_	I-Claim
316	advanced	_	_	I-Claim
317	NSCLC	_	_	I-Claim
318	.	_	_	I-Claim


0	Cisplatin	_	_	B-Claim
1	reduces	_	_	I-Claim
2	plasma	_	_	I-Claim
3	ghrelin	_	_	I-Claim
4	levels	_	_	I-Claim
5	through	_	_	I-Claim
6	the	_	_	I-Claim
7	5-hydroxytryptamine	_	_	I-Claim
8	(	_	_	I-Claim
9	5-HT	_	_	I-Claim
10	)	_	_	I-Claim
11	receptor	_	_	I-Claim
12	.	_	_	I-Claim

13	This	_	_	O
14	may	_	_	O
15	cause	_	_	O
16	cisplatin-induced	_	_	O
17	gastrointestinal	_	_	O
18	disorders	_	_	O
19	and	_	_	O
20	hinders	_	_	O
21	the	_	_	O
22	continuation	_	_	O
23	of	_	_	O
24	chemotherapy	_	_	O
25	.	_	_	O

26	The	_	_	O
27	authors	_	_	O
28	of	_	_	O
29	this	_	_	O
30	report	_	_	O
31	conducted	_	_	O
32	a	_	_	O
33	prospective	_	_	O
34	,	_	_	O
35	randomized	_	_	O
36	phase	_	_	O
37	2	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	evaluate	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	exogenous	_	_	O
45	ghrelin	_	_	O
46	during	_	_	O
47	cisplatin-based	_	_	O
48	chemotherapy	_	_	O
49	.	_	_	O

50	Forty-two	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	esophageal	_	_	O
54	cancer	_	_	O
55	who	_	_	O
56	were	_	_	O
57	receiving	_	_	O
58	cisplatin-based	_	_	O
59	neoadjuvant	_	_	O
60	chemotherapy	_	_	O
61	were	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	either	_	_	O
65	a	_	_	O
66	ghrelin	_	_	O
67	group	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	21	_	_	O
72	)	_	_	O
73	or	_	_	O
74	a	_	_	O
75	placebo	_	_	O
76	group	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	21	_	_	O
81	)	_	_	O
82	.	_	_	O

83	They	_	_	O
84	received	_	_	O
85	either	_	_	O
86	intravenous	_	_	O
87	infusions	_	_	O
88	of	_	_	O
89	synthetic	_	_	O
90	human	_	_	O
91	ghrelin	_	_	O
92	(	_	_	O
93	3	_	_	O
94	Î¼g/kg	_	_	O
95	)	_	_	O
96	or	_	_	O
97	saline	_	_	O
98	twice	_	_	O
99	daily	_	_	O
100	for	_	_	O
101	1	_	_	O
102	week	_	_	O
103	with	_	_	O
104	cisplatin	_	_	O
105	administration	_	_	O
106	.	_	_	O

107	The	_	_	O
108	primary	_	_	O
109	endpoint	_	_	O
110	was	_	_	O
111	changes	_	_	O
112	in	_	_	O
113	oral	_	_	O
114	calorie	_	_	O
115	intake	_	_	O
116	,	_	_	O
117	and	_	_	O
118	the	_	_	O
119	secondary	_	_	O
120	endpoints	_	_	O
121	were	_	_	O
122	chemotherapy-related	_	_	O
123	adverse	_	_	O
124	events	_	_	O
125	;	_	_	O
126	appetite	_	_	O
127	visual	_	_	O
128	analog	_	_	O
129	scale	_	_	O
130	(	_	_	O
131	VAS	_	_	O
132	)	_	_	O
133	scores	_	_	O
134	;	_	_	O
135	changes	_	_	O
136	in	_	_	O
137	gastrointestinal	_	_	O
138	hormones	_	_	O
139	and	_	_	O
140	nutritional	_	_	O
141	status	_	_	O
142	,	_	_	O
143	including	_	_	O
144	rapid	_	_	O
145	turnover	_	_	O
146	proteins	_	_	O
147	,	_	_	O
148	and	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	(	_	_	O
153	QoL	_	_	O
154	)	_	_	O
155	estimated	_	_	O
156	with	_	_	O
157	the	_	_	O
158	European	_	_	O
159	Organization	_	_	O
160	for	_	_	O
161	Research	_	_	O
162	and	_	_	O
163	Treatment	_	_	O
164	of	_	_	O
165	Cancer	_	_	O
166	QoL	_	_	O
167	core	_	_	O
168	questionnaire	_	_	O
169	(	_	_	O
170	QLQ-C30	_	_	O
171	)	_	_	O
172	.	_	_	O

173	Two	_	_	O
174	patients	_	_	O
175	were	_	_	O
176	excluded	_	_	O
177	from	_	_	O
178	the	_	_	O
179	final	_	_	O
180	analysis	_	_	O
181	:	_	_	O
182	One	_	_	O
183	patient	_	_	O
184	suspended	_	_	O
185	ghrelin	_	_	O
186	administration	_	_	O
187	because	_	_	O
188	of	_	_	O
189	excessive	_	_	O
190	diaphoresis	_	_	O
191	,	_	_	O
192	and	_	_	O
193	another	_	_	O
194	patient	_	_	O
195	in	_	_	O
196	the	_	_	O
197	placebo	_	_	O
198	group	_	_	O
199	failed	_	_	O
200	to	_	_	O
201	monitor	_	_	O
202	the	_	_	O
203	self-questionnaire	_	_	O
204	.	_	_	O

205	Food	_	_	B-Premise
206	intake	_	_	I-Premise
207	and	_	_	I-Premise
208	appetite	_	_	I-Premise
209	VAS	_	_	I-Premise
210	scores	_	_	I-Premise
211	were	_	_	I-Premise
212	significantly	_	_	I-Premise
213	higher	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	ghrelin	_	_	I-Premise
217	group	_	_	I-Premise
218	than	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	placebo	_	_	I-Premise
222	group	_	_	I-Premise
223	(	_	_	I-Premise
224	18.2	_	_	I-Premise
225	Â±	_	_	I-Premise
226	5.2	_	_	I-Premise
227	kcal/kg/day	_	_	I-Premise
228	vs	_	_	I-Premise
229	12.7	_	_	I-Premise
230	Â±	_	_	I-Premise
231	3.4	_	_	I-Premise
232	kcal/kg/day	_	_	I-Premise
233	[	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.001	_	_	I-Premise
237	]	_	_	I-Premise
238	and	_	_	I-Premise
239	6.2	_	_	I-Premise
240	Â±	_	_	I-Premise
241	0.9	_	_	I-Premise
242	vs	_	_	I-Premise
243	4.1	_	_	I-Premise
244	Â±	_	_	I-Premise
245	0.9	_	_	I-Premise
246	[	_	_	I-Premise
247	P	_	_	I-Premise
248	<	_	_	I-Premise
249	.0001	_	_	I-Premise
250	]	_	_	I-Premise
251	,	_	_	I-Premise
252	respectively	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Patients	_	_	B-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	ghrelin	_	_	I-Premise
259	group	_	_	I-Premise
260	had	_	_	I-Premise
261	fewer	_	_	I-Premise
262	adverse	_	_	I-Premise
263	events	_	_	I-Premise
264	during	_	_	I-Premise
265	chemotherapy	_	_	I-Premise
266	related	_	_	I-Premise
267	to	_	_	I-Premise
268	anorexia	_	_	I-Premise
269	and	_	_	I-Premise
270	nausea	_	_	I-Premise
271	than	_	_	I-Premise
272	patients	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	control	_	_	I-Premise
276	group	_	_	I-Premise
277	.	_	_	I-Premise

278	Significant	_	_	B-Premise
279	deterioration	_	_	I-Premise
280	was	_	_	I-Premise
281	noted	_	_	I-Premise
282	after	_	_	I-Premise
283	chemotherapy	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	placebo	_	_	I-Premise
287	group	_	_	I-Premise
288	in	_	_	I-Premise
289	QoL	_	_	I-Premise
290	scores	_	_	I-Premise
291	,	_	_	I-Premise
292	appetite	_	_	I-Premise
293	,	_	_	I-Premise
294	nausea	_	_	I-Premise
295	and	_	_	I-Premise
296	vomiting	_	_	I-Premise
297	,	_	_	I-Premise
298	and	_	_	I-Premise
299	global	_	_	I-Premise
300	health	_	_	I-Premise
301	status	_	_	I-Premise
302	.	_	_	I-Premise

303	Short-term	_	_	B-Claim
304	administration	_	_	I-Claim
305	of	_	_	I-Claim
306	exogenous	_	_	I-Claim
307	ghrelin	_	_	I-Claim
308	at	_	_	I-Claim
309	the	_	_	I-Claim
310	start	_	_	I-Claim
311	of	_	_	I-Claim
312	cisplatin-based	_	_	I-Claim
313	chemotherapy	_	_	I-Claim
314	stimulated	_	_	I-Claim
315	food	_	_	I-Claim
316	intake	_	_	I-Claim
317	and	_	_	I-Claim
318	minimized	_	_	I-Claim
319	adverse	_	_	I-Claim
320	events	_	_	I-Claim
321	.	_	_	I-Claim


0	Chemoradiotherapy	_	_	O
1	(	_	_	O
2	CRT	_	_	O
3	)	_	_	O
4	-induced	_	_	O
5	oral	_	_	O
6	mucositis	_	_	O
7	(	_	_	O
8	OM	_	_	O
9	)	_	_	O
10	adversely	_	_	O
11	affects	_	_	O
12	a	_	_	O
13	patient	_	_	O
14	's	_	_	O
15	oral	_	_	O
16	functions	_	_	O
17	and	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	QOL	_	_	O
23	)	_	_	O
24	.	_	_	O

25	Low-level	_	_	O
26	laser	_	_	O
27	therapy	_	_	O
28	(	_	_	O
29	LLLT	_	_	O
30	)	_	_	O
31	showed	_	_	O
32	some	_	_	O
33	preventive	_	_	O
34	and	_	_	O
35	curative	_	_	O
36	effects	_	_	O
37	against	_	_	O
38	clinically	_	_	O
39	reported	_	_	O
40	objective	_	_	O
41	measures	_	_	O
42	of	_	_	O
43	OM	_	_	O
44	in	_	_	O
45	few	_	_	O
46	trials	_	_	O
47	including	_	_	O
48	our	_	_	O
49	recently	_	_	O
50	published	_	_	O
51	study	_	_	O
52	.	_	_	O

53	There	_	_	O
54	is	_	_	O
55	dearth	_	_	O
56	of	_	_	O
57	evidence	_	_	O
58	regarding	_	_	O
59	the	_	_	O
60	effects	_	_	O
61	of	_	_	O
62	LLLT	_	_	O
63	on	_	_	O
64	patient	_	_	O
65	's	_	_	O
66	subjective	_	_	O
67	experience	_	_	O
68	of	_	_	O
69	OM	_	_	O
70	and	_	_	O
71	QOL	_	_	O
72	.	_	_	O

73	Hence	_	_	O
74	,	_	_	O
75	we	_	_	O
76	did	_	_	O
77	this	_	_	O
78	study	_	_	O
79	to	_	_	O
80	evaluate	_	_	O
81	the	_	_	O
82	effects	_	_	O
83	of	_	_	O
84	LLLT	_	_	O
85	on	_	_	O
86	a	_	_	O
87	patient	_	_	O
88	's	_	_	O
89	reported	_	_	O
90	measures	_	_	O
91	of	_	_	O
92	OM	_	_	O
93	and	_	_	O
94	QOL	_	_	O
95	in	_	_	O
96	head	_	_	O
97	and	_	_	O
98	neck	_	_	O
99	cancer	_	_	O
100	(	_	_	O
101	HNC	_	_	O
102	)	_	_	O
103	patients	_	_	O
104	receiving	_	_	O
105	CRT	_	_	O
106	.	_	_	O

107	This	_	_	O
108	triple	_	_	O
109	blinded	_	_	O
110	study	_	_	O
111	randomized	_	_	O
112	220	_	_	O
113	HNC	_	_	O
114	patients	_	_	O
115	scheduled	_	_	O
116	for	_	_	O
117	CRT	_	_	O
118	(	_	_	O
119	three	_	_	O
120	weekly	_	_	O
121	Cisplatin	_	_	O
122	+	_	_	O
123	RT	_	_	O
124	=	_	_	O
125	66	_	_	O
126	Gray	_	_	O
127	(	_	_	O
128	2	_	_	O
129	Gy/session	_	_	O
130	)	_	_	O
131	,	_	_	O
132	five	_	_	O
133	fractions/week	_	_	O
134	for	_	_	O
135	6.5	_	_	O
136	weeks	_	_	O
137	,	_	_	O
138	total	_	_	O
139	33	_	_	O
140	fractions	_	_	O
141	)	_	_	O
142	into	_	_	O
143	laser	_	_	O
144	(	_	_	O
145	110	_	_	O
146	)	_	_	O
147	and	_	_	O
148	placebo	_	_	O
149	(	_	_	O
150	110	_	_	O
151	)	_	_	O
152	groups	_	_	O
153	.	_	_	O

154	The	_	_	O
155	laser	_	_	O
156	group	_	_	O
157	received	_	_	O
158	LLLT	_	_	O
159	(	_	_	O
160	Technomed	_	_	O
161	Electronics	_	_	O
162	Advanced	_	_	O
163	Laser	_	_	O
164	Therapy	_	_	O
165	1000	_	_	O
166	,	_	_	O
167	He-Ne	_	_	O
168	,	_	_	O
169	Î»	_	_	O
170	=	_	_	O
171	632.8	_	_	O
172	nm	_	_	O
173	,	_	_	O
174	power	_	_	O
175	density	_	_	O
176	=	_	_	O
177	24	_	_	O
178	mW/cm	_	_	O
179	(	_	_	O
180	2	_	_	O
181	)	_	_	O
182	,	_	_	O
183	dosage	_	_	O
184	=	_	_	O
185	3.0	_	_	O
186	J	_	_	O
187	at	_	_	O
188	each	_	_	O
189	point	_	_	O
190	,	_	_	O
191	total	_	_	O
192	dose/session	_	_	O
193	=	_	_	O
194	36-40	_	_	O
195	J	_	_	O
196	,	_	_	O
197	spot	_	_	O
198	size	_	_	O
199	1	_	_	O
200	cm	_	_	O
201	(	_	_	O
202	2	_	_	O
203	)	_	_	O
204	,	_	_	O
205	irradiation	_	_	O
206	time/point	_	_	O
207	125	_	_	O
208	s	_	_	O
209	)	_	_	O
210	before	_	_	O
211	each	_	_	O
212	radiation	_	_	O
213	session	_	_	O
214	,	_	_	O
215	while	_	_	O
216	the	_	_	O
217	placebo	_	_	O
218	group	_	_	O
219	did	_	_	O
220	not	_	_	O
221	receive	_	_	O
222	laser	_	_	O
223	therapy	_	_	O
224	.	_	_	O

225	Methodology	_	_	O
226	was	_	_	O
227	similar	_	_	O
228	to	_	_	O
229	our	_	_	O
230	recently	_	_	O
231	published	_	_	O
232	study	_	_	O
233	(	_	_	O
234	Gautam	_	_	O
235	et	_	_	O
236	al	_	_	O
237	.	_	_	O

238	Radiother	_	_	O
239	Oncol	_	_	O
240	104:349-354	_	_	O
241	,	_	_	O
242	2012	_	_	O
243	)	_	_	O
244	.	_	_	O

245	In	_	_	O
246	this	_	_	O
247	part	_	_	O
248	of	_	_	O
249	our	_	_	O
250	study	_	_	O
251	,	_	_	O
252	a	_	_	O
253	blinded	_	_	O
254	assessor	_	_	O
255	collected	_	_	O
256	subjective	_	_	O
257	outcomes	_	_	O
258	of	_	_	O
259	the	_	_	O
260	patient	_	_	O
261	's	_	_	O
262	reported	_	_	O
263	measures	_	_	O
264	of	_	_	O
265	OM	_	_	O
266	using	_	_	O
267	Oral	_	_	O
268	Mucositis	_	_	O
269	Weekly	_	_	O
270	Questionnaire-Head	_	_	O
271	and	_	_	O
272	Neck	_	_	O
273	(	_	_	O
274	OMWQ-HN	_	_	O
275	)	_	_	O
276	and	_	_	O
277	QOL	_	_	O
278	using	_	_	O
279	Functional	_	_	O
280	Assessment	_	_	O
281	of	_	_	O
282	Cancer	_	_	O
283	Treatment-Head	_	_	O
284	and	_	_	O
285	Neck	_	_	O
286	(	_	_	O
287	FACT-HN	_	_	O
288	)	_	_	O
289	Questionnaire	_	_	O
290	.	_	_	O

291	Data	_	_	O
292	were	_	_	O
293	analyzed	_	_	O
294	using	_	_	O
295	repeated	_	_	O
296	measure	_	_	O
297	ANOVA	_	_	O
298	through	_	_	O
299	general	_	_	O
300	linear	_	_	O
301	model	_	_	O
302	.	_	_	O

303	Statistical	_	_	O
304	significance	_	_	O
305	was	_	_	O
306	kept	_	_	O
307	at	_	_	O
308	p	_	_	O
309	<	_	_	O
310	0.05	_	_	O
311	.	_	_	O

312	Results	_	_	B-Premise
313	analysis	_	_	I-Premise
314	revealed	_	_	I-Premise
315	that	_	_	I-Premise
316	OMWQ-HN	_	_	I-Premise
317	(	_	_	I-Premise
318	F	_	_	I-Premise
319	=	_	_	I-Premise
320	12.199	_	_	I-Premise
321	,	_	_	I-Premise
322	df	_	_	I-Premise
323	=	_	_	I-Premise
324	6,1314	_	_	I-Premise
325	,	_	_	I-Premise
326	p	_	_	I-Premise
327	<	_	_	I-Premise
328	0.001	_	_	I-Premise
329	)	_	_	I-Premise
330	and	_	_	I-Premise
331	FACT-HN	_	_	I-Premise
332	(	_	_	I-Premise
333	p	_	_	I-Premise
334	<	_	_	I-Premise
335	0.05	_	_	I-Premise
336	)	_	_	I-Premise
337	scores	_	_	I-Premise
338	were	_	_	I-Premise
339	significantly	_	_	I-Premise
340	lower	_	_	I-Premise
341	in	_	_	I-Premise
342	LLLT	_	_	I-Premise
343	than	_	_	I-Premise
344	placebo	_	_	I-Premise
345	group	_	_	I-Premise
346	patients	_	_	I-Premise
347	.	_	_	I-Premise

348	Also	_	_	O
349	,	_	_	O
350	a	_	_	B-Premise
351	significant	_	_	I-Premise
352	reduction	_	_	I-Premise
353	(	_	_	I-Premise
354	p	_	_	I-Premise
355	<	_	_	I-Premise
356	0.001	_	_	I-Premise
357	)	_	_	I-Premise
358	in	_	_	I-Premise
359	incidence	_	_	I-Premise
360	of	_	_	I-Premise
361	severe	_	_	I-Premise
362	OM	_	_	I-Premise
363	,	_	_	I-Premise
364	need	_	_	I-Premise
365	for	_	_	I-Premise
366	opioid	_	_	I-Premise
367	analgesics	_	_	I-Premise
368	,	_	_	I-Premise
369	and	_	_	I-Premise
370	total	_	_	I-Premise
371	parenteral	_	_	I-Premise
372	nutrition	_	_	I-Premise
373	was	_	_	I-Premise
374	observed	_	_	I-Premise
375	.	_	_	I-Premise

376	LLLT	_	_	B-Claim
377	was	_	_	I-Claim
378	effective	_	_	I-Claim
379	in	_	_	I-Claim
380	improving	_	_	I-Claim
381	the	_	_	I-Claim
382	patient	_	_	I-Claim
383	's	_	_	I-Claim
384	subjective	_	_	I-Claim
385	experience	_	_	I-Claim
386	of	_	_	I-Claim
387	OM	_	_	I-Claim
388	and	_	_	I-Claim
389	QOL	_	_	I-Claim
390	in	_	_	I-Claim
391	HNC	_	_	I-Claim
392	patients	_	_	I-Claim
393	receiving	_	_	I-Claim
394	CRT	_	_	I-Claim
395	.	_	_	I-Claim


0	Due	_	_	O
1	to	_	_	O
2	concerns	_	_	O
3	of	_	_	O
4	fragility	_	_	O
5	fracture	_	_	O
6	,	_	_	O
7	exercise	_	_	O
8	is	_	_	O
9	a	_	_	O
10	perceived	_	_	O
11	contraindication	_	_	O
12	for	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	bone	_	_	O
18	metastases	_	_	O
19	.	_	_	O

20	These	_	_	O
21	patients	_	_	O
22	experience	_	_	O
23	significant	_	_	O
24	functional	_	_	O
25	impairment	_	_	O
26	and	_	_	O
27	muscle	_	_	O
28	atrophy	_	_	O
29	,	_	_	O
30	which	_	_	O
31	may	_	_	O
32	lead	_	_	O
33	to	_	_	O
34	an	_	_	O
35	increased	_	_	O
36	likelihood	_	_	O
37	of	_	_	O
38	skeletal	_	_	O
39	complicaTIOns	_	_	O
40	(	_	_	O
41	i.e.	_	_	O
42	,	_	_	O
43	pathological	_	_	O
44	fracture	_	_	O
45	,	_	_	O
46	bone	_	_	O
47	pain	_	_	O
48	)	_	_	O
49	and/or	_	_	O
50	falls	_	_	O
51	.	_	_	O

52	Safe	_	_	O
53	resistance	_	_	O
54	exercise	_	_	O
55	prescription	_	_	O
56	may	_	_	O
57	counteract	_	_	O
58	this	_	_	O
59	effect	_	_	O
60	.	_	_	O

61	The	_	_	O
62	aim	_	_	O
63	of	_	_	O
64	this	_	_	O
65	feasibility	_	_	O
66	trial	_	_	O
67	was	_	_	O
68	to	_	_	O
69	determine	_	_	O
70	the	_	_	O
71	safety	_	_	O
72	and	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	resistance	_	_	O
76	exercise	_	_	O
77	by	_	_	O
78	prostate	_	_	O
79	cancer	_	_	O
80	survivors	_	_	O
81	with	_	_	O
82	bone	_	_	O
83	metastatic	_	_	O
84	disease	_	_	O
85	.	_	_	O

86	Twenty	_	_	O
87	men	_	_	O
88	with	_	_	O
89	established	_	_	O
90	bone	_	_	O
91	metastases	_	_	O
92	secondary	_	_	O
93	to	_	_	O
94	prostate	_	_	O
95	cancer	_	_	O
96	were	_	_	O
97	randomly	_	_	O
98	assigned	_	_	O
99	to	_	_	O
100	a	_	_	O
101	12-week	_	_	O
102	resistance	_	_	O
103	exercise	_	_	O
104	program	_	_	O
105	in	_	_	O
106	which	_	_	O
107	exercise	_	_	O
108	prescription	_	_	O
109	was	_	_	O
110	based	_	_	O
111	on	_	_	O
112	the	_	_	O
113	location	_	_	O
114	of	_	_	O
115	bone	_	_	O
116	lesions	_	_	O
117	(	_	_	O
118	n=10	_	_	O
119	)	_	_	O
120	or	_	_	O
121	usual	_	_	O
122	care	_	_	O
123	(	_	_	O
124	n=10	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Outcomes	_	_	O
128	included	_	_	O
129	safety	_	_	O
130	and	_	_	O
131	tolerance	_	_	O
132	of	_	_	O
133	the	_	_	O
134	exercise	_	_	O
135	program	_	_	O
136	,	_	_	O
137	physical	_	_	O
138	function	_	_	O
139	,	_	_	O
140	physical	_	_	O
141	activity	_	_	O
142	level	_	_	O
143	,	_	_	O
144	body	_	_	O
145	composition	_	_	O
146	,	_	_	O
147	fatigue	_	_	O
148	,	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	and	_	_	O
153	psychological	_	_	O
154	distress	_	_	O
155	.	_	_	O

156	Outcomes	_	_	O
157	were	_	_	O
158	compared	_	_	O
159	between	_	_	O
160	groups	_	_	O
161	using	_	_	O
162	analysis	_	_	O
163	of	_	_	O
164	covariance	_	_	O
165	adjusted	_	_	O
166	for	_	_	O
167	baseline	_	_	O
168	values	_	_	O
169	.	_	_	O

170	Participants	_	_	O
171	had	_	_	O
172	significant	_	_	O
173	disease	_	_	O
174	load	_	_	O
175	with	_	_	O
176	65	_	_	O
177	%	_	_	O
178	of	_	_	O
179	participants	_	_	O
180	presenting	_	_	O
181	with	_	_	O
182	two	_	_	O
183	or	_	_	O
184	more	_	_	O
185	regions	_	_	O
186	affected	_	_	O
187	by	_	_	O
188	bone	_	_	O
189	metastases	_	_	O
190	and	_	_	O
191	an	_	_	O
192	average	_	_	O
193	Gleason	_	_	O
194	score	_	_	O
195	of	_	_	O
196	8.2Â±0.9	_	_	O
197	.	_	_	O

198	Five	_	_	O
199	participants	_	_	O
200	(	_	_	O
201	exercise=2	_	_	O
202	;	_	_	O
203	usual	_	_	O
204	care=3	_	_	O
205	)	_	_	O
206	did	_	_	O
207	not	_	_	O
208	complete	_	_	O
209	the	_	_	O
210	intervention	_	_	O
211	,	_	_	O
212	three	_	_	O
213	of	_	_	O
214	which	_	_	O
215	were	_	_	O
216	due	_	_	O
217	to	_	_	O
218	advancing	_	_	O
219	disease	_	_	O
220	(	_	_	O
221	exercise=2	_	_	O
222	;	_	_	O
223	usual	_	_	O
224	care=1	_	_	O
225	)	_	_	O
226	.	_	_	O

227	No	_	_	B-Premise
228	adverse	_	_	I-Premise
229	events	_	_	I-Premise
230	or	_	_	I-Premise
231	skeletal	_	_	I-Premise
232	complications	_	_	I-Premise
233	occurred	_	_	I-Premise
234	during	_	_	I-Premise
235	the	_	_	I-Premise
236	supervised	_	_	I-Premise
237	exercise	_	_	I-Premise
238	sessions	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	B-Premise
241	exercise	_	_	I-Premise
242	program	_	_	I-Premise
243	was	_	_	I-Premise
244	well	_	_	I-Premise
245	tolerated	_	_	I-Premise
246	as	_	_	I-Premise
247	evidenced	_	_	I-Premise
248	by	_	_	I-Premise
249	high	_	_	I-Premise
250	attendance	_	_	I-Premise
251	(	_	_	I-Premise
252	83	_	_	I-Premise
253	%	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	compliance	_	_	I-Premise
257	rates	_	_	I-Premise
258	(	_	_	I-Premise
259	93	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	ability	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	participants	_	_	I-Premise
269	to	_	_	I-Premise
270	exercise	_	_	I-Premise
271	at	_	_	I-Premise
272	an	_	_	I-Premise
273	intensity	_	_	I-Premise
274	within	_	_	I-Premise
275	the	_	_	I-Premise
276	target	_	_	I-Premise
277	range	_	_	I-Premise
278	for	_	_	I-Premise
279	cancer	_	_	I-Premise
280	survivors	_	_	I-Premise
281	(	_	_	I-Premise
282	rating	_	_	I-Premise
283	of	_	_	I-Premise
284	perceived	_	_	I-Premise
285	exertion	_	_	I-Premise
286	=13.8Â±1.5	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Premise
290	change	_	_	I-Premise
291	in	_	_	I-Premise
292	physical	_	_	I-Premise
293	function	_	_	I-Premise
294	(	_	_	I-Premise
295	muscle	_	_	I-Premise
296	strength	_	_	I-Premise
297	âˆ¼11	_	_	I-Premise
298	%	_	_	I-Premise
299	;	_	_	I-Premise
300	submaximal	_	_	I-Premise
301	aerobic	_	_	I-Premise
302	exercise	_	_	I-Premise
303	capacity	_	_	I-Premise
304	âˆ¼5	_	_	I-Premise
305	%	_	_	I-Premise
306	and	_	_	I-Premise
307	ambulation	_	_	I-Premise
308	âˆ¼12	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	physical	_	_	I-Premise
313	activity	_	_	I-Premise
314	level	_	_	I-Premise
315	(	_	_	I-Premise
316	âˆ¼24	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	lean	_	_	I-Premise
321	mass	_	_	I-Premise
322	(	_	_	I-Premise
323	âˆ¼3	_	_	I-Premise
324	%	_	_	I-Premise
325	)	_	_	I-Premise
326	differed	_	_	I-Premise
327	significantly	_	_	I-Premise
328	between	_	_	I-Premise
329	groups	_	_	I-Premise
330	following	_	_	I-Premise
331	the	_	_	I-Premise
332	intervention	_	_	I-Premise
333	,	_	_	I-Premise
334	with	_	_	I-Premise
335	favorable	_	_	I-Premise
336	changes	_	_	I-Premise
337	in	_	_	I-Premise
338	the	_	_	I-Premise
339	exercise	_	_	I-Premise
340	group	_	_	I-Premise
341	compared	_	_	I-Premise
342	with	_	_	I-Premise
343	the	_	_	I-Premise
344	usual	_	_	I-Premise
345	care	_	_	I-Premise
346	group	_	_	I-Premise
347	.	_	_	I-Premise

348	No	_	_	B-Premise
349	significant	_	_	I-Premise
350	between-group	_	_	I-Premise
351	differences	_	_	I-Premise
352	were	_	_	I-Premise
353	observed	_	_	I-Premise
354	for	_	_	I-Premise
355	fatigue	_	_	I-Premise
356	,	_	_	I-Premise
357	quality	_	_	I-Premise
358	of	_	_	I-Premise
359	life	_	_	I-Premise
360	or	_	_	I-Premise
361	psychological	_	_	I-Premise
362	distress	_	_	I-Premise
363	.	_	_	I-Premise

364	This	_	_	B-Claim
365	initial	_	_	I-Claim
366	evidence	_	_	I-Claim
367	involving	_	_	I-Claim
368	a	_	_	I-Claim
369	small	_	_	I-Claim
370	sample	_	_	I-Claim
371	size	_	_	I-Claim
372	suggests	_	_	I-Claim
373	that	_	_	I-Claim
374	appropriately	_	_	I-Claim
375	designed	_	_	I-Claim
376	and	_	_	I-Claim
377	supervised	_	_	I-Claim
378	resistance	_	_	I-Claim
379	exercise	_	_	I-Claim
380	may	_	_	I-Claim
381	be	_	_	I-Claim
382	safe	_	_	I-Claim
383	and	_	_	I-Claim
384	well	_	_	I-Claim
385	tolerated	_	_	I-Claim
386	by	_	_	I-Claim
387	prostate	_	_	I-Claim
388	cancer	_	_	I-Claim
389	patients	_	_	I-Claim
390	with	_	_	I-Claim
391	bone	_	_	I-Claim
392	metastatic	_	_	I-Claim
393	disease	_	_	I-Claim
394	and	_	_	I-Claim
395	can	_	_	I-Claim
396	lead	_	_	I-Claim
397	to	_	_	I-Claim
398	improvements	_	_	I-Claim
399	in	_	_	I-Claim
400	physical	_	_	I-Claim
401	function	_	_	I-Claim
402	,	_	_	I-Claim
403	physical	_	_	I-Claim
404	activity	_	_	I-Claim
405	levels	_	_	I-Claim
406	and	_	_	I-Claim
407	lean	_	_	I-Claim
408	mass	_	_	I-Claim
409	.	_	_	I-Claim

410	Future	_	_	B-Claim
411	trials	_	_	I-Claim
412	involving	_	_	I-Claim
413	larger	_	_	I-Claim
414	sample	_	_	I-Claim
415	sizes	_	_	I-Claim
416	are	_	_	I-Claim
417	required	_	_	I-Claim
418	to	_	_	I-Claim
419	expand	_	_	I-Claim
420	these	_	_	I-Claim
421	preliminary	_	_	I-Claim
422	findings	_	_	I-Claim
423	.	_	_	I-Claim


0	A	_	_	O
1	recent	_	_	O
2	randomized	_	_	O
3	trial	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	external	_	_	O
7	beam	_	_	O
8	radiation	_	_	O
9	therapy	_	_	O
10	(	_	_	O
11	EBRT	_	_	O
12	)	_	_	O
13	to	_	_	O
14	cryoablation	_	_	O
15	for	_	_	O
16	localized	_	_	O
17	disease	_	_	O
18	showed	_	_	O
19	cryoablation	_	_	O
20	to	_	_	O
21	be	_	_	O
22	noninferior	_	_	O
23	to	_	_	O
24	external	_	_	O
25	beam	_	_	O
26	EBRT	_	_	O
27	in	_	_	O
28	disease	_	_	O
29	progression	_	_	O
30	and	_	_	O
31	overall	_	_	O
32	and	_	_	O
33	disease-specific	_	_	O
34	survival	_	_	O
35	.	_	_	O

36	We	_	_	O
37	report	_	_	O
38	on	_	_	O
39	the	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	outcomes	_	_	O
47	for	_	_	O
48	this	_	_	O
49	trial	_	_	O
50	.	_	_	O

51	From	_	_	O
52	December	_	_	O
53	1997	_	_	O
54	through	_	_	O
55	February	_	_	O
56	2003	_	_	O
57	,	_	_	O
58	244	_	_	O
59	men	_	_	O
60	with	_	_	O
61	newly	_	_	O
62	diagnosed	_	_	O
63	localized	_	_	O
64	prostate	_	_	O
65	cancer	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	cryoablation	_	_	O
71	or	_	_	O
72	EBRT	_	_	O
73	(	_	_	O
74	median	_	_	O
75	dose	_	_	O
76	68	_	_	O
77	Gy	_	_	O
78	)	_	_	O
79	.	_	_	O

80	All	_	_	O
81	patients	_	_	O
82	received	_	_	O
83	neoadjuvant	_	_	O
84	antiandrogen	_	_	O
85	therapy	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	EORTC	_	_	O
91	QLQ	_	_	O
92	C30	_	_	O
93	and	_	_	O
94	the	_	_	O
95	Prostate	_	_	O
96	Cancer	_	_	O
97	Index	_	_	O
98	(	_	_	O
99	PCI	_	_	O
100	)	_	_	O
101	before	_	_	O
102	treatment	_	_	O
103	and	_	_	O
104	at	_	_	O
105	1.5	_	_	O
106	,	_	_	O
107	3	_	_	O
108	,	_	_	O
109	6	_	_	O
110	,	_	_	O
111	12	_	_	O
112	,	_	_	O
113	18	_	_	O
114	,	_	_	O
115	24	_	_	O
116	,	_	_	O
117	and	_	_	O
118	36	_	_	O
119	months	_	_	O
120	post-treatment	_	_	O
121	.	_	_	O

122	Regardless	_	_	B-Premise
123	of	_	_	I-Premise
124	treatment	_	_	I-Premise
125	arm	_	_	I-Premise
126	,	_	_	I-Premise
127	participants	_	_	I-Premise
128	reported	_	_	I-Premise
129	high	_	_	I-Premise
130	levels	_	_	I-Premise
131	of	_	_	I-Premise
132	QOL	_	_	I-Premise
133	with	_	_	I-Premise
134	few	_	_	I-Premise
135	exceptions	_	_	I-Premise
136	.	_	_	I-Premise

137	cryoablation	_	_	B-Premise
138	was	_	_	I-Premise
139	associated	_	_	I-Premise
140	with	_	_	I-Premise
141	more	_	_	I-Premise
142	acute	_	_	I-Premise
143	urinary	_	_	I-Premise
144	dysfunction	_	_	I-Premise
145	(	_	_	I-Premise
146	mean	_	_	I-Premise
147	PCI	_	_	I-Premise
148	urinary	_	_	I-Premise
149	function	_	_	I-Premise
150	cryoablation=69.4	_	_	I-Premise
151	;	_	_	I-Premise
152	mean	_	_	I-Premise
153	EBRT=90.7	_	_	I-Premise
154	;	_	_	I-Premise
155	P	_	_	I-Premise
156	<	_	_	I-Premise
157	.001	_	_	I-Premise
158	)	_	_	I-Premise
159	,	_	_	I-Premise
160	which	_	_	I-Premise
161	resolved	_	_	I-Premise
162	over	_	_	I-Premise
163	time	_	_	I-Premise
164	.	_	_	I-Premise

165	No	_	_	B-Premise
166	late	_	_	I-Premise
167	arising	_	_	I-Premise
168	QOL	_	_	I-Premise
169	issues	_	_	I-Premise
170	were	_	_	I-Premise
171	observed	_	_	I-Premise
172	.	_	_	I-Premise

173	Both	_	_	B-Premise
174	EBRT	_	_	I-Premise
175	and	_	_	I-Premise
176	cryoablation	_	_	I-Premise
177	participants	_	_	I-Premise
178	reported	_	_	I-Premise
179	decreases	_	_	I-Premise
180	in	_	_	I-Premise
181	sexual	_	_	I-Premise
182	function	_	_	I-Premise
183	at	_	_	I-Premise
184	3	_	_	I-Premise
185	months	_	_	I-Premise
186	with	_	_	I-Premise
187	the	_	_	I-Premise
188	cryoablation	_	_	I-Premise
189	patients	_	_	I-Premise
190	reporting	_	_	I-Premise
191	poorer	_	_	I-Premise
192	functioning	_	_	I-Premise
193	(	_	_	I-Premise
194	mean	_	_	I-Premise
195	cryoablation=7.2	_	_	I-Premise
196	:	_	_	I-Premise
197	mean	_	_	I-Premise
198	EBRT=32.9	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	<	_	_	I-Premise
202	.001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Mean	_	_	B-Premise
206	sexual	_	_	I-Premise
207	function	_	_	I-Premise
208	score	_	_	I-Premise
209	was	_	_	I-Premise
210	15	_	_	I-Premise
211	points	_	_	I-Premise
212	lower	_	_	I-Premise
213	at	_	_	I-Premise
214	3	_	_	I-Premise
215	years	_	_	I-Premise
216	for	_	_	I-Premise
217	the	_	_	I-Premise
218	cryoablation	_	_	I-Premise
219	group	_	_	I-Premise
220	and	_	_	I-Premise
221	13	_	_	I-Premise
222	%	_	_	I-Premise
223	more	_	_	I-Premise
224	of	_	_	I-Premise
225	the	_	_	I-Premise
226	cryoablation	_	_	I-Premise
227	men	_	_	I-Premise
228	said	_	_	I-Premise
229	that	_	_	I-Premise
230	sexuality	_	_	I-Premise
231	was	_	_	I-Premise
232	a	_	_	I-Premise
233	moderate	_	_	I-Premise
234	or	_	_	I-Premise
235	big	_	_	I-Premise
236	problem	_	_	I-Premise
237	.	_	_	I-Premise

238	In	_	_	B-Claim
239	this	_	_	I-Claim
240	randomized	_	_	I-Claim
241	trial	_	_	I-Claim
242	,	_	_	I-Claim
243	no	_	_	I-Claim
244	long-term	_	_	I-Claim
245	QOL	_	_	I-Claim
246	advantage	_	_	I-Claim
247	for	_	_	I-Claim
248	either	_	_	I-Claim
249	treatment	_	_	I-Claim
250	was	_	_	I-Claim
251	apparent	_	_	I-Claim
252	with	_	_	B-Claim
253	the	_	_	I-Claim
254	exception	_	_	I-Claim
255	of	_	_	I-Claim
256	poorer	_	_	I-Claim
257	sexual	_	_	I-Claim
258	function	_	_	I-Claim
259	reported	_	_	I-Claim
260	by	_	_	I-Claim
261	those	_	_	I-Claim
262	treated	_	_	I-Claim
263	with	_	_	I-Claim
264	cryoablation	_	_	I-Claim
265	.	_	_	I-Claim

266	Men	_	_	O
267	who	_	_	O
268	wish	_	_	O
269	to	_	_	O
270	increase	_	_	O
271	their	_	_	O
272	odds	_	_	O
273	of	_	_	O
274	retaining	_	_	O
275	sexual	_	_	O
276	function	_	_	O
277	might	_	_	O
278	be	_	_	O
279	counseled	_	_	O
280	to	_	_	O
281	choose	_	_	O
282	EBRT	_	_	O
283	over	_	_	O
284	cryoablation	_	_	O
285	.	_	_	O


0	It	_	_	B-Claim
1	has	_	_	I-Claim
2	been	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	nonpharmacologic	_	_	I-Claim
6	interventions	_	_	I-Claim
7	are	_	_	I-Claim
8	effective	_	_	I-Claim
9	management	_	_	I-Claim
10	techniques	_	_	I-Claim
11	for	_	_	I-Claim
12	cancer-related	_	_	I-Claim
13	fatigue	_	_	I-Claim
14	(	_	_	I-Claim
15	CRF	_	_	I-Claim
16	)	_	_	I-Claim
17	in	_	_	I-Claim
18	cancer	_	_	I-Claim
19	survivors	_	_	I-Claim
20	.	_	_	I-Claim

21	However	_	_	O
22	,	_	_	O
23	few	_	_	O
24	studies	_	_	O
25	have	_	_	O
26	investigated	_	_	O
27	their	_	_	O
28	effectiveness	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	who	_	_	O
32	are	_	_	O
33	receiving	_	_	O
34	chemotherapy	_	_	O
35	.	_	_	O

36	In	_	_	O
37	this	_	_	O
38	study	_	_	O
39	,	_	_	O
40	the	_	_	O
41	authors	_	_	O
42	tested	_	_	O
43	the	_	_	O
44	effectiveness	_	_	O
45	of	_	_	O
46	a	_	_	O
47	brief	_	_	O
48	behaviorally	_	_	O
49	oriented	_	_	O
50	intervention	_	_	O
51	in	_	_	O
52	reducing	_	_	O
53	CRF	_	_	O
54	and	_	_	O
55	improving	_	_	O
56	physical	_	_	O
57	function	_	_	O
58	and	_	_	O
59	associated	_	_	O
60	distress	_	_	O
61	in	_	_	O
62	individuals	_	_	O
63	who	_	_	O
64	were	_	_	O
65	receiving	_	_	O
66	chemotherapy	_	_	O
67	.	_	_	O

68	For	_	_	O
69	this	_	_	O
70	randomized	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	60	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	cancer	_	_	O
78	were	_	_	O
79	recruited	_	_	O
80	and	_	_	O
81	received	_	_	O
82	either	_	_	O
83	usual	_	_	O
84	care	_	_	O
85	or	_	_	O
86	the	_	_	O
87	intervention	_	_	O
88	.	_	_	O

89	The	_	_	O
90	intervention	_	_	O
91	was	_	_	O
92	delivered	_	_	O
93	on	_	_	O
94	an	_	_	O
95	individual	_	_	O
96	basis	_	_	O
97	on	_	_	O
98	3	_	_	O
99	occasions	_	_	O
100	over	_	_	O
101	a	_	_	O
102	period	_	_	O
103	from	_	_	O
104	9	_	_	O
105	weeks	_	_	O
106	to	_	_	O
107	12	_	_	O
108	weeks	_	_	O
109	,	_	_	O
110	and	_	_	O
111	the	_	_	O
112	objective	_	_	O
113	of	_	_	O
114	the	_	_	O
115	intervention	_	_	O
116	was	_	_	O
117	to	_	_	O
118	alter	_	_	O
119	fatigue-related	_	_	O
120	thoughts	_	_	O
121	and	_	_	O
122	behavior	_	_	O
123	.	_	_	O

124	Primary	_	_	O
125	outcomes	_	_	O
126	were	_	_	O
127	assessed	_	_	O
128	as	_	_	O
129	follows	_	_	O
130	:	_	_	O
131	CRF	_	_	O
132	using	_	_	O
133	the	_	_	O
134	Visual	_	_	O
135	Analogue	_	_	O
136	Scale-Global	_	_	O
137	Fatigue	_	_	O
138	;	_	_	O
139	physical	_	_	O
140	functioning	_	_	O
141	using	_	_	O
142	the	_	_	O
143	European	_	_	O
144	Organization	_	_	O
145	for	_	_	O
146	Research	_	_	O
147	and	_	_	O
148	Treatment	_	_	O
149	of	_	_	O
150	Cancer	_	_	O
151	Quality-of-Life	_	_	O
152	Core	_	_	O
153	30	_	_	O
154	Questionnaire	_	_	O
155	,	_	_	O
156	and	_	_	O
157	CRF-associated	_	_	O
158	distress	_	_	O
159	using	_	_	O
160	the	_	_	O
161	Fatigue	_	_	O
162	Outcome	_	_	O
163	Measure	_	_	O
164	.	_	_	O

165	Assessments	_	_	O
166	were	_	_	O
167	made	_	_	O
168	on	_	_	O
169	4	_	_	O
170	occasions	_	_	O
171	:	_	_	O
172	at	_	_	O
173	baseline	_	_	O
174	(	_	_	O
175	T0	_	_	O
176	)	_	_	O
177	,	_	_	O
178	at	_	_	O
179	the	_	_	O
180	end	_	_	O
181	of	_	_	O
182	chemotherapy	_	_	O
183	(	_	_	O
184	T1	_	_	O
185	)	_	_	O
186	,	_	_	O
187	1	_	_	O
188	month	_	_	O
189	after	_	_	O
190	chemotherapy	_	_	O
191	(	_	_	O
192	T2	_	_	O
193	)	_	_	O
194	,	_	_	O
195	and	_	_	O
196	9	_	_	O
197	months	_	_	O
198	after	_	_	O
199	recruitment	_	_	O
200	(	_	_	O
201	T3	_	_	O
202	)	_	_	O
203	.	_	_	O

204	Normally	_	_	O
205	distributed	_	_	O
206	data	_	_	O
207	were	_	_	O
208	analyzed	_	_	O
209	using	_	_	O
210	t	_	_	O
211	tests	_	_	O
212	and	_	_	O
213	random-slope/random-intercept	_	_	O
214	mixed	_	_	O
215	models	_	_	O
216	.	_	_	O

217	The	_	_	B-Premise
218	intervention	_	_	I-Premise
219	demonstrated	_	_	I-Premise
220	a	_	_	I-Premise
221	trend	_	_	I-Premise
222	toward	_	_	I-Premise
223	improved	_	_	I-Premise
224	CRF	_	_	I-Premise
225	,	_	_	I-Premise
226	although	_	_	B-Premise
227	this	_	_	I-Premise
228	effect	_	_	I-Premise
229	was	_	_	I-Premise
230	reduced	_	_	I-Premise
231	once	_	_	I-Premise
232	confounders	_	_	I-Premise
233	had	_	_	I-Premise
234	been	_	_	I-Premise
235	controlled	_	_	I-Premise
236	statistically	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	a	_	_	I-Premise
241	significant	_	_	I-Premise
242	improvement	_	_	I-Premise
243	in	_	_	I-Premise
244	physical	_	_	I-Premise
245	functioning	_	_	I-Premise
246	(	_	_	I-Premise
247	coefficient	_	_	I-Premise
248	,	_	_	I-Premise
249	10.0	_	_	I-Premise
250	;	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	confidence	_	_	I-Premise
254	interval	_	_	I-Premise
255	,	_	_	I-Premise
256	2.5-17.5	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.009	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	this	_	_	I-Premise
265	effect	_	_	I-Premise
266	remained	_	_	I-Premise
267	once	_	_	I-Premise
268	the	_	_	I-Premise
269	confounding	_	_	I-Premise
270	effects	_	_	I-Premise
271	of	_	_	I-Premise
272	mood	_	_	I-Premise
273	disturbance	_	_	I-Premise
274	and	_	_	I-Premise
275	comorbid	_	_	I-Premise
276	disorders	_	_	I-Premise
277	were	_	_	I-Premise
278	controlled	_	_	I-Premise
279	statistically	_	_	I-Premise
280	.	_	_	I-Premise

281	No	_	_	B-Premise
282	decrease	_	_	I-Premise
283	in	_	_	I-Premise
284	fatigue-related	_	_	I-Premise
285	distress	_	_	I-Premise
286	was	_	_	I-Premise
287	detected	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Claim
290	behaviorally	_	_	I-Claim
291	oriented	_	_	I-Claim
292	intervention	_	_	I-Claim
293	brought	_	_	I-Claim
294	about	_	_	I-Claim
295	significant	_	_	I-Claim
296	improvements	_	_	I-Claim
297	in	_	_	I-Claim
298	physical	_	_	I-Claim
299	functioning	_	_	I-Claim
300	,	_	_	I-Claim
301	indicated	_	_	I-Claim
302	a	_	_	I-Claim
303	trend	_	_	I-Claim
304	toward	_	_	I-Claim
305	improved	_	_	I-Claim
306	CRF	_	_	I-Claim
307	,	_	_	I-Claim
308	but	_	_	I-Claim
309	detected	_	_	I-Claim
310	no	_	_	I-Claim
311	effect	_	_	I-Claim
312	for	_	_	I-Claim
313	fatigue-related	_	_	I-Claim
314	distress	_	_	I-Claim
315	.	_	_	I-Claim


0	Radiotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	effective	_	_	I-Claim
4	palliative	_	_	I-Claim
5	treatment	_	_	I-Claim
6	for	_	_	I-Claim
7	cancer	_	_	I-Claim
8	patients	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	bone	_	_	I-Claim
12	metastases	_	_	I-Claim
13	.	_	_	I-Claim

14	Although	_	_	O
15	single-	_	_	O
16	and	_	_	O
17	multiple-fraction	_	_	O
18	radiotherapy	_	_	O
19	are	_	_	O
20	thought	_	_	O
21	to	_	_	O
22	provide	_	_	O
23	equal	_	_	O
24	palliation	_	_	O
25	,	_	_	O
26	which	_	_	O
27	treatment	_	_	O
28	schedule	_	_	O
29	provides	_	_	O
30	better	_	_	O
31	value	_	_	O
32	for	_	_	O
33	the	_	_	O
34	money	_	_	O
35	is	_	_	O
36	unknown	_	_	O
37	.	_	_	O

38	We	_	_	O
39	compared	_	_	O
40	quality-adjusted	_	_	O
41	life	_	_	O
42	expectancy	_	_	O
43	(	_	_	O
44	the	_	_	O
45	overall	_	_	O
46	valuation	_	_	O
47	of	_	_	O
48	the	_	_	O
49	health	_	_	O
50	of	_	_	O
51	the	_	_	O
52	patients	_	_	O
53	)	_	_	O
54	and	_	_	O
55	societal	_	_	O
56	costs	_	_	O
57	for	_	_	O
58	patients	_	_	O
59	receiving	_	_	O
60	either	_	_	O
61	single-	_	_	O
62	or	_	_	O
63	multiple-fraction	_	_	O
64	radiotherapy	_	_	O
65	.	_	_	O

66	A	_	_	O
67	societal	_	_	O
68	cost-utility	_	_	O
69	analysis	_	_	O
70	was	_	_	O
71	performed	_	_	O
72	on	_	_	O
73	a	_	_	O
74	Dutch	_	_	O
75	randomized	_	_	O
76	,	_	_	O
77	controlled	_	_	O
78	trial	_	_	O
79	of	_	_	O
80	1157	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	painful	_	_	O
84	bone	_	_	O
85	metastases	_	_	O
86	that	_	_	O
87	compared	_	_	O
88	pain	_	_	O
89	responses	_	_	O
90	and	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	from	_	_	O
95	a	_	_	O
96	single-fraction	_	_	O
97	treatment	_	_	O
98	schedule	_	_	O
99	of	_	_	O
100	8	_	_	O
101	Gy	_	_	O
102	with	_	_	O
103	a	_	_	O
104	treatment	_	_	O
105	schedule	_	_	O
106	of	_	_	O
107	six	_	_	O
108	fractions	_	_	O
109	of	_	_	O
110	4	_	_	O
111	Gy	_	_	O
112	each	_	_	O
113	.	_	_	O

114	The	_	_	O
115	societal	_	_	O
116	values	_	_	O
117	of	_	_	O
118	life	_	_	O
119	expectancies	_	_	O
120	were	_	_	O
121	assessed	_	_	O
122	with	_	_	O
123	the	_	_	O
124	EuroQol	_	_	O
125	classification	_	_	O
126	system	_	_	O
127	(	_	_	O
128	EQ-5D	_	_	O
129	)	_	_	O
130	questionnaire	_	_	O
131	.	_	_	O

132	A	_	_	O
133	subset	_	_	O
134	of	_	_	O
135	166	_	_	O
136	patients	_	_	O
137	also	_	_	O
138	answered	_	_	O
139	additional	_	_	O
140	questionnaires	_	_	O
141	to	_	_	O
142	estimate	_	_	O
143	nonradiotherapy	_	_	O
144	and	_	_	O
145	nonmedical	_	_	O
146	costs	_	_	O
147	.	_	_	O

148	Statistical	_	_	O
149	tests	_	_	O
150	were	_	_	O
151	two-sided	_	_	O
152	.	_	_	O

153	Comparing	_	_	B-Premise
154	the	_	_	I-Premise
155	single-	_	_	I-Premise
156	and	_	_	I-Premise
157	multiple-fraction	_	_	I-Premise
158	radiotherapy	_	_	I-Premise
159	schedules	_	_	I-Premise
160	,	_	_	I-Premise
161	no	_	_	I-Premise
162	differences	_	_	I-Premise
163	were	_	_	I-Premise
164	found	_	_	I-Premise
165	in	_	_	I-Premise
166	life	_	_	I-Premise
167	expectancy	_	_	I-Premise
168	(	_	_	I-Premise
169	43.0	_	_	I-Premise
170	versus	_	_	I-Premise
171	40.4	_	_	I-Premise
172	weeks	_	_	I-Premise
173	,	_	_	I-Premise
174	P	_	_	I-Premise
175	=.20	_	_	I-Premise
176	)	_	_	I-Premise
177	or	_	_	I-Premise
178	quality-adjusted	_	_	I-Premise
179	life	_	_	I-Premise
180	expectancy	_	_	I-Premise
181	(	_	_	I-Premise
182	17.7	_	_	I-Premise
183	versus	_	_	I-Premise
184	16.0	_	_	I-Premise
185	weeks	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	=.21	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	estimated	_	_	I-Premise
193	cost	_	_	I-Premise
194	of	_	_	I-Premise
195	radiotherapy	_	_	I-Premise
196	,	_	_	I-Premise
197	including	_	_	I-Premise
198	retreatments	_	_	I-Premise
199	and	_	_	I-Premise
200	nonmedical	_	_	I-Premise
201	costs	_	_	I-Premise
202	,	_	_	I-Premise
203	was	_	_	I-Premise
204	statistically	_	_	I-Premise
205	significantly	_	_	I-Premise
206	lower	_	_	I-Premise
207	for	_	_	I-Premise
208	the	_	_	I-Premise
209	single-fraction	_	_	I-Premise
210	schedule	_	_	I-Premise
211	than	_	_	I-Premise
212	for	_	_	I-Premise
213	the	_	_	I-Premise
214	multiple-fraction	_	_	I-Premise
215	schedule	_	_	I-Premise
216	(	_	_	I-Premise
217	$	_	_	I-Premise
218	2438	_	_	I-Premise
219	versus	_	_	I-Premise
220	$	_	_	I-Premise
221	3311	_	_	I-Premise
222	,	_	_	I-Premise
223	difference	_	_	I-Premise
224	=	_	_	I-Premise
225	$	_	_	I-Premise
226	873	_	_	I-Premise
227	,	_	_	I-Premise
228	95	_	_	I-Premise
229	%	_	_	I-Premise
230	confidence	_	_	I-Premise
231	interval	_	_	I-Premise
232	[	_	_	I-Premise
233	CI	_	_	I-Premise
234	]	_	_	I-Premise
235	on	_	_	I-Premise
236	the	_	_	I-Premise
237	difference	_	_	I-Premise
238	=	_	_	I-Premise
239	$	_	_	I-Premise
240	449	_	_	I-Premise
241	to	_	_	I-Premise
242	$	_	_	I-Premise
243	1297	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	.001	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	estimated	_	_	I-Premise
252	difference	_	_	I-Premise
253	in	_	_	I-Premise
254	total	_	_	I-Premise
255	societal	_	_	I-Premise
256	costs	_	_	I-Premise
257	was	_	_	I-Premise
258	larger	_	_	I-Premise
259	,	_	_	I-Premise
260	also	_	_	I-Premise
261	in	_	_	I-Premise
262	favor	_	_	I-Premise
263	of	_	_	I-Premise
264	the	_	_	I-Premise
265	single-fraction	_	_	I-Premise
266	schedule	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	it	_	_	I-Premise
270	was	_	_	I-Premise
271	not	_	_	I-Premise
272	statistically	_	_	I-Premise
273	significant	_	_	I-Premise
274	(	_	_	I-Premise
275	$	_	_	I-Premise
276	4700	_	_	I-Premise
277	versus	_	_	I-Premise
278	$	_	_	I-Premise
279	6453	_	_	I-Premise
280	,	_	_	I-Premise
281	difference	_	_	I-Premise
282	=	_	_	I-Premise
283	$	_	_	I-Premise
284	1753	_	_	I-Premise
285	,	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	on	_	_	I-Premise
290	the	_	_	I-Premise
291	difference	_	_	I-Premise
292	=	_	_	I-Premise
293	-	_	_	I-Premise
294	$	_	_	I-Premise
295	99	_	_	I-Premise
296	to	_	_	I-Premise
297	$	_	_	I-Premise
298	3604	_	_	I-Premise
299	;	_	_	I-Premise
300	P	_	_	I-Premise
301	=.06	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	For	_	_	B-Premise
305	willingness-to-pay	_	_	I-Premise
306	between	_	_	I-Premise
307	$	_	_	I-Premise
308	5000	_	_	I-Premise
309	and	_	_	I-Premise
310	$	_	_	I-Premise
311	40	_	_	I-Premise
312	000	_	_	I-Premise
313	per	_	_	I-Premise
314	quality-adjusted	_	_	I-Premise
315	life	_	_	I-Premise
316	year	_	_	I-Premise
317	,	_	_	I-Premise
318	the	_	_	I-Premise
319	single-fraction	_	_	I-Premise
320	schedule	_	_	I-Premise
321	was	_	_	I-Premise
322	statistically	_	_	I-Premise
323	significantly	_	_	I-Premise
324	more	_	_	I-Premise
325	cost-effective	_	_	I-Premise
326	than	_	_	I-Premise
327	the	_	_	I-Premise
328	multiple-fraction	_	_	I-Premise
329	schedule	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	or	_	_	I-Premise
334	=.05	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	Compared	_	_	B-Claim
338	with	_	_	I-Claim
339	multiple-fraction	_	_	I-Claim
340	radiotherapy	_	_	I-Claim
341	,	_	_	I-Claim
342	single-fraction	_	_	I-Claim
343	radiotherapy	_	_	I-Claim
344	provides	_	_	I-Claim
345	equal	_	_	I-Claim
346	palliation	_	_	I-Claim
347	and	_	_	I-Claim
348	quality	_	_	I-Claim
349	of	_	_	I-Claim
350	life	_	_	I-Claim
351	and	_	_	I-Claim
352	has	_	_	I-Claim
353	lower	_	_	I-Claim
354	medical	_	_	I-Claim
355	and	_	_	I-Claim
356	societal	_	_	I-Claim
357	costs	_	_	I-Claim
358	,	_	_	I-Claim
359	at	_	_	I-Claim
360	least	_	_	I-Claim
361	in	_	_	I-Claim
362	The	_	_	I-Claim
363	Netherlands	_	_	I-Claim
364	.	_	_	I-Claim

365	Therefore	_	_	B-Claim
366	,	_	_	I-Claim
367	single-fraction	_	_	I-Claim
368	radiotherapy	_	_	I-Claim
369	should	_	_	I-Claim
370	be	_	_	I-Claim
371	considered	_	_	I-Claim
372	as	_	_	I-Claim
373	the	_	_	I-Claim
374	palliative	_	_	I-Claim
375	treatment	_	_	I-Claim
376	of	_	_	I-Claim
377	choice	_	_	I-Claim
378	for	_	_	I-Claim
379	cancer	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	painful	_	_	I-Claim
383	bone	_	_	I-Claim
384	metastases	_	_	I-Claim
385	.	_	_	I-Claim


0	For	_	_	B-Claim
1	malignant	_	_	I-Claim
2	pleural	_	_	I-Claim
3	mesothelioma	_	_	I-Claim
4	(	_	_	I-Claim
5	MPM	_	_	I-Claim
6	)	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	a	_	_	I-Claim
10	poor	_	_	I-Claim
11	prognosis	_	_	I-Claim
12	,	_	_	I-Claim
13	maintaining	_	_	I-Claim
14	health-related	_	_	I-Claim
15	quality	_	_	I-Claim
16	of	_	_	I-Claim
17	life	_	_	I-Claim
18	(	_	_	I-Claim
19	HRQOL	_	_	I-Claim
20	)	_	_	I-Claim
21	is	_	_	I-Claim
22	important	_	_	I-Claim
23	.	_	_	I-Claim

24	This	_	_	O
25	article	_	_	O
26	compares	_	_	O
27	the	_	_	O
28	impact	_	_	O
29	on	_	_	O
30	HRQOL	_	_	O
31	of	_	_	O
32	first-line	_	_	O
33	treatment	_	_	O
34	with	_	_	O
35	cisplatin	_	_	O
36	versus	_	_	O
37	raltitrexed	_	_	O
38	and	_	_	O
39	cisplatin	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	histologically-proven	_	_	O
44	unresectable	_	_	O
45	MPM	_	_	O
46	,	_	_	O
47	not	_	_	O
48	pretreated	_	_	O
49	with	_	_	O
50	chemotherapy	_	_	O
51	were	_	_	O
52	randomly	_	_	O
53	assigned	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	cisplatin	_	_	O
57	80	_	_	O
58	mg/m2	_	_	O
59	intravenously	_	_	O
60	on	_	_	O
61	day	_	_	O
62	1	_	_	O
63	,	_	_	O
64	with	_	_	O
65	or	_	_	O
66	without	_	_	O
67	preceding	_	_	O
68	infusion	_	_	O
69	of	_	_	O
70	raltitrexed	_	_	O
71	3	_	_	O
72	mg/m2	_	_	O
73	.	_	_	O

74	HRQOL	_	_	O
75	was	_	_	O
76	assessed	_	_	O
77	with	_	_	O
78	the	_	_	O
79	European	_	_	O
80	Organisation	_	_	O
81	for	_	_	O
82	Research	_	_	O
83	and	_	_	O
84	Treatment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Core	_	_	O
88	Quality	_	_	O
89	of	_	_	O
90	Life	_	_	O
91	Questionnaire	_	_	O
92	C30	_	_	O
93	(	_	_	O
94	EORTC	_	_	O
95	QLQ-C30	_	_	O
96	)	_	_	O
97	and	_	_	O
98	EORTC	_	_	O
99	Lung	_	_	O
100	Cancer	_	_	O
101	Module	_	_	O
102	(	_	_	O
103	QLQ-LC13	_	_	O
104	)	_	_	O
105	tools	_	_	O
106	.	_	_	O

107	Assessments	_	_	O
108	were	_	_	O
109	conducted	_	_	O
110	at	_	_	O
111	baseline	_	_	O
112	,	_	_	O
113	immediately	_	_	O
114	before	_	_	O
115	every	_	_	O
116	treatment	_	_	O
117	cycle	_	_	O
118	,	_	_	O
119	at	_	_	O
120	the	_	_	O
121	end	_	_	O
122	of	_	_	O
123	treatment	_	_	O
124	,	_	_	O
125	and	_	_	O
126	every	_	_	O
127	six	_	_	O
128	weeks	_	_	O
129	for	_	_	O
130	12	_	_	O
131	months	_	_	O
132	.	_	_	O

133	Two	_	_	O
134	hundred	_	_	O
135	fifty	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	randomly	_	_	O
139	assigned	_	_	O
140	,	_	_	O
141	80	_	_	O
142	%	_	_	O
143	were	_	_	O
144	male	_	_	O
145	with	_	_	O
146	a	_	_	O
147	median	_	_	O
148	age	_	_	O
149	of	_	_	O
150	58	_	_	O
151	years	_	_	O
152	,	_	_	O
153	WHO	_	_	O
154	performance	_	_	O
155	status	_	_	O
156	0	_	_	O
157	,	_	_	O
158	1	_	_	O
159	,	_	_	O
160	and	_	_	O
161	2	_	_	O
162	,	_	_	O
163	in	_	_	O
164	25	_	_	O
165	%	_	_	O
166	,	_	_	O
167	62	_	_	O
168	%	_	_	O
169	,	_	_	O
170	and	_	_	O
171	13	_	_	O
172	%	_	_	O
173	of	_	_	O
174	cases	_	_	O
175	.	_	_	O

176	The	_	_	B-Premise
177	clinical	_	_	I-Premise
178	results	_	_	I-Premise
179	found	_	_	I-Premise
180	raltitrexed	_	_	I-Premise
181	and	_	_	I-Premise
182	cisplatin	_	_	I-Premise
183	to	_	_	I-Premise
184	be	_	_	I-Premise
185	superior	_	_	I-Premise
186	to	_	_	I-Premise
187	cisplatin	_	_	I-Premise
188	with	_	_	I-Premise
189	regard	_	_	I-Premise
190	to	_	_	I-Premise
191	overall	_	_	I-Premise
192	survival	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	.048	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	global	_	_	I-Premise
201	HRQOL	_	_	I-Premise
202	scale	_	_	I-Premise
203	was	_	_	I-Premise
204	comparable	_	_	I-Premise
205	at	_	_	I-Premise
206	baseline	_	_	I-Premise
207	on	_	_	I-Premise
208	both	_	_	I-Premise
209	treatment	_	_	I-Premise
210	arms	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	=	_	_	I-Premise
214	.848	_	_	I-Premise
215	)	_	_	I-Premise
216	;	_	_	I-Premise
217	at	_	_	B-Premise
218	no	_	_	I-Premise
219	point	_	_	I-Premise
220	was	_	_	I-Premise
221	any	_	_	I-Premise
222	significant	_	_	I-Premise
223	difference	_	_	I-Premise
224	apparent	_	_	I-Premise
225	on	_	_	I-Premise
226	this	_	_	I-Premise
227	end	_	_	I-Premise
228	point	_	_	I-Premise
229	.	_	_	I-Premise

230	Both	_	_	B-Premise
231	treatments	_	_	I-Premise
232	led	_	_	I-Premise
233	to	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	,	_	_	I-Premise
237	over	_	_	I-Premise
238	time	_	_	I-Premise
239	,	_	_	I-Premise
240	in	_	_	I-Premise
241	dyspnoea	_	_	I-Premise
242	.	_	_	I-Premise

243	This	_	_	B-Claim
244	effect	_	_	I-Claim
245	is	_	_	I-Claim
246	an	_	_	I-Claim
247	important	_	_	I-Claim
248	clinically	_	_	I-Claim
249	meaningful	_	_	I-Claim
250	reduction	_	_	I-Claim
251	from	_	_	I-Claim
252	baseline	_	_	I-Claim
253	in	_	_	I-Claim
254	the	_	_	I-Claim
255	cisplatin/raltitrexed	_	_	I-Claim
256	arm	_	_	I-Claim
257	.	_	_	I-Claim

258	However	_	_	B-Premise
259	,	_	_	I-Premise
260	the	_	_	I-Premise
261	majority	_	_	I-Premise
262	of	_	_	I-Premise
263	scales	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	EORTC	_	_	I-Premise
267	QLQ-C30	_	_	I-Premise
268	or	_	_	I-Premise
269	LC13	_	_	I-Premise
270	showed	_	_	I-Premise
271	stabilization	_	_	I-Premise
272	of	_	_	I-Premise
273	HRQOL	_	_	I-Premise
274	with	_	_	I-Premise
275	few	_	_	I-Premise
276	clinically	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	between	_	_	I-Premise
280	the	_	_	I-Premise
281	treatment	_	_	I-Premise
282	arms	_	_	I-Premise
283	.	_	_	I-Premise

284	This	_	_	B-Claim
285	study	_	_	I-Claim
286	provides	_	_	I-Claim
287	important	_	_	I-Claim
288	information	_	_	I-Claim
289	about	_	_	I-Claim
290	the	_	_	I-Claim
291	HRQOL	_	_	I-Claim
292	of	_	_	I-Claim
293	chemotherapy-treated	_	_	I-Claim
294	MPM	_	_	I-Claim
295	patients	_	_	I-Claim
296	.	_	_	I-Claim


0	The	_	_	O
1	physiological	_	_	O
2	and	_	_	O
3	psychological	_	_	O
4	stress	_	_	O
5	that	_	_	O
6	brain	_	_	O
7	tumor	_	_	O
8	patients	_	_	O
9	undergo	_	_	O
10	during	_	_	O
11	the	_	_	O
12	entire	_	_	O
13	surgical	_	_	O
14	experience	_	_	O
15	can	_	_	O
16	considerably	_	_	O
17	affect	_	_	O
18	several	_	_	O
19	aspects	_	_	O
20	of	_	_	O
21	their	_	_	O
22	hospitalization	_	_	O
23	.	_	_	O

24	The	_	_	O
25	purpose	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	examine	_	_	O
32	the	_	_	O
33	effects	_	_	O
34	of	_	_	O
35	live	_	_	O
36	music	_	_	O
37	therapy	_	_	O
38	on	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	indicators	_	_	O
43	,	_	_	O
44	amount	_	_	O
45	of	_	_	O
46	medications	_	_	O
47	administered	_	_	O
48	and	_	_	O
49	length	_	_	O
50	of	_	_	O
51	stay	_	_	O
52	for	_	_	O
53	persons	_	_	O
54	receiving	_	_	O
55	elective	_	_	O
56	surgical	_	_	O
57	procedures	_	_	O
58	of	_	_	O
59	the	_	_	O
60	brain	_	_	O
61	.	_	_	O

62	Subjects	_	_	O
63	(	_	_	O
64	N	_	_	O
65	=	_	_	O
66	27	_	_	O
67	)	_	_	O
68	were	_	_	O
69	patients	_	_	O
70	admitted	_	_	O
71	for	_	_	O
72	some	_	_	O
73	type	_	_	O
74	of	_	_	O
75	surgical	_	_	O
76	procedure	_	_	O
77	of	_	_	O
78	the	_	_	O
79	brain	_	_	O
80	.	_	_	O

81	Subjects	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	either	_	_	O
87	the	_	_	O
88	control	_	_	O
89	group	_	_	O
90	receiving	_	_	O
91	no	_	_	O
92	music	_	_	O
93	intervention	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	13	_	_	O
98	)	_	_	O
99	or	_	_	O
100	the	_	_	O
101	experimental	_	_	O
102	group	_	_	O
103	receiving	_	_	O
104	pre	_	_	O
105	and	_	_	O
106	postoperative	_	_	O
107	live	_	_	O
108	music	_	_	O
109	therapy	_	_	O
110	sessions	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	14	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Anxiety	_	_	O
118	,	_	_	O
119	mood	_	_	O
120	,	_	_	O
121	pain	_	_	O
122	,	_	_	O
123	perception	_	_	O
124	of	_	_	O
125	hospitalization	_	_	O
126	or	_	_	O
127	procedure	_	_	O
128	,	_	_	O
129	relaxation	_	_	O
130	,	_	_	O
131	and	_	_	O
132	stress	_	_	O
133	were	_	_	O
134	measured	_	_	O
135	using	_	_	O
136	a	_	_	O
137	self-report	_	_	O
138	Visual	_	_	O
139	Analog	_	_	O
140	Scale	_	_	O
141	(	_	_	O
142	VAS	_	_	O
143	)	_	_	O
144	for	_	_	O
145	each	_	_	O
146	of	_	_	O
147	the	_	_	O
148	variables	_	_	O
149	.	_	_	O

150	The	_	_	O
151	documented	_	_	O
152	administration	_	_	O
153	of	_	_	O
154	postoperative	_	_	O
155	pain	_	_	O
156	medications	_	_	O
157	;	_	_	O
158	the	_	_	O
159	frequency	_	_	O
160	,	_	_	O
161	dosage	_	_	O
162	,	_	_	O
163	type	_	_	O
164	,	_	_	O
165	and	_	_	O
166	how	_	_	O
167	it	_	_	O
168	was	_	_	O
169	given	_	_	O
170	was	_	_	O
171	also	_	_	O
172	compared	_	_	O
173	between	_	_	O
174	groups	_	_	O
175	.	_	_	O

176	Experimental	_	_	O
177	subjects	_	_	O
178	live	_	_	O
179	and	_	_	O
180	interactive	_	_	O
181	music	_	_	O
182	therapy	_	_	O
183	sessions	_	_	O
184	,	_	_	O
185	including	_	_	O
186	a	_	_	O
187	pre-operative	_	_	O
188	session	_	_	O
189	and	_	_	O
190	continuing	_	_	O
191	with	_	_	O
192	daily	_	_	O
193	sessions	_	_	O
194	until	_	_	O
195	the	_	_	O
196	patient	_	_	O
197	was	_	_	O
198	discharged	_	_	O
199	home	_	_	O
200	.	_	_	O

201	Control	_	_	O
202	subjects	_	_	O
203	received	_	_	O
204	routine	_	_	O
205	hospital	_	_	O
206	care	_	_	O
207	without	_	_	O
208	any	_	_	O
209	music	_	_	O
210	therapy	_	_	O
211	intervention	_	_	O
212	.	_	_	O

213	Differences	_	_	O
214	in	_	_	O
215	experimental	_	_	O
216	pretest	_	_	O
217	and	_	_	O
218	posttest	_	_	O
219	scores	_	_	O
220	were	_	_	O
221	analyzed	_	_	O
222	using	_	_	O
223	a	_	_	O
224	Wilcoxon	_	_	O
225	Matched-Pairs	_	_	O
226	Signed-Rank	_	_	O
227	test	_	_	O
228	.	_	_	O

229	Results	_	_	B-Premise
230	indicated	_	_	I-Premise
231	statistically	_	_	I-Premise
232	significant	_	_	I-Premise
233	differences	_	_	I-Premise
234	for	_	_	I-Premise
235	4	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	6	_	_	I-Premise
239	quality	_	_	I-Premise
240	of	_	_	I-Premise
241	life	_	_	I-Premise
242	measures	_	_	I-Premise
243	:	_	_	I-Premise
244	anxiety	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	.03	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	perception	_	_	I-Premise
252	of	_	_	I-Premise
253	hospitalization	_	_	I-Premise
254	(	_	_	I-Premise
255	p	_	_	I-Premise
256	=	_	_	I-Premise
257	.03	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	relaxation	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	.001	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	stress	_	_	I-Premise
269	(	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	.001	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	No	_	_	B-Premise
276	statistically	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	were	_	_	I-Premise
280	found	_	_	I-Premise
281	for	_	_	I-Premise
282	mood	_	_	I-Premise
283	(	_	_	I-Premise
284	p	_	_	I-Premise
285	>	_	_	I-Premise
286	.05	_	_	I-Premise
287	)	_	_	I-Premise
288	or	_	_	I-Premise
289	pain	_	_	I-Premise
290	(	_	_	I-Premise
291	p	_	_	I-Premise
292	>	_	_	I-Premise
293	.05	_	_	I-Premise
294	)	_	_	I-Premise
295	levels	_	_	I-Premise
296	.	_	_	I-Premise

297	Administration	_	_	O
298	amounts	_	_	O
299	of	_	_	O
300	nausea	_	_	O
301	and	_	_	O
302	pain	_	_	O
303	medications	_	_	O
304	were	_	_	O
305	compared	_	_	O
306	with	_	_	O
307	a	_	_	O
308	Two-Way	_	_	O
309	ANOVA	_	_	O
310	with	_	_	O
311	One	_	_	O
312	Repeated	_	_	O
313	Measure	_	_	O
314	resulting	_	_	O
315	in	_	_	O
316	no	_	_	O
317	significant	_	_	O
318	differences	_	_	O
319	between	_	_	O
320	groups	_	_	O
321	and	_	_	O
322	medications	_	_	O
323	,	_	_	O
324	F	_	_	O
325	(	_	_	O
326	1	_	_	O
327	,	_	_	O
328	51	_	_	O
329	)	_	_	O
330	=	_	_	O
331	0.03	_	_	O
332	;	_	_	O
333	p	_	_	O
334	>	_	_	O
335	.05	_	_	O
336	.	_	_	O

337	Results	_	_	O
338	indicate	_	_	O
339	no	_	_	O
340	significant	_	_	O
341	differences	_	_	O
342	between	_	_	O
343	groups	_	_	O
344	for	_	_	O
345	length	_	_	O
346	of	_	_	O
347	stay	_	_	O
348	(	_	_	O
349	t	_	_	O
350	=	_	_	O
351	.97	_	_	O
352	,	_	_	O
353	df	_	_	O
354	=	_	_	O
355	25	_	_	O
356	,	_	_	O
357	p	_	_	O
358	>	_	_	O
359	.05	_	_	O
360	)	_	_	O
361	.	_	_	O

362	This	_	_	B-Claim
363	research	_	_	I-Claim
364	study	_	_	I-Claim
365	indicates	_	_	I-Claim
366	that	_	_	I-Claim
367	live	_	_	I-Claim
368	music	_	_	I-Claim
369	therapy	_	_	I-Claim
370	using	_	_	I-Claim
371	patient-preferred	_	_	I-Claim
372	music	_	_	I-Claim
373	can	_	_	I-Claim
374	be	_	_	I-Claim
375	beneficial	_	_	I-Claim
376	in	_	_	I-Claim
377	improving	_	_	I-Claim
378	quality	_	_	I-Claim
379	of	_	_	I-Claim
380	life	_	_	I-Claim
381	indicators	_	_	I-Claim
382	such	_	_	I-Claim
383	as	_	_	I-Claim
384	anxiety	_	_	I-Claim
385	,	_	_	I-Claim
386	perception	_	_	I-Claim
387	of	_	_	I-Claim
388	the	_	_	I-Claim
389	hospitalization	_	_	I-Claim
390	or	_	_	I-Claim
391	procedure	_	_	I-Claim
392	,	_	_	I-Claim
393	relaxation	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	stress	_	_	I-Claim
397	in	_	_	I-Claim
398	patients	_	_	I-Claim
399	undergoing	_	_	I-Claim
400	surgical	_	_	I-Claim
401	procedures	_	_	I-Claim
402	of	_	_	I-Claim
403	the	_	_	I-Claim
404	brain	_	_	I-Claim
405	.	_	_	I-Claim


0	Spiritual	_	_	O
1	well-being	_	_	O
2	and	_	_	O
3	sense	_	_	O
4	of	_	_	O
5	meaning	_	_	O
6	are	_	_	O
7	important	_	_	O
8	concerns	_	_	O
9	for	_	_	O
10	clinicians	_	_	O
11	who	_	_	O
12	care	_	_	O
13	for	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	We	_	_	O
19	developed	_	_	O
20	Individual	_	_	O
21	Meaning-Centered	_	_	O
22	Psychotherapy	_	_	O
23	(	_	_	O
24	IMCP	_	_	O
25	)	_	_	O
26	to	_	_	O
27	address	_	_	O
28	the	_	_	O
29	need	_	_	O
30	for	_	_	O
31	brief	_	_	O
32	interventions	_	_	O
33	targeting	_	_	O
34	spiritual	_	_	O
35	well-being	_	_	O
36	and	_	_	O
37	meaning	_	_	O
38	for	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	advanced	_	_	O
42	cancer	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	with	_	_	O
46	stage	_	_	O
47	III	_	_	O
48	or	_	_	O
49	IV	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	N	_	_	O
53	=	_	_	O
54	120	_	_	O
55	)	_	_	O
56	were	_	_	O
57	randomly	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	seven	_	_	O
61	sessions	_	_	O
62	of	_	_	O
63	either	_	_	O
64	IMCP	_	_	O
65	or	_	_	O
66	therapeutic	_	_	O
67	massage	_	_	O
68	(	_	_	O
69	TM	_	_	O
70	)	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	assessed	_	_	O
75	before	_	_	O
76	and	_	_	O
77	after	_	_	O
78	completing	_	_	O
79	the	_	_	O
80	intervention	_	_	O
81	and	_	_	O
82	2	_	_	O
83	months	_	_	O
84	postintervention	_	_	O
85	.	_	_	O

86	Primary	_	_	O
87	outcome	_	_	O
88	measures	_	_	O
89	assessed	_	_	O
90	spiritual	_	_	O
91	well-being	_	_	O
92	and	_	_	O
93	quality	_	_	O
94	of	_	_	O
95	life	_	_	O
96	;	_	_	O
97	secondary	_	_	O
98	outcomes	_	_	O
99	included	_	_	O
100	anxiety	_	_	O
101	,	_	_	O
102	depression	_	_	O
103	,	_	_	O
104	hopelessness	_	_	O
105	,	_	_	O
106	symptom	_	_	O
107	burden	_	_	O
108	,	_	_	O
109	and	_	_	O
110	symptom-related	_	_	O
111	distress	_	_	O
112	.	_	_	O

113	Of	_	_	O
114	the	_	_	O
115	120	_	_	O
116	participants	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	,	_	_	O
120	78	_	_	O
121	(	_	_	O
122	65	_	_	O
123	%	_	_	O
124	)	_	_	O
125	completed	_	_	O
126	the	_	_	O
127	post-treatment	_	_	O
128	assessment	_	_	O
129	and	_	_	O
130	67	_	_	O
131	(	_	_	O
132	56	_	_	O
133	%	_	_	O
134	)	_	_	O
135	completed	_	_	O
136	the	_	_	O
137	2-month	_	_	O
138	follow-up	_	_	O
139	.	_	_	O

140	At	_	_	B-Premise
141	the	_	_	I-Premise
142	post-treatment	_	_	I-Premise
143	assessment	_	_	I-Premise
144	,	_	_	I-Premise
145	IMCP	_	_	I-Premise
146	participants	_	_	I-Premise
147	demonstrated	_	_	I-Premise
148	significantly	_	_	I-Premise
149	greater	_	_	I-Premise
150	improvement	_	_	I-Premise
151	than	_	_	I-Premise
152	the	_	_	I-Premise
153	control	_	_	I-Premise
154	condition	_	_	I-Premise
155	for	_	_	I-Premise
156	the	_	_	I-Premise
157	primary	_	_	I-Premise
158	outcomes	_	_	I-Premise
159	of	_	_	I-Premise
160	spiritual	_	_	I-Premise
161	well-being	_	_	I-Premise
162	(	_	_	I-Premise
163	b	_	_	I-Premise
164	=	_	_	I-Premise
165	0.39	_	_	I-Premise
166	;	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	.001	_	_	I-Premise
170	,	_	_	I-Premise
171	including	_	_	I-Premise
172	both	_	_	I-Premise
173	components	_	_	I-Premise
174	of	_	_	I-Premise
175	spiritual	_	_	I-Premise
176	well-being	_	_	I-Premise
177	(	_	_	I-Premise
178	sense	_	_	I-Premise
179	of	_	_	I-Premise
180	meaning	_	_	I-Premise
181	:	_	_	I-Premise
182	b	_	_	I-Premise
183	=	_	_	I-Premise
184	0.34	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.003	_	_	I-Premise
189	and	_	_	I-Premise
190	faith	_	_	I-Premise
191	:	_	_	I-Premise
192	b	_	_	I-Premise
193	=	_	_	I-Premise
194	0.42	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.03	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	quality	_	_	I-Premise
203	of	_	_	I-Premise
204	life	_	_	I-Premise
205	(	_	_	I-Premise
206	b	_	_	I-Premise
207	=	_	_	I-Premise
208	0.76	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.013	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Significantly	_	_	B-Premise
216	greater	_	_	I-Premise
217	improvements	_	_	I-Premise
218	for	_	_	I-Premise
219	IMCP	_	_	I-Premise
220	patients	_	_	I-Premise
221	were	_	_	I-Premise
222	also	_	_	I-Premise
223	observed	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	secondary	_	_	I-Premise
227	outcomes	_	_	I-Premise
228	of	_	_	I-Premise
229	symptom	_	_	I-Premise
230	burden	_	_	I-Premise
231	(	_	_	I-Premise
232	b	_	_	I-Premise
233	=	_	_	I-Premise
234	-6.56	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	.001	_	_	I-Premise
239	)	_	_	I-Premise
240	and	_	_	I-Premise
241	symptom-related	_	_	I-Premise
242	distress	_	_	I-Premise
243	(	_	_	I-Premise
244	b	_	_	I-Premise
245	=	_	_	I-Premise
246	-0.47	_	_	I-Premise
247	;	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	.001	_	_	I-Premise
251	)	_	_	I-Premise
252	but	_	_	I-Premise
253	not	_	_	I-Premise
254	for	_	_	I-Premise
255	anxiety	_	_	I-Premise
256	,	_	_	I-Premise
257	depression	_	_	I-Premise
258	,	_	_	I-Premise
259	or	_	_	I-Premise
260	hopelessness	_	_	I-Premise
261	.	_	_	I-Premise

262	At	_	_	B-Premise
263	the	_	_	I-Premise
264	2-month	_	_	I-Premise
265	follow-up	_	_	I-Premise
266	assessment	_	_	I-Premise
267	,	_	_	I-Premise
268	the	_	_	I-Premise
269	improvements	_	_	I-Premise
270	observed	_	_	I-Premise
271	for	_	_	I-Premise
272	the	_	_	I-Premise
273	IMCP	_	_	I-Premise
274	group	_	_	I-Premise
275	were	_	_	I-Premise
276	no	_	_	I-Premise
277	longer	_	_	I-Premise
278	significantly	_	_	I-Premise
279	greater	_	_	I-Premise
280	than	_	_	I-Premise
281	those	_	_	I-Premise
282	observed	_	_	I-Premise
283	for	_	_	I-Premise
284	the	_	_	I-Premise
285	TM	_	_	I-Premise
286	group	_	_	I-Premise
287	.	_	_	I-Premise

288	IMCP	_	_	B-Claim
289	has	_	_	I-Claim
290	clear	_	_	I-Claim
291	short-term	_	_	I-Claim
292	benefits	_	_	I-Claim
293	for	_	_	I-Claim
294	spiritual	_	_	I-Claim
295	suffering	_	_	I-Claim
296	and	_	_	I-Claim
297	quality	_	_	I-Claim
298	of	_	_	I-Claim
299	life	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	advanced	_	_	I-Claim
304	cancer	_	_	I-Claim
305	.	_	_	I-Claim

306	Clinicians	_	_	O
307	working	_	_	O
308	with	_	_	O
309	patients	_	_	O
310	who	_	_	O
311	have	_	_	O
312	advanced	_	_	O
313	cancer	_	_	O
314	should	_	_	O
315	consider	_	_	O
316	IMCP	_	_	O
317	as	_	_	O
318	an	_	_	O
319	approach	_	_	O
320	to	_	_	O
321	enhance	_	_	O
322	quality	_	_	O
323	of	_	_	O
324	life	_	_	O
325	and	_	_	O
326	spiritual	_	_	O
327	well-being	_	_	O
328	.	_	_	O


0	Recently	_	_	B-Claim
1	,	_	_	I-Claim
2	the	_	_	I-Claim
3	treatment	_	_	I-Claim
4	of	_	_	I-Claim
5	advanced	_	_	I-Claim
6	gastric	_	_	I-Claim
7	cancer	_	_	I-Claim
8	by	_	_	I-Claim
9	continuous	_	_	I-Claim
10	infusion	_	_	I-Claim
11	of	_	_	I-Claim
12	5-fluorouracil	_	_	I-Claim
13	(	_	_	I-Claim
14	5-FU	_	_	I-Claim
15	)	_	_	I-Claim
16	with	_	_	I-Claim
17	low-dose	_	_	I-Claim
18	cisplatin	_	_	I-Claim
19	(	_	_	I-Claim
20	CDDP	_	_	I-Claim
21	)	_	_	I-Claim
22	has	_	_	I-Claim
23	improved	_	_	I-Claim
24	efficacy	_	_	I-Claim
25	without	_	_	I-Claim
26	severe	_	_	I-Claim
27	toxicities	_	_	I-Claim
28	.	_	_	I-Claim

29	The	_	_	B-Claim
30	possible	_	_	I-Claim
31	effectiveness	_	_	I-Claim
32	of	_	_	I-Claim
33	5-FU+low-dose	_	_	I-Claim
34	CDDP	_	_	I-Claim
35	for	_	_	I-Claim
36	colorectal	_	_	I-Claim
37	cancer	_	_	I-Claim
38	(	_	_	I-Claim
39	CRC	_	_	I-Claim
40	)	_	_	I-Claim
41	is	_	_	I-Claim
42	intriguing	_	_	I-Claim
43	.	_	_	I-Claim

44	One	_	_	O
45	hundred	_	_	O
46	fifty-five	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	far-advanced	_	_	O
50	CRC	_	_	O
51	including	_	_	O
52	at	_	_	O
53	least	_	_	O
54	one	_	_	O
55	measurable	_	_	O
56	lesion	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	a	_	_	O
61	prospective	_	_	O
62	randomized	_	_	O
63	clinical	_	_	O
64	trial	_	_	O
65	funded	_	_	O
66	by	_	_	O
67	the	_	_	O
68	Japanese	_	_	O
69	Foundation	_	_	O
70	for	_	_	O
71	Multidisciplinary	_	_	O
72	Treatment	_	_	O
73	of	_	_	O
74	Cancer	_	_	O
75	.	_	_	O

76	These	_	_	O
77	patients	_	_	O
78	were	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	the	_	_	O
82	two	_	_	O
83	arms	_	_	O
84	to	_	_	O
85	assess	_	_	O
86	the	_	_	O
87	value	_	_	O
88	of	_	_	O
89	low-dose	_	_	O
90	CDDP	_	_	O
91	when	_	_	O
92	added	_	_	O
93	to	_	_	O
94	a	_	_	O
95	continuous	_	_	O
96	intravenous	_	_	O
97	infusion	_	_	O
98	of	_	_	O
99	5-FU	_	_	O
100	at	_	_	O
101	a	_	_	O
102	dose	_	_	O
103	of	_	_	O
104	300	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	/24	_	_	O
110	hrs	_	_	O
111	in	_	_	O
112	a	_	_	O
113	one-week	_	_	O
114	cycle	_	_	O
115	consisting	_	_	O
116	of	_	_	O
117	5	_	_	O
118	days	_	_	O
119	of	_	_	O
120	treatment	_	_	O
121	and	_	_	O
122	2	_	_	O
123	days	_	_	O
124	of	_	_	O
125	rest	_	_	O
126	for	_	_	O
127	at	_	_	O
128	least	_	_	O
129	12	_	_	O
130	weeks	_	_	O
131	.	_	_	O

132	CD-DP	_	_	O
133	was	_	_	O
134	given	_	_	O
135	intravenously	_	_	O
136	at	_	_	O
137	a	_	_	O
138	dose	_	_	O
139	of	_	_	O
140	3	_	_	O
141	mg/m	_	_	O
142	(	_	_	O
143	2	_	_	O
144	)	_	_	O
145	on	_	_	O
146	days	_	_	O
147	1-5	_	_	O
148	and	_	_	O
149	days	_	_	O
150	8-12	_	_	O
151	,	_	_	O
152	and	_	_	O
153	then	_	_	O
154	at	_	_	O
155	a	_	_	O
156	dose	_	_	O
157	of	_	_	O
158	7	_	_	O
159	mg/m	_	_	O
160	(	_	_	O
161	2	_	_	O
162	)	_	_	O
163	twice	_	_	O
164	a	_	_	O
165	week	_	_	O
166	.	_	_	O

167	Three	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	excluded	_	_	O
171	from	_	_	O
172	the	_	_	O
173	trial	_	_	O
174	.	_	_	O

175	The	_	_	B-Premise
176	response	_	_	I-Premise
177	rate	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	5-FU+low-dose	_	_	I-Premise
181	CDDP	_	_	I-Premise
182	arm	_	_	I-Premise
183	(	_	_	I-Premise
184	n=75	_	_	I-Premise
185	)	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	higher	_	_	I-Premise
189	than	_	_	I-Premise
190	that	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	5-FU	_	_	I-Premise
194	arm	_	_	I-Premise
195	(	_	_	I-Premise
196	n=77	_	_	I-Premise
197	)	_	_	I-Premise
198	(	_	_	I-Premise
199	25.3	_	_	I-Premise
200	%	_	_	I-Premise
201	vs.	_	_	I-Premise
202	11.7	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	0.037	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	B-Premise
211	was	_	_	I-Premise
212	no	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	median	_	_	I-Premise
218	overall	_	_	I-Premise
219	survival	_	_	I-Premise
220	time	_	_	I-Premise
221	between	_	_	I-Premise
222	the	_	_	I-Premise
223	5-FU+low-dose	_	_	I-Premise
224	CDDP	_	_	I-Premise
225	arm	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	5-FU	_	_	I-Premise
229	arm	_	_	I-Premise
230	(	_	_	I-Premise
231	479	_	_	I-Premise
232	and	_	_	I-Premise
233	491	_	_	I-Premise
234	days	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Grades	_	_	B-Premise
240	3/4	_	_	I-Premise
241	toxicities	_	_	I-Premise
242	occurred	_	_	I-Premise
243	infrequently	_	_	I-Premise
244	in	_	_	I-Premise
245	both	_	_	I-Premise
246	arms	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	quality	_	_	I-Premise
250	of	_	_	I-Premise
251	life	_	_	I-Premise
252	was	_	_	I-Premise
253	almost	_	_	I-Premise
254	the	_	_	I-Premise
255	same	_	_	I-Premise
256	between	_	_	I-Premise
257	the	_	_	I-Premise
258	arms	_	_	I-Premise
259	.	_	_	O

260	Low-dose	_	_	B-Claim
261	CDDP	_	_	I-Claim
262	improved	_	_	I-Claim
263	the	_	_	I-Claim
264	response	_	_	I-Claim
265	rate	_	_	I-Claim
266	while	_	_	I-Claim
267	keeping	_	_	I-Claim
268	toxicities	_	_	I-Claim
269	within	_	_	I-Claim
270	clinically	_	_	I-Claim
271	acceptable	_	_	I-Claim
272	limits	_	_	I-Claim
273	.	_	_	I-Claim

274	However	_	_	B-Claim
275	,	_	_	I-Claim
276	this	_	_	I-Claim
277	combined	_	_	I-Claim
278	treatment	_	_	I-Claim
279	did	_	_	I-Claim
280	not	_	_	I-Claim
281	confer	_	_	I-Claim
282	a	_	_	I-Claim
283	survival	_	_	I-Claim
284	advantage	_	_	I-Claim
285	over	_	_	I-Claim
286	treatment	_	_	I-Claim
287	with	_	_	I-Claim
288	continuous	_	_	I-Claim
289	infusion	_	_	I-Claim
290	of	_	_	I-Claim
291	5-FU	_	_	I-Claim
292	alone	_	_	I-Claim
293	for	_	_	I-Claim
294	patients	_	_	I-Claim
295	with	_	_	I-Claim
296	far-advanced	_	_	I-Claim
297	CRC	_	_	I-Claim
298	;	_	_	I-Claim
299	that	_	_	I-Claim
300	might	_	_	I-Claim
301	be	_	_	I-Claim
302	attributable	_	_	I-Claim
303	to	_	_	I-Claim
304	the	_	_	I-Claim
305	short	_	_	I-Claim
306	CDDP	_	_	I-Claim
307	administration	_	_	I-Claim
308	setting	_	_	I-Claim
309	of	_	_	I-Claim
310	12	_	_	I-Claim
311	weeks	_	_	I-Claim
312	.	_	_	I-Claim


0	Recent	_	_	B-Claim
1	studies	_	_	I-Claim
2	have	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	administering	_	_	I-Claim
6	the	_	_	I-Claim
7	aromatase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	exemestane	_	_	I-Claim
10	after	_	_	I-Claim
11	2-3	_	_	I-Claim
12	years	_	_	I-Claim
13	of	_	_	I-Claim
14	tamoxifen	_	_	I-Claim
15	therapy	_	_	I-Claim
16	significantly	_	_	I-Claim
17	improves	_	_	I-Claim
18	disease-free	_	_	I-Claim
19	survival	_	_	I-Claim
20	in	_	_	I-Claim
21	postmenopausal	_	_	I-Claim
22	women	_	_	I-Claim
23	with	_	_	I-Claim
24	primary	_	_	I-Claim
25	breast	_	_	I-Claim
26	cancer	_	_	I-Claim
27	in	_	_	I-Claim
28	comparison	_	_	I-Claim
29	with	_	_	I-Claim
30	standard	_	_	I-Claim
31	5-year	_	_	I-Claim
32	tamoxifen	_	_	I-Claim
33	treatment	_	_	I-Claim
34	.	_	_	I-Claim

35	Although	_	_	O
36	many	_	_	O
37	of	_	_	O
38	the	_	_	O
39	adverse	_	_	O
40	effects	_	_	O
41	associated	_	_	O
42	with	_	_	O
43	exemestane	_	_	O
44	and	_	_	O
45	tamoxifen	_	_	O
46	have	_	_	O
47	been	_	_	O
48	analysed	_	_	O
49	,	_	_	O
50	there	_	_	O
51	are	_	_	O
52	no	_	_	O
53	comparative	_	_	O
54	data	_	_	O
55	concerning	_	_	O
56	body	_	_	O
57	weight	_	_	O
58	and	_	_	O
59	body	_	_	O
60	composition	_	_	O
61	.	_	_	O

62	The	_	_	O
63	aim	_	_	O
64	of	_	_	O
65	this	_	_	O
66	randomised	_	_	O
67	study	_	_	O
68	was	_	_	O
69	to	_	_	O
70	evaluate	_	_	O
71	the	_	_	O
72	longitudinal	_	_	O
73	changes	_	_	O
74	in	_	_	O
75	body	_	_	O
76	composition	_	_	O
77	and	_	_	O
78	lipid	_	_	O
79	profiles	_	_	O
80	in	_	_	O
81	postmenopausal	_	_	O
82	women	_	_	O
83	switched	_	_	O
84	from	_	_	O
85	tamoxifen	_	_	O
86	to	_	_	O
87	exemestane	_	_	O
88	.	_	_	O

89	In	_	_	O
90	total	_	_	O
91	,	_	_	O
92	60	_	_	O
93	overweight	_	_	O
94	or	_	_	O
95	obese	_	_	O
96	postmenopausal	_	_	O
97	patients	_	_	O
98	were	_	_	O
99	enrolled	_	_	O
100	.	_	_	O

101	Their	_	_	O
102	anthropometric	_	_	O
103	data	_	_	O
104	,	_	_	O
105	body	_	_	O
106	composition	_	_	O
107	,	_	_	O
108	including	_	_	O
109	fat	_	_	O
110	mass	_	_	O
111	(	_	_	O
112	FM	_	_	O
113	)	_	_	O
114	and	_	_	O
115	fat-free	_	_	O
116	mass	_	_	O
117	(	_	_	O
118	FFM	_	_	O
119	)	_	_	O
120	,	_	_	O
121	and	_	_	O
122	lipid	_	_	O
123	profiles	_	_	O
124	,	_	_	O
125	caloric	_	_	O
126	intake	_	_	O
127	and	_	_	O
128	physical	_	_	O
129	activity	_	_	O
130	were	_	_	O
131	assessed	_	_	O
132	1	_	_	O
133	week	_	_	O
134	before	_	_	O
135	randomisation	_	_	O
136	,	_	_	O
137	and	_	_	O
138	6	_	_	O
139	and	_	_	O
140	12	_	_	O
141	months	_	_	O
142	later	_	_	O
143	.	_	_	O

144	In	_	_	O
145	all	_	_	O
146	,	_	_	O
147	55	_	_	O
148	patients	_	_	O
149	(	_	_	O
150	27	_	_	O
151	on	_	_	O
152	tamoxifen	_	_	O
153	and	_	_	O
154	28	_	_	O
155	on	_	_	O
156	exemestane	_	_	O
157	)	_	_	O
158	completed	_	_	O
159	the	_	_	O
160	1-year	_	_	O
161	study	_	_	O
162	period	_	_	O
163	.	_	_	O

164	Fat	_	_	B-Premise
165	mass	_	_	I-Premise
166	had	_	_	I-Premise
167	significantly	_	_	I-Premise
168	decreased	_	_	I-Premise
169	by	_	_	I-Premise
170	month	_	_	I-Premise
171	12	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	exemestane	_	_	I-Premise
175	,	_	_	I-Premise
176	but	_	_	I-Premise
177	not	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	tamoxifen	_	_	I-Premise
181	group	_	_	I-Premise
182	;	_	_	I-Premise
183	the	_	_	B-Premise
184	between-group	_	_	I-Premise
185	difference	_	_	I-Premise
186	was	_	_	I-Premise
187	statistically	_	_	I-Premise
188	significant	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.01	_	_	I-Premise
193	)	_	_	I-Premise
194	.	_	_	I-Premise

195	The	_	_	B-Premise
196	FFM/FM	_	_	I-Premise
197	ratio	_	_	I-Premise
198	had	_	_	I-Premise
199	significantly	_	_	I-Premise
200	increased	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	exemestane	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	but	_	_	I-Premise
207	not	_	_	I-Premise
208	the	_	_	I-Premise
209	tamoxifen	_	_	I-Premise
210	group	_	_	I-Premise
211	;	_	_	I-Premise
212	the	_	_	B-Premise
213	between-group	_	_	I-Premise
214	difference	_	_	I-Premise
215	was	_	_	I-Premise
216	statistically	_	_	I-Premise
217	significant	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	<	_	_	I-Premise
221	0.05	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Triglycerides	_	_	B-Premise
225	and	_	_	I-Premise
226	high-density	_	_	I-Premise
227	lipoprotein	_	_	I-Premise
228	cholesterol	_	_	I-Premise
229	significantly	_	_	I-Premise
230	decreased	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0.01	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	0.05	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	and	_	_	O
242	low-density	_	_	B-Premise
243	lipoprotein	_	_	I-Premise
244	cholesterol	_	_	I-Premise
245	significantly	_	_	I-Premise
246	increased	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0.01	_	_	I-Premise
251	)	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	exemestane	_	_	I-Premise
255	group	_	_	I-Premise
256	at	_	_	I-Premise
257	the	_	_	I-Premise
258	end	_	_	I-Premise
259	of	_	_	I-Premise
260	the	_	_	I-Premise
261	1-year	_	_	I-Premise
262	study	_	_	I-Premise
263	period	_	_	I-Premise
264	.	_	_	I-Premise

265	Our	_	_	B-Claim
266	findings	_	_	I-Claim
267	suggest	_	_	I-Claim
268	that	_	_	I-Claim
269	switching	_	_	I-Claim
270	patients	_	_	I-Claim
271	to	_	_	I-Claim
272	adjuvant	_	_	I-Claim
273	exemestane	_	_	I-Claim
274	treatment	_	_	I-Claim
275	after	_	_	I-Claim
276	at	_	_	I-Claim
277	least	_	_	I-Claim
278	2	_	_	I-Claim
279	years	_	_	I-Claim
280	of	_	_	I-Claim
281	tamoxifen	_	_	I-Claim
282	therapy	_	_	I-Claim
283	may	_	_	I-Claim
284	be	_	_	I-Claim
285	associated	_	_	I-Claim
286	with	_	_	I-Claim
287	an	_	_	I-Claim
288	advantage	_	_	I-Claim
289	over	_	_	I-Claim
290	continuing	_	_	I-Claim
291	adjuvant	_	_	I-Claim
292	tamoxifen	_	_	I-Claim
293	treatment	_	_	I-Claim
294	in	_	_	I-Claim
295	terms	_	_	I-Claim
296	of	_	_	I-Claim
297	body	_	_	I-Claim
298	composition	_	_	I-Claim
299	.	_	_	I-Claim


0	Anti-aromatase	_	_	B-Claim
1	therapy	_	_	I-Claim
2	is	_	_	I-Claim
3	important	_	_	I-Claim
4	in	_	_	I-Claim
5	the	_	_	I-Claim
6	treatment	_	_	I-Claim
7	of	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	in	_	_	I-Claim
11	postmenopausal	_	_	I-Claim
12	women	_	_	I-Claim
13	but	_	_	O
14	they	_	_	O
15	have	_	_	O
16	effects	_	_	O
17	on	_	_	O
18	the	_	_	O
19	bone	_	_	O
20	mineral	_	_	O
21	density	_	_	O
22	(	_	_	O
23	BMD	_	_	O
24	)	_	_	O
25	and	_	_	O
26	osteoporosis	_	_	O
27	.	_	_	O

28	Cyclooxygenase-2	_	_	B-Claim
29	(	_	_	I-Claim
30	COX-2	_	_	I-Claim
31	)	_	_	I-Claim
32	inhibitors	_	_	I-Claim
33	have	_	_	I-Claim
34	been	_	_	I-Claim
35	shown	_	_	I-Claim
36	to	_	_	I-Claim
37	be	_	_	I-Claim
38	effective	_	_	I-Claim
39	in	_	_	I-Claim
40	chemoprevention	_	_	I-Claim
41	in	_	_	I-Claim
42	animal	_	_	I-Claim
43	and	_	_	I-Claim
44	clinical	_	_	I-Claim
45	studies	_	_	I-Claim
46	.	_	_	I-Claim

47	A	_	_	O
48	proof	_	_	O
49	of	_	_	O
50	principle	_	_	O
51	study	_	_	O
52	was	_	_	O
53	performed	_	_	O
54	to	_	_	O
55	investigate	_	_	O
56	the	_	_	O
57	efficacy	_	_	O
58	of	_	_	O
59	combing	_	_	O
60	anti-aromatase	_	_	O
61	therapy	_	_	O
62	(	_	_	O
63	exemestane	_	_	O
64	)	_	_	O
65	and	_	_	O
66	COX-2	_	_	O
67	inhibitors	_	_	O
68	neoadjuvantly	_	_	O
69	.	_	_	O

70	The	_	_	O
71	changes	_	_	O
72	in	_	_	O
73	the	_	_	O
74	BMD	_	_	O
75	,	_	_	O
76	bone	_	_	O
77	turnover	_	_	O
78	proteins	_	_	O
79	and	_	_	O
80	quality-of-life	_	_	O
81	(	_	_	O
82	QoL	_	_	O
83	)	_	_	O
84	were	_	_	O
85	analyzed	_	_	O
86	and	_	_	O
87	presented	_	_	O
88	here	_	_	O
89	.	_	_	O

90	82	_	_	O
91	postmenopausal	_	_	O
92	patients	_	_	O
93	with	_	_	O
94	histologically	_	_	O
95	confirmed	_	_	O
96	invasive	_	_	O
97	hormone-sensitive	_	_	O
98	breast	_	_	O
99	cancers	_	_	O
100	were	_	_	O
101	included	_	_	O
102	for	_	_	O
103	the	_	_	O
104	neoadjuvant	_	_	O
105	therapy	_	_	O
106	(	_	_	O
107	NHT	_	_	O
108	)	_	_	O
109	.	_	_	O

110	30	_	_	O
111	patients	_	_	O
112	received	_	_	O
113	exemestane	_	_	O
114	(	_	_	O
115	EXE	_	_	O
116	)	_	_	O
117	25	_	_	O
118	mg	_	_	O
119	daily	_	_	O
120	and	_	_	O
121	celecoxib	_	_	O
122	(	_	_	O
123	CXB	_	_	O
124	)	_	_	O
125	400	_	_	O
126	mg	_	_	O
127	twice	_	_	O
128	daily	_	_	O
129	(	_	_	O
130	group	_	_	O
131	A	_	_	O
132	)	_	_	O
133	,	_	_	O
134	24	_	_	O
135	patients	_	_	O
136	received	_	_	O
137	EXE	_	_	O
138	25	_	_	O
139	mg	_	_	O
140	daily	_	_	O
141	(	_	_	O
142	group	_	_	O
143	B	_	_	O
144	)	_	_	O
145	and	_	_	O
146	28	_	_	O
147	patients	_	_	O
148	received	_	_	O
149	letrozole	_	_	O
150	(	_	_	O
151	LET	_	_	O
152	)	_	_	O
153	2.5	_	_	O
154	mg	_	_	O
155	daily	_	_	O
156	(	_	_	O
157	group	_	_	O
158	C	_	_	O
159	)	_	_	O
160	.	_	_	O

161	The	_	_	O
162	same	_	_	O
163	assigned	_	_	O
164	treatment	_	_	O
165	was	_	_	O
166	intended	_	_	O
167	to	_	_	O
168	continue	_	_	O
169	for	_	_	O
170	2	_	_	O
171	years	_	_	O
172	to	_	_	O
173	study	_	_	O
174	the	_	_	O
175	changes	_	_	O
176	in	_	_	O
177	the	_	_	O
178	bone	_	_	O
179	metabolism	_	_	O
180	.	_	_	O

181	BMD	_	_	O
182	of	_	_	O
183	48	_	_	O
184	patients	_	_	O
185	were	_	_	O
186	analyzed	_	_	O
187	;	_	_	O
188	23	_	_	O
189	belongs	_	_	O
190	to	_	_	O
191	group	_	_	O
192	A	_	_	O
193	,	_	_	O
194	10	_	_	O
195	to	_	_	O
196	group	_	_	O
197	B	_	_	O
198	and	_	_	O
199	15	_	_	O
200	to	_	_	O
201	group	_	_	O
202	C.	_	_	O
203	The	_	_	O
204	serum	_	_	O
205	bone	_	_	O
206	turnover	_	_	O
207	proteins	_	_	O
208	bone-specific	_	_	O
209	alkaline	_	_	O
210	phosphatase	_	_	O
211	(	_	_	O
212	BAP	_	_	O
213	)	_	_	O
214	and	_	_	O
215	carboxyterminal	_	_	O
216	crosslinked	_	_	O
217	telopeptide	_	_	O
218	of	_	_	O
219	type	_	_	O
220	I	_	_	O
221	collagen	_	_	O
222	(	_	_	O
223	ICTP	_	_	O
224	)	_	_	O
225	,	_	_	O
226	were	_	_	O
227	measured	_	_	O
228	with	_	_	O
229	commercially	_	_	O
230	available	_	_	O
231	test	_	_	O
232	kits	_	_	O
233	before	_	_	O
234	treatment	_	_	O
235	,	_	_	O
236	3	_	_	O
237	months	_	_	O
238	and	_	_	O
239	15	_	_	O
240	months	_	_	O
241	after	_	_	O
242	treatment	_	_	O
243	.	_	_	O

244	Functional	_	_	O
245	Assessment	_	_	O
246	of	_	_	O
247	Cancer	_	_	O
248	Therapy	_	_	O
249	core	_	_	O
250	questionnaire	_	_	O
251	(	_	_	O
252	FACT-G	_	_	O
253	)	_	_	O
254	with	_	_	O
255	its	_	_	O
256	additional	_	_	O
257	breast	_	_	O
258	cancer	_	_	O
259	subscale	_	_	O
260	were	_	_	O
261	performed	_	_	O
262	at	_	_	O
263	baseline	_	_	O
264	,	_	_	O
265	4	_	_	O
266	,	_	_	O
267	8	_	_	O
268	,	_	_	O
269	and	_	_	O
270	12	_	_	O
271	weeks	_	_	O
272	after	_	_	O
273	NHT	_	_	O
274	.	_	_	O

275	Difference	_	_	B-Premise
276	between	_	_	I-Premise
277	groups	_	_	I-Premise
278	(	_	_	I-Premise
279	p=0.007	_	_	I-Premise
280	)	_	_	I-Premise
281	for	_	_	I-Premise
282	BMD	_	_	I-Premise
283	at	_	_	I-Premise
284	femur	_	_	I-Premise
285	was	_	_	I-Premise
286	significant	_	_	I-Premise
287	.	_	_	I-Premise

288	The	_	_	B-Premise
289	changes	_	_	I-Premise
290	of	_	_	I-Premise
291	BMD	_	_	I-Premise
292	in	_	_	I-Premise
293	group	_	_	I-Premise
294	B	_	_	I-Premise
295	patients	_	_	I-Premise
296	were	_	_	I-Premise
297	significantly	_	_	I-Premise
298	greater	_	_	I-Premise
299	than	_	_	I-Premise
300	patients	_	_	I-Premise
301	in	_	_	I-Premise
302	group	_	_	I-Premise
303	A	_	_	I-Premise
304	(	_	_	I-Premise
305	p=0.011	_	_	I-Premise
306	,	_	_	I-Premise
307	CI=0.063-0.437	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	and	_	_	I-Premise
311	group	_	_	I-Premise
312	C	_	_	I-Premise
313	(	_	_	I-Premise
314	p=0.003	_	_	I-Premise
315	,	_	_	I-Premise
316	CI=0.146-0.620	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Premise
320	mean	_	_	I-Premise
321	BAP	_	_	I-Premise
322	increased	_	_	I-Premise
323	from	_	_	I-Premise
324	baseline	_	_	I-Premise
325	in	_	_	I-Premise
326	group	_	_	I-Premise
327	B	_	_	I-Premise
328	patients	_	_	I-Premise
329	but	_	_	I-Premise
330	decreased	_	_	I-Premise
331	from	_	_	I-Premise
332	baseline	_	_	I-Premise
333	in	_	_	I-Premise
334	group	_	_	I-Premise
335	C	_	_	I-Premise
336	patients	_	_	I-Premise
337	at	_	_	I-Premise
338	3	_	_	I-Premise
339	months	_	_	I-Premise
340	and	_	_	I-Premise
341	15	_	_	I-Premise
342	months	_	_	I-Premise
343	.	_	_	I-Premise

344	No	_	_	B-Premise
345	statistical	_	_	I-Premise
346	significance	_	_	I-Premise
347	was	_	_	I-Premise
348	found	_	_	I-Premise
349	in	_	_	I-Premise
350	the	_	_	I-Premise
351	FACT-G	_	_	I-Premise
352	scores	_	_	I-Premise
353	and	_	_	I-Premise
354	FACT-B	_	_	I-Premise
355	scores	_	_	I-Premise
356	among	_	_	I-Premise
357	different	_	_	I-Premise
358	groups	_	_	I-Premise
359	at	_	_	I-Premise
360	baseline	_	_	I-Premise
361	,	_	_	I-Premise
362	week	_	_	I-Premise
363	4	_	_	I-Premise
364	,	_	_	I-Premise
365	week	_	_	I-Premise
366	8	_	_	I-Premise
367	and	_	_	I-Premise
368	week	_	_	I-Premise
369	12	_	_	I-Premise
370	after	_	_	I-Premise
371	NHT	_	_	I-Premise
372	.	_	_	I-Premise

373	The	_	_	B-Premise
374	Breast	_	_	I-Premise
375	Cancer	_	_	I-Premise
376	Subscale	_	_	I-Premise
377	scores	_	_	I-Premise
378	in	_	_	I-Premise
379	group	_	_	I-Premise
380	A	_	_	I-Premise
381	patients	_	_	I-Premise
382	were	_	_	I-Premise
383	significantly	_	_	I-Premise
384	higher	_	_	I-Premise
385	than	_	_	I-Premise
386	that	_	_	I-Premise
387	of	_	_	I-Premise
388	group	_	_	I-Premise
389	C	_	_	I-Premise
390	patients	_	_	I-Premise
391	(	_	_	I-Premise
392	p=0.021	_	_	I-Premise
393	)	_	_	I-Premise
394	.	_	_	I-Premise

395	After	_	_	B-Premise
396	4	_	_	I-Premise
397	weeks	_	_	I-Premise
398	of	_	_	I-Premise
399	NHT	_	_	I-Premise
400	,	_	_	I-Premise
401	negative	_	_	I-Premise
402	changes	_	_	I-Premise
403	of	_	_	I-Premise
404	FACT-B	_	_	I-Premise
405	and	_	_	I-Premise
406	FACT-G	_	_	I-Premise
407	scores	_	_	I-Premise
408	were	_	_	I-Premise
409	found	_	_	I-Premise
410	in	_	_	I-Premise
411	group	_	_	I-Premise
412	B	_	_	I-Premise
413	and	_	_	I-Premise
414	C	_	_	I-Premise
415	patients	_	_	I-Premise
416	,	_	_	I-Premise
417	but	_	_	B-Premise
418	there	_	_	I-Premise
419	were	_	_	I-Premise
420	positive	_	_	I-Premise
421	changes	_	_	I-Premise
422	in	_	_	I-Premise
423	group	_	_	I-Premise
424	A	_	_	I-Premise
425	patients	_	_	I-Premise
426	.	_	_	I-Premise

427	Significant	_	_	B-Premise
428	differences	_	_	I-Premise
429	of	_	_	I-Premise
430	FACT-B	_	_	I-Premise
431	score	_	_	I-Premise
432	(	_	_	I-Premise
433	p=0.008	_	_	I-Premise
434	)	_	_	I-Premise
435	and	_	_	I-Premise
436	FACT-G	_	_	I-Premise
437	score	_	_	I-Premise
438	(	_	_	I-Premise
439	p=0.019	_	_	I-Premise
440	)	_	_	I-Premise
441	were	_	_	I-Premise
442	observed	_	_	I-Premise
443	at	_	_	I-Premise
444	that	_	_	I-Premise
445	time	_	_	I-Premise
446	point	_	_	I-Premise
447	.	_	_	I-Premise

448	Article	_	_	O
449	from	_	_	O
450	the	_	_	O
451	Special	_	_	O
452	issue	_	_	O
453	on	_	_	O
454	Targeted	_	_	O
455	Inhibitors	_	_	O
456	.	_	_	O


0	Hot	_	_	O
1	flushes	_	_	O
2	and	_	_	O
3	night	_	_	O
4	sweats	_	_	O
5	(	_	_	O
6	HFNS	_	_	O
7	)	_	_	O
8	affect	_	_	O
9	65-85	_	_	O
10	%	_	_	O
11	of	_	_	O
12	women	_	_	O
13	after	_	_	O
14	breast	_	_	O
15	cancer	_	_	O
16	treatment	_	_	O
17	;	_	_	O
18	they	_	_	O
19	are	_	_	O
20	distressing	_	_	O
21	,	_	_	O
22	causing	_	_	O
23	sleep	_	_	O
24	problems	_	_	O
25	and	_	_	O
26	decreased	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	.	_	_	O

31	Hormone	_	_	B-Claim
32	replacement	_	_	I-Claim
33	therapy	_	_	I-Claim
34	is	_	_	I-Claim
35	often	_	_	I-Claim
36	either	_	_	I-Claim
37	undesirable	_	_	I-Claim
38	or	_	_	I-Claim
39	contraindicated	_	_	I-Claim
40	.	_	_	I-Claim

41	Safe	_	_	B-Claim
42	,	_	_	I-Claim
43	effective	_	_	I-Claim
44	non-hormonal	_	_	I-Claim
45	treatments	_	_	I-Claim
46	are	_	_	I-Claim
47	needed	_	_	I-Claim
48	.	_	_	I-Claim

49	We	_	_	O
50	investigated	_	_	O
51	whether	_	_	O
52	cognitive	_	_	O
53	behavioural	_	_	O
54	therapy	_	_	O
55	(	_	_	O
56	CBT	_	_	O
57	)	_	_	O
58	can	_	_	O
59	help	_	_	O
60	breast	_	_	O
61	cancer	_	_	O
62	survivors	_	_	O
63	to	_	_	O
64	effectively	_	_	O
65	manage	_	_	O
66	HFNS	_	_	O
67	.	_	_	O

68	In	_	_	O
69	this	_	_	O
70	randomised	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	we	_	_	O
75	recruited	_	_	O
76	women	_	_	O
77	from	_	_	O
78	breast	_	_	O
79	clinics	_	_	O
80	in	_	_	O
81	London	_	_	O
82	,	_	_	O
83	UK	_	_	O
84	,	_	_	O
85	who	_	_	O
86	had	_	_	O
87	problematic	_	_	O
88	HFNS	_	_	O
89	(	_	_	O
90	minimum	_	_	O
91	ten	_	_	O
92	problematic	_	_	O
93	episodes	_	_	O
94	a	_	_	O
95	week	_	_	O
96	)	_	_	O
97	after	_	_	O
98	breast-cancer	_	_	O
99	treatment	_	_	O
100	.	_	_	O

101	Participants	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	allocated	_	_	O
105	to	_	_	O
106	receive	_	_	O
107	either	_	_	O
108	usual	_	_	O
109	care	_	_	O
110	or	_	_	O
111	usual	_	_	O
112	care	_	_	O
113	plus	_	_	O
114	group	_	_	O
115	CBT	_	_	O
116	(	_	_	O
117	1:1	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Randomisation	_	_	O
121	was	_	_	O
122	done	_	_	O
123	in	_	_	O
124	blocks	_	_	O
125	of	_	_	O
126	12-20	_	_	O
127	participants	_	_	O
128	,	_	_	O
129	stratifying	_	_	O
130	by	_	_	O
131	age	_	_	O
132	(	_	_	O
133	younger	_	_	O
134	than	_	_	O
135	50	_	_	O
136	years	_	_	O
137	,	_	_	O
138	50	_	_	O
139	years	_	_	O
140	or	_	_	O
141	older	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	was	_	_	O
146	done	_	_	O
147	with	_	_	O
148	a	_	_	O
149	computer-generated	_	_	O
150	sequence	_	_	O
151	.	_	_	O

152	The	_	_	O
153	trial	_	_	O
154	statistician	_	_	O
155	and	_	_	O
156	researchers	_	_	O
157	collecting	_	_	O
158	outcome	_	_	O
159	measures	_	_	O
160	were	_	_	O
161	masked	_	_	O
162	to	_	_	O
163	group	_	_	O
164	allocation	_	_	O
165	.	_	_	O

166	Group	_	_	O
167	CBT	_	_	O
168	comprised	_	_	O
169	one	_	_	O
170	90	_	_	O
171	min	_	_	O
172	session	_	_	O
173	a	_	_	O
174	week	_	_	O
175	for	_	_	O
176	6	_	_	O
177	weeks	_	_	O
178	,	_	_	O
179	and	_	_	O
180	included	_	_	O
181	psycho-education	_	_	O
182	,	_	_	O
183	paced	_	_	O
184	breathing	_	_	O
185	,	_	_	O
186	and	_	_	O
187	cognitive	_	_	O
188	and	_	_	O
189	behavioural	_	_	O
190	strategies	_	_	O
191	to	_	_	O
192	manage	_	_	O
193	HFNS	_	_	O
194	.	_	_	O

195	Assessments	_	_	O
196	were	_	_	O
197	done	_	_	O
198	at	_	_	O
199	baseline	_	_	O
200	,	_	_	O
201	9	_	_	O
202	weeks	_	_	O
203	,	_	_	O
204	and	_	_	O
205	26	_	_	O
206	weeks	_	_	O
207	after	_	_	O
208	randomisation	_	_	O
209	.	_	_	O

210	The	_	_	O
211	primary	_	_	O
212	outcome	_	_	O
213	was	_	_	O
214	the	_	_	O
215	adjusted	_	_	O
216	mean	_	_	O
217	difference	_	_	O
218	in	_	_	O
219	HFNS	_	_	O
220	problem	_	_	O
221	rating	_	_	O
222	(	_	_	O
223	1-10	_	_	O
224	)	_	_	O
225	between	_	_	O
226	CBT	_	_	O
227	and	_	_	O
228	usual	_	_	O
229	care	_	_	O
230	groups	_	_	O
231	at	_	_	O
232	9	_	_	O
233	weeks	_	_	O
234	after	_	_	O
235	randomisation	_	_	O
236	.	_	_	O

237	Analysis	_	_	O
238	of	_	_	O
239	the	_	_	O
240	primary	_	_	O
241	endpoint	_	_	O
242	was	_	_	O
243	done	_	_	O
244	by	_	_	O
245	modified	_	_	O
246	intention	_	_	O
247	to	_	_	O
248	treat	_	_	O
249	.	_	_	O

250	The	_	_	O
251	trial	_	_	O
252	is	_	_	O
253	registered	_	_	O
254	,	_	_	O
255	ISRCTN13771934	_	_	O
256	,	_	_	O
257	and	_	_	O
258	was	_	_	O
259	closed	_	_	O
260	March	_	_	O
261	15	_	_	O
262	,	_	_	O
263	2011	_	_	O
264	.	_	_	O

265	Between	_	_	O
266	May	_	_	O
267	5	_	_	O
268	,	_	_	O
269	2009	_	_	O
270	,	_	_	O
271	and	_	_	O
272	Aug	_	_	O
273	27	_	_	O
274	,	_	_	O
275	2010	_	_	O
276	,	_	_	O
277	96	_	_	O
278	women	_	_	O
279	were	_	_	O
280	randomly	_	_	O
281	allocated	_	_	O
282	to	_	_	O
283	group	_	_	O
284	CBT	_	_	O
285	(	_	_	O
286	n=47	_	_	O
287	)	_	_	O
288	or	_	_	O
289	usual	_	_	O
290	care	_	_	O
291	(	_	_	O
292	n=49	_	_	O
293	)	_	_	O
294	.	_	_	O

295	Group	_	_	B-Premise
296	CBT	_	_	I-Premise
297	significantly	_	_	I-Premise
298	reduced	_	_	I-Premise
299	HFNS	_	_	I-Premise
300	problem	_	_	I-Premise
301	rating	_	_	I-Premise
302	at	_	_	I-Premise
303	9	_	_	I-Premise
304	weeks	_	_	I-Premise
305	after	_	_	I-Premise
306	randomisation	_	_	I-Premise
307	compared	_	_	I-Premise
308	with	_	_	I-Premise
309	usual	_	_	I-Premise
310	care	_	_	I-Premise
311	(	_	_	I-Premise
312	mean	_	_	I-Premise
313	difference	_	_	I-Premise
314	-1Â·67	_	_	I-Premise
315	,	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	-2Â·43	_	_	I-Premise
320	to	_	_	I-Premise
321	-0Â·91	_	_	I-Premise
322	;	_	_	I-Premise
323	p	_	_	I-Premise
324	<	_	_	I-Premise
325	0Â·0001	_	_	I-Premise
326	)	_	_	I-Premise
327	and	_	_	I-Premise
328	improvements	_	_	I-Premise
329	were	_	_	I-Premise
330	maintained	_	_	I-Premise
331	at	_	_	I-Premise
332	26	_	_	I-Premise
333	weeks	_	_	I-Premise
334	(	_	_	I-Premise
335	mean	_	_	I-Premise
336	difference	_	_	I-Premise
337	-1Â·76	_	_	I-Premise
338	,	_	_	I-Premise
339	-2Â·54	_	_	I-Premise
340	to	_	_	I-Premise
341	-0Â·99	_	_	I-Premise
342	;	_	_	I-Premise
343	p	_	_	I-Premise
344	<	_	_	I-Premise
345	0Â·0001	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	We	_	_	B-Premise
349	recorded	_	_	I-Premise
350	no	_	_	I-Premise
351	CBT-related	_	_	I-Premise
352	adverse	_	_	I-Premise
353	events	_	_	I-Premise
354	.	_	_	I-Premise

355	Group	_	_	B-Claim
356	CBT	_	_	I-Claim
357	seems	_	_	I-Claim
358	to	_	_	I-Claim
359	be	_	_	I-Claim
360	a	_	_	I-Claim
361	safe	_	_	I-Claim
362	and	_	_	I-Claim
363	effective	_	_	I-Claim
364	treatment	_	_	I-Claim
365	for	_	_	I-Claim
366	women	_	_	I-Claim
367	who	_	_	I-Claim
368	have	_	_	I-Claim
369	problematic	_	_	I-Claim
370	HFNS	_	_	I-Claim
371	after	_	_	I-Claim
372	breast	_	_	I-Claim
373	cancer	_	_	I-Claim
374	treatment	_	_	I-Claim
375	with	_	_	I-Claim
376	additional	_	_	I-Claim
377	benefits	_	_	I-Claim
378	to	_	_	I-Claim
379	mood	_	_	I-Claim
380	,	_	_	I-Claim
381	sleep	_	_	I-Claim
382	,	_	_	I-Claim
383	and	_	_	I-Claim
384	quality	_	_	I-Claim
385	of	_	_	I-Claim
386	life	_	_	I-Claim
387	.	_	_	I-Claim

388	The	_	_	O
389	treatment	_	_	O
390	could	_	_	O
391	be	_	_	O
392	incorporated	_	_	O
393	into	_	_	O
394	breast	_	_	O
395	cancer	_	_	O
396	survivorship	_	_	O
397	programmes	_	_	O
398	and	_	_	O
399	delivered	_	_	O
400	by	_	_	O
401	trained	_	_	O
402	breast	_	_	O
403	cancer	_	_	O
404	nurses	_	_	O
405	.	_	_	O


0	Most	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	ovarian	_	_	I-Claim
5	cancer	_	_	I-Claim
6	develop	_	_	I-Claim
7	recurrent	_	_	I-Claim
8	disease	_	_	I-Claim
9	.	_	_	I-Claim

10	For	_	_	B-Claim
11	those	_	_	I-Claim
12	patients	_	_	I-Claim
13	who	_	_	I-Claim
14	recur	_	_	I-Claim
15	at	_	_	I-Claim
16	least	_	_	I-Claim
17	6	_	_	I-Claim
18	months	_	_	I-Claim
19	after	_	_	I-Claim
20	initial	_	_	I-Claim
21	therapy	_	_	I-Claim
22	,	_	_	I-Claim
23	paclitaxel	_	_	I-Claim
24	platinum	_	_	I-Claim
25	has	_	_	I-Claim
26	shown	_	_	I-Claim
27	a	_	_	I-Claim
28	modest	_	_	I-Claim
29	survival	_	_	I-Claim
30	advantage	_	_	I-Claim
31	over	_	_	I-Claim
32	platinum	_	_	I-Claim
33	without	_	_	I-Claim
34	paclitaxel	_	_	I-Claim
35	;	_	_	I-Claim
36	however	_	_	B-Premise
37	,	_	_	I-Premise
38	many	_	_	I-Premise
39	patients	_	_	I-Premise
40	develop	_	_	I-Premise
41	clinically	_	_	I-Premise
42	relevant	_	_	I-Premise
43	neurotoxicity	_	_	I-Premise
44	,	_	_	I-Premise
45	frequently	_	_	I-Premise
46	resulting	_	_	I-Premise
47	in	_	_	I-Premise
48	treatment	_	_	I-Premise
49	discontinuation	_	_	I-Premise
50	.	_	_	O

51	Thus	_	_	O
52	,	_	_	O
53	an	_	_	O
54	alternative	_	_	O
55	regimen	_	_	O
56	without	_	_	O
57	significant	_	_	O
58	neurotoxicity	_	_	O
59	was	_	_	O
60	evaluated	_	_	O
61	by	_	_	O
62	comparing	_	_	O
63	gemcitabine	_	_	O
64	plus	_	_	O
65	carboplatin	_	_	O
66	with	_	_	O
67	single-agent	_	_	O
68	carboplatin	_	_	O
69	in	_	_	O
70	platinum-sensitive	_	_	O
71	recurrent	_	_	O
72	ovarian	_	_	O
73	cancer	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	with	_	_	O
78	platinum-sensitive	_	_	O
79	recurrent	_	_	O
80	ovarian	_	_	O
81	cancer	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	receive	_	_	O
87	either	_	_	O
88	gemcitabine	_	_	O
89	plus	_	_	O
90	carboplatin	_	_	O
91	or	_	_	O
92	carboplatin	_	_	O
93	alone	_	_	O
94	,	_	_	O
95	every	_	_	O
96	21	_	_	O
97	days	_	_	O
98	.	_	_	O

99	The	_	_	O
100	primary	_	_	O
101	objective	_	_	O
102	was	_	_	O
103	to	_	_	O
104	compare	_	_	O
105	progression-free	_	_	O
106	survival	_	_	O
107	(	_	_	O
108	PFS	_	_	O
109	)	_	_	O
110	.	_	_	O

111	Three	_	_	O
112	hundred	_	_	O
113	fifty-six	_	_	O
114	patients	_	_	O
115	(	_	_	O
116	178	_	_	O
117	gemcitabine	_	_	O
118	plus	_	_	O
119	carboplatin	_	_	O
120	;	_	_	O
121	178	_	_	O
122	carboplatin	_	_	O
123	)	_	_	O
124	were	_	_	O
125	randomly	_	_	O
126	assigned	_	_	O
127	.	_	_	O

128	Patients	_	_	O
129	received	_	_	O
130	a	_	_	O
131	median	_	_	O
132	of	_	_	O
133	six	_	_	O
134	cycles	_	_	O
135	in	_	_	O
136	both	_	_	O
137	arms	_	_	O
138	.	_	_	O

139	With	_	_	B-Premise
140	a	_	_	I-Premise
141	median	_	_	I-Premise
142	follow-up	_	_	I-Premise
143	of	_	_	I-Premise
144	17	_	_	I-Premise
145	months	_	_	I-Premise
146	,	_	_	I-Premise
147	median	_	_	I-Premise
148	PFS	_	_	I-Premise
149	was	_	_	I-Premise
150	8.6	_	_	I-Premise
151	months	_	_	I-Premise
152	(	_	_	I-Premise
153	95	_	_	I-Premise
154	%	_	_	I-Premise
155	CI	_	_	I-Premise
156	,	_	_	I-Premise
157	7.9	_	_	I-Premise
158	to	_	_	I-Premise
159	9.7	_	_	I-Premise
160	months	_	_	I-Premise
161	)	_	_	I-Premise
162	for	_	_	I-Premise
163	gemcitabine	_	_	I-Premise
164	plus	_	_	I-Premise
165	carboplatin	_	_	I-Premise
166	and	_	_	I-Premise
167	5.8	_	_	I-Premise
168	months	_	_	I-Premise
169	(	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	,	_	_	I-Premise
174	5.2	_	_	I-Premise
175	to	_	_	I-Premise
176	7.1	_	_	I-Premise
177	months	_	_	I-Premise
178	)	_	_	I-Premise
179	for	_	_	I-Premise
180	carboplatin	_	_	I-Premise
181	.	_	_	I-Premise

182	The	_	_	B-Premise
183	hazard	_	_	I-Premise
184	ration	_	_	I-Premise
185	(	_	_	I-Premise
186	HR	_	_	I-Premise
187	)	_	_	I-Premise
188	for	_	_	I-Premise
189	PFS	_	_	I-Premise
190	was	_	_	I-Premise
191	0.72	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.58	_	_	I-Premise
198	to	_	_	I-Premise
199	0.90	_	_	I-Premise
200	;	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.0031	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Response	_	_	B-Premise
207	rate	_	_	I-Premise
208	was	_	_	I-Premise
209	47.2	_	_	I-Premise
210	%	_	_	I-Premise
211	(	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	CI	_	_	I-Premise
215	,	_	_	I-Premise
216	39.9	_	_	I-Premise
217	%	_	_	I-Premise
218	to	_	_	I-Premise
219	54.5	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	for	_	_	I-Premise
223	gemcitabine	_	_	I-Premise
224	plus	_	_	I-Premise
225	carboplatin	_	_	I-Premise
226	and	_	_	I-Premise
227	30.9	_	_	I-Premise
228	%	_	_	I-Premise
229	(	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	24.1	_	_	I-Premise
235	%	_	_	I-Premise
236	to	_	_	I-Premise
237	37.7	_	_	I-Premise
238	%	_	_	I-Premise
239	)	_	_	I-Premise
240	for	_	_	I-Premise
241	carboplatin	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.0016	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	HR	_	_	I-Premise
250	for	_	_	I-Premise
251	overall	_	_	I-Premise
252	survival	_	_	I-Premise
253	was	_	_	I-Premise
254	0.96	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.75	_	_	I-Premise
261	to1.23	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.7349	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	While	_	_	B-Premise
269	myelosuppression	_	_	I-Premise
270	was	_	_	I-Premise
271	significantly	_	_	I-Premise
272	more	_	_	I-Premise
273	common	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	combination	_	_	I-Premise
277	,	_	_	I-Premise
278	sequelae	_	_	I-Premise
279	such	_	_	I-Premise
280	as	_	_	I-Premise
281	febrile	_	_	I-Premise
282	neutropenia	_	_	I-Premise
283	or	_	_	I-Premise
284	infections	_	_	I-Premise
285	were	_	_	I-Premise
286	uncommon	_	_	I-Premise
287	.	_	_	I-Premise

288	No	_	_	B-Premise
289	statistically	_	_	I-Premise
290	significant	_	_	I-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	quality	_	_	I-Premise
294	of	_	_	I-Premise
295	life	_	_	I-Premise
296	scores	_	_	I-Premise
297	between	_	_	I-Premise
298	arms	_	_	I-Premise
299	were	_	_	I-Premise
300	noted	_	_	I-Premise
301	.	_	_	I-Premise

302	Gemcitabine	_	_	B-Claim
303	plus	_	_	I-Claim
304	carboplatin	_	_	I-Claim
305	significantly	_	_	I-Claim
306	improves	_	_	I-Claim
307	PFS	_	_	I-Claim
308	and	_	_	I-Claim
309	response	_	_	I-Claim
310	rate	_	_	I-Claim
311	without	_	_	I-Claim
312	worsening	_	_	I-Claim
313	quality	_	_	I-Claim
314	of	_	_	I-Claim
315	life	_	_	I-Claim
316	for	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	platinum-sensitive	_	_	I-Claim
320	recurrent	_	_	I-Claim
321	ovarian	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	very	_	_	O
3	few	_	_	O
4	randomized	_	_	O
5	controlled	_	_	O
6	studies	_	_	O
7	on	_	_	O
8	exercise	_	_	O
9	in	_	_	O
10	cancer	_	_	O
11	patients	_	_	O
12	.	_	_	O

13	Consequently	_	_	O
14	,	_	_	O
15	there	_	_	O
16	are	_	_	O
17	no	_	_	O
18	guidelines	_	_	O
19	available	_	_	O
20	with	_	_	O
21	regard	_	_	O
22	to	_	_	O
23	the	_	_	O
24	exercises	_	_	O
25	that	_	_	O
26	can	_	_	O
27	be	_	_	O
28	recommended	_	_	O
29	and	_	_	O
30	difficulties	_	_	O
31	are	_	_	O
32	encountered	_	_	O
33	in	_	_	O
34	the	_	_	O
35	clinical	_	_	O
36	practice	_	_	O
37	as	_	_	O
38	to	_	_	O
39	which	_	_	O
40	exercise	_	_	O
41	is	_	_	O
42	more	_	_	O
43	suitable	_	_	O
44	to	_	_	O
45	the	_	_	O
46	patients	_	_	O
47	.	_	_	O

48	The	_	_	O
49	purpose	_	_	O
50	of	_	_	O
51	this	_	_	O
52	study	_	_	O
53	was	_	_	O
54	to	_	_	O
55	investigate	_	_	O
56	the	_	_	O
57	impact	_	_	O
58	of	_	_	O
59	pilates	_	_	O
60	exercises	_	_	O
61	on	_	_	O
62	physical	_	_	O
63	performance	_	_	O
64	,	_	_	O
65	flexibility	_	_	O
66	,	_	_	O
67	fatigue	_	_	O
68	,	_	_	O
69	depression	_	_	O
70	and	_	_	O
71	quality	_	_	O
72	of	_	_	O
73	life	_	_	O
74	in	_	_	O
75	women	_	_	O
76	who	_	_	O
77	had	_	_	O
78	been	_	_	O
79	treated	_	_	O
80	for	_	_	O
81	breast	_	_	O
82	cancer	_	_	O
83	.	_	_	O

84	Randomized	_	_	O
85	controlled	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	Out	_	_	O
89	patient	_	_	O
90	group	_	_	O
91	,	_	_	O
92	Department	_	_	O
93	of	_	_	O
94	Physical	_	_	O
95	Medicine	_	_	O
96	and	_	_	O
97	Rehabilitation	_	_	O
98	and	_	_	O
99	Medical	_	_	O
100	Oncology	_	_	O
101	Department	_	_	O
102	,	_	_	O
103	University	_	_	O
104	Hospital	_	_	O
105	.	_	_	O

106	Fifty-two	_	_	O
107	patients	_	_	O
108	with	_	_	O
109	breast	_	_	O
110	cancer	_	_	O
111	were	_	_	O
112	divided	_	_	O
113	into	_	_	O
114	either	_	_	O
115	pilates	_	_	O
116	exercise	_	_	O
117	(	_	_	O
118	group	_	_	O
119	1	_	_	O
120	)	_	_	O
121	and	_	_	O
122	control	_	_	O
123	group	_	_	O
124	(	_	_	O
125	group	_	_	O
126	2	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	in	_	_	O
131	Group	_	_	O
132	1	_	_	O
133	performed	_	_	O
134	pilates	_	_	O
135	and	_	_	O
136	home	_	_	O
137	exercises	_	_	O
138	and	_	_	O
139	patients	_	_	O
140	in	_	_	O
141	group	_	_	O
142	2	_	_	O
143	performed	_	_	O
144	only	_	_	O
145	home	_	_	O
146	exercises	_	_	O
147	.	_	_	O

148	Pilates	_	_	O
149	exercise	_	_	O
150	sessions	_	_	O
151	were	_	_	O
152	performed	_	_	O
153	three	_	_	O
154	times	_	_	O
155	a	_	_	O
156	week	_	_	O
157	for	_	_	O
158	a	_	_	O
159	period	_	_	O
160	of	_	_	O
161	eight	_	_	O
162	weeks	_	_	O
163	in	_	_	O
164	the	_	_	O
165	rehabilitation	_	_	O
166	unit	_	_	O
167	.	_	_	O

168	Subjects	_	_	O
169	were	_	_	O
170	assessed	_	_	O
171	before	_	_	O
172	and	_	_	O
173	after	_	_	O
174	rehabilitation	_	_	O
175	program	_	_	O
176	,	_	_	O
177	with	_	_	O
178	respect	_	_	O
179	to	_	_	O
180	,	_	_	O
181	6-min	_	_	O
182	walk	_	_	O
183	test	_	_	O
184	(	_	_	O
185	6MWT	_	_	O
186	)	_	_	O
187	,	_	_	O
188	modified	_	_	O
189	sit	_	_	O
190	and	_	_	O
191	reach	_	_	O
192	test	_	_	O
193	,	_	_	O
194	Brief	_	_	O
195	Fatigue	_	_	O
196	Inventory	_	_	O
197	(	_	_	O
198	BFI	_	_	O
199	)	_	_	O
200	,	_	_	O
201	Beck	_	_	O
202	Depression	_	_	O
203	Index	_	_	O
204	(	_	_	O
205	BDI	_	_	O
206	)	_	_	O
207	and	_	_	O
208	the	_	_	O
209	European	_	_	O
210	Organisation	_	_	O
211	for	_	_	O
212	Research	_	_	O
213	and	_	_	O
214	Treatment	_	_	O
215	of	_	_	O
216	Cancer	_	_	O
217	Quality	_	_	O
218	of	_	_	O
219	Life	_	_	O
220	C30	_	_	O
221	(	_	_	O
222	EORTC	_	_	O
223	QLQ-C30	_	_	O
224	)	_	_	O
225	and	_	_	O
226	EORTC	_	_	O
227	QLQ	_	_	O
228	BR23	_	_	O
229	.	_	_	O

230	After	_	_	B-Premise
231	the	_	_	I-Premise
232	exercise	_	_	I-Premise
233	program	_	_	I-Premise
234	,	_	_	I-Premise
235	improvements	_	_	I-Premise
236	were	_	_	I-Premise
237	observed	_	_	I-Premise
238	in	_	_	I-Premise
239	Group	_	_	I-Premise
240	1	_	_	I-Premise
241	in	_	_	I-Premise
242	6-minute	_	_	I-Premise
243	walk	_	_	I-Premise
244	test	_	_	I-Premise
245	,	_	_	I-Premise
246	BDI	_	_	I-Premise
247	,	_	_	I-Premise
248	EORTC	_	_	I-Premise
249	QLQ-C30	_	_	I-Premise
250	functional	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	EORTC	_	_	I-Premise
254	QLQ-C30	_	_	I-Premise
255	BR23	_	_	I-Premise
256	functional	_	_	I-Premise
257	scores	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	In	_	_	O
265	contrast	_	_	O
266	,	_	_	O
267	no	_	_	B-Premise
268	significant	_	_	I-Premise
269	improvement	_	_	I-Premise
270	was	_	_	I-Premise
271	observed	_	_	I-Premise
272	in	_	_	I-Premise
273	Group	_	_	I-Premise
274	2	_	_	I-Premise
275	after	_	_	I-Premise
276	the	_	_	I-Premise
277	exercise	_	_	I-Premise
278	program	_	_	I-Premise
279	in	_	_	I-Premise
280	any	_	_	I-Premise
281	of	_	_	I-Premise
282	parameters	_	_	I-Premise
283	in	_	_	I-Premise
284	comparison	_	_	I-Premise
285	to	_	_	I-Premise
286	the	_	_	I-Premise
287	pre-exercise	_	_	I-Premise
288	period	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	>	_	_	I-Premise
292	0.05	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	When	_	_	B-Premise
296	the	_	_	I-Premise
297	two	_	_	I-Premise
298	exercise	_	_	I-Premise
299	groups	_	_	I-Premise
300	were	_	_	I-Premise
301	compared	_	_	I-Premise
302	,	_	_	I-Premise
303	there	_	_	I-Premise
304	were	_	_	I-Premise
305	significant	_	_	I-Premise
306	differences	_	_	I-Premise
307	in	_	_	I-Premise
308	6MWT	_	_	I-Premise
309	in	_	_	I-Premise
310	pilates-exercise	_	_	I-Premise
311	group	_	_	I-Premise
312	(	_	_	I-Premise
313	P	_	_	I-Premise
314	<	_	_	I-Premise
315	0.05	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	Pilates	_	_	B-Claim
319	exercises	_	_	I-Claim
320	are	_	_	I-Claim
321	effective	_	_	I-Claim
322	and	_	_	I-Claim
323	safe	_	_	I-Claim
324	in	_	_	I-Claim
325	female	_	_	I-Claim
326	breast	_	_	I-Claim
327	cancer	_	_	I-Claim
328	patients	_	_	I-Claim
329	.	_	_	I-Claim

330	There	_	_	B-Claim
331	is	_	_	I-Claim
332	a	_	_	I-Claim
333	need	_	_	I-Claim
334	for	_	_	I-Claim
335	further	_	_	I-Claim
336	studies	_	_	I-Claim
337	so	_	_	I-Claim
338	that	_	_	I-Claim
339	its	_	_	I-Claim
340	effect	_	_	I-Claim
341	can	_	_	I-Claim
342	be	_	_	I-Claim
343	confirmed	_	_	I-Claim
344	.	_	_	I-Claim

345	This	_	_	O
346	study	_	_	O
347	addressed	_	_	O
348	the	_	_	O
349	effects	_	_	O
350	of	_	_	O
351	pilates	_	_	O
352	exercise	_	_	O
353	,	_	_	O
354	as	_	_	O
355	a	_	_	O
356	new	_	_	O
357	approach	_	_	O
358	,	_	_	O
359	on	_	_	O
360	functional	_	_	O
361	capacity	_	_	O
362	,	_	_	O
363	fatigue	_	_	O
364	,	_	_	O
365	depression	_	_	O
366	and	_	_	O
367	quality	_	_	O
368	of	_	_	O
369	life	_	_	O
370	in	_	_	O
371	breast	_	_	O
372	cancer	_	_	O
373	patients	_	_	O
374	in	_	_	O
375	whom	_	_	O
376	there	_	_	O
377	are	_	_	O
378	doubts	_	_	O
379	regarding	_	_	O
380	the	_	_	O
381	efficacy	_	_	O
382	and	_	_	O
383	usefulness	_	_	O
384	of	_	_	O
385	the	_	_	O
386	exercise	_	_	O
387	.	_	_	O


0	Treatment-induced	_	_	O
1	arm	_	_	O
2	lymphoedema	_	_	O
3	is	_	_	O
4	a	_	_	O
5	common	_	_	O
6	and	_	_	O
7	distressing	_	_	O
8	complication	_	_	O
9	of	_	_	O
10	curative	_	_	O
11	surgery	_	_	O
12	and	_	_	O
13	radiotherapy	_	_	O
14	for	_	_	O
15	early	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	A	_	_	O
20	number	_	_	O
21	of	_	_	O
22	studies	_	_	O
23	testing	_	_	O
24	alpha-tocopherol	_	_	O
25	(	_	_	O
26	vitamin	_	_	O
27	E	_	_	O
28	)	_	_	O
29	and	_	_	O
30	pentoxifylline	_	_	O
31	suggest	_	_	O
32	evidence	_	_	O
33	of	_	_	O
34	clinical	_	_	O
35	regression	_	_	O
36	of	_	_	O
37	superficial	_	_	O
38	radiation-induced	_	_	O
39	fibrosis	_	_	O
40	but	_	_	O
41	there	_	_	O
42	is	_	_	O
43	only	_	_	O
44	very	_	_	O
45	limited	_	_	O
46	evidence	_	_	O
47	from	_	_	O
48	randomised	_	_	O
49	trials	_	_	O
50	.	_	_	O

51	Arm	_	_	O
52	lymphoedema	_	_	O
53	after	_	_	O
54	lymphatic	_	_	O
55	radiotherapy	_	_	O
56	and	_	_	O
57	surgery	_	_	O
58	has	_	_	O
59	been	_	_	O
60	used	_	_	O
61	in	_	_	O
62	the	_	_	O
63	present	_	_	O
64	study	_	_	O
65	as	_	_	O
66	a	_	_	O
67	clinical	_	_	O
68	system	_	_	O
69	for	_	_	O
70	testing	_	_	O
71	these	_	_	O
72	drugs	_	_	O
73	in	_	_	O
74	a	_	_	O
75	double-blind	_	_	O
76	placebo-controlled	_	_	O
77	randomised	_	_	O
78	phase	_	_	O
79	II	_	_	O
80	trial	_	_	O
81	.	_	_	O

82	Sixty-eight	_	_	O
83	eligible	_	_	O
84	research	_	_	O
85	volunteers	_	_	O
86	with	_	_	O
87	a	_	_	O
88	minimum	_	_	O
89	20	_	_	O
90	%	_	_	O
91	increase	_	_	O
92	in	_	_	O
93	arm	_	_	O
94	volume	_	_	O
95	at	_	_	O
96	a	_	_	O
97	median	_	_	O
98	15.5	_	_	O
99	years	_	_	O
100	(	_	_	O
101	range	_	_	O
102	2-41	_	_	O
103	)	_	_	O
104	after	_	_	O
105	axillary/supraclavicular	_	_	O
106	radiotherapy	_	_	O
107	(	_	_	O
108	plus	_	_	O
109	axillary	_	_	O
110	surgery	_	_	O
111	in	_	_	O
112	51/68	_	_	O
113	(	_	_	O
114	75	_	_	O
115	%	_	_	O
116	)	_	_	O
117	cases	_	_	O
118	)	_	_	O
119	were	_	_	O
120	randomised	_	_	O
121	to	_	_	O
122	active	_	_	O
123	drugs	_	_	O
124	or	_	_	O
125	placebo	_	_	O
126	.	_	_	O

127	All	_	_	O
128	volunteers	_	_	O
129	were	_	_	O
130	given	_	_	O
131	dl-alpha	_	_	O
132	tocopheryl	_	_	O
133	acetate	_	_	O
134	500	_	_	O
135	mg	_	_	O
136	twice	_	_	O
137	a	_	_	O
138	day	_	_	O
139	orally	_	_	O
140	plus	_	_	O
141	pentoxifylline	_	_	O
142	400	_	_	O
143	mg	_	_	O
144	twice	_	_	O
145	a	_	_	O
146	day	_	_	O
147	orally	_	_	O
148	,	_	_	O
149	or	_	_	O
150	corresponding	_	_	O
151	placebos	_	_	O
152	,	_	_	O
153	for	_	_	O
154	6	_	_	O
155	months	_	_	O
156	.	_	_	O

157	The	_	_	O
158	primary	_	_	O
159	endpoint	_	_	O
160	was	_	_	O
161	volume	_	_	O
162	of	_	_	O
163	the	_	_	O
164	ipsilateral	_	_	O
165	limb	_	_	O
166	measured	_	_	O
167	opto-electronically	_	_	O
168	using	_	_	O
169	a	_	_	O
170	perometer	_	_	O
171	and	_	_	O
172	expressed	_	_	O
173	as	_	_	O
174	a	_	_	O
175	percentage	_	_	O
176	of	_	_	O
177	the	_	_	O
178	contralateral	_	_	O
179	limb	_	_	O
180	volume	_	_	O
181	.	_	_	O

182	At	_	_	B-Premise
183	12	_	_	I-Premise
184	months	_	_	I-Premise
185	post-randomisation	_	_	I-Premise
186	,	_	_	I-Premise
187	there	_	_	I-Premise
188	was	_	_	I-Premise
189	no	_	_	I-Premise
190	significant	_	_	I-Premise
191	difference	_	_	I-Premise
192	between	_	_	I-Premise
193	treatment	_	_	I-Premise
194	and	_	_	I-Premise
195	control	_	_	I-Premise
196	groups	_	_	I-Premise
197	in	_	_	I-Premise
198	terms	_	_	I-Premise
199	of	_	_	I-Premise
200	arm	_	_	I-Premise
201	volume	_	_	I-Premise
202	.	_	_	I-Premise

203	Absolute	_	_	B-Premise
204	change	_	_	I-Premise
205	in	_	_	I-Premise
206	arm	_	_	I-Premise
207	volume	_	_	I-Premise
208	at	_	_	I-Premise
209	12	_	_	I-Premise
210	months	_	_	I-Premise
211	was	_	_	I-Premise
212	2.5	_	_	I-Premise
213	%	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	-0.40	_	_	I-Premise
219	to	_	_	I-Premise
220	5.3	_	_	I-Premise
221	)	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	treatment	_	_	I-Premise
225	group	_	_	I-Premise
226	compared	_	_	I-Premise
227	to	_	_	I-Premise
228	1.2	_	_	I-Premise
229	%	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	-2.8	_	_	I-Premise
235	to	_	_	I-Premise
236	5.1	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	placebo	_	_	I-Premise
241	group	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	difference	_	_	I-Premise
245	in	_	_	I-Premise
246	mean	_	_	I-Premise
247	volume	_	_	I-Premise
248	change	_	_	I-Premise
249	between	_	_	I-Premise
250	randomisation	_	_	I-Premise
251	groups	_	_	I-Premise
252	at	_	_	I-Premise
253	12	_	_	I-Premise
254	months	_	_	I-Premise
255	was	_	_	I-Premise
256	not	_	_	I-Premise
257	statistically	_	_	I-Premise
258	significant	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	0.6	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	-1.3	_	_	I-Premise
266	%	_	_	I-Premise
267	(	_	_	I-Premise
268	95	_	_	I-Premise
269	%	_	_	I-Premise
270	CI	_	_	I-Premise
271	-6.1	_	_	I-Premise
272	to	_	_	I-Premise
273	3.5	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	nor	_	_	I-Premise
277	was	_	_	I-Premise
278	there	_	_	I-Premise
279	a	_	_	I-Premise
280	significant	_	_	I-Premise
281	difference	_	_	I-Premise
282	in	_	_	I-Premise
283	response	_	_	I-Premise
284	at	_	_	I-Premise
285	6	_	_	I-Premise
286	months	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	0.7	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	where	_	_	I-Premise
294	mean	_	_	I-Premise
295	change	_	_	I-Premise
296	in	_	_	I-Premise
297	arm	_	_	I-Premise
298	volume	_	_	I-Premise
299	from	_	_	I-Premise
300	baseline	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	treatment	_	_	I-Premise
304	and	_	_	I-Premise
305	placebo	_	_	I-Premise
306	groups	_	_	I-Premise
307	was	_	_	I-Premise
308	-2.3	_	_	I-Premise
309	%	_	_	I-Premise
310	(	_	_	I-Premise
311	95	_	_	I-Premise
312	%	_	_	I-Premise
313	CI	_	_	I-Premise
314	-7.9	_	_	I-Premise
315	to	_	_	I-Premise
316	3.4	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	-1.1	_	_	I-Premise
320	%	_	_	I-Premise
321	(	_	_	I-Premise
322	95	_	_	I-Premise
323	%	_	_	I-Premise
324	CI	_	_	I-Premise
325	-3.9	_	_	I-Premise
326	to	_	_	I-Premise
327	1.7	_	_	I-Premise
328	)	_	_	I-Premise
329	,	_	_	I-Premise
330	respectively	_	_	I-Premise
331	.	_	_	I-Premise

332	There	_	_	B-Premise
333	were	_	_	I-Premise
334	no	_	_	I-Premise
335	significant	_	_	I-Premise
336	differences	_	_	I-Premise
337	between	_	_	I-Premise
338	randomised	_	_	I-Premise
339	groups	_	_	I-Premise
340	in	_	_	I-Premise
341	terms	_	_	I-Premise
342	of	_	_	I-Premise
343	secondary	_	_	I-Premise
344	endpoints	_	_	I-Premise
345	,	_	_	I-Premise
346	including	_	_	I-Premise
347	tissue	_	_	I-Premise
348	induration	_	_	I-Premise
349	(	_	_	I-Premise
350	fibrosis	_	_	I-Premise
351	)	_	_	I-Premise
352	in	_	_	I-Premise
353	the	_	_	I-Premise
354	irradiated	_	_	I-Premise
355	breast	_	_	I-Premise
356	or	_	_	I-Premise
357	chest	_	_	I-Premise
358	wall	_	_	I-Premise
359	,	_	_	I-Premise
360	pectoral	_	_	I-Premise
361	fold	_	_	I-Premise
362	or	_	_	I-Premise
363	supraclavicular	_	_	I-Premise
364	fossa	_	_	I-Premise
365	,	_	_	I-Premise
366	change	_	_	I-Premise
367	in	_	_	I-Premise
368	photographic	_	_	I-Premise
369	breast/chest	_	_	I-Premise
370	wall	_	_	I-Premise
371	appearance	_	_	I-Premise
372	or	_	_	I-Premise
373	patient	_	_	I-Premise
374	self-assessment	_	_	I-Premise
375	of	_	_	I-Premise
376	function	_	_	I-Premise
377	and	_	_	I-Premise
378	Quality	_	_	I-Premise
379	of	_	_	I-Premise
380	Life	_	_	I-Premise
381	at	_	_	I-Premise
382	either	_	_	I-Premise
383	6	_	_	I-Premise
384	or	_	_	I-Premise
385	12	_	_	I-Premise
386	months	_	_	I-Premise
387	.	_	_	I-Premise

388	The	_	_	B-Claim
389	study	_	_	I-Claim
390	fails	_	_	I-Claim
391	to	_	_	I-Claim
392	demonstrate	_	_	I-Claim
393	efficacy	_	_	I-Claim
394	of	_	_	I-Claim
395	dl-alpha	_	_	I-Claim
396	tocopheryl	_	_	I-Claim
397	acetate	_	_	I-Claim
398	plus	_	_	I-Claim
399	pentoxifylline	_	_	I-Claim
400	in	_	_	I-Claim
401	patients	_	_	I-Claim
402	with	_	_	I-Claim
403	arm	_	_	I-Claim
404	lymphoedema	_	_	I-Claim
405	following	_	_	I-Claim
406	axillary	_	_	I-Claim
407	surgery	_	_	I-Claim
408	and	_	_	I-Claim
409	lymphatic	_	_	I-Claim
410	radiotherapy	_	_	I-Claim
411	,	_	_	I-Claim
412	nor	_	_	I-Claim
413	does	_	_	I-Claim
414	it	_	_	I-Claim
415	suggest	_	_	I-Claim
416	any	_	_	I-Claim
417	benefits	_	_	I-Claim
418	of	_	_	I-Claim
419	these	_	_	I-Claim
420	drugs	_	_	I-Claim
421	in	_	_	I-Claim
422	radiation-induced	_	_	I-Claim
423	induration	_	_	I-Claim
424	(	_	_	I-Claim
425	fibrosis	_	_	I-Claim
426	)	_	_	I-Claim
427	in	_	_	I-Claim
428	the	_	_	I-Claim
429	breast	_	_	I-Claim
430	,	_	_	I-Claim
431	chest	_	_	I-Claim
432	wall	_	_	I-Claim
433	,	_	_	I-Claim
434	pectoral	_	_	I-Claim
435	fold	_	_	I-Claim
436	,	_	_	I-Claim
437	axilla	_	_	I-Claim
438	or	_	_	I-Claim
439	supraclavicular	_	_	I-Claim
440	fossa	_	_	I-Claim
441	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	advanced	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	will	_	_	O
7	develop	_	_	O
8	recurrent	_	_	O
9	disease	_	_	O
10	.	_	_	O

11	For	_	_	B-Premise
12	those	_	_	I-Premise
13	patients	_	_	I-Premise
14	who	_	_	I-Premise
15	have	_	_	I-Premise
16	recurrence	_	_	I-Premise
17	of	_	_	I-Premise
18	disease	_	_	I-Premise
19	at	_	_	I-Premise
20	least	_	_	I-Premise
21	6	_	_	I-Premise
22	months	_	_	I-Premise
23	after	_	_	I-Premise
24	initial	_	_	I-Premise
25	therapy	_	_	I-Premise
26	,	_	_	I-Premise
27	the	_	_	I-Premise
28	paclitaxel-platinum	_	_	I-Premise
29	combination	_	_	I-Premise
30	has	_	_	I-Premise
31	been	_	_	I-Premise
32	shown	_	_	I-Premise
33	to	_	_	I-Premise
34	be	_	_	I-Premise
35	a	_	_	I-Premise
36	superior	_	_	I-Premise
37	treatment	_	_	I-Premise
38	to	_	_	I-Premise
39	platinum	_	_	I-Premise
40	monotherapy	_	_	I-Premise
41	.	_	_	I-Premise

42	However	_	_	B-Claim
43	,	_	_	I-Claim
44	many	_	_	I-Claim
45	patients	_	_	I-Claim
46	develop	_	_	I-Claim
47	clinically	_	_	I-Claim
48	relevant	_	_	I-Claim
49	neurotoxicity	_	_	I-Claim
50	,	_	_	I-Claim
51	frequently	_	_	I-Claim
52	resulting	_	_	I-Claim
53	in	_	_	I-Claim
54	treatment	_	_	I-Claim
55	discontinuation	_	_	I-Claim
56	.	_	_	I-Claim

57	The	_	_	O
58	efficacy	_	_	O
59	and	_	_	O
60	safety	_	_	O
61	of	_	_	O
62	an	_	_	O
63	alternative	_	_	O
64	regimen	_	_	O
65	that	_	_	O
66	does	_	_	O
67	not	_	_	O
68	show	_	_	O
69	significant	_	_	O
70	neurotoxicity	_	_	O
71	were	_	_	O
72	evaluated	_	_	O
73	by	_	_	O
74	comparing	_	_	O
75	gemcitabine-carboplatin	_	_	O
76	with	_	_	O
77	carboplatin	_	_	O
78	in	_	_	O
79	platinum-sensitive	_	_	O
80	recurrent	_	_	O
81	ovarian	_	_	O
82	cancer	_	_	O
83	patients	_	_	O
84	in	_	_	O
85	a	_	_	O
86	Gynecologic	_	_	O
87	Cancer	_	_	O
88	InterGroup	_	_	O
89	trial	_	_	O
90	of	_	_	O
91	the	_	_	O
92	Arbeitsgemeinschaft	_	_	O
93	Gynakologische	_	_	O
94	Onkologie	_	_	O
95	Ovarian	_	_	O
96	Cancer	_	_	O
97	Study	_	_	O
98	Group	_	_	O
99	,	_	_	O
100	the	_	_	O
101	National	_	_	O
102	Cancer	_	_	O
103	Institute	_	_	O
104	of	_	_	O
105	Canada	_	_	O
106	Clinical	_	_	O
107	Trials	_	_	O
108	Group	_	_	O
109	,	_	_	O
110	and	_	_	O
111	the	_	_	O
112	European	_	_	O
113	Organisation	_	_	O
114	for	_	_	O
115	Research	_	_	O
116	and	_	_	O
117	Treatment	_	_	O
118	of	_	_	O
119	Cancer	_	_	O
120	Gynaecological	_	_	O
121	Cancer	_	_	O
122	Group	_	_	O
123	.	_	_	O

124	Participants	_	_	O
125	with	_	_	O
126	recurrent	_	_	O
127	platinum-sensitive	_	_	O
128	ovarian	_	_	O
129	cancer	_	_	O
130	were	_	_	O
131	randomly	_	_	O
132	assigned	_	_	O
133	to	_	_	O
134	receive	_	_	O
135	either	_	_	O
136	gemcitabine-carboplatin	_	_	O
137	or	_	_	O
138	carboplatin	_	_	O
139	every	_	_	O
140	21	_	_	O
141	days	_	_	O
142	.	_	_	O

143	The	_	_	O
144	primary	_	_	O
145	objective	_	_	O
146	was	_	_	O
147	to	_	_	O
148	compare	_	_	O
149	progression-free	_	_	O
150	survival	_	_	O
151	(	_	_	O
152	PFS	_	_	O
153	)	_	_	O
154	between	_	_	O
155	the	_	_	O
156	groups	_	_	O
157	.	_	_	O

158	From	_	_	O
159	September	_	_	O
160	1999	_	_	O
161	to	_	_	O
162	April	_	_	O
163	2002	_	_	O
164	,	_	_	O
165	356	_	_	O
166	patients	_	_	O
167	(	_	_	O
168	178	_	_	O
169	participants	_	_	O
170	received	_	_	O
171	gemcitabine-carboplatin	_	_	O
172	,	_	_	O
173	178	_	_	O
174	received	_	_	O
175	carboplatin	_	_	O
176	only	_	_	O
177	)	_	_	O
178	were	_	_	O
179	randomized	_	_	O
180	to	_	_	O
181	treatment	_	_	O
182	.	_	_	O

183	Patients	_	_	O
184	received	_	_	O
185	six	_	_	O
186	cycles	_	_	O
187	of	_	_	O
188	either	_	_	O
189	gemcitabine-carboplatin	_	_	O
190	or	_	_	O
191	carboplatin	_	_	O
192	.	_	_	O

193	With	_	_	B-Premise
194	a	_	_	I-Premise
195	median	_	_	I-Premise
196	follow-up	_	_	I-Premise
197	of	_	_	I-Premise
198	17	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	median	_	_	I-Premise
202	PFS	_	_	I-Premise
203	was	_	_	I-Premise
204	8.6	_	_	I-Premise
205	months	_	_	I-Premise
206	for	_	_	I-Premise
207	gemcitabine-carboplatin	_	_	I-Premise
208	(	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	confidence	_	_	I-Premise
212	interval	_	_	I-Premise
213	[	_	_	I-Premise
214	CI	_	_	I-Premise
215	]	_	_	I-Premise
216	7.9-9.7	_	_	I-Premise
217	months	_	_	I-Premise
218	)	_	_	I-Premise
219	and	_	_	I-Premise
220	5.8	_	_	I-Premise
221	months	_	_	I-Premise
222	for	_	_	I-Premise
223	carboplatin	_	_	I-Premise
224	(	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	CI	_	_	I-Premise
228	5.2-7.1	_	_	I-Premise
229	months	_	_	I-Premise
230	;	_	_	I-Premise
231	hazard	_	_	I-Premise
232	ratio	_	_	I-Premise
233	[	_	_	I-Premise
234	HR	_	_	I-Premise
235	]	_	_	I-Premise
236	0.72	_	_	I-Premise
237	[	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	0.58-0.90	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	0.0032	_	_	I-Premise
246	]	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	response	_	_	I-Premise
251	rate	_	_	I-Premise
252	for	_	_	I-Premise
253	the	_	_	I-Premise
254	gemcitabine-carboplatin	_	_	I-Premise
255	group	_	_	I-Premise
256	was	_	_	I-Premise
257	47.2	_	_	I-Premise
258	%	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	39.9-54.5	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	and	_	_	I-Premise
267	30.9	_	_	I-Premise
268	%	_	_	I-Premise
269	for	_	_	I-Premise
270	carboplatin	_	_	I-Premise
271	group	_	_	I-Premise
272	(	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	24.1-37.7	_	_	I-Premise
277	%	_	_	I-Premise
278	;	_	_	I-Premise
279	P	_	_	I-Premise
280	=	_	_	I-Premise
281	0.0016	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Premise
285	HR	_	_	I-Premise
286	for	_	_	I-Premise
287	overall	_	_	I-Premise
288	survival	_	_	I-Premise
289	was	_	_	I-Premise
290	0.96	_	_	I-Premise
291	(	_	_	I-Premise
292	95	_	_	I-Premise
293	%	_	_	I-Premise
294	CI	_	_	I-Premise
295	0.75-1.23	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	0.7349	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Patients	_	_	B-Premise
303	treated	_	_	I-Premise
304	with	_	_	I-Premise
305	gemcitabine-carboplatin	_	_	I-Premise
306	reported	_	_	I-Premise
307	significantly	_	_	I-Premise
308	faster	_	_	I-Premise
309	palliation	_	_	I-Premise
310	of	_	_	I-Premise
311	abdominal	_	_	I-Premise
312	symptoms	_	_	I-Premise
313	and	_	_	I-Premise
314	a	_	_	I-Premise
315	significantly	_	_	I-Premise
316	improved	_	_	I-Premise
317	global	_	_	I-Premise
318	quality	_	_	I-Premise
319	of	_	_	I-Premise
320	life	_	_	I-Premise
321	.	_	_	I-Premise

322	Gemcitabine-carboplatin	_	_	B-Claim
323	treatment	_	_	I-Claim
324	significantly	_	_	I-Claim
325	improves	_	_	I-Claim
326	the	_	_	I-Claim
327	PFS	_	_	I-Claim
328	of	_	_	I-Claim
329	patients	_	_	I-Claim
330	with	_	_	I-Claim
331	platinum-sensitive	_	_	I-Claim
332	recurrent	_	_	I-Claim
333	ovarian	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	cisplatin	_	_	O
4	and	_	_	O
5	etoposide	_	_	O
6	(	_	_	O
7	PE	_	_	O
8	)	_	_	O
9	has	_	_	O
10	been	_	_	O
11	a	_	_	O
12	standard	_	_	O
13	treatment	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	poor-prognosis	_	_	O
18	small	_	_	O
19	cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	SCLC	_	_	O
24	)	_	_	O
25	.	_	_	O

26	This	_	_	O
27	non-inferiority	_	_	O
28	design	_	_	O
29	trial	_	_	O
30	aimed	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	whether	_	_	O
34	the	_	_	O
35	combination	_	_	O
36	of	_	_	O
37	gemcitabine	_	_	O
38	and	_	_	O
39	carboplatin	_	_	O
40	(	_	_	O
41	GC	_	_	O
42	)	_	_	O
43	results	_	_	O
44	in	_	_	O
45	similar	_	_	O
46	survival	_	_	O
47	but	_	_	O
48	is	_	_	O
49	less	_	_	O
50	toxic	_	_	O
51	with	_	_	O
52	better	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	.	_	_	O

57	Previously	_	_	O
58	untreated	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	SCLC	_	_	O
62	with	_	_	O
63	extensive	_	_	O
64	disease	_	_	O
65	or	_	_	O
66	limited	_	_	O
67	stage	_	_	O
68	with	_	_	O
69	poor	_	_	O
70	prognostic	_	_	O
71	factors	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	six	_	_	O
77	3-weekly	_	_	O
78	cycles	_	_	O
79	of	_	_	O
80	GC	_	_	O
81	or	_	_	O
82	PE	_	_	O
83	.	_	_	O

84	241	_	_	O
85	patients	_	_	O
86	(	_	_	O
87	121	_	_	O
88	GC	_	_	O
89	,	_	_	O
90	120	_	_	O
91	PE	_	_	O
92	)	_	_	O
93	were	_	_	O
94	recruited	_	_	O
95	,	_	_	O
96	of	_	_	O
97	which	_	_	O
98	216	_	_	O
99	(	_	_	O
100	90	_	_	O
101	%	_	_	O
102	)	_	_	O
103	had	_	_	O
104	died	_	_	O
105	.	_	_	O

106	There	_	_	B-Premise
107	was	_	_	I-Premise
108	no	_	_	I-Premise
109	difference	_	_	I-Premise
110	in	_	_	I-Premise
111	overall	_	_	I-Premise
112	survival	_	_	I-Premise
113	(	_	_	I-Premise
114	HR	_	_	I-Premise
115	1.01	_	_	I-Premise
116	,	_	_	I-Premise
117	95	_	_	I-Premise
118	%	_	_	I-Premise
119	CI	_	_	I-Premise
120	0.77	_	_	I-Premise
121	to	_	_	I-Premise
122	1.32	_	_	I-Premise
123	)	_	_	I-Premise
124	.	_	_	I-Premise

125	Median	_	_	B-Premise
126	survival	_	_	I-Premise
127	with	_	_	I-Premise
128	GC	_	_	I-Premise
129	and	_	_	I-Premise
130	PE	_	_	I-Premise
131	was	_	_	I-Premise
132	8.0	_	_	I-Premise
133	and	_	_	I-Premise
134	8.1	_	_	I-Premise
135	months	_	_	I-Premise
136	,	_	_	I-Premise
137	respectively	_	_	I-Premise
138	.	_	_	I-Premise

139	Median	_	_	B-Premise
140	progression-free	_	_	I-Premise
141	survival	_	_	I-Premise
142	was	_	_	I-Premise
143	5.9	_	_	I-Premise
144	months	_	_	I-Premise
145	with	_	_	I-Premise
146	GC	_	_	I-Premise
147	and	_	_	I-Premise
148	6.3	_	_	I-Premise
149	months	_	_	I-Premise
150	with	_	_	I-Premise
151	PE	_	_	I-Premise
152	.	_	_	I-Premise

153	Grade	_	_	B-Premise
154	3	_	_	I-Premise
155	or	_	_	I-Premise
156	4	_	_	I-Premise
157	myelosuppressions	_	_	I-Premise
158	were	_	_	I-Premise
159	more	_	_	I-Premise
160	frequent	_	_	I-Premise
161	with	_	_	I-Premise
162	GC	_	_	I-Premise
163	(	_	_	I-Premise
164	anaemia	_	_	I-Premise
165	:	_	_	I-Premise
166	14	_	_	I-Premise
167	%	_	_	I-Premise
168	GC	_	_	I-Premise
169	vs	_	_	I-Premise
170	2	_	_	I-Premise
171	%	_	_	I-Premise
172	PE	_	_	I-Premise
173	;	_	_	I-Premise
174	leucopenia	_	_	I-Premise
175	:	_	_	I-Premise
176	32	_	_	I-Premise
177	%	_	_	I-Premise
178	GC	_	_	I-Premise
179	vs	_	_	I-Premise
180	13	_	_	I-Premise
181	%	_	_	I-Premise
182	PE	_	_	I-Premise
183	;	_	_	I-Premise
184	thrombocytopenia	_	_	I-Premise
185	:	_	_	I-Premise
186	22	_	_	I-Premise
187	%	_	_	I-Premise
188	GC	_	_	I-Premise
189	vs	_	_	I-Premise
190	4	_	_	I-Premise
191	%	_	_	I-Premise
192	PE	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	but	_	_	B-Premise
196	these	_	_	I-Premise
197	were	_	_	I-Premise
198	not	_	_	I-Premise
199	associated	_	_	I-Premise
200	with	_	_	I-Premise
201	increased	_	_	I-Premise
202	hospital	_	_	I-Premise
203	admissions	_	_	I-Premise
204	,	_	_	I-Premise
205	infections	_	_	I-Premise
206	or	_	_	I-Premise
207	fatalities	_	_	I-Premise
208	.	_	_	I-Premise

209	Grade	_	_	B-Premise
210	2-3	_	_	I-Premise
211	alopecia	_	_	I-Premise
212	(	_	_	I-Premise
213	68	_	_	I-Premise
214	%	_	_	I-Premise
215	PE	_	_	I-Premise
216	vs	_	_	I-Premise
217	17	_	_	I-Premise
218	%	_	_	I-Premise
219	GC	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	nausea	_	_	I-Premise
223	(	_	_	I-Premise
224	43	_	_	I-Premise
225	%	_	_	I-Premise
226	PE	_	_	I-Premise
227	vs	_	_	I-Premise
228	26	_	_	I-Premise
229	%	_	_	I-Premise
230	GC	_	_	I-Premise
231	)	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	frequent	_	_	I-Premise
235	with	_	_	I-Premise
236	PE	_	_	I-Premise
237	.	_	_	I-Premise

238	Patients	_	_	O
239	given	_	_	O
240	GC	_	_	O
241	received	_	_	O
242	more	_	_	O
243	chemotherapy	_	_	O
244	as	_	_	O
245	outpatients	_	_	O
246	(	_	_	O
247	89	_	_	O
248	%	_	_	O
249	GC	_	_	O
250	vs	_	_	O
251	66	_	_	O
252	%	_	_	O
253	PE	_	_	O
254	of	_	_	O
255	treatment	_	_	O
256	cycles	_	_	O
257	)	_	_	O
258	.	_	_	O

259	In	_	_	B-Premise
260	QoL	_	_	I-Premise
261	questionnaires	_	_	I-Premise
262	,	_	_	I-Premise
263	more	_	_	I-Premise
264	patients	_	_	I-Premise
265	receiving	_	_	I-Premise
266	PE	_	_	I-Premise
267	reported	_	_	I-Premise
268	being	_	_	I-Premise
269	upset	_	_	I-Premise
270	by	_	_	I-Premise
271	hair	_	_	I-Premise
272	loss	_	_	I-Premise
273	(	_	_	I-Premise
274	p	_	_	I-Premise
275	=	_	_	I-Premise
276	0.004	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	impaired	_	_	I-Premise
280	cognitive	_	_	I-Premise
281	functioning	_	_	I-Premise
282	(	_	_	I-Premise
283	p	_	_	I-Premise
284	=	_	_	I-Premise
285	0.04	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	GC	_	_	B-Claim
289	is	_	_	I-Claim
290	as	_	_	I-Claim
291	effective	_	_	I-Claim
292	as	_	_	I-Claim
293	PE	_	_	I-Claim
294	in	_	_	I-Claim
295	terms	_	_	I-Claim
296	of	_	_	I-Claim
297	overall	_	_	I-Claim
298	survival	_	_	I-Claim
299	and	_	_	I-Claim
300	progression-free	_	_	I-Claim
301	survival	_	_	I-Claim
302	and	_	_	I-Claim
303	has	_	_	I-Claim
304	a	_	_	I-Claim
305	toxicity	_	_	I-Claim
306	profile	_	_	I-Claim
307	more	_	_	I-Claim
308	acceptable	_	_	I-Claim
309	to	_	_	I-Claim
310	patients	_	_	I-Claim
311	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	novel	_	_	O
7	coloplasty	_	_	O
8	colonic	_	_	O
9	pouch	_	_	O
10	design	_	_	O
11	in	_	_	O
12	optimizing	_	_	O
13	bowel	_	_	O
14	function	_	_	O
15	after	_	_	O
16	ultralow	_	_	O
17	anterior	_	_	O
18	resection	_	_	O
19	.	_	_	O

20	A	_	_	B-Claim
21	colonic	_	_	I-Claim
22	J-pouch	_	_	I-Claim
23	may	_	_	I-Claim
24	reduce	_	_	I-Claim
25	excessive	_	_	I-Claim
26	stool	_	_	I-Claim
27	frequency	_	_	I-Claim
28	and	_	_	I-Claim
29	incontinence	_	_	I-Claim
30	after	_	_	I-Claim
31	anterior	_	_	I-Claim
32	resection	_	_	I-Claim
33	,	_	_	I-Claim
34	but	_	_	I-Claim
35	at	_	_	I-Claim
36	the	_	_	I-Claim
37	risk	_	_	I-Claim
38	of	_	_	I-Claim
39	evacuation	_	_	I-Claim
40	problems	_	_	I-Claim
41	.	_	_	I-Claim

42	Experimental	_	_	B-Claim
43	surgery	_	_	I-Claim
44	on	_	_	I-Claim
45	pigs	_	_	I-Claim
46	has	_	_	I-Claim
47	suggested	_	_	I-Claim
48	that	_	_	I-Claim
49	a	_	_	I-Claim
50	coloplasty	_	_	I-Claim
51	pouch	_	_	I-Claim
52	(	_	_	I-Claim
53	CP	_	_	I-Claim
54	)	_	_	I-Claim
55	may	_	_	I-Claim
56	be	_	_	I-Claim
57	a	_	_	I-Claim
58	useful	_	_	I-Claim
59	alternative	_	_	I-Claim
60	.	_	_	O

61	Although	_	_	O
62	CP	_	_	O
63	has	_	_	O
64	recently	_	_	O
65	been	_	_	O
66	shown	_	_	O
67	to	_	_	O
68	be	_	_	O
69	feasible	_	_	O
70	in	_	_	O
71	patients	_	_	O
72	,	_	_	O
73	there	_	_	O
74	is	_	_	O
75	no	_	_	O
76	randomized	_	_	O
77	controlled	_	_	O
78	trial	_	_	O
79	comparing	_	_	O
80	bowel	_	_	O
81	function	_	_	O
82	with	_	_	O
83	the	_	_	O
84	J-pouch	_	_	O
85	.	_	_	O

86	After	_	_	O
87	anterior	_	_	O
88	resection	_	_	O
89	for	_	_	O
90	cancer	_	_	O
91	,	_	_	O
92	patients	_	_	O
93	were	_	_	O
94	allocated	_	_	O
95	to	_	_	O
96	either	_	_	O
97	J-pouch	_	_	O
98	or	_	_	O
99	CP-anal	_	_	O
100	anastomoses	_	_	O
101	.	_	_	O

102	Continence	_	_	O
103	scoring	_	_	O
104	,	_	_	O
105	anorectal	_	_	O
106	manometry	_	_	O
107	,	_	_	O
108	and	_	_	O
109	endoanal	_	_	O
110	ultrasound	_	_	O
111	assessments	_	_	O
112	were	_	_	O
113	made	_	_	O
114	before	_	_	O
115	surgery	_	_	O
116	.	_	_	O

117	All	_	_	O
118	complications	_	_	O
119	were	_	_	O
120	recorded	_	_	O
121	,	_	_	O
122	and	_	_	O
123	these	_	_	O
124	preoperative	_	_	O
125	assessments	_	_	O
126	were	_	_	O
127	repeated	_	_	O
128	at	_	_	O
129	4	_	_	O
130	months	_	_	O
131	.	_	_	O

132	The	_	_	O
133	assessments	_	_	O
134	were	_	_	O
135	repeated	_	_	O
136	again	_	_	O
137	at	_	_	O
138	1	_	_	O
139	year	_	_	O
140	,	_	_	O
141	and	_	_	O
142	a	_	_	O
143	quality	_	_	O
144	of	_	_	O
145	life	_	_	O
146	questionnaire	_	_	O
147	was	_	_	O
148	added	_	_	O
149	.	_	_	O

150	Eighty-eight	_	_	O
151	patients	_	_	O
152	were	_	_	O
153	recruited	_	_	O
154	from	_	_	O
155	October	_	_	O
156	1998	_	_	O
157	to	_	_	O
158	April	_	_	O
159	2000	_	_	O
160	.	_	_	O

161	Both	_	_	O
162	groups	_	_	O
163	were	_	_	O
164	well	_	_	O
165	matched	_	_	O
166	for	_	_	O
167	age	_	_	O
168	,	_	_	O
169	gender	_	_	O
170	,	_	_	O
171	staging	_	_	O
172	,	_	_	O
173	adjuvant	_	_	O
174	therapy	_	_	O
175	,	_	_	O
176	and	_	_	O
177	mean	_	_	O
178	follow-up	_	_	O
179	.	_	_	O

180	There	_	_	O
181	were	_	_	O
182	no	_	_	O
183	differences	_	_	O
184	in	_	_	O
185	the	_	_	O
186	intraoperative	_	_	O
187	time	_	_	O
188	and	_	_	O
189	hospital	_	_	O
190	stay	_	_	O
191	.	_	_	O

192	CP	_	_	B-Premise
193	resulted	_	_	I-Premise
194	in	_	_	I-Premise
195	more	_	_	I-Premise
196	anastomotic	_	_	I-Premise
197	leaks	_	_	I-Premise
198	.	_	_	I-Premise

199	At	_	_	B-Premise
200	4	_	_	I-Premise
201	months	_	_	I-Premise
202	,	_	_	I-Premise
203	J-pouch	_	_	I-Premise
204	patients	_	_	I-Premise
205	had	_	_	I-Premise
206	10.3	_	_	I-Premise
207	%	_	_	I-Premise
208	less	_	_	I-Premise
209	stool	_	_	I-Premise
210	fragmentation	_	_	I-Premise
211	but	_	_	I-Premise
212	poorer	_	_	I-Premise
213	stool	_	_	I-Premise
214	deferment	_	_	I-Premise
215	and	_	_	I-Premise
216	more	_	_	I-Premise
217	nocturnal	_	_	I-Premise
218	leakage	_	_	I-Premise
219	.	_	_	I-Premise

220	However	_	_	O
221	,	_	_	O
222	there	_	_	B-Premise
223	were	_	_	I-Premise
224	no	_	_	I-Premise
225	differences	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	bowel	_	_	I-Premise
229	function	_	_	I-Premise
230	,	_	_	I-Premise
231	continence	_	_	I-Premise
232	score	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	quality	_	_	I-Premise
236	of	_	_	I-Premise
237	life	_	_	I-Premise
238	at	_	_	I-Premise
239	1	_	_	I-Premise
240	year	_	_	I-Premise
241	.	_	_	I-Premise

242	There	_	_	B-Premise
243	were	_	_	I-Premise
244	no	_	_	I-Premise
245	differences	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	anorectal	_	_	I-Premise
249	manometry	_	_	I-Premise
250	and	_	_	I-Premise
251	endoanal	_	_	I-Premise
252	ultrasound	_	_	I-Premise
253	findings	_	_	I-Premise
254	.	_	_	I-Premise

255	Coloplasty	_	_	B-Claim
256	pouches	_	_	I-Claim
257	resulted	_	_	I-Claim
258	in	_	_	I-Claim
259	more	_	_	I-Claim
260	anastomotic	_	_	I-Claim
261	leaks	_	_	I-Claim
262	and	_	_	I-Claim
263	minimal	_	_	I-Claim
264	differences	_	_	I-Claim
265	in	_	_	I-Claim
266	bowel	_	_	I-Claim
267	function	_	_	I-Claim
268	.	_	_	I-Claim

269	At	_	_	O
270	present	_	_	O
271	,	_	_	O
272	the	_	_	B-Claim
273	J-pouch	_	_	I-Claim
274	remains	_	_	I-Claim
275	the	_	_	I-Claim
276	benchmark	_	_	I-Claim
277	for	_	_	I-Claim
278	routine	_	_	I-Claim
279	clinical	_	_	I-Claim
280	practice	_	_	I-Claim
281	,	_	_	I-Claim
282	and	_	_	O
283	due	_	_	B-Claim
284	care	_	_	I-Claim
285	(	_	_	I-Claim
286	including	_	_	I-Claim
287	defunctioning	_	_	I-Claim
288	stoma	_	_	I-Claim
289	)	_	_	I-Claim
290	should	_	_	I-Claim
291	be	_	_	I-Claim
292	exercised	_	_	I-Claim
293	in	_	_	I-Claim
294	situations	_	_	I-Claim
295	requiring	_	_	I-Claim
296	CP	_	_	I-Claim
297	.	_	_	I-Claim


0	From	_	_	O
1	1984	_	_	O
2	to	_	_	O
3	1989	_	_	O
4	,	_	_	O
5	the	_	_	O
6	Swiss	_	_	O
7	Group	_	_	O
8	for	_	_	O
9	Clinical	_	_	O
10	Cancer	_	_	O
11	Research	_	_	O
12	(	_	_	O
13	SAKK	_	_	O
14	)	_	_	O
15	performed	_	_	O
16	a	_	_	O
17	randomized	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	trial	_	_	O
21	comparing	_	_	O
22	early	_	_	O
23	versus	_	_	O
24	late	_	_	O
25	alternating	_	_	O
26	chemotherapy	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	.	_	_	O

34	406	_	_	O
35	eligible	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	entered	_	_	O
39	into	_	_	O
40	the	_	_	O
41	trial	_	_	O
42	.	_	_	O

43	Regimen	_	_	O
44	A	_	_	O
45	consisted	_	_	O
46	of	_	_	O
47	PAV	_	_	O
48	(	_	_	O
49	cisPlatin	_	_	O
50	,	_	_	O
51	Adriamycin	_	_	O
52	,	_	_	O
53	VP	_	_	O
54	16-213	_	_	O
55	,	_	_	O
56	and	_	_	O
57	Regimen	_	_	O
58	B	_	_	O
59	of	_	_	O
60	CyMOC	_	_	O
61	(	_	_	O
62	Cyclophosphamide	_	_	O
63	,	_	_	O
64	Methotrexate	_	_	O
65	,	_	_	O
66	Oncovin	_	_	O
67	,	_	_	O
68	CCNU	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Cycles	_	_	O
72	were	_	_	O
73	repeated	_	_	O
74	as	_	_	O
75	rapidly	_	_	O
76	as	_	_	O
77	possible	_	_	O
78	.	_	_	O

79	patients	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	either	_	_	O
85	ABABAB	_	_	O
86	(	_	_	O
87	early	_	_	O
88	alternating	_	_	O
89	chemotherapy	_	_	O
90	)	_	_	O
91	or	_	_	O
92	AAABBB	_	_	O
93	(	_	_	O
94	late	_	_	O
95	alternating	_	_	O
96	chemotherapy	_	_	O
97	)	_	_	O
98	.	_	_	O

99	After	_	_	O
100	six	_	_	O
101	cycles	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	limited	_	_	O
105	disease	_	_	O
106	in	_	_	O
107	complete	_	_	O
108	or	_	_	O
109	partial	_	_	O
110	remission	_	_	O
111	and	_	_	O
112	those	_	_	O
113	with	_	_	O
114	extensive	_	_	O
115	disease	_	_	O
116	in	_	_	O
117	complete	_	_	O
118	remission	_	_	O
119	received	_	_	O
120	irradiation	_	_	O
121	to	_	_	O
122	the	_	_	O
123	primary	_	_	O
124	(	_	_	O
125	45	_	_	O
126	Gy	_	_	O
127	)	_	_	O
128	and	_	_	O
129	the	_	_	O
130	CNS	_	_	O
131	(	_	_	O
132	36	_	_	O
133	Gy	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	overall	_	_	I-Premise
138	remission	_	_	I-Premise
139	rate	_	_	I-Premise
140	was	_	_	I-Premise
141	87	_	_	I-Premise
142	%	_	_	I-Premise
143	with	_	_	I-Premise
144	31	_	_	I-Premise
145	%	_	_	I-Premise
146	complete	_	_	I-Premise
147	remissions	_	_	I-Premise
148	.	_	_	I-Premise

149	The	_	_	B-Premise
150	median	_	_	I-Premise
151	survival	_	_	I-Premise
152	of	_	_	I-Premise
153	all	_	_	I-Premise
154	406	_	_	I-Premise
155	eligible	_	_	I-Premise
156	patients	_	_	I-Premise
157	was	_	_	I-Premise
158	346	_	_	I-Premise
159	days	_	_	I-Premise
160	with	_	_	I-Premise
161	15	_	_	I-Premise
162	%	_	_	I-Premise
163	of	_	_	I-Premise
164	the	_	_	I-Premise
165	patients	_	_	I-Premise
166	alive	_	_	I-Premise
167	at	_	_	I-Premise
168	two	_	_	I-Premise
169	years	_	_	I-Premise
170	.	_	_	I-Premise

171	The	_	_	B-Premise
172	overall	_	_	I-Premise
173	remission	_	_	I-Premise
174	rate	_	_	I-Premise
175	,	_	_	I-Premise
176	the	_	_	I-Premise
177	rate	_	_	I-Premise
178	of	_	_	I-Premise
179	complete	_	_	I-Premise
180	remission	_	_	I-Premise
181	,	_	_	I-Premise
182	the	_	_	I-Premise
183	median	_	_	I-Premise
184	survival	_	_	I-Premise
185	and	_	_	I-Premise
186	the	_	_	I-Premise
187	rate	_	_	I-Premise
188	of	_	_	I-Premise
189	long-term	_	_	I-Premise
190	survival	_	_	I-Premise
191	were	_	_	I-Premise
192	not	_	_	I-Premise
193	significantly	_	_	I-Premise
194	different	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	two	_	_	I-Premise
198	treatment	_	_	I-Premise
199	arms	_	_	I-Premise
200	.	_	_	I-Premise

201	In	_	_	B-Premise
202	limited	_	_	I-Premise
203	disease	_	_	I-Premise
204	the	_	_	I-Premise
205	estimated	_	_	I-Premise
206	percentages	_	_	I-Premise
207	of	_	_	I-Premise
208	survival	_	_	I-Premise
209	at	_	_	I-Premise
210	2	_	_	I-Premise
211	years	_	_	I-Premise
212	were	_	_	I-Premise
213	33	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	early	_	_	I-Premise
218	and	_	_	I-Premise
219	24	_	_	I-Premise
220	%	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	late	_	_	I-Premise
224	alternating	_	_	I-Premise
225	chemotherapy	_	_	I-Premise
226	arms	_	_	I-Premise
227	.	_	_	I-Premise

228	Patients	_	_	B-Premise
229	with	_	_	I-Premise
230	extensive	_	_	I-Premise
231	disease	_	_	I-Premise
232	survived	_	_	I-Premise
233	significantly	_	_	I-Premise
234	longer	_	_	I-Premise
235	with	_	_	I-Premise
236	late	_	_	I-Premise
237	alternating	_	_	I-Premise
238	chemotherapy	_	_	I-Premise
239	than	_	_	I-Premise
240	on	_	_	I-Premise
241	the	_	_	I-Premise
242	early	_	_	I-Premise
243	alternation	_	_	I-Premise
244	regimen	_	_	I-Premise
245	(	_	_	I-Premise
246	median	_	_	I-Premise
247	survival	_	_	I-Premise
248	336	_	_	I-Premise
249	days	_	_	I-Premise
250	versus	_	_	I-Premise
251	301	_	_	I-Premise
252	days	_	_	I-Premise
253	,	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0.01	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	In	_	_	B-Premise
260	the	_	_	I-Premise
261	latter	_	_	I-Premise
262	patients	_	_	I-Premise
263	the	_	_	I-Premise
264	received	_	_	I-Premise
265	dose	_	_	I-Premise
266	intensities	_	_	I-Premise
267	(	_	_	I-Premise
268	RDI	_	_	I-Premise
269	)	_	_	I-Premise
270	of	_	_	I-Premise
271	cisplatin	_	_	I-Premise
272	,	_	_	I-Premise
273	adriamycin	_	_	I-Premise
274	and	_	_	I-Premise
275	etoposide	_	_	I-Premise
276	were	_	_	I-Premise
277	significantly	_	_	I-Premise
278	higher	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	late-alternation	_	_	I-Premise
282	arm	_	_	I-Premise
283	.	_	_	I-Premise

284	Patients	_	_	B-Premise
285	treated	_	_	I-Premise
286	with	_	_	I-Premise
287	early	_	_	I-Premise
288	alternating	_	_	I-Premise
289	chemotherapy	_	_	I-Premise
290	rated	_	_	I-Premise
291	their	_	_	I-Premise
292	tumor	_	_	I-Premise
293	symptoms	_	_	I-Premise
294	,	_	_	I-Premise
295	functional	_	_	I-Premise
296	states	_	_	I-Premise
297	,	_	_	I-Premise
298	fatigue/malaise	_	_	I-Premise
299	and	_	_	I-Premise
300	restriction	_	_	I-Premise
301	of	_	_	I-Premise
302	social	_	_	I-Premise
303	activity	_	_	I-Premise
304	significantly	_	_	I-Premise
305	better	_	_	I-Premise
306	,	_	_	I-Premise
307	reflecting	_	_	I-Premise
308	an	_	_	I-Premise
309	improved	_	_	I-Premise
310	subjective	_	_	I-Premise
311	adjustment	_	_	I-Premise
312	.	_	_	I-Premise

313	Alternating	_	_	B-Claim
314	chemotherapy	_	_	I-Claim
315	with	_	_	I-Claim
316	PAV-CyMOC	_	_	I-Claim
317	plus	_	_	I-Claim
318	consolidating	_	_	I-Claim
319	radiotherapy	_	_	I-Claim
320	is	_	_	I-Claim
321	a	_	_	I-Claim
322	feasible	_	_	I-Claim
323	and	_	_	I-Claim
324	effective	_	_	I-Claim
325	treatment	_	_	I-Claim
326	for	_	_	I-Claim
327	small-cell	_	_	I-Claim
328	lung	_	_	I-Claim
329	cancer	_	_	I-Claim
330	,	_	_	I-Claim
331	with	_	_	I-Claim
332	acceptable	_	_	I-Claim
333	toxicity	_	_	I-Claim
334	.	_	_	I-Claim

335	Whereas	_	_	O
336	patients	_	_	B-Claim
337	with	_	_	I-Claim
338	early	_	_	I-Claim
339	alternating	_	_	I-Claim
340	chemotherapy	_	_	I-Claim
341	achieve	_	_	I-Claim
342	a	_	_	I-Claim
343	better	_	_	I-Claim
344	subjective	_	_	I-Claim
345	adjustment	_	_	I-Claim
346	,	_	_	I-Claim
347	late	_	_	B-Claim
348	alternating	_	_	I-Claim
349	chemotherapy	_	_	I-Claim
350	allows	_	_	I-Claim
351	for	_	_	I-Claim
352	a	_	_	I-Claim
353	higher	_	_	I-Claim
354	RDI	_	_	I-Claim
355	of	_	_	I-Claim
356	cisplatin	_	_	I-Claim
357	,	_	_	I-Claim
358	adriamycin	_	_	I-Claim
359	and	_	_	I-Claim
360	etoposide	_	_	I-Claim
361	,	_	_	I-Claim
362	which	_	_	I-Claim
363	results	_	_	I-Claim
364	in	_	_	I-Claim
365	a	_	_	I-Claim
366	significantly	_	_	I-Claim
367	longer	_	_	I-Claim
368	median	_	_	I-Claim
369	survival	_	_	I-Claim
370	of	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	extensive	_	_	I-Claim
374	disease	_	_	I-Claim
375	.	_	_	I-Claim


0	Assess	_	_	O
1	toxicity	_	_	O
2	and	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	cisplatin	_	_	O
6	(	_	_	O
7	Cis	_	_	O
8	)	_	_	O
9	doublet	_	_	O
10	combinations	_	_	O
11	in	_	_	O
12	advanced	_	_	O
13	and	_	_	O
14	recurrent	_	_	O
15	cervical	_	_	O
16	carcinoma	_	_	O
17	.	_	_	O

18	Patients	_	_	O
19	were	_	_	O
20	randomly	_	_	O
21	assigned	_	_	O
22	to	_	_	O
23	paclitaxel	_	_	O
24	135	_	_	O
25	mg/m	_	_	O
26	(	_	_	O
27	2	_	_	O
28	)	_	_	O
29	over	_	_	O
30	24	_	_	O
31	hours	_	_	O
32	plus	_	_	O
33	Cis	_	_	O
34	50	_	_	O
35	mg/m	_	_	O
36	(	_	_	O
37	2	_	_	O
38	)	_	_	O
39	day	_	_	O
40	2	_	_	O
41	every	_	_	O
42	3	_	_	O
43	weeks	_	_	O
44	(	_	_	O
45	PC	_	_	O
46	,	_	_	O
47	reference	_	_	O
48	arm	_	_	O
49	)	_	_	O
50	;	_	_	O
51	vinorelbine	_	_	O
52	30	_	_	O
53	mg/m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	days	_	_	O
58	1	_	_	O
59	and	_	_	O
60	8	_	_	O
61	plus	_	_	O
62	Cis	_	_	O
63	50	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	day	_	_	O
69	1	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	(	_	_	O
74	VC	_	_	O
75	)	_	_	O
76	;	_	_	O
77	gemcitabine	_	_	O
78	1,000	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	day	_	_	O
84	1	_	_	O
85	and	_	_	O
86	8	_	_	O
87	plus	_	_	O
88	Cis	_	_	O
89	50	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	day	_	_	O
95	1	_	_	O
96	every	_	_	O
97	3	_	_	O
98	weeks	_	_	O
99	(	_	_	O
100	GC	_	_	O
101	)	_	_	O
102	;	_	_	O
103	or	_	_	O
104	topotecan	_	_	O
105	0.75	_	_	O
106	mg/m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	days	_	_	O
111	1	_	_	O
112	,	_	_	O
113	2	_	_	O
114	,	_	_	O
115	and	_	_	O
116	3	_	_	O
117	plus	_	_	O
118	Cis	_	_	O
119	50	_	_	O
120	mg/m	_	_	O
121	(	_	_	O
122	2	_	_	O
123	)	_	_	O
124	day	_	_	O
125	1	_	_	O
126	every	_	_	O
127	3	_	_	O
128	weeks	_	_	O
129	(	_	_	O
130	TC	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Survival	_	_	O
134	was	_	_	O
135	the	_	_	O
136	primary	_	_	O
137	end	_	_	O
138	point	_	_	O
139	with	_	_	O
140	a	_	_	O
141	33	_	_	O
142	%	_	_	O
143	improvement	_	_	O
144	relative	_	_	O
145	to	_	_	O
146	PC	_	_	O
147	considered	_	_	O
148	important	_	_	O
149	(	_	_	O
150	85	_	_	O
151	%	_	_	O
152	power	_	_	O
153	,	_	_	O
154	alpha	_	_	O
155	=	_	_	O
156	5	_	_	O
157	%	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Quality-of-life	_	_	O
161	data	_	_	O
162	were	_	_	O
163	prospectively	_	_	O
164	collected	_	_	O
165	.	_	_	O

166	A	_	_	O
167	total	_	_	O
168	of	_	_	O
169	513	_	_	O
170	patients	_	_	O
171	were	_	_	O
172	enrolled	_	_	O
173	when	_	_	O
174	a	_	_	O
175	planned	_	_	O
176	interim	_	_	O
177	analysis	_	_	O
178	recommended	_	_	O
179	early	_	_	O
180	closure	_	_	O
181	for	_	_	O
182	futility	_	_	O
183	.	_	_	O

184	The	_	_	B-Premise
185	experimental-to-PC	_	_	I-Premise
186	hazard	_	_	I-Premise
187	ratios	_	_	I-Premise
188	of	_	_	I-Premise
189	death	_	_	I-Premise
190	were	_	_	I-Premise
191	1.15	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.79	_	_	I-Premise
198	to	_	_	I-Premise
199	1.67	_	_	I-Premise
200	)	_	_	I-Premise
201	for	_	_	I-Premise
202	VC	_	_	I-Premise
203	,	_	_	I-Premise
204	1.32	_	_	I-Premise
205	(	_	_	I-Premise
206	95	_	_	I-Premise
207	%	_	_	I-Premise
208	CI	_	_	I-Premise
209	,	_	_	I-Premise
210	0.91	_	_	I-Premise
211	to	_	_	I-Premise
212	1.92	_	_	I-Premise
213	)	_	_	I-Premise
214	for	_	_	I-Premise
215	GC	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	1.26	_	_	I-Premise
219	(	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	,	_	_	I-Premise
224	0.86	_	_	I-Premise
225	to	_	_	I-Premise
226	1.82	_	_	I-Premise
227	)	_	_	I-Premise
228	for	_	_	I-Premise
229	TC	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	hazard	_	_	I-Premise
233	ratios	_	_	I-Premise
234	for	_	_	I-Premise
235	progression-free	_	_	I-Premise
236	survival	_	_	I-Premise
237	(	_	_	I-Premise
238	PFS	_	_	I-Premise
239	)	_	_	I-Premise
240	were	_	_	I-Premise
241	1.36	_	_	I-Premise
242	(	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	,	_	_	I-Premise
247	0.97	_	_	I-Premise
248	to	_	_	I-Premise
249	1.90	_	_	I-Premise
250	)	_	_	I-Premise
251	for	_	_	I-Premise
252	VC	_	_	I-Premise
253	,	_	_	I-Premise
254	1.39	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.99	_	_	I-Premise
261	to	_	_	I-Premise
262	1.96	_	_	I-Premise
263	)	_	_	I-Premise
264	for	_	_	I-Premise
265	GC	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	1.27	_	_	I-Premise
269	(	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	,	_	_	I-Premise
274	0.90	_	_	I-Premise
275	to	_	_	I-Premise
276	1.78	_	_	I-Premise
277	)	_	_	I-Premise
278	for	_	_	I-Premise
279	TC	_	_	I-Premise
280	.	_	_	I-Premise

281	Response	_	_	B-Premise
282	rates	_	_	I-Premise
283	(	_	_	I-Premise
284	RRs	_	_	I-Premise
285	)	_	_	I-Premise
286	for	_	_	I-Premise
287	PC	_	_	I-Premise
288	,	_	_	I-Premise
289	VC	_	_	I-Premise
290	,	_	_	I-Premise
291	GC	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	TC	_	_	I-Premise
295	were	_	_	I-Premise
296	29.1	_	_	I-Premise
297	%	_	_	I-Premise
298	,	_	_	I-Premise
299	25.9	_	_	I-Premise
300	%	_	_	I-Premise
301	,	_	_	I-Premise
302	22.3	_	_	I-Premise
303	%	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	23.4	_	_	I-Premise
307	%	_	_	I-Premise
308	,	_	_	I-Premise
309	respectively	_	_	I-Premise
310	.	_	_	I-Premise

311	The	_	_	B-Premise
312	arms	_	_	I-Premise
313	were	_	_	I-Premise
314	comparable	_	_	I-Premise
315	with	_	_	I-Premise
316	respect	_	_	I-Premise
317	to	_	_	I-Premise
318	toxicity	_	_	I-Premise
319	except	_	_	I-Premise
320	for	_	_	I-Premise
321	leucopenia	_	_	I-Premise
322	,	_	_	I-Premise
323	neutropenia	_	_	I-Premise
324	,	_	_	I-Premise
325	infection	_	_	I-Premise
326	,	_	_	I-Premise
327	and	_	_	I-Premise
328	alopecia	_	_	I-Premise
329	.	_	_	I-Premise

330	VC	_	_	B-Claim
331	,	_	_	I-Claim
332	GC	_	_	I-Claim
333	,	_	_	I-Claim
334	and	_	_	I-Claim
335	TC	_	_	I-Claim
336	are	_	_	I-Claim
337	not	_	_	I-Claim
338	superior	_	_	I-Claim
339	to	_	_	I-Claim
340	PC	_	_	I-Claim
341	in	_	_	I-Claim
342	terms	_	_	I-Claim
343	of	_	_	I-Claim
344	overall	_	_	I-Claim
345	survival	_	_	I-Claim
346	(	_	_	I-Claim
347	OS	_	_	I-Claim
348	)	_	_	I-Claim
349	.	_	_	I-Claim

350	However	_	_	B-Claim
351	,	_	_	I-Claim
352	the	_	_	I-Claim
353	trend	_	_	I-Claim
354	in	_	_	I-Claim
355	RR	_	_	I-Claim
356	,	_	_	I-Claim
357	PFS	_	_	I-Claim
358	,	_	_	I-Claim
359	and	_	_	I-Claim
360	OS	_	_	I-Claim
361	favors	_	_	I-Claim
362	PC	_	_	I-Claim
363	.	_	_	I-Claim

364	Differences	_	_	B-Claim
365	in	_	_	I-Claim
366	chemotherapy	_	_	I-Claim
367	scheduling	_	_	I-Claim
368	,	_	_	I-Claim
369	pre-existing	_	_	I-Claim
370	morbidity	_	_	I-Claim
371	,	_	_	I-Claim
372	and	_	_	I-Claim
373	toxicity	_	_	I-Claim
374	are	_	_	I-Claim
375	important	_	_	I-Claim
376	in	_	_	I-Claim
377	individualizing	_	_	I-Claim
378	therapy	_	_	I-Claim
379	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	5-year	_	_	O
3	contrast-enhanced	_	_	O
4	magnetic	_	_	O
5	resonance	_	_	O
6	imaging	_	_	O
7	findings	_	_	O
8	of	_	_	O
9	the	_	_	O
10	REST	_	_	O
11	trial	_	_	O
12	recruits	_	_	O
13	who	_	_	O
14	underwent	_	_	O
15	either	_	_	O
16	uterine	_	_	O
17	artery	_	_	O
18	embolization	_	_	O
19	(	_	_	O
20	UAE	_	_	O
21	)	_	_	O
22	or	_	_	O
23	myomectomy	_	_	O
24	.	_	_	O

25	A	_	_	O
26	total	_	_	O
27	of	_	_	O
28	157	_	_	O
29	patients	_	_	O
30	were	_	_	O
31	randomized	_	_	O
32	to	_	_	O
33	UAE	_	_	O
34	or	_	_	O
35	surgery	_	_	O
36	(	_	_	O
37	hysterectomy	_	_	O
38	or	_	_	O
39	myomectomy	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Ninety-nine	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	had	_	_	O
46	UAE	_	_	O
47	and	_	_	O
48	eight	_	_	O
49	patients	_	_	O
50	who	_	_	O
51	had	_	_	O
52	myomectomy	_	_	O
53	were	_	_	O
54	analyzed	_	_	O
55	.	_	_	O

56	MRI	_	_	O
57	scans	_	_	O
58	at	_	_	O
59	baseline	_	_	O
60	,	_	_	O
61	6	_	_	O
62	months	_	_	O
63	,	_	_	O
64	and	_	_	O
65	5	_	_	O
66	years	_	_	O
67	were	_	_	O
68	independently	_	_	O
69	interpreted	_	_	O
70	by	_	_	O
71	two	_	_	O
72	radiologists	_	_	O
73	.	_	_	O

74	Dominant	_	_	O
75	fibroid	_	_	O
76	diameter	_	_	O
77	,	_	_	O
78	uterine	_	_	O
79	volume	_	_	O
80	,	_	_	O
81	total	_	_	O
82	fibroid	_	_	O
83	infarction	_	_	O
84	(	_	_	O
85	complete	_	_	O
86	100	_	_	O
87	%	_	_	O
88	,	_	_	O
89	almost	_	_	O
90	complete	_	_	O
91	90-99	_	_	O
92	%	_	_	O
93	,	_	_	O
94	partial	_	_	O
95	<	_	_	O
96	90	_	_	O
97	%	_	_	O
98	)	_	_	O
99	,	_	_	O
100	and	_	_	O
101	new	_	_	O
102	fibroid	_	_	O
103	formation	_	_	O
104	were	_	_	O
105	the	_	_	O
106	main	_	_	O
107	parameters	_	_	O
108	assessed	_	_	O
109	and	_	_	O
110	related	_	_	O
111	to	_	_	O
112	the	_	_	O
113	need	_	_	O
114	for	_	_	O
115	reintervention	_	_	O
116	.	_	_	O

117	In	_	_	B-Premise
118	the	_	_	I-Premise
119	UAE	_	_	I-Premise
120	group	_	_	I-Premise
121	,	_	_	I-Premise
122	mean	_	_	I-Premise
123	Â±	_	_	I-Premise
124	standard	_	_	I-Premise
125	deviation	_	_	I-Premise
126	uterine	_	_	I-Premise
127	volume	_	_	I-Premise
128	was	_	_	I-Premise
129	670	_	_	I-Premise
130	Â±	_	_	I-Premise
131	503	_	_	I-Premise
132	,	_	_	I-Premise
133	422	_	_	I-Premise
134	Â±	_	_	I-Premise
135	353	_	_	I-Premise
136	,	_	_	I-Premise
137	and	_	_	I-Premise
138	292	_	_	I-Premise
139	Â±	_	_	I-Premise
140	287	_	_	I-Premise
141	mL	_	_	I-Premise
142	at	_	_	I-Premise
143	baseline	_	_	I-Premise
144	,	_	_	I-Premise
145	6	_	_	I-Premise
146	months	_	_	I-Premise
147	,	_	_	I-Premise
148	and	_	_	I-Premise
149	5	_	_	I-Premise
150	years	_	_	I-Premise
151	,	_	_	I-Premise
152	respectively	_	_	I-Premise
153	.	_	_	I-Premise

154	Mean	_	_	B-Premise
155	dominant	_	_	I-Premise
156	fibroid	_	_	I-Premise
157	diameter	_	_	I-Premise
158	was	_	_	I-Premise
159	7.6	_	_	I-Premise
160	Â±	_	_	I-Premise
161	3.0	_	_	I-Premise
162	,	_	_	I-Premise
163	5.8	_	_	I-Premise
164	Â±	_	_	I-Premise
165	2.9	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	5	_	_	I-Premise
169	Â±	_	_	I-Premise
170	2.9	_	_	I-Premise
171	cm	_	_	I-Premise
172	at	_	_	I-Premise
173	baseline	_	_	I-Premise
174	,	_	_	I-Premise
175	6	_	_	I-Premise
176	months	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	5	_	_	I-Premise
180	years	_	_	I-Premise
181	.	_	_	I-Premise

182	Fibroid	_	_	B-Premise
183	infarction	_	_	I-Premise
184	at	_	_	I-Premise
185	6	_	_	I-Premise
186	months	_	_	I-Premise
187	was	_	_	I-Premise
188	complete	_	_	I-Premise
189	in	_	_	I-Premise
190	35	_	_	I-Premise
191	%	_	_	I-Premise
192	of	_	_	I-Premise
193	women	_	_	I-Premise
194	,	_	_	I-Premise
195	almost	_	_	I-Premise
196	complete	_	_	I-Premise
197	in	_	_	I-Premise
198	29	_	_	I-Premise
199	%	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	partial	_	_	I-Premise
203	in	_	_	I-Premise
204	36	_	_	I-Premise
205	%	_	_	I-Premise
206	.	_	_	I-Premise

207	Need	_	_	B-Premise
208	for	_	_	I-Premise
209	reintervention	_	_	I-Premise
210	was	_	_	I-Premise
211	19	_	_	I-Premise
212	,	_	_	I-Premise
213	10	_	_	I-Premise
214	,	_	_	I-Premise
215	and	_	_	I-Premise
216	33	_	_	I-Premise
217	%	_	_	I-Premise
218	in	_	_	I-Premise
219	these	_	_	I-Premise
220	groups	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.123	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	No	_	_	B-Premise
230	myomectomy	_	_	I-Premise
231	cases	_	_	I-Premise
232	had	_	_	I-Premise
233	further	_	_	I-Premise
234	intervention	_	_	I-Premise
235	.	_	_	I-Premise

236	At	_	_	B-Premise
237	5	_	_	I-Premise
238	years	_	_	I-Premise
239	,	_	_	I-Premise
240	the	_	_	I-Premise
241	prevalence	_	_	I-Premise
242	of	_	_	I-Premise
243	new	_	_	I-Premise
244	fibroid	_	_	I-Premise
245	was	_	_	I-Premise
246	60	_	_	I-Premise
247	%	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	myomectomy	_	_	I-Premise
251	group	_	_	I-Premise
252	and	_	_	I-Premise
253	7	_	_	I-Premise
254	%	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	UAE	_	_	I-Premise
258	group	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	=	_	_	I-Premise
262	0.008	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	There	_	_	B-Premise
266	is	_	_	I-Premise
267	a	_	_	I-Premise
268	further	_	_	I-Premise
269	significant	_	_	I-Premise
270	reduction	_	_	I-Premise
271	in	_	_	I-Premise
272	both	_	_	I-Premise
273	uterine	_	_	I-Premise
274	volume	_	_	I-Premise
275	and	_	_	I-Premise
276	dominant	_	_	I-Premise
277	fibroid	_	_	I-Premise
278	diameter	_	_	I-Premise
279	between	_	_	I-Premise
280	6	_	_	I-Premise
281	months	_	_	I-Premise
282	and	_	_	I-Premise
283	5	_	_	I-Premise
284	years	_	_	I-Premise
285	after	_	_	I-Premise
286	UAE	_	_	I-Premise
287	.	_	_	I-Premise

288	Complete	_	_	B-Claim
289	fibroid	_	_	I-Claim
290	infarction	_	_	I-Claim
291	does	_	_	I-Claim
292	not	_	_	I-Claim
293	translate	_	_	I-Claim
294	into	_	_	I-Claim
295	total	_	_	I-Claim
296	freedom	_	_	I-Claim
297	from	_	_	I-Claim
298	a	_	_	I-Claim
299	subsequent	_	_	I-Claim
300	reintervention	_	_	I-Claim
301	.	_	_	I-Claim

302	New	_	_	B-Claim
303	fibroid	_	_	I-Claim
304	formation	_	_	I-Claim
305	is	_	_	I-Claim
306	significantly	_	_	I-Claim
307	higher	_	_	I-Claim
308	after	_	_	I-Claim
309	myomectomy	_	_	I-Claim
310	.	_	_	I-Claim


0	The	_	_	O
1	current	_	_	O
2	study	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	deoxyribonuclease	_	_	O
10	(	_	_	O
11	rhDNase	_	_	O
12	)	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	measures	_	_	O
21	,	_	_	O
22	clinical	_	_	O
23	improvement	_	_	O
24	,	_	_	O
25	and	_	_	O
26	DNA	_	_	O
27	content	_	_	O
28	of	_	_	O
29	thick	_	_	O
30	oropharyngeal	_	_	O
31	secretions	_	_	O
32	(	_	_	O
33	OPS	_	_	O
34	)	_	_	O
35	in	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	head-and-neck	_	_	O
39	(	_	_	O
40	H	_	_	O
41	&	_	_	O
42	N	_	_	O
43	)	_	_	O
44	cancers	_	_	O
45	.	_	_	O

46	Thirty-six	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	local-regional	_	_	O
50	advanced	_	_	O
51	H	_	_	O
52	&	_	_	O
53	amp	_	_	O
54	;	_	_	O
55	N	_	_	O
56	cancer	_	_	O
57	receiving	_	_	O
58	chemoradiationtherapy	_	_	O
59	(	_	_	O
60	CRT	_	_	O
61	)	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	receive	_	_	O
66	either	_	_	O
67	placebo	_	_	O
68	or	_	_	O
69	rhDNase	_	_	O
70	.	_	_	O

71	Endpoints	_	_	O
72	included	_	_	O
73	MD	_	_	O
74	Anderson	_	_	O
75	Symptom	_	_	O
76	Inventory-Head	_	_	O
77	and	_	_	O
78	Neck	_	_	O
79	(	_	_	O
80	MDASI-HN	_	_	O
81	)	_	_	O
82	and	_	_	O
83	Functional	_	_	O
84	Assessment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Therapy-Head	_	_	O
88	and	_	_	O
89	Neck	_	_	O
90	(	_	_	O
91	FACT-NH	_	_	O
92	)	_	_	O
93	scores	_	_	O
94	,	_	_	O
95	along	_	_	O
96	with	_	_	O
97	clinical	_	_	O
98	assessment	_	_	O
99	and	_	_	O
100	DNA	_	_	O
101	concentration	_	_	O
102	of	_	_	O
103	OPS	_	_	O
104	.	_	_	O

105	There	_	_	B-Premise
106	were	_	_	I-Premise
107	no	_	_	I-Premise
108	statistically	_	_	I-Premise
109	significant	_	_	I-Premise
110	differences	_	_	I-Premise
111	in	_	_	I-Premise
112	patients	_	_	I-Premise
113	'	_	_	I-Premise
114	QOL	_	_	I-Premise
115	outcomes	_	_	I-Premise
116	over	_	_	I-Premise
117	the	_	_	I-Premise
118	study	_	_	I-Premise
119	period	_	_	I-Premise
120	.	_	_	I-Premise

121	Both	_	_	B-Premise
122	groups	_	_	I-Premise
123	showed	_	_	I-Premise
124	an	_	_	I-Premise
125	increase	_	_	I-Premise
126	in	_	_	I-Premise
127	symptom	_	_	I-Premise
128	and	_	_	I-Premise
129	interference	_	_	I-Premise
130	scores	_	_	I-Premise
131	,	_	_	I-Premise
132	although	_	_	O
133	patients	_	_	B-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	rhDNase	_	_	I-Premise
137	group	_	_	I-Premise
138	showed	_	_	I-Premise
139	a	_	_	I-Premise
140	greater	_	_	I-Premise
141	decline	_	_	I-Premise
142	in	_	_	I-Premise
143	both	_	_	I-Premise
144	scores	_	_	I-Premise
145	during	_	_	I-Premise
146	the	_	_	I-Premise
147	3	_	_	I-Premise
148	months	_	_	I-Premise
149	posttreatment	_	_	I-Premise
150	.	_	_	I-Premise

151	Similarly	_	_	B-Premise
152	,	_	_	I-Premise
153	both	_	_	I-Premise
154	groups	_	_	I-Premise
155	showed	_	_	I-Premise
156	a	_	_	I-Premise
157	decline	_	_	I-Premise
158	in	_	_	I-Premise
159	physical	_	_	I-Premise
160	and	_	_	I-Premise
161	functional	_	_	I-Premise
162	well	_	_	I-Premise
163	being	_	_	I-Premise
164	but	_	_	I-Premise
165	recovered	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	3	_	_	I-Premise
169	months	_	_	I-Premise
170	posttreatment	_	_	I-Premise
171	follow-up	_	_	I-Premise
172	,	_	_	I-Premise
173	with	_	_	I-Premise
174	the	_	_	I-Premise
175	rhDNase	_	_	I-Premise
176	group	_	_	I-Premise
177	exhibiting	_	_	I-Premise
178	speedier	_	_	I-Premise
179	recovery	_	_	I-Premise
180	.	_	_	I-Premise

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	rhDNase	_	_	I-Premise
185	group	_	_	I-Premise
186	exhibited	_	_	I-Premise
187	significant	_	_	I-Premise
188	clinical	_	_	I-Premise
189	improvement	_	_	I-Premise
190	in	_	_	I-Premise
191	OPS	_	_	I-Premise
192	,	_	_	I-Premise
193	blindly	_	_	I-Premise
194	assessed	_	_	I-Premise
195	by	_	_	I-Premise
196	a	_	_	I-Premise
197	physician	_	_	I-Premise
198	,	_	_	I-Premise
199	compared	_	_	I-Premise
200	with	_	_	I-Premise
201	the	_	_	I-Premise
202	placebo	_	_	I-Premise
203	group	_	_	I-Premise
204	(	_	_	I-Premise
205	67	_	_	I-Premise
206	%	_	_	I-Premise
207	vs	_	_	I-Premise
208	27	_	_	I-Premise
209	%	_	_	I-Premise
210	,	_	_	I-Premise
211	respectively	_	_	I-Premise
212	;	_	_	I-Premise
213	P=.046	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	rhDNase	_	_	I-Premise
218	group	_	_	I-Premise
219	showed	_	_	I-Premise
220	no	_	_	I-Premise
221	change	_	_	I-Premise
222	in	_	_	I-Premise
223	OPS-DNA	_	_	I-Premise
224	concentration	_	_	I-Premise
225	,	_	_	I-Premise
226	although	_	_	O
227	the	_	_	B-Premise
228	placebo	_	_	I-Premise
229	group	_	_	I-Premise
230	showed	_	_	I-Premise
231	a	_	_	I-Premise
232	significant	_	_	I-Premise
233	increase	_	_	I-Premise
234	in	_	_	I-Premise
235	DNA	_	_	I-Premise
236	concentration	_	_	I-Premise
237	during	_	_	I-Premise
238	the	_	_	I-Premise
239	drug	_	_	I-Premise
240	trial	_	_	I-Premise
241	(	_	_	I-Premise
242	P=.045	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	There	_	_	B-Claim
246	was	_	_	I-Claim
247	no	_	_	I-Claim
248	differences	_	_	I-Claim
249	in	_	_	I-Claim
250	acute	_	_	I-Claim
251	toxicities	_	_	I-Claim
252	between	_	_	I-Claim
253	the	_	_	I-Claim
254	2	_	_	I-Claim
255	groups	_	_	I-Claim
256	.	_	_	I-Claim

257	Our	_	_	B-Claim
258	preliminary	_	_	I-Claim
259	data	_	_	I-Claim
260	suggest	_	_	I-Claim
261	that	_	_	I-Claim
262	rhDNase	_	_	I-Claim
263	did	_	_	I-Claim
264	not	_	_	I-Claim
265	significantly	_	_	I-Claim
266	improve	_	_	I-Claim
267	study	_	_	I-Claim
268	primary	_	_	I-Claim
269	endpoints	_	_	I-Claim
270	of	_	_	I-Claim
271	QOL	_	_	I-Claim
272	measures	_	_	I-Claim
273	compared	_	_	I-Claim
274	with	_	_	I-Claim
275	the	_	_	I-Claim
276	placebo	_	_	I-Claim
277	group	_	_	I-Claim
278	.	_	_	I-Claim

279	However	_	_	O
280	,	_	_	O
281	there	_	_	B-Claim
282	was	_	_	I-Claim
283	a	_	_	I-Claim
284	significant	_	_	I-Claim
285	improvement	_	_	I-Claim
286	in	_	_	I-Claim
287	secondary	_	_	I-Claim
288	endpoints	_	_	I-Claim
289	of	_	_	I-Claim
290	clinically	_	_	I-Claim
291	assessed	_	_	I-Claim
292	OPS	_	_	I-Claim
293	and	_	_	I-Claim
294	DNA	_	_	I-Claim
295	concentration	_	_	I-Claim
296	compared	_	_	I-Claim
297	with	_	_	I-Claim
298	placebo	_	_	I-Claim
299	in	_	_	I-Claim
300	H	_	_	I-Claim
301	&	_	_	I-Claim
302	N	_	_	I-Claim
303	cancer	_	_	I-Claim
304	patients	_	_	I-Claim
305	treated	_	_	I-Claim
306	with	_	_	I-Claim
307	CRT	_	_	I-Claim
308	.	_	_	I-Claim

309	Further	_	_	O
310	investigation	_	_	O
311	in	_	_	O
312	larger	_	_	O
313	numbers	_	_	O
314	of	_	_	O
315	patients	_	_	O
316	is	_	_	O
317	warranted	_	_	O
318	.	_	_	O


0	Thalidomide	_	_	O
1	with	_	_	O
2	melphalan/prednisone	_	_	O
3	(	_	_	O
4	MPT	_	_	O
5	)	_	_	O
6	was	_	_	O
7	defined	_	_	O
8	as	_	_	O
9	standard	_	_	O
10	treatment	_	_	O
11	in	_	_	O
12	elderly	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	multiple	_	_	O
16	myeloma	_	_	O
17	(	_	_	O
18	MM	_	_	O
19	)	_	_	O
20	based	_	_	O
21	on	_	_	O
22	five	_	_	O
23	randomized	_	_	O
24	trials	_	_	O
25	.	_	_	O

26	In	_	_	O
27	one	_	_	O
28	of	_	_	O
29	these	_	_	O
30	trials	_	_	O
31	,	_	_	O
32	HOVON49	_	_	O
33	,	_	_	O
34	a	_	_	O
35	prospective	_	_	O
36	health-related	_	_	O
37	quality-of-life	_	_	O
38	(	_	_	O
39	HRQoL	_	_	O
40	)	_	_	O
41	study	_	_	O
42	was	_	_	O
43	initiated	_	_	O
44	in	_	_	O
45	order	_	_	O
46	to	_	_	O
47	assess	_	_	O
48	the	_	_	O
49	impact	_	_	O
50	of	_	_	O
51	thalidomide	_	_	O
52	on	_	_	O
53	QoL	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	aged	_	_	O
57	>	_	_	O
58	65	_	_	O
59	years	_	_	O
60	with	_	_	O
61	newly	_	_	O
62	diagnosed	_	_	O
63	MM	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	melphalan	_	_	O
69	plus	_	_	O
70	prednisone	_	_	O
71	(	_	_	O
72	MP	_	_	O
73	)	_	_	O
74	or	_	_	O
75	MPT	_	_	O
76	,	_	_	O
77	followed	_	_	O
78	by	_	_	O
79	thalidomide	_	_	O
80	maintenance	_	_	O
81	in	_	_	O
82	the	_	_	O
83	MPT	_	_	O
84	arm	_	_	O
85	.	_	_	O

86	Two	_	_	O
87	hundred	_	_	O
88	eighty-four	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	included	_	_	O
92	in	_	_	O
93	this	_	_	O
94	side	_	_	O
95	study	_	_	O
96	(	_	_	O
97	MP	_	_	O
98	,	_	_	O
99	n=149	_	_	O
100	;	_	_	O
101	MPT	_	_	O
102	n=135	_	_	O
103	)	_	_	O
104	.	_	_	O

105	HRQoL	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	the	_	_	O
110	EORTC	_	_	O
111	Core	_	_	O
112	QoL	_	_	O
113	Questionnaire	_	_	O
114	(	_	_	O
115	QLQ-C30	_	_	O
116	)	_	_	O
117	and	_	_	O
118	the	_	_	O
119	myeloma-specific	_	_	O
120	module	_	_	O
121	(	_	_	O
122	QLQ-MY24	_	_	O
123	)	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	and	_	_	O
127	at	_	_	O
128	predetermined	_	_	O
129	intervals	_	_	O
130	during	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	The	_	_	B-Premise
134	QLQ-C30	_	_	I-Premise
135	subscales	_	_	I-Premise
136	physical	_	_	I-Premise
137	function	_	_	I-Premise
138	(	_	_	I-Premise
139	P=0.044	_	_	I-Premise
140	)	_	_	I-Premise
141	and	_	_	I-Premise
142	constipation	_	_	I-Premise
143	(	_	_	I-Premise
144	P	_	_	I-Premise
145	<	_	_	I-Premise
146	0.001	_	_	I-Premise
147	)	_	_	I-Premise
148	showed	_	_	I-Premise
149	an	_	_	I-Premise
150	improvement	_	_	I-Premise
151	during	_	_	I-Premise
152	induction	_	_	I-Premise
153	in	_	_	I-Premise
154	favour	_	_	I-Premise
155	of	_	_	I-Premise
156	the	_	_	I-Premise
157	MP	_	_	I-Premise
158	arm	_	_	I-Premise
159	.	_	_	I-Premise

160	During	_	_	B-Premise
161	thalidomide	_	_	I-Premise
162	maintenance	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	scores	_	_	I-Premise
166	for	_	_	I-Premise
167	the	_	_	I-Premise
168	QLQ-MY24	_	_	I-Premise
169	paraesthesia	_	_	I-Premise
170	became	_	_	I-Premise
171	significantly	_	_	I-Premise
172	higher	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	MPT	_	_	I-Premise
176	arm	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	0.001	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	The	_	_	B-Premise
184	QLQ-C30	_	_	I-Premise
185	subscales	_	_	I-Premise
186	pain	_	_	I-Premise
187	(	_	_	I-Premise
188	P=0.12	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	insomnia	_	_	I-Premise
192	(	_	_	I-Premise
193	P=0.068	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	appetite	_	_	I-Premise
197	loss	_	_	I-Premise
198	(	_	_	I-Premise
199	P=0.074	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	the	_	_	I-Premise
203	QLQ-MY24	_	_	I-Premise
204	item	_	_	I-Premise
205	sick	_	_	I-Premise
206	(	_	_	I-Premise
207	P=0.086	_	_	I-Premise
208	)	_	_	I-Premise
209	scored	_	_	I-Premise
210	marginally	_	_	I-Premise
211	better	_	_	I-Premise
212	during	_	_	I-Premise
213	thalidomide	_	_	I-Premise
214	maintenance	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	overall	_	_	I-Premise
218	QoL-scale	_	_	I-Premise
219	QLQ-C30-HRQoL	_	_	I-Premise
220	showed	_	_	I-Premise
221	a	_	_	I-Premise
222	significant	_	_	I-Premise
223	time	_	_	I-Premise
224	trend	_	_	I-Premise
225	towards	_	_	I-Premise
226	more	_	_	I-Premise
227	favourable	_	_	I-Premise
228	mean	_	_	I-Premise
229	values	_	_	I-Premise
230	during	_	_	I-Premise
231	protocol	_	_	I-Premise
232	treatment	_	_	I-Premise
233	without	_	_	I-Premise
234	differences	_	_	I-Premise
235	between	_	_	I-Premise
236	MP	_	_	I-Premise
237	and	_	_	I-Premise
238	MPT	_	_	I-Premise
239	.	_	_	I-Premise

240	For	_	_	B-Premise
241	the	_	_	I-Premise
242	QLQ-C30	_	_	I-Premise
243	subscales	_	_	I-Premise
244	emotional	_	_	I-Premise
245	function	_	_	I-Premise
246	and	_	_	I-Premise
247	future	_	_	I-Premise
248	perspectives	_	_	I-Premise
249	,	_	_	I-Premise
250	difference	_	_	I-Premise
251	in	_	_	I-Premise
252	favour	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	MPT	_	_	I-Premise
256	arm	_	_	I-Premise
257	from	_	_	I-Premise
258	the	_	_	I-Premise
259	start	_	_	I-Premise
260	of	_	_	I-Premise
261	treatment	_	_	I-Premise
262	was	_	_	I-Premise
263	observed	_	_	I-Premise
264	(	_	_	I-Premise
265	P=0.018	_	_	I-Premise
266	and	_	_	I-Premise
267	P=0.045	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	)	_	_	I-Premise
271	with	_	_	I-Premise
272	no	_	_	I-Premise
273	significant	_	_	I-Premise
274	'time	_	_	I-Premise
275	Ã—	_	_	I-Premise
276	arm	_	_	I-Premise
277	'	_	_	I-Premise
278	interaction	_	_	I-Premise
279	,	_	_	I-Premise
280	indicating	_	_	I-Premise
281	a	_	_	I-Premise
282	persistent	_	_	I-Premise
283	better	_	_	I-Premise
284	patient	_	_	I-Premise
285	perspective	_	_	I-Premise
286	with	_	_	I-Premise
287	MPT	_	_	I-Premise
288	treatment	_	_	I-Premise
289	.	_	_	I-Premise

290	This	_	_	B-Claim
291	study	_	_	I-Claim
292	shows	_	_	I-Claim
293	that	_	_	I-Claim
294	the	_	_	I-Claim
295	higher	_	_	I-Claim
296	frequency	_	_	I-Claim
297	of	_	_	I-Claim
298	toxicity	_	_	I-Claim
299	associated	_	_	I-Claim
300	with	_	_	I-Claim
301	MPT	_	_	I-Claim
302	does	_	_	I-Claim
303	not	_	_	I-Claim
304	translate	_	_	I-Claim
305	into	_	_	I-Claim
306	a	_	_	I-Claim
307	negative	_	_	I-Claim
308	effect	_	_	I-Claim
309	on	_	_	I-Claim
310	HRQoL	_	_	I-Claim
311	and	_	_	I-Claim
312	that	_	_	I-Claim
313	MPT	_	_	I-Claim
314	holds	_	_	I-Claim
315	a	_	_	I-Claim
316	better	_	_	I-Claim
317	patient	_	_	I-Claim
318	perspective	_	_	I-Claim
319	.	_	_	I-Claim


0	Paclitaxel	_	_	O
1	and	_	_	O
2	pegylated	_	_	O
3	liposomal	_	_	O
4	doxorubicin	_	_	O
5	(	_	_	O
6	PLD	_	_	O
7	)	_	_	O
8	are	_	_	O
9	active	_	_	O
10	cytotoxic	_	_	O
11	agents	_	_	O
12	for	_	_	O
13	the	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	human	_	_	O
17	immunodeficiency	_	_	O
18	virus	_	_	O
19	(	_	_	O
20	HIV	_	_	O
21	)	_	_	O
22	-associated	_	_	O
23	Kaposi	_	_	O
24	sarcoma	_	_	O
25	(	_	_	O
26	KS	_	_	O
27	)	_	_	O
28	.	_	_	O

29	A	_	_	O
30	randomized	_	_	O
31	trial	_	_	O
32	comparing	_	_	O
33	the	_	_	O
34	efficacy	_	_	O
35	and	_	_	O
36	toxicity	_	_	O
37	of	_	_	O
38	paclitaxel	_	_	O
39	and	_	_	O
40	PLD	_	_	O
41	was	_	_	O
42	performed	_	_	O
43	,	_	_	O
44	and	_	_	O
45	the	_	_	O
46	effects	_	_	O
47	of	_	_	O
48	therapy	_	_	O
49	on	_	_	O
50	symptom	_	_	O
51	palliation	_	_	O
52	and	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	were	_	_	O
57	determined	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	with	_	_	O
61	advanced	_	_	O
62	HIV-associated	_	_	O
63	KS	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	receive	_	_	O
69	paclitaxel	_	_	O
70	at	_	_	O
71	a	_	_	O
72	dose	_	_	O
73	of	_	_	O
74	100	_	_	O
75	mg/m2	_	_	O
76	intravenously	_	_	O
77	(	_	_	O
78	iv	_	_	O
79	)	_	_	O
80	every	_	_	O
81	2	_	_	O
82	weeks	_	_	O
83	or	_	_	O
84	PLD	_	_	O
85	at	_	_	O
86	a	_	_	O
87	dose	_	_	O
88	of	_	_	O
89	20	_	_	O
90	mg/m2	_	_	O
91	iv	_	_	O
92	every	_	_	O
93	3	_	_	O
94	weeks	_	_	O
95	.	_	_	O

96	The	_	_	O
97	KS	_	_	O
98	Functional	_	_	O
99	Assessment	_	_	O
100	of	_	_	O
101	HIV	_	_	O
102	(	_	_	O
103	FAHI	_	_	O
104	)	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	instrument	_	_	O
109	was	_	_	O
110	used	_	_	O
111	before	_	_	O
112	and	_	_	O
113	after	_	_	O
114	every	_	_	O
115	other	_	_	O
116	treatment	_	_	O
117	cycle	_	_	O
118	.	_	_	O

119	The	_	_	O
120	study	_	_	O
121	included	_	_	O
122	73	_	_	O
123	analyzable	_	_	O
124	patients	_	_	O
125	enrolled	_	_	O
126	between	_	_	O
127	1998	_	_	O
128	and	_	_	O
129	2002	_	_	O
130	,	_	_	O
131	including	_	_	O
132	36	_	_	O
133	in	_	_	O
134	the	_	_	O
135	paclitaxel	_	_	O
136	arm	_	_	O
137	and	_	_	O
138	37	_	_	O
139	in	_	_	O
140	the	_	_	O
141	PLD	_	_	O
142	arm	_	_	O
143	;	_	_	O
144	73	_	_	O
145	%	_	_	O
146	of	_	_	O
147	patients	_	_	O
148	received	_	_	O
149	highly	_	_	O
150	active	_	_	O
151	antiretroviral	_	_	O
152	therapy	_	_	O
153	(	_	_	O
154	HAART	_	_	O
155	)	_	_	O
156	and	_	_	O
157	32	_	_	O
158	%	_	_	O
159	had	_	_	O
160	an	_	_	O
161	undetectable	_	_	O
162	viral	_	_	O
163	load	_	_	O
164	(	_	_	O
165	<	_	_	O
166	400	_	_	O
167	copies/mL	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Treatment	_	_	B-Premise
171	was	_	_	I-Premise
172	associated	_	_	I-Premise
173	with	_	_	I-Premise
174	significant	_	_	I-Premise
175	improvements	_	_	I-Premise
176	in	_	_	I-Premise
177	pain	_	_	I-Premise
178	(	_	_	I-Premise
179	P=.024	_	_	I-Premise
180	)	_	_	I-Premise
181	and	_	_	I-Premise
182	swelling	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	.001	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	Of	_	_	B-Premise
190	the	_	_	I-Premise
191	36	_	_	I-Premise
192	patients	_	_	I-Premise
193	who	_	_	I-Premise
194	reported	_	_	I-Premise
195	that	_	_	I-Premise
196	pain	_	_	I-Premise
197	interfered	_	_	I-Premise
198	with	_	_	I-Premise
199	their	_	_	I-Premise
200	normal	_	_	I-Premise
201	work	_	_	I-Premise
202	or	_	_	I-Premise
203	activities	_	_	I-Premise
204	at	_	_	I-Premise
205	baseline	_	_	I-Premise
206	,	_	_	I-Premise
207	25	_	_	I-Premise
208	(	_	_	I-Premise
209	69	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	improved	_	_	I-Premise
213	.	_	_	I-Premise

214	Of	_	_	B-Premise
215	the	_	_	I-Premise
216	41	_	_	I-Premise
217	patients	_	_	I-Premise
218	who	_	_	I-Premise
219	reported	_	_	I-Premise
220	swelling	_	_	I-Premise
221	at	_	_	I-Premise
222	baseline	_	_	I-Premise
223	,	_	_	I-Premise
224	38	_	_	I-Premise
225	(	_	_	I-Premise
226	93	_	_	I-Premise
227	%	_	_	I-Premise
228	)	_	_	I-Premise
229	improved	_	_	I-Premise
230	.	_	_	I-Premise

231	Comparing	_	_	B-Premise
232	the	_	_	I-Premise
233	paclitaxel	_	_	I-Premise
234	and	_	_	I-Premise
235	PLD	_	_	I-Premise
236	arms	_	_	I-Premise
237	revealed	_	_	I-Premise
238	comparable	_	_	I-Premise
239	response	_	_	I-Premise
240	rates	_	_	I-Premise
241	(	_	_	I-Premise
242	56	_	_	I-Premise
243	%	_	_	I-Premise
244	vs	_	_	I-Premise
245	46	_	_	I-Premise
246	%	_	_	I-Premise
247	;	_	_	I-Premise
248	P=.49	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	median	_	_	I-Premise
252	progression-free	_	_	I-Premise
253	survival	_	_	I-Premise
254	(	_	_	I-Premise
255	17.5	_	_	I-Premise
256	months	_	_	I-Premise
257	vs	_	_	I-Premise
258	12.2	_	_	I-Premise
259	months	_	_	I-Premise
260	;	_	_	I-Premise
261	P=.66	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	2-year	_	_	I-Premise
266	survival	_	_	I-Premise
267	rates	_	_	I-Premise
268	(	_	_	I-Premise
269	79	_	_	I-Premise
270	%	_	_	I-Premise
271	vs	_	_	I-Premise
272	78	_	_	I-Premise
273	%	_	_	I-Premise
274	;	_	_	I-Premise
275	P=.75	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	but	_	_	B-Premise
279	somewhat	_	_	I-Premise
280	more	_	_	I-Premise
281	grade	_	_	I-Premise
282	3	_	_	I-Premise
283	to	_	_	I-Premise
284	5	_	_	I-Premise
285	toxicity	_	_	I-Premise
286	for	_	_	I-Premise
287	paclitaxel	_	_	I-Premise
288	(	_	_	I-Premise
289	84	_	_	I-Premise
290	%	_	_	I-Premise
291	vs	_	_	I-Premise
292	66	_	_	I-Premise
293	%	_	_	I-Premise
294	;	_	_	I-Premise
295	P=.077	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Treatment	_	_	B-Claim
299	with	_	_	I-Claim
300	either	_	_	I-Claim
301	paclitaxel	_	_	I-Claim
302	or	_	_	I-Claim
303	PLD	_	_	I-Claim
304	appears	_	_	I-Claim
305	to	_	_	I-Claim
306	produce	_	_	I-Claim
307	significant	_	_	I-Claim
308	improvements	_	_	I-Claim
309	in	_	_	I-Claim
310	pain	_	_	I-Claim
311	and	_	_	I-Claim
312	swelling	_	_	I-Claim
313	in	_	_	I-Claim
314	patients	_	_	I-Claim
315	with	_	_	I-Claim
316	advanced	_	_	I-Claim
317	,	_	_	I-Claim
318	symptomatic	_	_	I-Claim
319	,	_	_	I-Claim
320	HIV-associated	_	_	I-Claim
321	KS	_	_	I-Claim
322	treated	_	_	I-Claim
323	in	_	_	I-Claim
324	the	_	_	I-Claim
325	HAART	_	_	I-Claim
326	era	_	_	I-Claim
327	.	_	_	I-Claim


0	The	_	_	O
1	phase	_	_	O
2	3	_	_	O
3	VISTA	_	_	O
4	study	_	_	O
5	in	_	_	O
6	transplant-ineligible	_	_	O
7	myeloma	_	_	O
8	patients	_	_	O
9	demonstrated	_	_	O
10	superior	_	_	O
11	efficacy	_	_	O
12	with	_	_	O
13	bortezomib-melphalan-prednisone	_	_	O
14	(	_	_	O
15	VMP	_	_	O
16	;	_	_	O
17	nine	_	_	O
18	6-wk	_	_	O
19	cycles	_	_	O
20	)	_	_	O
21	vs.	_	_	O
22	melphalan-prednisone	_	_	O
23	(	_	_	O
24	MP	_	_	O
25	)	_	_	O
26	but	_	_	O
27	also	_	_	O
28	increased	_	_	O
29	toxicity	_	_	O
30	.	_	_	O

31	Health-related	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	HRQoL	_	_	O
37	;	_	_	O
38	exploratory	_	_	O
39	endpoint	_	_	O
40	)	_	_	O
41	was	_	_	O
42	evaluated	_	_	O
43	using	_	_	O
44	the	_	_	O
45	European	_	_	O
46	Organization	_	_	O
47	for	_	_	O
48	Research	_	_	O
49	and	_	_	O
50	Treatment	_	_	O
51	of	_	_	O
52	Cancer	_	_	O
53	(	_	_	O
54	EORTC	_	_	O
55	)	_	_	O
56	Quality	_	_	O
57	of	_	_	O
58	Life	_	_	O
59	Questionnaire	_	_	O
60	(	_	_	O
61	QLQ-C30	_	_	O
62	)	_	_	O
63	.	_	_	O

64	The	_	_	O
65	phase	_	_	O
66	3	_	_	O
67	VISTA	_	_	O
68	study	_	_	O
69	in	_	_	O
70	transplant-ineligible	_	_	O
71	myeloma	_	_	O
72	patients	_	_	O
73	demonstrated	_	_	O
74	superior	_	_	O
75	efficacy	_	_	O
76	with	_	_	O
77	bortezomib-melphalan-prednisone	_	_	O
78	(	_	_	O
79	VMP	_	_	O
80	;	_	_	O
81	nine	_	_	O
82	6-wk	_	_	O
83	cycles	_	_	O
84	)	_	_	O
85	vs.	_	_	O
86	melphalan-prednisone	_	_	O
87	(	_	_	O
88	MP	_	_	O
89	)	_	_	O
90	but	_	_	O
91	also	_	_	O
92	increased	_	_	O
93	toxicity	_	_	O
94	.	_	_	O

95	Health-related	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	(	_	_	O
100	HRQoL	_	_	O
101	;	_	_	O
102	exploratory	_	_	O
103	endpoint	_	_	O
104	)	_	_	O
105	was	_	_	O
106	evaluated	_	_	O
107	using	_	_	O
108	the	_	_	O
109	European	_	_	O
110	Organization	_	_	O
111	for	_	_	O
112	Research	_	_	O
113	and	_	_	O
114	Treatment	_	_	O
115	of	_	_	O
116	Cancer	_	_	O
117	(	_	_	O
118	EORTC	_	_	O
119	)	_	_	O
120	Quality	_	_	O
121	of	_	_	O
122	Life	_	_	O
123	Questionnaire	_	_	O
124	(	_	_	O
125	QLQ-C30	_	_	O
126	)	_	_	O
127	.	_	_	O

128	EORTC	_	_	O
129	QLQ-C30	_	_	O
130	was	_	_	O
131	administered	_	_	O
132	at	_	_	O
133	screening	_	_	O
134	,	_	_	O
135	on	_	_	O
136	day	_	_	O
137	1	_	_	O
138	of	_	_	O
139	each	_	_	O
140	cycle	_	_	O
141	,	_	_	O
142	at	_	_	O
143	the	_	_	O
144	end-of-treatment	_	_	O
145	visit	_	_	O
146	,	_	_	O
147	and	_	_	O
148	every	_	_	O
149	8	_	_	O
150	wk	_	_	O
151	until	_	_	O
152	progression	_	_	O
153	.	_	_	O

154	EORTC	_	_	O
155	QLQ-C30	_	_	O
156	scores	_	_	O
157	were	_	_	O
158	evaluated	_	_	O
159	among	_	_	O
160	patients	_	_	O
161	with	_	_	O
162	a	_	_	O
163	valid	_	_	O
164	baseline	_	_	O
165	and	_	_	O
166	at	_	_	O
167	least	_	_	O
168	one	_	_	O
169	post-baseline	_	_	O
170	HRQoL	_	_	O
171	assessment	_	_	O
172	.	_	_	O

173	At	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	domain	_	_	O
177	scores	_	_	O
178	were	_	_	O
179	similar	_	_	O
180	between	_	_	O
181	arms	_	_	O
182	.	_	_	O

183	By	_	_	B-Premise
184	cycle	_	_	I-Premise
185	4	_	_	I-Premise
186	,	_	_	I-Premise
187	mean	_	_	I-Premise
188	differences	_	_	I-Premise
189	were	_	_	I-Premise
190	clinically	_	_	I-Premise
191	meaningful	_	_	I-Premise
192	for	_	_	I-Premise
193	most	_	_	I-Premise
194	domains	_	_	I-Premise
195	,	_	_	I-Premise
196	indicating	_	_	I-Premise
197	poorer	_	_	I-Premise
198	health	_	_	I-Premise
199	status	_	_	I-Premise
200	with	_	_	I-Premise
201	VMP	_	_	I-Premise
202	.	_	_	I-Premise

203	From	_	_	B-Premise
204	cycle	_	_	I-Premise
205	5	_	_	I-Premise
206	onwards	_	_	I-Premise
207	,	_	_	I-Premise
208	improvements	_	_	I-Premise
209	relative	_	_	I-Premise
210	to	_	_	I-Premise
211	baseline/MP	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	for	_	_	I-Premise
215	all	_	_	I-Premise
216	domains	_	_	I-Premise
217	with	_	_	I-Premise
218	VMP	_	_	I-Premise
219	.	_	_	I-Premise

220	Mean	_	_	B-Premise
221	scores	_	_	I-Premise
222	were	_	_	I-Premise
223	generally	_	_	I-Premise
224	improved	_	_	I-Premise
225	by	_	_	I-Premise
226	the	_	_	I-Premise
227	end-of-treatment	_	_	I-Premise
228	assessment	_	_	I-Premise
229	vs.	_	_	I-Premise
230	baseline	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	arms	_	_	I-Premise
234	.	_	_	I-Premise

235	Among	_	_	B-Premise
236	responding	_	_	I-Premise
237	patients	_	_	I-Premise
238	,	_	_	I-Premise
239	mean	_	_	I-Premise
240	scores	_	_	I-Premise
241	generally	_	_	I-Premise
242	improved	_	_	I-Premise
243	from	_	_	I-Premise
244	time	_	_	I-Premise
245	of	_	_	I-Premise
246	response	_	_	I-Premise
247	to	_	_	I-Premise
248	end-of-treatment	_	_	I-Premise
249	assessment	_	_	I-Premise
250	,	_	_	I-Premise
251	substantially	_	_	I-Premise
252	driven	_	_	I-Premise
253	by	_	_	I-Premise
254	patients	_	_	I-Premise
255	achieving	_	_	I-Premise
256	complete	_	_	I-Premise
257	response	_	_	I-Premise
258	(	_	_	I-Premise
259	CR	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Multivariate	_	_	B-Premise
263	analysis	_	_	I-Premise
264	showed	_	_	I-Premise
265	a	_	_	I-Premise
266	significant	_	_	I-Premise
267	impact	_	_	I-Premise
268	of	_	_	I-Premise
269	duration	_	_	I-Premise
270	of	_	_	I-Premise
271	response/CR	_	_	I-Premise
272	on	_	_	I-Premise
273	improving	_	_	I-Premise
274	global	_	_	I-Premise
275	health	_	_	I-Premise
276	status	_	_	I-Premise
277	,	_	_	I-Premise
278	pain	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	appetite	_	_	I-Premise
282	loss	_	_	I-Premise
283	scores	_	_	I-Premise
284	.	_	_	I-Premise

285	Analyses	_	_	B-Claim
286	by	_	_	I-Claim
287	bortezomib	_	_	I-Claim
288	dose	_	_	I-Claim
289	intensity	_	_	I-Claim
290	indicated	_	_	I-Claim
291	better	_	_	I-Claim
292	HRQoL	_	_	I-Claim
293	in	_	_	I-Claim
294	patients	_	_	I-Claim
295	receiving	_	_	I-Claim
296	lower	_	_	I-Claim
297	dose	_	_	I-Claim
298	intensity	_	_	I-Claim
299	.	_	_	I-Claim

300	These	_	_	B-Claim
301	findings	_	_	I-Claim
302	demonstrate	_	_	I-Claim
303	clinically	_	_	I-Claim
304	meaningful	_	_	I-Claim
305	,	_	_	I-Claim
306	transitory	_	_	I-Claim
307	HRQoL	_	_	I-Claim
308	decrements	_	_	I-Claim
309	with	_	_	I-Claim
310	VMP	_	_	I-Claim
311	and	_	_	I-Claim
312	relatively	_	_	I-Claim
313	lower	_	_	I-Claim
314	HRQoL	_	_	I-Claim
315	vs.	_	_	I-Claim
316	MP	_	_	I-Claim
317	during	_	_	I-Claim
318	early	_	_	I-Claim
319	treatment	_	_	I-Claim
320	cycles	_	_	I-Claim
321	,	_	_	I-Claim
322	associated	_	_	I-Claim
323	with	_	_	I-Claim
324	the	_	_	I-Claim
325	expected	_	_	I-Claim
326	additional	_	_	I-Claim
327	toxicities	_	_	I-Claim
328	.	_	_	I-Claim

329	However	_	_	B-Claim
330	,	_	_	I-Claim
331	HRQoL	_	_	I-Claim
332	is	_	_	I-Claim
333	not	_	_	I-Claim
334	compromised	_	_	I-Claim
335	in	_	_	I-Claim
336	the	_	_	I-Claim
337	long	_	_	I-Claim
338	term	_	_	I-Claim
339	,	_	_	I-Claim
340	recovering	_	_	I-Claim
341	by	_	_	I-Claim
342	the	_	_	I-Claim
343	end-of-treatment	_	_	I-Claim
344	visit	_	_	I-Claim
345	to	_	_	I-Claim
346	be	_	_	I-Claim
347	comparable	_	_	I-Claim
348	vs.	_	_	I-Claim
349	MP	_	_	I-Claim
350	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	(	_	_	I-Claim
9	QOL	_	_	I-Claim
10	)	_	_	I-Claim
11	for	_	_	I-Claim
12	good	_	_	I-Claim
13	performance	_	_	I-Claim
14	status	_	_	I-Claim
15	(	_	_	I-Claim
16	PS	_	_	I-Claim
17	)	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	non-small	_	_	I-Claim
22	cell	_	_	I-Claim
23	lung	_	_	I-Claim
24	cancer	_	_	I-Claim
25	(	_	_	I-Claim
26	NSCLC	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	Targeted	_	_	B-Claim
30	therapies	_	_	I-Claim
31	may	_	_	I-Claim
32	improve	_	_	I-Claim
33	chemotherapy	_	_	I-Claim
34	effectiveness	_	_	I-Claim
35	without	_	_	I-Claim
36	worsening	_	_	I-Claim
37	toxicity	_	_	I-Claim
38	.	_	_	I-Claim

39	SGN-15	_	_	O
40	is	_	_	O
41	an	_	_	O
42	antibody-drug	_	_	O
43	conjugate	_	_	O
44	(	_	_	O
45	ADC	_	_	O
46	)	_	_	O
47	,	_	_	O
48	consisting	_	_	O
49	of	_	_	O
50	a	_	_	O
51	chimeric	_	_	O
52	murine	_	_	O
53	monoclonal	_	_	O
54	antibody	_	_	O
55	recognizing	_	_	O
56	the	_	_	O
57	Lewis	_	_	O
58	Y	_	_	O
59	(	_	_	O
60	Le	_	_	O
61	(	_	_	O
62	y	_	_	O
63	)	_	_	O
64	)	_	_	O
65	antigen	_	_	O
66	,	_	_	O
67	conjugated	_	_	O
68	to	_	_	O
69	doxorubicin	_	_	O
70	.	_	_	O

71	Le	_	_	B-Claim
72	(	_	_	I-Claim
73	y	_	_	I-Claim
74	)	_	_	I-Claim
75	is	_	_	I-Claim
76	an	_	_	I-Claim
77	attractive	_	_	I-Claim
78	target	_	_	I-Claim
79	since	_	_	I-Claim
80	it	_	_	I-Claim
81	is	_	_	I-Claim
82	expressed	_	_	I-Claim
83	by	_	_	I-Claim
84	most	_	_	I-Claim
85	NSCLC	_	_	I-Claim
86	.	_	_	I-Claim

87	SGN-15	_	_	B-Premise
88	was	_	_	I-Premise
89	active	_	_	I-Premise
90	against	_	_	I-Premise
91	Le	_	_	I-Premise
92	(	_	_	I-Premise
93	y	_	_	I-Premise
94	)	_	_	I-Premise
95	-positive	_	_	I-Premise
96	tumors	_	_	I-Premise
97	in	_	_	I-Premise
98	early	_	_	I-Premise
99	phase	_	_	I-Premise
100	clinical	_	_	I-Premise
101	trials	_	_	I-Premise
102	and	_	_	I-Premise
103	was	_	_	I-Premise
104	synergistic	_	_	I-Premise
105	with	_	_	I-Premise
106	docetaxel	_	_	I-Premise
107	in	_	_	I-Premise
108	preclinical	_	_	I-Premise
109	experiments	_	_	I-Premise
110	.	_	_	I-Premise

111	This	_	_	O
112	Phase	_	_	O
113	II	_	_	O
114	,	_	_	O
115	open-label	_	_	O
116	study	_	_	O
117	was	_	_	O
118	conducted	_	_	O
119	to	_	_	O
120	confirm	_	_	O
121	the	_	_	O
122	activity	_	_	O
123	of	_	_	O
124	SGN-15	_	_	O
125	plus	_	_	O
126	docetaxel	_	_	O
127	in	_	_	O
128	previously	_	_	O
129	treated	_	_	O
130	NSCLC	_	_	O
131	patients	_	_	O
132	.	_	_	O

133	Sixty-two	_	_	O
134	patients	_	_	O
135	with	_	_	O
136	recurrent	_	_	O
137	or	_	_	O
138	metastatic	_	_	O
139	NSCLC	_	_	O
140	expressing	_	_	O
141	Le	_	_	O
142	(	_	_	O
143	y	_	_	O
144	)	_	_	O
145	,	_	_	O
146	one	_	_	O
147	or	_	_	O
148	two	_	_	O
149	prior	_	_	O
150	chemotherapy	_	_	O
151	regimens	_	_	O
152	,	_	_	O
153	and	_	_	O
154	PS	_	_	O
155	<	_	_	O
156	or	_	_	O
157	=2	_	_	O
158	were	_	_	O
159	randomized	_	_	O
160	2:1	_	_	O
161	to	_	_	O
162	receive	_	_	O
163	SGN-15	_	_	O
164	200	_	_	O
165	mg/m2/week	_	_	O
166	with	_	_	O
167	docetaxel	_	_	O
168	35	_	_	O
169	mg/m2/week	_	_	O
170	(	_	_	O
171	Arm	_	_	O
172	A	_	_	O
173	)	_	_	O
174	or	_	_	O
175	docetaxel	_	_	O
176	35	_	_	O
177	mg/m2/week	_	_	O
178	alone	_	_	O
179	(	_	_	O
180	Arm	_	_	O
181	B	_	_	O
182	)	_	_	O
183	for	_	_	O
184	6	_	_	O
185	of	_	_	O
186	8	_	_	O
187	weeks	_	_	O
188	.	_	_	O

189	Intrapatient	_	_	O
190	dose-escalation	_	_	O
191	of	_	_	O
192	SGN-15	_	_	O
193	to	_	_	O
194	350	_	_	O
195	mg/m2	_	_	O
196	was	_	_	O
197	permitted	_	_	O
198	in	_	_	O
199	the	_	_	O
200	second	_	_	O
201	half	_	_	O
202	of	_	_	O
203	the	_	_	O
204	study	_	_	O
205	.	_	_	O

206	Endpoints	_	_	O
207	were	_	_	O
208	survival	_	_	O
209	,	_	_	O
210	safety	_	_	O
211	,	_	_	O
212	efficacy	_	_	O
213	,	_	_	O
214	and	_	_	O
215	quality	_	_	O
216	of	_	_	O
217	life	_	_	O
218	.	_	_	O

219	Forty	_	_	O
220	patients	_	_	O
221	on	_	_	O
222	Arm	_	_	O
223	A	_	_	O
224	and	_	_	O
225	19	_	_	O
226	on	_	_	O
227	Arm	_	_	O
228	B	_	_	O
229	received	_	_	O
230	at	_	_	O
231	least	_	_	O
232	one	_	_	O
233	treatment	_	_	O
234	.	_	_	O

235	Patients	_	_	B-Premise
236	on	_	_	I-Premise
237	Arms	_	_	I-Premise
238	A	_	_	I-Premise
239	and	_	_	I-Premise
240	B	_	_	I-Premise
241	had	_	_	I-Premise
242	median	_	_	I-Premise
243	survivals	_	_	I-Premise
244	of	_	_	I-Premise
245	31.4	_	_	I-Premise
246	and	_	_	I-Premise
247	25.3	_	_	I-Premise
248	weeks	_	_	I-Premise
249	,	_	_	I-Premise
250	12-month	_	_	I-Premise
251	survivals	_	_	I-Premise
252	of	_	_	I-Premise
253	29	_	_	I-Premise
254	%	_	_	I-Premise
255	and	_	_	I-Premise
256	24	_	_	I-Premise
257	%	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	18-month	_	_	I-Premise
261	survivals	_	_	I-Premise
262	of	_	_	I-Premise
263	18	_	_	I-Premise
264	%	_	_	I-Premise
265	and	_	_	I-Premise
266	8	_	_	I-Premise
267	%	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	.	_	_	O

271	Toxicity	_	_	B-Premise
272	was	_	_	I-Premise
273	mild	_	_	I-Premise
274	in	_	_	I-Premise
275	both	_	_	I-Premise
276	arms	_	_	I-Premise
277	.	_	_	I-Premise

278	QOL	_	_	B-Premise
279	analyses	_	_	I-Premise
280	favored	_	_	I-Premise
281	Arm	_	_	I-Premise
282	A.	_	_	I-Premise
283	SGN-15	_	_	B-Claim
284	plus	_	_	I-Claim
285	docetaxel	_	_	I-Claim
286	is	_	_	I-Claim
287	a	_	_	I-Claim
288	well-tolerated	_	_	I-Claim
289	and	_	_	I-Claim
290	active	_	_	I-Claim
291	second	_	_	I-Claim
292	and	_	_	I-Claim
293	third	_	_	I-Claim
294	line	_	_	I-Claim
295	treatment	_	_	I-Claim
296	for	_	_	I-Claim
297	NSCLC	_	_	I-Claim
298	patients	_	_	I-Claim
299	.	_	_	O

300	Ongoing	_	_	O
301	studies	_	_	O
302	are	_	_	O
303	exploring	_	_	O
304	alternate	_	_	O
305	schedules	_	_	O
306	to	_	_	O
307	maximize	_	_	O
308	synergy	_	_	O
309	between	_	_	O
310	these	_	_	O
311	agents	_	_	O
312	.	_	_	O


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	radiotherapy	_	_	O
4	plus	_	_	O
5	long-term	_	_	O
6	medical	_	_	O
7	suppression	_	_	O
8	of	_	_	O
9	androgens	_	_	O
10	(	_	_	O
11	>	_	_	O
12	or	_	_	O
13	=	_	_	O
14	2	_	_	O
15	years	_	_	O
16	)	_	_	O
17	improves	_	_	O
18	overall	_	_	O
19	survival	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	locally	_	_	O
24	advanced	_	_	O
25	prostate	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	We	_	_	O
29	compared	_	_	O
30	the	_	_	O
31	use	_	_	O
32	of	_	_	O
33	radiotherapy	_	_	O
34	plus	_	_	O
35	short-term	_	_	O
36	androgen	_	_	O
37	suppression	_	_	O
38	with	_	_	O
39	the	_	_	O
40	use	_	_	O
41	of	_	_	O
42	radiotherapy	_	_	O
43	plus	_	_	O
44	long-term	_	_	O
45	androgen	_	_	O
46	suppression	_	_	O
47	in	_	_	O
48	the	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	locally	_	_	O
52	advanced	_	_	O
53	prostate	_	_	O
54	cancer	_	_	O
55	.	_	_	O

56	We	_	_	O
57	randomly	_	_	O
58	assigned	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	locally	_	_	O
62	advanced	_	_	O
63	prostate	_	_	O
64	cancer	_	_	O
65	who	_	_	O
66	had	_	_	O
67	received	_	_	O
68	external-beam	_	_	O
69	radiotherapy	_	_	O
70	plus	_	_	O
71	6	_	_	O
72	months	_	_	O
73	of	_	_	O
74	androgen	_	_	O
75	suppression	_	_	O
76	to	_	_	O
77	two	_	_	O
78	groups	_	_	O
79	,	_	_	O
80	one	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	no	_	_	O
84	further	_	_	O
85	treatment	_	_	O
86	(	_	_	O
87	short-term	_	_	O
88	suppression	_	_	O
89	)	_	_	O
90	and	_	_	O
91	the	_	_	O
92	other	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	2.5	_	_	O
96	years	_	_	O
97	of	_	_	O
98	further	_	_	O
99	treatment	_	_	O
100	with	_	_	O
101	a	_	_	O
102	luteinizing	_	_	O
103	hormone-releasing	_	_	O
104	hormone	_	_	O
105	agonist	_	_	O
106	(	_	_	O
107	long-term	_	_	O
108	suppression	_	_	O
109	)	_	_	O
110	.	_	_	O

111	An	_	_	O
112	outcome	_	_	O
113	of	_	_	O
114	noninferiority	_	_	O
115	of	_	_	O
116	short-term	_	_	O
117	androgen	_	_	O
118	suppression	_	_	O
119	as	_	_	O
120	compared	_	_	O
121	with	_	_	O
122	long-term	_	_	O
123	suppression	_	_	O
124	required	_	_	O
125	a	_	_	O
126	hazard	_	_	O
127	ratio	_	_	O
128	of	_	_	O
129	more	_	_	O
130	than	_	_	O
131	1.35	_	_	O
132	for	_	_	O
133	overall	_	_	O
134	survival	_	_	O
135	,	_	_	O
136	with	_	_	O
137	a	_	_	O
138	one-sided	_	_	O
139	alpha	_	_	O
140	level	_	_	O
141	of	_	_	O
142	0.05	_	_	O
143	.	_	_	O

144	An	_	_	O
145	interim	_	_	O
146	analysis	_	_	O
147	showed	_	_	O
148	futility	_	_	O
149	,	_	_	O
150	and	_	_	O
151	the	_	_	O
152	results	_	_	O
153	are	_	_	O
154	presented	_	_	O
155	with	_	_	O
156	an	_	_	O
157	adjusted	_	_	O
158	one-sided	_	_	O
159	alpha	_	_	O
160	level	_	_	O
161	of	_	_	O
162	0.0429	_	_	O
163	.	_	_	O

164	A	_	_	O
165	total	_	_	O
166	of	_	_	O
167	1113	_	_	O
168	men	_	_	O
169	were	_	_	O
170	registered	_	_	O
171	,	_	_	O
172	of	_	_	O
173	whom	_	_	O
174	970	_	_	O
175	were	_	_	O
176	randomly	_	_	O
177	assigned	_	_	O
178	,	_	_	O
179	483	_	_	O
180	to	_	_	O
181	short-term	_	_	O
182	suppression	_	_	O
183	and	_	_	O
184	487	_	_	O
185	to	_	_	O
186	long-term	_	_	O
187	suppression	_	_	O
188	.	_	_	O

189	After	_	_	B-Premise
190	a	_	_	I-Premise
191	median	_	_	I-Premise
192	follow-up	_	_	I-Premise
193	of	_	_	I-Premise
194	6.4	_	_	I-Premise
195	years	_	_	I-Premise
196	,	_	_	I-Premise
197	132	_	_	I-Premise
198	patients	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	short-term	_	_	I-Premise
202	group	_	_	I-Premise
203	and	_	_	I-Premise
204	98	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	long-term	_	_	I-Premise
208	group	_	_	I-Premise
209	had	_	_	I-Premise
210	died	_	_	I-Premise
211	;	_	_	I-Premise
212	the	_	_	B-Premise
213	number	_	_	I-Premise
214	of	_	_	I-Premise
215	deaths	_	_	I-Premise
216	due	_	_	I-Premise
217	to	_	_	I-Premise
218	prostate	_	_	I-Premise
219	cancer	_	_	I-Premise
220	was	_	_	I-Premise
221	47	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	short-term	_	_	I-Premise
225	group	_	_	I-Premise
226	and	_	_	I-Premise
227	29	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	long-term	_	_	I-Premise
231	group	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	5-year	_	_	I-Premise
235	overall	_	_	I-Premise
236	mortality	_	_	I-Premise
237	for	_	_	I-Premise
238	short-term	_	_	I-Premise
239	and	_	_	I-Premise
240	long-term	_	_	I-Premise
241	suppression	_	_	I-Premise
242	was	_	_	I-Premise
243	19.0	_	_	I-Premise
244	%	_	_	I-Premise
245	and	_	_	I-Premise
246	15.2	_	_	I-Premise
247	%	_	_	I-Premise
248	,	_	_	I-Premise
249	respectively	_	_	I-Premise
250	;	_	_	I-Premise
251	the	_	_	O
252	observed	_	_	O
253	hazard	_	_	O
254	ratio	_	_	O
255	was	_	_	O
256	1.42	_	_	O
257	(	_	_	O
258	upper	_	_	O
259	95.71	_	_	O
260	%	_	_	O
261	confidence	_	_	O
262	limit	_	_	O
263	,	_	_	O
264	1.79	_	_	O
265	;	_	_	O
266	P=0.65	_	_	O
267	for	_	_	O
268	noninferiority	_	_	O
269	)	_	_	O
270	.	_	_	O

271	Adverse	_	_	B-Premise
272	events	_	_	I-Premise
273	in	_	_	I-Premise
274	both	_	_	I-Premise
275	groups	_	_	I-Premise
276	included	_	_	I-Premise
277	fatigue	_	_	I-Premise
278	,	_	_	I-Premise
279	diminished	_	_	I-Premise
280	sexual	_	_	I-Premise
281	function	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	hot	_	_	I-Premise
285	flushes	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Claim
288	combination	_	_	I-Claim
289	of	_	_	I-Claim
290	radiotherapy	_	_	I-Claim
291	plus	_	_	I-Claim
292	6	_	_	I-Claim
293	months	_	_	I-Claim
294	of	_	_	I-Claim
295	androgen	_	_	I-Claim
296	suppression	_	_	I-Claim
297	provides	_	_	I-Claim
298	inferior	_	_	I-Claim
299	survival	_	_	I-Claim
300	as	_	_	I-Claim
301	compared	_	_	I-Claim
302	with	_	_	I-Claim
303	radiotherapy	_	_	I-Claim
304	plus	_	_	I-Claim
305	3	_	_	I-Claim
306	years	_	_	I-Claim
307	of	_	_	I-Claim
308	androgen	_	_	I-Claim
309	suppression	_	_	I-Claim
310	in	_	_	I-Claim
311	the	_	_	I-Claim
312	treatment	_	_	I-Claim
313	of	_	_	I-Claim
314	locally	_	_	I-Claim
315	advanced	_	_	I-Claim
316	prostate	_	_	I-Claim
317	cancer	_	_	I-Claim
318	.	_	_	I-Claim


0	Cancer	_	_	O
1	cachexia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	problem	_	_	O
6	among	_	_	O
7	advanced	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	.	_	_	O

11	A	_	_	O
12	mixture	_	_	O
13	of	_	_	O
14	beta-hydroxyl	_	_	O
15	beta-methyl	_	_	O
16	butyrate	_	_	O
17	,	_	_	O
18	glutamine	_	_	O
19	,	_	_	O
20	and	_	_	O
21	arginine	_	_	O
22	(	_	_	O
23	HMB/Arg/Gln	_	_	O
24	)	_	_	O
25	previously	_	_	O
26	showed	_	_	O
27	activity	_	_	O
28	for	_	_	O
29	increasing	_	_	O
30	lean	_	_	O
31	body	_	_	O
32	mass	_	_	O
33	(	_	_	O
34	LBM	_	_	O
35	)	_	_	O
36	among	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	cancer	_	_	O
40	cachexia	_	_	O
41	.	_	_	O

42	Therefore	_	_	O
43	a	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	trial	_	_	O
47	was	_	_	O
48	implemented	_	_	O
49	to	_	_	O
50	confirm	_	_	O
51	this	_	_	O
52	activity	_	_	O
53	.	_	_	O

54	Four	_	_	O
55	hundred	_	_	O
56	seventy-two	_	_	O
57	advanced	_	_	O
58	cancer	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	between	_	_	O
62	2	_	_	O
63	%	_	_	O
64	and	_	_	O
65	10	_	_	O
66	%	_	_	O
67	weight	_	_	O
68	loss	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	a	_	_	O
73	mixture	_	_	O
74	of	_	_	O
75	beta-hydroxyl	_	_	O
76	beta-methyl	_	_	O
77	butyrate	_	_	O
78	,	_	_	O
79	glutamine	_	_	O
80	,	_	_	O
81	and	_	_	O
82	arginine	_	_	O
83	or	_	_	O
84	an	_	_	O
85	isonitrogenous	_	_	O
86	,	_	_	O
87	isocaloric	_	_	O
88	control	_	_	O
89	mixture	_	_	O
90	taken	_	_	O
91	twice	_	_	O
92	a	_	_	O
93	day	_	_	O
94	for	_	_	O
95	8	_	_	O
96	weeks	_	_	O
97	.	_	_	O

98	Lean	_	_	O
99	body	_	_	O
100	mass	_	_	O
101	was	_	_	O
102	estimated	_	_	O
103	by	_	_	O
104	bioimpedance	_	_	O
105	and	_	_	O
106	skin-fold	_	_	O
107	measurements	_	_	O
108	.	_	_	O

109	Body	_	_	O
110	plethysmography	_	_	O
111	was	_	_	O
112	used	_	_	O
113	when	_	_	O
114	available	_	_	O
115	.	_	_	O

116	Weight	_	_	O
117	,	_	_	O
118	the	_	_	O
119	Schwartz	_	_	O
120	Fatigue	_	_	O
121	Scale	_	_	O
122	,	_	_	O
123	and	_	_	O
124	the	_	_	O
125	Spitzer	_	_	O
126	Quality	_	_	O
127	of	_	_	O
128	Life	_	_	O
129	Scale	_	_	O
130	were	_	_	O
131	also	_	_	O
132	measured	_	_	O
133	.	_	_	O

134	Only	_	_	O
135	37	_	_	O
136	%	_	_	O
137	of	_	_	O
138	the	_	_	O
139	patients	_	_	O
140	completed	_	_	O
141	protocol	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	The	_	_	O
145	majority	_	_	O
146	of	_	_	O
147	the	_	_	O
148	patient	_	_	O
149	loss	_	_	O
150	was	_	_	O
151	because	_	_	O
152	of	_	_	O
153	patient	_	_	O
154	preference	_	_	O
155	(	_	_	O
156	45	_	_	O
157	%	_	_	O
158	of	_	_	O
159	enrolled	_	_	O
160	patients	_	_	O
161	)	_	_	O
162	.	_	_	O

163	However	_	_	O
164	,	_	_	O
165	loss	_	_	O
166	of	_	_	O
167	power	_	_	O
168	was	_	_	O
169	not	_	_	O
170	an	_	_	O
171	issue	_	_	O
172	because	_	_	O
173	of	_	_	O
174	the	_	_	O
175	planned	_	_	O
176	large	_	_	O
177	target	_	_	O
178	sample	_	_	O
179	size	_	_	O
180	.	_	_	O

181	Based	_	_	O
182	on	_	_	O
183	an	_	_	O
184	intention	_	_	O
185	to	_	_	O
186	treat	_	_	O
187	analysis	_	_	O
188	,	_	_	O
189	there	_	_	O
190	was	_	_	O
191	no	_	_	O
192	statistically	_	_	O
193	significant	_	_	O
194	difference	_	_	O
195	in	_	_	O
196	the	_	_	O
197	8-week	_	_	O
198	lean	_	_	O
199	body	_	_	O
200	mass	_	_	O
201	between	_	_	O
202	the	_	_	O
203	two	_	_	O
204	arms	_	_	O
205	.	_	_	O

206	The	_	_	O
207	secondary	_	_	O
208	endpoints	_	_	O
209	were	_	_	O
210	also	_	_	O
211	not	_	_	O
212	significantly	_	_	O
213	different	_	_	O
214	between	_	_	O
215	the	_	_	O
216	arms	_	_	O
217	.	_	_	O

218	Based	_	_	B-Premise
219	on	_	_	I-Premise
220	the	_	_	I-Premise
221	results	_	_	I-Premise
222	of	_	_	I-Premise
223	the	_	_	I-Premise
224	area	_	_	I-Premise
225	under	_	_	I-Premise
226	the	_	_	I-Premise
227	curve	_	_	I-Premise
228	(	_	_	I-Premise
229	AUC	_	_	I-Premise
230	)	_	_	I-Premise
231	analysis	_	_	I-Premise
232	,	_	_	I-Premise
233	patients	_	_	I-Premise
234	receiving	_	_	I-Premise
235	HMB/Arg/Gln	_	_	I-Premise
236	had	_	_	I-Premise
237	a	_	_	I-Premise
238	strong	_	_	I-Premise
239	trend	_	_	I-Premise
240	higher	_	_	I-Premise
241	LBM	_	_	I-Premise
242	throughout	_	_	I-Premise
243	the	_	_	I-Premise
244	study	_	_	I-Premise
245	as	_	_	I-Premise
246	measured	_	_	I-Premise
247	by	_	_	I-Premise
248	both	_	_	I-Premise
249	bioimpedance	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.08	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	skin-fold	_	_	I-Premise
257	measurements	_	_	I-Premise
258	(	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	0.08	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Among	_	_	B-Premise
265	the	_	_	I-Premise
266	subset	_	_	I-Premise
267	of	_	_	I-Premise
268	patients	_	_	I-Premise
269	receiving	_	_	I-Premise
270	concurrent	_	_	I-Premise
271	chemotherapy	_	_	I-Premise
272	,	_	_	I-Premise
273	there	_	_	I-Premise
274	were	_	_	I-Premise
275	again	_	_	I-Premise
276	no	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	endpoints	_	_	I-Premise
282	.	_	_	I-Premise

283	The	_	_	O
284	secondary	_	_	O
285	endpoints	_	_	O
286	were	_	_	O
287	also	_	_	O
288	not	_	_	O
289	significantly	_	_	O
290	different	_	_	O
291	between	_	_	O
292	the	_	_	O
293	arms	_	_	O
294	.	_	_	O

295	This	_	_	B-Claim
296	trial	_	_	I-Claim
297	was	_	_	I-Claim
298	unable	_	_	I-Claim
299	to	_	_	I-Claim
300	adequately	_	_	I-Claim
301	test	_	_	I-Claim
302	the	_	_	I-Claim
303	ability	_	_	I-Claim
304	of	_	_	I-Claim
305	beta-hydroxy	_	_	I-Claim
306	beta-methylbutyrate	_	_	I-Claim
307	,	_	_	I-Claim
308	glutamine	_	_	I-Claim
309	,	_	_	I-Claim
310	and	_	_	I-Claim
311	arginine	_	_	I-Claim
312	to	_	_	I-Claim
313	reverse	_	_	I-Claim
314	or	_	_	I-Claim
315	prevent	_	_	I-Claim
316	lean	_	_	I-Claim
317	body	_	_	I-Claim
318	mass	_	_	I-Claim
319	wasting	_	_	I-Claim
320	among	_	_	I-Claim
321	cancer	_	_	I-Claim
322	patients	_	_	I-Claim
323	.	_	_	I-Claim

324	Possible	_	_	O
325	contributing	_	_	O
326	factors	_	_	O
327	beyond	_	_	O
328	the	_	_	O
329	efficacy	_	_	O
330	of	_	_	O
331	the	_	_	O
332	intervention	_	_	O
333	were	_	_	O
334	the	_	_	O
335	inability	_	_	O
336	of	_	_	O
337	patients	_	_	O
338	to	_	_	O
339	complete	_	_	O
340	an	_	_	O
341	8-week	_	_	O
342	course	_	_	O
343	of	_	_	O
344	treatment	_	_	O
345	and	_	_	O
346	return	_	_	O
347	in	_	_	O
348	a	_	_	O
349	timely	_	_	O
350	fashion	_	_	O
351	for	_	_	O
352	follow-up	_	_	O
353	assessment	_	_	O
354	,	_	_	O
355	and	_	_	O
356	because	_	_	O
357	the	_	_	O
358	patients	_	_	O
359	may	_	_	O
360	have	_	_	O
361	only	_	_	O
362	had	_	_	O
363	weight	_	_	O
364	loss	_	_	O
365	possible	_	_	O
366	not	_	_	O
367	related	_	_	O
368	to	_	_	O
369	cachexia	_	_	O
370	,	_	_	O
371	but	_	_	O
372	other	_	_	O
373	causes	_	_	O
374	of	_	_	O
375	weight	_	_	O
376	loss	_	_	O
377	,	_	_	O
378	such	_	_	O
379	as	_	_	O
380	decreased	_	_	O
381	appetite	_	_	O
382	.	_	_	O

383	However	_	_	O
384	,	_	_	O
385	there	_	_	O
386	was	_	_	O
387	a	_	_	O
388	strong	_	_	O
389	trend	_	_	O
390	towards	_	_	O
391	an	_	_	O
392	increased	_	_	O
393	body	_	_	O
394	mass	_	_	O
395	among	_	_	O
396	patients	_	_	O
397	taking	_	_	O
398	the	_	_	O
399	Juven	_	_	O
400	compound	_	_	O
401	using	_	_	O
402	the	_	_	O
403	secondary	_	_	O
404	endpoint	_	_	O
405	of	_	_	O
406	AUC	_	_	O
407	.	_	_	O


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	,	_	_	O
5	tolerability	_	_	O
6	and	_	_	O
7	efficacy	_	_	O
8	of	_	_	O
9	abatacept	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	rheumatoid	_	_	O
14	arthritis	_	_	O
15	(	_	_	O
16	RA	_	_	O
17	)	_	_	O
18	who	_	_	O
19	had	_	_	O
20	failed	_	_	O
21	anti-tumour	_	_	O
22	necrosis	_	_	O
23	factor	_	_	O
24	(	_	_	O
25	TNF	_	_	O
26	)	_	_	O
27	therapy	_	_	O
28	and	_	_	O
29	were	_	_	O
30	switched	_	_	O
31	to	_	_	O
32	abatacept	_	_	O
33	directly	_	_	O
34	or	_	_	O
35	after	_	_	O
36	completing	_	_	O
37	washout	_	_	O
38	.	_	_	O

39	In	_	_	O
40	this	_	_	O
41	international	_	_	O
42	,	_	_	O
43	6-month	_	_	O
44	,	_	_	O
45	open-label	_	_	O
46	trial	_	_	O
47	,	_	_	O
48	patients	_	_	O
49	had	_	_	O
50	active	_	_	O
51	RA	_	_	O
52	,	_	_	O
53	an	_	_	O
54	inadequate	_	_	O
55	response	_	_	O
56	to	_	_	O
57	anti-TNF	_	_	O
58	therapy	_	_	O
59	for	_	_	O
60	3	_	_	O
61	months	_	_	O
62	or	_	_	O
63	longer	_	_	O
64	and	_	_	O
65	a	_	_	O
66	disease	_	_	O
67	activity	_	_	O
68	score	_	_	O
69	in	_	_	O
70	28	_	_	O
71	joints	_	_	O
72	(	_	_	O
73	DAS28	_	_	O
74	(	_	_	O
75	C-reactive	_	_	O
76	protein	_	_	O
77	;	_	_	O
78	CRP	_	_	O
79	)	_	_	O
80	of	_	_	O
81	5.1	_	_	O
82	or	_	_	O
83	greater	_	_	O
84	.	_	_	O

85	"	_	_	O
86	Washout	_	_	O
87	"	_	_	O
88	patients	_	_	O
89	discontinued	_	_	O
90	anti-TNF	_	_	O
91	therapy	_	_	O
92	2	_	_	O
93	months	_	_	O
94	or	_	_	O
95	longer	_	_	O
96	pre-screening	_	_	O
97	;	_	_	O
98	"	_	_	O
99	direct-switch	_	_	O
100	"	_	_	O
101	patients	_	_	O
102	began	_	_	O
103	abatacept	_	_	O
104	(	_	_	O
105	approximately	_	_	O
106	10	_	_	O
107	mg/kg	_	_	O
108	)	_	_	O
109	at	_	_	O
110	their	_	_	O
111	next	_	_	O
112	scheduled	_	_	O
113	anti-TNF	_	_	O
114	therapy	_	_	O
115	dose	_	_	O
116	.	_	_	O

117	1046	_	_	O
118	patients	_	_	O
119	were	_	_	O
120	treated	_	_	O
121	(	_	_	O
122	449	_	_	O
123	washout	_	_	O
124	,	_	_	O
125	597	_	_	O
126	direct-switch	_	_	O
127	;	_	_	O
128	baseline	_	_	O
129	characteristics	_	_	O
130	were	_	_	O
131	similar	_	_	O
132	between	_	_	O
133	groups	_	_	O
134	)	_	_	O
135	.	_	_	O

136	At	_	_	B-Premise
137	6	_	_	I-Premise
138	months	_	_	I-Premise
139	,	_	_	I-Premise
140	adverse	_	_	I-Premise
141	events	_	_	I-Premise
142	(	_	_	I-Premise
143	AE	_	_	I-Premise
144	;	_	_	I-Premise
145	78.0	_	_	I-Premise
146	%	_	_	I-Premise
147	vs	_	_	I-Premise
148	79.2	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	,	_	_	I-Premise
152	serious	_	_	I-Premise
153	AE	_	_	I-Premise
154	(	_	_	I-Premise
155	11.1	_	_	I-Premise
156	%	_	_	I-Premise
157	vs	_	_	I-Premise
158	9.9	_	_	I-Premise
159	%	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	discontinuations	_	_	I-Premise
163	due	_	_	I-Premise
164	to	_	_	I-Premise
165	AE	_	_	I-Premise
166	(	_	_	I-Premise
167	3.8	_	_	I-Premise
168	%	_	_	I-Premise
169	vs	_	_	I-Premise
170	4.0	_	_	I-Premise
171	%	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	serious	_	_	I-Premise
175	AE	_	_	I-Premise
176	(	_	_	I-Premise
177	2.0	_	_	I-Premise
178	%	_	_	I-Premise
179	vs	_	_	I-Premise
180	1.3	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	were	_	_	I-Premise
184	comparable	_	_	I-Premise
185	in	_	_	I-Premise
186	washout	_	_	I-Premise
187	versus	_	_	I-Premise
188	direct-switch	_	_	I-Premise
189	patients	_	_	I-Premise
190	.	_	_	I-Premise

191	There	_	_	B-Premise
192	were	_	_	I-Premise
193	no	_	_	I-Premise
194	opportunistic	_	_	I-Premise
195	infections	_	_	I-Premise
196	.	_	_	I-Premise

197	At	_	_	B-Premise
198	6	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	in	_	_	I-Premise
202	washout	_	_	I-Premise
203	versus	_	_	I-Premise
204	direct-switch	_	_	I-Premise
205	patients	_	_	I-Premise
206	,	_	_	I-Premise
207	similar	_	_	I-Premise
208	clinically	_	_	I-Premise
209	meaningful	_	_	I-Premise
210	improvements	_	_	I-Premise
211	were	_	_	I-Premise
212	seen	_	_	I-Premise
213	in	_	_	I-Premise
214	DAS28	_	_	I-Premise
215	(	_	_	I-Premise
216	CRP	_	_	I-Premise
217	)	_	_	I-Premise
218	(	_	_	I-Premise
219	>	_	_	I-Premise
220	or	_	_	I-Premise
221	=1.2	_	_	I-Premise
222	unit	_	_	I-Premise
223	improvement	_	_	I-Premise
224	,	_	_	I-Premise
225	59.5	_	_	I-Premise
226	%	_	_	I-Premise
227	vs	_	_	I-Premise
228	53.6	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	;	_	_	I-Premise
233	low	_	_	I-Premise
234	disease	_	_	I-Premise
235	activity	_	_	I-Premise
236	state	_	_	I-Premise
237	,	_	_	I-Premise
238	22.5	_	_	I-Premise
239	%	_	_	I-Premise
240	vs	_	_	I-Premise
241	22.3	_	_	I-Premise
242	%	_	_	I-Premise
243	;	_	_	I-Premise
244	DAS28-defined	_	_	I-Premise
245	remission	_	_	I-Premise
246	,	_	_	I-Premise
247	12.0	_	_	I-Premise
248	%	_	_	I-Premise
249	vs	_	_	I-Premise
250	13.7	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	physical	_	_	I-Premise
255	function	_	_	I-Premise
256	(	_	_	I-Premise
257	health	_	_	I-Premise
258	assessment	_	_	I-Premise
259	questionnaire	_	_	I-Premise
260	disability	_	_	I-Premise
261	index	_	_	I-Premise
262	>	_	_	I-Premise
263	or	_	_	I-Premise
264	=0.22	_	_	I-Premise
265	improvement	_	_	I-Premise
266	;	_	_	I-Premise
267	46.3	_	_	I-Premise
268	%	_	_	I-Premise
269	vs	_	_	I-Premise
270	47.1	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	health-related	_	_	I-Premise
275	quality	_	_	I-Premise
276	of	_	_	I-Premise
277	life	_	_	I-Premise
278	(	_	_	I-Premise
279	mean	_	_	I-Premise
280	change	_	_	I-Premise
281	in	_	_	I-Premise
282	short-form	_	_	I-Premise
283	36	_	_	I-Premise
284	scores	_	_	I-Premise
285	:	_	_	I-Premise
286	physical	_	_	I-Premise
287	component	_	_	I-Premise
288	summary	_	_	I-Premise
289	,	_	_	I-Premise
290	5.5	_	_	I-Premise
291	vs	_	_	I-Premise
292	6.1	_	_	I-Premise
293	;	_	_	I-Premise
294	mental	_	_	I-Premise
295	component	_	_	I-Premise
296	summary	_	_	I-Premise
297	,	_	_	I-Premise
298	4.8	_	_	I-Premise
299	vs	_	_	I-Premise
300	5.4	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Abatacept	_	_	B-Claim
304	demonstrated	_	_	I-Claim
305	acceptable	_	_	I-Claim
306	safety	_	_	I-Claim
307	and	_	_	I-Claim
308	tolerability	_	_	I-Claim
309	and	_	_	I-Claim
310	clinically	_	_	I-Claim
311	meaningful	_	_	I-Claim
312	efficacy	_	_	I-Claim
313	over	_	_	I-Claim
314	6	_	_	I-Claim
315	months	_	_	I-Claim
316	in	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	inadequate	_	_	I-Claim
320	response	_	_	I-Claim
321	to	_	_	I-Claim
322	anti-TNF	_	_	I-Claim
323	therapy	_	_	I-Claim
324	.	_	_	I-Claim

325	Results	_	_	B-Claim
326	were	_	_	I-Claim
327	comparable	_	_	I-Claim
328	with	_	_	I-Claim
329	or	_	_	I-Claim
330	without	_	_	I-Claim
331	a	_	_	I-Claim
332	washout	_	_	I-Claim
333	,	_	_	I-Claim
334	supporting	_	_	I-Claim
335	direct	_	_	I-Claim
336	switching	_	_	I-Claim
337	from	_	_	I-Claim
338	anti-TNF	_	_	I-Claim
339	therapy	_	_	I-Claim
340	to	_	_	I-Claim
341	abatacept	_	_	I-Claim
342	as	_	_	I-Claim
343	an	_	_	I-Claim
344	option	_	_	I-Claim
345	in	_	_	I-Claim
346	clinical	_	_	I-Claim
347	practice	_	_	I-Claim
348	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	patient-reported	_	_	O
3	prostate	_	_	O
4	cancer-specific	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	2	_	_	O
9	and	_	_	O
10	3	_	_	O
11	years	_	_	O
12	after	_	_	O
13	radiotherapy	_	_	O
14	to	_	_	O
15	the	_	_	O
16	prostate	_	_	O
17	in	_	_	O
18	a	_	_	O
19	randomized	_	_	O
20	dose-escalation	_	_	O
21	trial	_	_	O
22	of	_	_	O
23	70	_	_	O
24	versus	_	_	O
25	78	_	_	O
26	Gy	_	_	O
27	conducted	_	_	O
28	from	_	_	O
29	1993	_	_	O
30	to	_	_	O
31	1998	_	_	O
32	.	_	_	O

33	Two	_	_	O
34	years	_	_	O
35	after	_	_	O
36	completing	_	_	O
37	radiotherapy	_	_	O
38	,	_	_	O
39	a	_	_	O
40	questionnaire	_	_	O
41	that	_	_	O
42	assessed	_	_	O
43	bladder	_	_	O
44	,	_	_	O
45	rectal	_	_	O
46	,	_	_	O
47	and	_	_	O
48	sexual	_	_	O
49	function	_	_	O
50	was	_	_	O
51	sent	_	_	O
52	to	_	_	O
53	301	_	_	O
54	patients	_	_	O
55	in	_	_	O
56	the	_	_	O
57	study	_	_	O
58	.	_	_	O

59	Three	_	_	O
60	years	_	_	O
61	after	_	_	O
62	treatment	_	_	O
63	,	_	_	O
64	a	_	_	O
65	second	_	_	O
66	questionnaire	_	_	O
67	was	_	_	O
68	sent	_	_	O
69	to	_	_	O
70	the	_	_	O
71	175	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	adequate	_	_	O
75	follow-up	_	_	O
76	.	_	_	O

77	Three	_	_	B-Premise
78	years	_	_	I-Premise
79	after	_	_	I-Premise
80	radiotherapy	_	_	I-Premise
81	,	_	_	I-Premise
82	urinary	_	_	I-Premise
83	incontinence	_	_	I-Premise
84	was	_	_	I-Premise
85	reported	_	_	I-Premise
86	by	_	_	I-Premise
87	35	_	_	I-Premise
88	%	_	_	I-Premise
89	of	_	_	I-Premise
90	patients	_	_	I-Premise
91	,	_	_	I-Premise
92	but	_	_	I-Premise
93	only	_	_	I-Premise
94	6	_	_	I-Premise
95	%	_	_	I-Premise
96	required	_	_	I-Premise
97	the	_	_	I-Premise
98	use	_	_	I-Premise
99	of	_	_	I-Premise
100	a	_	_	I-Premise
101	pad	_	_	I-Premise
102	or	_	_	I-Premise
103	other	_	_	I-Premise
104	protective	_	_	I-Premise
105	device	_	_	I-Premise
106	.	_	_	I-Premise

107	Patients	_	_	B-Premise
108	reported	_	_	I-Premise
109	increased	_	_	I-Premise
110	leakage	_	_	I-Premise
111	with	_	_	I-Premise
112	a	_	_	I-Premise
113	full	_	_	I-Premise
114	bladder	_	_	I-Premise
115	(	_	_	I-Premise
116	urge	_	_	I-Premise
117	incontinence	_	_	I-Premise
118	)	_	_	I-Premise
119	between	_	_	I-Premise
120	the	_	_	I-Premise
121	2	_	_	I-Premise
122	and	_	_	I-Premise
123	3-year	_	_	I-Premise
124	questionnaires	_	_	I-Premise
125	(	_	_	I-Premise
126	42	_	_	I-Premise
127	%	_	_	I-Premise
128	versus	_	_	I-Premise
129	50	_	_	I-Premise
130	%	_	_	I-Premise
131	;	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	0.03	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	At	_	_	B-Premise
138	3	_	_	I-Premise
139	years	_	_	I-Premise
140	,	_	_	I-Premise
141	33	_	_	I-Premise
142	%	_	_	I-Premise
143	of	_	_	I-Premise
144	patients	_	_	I-Premise
145	reported	_	_	I-Premise
146	rectal	_	_	I-Premise
147	bleeding	_	_	I-Premise
148	compared	_	_	I-Premise
149	with	_	_	I-Premise
150	47	_	_	I-Premise
151	%	_	_	I-Premise
152	at	_	_	I-Premise
153	2	_	_	I-Premise
154	years	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.006	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	Patients	_	_	B-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	78-Gy	_	_	I-Premise
165	arm	_	_	I-Premise
166	reported	_	_	I-Premise
167	more	_	_	I-Premise
168	frequent	_	_	I-Premise
169	bowel	_	_	I-Premise
170	movements	_	_	I-Premise
171	at	_	_	I-Premise
172	3	_	_	I-Premise
173	years	_	_	I-Premise
174	and	_	_	I-Premise
175	less	_	_	I-Premise
176	change	_	_	I-Premise
177	in	_	_	I-Premise
178	bowel	_	_	I-Premise
179	function	_	_	I-Premise
180	at	_	_	I-Premise
181	2	_	_	I-Premise
182	years	_	_	I-Premise
183	than	_	_	I-Premise
184	patients	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	70-Gy	_	_	I-Premise
188	arm	_	_	I-Premise
189	.	_	_	I-Premise

190	Before	_	_	B-Premise
191	radiotherapy	_	_	I-Premise
192	,	_	_	I-Premise
193	84	_	_	I-Premise
194	%	_	_	I-Premise
195	of	_	_	I-Premise
196	patients	_	_	I-Premise
197	reported	_	_	I-Premise
198	erections	_	_	I-Premise
199	adequate	_	_	I-Premise
200	for	_	_	I-Premise
201	intercourse	_	_	I-Premise
202	at	_	_	I-Premise
203	least	_	_	I-Premise
204	a	_	_	I-Premise
205	few	_	_	I-Premise
206	times	_	_	I-Premise
207	during	_	_	I-Premise
208	the	_	_	I-Premise
209	previous	_	_	I-Premise
210	year	_	_	I-Premise
211	.	_	_	I-Premise

212	After	_	_	B-Premise
213	2	_	_	I-Premise
214	and	_	_	I-Premise
215	3	_	_	I-Premise
216	years	_	_	I-Premise
217	,	_	_	I-Premise
218	this	_	_	I-Premise
219	had	_	_	I-Premise
220	decreased	_	_	I-Premise
221	to	_	_	I-Premise
222	49	_	_	I-Premise
223	%	_	_	I-Premise
224	and	_	_	I-Premise
225	41	_	_	I-Premise
226	%	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	0.02	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	By	_	_	B-Claim
236	patient-reported	_	_	I-Claim
237	questionnaire	_	_	I-Claim
238	,	_	_	I-Claim
239	78	_	_	I-Claim
240	Gy	_	_	I-Claim
241	produced	_	_	I-Claim
242	an	_	_	I-Claim
243	increase	_	_	I-Claim
244	in	_	_	I-Claim
245	bowel	_	_	I-Claim
246	movement	_	_	I-Claim
247	frequency	_	_	I-Claim
248	and	_	_	I-Claim
249	no	_	_	I-Claim
250	increase	_	_	I-Claim
251	in	_	_	I-Claim
252	bladder	_	_	I-Claim
253	or	_	_	I-Claim
254	sexual	_	_	I-Claim
255	side	_	_	I-Claim
256	effects	_	_	I-Claim
257	at	_	_	I-Claim
258	3	_	_	I-Claim
259	years	_	_	I-Claim
260	compared	_	_	I-Claim
261	with	_	_	I-Claim
262	70	_	_	I-Claim
263	Gy	_	_	I-Claim
264	.	_	_	I-Claim

265	Comparing	_	_	B-Claim
266	the	_	_	I-Claim
267	results	_	_	I-Claim
268	2	_	_	I-Claim
269	and	_	_	I-Claim
270	3	_	_	I-Claim
271	years	_	_	I-Claim
272	after	_	_	I-Claim
273	radiotherapy	_	_	I-Claim
274	,	_	_	I-Claim
275	the	_	_	I-Claim
276	symptoms	_	_	I-Claim
277	of	_	_	I-Claim
278	rectal	_	_	I-Claim
279	bleeding	_	_	I-Claim
280	had	_	_	I-Claim
281	improved	_	_	I-Claim
282	,	_	_	I-Claim
283	erectile	_	_	I-Claim
284	function	_	_	I-Claim
285	had	_	_	I-Claim
286	decreased	_	_	I-Claim
287	,	_	_	I-Claim
288	and	_	_	I-Claim
289	urinary	_	_	I-Claim
290	urge	_	_	I-Claim
291	incontinence	_	_	I-Claim
292	had	_	_	I-Claim
293	increased	_	_	I-Claim
294	.	_	_	I-Claim


0	Due	_	_	O
1	to	_	_	O
2	the	_	_	O
3	various	_	_	O
4	inter-individual	_	_	O
5	differences	_	_	O
6	in	_	_	O
7	the	_	_	O
8	biological	_	_	O
9	characteristics	_	_	O
10	of	_	_	O
11	tumor	_	_	O
12	cells	_	_	O
13	,	_	_	O
14	as	_	_	O
15	well	_	_	O
16	as	_	_	O
17	issues	_	_	O
18	on	_	_	O
19	the	_	_	O
20	efficacy	_	_	O
21	,	_	_	O
22	adverse	_	_	O
23	reactions	_	_	O
24	,	_	_	O
25	and	_	_	O
26	defects	_	_	O
27	of	_	_	O
28	existing	_	_	O
29	drugs	_	_	O
30	,	_	_	O
31	we	_	_	O
32	compared	_	_	O
33	the	_	_	O
34	clinical	_	_	O
35	efficacy	_	_	O
36	and	_	_	O
37	toxicity	_	_	O
38	of	_	_	O
39	pemetrexed	_	_	O
40	and	_	_	O
41	gemcitabine	_	_	O
42	combined	_	_	O
43	with	_	_	O
44	cisplatin	_	_	O
45	for	_	_	O
46	the	_	_	O
47	treatment	_	_	O
48	of	_	_	O
49	previously	_	_	O
50	untreated	_	_	O
51	advanced	_	_	O
52	non-small	_	_	O
53	cell	_	_	O
54	lung	_	_	O
55	cancer	_	_	O
56	(	_	_	O
57	NSCLC	_	_	O
58	)	_	_	O
59	.	_	_	O

60	251	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	randomly	_	_	O
64	divided	_	_	O
65	into	_	_	O
66	pemetrexed	_	_	O
67	combined	_	_	O
68	with	_	_	O
69	cisplatin	_	_	O
70	group	_	_	O
71	(	_	_	O
72	PP	_	_	O
73	group	_	_	O
74	)	_	_	O
75	with	_	_	O
76	127	_	_	O
77	cases	_	_	O
78	and	_	_	O
79	gemcitabine	_	_	O
80	combined	_	_	O
81	with	_	_	O
82	cisplatin	_	_	O
83	group	_	_	O
84	(	_	_	O
85	GP	_	_	O
86	group	_	_	O
87	)	_	_	O
88	with	_	_	O
89	124	_	_	O
90	cases	_	_	O
91	.	_	_	O

92	PP	_	_	O
93	group	_	_	O
94	received	_	_	O
95	pemetrexed	_	_	O
96	500	_	_	O
97	mg/mÂ²	_	_	O
98	iv	_	_	O
99	infusion	_	_	O
100	d1	_	_	O
101	and	_	_	O
102	cisplatin	_	_	O
103	75	_	_	O
104	mg/mÂ²	_	_	O
105	iv	_	_	O
106	infusion	_	_	O
107	d1	_	_	O
108	,	_	_	O
109	whereas	_	_	O
110	GP	_	_	O
111	group	_	_	O
112	received	_	_	O
113	gemcitabine	_	_	O
114	1,000	_	_	O
115	mg/mÂ²	_	_	O
116	iv	_	_	O
117	infusion	_	_	O
118	d1,8	_	_	O
119	and	_	_	O
120	cisplatin	_	_	O
121	75	_	_	O
122	mg/mÂ²	_	_	O
123	iv	_	_	O
124	infusion	_	_	O
125	d1	_	_	O
126	.	_	_	O

127	The	_	_	O
128	treatment	_	_	O
129	cycle	_	_	O
130	was	_	_	O
131	once	_	_	O
132	every	_	_	O
133	three	_	_	O
134	weeks	_	_	O
135	.	_	_	O

136	In	_	_	O
137	addition	_	_	O
138	,	_	_	O
139	folic	_	_	O
140	acid	_	_	O
141	,	_	_	O
142	vitamin	_	_	O
143	B12	_	_	O
144	,	_	_	O
145	and	_	_	O
146	dexamethasone	_	_	O
147	were	_	_	O
148	administered	_	_	O
149	in	_	_	O
150	both	_	_	O
151	groups	_	_	O
152	.	_	_	O

153	The	_	_	B-Premise
154	total	_	_	I-Premise
155	clinical	_	_	I-Premise
156	effective	_	_	I-Premise
157	rates	_	_	I-Premise
158	in	_	_	I-Premise
159	PP	_	_	I-Premise
160	group	_	_	I-Premise
161	and	_	_	I-Premise
162	GP	_	_	I-Premise
163	group	_	_	I-Premise
164	were	_	_	I-Premise
165	25.20	_	_	I-Premise
166	%	_	_	I-Premise
167	and	_	_	I-Premise
168	17.74	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	respectively	_	_	I-Premise
172	.	_	_	I-Premise

173	The	_	_	B-Premise
174	total	_	_	I-Premise
175	efficiencies	_	_	I-Premise
176	of	_	_	I-Premise
177	non-squamous	_	_	I-Premise
178	cell	_	_	I-Premise
179	carcinoma	_	_	I-Premise
180	were	_	_	I-Premise
181	27.62	_	_	I-Premise
182	%	_	_	I-Premise
183	and	_	_	I-Premise
184	16.00	_	_	I-Premise
185	%	_	_	I-Premise
186	.	_	_	I-Premise

187	The	_	_	B-Premise
188	tumor	_	_	I-Premise
189	progression	_	_	I-Premise
190	duration	_	_	I-Premise
191	in	_	_	I-Premise
192	these	_	_	I-Premise
193	two	_	_	I-Premise
194	groups	_	_	I-Premise
195	was	_	_	I-Premise
196	6.5	_	_	I-Premise
197	and	_	_	I-Premise
198	5.6	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	respectively	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	median	_	_	I-Premise
205	survival	_	_	I-Premise
206	time	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	two	_	_	I-Premise
210	groups	_	_	I-Premise
211	was	_	_	I-Premise
212	16.9	_	_	I-Premise
213	and	_	_	I-Premise
214	17.0	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	,	_	_	I-Premise
219	with	_	_	I-Premise
220	59.62	_	_	I-Premise
221	%	_	_	I-Premise
222	and	_	_	I-Premise
223	65.87	_	_	I-Premise
224	%	_	_	I-Premise
225	survival	_	_	I-Premise
226	rates	_	_	I-Premise
227	of	_	_	I-Premise
228	1	_	_	I-Premise
229	year	_	_	I-Premise
230	and	_	_	I-Premise
231	27.28	_	_	I-Premise
232	%	_	_	I-Premise
233	and	_	_	I-Premise
234	27.93	_	_	I-Premise
235	%	_	_	I-Premise
236	survival	_	_	I-Premise
237	rates	_	_	I-Premise
238	of	_	_	I-Premise
239	2	_	_	I-Premise
240	years	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	total	_	_	I-Premise
246	efficacy	_	_	I-Premise
247	of	_	_	I-Premise
248	non-squamous	_	_	I-Premise
249	cell	_	_	I-Premise
250	carcinoma	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	PP	_	_	I-Premise
254	group	_	_	I-Premise
255	was	_	_	I-Premise
256	significantly	_	_	I-Premise
257	higher	_	_	I-Premise
258	than	_	_	I-Premise
259	that	_	_	I-Premise
260	in	_	_	I-Premise
261	GP	_	_	I-Premise
262	group	_	_	I-Premise
263	.	_	_	I-Premise

264	The	_	_	B-Premise
265	results	_	_	I-Premise
266	were	_	_	I-Premise
267	statistically	_	_	I-Premise
268	significant	_	_	I-Premise
269	.	_	_	I-Premise

270	However	_	_	O
271	,	_	_	O
272	there	_	_	O
273	were	_	_	O
274	no	_	_	O
275	significant	_	_	O
276	differences	_	_	O
277	in	_	_	O
278	total	_	_	O
279	response	_	_	O
280	rates	_	_	O
281	,	_	_	O
282	tumor	_	_	O
283	progression	_	_	O
284	duration	_	_	O
285	,	_	_	O
286	and	_	_	O
287	median	_	_	O
288	survival	_	_	O
289	rates	_	_	O
290	of	_	_	O
291	1	_	_	O
292	and	_	_	O
293	2	_	_	O
294	years	_	_	O
295	.	_	_	O

296	The	_	_	B-Premise
297	rate	_	_	I-Premise
298	of	_	_	I-Premise
299	adverse	_	_	I-Premise
300	reactions	_	_	I-Premise
301	,	_	_	I-Premise
302	including	_	_	I-Premise
303	white	_	_	I-Premise
304	blood	_	_	I-Premise
305	cell	_	_	I-Premise
306	reduction	_	_	I-Premise
307	,	_	_	I-Premise
308	lower	_	_	I-Premise
309	platelet	_	_	I-Premise
310	count	_	_	I-Premise
311	,	_	_	I-Premise
312	lower	_	_	I-Premise
313	hemoglobin	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	hair	_	_	I-Premise
317	loss	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	PP	_	_	I-Premise
321	group	_	_	I-Premise
322	was	_	_	I-Premise
323	significantly	_	_	I-Premise
324	lower	_	_	I-Premise
325	than	_	_	I-Premise
326	that	_	_	I-Premise
327	in	_	_	I-Premise
328	the	_	_	I-Premise
329	GP	_	_	I-Premise
330	group	_	_	I-Premise
331	.	_	_	I-Premise

332	The	_	_	O
333	results	_	_	O
334	were	_	_	O
335	statistically	_	_	O
336	significant	_	_	O
337	.	_	_	O

338	The	_	_	B-Claim
339	clinical	_	_	I-Claim
340	efficacy	_	_	I-Claim
341	of	_	_	I-Claim
342	pemetrexed	_	_	I-Claim
343	and	_	_	I-Claim
344	gemcitabine	_	_	I-Claim
345	combined	_	_	I-Claim
346	with	_	_	I-Claim
347	cisplatin	_	_	I-Claim
348	for	_	_	I-Claim
349	the	_	_	I-Claim
350	treatment	_	_	I-Claim
351	of	_	_	I-Claim
352	previously	_	_	I-Claim
353	untreated	_	_	I-Claim
354	advanced	_	_	I-Claim
355	NSCLC	_	_	I-Claim
356	was	_	_	I-Claim
357	roughly	_	_	I-Claim
358	the	_	_	I-Claim
359	same	_	_	I-Claim
360	,	_	_	I-Claim
361	but	_	_	B-Claim
362	the	_	_	I-Claim
363	adverse	_	_	I-Claim
364	reactions	_	_	I-Claim
365	decreased	_	_	I-Claim
366	significantly	_	_	I-Claim
367	in	_	_	I-Claim
368	the	_	_	I-Claim
369	PP	_	_	I-Claim
370	group	_	_	I-Claim
371	compared	_	_	I-Claim
372	with	_	_	I-Claim
373	those	_	_	I-Claim
374	in	_	_	I-Claim
375	the	_	_	I-Claim
376	GP	_	_	I-Claim
377	group	_	_	I-Claim
378	.	_	_	I-Claim

379	Therefore	_	_	B-Claim
380	,	_	_	I-Claim
381	pemetrexed	_	_	I-Claim
382	combined	_	_	I-Claim
383	with	_	_	I-Claim
384	cisplatin	_	_	I-Claim
385	can	_	_	I-Claim
386	be	_	_	I-Claim
387	used	_	_	I-Claim
388	as	_	_	I-Claim
389	a	_	_	I-Claim
390	safe	_	_	I-Claim
391	and	_	_	I-Claim
392	effective	_	_	I-Claim
393	drug	_	_	I-Claim
394	for	_	_	I-Claim
395	clinical	_	_	I-Claim
396	first-line	_	_	I-Claim
397	treatment	_	_	I-Claim
398	for	_	_	I-Claim
399	previously	_	_	I-Claim
400	untreated	_	_	I-Claim
401	NSCLC	_	_	I-Claim
402	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	multicentre	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	establish	_	_	O
8	the	_	_	O
9	optimal	_	_	O
10	duration	_	_	O
11	of	_	_	O
12	palliative	_	_	O
13	chemotherapy	_	_	O
14	in	_	_	O
15	advanced	_	_	O
16	non-small-cell	_	_	O
17	lung	_	_	O
18	cancer	_	_	O
19	(	_	_	O
20	NSCLC	_	_	O
21	)	_	_	O
22	.	_	_	O

23	We	_	_	O
24	compared	_	_	O
25	a	_	_	O
26	policy	_	_	O
27	of	_	_	O
28	three	_	_	O
29	vs	_	_	O
30	six	_	_	O
31	courses	_	_	O
32	of	_	_	O
33	new-generation	_	_	O
34	platinum-based	_	_	O
35	combination	_	_	O
36	chemotherapy	_	_	O
37	with	_	_	O
38	regard	_	_	O
39	to	_	_	O
40	effects	_	_	O
41	on	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	and	_	_	O
49	survival	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	with	_	_	O
53	stage	_	_	O
54	IIIB	_	_	O
55	or	_	_	O
56	IV	_	_	O
57	NSCLC	_	_	O
58	and	_	_	O
59	WHO	_	_	O
60	performance	_	_	O
61	status	_	_	O
62	(	_	_	O
63	PS	_	_	O
64	)	_	_	O
65	0-2	_	_	O
66	were	_	_	O
67	randomised	_	_	O
68	to	_	_	O
69	receive	_	_	O
70	three	_	_	O
71	(	_	_	O
72	C3	_	_	O
73	)	_	_	O
74	or	_	_	O
75	six	_	_	O
76	(	_	_	O
77	C6	_	_	O
78	)	_	_	O
79	courses	_	_	O
80	of	_	_	O
81	carboplatin	_	_	O
82	(	_	_	O
83	area	_	_	O
84	under	_	_	O
85	the	_	_	O
86	curve	_	_	O
87	(	_	_	O
88	AUC	_	_	O
89	)	_	_	O
90	4	_	_	O
91	,	_	_	O
92	Chatelut	_	_	O
93	's	_	_	O
94	formula	_	_	O
95	,	_	_	O
96	equivalent	_	_	O
97	to	_	_	O
98	Calvert	_	_	O
99	's	_	_	O
100	AUC	_	_	O
101	5	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	1	_	_	O
106	and	_	_	O
107	vinorelbine	_	_	O
108	25	_	_	O
109	mg	_	_	O
110	m	_	_	O
111	(	_	_	O
112	-2	_	_	O
113	)	_	_	O
114	on	_	_	O
115	days	_	_	O
116	1	_	_	O
117	and	_	_	O
118	8	_	_	O
119	of	_	_	O
120	a	_	_	O
121	3-week	_	_	O
122	cycle	_	_	O
123	.	_	_	O

124	Key	_	_	O
125	end	_	_	O
126	points	_	_	O
127	were	_	_	O
128	QoL	_	_	O
129	at	_	_	O
130	18	_	_	O
131	weeks	_	_	O
132	,	_	_	O
133	measured	_	_	O
134	with	_	_	O
135	EORTC	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	(	_	_	O
141	QLQ	_	_	O
142	)	_	_	O
143	-C30	_	_	O
144	and	_	_	O
145	QLQ-LC13	_	_	O
146	,	_	_	O
147	and	_	_	O
148	overall	_	_	O
149	survival	_	_	O
150	.	_	_	O

151	Secondary	_	_	O
152	end	_	_	O
153	points	_	_	O
154	were	_	_	O
155	progression-free	_	_	O
156	survival	_	_	O
157	and	_	_	O
158	need	_	_	O
159	of	_	_	O
160	palliative	_	_	O
161	radiotherapy	_	_	O
162	.	_	_	O

163	Two	_	_	O
164	hundred	_	_	O
165	and	_	_	O
166	ninety-seven	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	randomised	_	_	O
170	(	_	_	O
171	C3	_	_	O
172	150	_	_	O
173	,	_	_	O
174	C6	_	_	O
175	147	_	_	O
176	)	_	_	O
177	.	_	_	O

178	Their	_	_	O
179	median	_	_	O
180	age	_	_	O
181	was	_	_	O
182	65	_	_	O
183	years	_	_	O
184	,	_	_	O
185	30	_	_	O
186	%	_	_	O
187	had	_	_	O
188	PS	_	_	O
189	2	_	_	O
190	and	_	_	O
191	76	_	_	O
192	%	_	_	O
193	stage	_	_	O
194	IV	_	_	O
195	disease	_	_	O
196	.	_	_	O

197	Seventy-eight	_	_	O
198	and	_	_	O
199	54	_	_	O
200	%	_	_	O
201	of	_	_	O
202	C3	_	_	O
203	and	_	_	O
204	C6	_	_	O
205	patients	_	_	O
206	,	_	_	O
207	respectively	_	_	O
208	,	_	_	O
209	completed	_	_	O
210	all	_	_	O
211	scheduled	_	_	O
212	chemotherapy	_	_	O
213	courses	_	_	O
214	.	_	_	O

215	Compliance	_	_	O
216	with	_	_	O
217	QoL	_	_	O
218	questionnaires	_	_	O
219	was	_	_	O
220	88	_	_	O
221	%	_	_	O
222	.	_	_	O

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	significant	_	_	I-Premise
227	group	_	_	I-Premise
228	differences	_	_	I-Premise
229	in	_	_	I-Premise
230	global	_	_	I-Premise
231	QoL	_	_	I-Premise
232	,	_	_	I-Premise
233	pain	_	_	I-Premise
234	or	_	_	I-Premise
235	fatigue	_	_	I-Premise
236	up	_	_	I-Premise
237	to	_	_	I-Premise
238	26	_	_	I-Premise
239	weeks	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	dyspnoea	_	_	I-Premise
243	palliation	_	_	I-Premise
244	rate	_	_	I-Premise
245	was	_	_	I-Premise
246	lower	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	C3	_	_	I-Premise
250	arm	_	_	I-Premise
251	at	_	_	I-Premise
252	18	_	_	I-Premise
253	and	_	_	I-Premise
254	26	_	_	I-Premise
255	weeks	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0.05	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	but	_	_	B-Premise
263	this	_	_	I-Premise
264	finding	_	_	I-Premise
265	was	_	_	I-Premise
266	inconsistent	_	_	I-Premise
267	across	_	_	I-Premise
268	different	_	_	I-Premise
269	methods	_	_	I-Premise
270	of	_	_	I-Premise
271	analysis	_	_	I-Premise
272	.	_	_	I-Premise

273	Median	_	_	B-Premise
274	survival	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	C3	_	_	I-Premise
278	group	_	_	I-Premise
279	was	_	_	I-Premise
280	28	_	_	I-Premise
281	vs	_	_	I-Premise
282	32	_	_	I-Premise
283	weeks	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	C6	_	_	I-Premise
287	group	_	_	I-Premise
288	(	_	_	I-Premise
289	P=0.75	_	_	I-Premise
290	,	_	_	I-Premise
291	HR	_	_	I-Premise
292	1.04	_	_	I-Premise
293	,	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	0.82-1.31	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	One-	_	_	B-Premise
301	and	_	_	I-Premise
302	2-year	_	_	I-Premise
303	survival	_	_	I-Premise
304	rates	_	_	I-Premise
305	were	_	_	I-Premise
306	25	_	_	I-Premise
307	and	_	_	I-Premise
308	9	_	_	I-Premise
309	%	_	_	I-Premise
310	vs	_	_	I-Premise
311	25	_	_	I-Premise
312	and	_	_	I-Premise
313	5	_	_	I-Premise
314	%	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	C3	_	_	I-Premise
318	and	_	_	I-Premise
319	C6	_	_	I-Premise
320	arm	_	_	I-Premise
321	,	_	_	I-Premise
322	respectively	_	_	I-Premise
323	.	_	_	I-Premise

324	Median	_	_	B-Premise
325	progression-free	_	_	I-Premise
326	survival	_	_	I-Premise
327	was	_	_	I-Premise
328	16	_	_	I-Premise
329	and	_	_	I-Premise
330	21	_	_	I-Premise
331	weeks	_	_	I-Premise
332	in	_	_	I-Premise
333	the	_	_	I-Premise
334	C3	_	_	I-Premise
335	and	_	_	I-Premise
336	C6	_	_	I-Premise
337	groups	_	_	I-Premise
338	,	_	_	I-Premise
339	respectively	_	_	I-Premise
340	(	_	_	I-Premise
341	P=0.21	_	_	I-Premise
342	,	_	_	I-Premise
343	HR	_	_	I-Premise
344	0.86	_	_	I-Premise
345	,	_	_	I-Premise
346	95	_	_	I-Premise
347	%	_	_	I-Premise
348	CI	_	_	I-Premise
349	0.68-1.08	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	In	_	_	B-Claim
353	conclusion	_	_	I-Claim
354	,	_	_	I-Claim
355	palliative	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	with	_	_	I-Claim
358	carboplatin	_	_	I-Claim
359	and	_	_	I-Claim
360	vinorelbine	_	_	I-Claim
361	beyond	_	_	I-Claim
362	three	_	_	I-Claim
363	courses	_	_	I-Claim
364	conveys	_	_	I-Claim
365	no	_	_	I-Claim
366	survival	_	_	I-Claim
367	or	_	_	I-Claim
368	consistent	_	_	I-Claim
369	QoL	_	_	I-Claim
370	benefits	_	_	I-Claim
371	in	_	_	I-Claim
372	advanced	_	_	I-Claim
373	NSCLC	_	_	I-Claim
374	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	,	_	_	O
5	impact	_	_	O
6	on	_	_	O
7	quality-of-life	_	_	O
8	(	_	_	O
9	QoL	_	_	O
10	)	_	_	O
11	and	_	_	O
12	tolerability	_	_	O
13	of	_	_	O
14	two	_	_	O
15	different	_	_	O
16	irinotecan	_	_	O
17	administration	_	_	O
18	schedules	_	_	O
19	in	_	_	O
20	combination	_	_	O
21	with	_	_	O
22	capecitabine	_	_	O
23	as	_	_	O
24	first-line	_	_	O
25	treatment	_	_	O
26	of	_	_	O
27	metastatic	_	_	O
28	colorectal	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	We	_	_	O
32	carried	_	_	O
33	out	_	_	O
34	a	_	_	O
35	randomized	_	_	O
36	phase	_	_	O
37	II	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	select	_	_	O
41	one	_	_	O
42	of	_	_	O
43	the	_	_	O
44	following	_	_	O
45	treatment	_	_	O
46	regimens	_	_	O
47	for	_	_	O
48	further	_	_	O
49	investigation	_	_	O
50	:	_	_	O
51	weekly	_	_	O
52	irinotecan	_	_	O
53	at	_	_	O
54	a	_	_	O
55	dose	_	_	O
56	of	_	_	O
57	70	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	days	_	_	O
63	1	_	_	O
64	,	_	_	O
65	8	_	_	O
66	,	_	_	O
67	15	_	_	O
68	,	_	_	O
69	22	_	_	O
70	,	_	_	O
71	29	_	_	O
72	(	_	_	O
73	arm	_	_	O
74	A	_	_	O
75	)	_	_	O
76	or	_	_	O
77	3-weekly	_	_	O
78	irinotecan	_	_	O
79	at	_	_	O
80	a	_	_	O
81	dose	_	_	O
82	of	_	_	O
83	300/240	_	_	O
84	mg/m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	day	_	_	O
89	1	_	_	O
90	and	_	_	O
91	days	_	_	O
92	22	_	_	O
93	(	_	_	O
94	arm	_	_	O
95	B	_	_	O
96	)	_	_	O
97	in	_	_	O
98	combination	_	_	O
99	with	_	_	O
100	capecitabine	_	_	O
101	1000	_	_	O
102	mg/m	_	_	O
103	(	_	_	O
104	2	_	_	O
105	)	_	_	O
106	twice	_	_	O
107	daily	_	_	O
108	days	_	_	O
109	1-14	_	_	O
110	and	_	_	O
111	days	_	_	O
112	22-35	_	_	O
113	every	_	_	O
114	6	_	_	O
115	weeks	_	_	O
116	.	_	_	O

117	Seventy-five	_	_	O
118	patients	_	_	O
119	with	_	_	O
120	good	_	_	O
121	performance	_	_	O
122	status	_	_	O
123	entered	_	_	O
124	the	_	_	O
125	trial	_	_	O
126	.	_	_	O

127	The	_	_	O
128	two	_	_	O
129	arms	_	_	O
130	were	_	_	O
131	well	_	_	O
132	balanced	_	_	O
133	for	_	_	O
134	relevant	_	_	O
135	patient	_	_	O
136	and	_	_	O
137	disease	_	_	O
138	characteristics	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	most	_	_	I-Premise
142	frequent	_	_	I-Premise
143	toxic	_	_	I-Premise
144	effects	_	_	I-Premise
145	were	_	_	I-Premise
146	grade	_	_	I-Premise
147	3/4	_	_	I-Premise
148	diarrhea	_	_	I-Premise
149	(	_	_	I-Premise
150	arm	_	_	I-Premise
151	A	_	_	I-Premise
152	:	_	_	I-Premise
153	34	_	_	I-Premise
154	%	_	_	I-Premise
155	,	_	_	I-Premise
156	B	_	_	I-Premise
157	:	_	_	I-Premise
158	19	_	_	I-Premise
159	%	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	grade	_	_	I-Premise
163	3/4	_	_	I-Premise
164	neutropenia	_	_	I-Premise
165	(	_	_	I-Premise
166	A	_	_	I-Premise
167	:	_	_	I-Premise
168	5	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	B	_	_	I-Premise
172	:	_	_	I-Premise
173	19	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	grade	_	_	I-Premise
178	2/3	_	_	I-Premise
179	alopecia	_	_	I-Premise
180	(	_	_	I-Premise
181	A	_	_	I-Premise
182	:	_	_	I-Premise
183	26	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	B	_	_	I-Premise
187	:	_	_	I-Premise
188	65	_	_	I-Premise
189	%	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Other	_	_	B-Premise
193	grade	_	_	I-Premise
194	3/4	_	_	I-Premise
195	toxic	_	_	I-Premise
196	effects	_	_	I-Premise
197	were	_	_	I-Premise
198	rare	_	_	I-Premise
199	(	_	_	I-Premise
200	<	_	_	I-Premise
201	5	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Response	_	_	B-Premise
206	rates	_	_	I-Premise
207	were	_	_	I-Premise
208	34	_	_	I-Premise
209	%	_	_	I-Premise
210	[	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	confidence	_	_	I-Premise
214	interval	_	_	I-Premise
215	(	_	_	I-Premise
216	CI	_	_	I-Premise
217	)	_	_	I-Premise
218	20	_	_	I-Premise
219	%	_	_	I-Premise
220	to	_	_	I-Premise
221	51	_	_	I-Premise
222	%	_	_	I-Premise
223	]	_	_	I-Premise
224	in	_	_	I-Premise
225	arm	_	_	I-Premise
226	A	_	_	I-Premise
227	and	_	_	I-Premise
228	35	_	_	I-Premise
229	%	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	:	_	_	I-Premise
235	20	_	_	I-Premise
236	%	_	_	I-Premise
237	to	_	_	I-Premise
238	53	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	in	_	_	I-Premise
242	arm	_	_	I-Premise
243	B	_	_	I-Premise
244	.	_	_	I-Premise

245	Median	_	_	B-Premise
246	time	_	_	I-Premise
247	to	_	_	I-Premise
248	progression	_	_	I-Premise
249	was	_	_	I-Premise
250	6.9	_	_	I-Premise
251	(	_	_	I-Premise
252	4.6-10.1	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	9.2	_	_	I-Premise
256	(	_	_	I-Premise
257	7.9-11.5	_	_	I-Premise
258	)	_	_	I-Premise
259	months	_	_	I-Premise
260	and	_	_	I-Premise
261	median	_	_	I-Premise
262	overall	_	_	I-Premise
263	survival	_	_	I-Premise
264	was	_	_	I-Premise
265	17.4	_	_	I-Premise
266	(	_	_	I-Premise
267	12.6-23.0+	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	24.7	_	_	I-Premise
271	(	_	_	I-Premise
272	16.3-26.4+	_	_	I-Premise
273	)	_	_	I-Premise
274	months	_	_	I-Premise
275	.	_	_	I-Premise

276	Patients	_	_	B-Premise
277	with	_	_	I-Premise
278	an	_	_	I-Premise
279	objective	_	_	I-Premise
280	tumor	_	_	I-Premise
281	response	_	_	I-Premise
282	reported	_	_	I-Premise
283	better	_	_	I-Premise
284	physical	_	_	I-Premise
285	well-being	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	0.01	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	mood	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	0.05	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	functional	_	_	I-Premise
300	performance	_	_	I-Premise
301	(	_	_	I-Premise
302	P	_	_	I-Premise
303	<	_	_	I-Premise
304	0.05	_	_	I-Premise
305	)	_	_	I-Premise
306	and	_	_	I-Premise
307	less	_	_	I-Premise
308	effort	_	_	I-Premise
309	to	_	_	I-Premise
310	cope	_	_	I-Premise
311	(	_	_	I-Premise
312	P	_	_	I-Premise
313	<	_	_	I-Premise
314	0.05	_	_	I-Premise
315	)	_	_	I-Premise
316	compared	_	_	I-Premise
317	with	_	_	I-Premise
318	the	_	_	I-Premise
319	non-responders	_	_	I-Premise
320	and	_	_	I-Premise
321	stable	_	_	I-Premise
322	disease	_	_	I-Premise
323	patients	_	_	I-Premise
324	.	_	_	I-Premise

325	The	_	_	O
326	primary	_	_	O
327	end	_	_	O
328	point	_	_	O
329	of	_	_	O
330	this	_	_	O
331	study	_	_	O
332	was	_	_	O
333	the	_	_	O
334	objective	_	_	O
335	response	_	_	O
336	rate	_	_	O
337	and	_	_	O
338	based	_	_	O
339	on	_	_	O
340	the	_	_	O
341	statistical	_	_	O
342	design	_	_	O
343	of	_	_	O
344	the	_	_	O
345	trial	_	_	O
346	,	_	_	O
347	the	_	_	O
348	3-weekly	_	_	O
349	irinotecan	_	_	O
350	schedule	_	_	O
351	was	_	_	O
352	selected	_	_	O
353	over	_	_	O
354	weekly	_	_	O
355	irinotecan	_	_	O
356	administration	_	_	O
357	.	_	_	O

358	The	_	_	B-Claim
359	3-weekly	_	_	I-Claim
360	irinotecan	_	_	I-Claim
361	schedule	_	_	I-Claim
362	also	_	_	I-Claim
363	seemed	_	_	I-Claim
364	advantageous	_	_	I-Claim
365	in	_	_	I-Claim
366	terms	_	_	I-Claim
367	of	_	_	I-Claim
368	grade	_	_	I-Claim
369	3/4	_	_	I-Claim
370	diarrhea	_	_	I-Claim
371	,	_	_	I-Claim
372	time	_	_	I-Claim
373	to	_	_	I-Claim
374	progression	_	_	I-Claim
375	,	_	_	I-Claim
376	overall	_	_	I-Claim
377	survival	_	_	I-Claim
378	and	_	_	I-Claim
379	patient	_	_	I-Claim
380	convenience	_	_	I-Claim
381	,	_	_	I-Claim
382	but	_	_	B-Claim
383	the	_	_	I-Claim
384	study	_	_	I-Claim
385	was	_	_	I-Claim
386	not	_	_	I-Claim
387	designed	_	_	I-Claim
388	to	_	_	I-Claim
389	detect	_	_	I-Claim
390	differences	_	_	I-Claim
391	in	_	_	I-Claim
392	these	_	_	I-Claim
393	parameters	_	_	I-Claim
394	.	_	_	I-Claim

395	In	_	_	O
396	addition	_	_	O
397	,	_	_	O
398	tumor	_	_	B-Claim
399	response	_	_	I-Claim
400	was	_	_	I-Claim
401	shown	_	_	I-Claim
402	to	_	_	I-Claim
403	have	_	_	I-Claim
404	a	_	_	I-Claim
405	beneficial	_	_	I-Claim
406	effect	_	_	I-Claim
407	on	_	_	I-Claim
408	QoL	_	_	I-Claim
409	indicators	_	_	I-Claim
410	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	5-fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	with	_	_	O
13	and	_	_	O
14	without	_	_	O
15	mitomycin	_	_	O
16	C	_	_	O
17	(	_	_	O
18	MMC	_	_	O
19	)	_	_	O
20	in	_	_	O
21	a	_	_	O
22	prospectively	_	_	O
23	randomised	_	_	O
24	study	_	_	O
25	and	_	_	O
26	analyse	_	_	O
27	for	_	_	O
28	tumour	_	_	O
29	response	_	_	O
30	,	_	_	O
31	survival	_	_	O
32	,	_	_	O
33	toxicity	_	_	O
34	and	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QL	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Two	_	_	O
43	hundred	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	advanced	_	_	O
47	colorectal	_	_	O
48	cancer	_	_	O
49	received	_	_	O
50	PVI	_	_	O
51	5-FU	_	_	O
52	300	_	_	O
53	mg/m2/day	_	_	O
54	for	_	_	O
55	a	_	_	O
56	maximum	_	_	O
57	of	_	_	O
58	24	_	_	O
59	weeks	_	_	O
60	and	_	_	O
61	were	_	_	O
62	randomised	_	_	O
63	to	_	_	O
64	PVI	_	_	O
65	5-FU	_	_	O
66	alone	_	_	O
67	or	_	_	O
68	PVI	_	_	O
69	5-FU	_	_	O
70	+	_	_	O
71	MMC	_	_	O
72	10	_	_	O
73	mg/m2	_	_	O
74	(	_	_	O
75	7	_	_	O
76	mg/m2	_	_	O
77	from	_	_	O
78	June	_	_	O
79	1995	_	_	O
80	)	_	_	O
81	6	_	_	O
82	weekly	_	_	O
83	for	_	_	O
84	4	_	_	O
85	courses	_	_	O
86	.	_	_	O

87	Overall	_	_	B-Premise
88	response	_	_	I-Premise
89	was	_	_	I-Premise
90	54	_	_	I-Premise
91	%	_	_	I-Premise
92	(	_	_	I-Premise
93	95	_	_	I-Premise
94	%	_	_	I-Premise
95	confidence	_	_	I-Premise
96	interval	_	_	I-Premise
97	[	_	_	I-Premise
98	CI	_	_	I-Premise
99	]	_	_	I-Premise
100	44.1	_	_	I-Premise
101	%	_	_	I-Premise
102	-63.9	_	_	I-Premise
103	%	_	_	I-Premise
104	)	_	_	I-Premise
105	with	_	_	I-Premise
106	PVI	_	_	I-Premise
107	5-FU	_	_	I-Premise
108	+	_	_	I-Premise
109	MMC	_	_	I-Premise
110	compared	_	_	I-Premise
111	to	_	_	I-Premise
112	38	_	_	I-Premise
113	%	_	_	I-Premise
114	(	_	_	I-Premise
115	95	_	_	I-Premise
116	%	_	_	I-Premise
117	CI	_	_	I-Premise
118	:	_	_	I-Premise
119	28.3	_	_	I-Premise
120	%	_	_	I-Premise
121	-47.7	_	_	I-Premise
122	%	_	_	I-Premise
123	)	_	_	I-Premise
124	for	_	_	I-Premise
125	PVI	_	_	I-Premise
126	5-FU	_	_	I-Premise
127	alone	_	_	I-Premise
128	(	_	_	I-Premise
129	P	_	_	I-Premise
130	=	_	_	I-Premise
131	0.024	_	_	I-Premise
132	)	_	_	I-Premise
133	.	_	_	I-Premise

134	The	_	_	B-Premise
135	median	_	_	I-Premise
136	failure	_	_	I-Premise
137	free	_	_	I-Premise
138	survival	_	_	I-Premise
139	was	_	_	I-Premise
140	7.9	_	_	I-Premise
141	months	_	_	I-Premise
142	in	_	_	I-Premise
143	PVI	_	_	I-Premise
144	5-FU	_	_	I-Premise
145	plus	_	_	I-Premise
146	MMC	_	_	I-Premise
147	and	_	_	I-Premise
148	5.4	_	_	I-Premise
149	months	_	_	I-Premise
150	with	_	_	I-Premise
151	PVI	_	_	I-Premise
152	5-FU	_	_	I-Premise
153	alone	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.033	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	at	_	_	I-Premise
161	one	_	_	I-Premise
162	year	_	_	I-Premise
163	31.9	_	_	I-Premise
164	%	_	_	I-Premise
165	for	_	_	I-Premise
166	the	_	_	I-Premise
167	combination	_	_	I-Premise
168	compared	_	_	I-Premise
169	to	_	_	I-Premise
170	17.7	_	_	I-Premise
171	%	_	_	I-Premise
172	for	_	_	I-Premise
173	PVI	_	_	I-Premise
174	5-FU	_	_	I-Premise
175	alone	_	_	I-Premise
176	.	_	_	I-Premise

177	Median	_	_	B-Premise
178	survival	_	_	I-Premise
179	was	_	_	I-Premise
180	14	_	_	I-Premise
181	months	_	_	I-Premise
182	with	_	_	I-Premise
183	MMC	_	_	I-Premise
184	and	_	_	I-Premise
185	15	_	_	I-Premise
186	months	_	_	I-Premise
187	in	_	_	I-Premise
188	5-FU	_	_	I-Premise
189	alone	_	_	I-Premise
190	;	_	_	I-Premise
191	one-year	_	_	I-Premise
192	survival	_	_	I-Premise
193	51.7	_	_	I-Premise
194	%	_	_	I-Premise
195	vs.	_	_	I-Premise
196	57.2	_	_	I-Premise
197	%	_	_	I-Premise
198	.	_	_	I-Premise

199	PVI	_	_	B-Premise
200	5-FU	_	_	I-Premise
201	+	_	_	I-Premise
202	MMC	_	_	I-Premise
203	caused	_	_	I-Premise
204	more	_	_	I-Premise
205	overall	_	_	I-Premise
206	haematological	_	_	I-Premise
207	toxicity	_	_	I-Premise
208	but	_	_	I-Premise
209	CTC	_	_	I-Premise
210	grades	_	_	I-Premise
211	3/4	_	_	I-Premise
212	was	_	_	I-Premise
213	increased	_	_	I-Premise
214	only	_	_	I-Premise
215	for	_	_	I-Premise
216	thrombocytopaenia	_	_	I-Premise
217	.	_	_	I-Premise

218	Two	_	_	B-Premise
219	patients	_	_	I-Premise
220	treated	_	_	I-Premise
221	with	_	_	I-Premise
222	a	_	_	I-Premise
223	cumulative	_	_	I-Premise
224	dose	_	_	I-Premise
225	of	_	_	I-Premise
226	MMC	_	_	I-Premise
227	of	_	_	I-Premise
228	40	_	_	I-Premise
229	mg/m2	_	_	I-Premise
230	developed	_	_	I-Premise
231	haemolytic	_	_	I-Premise
232	uraemic	_	_	I-Premise
233	syndrome	_	_	I-Premise
234	warranting	_	_	I-Premise
235	the	_	_	I-Premise
236	reduction	_	_	I-Premise
237	in	_	_	I-Premise
238	cumulative	_	_	I-Premise
239	MMC	_	_	I-Premise
240	dose	_	_	I-Premise
241	to	_	_	I-Premise
242	28	_	_	I-Premise
243	mg/m2	_	_	I-Premise
244	.	_	_	I-Premise

245	The	_	_	B-Premise
246	global	_	_	I-Premise
247	QL	_	_	I-Premise
248	scores	_	_	I-Premise
249	were	_	_	I-Premise
250	better	_	_	I-Premise
251	for	_	_	I-Premise
252	PVI	_	_	I-Premise
253	5-FU	_	_	I-Premise
254	+	_	_	I-Premise
255	MMC	_	_	I-Premise
256	arm	_	_	I-Premise
257	at	_	_	I-Premise
258	24	_	_	I-Premise
259	weeks	_	_	I-Premise
260	,	_	_	I-Premise
261	but	_	_	B-Premise
262	the	_	_	I-Premise
263	remaining	_	_	I-Premise
264	QL	_	_	I-Premise
265	data	_	_	I-Premise
266	showed	_	_	I-Premise
267	no	_	_	I-Premise
268	differences	_	_	I-Premise
269	.	_	_	I-Premise

270	PVI	_	_	B-Claim
271	5-FU	_	_	I-Claim
272	+	_	_	I-Claim
273	MMC	_	_	I-Claim
274	results	_	_	I-Claim
275	in	_	_	I-Claim
276	failure-free	_	_	I-Claim
277	survival	_	_	I-Claim
278	and	_	_	I-Claim
279	response	_	_	I-Claim
280	advantage	_	_	I-Claim
281	,	_	_	I-Claim
282	tolerable	_	_	I-Claim
283	toxicity	_	_	I-Claim
284	and	_	_	I-Claim
285	better	_	_	I-Claim
286	QL	_	_	I-Claim
287	when	_	_	I-Claim
288	compared	_	_	I-Claim
289	to	_	_	I-Claim
290	PVI	_	_	I-Claim
291	5-FU	_	_	I-Claim
292	alone	_	_	I-Claim
293	but	_	_	I-Claim
294	no	_	_	I-Claim
295	overall	_	_	I-Claim
296	survival	_	_	I-Claim
297	advantage	_	_	I-Claim
298	.	_	_	I-Claim

299	There	_	_	B-Premise
300	is	_	_	I-Premise
301	no	_	_	I-Premise
302	irreversible	_	_	I-Premise
303	toxicity	_	_	I-Premise
304	with	_	_	I-Premise
305	MMC	_	_	I-Premise
306	at	_	_	I-Premise
307	a	_	_	I-Premise
308	cumulative	_	_	I-Premise
309	dose	_	_	I-Premise
310	of	_	_	I-Premise
311	28	_	_	I-Premise
312	mg/m2	_	_	I-Premise
313	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	in	_	_	O
3	a	_	_	O
4	phase	_	_	O
5	III	_	_	O
6	study	_	_	O
7	the	_	_	O
8	safety	_	_	O
9	and	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	fludarabine	_	_	O
13	to	_	_	O
14	that	_	_	O
15	of	_	_	O
16	cyclophosphamide	_	_	O
17	,	_	_	O
18	vincristine	_	_	O
19	,	_	_	O
20	and	_	_	O
21	prednisone	_	_	O
22	(	_	_	O
23	CVP	_	_	O
24	)	_	_	O
25	in	_	_	O
26	recurrent	_	_	O
27	,	_	_	O
28	low-grade	_	_	O
29	,	_	_	O
30	non-Hodgkin	_	_	O
31	's	_	_	O
32	lymphoma	_	_	O
33	after	_	_	O
34	previous	_	_	O
35	response	_	_	O
36	to	_	_	O
37	systemic	_	_	O
38	treatment	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	were	_	_	O
42	randomized	_	_	O
43	to	_	_	O
44	fludarabine	_	_	O
45	(	_	_	O
46	25	_	_	O
47	mg/m	_	_	O
48	(	_	_	O
49	2	_	_	O
50	)	_	_	O
51	intravenously	_	_	O
52	on	_	_	O
53	days	_	_	O
54	1	_	_	O
55	to	_	_	O
56	5	_	_	O
57	,	_	_	O
58	every	_	_	O
59	28	_	_	O
60	days	_	_	O
61	)	_	_	O
62	or	_	_	O
63	CVP	_	_	O
64	(	_	_	O
65	cyclophosphamide	_	_	O
66	750	_	_	O
67	mg/m	_	_	O
68	(	_	_	O
69	2	_	_	O
70	)	_	_	O
71	and	_	_	O
72	vincristine	_	_	O
73	1.2	_	_	O
74	mg/m	_	_	O
75	(	_	_	O
76	2	_	_	O
77	)	_	_	O
78	both	_	_	O
79	intravenously	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	prednisone	_	_	O
85	40	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	orally	_	_	O
91	on	_	_	O
92	days	_	_	O
93	1	_	_	O
94	to	_	_	O
95	5	_	_	O
96	,	_	_	O
97	every	_	_	O
98	21	_	_	O
99	days	_	_	O
100	)	_	_	O
101	.	_	_	O

102	The	_	_	O
103	primary	_	_	O
104	outcome	_	_	O
105	assessed	_	_	O
106	was	_	_	O
107	progression-free	_	_	O
108	survival	_	_	O
109	(	_	_	O
110	PFS	_	_	O
111	)	_	_	O
112	;	_	_	O
113	secondary	_	_	O
114	outcomes	_	_	O
115	included	_	_	O
116	treatment-free	_	_	O
117	survival	_	_	O
118	(	_	_	O
119	TFS	_	_	O
120	)	_	_	O
121	,	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	(	_	_	O
125	OS	_	_	O
126	)	_	_	O
127	,	_	_	O
128	treatment-related	_	_	O
129	toxicity	_	_	O
130	,	_	_	O
131	and	_	_	O
132	quality	_	_	O
133	of	_	_	O
134	life	_	_	O
135	(	_	_	O
136	QoL	_	_	O
137	)	_	_	O
138	according	_	_	O
139	to	_	_	O
140	the	_	_	O
141	European	_	_	O
142	Organization	_	_	O
143	for	_	_	O
144	Research	_	_	O
145	and	_	_	O
146	Treatment	_	_	O
147	of	_	_	O
148	Cancer	_	_	O
149	's	_	_	O
150	Quality	_	_	O
151	of	_	_	O
152	Life	_	_	O
153	Questionnaire	_	_	O
154	C-30	_	_	O
155	version	_	_	O
156	1.0	_	_	O
157	instrument	_	_	O
158	.	_	_	O

159	Ninety-one	_	_	O
160	patients	_	_	O
161	were	_	_	O
162	randomized	_	_	O
163	,	_	_	O
164	47	_	_	O
165	to	_	_	O
166	fludarabine	_	_	O
167	and	_	_	O
168	44	_	_	O
169	to	_	_	O
170	CVP	_	_	O
171	.	_	_	O

172	There	_	_	B-Premise
173	was	_	_	I-Premise
174	no	_	_	I-Premise
175	difference	_	_	I-Premise
176	in	_	_	I-Premise
177	response	_	_	I-Premise
178	rates	_	_	I-Premise
179	,	_	_	I-Premise
180	with	_	_	I-Premise
181	64	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	complete	_	_	I-Premise
185	response	_	_	I-Premise
186	[	_	_	I-Premise
187	CR	_	_	I-Premise
188	]	_	_	I-Premise
189	,	_	_	I-Premise
190	9	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	for	_	_	I-Premise
194	fludarabine	_	_	I-Premise
195	versus	_	_	I-Premise
196	52	_	_	I-Premise
197	%	_	_	I-Premise
198	(	_	_	I-Premise
199	CR	_	_	I-Premise
200	,	_	_	I-Premise
201	7	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	for	_	_	I-Premise
205	CVP	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=.72	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	With	_	_	B-Premise
212	a	_	_	I-Premise
213	median	_	_	I-Premise
214	follow-up	_	_	I-Premise
215	of	_	_	I-Premise
216	42	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	median	_	_	I-Premise
220	PFS	_	_	I-Premise
221	(	_	_	I-Premise
222	11	_	_	I-Premise
223	months	_	_	I-Premise
224	v	_	_	I-Premise
225	9.1	_	_	I-Premise
226	months	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=.03	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	TFS	_	_	I-Premise
233	(	_	_	I-Premise
234	15	_	_	I-Premise
235	months	_	_	I-Premise
236	v	_	_	I-Premise
237	11	_	_	I-Premise
238	months	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	=.02	_	_	I-Premise
242	)	_	_	I-Premise
243	were	_	_	I-Premise
244	superior	_	_	I-Premise
245	in	_	_	I-Premise
246	patients	_	_	I-Premise
247	receiving	_	_	I-Premise
248	fludarabine	_	_	I-Premise
249	.	_	_	I-Premise

250	No	_	_	B-Premise
251	difference	_	_	I-Premise
252	in	_	_	I-Premise
253	median	_	_	I-Premise
254	overall	_	_	I-Premise
255	survival	_	_	I-Premise
256	was	_	_	I-Premise
257	detected	_	_	I-Premise
258	(	_	_	I-Premise
259	57	_	_	I-Premise
260	months	_	_	I-Premise
261	for	_	_	I-Premise
262	fludarabine	_	_	I-Premise
263	v	_	_	I-Premise
264	44	_	_	I-Premise
265	months	_	_	I-Premise
266	for	_	_	I-Premise
267	CVP	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=.95	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Three	_	_	B-Premise
274	patients	_	_	I-Premise
275	receiving	_	_	I-Premise
276	fludarabine	_	_	I-Premise
277	died	_	_	I-Premise
278	of	_	_	I-Premise
279	treatment-related	_	_	I-Premise
280	toxicity	_	_	I-Premise
281	compared	_	_	I-Premise
282	with	_	_	I-Premise
283	none	_	_	I-Premise
284	of	_	_	I-Premise
285	the	_	_	I-Premise
286	patients	_	_	I-Premise
287	receiving	_	_	I-Premise
288	CVP	_	_	I-Premise
289	.	_	_	I-Premise

290	Peripheral	_	_	B-Premise
291	neuropathy	_	_	I-Premise
292	and	_	_	I-Premise
293	alopecia	_	_	I-Premise
294	were	_	_	I-Premise
295	more	_	_	I-Premise
296	common	_	_	I-Premise
297	with	_	_	I-Premise
298	CVP	_	_	I-Premise
299	.	_	_	I-Premise

300	Patients	_	_	B-Premise
301	receiving	_	_	I-Premise
302	fludarabine	_	_	I-Premise
303	had	_	_	I-Premise
304	higher	_	_	I-Premise
305	scores	_	_	I-Premise
306	for	_	_	I-Premise
307	social	_	_	I-Premise
308	function	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=.008	_	_	I-Premise
312	)	_	_	I-Premise
313	;	_	_	I-Premise
314	no	_	_	B-Premise
315	other	_	_	I-Premise
316	differences	_	_	I-Premise
317	in	_	_	I-Premise
318	QoL	_	_	I-Premise
319	were	_	_	I-Premise
320	detected	_	_	I-Premise
321	.	_	_	I-Premise

322	In	_	_	B-Claim
323	recurrent	_	_	I-Claim
324	low-grade	_	_	I-Claim
325	lymphoma	_	_	I-Claim
326	,	_	_	I-Claim
327	fludarabine	_	_	I-Claim
328	improves	_	_	I-Claim
329	PFS	_	_	I-Claim
330	,	_	_	I-Claim
331	TFS	_	_	I-Claim
332	,	_	_	I-Claim
333	and	_	_	I-Claim
334	social	_	_	I-Claim
335	function	_	_	I-Claim
336	scores	_	_	I-Claim
337	in	_	_	I-Claim
338	comparison	_	_	I-Claim
339	with	_	_	I-Claim
340	CVP	_	_	I-Claim
341	but	_	_	I-Claim
342	does	_	_	I-Claim
343	not	_	_	I-Claim
344	improve	_	_	I-Claim
345	OS	_	_	I-Claim
346	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	anthracycline-pretreated	_	_	I-Claim
4	metastatic	_	_	I-Claim
5	breast	_	_	I-Claim
6	carcinoma	_	_	I-Claim
7	,	_	_	I-Claim
8	capecitabine	_	_	I-Claim
9	plus	_	_	I-Claim
10	docetaxel	_	_	I-Claim
11	significantly	_	_	I-Claim
12	increased	_	_	I-Claim
13	overall	_	_	I-Claim
14	survival	_	_	I-Claim
15	compared	_	_	I-Claim
16	with	_	_	I-Claim
17	docetaxel	_	_	I-Claim
18	alone	_	_	I-Claim
19	.	_	_	I-Claim

20	The	_	_	O
21	current	_	_	O
22	study	_	_	O
23	evaluated	_	_	O
24	the	_	_	O
25	cost-effectiveness	_	_	O
26	of	_	_	O
27	the	_	_	O
28	capecitabine/docetaxel	_	_	O
29	combination	_	_	O
30	versus	_	_	O
31	docetaxel	_	_	O
32	monotherapy	_	_	O
33	,	_	_	O
34	comparing	_	_	O
35	the	_	_	O
36	gain	_	_	O
37	in	_	_	O
38	quality-adjusted	_	_	O
39	survival	_	_	O
40	with	_	_	O
41	associated	_	_	O
42	health	_	_	O
43	care	_	_	O
44	costs	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	21-day	_	_	O
52	cycles	_	_	O
53	of	_	_	O
54	oral	_	_	O
55	capecitabine	_	_	O
56	1250	_	_	O
57	mg/m2	_	_	O
58	twice	_	_	O
59	daily	_	_	O
60	,	_	_	O
61	on	_	_	O
62	Days	_	_	O
63	1-14	_	_	O
64	,	_	_	O
65	plus	_	_	O
66	docetaxel	_	_	O
67	75	_	_	O
68	mg/m2	_	_	O
69	Day	_	_	O
70	1	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	255	_	_	O
75	)	_	_	O
76	,	_	_	O
77	or	_	_	O
78	docetaxel	_	_	O
79	100	_	_	O
80	mg/m2	_	_	O
81	on	_	_	O
82	Day	_	_	O
83	1	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	256	_	_	O
88	)	_	_	O
89	.	_	_	O

90	Health	_	_	O
91	and	_	_	O
92	cost	_	_	O
93	outcomes	_	_	O
94	in	_	_	O
95	the	_	_	O
96	two	_	_	O
97	arms	_	_	O
98	were	_	_	O
99	compared	_	_	O
100	,	_	_	O
101	and	_	_	O
102	cost-effectiveness	_	_	O
103	was	_	_	O
104	estimated	_	_	O
105	.	_	_	O

106	Data	_	_	O
107	on	_	_	O
108	survival	_	_	O
109	time	_	_	O
110	and	_	_	O
111	medical	_	_	O
112	care	_	_	O
113	resource	_	_	O
114	use	_	_	O
115	were	_	_	O
116	prospectively	_	_	O
117	collected	_	_	O
118	in	_	_	O
119	the	_	_	O
120	trial	_	_	O
121	.	_	_	O

122	Costs	_	_	O
123	associated	_	_	O
124	with	_	_	O
125	medical	_	_	O
126	care	_	_	O
127	resource	_	_	O
128	use	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	adjustments	_	_	O
132	were	_	_	O
133	obtained	_	_	O
134	from	_	_	O
135	the	_	_	O
136	published	_	_	O
137	literature	_	_	O
138	.	_	_	O

139	The	_	_	O
140	incremental	_	_	O
141	cost-effectiveness	_	_	O
142	ratio	_	_	O
143	was	_	_	O
144	calculated	_	_	O
145	as	_	_	O
146	the	_	_	O
147	cost	_	_	O
148	per	_	_	O
149	quality-adjusted	_	_	O
150	life	_	_	O
151	year	_	_	O
152	(	_	_	O
153	QALY	_	_	O
154	)	_	_	O
155	gained	_	_	O
156	.	_	_	O

157	Capecitabine/docetaxel	_	_	B-Premise
158	increased	_	_	I-Premise
159	the	_	_	I-Premise
160	median	_	_	I-Premise
161	overall	_	_	I-Premise
162	survival	_	_	I-Premise
163	by	_	_	I-Premise
164	3	_	_	I-Premise
165	months	_	_	I-Premise
166	compared	_	_	I-Premise
167	with	_	_	I-Premise
168	docetaxel	_	_	I-Premise
169	alone	_	_	I-Premise
170	(	_	_	I-Premise
171	14.5	_	_	I-Premise
172	vs.	_	_	I-Premise
173	11.5	_	_	I-Premise
174	months	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	mean	_	_	I-Premise
179	quality-adjusted	_	_	I-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	increased	_	_	I-Premise
183	by	_	_	I-Premise
184	1.8	_	_	I-Premise
185	months	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	capecitabine/docetaxel	_	_	I-Premise
189	group	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	total	_	_	I-Premise
193	medical-resource	_	_	I-Premise
194	utilization	_	_	I-Premise
195	cost	_	_	I-Premise
196	per	_	_	I-Premise
197	patient	_	_	I-Premise
198	was	_	_	I-Premise
199	8.9	_	_	I-Premise
200	%	_	_	I-Premise
201	higher	_	_	I-Premise
202	with	_	_	I-Premise
203	the	_	_	I-Premise
204	combination	_	_	I-Premise
205	:	_	_	I-Premise
206	24,475	_	_	I-Premise
207	dollars	_	_	I-Premise
208	for	_	_	I-Premise
209	combination	_	_	I-Premise
210	therapy	_	_	I-Premise
211	versus	_	_	I-Premise
212	22,477	_	_	I-Premise
213	dollars	_	_	I-Premise
214	for	_	_	I-Premise
215	single-agent	_	_	I-Premise
216	docetaxel	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	mean	_	_	I-Premise
220	cost	_	_	I-Premise
221	per	_	_	I-Premise
222	QALY	_	_	I-Premise
223	gained	_	_	I-Premise
224	with	_	_	I-Premise
225	combination	_	_	I-Premise
226	therapy	_	_	I-Premise
227	was	_	_	I-Premise
228	13,558	_	_	I-Premise
229	dollars	_	_	I-Premise
230	(	_	_	I-Premise
231	standard	_	_	I-Premise
232	deviation	_	_	I-Premise
233	,	_	_	I-Premise
234	6742	_	_	I-Premise
235	dollars	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Cost	_	_	B-Premise
239	savings	_	_	I-Premise
240	due	_	_	I-Premise
241	to	_	_	I-Premise
242	reduced	_	_	I-Premise
243	docetaxel	_	_	I-Premise
244	dose	_	_	I-Premise
245	and	_	_	I-Premise
246	hospital	_	_	I-Premise
247	use	_	_	I-Premise
248	were	_	_	I-Premise
249	the	_	_	I-Premise
250	major	_	_	I-Premise
251	cost	_	_	I-Premise
252	offsets	_	_	I-Premise
253	with	_	_	I-Premise
254	the	_	_	I-Premise
255	combination	_	_	I-Premise
256	.	_	_	I-Premise

257	Sensitivity	_	_	B-Premise
258	analyses	_	_	I-Premise
259	showed	_	_	I-Premise
260	that	_	_	I-Premise
261	varying	_	_	I-Premise
262	the	_	_	I-Premise
263	mean	_	_	I-Premise
264	hospital	_	_	I-Premise
265	cost	_	_	I-Premise
266	per	_	_	I-Premise
267	day	_	_	I-Premise
268	from	_	_	I-Premise
269	the	_	_	I-Premise
270	5th	_	_	I-Premise
271	to	_	_	I-Premise
272	the	_	_	I-Premise
273	95th	_	_	I-Premise
274	percentile	_	_	I-Premise
275	resulted	_	_	I-Premise
276	in	_	_	I-Premise
277	cost-utility	_	_	I-Premise
278	ratios	_	_	I-Premise
279	ranging	_	_	I-Premise
280	from	_	_	I-Premise
281	20,326	_	_	I-Premise
282	dollars	_	_	I-Premise
283	to	_	_	I-Premise
284	as	_	_	I-Premise
285	low	_	_	I-Premise
286	as	_	_	I-Premise
287	6360	_	_	I-Premise
288	dollars	_	_	I-Premise
289	.	_	_	I-Premise

290	Capecitabine/docetaxel	_	_	B-Claim
291	was	_	_	I-Claim
292	a	_	_	I-Claim
293	cost-effective	_	_	I-Claim
294	treatment	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	anthracycline-pretreated	_	_	I-Claim
299	advanced	_	_	I-Claim
300	breast	_	_	I-Claim
301	carcinoma	_	_	I-Claim
302	,	_	_	I-Claim
303	and	_	_	I-Claim
304	had	_	_	I-Claim
305	an	_	_	I-Claim
306	incremental	_	_	I-Claim
307	cost-effectiveness	_	_	I-Claim
308	ratio	_	_	I-Claim
309	that	_	_	I-Claim
310	compares	_	_	I-Claim
311	very	_	_	I-Claim
312	favorably	_	_	I-Claim
313	with	_	_	I-Claim
314	that	_	_	I-Claim
315	of	_	_	I-Claim
316	many	_	_	I-Claim
317	other	_	_	I-Claim
318	oncology	_	_	I-Claim
319	therapies	_	_	I-Claim
320	.	_	_	I-Claim


0	Epoetin	_	_	B-Claim
1	alfa	_	_	I-Claim
2	administered	_	_	I-Claim
3	at	_	_	I-Claim
4	40,000	_	_	I-Claim
5	U	_	_	I-Claim
6	once	_	_	I-Claim
7	weekly	_	_	I-Claim
8	(	_	_	I-Claim
9	qw	_	_	I-Claim
10	)	_	_	I-Claim
11	to	_	_	I-Claim
12	anemic	_	_	I-Claim
13	cancer	_	_	I-Claim
14	patients	_	_	I-Claim
15	receiving	_	_	I-Claim
16	chemotherapy	_	_	I-Claim
17	increases	_	_	I-Claim
18	hemoglobin	_	_	I-Claim
19	levels	_	_	I-Claim
20	,	_	_	I-Claim
21	improves	_	_	I-Claim
22	quality	_	_	I-Claim
23	of	_	_	I-Claim
24	life	_	_	I-Claim
25	(	_	_	I-Claim
26	QOL	_	_	I-Claim
27	)	_	_	I-Claim
28	,	_	_	I-Claim
29	and	_	_	I-Claim
30	reduces	_	_	I-Claim
31	transfusions	_	_	I-Claim
32	.	_	_	I-Claim

33	The	_	_	O
34	benefit	_	_	O
35	of	_	_	O
36	epoetin	_	_	O
37	alfa	_	_	O
38	in	_	_	O
39	maintaining	_	_	O
40	hemoglobin	_	_	O
41	levels	_	_	O
42	in	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	hemoglobin	_	_	O
47	less	_	_	O
48	than	_	_	O
49	12	_	_	O
50	g/dL	_	_	O
51	has	_	_	O
52	not	_	_	O
53	been	_	_	O
54	evaluated	_	_	O
55	.	_	_	O

56	Breast	_	_	O
57	cancer	_	_	O
58	patients	_	_	O
59	(	_	_	O
60	N	_	_	O
61	=	_	_	O
62	354	_	_	O
63	)	_	_	O
64	receiving	_	_	O
65	chemotherapy	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	in	_	_	O
70	1:1	_	_	O
71	ratio	_	_	O
72	to	_	_	O
73	epoetin	_	_	O
74	alfa	_	_	O
75	(	_	_	O
76	40,000	_	_	O
77	U	_	_	O
78	qw	_	_	O
79	)	_	_	O
80	or	_	_	O
81	standard	_	_	O
82	of	_	_	O
83	care	_	_	O
84	(	_	_	O
85	SOC	_	_	O
86	)	_	_	O
87	.	_	_	O

88	QOL	_	_	O
89	was	_	_	O
90	assessed	_	_	O
91	at	_	_	O
92	baseline	_	_	O
93	and	_	_	O
94	week	_	_	O
95	12	_	_	O
96	.	_	_	O

97	Hemoglobin	_	_	O
98	responses	_	_	O
99	,	_	_	O
100	transfusion	_	_	O
101	requirements	_	_	O
102	,	_	_	O
103	and	_	_	O
104	prognostic	_	_	O
105	factors	_	_	O
106	for	_	_	O
107	responses	_	_	O
108	were	_	_	O
109	measured	_	_	O
110	.	_	_	O

111	At	_	_	B-Premise
112	week	_	_	I-Premise
113	12	_	_	I-Premise
114	,	_	_	I-Premise
115	Functional	_	_	I-Premise
116	Assessment	_	_	I-Premise
117	of	_	_	I-Premise
118	Cancer	_	_	I-Premise
119	Therapy-Anemia	_	_	I-Premise
120	(	_	_	I-Premise
121	FACT-An	_	_	I-Premise
122	;	_	_	I-Premise
123	mean	_	_	I-Premise
124	,	_	_	I-Premise
125	2.16	_	_	I-Premise
126	+/-	_	_	I-Premise
127	12.84	_	_	I-Premise
128	for	_	_	I-Premise
129	epoetin	_	_	I-Premise
130	alfa	_	_	I-Premise
131	v	_	_	I-Premise
132	-4.43	_	_	I-Premise
133	+/-	_	_	I-Premise
134	13.42	_	_	I-Premise
135	for	_	_	I-Premise
136	SOC	_	_	I-Premise
137	)	_	_	I-Premise
138	and	_	_	I-Premise
139	FACT-An	_	_	I-Premise
140	fatigue	_	_	I-Premise
141	(	_	_	I-Premise
142	mean	_	_	I-Premise
143	,	_	_	I-Premise
144	1.85	_	_	I-Premise
145	+/-	_	_	I-Premise
146	10.52	_	_	I-Premise
147	for	_	_	I-Premise
148	epoetin	_	_	I-Premise
149	alfa	_	_	I-Premise
150	v	_	_	I-Premise
151	-3.55	_	_	I-Premise
152	+/-	_	_	I-Premise
153	11.14	_	_	I-Premise
154	for	_	_	I-Premise
155	SOC	_	_	I-Premise
156	)	_	_	I-Premise
157	change	_	_	I-Premise
158	scores	_	_	I-Premise
159	were	_	_	I-Premise
160	significantly	_	_	I-Premise
161	higher	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	epoetin	_	_	I-Premise
165	alfa	_	_	I-Premise
166	group	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	.0001	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	Hemoglobin	_	_	B-Premise
174	responses	_	_	I-Premise
175	defined	_	_	I-Premise
176	as	_	_	I-Premise
177	mean	_	_	I-Premise
178	hemoglobin	_	_	I-Premise
179	>	_	_	I-Premise
180	or	_	_	I-Premise
181	=	_	_	I-Premise
182	12	_	_	I-Premise
183	g/dL	_	_	I-Premise
184	or	_	_	I-Premise
185	a	_	_	I-Premise
186	>	_	_	I-Premise
187	or	_	_	I-Premise
188	=	_	_	I-Premise
189	2	_	_	I-Premise
190	g/dL	_	_	I-Premise
191	increase	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	baseline	_	_	I-Premise
195	were	_	_	I-Premise
196	significantly	_	_	I-Premise
197	higher	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	epoetin	_	_	I-Premise
201	alfa	_	_	I-Premise
202	group	_	_	I-Premise
203	versus	_	_	I-Premise
204	SOC	_	_	I-Premise
205	:	_	_	I-Premise
206	52.0	_	_	I-Premise
207	%	_	_	I-Premise
208	v	_	_	I-Premise
209	5.1	_	_	I-Premise
210	%	_	_	I-Premise
211	and	_	_	I-Premise
212	65.7	_	_	I-Premise
213	%	_	_	I-Premise
214	v	_	_	I-Premise
215	6.3	_	_	I-Premise
216	%	_	_	I-Premise
217	,	_	_	I-Premise
218	respectively	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	.0001	_	_	I-Premise
223	for	_	_	I-Premise
224	both	_	_	I-Premise
225	comparisons	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Percentage	_	_	B-Premise
229	transfused	_	_	I-Premise
230	was	_	_	I-Premise
231	significantly	_	_	I-Premise
232	lower	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	epoetin	_	_	I-Premise
236	alfa	_	_	I-Premise
237	group	_	_	I-Premise
238	compared	_	_	I-Premise
239	with	_	_	I-Premise
240	SOC	_	_	I-Premise
241	(	_	_	I-Premise
242	8.6	_	_	I-Premise
243	%	_	_	I-Premise
244	v	_	_	I-Premise
245	22.9	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	More	_	_	B-Premise
250	than	_	_	I-Premise
251	90	_	_	I-Premise
252	%	_	_	I-Premise
253	of	_	_	I-Premise
254	patients	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	require	_	_	I-Premise
258	a	_	_	I-Premise
259	dose	_	_	I-Premise
260	increase	_	_	I-Premise
261	and	_	_	I-Premise
262	28.7	_	_	I-Premise
263	%	_	_	I-Premise
264	had	_	_	I-Premise
265	a	_	_	I-Premise
266	dose	_	_	I-Premise
267	reduction	_	_	I-Premise
268	.	_	_	I-Premise

269	Epoetin	_	_	B-Claim
270	alfa	_	_	I-Claim
271	administered	_	_	I-Claim
272	at	_	_	I-Claim
273	40,000	_	_	I-Claim
274	U	_	_	I-Claim
275	qw	_	_	I-Claim
276	is	_	_	I-Claim
277	effective	_	_	I-Claim
278	in	_	_	I-Claim
279	improving	_	_	I-Claim
280	QOL	_	_	I-Claim
281	,	_	_	I-Claim
282	maintaining	_	_	I-Claim
283	hemoglobin	_	_	I-Claim
284	level	_	_	I-Claim
285	,	_	_	I-Claim
286	and	_	_	I-Claim
287	reducing	_	_	I-Claim
288	transfusion	_	_	I-Claim
289	requirements	_	_	I-Claim
290	in	_	_	I-Claim
291	breast	_	_	I-Claim
292	cancer	_	_	I-Claim
293	patients	_	_	I-Claim
294	.	_	_	I-Claim

295	The	_	_	B-Claim
296	high	_	_	I-Claim
297	effectiveness	_	_	I-Claim
298	observed	_	_	I-Claim
299	could	_	_	I-Claim
300	be	_	_	I-Claim
301	attributed	_	_	I-Claim
302	in	_	_	I-Claim
303	part	_	_	I-Claim
304	to	_	_	I-Claim
305	early	_	_	I-Claim
306	treatment	_	_	I-Claim
307	with	_	_	I-Claim
308	epoetin	_	_	I-Claim
309	alfa	_	_	I-Claim
310	.	_	_	I-Claim


0	During	_	_	B-Premise
1	the	_	_	I-Premise
2	last	_	_	I-Premise
3	decade	_	_	I-Premise
4	,	_	_	I-Premise
5	survival	_	_	I-Premise
6	rates	_	_	I-Premise
7	for	_	_	I-Premise
8	breast	_	_	I-Premise
9	cancer	_	_	I-Premise
10	have	_	_	I-Premise
11	increased	_	_	I-Premise
12	as	_	_	I-Premise
13	a	_	_	I-Premise
14	result	_	_	I-Premise
15	of	_	_	I-Premise
16	earlier	_	_	I-Premise
17	detection	_	_	I-Premise
18	and	_	_	I-Premise
19	increased	_	_	I-Premise
20	use	_	_	I-Premise
21	of	_	_	I-Premise
22	adjuvant	_	_	I-Premise
23	therapy	_	_	I-Premise
24	.	_	_	I-Premise

25	Limited	_	_	O
26	data	_	_	O
27	exist	_	_	O
28	on	_	_	O
29	the	_	_	O
30	psychosocial	_	_	O
31	aspects	_	_	O
32	of	_	_	O
33	the	_	_	O
34	transitional	_	_	O
35	period	_	_	O
36	between	_	_	O
37	the	_	_	O
38	end	_	_	O
39	of	_	_	O
40	primary	_	_	O
41	treatment	_	_	O
42	and	_	_	O
43	survivorship	_	_	O
44	.	_	_	O

45	We	_	_	O
46	investigated	_	_	O
47	the	_	_	O
48	baseline	_	_	O
49	psychosocial	_	_	O
50	status	_	_	O
51	of	_	_	O
52	women	_	_	O
53	enrolled	_	_	O
54	in	_	_	O
55	a	_	_	O
56	randomized	_	_	O
57	trial	_	_	O
58	testing	_	_	O
59	two	_	_	O
60	psychosocial	_	_	O
61	interventions	_	_	O
62	for	_	_	O
63	women	_	_	O
64	at	_	_	O
65	the	_	_	O
66	end	_	_	O
67	of	_	_	O
68	primary	_	_	O
69	treatment	_	_	O
70	.	_	_	O

71	Participants	_	_	O
72	,	_	_	O
73	identified	_	_	O
74	within	_	_	O
75	1	_	_	O
76	month	_	_	O
77	after	_	_	O
78	surgery	_	_	O
79	(	_	_	O
80	registration	_	_	O
81	)	_	_	O
82	,	_	_	O
83	provided	_	_	O
84	demographic	_	_	O
85	information	_	_	O
86	and	_	_	O
87	limited	_	_	O
88	measures	_	_	O
89	of	_	_	O
90	quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	.	_	_	O

94	They	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	until	_	_	O
98	they	_	_	O
99	finished	_	_	O
100	primary	_	_	O
101	treatment	_	_	O
102	(	_	_	O
103	enrollment	_	_	O
104	)	_	_	O
105	,	_	_	O
106	at	_	_	O
107	which	_	_	O
108	time	_	_	O
109	they	_	_	O
110	completed	_	_	O
111	a	_	_	O
112	mailed	_	_	O
113	baseline	_	_	O
114	survey	_	_	O
115	that	_	_	O
116	included	_	_	O
117	standardized	_	_	O
118	measures	_	_	O
119	of	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	(	_	_	O
124	including	_	_	O
125	standardized	_	_	O
126	scales	_	_	O
127	of	_	_	O
128	physical	_	_	O
129	and	_	_	O
130	emotional	_	_	O
131	functioning	_	_	O
132	)	_	_	O
133	,	_	_	O
134	mood	_	_	O
135	,	_	_	O
136	symptoms	_	_	O
137	,	_	_	O
138	and	_	_	O
139	sexual	_	_	O
140	functioning	_	_	O
141	.	_	_	O

142	A	_	_	O
143	total	_	_	O
144	of	_	_	O
145	558	_	_	O
146	patients	_	_	O
147	(	_	_	O
148	mean	_	_	O
149	age	_	_	O
150	=	_	_	O
151	56.9	_	_	O
152	years	_	_	O
153	)	_	_	O
154	were	_	_	O
155	enrolled	_	_	O
156	in	_	_	O
157	the	_	_	O
158	study	_	_	O
159	between	_	_	O
160	July	_	_	O
161	1	_	_	O
162	,	_	_	O
163	1999	_	_	O
164	,	_	_	O
165	and	_	_	O
166	June	_	_	O
167	30	_	_	O
168	,	_	_	O
169	2002	_	_	O
170	.	_	_	O

171	Health	_	_	O
172	outcomes	_	_	O
173	were	_	_	O
174	examined	_	_	O
175	according	_	_	O
176	to	_	_	O
177	treatment	_	_	O
178	received	_	_	O
179	:	_	_	O
180	mastectomy	_	_	O
181	with	_	_	O
182	and	_	_	O
183	without	_	_	O
184	chemotherapy	_	_	O
185	,	_	_	O
186	and	_	_	O
187	lumpectomy	_	_	O
188	with	_	_	O
189	and	_	_	O
190	without	_	_	O
191	chemotherapy	_	_	O
192	.	_	_	O

193	All	_	_	O
194	statistical	_	_	O
195	tests	_	_	O
196	were	_	_	O
197	two-sided	_	_	O
198	.	_	_	O

199	Among	_	_	B-Premise
200	all	_	_	I-Premise
201	treatment	_	_	I-Premise
202	groups	_	_	I-Premise
203	,	_	_	I-Premise
204	patients	_	_	I-Premise
205	who	_	_	I-Premise
206	had	_	_	I-Premise
207	a	_	_	I-Premise
208	mastectomy	_	_	I-Premise
209	had	_	_	I-Premise
210	the	_	_	I-Premise
211	poorest	_	_	I-Premise
212	physical	_	_	I-Premise
213	functioning	_	_	I-Premise
214	at	_	_	I-Premise
215	registration	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	.001	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	at	_	_	I-Premise
223	enrollment	_	_	I-Premise
224	(	_	_	I-Premise
225	P=.05	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	At	_	_	B-Premise
229	enrollment	_	_	I-Premise
230	,	_	_	I-Premise
231	mood	_	_	I-Premise
232	and	_	_	I-Premise
233	emotional	_	_	I-Premise
234	functioning	_	_	I-Premise
235	were	_	_	I-Premise
236	similar	_	_	I-Premise
237	among	_	_	I-Premise
238	all	_	_	I-Premise
239	patients	_	_	I-Premise
240	,	_	_	I-Premise
241	with	_	_	I-Premise
242	no	_	_	I-Premise
243	differences	_	_	I-Premise
244	by	_	_	I-Premise
245	type	_	_	I-Premise
246	of	_	_	I-Premise
247	treatment	_	_	I-Premise
248	received	_	_	I-Premise
249	.	_	_	I-Premise

250	At	_	_	B-Premise
251	enrollment	_	_	I-Premise
252	,	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	,	_	_	I-Premise
255	including	_	_	I-Premise
256	muscle	_	_	I-Premise
257	stiffness	_	_	I-Premise
258	,	_	_	I-Premise
259	breast	_	_	I-Premise
260	sensitivity	_	_	I-Premise
261	,	_	_	I-Premise
262	aches	_	_	I-Premise
263	and	_	_	I-Premise
264	pains	_	_	I-Premise
265	,	_	_	I-Premise
266	tendency	_	_	I-Premise
267	to	_	_	I-Premise
268	take	_	_	I-Premise
269	naps	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	difficulty	_	_	I-Premise
273	concentrating	_	_	I-Premise
274	,	_	_	I-Premise
275	were	_	_	I-Premise
276	common	_	_	I-Premise
277	among	_	_	I-Premise
278	patients	_	_	I-Premise
279	in	_	_	I-Premise
280	all	_	_	I-Premise
281	groups	_	_	I-Premise
282	and	_	_	I-Premise
283	were	_	_	I-Premise
284	statistically	_	_	I-Premise
285	significantly	_	_	I-Premise
286	associated	_	_	I-Premise
287	with	_	_	I-Premise
288	poor	_	_	I-Premise
289	physical	_	_	I-Premise
290	functioning	_	_	I-Premise
291	and	_	_	I-Premise
292	emotional	_	_	I-Premise
293	well-being	_	_	I-Premise
294	.	_	_	I-Premise

295	Sexual	_	_	B-Premise
296	functioning	_	_	I-Premise
297	was	_	_	I-Premise
298	worse	_	_	I-Premise
299	for	_	_	I-Premise
300	women	_	_	I-Premise
301	who	_	_	I-Premise
302	received	_	_	I-Premise
303	chemotherapy	_	_	I-Premise
304	than	_	_	I-Premise
305	for	_	_	I-Premise
306	those	_	_	I-Premise
307	who	_	_	I-Premise
308	did	_	_	I-Premise
309	not	_	_	I-Premise
310	,	_	_	I-Premise
311	regardless	_	_	I-Premise
312	of	_	_	I-Premise
313	type	_	_	I-Premise
314	of	_	_	I-Premise
315	surgery	_	_	I-Premise
316	(	_	_	I-Premise
317	P	_	_	I-Premise
318	<	_	_	I-Premise
319	.001	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	At	_	_	B-Claim
323	the	_	_	I-Claim
324	end	_	_	I-Claim
325	of	_	_	I-Claim
326	primary	_	_	I-Claim
327	treatment	_	_	I-Claim
328	for	_	_	I-Claim
329	breast	_	_	I-Claim
330	cancer	_	_	I-Claim
331	,	_	_	I-Claim
332	women	_	_	I-Claim
333	in	_	_	I-Claim
334	all	_	_	I-Claim
335	treatment	_	_	I-Claim
336	groups	_	_	I-Claim
337	report	_	_	I-Claim
338	good	_	_	I-Claim
339	emotional	_	_	I-Claim
340	functioning	_	_	I-Claim
341	but	_	_	I-Claim
342	report	_	_	I-Claim
343	decreased	_	_	I-Claim
344	physical	_	_	I-Claim
345	functioning	_	_	I-Claim
346	,	_	_	I-Claim
347	particularly	_	_	I-Claim
348	among	_	_	I-Claim
349	women	_	_	I-Claim
350	who	_	_	I-Claim
351	have	_	_	I-Claim
352	a	_	_	I-Claim
353	mastectomy	_	_	I-Claim
354	or	_	_	I-Claim
355	receive	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	.	_	_	I-Claim

358	Clinical	_	_	B-Claim
359	interventions	_	_	I-Claim
360	to	_	_	I-Claim
361	address	_	_	I-Claim
362	common	_	_	I-Claim
363	symptoms	_	_	I-Claim
364	associated	_	_	I-Claim
365	with	_	_	I-Claim
366	treatment	_	_	I-Claim
367	should	_	_	I-Claim
368	be	_	_	I-Claim
369	considered	_	_	I-Claim
370	to	_	_	I-Claim
371	improve	_	_	I-Claim
372	physical	_	_	I-Claim
373	and	_	_	I-Claim
374	emotional	_	_	I-Claim
375	functioning	_	_	I-Claim
376	at	_	_	I-Claim
377	the	_	_	I-Claim
378	end	_	_	I-Claim
379	of	_	_	I-Claim
380	primary	_	_	I-Claim
381	treatment	_	_	I-Claim
382	for	_	_	I-Claim
383	breast	_	_	I-Claim
384	cancer	_	_	I-Claim
385	.	_	_	I-Claim


0	In	_	_	B-Premise
1	a	_	_	I-Premise
2	multinational	_	_	I-Premise
3	trial	_	_	I-Premise
4	of	_	_	I-Premise
5	anaemic	_	_	I-Premise
6	patients	_	_	I-Premise
7	with	_	_	I-Premise
8	cancer	_	_	I-Premise
9	receiving	_	_	I-Premise
10	nonplatinum-containing	_	_	I-Premise
11	chemotherapy	_	_	I-Premise
12	,	_	_	I-Premise
13	epoetin-alfa	_	_	I-Premise
14	effectively	_	_	I-Premise
15	increased	_	_	I-Premise
16	haemoglobin	_	_	I-Premise
17	levels	_	_	I-Premise
18	,	_	_	I-Premise
19	reduced	_	_	I-Premise
20	red	_	_	I-Premise
21	blood	_	_	I-Premise
22	cell	_	_	I-Premise
23	transfusion	_	_	I-Premise
24	requirements	_	_	I-Premise
25	,	_	_	I-Premise
26	and	_	_	I-Premise
27	improved	_	_	I-Premise
28	QOL	_	_	I-Premise
29	.	_	_	I-Premise

30	Although	_	_	O
31	the	_	_	O
32	study	_	_	O
33	was	_	_	O
34	not	_	_	O
35	designed	_	_	O
36	or	_	_	O
37	powered	_	_	O
38	to	_	_	O
39	evaluate	_	_	O
40	survival	_	_	O
41	,	_	_	O
42	a	_	_	B-Premise
43	survival	_	_	I-Premise
44	trend	_	_	I-Premise
45	was	_	_	I-Premise
46	noted	_	_	I-Premise
47	favouring	_	_	I-Premise
48	epoetin-alfa	_	_	I-Premise
49	compared	_	_	I-Premise
50	with	_	_	I-Premise
51	placebo	_	_	I-Premise
52	(	_	_	I-Premise
53	median	_	_	I-Premise
54	survival	_	_	I-Premise
55	17	_	_	I-Premise
56	vs	_	_	I-Premise
57	11	_	_	I-Premise
58	months	_	_	I-Premise
59	[	_	_	I-Premise
60	p	_	_	I-Premise
61	=	_	_	I-Premise
62	0.126	_	_	I-Premise
63	]	_	_	I-Premise
64	)	_	_	I-Premise
65	.	_	_	I-Premise

66	To	_	_	O
67	determine	_	_	O
68	the	_	_	O
69	incremental	_	_	O
70	cost	_	_	O
71	utility	_	_	O
72	of	_	_	O
73	epoetin-alfa	_	_	O
74	versus	_	_	O
75	placebo	_	_	O
76	in	_	_	O
77	anaemic	_	_	O
78	patients	_	_	O
79	with	_	_	O
80	stage	_	_	O
81	IV	_	_	O
82	breast	_	_	O
83	cancer	_	_	O
84	from	_	_	O
85	a	_	_	O
86	UK	_	_	O
87	National	_	_	O
88	Health	_	_	O
89	Service	_	_	O
90	perspective	_	_	O
91	.	_	_	O

92	Patient	_	_	O
93	data	_	_	O
94	regarding	_	_	O
95	transfusions	_	_	O
96	,	_	_	O
97	epoetin-alfa	_	_	O
98	usage	_	_	O
99	,	_	_	O
100	chemotherapy	_	_	O
101	treatment	_	_	O
102	cycles	_	_	O
103	,	_	_	O
104	and	_	_	O
105	adverse	_	_	O
106	events	_	_	O
107	were	_	_	O
108	recorded	_	_	O
109	,	_	_	O
110	with	_	_	O
111	survival	_	_	O
112	follow-up	_	_	O
113	for	_	_	O
114	12-36	_	_	O
115	months	_	_	O
116	post-study	_	_	O
117	.	_	_	O

118	Stage	_	_	O
119	IV	_	_	O
120	breast	_	_	O
121	cancer	_	_	O
122	therapy	_	_	O
123	costs	_	_	O
124	were	_	_	O
125	collected	_	_	O
126	by	_	_	O
127	surveying	_	_	O
128	UK	_	_	O
129	oncologists	_	_	O
130	,	_	_	O
131	and	_	_	O
132	utilities	_	_	O
133	for	_	_	O
134	associated	_	_	O
135	health	_	_	O
136	states	_	_	O
137	were	_	_	O
138	from	_	_	O
139	published	_	_	O
140	sources	_	_	O
141	.	_	_	O

142	Costs	_	_	O
143	were	_	_	O
144	in	_	_	O
145	British	_	_	O
146	pounds	_	_	O
147	and	_	_	O
148	year	_	_	O
149	2000	_	_	O
150	values	_	_	O
151	.	_	_	O

152	Costs	_	_	O
153	and	_	_	O
154	benefits	_	_	O
155	were	_	_	O
156	jointly	_	_	O
157	determined	_	_	O
158	for	_	_	O
159	the	_	_	O
160	stage	_	_	O
161	IV	_	_	O
162	breast	_	_	O
163	cancer	_	_	O
164	subgroup	_	_	O
165	(	_	_	O
166	n	_	_	O
167	=	_	_	O
168	55	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Incremental	_	_	O
172	cost-utility	_	_	O
173	ratios	_	_	O
174	(	_	_	O
175	ICURs	_	_	O
176	)	_	_	O
177	were	_	_	O
178	calculated	_	_	O
179	assuming	_	_	O
180	a	_	_	O
181	6	_	_	O
182	%	_	_	O
183	annual	_	_	O
184	discount	_	_	O
185	rate	_	_	O
186	for	_	_	O
187	costs	_	_	O
188	and	_	_	O
189	a	_	_	O
190	1.5	_	_	O
191	%	_	_	O
192	annual	_	_	O
193	discount	_	_	O
194	rate	_	_	O
195	for	_	_	O
196	benefits	_	_	O
197	.	_	_	O

198	Bootstrap	_	_	O
199	simulations	_	_	O
200	(	_	_	O
201	10,000	_	_	O
202	iterations	_	_	O
203	)	_	_	O
204	were	_	_	O
205	conducted	_	_	O
206	to	_	_	O
207	account	_	_	O
208	for	_	_	O
209	uncertainty	_	_	O
210	,	_	_	O
211	and	_	_	O
212	sensitivity	_	_	O
213	analyses	_	_	O
214	were	_	_	O
215	conducted	_	_	O
216	to	_	_	O
217	establish	_	_	O
218	robustness	_	_	O
219	.	_	_	O

220	The	_	_	B-Premise
221	ICUR	_	_	I-Premise
222	for	_	_	I-Premise
223	epoetin-alfa	_	_	I-Premise
224	treatment	_	_	I-Premise
225	was	_	_	I-Premise
226	pounds	_	_	I-Premise
227	8,851	_	_	I-Premise
228	per	_	_	I-Premise
229	QALY	_	_	I-Premise
230	,	_	_	I-Premise
231	with	_	_	I-Premise
232	a	_	_	I-Premise
233	99	_	_	I-Premise
234	%	_	_	I-Premise
235	probability	_	_	I-Premise
236	of	_	_	I-Premise
237	a	_	_	I-Premise
238	positive	_	_	I-Premise
239	net	_	_	I-Premise
240	benefit	_	_	I-Premise
241	in	_	_	I-Premise
242	QALYs	_	_	I-Premise
243	(	_	_	I-Premise
244	net	_	_	I-Premise
245	benefit	_	_	I-Premise
246	=	_	_	I-Premise
247	0.4805	_	_	I-Premise
248	years	_	_	I-Premise
249	of	_	_	I-Premise
250	perfect	_	_	I-Premise
251	life	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	a	_	_	I-Premise
255	94	_	_	I-Premise
256	%	_	_	I-Premise
257	probability	_	_	I-Premise
258	of	_	_	I-Premise
259	being	_	_	I-Premise
260	acceptable	_	_	I-Premise
261	using	_	_	I-Premise
262	a	_	_	I-Premise
263	threshold	_	_	I-Premise
264	ICUR	_	_	I-Premise
265	of	_	_	I-Premise
266	pounds	_	_	I-Premise
267	30,000/QALY	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	B-Premise
270	main	_	_	I-Premise
271	cost	_	_	I-Premise
272	drivers	_	_	I-Premise
273	distinguishing	_	_	I-Premise
274	epoetin-alfa	_	_	I-Premise
275	from	_	_	I-Premise
276	placebo	_	_	I-Premise
277	were	_	_	I-Premise
278	the	_	_	I-Premise
279	costs	_	_	I-Premise
280	of	_	_	I-Premise
281	drug	_	_	I-Premise
282	and	_	_	I-Premise
283	patient	_	_	I-Premise
284	care	_	_	I-Premise
285	due	_	_	I-Premise
286	to	_	_	I-Premise
287	increased	_	_	I-Premise
288	survival	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Claim
291	available	_	_	I-Claim
292	data	_	_	I-Claim
293	suggest	_	_	I-Claim
294	a	_	_	I-Claim
295	high	_	_	I-Claim
296	probability	_	_	I-Claim
297	of	_	_	I-Claim
298	favourable	_	_	I-Claim
299	cost-utility	_	_	I-Claim
300	outcomes	_	_	I-Claim
301	with	_	_	I-Claim
302	epoetin-alfa	_	_	I-Claim
303	treatment	_	_	I-Claim
304	for	_	_	I-Claim
305	anaemia	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	stage	_	_	I-Claim
310	IV	_	_	I-Claim
311	breast	_	_	I-Claim
312	cancer	_	_	I-Claim
313	receiving	_	_	I-Claim
314	nonplatinum-containing	_	_	I-Claim
315	chemotherapy	_	_	I-Claim
316	.	_	_	I-Claim

317	Additional	_	_	B-Claim
318	studies	_	_	I-Claim
319	are	_	_	I-Claim
320	warranted	_	_	I-Claim
321	.	_	_	I-Claim


0	The	_	_	O
1	EORTC	_	_	O
2	24971/TAX	_	_	O
3	323	_	_	O
4	,	_	_	O
5	a	_	_	O
6	phase	_	_	O
7	III	_	_	O
8	study	_	_	O
9	of	_	_	O
10	358	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	unresectable	_	_	O
14	locoregionally	_	_	O
15	advanced	_	_	O
16	squamous	_	_	O
17	cell	_	_	O
18	carcinoma	_	_	O
19	of	_	_	O
20	the	_	_	O
21	head	_	_	O
22	and	_	_	O
23	neck	_	_	O
24	,	_	_	O
25	showed	_	_	O
26	an	_	_	O
27	improved	_	_	O
28	progression-free	_	_	O
29	and	_	_	O
30	overall	_	_	O
31	survival	_	_	O
32	(	_	_	O
33	OS	_	_	O
34	)	_	_	O
35	with	_	_	O
36	less	_	_	O
37	toxicity	_	_	O
38	when	_	_	O
39	docetaxel	_	_	O
40	(	_	_	O
41	T	_	_	O
42	)	_	_	O
43	was	_	_	O
44	added	_	_	O
45	to	_	_	O
46	cisplatin	_	_	O
47	and	_	_	O
48	5-fluorouracil	_	_	O
49	(	_	_	O
50	PF	_	_	O
51	)	_	_	O
52	for	_	_	O
53	induction	_	_	O
54	and	_	_	O
55	given	_	_	O
56	before	_	_	O
57	radiotherapy	_	_	O
58	(	_	_	O
59	RT	_	_	O
60	)	_	_	O
61	.	_	_	O

62	The	_	_	O
63	impact	_	_	O
64	of	_	_	O
65	the	_	_	O
66	addition	_	_	O
67	of	_	_	O
68	docetaxel	_	_	O
69	on	_	_	O
70	patients	_	_	O
71	'	_	_	O
72	health-related	_	_	O
73	quality	_	_	O
74	of	_	_	O
75	life	_	_	O
76	(	_	_	O
77	HRQOL	_	_	O
78	)	_	_	O
79	and	_	_	O
80	symptoms	_	_	O
81	was	_	_	O
82	investigated	_	_	O
83	.	_	_	O

84	HRQOL	_	_	O
85	was	_	_	O
86	assessed	_	_	O
87	at	_	_	O
88	baseline	_	_	O
89	,	_	_	O
90	at	_	_	O
91	end	_	_	O
92	of	_	_	O
93	cycle	_	_	O
94	2	_	_	O
95	,	_	_	O
96	and	_	_	O
97	4	_	_	O
98	,	_	_	O
99	6	_	_	O
100	,	_	_	O
101	and	_	_	O
102	9	_	_	O
103	months	_	_	O
104	after	_	_	O
105	completion	_	_	O
106	of	_	_	O
107	RT	_	_	O
108	using	_	_	O
109	the	_	_	O
110	European	_	_	O
111	Organisation	_	_	O
112	for	_	_	O
113	Research	_	_	O
114	and	_	_	O
115	Treatment	_	_	O
116	of	_	_	O
117	Cancer	_	_	O
118	(	_	_	O
119	EORTC	_	_	O
120	)	_	_	O
121	Quality	_	_	O
122	of	_	_	O
123	Life	_	_	O
124	Questionnaire	_	_	O
125	C30	_	_	O
126	(	_	_	O
127	QLQ-C30	_	_	O
128	)	_	_	O
129	and	_	_	O
130	the	_	_	O
131	EORTC	_	_	O
132	QLQ	_	_	O
133	Head	_	_	O
134	and	_	_	O
135	Neck	_	_	O
136	Cancer-Specific	_	_	O
137	Module	_	_	O
138	(	_	_	O
139	EORTC	_	_	O
140	QLQ-H	_	_	O
141	&	_	_	O
142	amp	_	_	O
143	;	_	_	O
144	N35	_	_	O
145	)	_	_	O
146	.	_	_	O

147	The	_	_	O
148	primary	_	_	O
149	HRQOL	_	_	O
150	scale	_	_	O
151	was	_	_	O
152	global	_	_	O
153	HRQOL	_	_	O
154	per	_	_	O
155	protocol	_	_	O
156	.	_	_	O

157	Compliance	_	_	O
158	to	_	_	O
159	HRQOL	_	_	O
160	assessments	_	_	O
161	was	_	_	O
162	97	_	_	O
163	%	_	_	O
164	at	_	_	O
165	baseline	_	_	O
166	,	_	_	O
167	but	_	_	O
168	dropped	_	_	O
169	to	_	_	O
170	54	_	_	O
171	%	_	_	O
172	by	_	_	O
173	6	_	_	O
174	months	_	_	O
175	.	_	_	O

176	Data	_	_	O
177	were	_	_	O
178	analysed	_	_	O
179	up	_	_	O
180	to	_	_	O
181	6	_	_	O
182	months	_	_	O
183	.	_	_	O

184	There	_	_	B-Premise
185	was	_	_	I-Premise
186	a	_	_	I-Premise
187	trend	_	_	I-Premise
188	towards	_	_	I-Premise
189	improved	_	_	I-Premise
190	global	_	_	I-Premise
191	HRQOL	_	_	I-Premise
192	during	_	_	I-Premise
193	the	_	_	I-Premise
194	treatment	_	_	I-Premise
195	period	_	_	I-Premise
196	.	_	_	I-Premise

197	At	_	_	B-Premise
198	6	_	_	I-Premise
199	months	_	_	I-Premise
200	after	_	_	I-Premise
201	the	_	_	I-Premise
202	end	_	_	I-Premise
203	of	_	_	I-Premise
204	RT	_	_	I-Premise
205	,	_	_	I-Premise
206	global	_	_	I-Premise
207	HRQOL	_	_	I-Premise
208	was	_	_	I-Premise
209	higher	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	TPF	_	_	I-Premise
213	arm	_	_	I-Premise
214	than	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	PF	_	_	I-Premise
218	arm	_	_	I-Premise
219	,	_	_	I-Premise
220	but	_	_	B-Premise
221	the	_	_	I-Premise
222	low	_	_	I-Premise
223	compliance	_	_	I-Premise
224	does	_	_	I-Premise
225	not	_	_	I-Premise
226	allow	_	_	I-Premise
227	to	_	_	I-Premise
228	draw	_	_	I-Premise
229	definitive	_	_	I-Premise
230	conclusions	_	_	I-Premise
231	.	_	_	I-Premise

232	Swallowing	_	_	B-Premise
233	and	_	_	I-Premise
234	coughing	_	_	I-Premise
235	problems	_	_	I-Premise
236	decreased	_	_	I-Premise
237	more	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	TPF	_	_	I-Premise
241	arm	_	_	I-Premise
242	than	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	PF	_	_	I-Premise
246	arm	_	_	I-Premise
247	at	_	_	I-Premise
248	the	_	_	I-Premise
249	end	_	_	I-Premise
250	of	_	_	I-Premise
251	cycle	_	_	I-Premise
252	2	_	_	I-Premise
253	,	_	_	I-Premise
254	but	_	_	B-Premise
255	to	_	_	I-Premise
256	a	_	_	I-Premise
257	limited	_	_	I-Premise
258	extent	_	_	I-Premise
259	.	_	_	I-Premise

260	Induction	_	_	B-Claim
261	chemotherapy	_	_	I-Claim
262	with	_	_	I-Claim
263	TPF	_	_	I-Claim
264	before	_	_	I-Claim
265	RT	_	_	I-Claim
266	not	_	_	I-Claim
267	only	_	_	I-Claim
268	improves	_	_	I-Claim
269	survival	_	_	I-Claim
270	and	_	_	I-Claim
271	reduces	_	_	I-Claim
272	toxicity	_	_	I-Claim
273	compared	_	_	I-Claim
274	with	_	_	I-Claim
275	PF	_	_	I-Claim
276	but	_	_	I-Claim
277	also	_	_	I-Claim
278	seems	_	_	I-Claim
279	to	_	_	I-Claim
280	improve	_	_	I-Claim
281	global	_	_	I-Claim
282	HRQOL	_	_	I-Claim
283	in	_	_	I-Claim
284	a	_	_	I-Claim
285	more	_	_	I-Claim
286	sustainable	_	_	I-Claim
287	manner	_	_	I-Claim
288	.	_	_	I-Claim


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	RCT	_	_	O
6	)	_	_	O
7	demonstrated	_	_	O
8	that	_	_	O
9	cognitive	_	_	O
10	behaviour	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	CBT	_	_	O
14	)	_	_	O
15	for	_	_	O
16	fatigue	_	_	O
17	during	_	_	O
18	curative	_	_	O
19	cancer	_	_	O
20	treatment	_	_	O
21	was	_	_	O
22	effective	_	_	O
23	shortly	_	_	O
24	after	_	_	O
25	cancer	_	_	O
26	treatment	_	_	O
27	.	_	_	O

28	This	_	_	O
29	study	_	_	O
30	aimed	_	_	O
31	to	_	_	O
32	identify	_	_	O
33	which	_	_	O
34	patient	_	_	O
35	characteristics	_	_	O
36	predict	_	_	O
37	fatigue	_	_	O
38	improvement	_	_	O
39	after	_	_	O
40	CBT	_	_	O
41	.	_	_	O

42	In	_	_	O
43	addition	_	_	O
44	,	_	_	O
45	the	_	_	O
46	long-term	_	_	O
47	effectiveness	_	_	O
48	was	_	_	O
49	investigated	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	with	_	_	O
53	various	_	_	O
54	malignancies	_	_	O
55	participated	_	_	O
56	in	_	_	O
57	the	_	_	O
58	RCT	_	_	O
59	(	_	_	O
60	n	_	_	O
61	=	_	_	O
62	210	_	_	O
63	)	_	_	O
64	.	_	_	O

65	Participants	_	_	O
66	were	_	_	O
67	assessed	_	_	O
68	before	_	_	O
69	cancer	_	_	O
70	treatment	_	_	O
71	(	_	_	O
72	T1	_	_	O
73	)	_	_	O
74	,	_	_	O
75	postintervention	_	_	O
76	(	_	_	O
77	T2	_	_	O
78	)	_	_	O
79	,	_	_	O
80	which	_	_	O
81	was	_	_	O
82	at	_	_	O
83	least	_	_	O
84	2	_	_	O
85	months	_	_	O
86	after	_	_	O
87	cancer	_	_	O
88	treatment	_	_	O
89	,	_	_	O
90	and	_	_	O
91	after	_	_	O
92	1-year	_	_	O
93	follow-up	_	_	O
94	(	_	_	O
95	T3	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Monthly	_	_	O
99	fatigue	_	_	O
100	assessments	_	_	O
101	were	_	_	O
102	completed	_	_	O
103	between	_	_	O
104	T2	_	_	O
105	and	_	_	O
106	T3	_	_	O
107	.	_	_	O

108	A	_	_	O
109	regression	_	_	O
110	analysis	_	_	O
111	with	_	_	O
112	interactions	_	_	O
113	was	_	_	O
114	performed	_	_	O
115	to	_	_	O
116	determine	_	_	O
117	if	_	_	O
118	domains	_	_	O
119	of	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	(	_	_	O
124	EORTC-QLQ-C30	_	_	O
125	)	_	_	O
126	functioning	_	_	O
127	(	_	_	O
128	Health	_	_	O
129	Survey	_	_	O
130	Short	_	_	O
131	Form-36	_	_	O
132	)	_	_	O
133	or	_	_	O
134	psychological	_	_	O
135	distress	_	_	O
136	(	_	_	O
137	Symptom	_	_	O
138	Checklist-90	_	_	O
139	)	_	_	O
140	moderated	_	_	O
141	the	_	_	O
142	effect	_	_	O
143	of	_	_	O
144	CBT	_	_	O
145	on	_	_	O
146	fatigue	_	_	O
147	.	_	_	O

148	Analyses	_	_	O
149	of	_	_	O
150	covariance	_	_	O
151	were	_	_	O
152	used	_	_	O
153	to	_	_	O
154	study	_	_	O
155	the	_	_	O
156	long-term	_	_	O
157	effectiveness	_	_	O
158	of	_	_	O
159	CBT	_	_	O
160	.	_	_	O

161	Fatigue	_	_	B-Premise
162	at	_	_	I-Premise
163	T2	_	_	I-Premise
164	was	_	_	I-Premise
165	predicted	_	_	I-Premise
166	by	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	interaction	_	_	I-Premise
170	between	_	_	I-Premise
171	self-reported	_	_	I-Premise
172	cognitive	_	_	I-Premise
173	functioning	_	_	I-Premise
174	and	_	_	I-Premise
175	CBT	_	_	I-Premise
176	.	_	_	I-Premise

177	No	_	_	B-Premise
178	interactions	_	_	I-Premise
179	were	_	_	I-Premise
180	found	_	_	I-Premise
181	between	_	_	I-Premise
182	other	_	_	I-Premise
183	domains	_	_	I-Premise
184	of	_	_	I-Premise
185	quality	_	_	I-Premise
186	of	_	_	I-Premise
187	life	_	_	I-Premise
188	,	_	_	I-Premise
189	functioning	_	_	I-Premise
190	,	_	_	I-Premise
191	psychological	_	_	I-Premise
192	distress	_	_	I-Premise
193	and	_	_	I-Premise
194	CBT	_	_	I-Premise
195	.	_	_	I-Premise

196	At	_	_	B-Premise
197	T3	_	_	I-Premise
198	,	_	_	I-Premise
199	no	_	_	I-Premise
200	significant	_	_	I-Premise
201	difference	_	_	I-Premise
202	on	_	_	I-Premise
203	fatigue	_	_	I-Premise
204	was	_	_	I-Premise
205	found	_	_	I-Premise
206	between	_	_	I-Premise
207	CBT	_	_	I-Premise
208	and	_	_	I-Premise
209	usual	_	_	I-Premise
210	care	_	_	I-Premise
211	.	_	_	I-Premise

212	Exploratory	_	_	B-Premise
213	analyses	_	_	I-Premise
214	showed	_	_	I-Premise
215	that	_	_	I-Premise
216	the	_	_	I-Premise
217	difference	_	_	I-Premise
218	nearly	_	_	I-Premise
219	reached	_	_	I-Premise
220	significance	_	_	I-Premise
221	until	_	_	I-Premise
222	7	_	_	I-Premise
223	months	_	_	I-Premise
224	postintervention	_	_	I-Premise
225	.	_	_	I-Premise

226	Patients	_	_	B-Premise
227	who	_	_	I-Premise
228	experienced	_	_	I-Premise
229	more	_	_	I-Premise
230	concentration	_	_	I-Premise
231	and	_	_	I-Premise
232	memory	_	_	I-Premise
233	problems	_	_	I-Premise
234	at	_	_	I-Premise
235	T1	_	_	I-Premise
236	benefited	_	_	I-Premise
237	more	_	_	I-Premise
238	from	_	_	I-Premise
239	CBT	_	_	I-Premise
240	for	_	_	I-Premise
241	fatigue	_	_	I-Premise
242	and	_	_	I-Premise
243	are	_	_	I-Premise
244	indicators	_	_	I-Premise
245	.	_	_	I-Premise

246	After	_	_	B-Premise
247	a	_	_	I-Premise
248	year	_	_	I-Premise
249	of	_	_	I-Premise
250	follow-up	_	_	I-Premise
251	,	_	_	I-Premise
252	the	_	_	I-Premise
253	effect	_	_	I-Premise
254	of	_	_	I-Premise
255	CBT	_	_	I-Premise
256	for	_	_	I-Premise
257	fatigue	_	_	I-Premise
258	was	_	_	I-Premise
259	no	_	_	I-Premise
260	longer	_	_	I-Premise
261	observed	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	effect	_	_	I-Premise
266	on	_	_	I-Premise
267	fatigue	_	_	I-Premise
268	seemed	_	_	I-Premise
269	to	_	_	I-Premise
270	be	_	_	I-Premise
271	diminished	_	_	I-Premise
272	7	_	_	I-Premise
273	months	_	_	I-Premise
274	postintervention	_	_	I-Premise
275	.	_	_	I-Premise

276	The	_	_	B-Claim
277	implication	_	_	I-Claim
278	is	_	_	I-Claim
279	that	_	_	I-Claim
280	CBT	_	_	I-Claim
281	for	_	_	I-Claim
282	fatigue	_	_	I-Claim
283	should	_	_	I-Claim
284	be	_	_	I-Claim
285	offered	_	_	I-Claim
286	to	_	_	I-Claim
287	patients	_	_	I-Claim
288	with	_	_	I-Claim
289	cancer	_	_	I-Claim
290	with	_	_	I-Claim
291	the	_	_	I-Claim
292	highest	_	_	I-Claim
293	chance	_	_	I-Claim
294	to	_	_	I-Claim
295	benefit	_	_	I-Claim
296	.	_	_	I-Claim


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	carried	_	_	O
7	out	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	two	_	_	O
11	schedules	_	_	O
12	of	_	_	O
13	the	_	_	O
14	vinorelbine	_	_	O
15	(	_	_	O
16	VNR	_	_	O
17	)	_	_	O
18	-cisplatin	_	_	O
19	(	_	_	O
20	CDDP	_	_	O
21	)	_	_	O
22	regimen	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	locally	_	_	O
27	advanced	_	_	O
28	unresectable	_	_	O
29	poor	_	_	O
30	prognosis	_	_	O
31	stage	_	_	O
32	IIIB	_	_	O
33	or	_	_	O
34	metastatic	_	_	O
35	stage	_	_	O
36	IV	_	_	O
37	non-small	_	_	O
38	cell	_	_	O
39	lung	_	_	O
40	cancer	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	endpoints	_	_	O
45	were	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	(	_	_	O
49	OS	_	_	O
50	)	_	_	O
51	and	_	_	O
52	analysis	_	_	O
53	of	_	_	O
54	toxicity	_	_	O
55	,	_	_	O
56	while	_	_	O
57	secondary	_	_	O
58	endpoints	_	_	O
59	included	_	_	O
60	response	_	_	O
61	rates	_	_	O
62	,	_	_	O
63	time-to-progression	_	_	O
64	(	_	_	O
65	TTP	_	_	O
66	)	_	_	O
67	and	_	_	O
68	quality	_	_	O
69	of	_	_	O
70	life	_	_	O
71	(	_	_	O
72	QoL	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Eligible	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	:	_	_	O
82	(	_	_	O
83	a	_	_	O
84	)	_	_	O
85	VNR	_	_	O
86	25mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	on	_	_	O
91	day	_	_	O
92	1	_	_	O
93	,	_	_	O
94	8	_	_	O
95	and	_	_	O
96	15	_	_	O
97	plus	_	_	O
98	CDDP	_	_	O
99	100mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	1	_	_	O
106	every	_	_	O
107	4	_	_	O
108	weeks	_	_	O
109	or	_	_	O
110	(	_	_	O
111	b	_	_	O
112	)	_	_	O
113	VNR	_	_	O
114	30	_	_	O
115	mg/m	_	_	O
116	(	_	_	O
117	2	_	_	O
118	)	_	_	O
119	on	_	_	O
120	day	_	_	O
121	1	_	_	O
122	and	_	_	O
123	8	_	_	O
124	plus	_	_	O
125	CDDP	_	_	O
126	80	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	on	_	_	O
132	day	_	_	O
133	1	_	_	O
134	every	_	_	O
135	3	_	_	O
136	weeks	_	_	O
137	.	_	_	O

138	All	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	chemotherapy-naÃ¯ve	_	_	O
142	and	_	_	O
143	had	_	_	O
144	an	_	_	O
145	ECOG	_	_	O
146	performance	_	_	O
147	status	_	_	O
148	(	_	_	O
149	PS	_	_	O
150	)	_	_	O
151	of	_	_	O
152	0-1	_	_	O
153	.	_	_	O

154	Overall	_	_	O
155	278	_	_	O
156	patients	_	_	O
157	were	_	_	O
158	enrolled	_	_	O
159	into	_	_	O
160	the	_	_	O
161	trial	_	_	O
162	.	_	_	O

163	Overall	_	_	O
164	response	_	_	O
165	rate	_	_	O
166	was	_	_	O
167	34	_	_	O
168	%	_	_	O
169	(	_	_	O
170	95	_	_	O
171	%	_	_	O
172	CL	_	_	O
173	26-42	_	_	O
174	%	_	_	O
175	)	_	_	O
176	in	_	_	O
177	the	_	_	O
178	weekly	_	_	O
179	VNR/CDDP	_	_	O
180	arm	_	_	O
181	,	_	_	O
182	and	_	_	O
183	32	_	_	O
184	%	_	_	O
185	(	_	_	O
186	95	_	_	O
187	%	_	_	O
188	CL	_	_	O
189	24-40	_	_	O
190	%	_	_	O
191	)	_	_	O
192	in	_	_	O
193	patients	_	_	O
194	treated	_	_	O
195	with	_	_	O
196	day	_	_	O
197	1-8	_	_	O
198	VNR/CDDP	_	_	O
199	without	_	_	O
200	any	_	_	O
201	statistically	_	_	O
202	significant	_	_	O
203	difference	_	_	O
204	.	_	_	O

205	Median	_	_	B-Premise
206	TTP	_	_	I-Premise
207	was	_	_	I-Premise
208	4.5	_	_	I-Premise
209	and	_	_	I-Premise
210	4.6	_	_	I-Premise
211	months	_	_	I-Premise
212	respectively	_	_	I-Premise
213	for	_	_	I-Premise
214	weekly	_	_	I-Premise
215	VNR/CDDP	_	_	I-Premise
216	arm	_	_	I-Premise
217	and	_	_	I-Premise
218	the	_	_	I-Premise
219	day	_	_	I-Premise
220	1-8	_	_	I-Premise
221	VNR/CDDP	_	_	I-Premise
222	one	_	_	I-Premise
223	.	_	_	I-Premise

224	This	_	_	B-Premise
225	difference	_	_	I-Premise
226	was	_	_	I-Premise
227	not	_	_	I-Premise
228	statistically	_	_	I-Premise
229	significant	_	_	I-Premise
230	(	_	_	I-Premise
231	log-rank	_	_	I-Premise
232	test	_	_	I-Premise
233	,	_	_	I-Premise
234	p=0.818	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Median	_	_	B-Premise
238	OS	_	_	I-Premise
239	was	_	_	I-Premise
240	9.45	_	_	I-Premise
241	and	_	_	I-Premise
242	10	_	_	I-Premise
243	months	_	_	I-Premise
244	respectively	_	_	I-Premise
245	for	_	_	I-Premise
246	weekly	_	_	I-Premise
247	VNR/CDDP	_	_	I-Premise
248	arm	_	_	I-Premise
249	and	_	_	I-Premise
250	the	_	_	I-Premise
251	day	_	_	I-Premise
252	1-8	_	_	I-Premise
253	VNR/CDDP	_	_	I-Premise
254	one	_	_	I-Premise
255	without	_	_	I-Premise
256	statistically	_	_	I-Premise
257	a	_	_	I-Premise
258	significant	_	_	I-Premise
259	difference	_	_	I-Premise
260	(	_	_	I-Premise
261	log-rank	_	_	I-Premise
262	test	_	_	I-Premise
263	,	_	_	I-Premise
264	p=0.259	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	The	_	_	B-Premise
268	1-	_	_	I-Premise
269	and	_	_	I-Premise
270	2-year	_	_	I-Premise
271	survival	_	_	I-Premise
272	rates	_	_	I-Premise
273	were	_	_	I-Premise
274	31	_	_	I-Premise
275	and	_	_	I-Premise
276	36	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	10	_	_	I-Premise
281	and	_	_	I-Premise
282	11	_	_	I-Premise
283	%	_	_	I-Premise
284	respectively	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	incidence	_	_	I-Premise
288	of	_	_	I-Premise
289	severe	_	_	I-Premise
290	neutropenia	_	_	I-Premise
291	(	_	_	I-Premise
292	34	_	_	I-Premise
293	%	_	_	I-Premise
294	versus	_	_	I-Premise
295	68	_	_	I-Premise
296	%	_	_	I-Premise
297	;	_	_	I-Premise
298	p=0.0001	_	_	I-Premise
299	)	_	_	I-Premise
300	and	_	_	I-Premise
301	of	_	_	I-Premise
302	febrile	_	_	I-Premise
303	neutropenia	_	_	I-Premise
304	(	_	_	I-Premise
305	5	_	_	I-Premise
306	%	_	_	I-Premise
307	versus	_	_	I-Premise
308	12	_	_	I-Premise
309	%	_	_	I-Premise
310	;	_	_	I-Premise
311	p=0.026	_	_	I-Premise
312	)	_	_	I-Premise
313	,	_	_	I-Premise
314	as	_	_	I-Premise
315	well	_	_	I-Premise
316	as	_	_	I-Premise
317	the	_	_	I-Premise
318	rate	_	_	I-Premise
319	of	_	_	I-Premise
320	therapy	_	_	I-Premise
321	omissions	_	_	I-Premise
322	(	_	_	I-Premise
323	10	_	_	I-Premise
324	%	_	_	I-Premise
325	versus	_	_	I-Premise
326	24	_	_	I-Premise
327	%	_	_	I-Premise
328	;	_	_	I-Premise
329	p=0.0037	_	_	I-Premise
330	)	_	_	I-Premise
331	were	_	_	I-Premise
332	higher	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	weekly	_	_	I-Premise
336	VNR/CDDP	_	_	I-Premise
337	arm	_	_	I-Premise
338	than	_	_	I-Premise
339	in	_	_	I-Premise
340	the	_	_	I-Premise
341	day	_	_	I-Premise
342	1-8	_	_	I-Premise
343	VNR/CDDP	_	_	I-Premise
344	one	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	weekly	_	_	I-Premise
348	VNR/CDDP	_	_	I-Premise
349	regimen	_	_	I-Premise
350	was	_	_	I-Premise
351	associated	_	_	I-Premise
352	with	_	_	I-Premise
353	a	_	_	I-Premise
354	lower	_	_	I-Premise
355	received	_	_	I-Premise
356	dose	_	_	I-Premise
357	intensity	_	_	I-Premise
358	in	_	_	I-Premise
359	a	_	_	I-Premise
360	statistically	_	_	I-Premise
361	significant	_	_	I-Premise
362	fashion	_	_	I-Premise
363	(	_	_	I-Premise
364	9	_	_	I-Premise
365	%	_	_	I-Premise
366	versus	_	_	I-Premise
367	22	_	_	I-Premise
368	%	_	_	I-Premise
369	;	_	_	I-Premise
370	p=0.0001	_	_	I-Premise
371	)	_	_	I-Premise
372	and	_	_	I-Premise
373	with	_	_	I-Premise
374	a	_	_	I-Premise
375	lower	_	_	I-Premise
376	non-statistically	_	_	I-Premise
377	significant	_	_	I-Premise
378	quality	_	_	I-Premise
379	of	_	_	I-Premise
380	life	_	_	I-Premise
381	score	_	_	I-Premise
382	as	_	_	I-Premise
383	compared	_	_	I-Premise
384	to	_	_	I-Premise
385	the	_	_	I-Premise
386	day	_	_	I-Premise
387	1-8	_	_	I-Premise
388	VNR/CDDP	_	_	I-Premise
389	schedule	_	_	I-Premise
390	.	_	_	I-Premise

391	The	_	_	B-Claim
392	combination	_	_	I-Claim
393	of	_	_	I-Claim
394	day	_	_	I-Claim
395	1-8	_	_	I-Claim
396	VNR	_	_	I-Claim
397	plus	_	_	I-Claim
398	CDDP	_	_	I-Claim
399	every	_	_	I-Claim
400	3	_	_	I-Claim
401	weeks	_	_	I-Claim
402	is	_	_	I-Claim
403	less	_	_	I-Claim
404	toxic	_	_	I-Claim
405	and	_	_	I-Claim
406	better	_	_	I-Claim
407	tolerated	_	_	I-Claim
408	than	_	_	I-Claim
409	the	_	_	I-Claim
410	regimen	_	_	I-Claim
411	of	_	_	I-Claim
412	weekly	_	_	I-Claim
413	VNR	_	_	I-Claim
414	plus	_	_	I-Claim
415	CDDP	_	_	I-Claim
416	every	_	_	I-Claim
417	4	_	_	I-Claim
418	weeks	_	_	I-Claim
419	.	_	_	I-Claim

420	The	_	_	B-Claim
421	two	_	_	I-Claim
422	schedules	_	_	I-Claim
423	are	_	_	I-Claim
424	equivalent	_	_	I-Claim
425	in	_	_	I-Claim
426	terms	_	_	I-Claim
427	of	_	_	I-Claim
428	overall	_	_	I-Claim
429	response	_	_	I-Claim
430	rate	_	_	I-Claim
431	,	_	_	I-Claim
432	median	_	_	I-Claim
433	time-to-progression	_	_	I-Claim
434	and	_	_	I-Claim
435	overall	_	_	I-Claim
436	survival	_	_	I-Claim
437	.	_	_	I-Claim

438	The	_	_	B-Claim
439	combination	_	_	I-Claim
440	of	_	_	I-Claim
441	VNR	_	_	I-Claim
442	on	_	_	I-Claim
443	day	_	_	I-Claim
444	1-8	_	_	I-Claim
445	plus	_	_	I-Claim
446	CDDP	_	_	I-Claim
447	every	_	_	I-Claim
448	3	_	_	I-Claim
449	weeks	_	_	I-Claim
450	may	_	_	I-Claim
451	be	_	_	I-Claim
452	considered	_	_	I-Claim
453	as	_	_	I-Claim
454	a	_	_	I-Claim
455	reference	_	_	I-Claim
456	regimen	_	_	I-Claim
457	for	_	_	I-Claim
458	the	_	_	I-Claim
459	treatment	_	_	I-Claim
460	of	_	_	I-Claim
461	patients	_	_	I-Claim
462	with	_	_	I-Claim
463	advanced	_	_	I-Claim
464	disease	_	_	I-Claim
465	and	_	_	I-Claim
466	those	_	_	I-Claim
467	who	_	_	I-Claim
468	deserve	_	_	I-Claim
469	a	_	_	I-Claim
470	postoperative	_	_	I-Claim
471	therapy	_	_	I-Claim
472	,	_	_	I-Claim
473	and	_	_	I-Claim
474	for	_	_	I-Claim
475	future	_	_	I-Claim
476	studies	_	_	I-Claim
477	.	_	_	I-Claim


0	Cancer	_	_	O
1	related	_	_	O
2	fatigue	_	_	O
3	(	_	_	O
4	CRF	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	common	_	_	O
9	problem	_	_	O
10	for	_	_	O
11	cancer	_	_	O
12	patients	_	_	O
13	across	_	_	O
14	diagnoses	_	_	O
15	during	_	_	O
16	chemotherapy	_	_	O
17	and	_	_	O
18	is	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	physical	_	_	O
22	inactivity	_	_	O
23	,	_	_	O
24	lower	_	_	O
25	functional	_	_	O
26	level	_	_	O
27	and	_	_	O
28	lack	_	_	O
29	of	_	_	O
30	energy	_	_	O
31	.	_	_	O

32	Few	_	_	O
33	RCT	_	_	O
34	exercise	_	_	O
35	intervention	_	_	O
36	studies	_	_	O
37	have	_	_	O
38	included	_	_	O
39	cancer	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	chemotherapy	_	_	O
43	.	_	_	O

44	The	_	_	O
45	objective	_	_	O
46	of	_	_	O
47	this	_	_	O
48	study	_	_	O
49	is	_	_	O
50	to	_	_	O
51	evaluate	_	_	O
52	whether	_	_	O
53	a	_	_	O
54	six-week	_	_	O
55	supervised	_	_	O
56	multimodal	_	_	O
57	exercise	_	_	O
58	intervention	_	_	O
59	,	_	_	O
60	adjunct	_	_	O
61	to	_	_	O
62	chemotherapy	_	_	O
63	and	_	_	O
64	standard	_	_	O
65	care	_	_	O
66	,	_	_	O
67	can	_	_	O
68	reduce	_	_	O
69	the	_	_	O
70	patient	_	_	O
71	's	_	_	O
72	CRF	_	_	O
73	level	_	_	O
74	.	_	_	O

75	Data	_	_	O
76	is	_	_	O
77	based	_	_	O
78	on	_	_	O
79	analyses	_	_	O
80	of	_	_	O
81	a	_	_	O
82	prospective	_	_	O
83	randomised	_	_	O
84	controlled	_	_	O
85	trial	_	_	O
86	'The	_	_	O
87	Body	_	_	O
88	Cancer	_	_	O
89	Trial	_	_	O
90	'	_	_	O
91	.	_	_	O

92	213	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	different	_	_	O
97	diagnoses	_	_	O
98	were	_	_	O
99	randomised	_	_	O
100	into	_	_	O
101	an	_	_	O
102	intervention	_	_	O
103	group	_	_	O
104	or	_	_	O
105	wait-list	_	_	O
106	control	_	_	O
107	group	_	_	O
108	.	_	_	O

109	The	_	_	O
110	primary	_	_	O
111	outcome	_	_	O
112	,	_	_	O
113	Fatigue	_	_	O
114	score	_	_	O
115	(	_	_	O
116	CRF	_	_	O
117	)	_	_	O
118	,	_	_	O
119	was	_	_	O
120	evaluated	_	_	O
121	by	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Anaemia	_	_	O
128	Questionnaire	_	_	O
129	(	_	_	O
130	FACT-An-	_	_	O
131	)	_	_	O
132	(	_	_	O
133	FACT-G	_	_	O
134	score	_	_	O
135	&	_	_	O
136	FACT-An	_	_	O
137	Anemia	_	_	O
138	subscale	_	_	O
139	)	_	_	O
140	.	_	_	O

141	Supervised	_	_	O
142	exercise	_	_	O
143	,	_	_	O
144	comprising	_	_	O
145	high-intensity	_	_	O
146	cardiovascular	_	_	O
147	and	_	_	O
148	heavy	_	_	O
149	resistance	_	_	O
150	training	_	_	O
151	,	_	_	O
152	relaxation-	_	_	O
153	and	_	_	O
154	body	_	_	O
155	awareness	_	_	O
156	training	_	_	O
157	and	_	_	O
158	massage	_	_	O
159	,	_	_	O
160	9	_	_	O
161	h	_	_	O
162	weekly	_	_	O
163	for	_	_	O
164	6	_	_	O
165	weeks	_	_	O
166	.	_	_	O

167	CRF	_	_	B-Premise
168	was	_	_	I-Premise
169	significantly	_	_	I-Premise
170	reduced	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	group	_	_	I-Premise
175	,	_	_	I-Premise
176	corresponding	_	_	I-Premise
177	to	_	_	I-Premise
178	a	_	_	I-Premise
179	Fatigue	_	_	I-Premise
180	score	_	_	I-Premise
181	reduction	_	_	I-Premise
182	of	_	_	I-Premise
183	3.04	_	_	I-Premise
184	(	_	_	I-Premise
185	effect	_	_	I-Premise
186	size	_	_	I-Premise
187	of	_	_	I-Premise
188	0.44	_	_	I-Premise
189	,	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	0.17-0.72	_	_	I-Premise
194	)	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.002	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	the	_	_	I-Premise
202	FACT-An	_	_	I-Premise
203	score	_	_	I-Premise
204	by	_	_	I-Premise
205	5.40	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.015	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	the	_	_	I-Premise
213	FACT-An	_	_	I-Premise
214	Toi	_	_	I-Premise
215	score	_	_	I-Premise
216	by	_	_	I-Premise
217	5.22	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.009	_	_	I-Premise
222	)	_	_	I-Premise
223	and	_	_	I-Premise
224	the	_	_	I-Premise
225	Anaemia-ANS	_	_	I-Premise
226	by	_	_	I-Premise
227	3.76	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.002	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	There	_	_	B-Premise
235	was	_	_	I-Premise
236	no	_	_	I-Premise
237	statistically	_	_	I-Premise
238	significant	_	_	I-Premise
239	effect	_	_	I-Premise
240	on	_	_	I-Premise
241	the	_	_	I-Premise
242	General	_	_	I-Premise
243	Quality	_	_	I-Premise
244	of	_	_	I-Premise
245	Life	_	_	I-Premise
246	score	_	_	I-Premise
247	(	_	_	I-Premise
248	FACT-G	_	_	I-Premise
249	)	_	_	I-Premise
250	or	_	_	I-Premise
251	on	_	_	I-Premise
252	any	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	individual	_	_	I-Premise
256	wellbeing	_	_	I-Premise
257	scores	_	_	I-Premise
258	;	_	_	I-Premise
259	Physical	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.13	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	Emotional	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.87	_	_	I-Premise
271	)	_	_	I-Premise
272	,	_	_	I-Premise
273	Social	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	.83	_	_	I-Premise
278	)	_	_	I-Premise
279	and	_	_	I-Premise
280	Functional	_	_	I-Premise
281	(	_	_	I-Premise
282	P	_	_	I-Premise
283	=	_	_	I-Premise
284	.26	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	In	_	_	B-Claim
288	summary	_	_	I-Claim
289	,	_	_	I-Claim
290	this	_	_	I-Claim
291	six-week	_	_	I-Claim
292	supervised	_	_	I-Claim
293	multimodal	_	_	I-Claim
294	exercise	_	_	I-Claim
295	intervention	_	_	I-Claim
296	can	_	_	I-Claim
297	lead	_	_	I-Claim
298	to	_	_	I-Claim
299	significant	_	_	I-Claim
300	reduction	_	_	I-Claim
301	in	_	_	I-Claim
302	self-reported	_	_	I-Claim
303	CRF	_	_	I-Claim
304	in	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	undergoing	_	_	I-Claim
308	chemotherapy	_	_	I-Claim
309	.	_	_	I-Claim


0	Chemotherapy	_	_	O
1	with	_	_	O
2	a	_	_	O
3	platinum	_	_	O
4	agent	_	_	O
5	and	_	_	O
6	a	_	_	O
7	taxane	_	_	O
8	(	_	_	O
9	paclitaxel	_	_	O
10	)	_	_	O
11	is	_	_	O
12	considered	_	_	O
13	the	_	_	O
14	standard	_	_	O
15	of	_	_	O
16	care	_	_	O
17	for	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	ovarian	_	_	O
21	carcinoma	_	_	O
22	.	_	_	O

23	We	_	_	O
24	compared	_	_	O
25	the	_	_	O
26	combination	_	_	O
27	of	_	_	O
28	docetaxel-carboplatin	_	_	O
29	with	_	_	O
30	the	_	_	O
31	combination	_	_	O
32	of	_	_	O
33	paclitaxel-carboplatin	_	_	O
34	as	_	_	O
35	first-line	_	_	O
36	chemotherapy	_	_	O
37	for	_	_	O
38	stage	_	_	O
39	Ic-IV	_	_	O
40	epithelial	_	_	O
41	ovarian	_	_	O
42	or	_	_	O
43	primary	_	_	O
44	peritoneal	_	_	O
45	cancer	_	_	O
46	.	_	_	O

47	We	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	1077	_	_	O
51	patients	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	docetaxel	_	_	O
55	at	_	_	O
56	75	_	_	O
57	mg/m2	_	_	O
58	of	_	_	O
59	body	_	_	O
60	surface	_	_	O
61	area	_	_	O
62	(	_	_	O
63	1-hour	_	_	O
64	intravenous	_	_	O
65	infusion	_	_	O
66	)	_	_	O
67	or	_	_	O
68	paclitaxel	_	_	O
69	at	_	_	O
70	175	_	_	O
71	mg/m2	_	_	O
72	(	_	_	O
73	3-hour	_	_	O
74	intravenous	_	_	O
75	infusion	_	_	O
76	)	_	_	O
77	.	_	_	O

78	Both	_	_	O
79	treatments	_	_	O
80	then	_	_	O
81	were	_	_	O
82	followed	_	_	O
83	by	_	_	O
84	carboplatin	_	_	O
85	to	_	_	O
86	an	_	_	O
87	area	_	_	O
88	under	_	_	O
89	the	_	_	O
90	plasma	_	_	O
91	concentration-time	_	_	O
92	curve	_	_	O
93	of	_	_	O
94	5	_	_	O
95	.	_	_	O

96	The	_	_	O
97	treatments	_	_	O
98	were	_	_	O
99	repeated	_	_	O
100	every	_	_	O
101	3	_	_	O
102	weeks	_	_	O
103	for	_	_	O
104	six	_	_	O
105	cycles	_	_	O
106	;	_	_	O
107	in	_	_	O
108	responding	_	_	O
109	patients	_	_	O
110	,	_	_	O
111	an	_	_	O
112	additional	_	_	O
113	three	_	_	O
114	cycles	_	_	O
115	of	_	_	O
116	single-agent	_	_	O
117	carboplatin	_	_	O
118	was	_	_	O
119	permitted	_	_	O
120	.	_	_	O

121	Survival	_	_	O
122	curves	_	_	O
123	were	_	_	O
124	calculated	_	_	O
125	by	_	_	O
126	the	_	_	O
127	Kaplan-Meier	_	_	O
128	method	_	_	O
129	,	_	_	O
130	and	_	_	O
131	hazard	_	_	O
132	ratios	_	_	O
133	were	_	_	O
134	estimated	_	_	O
135	with	_	_	O
136	the	_	_	O
137	Cox	_	_	O
138	proportional	_	_	O
139	hazards	_	_	O
140	model	_	_	O
141	.	_	_	O

142	All	_	_	O
143	statistical	_	_	O
144	tests	_	_	O
145	were	_	_	O
146	two-sided	_	_	O
147	.	_	_	O

148	After	_	_	B-Premise
149	a	_	_	I-Premise
150	median	_	_	I-Premise
151	follow-up	_	_	I-Premise
152	of	_	_	I-Premise
153	23	_	_	I-Premise
154	months	_	_	I-Premise
155	,	_	_	I-Premise
156	both	_	_	I-Premise
157	groups	_	_	I-Premise
158	had	_	_	I-Premise
159	similar	_	_	I-Premise
160	progression-free	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	medians	_	_	I-Premise
164	of	_	_	I-Premise
165	15.0	_	_	I-Premise
166	months	_	_	I-Premise
167	for	_	_	I-Premise
168	docetaxel-carboplatin	_	_	I-Premise
169	and	_	_	I-Premise
170	14.8	_	_	I-Premise
171	months	_	_	I-Premise
172	for	_	_	I-Premise
173	paclitaxel-carboplatin	_	_	I-Premise
174	;	_	_	I-Premise
175	hazard	_	_	I-Premise
176	ratio	_	_	I-Premise
177	[	_	_	I-Premise
178	HR	_	_	I-Premise
179	]	_	_	I-Premise
180	docetaxel-paclitaxel	_	_	I-Premise
181	=	_	_	I-Premise
182	0.97	_	_	I-Premise
183	,	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	confidence	_	_	I-Premise
187	interval	_	_	I-Premise
188	[	_	_	I-Premise
189	CI	_	_	I-Premise
190	]	_	_	I-Premise
191	=	_	_	I-Premise
192	0.83	_	_	I-Premise
193	to	_	_	I-Premise
194	1.13	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.707	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	overall	_	_	I-Premise
202	survival	_	_	I-Premise
203	rates	_	_	I-Premise
204	at	_	_	I-Premise
205	2	_	_	I-Premise
206	years	_	_	I-Premise
207	(	_	_	I-Premise
208	64.2	_	_	I-Premise
209	%	_	_	I-Premise
210	and	_	_	I-Premise
211	68.9	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	;	_	_	I-Premise
216	HR	_	_	I-Premise
217	=	_	_	I-Premise
218	1.13	_	_	I-Premise
219	,	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	=	_	_	I-Premise
224	0.92	_	_	I-Premise
225	to	_	_	I-Premise
226	1.39	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.238	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	objective	_	_	I-Premise
235	tumor	_	_	I-Premise
236	(	_	_	I-Premise
237	58.7	_	_	I-Premise
238	%	_	_	I-Premise
239	and	_	_	I-Premise
240	59.5	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	;	_	_	I-Premise
245	difference	_	_	I-Premise
246	between	_	_	I-Premise
247	docetaxel	_	_	I-Premise
248	and	_	_	I-Premise
249	paclitaxel	_	_	I-Premise
250	=	_	_	I-Premise
251	-0.8	_	_	I-Premise
252	%	_	_	I-Premise
253	,	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	=	_	_	I-Premise
258	-8.6	_	_	I-Premise
259	%	_	_	I-Premise
260	to	_	_	I-Premise
261	7.1	_	_	I-Premise
262	%	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.868	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	CA-125	_	_	I-Premise
270	(	_	_	I-Premise
271	75.8	_	_	I-Premise
272	%	_	_	I-Premise
273	and	_	_	I-Premise
274	76.8	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	respectively	_	_	I-Premise
278	;	_	_	I-Premise
279	difference	_	_	I-Premise
280	docetaxel-paclitaxel	_	_	I-Premise
281	=	_	_	I-Premise
282	-1.0	_	_	I-Premise
283	%	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	-7.2	_	_	I-Premise
290	%	_	_	I-Premise
291	to	_	_	I-Premise
292	5.1	_	_	I-Premise
293	%	_	_	I-Premise
294	;	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.794	_	_	I-Premise
298	)	_	_	I-Premise
299	response	_	_	I-Premise
300	rates	_	_	I-Premise
301	.	_	_	I-Premise

302	However	_	_	B-Premise
303	,	_	_	I-Premise
304	docetaxel-carboplatin	_	_	I-Premise
305	was	_	_	I-Premise
306	associated	_	_	I-Premise
307	with	_	_	I-Premise
308	substantially	_	_	I-Premise
309	less	_	_	I-Premise
310	overall	_	_	I-Premise
311	and	_	_	I-Premise
312	grade	_	_	I-Premise
313	2	_	_	I-Premise
314	or	_	_	I-Premise
315	higher	_	_	I-Premise
316	neurotoxicity	_	_	I-Premise
317	than	_	_	I-Premise
318	paclitaxel-carboplatin	_	_	I-Premise
319	(	_	_	I-Premise
320	grade	_	_	I-Premise
321	>	_	_	I-Premise
322	or	_	_	I-Premise
323	=2	_	_	I-Premise
324	neurosensory	_	_	I-Premise
325	toxicity	_	_	I-Premise
326	in	_	_	I-Premise
327	11	_	_	I-Premise
328	%	_	_	I-Premise
329	versus	_	_	I-Premise
330	30	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	difference	_	_	I-Premise
334	=	_	_	I-Premise
335	19	_	_	I-Premise
336	%	_	_	I-Premise
337	,	_	_	I-Premise
338	95	_	_	I-Premise
339	%	_	_	I-Premise
340	CI	_	_	I-Premise
341	=	_	_	I-Premise
342	15	_	_	I-Premise
343	%	_	_	I-Premise
344	to	_	_	I-Premise
345	24	_	_	I-Premise
346	%	_	_	I-Premise
347	;	_	_	I-Premise
348	P	_	_	I-Premise
349	<	_	_	I-Premise
350	.001	_	_	I-Premise
351	;	_	_	I-Premise
352	grade	_	_	I-Premise
353	>	_	_	I-Premise
354	or	_	_	I-Premise
355	=2	_	_	I-Premise
356	neuromotor	_	_	I-Premise
357	toxicity	_	_	I-Premise
358	in	_	_	I-Premise
359	3	_	_	I-Premise
360	%	_	_	I-Premise
361	versus	_	_	I-Premise
362	7	_	_	I-Premise
363	%	_	_	I-Premise
364	,	_	_	I-Premise
365	difference	_	_	I-Premise
366	=	_	_	I-Premise
367	4	_	_	I-Premise
368	%	_	_	I-Premise
369	,	_	_	I-Premise
370	95	_	_	I-Premise
371	%	_	_	I-Premise
372	CI	_	_	I-Premise
373	=	_	_	I-Premise
374	1	_	_	I-Premise
375	%	_	_	I-Premise
376	to	_	_	I-Premise
377	7	_	_	I-Premise
378	%	_	_	I-Premise
379	;	_	_	I-Premise
380	P	_	_	I-Premise
381	<	_	_	I-Premise
382	.001	_	_	I-Premise
383	)	_	_	I-Premise
384	.	_	_	I-Premise

385	Treatment	_	_	B-Premise
386	with	_	_	I-Premise
387	docetaxel-carboplatin	_	_	I-Premise
388	was	_	_	I-Premise
389	associated	_	_	I-Premise
390	with	_	_	I-Premise
391	statistically	_	_	I-Premise
392	significantly	_	_	I-Premise
393	more	_	_	I-Premise
394	grade	_	_	I-Premise
395	3-4	_	_	I-Premise
396	neutropenia	_	_	I-Premise
397	(	_	_	I-Premise
398	94	_	_	I-Premise
399	%	_	_	I-Premise
400	versus	_	_	I-Premise
401	84	_	_	I-Premise
402	%	_	_	I-Premise
403	,	_	_	I-Premise
404	difference	_	_	I-Premise
405	=	_	_	I-Premise
406	11	_	_	I-Premise
407	%	_	_	I-Premise
408	,	_	_	I-Premise
409	95	_	_	I-Premise
410	%	_	_	I-Premise
411	CI	_	_	I-Premise
412	=	_	_	I-Premise
413	7	_	_	I-Premise
414	%	_	_	I-Premise
415	to	_	_	I-Premise
416	14	_	_	I-Premise
417	%	_	_	I-Premise
418	;	_	_	I-Premise
419	P	_	_	I-Premise
420	<	_	_	I-Premise
421	.001	_	_	I-Premise
422	)	_	_	I-Premise
423	and	_	_	I-Premise
424	neutropenic	_	_	I-Premise
425	complications	_	_	I-Premise
426	than	_	_	I-Premise
427	treatment	_	_	I-Premise
428	with	_	_	I-Premise
429	paclitaxel-carboplatin	_	_	I-Premise
430	,	_	_	I-Premise
431	although	_	_	B-Premise
432	myelosuppression	_	_	I-Premise
433	did	_	_	I-Premise
434	not	_	_	I-Premise
435	influence	_	_	I-Premise
436	dose	_	_	I-Premise
437	delivery	_	_	I-Premise
438	or	_	_	I-Premise
439	patient	_	_	I-Premise
440	safety	_	_	I-Premise
441	.	_	_	I-Premise

442	Global	_	_	B-Premise
443	quality	_	_	I-Premise
444	of	_	_	I-Premise
445	life	_	_	I-Premise
446	was	_	_	I-Premise
447	similar	_	_	I-Premise
448	in	_	_	I-Premise
449	both	_	_	I-Premise
450	arms	_	_	I-Premise
451	,	_	_	I-Premise
452	but	_	_	B-Premise
453	substantive	_	_	I-Premise
454	differences	_	_	I-Premise
455	in	_	_	I-Premise
456	many	_	_	I-Premise
457	symptom	_	_	I-Premise
458	scores	_	_	I-Premise
459	favored	_	_	I-Premise
460	docetaxel	_	_	I-Premise
461	.	_	_	I-Premise

462	Docetaxel-carboplatin	_	_	B-Claim
463	appears	_	_	I-Claim
464	to	_	_	I-Claim
465	be	_	_	I-Claim
466	similar	_	_	I-Claim
467	to	_	_	I-Claim
468	paclitaxel-carboplatin	_	_	I-Claim
469	in	_	_	I-Claim
470	terms	_	_	I-Claim
471	of	_	_	I-Claim
472	progression-free	_	_	I-Claim
473	survival	_	_	I-Claim
474	and	_	_	I-Claim
475	response	_	_	I-Claim
476	,	_	_	I-Claim
477	although	_	_	B-Claim
478	longer	_	_	I-Claim
479	follow-up	_	_	I-Claim
480	is	_	_	I-Claim
481	required	_	_	I-Claim
482	for	_	_	I-Claim
483	a	_	_	I-Claim
484	definitive	_	_	I-Claim
485	statement	_	_	I-Claim
486	on	_	_	I-Claim
487	survival	_	_	I-Claim
488	.	_	_	I-Claim

489	Thus	_	_	B-Claim
490	,	_	_	I-Claim
491	docetaxel-carboplatin	_	_	I-Claim
492	represents	_	_	I-Claim
493	an	_	_	I-Claim
494	alternative	_	_	I-Claim
495	first-line	_	_	I-Claim
496	chemotherapy	_	_	I-Claim
497	regimen	_	_	I-Claim
498	for	_	_	I-Claim
499	patients	_	_	I-Claim
500	with	_	_	I-Claim
501	newly	_	_	I-Claim
502	diagnosed	_	_	I-Claim
503	ovarian	_	_	I-Claim
504	cancer	_	_	I-Claim
505	.	_	_	I-Claim


0	Exercise	_	_	O
1	for	_	_	O
2	Health	_	_	O
3	was	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	controlled	_	_	O
8	trial	_	_	O
9	designed	_	_	O
10	to	_	_	O
11	evaluate	_	_	O
12	two	_	_	O
13	modes	_	_	O
14	of	_	_	O
15	delivering	_	_	O
16	(	_	_	O
17	face-to-face	_	_	O
18	[	_	_	O
19	FtF	_	_	O
20	]	_	_	O
21	and	_	_	O
22	over-the-telephone	_	_	O
23	[	_	_	O
24	Tel	_	_	O
25	]	_	_	O
26	)	_	_	O
27	an	_	_	O
28	8-month	_	_	O
29	translational	_	_	O
30	exercise	_	_	O
31	intervention	_	_	O
32	,	_	_	O
33	commencing	_	_	O
34	6-weeks	_	_	O
35	post-breast	_	_	O
36	cancer	_	_	O
37	surgery	_	_	O
38	(	_	_	O
39	PS	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Outcomes	_	_	O
43	included	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	(	_	_	O
48	QoL	_	_	O
49	)	_	_	O
50	,	_	_	O
51	function	_	_	O
52	(	_	_	O
53	fitness	_	_	O
54	and	_	_	O
55	upper	_	_	O
56	body	_	_	O
57	)	_	_	O
58	and	_	_	O
59	treatment-related	_	_	O
60	side	_	_	O
61	effects	_	_	O
62	(	_	_	O
63	fatigue	_	_	O
64	,	_	_	O
65	lymphoedema	_	_	O
66	,	_	_	O
67	body	_	_	O
68	mass	_	_	O
69	index	_	_	O
70	,	_	_	O
71	menopausal	_	_	O
72	symptoms	_	_	O
73	,	_	_	O
74	anxiety	_	_	O
75	,	_	_	O
76	depression	_	_	O
77	and	_	_	O
78	pain	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Generalised	_	_	O
82	estimating	_	_	O
83	equation	_	_	O
84	modelling	_	_	O
85	determined	_	_	O
86	time	_	_	O
87	(	_	_	O
88	baseline	_	_	O
89	[	_	_	O
90	5	_	_	O
91	weeks	_	_	O
92	PS	_	_	O
93	]	_	_	O
94	,	_	_	O
95	mid-intervention	_	_	O
96	[	_	_	O
97	6	_	_	O
98	months	_	_	O
99	PS	_	_	O
100	]	_	_	O
101	,	_	_	O
102	post-intervention	_	_	O
103	[	_	_	O
104	12	_	_	O
105	months	_	_	O
106	PS	_	_	O
107	]	_	_	O
108	)	_	_	O
109	,	_	_	O
110	group	_	_	O
111	(	_	_	O
112	FtF	_	_	O
113	,	_	_	O
114	Tel	_	_	O
115	,	_	_	O
116	Usual	_	_	O
117	Care	_	_	O
118	[	_	_	O
119	UC	_	_	O
120	]	_	_	O
121	)	_	_	O
122	and	_	_	O
123	time-by-group	_	_	O
124	effects	_	_	O
125	.	_	_	O

126	194	_	_	O
127	women	_	_	O
128	representative	_	_	O
129	of	_	_	O
130	the	_	_	O
131	breast	_	_	O
132	cancer	_	_	O
133	population	_	_	O
134	were	_	_	O
135	randomised	_	_	O
136	to	_	_	O
137	the	_	_	O
138	FtF	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	67	_	_	O
143	)	_	_	O
144	,	_	_	O
145	Tel	_	_	O
146	(	_	_	O
147	n	_	_	O
148	=	_	_	O
149	67	_	_	O
150	)	_	_	O
151	and	_	_	O
152	UC	_	_	O
153	(	_	_	O
154	n	_	_	O
155	=	_	_	O
156	60	_	_	O
157	)	_	_	O
158	groups	_	_	O
159	.	_	_	O

160	There	_	_	B-Premise
161	were	_	_	I-Premise
162	significant	_	_	I-Premise
163	(	_	_	I-Premise
164	p	_	_	I-Premise
165	<	_	_	I-Premise
166	0.05	_	_	I-Premise
167	)	_	_	I-Premise
168	interaction	_	_	I-Premise
169	effects	_	_	I-Premise
170	on	_	_	I-Premise
171	QoL	_	_	I-Premise
172	,	_	_	I-Premise
173	fitness	_	_	I-Premise
174	and	_	_	I-Premise
175	fatigue	_	_	I-Premise
176	with	_	_	I-Premise
177	differences	_	_	I-Premise
178	being	_	_	I-Premise
179	observed	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	treatment	_	_	I-Premise
183	groups	_	_	I-Premise
184	and	_	_	I-Premise
185	the	_	_	I-Premise
186	UC	_	_	I-Premise
187	group	_	_	I-Premise
188	.	_	_	I-Premise

189	Trends	_	_	B-Premise
190	observed	_	_	I-Premise
191	for	_	_	I-Premise
192	the	_	_	I-Premise
193	treatment	_	_	I-Premise
194	groups	_	_	I-Premise
195	were	_	_	I-Premise
196	similar	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Premise
199	treatment	_	_	I-Premise
200	groups	_	_	I-Premise
201	reported	_	_	I-Premise
202	improved	_	_	I-Premise
203	QoL	_	_	I-Premise
204	,	_	_	I-Premise
205	fitness	_	_	I-Premise
206	and	_	_	I-Premise
207	fatigue	_	_	I-Premise
208	over	_	_	I-Premise
209	time	_	_	I-Premise
210	and	_	_	I-Premise
211	changes	_	_	I-Premise
212	observed	_	_	I-Premise
213	between	_	_	I-Premise
214	baseline	_	_	I-Premise
215	and	_	_	I-Premise
216	post-intervention	_	_	I-Premise
217	were	_	_	I-Premise
218	clinically	_	_	I-Premise
219	relevant	_	_	I-Premise
220	.	_	_	I-Premise

221	In	_	_	B-Premise
222	contrast	_	_	I-Premise
223	,	_	_	I-Premise
224	the	_	_	I-Premise
225	UC	_	_	I-Premise
226	group	_	_	I-Premise
227	experienced	_	_	I-Premise
228	no	_	_	I-Premise
229	change	_	_	I-Premise
230	,	_	_	I-Premise
231	or	_	_	I-Premise
232	worsening	_	_	I-Premise
233	QoL	_	_	I-Premise
234	,	_	_	I-Premise
235	fitness	_	_	I-Premise
236	and	_	_	I-Premise
237	fatigue	_	_	I-Premise
238	,	_	_	I-Premise
239	mid-intervention	_	_	I-Premise
240	.	_	_	I-Premise

241	Although	_	_	B-Premise
242	improvements	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	UC	_	_	I-Premise
246	group	_	_	I-Premise
247	occurred	_	_	I-Premise
248	by	_	_	I-Premise
249	12-months	_	_	I-Premise
250	post-surgery	_	_	I-Premise
251	,	_	_	I-Premise
252	the	_	_	B-Premise
253	change	_	_	I-Premise
254	did	_	_	I-Premise
255	not	_	_	I-Premise
256	meet	_	_	I-Premise
257	the	_	_	I-Premise
258	clinically	_	_	I-Premise
259	relevant	_	_	I-Premise
260	threshold	_	_	I-Premise
261	.	_	_	I-Premise

262	There	_	_	B-Premise
263	were	_	_	I-Premise
264	no	_	_	I-Premise
265	differences	_	_	I-Premise
266	in	_	_	I-Premise
267	other	_	_	I-Premise
268	treatment-related	_	_	I-Premise
269	side	_	_	I-Premise
270	effects	_	_	I-Premise
271	between	_	_	I-Premise
272	groups	_	_	I-Premise
273	.	_	_	I-Premise

274	This	_	_	B-Claim
275	translational	_	_	I-Claim
276	intervention	_	_	I-Claim
277	trial	_	_	I-Claim
278	,	_	_	I-Claim
279	delivered	_	_	I-Claim
280	either	_	_	I-Claim
281	FtF	_	_	I-Claim
282	or	_	_	I-Claim
283	Tel	_	_	I-Claim
284	,	_	_	I-Claim
285	supports	_	_	I-Claim
286	exercise	_	_	I-Claim
287	as	_	_	I-Claim
288	a	_	_	I-Claim
289	form	_	_	I-Claim
290	of	_	_	I-Claim
291	adjuvant	_	_	I-Claim
292	breast	_	_	I-Claim
293	cancer	_	_	I-Claim
294	therapy	_	_	I-Claim
295	that	_	_	I-Claim
296	can	_	_	I-Claim
297	prevent	_	_	I-Claim
298	declines	_	_	I-Claim
299	in	_	_	I-Claim
300	fitness	_	_	I-Claim
301	and	_	_	I-Claim
302	function	_	_	I-Claim
303	during	_	_	I-Claim
304	treatment	_	_	I-Claim
305	and	_	_	I-Claim
306	optimise	_	_	I-Claim
307	recovery	_	_	I-Claim
308	post-treatment	_	_	I-Claim
309	.	_	_	I-Claim


0	Malignant	_	_	B-Claim
1	pleural	_	_	I-Claim
2	effusion	_	_	I-Claim
3	(	_	_	I-Claim
4	MPE	_	_	I-Claim
5	)	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	common	_	_	I-Claim
9	complication	_	_	I-Claim
10	of	_	_	I-Claim
11	advanced	_	_	I-Claim
12	non-small	_	_	I-Claim
13	cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	.	_	_	I-Claim

20	Bevacizumab	_	_	B-Claim
21	,	_	_	I-Claim
22	a	_	_	I-Claim
23	humanized	_	_	I-Claim
24	monoclonal	_	_	I-Claim
25	antibody	_	_	I-Claim
26	against	_	_	I-Claim
27	vascular	_	_	I-Claim
28	endothelial	_	_	I-Claim
29	growth	_	_	I-Claim
30	factor	_	_	I-Claim
31	(	_	_	I-Claim
32	VEGF	_	_	I-Claim
33	)	_	_	I-Claim
34	,	_	_	I-Claim
35	has	_	_	I-Claim
36	been	_	_	I-Claim
37	shown	_	_	I-Claim
38	to	_	_	I-Claim
39	be	_	_	I-Claim
40	efficient	_	_	I-Claim
41	in	_	_	I-Claim
42	suppressing	_	_	I-Claim
43	the	_	_	I-Claim
44	accumulation	_	_	I-Claim
45	of	_	_	I-Claim
46	pleural	_	_	I-Claim
47	fluid	_	_	I-Claim
48	.	_	_	I-Claim

49	However	_	_	O
50	,	_	_	O
51	whether	_	_	O
52	intrapleural	_	_	O
53	delivery	_	_	O
54	of	_	_	O
55	bevacizumab	_	_	O
56	can	_	_	O
57	be	_	_	O
58	used	_	_	O
59	to	_	_	O
60	treat	_	_	O
61	MPE	_	_	O
62	remains	_	_	O
63	unknown	_	_	O
64	.	_	_	O

65	The	_	_	O
66	aim	_	_	O
67	of	_	_	O
68	the	_	_	O
69	present	_	_	O
70	study	_	_	O
71	was	_	_	O
72	to	_	_	O
73	evaluate	_	_	O
74	the	_	_	O
75	efficacy	_	_	O
76	and	_	_	O
77	safety	_	_	O
78	of	_	_	O
79	combined	_	_	O
80	intrapleural	_	_	O
81	therapy	_	_	O
82	with	_	_	O
83	bevacizumab	_	_	O
84	and	_	_	O
85	cisplatin	_	_	O
86	,	_	_	O
87	an	_	_	O
88	antineoplastic	_	_	O
89	agent	_	_	O
90	,	_	_	O
91	in	_	_	O
92	controlling	_	_	O
93	MPE	_	_	O
94	.	_	_	O

95	A	_	_	O
96	total	_	_	O
97	of	_	_	O
98	72	_	_	O
99	NSCLC	_	_	O
100	study	_	_	O
101	subjects	_	_	O
102	with	_	_	O
103	MPE	_	_	O
104	were	_	_	O
105	randomly	_	_	O
106	assigned	_	_	O
107	to	_	_	O
108	one	_	_	O
109	of	_	_	O
110	two	_	_	O
111	groups	_	_	O
112	.	_	_	O

113	The	_	_	O
114	first	_	_	O
115	group	_	_	O
116	received	_	_	O
117	intrapleural	_	_	O
118	bevacizumab	_	_	O
119	(	_	_	O
120	300	_	_	O
121	mg	_	_	O
122	)	_	_	O
123	with	_	_	O
124	cisplatin	_	_	O
125	(	_	_	O
126	30	_	_	O
127	mg	_	_	O
128	)	_	_	O
129	therapy	_	_	O
130	and	_	_	O
131	the	_	_	O
132	second	_	_	O
133	group	_	_	O
134	received	_	_	O
135	intrapleural	_	_	O
136	cisplatin	_	_	O
137	(	_	_	O
138	30	_	_	O
139	mg	_	_	O
140	)	_	_	O
141	therapy	_	_	O
142	alone	_	_	O
143	.	_	_	O

144	Pleural	_	_	O
145	fluid	_	_	O
146	was	_	_	O
147	collected	_	_	O
148	from	_	_	O
149	both	_	_	O
150	groups	_	_	O
151	prior	_	_	O
152	to	_	_	O
153	and	_	_	O
154	following	_	_	O
155	treatment	_	_	O
156	.	_	_	O

157	The	_	_	O
158	levels	_	_	O
159	of	_	_	O
160	VEGF	_	_	O
161	and	_	_	O
162	carcinoembryonic	_	_	O
163	antigen	_	_	O
164	(	_	_	O
165	CEA	_	_	O
166	)	_	_	O
167	in	_	_	O
168	the	_	_	O
169	pleural	_	_	O
170	fluid	_	_	O
171	were	_	_	O
172	determined	_	_	O
173	by	_	_	O
174	ELISA	_	_	O
175	.	_	_	O

176	In	_	_	B-Premise
177	70	_	_	I-Premise
178	evaluable	_	_	I-Premise
179	study	_	_	I-Premise
180	subjects	_	_	I-Premise
181	,	_	_	I-Premise
182	the	_	_	I-Premise
183	curative	_	_	I-Premise
184	efficacy	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	bevacizumab	_	_	I-Premise
188	group	_	_	I-Premise
189	was	_	_	I-Premise
190	significantly	_	_	I-Premise
191	higher	_	_	I-Premise
192	than	_	_	I-Premise
193	that	_	_	I-Premise
194	found	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	cisplatin	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	83.33	_	_	I-Premise
201	vs.	_	_	I-Premise
202	50.00	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	;	_	_	I-Premise
207	p	_	_	I-Premise
208	<	_	_	I-Premise
209	0.05	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Therapy	_	_	B-Premise
213	with	_	_	I-Premise
214	combined	_	_	I-Premise
215	bevacizumab	_	_	I-Premise
216	plus	_	_	I-Premise
217	cisplatin	_	_	I-Premise
218	significantly	_	_	I-Premise
219	reduced	_	_	I-Premise
220	VEGF	_	_	I-Premise
221	levels	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	pleural	_	_	I-Premise
225	fluid	_	_	I-Premise
226	(	_	_	I-Premise
227	p	_	_	I-Premise
228	<	_	_	I-Premise
229	0.01	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	In	_	_	B-Premise
233	the	_	_	I-Premise
234	bevacizumab	_	_	I-Premise
235	group	_	_	I-Premise
236	,	_	_	I-Premise
237	the	_	_	I-Premise
238	levels	_	_	I-Premise
239	of	_	_	I-Premise
240	VEGF	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	pleural	_	_	I-Premise
244	fluid	_	_	I-Premise
245	were	_	_	I-Premise
246	significantly	_	_	I-Premise
247	lower	_	_	I-Premise
248	compared	_	_	I-Premise
249	to	_	_	I-Premise
250	those	_	_	I-Premise
251	of	_	_	I-Premise
252	the	_	_	I-Premise
253	cisplatin	_	_	I-Premise
254	group	_	_	I-Premise
255	after	_	_	I-Premise
256	treatment	_	_	I-Premise
257	,	_	_	I-Premise
258	which	_	_	I-Premise
259	showed	_	_	I-Premise
260	greater	_	_	I-Premise
261	efficacy	_	_	I-Premise
262	(	_	_	I-Premise
263	p	_	_	I-Premise
264	<	_	_	I-Premise
265	0.01	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	In	_	_	B-Premise
269	addition	_	_	I-Premise
270	,	_	_	I-Premise
271	combination	_	_	I-Premise
272	therapy	_	_	I-Premise
273	showed	_	_	I-Premise
274	greater	_	_	I-Premise
275	efficacy	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	patients	_	_	I-Premise
279	with	_	_	I-Premise
280	high	_	_	I-Premise
281	levels	_	_	I-Premise
282	of	_	_	I-Premise
283	VEGF	_	_	I-Premise
284	expression	_	_	I-Premise
285	(	_	_	I-Premise
286	p	_	_	I-Premise
287	<	_	_	I-Premise
288	0.01	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	There	_	_	B-Premise
292	was	_	_	I-Premise
293	no	_	_	I-Premise
294	significant	_	_	I-Premise
295	difference	_	_	I-Premise
296	in	_	_	I-Premise
297	grade	_	_	I-Premise
298	III/IV	_	_	I-Premise
299	adverse	_	_	I-Premise
300	events	_	_	I-Premise
301	between	_	_	I-Premise
302	the	_	_	I-Premise
303	two	_	_	I-Premise
304	groups	_	_	I-Premise
305	.	_	_	I-Premise

306	All	_	_	B-Premise
307	procedures	_	_	I-Premise
308	were	_	_	I-Premise
309	well	_	_	I-Premise
310	tolerated	_	_	I-Premise
311	by	_	_	I-Premise
312	the	_	_	I-Premise
313	patients	_	_	I-Premise
314	.	_	_	I-Premise

315	Combined	_	_	B-Claim
316	intrapleural	_	_	I-Claim
317	therapy	_	_	I-Claim
318	with	_	_	I-Claim
319	bevacizumab	_	_	I-Claim
320	and	_	_	I-Claim
321	cisplatin	_	_	I-Claim
322	was	_	_	I-Claim
323	effective	_	_	I-Claim
324	and	_	_	I-Claim
325	safe	_	_	I-Claim
326	in	_	_	I-Claim
327	managing	_	_	I-Claim
328	NSCLC-mediated	_	_	I-Claim
329	MPE	_	_	I-Claim
330	.	_	_	I-Claim

331	We	_	_	B-Claim
332	propose	_	_	I-Claim
333	that	_	_	I-Claim
334	VEGF	_	_	I-Claim
335	expression	_	_	I-Claim
336	levels	_	_	I-Claim
337	in	_	_	I-Claim
338	MPE	_	_	I-Claim
339	could	_	_	I-Claim
340	serve	_	_	I-Claim
341	as	_	_	I-Claim
342	a	_	_	I-Claim
343	prognostic	_	_	I-Claim
344	marker	_	_	I-Claim
345	for	_	_	I-Claim
346	bevacizumab	_	_	I-Claim
347	therapy	_	_	I-Claim
348	.	_	_	I-Claim


0	In	_	_	B-Claim
1	endocrine	_	_	I-Claim
2	therapy	_	_	I-Claim
3	trials	_	_	I-Claim
4	in	_	_	I-Claim
5	advanced	_	_	I-Claim
6	breast	_	_	I-Claim
7	cancer	_	_	I-Claim
8	,	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	response	_	_	I-Claim
12	(	_	_	I-Claim
13	complete	_	_	I-Claim
14	response/partial	_	_	I-Claim
15	response	_	_	I-Claim
16	[	_	_	I-Claim
17	CR/PR	_	_	I-Claim
18	]	_	_	I-Claim
19	)	_	_	I-Claim
20	and	_	_	I-Claim
21	patients	_	_	I-Claim
22	with	_	_	I-Claim
23	stable	_	_	I-Claim
24	disease	_	_	I-Claim
25	for	_	_	I-Claim
26	at	_	_	I-Claim
27	least	_	_	I-Claim
28	6	_	_	I-Claim
29	months	_	_	I-Claim
30	(	_	_	I-Claim
31	SD	_	_	I-Claim
32	(	_	_	I-Claim
33	6m	_	_	I-Claim
34	)	_	_	I-Claim
35	)	_	_	I-Claim
36	have	_	_	I-Claim
37	shown	_	_	I-Claim
38	similar	_	_	I-Claim
39	survival	_	_	I-Claim
40	and	_	_	I-Claim
41	therefore	_	_	I-Claim
42	are	_	_	I-Claim
43	often	_	_	I-Claim
44	defined	_	_	I-Claim
45	as	_	_	I-Claim
46	a	_	_	I-Claim
47	population	_	_	I-Claim
48	with	_	_	I-Claim
49	clinical	_	_	I-Claim
50	benefit	_	_	I-Claim
51	(	_	_	I-Claim
52	patients	_	_	I-Claim
53	with	_	_	I-Claim
54	CR/PR	_	_	I-Claim
55	or	_	_	I-Claim
56	SD	_	_	I-Claim
57	(	_	_	I-Claim
58	6m	_	_	I-Claim
59	)	_	_	I-Claim
60	)	_	_	I-Claim
61	.	_	_	I-Claim

62	We	_	_	O
63	evaluated	_	_	O
64	the	_	_	O
65	impact	_	_	O
66	of	_	_	O
67	response	_	_	O
68	and/or	_	_	O
69	clinical	_	_	O
70	benefit	_	_	O
71	on	_	_	O
72	quality	_	_	O
73	of	_	_	O
74	life	_	_	O
75	(	_	_	O
76	QL	_	_	O
77	)	_	_	O
78	in	_	_	O
79	postmenopausal	_	_	O
80	patients	_	_	O
81	under	_	_	O
82	second-line	_	_	O
83	endocrine	_	_	O
84	treatment	_	_	O
85	after	_	_	O
86	failure	_	_	O
87	of	_	_	O
88	tamoxifen	_	_	O
89	.	_	_	O

90	One	_	_	O
91	hundred	_	_	O
92	twenty-eight	_	_	O
93	of	_	_	O
94	177	_	_	O
95	eligible	_	_	O
96	patients	_	_	O
97	of	_	_	O
98	a	_	_	O
99	randomized	_	_	O
100	trial	_	_	O
101	(	_	_	O
102	Swiss	_	_	O
103	Group	_	_	O
104	for	_	_	O
105	Clinical	_	_	O
106	Cancer	_	_	O
107	Research	_	_	O
108	20/90	_	_	O
109	)	_	_	O
110	receiving	_	_	O
111	either	_	_	O
112	formestane	_	_	O
113	(	_	_	O
114	250	_	_	O
115	mg	_	_	O
116	intramuscularly	_	_	O
117	biweekly	_	_	O
118	)	_	_	O
119	or	_	_	O
120	megestrol	_	_	O
121	acetate	_	_	O
122	(	_	_	O
123	160	_	_	O
124	mg	_	_	O
125	orally	_	_	O
126	daily	_	_	O
127	)	_	_	O
128	were	_	_	O
129	analyzed	_	_	O
130	.	_	_	O

131	The	_	_	O
132	baseline	_	_	O
133	characteristics	_	_	O
134	(	_	_	O
135	with	_	_	O
136	the	_	_	O
137	exception	_	_	O
138	of	_	_	O
139	site	_	_	O
140	of	_	_	O
141	metastases	_	_	O
142	)	_	_	O
143	were	_	_	O
144	balanced	_	_	O
145	among	_	_	O
146	patients	_	_	O
147	with	_	_	O
148	CR/PR	_	_	O
149	,	_	_	O
150	SD	_	_	O
151	(	_	_	O
152	6m	_	_	O
153	)	_	_	O
154	,	_	_	O
155	and	_	_	O
156	progressive	_	_	O
157	disease	_	_	O
158	(	_	_	O
159	PD	_	_	O
160	)	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	completed	_	_	O
164	QL	_	_	O
165	indicators	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	and	_	_	O
169	at	_	_	O
170	1	_	_	O
171	,	_	_	O
172	3	_	_	O
173	,	_	_	O
174	5	_	_	O
175	,	_	_	O
176	7	_	_	O
177	,	_	_	O
178	9	_	_	O
179	,	_	_	O
180	and	_	_	O
181	11	_	_	O
182	months	_	_	O
183	.	_	_	O

184	Responders	_	_	O
185	were	_	_	O
186	separately	_	_	O
187	compared	_	_	O
188	with	_	_	O
189	nonresponders	_	_	O
190	(	_	_	O
191	patients	_	_	O
192	with	_	_	O
193	SD	_	_	O
194	(	_	_	O
195	6m	_	_	O
196	)	_	_	O
197	or	_	_	O
198	PD	_	_	O
199	)	_	_	O
200	and	_	_	O
201	with	_	_	O
202	patients	_	_	O
203	with	_	_	O
204	SD	_	_	O
205	(	_	_	O
206	6m	_	_	O
207	)	_	_	O
208	,	_	_	O
209	and	_	_	O
210	patients	_	_	O
211	with	_	_	O
212	clinical	_	_	O
213	benefit	_	_	O
214	were	_	_	O
215	compared	_	_	O
216	with	_	_	O
217	patients	_	_	O
218	with	_	_	O
219	PD	_	_	O
220	by	_	_	O
221	analysis	_	_	O
222	of	_	_	O
223	covariance	_	_	O
224	with	_	_	O
225	adjustment	_	_	O
226	for	_	_	O
227	baseline	_	_	O
228	scores	_	_	O
229	.	_	_	O

230	Overall	_	_	O
231	,	_	_	O
232	88	_	_	O
233	%	_	_	O
234	(	_	_	O
235	557	_	_	O
236	of	_	_	O
237	634	_	_	O
238	)	_	_	O
239	of	_	_	O
240	expected	_	_	O
241	QL	_	_	O
242	forms	_	_	O
243	were	_	_	O
244	received	_	_	O
245	.	_	_	O

246	In	_	_	O
247	the	_	_	O
248	comparison	_	_	O
249	of	_	_	O
250	responders	_	_	O
251	versus	_	_	O
252	patients	_	_	O
253	with	_	_	O
254	both	_	_	O
255	SD	_	_	O
256	(	_	_	O
257	6m	_	_	O
258	)	_	_	O
259	and	_	_	O
260	PD	_	_	O
261	,	_	_	O
262	responders	_	_	B-Premise
263	indicated	_	_	I-Premise
264	better	_	_	I-Premise
265	physical	_	_	I-Premise
266	well-being	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.	_	_	I-Premise

271	004	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	mood	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	=.02	_	_	I-Premise
278	)	_	_	I-Premise
279	at	_	_	I-Premise
280	month	_	_	I-Premise
281	3	_	_	I-Premise
282	.	_	_	I-Premise

283	Compared	_	_	B-Premise
284	only	_	_	I-Premise
285	with	_	_	I-Premise
286	patients	_	_	I-Premise
287	with	_	_	I-Premise
288	SD	_	_	I-Premise
289	(	_	_	I-Premise
290	6m	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	responders	_	_	I-Premise
294	showed	_	_	I-Premise
295	no	_	_	I-Premise
296	significant	_	_	I-Premise
297	difference	_	_	I-Premise
298	in	_	_	I-Premise
299	baseline	_	_	I-Premise
300	QL	_	_	I-Premise
301	and	_	_	I-Premise
302	time	_	_	I-Premise
303	to	_	_	I-Premise
304	treatment	_	_	I-Premise
305	failure	_	_	I-Premise
306	(	_	_	I-Premise
307	328.5	_	_	I-Premise
308	v	_	_	I-Premise
309	340	_	_	I-Premise
310	days	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	While	_	_	B-Premise
314	under	_	_	I-Premise
315	treatment	_	_	I-Premise
316	,	_	_	I-Premise
317	responders	_	_	I-Premise
318	reported	_	_	I-Premise
319	significantly	_	_	I-Premise
320	better	_	_	I-Premise
321	physical	_	_	I-Premise
322	well-being	_	_	I-Premise
323	(	_	_	I-Premise
324	months	_	_	I-Premise
325	3	_	_	I-Premise
326	to	_	_	I-Premise
327	11	_	_	I-Premise
328	)	_	_	I-Premise
329	,	_	_	I-Premise
330	mood	_	_	I-Premise
331	(	_	_	I-Premise
332	months	_	_	I-Premise
333	5	_	_	I-Premise
334	to	_	_	I-Premise
335	11	_	_	I-Premise
336	)	_	_	I-Premise
337	,	_	_	I-Premise
338	coping	_	_	I-Premise
339	(	_	_	I-Premise
340	months	_	_	I-Premise
341	5	_	_	I-Premise
342	to	_	_	I-Premise
343	9	_	_	I-Premise
344	)	_	_	I-Premise
345	,	_	_	I-Premise
346	and	_	_	I-Premise
347	appetite	_	_	I-Premise
348	(	_	_	I-Premise
349	months	_	_	I-Premise
350	7	_	_	I-Premise
351	to	_	_	I-Premise
352	11	_	_	I-Premise
353	)	_	_	I-Premise
354	and	_	_	I-Premise
355	less	_	_	I-Premise
356	dizziness	_	_	I-Premise
357	(	_	_	I-Premise
358	month	_	_	I-Premise
359	9	_	_	I-Premise
360	)	_	_	I-Premise
361	than	_	_	I-Premise
362	patients	_	_	I-Premise
363	with	_	_	I-Premise
364	SD	_	_	I-Premise
365	(	_	_	I-Premise
366	6m	_	_	I-Premise
367	)	_	_	I-Premise
368	.	_	_	I-Premise

369	The	_	_	B-Premise
370	changes	_	_	I-Premise
371	between	_	_	I-Premise
372	baseline	_	_	I-Premise
373	and	_	_	I-Premise
374	months	_	_	I-Premise
375	5	_	_	I-Premise
376	and	_	_	I-Premise
377	7	_	_	I-Premise
378	,	_	_	I-Premise
379	respectively	_	_	I-Premise
380	,	_	_	I-Premise
381	indicated	_	_	I-Premise
382	improvement	_	_	I-Premise
383	in	_	_	I-Premise
384	responders	_	_	I-Premise
385	but	_	_	I-Premise
386	heterogeneous	_	_	I-Premise
387	patterns	_	_	I-Premise
388	in	_	_	I-Premise
389	patients	_	_	I-Premise
390	with	_	_	I-Premise
391	SD	_	_	I-Premise
392	(	_	_	I-Premise
393	6m	_	_	I-Premise
394	)	_	_	I-Premise
395	.	_	_	I-Premise

396	Although	_	_	B-Premise
397	the	_	_	I-Premise
398	CR/PR	_	_	I-Premise
399	and	_	_	I-Premise
400	SD	_	_	I-Premise
401	(	_	_	I-Premise
402	6m	_	_	I-Premise
403	)	_	_	I-Premise
404	groups	_	_	I-Premise
405	had	_	_	I-Premise
406	similar	_	_	I-Premise
407	times	_	_	I-Premise
408	to	_	_	I-Premise
409	treatment	_	_	I-Premise
410	failure	_	_	I-Premise
411	,	_	_	I-Premise
412	patients	_	_	B-Claim
413	with	_	_	I-Claim
414	CR/PR	_	_	I-Claim
415	reported	_	_	I-Claim
416	better	_	_	I-Claim
417	QL	_	_	I-Claim
418	,	_	_	I-Claim
419	suggesting	_	_	I-Claim
420	more	_	_	I-Claim
421	beneficial	_	_	I-Claim
422	response	_	_	I-Claim
423	to	_	_	I-Claim
424	second-line	_	_	I-Claim
425	endocrine	_	_	I-Claim
426	treatment	_	_	I-Claim
427	.	_	_	I-Claim

428	Patients	_	_	O
429	'	_	_	O
430	subjective	_	_	O
431	perspective	_	_	O
432	should	_	_	O
433	be	_	_	O
434	taken	_	_	O
435	into	_	_	O
436	account	_	_	O
437	in	_	_	O
438	this	_	_	O
439	mainly	_	_	O
440	palliative	_	_	O
441	setting	_	_	O
442	.	_	_	O

443	Future	_	_	O
444	trials	_	_	O
445	should	_	_	O
446	be	_	_	O
447	designed	_	_	O
448	so	_	_	O
449	that	_	_	O
450	the	_	_	O
451	CR/PR	_	_	O
452	and	_	_	O
453	SD	_	_	O
454	(	_	_	O
455	6m	_	_	O
456	)	_	_	O
457	groups	_	_	O
458	are	_	_	O
459	investigated	_	_	O
460	separately	_	_	O
461	.	_	_	O


0	To	_	_	O
1	describe	_	_	O
2	the	_	_	O
3	Food	_	_	O
4	and	_	_	O
5	Drug	_	_	O
6	Administration	_	_	O
7	(	_	_	O
8	FDA	_	_	O
9	)	_	_	O
10	review	_	_	O
11	and	_	_	O
12	approval	_	_	O
13	of	_	_	O
14	erlotinib	_	_	O
15	(	_	_	O
16	Tarceva	_	_	O
17	,	_	_	O
18	OSI	_	_	O
19	Pharmaceuticals	_	_	O
20	,	_	_	O
21	Melville	_	_	O
22	,	_	_	O
23	NY	_	_	O
24	)	_	_	O
25	for	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	locally	_	_	O
31	advanced	_	_	O
32	or	_	_	O
33	metastatic	_	_	O
34	non-small	_	_	O
35	cell	_	_	O
36	lung	_	_	O
37	cancer	_	_	O
38	(	_	_	O
39	NSCLC	_	_	O
40	)	_	_	O
41	after	_	_	O
42	failure	_	_	O
43	of	_	_	O
44	at	_	_	O
45	least	_	_	O
46	one	_	_	O
47	prior	_	_	O
48	chemotherapy	_	_	O
49	regimen	_	_	O
50	.	_	_	O

51	The	_	_	O
52	FDA	_	_	O
53	reviewed	_	_	O
54	raw	_	_	O
55	data	_	_	O
56	in	_	_	O
57	electronic	_	_	O
58	format	_	_	O
59	from	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	clinical	_	_	O
64	trial	_	_	O
65	comparing	_	_	O
66	erlotinib	_	_	O
67	with	_	_	O
68	placebo	_	_	O
69	in	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	locally	_	_	O
73	advanced	_	_	O
74	or	_	_	O
75	metastatic	_	_	O
76	NSCLC	_	_	O
77	after	_	_	O
78	failure	_	_	O
79	of	_	_	O
80	at	_	_	O
81	least	_	_	O
82	one	_	_	O
83	prior	_	_	O
84	chemotherapy	_	_	O
85	regimen	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	in	_	_	O
91	a	_	_	O
92	2:1	_	_	O
93	ratio	_	_	O
94	(	_	_	O
95	erlotinib	_	_	O
96	,	_	_	O
97	n	_	_	O
98	=	_	_	O
99	488	_	_	O
100	and	_	_	O
101	placebo	_	_	O
102	,	_	_	O
103	n	_	_	O
104	=	_	_	O
105	243	_	_	O
106	)	_	_	O
107	.	_	_	O

108	Erlotinib	_	_	B-Claim
109	was	_	_	I-Claim
110	superior	_	_	I-Claim
111	to	_	_	I-Claim
112	placebo	_	_	I-Claim
113	for	_	_	I-Claim
114	survival	_	_	I-Claim
115	,	_	_	I-Claim
116	progression-free	_	_	I-Claim
117	survival	_	_	I-Claim
118	,	_	_	I-Claim
119	and	_	_	I-Claim
120	tumor	_	_	I-Claim
121	response	_	_	I-Claim
122	rate	_	_	I-Claim
123	.	_	_	I-Claim

124	Exploratory	_	_	B-Claim
125	analyses	_	_	I-Claim
126	indicate	_	_	I-Claim
127	that	_	_	I-Claim
128	epidermal	_	_	I-Claim
129	growth	_	_	I-Claim
130	factor	_	_	I-Claim
131	receptor	_	_	I-Claim
132	status	_	_	I-Claim
133	may	_	_	I-Claim
134	be	_	_	I-Claim
135	an	_	_	I-Claim
136	important	_	_	I-Claim
137	predictor	_	_	I-Claim
138	of	_	_	I-Claim
139	the	_	_	I-Claim
140	erlotinib	_	_	I-Claim
141	survival	_	_	I-Claim
142	effect	_	_	I-Claim
143	.	_	_	I-Claim

144	Rash	_	_	B-Premise
145	(	_	_	I-Premise
146	75	_	_	I-Premise
147	%	_	_	I-Premise
148	versus	_	_	I-Premise
149	17	_	_	I-Premise
150	%	_	_	I-Premise
151	)	_	_	I-Premise
152	and	_	_	I-Premise
153	diarrhea	_	_	I-Premise
154	(	_	_	I-Premise
155	54	_	_	I-Premise
156	%	_	_	I-Premise
157	versus	_	_	I-Premise
158	18	_	_	I-Premise
159	%	_	_	I-Premise
160	)	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	erlotnib	_	_	I-Premise
164	and	_	_	I-Premise
165	placebo	_	_	I-Premise
166	group	_	_	I-Premise
167	respectively	_	_	I-Premise
168	were	_	_	I-Premise
169	the	_	_	I-Premise
170	most	_	_	I-Premise
171	common	_	_	I-Premise
172	adverse	_	_	I-Premise
173	events	_	_	I-Premise
174	.	_	_	I-Premise

175	Severe	_	_	B-Premise
176	rash	_	_	I-Premise
177	occurred	_	_	I-Premise
178	in	_	_	I-Premise
179	9	_	_	I-Premise
180	%	_	_	I-Premise
181	and	_	_	I-Premise
182	severe	_	_	I-Premise
183	diarrhea	_	_	I-Premise
184	in	_	_	I-Premise
185	6	_	_	I-Premise
186	%	_	_	I-Premise
187	of	_	_	I-Premise
188	erlotinib-treated	_	_	I-Premise
189	patients	_	_	I-Premise
190	and	_	_	I-Premise
191	each	_	_	I-Premise
192	resulted	_	_	I-Premise
193	in	_	_	I-Premise
194	study	_	_	I-Premise
195	discontinuation	_	_	I-Premise
196	in	_	_	I-Premise
197	1	_	_	I-Premise
198	%	_	_	I-Premise
199	of	_	_	I-Premise
200	patients	_	_	I-Premise
201	.	_	_	I-Premise

202	Dose	_	_	B-Premise
203	reductions	_	_	I-Premise
204	were	_	_	I-Premise
205	required	_	_	I-Premise
206	for	_	_	I-Premise
207	10	_	_	I-Premise
208	%	_	_	I-Premise
209	of	_	_	I-Premise
210	patients	_	_	I-Premise
211	with	_	_	I-Premise
212	rash	_	_	I-Premise
213	and	_	_	I-Premise
214	4	_	_	I-Premise
215	%	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	with	_	_	I-Premise
219	diarrhea	_	_	I-Premise
220	.	_	_	I-Premise

221	On	_	_	O
222	November	_	_	O
223	18	_	_	O
224	,	_	_	O
225	2004	_	_	O
226	,	_	_	O
227	the	_	_	O
228	FDA	_	_	O
229	granted	_	_	O
230	erlotinib	_	_	O
231	regular	_	_	O
232	approval	_	_	O
233	for	_	_	O
234	treatment	_	_	O
235	of	_	_	O
236	patients	_	_	O
237	with	_	_	O
238	locally	_	_	O
239	advanced	_	_	O
240	or	_	_	O
241	metastatic	_	_	O
242	NSCLC	_	_	O
243	after	_	_	O
244	failure	_	_	O
245	of	_	_	O
246	at	_	_	O
247	least	_	_	O
248	one	_	_	O
249	prior	_	_	O
250	chemotherapy	_	_	O
251	regimen	_	_	O
252	.	_	_	O

253	The	_	_	O
254	applicant	_	_	O
255	has	_	_	O
256	committed	_	_	O
257	to	_	_	O
258	conduct	_	_	O
259	post-marketing	_	_	O
260	clinical	_	_	O
261	trials	_	_	O
262	to	_	_	O
263	assess	_	_	O
264	further	_	_	O
265	the	_	_	O
266	effect	_	_	O
267	of	_	_	O
268	epidermal	_	_	O
269	growth	_	_	O
270	factor	_	_	O
271	receptor	_	_	O
272	expression	_	_	O
273	,	_	_	O
274	measured	_	_	O
275	with	_	_	O
276	immunohistochemical	_	_	O
277	staining	_	_	O
278	,	_	_	O
279	on	_	_	O
280	erlotinib	_	_	O
281	treatment	_	_	O
282	effect	_	_	O
283	.	_	_	O


0	Gastrojejunostomy	_	_	O
1	(	_	_	O
2	GJJ	_	_	O
3	)	_	_	O
4	and	_	_	O
5	stent	_	_	O
6	placement	_	_	O
7	are	_	_	O
8	the	_	_	O
9	most	_	_	O
10	commonly	_	_	O
11	used	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	for	_	_	O
15	malignant	_	_	O
16	gastric	_	_	O
17	outlet	_	_	O
18	obstruction	_	_	O
19	(	_	_	O
20	GOO	_	_	O
21	)	_	_	O
22	.	_	_	O

23	In	_	_	O
24	a	_	_	O
25	recent	_	_	O
26	randomized	_	_	O
27	trial	_	_	O
28	,	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	was	_	_	O
32	preferred	_	_	O
33	in	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	a	_	_	O
37	relatively	_	_	O
38	short	_	_	O
39	survival	_	_	O
40	and	_	_	O
41	GJJ	_	_	O
42	in	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	a	_	_	O
46	longer	_	_	O
47	survival	_	_	O
48	.	_	_	O

49	As	_	_	O
50	health	_	_	O
51	economic	_	_	O
52	aspects	_	_	O
53	have	_	_	O
54	only	_	_	O
55	been	_	_	O
56	studied	_	_	O
57	in	_	_	O
58	general	_	_	O
59	terms	_	_	O
60	,	_	_	O
61	we	_	_	O
62	estimated	_	_	O
63	the	_	_	O
64	cost	_	_	O
65	of	_	_	O
66	GJJ	_	_	O
67	and	_	_	O
68	that	_	_	O
69	of	_	_	O
70	stent	_	_	O
71	placement	_	_	O
72	in	_	_	O
73	such	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	In	_	_	O
77	the	_	_	O
78	SUSTENT	_	_	O
79	study	_	_	O
80	,	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	GJJ	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	18	_	_	O
90	)	_	_	O
91	or	_	_	O
92	stent	_	_	O
93	placement	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	21	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Pancreatic	_	_	O
101	cancer	_	_	O
102	was	_	_	O
103	the	_	_	O
104	most	_	_	O
105	common	_	_	O
106	cause	_	_	O
107	of	_	_	O
108	GOO	_	_	O
109	.	_	_	O

110	We	_	_	O
111	compared	_	_	O
112	initial	_	_	O
113	costs	_	_	O
114	and	_	_	O
115	costs	_	_	O
116	during	_	_	O
117	follow-up	_	_	O
118	.	_	_	O

119	For	_	_	O
120	cost-effectiveness	_	_	O
121	,	_	_	O
122	the	_	_	O
123	incremental	_	_	O
124	cost-effectiveness	_	_	O
125	ratio	_	_	O
126	was	_	_	O
127	calculated	_	_	O
128	.	_	_	O

129	Food	_	_	B-Premise
130	intake	_	_	I-Premise
131	improved	_	_	I-Premise
132	more	_	_	I-Premise
133	rapidly	_	_	I-Premise
134	after	_	_	I-Premise
135	stent	_	_	I-Premise
136	placement	_	_	I-Premise
137	than	_	_	I-Premise
138	after	_	_	I-Premise
139	GJJ	_	_	I-Premise
140	,	_	_	I-Premise
141	but	_	_	B-Premise
142	long-term	_	_	I-Premise
143	relief	_	_	I-Premise
144	of	_	_	I-Premise
145	obstructive	_	_	I-Premise
146	symptoms	_	_	I-Premise
147	was	_	_	I-Premise
148	better	_	_	I-Premise
149	after	_	_	I-Premise
150	GJJ	_	_	I-Premise
151	.	_	_	I-Premise

152	More	_	_	B-Premise
153	major	_	_	I-Premise
154	complications	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.02	_	_	I-Premise
159	)	_	_	I-Premise
160	occurred	_	_	I-Premise
161	and	_	_	I-Premise
162	more	_	_	I-Premise
163	reinterventions	_	_	I-Premise
164	were	_	_	I-Premise
165	performed	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	0.01	_	_	I-Premise
170	)	_	_	I-Premise
171	after	_	_	I-Premise
172	stent	_	_	I-Premise
173	placement	_	_	I-Premise
174	than	_	_	I-Premise
175	after	_	_	I-Premise
176	GJJ	_	_	I-Premise
177	.	_	_	I-Premise

178	Initial	_	_	B-Premise
179	costs	_	_	I-Premise
180	were	_	_	I-Premise
181	higher	_	_	I-Premise
182	for	_	_	I-Premise
183	GJJ	_	_	I-Premise
184	compared	_	_	I-Premise
185	to	_	_	I-Premise
186	stent	_	_	I-Premise
187	placement	_	_	I-Premise
188	(	_	_	I-Premise
189	euro8315	_	_	I-Premise
190	vs.	_	_	I-Premise
191	euro4820	_	_	I-Premise
192	,	_	_	I-Premise
193	P	_	_	I-Premise
194	<	_	_	I-Premise
195	0.001	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	We	_	_	B-Premise
199	found	_	_	I-Premise
200	no	_	_	I-Premise
201	difference	_	_	I-Premise
202	in	_	_	I-Premise
203	follow-up	_	_	I-Premise
204	costs	_	_	I-Premise
205	.	_	_	I-Premise

206	Total	_	_	B-Premise
207	costs	_	_	I-Premise
208	per	_	_	I-Premise
209	patient	_	_	I-Premise
210	were	_	_	I-Premise
211	higher	_	_	I-Premise
212	for	_	_	I-Premise
213	GJJ	_	_	I-Premise
214	compared	_	_	I-Premise
215	to	_	_	I-Premise
216	stent	_	_	I-Premise
217	placement	_	_	I-Premise
218	(	_	_	I-Premise
219	euro12433	_	_	I-Premise
220	vs.	_	_	I-Premise
221	euro8819	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0.049	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	incremental	_	_	I-Premise
230	cost-effectiveness	_	_	I-Premise
231	ratio	_	_	I-Premise
232	of	_	_	I-Premise
233	GJJ	_	_	I-Premise
234	compared	_	_	I-Premise
235	to	_	_	I-Premise
236	stent	_	_	I-Premise
237	placement	_	_	I-Premise
238	was	_	_	I-Premise
239	euro164	_	_	I-Premise
240	per	_	_	I-Premise
241	extra	_	_	I-Premise
242	day	_	_	I-Premise
243	with	_	_	I-Premise
244	a	_	_	I-Premise
245	gastric	_	_	I-Premise
246	outlet	_	_	I-Premise
247	obstruction	_	_	I-Premise
248	scoring	_	_	I-Premise
249	system	_	_	I-Premise
250	(	_	_	I-Premise
251	GOOSS	_	_	I-Premise
252	)	_	_	I-Premise
253	>	_	_	I-Premise
254	or=2	_	_	I-Premise
255	adjusted	_	_	I-Premise
256	for	_	_	I-Premise
257	survival	_	_	I-Premise
258	.	_	_	I-Premise

259	Medical	_	_	B-Claim
260	effects	_	_	I-Claim
261	were	_	_	I-Claim
262	better	_	_	I-Claim
263	after	_	_	I-Claim
264	GJJ	_	_	I-Claim
265	,	_	_	O
266	although	_	_	B-Claim
267	GJJ	_	_	I-Claim
268	had	_	_	I-Claim
269	higher	_	_	I-Claim
270	total	_	_	I-Claim
271	costs	_	_	I-Claim
272	.	_	_	I-Claim

273	Since	_	_	B-Claim
274	the	_	_	I-Claim
275	cost	_	_	I-Claim
276	difference	_	_	I-Claim
277	between	_	_	I-Claim
278	the	_	_	I-Claim
279	two	_	_	I-Claim
280	treatments	_	_	I-Claim
281	was	_	_	I-Claim
282	only	_	_	I-Claim
283	small	_	_	I-Claim
284	,	_	_	I-Claim
285	cost	_	_	B-Claim
286	should	_	_	I-Claim
287	not	_	_	I-Claim
288	play	_	_	I-Claim
289	a	_	_	I-Claim
290	predominant	_	_	I-Claim
291	role	_	_	I-Claim
292	when	_	_	I-Claim
293	deciding	_	_	I-Claim
294	on	_	_	I-Claim
295	the	_	_	I-Claim
296	type	_	_	I-Claim
297	of	_	_	I-Claim
298	treatment	_	_	I-Claim
299	assigned	_	_	I-Claim
300	to	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	malignant	_	_	I-Claim
304	GOO	_	_	I-Claim
305	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	prospective	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	multicentre	_	_	O
8	clinical	_	_	O
9	trial	_	_	O
10	comparing	_	_	O
11	the	_	_	O
12	effects	_	_	O
13	and	_	_	O
14	costs	_	_	O
15	of	_	_	O
16	GM-CSF	_	_	O
17	as	_	_	O
18	an	_	_	O
19	adjunct	_	_	O
20	to	_	_	O
21	intensive	_	_	O
22	chemotherapy	_	_	O
23	in	_	_	O
24	elderly	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	acute	_	_	O
28	myeloid	_	_	O
29	leukaemia	_	_	O
30	(	_	_	O
31	AML	_	_	O
32	)	_	_	O
33	.	_	_	O

34	The	_	_	O
35	patients	_	_	O
36	were	_	_	O
37	randomized	_	_	O
38	to	_	_	O
39	either	_	_	O
40	daunomycin-cytosine	_	_	O
41	arabinoside	_	_	O
42	(	_	_	O
43	control	_	_	O
44	arm	_	_	O
45	:	_	_	O
46	n	_	_	O
47	=	_	_	O
48	161	_	_	O
49	)	_	_	O
50	or	_	_	O
51	daunomycin-cytosine	_	_	O
52	arabinoside	_	_	O
53	with	_	_	O
54	GM-CSF	_	_	O
55	(	_	_	O
56	GM-CSF	_	_	O
57	arm	_	_	O
58	:	_	_	O
59	n	_	_	O
60	=	_	_	O
61	157	_	_	O
62	)	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	end-point	_	_	O
67	was	_	_	O
68	the	_	_	O
69	effect	_	_	O
70	of	_	_	O
71	GM-CSF	_	_	O
72	on	_	_	O
73	the	_	_	O
74	percentage	_	_	O
75	of	_	_	O
76	complete	_	_	O
77	remissions	_	_	O
78	(	_	_	O
79	CR	_	_	O
80	)	_	_	O
81	.	_	_	O

82	Survival	_	_	O
83	duration	_	_	O
84	,	_	_	O
85	disease-free	_	_	O
86	survival	_	_	O
87	,	_	_	O
88	quality	_	_	O
89	of	_	_	O
90	life	_	_	O
91	and	_	_	O
92	costs	_	_	O
93	were	_	_	O
94	evaluated	_	_	O
95	separately	_	_	O
96	.	_	_	O

97	CR	_	_	B-Premise
98	after	_	_	I-Premise
99	remission	_	_	I-Premise
100	induction	_	_	I-Premise
101	treatment	_	_	I-Premise
102	was	_	_	I-Premise
103	achieved	_	_	I-Premise
104	in	_	_	I-Premise
105	55	_	_	I-Premise
106	%	_	_	I-Premise
107	of	_	_	I-Premise
108	the	_	_	I-Premise
109	patients	_	_	I-Premise
110	in	_	_	I-Premise
111	the	_	_	I-Premise
112	control	_	_	I-Premise
113	group	_	_	I-Premise
114	and	_	_	I-Premise
115	in	_	_	I-Premise
116	56	_	_	I-Premise
117	%	_	_	I-Premise
118	of	_	_	I-Premise
119	the	_	_	I-Premise
120	patients	_	_	I-Premise
121	in	_	_	I-Premise
122	the	_	_	I-Premise
123	GM-CSF	_	_	I-Premise
124	group	_	_	I-Premise
125	(	_	_	I-Premise
126	P	_	_	I-Premise
127	=	_	_	I-Premise
128	NS	_	_	I-Premise
129	)	_	_	I-Premise
130	.	_	_	I-Premise

131	The	_	_	B-Premise
132	duration	_	_	I-Premise
133	of	_	_	I-Premise
134	survival	_	_	I-Premise
135	and	_	_	I-Premise
136	disease-free	_	_	I-Premise
137	survival	_	_	I-Premise
138	at	_	_	I-Premise
139	2	_	_	I-Premise
140	years	_	_	I-Premise
141	after	_	_	I-Premise
142	randomization	_	_	I-Premise
143	were	_	_	I-Premise
144	estimated	_	_	I-Premise
145	at	_	_	I-Premise
146	22	_	_	I-Premise
147	%	_	_	I-Premise
148	and	_	_	I-Premise
149	19	_	_	I-Premise
150	%	_	_	I-Premise
151	for	_	_	I-Premise
152	the	_	_	I-Premise
153	control	_	_	I-Premise
154	group	_	_	I-Premise
155	and	_	_	I-Premise
156	22	_	_	I-Premise
157	%	_	_	I-Premise
158	and	_	_	I-Premise
159	14	_	_	I-Premise
160	%	_	_	I-Premise
161	for	_	_	I-Premise
162	the	_	_	I-Premise
163	GM-CSF	_	_	I-Premise
164	group	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	=	_	_	I-Premise
168	NS	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Considering	_	_	B-Premise
172	the	_	_	I-Premise
173	short-term	_	_	I-Premise
174	quality	_	_	I-Premise
175	of	_	_	I-Premise
176	life	_	_	I-Premise
177	,	_	_	I-Premise
178	the	_	_	I-Premise
179	administration	_	_	I-Premise
180	of	_	_	I-Premise
181	GM-CSF	_	_	I-Premise
182	resulted	_	_	I-Premise
183	in	_	_	I-Premise
184	more	_	_	I-Premise
185	problems	_	_	I-Premise
186	with	_	_	I-Premise
187	regard	_	_	I-Premise
188	to	_	_	I-Premise
189	depressed	_	_	I-Premise
190	mood	_	_	I-Premise
191	,	_	_	I-Premise
192	diarrhoea	_	_	I-Premise
193	and	_	_	I-Premise
194	rash/eczema	_	_	I-Premise
195	.	_	_	I-Premise

196	With	_	_	B-Premise
197	regard	_	_	I-Premise
198	to	_	_	I-Premise
199	the	_	_	I-Premise
200	long-term	_	_	I-Premise
201	quality	_	_	I-Premise
202	of	_	_	I-Premise
203	life	_	_	I-Premise
204	there	_	_	I-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	significant	_	_	I-Premise
208	differences	_	_	I-Premise
209	between	_	_	I-Premise
210	the	_	_	I-Premise
211	two	_	_	I-Premise
212	groups	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	average	_	_	I-Premise
216	costs	_	_	I-Premise
217	of	_	_	I-Premise
218	the	_	_	I-Premise
219	primary	_	_	I-Premise
220	treatment	_	_	I-Premise
221	were	_	_	I-Premise
222	higher	_	_	I-Premise
223	in	_	_	I-Premise
224	GM-CSF-treated	_	_	I-Premise
225	patients	_	_	I-Premise
226	than	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	control	_	_	I-Premise
230	group	_	_	I-Premise
231	,	_	_	I-Premise
232	i.e	_	_	I-Premise
233	.	_	_	I-Premise

234	US	_	_	I-Premise
235	$	_	_	I-Premise
236	40782	_	_	I-Premise
237	and	_	_	I-Premise
238	US	_	_	I-Premise
239	$	_	_	I-Premise
240	34465	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.01	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	costs	_	_	I-Premise
251	during	_	_	I-Premise
252	the	_	_	I-Premise
253	follow-up	_	_	I-Premise
254	period	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	differ	_	_	I-Premise
258	between	_	_	I-Premise
259	the	_	_	I-Premise
260	two	_	_	I-Premise
261	groups	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Claim
264	results	_	_	I-Claim
265	of	_	_	I-Claim
266	this	_	_	I-Claim
267	randomized	_	_	I-Claim
268	clinical	_	_	I-Claim
269	trial	_	_	I-Claim
270	indicate	_	_	I-Claim
271	that	_	_	I-Claim
272	daunomycin-cytosine	_	_	I-Claim
273	arabinoside	_	_	I-Claim
274	plus	_	_	I-Claim
275	GM-CSF	_	_	I-Claim
276	is	_	_	I-Claim
277	not	_	_	I-Claim
278	a	_	_	I-Claim
279	cost-effective	_	_	I-Claim
280	treatment	_	_	I-Claim
281	strategy	_	_	I-Claim
282	when	_	_	I-Claim
283	compared	_	_	I-Claim
284	with	_	_	I-Claim
285	daunomycin-cytosine	_	_	I-Claim
286	arabinoside	_	_	I-Claim
287	alone	_	_	I-Claim
288	.	_	_	I-Claim


0	Androgen	_	_	O
1	treatment	_	_	O
2	for	_	_	O
3	prostate	_	_	O
4	cancer	_	_	O
5	can	_	_	O
6	adversely	_	_	O
7	affect	_	_	O
8	functional	_	_	O
9	domains	_	_	O
10	of	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	.	_	_	O

15	We	_	_	O
16	aimed	_	_	O
17	to	_	_	O
18	assess	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	in	_	_	O
23	men	_	_	O
24	with	_	_	O
25	locally	_	_	O
26	advanced	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	in	_	_	O
30	an	_	_	O
31	open-label	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	randomised	_	_	O
35	comparison	_	_	O
36	between	_	_	O
37	lifelong	_	_	O
38	endocrine	_	_	O
39	treatment	_	_	O
40	with	_	_	O
41	and	_	_	O
42	without	_	_	O
43	radiotherapy	_	_	O
44	.	_	_	O

45	We	_	_	O
46	obtained	_	_	O
47	quality-of-life	_	_	O
48	information	_	_	O
49	from	_	_	O
50	872	_	_	O
51	(	_	_	O
52	99	_	_	O
53	%	_	_	O
54	)	_	_	O
55	of	_	_	O
56	875	_	_	O
57	eligible	_	_	O
58	men	_	_	O
59	with	_	_	O
60	locally	_	_	O
61	advanced	_	_	O
62	prostate	_	_	O
63	cancer	_	_	O
64	(	_	_	O
65	T3	_	_	O
66	;	_	_	O
67	78	_	_	O
68	%	_	_	O
69	)	_	_	O
70	who	_	_	O
71	were	_	_	O
72	randomly	_	_	O
73	assigned	_	_	O
74	,	_	_	O
75	between	_	_	O
76	1996	_	_	O
77	and	_	_	O
78	2002	_	_	O
79	,	_	_	O
80	to	_	_	O
81	3	_	_	O
82	months	_	_	O
83	of	_	_	O
84	total	_	_	O
85	androgen	_	_	O
86	blockade	_	_	O
87	followed	_	_	O
88	by	_	_	O
89	continuous	_	_	O
90	endocrine	_	_	O
91	treatment	_	_	O
92	(	_	_	O
93	439	_	_	O
94	patients	_	_	O
95	)	_	_	O
96	or	_	_	O
97	the	_	_	O
98	same	_	_	O
99	hormonal	_	_	O
100	treatment	_	_	O
101	with	_	_	O
102	radiotherapy	_	_	O
103	3	_	_	O
104	months	_	_	O
105	after	_	_	O
106	randomisation	_	_	O
107	(	_	_	O
108	436	_	_	O
109	patients	_	_	O
110	)	_	_	O
111	.	_	_	O

112	Prospective	_	_	O
113	outcomes	_	_	O
114	included	_	_	O
115	patient-reported	_	_	O
116	symptoms	_	_	O
117	and	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	assessed	_	_	O
122	with	_	_	O
123	questionnaires	_	_	O
124	from	_	_	O
125	baseline	_	_	O
126	to	_	_	O
127	4	_	_	O
128	years	_	_	O
129	after	_	_	O
130	randomisation	_	_	O
131	.	_	_	O

132	Analysis	_	_	O
133	was	_	_	O
134	by	_	_	O
135	intention	_	_	O
136	to	_	_	O
137	treat	_	_	O
138	.	_	_	O

139	This	_	_	O
140	study	_	_	O
141	is	_	_	O
142	registered	_	_	O
143	as	_	_	O
144	an	_	_	O
145	international	_	_	O
146	standard	_	_	O
147	randomised	_	_	O
148	controlled	_	_	O
149	trial	_	_	O
150	,	_	_	O
151	number	_	_	O
152	ISRCTN01534787	_	_	O
153	.	_	_	O

154	438	_	_	O
155	of	_	_	O
156	439	_	_	O
157	men	_	_	O
158	assigned	_	_	O
159	endocrine	_	_	O
160	treatment	_	_	O
161	and	_	_	O
162	434	_	_	O
163	of	_	_	O
164	436	_	_	O
165	assigned	_	_	O
166	endocrine	_	_	O
167	plus	_	_	O
168	radiotherapy	_	_	O
169	completed	_	_	O
170	at	_	_	O
171	least	_	_	O
172	one	_	_	O
173	questionnaire	_	_	O
174	.	_	_	O

175	Missing	_	_	O
176	data	_	_	O
177	at	_	_	O
178	baseline	_	_	O
179	and	_	_	O
180	during	_	_	O
181	follow-up	_	_	O
182	was	_	_	O
183	equally	_	_	O
184	distributed	_	_	O
185	between	_	_	O
186	groups	_	_	O
187	.	_	_	O

188	At	_	_	B-Premise
189	4	_	_	I-Premise
190	years	_	_	I-Premise
191	,	_	_	I-Premise
192	64	_	_	I-Premise
193	(	_	_	I-Premise
194	18	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	of	_	_	I-Premise
198	353	_	_	I-Premise
199	patients	_	_	I-Premise
200	on	_	_	I-Premise
201	combined	_	_	I-Premise
202	therapy	_	_	I-Premise
203	and	_	_	I-Premise
204	39	_	_	I-Premise
205	(	_	_	I-Premise
206	12	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	of	_	_	I-Premise
210	337	_	_	I-Premise
211	on	_	_	I-Premise
212	endocrine-alone	_	_	I-Premise
213	therapy	_	_	I-Premise
214	had	_	_	I-Premise
215	moderate	_	_	I-Premise
216	to	_	_	I-Premise
217	severe	_	_	I-Premise
218	urinary	_	_	I-Premise
219	bother	_	_	I-Premise
220	(	_	_	I-Premise
221	p=0.005	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	and	_	_	I-Premise
225	16	_	_	I-Premise
226	(	_	_	I-Premise
227	4	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	of	_	_	I-Premise
231	355	_	_	I-Premise
232	on	_	_	I-Premise
233	combined	_	_	I-Premise
234	therapy	_	_	I-Premise
235	and	_	_	I-Premise
236	five	_	_	I-Premise
237	(	_	_	I-Premise
238	2	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	of	_	_	I-Premise
242	338	_	_	I-Premise
243	on	_	_	I-Premise
244	endocrine	_	_	I-Premise
245	treatment	_	_	I-Premise
246	alone	_	_	I-Premise
247	had	_	_	I-Premise
248	pain	_	_	I-Premise
249	while	_	_	I-Premise
250	urinating	_	_	I-Premise
251	(	_	_	I-Premise
252	p=0.024	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	37	_	_	B-Premise
256	(	_	_	I-Premise
257	11	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	of	_	_	I-Premise
261	350	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	combined	_	_	I-Premise
265	group	_	_	I-Premise
266	and	_	_	I-Premise
267	23	_	_	I-Premise
268	(	_	_	I-Premise
269	7	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	of	_	_	I-Premise
273	35	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	endocrine-only	_	_	I-Premise
277	group	_	_	I-Premise
278	had	_	_	I-Premise
279	overall	_	_	I-Premise
280	bother	_	_	I-Premise
281	from	_	_	I-Premise
282	all	_	_	I-Premise
283	bowel	_	_	I-Premise
284	symptoms	_	_	I-Premise
285	(	_	_	I-Premise
286	p=0.022	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	281	_	_	B-Premise
290	(	_	_	I-Premise
291	85	_	_	I-Premise
292	%	_	_	I-Premise
293	)	_	_	I-Premise
294	of	_	_	I-Premise
295	332	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	combined-treatment	_	_	I-Premise
299	group	_	_	I-Premise
300	and	_	_	I-Premise
301	227	_	_	I-Premise
302	(	_	_	I-Premise
303	72	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	of	_	_	I-Premise
307	313	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	endocrine-only	_	_	I-Premise
311	group	_	_	I-Premise
312	had	_	_	I-Premise
313	erectile	_	_	I-Premise
314	dysfunction	_	_	I-Premise
315	(	_	_	I-Premise
316	p=0.0002	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Quality	_	_	B-Premise
320	of	_	_	I-Premise
321	life	_	_	I-Premise
322	at	_	_	I-Premise
323	4	_	_	I-Premise
324	years	_	_	I-Premise
325	was	_	_	I-Premise
326	similar	_	_	I-Premise
327	,	_	_	I-Premise
328	with	_	_	I-Premise
329	the	_	_	I-Premise
330	exception	_	_	I-Premise
331	of	_	_	I-Premise
332	decreased	_	_	I-Premise
333	social	_	_	I-Premise
334	function	_	_	I-Premise
335	in	_	_	I-Premise
336	patients	_	_	I-Premise
337	receiving	_	_	I-Premise
338	endocrine	_	_	I-Premise
339	treatment	_	_	I-Premise
340	plus	_	_	I-Premise
341	radiotherapy	_	_	I-Premise
342	.	_	_	I-Premise

343	Although	_	_	B-Claim
344	addition	_	_	I-Claim
345	of	_	_	I-Claim
346	radiotherapy	_	_	I-Claim
347	to	_	_	I-Claim
348	endocrine	_	_	I-Claim
349	treatment	_	_	I-Claim
350	significantly	_	_	I-Claim
351	increased	_	_	I-Claim
352	some	_	_	I-Claim
353	treatment-related	_	_	I-Claim
354	symptoms	_	_	I-Claim
355	,	_	_	I-Claim
356	none	_	_	I-Claim
357	were	_	_	I-Claim
358	serious	_	_	I-Claim
359	.	_	_	I-Claim

360	Given	_	_	O
361	the	_	_	O
362	substantial	_	_	O
363	survival	_	_	O
364	benefit	_	_	O
365	of	_	_	O
366	combined	_	_	O
367	treatment	_	_	O
368	,	_	_	O
369	the	_	_	B-Claim
370	increase	_	_	I-Claim
371	of	_	_	I-Claim
372	symptoms	_	_	I-Claim
373	seems	_	_	I-Claim
374	acceptable	_	_	I-Claim
375	and	_	_	I-Claim
376	has	_	_	I-Claim
377	little	_	_	I-Claim
378	extra	_	_	I-Claim
379	effect	_	_	I-Claim
380	on	_	_	I-Claim
381	quality	_	_	I-Claim
382	of	_	_	I-Claim
383	life	_	_	I-Claim
384	after	_	_	I-Claim
385	4	_	_	I-Claim
386	years	_	_	I-Claim
387	compared	_	_	I-Claim
388	with	_	_	I-Claim
389	endocrine	_	_	I-Claim
390	treatment	_	_	I-Claim
391	alone	_	_	I-Claim
392	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	randomised	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	activity	_	_	O
11	and	_	_	O
12	toxicity	_	_	O
13	of	_	_	O
14	a	_	_	O
15	biweekly	_	_	O
16	regimen	_	_	O
17	including	_	_	O
18	6S-leucovorin-modulated	_	_	O
19	5-fluorouracil	_	_	O
20	(	_	_	O
21	LFA-5-FU	_	_	O
22	)	_	_	O
23	,	_	_	O
24	combined	_	_	O
25	with	_	_	O
26	either	_	_	O
27	irinotecan	_	_	O
28	(	_	_	O
29	CPT-11	_	_	O
30	+	_	_	O
31	LFA	_	_	O
32	5-FU	_	_	O
33	)	_	_	O
34	or	_	_	O
35	raltitrexed	_	_	O
36	(	_	_	O
37	Tomudex	_	_	O
38	)	_	_	O
39	(	_	_	O
40	TOM	_	_	O
41	+	_	_	O
42	LFA-5-FU	_	_	O
43	)	_	_	O
44	,	_	_	O
45	in	_	_	O
46	advanced	_	_	O
47	colorectal	_	_	O
48	cancer	_	_	O
49	patients	_	_	O
50	,	_	_	O
51	and	_	_	O
52	to	_	_	O
53	make	_	_	O
54	a	_	_	O
55	preliminary	_	_	O
56	comparison	_	_	O
57	of	_	_	O
58	both	_	_	O
59	these	_	_	O
60	experimental	_	_	O
61	regimens	_	_	O
62	with	_	_	O
63	a	_	_	O
64	biweekly	_	_	O
65	administration	_	_	O
66	of	_	_	O
67	LFA-5-FU	_	_	O
68	modulated	_	_	O
69	by	_	_	O
70	methotrexate	_	_	O
71	(	_	_	O
72	MTX	_	_	O
73	+	_	_	O
74	LFA-5-FU	_	_	O
75	)	_	_	O
76	.	_	_	O

77	One	_	_	O
78	hundred	_	_	O
79	fifty-nine	_	_	O
80	patients	_	_	O
81	with	_	_	O
82	advanced	_	_	O
83	colorectal	_	_	O
84	carcinoma	_	_	O
85	previously	_	_	O
86	untreated	_	_	O
87	for	_	_	O
88	the	_	_	O
89	metastatic	_	_	O
90	disease	_	_	O
91	(	_	_	O
92	34	_	_	O
93	of	_	_	O
94	them	_	_	O
95	previously	_	_	O
96	exposed	_	_	O
97	to	_	_	O
98	adjuvant	_	_	O
99	5-FU	_	_	O
100	)	_	_	O
101	were	_	_	O
102	randomly	_	_	O
103	allocated	_	_	O
104	to	_	_	O
105	receive	_	_	O
106	:	_	_	O
107	CPT-11	_	_	O
108	,	_	_	O
109	200	_	_	O
110	mg/m2	_	_	O
111	i.v	_	_	O
112	.	_	_	O

113	on	_	_	O
114	day	_	_	O
115	1	_	_	O
116	,	_	_	O
117	followed	_	_	O
118	on	_	_	O
119	day	_	_	O
120	2	_	_	O
121	by	_	_	O
122	LFA	_	_	O
123	,	_	_	O
124	250	_	_	O
125	mg/m2	_	_	O
126	i.v	_	_	O
127	.	_	_	O

128	infusion	_	_	O
129	and	_	_	O
130	5-FU	_	_	O
131	,	_	_	O
132	850	_	_	O
133	mg/m2	_	_	O
134	s	_	_	O
135	i.v	_	_	O
136	.	_	_	O

137	bolus	_	_	O
138	(	_	_	O
139	arm	_	_	O
140	A	_	_	O
141	)	_	_	O
142	;	_	_	O
143	TOM	_	_	O
144	,	_	_	O
145	3	_	_	O
146	mg/m2	_	_	O
147	i.v	_	_	O
148	.	_	_	O

149	on	_	_	O
150	day	_	_	O
151	1	_	_	O
152	,	_	_	O
153	followed	_	_	O
154	on	_	_	O
155	day	_	_	O
156	2	_	_	O
157	by	_	_	O
158	LFA	_	_	O
159	,	_	_	O
160	250	_	_	O
161	mg/m2	_	_	O
162	i.v	_	_	O
163	.	_	_	O

164	infusion	_	_	O
165	and	_	_	O
166	5-FU	_	_	O
167	,	_	_	O
168	1050	_	_	O
169	mg/m2	_	_	O
170	i.v	_	_	O
171	.	_	_	O

172	bolus	_	_	O
173	(	_	_	O
174	arm	_	_	O
175	B	_	_	O
176	)	_	_	O
177	;	_	_	O
178	or	_	_	O
179	MTX	_	_	O
180	,	_	_	O
181	750	_	_	O
182	mg/m2	_	_	O
183	i.v	_	_	O
184	.	_	_	O

185	on	_	_	O
186	day	_	_	O
187	1	_	_	O
188	,	_	_	O
189	followed	_	_	O
190	on	_	_	O
191	day	_	_	O
192	2	_	_	O
193	by	_	_	O
194	LFA	_	_	O
195	,	_	_	O
196	250	_	_	O
197	mg/m2	_	_	O
198	i.v	_	_	O
199	.	_	_	O

200	infusion	_	_	O
201	and	_	_	O
202	5-FU	_	_	O
203	,	_	_	O
204	800	_	_	O
205	mg/m2	_	_	O
206	i.v	_	_	O
207	.	_	_	O

208	bolus	_	_	O
209	(	_	_	O
210	arm	_	_	O
211	C	_	_	O
212	)	_	_	O
213	.	_	_	O

214	Courses	_	_	O
215	were	_	_	O
216	repeated	_	_	O
217	every	_	_	O
218	two	_	_	O
219	weeks	_	_	O
220	in	_	_	O
221	all	_	_	O
222	arms	_	_	O
223	of	_	_	O
224	the	_	_	O
225	trial	_	_	O
226	.	_	_	O

227	Response	_	_	O
228	rate	_	_	O
229	(	_	_	O
230	RR	_	_	O
231	)	_	_	O
232	was	_	_	O
233	evaluated	_	_	O
234	after	_	_	O
235	every	_	_	O
236	four	_	_	O
237	courses	_	_	O
238	.	_	_	O

239	The	_	_	O
240	sample	_	_	O
241	size	_	_	O
242	was	_	_	O
243	defined	_	_	O
244	to	_	_	O
245	have	_	_	O
246	an	_	_	O
247	80	_	_	O
248	%	_	_	O
249	power	_	_	O
250	to	_	_	O
251	detect	_	_	O
252	a	_	_	O
253	35	_	_	O
254	%	_	_	O
255	RR	_	_	O
256	for	_	_	O
257	each	_	_	O
258	experimental	_	_	O
259	treatment	_	_	O
260	,	_	_	O
261	and	_	_	O
262	to	_	_	O
263	show	_	_	O
264	a	_	_	O
265	difference	_	_	O
266	of	_	_	O
267	at	_	_	O
268	least	_	_	O
269	4	_	_	O
270	%	_	_	O
271	in	_	_	O
272	RR	_	_	O
273	with	_	_	O
274	the	_	_	O
275	standard	_	_	O
276	treatment	_	_	O
277	if	_	_	O
278	the	_	_	O
279	true	_	_	O
280	difference	_	_	O
281	is	_	_	O
282	15	_	_	O
283	%	_	_	O
284	or	_	_	O
285	more	_	_	O
286	.	_	_	O

287	The	_	_	O
288	RRs	_	_	O
289	were	_	_	O
290	:	_	_	O
291	34	_	_	O
292	%	_	_	O
293	(	_	_	O
294	95	_	_	O
295	%	_	_	O
296	confidence	_	_	O
297	interval	_	_	O
298	(	_	_	O
299	95	_	_	O
300	%	_	_	O
301	,	_	_	O
302	CI	_	_	O
303	)	_	_	O
304	:	_	_	O
305	21	_	_	O
306	%	_	_	O
307	-48	_	_	O
308	%	_	_	O
309	)	_	_	O
310	in	_	_	O
311	arm	_	_	O
312	A	_	_	O
313	,	_	_	O
314	including	_	_	O
315	3	_	_	O
316	complete	_	_	O
317	responses	_	_	O
318	(	_	_	O
319	CRs	_	_	O
320	)	_	_	O
321	and	_	_	O
322	15	_	_	O
323	partial	_	_	O
324	responses	_	_	O
325	(	_	_	O
326	PRs	_	_	O
327	)	_	_	O
328	,	_	_	O
329	24	_	_	O
330	%	_	_	O
331	(	_	_	O
332	95	_	_	O
333	%	_	_	O
334	CI	_	_	O
335	:	_	_	O
336	14	_	_	O
337	%	_	_	O
338	-38	_	_	O
339	%	_	_	O
340	)	_	_	O
341	in	_	_	O
342	arm	_	_	O
343	B	_	_	O
344	,	_	_	O
345	including	_	_	O
346	2	_	_	O
347	CRs	_	_	O
348	and	_	_	O
349	11	_	_	O
350	PRs	_	_	O
351	,	_	_	O
352	and	_	_	O
353	24	_	_	O
354	%	_	_	O
355	(	_	_	O
356	95	_	_	O
357	%	_	_	O
358	CI	_	_	O
359	:	_	_	O
360	14	_	_	O
361	%	_	_	O
362	-38	_	_	O
363	%	_	_	O
364	)	_	_	O
365	,	_	_	O
366	with	_	_	O
367	2	_	_	O
368	CRs	_	_	O
369	and	_	_	O
370	11	_	_	O
371	PRs	_	_	O
372	,	_	_	O
373	in	_	_	O
374	arm	_	_	O
375	C.	_	_	O
376	After	_	_	B-Premise
377	a	_	_	I-Premise
378	median	_	_	I-Premise
379	follow-up	_	_	I-Premise
380	time	_	_	I-Premise
381	of	_	_	I-Premise
382	62	_	_	I-Premise
383	(	_	_	I-Premise
384	range	_	_	I-Premise
385	18-108	_	_	I-Premise
386	)	_	_	I-Premise
387	weeks	_	_	I-Premise
388	,	_	_	I-Premise
389	the	_	_	I-Premise
390	median	_	_	I-Premise
391	time	_	_	I-Premise
392	to	_	_	I-Premise
393	progression	_	_	I-Premise
394	was	_	_	I-Premise
395	38	_	_	I-Premise
396	,	_	_	I-Premise
397	25	_	_	I-Premise
398	,	_	_	I-Premise
399	and	_	_	I-Premise
400	27	_	_	I-Premise
401	weeks	_	_	I-Premise
402	for	_	_	I-Premise
403	arm	_	_	I-Premise
404	A	_	_	I-Premise
405	,	_	_	I-Premise
406	B	_	_	I-Premise
407	,	_	_	I-Premise
408	and	_	_	I-Premise
409	C	_	_	I-Premise
410	,	_	_	I-Premise
411	respectively	_	_	I-Premise
412	.	_	_	I-Premise

413	With	_	_	B-Premise
414	94	_	_	I-Premise
415	patients	_	_	I-Premise
416	still	_	_	I-Premise
417	alive	_	_	I-Premise
418	,	_	_	I-Premise
419	the	_	_	I-Premise
420	one-year	_	_	I-Premise
421	probability	_	_	I-Premise
422	of	_	_	I-Premise
423	survival	_	_	I-Premise
424	was	_	_	I-Premise
425	61	_	_	I-Premise
426	%	_	_	I-Premise
427	,	_	_	I-Premise
428	54	_	_	I-Premise
429	%	_	_	I-Premise
430	,	_	_	I-Premise
431	and	_	_	I-Premise
432	59	_	_	I-Premise
433	%	_	_	I-Premise
434	,	_	_	I-Premise
435	respectively	_	_	I-Premise
436	.	_	_	I-Premise

437	WHO	_	_	B-Premise
438	grade	_	_	I-Premise
439	3	_	_	I-Premise
440	or	_	_	I-Premise
441	4	_	_	I-Premise
442	neutropenia	_	_	I-Premise
443	and	_	_	I-Premise
444	diarrhoea	_	_	I-Premise
445	affected	_	_	I-Premise
446	46	_	_	I-Premise
447	%	_	_	I-Premise
448	and	_	_	I-Premise
449	16	_	_	I-Premise
450	%	_	_	I-Premise
451	,	_	_	I-Premise
452	respectively	_	_	I-Premise
453	,	_	_	I-Premise
454	of	_	_	I-Premise
455	patients	_	_	I-Premise
456	treated	_	_	I-Premise
457	with	_	_	I-Premise
458	CPT-11	_	_	I-Premise
459	+	_	_	I-Premise
460	LFA	_	_	I-Premise
461	5-FU	_	_	I-Premise
462	.	_	_	I-Premise

463	Median	_	_	B-Premise
464	relative	_	_	I-Premise
465	dose	_	_	I-Premise
466	intensity	_	_	I-Premise
467	over	_	_	I-Premise
468	eight	_	_	I-Premise
469	cycles	_	_	I-Premise
470	(	_	_	I-Premise
471	DI8	_	_	I-Premise
472	)	_	_	I-Premise
473	was	_	_	I-Premise
474	78	_	_	I-Premise
475	%	_	_	I-Premise
476	for	_	_	I-Premise
477	CPT-11	_	_	I-Premise
478	and	_	_	I-Premise
479	82	_	_	I-Premise
480	%	_	_	I-Premise
481	for	_	_	I-Premise
482	5-FU	_	_	I-Premise
483	.	_	_	I-Premise

484	Severe	_	_	B-Premise
485	toxicities	_	_	I-Premise
486	of	_	_	I-Premise
487	TOM	_	_	I-Premise
488	+	_	_	I-Premise
489	LFA-5-FU	_	_	I-Premise
490	were	_	_	I-Premise
491	neutropenia	_	_	I-Premise
492	(	_	_	I-Premise
493	16	_	_	I-Premise
494	%	_	_	I-Premise
495	)	_	_	I-Premise
496	and	_	_	I-Premise
497	diarrhoea	_	_	I-Premise
498	(	_	_	I-Premise
499	16	_	_	I-Premise
500	%	_	_	I-Premise
501	)	_	_	I-Premise
502	,	_	_	I-Premise
503	but	_	_	I-Premise
504	median	_	_	I-Premise
505	relative	_	_	I-Premise
506	DI8	_	_	I-Premise
507	was	_	_	I-Premise
508	93	_	_	I-Premise
509	%	_	_	I-Premise
510	for	_	_	I-Premise
511	TOM	_	_	I-Premise
512	,	_	_	I-Premise
513	and	_	_	I-Premise
514	82	_	_	I-Premise
515	%	_	_	I-Premise
516	for	_	_	I-Premise
517	5-FU	_	_	I-Premise
518	.	_	_	I-Premise

519	CPT-11	_	_	B-Premise
520	+	_	_	I-Premise
521	LFA-5-FU	_	_	I-Premise
522	compares	_	_	I-Premise
523	favorably	_	_	I-Premise
524	in	_	_	I-Premise
525	term	_	_	I-Premise
526	of	_	_	I-Premise
527	activity	_	_	I-Premise
528	and	_	_	I-Premise
529	toxicity	_	_	I-Premise
530	with	_	_	I-Premise
531	other	_	_	I-Premise
532	combination	_	_	I-Premise
533	regimens	_	_	I-Premise
534	including	_	_	I-Premise
535	CPT-11	_	_	I-Premise
536	and	_	_	I-Premise
537	continuous	_	_	I-Premise
538	infusional	_	_	I-Premise
539	5-FU	_	_	I-Premise
540	.	_	_	I-Premise

541	The	_	_	B-Claim
542	hypothesis	_	_	I-Claim
543	of	_	_	I-Claim
544	a	_	_	I-Claim
545	RR	_	_	I-Claim
546	15	_	_	I-Claim
547	%	_	_	I-Claim
548	higher	_	_	I-Claim
549	than	_	_	I-Claim
550	the	_	_	I-Claim
551	MTX	_	_	I-Claim
552	+	_	_	I-Claim
553	LFA-5-FU	_	_	I-Claim
554	treatment	_	_	I-Claim
555	can	_	_	I-Claim
556	not	_	_	I-Claim
557	be	_	_	I-Claim
558	ruled	_	_	I-Claim
559	out	_	_	I-Claim
560	after	_	_	I-Claim
561	this	_	_	I-Claim
562	interim	_	_	I-Claim
563	analysis	_	_	I-Claim
564	.	_	_	I-Claim

565	The	_	_	B-Claim
566	TOM	_	_	I-Claim
567	+	_	_	I-Claim
568	LFA	_	_	I-Claim
569	5-FU	_	_	I-Claim
570	regimen	_	_	I-Claim
571	showed	_	_	I-Claim
572	a	_	_	I-Claim
573	RR	_	_	I-Claim
574	and	_	_	I-Claim
575	a	_	_	I-Claim
576	toxicity	_	_	I-Claim
577	profile	_	_	I-Claim
578	very	_	_	I-Claim
579	close	_	_	I-Claim
580	to	_	_	I-Claim
581	the	_	_	I-Claim
582	MTX	_	_	I-Claim
583	+	_	_	I-Claim
584	LFA	_	_	I-Claim
585	5-FU	_	_	I-Claim
586	combination	_	_	I-Claim
587	,	_	_	I-Claim
588	and	_	_	I-Claim
589	does	_	_	I-Claim
590	not	_	_	I-Claim
591	deserve	_	_	I-Claim
592	further	_	_	I-Claim
593	evaluation	_	_	I-Claim
594	in	_	_	I-Claim
595	advanced	_	_	I-Claim
596	colorectal	_	_	I-Claim
597	cancer	_	_	I-Claim
598	patients	_	_	I-Claim
599	.	_	_	I-Claim


0	Adjuvant	_	_	O
1	chemotherapy	_	_	O
2	for	_	_	O
3	early	_	_	O
4	stage	_	_	O
5	non-small-cell	_	_	O
6	lung	_	_	O
7	cancer	_	_	O
8	(	_	_	O
9	NSCLC	_	_	O
10	)	_	_	O
11	is	_	_	O
12	now	_	_	O
13	the	_	_	O
14	standard	_	_	O
15	of	_	_	O
16	care	_	_	O
17	,	_	_	O
18	but	_	_	O
19	there	_	_	O
20	is	_	_	O
21	little	_	_	O
22	information	_	_	O
23	regarding	_	_	O
24	its	_	_	O
25	impact	_	_	O
26	on	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	.	_	_	O

34	We	_	_	O
35	report	_	_	O
36	the	_	_	O
37	QOL	_	_	O
38	results	_	_	O
39	of	_	_	O
40	JBR.10	_	_	O
41	,	_	_	O
42	a	_	_	O
43	North	_	_	O
44	American	_	_	O
45	,	_	_	O
46	intergroup	_	_	O
47	,	_	_	O
48	randomized	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	adjuvant	_	_	O
52	cisplatin	_	_	O
53	and	_	_	O
54	vinorelbine	_	_	O
55	compared	_	_	O
56	with	_	_	O
57	observation	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	who	_	_	O
61	have	_	_	O
62	completely	_	_	O
63	resected	_	_	O
64	,	_	_	O
65	stages	_	_	O
66	IB	_	_	O
67	to	_	_	O
68	II	_	_	O
69	NSCLC	_	_	O
70	.	_	_	O

71	QOL	_	_	O
72	was	_	_	O
73	assessed	_	_	O
74	with	_	_	O
75	the	_	_	O
76	European	_	_	O
77	Organisation	_	_	O
78	for	_	_	O
79	Research	_	_	O
80	and	_	_	O
81	Treatment	_	_	O
82	of	_	_	O
83	Cancer	_	_	O
84	Quality	_	_	O
85	of	_	_	O
86	Life	_	_	O
87	Questionnaire	_	_	O
88	C30	_	_	O
89	and	_	_	O
90	a	_	_	O
91	trial-specific	_	_	O
92	checklist	_	_	O
93	at	_	_	O
94	baseline	_	_	O
95	and	_	_	O
96	at	_	_	O
97	weeks	_	_	O
98	5	_	_	O
99	and	_	_	O
100	9	_	_	O
101	for	_	_	O
102	those	_	_	O
103	who	_	_	O
104	received	_	_	O
105	chemotherapy	_	_	O
106	and	_	_	O
107	at	_	_	O
108	follow-up	_	_	O
109	months	_	_	O
110	3	_	_	O
111	,	_	_	O
112	6	_	_	O
113	,	_	_	O
114	9	_	_	O
115	,	_	_	O
116	12	_	_	O
117	,	_	_	O
118	18	_	_	O
119	,	_	_	O
120	24	_	_	O
121	,	_	_	O
122	30	_	_	O
123	and	_	_	O
124	36	_	_	O
125	.	_	_	O

126	A	_	_	O
127	10-point	_	_	O
128	change	_	_	O
129	in	_	_	O
130	QOL	_	_	O
131	scores	_	_	O
132	from	_	_	O
133	baseline	_	_	O
134	was	_	_	O
135	considered	_	_	O
136	clinically	_	_	O
137	significant	_	_	O
138	.	_	_	O

139	Four	_	_	O
140	hundred	_	_	O
141	eighty-two	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomly	_	_	O
145	assigned	_	_	O
146	on	_	_	O
147	JBR.10	_	_	O
148	.	_	_	O

149	A	_	_	O
150	total	_	_	O
151	of	_	_	O
152	173	_	_	O
153	patients	_	_	O
154	(	_	_	O
155	82	_	_	O
156	%	_	_	O
157	of	_	_	O
158	the	_	_	O
159	expected	_	_	O
160	)	_	_	O
161	in	_	_	O
162	the	_	_	O
163	observation	_	_	O
164	arm	_	_	O
165	and	_	_	O
166	186	_	_	O
167	(	_	_	O
168	85	_	_	O
169	%	_	_	O
170	of	_	_	O
171	expected	_	_	O
172	)	_	_	O
173	in	_	_	O
174	the	_	_	O
175	chemotherapy	_	_	O
176	arm	_	_	O
177	completed	_	_	O
178	baseline	_	_	O
179	QOL	_	_	O
180	assessments	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	two	_	_	I-Premise
184	groups	_	_	I-Premise
185	were	_	_	I-Premise
186	comparable	_	_	I-Premise
187	,	_	_	I-Premise
188	with	_	_	I-Premise
189	low	_	_	I-Premise
190	global	_	_	I-Premise
191	QOL	_	_	I-Premise
192	scores	_	_	I-Premise
193	and	_	_	I-Premise
194	significant	_	_	I-Premise
195	symptom	_	_	I-Premise
196	burden	_	_	I-Premise
197	,	_	_	I-Premise
198	especially	_	_	I-Premise
199	pain	_	_	I-Premise
200	and	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	,	_	_	I-Premise
203	after	_	_	I-Premise
204	thoracotomy	_	_	I-Premise
205	.	_	_	I-Premise

206	Changes	_	_	O
207	in	_	_	O
208	QOL	_	_	O
209	during	_	_	O
210	chemotherapy	_	_	O
211	were	_	_	O
212	relatively	_	_	O
213	modest	_	_	O
214	;	_	_	O
215	fatigue	_	_	B-Premise
216	,	_	_	I-Premise
217	nausea	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	vomiting	_	_	I-Premise
221	worsened	_	_	I-Premise
222	,	_	_	I-Premise
223	but	_	_	B-Premise
224	there	_	_	I-Premise
225	was	_	_	I-Premise
226	a	_	_	I-Premise
227	reduction	_	_	I-Premise
228	in	_	_	I-Premise
229	pain	_	_	I-Premise
230	and	_	_	I-Premise
231	no	_	_	I-Premise
232	change	_	_	I-Premise
233	in	_	_	I-Premise
234	global	_	_	I-Premise
235	QOL	_	_	I-Premise
236	.	_	_	I-Premise

237	Patients	_	_	B-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	observation	_	_	I-Premise
241	arm	_	_	I-Premise
242	showed	_	_	I-Premise
243	considerable	_	_	I-Premise
244	improvements	_	_	I-Premise
245	in	_	_	I-Premise
246	QOL	_	_	I-Premise
247	by	_	_	I-Premise
248	3	_	_	I-Premise
249	months	_	_	I-Premise
250	.	_	_	I-Premise

251	QOL	_	_	B-Premise
252	,	_	_	I-Premise
253	except	_	_	I-Premise
254	for	_	_	I-Premise
255	symptoms	_	_	I-Premise
256	of	_	_	I-Premise
257	sensory	_	_	I-Premise
258	neuropathy	_	_	I-Premise
259	and	_	_	I-Premise
260	hearing	_	_	I-Premise
261	loss	_	_	I-Premise
262	,	_	_	I-Premise
263	in	_	_	I-Premise
264	those	_	_	I-Premise
265	treated	_	_	I-Premise
266	with	_	_	I-Premise
267	chemotherapy	_	_	I-Premise
268	returned	_	_	I-Premise
269	to	_	_	I-Premise
270	baseline	_	_	I-Premise
271	by	_	_	I-Premise
272	9	_	_	I-Premise
273	months	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Claim
276	findings	_	_	I-Claim
277	of	_	_	I-Claim
278	this	_	_	I-Claim
279	trial	_	_	I-Claim
280	indicate	_	_	I-Claim
281	that	_	_	I-Claim
282	the	_	_	I-Claim
283	negative	_	_	I-Claim
284	effects	_	_	I-Claim
285	of	_	_	I-Claim
286	adjuvant	_	_	I-Claim
287	chemotherapy	_	_	I-Claim
288	on	_	_	I-Claim
289	QOL	_	_	I-Claim
290	appear	_	_	I-Claim
291	to	_	_	I-Claim
292	be	_	_	I-Claim
293	temporary	_	_	I-Claim
294	,	_	_	I-Claim
295	and	_	_	I-Claim
296	that	_	_	I-Claim
297	improvements	_	_	I-Claim
298	(	_	_	I-Claim
299	with	_	_	I-Claim
300	a	_	_	I-Claim
301	return	_	_	I-Claim
302	to	_	_	I-Claim
303	baseline	_	_	I-Claim
304	function	_	_	I-Claim
305	)	_	_	I-Claim
306	are	_	_	I-Claim
307	likely	_	_	I-Claim
308	in	_	_	I-Claim
309	most	_	_	I-Claim
310	patients	_	_	I-Claim
311	.	_	_	I-Claim


0	Promising	_	_	O
1	results	_	_	O
2	in	_	_	O
3	a	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	II	_	_	O
7	trial	_	_	O
8	with	_	_	O
9	the	_	_	O
10	hypoxic	_	_	O
11	cytotoxin	_	_	O
12	tirapazamine	_	_	O
13	(	_	_	O
14	TPZ	_	_	O
15	)	_	_	O
16	combined	_	_	O
17	with	_	_	O
18	cisplatin	_	_	O
19	(	_	_	O
20	CIS	_	_	O
21	)	_	_	O
22	and	_	_	O
23	radiation	_	_	O
24	led	_	_	O
25	to	_	_	O
26	this	_	_	O
27	phase	_	_	O
28	III	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	with	_	_	O
33	previously	_	_	O
34	untreated	_	_	O
35	stage	_	_	O
36	III	_	_	O
37	or	_	_	O
38	IV	_	_	O
39	(	_	_	O
40	excluding	_	_	O
41	T1-2N1	_	_	O
42	and	_	_	O
43	M1	_	_	O
44	)	_	_	O
45	squamous	_	_	O
46	cell	_	_	O
47	carcinoma	_	_	O
48	of	_	_	O
49	the	_	_	O
50	oral	_	_	O
51	cavity	_	_	O
52	,	_	_	O
53	oropharynx	_	_	O
54	,	_	_	O
55	hypopharynx	_	_	O
56	,	_	_	O
57	or	_	_	O
58	larynx	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	definitive	_	_	O
65	radiotherapy	_	_	O
66	(	_	_	O
67	70	_	_	O
68	Gy	_	_	O
69	in	_	_	O
70	7	_	_	O
71	weeks	_	_	O
72	)	_	_	O
73	concurrently	_	_	O
74	with	_	_	O
75	either	_	_	O
76	CIS	_	_	O
77	(	_	_	O
78	100	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	)	_	_	O
84	on	_	_	O
85	day	_	_	O
86	1	_	_	O
87	of	_	_	O
88	weeks	_	_	O
89	1	_	_	O
90	,	_	_	O
91	4	_	_	O
92	,	_	_	O
93	and	_	_	O
94	7	_	_	O
95	or	_	_	O
96	CIS	_	_	O
97	(	_	_	O
98	75	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	)	_	_	O
104	plus	_	_	O
105	TPZ	_	_	O
106	(	_	_	O
107	290	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	/d	_	_	O
113	)	_	_	O
114	on	_	_	O
115	day	_	_	O
116	1	_	_	O
117	of	_	_	O
118	weeks	_	_	O
119	1	_	_	O
120	,	_	_	O
121	4	_	_	O
122	,	_	_	O
123	and	_	_	O
124	7	_	_	O
125	and	_	_	O
126	TPZ	_	_	O
127	alone	_	_	O
128	(	_	_	O
129	160	_	_	O
130	mg/m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	/d	_	_	O
135	)	_	_	O
136	on	_	_	O
137	days	_	_	O
138	1	_	_	O
139	,	_	_	O
140	3	_	_	O
141	,	_	_	O
142	and	_	_	O
143	5	_	_	O
144	of	_	_	O
145	weeks	_	_	O
146	2	_	_	O
147	and	_	_	O
148	3	_	_	O
149	(	_	_	O
150	TPZ/CIS	_	_	O
151	)	_	_	O
152	.	_	_	O

153	The	_	_	O
154	primary	_	_	O
155	end	_	_	O
156	point	_	_	O
157	was	_	_	O
158	overall	_	_	O
159	survival	_	_	O
160	(	_	_	O
161	OS	_	_	O
162	)	_	_	O
163	.	_	_	O

164	The	_	_	O
165	planned	_	_	O
166	sample	_	_	O
167	size	_	_	O
168	was	_	_	O
169	850	_	_	O
170	,	_	_	O
171	estimated	_	_	O
172	to	_	_	O
173	result	_	_	O
174	in	_	_	O
175	334	_	_	O
176	deaths	_	_	O
177	,	_	_	O
178	which	_	_	O
179	would	_	_	O
180	provide	_	_	O
181	90	_	_	O
182	%	_	_	O
183	power	_	_	O
184	to	_	_	O
185	detect	_	_	O
186	a	_	_	O
187	difference	_	_	O
188	in	_	_	O
189	2-year	_	_	O
190	survival	_	_	O
191	rates	_	_	O
192	of	_	_	O
193	60	_	_	O
194	%	_	_	O
195	v	_	_	O
196	70	_	_	O
197	%	_	_	O
198	for	_	_	O
199	CIS	_	_	O
200	versus	_	_	O
201	TPZ/CIS	_	_	O
202	,	_	_	O
203	respectively	_	_	O
204	(	_	_	O
205	hazard	_	_	O
206	ratio	_	_	O
207	=	_	_	O
208	0.69	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Eight	_	_	O
212	hundred	_	_	O
213	sixty-one	_	_	O
214	patients	_	_	O
215	were	_	_	O
216	accrued	_	_	O
217	from	_	_	O
218	89	_	_	O
219	sites	_	_	O
220	in	_	_	O
221	16	_	_	O
222	countries	_	_	O
223	.	_	_	O

224	In	_	_	B-Premise
225	an	_	_	I-Premise
226	intent-to-treat	_	_	I-Premise
227	analysis	_	_	I-Premise
228	,	_	_	I-Premise
229	the	_	_	I-Premise
230	2-year	_	_	I-Premise
231	OS	_	_	I-Premise
232	rates	_	_	I-Premise
233	were	_	_	I-Premise
234	65.7	_	_	I-Premise
235	%	_	_	I-Premise
236	for	_	_	I-Premise
237	CIS	_	_	I-Premise
238	and	_	_	I-Premise
239	66.2	_	_	I-Premise
240	%	_	_	I-Premise
241	for	_	_	I-Premise
242	TPZ/CIS	_	_	I-Premise
243	(	_	_	I-Premise
244	TPZ/CIS	_	_	I-Premise
245	--	_	_	I-Premise
246	CIS	_	_	I-Premise
247	:	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	-5.9	_	_	I-Premise
253	%	_	_	I-Premise
254	to	_	_	I-Premise
255	6.9	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	There	_	_	B-Premise
260	were	_	_	I-Premise
261	no	_	_	I-Premise
262	significant	_	_	I-Premise
263	differences	_	_	I-Premise
264	in	_	_	I-Premise
265	failure-free	_	_	I-Premise
266	survival	_	_	I-Premise
267	,	_	_	I-Premise
268	time	_	_	I-Premise
269	to	_	_	I-Premise
270	locoregional	_	_	I-Premise
271	failure	_	_	I-Premise
272	,	_	_	I-Premise
273	or	_	_	I-Premise
274	quality	_	_	I-Premise
275	of	_	_	I-Premise
276	life	_	_	I-Premise
277	as	_	_	I-Premise
278	measured	_	_	I-Premise
279	by	_	_	I-Premise
280	Functional	_	_	I-Premise
281	Assessment	_	_	I-Premise
282	of	_	_	I-Premise
283	Cancer	_	_	I-Premise
284	Therapy-Head	_	_	I-Premise
285	and	_	_	I-Premise
286	Neck	_	_	I-Premise
287	.	_	_	I-Premise

288	We	_	_	B-Claim
289	found	_	_	I-Claim
290	no	_	_	I-Claim
291	evidence	_	_	I-Claim
292	that	_	_	I-Claim
293	the	_	_	I-Claim
294	addition	_	_	I-Claim
295	of	_	_	I-Claim
296	TPZ	_	_	I-Claim
297	to	_	_	I-Claim
298	chemoradiotherapy	_	_	I-Claim
299	,	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	advanced	_	_	I-Claim
304	head	_	_	I-Claim
305	and	_	_	I-Claim
306	neck	_	_	I-Claim
307	cancer	_	_	I-Claim
308	not	_	_	I-Claim
309	selected	_	_	I-Claim
310	for	_	_	I-Claim
311	the	_	_	I-Claim
312	presence	_	_	I-Claim
313	of	_	_	I-Claim
314	hypoxia	_	_	I-Claim
315	,	_	_	I-Claim
316	improves	_	_	I-Claim
317	OS	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	carboplatin	_	_	O
4	and	_	_	O
5	paclitaxel	_	_	O
6	is	_	_	O
7	the	_	_	O
8	standard	_	_	O
9	of	_	_	O
10	care	_	_	O
11	for	_	_	O
12	the	_	_	O
13	treatment	_	_	O
14	of	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	yet	_	_	O
19	rates	_	_	O
20	of	_	_	O
21	recurrence	_	_	O
22	and	_	_	O
23	death	_	_	O
24	remain	_	_	O
25	high	_	_	O
26	.	_	_	O

27	We	_	_	O
28	performed	_	_	O
29	a	_	_	O
30	prospective	_	_	O
31	randomized	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	study	_	_	O
35	to	_	_	O
36	examine	_	_	O
37	whether	_	_	O
38	sequential	_	_	O
39	administration	_	_	O
40	of	_	_	O
41	topotecan	_	_	O
42	can	_	_	O
43	improve	_	_	O
44	the	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	carboplatin	_	_	O
48	and	_	_	O
49	paclitaxel	_	_	O
50	in	_	_	O
51	first-line	_	_	O
52	treatment	_	_	O
53	of	_	_	O
54	advanced	_	_	O
55	epithelial	_	_	O
56	ovarian	_	_	O
57	cancer	_	_	O
58	.	_	_	O

59	A	_	_	O
60	total	_	_	O
61	of	_	_	O
62	1308	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	previously	_	_	O
66	untreated	_	_	O
67	ovarian	_	_	O
68	cancer	_	_	O
69	(	_	_	O
70	International	_	_	O
71	Federation	_	_	O
72	of	_	_	O
73	Gynecology	_	_	O
74	and	_	_	O
75	Obstetrics	_	_	O
76	stages	_	_	O
77	IIB-IV	_	_	O
78	)	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	six	_	_	O
85	cycles	_	_	O
86	of	_	_	O
87	paclitaxel	_	_	O
88	and	_	_	O
89	carboplatin	_	_	O
90	followed	_	_	O
91	by	_	_	O
92	either	_	_	O
93	four	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	topotecan	_	_	O
97	(	_	_	O
98	TC-Top	_	_	O
99	;	_	_	O
100	658	_	_	O
101	patients	_	_	O
102	)	_	_	O
103	or	_	_	O
104	surveillance	_	_	O
105	(	_	_	O
106	TC	_	_	O
107	;	_	_	O
108	650	_	_	O
109	patients	_	_	O
110	)	_	_	O
111	on	_	_	O
112	a	_	_	O
113	3-week	_	_	O
114	per	_	_	O
115	cycle	_	_	O
116	schedule	_	_	O
117	.	_	_	O

118	The	_	_	O
119	primary	_	_	O
120	endpoint	_	_	O
121	was	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	,	_	_	O
125	and	_	_	O
126	secondary	_	_	O
127	endpoints	_	_	O
128	were	_	_	O
129	progression-free	_	_	O
130	survival	_	_	O
131	,	_	_	O
132	response	_	_	O
133	rate	_	_	O
134	,	_	_	O
135	toxicity	_	_	O
136	,	_	_	O
137	and	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	.	_	_	O

142	Time-to-event	_	_	O
143	data	_	_	O
144	were	_	_	O
145	analyzed	_	_	O
146	using	_	_	O
147	the	_	_	O
148	Kaplan-Meier	_	_	O
149	method	_	_	O
150	,	_	_	O
151	and	_	_	O
152	a	_	_	O
153	stratified	_	_	O
154	log-rank	_	_	O
155	test	_	_	O
156	was	_	_	O
157	used	_	_	O
158	to	_	_	O
159	compare	_	_	O
160	distributions	_	_	O
161	between	_	_	O
162	treatment	_	_	O
163	groups	_	_	O
164	.	_	_	O

165	Hazard	_	_	O
166	ratios	_	_	O
167	(	_	_	O
168	HRs	_	_	O
169	)	_	_	O
170	with	_	_	O
171	95	_	_	O
172	%	_	_	O
173	confidence	_	_	O
174	intervals	_	_	O
175	(	_	_	O
176	CIs	_	_	O
177	)	_	_	O
178	were	_	_	O
179	estimated	_	_	O
180	using	_	_	O
181	a	_	_	O
182	Cox	_	_	O
183	proportional	_	_	O
184	hazards	_	_	O
185	model	_	_	O
186	.	_	_	O

187	Categorical	_	_	O
188	data	_	_	O
189	were	_	_	O
190	compared	_	_	O
191	using	_	_	O
192	a	_	_	O
193	stratified	_	_	O
194	Cochran-Mantel-Haenszel	_	_	O
195	test	_	_	O
196	.	_	_	O

197	All	_	_	O
198	statistical	_	_	O
199	tests	_	_	O
200	were	_	_	O
201	two-sided	_	_	O
202	.	_	_	O

203	Median	_	_	B-Premise
204	progression-free	_	_	I-Premise
205	survival	_	_	I-Premise
206	was	_	_	I-Premise
207	18.2	_	_	I-Premise
208	months	_	_	I-Premise
209	in	_	_	I-Premise
210	the	_	_	I-Premise
211	TC-Top	_	_	I-Premise
212	arm	_	_	I-Premise
213	versus	_	_	I-Premise
214	18.5	_	_	I-Premise
215	months	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	TC	_	_	I-Premise
219	arm	_	_	I-Premise
220	(	_	_	I-Premise
221	stratum-adjusted	_	_	I-Premise
222	HR	_	_	I-Premise
223	=	_	_	I-Premise
224	0.97	_	_	I-Premise
225	[	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	=	_	_	I-Premise
230	0.85	_	_	I-Premise
231	to	_	_	I-Premise
232	1.10	_	_	I-Premise
233	]	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.688	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Median	_	_	B-Premise
241	overall	_	_	I-Premise
242	survival	_	_	I-Premise
243	was	_	_	I-Premise
244	43.1	_	_	I-Premise
245	months	_	_	I-Premise
246	for	_	_	I-Premise
247	the	_	_	I-Premise
248	TC-Top	_	_	I-Premise
249	arm	_	_	I-Premise
250	versus	_	_	I-Premise
251	44.5	_	_	I-Premise
252	months	_	_	I-Premise
253	for	_	_	I-Premise
254	the	_	_	I-Premise
255	TC	_	_	I-Premise
256	arm	_	_	I-Premise
257	(	_	_	I-Premise
258	stratum-adjusted	_	_	I-Premise
259	HR	_	_	I-Premise
260	=	_	_	I-Premise
261	1.01	_	_	I-Premise
262	[	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	CI	_	_	I-Premise
266	=	_	_	I-Premise
267	0.86	_	_	I-Premise
268	to	_	_	I-Premise
269	1.18	_	_	I-Premise
270	]	_	_	I-Premise
271	;	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.885	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	At	_	_	B-Premise
278	3	_	_	I-Premise
279	years	_	_	I-Premise
280	,	_	_	I-Premise
281	overall	_	_	I-Premise
282	survival	_	_	I-Premise
283	in	_	_	I-Premise
284	both	_	_	I-Premise
285	arms	_	_	I-Premise
286	was	_	_	I-Premise
287	57	_	_	I-Premise
288	%	_	_	I-Premise
289	(	_	_	I-Premise
290	58.5	_	_	I-Premise
291	%	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	TC	_	_	I-Premise
295	arm	_	_	I-Premise
296	and	_	_	I-Premise
297	55.7	_	_	I-Premise
298	%	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	TC-Top	_	_	I-Premise
302	arm	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	Compared	_	_	B-Premise
306	with	_	_	I-Premise
307	patients	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	TC	_	_	I-Premise
311	arm	_	_	I-Premise
312	,	_	_	I-Premise
313	patients	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	TC-Top	_	_	I-Premise
317	arm	_	_	I-Premise
318	had	_	_	I-Premise
319	more	_	_	I-Premise
320	grade	_	_	I-Premise
321	3-4	_	_	I-Premise
322	hematologic	_	_	I-Premise
323	toxic	_	_	I-Premise
324	effects	_	_	I-Premise
325	(	_	_	I-Premise
326	requiring	_	_	I-Premise
327	more	_	_	I-Premise
328	supportive	_	_	I-Premise
329	care	_	_	I-Premise
330	)	_	_	I-Premise
331	and	_	_	I-Premise
332	more	_	_	I-Premise
333	grade	_	_	I-Premise
334	3-4	_	_	I-Premise
335	infections	_	_	I-Premise
336	(	_	_	I-Premise
337	5.1	_	_	I-Premise
338	%	_	_	I-Premise
339	versus	_	_	I-Premise
340	2.7	_	_	I-Premise
341	%	_	_	I-Premise
342	;	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	.034	_	_	I-Premise
346	)	_	_	I-Premise
347	but	_	_	I-Premise
348	did	_	_	I-Premise
349	not	_	_	I-Premise
350	have	_	_	I-Premise
351	a	_	_	I-Premise
352	statistically	_	_	I-Premise
353	significant	_	_	I-Premise
354	increase	_	_	I-Premise
355	in	_	_	I-Premise
356	febrile	_	_	I-Premise
357	neutropenia	_	_	I-Premise
358	(	_	_	I-Premise
359	3.3	_	_	I-Premise
360	%	_	_	I-Premise
361	versus	_	_	I-Premise
362	3.1	_	_	I-Premise
363	%	_	_	I-Premise
364	;	_	_	I-Premise
365	P	_	_	I-Premise
366	=	_	_	I-Premise
367	.80	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	Among	_	_	B-Premise
371	patients	_	_	I-Premise
372	who	_	_	I-Premise
373	had	_	_	I-Premise
374	measurable	_	_	I-Premise
375	disease	_	_	I-Premise
376	(	_	_	I-Premise
377	TC	_	_	I-Premise
378	,	_	_	I-Premise
379	n	_	_	I-Premise
380	=	_	_	I-Premise
381	147	_	_	I-Premise
382	;	_	_	I-Premise
383	TC-Top	_	_	I-Premise
384	,	_	_	I-Premise
385	n	_	_	I-Premise
386	=	_	_	I-Premise
387	145	_	_	I-Premise
388	)	_	_	I-Premise
389	,	_	_	I-Premise
390	overall	_	_	I-Premise
391	(	_	_	I-Premise
392	i.e.	_	_	I-Premise
393	,	_	_	I-Premise
394	complete	_	_	I-Premise
395	or	_	_	I-Premise
396	partial	_	_	I-Premise
397	)	_	_	I-Premise
398	response	_	_	I-Premise
399	was	_	_	I-Premise
400	69.0	_	_	I-Premise
401	%	_	_	I-Premise
402	(	_	_	I-Premise
403	95	_	_	I-Premise
404	%	_	_	I-Premise
405	CI	_	_	I-Premise
406	=	_	_	I-Premise
407	61.4	_	_	I-Premise
408	%	_	_	I-Premise
409	to	_	_	I-Premise
410	76.5	_	_	I-Premise
411	%	_	_	I-Premise
412	)	_	_	I-Premise
413	in	_	_	I-Premise
414	the	_	_	I-Premise
415	TC-Top	_	_	I-Premise
416	arm	_	_	I-Premise
417	and	_	_	I-Premise
418	76.2	_	_	I-Premise
419	%	_	_	I-Premise
420	(	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	=	_	_	I-Premise
425	69.3	_	_	I-Premise
426	%	_	_	I-Premise
427	to	_	_	I-Premise
428	83.1	_	_	I-Premise
429	%	_	_	I-Premise
430	)	_	_	I-Premise
431	in	_	_	I-Premise
432	the	_	_	I-Premise
433	TC	_	_	I-Premise
434	arm	_	_	I-Premise
435	(	_	_	I-Premise
436	P	_	_	I-Premise
437	=	_	_	I-Premise
438	.166	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	The	_	_	B-Claim
442	sequential	_	_	I-Claim
443	addition	_	_	I-Claim
444	of	_	_	I-Claim
445	topotecan	_	_	I-Claim
446	to	_	_	I-Claim
447	carboplatin-paclitaxel	_	_	I-Claim
448	did	_	_	I-Claim
449	not	_	_	I-Claim
450	result	_	_	I-Claim
451	in	_	_	I-Claim
452	superior	_	_	I-Claim
453	overall	_	_	I-Claim
454	response	_	_	I-Claim
455	or	_	_	I-Claim
456	progression-free	_	_	I-Claim
457	or	_	_	I-Claim
458	overall	_	_	I-Claim
459	survival	_	_	I-Claim
460	.	_	_	I-Claim

461	Therefore	_	_	B-Claim
462	,	_	_	I-Claim
463	this	_	_	I-Claim
464	regimen	_	_	I-Claim
465	is	_	_	I-Claim
466	not	_	_	I-Claim
467	recommended	_	_	I-Claim
468	as	_	_	I-Claim
469	standard	_	_	I-Claim
470	of	_	_	I-Claim
471	care	_	_	I-Claim
472	treatment	_	_	I-Claim
473	for	_	_	I-Claim
474	ovarian	_	_	I-Claim
475	cancer	_	_	I-Claim
476	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	health-related	_	_	O
3	quality	_	_	O
4	of	_	_	O
5	life	_	_	O
6	,	_	_	O
7	we	_	_	O
8	investigated	_	_	O
9	the	_	_	O
10	effect	_	_	O
11	of	_	_	O
12	adjuvant	_	_	O
13	chemotherapy	_	_	O
14	regimens	_	_	O
15	on	_	_	O
16	utility	_	_	O
17	scores	_	_	O
18	assessed	_	_	O
19	by	_	_	O
20	the	_	_	O
21	EuroQoL-5D	_	_	O
22	(	_	_	O
23	EQ-5D	_	_	O
24	)	_	_	O
25	instrument	_	_	O
26	in	_	_	O
27	a	_	_	O
28	randomized	_	_	O
29	,	_	_	O
30	controlled	_	_	O
31	trial	_	_	O
32	for	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	patients	_	_	O
36	after	_	_	O
37	surgery	_	_	O
38	.	_	_	O

39	We	_	_	O
40	also	_	_	O
41	investigated	_	_	O
42	the	_	_	O
43	relationship	_	_	O
44	between	_	_	O
45	Functional	_	_	O
46	Assessment	_	_	O
47	of	_	_	O
48	Cancer	_	_	O
49	Therapy	_	_	O
50	(	_	_	O
51	FACT	_	_	O
52	)	_	_	O
53	scale	_	_	O
54	scores	_	_	O
55	and	_	_	O
56	EQ-5D	_	_	O
57	utilities	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	the	_	_	O
65	following	_	_	O
66	four	_	_	O
67	chemotherapy	_	_	O
68	regimens	_	_	O
69	:	_	_	O
70	four	_	_	O
71	cycles	_	_	O
72	of	_	_	O
73	anthracycline	_	_	O
74	followed	_	_	O
75	by	_	_	O
76	paclitaxel	_	_	O
77	(	_	_	O
78	ACP	_	_	O
79	)	_	_	O
80	,	_	_	O
81	four	_	_	O
82	cycles	_	_	O
83	of	_	_	O
84	anthracycline-containing	_	_	O
85	regimens	_	_	O
86	followed	_	_	O
87	by	_	_	O
88	docetaxel	_	_	O
89	(	_	_	O
90	ACD	_	_	O
91	)	_	_	O
92	,	_	_	O
93	eight	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	paclitaxel	_	_	O
97	(	_	_	O
98	PTX	_	_	O
99	)	_	_	O
100	,	_	_	O
101	and	_	_	O
102	eight	_	_	O
103	cycles	_	_	O
104	of	_	_	O
105	docetaxel	_	_	O
106	(	_	_	O
107	DTX	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Of	_	_	O
111	1060	_	_	O
112	registered	_	_	O
113	,	_	_	O
114	the	_	_	O
115	first	_	_	O
116	300	_	_	O
117	consecutive	_	_	O
118	patients	_	_	O
119	were	_	_	O
120	included	_	_	O
121	in	_	_	O
122	the	_	_	O
123	current	_	_	O
124	utility	_	_	O
125	study	_	_	O
126	.	_	_	O

127	Utility	_	_	O
128	scores	_	_	O
129	were	_	_	O
130	assessed	_	_	O
131	using	_	_	O
132	the	_	_	O
133	EQ-5D	_	_	O
134	instrument	_	_	O
135	at	_	_	O
136	baseline	_	_	O
137	;	_	_	O
138	cycles	_	_	O
139	3	_	_	O
140	,	_	_	O
141	5	_	_	O
142	,	_	_	O
143	and	_	_	O
144	7	_	_	O
145	;	_	_	O
146	7	_	_	O
147	months	_	_	O
148	;	_	_	O
149	and	_	_	O
150	1	_	_	O
151	year	_	_	O
152	.	_	_	O

153	We	_	_	O
154	also	_	_	O
155	evaluated	_	_	O
156	the	_	_	O
157	correlation	_	_	O
158	between	_	_	O
159	these	_	_	O
160	scores	_	_	O
161	and	_	_	O
162	FACT-G	_	_	O
163	,	_	_	O
164	-B	_	_	O
165	,	_	_	O
166	and	_	_	O
167	-Taxane	_	_	O
168	scores	_	_	O
169	at	_	_	O
170	each	_	_	O
171	time	_	_	O
172	point	_	_	O
173	.	_	_	O

174	Utility	_	_	B-Premise
175	scores	_	_	I-Premise
176	were	_	_	I-Premise
177	significantly	_	_	I-Premise
178	lower	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	DTX	_	_	I-Premise
182	group	_	_	I-Premise
183	than	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	ACP	_	_	I-Premise
187	and	_	_	I-Premise
188	ACD	_	_	I-Premise
189	groups	_	_	I-Premise
190	.	_	_	I-Premise

191	Mean	_	_	B-Premise
192	utility	_	_	I-Premise
193	scores	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	DTX	_	_	I-Premise
197	group	_	_	I-Premise
198	were	_	_	I-Premise
199	lowest	_	_	I-Premise
200	at	_	_	I-Premise
201	7	_	_	I-Premise
202	months	_	_	I-Premise
203	and	_	_	I-Premise
204	tended	_	_	I-Premise
205	to	_	_	I-Premise
206	remain	_	_	I-Premise
207	low	_	_	I-Premise
208	for	_	_	I-Premise
209	a	_	_	I-Premise
210	long	_	_	I-Premise
211	time	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	combined	_	_	I-Premise
215	anthracycline	_	_	I-Premise
216	followed	_	_	I-Premise
217	by	_	_	I-Premise
218	taxane	_	_	I-Premise
219	group	_	_	I-Premise
220	had	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	utility	_	_	I-Premise
224	scores	_	_	I-Premise
225	that	_	_	I-Premise
226	the	_	_	I-Premise
227	taxane-alone	_	_	I-Premise
228	group	_	_	I-Premise
229	,	_	_	I-Premise
230	with	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	depending	_	_	I-Premise
235	on	_	_	I-Premise
236	the	_	_	I-Premise
237	type	_	_	I-Premise
238	of	_	_	I-Premise
239	taxane	_	_	I-Premise
240	.	_	_	I-Premise

241	Only	_	_	B-Premise
242	the	_	_	I-Premise
243	FACT-G	_	_	I-Premise
244	social/family	_	_	I-Premise
245	well-being	_	_	I-Premise
246	subscale	_	_	I-Premise
247	had	_	_	I-Premise
248	no	_	_	I-Premise
249	relationship	_	_	I-Premise
250	with	_	_	I-Premise
251	EQ-5D	_	_	I-Premise
252	responses	_	_	I-Premise
253	and	_	_	I-Premise
254	utility	_	_	I-Premise
255	scores	_	_	I-Premise
256	.	_	_	I-Premise

257	Although	_	_	B-Claim
258	the	_	_	I-Claim
259	regimens	_	_	I-Claim
260	in	_	_	I-Claim
261	this	_	_	I-Claim
262	study	_	_	I-Claim
263	were	_	_	I-Claim
264	similar	_	_	I-Claim
265	in	_	_	I-Claim
266	that	_	_	I-Claim
267	they	_	_	I-Claim
268	included	_	_	I-Claim
269	taxane	_	_	I-Claim
270	,	_	_	I-Claim
271	the	_	_	I-Claim
272	mean	_	_	I-Claim
273	utility	_	_	I-Claim
274	scores	_	_	I-Claim
275	and	_	_	I-Claim
276	longitudinal	_	_	I-Claim
277	patterns	_	_	I-Claim
278	of	_	_	I-Claim
279	utility	_	_	I-Claim
280	scores	_	_	I-Claim
281	were	_	_	I-Claim
282	different	_	_	I-Claim
283	among	_	_	I-Claim
284	regimens	_	_	I-Claim
285	.	_	_	I-Claim


0	Topical	_	_	O
1	photodynamic	_	_	O
2	therapy	_	_	O
3	(	_	_	O
4	PDT	_	_	O
5	)	_	_	O
6	with	_	_	O
7	aminolevulinic	_	_	O
8	acid	_	_	O
9	(	_	_	O
10	ALA	_	_	O
11	)	_	_	O
12	and	_	_	O
13	5	_	_	O
14	%	_	_	O
15	imiquimod	_	_	O
16	cream	_	_	O
17	are	_	_	O
18	effective	_	_	O
19	therapies	_	_	O
20	for	_	_	O
21	the	_	_	O
22	treatment	_	_	O
23	of	_	_	O
24	actinic	_	_	O
25	keratoses	_	_	O
26	(	_	_	O
27	AKs	_	_	O
28	)	_	_	O
29	,	_	_	O
30	but	_	_	O
31	no	_	_	O
32	split-face	_	_	O
33	studies	_	_	O
34	directly	_	_	O
35	comparing	_	_	O
36	these	_	_	O
37	treatment	_	_	O
38	options	_	_	O
39	are	_	_	O
40	available	_	_	O
41	in	_	_	O
42	the	_	_	O
43	literature	_	_	O
44	.	_	_	O

45	To	_	_	O
46	compare	_	_	O
47	the	_	_	O
48	efficacy	_	_	O
49	and	_	_	O
50	tolerability	_	_	O
51	of	_	_	O
52	ALA-PDT	_	_	O
53	and	_	_	O
54	imiquimod	_	_	O
55	5	_	_	O
56	%	_	_	O
57	cream	_	_	O
58	for	_	_	O
59	the	_	_	O
60	treatment	_	_	O
61	of	_	_	O
62	AKs	_	_	O
63	.	_	_	O

64	Sixty-one	_	_	O
65	patients	_	_	O
66	were	_	_	O
67	enrolled	_	_	O
68	from	_	_	O
69	the	_	_	O
70	Salt	_	_	O
71	Lake	_	_	O
72	City	_	_	O
73	Veterans	_	_	O
74	Affairs	_	_	O
75	Hospital	_	_	O
76	;	_	_	O
77	51	_	_	O
78	completed	_	_	O
79	the	_	_	O
80	study	_	_	O
81	and	_	_	O
82	were	_	_	O
83	included	_	_	O
84	in	_	_	O
85	the	_	_	O
86	analysis	_	_	O
87	.	_	_	O

88	All	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	randomized	_	_	O
92	to	_	_	O
93	receive	_	_	O
94	half	_	_	O
95	of	_	_	O
96	a	_	_	O
97	sachet	_	_	O
98	of	_	_	O
99	imiquimod	_	_	O
100	5	_	_	O
101	%	_	_	O
102	cream	_	_	O
103	twice	_	_	O
104	weekly	_	_	O
105	on	_	_	O
106	half	_	_	O
107	of	_	_	O
108	their	_	_	O
109	face	_	_	O
110	and	_	_	O
111	two	_	_	O
112	sessions	_	_	O
113	of	_	_	O
114	PDT	_	_	O
115	with	_	_	O
116	20	_	_	O
117	%	_	_	O
118	solution	_	_	O
119	of	_	_	O
120	ALA	_	_	O
121	applied	_	_	O
122	for	_	_	O
123	1	_	_	O
124	hour	_	_	O
125	to	_	_	O
126	the	_	_	O
127	other	_	_	O
128	side	_	_	O
129	of	_	_	O
130	the	_	_	O
131	face	_	_	O
132	.	_	_	O

133	The	_	_	B-Premise
134	75	_	_	I-Premise
135	%	_	_	I-Premise
136	AK	_	_	I-Premise
137	clearance	_	_	I-Premise
138	rate	_	_	I-Premise
139	was	_	_	I-Premise
140	34.6	_	_	I-Premise
141	%	_	_	I-Premise
142	for	_	_	I-Premise
143	ALA-PDT	_	_	I-Premise
144	and	_	_	I-Premise
145	25	_	_	I-Premise
146	%	_	_	I-Premise
147	for	_	_	I-Premise
148	imiquimod	_	_	I-Premise
149	5	_	_	I-Premise
150	%	_	_	I-Premise
151	cream	_	_	I-Premise
152	(	_	_	I-Premise
153	p	_	_	I-Premise
154	=	_	_	I-Premise
155	.30	_	_	I-Premise
156	)	_	_	I-Premise
157	.	_	_	I-Premise

158	The	_	_	B-Premise
159	mean	_	_	I-Premise
160	reduction	_	_	I-Premise
161	in	_	_	I-Premise
162	AK	_	_	I-Premise
163	count	_	_	I-Premise
164	was	_	_	I-Premise
165	59.2	_	_	I-Premise
166	%	_	_	I-Premise
167	for	_	_	I-Premise
168	ALA-PDT	_	_	I-Premise
169	and	_	_	I-Premise
170	41.4	_	_	I-Premise
171	%	_	_	I-Premise
172	for	_	_	I-Premise
173	imiquimod	_	_	I-Premise
174	5	_	_	I-Premise
175	%	_	_	I-Premise
176	cream	_	_	I-Premise
177	(	_	_	I-Premise
178	p	_	_	I-Premise
179	=	_	_	I-Premise
180	.002	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	Dermatology	_	_	B-Premise
184	Life	_	_	I-Premise
185	Quality	_	_	I-Premise
186	Index	_	_	I-Premise
187	(	_	_	I-Premise
188	DLQI	_	_	I-Premise
189	)	_	_	I-Premise
190	scores	_	_	I-Premise
191	were	_	_	I-Premise
192	assessed	_	_	I-Premise
193	for	_	_	I-Premise
194	each	_	_	I-Premise
195	treatment	_	_	I-Premise
196	modality	_	_	I-Premise
197	at	_	_	I-Premise
198	week	_	_	I-Premise
199	4	_	_	I-Premise
200	and	_	_	I-Premise
201	were	_	_	I-Premise
202	1.95	_	_	I-Premise
203	and	_	_	I-Premise
204	1.38	_	_	I-Premise
205	,	_	_	I-Premise
206	respectively	_	_	I-Premise
207	(	_	_	I-Premise
208	p	_	_	I-Premise
209	=	_	_	I-Premise
210	.20	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	sample	_	_	I-Premise
215	size	_	_	I-Premise
216	was	_	_	I-Premise
217	small	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	patients	_	_	I-Premise
221	applied	_	_	I-Premise
222	a	_	_	I-Premise
223	small	_	_	I-Premise
224	amount	_	_	I-Premise
225	of	_	_	I-Premise
226	imiquimod	_	_	I-Premise
227	5	_	_	I-Premise
228	%	_	_	I-Premise
229	cream	_	_	I-Premise
230	(	_	_	I-Premise
231	half	_	_	I-Premise
232	a	_	_	I-Premise
233	sachet	_	_	I-Premise
234	)	_	_	I-Premise
235	to	_	_	I-Premise
236	a	_	_	I-Premise
237	large	_	_	I-Premise
238	surface	_	_	I-Premise
239	area	_	_	I-Premise
240	.	_	_	I-Premise

241	There	_	_	B-Claim
242	was	_	_	I-Claim
243	no	_	_	I-Claim
244	statistically	_	_	I-Claim
245	significant	_	_	I-Claim
246	difference	_	_	I-Claim
247	in	_	_	I-Claim
248	treatment	_	_	I-Claim
249	response	_	_	I-Claim
250	when	_	_	I-Claim
251	the	_	_	I-Claim
252	100	_	_	I-Claim
253	%	_	_	I-Claim
254	or	_	_	I-Claim
255	75	_	_	I-Claim
256	%	_	_	I-Claim
257	clearance	_	_	I-Claim
258	rate	_	_	I-Claim
259	cutoff	_	_	I-Claim
260	was	_	_	I-Claim
261	used	_	_	I-Claim
262	,	_	_	I-Claim
263	but	_	_	B-Claim
264	our	_	_	I-Claim
265	secondary	_	_	I-Claim
266	outcome	_	_	I-Claim
267	suggests	_	_	I-Claim
268	that	_	_	I-Claim
269	two	_	_	I-Claim
270	sessions	_	_	I-Claim
271	of	_	_	I-Claim
272	ALA-PDT	_	_	I-Claim
273	is	_	_	I-Claim
274	superior	_	_	I-Claim
275	to	_	_	I-Claim
276	imiquimod	_	_	I-Claim
277	5	_	_	I-Claim
278	%	_	_	I-Claim
279	cream	_	_	I-Claim
280	for	_	_	I-Claim
281	the	_	_	I-Claim
282	treatment	_	_	I-Claim
283	of	_	_	I-Claim
284	AKs	_	_	I-Claim
285	.	_	_	I-Claim

286	There	_	_	B-Claim
287	was	_	_	I-Claim
288	no	_	_	I-Claim
289	statistically	_	_	I-Claim
290	significant	_	_	I-Claim
291	difference	_	_	I-Claim
292	in	_	_	I-Claim
293	effect	_	_	I-Claim
294	on	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	as	_	_	I-Claim
299	assessed	_	_	I-Claim
300	using	_	_	I-Claim
301	the	_	_	I-Claim
302	DLQI	_	_	I-Claim
303	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	at	_	_	O
3	investigating	_	_	O
4	the	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	tolerability	_	_	O
8	,	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QOL	_	_	O
15	)	_	_	O
16	of	_	_	O
17	gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	pegylated	_	_	O
24	liposomal	_	_	O
25	doxorubicin	_	_	O
26	(	_	_	O
27	PLD	_	_	O
28	)	_	_	O
29	in	_	_	O
30	the	_	_	O
31	salvage	_	_	O
32	treatment	_	_	O
33	of	_	_	O
34	recurrent	_	_	O
35	ovarian	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	A	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	randomized	_	_	O
42	multicenter	_	_	O
43	trial	_	_	O
44	was	_	_	O
45	planned	_	_	O
46	to	_	_	O
47	compare	_	_	O
48	GEM	_	_	O
49	(	_	_	O
50	1,000	_	_	O
51	mg/m	_	_	O
52	(	_	_	O
53	2	_	_	O
54	)	_	_	O
55	on	_	_	O
56	days	_	_	O
57	1	_	_	O
58	,	_	_	O
59	8	_	_	O
60	,	_	_	O
61	and	_	_	O
62	15	_	_	O
63	every	_	_	O
64	28	_	_	O
65	days	_	_	O
66	)	_	_	O
67	with	_	_	O
68	PLD	_	_	O
69	(	_	_	O
70	40	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	every	_	_	O
76	28	_	_	O
77	days	_	_	O
78	)	_	_	O
79	in	_	_	O
80	ovarian	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	who	_	_	O
84	experienced	_	_	O
85	treatment	_	_	O
86	failure	_	_	O
87	with	_	_	O
88	only	_	_	O
89	one	_	_	O
90	platinum/paclitaxel	_	_	O
91	regimen	_	_	O
92	and	_	_	O
93	who	_	_	O
94	experienced	_	_	O
95	recurrence	_	_	O
96	or	_	_	O
97	progression	_	_	O
98	within	_	_	O
99	12	_	_	O
100	months	_	_	O
101	after	_	_	O
102	completion	_	_	O
103	of	_	_	O
104	primary	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	One	_	_	O
108	hundred	_	_	O
109	fifty-three	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	PLD	_	_	O
116	(	_	_	O
117	n	_	_	O
118	=	_	_	O
119	76	_	_	O
120	)	_	_	O
121	or	_	_	O
122	GEM	_	_	O
123	(	_	_	O
124	n	_	_	O
125	=	_	_	O
126	77	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Treatment	_	_	O
130	arms	_	_	O
131	were	_	_	O
132	well	_	_	O
133	balanced	_	_	O
134	for	_	_	O
135	clinicopathologic	_	_	O
136	characteristics	_	_	O
137	.	_	_	O

138	Grade	_	_	O
139	3	_	_	O
140	or	_	_	O
141	4	_	_	O
142	neutropenia	_	_	O
143	was	_	_	O
144	more	_	_	O
145	frequent	_	_	O
146	in	_	_	O
147	GEM-treated	_	_	O
148	patients	_	_	O
149	versus	_	_	O
150	PLD-treated	_	_	O
151	patients	_	_	O
152	(	_	_	O
153	P	_	_	O
154	=	_	_	O
155	.007	_	_	O
156	)	_	_	O
157	.	_	_	O

158	Grade	_	_	O
159	3	_	_	O
160	or	_	_	O
161	4	_	_	O
162	palmar-plantar	_	_	O
163	erythrodysesthesia	_	_	O
164	was	_	_	O
165	documented	_	_	O
166	in	_	_	O
167	a	_	_	O
168	higher	_	_	O
169	proportion	_	_	O
170	of	_	_	O
171	PLD	_	_	O
172	patients	_	_	O
173	(	_	_	O
174	6	_	_	O
175	%	_	_	O
176	)	_	_	O
177	versus	_	_	O
178	GEM	_	_	O
179	patients	_	_	O
180	(	_	_	O
181	0	_	_	O
182	%	_	_	O
183	;	_	_	O
184	P	_	_	O
185	=	_	_	O
186	.061	_	_	O
187	)	_	_	O
188	.	_	_	O

189	The	_	_	B-Premise
190	overall	_	_	I-Premise
191	response	_	_	I-Premise
192	rate	_	_	I-Premise
193	was	_	_	I-Premise
194	16	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	PLD	_	_	I-Premise
199	arm	_	_	I-Premise
200	compared	_	_	I-Premise
201	with	_	_	I-Premise
202	29	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	GEM	_	_	I-Premise
207	arm	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.056	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	No	_	_	B-Premise
215	statistically	_	_	I-Premise
216	significant	_	_	I-Premise
217	difference	_	_	I-Premise
218	in	_	_	I-Premise
219	time	_	_	I-Premise
220	to	_	_	I-Premise
221	progression	_	_	I-Premise
222	(	_	_	I-Premise
223	TTP	_	_	I-Premise
224	)	_	_	I-Premise
225	curves	_	_	I-Premise
226	according	_	_	I-Premise
227	to	_	_	I-Premise
228	treatment	_	_	I-Premise
229	allocation	_	_	I-Premise
230	was	_	_	I-Premise
231	documented	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.411	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	However	_	_	B-Premise
239	,	_	_	I-Premise
240	a	_	_	I-Premise
241	trend	_	_	I-Premise
242	for	_	_	I-Premise
243	more	_	_	I-Premise
244	favorable	_	_	I-Premise
245	overall	_	_	I-Premise
246	survival	_	_	I-Premise
247	was	_	_	I-Premise
248	documented	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	PLD	_	_	I-Premise
252	arm	_	_	I-Premise
253	compared	_	_	I-Premise
254	with	_	_	I-Premise
255	the	_	_	I-Premise
256	GEM	_	_	I-Premise
257	arm	_	_	I-Premise
258	,	_	_	I-Premise
259	although	_	_	B-Premise
260	the	_	_	I-Premise
261	P	_	_	I-Premise
262	value	_	_	I-Premise
263	was	_	_	I-Premise
264	of	_	_	I-Premise
265	borderline	_	_	I-Premise
266	statistical	_	_	I-Premise
267	significance	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.048	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Statistically	_	_	B-Premise
275	significantly	_	_	I-Premise
276	higher	_	_	I-Premise
277	global	_	_	I-Premise
278	QOL	_	_	I-Premise
279	scores	_	_	I-Premise
280	were	_	_	I-Premise
281	found	_	_	I-Premise
282	in	_	_	I-Premise
283	PLD-treated	_	_	I-Premise
284	patients	_	_	I-Premise
285	at	_	_	I-Premise
286	the	_	_	I-Premise
287	first	_	_	I-Premise
288	and	_	_	I-Premise
289	second	_	_	I-Premise
290	postbaseline	_	_	I-Premise
291	QOL	_	_	I-Premise
292	assessments	_	_	I-Premise
293	.	_	_	I-Premise

294	GEM	_	_	B-Claim
295	does	_	_	I-Claim
296	not	_	_	I-Claim
297	provide	_	_	I-Claim
298	an	_	_	I-Claim
299	advantage	_	_	I-Claim
300	compared	_	_	I-Claim
301	with	_	_	I-Claim
302	PLD	_	_	I-Claim
303	in	_	_	I-Claim
304	terms	_	_	I-Claim
305	of	_	_	I-Claim
306	TTP	_	_	I-Claim
307	in	_	_	I-Claim
308	ovarian	_	_	I-Claim
309	cancer	_	_	I-Claim
310	patients	_	_	I-Claim
311	who	_	_	I-Claim
312	experience	_	_	I-Claim
313	recurrence	_	_	I-Claim
314	within	_	_	I-Claim
315	12	_	_	I-Claim
316	months	_	_	I-Claim
317	after	_	_	I-Claim
318	primary	_	_	I-Claim
319	treatment	_	_	I-Claim
320	but	_	_	I-Claim
321	should	_	_	I-Claim
322	be	_	_	I-Claim
323	considered	_	_	I-Claim
324	in	_	_	I-Claim
325	the	_	_	I-Claim
326	spectrum	_	_	I-Claim
327	of	_	_	I-Claim
328	drugs	_	_	I-Claim
329	to	_	_	I-Claim
330	be	_	_	I-Claim
331	possibly	_	_	I-Claim
332	used	_	_	I-Claim
333	in	_	_	I-Claim
334	the	_	_	I-Claim
335	salvage	_	_	I-Claim
336	setting	_	_	I-Claim
337	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	multicenter	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	sentinel	_	_	O
16	lymph	_	_	O
17	node	_	_	O
18	(	_	_	O
19	SLN	_	_	O
20	)	_	_	O
21	biopsy	_	_	O
22	compared	_	_	O
23	with	_	_	O
24	axillary	_	_	O
25	lymph	_	_	O
26	node	_	_	O
27	dissection	_	_	O
28	(	_	_	O
29	ALND	_	_	O
30	)	_	_	O
31	.	_	_	O

32	All	_	_	O
33	studies	_	_	O
34	on	_	_	O
35	SLN	_	_	O
36	biopsy	_	_	O
37	in	_	_	O
38	breast	_	_	O
39	cancer	_	_	O
40	report	_	_	O
41	a	_	_	O
42	variable	_	_	O
43	false	_	_	O
44	negative	_	_	O
45	rate	_	_	O
46	,	_	_	O
47	whose	_	_	O
48	prognostic	_	_	O
49	consequences	_	_	O
50	are	_	_	O
51	still	_	_	O
52	unclear	_	_	O
53	.	_	_	O

54	From	_	_	O
55	May	_	_	O
56	1999	_	_	O
57	to	_	_	O
58	December	_	_	O
59	2004	_	_	O
60	,	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	breast	_	_	O
64	cancer	_	_	O
65	<	_	_	O
66	or	_	_	O
67	=3	_	_	O
68	cm	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	assigned	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	SLN	_	_	O
75	biopsy	_	_	O
76	associated	_	_	O
77	with	_	_	O
78	ALND	_	_	O
79	(	_	_	O
80	ALND	_	_	O
81	arm	_	_	O
82	)	_	_	O
83	or	_	_	O
84	SLN	_	_	O
85	biopsy	_	_	O
86	followed	_	_	O
87	by	_	_	O
88	ALND	_	_	O
89	only	_	_	O
90	if	_	_	O
91	the	_	_	O
92	SLN	_	_	O
93	was	_	_	O
94	metastatic	_	_	O
95	(	_	_	O
96	SLN	_	_	O
97	arm	_	_	O
98	)	_	_	O
99	.	_	_	O

100	The	_	_	O
101	main	_	_	O
102	aim	_	_	O
103	was	_	_	O
104	the	_	_	O
105	comparison	_	_	O
106	of	_	_	O
107	disease-free	_	_	O
108	survival	_	_	O
109	in	_	_	O
110	the	_	_	O
111	2	_	_	O
112	arms	_	_	O
113	.	_	_	O

114	A	_	_	O
115	total	_	_	O
116	of	_	_	O
117	749	_	_	O
118	patients	_	_	O
119	were	_	_	O
120	randomized	_	_	O
121	and	_	_	O
122	697	_	_	O
123	were	_	_	O
124	available	_	_	O
125	for	_	_	O
126	analysis	_	_	O
127	.	_	_	O

128	SLNs	_	_	O
129	were	_	_	O
130	identified	_	_	O
131	in	_	_	O
132	662	_	_	O
133	of	_	_	O
134	697	_	_	O
135	patients	_	_	O
136	(	_	_	O
137	95	_	_	O
138	%	_	_	O
139	)	_	_	O
140	and	_	_	O
141	positive	_	_	O
142	SLNs	_	_	O
143	were	_	_	O
144	found	_	_	O
145	in	_	_	O
146	189	_	_	O
147	of	_	_	O
148	662	_	_	O
149	patients	_	_	O
150	(	_	_	O
151	28.5	_	_	O
152	%	_	_	O
153	)	_	_	O
154	.	_	_	O

155	In	_	_	O
156	the	_	_	O
157	ALND	_	_	O
158	group	_	_	O
159	,	_	_	O
160	positive	_	_	O
161	non-SLNs	_	_	O
162	were	_	_	O
163	found	_	_	O
164	in	_	_	O
165	18	_	_	O
166	patients	_	_	O
167	with	_	_	O
168	negative	_	_	O
169	SLN	_	_	O
170	,	_	_	O
171	giving	_	_	O
172	a	_	_	O
173	false	_	_	O
174	negative	_	_	O
175	rate	_	_	O
176	of	_	_	O
177	16.7	_	_	O
178	%	_	_	O
179	(	_	_	O
180	18	_	_	O
181	of	_	_	O
182	108	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Postoperative	_	_	B-Premise
186	side	_	_	I-Premise
187	effects	_	_	I-Premise
188	were	_	_	I-Premise
189	significantly	_	_	I-Premise
190	less	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	SLN	_	_	I-Premise
194	group	_	_	I-Premise
195	and	_	_	I-Premise
196	there	_	_	I-Premise
197	was	_	_	I-Premise
198	no	_	_	I-Premise
199	negative	_	_	I-Premise
200	impact	_	_	I-Premise
201	of	_	_	I-Premise
202	the	_	_	I-Premise
203	SLN	_	_	I-Premise
204	procedure	_	_	I-Premise
205	on	_	_	I-Premise
206	psychologic	_	_	I-Premise
207	well	_	_	I-Premise
208	being	_	_	I-Premise
209	.	_	_	I-Premise

210	At	_	_	O
211	a	_	_	O
212	median	_	_	O
213	follow-up	_	_	O
214	of	_	_	O
215	56	_	_	O
216	months	_	_	O
217	,	_	_	O
218	there	_	_	O
219	were	_	_	O
220	more	_	_	O
221	locoregional	_	_	O
222	recurrences	_	_	O
223	in	_	_	O
224	the	_	_	O
225	SLN	_	_	O
226	arm	_	_	O
227	,	_	_	O
228	and	_	_	O
229	the	_	_	O
230	5-year	_	_	O
231	disease-free	_	_	O
232	survival	_	_	O
233	was	_	_	O
234	89.9	_	_	O
235	%	_	_	O
236	in	_	_	O
237	the	_	_	O
238	ALND	_	_	O
239	arm	_	_	O
240	and	_	_	O
241	87.6	_	_	O
242	%	_	_	O
243	in	_	_	O
244	the	_	_	O
245	SLN	_	_	O
246	arm	_	_	O
247	,	_	_	O
248	with	_	_	O
249	a	_	_	O
250	difference	_	_	O
251	of	_	_	O
252	2.3	_	_	O
253	%	_	_	O
254	(	_	_	O
255	95	_	_	O
256	%	_	_	O
257	confidence	_	_	O
258	interval	_	_	O
259	:	_	_	O
260	-3.1	_	_	O
261	%	_	_	O
262	to	_	_	O
263	7.6	_	_	O
264	%	_	_	O
265	)	_	_	O
266	.	_	_	O

267	However	_	_	B-Premise
268	,	_	_	I-Premise
269	the	_	_	I-Premise
270	number	_	_	I-Premise
271	of	_	_	I-Premise
272	enrolled	_	_	I-Premise
273	patients	_	_	I-Premise
274	was	_	_	I-Premise
275	not	_	_	I-Premise
276	sufficient	_	_	I-Premise
277	to	_	_	I-Premise
278	draw	_	_	I-Premise
279	definitive	_	_	I-Premise
280	conclusions	_	_	I-Premise
281	.	_	_	I-Premise

282	SLN	_	_	B-Claim
283	biopsy	_	_	I-Claim
284	is	_	_	I-Claim
285	an	_	_	I-Claim
286	effective	_	_	I-Claim
287	and	_	_	I-Claim
288	well-tolerated	_	_	I-Claim
289	procedure	_	_	I-Claim
290	.	_	_	I-Claim

291	However	_	_	B-Claim
292	,	_	_	I-Claim
293	its	_	_	I-Claim
294	safety	_	_	I-Claim
295	should	_	_	I-Claim
296	be	_	_	I-Claim
297	confirmed	_	_	I-Claim
298	by	_	_	I-Claim
299	the	_	_	I-Claim
300	results	_	_	I-Claim
301	of	_	_	I-Claim
302	larger	_	_	I-Claim
303	randomized	_	_	I-Claim
304	trials	_	_	I-Claim
305	and	_	_	I-Claim
306	meta-analyses	_	_	I-Claim
307	.	_	_	I-Claim


0	Nocturnal	_	_	O
1	administration	_	_	O
2	of	_	_	O
3	branched-chain	_	_	O
4	amino	_	_	O
5	acid	_	_	O
6	(	_	_	O
7	BCAA	_	_	O
8	)	_	_	O
9	granules	_	_	O
10	improves	_	_	O
11	serum	_	_	O
12	albumin	_	_	O
13	levels	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	cirrhosis	_	_	O
18	.	_	_	O

19	However	_	_	O
20	,	_	_	O
21	it	_	_	O
22	is	_	_	O
23	unclear	_	_	O
24	whether	_	_	O
25	or	_	_	O
26	not	_	_	O
27	this	_	_	O
28	administration	_	_	O
29	method	_	_	O
30	can	_	_	O
31	improve	_	_	O
32	the	_	_	O
33	patients	_	_	O
34	'	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QOL	_	_	O
40	)	_	_	O
41	.	_	_	O

42	In	_	_	O
43	this	_	_	O
44	study	_	_	O
45	,	_	_	O
46	we	_	_	O
47	aimed	_	_	O
48	to	_	_	O
49	investigate	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	BCAA	_	_	O
54	granules	_	_	O
55	,	_	_	O
56	given	_	_	O
57	nocturnally	_	_	O
58	,	_	_	O
59	in	_	_	O
60	improving	_	_	O
61	QOL	_	_	O
62	in	_	_	O
63	these	_	_	O
64	patients	_	_	O
65	.	_	_	O

66	We	_	_	O
67	performed	_	_	O
68	a	_	_	O
69	multicenter	_	_	O
70	,	_	_	O
71	randomized	_	_	O
72	controlled	_	_	O
73	trial	_	_	O
74	examining	_	_	O
75	the	_	_	O
76	comparative	_	_	O
77	effects	_	_	O
78	of	_	_	O
79	BCAA	_	_	O
80	granules	_	_	O
81	given	_	_	O
82	orally	_	_	O
83	for	_	_	O
84	3	_	_	O
85	months	_	_	O
86	with	_	_	O
87	daytime	_	_	O
88	or	_	_	O
89	nocturnal	_	_	O
90	administration	_	_	O
91	in	_	_	O
92	patients	_	_	O
93	with	_	_	O
94	compensated	_	_	O
95	cirrhosis	_	_	O
96	.	_	_	O

97	Health-related	_	_	O
98	QOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	by	_	_	O
102	a	_	_	O
103	Japanese	_	_	O
104	version	_	_	O
105	of	_	_	O
106	the	_	_	O
107	questionnaire	_	_	O
108	on	_	_	O
109	subjective	_	_	O
110	and	_	_	O
111	objective	_	_	O
112	symptoms	_	_	O
113	,	_	_	O
114	and	_	_	O
115	the	_	_	O
116	Short	_	_	O
117	Form-8	_	_	O
118	(	_	_	O
119	SF-8	_	_	O
120	)	_	_	O
121	questionnaire	_	_	O
122	.	_	_	O

123	Twenty-one	_	_	O
124	patients	_	_	O
125	received	_	_	O
126	BCAA	_	_	O
127	granules	_	_	O
128	three	_	_	O
129	times	_	_	O
130	a	_	_	O
131	day	_	_	O
132	(	_	_	O
133	one	_	_	O
134	sachet	_	_	O
135	after	_	_	O
136	each	_	_	O
137	meal	_	_	O
138	:	_	_	O
139	the	_	_	O
140	daytime	_	_	O
141	group	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	16	_	_	O
146	patients	_	_	O
147	received	_	_	O
148	the	_	_	O
149	granules	_	_	O
150	twice	_	_	O
151	a	_	_	O
152	day	_	_	O
153	(	_	_	O
154	one	_	_	O
155	sachet	_	_	O
156	after	_	_	O
157	breakfast	_	_	O
158	,	_	_	O
159	and	_	_	O
160	two	_	_	O
161	sachets	_	_	O
162	before	_	_	O
163	bedtime	_	_	O
164	:	_	_	O
165	the	_	_	O
166	nocturnal	_	_	O
167	group	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Baseline	_	_	O
171	characteristics	_	_	O
172	did	_	_	O
173	not	_	_	O
174	differ	_	_	O
175	between	_	_	O
176	the	_	_	O
177	groups	_	_	O
178	(	_	_	O
179	whole	_	_	O
180	cohort	_	_	O
181	:	_	_	O
182	Child-Pugh	_	_	O
183	grade	_	_	O
184	A/B	_	_	O
185	,	_	_	O
186	21/16	_	_	O
187	;	_	_	O
188	mean	_	_	O
189	age	_	_	O
190	,	_	_	O
191	68.2	_	_	O
192	years	_	_	O
193	)	_	_	O
194	.	_	_	O

195	There	_	_	B-Premise
196	was	_	_	I-Premise
197	no	_	_	I-Premise
198	significant	_	_	I-Premise
199	difference	_	_	I-Premise
200	in	_	_	I-Premise
201	any	_	_	I-Premise
202	of	_	_	I-Premise
203	the	_	_	I-Premise
204	subjects	_	_	I-Premise
205	revealed	_	_	I-Premise
206	by	_	_	I-Premise
207	the	_	_	I-Premise
208	questionnaire	_	_	I-Premise
209	regarding	_	_	I-Premise
210	subjective	_	_	I-Premise
211	or	_	_	I-Premise
212	objective	_	_	I-Premise
213	symptoms	_	_	I-Premise
214	,	_	_	I-Premise
215	or	_	_	I-Premise
216	by	_	_	I-Premise
217	the	_	_	I-Premise
218	SF-8	_	_	I-Premise
219	between	_	_	I-Premise
220	the	_	_	I-Premise
221	daytime	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	the	_	_	I-Premise
225	nocturnal	_	_	I-Premise
226	group	_	_	I-Premise
227	after	_	_	I-Premise
228	3	_	_	I-Premise
229	months	_	_	I-Premise
230	of	_	_	I-Premise
231	treatment	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	daytime	_	_	I-Premise
235	group	_	_	I-Premise
236	showed	_	_	I-Premise
237	a	_	_	I-Premise
238	significant	_	_	I-Premise
239	effect	_	_	I-Premise
240	on	_	_	I-Premise
241	general	_	_	I-Premise
242	health	_	_	I-Premise
243	,	_	_	I-Premise
244	vitality	_	_	I-Premise
245	,	_	_	I-Premise
246	social	_	_	I-Premise
247	functioning	_	_	I-Premise
248	,	_	_	I-Premise
249	mental	_	_	I-Premise
250	health	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	role	_	_	I-Premise
254	emotional	_	_	I-Premise
255	as	_	_	I-Premise
256	revealed	_	_	I-Premise
257	on	_	_	I-Premise
258	the	_	_	I-Premise
259	SF-8	_	_	I-Premise
260	.	_	_	I-Premise

261	Conversely	_	_	B-Premise
262	,	_	_	I-Premise
263	the	_	_	I-Premise
264	nocturnal	_	_	I-Premise
265	group	_	_	I-Premise
266	exhibited	_	_	I-Premise
267	a	_	_	I-Premise
268	significant	_	_	I-Premise
269	decrease	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	occurrence	_	_	I-Premise
273	of	_	_	I-Premise
274	muscle	_	_	I-Premise
275	cramps	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	legs	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	0.014	_	_	I-Premise
283	)	_	_	I-Premise
284	and	_	_	I-Premise
285	significantly	_	_	I-Premise
286	improved	_	_	I-Premise
287	Fisher	_	_	I-Premise
288	's	_	_	I-Premise
289	ratio	_	_	I-Premise
290	after	_	_	I-Premise
291	3	_	_	I-Premise
292	months	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	0.04	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Nocturnal	_	_	B-Claim
300	administration	_	_	I-Claim
301	of	_	_	I-Claim
302	BCAA	_	_	I-Claim
303	granules	_	_	I-Claim
304	in	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	cirrhosis	_	_	I-Claim
308	reduced	_	_	I-Claim
309	the	_	_	I-Claim
310	occurrence	_	_	I-Claim
311	of	_	_	I-Claim
312	muscle	_	_	I-Claim
313	cramps	_	_	I-Claim
314	in	_	_	I-Claim
315	the	_	_	I-Claim
316	leg	_	_	I-Claim
317	but	_	_	I-Claim
318	did	_	_	I-Claim
319	not	_	_	I-Claim
320	improve	_	_	I-Claim
321	the	_	_	I-Claim
322	patients	_	_	I-Claim
323	'	_	_	I-Claim
324	QOL	_	_	I-Claim
325	.	_	_	I-Claim


0	Treatment	_	_	O
1	of	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	advanced	_	_	O
5	or	_	_	O
6	metastatic	_	_	O
7	esophagogastric	_	_	O
8	adenocarcinoma	_	_	O
9	should	_	_	O
10	not	_	_	O
11	only	_	_	O
12	prolong	_	_	O
13	life	_	_	O
14	but	_	_	O
15	also	_	_	O
16	provide	_	_	O
17	relief	_	_	O
18	of	_	_	O
19	symptoms	_	_	O
20	and	_	_	O
21	improve	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	(	_	_	O
26	QOL	_	_	O
27	)	_	_	O
28	.	_	_	O

29	Esophagogastric	_	_	O
30	adenocarcinoma	_	_	O
31	mainly	_	_	O
32	occurs	_	_	O
33	in	_	_	O
34	elderly	_	_	O
35	patients	_	_	O
36	,	_	_	O
37	but	_	_	O
38	they	_	_	O
39	are	_	_	O
40	underrepresented	_	_	O
41	in	_	_	O
42	most	_	_	O
43	clinical	_	_	O
44	trials	_	_	O
45	and	_	_	O
46	often	_	_	O
47	do	_	_	O
48	not	_	_	O
49	receive	_	_	O
50	effective	_	_	O
51	combination	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	most	_	_	O
55	probably	_	_	O
56	for	_	_	O
57	fear	_	_	O
58	of	_	_	O
59	intolerance	_	_	O
60	.	_	_	O

61	Using	_	_	O
62	validated	_	_	O
63	instruments	_	_	O
64	,	_	_	O
65	we	_	_	O
66	prospectively	_	_	O
67	assessed	_	_	O
68	QOL	_	_	O
69	within	_	_	O
70	the	_	_	O
71	randomized	_	_	O
72	FLOT65+	_	_	O
73	phase	_	_	O
74	II	_	_	O
75	trial	_	_	O
76	.	_	_	O

77	Within	_	_	O
78	the	_	_	O
79	FLOT65+	_	_	O
80	trial	_	_	O
81	,	_	_	O
82	a	_	_	O
83	total	_	_	O
84	of	_	_	O
85	143	_	_	O
86	patients	_	_	O
87	aged	_	_	O
88	â‰¥65	_	_	O
89	years	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	allocated	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	biweekly	_	_	O
96	oxaliplatin	_	_	O
97	plus	_	_	O
98	5-fluorouracil	_	_	O
99	(	_	_	O
100	5-FU	_	_	O
101	)	_	_	O
102	continuous	_	_	O
103	infusion	_	_	O
104	and	_	_	O
105	folinic	_	_	O
106	acid	_	_	O
107	(	_	_	O
108	FLO	_	_	O
109	)	_	_	O
110	or	_	_	O
111	the	_	_	O
112	same	_	_	O
113	regimen	_	_	O
114	in	_	_	O
115	combination	_	_	O
116	with	_	_	O
117	docetaxel	_	_	O
118	50	_	_	O
119	mg/m	_	_	O
120	(	_	_	O
121	2	_	_	O
122	)	_	_	O
123	(	_	_	O
124	FLOT	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	European	_	_	O
129	Organisation	_	_	O
130	for	_	_	O
131	Research	_	_	O
132	and	_	_	O
133	Treatment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	C30	_	_	O
141	(	_	_	O
142	EORTC	_	_	O
143	QLQ-C30	_	_	O
144	)	_	_	O
145	and	_	_	O
146	the	_	_	O
147	gastric	_	_	O
148	module	_	_	O
149	STO22	_	_	O
150	were	_	_	O
151	administered	_	_	O
152	every	_	_	O
153	8	_	_	O
154	weeks	_	_	O
155	until	_	_	O
156	progression	_	_	O
157	.	_	_	O

158	Time	_	_	O
159	to	_	_	O
160	definitive	_	_	O
161	deterioration	_	_	O
162	of	_	_	O
163	QOL	_	_	O
164	parameters	_	_	O
165	was	_	_	O
166	analyzed	_	_	O
167	and	_	_	O
168	compared	_	_	O
169	within	_	_	O
170	the	_	_	O
171	treatment	_	_	O
172	arms	_	_	O
173	.	_	_	O

174	The	_	_	O
175	median	_	_	O
176	age	_	_	O
177	of	_	_	O
178	patients	_	_	O
179	was	_	_	O
180	70	_	_	O
181	years	_	_	O
182	.	_	_	O

183	Patients	_	_	B-Premise
184	receiving	_	_	I-Premise
185	FLOT	_	_	I-Premise
186	exhibited	_	_	I-Premise
187	higher	_	_	I-Premise
188	response	_	_	I-Premise
189	rates	_	_	I-Premise
190	and	_	_	I-Premise
191	had	_	_	I-Premise
192	improved	_	_	I-Premise
193	disease-free	_	_	I-Premise
194	and	_	_	I-Premise
195	progression-free	_	_	I-Premise
196	survival	_	_	I-Premise
197	(	_	_	I-Premise
198	PFS	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	O
202	proportions	_	_	O
203	of	_	_	O
204	patients	_	_	O
205	with	_	_	O
206	evaluable	_	_	O
207	baseline	_	_	O
208	EORTC	_	_	O
209	QLQ-C30	_	_	O
210	and	_	_	O
211	STO22	_	_	O
212	questionnaires	_	_	O
213	were	_	_	O
214	balanced	_	_	O
215	(	_	_	O
216	83	_	_	O
217	%	_	_	O
218	in	_	_	O
219	FLOT	_	_	O
220	and	_	_	O
221	89	_	_	O
222	%	_	_	O
223	in	_	_	O
224	FLO	_	_	O
225	)	_	_	O
226	.	_	_	O

227	Considering	_	_	O
228	evaluable	_	_	O
229	patients	_	_	O
230	with	_	_	O
231	assessable	_	_	O
232	questionnaires	_	_	O
233	(	_	_	O
234	n	_	_	O
235	=	_	_	O
236	123	_	_	O
237	)	_	_	O
238	,	_	_	O
239	neither	_	_	O
240	functioning	_	_	O
241	nor	_	_	O
242	symptom	_	_	O
243	parameters	_	_	O
244	differed	_	_	O
245	significantly	_	_	O
246	in	_	_	O
247	favor	_	_	O
248	of	_	_	O
249	one	_	_	O
250	of	_	_	O
251	the	_	_	O
252	two	_	_	O
253	treatment	_	_	O
254	groups	_	_	O
255	.	_	_	O

256	Particularly	_	_	O
257	,	_	_	O
258	there	_	_	B-Premise
259	was	_	_	I-Premise
260	no	_	_	I-Premise
261	significant	_	_	I-Premise
262	difference	_	_	I-Premise
263	regarding	_	_	I-Premise
264	time	_	_	I-Premise
265	to	_	_	I-Premise
266	definitive	_	_	I-Premise
267	deterioration	_	_	I-Premise
268	of	_	_	I-Premise
269	global	_	_	I-Premise
270	health	_	_	I-Premise
271	status/quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	from	_	_	I-Premise
275	baseline	_	_	I-Premise
276	(	_	_	I-Premise
277	primary	_	_	I-Premise
278	endpoint	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Notably	_	_	O
282	,	_	_	O
283	patients	_	_	B-Premise
284	receiving	_	_	I-Premise
285	FLO	_	_	I-Premise
286	or	_	_	I-Premise
287	FLOT	_	_	I-Premise
288	as	_	_	I-Premise
289	palliative	_	_	I-Premise
290	treatment	_	_	I-Premise
291	(	_	_	I-Premise
292	n	_	_	I-Premise
293	=	_	_	I-Premise
294	98	_	_	I-Premise
295	)	_	_	I-Premise
296	achieved	_	_	I-Premise
297	comparable	_	_	I-Premise
298	QOL	_	_	I-Premise
299	results	_	_	I-Premise
300	.	_	_	I-Premise

301	Although	_	_	B-Premise
302	toxicity	_	_	I-Premise
303	was	_	_	I-Premise
304	higher	_	_	I-Premise
305	in	_	_	I-Premise
306	patients	_	_	I-Premise
307	receiving	_	_	I-Premise
308	FLOT	_	_	I-Premise
309	,	_	_	I-Premise
310	no	_	_	B-Premise
311	negative	_	_	I-Premise
312	impact	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	addition	_	_	I-Premise
316	of	_	_	I-Premise
317	docetaxel	_	_	I-Premise
318	on	_	_	I-Premise
319	QOL	_	_	I-Premise
320	parameters	_	_	I-Premise
321	could	_	_	I-Premise
322	be	_	_	I-Premise
323	demonstrated	_	_	I-Premise
324	.	_	_	I-Premise

325	Thus	_	_	O
326	,	_	_	O
327	elderly	_	_	B-Claim
328	patients	_	_	I-Claim
329	in	_	_	I-Claim
330	need	_	_	I-Claim
331	of	_	_	I-Claim
332	intensified	_	_	I-Claim
333	chemotherapy	_	_	I-Claim
334	may	_	_	I-Claim
335	receive	_	_	I-Claim
336	FLOT	_	_	I-Claim
337	without	_	_	I-Claim
338	compromising	_	_	I-Claim
339	patient-reported	_	_	I-Claim
340	outcome	_	_	I-Claim
341	parameters	_	_	I-Claim
342	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	toxicities	_	_	O
4	,	_	_	O
5	tumor	_	_	O
6	control	_	_	O
7	,	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	nasopharyngeal	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NPC	_	_	O
19	)	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	sequential	_	_	O
24	neoadjuvant	_	_	O
25	chemotherapy	_	_	O
26	followed	_	_	O
27	by	_	_	O
28	concurrent	_	_	O
29	cisplatin-radiotherapy	_	_	O
30	(	_	_	O
31	CRT	_	_	O
32	)	_	_	O
33	or	_	_	O
34	CRT	_	_	O
35	alone	_	_	O
36	.	_	_	O

37	Previously	_	_	O
38	untreated	_	_	O
39	stage	_	_	O
40	III	_	_	O
41	to	_	_	O
42	IVB	_	_	O
43	NPC	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	(	_	_	O
49	1	_	_	O
50	)	_	_	O
51	neoadjuvant	_	_	O
52	docetaxel	_	_	O
53	75	_	_	O
54	mg/m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	and	_	_	O
59	cisplatin	_	_	O
60	75	_	_	O
61	mg/m	_	_	O
62	(	_	_	O
63	2	_	_	O
64	)	_	_	O
65	every	_	_	O
66	3	_	_	O
67	weeks	_	_	O
68	for	_	_	O
69	two	_	_	O
70	cycles	_	_	O
71	,	_	_	O
72	followed	_	_	O
73	by	_	_	O
74	cisplatin	_	_	O
75	40	_	_	O
76	mg/m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	/wk	_	_	O
81	concurrent	_	_	O
82	with	_	_	O
83	radiotherapy	_	_	O
84	,	_	_	O
85	or	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	CRT	_	_	O
90	alone	_	_	O
91	.	_	_	O

92	Planned	_	_	O
93	accrual	_	_	O
94	was	_	_	O
95	30	_	_	O
96	patients	_	_	O
97	per	_	_	O
98	arm	_	_	O
99	to	_	_	O
100	detect	_	_	O
101	20	_	_	O
102	%	_	_	O
103	difference	_	_	O
104	of	_	_	O
105	toxicities	_	_	O
106	based	_	_	O
107	on	_	_	O
108	95	_	_	O
109	%	_	_	O
110	CIs	_	_	O
111	.	_	_	O

112	From	_	_	O
113	November	_	_	O
114	2002	_	_	O
115	to	_	_	O
116	November	_	_	O
117	2004	_	_	O
118	,	_	_	O
119	65	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	randomly	_	_	O
124	assigned	_	_	O
125	to	_	_	O
126	neoadjuvant	_	_	O
127	chemotherapy	_	_	O
128	followed	_	_	O
129	by	_	_	O
130	CRT	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	34	_	_	O
135	)	_	_	O
136	or	_	_	O
137	CRT	_	_	O
138	alone	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	31	_	_	O
143	)	_	_	O
144	.	_	_	O

145	There	_	_	B-Premise
146	was	_	_	I-Premise
147	a	_	_	I-Premise
148	high	_	_	I-Premise
149	rate	_	_	I-Premise
150	of	_	_	I-Premise
151	grade	_	_	I-Premise
152	3/4	_	_	I-Premise
153	neutropenia	_	_	I-Premise
154	(	_	_	I-Premise
155	97	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	but	_	_	I-Premise
159	not	_	_	I-Premise
160	neutropenic	_	_	I-Premise
161	fever	_	_	I-Premise
162	(	_	_	I-Premise
163	12	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	during	_	_	I-Premise
167	neoadjuvant	_	_	I-Premise
168	chemotherapy	_	_	I-Premise
169	.	_	_	I-Premise

170	No	_	_	B-Premise
171	significant	_	_	I-Premise
172	differences	_	_	I-Premise
173	in	_	_	I-Premise
174	rates	_	_	I-Premise
175	of	_	_	I-Premise
176	acute	_	_	I-Premise
177	toxicities	_	_	I-Premise
178	were	_	_	I-Premise
179	observed	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	two	_	_	I-Premise
183	arms	_	_	I-Premise
184	during	_	_	I-Premise
185	CRT	_	_	I-Premise
186	.	_	_	I-Premise

187	Dose	_	_	B-Premise
188	intensities	_	_	I-Premise
189	of	_	_	I-Premise
190	concurrent	_	_	I-Premise
191	cisplatin	_	_	I-Premise
192	,	_	_	I-Premise
193	late	_	_	I-Premise
194	RT	_	_	I-Premise
195	toxicities	_	_	I-Premise
196	and	_	_	I-Premise
197	quality	_	_	I-Premise
198	of	_	_	I-Premise
199	life	_	_	I-Premise
200	scores	_	_	I-Premise
201	were	_	_	I-Premise
202	comparable	_	_	I-Premise
203	in	_	_	I-Premise
204	both	_	_	I-Premise
205	arms	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	B-Premise
208	3-year	_	_	I-Premise
209	progression-free	_	_	I-Premise
210	survival	_	_	I-Premise
211	for	_	_	I-Premise
212	neoadjuvant	_	_	I-Premise
213	versus	_	_	I-Premise
214	control	_	_	I-Premise
215	arm	_	_	I-Premise
216	was	_	_	I-Premise
217	88.2	_	_	I-Premise
218	%	_	_	I-Premise
219	and	_	_	I-Premise
220	59.5	_	_	I-Premise
221	%	_	_	I-Premise
222	(	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	=	_	_	I-Premise
226	0.49	_	_	I-Premise
227	;	_	_	I-Premise
228	95	_	_	I-Premise
229	%	_	_	I-Premise
230	CI	_	_	I-Premise
231	,	_	_	I-Premise
232	0.20	_	_	I-Premise
233	to	_	_	I-Premise
234	1.19	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.12	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	3-year	_	_	I-Premise
243	overall	_	_	I-Premise
244	survival	_	_	I-Premise
245	for	_	_	I-Premise
246	neoadjuvant	_	_	I-Premise
247	versus	_	_	I-Premise
248	control	_	_	I-Premise
249	arm	_	_	I-Premise
250	was	_	_	I-Premise
251	94.1	_	_	I-Premise
252	%	_	_	I-Premise
253	and	_	_	I-Premise
254	67.7	_	_	I-Premise
255	%	_	_	I-Premise
256	(	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	=	_	_	I-Premise
260	0.24	_	_	I-Premise
261	;	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	,	_	_	I-Premise
266	0.078	_	_	I-Premise
267	to	_	_	I-Premise
268	0.73	_	_	I-Premise
269	;	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.012	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Neoadjuvant	_	_	B-Claim
276	docetaxel-cisplatin	_	_	I-Claim
277	followed	_	_	I-Claim
278	by	_	_	I-Claim
279	CRT	_	_	I-Claim
280	was	_	_	I-Claim
281	well	_	_	I-Claim
282	tolerated	_	_	I-Claim
283	with	_	_	I-Claim
284	a	_	_	I-Claim
285	manageable	_	_	I-Claim
286	toxicity	_	_	I-Claim
287	profile	_	_	I-Claim
288	that	_	_	I-Claim
289	allowed	_	_	I-Claim
290	subsequent	_	_	I-Claim
291	delivery	_	_	I-Claim
292	of	_	_	I-Claim
293	full-dose	_	_	I-Claim
294	CRT	_	_	I-Claim
295	.	_	_	I-Claim

296	Preliminary	_	_	B-Claim
297	results	_	_	I-Claim
298	suggested	_	_	I-Claim
299	a	_	_	I-Claim
300	positive	_	_	I-Claim
301	impact	_	_	I-Claim
302	on	_	_	I-Claim
303	survival	_	_	I-Claim
304	.	_	_	I-Claim

305	A	_	_	O
306	phase	_	_	O
307	III	_	_	O
308	study	_	_	O
309	to	_	_	O
310	definitively	_	_	O
311	test	_	_	O
312	this	_	_	O
313	neoadjuvant-concurrent	_	_	O
314	strategy	_	_	O
315	is	_	_	O
316	warranted	_	_	O
317	.	_	_	O


0	Fatigue	_	_	O
1	is	_	_	O
2	a	_	_	O
3	frequent	_	_	O
4	problem	_	_	O
5	after	_	_	O
6	surgical	_	_	O
7	treatment	_	_	O
8	of	_	_	O
9	solid	_	_	O
10	tumours	_	_	O
11	.	_	_	O

12	Aerobic	_	_	B-Claim
13	exercise	_	_	I-Claim
14	and	_	_	I-Claim
15	psychosocial	_	_	I-Claim
16	interventions	_	_	I-Claim
17	have	_	_	I-Claim
18	been	_	_	I-Claim
19	shown	_	_	I-Claim
20	to	_	_	I-Claim
21	reduce	_	_	I-Claim
22	the	_	_	I-Claim
23	severity	_	_	I-Claim
24	of	_	_	I-Claim
25	this	_	_	I-Claim
26	symptom	_	_	I-Claim
27	in	_	_	I-Claim
28	cancer	_	_	I-Claim
29	patients	_	_	I-Claim
30	.	_	_	I-Claim

31	Therefore	_	_	O
32	,	_	_	O
33	we	_	_	O
34	compared	_	_	O
35	the	_	_	O
36	effect	_	_	O
37	of	_	_	O
38	the	_	_	O
39	two	_	_	O
40	therapies	_	_	O
41	on	_	_	O
42	fatigue	_	_	O
43	in	_	_	O
44	a	_	_	O
45	randomised	_	_	O
46	controlled	_	_	O
47	study	_	_	O
48	.	_	_	O

49	Seventy-two	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	underwent	_	_	O
53	surgery	_	_	O
54	for	_	_	O
55	lung	_	_	O
56	(	_	_	O
57	n=27	_	_	O
58	)	_	_	O
59	or	_	_	O
60	gastrointestinal	_	_	O
61	tumours	_	_	O
62	(	_	_	O
63	n=42	_	_	O
64	)	_	_	O
65	were	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	an	_	_	O
69	aerobic	_	_	O
70	exercise	_	_	O
71	group	_	_	O
72	(	_	_	O
73	stationary	_	_	O
74	biking	_	_	O
75	30	_	_	O
76	min	_	_	O
77	five	_	_	O
78	times	_	_	O
79	weekly	_	_	O
80	)	_	_	O
81	or	_	_	O
82	a	_	_	O
83	progressive	_	_	O
84	relaxation	_	_	O
85	training	_	_	O
86	group	_	_	O
87	(	_	_	O
88	45	_	_	O
89	min	_	_	O
90	three	_	_	O
91	times	_	_	O
92	per	_	_	O
93	week	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Both	_	_	O
97	interventions	_	_	O
98	were	_	_	O
99	carried	_	_	O
100	out	_	_	O
101	for	_	_	O
102	3	_	_	O
103	weeks	_	_	O
104	.	_	_	O

105	At	_	_	O
106	the	_	_	O
107	beginning	_	_	O
108	and	_	_	O
109	the	_	_	O
110	end	_	_	O
111	of	_	_	O
112	the	_	_	O
113	study	_	_	O
114	,	_	_	O
115	we	_	_	O
116	evaluated	_	_	O
117	physical	_	_	O
118	,	_	_	O
119	cognitive	_	_	O
120	and	_	_	O
121	emotional	_	_	O
122	status	_	_	O
123	and	_	_	O
124	somatic	_	_	O
125	complaints	_	_	O
126	with	_	_	O
127	the	_	_	O
128	European	_	_	O
129	Organization	_	_	O
130	for	_	_	O
131	Research	_	_	O
132	and	_	_	O
133	Treatment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	Core	_	_	O
141	Module	_	_	O
142	(	_	_	O
143	EORTC-QLQ-30	_	_	O
144	)	_	_	O
145	questionnaire	_	_	O
146	,	_	_	O
147	and	_	_	O
148	maximal	_	_	O
149	physical	_	_	O
150	performance	_	_	O
151	with	_	_	O
152	an	_	_	O
153	ergometric	_	_	O
154	stress	_	_	O
155	test	_	_	O
156	.	_	_	O

157	Physical	_	_	B-Premise
158	performance	_	_	I-Premise
159	of	_	_	I-Premise
160	the	_	_	I-Premise
161	training	_	_	I-Premise
162	group	_	_	I-Premise
163	improved	_	_	I-Premise
164	significantly	_	_	I-Premise
165	during	_	_	I-Premise
166	the	_	_	I-Premise
167	programme	_	_	I-Premise
168	(	_	_	I-Premise
169	9.4+/-20	_	_	I-Premise
170	watts	_	_	I-Premise
171	,	_	_	I-Premise
172	p=0.01	_	_	I-Premise
173	)	_	_	I-Premise
174	but	_	_	I-Premise
175	remained	_	_	I-Premise
176	unchanged	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	relaxation	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	1.5+/-14.8	_	_	I-Premise
183	watts	_	_	I-Premise
184	,	_	_	I-Premise
185	p=0.37	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	Fatigue	_	_	B-Premise
189	and	_	_	I-Premise
190	global	_	_	I-Premise
191	health	_	_	I-Premise
192	scores	_	_	I-Premise
193	improved	_	_	I-Premise
194	in	_	_	I-Premise
195	both	_	_	I-Premise
196	groups	_	_	I-Premise
197	during	_	_	I-Premise
198	the	_	_	I-Premise
199	intervention	_	_	I-Premise
200	(	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	:	_	_	I-Premise
203	training	_	_	I-Premise
204	group	_	_	I-Premise
205	21	_	_	I-Premise
206	%	_	_	I-Premise
207	,	_	_	I-Premise
208	relaxation	_	_	I-Premise
209	group	_	_	I-Premise
210	19	_	_	I-Premise
211	%	_	_	I-Premise
212	;	_	_	I-Premise
213	global	_	_	I-Premise
214	health	_	_	I-Premise
215	of	_	_	I-Premise
216	both	_	_	I-Premise
217	groups	_	_	I-Premise
218	19	_	_	I-Premise
219	%	_	_	I-Premise
220	,	_	_	I-Premise
221	p	_	_	I-Premise
222	for	_	_	I-Premise
223	all	_	_	I-Premise
224	<	_	_	I-Premise
225	or	_	_	I-Premise
226	=0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	;	_	_	I-Premise
229	however	_	_	B-Premise
230	,	_	_	I-Premise
231	there	_	_	I-Premise
232	was	_	_	I-Premise
233	no	_	_	I-Premise
234	significant	_	_	I-Premise
235	difference	_	_	I-Premise
236	between	_	_	I-Premise
237	changes	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	scores	_	_	I-Premise
241	of	_	_	I-Premise
242	both	_	_	I-Premise
243	groups	_	_	I-Premise
244	(	_	_	I-Premise
245	p=0.67	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	We	_	_	B-Claim
249	conclude	_	_	I-Claim
250	that	_	_	I-Claim
251	a	_	_	I-Claim
252	structured	_	_	I-Claim
253	aerobic	_	_	I-Claim
254	training	_	_	I-Claim
255	programme	_	_	I-Claim
256	improves	_	_	I-Claim
257	the	_	_	I-Claim
258	physical	_	_	I-Claim
259	performance	_	_	I-Claim
260	of	_	_	I-Claim
261	patients	_	_	I-Claim
262	recovering	_	_	I-Claim
263	from	_	_	I-Claim
264	surgery	_	_	I-Claim
265	for	_	_	I-Claim
266	solid	_	_	I-Claim
267	tumours	_	_	I-Claim
268	.	_	_	I-Claim

269	However	_	_	B-Claim
270	,	_	_	I-Claim
271	exercise	_	_	I-Claim
272	is	_	_	I-Claim
273	not	_	_	I-Claim
274	better	_	_	I-Claim
275	than	_	_	I-Claim
276	progressive	_	_	I-Claim
277	relaxation	_	_	I-Claim
278	training	_	_	I-Claim
279	for	_	_	I-Claim
280	the	_	_	I-Claim
281	treatment	_	_	I-Claim
282	of	_	_	I-Claim
283	fatigue	_	_	I-Claim
284	in	_	_	I-Claim
285	this	_	_	I-Claim
286	setting	_	_	I-Claim
287	.	_	_	I-Claim


0	The	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	controlled	_	_	O
4	BOLERO-2	_	_	O
5	(	_	_	O
6	Breast	_	_	O
7	Cancer	_	_	O
8	Trials	_	_	O
9	of	_	_	O
10	Oral	_	_	O
11	Everolimus	_	_	O
12	)	_	_	O
13	trial	_	_	O
14	demonstrated	_	_	O
15	significantly	_	_	O
16	improved	_	_	O
17	progression-free	_	_	O
18	survival	_	_	O
19	with	_	_	O
20	the	_	_	O
21	use	_	_	O
22	of	_	_	O
23	everolimus	_	_	O
24	plus	_	_	O
25	exemestane	_	_	O
26	(	_	_	O
27	EVE	_	_	O
28	+	_	_	O
29	EXE	_	_	O
30	)	_	_	O
31	versus	_	_	O
32	placebo	_	_	O
33	plus	_	_	O
34	exemestane	_	_	O
35	(	_	_	O
36	PBO	_	_	O
37	+	_	_	O
38	EXE	_	_	O
39	)	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	advanced	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	who	_	_	O
47	developed	_	_	O
48	disease	_	_	O
49	progression	_	_	O
50	after	_	_	O
51	treatment	_	_	O
52	with	_	_	O
53	nonsteroidal	_	_	O
54	aromatase	_	_	O
55	inhibitors	_	_	O
56	.	_	_	O

57	This	_	_	O
58	analysis	_	_	O
59	investigated	_	_	O
60	the	_	_	O
61	treatment	_	_	O
62	effects	_	_	O
63	on	_	_	O
64	health-related	_	_	O
65	quality	_	_	O
66	of	_	_	O
67	life	_	_	O
68	(	_	_	O
69	HRQOL	_	_	O
70	)	_	_	O
71	.	_	_	O

72	Using	_	_	O
73	the	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	Quality	_	_	O
83	of	_	_	O
84	Life	_	_	O
85	Questionnaire-Core	_	_	O
86	30	_	_	O
87	(	_	_	O
88	EORTC	_	_	O
89	QLQ-C30	_	_	O
90	)	_	_	O
91	questionnaire	_	_	O
92	,	_	_	O
93	HRQOL	_	_	O
94	was	_	_	O
95	assessed	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	every	_	_	O
100	6	_	_	O
101	weeks	_	_	O
102	thereafter	_	_	O
103	until	_	_	O
104	disease	_	_	O
105	progression	_	_	O
106	and/or	_	_	O
107	treatment	_	_	O
108	discontinuation	_	_	O
109	.	_	_	O

110	The	_	_	O
111	30	_	_	O
112	items	_	_	O
113	in	_	_	O
114	15	_	_	O
115	subscales	_	_	O
116	of	_	_	O
117	the	_	_	O
118	QLQ-C30	_	_	O
119	include	_	_	O
120	global	_	_	O
121	health	_	_	O
122	status	_	_	O
123	wherein	_	_	O
124	higher	_	_	O
125	scores	_	_	O
126	(	_	_	O
127	range	_	_	O
128	,	_	_	O
129	0-100	_	_	O
130	)	_	_	O
131	indicate	_	_	O
132	better	_	_	O
133	HRQOL	_	_	O
134	.	_	_	O

135	This	_	_	O
136	analysis	_	_	O
137	included	_	_	O
138	a	_	_	O
139	protocol-specified	_	_	O
140	time	_	_	O
141	to	_	_	O
142	definitive	_	_	O
143	deterioration	_	_	O
144	(	_	_	O
145	TDD	_	_	O
146	)	_	_	O
147	analysis	_	_	O
148	at	_	_	O
149	a	_	_	O
150	5	_	_	O
151	%	_	_	O
152	decrease	_	_	O
153	in	_	_	O
154	HRQOL	_	_	O
155	versus	_	_	O
156	baseline	_	_	O
157	,	_	_	O
158	with	_	_	O
159	no	_	_	O
160	subsequent	_	_	O
161	increase	_	_	O
162	above	_	_	O
163	this	_	_	O
164	threshold	_	_	O
165	.	_	_	O

166	The	_	_	O
167	authors	_	_	O
168	report	_	_	O
169	additional	_	_	O
170	sensitivity	_	_	O
171	analyses	_	_	O
172	using	_	_	O
173	10-point	_	_	O
174	minimal	_	_	O
175	important	_	_	O
176	difference	_	_	O
177	decreases	_	_	O
178	in	_	_	O
179	the	_	_	O
180	global	_	_	O
181	health	_	_	O
182	status	_	_	O
183	score	_	_	O
184	versus	_	_	O
185	baseline	_	_	O
186	.	_	_	O

187	Treatment	_	_	O
188	arms	_	_	O
189	were	_	_	O
190	compared	_	_	O
191	using	_	_	O
192	the	_	_	O
193	stratified	_	_	O
194	log-rank	_	_	O
195	test	_	_	O
196	and	_	_	O
197	Cox	_	_	O
198	proportional	_	_	O
199	hazards	_	_	O
200	model	_	_	O
201	adjusted	_	_	O
202	for	_	_	O
203	trial	_	_	O
204	stratum	_	_	O
205	(	_	_	O
206	visceral	_	_	O
207	metastases	_	_	O
208	,	_	_	O
209	previous	_	_	O
210	hormone	_	_	O
211	sensitivity	_	_	O
212	)	_	_	O
213	,	_	_	O
214	age	_	_	O
215	,	_	_	O
216	sex	_	_	O
217	,	_	_	O
218	race	_	_	O
219	,	_	_	O
220	baseline	_	_	O
221	global	_	_	O
222	health	_	_	O
223	status	_	_	O
224	score	_	_	O
225	and	_	_	O
226	Eastern	_	_	O
227	Cooperative	_	_	O
228	Oncology	_	_	O
229	Group	_	_	O
230	performance	_	_	O
231	status	_	_	O
232	,	_	_	O
233	prognostic	_	_	O
234	risk	_	_	O
235	factors	_	_	O
236	,	_	_	O
237	and	_	_	O
238	treatment	_	_	O
239	history	_	_	O
240	.	_	_	O

241	Baseline	_	_	O
242	global	_	_	O
243	health	_	_	O
244	status	_	_	O
245	scores	_	_	O
246	were	_	_	O
247	found	_	_	O
248	to	_	_	O
249	be	_	_	O
250	similar	_	_	O
251	between	_	_	O
252	treatment	_	_	O
253	groups	_	_	O
254	(	_	_	O
255	64.7	_	_	O
256	vs	_	_	O
257	65.3	_	_	O
258	)	_	_	O
259	.	_	_	O

260	The	_	_	B-Premise
261	median	_	_	I-Premise
262	TDD	_	_	I-Premise
263	in	_	_	I-Premise
264	HRQOL	_	_	I-Premise
265	was	_	_	I-Premise
266	8.3	_	_	I-Premise
267	months	_	_	I-Premise
268	with	_	_	I-Premise
269	EVE	_	_	I-Premise
270	+	_	_	I-Premise
271	EXE	_	_	I-Premise
272	versus	_	_	I-Premise
273	5.8	_	_	I-Premise
274	months	_	_	I-Premise
275	with	_	_	I-Premise
276	PBO	_	_	I-Premise
277	+	_	_	I-Premise
278	EXE	_	_	I-Premise
279	(	_	_	I-Premise
280	hazard	_	_	I-Premise
281	ratio	_	_	I-Premise
282	,	_	_	I-Premise
283	0.74	_	_	I-Premise
284	;	_	_	I-Premise
285	P	_	_	I-Premise
286	=	_	_	I-Premise
287	.0084	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	At	_	_	B-Premise
291	the	_	_	I-Premise
292	10-point	_	_	I-Premise
293	minimal	_	_	I-Premise
294	important	_	_	I-Premise
295	difference	_	_	I-Premise
296	,	_	_	I-Premise
297	the	_	_	I-Premise
298	median	_	_	I-Premise
299	TDD	_	_	I-Premise
300	with	_	_	I-Premise
301	EVE	_	_	I-Premise
302	+	_	_	I-Premise
303	EXE	_	_	I-Premise
304	was	_	_	I-Premise
305	11.7	_	_	I-Premise
306	months	_	_	I-Premise
307	versus	_	_	I-Premise
308	8.4	_	_	I-Premise
309	months	_	_	I-Premise
310	with	_	_	I-Premise
311	PBO	_	_	I-Premise
312	+	_	_	I-Premise
313	EXE	_	_	I-Premise
314	(	_	_	I-Premise
315	hazard	_	_	I-Premise
316	ratio	_	_	I-Premise
317	,	_	_	I-Premise
318	0.80	_	_	I-Premise
319	;	_	_	I-Premise
320	P	_	_	I-Premise
321	=	_	_	I-Premise
322	.1017	_	_	I-Premise
323	)	_	_	I-Premise
324	.	_	_	I-Premise

325	In	_	_	B-Claim
326	patients	_	_	I-Claim
327	with	_	_	I-Claim
328	advanced	_	_	I-Claim
329	breast	_	_	I-Claim
330	cancer	_	_	I-Claim
331	who	_	_	I-Claim
332	develop	_	_	I-Claim
333	disease	_	_	I-Claim
334	progression	_	_	I-Claim
335	after	_	_	I-Claim
336	treatment	_	_	I-Claim
337	with	_	_	I-Claim
338	nonsteroidal	_	_	I-Claim
339	aromatase	_	_	I-Claim
340	inhibitors	_	_	I-Claim
341	,	_	_	I-Claim
342	EVE	_	_	I-Claim
343	+	_	_	I-Claim
344	EXE	_	_	I-Claim
345	was	_	_	I-Claim
346	associated	_	_	I-Claim
347	with	_	_	I-Claim
348	a	_	_	I-Claim
349	longer	_	_	I-Claim
350	TDD	_	_	I-Claim
351	in	_	_	I-Claim
352	global	_	_	I-Claim
353	HRQOL	_	_	I-Claim
354	versus	_	_	I-Claim
355	PBO	_	_	I-Claim
356	+	_	_	I-Claim
357	EXE	_	_	I-Claim
358	.	_	_	I-Claim


0	Mucositis	_	_	B-Premise
1	occurs	_	_	I-Premise
2	in	_	_	I-Premise
3	almost	_	_	I-Premise
4	all	_	_	I-Premise
5	patients	_	_	I-Premise
6	treated	_	_	I-Premise
7	with	_	_	I-Premise
8	radiotherapy	_	_	I-Premise
9	for	_	_	I-Premise
10	head	_	_	I-Premise
11	and	_	_	I-Premise
12	neck	_	_	I-Premise
13	cancer	_	_	I-Premise
14	.	_	_	I-Premise

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	multicenter	_	_	O
20	,	_	_	O
21	double-blind	_	_	O
22	,	_	_	O
23	prospective	_	_	O
24	,	_	_	O
25	randomized	_	_	O
26	trial	_	_	O
27	was	_	_	O
28	to	_	_	O
29	evaluate	_	_	O
30	the	_	_	O
31	clinical	_	_	O
32	efficacy	_	_	O
33	of	_	_	O
34	an	_	_	O
35	economically	_	_	O
36	viable	_	_	O
37	antimicrobial	_	_	O
38	lozenge	_	_	O
39	(	_	_	O
40	bacitracin	_	_	O
41	,	_	_	O
42	clotrimazole	_	_	O
43	,	_	_	O
44	and	_	_	O
45	gentamicin	_	_	O
46	[	_	_	O
47	BcoG	_	_	O
48	]	_	_	O
49	)	_	_	O
50	in	_	_	O
51	the	_	_	O
52	alleviation	_	_	O
53	of	_	_	O
54	radiation-induced	_	_	O
55	mucositis	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	head	_	_	O
60	and	_	_	O
61	neck	_	_	O
62	cancer	_	_	O
63	.	_	_	O

64	One	_	_	O
65	hundred	_	_	O
66	thirty-seven	_	_	O
67	eligible	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	treatment	_	_	O
73	with	_	_	O
74	either	_	_	O
75	antimicrobial	_	_	O
76	lozenge	_	_	O
77	(	_	_	O
78	69	_	_	O
79	patients	_	_	O
80	)	_	_	O
81	or	_	_	O
82	placebo	_	_	O
83	lozenge	_	_	O
84	(	_	_	O
85	68	_	_	O
86	patients	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	primary	_	_	O
91	end	_	_	O
92	point	_	_	O
93	of	_	_	O
94	the	_	_	O
95	study	_	_	O
96	was	_	_	O
97	the	_	_	O
98	time	_	_	O
99	to	_	_	O
100	development	_	_	O
101	of	_	_	O
102	severe	_	_	O
103	mucositis	_	_	O
104	from	_	_	O
105	the	_	_	O
106	start	_	_	O
107	of	_	_	O
108	radiotherapy	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	included	_	_	O
114	severity	_	_	O
115	and	_	_	O
116	duration	_	_	O
117	of	_	_	O
118	mucositis	_	_	O
119	,	_	_	O
120	pain	_	_	O
121	measurement	_	_	O
122	,	_	_	O
123	radiation	_	_	O
124	therapy	_	_	O
125	interruption	_	_	O
126	,	_	_	O
127	and	_	_	O
128	quality	_	_	O
129	of	_	_	O
130	life	_	_	O
131	.	_	_	O

132	Mucositis	_	_	O
133	was	_	_	O
134	scored	_	_	O
135	using	_	_	O
136	a	_	_	O
137	validated	_	_	O
138	mucositis	_	_	O
139	scoring	_	_	O
140	system	_	_	O
141	.	_	_	O

142	Toxicity	_	_	B-Premise
143	profiles	_	_	I-Premise
144	were	_	_	I-Premise
145	similar	_	_	I-Premise
146	between	_	_	I-Premise
147	the	_	_	I-Premise
148	two	_	_	I-Premise
149	arms	_	_	I-Premise
150	of	_	_	I-Premise
151	the	_	_	I-Premise
152	study	_	_	I-Premise
153	.	_	_	I-Premise

154	The	_	_	B-Premise
155	median	_	_	I-Premise
156	time	_	_	I-Premise
157	to	_	_	I-Premise
158	development	_	_	I-Premise
159	of	_	_	I-Premise
160	severe	_	_	I-Premise
161	mucositis	_	_	I-Premise
162	from	_	_	I-Premise
163	the	_	_	I-Premise
164	start	_	_	I-Premise
165	of	_	_	I-Premise
166	radiotherapy	_	_	I-Premise
167	was	_	_	I-Premise
168	3.61	_	_	I-Premise
169	weeks	_	_	I-Premise
170	on	_	_	I-Premise
171	BCoG	_	_	I-Premise
172	and	_	_	I-Premise
173	3.96	_	_	I-Premise
174	weeks	_	_	I-Premise
175	on	_	_	I-Premise
176	placebo	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=.61	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	There	_	_	B-Premise
183	were	_	_	I-Premise
184	no	_	_	I-Premise
185	statistically	_	_	I-Premise
186	significant	_	_	I-Premise
187	differences	_	_	I-Premise
188	between	_	_	I-Premise
189	the	_	_	I-Premise
190	arms	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	extent	_	_	I-Premise
194	of	_	_	I-Premise
195	severe	_	_	I-Premise
196	mucositis	_	_	I-Premise
197	as	_	_	I-Premise
198	measured	_	_	I-Premise
199	by	_	_	I-Premise
200	physician	_	_	I-Premise
201	,	_	_	I-Premise
202	in	_	_	I-Premise
203	oral	_	_	I-Premise
204	toxicities	_	_	I-Premise
205	as	_	_	I-Premise
206	recorded	_	_	I-Premise
207	by	_	_	I-Premise
208	patients	_	_	I-Premise
209	,	_	_	I-Premise
210	or	_	_	I-Premise
211	in	_	_	I-Premise
212	radiotherapy	_	_	I-Premise
213	delays	_	_	I-Premise
214	.	_	_	I-Premise

215	This	_	_	O
216	study	_	_	O
217	was	_	_	O
218	conducted	_	_	O
219	on	_	_	O
220	the	_	_	O
221	basis	_	_	O
222	of	_	_	O
223	a	_	_	O
224	pilot	_	_	O
225	study	_	_	O
226	that	_	_	O
227	demonstrated	_	_	O
228	the	_	_	O
229	BCoG	_	_	O
230	lozenge	_	_	O
231	to	_	_	O
232	be	_	_	O
233	tolerable	_	_	O
234	and	_	_	O
235	microbiologically	_	_	O
236	efficacious	_	_	O
237	.	_	_	O

238	A	_	_	O
239	validated	_	_	O
240	mucositis	_	_	O
241	scoring	_	_	O
242	system	_	_	O
243	was	_	_	O
244	used	_	_	O
245	.	_	_	O

246	However	_	_	O
247	,	_	_	O
248	in	_	_	B-Claim
249	this	_	_	I-Claim
250	group	_	_	I-Claim
251	of	_	_	I-Claim
252	patients	_	_	I-Claim
253	treated	_	_	I-Claim
254	with	_	_	I-Claim
255	conventional	_	_	I-Claim
256	radiotherapy	_	_	I-Claim
257	,	_	_	I-Claim
258	the	_	_	I-Claim
259	lozenge	_	_	I-Claim
260	did	_	_	I-Claim
261	not	_	_	I-Claim
262	impact	_	_	I-Claim
263	significantly	_	_	I-Claim
264	on	_	_	I-Claim
265	the	_	_	I-Claim
266	severity	_	_	I-Claim
267	of	_	_	I-Claim
268	mucositis	_	_	I-Claim
269	.	_	_	I-Claim

270	Whether	_	_	B-Claim
271	such	_	_	I-Claim
272	a	_	_	I-Claim
273	lozenge	_	_	I-Claim
274	would	_	_	I-Claim
275	be	_	_	I-Claim
276	beneficial	_	_	I-Claim
277	in	_	_	I-Claim
278	treatment	_	_	I-Claim
279	situations	_	_	I-Claim
280	where	_	_	I-Claim
281	rate	_	_	I-Claim
282	of	_	_	I-Claim
283	severe	_	_	I-Claim
284	mucositis	_	_	I-Claim
285	is	_	_	I-Claim
286	higher	_	_	I-Claim
287	(	_	_	I-Claim
288	ie	_	_	I-Claim
289	,	_	_	I-Claim
290	in	_	_	I-Claim
291	patients	_	_	I-Claim
292	treated	_	_	I-Claim
293	with	_	_	I-Claim
294	unconventional	_	_	I-Claim
295	fractionation	_	_	I-Claim
296	or	_	_	I-Claim
297	with	_	_	I-Claim
298	concomitant	_	_	I-Claim
299	chemotherapy	_	_	I-Claim
300	)	_	_	I-Claim
301	is	_	_	I-Claim
302	unknown	_	_	I-Claim
303	.	_	_	I-Claim


0	For	_	_	B-Claim
1	men	_	_	I-Claim
2	with	_	_	I-Claim
3	localised	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	surgery	_	_	I-Claim
8	provides	_	_	I-Claim
9	a	_	_	I-Claim
10	survival	_	_	I-Claim
11	benefit	_	_	I-Claim
12	compared	_	_	I-Claim
13	with	_	_	I-Claim
14	watchful	_	_	I-Claim
15	waiting	_	_	I-Claim
16	.	_	_	I-Claim

17	Treatments	_	_	O
18	are	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	morbidity	_	_	O
22	.	_	_	O

23	Results	_	_	O
24	for	_	_	O
25	functional	_	_	O
26	outcome	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	are	_	_	O
32	rarely	_	_	O
33	reported	_	_	O
34	beyond	_	_	O
35	10	_	_	O
36	years	_	_	O
37	and	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	from	_	_	O
41	randomised	_	_	O
42	settings	_	_	O
43	.	_	_	O

44	We	_	_	O
45	report	_	_	O
46	results	_	_	O
47	for	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	for	_	_	O
52	men	_	_	O
53	in	_	_	O
54	the	_	_	O
55	Scandinavian	_	_	O
56	Prostate	_	_	O
57	Cancer	_	_	O
58	Group	_	_	O
59	Study	_	_	O
60	Number	_	_	O
61	4	_	_	O
62	(	_	_	O
63	SPCG-4	_	_	O
64	)	_	_	O
65	after	_	_	O
66	a	_	_	O
67	median	_	_	O
68	follow-up	_	_	O
69	of	_	_	O
70	more	_	_	O
71	than	_	_	O
72	12	_	_	O
73	years	_	_	O
74	.	_	_	O

75	All	_	_	O
76	living	_	_	O
77	Swedish	_	_	O
78	and	_	_	O
79	Finnish	_	_	O
80	men	_	_	O
81	(	_	_	O
82	400	_	_	O
83	of	_	_	O
84	695	_	_	O
85	)	_	_	O
86	randomly	_	_	O
87	assigned	_	_	O
88	to	_	_	O
89	radical	_	_	O
90	prostatectomy	_	_	O
91	or	_	_	O
92	watchful	_	_	O
93	waiting	_	_	O
94	in	_	_	O
95	SPCG-4	_	_	O
96	from	_	_	O
97	1989	_	_	O
98	to	_	_	O
99	1999	_	_	O
100	were	_	_	O
101	included	_	_	O
102	in	_	_	O
103	our	_	_	O
104	analysis	_	_	O
105	.	_	_	O

106	An	_	_	O
107	additional	_	_	O
108	281	_	_	O
109	men	_	_	O
110	were	_	_	O
111	included	_	_	O
112	in	_	_	O
113	a	_	_	O
114	population-based	_	_	O
115	control	_	_	O
116	group	_	_	O
117	matched	_	_	O
118	for	_	_	O
119	region	_	_	O
120	and	_	_	O
121	age	_	_	O
122	.	_	_	O

123	Physical	_	_	O
124	symptoms	_	_	O
125	,	_	_	O
126	symptom-induced	_	_	O
127	stress	_	_	O
128	,	_	_	O
129	and	_	_	O
130	self-assessed	_	_	O
131	quality	_	_	O
132	of	_	_	O
133	life	_	_	O
134	were	_	_	O
135	evaluated	_	_	O
136	with	_	_	O
137	a	_	_	O
138	study-specific	_	_	O
139	questionnaire	_	_	O
140	.	_	_	O

141	Longitudinal	_	_	O
142	data	_	_	O
143	were	_	_	O
144	available	_	_	O
145	for	_	_	O
146	166	_	_	O
147	Swedish	_	_	O
148	men	_	_	O
149	who	_	_	O
150	had	_	_	O
151	answered	_	_	O
152	quality-of-life	_	_	O
153	questionnaires	_	_	O
154	at	_	_	O
155	an	_	_	O
156	earlier	_	_	O
157	timepoint	_	_	O
158	.	_	_	O

159	182	_	_	O
160	(	_	_	O
161	88	_	_	O
162	%	_	_	O
163	)	_	_	O
164	of	_	_	O
165	208	_	_	O
166	men	_	_	O
167	in	_	_	O
168	the	_	_	O
169	radical	_	_	O
170	prostatectomy	_	_	O
171	group	_	_	O
172	,	_	_	O
173	167	_	_	O
174	(	_	_	O
175	87	_	_	O
176	%	_	_	O
177	)	_	_	O
178	of	_	_	O
179	192	_	_	O
180	men	_	_	O
181	in	_	_	O
182	the	_	_	O
183	watchful-waiting	_	_	O
184	group	_	_	O
185	,	_	_	O
186	and	_	_	O
187	214	_	_	O
188	(	_	_	O
189	76	_	_	O
190	%	_	_	O
191	)	_	_	O
192	of	_	_	O
193	281	_	_	O
194	men	_	_	O
195	in	_	_	O
196	the	_	_	O
197	population-based	_	_	O
198	control	_	_	O
199	group	_	_	O
200	answered	_	_	O
201	the	_	_	O
202	questionnaire	_	_	O
203	.	_	_	O

204	Men	_	_	O
205	in	_	_	O
206	SPCG-4	_	_	O
207	had	_	_	O
208	a	_	_	O
209	median	_	_	O
210	follow-up	_	_	O
211	of	_	_	O
212	12Â·2	_	_	O
213	years	_	_	O
214	(	_	_	O
215	range	_	_	O
216	7-17	_	_	O
217	)	_	_	O
218	and	_	_	O
219	a	_	_	O
220	median	_	_	O
221	age	_	_	O
222	of	_	_	O
223	77Â·0	_	_	O
224	years	_	_	O
225	(	_	_	O
226	range	_	_	O
227	61-88	_	_	O
228	)	_	_	O
229	.	_	_	O

230	High	_	_	B-Premise
231	self-assessed	_	_	I-Premise
232	quality	_	_	I-Premise
233	of	_	_	I-Premise
234	life	_	_	I-Premise
235	was	_	_	I-Premise
236	reported	_	_	I-Premise
237	by	_	_	I-Premise
238	62	_	_	I-Premise
239	(	_	_	I-Premise
240	35	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	of	_	_	I-Premise
244	179	_	_	I-Premise
245	men	_	_	I-Premise
246	allocated	_	_	I-Premise
247	radical	_	_	I-Premise
248	prostatectomy	_	_	I-Premise
249	,	_	_	I-Premise
250	55	_	_	I-Premise
251	(	_	_	I-Premise
252	34	_	_	I-Premise
253	%	_	_	I-Premise
254	)	_	_	I-Premise
255	of	_	_	I-Premise
256	160	_	_	I-Premise
257	men	_	_	I-Premise
258	assigned	_	_	I-Premise
259	to	_	_	I-Premise
260	watchful	_	_	I-Premise
261	waiting	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	93	_	_	I-Premise
265	(	_	_	I-Premise
266	45	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	of	_	_	I-Premise
270	208	_	_	I-Premise
271	men	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	control	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Anxiety	_	_	B-Premise
278	was	_	_	I-Premise
279	higher	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	SPCG-4	_	_	I-Premise
283	groups	_	_	I-Premise
284	(	_	_	I-Premise
285	77	_	_	I-Premise
286	[	_	_	I-Premise
287	43	_	_	I-Premise
288	%	_	_	I-Premise
289	]	_	_	I-Premise
290	of	_	_	I-Premise
291	178	_	_	I-Premise
292	and	_	_	I-Premise
293	69	_	_	I-Premise
294	[	_	_	I-Premise
295	43	_	_	I-Premise
296	%	_	_	I-Premise
297	]	_	_	I-Premise
298	of	_	_	I-Premise
299	161	_	_	I-Premise
300	men	_	_	I-Premise
301	)	_	_	I-Premise
302	than	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	control	_	_	I-Premise
306	group	_	_	I-Premise
307	(	_	_	I-Premise
308	68	_	_	I-Premise
309	[	_	_	I-Premise
310	33	_	_	I-Premise
311	%	_	_	I-Premise
312	]	_	_	I-Premise
313	of	_	_	I-Premise
314	208	_	_	I-Premise
315	men	_	_	I-Premise
316	;	_	_	I-Premise
317	relative	_	_	I-Premise
318	risk	_	_	I-Premise
319	1Â·42	_	_	I-Premise
320	,	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	CI	_	_	I-Premise
324	1Â·07-1Â·88	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	Prevalence	_	_	B-Premise
328	of	_	_	I-Premise
329	erectile	_	_	I-Premise
330	dysfunction	_	_	I-Premise
331	was	_	_	I-Premise
332	84	_	_	I-Premise
333	%	_	_	I-Premise
334	(	_	_	I-Premise
335	146	_	_	I-Premise
336	of	_	_	I-Premise
337	173	_	_	I-Premise
338	men	_	_	I-Premise
339	)	_	_	I-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	radical	_	_	I-Premise
343	prostatectomy	_	_	I-Premise
344	group	_	_	I-Premise
345	,	_	_	I-Premise
346	80	_	_	I-Premise
347	%	_	_	I-Premise
348	(	_	_	I-Premise
349	122	_	_	I-Premise
350	of	_	_	I-Premise
351	153	_	_	I-Premise
352	)	_	_	I-Premise
353	in	_	_	I-Premise
354	the	_	_	I-Premise
355	watchful-waiting	_	_	I-Premise
356	group	_	_	I-Premise
357	,	_	_	I-Premise
358	and	_	_	I-Premise
359	46	_	_	I-Premise
360	%	_	_	I-Premise
361	(	_	_	I-Premise
362	95	_	_	I-Premise
363	of	_	_	I-Premise
364	208	_	_	I-Premise
365	)	_	_	I-Premise
366	in	_	_	I-Premise
367	the	_	_	I-Premise
368	control	_	_	I-Premise
369	group	_	_	I-Premise
370	and	_	_	I-Premise
371	prevalence	_	_	I-Premise
372	of	_	_	I-Premise
373	urinary	_	_	I-Premise
374	leakage	_	_	I-Premise
375	was	_	_	I-Premise
376	41	_	_	I-Premise
377	%	_	_	I-Premise
378	(	_	_	I-Premise
379	71	_	_	I-Premise
380	of	_	_	I-Premise
381	173	_	_	I-Premise
382	)	_	_	I-Premise
383	,	_	_	I-Premise
384	11	_	_	I-Premise
385	%	_	_	I-Premise
386	(	_	_	I-Premise
387	18	_	_	I-Premise
388	of	_	_	I-Premise
389	164	_	_	I-Premise
390	)	_	_	I-Premise
391	,	_	_	I-Premise
392	and	_	_	I-Premise
393	3	_	_	I-Premise
394	%	_	_	I-Premise
395	(	_	_	I-Premise
396	six	_	_	I-Premise
397	of	_	_	I-Premise
398	209	_	_	I-Premise
399	)	_	_	I-Premise
400	,	_	_	I-Premise
401	respectively	_	_	I-Premise
402	.	_	_	I-Premise

403	Distress	_	_	B-Premise
404	caused	_	_	I-Premise
405	by	_	_	I-Premise
406	these	_	_	I-Premise
407	symptoms	_	_	I-Premise
408	was	_	_	I-Premise
409	reported	_	_	I-Premise
410	significantly	_	_	I-Premise
411	more	_	_	I-Premise
412	often	_	_	I-Premise
413	by	_	_	I-Premise
414	men	_	_	I-Premise
415	allocated	_	_	I-Premise
416	radical	_	_	I-Premise
417	prostatectomy	_	_	I-Premise
418	than	_	_	I-Premise
419	by	_	_	I-Premise
420	men	_	_	I-Premise
421	assigned	_	_	I-Premise
422	to	_	_	I-Premise
423	watchful	_	_	I-Premise
424	waiting	_	_	I-Premise
425	.	_	_	I-Premise

426	In	_	_	B-Premise
427	a	_	_	I-Premise
428	longitudinal	_	_	I-Premise
429	analysis	_	_	I-Premise
430	of	_	_	I-Premise
431	men	_	_	I-Premise
432	in	_	_	I-Premise
433	SPCG-4	_	_	I-Premise
434	who	_	_	I-Premise
435	provided	_	_	I-Premise
436	information	_	_	I-Premise
437	at	_	_	I-Premise
438	two	_	_	I-Premise
439	follow-up	_	_	I-Premise
440	points	_	_	I-Premise
441	9	_	_	I-Premise
442	years	_	_	I-Premise
443	apart	_	_	I-Premise
444	,	_	_	I-Premise
445	38	_	_	I-Premise
446	(	_	_	I-Premise
447	45	_	_	I-Premise
448	%	_	_	I-Premise
449	)	_	_	I-Premise
450	of	_	_	I-Premise
451	85	_	_	I-Premise
452	men	_	_	I-Premise
453	allocated	_	_	I-Premise
454	radical	_	_	I-Premise
455	prostatectomy	_	_	I-Premise
456	and	_	_	I-Premise
457	48	_	_	I-Premise
458	(	_	_	I-Premise
459	60	_	_	I-Premise
460	%	_	_	I-Premise
461	)	_	_	I-Premise
462	of	_	_	I-Premise
463	80	_	_	I-Premise
464	men	_	_	I-Premise
465	allocated	_	_	I-Premise
466	watchful	_	_	I-Premise
467	waiting	_	_	I-Premise
468	reported	_	_	I-Premise
469	an	_	_	I-Premise
470	increase	_	_	I-Premise
471	in	_	_	I-Premise
472	number	_	_	I-Premise
473	of	_	_	I-Premise
474	physical	_	_	I-Premise
475	symptoms	_	_	I-Premise
476	;	_	_	I-Premise
477	50	_	_	I-Premise
478	(	_	_	I-Premise
479	61	_	_	I-Premise
480	%	_	_	I-Premise
481	)	_	_	I-Premise
482	of	_	_	I-Premise
483	82	_	_	I-Premise
484	and	_	_	I-Premise
485	47	_	_	I-Premise
486	(	_	_	I-Premise
487	64	_	_	I-Premise
488	%	_	_	I-Premise
489	)	_	_	I-Premise
490	of	_	_	I-Premise
491	74	_	_	I-Premise
492	men	_	_	I-Premise
493	,	_	_	I-Premise
494	respectively	_	_	I-Premise
495	,	_	_	I-Premise
496	reported	_	_	I-Premise
497	a	_	_	I-Premise
498	reduction	_	_	I-Premise
499	in	_	_	I-Premise
500	quality	_	_	I-Premise
501	of	_	_	I-Premise
502	life	_	_	I-Premise
503	.	_	_	I-Premise

504	For	_	_	B-Premise
505	men	_	_	I-Premise
506	in	_	_	I-Premise
507	SPCG-4	_	_	I-Premise
508	,	_	_	I-Premise
509	negative	_	_	I-Premise
510	side-effects	_	_	I-Premise
511	were	_	_	I-Premise
512	common	_	_	I-Premise
513	and	_	_	I-Premise
514	added	_	_	I-Premise
515	more	_	_	I-Premise
516	stress	_	_	I-Premise
517	than	_	_	I-Premise
518	was	_	_	I-Premise
519	reported	_	_	I-Premise
520	in	_	_	I-Premise
521	the	_	_	I-Premise
522	control	_	_	I-Premise
523	population	_	_	I-Premise
524	.	_	_	I-Premise

525	In	_	_	B-Claim
526	the	_	_	I-Claim
527	radical	_	_	I-Claim
528	prostatectomy	_	_	I-Claim
529	group	_	_	I-Claim
530	,	_	_	I-Claim
531	erectile	_	_	I-Claim
532	dysfunction	_	_	I-Claim
533	and	_	_	I-Claim
534	urinary	_	_	I-Claim
535	leakage	_	_	I-Claim
536	were	_	_	I-Claim
537	often	_	_	I-Claim
538	consequences	_	_	I-Claim
539	of	_	_	I-Claim
540	surgery	_	_	I-Claim
541	.	_	_	I-Claim

542	In	_	_	B-Claim
543	the	_	_	I-Claim
544	watchful-waiting	_	_	I-Claim
545	group	_	_	I-Claim
546	,	_	_	I-Claim
547	side-effects	_	_	I-Claim
548	can	_	_	I-Claim
549	be	_	_	I-Claim
550	caused	_	_	I-Claim
551	by	_	_	I-Claim
552	tumour	_	_	I-Claim
553	progression	_	_	I-Claim
554	.	_	_	I-Claim

555	The	_	_	B-Claim
556	number	_	_	I-Claim
557	and	_	_	I-Claim
558	severity	_	_	I-Claim
559	of	_	_	I-Claim
560	side-effects	_	_	I-Claim
561	changes	_	_	I-Claim
562	over	_	_	I-Claim
563	time	_	_	I-Claim
564	at	_	_	I-Claim
565	a	_	_	I-Claim
566	higher	_	_	I-Claim
567	rate	_	_	I-Claim
568	than	_	_	I-Claim
569	is	_	_	I-Claim
570	caused	_	_	I-Claim
571	by	_	_	I-Claim
572	normal	_	_	I-Claim
573	ageing	_	_	I-Claim
574	and	_	_	I-Claim
575	a	_	_	I-Claim
576	loss	_	_	I-Claim
577	of	_	_	I-Claim
578	sexual	_	_	I-Claim
579	ability	_	_	I-Claim
580	is	_	_	I-Claim
581	a	_	_	I-Claim
582	persistent	_	_	I-Claim
583	psychological	_	_	I-Claim
584	problem	_	_	I-Claim
585	for	_	_	I-Claim
586	both	_	_	I-Claim
587	interventions	_	_	I-Claim
588	.	_	_	I-Claim

589	An	_	_	O
590	understanding	_	_	O
591	of	_	_	O
592	the	_	_	O
593	patterns	_	_	O
594	of	_	_	O
595	side-effects	_	_	O
596	and	_	_	O
597	time	_	_	O
598	dimension	_	_	O
599	of	_	_	O
600	their	_	_	O
601	occurrence	_	_	O
602	for	_	_	O
603	each	_	_	O
604	treatment	_	_	O
605	is	_	_	O
606	important	_	_	O
607	for	_	_	O
608	full	_	_	O
609	patient	_	_	O
610	information	_	_	O
611	.	_	_	O


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	metastatic	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	treatment	_	_	I-Claim
8	is	_	_	I-Claim
9	primarily	_	_	I-Claim
10	palliative	_	_	I-Claim
11	,	_	_	I-Claim
12	relying	_	_	I-Claim
13	mainly	_	_	I-Claim
14	on	_	_	I-Claim
15	the	_	_	I-Claim
16	suppression	_	_	I-Claim
17	of	_	_	I-Claim
18	systemic	_	_	I-Claim
19	androgen	_	_	I-Claim
20	hormone	_	_	I-Claim
21	levels	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	help	_	_	O
25	document	_	_	O
26	the	_	_	O
27	achievement	_	_	O
28	of	_	_	O
29	palliation	_	_	O
30	and	_	_	O
31	to	_	_	O
32	characterize	_	_	O
33	positive	_	_	O
34	and	_	_	O
35	negative	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	,	_	_	O
40	we	_	_	O
41	evaluated	_	_	O
42	quality-of-life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	parameters	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	metastatic	_	_	O
51	prostate	_	_	O
52	cancer	_	_	O
53	who	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	two	_	_	O
59	methods	_	_	O
60	of	_	_	O
61	androgen	_	_	O
62	deprivation	_	_	O
63	.	_	_	O

64	Patients	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	739	_	_	O
69	)	_	_	O
70	with	_	_	O
71	stage	_	_	O
72	M1	_	_	O
73	(	_	_	O
74	bone	_	_	O
75	or	_	_	O
76	soft	_	_	O
77	tissue	_	_	O
78	metastasis	_	_	O
79	)	_	_	O
80	prostate	_	_	O
81	cancer	_	_	O
82	were	_	_	O
83	enrolled	_	_	O
84	in	_	_	O
85	a	_	_	O
86	QOL	_	_	O
87	protocol	_	_	O
88	that	_	_	O
89	was	_	_	O
90	a	_	_	O
91	companion	_	_	O
92	to	_	_	O
93	Southwest	_	_	O
94	Oncology	_	_	O
95	Group	_	_	O
96	INT-0105	_	_	O
97	,	_	_	O
98	a	_	_	O
99	randomized	_	_	O
100	double-blind	_	_	O
101	trial	_	_	O
102	comparing	_	_	O
103	treatment	_	_	O
104	with	_	_	O
105	bilateral	_	_	O
106	orchiectomy	_	_	O
107	(	_	_	O
108	surgical	_	_	O
109	castration	_	_	O
110	)	_	_	O
111	plus	_	_	O
112	either	_	_	O
113	flutamide	_	_	O
114	or	_	_	O
115	placebo	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	completed	_	_	O
119	a	_	_	O
120	comprehensive	_	_	O
121	battery	_	_	O
122	of	_	_	O
123	QOL	_	_	O
124	questionnaires	_	_	O
125	at	_	_	O
126	random	_	_	O
127	assignment	_	_	O
128	to	_	_	O
129	treatment	_	_	O
130	and	_	_	O
131	at	_	_	O
132	1	_	_	O
133	,	_	_	O
134	3	_	_	O
135	,	_	_	O
136	and	_	_	O
137	6	_	_	O
138	months	_	_	O
139	later	_	_	O
140	.	_	_	O

141	Data	_	_	O
142	were	_	_	O
143	collected	_	_	O
144	on	_	_	O
145	three	_	_	O
146	treatment-specific	_	_	O
147	symptoms	_	_	O
148	(	_	_	O
149	diarrhea	_	_	O
150	,	_	_	O
151	gas	_	_	O
152	pain	_	_	O
153	,	_	_	O
154	and	_	_	O
155	body	_	_	O
156	image	_	_	O
157	)	_	_	O
158	,	_	_	O
159	on	_	_	O
160	physical	_	_	O
161	functioning	_	_	O
162	,	_	_	O
163	and	_	_	O
164	on	_	_	O
165	emotional	_	_	O
166	functioning	_	_	O
167	.	_	_	O

168	All	_	_	O
169	P	_	_	O
170	values	_	_	O
171	are	_	_	O
172	two-sided	_	_	O
173	.	_	_	O

174	Questionnaire	_	_	O
175	return	_	_	O
176	rates	_	_	O
177	for	_	_	O
178	this	_	_	O
179	study	_	_	O
180	never	_	_	O
181	dropped	_	_	O
182	below	_	_	O
183	80	_	_	O
184	%	_	_	O
185	;	_	_	O
186	only	_	_	O
187	2	_	_	O
188	%	_	_	O
189	of	_	_	O
190	the	_	_	O
191	patients	_	_	O
192	did	_	_	O
193	not	_	_	O
194	submit	_	_	O
195	baseline	_	_	O
196	QOL	_	_	O
197	assessments	_	_	O
198	.	_	_	O

199	Cross-sectional	_	_	B-Premise
200	analyses	_	_	I-Premise
201	(	_	_	I-Premise
202	corrected	_	_	I-Premise
203	for	_	_	I-Premise
204	multiple	_	_	I-Premise
205	testing	_	_	I-Premise
206	)	_	_	I-Premise
207	identified	_	_	I-Premise
208	statistically	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	that	_	_	I-Premise
212	favored	_	_	I-Premise
213	orchiectomy	_	_	I-Premise
214	plus	_	_	I-Premise
215	placebo	_	_	I-Premise
216	for	_	_	I-Premise
217	two	_	_	I-Premise
218	of	_	_	I-Premise
219	the	_	_	I-Premise
220	five	_	_	I-Premise
221	primary	_	_	I-Premise
222	QOL	_	_	I-Premise
223	parameters	_	_	I-Premise
224	as	_	_	I-Premise
225	follows	_	_	I-Premise
226	:	_	_	I-Premise
227	patients	_	_	I-Premise
228	receiving	_	_	I-Premise
229	flutamide	_	_	I-Premise
230	reported	_	_	I-Premise
231	more	_	_	I-Premise
232	diarrhea	_	_	I-Premise
233	at	_	_	I-Premise
234	3	_	_	I-Premise
235	months	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.001	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	worse	_	_	I-Premise
243	emotional	_	_	I-Premise
244	functioning	_	_	I-Premise
245	at	_	_	I-Premise
246	3	_	_	I-Premise
247	and	_	_	I-Premise
248	6	_	_	I-Premise
249	months	_	_	I-Premise
250	(	_	_	I-Premise
251	both	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.003	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Longitudinal	_	_	B-Premise
258	analyses	_	_	I-Premise
259	replicated	_	_	I-Premise
260	these	_	_	I-Premise
261	findings	_	_	I-Premise
262	.	_	_	I-Premise

263	Other	_	_	B-Premise
264	analyzed	_	_	I-Premise
265	QOL	_	_	I-Premise
266	parameters	_	_	I-Premise
267	favored	_	_	I-Premise
268	the	_	_	I-Premise
269	group	_	_	I-Premise
270	receiving	_	_	I-Premise
271	placebo	_	_	I-Premise
272	but	_	_	B-Premise
273	were	_	_	I-Premise
274	not	_	_	I-Premise
275	statistically	_	_	I-Premise
276	significant	_	_	I-Premise
277	after	_	_	I-Premise
278	adjustment	_	_	I-Premise
279	for	_	_	I-Premise
280	multiple	_	_	I-Premise
281	testing	_	_	I-Premise
282	.	_	_	I-Premise

283	We	_	_	B-Claim
284	found	_	_	I-Claim
285	a	_	_	I-Claim
286	consistent	_	_	I-Claim
287	pattern	_	_	I-Claim
288	of	_	_	I-Claim
289	better	_	_	I-Claim
290	QOL	_	_	I-Claim
291	outcomes	_	_	I-Claim
292	at	_	_	I-Claim
293	each	_	_	I-Claim
294	follow-up	_	_	I-Claim
295	assessment	_	_	I-Claim
296	during	_	_	I-Claim
297	the	_	_	I-Claim
298	first	_	_	I-Claim
299	6	_	_	I-Claim
300	months	_	_	I-Claim
301	of	_	_	I-Claim
302	treatment	_	_	I-Claim
303	for	_	_	I-Claim
304	orchiectomized	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	metastatic	_	_	I-Claim
308	prostate	_	_	I-Claim
309	cancer	_	_	I-Claim
310	who	_	_	I-Claim
311	received	_	_	I-Claim
312	placebo	_	_	I-Claim
313	versus	_	_	I-Claim
314	flutamide	_	_	I-Claim
315	.	_	_	I-Claim

316	Improvement	_	_	B-Claim
317	over	_	_	I-Claim
318	time	_	_	I-Claim
319	was	_	_	I-Claim
320	evident	_	_	I-Claim
321	in	_	_	I-Claim
322	both	_	_	I-Claim
323	treatment	_	_	I-Claim
324	groups	_	_	I-Claim
325	but	_	_	I-Claim
326	more	_	_	I-Claim
327	so	_	_	I-Claim
328	for	_	_	I-Claim
329	patients	_	_	I-Claim
330	receiving	_	_	I-Claim
331	placebo	_	_	I-Claim
332	.	_	_	I-Claim


0	Regularly	_	_	O
1	collecting	_	_	O
2	patient-reported	_	_	O
3	outcomes	_	_	O
4	(	_	_	O
5	PROs	_	_	O
6	)	_	_	O
7	of	_	_	O
8	health-related	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	with	_	_	O
13	feedback	_	_	O
14	to	_	_	O
15	oncologists	_	_	O
16	may	_	_	O
17	assist	_	_	O
18	in	_	_	O
19	eliciting	_	_	O
20	and	_	_	O
21	monitoring	_	_	O
22	patients	_	_	O
23	'	_	_	O
24	problems	_	_	O
25	during	_	_	O
26	cancer	_	_	O
27	treatment	_	_	O
28	.	_	_	O

29	This	_	_	O
30	study	_	_	O
31	examined	_	_	O
32	how	_	_	O
33	PRO	_	_	O
34	feedback	_	_	O
35	had	_	_	O
36	an	_	_	O
37	impact	_	_	O
38	on	_	_	O
39	patient-physician	_	_	O
40	communication	_	_	O
41	over	_	_	O
42	time	_	_	O
43	to	_	_	O
44	gain	_	_	O
45	a	_	_	O
46	better	_	_	O
47	understanding	_	_	O
48	of	_	_	O
49	how	_	_	O
50	it	_	_	O
51	may	_	_	O
52	influence	_	_	O
53	patient	_	_	O
54	care	_	_	O
55	.	_	_	O

56	Exploratory	_	_	O
57	analyses	_	_	O
58	were	_	_	O
59	performed	_	_	O
60	on	_	_	O
61	a	_	_	O
62	data	_	_	O
63	set	_	_	O
64	from	_	_	O
65	a	_	_	O
66	previous	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	intervention	_	_	O
75	(	_	_	O
76	regular	_	_	O
77	completion	_	_	O
78	of	_	_	O
79	European	_	_	O
80	Organisation	_	_	O
81	for	_	_	O
82	Research	_	_	O
83	and	_	_	O
84	Treatment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Quality	_	_	O
88	of	_	_	O
89	Life	_	_	O
90	Questionnaire-Core	_	_	O
91	30	_	_	O
92	and	_	_	O
93	Hospital	_	_	O
94	Anxiety	_	_	O
95	and	_	_	O
96	Depression	_	_	O
97	Scale	_	_	O
98	with	_	_	O
99	feedback	_	_	O
100	to	_	_	O
101	oncologists	_	_	O
102	)	_	_	O
103	,	_	_	O
104	attention-control	_	_	O
105	(	_	_	O
106	completion	_	_	O
107	of	_	_	O
108	same	_	_	O
109	questionnaires	_	_	O
110	without	_	_	O
111	feedback	_	_	O
112	)	_	_	O
113	,	_	_	O
114	and	_	_	O
115	control	_	_	O
116	(	_	_	O
117	standard	_	_	O
118	care	_	_	O
119	)	_	_	O
120	arms	_	_	O
121	.	_	_	O

122	The	_	_	O
123	content	_	_	O
124	of	_	_	O
125	consultation	_	_	O
126	audio	_	_	O
127	recordings	_	_	O
128	between	_	_	O
129	28	_	_	O
130	oncologists	_	_	O
131	and	_	_	O
132	198	_	_	O
133	patients	_	_	O
134	over	_	_	O
135	four	_	_	O
136	consecutive	_	_	O
137	visits	_	_	O
138	(	_	_	O
139	792	_	_	O
140	consultations	_	_	O
141	)	_	_	O
142	was	_	_	O
143	analyzed	_	_	O
144	.	_	_	O

145	Mixed-effects	_	_	O
146	models	_	_	O
147	and	_	_	O
148	multivariate	_	_	O
149	regressions	_	_	O
150	were	_	_	O
151	used	_	_	O
152	to	_	_	O
153	examine	_	_	O
154	the	_	_	O
155	longitudinal	_	_	O
156	impact	_	_	O
157	of	_	_	O
158	the	_	_	O
159	intervention	_	_	O
160	on	_	_	O
161	patient-physician	_	_	O
162	communication	_	_	O
163	,	_	_	O
164	dynamics	_	_	O
165	of	_	_	O
166	patient-physician	_	_	O
167	interaction	_	_	O
168	,	_	_	O
169	and	_	_	O
170	the	_	_	O
171	association	_	_	O
172	between	_	_	O
173	PROs	_	_	O
174	and	_	_	O
175	the	_	_	O
176	content	_	_	O
177	of	_	_	O
178	clinic	_	_	O
179	discussion	_	_	O
180	.	_	_	O

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	intervention	_	_	I-Premise
185	arm	_	_	I-Premise
186	discussed	_	_	I-Premise
187	more	_	_	I-Premise
188	symptoms	_	_	I-Premise
189	over	_	_	I-Premise
190	time	_	_	I-Premise
191	compared	_	_	I-Premise
192	with	_	_	I-Premise
193	patients	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	attention-control	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.008	_	_	I-Premise
201	)	_	_	I-Premise
202	and	_	_	I-Premise
203	control	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.04	_	_	I-Premise
208	)	_	_	I-Premise
209	arms	_	_	I-Premise
210	.	_	_	I-Premise

211	No	_	_	B-Premise
212	study	_	_	I-Premise
213	arm	_	_	I-Premise
214	effect	_	_	I-Premise
215	was	_	_	I-Premise
216	observed	_	_	I-Premise
217	for	_	_	I-Premise
218	function	_	_	I-Premise
219	discussions	_	_	I-Premise
220	.	_	_	I-Premise

221	Discussion	_	_	O
222	topics	_	_	O
223	were	_	_	O
224	predominantly	_	_	O
225	raised	_	_	O
226	by	_	_	O
227	patients/relatives	_	_	O
228	,	_	_	O
229	regardless	_	_	O
230	of	_	_	O
231	arm	_	_	O
232	allocation	_	_	O
233	.	_	_	O

234	Clinic	_	_	B-Premise
235	discussions	_	_	I-Premise
236	were	_	_	I-Premise
237	associated	_	_	I-Premise
238	with	_	_	I-Premise
239	severity	_	_	I-Premise
240	of	_	_	I-Premise
241	patient-reported	_	_	I-Premise
242	symptoms	_	_	I-Premise
243	but	_	_	I-Premise
244	not	_	_	I-Premise
245	with	_	_	I-Premise
246	patient-reported	_	_	I-Premise
247	functional	_	_	I-Premise
248	concerns	_	_	I-Premise
249	.	_	_	I-Premise

250	A	_	_	B-Premise
251	positive	_	_	I-Premise
252	longitudinal	_	_	I-Premise
253	impact	_	_	I-Premise
254	of	_	_	I-Premise
255	the	_	_	I-Premise
256	intervention	_	_	I-Premise
257	on	_	_	I-Premise
258	symptom	_	_	I-Premise
259	discussion	_	_	I-Premise
260	was	_	_	I-Premise
261	observed	_	_	I-Premise
262	,	_	_	I-Premise
263	but	_	_	B-Premise
264	not	_	_	I-Premise
265	for	_	_	I-Premise
266	function	_	_	I-Premise
267	discussion	_	_	I-Premise
268	,	_	_	I-Premise
269	suggesting	_	_	I-Premise
270	that	_	_	I-Premise
271	potentially	_	_	I-Premise
272	serious	_	_	I-Premise
273	problems	_	_	I-Premise
274	may	_	_	I-Premise
275	remain	_	_	I-Premise
276	unaddressed	_	_	I-Premise
277	.	_	_	I-Premise

278	Training	_	_	B-Claim
279	oncologists	_	_	I-Claim
280	in	_	_	I-Claim
281	responding	_	_	I-Claim
282	to	_	_	I-Claim
283	patient-reported	_	_	I-Claim
284	functional	_	_	I-Claim
285	concerns	_	_	I-Claim
286	may	_	_	I-Claim
287	increase	_	_	I-Claim
288	the	_	_	I-Claim
289	impact	_	_	I-Claim
290	of	_	_	I-Claim
291	this	_	_	I-Claim
292	intervention	_	_	I-Claim
293	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	expected	_	_	I-Claim
4	consequence	_	_	I-Claim
5	of	_	_	I-Claim
6	intensive	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	regimens	_	_	I-Claim
9	administered	_	_	I-Claim
10	to	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	acute	_	_	I-Claim
14	leukemia	_	_	I-Claim
15	.	_	_	I-Claim

16	This	_	_	O
17	study	_	_	O
18	was	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	determine	_	_	O
22	whether	_	_	O
23	epoetin	_	_	O
24	alpha	_	_	O
25	would	_	_	O
26	decrease	_	_	O
27	the	_	_	O
28	number	_	_	O
29	of	_	_	O
30	transfusion	_	_	O
31	events	_	_	O
32	and	_	_	O
33	units	_	_	O
34	of	_	_	O
35	packed	_	_	O
36	erythrocytes	_	_	O
37	(	_	_	O
38	PRBCs	_	_	O
39	)	_	_	O
40	transfused	_	_	O
41	,	_	_	O
42	and	_	_	O
43	the	_	_	O
44	secondary	_	_	O
45	objective	_	_	O
46	was	_	_	O
47	to	_	_	O
48	study	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	epoetin	_	_	O
53	alpha	_	_	O
54	on	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QOL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	complete	_	_	O
63	remission	_	_	O
64	(	_	_	O
65	CR	_	_	O
66	)	_	_	O
67	rates	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	acute	_	_	O
72	lymphoblastic	_	_	O
73	leukemia	_	_	O
74	(	_	_	O
75	ALL	_	_	O
76	)	_	_	O
77	,	_	_	O
78	lymphoblastic	_	_	O
79	lymphoma	_	_	O
80	(	_	_	O
81	LL	_	_	O
82	)	_	_	O
83	,	_	_	O
84	or	_	_	O
85	Burkitt	_	_	O
86	lymphoma	_	_	O
87	(	_	_	O
88	BL	_	_	O
89	)	_	_	O
90	who	_	_	O
91	were	_	_	O
92	receiving	_	_	O
93	frontline	_	_	O
94	myelosuppressive	_	_	O
95	chemotherapy	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	epoetin	_	_	O
101	alpha	_	_	O
102	or	_	_	O
103	no	_	_	O
104	epoetin	_	_	O
105	during	_	_	O
106	the	_	_	O
107	first	_	_	O
108	6	_	_	O
109	cycles	_	_	O
110	of	_	_	O
111	their	_	_	O
112	planned	_	_	O
113	chemotherapy	_	_	O
114	.	_	_	O

115	QOL	_	_	O
116	was	_	_	O
117	assessed	_	_	O
118	by	_	_	O
119	using	_	_	O
120	the	_	_	O
121	Edmonton	_	_	O
122	Symptom	_	_	O
123	Assessment	_	_	O
124	Scale	_	_	O
125	(	_	_	O
126	ESAS	_	_	O
127	)	_	_	O
128	and	_	_	O
129	the	_	_	O
130	Functional	_	_	O
131	Assessment	_	_	O
132	of	_	_	O
133	Cancer	_	_	O
134	Therapy	_	_	O
135	(	_	_	O
136	FACT	_	_	O
137	)	_	_	O
138	-Anemia	_	_	O
139	questionnaires	_	_	O
140	.	_	_	O

141	Fifty-five	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomized	_	_	O
145	to	_	_	O
146	receive	_	_	O
147	epoetin	_	_	O
148	alpha	_	_	O
149	,	_	_	O
150	and	_	_	O
151	54	_	_	O
152	patients	_	_	O
153	received	_	_	O
154	no	_	_	O
155	epoetin	_	_	O
156	.	_	_	O

157	Transfusion	_	_	O
158	data	_	_	O
159	were	_	_	O
160	available	_	_	O
161	for	_	_	O
162	79	_	_	O
163	of	_	_	O
164	81	_	_	O
165	evaluable	_	_	O
166	patients	_	_	O
167	(	_	_	O
168	98	_	_	O
169	%	_	_	O
170	)	_	_	O
171	who	_	_	O
172	completed	_	_	O
173	the	_	_	O
174	treatment/observation	_	_	O
175	period	_	_	O
176	.	_	_	O

177	The	_	_	B-Premise
178	trial	_	_	I-Premise
179	was	_	_	I-Premise
180	stopped	_	_	I-Premise
181	early	_	_	I-Premise
182	because	_	_	I-Premise
183	of	_	_	I-Premise
184	poor	_	_	I-Premise
185	accrual	_	_	I-Premise
186	before	_	_	I-Premise
187	the	_	_	I-Premise
188	target	_	_	I-Premise
189	of	_	_	I-Premise
190	123	_	_	I-Premise
191	evaluable	_	_	I-Premise
192	patients	_	_	I-Premise
193	was	_	_	I-Premise
194	met	_	_	I-Premise
195	.	_	_	I-Premise

196	A	_	_	B-Premise
197	mean	_	_	I-Premise
198	of	_	_	I-Premise
199	10.6	_	_	I-Premise
200	units	_	_	I-Premise
201	of	_	_	I-Premise
202	PRBCs	_	_	I-Premise
203	over	_	_	I-Premise
204	5	_	_	I-Premise
205	months	_	_	I-Premise
206	were	_	_	I-Premise
207	administered	_	_	I-Premise
208	to	_	_	I-Premise
209	those	_	_	I-Premise
210	who	_	_	I-Premise
211	received	_	_	I-Premise
212	epoetin	_	_	I-Premise
213	alpha	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	13	_	_	I-Premise
217	units	_	_	I-Premise
218	for	_	_	I-Premise
219	those	_	_	I-Premise
220	who	_	_	I-Premise
221	did	_	_	I-Premise
222	not	_	_	I-Premise
223	receive	_	_	I-Premise
224	epoetin	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.04	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	no	_	_	I-Premise
234	significant	_	_	I-Premise
235	difference	_	_	I-Premise
236	in	_	_	I-Premise
237	QOL	_	_	I-Premise
238	as	_	_	I-Premise
239	assessed	_	_	I-Premise
240	by	_	_	I-Premise
241	the	_	_	I-Premise
242	FACT-Anemia	_	_	I-Premise
243	or	_	_	I-Premise
244	ESAS	_	_	I-Premise
245	instruments	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	CR	_	_	I-Premise
249	rate	_	_	I-Premise
250	and	_	_	I-Premise
251	the	_	_	I-Premise
252	3-year	_	_	I-Premise
253	CR	_	_	I-Premise
254	duration	_	_	I-Premise
255	were	_	_	I-Premise
256	not	_	_	I-Premise
257	affected	_	_	I-Premise
258	adversely	_	_	I-Premise
259	by	_	_	I-Premise
260	use	_	_	I-Premise
261	of	_	_	I-Premise
262	epoetin	_	_	I-Premise
263	alpha	_	_	I-Premise
264	.	_	_	I-Premise

265	Epoetin	_	_	B-Claim
266	alpha	_	_	I-Claim
267	decreased	_	_	I-Claim
268	the	_	_	I-Claim
269	number	_	_	I-Claim
270	of	_	_	I-Claim
271	PRBC	_	_	I-Claim
272	transfusions	_	_	I-Claim
273	and	_	_	I-Claim
274	did	_	_	I-Claim
275	not	_	_	I-Claim
276	appear	_	_	I-Claim
277	to	_	_	I-Claim
278	have	_	_	I-Claim
279	a	_	_	I-Claim
280	negative	_	_	I-Claim
281	impact	_	_	I-Claim
282	on	_	_	I-Claim
283	remission	_	_	I-Claim
284	duration	_	_	I-Claim
285	.	_	_	I-Claim

286	No	_	_	B-Claim
287	difference	_	_	I-Claim
288	in	_	_	I-Claim
289	QOL	_	_	I-Claim
290	was	_	_	I-Claim
291	observed	_	_	I-Claim
292	.	_	_	I-Claim


0	A	_	_	O
1	single-item	_	_	O
2	linear	_	_	O
3	analogue	_	_	O
4	self-assessment	_	_	O
5	scale	_	_	O
6	for	_	_	O
7	mood	_	_	O
8	was	_	_	O
9	compared	_	_	O
10	with	_	_	O
11	a	_	_	O
12	28-item	_	_	O
13	adjective	_	_	O
14	checklist	_	_	O
15	for	_	_	O
16	emotional	_	_	O
17	well-being	_	_	O
18	.	_	_	O

19	To	_	_	O
20	confirm	_	_	O
21	its	_	_	O
22	concurrent	_	_	O
23	validity	_	_	O
24	and	_	_	O
25	responsiveness	_	_	O
26	to	_	_	O
27	treatment	_	_	O
28	and	_	_	O
29	recurrence	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	,	_	_	O
36	emotional	_	_	O
37	well-being	_	_	O
38	was	_	_	O
39	assessed	_	_	O
40	every	_	_	O
41	3	_	_	O
42	months	_	_	O
43	for	_	_	O
44	2	_	_	O
45	years	_	_	O
46	and	_	_	O
47	at	_	_	O
48	1	_	_	O
49	and	_	_	O
50	6	_	_	O
51	months	_	_	O
52	after	_	_	O
53	recurrence	_	_	O
54	in	_	_	O
55	1,169	_	_	O
56	patients	_	_	O
57	who	_	_	O
58	were	_	_	O
59	premenopausal	_	_	O
60	and	_	_	O
61	960	_	_	O
62	patients	_	_	O
63	who	_	_	O
64	were	_	_	O
65	postmenopausal	_	_	O
66	.	_	_	O

67	These	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	enrolled	_	_	O
71	in	_	_	O
72	two	_	_	O
73	International	_	_	O
74	Breast	_	_	O
75	Cancer	_	_	O
76	Study	_	_	O
77	Group	_	_	O
78	randomized	_	_	O
79	clinical	_	_	O
80	trials	_	_	O
81	in	_	_	O
82	operable	_	_	O
83	breast	_	_	O
84	cancer	_	_	O
85	conducted	_	_	O
86	from	_	_	O
87	1986	_	_	O
88	to	_	_	O
89	1993	_	_	O
90	.	_	_	O

91	To	_	_	O
92	assess	_	_	O
93	concurrent	_	_	O
94	validity	_	_	O
95	,	_	_	O
96	Pearson	_	_	O
97	's	_	_	O
98	correlation	_	_	O
99	between	_	_	O
100	the	_	_	O
101	linear	_	_	O
102	analogue	_	_	O
103	self-assessment	_	_	O
104	scale	_	_	O
105	and	_	_	O
106	the	_	_	O
107	adjective	_	_	O
108	checklist	_	_	O
109	were	_	_	O
110	calculated	_	_	O
111	for	_	_	O
112	each	_	_	O
113	time-point	_	_	O
114	within	_	_	O
115	each	_	_	O
116	treatment	_	_	O
117	group	_	_	O
118	and	_	_	O
119	for	_	_	O
120	the	_	_	O
121	two	_	_	O
122	assessments	_	_	O
123	after	_	_	O
124	recurrence	_	_	O
125	.	_	_	O

126	Responsiveness	_	_	O
127	to	_	_	O
128	treatment	_	_	O
129	and	_	_	O
130	recurrence	_	_	O
131	were	_	_	O
132	analyzed	_	_	O
133	using	_	_	O
134	paired	_	_	O
135	t	_	_	O
136	tests	_	_	O
137	and	_	_	O
138	the	_	_	O
139	squared	_	_	O
140	ratio	_	_	O
141	of	_	_	O
142	these	_	_	O
143	t	_	_	O
144	tests	_	_	O
145	,	_	_	O
146	an	_	_	O
147	estimate	_	_	O
148	of	_	_	O
149	relative	_	_	O
150	efficiency	_	_	O
151	.	_	_	O

152	Concurrent	_	_	O
153	validity	_	_	O
154	of	_	_	O
155	the	_	_	O
156	mood	_	_	O
157	linear	_	_	O
158	analogue	_	_	O
159	self-assessment	_	_	O
160	was	_	_	O
161	consistently	_	_	O
162	confirmed	_	_	O
163	across	_	_	O
164	four	_	_	O
165	language	_	_	O
166	groups	_	_	O
167	.	_	_	O

168	Both	_	_	B-Claim
169	measures	_	_	I-Claim
170	were	_	_	I-Claim
171	responsive	_	_	I-Claim
172	;	_	_	I-Claim
173	out	_	_	B-Premise
174	of	_	_	I-Premise
175	24	_	_	I-Premise
176	changes	_	_	I-Premise
177	over	_	_	I-Premise
178	time	_	_	I-Premise
179	,	_	_	I-Premise
180	19	_	_	I-Premise
181	were	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	expected	_	_	I-Premise
185	direction	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	linear	_	_	I-Premise
189	analogue	_	_	I-Premise
190	self-assessment	_	_	I-Premise
191	scale	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	<	_	_	I-Premise
195	or	_	_	I-Premise
196	=	_	_	I-Premise
197	0.05	_	_	I-Premise
198	for	_	_	I-Premise
199	9	_	_	I-Premise
200	of	_	_	I-Premise
201	19	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	17	_	_	I-Premise
205	for	_	_	I-Premise
206	the	_	_	I-Premise
207	adjective	_	_	I-Premise
208	checklist	_	_	I-Premise
209	(	_	_	I-Premise
210	p	_	_	I-Premise
211	<	_	_	I-Premise
212	or	_	_	I-Premise
213	=	_	_	I-Premise
214	0.05	_	_	I-Premise
215	for	_	_	I-Premise
216	10	_	_	I-Premise
217	of	_	_	I-Premise
218	17	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	linear	_	_	I-Premise
223	analogue	_	_	I-Premise
224	self-assessment	_	_	I-Premise
225	scale	_	_	I-Premise
226	was	_	_	I-Premise
227	less	_	_	I-Premise
228	but	_	_	I-Premise
229	significantly	_	_	I-Premise
230	efficient	_	_	I-Premise
231	for	_	_	I-Premise
232	detection	_	_	I-Premise
233	of	_	_	I-Premise
234	treatment	_	_	I-Premise
235	effects	_	_	I-Premise
236	,	_	_	I-Premise
237	with	_	_	I-Premise
238	relative	_	_	I-Premise
239	efficiency	_	_	I-Premise
240	estimates	_	_	I-Premise
241	ranging	_	_	I-Premise
242	from	_	_	I-Premise
243	0.16	_	_	I-Premise
244	to	_	_	I-Premise
245	2.45	_	_	I-Premise
246	and	_	_	I-Premise
247	a	_	_	I-Premise
248	median	_	_	I-Premise
249	of	_	_	I-Premise
250	0.66	_	_	I-Premise
251	among	_	_	I-Premise
252	the	_	_	I-Premise
253	comparisons	_	_	I-Premise
254	with	_	_	I-Premise
255	relatively	_	_	I-Premise
256	stable	_	_	I-Premise
257	estimates	_	_	I-Premise
258	(	_	_	I-Premise
259	/t/	_	_	I-Premise
260	>	_	_	I-Premise
261	or	_	_	I-Premise
262	=	_	_	I-Premise
263	1.0	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	more	_	_	I-Premise
267	efficient	_	_	I-Premise
268	for	_	_	I-Premise
269	recurrence	_	_	I-Premise
270	than	_	_	I-Premise
271	the	_	_	I-Premise
272	adjective	_	_	I-Premise
273	checklist	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Claim
276	mood	_	_	I-Claim
277	linear	_	_	I-Claim
278	analogue	_	_	I-Claim
279	self-assessment	_	_	I-Claim
280	scale	_	_	I-Claim
281	is	_	_	I-Claim
282	a	_	_	I-Claim
283	valid	_	_	I-Claim
284	indicator	_	_	I-Claim
285	of	_	_	I-Claim
286	emotional	_	_	I-Claim
287	well-being	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	breast	_	_	I-Claim
292	cancer	_	_	I-Claim
293	in	_	_	I-Claim
294	large	_	_	I-Claim
295	multicenter	_	_	I-Claim
296	,	_	_	I-Claim
297	multicultural	_	_	I-Claim
298	trials	_	_	I-Claim
299	in	_	_	I-Claim
300	which	_	_	I-Claim
301	comprehensive	_	_	I-Claim
302	scales	_	_	I-Claim
303	are	_	_	I-Claim
304	less	_	_	I-Claim
305	feasible	_	_	I-Claim
306	.	_	_	I-Claim

307	This	_	_	B-Claim
308	investigation	_	_	I-Claim
309	supports	_	_	I-Claim
310	the	_	_	I-Claim
311	clinical	_	_	I-Claim
312	relevance	_	_	I-Claim
313	of	_	_	I-Claim
314	linear	_	_	I-Claim
315	analogue	_	_	I-Claim
316	self-assessment	_	_	I-Claim
317	scales	_	_	I-Claim
318	as	_	_	I-Claim
319	indicators	_	_	I-Claim
320	of	_	_	I-Claim
321	components	_	_	I-Claim
322	of	_	_	I-Claim
323	quality	_	_	I-Claim
324	of	_	_	I-Claim
325	life	_	_	I-Claim
326	in	_	_	I-Claim
327	cancer	_	_	I-Claim
328	clinical	_	_	I-Claim
329	trials	_	_	I-Claim
330	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	predictive	_	_	O
4	value	_	_	O
5	of	_	_	O
6	PSA	_	_	O
7	for	_	_	O
8	progression	_	_	O
9	and	_	_	O
10	the	_	_	O
11	role	_	_	O
12	of	_	_	O
13	testosterone	_	_	O
14	for	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	androgen	_	_	O
25	deprivation	_	_	O
26	therapy	_	_	O
27	(	_	_	O
28	ADT	_	_	O
29	)	_	_	O
30	for	_	_	O
31	metastatic	_	_	O
32	prostate	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	PSA	_	_	O
36	and	_	_	O
37	testosterone	_	_	O
38	data	_	_	O
39	were	_	_	O
40	used	_	_	O
41	from	_	_	O
42	a	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	trial	_	_	O
46	randomizing	_	_	O
47	patients	_	_	O
48	without	_	_	O
49	progression	_	_	O
50	and	_	_	O
51	PSA	_	_	O
52	<	_	_	O
53	4	_	_	O
54	ng/ml	_	_	O
55	(	_	_	O
56	n	_	_	O
57	=	_	_	O
58	193	_	_	O
59	)	_	_	O
60	,	_	_	O
61	after	_	_	O
62	6	_	_	O
63	months	_	_	O
64	induction	_	_	O
65	course	_	_	O
66	,	_	_	O
67	between	_	_	O
68	continuous	_	_	O
69	(	_	_	O
70	CAD	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	96	_	_	O
76	)	_	_	O
77	and	_	_	O
78	intermittent	_	_	O
79	(	_	_	O
80	IAD	_	_	O
81	)	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	97	_	_	O
86	)	_	_	O
87	ADT	_	_	O
88	.	_	_	O

89	The	_	_	O
90	2-year	_	_	O
91	risk	_	_	O
92	of	_	_	O
93	progression	_	_	O
94	was	_	_	O
95	calculated	_	_	O
96	for	_	_	O
97	baseline	_	_	O
98	PSA	_	_	O
99	,	_	_	O
100	'fast	_	_	O
101	'	_	_	O
102	and	_	_	O
103	'slow	_	_	O
104	'	_	_	O
105	PSA	_	_	O
106	decline	_	_	O
107	to	_	_	O
108	<	_	_	O
109	4	_	_	O
110	ng/ml	_	_	O
111	(	_	_	O
112	60	_	_	O
113	days	_	_	O
114	cut-off	_	_	O
115	)	_	_	O
116	,	_	_	O
117	PSA	_	_	O
118	nadir	_	_	O
119	,	_	_	O
120	performance	_	_	O
121	status	_	_	O
122	and	_	_	O
123	pain	_	_	O
124	.	_	_	O

125	Testosterone	_	_	O
126	kinetics	_	_	O
127	and	_	_	O
128	QOL	_	_	O
129	were	_	_	O
130	also	_	_	O
131	evaluated	_	_	O
132	.	_	_	O

133	Univariate	_	_	O
134	Kaplan	_	_	O
135	Meier	_	_	O
136	survival	_	_	O
137	analysis	_	_	O
138	and	_	_	O
139	log	_	_	O
140	rank	_	_	O
141	tests	_	_	O
142	were	_	_	O
143	used	_	_	O
144	to	_	_	O
145	compare	_	_	O
146	the	_	_	O
147	risk	_	_	O
148	of	_	_	O
149	progression	_	_	O
150	.	_	_	O

151	For	_	_	O
152	progression	_	_	O
153	analysis	_	_	O
154	,	_	_	O
155	173	_	_	O
156	patients	_	_	O
157	'	_	_	O
158	data	_	_	O
159	were	_	_	O
160	available	_	_	O
161	.	_	_	O

162	The	_	_	O
163	2-year	_	_	O
164	risk	_	_	O
165	of	_	_	O
166	progression	_	_	O
167	for	_	_	O
168	baseline	_	_	O
169	PSA	_	_	O
170	<	_	_	O
171	50	_	_	O
172	ng/ml	_	_	O
173	,	_	_	O
174	50	_	_	O
175	to	_	_	O
176	<	_	_	O
177	500	_	_	O
178	ng/ml	_	_	O
179	,	_	_	O
180	and	_	_	O
181	â‰¥	_	_	O
182	500	_	_	O
183	ng/ml	_	_	O
184	was	_	_	O
185	25	_	_	O
186	%	_	_	O
187	,	_	_	O
188	55	_	_	O
189	%	_	_	O
190	,	_	_	O
191	and	_	_	O
192	76	_	_	O
193	%	_	_	O
194	(	_	_	O
195	P	_	_	O
196	=	_	_	O
197	0.03	_	_	O
198	)	_	_	O
199	in	_	_	O
200	CAD	_	_	O
201	,	_	_	O
202	and	_	_	O
203	38	_	_	O
204	%	_	_	O
205	,	_	_	O
206	64	_	_	O
207	%	_	_	O
208	,	_	_	O
209	and	_	_	O
210	85	_	_	O
211	%	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	0.006	_	_	O
216	)	_	_	O
217	in	_	_	O
218	IAD	_	_	O
219	,	_	_	O
220	respectively	_	_	O
221	.	_	_	O

222	The	_	_	B-Premise
223	2-year	_	_	I-Premise
224	risk	_	_	I-Premise
225	of	_	_	I-Premise
226	progression	_	_	I-Premise
227	for	_	_	I-Premise
228	PSA	_	_	I-Premise
229	nadir	_	_	I-Premise
230	â‰¤	_	_	I-Premise
231	0.2	_	_	I-Premise
232	ng/ml	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	>	_	_	I-Premise
236	0.2	_	_	I-Premise
237	to	_	_	I-Premise
238	4	_	_	I-Premise
239	ng/ml	_	_	I-Premise
240	in	_	_	I-Premise
241	CAD	_	_	I-Premise
242	was	_	_	I-Premise
243	31	_	_	I-Premise
244	%	_	_	I-Premise
245	and	_	_	I-Premise
246	70	_	_	I-Premise
247	%	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	0.001	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	respectively	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	the	_	_	I-Premise
258	IAD	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	a	_	_	I-Premise
262	similar	_	_	I-Premise
263	trend	_	_	I-Premise
264	was	_	_	I-Premise
265	seen	_	_	I-Premise
266	.	_	_	I-Premise

267	Patients	_	_	B-Premise
268	with	_	_	I-Premise
269	PSA	_	_	I-Premise
270	nadir	_	_	I-Premise
271	â‰¤	_	_	I-Premise
272	0.2	_	_	I-Premise
273	ng/ml	_	_	I-Premise
274	,	_	_	I-Premise
275	though	_	_	I-Premise
276	had	_	_	I-Premise
277	significantly	_	_	I-Premise
278	higher	_	_	I-Premise
279	2-year	_	_	I-Premise
280	risk	_	_	I-Premise
281	of	_	_	I-Premise
282	progression	_	_	I-Premise
283	compared	_	_	I-Premise
284	to	_	_	I-Premise
285	CAD	_	_	I-Premise
286	(	_	_	I-Premise
287	53	_	_	I-Premise
288	%	_	_	I-Premise
289	vs.	_	_	I-Premise
290	31	_	_	I-Premise
291	%	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	0.03	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	respectively	_	_	I-Premise
299	.	_	_	I-Premise

300	PSA	_	_	O
301	decline	_	_	O
302	showed	_	_	O
303	no	_	_	O
304	predictive	_	_	O
305	value	_	_	O
306	.	_	_	O

307	Patients	_	_	B-Premise
308	without	_	_	I-Premise
309	pain	_	_	I-Premise
310	had	_	_	I-Premise
311	a	_	_	I-Premise
312	significantly	_	_	I-Premise
313	lower	_	_	I-Premise
314	2-year	_	_	I-Premise
315	risk	_	_	I-Premise
316	of	_	_	I-Premise
317	progression	_	_	I-Premise
318	in	_	_	I-Premise
319	both	_	_	I-Premise
320	groups	_	_	I-Premise
321	.	_	_	I-Premise

322	Without	_	_	B-Premise
323	ADT	_	_	I-Premise
324	testosterone	_	_	I-Premise
325	remained	_	_	I-Premise
326	at	_	_	I-Premise
327	castrate	_	_	I-Premise
328	level	_	_	I-Premise
329	for	_	_	I-Premise
330	4	_	_	I-Premise
331	months	_	_	I-Premise
332	.	_	_	I-Premise

333	After	_	_	O
334	the	_	_	O
335	first	_	_	O
336	and	_	_	O
337	second	_	_	O
338	IAD	_	_	O
339	cycle	_	_	O
340	92	_	_	O
341	%	_	_	O
342	and	_	_	O
343	46	_	_	O
344	%	_	_	O
345	,	_	_	O
346	respectively	_	_	O
347	,	_	_	O
348	had	_	_	O
349	a	_	_	O
350	normalized	_	_	O
351	testosterone	_	_	O
352	.	_	_	O

353	No	_	_	B-Premise
354	QOL	_	_	I-Premise
355	difference	_	_	I-Premise
356	was	_	_	I-Premise
357	found	_	_	I-Premise
358	,	_	_	I-Premise
359	although	_	_	I-Premise
360	more	_	_	I-Premise
361	side	_	_	I-Premise
362	effects	_	_	I-Premise
363	occurred	_	_	I-Premise
364	in	_	_	I-Premise
365	CAD	_	_	I-Premise
366	.	_	_	I-Premise

367	Metastatic	_	_	B-Claim
368	prostate	_	_	I-Claim
369	cancer	_	_	I-Claim
370	patients	_	_	I-Claim
371	with	_	_	I-Claim
372	high	_	_	I-Claim
373	baseline	_	_	I-Claim
374	PSA	_	_	I-Claim
375	,	_	_	I-Claim
376	pain	_	_	I-Claim
377	,	_	_	I-Claim
378	and	_	_	I-Claim
379	high	_	_	I-Claim
380	PSA	_	_	I-Claim
381	nadir	_	_	I-Claim
382	have	_	_	I-Claim
383	a	_	_	I-Claim
384	poor	_	_	I-Claim
385	prognosis	_	_	I-Claim
386	with	_	_	I-Claim
387	ADT	_	_	I-Claim
388	.	_	_	I-Claim

389	Patients	_	_	B-Claim
390	with	_	_	I-Claim
391	low	_	_	I-Claim
392	PSA	_	_	I-Claim
393	nadir	_	_	I-Claim
394	do	_	_	I-Claim
395	significantly	_	_	I-Claim
396	worse	_	_	I-Claim
397	with	_	_	I-Claim
398	IAD	_	_	I-Claim
399	compared	_	_	I-Claim
400	with	_	_	I-Claim
401	CAD	_	_	I-Claim
402	.	_	_	I-Claim

403	Low	_	_	O
404	testosterone	_	_	O
405	after	_	_	O
406	ADT	_	_	O
407	and	_	_	O
408	incomplete	_	_	O
409	testosterone	_	_	O
410	recovery	_	_	O
411	may	_	_	O
412	explain	_	_	O
413	similar	_	_	O
414	QOL	_	_	O
415	.	_	_	O

416	Therefore	_	_	O
417	,	_	_	O
418	IAD	_	_	B-Claim
419	is	_	_	I-Claim
420	not	_	_	I-Claim
421	a	_	_	I-Claim
422	good	_	_	I-Claim
423	treatment	_	_	I-Claim
424	option	_	_	I-Claim
425	for	_	_	I-Claim
426	many	_	_	I-Claim
427	metastatic	_	_	I-Claim
428	prostate	_	_	I-Claim
429	cancer	_	_	I-Claim
430	patients	_	_	I-Claim
431	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	low-frequency	_	_	O
6	low-intensity	_	_	O
7	electrotherapy	_	_	O
8	and	_	_	O
9	manual	_	_	O
10	lymphatic	_	_	O
11	drainage	_	_	O
12	in	_	_	O
13	the	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	chronic	_	_	O
17	upper	_	_	O
18	limb	_	_	O
19	breast	_	_	O
20	cancer-related	_	_	O
21	lymphoedema	_	_	O
22	.	_	_	O

23	Cross-over	_	_	O
24	single-blind	_	_	O
25	random	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	.	_	_	O

29	Rehabilitation	_	_	O
30	service	_	_	O
31	.	_	_	O

32	Thirty-six	_	_	O
33	women	_	_	O
34	with	_	_	O
35	chronic	_	_	O
36	upper	_	_	O
37	limb	_	_	O
38	breast	_	_	O
39	cancer-related	_	_	O
40	lymphoedema	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	undergo	_	_	O
47	10	_	_	O
48	sessions	_	_	O
49	of	_	_	O
50	manual	_	_	O
51	lymphatic	_	_	O
52	drainage	_	_	O
53	followed	_	_	O
54	by	_	_	O
55	10	_	_	O
56	sessions	_	_	O
57	of	_	_	O
58	low-frequency	_	_	O
59	low-intensity	_	_	O
60	electrotherapy	_	_	O
61	or	_	_	O
62	to	_	_	O
63	undergo	_	_	O
64	first	_	_	O
65	low-frequency	_	_	O
66	low-intensity	_	_	O
67	electrotherapy	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	manual	_	_	O
71	lymphatic	_	_	O
72	drainage	_	_	O
73	.	_	_	O

74	There	_	_	O
75	was	_	_	O
76	a	_	_	O
77	month	_	_	O
78	of	_	_	O
79	washout	_	_	O
80	time	_	_	O
81	between	_	_	O
82	treatments	_	_	O
83	.	_	_	O

84	Each	_	_	O
85	patient	_	_	O
86	was	_	_	O
87	examined	_	_	O
88	just	_	_	O
89	before	_	_	O
90	and	_	_	O
91	after	_	_	O
92	each	_	_	O
93	treatment	_	_	O
94	.	_	_	O

95	Researchers	_	_	O
96	and	_	_	O
97	outcome	_	_	O
98	assessors	_	_	O
99	were	_	_	O
100	blinded	_	_	O
101	for	_	_	O
102	assigned	_	_	O
103	treatment	_	_	O
104	.	_	_	O

105	Outcomes	_	_	O
106	were	_	_	O
107	lymphoedema	_	_	O
108	volume	_	_	O
109	,	_	_	O
110	pain	_	_	O
111	,	_	_	O
112	heaviness	_	_	O
113	and	_	_	O
114	tightness	_	_	O
115	,	_	_	O
116	and	_	_	O
117	health-related	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	measured	_	_	O
122	with	_	_	O
123	the	_	_	O
124	Functional	_	_	O
125	Assessment	_	_	O
126	of	_	_	O
127	Cancer	_	_	O
128	Therapy	_	_	O
129	Questionnaire	_	_	O
130	for	_	_	O
131	Breast	_	_	O
132	Cancer	_	_	O
133	version	_	_	O
134	4	_	_	O
135	(	_	_	O
136	FACT-B+4	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Carry-over	_	_	O
140	,	_	_	O
141	period	_	_	O
142	and	_	_	O
143	treatment	_	_	O
144	effects	_	_	O
145	were	_	_	O
146	analysed	_	_	O
147	.	_	_	O

148	Treatment	_	_	O
149	effect	_	_	O
150	was	_	_	O
151	assessed	_	_	O
152	using	_	_	O
153	paired	_	_	O
154	t-test	_	_	O
155	.	_	_	O

156	Thirty	_	_	O
157	patients	_	_	O
158	finalized	_	_	O
159	treatment	_	_	O
160	.	_	_	O

161	Comparing	_	_	B-Premise
162	the	_	_	I-Premise
163	changes	_	_	I-Premise
164	in	_	_	I-Premise
165	low-frequency	_	_	I-Premise
166	low-intensity	_	_	I-Premise
167	electrotherapy	_	_	I-Premise
168	with	_	_	I-Premise
169	manual	_	_	I-Premise
170	lymphatic	_	_	I-Premise
171	drainage	_	_	I-Premise
172	changes	_	_	I-Premise
173	,	_	_	I-Premise
174	there	_	_	I-Premise
175	were	_	_	I-Premise
176	no	_	_	I-Premise
177	significant	_	_	I-Premise
178	differences	_	_	I-Premise
179	.	_	_	I-Premise

180	Low-frequency	_	_	B-Premise
181	low-intensity	_	_	I-Premise
182	electrotherapy	_	_	I-Premise
183	did	_	_	I-Premise
184	not	_	_	I-Premise
185	reduce	_	_	I-Premise
186	lymphoedema	_	_	I-Premise
187	volume	_	_	I-Premise
188	(	_	_	I-Premise
189	mean	_	_	I-Premise
190	of	_	_	I-Premise
191	change	_	_	I-Premise
192	=	_	_	I-Premise
193	19.77	_	_	I-Premise
194	mL	_	_	I-Premise
195	,	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	0.36	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	but	_	_	O
202	significant	_	_	B-Premise
203	reductions	_	_	I-Premise
204	were	_	_	I-Premise
205	observed	_	_	I-Premise
206	in	_	_	I-Premise
207	pain	_	_	I-Premise
208	,	_	_	I-Premise
209	heaviness	_	_	I-Premise
210	and	_	_	I-Premise
211	tightness	_	_	I-Premise
212	(	_	_	I-Premise
213	mean	_	_	I-Premise
214	of	_	_	I-Premise
215	change	_	_	I-Premise
216	=	_	_	I-Premise
217	13.1	_	_	I-Premise
218	,	_	_	I-Premise
219	16.2	_	_	I-Premise
220	and	_	_	I-Premise
221	6.4	_	_	I-Premise
222	mm	_	_	I-Premise
223	,	_	_	I-Premise
224	respectively	_	_	I-Premise
225	)	_	_	I-Premise
226	,	_	_	I-Premise
227	and	_	_	I-Premise
228	FACT-B+4	_	_	I-Premise
229	summaries	_	_	I-Premise
230	improved	_	_	I-Premise
231	significantly	_	_	I-Premise
232	(	_	_	I-Premise
233	Trial	_	_	I-Premise
234	Outcome	_	_	I-Premise
235	Index	_	_	I-Premise
236	mean	_	_	I-Premise
237	of	_	_	I-Premise
238	change	_	_	I-Premise
239	=	_	_	I-Premise
240	5.4	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.015	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Manual	_	_	B-Premise
248	lymphatic	_	_	I-Premise
249	drainage	_	_	I-Premise
250	showed	_	_	I-Premise
251	no	_	_	I-Premise
252	significant	_	_	I-Premise
253	changes	_	_	I-Premise
254	in	_	_	I-Premise
255	any	_	_	I-Premise
256	of	_	_	I-Premise
257	the	_	_	I-Premise
258	outcomes	_	_	I-Premise
259	.	_	_	I-Premise

260	Although	_	_	B-Claim
261	there	_	_	I-Claim
262	are	_	_	I-Claim
263	no	_	_	I-Claim
264	significant	_	_	I-Claim
265	differences	_	_	I-Claim
266	between	_	_	I-Claim
267	treatment	_	_	I-Claim
268	changes	_	_	I-Claim
269	,	_	_	I-Claim
270	the	_	_	B-Claim
271	observed	_	_	I-Claim
272	trend	_	_	I-Claim
273	towards	_	_	I-Claim
274	a	_	_	I-Claim
275	better	_	_	I-Claim
276	health-related	_	_	I-Claim
277	quality	_	_	I-Claim
278	of	_	_	I-Claim
279	life	_	_	I-Claim
280	is	_	_	I-Claim
281	remarkable	_	_	I-Claim
282	in	_	_	I-Claim
283	low-frequency	_	_	I-Claim
284	low-intensity	_	_	I-Claim
285	electrotherapy	_	_	I-Claim
286	.	_	_	I-Claim


0	Molecular	_	_	O
1	markers	_	_	O
2	to	_	_	O
3	predict	_	_	O
4	response	_	_	O
5	to	_	_	O
6	5-fluorouracil	_	_	O
7	(	_	_	O
8	FU	_	_	O
9	)	_	_	O
10	-based	_	_	O
11	treatment	_	_	O
12	of	_	_	O
13	recurrent	_	_	O
14	or	_	_	O
15	metastasised	_	_	O
16	colorectal	_	_	O
17	cancer	_	_	O
18	(	_	_	O
19	mCRC	_	_	O
20	)	_	_	O
21	are	_	_	O
22	not	_	_	O
23	established	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	trial	_	_	O
30	was	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	value	_	_	O
35	of	_	_	O
36	thymidylate	_	_	O
37	synthase	_	_	O
38	(	_	_	O
39	TS	_	_	O
40	)	_	_	O
41	,	_	_	O
42	a	_	_	O
43	key	_	_	O
44	enzyme	_	_	O
45	of	_	_	O
46	DNA	_	_	O
47	synthesis	_	_	O
48	and	_	_	O
49	target	_	_	O
50	of	_	_	O
51	5-FU	_	_	O
52	,	_	_	O
53	to	_	_	O
54	predict	_	_	O
55	response	_	_	O
56	to	_	_	O
57	chemotherapy	_	_	O
58	of	_	_	O
59	mCRC	_	_	O
60	.	_	_	O

61	Tumour	_	_	O
62	tissue	_	_	O
63	was	_	_	O
64	obtained	_	_	O
65	from	_	_	O
66	168	_	_	O
67	patients	_	_	O
68	with	_	_	O
69	mCRC	_	_	O
70	for	_	_	O
71	relative	_	_	O
72	thymidylate	_	_	O
73	synthase	_	_	O
74	(	_	_	O
75	TS	_	_	O
76	)	_	_	O
77	mRNA	_	_	O
78	quantitation	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	were	_	_	O
82	randomised	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	either	_	_	O
86	5-FU/folinic	_	_	O
87	acid	_	_	O
88	(	_	_	O
89	FA	_	_	O
90	,	_	_	O
91	FUFA	_	_	O
92	)	_	_	O
93	alone	_	_	O
94	or	_	_	O
95	in	_	_	O
96	combination	_	_	O
97	with	_	_	O
98	irinotecan	_	_	O
99	5-fluorouracil/folinic	_	_	O
100	acid	_	_	O
101	and	_	_	O
102	irinotecan	_	_	O
103	(	_	_	O
104	FOLFIRI	_	_	O
105	)	_	_	O
106	stratified	_	_	O
107	by	_	_	O
108	TS	_	_	O
109	(	_	_	O
110	low	_	_	O
111	versus	_	_	O
112	high	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Primary	_	_	O
116	end-point	_	_	O
117	was	_	_	O
118	overall	_	_	O
119	response	_	_	O
120	to	_	_	O
121	first-line	_	_	O
122	treatment	_	_	O
123	among	_	_	O
124	TS	_	_	O
125	high	_	_	O
126	patients	_	_	O
127	.	_	_	O

128	All	_	_	O
129	parties	_	_	O
130	,	_	_	O
131	except	_	_	O
132	for	_	_	O
133	the	_	_	O
134	randomisation	_	_	O
135	centre	_	_	O
136	,	_	_	O
137	were	_	_	O
138	blinded	_	_	O
139	for	_	_	O
140	TS	_	_	O
141	status	_	_	O
142	.	_	_	O

143	Biopsies	_	_	O
144	(	_	_	O
145	n=168	_	_	O
146	)	_	_	O
147	were	_	_	O
148	taken	_	_	O
149	without	_	_	O
150	complications	_	_	O
151	.	_	_	O

152	TS	_	_	O
153	levels	_	_	O
154	were	_	_	O
155	available	_	_	O
156	for	_	_	O
157	147	_	_	O
158	patients	_	_	O
159	(	_	_	O
160	87.5	_	_	O
161	%	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Analysing	_	_	B-Premise
165	response	_	_	I-Premise
166	to	_	_	I-Premise
167	FUFA	_	_	I-Premise
168	and	_	_	I-Premise
169	FOLFIRI	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	per	_	_	I-Premise
173	protocol	_	_	I-Premise
174	set	_	_	I-Premise
175	(	_	_	I-Premise
176	n=119	_	_	I-Premise
177	)	_	_	I-Premise
178	after	_	_	I-Premise
179	un-blinding	_	_	I-Premise
180	TS	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	data	_	_	I-Premise
184	base	_	_	I-Premise
185	revealed	_	_	I-Premise
186	a	_	_	I-Premise
187	trend	_	_	I-Premise
188	to	_	_	I-Premise
189	better	_	_	I-Premise
190	overall	_	_	I-Premise
191	response	_	_	I-Premise
192	to	_	_	I-Premise
193	FOLFIRI	_	_	I-Premise
194	(	_	_	I-Premise
195	9/19	_	_	I-Premise
196	,	_	_	I-Premise
197	47	_	_	I-Premise
198	%	_	_	I-Premise
199	)	_	_	I-Premise
200	in	_	_	I-Premise
201	TS	_	_	I-Premise
202	high	_	_	I-Premise
203	compared	_	_	I-Premise
204	to	_	_	I-Premise
205	FUFA	_	_	I-Premise
206	(	_	_	I-Premise
207	5/23	_	_	I-Premise
208	,	_	_	I-Premise
209	22	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	p=0.077	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	In	_	_	B-Premise
216	patients	_	_	I-Premise
217	with	_	_	I-Premise
218	biopsies	_	_	I-Premise
219	taken	_	_	I-Premise
220	from	_	_	I-Premise
221	liver	_	_	I-Premise
222	lesions	_	_	I-Premise
223	(	_	_	I-Premise
224	n=91	_	_	I-Premise
225	)	_	_	I-Premise
226	overall	_	_	I-Premise
227	response	_	_	I-Premise
228	to	_	_	I-Premise
229	FOLFIRI	_	_	I-Premise
230	and	_	_	I-Premise
231	FUFA	_	_	I-Premise
232	in	_	_	I-Premise
233	TS	_	_	I-Premise
234	high	_	_	I-Premise
235	was	_	_	I-Premise
236	53	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	9/17	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	18	_	_	I-Premise
243	%	_	_	I-Premise
244	(	_	_	I-Premise
245	3/17	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	respectively	_	_	I-Premise
249	(	_	_	I-Premise
250	p=0.035	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	In	_	_	B-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	low	_	_	I-Premise
257	TS	_	_	I-Premise
258	,	_	_	I-Premise
259	no	_	_	I-Premise
260	remarkable	_	_	I-Premise
261	difference	_	_	I-Premise
262	in	_	_	I-Premise
263	overall	_	_	I-Premise
264	response	_	_	I-Premise
265	to	_	_	I-Premise
266	FOLFIRI	_	_	I-Premise
267	and	_	_	I-Premise
268	FUFA	_	_	I-Premise
269	was	_	_	I-Premise
270	observed	_	_	I-Premise
271	.	_	_	I-Premise

272	Taking	_	_	B-Claim
273	a	_	_	I-Claim
274	pre-treatment	_	_	I-Claim
275	biopsy	_	_	I-Claim
276	is	_	_	I-Claim
277	a	_	_	I-Claim
278	safe	_	_	I-Claim
279	and	_	_	I-Claim
280	feasible	_	_	I-Claim
281	procedure	_	_	I-Claim
282	in	_	_	I-Claim
283	mCRC	_	_	I-Claim
284	.	_	_	I-Claim

285	After	_	_	B-Claim
286	validation	_	_	I-Claim
287	of	_	_	I-Claim
288	our	_	_	I-Claim
289	data	_	_	I-Claim
290	in	_	_	I-Claim
291	a	_	_	I-Claim
292	larger	_	_	I-Claim
293	group	_	_	I-Claim
294	TS	_	_	I-Claim
295	determination	_	_	I-Claim
296	may	_	_	I-Claim
297	have	_	_	I-Claim
298	the	_	_	I-Claim
299	potential	_	_	I-Claim
300	to	_	_	I-Claim
301	better	_	_	I-Claim
302	help	_	_	I-Claim
303	direct	_	_	I-Claim
304	systemic	_	_	I-Claim
305	treatment	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	primarily	_	_	I-Claim
310	non-resectable	_	_	I-Claim
311	mCRC	_	_	I-Claim
312	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	known	_	_	O
4	whether	_	_	O
5	low-dose	_	_	O
6	radioiodine	_	_	O
7	(	_	_	O
8	1.1	_	_	O
9	GBq	_	_	O
10	[	_	_	O
11	30	_	_	O
12	mCi	_	_	O
13	]	_	_	O
14	)	_	_	O
15	is	_	_	O
16	as	_	_	O
17	effective	_	_	O
18	as	_	_	O
19	high-dose	_	_	O
20	radioiodine	_	_	O
21	(	_	_	O
22	3.7	_	_	O
23	GBq	_	_	O
24	[	_	_	O
25	100	_	_	O
26	mCi	_	_	O
27	]	_	_	O
28	)	_	_	O
29	for	_	_	O
30	treating	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	differentiated	_	_	O
34	thyroid	_	_	O
35	cancer	_	_	O
36	or	_	_	O
37	whether	_	_	O
38	the	_	_	O
39	effects	_	_	O
40	of	_	_	O
41	radioiodine	_	_	O
42	(	_	_	O
43	especially	_	_	O
44	at	_	_	O
45	a	_	_	O
46	low	_	_	O
47	dose	_	_	O
48	)	_	_	O
49	are	_	_	O
50	influenced	_	_	O
51	by	_	_	O
52	using	_	_	O
53	either	_	_	O
54	recombinant	_	_	O
55	human	_	_	O
56	thyrotropin	_	_	O
57	(	_	_	O
58	thyrotropin	_	_	O
59	alfa	_	_	O
60	)	_	_	O
61	or	_	_	O
62	thyroid	_	_	O
63	hormone	_	_	O
64	withdrawal	_	_	O
65	.	_	_	O

66	At	_	_	O
67	29	_	_	O
68	centers	_	_	O
69	in	_	_	O
70	the	_	_	O
71	United	_	_	O
72	Kingdom	_	_	O
73	,	_	_	O
74	we	_	_	O
75	conducted	_	_	O
76	a	_	_	O
77	randomized	_	_	O
78	noninferiority	_	_	O
79	trial	_	_	O
80	comparing	_	_	O
81	low-dose	_	_	O
82	and	_	_	O
83	high-dose	_	_	O
84	radioiodine	_	_	O
85	,	_	_	O
86	each	_	_	O
87	in	_	_	O
88	combination	_	_	O
89	with	_	_	O
90	either	_	_	O
91	thyrotropin	_	_	O
92	alfa	_	_	O
93	or	_	_	O
94	thyroid	_	_	O
95	hormone	_	_	O
96	withdrawal	_	_	O
97	before	_	_	O
98	ablation	_	_	O
99	.	_	_	O

100	Patients	_	_	O
101	(	_	_	O
102	age	_	_	O
103	range	_	_	O
104	,	_	_	O
105	16	_	_	O
106	to	_	_	O
107	80	_	_	O
108	years	_	_	O
109	)	_	_	O
110	had	_	_	O
111	tumor	_	_	O
112	stage	_	_	O
113	T1	_	_	O
114	to	_	_	O
115	T3	_	_	O
116	,	_	_	O
117	with	_	_	O
118	possible	_	_	O
119	spread	_	_	O
120	to	_	_	O
121	nearby	_	_	O
122	lymph	_	_	O
123	nodes	_	_	O
124	but	_	_	O
125	without	_	_	O
126	metastasis	_	_	O
127	.	_	_	O

128	End	_	_	O
129	points	_	_	O
130	were	_	_	O
131	the	_	_	O
132	rate	_	_	O
133	of	_	_	O
134	success	_	_	O
135	of	_	_	O
136	ablation	_	_	O
137	at	_	_	O
138	6	_	_	O
139	to	_	_	O
140	9	_	_	O
141	months	_	_	O
142	,	_	_	O
143	adverse	_	_	O
144	events	_	_	O
145	,	_	_	O
146	quality	_	_	O
147	of	_	_	O
148	life	_	_	O
149	,	_	_	O
150	and	_	_	O
151	length	_	_	O
152	of	_	_	O
153	hospital	_	_	O
154	stay	_	_	O
155	.	_	_	O

156	A	_	_	O
157	total	_	_	O
158	of	_	_	O
159	438	_	_	O
160	patients	_	_	O
161	underwent	_	_	O
162	randomization	_	_	O
163	;	_	_	O
164	data	_	_	O
165	could	_	_	O
166	be	_	_	O
167	analyzed	_	_	O
168	for	_	_	O
169	421	_	_	O
170	.	_	_	O

171	Ablation	_	_	B-Premise
172	success	_	_	I-Premise
173	rates	_	_	I-Premise
174	were	_	_	I-Premise
175	85.0	_	_	I-Premise
176	%	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	group	_	_	I-Premise
180	receiving	_	_	I-Premise
181	low-dose	_	_	I-Premise
182	radioiodine	_	_	I-Premise
183	versus	_	_	I-Premise
184	88.9	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	group	_	_	I-Premise
189	receiving	_	_	I-Premise
190	the	_	_	I-Premise
191	high	_	_	I-Premise
192	dose	_	_	I-Premise
193	and	_	_	I-Premise
194	87.1	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	thyrotropin	_	_	I-Premise
199	alfa	_	_	I-Premise
200	group	_	_	I-Premise
201	versus	_	_	I-Premise
202	86.7	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	group	_	_	I-Premise
207	undergoing	_	_	I-Premise
208	thyroid	_	_	I-Premise
209	hormone	_	_	I-Premise
210	withdrawal	_	_	I-Premise
211	.	_	_	I-Premise

212	All	_	_	B-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	confidence	_	_	I-Premise
216	intervals	_	_	I-Premise
217	for	_	_	I-Premise
218	the	_	_	I-Premise
219	differences	_	_	I-Premise
220	were	_	_	I-Premise
221	within	_	_	I-Premise
222	Â±10	_	_	I-Premise
223	percentage	_	_	I-Premise
224	points	_	_	I-Premise
225	,	_	_	I-Premise
226	indicating	_	_	I-Premise
227	noninferiority	_	_	I-Premise
228	.	_	_	I-Premise

229	Similar	_	_	B-Premise
230	results	_	_	I-Premise
231	were	_	_	I-Premise
232	found	_	_	I-Premise
233	for	_	_	I-Premise
234	low-dose	_	_	I-Premise
235	radioiodine	_	_	I-Premise
236	plus	_	_	I-Premise
237	thyrotropin	_	_	I-Premise
238	alfa	_	_	I-Premise
239	(	_	_	I-Premise
240	84.3	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	versus	_	_	I-Premise
244	high-dose	_	_	I-Premise
245	radioiodine	_	_	I-Premise
246	plus	_	_	I-Premise
247	thyroid	_	_	I-Premise
248	hormone	_	_	I-Premise
249	withdrawal	_	_	I-Premise
250	(	_	_	I-Premise
251	87.6	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	or	_	_	I-Premise
255	high-dose	_	_	I-Premise
256	radioiodine	_	_	I-Premise
257	plus	_	_	I-Premise
258	thyrotropin	_	_	I-Premise
259	alfa	_	_	I-Premise
260	(	_	_	I-Premise
261	90.2	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	More	_	_	B-Premise
266	patients	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	high-dose	_	_	I-Premise
270	group	_	_	I-Premise
271	than	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	low-dose	_	_	I-Premise
275	group	_	_	I-Premise
276	were	_	_	I-Premise
277	hospitalized	_	_	I-Premise
278	for	_	_	I-Premise
279	at	_	_	I-Premise
280	least	_	_	I-Premise
281	3	_	_	I-Premise
282	days	_	_	I-Premise
283	(	_	_	I-Premise
284	36.3	_	_	I-Premise
285	%	_	_	I-Premise
286	vs.	_	_	I-Premise
287	13.0	_	_	I-Premise
288	%	_	_	I-Premise
289	,	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	0.001	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Premise
296	proportions	_	_	I-Premise
297	of	_	_	I-Premise
298	patients	_	_	I-Premise
299	with	_	_	I-Premise
300	adverse	_	_	I-Premise
301	events	_	_	I-Premise
302	were	_	_	I-Premise
303	21	_	_	I-Premise
304	%	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	low-dose	_	_	I-Premise
308	group	_	_	I-Premise
309	versus	_	_	I-Premise
310	33	_	_	I-Premise
311	%	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	high-dose	_	_	I-Premise
315	group	_	_	I-Premise
316	(	_	_	I-Premise
317	P=0.007	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	23	_	_	I-Premise
321	%	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	thyrotropin	_	_	I-Premise
325	alfa	_	_	I-Premise
326	group	_	_	I-Premise
327	versus	_	_	I-Premise
328	30	_	_	I-Premise
329	%	_	_	I-Premise
330	in	_	_	I-Premise
331	the	_	_	I-Premise
332	group	_	_	I-Premise
333	undergoing	_	_	I-Premise
334	thyroid	_	_	I-Premise
335	hormone	_	_	I-Premise
336	withdrawal	_	_	I-Premise
337	(	_	_	I-Premise
338	P=0.11	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	Low-dose	_	_	B-Claim
342	radioiodine	_	_	I-Claim
343	plus	_	_	I-Claim
344	thyrotropin	_	_	I-Claim
345	alfa	_	_	I-Claim
346	was	_	_	I-Claim
347	as	_	_	I-Claim
348	effective	_	_	I-Claim
349	as	_	_	I-Claim
350	high-dose	_	_	I-Claim
351	radioiodine	_	_	I-Claim
352	,	_	_	I-Claim
353	with	_	_	I-Claim
354	a	_	_	I-Claim
355	lower	_	_	I-Claim
356	rate	_	_	I-Claim
357	of	_	_	I-Claim
358	adverse	_	_	I-Claim
359	events	_	_	I-Claim
360	.	_	_	I-Claim


0	Although	_	_	O
1	numerous	_	_	O
2	treatment	_	_	O
3	modalities	_	_	O
4	have	_	_	O
5	been	_	_	O
6	explored	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	HCC	_	_	O
12	,	_	_	O
13	the	_	_	O
14	therapeutic	_	_	O
15	options	_	_	O
16	are	_	_	O
17	still	_	_	O
18	limited	_	_	O
19	.	_	_	O

20	Somatostatin	_	_	B-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	shown	_	_	I-Claim
24	to	_	_	I-Claim
25	have	_	_	I-Claim
26	antimitotic	_	_	I-Claim
27	activity	_	_	I-Claim
28	in	_	_	I-Claim
29	endocrine	_	_	I-Claim
30	as	_	_	I-Claim
31	well	_	_	I-Claim
32	as	_	_	I-Claim
33	in	_	_	I-Claim
34	a	_	_	I-Claim
35	variety	_	_	I-Claim
36	of	_	_	I-Claim
37	nonendocrine	_	_	I-Claim
38	tumors	_	_	I-Claim
39	.	_	_	I-Claim

40	Expression	_	_	B-Premise
41	of	_	_	I-Premise
42	somatostatin	_	_	I-Premise
43	receptors	_	_	I-Premise
44	is	_	_	I-Premise
45	found	_	_	I-Premise
46	in	_	_	I-Premise
47	HCCs	_	_	I-Premise
48	,	_	_	I-Premise
49	but	_	_	O
50	the	_	_	B-Claim
51	efficacy	_	_	I-Claim
52	of	_	_	I-Claim
53	the	_	_	I-Claim
54	somatostatin	_	_	I-Claim
55	analogue	_	_	I-Claim
56	octreotide	_	_	I-Claim
57	remains	_	_	I-Claim
58	controversial	_	_	I-Claim
59	.	_	_	I-Claim

60	Therefore	_	_	O
61	,	_	_	O
62	a	_	_	O
63	randomized	_	_	O
64	double-blind	_	_	O
65	placebo-controlled	_	_	O
66	multicenter	_	_	O
67	trial	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	to	_	_	O
71	assess	_	_	O
72	the	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	long-acting	_	_	O
76	octreotide	_	_	O
77	for	_	_	O
78	the	_	_	O
79	treatment	_	_	O
80	of	_	_	O
81	advanced	_	_	O
82	HCC	_	_	O
83	.	_	_	O

84	One	_	_	O
85	hundred	_	_	O
86	twenty	_	_	O
87	untreated	_	_	O
88	patients	_	_	O
89	with	_	_	O
90	histologically	_	_	O
91	confirmed	_	_	O
92	HCC	_	_	O
93	were	_	_	O
94	randomized	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	either	_	_	O
98	long-acting	_	_	O
99	octreotide	_	_	O
100	(	_	_	O
101	Sandostation	_	_	O
102	LAR	_	_	O
103	30	_	_	O
104	mg	_	_	O
105	)	_	_	O
106	intramuscularly	_	_	O
107	every	_	_	O
108	4	_	_	O
109	weeks	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	.	_	_	O

113	The	_	_	O
114	study	_	_	O
115	groups	_	_	O
116	were	_	_	O
117	comparable	_	_	O
118	with	_	_	O
119	respect	_	_	O
120	to	_	_	O
121	clinical	_	_	O
122	characteristics	_	_	O
123	.	_	_	O

124	There	_	_	B-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	difference	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	cumulative	_	_	I-Premise
131	survival	_	_	I-Premise
132	.	_	_	I-Premise

133	The	_	_	B-Premise
134	median	_	_	I-Premise
135	survival	_	_	I-Premise
136	time	_	_	I-Premise
137	was	_	_	I-Premise
138	4.7	_	_	I-Premise
139	months	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	octreotide	_	_	I-Premise
143	group	_	_	I-Premise
144	compared	_	_	I-Premise
145	with	_	_	I-Premise
146	5.3	_	_	I-Premise
147	months	_	_	I-Premise
148	in	_	_	I-Premise
149	the	_	_	I-Premise
150	control	_	_	I-Premise
151	group	_	_	I-Premise
152	.	_	_	I-Premise

153	Six-month	_	_	B-Premise
154	survival	_	_	I-Premise
155	rates	_	_	I-Premise
156	were	_	_	I-Premise
157	41	_	_	I-Premise
158	%	_	_	I-Premise
159	for	_	_	I-Premise
160	octreotide	_	_	I-Premise
161	patients	_	_	I-Premise
162	and	_	_	I-Premise
163	42	_	_	I-Premise
164	%	_	_	I-Premise
165	for	_	_	I-Premise
166	control	_	_	I-Premise
167	patients	_	_	I-Premise
168	,	_	_	I-Premise
169	respectively	_	_	I-Premise
170	.	_	_	I-Premise

171	The	_	_	B-Premise
172	unadjusted	_	_	I-Premise
173	relative	_	_	I-Premise
174	risk	_	_	I-Premise
175	for	_	_	I-Premise
176	mortality	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	octreotide	_	_	I-Premise
180	group	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	patients	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	control	_	_	I-Premise
187	group	_	_	I-Premise
188	was	_	_	I-Premise
189	1.11	_	_	I-Premise
190	(	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	CI	_	_	I-Premise
194	0.76-1.63	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	0.59	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	When	_	_	B-Premise
202	adjusted	_	_	I-Premise
203	for	_	_	I-Premise
204	Okuda	_	_	I-Premise
205	,	_	_	I-Premise
206	CTP	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	Cancer	_	_	I-Premise
210	of	_	_	I-Premise
211	the	_	_	I-Premise
212	Liver	_	_	I-Premise
213	Italian	_	_	I-Premise
214	Program	_	_	I-Premise
215	(	_	_	I-Premise
216	CLIP	_	_	I-Premise
217	)	_	_	I-Premise
218	scores	_	_	I-Premise
219	,	_	_	I-Premise
220	the	_	_	I-Premise
221	relative	_	_	I-Premise
222	risk	_	_	I-Premise
223	for	_	_	I-Premise
224	octreotide	_	_	I-Premise
225	did	_	_	I-Premise
226	not	_	_	I-Premise
227	change	_	_	I-Premise
228	markedly	_	_	I-Premise
229	and	_	_	I-Premise
230	was	_	_	I-Premise
231	1.05	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	0.71-1.55	_	_	I-Premise
237	;	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	0.83	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Claim
244	CLIP	_	_	I-Claim
245	score	_	_	I-Claim
246	seems	_	_	I-Claim
247	to	_	_	I-Claim
248	predict	_	_	I-Claim
249	survival	_	_	I-Claim
250	better	_	_	I-Claim
251	than	_	_	I-Claim
252	both	_	_	I-Claim
253	Okuda	_	_	I-Claim
254	and	_	_	I-Claim
255	CTP	_	_	I-Claim
256	score	_	_	I-Claim
257	.	_	_	I-Claim

258	The	_	_	B-Claim
259	randomized	_	_	I-Claim
260	controlled	_	_	I-Claim
261	double-blind	_	_	I-Claim
262	HECTOR	_	_	I-Claim
263	trial	_	_	I-Claim
264	showed	_	_	I-Claim
265	no	_	_	I-Claim
266	survival	_	_	I-Claim
267	benefit	_	_	I-Claim
268	for	_	_	I-Claim
269	HCC	_	_	I-Claim
270	patients	_	_	I-Claim
271	treated	_	_	I-Claim
272	with	_	_	I-Claim
273	long-acting	_	_	I-Claim
274	octreotide	_	_	I-Claim
275	compared	_	_	I-Claim
276	with	_	_	I-Claim
277	placebo	_	_	I-Claim
278	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	tamoxifen	_	_	O
6	and	_	_	O
7	radiotherapy	_	_	O
8	(	_	_	O
9	RT	_	_	O
10	)	_	_	O
11	for	_	_	O
12	the	_	_	O
13	prevention	_	_	O
14	and	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	gynecomastia	_	_	O
18	and	_	_	O
19	breast	_	_	O
20	pain	_	_	O
21	during	_	_	O
22	adjuvant	_	_	O
23	bicalutamide	_	_	O
24	monotherapy	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	prostatectomy	_	_	O
28	(	_	_	O
29	RP	_	_	O
30	)	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	prostate	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Also	_	_	O
38	,	_	_	O
39	we	_	_	O
40	evaluated	_	_	O
41	their	_	_	O
42	effects	_	_	O
43	on	_	_	O
44	patient	_	_	O
45	hormonal	_	_	O
46	status	_	_	O
47	,	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	(	_	_	O
52	QOL	_	_	O
53	)	_	_	O
54	,	_	_	O
55	sexual	_	_	O
56	function	_	_	O
57	and	_	_	O
58	prostate	_	_	O
59	specific	_	_	O
60	antigen	_	_	O
61	relapse-free	_	_	O
62	survival	_	_	O
63	.	_	_	O

64	This	_	_	O
65	was	_	_	O
66	a	_	_	O
67	multicenter	_	_	O
68	prospective	_	_	O
69	trial	_	_	O
70	.	_	_	O

71	From	_	_	O
72	January	_	_	O
73	2002	_	_	O
74	to	_	_	O
75	February	_	_	O
76	2004	_	_	O
77	,	_	_	O
78	102	_	_	O
79	patients	_	_	O
80	who	_	_	O
81	had	_	_	O
82	undergone	_	_	O
83	RP	_	_	O
84	for	_	_	O
85	localized	_	_	O
86	or	_	_	O
87	locally	_	_	O
88	advanced	_	_	O
89	prostate	_	_	O
90	cancer	_	_	O
91	were	_	_	O
92	recruited	_	_	O
93	and	_	_	O
94	randomized	_	_	O
95	into	_	_	O
96	3	_	_	O
97	groups	_	_	O
98	,	_	_	O
99	namely	_	_	O
100	group	_	_	O
101	1-those	_	_	O
102	receiving	_	_	O
103	only	_	_	O
104	150	_	_	O
105	mg	_	_	O
106	bicalutamide	_	_	O
107	as	_	_	O
108	adjuvant	_	_	O
109	hormonal	_	_	O
110	therapy	_	_	O
111	,	_	_	O
112	group	_	_	O
113	2-those	_	_	O
114	receiving	_	_	O
115	bicalutamide	_	_	O
116	and	_	_	O
117	10	_	_	O
118	mg	_	_	O
119	tamoxifen	_	_	O
120	,	_	_	O
121	and	_	_	O
122	group	_	_	O
123	3-those	_	_	O
124	receiving	_	_	O
125	bicalutamide	_	_	O
126	and	_	_	O
127	RT	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	in	_	_	O
131	group	_	_	O
132	1	_	_	O
133	in	_	_	O
134	whom	_	_	O
135	gynecomastia	_	_	O
136	or	_	_	O
137	breast	_	_	O
138	pain	_	_	O
139	developed	_	_	O
140	were	_	_	O
141	subsequently	_	_	O
142	randomized	_	_	O
143	to	_	_	O
144	receive	_	_	O
145	tamoxifen	_	_	O
146	or	_	_	O
147	RT	_	_	O
148	soon	_	_	O
149	after	_	_	O
150	symptoms	_	_	O
151	started	_	_	O
152	.	_	_	O

153	Gynecomastia	_	_	O
154	,	_	_	O
155	breast	_	_	O
156	pain	_	_	O
157	,	_	_	O
158	prostate	_	_	O
159	specific	_	_	O
160	antigen	_	_	O
161	,	_	_	O
162	QOL	_	_	O
163	,	_	_	O
164	sexual	_	_	O
165	function	_	_	O
166	and	_	_	O
167	hormonal	_	_	O
168	levels	_	_	O
169	were	_	_	O
170	assessed	_	_	O
171	.	_	_	O

172	Minimum	_	_	O
173	followup	_	_	O
174	was	_	_	O
175	12	_	_	O
176	months	_	_	O
177	.	_	_	O

178	Of	_	_	B-Premise
179	group	_	_	I-Premise
180	1	_	_	I-Premise
181	patients	_	_	I-Premise
182	67	_	_	I-Premise
183	%	_	_	I-Premise
184	had	_	_	I-Premise
185	gynecomastia	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	8	_	_	I-Premise
189	%	_	_	I-Premise
190	in	_	_	I-Premise
191	group	_	_	I-Premise
192	2	_	_	I-Premise
193	and	_	_	I-Premise
194	34	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	group	_	_	I-Premise
198	3	_	_	I-Premise
199	.	_	_	I-Premise

200	Breast	_	_	B-Premise
201	pain	_	_	I-Premise
202	was	_	_	I-Premise
203	more	_	_	I-Premise
204	frequent	_	_	I-Premise
205	in	_	_	I-Premise
206	group	_	_	I-Premise
207	1	_	_	I-Premise
208	than	_	_	I-Premise
209	in	_	_	I-Premise
210	groups	_	_	I-Premise
211	2	_	_	I-Premise
212	and	_	_	I-Premise
213	3	_	_	I-Premise
214	(	_	_	I-Premise
215	58	_	_	I-Premise
216	%	_	_	I-Premise
217	vs	_	_	I-Premise
218	7	_	_	I-Premise
219	%	_	_	I-Premise
220	and	_	_	I-Premise
221	30	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	respectively	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Differences	_	_	B-Premise
228	were	_	_	I-Premise
229	significant	_	_	I-Premise
230	between	_	_	I-Premise
231	groups	_	_	I-Premise
232	1	_	_	I-Premise
233	and	_	_	I-Premise
234	2	_	_	I-Premise
235	(	_	_	I-Premise
236	OR	_	_	I-Premise
237	0.12	_	_	I-Premise
238	p	_	_	I-Premise
239	<	_	_	I-Premise
240	0.001	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	groups	_	_	I-Premise
245	1	_	_	I-Premise
246	and	_	_	I-Premise
247	3	_	_	I-Premise
248	(	_	_	I-Premise
249	OR	_	_	I-Premise
250	0.52	_	_	I-Premise
251	p	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	patients	_	_	I-Premise
258	in	_	_	I-Premise
259	group	_	_	I-Premise
260	1	_	_	I-Premise
261	who	_	_	I-Premise
262	had	_	_	I-Premise
263	gynecomastia	_	_	I-Premise
264	or	_	_	I-Premise
265	breast	_	_	I-Premise
266	pain	_	_	I-Premise
267	a	_	_	I-Premise
268	significant	_	_	I-Premise
269	decrease	_	_	I-Premise
270	in	_	_	I-Premise
271	symptoms	_	_	I-Premise
272	was	_	_	I-Premise
273	achieved	_	_	I-Premise
274	in	_	_	I-Premise
275	those	_	_	I-Premise
276	receiving	_	_	I-Premise
277	tamoxifen	_	_	I-Premise
278	(	_	_	I-Premise
279	p	_	_	I-Premise
280	<	_	_	I-Premise
281	0.05	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Treatments	_	_	B-Premise
285	were	_	_	I-Premise
286	well	_	_	I-Premise
287	tolerated	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	3	_	_	I-Premise
291	groups	_	_	I-Premise
292	.	_	_	I-Premise

293	No	_	_	B-Premise
294	differences	_	_	I-Premise
295	in	_	_	I-Premise
296	QOL	_	_	I-Premise
297	between	_	_	I-Premise
298	groups	_	_	I-Premise
299	2	_	_	I-Premise
300	and	_	_	I-Premise
301	3	_	_	I-Premise
302	were	_	_	I-Premise
303	found	_	_	I-Premise
304	.	_	_	I-Premise

305	At	_	_	B-Premise
306	a	_	_	I-Premise
307	median	_	_	I-Premise
308	followup	_	_	I-Premise
309	of	_	_	I-Premise
310	26	_	_	I-Premise
311	months	_	_	I-Premise
312	we	_	_	I-Premise
313	observed	_	_	I-Premise
314	12	_	_	I-Premise
315	biochemical	_	_	I-Premise
316	relapses	_	_	I-Premise
317	.	_	_	I-Premise

318	Gynecomastia	_	_	B-Claim
319	and	_	_	I-Claim
320	breast	_	_	I-Claim
321	pain	_	_	I-Claim
322	induced	_	_	I-Claim
323	by	_	_	I-Claim
324	bicalutamide	_	_	I-Claim
325	monotherapy	_	_	I-Claim
326	after	_	_	I-Claim
327	RP	_	_	I-Claim
328	can	_	_	I-Claim
329	be	_	_	I-Claim
330	prevented	_	_	I-Claim
331	and	_	_	I-Claim
332	treated	_	_	I-Claim
333	.	_	_	I-Claim

334	Tamoxifen	_	_	B-Claim
335	has	_	_	I-Claim
336	been	_	_	I-Claim
337	shown	_	_	I-Claim
338	to	_	_	I-Claim
339	be	_	_	I-Claim
340	more	_	_	I-Claim
341	effective	_	_	I-Claim
342	and	_	_	I-Claim
343	safe	_	_	I-Claim
344	than	_	_	I-Claim
345	RT	_	_	I-Claim
346	in	_	_	I-Claim
347	this	_	_	I-Claim
348	setting	_	_	I-Claim
349	.	_	_	I-Claim

350	QOL	_	_	B-Claim
351	and	_	_	I-Claim
352	sexual	_	_	I-Claim
353	function	_	_	I-Claim
354	are	_	_	I-Claim
355	not	_	_	I-Claim
356	negatively	_	_	I-Claim
357	influenced	_	_	I-Claim
358	by	_	_	I-Claim
359	these	_	_	I-Claim
360	2	_	_	I-Claim
361	treatment	_	_	I-Claim
362	options	_	_	I-Claim
363	.	_	_	O


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	hypothesis	_	_	O
4	that	_	_	O
5	modulation	_	_	O
6	of	_	_	O
7	Bcl-2	_	_	O
8	with	_	_	O
9	13-cis	_	_	O
10	retinoic	_	_	O
11	acid	_	_	O
12	(	_	_	O
13	CRA	_	_	O
14	)	_	_	O
15	/interferon-alpha2b	_	_	O
16	(	_	_	O
17	IFN	_	_	O
18	)	_	_	O
19	with	_	_	O
20	paclitaxel	_	_	O
21	(	_	_	O
22	TAX	_	_	O
23	)	_	_	O
24	,	_	_	O
25	or	_	_	O
26	mitoxantrone	_	_	O
27	,	_	_	O
28	estramustine	_	_	O
29	and	_	_	O
30	vinorelbine	_	_	O
31	(	_	_	O
32	MEV	_	_	O
33	)	_	_	O
34	will	_	_	O
35	have	_	_	O
36	clinical	_	_	O
37	activity	_	_	O
38	in	_	_	O
39	men	_	_	O
40	with	_	_	O
41	metastatic	_	_	O
42	castrate-resistant	_	_	O
43	prostate	_	_	O
44	cancer	_	_	O
45	(	_	_	O
46	CRPC	_	_	O
47	)	_	_	O
48	.	_	_	O

49	70	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	treated	_	_	O
53	with	_	_	O
54	either	_	_	O
55	MEV	_	_	O
56	(	_	_	O
57	Arm	_	_	O
58	A	_	_	O
59	)	_	_	O
60	in	_	_	O
61	a	_	_	O
62	3-week	_	_	O
63	cycle	_	_	O
64	or	_	_	O
65	CRA/IFN/TAX	_	_	O
66	with	_	_	O
67	an	_	_	O
68	8-week	_	_	O
69	cycle	_	_	O
70	(	_	_	O
71	Arm	_	_	O
72	B	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	assessed	_	_	O
78	for	_	_	O
79	response	_	_	O
80	,	_	_	O
81	toxicity	_	_	O
82	,	_	_	O
83	quality	_	_	O
84	of	_	_	O
85	life	_	_	O
86	(	_	_	O
87	QOL	_	_	O
88	)	_	_	O
89	,	_	_	O
90	and	_	_	O
91	the	_	_	O
92	effect	_	_	O
93	of	_	_	O
94	treatment	_	_	O
95	on	_	_	O
96	Bcl-2	_	_	O
97	levels	_	_	O
98	in	_	_	O
99	peripheral	_	_	O
100	blood	_	_	O
101	mononuclear	_	_	O
102	cells	_	_	O
103	(	_	_	O
104	PBMC	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	B-Premise
108	PSA	_	_	I-Premise
109	response	_	_	I-Premise
110	rates	_	_	I-Premise
111	were	_	_	I-Premise
112	50	_	_	I-Premise
113	%	_	_	I-Premise
114	and	_	_	I-Premise
115	23	_	_	I-Premise
116	%	_	_	I-Premise
117	,	_	_	I-Premise
118	measurable	_	_	I-Premise
119	disease	_	_	I-Premise
120	response	_	_	I-Premise
121	rates	_	_	I-Premise
122	(	_	_	I-Premise
123	CR+PR	_	_	I-Premise
124	)	_	_	I-Premise
125	14	_	_	I-Premise
126	%	_	_	I-Premise
127	and	_	_	I-Premise
128	15	_	_	I-Premise
129	%	_	_	I-Premise
130	,	_	_	I-Premise
131	and	_	_	I-Premise
132	median	_	_	I-Premise
133	overall	_	_	I-Premise
134	survival	_	_	I-Premise
135	19.4	_	_	I-Premise
136	months	_	_	I-Premise
137	and	_	_	I-Premise
138	13.9	_	_	I-Premise
139	months	_	_	I-Premise
140	on	_	_	I-Premise
141	Arm	_	_	I-Premise
142	A	_	_	I-Premise
143	and	_	_	I-Premise
144	Arm	_	_	I-Premise
145	B	_	_	I-Premise
146	respectively	_	_	I-Premise
147	.	_	_	I-Premise

148	Transient	_	_	B-Premise
149	grade	_	_	I-Premise
150	4	_	_	I-Premise
151	neutropenia	_	_	I-Premise
152	occurred	_	_	I-Premise
153	in	_	_	I-Premise
154	18	_	_	I-Premise
155	and	_	_	I-Premise
156	2	_	_	I-Premise
157	patients	_	_	I-Premise
158	,	_	_	I-Premise
159	and	_	_	I-Premise
160	grade	_	_	I-Premise
161	3	_	_	I-Premise
162	to	_	_	I-Premise
163	4	_	_	I-Premise
164	thrombosis	_	_	I-Premise
165	in	_	_	I-Premise
166	7	_	_	I-Premise
167	patients	_	_	I-Premise
168	and	_	_	I-Premise
169	1	_	_	I-Premise
170	patient	_	_	I-Premise
171	in	_	_	I-Premise
172	Arm	_	_	I-Premise
173	A	_	_	I-Premise
174	and	_	_	I-Premise
175	Arm	_	_	I-Premise
176	B	_	_	I-Premise
177	respectively	_	_	I-Premise
178	.	_	_	I-Premise

179	Patients	_	_	B-Premise
180	on	_	_	I-Premise
181	Arm	_	_	I-Premise
182	B	_	_	I-Premise
183	reported	_	_	I-Premise
184	a	_	_	I-Premise
185	clinically	_	_	I-Premise
186	significant	_	_	I-Premise
187	decline	_	_	I-Premise
188	in	_	_	I-Premise
189	QOL	_	_	I-Premise
190	between	_	_	I-Premise
191	baseline	_	_	I-Premise
192	and	_	_	I-Premise
193	week	_	_	I-Premise
194	9/10	_	_	I-Premise
195	(	_	_	I-Premise
196	.71	_	_	I-Premise
197	s.d	_	_	I-Premise
198	.	_	_	I-Premise

199	)	_	_	O
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	a	_	_	I-Premise
203	significantly	_	_	I-Premise
204	lower	_	_	I-Premise
205	level	_	_	I-Premise
206	of	_	_	I-Premise
207	QOL	_	_	I-Premise
208	than	_	_	I-Premise
209	Arm	_	_	I-Premise
210	A	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.01	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	As	_	_	B-Premise
218	hypothesized	_	_	I-Premise
219	,	_	_	I-Premise
220	Bcl-2	_	_	I-Premise
221	levels	_	_	I-Premise
222	decreased	_	_	I-Premise
223	with	_	_	I-Premise
224	CRA/IFN	_	_	I-Premise
225	therapy	_	_	I-Premise
226	only	_	_	I-Premise
227	in	_	_	I-Premise
228	Arm	_	_	I-Premise
229	B	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.03	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Treatment	_	_	B-Claim
237	with	_	_	I-Claim
238	MEV	_	_	I-Claim
239	was	_	_	I-Claim
240	well	_	_	I-Claim
241	tolerated	_	_	I-Claim
242	and	_	_	I-Claim
243	demonstrated	_	_	I-Claim
244	clinical	_	_	I-Claim
245	activity	_	_	I-Claim
246	in	_	_	I-Claim
247	patients	_	_	I-Claim
248	with	_	_	I-Claim
249	CRPC	_	_	I-Claim
250	.	_	_	I-Claim

251	Given	_	_	B-Claim
252	the	_	_	I-Claim
253	adverse	_	_	I-Claim
254	effect	_	_	I-Claim
255	of	_	_	I-Claim
256	CRA/IFN/TAX	_	_	I-Claim
257	on	_	_	I-Claim
258	QOL	_	_	I-Claim
259	,	_	_	I-Claim
260	the	_	_	I-Claim
261	study	_	_	I-Claim
262	of	_	_	I-Claim
263	other	_	_	I-Claim
264	novel	_	_	I-Claim
265	agents	_	_	I-Claim
266	that	_	_	I-Claim
267	target	_	_	I-Claim
268	Bcl-2	_	_	I-Claim
269	family	_	_	I-Claim
270	proteins	_	_	I-Claim
271	is	_	_	I-Claim
272	warranted	_	_	I-Claim
273	.	_	_	I-Claim

274	The	_	_	O
275	feasibility	_	_	O
276	of	_	_	O
277	measuring	_	_	O
278	Bcl-2	_	_	O
279	protein	_	_	O
280	in	_	_	O
281	a	_	_	O
282	cooperative	_	_	O
283	group	_	_	O
284	setting	_	_	O
285	is	_	_	O
286	hypothesis	_	_	O
287	generating	_	_	O
288	and	_	_	O
289	supports	_	_	O
290	further	_	_	O
291	study	_	_	O
292	as	_	_	O
293	a	_	_	O
294	marker	_	_	O
295	for	_	_	O
296	Bcl-2	_	_	O
297	targeted	_	_	O
298	therapy	_	_	O
299	.	_	_	O


0	Taxol	_	_	B-Premise
1	(	_	_	I-Premise
2	paclitaxel	_	_	I-Premise
3	;	_	_	I-Premise
4	Bristol-Myers	_	_	I-Premise
5	Squibb	_	_	I-Premise
6	,	_	_	I-Premise
7	Wallingford	_	_	I-Premise
8	,	_	_	I-Premise
9	CT	_	_	I-Premise
10	)	_	_	I-Premise
11	is	_	_	I-Premise
12	a	_	_	I-Premise
13	new	_	_	I-Premise
14	anticancer	_	_	I-Premise
15	agent	_	_	I-Premise
16	with	_	_	I-Premise
17	activity	_	_	I-Premise
18	in	_	_	I-Premise
19	a	_	_	I-Premise
20	number	_	_	I-Premise
21	of	_	_	I-Premise
22	human	_	_	I-Premise
23	tumors	_	_	I-Premise
24	,	_	_	I-Premise
25	including	_	_	I-Premise
26	epithelial	_	_	I-Premise
27	ovarian	_	_	I-Premise
28	cancer	_	_	I-Premise
29	.	_	_	I-Premise

30	In	_	_	O
31	nonrandomized	_	_	O
32	trials	_	_	O
33	,	_	_	O
34	doses	_	_	O
35	studied	_	_	O
36	have	_	_	O
37	ranged	_	_	O
38	from	_	_	O
39	135	_	_	O
40	mg/m2	_	_	O
41	to	_	_	O
42	250	_	_	O
43	mg/m2	_	_	O
44	administered	_	_	O
45	over	_	_	O
46	24	_	_	O
47	hours	_	_	O
48	with	_	_	O
49	premedication	_	_	O
50	to	_	_	O
51	avoid	_	_	O
52	hypersensitivity	_	_	O
53	reactions	_	_	O
54	(	_	_	O
55	HSRs	_	_	O
56	)	_	_	O
57	.	_	_	O

58	This	_	_	O
59	study	_	_	O
60	addressed	_	_	O
61	two	_	_	O
62	questions	_	_	O
63	:	_	_	O
64	the	_	_	O
65	dose-response	_	_	O
66	relationship	_	_	O
67	of	_	_	O
68	Taxol	_	_	O
69	in	_	_	O
70	relapsed	_	_	O
71	ovarian	_	_	O
72	cancer	_	_	O
73	and	_	_	O
74	the	_	_	O
75	safety	_	_	O
76	of	_	_	O
77	a	_	_	O
78	short	_	_	O
79	infusion	_	_	O
80	given	_	_	O
81	with	_	_	O
82	premedication	_	_	O
83	.	_	_	O

84	Women	_	_	O
85	with	_	_	O
86	platinum-pretreated	_	_	O
87	epithelial	_	_	O
88	ovarian	_	_	O
89	cancer	_	_	O
90	and	_	_	O
91	measurable	_	_	O
92	recurrent	_	_	O
93	disease	_	_	O
94	were	_	_	O
95	randomized	_	_	O
96	in	_	_	O
97	a	_	_	O
98	bifactorial	_	_	O
99	design	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	175	_	_	O
104	or	_	_	O
105	135	_	_	O
106	mg/m2	_	_	O
107	of	_	_	O
108	Taxol	_	_	O
109	over	_	_	O
110	either	_	_	O
111	24	_	_	O
112	or	_	_	O
113	3	_	_	O
114	hours	_	_	O
115	.	_	_	O

116	Major	_	_	O
117	end	_	_	O
118	points	_	_	O
119	were	_	_	O
120	the	_	_	O
121	frequency	_	_	O
122	of	_	_	O
123	significant	_	_	O
124	HSRs	_	_	O
125	and	_	_	O
126	objective	_	_	O
127	response	_	_	O
128	rate	_	_	O
129	.	_	_	O

130	Secondary	_	_	O
131	end	_	_	O
132	points	_	_	O
133	were	_	_	O
134	progression-free	_	_	O
135	and	_	_	O
136	overall	_	_	O
137	survival	_	_	O
138	.	_	_	O

139	Of	_	_	O
140	407	_	_	O
141	patients	_	_	O
142	randomized	_	_	O
143	,	_	_	O
144	391	_	_	O
145	were	_	_	O
146	eligible	_	_	O
147	and	_	_	O
148	382	_	_	O
149	assessable	_	_	O
150	for	_	_	O
151	response	_	_	O
152	.	_	_	O

153	Analysis	_	_	O
154	was	_	_	O
155	performed	_	_	O
156	according	_	_	O
157	to	_	_	O
158	the	_	_	O
159	bifactorial	_	_	O
160	design	_	_	O
161	.	_	_	O

162	Severe	_	_	B-Premise
163	HSRs	_	_	I-Premise
164	were	_	_	I-Premise
165	rare	_	_	I-Premise
166	(	_	_	I-Premise
167	1.5	_	_	I-Premise
168	%	_	_	I-Premise
169	patients	_	_	I-Premise
170	)	_	_	I-Premise
171	and	_	_	I-Premise
172	were	_	_	I-Premise
173	not	_	_	I-Premise
174	affected	_	_	I-Premise
175	by	_	_	I-Premise
176	either	_	_	I-Premise
177	dose	_	_	I-Premise
178	or	_	_	I-Premise
179	schedule	_	_	I-Premise
180	.	_	_	I-Premise

181	Response	_	_	B-Premise
182	was	_	_	I-Premise
183	slightly	_	_	I-Premise
184	higher	_	_	I-Premise
185	at	_	_	I-Premise
186	the	_	_	I-Premise
187	175-mg/m2	_	_	I-Premise
188	dose	_	_	I-Premise
189	(	_	_	I-Premise
190	20	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	than	_	_	I-Premise
194	at	_	_	I-Premise
195	135	_	_	I-Premise
196	mg/m2	_	_	I-Premise
197	(	_	_	I-Premise
198	15	_	_	I-Premise
199	%	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	but	_	_	B-Premise
203	this	_	_	I-Premise
204	was	_	_	I-Premise
205	not	_	_	I-Premise
206	statistically	_	_	I-Premise
207	significant	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.2	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	However	_	_	B-Premise
215	,	_	_	I-Premise
216	progression-free	_	_	I-Premise
217	survival	_	_	I-Premise
218	was	_	_	I-Premise
219	significantly	_	_	I-Premise
220	longer	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	high-dose	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	19	_	_	I-Premise
227	v	_	_	I-Premise
228	14	_	_	I-Premise
229	weeks	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.02	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Significantly	_	_	B-Premise
237	more	_	_	I-Premise
238	neutropenia	_	_	I-Premise
239	was	_	_	I-Premise
240	seen	_	_	I-Premise
241	when	_	_	I-Premise
242	Taxol	_	_	I-Premise
243	was	_	_	I-Premise
244	administered	_	_	I-Premise
245	as	_	_	I-Premise
246	a	_	_	I-Premise
247	24-hour	_	_	I-Premise
248	infusion	_	_	I-Premise
249	.	_	_	I-Premise

250	Response	_	_	B-Premise
251	rates	_	_	I-Premise
252	were	_	_	I-Premise
253	similar	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	24-	_	_	I-Premise
257	and	_	_	I-Premise
258	3-hour	_	_	I-Premise
259	groups	_	_	I-Premise
260	(	_	_	I-Premise
261	19	_	_	I-Premise
262	%	_	_	I-Premise
263	and	_	_	I-Premise
264	16	_	_	I-Premise
265	%	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.6	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	No	_	_	B-Premise
275	survival	_	_	I-Premise
276	differences	_	_	I-Premise
277	were	_	_	I-Premise
278	noted	_	_	I-Premise
279	.	_	_	I-Premise

280	The	_	_	B-Claim
281	3-hour	_	_	I-Claim
282	infusion	_	_	I-Claim
283	of	_	_	I-Claim
284	Taxol	_	_	I-Claim
285	is	_	_	I-Claim
286	safe	_	_	I-Claim
287	when	_	_	I-Claim
288	given	_	_	I-Claim
289	with	_	_	I-Claim
290	premedication	_	_	I-Claim
291	and	_	_	I-Claim
292	is	_	_	I-Claim
293	associated	_	_	I-Claim
294	with	_	_	I-Claim
295	less	_	_	I-Claim
296	neutropenia	_	_	I-Claim
297	.	_	_	I-Claim

298	There	_	_	O
299	is	_	_	O
300	a	_	_	O
301	modest	_	_	O
302	dose	_	_	O
303	effect	_	_	O
304	with	_	_	O
305	longer	_	_	O
306	time	_	_	O
307	to	_	_	O
308	progression	_	_	O
309	at	_	_	O
310	175	_	_	O
311	mg/m2	_	_	O
312	.	_	_	O

313	The	_	_	B-Claim
314	observation	_	_	I-Claim
315	that	_	_	I-Claim
316	longer	_	_	I-Claim
317	infusion	_	_	I-Claim
318	produces	_	_	I-Claim
319	more	_	_	I-Claim
320	myelosuppression	_	_	I-Claim
321	but	_	_	I-Claim
322	does	_	_	I-Claim
323	not	_	_	I-Claim
324	yield	_	_	I-Claim
325	higher	_	_	I-Claim
326	response	_	_	I-Claim
327	rates	_	_	I-Claim
328	should	_	_	I-Claim
329	lead	_	_	I-Claim
330	to	_	_	I-Claim
331	further	_	_	I-Claim
332	studies	_	_	I-Claim
333	to	_	_	I-Claim
334	determine	_	_	I-Claim
335	the	_	_	I-Claim
336	optimal	_	_	I-Claim
337	dose	_	_	I-Claim
338	and	_	_	I-Claim
339	schedule	_	_	I-Claim
340	of	_	_	I-Claim
341	this	_	_	I-Claim
342	interesting	_	_	I-Claim
343	new	_	_	I-Claim
344	agent	_	_	I-Claim
345	.	_	_	I-Claim


0	Anaemia	_	_	O
1	is	_	_	O
2	common	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	receiving	_	_	O
6	chemotherapy	_	_	O
7	,	_	_	O
8	causing	_	_	O
9	symptoms	_	_	O
10	that	_	_	O
11	have	_	_	O
12	a	_	_	O
13	major	_	_	O
14	impact	_	_	O
15	on	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QoL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	Epoetin	_	_	O
24	beta	_	_	O
25	rapidly	_	_	O
26	increases	_	_	O
27	haemoglobin	_	_	O
28	(	_	_	O
29	Hb	_	_	O
30	)	_	_	O
31	levels	_	_	O
32	and	_	_	O
33	improves	_	_	O
34	QoL	_	_	O
35	in	_	_	O
36	anaemic	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	a	_	_	O
40	variety	_	_	O
41	of	_	_	O
42	tumours	_	_	O
43	.	_	_	O

44	This	_	_	O
45	was	_	_	O
46	a	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	double-blind	_	_	O
50	,	_	_	O
51	parallel-group	_	_	O
52	,	_	_	O
53	dose-finding	_	_	O
54	study	_	_	O
55	assessing	_	_	O
56	the	_	_	O
57	efficacy	_	_	O
58	and	_	_	O
59	safety	_	_	O
60	of	_	_	O
61	once-weekly	_	_	O
62	epoetin	_	_	O
63	beta	_	_	O
64	in	_	_	O
65	patients	_	_	O
66	with	_	_	O
67	solid	_	_	O
68	tumours	_	_	O
69	receiving	_	_	O
70	chemotherapy	_	_	O
71	.	_	_	O

72	Adult	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	anaemia	_	_	O
76	(	_	_	O
77	Hb	_	_	O
78	<	_	_	O
79	11	_	_	O
80	g/dL	_	_	O
81	)	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	epoetin	_	_	O
87	beta	_	_	O
88	30,000	_	_	O
89	IU	_	_	O
90	or	_	_	O
91	20,000	_	_	O
92	IU	_	_	O
93	once	_	_	O
94	weekly	_	_	O
95	for	_	_	O
96	12	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	All	_	_	O
100	patients	_	_	O
101	received	_	_	O
102	oral	_	_	O
103	iron	_	_	O
104	supplementation	_	_	O
105	.	_	_	O

106	Haemoglobin	_	_	O
107	levels	_	_	O
108	,	_	_	O
109	transfusion	_	_	O
110	need	_	_	O
111	and	_	_	O
112	QoL	_	_	O
113	[	_	_	O
114	Functional	_	_	O
115	Assessment	_	_	O
116	of	_	_	O
117	Cancer	_	_	O
118	Therapy-fatigue	_	_	O
119	(	_	_	O
120	FACT-F	_	_	O
121	)	_	_	O
122	subscale	_	_	O
123	score	_	_	O
124	]	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	at	_	_	O
128	regular	_	_	O
129	intervals	_	_	O
130	.	_	_	O

131	Fifty	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	randomized	_	_	O
135	;	_	_	O
136	30	_	_	O
137	patients	_	_	O
138	received	_	_	O
139	epoetin	_	_	O
140	beta	_	_	O
141	30,000	_	_	O
142	IU	_	_	O
143	once	_	_	O
144	weekly	_	_	O
145	and	_	_	O
146	20	_	_	O
147	received	_	_	O
148	20,000	_	_	O
149	IU	_	_	O
150	once	_	_	O
151	weekly	_	_	O
152	.	_	_	O

153	Mean	_	_	B-Premise
154	(	_	_	I-Premise
155	+/-	_	_	I-Premise
156	SD	_	_	I-Premise
157	)	_	_	I-Premise
158	increase	_	_	I-Premise
159	in	_	_	I-Premise
160	Hb	_	_	I-Premise
161	from	_	_	I-Premise
162	baseline	_	_	I-Premise
163	to	_	_	I-Premise
164	week	_	_	I-Premise
165	12	_	_	I-Premise
166	was	_	_	I-Premise
167	1.75	_	_	I-Premise
168	+/-	_	_	I-Premise
169	2.15	_	_	I-Premise
170	g/dL	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	30,000	_	_	I-Premise
174	IU	_	_	I-Premise
175	group	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	0.008	_	_	I-Premise
180	vs.	_	_	I-Premise
181	baseline	_	_	I-Premise
182	)	_	_	I-Premise
183	and	_	_	I-Premise
184	1.04	_	_	I-Premise
185	+/-	_	_	I-Premise
186	1.75	_	_	I-Premise
187	g/dL	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	20,000	_	_	I-Premise
191	IU	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	non-significant	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Haemoglobin	_	_	B-Premise
198	response	_	_	I-Premise
199	(	_	_	I-Premise
200	increase	_	_	I-Premise
201	in	_	_	I-Premise
202	Hb	_	_	I-Premise
203	>	_	_	I-Premise
204	or=2	_	_	I-Premise
205	g/dL	_	_	I-Premise
206	from	_	_	I-Premise
207	baseline	_	_	I-Premise
208	)	_	_	I-Premise
209	was	_	_	I-Premise
210	observed	_	_	I-Premise
211	in	_	_	I-Premise
212	78.3	_	_	I-Premise
213	%	_	_	I-Premise
214	of	_	_	I-Premise
215	patients	_	_	I-Premise
216	receiving	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	beta	_	_	I-Premise
219	30,000	_	_	I-Premise
220	IU	_	_	I-Premise
221	and	_	_	I-Premise
222	66.7	_	_	I-Premise
223	%	_	_	I-Premise
224	receiving	_	_	I-Premise
225	epoetin	_	_	I-Premise
226	beta	_	_	I-Premise
227	20,000	_	_	I-Premise
228	IU	_	_	I-Premise
229	.	_	_	I-Premise

230	Improvements	_	_	O
231	in	_	_	O
232	FACT-F	_	_	O
233	subscale	_	_	O
234	score	_	_	O
235	were	_	_	O
236	significantly	_	_	O
237	(	_	_	O
238	P	_	_	O
239	<	_	_	O
240	0.001	_	_	O
241	)	_	_	O
242	correlated	_	_	O
243	with	_	_	O
244	increases	_	_	O
245	in	_	_	O
246	Hb	_	_	O
247	level	_	_	O
248	.	_	_	O

249	Transfusion	_	_	O
250	use	_	_	O
251	was	_	_	O
252	low	_	_	O
253	during	_	_	O
254	the	_	_	O
255	study	_	_	O
256	in	_	_	O
257	both	_	_	O
258	groups	_	_	O
259	.	_	_	O

260	Both	_	_	B-Premise
261	epoetin	_	_	I-Premise
262	beta	_	_	I-Premise
263	regiments	_	_	I-Premise
264	were	_	_	I-Premise
265	well	_	_	I-Premise
266	tolerated	_	_	I-Premise
267	and	_	_	I-Premise
268	there	_	_	I-Premise
269	were	_	_	I-Premise
270	no	_	_	I-Premise
271	dose-dependent	_	_	I-Premise
272	adverse	_	_	I-Premise
273	events	_	_	I-Premise
274	.	_	_	I-Premise

275	Epoetin	_	_	B-Claim
276	beta	_	_	I-Claim
277	30,000	_	_	I-Claim
278	IU	_	_	I-Claim
279	once	_	_	I-Claim
280	weekly	_	_	I-Claim
281	is	_	_	I-Claim
282	an	_	_	I-Claim
283	effective	_	_	I-Claim
284	and	_	_	I-Claim
285	well-tolerated	_	_	I-Claim
286	treatment	_	_	I-Claim
287	of	_	_	I-Claim
288	anaemia	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	solid	_	_	I-Claim
293	tumours	_	_	I-Claim
294	.	_	_	I-Claim


0	Before	_	_	O
1	the	_	_	O
2	knowledge	_	_	O
3	that	_	_	O
4	5	_	_	O
5	years	_	_	O
6	of	_	_	O
7	adjuvant	_	_	O
8	tamoxifen	_	_	O
9	is	_	_	O
10	less	_	_	O
11	efficacious	_	_	O
12	than	_	_	O
13	2	_	_	O
14	to	_	_	O
15	3	_	_	O
16	years	_	_	O
17	of	_	_	O
18	tamoxifen	_	_	O
19	followed	_	_	O
20	by	_	_	O
21	2	_	_	O
22	to	_	_	O
23	3	_	_	O
24	years	_	_	O
25	of	_	_	O
26	anastrozole/exemestane	_	_	O
27	,	_	_	O
28	we	_	_	O
29	designed	_	_	O
30	a	_	_	O
31	multicenter	_	_	O
32	double-blind	_	_	O
33	randomized	_	_	O
34	controlled	_	_	O
35	trial	_	_	O
36	in	_	_	O
37	women	_	_	O
38	taking	_	_	O
39	tamoxifen	_	_	O
40	with	_	_	O
41	a	_	_	O
42	thickened	_	_	O
43	endometrium	_	_	O
44	to	_	_	O
45	compare	_	_	O
46	uterine	_	_	O
47	and	_	_	O
48	quality-of-life	_	_	O
49	parameters	_	_	O
50	between	_	_	O
51	those	_	_	O
52	switching	_	_	O
53	to	_	_	O
54	anastrozole	_	_	O
55	and	_	_	O
56	those	_	_	O
57	continuing	_	_	O
58	tamoxifen	_	_	O
59	.	_	_	O

60	Asymptomatic	_	_	O
61	postmenopausal	_	_	O
62	women	_	_	O
63	who	_	_	O
64	took	_	_	O
65	adjuvant	_	_	O
66	tamoxifen	_	_	O
67	for	_	_	O
68	2	_	_	O
69	to	_	_	O
70	3	_	_	O
71	years	_	_	O
72	for	_	_	O
73	operable	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	with	_	_	O
77	a	_	_	O
78	double	_	_	O
79	endometrial	_	_	O
80	thickness	_	_	O
81	greater	_	_	O
82	than	_	_	O
83	7	_	_	O
84	mm	_	_	O
85	were	_	_	O
86	randomized	_	_	O
87	to	_	_	O
88	20	_	_	O
89	mg	_	_	O
90	tamoxifen	_	_	O
91	or	_	_	O
92	1	_	_	O
93	mg	_	_	O
94	anastrozole	_	_	O
95	for	_	_	O
96	the	_	_	O
97	remaining	_	_	O
98	duration	_	_	O
99	,	_	_	O
100	totaling	_	_	O
101	5	_	_	O
102	years	_	_	O
103	.	_	_	O

104	Tablets	_	_	O
105	were	_	_	O
106	unrecognizable	_	_	O
107	for	_	_	O
108	drug	_	_	O
109	assignment	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	endpoints	_	_	O
114	were	_	_	O
115	the	_	_	O
116	differences	_	_	O
117	in	_	_	O
118	double	_	_	O
119	endometrial	_	_	O
120	thickness	_	_	O
121	and	_	_	O
122	uterine	_	_	O
123	volume	_	_	O
124	after	_	_	O
125	1	_	_	O
126	year	_	_	O
127	.	_	_	O

128	Uterine	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	data	_	_	O
132	were	_	_	O
133	analyzed	_	_	O
134	using	_	_	O
135	regression	_	_	O
136	methods	_	_	O
137	,	_	_	O
138	and	_	_	O
139	missing	_	_	O
140	values	_	_	O
141	were	_	_	O
142	handled	_	_	O
143	using	_	_	O
144	multiple	_	_	O
145	imputation	_	_	O
146	.	_	_	O

147	Seventy-two	_	_	O
148	women	_	_	O
149	(	_	_	O
150	median	_	_	O
151	age	_	_	O
152	,	_	_	O
153	60	_	_	O
154	y	_	_	O
155	)	_	_	O
156	were	_	_	O
157	randomized	_	_	O
158	in	_	_	O
159	five	_	_	O
160	hospitals	_	_	O
161	.	_	_	O

162	Relative	_	_	B-Premise
163	to	_	_	I-Premise
164	women	_	_	I-Premise
165	continuing	_	_	I-Premise
166	tamoxifen	_	_	I-Premise
167	,	_	_	I-Premise
168	women	_	_	I-Premise
169	switching	_	_	I-Premise
170	to	_	_	I-Premise
171	anastrozole	_	_	I-Premise
172	experienced	_	_	I-Premise
173	a	_	_	I-Premise
174	decrease	_	_	I-Premise
175	of	_	_	I-Premise
176	53	_	_	I-Premise
177	%	_	_	I-Premise
178	(	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	CI	_	_	I-Premise
182	,	_	_	I-Premise
183	41	_	_	I-Premise
184	%	_	_	I-Premise
185	-63	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	in	_	_	I-Premise
189	double	_	_	I-Premise
190	endometrial	_	_	I-Premise
191	thickness	_	_	I-Premise
192	and	_	_	I-Premise
193	a	_	_	I-Premise
194	decrease	_	_	I-Premise
195	of	_	_	I-Premise
196	51	_	_	I-Premise
197	%	_	_	I-Premise
198	(	_	_	I-Premise
199	95	_	_	I-Premise
200	%	_	_	I-Premise
201	CI	_	_	I-Premise
202	,	_	_	I-Premise
203	39	_	_	I-Premise
204	%	_	_	I-Premise
205	-60	_	_	I-Premise
206	%	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	uterine	_	_	I-Premise
210	volume	_	_	I-Premise
211	.	_	_	I-Premise

212	Vaginal	_	_	B-Premise
213	dryness	_	_	I-Premise
214	(	_	_	I-Premise
215	b	_	_	I-Premise
216	=	_	_	I-Premise
217	0.064	_	_	I-Premise
218	;	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	0.016-0.112	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	sexual	_	_	I-Premise
227	problems	_	_	I-Premise
228	(	_	_	I-Premise
229	b	_	_	I-Premise
230	=	_	_	I-Premise
231	0.054	_	_	I-Premise
232	;	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	0.007-0.102	_	_	I-Premise
238	)	_	_	I-Premise
239	increased	_	_	I-Premise
240	in	_	_	I-Premise
241	women	_	_	I-Premise
242	taking	_	_	I-Premise
243	anastrozole	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	women	_	_	I-Premise
247	taking	_	_	I-Premise
248	tamoxifen	_	_	I-Premise
249	.	_	_	I-Premise

250	Treatment	_	_	B-Premise
251	arms	_	_	I-Premise
252	did	_	_	I-Premise
253	not	_	_	I-Premise
254	differ	_	_	I-Premise
255	regarding	_	_	I-Premise
256	withdrawal	_	_	I-Premise
257	rate	_	_	I-Premise
258	and	_	_	I-Premise
259	the	_	_	I-Premise
260	experience	_	_	I-Premise
261	of	_	_	I-Premise
262	(	_	_	I-Premise
263	serious	_	_	I-Premise
264	)	_	_	I-Premise
265	adverse	_	_	I-Premise
266	events	_	_	I-Premise
267	.	_	_	I-Premise

268	Despite	_	_	O
269	premature	_	_	O
270	trial	_	_	O
271	closure	_	_	O
272	,	_	_	O
273	our	_	_	O
274	data	_	_	O
275	provided	_	_	O
276	valuable	_	_	O
277	insights	_	_	O
278	.	_	_	O

279	Switching	_	_	B-Claim
280	to	_	_	I-Claim
281	anastrozole	_	_	I-Claim
282	strongly	_	_	I-Claim
283	decreased	_	_	I-Claim
284	the	_	_	I-Claim
285	endometrial	_	_	I-Claim
286	thickness	_	_	I-Claim
287	and	_	_	I-Claim
288	uterine	_	_	I-Claim
289	volume	_	_	I-Claim
290	but	_	_	I-Claim
291	increased	_	_	I-Claim
292	sexual	_	_	I-Claim
293	disturbances	_	_	I-Claim
294	.	_	_	I-Claim

295	Safe	_	_	B-Claim
296	and	_	_	I-Claim
297	effective	_	_	I-Claim
298	interventions	_	_	I-Claim
299	are	_	_	I-Claim
300	needed	_	_	I-Claim
301	to	_	_	I-Claim
302	alleviate	_	_	I-Claim
303	sexual	_	_	I-Claim
304	dysfunction	_	_	I-Claim
305	.	_	_	I-Claim


0	Depression	_	_	B-Claim
1	,	_	_	I-Claim
2	anxiety	_	_	I-Claim
3	,	_	_	I-Claim
4	fatigue	_	_	I-Claim
5	,	_	_	I-Claim
6	and	_	_	I-Claim
7	impaired	_	_	I-Claim
8	wellbeing	_	_	I-Claim
9	are	_	_	I-Claim
10	common	_	_	I-Claim
11	,	_	_	I-Claim
12	important	_	_	I-Claim
13	,	_	_	I-Claim
14	and	_	_	I-Claim
15	closely	_	_	I-Claim
16	related	_	_	I-Claim
17	in	_	_	I-Claim
18	advanced	_	_	I-Claim
19	cancer	_	_	I-Claim
20	.	_	_	I-Claim

21	We	_	_	O
22	aimed	_	_	O
23	to	_	_	O
24	identify	_	_	O
25	the	_	_	O
26	effects	_	_	O
27	of	_	_	O
28	an	_	_	O
29	established	_	_	O
30	antidepressant	_	_	O
31	on	_	_	O
32	these	_	_	O
33	symptoms	_	_	O
34	and	_	_	O
35	survival	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	advanced	_	_	O
40	cancer	_	_	O
41	who	_	_	O
42	did	_	_	O
43	not	_	_	O
44	have	_	_	O
45	major	_	_	O
46	depression	_	_	O
47	as	_	_	O
48	assessed	_	_	O
49	by	_	_	O
50	clinicians	_	_	O
51	.	_	_	O

52	Between	_	_	O
53	July	_	_	O
54	,	_	_	O
55	2001	_	_	O
56	,	_	_	O
57	and	_	_	O
58	February	_	_	O
59	,	_	_	O
60	2006	_	_	O
61	,	_	_	O
62	189	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	cancer	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	sertraline	_	_	O
71	50	_	_	O
72	mg	_	_	O
73	(	_	_	O
74	n=95	_	_	O
75	)	_	_	O
76	,	_	_	O
77	or	_	_	O
78	placebo	_	_	O
79	(	_	_	O
80	n=94	_	_	O
81	)	_	_	O
82	,	_	_	O
83	once	_	_	O
84	per	_	_	O
85	day	_	_	O
86	.	_	_	O

87	The	_	_	O
88	primary	_	_	O
89	outcome	_	_	O
90	was	_	_	O
91	depression	_	_	O
92	as	_	_	O
93	assessed	_	_	O
94	by	_	_	O
95	the	_	_	O
96	Centre	_	_	O
97	for	_	_	O
98	Epidemiologic	_	_	O
99	Studies	_	_	O
100	Depression	_	_	O
101	scale	_	_	O
102	(	_	_	O
103	CES-D	_	_	O
104	)	_	_	O
105	;	_	_	O
106	the	_	_	O
107	main	_	_	O
108	secondary	_	_	O
109	outcomes	_	_	O
110	were	_	_	O
111	:	_	_	O
112	anxiety	_	_	O
113	as	_	_	O
114	assessed	_	_	O
115	by	_	_	O
116	Hospital	_	_	O
117	Anxiety	_	_	O
118	and	_	_	O
119	Depression	_	_	O
120	Scales	_	_	O
121	(	_	_	O
122	HADS-A	_	_	O
123	)	_	_	O
124	;	_	_	O
125	overall	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	and	_	_	O
130	fatigue	_	_	O
131	as	_	_	O
132	assessed	_	_	O
133	by	_	_	O
134	Functional	_	_	O
135	Assessment	_	_	O
136	of	_	_	O
137	Cancer	_	_	O
138	Therapy	_	_	O
139	General	_	_	O
140	and	_	_	O
141	Fatigue	_	_	O
142	scales	_	_	O
143	(	_	_	O
144	FACT-G	_	_	O
145	and	_	_	O
146	FACT-F	_	_	O
147	,	_	_	O
148	respectively	_	_	O
149	)	_	_	O
150	;	_	_	O
151	and	_	_	O
152	clinicians	_	_	O
153	'	_	_	O
154	ratings	_	_	O
155	of	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	by	_	_	O
160	use	_	_	O
161	of	_	_	O
162	Spizter	_	_	O
163	's	_	_	O
164	Quality	_	_	O
165	of	_	_	O
166	Life	_	_	O
167	Index	_	_	O
168	(	_	_	O
169	SQLI	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Multiple	_	_	O
173	measures	_	_	O
174	were	_	_	O
175	used	_	_	O
176	for	_	_	O
177	corroboration	_	_	O
178	of	_	_	O
179	the	_	_	O
180	most	_	_	O
181	important	_	_	O
182	outcomes	_	_	O
183	.	_	_	O

184	Primary	_	_	O
185	analyses	_	_	O
186	were	_	_	O
187	done	_	_	O
188	by	_	_	O
189	intention	_	_	O
190	to	_	_	O
191	treat	_	_	O
192	and	_	_	O
193	were	_	_	O
194	based	_	_	O
195	on	_	_	O
196	scale	_	_	O
197	scores	_	_	O
198	at	_	_	O
199	4	_	_	O
200	weeks	_	_	O
201	and	_	_	O
202	8	_	_	O
203	weeks	_	_	O
204	.	_	_	O

205	The	_	_	O
206	benefits	_	_	O
207	of	_	_	O
208	sertraline	_	_	O
209	compared	_	_	O
210	with	_	_	O
211	placebo	_	_	O
212	are	_	_	O
213	expressed	_	_	O
214	on	_	_	O
215	a	_	_	O
216	range	_	_	O
217	from	_	_	O
218	+100	_	_	O
219	(	_	_	O
220	ie	_	_	O
221	,	_	_	O
222	maximum	_	_	O
223	benefit	_	_	O
224	)	_	_	O
225	to	_	_	O
226	-100	_	_	O
227	(	_	_	O
228	ie	_	_	O
229	,	_	_	O
230	maximum	_	_	O
231	harm	_	_	O
232	)	_	_	O
233	;	_	_	O
234	a	_	_	O
235	difference	_	_	O
236	of	_	_	O
237	10	_	_	O
238	was	_	_	O
239	deemed	_	_	O
240	clinically	_	_	O
241	significant	_	_	O
242	.	_	_	O

243	This	_	_	O
244	clinical	_	_	O
245	trial	_	_	O
246	is	_	_	O
247	registered	_	_	O
248	at	_	_	O
249	Current	_	_	O
250	Controlled	_	_	O
251	Trials	_	_	O
252	website	_	_	O
253	http	_	_	O
254	:	_	_	O
255	//www.controlled-trials.com/ISRCTN72466475	_	_	O
256	.	_	_	O

257	Sertraline	_	_	B-Premise
258	had	_	_	I-Premise
259	no	_	_	I-Premise
260	significant	_	_	I-Premise
261	effect	_	_	I-Premise
262	(	_	_	I-Premise
263	scale	_	_	I-Premise
264	,	_	_	I-Premise
265	benefit	_	_	I-Premise
266	over	_	_	I-Premise
267	placebo	_	_	I-Premise
268	[	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	]	_	_	I-Premise
273	)	_	_	I-Premise
274	on	_	_	I-Premise
275	depression	_	_	I-Premise
276	(	_	_	I-Premise
277	CES-D	_	_	I-Premise
278	0.4	_	_	I-Premise
279	[	_	_	I-Premise
280	-2.6	_	_	I-Premise
281	to	_	_	I-Premise
282	3.4	_	_	I-Premise
283	]	_	_	I-Premise
284	)	_	_	I-Premise
285	,	_	_	I-Premise
286	anxiety	_	_	I-Premise
287	(	_	_	I-Premise
288	HADS-A	_	_	I-Premise
289	2.0	_	_	I-Premise
290	[	_	_	I-Premise
291	-1.5	_	_	I-Premise
292	to	_	_	I-Premise
293	5.5	_	_	I-Premise
294	]	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	fatigue	_	_	I-Premise
298	(	_	_	I-Premise
299	FACT-F	_	_	I-Premise
300	0.3	_	_	I-Premise
301	[	_	_	I-Premise
302	-4.3	_	_	I-Premise
303	to	_	_	I-Premise
304	4.9	_	_	I-Premise
305	]	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	overall	_	_	I-Premise
309	quality	_	_	I-Premise
310	of	_	_	I-Premise
311	life	_	_	I-Premise
312	(	_	_	I-Premise
313	FACT-G	_	_	I-Premise
314	1.7	_	_	I-Premise
315	[	_	_	I-Premise
316	-1.3	_	_	I-Premise
317	to	_	_	I-Premise
318	4.7	_	_	I-Premise
319	]	_	_	I-Premise
320	)	_	_	I-Premise
321	,	_	_	I-Premise
322	or	_	_	I-Premise
323	clinicians	_	_	I-Premise
324	'	_	_	I-Premise
325	ratings	_	_	I-Premise
326	(	_	_	I-Premise
327	SQLI	_	_	I-Premise
328	2.0	_	_	I-Premise
329	[	_	_	I-Premise
330	-2.5	_	_	I-Premise
331	to	_	_	I-Premise
332	6.5	_	_	I-Premise
333	]	_	_	I-Premise
334	)	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	the	_	_	I-Premise
338	95	_	_	I-Premise
339	%	_	_	I-Premise
340	CI	_	_	I-Premise
341	ruled	_	_	I-Premise
342	out	_	_	I-Premise
343	a	_	_	I-Premise
344	clinically	_	_	I-Premise
345	significant	_	_	I-Premise
346	benefit	_	_	I-Premise
347	for	_	_	I-Premise
348	all	_	_	I-Premise
349	main	_	_	I-Premise
350	outcomes	_	_	I-Premise
351	.	_	_	I-Premise

352	Sertraline	_	_	B-Premise
353	was	_	_	I-Premise
354	discontinued	_	_	I-Premise
355	more	_	_	I-Premise
356	often	_	_	I-Premise
357	and	_	_	I-Premise
358	earlier	_	_	I-Premise
359	than	_	_	I-Premise
360	was	_	_	I-Premise
361	placebo	_	_	I-Premise
362	(	_	_	I-Premise
363	hazard	_	_	I-Premise
364	ratio	_	_	I-Premise
365	1.46	_	_	I-Premise
366	[	_	_	I-Premise
367	1.03-2.06	_	_	I-Premise
368	]	_	_	I-Premise
369	,	_	_	I-Premise
370	p=0.03	_	_	I-Premise
371	)	_	_	I-Premise
372	.	_	_	I-Premise

373	Recruitment	_	_	O
374	was	_	_	O
375	stopped	_	_	O
376	after	_	_	O
377	the	_	_	B-Premise
378	first	_	_	I-Premise
379	planned	_	_	I-Premise
380	interim	_	_	I-Premise
381	analysis	_	_	I-Premise
382	in	_	_	I-Premise
383	February	_	_	I-Premise
384	2006	_	_	I-Premise
385	(	_	_	I-Premise
386	n=150	_	_	I-Premise
387	)	_	_	I-Premise
388	showed	_	_	I-Premise
389	that	_	_	I-Premise
390	survival	_	_	I-Premise
391	was	_	_	I-Premise
392	longer	_	_	I-Premise
393	in	_	_	I-Premise
394	patients	_	_	I-Premise
395	assigned	_	_	I-Premise
396	placebo	_	_	I-Premise
397	than	_	_	I-Premise
398	in	_	_	I-Premise
399	patients	_	_	I-Premise
400	assigned	_	_	I-Premise
401	sertraline	_	_	I-Premise
402	(	_	_	I-Premise
403	unadjusted	_	_	I-Premise
404	hazard	_	_	I-Premise
405	ratio	_	_	I-Premise
406	1.60	_	_	I-Premise
407	[	_	_	I-Premise
408	95	_	_	I-Premise
409	%	_	_	I-Premise
410	CI	_	_	I-Premise
411	1.04-2.45	_	_	I-Premise
412	]	_	_	I-Premise
413	,	_	_	I-Premise
414	log-rank	_	_	I-Premise
415	p=0.04	_	_	I-Premise
416	;	_	_	I-Premise
417	adjusted	_	_	I-Premise
418	hazard	_	_	I-Premise
419	ratio	_	_	I-Premise
420	1.62	_	_	I-Premise
421	[	_	_	I-Premise
422	1.06-2.41	_	_	I-Premise
423	]	_	_	I-Premise
424	,	_	_	I-Premise
425	Cox	_	_	I-Premise
426	model	_	_	I-Premise
427	p=0.02	_	_	I-Premise
428	)	_	_	I-Premise
429	.	_	_	I-Premise

430	However	_	_	B-Premise
431	,	_	_	I-Premise
432	at	_	_	I-Premise
433	the	_	_	I-Premise
434	final	_	_	I-Premise
435	analysis	_	_	I-Premise
436	in	_	_	I-Premise
437	July	_	_	I-Premise
438	2006	_	_	I-Premise
439	of	_	_	I-Premise
440	all	_	_	I-Premise
441	patients	_	_	I-Premise
442	(	_	_	I-Premise
443	n=189	_	_	I-Premise
444	)	_	_	I-Premise
445	and	_	_	I-Premise
446	with	_	_	I-Premise
447	longer	_	_	I-Premise
448	follow-up	_	_	I-Premise
449	,	_	_	I-Premise
450	survival	_	_	I-Premise
451	did	_	_	I-Premise
452	not	_	_	I-Premise
453	differ	_	_	I-Premise
454	significantly	_	_	I-Premise
455	between	_	_	I-Premise
456	the	_	_	I-Premise
457	treatment	_	_	I-Premise
458	groups	_	_	I-Premise
459	(	_	_	I-Premise
460	unadjusted	_	_	I-Premise
461	hazard	_	_	I-Premise
462	ratio	_	_	I-Premise
463	1.35	_	_	I-Premise
464	[	_	_	I-Premise
465	0.95-1.91	_	_	I-Premise
466	]	_	_	I-Premise
467	,	_	_	I-Premise
468	log-rank	_	_	I-Premise
469	p=0.09	_	_	I-Premise
470	;	_	_	I-Premise
471	adjusted	_	_	I-Premise
472	hazard	_	_	I-Premise
473	ratio	_	_	I-Premise
474	1.27	_	_	I-Premise
475	[	_	_	I-Premise
476	0.87-1.84	_	_	I-Premise
477	]	_	_	I-Premise
478	,	_	_	I-Premise
479	Cox	_	_	I-Premise
480	model	_	_	I-Premise
481	p=0.20	_	_	I-Premise
482	)	_	_	I-Premise
483	.	_	_	I-Premise

484	The	_	_	O
485	trial	_	_	O
486	was	_	_	O
487	closed	_	_	O
488	because	_	_	O
489	it	_	_	O
490	had	_	_	O
491	ruled	_	_	O
492	out	_	_	O
493	a	_	_	O
494	significant	_	_	O
495	benefit	_	_	O
496	of	_	_	O
497	sertraline	_	_	O
498	.	_	_	O

499	Sertraline	_	_	B-Claim
500	did	_	_	I-Claim
501	not	_	_	I-Claim
502	improve	_	_	I-Claim
503	symptoms	_	_	I-Claim
504	,	_	_	I-Claim
505	wellbeing	_	_	I-Claim
506	,	_	_	I-Claim
507	or	_	_	I-Claim
508	survival	_	_	I-Claim
509	in	_	_	I-Claim
510	patients	_	_	I-Claim
511	with	_	_	I-Claim
512	advanced	_	_	I-Claim
513	cancer	_	_	I-Claim
514	who	_	_	I-Claim
515	do	_	_	I-Claim
516	not	_	_	I-Claim
517	have	_	_	I-Claim
518	major	_	_	I-Claim
519	depression	_	_	I-Claim
520	,	_	_	I-Claim
521	and	_	_	I-Claim
522	should	_	_	I-Claim
523	be	_	_	I-Claim
524	reserved	_	_	I-Claim
525	for	_	_	I-Claim
526	those	_	_	I-Claim
527	with	_	_	I-Claim
528	a	_	_	I-Claim
529	proven	_	_	I-Claim
530	indication	_	_	I-Claim
531	.	_	_	I-Claim


0	This	_	_	O
1	double-blind	_	_	O
2	randomized	_	_	O
3	phase	_	_	O
4	II	_	_	O
5	trial	_	_	O
6	examined	_	_	O
7	whether	_	_	O
8	vandetanib	_	_	O
9	,	_	_	O
10	an	_	_	O
11	inhibitor	_	_	O
12	of	_	_	O
13	vascular	_	_	O
14	endothelial	_	_	O
15	and	_	_	O
16	epidermal	_	_	O
17	growth	_	_	O
18	factor	_	_	O
19	receptors	_	_	O
20	,	_	_	O
21	could	_	_	O
22	prolong	_	_	O
23	progression-free	_	_	O
24	survival	_	_	O
25	in	_	_	O
26	responding	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	small-cell	_	_	O
30	lung	_	_	O
31	cancer	_	_	O
32	.	_	_	O

33	Eligible	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	complete	_	_	O
37	response	_	_	O
38	(	_	_	O
39	CR	_	_	O
40	)	_	_	O
41	or	_	_	O
42	partial	_	_	O
43	response	_	_	O
44	(	_	_	O
45	PR	_	_	O
46	)	_	_	O
47	to	_	_	O
48	combination	_	_	O
49	chemotherapy	_	_	O
50	(	_	_	O
51	+/-	_	_	O
52	thoracic	_	_	O
53	or	_	_	O
54	prophylactic	_	_	O
55	cranial	_	_	O
56	radiation	_	_	O
57	)	_	_	O
58	received	_	_	O
59	oral	_	_	O
60	vandetanib	_	_	O
61	300	_	_	O
62	mg/d	_	_	O
63	or	_	_	O
64	matched	_	_	O
65	placebo	_	_	O
66	.	_	_	O

67	With	_	_	O
68	100	_	_	O
69	patients	_	_	O
70	and	_	_	O
71	77	_	_	O
72	events	_	_	O
73	,	_	_	O
74	the	_	_	O
75	study	_	_	O
76	had	_	_	O
77	80	_	_	O
78	%	_	_	O
79	power	_	_	O
80	to	_	_	O
81	detect	_	_	O
82	an	_	_	O
83	improvement	_	_	O
84	in	_	_	O
85	median	_	_	O
86	progression-free	_	_	O
87	survival	_	_	O
88	from	_	_	O
89	4	_	_	O
90	to	_	_	O
91	6.5	_	_	O
92	months	_	_	O
93	(	_	_	O
94	one-sided	_	_	O
95	,	_	_	O
96	10	_	_	O
97	%	_	_	O
98	-level	_	_	O
99	test	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Between	_	_	O
103	May	_	_	O
104	2003	_	_	O
105	and	_	_	O
106	March	_	_	O
107	2006	_	_	O
108	,	_	_	O
109	107	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	accrued	_	_	O
113	;	_	_	O
114	46	_	_	O
115	had	_	_	O
116	limited	_	_	O
117	disease	_	_	O
118	and	_	_	O
119	61	_	_	O
120	extensive	_	_	O
121	disease	_	_	O
122	.	_	_	O

123	There	_	_	O
124	were	_	_	O
125	fewer	_	_	O
126	patients	_	_	O
127	with	_	_	O
128	a	_	_	O
129	performance	_	_	O
130	status	_	_	O
131	of	_	_	O
132	0	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	11	_	_	O
137	v	_	_	O
138	20	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	fewer	_	_	O
143	had	_	_	O
144	CR	_	_	O
145	to	_	_	O
146	initial	_	_	O
147	therapy	_	_	O
148	(	_	_	O
149	n	_	_	O
150	=	_	_	O
151	4	_	_	O
152	v	_	_	O
153	8	_	_	O
154	)	_	_	O
155	in	_	_	O
156	the	_	_	O
157	vandetanib	_	_	O
158	arm	_	_	O
159	.	_	_	O

160	Vandetanib	_	_	B-Premise
161	patients	_	_	I-Premise
162	had	_	_	I-Premise
163	more	_	_	I-Premise
164	toxicity	_	_	I-Premise
165	and	_	_	I-Premise
166	required	_	_	I-Premise
167	more	_	_	I-Premise
168	dose	_	_	I-Premise
169	modifications	_	_	I-Premise
170	for	_	_	I-Premise
171	gastrointestinal	_	_	I-Premise
172	toxicity	_	_	I-Premise
173	and	_	_	I-Premise
174	rash	_	_	I-Premise
175	.	_	_	I-Premise

176	Asymptomatic	_	_	B-Premise
177	Corrected	_	_	I-Premise
178	QT	_	_	I-Premise
179	interval	_	_	I-Premise
180	(	_	_	I-Premise
181	QTC	_	_	I-Premise
182	)	_	_	I-Premise
183	prolongation	_	_	I-Premise
184	was	_	_	I-Premise
185	observed	_	_	I-Premise
186	in	_	_	I-Premise
187	eight	_	_	I-Premise
188	vandetanib	_	_	I-Premise
189	patients	_	_	I-Premise
190	.	_	_	I-Premise

191	Median	_	_	B-Premise
192	progression-free	_	_	I-Premise
193	survival	_	_	I-Premise
194	for	_	_	I-Premise
195	vandetanib	_	_	I-Premise
196	and	_	_	I-Premise
197	placebo	_	_	I-Premise
198	was	_	_	I-Premise
199	2.7	_	_	I-Premise
200	and	_	_	I-Premise
201	2.8	_	_	I-Premise
202	months	_	_	I-Premise
203	,	_	_	I-Premise
204	respectively	_	_	I-Premise
205	(	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	[	_	_	I-Premise
209	HR	_	_	I-Premise
210	]	_	_	I-Premise
211	,	_	_	I-Premise
212	1.01	_	_	I-Premise
213	;	_	_	I-Premise
214	80	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	0.75	_	_	I-Premise
219	to	_	_	I-Premise
220	1.36	_	_	I-Premise
221	;	_	_	I-Premise
222	one-sided	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.51	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Overall	_	_	B-Premise
229	survival	_	_	I-Premise
230	for	_	_	I-Premise
231	vandetanib	_	_	I-Premise
232	was	_	_	I-Premise
233	10.6	_	_	I-Premise
234	versus	_	_	I-Premise
235	11.9	_	_	I-Premise
236	months	_	_	I-Premise
237	for	_	_	I-Premise
238	placebo	_	_	I-Premise
239	(	_	_	I-Premise
240	HR	_	_	I-Premise
241	,	_	_	I-Premise
242	1.43	_	_	I-Premise
243	;	_	_	I-Premise
244	80	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	,	_	_	I-Premise
248	1.00	_	_	I-Premise
249	to	_	_	I-Premise
250	2.05	_	_	I-Premise
251	;	_	_	I-Premise
252	one-sided	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	0.9	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	In	_	_	B-Premise
259	planned	_	_	I-Premise
260	subgroup	_	_	I-Premise
261	analyses	_	_	I-Premise
262	,	_	_	I-Premise
263	a	_	_	I-Premise
264	significant	_	_	I-Premise
265	interaction	_	_	I-Premise
266	was	_	_	I-Premise
267	noted	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.01	_	_	I-Premise
272	)	_	_	I-Premise
273	:	_	_	I-Premise
274	limited-stage	_	_	I-Premise
275	vandetanib	_	_	I-Premise
276	patients	_	_	I-Premise
277	had	_	_	I-Premise
278	longer	_	_	I-Premise
279	overall	_	_	I-Premise
280	survival	_	_	I-Premise
281	(	_	_	I-Premise
282	HR	_	_	I-Premise
283	,	_	_	I-Premise
284	0.45	_	_	I-Premise
285	;	_	_	I-Premise
286	one-sided	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.07	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	extensive-stage	_	_	I-Premise
293	vandetanib	_	_	I-Premise
294	patients	_	_	I-Premise
295	shorter	_	_	I-Premise
296	survival	_	_	I-Premise
297	compared	_	_	I-Premise
298	with	_	_	I-Premise
299	placebo	_	_	I-Premise
300	(	_	_	I-Premise
301	HR	_	_	I-Premise
302	,	_	_	I-Premise
303	2.27	_	_	I-Premise
304	;	_	_	I-Premise
305	one-sided	_	_	I-Premise
306	P	_	_	I-Premise
307	=	_	_	I-Premise
308	.996	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	Vandetanib	_	_	B-Claim
312	failed	_	_	I-Claim
313	to	_	_	I-Claim
314	demonstrate	_	_	I-Claim
315	efficacy	_	_	I-Claim
316	as	_	_	I-Claim
317	maintenance	_	_	I-Claim
318	therapy	_	_	I-Claim
319	for	_	_	I-Claim
320	small-cell	_	_	I-Claim
321	lung	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim


0	Cancer	_	_	O
1	cells	_	_	O
2	rely	_	_	O
3	on	_	_	O
4	angiogenesis	_	_	O
5	for	_	_	O
6	growth	_	_	O
7	and	_	_	O
8	dissemination	_	_	O
9	,	_	_	O
10	and	_	_	O
11	small	_	_	O
12	cell	_	_	O
13	lung	_	_	O
14	cancer	_	_	O
15	(	_	_	O
16	SCLC	_	_	O
17	)	_	_	O
18	is	_	_	O
19	a	_	_	O
20	highly	_	_	O
21	angiogenic	_	_	O
22	tumor	_	_	O
23	.	_	_	O

24	We	_	_	O
25	evaluated	_	_	O
26	thalidomide	_	_	O
27	,	_	_	O
28	an	_	_	O
29	anti-angiogenic	_	_	O
30	agent	_	_	O
31	,	_	_	O
32	when	_	_	O
33	combined	_	_	O
34	with	_	_	O
35	chemotherapy	_	_	O
36	and	_	_	O
37	as	_	_	O
38	maintenance	_	_	O
39	treatment	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	724	_	_	O
45	patients	_	_	O
46	(	_	_	O
47	51	_	_	O
48	%	_	_	O
49	with	_	_	O
50	limited	_	_	O
51	and	_	_	O
52	49	_	_	O
53	%	_	_	O
54	with	_	_	O
55	extensive	_	_	O
56	disease	_	_	O
57	)	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	placebo	_	_	O
64	or	_	_	O
65	thalidomide	_	_	O
66	capsules	_	_	O
67	,	_	_	O
68	100-200	_	_	O
69	mg	_	_	O
70	daily	_	_	O
71	for	_	_	O
72	up	_	_	O
73	to	_	_	O
74	2	_	_	O
75	years	_	_	O
76	.	_	_	O

77	All	_	_	O
78	patients	_	_	O
79	received	_	_	O
80	etoposide	_	_	O
81	and	_	_	O
82	carboplatin	_	_	O
83	every	_	_	O
84	3	_	_	O
85	weeks	_	_	O
86	for	_	_	O
87	up	_	_	O
88	to	_	_	O
89	six	_	_	O
90	cycles	_	_	O
91	.	_	_	O

92	Endpoints	_	_	O
93	were	_	_	O
94	overall	_	_	O
95	survival	_	_	O
96	,	_	_	O
97	progression-free	_	_	O
98	survival	_	_	O
99	,	_	_	O
100	tumor	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	,	_	_	O
104	toxicity	_	_	O
105	,	_	_	O
106	and	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	(	_	_	O
111	QoL	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Hazard	_	_	O
115	ratios	_	_	O
116	(	_	_	O
117	HRs	_	_	O
118	)	_	_	O
119	for	_	_	O
120	comparing	_	_	O
121	thalidomide	_	_	O
122	against	_	_	O
123	placebo	_	_	O
124	were	_	_	O
125	estimated	_	_	O
126	using	_	_	O
127	Cox	_	_	O
128	regression	_	_	O
129	modeling	_	_	O
130	.	_	_	O

131	Statistical	_	_	O
132	tests	_	_	O
133	were	_	_	O
134	two-sided	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	median	_	_	I-Premise
138	overall	_	_	I-Premise
139	survival	_	_	I-Premise
140	was	_	_	I-Premise
141	10.5	_	_	I-Premise
142	months	_	_	I-Premise
143	(	_	_	I-Premise
144	placebo	_	_	I-Premise
145	)	_	_	I-Premise
146	and	_	_	I-Premise
147	10.1	_	_	I-Premise
148	months	_	_	I-Premise
149	(	_	_	I-Premise
150	thalidomide	_	_	I-Premise
151	)	_	_	I-Premise
152	(	_	_	I-Premise
153	HR	_	_	I-Premise
154	for	_	_	I-Premise
155	death	_	_	I-Premise
156	=	_	_	I-Premise
157	1.09	_	_	I-Premise
158	,	_	_	I-Premise
159	95	_	_	I-Premise
160	%	_	_	I-Premise
161	confidence	_	_	I-Premise
162	interval	_	_	I-Premise
163	[	_	_	I-Premise
164	CI	_	_	I-Premise
165	]	_	_	I-Premise
166	=	_	_	I-Premise
167	0.93	_	_	I-Premise
168	to	_	_	I-Premise
169	1.27	_	_	I-Premise
170	;	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	.28	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Among	_	_	B-Premise
177	patients	_	_	I-Premise
178	with	_	_	I-Premise
179	limited-stage	_	_	I-Premise
180	disease	_	_	I-Premise
181	,	_	_	I-Premise
182	there	_	_	I-Premise
183	was	_	_	I-Premise
184	no	_	_	I-Premise
185	evidence	_	_	I-Premise
186	of	_	_	I-Premise
187	a	_	_	I-Premise
188	survival	_	_	I-Premise
189	difference	_	_	I-Premise
190	(	_	_	I-Premise
191	HR	_	_	I-Premise
192	for	_	_	I-Premise
193	death	_	_	I-Premise
194	=	_	_	I-Premise
195	0.91	_	_	I-Premise
196	,	_	_	I-Premise
197	95	_	_	I-Premise
198	%	_	_	I-Premise
199	CI	_	_	I-Premise
200	=	_	_	I-Premise
201	0.73	_	_	I-Premise
202	to	_	_	I-Premise
203	1.15	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	but	_	_	B-Premise
207	among	_	_	I-Premise
208	patients	_	_	I-Premise
209	with	_	_	I-Premise
210	extensive	_	_	I-Premise
211	disease	_	_	I-Premise
212	,	_	_	I-Premise
213	survival	_	_	I-Premise
214	was	_	_	I-Premise
215	worse	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	thalidomide	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	HR	_	_	I-Premise
222	for	_	_	I-Premise
223	death	_	_	I-Premise
224	=	_	_	I-Premise
225	1.36	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	1.10	_	_	I-Premise
232	to	_	_	I-Premise
233	1.68	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Progression-free	_	_	B-Premise
237	survival	_	_	I-Premise
238	rates	_	_	I-Premise
239	were	_	_	I-Premise
240	also	_	_	I-Premise
241	similar	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	two	_	_	I-Premise
245	groups	_	_	I-Premise
246	(	_	_	I-Premise
247	HR	_	_	I-Premise
248	=	_	_	I-Premise
249	1.07	_	_	I-Premise
250	,	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	=	_	_	I-Premise
255	0.92	_	_	I-Premise
256	to	_	_	I-Premise
257	1.24	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Thalidomide	_	_	B-Premise
261	was	_	_	I-Premise
262	associated	_	_	I-Premise
263	with	_	_	I-Premise
264	an	_	_	I-Premise
265	increased	_	_	I-Premise
266	risk	_	_	I-Premise
267	of	_	_	I-Premise
268	having	_	_	I-Premise
269	a	_	_	I-Premise
270	thrombotic	_	_	I-Premise
271	event	_	_	I-Premise
272	,	_	_	I-Premise
273	mainly	_	_	I-Premise
274	pulmonary	_	_	I-Premise
275	embolus	_	_	I-Premise
276	and	_	_	I-Premise
277	deep	_	_	I-Premise
278	vein	_	_	I-Premise
279	thrombosis	_	_	I-Premise
280	(	_	_	I-Premise
281	19	_	_	I-Premise
282	%	_	_	I-Premise
283	thalidomide	_	_	I-Premise
284	vs	_	_	I-Premise
285	10	_	_	I-Premise
286	%	_	_	I-Premise
287	placebo	_	_	I-Premise
288	;	_	_	I-Premise
289	HR	_	_	I-Premise
290	=	_	_	I-Premise
291	2.13	_	_	I-Premise
292	,	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	=	_	_	I-Premise
297	1.41	_	_	I-Premise
298	to	_	_	I-Premise
299	3.20	_	_	I-Premise
300	;	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	.001	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	There	_	_	B-Premise
307	were	_	_	I-Premise
308	no	_	_	I-Premise
309	statistically	_	_	I-Premise
310	significant	_	_	I-Premise
311	differences	_	_	I-Premise
312	between	_	_	I-Premise
313	treatments	_	_	I-Premise
314	in	_	_	I-Premise
315	hematological	_	_	I-Premise
316	and	_	_	I-Premise
317	nonhematological	_	_	I-Premise
318	toxic	_	_	I-Premise
319	effects	_	_	I-Premise
320	,	_	_	I-Premise
321	except	_	_	B-Premise
322	more	_	_	I-Premise
323	patients	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	thalidomide	_	_	I-Premise
327	group	_	_	I-Premise
328	had	_	_	I-Premise
329	rash	_	_	I-Premise
330	,	_	_	I-Premise
331	constipation	_	_	I-Premise
332	,	_	_	I-Premise
333	or	_	_	I-Premise
334	neuropathy	_	_	I-Premise
335	.	_	_	I-Premise

336	Overall	_	_	O
337	,	_	_	O
338	QoL	_	_	B-Claim
339	scores	_	_	I-Claim
340	were	_	_	I-Claim
341	similar	_	_	I-Claim
342	in	_	_	I-Claim
343	the	_	_	I-Claim
344	two	_	_	I-Claim
345	treatment	_	_	I-Claim
346	groups	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	B-Claim
349	thalidomide	_	_	I-Claim
350	was	_	_	I-Claim
351	associated	_	_	I-Claim
352	with	_	_	I-Claim
353	less	_	_	I-Claim
354	insomnia	_	_	I-Claim
355	and	_	_	I-Claim
356	diarrhea	_	_	I-Claim
357	and	_	_	I-Claim
358	more	_	_	I-Claim
359	constipation	_	_	I-Claim
360	and	_	_	I-Claim
361	peripheral	_	_	I-Claim
362	neuropathy	_	_	I-Claim
363	.	_	_	I-Claim

364	In	_	_	O
365	this	_	_	O
366	large	_	_	O
367	randomized	_	_	O
368	trial	_	_	O
369	,	_	_	O
370	thalidomide	_	_	B-Claim
371	in	_	_	I-Claim
372	combination	_	_	I-Claim
373	with	_	_	I-Claim
374	chemotherapy	_	_	I-Claim
375	did	_	_	I-Claim
376	not	_	_	I-Claim
377	improve	_	_	I-Claim
378	survival	_	_	I-Claim
379	of	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	SCLC	_	_	I-Claim
383	but	_	_	I-Claim
384	was	_	_	I-Claim
385	associated	_	_	I-Claim
386	with	_	_	I-Claim
387	an	_	_	I-Claim
388	increased	_	_	I-Claim
389	risk	_	_	I-Claim
390	of	_	_	I-Claim
391	thrombotic	_	_	I-Claim
392	events	_	_	I-Claim
393	.	_	_	I-Claim


0	Vinorelbine	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	semisynthetic	_	_	I-Claim
4	vinca	_	_	I-Claim
5	alkaloid	_	_	I-Claim
6	,	_	_	I-Claim
7	represents	_	_	I-Claim
8	a	_	_	I-Claim
9	well-tolerated	_	_	I-Claim
10	treatment	_	_	I-Claim
11	for	_	_	I-Claim
12	elderly	_	_	I-Claim
13	patients	_	_	I-Claim
14	with	_	_	I-Claim
15	advanced	_	_	I-Claim
16	non-small-cell	_	_	I-Claim
17	lung	_	_	I-Claim
18	cancer	_	_	I-Claim
19	(	_	_	I-Claim
20	NSCLC	_	_	I-Claim
21	)	_	_	I-Claim
22	.	_	_	I-Claim

23	We	_	_	O
24	explored	_	_	O
25	the	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	QoL	_	_	O
31	)	_	_	O
32	of	_	_	O
33	such	_	_	O
34	patients	_	_	O
35	in	_	_	O
36	a	_	_	O
37	multicenter	_	_	O
38	randomized	_	_	O
39	trial	_	_	O
40	that	_	_	O
41	compared	_	_	O
42	vinorelbine	_	_	O
43	treatment	_	_	O
44	with	_	_	O
45	supportive	_	_	O
46	care	_	_	O
47	alone	_	_	O
48	.	_	_	O

49	Eligible	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	70	_	_	O
53	years	_	_	O
54	of	_	_	O
55	age	_	_	O
56	or	_	_	O
57	older	_	_	O
58	,	_	_	O
59	had	_	_	O
60	stage	_	_	O
61	IV	_	_	O
62	or	_	_	O
63	IIIB	_	_	O
64	NSCLC	_	_	O
65	that	_	_	O
66	was	_	_	O
67	ineligible	_	_	O
68	for	_	_	O
69	radiotherapy	_	_	O
70	,	_	_	O
71	and	_	_	O
72	had	_	_	O
73	a	_	_	O
74	performance	_	_	O
75	status	_	_	O
76	of	_	_	O
77	0-2	_	_	O
78	(	_	_	O
79	a	_	_	O
80	status	_	_	O
81	of	_	_	O
82	fully	_	_	O
83	active	_	_	O
84	to	_	_	O
85	a	_	_	O
86	status	_	_	O
87	of	_	_	O
88	capable	_	_	O
89	of	_	_	O
90	all	_	_	O
91	self-care	_	_	O
92	but	_	_	O
93	unable	_	_	O
94	to	_	_	O
95	work	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Vinorelbine	_	_	O
99	was	_	_	O
100	given	_	_	O
101	intravenously	_	_	O
102	on	_	_	O
103	days	_	_	O
104	1	_	_	O
105	and	_	_	O
106	8	_	_	O
107	of	_	_	O
108	a	_	_	O
109	21-day	_	_	O
110	treatment	_	_	O
111	cycle	_	_	O
112	,	_	_	O
113	for	_	_	O
114	a	_	_	O
115	total	_	_	O
116	of	_	_	O
117	six	_	_	O
118	cycles	_	_	O
119	.	_	_	O

120	QoL	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	with	_	_	O
124	European	_	_	O
125	Organization	_	_	O
126	for	_	_	O
127	Research	_	_	O
128	and	_	_	O
129	Treatment	_	_	O
130	of	_	_	O
131	Cancer	_	_	O
132	questionnaires	_	_	O
133	QLQ-C30	_	_	O
134	and	_	_	O
135	QLQ-LC13	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	QoL	_	_	O
140	data	_	_	O
141	were	_	_	O
142	analyzed	_	_	O
143	by	_	_	O
144	fitting	_	_	O
145	a	_	_	O
146	linear	_	_	O
147	mixed	_	_	O
148	model	_	_	O
149	for	_	_	O
150	each	_	_	O
151	QoL	_	_	O
152	scale	_	_	O
153	.	_	_	O

154	Survival	_	_	O
155	curves	_	_	O
156	were	_	_	O
157	plotted	_	_	O
158	and	_	_	O
159	were	_	_	O
160	compared	_	_	O
161	with	_	_	O
162	the	_	_	O
163	Mantel-Haenszel	_	_	O
164	test	_	_	O
165	.	_	_	O

166	Relative	_	_	O
167	hazards	_	_	O
168	of	_	_	O
169	death	_	_	O
170	and	_	_	O
171	95	_	_	O
172	%	_	_	O
173	confidence	_	_	O
174	intervals	_	_	O
175	(	_	_	O
176	CIs	_	_	O
177	)	_	_	O
178	were	_	_	O
179	estimated	_	_	O
180	by	_	_	O
181	the	_	_	O
182	Cox	_	_	O
183	model	_	_	O
184	.	_	_	O

185	Investigators	_	_	O
186	,	_	_	O
187	blinded	_	_	O
188	to	_	_	O
189	the	_	_	O
190	results	_	_	O
191	,	_	_	O
192	stopped	_	_	O
193	the	_	_	O
194	trial	_	_	O
195	early	_	_	O
196	because	_	_	O
197	of	_	_	O
198	a	_	_	O
199	low	_	_	O
200	enrollment	_	_	O
201	rate	_	_	O
202	.	_	_	O

203	(	_	_	O
204	From	_	_	O
205	April	_	_	O
206	1996	_	_	O
207	to	_	_	O
208	November	_	_	O
209	1997	_	_	O
210	,	_	_	O
211	191	_	_	O
212	of	_	_	O
213	the	_	_	O
214	350	_	_	O
215	targeted	_	_	O
216	patients	_	_	O
217	were	_	_	O
218	randomly	_	_	O
219	assigned	_	_	O
220	.	_	_	O
221	)	_	_	O

222	Data	_	_	O
223	from	_	_	O
224	161	_	_	O
225	patients	_	_	O
226	have	_	_	O
227	been	_	_	O
228	analyzed	_	_	O
229	.	_	_	O

230	Vinorelbine-treated	_	_	B-Premise
231	patients	_	_	I-Premise
232	scored	_	_	I-Premise
233	better	_	_	I-Premise
234	than	_	_	I-Premise
235	control	_	_	I-Premise
236	patients	_	_	I-Premise
237	on	_	_	I-Premise
238	QoL	_	_	I-Premise
239	functioning	_	_	I-Premise
240	scales	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	they	_	_	I-Premise
244	reported	_	_	I-Premise
245	fewer	_	_	I-Premise
246	lung	_	_	I-Premise
247	cancer-related	_	_	I-Premise
248	symptoms	_	_	I-Premise
249	but	_	_	I-Premise
250	reported	_	_	I-Premise
251	worse	_	_	I-Premise
252	toxicity-related	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	.	_	_	I-Premise

255	There	_	_	B-Premise
256	was	_	_	I-Premise
257	a	_	_	I-Premise
258	statistically	_	_	I-Premise
259	significant	_	_	I-Premise
260	(	_	_	I-Premise
261	two-sided	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.03	_	_	I-Premise
265	)	_	_	I-Premise
266	survival	_	_	I-Premise
267	advantage	_	_	I-Premise
268	for	_	_	I-Premise
269	patients	_	_	I-Premise
270	receiving	_	_	I-Premise
271	vinorelbine	_	_	I-Premise
272	;	_	_	I-Premise
273	median	_	_	B-Premise
274	survival	_	_	I-Premise
275	increased	_	_	I-Premise
276	from	_	_	I-Premise
277	21	_	_	I-Premise
278	to	_	_	I-Premise
279	28	_	_	I-Premise
280	weeks	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	vinorelbine-treated	_	_	I-Premise
284	group	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	relative	_	_	I-Premise
288	hazard	_	_	I-Premise
289	of	_	_	I-Premise
290	death	_	_	I-Premise
291	for	_	_	I-Premise
292	vinorelbine-treated	_	_	I-Premise
293	patients	_	_	I-Premise
294	was	_	_	I-Premise
295	0.65	_	_	I-Premise
296	(	_	_	I-Premise
297	95	_	_	I-Premise
298	%	_	_	I-Premise
299	CI	_	_	I-Premise
300	=	_	_	I-Premise
301	0.45-0.93	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Vinorelbine	_	_	B-Claim
305	improves	_	_	I-Claim
306	survival	_	_	I-Claim
307	of	_	_	I-Claim
308	elderly	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	advanced	_	_	I-Claim
312	NSCLC	_	_	I-Claim
313	and	_	_	I-Claim
314	possibly	_	_	I-Claim
315	improves	_	_	I-Claim
316	overall	_	_	I-Claim
317	QoL	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	cancer-related	_	_	O
4	anorexia/cachexia	_	_	O
5	syndrome	_	_	O
6	(	_	_	O
7	CACS	_	_	O
8	)	_	_	O
9	is	_	_	O
10	a	_	_	O
11	great	_	_	O
12	challenge	_	_	O
13	in	_	_	O
14	clinical	_	_	O
15	practice	_	_	O
16	.	_	_	O

17	To	_	_	O
18	date	_	_	O
19	,	_	_	O
20	practice	_	_	O
21	guidelines	_	_	O
22	for	_	_	O
23	the	_	_	O
24	prevention	_	_	O
25	and	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	CACS	_	_	O
29	are	_	_	O
30	lacking	_	_	O
31	.	_	_	O

32	The	_	_	O
33	authors	_	_	O
34	conducted	_	_	O
35	a	_	_	O
36	randomized	_	_	O
37	study	_	_	O
38	to	_	_	O
39	confirm	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	and	_	_	O
43	safety	_	_	O
44	of	_	_	O
45	treatment	_	_	O
46	of	_	_	O
47	CACS	_	_	O
48	utilizing	_	_	O
49	megestrol	_	_	O
50	acetate	_	_	O
51	(	_	_	O
52	MA	_	_	O
53	)	_	_	O
54	plus	_	_	O
55	thalidomide	_	_	O
56	.	_	_	O

57	One	_	_	O
58	hundred	_	_	O
59	and	_	_	O
60	two	_	_	O
61	candidates	_	_	O
62	with	_	_	O
63	CACS	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	two	_	_	O
69	treatment	_	_	O
70	groups	_	_	O
71	(	_	_	O
72	trial	_	_	O
73	group	_	_	O
74	and	_	_	O
75	control	_	_	O
76	group	_	_	O
77	)	_	_	O
78	:	_	_	O
79	the	_	_	O
80	trial	_	_	O
81	group	_	_	O
82	received	_	_	O
83	MA	_	_	O
84	(	_	_	O
85	160	_	_	O
86	mg	_	_	O
87	po	_	_	O
88	,	_	_	O
89	bid	_	_	O
90	)	_	_	O
91	plus	_	_	O
92	thalidomide	_	_	O
93	(	_	_	O
94	50	_	_	O
95	mg	_	_	O
96	po	_	_	O
97	,	_	_	O
98	bid	_	_	O
99	)	_	_	O
100	,	_	_	O
101	while	_	_	O
102	the	_	_	O
103	control	_	_	O
104	group	_	_	O
105	received	_	_	O
106	MA	_	_	O
107	(	_	_	O
108	160	_	_	O
109	mg	_	_	O
110	po	_	_	O
111	,	_	_	O
112	bid	_	_	O
113	)	_	_	O
114	alone	_	_	O
115	.	_	_	O

116	Treatment	_	_	O
117	duration	_	_	O
118	was	_	_	O
119	8	_	_	O
120	weeks	_	_	O
121	.	_	_	O

122	Analysis	_	_	B-Premise
123	of	_	_	I-Premise
124	the	_	_	I-Premise
125	trial	_	_	I-Premise
126	group	_	_	I-Premise
127	demonstrated	_	_	I-Premise
128	a	_	_	I-Premise
129	significant	_	_	I-Premise
130	increase	_	_	I-Premise
131	from	_	_	I-Premise
132	baseline	_	_	I-Premise
133	in	_	_	I-Premise
134	body	_	_	I-Premise
135	weight	_	_	I-Premise
136	(	_	_	I-Premise
137	<	_	_	I-Premise
138	0.01	_	_	I-Premise
139	)	_	_	I-Premise
140	,	_	_	I-Premise
141	quality	_	_	I-Premise
142	of	_	_	I-Premise
143	life	_	_	I-Premise
144	(	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.02	_	_	I-Premise
148	)	_	_	I-Premise
149	,	_	_	I-Premise
150	appetite	_	_	I-Premise
151	(	_	_	I-Premise
152	p	_	_	I-Premise
153	=	_	_	I-Premise
154	0.01	_	_	I-Premise
155	)	_	_	I-Premise
156	,	_	_	I-Premise
157	and	_	_	I-Premise
158	grip	_	_	I-Premise
159	strength	_	_	I-Premise
160	(	_	_	I-Premise
161	p	_	_	I-Premise
162	=	_	_	I-Premise
163	0.01	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	and	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	decrease	_	_	I-Premise
170	in	_	_	I-Premise
171	fatigue	_	_	I-Premise
172	,	_	_	I-Premise
173	Glasgow	_	_	I-Premise
174	Prognostic	_	_	I-Premise
175	Score	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	=	_	_	I-Premise
179	0.05	_	_	I-Premise
180	)	_	_	I-Premise
181	,	_	_	I-Premise
182	Eastern	_	_	I-Premise
183	Cooperative	_	_	I-Premise
184	Oncology	_	_	I-Premise
185	Group	_	_	I-Premise
186	performance	_	_	I-Premise
187	status	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.03	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	IL-6	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	<	_	_	I-Premise
198	0.01	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	tumor	_	_	I-Premise
203	necrosis	_	_	I-Premise
204	factor-Î±	_	_	I-Premise
205	(	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.02	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	In	_	_	B-Premise
212	contrast	_	_	I-Premise
213	,	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	control	_	_	I-Premise
217	group	_	_	I-Premise
218	,	_	_	I-Premise
219	endpoints	_	_	I-Premise
220	with	_	_	I-Premise
221	a	_	_	I-Premise
222	significant	_	_	I-Premise
223	improvement	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	included	_	_	I-Premise
227	body	_	_	I-Premise
228	weight	_	_	I-Premise
229	(	_	_	I-Premise
230	p	_	_	I-Premise
231	<	_	_	I-Premise
232	0.02	_	_	I-Premise
233	)	_	_	I-Premise
234	and	_	_	I-Premise
235	appetite	_	_	I-Premise
236	(	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.02	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	mean	_	_	I-Premise
244	changes	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	endpoints	_	_	I-Premise
248	from	_	_	I-Premise
249	baseline	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	trial	_	_	I-Premise
253	group	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	greater	_	_	I-Premise
257	compared	_	_	I-Premise
258	with	_	_	I-Premise
259	the	_	_	I-Premise
260	control	_	_	I-Premise
261	group	_	_	I-Premise
262	:	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	primary	_	_	I-Premise
266	endpoints	_	_	I-Premise
267	,	_	_	I-Premise
268	body	_	_	I-Premise
269	weight	_	_	I-Premise
270	(	_	_	I-Premise
271	p	_	_	I-Premise
272	=	_	_	I-Premise
273	0.05	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	fatigue	_	_	I-Premise
277	(	_	_	I-Premise
278	p	_	_	I-Premise
279	<	_	_	I-Premise
280	0.01	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	quality	_	_	I-Premise
284	of	_	_	I-Premise
285	life	_	_	I-Premise
286	(	_	_	I-Premise
287	p	_	_	I-Premise
288	=	_	_	I-Premise
289	0.01	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	and	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	secondary	_	_	I-Premise
296	endpoints	_	_	I-Premise
297	,	_	_	I-Premise
298	grip	_	_	I-Premise
299	strength	_	_	I-Premise
300	(	_	_	I-Premise
301	p	_	_	I-Premise
302	=	_	_	I-Premise
303	0.05	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	Glasgow	_	_	I-Premise
307	Prognostic	_	_	I-Premise
308	Score	_	_	I-Premise
309	(	_	_	I-Premise
310	p	_	_	I-Premise
311	=	_	_	I-Premise
312	0.02	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	Eastern	_	_	I-Premise
316	Cooperative	_	_	I-Premise
317	Oncology	_	_	I-Premise
318	Group	_	_	I-Premise
319	performance	_	_	I-Premise
320	status	_	_	I-Premise
321	(	_	_	I-Premise
322	p	_	_	I-Premise
323	=	_	_	I-Premise
324	0.02	_	_	I-Premise
325	)	_	_	I-Premise
326	,	_	_	I-Premise
327	IL-6	_	_	I-Premise
328	(	_	_	I-Premise
329	p	_	_	I-Premise
330	<	_	_	I-Premise
331	0.01	_	_	I-Premise
332	)	_	_	I-Premise
333	and	_	_	I-Premise
334	tumor	_	_	I-Premise
335	necrosis	_	_	I-Premise
336	factor-Î±	_	_	I-Premise
337	(	_	_	I-Premise
338	p	_	_	I-Premise
339	=	_	_	I-Premise
340	0.01	_	_	I-Premise
341	)	_	_	I-Premise
342	.	_	_	I-Premise

343	Toxicity	_	_	B-Premise
344	was	_	_	I-Premise
345	found	_	_	I-Premise
346	to	_	_	I-Premise
347	be	_	_	I-Premise
348	relatively	_	_	I-Premise
349	negligible	_	_	I-Premise
350	in	_	_	I-Premise
351	both	_	_	I-Premise
352	groups	_	_	I-Premise
353	.	_	_	I-Premise

354	A	_	_	B-Claim
355	combination	_	_	I-Claim
356	regimen	_	_	I-Claim
357	of	_	_	I-Claim
358	MA	_	_	I-Claim
359	and	_	_	I-Claim
360	thalidomide	_	_	I-Claim
361	is	_	_	I-Claim
362	more	_	_	I-Claim
363	effective	_	_	I-Claim
364	than	_	_	I-Claim
365	MA	_	_	I-Claim
366	alone	_	_	I-Claim
367	in	_	_	I-Claim
368	the	_	_	I-Claim
369	treatment	_	_	I-Claim
370	of	_	_	I-Claim
371	CACS	_	_	I-Claim
372	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	non-inferiority	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	designed	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	whether	_	_	O
9	radiosurgery	_	_	O
10	plus	_	_	O
11	adjuvant	_	_	O
12	whole	_	_	O
13	brain	_	_	O
14	radiotherapy	_	_	O
15	(	_	_	O
16	RS	_	_	O
17	+	_	_	O
18	WBRT	_	_	O
19	)	_	_	O
20	is	_	_	O
21	as	_	_	O
22	effective	_	_	O
23	as	_	_	O
24	surgery	_	_	O
25	plus	_	_	O
26	whole	_	_	O
27	brain	_	_	O
28	radiotherapy	_	_	O
29	(	_	_	O
30	S	_	_	O
31	+	_	_	O
32	WBRT	_	_	O
33	)	_	_	O
34	for	_	_	O
35	cancer	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	solitary	_	_	O
40	brain	_	_	O
41	metastasis	_	_	O
42	,	_	_	O
43	with	_	_	O
44	respect	_	_	O
45	to	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	and	_	_	O
49	quality	_	_	O
50	of	_	_	O
51	life	_	_	O
52	.	_	_	O

53	Major	_	_	O
54	inclusion	_	_	O
55	criteria	_	_	O
56	were	_	_	O
57	a	_	_	O
58	history	_	_	O
59	of	_	_	O
60	systemic	_	_	O
61	cancer	_	_	O
62	within	_	_	O
63	5	_	_	O
64	years	_	_	O
65	and	_	_	O
66	enhanced	_	_	O
67	magnetic	_	_	O
68	resonance	_	_	O
69	imaging-confirmed	_	_	O
70	solitary	_	_	O
71	brain	_	_	O
72	metastasis	_	_	O
73	suitable	_	_	O
74	for	_	_	O
75	both	_	_	O
76	radiosurgery	_	_	O
77	and	_	_	O
78	surgery	_	_	O
79	.	_	_	O

80	All	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	WBRT	_	_	O
86	(	_	_	O
87	30	_	_	O
88	Gy	_	_	O
89	in	_	_	O
90	10	_	_	O
91	fractions	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Between	_	_	O
95	February	_	_	O
96	2003	_	_	O
97	and	_	_	O
98	April	_	_	O
99	2009	_	_	O
100	,	_	_	O
101	40	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	considered	_	_	O
105	eligible	_	_	O
106	,	_	_	O
107	22	_	_	O
108	consented	_	_	O
109	to	_	_	O
110	randomisation	_	_	O
111	and	_	_	O
112	21	_	_	O
113	were	_	_	O
114	analysed	_	_	O
115	(	_	_	O
116	11	_	_	O
117	RS	_	_	O
118	+	_	_	O
119	WBRT	_	_	O
120	,	_	_	O
121	10	_	_	O
122	S	_	_	O
123	+	_	_	O
124	WBRT	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	trial	_	_	O
129	was	_	_	O
130	closed	_	_	O
131	early	_	_	O
132	due	_	_	O
133	to	_	_	O
134	slow	_	_	O
135	accrual	_	_	O
136	.	_	_	O

137	The	_	_	B-Premise
138	estimated	_	_	I-Premise
139	median	_	_	I-Premise
140	overall	_	_	I-Premise
141	survival	_	_	I-Premise
142	times	_	_	I-Premise
143	for	_	_	I-Premise
144	RS	_	_	I-Premise
145	+	_	_	I-Premise
146	WBRT	_	_	I-Premise
147	and	_	_	I-Premise
148	S	_	_	I-Premise
149	+	_	_	I-Premise
150	WBRT	_	_	I-Premise
151	patients	_	_	I-Premise
152	were	_	_	I-Premise
153	6.2	_	_	I-Premise
154	and	_	_	I-Premise
155	2.8	_	_	I-Premise
156	months	_	_	I-Premise
157	,	_	_	I-Premise
158	respectively	_	_	I-Premise
159	(	_	_	I-Premise
160	hazard	_	_	I-Premise
161	ratio	_	_	I-Premise
162	0.53	_	_	I-Premise
163	,	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	0.20-1.43	_	_	I-Premise
169	,	_	_	I-Premise
170	P	_	_	I-Premise
171	=	_	_	I-Premise
172	0.20	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	Corresponding	_	_	B-Premise
176	median	_	_	I-Premise
177	failure-free	_	_	I-Premise
178	survival	_	_	I-Premise
179	times	_	_	I-Premise
180	were	_	_	I-Premise
181	3.1	_	_	I-Premise
182	and	_	_	I-Premise
183	1.7	_	_	I-Premise
184	months	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	0.20	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	For	_	_	B-Premise
192	19	_	_	I-Premise
193	'per	_	_	I-Premise
194	protocol	_	_	I-Premise
195	'	_	_	I-Premise
196	patients	_	_	I-Premise
197	,	_	_	I-Premise
198	2/10	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	RS	_	_	I-Premise
202	+	_	_	I-Premise
203	WBRT	_	_	I-Premise
204	arm	_	_	I-Premise
205	had	_	_	I-Premise
206	distant	_	_	I-Premise
207	intracranial	_	_	I-Premise
208	failure	_	_	I-Premise
209	(	_	_	I-Premise
210	one	_	_	I-Premise
211	also	_	_	I-Premise
212	had	_	_	I-Premise
213	local	_	_	I-Premise
214	failure	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	3/9	_	_	I-Premise
218	S	_	_	I-Premise
219	+	_	_	I-Premise
220	WBRT	_	_	I-Premise
221	patients	_	_	I-Premise
222	had	_	_	I-Premise
223	distant	_	_	I-Premise
224	intracranial	_	_	I-Premise
225	failure	_	_	I-Premise
226	(	_	_	I-Premise
227	no	_	_	I-Premise
228	local	_	_	I-Premise
229	failures	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	There	_	_	B-Premise
233	were	_	_	I-Premise
234	no	_	_	I-Premise
235	grade	_	_	I-Premise
236	3-4	_	_	I-Premise
237	late	_	_	I-Premise
238	radiation	_	_	I-Premise
239	toxicities	_	_	I-Premise
240	.	_	_	I-Premise

241	Two	_	_	B-Claim
242	months	_	_	I-Claim
243	after	_	_	I-Claim
244	starting	_	_	I-Claim
245	treatment	_	_	I-Claim
246	there	_	_	I-Claim
247	were	_	_	I-Claim
248	no	_	_	I-Claim
249	significant	_	_	I-Claim
250	differences	_	_	I-Claim
251	in	_	_	I-Claim
252	quality	_	_	I-Claim
253	of	_	_	I-Claim
254	life	_	_	I-Claim
255	between	_	_	I-Claim
256	the	_	_	I-Claim
257	arms	_	_	I-Claim
258	.	_	_	I-Claim

259	This	_	_	B-Claim
260	randomised	_	_	I-Claim
261	trial	_	_	I-Claim
262	encountered	_	_	I-Claim
263	the	_	_	I-Claim
264	accrual	_	_	I-Claim
265	difficulties	_	_	I-Claim
266	and	_	_	I-Claim
267	consequent	_	_	I-Claim
268	low	_	_	I-Claim
269	statistical	_	_	I-Claim
270	power	_	_	I-Claim
271	commonly	_	_	I-Claim
272	associated	_	_	I-Claim
273	with	_	_	I-Claim
274	interdisciplinary	_	_	I-Claim
275	studies	_	_	I-Claim
276	drawing	_	_	I-Claim
277	from	_	_	I-Claim
278	a	_	_	I-Claim
279	small	_	_	I-Claim
280	eligible	_	_	I-Claim
281	population	_	_	I-Claim
282	,	_	_	I-Claim
283	but	_	_	O
284	can	_	_	O
285	contribute	_	_	O
286	to	_	_	O
287	future	_	_	O
288	overviews	_	_	O
289	on	_	_	O
290	the	_	_	O
291	management	_	_	O
292	of	_	_	O
293	solitary	_	_	O
294	brain	_	_	O
295	metastases	_	_	O
296	.	_	_	O


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	treatment	_	_	I-Claim
4	on	_	_	I-Claim
5	health-related	_	_	I-Claim
6	quality	_	_	I-Claim
7	of	_	_	I-Claim
8	life	_	_	I-Claim
9	(	_	_	I-Claim
10	HRQoL	_	_	I-Claim
11	)	_	_	I-Claim
12	is	_	_	I-Claim
13	an	_	_	I-Claim
14	important	_	_	I-Claim
15	consideration	_	_	I-Claim
16	in	_	_	I-Claim
17	the	_	_	I-Claim
18	adjuvant	_	_	I-Claim
19	treatment	_	_	I-Claim
20	of	_	_	I-Claim
21	operable	_	_	I-Claim
22	breast	_	_	I-Claim
23	cancer	_	_	I-Claim
24	.	_	_	I-Claim

25	Here	_	_	O
26	we	_	_	O
27	report	_	_	O
28	mature	_	_	O
29	HRQoL	_	_	O
30	outcomes	_	_	O
31	from	_	_	O
32	the	_	_	O
33	ATAC	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	comparing	_	_	O
37	anastrozole	_	_	O
38	with	_	_	O
39	tamoxifen	_	_	O
40	as	_	_	O
41	primary	_	_	O
42	adjuvant	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	postmenopausal	_	_	O
46	women	_	_	O
47	with	_	_	O
48	localized	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	.	_	_	O

52	Patients	_	_	O
53	completed	_	_	O
54	the	_	_	O
55	Functional	_	_	O
56	Assessment	_	_	O
57	of	_	_	O
58	Cancer	_	_	O
59	Therapy-Breast	_	_	O
60	(	_	_	O
61	FACT-B	_	_	O
62	)	_	_	O
63	questionnaire	_	_	O
64	plus	_	_	O
65	endocrine	_	_	O
66	subscale	_	_	O
67	(	_	_	O
68	ES	_	_	O
69	)	_	_	O
70	at	_	_	O
71	baseline	_	_	O
72	,	_	_	O
73	3	_	_	O
74	and	_	_	O
75	6	_	_	O
76	months	_	_	O
77	,	_	_	O
78	and	_	_	O
79	every	_	_	O
80	6	_	_	O
81	months	_	_	O
82	thereafter	_	_	O
83	.	_	_	O

84	Baseline	_	_	O
85	characteristics	_	_	O
86	in	_	_	O
87	the	_	_	O
88	HRQoL	_	_	O
89	sub-protocol	_	_	O
90	were	_	_	O
91	well	_	_	O
92	balanced	_	_	O
93	between	_	_	O
94	the	_	_	O
95	anastrozole	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	335	_	_	O
100	)	_	_	O
101	and	_	_	O
102	tamoxifen	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	347	_	_	O
107	)	_	_	O
108	groups	_	_	O
109	in	_	_	O
110	the	_	_	O
111	primary	_	_	O
112	analysis	_	_	O
113	population	_	_	O
114	.	_	_	O

115	As	_	_	B-Premise
116	with	_	_	I-Premise
117	previously	_	_	I-Premise
118	published	_	_	I-Premise
119	results	_	_	I-Premise
120	at	_	_	I-Premise
121	2	_	_	I-Premise
122	years	_	_	I-Premise
123	,	_	_	I-Premise
124	there	_	_	I-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	difference	_	_	I-Premise
130	in	_	_	I-Premise
131	the	_	_	I-Premise
132	Trial	_	_	I-Premise
133	Outcome	_	_	I-Premise
134	Index	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	FACT-B	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	primary	_	_	I-Premise
141	endpoint	_	_	I-Premise
142	of	_	_	I-Premise
143	the	_	_	I-Premise
144	study	_	_	I-Premise
145	,	_	_	I-Premise
146	between	_	_	I-Premise
147	treatments	_	_	I-Premise
148	at	_	_	I-Premise
149	5	_	_	I-Premise
150	years	_	_	I-Premise
151	.	_	_	I-Premise

152	There	_	_	B-Premise
153	were	_	_	I-Premise
154	no	_	_	I-Premise
155	statistically	_	_	I-Premise
156	significant	_	_	I-Premise
157	differences	_	_	I-Premise
158	between	_	_	I-Premise
159	treatment	_	_	I-Premise
160	groups	_	_	I-Premise
161	in	_	_	I-Premise
162	ES	_	_	I-Premise
163	total	_	_	I-Premise
164	scores	_	_	I-Premise
165	.	_	_	I-Premise

166	Consistent	_	_	O
167	with	_	_	O
168	the	_	_	O
169	2-year	_	_	O
170	analysis	_	_	O
171	,	_	_	O
172	there	_	_	B-Claim
173	were	_	_	I-Claim
174	differences	_	_	I-Claim
175	between	_	_	I-Claim
176	treatment	_	_	I-Claim
177	groups	_	_	I-Claim
178	in	_	_	I-Claim
179	patient-reported	_	_	I-Claim
180	side	_	_	I-Claim
181	effects	_	_	I-Claim
182	:	_	_	I-Claim
183	diarrhea	_	_	B-Premise
184	(	_	_	I-Premise
185	anastrozole	_	_	I-Premise
186	3.1	_	_	I-Premise
187	%	_	_	I-Premise
188	vs.	_	_	I-Premise
189	tamoxifen	_	_	I-Premise
190	1.3	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	vaginal	_	_	I-Premise
195	dryness	_	_	I-Premise
196	(	_	_	I-Premise
197	18.5	_	_	I-Premise
198	%	_	_	I-Premise
199	vs.	_	_	I-Premise
200	9.1	_	_	I-Premise
201	%	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	diminished	_	_	I-Premise
205	libido	_	_	I-Premise
206	(	_	_	I-Premise
207	34.0	_	_	I-Premise
208	%	_	_	I-Premise
209	vs.	_	_	I-Premise
210	26.1	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	dyspareunia	_	_	I-Premise
216	(	_	_	I-Premise
217	17.3	_	_	I-Premise
218	%	_	_	I-Premise
219	vs.	_	_	I-Premise
220	8.1	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	were	_	_	I-Premise
224	significantly	_	_	I-Premise
225	more	_	_	I-Premise
226	frequent	_	_	I-Premise
227	with	_	_	I-Premise
228	anastrozole	_	_	I-Premise
229	compared	_	_	I-Premise
230	to	_	_	I-Premise
231	tamoxifen	_	_	I-Premise
232	.	_	_	I-Premise

233	Dizziness	_	_	B-Premise
234	(	_	_	I-Premise
235	3.1	_	_	I-Premise
236	%	_	_	I-Premise
237	vs.	_	_	I-Premise
238	5.4	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	vaginal	_	_	I-Premise
243	discharge	_	_	I-Premise
244	(	_	_	I-Premise
245	1.2	_	_	I-Premise
246	%	_	_	I-Premise
247	vs.	_	_	I-Premise
248	5.2	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	were	_	_	I-Premise
252	significantly	_	_	I-Premise
253	less	_	_	I-Premise
254	frequent	_	_	I-Premise
255	with	_	_	I-Premise
256	anastrozole	_	_	I-Premise
257	compared	_	_	I-Premise
258	to	_	_	I-Premise
259	tamoxifen	_	_	I-Premise
260	.	_	_	I-Premise

261	In	_	_	B-Claim
262	this	_	_	I-Claim
263	,	_	_	I-Claim
264	the	_	_	I-Claim
265	first	_	_	I-Claim
266	report	_	_	I-Claim
267	of	_	_	I-Claim
268	HRQoL	_	_	I-Claim
269	over	_	_	I-Claim
270	5	_	_	I-Claim
271	years	_	_	I-Claim
272	of	_	_	I-Claim
273	initial	_	_	I-Claim
274	adjuvant	_	_	I-Claim
275	therapy	_	_	I-Claim
276	with	_	_	I-Claim
277	an	_	_	I-Claim
278	aromatase	_	_	I-Claim
279	inhibitor	_	_	I-Claim
280	,	_	_	I-Claim
281	we	_	_	I-Claim
282	conclude	_	_	I-Claim
283	that	_	_	I-Claim
284	anastrozole	_	_	I-Claim
285	and	_	_	I-Claim
286	tamoxifen	_	_	I-Claim
287	had	_	_	I-Claim
288	similar	_	_	I-Claim
289	impacts	_	_	I-Claim
290	on	_	_	I-Claim
291	HRQoL	_	_	I-Claim
292	,	_	_	I-Claim
293	which	_	_	I-Claim
294	was	_	_	I-Claim
295	maintained	_	_	I-Claim
296	or	_	_	I-Claim
297	slightly	_	_	I-Claim
298	improved	_	_	I-Claim
299	during	_	_	I-Claim
300	the	_	_	I-Claim
301	treatment	_	_	I-Claim
302	period	_	_	I-Claim
303	for	_	_	I-Claim
304	both	_	_	I-Claim
305	groups	_	_	I-Claim
306	.	_	_	I-Claim


0	Axillary	_	_	B-Claim
1	clearance	_	_	I-Claim
2	in	_	_	I-Claim
3	early	_	_	I-Claim
4	breast	_	_	I-Claim
5	cancer	_	_	I-Claim
6	aims	_	_	I-Claim
7	to	_	_	I-Claim
8	improve	_	_	I-Claim
9	locoregional	_	_	I-Claim
10	control	_	_	I-Claim
11	and	_	_	I-Claim
12	provide	_	_	I-Claim
13	staging	_	_	I-Claim
14	information	_	_	I-Claim
15	but	_	_	O
16	is	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	undesirable	_	_	O
20	morbidity	_	_	O
21	.	_	_	O

22	We	_	_	O
23	therefore	_	_	O
24	investigated	_	_	O
25	whether	_	_	O
26	avoiding	_	_	O
27	axillary	_	_	O
28	surgery	_	_	O
29	in	_	_	O
30	older	_	_	O
31	women	_	_	O
32	would	_	_	O
33	result	_	_	O
34	in	_	_	O
35	improved	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	(	_	_	O
40	QL	_	_	O
41	)	_	_	O
42	with	_	_	O
43	similar	_	_	O
44	disease-free	_	_	O
45	survival	_	_	O
46	(	_	_	O
47	DFS	_	_	O
48	)	_	_	O
49	and	_	_	O
50	overall	_	_	O
51	survival	_	_	O
52	(	_	_	O
53	OS	_	_	O
54	)	_	_	O
55	.	_	_	O

56	Between	_	_	O
57	1993	_	_	O
58	and	_	_	O
59	2002	_	_	O
60	,	_	_	O
61	women	_	_	O
62	>	_	_	O
63	or	_	_	O
64	=	_	_	O
65	60	_	_	O
66	years	_	_	O
67	old	_	_	O
68	with	_	_	O
69	clinically	_	_	O
70	node-negative	_	_	O
71	operable	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	in	_	_	O
75	whom	_	_	O
76	adjuvant	_	_	O
77	tamoxifen	_	_	O
78	was	_	_	O
79	considered	_	_	O
80	indicated	_	_	O
81	regardless	_	_	O
82	of	_	_	O
83	pathologic	_	_	O
84	nodal	_	_	O
85	status	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	primary	_	_	O
91	surgery	_	_	O
92	plus	_	_	O
93	axillary	_	_	O
94	clearance	_	_	O
95	(	_	_	O
96	Sx	_	_	O
97	+	_	_	O
98	Ax	_	_	O
99	)	_	_	O
100	followed	_	_	O
101	by	_	_	O
102	tamoxifen	_	_	O
103	(	_	_	O
104	Tam	_	_	O
105	)	_	_	O
106	versus	_	_	O
107	Sx	_	_	O
108	without	_	_	O
109	Ax	_	_	O
110	followed	_	_	O
111	by	_	_	O
112	Tam	_	_	O
113	for	_	_	O
114	5	_	_	O
115	consecutive	_	_	O
116	years	_	_	O
117	.	_	_	O

118	The	_	_	O
119	primary	_	_	O
120	end	_	_	O
121	point	_	_	O
122	was	_	_	O
123	QL	_	_	O
124	reported	_	_	O
125	by	_	_	O
126	the	_	_	O
127	patient	_	_	O
128	and	_	_	O
129	by	_	_	O
130	physician	_	_	O
131	assessment	_	_	O
132	.	_	_	O

133	A	_	_	O
134	total	_	_	O
135	of	_	_	O
136	473	_	_	O
137	patients	_	_	O
138	(	_	_	O
139	234	_	_	O
140	to	_	_	O
141	Sx	_	_	O
142	+	_	_	O
143	Ax	_	_	O
144	,	_	_	O
145	239	_	_	O
146	to	_	_	O
147	Sx	_	_	O
148	)	_	_	O
149	were	_	_	O
150	randomly	_	_	O
151	assigned	_	_	O
152	.	_	_	O

153	The	_	_	O
154	median	_	_	O
155	age	_	_	O
156	was	_	_	O
157	74	_	_	O
158	years	_	_	O
159	;	_	_	O
160	80	_	_	O
161	%	_	_	O
162	had	_	_	O
163	estrogen	_	_	O
164	receptor-positive	_	_	O
165	disease	_	_	O
166	.	_	_	O

167	In	_	_	B-Premise
168	both	_	_	I-Premise
169	the	_	_	I-Premise
170	patients	_	_	I-Premise
171	'	_	_	I-Premise
172	subjective	_	_	I-Premise
173	assessment	_	_	I-Premise
174	of	_	_	I-Premise
175	their	_	_	I-Premise
176	QL	_	_	I-Premise
177	and	_	_	I-Premise
178	the	_	_	I-Premise
179	physicians	_	_	I-Premise
180	'	_	_	I-Premise
181	perception	_	_	I-Premise
182	of	_	_	I-Premise
183	the	_	_	I-Premise
184	patients	_	_	I-Premise
185	'	_	_	I-Premise
186	QL	_	_	I-Premise
187	,	_	_	I-Premise
188	the	_	_	I-Premise
189	largest	_	_	I-Premise
190	adverse	_	_	I-Premise
191	QL	_	_	I-Premise
192	effects	_	_	I-Premise
193	of	_	_	I-Premise
194	Ax	_	_	I-Premise
195	were	_	_	I-Premise
196	observed	_	_	I-Premise
197	from	_	_	I-Premise
198	baseline	_	_	I-Premise
199	to	_	_	I-Premise
200	the	_	_	I-Premise
201	first	_	_	I-Premise
202	postoperative	_	_	I-Premise
203	assessment	_	_	I-Premise
204	,	_	_	I-Premise
205	but	_	_	B-Premise
206	the	_	_	I-Premise
207	differences	_	_	I-Premise
208	tended	_	_	I-Premise
209	to	_	_	I-Premise
210	disappear	_	_	I-Premise
211	in	_	_	I-Premise
212	6	_	_	I-Premise
213	to	_	_	I-Premise
214	12	_	_	I-Premise
215	months	_	_	I-Premise
216	.	_	_	I-Premise

217	At	_	_	B-Premise
218	a	_	_	I-Premise
219	median	_	_	I-Premise
220	follow-up	_	_	I-Premise
221	of	_	_	I-Premise
222	6.6	_	_	I-Premise
223	years	_	_	I-Premise
224	,	_	_	I-Premise
225	results	_	_	I-Premise
226	for	_	_	I-Premise
227	Sx	_	_	I-Premise
228	+	_	_	I-Premise
229	Ax	_	_	I-Premise
230	and	_	_	I-Premise
231	Sx	_	_	I-Premise
232	yielded	_	_	I-Premise
233	similar	_	_	I-Premise
234	DFS	_	_	I-Premise
235	(	_	_	I-Premise
236	6-year	_	_	I-Premise
237	DFS	_	_	I-Premise
238	,	_	_	I-Premise
239	67	_	_	I-Premise
240	%	_	_	I-Premise
241	v	_	_	I-Premise
242	66	_	_	I-Premise
243	%	_	_	I-Premise
244	;	_	_	I-Premise
245	hazard	_	_	I-Premise
246	ratio	_	_	I-Premise
247	[	_	_	I-Premise
248	HR	_	_	I-Premise
249	]	_	_	I-Premise
250	Sx	_	_	I-Premise
251	+	_	_	I-Premise
252	Ax/Sx	_	_	I-Premise
253	,	_	_	I-Premise
254	1.06	_	_	I-Premise
255	;	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.79	_	_	I-Premise
261	to	_	_	I-Premise
262	1.42	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.69	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	OS	_	_	I-Premise
270	(	_	_	I-Premise
271	6-year	_	_	I-Premise
272	OS	_	_	I-Premise
273	,	_	_	I-Premise
274	75	_	_	I-Premise
275	%	_	_	I-Premise
276	v	_	_	I-Premise
277	73	_	_	I-Premise
278	%	_	_	I-Premise
279	;	_	_	I-Premise
280	HR	_	_	I-Premise
281	Sx	_	_	I-Premise
282	+	_	_	I-Premise
283	Ax/Sx	_	_	I-Premise
284	,	_	_	I-Premise
285	1.05	_	_	I-Premise
286	;	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	CI	_	_	I-Premise
290	,	_	_	I-Premise
291	0.76	_	_	I-Premise
292	to	_	_	I-Premise
293	1.46	_	_	I-Premise
294	;	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.77	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Avoiding	_	_	B-Claim
301	axillary	_	_	I-Claim
302	clearance	_	_	I-Claim
303	for	_	_	I-Claim
304	women	_	_	I-Claim
305	>	_	_	I-Claim
306	or	_	_	I-Claim
307	=	_	_	I-Claim
308	60	_	_	I-Claim
309	years	_	_	I-Claim
310	old	_	_	I-Claim
311	who	_	_	I-Claim
312	have	_	_	I-Claim
313	clinically	_	_	I-Claim
314	node-negative	_	_	I-Claim
315	disease	_	_	I-Claim
316	and	_	_	I-Claim
317	receive	_	_	I-Claim
318	Tam	_	_	I-Claim
319	for	_	_	I-Claim
320	endocrine-responsive	_	_	I-Claim
321	disease	_	_	I-Claim
322	yields	_	_	I-Claim
323	similar	_	_	I-Claim
324	efficacy	_	_	I-Claim
325	with	_	_	I-Claim
326	better	_	_	I-Claim
327	early	_	_	I-Claim
328	QL	_	_	I-Claim
329	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	moderately	_	_	I-Claim
3	efficient	_	_	I-Claim
4	as	_	_	I-Claim
5	a	_	_	I-Claim
6	treatment	_	_	I-Claim
7	for	_	_	I-Claim
8	pancreatic	_	_	I-Claim
9	adenocarcinoma	_	_	I-Claim
10	,	_	_	I-Claim
11	but	_	_	B-Claim
12	patient	_	_	I-Claim
13	survival	_	_	I-Claim
14	and	_	_	I-Claim
15	quality	_	_	I-Claim
16	of	_	_	I-Claim
17	life	_	_	I-Claim
18	has	_	_	I-Claim
19	improved	_	_	I-Claim
20	with	_	_	I-Claim
21	this	_	_	I-Claim
22	modality	_	_	I-Claim
23	in	_	_	I-Claim
24	some	_	_	I-Claim
25	trials	_	_	I-Claim
26	.	_	_	I-Claim

27	In	_	_	O
28	a	_	_	O
29	previous	_	_	O
30	phase	_	_	O
31	II	_	_	O
32	trial	_	_	O
33	,	_	_	O
34	5-fluorouracil	_	_	O
35	(	_	_	O
36	5-FU	_	_	O
37	)	_	_	O
38	plus	_	_	O
39	cisplatin	_	_	O
40	(	_	_	O
41	FUP	_	_	O
42	)	_	_	O
43	yielded	_	_	O
44	a	_	_	O
45	26.5	_	_	O
46	%	_	_	O
47	response	_	_	O
48	rate	_	_	O
49	and	_	_	O
50	a	_	_	O
51	29	_	_	O
52	%	_	_	O
53	survival	_	_	O
54	rate	_	_	O
55	at	_	_	O
56	1	_	_	O
57	year	_	_	O
58	.	_	_	O

59	The	_	_	O
60	present	_	_	O
61	study	_	_	O
62	aimed	_	_	O
63	to	_	_	O
64	compare	_	_	O
65	FUP	_	_	O
66	with	_	_	O
67	5-FU	_	_	O
68	alone	_	_	O
69	,	_	_	O
70	which	_	_	O
71	was	_	_	O
72	the	_	_	O
73	control	_	_	O
74	arm	_	_	O
75	in	_	_	O
76	former	_	_	O
77	Mayo	_	_	O
78	Clinic	_	_	O
79	trials	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	untreated	_	_	O
84	cytologically	_	_	O
85	or	_	_	O
86	histologically	_	_	O
87	proven	_	_	O
88	metastatic	_	_	O
89	or	_	_	O
90	locally	_	_	O
91	advanced	_	_	O
92	adenocarcinoma	_	_	O
93	of	_	_	O
94	the	_	_	O
95	pancreas	_	_	O
96	were	_	_	O
97	deemed	_	_	O
98	measurable	_	_	O
99	or	_	_	O
100	evaluable	_	_	O
101	.	_	_	O

102	Chemotherapy	_	_	O
103	regimens	_	_	O
104	consisted	_	_	O
105	of	_	_	O
106	a	_	_	O
107	control	_	_	O
108	FU	_	_	O
109	arm	_	_	O
110	(	_	_	O
111	5-FU	_	_	O
112	500	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	/day	_	_	O
118	for	_	_	O
119	5	_	_	O
120	days	_	_	O
121	)	_	_	O
122	and	_	_	O
123	the	_	_	O
124	investigational	_	_	O
125	FUP	_	_	O
126	arm	_	_	O
127	(	_	_	O
128	continuous	_	_	O
129	5-FU	_	_	O
130	1000	_	_	O
131	mg/m	_	_	O
132	(	_	_	O
133	2	_	_	O
134	)	_	_	O
135	/day	_	_	O
136	for	_	_	O
137	5	_	_	O
138	days	_	_	O
139	plus	_	_	O
140	cisplatin	_	_	O
141	100	_	_	O
142	mg/m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	on	_	_	O
147	day	_	_	O
148	1	_	_	O
149	or	_	_	O
150	day	_	_	O
151	2	_	_	O
152	)	_	_	O
153	.	_	_	O

154	In	_	_	O
155	both	_	_	O
156	arms	_	_	O
157	,	_	_	O
158	chemotherapy	_	_	O
159	was	_	_	O
160	repeated	_	_	O
161	at	_	_	O
162	day	_	_	O
163	29	_	_	O
164	.	_	_	O

165	Two-hundred	_	_	O
166	and	_	_	O
167	seven	_	_	O
168	patients	_	_	O
169	from	_	_	O
170	18	_	_	O
171	centres	_	_	O
172	were	_	_	O
173	randomised	_	_	O
174	:	_	_	O
175	103	_	_	O
176	in	_	_	O
177	the	_	_	O
178	FU	_	_	O
179	arm	_	_	O
180	and	_	_	O
181	104	_	_	O
182	in	_	_	O
183	FUP	_	_	O
184	arm	_	_	O
185	.	_	_	O

186	Treatment	_	_	O
187	arms	_	_	O
188	were	_	_	O
189	balanced	_	_	O
190	with	_	_	O
191	respect	_	_	O
192	to	_	_	O
193	performance	_	_	O
194	status	_	_	O
195	grade	_	_	O
196	0-1	_	_	O
197	(	_	_	O
198	83	_	_	O
199	%	_	_	O
200	versus	_	_	O
201	86	_	_	O
202	%	_	_	O
203	,	_	_	O
204	respectively	_	_	O
205	)	_	_	O
206	and	_	_	O
207	the	_	_	O
208	presence	_	_	O
209	of	_	_	O
210	metastases	_	_	O
211	(	_	_	O
212	92	_	_	O
213	%	_	_	O
214	versus	_	_	O
215	89	_	_	O
216	%	_	_	O
217	,	_	_	O
218	respectively	_	_	O
219	)	_	_	O
220	.	_	_	O

221	The	_	_	O
222	median	_	_	O
223	number	_	_	O
224	of	_	_	O
225	cycles	_	_	O
226	administered	_	_	O
227	was	_	_	O
228	two	_	_	O
229	in	_	_	O
230	both	_	_	O
231	arms	_	_	O
232	(	_	_	O
233	range	_	_	O
234	0-14	_	_	O
235	)	_	_	O
236	.	_	_	O

237	Five	_	_	O
238	patients	_	_	O
239	did	_	_	O
240	not	_	_	O
241	receive	_	_	O
242	any	_	_	O
243	chemotherapy	_	_	O
244	and	_	_	O
245	45	_	_	O
246	received	_	_	O
247	only	_	_	O
248	one	_	_	O
249	cycle	_	_	O
250	.	_	_	O

251	Toxicity	_	_	B-Premise
252	(	_	_	I-Premise
253	WHO	_	_	I-Premise
254	grade	_	_	I-Premise
255	3-4	_	_	I-Premise
256	)	_	_	I-Premise
257	was	_	_	I-Premise
258	lower	_	_	I-Premise
259	with	_	_	I-Premise
260	FU	_	_	I-Premise
261	than	_	_	I-Premise
262	with	_	_	I-Premise
263	FUP	_	_	I-Premise
264	(	_	_	I-Premise
265	20	_	_	I-Premise
266	%	_	_	I-Premise
267	versus	_	_	I-Premise
268	48	_	_	I-Premise
269	%	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	0.001	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	as	_	_	I-Premise
277	was	_	_	I-Premise
278	neutropenia	_	_	I-Premise
279	(	_	_	I-Premise
280	6	_	_	I-Premise
281	%	_	_	I-Premise
282	versus	_	_	I-Premise
283	23	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	vomiting	_	_	I-Premise
288	(	_	_	I-Premise
289	4	_	_	I-Premise
290	%	_	_	I-Premise
291	versus	_	_	I-Premise
292	17	_	_	I-Premise
293	%	_	_	I-Premise
294	)	_	_	I-Premise
295	and	_	_	I-Premise
296	toxicity-related	_	_	I-Premise
297	deaths	_	_	I-Premise
298	(	_	_	I-Premise
299	one	_	_	I-Premise
300	versus	_	_	I-Premise
301	four	_	_	I-Premise
302	early	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	trial	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Premise
309	response	_	_	I-Premise
310	rate	_	_	I-Premise
311	was	_	_	I-Premise
312	low	_	_	I-Premise
313	in	_	_	I-Premise
314	both	_	_	I-Premise
315	arms	_	_	I-Premise
316	,	_	_	I-Premise
317	but	_	_	I-Premise
318	superior	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	FUP	_	_	I-Premise
322	arm	_	_	I-Premise
323	:	_	_	I-Premise
324	12	_	_	I-Premise
325	%	_	_	I-Premise
326	versus	_	_	I-Premise
327	0	_	_	I-Premise
328	%	_	_	I-Premise
329	(	_	_	I-Premise
330	intention-to-treat	_	_	I-Premise
331	analysis	_	_	I-Premise
332	,	_	_	I-Premise
333	P	_	_	I-Premise
334	<	_	_	I-Premise
335	0.01	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	The	_	_	B-Premise
339	survival	_	_	I-Premise
340	rates	_	_	I-Premise
341	at	_	_	I-Premise
342	6	_	_	I-Premise
343	months	_	_	I-Premise
344	were	_	_	I-Premise
345	28	_	_	I-Premise
346	%	_	_	I-Premise
347	and	_	_	I-Premise
348	38	_	_	I-Premise
349	%	_	_	I-Premise
350	for	_	_	I-Premise
351	the	_	_	I-Premise
352	FU	_	_	I-Premise
353	and	_	_	I-Premise
354	FUP	_	_	I-Premise
355	arms	_	_	I-Premise
356	,	_	_	I-Premise
357	respectively	_	_	I-Premise
358	,	_	_	I-Premise
359	and	_	_	I-Premise
360	1-year	_	_	I-Premise
361	survival	_	_	I-Premise
362	rates	_	_	I-Premise
363	were	_	_	I-Premise
364	9	_	_	I-Premise
365	%	_	_	I-Premise
366	and	_	_	I-Premise
367	17	_	_	I-Premise
368	%	_	_	I-Premise
369	(	_	_	I-Premise
370	log-rank	_	_	I-Premise
371	test	_	_	I-Premise
372	,	_	_	I-Premise
373	P	_	_	I-Premise
374	=	_	_	I-Premise
375	0.10	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	One-year	_	_	B-Premise
379	progression-free	_	_	I-Premise
380	survival	_	_	I-Premise
381	was	_	_	I-Premise
382	0	_	_	I-Premise
383	%	_	_	I-Premise
384	with	_	_	I-Premise
385	FU	_	_	I-Premise
386	versus	_	_	I-Premise
387	10	_	_	I-Premise
388	%	_	_	I-Premise
389	with	_	_	I-Premise
390	FUP	_	_	I-Premise
391	(	_	_	I-Premise
392	log-rank	_	_	I-Premise
393	test	_	_	I-Premise
394	,	_	_	I-Premise
395	P	_	_	I-Premise
396	=	_	_	I-Premise
397	0.0001	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	In	_	_	B-Claim
401	advanced	_	_	I-Claim
402	pancreatic	_	_	I-Claim
403	carcinomas	_	_	I-Claim
404	with	_	_	I-Claim
405	a	_	_	I-Claim
406	poor	_	_	I-Claim
407	prognosis	_	_	I-Claim
408	,	_	_	I-Claim
409	FUP	_	_	I-Claim
410	was	_	_	I-Claim
411	superior	_	_	I-Claim
412	to	_	_	I-Claim
413	FU	_	_	I-Claim
414	in	_	_	I-Claim
415	terms	_	_	I-Claim
416	of	_	_	I-Claim
417	response	_	_	I-Claim
418	and	_	_	I-Claim
419	progression-free	_	_	I-Claim
420	survival	_	_	I-Claim
421	,	_	_	I-Claim
422	but	_	_	I-Claim
423	not	_	_	I-Claim
424	in	_	_	I-Claim
425	terms	_	_	I-Claim
426	of	_	_	I-Claim
427	overall	_	_	I-Claim
428	survival	_	_	I-Claim
429	.	_	_	I-Claim

430	The	_	_	O
431	low	_	_	O
432	response	_	_	O
433	rate	_	_	O
434	is	_	_	O
435	partly	_	_	O
436	related	_	_	O
437	to	_	_	O
438	the	_	_	O
439	number	_	_	O
440	of	_	_	O
441	patients	_	_	O
442	who	_	_	O
443	received	_	_	O
444	only	_	_	O
445	one	_	_	O
446	cycle	_	_	O
447	of	_	_	O
448	chemotherapy	_	_	O
449	.	_	_	O

450	A	_	_	B-Claim
451	more	_	_	I-Claim
452	effective	_	_	I-Claim
453	,	_	_	I-Claim
454	better	_	_	I-Claim
455	tolerated	_	_	I-Claim
456	version	_	_	I-Claim
457	of	_	_	I-Claim
458	this	_	_	I-Claim
459	FUP	_	_	I-Claim
460	combination	_	_	I-Claim
461	is	_	_	I-Claim
462	needed	_	_	I-Claim
463	.	_	_	I-Claim


0	After	_	_	O
1	surgery	_	_	O
2	for	_	_	O
3	differentiated	_	_	O
4	thyroid	_	_	O
5	carcinoma	_	_	O
6	,	_	_	O
7	many	_	_	O
8	patients	_	_	O
9	are	_	_	O
10	treated	_	_	O
11	with	_	_	O
12	radioiodine	_	_	O
13	to	_	_	O
14	ablate	_	_	O
15	remnant	_	_	O
16	thyroid	_	_	O
17	tissue	_	_	O
18	.	_	_	O

19	This	_	_	B-Claim
20	procedure	_	_	I-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	performed	_	_	I-Claim
24	with	_	_	I-Claim
25	the	_	_	I-Claim
26	patient	_	_	I-Claim
27	in	_	_	I-Claim
28	the	_	_	I-Claim
29	hypothyroid	_	_	I-Claim
30	state	_	_	I-Claim
31	to	_	_	I-Claim
32	promote	_	_	I-Claim
33	endogenous	_	_	I-Claim
34	TSH	_	_	I-Claim
35	stimulation	_	_	I-Claim
36	and	_	_	I-Claim
37	is	_	_	I-Claim
38	often	_	_	I-Claim
39	associated	_	_	I-Claim
40	with	_	_	I-Claim
41	hypothyroid	_	_	I-Claim
42	symptoms	_	_	I-Claim
43	and	_	_	I-Claim
44	impaired	_	_	I-Claim
45	quality	_	_	I-Claim
46	of	_	_	I-Claim
47	life	_	_	I-Claim
48	.	_	_	I-Claim

49	This	_	_	O
50	international	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	controlled	_	_	O
55	,	_	_	O
56	multicenter	_	_	O
57	trial	_	_	O
58	aimed	_	_	O
59	to	_	_	O
60	compare	_	_	O
61	the	_	_	O
62	efficacy	_	_	O
63	and	_	_	O
64	safety	_	_	O
65	of	_	_	O
66	recombinant	_	_	O
67	human	_	_	O
68	TSH	_	_	O
69	(	_	_	O
70	rhTSH	_	_	O
71	)	_	_	O
72	to	_	_	O
73	prepare	_	_	O
74	euthyroid	_	_	O
75	patients	_	_	O
76	on	_	_	O
77	L-thyroxine	_	_	O
78	therapy	_	_	O
79	(	_	_	O
80	euthyroid	_	_	O
81	group	_	_	O
82	)	_	_	O
83	to	_	_	O
84	ablate	_	_	O
85	remnant	_	_	O
86	thyroid	_	_	O
87	tissue	_	_	O
88	with	_	_	O
89	3.7	_	_	O
90	GBq	_	_	O
91	(	_	_	O
92	100	_	_	O
93	mCi	_	_	O
94	)	_	_	O
95	131I	_	_	O
96	,	_	_	O
97	compared	_	_	O
98	with	_	_	O
99	that	_	_	O
100	with	_	_	O
101	conventional	_	_	O
102	remnant	_	_	O
103	ablation	_	_	O
104	performed	_	_	O
105	in	_	_	O
106	the	_	_	O
107	hypothyroid	_	_	O
108	state	_	_	O
109	(	_	_	O
110	hypothyroid	_	_	O
111	group	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Quality	_	_	O
115	of	_	_	O
116	life	_	_	O
117	was	_	_	O
118	determined	_	_	O
119	at	_	_	O
120	the	_	_	O
121	time	_	_	O
122	of	_	_	O
123	randomization	_	_	O
124	and	_	_	O
125	ablation	_	_	O
126	.	_	_	O

127	After	_	_	O
128	the	_	_	O
129	administration	_	_	O
130	of	_	_	O
131	the	_	_	O
132	131-I	_	_	O
133	dose	_	_	O
134	,	_	_	O
135	the	_	_	O
136	rate	_	_	O
137	of	_	_	O
138	radiation	_	_	O
139	clearance	_	_	O
140	from	_	_	O
141	blood	_	_	O
142	,	_	_	O
143	thyroid	_	_	O
144	remnant	_	_	O
145	,	_	_	O
146	and	_	_	O
147	whole	_	_	O
148	body	_	_	O
149	was	_	_	O
150	measured	_	_	O
151	.	_	_	O

152	The	_	_	O
153	predefined	_	_	O
154	primary	_	_	O
155	criterion	_	_	O
156	for	_	_	O
157	successful	_	_	O
158	ablation	_	_	O
159	was	_	_	O
160	"	_	_	O
161	no	_	_	O
162	visible	_	_	O
163	uptake	_	_	O
164	in	_	_	O
165	the	_	_	O
166	thyroid	_	_	O
167	bed	_	_	O
168	,	_	_	O
169	or	_	_	O
170	if	_	_	O
171	visible	_	_	O
172	,	_	_	O
173	fractional	_	_	O
174	uptake	_	_	O
175	less	_	_	O
176	than	_	_	O
177	0.1	_	_	O
178	%	_	_	O
179	"	_	_	O
180	on	_	_	O
181	neck	_	_	O
182	scans	_	_	O
183	performed	_	_	O
184	8	_	_	O
185	months	_	_	O
186	after	_	_	O
187	therapy	_	_	O
188	and	_	_	O
189	was	_	_	O
190	satisfied	_	_	O
191	in	_	_	O
192	100	_	_	O
193	%	_	_	O
194	of	_	_	O
195	patients	_	_	O
196	in	_	_	O
197	both	_	_	O
198	groups	_	_	O
199	.	_	_	O

200	A	_	_	O
201	secondary	_	_	O
202	criterion	_	_	O
203	for	_	_	O
204	ablation	_	_	O
205	,	_	_	O
206	an	_	_	O
207	rhTSH-stimulated	_	_	O
208	serum	_	_	O
209	thyroglobulin	_	_	O
210	concentration	_	_	O
211	less	_	_	O
212	than	_	_	O
213	2	_	_	O
214	ng/ml	_	_	O
215	,	_	_	O
216	was	_	_	O
217	fulfilled	_	_	O
218	by	_	_	O
219	23	_	_	O
220	of	_	_	O
221	24	_	_	O
222	(	_	_	O
223	96	_	_	O
224	%	_	_	O
225	)	_	_	O
226	euthyroid	_	_	O
227	patients	_	_	O
228	and	_	_	O
229	18	_	_	O
230	of	_	_	O
231	21	_	_	O
232	(	_	_	O
233	86	_	_	O
234	%	_	_	O
235	)	_	_	O
236	hypothyroid	_	_	O
237	patients	_	_	O
238	(	_	_	O
239	P	_	_	O
240	=	_	_	O
241	0.2341	_	_	O
242	)	_	_	O
243	.	_	_	O

244	Quality	_	_	B-Premise
245	of	_	_	I-Premise
246	life	_	_	I-Premise
247	was	_	_	I-Premise
248	well	_	_	I-Premise
249	preserved	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	euthyroid	_	_	I-Premise
253	group	_	_	I-Premise
254	,	_	_	I-Premise
255	compared	_	_	I-Premise
256	with	_	_	I-Premise
257	the	_	_	I-Premise
258	hypothyroid	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	as	_	_	I-Premise
262	demonstrated	_	_	I-Premise
263	by	_	_	I-Premise
264	their	_	_	I-Premise
265	lower	_	_	I-Premise
266	pretreatment	_	_	I-Premise
267	scores	_	_	I-Premise
268	on	_	_	I-Premise
269	the	_	_	I-Premise
270	Billewicz	_	_	I-Premise
271	scale	_	_	I-Premise
272	for	_	_	I-Premise
273	hypothyroid	_	_	I-Premise
274	signs	_	_	I-Premise
275	and	_	_	I-Premise
276	symptoms	_	_	I-Premise
277	,	_	_	I-Premise
278	27	_	_	I-Premise
279	+/-	_	_	I-Premise
280	7	_	_	I-Premise
281	vs.	_	_	I-Premise
282	18	_	_	I-Premise
283	+/-	_	_	I-Premise
284	4	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	0.0001	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	their	_	_	I-Premise
292	significantly	_	_	I-Premise
293	higher	_	_	I-Premise
294	Short	_	_	I-Premise
295	Form-36	_	_	I-Premise
296	Health	_	_	I-Premise
297	Assessment	_	_	I-Premise
298	Scale	_	_	I-Premise
299	scores	_	_	I-Premise
300	in	_	_	I-Premise
301	five	_	_	I-Premise
302	of	_	_	I-Premise
303	eight	_	_	I-Premise
304	categories	_	_	I-Premise
305	.	_	_	I-Premise

306	Euthyroid	_	_	B-Premise
307	patients	_	_	I-Premise
308	had	_	_	I-Premise
309	a	_	_	I-Premise
310	statistically	_	_	I-Premise
311	significant	_	_	I-Premise
312	one	_	_	I-Premise
313	third	_	_	I-Premise
314	lower	_	_	I-Premise
315	radiation	_	_	I-Premise
316	dose	_	_	I-Premise
317	to	_	_	I-Premise
318	the	_	_	I-Premise
319	blood	_	_	I-Premise
320	,	_	_	I-Premise
321	compared	_	_	I-Premise
322	with	_	_	I-Premise
323	patients	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	hypothyroid	_	_	I-Premise
327	group	_	_	I-Premise
328	.	_	_	I-Premise

329	This	_	_	B-Claim
330	study	_	_	I-Claim
331	demonstrates	_	_	I-Claim
332	comparable	_	_	I-Claim
333	remnant	_	_	I-Claim
334	ablation	_	_	I-Claim
335	rates	_	_	I-Claim
336	in	_	_	I-Claim
337	patients	_	_	I-Claim
338	prepared	_	_	I-Claim
339	for	_	_	I-Claim
340	131I	_	_	I-Claim
341	remnant	_	_	I-Claim
342	ablation	_	_	I-Claim
343	with	_	_	I-Claim
344	3.7	_	_	I-Claim
345	GBq	_	_	I-Claim
346	by	_	_	I-Claim
347	either	_	_	I-Claim
348	administering	_	_	I-Claim
349	rhTSH	_	_	I-Claim
350	or	_	_	I-Claim
351	withholding	_	_	I-Claim
352	thyroid	_	_	I-Claim
353	hormone	_	_	I-Claim
354	.	_	_	I-Claim

355	rhTSH-prepared	_	_	B-Claim
356	patients	_	_	I-Claim
357	maintained	_	_	I-Claim
358	a	_	_	I-Claim
359	higher	_	_	I-Claim
360	quality	_	_	I-Claim
361	of	_	_	I-Claim
362	life	_	_	I-Claim
363	and	_	_	I-Claim
364	received	_	_	I-Claim
365	less	_	_	I-Claim
366	radiation	_	_	I-Claim
367	exposure	_	_	I-Claim
368	to	_	_	I-Claim
369	the	_	_	I-Claim
370	blood	_	_	I-Claim
371	.	_	_	I-Claim


0	As	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	pancreas	_	_	O
4	and	_	_	O
5	periampullary	_	_	O
6	cancer	_	_	O
7	(	_	_	O
8	PPC	_	_	O
9	)	_	_	O
10	experience	_	_	O
11	improved	_	_	O
12	survival	_	_	O
13	rates	_	_	O
14	and	_	_	O
15	longevity	_	_	O
16	,	_	_	O
17	the	_	_	O
18	focus	_	_	O
19	shifts	_	_	O
20	toward	_	_	O
21	living	_	_	O
22	life	_	_	O
23	while	_	_	O
24	surviving	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Fatigue	_	_	O
28	is	_	_	O
29	the	_	_	O
30	most	_	_	O
31	commonly	_	_	O
32	reported	_	_	O
33	symptom	_	_	O
34	in	_	_	O
35	all	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	.	_	_	O

39	Exercise	_	_	O
40	has	_	_	O
41	been	_	_	O
42	found	_	_	O
43	to	_	_	O
44	effectively	_	_	O
45	decrease	_	_	O
46	fatigue	_	_	O
47	levels	_	_	O
48	and	_	_	O
49	improve	_	_	O
50	physical	_	_	O
51	functioning	_	_	O
52	in	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	One	_	_	O
57	hundred	_	_	O
58	two	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	resected	_	_	O
62	PPC	_	_	O
63	consented	_	_	O
64	to	_	_	O
65	participate	_	_	O
66	in	_	_	O
67	this	_	_	O
68	study	_	_	O
69	and	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	either	_	_	O
74	an	_	_	O
75	intervention	_	_	O
76	group	_	_	O
77	(	_	_	O
78	IG	_	_	O
79	)	_	_	O
80	or	_	_	O
81	a	_	_	O
82	usual	_	_	O
83	care	_	_	O
84	group	_	_	O
85	(	_	_	O
86	UCG	_	_	O
87	)	_	_	O
88	.	_	_	O

89	Subjects	_	_	O
90	completed	_	_	O
91	visual	_	_	O
92	analog	_	_	O
93	scales	_	_	O
94	,	_	_	O
95	the	_	_	O
96	FACIT-Fatigue	_	_	O
97	Scale	_	_	O
98	and	_	_	O
99	the	_	_	O
100	Short	_	_	O
101	Form-36v2	_	_	O
102	after	_	_	O
103	surgery	_	_	O
104	and	_	_	O
105	again	_	_	O
106	3	_	_	O
107	to	_	_	O
108	6	_	_	O
109	months	_	_	O
110	after	_	_	O
111	hospital	_	_	O
112	discharge	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	in	_	_	O
116	the	_	_	O
117	IG	_	_	O
118	and	_	_	O
119	UCG	_	_	O
120	were	_	_	O
121	comparable	_	_	O
122	with	_	_	O
123	regard	_	_	O
124	to	_	_	O
125	demographics	_	_	O
126	,	_	_	O
127	comorbidities	_	_	O
128	,	_	_	O
129	cancer	_	_	O
130	type	_	_	O
131	and	_	_	O
132	staging	_	_	O
133	,	_	_	O
134	type	_	_	O
135	of	_	_	O
136	resection	_	_	O
137	,	_	_	O
138	preoperative	_	_	O
139	fatigue	_	_	O
140	and	_	_	O
141	pain	_	_	O
142	levels	_	_	O
143	,	_	_	O
144	adjuvant	_	_	O
145	therapy	_	_	O
146	,	_	_	O
147	and	_	_	O
148	baseline	_	_	O
149	walking	_	_	O
150	distance	_	_	O
151	.	_	_	O

152	Patients	_	_	B-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	IG	_	_	I-Premise
156	had	_	_	I-Premise
157	significantly	_	_	I-Premise
158	improved	_	_	I-Premise
159	scores	_	_	I-Premise
160	on	_	_	I-Premise
161	the	_	_	I-Premise
162	FACIT-Fatigue	_	_	I-Premise
163	Scale	_	_	I-Premise
164	at	_	_	I-Premise
165	study	_	_	I-Premise
166	completion	_	_	I-Premise
167	,	_	_	I-Premise
168	improved	_	_	I-Premise
169	fatigue	_	_	I-Premise
170	and	_	_	I-Premise
171	pain	_	_	I-Premise
172	scores	_	_	I-Premise
173	,	_	_	I-Premise
174	as	_	_	I-Premise
175	well	_	_	I-Premise
176	as	_	_	I-Premise
177	overall	_	_	I-Premise
178	physical	_	_	I-Premise
179	functioning	_	_	I-Premise
180	and	_	_	I-Premise
181	mental	_	_	I-Premise
182	health	_	_	I-Premise
183	composite	_	_	I-Premise
184	scores	_	_	I-Premise
185	.	_	_	I-Premise

186	At	_	_	B-Premise
187	study	_	_	I-Premise
188	completion	_	_	I-Premise
189	,	_	_	I-Premise
190	participants	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	IG	_	_	I-Premise
194	were	_	_	I-Premise
195	walking	_	_	I-Premise
196	twice	_	_	I-Premise
197	as	_	_	I-Premise
198	far	_	_	I-Premise
199	and	_	_	I-Premise
200	were	_	_	I-Premise
201	significantly	_	_	I-Premise
202	more	_	_	I-Premise
203	likely	_	_	I-Premise
204	to	_	_	I-Premise
205	have	_	_	I-Premise
206	continued	_	_	I-Premise
207	walking	_	_	I-Premise
208	or	_	_	I-Premise
209	another	_	_	I-Premise
210	form	_	_	I-Premise
211	of	_	_	I-Premise
212	exercise	_	_	I-Premise
213	as	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	the	_	_	I-Premise
217	UCG	_	_	I-Premise
218	.	_	_	I-Premise

219	Using	_	_	O
220	hierarchical	_	_	O
221	cluster	_	_	O
222	analysis	_	_	O
223	,	_	_	O
224	3	_	_	O
225	mutually	_	_	O
226	exclusive	_	_	O
227	symptom	_	_	O
228	groupings	_	_	O
229	were	_	_	O
230	identified	_	_	O
231	in	_	_	O
232	the	_	_	O
233	cohort	_	_	O
234	.	_	_	O

235	Kaplan-Meier	_	_	B-Premise
236	survival	_	_	I-Premise
237	analysis	_	_	I-Premise
238	did	_	_	I-Premise
239	not	_	_	I-Premise
240	indicate	_	_	I-Premise
241	an	_	_	I-Premise
242	overall	_	_	I-Premise
243	survival	_	_	I-Premise
244	benefit	_	_	I-Premise
245	for	_	_	I-Premise
246	the	_	_	I-Premise
247	IG	_	_	I-Premise
248	.	_	_	I-Premise

249	This	_	_	B-Claim
250	is	_	_	I-Claim
251	the	_	_	I-Claim
252	first	_	_	I-Claim
253	prospective	_	_	I-Claim
254	,	_	_	I-Claim
255	randomized	_	_	I-Claim
256	controlled	_	_	I-Claim
257	trial	_	_	I-Claim
258	to	_	_	I-Claim
259	report	_	_	I-Claim
260	that	_	_	I-Claim
261	participation	_	_	I-Claim
262	in	_	_	I-Claim
263	a	_	_	I-Claim
264	home	_	_	I-Claim
265	walking	_	_	I-Claim
266	program	_	_	I-Claim
267	confers	_	_	I-Claim
268	a	_	_	I-Claim
269	significant	_	_	I-Claim
270	benefit	_	_	I-Claim
271	in	_	_	I-Claim
272	resected	_	_	I-Claim
273	PPC	_	_	I-Claim
274	patients	_	_	I-Claim
275	with	_	_	I-Claim
276	regard	_	_	I-Claim
277	to	_	_	I-Claim
278	fatigue	_	_	I-Claim
279	levels	_	_	I-Claim
280	,	_	_	I-Claim
281	physical	_	_	I-Claim
282	functioning	_	_	I-Claim
283	,	_	_	I-Claim
284	and	_	_	I-Claim
285	health-related	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim


0	Treatment	_	_	B-Claim
1	with	_	_	I-Claim
2	cisplatin-based	_	_	I-Claim
3	chemotherapy	_	_	I-Claim
4	provides	_	_	I-Claim
5	a	_	_	I-Claim
6	modest	_	_	I-Claim
7	survival	_	_	I-Claim
8	advantage	_	_	I-Claim
9	over	_	_	I-Claim
10	supportive	_	_	I-Claim
11	care	_	_	I-Claim
12	alone	_	_	I-Claim
13	in	_	_	I-Claim
14	advanced	_	_	I-Claim
15	non-small-cell	_	_	I-Claim
16	lung	_	_	I-Claim
17	cancer	_	_	I-Claim
18	(	_	_	I-Claim
19	NSCLC	_	_	I-Claim
20	)	_	_	I-Claim
21	.	_	_	I-Claim

22	To	_	_	O
23	determine	_	_	O
24	whether	_	_	O
25	a	_	_	O
26	new	_	_	O
27	agent	_	_	O
28	,	_	_	O
29	paclitaxel	_	_	O
30	,	_	_	O
31	would	_	_	O
32	further	_	_	O
33	improve	_	_	O
34	survival	_	_	O
35	in	_	_	O
36	NSCLC	_	_	O
37	,	_	_	O
38	the	_	_	O
39	Eastern	_	_	O
40	Cooperative	_	_	O
41	Oncology	_	_	O
42	Group	_	_	O
43	conducted	_	_	O
44	a	_	_	O
45	randomized	_	_	O
46	trial	_	_	O
47	comparing	_	_	O
48	paclitaxel	_	_	O
49	plus	_	_	O
50	cisplatin	_	_	O
51	to	_	_	O
52	a	_	_	O
53	standard	_	_	O
54	chemotherapy	_	_	O
55	regimen	_	_	O
56	consisting	_	_	O
57	of	_	_	O
58	cisplatin	_	_	O
59	and	_	_	O
60	etoposide	_	_	O
61	.	_	_	O

62	The	_	_	O
63	study	_	_	O
64	was	_	_	O
65	carried	_	_	O
66	out	_	_	O
67	by	_	_	O
68	a	_	_	O
69	multi-institutional	_	_	O
70	cooperative	_	_	O
71	group	_	_	O
72	in	_	_	O
73	chemotherapy-naive	_	_	O
74	stage	_	_	O
75	IIIB	_	_	O
76	to	_	_	O
77	IV	_	_	O
78	NSCLC	_	_	O
79	patients	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	paclitaxel	_	_	O
84	plus	_	_	O
85	cisplatin	_	_	O
86	or	_	_	O
87	etoposide	_	_	O
88	plus	_	_	O
89	cisplatin	_	_	O
90	.	_	_	O

91	Paclitaxel	_	_	O
92	was	_	_	O
93	administered	_	_	O
94	at	_	_	O
95	two	_	_	O
96	different	_	_	O
97	dose	_	_	O
98	levels	_	_	O
99	(	_	_	O
100	135	_	_	O
101	mg/m	_	_	O
102	(	_	_	O
103	2	_	_	O
104	)	_	_	O
105	and	_	_	O
106	250	_	_	O
107	mg/m	_	_	O
108	(	_	_	O
109	2	_	_	O
110	)	_	_	O
111	)	_	_	O
112	,	_	_	O
113	and	_	_	O
114	etoposide	_	_	O
115	was	_	_	O
116	given	_	_	O
117	at	_	_	O
118	a	_	_	O
119	dose	_	_	O
120	of	_	_	O
121	100	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	daily	_	_	O
127	on	_	_	O
128	days	_	_	O
129	1	_	_	O
130	to	_	_	O
131	3	_	_	O
132	.	_	_	O

133	Each	_	_	O
134	regimen	_	_	O
135	was	_	_	O
136	repeated	_	_	O
137	every	_	_	O
138	21	_	_	O
139	days	_	_	O
140	and	_	_	O
141	each	_	_	O
142	included	_	_	O
143	cisplatin	_	_	O
144	(	_	_	O
145	75	_	_	O
146	mg/m	_	_	O
147	(	_	_	O
148	2	_	_	O
149	)	_	_	O
150	)	_	_	O
151	.	_	_	O

152	The	_	_	O
153	characteristics	_	_	O
154	of	_	_	O
155	the	_	_	O
156	599	_	_	O
157	patients	_	_	O
158	were	_	_	O
159	well-balanced	_	_	O
160	across	_	_	O
161	the	_	_	O
162	three	_	_	O
163	treatment	_	_	O
164	groups	_	_	O
165	.	_	_	O

166	Superior	_	_	B-Premise
167	survival	_	_	I-Premise
168	was	_	_	I-Premise
169	observed	_	_	I-Premise
170	with	_	_	I-Premise
171	the	_	_	I-Premise
172	combined	_	_	I-Premise
173	paclitaxel	_	_	I-Premise
174	regimens	_	_	I-Premise
175	(	_	_	I-Premise
176	median	_	_	I-Premise
177	survival	_	_	I-Premise
178	time	_	_	I-Premise
179	,	_	_	I-Premise
180	9.9	_	_	I-Premise
181	months	_	_	I-Premise
182	;	_	_	I-Premise
183	1-year	_	_	I-Premise
184	survival	_	_	I-Premise
185	rate	_	_	I-Premise
186	,	_	_	I-Premise
187	38.9	_	_	I-Premise
188	%	_	_	I-Premise
189	)	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	etoposide	_	_	I-Premise
193	plus	_	_	I-Premise
194	cisplatin	_	_	I-Premise
195	(	_	_	I-Premise
196	median	_	_	I-Premise
197	survival	_	_	I-Premise
198	time	_	_	I-Premise
199	,	_	_	I-Premise
200	7.6	_	_	I-Premise
201	months	_	_	I-Premise
202	;	_	_	I-Premise
203	1-year	_	_	I-Premise
204	survival	_	_	I-Premise
205	rate	_	_	I-Premise
206	,	_	_	I-Premise
207	31.8	_	_	I-Premise
208	%	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.	_	_	I-Premise

213	048	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	Comparing	_	_	B-Premise
217	survival	_	_	I-Premise
218	for	_	_	I-Premise
219	the	_	_	I-Premise
220	two	_	_	I-Premise
221	dose	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	paclitaxel	_	_	I-Premise
225	revealed	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Premise
231	median	_	_	I-Premise
232	survival	_	_	I-Premise
233	duration	_	_	I-Premise
234	for	_	_	I-Premise
235	the	_	_	I-Premise
236	stage	_	_	I-Premise
237	IIIB	_	_	I-Premise
238	subgroup	_	_	I-Premise
239	was	_	_	I-Premise
240	7.9	_	_	I-Premise
241	months	_	_	I-Premise
242	for	_	_	I-Premise
243	etoposide	_	_	I-Premise
244	plus	_	_	I-Premise
245	cisplatin	_	_	I-Premise
246	patients	_	_	I-Premise
247	versus	_	_	I-Premise
248	13.1	_	_	I-Premise
249	months	_	_	I-Premise
250	for	_	_	I-Premise
251	all	_	_	I-Premise
252	paclitaxel	_	_	I-Premise
253	patients	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=.152	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	For	_	_	B-Premise
260	the	_	_	I-Premise
261	stage	_	_	I-Premise
262	IV	_	_	I-Premise
263	subgroup	_	_	I-Premise
264	,	_	_	I-Premise
265	the	_	_	I-Premise
266	median	_	_	I-Premise
267	survival	_	_	I-Premise
268	time	_	_	I-Premise
269	for	_	_	I-Premise
270	etoposide	_	_	I-Premise
271	plus	_	_	I-Premise
272	cisplatin	_	_	I-Premise
273	was	_	_	I-Premise
274	7.6	_	_	I-Premise
275	months	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	8.9	_	_	I-Premise
279	months	_	_	I-Premise
280	for	_	_	I-Premise
281	paclitaxel	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=.246	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	With	_	_	B-Premise
288	the	_	_	I-Premise
289	exceptions	_	_	I-Premise
290	of	_	_	I-Premise
291	increased	_	_	I-Premise
292	granulocytopenia	_	_	I-Premise
293	on	_	_	I-Premise
294	the	_	_	I-Premise
295	low-dose	_	_	I-Premise
296	paclitaxel	_	_	I-Premise
297	regimen	_	_	I-Premise
298	and	_	_	I-Premise
299	increased	_	_	I-Premise
300	myalgias	_	_	I-Premise
301	,	_	_	I-Premise
302	neurotoxicity	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	,	_	_	I-Premise
306	possibly	_	_	I-Premise
307	,	_	_	I-Premise
308	increased	_	_	I-Premise
309	treatment-related	_	_	I-Premise
310	cardiac	_	_	I-Premise
311	events	_	_	I-Premise
312	with	_	_	I-Premise
313	high-dose	_	_	I-Premise
314	paclitaxel	_	_	I-Premise
315	,	_	_	I-Premise
316	toxicity	_	_	I-Premise
317	was	_	_	I-Premise
318	similar	_	_	I-Premise
319	across	_	_	I-Premise
320	all	_	_	I-Premise
321	three	_	_	I-Premise
322	arms	_	_	I-Premise
323	.	_	_	I-Premise

324	Quality	_	_	B-Premise
325	of	_	_	I-Premise
326	life	_	_	I-Premise
327	(	_	_	I-Premise
328	QOL	_	_	I-Premise
329	)	_	_	I-Premise
330	declined	_	_	I-Premise
331	significantly	_	_	I-Premise
332	over	_	_	I-Premise
333	the	_	_	I-Premise
334	6	_	_	I-Premise
335	months	_	_	I-Premise
336	.	_	_	I-Premise

337	However	_	_	O
338	,	_	_	O
339	QOL	_	_	B-Claim
340	scores	_	_	I-Claim
341	were	_	_	I-Claim
342	not	_	_	I-Claim
343	significantly	_	_	I-Claim
344	different	_	_	I-Claim
345	among	_	_	I-Claim
346	the	_	_	I-Claim
347	regimens	_	_	I-Claim
348	.	_	_	I-Claim

349	As	_	_	O
350	a	_	_	O
351	result	_	_	O
352	of	_	_	O
353	these	_	_	O
354	observations	_	_	O
355	,	_	_	O
356	paclitaxel	_	_	B-Claim
357	(	_	_	I-Claim
358	135	_	_	I-Claim
359	mg/m	_	_	I-Claim
360	(	_	_	I-Claim
361	2	_	_	I-Claim
362	)	_	_	I-Claim
363	)	_	_	I-Claim
364	combined	_	_	I-Claim
365	with	_	_	I-Claim
366	cisplatin	_	_	I-Claim
367	has	_	_	I-Claim
368	replaced	_	_	I-Claim
369	etoposide	_	_	I-Claim
370	plus	_	_	I-Claim
371	cisplatin	_	_	I-Claim
372	as	_	_	I-Claim
373	the	_	_	I-Claim
374	reference	_	_	I-Claim
375	regimen	_	_	I-Claim
376	in	_	_	I-Claim
377	our	_	_	I-Claim
378	recently	_	_	I-Claim
379	completed	_	_	I-Claim
380	phase	_	_	I-Claim
381	III	_	_	I-Claim
382	trial	_	_	I-Claim
383	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long	_	_	O
4	term	_	_	O
5	risks	_	_	O
6	and	_	_	O
7	benefits	_	_	O
8	of	_	_	O
9	hormone	_	_	O
10	replacement	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	combined	_	_	O
14	hormone	_	_	O
15	therapy	_	_	O
16	versus	_	_	O
17	placebo	_	_	O
18	,	_	_	O
19	and	_	_	O
20	oestrogen	_	_	O
21	alone	_	_	O
22	versus	_	_	O
23	combined	_	_	O
24	hormone	_	_	O
25	therapy	_	_	O
26	)	_	_	O
27	.	_	_	O

28	Multicentre	_	_	O
29	,	_	_	O
30	randomised	_	_	O
31	,	_	_	O
32	placebo	_	_	O
33	controlled	_	_	O
34	,	_	_	O
35	double	_	_	O
36	blind	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	General	_	_	O
40	practices	_	_	O
41	in	_	_	O
42	UK	_	_	O
43	(	_	_	O
44	384	_	_	O
45	)	_	_	O
46	,	_	_	O
47	Australia	_	_	O
48	(	_	_	O
49	91	_	_	O
50	)	_	_	O
51	,	_	_	O
52	and	_	_	O
53	New	_	_	O
54	Zealand	_	_	O
55	(	_	_	O
56	24	_	_	O
57	)	_	_	O
58	.	_	_	O

59	Postmenopausal	_	_	O
60	women	_	_	O
61	aged	_	_	O
62	50-69	_	_	O
63	years	_	_	O
64	at	_	_	O
65	randomisation	_	_	O
66	.	_	_	O

67	At	_	_	O
68	early	_	_	O
69	closure	_	_	O
70	of	_	_	O
71	the	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	56,583	_	_	O
75	had	_	_	O
76	been	_	_	O
77	screened	_	_	O
78	,	_	_	O
79	8980	_	_	O
80	entered	_	_	O
81	run-in	_	_	O
82	,	_	_	O
83	and	_	_	O
84	5692	_	_	O
85	(	_	_	O
86	26	_	_	O
87	%	_	_	O
88	of	_	_	O
89	target	_	_	O
90	of	_	_	O
91	22,300	_	_	O
92	)	_	_	O
93	started	_	_	O
94	treatment	_	_	O
95	.	_	_	O

96	Oestrogen	_	_	O
97	only	_	_	O
98	therapy	_	_	O
99	(	_	_	O
100	conjugated	_	_	O
101	equine	_	_	O
102	oestrogens	_	_	O
103	0.625	_	_	O
104	mg	_	_	O
105	orally	_	_	O
106	daily	_	_	O
107	)	_	_	O
108	or	_	_	O
109	combined	_	_	O
110	hormone	_	_	O
111	therapy	_	_	O
112	(	_	_	O
113	conjugated	_	_	O
114	equine	_	_	O
115	oestrogens	_	_	O
116	plus	_	_	O
117	medroxyprogesterone	_	_	O
118	acetate	_	_	O
119	2.5/5.0	_	_	O
120	mg	_	_	O
121	orally	_	_	O
122	daily	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Ten	_	_	O
126	years	_	_	O
127	of	_	_	O
128	treatment	_	_	O
129	planned	_	_	O
130	.	_	_	O

131	major	_	_	O
132	cardiovascular	_	_	O
133	disease	_	_	O
134	,	_	_	O
135	osteoporotic	_	_	O
136	fractures	_	_	O
137	,	_	_	O
138	and	_	_	O
139	breast	_	_	O
140	cancer	_	_	O
141	.	_	_	O

142	other	_	_	O
143	cancers	_	_	O
144	,	_	_	O
145	death	_	_	O
146	from	_	_	O
147	all	_	_	O
148	causes	_	_	O
149	,	_	_	O
150	venous	_	_	O
151	thromboembolism	_	_	O
152	,	_	_	O
153	cerebrovascular	_	_	O
154	disease	_	_	O
155	,	_	_	O
156	dementia	_	_	O
157	,	_	_	O
158	and	_	_	O
159	quality	_	_	O
160	of	_	_	O
161	life	_	_	O
162	.	_	_	O

163	The	_	_	O
164	trial	_	_	O
165	was	_	_	O
166	prematurely	_	_	O
167	closed	_	_	O
168	during	_	_	O
169	recruitment	_	_	O
170	,	_	_	O
171	after	_	_	O
172	a	_	_	O
173	median	_	_	O
174	follow-up	_	_	O
175	of	_	_	O
176	11.9	_	_	O
177	months	_	_	O
178	(	_	_	O
179	interquartile	_	_	O
180	range	_	_	O
181	7.1-19.6	_	_	O
182	,	_	_	O
183	total	_	_	O
184	6498	_	_	O
185	women	_	_	O
186	years	_	_	O
187	)	_	_	O
188	in	_	_	O
189	those	_	_	O
190	enrolled	_	_	O
191	,	_	_	O
192	after	_	_	O
193	the	_	_	O
194	publication	_	_	O
195	of	_	_	O
196	early	_	_	O
197	results	_	_	O
198	from	_	_	O
199	the	_	_	O
200	women	_	_	O
201	's	_	_	O
202	health	_	_	O
203	initiative	_	_	O
204	study	_	_	O
205	.	_	_	O

206	The	_	_	O
207	mean	_	_	O
208	age	_	_	O
209	of	_	_	O
210	randomised	_	_	O
211	women	_	_	O
212	was	_	_	O
213	62.8	_	_	O
214	(	_	_	O
215	SD	_	_	O
216	4.8	_	_	O
217	)	_	_	O
218	years	_	_	O
219	.	_	_	O

220	When	_	_	B-Premise
221	combined	_	_	I-Premise
222	hormone	_	_	I-Premise
223	therapy	_	_	I-Premise
224	(	_	_	I-Premise
225	n=2196	_	_	I-Premise
226	)	_	_	I-Premise
227	was	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	placebo	_	_	I-Premise
231	(	_	_	I-Premise
232	n=2189	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	there	_	_	I-Premise
236	was	_	_	I-Premise
237	a	_	_	I-Premise
238	significant	_	_	I-Premise
239	increase	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	number	_	_	I-Premise
243	of	_	_	I-Premise
244	major	_	_	I-Premise
245	cardiovascular	_	_	I-Premise
246	events	_	_	I-Premise
247	(	_	_	I-Premise
248	7	_	_	I-Premise
249	v	_	_	I-Premise
250	0	_	_	I-Premise
251	,	_	_	I-Premise
252	P=0.016	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	venous	_	_	I-Premise
256	thromboembolisms	_	_	I-Premise
257	(	_	_	I-Premise
258	22	_	_	I-Premise
259	v	_	_	I-Premise
260	3	_	_	I-Premise
261	,	_	_	I-Premise
262	hazard	_	_	I-Premise
263	ratio	_	_	I-Premise
264	7.36	_	_	I-Premise
265	(	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	2.20	_	_	I-Premise
270	to	_	_	I-Premise
271	24.60	_	_	I-Premise
272	)	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	There	_	_	B-Premise
276	were	_	_	I-Premise
277	no	_	_	I-Premise
278	statistically	_	_	I-Premise
279	significant	_	_	I-Premise
280	differences	_	_	I-Premise
281	in	_	_	I-Premise
282	numbers	_	_	I-Premise
283	of	_	_	I-Premise
284	breast	_	_	I-Premise
285	or	_	_	I-Premise
286	other	_	_	I-Premise
287	cancers	_	_	I-Premise
288	(	_	_	I-Premise
289	22	_	_	I-Premise
290	v	_	_	I-Premise
291	25	_	_	I-Premise
292	,	_	_	I-Premise
293	hazard	_	_	I-Premise
294	ratio	_	_	I-Premise
295	0.88	_	_	I-Premise
296	(	_	_	I-Premise
297	0.49	_	_	I-Premise
298	to	_	_	I-Premise
299	1.56	_	_	I-Premise
300	)	_	_	I-Premise
301	)	_	_	I-Premise
302	,	_	_	I-Premise
303	cerebrovascular	_	_	I-Premise
304	events	_	_	I-Premise
305	(	_	_	I-Premise
306	14	_	_	I-Premise
307	v	_	_	I-Premise
308	19	_	_	I-Premise
309	,	_	_	I-Premise
310	0.73	_	_	I-Premise
311	(	_	_	I-Premise
312	0.37	_	_	I-Premise
313	to	_	_	I-Premise
314	1.46	_	_	I-Premise
315	)	_	_	I-Premise
316	)	_	_	I-Premise
317	,	_	_	I-Premise
318	fractures	_	_	I-Premise
319	(	_	_	I-Premise
320	40	_	_	I-Premise
321	v	_	_	I-Premise
322	58	_	_	I-Premise
323	,	_	_	I-Premise
324	0.69	_	_	I-Premise
325	(	_	_	I-Premise
326	0.46	_	_	I-Premise
327	to	_	_	I-Premise
328	1.03	_	_	I-Premise
329	)	_	_	I-Premise
330	)	_	_	I-Premise
331	,	_	_	I-Premise
332	and	_	_	I-Premise
333	overall	_	_	I-Premise
334	deaths	_	_	I-Premise
335	(	_	_	I-Premise
336	8	_	_	I-Premise
337	v	_	_	I-Premise
338	5	_	_	I-Premise
339	,	_	_	I-Premise
340	1.60	_	_	I-Premise
341	(	_	_	I-Premise
342	0.52	_	_	I-Premise
343	to	_	_	I-Premise
344	4.89	_	_	I-Premise
345	)	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Comparison	_	_	B-Premise
349	of	_	_	I-Premise
350	combined	_	_	I-Premise
351	hormone	_	_	I-Premise
352	therapy	_	_	I-Premise
353	(	_	_	I-Premise
354	n=815	_	_	I-Premise
355	)	_	_	I-Premise
356	versus	_	_	I-Premise
357	oestrogen	_	_	I-Premise
358	therapy	_	_	I-Premise
359	(	_	_	I-Premise
360	n=826	_	_	I-Premise
361	)	_	_	I-Premise
362	outcomes	_	_	I-Premise
363	revealed	_	_	I-Premise
364	no	_	_	I-Premise
365	significant	_	_	I-Premise
366	differences	_	_	I-Premise
367	.	_	_	I-Premise

368	Hormone	_	_	B-Claim
369	replacement	_	_	I-Claim
370	therapy	_	_	I-Claim
371	increases	_	_	I-Claim
372	cardiovascular	_	_	I-Claim
373	and	_	_	I-Claim
374	thromboembolic	_	_	I-Claim
375	risk	_	_	I-Claim
376	when	_	_	I-Claim
377	started	_	_	I-Claim
378	many	_	_	I-Claim
379	years	_	_	I-Claim
380	after	_	_	I-Claim
381	the	_	_	I-Claim
382	menopause	_	_	I-Claim
383	.	_	_	I-Claim

384	The	_	_	B-Claim
385	results	_	_	I-Claim
386	are	_	_	I-Claim
387	consistent	_	_	I-Claim
388	with	_	_	I-Claim
389	the	_	_	I-Claim
390	findings	_	_	I-Claim
391	of	_	_	I-Claim
392	the	_	_	I-Claim
393	women	_	_	I-Claim
394	's	_	_	I-Claim
395	health	_	_	I-Claim
396	initiative	_	_	I-Claim
397	study	_	_	I-Claim
398	and	_	_	I-Claim
399	secondary	_	_	I-Claim
400	prevention	_	_	I-Claim
401	studies	_	_	I-Claim
402	.	_	_	I-Claim

403	Research	_	_	B-Claim
404	is	_	_	I-Claim
405	needed	_	_	I-Claim
406	to	_	_	I-Claim
407	assess	_	_	I-Claim
408	the	_	_	I-Claim
409	long	_	_	I-Claim
410	term	_	_	I-Claim
411	risks	_	_	I-Claim
412	and	_	_	I-Claim
413	benefits	_	_	I-Claim
414	of	_	_	I-Claim
415	starting	_	_	I-Claim
416	hormone	_	_	I-Claim
417	replacement	_	_	I-Claim
418	therapy	_	_	I-Claim
419	near	_	_	I-Claim
420	the	_	_	I-Claim
421	menopause	_	_	I-Claim
422	,	_	_	I-Claim
423	when	_	_	I-Claim
424	the	_	_	I-Claim
425	effect	_	_	I-Claim
426	may	_	_	I-Claim
427	be	_	_	I-Claim
428	different	_	_	I-Claim
429	.	_	_	I-Claim


0	Imatinib	_	_	O
1	is	_	_	O
2	the	_	_	O
3	standard	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	advanced	_	_	O
7	GI	_	_	O
8	stromal	_	_	O
9	tumors	_	_	O
10	(	_	_	O
11	GISTs	_	_	O
12	)	_	_	O
13	.	_	_	O

14	It	_	_	B-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	known	_	_	I-Claim
18	whether	_	_	I-Claim
19	imatinib	_	_	I-Claim
20	may	_	_	I-Claim
21	be	_	_	I-Claim
22	stopped	_	_	I-Claim
23	in	_	_	I-Claim
24	patients	_	_	I-Claim
25	in	_	_	I-Claim
26	whom	_	_	I-Claim
27	disease	_	_	I-Claim
28	is	_	_	I-Claim
29	controlled	_	_	I-Claim
30	.	_	_	I-Claim

31	This	_	_	O
32	prospective	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	multicentric	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	study	_	_	O
40	was	_	_	O
41	designed	_	_	O
42	to	_	_	O
43	compare	_	_	O
44	continuous	_	_	O
45	(	_	_	O
46	CONT	_	_	O
47	)	_	_	O
48	compared	_	_	O
49	with	_	_	O
50	interrupted	_	_	O
51	(	_	_	O
52	INT	_	_	O
53	)	_	_	O
54	imatinib	_	_	O
55	beyond	_	_	O
56	1	_	_	O
57	year	_	_	O
58	of	_	_	O
59	treatment	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	advanced	_	_	O
64	GIST	_	_	O
65	.	_	_	O

66	The	_	_	O
67	primary	_	_	O
68	end	_	_	O
69	point	_	_	O
70	was	_	_	O
71	progression-free	_	_	O
72	survival	_	_	O
73	.	_	_	O

74	Secondary	_	_	O
75	end	_	_	O
76	points	_	_	O
77	included	_	_	O
78	overall	_	_	O
79	survival	_	_	O
80	,	_	_	O
81	response	_	_	O
82	rate	_	_	O
83	after	_	_	O
84	reinitiation	_	_	O
85	of	_	_	O
86	imatinib	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	.	_	_	O

93	Early	_	_	O
94	stopping	_	_	O
95	rules	_	_	O
96	in	_	_	O
97	cases	_	_	O
98	of	_	_	O
99	rapid	_	_	O
100	progression	_	_	O
101	of	_	_	O
102	disease	_	_	O
103	were	_	_	O
104	defined	_	_	O
105	,	_	_	O
106	with	_	_	O
107	preplanned	_	_	O
108	interim	_	_	O
109	analyses	_	_	O
110	.	_	_	O

111	Between	_	_	O
112	May	_	_	O
113	2002	_	_	O
114	and	_	_	O
115	April	_	_	O
116	2004	_	_	O
117	,	_	_	O
118	182	_	_	O
119	patients	_	_	O
120	with	_	_	O
121	advanced	_	_	O
122	GIST	_	_	O
123	were	_	_	O
124	enrolled	_	_	O
125	.	_	_	O

126	Between	_	_	O
127	May	_	_	O
128	2003	_	_	O
129	and	_	_	O
130	April	_	_	O
131	2004	_	_	O
132	,	_	_	O
133	98	_	_	O
134	patients	_	_	O
135	in	_	_	O
136	response	_	_	O
137	or	_	_	O
138	stable	_	_	O
139	disease	_	_	O
140	under	_	_	O
141	imatinib	_	_	O
142	reached	_	_	O
143	more	_	_	O
144	than	_	_	O
145	1	_	_	O
146	year	_	_	O
147	of	_	_	O
148	follow-up	_	_	O
149	.	_	_	O

150	Forty	_	_	O
151	were	_	_	O
152	not	_	_	O
153	eligible	_	_	O
154	for	_	_	O
155	randomization	_	_	O
156	,	_	_	O
157	and	_	_	O
158	58	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	,	_	_	O
164	32	_	_	O
165	and	_	_	O
166	26	_	_	O
167	patients	_	_	O
168	in	_	_	O
169	the	_	_	O
170	INT	_	_	O
171	and	_	_	O
172	CONT	_	_	O
173	arms	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	.	_	_	O

177	As	_	_	B-Premise
178	of	_	_	I-Premise
179	October	_	_	I-Premise
180	15	_	_	I-Premise
181	,	_	_	I-Premise
182	2005	_	_	I-Premise
183	,	_	_	I-Premise
184	eight	_	_	I-Premise
185	of	_	_	I-Premise
186	26	_	_	I-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	CONT	_	_	I-Premise
191	group	_	_	I-Premise
192	and	_	_	I-Premise
193	26	_	_	I-Premise
194	of	_	_	I-Premise
195	32	_	_	I-Premise
196	patients	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	INT	_	_	I-Premise
200	group	_	_	I-Premise
201	had	_	_	I-Premise
202	documented	_	_	I-Premise
203	disease	_	_	I-Premise
204	progression	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Twenty-four	_	_	B-Premise
212	of	_	_	I-Premise
213	26	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	documented	_	_	I-Premise
217	progression	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	INT	_	_	I-Premise
221	arm	_	_	I-Premise
222	responded	_	_	I-Premise
223	to	_	_	I-Premise
224	imatinib	_	_	I-Premise
225	reintroduction	_	_	I-Premise
226	.	_	_	I-Premise

227	No	_	_	B-Premise
228	differences	_	_	I-Premise
229	in	_	_	I-Premise
230	overall	_	_	I-Premise
231	survival	_	_	I-Premise
232	or	_	_	I-Premise
233	imatinib	_	_	I-Premise
234	resistance	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	two	_	_	I-Premise
240	arms	_	_	I-Premise
241	.	_	_	I-Premise

242	Quality	_	_	B-Premise
243	of	_	_	I-Premise
244	life	_	_	I-Premise
245	evaluated	_	_	I-Premise
246	6	_	_	I-Premise
247	months	_	_	I-Premise
248	after	_	_	I-Premise
249	random	_	_	I-Premise
250	assignment	_	_	I-Premise
251	using	_	_	I-Premise
252	the	_	_	I-Premise
253	30-item	_	_	I-Premise
254	Quality	_	_	I-Premise
255	of	_	_	I-Premise
256	Life	_	_	I-Premise
257	Questionnaire	_	_	I-Premise
258	was	_	_	I-Premise
259	not	_	_	I-Premise
260	significantly	_	_	I-Premise
261	different	_	_	I-Premise
262	between	_	_	I-Premise
263	the	_	_	I-Premise
264	two	_	_	I-Premise
265	groups	_	_	I-Premise
266	of	_	_	I-Premise
267	randomly	_	_	I-Premise
268	assigned	_	_	I-Premise
269	patients	_	_	I-Premise
270	.	_	_	I-Premise

271	Imatinib	_	_	B-Claim
272	interruption	_	_	I-Claim
273	results	_	_	I-Claim
274	in	_	_	I-Claim
275	rapid	_	_	I-Claim
276	progression	_	_	I-Claim
277	in	_	_	I-Claim
278	most	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	advanced	_	_	I-Claim
282	GIST	_	_	I-Claim
283	,	_	_	I-Claim
284	and	_	_	I-Claim
285	can	_	_	I-Claim
286	not	_	_	I-Claim
287	be	_	_	I-Claim
288	recommended	_	_	I-Claim
289	in	_	_	I-Claim
290	routine	_	_	I-Claim
291	practice	_	_	I-Claim
292	unless	_	_	I-Claim
293	patient	_	_	I-Claim
294	experience	_	_	I-Claim
295	significant	_	_	I-Claim
296	toxicity	_	_	I-Claim
297	.	_	_	I-Claim


0	This	_	_	O
1	report	_	_	O
2	describes	_	_	O
3	the	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	findings	_	_	O
11	of	_	_	O
12	a	_	_	O
13	randomized	_	_	O
14	placebo	_	_	O
15	controlled	_	_	O
16	study	_	_	O
17	of	_	_	O
18	erlotinib	_	_	O
19	,	_	_	O
20	an	_	_	O
21	epidermal	_	_	O
22	growth	_	_	O
23	factor	_	_	O
24	receptor	_	_	O
25	inhibitor	_	_	O
26	,	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	non-small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	(	_	_	O
34	NSCLC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	This	_	_	O
38	double-blind	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	trial	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	731	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	NSCLC	_	_	O
48	who	_	_	O
49	had	_	_	O
50	progressed	_	_	O
51	after	_	_	O
52	prior	_	_	O
53	chemotherapy	_	_	O
54	to	_	_	O
55	erlotinib	_	_	O
56	150	_	_	O
57	mg	_	_	O
58	daily	_	_	O
59	or	_	_	O
60	placebo	_	_	O
61	,	_	_	O
62	with	_	_	O
63	survival	_	_	O
64	as	_	_	O
65	the	_	_	O
66	primary	_	_	O
67	study	_	_	O
68	outcome	_	_	O
69	.	_	_	O

70	QOL	_	_	O
71	was	_	_	O
72	assessed	_	_	O
73	by	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	QLQ-C30	_	_	O
83	and	_	_	O
84	the	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	module	_	_	O
88	QLQ-LC13	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	end	_	_	O
93	points	_	_	O
94	for	_	_	O
95	QOL	_	_	O
96	analysis	_	_	O
97	were	_	_	O
98	time	_	_	O
99	to	_	_	O
100	deterioration	_	_	O
101	of	_	_	O
102	three	_	_	O
103	common	_	_	O
104	lung	_	_	O
105	cancer	_	_	O
106	symptoms	_	_	O
107	:	_	_	O
108	cough	_	_	O
109	,	_	_	O
110	dyspnea	_	_	O
111	,	_	_	O
112	and	_	_	O
113	pain	_	_	O
114	.	_	_	O

115	Survival	_	_	B-Premise
116	was	_	_	I-Premise
117	significantly	_	_	I-Premise
118	longer	_	_	I-Premise
119	(	_	_	I-Premise
120	hazard	_	_	I-Premise
121	ratio	_	_	I-Premise
122	,	_	_	I-Premise
123	0.70	_	_	I-Premise
124	;	_	_	I-Premise
125	P	_	_	I-Premise
126	<	_	_	I-Premise
127	.0001	_	_	I-Premise
128	)	_	_	I-Premise
129	in	_	_	I-Premise
130	the	_	_	I-Premise
131	erlotinib	_	_	I-Premise
132	arm	_	_	I-Premise
133	.	_	_	I-Premise

134	Compliance	_	_	B-Premise
135	with	_	_	I-Premise
136	QOL	_	_	I-Premise
137	was	_	_	I-Premise
138	87	_	_	I-Premise
139	%	_	_	I-Premise
140	at	_	_	I-Premise
141	baseline	_	_	I-Premise
142	and	_	_	I-Premise
143	more	_	_	I-Premise
144	than	_	_	I-Premise
145	70	_	_	I-Premise
146	%	_	_	I-Premise
147	during	_	_	I-Premise
148	treatment	_	_	I-Premise
149	.	_	_	I-Premise

150	Patients	_	_	B-Premise
151	receiving	_	_	I-Premise
152	erlotinib	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	longer	_	_	I-Premise
156	median	_	_	I-Premise
157	time	_	_	I-Premise
158	to	_	_	I-Premise
159	deterioration	_	_	I-Premise
160	for	_	_	I-Premise
161	all	_	_	I-Premise
162	three	_	_	I-Premise
163	symptoms	_	_	I-Premise
164	(	_	_	I-Premise
165	4.9	_	_	I-Premise
166	v	_	_	I-Premise
167	3.7	_	_	I-Premise
168	months	_	_	I-Premise
169	for	_	_	I-Premise
170	cough	_	_	I-Premise
171	[	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.04	_	_	I-Premise
175	]	_	_	I-Premise
176	;	_	_	I-Premise
177	4.7	_	_	I-Premise
178	v	_	_	I-Premise
179	2.9	_	_	I-Premise
180	months	_	_	I-Premise
181	for	_	_	I-Premise
182	dyspnea	_	_	I-Premise
183	[	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.04	_	_	I-Premise
187	]	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	2.8	_	_	I-Premise
191	v	_	_	I-Premise
192	1.9	_	_	I-Premise
193	months	_	_	I-Premise
194	for	_	_	I-Premise
195	pain	_	_	I-Premise
196	[	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.03	_	_	I-Premise
200	]	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	QOL	_	_	B-Premise
204	response	_	_	I-Premise
205	analyses	_	_	I-Premise
206	showed	_	_	I-Premise
207	that	_	_	I-Premise
208	44	_	_	I-Premise
209	%	_	_	I-Premise
210	,	_	_	I-Premise
211	34	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	42	_	_	I-Premise
216	%	_	_	I-Premise
217	of	_	_	I-Premise
218	patients	_	_	I-Premise
219	receiving	_	_	I-Premise
220	erlotinib	_	_	I-Premise
221	had	_	_	I-Premise
222	improvement	_	_	I-Premise
223	in	_	_	I-Premise
224	these	_	_	I-Premise
225	three	_	_	I-Premise
226	symptoms	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	.	_	_	I-Premise

230	This	_	_	B-Premise
231	was	_	_	I-Premise
232	accompanied	_	_	I-Premise
233	by	_	_	I-Premise
234	a	_	_	I-Premise
235	significant	_	_	I-Premise
236	improvement	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	physical	_	_	I-Premise
240	function	_	_	I-Premise
241	(	_	_	I-Premise
242	31	_	_	I-Premise
243	%	_	_	I-Premise
244	erlotinib	_	_	I-Premise
245	v	_	_	I-Premise
246	19	_	_	I-Premise
247	%	_	_	I-Premise
248	placebo	_	_	I-Premise
249	,	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.01	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	and	_	_	I-Premise
256	global	_	_	I-Premise
257	QOL	_	_	I-Premise
258	(	_	_	I-Premise
259	35	_	_	I-Premise
260	%	_	_	I-Premise
261	v	_	_	I-Premise
262	26	_	_	I-Premise
263	%	_	_	I-Premise
264	,	_	_	I-Premise
265	P	_	_	I-Premise
266	<	_	_	I-Premise
267	.0001	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Patients	_	_	B-Premise
271	with	_	_	I-Premise
272	complete	_	_	I-Premise
273	or	_	_	I-Premise
274	partial	_	_	I-Premise
275	response	_	_	I-Premise
276	were	_	_	I-Premise
277	more	_	_	I-Premise
278	likely	_	_	I-Premise
279	to	_	_	I-Premise
280	have	_	_	I-Premise
281	improvement	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	QOL	_	_	I-Premise
285	response	_	_	I-Premise
286	than	_	_	I-Premise
287	patients	_	_	I-Premise
288	with	_	_	I-Premise
289	stable	_	_	I-Premise
290	or	_	_	I-Premise
291	progressive	_	_	I-Premise
292	disease	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	.01	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Erlotinib	_	_	B-Claim
300	not	_	_	I-Claim
301	only	_	_	I-Claim
302	improves	_	_	I-Claim
303	survival	_	_	I-Claim
304	in	_	_	I-Claim
305	previously	_	_	I-Claim
306	treated	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	NSCLC	_	_	I-Claim
310	,	_	_	I-Claim
311	but	_	_	I-Claim
312	also	_	_	I-Claim
313	improves	_	_	I-Claim
314	tumor-related	_	_	I-Claim
315	symptoms	_	_	I-Claim
316	and	_	_	I-Claim
317	important	_	_	I-Claim
318	aspects	_	_	I-Claim
319	of	_	_	I-Claim
320	QOL	_	_	I-Claim
321	.	_	_	I-Claim


0	Menopausal	_	_	B-Claim
1	symptoms	_	_	I-Claim
2	(	_	_	I-Claim
3	e.g.	_	_	I-Claim
4	,	_	_	I-Claim
5	hot	_	_	I-Claim
6	flashes	_	_	I-Claim
7	,	_	_	I-Claim
8	vaginal	_	_	I-Claim
9	dryness	_	_	I-Claim
10	,	_	_	I-Claim
11	and	_	_	I-Claim
12	stress	_	_	I-Claim
13	urinary	_	_	I-Claim
14	incontinence	_	_	I-Claim
15	)	_	_	I-Claim
16	are	_	_	I-Claim
17	very	_	_	I-Claim
18	common	_	_	I-Claim
19	in	_	_	I-Claim
20	breast	_	_	I-Claim
21	cancer	_	_	I-Claim
22	survivors	_	_	I-Claim
23	and	_	_	I-Claim
24	can	_	_	I-Claim
25	not	_	_	I-Claim
26	be	_	_	I-Claim
27	managed	_	_	I-Claim
28	with	_	_	I-Claim
29	standard	_	_	I-Claim
30	estrogen	_	_	I-Claim
31	replacement	_	_	I-Claim
32	therapy	_	_	I-Claim
33	(	_	_	I-Claim
34	ERT	_	_	I-Claim
35	)	_	_	I-Claim
36	in	_	_	I-Claim
37	these	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	The	_	_	O
41	purpose	_	_	O
42	of	_	_	O
43	this	_	_	O
44	study	_	_	O
45	was	_	_	O
46	to	_	_	O
47	test	_	_	O
48	the	_	_	O
49	efficacy	_	_	O
50	of	_	_	O
51	a	_	_	O
52	comprehensive	_	_	O
53	menopausal	_	_	O
54	assessment	_	_	O
55	(	_	_	O
56	CMA	_	_	O
57	)	_	_	O
58	intervention	_	_	O
59	program	_	_	O
60	in	_	_	O
61	achieving	_	_	O
62	relief	_	_	O
63	of	_	_	O
64	symptoms	_	_	O
65	,	_	_	O
66	the	_	_	O
67	improvement	_	_	O
68	in	_	_	O
69	quality	_	_	O
70	of	_	_	O
71	life	_	_	O
72	(	_	_	O
73	QOL	_	_	O
74	)	_	_	O
75	,	_	_	O
76	and	_	_	O
77	sexual	_	_	O
78	functioning	_	_	O
79	in	_	_	O
80	breast	_	_	O
81	cancer	_	_	O
82	survivors	_	_	O
83	.	_	_	O

84	Using	_	_	O
85	a	_	_	O
86	two-group	_	_	O
87	,	_	_	O
88	randomized	_	_	O
89	controlled	_	_	O
90	design	_	_	O
91	,	_	_	O
92	we	_	_	O
93	assigned	_	_	O
94	76	_	_	O
95	postmenopausal	_	_	O
96	breast	_	_	O
97	cancer	_	_	O
98	survivors	_	_	O
99	with	_	_	O
100	at	_	_	O
101	least	_	_	O
102	one	_	_	O
103	severe	_	_	O
104	target	_	_	O
105	symptom	_	_	O
106	either	_	_	O
107	to	_	_	O
108	the	_	_	O
109	intervention	_	_	O
110	group	_	_	O
111	or	_	_	O
112	to	_	_	O
113	a	_	_	O
114	usual-care	_	_	O
115	group	_	_	O
116	.	_	_	O

117	Seventy-two	_	_	O
118	women	_	_	O
119	were	_	_	O
120	evaluable	_	_	O
121	at	_	_	O
122	the	_	_	O
123	end	_	_	O
124	of	_	_	O
125	the	_	_	O
126	study	_	_	O
127	period	_	_	O
128	.	_	_	O

129	The	_	_	O
130	CMA	_	_	O
131	intervention	_	_	O
132	,	_	_	O
133	delivered	_	_	O
134	by	_	_	O
135	a	_	_	O
136	nurse	_	_	O
137	practitioner	_	_	O
138	,	_	_	O
139	focused	_	_	O
140	on	_	_	O
141	symptom	_	_	O
142	assessment	_	_	O
143	,	_	_	O
144	education	_	_	O
145	,	_	_	O
146	counseling	_	_	O
147	and	_	_	O
148	,	_	_	O
149	as	_	_	O
150	appropriate	_	_	O
151	,	_	_	O
152	specific	_	_	O
153	pharmacologic	_	_	O
154	and	_	_	O
155	behavioral	_	_	O
156	interventions	_	_	O
157	for	_	_	O
158	each	_	_	O
159	of	_	_	O
160	the	_	_	O
161	three	_	_	O
162	target	_	_	O
163	symptoms	_	_	O
164	.	_	_	O

165	Psychosocial	_	_	O
166	symptoms	_	_	O
167	were	_	_	O
168	assessed	_	_	O
169	with	_	_	O
170	the	_	_	O
171	use	_	_	O
172	of	_	_	O
173	a	_	_	O
174	self-report	_	_	O
175	screening	_	_	O
176	instrument	_	_	O
177	,	_	_	O
178	and	_	_	O
179	distressed	_	_	O
180	women	_	_	O
181	were	_	_	O
182	referred	_	_	O
183	for	_	_	O
184	counseling	_	_	O
185	if	_	_	O
186	needed	_	_	O
187	.	_	_	O

188	The	_	_	O
189	intervention	_	_	O
190	took	_	_	O
191	place	_	_	O
192	over	_	_	O
193	a	_	_	O
194	4-month	_	_	O
195	period	_	_	O
196	.	_	_	O

197	Outcomes	_	_	O
198	measured	_	_	O
199	were	_	_	O
200	scores	_	_	O
201	on	_	_	O
202	a	_	_	O
203	composite	_	_	O
204	menopausal	_	_	O
205	symptom	_	_	O
206	scale	_	_	O
207	,	_	_	O
208	the	_	_	O
209	RAND	_	_	O
210	Short	_	_	O
211	Form	_	_	O
212	Health	_	_	O
213	Survey	_	_	O
214	Vitality	_	_	O
215	Scale	_	_	O
216	,	_	_	O
217	and	_	_	O
218	the	_	_	O
219	Cancer	_	_	O
220	Rehabilitation	_	_	O
221	Evaluation	_	_	O
222	System	_	_	O
223	(	_	_	O
224	CARES	_	_	O
225	)	_	_	O
226	Sexual	_	_	O
227	Functioning	_	_	O
228	Scale	_	_	O
229	at	_	_	O
230	baseline	_	_	O
231	and	_	_	O
232	at	_	_	O
233	4-month	_	_	O
234	follow-up	_	_	O
235	.	_	_	O

236	All	_	_	O
237	statistical	_	_	O
238	tests	_	_	O
239	were	_	_	O
240	two-sided	_	_	O
241	and	_	_	O
242	were	_	_	O
243	performed	_	_	O
244	at	_	_	O
245	the	_	_	O
246	alpha	_	_	O
247	=	_	_	O
248	.	_	_	O

249	05	_	_	O
250	significance	_	_	O
251	level	_	_	O
252	.	_	_	O

253	Patients	_	_	B-Premise
254	receiving	_	_	I-Premise
255	the	_	_	I-Premise
256	intervention	_	_	I-Premise
257	demonstrated	_	_	I-Premise
258	statistically	_	_	I-Premise
259	significant	_	_	I-Premise
260	improvement	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=.0004	_	_	I-Premise
264	)	_	_	I-Premise
265	in	_	_	I-Premise
266	menopausal	_	_	I-Premise
267	symptoms	_	_	I-Premise
268	but	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	change	_	_	I-Premise
272	in	_	_	I-Premise
273	vitality	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=.77	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Sexual	_	_	B-Premise
280	functioning	_	_	I-Premise
281	was	_	_	I-Premise
282	statistically	_	_	I-Premise
283	significantly	_	_	I-Premise
284	improved	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=.04	_	_	I-Premise
288	)	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	treatment	_	_	I-Premise
292	group	_	_	I-Premise
293	compared	_	_	I-Premise
294	with	_	_	I-Premise
295	the	_	_	I-Premise
296	usual-care	_	_	I-Premise
297	group	_	_	I-Premise
298	.	_	_	I-Premise

299	A	_	_	B-Claim
300	clinical	_	_	I-Claim
301	assessment	_	_	I-Claim
302	and	_	_	I-Claim
303	intervention	_	_	I-Claim
304	program	_	_	I-Claim
305	for	_	_	I-Claim
306	menopausal	_	_	I-Claim
307	symptom	_	_	I-Claim
308	management	_	_	I-Claim
309	in	_	_	I-Claim
310	breast	_	_	I-Claim
311	cancer	_	_	I-Claim
312	survivors	_	_	I-Claim
313	is	_	_	I-Claim
314	feasible	_	_	I-Claim
315	and	_	_	I-Claim
316	acceptable	_	_	I-Claim
317	to	_	_	I-Claim
318	patients	_	_	I-Claim
319	,	_	_	I-Claim
320	leading	_	_	I-Claim
321	to	_	_	I-Claim
322	reduction	_	_	I-Claim
323	in	_	_	I-Claim
324	symptoms	_	_	I-Claim
325	and	_	_	I-Claim
326	improvement	_	_	I-Claim
327	in	_	_	I-Claim
328	sexual	_	_	I-Claim
329	functioning	_	_	I-Claim
330	.	_	_	I-Claim

331	Measurable	_	_	B-Claim
332	improvement	_	_	I-Claim
333	in	_	_	I-Claim
334	a	_	_	I-Claim
335	general	_	_	I-Claim
336	QOL	_	_	I-Claim
337	measure	_	_	I-Claim
338	was	_	_	I-Claim
339	not	_	_	I-Claim
340	demonstrated	_	_	I-Claim
341	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	is	_	_	O
3	the	_	_	O
4	first	_	_	O
5	large	_	_	O
6	prospective	_	_	O
7	RCT	_	_	O
8	of	_	_	O
9	sentinel	_	_	O
10	node	_	_	O
11	biopsy	_	_	O
12	(	_	_	O
13	SNB	_	_	O
14	)	_	_	O
15	compared	_	_	O
16	with	_	_	O
17	standard	_	_	O
18	axillary	_	_	O
19	treatment	_	_	O
20	(	_	_	O
21	level	_	_	O
22	I-III	_	_	O
23	axillary	_	_	O
24	lymph	_	_	O
25	node	_	_	O
26	dissection	_	_	O
27	or	_	_	O
28	four	_	_	O
29	node	_	_	O
30	sampling	_	_	O
31	)	_	_	O
32	,	_	_	O
33	which	_	_	O
34	includes	_	_	O
35	comprehensive	_	_	O
36	and	_	_	O
37	repeated	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QOL	_	_	O
43	)	_	_	O
44	assessments	_	_	O
45	over	_	_	O
46	18	_	_	O
47	months	_	_	O
48	.	_	_	O

49	Patients	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	829	_	_	O
54	)	_	_	O
55	completed	_	_	O
56	the	_	_	O
57	Functional	_	_	O
58	Assessment	_	_	O
59	of	_	_	O
60	Cancer	_	_	O
61	Therapy	_	_	O
62	-	_	_	O
63	Breast	_	_	O
64	(	_	_	O
65	FACT-B+4	_	_	O
66	)	_	_	O
67	and	_	_	O
68	the	_	_	O
69	Spielberger	_	_	O
70	State/Trait	_	_	O
71	Anxiety	_	_	O
72	Inventory	_	_	O
73	(	_	_	O
74	STAI	_	_	O
75	)	_	_	O
76	at	_	_	O
77	baseline	_	_	O
78	(	_	_	O
79	pre-surgery	_	_	O
80	)	_	_	O
81	and	_	_	O
82	at	_	_	O
83	1	_	_	O
84	,	_	_	O
85	3	_	_	O
86	,	_	_	O
87	6	_	_	O
88	,	_	_	O
89	12	_	_	O
90	,	_	_	O
91	and	_	_	O
92	18	_	_	O
93	months	_	_	O
94	post-surgery	_	_	O
95	.	_	_	O

96	There	_	_	B-Claim
97	were	_	_	I-Claim
98	significant	_	_	I-Claim
99	differences	_	_	I-Claim
100	between	_	_	I-Claim
101	treatment	_	_	I-Claim
102	groups	_	_	I-Claim
103	favouring	_	_	I-Claim
104	the	_	_	I-Claim
105	SNB	_	_	I-Claim
106	group	_	_	I-Claim
107	throughout	_	_	I-Claim
108	the	_	_	I-Claim
109	18	_	_	I-Claim
110	months	_	_	I-Claim
111	assessment	_	_	I-Claim
112	.	_	_	I-Claim

113	Patients	_	_	B-Premise
114	in	_	_	I-Premise
115	the	_	_	I-Premise
116	standard	_	_	I-Premise
117	treatment	_	_	I-Premise
118	group	_	_	I-Premise
119	showed	_	_	I-Premise
120	a	_	_	I-Premise
121	greater	_	_	I-Premise
122	decline	_	_	I-Premise
123	in	_	_	I-Premise
124	Trial	_	_	I-Premise
125	Outcome	_	_	I-Premise
126	Index	_	_	I-Premise
127	(	_	_	I-Premise
128	TOI	_	_	I-Premise
129	)	_	_	I-Premise
130	scores	_	_	I-Premise
131	(	_	_	I-Premise
132	physical	_	_	I-Premise
133	well-being	_	_	I-Premise
134	,	_	_	I-Premise
135	functional	_	_	I-Premise
136	well-being	_	_	I-Premise
137	and	_	_	I-Premise
138	breast	_	_	I-Premise
139	cancer	_	_	I-Premise
140	concerns	_	_	I-Premise
141	subscales	_	_	I-Premise
142	in	_	_	I-Premise
143	FACT-B+4	_	_	I-Premise
144	)	_	_	I-Premise
145	and	_	_	I-Premise
146	recovered	_	_	I-Premise
147	more	_	_	I-Premise
148	slowly	_	_	I-Premise
149	than	_	_	I-Premise
150	patients	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	SNB	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	p	_	_	I-Premise
157	<	_	_	I-Premise
158	0.01	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	change	_	_	I-Premise
163	in	_	_	I-Premise
164	total	_	_	I-Premise
165	FACT-B+4	_	_	I-Premise
166	scores	_	_	I-Premise
167	(	_	_	I-Premise
168	measuring	_	_	I-Premise
169	global	_	_	I-Premise
170	QOL	_	_	I-Premise
171	)	_	_	I-Premise
172	closely	_	_	I-Premise
173	resembled	_	_	I-Premise
174	the	_	_	I-Premise
175	TOI	_	_	I-Premise
176	results	_	_	I-Premise
177	.	_	_	I-Premise

178	18	_	_	B-Premise
179	months	_	_	I-Premise
180	post-surgery	_	_	I-Premise
181	approximately	_	_	I-Premise
182	twice	_	_	I-Premise
183	as	_	_	I-Premise
184	many	_	_	I-Premise
185	patients	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	standard	_	_	I-Premise
189	group	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	the	_	_	I-Premise
193	SNB	_	_	I-Premise
194	group	_	_	I-Premise
195	reported	_	_	I-Premise
196	substantial	_	_	I-Premise
197	arm	_	_	I-Premise
198	swelling	_	_	I-Premise
199	(	_	_	I-Premise
200	14	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	7	_	_	I-Premise
204	%	_	_	I-Premise
205	)	_	_	I-Premise
206	(	_	_	I-Premise
207	p	_	_	I-Premise
208	=	_	_	I-Premise
209	0.002	_	_	I-Premise
210	)	_	_	I-Premise
211	or	_	_	I-Premise
212	numbness	_	_	I-Premise
213	(	_	_	I-Premise
214	19	_	_	I-Premise
215	%	_	_	I-Premise
216	versus	_	_	I-Premise
217	8.7	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	(	_	_	I-Premise
221	p	_	_	I-Premise
222	<	_	_	I-Premise
223	0.001	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	Despite	_	_	O
227	the	_	_	O
228	uncertainty	_	_	O
229	about	_	_	O
230	undergoing	_	_	O
231	a	_	_	O
232	relatively	_	_	O
233	new	_	_	O
234	procedure	_	_	O
235	and	_	_	O
236	the	_	_	O
237	possible	_	_	O
238	need	_	_	O
239	for	_	_	O
240	further	_	_	O
241	surgery	_	_	O
242	,	_	_	O
243	there	_	_	B-Premise
244	was	_	_	I-Premise
245	no	_	_	I-Premise
246	evidence	_	_	I-Premise
247	of	_	_	I-Premise
248	increased	_	_	I-Premise
249	anxiety	_	_	I-Premise
250	amongst	_	_	I-Premise
251	patients	_	_	I-Premise
252	randomised	_	_	I-Premise
253	to	_	_	I-Premise
254	SNB	_	_	I-Premise
255	(	_	_	I-Premise
256	p	_	_	I-Premise
257	>	_	_	I-Premise
258	0.05	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	For	_	_	B-Premise
262	6	_	_	I-Premise
263	months	_	_	I-Premise
264	post-surgery	_	_	I-Premise
265	younger	_	_	I-Premise
266	patients	_	_	I-Premise
267	reported	_	_	I-Premise
268	less	_	_	I-Premise
269	favourable	_	_	I-Premise
270	QOL	_	_	I-Premise
271	scores	_	_	I-Premise
272	(	_	_	I-Premise
273	p	_	_	I-Premise
274	<	_	_	I-Premise
275	0.001	_	_	I-Premise
276	)	_	_	I-Premise
277	and	_	_	I-Premise
278	greater	_	_	I-Premise
279	levels	_	_	I-Premise
280	of	_	_	I-Premise
281	anxiety	_	_	I-Premise
282	(	_	_	I-Premise
283	p	_	_	I-Premise
284	<	_	_	I-Premise
285	0.01	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	In	_	_	B-Claim
289	view	_	_	I-Claim
290	of	_	_	I-Claim
291	the	_	_	I-Claim
292	benefits	_	_	I-Claim
293	regarding	_	_	I-Claim
294	arm	_	_	I-Claim
295	functioning	_	_	I-Claim
296	and	_	_	I-Claim
297	quality	_	_	I-Claim
298	of	_	_	I-Claim
299	life	_	_	I-Claim
300	,	_	_	I-Claim
301	the	_	_	I-Claim
302	data	_	_	I-Claim
303	from	_	_	I-Claim
304	this	_	_	I-Claim
305	randomised	_	_	I-Claim
306	study	_	_	I-Claim
307	support	_	_	I-Claim
308	the	_	_	I-Claim
309	use	_	_	I-Claim
310	of	_	_	I-Claim
311	SNB	_	_	I-Claim
312	in	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	clinically	_	_	I-Claim
316	node	_	_	I-Claim
317	negative	_	_	I-Claim
318	breast	_	_	I-Claim
319	cancer	_	_	I-Claim
320	.	_	_	I-Claim


0	Treosulfan	_	_	O
1	,	_	_	O
2	an	_	_	O
3	alkylating	_	_	O
4	agent	_	_	O
5	,	_	_	O
6	has	_	_	O
7	demonstrated	_	_	O
8	activity	_	_	O
9	in	_	_	O
10	recurrent	_	_	O
11	ovarian	_	_	O
12	carcinoma	_	_	O
13	.	_	_	O

14	It	_	_	O
15	is	_	_	O
16	equieffective	_	_	O
17	as	_	_	O
18	oral	_	_	O
19	(	_	_	O
20	p.o	_	_	O
21	.	_	_	O
22	)	_	_	O

23	and	_	_	O
24	intravenous	_	_	O
25	(	_	_	O
26	i.v	_	_	O
27	.	_	_	O
28	)	_	_	O

29	formulation	_	_	O
30	.	_	_	O

31	To	_	_	O
32	explore	_	_	O
33	the	_	_	O
34	preference	_	_	O
35	and	_	_	O
36	compliance	_	_	O
37	of	_	_	O
38	elderly	_	_	O
39	patients	_	_	O
40	regarding	_	_	O
41	p.o	_	_	O
42	.	_	_	O

43	or	_	_	O
44	i.v	_	_	O
45	.	_	_	O

46	treosulfan	_	_	O
47	for	_	_	O
48	the	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	relapsed	_	_	O
52	ovarian	_	_	O
53	carcinoma	_	_	O
54	,	_	_	O
55	women	_	_	O
56	aged	_	_	O
57	65	_	_	O
58	years	_	_	O
59	or	_	_	O
60	older	_	_	O
61	were	_	_	O
62	included	_	_	O
63	in	_	_	O
64	this	_	_	O
65	prospective	_	_	O
66	multicenter	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Since	_	_	O
70	elderly	_	_	O
71	patients	_	_	O
72	usually	_	_	O
73	have	_	_	O
74	several	_	_	O
75	concomitant	_	_	O
76	diseases	_	_	O
77	and	_	_	O
78	experience	_	_	O
79	more	_	_	O
80	treatment	_	_	O
81	toxicity	_	_	O
82	,	_	_	O
83	an	_	_	O
84	interim	_	_	O
85	safety	_	_	O
86	analysis	_	_	O
87	was	_	_	O
88	planned	_	_	O
89	and	_	_	O
90	performed	_	_	O
91	after	_	_	O
92	25	_	_	O
93	patients	_	_	O
94	finished	_	_	O
95	therapy	_	_	O
96	to	_	_	O
97	assess	_	_	O
98	the	_	_	O
99	tolerability	_	_	O
100	of	_	_	O
101	the	_	_	O
102	treatment	_	_	O
103	regimens	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	had	_	_	O
107	a	_	_	O
108	free	_	_	O
109	choice	_	_	O
110	of	_	_	O
111	treosulfan	_	_	O
112	i.v	_	_	O
113	.	_	_	O

114	(	_	_	O
115	7,000	_	_	O
116	mg/m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	day	_	_	O
121	1	_	_	O
122	of	_	_	O
123	a	_	_	O
124	28-day	_	_	O
125	cycle	_	_	O
126	)	_	_	O
127	or	_	_	O
128	p.o	_	_	O
129	.	_	_	O

130	(	_	_	O
131	600	_	_	O
132	mg/m	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	day	_	_	O
137	1-28	_	_	O
138	of	_	_	O
139	a	_	_	O
140	56-day	_	_	O
141	cycle	_	_	O
142	)	_	_	O
143	for	_	_	O
144	a	_	_	O
145	maximum	_	_	O
146	of	_	_	O
147	12	_	_	O
148	cycles	_	_	O
149	(	_	_	O
150	i.v	_	_	O
151	.	_	_	O
152	)	_	_	O

153	or	_	_	O
154	12	_	_	O
155	months	_	_	O
156	(	_	_	O
157	p.o	_	_	O
158	.	_	_	O
159	)	_	_	O
160	.	_	_	O

161	Indecisive	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	randomized	_	_	O
165	.	_	_	O

166	Toxicity	_	_	O
167	was	_	_	O
168	evaluated	_	_	O
169	according	_	_	O
170	to	_	_	O
171	the	_	_	O
172	NCI-CTC	_	_	O
173	version	_	_	O
174	2.0	_	_	O
175	.	_	_	O

176	Twenty-five	_	_	O
177	of	_	_	O
178	51	_	_	O
179	recruited	_	_	O
180	patients	_	_	O
181	completed	_	_	O
182	therapy	_	_	O
183	at	_	_	O
184	the	_	_	O
185	time	_	_	O
186	of	_	_	O
187	the	_	_	O
188	planned	_	_	O
189	interim	_	_	O
190	analysis	_	_	O
191	(	_	_	O
192	median	_	_	O
193	age	_	_	O
194	,	_	_	O
195	75	_	_	O
196	years	_	_	O
197	;	_	_	O
198	range	_	_	O
199	,	_	_	O
200	70-82	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Median	_	_	O
204	ECOG	_	_	O
205	was	_	_	O
206	1	_	_	O
207	,	_	_	O
208	and	_	_	O
209	median	_	_	O
210	number	_	_	O
211	of	_	_	O
212	prior	_	_	O
213	chemotherapy	_	_	O
214	regimens	_	_	O
215	was	_	_	O
216	2	_	_	O
217	.	_	_	O

218	A	_	_	O
219	median	_	_	O
220	number	_	_	O
221	of	_	_	O
222	4	_	_	O
223	cycles	_	_	O
224	(	_	_	O
225	range	_	_	O
226	,	_	_	O
227	1-12	_	_	O
228	)	_	_	O
229	were	_	_	O
230	administered	_	_	O
231	per	_	_	O
232	patient	_	_	O
233	.	_	_	O

234	Anemia	_	_	B-Premise
235	was	_	_	I-Premise
236	the	_	_	I-Premise
237	most	_	_	I-Premise
238	common	_	_	I-Premise
239	hematological	_	_	I-Premise
240	toxicity	_	_	I-Premise
241	(	_	_	I-Premise
242	88	_	_	I-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	patients	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Most	_	_	B-Premise
249	frequent	_	_	I-Premise
250	non-hematological	_	_	I-Premise
251	toxicities	_	_	I-Premise
252	were	_	_	I-Premise
253	nausea	_	_	I-Premise
254	(	_	_	I-Premise
255	76	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	constipation	_	_	I-Premise
260	(	_	_	I-Premise
261	68	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	(	_	_	I-Premise
268	64	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	Treatment	_	_	B-Claim
273	was	_	_	I-Claim
274	generally	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	despite	_	_	I-Claim
278	the	_	_	I-Claim
279	fact	_	_	I-Claim
280	that	_	_	I-Claim
281	most	_	_	I-Claim
282	patients	_	_	I-Claim
283	suffered	_	_	I-Claim
284	from	_	_	I-Claim
285	multiple	_	_	I-Claim
286	comorbidities	_	_	I-Claim
287	and	_	_	I-Claim
288	were	_	_	I-Claim
289	heavily	_	_	I-Claim
290	pretreated	_	_	I-Claim
291	.	_	_	I-Claim

292	There	_	_	B-Claim
293	were	_	_	I-Claim
294	no	_	_	I-Claim
295	unexpected	_	_	I-Claim
296	hematological	_	_	I-Claim
297	or	_	_	I-Claim
298	non-hematological	_	_	I-Claim
299	toxicities	_	_	I-Claim
300	.	_	_	I-Claim

301	Based	_	_	O
302	on	_	_	O
303	this	_	_	O
304	safety	_	_	O
305	analysis	_	_	O
306	,	_	_	O
307	the	_	_	O
308	next	_	_	O
309	step	_	_	O
310	of	_	_	O
311	study	_	_	O
312	recruitment	_	_	O
313	was	_	_	O
314	continued	_	_	O
315	.	_	_	O


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	article	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	and	_	_	O
15	menopausal	_	_	O
16	symptoms	_	_	O
17	among	_	_	O
18	premenopausal	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	lymph	_	_	O
22	node-negative	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	receiving	_	_	O
26	chemotherapy	_	_	O
27	,	_	_	O
28	goserelin	_	_	O
29	,	_	_	O
30	or	_	_	O
31	their	_	_	O
32	sequential	_	_	O
33	combination	_	_	O
34	,	_	_	O
35	and	_	_	O
36	to	_	_	O
37	investigate	_	_	O
38	differential	_	_	O
39	effects	_	_	O
40	by	_	_	O
41	age	_	_	O
42	.	_	_	O

43	We	_	_	O
44	evaluated	_	_	O
45	QOL	_	_	O
46	data	_	_	O
47	from	_	_	O
48	874	_	_	O
49	pre-	_	_	O
50	and	_	_	O
51	perimenopausal	_	_	O
52	women	_	_	O
53	with	_	_	O
54	lymph	_	_	O
55	node-negative	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	who	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	six	_	_	O
65	courses	_	_	O
66	of	_	_	O
67	classical	_	_	O
68	cyclophosphamide	_	_	O
69	,	_	_	O
70	methotrexate	_	_	O
71	,	_	_	O
72	and	_	_	O
73	fluorouracil	_	_	O
74	(	_	_	O
75	CMF	_	_	O
76	)	_	_	O
77	chemotherapy	_	_	O
78	,	_	_	O
79	ovarian	_	_	O
80	suppression	_	_	O
81	with	_	_	O
82	goserelin	_	_	O
83	for	_	_	O
84	24	_	_	O
85	months	_	_	O
86	,	_	_	O
87	or	_	_	O
88	six	_	_	O
89	courses	_	_	O
90	of	_	_	O
91	classical	_	_	O
92	CMF	_	_	O
93	followed	_	_	O
94	by	_	_	O
95	18	_	_	O
96	months	_	_	O
97	of	_	_	O
98	goserelin	_	_	O
99	.	_	_	O

100	We	_	_	O
101	report	_	_	O
102	QOL	_	_	O
103	data	_	_	O
104	collected	_	_	O
105	during	_	_	O
106	3	_	_	O
107	years	_	_	O
108	after	_	_	O
109	random	_	_	O
110	assignment	_	_	O
111	in	_	_	O
112	patients	_	_	O
113	without	_	_	O
114	disease	_	_	O
115	recurrence	_	_	O
116	.	_	_	O

117	Overall	_	_	B-Premise
118	,	_	_	I-Premise
119	patients	_	_	I-Premise
120	receiving	_	_	I-Premise
121	goserelin	_	_	I-Premise
122	alone	_	_	I-Premise
123	showed	_	_	I-Premise
124	a	_	_	I-Premise
125	marked	_	_	I-Premise
126	improvement	_	_	I-Premise
127	or	_	_	I-Premise
128	less	_	_	I-Premise
129	deterioration	_	_	I-Premise
130	in	_	_	I-Premise
131	QOL	_	_	I-Premise
132	measures	_	_	I-Premise
133	over	_	_	I-Premise
134	the	_	_	I-Premise
135	first	_	_	I-Premise
136	6	_	_	I-Premise
137	months	_	_	I-Premise
138	than	_	_	I-Premise
139	those	_	_	I-Premise
140	patients	_	_	I-Premise
141	treated	_	_	I-Premise
142	with	_	_	I-Premise
143	CMF	_	_	I-Premise
144	.	_	_	I-Premise

145	There	_	_	B-Premise
146	were	_	_	I-Premise
147	no	_	_	I-Premise
148	differences	_	_	I-Premise
149	at	_	_	I-Premise
150	3	_	_	I-Premise
151	years	_	_	I-Premise
152	after	_	_	I-Premise
153	random	_	_	I-Premise
154	assignment	_	_	I-Premise
155	according	_	_	I-Premise
156	to	_	_	I-Premise
157	treatment	_	_	I-Premise
158	except	_	_	I-Premise
159	for	_	_	I-Premise
160	hot	_	_	I-Premise
161	flashes	_	_	I-Premise
162	.	_	_	I-Premise

163	As	_	_	B-Premise
164	reflected	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	hot	_	_	I-Premise
168	flashes	_	_	I-Premise
169	scores	_	_	I-Premise
170	,	_	_	I-Premise
171	patients	_	_	I-Premise
172	in	_	_	I-Premise
173	all	_	_	I-Premise
174	three	_	_	I-Premise
175	treatment	_	_	I-Premise
176	groups	_	_	I-Premise
177	experienced	_	_	I-Premise
178	induced	_	_	I-Premise
179	amenorrhea	_	_	I-Premise
180	,	_	_	I-Premise
181	but	_	_	B-Premise
182	the	_	_	I-Premise
183	onset	_	_	I-Premise
184	of	_	_	I-Premise
185	ovarian	_	_	I-Premise
186	function	_	_	I-Premise
187	suppression	_	_	I-Premise
188	was	_	_	I-Premise
189	slightly	_	_	I-Premise
190	delayed	_	_	I-Premise
191	for	_	_	I-Premise
192	patients	_	_	I-Premise
193	receiving	_	_	I-Premise
194	chemotherapy	_	_	I-Premise
195	.	_	_	I-Premise

196	Younger	_	_	B-Premise
197	patients	_	_	I-Premise
198	(	_	_	I-Premise
199	<	_	_	I-Premise
200	40	_	_	I-Premise
201	years	_	_	I-Premise
202	)	_	_	I-Premise
203	who	_	_	I-Premise
204	received	_	_	I-Premise
205	goserelin	_	_	I-Premise
206	alone	_	_	I-Premise
207	returned	_	_	I-Premise
208	to	_	_	I-Premise
209	their	_	_	I-Premise
210	premenopausal	_	_	I-Premise
211	status	_	_	I-Premise
212	at	_	_	I-Premise
213	6	_	_	I-Premise
214	months	_	_	I-Premise
215	after	_	_	I-Premise
216	the	_	_	I-Premise
217	cessation	_	_	I-Premise
218	of	_	_	I-Premise
219	therapy	_	_	I-Premise
220	,	_	_	I-Premise
221	while	_	_	I-Premise
222	those	_	_	I-Premise
223	who	_	_	I-Premise
224	received	_	_	I-Premise
225	CMF	_	_	I-Premise
226	showed	_	_	I-Premise
227	marginal	_	_	I-Premise
228	changes	_	_	I-Premise
229	from	_	_	I-Premise
230	their	_	_	I-Premise
231	baseline	_	_	I-Premise
232	hot	_	_	I-Premise
233	flashes	_	_	I-Premise
234	scores	_	_	I-Premise
235	.	_	_	I-Premise

236	Age-adjusted	_	_	B-Claim
237	risk	_	_	I-Claim
238	profiles	_	_	I-Claim
239	that	_	_	I-Claim
240	consider	_	_	I-Claim
241	patient-reported	_	_	I-Claim
242	outcomes	_	_	I-Claim
243	enable	_	_	I-Claim
244	patients	_	_	I-Claim
245	to	_	_	I-Claim
246	adapt	_	_	I-Claim
247	to	_	_	I-Claim
248	their	_	_	I-Claim
249	disease	_	_	I-Claim
250	and	_	_	I-Claim
251	treatment	_	_	I-Claim
252	,	_	_	I-Claim
253	such	_	_	I-Claim
254	as	_	_	I-Claim
255	considering	_	_	I-Claim
256	the	_	_	I-Claim
257	trade-offs	_	_	I-Claim
258	between	_	_	I-Claim
259	delayed	_	_	I-Claim
260	endocrine	_	_	I-Claim
261	symptoms	_	_	I-Claim
262	,	_	_	I-Claim
263	but	_	_	I-Claim
264	higher	_	_	I-Claim
265	risk	_	_	I-Claim
266	of	_	_	I-Claim
267	permanent	_	_	I-Claim
268	menopause	_	_	I-Claim
269	with	_	_	I-Claim
270	chemotherapy	_	_	I-Claim
271	,	_	_	I-Claim
272	and	_	_	I-Claim
273	immediate	_	_	I-Claim
274	but	_	_	I-Claim
275	reversible	_	_	I-Claim
276	endocrine	_	_	I-Claim
277	symptoms	_	_	I-Claim
278	with	_	_	I-Claim
279	goserelin	_	_	I-Claim
280	,	_	_	I-Claim
281	in	_	_	I-Claim
282	younger	_	_	I-Claim
283	premenopausal	_	_	I-Claim
284	patients	_	_	I-Claim
285	.	_	_	I-Claim


0	With	_	_	O
1	the	_	_	O
2	adoption	_	_	O
3	of	_	_	O
4	enhanced	_	_	O
5	recovery	_	_	O
6	and	_	_	O
7	emerging	_	_	O
8	new	_	_	O
9	modalities	_	_	O
10	of	_	_	O
11	analgesia	_	_	O
12	after	_	_	O
13	laparoscopic	_	_	O
14	colorectal	_	_	O
15	resection	_	_	O
16	(	_	_	O
17	LCR	_	_	O
18	)	_	_	O
19	,	_	_	O
20	the	_	_	O
21	role	_	_	O
22	of	_	_	O
23	epidural	_	_	O
24	analgesia	_	_	O
25	has	_	_	O
26	been	_	_	O
27	questioned	_	_	O
28	.	_	_	O

29	This	_	_	O
30	pilot	_	_	O
31	trial	_	_	O
32	assessed	_	_	O
33	the	_	_	O
34	feasibility	_	_	O
35	of	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	trial	_	_	O
40	(	_	_	O
41	RCT	_	_	O
42	)	_	_	O
43	comparing	_	_	O
44	epidural	_	_	O
45	analgesia	_	_	O
46	and	_	_	O
47	use	_	_	O
48	of	_	_	O
49	a	_	_	O
50	local	_	_	O
51	anaesthetic	_	_	O
52	wound	_	_	O
53	infusion	_	_	O
54	catheter	_	_	O
55	(	_	_	O
56	WIC	_	_	O
57	)	_	_	O
58	following	_	_	O
59	LCR	_	_	O
60	.	_	_	O

61	Between	_	_	O
62	April	_	_	O
63	2010	_	_	O
64	and	_	_	O
65	May	_	_	O
66	2011	_	_	O
67	,	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	elective	_	_	O
71	LCR	_	_	O
72	in	_	_	O
73	two	_	_	O
74	centres	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	analgesia	_	_	O
79	via	_	_	O
80	epidural	_	_	O
81	or	_	_	O
82	WIC	_	_	O
83	.	_	_	O

84	Sham	_	_	O
85	procedures	_	_	O
86	were	_	_	O
87	used	_	_	O
88	to	_	_	O
89	blind	_	_	O
90	surgeons	_	_	O
91	,	_	_	O
92	patients	_	_	O
93	and	_	_	O
94	outcome	_	_	O
95	assessors	_	_	O
96	.	_	_	O

97	The	_	_	O
98	primary	_	_	O
99	outcome	_	_	O
100	was	_	_	O
101	the	_	_	O
102	feasibility	_	_	O
103	of	_	_	O
104	a	_	_	O
105	large	_	_	O
106	RCT	_	_	O
107	,	_	_	O
108	and	_	_	O
109	all	_	_	O
110	outcomes	_	_	O
111	for	_	_	O
112	a	_	_	O
113	definitive	_	_	O
114	trial	_	_	O
115	were	_	_	O
116	tested	_	_	O
117	.	_	_	O

118	The	_	_	O
119	success	_	_	O
120	of	_	_	O
121	blinding	_	_	O
122	was	_	_	O
123	assessed	_	_	O
124	using	_	_	O
125	a	_	_	O
126	mixed-methods	_	_	O
127	approach	_	_	O
128	.	_	_	O

129	Forty-five	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	eligible	_	_	O
133	,	_	_	O
134	of	_	_	O
135	whom	_	_	O
136	34	_	_	O
137	were	_	_	O
138	randomized	_	_	O
139	(	_	_	O
140	mean	_	_	O
141	(	_	_	O
142	s.d	_	_	O
143	.	_	_	O
144	)	_	_	O

145	age	_	_	O
146	70	_	_	O
147	(	_	_	O
148	11Â·8	_	_	O
149	)	_	_	O
150	years	_	_	O
151	)	_	_	O
152	.	_	_	O

153	Patients	_	_	O
154	were	_	_	O
155	followed	_	_	O
156	up	_	_	O
157	per-protocol	_	_	O
158	;	_	_	O
159	there	_	_	O
160	were	_	_	O
161	no	_	_	O
162	deaths	_	_	O
163	,	_	_	O
164	and	_	_	O
165	five	_	_	O
166	patients	_	_	O
167	had	_	_	O
168	a	_	_	O
169	total	_	_	O
170	of	_	_	O
171	six	_	_	O
172	complications	_	_	O
173	.	_	_	O

174	Challenges	_	_	O
175	with	_	_	O
176	capturing	_	_	O
177	pain	_	_	O
178	data	_	_	O
179	were	_	_	O
180	identified	_	_	O
181	and	_	_	O
182	resolved	_	_	O
183	.	_	_	O

184	Mean	_	_	B-Premise
185	(	_	_	I-Premise
186	s.d	_	_	I-Premise
187	.	_	_	I-Premise
188	)	_	_	I-Premise

189	pain	_	_	I-Premise
190	scores	_	_	I-Premise
191	on	_	_	I-Premise
192	the	_	_	I-Premise
193	day	_	_	I-Premise
194	of	_	_	I-Premise
195	discharge	_	_	I-Premise
196	were	_	_	I-Premise
197	1Â·9	_	_	I-Premise
198	(	_	_	I-Premise
199	3Â·1	_	_	I-Premise
200	)	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	epidural	_	_	I-Premise
204	group	_	_	I-Premise
205	and	_	_	I-Premise
206	0Â·7	_	_	I-Premise
207	(	_	_	I-Premise
208	0Â·7	_	_	I-Premise
209	)	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	WIC	_	_	I-Premise
213	group	_	_	I-Premise
214	.	_	_	I-Premise

215	Median	_	_	B-Premise
216	length	_	_	I-Premise
217	of	_	_	I-Premise
218	stay	_	_	I-Premise
219	was	_	_	I-Premise
220	4	_	_	I-Premise
221	(	_	_	I-Premise
222	range	_	_	I-Premise
223	2-35	_	_	I-Premise
224	,	_	_	I-Premise
225	interquartile	_	_	I-Premise
226	range	_	_	I-Premise
227	3-5	_	_	I-Premise
228	)	_	_	I-Premise
229	days	_	_	I-Premise
230	.	_	_	I-Premise

231	Mean	_	_	B-Premise
232	use	_	_	I-Premise
233	of	_	_	I-Premise
234	additional	_	_	I-Premise
235	analgesia	_	_	I-Premise
236	(	_	_	I-Premise
237	intravenous	_	_	I-Premise
238	morphine	_	_	I-Premise
239	equivalents	_	_	I-Premise
240	)	_	_	I-Premise
241	was	_	_	I-Premise
242	12	_	_	I-Premise
243	mg	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	WIC	_	_	I-Premise
247	arm	_	_	I-Premise
248	and	_	_	I-Premise
249	9	_	_	I-Premise
250	mg	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	epidural	_	_	I-Premise
254	arm	_	_	I-Premise
255	.	_	_	I-Premise

256	Patient	_	_	O
257	blinding	_	_	O
258	was	_	_	O
259	successful	_	_	O
260	in	_	_	O
261	both	_	_	O
262	arms	_	_	O
263	.	_	_	O

264	Qualitative	_	_	B-Claim
265	interviews	_	_	I-Claim
266	suggested	_	_	I-Claim
267	that	_	_	I-Claim
268	patients	_	_	I-Claim
269	found	_	_	I-Claim
270	participation	_	_	I-Claim
271	in	_	_	I-Claim
272	the	_	_	I-Claim
273	trial	_	_	I-Claim
274	acceptable	_	_	I-Claim
275	and	_	_	I-Claim
276	that	_	_	I-Claim
277	they	_	_	I-Claim
278	would	_	_	I-Claim
279	consider	_	_	I-Claim
280	participating	_	_	I-Claim
281	in	_	_	I-Claim
282	a	_	_	I-Claim
283	future	_	_	I-Claim
284	trial	_	_	I-Claim
285	.	_	_	I-Claim

286	A	_	_	B-Claim
287	blinded	_	_	I-Claim
288	RCT	_	_	I-Claim
289	investigating	_	_	I-Claim
290	the	_	_	I-Claim
291	role	_	_	I-Claim
292	of	_	_	I-Claim
293	epidural	_	_	I-Claim
294	and	_	_	I-Claim
295	WIC	_	_	I-Claim
296	administration	_	_	I-Claim
297	for	_	_	I-Claim
298	postoperative	_	_	I-Claim
299	analgesia	_	_	I-Claim
300	following	_	_	I-Claim
301	LCR	_	_	I-Claim
302	is	_	_	I-Claim
303	feasible	_	_	I-Claim
304	.	_	_	I-Claim

305	Rigorous	_	_	B-Claim
306	standard	_	_	I-Claim
307	operating	_	_	I-Claim
308	procedures	_	_	I-Claim
309	for	_	_	I-Claim
310	data	_	_	I-Claim
311	collection	_	_	I-Claim
312	are	_	_	I-Claim
313	required	_	_	I-Claim
314	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	previous	_	_	O
3	study	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	for	_	_	O
7	advanced	_	_	O
8	colorectal	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	the	_	_	O
12	LV5FU2	_	_	O
13	regimen	_	_	O
14	,	_	_	O
15	comprising	_	_	O
16	leucovorin	_	_	O
17	(	_	_	O
18	LV	_	_	O
19	)	_	_	O
20	plus	_	_	O
21	bolus	_	_	O
22	and	_	_	O
23	infusional	_	_	O
24	fluorouracil	_	_	O
25	(	_	_	O
26	5FU	_	_	O
27	)	_	_	O
28	every	_	_	O
29	2	_	_	O
30	weeks	_	_	O
31	,	_	_	O
32	was	_	_	O
33	superior	_	_	O
34	to	_	_	O
35	the	_	_	O
36	standard	_	_	O
37	North	_	_	O
38	Central	_	_	O
39	Cancer	_	_	O
40	Treatment	_	_	O
41	Group/Mayo	_	_	O
42	Clinic	_	_	O
43	5-day	_	_	O
44	bolus	_	_	O
45	5FU/LV	_	_	O
46	regimen	_	_	O
47	.	_	_	O

48	This	_	_	O
49	phase	_	_	O
50	III	_	_	O
51	study	_	_	O
52	investigated	_	_	O
53	the	_	_	O
54	effect	_	_	O
55	of	_	_	O
56	combining	_	_	O
57	oxaliplatin	_	_	O
58	with	_	_	O
59	LV5FU2	_	_	O
60	,	_	_	O
61	with	_	_	O
62	progression-free	_	_	O
63	survival	_	_	O
64	as	_	_	O
65	the	_	_	O
66	primary	_	_	O
67	end	_	_	O
68	point	_	_	O
69	.	_	_	O

70	Four	_	_	O
71	hundred	_	_	O
72	twenty	_	_	O
73	previously	_	_	O
74	untreated	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	measurable	_	_	O
78	disease	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	a	_	_	O
84	2-hour	_	_	O
85	infusion	_	_	O
86	of	_	_	O
87	LV	_	_	O
88	(	_	_	O
89	200	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	/d	_	_	O
95	)	_	_	O
96	followed	_	_	O
97	by	_	_	O
98	a	_	_	O
99	5FU	_	_	O
100	bolus	_	_	O
101	(	_	_	O
102	400	_	_	O
103	mg/m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	/d	_	_	O
108	)	_	_	O
109	and	_	_	O
110	22-hour	_	_	O
111	infusion	_	_	O
112	(	_	_	O
113	600	_	_	O
114	mg/m	_	_	O
115	(	_	_	O
116	2	_	_	O
117	)	_	_	O
118	/d	_	_	O
119	)	_	_	O
120	for	_	_	O
121	2	_	_	O
122	consecutive	_	_	O
123	days	_	_	O
124	every	_	_	O
125	2	_	_	O
126	weeks	_	_	O
127	,	_	_	O
128	either	_	_	O
129	alone	_	_	O
130	or	_	_	O
131	together	_	_	O
132	with	_	_	O
133	oxaliplatin	_	_	O
134	85	_	_	O
135	mg/m	_	_	O
136	(	_	_	O
137	2	_	_	O
138	)	_	_	O
139	as	_	_	O
140	a	_	_	O
141	2-hour	_	_	O
142	infusion	_	_	O
143	on	_	_	O
144	day	_	_	O
145	1	_	_	O
146	.	_	_	O

147	Patients	_	_	B-Premise
148	allocated	_	_	I-Premise
149	to	_	_	I-Premise
150	oxaliplatin	_	_	I-Premise
151	plus	_	_	I-Premise
152	LV5FU2	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	longer	_	_	I-Premise
156	progression-free	_	_	I-Premise
157	survival	_	_	I-Premise
158	(	_	_	I-Premise
159	median	_	_	I-Premise
160	,	_	_	I-Premise
161	9.0	_	_	I-Premise
162	v	_	_	I-Premise
163	6.2	_	_	I-Premise
164	months	_	_	I-Premise
165	;	_	_	I-Premise
166	P	_	_	I-Premise
167	=.0003	_	_	I-Premise
168	)	_	_	I-Premise
169	and	_	_	I-Premise
170	better	_	_	I-Premise
171	response	_	_	I-Premise
172	rate	_	_	I-Premise
173	(	_	_	I-Premise
174	50.7	_	_	I-Premise
175	%	_	_	I-Premise
176	v	_	_	I-Premise
177	22.3	_	_	I-Premise
178	%	_	_	I-Premise
179	;	_	_	I-Premise
180	P	_	_	I-Premise
181	=.0001	_	_	I-Premise
182	)	_	_	I-Premise
183	when	_	_	I-Premise
184	compared	_	_	I-Premise
185	with	_	_	I-Premise
186	the	_	_	I-Premise
187	control	_	_	I-Premise
188	arm	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	improvement	_	_	I-Premise
192	in	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	did	_	_	I-Premise
196	not	_	_	I-Premise
197	reach	_	_	I-Premise
198	significance	_	_	I-Premise
199	(	_	_	I-Premise
200	median	_	_	I-Premise
201	,	_	_	I-Premise
202	16.2	_	_	I-Premise
203	v	_	_	I-Premise
204	14.7	_	_	I-Premise
205	months	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.	_	_	I-Premise

210	12	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	LV5FU2	_	_	B-Premise
214	plus	_	_	I-Premise
215	oxaliplatin	_	_	I-Premise
216	gave	_	_	I-Premise
217	higher	_	_	I-Premise
218	frequencies	_	_	I-Premise
219	of	_	_	I-Premise
220	National	_	_	I-Premise
221	Cancer	_	_	I-Premise
222	Institute	_	_	I-Premise
223	common	_	_	I-Premise
224	toxicity	_	_	I-Premise
225	criteria	_	_	I-Premise
226	grade	_	_	I-Premise
227	3/4	_	_	I-Premise
228	neutropenia	_	_	I-Premise
229	(	_	_	I-Premise
230	41	_	_	I-Premise
231	.	_	_	I-Premise

232	7	_	_	I-Premise
233	%	_	_	I-Premise
234	v	_	_	I-Premise
235	5.3	_	_	I-Premise
236	%	_	_	I-Premise
237	of	_	_	I-Premise
238	patients	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	grade	_	_	I-Premise
242	3/4	_	_	I-Premise
243	diarrhea	_	_	I-Premise
244	(	_	_	I-Premise
245	11.9	_	_	I-Premise
246	%	_	_	I-Premise
247	v	_	_	I-Premise
248	5.3	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	grade	_	_	I-Premise
254	3	_	_	I-Premise
255	neurosensory	_	_	I-Premise
256	toxicity	_	_	I-Premise
257	(	_	_	I-Premise
258	18.2	_	_	I-Premise
259	%	_	_	I-Premise
260	v	_	_	I-Premise
261	0	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	but	_	_	I-Premise
266	this	_	_	I-Premise
267	did	_	_	I-Premise
268	not	_	_	I-Premise
269	result	_	_	I-Premise
270	in	_	_	I-Premise
271	impairment	_	_	I-Premise
272	of	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	(	_	_	I-Premise
277	QoL	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Survival	_	_	B-Premise
281	without	_	_	I-Premise
282	disease	_	_	I-Premise
283	progression	_	_	I-Premise
284	or	_	_	I-Premise
285	deterioration	_	_	I-Premise
286	in	_	_	I-Premise
287	global	_	_	I-Premise
288	health	_	_	I-Premise
289	status	_	_	I-Premise
290	was	_	_	I-Premise
291	longer	_	_	I-Premise
292	in	_	_	I-Premise
293	patients	_	_	I-Premise
294	allocated	_	_	I-Premise
295	to	_	_	I-Premise
296	oxaliplatin	_	_	I-Premise
297	treatment	_	_	I-Premise
298	(	_	_	I-Premise
299	P	_	_	I-Premise
300	=.004	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Claim
304	LV5FU2-oxaliplatin	_	_	I-Claim
305	combination	_	_	I-Claim
306	seems	_	_	I-Claim
307	beneficial	_	_	I-Claim
308	as	_	_	I-Claim
309	first-line	_	_	I-Claim
310	therapy	_	_	I-Claim
311	in	_	_	I-Claim
312	advanced	_	_	I-Claim
313	colorectal	_	_	I-Claim
314	cancer	_	_	I-Claim
315	,	_	_	I-Claim
316	demonstrating	_	_	I-Claim
317	a	_	_	I-Claim
318	prolonged	_	_	I-Claim
319	progression-free	_	_	I-Claim
320	survival	_	_	I-Claim
321	with	_	_	I-Claim
322	acceptable	_	_	I-Claim
323	tolerability	_	_	I-Claim
324	and	_	_	I-Claim
325	maintenance	_	_	I-Claim
326	of	_	_	I-Claim
327	QoL	_	_	I-Claim
328	.	_	_	I-Claim


0	Few	_	_	O
1	reports	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	use	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	thyroid-stimulating	_	_	O
10	hormone	_	_	O
11	(	_	_	O
12	rhTSH	_	_	O
13	)	_	_	O
14	for	_	_	O
15	ablation	_	_	O
16	of	_	_	O
17	postsurgical	_	_	O
18	thyroid	_	_	O
19	remnants	_	_	O
20	after	_	_	O
21	low-dose	_	_	O
22	radioactive	_	_	O
23	iodine	_	_	O
24	(	_	_	O
25	RI	_	_	O
26	)	_	_	O
27	therapy	_	_	O
28	,	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	conventional	_	_	O
32	thyroid	_	_	O
33	hormone	_	_	O
34	withdrawal	_	_	O
35	.	_	_	O

36	We	_	_	O
37	investigated	_	_	O
38	whether	_	_	O
39	patient	_	_	O
40	preparation	_	_	O
41	using	_	_	O
42	rhTSH	_	_	O
43	was	_	_	O
44	comparable	_	_	O
45	to	_	_	O
46	conventional	_	_	O
47	thyroid	_	_	O
48	hormone	_	_	O
49	withdrawal	_	_	O
50	with	_	_	O
51	respect	_	_	O
52	to	_	_	O
53	efficacy	_	_	O
54	of	_	_	O
55	postsurgical	_	_	O
56	remnant	_	_	O
57	ablation	_	_	O
58	in	_	_	O
59	low-risk	_	_	O
60	patients	_	_	O
61	receiving	_	_	O
62	a	_	_	O
63	30	_	_	O
64	mCi	_	_	O
65	RI	_	_	O
66	.	_	_	O

67	In	_	_	O
68	addition	_	_	O
69	,	_	_	O
70	we	_	_	O
71	also	_	_	O
72	evaluated	_	_	O
73	the	_	_	O
74	impact	_	_	O
75	of	_	_	O
76	rhTSH	_	_	O
77	(	_	_	O
78	rhTSH	_	_	O
79	vs.	_	_	O
80	conventional	_	_	O
81	thyroid	_	_	O
82	hormone	_	_	O
83	withdrawal	_	_	O
84	)	_	_	O
85	on	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	(	_	_	O
90	QoL	_	_	O
91	)	_	_	O
92	of	_	_	O
93	thyroid	_	_	O
94	cancer	_	_	O
95	patients	_	_	O
96	undergoing	_	_	O
97	RI	_	_	O
98	ablation	_	_	O
99	.	_	_	O

100	This	_	_	O
101	study	_	_	O
102	included	_	_	O
103	three	_	_	O
104	groups	_	_	O
105	of	_	_	O
106	patients	_	_	O
107	,	_	_	O
108	enrolled	_	_	O
109	consecutively	_	_	O
110	.	_	_	O

111	From	_	_	O
112	February	_	_	O
113	2006	_	_	O
114	to	_	_	O
115	March	_	_	O
116	2007	_	_	O
117	,	_	_	O
118	291	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	enrolled	_	_	O
122	and	_	_	O
123	randomized	_	_	O
124	,	_	_	O
125	after	_	_	O
126	total	_	_	O
127	thyroidectomy	_	_	O
128	:	_	_	O
129	(	_	_	O
130	1	_	_	O
131	)	_	_	O
132	withdrawal	_	_	O
133	of	_	_	O
134	levothyroxine	_	_	O
135	(	_	_	O
136	LT4	_	_	O
137	)	_	_	O
138	for	_	_	O
139	4	_	_	O
140	weeks	_	_	O
141	(	_	_	O
142	T4-WD	_	_	O
143	Group	_	_	O
144	,	_	_	O
145	n	_	_	O
146	=	_	_	O
147	89	_	_	O
148	)	_	_	O
149	,	_	_	O
150	(	_	_	O
151	2	_	_	O
152	)	_	_	O
153	withdrawal	_	_	O
154	of	_	_	O
155	LT4	_	_	O
156	for	_	_	O
157	4	_	_	O
158	weeks	_	_	O
159	plus	_	_	O
160	2	_	_	O
161	weeks	_	_	O
162	on	_	_	O
163	and	_	_	O
164	then	_	_	O
165	2	_	_	O
166	weeks	_	_	O
167	off	_	_	O
168	liothyronine	_	_	O
169	(	_	_	O
170	LT3	_	_	O
171	)	_	_	O
172	(	_	_	O
173	T3-WD	_	_	O
174	Group	_	_	O
175	,	_	_	O
176	n	_	_	O
177	=	_	_	O
178	133	_	_	O
179	)	_	_	O
180	,	_	_	O
181	and	_	_	O
182	(	_	_	O
183	3	_	_	O
184	)	_	_	O
185	rhTSH	_	_	O
186	administration	_	_	O
187	(	_	_	O
188	rhTSH	_	_	O
189	Group	_	_	O
190	,	_	_	O
191	n	_	_	O
192	=	_	_	O
193	69	_	_	O
194	)	_	_	O
195	.	_	_	O

196	QoL	_	_	O
197	was	_	_	O
198	determined	_	_	O
199	at	_	_	O
200	the	_	_	O
201	time	_	_	O
202	of	_	_	O
203	ablation	_	_	O
204	.	_	_	O

205	Patients	_	_	O
206	in	_	_	O
207	the	_	_	O
208	three	_	_	O
209	groups	_	_	O
210	did	_	_	O
211	not	_	_	O
212	differ	_	_	O
213	significantly	_	_	O
214	in	_	_	O
215	baseline	_	_	O
216	characteristics	_	_	O
217	or	_	_	O
218	tumor	_	_	O
219	,	_	_	O
220	node	_	_	O
221	and	_	_	O
222	metastasis	_	_	O
223	(	_	_	O
224	TNM	_	_	O
225	)	_	_	O
226	staging	_	_	O
227	.	_	_	O

228	In	_	_	B-Premise
229	all	_	_	I-Premise
230	study	_	_	I-Premise
231	groups	_	_	I-Premise
232	,	_	_	I-Premise
233	serum	_	_	I-Premise
234	TSH	_	_	I-Premise
235	levels	_	_	I-Premise
236	showed	_	_	I-Premise
237	very	_	_	I-Premise
238	good	_	_	I-Premise
239	stimulation	_	_	I-Premise
240	(	_	_	I-Premise
241	mean	_	_	I-Premise
242	,	_	_	I-Premise
243	82.24	_	_	I-Premise
244	+/-	_	_	I-Premise
245	18.21	_	_	I-Premise
246	mU/L	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	without	_	_	I-Premise
250	significant	_	_	I-Premise
251	between-group	_	_	I-Premise
252	differences	_	_	I-Premise
253	(	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0.5213	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Follow-up	_	_	O
260	examinations	_	_	O
261	were	_	_	O
262	performed	_	_	O
263	12	_	_	O
264	months	_	_	O
265	after	_	_	O
266	ablation	_	_	O
267	to	_	_	O
268	assess	_	_	O
269	ablation	_	_	O
270	outcome	_	_	O
271	in	_	_	O
272	each	_	_	O
273	group	_	_	O
274	by	_	_	O
275	131	_	_	O
276	whole	_	_	O
277	body	_	_	O
278	scans	_	_	O
279	(	_	_	O
280	WBSs	_	_	O
281	)	_	_	O
282	,	_	_	O
283	serum	_	_	O
284	thyroglobulin	_	_	O
285	measurement	_	_	O
286	after	_	_	O
287	TSH	_	_	O
288	stimulation	_	_	O
289	,	_	_	O
290	and	_	_	O
291	neck	_	_	O
292	ultrasonography	_	_	O
293	.	_	_	O

294	The	_	_	B-Premise
295	successful	_	_	I-Premise
296	ablation	_	_	I-Premise
297	rate	_	_	I-Premise
298	was	_	_	I-Premise
299	91.0	_	_	I-Premise
300	%	_	_	I-Premise
301	in	_	_	I-Premise
302	T4-WD	_	_	I-Premise
303	Group	_	_	I-Premise
304	,	_	_	I-Premise
305	91.7	_	_	I-Premise
306	%	_	_	I-Premise
307	in	_	_	I-Premise
308	T3-WD	_	_	I-Premise
309	Group	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	91.3	_	_	I-Premise
313	%	_	_	I-Premise
314	in	_	_	I-Premise
315	rhTSH	_	_	I-Premise
316	Group	_	_	I-Premise
317	,	_	_	I-Premise
318	without	_	_	I-Premise
319	significant	_	_	I-Premise
320	between-preparation	_	_	I-Premise
321	differences	_	_	I-Premise
322	(	_	_	I-Premise
323	p	_	_	I-Premise
324	=	_	_	I-Premise
325	0.2061	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	QoL	_	_	B-Premise
329	was	_	_	I-Premise
330	better	_	_	I-Premise
331	preserved	_	_	I-Premise
332	in	_	_	I-Premise
333	rhTSH	_	_	I-Premise
334	Group	_	_	I-Premise
335	than	_	_	I-Premise
336	in	_	_	I-Premise
337	T4-WD	_	_	I-Premise
338	and	_	_	I-Premise
339	T3-WD	_	_	I-Premise
340	Groups	_	_	I-Premise
341	(	_	_	I-Premise
342	p	_	_	I-Premise
343	<	_	_	I-Premise
344	0.0001	_	_	I-Premise
345	)	_	_	I-Premise
346	.	_	_	I-Premise

347	However	_	_	B-Premise
348	,	_	_	I-Premise
349	there	_	_	I-Premise
350	was	_	_	I-Premise
351	no	_	_	I-Premise
352	QoL	_	_	I-Premise
353	difference	_	_	I-Premise
354	at	_	_	I-Premise
355	the	_	_	I-Premise
356	time	_	_	I-Premise
357	of	_	_	I-Premise
358	ablation	_	_	I-Premise
359	between	_	_	I-Premise
360	T4-WD	_	_	I-Premise
361	and	_	_	I-Premise
362	T3-WD	_	_	I-Premise
363	Groups	_	_	I-Premise
364	.	_	_	I-Premise

365	Our	_	_	B-Claim
366	study	_	_	I-Claim
367	indicates	_	_	I-Claim
368	that	_	_	I-Claim
369	use	_	_	I-Claim
370	of	_	_	I-Claim
371	rhTSH	_	_	I-Claim
372	preserves	_	_	I-Claim
373	QoL	_	_	I-Claim
374	in	_	_	I-Claim
375	patients	_	_	I-Claim
376	undergoing	_	_	I-Claim
377	RI	_	_	I-Claim
378	ablation	_	_	I-Claim
379	and	_	_	I-Claim
380	affords	_	_	I-Claim
381	an	_	_	I-Claim
382	ablation	_	_	I-Claim
383	success	_	_	I-Claim
384	rate	_	_	I-Claim
385	comparable	_	_	I-Claim
386	to	_	_	I-Claim
387	that	_	_	I-Claim
388	seen	_	_	I-Claim
389	after	_	_	I-Claim
390	thyroid	_	_	I-Claim
391	hormone	_	_	I-Claim
392	withdrawal	_	_	I-Claim
393	.	_	_	I-Claim

394	Notably	_	_	O
395	,	_	_	O
396	ablation	_	_	O
397	preparation	_	_	O
398	using	_	_	O
399	withdrawal	_	_	O
400	of	_	_	O
401	LT3	_	_	O
402	for	_	_	O
403	2	_	_	O
404	weeks	_	_	O
405	did	_	_	O
406	not	_	_	O
407	prevent	_	_	O
408	development	_	_	O
409	of	_	_	O
410	profound	_	_	O
411	hypothyroidism	_	_	O
412	,	_	_	O
413	as	_	_	O
414	also	_	_	O
415	occurred	_	_	O
416	when	_	_	O
417	LT4	_	_	O
418	alone	_	_	O
419	was	_	_	O
420	withdrawn	_	_	O
421	for	_	_	O
422	4	_	_	O
423	weeks	_	_	O
424	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	an	_	_	O
4	Internet-based	_	_	B-Claim
5	tailored	_	_	I-Claim
6	education	_	_	I-Claim
7	program	_	_	I-Claim
8	is	_	_	I-Claim
9	effective	_	_	I-Claim
10	for	_	_	I-Claim
11	disease-free	_	_	I-Claim
12	cancer	_	_	I-Claim
13	survivors	_	_	I-Claim
14	with	_	_	I-Claim
15	cancer-related	_	_	I-Claim
16	fatigue	_	_	I-Claim
17	(	_	_	I-Claim
18	CRF	_	_	I-Claim
19	)	_	_	I-Claim
20	.	_	_	I-Claim

21	We	_	_	O
22	randomly	_	_	O
23	assigned	_	_	O
24	patients	_	_	O
25	who	_	_	O
26	had	_	_	O
27	completed	_	_	O
28	primary	_	_	O
29	cancer	_	_	O
30	treatment	_	_	O
31	within	_	_	O
32	the	_	_	O
33	past	_	_	O
34	24	_	_	O
35	months	_	_	O
36	in	_	_	O
37	any	_	_	O
38	of	_	_	O
39	four	_	_	O
40	Korean	_	_	O
41	hospitals	_	_	O
42	and	_	_	O
43	had	_	_	O
44	reported	_	_	O
45	moderate	_	_	O
46	to	_	_	O
47	severe	_	_	O
48	fatigue	_	_	O
49	for	_	_	O
50	at	_	_	O
51	least	_	_	O
52	1	_	_	O
53	week	_	_	O
54	to	_	_	O
55	participate	_	_	O
56	in	_	_	O
57	a	_	_	O
58	12-week	_	_	O
59	,	_	_	O
60	Internet-based	_	_	O
61	,	_	_	O
62	individually	_	_	O
63	tailored	_	_	O
64	CRF	_	_	O
65	education	_	_	O
66	program	_	_	O
67	or	_	_	O
68	to	_	_	O
69	receive	_	_	O
70	routine	_	_	O
71	care	_	_	O
72	.	_	_	O

73	We	_	_	O
74	based	_	_	O
75	the	_	_	O
76	program	_	_	O
77	on	_	_	O
78	the	_	_	O
79	CRF	_	_	O
80	guidelines	_	_	O
81	of	_	_	O
82	the	_	_	O
83	National	_	_	O
84	Comprehensive	_	_	O
85	Cancer	_	_	O
86	Network	_	_	O
87	(	_	_	O
88	NCCN	_	_	O
89	)	_	_	O
90	and	_	_	O
91	incorporated	_	_	O
92	the	_	_	O
93	transtheoretic	_	_	O
94	model	_	_	O
95	(	_	_	O
96	TTM	_	_	O
97	)	_	_	O
98	.	_	_	O

99	At	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	,	_	_	O
105	we	_	_	O
106	used	_	_	O
107	the	_	_	O
108	Brief	_	_	O
109	Fatigue	_	_	O
110	Inventory	_	_	O
111	(	_	_	O
112	BFI	_	_	O
113	)	_	_	O
114	and	_	_	O
115	Fatigue	_	_	O
116	Severity	_	_	O
117	Scale	_	_	O
118	(	_	_	O
119	FSS	_	_	O
120	)	_	_	O
121	as	_	_	O
122	primary	_	_	O
123	outcomes	_	_	O
124	and	_	_	O
125	the	_	_	O
126	Hospital	_	_	O
127	Anxiety	_	_	O
128	and	_	_	O
129	Depression	_	_	O
130	Scale	_	_	O
131	(	_	_	O
132	HADS	_	_	O
133	)	_	_	O
134	and	_	_	O
135	European	_	_	O
136	Organisation	_	_	O
137	for	_	_	O
138	Research	_	_	O
139	and	_	_	O
140	Treatment	_	_	O
141	of	_	_	O
142	Cancer	_	_	O
143	Quality	_	_	O
144	of	_	_	O
145	Life	_	_	O
146	Questionnaire	_	_	O
147	C30	_	_	O
148	(	_	_	O
149	EORTC	_	_	O
150	QLQ-C30	_	_	O
151	)	_	_	O
152	for	_	_	O
153	secondary	_	_	O
154	outcomes	_	_	O
155	.	_	_	O

156	We	_	_	O
157	recruited	_	_	O
158	273	_	_	O
159	participants	_	_	O
160	and	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	136	_	_	O
164	to	_	_	O
165	the	_	_	O
166	intervention	_	_	O
167	group	_	_	O
168	.	_	_	O

169	Compared	_	_	B-Premise
170	with	_	_	I-Premise
171	the	_	_	I-Premise
172	control	_	_	I-Premise
173	group	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	intervention	_	_	I-Premise
177	group	_	_	I-Premise
178	had	_	_	I-Premise
179	an	_	_	I-Premise
180	improvement	_	_	I-Premise
181	in	_	_	I-Premise
182	fatigue	_	_	I-Premise
183	as	_	_	I-Premise
184	shown	_	_	I-Premise
185	by	_	_	I-Premise
186	a	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	decrease	_	_	I-Premise
190	in	_	_	I-Premise
191	BFI	_	_	I-Premise
192	global	_	_	I-Premise
193	score	_	_	I-Premise
194	(	_	_	I-Premise
195	-0.66	_	_	I-Premise
196	points	_	_	I-Premise
197	;	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	-1.04	_	_	I-Premise
202	to	_	_	I-Premise
203	-0.27	_	_	I-Premise
204	)	_	_	I-Premise
205	and	_	_	I-Premise
206	FSS	_	_	I-Premise
207	total	_	_	I-Premise
208	score	_	_	I-Premise
209	(	_	_	I-Premise
210	-0.49	_	_	I-Premise
211	;	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	CI	_	_	I-Premise
215	,	_	_	I-Premise
216	-0.78	_	_	I-Premise
217	to	_	_	I-Premise
218	-0.21	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	In	_	_	B-Premise
222	secondary	_	_	I-Premise
223	outcomes	_	_	I-Premise
224	,	_	_	I-Premise
225	the	_	_	I-Premise
226	intervention	_	_	I-Premise
227	group	_	_	I-Premise
228	experienced	_	_	I-Premise
229	a	_	_	I-Premise
230	significantly	_	_	I-Premise
231	greater	_	_	I-Premise
232	decrease	_	_	I-Premise
233	in	_	_	I-Premise
234	HADS	_	_	I-Premise
235	anxiety	_	_	I-Premise
236	score	_	_	I-Premise
237	(	_	_	I-Premise
238	-0.90	_	_	I-Premise
239	;	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	,	_	_	I-Premise
244	-1.51	_	_	I-Premise
245	to	_	_	I-Premise
246	-0.29	_	_	I-Premise
247	)	_	_	I-Premise
248	as	_	_	I-Premise
249	well	_	_	I-Premise
250	as	_	_	I-Premise
251	global	_	_	I-Premise
252	quality	_	_	I-Premise
253	of	_	_	I-Premise
254	life	_	_	I-Premise
255	(	_	_	I-Premise
256	5.22	_	_	I-Premise
257	;	_	_	I-Premise
258	95	_	_	I-Premise
259	%	_	_	I-Premise
260	CI	_	_	I-Premise
261	,	_	_	I-Premise
262	0.93	_	_	I-Premise
263	to	_	_	I-Premise
264	9.50	_	_	I-Premise
265	)	_	_	I-Premise
266	and	_	_	I-Premise
267	several	_	_	I-Premise
268	functioning	_	_	I-Premise
269	scores	_	_	I-Premise
270	of	_	_	I-Premise
271	the	_	_	I-Premise
272	EORTC	_	_	I-Premise
273	QLQ-C30	_	_	I-Premise
274	.	_	_	I-Premise

275	An	_	_	B-Claim
276	Internet-based	_	_	I-Claim
277	education	_	_	I-Claim
278	program	_	_	I-Claim
279	based	_	_	I-Claim
280	on	_	_	I-Claim
281	NCCN	_	_	I-Claim
282	guidelines	_	_	I-Claim
283	and	_	_	I-Claim
284	TTM	_	_	I-Claim
285	may	_	_	I-Claim
286	help	_	_	I-Claim
287	patients	_	_	I-Claim
288	manage	_	_	I-Claim
289	CRF	_	_	I-Claim
290	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QOL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	high-risk	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	patients	_	_	O
20	included	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	(	_	_	O
27	PEGASE	_	_	O
28	01	_	_	O
29	)	_	_	O
30	comparing	_	_	O
31	conventional	_	_	O
32	chemotherapy	_	_	O
33	versus	_	_	O
34	adding	_	_	O
35	an	_	_	O
36	additional	_	_	O
37	high-dose	_	_	O
38	chemotherapy	_	_	O
39	(	_	_	O
40	HDC	_	_	O
41	)	_	_	O
42	cycle	_	_	O
43	with	_	_	O
44	blood	_	_	O
45	stem	_	_	O
46	cell	_	_	O
47	support	_	_	O
48	.	_	_	O

49	A	_	_	O
50	total	_	_	O
51	of	_	_	O
52	314	_	_	O
53	patients	_	_	O
54	were	_	_	O
55	included	_	_	O
56	in	_	_	O
57	the	_	_	O
58	clinical	_	_	O
59	trial	_	_	O
60	.	_	_	O

61	QOL	_	_	O
62	evaluations	_	_	O
63	were	_	_	O
64	available	_	_	O
65	for	_	_	O
66	199	_	_	O
67	patients	_	_	O
68	.	_	_	O

69	QOL	_	_	O
70	was	_	_	O
71	assessed	_	_	O
72	over	_	_	O
73	a	_	_	O
74	1-year	_	_	O
75	follow-up	_	_	O
76	period	_	_	O
77	,	_	_	O
78	using	_	_	O
79	the	_	_	O
80	European	_	_	O
81	Organization	_	_	O
82	for	_	_	O
83	Research	_	_	O
84	and	_	_	O
85	Treatment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	Quality	_	_	O
89	of	_	_	O
90	Life	_	_	O
91	Questionnaire	_	_	O
92	C-30	_	_	O
93	.	_	_	O

94	The	_	_	O
95	results	_	_	O
96	were	_	_	O
97	analyzed	_	_	O
98	using	_	_	O
99	a	_	_	O
100	linear	_	_	O
101	mixed-effects	_	_	O
102	model	_	_	O
103	.	_	_	O

104	Toxicity	_	_	B-Premise
105	of	_	_	I-Premise
106	HDC	_	_	I-Premise
107	has	_	_	I-Premise
108	a	_	_	I-Premise
109	strong	_	_	I-Premise
110	negative	_	_	I-Premise
111	impact	_	_	I-Premise
112	on	_	_	I-Premise
113	patients	_	_	I-Premise
114	'	_	_	I-Premise
115	QOL	_	_	I-Premise
116	during	_	_	I-Premise
117	the	_	_	I-Premise
118	treatment	_	_	I-Premise
119	phase	_	_	I-Premise
120	.	_	_	I-Premise

121	This	_	_	B-Premise
122	negative	_	_	I-Premise
123	impact	_	_	I-Premise
124	tended	_	_	I-Premise
125	to	_	_	I-Premise
126	last	_	_	I-Premise
127	longer	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	HDC	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	as	_	_	I-Premise
134	for	_	_	I-Premise
135	most	_	_	I-Premise
136	of	_	_	I-Premise
137	the	_	_	I-Premise
138	QLQ-C30	_	_	I-Premise
139	scales	_	_	I-Premise
140	,	_	_	I-Premise
141	the	_	_	I-Premise
142	QOL	_	_	I-Premise
143	scores	_	_	I-Premise
144	of	_	_	I-Premise
145	HDC	_	_	I-Premise
146	patients	_	_	I-Premise
147	tend	_	_	I-Premise
148	to	_	_	I-Premise
149	improve	_	_	I-Premise
150	at	_	_	I-Premise
151	a	_	_	I-Premise
152	slower	_	_	I-Premise
153	rate	_	_	I-Premise
154	than	_	_	I-Premise
155	that	_	_	I-Premise
156	of	_	_	I-Premise
157	patients	_	_	I-Premise
158	receiving	_	_	I-Premise
159	standard	_	_	I-Premise
160	chemotherapy	_	_	I-Premise
161	.	_	_	I-Premise

162	In	_	_	O
163	particular	_	_	O
164	,	_	_	O
165	physical	_	_	B-Premise
166	functioning	_	_	I-Premise
167	remains	_	_	I-Premise
168	deteriorated	_	_	I-Premise
169	1	_	_	I-Premise
170	year	_	_	I-Premise
171	after	_	_	I-Premise
172	inclusion	_	_	I-Premise
173	for	_	_	I-Premise
174	HDC	_	_	I-Premise
175	patients	_	_	I-Premise
176	comparatively	_	_	I-Premise
177	to	_	_	I-Premise
178	conventional	_	_	I-Premise
179	chemotherapy	_	_	I-Premise
180	patients	_	_	I-Premise
181	(	_	_	I-Premise
182	85.99	_	_	I-Premise
183	vs.	_	_	I-Premise
184	76.65	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	0.021	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	O
191	and	_	_	B-Premise
192	the	_	_	I-Premise
193	pain	_	_	I-Premise
194	score	_	_	I-Premise
195	was	_	_	I-Premise
196	still	_	_	I-Premise
197	higher	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	HDC	_	_	I-Premise
201	group	_	_	I-Premise
202	at	_	_	I-Premise
203	that	_	_	I-Premise
204	time	_	_	I-Premise
205	(	_	_	I-Premise
206	28.32	_	_	I-Premise
207	vs.	_	_	I-Premise
208	15.97	_	_	I-Premise
209	,	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.004	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	HDC	_	_	B-Claim
216	has	_	_	I-Claim
217	a	_	_	I-Claim
218	negative	_	_	I-Claim
219	impact	_	_	I-Claim
220	on	_	_	I-Claim
221	QOL	_	_	I-Claim
222	even	_	_	I-Claim
223	after	_	_	I-Claim
224	treatment	_	_	I-Claim
225	phase	_	_	I-Claim
226	.	_	_	I-Claim

227	In	_	_	O
228	the	_	_	O
229	absence	_	_	O
230	of	_	_	O
231	an	_	_	O
232	overall	_	_	O
233	survival	_	_	O
234	benefit	_	_	O
235	of	_	_	O
236	using	_	_	O
237	HDC	_	_	O
238	for	_	_	O
239	high-risk	_	_	O
240	breast	_	_	O
241	cancer	_	_	O
242	patients	_	_	O
243	,	_	_	O
244	QOL	_	_	O
245	studies	_	_	O
246	with	_	_	O
247	a	_	_	O
248	longer	_	_	O
249	follow-up	_	_	O
250	play	_	_	O
251	an	_	_	O
252	important	_	_	O
253	role	_	_	O
254	in	_	_	O
255	informing	_	_	O
256	the	_	_	O
257	complex	_	_	O
258	trade-off	_	_	O
259	implied	_	_	O
260	by	_	_	O
261	HDC	_	_	O
262	between	_	_	O
263	higher	_	_	O
264	toxicity	_	_	O
265	,	_	_	O
266	reduced	_	_	O
267	risk	_	_	O
268	of	_	_	O
269	relapse	_	_	O
270	,	_	_	O
271	and	_	_	O
272	QOL	_	_	O
273	decrease	_	_	O
274	after	_	_	O
275	the	_	_	O
276	active	_	_	O
277	phase	_	_	O
278	of	_	_	O
279	treatment	_	_	O
280	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	analgesic	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	,	_	_	O
14	doses	_	_	O
15	,	_	_	O
16	as	_	_	O
17	well	_	_	O
18	as	_	_	O
19	cost	_	_	O
20	of	_	_	O
21	opioid	_	_	O
22	drugs	_	_	O
23	,	_	_	O
24	supportive	_	_	O
25	drug	_	_	O
26	therapy	_	_	O
27	and	_	_	O
28	other	_	_	O
29	analgesic	_	_	O
30	drugs	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	treated	_	_	O
34	with	_	_	O
35	oral	_	_	O
36	sustained-release	_	_	O
37	morphine	_	_	O
38	,	_	_	O
39	transdermal	_	_	O
40	fentanyl	_	_	O
41	,	_	_	O
42	and	_	_	O
43	oral	_	_	O
44	methadone	_	_	O
45	.	_	_	O

46	One	_	_	O
47	hundred	_	_	O
48	and	_	_	O
49	eight	_	_	O
50	cancer	_	_	O
51	patients	_	_	O
52	,	_	_	O
53	no	_	_	O
54	longer	_	_	O
55	responsive	_	_	O
56	to	_	_	O
57	opioids	_	_	O
58	for	_	_	O
59	moderate	_	_	O
60	pain	_	_	O
61	,	_	_	O
62	were	_	_	O
63	selected	_	_	O
64	to	_	_	O
65	randomly	_	_	O
66	receive	_	_	O
67	initial	_	_	O
68	daily	_	_	O
69	doses	_	_	O
70	of	_	_	O
71	60	_	_	O
72	mg	_	_	O
73	of	_	_	O
74	oral	_	_	O
75	sustained-release	_	_	O
76	morphine	_	_	O
77	,	_	_	O
78	15	_	_	O
79	mg	_	_	O
80	of	_	_	O
81	oral	_	_	O
82	methadone	_	_	O
83	,	_	_	O
84	or	_	_	O
85	0.6	_	_	O
86	mg	_	_	O
87	(	_	_	O
88	25	_	_	O
89	microg/h	_	_	O
90	)	_	_	O
91	of	_	_	O
92	transdermal	_	_	O
93	fentanyl	_	_	O
94	.	_	_	O

95	Oral	_	_	O
96	morphine	_	_	O
97	was	_	_	O
98	used	_	_	O
99	as	_	_	O
100	breakthrough	_	_	O
101	pain	_	_	O
102	medication	_	_	O
103	during	_	_	O
104	opioid	_	_	O
105	titration	_	_	O
106	.	_	_	O

107	Opioid	_	_	O
108	doses	_	_	O
109	,	_	_	O
110	pain	_	_	O
111	intensity	_	_	O
112	,	_	_	O
113	adverse	_	_	O
114	effects	_	_	O
115	,	_	_	O
116	symptomatic	_	_	O
117	drugs	_	_	O
118	,	_	_	O
119	were	_	_	O
120	recorded	_	_	O
121	at	_	_	O
122	week	_	_	O
123	intervals	_	_	O
124	for	_	_	O
125	4	_	_	O
126	weeks	_	_	O
127	.	_	_	O

128	Costs	_	_	O
129	of	_	_	O
130	opioid	_	_	O
131	therapy	_	_	O
132	,	_	_	O
133	supportive	_	_	O
134	drugs	_	_	O
135	,	_	_	O
136	and	_	_	O
137	other	_	_	O
138	analgesic	_	_	O
139	drugs	_	_	O
140	were	_	_	O
141	also	_	_	O
142	evaluated	_	_	O
143	.	_	_	O

144	Seventy	_	_	O
145	patients	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	4	_	_	O
149	weeks	_	_	O
150	period	_	_	O
151	of	_	_	O
152	study	_	_	O
153	.	_	_	O

154	Five	_	_	O
155	,	_	_	O
156	five	_	_	O
157	,	_	_	O
158	and	_	_	O
159	four	_	_	O
160	patients	_	_	O
161	,	_	_	O
162	treated	_	_	O
163	with	_	_	O
164	oral	_	_	O
165	morphine	_	_	O
166	,	_	_	O
167	transdermal	_	_	O
168	fentanyl	_	_	O
169	,	_	_	O
170	and	_	_	O
171	oral	_	_	O
172	methadone	_	_	O
173	,	_	_	O
174	respectively	_	_	O
175	,	_	_	O
176	required	_	_	O
177	opioid	_	_	O
178	switching	_	_	O
179	.	_	_	O

180	No	_	_	B-Premise
181	differences	_	_	I-Premise
182	in	_	_	I-Premise
183	pain	_	_	I-Premise
184	and	_	_	I-Premise
185	symptom	_	_	I-Premise
186	intensity	_	_	I-Premise
187	were	_	_	I-Premise
188	observed	_	_	I-Premise
189	.	_	_	I-Premise

190	Opioid	_	_	B-Premise
191	escalation	_	_	I-Premise
192	index	_	_	I-Premise
193	was	_	_	I-Premise
194	significantly	_	_	I-Premise
195	lower	_	_	I-Premise
196	in	_	_	I-Premise
197	patients	_	_	I-Premise
198	receiving	_	_	I-Premise
199	methadone	_	_	I-Premise
200	(	_	_	I-Premise
201	p	_	_	I-Premise
202	<	_	_	I-Premise
203	0.0001	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	although	_	_	I-Premise
207	requiring	_	_	I-Premise
208	up	_	_	I-Premise
209	and	_	_	I-Premise
210	down	_	_	I-Premise
211	changes	_	_	I-Premise
212	in	_	_	I-Premise
213	doses	_	_	I-Premise
214	.	_	_	I-Premise

215	At	_	_	B-Premise
216	the	_	_	I-Premise
217	doses	_	_	I-Premise
218	used	_	_	I-Premise
219	,	_	_	I-Premise
220	methadone	_	_	I-Premise
221	was	_	_	I-Premise
222	significantly	_	_	I-Premise
223	less	_	_	I-Premise
224	expensive	_	_	I-Premise
225	(	_	_	I-Premise
226	p	_	_	I-Premise
227	<	_	_	I-Premise
228	0.0001	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	while	_	_	I-Premise
232	the	_	_	I-Premise
233	use	_	_	I-Premise
234	and	_	_	I-Premise
235	costs	_	_	I-Premise
236	of	_	_	I-Premise
237	supportive	_	_	I-Premise
238	drugs	_	_	I-Premise
239	and	_	_	I-Premise
240	other	_	_	I-Premise
241	analgesics	_	_	I-Premise
242	were	_	_	I-Premise
243	similar	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	three	_	_	I-Premise
247	groups	_	_	I-Premise
248	.	_	_	I-Premise

249	No	_	_	B-Premise
250	relevant	_	_	I-Premise
251	differences	_	_	I-Premise
252	in	_	_	I-Premise
253	adverse	_	_	I-Premise
254	effects	_	_	I-Premise
255	were	_	_	I-Premise
256	observed	_	_	I-Premise
257	among	_	_	I-Premise
258	the	_	_	I-Premise
259	groups	_	_	I-Premise
260	during	_	_	I-Premise
261	either	_	_	I-Premise
262	the	_	_	I-Premise
263	titration	_	_	I-Premise
264	phase	_	_	I-Premise
265	and	_	_	I-Premise
266	chronic	_	_	I-Premise
267	treatment	_	_	I-Premise
268	.	_	_	I-Premise

269	All	_	_	B-Claim
270	the	_	_	I-Claim
271	three	_	_	I-Claim
272	opioids	_	_	I-Claim
273	used	_	_	I-Claim
274	as	_	_	I-Claim
275	first-line	_	_	I-Claim
276	therapy	_	_	I-Claim
277	were	_	_	I-Claim
278	effective	_	_	I-Claim
279	,	_	_	I-Claim
280	well	_	_	I-Claim
281	tolerated	_	_	I-Claim
282	,	_	_	I-Claim
283	and	_	_	I-Claim
284	required	_	_	I-Claim
285	similar	_	_	I-Claim
286	amounts	_	_	I-Claim
287	of	_	_	I-Claim
288	symptomatic	_	_	I-Claim
289	drugs	_	_	I-Claim
290	or	_	_	I-Claim
291	co-analgesics	_	_	I-Claim
292	.	_	_	I-Claim

293	Methadone	_	_	B-Claim
294	was	_	_	I-Claim
295	significantly	_	_	I-Claim
296	less	_	_	I-Claim
297	expensive	_	_	I-Claim
298	,	_	_	I-Claim
299	but	_	_	I-Claim
300	required	_	_	I-Claim
301	more	_	_	I-Claim
302	changes	_	_	I-Claim
303	,	_	_	I-Claim
304	up	_	_	I-Claim
305	and	_	_	I-Claim
306	down	_	_	I-Claim
307	,	_	_	I-Claim
308	of	_	_	I-Claim
309	the	_	_	I-Claim
310	doses	_	_	I-Claim
311	,	_	_	I-Claim
312	suggesting	_	_	I-Claim
313	that	_	_	I-Claim
314	dose	_	_	I-Claim
315	titration	_	_	I-Claim
316	of	_	_	I-Claim
317	this	_	_	I-Claim
318	drug	_	_	I-Claim
319	requires	_	_	I-Claim
320	major	_	_	I-Claim
321	clinical	_	_	I-Claim
322	expertise	_	_	I-Claim
323	.	_	_	I-Claim


0	We	_	_	O
1	sought	_	_	O
2	the	_	_	O
3	extent	_	_	O
4	to	_	_	O
5	which	_	_	O
6	arm	_	_	O
7	morbidity	_	_	O
8	could	_	_	O
9	be	_	_	O
10	reduced	_	_	O
11	by	_	_	O
12	using	_	_	O
13	sentinel-lymph-node-based	_	_	O
14	management	_	_	O
15	in	_	_	O
16	women	_	_	O
17	with	_	_	O
18	clinically	_	_	O
19	node-negative	_	_	O
20	early	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	One	_	_	O
25	thousand	_	_	O
26	eighty-eight	_	_	O
27	women	_	_	O
28	were	_	_	O
29	randomly	_	_	O
30	allocated	_	_	O
31	to	_	_	O
32	sentinel-lymph-node	_	_	O
33	biopsy	_	_	O
34	followed	_	_	O
35	by	_	_	O
36	axillary	_	_	O
37	clearance	_	_	O
38	if	_	_	O
39	the	_	_	O
40	sentinel	_	_	O
41	node	_	_	O
42	was	_	_	O
43	positive	_	_	O
44	or	_	_	O
45	not	_	_	O
46	detected	_	_	O
47	(	_	_	O
48	SNBM	_	_	O
49	)	_	_	O
50	or	_	_	O
51	routine	_	_	O
52	axillary	_	_	O
53	clearance	_	_	O
54	(	_	_	O
55	RAC	_	_	O
56	,	_	_	O
57	sentinel-lymph-node	_	_	O
58	biopsy	_	_	O
59	followed	_	_	O
60	immediately	_	_	O
61	by	_	_	O
62	axillary	_	_	O
63	clearance	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Sentinel	_	_	O
67	nodes	_	_	O
68	were	_	_	O
69	located	_	_	O
70	using	_	_	O
71	blue	_	_	O
72	dye	_	_	O
73	,	_	_	O
74	alone	_	_	O
75	or	_	_	O
76	with	_	_	O
77	technetium-labeled	_	_	O
78	antimony	_	_	O
79	sulfide	_	_	O
80	colloid	_	_	O
81	.	_	_	O

82	The	_	_	O
83	primary	_	_	O
84	endpoint	_	_	O
85	was	_	_	O
86	increase	_	_	O
87	in	_	_	O
88	arm	_	_	O
89	volume	_	_	O
90	from	_	_	O
91	baseline	_	_	O
92	to	_	_	O
93	the	_	_	O
94	average	_	_	O
95	of	_	_	O
96	measurements	_	_	O
97	at	_	_	O
98	6	_	_	O
99	and	_	_	O
100	12	_	_	O
101	months	_	_	O
102	.	_	_	O

103	Secondary	_	_	O
104	endpoints	_	_	O
105	were	_	_	O
106	the	_	_	O
107	proportions	_	_	O
108	of	_	_	O
109	women	_	_	O
110	with	_	_	O
111	at	_	_	O
112	least	_	_	O
113	15	_	_	O
114	%	_	_	O
115	increase	_	_	O
116	in	_	_	O
117	arm	_	_	O
118	volume	_	_	O
119	or	_	_	O
120	early	_	_	O
121	axillary	_	_	O
122	morbidity	_	_	O
123	,	_	_	O
124	and	_	_	O
125	average	_	_	O
126	scores	_	_	O
127	for	_	_	O
128	arm	_	_	O
129	symptoms	_	_	O
130	,	_	_	O
131	dysfunctions	_	_	O
132	,	_	_	O
133	and	_	_	O
134	disabilities	_	_	O
135	assessed	_	_	O
136	at	_	_	O
137	6	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	by	_	_	O
142	patients	_	_	O
143	with	_	_	O
144	the	_	_	O
145	SNAC	_	_	O
146	Study-Specific	_	_	O
147	Scales	_	_	O
148	and	_	_	O
149	other	_	_	O
150	quality-of-life	_	_	O
151	instruments	_	_	O
152	.	_	_	O

153	Sensitivity	_	_	O
154	,	_	_	O
155	false-negative	_	_	O
156	rates	_	_	O
157	,	_	_	O
158	and	_	_	O
159	negative	_	_	O
160	predictive	_	_	O
161	values	_	_	O
162	for	_	_	O
163	sentinel-lymph-node	_	_	O
164	biopsy	_	_	O
165	were	_	_	O
166	estimated	_	_	O
167	in	_	_	O
168	the	_	_	O
169	RAC	_	_	O
170	group	_	_	O
171	.	_	_	O

172	The	_	_	B-Premise
173	average	_	_	I-Premise
174	increase	_	_	I-Premise
175	in	_	_	I-Premise
176	arm	_	_	I-Premise
177	volume	_	_	I-Premise
178	was	_	_	I-Premise
179	2.8	_	_	I-Premise
180	%	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	SNBM	_	_	I-Premise
184	group	_	_	I-Premise
185	and	_	_	I-Premise
186	4.2	_	_	I-Premise
187	%	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	RAC	_	_	I-Premise
191	group	_	_	I-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	0.002	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Patients	_	_	B-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	SNBM	_	_	I-Premise
202	group	_	_	I-Premise
203	gave	_	_	I-Premise
204	lower	_	_	I-Premise
205	ratings	_	_	I-Premise
206	for	_	_	I-Premise
207	arm	_	_	I-Premise
208	swelling	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.001	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	symptoms	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	0.001	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	dysfunctions	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	0.02	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	but	_	_	I-Premise
231	not	_	_	I-Premise
232	disabilities	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	0.5	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Sentinel	_	_	B-Premise
240	nodes	_	_	I-Premise
241	were	_	_	I-Premise
242	found	_	_	I-Premise
243	in	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	SNBM	_	_	I-Premise
249	group	_	_	I-Premise
250	(	_	_	I-Premise
251	29	_	_	I-Premise
252	%	_	_	I-Premise
253	positive	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	93	_	_	I-Premise
257	%	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	RAC	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	25	_	_	I-Premise
264	%	_	_	I-Premise
265	positive	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	SNB	_	_	O
269	had	_	_	O
270	sensitivity	_	_	O
271	94.5	_	_	O
272	%	_	_	O
273	,	_	_	O
274	false-negative	_	_	O
275	rate	_	_	O
276	5.5	_	_	O
277	%	_	_	O
278	,	_	_	O
279	and	_	_	O
280	negative	_	_	O
281	predictive	_	_	O
282	value	_	_	O
283	98	_	_	O
284	%	_	_	O
285	.	_	_	O

286	SNBM	_	_	B-Claim
287	was	_	_	I-Claim
288	successfully	_	_	I-Claim
289	undertaken	_	_	I-Claim
290	in	_	_	I-Claim
291	a	_	_	I-Claim
292	wide	_	_	I-Claim
293	range	_	_	I-Claim
294	of	_	_	I-Claim
295	surgical	_	_	I-Claim
296	centers	_	_	I-Claim
297	and	_	_	I-Claim
298	caused	_	_	I-Claim
299	significantly	_	_	I-Claim
300	less	_	_	I-Claim
301	morbidity	_	_	I-Claim
302	than	_	_	I-Claim
303	RAC	_	_	I-Claim
304	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	,	_	_	O
4	double-blind	_	_	O
5	,	_	_	O
6	randomized	_	_	O
7	,	_	_	O
8	multicenter	_	_	O
9	study	_	_	O
10	evaluated	_	_	O
11	the	_	_	O
12	efficacy	_	_	O
13	,	_	_	O
14	pharmacodynamics	_	_	O
15	,	_	_	O
16	and	_	_	O
17	safety	_	_	O
18	of	_	_	O
19	the	_	_	O
20	oral	_	_	O
21	aromatase	_	_	O
22	inactivator	_	_	O
23	exemestane	_	_	O
24	(	_	_	O
25	EXE	_	_	O
26	)	_	_	O
27	versus	_	_	O
28	megestrol	_	_	O
29	acetate	_	_	O
30	(	_	_	O
31	MA	_	_	O
32	)	_	_	O
33	in	_	_	O
34	postmenopausal	_	_	O
35	women	_	_	O
36	with	_	_	O
37	progressive	_	_	O
38	advanced	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	who	_	_	O
42	experienced	_	_	O
43	failure	_	_	O
44	of	_	_	O
45	tamoxifen	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	769	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	EXE	_	_	O
56	25	_	_	O
57	mg/d	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	366	_	_	O
62	)	_	_	O
63	or	_	_	O
64	MA	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	403	_	_	O
69	)	_	_	O
70	40	_	_	O
71	mg	_	_	O
72	four	_	_	O
73	times	_	_	O
74	daily	_	_	O
75	.	_	_	O

76	Tumor	_	_	O
77	response	_	_	O
78	,	_	_	O
79	duration	_	_	O
80	of	_	_	O
81	tumor	_	_	O
82	control	_	_	O
83	,	_	_	O
84	tumor-related	_	_	O
85	signs	_	_	O
86	and	_	_	O
87	symptoms	_	_	O
88	(	_	_	O
89	TRSS	_	_	O
90	)	_	_	O
91	,	_	_	O
92	quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	(	_	_	O
96	QOL	_	_	O
97	)	_	_	O
98	,	_	_	O
99	survival	_	_	O
100	,	_	_	O
101	and	_	_	O
102	tolerability	_	_	O
103	were	_	_	O
104	evaluated	_	_	O
105	.	_	_	O

106	Overall	_	_	B-Premise
107	objective	_	_	I-Premise
108	response	_	_	I-Premise
109	(	_	_	I-Premise
110	OR	_	_	I-Premise
111	)	_	_	I-Premise
112	rates	_	_	I-Premise
113	were	_	_	I-Premise
114	higher	_	_	I-Premise
115	in	_	_	I-Premise
116	patients	_	_	I-Premise
117	treated	_	_	I-Premise
118	with	_	_	I-Premise
119	EXE	_	_	I-Premise
120	than	_	_	I-Premise
121	in	_	_	I-Premise
122	those	_	_	I-Premise
123	treated	_	_	I-Premise
124	with	_	_	I-Premise
125	MA	_	_	I-Premise
126	(	_	_	I-Premise
127	15.0	_	_	I-Premise
128	%	_	_	I-Premise
129	v	_	_	I-Premise
130	12.4	_	_	I-Premise
131	%	_	_	I-Premise
132	)	_	_	I-Premise
133	;	_	_	I-Premise
134	a	_	_	B-Premise
135	similar	_	_	I-Premise
136	trend	_	_	I-Premise
137	was	_	_	I-Premise
138	noted	_	_	I-Premise
139	in	_	_	I-Premise
140	patients	_	_	I-Premise
141	with	_	_	I-Premise
142	visceral	_	_	I-Premise
143	metastases	_	_	I-Premise
144	(	_	_	I-Premise
145	13.5	_	_	I-Premise
146	%	_	_	I-Premise
147	v	_	_	I-Premise
148	10.5	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	Median	_	_	B-Premise
153	survival	_	_	I-Premise
154	time	_	_	I-Premise
155	was	_	_	I-Premise
156	significantly	_	_	I-Premise
157	longer	_	_	I-Premise
158	with	_	_	I-Premise
159	EXE	_	_	I-Premise
160	(	_	_	I-Premise
161	median	_	_	I-Premise
162	not	_	_	I-Premise
163	reached	_	_	I-Premise
164	)	_	_	I-Premise
165	than	_	_	I-Premise
166	with	_	_	I-Premise
167	MA	_	_	I-Premise
168	(	_	_	I-Premise
169	123.4	_	_	I-Premise
170	weeks	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=.039	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	as	_	_	I-Premise
177	were	_	_	I-Premise
178	the	_	_	I-Premise
179	median	_	_	I-Premise
180	duration	_	_	I-Premise
181	of	_	_	I-Premise
182	overall	_	_	I-Premise
183	success	_	_	I-Premise
184	(	_	_	I-Premise
185	OR	_	_	I-Premise
186	or	_	_	I-Premise
187	stable	_	_	I-Premise
188	disease	_	_	I-Premise
189	>	_	_	I-Premise
190	or	_	_	I-Premise
191	=	_	_	I-Premise
192	24	_	_	I-Premise
193	weeks	_	_	I-Premise
194	;	_	_	I-Premise
195	60.1	_	_	I-Premise
196	v	_	_	I-Premise
197	49.1	_	_	I-Premise
198	weeks	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=.025	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	time	_	_	I-Premise
205	to	_	_	I-Premise
206	tumor	_	_	I-Premise
207	progression	_	_	I-Premise
208	(	_	_	I-Premise
209	20.3	_	_	I-Premise
210	v	_	_	I-Premise
211	16.6	_	_	I-Premise
212	weeks	_	_	I-Premise
213	;	_	_	I-Premise
214	P	_	_	I-Premise
215	=.037	_	_	I-Premise
216	)	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	time	_	_	I-Premise
220	to	_	_	I-Premise
221	treatment	_	_	I-Premise
222	failure	_	_	I-Premise
223	(	_	_	I-Premise
224	16.3	_	_	I-Premise
225	v	_	_	I-Premise
226	15.7	_	_	I-Premise
227	weeks	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=.042	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Compared	_	_	B-Premise
234	with	_	_	I-Premise
235	MA	_	_	I-Premise
236	,	_	_	I-Premise
237	there	_	_	I-Premise
238	were	_	_	I-Premise
239	similar	_	_	I-Premise
240	or	_	_	I-Premise
241	greater	_	_	I-Premise
242	improvements	_	_	I-Premise
243	in	_	_	I-Premise
244	pain	_	_	I-Premise
245	,	_	_	I-Premise
246	TRSS	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	QOL	_	_	I-Premise
250	with	_	_	I-Premise
251	EXE	_	_	I-Premise
252	.	_	_	I-Premise

253	Both	_	_	B-Claim
254	drugs	_	_	I-Claim
255	were	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	.	_	_	I-Claim

259	Grade	_	_	B-Premise
260	3	_	_	I-Premise
261	or	_	_	I-Premise
262	4	_	_	I-Premise
263	weight	_	_	I-Premise
264	changes	_	_	I-Premise
265	were	_	_	I-Premise
266	more	_	_	I-Premise
267	common	_	_	I-Premise
268	with	_	_	I-Premise
269	MA	_	_	I-Premise
270	(	_	_	I-Premise
271	17.1	_	_	I-Premise
272	%	_	_	I-Premise
273	v	_	_	I-Premise
274	7.6	_	_	I-Premise
275	%	_	_	I-Premise
276	;	_	_	I-Premise
277	P	_	_	I-Premise
278	=.001	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	EXE	_	_	B-Claim
282	prolongs	_	_	I-Claim
283	survival	_	_	I-Claim
284	time	_	_	I-Claim
285	,	_	_	I-Claim
286	time	_	_	I-Claim
287	to	_	_	I-Claim
288	tumor	_	_	I-Claim
289	progression	_	_	I-Claim
290	,	_	_	I-Claim
291	and	_	_	I-Claim
292	time	_	_	I-Claim
293	to	_	_	I-Claim
294	treatment	_	_	I-Claim
295	failure	_	_	I-Claim
296	compared	_	_	I-Claim
297	with	_	_	I-Claim
298	MA	_	_	I-Claim
299	and	_	_	I-Claim
300	offers	_	_	I-Claim
301	a	_	_	I-Claim
302	well-tolerated	_	_	I-Claim
303	treatment	_	_	I-Claim
304	option	_	_	I-Claim
305	for	_	_	I-Claim
306	postmenopausal	_	_	I-Claim
307	women	_	_	I-Claim
308	with	_	_	I-Claim
309	progressive	_	_	I-Claim
310	advanced	_	_	I-Claim
311	breast	_	_	I-Claim
312	cancer	_	_	I-Claim
313	who	_	_	I-Claim
314	experienced	_	_	I-Claim
315	failure	_	_	I-Claim
316	of	_	_	I-Claim
317	tamoxifen	_	_	I-Claim
318	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	III	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	conducted	_	_	O
7	to	_	_	O
8	determine	_	_	O
9	whether	_	_	O
10	combination	_	_	O
11	therapy	_	_	O
12	with	_	_	O
13	13-cis-retinoic	_	_	O
14	acid	_	_	O
15	(	_	_	O
16	13-CRA	_	_	O
17	)	_	_	O
18	plus	_	_	O
19	interferon	_	_	O
20	alfa-2a	_	_	O
21	(	_	_	O
22	IFNalpha2a	_	_	O
23	)	_	_	O
24	is	_	_	O
25	superior	_	_	O
26	to	_	_	O
27	IFNalpha2a	_	_	O
28	alone	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	advanced	_	_	O
33	renal	_	_	O
34	cell	_	_	O
35	carcinoma	_	_	O
36	(	_	_	O
37	RCC	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Two	_	_	O
41	hundred	_	_	O
42	eighty-four	_	_	O
43	patients	_	_	O
44	were	_	_	O
45	randomized	_	_	O
46	to	_	_	O
47	treatment	_	_	O
48	with	_	_	O
49	IFNalpha2a	_	_	O
50	plus	_	_	O
51	13-CRA	_	_	O
52	or	_	_	O
53	treatment	_	_	O
54	with	_	_	O
55	IFNalpha2a	_	_	O
56	alone	_	_	O
57	.	_	_	O

58	IFNalpha2a	_	_	O
59	was	_	_	O
60	given	_	_	O
61	daily	_	_	O
62	subcutaneously	_	_	O
63	,	_	_	O
64	starting	_	_	O
65	at	_	_	O
66	a	_	_	O
67	dose	_	_	O
68	of	_	_	O
69	3	_	_	O
70	million	_	_	O
71	units	_	_	O
72	(	_	_	O
73	MU	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	dose	_	_	O
78	was	_	_	O
79	escalated	_	_	O
80	every	_	_	O
81	7	_	_	O
82	days	_	_	O
83	from	_	_	O
84	3	_	_	O
85	to	_	_	O
86	9	_	_	O
87	MU	_	_	O
88	(	_	_	O
89	by	_	_	O
90	increments	_	_	O
91	of	_	_	O
92	3	_	_	O
93	MU	_	_	O
94	)	_	_	O
95	,	_	_	O
96	unless	_	_	O
97	>	_	_	O
98	/=	_	_	O
99	grade	_	_	O
100	2	_	_	O
101	toxicity	_	_	O
102	occurred	_	_	O
103	,	_	_	O
104	in	_	_	O
105	which	_	_	O
106	case	_	_	O
107	dose	_	_	O
108	escalation	_	_	O
109	was	_	_	O
110	stopped	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	randomized	_	_	O
114	to	_	_	O
115	combination	_	_	O
116	therapy	_	_	O
117	were	_	_	O
118	given	_	_	O
119	oral	_	_	O
120	13-CRA	_	_	O
121	1	_	_	O
122	mg/kg/d	_	_	O
123	plus	_	_	O
124	IFNalpha2a	_	_	O
125	.	_	_	O

126	Quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	(	_	_	O
130	QOL	_	_	O
131	)	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	.	_	_	O

135	Complete	_	_	B-Premise
136	or	_	_	I-Premise
137	partial	_	_	I-Premise
138	responses	_	_	I-Premise
139	were	_	_	I-Premise
140	achieved	_	_	I-Premise
141	by	_	_	I-Premise
142	12	_	_	I-Premise
143	%	_	_	I-Premise
144	of	_	_	I-Premise
145	patients	_	_	I-Premise
146	treated	_	_	I-Premise
147	with	_	_	I-Premise
148	IFNalpha2a	_	_	I-Premise
149	plus	_	_	I-Premise
150	13-CRA	_	_	I-Premise
151	and	_	_	I-Premise
152	6	_	_	I-Premise
153	%	_	_	I-Premise
154	of	_	_	I-Premise
155	patients	_	_	I-Premise
156	treated	_	_	I-Premise
157	with	_	_	I-Premise
158	IFNalpha2a	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=.14	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	Median	_	_	B-Premise
165	duration	_	_	I-Premise
166	of	_	_	I-Premise
167	response	_	_	I-Premise
168	(	_	_	I-Premise
169	complete	_	_	I-Premise
170	and	_	_	I-Premise
171	partial	_	_	I-Premise
172	combined	_	_	I-Premise
173	)	_	_	I-Premise
174	in	_	_	I-Premise
175	the	_	_	I-Premise
176	group	_	_	I-Premise
177	treated	_	_	I-Premise
178	with	_	_	I-Premise
179	the	_	_	I-Premise
180	combination	_	_	I-Premise
181	was	_	_	I-Premise
182	33	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	range	_	_	I-Premise
186	,	_	_	I-Premise
187	9	_	_	I-Premise
188	to	_	_	I-Premise
189	50	_	_	I-Premise
190	months	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	versus	_	_	I-Premise
194	22	_	_	I-Premise
195	months	_	_	I-Premise
196	(	_	_	I-Premise
197	range	_	_	I-Premise
198	,	_	_	I-Premise
199	5	_	_	I-Premise
200	to	_	_	I-Premise
201	38	_	_	I-Premise
202	months	_	_	I-Premise
203	)	_	_	I-Premise
204	for	_	_	I-Premise
205	the	_	_	I-Premise
206	second	_	_	I-Premise
207	group	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=.03	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	Nineteen	_	_	B-Premise
214	percent	_	_	I-Premise
215	of	_	_	I-Premise
216	patients	_	_	I-Premise
217	treated	_	_	I-Premise
218	with	_	_	I-Premise
219	IFNalpha2a	_	_	I-Premise
220	plus	_	_	I-Premise
221	13-CRA	_	_	I-Premise
222	were	_	_	I-Premise
223	progression-free	_	_	I-Premise
224	at	_	_	I-Premise
225	24	_	_	I-Premise
226	months	_	_	I-Premise
227	,	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	10	_	_	I-Premise
231	%	_	_	I-Premise
232	of	_	_	I-Premise
233	patients	_	_	I-Premise
234	treated	_	_	I-Premise
235	with	_	_	I-Premise
236	IFNalpha2a	_	_	I-Premise
237	alone	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	=.05	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Median	_	_	B-Premise
244	survival	_	_	I-Premise
245	time	_	_	I-Premise
246	for	_	_	I-Premise
247	all	_	_	I-Premise
248	patients	_	_	I-Premise
249	was	_	_	I-Premise
250	15	_	_	I-Premise
251	months	_	_	I-Premise
252	,	_	_	I-Premise
253	with	_	_	I-Premise
254	no	_	_	I-Premise
255	difference	_	_	I-Premise
256	in	_	_	I-Premise
257	survival	_	_	I-Premise
258	between	_	_	I-Premise
259	the	_	_	I-Premise
260	two	_	_	I-Premise
261	treatment	_	_	I-Premise
262	arms	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=.26	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	QOL	_	_	B-Premise
269	decreased	_	_	I-Premise
270	during	_	_	I-Premise
271	the	_	_	I-Premise
272	first	_	_	I-Premise
273	8	_	_	I-Premise
274	weeks	_	_	I-Premise
275	of	_	_	I-Premise
276	treatment	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	a	_	_	I-Premise
280	partial	_	_	I-Premise
281	recovery	_	_	I-Premise
282	followed	_	_	I-Premise
283	.	_	_	I-Premise

284	Lower	_	_	B-Premise
285	scores	_	_	I-Premise
286	were	_	_	I-Premise
287	associated	_	_	I-Premise
288	with	_	_	I-Premise
289	the	_	_	I-Premise
290	combination	_	_	I-Premise
291	therapy	_	_	I-Premise
292	.	_	_	I-Premise

293	Response	_	_	B-Claim
294	proportion	_	_	I-Claim
295	and	_	_	I-Claim
296	survival	_	_	I-Claim
297	did	_	_	I-Claim
298	not	_	_	I-Claim
299	improve	_	_	I-Claim
300	significantly	_	_	I-Claim
301	with	_	_	I-Claim
302	the	_	_	I-Claim
303	addition	_	_	I-Claim
304	of	_	_	I-Claim
305	13-CRA	_	_	I-Claim
306	to	_	_	I-Claim
307	IFNalpha2a	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	patients	_	_	I-Claim
311	with	_	_	I-Claim
312	advanced	_	_	I-Claim
313	RCC	_	_	I-Claim
314	.	_	_	I-Claim

315	13-CRA	_	_	B-Claim
316	may	_	_	I-Claim
317	lengthen	_	_	I-Claim
318	response	_	_	I-Claim
319	to	_	_	I-Claim
320	IFNalpha2a	_	_	I-Claim
321	therapy	_	_	I-Claim
322	in	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	IFNalpha2a-sensitive	_	_	I-Claim
326	tumors	_	_	I-Claim
327	.	_	_	I-Claim

328	Treatment	_	_	B-Claim
329	,	_	_	I-Claim
330	particularly	_	_	I-Claim
331	the	_	_	I-Claim
332	combination	_	_	I-Claim
333	therapy	_	_	I-Claim
334	,	_	_	I-Claim
335	was	_	_	I-Claim
336	associated	_	_	I-Claim
337	with	_	_	I-Claim
338	a	_	_	I-Claim
339	decrease	_	_	I-Claim
340	in	_	_	I-Claim
341	QOL	_	_	I-Claim
342	.	_	_	I-Claim


0	Transthoracic	_	_	O
1	and	_	_	O
2	transhiatal	_	_	O
3	esophagectomy	_	_	O
4	are	_	_	O
5	two	_	_	O
6	common	_	_	O
7	procedures	_	_	O
8	for	_	_	O
9	esophageal	_	_	O
10	cancer	_	_	O
11	resection	_	_	O
12	.	_	_	O

13	Prospective	_	_	O
14	studies	_	_	O
15	comparing	_	_	O
16	the	_	_	O
17	two	_	_	O
18	methods	_	_	O
19	in	_	_	O
20	Asian	_	_	O
21	people	_	_	O
22	are	_	_	O
23	few	_	_	O
24	.	_	_	O

25	In	_	_	O
26	addition	_	_	O
27	,	_	_	O
28	the	_	_	O
29	data	_	_	O
30	comparing	_	_	O
31	their	_	_	O
32	effects	_	_	O
33	on	_	_	O
34	the	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	.	_	_	O

41	A	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	study	_	_	O
45	was	_	_	O
46	conducted	_	_	O
47	from	_	_	O
48	January	_	_	O
49	2003	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	of	_	_	O
53	resectable	_	_	O
54	esophageal	_	_	O
55	cancer	_	_	O
56	of	_	_	O
57	comparable	_	_	O
58	stage	_	_	O
59	were	_	_	O
60	allocated	_	_	O
61	to	_	_	O
62	undergo	_	_	O
63	the	_	_	O
64	transthoracic	_	_	O
65	or	_	_	O
66	transhiatal	_	_	O
67	procedure	_	_	O
68	in	_	_	O
69	turn	_	_	O
70	.	_	_	O

71	They	_	_	O
72	were	_	_	O
73	all	_	_	O
74	reconstructed	_	_	O
75	with	_	_	O
76	stomach	_	_	O
77	interposition	_	_	O
78	through	_	_	O
79	the	_	_	O
80	retrosternal	_	_	O
81	route	_	_	O
82	.	_	_	O

83	Discharged	_	_	O
84	patients	_	_	O
85	were	_	_	O
86	followed-up	_	_	O
87	in	_	_	O
88	the	_	_	O
89	outpatient	_	_	O
90	clinic	_	_	O
91	.	_	_	O

92	They	_	_	O
93	were	_	_	O
94	questioned	_	_	O
95	on	_	_	O
96	the	_	_	O
97	topics	_	_	O
98	of	_	_	O
99	(	_	_	O
100	i	_	_	O
101	)	_	_	O
102	severity	_	_	O
103	of	_	_	O
104	pain	_	_	O
105	,	_	_	O
106	(	_	_	O
107	ii	_	_	O
108	)	_	_	O
109	ease	_	_	O
110	of	_	_	O
111	swallowing	_	_	O
112	,	_	_	O
113	(	_	_	O
114	iii	_	_	O
115	)	_	_	O
116	satisfaction	_	_	O
117	of	_	_	O
118	daily	_	_	O
119	activities	_	_	O
120	,	_	_	O
121	(	_	_	O
122	iv	_	_	O
123	)	_	_	O
124	dependence	_	_	O
125	on	_	_	O
126	medications	_	_	O
127	,	_	_	O
128	(	_	_	O
129	v	_	_	O
130	)	_	_	O
131	working	_	_	O
132	ability	_	_	O
133	,	_	_	O
134	(	_	_	O
135	vi	_	_	O
136	)	_	_	O
137	fatigue	_	_	O
138	,	_	_	O
139	(	_	_	O
140	vii	_	_	O
141	)	_	_	O
142	appetite	_	_	O
143	,	_	_	O
144	(	_	_	O
145	viii	_	_	O
146	)	_	_	O
147	sociality	_	_	O
148	,	_	_	O
149	(	_	_	O
150	ix	_	_	O
151	)	_	_	O
152	happiness	_	_	O
153	and	_	_	O
154	(	_	_	O
155	x	_	_	O
156	)	_	_	O
157	self	_	_	O
158	respect	_	_	O
159	,	_	_	O
160	in	_	_	O
161	the	_	_	O
162	third	_	_	O
163	,	_	_	O
164	sixth	_	_	O
165	and	_	_	O
166	twelfth	_	_	O
167	month	_	_	O
168	.	_	_	O

169	Also	_	_	O
170	the	_	_	O
171	demographic	_	_	O
172	data	_	_	O
173	,	_	_	O
174	operative	_	_	O
175	results	_	_	O
176	and	_	_	O
177	survival	_	_	O
178	were	_	_	O
179	recorded	_	_	O
180	.	_	_	O

181	Up	_	_	O
182	to	_	_	O
183	December	_	_	O
184	2006	_	_	O
185	,	_	_	O
186	eighty-seven	_	_	O
187	patients	_	_	O
188	of	_	_	O
189	stage	_	_	O
190	II	_	_	O
191	and	_	_	O
192	III	_	_	O
193	,	_	_	O
194	including	_	_	O
195	71	_	_	O
196	patients	_	_	O
197	of	_	_	O
198	middle	_	_	O
199	third	_	_	O
200	lesions	_	_	O
201	and	_	_	O
202	16	_	_	O
203	lower	_	_	O
204	third	_	_	O
205	lesions	_	_	O
206	were	_	_	O
207	enrolled	_	_	O
208	.	_	_	O

209	The	_	_	B-Premise
210	operation	_	_	I-Premise
211	time	_	_	I-Premise
212	was	_	_	I-Premise
213	significantly	_	_	I-Premise
214	longer	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	the	_	_	I-Premise
218	leakage	_	_	I-Premise
219	rate	_	_	I-Premise
220	was	_	_	I-Premise
221	higher	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	transthoracic	_	_	I-Premise
225	group	_	_	I-Premise
226	(	_	_	I-Premise
227	Student	_	_	I-Premise
228	's	_	_	I-Premise
229	t-test	_	_	I-Premise
230	and	_	_	I-Premise
231	Fischer	_	_	I-Premise
232	's	_	_	I-Premise
233	exact	_	_	I-Premise
234	test	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	However	_	_	O
240	,	_	_	O
241	intraoperative	_	_	B-Premise
242	blood	_	_	I-Premise
243	loss	_	_	I-Premise
244	and	_	_	I-Premise
245	postoperative	_	_	I-Premise
246	hospital	_	_	I-Premise
247	stay	_	_	I-Premise
248	were	_	_	I-Premise
249	not	_	_	I-Premise
250	significantly	_	_	I-Premise
251	different	_	_	I-Premise
252	(	_	_	I-Premise
253	Student	_	_	I-Premise
254	t-test	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Also	_	_	O
258	,	_	_	O
259	the	_	_	B-Premise
260	Kaplan-Meier	_	_	I-Premise
261	survival	_	_	I-Premise
262	curves	_	_	I-Premise
263	of	_	_	I-Premise
264	these	_	_	I-Premise
265	two	_	_	I-Premise
266	groups	_	_	I-Premise
267	were	_	_	I-Premise
268	not	_	_	I-Premise
269	significantly	_	_	I-Premise
270	different	_	_	I-Premise
271	by	_	_	I-Premise
272	log-rank	_	_	I-Premise
273	test	_	_	I-Premise
274	(	_	_	I-Premise
275	p=0.286	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	The	_	_	B-Premise
279	score	_	_	I-Premise
280	on	_	_	I-Premise
281	the	_	_	I-Premise
282	quality	_	_	I-Premise
283	of	_	_	I-Premise
284	life	_	_	I-Premise
285	of	_	_	I-Premise
286	transhiatal	_	_	I-Premise
287	patients	_	_	I-Premise
288	was	_	_	I-Premise
289	significantly	_	_	I-Premise
290	higher	_	_	I-Premise
291	than	_	_	I-Premise
292	that	_	_	I-Premise
293	of	_	_	I-Premise
294	transthoracic	_	_	I-Premise
295	patients	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	third	_	_	I-Premise
299	,	_	_	I-Premise
300	sixth	_	_	I-Premise
301	and	_	_	I-Premise
302	twelfth	_	_	I-Premise
303	month	_	_	I-Premise
304	.	_	_	I-Premise

305	Transhiatal	_	_	B-Claim
306	esophagectomy	_	_	I-Claim
307	is	_	_	I-Claim
308	a	_	_	I-Claim
309	safe	_	_	I-Claim
310	and	_	_	I-Claim
311	fast	_	_	I-Claim
312	procedure	_	_	I-Claim
313	.	_	_	I-Claim

314	The	_	_	B-Claim
315	survival	_	_	I-Claim
316	was	_	_	I-Claim
317	similar	_	_	I-Claim
318	to	_	_	I-Claim
319	that	_	_	I-Claim
320	of	_	_	I-Claim
321	transthoracic	_	_	I-Claim
322	approach	_	_	I-Claim
323	.	_	_	I-Claim

324	Its	_	_	B-Claim
325	leakage	_	_	I-Claim
326	rate	_	_	I-Claim
327	was	_	_	I-Claim
328	lower	_	_	I-Claim
329	and	_	_	I-Claim
330	quality	_	_	I-Claim
331	of	_	_	I-Claim
332	life	_	_	I-Claim
333	was	_	_	I-Claim
334	better	_	_	I-Claim
335	.	_	_	I-Claim


0	Hot	_	_	B-Claim
1	flashes	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	significant	_	_	I-Claim
5	problem	_	_	I-Claim
6	for	_	_	I-Claim
7	many	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	survivors	_	_	I-Claim
11	.	_	_	I-Claim

12	Hot	_	_	B-Claim
13	flashes	_	_	I-Claim
14	can	_	_	I-Claim
15	cause	_	_	I-Claim
16	discomfort	_	_	I-Claim
17	,	_	_	I-Claim
18	disrupted	_	_	I-Claim
19	sleep	_	_	I-Claim
20	,	_	_	I-Claim
21	anxiety	_	_	I-Claim
22	,	_	_	I-Claim
23	and	_	_	I-Claim
24	decreased	_	_	I-Claim
25	quality	_	_	I-Claim
26	of	_	_	I-Claim
27	life	_	_	I-Claim
28	.	_	_	I-Claim

29	A	_	_	O
30	well-tolerated	_	_	O
31	and	_	_	O
32	effective	_	_	O
33	mind-body	_	_	O
34	treatment	_	_	O
35	for	_	_	O
36	hot	_	_	O
37	flashes	_	_	O
38	would	_	_	O
39	be	_	_	O
40	of	_	_	O
41	great	_	_	O
42	value	_	_	O
43	.	_	_	O

44	On	_	_	O
45	the	_	_	O
46	basis	_	_	O
47	of	_	_	O
48	previous	_	_	O
49	case	_	_	O
50	studies	_	_	O
51	,	_	_	O
52	this	_	_	O
53	study	_	_	O
54	was	_	_	O
55	developed	_	_	O
56	to	_	_	O
57	evaluate	_	_	O
58	the	_	_	O
59	effect	_	_	O
60	of	_	_	O
61	a	_	_	O
62	hypnosis	_	_	O
63	intervention	_	_	O
64	for	_	_	O
65	hot	_	_	O
66	flashes	_	_	O
67	.	_	_	O

68	Sixty	_	_	O
69	female	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	survivors	_	_	O
73	with	_	_	O
74	hot	_	_	O
75	flashes	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	hypnosis	_	_	O
82	intervention	_	_	O
83	(	_	_	O
84	five	_	_	O
85	weekly	_	_	O
86	sessions	_	_	O
87	)	_	_	O
88	or	_	_	O
89	no	_	_	O
90	treatment	_	_	O
91	.	_	_	O

92	Eligible	_	_	O
93	patients	_	_	O
94	had	_	_	O
95	to	_	_	O
96	have	_	_	O
97	a	_	_	O
98	history	_	_	O
99	of	_	_	O
100	primary	_	_	O
101	breast	_	_	O
102	cancer	_	_	O
103	without	_	_	O
104	evidence	_	_	O
105	of	_	_	O
106	detectable	_	_	O
107	disease	_	_	O
108	and	_	_	O
109	14	_	_	O
110	or	_	_	O
111	more	_	_	O
112	weekly	_	_	O
113	hot	_	_	O
114	flashes	_	_	O
115	for	_	_	O
116	at	_	_	O
117	least	_	_	O
118	1	_	_	O
119	month	_	_	O
120	.	_	_	O

121	The	_	_	O
122	major	_	_	O
123	outcome	_	_	O
124	measure	_	_	O
125	was	_	_	O
126	a	_	_	O
127	bivariate	_	_	O
128	construct	_	_	O
129	that	_	_	O
130	represented	_	_	O
131	hot	_	_	O
132	flash	_	_	O
133	frequency	_	_	O
134	and	_	_	O
135	hot	_	_	O
136	flash	_	_	O
137	score	_	_	O
138	,	_	_	O
139	which	_	_	O
140	was	_	_	O
141	analyzed	_	_	O
142	by	_	_	O
143	a	_	_	O
144	classic	_	_	O
145	sums	_	_	O
146	and	_	_	O
147	differences	_	_	O
148	comparison	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcome	_	_	O
152	measures	_	_	O
153	were	_	_	O
154	self-reports	_	_	O
155	of	_	_	O
156	interference	_	_	O
157	of	_	_	O
158	hot	_	_	O
159	flashes	_	_	O
160	on	_	_	O
161	daily	_	_	O
162	activities	_	_	O
163	.	_	_	O

164	Fifty-one	_	_	O
165	randomly	_	_	O
166	assigned	_	_	O
167	women	_	_	O
168	completed	_	_	O
169	the	_	_	O
170	study	_	_	O
171	.	_	_	O

172	By	_	_	B-Premise
173	the	_	_	I-Premise
174	end	_	_	I-Premise
175	of	_	_	I-Premise
176	the	_	_	I-Premise
177	treatment	_	_	I-Premise
178	period	_	_	I-Premise
179	,	_	_	I-Premise
180	hot	_	_	I-Premise
181	flash	_	_	I-Premise
182	scores	_	_	I-Premise
183	(	_	_	I-Premise
184	frequency	_	_	I-Premise
185	x	_	_	I-Premise
186	average	_	_	I-Premise
187	severity	_	_	I-Premise
188	)	_	_	I-Premise
189	decreased	_	_	I-Premise
190	68	_	_	I-Premise
191	%	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	to	_	_	I-Premise
195	end	_	_	I-Premise
196	point	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	hypnosis	_	_	I-Premise
200	arm	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	.001	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Significant	_	_	B-Premise
208	improvements	_	_	I-Premise
209	in	_	_	I-Premise
210	self-reported	_	_	I-Premise
211	anxiety	_	_	I-Premise
212	,	_	_	I-Premise
213	depression	_	_	I-Premise
214	,	_	_	I-Premise
215	interference	_	_	I-Premise
216	of	_	_	I-Premise
217	hot	_	_	I-Premise
218	flashes	_	_	I-Premise
219	on	_	_	I-Premise
220	daily	_	_	I-Premise
221	activities	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	sleep	_	_	I-Premise
225	were	_	_	I-Premise
226	observed	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	who	_	_	I-Premise
230	received	_	_	I-Premise
231	the	_	_	I-Premise
232	hypnosis	_	_	I-Premise
233	intervention	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	.005	_	_	I-Premise
238	)	_	_	I-Premise
239	in	_	_	I-Premise
240	comparison	_	_	I-Premise
241	to	_	_	I-Premise
242	the	_	_	I-Premise
243	no	_	_	I-Premise
244	treatment	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	.	_	_	I-Premise

248	Hypnosis	_	_	B-Claim
249	appears	_	_	I-Claim
250	to	_	_	I-Claim
251	reduce	_	_	I-Claim
252	perceived	_	_	I-Claim
253	hot	_	_	I-Claim
254	flashes	_	_	I-Claim
255	in	_	_	I-Claim
256	breast	_	_	I-Claim
257	cancer	_	_	I-Claim
258	survivors	_	_	I-Claim
259	and	_	_	I-Claim
260	may	_	_	I-Claim
261	have	_	_	I-Claim
262	additional	_	_	I-Claim
263	benefits	_	_	I-Claim
264	such	_	_	I-Claim
265	as	_	_	I-Claim
266	reduced	_	_	I-Claim
267	anxiety	_	_	I-Claim
268	and	_	_	I-Claim
269	depression	_	_	I-Claim
270	,	_	_	I-Claim
271	and	_	_	I-Claim
272	improved	_	_	I-Claim
273	sleep	_	_	I-Claim
274	.	_	_	I-Claim


0	The	_	_	O
1	TAX	_	_	O
2	327	_	_	O
3	study	_	_	O
4	compared	_	_	O
5	docetaxel	_	_	O
6	administered	_	_	O
7	every	_	_	O
8	3	_	_	O
9	weeks	_	_	O
10	(	_	_	O
11	D3	_	_	O
12	)	_	_	O
13	,	_	_	O
14	weekly	_	_	O
15	docetaxel	_	_	O
16	(	_	_	O
17	D1	_	_	O
18	)	_	_	O
19	,	_	_	O
20	and	_	_	O
21	mitoxantrone	_	_	O
22	(	_	_	O
23	M	_	_	O
24	)	_	_	O
25	,	_	_	O
26	each	_	_	O
27	with	_	_	O
28	prednisone	_	_	O
29	(	_	_	O
30	P	_	_	O
31	)	_	_	O
32	,	_	_	O
33	in	_	_	O
34	1,006	_	_	O
35	men	_	_	O
36	with	_	_	O
37	metastatic	_	_	O
38	hormone-resistant	_	_	O
39	prostate	_	_	O
40	cancer	_	_	O
41	(	_	_	O
42	HRPC	_	_	O
43	)	_	_	O
44	.	_	_	O

45	The	_	_	O
46	original	_	_	O
47	analysis	_	_	O
48	,	_	_	O
49	undertaken	_	_	O
50	in	_	_	O
51	August	_	_	O
52	2003	_	_	O
53	when	_	_	O
54	557	_	_	O
55	deaths	_	_	O
56	had	_	_	O
57	occurred	_	_	O
58	,	_	_	O
59	showed	_	_	O
60	significantly	_	_	O
61	better	_	_	O
62	survival	_	_	O
63	and	_	_	O
64	response	_	_	O
65	rates	_	_	O
66	for	_	_	O
67	pain	_	_	O
68	,	_	_	O
69	prostate-specific	_	_	O
70	antigen	_	_	O
71	(	_	_	O
72	PSA	_	_	O
73	)	_	_	O
74	,	_	_	O
75	and	_	_	O
76	quality	_	_	O
77	of	_	_	O
78	life	_	_	O
79	for	_	_	O
80	D3P	_	_	O
81	when	_	_	O
82	compared	_	_	O
83	with	_	_	O
84	MP	_	_	O
85	.	_	_	O

86	Here	_	_	O
87	,	_	_	O
88	we	_	_	O
89	report	_	_	O
90	an	_	_	O
91	updated	_	_	O
92	analysis	_	_	O
93	of	_	_	O
94	survival	_	_	O
95	.	_	_	O

96	Investigators	_	_	O
97	were	_	_	O
98	asked	_	_	O
99	to	_	_	O
100	provide	_	_	O
101	the	_	_	O
102	date	_	_	O
103	of	_	_	O
104	death	_	_	O
105	or	_	_	O
106	last	_	_	O
107	follow-up	_	_	O
108	for	_	_	O
109	all	_	_	O
110	participants	_	_	O
111	who	_	_	O
112	were	_	_	O
113	alive	_	_	O
114	in	_	_	O
115	August	_	_	O
116	2003	_	_	O
117	.	_	_	O

118	By	_	_	O
119	March	_	_	O
120	2007	_	_	O
121	,	_	_	O
122	data	_	_	O
123	on	_	_	O
124	310	_	_	O
125	additional	_	_	O
126	deaths	_	_	O
127	were	_	_	O
128	obtained	_	_	O
129	(	_	_	O
130	total	_	_	O
131	=	_	_	O
132	867	_	_	O
133	deaths	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	survival	_	_	I-Premise
138	benefit	_	_	I-Premise
139	of	_	_	I-Premise
140	D3P	_	_	I-Premise
141	compared	_	_	I-Premise
142	with	_	_	I-Premise
143	MP	_	_	I-Premise
144	has	_	_	I-Premise
145	persisted	_	_	I-Premise
146	with	_	_	I-Premise
147	extended	_	_	I-Premise
148	follow-up	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	=	_	_	I-Premise
152	.004	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Median	_	_	O
156	survival	_	_	O
157	time	_	_	O
158	was	_	_	O
159	19.2	_	_	O
160	months	_	_	O
161	(	_	_	O
162	95	_	_	O
163	%	_	_	O
164	CI	_	_	O
165	,	_	_	O
166	17.5	_	_	O
167	to	_	_	O
168	21.3	_	_	O
169	months	_	_	O
170	)	_	_	O
171	in	_	_	O
172	the	_	_	O
173	D3P	_	_	O
174	arm	_	_	O
175	,	_	_	O
176	17.8	_	_	O
177	months	_	_	O
178	(	_	_	O
179	95	_	_	O
180	%	_	_	O
181	CI	_	_	O
182	,	_	_	O
183	16.2	_	_	O
184	to	_	_	O
185	19.2	_	_	O
186	months	_	_	O
187	)	_	_	O
188	in	_	_	O
189	the	_	_	O
190	D1P	_	_	O
191	arm	_	_	O
192	,	_	_	O
193	and	_	_	O
194	16.3	_	_	O
195	months	_	_	O
196	(	_	_	O
197	95	_	_	O
198	%	_	_	O
199	CI	_	_	O
200	,	_	_	O
201	14.3	_	_	O
202	to	_	_	O
203	17.9	_	_	O
204	months	_	_	O
205	)	_	_	O
206	in	_	_	O
207	the	_	_	O
208	MP	_	_	O
209	arm	_	_	O
210	.	_	_	O

211	More	_	_	B-Premise
212	patients	_	_	I-Premise
213	survived	_	_	I-Premise
214	>	_	_	I-Premise
215	/=	_	_	I-Premise
216	3	_	_	I-Premise
217	years	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	D3P	_	_	I-Premise
221	and	_	_	I-Premise
222	D1P	_	_	I-Premise
223	arms	_	_	I-Premise
224	(	_	_	I-Premise
225	18.6	_	_	I-Premise
226	%	_	_	I-Premise
227	and	_	_	I-Premise
228	16.6	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	the	_	_	I-Premise
236	MP	_	_	I-Premise
237	arm	_	_	I-Premise
238	(	_	_	I-Premise
239	13.5	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Similar	_	_	B-Premise
244	trends	_	_	I-Premise
245	in	_	_	I-Premise
246	survival	_	_	I-Premise
247	between	_	_	I-Premise
248	treatment	_	_	I-Premise
249	arms	_	_	I-Premise
250	were	_	_	I-Premise
251	seen	_	_	I-Premise
252	for	_	_	I-Premise
253	men	_	_	I-Premise
254	greater	_	_	I-Premise
255	than	_	_	I-Premise
256	and	_	_	I-Premise
257	less	_	_	I-Premise
258	than	_	_	I-Premise
259	65	_	_	I-Premise
260	years	_	_	I-Premise
261	of	_	_	I-Premise
262	age	_	_	I-Premise
263	,	_	_	I-Premise
264	for	_	_	I-Premise
265	those	_	_	I-Premise
266	with	_	_	I-Premise
267	and	_	_	I-Premise
268	without	_	_	I-Premise
269	pain	_	_	I-Premise
270	at	_	_	I-Premise
271	baseline	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	for	_	_	I-Premise
275	those	_	_	I-Premise
276	with	_	_	I-Premise
277	baseline	_	_	I-Premise
278	PSA	_	_	I-Premise
279	greater	_	_	I-Premise
280	than	_	_	I-Premise
281	and	_	_	I-Premise
282	less	_	_	I-Premise
283	than	_	_	I-Premise
284	the	_	_	I-Premise
285	median	_	_	I-Premise
286	value	_	_	I-Premise
287	of	_	_	I-Premise
288	115	_	_	I-Premise
289	ng/mL	_	_	I-Premise
290	.	_	_	I-Premise

291	The	_	_	B-Claim
292	present	_	_	I-Claim
293	analysis	_	_	I-Claim
294	confirms	_	_	I-Claim
295	that	_	_	I-Claim
296	survival	_	_	I-Claim
297	of	_	_	I-Claim
298	men	_	_	I-Claim
299	with	_	_	I-Claim
300	metastatic	_	_	I-Claim
301	HRPC	_	_	I-Claim
302	is	_	_	I-Claim
303	significantly	_	_	I-Claim
304	longer	_	_	I-Claim
305	after	_	_	I-Claim
306	treatment	_	_	I-Claim
307	with	_	_	I-Claim
308	D3P	_	_	I-Claim
309	than	_	_	I-Claim
310	with	_	_	I-Claim
311	MP	_	_	I-Claim
312	.	_	_	I-Claim

313	Consistent	_	_	O
314	results	_	_	O
315	are	_	_	O
316	observed	_	_	O
317	across	_	_	O
318	subgroups	_	_	O
319	of	_	_	O
320	patients	_	_	O
321	.	_	_	O


0	Both	_	_	O
1	gastrojejunostomy	_	_	O
2	(	_	_	O
3	GJJ	_	_	O
4	)	_	_	O
5	and	_	_	O
6	stent	_	_	O
7	placement	_	_	O
8	are	_	_	O
9	commonly	_	_	O
10	used	_	_	O
11	palliative	_	_	O
12	treatments	_	_	O
13	of	_	_	O
14	obstructive	_	_	O
15	symptoms	_	_	O
16	caused	_	_	O
17	by	_	_	O
18	malignant	_	_	O
19	gastric	_	_	O
20	outlet	_	_	O
21	obstruction	_	_	O
22	(	_	_	O
23	GOO	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Compare	_	_	O
27	GJJ	_	_	O
28	and	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	.	_	_	O

32	Multicenter	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	Twenty-one	_	_	O
38	centers	_	_	O
39	in	_	_	O
40	The	_	_	O
41	Netherlands	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	with	_	_	O
45	GOO	_	_	O
46	.	_	_	O

47	GJJ	_	_	O
48	and	_	_	O
49	stent	_	_	O
50	placement	_	_	O
51	.	_	_	O

52	Outcomes	_	_	O
53	were	_	_	O
54	medical	_	_	O
55	effects	_	_	O
56	,	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	,	_	_	O
61	and	_	_	O
62	costs	_	_	O
63	.	_	_	O

64	Analysis	_	_	O
65	was	_	_	O
66	by	_	_	O
67	intent	_	_	O
68	to	_	_	O
69	treat	_	_	O
70	.	_	_	O

71	Eighteen	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	to	_	_	O
76	GJJ	_	_	O
77	and	_	_	O
78	21	_	_	O
79	to	_	_	O
80	stent	_	_	O
81	placement	_	_	O
82	.	_	_	O

83	Food	_	_	B-Premise
84	intake	_	_	I-Premise
85	improved	_	_	I-Premise
86	more	_	_	I-Premise
87	rapidly	_	_	I-Premise
88	after	_	_	I-Premise
89	stent	_	_	I-Premise
90	placement	_	_	I-Premise
91	than	_	_	I-Premise
92	after	_	_	I-Premise
93	GJJ	_	_	I-Premise
94	(	_	_	I-Premise
95	GOO	_	_	I-Premise
96	Scoring	_	_	I-Premise
97	System	_	_	I-Premise
98	score	_	_	I-Premise
99	>	_	_	I-Premise
100	or	_	_	I-Premise
101	=	_	_	I-Premise
102	2	_	_	I-Premise
103	:	_	_	I-Premise
104	median	_	_	I-Premise
105	5	_	_	I-Premise
106	vs	_	_	I-Premise
107	8	_	_	I-Premise
108	days	_	_	I-Premise
109	,	_	_	I-Premise
110	respectively	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	<	_	_	I-Premise
114	.01	_	_	I-Premise
115	)	_	_	I-Premise
116	but	_	_	B-Premise
117	long-term	_	_	I-Premise
118	relief	_	_	I-Premise
119	was	_	_	I-Premise
120	better	_	_	I-Premise
121	after	_	_	I-Premise
122	GJJ	_	_	I-Premise
123	,	_	_	I-Premise
124	with	_	_	I-Premise
125	more	_	_	I-Premise
126	patients	_	_	I-Premise
127	living	_	_	I-Premise
128	more	_	_	I-Premise
129	days	_	_	I-Premise
130	with	_	_	I-Premise
131	a	_	_	I-Premise
132	GOO	_	_	I-Premise
133	Scoring	_	_	I-Premise
134	System	_	_	I-Premise
135	score	_	_	I-Premise
136	of	_	_	I-Premise
137	2	_	_	I-Premise
138	or	_	_	I-Premise
139	more	_	_	I-Premise
140	than	_	_	I-Premise
141	after	_	_	I-Premise
142	stent	_	_	I-Premise
143	placement	_	_	I-Premise
144	(	_	_	I-Premise
145	72	_	_	I-Premise
146	vs	_	_	I-Premise
147	50	_	_	I-Premise
148	days	_	_	I-Premise
149	,	_	_	I-Premise
150	respectively	_	_	I-Premise
151	;	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.05	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	More	_	_	B-Premise
158	major	_	_	I-Premise
159	complications	_	_	I-Premise
160	(	_	_	I-Premise
161	stent	_	_	I-Premise
162	:	_	_	I-Premise
163	6	_	_	I-Premise
164	in	_	_	I-Premise
165	4	_	_	I-Premise
166	patients	_	_	I-Premise
167	vs	_	_	I-Premise
168	GJJ	_	_	I-Premise
169	:	_	_	I-Premise
170	0	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.02	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	recurrent	_	_	I-Premise
178	obstructive	_	_	I-Premise
179	symptoms	_	_	I-Premise
180	(	_	_	I-Premise
181	stent	_	_	I-Premise
182	:	_	_	I-Premise
183	8	_	_	I-Premise
184	in	_	_	I-Premise
185	5	_	_	I-Premise
186	patients	_	_	I-Premise
187	vs	_	_	I-Premise
188	GJJ	_	_	I-Premise
189	:	_	_	I-Premise
190	1	_	_	I-Premise
191	in	_	_	I-Premise
192	1	_	_	I-Premise
193	patient	_	_	I-Premise
194	;	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.02	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	reinterventions	_	_	I-Premise
202	(	_	_	I-Premise
203	stent	_	_	I-Premise
204	:	_	_	I-Premise
205	10	_	_	I-Premise
206	in	_	_	I-Premise
207	7	_	_	I-Premise
208	patients	_	_	I-Premise
209	vs	_	_	I-Premise
210	GJJ	_	_	I-Premise
211	:	_	_	I-Premise
212	2	_	_	I-Premise
213	in	_	_	I-Premise
214	2	_	_	I-Premise
215	patients	_	_	I-Premise
216	;	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	.01	_	_	I-Premise
220	)	_	_	I-Premise
221	were	_	_	I-Premise
222	observed	_	_	I-Premise
223	after	_	_	I-Premise
224	stent	_	_	I-Premise
225	placement	_	_	I-Premise
226	compared	_	_	I-Premise
227	with	_	_	I-Premise
228	GJJ	_	_	I-Premise
229	.	_	_	I-Premise

230	When	_	_	B-Premise
231	stent	_	_	I-Premise
232	obstruction	_	_	I-Premise
233	was	_	_	I-Premise
234	not	_	_	I-Premise
235	regarded	_	_	I-Premise
236	as	_	_	I-Premise
237	a	_	_	I-Premise
238	major	_	_	I-Premise
239	complication	_	_	I-Premise
240	,	_	_	I-Premise
241	no	_	_	I-Premise
242	differences	_	_	I-Premise
243	in	_	_	I-Premise
244	complications	_	_	I-Premise
245	were	_	_	I-Premise
246	found	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	.4	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Premise
254	were	_	_	I-Premise
255	also	_	_	I-Premise
256	no	_	_	I-Premise
257	differences	_	_	I-Premise
258	in	_	_	I-Premise
259	median	_	_	I-Premise
260	survival	_	_	I-Premise
261	(	_	_	I-Premise
262	stent	_	_	I-Premise
263	:	_	_	I-Premise
264	56	_	_	I-Premise
265	days	_	_	I-Premise
266	vs	_	_	I-Premise
267	GJJ	_	_	I-Premise
268	:	_	_	I-Premise
269	78	_	_	I-Premise
270	days	_	_	I-Premise
271	)	_	_	I-Premise
272	and	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	.	_	_	I-Premise

277	Mean	_	_	B-Premise
278	total	_	_	I-Premise
279	costs	_	_	I-Premise
280	of	_	_	I-Premise
281	GJJ	_	_	I-Premise
282	were	_	_	I-Premise
283	higher	_	_	I-Premise
284	compared	_	_	I-Premise
285	with	_	_	I-Premise
286	stent	_	_	I-Premise
287	placement	_	_	I-Premise
288	(	_	_	I-Premise
289	$	_	_	I-Premise
290	16,535	_	_	I-Premise
291	vs	_	_	I-Premise
292	$	_	_	I-Premise
293	11,720	_	_	I-Premise
294	,	_	_	I-Premise
295	respectively	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.049	_	_	I-Premise
300	[	_	_	I-Premise
301	comparing	_	_	I-Premise
302	medians	_	_	I-Premise
303	]	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Because	_	_	O
307	of	_	_	O
308	the	_	_	O
309	small	_	_	O
310	study	_	_	O
311	population	_	_	O
312	,	_	_	O
313	only	_	_	O
314	initial	_	_	O
315	hospital	_	_	O
316	costs	_	_	O
317	would	_	_	O
318	have	_	_	O
319	been	_	_	O
320	statistically	_	_	O
321	significant	_	_	O
322	if	_	_	O
323	the	_	_	O
324	Bonferroni	_	_	O
325	correction	_	_	O
326	for	_	_	O
327	multiple	_	_	O
328	testing	_	_	O
329	had	_	_	O
330	been	_	_	O
331	applied	_	_	O
332	.	_	_	O

333	Relatively	_	_	O
334	small	_	_	O
335	patient	_	_	O
336	population	_	_	O
337	.	_	_	O

338	Despite	_	_	B-Premise
339	slow	_	_	I-Premise
340	initial	_	_	I-Premise
341	symptom	_	_	I-Premise
342	improvement	_	_	I-Premise
343	,	_	_	I-Premise
344	GJJ	_	_	B-Claim
345	was	_	_	I-Claim
346	associated	_	_	I-Claim
347	with	_	_	I-Claim
348	better	_	_	I-Claim
349	long-term	_	_	I-Claim
350	results	_	_	I-Claim
351	and	_	_	I-Claim
352	is	_	_	I-Claim
353	therefore	_	_	I-Claim
354	the	_	_	I-Claim
355	treatment	_	_	I-Claim
356	of	_	_	I-Claim
357	choice	_	_	I-Claim
358	in	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	a	_	_	I-Claim
362	life	_	_	I-Claim
363	expectancy	_	_	I-Claim
364	of	_	_	I-Claim
365	2	_	_	I-Claim
366	months	_	_	I-Claim
367	or	_	_	I-Claim
368	longer	_	_	I-Claim
369	.	_	_	I-Claim

370	Because	_	_	B-Claim
371	stent	_	_	I-Claim
372	placement	_	_	I-Claim
373	was	_	_	I-Claim
374	associated	_	_	I-Claim
375	with	_	_	I-Claim
376	better	_	_	I-Claim
377	short-term	_	_	I-Claim
378	outcomes	_	_	I-Claim
379	,	_	_	I-Claim
380	this	_	_	B-Claim
381	treatment	_	_	I-Claim
382	is	_	_	I-Claim
383	preferable	_	_	I-Claim
384	for	_	_	I-Claim
385	patients	_	_	I-Claim
386	expected	_	_	I-Claim
387	to	_	_	I-Claim
388	live	_	_	I-Claim
389	less	_	_	I-Claim
390	than	_	_	I-Claim
391	2	_	_	I-Claim
392	months	_	_	I-Claim
393	.	_	_	I-Claim


0	Vasomotor	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	adverse	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	antiestrogen	_	_	O
8	hormone	_	_	O
9	treatment	_	_	O
10	in	_	_	O
11	conventional	_	_	O
12	breast	_	_	O
13	cancer	_	_	O
14	care	_	_	O
15	.	_	_	O

16	Hormone	_	_	O
17	replacement	_	_	O
18	therapy	_	_	O
19	is	_	_	O
20	contraindicated	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Venlafaxine	_	_	O
28	(	_	_	O
29	Effexor	_	_	O
30	)	_	_	O
31	,	_	_	O
32	the	_	_	O
33	therapy	_	_	O
34	of	_	_	O
35	choice	_	_	O
36	for	_	_	O
37	these	_	_	O
38	symptoms	_	_	O
39	,	_	_	O
40	has	_	_	O
41	numerous	_	_	O
42	adverse	_	_	O
43	effects	_	_	O
44	.	_	_	O

45	Recent	_	_	O
46	studies	_	_	O
47	suggest	_	_	O
48	acupuncture	_	_	O
49	may	_	_	O
50	be	_	_	O
51	effective	_	_	O
52	in	_	_	O
53	reducing	_	_	O
54	vasomotor	_	_	O
55	symptoms	_	_	O
56	in	_	_	O
57	menopausal	_	_	O
58	women	_	_	O
59	.	_	_	O

60	This	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	tested	_	_	O
65	whether	_	_	O
66	acupuncture	_	_	O
67	reduces	_	_	O
68	vasomotor	_	_	O
69	symptoms	_	_	O
70	and	_	_	O
71	produces	_	_	O
72	fewer	_	_	O
73	adverse	_	_	O
74	effects	_	_	O
75	than	_	_	O
76	venlafaxine	_	_	O
77	.	_	_	O

78	Fifty	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	12	_	_	O
86	weeks	_	_	O
87	of	_	_	O
88	acupuncture	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	25	_	_	O
93	)	_	_	O
94	or	_	_	O
95	venlafaxine	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	25	_	_	O
100	)	_	_	O
101	treatment	_	_	O
102	.	_	_	O

103	Health	_	_	O
104	outcomes	_	_	O
105	were	_	_	O
106	measured	_	_	O
107	for	_	_	O
108	up	_	_	O
109	to	_	_	O
110	1	_	_	O
111	year	_	_	O
112	post-treatment	_	_	O
113	.	_	_	O

114	Both	_	_	B-Premise
115	groups	_	_	I-Premise
116	exhibited	_	_	I-Premise
117	significant	_	_	I-Premise
118	decreases	_	_	I-Premise
119	in	_	_	I-Premise
120	hot	_	_	I-Premise
121	flashes	_	_	I-Premise
122	,	_	_	I-Premise
123	depressive	_	_	I-Premise
124	symptoms	_	_	I-Premise
125	,	_	_	I-Premise
126	and	_	_	I-Premise
127	other	_	_	I-Premise
128	quality-of-life	_	_	I-Premise
129	symptoms	_	_	I-Premise
130	,	_	_	I-Premise
131	including	_	_	I-Premise
132	significant	_	_	I-Premise
133	improvements	_	_	I-Premise
134	in	_	_	I-Premise
135	mental	_	_	I-Premise
136	health	_	_	I-Premise
137	from	_	_	I-Premise
138	pre-	_	_	I-Premise
139	to	_	_	I-Premise
140	post-treatment	_	_	I-Premise
141	.	_	_	I-Premise

142	These	_	_	B-Premise
143	changes	_	_	I-Premise
144	were	_	_	I-Premise
145	similar	_	_	I-Premise
146	in	_	_	I-Premise
147	both	_	_	I-Premise
148	groups	_	_	I-Premise
149	,	_	_	I-Premise
150	indicating	_	_	I-Premise
151	that	_	_	I-Premise
152	acupuncture	_	_	I-Premise
153	was	_	_	I-Premise
154	as	_	_	I-Premise
155	effective	_	_	I-Premise
156	as	_	_	I-Premise
157	venlafaxine	_	_	I-Premise
158	.	_	_	I-Premise

159	By	_	_	B-Premise
160	2	_	_	I-Premise
161	weeks	_	_	I-Premise
162	post-treatment	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	venlafaxine	_	_	I-Premise
166	group	_	_	I-Premise
167	experienced	_	_	I-Premise
168	significant	_	_	I-Premise
169	increases	_	_	I-Premise
170	in	_	_	I-Premise
171	hot	_	_	I-Premise
172	flashes	_	_	I-Premise
173	,	_	_	I-Premise
174	whereas	_	_	I-Premise
175	hot	_	_	I-Premise
176	flashes	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	acupuncture	_	_	I-Premise
180	group	_	_	I-Premise
181	remained	_	_	I-Premise
182	at	_	_	I-Premise
183	low	_	_	I-Premise
184	levels	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	venlafaxine	_	_	I-Premise
188	group	_	_	I-Premise
189	experienced	_	_	I-Premise
190	18	_	_	I-Premise
191	incidences	_	_	I-Premise
192	of	_	_	I-Premise
193	adverse	_	_	I-Premise
194	effects	_	_	I-Premise
195	(	_	_	I-Premise
196	eg	_	_	I-Premise
197	,	_	_	I-Premise
198	nausea	_	_	I-Premise
199	,	_	_	I-Premise
200	dry	_	_	I-Premise
201	mouth	_	_	I-Premise
202	,	_	_	I-Premise
203	dizziness	_	_	I-Premise
204	,	_	_	I-Premise
205	anxiety	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	whereas	_	_	I-Premise
209	the	_	_	I-Premise
210	acupuncture	_	_	I-Premise
211	group	_	_	I-Premise
212	experienced	_	_	I-Premise
213	no	_	_	I-Premise
214	negative	_	_	I-Premise
215	adverse	_	_	I-Premise
216	effects	_	_	I-Premise
217	.	_	_	I-Premise

218	Acupuncture	_	_	B-Premise
219	had	_	_	I-Premise
220	the	_	_	I-Premise
221	additional	_	_	I-Premise
222	benefit	_	_	I-Premise
223	of	_	_	I-Premise
224	increased	_	_	I-Premise
225	sex	_	_	I-Premise
226	drive	_	_	I-Premise
227	in	_	_	I-Premise
228	some	_	_	I-Premise
229	women	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	most	_	_	I-Premise
233	reported	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	their	_	_	I-Premise
238	energy	_	_	I-Premise
239	,	_	_	I-Premise
240	clarity	_	_	I-Premise
241	of	_	_	I-Premise
242	thought	_	_	I-Premise
243	,	_	_	I-Premise
244	and	_	_	I-Premise
245	sense	_	_	I-Premise
246	of	_	_	I-Premise
247	well-being	_	_	I-Premise
248	.	_	_	I-Premise

249	Acupuncture	_	_	B-Claim
250	appears	_	_	I-Claim
251	to	_	_	I-Claim
252	be	_	_	I-Claim
253	equivalent	_	_	I-Claim
254	to	_	_	I-Claim
255	drug	_	_	I-Claim
256	therapy	_	_	I-Claim
257	in	_	_	I-Claim
258	these	_	_	I-Claim
259	patients	_	_	I-Claim
260	.	_	_	I-Claim

261	It	_	_	B-Claim
262	is	_	_	I-Claim
263	a	_	_	I-Claim
264	safe	_	_	I-Claim
265	,	_	_	I-Claim
266	effective	_	_	I-Claim
267	and	_	_	I-Claim
268	durable	_	_	I-Claim
269	treatment	_	_	I-Claim
270	for	_	_	I-Claim
271	vasomotor	_	_	I-Claim
272	symptoms	_	_	I-Claim
273	secondary	_	_	I-Claim
274	to	_	_	I-Claim
275	long-term	_	_	I-Claim
276	antiestrogen	_	_	I-Claim
277	hormone	_	_	I-Claim
278	use	_	_	I-Claim
279	in	_	_	I-Claim
280	patients	_	_	I-Claim
281	with	_	_	I-Claim
282	breast	_	_	I-Claim
283	cancer	_	_	I-Claim
284	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	is	_	_	O
3	regarded	_	_	O
4	as	_	_	O
5	the	_	_	O
6	only	_	_	O
7	curative	_	_	O
8	option	_	_	O
9	for	_	_	O
10	resectable	_	_	O
11	oesophageal	_	_	O
12	cancer	_	_	O
13	,	_	_	O
14	but	_	_	O
15	pulmonary	_	_	O
16	complications	_	_	O
17	occurring	_	_	O
18	in	_	_	O
19	more	_	_	O
20	than	_	_	O
21	half	_	_	O
22	of	_	_	O
23	patients	_	_	O
24	after	_	_	O
25	open	_	_	O
26	oesophagectomy	_	_	O
27	are	_	_	O
28	a	_	_	O
29	great	_	_	O
30	concern	_	_	O
31	.	_	_	O

32	We	_	_	O
33	assessed	_	_	O
34	whether	_	_	O
35	minimally	_	_	O
36	invasive	_	_	O
37	oesophagectomy	_	_	O
38	reduces	_	_	O
39	morbidity	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	open	_	_	O
43	oesophagectomy	_	_	O
44	.	_	_	O

45	We	_	_	O
46	did	_	_	O
47	a	_	_	O
48	multicentre	_	_	O
49	,	_	_	O
50	open-label	_	_	O
51	,	_	_	O
52	randomised	_	_	O
53	controlled	_	_	O
54	trial	_	_	O
55	at	_	_	O
56	five	_	_	O
57	study	_	_	O
58	centres	_	_	O
59	in	_	_	O
60	three	_	_	O
61	countries	_	_	O
62	between	_	_	O
63	June	_	_	O
64	1	_	_	O
65	,	_	_	O
66	2009	_	_	O
67	,	_	_	O
68	and	_	_	O
69	March	_	_	O
70	31	_	_	O
71	,	_	_	O
72	2011	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	aged	_	_	O
76	18-75	_	_	O
77	years	_	_	O
78	with	_	_	O
79	resectable	_	_	O
80	cancer	_	_	O
81	of	_	_	O
82	the	_	_	O
83	oesophagus	_	_	O
84	or	_	_	O
85	gastro-oesophageal	_	_	O
86	junction	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	via	_	_	O
91	a	_	_	O
92	computer-generated	_	_	O
93	randomisation	_	_	O
94	sequence	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	either	_	_	O
98	open	_	_	O
99	transthoracic	_	_	O
100	or	_	_	O
101	minimally	_	_	O
102	invasive	_	_	O
103	transthoracic	_	_	O
104	oesophagectomy	_	_	O
105	.	_	_	O

106	Randomisation	_	_	O
107	was	_	_	O
108	stratified	_	_	O
109	by	_	_	O
110	centre	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	,	_	_	O
114	and	_	_	O
115	investigators	_	_	O
116	undertaking	_	_	O
117	interventions	_	_	O
118	,	_	_	O
119	assessing	_	_	O
120	outcomes	_	_	O
121	,	_	_	O
122	and	_	_	O
123	analysing	_	_	O
124	data	_	_	O
125	,	_	_	O
126	were	_	_	O
127	not	_	_	O
128	masked	_	_	O
129	to	_	_	O
130	group	_	_	O
131	assignment	_	_	O
132	.	_	_	O

133	The	_	_	O
134	primary	_	_	O
135	outcome	_	_	O
136	was	_	_	O
137	pulmonary	_	_	O
138	infection	_	_	O
139	within	_	_	O
140	the	_	_	O
141	first	_	_	O
142	2	_	_	O
143	weeks	_	_	O
144	after	_	_	O
145	surgery	_	_	O
146	and	_	_	O
147	during	_	_	O
148	the	_	_	O
149	whole	_	_	O
150	stay	_	_	O
151	in	_	_	O
152	hospital	_	_	O
153	.	_	_	O

154	Analysis	_	_	O
155	was	_	_	O
156	by	_	_	O
157	intention	_	_	O
158	to	_	_	O
159	treat	_	_	O
160	.	_	_	O

161	This	_	_	O
162	trial	_	_	O
163	is	_	_	O
164	registered	_	_	O
165	with	_	_	O
166	the	_	_	O
167	Netherlands	_	_	O
168	Trial	_	_	O
169	Register	_	_	O
170	,	_	_	O
171	NTR	_	_	O
172	TC	_	_	O
173	2452	_	_	O
174	.	_	_	O

175	We	_	_	O
176	randomly	_	_	O
177	assigned	_	_	O
178	56	_	_	O
179	patients	_	_	O
180	to	_	_	O
181	the	_	_	O
182	open	_	_	O
183	oesophagectomy	_	_	O
184	group	_	_	O
185	and	_	_	O
186	59	_	_	O
187	to	_	_	O
188	the	_	_	O
189	minimally	_	_	O
190	invasive	_	_	O
191	oesophagectomy	_	_	O
192	group	_	_	O
193	.	_	_	O

194	16	_	_	B-Premise
195	(	_	_	I-Premise
196	29	_	_	I-Premise
197	%	_	_	I-Premise
198	)	_	_	I-Premise
199	patients	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	open	_	_	I-Premise
203	oesophagectomy	_	_	I-Premise
204	group	_	_	I-Premise
205	had	_	_	I-Premise
206	pulmonary	_	_	I-Premise
207	infection	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	first	_	_	I-Premise
211	2	_	_	I-Premise
212	weeks	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	five	_	_	I-Premise
216	(	_	_	I-Premise
217	9	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	in	_	_	I-Premise
221	the	_	_	I-Premise
222	minimally	_	_	I-Premise
223	invasive	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	relative	_	_	I-Premise
227	risk	_	_	I-Premise
228	[	_	_	I-Premise
229	RR	_	_	I-Premise
230	]	_	_	I-Premise
231	0Â·30	_	_	I-Premise
232	,	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	0Â·12-0Â·76	_	_	I-Premise
237	;	_	_	I-Premise
238	p=0Â·005	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	19	_	_	B-Premise
242	(	_	_	I-Premise
243	34	_	_	I-Premise
244	%	_	_	I-Premise
245	)	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	open	_	_	I-Premise
250	oesophagectomy	_	_	I-Premise
251	group	_	_	I-Premise
252	had	_	_	I-Premise
253	pulmonary	_	_	I-Premise
254	infection	_	_	I-Premise
255	in-hospital	_	_	I-Premise
256	compared	_	_	I-Premise
257	with	_	_	I-Premise
258	seven	_	_	I-Premise
259	(	_	_	I-Premise
260	12	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	minimally	_	_	I-Premise
266	invasive	_	_	I-Premise
267	group	_	_	I-Premise
268	(	_	_	I-Premise
269	0Â·35	_	_	I-Premise
270	,	_	_	I-Premise
271	0Â·16-0Â·78	_	_	I-Premise
272	;	_	_	I-Premise
273	p=0Â·005	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	For	_	_	B-Premise
277	in-hospital	_	_	I-Premise
278	mortality	_	_	I-Premise
279	,	_	_	I-Premise
280	one	_	_	I-Premise
281	patient	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	open	_	_	I-Premise
285	oesophagectomy	_	_	I-Premise
286	group	_	_	I-Premise
287	died	_	_	I-Premise
288	from	_	_	I-Premise
289	anastomotic	_	_	I-Premise
290	leakage	_	_	I-Premise
291	and	_	_	I-Premise
292	two	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	minimally	_	_	I-Premise
296	invasive	_	_	I-Premise
297	group	_	_	I-Premise
298	from	_	_	I-Premise
299	aspiration	_	_	I-Premise
300	and	_	_	I-Premise
301	mediastinitis	_	_	I-Premise
302	after	_	_	I-Premise
303	anastomotic	_	_	I-Premise
304	leakage	_	_	I-Premise
305	.	_	_	I-Premise

306	These	_	_	B-Claim
307	findings	_	_	I-Claim
308	provide	_	_	I-Claim
309	evidence	_	_	I-Claim
310	for	_	_	I-Claim
311	the	_	_	I-Claim
312	short-term	_	_	I-Claim
313	benefits	_	_	I-Claim
314	of	_	_	I-Claim
315	minimally	_	_	I-Claim
316	invasive	_	_	I-Claim
317	oesophagectomy	_	_	I-Claim
318	for	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	resectable	_	_	I-Claim
322	oesophageal	_	_	I-Claim
323	cancer	_	_	I-Claim
324	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	assess	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	acupuncture	_	_	O
8	for	_	_	O
9	cancer-related	_	_	O
10	fatigue	_	_	O
11	(	_	_	O
12	CRF	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	.	_	_	O

20	We	_	_	O
21	conducted	_	_	O
22	a	_	_	O
23	pragmatic	_	_	O
24	,	_	_	O
25	randomized	_	_	O
26	controlled	_	_	O
27	trial	_	_	O
28	comparing	_	_	O
29	acupuncture	_	_	O
30	with	_	_	O
31	enhanced	_	_	O
32	usual	_	_	O
33	care	_	_	O
34	.	_	_	O

35	Three	_	_	O
36	hundred	_	_	O
37	two	_	_	O
38	outpatients	_	_	O
39	with	_	_	O
40	breast	_	_	O
41	cancer	_	_	O
42	participated	_	_	O
43	.	_	_	O

44	We	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	75	_	_	O
48	patients	_	_	O
49	to	_	_	O
50	usual	_	_	O
51	care	_	_	O
52	and	_	_	O
53	227	_	_	O
54	patients	_	_	O
55	to	_	_	O
56	acupuncture	_	_	O
57	plus	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	random	_	_	O
62	assignment	_	_	O
63	of	_	_	O
64	1:3	_	_	O
65	respectively	_	_	O
66	)	_	_	O
67	with	_	_	O
68	minimization	_	_	O
69	controlling	_	_	O
70	for	_	_	O
71	baseline	_	_	O
72	general	_	_	O
73	fatigue	_	_	O
74	and	_	_	O
75	maintenance	_	_	O
76	treatment	_	_	O
77	.	_	_	O

78	Treatment	_	_	O
79	was	_	_	O
80	delivered	_	_	O
81	by	_	_	O
82	acupuncturists	_	_	O
83	once	_	_	O
84	a	_	_	O
85	week	_	_	O
86	for	_	_	O
87	6	_	_	O
88	weeks	_	_	O
89	through	_	_	O
90	needling	_	_	O
91	three	_	_	O
92	pairs	_	_	O
93	of	_	_	O
94	acupoints	_	_	O
95	.	_	_	O

96	The	_	_	O
97	usual	_	_	O
98	care	_	_	O
99	group	_	_	O
100	received	_	_	O
101	a	_	_	O
102	booklet	_	_	O
103	with	_	_	O
104	information	_	_	O
105	about	_	_	O
106	fatigue	_	_	O
107	and	_	_	O
108	its	_	_	O
109	management	_	_	O
110	.	_	_	O

111	Primary	_	_	O
112	outcome	_	_	O
113	was	_	_	O
114	general	_	_	O
115	fatigue	_	_	O
116	at	_	_	O
117	6	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	measured	_	_	O
121	with	_	_	O
122	the	_	_	O
123	Multidimensional	_	_	O
124	Fatigue	_	_	O
125	Inventory	_	_	O
126	(	_	_	O
127	MFI	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Other	_	_	O
131	measurements	_	_	O
132	included	_	_	O
133	the	_	_	O
134	Hospital	_	_	O
135	Anxiety	_	_	O
136	and	_	_	O
137	Depression	_	_	O
138	Scale	_	_	O
139	,	_	_	O
140	Functional	_	_	O
141	Assessment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	Therapy-General	_	_	O
145	quality-of-life	_	_	O
146	scale	_	_	O
147	,	_	_	O
148	and	_	_	O
149	expectation	_	_	O
150	of	_	_	O
151	acupuncture	_	_	O
152	effect	_	_	O
153	.	_	_	O

154	Analyses	_	_	O
155	were	_	_	O
156	by	_	_	O
157	intention	_	_	O
158	to	_	_	O
159	treat	_	_	O
160	.	_	_	O

161	Two	_	_	O
162	hundred	_	_	O
163	forty-six	_	_	O
164	of	_	_	O
165	302	_	_	O
166	patients	_	_	O
167	randomly	_	_	O
168	assigned	_	_	O
169	provided	_	_	O
170	complete	_	_	O
171	data	_	_	O
172	at	_	_	O
173	6	_	_	O
174	weeks	_	_	O
175	.	_	_	O

176	The	_	_	B-Premise
177	difference	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	mean	_	_	I-Premise
181	General	_	_	I-Premise
182	Fatigue	_	_	I-Premise
183	score	_	_	I-Premise
184	,	_	_	I-Premise
185	between	_	_	I-Premise
186	those	_	_	I-Premise
187	who	_	_	I-Premise
188	received	_	_	I-Premise
189	the	_	_	I-Premise
190	intervention	_	_	I-Premise
191	and	_	_	I-Premise
192	those	_	_	I-Premise
193	who	_	_	I-Premise
194	did	_	_	I-Premise
195	not	_	_	I-Premise
196	,	_	_	I-Premise
197	was	_	_	I-Premise
198	-3.11	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	-3.97	_	_	I-Premise
205	to	_	_	I-Premise
206	-2.25	_	_	I-Premise
207	;	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	.001	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	intervention	_	_	I-Premise
215	also	_	_	I-Premise
216	improved	_	_	I-Premise
217	all	_	_	I-Premise
218	other	_	_	I-Premise
219	fatigue	_	_	I-Premise
220	aspects	_	_	I-Premise
221	measured	_	_	I-Premise
222	by	_	_	I-Premise
223	MFI	_	_	I-Premise
224	,	_	_	I-Premise
225	including	_	_	I-Premise
226	Physical	_	_	I-Premise
227	Fatigue	_	_	I-Premise
228	and	_	_	I-Premise
229	Mental	_	_	I-Premise
230	Fatigue	_	_	I-Premise
231	(	_	_	I-Premise
232	acupuncture	_	_	I-Premise
233	effect	_	_	I-Premise
234	,	_	_	I-Premise
235	-2.36	_	_	I-Premise
236	and	_	_	I-Premise
237	-1.94	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	;	_	_	I-Premise
241	both	_	_	I-Premise
242	at	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	.001	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	anxiety	_	_	I-Premise
249	and	_	_	I-Premise
250	depression	_	_	I-Premise
251	(	_	_	I-Premise
252	acupuncture	_	_	I-Premise
253	effect	_	_	I-Premise
254	,	_	_	I-Premise
255	-1.83	_	_	I-Premise
256	and	_	_	I-Premise
257	-2.13	_	_	I-Premise
258	,	_	_	I-Premise
259	respectively	_	_	I-Premise
260	;	_	_	I-Premise
261	both	_	_	I-Premise
262	at	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	.001	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	quality	_	_	I-Premise
270	of	_	_	I-Premise
271	life	_	_	I-Premise
272	(	_	_	I-Premise
273	Physical	_	_	I-Premise
274	Well-Being	_	_	I-Premise
275	effect	_	_	I-Premise
276	,	_	_	I-Premise
277	3.30	_	_	I-Premise
278	;	_	_	I-Premise
279	Functional	_	_	I-Premise
280	Well-Being	_	_	I-Premise
281	effect	_	_	I-Premise
282	,	_	_	I-Premise
283	3.57	_	_	I-Premise
284	;	_	_	I-Premise
285	both	_	_	I-Premise
286	at	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	.001	_	_	I-Premise
290	;	_	_	I-Premise
291	Emotional	_	_	I-Premise
292	Well-Being	_	_	I-Premise
293	effect	_	_	I-Premise
294	,	_	_	I-Premise
295	1.93	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.001	_	_	I-Premise
300	;	_	_	I-Premise
301	and	_	_	I-Premise
302	Social	_	_	I-Premise
303	Functioning	_	_	I-Premise
304	Well-Being	_	_	I-Premise
305	effect	_	_	I-Premise
306	,	_	_	I-Premise
307	1.05	_	_	I-Premise
308	;	_	_	I-Premise
309	P	_	_	I-Premise
310	<	_	_	I-Premise
311	.05	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	Acupuncture	_	_	B-Claim
315	is	_	_	I-Claim
316	an	_	_	I-Claim
317	effective	_	_	I-Claim
318	intervention	_	_	I-Claim
319	for	_	_	I-Claim
320	managing	_	_	I-Claim
321	the	_	_	I-Claim
322	symptom	_	_	I-Claim
323	of	_	_	I-Claim
324	CRF	_	_	I-Claim
325	and	_	_	I-Claim
326	improving	_	_	I-Claim
327	patients	_	_	I-Claim
328	'	_	_	I-Claim
329	quality	_	_	I-Claim
330	of	_	_	I-Claim
331	life	_	_	I-Claim
332	.	_	_	I-Claim


0	The	_	_	O
1	Intergroup	_	_	O
2	conducted	_	_	O
3	this	_	_	O
4	breast	_	_	O
5	cancer	_	_	O
6	adjuvant	_	_	O
7	trial	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	an	_	_	O
11	investigational	_	_	O
12	16-week	_	_	O
13	regimen	_	_	O
14	with	_	_	O
15	cyclophosphamide	_	_	O
16	,	_	_	O
17	doxorubicin	_	_	O
18	,	_	_	O
19	and	_	_	O
20	fluorouracil	_	_	O
21	(	_	_	O
22	5-FU	_	_	O
23	;	_	_	O
24	CAF	_	_	O
25	)	_	_	O
26	.	_	_	O

27	The	_	_	O
28	16-week	_	_	O
29	regimen	_	_	O
30	features	_	_	O
31	greater	_	_	O
32	doxorubicin	_	_	O
33	and	_	_	O
34	5-FU	_	_	O
35	dose-intensity	_	_	O
36	than	_	_	O
37	CAF	_	_	O
38	and	_	_	O
39	improved	_	_	O
40	scheduling	_	_	O
41	of	_	_	O
42	antimetabolites	_	_	O
43	with	_	_	O
44	sequential	_	_	O
45	methotrexate	_	_	O
46	and	_	_	O
47	5-FU	_	_	O
48	,	_	_	O
49	as	_	_	O
50	well	_	_	O
51	as	_	_	O
52	infusion	_	_	O
53	5-FU	_	_	O
54	.	_	_	O

55	A	_	_	O
56	total	_	_	O
57	of	_	_	O
58	646	_	_	O
59	node-positive	_	_	O
60	,	_	_	O
61	receptor-negative	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	either	_	_	O
69	the	_	_	O
70	1	_	_	O
71	6-week	_	_	O
72	regimen	_	_	O
73	or	_	_	O
74	six	_	_	O
75	cycles	_	_	O
76	of	_	_	O
77	CAF	_	_	O
78	.	_	_	O

79	Breast	_	_	O
80	cancer	_	_	O
81	outcomes	_	_	O
82	included	_	_	O
83	recurrence	_	_	O
84	as	_	_	O
85	well	_	_	O
86	as	_	_	O
87	disease-free	_	_	O
88	and	_	_	O
89	overall	_	_	O
90	survival	_	_	O
91	.	_	_	O

92	Toxicity	_	_	O
93	was	_	_	O
94	evaluated	_	_	O
95	by	_	_	O
96	the	_	_	O
97	Common	_	_	O
98	Toxicity	_	_	O
99	Criteria	_	_	O
100	(	_	_	O
101	CTC	_	_	O
102	)	_	_	O
103	.	_	_	O

104	Treatment-related	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	was	_	_	O
109	assessed	_	_	O
110	by	_	_	O
111	the	_	_	O
112	Breast	_	_	O
113	Chemotherapy	_	_	O
114	Questionnaire	_	_	O
115	(	_	_	O
116	BCQ	_	_	O
117	)	_	_	O
118	before	_	_	O
119	,	_	_	O
120	during	_	_	O
121	,	_	_	O
122	and	_	_	O
123	4	_	_	O
124	months	_	_	O
125	after	_	_	O
126	treatment	_	_	O
127	in	_	_	O
128	163	_	_	O
129	patients	_	_	O
130	.	_	_	O

131	The	_	_	O
132	trial	_	_	O
133	was	_	_	O
134	designed	_	_	O
135	to	_	_	O
136	use	_	_	O
137	one-sided	_	_	O
138	tests	_	_	O
139	of	_	_	O
140	significance	_	_	O
141	for	_	_	O
142	power	_	_	O
143	calculations	_	_	O
144	,	_	_	O
145	but	_	_	O
146	is	_	_	O
147	now	_	_	O
148	reported	_	_	O
149	with	_	_	O
150	both	_	_	O
151	one-sided	_	_	O
152	and	_	_	O
153	the	_	_	O
154	traditional	_	_	O
155	two-sided	_	_	O
156	tests	_	_	O
157	of	_	_	O
158	significance	_	_	O
159	.	_	_	O

160	At	_	_	B-Premise
161	a	_	_	I-Premise
162	median	_	_	I-Premise
163	follow-up	_	_	I-Premise
164	of	_	_	I-Premise
165	3.9	_	_	I-Premise
166	years	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	estimated	_	_	I-Premise
170	4-year	_	_	I-Premise
171	recurrence-free	_	_	I-Premise
172	survival	_	_	I-Premise
173	rate	_	_	I-Premise
174	was	_	_	I-Premise
175	67.5	_	_	I-Premise
176	%	_	_	I-Premise
177	with	_	_	I-Premise
178	the	_	_	I-Premise
179	16-week	_	_	I-Premise
180	regimen	_	_	I-Premise
181	versus	_	_	I-Premise
182	62.7	_	_	I-Premise
183	%	_	_	I-Premise
184	with	_	_	I-Premise
185	CAF	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.19	_	_	I-Premise
190	,	_	_	I-Premise
191	two-sided	_	_	I-Premise
192	;	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.095	_	_	I-Premise
196	,	_	_	I-Premise
197	one-sided	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	estimated	_	_	I-Premise
202	4-year	_	_	I-Premise
203	survival	_	_	I-Premise
204	rate	_	_	I-Premise
205	was	_	_	I-Premise
206	78.1	_	_	I-Premise
207	%	_	_	I-Premise
208	with	_	_	I-Premise
209	the	_	_	I-Premise
210	16-week	_	_	I-Premise
211	regimen	_	_	I-Premise
212	versus	_	_	I-Premise
213	71.4	_	_	I-Premise
214	%	_	_	I-Premise
215	with	_	_	I-Premise
216	CAF	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.10	_	_	I-Premise
221	,	_	_	I-Premise
222	two-sided	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.05	_	_	I-Premise
227	,	_	_	I-Premise
228	one-sided	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	CAF	_	_	B-Premise
232	produced	_	_	I-Premise
233	significantly	_	_	I-Premise
234	higher	_	_	I-Premise
235	grades	_	_	I-Premise
236	of	_	_	I-Premise
237	leukopenia	_	_	I-Premise
238	,	_	_	I-Premise
239	granulocytopenia	_	_	I-Premise
240	,	_	_	I-Premise
241	and	_	_	I-Premise
242	thrombocytopenia	_	_	I-Premise
243	,	_	_	I-Premise
244	as	_	_	I-Premise
245	well	_	_	I-Premise
246	as	_	_	I-Premise
247	liver	_	_	I-Premise
248	and	_	_	I-Premise
249	cardiac	_	_	I-Premise
250	toxicity	_	_	I-Premise
251	,	_	_	I-Premise
252	whereas	_	_	O
253	the	_	_	B-Premise
254	16-week	_	_	I-Premise
255	regimen	_	_	I-Premise
256	produced	_	_	I-Premise
257	significantly	_	_	I-Premise
258	higher	_	_	I-Premise
259	grades	_	_	I-Premise
260	of	_	_	I-Premise
261	anemia	_	_	I-Premise
262	,	_	_	I-Premise
263	nausea	_	_	I-Premise
264	,	_	_	I-Premise
265	stomatitis	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	weight	_	_	I-Premise
269	loss	_	_	I-Premise
270	,	_	_	I-Premise
271	as	_	_	I-Premise
272	well	_	_	I-Premise
273	as	_	_	I-Premise
274	skin	_	_	I-Premise
275	and	_	_	I-Premise
276	neurotoxicity	_	_	I-Premise
277	.	_	_	I-Premise

278	There	_	_	B-Premise
279	were	_	_	I-Premise
280	three	_	_	I-Premise
281	treatment-related	_	_	I-Premise
282	deaths	_	_	I-Premise
283	with	_	_	I-Premise
284	CAF	_	_	I-Premise
285	but	_	_	B-Premise
286	none	_	_	I-Premise
287	with	_	_	I-Premise
288	the	_	_	I-Premise
289	16-week	_	_	I-Premise
290	regimen	_	_	I-Premise
291	.	_	_	I-Premise

292	During	_	_	B-Premise
293	treatment	_	_	I-Premise
294	,	_	_	I-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	declined	_	_	I-Premise
299	significantly	_	_	I-Premise
300	more	_	_	I-Premise
301	with	_	_	I-Premise
302	the	_	_	I-Premise
303	16-week	_	_	I-Premise
304	regimen	_	_	I-Premise
305	than	_	_	I-Premise
306	CAF	_	_	I-Premise
307	,	_	_	I-Premise
308	but	_	_	B-Premise
309	by	_	_	I-Premise
310	4	_	_	I-Premise
311	months	_	_	I-Premise
312	posttreatment	_	_	I-Premise
313	,	_	_	I-Premise
314	there	_	_	I-Premise
315	was	_	_	I-Premise
316	no	_	_	I-Premise
317	difference	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Premise
320	16-week	_	_	I-Premise
321	regimen	_	_	I-Premise
322	produced	_	_	I-Premise
323	marginally	_	_	I-Premise
324	better	_	_	I-Premise
325	breast	_	_	I-Premise
326	cancer	_	_	I-Premise
327	outcomes	_	_	I-Premise
328	than	_	_	I-Premise
329	CAF	_	_	I-Premise
330	with	_	_	I-Premise
331	similar	_	_	I-Premise
332	toxicity	_	_	I-Premise
333	but	_	_	I-Premise
334	a	_	_	I-Premise
335	greater	_	_	I-Premise
336	reduction	_	_	I-Premise
337	in	_	_	I-Premise
338	during-treatment	_	_	I-Premise
339	quality	_	_	I-Premise
340	of	_	_	I-Premise
341	life	_	_	I-Premise
342	.	_	_	I-Premise

343	The	_	_	B-Claim
344	16-week	_	_	I-Claim
345	regimen	_	_	I-Claim
346	should	_	_	I-Claim
347	not	_	_	I-Claim
348	be	_	_	I-Claim
349	used	_	_	I-Claim
350	instead	_	_	I-Claim
351	of	_	_	I-Claim
352	a	_	_	I-Claim
353	standard-dose	_	_	I-Claim
354	regimen	_	_	I-Claim
355	without	_	_	I-Claim
356	careful	_	_	I-Claim
357	consideration	_	_	I-Claim
358	of	_	_	I-Claim
359	the	_	_	I-Claim
360	16-week	_	_	I-Claim
361	regimen	_	_	I-Claim
362	's	_	_	I-Claim
363	pros	_	_	I-Claim
364	and	_	_	I-Claim
365	cons	_	_	I-Claim
366	,	_	_	I-Claim
367	which	_	_	I-Claim
368	include	_	_	I-Claim
369	its	_	_	I-Claim
370	complicated	_	_	I-Claim
371	schedule	_	_	I-Claim
372	.	_	_	I-Claim

373	It	_	_	B-Claim
374	should	_	_	I-Claim
375	probably	_	_	I-Claim
376	not	_	_	I-Claim
377	be	_	_	I-Claim
378	tested	_	_	I-Claim
379	further	_	_	I-Claim
380	,	_	_	I-Claim
381	but	_	_	B-Claim
382	its	_	_	I-Claim
383	antimetabolite	_	_	I-Claim
384	schedules	_	_	I-Claim
385	and	_	_	I-Claim
386	frequent	_	_	I-Claim
387	drug	_	_	I-Claim
388	administration	_	_	I-Claim
389	(	_	_	I-Claim
390	ie	_	_	I-Claim
391	,	_	_	I-Claim
392	dose	_	_	I-Claim
393	density	_	_	I-Claim
394	)	_	_	I-Claim
395	should	_	_	I-Claim
396	be	_	_	I-Claim
397	considered	_	_	I-Claim
398	in	_	_	I-Claim
399	the	_	_	I-Claim
400	development	_	_	I-Claim
401	of	_	_	I-Claim
402	new	_	_	I-Claim
403	regimens	_	_	I-Claim
404	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	demonstrate	_	_	O
8	that	_	_	O
9	intrapatient	_	_	O
10	dose	_	_	O
11	escalation	_	_	O
12	of	_	_	O
13	carboplatin	_	_	O
14	would	_	_	O
15	improve	_	_	O
16	the	_	_	O
17	outcome	_	_	O
18	in	_	_	O
19	ovarian	_	_	O
20	cancer	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	flat	_	_	O
24	dosing	_	_	O
25	.	_	_	O

26	Patients	_	_	O
27	with	_	_	O
28	untreated	_	_	O
29	stage	_	_	O
30	IC-IV	_	_	O
31	ovarian	_	_	O
32	cancer	_	_	O
33	received	_	_	O
34	six	_	_	O
35	cycles	_	_	O
36	of	_	_	O
37	carboplatin	_	_	O
38	area	_	_	O
39	under	_	_	O
40	the	_	_	O
41	curve	_	_	O
42	6	_	_	O
43	(	_	_	O
44	AUC	_	_	O
45	6	_	_	O
46	)	_	_	O
47	3	_	_	O
48	weekly	_	_	O
49	either	_	_	O
50	with	_	_	O
51	no	_	_	O
52	dose	_	_	O
53	modification	_	_	O
54	except	_	_	O
55	for	_	_	O
56	toxicity	_	_	O
57	(	_	_	O
58	Arm	_	_	O
59	A	_	_	O
60	)	_	_	O
61	or	_	_	O
62	with	_	_	O
63	dose	_	_	O
64	escalations	_	_	O
65	in	_	_	O
66	cycles	_	_	O
67	2-6	_	_	O
68	based	_	_	O
69	on	_	_	O
70	nadir	_	_	O
71	neutrophil	_	_	O
72	and	_	_	O
73	platelet	_	_	O
74	counts	_	_	O
75	(	_	_	O
76	Arm	_	_	O
77	B	_	_	O
78	)	_	_	O
79	.	_	_	O

80	The	_	_	O
81	primary	_	_	O
82	end-point	_	_	O
83	was	_	_	O
84	progression-free	_	_	O
85	survival	_	_	O
86	(	_	_	O
87	PFS	_	_	O
88	)	_	_	O
89	.	_	_	O

90	Nine	_	_	O
91	hundred	_	_	O
92	and	_	_	O
93	sixty-four	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	recruited	_	_	O
97	from	_	_	O
98	71	_	_	O
99	centers	_	_	O
100	.	_	_	O

101	Dose	_	_	O
102	escalation	_	_	O
103	was	_	_	O
104	achieved	_	_	O
105	in	_	_	O
106	77	_	_	O
107	%	_	_	O
108	of	_	_	O
109	patients	_	_	O
110	who	_	_	O
111	had	_	_	O
112	â‰¥1	_	_	O
113	cycle	_	_	O
114	.	_	_	O

115	The	_	_	B-Premise
116	median	_	_	I-Premise
117	AUCs	_	_	I-Premise
118	(	_	_	I-Premise
119	cycle	_	_	I-Premise
120	2-6	_	_	I-Premise
121	)	_	_	I-Premise
122	received	_	_	I-Premise
123	were	_	_	I-Premise
124	6.0	_	_	I-Premise
125	(	_	_	I-Premise
126	Arm	_	_	I-Premise
127	A	_	_	I-Premise
128	)	_	_	I-Premise
129	and	_	_	I-Premise
130	7.2	_	_	I-Premise
131	(	_	_	I-Premise
132	Arm	_	_	I-Premise
133	B	_	_	I-Premise
134	)	_	_	I-Premise
135	(	_	_	I-Premise
136	P	_	_	I-Premise
137	<	_	_	I-Premise
138	0.001	_	_	I-Premise
139	)	_	_	I-Premise
140	.	_	_	I-Premise

141	Grade	_	_	B-Premise
142	3/4	_	_	I-Premise
143	non-hematological	_	_	I-Premise
144	toxicity	_	_	I-Premise
145	was	_	_	I-Premise
146	higher	_	_	I-Premise
147	in	_	_	I-Premise
148	Arm	_	_	I-Premise
149	B	_	_	I-Premise
150	(	_	_	I-Premise
151	31	_	_	I-Premise
152	%	_	_	I-Premise
153	versus	_	_	I-Premise
154	22	_	_	I-Premise
155	%	_	_	I-Premise
156	P	_	_	I-Premise
157	=	_	_	I-Premise
158	0.001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	median	_	_	I-Premise
163	PFS	_	_	I-Premise
164	was	_	_	I-Premise
165	12.1	_	_	I-Premise
166	months	_	_	I-Premise
167	in	_	_	I-Premise
168	Arm	_	_	I-Premise
169	A	_	_	I-Premise
170	and	_	_	I-Premise
171	B	_	_	I-Premise
172	[	_	_	I-Premise
173	hazard	_	_	I-Premise
174	ratio	_	_	I-Premise
175	(	_	_	I-Premise
176	HR	_	_	I-Premise
177	)	_	_	I-Premise
178	0.99	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	confidence	_	_	I-Premise
183	interval	_	_	I-Premise
184	(	_	_	I-Premise
185	CI	_	_	I-Premise
186	)	_	_	I-Premise
187	0.85-1.15	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	0.93	_	_	I-Premise
192	]	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	median	_	_	I-Premise
196	overall	_	_	I-Premise
197	survival	_	_	I-Premise
198	(	_	_	I-Premise
199	OS	_	_	I-Premise
200	)	_	_	I-Premise
201	was	_	_	I-Premise
202	34.1	_	_	I-Premise
203	and	_	_	I-Premise
204	30.7	_	_	I-Premise
205	months	_	_	I-Premise
206	in	_	_	I-Premise
207	Arms	_	_	I-Premise
208	A	_	_	I-Premise
209	and	_	_	I-Premise
210	B	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	(	_	_	I-Premise
214	HR	_	_	I-Premise
215	0.98	_	_	I-Premise
216	;	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI	_	_	I-Premise
220	0.81-1.18	_	_	I-Premise
221	,	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	0.82	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	In	_	_	B-Premise
228	multivariate	_	_	I-Premise
229	analysis	_	_	I-Premise
230	,	_	_	I-Premise
231	baseline	_	_	I-Premise
232	neutrophil	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	0.001	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	baseline	_	_	I-Premise
240	platelet	_	_	I-Premise
241	counts	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.001	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	the	_	_	I-Premise
249	difference	_	_	I-Premise
250	between	_	_	I-Premise
251	white	_	_	I-Premise
252	blood	_	_	I-Premise
253	cell	_	_	I-Premise
254	(	_	_	I-Premise
255	WBC	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	neutrophil	_	_	I-Premise
259	count	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0.009	_	_	I-Premise
264	)	_	_	I-Premise
265	had	_	_	I-Premise
266	a	_	_	I-Premise
267	significant	_	_	I-Premise
268	adverse	_	_	I-Premise
269	prognostic	_	_	I-Premise
270	value	_	_	I-Premise
271	.	_	_	I-Premise

272	Intrapatient	_	_	B-Claim
273	dose	_	_	I-Claim
274	escalation	_	_	I-Claim
275	of	_	_	I-Claim
276	carboplatin	_	_	I-Claim
277	based	_	_	I-Claim
278	on	_	_	I-Claim
279	nadir	_	_	I-Claim
280	blood	_	_	I-Claim
281	counts	_	_	I-Claim
282	is	_	_	I-Claim
283	feasible	_	_	I-Claim
284	and	_	_	I-Claim
285	safe	_	_	I-Claim
286	.	_	_	I-Claim

287	However	_	_	B-Claim
288	,	_	_	I-Claim
289	it	_	_	I-Claim
290	provided	_	_	I-Claim
291	no	_	_	I-Claim
292	improvement	_	_	I-Claim
293	in	_	_	I-Claim
294	PFS	_	_	I-Claim
295	or	_	_	I-Claim
296	OS	_	_	I-Claim
297	compared	_	_	I-Claim
298	with	_	_	I-Claim
299	flat	_	_	I-Claim
300	dosing	_	_	I-Claim
301	.	_	_	I-Claim

302	Baseline	_	_	O
303	neutrophils	_	_	O
304	over-ride	_	_	O
305	nadir	_	_	O
306	counts	_	_	O
307	in	_	_	O
308	prognostic	_	_	O
309	significance	_	_	O
310	.	_	_	O

311	These	_	_	O
312	data	_	_	O
313	may	_	_	O
314	have	_	_	O
315	wider	_	_	O
316	implications	_	_	O
317	particularly	_	_	O
318	in	_	_	O
319	respect	_	_	O
320	of	_	_	O
321	the	_	_	O
322	management	_	_	O
323	of	_	_	O
324	chemotherapy-induced	_	_	O
325	neutropenia	_	_	O
326	.	_	_	O


0	Lymphoma	_	_	O
1	patients	_	_	O
2	commonly	_	_	O
3	experience	_	_	O
4	declines	_	_	O
5	in	_	_	O
6	physical	_	_	O
7	functioning	_	_	O
8	and	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	that	_	_	O
16	may	_	_	O
17	be	_	_	O
18	reversed	_	_	O
19	with	_	_	O
20	exercise	_	_	O
21	training	_	_	O
22	.	_	_	O

23	We	_	_	O
24	conducted	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	in	_	_	O
30	Edmonton	_	_	O
31	,	_	_	O
32	Alberta	_	_	O
33	,	_	_	O
34	Canada	_	_	O
35	,	_	_	O
36	between	_	_	O
37	2005	_	_	O
38	and	_	_	O
39	2008	_	_	O
40	that	_	_	O
41	stratified	_	_	O
42	122	_	_	O
43	lymphoma	_	_	O
44	patients	_	_	O
45	by	_	_	O
46	major	_	_	O
47	disease	_	_	O
48	type	_	_	O
49	and	_	_	O
50	current	_	_	O
51	treatment	_	_	O
52	status	_	_	O
53	and	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	them	_	_	O
57	to	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	UC	_	_	O
62	;	_	_	O
63	n	_	_	O
64	=	_	_	O
65	62	_	_	O
66	)	_	_	O
67	or	_	_	O
68	12	_	_	O
69	weeks	_	_	O
70	of	_	_	O
71	supervised	_	_	O
72	aerobic	_	_	O
73	exercise	_	_	O
74	training	_	_	O
75	(	_	_	O
76	AET	_	_	O
77	;	_	_	O
78	n	_	_	O
79	=	_	_	O
80	60	_	_	O
81	)	_	_	O
82	.	_	_	O

83	Our	_	_	O
84	primary	_	_	O
85	end	_	_	O
86	point	_	_	O
87	was	_	_	O
88	patient-rated	_	_	O
89	physical	_	_	O
90	functioning	_	_	O
91	assessed	_	_	O
92	by	_	_	O
93	the	_	_	O
94	Trial	_	_	O
95	Outcome	_	_	O
96	Index-Anemia	_	_	O
97	.	_	_	O

98	Secondary	_	_	O
99	end	_	_	O
100	points	_	_	O
101	were	_	_	O
102	overall	_	_	O
103	QoL	_	_	O
104	,	_	_	O
105	psychosocial	_	_	O
106	functioning	_	_	O
107	,	_	_	O
108	cardiovascular	_	_	O
109	fitness	_	_	O
110	,	_	_	O
111	and	_	_	O
112	body	_	_	O
113	composition	_	_	O
114	.	_	_	O

115	Follow-up	_	_	O
116	assessment	_	_	O
117	for	_	_	O
118	our	_	_	O
119	primary	_	_	O
120	end	_	_	O
121	point	_	_	O
122	was	_	_	O
123	96	_	_	O
124	%	_	_	O
125	(	_	_	O
126	117	_	_	O
127	of	_	_	O
128	122	_	_	O
129	)	_	_	O
130	at	_	_	O
131	postintervention	_	_	O
132	and	_	_	O
133	90	_	_	O
134	%	_	_	O
135	(	_	_	O
136	110	_	_	O
137	of	_	_	O
138	122	_	_	O
139	)	_	_	O
140	at	_	_	O
141	6-month	_	_	O
142	follow-up	_	_	O
143	.	_	_	O

144	Median	_	_	O
145	adherence	_	_	O
146	to	_	_	O
147	the	_	_	O
148	supervised	_	_	O
149	exercise	_	_	O
150	program	_	_	O
151	was	_	_	O
152	92	_	_	O
153	%	_	_	O
154	.	_	_	O

155	At	_	_	B-Premise
156	postintervention	_	_	I-Premise
157	,	_	_	I-Premise
158	AET	_	_	I-Premise
159	was	_	_	I-Premise
160	superior	_	_	I-Premise
161	to	_	_	I-Premise
162	UC	_	_	I-Premise
163	for	_	_	I-Premise
164	patient-rated	_	_	I-Premise
165	physical	_	_	I-Premise
166	functioning	_	_	I-Premise
167	(	_	_	I-Premise
168	mean	_	_	I-Premise
169	group	_	_	I-Premise
170	difference	_	_	I-Premise
171	,	_	_	I-Premise
172	+9.0	_	_	I-Premise
173	;	_	_	I-Premise
174	95	_	_	I-Premise
175	%	_	_	I-Premise
176	CI	_	_	I-Premise
177	,	_	_	I-Premise
178	2.0	_	_	I-Premise
179	to	_	_	I-Premise
180	16.0	_	_	I-Premise
181	;	_	_	I-Premise
182	P	_	_	I-Premise
183	=	_	_	I-Premise
184	.012	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	overall	_	_	I-Premise
188	QoL	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.021	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	fatigue	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.013	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	happiness	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.004	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	depression	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.005	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	general	_	_	I-Premise
217	health	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	<	_	_	I-Premise
221	.001	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	cardiovascular	_	_	I-Premise
225	fitness	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.001	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	lean	_	_	I-Premise
234	body	_	_	I-Premise
235	mass	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.008	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Change	_	_	O
243	in	_	_	O
244	peak	_	_	O
245	cardiovascular	_	_	O
246	fitness	_	_	O
247	mediated	_	_	O
248	the	_	_	O
249	change	_	_	O
250	in	_	_	O
251	patient-rated	_	_	O
252	physical	_	_	O
253	functioning	_	_	O
254	.	_	_	O

255	AET	_	_	B-Premise
256	did	_	_	I-Premise
257	not	_	_	I-Premise
258	interfere	_	_	I-Premise
259	with	_	_	I-Premise
260	chemotherapy	_	_	I-Premise
261	completion	_	_	I-Premise
262	rate	_	_	I-Premise
263	or	_	_	I-Premise
264	treatment	_	_	I-Premise
265	response	_	_	I-Premise
266	.	_	_	I-Premise

267	At	_	_	B-Premise
268	6-month	_	_	I-Premise
269	follow-up	_	_	I-Premise
270	,	_	_	I-Premise
271	AET	_	_	I-Premise
272	was	_	_	I-Premise
273	still	_	_	I-Premise
274	borderline	_	_	I-Premise
275	or	_	_	I-Premise
276	significantly	_	_	I-Premise
277	superior	_	_	I-Premise
278	to	_	_	I-Premise
279	UC	_	_	I-Premise
280	for	_	_	I-Premise
281	overall	_	_	I-Premise
282	QoL	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.054	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	happiness	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.034	_	_	I-Premise
294	)	_	_	I-Premise
295	,	_	_	I-Premise
296	and	_	_	I-Premise
297	depression	_	_	I-Premise
298	(	_	_	I-Premise
299	P	_	_	I-Premise
300	=	_	_	I-Premise
301	.009	_	_	I-Premise
302	)	_	_	I-Premise
303	without	_	_	I-Premise
304	an	_	_	I-Premise
305	increased	_	_	I-Premise
306	risk	_	_	I-Premise
307	of	_	_	I-Premise
308	disease	_	_	I-Premise
309	recurrence/progression	_	_	I-Premise
310	.	_	_	I-Premise

311	AET	_	_	B-Claim
312	significantly	_	_	I-Claim
313	improved	_	_	I-Claim
314	important	_	_	I-Claim
315	patient-rated	_	_	I-Claim
316	outcomes	_	_	I-Claim
317	and	_	_	I-Claim
318	objective	_	_	I-Claim
319	physical	_	_	I-Claim
320	functioning	_	_	I-Claim
321	in	_	_	I-Claim
322	lymphoma	_	_	I-Claim
323	patients	_	_	I-Claim
324	without	_	_	I-Claim
325	interfering	_	_	I-Claim
326	with	_	_	I-Claim
327	medical	_	_	I-Claim
328	treatments	_	_	I-Claim
329	or	_	_	I-Claim
330	response	_	_	I-Claim
331	.	_	_	I-Claim

332	Exercise	_	_	B-Claim
333	training	_	_	I-Claim
334	to	_	_	I-Claim
335	improve	_	_	I-Claim
336	cardiovascular	_	_	I-Claim
337	fitness	_	_	I-Claim
338	should	_	_	I-Claim
339	be	_	_	I-Claim
340	considered	_	_	I-Claim
341	in	_	_	I-Claim
342	the	_	_	I-Claim
343	management	_	_	I-Claim
344	of	_	_	I-Claim
345	lymphoma	_	_	I-Claim
346	patients	_	_	I-Claim
347	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	blinded	_	_	O
5	,	_	_	O
6	randomized	_	_	O
7	clinical	_	_	O
8	trial	_	_	O
9	was	_	_	O
10	to	_	_	O
11	compare	_	_	O
12	two	_	_	O
13	topical	_	_	O
14	agents	_	_	O
15	(	_	_	O
16	Calendula	_	_	O
17	Weleda	_	_	O
18	cream	_	_	O
19	vs.	_	_	O
20	Essex	_	_	O
21	cream	_	_	O
22	)	_	_	O
23	in	_	_	O
24	reducing	_	_	O
25	the	_	_	O
26	risk	_	_	O
27	of	_	_	O
28	severe	_	_	O
29	acute	_	_	O
30	radiation	_	_	O
31	skin	_	_	O
32	reactions	_	_	O
33	(	_	_	O
34	ARSR	_	_	O
35	)	_	_	O
36	in	_	_	O
37	relation	_	_	O
38	to	_	_	O
39	adjuvant	_	_	O
40	radiotherapy	_	_	O
41	(	_	_	O
42	RT	_	_	O
43	)	_	_	O
44	for	_	_	O
45	breast	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	The	_	_	O
49	primary	_	_	O
50	endpoint	_	_	O
51	was	_	_	O
52	the	_	_	O
53	difference	_	_	O
54	in	_	_	O
55	proportion	_	_	O
56	of	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	ARSR	_	_	O
60	,	_	_	O
61	assessed	_	_	O
62	with	_	_	O
63	the	_	_	O
64	Radiation	_	_	O
65	Therapy	_	_	O
66	Oncology	_	_	O
67	Group/The	_	_	O
68	Organization	_	_	O
69	for	_	_	O
70	Research	_	_	O
71	and	_	_	O
72	Treatment	_	_	O
73	of	_	_	O
74	Cancer	_	_	O
75	Acute	_	_	O
76	Radiation	_	_	O
77	Morbidity	_	_	O
78	Scoring	_	_	O
79	Criteria	_	_	O
80	(	_	_	O
81	RTOG/EORTC	_	_	O
82	scale	_	_	O
83	)	_	_	O
84	at	_	_	O
85	follow-up	_	_	O
86	.	_	_	O

87	The	_	_	O
88	secondary	_	_	O
89	endpoints	_	_	O
90	included	_	_	O
91	patient	_	_	O
92	reported	_	_	O
93	outcome	_	_	O
94	measures	_	_	O
95	;	_	_	O
96	Quality	_	_	O
97	of	_	_	O
98	Life	_	_	O
99	Questionnaire	_	_	O
100	(	_	_	O
101	QLQ-C30	_	_	O
102	)	_	_	O
103	,	_	_	O
104	Sleep	_	_	O
105	disturbances	_	_	O
106	(	_	_	O
107	MOS-sleep	_	_	O
108	questionnaire	_	_	O
109	)	_	_	O
110	and	_	_	O
111	symptoms	_	_	O
112	from	_	_	O
113	the	_	_	O
114	irradiated	_	_	O
115	area	_	_	O
116	(	_	_	O
117	visual	_	_	O
118	analogue	_	_	O
119	scale	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Patients	_	_	O
123	'	_	_	O
124	experiences	_	_	O
125	and	_	_	O
126	adherence	_	_	O
127	to	_	_	O
128	the	_	_	O
129	topical	_	_	O
130	agents	_	_	O
131	were	_	_	O
132	also	_	_	O
133	evaluated	_	_	O
134	.	_	_	O

135	A	_	_	O
136	total	_	_	O
137	of	_	_	O
138	420	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	randomised	_	_	O
142	and	_	_	O
143	411	_	_	O
144	were	_	_	O
145	analysed	_	_	O
146	.	_	_	O

147	With	_	_	O
148	the	_	_	O
149	exception	_	_	O
150	of	_	_	O
151	previous	_	_	O
152	chemotherapy	_	_	O
153	,	_	_	O
154	the	_	_	O
155	treatment	_	_	O
156	groups	_	_	O
157	were	_	_	O
158	well	_	_	O
159	balanced	_	_	O
160	,	_	_	O
161	both	_	_	O
162	regarding	_	_	O
163	treatment-	_	_	O
164	and	_	_	O
165	patient-related	_	_	O
166	factors	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	incidence	_	_	I-Premise
170	of	_	_	I-Premise
171	severe	_	_	I-Premise
172	ARSR	_	_	I-Premise
173	(	_	_	I-Premise
174	RTOG/EORTC	_	_	I-Premise
175	grade	_	_	I-Premise
176	â‰¤2	_	_	I-Premise
177	)	_	_	I-Premise
178	at	_	_	I-Premise
179	the	_	_	I-Premise
180	follow-up	_	_	I-Premise
181	visit	_	_	I-Premise
182	was	_	_	I-Premise
183	23	_	_	I-Premise
184	%	_	_	I-Premise
185	(	_	_	I-Premise
186	n	_	_	I-Premise
187	=	_	_	I-Premise
188	45	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	Calendula	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	19	_	_	I-Premise
196	%	_	_	I-Premise
197	(	_	_	I-Premise
198	n	_	_	I-Premise
199	=	_	_	I-Premise
200	38	_	_	I-Premise
201	)	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	Essex	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	We	_	_	B-Premise
208	found	_	_	I-Premise
209	no	_	_	I-Premise
210	difference	_	_	I-Premise
211	in	_	_	I-Premise
212	severe	_	_	I-Premise
213	ARSR	_	_	I-Premise
214	between	_	_	I-Premise
215	the	_	_	I-Premise
216	groups	_	_	I-Premise
217	at	_	_	I-Premise
218	any	_	_	I-Premise
219	point	_	_	I-Premise
220	of	_	_	I-Premise
221	assessment	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	patients	_	_	I-Premise
225	reported	_	_	I-Premise
226	low	_	_	I-Premise
227	levels	_	_	I-Premise
228	of	_	_	I-Premise
229	skin	_	_	I-Premise
230	related	_	_	I-Premise
231	symptoms	_	_	I-Premise
232	and	_	_	I-Premise
233	no	_	_	I-Premise
234	statistically	_	_	I-Premise
235	significant	_	_	I-Premise
236	differences	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	groups	_	_	I-Premise
240	were	_	_	I-Premise
241	found	_	_	I-Premise
242	.	_	_	I-Premise

243	No	_	_	B-Claim
244	differences	_	_	I-Claim
245	in	_	_	I-Claim
246	ARSR	_	_	I-Claim
247	between	_	_	I-Claim
248	patients	_	_	I-Claim
249	randomised	_	_	I-Claim
250	to	_	_	I-Claim
251	Calendula	_	_	I-Claim
252	or	_	_	I-Claim
253	Essex	_	_	I-Claim
254	cream	_	_	I-Claim
255	was	_	_	I-Claim
256	found	_	_	I-Claim
257	.	_	_	I-Claim

258	ARSR	_	_	B-Claim
259	seem	_	_	I-Claim
260	to	_	_	I-Claim
261	be	_	_	I-Claim
262	a	_	_	I-Claim
263	relatively	_	_	I-Claim
264	limited	_	_	I-Claim
265	problem	_	_	I-Claim
266	,	_	_	I-Claim
267	probably	_	_	I-Claim
268	more	_	_	I-Claim
269	influenced	_	_	I-Claim
270	by	_	_	I-Claim
271	treatment	_	_	I-Claim
272	related	_	_	I-Claim
273	factors	_	_	I-Claim
274	than	_	_	I-Claim
275	by	_	_	I-Claim
276	choice	_	_	I-Claim
277	of	_	_	I-Claim
278	skin	_	_	I-Claim
279	care	_	_	I-Claim
280	products	_	_	I-Claim
281	in	_	_	I-Claim
282	this	_	_	I-Claim
283	patient	_	_	I-Claim
284	group	_	_	I-Claim
285	.	_	_	I-Claim


0	An	_	_	O
1	open	_	_	O
2	,	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	was	_	_	O
6	performed	_	_	O
7	to	_	_	O
8	assess	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	supportive	_	_	O
13	pamidronate	_	_	O
14	treatment	_	_	O
15	on	_	_	O
16	morbidity	_	_	O
17	from	_	_	O
18	bone	_	_	O
19	metastases	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	Eighty-one	_	_	O
26	pamidronate	_	_	O
27	patients	_	_	O
28	and	_	_	O
29	80	_	_	O
30	control	_	_	O
31	patients	_	_	O
32	were	_	_	O
33	monitored	_	_	O
34	for	_	_	O
35	a	_	_	O
36	median	_	_	O
37	of	_	_	O
38	18	_	_	O
39	and	_	_	O
40	21	_	_	O
41	months	_	_	O
42	,	_	_	O
43	respectively	_	_	O
44	,	_	_	O
45	for	_	_	O
46	events	_	_	O
47	of	_	_	O
48	skeletal	_	_	O
49	morbidity	_	_	O
50	and	_	_	O
51	the	_	_	O
52	radiologic	_	_	O
53	course	_	_	O
54	of	_	_	O
55	metastatic	_	_	O
56	bone	_	_	O
57	disease	_	_	O
58	.	_	_	O

59	The	_	_	O
60	oral	_	_	O
61	pamidronate	_	_	O
62	dose	_	_	O
63	was	_	_	O
64	600	_	_	O
65	mg/d	_	_	O
66	(	_	_	O
67	high	_	_	O
68	dose	_	_	O
69	[	_	_	O
70	HD	_	_	O
71	]	_	_	O
72	)	_	_	O
73	during	_	_	O
74	the	_	_	O
75	earliest	_	_	O
76	study	_	_	O
77	years	_	_	O
78	,	_	_	O
79	then	_	_	O
80	changed	_	_	O
81	to	_	_	O
82	300	_	_	O
83	mg/d	_	_	O
84	(	_	_	O
85	low	_	_	O
86	dose	_	_	O
87	[	_	_	O
88	LD	_	_	O
89	]	_	_	O
90	)	_	_	O
91	because	_	_	O
92	of	_	_	O
93	gastrointestinal	_	_	O
94	toxicity	_	_	O
95	.	_	_	O

96	Twenty-nine	_	_	O
97	of	_	_	O
98	81	_	_	O
99	pamidronate	_	_	O
100	(	_	_	O
101	HD/LD	_	_	O
102	)	_	_	O
103	patients	_	_	O
104	first	_	_	O
105	received	_	_	O
106	600	_	_	O
107	mg/d	_	_	O
108	and	_	_	O
109	were	_	_	O
110	then	_	_	O
111	changed	_	_	O
112	to	_	_	O
113	300	_	_	O
114	mg/d	_	_	O
115	;	_	_	O
116	52	_	_	O
117	of	_	_	O
118	81	_	_	O
119	pamidronate	_	_	O
120	LD	_	_	O
121	patients	_	_	O
122	received	_	_	O
123	300	_	_	O
124	mg/d	_	_	O
125	throughout	_	_	O
126	the	_	_	O
127	study	_	_	O
128	.	_	_	O

129	Tumor	_	_	O
130	treatment	_	_	O
131	was	_	_	O
132	unrestricted	_	_	O
133	.	_	_	O

134	An	_	_	O
135	overall	_	_	O
136	intent-to-treat	_	_	O
137	analysis	_	_	O
138	was	_	_	O
139	performed	_	_	O
140	.	_	_	O

141	In	_	_	B-Premise
142	the	_	_	I-Premise
143	pamidronate	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	the	_	_	I-Premise
147	occurrence	_	_	I-Premise
148	of	_	_	I-Premise
149	hypercalcemia	_	_	I-Premise
150	,	_	_	I-Premise
151	severe	_	_	I-Premise
152	bone	_	_	I-Premise
153	pain	_	_	I-Premise
154	,	_	_	I-Premise
155	and	_	_	I-Premise
156	symptomatic	_	_	I-Premise
157	impending	_	_	I-Premise
158	fractures	_	_	I-Premise
159	decreased	_	_	I-Premise
160	by	_	_	I-Premise
161	65	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	30	_	_	I-Premise
165	%	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	50	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	respectively	_	_	I-Premise
172	;	_	_	I-Premise
173	event-rates	_	_	I-Premise
174	of	_	_	I-Premise
175	systemic	_	_	I-Premise
176	treatment	_	_	I-Premise
177	and	_	_	I-Premise
178	radiotherapy	_	_	I-Premise
179	decreased	_	_	I-Premise
180	by	_	_	I-Premise
181	35	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	or	_	_	I-Premise
187	=	_	_	I-Premise
188	.02	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	event-free	_	_	I-Premise
193	period	_	_	I-Premise
194	(	_	_	I-Premise
195	EFP	_	_	I-Premise
196	)	_	_	I-Premise
197	,	_	_	I-Premise
198	radiologic	_	_	I-Premise
199	course	_	_	I-Premise
200	of	_	_	I-Premise
201	disease	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	survival	_	_	I-Premise
205	did	_	_	I-Premise
206	not	_	_	I-Premise
207	improve	_	_	I-Premise
208	.	_	_	I-Premise

209	Subgroup	_	_	B-Claim
210	analyses	_	_	I-Claim
211	suggested	_	_	I-Claim
212	a	_	_	I-Claim
213	dose-dependent	_	_	I-Claim
214	treatment	_	_	I-Claim
215	effect	_	_	I-Claim
216	.	_	_	I-Claim

217	Compared	_	_	B-Premise
218	with	_	_	I-Premise
219	their	_	_	I-Premise
220	controls	_	_	I-Premise
221	,	_	_	I-Premise
222	in	_	_	I-Premise
223	pamidronate	_	_	I-Premise
224	HD/LD	_	_	I-Premise
225	patients	_	_	I-Premise
226	,	_	_	I-Premise
227	events	_	_	I-Premise
228	occurred	_	_	I-Premise
229	60	_	_	I-Premise
230	%	_	_	I-Premise
231	to	_	_	I-Premise
232	90	_	_	I-Premise
233	%	_	_	I-Premise
234	less	_	_	I-Premise
235	frequently	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	or	_	_	I-Premise
240	=	_	_	I-Premise
241	.03	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	the	_	_	I-Premise
245	EFP	_	_	I-Premise
246	was	_	_	I-Premise
247	prolonged	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	.002	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	In	_	_	B-Premise
255	pamidronate	_	_	I-Premise
256	LD	_	_	I-Premise
257	patients	_	_	I-Premise
258	,	_	_	I-Premise
259	event-rates	_	_	I-Premise
260	decreased	_	_	I-Premise
261	by	_	_	I-Premise
262	15	_	_	I-Premise
263	%	_	_	I-Premise
264	to	_	_	I-Premise
265	45	_	_	I-Premise
266	%	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	or	_	_	I-Premise
271	=	_	_	I-Premise
272	.04	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Gastrointestinal	_	_	B-Premise
276	toxicity	_	_	I-Premise
277	of	_	_	I-Premise
278	pamidronate	_	_	I-Premise
279	caused	_	_	I-Premise
280	a	_	_	I-Premise
281	23	_	_	I-Premise
282	%	_	_	I-Premise
283	drop-out	_	_	I-Premise
284	rate	_	_	I-Premise
285	,	_	_	I-Premise
286	but	_	_	B-Claim
287	other	_	_	I-Claim
288	cancer-associated	_	_	I-Claim
289	factors	_	_	I-Claim
290	seemed	_	_	I-Claim
291	to	_	_	I-Claim
292	contribute	_	_	I-Claim
293	to	_	_	I-Claim
294	this	_	_	I-Claim
295	toxicity	_	_	I-Claim
296	.	_	_	I-Claim

297	Pamidronate	_	_	B-Claim
298	treatment	_	_	I-Claim
299	of	_	_	I-Claim
300	breast	_	_	I-Claim
301	cancer	_	_	I-Claim
302	patients	_	_	I-Claim
303	efficaciously	_	_	I-Claim
304	reduced	_	_	I-Claim
305	skeletal	_	_	I-Claim
306	morbidity	_	_	I-Claim
307	.	_	_	I-Claim

308	The	_	_	B-Claim
309	effect	_	_	I-Claim
310	appeared	_	_	I-Claim
311	to	_	_	I-Claim
312	be	_	_	I-Claim
313	dose-dependent	_	_	I-Claim
314	.	_	_	I-Claim

315	Further	_	_	B-Claim
316	research	_	_	I-Claim
317	on	_	_	I-Claim
318	dose	_	_	I-Claim
319	and	_	_	I-Claim
320	mode	_	_	I-Claim
321	of	_	_	I-Claim
322	treatment	_	_	I-Claim
323	is	_	_	I-Claim
324	mandatory	_	_	I-Claim
325	.	_	_	I-Claim


0	Dermatitis	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	frequent	_	_	I-Claim
4	adverse	_	_	I-Claim
5	effect	_	_	I-Claim
6	of	_	_	I-Claim
7	adjuvant	_	_	I-Claim
8	breast	_	_	I-Claim
9	radiotherapy	_	_	I-Claim
10	.	_	_	I-Claim

11	It	_	_	B-Claim
12	is	_	_	I-Claim
13	more	_	_	I-Claim
14	likely	_	_	I-Claim
15	in	_	_	I-Claim
16	full-breasted	_	_	I-Claim
17	women	_	_	I-Claim
18	and	_	_	I-Claim
19	when	_	_	I-Claim
20	the	_	_	I-Claim
21	radiation	_	_	I-Claim
22	is	_	_	I-Claim
23	distributed	_	_	I-Claim
24	nonhomogeneously	_	_	I-Claim
25	in	_	_	I-Claim
26	the	_	_	I-Claim
27	breast	_	_	I-Claim
28	.	_	_	I-Claim

29	Breast	_	_	O
30	intensity-modulated	_	_	O
31	radiation	_	_	O
32	therapy	_	_	O
33	(	_	_	O
34	IMRT	_	_	O
35	)	_	_	O
36	is	_	_	O
37	a	_	_	O
38	technique	_	_	O
39	that	_	_	O
40	ensures	_	_	O
41	a	_	_	O
42	more	_	_	O
43	homogeneous	_	_	O
44	dose	_	_	O
45	distribution	_	_	O
46	.	_	_	O

47	A	_	_	O
48	multicenter	_	_	O
49	,	_	_	O
50	double-blind	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	was	_	_	O
56	performed	_	_	O
57	to	_	_	O
58	test	_	_	O
59	if	_	_	O
60	breast	_	_	O
61	IMRT	_	_	O
62	would	_	_	O
63	reduce	_	_	O
64	the	_	_	O
65	rate	_	_	O
66	of	_	_	O
67	acute	_	_	O
68	skin	_	_	O
69	reaction	_	_	O
70	(	_	_	O
71	notably	_	_	O
72	moist	_	_	O
73	desquamation	_	_	O
74	)	_	_	O
75	,	_	_	O
76	decrease	_	_	O
77	pain	_	_	O
78	,	_	_	O
79	and	_	_	O
80	improve	_	_	O
81	quality	_	_	O
82	of	_	_	O
83	life	_	_	O
84	compared	_	_	O
85	with	_	_	O
86	standard	_	_	O
87	radiotherapy	_	_	O
88	using	_	_	O
89	wedges	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	were	_	_	O
93	assessed	_	_	O
94	each	_	_	O
95	week	_	_	O
96	during	_	_	O
97	and	_	_	O
98	up	_	_	O
99	to	_	_	O
100	6	_	_	O
101	weeks	_	_	O
102	after	_	_	O
103	radiotherapy	_	_	O
104	.	_	_	O

105	A	_	_	O
106	total	_	_	O
107	of	_	_	O
108	358	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomly	_	_	O
112	assigned	_	_	O
113	between	_	_	O
114	July	_	_	O
115	2003	_	_	O
116	and	_	_	O
117	March	_	_	O
118	2005	_	_	O
119	in	_	_	O
120	two	_	_	O
121	Canadian	_	_	O
122	centers	_	_	O
123	,	_	_	O
124	and	_	_	O
125	331	_	_	O
126	were	_	_	O
127	included	_	_	O
128	in	_	_	O
129	the	_	_	O
130	analysis	_	_	O
131	.	_	_	O

132	Breast	_	_	B-Premise
133	IMRT	_	_	I-Premise
134	significantly	_	_	I-Premise
135	improved	_	_	I-Premise
136	the	_	_	I-Premise
137	dose	_	_	I-Premise
138	distribution	_	_	I-Premise
139	compared	_	_	I-Premise
140	with	_	_	I-Premise
141	standard	_	_	I-Premise
142	radiation	_	_	I-Premise
143	.	_	_	I-Premise

144	This	_	_	B-Premise
145	translated	_	_	I-Premise
146	into	_	_	I-Premise
147	a	_	_	I-Premise
148	lower	_	_	I-Premise
149	proportion	_	_	I-Premise
150	of	_	_	I-Premise
151	patients	_	_	I-Premise
152	experiencing	_	_	I-Premise
153	moist	_	_	I-Premise
154	desquamation	_	_	I-Premise
155	during	_	_	I-Premise
156	or	_	_	I-Premise
157	up	_	_	I-Premise
158	to	_	_	I-Premise
159	6	_	_	I-Premise
160	weeks	_	_	I-Premise
161	after	_	_	I-Premise
162	their	_	_	I-Premise
163	radiation	_	_	I-Premise
164	treatment	_	_	I-Premise
165	;	_	_	I-Premise
166	31.2	_	_	I-Premise
167	%	_	_	I-Premise
168	with	_	_	I-Premise
169	IMRT	_	_	I-Premise
170	compared	_	_	I-Premise
171	with	_	_	I-Premise
172	47.8	_	_	I-Premise
173	%	_	_	I-Premise
174	with	_	_	I-Premise
175	standard	_	_	I-Premise
176	treatment	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	.002	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	A	_	_	B-Premise
184	multivariate	_	_	I-Premise
185	analysis	_	_	I-Premise
186	found	_	_	I-Premise
187	the	_	_	I-Premise
188	use	_	_	I-Premise
189	of	_	_	I-Premise
190	breast	_	_	I-Premise
191	IMRT	_	_	I-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.003	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	smaller	_	_	I-Premise
199	breast	_	_	I-Premise
200	size	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	.001	_	_	I-Premise
205	)	_	_	I-Premise
206	were	_	_	I-Premise
207	significantly	_	_	I-Premise
208	associated	_	_	I-Premise
209	with	_	_	I-Premise
210	a	_	_	I-Premise
211	decreased	_	_	I-Premise
212	risk	_	_	I-Premise
213	of	_	_	I-Premise
214	moist	_	_	I-Premise
215	desquamation	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	use	_	_	I-Premise
219	of	_	_	I-Premise
220	IMRT	_	_	I-Premise
221	did	_	_	I-Premise
222	not	_	_	I-Premise
223	correlate	_	_	I-Premise
224	with	_	_	I-Premise
225	pain	_	_	I-Premise
226	and	_	_	I-Premise
227	quality	_	_	I-Premise
228	of	_	_	I-Premise
229	life	_	_	I-Premise
230	,	_	_	O
231	but	_	_	O
232	the	_	_	B-Premise
233	presence	_	_	I-Premise
234	of	_	_	I-Premise
235	moist	_	_	I-Premise
236	desquamation	_	_	I-Premise
237	did	_	_	I-Premise
238	significantly	_	_	I-Premise
239	correlate	_	_	I-Premise
240	with	_	_	I-Premise
241	pain	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.002	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	a	_	_	I-Premise
249	reduced	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.003	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Breast	_	_	B-Claim
260	IMRT	_	_	I-Claim
261	significantly	_	_	I-Claim
262	reduced	_	_	I-Claim
263	the	_	_	I-Claim
264	occurrence	_	_	I-Claim
265	of	_	_	I-Claim
266	moist	_	_	I-Claim
267	desquamation	_	_	I-Claim
268	compared	_	_	I-Claim
269	with	_	_	I-Claim
270	a	_	_	I-Claim
271	standard	_	_	I-Claim
272	wedged	_	_	I-Claim
273	technique	_	_	I-Claim
274	.	_	_	I-Claim

275	Moist	_	_	B-Claim
276	desquamation	_	_	I-Claim
277	was	_	_	I-Claim
278	correlated	_	_	I-Claim
279	with	_	_	I-Claim
280	increased	_	_	I-Claim
281	pain	_	_	I-Claim
282	and	_	_	I-Claim
283	reduction	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	compare	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	(	_	_	O
9	QOL	_	_	O
10	)	_	_	O
11	,	_	_	O
12	functional	_	_	O
13	outcome	_	_	O
14	,	_	_	O
15	body	_	_	O
16	image	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cosmesis	_	_	O
20	after	_	_	O
21	hand-assisted	_	_	O
22	laparoscopic	_	_	O
23	(	_	_	O
24	LRP	_	_	O
25	)	_	_	O
26	versus	_	_	O
27	open	_	_	O
28	restorative	_	_	O
29	proctocolectomy	_	_	O
30	(	_	_	O
31	ORP	_	_	O
32	)	_	_	O
33	.	_	_	O

34	The	_	_	O
35	potential	_	_	O
36	long-term	_	_	O
37	advantages	_	_	O
38	of	_	_	O
39	LRP	_	_	O
40	over	_	_	O
41	ORP	_	_	O
42	remain	_	_	O
43	to	_	_	O
44	be	_	_	O
45	determined	_	_	O
46	.	_	_	O

47	The	_	_	O
48	most	_	_	O
49	likely	_	_	O
50	advantage	_	_	O
51	of	_	_	O
52	LRP	_	_	O
53	is	_	_	O
54	the	_	_	O
55	superior	_	_	O
56	cosmetic	_	_	O
57	result	_	_	O
58	.	_	_	O

59	It	_	_	O
60	is	_	_	O
61	,	_	_	O
62	however	_	_	O
63	,	_	_	O
64	unclear	_	_	O
65	whether	_	_	O
66	the	_	_	O
67	size	_	_	O
68	and	_	_	O
69	location	_	_	O
70	of	_	_	O
71	incisions	_	_	O
72	affect	_	_	O
73	body	_	_	O
74	image	_	_	O
75	and	_	_	O
76	QOL	_	_	O
77	.	_	_	O

78	In	_	_	O
79	a	_	_	O
80	previously	_	_	O
81	conducted	_	_	O
82	randomized	_	_	O
83	trial	_	_	O
84	comparing	_	_	O
85	LRP	_	_	O
86	with	_	_	O
87	ORP	_	_	O
88	,	_	_	O
89	60	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	prospectively	_	_	O
93	evaluated	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	end	_	_	O
98	points	_	_	O
99	were	_	_	O
100	body	_	_	O
101	image	_	_	O
102	and	_	_	O
103	cosmesis	_	_	O
104	.	_	_	O

105	The	_	_	O
106	secondary	_	_	O
107	end	_	_	O
108	points	_	_	O
109	were	_	_	O
110	morbidity	_	_	O
111	,	_	_	O
112	QOL	_	_	O
113	,	_	_	O
114	and	_	_	O
115	functional	_	_	O
116	outcome	_	_	O
117	.	_	_	O

118	A	_	_	O
119	body	_	_	O
120	image	_	_	O
121	questionnaire	_	_	O
122	was	_	_	O
123	used	_	_	O
124	to	_	_	O
125	evaluate	_	_	O
126	body	_	_	O
127	image	_	_	O
128	and	_	_	O
129	cosmesis	_	_	O
130	.	_	_	O

131	The	_	_	O
132	Short	_	_	O
133	Form-36	_	_	O
134	Health	_	_	O
135	Survey	_	_	O
136	and	_	_	O
137	the	_	_	O
138	Gastrointestinal	_	_	O
139	Quality	_	_	O
140	of	_	_	O
141	Life	_	_	O
142	Inventory	_	_	O
143	were	_	_	O
144	used	_	_	O
145	to	_	_	O
146	assess	_	_	O
147	QOL	_	_	O
148	.	_	_	O

149	Body	_	_	O
150	image	_	_	O
151	and	_	_	O
152	QOL	_	_	O
153	also	_	_	O
154	were	_	_	O
155	assessed	_	_	O
156	preoperatively	_	_	O
157	.	_	_	O

158	A	_	_	O
159	total	_	_	O
160	of	_	_	O
161	53	_	_	O
162	patients	_	_	O
163	completed	_	_	O
164	the	_	_	O
165	QOL	_	_	O
166	and	_	_	O
167	functional	_	_	O
168	outcome	_	_	O
169	questionnaires	_	_	O
170	.	_	_	O

171	There	_	_	B-Premise
172	were	_	_	I-Premise
173	no	_	_	I-Premise
174	differences	_	_	I-Premise
175	in	_	_	I-Premise
176	functional	_	_	I-Premise
177	outcome	_	_	I-Premise
178	,	_	_	I-Premise
179	morbidity	_	_	I-Premise
180	,	_	_	I-Premise
181	or	_	_	I-Premise
182	QOL	_	_	I-Premise
183	between	_	_	I-Premise
184	LRP	_	_	I-Premise
185	and	_	_	I-Premise
186	ORP	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	O
189	a	_	_	O
190	median	_	_	O
191	of	_	_	O
192	2.7	_	_	O
193	years	_	_	O
194	after	_	_	O
195	surgery	_	_	O
196	,	_	_	O
197	46	_	_	O
198	patients	_	_	O
199	returned	_	_	O
200	the	_	_	O
201	questionnaires	_	_	O
202	regarding	_	_	O
203	body	_	_	O
204	image	_	_	O
205	,	_	_	O
206	cosmesis	_	_	O
207	,	_	_	O
208	and	_	_	O
209	morbidity	_	_	O
210	.	_	_	O

211	The	_	_	B-Premise
212	body	_	_	I-Premise
213	image	_	_	I-Premise
214	and	_	_	I-Premise
215	cosmesis	_	_	I-Premise
216	scores	_	_	I-Premise
217	of	_	_	I-Premise
218	female	_	_	I-Premise
219	patients	_	_	I-Premise
220	were	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	LRP	_	_	I-Premise
226	group	_	_	I-Premise
227	than	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	ORP	_	_	I-Premise
231	group	_	_	I-Premise
232	(	_	_	I-Premise
233	body	_	_	I-Premise
234	image	_	_	I-Premise
235	,	_	_	I-Premise
236	17.4	_	_	I-Premise
237	vs	_	_	I-Premise
238	14.9	_	_	I-Premise
239	;	_	_	I-Premise
240	cosmesis	_	_	I-Premise
241	,	_	_	I-Premise
242	19.1	_	_	I-Premise
243	vs	_	_	I-Premise
244	13.0	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	female	_	_	I-Premise
251	patients	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	ORP	_	_	I-Premise
255	group	_	_	I-Premise
256	had	_	_	I-Premise
257	significantly	_	_	I-Premise
258	lower	_	_	I-Premise
259	body	_	_	I-Premise
260	image	_	_	I-Premise
261	scores	_	_	I-Premise
262	than	_	_	I-Premise
263	the	_	_	I-Premise
264	male	_	_	I-Premise
265	patients	_	_	I-Premise
266	(	_	_	I-Premise
267	14.9	_	_	I-Premise
268	vs	_	_	I-Premise
269	18.3	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	This	_	_	B-Claim
273	study	_	_	I-Claim
274	is	_	_	I-Claim
275	the	_	_	I-Claim
276	first	_	_	I-Claim
277	to	_	_	I-Claim
278	show	_	_	I-Claim
279	that	_	_	I-Claim
280	ORP	_	_	I-Claim
281	has	_	_	I-Claim
282	a	_	_	I-Claim
283	negative	_	_	I-Claim
284	impact	_	_	I-Claim
285	on	_	_	I-Claim
286	body	_	_	I-Claim
287	image	_	_	I-Claim
288	and	_	_	I-Claim
289	cosmesis	_	_	I-Claim
290	as	_	_	I-Claim
291	compared	_	_	I-Claim
292	with	_	_	I-Claim
293	LRP	_	_	I-Claim
294	.	_	_	I-Claim

295	Functional	_	_	B-Claim
296	outcome	_	_	I-Claim
297	,	_	_	I-Claim
298	QOL	_	_	I-Claim
299	,	_	_	I-Claim
300	and	_	_	I-Claim
301	morbidity	_	_	I-Claim
302	are	_	_	I-Claim
303	similar	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	two	_	_	I-Claim
307	approaches	_	_	I-Claim
308	.	_	_	I-Claim

309	The	_	_	B-Claim
310	advantages	_	_	I-Claim
311	of	_	_	I-Claim
312	a	_	_	I-Claim
313	long-lasting	_	_	I-Claim
314	improved	_	_	I-Claim
315	body	_	_	I-Claim
316	image	_	_	I-Claim
317	and	_	_	I-Claim
318	cosmesis	_	_	I-Claim
319	for	_	_	I-Claim
320	this	_	_	I-Claim
321	relatively	_	_	I-Claim
322	young	_	_	I-Claim
323	patient	_	_	I-Claim
324	population	_	_	I-Claim
325	may	_	_	I-Claim
326	compensate	_	_	I-Claim
327	for	_	_	I-Claim
328	the	_	_	I-Claim
329	longer	_	_	I-Claim
330	operating	_	_	I-Claim
331	times	_	_	I-Claim
332	and	_	_	I-Claim
333	higher	_	_	I-Claim
334	costs	_	_	I-Claim
335	,	_	_	I-Claim
336	particularly	_	_	I-Claim
337	for	_	_	I-Claim
338	women	_	_	I-Claim
339	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	randomized	_	_	O
4	controlled	_	_	O
5	trials	_	_	O
6	on	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	palliative	_	_	O
11	care	_	_	O
12	interventions	_	_	O
13	to	_	_	O
14	improve	_	_	O
15	the	_	_	O
16	care	_	_	O
17	of	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	advanced	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	To	_	_	O
24	determine	_	_	O
25	the	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	a	_	_	O
29	nursing-led	_	_	O
30	intervention	_	_	O
31	on	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	,	_	_	O
36	symptom	_	_	O
37	intensity	_	_	O
38	,	_	_	O
39	mood	_	_	O
40	,	_	_	O
41	and	_	_	O
42	resource	_	_	O
43	use	_	_	O
44	in	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	advanced	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Randomized	_	_	O
51	controlled	_	_	O
52	trial	_	_	O
53	conducted	_	_	O
54	from	_	_	O
55	November	_	_	O
56	2003	_	_	O
57	through	_	_	O
58	May	_	_	O
59	2008	_	_	O
60	of	_	_	O
61	322	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	advanced	_	_	O
65	cancer	_	_	O
66	in	_	_	O
67	a	_	_	O
68	rural	_	_	O
69	,	_	_	O
70	National	_	_	O
71	Cancer	_	_	O
72	Institute-designated	_	_	O
73	comprehensive	_	_	O
74	cancer	_	_	O
75	center	_	_	O
76	in	_	_	O
77	New	_	_	O
78	Hampshire	_	_	O
79	and	_	_	O
80	affiliated	_	_	O
81	outreach	_	_	O
82	clinics	_	_	O
83	and	_	_	O
84	a	_	_	O
85	VA	_	_	O
86	medical	_	_	O
87	center	_	_	O
88	in	_	_	O
89	Vermont	_	_	O
90	.	_	_	O

91	A	_	_	O
92	multicomponent	_	_	O
93	,	_	_	O
94	psychoeducational	_	_	O
95	intervention	_	_	O
96	(	_	_	O
97	Project	_	_	O
98	ENABLE	_	_	O
99	[	_	_	O
100	Educate	_	_	O
101	,	_	_	O
102	Nurture	_	_	O
103	,	_	_	O
104	Advise	_	_	O
105	,	_	_	O
106	Before	_	_	O
107	Life	_	_	O
108	Ends	_	_	O
109	]	_	_	O
110	)	_	_	O
111	conducted	_	_	O
112	by	_	_	O
113	advanced	_	_	O
114	practice	_	_	O
115	nurses	_	_	O
116	consisting	_	_	O
117	of	_	_	O
118	4	_	_	O
119	weekly	_	_	O
120	educational	_	_	O
121	sessions	_	_	O
122	and	_	_	O
123	monthly	_	_	O
124	follow-up	_	_	O
125	sessions	_	_	O
126	until	_	_	O
127	death	_	_	O
128	or	_	_	O
129	study	_	_	O
130	completion	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	161	_	_	O
135	)	_	_	O
136	vs	_	_	O
137	usual	_	_	O
138	care	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	161	_	_	O
143	)	_	_	O
144	.	_	_	O

145	Quality	_	_	O
146	of	_	_	O
147	life	_	_	O
148	was	_	_	O
149	measured	_	_	O
150	by	_	_	O
151	the	_	_	O
152	Functional	_	_	O
153	Assessment	_	_	O
154	of	_	_	O
155	Chronic	_	_	O
156	Illness	_	_	O
157	Therapy	_	_	O
158	for	_	_	O
159	Palliative	_	_	O
160	Care	_	_	O
161	(	_	_	O
162	score	_	_	O
163	range	_	_	O
164	,	_	_	O
165	0-184	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Symptom	_	_	O
169	intensity	_	_	O
170	was	_	_	O
171	measured	_	_	O
172	by	_	_	O
173	the	_	_	O
174	Edmonton	_	_	O
175	Symptom	_	_	O
176	Assessment	_	_	O
177	Scale	_	_	O
178	(	_	_	O
179	score	_	_	O
180	range	_	_	O
181	,	_	_	O
182	0-900	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Mood	_	_	O
186	was	_	_	O
187	measured	_	_	O
188	by	_	_	O
189	the	_	_	O
190	Center	_	_	O
191	for	_	_	O
192	Epidemiological	_	_	O
193	Studies	_	_	O
194	Depression	_	_	O
195	Scale	_	_	O
196	(	_	_	O
197	range	_	_	O
198	,	_	_	O
199	0-60	_	_	O
200	)	_	_	O
201	.	_	_	O

202	These	_	_	O
203	measures	_	_	O
204	were	_	_	O
205	assessed	_	_	O
206	at	_	_	O
207	baseline	_	_	O
208	,	_	_	O
209	1	_	_	O
210	month	_	_	O
211	,	_	_	O
212	and	_	_	O
213	every	_	_	O
214	3	_	_	O
215	months	_	_	O
216	until	_	_	O
217	death	_	_	O
218	or	_	_	O
219	study	_	_	O
220	completion	_	_	O
221	.	_	_	O

222	Intensity	_	_	O
223	of	_	_	O
224	service	_	_	O
225	was	_	_	O
226	measured	_	_	O
227	as	_	_	O
228	the	_	_	O
229	number	_	_	O
230	of	_	_	O
231	days	_	_	O
232	in	_	_	O
233	the	_	_	O
234	hospital	_	_	O
235	and	_	_	O
236	in	_	_	O
237	the	_	_	O
238	intensive	_	_	O
239	care	_	_	O
240	unit	_	_	O
241	(	_	_	O
242	ICU	_	_	O
243	)	_	_	O
244	and	_	_	O
245	the	_	_	O
246	number	_	_	O
247	of	_	_	O
248	emergency	_	_	O
249	department	_	_	O
250	visits	_	_	O
251	recorded	_	_	O
252	in	_	_	O
253	the	_	_	O
254	electronic	_	_	O
255	medical	_	_	O
256	record	_	_	O
257	.	_	_	O

258	A	_	_	O
259	total	_	_	O
260	of	_	_	O
261	322	_	_	O
262	participants	_	_	O
263	with	_	_	O
264	cancer	_	_	O
265	of	_	_	O
266	the	_	_	O
267	gastrointestinal	_	_	O
268	tract	_	_	O
269	(	_	_	O
270	41	_	_	O
271	%	_	_	O
272	;	_	_	O
273	67	_	_	O
274	in	_	_	O
275	the	_	_	O
276	usual	_	_	O
277	care	_	_	O
278	group	_	_	O
279	vs	_	_	O
280	66	_	_	O
281	in	_	_	O
282	the	_	_	O
283	intervention	_	_	O
284	group	_	_	O
285	)	_	_	O
286	,	_	_	O
287	lung	_	_	O
288	(	_	_	O
289	36	_	_	O
290	%	_	_	O
291	;	_	_	O
292	58	_	_	O
293	vs	_	_	O
294	59	_	_	O
295	)	_	_	O
296	,	_	_	O
297	genitourinary	_	_	O
298	tract	_	_	O
299	(	_	_	O
300	12	_	_	O
301	%	_	_	O
302	;	_	_	O
303	20	_	_	O
304	vs	_	_	O
305	19	_	_	O
306	)	_	_	O
307	,	_	_	O
308	and	_	_	O
309	breast	_	_	O
310	(	_	_	O
311	10	_	_	O
312	%	_	_	O
313	;	_	_	O
314	16	_	_	O
315	vs	_	_	O
316	17	_	_	O
317	)	_	_	O
318	were	_	_	O
319	randomized	_	_	O
320	.	_	_	O

321	The	_	_	B-Premise
322	estimated	_	_	I-Premise
323	treatment	_	_	I-Premise
324	effects	_	_	I-Premise
325	(	_	_	I-Premise
326	intervention	_	_	I-Premise
327	minus	_	_	I-Premise
328	usual	_	_	I-Premise
329	care	_	_	I-Premise
330	)	_	_	I-Premise
331	for	_	_	I-Premise
332	all	_	_	I-Premise
333	participants	_	_	I-Premise
334	were	_	_	I-Premise
335	a	_	_	I-Premise
336	mean	_	_	I-Premise
337	(	_	_	I-Premise
338	SE	_	_	I-Premise
339	)	_	_	I-Premise
340	of	_	_	I-Premise
341	4.6	_	_	I-Premise
342	(	_	_	I-Premise
343	2	_	_	I-Premise
344	)	_	_	I-Premise
345	for	_	_	I-Premise
346	quality	_	_	I-Premise
347	of	_	_	I-Premise
348	life	_	_	I-Premise
349	(	_	_	I-Premise
350	P	_	_	I-Premise
351	=	_	_	I-Premise
352	.02	_	_	I-Premise
353	)	_	_	I-Premise
354	,	_	_	I-Premise
355	-27.8	_	_	I-Premise
356	(	_	_	I-Premise
357	15	_	_	I-Premise
358	)	_	_	I-Premise
359	for	_	_	I-Premise
360	symptom	_	_	I-Premise
361	intensity	_	_	I-Premise
362	(	_	_	I-Premise
363	P	_	_	I-Premise
364	=	_	_	I-Premise
365	.06	_	_	I-Premise
366	)	_	_	I-Premise
367	,	_	_	I-Premise
368	and	_	_	I-Premise
369	-1.8	_	_	I-Premise
370	(	_	_	I-Premise
371	0.81	_	_	I-Premise
372	)	_	_	I-Premise
373	for	_	_	I-Premise
374	depressed	_	_	I-Premise
375	mood	_	_	I-Premise
376	(	_	_	I-Premise
377	P	_	_	I-Premise
378	=	_	_	I-Premise
379	.02	_	_	I-Premise
380	)	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Premise
383	estimated	_	_	I-Premise
384	treatment	_	_	I-Premise
385	effects	_	_	I-Premise
386	in	_	_	I-Premise
387	participants	_	_	I-Premise
388	who	_	_	I-Premise
389	died	_	_	I-Premise
390	during	_	_	I-Premise
391	the	_	_	I-Premise
392	study	_	_	I-Premise
393	were	_	_	I-Premise
394	a	_	_	I-Premise
395	mean	_	_	I-Premise
396	(	_	_	I-Premise
397	SE	_	_	I-Premise
398	)	_	_	I-Premise
399	of	_	_	I-Premise
400	8.6	_	_	I-Premise
401	(	_	_	I-Premise
402	3.6	_	_	I-Premise
403	)	_	_	I-Premise
404	for	_	_	I-Premise
405	quality	_	_	I-Premise
406	of	_	_	I-Premise
407	life	_	_	I-Premise
408	(	_	_	I-Premise
409	P	_	_	I-Premise
410	=	_	_	I-Premise
411	.02	_	_	I-Premise
412	)	_	_	I-Premise
413	,	_	_	I-Premise
414	-24.2	_	_	I-Premise
415	(	_	_	I-Premise
416	20.5	_	_	I-Premise
417	)	_	_	I-Premise
418	for	_	_	I-Premise
419	symptom	_	_	I-Premise
420	intensity	_	_	I-Premise
421	(	_	_	I-Premise
422	P	_	_	I-Premise
423	=	_	_	I-Premise
424	.24	_	_	I-Premise
425	)	_	_	I-Premise
426	,	_	_	I-Premise
427	and	_	_	I-Premise
428	-2.7	_	_	I-Premise
429	(	_	_	I-Premise
430	1.2	_	_	I-Premise
431	)	_	_	I-Premise
432	for	_	_	I-Premise
433	depressed	_	_	I-Premise
434	mood	_	_	I-Premise
435	(	_	_	I-Premise
436	P	_	_	I-Premise
437	=	_	_	I-Premise
438	.03	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	Intensity	_	_	O
442	of	_	_	O
443	service	_	_	O
444	did	_	_	O
445	not	_	_	O
446	differ	_	_	O
447	between	_	_	O
448	the	_	_	O
449	2	_	_	O
450	groups	_	_	O
451	.	_	_	O

452	Compared	_	_	B-Claim
453	with	_	_	I-Claim
454	participants	_	_	I-Claim
455	receiving	_	_	I-Claim
456	usual	_	_	I-Claim
457	oncology	_	_	I-Claim
458	care	_	_	I-Claim
459	,	_	_	I-Claim
460	those	_	_	I-Claim
461	receiving	_	_	I-Claim
462	a	_	_	I-Claim
463	nurse-led	_	_	I-Claim
464	,	_	_	I-Claim
465	palliative	_	_	I-Claim
466	care-focused	_	_	I-Claim
467	intervention	_	_	I-Claim
468	addressing	_	_	I-Claim
469	physical	_	_	I-Claim
470	,	_	_	I-Claim
471	psychosocial	_	_	I-Claim
472	,	_	_	I-Claim
473	and	_	_	I-Claim
474	care	_	_	I-Claim
475	coordination	_	_	I-Claim
476	provided	_	_	I-Claim
477	concurrently	_	_	I-Claim
478	with	_	_	I-Claim
479	oncology	_	_	I-Claim
480	care	_	_	I-Claim
481	had	_	_	I-Claim
482	higher	_	_	I-Claim
483	scores	_	_	I-Claim
484	for	_	_	I-Claim
485	quality	_	_	I-Claim
486	of	_	_	I-Claim
487	life	_	_	I-Claim
488	and	_	_	I-Claim
489	mood	_	_	I-Claim
490	,	_	_	I-Claim
491	but	_	_	B-Claim
492	did	_	_	I-Claim
493	not	_	_	I-Claim
494	have	_	_	I-Claim
495	improvements	_	_	I-Claim
496	in	_	_	I-Claim
497	symptom	_	_	I-Claim
498	intensity	_	_	I-Claim
499	scores	_	_	I-Claim
500	or	_	_	I-Claim
501	reduced	_	_	I-Claim
502	days	_	_	I-Claim
503	in	_	_	I-Claim
504	the	_	_	I-Claim
505	hospital	_	_	I-Claim
506	or	_	_	I-Claim
507	ICU	_	_	I-Claim
508	or	_	_	I-Claim
509	emergency	_	_	I-Claim
510	department	_	_	I-Claim
511	visits	_	_	I-Claim
512	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	topotecan	_	_	O
6	in	_	_	O
7	combination	_	_	O
8	with	_	_	O
9	standard	_	_	O
10	chemotherapy	_	_	O
11	in	_	_	O
12	previously	_	_	O
13	untreated	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	extensive-stage	_	_	O
17	small-cell	_	_	O
18	lung	_	_	O
19	cancer	_	_	O
20	(	_	_	O
21	SCLC	_	_	O
22	)	_	_	O
23	,	_	_	O
24	the	_	_	O
25	Eastern	_	_	O
26	Cooperative	_	_	O
27	Oncology	_	_	O
28	Group	_	_	O
29	(	_	_	O
30	ECOG	_	_	O
31	)	_	_	O
32	conducted	_	_	O
33	a	_	_	O
34	phase	_	_	O
35	III	_	_	O
36	trial	_	_	O
37	.	_	_	O

38	Eligible	_	_	O
39	patients	_	_	O
40	had	_	_	O
41	measurable	_	_	O
42	or	_	_	O
43	assessable	_	_	O
44	disease	_	_	O
45	and	_	_	O
46	an	_	_	O
47	ECOG	_	_	O
48	performance	_	_	O
49	status	_	_	O
50	of	_	_	O
51	0	_	_	O
52	to	_	_	O
53	2	_	_	O
54	;	_	_	O
55	stable	_	_	O
56	brain	_	_	O
57	metastases	_	_	O
58	were	_	_	O
59	allowed	_	_	O
60	.	_	_	O

61	All	_	_	O
62	patients	_	_	O
63	received	_	_	O
64	four	_	_	O
65	cycles	_	_	O
66	of	_	_	O
67	cisplatin	_	_	O
68	and	_	_	O
69	etoposide	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	(	_	_	O
74	step	_	_	O
75	1	_	_	O
76	;	_	_	O
77	PE	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	with	_	_	O
82	stable	_	_	O
83	or	_	_	O
84	responding	_	_	O
85	disease	_	_	O
86	were	_	_	O
87	then	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	observation	_	_	O
91	or	_	_	O
92	four	_	_	O
93	cycles	_	_	O
94	of	_	_	O
95	topotecan	_	_	O
96	(	_	_	O
97	1.5	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	/d	_	_	O
103	for	_	_	O
104	5	_	_	O
105	days	_	_	O
106	,	_	_	O
107	every	_	_	O
108	3	_	_	O
109	weeks	_	_	O
110	;	_	_	O
111	step	_	_	O
112	2	_	_	O
113	)	_	_	O
114	.	_	_	O

115	A	_	_	O
116	total	_	_	O
117	of	_	_	O
118	402	_	_	O
119	eligible	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	registered	_	_	O
123	to	_	_	O
124	step	_	_	O
125	1	_	_	O
126	,	_	_	O
127	and	_	_	O
128	223	_	_	O
129	eligible	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	registered	_	_	O
133	to	_	_	O
134	step	_	_	O
135	2	_	_	O
136	(	_	_	O
137	observation	_	_	O
138	,	_	_	O
139	n	_	_	O
140	=	_	_	O
141	111	_	_	O
142	;	_	_	O
143	topotecan	_	_	O
144	,	_	_	O
145	n	_	_	O
146	=	_	_	O
147	112	_	_	O
148	)	_	_	O
149	.	_	_	O

150	Complete	_	_	B-Premise
151	and	_	_	I-Premise
152	partial	_	_	I-Premise
153	response	_	_	I-Premise
154	rates	_	_	I-Premise
155	to	_	_	I-Premise
156	induction	_	_	I-Premise
157	PE	_	_	I-Premise
158	were	_	_	I-Premise
159	3	_	_	I-Premise
160	%	_	_	I-Premise
161	and	_	_	I-Premise
162	32	_	_	I-Premise
163	%	_	_	I-Premise
164	,	_	_	I-Premise
165	respectively	_	_	I-Premise
166	.	_	_	I-Premise

167	A	_	_	B-Premise
168	7	_	_	I-Premise
169	%	_	_	I-Premise
170	response	_	_	I-Premise
171	rate	_	_	I-Premise
172	was	_	_	I-Premise
173	observed	_	_	I-Premise
174	with	_	_	I-Premise
175	topotecan	_	_	I-Premise
176	(	_	_	I-Premise
177	complete	_	_	I-Premise
178	response	_	_	I-Premise
179	,	_	_	I-Premise
180	2	_	_	I-Premise
181	%	_	_	I-Premise
182	;	_	_	I-Premise
183	partial	_	_	I-Premise
184	response	_	_	I-Premise
185	,	_	_	I-Premise
186	5	_	_	I-Premise
187	%	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	median	_	_	I-Premise
192	survival	_	_	I-Premise
193	time	_	_	I-Premise
194	for	_	_	I-Premise
195	all	_	_	I-Premise
196	402	_	_	I-Premise
197	eligible	_	_	I-Premise
198	patients	_	_	I-Premise
199	was	_	_	I-Premise
200	9.6	_	_	I-Premise
201	months	_	_	I-Premise
202	.	_	_	I-Premise

203	Progression-free	_	_	B-Premise
204	survival	_	_	I-Premise
205	(	_	_	I-Premise
206	PFS	_	_	I-Premise
207	)	_	_	I-Premise
208	from	_	_	I-Premise
209	date	_	_	I-Premise
210	of	_	_	I-Premise
211	randomization	_	_	I-Premise
212	on	_	_	I-Premise
213	step	_	_	I-Premise
214	2	_	_	I-Premise
215	was	_	_	I-Premise
216	significantly	_	_	I-Premise
217	better	_	_	I-Premise
218	with	_	_	I-Premise
219	topotecan	_	_	I-Premise
220	compared	_	_	I-Premise
221	with	_	_	I-Premise
222	observation	_	_	I-Premise
223	(	_	_	I-Premise
224	3.6	_	_	I-Premise
225	months	_	_	I-Premise
226	v	_	_	I-Premise
227	2.3	_	_	I-Premise
228	months	_	_	I-Premise
229	;	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.001	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	O
236	,	_	_	O
237	overall	_	_	B-Premise
238	survival	_	_	I-Premise
239	from	_	_	I-Premise
240	date	_	_	I-Premise
241	of	_	_	I-Premise
242	randomization	_	_	I-Premise
243	on	_	_	I-Premise
244	step	_	_	I-Premise
245	2	_	_	I-Premise
246	was	_	_	I-Premise
247	not	_	_	I-Premise
248	significantly	_	_	I-Premise
249	different	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	observation	_	_	I-Premise
253	and	_	_	I-Premise
254	topotecan	_	_	I-Premise
255	arms	_	_	I-Premise
256	(	_	_	I-Premise
257	8.9	_	_	I-Premise
258	months	_	_	I-Premise
259	v	_	_	I-Premise
260	9.3	_	_	I-Premise
261	months	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.43	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Grade	_	_	B-Premise
268	4	_	_	I-Premise
269	neutropenia	_	_	I-Premise
270	and	_	_	I-Premise
271	thrombocytopenia	_	_	I-Premise
272	occurred	_	_	I-Premise
273	in	_	_	I-Premise
274	50	_	_	I-Premise
275	%	_	_	I-Premise
276	and	_	_	I-Premise
277	3	_	_	I-Premise
278	%	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	,	_	_	I-Premise
282	of	_	_	I-Premise
283	PE	_	_	I-Premise
284	patients	_	_	I-Premise
285	in	_	_	I-Premise
286	step	_	_	I-Premise
287	1	_	_	I-Premise
288	and	_	_	I-Premise
289	60	_	_	I-Premise
290	%	_	_	I-Premise
291	and	_	_	I-Premise
292	13	_	_	I-Premise
293	%	_	_	I-Premise
294	of	_	_	I-Premise
295	topotecan	_	_	I-Premise
296	patients	_	_	I-Premise
297	in	_	_	I-Premise
298	step	_	_	I-Premise
299	2	_	_	I-Premise
300	.	_	_	I-Premise

301	Grade	_	_	B-Premise
302	4/5	_	_	I-Premise
303	infection	_	_	I-Premise
304	was	_	_	I-Premise
305	observed	_	_	I-Premise
306	in	_	_	I-Premise
307	4.6	_	_	I-Premise
308	%	_	_	I-Premise
309	of	_	_	I-Premise
310	PE	_	_	I-Premise
311	patients	_	_	I-Premise
312	and	_	_	I-Premise
313	1.8	_	_	I-Premise
314	%	_	_	I-Premise
315	of	_	_	I-Premise
316	topotecan	_	_	I-Premise
317	patients	_	_	I-Premise
318	.	_	_	I-Premise

319	Grade	_	_	B-Premise
320	3/4	_	_	I-Premise
321	anemia	_	_	I-Premise
322	developed	_	_	I-Premise
323	in	_	_	I-Premise
324	22	_	_	I-Premise
325	%	_	_	I-Premise
326	of	_	_	I-Premise
327	patients	_	_	I-Premise
328	who	_	_	I-Premise
329	received	_	_	I-Premise
330	topotecan	_	_	I-Premise
331	.	_	_	I-Premise

332	No	_	_	B-Premise
333	difference	_	_	I-Premise
334	in	_	_	I-Premise
335	quality	_	_	I-Premise
336	of	_	_	I-Premise
337	life	_	_	I-Premise
338	between	_	_	I-Premise
339	topotecan	_	_	I-Premise
340	and	_	_	I-Premise
341	observation	_	_	I-Premise
342	was	_	_	I-Premise
343	observed	_	_	I-Premise
344	at	_	_	I-Premise
345	any	_	_	I-Premise
346	assessment	_	_	I-Premise
347	time	_	_	I-Premise
348	or	_	_	I-Premise
349	for	_	_	I-Premise
350	any	_	_	I-Premise
351	of	_	_	I-Premise
352	the	_	_	I-Premise
353	subscale	_	_	I-Premise
354	scores	_	_	I-Premise
355	.	_	_	I-Premise

356	Four	_	_	B-Claim
357	cycles	_	_	I-Claim
358	of	_	_	I-Claim
359	PE	_	_	I-Claim
360	induction	_	_	I-Claim
361	therapy	_	_	I-Claim
362	followed	_	_	I-Claim
363	by	_	_	I-Claim
364	four	_	_	I-Claim
365	cycles	_	_	I-Claim
366	of	_	_	I-Claim
367	topotecan	_	_	I-Claim
368	improved	_	_	I-Claim
369	PFS	_	_	I-Claim
370	but	_	_	I-Claim
371	failed	_	_	I-Claim
372	to	_	_	I-Claim
373	improve	_	_	I-Claim
374	overall	_	_	I-Claim
375	survival	_	_	I-Claim
376	or	_	_	I-Claim
377	quality	_	_	I-Claim
378	of	_	_	I-Claim
379	life	_	_	I-Claim
380	in	_	_	I-Claim
381	extensive-stage	_	_	I-Claim
382	SCLC	_	_	I-Claim
383	.	_	_	I-Claim

384	Four	_	_	B-Claim
385	cycles	_	_	I-Claim
386	of	_	_	I-Claim
387	standard	_	_	I-Claim
388	PE	_	_	I-Claim
389	remains	_	_	I-Claim
390	an	_	_	I-Claim
391	appropriate	_	_	I-Claim
392	first-line	_	_	I-Claim
393	treatment	_	_	I-Claim
394	for	_	_	I-Claim
395	extensive-stage	_	_	I-Claim
396	SCLC	_	_	I-Claim
397	patients	_	_	I-Claim
398	with	_	_	I-Claim
399	good	_	_	I-Claim
400	performance	_	_	I-Claim
401	status	_	_	I-Claim
402	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	lymphoma	_	_	O
3	experience	_	_	O
4	sleep	_	_	O
5	problems	_	_	O
6	that	_	_	O
7	may	_	_	O
8	be	_	_	O
9	managed	_	_	O
10	with	_	_	O
11	aerobic	_	_	O
12	exercise	_	_	O
13	but	_	_	O
14	no	_	_	O
15	previous	_	_	O
16	study	_	_	O
17	has	_	_	O
18	examined	_	_	O
19	this	_	_	O
20	issue	_	_	O
21	.	_	_	O

22	We	_	_	O
23	randomized	_	_	O
24	122	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	lymphoma	_	_	O
28	to	_	_	O
29	usual	_	_	O
30	care	_	_	O
31	(	_	_	O
32	n	_	_	O
33	=	_	_	O
34	62	_	_	O
35	)	_	_	O
36	or	_	_	O
37	12	_	_	O
38	weeks	_	_	O
39	of	_	_	O
40	supervised	_	_	O
41	aerobic	_	_	O
42	exercise	_	_	O
43	training	_	_	O
44	(	_	_	O
45	AET	_	_	O
46	;	_	_	O
47	n	_	_	O
48	=	_	_	O
49	60	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Our	_	_	O
53	primary	_	_	O
54	sleep	_	_	O
55	endpoint	_	_	O
56	was	_	_	O
57	global	_	_	O
58	sleep	_	_	O
59	quality	_	_	O
60	assessed	_	_	O
61	by	_	_	O
62	the	_	_	O
63	Pittsburgh	_	_	O
64	Sleep	_	_	O
65	Quality	_	_	O
66	Index	_	_	O
67	(	_	_	O
68	PSQI	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Secondary	_	_	O
72	endpoints	_	_	O
73	were	_	_	O
74	the	_	_	O
75	PSQI	_	_	O
76	component	_	_	O
77	scores	_	_	O
78	.	_	_	O

79	Planned	_	_	O
80	subgroup	_	_	O
81	analyses	_	_	O
82	were	_	_	O
83	also	_	_	O
84	conducted	_	_	O
85	.	_	_	O

86	Intention-to-treat	_	_	B-Premise
87	analyses	_	_	I-Premise
88	indicated	_	_	I-Premise
89	that	_	_	I-Premise
90	AET	_	_	I-Premise
91	resulted	_	_	I-Premise
92	in	_	_	I-Premise
93	a	_	_	I-Premise
94	nonsignificant	_	_	I-Premise
95	(	_	_	I-Premise
96	P	_	_	I-Premise
97	=	_	_	I-Premise
98	0.16	_	_	I-Premise
99	)	_	_	I-Premise
100	improvement	_	_	I-Premise
101	in	_	_	I-Premise
102	global	_	_	I-Premise
103	sleep	_	_	I-Premise
104	quality	_	_	I-Premise
105	compared	_	_	I-Premise
106	with	_	_	I-Premise
107	usual	_	_	I-Premise
108	care	_	_	I-Premise
109	[	_	_	I-Premise
110	mean	_	_	I-Premise
111	group	_	_	I-Premise
112	difference	_	_	I-Premise
113	=	_	_	I-Premise
114	-0.64	_	_	I-Premise
115	;	_	_	I-Premise
116	95	_	_	I-Premise
117	%	_	_	I-Premise
118	confidence	_	_	I-Premise
119	interval	_	_	I-Premise
120	(	_	_	I-Premise
121	CI	_	_	I-Premise
122	)	_	_	I-Premise
123	,	_	_	I-Premise
124	-1.56	_	_	I-Premise
125	to	_	_	I-Premise
126	+0.27	_	_	I-Premise
127	]	_	_	I-Premise
128	.	_	_	I-Premise

129	In	_	_	B-Premise
130	planned	_	_	I-Premise
131	subgroup	_	_	I-Premise
132	analyses	_	_	I-Premise
133	,	_	_	I-Premise
134	statistically	_	_	I-Premise
135	significant	_	_	I-Premise
136	or	_	_	I-Premise
137	borderline	_	_	I-Premise
138	significant	_	_	I-Premise
139	interactions	_	_	I-Premise
140	were	_	_	I-Premise
141	identified	_	_	I-Premise
142	for	_	_	I-Premise
143	type	_	_	I-Premise
144	of	_	_	I-Premise
145	lymphoma	_	_	I-Premise
146	(	_	_	I-Premise
147	P	_	_	I-Premise
148	(	_	_	I-Premise
149	interaction	_	_	I-Premise
150	)	_	_	I-Premise
151	=	_	_	I-Premise
152	0.006	_	_	I-Premise
153	)	_	_	I-Premise
154	,	_	_	I-Premise
155	current	_	_	I-Premise
156	treatment	_	_	I-Premise
157	status	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	(	_	_	I-Premise
161	interaction	_	_	I-Premise
162	)	_	_	I-Premise
163	=	_	_	I-Premise
164	0.036	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	time	_	_	I-Premise
168	since	_	_	I-Premise
169	diagnosis	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	(	_	_	I-Premise
173	interaction	_	_	I-Premise
174	)	_	_	I-Premise
175	=	_	_	I-Premise
176	0.010	_	_	I-Premise
177	)	_	_	I-Premise
178	,	_	_	I-Premise
179	body	_	_	I-Premise
180	mass	_	_	I-Premise
181	index	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	(	_	_	I-Premise
185	interaction	_	_	I-Premise
186	)	_	_	I-Premise
187	=	_	_	I-Premise
188	0.075	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	baseline	_	_	I-Premise
193	sleep	_	_	I-Premise
194	quality	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	(	_	_	I-Premise
198	interaction	_	_	I-Premise
199	)	_	_	I-Premise
200	=	_	_	I-Premise
201	0.041	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	Specifically	_	_	O
205	,	_	_	O
206	AET	_	_	B-Premise
207	improved	_	_	I-Premise
208	global	_	_	I-Premise
209	sleep	_	_	I-Premise
210	quality	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	with	_	_	I-Premise
214	lymphoma	_	_	I-Premise
215	who	_	_	I-Premise
216	had	_	_	I-Premise
217	indolent	_	_	I-Premise
218	non-Hodgkin	_	_	I-Premise
219	lymphoma	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	=	_	_	I-Premise
223	0.001	_	_	I-Premise
224	)	_	_	I-Premise
225	,	_	_	I-Premise
226	were	_	_	I-Premise
227	receiving	_	_	I-Premise
228	chemotherapy	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	0.013	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	were	_	_	I-Premise
236	<	_	_	I-Premise
237	2	_	_	I-Premise
238	years	_	_	I-Premise
239	post-diagnosis	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.005	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	were	_	_	I-Premise
247	obese	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	0.025	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	and	_	_	I-Premise
255	were	_	_	I-Premise
256	poor	_	_	I-Premise
257	sleepers	_	_	I-Premise
258	at	_	_	I-Premise
259	baseline	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0.007	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	AET	_	_	B-Claim
267	did	_	_	I-Claim
268	not	_	_	I-Claim
269	significantly	_	_	I-Claim
270	improve	_	_	I-Claim
271	sleep	_	_	I-Claim
272	quality	_	_	I-Claim
273	in	_	_	I-Claim
274	this	_	_	I-Claim
275	heterogeneous	_	_	I-Claim
276	sample	_	_	I-Claim
277	of	_	_	I-Claim
278	patients	_	_	I-Claim
279	with	_	_	I-Claim
280	lymphoma	_	_	I-Claim
281	;	_	_	I-Claim
282	however	_	_	B-Claim
283	,	_	_	I-Claim
284	clinically	_	_	I-Claim
285	identifiable	_	_	I-Claim
286	subgroups	_	_	I-Claim
287	appeared	_	_	I-Claim
288	to	_	_	I-Claim
289	benefit	_	_	I-Claim
290	.	_	_	I-Claim

291	Future	_	_	O
292	exercise	_	_	O
293	trials	_	_	O
294	targeting	_	_	O
295	these	_	_	O
296	responsive	_	_	O
297	subgroups	_	_	O
298	are	_	_	O
299	needed	_	_	O
300	to	_	_	O
301	confirm	_	_	O
302	these	_	_	O
303	findings	_	_	O
304	.	_	_	O

305	If	_	_	O
306	replicated	_	_	O
307	in	_	_	O
308	larger	_	_	O
309	and	_	_	O
310	more	_	_	O
311	focused	_	_	O
312	trials	_	_	O
313	,	_	_	O
314	aerobic	_	_	O
315	exercise	_	_	O
316	may	_	_	O
317	be	_	_	O
318	an	_	_	O
319	attractive	_	_	O
320	option	_	_	O
321	to	_	_	O
322	manage	_	_	O
323	sleep	_	_	O
324	dysfunction	_	_	O
325	in	_	_	O
326	patients	_	_	O
327	with	_	_	O
328	cancer	_	_	O
329	because	_	_	O
330	of	_	_	O
331	its	_	_	O
332	favorable	_	_	O
333	safety	_	_	O
334	profile	_	_	O
335	and	_	_	O
336	other	_	_	O
337	documented	_	_	O
338	health	_	_	O
339	benefits	_	_	O
340	.	_	_	O


0	In	_	_	B-Claim
1	vivo	_	_	I-Claim
2	data	_	_	I-Claim
3	have	_	_	I-Claim
4	shown	_	_	I-Claim
5	a	_	_	I-Claim
6	more	_	_	I-Claim
7	potent	_	_	I-Claim
8	antiangiogenic	_	_	I-Claim
9	effect	_	_	I-Claim
10	and	_	_	I-Claim
11	a	_	_	I-Claim
12	higher	_	_	I-Claim
13	antitumor	_	_	I-Claim
14	activity	_	_	I-Claim
15	of	_	_	I-Claim
16	low-dose	_	_	I-Claim
17	interferon	_	_	I-Claim
18	(	_	_	I-Claim
19	IFN	_	_	I-Claim
20	)	_	_	I-Claim
21	given	_	_	I-Claim
22	twice	_	_	I-Claim
23	daily	_	_	I-Claim
24	.	_	_	I-Claim

25	In	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	Phase	_	_	O
29	II	_	_	O
30	trial	_	_	O
31	,	_	_	O
32	the	_	_	O
33	authors	_	_	O
34	tested	_	_	O
35	the	_	_	O
36	hypothesis	_	_	O
37	that	_	_	O
38	twice-daily	_	_	O
39	low-dose	_	_	O
40	IFN	_	_	O
41	is	_	_	O
42	more	_	_	O
43	effective	_	_	O
44	than	_	_	O
45	daily	_	_	O
46	intermediate-dose	_	_	O
47	IFN	_	_	O
48	in	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	metastatic	_	_	O
52	renal	_	_	O
53	cell	_	_	O
54	cancer	_	_	O
55	(	_	_	O
56	MRCC	_	_	O
57	)	_	_	O
58	.	_	_	O

59	A	_	_	O
60	total	_	_	O
61	of	_	_	O
62	118	_	_	O
63	patients	_	_	O
64	(	_	_	O
65	59	_	_	O
66	per	_	_	O
67	arm	_	_	O
68	)	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	assigned	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	IFN	_	_	O
75	at	_	_	O
76	a	_	_	O
77	dose	_	_	O
78	of	_	_	O
79	0.5	_	_	O
80	million	_	_	O
81	units	_	_	O
82	(	_	_	O
83	MU	_	_	O
84	)	_	_	O
85	given	_	_	O
86	subcutaneously	_	_	O
87	twice	_	_	O
88	daily	_	_	O
89	(	_	_	O
90	IFN1	_	_	O
91	)	_	_	O
92	or	_	_	O
93	IFN	_	_	O
94	at	_	_	O
95	a	_	_	O
96	dose	_	_	O
97	of	_	_	O
98	5	_	_	O
99	MU	_	_	O
100	given	_	_	O
101	subcutaneously	_	_	O
102	daily	_	_	O
103	(	_	_	O
104	IFN5	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	O
108	primary	_	_	O
109	endpoint	_	_	O
110	was	_	_	O
111	progression-free	_	_	O
112	survival	_	_	O
113	(	_	_	O
114	PFS	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Secondary	_	_	O
118	endpoints	_	_	O
119	included	_	_	O
120	response	_	_	O
121	rate	_	_	O
122	(	_	_	O
123	RR	_	_	O
124	)	_	_	O
125	,	_	_	O
126	overall	_	_	O
127	survival	_	_	O
128	(	_	_	O
129	OS	_	_	O
130	)	_	_	O
131	,	_	_	O
132	toxicity	_	_	O
133	,	_	_	O
134	and	_	_	O
135	quality	_	_	O
136	of	_	_	O
137	life	_	_	O
138	(	_	_	O
139	QOL	_	_	O
140	)	_	_	O
141	.	_	_	O

142	There	_	_	B-Premise
143	were	_	_	I-Premise
144	no	_	_	I-Premise
145	significant	_	_	I-Premise
146	differences	_	_	I-Premise
147	in	_	_	I-Premise
148	either	_	_	I-Premise
149	PFS	_	_	I-Premise
150	or	_	_	I-Premise
151	OS	_	_	I-Premise
152	between	_	_	I-Premise
153	IFN1	_	_	I-Premise
154	and	_	_	I-Premise
155	IFN5	_	_	I-Premise
156	(	_	_	I-Premise
157	median	_	_	I-Premise
158	of	_	_	I-Premise
159	3.7	_	_	I-Premise
160	months	_	_	I-Premise
161	and	_	_	I-Premise
162	median	_	_	I-Premise
163	of	_	_	I-Premise
164	3.4	_	_	I-Premise
165	months	_	_	I-Premise
166	PFS	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	median	_	_	I-Premise
171	of	_	_	I-Premise
172	25.5	_	_	I-Premise
173	months	_	_	I-Premise
174	and	_	_	I-Premise
175	median	_	_	I-Premise
176	of	_	_	I-Premise
177	17.5	_	_	I-Premise
178	months	_	_	I-Premise
179	OS	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	The	_	_	B-Premise
185	RRs	_	_	I-Premise
186	were	_	_	I-Premise
187	identical	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	2	_	_	I-Premise
191	arms	_	_	I-Premise
192	(	_	_	I-Premise
193	6.7	_	_	I-Premise
194	%	_	_	I-Premise
195	;	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	confidence	_	_	I-Premise
199	interval	_	_	I-Premise
200	[	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	]	_	_	I-Premise
205	,	_	_	I-Premise
206	1.8-16.5	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Two	_	_	B-Premise
211	patients	_	_	I-Premise
212	,	_	_	I-Premise
213	1	_	_	I-Premise
214	in	_	_	I-Premise
215	each	_	_	I-Premise
216	arm	_	_	I-Premise
217	,	_	_	I-Premise
218	remained	_	_	I-Premise
219	in	_	_	I-Premise
220	complete	_	_	I-Premise
221	remission	_	_	I-Premise
222	at	_	_	I-Premise
223	the	_	_	I-Premise
224	time	_	_	I-Premise
225	of	_	_	I-Premise
226	last	_	_	I-Premise
227	follow-up	_	_	I-Premise
228	,	_	_	I-Premise
229	at	_	_	I-Premise
230	45+	_	_	I-Premise
231	and	_	_	I-Premise
232	38+	_	_	I-Premise
233	months	_	_	I-Premise
234	from	_	_	I-Premise
235	treatment	_	_	I-Premise
236	.	_	_	I-Premise

237	Thirty-two	_	_	B-Premise
238	patients	_	_	I-Premise
239	receiving	_	_	I-Premise
240	IFN5	_	_	I-Premise
241	and	_	_	I-Premise
242	19	_	_	I-Premise
243	patients	_	_	I-Premise
244	receiving	_	_	I-Premise
245	IFN1	_	_	I-Premise
246	experienced	_	_	I-Premise
247	Grade	_	_	I-Premise
248	3	_	_	I-Premise
249	or	_	_	I-Premise
250	higher	_	_	I-Premise
251	adverse	_	_	I-Premise
252	events	_	_	I-Premise
253	(	_	_	I-Premise
254	graded	_	_	I-Premise
255	using	_	_	I-Premise
256	the	_	_	I-Premise
257	National	_	_	I-Premise
258	Cancer	_	_	I-Premise
259	Institute	_	_	I-Premise
260	Common	_	_	I-Premise
261	Toxicity	_	_	I-Premise
262	Criteria	_	_	I-Premise
263	[	_	_	I-Premise
264	version	_	_	I-Premise
265	2.0	_	_	I-Premise
266	]	_	_	I-Premise
267	)	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.025	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Eighteen	_	_	B-Premise
275	patients	_	_	I-Premise
276	receiving	_	_	I-Premise
277	IFN5	_	_	I-Premise
278	and	_	_	I-Premise
279	4	_	_	I-Premise
280	patients	_	_	I-Premise
281	receiving	_	_	I-Premise
282	IFN1	_	_	I-Premise
283	had	_	_	I-Premise
284	dose	_	_	I-Premise
285	reductions	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.002	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	B-Premise
293	was	_	_	I-Premise
294	a	_	_	I-Premise
295	significant	_	_	I-Premise
296	deterioration	_	_	I-Premise
297	in	_	_	I-Premise
298	QOL	_	_	I-Premise
299	and	_	_	I-Premise
300	an	_	_	I-Premise
301	increase	_	_	I-Premise
302	in	_	_	I-Premise
303	depression	_	_	I-Premise
304	associated	_	_	I-Premise
305	with	_	_	I-Premise
306	IFN5	_	_	I-Premise
307	but	_	_	I-Premise
308	no	_	_	I-Premise
309	change	_	_	I-Premise
310	was	_	_	I-Premise
311	noted	_	_	I-Premise
312	with	_	_	I-Premise
313	IFN1	_	_	I-Premise
314	.	_	_	I-Premise

315	Compared	_	_	B-Claim
316	with	_	_	I-Claim
317	IFN5	_	_	I-Claim
318	,	_	_	I-Claim
319	IFN1	_	_	I-Claim
320	is	_	_	I-Claim
321	neither	_	_	I-Claim
322	more	_	_	I-Claim
323	nor	_	_	I-Claim
324	less	_	_	I-Claim
325	effective	_	_	I-Claim
326	but	_	_	I-Claim
327	is	_	_	I-Claim
328	less	_	_	I-Claim
329	toxic	_	_	I-Claim
330	,	_	_	I-Claim
331	with	_	_	I-Claim
332	a	_	_	I-Claim
333	better	_	_	I-Claim
334	reported	_	_	I-Claim
335	QOL	_	_	I-Claim
336	.	_	_	I-Claim

337	These	_	_	B-Claim
338	results	_	_	I-Claim
339	may	_	_	I-Claim
340	have	_	_	I-Claim
341	implications	_	_	I-Claim
342	for	_	_	I-Claim
343	the	_	_	I-Claim
344	design	_	_	I-Claim
345	of	_	_	I-Claim
346	combination	_	_	I-Claim
347	regimens	_	_	I-Claim
348	incorporating	_	_	I-Claim
349	IFN	_	_	I-Claim
350	with	_	_	I-Claim
351	targeted	_	_	I-Claim
352	agents	_	_	I-Claim
353	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	patients	_	_	O
4	with	_	_	O
5	locally	_	_	O
6	advanced	_	_	O
7	non-small	_	_	O
8	cell	_	_	O
9	lung	_	_	O
10	cancer	_	_	O
11	unsuitable	_	_	O
12	for	_	_	O
13	resection	_	_	O
14	or	_	_	O
15	radical	_	_	O
16	radiotherapy	_	_	O
17	,	_	_	O
18	and	_	_	O
19	with	_	_	O
20	minimal	_	_	O
21	thoracic	_	_	O
22	symptoms	_	_	O
23	,	_	_	O
24	should	_	_	O
25	be	_	_	O
26	given	_	_	O
27	palliative	_	_	O
28	thoracic	_	_	O
29	radiotherapy	_	_	O
30	immediately	_	_	O
31	or	_	_	O
32	as	_	_	O
33	needed	_	_	O
34	to	_	_	O
35	treat	_	_	O
36	symptoms	_	_	O
37	.	_	_	O

38	Multicentre	_	_	O
39	randomised	_	_	O
40	controlled	_	_	O
41	trial	_	_	O
42	.	_	_	O

43	23	_	_	O
44	centres	_	_	O
45	in	_	_	O
46	the	_	_	O
47	United	_	_	O
48	Kingdom	_	_	O
49	,	_	_	O
50	Ireland	_	_	O
51	,	_	_	O
52	and	_	_	O
53	South	_	_	O
54	Africa	_	_	O
55	.	_	_	O

56	230	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	previously	_	_	O
60	untreated	_	_	O
61	,	_	_	O
62	non-small	_	_	O
63	cell	_	_	O
64	lung	_	_	O
65	cancer	_	_	O
66	that	_	_	O
67	is	_	_	O
68	locally	_	_	O
69	too	_	_	O
70	advanced	_	_	O
71	for	_	_	O
72	resection	_	_	O
73	or	_	_	O
74	radical	_	_	O
75	radiotherapy	_	_	O
76	with	_	_	O
77	curative	_	_	O
78	intent	_	_	O
79	,	_	_	O
80	with	_	_	O
81	minimal	_	_	O
82	thoracic	_	_	O
83	symptoms	_	_	O
84	,	_	_	O
85	and	_	_	O
86	with	_	_	O
87	no	_	_	O
88	indication	_	_	O
89	for	_	_	O
90	immediate	_	_	O
91	thoracic	_	_	O
92	radiotherapy	_	_	O
93	.	_	_	O

94	All	_	_	O
95	patients	_	_	O
96	were	_	_	O
97	given	_	_	O
98	supportive	_	_	O
99	treatment	_	_	O
100	and	_	_	O
101	were	_	_	O
102	randomised	_	_	O
103	to	_	_	O
104	receive	_	_	O
105	palliative	_	_	O
106	thoracic	_	_	O
107	radiotherapy	_	_	O
108	either	_	_	O
109	immediately	_	_	O
110	or	_	_	O
111	delayed	_	_	O
112	until	_	_	O
113	needed	_	_	O
114	to	_	_	O
115	treat	_	_	O
116	symptoms	_	_	O
117	.	_	_	O

118	The	_	_	O
119	recommended	_	_	O
120	regimens	_	_	O
121	were	_	_	O
122	17	_	_	O
123	Gy	_	_	O
124	in	_	_	O
125	two	_	_	O
126	fractions	_	_	O
127	one	_	_	O
128	week	_	_	O
129	apart	_	_	O
130	or	_	_	O
131	10	_	_	O
132	Gy	_	_	O
133	as	_	_	O
134	a	_	_	O
135	single	_	_	O
136	dose	_	_	O
137	.	_	_	O

138	Primary	_	_	O
139	--	_	_	O
140	patients	_	_	O
141	alive	_	_	O
142	and	_	_	O
143	without	_	_	O
144	moderate	_	_	O
145	or	_	_	O
146	severe	_	_	O
147	cough	_	_	O
148	,	_	_	O
149	chest	_	_	O
150	pain	_	_	O
151	,	_	_	O
152	haemoptysis	_	_	O
153	,	_	_	O
154	or	_	_	O
155	dyspnoea	_	_	O
156	six	_	_	O
157	months	_	_	O
158	from	_	_	O
159	randomisation	_	_	O
160	,	_	_	O
161	as	_	_	O
162	recorded	_	_	O
163	by	_	_	O
164	clinicians	_	_	O
165	.	_	_	O

166	Secondary	_	_	O
167	--	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	,	_	_	O
172	adverse	_	_	O
173	events	_	_	O
174	,	_	_	O
175	survival	_	_	O
176	.	_	_	O

177	From	_	_	O
178	December	_	_	O
179	1992	_	_	O
180	to	_	_	O
181	May	_	_	O
182	1999	_	_	O
183	,	_	_	O
184	230	_	_	O
185	patients	_	_	O
186	were	_	_	O
187	randomised	_	_	O
188	.	_	_	O

189	104/115	_	_	O
190	of	_	_	O
191	the	_	_	O
192	patients	_	_	O
193	in	_	_	O
194	the	_	_	O
195	immediate	_	_	O
196	treatment	_	_	O
197	group	_	_	O
198	received	_	_	O
199	thoracic	_	_	O
200	radiotherapy	_	_	O
201	(	_	_	O
202	90	_	_	O
203	received	_	_	O
204	one	_	_	O
205	of	_	_	O
206	the	_	_	O
207	recommended	_	_	O
208	regimens	_	_	O
209	)	_	_	O
210	.	_	_	O

211	In	_	_	O
212	the	_	_	O
213	delayed	_	_	O
214	treatment	_	_	O
215	group	_	_	O
216	,	_	_	O
217	48/115	_	_	O
218	(	_	_	O
219	42	_	_	O
220	%	_	_	O
221	)	_	_	O
222	patients	_	_	O
223	received	_	_	O
224	thoracic	_	_	O
225	radiotherapy	_	_	O
226	(	_	_	O
227	29	_	_	O
228	received	_	_	O
229	one	_	_	O
230	of	_	_	O
231	the	_	_	O
232	recommended	_	_	O
233	regimens	_	_	O
234	)	_	_	O
235	;	_	_	O
236	64	_	_	O
237	(	_	_	O
238	56	_	_	O
239	%	_	_	O
240	)	_	_	O
241	died	_	_	O
242	without	_	_	O
243	receiving	_	_	O
244	thoracic	_	_	O
245	radiotherapy	_	_	O
246	;	_	_	O
247	the	_	_	O
248	remaining	_	_	O
249	three	_	_	O
250	(	_	_	O
251	3	_	_	O
252	%	_	_	O
253	)	_	_	O
254	were	_	_	O
255	alive	_	_	O
256	at	_	_	O
257	the	_	_	O
258	end	_	_	O
259	of	_	_	O
260	the	_	_	O
261	study	_	_	O
262	without	_	_	O
263	having	_	_	O
264	received	_	_	O
265	the	_	_	O
266	treatment	_	_	O
267	.	_	_	O

268	For	_	_	O
269	patients	_	_	O
270	who	_	_	O
271	received	_	_	O
272	thoracic	_	_	O
273	radiotherapy	_	_	O
274	,	_	_	O
275	the	_	_	O
276	median	_	_	O
277	time	_	_	O
278	to	_	_	O
279	start	_	_	O
280	was	_	_	O
281	15	_	_	O
282	days	_	_	O
283	in	_	_	O
284	the	_	_	O
285	immediate	_	_	O
286	treatment	_	_	O
287	group	_	_	O
288	and	_	_	O
289	125	_	_	O
290	days	_	_	O
291	in	_	_	O
292	the	_	_	O
293	delayed	_	_	O
294	treatment	_	_	O
295	group	_	_	O
296	.	_	_	O

297	The	_	_	B-Premise
298	primary	_	_	I-Premise
299	outcome	_	_	I-Premise
300	measure	_	_	I-Premise
301	was	_	_	I-Premise
302	achieved	_	_	I-Premise
303	in	_	_	I-Premise
304	28	_	_	I-Premise
305	%	_	_	I-Premise
306	of	_	_	I-Premise
307	the	_	_	I-Premise
308	immediate	_	_	I-Premise
309	treatment	_	_	I-Premise
310	group	_	_	I-Premise
311	and	_	_	I-Premise
312	26	_	_	I-Premise
313	%	_	_	I-Premise
314	of	_	_	I-Premise
315	patients	_	_	I-Premise
316	from	_	_	I-Premise
317	the	_	_	I-Premise
318	delayed	_	_	I-Premise
319	treatment	_	_	I-Premise
320	group	_	_	I-Premise
321	(	_	_	I-Premise
322	27/97	_	_	I-Premise
323	and	_	_	I-Premise
324	27/103	_	_	I-Premise
325	,	_	_	I-Premise
326	respectively	_	_	I-Premise
327	;	_	_	I-Premise
328	absolute	_	_	I-Premise
329	difference	_	_	I-Premise
330	1.6	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	95	_	_	I-Premise
334	%	_	_	I-Premise
335	confidence	_	_	I-Premise
336	interval	_	_	I-Premise
337	-10.7	_	_	I-Premise
338	%	_	_	I-Premise
339	to	_	_	I-Premise
340	13.9	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	No	_	_	B-Premise
345	evidence	_	_	I-Premise
346	of	_	_	I-Premise
347	a	_	_	I-Premise
348	difference	_	_	I-Premise
349	was	_	_	I-Premise
350	observed	_	_	I-Premise
351	between	_	_	I-Premise
352	the	_	_	I-Premise
353	two	_	_	I-Premise
354	treatment	_	_	I-Premise
355	groups	_	_	I-Premise
356	in	_	_	I-Premise
357	terms	_	_	I-Premise
358	of	_	_	I-Premise
359	activity	_	_	I-Premise
360	level	_	_	I-Premise
361	,	_	_	I-Premise
362	anxiety	_	_	I-Premise
363	,	_	_	I-Premise
364	depression	_	_	I-Premise
365	,	_	_	I-Premise
366	and	_	_	I-Premise
367	psychological	_	_	I-Premise
368	distress	_	_	I-Premise
369	,	_	_	I-Premise
370	as	_	_	I-Premise
371	recorded	_	_	I-Premise
372	by	_	_	I-Premise
373	the	_	_	I-Premise
374	patients	_	_	I-Premise
375	.	_	_	I-Premise

376	Adverse	_	_	B-Premise
377	events	_	_	I-Premise
378	were	_	_	I-Premise
379	more	_	_	I-Premise
380	common	_	_	I-Premise
381	in	_	_	I-Premise
382	the	_	_	I-Premise
383	immediate	_	_	I-Premise
384	treatment	_	_	I-Premise
385	group	_	_	I-Premise
386	.	_	_	I-Premise

387	Neither	_	_	B-Premise
388	group	_	_	I-Premise
389	had	_	_	I-Premise
390	a	_	_	I-Premise
391	survival	_	_	I-Premise
392	advantage	_	_	I-Premise
393	(	_	_	I-Premise
394	hazard	_	_	I-Premise
395	ratio	_	_	I-Premise
396	0.95	_	_	I-Premise
397	,	_	_	I-Premise
398	0.73	_	_	I-Premise
399	to	_	_	I-Premise
400	1.24	_	_	I-Premise
401	;	_	_	I-Premise
402	P=0.71	_	_	I-Premise
403	)	_	_	I-Premise
404	.	_	_	I-Premise

405	Median	_	_	B-Premise
406	survival	_	_	I-Premise
407	was	_	_	I-Premise
408	8.3	_	_	I-Premise
409	months	_	_	I-Premise
410	and	_	_	I-Premise
411	7.9	_	_	I-Premise
412	months	_	_	I-Premise
413	,	_	_	I-Premise
414	and	_	_	O
415	the	_	_	B-Premise
416	survival	_	_	I-Premise
417	rates	_	_	I-Premise
418	were	_	_	I-Premise
419	31	_	_	I-Premise
420	%	_	_	I-Premise
421	and	_	_	I-Premise
422	29	_	_	I-Premise
423	%	_	_	I-Premise
424	at	_	_	I-Premise
425	12	_	_	I-Premise
426	months	_	_	I-Premise
427	,	_	_	I-Premise
428	for	_	_	I-Premise
429	the	_	_	I-Premise
430	immediate	_	_	I-Premise
431	and	_	_	I-Premise
432	delayed	_	_	I-Premise
433	treatment	_	_	I-Premise
434	groups	_	_	I-Premise
435	,	_	_	I-Premise
436	respectively	_	_	I-Premise
437	.	_	_	I-Premise

438	In	_	_	B-Claim
439	minimally	_	_	I-Claim
440	symptomatic	_	_	I-Claim
441	patients	_	_	I-Claim
442	with	_	_	I-Claim
443	locally	_	_	I-Claim
444	advanced	_	_	I-Claim
445	non-small	_	_	I-Claim
446	cell	_	_	I-Claim
447	lung	_	_	I-Claim
448	cancer	_	_	I-Claim
449	,	_	_	I-Claim
450	no	_	_	I-Claim
451	persuasive	_	_	I-Claim
452	evidence	_	_	I-Claim
453	was	_	_	I-Claim
454	found	_	_	I-Claim
455	to	_	_	I-Claim
456	indicate	_	_	I-Claim
457	that	_	_	I-Claim
458	giving	_	_	I-Claim
459	immediate	_	_	I-Claim
460	palliative	_	_	I-Claim
461	thoracic	_	_	I-Claim
462	radiotherapy	_	_	I-Claim
463	improves	_	_	I-Claim
464	symptom	_	_	I-Claim
465	control	_	_	I-Claim
466	,	_	_	I-Claim
467	quality	_	_	I-Claim
468	of	_	_	I-Claim
469	life	_	_	I-Claim
470	,	_	_	I-Claim
471	or	_	_	I-Claim
472	survival	_	_	I-Claim
473	when	_	_	I-Claim
474	compared	_	_	I-Claim
475	with	_	_	I-Claim
476	delaying	_	_	I-Claim
477	until	_	_	I-Claim
478	symptoms	_	_	I-Claim
479	require	_	_	I-Claim
480	treatment	_	_	I-Claim
481	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	palliation	_	_	O
4	of	_	_	O
5	chest	_	_	O
6	symptoms	_	_	O
7	from	_	_	O
8	a	_	_	O
9	10	_	_	O
10	Gy	_	_	O
11	single	_	_	O
12	fraction	_	_	O
13	(	_	_	O
14	regimen	_	_	O
15	1	_	_	O
16	)	_	_	O
17	was	_	_	O
18	equivalent	_	_	O
19	to	_	_	O
20	that	_	_	O
21	from	_	_	O
22	30	_	_	O
23	Gy	_	_	O
24	in	_	_	O
25	10	_	_	O
26	fractions	_	_	O
27	(	_	_	O
28	regimen	_	_	O
29	2	_	_	O
30	)	_	_	O
31	.	_	_	O

32	Patients	_	_	O
33	with	_	_	O
34	cytologically	_	_	O
35	proven	_	_	O
36	,	_	_	O
37	symptomatic	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	not	_	_	O
41	amenable	_	_	O
42	to	_	_	O
43	curative	_	_	O
44	therapy	_	_	O
45	,	_	_	O
46	with	_	_	O
47	performance	_	_	O
48	status	_	_	O
49	0-3	_	_	O
50	,	_	_	O
51	were	_	_	O
52	randomised	_	_	O
53	to	_	_	O
54	receive	_	_	O
55	either	_	_	O
56	30	_	_	O
57	Gy	_	_	O
58	in	_	_	O
59	10	_	_	O
60	fractions	_	_	O
61	or	_	_	O
62	a	_	_	O
63	10	_	_	O
64	Gy	_	_	O
65	single	_	_	O
66	fraction	_	_	O
67	.	_	_	O

68	Local	_	_	O
69	symptoms	_	_	O
70	were	_	_	O
71	scored	_	_	O
72	on	_	_	O
73	a	_	_	O
74	physician-assessed	_	_	O
75	,	_	_	O
76	five-point	_	_	O
77	categorical	_	_	O
78	scale	_	_	O
79	and	_	_	O
80	summed	_	_	O
81	to	_	_	O
82	produce	_	_	O
83	a	_	_	O
84	total	_	_	O
85	symptom	_	_	O
86	score	_	_	O
87	(	_	_	O
88	TSS	_	_	O
89	)	_	_	O
90	.	_	_	O

91	This	_	_	O
92	,	_	_	O
93	performance	_	_	O
94	status	_	_	O
95	,	_	_	O
96	Hospital	_	_	O
97	Anxiety	_	_	O
98	and	_	_	O
99	Depression	_	_	O
100	(	_	_	O
101	HAD	_	_	O
102	)	_	_	O
103	score	_	_	O
104	and	_	_	O
105	Spitzer	_	_	O
106	's	_	_	O
107	quality-of-life	_	_	O
108	index	_	_	O
109	were	_	_	O
110	noted	_	_	O
111	before	_	_	O
112	treatment	_	_	O
113	,	_	_	O
114	at	_	_	O
115	1	_	_	O
116	month	_	_	O
117	after	_	_	O
118	treatment	_	_	O
119	and	_	_	O
120	every	_	_	O
121	2	_	_	O
122	months	_	_	O
123	thereafter	_	_	O
124	.	_	_	O

125	Palliation	_	_	O
126	was	_	_	O
127	defined	_	_	O
128	as	_	_	O
129	an	_	_	O
130	improvement	_	_	O
131	of	_	_	O
132	one	_	_	O
133	point	_	_	O
134	or	_	_	O
135	more	_	_	O
136	in	_	_	O
137	the	_	_	O
138	categorical	_	_	O
139	scale	_	_	O
140	.	_	_	O

141	Equivalence	_	_	O
142	was	_	_	O
143	defined	_	_	O
144	as	_	_	O
145	less	_	_	O
146	than	_	_	O
147	20	_	_	O
148	%	_	_	O
149	difference	_	_	O
150	in	_	_	O
151	the	_	_	O
152	number	_	_	O
153	achieving	_	_	O
154	an	_	_	O
155	improvement	_	_	O
156	in	_	_	O
157	the	_	_	O
158	TSS	_	_	O
159	.	_	_	O

160	We	_	_	O
161	randomised	_	_	O
162	149	_	_	O
163	patients	_	_	O
164	and	_	_	O
165	analysed	_	_	O
166	74	_	_	O
167	in	_	_	O
168	each	_	_	O
169	arm	_	_	O
170	.	_	_	O

171	According	_	_	O
172	to	_	_	O
173	the	_	_	O
174	design	_	_	O
175	criteria	_	_	O
176	,	_	_	O
177	palliation	_	_	O
178	was	_	_	O
179	equivalent	_	_	O
180	between	_	_	O
181	the	_	_	O
182	two	_	_	O
183	arms	_	_	O
184	.	_	_	O

185	TSS	_	_	B-Premise
186	improved	_	_	I-Premise
187	in	_	_	I-Premise
188	49	_	_	I-Premise
189	patients	_	_	I-Premise
190	(	_	_	I-Premise
191	77	_	_	I-Premise
192	%	_	_	I-Premise
193	)	_	_	I-Premise
194	on	_	_	I-Premise
195	regimen	_	_	I-Premise
196	1	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	in	_	_	I-Premise
200	57	_	_	I-Premise
201	(	_	_	I-Premise
202	92	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	patients	_	_	I-Premise
206	on	_	_	I-Premise
207	regimen	_	_	I-Premise
208	2	_	_	I-Premise
209	,	_	_	I-Premise
210	a	_	_	I-Premise
211	difference	_	_	I-Premise
212	of	_	_	I-Premise
213	15	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	confidence	_	_	I-Premise
219	interval	_	_	I-Premise
220	[	_	_	I-Premise
221	CI	_	_	I-Premise
222	]	_	_	I-Premise
223	3-28	_	_	I-Premise
224	)	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	proportion	_	_	I-Premise
228	improving	_	_	I-Premise
229	between	_	_	I-Premise
230	the	_	_	I-Premise
231	two	_	_	I-Premise
232	regimens	_	_	I-Premise
233	.	_	_	I-Premise

234	A	_	_	B-Premise
235	complete	_	_	I-Premise
236	resolution	_	_	I-Premise
237	of	_	_	I-Premise
238	all	_	_	I-Premise
239	symptoms	_	_	I-Premise
240	was	_	_	I-Premise
241	achieved	_	_	I-Premise
242	in	_	_	I-Premise
243	three	_	_	I-Premise
244	(	_	_	I-Premise
245	5	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	on	_	_	I-Premise
249	regimen	_	_	I-Premise
250	1	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	in	_	_	I-Premise
254	14	_	_	I-Premise
255	(	_	_	I-Premise
256	23	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	patients	_	_	I-Premise
260	on	_	_	I-Premise
261	regimen	_	_	I-Premise
262	2	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	<	_	_	I-Premise
266	0.001	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	a	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	proportion	_	_	I-Premise
274	between	_	_	I-Premise
275	the	_	_	I-Premise
276	two	_	_	I-Premise
277	regimens	_	_	I-Premise
278	of	_	_	I-Premise
279	21	_	_	I-Premise
280	%	_	_	I-Premise
281	(	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	10-33	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	A	_	_	B-Premise
289	significantly	_	_	I-Premise
290	higher	_	_	I-Premise
291	proportion	_	_	I-Premise
292	of	_	_	I-Premise
293	patients	_	_	I-Premise
294	experienced	_	_	I-Premise
295	palliation	_	_	I-Premise
296	and	_	_	I-Premise
297	complete	_	_	I-Premise
298	resolution	_	_	I-Premise
299	of	_	_	I-Premise
300	chest	_	_	I-Premise
301	pain	_	_	I-Premise
302	and	_	_	I-Premise
303	dyspnoea	_	_	I-Premise
304	with	_	_	I-Premise
305	regimen	_	_	I-Premise
306	2	_	_	I-Premise
307	.	_	_	I-Premise

308	No	_	_	B-Premise
309	differences	_	_	I-Premise
310	were	_	_	I-Premise
311	observed	_	_	I-Premise
312	in	_	_	I-Premise
313	toxicity	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Premise
316	median	_	_	I-Premise
317	survival	_	_	I-Premise
318	was	_	_	I-Premise
319	22.7	_	_	I-Premise
320	weeks	_	_	I-Premise
321	for	_	_	I-Premise
322	regimen	_	_	I-Premise
323	1	_	_	I-Premise
324	and	_	_	I-Premise
325	28.3	_	_	I-Premise
326	weeks	_	_	I-Premise
327	for	_	_	I-Premise
328	regimen	_	_	I-Premise
329	2	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	0.197	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Although	_	_	B-Claim
337	this	_	_	I-Claim
338	trial	_	_	I-Claim
339	met	_	_	I-Claim
340	the	_	_	I-Claim
341	pre-determined	_	_	I-Claim
342	criteria	_	_	I-Claim
343	for	_	_	I-Claim
344	equivalence	_	_	I-Claim
345	between	_	_	I-Claim
346	the	_	_	I-Claim
347	two	_	_	I-Claim
348	palliative	_	_	I-Claim
349	regimens	_	_	I-Claim
350	,	_	_	I-Claim
351	significantly	_	_	B-Claim
352	more	_	_	I-Claim
353	patients	_	_	I-Claim
354	achieved	_	_	I-Claim
355	complete	_	_	I-Claim
356	resolution	_	_	I-Claim
357	of	_	_	I-Claim
358	symptoms	_	_	I-Claim
359	and	_	_	I-Claim
360	palliation	_	_	I-Claim
361	of	_	_	I-Claim
362	chest	_	_	I-Claim
363	pain	_	_	I-Claim
364	and	_	_	I-Claim
365	dyspnoea	_	_	I-Claim
366	with	_	_	I-Claim
367	the	_	_	I-Claim
368	fractionated	_	_	I-Claim
369	regimen	_	_	I-Claim
370	.	_	_	I-Claim


0	Few	_	_	O
1	exercise	_	_	O
2	trials	_	_	O
3	in	_	_	O
4	cancer	_	_	O
5	patients	_	_	O
6	have	_	_	O
7	reported	_	_	O
8	longer-term	_	_	O
9	follow-up	_	_	O
10	.	_	_	O

11	Here	_	_	O
12	,	_	_	O
13	we	_	_	O
14	report	_	_	O
15	a	_	_	O
16	6-month	_	_	O
17	follow-up	_	_	O
18	of	_	_	O
19	exercise	_	_	O
20	behavior	_	_	O
21	and	_	_	O
22	patient-rated	_	_	O
23	outcomes	_	_	O
24	from	_	_	O
25	an	_	_	O
26	exercise	_	_	O
27	trial	_	_	O
28	in	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	patients	_	_	O
32	.	_	_	O

33	Breast	_	_	O
34	cancer	_	_	O
35	patients	_	_	O
36	initiating	_	_	O
37	adjuvant	_	_	O
38	chemotherapy	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	242	_	_	O
43	)	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	usual	_	_	O
49	care	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	82	_	_	O
54	)	_	_	O
55	,	_	_	O
56	resistance	_	_	O
57	exercise	_	_	O
58	training	_	_	O
59	(	_	_	O
60	RET	_	_	O
61	;	_	_	O
62	n	_	_	O
63	=	_	_	O
64	82	_	_	O
65	)	_	_	O
66	,	_	_	O
67	or	_	_	O
68	aerobic	_	_	O
69	exercise	_	_	O
70	training	_	_	O
71	(	_	_	O
72	AET	_	_	O
73	;	_	_	O
74	n	_	_	O
75	=	_	_	O
76	78	_	_	O
77	)	_	_	O
78	for	_	_	O
79	the	_	_	O
80	duration	_	_	O
81	of	_	_	O
82	their	_	_	O
83	chemotherapy	_	_	O
84	.	_	_	O

85	At	_	_	O
86	6-month	_	_	O
87	follow-up	_	_	O
88	,	_	_	O
89	participants	_	_	O
90	were	_	_	O
91	mailed	_	_	O
92	a	_	_	O
93	questionnaire	_	_	O
94	that	_	_	O
95	assessed	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	,	_	_	O
100	self-esteem	_	_	O
101	,	_	_	O
102	fatigue	_	_	O
103	,	_	_	O
104	anxiety	_	_	O
105	,	_	_	O
106	depression	_	_	O
107	,	_	_	O
108	and	_	_	O
109	exercise	_	_	O
110	behavior	_	_	O
111	.	_	_	O

112	Two	_	_	O
113	hundred	_	_	O
114	one	_	_	O
115	(	_	_	O
116	83.1	_	_	O
117	%	_	_	O
118	)	_	_	O
119	participants	_	_	O
120	provided	_	_	O
121	6-month	_	_	O
122	follow-up	_	_	O
123	data	_	_	O
124	.	_	_	O

125	Adjusted	_	_	B-Premise
126	linear	_	_	I-Premise
127	mixed-model	_	_	I-Premise
128	analyses	_	_	I-Premise
129	showed	_	_	I-Premise
130	that	_	_	I-Premise
131	,	_	_	I-Premise
132	at	_	_	I-Premise
133	6-month	_	_	I-Premise
134	follow-up	_	_	I-Premise
135	,	_	_	I-Premise
136	the	_	_	I-Premise
137	RET	_	_	I-Premise
138	group	_	_	I-Premise
139	reported	_	_	I-Premise
140	higher	_	_	I-Premise
141	self-esteem	_	_	I-Premise
142	[	_	_	I-Premise
143	adjusted	_	_	I-Premise
144	mean	_	_	I-Premise
145	difference	_	_	I-Premise
146	,	_	_	I-Premise
147	1.6	_	_	I-Premise
148	;	_	_	I-Premise
149	95	_	_	I-Premise
150	%	_	_	I-Premise
151	confidence	_	_	I-Premise
152	interval	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	)	_	_	I-Premise
158	,	_	_	I-Premise
159	0.1-3.2	_	_	I-Premise
160	;	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0.032	_	_	I-Premise
164	]	_	_	I-Premise
165	and	_	_	I-Premise
166	the	_	_	I-Premise
167	AET	_	_	I-Premise
168	group	_	_	I-Premise
169	reported	_	_	I-Premise
170	lower	_	_	I-Premise
171	anxiety	_	_	I-Premise
172	(	_	_	I-Premise
173	adjusted	_	_	I-Premise
174	mean	_	_	I-Premise
175	difference	_	_	I-Premise
176	,	_	_	I-Premise
177	-4.7	_	_	I-Premise
178	;	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	CI	_	_	I-Premise
182	,	_	_	I-Premise
183	-0.0	_	_	I-Premise
184	to	_	_	I-Premise
185	-9.3	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.049	_	_	I-Premise
190	)	_	_	I-Premise
191	compared	_	_	I-Premise
192	with	_	_	I-Premise
193	the	_	_	I-Premise
194	usual	_	_	I-Premise
195	care	_	_	I-Premise
196	group	_	_	I-Premise
197	.	_	_	I-Premise

198	Moreover	_	_	O
199	,	_	_	O
200	compared	_	_	B-Premise
201	with	_	_	I-Premise
202	participants	_	_	I-Premise
203	reporting	_	_	I-Premise
204	no	_	_	I-Premise
205	regular	_	_	I-Premise
206	exercise	_	_	I-Premise
207	during	_	_	I-Premise
208	the	_	_	I-Premise
209	follow-up	_	_	I-Premise
210	period	_	_	I-Premise
211	,	_	_	I-Premise
212	those	_	_	I-Premise
213	reporting	_	_	I-Premise
214	regular	_	_	I-Premise
215	aerobic	_	_	I-Premise
216	and	_	_	I-Premise
217	resistance	_	_	I-Premise
218	exercise	_	_	I-Premise
219	also	_	_	I-Premise
220	reported	_	_	I-Premise
221	better	_	_	I-Premise
222	patient-rated	_	_	I-Premise
223	outcomes	_	_	I-Premise
224	,	_	_	I-Premise
225	including	_	_	I-Premise
226	quality	_	_	I-Premise
227	of	_	_	I-Premise
228	life	_	_	I-Premise
229	(	_	_	I-Premise
230	adjusted	_	_	I-Premise
231	mean	_	_	I-Premise
232	difference	_	_	I-Premise
233	,	_	_	I-Premise
234	9.5	_	_	I-Premise
235	;	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	CI	_	_	I-Premise
239	,	_	_	I-Premise
240	1.2-17.8	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.025	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Improvements	_	_	B-Premise
248	in	_	_	I-Premise
249	self-esteem	_	_	I-Premise
250	observed	_	_	I-Premise
251	with	_	_	I-Premise
252	RET	_	_	I-Premise
253	during	_	_	I-Premise
254	breast	_	_	I-Premise
255	cancer	_	_	I-Premise
256	chemotherapy	_	_	I-Premise
257	were	_	_	I-Premise
258	maintained	_	_	I-Premise
259	at	_	_	I-Premise
260	6-month	_	_	I-Premise
261	follow-up	_	_	I-Premise
262	whereas	_	_	O
263	reductions	_	_	B-Premise
264	in	_	_	I-Premise
265	anxiety	_	_	I-Premise
266	not	_	_	I-Premise
267	observed	_	_	I-Premise
268	with	_	_	I-Premise
269	AET	_	_	I-Premise
270	during	_	_	I-Premise
271	breast	_	_	I-Premise
272	cancer	_	_	I-Premise
273	chemotherapy	_	_	I-Premise
274	emerged	_	_	I-Premise
275	at	_	_	I-Premise
276	6-month	_	_	I-Premise
277	follow-up	_	_	I-Premise
278	.	_	_	I-Premise

279	Moreover	_	_	O
280	,	_	_	O
281	adopting	_	_	B-Premise
282	a	_	_	I-Premise
283	combined	_	_	I-Premise
284	aerobic	_	_	I-Premise
285	and	_	_	I-Premise
286	resistance	_	_	I-Premise
287	exercise	_	_	I-Premise
288	program	_	_	I-Premise
289	after	_	_	I-Premise
290	breast	_	_	I-Premise
291	cancer	_	_	I-Premise
292	chemotherapy	_	_	I-Premise
293	was	_	_	I-Premise
294	associated	_	_	I-Premise
295	with	_	_	I-Premise
296	further	_	_	I-Premise
297	improvements	_	_	I-Premise
298	in	_	_	I-Premise
299	patient-rated	_	_	I-Premise
300	outcomes	_	_	I-Premise
301	.	_	_	I-Premise

302	Exercise	_	_	B-Claim
303	training	_	_	I-Claim
304	during	_	_	I-Claim
305	breast	_	_	I-Claim
306	cancer	_	_	I-Claim
307	chemotherapy	_	_	I-Claim
308	may	_	_	I-Claim
309	result	_	_	I-Claim
310	in	_	_	I-Claim
311	some	_	_	I-Claim
312	longer-term	_	_	I-Claim
313	and	_	_	I-Claim
314	late	_	_	I-Claim
315	effects	_	_	I-Claim
316	for	_	_	I-Claim
317	selected	_	_	I-Claim
318	patient-rated	_	_	I-Claim
319	outcomes	_	_	I-Claim
320	.	_	_	I-Claim


0	Two	_	_	O
1	million	_	_	O
2	people	_	_	O
3	across	_	_	O
4	the	_	_	O
5	U.K.	_	_	O
6	are	_	_	O
7	living	_	_	O
8	with	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	often	_	_	O
12	experienced	_	_	O
13	as	_	_	O
14	a	_	_	O
15	long-term	_	_	O
16	condition	_	_	O
17	.	_	_	O

18	They	_	_	O
19	may	_	_	O
20	have	_	_	O
21	unmet	_	_	O
22	needs	_	_	O
23	after	_	_	O
24	active	_	_	O
25	treatment	_	_	O
26	.	_	_	O

27	Rehabilitation	_	_	O
28	aims	_	_	O
29	to	_	_	O
30	address	_	_	O
31	these	_	_	O
32	needs	_	_	O
33	,	_	_	O
34	maximize	_	_	O
35	psychological	_	_	O
36	and	_	_	O
37	physical	_	_	O
38	function	_	_	O
39	,	_	_	O
40	and	_	_	O
41	enable	_	_	O
42	minimum	_	_	O
43	dependency	_	_	O
44	regardless	_	_	O
45	of	_	_	O
46	life	_	_	O
47	expectancy	_	_	O
48	.	_	_	O

49	We	_	_	O
50	aimed	_	_	O
51	to	_	_	O
52	test	_	_	O
53	,	_	_	O
54	in	_	_	O
55	a	_	_	O
56	randomized	_	_	O
57	controlled	_	_	O
58	trial	_	_	O
59	,	_	_	O
60	the	_	_	O
61	clinical	_	_	O
62	and	_	_	O
63	cost	_	_	O
64	effectiveness	_	_	O
65	of	_	_	O
66	a	_	_	O
67	rehabilitation	_	_	O
68	intervention	_	_	O
69	for	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	advanced	_	_	O
73	,	_	_	O
74	recurrent	_	_	O
75	cancer	_	_	O
76	.	_	_	O

77	We	_	_	O
78	conducted	_	_	O
79	a	_	_	O
80	two-arm	_	_	O
81	,	_	_	O
82	wait-list	_	_	O
83	control	_	_	O
84	,	_	_	O
85	randomized	_	_	O
86	trial	_	_	O
87	of	_	_	O
88	a	_	_	O
89	complex	_	_	O
90	rehabilitation	_	_	O
91	intervention	_	_	O
92	delivered	_	_	O
93	by	_	_	O
94	a	_	_	O
95	hospice-based	_	_	O
96	multidisciplinary	_	_	O
97	team	_	_	O
98	vs.	_	_	O
99	usual	_	_	O
100	care	_	_	O
101	for	_	_	O
102	active	_	_	O
103	,	_	_	O
104	progressive	_	_	O
105	,	_	_	O
106	recurrent	_	_	O
107	hematological	_	_	O
108	and	_	_	O
109	breast	_	_	O
110	malignancies	_	_	O
111	,	_	_	O
112	with	_	_	O
113	a	_	_	O
114	follow-up	_	_	O
115	at	_	_	O
116	three	_	_	O
117	months	_	_	O
118	.	_	_	O

119	The	_	_	O
120	primary	_	_	O
121	outcome	_	_	O
122	was	_	_	O
123	the	_	_	O
124	psychological	_	_	O
125	subscale	_	_	O
126	of	_	_	O
127	the	_	_	O
128	Supportive	_	_	O
129	Care	_	_	O
130	Needs	_	_	O
131	Survey	_	_	O
132	(	_	_	O
133	SCNS	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Secondary	_	_	O
137	outcomes	_	_	O
138	were	_	_	O
139	other	_	_	O
140	domains	_	_	O
141	of	_	_	O
142	the	_	_	O
143	SCNS	_	_	O
144	,	_	_	O
145	psychological	_	_	O
146	status	_	_	O
147	,	_	_	O
148	continuity	_	_	O
149	of	_	_	O
150	care	_	_	O
151	,	_	_	O
152	quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	,	_	_	O
156	and	_	_	O
157	resource	_	_	O
158	use	_	_	O
159	.	_	_	O

160	Forty-one	_	_	O
161	participants	_	_	O
162	were	_	_	O
163	enrolled	_	_	O
164	and	_	_	O
165	36	_	_	O
166	completed	_	_	O
167	the	_	_	O
168	trial	_	_	O
169	.	_	_	O

170	The	_	_	B-Premise
171	primary	_	_	I-Premise
172	outcome	_	_	I-Premise
173	was	_	_	I-Premise
174	significantly	_	_	I-Premise
175	lower	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	intervention	_	_	I-Premise
179	arm	_	_	I-Premise
180	(	_	_	I-Premise
181	adjusted	_	_	I-Premise
182	difference	_	_	I-Premise
183	-16.8	_	_	I-Premise
184	,	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	CI	_	_	I-Premise
188	-28.34	_	_	I-Premise
189	to	_	_	I-Premise
190	-5.3	_	_	I-Premise
191	;	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.006	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	SCNS	_	_	I-Premise
199	physical	_	_	I-Premise
200	and	_	_	I-Premise
201	patient	_	_	I-Premise
202	care	_	_	I-Premise
203	subscales	_	_	I-Premise
204	(	_	_	I-Premise
205	-14.2	_	_	I-Premise
206	,	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	-26.2	_	_	I-Premise
211	to	_	_	I-Premise
212	-2.2	_	_	I-Premise
213	;	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.02	_	_	I-Premise
217	and	_	_	I-Premise
218	-7.4	_	_	I-Premise
219	,	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	-13.7	_	_	I-Premise
224	to	_	_	I-Premise
225	-1.1	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.02	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	self-reported	_	_	I-Premise
235	health	_	_	I-Premise
236	state	_	_	I-Premise
237	(	_	_	I-Premise
238	12.8	_	_	I-Premise
239	,	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	3.2	_	_	I-Premise
244	to	_	_	I-Premise
245	22.4	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.01	_	_	I-Premise
250	)	_	_	I-Premise
251	also	_	_	I-Premise
252	differed	_	_	I-Premise
253	significantly	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	incremental	_	_	I-Premise
257	cost-effectiveness	_	_	I-Premise
258	ratio	_	_	I-Premise
259	was	_	_	I-Premise
260	Â£19,390	_	_	I-Premise
261	per	_	_	I-Premise
262	quality-adjusted	_	_	I-Premise
263	life	_	_	I-Premise
264	year	_	_	I-Premise
265	.	_	_	I-Premise

266	This	_	_	B-Claim
267	intervention	_	_	I-Claim
268	significantly	_	_	I-Claim
269	reduced	_	_	I-Claim
270	the	_	_	I-Claim
271	unmet	_	_	I-Claim
272	needs	_	_	I-Claim
273	of	_	_	I-Claim
274	cancer	_	_	I-Claim
275	survivors	_	_	I-Claim
276	and	_	_	I-Claim
277	it	_	_	I-Claim
278	is	_	_	I-Claim
279	likely	_	_	I-Claim
280	that	_	_	I-Claim
281	it	_	_	I-Claim
282	is	_	_	I-Claim
283	cost-effective	_	_	I-Claim
284	.	_	_	I-Claim

285	Despite	_	_	B-Claim
286	small	_	_	I-Claim
287	numbers	_	_	I-Claim
288	,	_	_	I-Claim
289	the	_	_	I-Claim
290	main	_	_	I-Claim
291	effect	_	_	I-Claim
292	size	_	_	I-Claim
293	was	_	_	I-Claim
294	robust	_	_	I-Claim
295	.	_	_	I-Claim

296	We	_	_	B-Claim
297	recommend	_	_	I-Claim
298	implementation	_	_	I-Claim
299	alongside	_	_	I-Claim
300	evaluation	_	_	I-Claim
301	in	_	_	I-Claim
302	wider	_	_	I-Claim
303	clinical	_	_	I-Claim
304	settings	_	_	I-Claim
305	and	_	_	I-Claim
306	patient	_	_	I-Claim
307	populations	_	_	I-Claim
308	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	safety	_	_	O
11	of	_	_	O
12	association	_	_	O
13	of	_	_	O
14	duloxetine	_	_	O
15	and	_	_	O
16	rehabilitation	_	_	O
17	compared	_	_	O
18	with	_	_	O
19	rehabilitation	_	_	O
20	alone	_	_	O
21	in	_	_	O
22	men	_	_	O
23	with	_	_	O
24	SUI	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	retropubic	_	_	O
28	prostatectomy	_	_	O
29	(	_	_	O
30	RRP	_	_	O
31	)	_	_	O
32	,	_	_	O
33	and	_	_	O
34	to	_	_	O
35	compare	_	_	O
36	continence	_	_	O
37	rate	_	_	O
38	even	_	_	O
39	after	_	_	O
40	planned	_	_	O
41	duloxetine	_	_	O
42	suspension	_	_	O
43	.	_	_	O

44	After	_	_	O
45	catheter	_	_	O
46	removal	_	_	O
47	,	_	_	O
48	112	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	rehabilitation	_	_	O
55	and	_	_	O
56	duloxetine	_	_	O
57	(	_	_	O
58	group	_	_	O
59	A	_	_	O
60	)	_	_	O
61	or	_	_	O
62	rehabilitation	_	_	O
63	alone	_	_	O
64	(	_	_	O
65	group	_	_	O
66	B	_	_	O
67	)	_	_	O
68	,	_	_	O
69	for	_	_	O
70	16	_	_	O
71	wk	_	_	O
72	.	_	_	O

73	postprostatectomy	_	_	O
74	SUI	_	_	O
75	with	_	_	O
76	daily	_	_	O
77	incontinent	_	_	O
78	episodes	_	_	O
79	frequency	_	_	O
80	(	_	_	O
81	IEF	_	_	O
82	)	_	_	O
83	of	_	_	O
84	four	_	_	O
85	or	_	_	O
86	greater	_	_	O
87	.	_	_	O

88	After	_	_	O
89	16	_	_	O
90	wk	_	_	O
91	both	_	_	O
92	groups	_	_	O
93	suspended	_	_	O
94	duloxetine/placebo	_	_	O
95	and	_	_	O
96	continued	_	_	O
97	rehabilitation	_	_	O
98	.	_	_	O

99	All	_	_	O
100	patients	_	_	O
101	completed	_	_	O
102	incontinence	_	_	O
103	quality	_	_	O
104	of	_	_	O
105	life	_	_	O
106	(	_	_	O
107	I-QoL	_	_	O
108	)	_	_	O
109	questionnaire	_	_	O
110	and	_	_	O
111	bladder	_	_	O
112	diary	_	_	O
113	.	_	_	O

114	Wilcoxon	_	_	O
115	test	_	_	O
116	was	_	_	O
117	used	_	_	O
118	to	_	_	O
119	analyse	_	_	O
120	changes	_	_	O
121	in	_	_	O
122	IEF	_	_	O
123	and	_	_	O
124	in	_	_	O
125	I-QoL	_	_	O
126	score	_	_	O
127	;	_	_	O
128	Fisher	_	_	O
129	exact	_	_	O
130	test	_	_	O
131	was	_	_	O
132	used	_	_	O
133	to	_	_	O
134	compare	_	_	O
135	continent	_	_	O
136	patients	_	_	O
137	between	_	_	O
138	the	_	_	O
139	groups	_	_	O
140	.	_	_	O

141	Adverse	_	_	O
142	events	_	_	O
143	for	_	_	O
144	duloxetine	_	_	O
145	was	_	_	O
146	15.2	_	_	O
147	%	_	_	O
148	.	_	_	O

149	102	_	_	O
150	men	_	_	O
151	completed	_	_	O
152	the	_	_	O
153	study	_	_	O
154	.	_	_	O

155	There	_	_	B-Premise
156	was	_	_	I-Premise
157	a	_	_	I-Premise
158	significant	_	_	I-Premise
159	decrease	_	_	I-Premise
160	in	_	_	I-Premise
161	pad	_	_	I-Premise
162	use	_	_	I-Premise
163	in	_	_	I-Premise
164	group	_	_	I-Premise
165	A	_	_	I-Premise
166	.	_	_	I-Premise

167	After	_	_	B-Premise
168	16	_	_	I-Premise
169	wk	_	_	I-Premise
170	,	_	_	I-Premise
171	39	_	_	I-Premise
172	patients	_	_	I-Premise
173	versus	_	_	I-Premise
174	27	_	_	I-Premise
175	were	_	_	I-Premise
176	dry	_	_	I-Premise
177	(	_	_	I-Premise
178	p=0.007	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	At	_	_	B-Premise
182	20	_	_	I-Premise
183	wk	_	_	I-Premise
184	,	_	_	I-Premise
185	4	_	_	I-Premise
186	wk	_	_	I-Premise
187	after	_	_	I-Premise
188	planned	_	_	I-Premise
189	interruption	_	_	I-Premise
190	of	_	_	I-Premise
191	duloxetine	_	_	I-Premise
192	,	_	_	I-Premise
193	we	_	_	I-Premise
194	observed	_	_	I-Premise
195	a	_	_	I-Premise
196	U-turn	_	_	I-Premise
197	,	_	_	I-Premise
198	23	_	_	I-Premise
199	patients	_	_	I-Premise
200	were	_	_	I-Premise
201	completely	_	_	I-Premise
202	dry	_	_	I-Premise
203	in	_	_	I-Premise
204	group	_	_	I-Premise
205	A	_	_	I-Premise
206	versus	_	_	I-Premise
207	38	_	_	I-Premise
208	in	_	_	I-Premise
209	group	_	_	I-Premise
210	B	_	_	I-Premise
211	(	_	_	I-Premise
212	p=0.008	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Whereas	_	_	B-Premise
216	,	_	_	I-Premise
217	after	_	_	I-Premise
218	24	_	_	I-Premise
219	wk	_	_	I-Premise
220	,	_	_	I-Premise
221	31	_	_	I-Premise
222	in	_	_	I-Premise
223	group	_	_	I-Premise
224	A	_	_	I-Premise
225	versus	_	_	I-Premise
226	41	_	_	I-Premise
227	in	_	_	I-Premise
228	group	_	_	I-Premise
229	B	_	_	I-Premise
230	were	_	_	I-Premise
231	dry	_	_	I-Premise
232	(	_	_	I-Premise
233	p=0.08	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	O

236	The	_	_	B-Claim
237	decrease	_	_	I-Claim
238	in	_	_	I-Claim
239	IEF	_	_	I-Claim
240	and	_	_	I-Claim
241	improvements	_	_	I-Claim
242	in	_	_	I-Claim
243	I-QoL	_	_	I-Claim
244	scores	_	_	I-Claim
245	were	_	_	I-Claim
246	significantly	_	_	I-Claim
247	greater	_	_	I-Claim
248	in	_	_	I-Claim
249	group	_	_	I-Claim
250	A	_	_	I-Claim
251	for	_	_	I-Claim
252	the	_	_	I-Claim
253	first	_	_	I-Claim
254	16	_	_	I-Claim
255	wk	_	_	I-Claim
256	.	_	_	I-Claim

257	The	_	_	B-Claim
258	data	_	_	I-Claim
259	suggest	_	_	I-Claim
260	that	_	_	I-Claim
261	combination	_	_	I-Claim
262	therapy	_	_	I-Claim
263	might	_	_	I-Claim
264	provide	_	_	I-Claim
265	another	_	_	I-Claim
266	treatment	_	_	I-Claim
267	option	_	_	I-Claim
268	for	_	_	I-Claim
269	SUI	_	_	I-Claim
270	in	_	_	I-Claim
271	men	_	_	I-Claim
272	that	_	_	I-Claim
273	might	_	_	I-Claim
274	increase	_	_	I-Claim
275	the	_	_	I-Claim
276	percentage	_	_	I-Claim
277	of	_	_	I-Claim
278	early	_	_	I-Claim
279	postsurgery	_	_	I-Claim
280	continence	_	_	I-Claim
281	.	_	_	I-Claim


0	To	_	_	O
1	pilot	_	_	O
2	an	_	_	O
3	investigation	_	_	O
4	of	_	_	O
5	individualized	_	_	O
6	homeopathy	_	_	O
7	for	_	_	O
8	symptoms	_	_	O
9	of	_	_	O
10	estrogen	_	_	O
11	withdrawal	_	_	O
12	in	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	.	_	_	O

17	Randomized	_	_	O
18	,	_	_	O
19	double-blinded	_	_	O
20	,	_	_	O
21	placebo-controlled	_	_	O
22	trial	_	_	O
23	.	_	_	O

24	Outpatient	_	_	O
25	department	_	_	O
26	of	_	_	O
27	a	_	_	O
28	National	_	_	O
29	Health	_	_	O
30	Service	_	_	O
31	(	_	_	O
32	NHS	_	_	O
33	)	_	_	O
34	homeopathic	_	_	O
35	hospital	_	_	O
36	.	_	_	O

37	Fifty-seven	_	_	O
38	(	_	_	O
39	57	_	_	O
40	)	_	_	O
41	women	_	_	O
42	met	_	_	O
43	inclusion	_	_	O
44	criteria	_	_	O
45	and	_	_	O
46	53	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	the	_	_	O
51	study	_	_	O
52	.	_	_	O

53	After	_	_	O
54	2	_	_	O
55	weeks	_	_	O
56	of	_	_	O
57	baseline	_	_	O
58	assessment	_	_	O
59	,	_	_	O
60	all	_	_	O
61	participants	_	_	O
62	received	_	_	O
63	a	_	_	O
64	consultation	_	_	O
65	plus	_	_	O
66	either	_	_	O
67	oral	_	_	O
68	homeopathic	_	_	O
69	medicine	_	_	O
70	or	_	_	O
71	placebo	_	_	O
72	,	_	_	O
73	assessed	_	_	O
74	every	_	_	O
75	4	_	_	O
76	weeks	_	_	O
77	for	_	_	O
78	16	_	_	O
79	weeks	_	_	O
80	.	_	_	O

81	The	_	_	O
82	primary	_	_	O
83	outcome	_	_	O
84	measures	_	_	O
85	were	_	_	O
86	the	_	_	O
87	activity	_	_	O
88	score	_	_	O
89	and	_	_	O
90	profile	_	_	O
91	score	_	_	O
92	of	_	_	O
93	the	_	_	O
94	Measure	_	_	O
95	Yourself	_	_	O
96	Medical	_	_	O
97	Outcome	_	_	O
98	Profile	_	_	O
99	(	_	_	O
100	MYMOP	_	_	O
101	)	_	_	O
102	.	_	_	O

103	Eighty-five	_	_	O
104	percent	_	_	O
105	(	_	_	O
106	85	_	_	O
107	%	_	_	O
108	)	_	_	O
109	(	_	_	O
110	45/53	_	_	O
111	)	_	_	O
112	of	_	_	O
113	women	_	_	O
114	completed	_	_	O
115	the	_	_	O
116	study	_	_	O
117	.	_	_	O

118	There	_	_	B-Premise
119	was	_	_	I-Premise
120	no	_	_	I-Premise
121	evidence	_	_	I-Premise
122	of	_	_	I-Premise
123	a	_	_	I-Premise
124	difference	_	_	I-Premise
125	seen	_	_	I-Premise
126	between	_	_	I-Premise
127	groups	_	_	I-Premise
128	for	_	_	I-Premise
129	either	_	_	I-Premise
130	activity	_	_	I-Premise
131	(	_	_	I-Premise
132	adjusted	_	_	I-Premise
133	difference	_	_	I-Premise
134	=-0.4	_	_	I-Premise
135	,	_	_	I-Premise
136	95	_	_	I-Premise
137	%	_	_	I-Premise
138	confidence	_	_	I-Premise
139	interval	_	_	I-Premise
140	CI	_	_	I-Premise
141	-1.0	_	_	I-Premise
142	to	_	_	I-Premise
143	0.2	_	_	I-Premise
144	,	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.17	_	_	I-Premise
148	)	_	_	I-Premise
149	or	_	_	I-Premise
150	profile	_	_	I-Premise
151	scores	_	_	I-Premise
152	(	_	_	I-Premise
153	adjusted	_	_	I-Premise
154	difference	_	_	I-Premise
155	=	_	_	I-Premise
156	-0.4	_	_	I-Premise
157	,	_	_	I-Premise
158	95	_	_	I-Premise
159	%	_	_	I-Premise
160	CI	_	_	I-Premise
161	-0.9	_	_	I-Premise
162	to	_	_	I-Premise
163	0.1	_	_	I-Premise
164	,	_	_	I-Premise
165	p	_	_	I-Premise
166	=	_	_	I-Premise
167	0.13	_	_	I-Premise
168	)	_	_	I-Premise
169	using	_	_	I-Premise
170	this	_	_	I-Premise
171	trial	_	_	I-Premise
172	design	_	_	I-Premise
173	,	_	_	I-Premise
174	although	_	_	B-Claim
175	post	_	_	I-Claim
176	hoc	_	_	I-Claim
177	power	_	_	I-Claim
178	calculations	_	_	I-Claim
179	suggests	_	_	I-Claim
180	that	_	_	I-Claim
181	65-175	_	_	I-Claim
182	would	_	_	I-Claim
183	be	_	_	I-Claim
184	needed	_	_	I-Claim
185	per	_	_	I-Claim
186	group	_	_	I-Claim
187	to	_	_	I-Claim
188	detect	_	_	I-Claim
189	differences	_	_	I-Claim
190	of	_	_	I-Claim
191	this	_	_	I-Claim
192	magnitude	_	_	I-Claim
193	with	_	_	I-Claim
194	sufficient	_	_	I-Claim
195	precision	_	_	I-Claim
196	.	_	_	I-Claim

197	Clinically	_	_	B-Premise
198	relevant	_	_	I-Premise
199	improvements	_	_	I-Premise
200	in	_	_	I-Premise
201	symptoms	_	_	I-Premise
202	and	_	_	I-Premise
203	mood	_	_	I-Premise
204	disturbance	_	_	I-Premise
205	were	_	_	I-Premise
206	seen	_	_	I-Premise
207	for	_	_	I-Premise
208	both	_	_	I-Premise
209	groups	_	_	I-Premise
210	over	_	_	I-Premise
211	the	_	_	I-Premise
212	study	_	_	I-Premise
213	period	_	_	I-Premise
214	.	_	_	I-Premise

215	Improvements	_	_	B-Claim
216	were	_	_	I-Claim
217	seen	_	_	I-Claim
218	for	_	_	I-Claim
219	symptom	_	_	I-Claim
220	scores	_	_	I-Claim
221	over	_	_	I-Claim
222	the	_	_	I-Claim
223	study	_	_	I-Claim
224	period	_	_	I-Claim
225	.	_	_	I-Claim

226	However	_	_	B-Claim
227	,	_	_	I-Claim
228	presuming	_	_	I-Claim
229	these	_	_	I-Claim
230	improvements	_	_	I-Claim
231	were	_	_	I-Claim
232	caused	_	_	I-Claim
233	by	_	_	I-Claim
234	the	_	_	I-Claim
235	individualized	_	_	I-Claim
236	homeopathic	_	_	I-Claim
237	approach	_	_	I-Claim
238	,	_	_	I-Claim
239	the	_	_	I-Claim
240	study	_	_	I-Claim
241	failed	_	_	I-Claim
242	to	_	_	I-Claim
243	show	_	_	I-Claim
244	clearly	_	_	I-Claim
245	that	_	_	I-Claim
246	the	_	_	I-Claim
247	specific	_	_	I-Claim
248	effect	_	_	I-Claim
249	of	_	_	I-Claim
250	the	_	_	I-Claim
251	remedy	_	_	I-Claim
252	added	_	_	I-Claim
253	further	_	_	I-Claim
254	to	_	_	I-Claim
255	the	_	_	I-Claim
256	nonspecific	_	_	I-Claim
257	effects	_	_	I-Claim
258	of	_	_	I-Claim
259	the	_	_	I-Claim
260	consultation	_	_	I-Claim
261	.	_	_	I-Claim

262	Future	_	_	B-Claim
263	trial	_	_	I-Claim
264	design	_	_	I-Claim
265	must	_	_	I-Claim
266	ensure	_	_	I-Claim
267	adequate	_	_	I-Claim
268	power	_	_	I-Claim
269	to	_	_	I-Claim
270	account	_	_	I-Claim
271	for	_	_	I-Claim
272	the	_	_	I-Claim
273	nonspecific	_	_	I-Claim
274	impact	_	_	I-Claim
275	of	_	_	I-Claim
276	such	_	_	I-Claim
277	complex	_	_	I-Claim
278	individualized	_	_	I-Claim
279	interventions	_	_	I-Claim
280	while	_	_	I-Claim
281	pragmatic	_	_	I-Claim
282	designs	_	_	I-Claim
283	may	_	_	I-Claim
284	more	_	_	I-Claim
285	readily	_	_	I-Claim
286	answer	_	_	I-Claim
287	questions	_	_	I-Claim
288	of	_	_	I-Claim
289	clinical	_	_	I-Claim
290	and	_	_	I-Claim
291	cost	_	_	I-Claim
292	effectiveness	_	_	I-Claim
293	.	_	_	O


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	Cancer	_	_	O
6	and	_	_	O
7	Leukemia	_	_	O
8	Group	_	_	O
9	B	_	_	O
10	CALGB-49907	_	_	O
11	)	_	_	O
12	was	_	_	O
13	conducted	_	_	O
14	to	_	_	O
15	test	_	_	O
16	whether	_	_	O
17	older	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	early-stage	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	would	_	_	O
24	have	_	_	O
25	equivalent	_	_	O
26	relapse-free	_	_	O
27	and	_	_	O
28	overall	_	_	O
29	survival	_	_	O
30	with	_	_	O
31	capecitabine	_	_	O
32	compared	_	_	O
33	with	_	_	O
34	standard	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	The	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QoL	_	_	O
43	)	_	_	O
44	substudy	_	_	O
45	tested	_	_	O
46	whether	_	_	O
47	capecitabine	_	_	O
48	treatment	_	_	O
49	would	_	_	O
50	be	_	_	O
51	associated	_	_	O
52	with	_	_	O
53	a	_	_	O
54	better	_	_	O
55	QoL	_	_	O
56	than	_	_	O
57	standard	_	_	O
58	chemotherapy	_	_	O
59	.	_	_	O

60	QoL	_	_	O
61	was	_	_	O
62	assessed	_	_	O
63	in	_	_	O
64	350	_	_	O
65	patients	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	either	_	_	O
70	standard	_	_	O
71	chemotherapy	_	_	O
72	(	_	_	O
73	cyclophosphamide	_	_	O
74	,	_	_	O
75	methotrexate	_	_	O
76	,	_	_	O
77	and	_	_	O
78	fluorouracil	_	_	O
79	[	_	_	O
80	CMF	_	_	O
81	]	_	_	O
82	or	_	_	O
83	doxorubicin	_	_	O
84	and	_	_	O
85	cyclophosphamide	_	_	O
86	[	_	_	O
87	AC	_	_	O
88	]	_	_	O
89	;	_	_	O
90	n	_	_	O
91	=	_	_	O
92	182	_	_	O
93	)	_	_	O
94	or	_	_	O
95	capecitabine	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	168	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	were	_	_	O
104	interviewed	_	_	O
105	by	_	_	O
106	telephone	_	_	O
107	before	_	_	O
108	treatment	_	_	O
109	(	_	_	O
110	baseline	_	_	O
111	)	_	_	O
112	,	_	_	O
113	midtreatment	_	_	O
114	,	_	_	O
115	within	_	_	O
116	1	_	_	O
117	month	_	_	O
118	post-treatment	_	_	O
119	,	_	_	O
120	and	_	_	O
121	at	_	_	O
122	12	_	_	O
123	,	_	_	O
124	18	_	_	O
125	,	_	_	O
126	and	_	_	O
127	24	_	_	O
128	months	_	_	O
129	postbaseline	_	_	O
130	by	_	_	O
131	using	_	_	O
132	questionnaires	_	_	O
133	from	_	_	O
134	the	_	_	O
135	European	_	_	O
136	Organisation	_	_	O
137	for	_	_	O
138	Research	_	_	O
139	and	_	_	O
140	Treatment	_	_	O
141	of	_	_	O
142	Cancer	_	_	O
143	Quality	_	_	O
144	of	_	_	O
145	Life	_	_	O
146	Questionnaire	_	_	O
147	C30	_	_	O
148	(	_	_	O
149	EORTC	_	_	O
150	QLQ-C30	_	_	O
151	)	_	_	O
152	,	_	_	O
153	a	_	_	O
154	breast	_	_	O
155	systemic	_	_	O
156	adverse	_	_	O
157	effects	_	_	O
158	scale	_	_	O
159	(	_	_	O
160	EORTC	_	_	O
161	BR23	_	_	O
162	)	_	_	O
163	,	_	_	O
164	and	_	_	O
165	the	_	_	O
166	Hospital	_	_	O
167	Anxiety	_	_	O
168	and	_	_	O
169	Depression	_	_	O
170	Scale	_	_	O
171	(	_	_	O
172	HADS	_	_	O
173	)	_	_	O
174	.	_	_	O

175	Compared	_	_	B-Premise
176	with	_	_	I-Premise
177	patients	_	_	I-Premise
178	who	_	_	I-Premise
179	were	_	_	I-Premise
180	treated	_	_	I-Premise
181	with	_	_	I-Premise
182	standard	_	_	I-Premise
183	chemotherapy	_	_	I-Premise
184	,	_	_	I-Premise
185	patients	_	_	I-Premise
186	who	_	_	I-Premise
187	were	_	_	I-Premise
188	treated	_	_	I-Premise
189	with	_	_	I-Premise
190	capecitabine	_	_	I-Premise
191	had	_	_	I-Premise
192	significantly	_	_	I-Premise
193	better	_	_	I-Premise
194	QoL	_	_	I-Premise
195	,	_	_	I-Premise
196	role	_	_	I-Premise
197	function	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	social	_	_	I-Premise
201	function	_	_	I-Premise
202	,	_	_	I-Premise
203	fewer	_	_	I-Premise
204	systemic	_	_	I-Premise
205	adverse	_	_	I-Premise
206	effects	_	_	I-Premise
207	,	_	_	I-Premise
208	less	_	_	I-Premise
209	psychological	_	_	I-Premise
210	distress	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	less	_	_	I-Premise
214	fatigue	_	_	I-Premise
215	during	_	_	I-Premise
216	and	_	_	I-Premise
217	at	_	_	I-Premise
218	the	_	_	I-Premise
219	completion	_	_	I-Premise
220	of	_	_	I-Premise
221	treatment	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	â‰¤	_	_	I-Premise
225	.005	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Capecitabine	_	_	B-Premise
229	treatment	_	_	I-Premise
230	was	_	_	I-Premise
231	associated	_	_	I-Premise
232	with	_	_	I-Premise
233	less	_	_	I-Premise
234	nausea	_	_	I-Premise
235	,	_	_	I-Premise
236	vomiting	_	_	I-Premise
237	,	_	_	I-Premise
238	and	_	_	I-Premise
239	constipation	_	_	I-Premise
240	and	_	_	I-Premise
241	with	_	_	I-Premise
242	better	_	_	I-Premise
243	appetite	_	_	I-Premise
244	than	_	_	I-Premise
245	standard	_	_	I-Premise
246	treatment	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	â‰¤	_	_	I-Premise
250	.004	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	but	_	_	I-Premise
254	worse	_	_	I-Premise
255	hand-foot	_	_	I-Premise
256	syndrome	_	_	I-Premise
257	and	_	_	I-Premise
258	diarrhea	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	<	_	_	I-Premise
262	.005	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	These	_	_	O
266	differences	_	_	O
267	all	_	_	O
268	resolved	_	_	O
269	by	_	_	O
270	12	_	_	O
271	months	_	_	O
272	.	_	_	O

273	Standard	_	_	B-Claim
274	chemotherapy	_	_	I-Claim
275	was	_	_	I-Claim
276	superior	_	_	I-Claim
277	to	_	_	I-Claim
278	capecitabine	_	_	I-Claim
279	in	_	_	I-Claim
280	improving	_	_	I-Claim
281	relapse-free	_	_	I-Claim
282	and	_	_	I-Claim
283	overall	_	_	I-Claim
284	survival	_	_	I-Claim
285	for	_	_	I-Claim
286	older	_	_	I-Claim
287	women	_	_	I-Claim
288	with	_	_	I-Claim
289	early-stage	_	_	I-Claim
290	breast	_	_	I-Claim
291	cancer	_	_	I-Claim
292	.	_	_	I-Claim

293	Although	_	_	O
294	capecitabine	_	_	B-Claim
295	was	_	_	I-Claim
296	associated	_	_	I-Claim
297	with	_	_	I-Claim
298	better	_	_	I-Claim
299	QoL	_	_	I-Claim
300	during	_	_	I-Claim
301	treatment	_	_	I-Claim
302	,	_	_	O
303	QoL	_	_	B-Premise
304	was	_	_	I-Premise
305	similar	_	_	I-Premise
306	for	_	_	I-Premise
307	both	_	_	I-Premise
308	groups	_	_	I-Premise
309	at	_	_	I-Premise
310	1	_	_	I-Premise
311	year	_	_	I-Premise
312	.	_	_	I-Premise

313	The	_	_	O
314	brief	_	_	O
315	period	_	_	O
316	of	_	_	O
317	poorer	_	_	O
318	QoL	_	_	O
319	with	_	_	O
320	standard	_	_	O
321	treatment	_	_	O
322	is	_	_	O
323	a	_	_	O
324	modest	_	_	O
325	price	_	_	O
326	to	_	_	O
327	pay	_	_	O
328	for	_	_	O
329	a	_	_	O
330	chance	_	_	O
331	at	_	_	O
332	improved	_	_	O
333	survival	_	_	O
334	.	_	_	O


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	administration	_	_	O
5	of	_	_	O
6	recombinant	_	_	O
7	human	_	_	O
8	erythropoietin	_	_	O
9	(	_	_	O
10	r-HuEPO	_	_	O
11	)	_	_	O
12	would	_	_	O
13	increase	_	_	O
14	the	_	_	O
15	hematocrit	_	_	O
16	,	_	_	O
17	reduce	_	_	O
18	the	_	_	O
19	requirement	_	_	O
20	for	_	_	O
21	transfusion	_	_	O
22	,	_	_	O
23	and	_	_	O
24	improve	_	_	O
25	the	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	in	_	_	O
30	anemic	_	_	O
31	cancer	_	_	O
32	patients	_	_	O
33	receiving	_	_	O
34	myelosuppressive	_	_	O
35	,	_	_	O
36	cisplatin-based	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	One	_	_	O
40	hundred	_	_	O
41	thirty-two	_	_	O
42	anemic	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	receiving	_	_	O
46	cyclic	_	_	O
47	,	_	_	O
48	cisplatin-containing	_	_	O
49	,	_	_	O
50	myelosuppressive	_	_	O
51	chemotherapy	_	_	O
52	were	_	_	O
53	evaluated	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	received	_	_	O
57	either	_	_	O
58	r-HuEPO	_	_	O
59	(	_	_	O
60	150	_	_	O
61	U/kg	_	_	O
62	)	_	_	O
63	or	_	_	O
64	placebo	_	_	O
65	,	_	_	O
66	subcutaneously	_	_	O
67	,	_	_	O
68	three	_	_	O
69	times	_	_	O
70	a	_	_	O
71	week	_	_	O
72	for	_	_	O
73	3	_	_	O
74	months	_	_	O
75	.	_	_	O

76	Responses	_	_	O
77	were	_	_	O
78	assessed	_	_	O
79	by	_	_	O
80	measuring	_	_	O
81	changes	_	_	O
82	in	_	_	O
83	hemoglobin/hematocrit	_	_	O
84	,	_	_	O
85	transfusion	_	_	O
86	requirement	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	.	_	_	O

93	The	_	_	B-Premise
94	mean	_	_	I-Premise
95	hematocrit	_	_	I-Premise
96	increased	_	_	I-Premise
97	by	_	_	I-Premise
98	6.0	_	_	I-Premise
99	percentage	_	_	I-Premise
100	points	_	_	I-Premise
101	in	_	_	I-Premise
102	the	_	_	I-Premise
103	r-HuEPO	_	_	I-Premise
104	group	_	_	I-Premise
105	versus	_	_	I-Premise
106	1.3	_	_	I-Premise
107	in	_	_	I-Premise
108	the	_	_	I-Premise
109	placebo	_	_	I-Premise
110	group	_	_	I-Premise
111	.	_	_	I-Premise

112	A	_	_	B-Premise
113	decrease	_	_	I-Premise
114	in	_	_	I-Premise
115	transfusion	_	_	I-Premise
116	requirement	_	_	I-Premise
117	did	_	_	I-Premise
118	not	_	_	I-Premise
119	reach	_	_	I-Premise
120	significance	_	_	I-Premise
121	over	_	_	I-Premise
122	all	_	_	I-Premise
123	3	_	_	I-Premise
124	months	_	_	I-Premise
125	,	_	_	I-Premise
126	but	_	_	I-Premise
127	there	_	_	I-Premise
128	was	_	_	I-Premise
129	a	_	_	I-Premise
130	significant	_	_	I-Premise
131	reduction	_	_	I-Premise
132	in	_	_	I-Premise
133	the	_	_	I-Premise
134	percentage	_	_	I-Premise
135	of	_	_	I-Premise
136	patients	_	_	I-Premise
137	transfused	_	_	I-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	second	_	_	I-Premise
141	and	_	_	I-Premise
142	third	_	_	I-Premise
143	months	_	_	I-Premise
144	(	_	_	I-Premise
145	27	_	_	I-Premise
146	%	_	_	I-Premise
147	r-HuEPO	_	_	I-Premise
148	vs.	_	_	I-Premise
149	56	_	_	I-Premise
150	%	_	_	I-Premise
151	placebo	_	_	I-Premise
152	)	_	_	I-Premise
153	and	_	_	I-Premise
154	a	_	_	I-Premise
155	trend	_	_	I-Premise
156	toward	_	_	I-Premise
157	reduction	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	mean	_	_	I-Premise
161	total	_	_	I-Premise
162	number	_	_	I-Premise
163	of	_	_	I-Premise
164	units	_	_	I-Premise
165	transfused	_	_	I-Premise
166	(	_	_	I-Premise
167	1.20	_	_	I-Premise
168	units	_	_	I-Premise
169	r-HuEPO	_	_	I-Premise
170	vs.	_	_	I-Premise
171	2.02	_	_	I-Premise
172	units	_	_	I-Premise
173	placebo	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	suggesting	_	_	I-Premise
177	a	_	_	I-Premise
178	lag	_	_	I-Premise
179	of	_	_	I-Premise
180	1	_	_	I-Premise
181	month	_	_	I-Premise
182	before	_	_	I-Premise
183	r-HuEPO	_	_	I-Premise
184	can	_	_	I-Premise
185	affect	_	_	I-Premise
186	the	_	_	I-Premise
187	transfusion	_	_	I-Premise
188	requirement	_	_	I-Premise
189	.	_	_	I-Premise

190	Pretreatment	_	_	B-Premise
191	serum	_	_	I-Premise
192	erythropoietin	_	_	I-Premise
193	levels	_	_	I-Premise
194	were	_	_	I-Premise
195	lower	_	_	I-Premise
196	in	_	_	I-Premise
197	responders	_	_	I-Premise
198	than	_	_	I-Premise
199	in	_	_	I-Premise
200	nonresponders	_	_	I-Premise
201	(	_	_	I-Premise
202	73.5	_	_	I-Premise
203	IU/L	_	_	I-Premise
204	and	_	_	I-Premise
205	86.3	_	_	I-Premise
206	IU/L	_	_	I-Premise
207	means	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	However	_	_	B-Premise
213	,	_	_	I-Premise
214	the	_	_	I-Premise
215	magnitude	_	_	I-Premise
216	of	_	_	I-Premise
217	this	_	_	I-Premise
218	difference	_	_	I-Premise
219	was	_	_	I-Premise
220	not	_	_	I-Premise
221	helpful	_	_	I-Premise
222	in	_	_	I-Premise
223	defining	_	_	I-Premise
224	which	_	_	I-Premise
225	patients	_	_	I-Premise
226	were	_	_	I-Premise
227	likely	_	_	I-Premise
228	to	_	_	I-Premise
229	respond	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	significant	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	overall	_	_	I-Premise
238	quality	_	_	I-Premise
239	of	_	_	I-Premise
240	life	_	_	I-Premise
241	between	_	_	I-Premise
242	the	_	_	I-Premise
243	two	_	_	I-Premise
244	treatment	_	_	I-Premise
245	arms	_	_	I-Premise
246	in	_	_	I-Premise
247	favor	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	r-HuEPO-treated	_	_	I-Premise
251	group	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Premise
254	were	_	_	I-Premise
255	no	_	_	I-Premise
256	significant	_	_	I-Premise
257	adverse	_	_	I-Premise
258	effects	_	_	I-Premise
259	associated	_	_	I-Premise
260	with	_	_	I-Premise
261	r-HuEPO	_	_	I-Premise
262	.	_	_	I-Premise

263	r-HuEPO	_	_	B-Claim
264	is	_	_	I-Claim
265	safe	_	_	I-Claim
266	and	_	_	I-Claim
267	can	_	_	I-Claim
268	cause	_	_	I-Claim
269	a	_	_	I-Claim
270	significant	_	_	I-Claim
271	improvement	_	_	I-Claim
272	in	_	_	I-Claim
273	the	_	_	I-Claim
274	hematocrit	_	_	I-Claim
275	and	_	_	I-Claim
276	quality	_	_	I-Claim
277	of	_	_	I-Claim
278	life	_	_	I-Claim
279	of	_	_	I-Claim
280	anemic	_	_	I-Claim
281	cancer	_	_	I-Claim
282	patients	_	_	I-Claim
283	receiving	_	_	I-Claim
284	myelosuppressive	_	_	I-Claim
285	,	_	_	I-Claim
286	cisplatin-based	_	_	I-Claim
287	chemotherapy	_	_	I-Claim
288	.	_	_	I-Claim

289	After	_	_	B-Claim
290	1	_	_	I-Claim
291	month	_	_	I-Claim
292	of	_	_	I-Claim
293	r-HuEPO	_	_	I-Claim
294	,	_	_	I-Claim
295	there	_	_	I-Claim
296	is	_	_	I-Claim
297	also	_	_	I-Claim
298	a	_	_	I-Claim
299	reduction	_	_	I-Claim
300	in	_	_	I-Claim
301	transfusion	_	_	I-Claim
302	requirement	_	_	I-Claim
303	.	_	_	I-Claim


0	Older	_	_	O
1	breast	_	_	O
2	cancer	_	_	O
3	survivors	_	_	O
4	(	_	_	O
5	BCSs	_	_	O
6	)	_	_	O
7	are	_	_	O
8	at	_	_	O
9	risk	_	_	O
10	for	_	_	O
11	late	_	_	O
12	and	_	_	O
13	long-term	_	_	O
14	treatment	_	_	O
15	effects	_	_	O
16	on	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	(	_	_	O
21	QOL	_	_	O
22	)	_	_	O
23	,	_	_	O
24	including	_	_	O
25	lower	_	_	O
26	physical	_	_	O
27	functioning	_	_	O
28	and	_	_	O
29	fear	_	_	O
30	of	_	_	O
31	recurrence	_	_	O
32	.	_	_	O

33	Two	_	_	O
34	promising	_	_	O
35	approaches	_	_	O
36	to	_	_	O
37	address	_	_	O
38	this	_	_	O
39	include	_	_	O
40	dance/movement	_	_	O
41	therapy	_	_	O
42	and	_	_	O
43	mindfulness	_	_	O
44	.	_	_	O

45	The	_	_	O
46	purpose	_	_	O
47	of	_	_	O
48	this	_	_	O
49	2-group	_	_	O
50	randomized	_	_	O
51	controlled	_	_	O
52	pilot	_	_	O
53	feasibility	_	_	O
54	study	_	_	O
55	was	_	_	O
56	to	_	_	O
57	test	_	_	O
58	short-term	_	_	O
59	effects	_	_	O
60	of	_	_	O
61	a	_	_	O
62	12-week	_	_	O
63	Mindful	_	_	O
64	Movement	_	_	O
65	Program	_	_	O
66	(	_	_	O
67	MMP	_	_	O
68	)	_	_	O
69	intervention	_	_	O
70	combining	_	_	O
71	mindfulness	_	_	O
72	with	_	_	O
73	self-directed	_	_	O
74	movement	_	_	O
75	on	_	_	O
76	QOL	_	_	O
77	and	_	_	O
78	mindfulness	_	_	O
79	in	_	_	O
80	female	_	_	O
81	BCSs	_	_	O
82	50	_	_	O
83	years	_	_	O
84	or	_	_	O
85	older	_	_	O
86	and	_	_	O
87	at	_	_	O
88	12	_	_	O
89	months	_	_	O
90	or	_	_	O
91	more	_	_	O
92	following	_	_	O
93	treatment	_	_	O
94	.	_	_	O

95	Consented	_	_	O
96	participants	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	an	_	_	O
101	experimental	_	_	O
102	group	_	_	O
103	(	_	_	O
104	EG	_	_	O
105	)	_	_	O
106	(	_	_	O
107	12	_	_	O
108	weekly	_	_	O
109	MMP	_	_	O
110	sessions	_	_	O
111	)	_	_	O
112	or	_	_	O
113	a	_	_	O
114	control	_	_	O
115	group	_	_	O
116	(	_	_	O
117	no	_	_	O
118	sessions	_	_	O
119	)	_	_	O
120	.	_	_	O

121	All	_	_	O
122	completed	_	_	O
123	questionnaires	_	_	O
124	3	_	_	O
125	times	_	_	O
126	.	_	_	O

127	The	_	_	O
128	EG	_	_	O
129	participants	_	_	O
130	kept	_	_	O
131	home	_	_	O
132	practice	_	_	O
133	diaries	_	_	O
134	.	_	_	O

135	Analysis	_	_	O
136	was	_	_	O
137	conducted	_	_	O
138	after	_	_	O
139	intervention	_	_	O
140	for	_	_	O
141	immediate	_	_	O
142	effects	_	_	O
143	on	_	_	O
144	outcome	_	_	O
145	variables	_	_	O
146	and	_	_	O
147	6	_	_	O
148	weeks	_	_	O
149	later	_	_	O
150	for	_	_	O
151	maintenance	_	_	O
152	of	_	_	O
153	effects	_	_	O
154	.	_	_	O

155	Participants	_	_	O
156	(	_	_	O
157	n	_	_	O
158	=	_	_	O
159	49	_	_	O
160	)	_	_	O
161	ranged	_	_	O
162	in	_	_	O
163	age	_	_	O
164	from	_	_	O
165	50	_	_	O
166	to	_	_	O
167	90	_	_	O
168	years	_	_	O
169	(	_	_	O
170	average	_	_	O
171	,	_	_	O
172	65.6	_	_	O
173	years	_	_	O
174	)	_	_	O
175	and	_	_	O
176	were	_	_	O
177	at	_	_	O
178	9.8	_	_	O
179	years	_	_	O
180	since	_	_	O
181	diagnosis	_	_	O
182	(	_	_	O
183	range	_	_	O
184	,	_	_	O
185	1-32	_	_	O
186	years	_	_	O
187	)	_	_	O
188	,	_	_	O
189	and	_	_	O
190	the	_	_	O
191	majority	_	_	O
192	were	_	_	O
193	white	_	_	O
194	,	_	_	O
195	unpartnered	_	_	O
196	,	_	_	O
197	and	_	_	O
198	retired	_	_	O
199	.	_	_	O

200	After	_	_	B-Premise
201	intervention	_	_	I-Premise
202	,	_	_	I-Premise
203	EG	_	_	I-Premise
204	participants	_	_	I-Premise
205	showed	_	_	I-Premise
206	improved	_	_	I-Premise
207	QOL	_	_	I-Premise
208	via	_	_	I-Premise
209	decreased	_	_	I-Premise
210	fear	_	_	I-Premise
211	of	_	_	I-Premise
212	recurrence	_	_	I-Premise
213	and	_	_	I-Premise
214	increased	_	_	I-Premise
215	mindfulness	_	_	I-Premise
216	attitude	_	_	I-Premise
217	.	_	_	I-Premise

218	At	_	_	B-Premise
219	6	_	_	I-Premise
220	weeks	_	_	I-Premise
221	,	_	_	I-Premise
222	initial	_	_	I-Premise
223	effects	_	_	I-Premise
224	were	_	_	I-Premise
225	retained	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	MMP	_	_	I-Premise
229	appears	_	_	I-Premise
230	to	_	_	I-Premise
231	benefit	_	_	I-Premise
232	older	_	_	I-Premise
233	BCSs	_	_	I-Premise
234	by	_	_	I-Premise
235	reducing	_	_	I-Premise
236	fear	_	_	I-Premise
237	of	_	_	I-Premise
238	recurrence	_	_	I-Premise
239	and	_	_	I-Premise
240	improving	_	_	I-Premise
241	mindfulness	_	_	I-Premise
242	attitude	_	_	I-Premise
243	.	_	_	I-Premise

244	Although	_	_	B-Claim
245	these	_	_	I-Claim
246	findings	_	_	I-Claim
247	are	_	_	I-Claim
248	promising	_	_	I-Claim
249	,	_	_	I-Claim
250	a	_	_	I-Claim
251	larger	_	_	I-Claim
252	study	_	_	I-Claim
253	is	_	_	I-Claim
254	needed	_	_	I-Claim
255	to	_	_	I-Claim
256	determine	_	_	I-Claim
257	more	_	_	I-Claim
258	specifically	_	_	I-Claim
259	what	_	_	I-Claim
260	short-	_	_	I-Claim
261	and	_	_	I-Claim
262	long-term	_	_	I-Claim
263	effects	_	_	I-Claim
264	are	_	_	I-Claim
265	possible	_	_	I-Claim
266	.	_	_	I-Claim

267	The	_	_	B-Claim
268	combination	_	_	I-Claim
269	of	_	_	I-Claim
270	self-directed	_	_	I-Claim
271	movement	_	_	I-Claim
272	and	_	_	I-Claim
273	mindfulness	_	_	I-Claim
274	,	_	_	I-Claim
275	as	_	_	I-Claim
276	tested	_	_	I-Claim
277	here	_	_	I-Claim
278	,	_	_	I-Claim
279	may	_	_	I-Claim
280	be	_	_	I-Claim
281	a	_	_	I-Claim
282	valuable	_	_	I-Claim
283	tool	_	_	I-Claim
284	for	_	_	I-Claim
285	promoting	_	_	I-Claim
286	health	_	_	I-Claim
287	and	_	_	I-Claim
288	well-being	_	_	I-Claim
289	in	_	_	I-Claim
290	older	_	_	I-Claim
291	long-term	_	_	I-Claim
292	survivors	_	_	I-Claim
293	of	_	_	I-Claim
294	breast	_	_	I-Claim
295	cancer	_	_	I-Claim
296	.	_	_	I-Claim


0	N	_	_	O
1	,	_	_	O
2	N-diethyl-2-	_	_	O
3	[	_	_	O
4	4-	_	_	O
5	(	_	_	O
6	phenylmethyl	_	_	O
7	)	_	_	O
8	phenoxy	_	_	O
9	]	_	_	O
10	ethanamine	_	_	O
11	(	_	_	O
12	DPPE	_	_	O
13	;	_	_	O
14	tesmilifene	_	_	O
15	)	_	_	O
16	is	_	_	O
17	a	_	_	O
18	novel	_	_	O
19	agent	_	_	O
20	that	_	_	O
21	augments	_	_	O
22	chemotherapy	_	_	O
23	cytotoxicity	_	_	O
24	in	_	_	O
25	vitro	_	_	O
26	and	_	_	O
27	in	_	_	O
28	vivo	_	_	O
29	.	_	_	O

30	A	_	_	O
31	phase	_	_	O
32	II	_	_	O
33	trial	_	_	O
34	combining	_	_	O
35	DPPE	_	_	O
36	and	_	_	O
37	doxorubicin	_	_	O
38	(	_	_	O
39	DOX	_	_	O
40	)	_	_	O
41	in	_	_	O
42	metastatic	_	_	O
43	breast	_	_	O
44	carcinoma	_	_	O
45	showed	_	_	O
46	increased	_	_	O
47	response	_	_	O
48	over	_	_	O
49	that	_	_	O
50	expected	_	_	O
51	with	_	_	O
52	DOX	_	_	O
53	.	_	_	O

54	We	_	_	O
55	report	_	_	O
56	a	_	_	O
57	phase	_	_	O
58	III	_	_	O
59	trial	_	_	O
60	comparing	_	_	O
61	DOX	_	_	O
62	with	_	_	O
63	DPPE	_	_	O
64	plus	_	_	O
65	DOX	_	_	O
66	in	_	_	O
67	metastatic	_	_	O
68	or	_	_	O
69	recurrent	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	.	_	_	O

73	Anthracycline-naive	_	_	O
74	women	_	_	O
75	with	_	_	O
76	measurable	_	_	O
77	metastatic	_	_	O
78	disease	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	,	_	_	O
85	every	_	_	O
86	21	_	_	O
87	days	_	_	O
88	,	_	_	O
89	either	_	_	O
90	DOX	_	_	O
91	60	_	_	O
92	mg/m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	intravenously	_	_	O
97	or	_	_	O
98	DOX	_	_	O
99	during	_	_	O
100	the	_	_	O
101	last	_	_	O
102	20	_	_	O
103	minutes	_	_	O
104	of	_	_	O
105	an	_	_	O
106	80-minute	_	_	O
107	infusion	_	_	O
108	of	_	_	O
109	DPPE	_	_	O
110	(	_	_	O
111	5.3	_	_	O
112	mg/kg	_	_	O
113	)	_	_	O
114	,	_	_	O
115	in	_	_	O
116	both	_	_	O
117	cases	_	_	O
118	to	_	_	O
119	cumulative	_	_	O
120	DOX	_	_	O
121	doses	_	_	O
122	of	_	_	O
123	450	_	_	O
124	mg/m	_	_	O
125	(	_	_	O
126	2	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	receiving	_	_	O
131	DPPE	_	_	O
132	were	_	_	O
133	aggressively	_	_	O
134	premedicated	_	_	O
135	to	_	_	O
136	ameliorate	_	_	O
137	toxicity	_	_	O
138	.	_	_	O

139	End	_	_	O
140	points	_	_	O
141	included	_	_	O
142	progression-free	_	_	O
143	survival	_	_	O
144	(	_	_	O
145	PFS	_	_	O
146	)	_	_	O
147	,	_	_	O
148	response	_	_	O
149	rate	_	_	O
150	(	_	_	O
151	RR	_	_	O
152	)	_	_	O
153	,	_	_	O
154	and	_	_	O
155	response	_	_	O
156	duration	_	_	O
157	(	_	_	O
158	RD	_	_	O
159	)	_	_	O
160	,	_	_	O
161	quality	_	_	O
162	of	_	_	O
163	life	_	_	O
164	(	_	_	O
165	QOL	_	_	O
166	)	_	_	O
167	,	_	_	O
168	toxicity	_	_	O
169	,	_	_	O
170	and	_	_	O
171	overall	_	_	O
172	survival	_	_	O
173	(	_	_	O
174	OS	_	_	O
175	)	_	_	O
176	.	_	_	O

177	A	_	_	O
178	planned	_	_	O
179	interim	_	_	O
180	analysis	_	_	O
181	failed	_	_	O
182	to	_	_	O
183	detect	_	_	O
184	an	_	_	O
185	RR	_	_	O
186	difference	_	_	O
187	more	_	_	O
188	than	_	_	O
189	5	_	_	O
190	%	_	_	O
191	.	_	_	O

192	The	_	_	O
193	study	_	_	O
194	was	_	_	O
195	closed	_	_	O
196	to	_	_	O
197	additional	_	_	O
198	accrual	_	_	O
199	and	_	_	O
200	all	_	_	O
201	DPPE	_	_	O
202	was	_	_	O
203	discontinued	_	_	O
204	.	_	_	O

205	The	_	_	O
206	final	_	_	O
207	analysis	_	_	O
208	was	_	_	O
209	conducted	_	_	O
210	as	_	_	O
211	planned	_	_	O
212	after	_	_	O
213	256	_	_	O
214	progression	_	_	O
215	events	_	_	O
216	(	_	_	O
217	median	_	_	O
218	follow-up	_	_	O
219	,	_	_	O
220	20.5	_	_	O
221	months	_	_	O
222	)	_	_	O
223	.	_	_	O

224	There	_	_	B-Premise
225	was	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	in	_	_	I-Premise
230	RR	_	_	I-Premise
231	,	_	_	I-Premise
232	RD	_	_	I-Premise
233	,	_	_	I-Premise
234	or	_	_	I-Premise
235	PFS	_	_	I-Premise
236	between	_	_	I-Premise
237	arms	_	_	I-Premise
238	.	_	_	I-Premise

239	DPPE	_	_	B-Premise
240	plus	_	_	I-Premise
241	DOX	_	_	I-Premise
242	was	_	_	I-Premise
243	statistically	_	_	I-Premise
244	superior	_	_	I-Premise
245	to	_	_	I-Premise
246	DOX	_	_	I-Premise
247	in	_	_	I-Premise
248	OS	_	_	I-Premise
249	(	_	_	I-Premise
250	hazard	_	_	I-Premise
251	ratio	_	_	I-Premise
252	,	_	_	I-Premise
253	0.66	_	_	I-Premise
254	;	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	,	_	_	I-Premise
259	0.48	_	_	I-Premise
260	to	_	_	I-Premise
261	0.91	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.021	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	DPPE	_	_	B-Premise
268	plus	_	_	I-Premise
269	DOX	_	_	I-Premise
270	was	_	_	I-Premise
271	associated	_	_	I-Premise
272	with	_	_	I-Premise
273	more	_	_	I-Premise
274	gastrointestinal	_	_	I-Premise
275	and	_	_	I-Premise
276	CNS	_	_	I-Premise
277	toxicity	_	_	I-Premise
278	.	_	_	I-Premise

279	No	_	_	B-Premise
280	consistent	_	_	I-Premise
281	influence	_	_	I-Premise
282	on	_	_	I-Premise
283	QOL	_	_	I-Premise
284	was	_	_	I-Premise
285	detected	_	_	I-Premise
286	.	_	_	I-Premise

287	This	_	_	B-Claim
288	study	_	_	I-Claim
289	demonstrated	_	_	I-Claim
290	no	_	_	I-Claim
291	advantage	_	_	I-Claim
292	in	_	_	I-Claim
293	RR	_	_	I-Claim
294	,	_	_	I-Claim
295	RD	_	_	I-Claim
296	,	_	_	I-Claim
297	or	_	_	I-Claim
298	PFS	_	_	I-Claim
299	but	_	_	I-Claim
300	significantly	_	_	I-Claim
301	superior	_	_	I-Claim
302	OS	_	_	I-Claim
303	for	_	_	I-Claim
304	DPPE	_	_	I-Claim
305	plus	_	_	I-Claim
306	DOX	_	_	I-Claim
307	.	_	_	I-Claim

308	Additional	_	_	B-Claim
309	studies	_	_	I-Claim
310	of	_	_	I-Claim
311	DPPE	_	_	I-Claim
312	are	_	_	I-Claim
313	warranted	_	_	I-Claim
314	.	_	_	I-Claim


0	Experimental	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	clinical	_	_	I-Claim
4	investigations	_	_	I-Claim
5	have	_	_	I-Claim
6	demonstrated	_	_	I-Claim
7	encouraging	_	_	I-Claim
8	results	_	_	I-Claim
9	for	_	_	I-Claim
10	estramustine	_	_	I-Claim
11	in	_	_	I-Claim
12	the	_	_	I-Claim
13	treatment	_	_	I-Claim
14	of	_	_	I-Claim
15	malignant	_	_	I-Claim
16	glioma	_	_	I-Claim
17	.	_	_	O

18	The	_	_	O
19	present	_	_	O
20	study	_	_	O
21	is	_	_	O
22	an	_	_	O
23	open	_	_	O
24	randomized	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	comparing	_	_	O
28	estramustine	_	_	O
29	phosphate	_	_	O
30	(	_	_	O
31	Estracyt	_	_	O
32	)	_	_	O
33	in	_	_	O
34	addition	_	_	O
35	to	_	_	O
36	radiotherapy	_	_	O
37	with	_	_	O
38	radiotherapy	_	_	O
39	alone	_	_	O
40	as	_	_	O
41	first	_	_	O
42	line	_	_	O
43	treatment	_	_	O
44	of	_	_	O
45	astrocytoma	_	_	O
46	grade	_	_	O
47	III	_	_	O
48	and	_	_	O
49	IV	_	_	O
50	.	_	_	O

51	The	_	_	O
52	140	_	_	O
53	patients	_	_	O
54	included	_	_	O
55	were	_	_	O
56	in	_	_	O
57	a	_	_	O
58	good	_	_	O
59	clinical	_	_	O
60	condition	_	_	O
61	with	_	_	O
62	a	_	_	O
63	median	_	_	O
64	age	_	_	O
65	of	_	_	O
66	55	_	_	O
67	years	_	_	O
68	(	_	_	O
69	range	_	_	O
70	22-87	_	_	O
71	)	_	_	O
72	.	_	_	O

73	Estramustine	_	_	O
74	was	_	_	O
75	given	_	_	O
76	orally	_	_	O
77	,	_	_	O
78	280	_	_	O
79	mg	_	_	O
80	twice	_	_	O
81	daily	_	_	O
82	,	_	_	O
83	as	_	_	O
84	soon	_	_	O
85	as	_	_	O
86	the	_	_	O
87	diagnosis	_	_	O
88	was	_	_	O
89	established	_	_	O
90	,	_	_	O
91	during	_	_	O
92	and	_	_	O
93	after	_	_	O
94	the	_	_	O
95	radiotherapy	_	_	O
96	for	_	_	O
97	a	_	_	O
98	period	_	_	O
99	of	_	_	O
100	in	_	_	O
101	total	_	_	O
102	3	_	_	O
103	months	_	_	O
104	.	_	_	O

105	Radiotherapy	_	_	O
106	was	_	_	O
107	delivered	_	_	O
108	on	_	_	O
109	weekdays	_	_	O
110	2	_	_	O
111	Gy	_	_	O
112	daily	_	_	O
113	up	_	_	O
114	to	_	_	O
115	56	_	_	O
116	Gy	_	_	O
117	.	_	_	O

118	Eighteen	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	excluded	_	_	O
122	due	_	_	O
123	to	_	_	O
124	misclassification	_	_	O
125	,	_	_	O
126	leaving	_	_	O
127	122	_	_	O
128	patients	_	_	O
129	eligible	_	_	O
130	for	_	_	O
131	evaluation	_	_	O
132	.	_	_	O

133	Overall	_	_	B-Premise
134	the	_	_	I-Premise
135	treatment	_	_	I-Premise
136	was	_	_	I-Premise
137	well	_	_	I-Premise
138	tolerated	_	_	I-Premise
139	.	_	_	O

140	Mild	_	_	B-Premise
141	or	_	_	I-Premise
142	moderate	_	_	I-Premise
143	nausea	_	_	I-Premise
144	was	_	_	I-Premise
145	the	_	_	I-Premise
146	most	_	_	I-Premise
147	common	_	_	I-Premise
148	side	_	_	I-Premise
149	effect	_	_	I-Premise
150	of	_	_	I-Premise
151	estramustine	_	_	I-Premise
152	.	_	_	I-Premise

153	The	_	_	O
154	minimum	_	_	O
155	follow-up	_	_	O
156	time	_	_	O
157	was	_	_	O
158	5.2	_	_	O
159	years	_	_	O
160	for	_	_	O
161	the	_	_	O
162	surviving	_	_	O
163	patients	_	_	O
164	.	_	_	O

165	For	_	_	B-Premise
166	astrocytoma	_	_	I-Premise
167	grade	_	_	I-Premise
168	III	_	_	I-Premise
169	the	_	_	I-Premise
170	median	_	_	I-Premise
171	survival	_	_	I-Premise
172	time	_	_	I-Premise
173	was	_	_	I-Premise
174	10.6	_	_	I-Premise
175	(	_	_	I-Premise
176	1.3-92.7	_	_	I-Premise
177	)	_	_	I-Premise
178	months	_	_	I-Premise
179	for	_	_	I-Premise
180	the	_	_	I-Premise
181	radiotherapy	_	_	I-Premise
182	only	_	_	I-Premise
183	group	_	_	I-Premise
184	and	_	_	I-Premise
185	17.3	_	_	I-Premise
186	(	_	_	I-Premise
187	0.4-96.9+	_	_	I-Premise
188	)	_	_	I-Premise
189	months	_	_	I-Premise
190	for	_	_	I-Premise
191	the	_	_	I-Premise
192	estramustine	_	_	I-Premise
193	+	_	_	I-Premise
194	radiotherapy	_	_	I-Premise
195	group	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	B-Premise
198	grade	_	_	I-Premise
199	IV	_	_	I-Premise
200	the	_	_	I-Premise
201	corresponding	_	_	I-Premise
202	median	_	_	I-Premise
203	survival	_	_	I-Premise
204	time	_	_	I-Premise
205	was	_	_	I-Premise
206	12.3	_	_	I-Premise
207	(	_	_	I-Premise
208	2.1-89.2	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	10.3	_	_	I-Premise
212	(	_	_	I-Premise
213	0.3-91.7+	_	_	I-Premise
214	)	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	.	_	_	I-Premise

219	Median	_	_	B-Premise
220	time	_	_	I-Premise
221	to	_	_	I-Premise
222	progress	_	_	I-Premise
223	for	_	_	I-Premise
224	radiotherapy	_	_	I-Premise
225	only	_	_	I-Premise
226	and	_	_	I-Premise
227	radiotherapy	_	_	I-Premise
228	and	_	_	I-Premise
229	estramustin	_	_	I-Premise
230	group	_	_	I-Premise
231	in	_	_	I-Premise
232	grade	_	_	I-Premise
233	III	_	_	I-Premise
234	tumours	_	_	I-Premise
235	was	_	_	I-Premise
236	6.5	_	_	I-Premise
237	and	_	_	I-Premise
238	10.1	_	_	I-Premise
239	months	_	_	I-Premise
240	,	_	_	I-Premise
241	respectively	_	_	I-Premise
242	.	_	_	I-Premise

243	In	_	_	B-Premise
244	grade	_	_	I-Premise
245	IV	_	_	I-Premise
246	tumours	_	_	I-Premise
247	the	_	_	I-Premise
248	corresponding	_	_	I-Premise
249	figures	_	_	I-Premise
250	were	_	_	I-Premise
251	5.1	_	_	I-Premise
252	and	_	_	I-Premise
253	3.3	_	_	I-Premise
254	months	_	_	I-Premise
255	,	_	_	I-Premise
256	respectively	_	_	I-Premise
257	.	_	_	I-Premise

258	Although	_	_	B-Premise
259	there	_	_	I-Premise
260	was	_	_	I-Premise
261	a	_	_	I-Premise
262	tendency	_	_	I-Premise
263	for	_	_	I-Premise
264	improved	_	_	I-Premise
265	survival	_	_	I-Premise
266	in	_	_	I-Premise
267	grade	_	_	I-Premise
268	III	_	_	I-Premise
269	,	_	_	I-Premise
270	no	_	_	I-Premise
271	statistical	_	_	I-Premise
272	significant	_	_	I-Premise
273	differences	_	_	I-Premise
274	were	_	_	I-Premise
275	found	_	_	I-Premise
276	between	_	_	I-Premise
277	the	_	_	I-Premise
278	treatment	_	_	I-Premise
279	groups	_	_	I-Premise
280	.	_	_	I-Premise

281	No	_	_	B-Premise
282	differences	_	_	I-Premise
283	between	_	_	I-Premise
284	the	_	_	I-Premise
285	two	_	_	I-Premise
286	treatment	_	_	I-Premise
287	groups	_	_	I-Premise
288	were	_	_	I-Premise
289	evident	_	_	I-Premise
290	with	_	_	I-Premise
291	respect	_	_	I-Premise
292	to	_	_	I-Premise
293	quality	_	_	I-Premise
294	of	_	_	I-Premise
295	life	_	_	I-Premise
296	according	_	_	I-Premise
297	to	_	_	I-Premise
298	the	_	_	I-Premise
299	EORTC	_	_	I-Premise
300	QLQ-protocol	_	_	I-Premise
301	.	_	_	I-Premise

302	In	_	_	B-Claim
303	conclusion	_	_	I-Claim
304	,	_	_	I-Claim
305	this	_	_	I-Claim
306	first	_	_	I-Claim
307	randomized	_	_	I-Claim
308	study	_	_	I-Claim
309	did	_	_	I-Claim
310	not	_	_	I-Claim
311	demonstrate	_	_	I-Claim
312	any	_	_	I-Claim
313	significant	_	_	I-Claim
314	improvement	_	_	I-Claim
315	of	_	_	I-Claim
316	using	_	_	I-Claim
317	estramustine	_	_	I-Claim
318	in	_	_	I-Claim
319	addition	_	_	I-Claim
320	to	_	_	I-Claim
321	conventional	_	_	I-Claim
322	radiotherapy	_	_	I-Claim
323	,	_	_	I-Claim
324	however	_	_	B-Claim
325	,	_	_	I-Claim
326	a	_	_	I-Claim
327	trend	_	_	I-Claim
328	for	_	_	I-Claim
329	a	_	_	I-Claim
330	positive	_	_	I-Claim
331	response	_	_	I-Claim
332	for	_	_	I-Claim
333	the	_	_	I-Claim
334	estramustine	_	_	I-Claim
335	group	_	_	I-Claim
336	was	_	_	I-Claim
337	found	_	_	I-Claim
338	in	_	_	I-Claim
339	patients	_	_	I-Claim
340	with	_	_	I-Claim
341	grade	_	_	I-Claim
342	III	_	_	I-Claim
343	glioma	_	_	I-Claim
344	.	_	_	I-Claim


0	In	_	_	B-Claim
1	advanced	_	_	I-Claim
2	not	_	_	I-Claim
3	selected	_	_	I-Claim
4	NSCLC	_	_	I-Claim
5	chemotherapy	_	_	I-Claim
6	achieved	_	_	I-Claim
7	an	_	_	I-Claim
8	advantage	_	_	I-Claim
9	of	_	_	I-Claim
10	approximately	_	_	I-Claim
11	1-2	_	_	I-Claim
12	months	_	_	I-Claim
13	on	_	_	I-Claim
14	median	_	_	I-Claim
15	survival	_	_	I-Claim
16	versus	_	_	I-Claim
17	best	_	_	I-Claim
18	supportive	_	_	I-Claim
19	care	_	_	I-Claim
20	.	_	_	I-Claim

21	Chemotherapy	_	_	B-Claim
22	seems	_	_	I-Claim
23	to	_	_	I-Claim
24	improve	_	_	I-Claim
25	symptoms	_	_	I-Claim
26	control	_	_	I-Claim
27	,	_	_	I-Claim
28	even	_	_	O
29	if	_	_	O
30	randomised	_	_	O
31	studies	_	_	O
32	with	_	_	O
33	quality	_	_	O
34	of	_	_	O
35	life	_	_	O
36	as	_	_	O
37	first	_	_	O
38	endpoint	_	_	O
39	are	_	_	O
40	lacking	_	_	O
41	and	_	_	O
42	often	_	_	O
43	chemotherapy	_	_	O
44	toxicity	_	_	O
45	compromises	_	_	O
46	the	_	_	O
47	frail	_	_	O
48	cost/benefit	_	_	O
49	ratio	_	_	O
50	.	_	_	O

51	The	_	_	O
52	aim	_	_	O
53	of	_	_	O
54	the	_	_	O
55	present	_	_	O
56	study	_	_	O
57	is	_	_	O
58	to	_	_	O
59	evaluate	_	_	O
60	the	_	_	O
61	impact	_	_	O
62	on	_	_	O
63	QoL	_	_	O
64	,	_	_	O
65	substituting	_	_	O
66	cisplatin	_	_	O
67	,	_	_	O
68	a	_	_	O
69	pivot	_	_	O
70	drug	_	_	O
71	in	_	_	O
72	NSCLC	_	_	O
73	therapy	_	_	O
74	,	_	_	O
75	with	_	_	O
76	carboplatin	_	_	O
77	,	_	_	O
78	an	_	_	O
79	analogue	_	_	O
80	with	_	_	O
81	an	_	_	O
82	improved	_	_	O
83	toxicity	_	_	O
84	profile	_	_	O
85	.	_	_	O

86	The	_	_	O
87	combination	_	_	O
88	of	_	_	O
89	cisplatin	_	_	O
90	with	_	_	O
91	Mitomycin	_	_	O
92	and	_	_	O
93	Vinblastine	_	_	O
94	was	_	_	O
95	one	_	_	O
96	of	_	_	O
97	the	_	_	O
98	most	_	_	O
99	frequently	_	_	O
100	used	_	_	O
101	in	_	_	O
102	the	_	_	O
103	palliative	_	_	O
104	setting	_	_	O
105	at	_	_	O
106	the	_	_	O
107	time	_	_	O
108	of	_	_	O
109	design	_	_	O
110	of	_	_	O
111	our	_	_	O
112	study	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	were	_	_	O
116	randomized	_	_	O
117	to	_	_	O
118	receive	_	_	O
119	MVP	_	_	O
120	regimen	_	_	O
121	(	_	_	O
122	Mitomycin-C	_	_	O
123	8	_	_	O
124	mg/m2	_	_	O
125	d1	_	_	O
126	,	_	_	O
127	Vinblastine	_	_	O
128	4	_	_	O
129	mg/m2	_	_	O
130	d	_	_	O
131	1-8	_	_	O
132	,	_	_	O
133	Cisplatin	_	_	O
134	100	_	_	O
135	mg/m2	_	_	O
136	d1	_	_	O
137	)	_	_	O
138	or	_	_	O
139	MVC	_	_	O
140	regimen	_	_	O
141	(	_	_	O
142	Mitomycin-C	_	_	O
143	8	_	_	O
144	mg/m2	_	_	O
145	d1	_	_	O
146	,	_	_	O
147	Vinblastine	_	_	O
148	4	_	_	O
149	mg/m2	_	_	O
150	d	_	_	O
151	1-8	_	_	O
152	,	_	_	O
153	Carboplatin	_	_	O
154	300	_	_	O
155	mg/m2	_	_	O
156	d1	_	_	O
157	)	_	_	O
158	every	_	_	O
159	3	_	_	O
160	weeks	_	_	O
161	.	_	_	O

162	The	_	_	O
163	QoL	_	_	O
164	was	_	_	O
165	evaluated	_	_	O
166	by	_	_	O
167	the	_	_	O
168	Spitzer	_	_	O
169	QL-Index	_	_	O
170	and	_	_	O
171	by	_	_	O
172	the	_	_	O
173	EORTC	_	_	O
174	QLQ-C30+LC	_	_	O
175	13	_	_	O
176	questionnaires	_	_	O
177	before	_	_	O
178	chemotherapy	_	_	O
179	,	_	_	O
180	after	_	_	O
181	one	_	_	O
182	cycle	_	_	O
183	,	_	_	O
184	after	_	_	O
185	three	_	_	O
186	cycles	_	_	O
187	,	_	_	O
188	and	_	_	O
189	then	_	_	O
190	every	_	_	O
191	6	_	_	O
192	weeks	_	_	O
193	in	_	_	O
194	the	_	_	O
195	first	_	_	O
196	6	_	_	O
197	months	_	_	O
198	and	_	_	O
199	every	_	_	O
200	3	_	_	O
201	months	_	_	O
202	thenafter	_	_	O
203	.	_	_	O

204	From	_	_	O
205	September	_	_	O
206	1994	_	_	O
207	to	_	_	O
208	July	_	_	O
209	1997	_	_	O
210	,	_	_	O
211	153	_	_	O
212	consecutive	_	_	O
213	patients	_	_	O
214	were	_	_	O
215	randomized	_	_	O
216	to	_	_	O
217	MVP	_	_	O
218	(	_	_	O
219	75	_	_	O
220	patients	_	_	O
221	)	_	_	O
222	or	_	_	O
223	MVC	_	_	O
224	arm	_	_	O
225	(	_	_	O
226	78	_	_	O
227	patients	_	_	O
228	)	_	_	O
229	.	_	_	O

230	Despite	_	_	B-Premise
231	difficulties	_	_	I-Premise
232	in	_	_	I-Premise
233	carrying	_	_	I-Premise
234	out	_	_	I-Premise
235	and	_	_	I-Premise
236	analysing	_	_	I-Premise
237	QoL	_	_	I-Premise
238	items	_	_	I-Premise
239	in	_	_	I-Premise
240	such	_	_	I-Premise
241	patients	_	_	I-Premise
242	,	_	_	I-Premise
243	the	_	_	I-Premise
244	global	_	_	I-Premise
245	QoL	_	_	I-Premise
246	evaluated	_	_	I-Premise
247	by	_	_	I-Premise
248	the	_	_	I-Premise
249	Spitzer	_	_	I-Premise
250	's	_	_	I-Premise
251	questionnaire	_	_	I-Premise
252	suggested	_	_	I-Premise
253	an	_	_	I-Premise
254	advantage	_	_	I-Premise
255	for	_	_	I-Premise
256	MVC	_	_	I-Premise
257	regimen	_	_	I-Premise
258	(	_	_	I-Premise
259	P=0.05	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	difference	_	_	I-Premise
265	was	_	_	I-Premise
266	observed	_	_	I-Premise
267	in	_	_	I-Premise
268	global	_	_	I-Premise
269	health	_	_	I-Premise
270	subdomain	_	_	I-Premise
271	(	_	_	I-Premise
272	P=0.04	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Premise
276	disease-related	_	_	I-Premise
277	symptoms	_	_	I-Premise
278	improved	_	_	I-Premise
279	with	_	_	I-Premise
280	time	_	_	I-Premise
281	,	_	_	I-Premise
282	and	_	_	O
283	the	_	_	B-Premise
284	benefits	_	_	I-Premise
285	lasted	_	_	I-Premise
286	for	_	_	I-Premise
287	the	_	_	I-Premise
288	entire	_	_	I-Premise
289	treatment	_	_	I-Premise
290	period	_	_	I-Premise
291	.	_	_	I-Premise

292	When	_	_	B-Premise
293	evaluated	_	_	I-Premise
294	with	_	_	I-Premise
295	the	_	_	I-Premise
296	EORTC	_	_	I-Premise
297	questionnaire	_	_	I-Premise
298	there	_	_	I-Premise
299	was	_	_	I-Premise
300	significantly	_	_	I-Premise
301	less	_	_	I-Premise
302	nausea	_	_	I-Premise
303	and	_	_	I-Premise
304	vomiting	_	_	I-Premise
305	(	_	_	I-Premise
306	P=0.0001	_	_	I-Premise
307	)	_	_	I-Premise
308	,	_	_	I-Premise
309	appetite	_	_	I-Premise
310	loss	_	_	I-Premise
311	(	_	_	I-Premise
312	P=0.01	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	insomnia	_	_	I-Premise
316	(	_	_	I-Premise
317	P=0.03	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	constipation	_	_	I-Premise
321	(	_	_	I-Premise
322	P=0.01	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	peripheral	_	_	I-Premise
326	neuropathy	_	_	I-Premise
327	(	_	_	I-Premise
328	P=0.01	_	_	I-Premise
329	)	_	_	I-Premise
330	in	_	_	I-Premise
331	favour	_	_	I-Premise
332	of	_	_	I-Premise
333	MVC	_	_	I-Premise
334	,	_	_	I-Premise
335	and	_	_	I-Premise
336	a	_	_	I-Premise
337	trend	_	_	I-Premise
338	for	_	_	I-Premise
339	less	_	_	I-Premise
340	hair	_	_	I-Premise
341	loss	_	_	I-Premise
342	(	_	_	I-Premise
343	P=0.05	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	advantage	_	_	I-Premise
348	lasted	_	_	I-Premise
349	for	_	_	I-Premise
350	all	_	_	I-Premise
351	the	_	_	I-Premise
352	duration	_	_	I-Premise
353	of	_	_	I-Premise
354	chemotherapy	_	_	I-Premise
355	.	_	_	I-Premise

356	No	_	_	B-Premise
357	differences	_	_	I-Premise
358	were	_	_	I-Premise
359	observed	_	_	I-Premise
360	in	_	_	I-Premise
361	global	_	_	I-Premise
362	quality	_	_	I-Premise
363	of	_	_	I-Premise
364	life	_	_	I-Premise
365	subdomain	_	_	I-Premise
366	(	_	_	I-Premise
367	P=0.40	_	_	I-Premise
368	)	_	_	I-Premise
369	between	_	_	I-Premise
370	the	_	_	I-Premise
371	two	_	_	I-Premise
372	regimen	_	_	I-Premise
373	.	_	_	I-Premise

374	QoL	_	_	O
375	was	_	_	O
376	the	_	_	O
377	first	_	_	O
378	endpoint	_	_	O
379	and	_	_	O
380	the	_	_	O
381	statistical	_	_	O
382	power	_	_	O
383	was	_	_	O
384	inadequate	_	_	O
385	to	_	_	O
386	assess	_	_	O
387	other	_	_	O
388	parameters	_	_	O
389	.	_	_	O

390	However	_	_	O
391	,	_	_	O
392	we	_	_	B-Premise
393	reported	_	_	I-Premise
394	a	_	_	I-Premise
395	response	_	_	I-Premise
396	rate	_	_	I-Premise
397	of	_	_	I-Premise
398	43.1	_	_	I-Premise
399	and	_	_	I-Premise
400	38.6	_	_	I-Premise
401	%	_	_	I-Premise
402	,	_	_	I-Premise
403	respectively	_	_	I-Premise
404	,	_	_	I-Premise
405	in	_	_	I-Premise
406	MVP	_	_	I-Premise
407	and	_	_	I-Premise
408	MVC	_	_	I-Premise
409	arm	_	_	I-Premise
410	(	_	_	I-Premise
411	P=0.59	_	_	I-Premise
412	)	_	_	I-Premise
413	and	_	_	I-Premise
414	a	_	_	I-Premise
415	median	_	_	I-Premise
416	survival	_	_	I-Premise
417	of	_	_	I-Premise
418	10.2	_	_	I-Premise
419	and	_	_	I-Premise
420	7.2	_	_	I-Premise
421	months	_	_	I-Premise
422	,	_	_	I-Premise
423	respectively	_	_	I-Premise
424	,	_	_	I-Premise
425	for	_	_	I-Premise
426	cisplatin	_	_	I-Premise
427	and	_	_	I-Premise
428	carboplatin	_	_	I-Premise
429	arm	_	_	I-Premise
430	(	_	_	I-Premise
431	P=0.39	_	_	I-Premise
432	)	_	_	I-Premise
433	.	_	_	I-Premise

434	The	_	_	B-Premise
435	carboplatin	_	_	I-Premise
436	containing	_	_	I-Premise
437	regimen	_	_	I-Premise
438	(	_	_	I-Premise
439	MVC	_	_	I-Premise
440	)	_	_	I-Premise
441	has	_	_	I-Premise
442	a	_	_	I-Premise
443	significant	_	_	I-Premise
444	better	_	_	I-Premise
445	toxicity	_	_	I-Premise
446	profile	_	_	I-Premise
447	than	_	_	I-Premise
448	the	_	_	I-Premise
449	cisplatin	_	_	I-Premise
450	containing	_	_	I-Premise
451	(	_	_	I-Premise
452	MVP	_	_	I-Premise
453	)	_	_	I-Premise
454	regimen	_	_	I-Premise
455	as	_	_	I-Premise
456	proven	_	_	I-Premise
457	both	_	_	I-Premise
458	by	_	_	I-Premise
459	the	_	_	I-Premise
460	EORTC	_	_	I-Premise
461	questionnaires	_	_	I-Premise
462	and	_	_	I-Premise
463	by	_	_	I-Premise
464	the	_	_	I-Premise
465	WHO	_	_	I-Premise
466	toxicity	_	_	I-Premise
467	data	_	_	I-Premise
468	reported	_	_	I-Premise
469	by	_	_	I-Premise
470	physicians	_	_	I-Premise
471	.	_	_	I-Premise

472	No	_	_	B-Claim
473	significant	_	_	I-Claim
474	differences	_	_	I-Claim
475	in	_	_	I-Claim
476	terms	_	_	I-Claim
477	of	_	_	I-Claim
478	response	_	_	I-Claim
479	rate	_	_	I-Claim
480	,	_	_	I-Claim
481	time	_	_	I-Claim
482	to	_	_	I-Claim
483	progression	_	_	I-Claim
484	and	_	_	I-Claim
485	overall	_	_	I-Claim
486	survival	_	_	I-Claim
487	were	_	_	I-Claim
488	observed	_	_	I-Claim
489	between	_	_	I-Claim
490	the	_	_	I-Claim
491	two	_	_	I-Claim
492	regimen	_	_	I-Claim
493	.	_	_	I-Claim

494	The	_	_	B-Claim
495	two	_	_	I-Claim
496	chemotherapy	_	_	I-Claim
497	regimen	_	_	I-Claim
498	showed	_	_	I-Claim
499	a	_	_	I-Claim
500	similar	_	_	I-Claim
501	effectiveness	_	_	I-Claim
502	in	_	_	I-Claim
503	symptom	_	_	I-Claim
504	palliation	_	_	I-Claim
505	when	_	_	I-Claim
506	evaluated	_	_	I-Claim
507	with	_	_	I-Claim
508	C30	_	_	I-Claim
509	addendum	_	_	I-Claim
510	of	_	_	I-Claim
511	EORTC	_	_	I-Claim
512	QOL	_	_	I-Claim
513	questionnaire	_	_	I-Claim
514	.	_	_	I-Claim

515	With	_	_	B-Premise
516	the	_	_	I-Premise
517	Spitzer	_	_	I-Premise
518	's	_	_	I-Premise
519	questionnaires	_	_	I-Premise
520	a	_	_	I-Premise
521	trend	_	_	I-Premise
522	towards	_	_	I-Premise
523	an	_	_	I-Premise
524	improved	_	_	I-Premise
525	quality	_	_	I-Premise
526	of	_	_	I-Premise
527	life	_	_	I-Premise
528	index	_	_	I-Premise
529	was	_	_	I-Premise
530	observed	_	_	I-Premise
531	during	_	_	I-Premise
532	treatment	_	_	I-Premise
533	with	_	_	I-Premise
534	the	_	_	I-Premise
535	carboplatin	_	_	I-Premise
536	combination	_	_	I-Premise
537	in	_	_	I-Premise
538	comparison	_	_	I-Premise
539	to	_	_	I-Premise
540	the	_	_	I-Premise
541	cisplatin	_	_	I-Premise
542	combination	_	_	I-Premise
543	.	_	_	I-Premise

544	This	_	_	B-Premise
545	difference	_	_	I-Premise
546	,	_	_	I-Premise
547	however	_	_	I-Premise
548	,	_	_	I-Premise
549	was	_	_	I-Premise
550	not	_	_	I-Premise
551	observed	_	_	I-Premise
552	when	_	_	I-Premise
553	the	_	_	I-Premise
554	global	_	_	I-Premise
555	quality	_	_	I-Premise
556	of	_	_	I-Premise
557	life	_	_	I-Premise
558	was	_	_	I-Premise
559	evaluated	_	_	I-Premise
560	with	_	_	I-Premise
561	the	_	_	I-Premise
562	EORTC	_	_	I-Premise
563	patients	_	_	I-Premise
564	compiled	_	_	I-Premise
565	questionnaires	_	_	I-Premise
566	.	_	_	I-Premise

567	A	_	_	B-Claim
568	carboplatin	_	_	I-Claim
569	containing	_	_	I-Claim
570	regimen	_	_	I-Claim
571	with	_	_	I-Claim
572	better	_	_	I-Claim
573	toxicity	_	_	I-Claim
574	profile	_	_	I-Claim
575	and	_	_	I-Claim
576	a	_	_	I-Claim
577	similar	_	_	I-Claim
578	potentiality	_	_	I-Claim
579	for	_	_	I-Claim
580	symptoms	_	_	I-Claim
581	control	_	_	I-Claim
582	offers	_	_	I-Claim
583	an	_	_	I-Claim
584	option	_	_	I-Claim
585	in	_	_	I-Claim
586	comparison	_	_	I-Claim
587	to	_	_	I-Claim
588	similar	_	_	I-Claim
589	cisplatin	_	_	I-Claim
590	containing	_	_	I-Claim
591	combinations	_	_	I-Claim
592	in	_	_	I-Claim
593	the	_	_	I-Claim
594	palliative	_	_	I-Claim
595	treatment	_	_	I-Claim
596	of	_	_	I-Claim
597	advanced	_	_	I-Claim
598	NSCLC	_	_	I-Claim
599	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	1-year	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	a	_	_	O
6	four-component	_	_	O
7	behavioral	_	_	O
8	therapy	_	_	O
9	(	_	_	O
10	BT	_	_	O
11	)	_	_	O
12	sleep	_	_	O
13	intervention	_	_	O
14	(	_	_	O
15	Individualized	_	_	O
16	Sleep	_	_	O
17	Promotion	_	_	O
18	Plan	_	_	O
19	[	_	_	O
20	ISPP	_	_	O
21	]	_	_	O
22	)	_	_	O
23	versus	_	_	O
24	a	_	_	O
25	healthy	_	_	O
26	eating	_	_	O
27	control	_	_	O
28	(	_	_	O
29	HEC	_	_	O
30	)	_	_	O
31	on	_	_	O
32	cancer-related	_	_	O
33	fatigue	_	_	O
34	in	_	_	O
35	women	_	_	O
36	receiving	_	_	O
37	breast	_	_	O
38	cancer	_	_	O
39	adjuvant	_	_	O
40	chemotherapy	_	_	O
41	treatment	_	_	O
42	(	_	_	O
43	CTX	_	_	O
44	)	_	_	O
45	.	_	_	O

46	A	_	_	O
47	total	_	_	O
48	of	_	_	O
49	219	_	_	O
50	participants	_	_	O
51	from	_	_	O
52	12	_	_	O
53	oncology	_	_	O
54	clinics	_	_	O
55	were	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	in	_	_	O
59	a	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	Before	_	_	O
64	CTX	_	_	O
65	,	_	_	O
66	research	_	_	O
67	nurses	_	_	O
68	coached	_	_	O
69	intervention	_	_	O
70	participants	_	_	O
71	to	_	_	O
72	develop	_	_	O
73	a	_	_	O
74	BT	_	_	O
75	plan	_	_	O
76	including	_	_	O
77	stimulus	_	_	O
78	control	_	_	O
79	,	_	_	O
80	modified	_	_	O
81	sleep	_	_	O
82	restriction	_	_	O
83	,	_	_	O
84	relaxation	_	_	O
85	therapy	_	_	O
86	,	_	_	O
87	and	_	_	O
88	sleep	_	_	O
89	hygiene	_	_	O
90	.	_	_	O

91	BT	_	_	O
92	plans	_	_	O
93	were	_	_	O
94	revised	_	_	O
95	before	_	_	O
96	each	_	_	O
97	CTX	_	_	O
98	and	_	_	O
99	30	_	_	O
100	,	_	_	O
101	60	_	_	O
102	,	_	_	O
103	and	_	_	O
104	90	_	_	O
105	days	_	_	O
106	after	_	_	O
107	the	_	_	O
108	last	_	_	O
109	CTX	_	_	O
110	and	_	_	O
111	reinforced	_	_	O
112	7	_	_	O
113	to	_	_	O
114	9	_	_	O
115	days	_	_	O
116	later	_	_	O
117	.	_	_	O

118	HEC	_	_	O
119	participants	_	_	O
120	received	_	_	O
121	nutritional	_	_	O
122	information	_	_	O
123	and	_	_	O
124	equal	_	_	O
125	attention	_	_	O
126	.	_	_	O

127	Pittsburgh	_	_	O
128	Sleep	_	_	O
129	Quality	_	_	O
130	Index	_	_	O
131	(	_	_	O
132	PSQI	_	_	O
133	)	_	_	O
134	,	_	_	O
135	Daily	_	_	O
136	Diary	_	_	O
137	,	_	_	O
138	Wrist	_	_	O
139	Actigraph	_	_	O
140	,	_	_	O
141	and	_	_	O
142	Piper	_	_	O
143	Fatigue	_	_	O
144	Scale	_	_	O
145	measures	_	_	O
146	and	_	_	O
147	Repeated	_	_	O
148	Linear	_	_	O
149	Mixed	_	_	O
150	Model	_	_	O
151	analysis	_	_	O
152	following	_	_	O
153	the	_	_	O
154	Intent	_	_	O
155	to	_	_	O
156	Treat	_	_	O
157	paradigm	_	_	O
158	were	_	_	O
159	used	_	_	O
160	.	_	_	O

161	Sleep	_	_	B-Premise
162	quality	_	_	I-Premise
163	differed	_	_	I-Premise
164	over	_	_	I-Premise
165	1	_	_	I-Premise
166	years	_	_	I-Premise
167	time	_	_	I-Premise
168	(	_	_	I-Premise
169	F	_	_	I-Premise
170	[	_	_	I-Premise
171	4,162	_	_	I-Premise
172	]	_	_	I-Premise
173	=	_	_	I-Premise
174	7.7	_	_	I-Premise
175	,	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.001	_	_	I-Premise
179	;	_	_	I-Premise
180	by	_	_	I-Premise
181	group	_	_	I-Premise
182	,	_	_	I-Premise
183	F	_	_	I-Premise
184	[	_	_	I-Premise
185	1,173	_	_	I-Premise
186	]	_	_	I-Premise
187	=	_	_	I-Premise
188	4.8	_	_	I-Premise
189	,	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.029	_	_	I-Premise
193	;	_	_	I-Premise
194	and	_	_	I-Premise
195	over	_	_	I-Premise
196	time	_	_	I-Premise
197	by	_	_	I-Premise
198	group	_	_	I-Premise
199	,	_	_	I-Premise
200	F	_	_	I-Premise
201	[	_	_	I-Premise
202	4,162	_	_	I-Premise
203	]	_	_	I-Premise
204	=	_	_	I-Premise
205	3.3	_	_	I-Premise
206	,	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.013	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Pairwise	_	_	B-Premise
213	comparisons	_	_	I-Premise
214	revealed	_	_	I-Premise
215	significant	_	_	I-Premise
216	differences	_	_	I-Premise
217	between	_	_	I-Premise
218	groups	_	_	I-Premise
219	at	_	_	I-Premise
220	90	_	_	I-Premise
221	days	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.002	_	_	I-Premise
226	)	_	_	I-Premise
227	but	_	_	B-Premise
228	not	_	_	I-Premise
229	at	_	_	I-Premise
230	1	_	_	I-Premise
231	year	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.052	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Seven	_	_	O
239	days	_	_	O
240	of	_	_	O
241	diary	_	_	O
242	and	_	_	O
243	actigraphy	_	_	O
244	data	_	_	O
245	did	_	_	O
246	not	_	_	O
247	corroborate	_	_	O
248	with	_	_	O
249	monthly	_	_	O
250	reflections	_	_	O
251	(	_	_	O
252	PSQI	_	_	O
253	)	_	_	O
254	.	_	_	O

255	The	_	_	B-Premise
256	night	_	_	I-Premise
257	awakenings	_	_	I-Premise
258	(	_	_	I-Premise
259	Actigraph	_	_	I-Premise
260	)	_	_	I-Premise
261	pattern	_	_	I-Premise
262	was	_	_	I-Premise
263	significantly	_	_	I-Premise
264	different	_	_	I-Premise
265	by	_	_	I-Premise
266	group	_	_	I-Premise
267	over	_	_	I-Premise
268	time	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.046	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	with	_	_	I-Premise
276	no	_	_	I-Premise
277	differences	_	_	I-Premise
278	between	_	_	I-Premise
279	groups	_	_	I-Premise
280	at	_	_	I-Premise
281	90	_	_	I-Premise
282	days	_	_	I-Premise
283	or	_	_	I-Premise
284	at	_	_	I-Premise
285	1	_	_	I-Premise
286	year	_	_	I-Premise
287	.	_	_	I-Premise

288	Fatigue	_	_	B-Premise
289	was	_	_	I-Premise
290	lower	_	_	I-Premise
291	at	_	_	I-Premise
292	1	_	_	I-Premise
293	year	_	_	I-Premise
294	than	_	_	I-Premise
295	before	_	_	I-Premise
296	CTX	_	_	I-Premise
297	;	_	_	I-Premise
298	no	_	_	B-Premise
299	group	_	_	I-Premise
300	effects	_	_	I-Premise
301	were	_	_	I-Premise
302	found	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	BT	_	_	I-Claim
306	group	_	_	I-Claim
307	,	_	_	I-Claim
308	on	_	_	I-Claim
309	average	_	_	I-Claim
310	,	_	_	I-Claim
311	experienced	_	_	I-Claim
312	significant	_	_	I-Claim
313	improvement	_	_	I-Claim
314	on	_	_	I-Claim
315	global	_	_	I-Claim
316	sleep	_	_	I-Claim
317	quality	_	_	I-Claim
318	compared	_	_	I-Claim
319	with	_	_	I-Claim
320	the	_	_	I-Claim
321	HEC	_	_	I-Claim
322	group	_	_	I-Claim
323	,	_	_	I-Claim
324	but	_	_	B-Claim
325	not	_	_	I-Claim
326	on	_	_	I-Claim
327	objective	_	_	I-Claim
328	sleep	_	_	I-Claim
329	or	_	_	I-Claim
330	fatigue	_	_	I-Claim
331	outcomes	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	uterine	_	_	O
6	artery	_	_	O
7	embolization	_	_	O
8	(	_	_	O
9	UAE	_	_	O
10	)	_	_	O
11	for	_	_	O
12	leiomyomas	_	_	O
13	with	_	_	O
14	use	_	_	O
15	of	_	_	O
16	tris-acryl	_	_	O
17	gelatin	_	_	O
18	microspheres	_	_	O
19	(	_	_	O
20	TAGM	_	_	O
21	)	_	_	O
22	versus	_	_	O
23	spherical	_	_	O
24	polyvinyl	_	_	O
25	alcohol	_	_	O
26	(	_	_	O
27	PVA	_	_	O
28	)	_	_	O
29	particles	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	undergoing	_	_	O
33	UAE	_	_	O
34	were	_	_	O
35	randomly	_	_	O
36	assigned	_	_	O
37	to	_	_	O
38	receive	_	_	O
39	TAGMs	_	_	O
40	or	_	_	O
41	PVA	_	_	O
42	.	_	_	O

43	Embolization	_	_	O
44	was	_	_	O
45	performed	_	_	O
46	in	_	_	O
47	a	_	_	O
48	standardized	_	_	O
49	manner	_	_	O
50	.	_	_	O

51	Outcome	_	_	O
52	data	_	_	O
53	were	_	_	O
54	collected	_	_	O
55	at	_	_	O
56	3	_	_	O
57	months	_	_	O
58	after	_	_	O
59	embolization	_	_	O
60	,	_	_	O
61	including	_	_	O
62	assessment	_	_	O
63	of	_	_	O
64	clinical	_	_	O
65	symptoms	_	_	O
66	,	_	_	O
67	scores	_	_	O
68	from	_	_	O
69	a	_	_	O
70	fibroid	_	_	O
71	tumor-specific	_	_	O
72	symptom	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	(	_	_	O
78	QOL	_	_	O
79	)	_	_	O
80	questionnaire	_	_	O
81	,	_	_	O
82	and	_	_	O
83	findings	_	_	O
84	on	_	_	O
85	contrast	_	_	O
86	material-enhanced	_	_	O
87	magnetic	_	_	O
88	resonance	_	_	O
89	(	_	_	O
90	MR	_	_	O
91	)	_	_	O
92	imaging	_	_	O
93	,	_	_	O
94	including	_	_	O
95	the	_	_	O
96	degree	_	_	O
97	of	_	_	O
98	tumor	_	_	O
99	infarction	_	_	O
100	and	_	_	O
101	volume	_	_	O
102	reduction	_	_	O
103	.	_	_	O

104	Data	_	_	O
105	were	_	_	O
106	analyzed	_	_	O
107	with	_	_	O
108	use	_	_	O
109	of	_	_	O
110	t	_	_	O
111	tests	_	_	O
112	,	_	_	O
113	the	_	_	O
114	Mann-Whitney	_	_	O
115	U	_	_	O
116	test	_	_	O
117	,	_	_	O
118	and	_	_	O
119	chi2	_	_	O
120	tests	_	_	O
121	as	_	_	O
122	appropriate	_	_	O
123	.	_	_	O

124	Thirty-six	_	_	O
125	patients	_	_	O
126	were	_	_	O
127	treated	_	_	O
128	.	_	_	O

129	There	_	_	O
130	were	_	_	O
131	no	_	_	O
132	differences	_	_	O
133	in	_	_	O
134	the	_	_	O
135	two	_	_	O
136	treatment	_	_	O
137	groups	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	.	_	_	O

141	Clinical	_	_	O
142	follow-up	_	_	O
143	was	_	_	O
144	obtained	_	_	O
145	in	_	_	O
146	35	_	_	O
147	patients	_	_	O
148	.	_	_	O

149	Among	_	_	B-Premise
150	the	_	_	I-Premise
151	clinical	_	_	I-Premise
152	outcome	_	_	I-Premise
153	measures	_	_	I-Premise
154	,	_	_	I-Premise
155	QOL	_	_	I-Premise
156	score	_	_	I-Premise
157	improvement	_	_	I-Premise
158	was	_	_	I-Premise
159	greater	_	_	I-Premise
160	for	_	_	I-Premise
161	UAE	_	_	I-Premise
162	with	_	_	I-Premise
163	TAGMs	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	PVA	_	_	I-Premise
167	(	_	_	I-Premise
168	49.0	_	_	I-Premise
169	vs	_	_	I-Premise
170	27.9	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.02	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	but	_	_	B-Premise
178	no	_	_	I-Premise
179	other	_	_	I-Premise
180	differences	_	_	I-Premise
181	were	_	_	I-Premise
182	noted	_	_	I-Premise
183	.	_	_	I-Premise

184	Of	_	_	B-Premise
185	the	_	_	I-Premise
186	25	_	_	I-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	whom	_	_	I-Premise
190	3-month	_	_	I-Premise
191	MR	_	_	I-Premise
192	imaging	_	_	I-Premise
193	follow-up	_	_	I-Premise
194	was	_	_	I-Premise
195	completed	_	_	I-Premise
196	,	_	_	I-Premise
197	those	_	_	I-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	TAGM	_	_	I-Premise
201	were	_	_	I-Premise
202	significantly	_	_	I-Premise
203	more	_	_	I-Premise
204	likely	_	_	I-Premise
205	to	_	_	I-Premise
206	have	_	_	I-Premise
207	complete	_	_	I-Premise
208	infarction	_	_	I-Premise
209	of	_	_	I-Premise
210	all	_	_	I-Premise
211	leiomyomas	_	_	I-Premise
212	(	_	_	I-Premise
213	six	_	_	I-Premise
214	patients	_	_	I-Premise
215	vs	_	_	I-Premise
216	one	_	_	I-Premise
217	patient	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.02	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	were	_	_	I-Premise
225	more	_	_	I-Premise
226	likely	_	_	I-Premise
227	to	_	_	I-Premise
228	have	_	_	I-Premise
229	at	_	_	I-Premise
230	least	_	_	I-Premise
231	90	_	_	I-Premise
232	%	_	_	I-Premise
233	tumor	_	_	I-Premise
234	infarction	_	_	I-Premise
235	(	_	_	I-Premise
236	eight	_	_	I-Premise
237	patients	_	_	I-Premise
238	vs	_	_	I-Premise
239	four	_	_	I-Premise
240	patients	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.03	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	had	_	_	I-Premise
249	a	_	_	I-Premise
250	lower	_	_	I-Premise
251	mean	_	_	I-Premise
252	percent	_	_	I-Premise
253	of	_	_	I-Premise
254	residual	_	_	I-Premise
255	perfused	_	_	I-Premise
256	fibroid	_	_	I-Premise
257	tumor	_	_	I-Premise
258	tissue	_	_	I-Premise
259	(	_	_	I-Premise
260	9.6	_	_	I-Premise
261	%	_	_	I-Premise
262	vs	_	_	I-Premise
263	44.3	_	_	I-Premise
264	%	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.004	_	_	I-Premise
269	)	_	_	I-Premise
270	compared	_	_	I-Premise
271	with	_	_	I-Premise
272	patients	_	_	I-Premise
273	treated	_	_	I-Premise
274	with	_	_	I-Premise
275	PVA	_	_	I-Premise
276	.	_	_	I-Premise

277	Based	_	_	O
278	on	_	_	O
279	these	_	_	O
280	differences	_	_	O
281	between	_	_	O
282	the	_	_	O
283	embolic	_	_	O
284	agents	_	_	O
285	,	_	_	O
286	enrollment	_	_	O
287	in	_	_	O
288	this	_	_	O
289	study	_	_	O
290	was	_	_	O
291	terminated	_	_	O
292	.	_	_	O

293	The	_	_	B-Claim
294	use	_	_	I-Claim
295	of	_	_	I-Claim
296	spherical	_	_	I-Claim
297	PVA	_	_	I-Claim
298	particles	_	_	I-Claim
299	in	_	_	I-Claim
300	the	_	_	I-Claim
301	manner	_	_	I-Claim
302	described	_	_	I-Claim
303	herein	_	_	I-Claim
304	results	_	_	I-Claim
305	in	_	_	I-Claim
306	an	_	_	I-Claim
307	unacceptably	_	_	I-Claim
308	high	_	_	I-Claim
309	rate	_	_	I-Claim
310	of	_	_	I-Claim
311	failed	_	_	I-Claim
312	tumor	_	_	I-Claim
313	infarction	_	_	I-Claim
314	in	_	_	I-Claim
315	UAE	_	_	I-Claim
316	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	biweekly	_	_	O
9	regimen	_	_	O
10	of	_	_	O
11	leucovorin	_	_	O
12	(	_	_	O
13	LV	_	_	O
14	)	_	_	O
15	plus	_	_	O
16	fluorouracil	_	_	O
17	(	_	_	O
18	FU	_	_	O
19	)	_	_	O
20	alone	_	_	O
21	or	_	_	O
22	in	_	_	O
23	combination	_	_	O
24	with	_	_	O
25	cisplatin	_	_	O
26	or	_	_	O
27	irinotecan	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	previously	_	_	O
32	untreated	_	_	O
33	metastatic	_	_	O
34	gastric	_	_	O
35	adenocarcinoma	_	_	O
36	and	_	_	O
37	to	_	_	O
38	select	_	_	O
39	the	_	_	O
40	best	_	_	O
41	arm	_	_	O
42	for	_	_	O
43	a	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	study	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	thirty-six	_	_	O
51	patients	_	_	O
52	(	_	_	O
53	two	_	_	O
54	were	_	_	O
55	ineligible	_	_	O
56	)	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	onto	_	_	O
60	the	_	_	O
61	randomized	_	_	O
62	multicenter	_	_	O
63	phase	_	_	O
64	II	_	_	O
65	trial	_	_	O
66	.	_	_	O

67	Patients	_	_	O
68	received	_	_	O
69	LV	_	_	O
70	200	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	(	_	_	O
76	2-hour	_	_	O
77	infusion	_	_	O
78	)	_	_	O
79	followed	_	_	O
80	by	_	_	O
81	FU	_	_	O
82	400	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	(	_	_	O
88	bolus	_	_	O
89	)	_	_	O
90	and	_	_	O
91	FU	_	_	O
92	600	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	(	_	_	O
98	22-hour	_	_	O
99	continuous	_	_	O
100	infusion	_	_	O
101	)	_	_	O
102	on	_	_	O
103	days	_	_	O
104	1	_	_	O
105	and	_	_	O
106	2	_	_	O
107	every	_	_	O
108	14	_	_	O
109	days	_	_	O
110	(	_	_	O
111	LV5FU2	_	_	O
112	;	_	_	O
113	arm	_	_	O
114	A	_	_	O
115	)	_	_	O
116	,	_	_	O
117	LV5FU2	_	_	O
118	plus	_	_	O
119	cisplatin	_	_	O
120	50	_	_	O
121	mg/m	_	_	O
122	(	_	_	O
123	2	_	_	O
124	)	_	_	O
125	(	_	_	O
126	1-hour	_	_	O
127	infusion	_	_	O
128	)	_	_	O
129	on	_	_	O
130	day	_	_	O
131	1	_	_	O
132	or	_	_	O
133	2	_	_	O
134	(	_	_	O
135	arm	_	_	O
136	B	_	_	O
137	)	_	_	O
138	,	_	_	O
139	or	_	_	O
140	LV5FU2	_	_	O
141	plus	_	_	O
142	irinotecan	_	_	O
143	180	_	_	O
144	mg/m	_	_	O
145	(	_	_	O
146	2	_	_	O
147	)	_	_	O
148	(	_	_	O
149	2-hour	_	_	O
150	infusion	_	_	O
151	)	_	_	O
152	on	_	_	O
153	day	_	_	O
154	1	_	_	O
155	(	_	_	O
156	arm	_	_	O
157	C	_	_	O
158	)	_	_	O
159	.	_	_	O

160	The	_	_	B-Premise
161	overall	_	_	I-Premise
162	response	_	_	I-Premise
163	rates	_	_	I-Premise
164	,	_	_	I-Premise
165	which	_	_	I-Premise
166	were	_	_	I-Premise
167	confirmed	_	_	I-Premise
168	by	_	_	I-Premise
169	an	_	_	I-Premise
170	independent	_	_	I-Premise
171	expert	_	_	I-Premise
172	panel	_	_	I-Premise
173	,	_	_	I-Premise
174	were	_	_	I-Premise
175	13	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	,	_	_	I-Premise
182	3.4	_	_	I-Premise
183	%	_	_	I-Premise
184	to	_	_	I-Premise
185	23.3	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	27	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	14.1	_	_	I-Premise
197	%	_	_	I-Premise
198	to	_	_	I-Premise
199	40.4	_	_	I-Premise
200	%	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	40	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	,	_	_	I-Premise
211	25.7	_	_	I-Premise
212	%	_	_	I-Premise
213	to	_	_	I-Premise
214	54.3	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	for	_	_	I-Premise
218	arms	_	_	I-Premise
219	A	_	_	I-Premise
220	,	_	_	I-Premise
221	B	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	C	_	_	I-Premise
225	,	_	_	I-Premise
226	respectively	_	_	I-Premise
227	.	_	_	I-Premise

228	Median	_	_	B-Premise
229	progression-free	_	_	I-Premise
230	survival	_	_	I-Premise
231	and	_	_	I-Premise
232	overall	_	_	I-Premise
233	survival	_	_	I-Premise
234	times	_	_	I-Premise
235	were	_	_	I-Premise
236	3.2	_	_	I-Premise
237	months	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	CI	_	_	I-Premise
242	,	_	_	I-Premise
243	1.8	_	_	I-Premise
244	to	_	_	I-Premise
245	4.6	_	_	I-Premise
246	months	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	6.8	_	_	I-Premise
250	months	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	CI	_	_	I-Premise
255	,	_	_	I-Premise
256	2.6	_	_	I-Premise
257	to	_	_	I-Premise
258	11.1	_	_	I-Premise
259	months	_	_	I-Premise
260	)	_	_	I-Premise
261	with	_	_	I-Premise
262	LV5FU2	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	;	_	_	I-Premise
266	4.9	_	_	I-Premise
267	months	_	_	I-Premise
268	(	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	,	_	_	I-Premise
273	3.5	_	_	I-Premise
274	to	_	_	I-Premise
275	6.3	_	_	I-Premise
276	months	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	9.5	_	_	I-Premise
280	months	_	_	I-Premise
281	(	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	6.9	_	_	I-Premise
287	to	_	_	I-Premise
288	12.2	_	_	I-Premise
289	months	_	_	I-Premise
290	)	_	_	I-Premise
291	with	_	_	I-Premise
292	LV5FU2-cisplatin	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	;	_	_	I-Premise
296	and	_	_	I-Premise
297	6.9	_	_	I-Premise
298	months	_	_	I-Premise
299	(	_	_	I-Premise
300	95	_	_	I-Premise
301	%	_	_	I-Premise
302	CI	_	_	I-Premise
303	,	_	_	I-Premise
304	5.5	_	_	I-Premise
305	to	_	_	I-Premise
306	8.3	_	_	I-Premise
307	months	_	_	I-Premise
308	)	_	_	I-Premise
309	and	_	_	I-Premise
310	11.3	_	_	I-Premise
311	months	_	_	I-Premise
312	(	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	,	_	_	I-Premise
317	9.3	_	_	I-Premise
318	to	_	_	I-Premise
319	13.3	_	_	I-Premise
320	months	_	_	I-Premise
321	)	_	_	I-Premise
322	with	_	_	I-Premise
323	LV5FU2-irinotecan	_	_	I-Premise
324	,	_	_	I-Premise
325	respectively	_	_	I-Premise
326	.	_	_	I-Premise

327	Of	_	_	B-Claim
328	the	_	_	I-Claim
329	three	_	_	I-Claim
330	regimens	_	_	I-Claim
331	tested	_	_	I-Claim
332	,	_	_	I-Claim
333	the	_	_	I-Claim
334	combination	_	_	I-Claim
335	of	_	_	I-Claim
336	LV5FU2-irinotecan	_	_	I-Claim
337	is	_	_	I-Claim
338	the	_	_	I-Claim
339	most	_	_	I-Claim
340	promising	_	_	I-Claim
341	and	_	_	I-Claim
342	will	_	_	I-Claim
343	be	_	_	I-Claim
344	assessed	_	_	I-Claim
345	in	_	_	I-Claim
346	a	_	_	I-Claim
347	phase	_	_	I-Claim
348	III	_	_	I-Claim
349	trial	_	_	I-Claim
350	.	_	_	I-Claim


0	LV5FU2	_	_	O
1	with	_	_	O
2	high-dose	_	_	O
3	leucovorin	_	_	O
4	(	_	_	O
5	LV	_	_	O
6	)	_	_	O
7	,	_	_	O
8	weekly	_	_	O
9	infusional	_	_	O
10	5-fluorouracil	_	_	O
11	(	_	_	O
12	5FU	_	_	O
13	)	_	_	O
14	(	_	_	O
15	AIO	_	_	O
16	schedule	_	_	O
17	)	_	_	O
18	and	_	_	O
19	raltitrexed	_	_	O
20	have	_	_	O
21	been	_	_	O
22	demonstrated	_	_	O
23	to	_	_	O
24	be	_	_	O
25	active	_	_	O
26	agents	_	_	O
27	in	_	_	O
28	first-line	_	_	O
29	treatment	_	_	O
30	of	_	_	O
31	colorectal	_	_	O
32	cancer	_	_	O
33	.	_	_	O

34	We	_	_	O
35	performed	_	_	O
36	a	_	_	O
37	4-arm	_	_	O
38	randomised	_	_	O
39	trial	_	_	O
40	to	_	_	O
41	compare	_	_	O
42	(	_	_	O
43	1	_	_	O
44	)	_	_	O
45	a	_	_	O
46	low-dose	_	_	O
47	intravenous	_	_	O
48	bolus	_	_	O
49	of	_	_	O
50	LV	_	_	O
51	(	_	_	O
52	20	_	_	O
53	mg/m2	_	_	O
54	)	_	_	O
55	,	_	_	O
56	followed	_	_	O
57	by	_	_	O
58	an	_	_	O
59	intravenous	_	_	O
60	bolus	_	_	O
61	of	_	_	O
62	5FU	_	_	O
63	(	_	_	O
64	400	_	_	O
65	mg/m2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	a	_	_	O
71	22-hour	_	_	O
72	continuous	_	_	O
73	infusion	_	_	O
74	of	_	_	O
75	5FU	_	_	O
76	(	_	_	O
77	600	_	_	O
78	mg/m2	_	_	O
79	)	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	day	_	_	O
85	2/2	_	_	O
86	weeks	_	_	O
87	(	_	_	O
88	ldLV5FU2	_	_	O
89	arm	_	_	O
90	)	_	_	O
91	,	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	a	_	_	O
96	weekly	_	_	O
97	continuous	_	_	O
98	infusion	_	_	O
99	of	_	_	O
100	high-dose	_	_	O
101	5FU	_	_	O
102	(	_	_	O
103	2.6	_	_	O
104	g/m2/week	_	_	O
105	)	_	_	O
106	for	_	_	O
107	6	_	_	O
108	weeks	_	_	O
109	followed	_	_	O
110	by	_	_	O
111	a	_	_	O
112	rest	_	_	O
113	week	_	_	O
114	(	_	_	O
115	HD-FU	_	_	O
116	arm	_	_	O
117	)	_	_	O
118	and	_	_	O
119	(	_	_	O
120	3	_	_	O
121	)	_	_	O
122	raltitrexed	_	_	O
123	(	_	_	O
124	Tomudex	_	_	O
125	arm	_	_	O
126	;	_	_	O
127	3	_	_	O
128	mg/m2/3	_	_	O
129	weeks	_	_	O
130	)	_	_	O
131	to	_	_	O
132	standard	_	_	O
133	LV5FU2	_	_	O
134	.	_	_	O

135	From	_	_	O
136	1997	_	_	O
137	to	_	_	O
138	2001	_	_	O
139	,	_	_	O
140	294	_	_	O
141	patients	_	_	O
142	were	_	_	O
143	included	_	_	O
144	.	_	_	O

145	The	_	_	O
146	4	_	_	O
147	arms	_	_	O
148	were	_	_	O
149	well	_	_	O
150	balanced	_	_	O
151	for	_	_	O
152	sex	_	_	O
153	ratio	_	_	O
154	,	_	_	O
155	age	_	_	O
156	,	_	_	O
157	WHO	_	_	O
158	performance	_	_	O
159	status	_	_	O
160	,	_	_	O
161	the	_	_	O
162	primary	_	_	O
163	tumour	_	_	O
164	site	_	_	O
165	and	_	_	O
166	prior	_	_	O
167	adjuvant	_	_	O
168	chemotherapy	_	_	O
169	.	_	_	O

170	Treatment	_	_	O
171	was	_	_	O
172	stopped	_	_	O
173	due	_	_	O
174	to	_	_	O
175	low	_	_	O
176	accrual	_	_	O
177	.	_	_	O

178	Two	_	_	B-Premise
179	toxicity-related	_	_	I-Premise
180	deaths	_	_	I-Premise
181	were	_	_	I-Premise
182	observed	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	Tomudex	_	_	I-Premise
186	arm	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	treatments	_	_	I-Premise
190	gave	_	_	I-Premise
191	rise	_	_	I-Premise
192	to	_	_	I-Premise
193	different	_	_	I-Premise
194	rates	_	_	I-Premise
195	of	_	_	I-Premise
196	grade	_	_	I-Premise
197	3-4	_	_	I-Premise
198	neutropenia	_	_	I-Premise
199	(	_	_	I-Premise
200	3	_	_	I-Premise
201	,	_	_	I-Premise
202	4	_	_	I-Premise
203	,	_	_	I-Premise
204	11	_	_	I-Premise
205	and	_	_	I-Premise
206	14	_	_	I-Premise
207	%	_	_	I-Premise
208	of	_	_	I-Premise
209	the	_	_	I-Premise
210	patients	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	LV5FU2	_	_	I-Premise
214	,	_	_	I-Premise
215	ldLV5FU2	_	_	I-Premise
216	,	_	_	I-Premise
217	HD-FU	_	_	I-Premise
218	and	_	_	I-Premise
219	Tomudex	_	_	I-Premise
220	arms	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	,	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.028	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	leucopenia	_	_	I-Premise
230	and	_	_	I-Premise
231	vomiting	_	_	I-Premise
232	.	_	_	I-Premise

233	At	_	_	B-Premise
234	least	_	_	I-Premise
235	one	_	_	I-Premise
236	episode	_	_	I-Premise
237	of	_	_	I-Premise
238	grade	_	_	I-Premise
239	3-4	_	_	I-Premise
240	toxicity	_	_	I-Premise
241	was	_	_	I-Premise
242	observed	_	_	I-Premise
243	in	_	_	I-Premise
244	27	_	_	I-Premise
245	,	_	_	I-Premise
246	25	_	_	I-Premise
247	,	_	_	I-Premise
248	38	_	_	I-Premise
249	and	_	_	I-Premise
250	47	_	_	I-Premise
251	%	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	patients	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	LV5FU2	_	_	I-Premise
258	,	_	_	I-Premise
259	ldLV5FU2	_	_	I-Premise
260	,	_	_	I-Premise
261	HD-FU	_	_	I-Premise
262	and	_	_	I-Premise
263	Tomudex	_	_	I-Premise
264	arms	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.016	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	An	_	_	B-Premise
274	objective	_	_	I-Premise
275	response	_	_	I-Premise
276	was	_	_	I-Premise
277	observed	_	_	I-Premise
278	in	_	_	I-Premise
279	28	_	_	I-Premise
280	,	_	_	I-Premise
281	21	_	_	I-Premise
282	,	_	_	I-Premise
283	22	_	_	I-Premise
284	and	_	_	I-Premise
285	10	_	_	I-Premise
286	%	_	_	I-Premise
287	of	_	_	I-Premise
288	the	_	_	I-Premise
289	patients	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	LV5FU2	_	_	I-Premise
293	,	_	_	I-Premise
294	ldLV5FU2	_	_	I-Premise
295	,	_	_	I-Premise
296	HD-FU	_	_	I-Premise
297	and	_	_	I-Premise
298	Tomudex	_	_	I-Premise
299	arms	_	_	I-Premise
300	,	_	_	I-Premise
301	respectively	_	_	I-Premise
302	(	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0.04	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Progression-free	_	_	B-Premise
309	survival	_	_	I-Premise
310	(	_	_	I-Premise
311	PFS	_	_	I-Premise
312	)	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	patients	_	_	I-Premise
316	in	_	_	I-Premise
317	the	_	_	I-Premise
318	Tomudex	_	_	I-Premise
319	arm	_	_	I-Premise
320	was	_	_	I-Premise
321	statistically	_	_	I-Premise
322	lower	_	_	I-Premise
323	compared	_	_	I-Premise
324	to	_	_	I-Premise
325	that	_	_	I-Premise
326	of	_	_	I-Premise
327	patients	_	_	I-Premise
328	treated	_	_	I-Premise
329	with	_	_	I-Premise
330	LV5FU2	_	_	I-Premise
331	or	_	_	I-Premise
332	ldLV5FU2	_	_	I-Premise
333	(	_	_	I-Premise
334	combined	_	_	I-Premise
335	group	_	_	I-Premise
336	;	_	_	I-Premise
337	p	_	_	I-Premise
338	=	_	_	I-Premise
339	0.013	_	_	I-Premise
340	,	_	_	I-Premise
341	log	_	_	I-Premise
342	rank	_	_	I-Premise
343	test	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	In	_	_	B-Claim
347	conclusion	_	_	I-Claim
348	,	_	_	I-Claim
349	Tomudex	_	_	I-Claim
350	is	_	_	I-Claim
351	more	_	_	I-Claim
352	toxic	_	_	I-Claim
353	and	_	_	I-Claim
354	yields	_	_	I-Claim
355	shorter	_	_	I-Claim
356	PFS	_	_	I-Claim
357	than	_	_	I-Claim
358	infusional	_	_	I-Claim
359	5FU	_	_	I-Claim
360	.	_	_	I-Claim

361	Despite	_	_	B-Claim
362	the	_	_	I-Claim
363	early	_	_	I-Claim
364	closure	_	_	I-Claim
365	of	_	_	I-Claim
366	the	_	_	I-Claim
367	study	_	_	I-Claim
368	and	_	_	I-Claim
369	the	_	_	I-Claim
370	lack	_	_	I-Claim
371	of	_	_	I-Claim
372	power	_	_	I-Claim
373	of	_	_	I-Claim
374	the	_	_	I-Claim
375	comparison	_	_	I-Claim
376	,	_	_	I-Claim
377	it	_	_	I-Claim
378	seems	_	_	I-Claim
379	that	_	_	I-Claim
380	ldLV5FU2	_	_	I-Claim
381	could	_	_	I-Claim
382	be	_	_	I-Claim
383	considered	_	_	I-Claim
384	as	_	_	I-Claim
385	an	_	_	I-Claim
386	active	_	_	I-Claim
387	,	_	_	I-Claim
388	easier	_	_	I-Claim
389	and	_	_	I-Claim
390	less	_	_	I-Claim
391	expensive	_	_	I-Claim
392	option	_	_	I-Claim
393	for	_	_	I-Claim
394	the	_	_	I-Claim
395	treatment	_	_	I-Claim
396	of	_	_	I-Claim
397	metastatic	_	_	I-Claim
398	colorectal	_	_	I-Claim
399	cancer	_	_	I-Claim
400	compared	_	_	I-Claim
401	to	_	_	I-Claim
402	classic	_	_	I-Claim
403	LV5FU2	_	_	I-Claim
404	or	_	_	I-Claim
405	weekly	_	_	I-Claim
406	HD-FU	_	_	I-Claim
407	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcome	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	of	_	_	O
7	mediastinoscopy-verified	_	_	O
8	N2	_	_	O
9	non-small-cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	treated	_	_	O
13	with	_	_	O
14	induction	_	_	O
15	chemotherapy	_	_	O
16	followed	_	_	O
17	by	_	_	O
18	either	_	_	O
19	surgery	_	_	O
20	or	_	_	O
21	radiotherapy	_	_	O
22	(	_	_	O
23	RT	_	_	O
24	)	_	_	O
25	,	_	_	O
26	with	_	_	O
27	both	_	_	O
28	options	_	_	O
29	followed	_	_	O
30	by	_	_	O
31	consolidation	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	A	_	_	O
35	randomized	_	_	O
36	Phase	_	_	O
37	III	_	_	O
38	trial	_	_	O
39	for	_	_	O
40	Stage	_	_	O
41	IIIA	_	_	O
42	(	_	_	O
43	T1-T3N2M0	_	_	O
44	)	_	_	O
45	non-small	_	_	O
46	cell	_	_	O
47	lung	_	_	O
48	cancer	_	_	O
49	was	_	_	O
50	conducted	_	_	O
51	by	_	_	O
52	the	_	_	O
53	Radiation	_	_	O
54	Therapy	_	_	O
55	Oncology	_	_	O
56	Group	_	_	O
57	(	_	_	O
58	RTOG	_	_	O
59	)	_	_	O
60	and	_	_	O
61	Eastern	_	_	O
62	Cooperative	_	_	O
63	Oncology	_	_	O
64	Group	_	_	O
65	between	_	_	O
66	April	_	_	O
67	1990	_	_	O
68	and	_	_	O
69	April	_	_	O
70	1994	_	_	O
71	.	_	_	O

72	After	_	_	O
73	documentation	_	_	O
74	of	_	_	O
75	N2	_	_	O
76	disease	_	_	O
77	by	_	_	O
78	mediastinoscopy	_	_	O
79	or	_	_	O
80	anterior	_	_	O
81	mediastinotomy	_	_	O
82	,	_	_	O
83	patients	_	_	O
84	received	_	_	O
85	induction	_	_	O
86	chemotherapy	_	_	O
87	with	_	_	O
88	cisplatin	_	_	O
89	,	_	_	O
90	vinblastine	_	_	O
91	,	_	_	O
92	and	_	_	O
93	mitomycin-C.	_	_	O
94	Mitomycin-C	_	_	O
95	was	_	_	O
96	later	_	_	O
97	dropped	_	_	O
98	from	_	_	O
99	the	_	_	O
100	induction	_	_	O
101	regimen	_	_	O
102	.	_	_	O

103	Patients	_	_	O
104	were	_	_	O
105	then	_	_	O
106	randomized	_	_	O
107	to	_	_	O
108	surgery	_	_	O
109	or	_	_	O
110	RT	_	_	O
111	(	_	_	O
112	64	_	_	O
113	Gy	_	_	O
114	in	_	_	O
115	7	_	_	O
116	weeks	_	_	O
117	)	_	_	O
118	followed	_	_	O
119	by	_	_	O
120	cisplatin	_	_	O
121	and	_	_	O
122	vinblastine	_	_	O
123	.	_	_	O

124	RTOG	_	_	O
125	89-01	_	_	O
126	accrued	_	_	O
127	75	_	_	O
128	patients	_	_	O
129	,	_	_	O
130	of	_	_	O
131	whom	_	_	O
132	73	_	_	O
133	were	_	_	O
134	eligible	_	_	O
135	and	_	_	O
136	analyzable	_	_	O
137	.	_	_	O

138	Twelve	_	_	O
139	patients	_	_	O
140	received	_	_	O
141	induction	_	_	O
142	chemotherapy	_	_	O
143	but	_	_	O
144	were	_	_	O
145	not	_	_	O
146	randomized	_	_	O
147	to	_	_	O
148	RT	_	_	O
149	or	_	_	O
150	surgery	_	_	O
151	thereafter	_	_	O
152	.	_	_	O

153	Forty-five	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	postinduction	_	_	O
159	RT	_	_	O
160	or	_	_	O
161	surgery	_	_	O
162	.	_	_	O

163	Of	_	_	O
164	the	_	_	O
165	analyzable	_	_	O
166	patients	_	_	O
167	,	_	_	O
168	90	_	_	O
169	%	_	_	O
170	had	_	_	O
171	a	_	_	O
172	Karnofsky	_	_	O
173	performance	_	_	O
174	score	_	_	O
175	of	_	_	O
176	90-100	_	_	O
177	,	_	_	O
178	18	_	_	O
179	%	_	_	O
180	had	_	_	O
181	weight	_	_	O
182	loss	_	_	O
183	>	_	_	O
184	5	_	_	O
185	%	_	_	O
186	,	_	_	O
187	37	_	_	O
188	%	_	_	O
189	had	_	_	O
190	squamous	_	_	O
191	cell	_	_	O
192	histologic	_	_	O
193	features	_	_	O
194	,	_	_	O
195	and	_	_	O
196	54	_	_	O
197	%	_	_	O
198	had	_	_	O
199	bulky	_	_	O
200	N2	_	_	O
201	disease	_	_	O
202	.	_	_	O

203	The	_	_	O
204	distribution	_	_	O
205	of	_	_	O
206	bulky	_	_	O
207	N2	_	_	O
208	disease	_	_	O
209	was	_	_	O
210	uniform	_	_	O
211	among	_	_	O
212	the	_	_	O
213	treatment	_	_	O
214	arms	_	_	O
215	.	_	_	O

216	The	_	_	B-Premise
217	incidence	_	_	I-Premise
218	of	_	_	I-Premise
219	Grade	_	_	I-Premise
220	4	_	_	I-Premise
221	toxicity	_	_	I-Premise
222	was	_	_	I-Premise
223	56	_	_	I-Premise
224	%	_	_	I-Premise
225	in	_	_	I-Premise
226	patients	_	_	I-Premise
227	receiving	_	_	I-Premise
228	mitomycin-C	_	_	I-Premise
229	and	_	_	I-Premise
230	29	_	_	I-Premise
231	%	_	_	I-Premise
232	in	_	_	I-Premise
233	those	_	_	I-Premise
234	who	_	_	I-Premise
235	did	_	_	I-Premise
236	not	_	_	I-Premise
237	.	_	_	I-Premise

238	Only	_	_	B-Premise
239	1	_	_	I-Premise
240	patient	_	_	I-Premise
241	in	_	_	I-Premise
242	each	_	_	I-Premise
243	group	_	_	I-Premise
244	had	_	_	I-Premise
245	acute	_	_	I-Premise
246	nonhematologic	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	greater	_	_	I-Premise
249	than	_	_	I-Premise
250	Grade	_	_	I-Premise
251	3	_	_	I-Premise
252	(	_	_	I-Premise
253	nausea	_	_	I-Premise
254	and	_	_	I-Premise
255	vomiting	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	No	_	_	B-Premise
259	acute	_	_	I-Premise
260	Grade	_	_	I-Premise
261	4	_	_	I-Premise
262	radiation	_	_	I-Premise
263	toxicity	_	_	I-Premise
264	developed	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Premise
267	incidences	_	_	I-Premise
268	of	_	_	I-Premise
269	long-term	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	were	_	_	I-Premise
272	equivalent	_	_	I-Premise
273	across	_	_	I-Premise
274	the	_	_	I-Premise
275	arms	_	_	I-Premise
276	.	_	_	I-Premise

277	Three	_	_	B-Premise
278	treatment-related	_	_	I-Premise
279	deaths	_	_	I-Premise
280	occurred	_	_	I-Premise
281	:	_	_	I-Premise
282	2	_	_	I-Premise
283	patients	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	surgical	_	_	I-Premise
287	arms	_	_	I-Premise
288	(	_	_	I-Premise
289	one	_	_	I-Premise
290	late	_	_	I-Premise
291	pulmonary	_	_	I-Premise
292	toxicity	_	_	I-Premise
293	and	_	_	I-Premise
294	one	_	_	I-Premise
295	pulmonary	_	_	I-Premise
296	embolus	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	1	_	_	I-Premise
301	patient	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	radiation	_	_	I-Premise
305	arm	_	_	I-Premise
306	(	_	_	I-Premise
307	radiation	_	_	I-Premise
308	pneumonitis	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	Induction	_	_	B-Premise
312	chemotherapy	_	_	I-Premise
313	was	_	_	I-Premise
314	completed	_	_	I-Premise
315	in	_	_	I-Premise
316	78	_	_	I-Premise
317	%	_	_	I-Premise
318	of	_	_	I-Premise
319	the	_	_	I-Premise
320	patients	_	_	I-Premise
321	.	_	_	I-Premise

322	Complete	_	_	B-Premise
323	resection	_	_	I-Premise
324	was	_	_	I-Premise
325	performed	_	_	I-Premise
326	in	_	_	I-Premise
327	73	_	_	I-Premise
328	%	_	_	I-Premise
329	of	_	_	I-Premise
330	26	_	_	I-Premise
331	patients	_	_	I-Premise
332	undergoing	_	_	I-Premise
333	thoracotomy	_	_	I-Premise
334	.	_	_	I-Premise

335	Consolidation	_	_	B-Premise
336	chemotherapy	_	_	I-Premise
337	was	_	_	I-Premise
338	completed	_	_	I-Premise
339	in	_	_	I-Premise
340	75	_	_	I-Premise
341	%	_	_	I-Premise
342	of	_	_	I-Premise
343	the	_	_	I-Premise
344	patients	_	_	I-Premise
345	.	_	_	I-Premise

346	No	_	_	B-Premise
347	statistically	_	_	I-Premise
348	significant	_	_	I-Premise
349	difference	_	_	I-Premise
350	was	_	_	I-Premise
351	found	_	_	I-Premise
352	among	_	_	I-Premise
353	the	_	_	I-Premise
354	treatment	_	_	I-Premise
355	arms	_	_	I-Premise
356	.	_	_	I-Premise

357	The	_	_	B-Premise
358	overall	_	_	I-Premise
359	progression-free	_	_	I-Premise
360	survival	_	_	I-Premise
361	rate	_	_	I-Premise
362	was	_	_	I-Premise
363	53	_	_	I-Premise
364	%	_	_	I-Premise
365	at	_	_	I-Premise
366	1	_	_	I-Premise
367	year	_	_	I-Premise
368	and	_	_	I-Premise
369	17	_	_	I-Premise
370	%	_	_	I-Premise
371	at	_	_	I-Premise
372	3	_	_	I-Premise
373	years	_	_	I-Premise
374	.	_	_	I-Premise

375	The	_	_	B-Premise
376	median	_	_	I-Premise
377	progression-free	_	_	I-Premise
378	survival	_	_	I-Premise
379	was	_	_	I-Premise
380	14	_	_	I-Premise
381	months	_	_	I-Premise
382	.	_	_	I-Premise

383	No	_	_	B-Premise
384	difference	_	_	I-Premise
385	in	_	_	I-Premise
386	the	_	_	I-Premise
387	1-year	_	_	I-Premise
388	survival	_	_	I-Premise
389	rate	_	_	I-Premise
390	(	_	_	I-Premise
391	70	_	_	I-Premise
392	%	_	_	I-Premise
393	vs.	_	_	I-Premise
394	66	_	_	I-Premise
395	%	_	_	I-Premise
396	)	_	_	I-Premise
397	or	_	_	I-Premise
398	median	_	_	I-Premise
399	survival	_	_	I-Premise
400	time	_	_	I-Premise
401	(	_	_	I-Premise
402	19.4	_	_	I-Premise
403	vs.	_	_	I-Premise
404	17.4	_	_	I-Premise
405	months	_	_	I-Premise
406	)	_	_	I-Premise
407	between	_	_	I-Premise
408	the	_	_	I-Premise
409	surgery	_	_	I-Premise
410	and	_	_	I-Premise
411	RT	_	_	I-Premise
412	arms	_	_	I-Premise
413	.	_	_	I-Premise

414	The	_	_	B-Premise
415	median	_	_	I-Premise
416	survival	_	_	I-Premise
417	in	_	_	I-Premise
418	the	_	_	I-Premise
419	patients	_	_	I-Premise
420	receiving	_	_	I-Premise
421	induction	_	_	I-Premise
422	chemotherapy	_	_	I-Premise
423	only	_	_	I-Premise
424	was	_	_	I-Premise
425	8.9	_	_	I-Premise
426	months	_	_	I-Premise
427	.	_	_	I-Premise

428	Mitomycin-C	_	_	B-Premise
429	had	_	_	I-Premise
430	no	_	_	I-Premise
431	impact	_	_	I-Premise
432	on	_	_	I-Premise
433	survival	_	_	I-Premise
434	(	_	_	I-Premise
435	p	_	_	I-Premise
436	=	_	_	I-Premise
437	0.75	_	_	I-Premise
438	)	_	_	I-Premise
439	.	_	_	I-Premise

440	No	_	_	B-Premise
441	statistically	_	_	I-Premise
442	significant	_	_	I-Premise
443	difference	_	_	I-Premise
444	was	_	_	I-Premise
445	noted	_	_	I-Premise
446	in	_	_	I-Premise
447	the	_	_	I-Premise
448	time	_	_	I-Premise
449	to	_	_	I-Premise
450	local	_	_	I-Premise
451	failure	_	_	I-Premise
452	between	_	_	I-Premise
453	the	_	_	I-Premise
454	surgical	_	_	I-Premise
455	and	_	_	I-Premise
456	RT	_	_	I-Premise
457	arms	_	_	I-Premise
458	.	_	_	I-Premise

459	The	_	_	B-Claim
460	patient	_	_	I-Claim
461	accrual	_	_	I-Claim
462	to	_	_	I-Claim
463	this	_	_	I-Claim
464	trial	_	_	I-Claim
465	made	_	_	I-Claim
466	its	_	_	I-Claim
467	results	_	_	I-Claim
468	inconclusive	_	_	I-Claim
469	,	_	_	I-Claim
470	but	_	_	O
471	several	_	_	O
472	observations	_	_	O
473	are	_	_	O
474	notable	_	_	O
475	.	_	_	O

476	In	_	_	O
477	this	_	_	O
478	trial	_	_	O
479	,	_	_	O
480	histologic	_	_	B-Claim
481	confirmation	_	_	I-Claim
482	of	_	_	I-Claim
483	N2	_	_	I-Claim
484	disease	_	_	I-Claim
485	in	_	_	I-Claim
486	the	_	_	I-Claim
487	surgical	_	_	I-Claim
488	and	_	_	I-Claim
489	nonsurgical	_	_	I-Claim
490	arms	_	_	I-Claim
491	eliminated	_	_	I-Claim
492	the	_	_	I-Claim
493	usual	_	_	I-Claim
494	biases	_	_	I-Claim
495	from	_	_	I-Claim
496	clinical	_	_	I-Claim
497	staging	_	_	I-Claim
498	.	_	_	I-Claim

499	In	_	_	O
500	this	_	_	O
501	setting	_	_	O
502	,	_	_	O
503	local	_	_	B-Claim
504	control	_	_	I-Claim
505	and	_	_	I-Claim
506	survival	_	_	I-Claim
507	were	_	_	I-Claim
508	essentially	_	_	I-Claim
509	equal	_	_	I-Claim
510	between	_	_	I-Claim
511	the	_	_	I-Claim
512	surgical	_	_	I-Claim
513	and	_	_	I-Claim
514	RT	_	_	I-Claim
515	arms	_	_	I-Claim
516	.	_	_	I-Claim

517	The	_	_	B-Claim
518	3-	_	_	I-Claim
519	and	_	_	I-Claim
520	5-year	_	_	I-Claim
521	survival	_	_	I-Claim
522	rates	_	_	I-Claim
523	of	_	_	I-Claim
524	nonsurgical	_	_	I-Claim
525	therapy	_	_	I-Claim
526	were	_	_	I-Claim
527	comparable	_	_	I-Claim
528	to	_	_	I-Claim
529	published	_	_	I-Claim
530	surgical	_	_	I-Claim
531	trials	_	_	I-Claim
532	of	_	_	I-Claim
533	N2	_	_	I-Claim
534	disease	_	_	I-Claim
535	.	_	_	I-Claim


0	Amitriptyline	_	_	B-Claim
1	is	_	_	I-Claim
2	the	_	_	I-Claim
3	most	_	_	I-Claim
4	common	_	_	I-Claim
5	analgesic	_	_	I-Claim
6	adjuvant	_	_	I-Claim
7	used	_	_	I-Claim
8	in	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	neuropathic	_	_	I-Claim
13	pain	_	_	I-Claim
14	,	_	_	I-Claim
15	even	_	_	O
16	though	_	_	O
17	no	_	_	B-Claim
18	specific	_	_	I-Claim
19	studies	_	_	I-Claim
20	have	_	_	I-Claim
21	demonstrated	_	_	I-Claim
22	a	_	_	I-Claim
23	benefit	_	_	I-Claim
24	.	_	_	I-Claim

25	A	_	_	O
26	randomized	_	_	O
27	placebo-controlled	_	_	O
28	,	_	_	O
29	double-blind	_	_	O
30	crossover	_	_	O
31	study	_	_	O
32	was	_	_	O
33	designed	_	_	O
34	to	_	_	O
35	evidence	_	_	O
36	the	_	_	O
37	effects	_	_	O
38	of	_	_	O
39	amitriptyline	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	neuropathic	_	_	O
44	cancer	_	_	O
45	pain	_	_	O
46	.	_	_	O

47	Sixteen	_	_	O
48	advanced	_	_	O
49	cancer	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	neuropathic	_	_	O
53	pain	_	_	O
54	on	_	_	O
55	systemic	_	_	O
56	morphine	_	_	O
57	therapy	_	_	O
58	,	_	_	O
59	no	_	_	O
60	longer	_	_	O
61	receiving	_	_	O
62	oncologic	_	_	O
63	treatment	_	_	O
64	,	_	_	O
65	presenting	_	_	O
66	moderate	_	_	O
67	pain	_	_	O
68	(	_	_	O
69	about	_	_	O
70	4	_	_	O
71	or	_	_	O
72	more	_	_	O
73	,	_	_	O
74	but	_	_	O
75	less	_	_	O
76	than	_	_	O
77	7	_	_	O
78	,	_	_	O
79	on	_	_	O
80	a	_	_	O
81	numerical	_	_	O
82	scale	_	_	O
83	of	_	_	O
84	0-10	_	_	O
85	)	_	_	O
86	in	_	_	O
87	the	_	_	O
88	last	_	_	O
89	week	_	_	O
90	,	_	_	O
91	and	_	_	O
92	given	_	_	O
93	a	_	_	O
94	stable	_	_	O
95	morphine	_	_	O
96	dose	_	_	O
97	in	_	_	O
98	the	_	_	O
99	last	_	_	O
100	2	_	_	O
101	days	_	_	O
102	were	_	_	O
103	admitted	_	_	O
104	to	_	_	O
105	the	_	_	O
106	study	_	_	O
107	.	_	_	O

108	During	_	_	O
109	the	_	_	O
110	first	_	_	O
111	week	_	_	O
112	of	_	_	O
113	study	_	_	O
114	,	_	_	O
115	patients	_	_	O
116	were	_	_	O
117	administered	_	_	O
118	25	_	_	O
119	mg	_	_	O
120	of	_	_	O
121	amitriptyline	_	_	O
122	or	_	_	O
123	equivalent	_	_	O
124	drops	_	_	O
125	of	_	_	O
126	placebo	_	_	O
127	at	_	_	O
128	night	_	_	O
129	for	_	_	O
130	3	_	_	O
131	days	_	_	O
132	and	_	_	O
133	50	_	_	O
134	mg	_	_	O
135	for	_	_	O
136	the	_	_	O
137	following	_	_	O
138	4	_	_	O
139	days	_	_	O
140	.	_	_	O

141	Doses	_	_	O
142	for	_	_	O
143	patients	_	_	O
144	aged	_	_	O
145	more	_	_	O
146	than	_	_	O
147	65	_	_	O
148	years	_	_	O
149	were	_	_	O
150	15	_	_	O
151	mg	_	_	O
152	(	_	_	O
153	first	_	_	O
154	3	_	_	O
155	days	_	_	O
156	)	_	_	O
157	and	_	_	O
158	30	_	_	O
159	mg	_	_	O
160	(	_	_	O
161	3	_	_	O
162	days	_	_	O
163	after	_	_	O
164	)	_	_	O
165	.	_	_	O

166	After	_	_	O
167	a	_	_	O
168	week	_	_	O
169	,	_	_	O
170	a	_	_	O
171	crossover	_	_	O
172	took	_	_	O
173	place	_	_	O
174	for	_	_	O
175	the	_	_	O
176	second	_	_	O
177	week	_	_	O
178	,	_	_	O
179	with	_	_	O
180	the	_	_	O
181	other	_	_	O
182	treatment	_	_	O
183	at	_	_	O
184	an	_	_	O
185	inverse	_	_	O
186	sequence	_	_	O
187	.	_	_	O

188	Opioid	_	_	O
189	consumption	_	_	O
190	,	_	_	O
191	pain	_	_	O
192	intensity	_	_	O
193	,	_	_	O
194	symptoms	_	_	O
195	and	_	_	O
196	adverse	_	_	O
197	effects	_	_	O
198	,	_	_	O
199	mood	_	_	O
200	,	_	_	O
201	sleep	_	_	O
202	,	_	_	O
203	patient	_	_	O
204	's	_	_	O
205	preference	_	_	O
206	,	_	_	O
207	quality	_	_	O
208	of	_	_	O
209	life	_	_	O
210	before	_	_	O
211	starting	_	_	O
212	the	_	_	O
213	study	_	_	O
214	,	_	_	O
215	the	_	_	O
216	first	_	_	O
217	week	_	_	O
218	after	_	_	O
219	and	_	_	O
220	the	_	_	O
221	second	_	_	O
222	week	_	_	O
223	after	_	_	O
224	were	_	_	O
225	recorded	_	_	O
226	.	_	_	O

227	No	_	_	B-Premise
228	significant	_	_	I-Premise
229	benefits	_	_	I-Premise
230	in	_	_	I-Premise
231	analgesia	_	_	I-Premise
232	were	_	_	I-Premise
233	found	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	global	_	_	I-Premise
237	pain	_	_	I-Premise
238	intensity	_	_	I-Premise
239	of	_	_	I-Premise
240	the	_	_	I-Premise
241	previous	_	_	I-Premise
242	week	_	_	I-Premise
243	of	_	_	I-Premise
244	treatment	_	_	I-Premise
245	,	_	_	I-Premise
246	the	_	_	I-Premise
247	least	_	_	I-Premise
248	pain	_	_	I-Premise
249	intensity	_	_	I-Premise
250	or	_	_	I-Premise
251	the	_	_	I-Premise
252	pain	_	_	I-Premise
253	evaluated	_	_	I-Premise
254	just	_	_	I-Premise
255	after	_	_	I-Premise
256	a	_	_	I-Premise
257	week	_	_	I-Premise
258	of	_	_	I-Premise
259	treatment	_	_	I-Premise
260	,	_	_	I-Premise
261	at	_	_	I-Premise
262	the	_	_	I-Premise
263	moment	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	visit	_	_	I-Premise
267	,	_	_	I-Premise
268	when	_	_	I-Premise
269	amitriptyline	_	_	I-Premise
270	was	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	placebo	_	_	I-Premise
274	.	_	_	I-Premise

275	A	_	_	B-Premise
276	significant	_	_	I-Premise
277	difference	_	_	I-Premise
278	was	_	_	I-Premise
279	evidenced	_	_	I-Premise
280	for	_	_	I-Premise
281	the	_	_	I-Premise
282	worst	_	_	I-Premise
283	pain	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0.035	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	No	_	_	B-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	opioid	_	_	I-Premise
294	doses	_	_	I-Premise
295	during	_	_	I-Premise
296	the	_	_	I-Premise
297	period	_	_	I-Premise
298	of	_	_	I-Premise
299	study	_	_	I-Premise
300	were	_	_	I-Premise
301	found	_	_	I-Premise
302	.	_	_	I-Premise

303	Drowsiness	_	_	B-Premise
304	,	_	_	I-Premise
305	confusion	_	_	I-Premise
306	and	_	_	I-Premise
307	dry	_	_	I-Premise
308	mouth	_	_	I-Premise
309	were	_	_	I-Premise
310	significantly	_	_	I-Premise
311	more	_	_	I-Premise
312	intense	_	_	I-Premise
313	with	_	_	I-Premise
314	amitriptyline	_	_	I-Premise
315	than	_	_	I-Premise
316	with	_	_	I-Premise
317	placebo	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	0.036	_	_	I-Premise
322	,	_	_	I-Premise
323	0.003	_	_	I-Premise
324	,	_	_	I-Premise
325	and	_	_	I-Premise
326	0.034	_	_	I-Premise
327	,	_	_	I-Premise
328	respectively	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	There	_	_	B-Premise
332	were	_	_	I-Premise
333	no	_	_	I-Premise
334	substantial	_	_	I-Premise
335	differences	_	_	I-Premise
336	between	_	_	I-Premise
337	the	_	_	I-Premise
338	two	_	_	I-Premise
339	treatments	_	_	I-Premise
340	in	_	_	I-Premise
341	Spitzer	_	_	I-Premise
342	's	_	_	I-Premise
343	quality	_	_	I-Premise
344	of	_	_	I-Premise
345	life	_	_	I-Premise
346	score	_	_	I-Premise
347	and	_	_	I-Premise
348	for	_	_	I-Premise
349	each	_	_	I-Premise
350	item	_	_	I-Premise
351	.	_	_	I-Premise

352	No	_	_	B-Premise
353	differences	_	_	I-Premise
354	in	_	_	I-Premise
355	patients	_	_	I-Premise
356	'	_	_	I-Premise
357	preference	_	_	I-Premise
358	for	_	_	I-Premise
359	the	_	_	I-Premise
360	two	_	_	I-Premise
361	treatment	_	_	I-Premise
362	periods	_	_	I-Premise
363	were	_	_	I-Premise
364	found	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Claim
367	analgesic	_	_	I-Claim
368	effects	_	_	I-Claim
369	of	_	_	I-Claim
370	amitriptyline	_	_	I-Claim
371	were	_	_	I-Claim
372	slight	_	_	I-Claim
373	and	_	_	I-Claim
374	associated	_	_	I-Claim
375	with	_	_	I-Claim
376	adverse	_	_	I-Claim
377	effects	_	_	I-Claim
378	.	_	_	I-Claim

379	In	_	_	O
380	light	_	_	O
381	of	_	_	O
382	the	_	_	O
383	results	_	_	O
384	obtained	_	_	O
385	in	_	_	O
386	the	_	_	O
387	study	_	_	O
388	,	_	_	O
389	the	_	_	B-Claim
390	extensive	_	_	I-Claim
391	use	_	_	I-Claim
392	of	_	_	I-Claim
393	the	_	_	I-Claim
394	drug	_	_	I-Claim
395	for	_	_	I-Claim
396	cancer	_	_	I-Claim
397	pain	_	_	I-Claim
398	should	_	_	I-Claim
399	be	_	_	I-Claim
400	questioned	_	_	I-Claim
401	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	,	_	_	I-Claim
2	highly	_	_	I-Claim
3	common	_	_	I-Claim
4	among	_	_	I-Claim
5	cancer	_	_	I-Claim
6	patients	_	_	I-Claim
7	,	_	_	I-Claim
8	is	_	_	I-Claim
9	often	_	_	I-Claim
10	an	_	_	I-Claim
11	underlying	_	_	I-Claim
12	cause	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer-related	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	and	_	_	I-Claim
17	other	_	_	I-Claim
18	quality-of-life	_	_	I-Claim
19	(	_	_	I-Claim
20	QOL	_	_	I-Claim
21	)	_	_	I-Claim
22	deficits	_	_	I-Claim
23	.	_	_	I-Claim

24	Although	_	_	O
25	randomized	_	_	O
26	clinical	_	_	O
27	trials	_	_	O
28	have	_	_	O
29	shown	_	_	O
30	that	_	_	O
31	treatment	_	_	O
32	with	_	_	O
33	epoetin	_	_	O
34	alfa	_	_	O
35	increases	_	_	O
36	hemoglobin	_	_	O
37	levels	_	_	O
38	,	_	_	O
39	reduces	_	_	O
40	fatigue	_	_	O
41	,	_	_	O
42	lessens	_	_	O
43	transfusion	_	_	O
44	requirements	_	_	O
45	,	_	_	O
46	and	_	_	O
47	improves	_	_	O
48	overall	_	_	O
49	QOL	_	_	O
50	,	_	_	O
51	cancer-related	_	_	O
52	anemia	_	_	O
53	and	_	_	O
54	fatigue	_	_	O
55	remain	_	_	O
56	undertreated	_	_	O
57	.	_	_	O

58	This	_	_	O
59	is	_	_	O
60	,	_	_	O
61	in	_	_	O
62	part	_	_	O
63	,	_	_	O
64	because	_	_	O
65	scales	_	_	O
66	and	_	_	O
67	measures	_	_	O
68	of	_	_	O
69	QOL	_	_	O
70	are	_	_	O
71	still	_	_	O
72	relatively	_	_	O
73	unfamiliar	_	_	O
74	to	_	_	O
75	most	_	_	O
76	clinicians	_	_	O
77	and	_	_	O
78	because	_	_	O
79	population-based	_	_	O
80	reference	_	_	O
81	ranges	_	_	O
82	are	_	_	O
83	lacking	_	_	O
84	,	_	_	O
85	thus	_	_	O
86	making	_	_	O
87	clinical	_	_	O
88	trial	_	_	O
89	results	_	_	O
90	difficult	_	_	O
91	to	_	_	O
92	interpret	_	_	O
93	.	_	_	O

94	To	_	_	O
95	aid	_	_	O
96	in	_	_	O
97	the	_	_	O
98	interpretation	_	_	O
99	of	_	_	O
100	QOL	_	_	O
101	results	_	_	O
102	from	_	_	O
103	clinical	_	_	O
104	trials	_	_	O
105	,	_	_	O
106	we	_	_	O
107	administered	_	_	O
108	the	_	_	O
109	Functional	_	_	O
110	Assessment	_	_	O
111	of	_	_	O
112	Cancer	_	_	O
113	Therapy-Anemia	_	_	O
114	(	_	_	O
115	FACT-An	_	_	O
116	)	_	_	O
117	QOL	_	_	O
118	instrument	_	_	O
119	to	_	_	O
120	a	_	_	O
121	nationally	_	_	O
122	representative	_	_	O
123	sample	_	_	O
124	of	_	_	O
125	1,400	_	_	O
126	people	_	_	O
127	using	_	_	O
128	an	_	_	O
129	Internet	_	_	O
130	survey	_	_	O
131	panel	_	_	O
132	in	_	_	O
133	the	_	_	O
134	United	_	_	O
135	States	_	_	O
136	.	_	_	O

137	We	_	_	O
138	then	_	_	O
139	compared	_	_	O
140	the	_	_	O
141	FACT-An	_	_	O
142	data	_	_	O
143	from	_	_	O
144	the	_	_	O
145	Internet	_	_	O
146	survey	_	_	O
147	with	_	_	O
148	the	_	_	O
149	QOL	_	_	O
150	data	_	_	O
151	of	_	_	O
152	a	_	_	O
153	375-patient	_	_	O
154	randomized	_	_	O
155	,	_	_	O
156	double-blind	_	_	O
157	clinical	_	_	O
158	trial	_	_	O
159	evaluating	_	_	O
160	epoetin	_	_	O
161	alfa	_	_	O
162	versus	_	_	O
163	placebo	_	_	O
164	in	_	_	O
165	anemic	_	_	O
166	cancer	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	FACT-An	_	_	O
170	,	_	_	O
171	as	_	_	O
172	administered	_	_	O
173	to	_	_	O
174	the	_	_	O
175	survey	_	_	O
176	population	_	_	O
177	,	_	_	O
178	displayed	_	_	O
179	good	_	_	O
180	psychometric	_	_	O
181	properties	_	_	O
182	and	_	_	O
183	was	_	_	O
184	able	_	_	O
185	to	_	_	O
186	discriminate	_	_	O
187	between	_	_	O
188	respondents	_	_	O
189	with	_	_	O
190	histories	_	_	O
191	of	_	_	O
192	specified	_	_	O
193	illnesses	_	_	O
194	,	_	_	O
195	including	_	_	O
196	anemia	_	_	O
197	and	_	_	O
198	cancer	_	_	O
199	,	_	_	O
200	and	_	_	O
201	those	_	_	O
202	without	_	_	O
203	.	_	_	O

204	Comparison	_	_	B-Premise
205	of	_	_	I-Premise
206	the	_	_	I-Premise
207	population	_	_	I-Premise
208	norm	_	_	I-Premise
209	and	_	_	I-Premise
210	clinical	_	_	I-Premise
211	trial	_	_	I-Premise
212	data	_	_	I-Premise
213	showed	_	_	I-Premise
214	that	_	_	I-Premise
215	treatment	_	_	I-Premise
216	with	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	alfa	_	_	I-Premise
219	resulted	_	_	I-Premise
220	in	_	_	I-Premise
221	clinically	_	_	I-Premise
222	meaningful	_	_	I-Premise
223	as	_	_	I-Premise
224	well	_	_	I-Premise
225	as	_	_	I-Premise
226	statistically	_	_	I-Premise
227	significant	_	_	I-Premise
228	improvements	_	_	I-Premise
229	in	_	_	I-Premise
230	QOL	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	.01	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Reliable	_	_	O
238	population	_	_	O
239	norm	_	_	O
240	data	_	_	O
241	are	_	_	O
242	now	_	_	O
243	available	_	_	O
244	to	_	_	O
245	aid	_	_	O
246	in	_	_	O
247	the	_	_	O
248	interpretation	_	_	O
249	of	_	_	O
250	clinical	_	_	O
251	trial	_	_	O
252	results	_	_	O
253	where	_	_	O
254	the	_	_	O
255	FACT-An	_	_	O
256	questionnaire	_	_	O
257	is	_	_	O
258	administered	_	_	O
259	.	_	_	O

260	In	_	_	B-Claim
261	the	_	_	I-Claim
262	clinical	_	_	I-Claim
263	trial	_	_	I-Claim
264	,	_	_	I-Claim
265	treatment	_	_	I-Claim
266	with	_	_	I-Claim
267	epoetin	_	_	I-Claim
268	alfa	_	_	I-Claim
269	overcame	_	_	I-Claim
270	much	_	_	I-Claim
271	of	_	_	I-Claim
272	the	_	_	I-Claim
273	QOL	_	_	I-Claim
274	deficit	_	_	I-Claim
275	seen	_	_	I-Claim
276	in	_	_	I-Claim
277	anemic	_	_	I-Claim
278	cancer	_	_	I-Claim
279	patients	_	_	I-Claim
280	compared	_	_	I-Claim
281	with	_	_	I-Claim
282	the	_	_	I-Claim
283	norm	_	_	I-Claim
284	population	_	_	I-Claim
285	sample	_	_	I-Claim
286	.	_	_	I-Claim


0	A	_	_	O
1	multicenter	_	_	O
2	trial	_	_	O
3	was	_	_	O
4	conducted	_	_	O
5	to	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	toxicity	_	_	O
11	of	_	_	O
12	escalating	_	_	O
13	dosages	_	_	O
14	of	_	_	O
15	liposomal	_	_	O
16	tretinoin	_	_	O
17	(	_	_	O
18	all-trans-retinoic	_	_	O
19	acid	_	_	O
20	)	_	_	O
21	administered	_	_	O
22	once	_	_	O
23	or	_	_	O
24	three	_	_	O
25	times	_	_	O
26	weekly	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	acquired	_	_	O
31	immunodeficiency	_	_	O
32	syndrome	_	_	O
33	(	_	_	O
34	AIDS	_	_	O
35	)	_	_	O
36	-associated	_	_	O
37	Kaposi	_	_	O
38	sarcoma	_	_	O
39	.	_	_	O

40	Seventy-six	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	acquired	_	_	O
44	immunodeficiency	_	_	O
45	syndrome	_	_	O
46	(	_	_	O
47	AIDS	_	_	O
48	)	_	_	O
49	-associated	_	_	O
50	Kaposi	_	_	O
51	sarcoma	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	the	_	_	O
57	study	_	_	O
58	drug	_	_	O
59	either	_	_	O
60	once	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	30	_	_	O
65	)	_	_	O
66	or	_	_	O
67	3	_	_	O
68	times	_	_	O
69	weekly	_	_	O
70	(	_	_	O
71	n	_	_	O
72	=	_	_	O
73	46	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	starting	_	_	O
78	dosage	_	_	O
79	was	_	_	O
80	60	_	_	O
81	mg/m	_	_	O
82	(	_	_	O
83	2	_	_	O
84	)	_	_	O
85	,	_	_	O
86	which	_	_	O
87	was	_	_	O
88	escalated	_	_	O
89	to	_	_	O
90	90	_	_	O
91	mg/m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	and	_	_	O
96	then	_	_	O
97	120	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	if	_	_	O
103	the	_	_	O
104	drug	_	_	O
105	was	_	_	O
106	well	_	_	O
107	tolerated	_	_	O
108	(	_	_	O
109	<	_	_	O
110	or=	_	_	O
111	Grade	_	_	O
112	2	_	_	O
113	toxicities	_	_	O
114	[	_	_	O
115	according	_	_	O
116	to	_	_	O
117	the	_	_	O
118	Southwest	_	_	O
119	Oncology	_	_	O
120	Group	_	_	O
121	toxicity	_	_	O
122	scale	_	_	O
123	]	_	_	O
124	)	_	_	O
125	.	_	_	O

126	Four	_	_	O
127	weeks	_	_	O
128	of	_	_	O
129	therapy	_	_	O
130	constituted	_	_	O
131	1	_	_	O
132	cycle	_	_	O
133	;	_	_	O
134	patients	_	_	O
135	could	_	_	O
136	receive	_	_	O
137	up	_	_	O
138	to	_	_	O
139	8	_	_	O
140	cycles	_	_	O
141	and	_	_	O
142	those	_	_	O
143	who	_	_	O
144	completed	_	_	O
145	8	_	_	O
146	cycles	_	_	O
147	were	_	_	O
148	given	_	_	O
149	the	_	_	O
150	option	_	_	O
151	of	_	_	O
152	receiving	_	_	O
153	extended	_	_	O
154	therapy	_	_	O
155	.	_	_	O

156	Clinical	_	_	O
157	response	_	_	O
158	was	_	_	O
159	defined	_	_	O
160	as	_	_	O
161	complete	_	_	O
162	response	_	_	O
163	(	_	_	O
164	CR	_	_	O
165	)	_	_	O
166	,	_	_	O
167	partial	_	_	O
168	response	_	_	O
169	(	_	_	O
170	PR	_	_	O
171	)	_	_	O
172	,	_	_	O
173	or	_	_	O
174	stable	_	_	O
175	disease	_	_	O
176	(	_	_	O
177	SD	_	_	O
178	)	_	_	O
179	.	_	_	O

180	Efficacy	_	_	O
181	was	_	_	O
182	assessed	_	_	O
183	after	_	_	O
184	the	_	_	O
185	completion	_	_	O
186	of	_	_	O
187	3	_	_	O
188	treatment	_	_	O
189	cycles	_	_	O
190	;	_	_	O
191	28.9	_	_	O
192	%	_	_	O
193	of	_	_	O
194	patients	_	_	O
195	(	_	_	O
196	22	_	_	O
197	of	_	_	O
198	76	_	_	O
199	patients	_	_	O
200	)	_	_	O
201	responded	_	_	O
202	(	_	_	O
203	no	_	_	O
204	CRs	_	_	O
205	,	_	_	O
206	1	_	_	O
207	PR	_	_	O
208	,	_	_	O
209	and	_	_	O
210	21	_	_	O
211	SDs	_	_	O
212	)	_	_	O
213	.	_	_	O

214	Among	_	_	B-Premise
215	the	_	_	I-Premise
216	patients	_	_	I-Premise
217	receiving	_	_	I-Premise
218	treatment	_	_	I-Premise
219	3	_	_	I-Premise
220	times	_	_	I-Premise
221	weekly	_	_	I-Premise
222	,	_	_	I-Premise
223	16	_	_	I-Premise
224	of	_	_	I-Premise
225	49	_	_	I-Premise
226	patients	_	_	I-Premise
227	(	_	_	I-Premise
228	32.7	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	achieved	_	_	I-Premise
232	a	_	_	I-Premise
233	clinical	_	_	I-Premise
234	response	_	_	I-Premise
235	at	_	_	I-Premise
236	the	_	_	I-Premise
237	end	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	third	_	_	I-Premise
241	treatment	_	_	I-Premise
242	cycle	_	_	I-Premise
243	(	_	_	I-Premise
244	no	_	_	I-Premise
245	CRs	_	_	I-Premise
246	,	_	_	I-Premise
247	1	_	_	I-Premise
248	PR	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	15	_	_	I-Premise
252	SDs	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Concomitant	_	_	B-Premise
256	or	_	_	I-Premise
257	prior	_	_	I-Premise
258	use	_	_	I-Premise
259	of	_	_	I-Premise
260	protease	_	_	I-Premise
261	inhibitors	_	_	I-Premise
262	did	_	_	I-Premise
263	not	_	_	I-Premise
264	appear	_	_	I-Premise
265	to	_	_	I-Premise
266	affect	_	_	I-Premise
267	the	_	_	I-Premise
268	patient	_	_	I-Premise
269	's	_	_	I-Premise
270	response	_	_	I-Premise
271	to	_	_	I-Premise
272	treatment	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	0.183	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Liposomal	_	_	B-Premise
280	tretinoin	_	_	I-Premise
281	is	_	_	I-Premise
282	a	_	_	I-Premise
283	new	_	_	I-Premise
284	therapeutic	_	_	I-Premise
285	agent	_	_	I-Premise
286	that	_	_	I-Premise
287	has	_	_	I-Premise
288	been	_	_	I-Premise
289	reported	_	_	I-Premise
290	to	_	_	I-Premise
291	have	_	_	I-Premise
292	some	_	_	I-Premise
293	clinical	_	_	I-Premise
294	activity	_	_	I-Premise
295	in	_	_	I-Premise
296	patients	_	_	I-Premise
297	with	_	_	I-Premise
298	AIDS-associated	_	_	I-Premise
299	Kaposi	_	_	I-Premise
300	sarcoma	_	_	I-Premise
301	.	_	_	I-Premise

302	A	_	_	B-Claim
303	three-times-per-week	_	_	I-Claim
304	dosing	_	_	I-Claim
305	schedule	_	_	I-Claim
306	was	_	_	I-Claim
307	noted	_	_	I-Claim
308	to	_	_	I-Claim
309	be	_	_	I-Claim
310	more	_	_	I-Claim
311	effective	_	_	I-Claim
312	compared	_	_	I-Claim
313	with	_	_	I-Claim
314	a	_	_	I-Claim
315	once-a-week	_	_	I-Claim
316	schedule	_	_	I-Claim
317	without	_	_	I-Claim
318	any	_	_	I-Claim
319	significant	_	_	I-Claim
320	difference	_	_	I-Claim
321	in	_	_	I-Claim
322	toxicity	_	_	I-Claim
323	reported	_	_	I-Claim
324	.	_	_	I-Claim


0	Chronic	_	_	O
1	gastrointestinal	_	_	O
2	symptoms	_	_	O
3	after	_	_	O
4	pelvic	_	_	O
5	radiotherapy	_	_	O
6	are	_	_	O
7	common	_	_	O
8	,	_	_	O
9	multifactorial	_	_	O
10	in	_	_	O
11	cause	_	_	O
12	,	_	_	O
13	and	_	_	O
14	affect	_	_	O
15	patients	_	_	O
16	'	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	.	_	_	O

21	We	_	_	O
22	assessed	_	_	O
23	whether	_	_	O
24	such	_	_	O
25	patients	_	_	O
26	could	_	_	O
27	be	_	_	O
28	helped	_	_	O
29	if	_	_	O
30	a	_	_	O
31	practitioner	_	_	O
32	followed	_	_	O
33	an	_	_	O
34	investigative	_	_	O
35	and	_	_	O
36	management	_	_	O
37	algorithm	_	_	O
38	,	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	outcomes	_	_	O
42	differed	_	_	O
43	by	_	_	O
44	whether	_	_	O
45	a	_	_	O
46	nurse	_	_	O
47	or	_	_	O
48	a	_	_	O
49	gastroenterologist	_	_	O
50	led	_	_	O
51	this	_	_	O
52	algorithm-based	_	_	O
53	care	_	_	O
54	.	_	_	O

55	For	_	_	O
56	this	_	_	O
57	three-arm	_	_	O
58	randomised	_	_	O
59	controlled	_	_	O
60	trial	_	_	O
61	we	_	_	O
62	recruited	_	_	O
63	patients	_	_	O
64	(	_	_	O
65	aged	_	_	O
66	â‰¥18	_	_	O
67	years	_	_	O
68	)	_	_	O
69	from	_	_	O
70	clinics	_	_	O
71	in	_	_	O
72	London	_	_	O
73	,	_	_	O
74	UK	_	_	O
75	,	_	_	O
76	with	_	_	O
77	new-onset	_	_	O
78	gastrointestinal	_	_	O
79	symptoms	_	_	O
80	persisting	_	_	O
81	6	_	_	O
82	months	_	_	O
83	after	_	_	O
84	pelvic	_	_	O
85	radiotherapy	_	_	O
86	.	_	_	O

87	Using	_	_	O
88	a	_	_	O
89	computer-generated	_	_	O
90	randomisation	_	_	O
91	sequence	_	_	O
92	,	_	_	O
93	we	_	_	O
94	randomly	_	_	O
95	allocated	_	_	O
96	patients	_	_	O
97	to	_	_	O
98	one	_	_	O
99	of	_	_	O
100	three	_	_	O
101	groups	_	_	O
102	(	_	_	O
103	1:1:1	_	_	O
104	;	_	_	O
105	stratified	_	_	O
106	by	_	_	O
107	tumour	_	_	O
108	site	_	_	O
109	[	_	_	O
110	urological	_	_	O
111	,	_	_	O
112	gynaecological	_	_	O
113	,	_	_	O
114	or	_	_	O
115	gastrointestinal	_	_	O
116	]	_	_	O
117	,	_	_	O
118	and	_	_	O
119	degree	_	_	O
120	of	_	_	O
121	bowel	_	_	O
122	dysfunction	_	_	O
123	[	_	_	O
124	IBDQ-B	_	_	O
125	score	_	_	O
126	<	_	_	O
127	60	_	_	O
128	vs	_	_	O
129	60-70	_	_	O
130	]	_	_	O
131	)	_	_	O
132	:	_	_	O
133	usual	_	_	O
134	care	_	_	O
135	(	_	_	O
136	a	_	_	O
137	detailed	_	_	O
138	self-help	_	_	O
139	booklet	_	_	O
140	)	_	_	O
141	,	_	_	O
142	gastroenterologist-led	_	_	O
143	algorithm-based	_	_	O
144	treatment	_	_	O
145	,	_	_	O
146	or	_	_	O
147	nurse-led	_	_	O
148	algorithm-based	_	_	O
149	treatment	_	_	O
150	.	_	_	O

151	The	_	_	O
152	primary	_	_	O
153	endpoint	_	_	O
154	was	_	_	O
155	change	_	_	O
156	in	_	_	O
157	Inflammatory	_	_	O
158	Bowel	_	_	O
159	Disease	_	_	O
160	Questionnaire-Bowel	_	_	O
161	subset	_	_	O
162	score	_	_	O
163	(	_	_	O
164	IBDQ-B	_	_	O
165	)	_	_	O
166	at	_	_	O
167	6	_	_	O
168	months	_	_	O
169	,	_	_	O
170	analysed	_	_	O
171	by	_	_	O
172	intention	_	_	O
173	to	_	_	O
174	treat	_	_	O
175	.	_	_	O

176	Between	_	_	O
177	Nov	_	_	O
178	26	_	_	O
179	,	_	_	O
180	2007	_	_	O
181	,	_	_	O
182	and	_	_	O
183	Dec	_	_	O
184	12	_	_	O
185	,	_	_	O
186	2011	_	_	O
187	,	_	_	O
188	we	_	_	O
189	enrolled	_	_	O
190	and	_	_	O
191	randomly	_	_	O
192	allocated	_	_	O
193	218	_	_	O
194	patients	_	_	O
195	to	_	_	O
196	treatment	_	_	O
197	:	_	_	O
198	80	_	_	O
199	to	_	_	O
200	the	_	_	O
201	nurse	_	_	O
202	group	_	_	O
203	,	_	_	O
204	70	_	_	O
205	to	_	_	O
206	the	_	_	O
207	gastroenterologist	_	_	O
208	group	_	_	O
209	,	_	_	O
210	and	_	_	O
211	68	_	_	O
212	to	_	_	O
213	the	_	_	O
214	booklet	_	_	O
215	group	_	_	O
216	(	_	_	O
217	figure	_	_	O
218	)	_	_	O
219	.	_	_	O

220	Most	_	_	O
221	had	_	_	O
222	a	_	_	O
223	baseline	_	_	O
224	IBDQ-B	_	_	O
225	score	_	_	O
226	indicating	_	_	O
227	moderate-to-severe	_	_	O
228	symptoms	_	_	O
229	.	_	_	O

230	We	_	_	B-Premise
231	recorded	_	_	I-Premise
232	the	_	_	I-Premise
233	following	_	_	I-Premise
234	pair-wise	_	_	I-Premise
235	mean	_	_	I-Premise
236	difference	_	_	I-Premise
237	in	_	_	I-Premise
238	change	_	_	I-Premise
239	in	_	_	I-Premise
240	IBDQ-B	_	_	I-Premise
241	score	_	_	I-Premise
242	between	_	_	I-Premise
243	groups	_	_	I-Premise
244	:	_	_	I-Premise
245	nurse	_	_	I-Premise
246	versus	_	_	I-Premise
247	booklet	_	_	I-Premise
248	4Â·12	_	_	I-Premise
249	(	_	_	I-Premise
250	95	_	_	I-Premise
251	%	_	_	I-Premise
252	CI	_	_	I-Premise
253	0Â·04-8Â·19	_	_	I-Premise
254	;	_	_	I-Premise
255	p=0Â·04	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	gastroenterologist	_	_	I-Premise
259	versus	_	_	I-Premise
260	booklet	_	_	I-Premise
261	5Â·47	_	_	I-Premise
262	(	_	_	I-Premise
263	1Â·14-9Â·81	_	_	I-Premise
264	;	_	_	I-Premise
265	p=0Â·01	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	Outcomes	_	_	B-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	nurse	_	_	I-Premise
272	group	_	_	I-Premise
273	were	_	_	I-Premise
274	not	_	_	I-Premise
275	inferior	_	_	I-Premise
276	to	_	_	I-Premise
277	outcomes	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	gastroenterologist	_	_	I-Premise
281	group	_	_	I-Premise
282	(	_	_	I-Premise
283	mean	_	_	I-Premise
284	difference	_	_	I-Premise
285	1Â·36	_	_	I-Premise
286	,	_	_	I-Premise
287	one	_	_	I-Premise
288	sided	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	-1Â·48	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Patients	_	_	B-Claim
296	given	_	_	I-Claim
297	targeted	_	_	I-Claim
298	intervention	_	_	I-Claim
299	following	_	_	I-Claim
300	a	_	_	I-Claim
301	detailed	_	_	I-Claim
302	clinical	_	_	I-Claim
303	algorithm	_	_	I-Claim
304	had	_	_	I-Claim
305	better	_	_	I-Claim
306	improvements	_	_	I-Claim
307	in	_	_	I-Claim
308	radiotherapy-induced	_	_	I-Claim
309	gastrointestinal	_	_	I-Claim
310	symptoms	_	_	I-Claim
311	than	_	_	I-Claim
312	did	_	_	I-Claim
313	patients	_	_	I-Claim
314	given	_	_	I-Claim
315	usual	_	_	I-Claim
316	care	_	_	I-Claim
317	.	_	_	I-Claim

318	Our	_	_	B-Claim
319	findings	_	_	I-Claim
320	suggest	_	_	I-Claim
321	that	_	_	I-Claim
322	,	_	_	I-Claim
323	for	_	_	I-Claim
324	most	_	_	I-Claim
325	patients	_	_	I-Claim
326	,	_	_	I-Claim
327	this	_	_	I-Claim
328	algorithm-based	_	_	I-Claim
329	care	_	_	I-Claim
330	can	_	_	I-Claim
331	be	_	_	I-Claim
332	given	_	_	I-Claim
333	by	_	_	I-Claim
334	a	_	_	I-Claim
335	trained	_	_	I-Claim
336	nurse	_	_	I-Claim
337	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	analysis	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	pretreatment	_	_	O
12	factors	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	locally	_	_	O
24	advanced	_	_	O
25	nonsmall	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	(	_	_	O
30	NSCLC	_	_	O
31	)	_	_	O
32	.	_	_	O

33	In	_	_	O
34	particular	_	_	O
35	,	_	_	O
36	this	_	_	O
37	study	_	_	O
38	focused	_	_	O
39	on	_	_	O
40	the	_	_	O
41	possible	_	_	O
42	interaction	_	_	O
43	between	_	_	O
44	gender-specific	_	_	O
45	baseline	_	_	O
46	health-related	_	_	O
47	QOL	_	_	O
48	and	_	_	O
49	Karnofsky	_	_	O
50	performance	_	_	O
51	score	_	_	O
52	(	_	_	O
53	KPS	_	_	O
54	)	_	_	O
55	in	_	_	O
56	a	_	_	O
57	prospective	_	_	O
58	randomized	_	_	O
59	lung	_	_	O
60	cancer	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	QOL	_	_	O
64	information	_	_	O
65	,	_	_	O
66	using	_	_	O
67	validated	_	_	O
68	instruments	_	_	O
69	(	_	_	O
70	Functional	_	_	O
71	Assessment	_	_	O
72	of	_	_	O
73	Cancer	_	_	O
74	Therapy-Lung	_	_	O
75	[	_	_	O
76	FACT-L	_	_	O
77	]	_	_	O
78	,	_	_	O
79	version	_	_	O
80	2	_	_	O
81	,	_	_	O
82	and	_	_	O
83	Functional	_	_	O
84	Living	_	_	O
85	Index-Cancer	_	_	O
86	[	_	_	O
87	FLIC	_	_	O
88	]	_	_	O
89	)	_	_	O
90	,	_	_	O
91	was	_	_	O
92	prospectively	_	_	O
93	collected	_	_	O
94	in	_	_	O
95	patients	_	_	O
96	with	_	_	O
97	locally	_	_	O
98	advanced	_	_	O
99	NSCLC	_	_	O
100	treated	_	_	O
101	on	_	_	O
102	Radiation	_	_	O
103	Therapy	_	_	O
104	Oncology	_	_	O
105	Group	_	_	O
106	(	_	_	O
107	RTOG	_	_	O
108	)	_	_	O
109	trial	_	_	O
110	89-01	_	_	O
111	.	_	_	O

112	Between	_	_	O
113	April	_	_	O
114	1990	_	_	O
115	and	_	_	O
116	April	_	_	O
117	1994	_	_	O
118	,	_	_	O
119	70	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	participated	_	_	O
123	in	_	_	O
124	a	_	_	O
125	phase	_	_	O
126	III	_	_	O
127	trial	_	_	O
128	comparing	_	_	O
129	a	_	_	O
130	regimen	_	_	O
131	containing	_	_	O
132	sequential	_	_	O
133	chemotherapy	_	_	O
134	and	_	_	O
135	radiation	_	_	O
136	therapy	_	_	O
137	versus	_	_	O
138	sequential	_	_	O
139	chemotherapy	_	_	O
140	plus	_	_	O
141	surgery	_	_	O
142	.	_	_	O

143	Of	_	_	O
144	these	_	_	O
145	70	_	_	O
146	patients	_	_	O
147	,	_	_	O
148	46	_	_	O
149	underwent	_	_	O
150	pretreatment	_	_	O
151	FLIC	_	_	O
152	and	_	_	O
153	49	_	_	O
154	underwent	_	_	O
155	pretreatment	_	_	O
156	FACT-L	_	_	O
157	.	_	_	O

158	There	_	_	B-Premise
159	was	_	_	I-Premise
160	a	_	_	I-Premise
161	significant	_	_	I-Premise
162	interaction	_	_	I-Premise
163	between	_	_	I-Premise
164	gender	_	_	I-Premise
165	and	_	_	I-Premise
166	KPS	_	_	I-Premise
167	using	_	_	I-Premise
168	FLIC	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	=	_	_	I-Premise
172	0.009	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	which	_	_	I-Premise
176	also	_	_	I-Premise
177	showed	_	_	I-Premise
178	a	_	_	I-Premise
179	trend	_	_	I-Premise
180	toward	_	_	I-Premise
181	significance	_	_	I-Premise
182	with	_	_	I-Premise
183	FACT	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	0.09	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Significant	_	_	B-Premise
191	KPS-by-gender	_	_	I-Premise
192	interactions	_	_	I-Premise
193	were	_	_	I-Premise
194	noted	_	_	I-Premise
195	for	_	_	I-Premise
196	FACT-L	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	physical	_	_	I-Premise
200	well-being	_	_	I-Premise
201	and	_	_	I-Premise
202	additional	_	_	I-Premise
203	concerns-lung	_	_	I-Premise
204	subscales	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	0.012	_	_	I-Premise
209	and	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.0003	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	results	_	_	I-Premise
219	of	_	_	I-Premise
220	both	_	_	I-Premise
221	the	_	_	I-Premise
222	FLIC	_	_	I-Premise
223	and	_	_	I-Premise
224	FACT-L	_	_	I-Premise
225	demonstrated	_	_	I-Premise
226	significantly	_	_	I-Premise
227	lower	_	_	I-Premise
228	scores	_	_	I-Premise
229	corresponding	_	_	I-Premise
230	to	_	_	I-Premise
231	lower	_	_	I-Premise
232	KPS	_	_	I-Premise
233	values	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0.009	_	_	I-Premise
238	and	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	0.016	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Results	_	_	B-Claim
247	of	_	_	I-Claim
248	this	_	_	I-Claim
249	randomized	_	_	I-Claim
250	study	_	_	I-Claim
251	incorporating	_	_	I-Claim
252	prospective	_	_	I-Claim
253	QOL	_	_	I-Claim
254	measurements	_	_	I-Claim
255	suggested	_	_	I-Claim
256	that	_	_	I-Claim
257	in	_	_	I-Claim
258	patients	_	_	I-Claim
259	with	_	_	I-Claim
260	locally	_	_	I-Claim
261	advanced	_	_	I-Claim
262	NSCLC	_	_	I-Claim
263	,	_	_	I-Claim
264	analyzing	_	_	I-Claim
265	QOL	_	_	I-Claim
266	data	_	_	I-Claim
267	by	_	_	I-Claim
268	either	_	_	I-Claim
269	gender	_	_	I-Claim
270	or	_	_	I-Claim
271	performance	_	_	I-Claim
272	status	_	_	I-Claim
273	alone	_	_	I-Claim
274	may	_	_	I-Claim
275	not	_	_	I-Claim
276	accurately	_	_	I-Claim
277	reflect	_	_	I-Claim
278	how	_	_	I-Claim
279	these	_	_	I-Claim
280	factors	_	_	I-Claim
281	depend	_	_	I-Claim
282	upon	_	_	I-Claim
283	each	_	_	I-Claim
284	another	_	_	I-Claim
285	.	_	_	I-Claim

286	Understanding	_	_	O
287	the	_	_	O
288	interaction	_	_	O
289	between	_	_	O
290	gender	_	_	O
291	and	_	_	O
292	performance	_	_	O
293	status	_	_	O
294	could	_	_	O
295	lead	_	_	O
296	to	_	_	O
297	better	_	_	O
298	prognosticators	_	_	O
299	and	_	_	O
300	potentially	_	_	O
301	could	_	_	O
302	tailor	_	_	O
303	interventions	_	_	O
304	for	_	_	O
305	specific	_	_	O
306	groups	_	_	O
307	of	_	_	O
308	patients	_	_	O
309	with	_	_	O
310	lung	_	_	O
311	cancer	_	_	O
312	.	_	_	O


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	autologous	_	_	O
8	dendritic	_	_	O
9	cell	_	_	O
10	vaccine	_	_	O
11	(	_	_	O
12	immunotherapy	_	_	O
13	)	_	_	O
14	for	_	_	O
15	glioblastoma	_	_	O
16	multiforme	_	_	O
17	(	_	_	O
18	GBM	_	_	O
19	)	_	_	O
20	.	_	_	O

21	Patients	_	_	O
22	14	_	_	O
23	to	_	_	O
24	70	_	_	O
25	years	_	_	O
26	of	_	_	O
27	age	_	_	O
28	with	_	_	O
29	newly	_	_	O
30	diagnosed	_	_	O
31	GBM	_	_	O
32	and	_	_	O
33	Karnofsky	_	_	O
34	Performance	_	_	O
35	Scale	_	_	O
36	(	_	_	O
37	KPS	_	_	O
38	)	_	_	O
39	score	_	_	O
40	>	_	_	O
41	70	_	_	O
42	who	_	_	O
43	were	_	_	O
44	receiving	_	_	O
45	initial	_	_	O
46	treatment	_	_	O
47	were	_	_	O
48	enrolled	_	_	O
49	and	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	into	_	_	O
53	2	_	_	O
54	groups	_	_	O
55	during	_	_	O
56	the	_	_	O
57	5-year	_	_	O
58	study	_	_	O
59	period	_	_	O
60	.	_	_	O

61	Eighteen	_	_	O
62	patients	_	_	O
63	underwent	_	_	O
64	conventional	_	_	O
65	treatment	_	_	O
66	(	_	_	O
67	surgery	_	_	O
68	,	_	_	O
69	radiotherapy	_	_	O
70	,	_	_	O
71	and	_	_	O
72	chemotherapy	_	_	O
73	)	_	_	O
74	and	_	_	O
75	received	_	_	O
76	adjuvant	_	_	O
77	autologous	_	_	O
78	dendritic	_	_	O
79	cell	_	_	O
80	vaccine	_	_	O
81	,	_	_	O
82	and	_	_	O
83	16	_	_	O
84	patients	_	_	O
85	(	_	_	O
86	control	_	_	O
87	group	_	_	O
88	)	_	_	O
89	underwent	_	_	O
90	conventional	_	_	O
91	treatment	_	_	O
92	only	_	_	O
93	.	_	_	O

94	Administration	_	_	O
95	of	_	_	O
96	the	_	_	O
97	vaccine	_	_	O
98	was	_	_	O
99	begun	_	_	O
100	within	_	_	O
101	1	_	_	O
102	to	_	_	O
103	2	_	_	O
104	months	_	_	O
105	postoperatively	_	_	O
106	,	_	_	O
107	with	_	_	O
108	10	_	_	O
109	inoculations	_	_	O
110	given	_	_	O
111	over	_	_	O
112	6	_	_	O
113	months	_	_	O
114	.	_	_	O

115	Outcome	_	_	O
116	measures	_	_	O
117	were	_	_	O
118	overall	_	_	O
119	survival	_	_	O
120	(	_	_	O
121	OS	_	_	O
122	)	_	_	O
123	;	_	_	O
124	progression-free	_	_	O
125	survival	_	_	O
126	(	_	_	O
127	PFS	_	_	O
128	)	_	_	O
129	;	_	_	O
130	1-	_	_	O
131	,	_	_	O
132	2-	_	_	O
133	,	_	_	O
134	and	_	_	O
135	3-year	_	_	O
136	survival	_	_	O
137	rates	_	_	O
138	,	_	_	O
139	and	_	_	O
140	quality	_	_	O
141	of	_	_	O
142	life	_	_	O
143	(	_	_	O
144	QoL	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Follow-up	_	_	O
148	time	_	_	O
149	ranged	_	_	O
150	from	_	_	O
151	14	_	_	O
152	to	_	_	O
153	56	_	_	O
154	months	_	_	O
155	(	_	_	O
156	median	_	_	O
157	,	_	_	O
158	33	_	_	O
159	months	_	_	O
160	)	_	_	O
161	.	_	_	O

162	The	_	_	B-Premise
163	1-	_	_	I-Premise
164	,	_	_	I-Premise
165	2-	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	3-year	_	_	I-Premise
169	survival	_	_	I-Premise
170	rates	_	_	I-Premise
171	were	_	_	I-Premise
172	88.9	_	_	I-Premise
173	%	_	_	I-Premise
174	,	_	_	I-Premise
175	44.4	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	16.7	_	_	I-Premise
180	%	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	vaccine	_	_	I-Premise
184	group	_	_	I-Premise
185	,	_	_	I-Premise
186	respectively	_	_	I-Premise
187	,	_	_	I-Premise
188	and	_	_	I-Premise
189	75.0	_	_	I-Premise
190	%	_	_	I-Premise
191	,	_	_	I-Premise
192	18.8	_	_	I-Premise
193	%	_	_	I-Premise
194	,	_	_	I-Premise
195	and	_	_	I-Premise
196	0	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	,	_	_	I-Premise
201	for	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.299	_	_	I-Premise
210	,	_	_	I-Premise
211	0.0035	_	_	I-Premise
212	,	_	_	I-Premise
213	0.0014	_	_	I-Premise
214	,	_	_	I-Premise
215	respectively	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	median	_	_	I-Premise
220	OS	_	_	I-Premise
221	for	_	_	I-Premise
222	the	_	_	I-Premise
223	vaccine	_	_	I-Premise
224	group	_	_	I-Premise
225	was	_	_	I-Premise
226	31.9	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	for	_	_	I-Premise
230	the	_	_	I-Premise
231	control	_	_	I-Premise
232	group	_	_	I-Premise
233	was	_	_	I-Premise
234	15.0	_	_	I-Premise
235	months	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0.002	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	median	_	_	I-Premise
244	progression-free	_	_	I-Premise
245	survival	_	_	I-Premise
246	(	_	_	I-Premise
247	PFS	_	_	I-Premise
248	)	_	_	I-Premise
249	for	_	_	I-Premise
250	the	_	_	I-Premise
251	vaccine	_	_	I-Premise
252	group	_	_	I-Premise
253	was	_	_	I-Premise
254	8.5	_	_	I-Premise
255	months	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	8.0	_	_	I-Premise
259	months	_	_	I-Premise
260	for	_	_	I-Premise
261	the	_	_	I-Premise
262	control	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	0.075	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	surviving	_	_	I-Premise
272	fraction	_	_	I-Premise
273	was	_	_	I-Premise
274	significantly	_	_	I-Premise
275	higher	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	vaccine	_	_	I-Premise
279	group	_	_	I-Premise
280	based	_	_	I-Premise
281	on	_	_	I-Premise
282	Kaplan-Meier	_	_	I-Premise
283	analysis	_	_	I-Premise
284	.	_	_	I-Premise

285	Adjuvant	_	_	B-Claim
286	immunotherapy	_	_	I-Claim
287	with	_	_	I-Claim
288	whole-cell	_	_	I-Claim
289	lysate	_	_	I-Claim
290	dendritic	_	_	I-Claim
291	cell	_	_	I-Claim
292	vaccine	_	_	I-Claim
293	may	_	_	I-Claim
294	improve	_	_	I-Claim
295	short-term	_	_	I-Claim
296	survival	_	_	I-Claim
297	.	_	_	I-Claim

298	It	_	_	B-Claim
299	seems	_	_	I-Claim
300	to	_	_	I-Claim
301	be	_	_	I-Claim
302	safe	_	_	I-Claim
303	,	_	_	I-Claim
304	and	_	_	I-Claim
305	its	_	_	I-Claim
306	long-term	_	_	I-Claim
307	effectiveness	_	_	I-Claim
308	is	_	_	I-Claim
309	worthy	_	_	I-Claim
310	of	_	_	I-Claim
311	further	_	_	I-Claim
312	investigation	_	_	I-Claim
313	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	cancer	_	_	O
3	are	_	_	O
4	characterized	_	_	O
5	by	_	_	O
6	a	_	_	O
7	profound	_	_	O
8	impairment	_	_	O
9	of	_	_	O
10	glucose	_	_	O
11	utilization	_	_	O
12	,	_	_	O
13	with	_	_	O
14	lipids	_	_	O
15	being	_	_	O
16	the	_	_	O
17	preferred	_	_	O
18	metabolic	_	_	O
19	fuel	_	_	O
20	.	_	_	O

21	In	_	_	O
22	contrast	_	_	O
23	,	_	_	O
24	the	_	_	O
25	energy	_	_	O
26	needs	_	_	O
27	of	_	_	O
28	malignant	_	_	O
29	tumors	_	_	O
30	are	_	_	O
31	almost	_	_	O
32	entirely	_	_	O
33	met	_	_	O
34	by	_	_	O
35	glucose	_	_	O
36	.	_	_	O

37	We	_	_	O
38	therefore	_	_	O
39	studied	_	_	O
40	the	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	a	_	_	O
44	high-fat	_	_	O
45	diet	_	_	O
46	,	_	_	O
47	particularly	_	_	O
48	on	_	_	O
49	body	_	_	O
50	composition	_	_	O
51	.	_	_	O

52	Twenty-three	_	_	O
53	moderately	_	_	O
54	malnourished	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	gastrointestinal	_	_	O
58	carcinomas	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	either	_	_	O
64	a	_	_	O
65	conventional	_	_	O
66	diet	_	_	O
67	supplying	_	_	O
68	35	_	_	O
69	nonprotein	_	_	O
70	kcal	_	_	O
71	and	_	_	O
72	1.1	_	_	O
73	g	_	_	O
74	of	_	_	O
75	protein/kg	_	_	O
76	per	_	_	O
77	day	_	_	O
78	(	_	_	O
79	group	_	_	O
80	A	_	_	O
81	,	_	_	O
82	n	_	_	O
83	=	_	_	O
84	11	_	_	O
85	)	_	_	O
86	or	_	_	O
87	a	_	_	O
88	fat-enriched	_	_	O
89	artificial	_	_	O
90	liquid	_	_	O
91	diet	_	_	O
92	(	_	_	O
93	20	_	_	O
94	nonprotein	_	_	O
95	kcal/kg	_	_	O
96	per	_	_	O
97	day	_	_	O
98	)	_	_	O
99	plus	_	_	O
100	normal	_	_	O
101	meals	_	_	O
102	(	_	_	O
103	group	_	_	O
104	B	_	_	O
105	,	_	_	O
106	n	_	_	O
107	=	_	_	O
108	12	_	_	O
109	)	_	_	O
110	for	_	_	O
111	a	_	_	O
112	period	_	_	O
113	of	_	_	O
114	eight	_	_	O
115	weeks	_	_	O
116	,	_	_	O
117	i.e.	_	_	O
118	,	_	_	O
119	from	_	_	O
120	the	_	_	O
121	first	_	_	O
122	to	_	_	O
123	the	_	_	O
124	third	_	_	O
125	chemotherapy	_	_	O
126	cycle	_	_	O
127	.	_	_	O

128	The	_	_	O
129	fat	_	_	O
130	content	_	_	O
131	of	_	_	O
132	the	_	_	O
133	artificial	_	_	O
134	diet	_	_	O
135	was	_	_	O
136	66	_	_	O
137	%	_	_	O
138	of	_	_	O
139	the	_	_	O
140	nonprotein	_	_	O
141	calories	_	_	O
142	.	_	_	O

143	The	_	_	O
144	day	_	_	O
145	before	_	_	O
146	the	_	_	O
147	nutritional	_	_	O
148	interventions	_	_	O
149	,	_	_	O
150	and	_	_	O
151	again	_	_	O
152	after	_	_	O
153	four	_	_	O
154	and	_	_	O
155	eight	_	_	O
156	weeks	_	_	O
157	,	_	_	O
158	body	_	_	O
159	compartments	_	_	O
160	were	_	_	O
161	determined	_	_	O
162	using	_	_	O
163	bioelectrical	_	_	O
164	impedance	_	_	O
165	analysis	_	_	O
166	,	_	_	O
167	lymphocyte	_	_	O
168	subpopulations	_	_	O
169	were	_	_	O
170	quantified	_	_	O
171	using	_	_	O
172	flow	_	_	O
173	cytometry	_	_	O
174	,	_	_	O
175	and	_	_	O
176	some	_	_	O
177	aspects	_	_	O
178	of	_	_	O
179	the	_	_	O
180	quality	_	_	O
181	of	_	_	O
182	life	_	_	O
183	were	_	_	O
184	rated	_	_	O
185	using	_	_	O
186	four	_	_	O
187	linear	_	_	O
188	analog	_	_	O
189	self-assessment	_	_	O
190	(	_	_	O
191	LASA	_	_	O
192	)	_	_	O
193	scales	_	_	O
194	.	_	_	O

195	The	_	_	O
196	statistical	_	_	O
197	calculations	_	_	O
198	were	_	_	O
199	done	_	_	O
200	as	_	_	O
201	an	_	_	O
202	exploratory	_	_	O
203	data	_	_	O
204	analysis	_	_	O
205	.	_	_	O

206	The	_	_	O
207	consumption	_	_	O
208	of	_	_	O
209	non-protein	_	_	O
210	calories	_	_	O
211	did	_	_	O
212	not	_	_	O
213	differ	_	_	O
214	significantly	_	_	O
215	between	_	_	O
216	the	_	_	O
217	two	_	_	O
218	patient	_	_	O
219	groups	_	_	O
220	.	_	_	O

221	An	_	_	B-Premise
222	average	_	_	I-Premise
223	weight	_	_	I-Premise
224	gain	_	_	I-Premise
225	in	_	_	I-Premise
226	group	_	_	I-Premise
227	B	_	_	I-Premise
228	contrasted	_	_	I-Premise
229	with	_	_	I-Premise
230	an	_	_	I-Premise
231	average	_	_	I-Premise
232	weight	_	_	I-Premise
233	loss	_	_	I-Premise
234	in	_	_	I-Premise
235	group	_	_	I-Premise
236	A	_	_	I-Premise
237	after	_	_	I-Premise
238	four	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	and	_	_	I-Premise
245	eight	_	_	I-Premise
246	weeks	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0.05	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Fat-free	_	_	B-Premise
254	mass	_	_	I-Premise
255	showed	_	_	I-Premise
256	an	_	_	I-Premise
257	intergroup	_	_	I-Premise
258	difference	_	_	I-Premise
259	in	_	_	I-Premise
260	favor	_	_	I-Premise
261	of	_	_	I-Premise
262	group	_	_	I-Premise
263	B	_	_	I-Premise
264	after	_	_	I-Premise
265	eight	_	_	I-Premise
266	weeks	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	0.05	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Body	_	_	B-Premise
274	cell	_	_	I-Premise
275	mass	_	_	I-Premise
276	was	_	_	I-Premise
277	maintained	_	_	I-Premise
278	throughout	_	_	I-Premise
279	the	_	_	I-Premise
280	study	_	_	I-Premise
281	in	_	_	I-Premise
282	group	_	_	I-Premise
283	B	_	_	I-Premise
284	,	_	_	I-Premise
285	but	_	_	I-Premise
286	declined	_	_	I-Premise
287	significantly	_	_	I-Premise
288	up	_	_	I-Premise
289	to	_	_	I-Premise
290	weeks	_	_	I-Premise
291	4	_	_	I-Premise
292	and	_	_	I-Premise
293	8	_	_	I-Premise
294	in	_	_	I-Premise
295	group	_	_	I-Premise
296	A	_	_	I-Premise
297	(	_	_	I-Premise
298	intergroup	_	_	I-Premise
299	difference	_	_	I-Premise
300	:	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	0.05	_	_	I-Premise
304	and	_	_	I-Premise
305	0.01	_	_	I-Premise
306	,	_	_	I-Premise
307	respectively	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	A	_	_	B-Premise
311	decrease	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	total	_	_	I-Premise
315	lymphocyte	_	_	I-Premise
316	count	_	_	I-Premise
317	by	_	_	I-Premise
318	559	_	_	I-Premise
319	cells/mul	_	_	I-Premise
320	occurred	_	_	I-Premise
321	with	_	_	I-Premise
322	the	_	_	I-Premise
323	fat-enriched	_	_	I-Premise
324	diet	_	_	I-Premise
325	(	_	_	I-Premise
326	P	_	_	I-Premise
327	<	_	_	I-Premise
328	0.05	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	Several	_	_	B-Premise
332	aspects	_	_	I-Premise
333	of	_	_	I-Premise
334	the	_	_	I-Premise
335	quality	_	_	I-Premise
336	of	_	_	I-Premise
337	life	_	_	I-Premise
338	were	_	_	I-Premise
339	rated	_	_	I-Premise
340	to	_	_	I-Premise
341	be	_	_	I-Premise
342	better	_	_	I-Premise
343	in	_	_	I-Premise
344	group	_	_	I-Premise
345	B	_	_	I-Premise
346	than	_	_	I-Premise
347	in	_	_	I-Premise
348	group	_	_	I-Premise
349	A	_	_	I-Premise
350	,	_	_	I-Premise
351	although	_	_	B-Premise
352	not	_	_	I-Premise
353	all	_	_	I-Premise
354	differences	_	_	I-Premise
355	reached	_	_	I-Premise
356	statistical	_	_	I-Premise
357	significance	_	_	I-Premise
358	.	_	_	I-Premise

359	In	_	_	B-Claim
360	patients	_	_	I-Claim
361	with	_	_	I-Claim
362	cancer	_	_	I-Claim
363	,	_	_	I-Claim
364	a	_	_	I-Claim
365	high-fat	_	_	I-Claim
366	diet	_	_	I-Claim
367	may	_	_	I-Claim
368	possibly	_	_	I-Claim
369	support	_	_	I-Claim
370	the	_	_	I-Claim
371	maintenance	_	_	I-Claim
372	of	_	_	I-Claim
373	both	_	_	I-Claim
374	body	_	_	I-Claim
375	weight	_	_	I-Claim
376	and	_	_	I-Claim
377	body	_	_	I-Claim
378	cell	_	_	I-Claim
379	mass	_	_	I-Claim
380	.	_	_	I-Claim

381	However	_	_	B-Claim
382	,	_	_	I-Claim
383	monitoring	_	_	I-Claim
384	the	_	_	I-Claim
385	lymphocyte	_	_	I-Claim
386	count	_	_	I-Claim
387	is	_	_	I-Claim
388	advisable	_	_	I-Claim
389	.	_	_	I-Claim


0	Prior	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	melatonin	_	_	O
6	,	_	_	O
7	a	_	_	O
8	frequently	_	_	O
9	used	_	_	O
10	integrative	_	_	O
11	medicine	_	_	O
12	,	_	_	O
13	can	_	_	O
14	attenuate	_	_	O
15	weight	_	_	O
16	loss	_	_	O
17	,	_	_	O
18	anorexia	_	_	O
19	,	_	_	O
20	and	_	_	O
21	fatigue	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	These	_	_	O
28	studies	_	_	O
29	were	_	_	O
30	limited	_	_	O
31	by	_	_	O
32	a	_	_	O
33	lack	_	_	O
34	of	_	_	O
35	blinding	_	_	O
36	and	_	_	O
37	absence	_	_	O
38	of	_	_	O
39	placebo	_	_	O
40	controls	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	purpose	_	_	O
45	of	_	_	O
46	this	_	_	O
47	study	_	_	O
48	was	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	melatonin	_	_	O
52	with	_	_	O
53	placebo	_	_	O
54	for	_	_	O
55	appetite	_	_	O
56	improvement	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	cancer	_	_	O
61	cachexia	_	_	O
62	.	_	_	O

63	We	_	_	O
64	performed	_	_	O
65	a	_	_	O
66	randomized	_	_	O
67	,	_	_	O
68	double-blind	_	_	O
69	,	_	_	O
70	28-day	_	_	O
71	trial	_	_	O
72	of	_	_	O
73	melatonin	_	_	O
74	20	_	_	O
75	mg	_	_	O
76	versus	_	_	O
77	placebo	_	_	O
78	in	_	_	O
79	patients	_	_	O
80	with	_	_	O
81	advanced	_	_	O
82	lung	_	_	O
83	or	_	_	O
84	GI	_	_	O
85	cancer	_	_	O
86	,	_	_	O
87	appetite	_	_	O
88	scores	_	_	O
89	â‰¥	_	_	O
90	4	_	_	O
91	on	_	_	O
92	a	_	_	O
93	0	_	_	O
94	to	_	_	O
95	10	_	_	O
96	scale	_	_	O
97	(	_	_	O
98	10	_	_	O
99	=	_	_	O
100	worst	_	_	O
101	appetite	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	history	_	_	O
106	of	_	_	O
107	weight	_	_	O
108	loss	_	_	O
109	â‰¥	_	_	O
110	5	_	_	O
111	%	_	_	O
112	.	_	_	O

113	Assessments	_	_	O
114	included	_	_	O
115	weight	_	_	O
116	,	_	_	O
117	symptoms	_	_	O
118	by	_	_	O
119	the	_	_	O
120	Edmonton	_	_	O
121	Symptom	_	_	O
122	Assessment	_	_	O
123	Scale	_	_	O
124	,	_	_	O
125	and	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	by	_	_	O
130	the	_	_	O
131	Functional	_	_	O
132	Assessment	_	_	O
133	of	_	_	O
134	Anorexia/Cachexia	_	_	O
135	Therapy	_	_	O
136	(	_	_	O
137	FAACT	_	_	O
138	)	_	_	O
139	questionnaire	_	_	O
140	.	_	_	O

141	Differences	_	_	O
142	between	_	_	O
143	groups	_	_	O
144	from	_	_	O
145	baseline	_	_	O
146	to	_	_	O
147	day	_	_	O
148	28	_	_	O
149	were	_	_	O
150	analyzed	_	_	O
151	using	_	_	O
152	one-sided	_	_	O
153	,	_	_	O
154	two-sample	_	_	O
155	t	_	_	O
156	tests	_	_	O
157	or	_	_	O
158	Wilcoxon	_	_	O
159	two-sample	_	_	O
160	tests	_	_	O
161	.	_	_	O

162	Interim	_	_	O
163	analysis	_	_	O
164	halfway	_	_	O
165	through	_	_	O
166	the	_	_	O
167	trial	_	_	O
168	had	_	_	O
169	a	_	_	O
170	Lan-DeMets	_	_	O
171	monitoring	_	_	O
172	boundary	_	_	O
173	with	_	_	O
174	an	_	_	O
175	O'Brien-Fleming	_	_	O
176	stopping	_	_	O
177	rule	_	_	O
178	.	_	_	O

179	Decision	_	_	O
180	boundaries	_	_	O
181	were	_	_	O
182	to	_	_	O
183	accept	_	_	O
184	the	_	_	O
185	null	_	_	O
186	hypothesis	_	_	O
187	of	_	_	O
188	futility	_	_	O
189	if	_	_	O
190	the	_	_	O
191	test	_	_	O
192	statistic	_	_	O
193	z	_	_	O
194	<	_	_	O
195	0.39	_	_	O
196	(	_	_	O
197	P	_	_	O
198	â‰¥	_	_	O
199	.348	_	_	O
200	)	_	_	O
201	and	_	_	O
202	reject	_	_	O
203	the	_	_	O
204	null	_	_	O
205	hypothesis	_	_	O
206	if	_	_	O
207	z	_	_	O
208	>	_	_	O
209	2.54	_	_	O
210	(	_	_	O
211	P	_	_	O
212	â‰¤	_	_	O
213	.0056	_	_	O
214	)	_	_	O
215	.	_	_	O

216	After	_	_	O
217	interim	_	_	O
218	analysis	_	_	O
219	of	_	_	O
220	48	_	_	O
221	patients	_	_	O
222	,	_	_	O
223	the	_	_	O
224	study	_	_	O
225	was	_	_	O
226	closed	_	_	O
227	for	_	_	O
228	futility	_	_	O
229	.	_	_	O

230	There	_	_	B-Premise
231	were	_	_	I-Premise
232	no	_	_	I-Premise
233	significant	_	_	I-Premise
234	differences	_	_	I-Premise
235	between	_	_	I-Premise
236	groups	_	_	I-Premise
237	for	_	_	I-Premise
238	appetite	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.78	_	_	I-Premise
243	)	_	_	I-Premise
244	or	_	_	I-Premise
245	other	_	_	I-Premise
246	symptoms	_	_	I-Premise
247	,	_	_	I-Premise
248	weight	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.17	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	FAACT	_	_	I-Premise
256	score	_	_	I-Premise
257	(	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.95	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	toxicity	_	_	I-Premise
264	,	_	_	I-Premise
265	or	_	_	I-Premise
266	survival	_	_	I-Premise
267	from	_	_	I-Premise
268	baseline	_	_	I-Premise
269	to	_	_	I-Premise
270	day	_	_	I-Premise
271	28	_	_	I-Premise
272	.	_	_	I-Premise

273	In	_	_	B-Claim
274	cachectic	_	_	I-Claim
275	patients	_	_	I-Claim
276	with	_	_	I-Claim
277	advanced	_	_	I-Claim
278	cancer	_	_	I-Claim
279	,	_	_	I-Claim
280	oral	_	_	I-Claim
281	melatonin	_	_	I-Claim
282	20	_	_	I-Claim
283	mg	_	_	I-Claim
284	at	_	_	I-Claim
285	night	_	_	I-Claim
286	did	_	_	I-Claim
287	not	_	_	I-Claim
288	improve	_	_	I-Claim
289	appetite	_	_	I-Claim
290	,	_	_	I-Claim
291	weight	_	_	I-Claim
292	,	_	_	I-Claim
293	or	_	_	I-Claim
294	quality	_	_	I-Claim
295	of	_	_	I-Claim
296	life	_	_	I-Claim
297	compared	_	_	I-Claim
298	with	_	_	I-Claim
299	placebo	_	_	I-Claim
300	.	_	_	I-Claim


0	Gynecological	_	_	O
1	neoplastic	_	_	O
2	disease	_	_	O
3	progression	_	_	O
4	is	_	_	O
5	characterized	_	_	O
6	by	_	_	O
7	specific	_	_	O
8	energy	_	_	O
9	metabolism	_	_	O
10	alterations	_	_	O
11	and	_	_	O
12	by	_	_	O
13	symptoms	_	_	O
14	including	_	_	O
15	fatigue	_	_	O
16	,	_	_	O
17	anorexia	_	_	O
18	,	_	_	O
19	nausea	_	_	O
20	,	_	_	O
21	anemia	_	_	O
22	,	_	_	O
23	and	_	_	O
24	immunodepression	_	_	O
25	,	_	_	O
26	which	_	_	O
27	result	_	_	O
28	in	_	_	O
29	a	_	_	O
30	cachexia	_	_	O
31	syndrome	_	_	O
32	and	_	_	O
33	a	_	_	O
34	marked	_	_	O
35	decrease	_	_	O
36	in	_	_	O
37	patient	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QoL	_	_	O
43	)	_	_	O
44	.	_	_	O

45	Therapeutic	_	_	O
46	protocols	_	_	O
47	associated	_	_	O
48	with	_	_	O
49	appropriate	_	_	O
50	and	_	_	O
51	effective	_	_	O
52	psychological	_	_	O
53	and	_	_	O
54	social	_	_	O
55	support	_	_	O
56	systems	_	_	O
57	are	_	_	O
58	essential	_	_	O
59	to	_	_	O
60	counteract	_	_	O
61	the	_	_	O
62	symptoms	_	_	O
63	of	_	_	O
64	neoplastic	_	_	O
65	disease	_	_	O
66	in	_	_	O
67	incurable	_	_	O
68	patients	_	_	O
69	.	_	_	O

70	A	_	_	O
71	phase	_	_	O
72	III	_	_	O
73	randomized	_	_	O
74	study	_	_	O
75	was	_	_	O
76	performed	_	_	O
77	to	_	_	O
78	establish	_	_	O
79	the	_	_	O
80	most	_	_	O
81	effective	_	_	O
82	and	_	_	O
83	safest	_	_	O
84	treatment	_	_	O
85	to	_	_	O
86	improve	_	_	O
87	the	_	_	O
88	key	_	_	O
89	symptoms	_	_	O
90	in	_	_	O
91	advanced	_	_	O
92	gynecological	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	,	_	_	O
96	i.e.	_	_	O
97	,	_	_	O
98	lean	_	_	O
99	body	_	_	O
100	mass	_	_	O
101	(	_	_	O
102	LBM	_	_	O
103	)	_	_	O
104	,	_	_	O
105	resting	_	_	O
106	energy	_	_	O
107	expenditure	_	_	O
108	(	_	_	O
109	REE	_	_	O
110	)	_	_	O
111	,	_	_	O
112	fatigue	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QoL	_	_	O
116	.	_	_	O

117	In	_	_	O
118	addition	_	_	O
119	,	_	_	O
120	the	_	_	O
121	impact	_	_	O
122	of	_	_	O
123	the	_	_	O
124	treatment	_	_	O
125	arms	_	_	O
126	on	_	_	O
127	the	_	_	O
128	main	_	_	O
129	metabolic	_	_	O
130	and	_	_	O
131	inflammatory	_	_	O
132	parameters	_	_	O
133	,	_	_	O
134	including	_	_	O
135	C-reactive	_	_	O
136	protein	_	_	O
137	(	_	_	O
138	CRP	_	_	O
139	)	_	_	O
140	,	_	_	O
141	interleukin	_	_	O
142	(	_	_	O
143	IL	_	_	O
144	)	_	_	O
145	-6	_	_	O
146	,	_	_	O
147	tumor	_	_	O
148	necrosis	_	_	O
149	factor	_	_	O
150	(	_	_	O
151	TNF	_	_	O
152	)	_	_	O
153	-Î±	_	_	O
154	,	_	_	O
155	leptin	_	_	O
156	,	_	_	O
157	reactive	_	_	O
158	oxygen	_	_	O
159	species	_	_	O
160	(	_	_	O
161	ROS	_	_	O
162	)	_	_	O
163	,	_	_	O
164	and	_	_	O
165	glutathione	_	_	O
166	peroxidase	_	_	O
167	,	_	_	O
168	was	_	_	O
169	evaluated	_	_	O
170	.	_	_	O

171	The	_	_	O
172	change	_	_	O
173	in	_	_	O
174	the	_	_	O
175	Glasgow	_	_	O
176	Prognostic	_	_	O
177	Score	_	_	O
178	(	_	_	O
179	GPS	_	_	O
180	)	_	_	O
181	during	_	_	O
182	treatment	_	_	O
183	was	_	_	O
184	also	_	_	O
185	assessed	_	_	O
186	.	_	_	O

187	A	_	_	O
188	total	_	_	O
189	of	_	_	O
190	104	_	_	O
191	advanced-stage	_	_	O
192	gynecological	_	_	O
193	cancer	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	enrolled	_	_	O
197	and	_	_	O
198	randomly	_	_	O
199	assigned	_	_	O
200	to	_	_	O
201	receive	_	_	O
202	either	_	_	O
203	megestrol	_	_	O
204	acetate	_	_	O
205	(	_	_	O
206	MA	_	_	O
207	)	_	_	O
208	plus	_	_	O
209	l-carnitine	_	_	O
210	,	_	_	O
211	celecoxib	_	_	O
212	,	_	_	O
213	and	_	_	O
214	antioxidants	_	_	O
215	(	_	_	O
216	arm	_	_	O
217	1	_	_	O
218	)	_	_	O
219	or	_	_	O
220	MA	_	_	O
221	alone	_	_	O
222	(	_	_	O
223	arm	_	_	O
224	2	_	_	O
225	)	_	_	O
226	.	_	_	O

227	The	_	_	O
228	treatment	_	_	O
229	duration	_	_	O
230	was	_	_	O
231	4	_	_	O
232	months	_	_	O
233	.	_	_	O

234	The	_	_	B-Premise
235	combination	_	_	I-Premise
236	arm	_	_	I-Premise
237	was	_	_	I-Premise
238	more	_	_	I-Premise
239	effective	_	_	I-Premise
240	than	_	_	I-Premise
241	arm	_	_	I-Premise
242	2	_	_	I-Premise
243	with	_	_	I-Premise
244	respect	_	_	I-Premise
245	to	_	_	I-Premise
246	LBM	_	_	I-Premise
247	,	_	_	I-Premise
248	REE	_	_	I-Premise
249	,	_	_	I-Premise
250	fatigue	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	global	_	_	I-Premise
254	QoL	_	_	I-Premise
255	.	_	_	I-Premise

256	As	_	_	B-Premise
257	for	_	_	I-Premise
258	the	_	_	I-Premise
259	secondary	_	_	I-Premise
260	efficacy	_	_	I-Premise
261	endpoints	_	_	I-Premise
262	,	_	_	I-Premise
263	patient	_	_	I-Premise
264	appetite	_	_	I-Premise
265	increased	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	ECOG	_	_	I-Premise
269	PS	_	_	I-Premise
270	decreased	_	_	I-Premise
271	significantly	_	_	I-Premise
272	in	_	_	I-Premise
273	both	_	_	I-Premise
274	arms	_	_	I-Premise
275	.	_	_	I-Premise

276	The	_	_	B-Premise
277	inflammation	_	_	I-Premise
278	and	_	_	I-Premise
279	oxidative	_	_	I-Premise
280	stress	_	_	I-Premise
281	parameters	_	_	I-Premise
282	IL-6	_	_	I-Premise
283	,	_	_	I-Premise
284	TNF-Î±	_	_	I-Premise
285	,	_	_	I-Premise
286	CRP	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	ROS	_	_	I-Premise
290	decreased	_	_	I-Premise
291	significantly	_	_	I-Premise
292	in	_	_	I-Premise
293	arm	_	_	I-Premise
294	1	_	_	I-Premise
295	,	_	_	I-Premise
296	while	_	_	I-Premise
297	no	_	_	I-Premise
298	significant	_	_	I-Premise
299	change	_	_	I-Premise
300	was	_	_	I-Premise
301	observed	_	_	I-Premise
302	in	_	_	I-Premise
303	arm	_	_	I-Premise
304	2	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Claim
307	combined	_	_	I-Claim
308	treatment	_	_	I-Claim
309	improved	_	_	I-Claim
310	both	_	_	I-Claim
311	immunometabolic	_	_	I-Claim
312	alterations	_	_	I-Claim
313	and	_	_	I-Claim
314	patient	_	_	I-Claim
315	QoL	_	_	I-Claim
316	.	_	_	I-Claim

317	Multimodality	_	_	B-Claim
318	therapies	_	_	I-Claim
319	for	_	_	I-Claim
320	cachexia	_	_	I-Claim
321	ideally	_	_	I-Claim
322	should	_	_	I-Claim
323	be	_	_	I-Claim
324	introduced	_	_	I-Claim
325	within	_	_	I-Claim
326	a	_	_	I-Claim
327	context	_	_	I-Claim
328	of	_	_	I-Claim
329	"	_	_	I-Claim
330	best	_	_	I-Claim
331	supportive	_	_	I-Claim
332	care	_	_	I-Claim
333	"	_	_	I-Claim
334	that	_	_	I-Claim
335	includes	_	_	I-Claim
336	optimal	_	_	I-Claim
337	symptom	_	_	I-Claim
338	management	_	_	I-Claim
339	and	_	_	I-Claim
340	careful	_	_	I-Claim
341	psychosocial	_	_	I-Claim
342	counseling	_	_	I-Claim
343	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	pamidronate	_	_	O
9	for	_	_	O
10	bone	_	_	O
11	pain	_	_	O
12	in	_	_	O
13	a	_	_	O
14	randomised	_	_	O
15	double-blind	_	_	O
16	trial	_	_	O
17	and	_	_	O
18	to	_	_	O
19	evaluate	_	_	O
20	the	_	_	O
21	contribution	_	_	O
22	of	_	_	O
23	new	_	_	O
24	markers	_	_	O
25	of	_	_	O
26	bone	_	_	O
27	resorption	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	bone	_	_	O
32	metastases	_	_	O
33	.	_	_	O

34	Fifty-two	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	painful	_	_	O
38	bone	_	_	O
39	metastases	_	_	O
40	were	_	_	O
41	randomised	_	_	O
42	to	_	_	O
43	receive	_	_	O
44	a	_	_	O
45	two-hour	_	_	O
46	infusion	_	_	O
47	of	_	_	O
48	pamidronate	_	_	O
49	120	_	_	O
50	mg	_	_	O
51	or	_	_	O
52	an	_	_	O
53	identical	_	_	O
54	infusion	_	_	O
55	of	_	_	O
56	saline	_	_	O
57	.	_	_	O

58	Four	_	_	O
59	weeks	_	_	O
60	later	_	_	O
61	,	_	_	O
62	all	_	_	O
63	patients	_	_	O
64	received	_	_	O
65	pamidronate	_	_	O
66	120	_	_	O
67	mg	_	_	O
68	.	_	_	O

69	Bone	_	_	O
70	resorption	_	_	O
71	markers	_	_	O
72	measured	_	_	O
73	included	_	_	O
74	urinary	_	_	O
75	calcium	_	_	O
76	(	_	_	O
77	uCa	_	_	O
78	)	_	_	O
79	,	_	_	O
80	hydroxyproline	_	_	O
81	(	_	_	O
82	Hyp	_	_	O
83	)	_	_	O
84	,	_	_	O
85	and	_	_	O
86	the	_	_	O
87	collagen	_	_	O
88	breakdown	_	_	O
89	products	_	_	O
90	:	_	_	O
91	NTx	_	_	O
92	,	_	_	O
93	Crosslaps	_	_	O
94	and	_	_	O
95	Free	_	_	O
96	Dpd	_	_	O
97	.	_	_	O

98	Symptomatic	_	_	B-Premise
99	response	_	_	I-Premise
100	during	_	_	I-Premise
101	the	_	_	I-Premise
102	first	_	_	I-Premise
103	four	_	_	I-Premise
104	weeks	_	_	I-Premise
105	was	_	_	I-Premise
106	seen	_	_	I-Premise
107	after	_	_	I-Premise
108	pamidronate	_	_	I-Premise
109	,	_	_	I-Premise
110	but	_	_	I-Premise
111	not	_	_	I-Premise
112	with	_	_	I-Premise
113	placebo	_	_	I-Premise
114	(	_	_	I-Premise
115	P	_	_	I-Premise
116	<	_	_	I-Premise
117	0.05	_	_	I-Premise
118	)	_	_	I-Premise
119	.	_	_	I-Premise

120	Quality	_	_	B-Premise
121	of	_	_	I-Premise
122	life	_	_	I-Premise
123	was	_	_	I-Premise
124	maintained	_	_	I-Premise
125	with	_	_	I-Premise
126	pamidronate	_	_	I-Premise
127	and	_	_	I-Premise
128	deteriorated	_	_	I-Premise
129	after	_	_	I-Premise
130	placebo	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	0.05	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Resorption	_	_	B-Premise
138	markers	_	_	I-Premise
139	did	_	_	I-Premise
140	not	_	_	I-Premise
141	decrease	_	_	I-Premise
142	after	_	_	I-Premise
143	placebo	_	_	I-Premise
144	,	_	_	I-Premise
145	but	_	_	B-Premise
146	NTx	_	_	I-Premise
147	and	_	_	I-Premise
148	Crosslaps	_	_	I-Premise
149	both	_	_	I-Premise
150	decreased	_	_	I-Premise
151	by	_	_	I-Premise
152	70	_	_	I-Premise
153	%	_	_	I-Premise
154	after	_	_	I-Premise
155	pamidronate	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	0.001	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	A	_	_	B-Premise
163	second	_	_	I-Premise
164	infusion	_	_	I-Premise
165	of	_	_	I-Premise
166	pamidronate	_	_	I-Premise
167	did	_	_	I-Premise
168	not	_	_	I-Premise
169	decrease	_	_	I-Premise
170	resorption	_	_	I-Premise
171	further	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	B-Premise
174	maintained	_	_	I-Premise
175	the	_	_	I-Premise
176	suppression	_	_	I-Premise
177	of	_	_	I-Premise
178	resorption	_	_	I-Premise
179	at	_	_	I-Premise
180	similar	_	_	I-Premise
181	levels	_	_	I-Premise
182	for	_	_	I-Premise
183	a	_	_	I-Premise
184	further	_	_	I-Premise
185	four	_	_	I-Premise
186	weeks	_	_	I-Premise
187	.	_	_	I-Premise

188	Symptomatic	_	_	B-Premise
189	response	_	_	I-Premise
190	to	_	_	I-Premise
191	pamidronate	_	_	I-Premise
192	correlated	_	_	I-Premise
193	closely	_	_	I-Premise
194	with	_	_	I-Premise
195	the	_	_	I-Premise
196	rate	_	_	I-Premise
197	of	_	_	I-Premise
198	bone	_	_	I-Premise
199	resorption	_	_	I-Premise
200	;	_	_	I-Premise
201	it	_	_	B-Premise
202	was	_	_	I-Premise
203	more	_	_	I-Premise
204	frequent	_	_	I-Premise
205	in	_	_	I-Premise
206	those	_	_	I-Premise
207	patients	_	_	I-Premise
208	with	_	_	I-Premise
209	an	_	_	I-Premise
210	initial	_	_	I-Premise
211	NTx	_	_	I-Premise
212	value	_	_	I-Premise
213	of	_	_	I-Premise
214	<	_	_	I-Premise
215	2	_	_	I-Premise
216	times	_	_	I-Premise
217	the	_	_	I-Premise
218	upper	_	_	I-Premise
219	limit	_	_	I-Premise
220	of	_	_	I-Premise
221	normal	_	_	I-Premise
222	(	_	_	I-Premise
223	17	_	_	I-Premise
224	of	_	_	I-Premise
225	27	_	_	I-Premise
226	,	_	_	I-Premise
227	62	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	and	_	_	I-Premise
231	in	_	_	I-Premise
232	those	_	_	I-Premise
233	where	_	_	I-Premise
234	the	_	_	I-Premise
235	level	_	_	I-Premise
236	of	_	_	I-Premise
237	Ntx	_	_	I-Premise
238	returned	_	_	I-Premise
239	to	_	_	I-Premise
240	normal	_	_	I-Premise
241	(	_	_	I-Premise
242	19	_	_	I-Premise
243	of	_	_	I-Premise
244	32	_	_	I-Premise
245	,	_	_	I-Premise
246	59	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	than	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	patients	_	_	I-Premise
254	with	_	_	I-Premise
255	either	_	_	I-Premise
256	high	_	_	I-Premise
257	baseline	_	_	I-Premise
258	values	_	_	I-Premise
259	of	_	_	I-Premise
260	NTx	_	_	I-Premise
261	(	_	_	I-Premise
262	>	_	_	I-Premise
263	2	_	_	I-Premise
264	times	_	_	I-Premise
265	the	_	_	I-Premise
266	upper	_	_	I-Premise
267	limit	_	_	I-Premise
268	of	_	_	I-Premise
269	normal	_	_	I-Premise
270	)	_	_	I-Premise
271	or	_	_	I-Premise
272	Ntx	_	_	I-Premise
273	levels	_	_	I-Premise
274	which	_	_	I-Premise
275	failed	_	_	I-Premise
276	to	_	_	I-Premise
277	normalise	_	_	I-Premise
278	for	_	_	I-Premise
279	whom	_	_	I-Premise
280	the	_	_	I-Premise
281	response	_	_	I-Premise
282	frequencies	_	_	I-Premise
283	were	_	_	I-Premise
284	2	_	_	I-Premise
285	of	_	_	I-Premise
286	16	_	_	I-Premise
287	(	_	_	I-Premise
288	13	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	0	_	_	I-Premise
293	of	_	_	I-Premise
294	11	_	_	I-Premise
295	(	_	_	I-Premise
296	0	_	_	I-Premise
297	%	_	_	I-Premise
298	)	_	_	I-Premise
299	,	_	_	I-Premise
300	respectively	_	_	I-Premise
301	.	_	_	I-Premise

302	Subjective	_	_	B-Claim
303	benefit	_	_	I-Claim
304	after	_	_	I-Claim
305	intravenous	_	_	I-Claim
306	pamidronate	_	_	I-Claim
307	is	_	_	I-Claim
308	confirmed	_	_	I-Claim
309	in	_	_	I-Claim
310	this	_	_	I-Claim
311	placebo-controlled	_	_	I-Claim
312	study	_	_	I-Claim
313	.	_	_	I-Claim

314	The	_	_	B-Claim
315	new	_	_	I-Claim
316	bone	_	_	I-Claim
317	resorption	_	_	I-Claim
318	markers	_	_	I-Claim
319	of	_	_	I-Claim
320	collagen	_	_	I-Claim
321	breakdown	_	_	I-Claim
322	were	_	_	I-Claim
323	able	_	_	I-Claim
324	to	_	_	I-Claim
325	predict	_	_	I-Claim
326	clinical	_	_	I-Claim
327	response	_	_	I-Claim
328	to	_	_	I-Claim
329	pamidronate	_	_	I-Claim
330	.	_	_	I-Claim


0	Over	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	non-small	_	_	O
7	cell	_	_	O
8	lung	_	_	O
9	cancer	_	_	O
10	(	_	_	O
11	NSCLC	_	_	O
12	)	_	_	O
13	develop	_	_	O
14	brain	_	_	O
15	metastases	_	_	O
16	.	_	_	O

17	If	_	_	O
18	inoperable	_	_	O
19	,	_	_	O
20	optimal	_	_	O
21	supportive	_	_	O
22	care	_	_	O
23	(	_	_	O
24	OSC	_	_	O
25	)	_	_	O
26	,	_	_	O
27	including	_	_	O
28	steroids	_	_	O
29	,	_	_	O
30	and	_	_	O
31	whole	_	_	O
32	brain	_	_	O
33	radiotherapy	_	_	O
34	(	_	_	O
35	WBRT	_	_	O
36	)	_	_	O
37	are	_	_	O
38	generally	_	_	O
39	considered	_	_	O
40	to	_	_	O
41	be	_	_	O
42	standard	_	_	O
43	care	_	_	O
44	,	_	_	O
45	although	_	_	O
46	there	_	_	O
47	is	_	_	O
48	no	_	_	O
49	randomised	_	_	O
50	evidence	_	_	O
51	demonstrating	_	_	O
52	that	_	_	O
53	the	_	_	O
54	addition	_	_	O
55	of	_	_	O
56	WBRT	_	_	O
57	to	_	_	O
58	OSC	_	_	O
59	improves	_	_	O
60	survival	_	_	O
61	or	_	_	O
62	quality	_	_	O
63	of	_	_	O
64	life	_	_	O
65	.	_	_	O

66	QUARTZ	_	_	O
67	is	_	_	O
68	a	_	_	O
69	randomised	_	_	O
70	,	_	_	O
71	non-inferiority	_	_	O
72	,	_	_	O
73	phase	_	_	O
74	III	_	_	O
75	trial	_	_	O
76	comparing	_	_	O
77	OSC	_	_	O
78	+	_	_	O
79	WBRT	_	_	O
80	versus	_	_	O
81	OSC	_	_	O
82	in	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	inoperable	_	_	O
86	brain	_	_	O
87	metastases	_	_	O
88	from	_	_	O
89	NSCLC	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	outcome	_	_	O
94	measure	_	_	O
95	is	_	_	O
96	quality-adjusted	_	_	O
97	life	_	_	O
98	years	_	_	O
99	(	_	_	O
100	QALYs	_	_	O
101	)	_	_	O
102	.	_	_	O

103	QUARTZ	_	_	O
104	was	_	_	O
105	threatened	_	_	O
106	with	_	_	O
107	both	_	_	O
108	loss	_	_	O
109	of	_	_	O
110	funding	_	_	O
111	and	_	_	O
112	early	_	_	O
113	closure	_	_	O
114	due	_	_	O
115	to	_	_	O
116	poor	_	_	O
117	accrual	_	_	O
118	.	_	_	O

119	A	_	_	O
120	lack	_	_	O
121	of	_	_	O
122	preliminary	_	_	O
123	randomised	_	_	O
124	data	_	_	O
125	supporting	_	_	O
126	the	_	_	O
127	trial	_	_	O
128	's	_	_	O
129	hypotheses	_	_	O
130	was	_	_	O
131	thought	_	_	O
132	to	_	_	O
133	underlie	_	_	O
134	the	_	_	O
135	poor	_	_	O
136	accrual	_	_	O
137	,	_	_	O
138	so	_	_	O
139	,	_	_	O
140	with	_	_	O
141	no	_	_	O
142	knowledge	_	_	O
143	of	_	_	O
144	the	_	_	O
145	data	_	_	O
146	,	_	_	O
147	the	_	_	O
148	independent	_	_	O
149	trial	_	_	O
150	steering	_	_	O
151	committee	_	_	O
152	agreed	_	_	O
153	to	_	_	O
154	the	_	_	O
155	unusual	_	_	O
156	step	_	_	O
157	of	_	_	O
158	releasing	_	_	O
159	interim	_	_	O
160	data	_	_	O
161	.	_	_	O

162	Between	_	_	O
163	March	_	_	O
164	2007	_	_	O
165	and	_	_	O
166	April	_	_	O
167	2010	_	_	O
168	,	_	_	O
169	151	_	_	O
170	(	_	_	O
171	of	_	_	O
172	the	_	_	O
173	planned	_	_	O
174	534	_	_	O
175	)	_	_	O
176	patients	_	_	O
177	were	_	_	O
178	randomised	_	_	O
179	(	_	_	O
180	75	_	_	O
181	OSC	_	_	O
182	+	_	_	O
183	WBRT	_	_	O
184	,	_	_	O
185	76	_	_	O
186	OSC	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Participants	_	_	O
190	'	_	_	O
191	baseline	_	_	O
192	demographics	_	_	O
193	included	_	_	O
194	median	_	_	O
195	age	_	_	O
196	67	_	_	O
197	years	_	_	O
198	(	_	_	O
199	interquartile	_	_	O
200	range	_	_	O
201	62-73	_	_	O
202	)	_	_	O
203	,	_	_	O
204	60	_	_	O
205	%	_	_	O
206	male	_	_	O
207	,	_	_	O
208	50	_	_	O
209	%	_	_	O
210	with	_	_	O
211	a	_	_	O
212	Karnofsky	_	_	O
213	performance	_	_	O
214	status	_	_	O
215	<	_	_	O
216	70	_	_	O
217	;	_	_	O
218	steroid	_	_	O
219	usage	_	_	O
220	was	_	_	O
221	similar	_	_	O
222	in	_	_	O
223	the	_	_	O
224	two	_	_	O
225	groups	_	_	O
226	;	_	_	O
227	64/75	_	_	O
228	(	_	_	O
229	85	_	_	O
230	%	_	_	O
231	)	_	_	O
232	received	_	_	O
233	WBRT	_	_	O
234	(	_	_	O
235	20	_	_	O
236	Gy	_	_	O
237	in	_	_	O
238	five	_	_	O
239	fractions	_	_	O
240	)	_	_	O
241	.	_	_	O

242	Median	_	_	B-Premise
243	survival	_	_	I-Premise
244	was	_	_	I-Premise
245	:	_	_	I-Premise
246	OSC	_	_	I-Premise
247	+	_	_	I-Premise
248	WBRT	_	_	I-Premise
249	49	_	_	I-Premise
250	days	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	confidence	_	_	I-Premise
255	interval	_	_	I-Premise
256	39-61	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	OSC	_	_	I-Premise
260	51	_	_	I-Premise
261	days	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	confidence	_	_	I-Premise
266	interval	_	_	I-Premise
267	27-57	_	_	I-Premise
268	)	_	_	I-Premise
269	-	_	_	I-Premise
270	hazard	_	_	I-Premise
271	ratio	_	_	I-Premise
272	1.11	_	_	I-Premise
273	(	_	_	I-Premise
274	95	_	_	I-Premise
275	%	_	_	I-Premise
276	confidence	_	_	I-Premise
277	interval	_	_	I-Premise
278	0.80-1.53	_	_	I-Premise
279	)	_	_	I-Premise
280	in	_	_	I-Premise
281	favour	_	_	I-Premise
282	of	_	_	I-Premise
283	WBRT	_	_	I-Premise
284	.	_	_	I-Premise

285	Quality	_	_	B-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	assessed	_	_	I-Premise
289	using	_	_	I-Premise
290	EQ-5D	_	_	I-Premise
291	showed	_	_	I-Premise
292	no	_	_	I-Premise
293	evidence	_	_	I-Premise
294	of	_	_	I-Premise
295	a	_	_	I-Premise
296	difference	_	_	I-Premise
297	.	_	_	I-Premise

298	The	_	_	B-Premise
299	estimated	_	_	I-Premise
300	mean	_	_	I-Premise
301	QALYs	_	_	I-Premise
302	was	_	_	I-Premise
303	:	_	_	I-Premise
304	OSC	_	_	I-Premise
305	+	_	_	I-Premise
306	WBRT	_	_	I-Premise
307	31	_	_	I-Premise
308	days	_	_	I-Premise
309	and	_	_	I-Premise
310	OSC	_	_	I-Premise
311	30	_	_	I-Premise
312	days	_	_	I-Premise
313	,	_	_	I-Premise
314	difference	_	_	I-Premise
315	-1	_	_	I-Premise
316	day	_	_	I-Premise
317	(	_	_	I-Premise
318	95	_	_	I-Premise
319	%	_	_	I-Premise
320	confidence	_	_	I-Premise
321	interval	_	_	I-Premise
322	-12.0	_	_	I-Premise
323	to	_	_	I-Premise
324	+13.2	_	_	I-Premise
325	days	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	These	_	_	B-Claim
329	interim	_	_	I-Claim
330	data	_	_	I-Claim
331	indicate	_	_	I-Claim
332	no	_	_	I-Claim
333	early	_	_	I-Claim
334	evidence	_	_	I-Claim
335	of	_	_	I-Claim
336	detriment	_	_	I-Claim
337	to	_	_	I-Claim
338	quality	_	_	I-Claim
339	of	_	_	I-Claim
340	life	_	_	I-Claim
341	,	_	_	I-Claim
342	overall	_	_	I-Claim
343	survival	_	_	I-Claim
344	or	_	_	I-Claim
345	QALYs	_	_	I-Claim
346	for	_	_	I-Claim
347	patients	_	_	I-Claim
348	allocated	_	_	I-Claim
349	to	_	_	I-Claim
350	OSC	_	_	I-Claim
351	alone	_	_	I-Claim
352	.	_	_	I-Claim

353	They	_	_	O
354	provide	_	_	O
355	key	_	_	O
356	information	_	_	O
357	for	_	_	O
358	discussing	_	_	O
359	the	_	_	O
360	trial	_	_	O
361	with	_	_	O
362	patients	_	_	O
363	and	_	_	O
364	strengthen	_	_	O
365	the	_	_	O
366	argument	_	_	O
367	for	_	_	O
368	continuing	_	_	O
369	QUARTZ	_	_	O
370	to	_	_	O
371	definitively	_	_	O
372	answer	_	_	O
373	this	_	_	O
374	important	_	_	O
375	clinical	_	_	O
376	question	_	_	O
377	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	clinical	_	_	O
9	outcomes	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	undergoing	_	_	O
17	surgery	_	_	O
18	for	_	_	O
19	pilonidal	_	_	O
20	disease	_	_	O
21	with	_	_	O
22	unroofing	_	_	O
23	and	_	_	O
24	marsupialization	_	_	O
25	(	_	_	O
26	UM	_	_	O
27	)	_	_	O
28	or	_	_	O
29	rhomboid	_	_	O
30	excision	_	_	O
31	and	_	_	O
32	Limberg	_	_	O
33	flap	_	_	O
34	(	_	_	O
35	RELP	_	_	O
36	)	_	_	O
37	procedures	_	_	O
38	.	_	_	O

39	One	_	_	O
40	hundred	_	_	O
41	forty	_	_	O
42	consecutive	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	pilonidal	_	_	O
46	sinus	_	_	O
47	were	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	to	_	_	O
51	receive	_	_	O
52	either	_	_	O
53	UM	_	_	O
54	or	_	_	O
55	RELP	_	_	O
56	procedures	_	_	O
57	.	_	_	O

58	A	_	_	O
59	specifically	_	_	O
60	designed	_	_	O
61	questionnaire	_	_	O
62	was	_	_	O
63	administered	_	_	O
64	at	_	_	O
65	three	_	_	O
66	months	_	_	O
67	to	_	_	O
68	assess	_	_	O
69	time	_	_	O
70	from	_	_	O
71	the	_	_	O
72	operation	_	_	O
73	until	_	_	O
74	the	_	_	O
75	patient	_	_	O
76	was	_	_	O
77	able	_	_	O
78	to	_	_	O
79	walk	_	_	O
80	,	_	_	O
81	return	_	_	O
82	to	_	_	O
83	daily	_	_	O
84	activities	_	_	O
85	,	_	_	O
86	or	_	_	O
87	sit	_	_	O
88	without	_	_	O
89	pain	_	_	O
90	,	_	_	O
91	time	_	_	O
92	to	_	_	O
93	return	_	_	O
94	to	_	_	O
95	work	_	_	O
96	or	_	_	O
97	school	_	_	O
98	,	_	_	O
99	and	_	_	O
100	time	_	_	O
101	to	_	_	O
102	healing	_	_	O
103	.	_	_	O

104	Postoperative	_	_	O
105	pain	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	a	_	_	O
110	visual	_	_	O
111	analog	_	_	O
112	scale	_	_	O
113	and	_	_	O
114	the	_	_	O
115	McGill	_	_	O
116	Pain	_	_	O
117	Questionnaire	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	'	_	_	O
121	quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	was	_	_	O
125	evaluated	_	_	O
126	with	_	_	O
127	the	_	_	O
128	Cardiff	_	_	O
129	Wound	_	_	O
130	Impact	_	_	O
131	Schedule	_	_	O
132	(	_	_	O
133	CWIS	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Questionnaires	_	_	O
137	were	_	_	O
138	administered	_	_	O
139	by	_	_	O
140	a	_	_	O
141	clinician	_	_	O
142	blinded	_	_	O
143	to	_	_	O
144	treatment	_	_	O
145	.	_	_	O

146	Compared	_	_	B-Premise
147	with	_	_	I-Premise
148	RELP	_	_	I-Premise
149	,	_	_	I-Premise
150	patients	_	_	I-Premise
151	receiving	_	_	I-Premise
152	UM	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	shorter	_	_	I-Premise
156	duration	_	_	I-Premise
157	of	_	_	I-Premise
158	operation	_	_	I-Premise
159	and	_	_	I-Premise
160	hospital	_	_	I-Premise
161	stay	_	_	I-Premise
162	,	_	_	I-Premise
163	shorter	_	_	I-Premise
164	time	_	_	I-Premise
165	periods	_	_	I-Premise
166	to	_	_	I-Premise
167	walk	_	_	I-Premise
168	,	_	_	I-Premise
169	return	_	_	I-Premise
170	to	_	_	I-Premise
171	daily	_	_	I-Premise
172	activities	_	_	I-Premise
173	,	_	_	I-Premise
174	or	_	_	I-Premise
175	sit	_	_	I-Premise
176	without	_	_	I-Premise
177	pain	_	_	I-Premise
178	and	_	_	I-Premise
179	to	_	_	I-Premise
180	return	_	_	I-Premise
181	to	_	_	I-Premise
182	work	_	_	I-Premise
183	or	_	_	I-Premise
184	school	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	fewer	_	_	I-Premise
188	complications	_	_	I-Premise
189	.	_	_	I-Premise

190	Time	_	_	B-Premise
191	to	_	_	I-Premise
192	final	_	_	I-Premise
193	healing	_	_	I-Premise
194	was	_	_	I-Premise
195	significantly	_	_	I-Premise
196	shorter	_	_	I-Premise
197	and	_	_	I-Premise
198	quality	_	_	I-Premise
199	of	_	_	I-Premise
200	life	_	_	I-Premise
201	scores	_	_	I-Premise
202	on	_	_	I-Premise
203	the	_	_	I-Premise
204	CWIS	_	_	I-Premise
205	were	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	patients	_	_	I-Premise
209	receiving	_	_	I-Premise
210	RELP	_	_	I-Premise
211	than	_	_	I-Premise
212	in	_	_	I-Premise
213	those	_	_	I-Premise
214	receiving	_	_	I-Premise
215	UM	_	_	I-Premise
216	.	_	_	I-Premise

217	Patients	_	_	B-Premise
218	with	_	_	I-Premise
219	UM	_	_	I-Premise
220	had	_	_	I-Premise
221	lower	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	pain	_	_	I-Premise
225	one	_	_	I-Premise
226	week	_	_	I-Premise
227	after	_	_	I-Premise
228	surgery	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Claim
231	unroofing	_	_	I-Claim
232	and	_	_	I-Claim
233	marsupialization	_	_	I-Claim
234	procedure	_	_	I-Claim
235	provides	_	_	I-Claim
236	more	_	_	I-Claim
237	clinical	_	_	I-Claim
238	benefits	_	_	I-Claim
239	in	_	_	I-Claim
240	the	_	_	I-Claim
241	treatment	_	_	I-Claim
242	of	_	_	I-Claim
243	pilonidal	_	_	I-Claim
244	disease	_	_	I-Claim
245	than	_	_	I-Claim
246	rhomboid	_	_	I-Claim
247	excision	_	_	I-Claim
248	and	_	_	I-Claim
249	Limberg	_	_	I-Claim
250	flap	_	_	I-Claim
251	and	_	_	I-Claim
252	should	_	_	I-Claim
253	be	_	_	I-Claim
254	considered	_	_	I-Claim
255	the	_	_	I-Claim
256	procedure	_	_	I-Claim
257	of	_	_	I-Claim
258	choice	_	_	I-Claim
259	.	_	_	I-Claim

260	However	_	_	B-Claim
261	,	_	_	I-Claim
262	it	_	_	I-Claim
263	may	_	_	I-Claim
264	be	_	_	I-Claim
265	associated	_	_	I-Claim
266	with	_	_	I-Claim
267	more	_	_	I-Claim
268	inconvenience	_	_	I-Claim
269	in	_	_	I-Claim
270	wound	_	_	I-Claim
271	care	_	_	I-Claim
272	and	_	_	I-Claim
273	longer	_	_	I-Claim
274	healing	_	_	I-Claim
275	time	_	_	I-Claim
276	than	_	_	I-Claim
277	rhomboid	_	_	I-Claim
278	excision	_	_	I-Claim
279	and	_	_	I-Claim
280	Lindberg	_	_	I-Claim
281	flap	_	_	I-Claim
282	.	_	_	I-Claim


0	Maintenance	_	_	O
1	therapy	_	_	O
2	can	_	_	O
3	delay	_	_	O
4	progression	_	_	O
5	and	_	_	O
6	prolong	_	_	O
7	survival	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	non-small-cell	_	_	O
11	lung	_	_	O
12	cancer	_	_	O
13	(	_	_	O
14	mNSCLC	_	_	O
15	)	_	_	O
16	.	_	_	O

17	As	_	_	O
18	treatment	_	_	O
19	for	_	_	O
20	mNSCLC	_	_	O
21	is	_	_	O
22	non-curative	_	_	O
23	,	_	_	O
24	its	_	_	O
25	impact	_	_	O
26	on	_	_	O
27	patient	_	_	O
28	health-related	_	_	O
29	quality	_	_	O
30	of	_	_	O
31	life	_	_	O
32	(	_	_	O
33	HRQoL	_	_	O
34	)	_	_	O
35	is	_	_	O
36	an	_	_	O
37	important	_	_	O
38	consideration	_	_	O
39	.	_	_	O

40	SATURN	_	_	O
41	(	_	_	O
42	Sequential	_	_	O
43	Tarceva	_	_	O
44	in	_	_	O
45	Unresectable	_	_	O
46	NSCLC	_	_	O
47	)	_	_	O
48	was	_	_	O
49	a	_	_	O
50	randomised	_	_	O
51	,	_	_	O
52	double-blind	_	_	O
53	,	_	_	O
54	placebo-controlled	_	_	O
55	,	_	_	O
56	multicentre	_	_	O
57	study	_	_	O
58	investigating	_	_	O
59	the	_	_	O
60	impact	_	_	O
61	of	_	_	O
62	erlotinib	_	_	O
63	maintenance	_	_	O
64	therapy	_	_	O
65	on	_	_	O
66	HRQoL	_	_	O
67	in	_	_	O
68	patients	_	_	O
69	with	_	_	O
70	locally	_	_	O
71	advanced	_	_	O
72	or	_	_	O
73	recurrent	_	_	O
74	NSCLC	_	_	O
75	.	_	_	O

76	Eligible	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	had	_	_	O
80	previously	_	_	O
81	completed	_	_	O
82	four	_	_	O
83	cycles	_	_	O
84	of	_	_	O
85	platinum-based	_	_	O
86	chemotherapy	_	_	O
87	were	_	_	O
88	randomised	_	_	O
89	1:1	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	erlotinib	_	_	O
93	150	_	_	O
94	mg/day	_	_	O
95	or	_	_	O
96	placebo	_	_	O
97	until	_	_	O
98	disease	_	_	O
99	progression	_	_	O
100	,	_	_	O
101	unacceptable	_	_	O
102	toxicity	_	_	O
103	or	_	_	O
104	death	_	_	O
105	.	_	_	O

106	Patient	_	_	O
107	HRQoL	_	_	O
108	was	_	_	O
109	assessed	_	_	O
110	using	_	_	O
111	the	_	_	O
112	Functional	_	_	O
113	Assessment	_	_	O
114	of	_	_	O
115	Cancer	_	_	O
116	Therapy-Lung	_	_	O
117	questionnaire	_	_	O
118	,	_	_	O
119	in	_	_	O
120	terms	_	_	O
121	of	_	_	O
122	time	_	_	O
123	to	_	_	O
124	symptom	_	_	O
125	progression	_	_	O
126	(	_	_	O
127	TSP	_	_	O
128	)	_	_	O
129	,	_	_	O
130	time	_	_	O
131	to	_	_	O
132	deterioration	_	_	O
133	(	_	_	O
134	TTD	_	_	O
135	)	_	_	O
136	in	_	_	O
137	Trial	_	_	O
138	Outcome	_	_	O
139	Index	_	_	O
140	(	_	_	O
141	TOI	_	_	O
142	)	_	_	O
143	and	_	_	O
144	TTD	_	_	O
145	.	_	_	O

146	Exploratory	_	_	O
147	analysis	_	_	O
148	was	_	_	O
149	based	_	_	O
150	on	_	_	O
151	time	_	_	O
152	to	_	_	O
153	analgesia	_	_	O
154	and	_	_	O
155	appearance	_	_	O
156	of	_	_	O
157	key	_	_	O
158	symptoms	_	_	O
159	(	_	_	O
160	pain	_	_	O
161	,	_	_	O
162	cough	_	_	O
163	and	_	_	O
164	dyspnoea	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Compared	_	_	B-Premise
168	with	_	_	I-Premise
169	placebo	_	_	I-Premise
170	,	_	_	I-Premise
171	erlotinib	_	_	I-Premise
172	maintenance	_	_	I-Premise
173	therapy	_	_	I-Premise
174	prolonged	_	_	I-Premise
175	progression-free	_	_	I-Premise
176	and	_	_	I-Premise
177	overall	_	_	I-Premise
178	survival	_	_	I-Premise
179	by	_	_	I-Premise
180	41	_	_	I-Premise
181	%	_	_	I-Premise
182	and	_	_	I-Premise
183	23	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	respectively	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	O
189	baseline	_	_	O
190	,	_	_	O
191	HRQoL	_	_	O
192	measures	_	_	O
193	were	_	_	O
194	comparable	_	_	O
195	between	_	_	O
196	the	_	_	O
197	two	_	_	O
198	treatment	_	_	O
199	groups	_	_	O
200	.	_	_	O

201	Maintenance	_	_	B-Premise
202	therapy	_	_	I-Premise
203	with	_	_	I-Premise
204	erlotinib	_	_	I-Premise
205	did	_	_	I-Premise
206	not	_	_	I-Premise
207	impact	_	_	I-Premise
208	on	_	_	I-Premise
209	deterioration	_	_	I-Premise
210	in	_	_	I-Premise
211	HRQoL	_	_	I-Premise
212	:	_	_	I-Premise
213	TSP	_	_	I-Premise
214	(	_	_	I-Premise
215	hazard	_	_	I-Premise
216	ratio	_	_	I-Premise
217	[	_	_	I-Premise
218	HR	_	_	I-Premise
219	]	_	_	I-Premise
220	=0.91	_	_	I-Premise
221	[	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	confidence	_	_	I-Premise
225	interval	_	_	I-Premise
226	(	_	_	I-Premise
227	CI	_	_	I-Premise
228	)	_	_	I-Premise
229	0.74-1.12	_	_	I-Premise
230	]	_	_	I-Premise
231	;	_	_	I-Premise
232	n=785	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	TTD	_	_	I-Premise
236	in	_	_	I-Premise
237	TOI	_	_	I-Premise
238	(	_	_	I-Premise
239	HR=1.06	_	_	I-Premise
240	[	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	0.87-1.31	_	_	I-Premise
245	]	_	_	I-Premise
246	;	_	_	I-Premise
247	n=781	_	_	I-Premise
248	)	_	_	I-Premise
249	and	_	_	I-Premise
250	TTD	_	_	I-Premise
251	in	_	_	I-Premise
252	HRQoL	_	_	I-Premise
253	(	_	_	I-Premise
254	HR=0.96	_	_	I-Premise
255	[	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	0.79-1.16	_	_	I-Premise
260	]	_	_	I-Premise
261	;	_	_	I-Premise
262	n=776	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Time	_	_	B-Premise
266	to	_	_	I-Premise
267	pain	_	_	I-Premise
268	and	_	_	I-Premise
269	time	_	_	I-Premise
270	to	_	_	I-Premise
271	analgesic	_	_	I-Premise
272	use	_	_	I-Premise
273	were	_	_	I-Premise
274	significantly	_	_	I-Premise
275	delayed	_	_	I-Premise
276	in	_	_	I-Premise
277	patients	_	_	I-Premise
278	receiving	_	_	I-Premise
279	erlotinib	_	_	I-Premise
280	compared	_	_	I-Premise
281	with	_	_	I-Premise
282	placebo	_	_	I-Premise
283	(	_	_	I-Premise
284	HR=0.61	_	_	I-Premise
285	[	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	0.42-0.88	_	_	I-Premise
290	]	_	_	I-Premise
291	;	_	_	I-Premise
292	p=0.0080	_	_	I-Premise
293	and	_	_	I-Premise
294	HR=0.66	_	_	I-Premise
295	[	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	CI	_	_	I-Premise
299	0.46-0.94	_	_	I-Premise
300	]	_	_	I-Premise
301	;	_	_	I-Premise
302	p=0.0199	_	_	I-Premise
303	,	_	_	I-Premise
304	respectively	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	A	_	_	B-Premise
308	non-significant	_	_	I-Premise
309	trend	_	_	I-Premise
310	towards	_	_	I-Premise
311	delayed	_	_	I-Premise
312	time	_	_	I-Premise
313	to	_	_	I-Premise
314	cough	_	_	I-Premise
315	and	_	_	I-Premise
316	time	_	_	I-Premise
317	to	_	_	I-Premise
318	dyspnoea	_	_	I-Premise
319	(	_	_	I-Premise
320	HR=0.77	_	_	I-Premise
321	[	_	_	I-Premise
322	95	_	_	I-Premise
323	%	_	_	I-Premise
324	CI	_	_	I-Premise
325	0.49-1.21	_	_	I-Premise
326	]	_	_	I-Premise
327	and	_	_	I-Premise
328	HR=0.75	_	_	I-Premise
329	[	_	_	I-Premise
330	95	_	_	I-Premise
331	%	_	_	I-Premise
332	CI	_	_	I-Premise
333	0.48-1.17	_	_	I-Premise
334	]	_	_	I-Premise
335	,	_	_	I-Premise
336	respectively	_	_	I-Premise
337	)	_	_	I-Premise
338	was	_	_	I-Premise
339	also	_	_	I-Premise
340	observed	_	_	I-Premise
341	.	_	_	I-Premise

342	Erlotinib	_	_	B-Claim
343	maintenance	_	_	I-Claim
344	therapy	_	_	I-Claim
345	significantly	_	_	I-Claim
346	extends	_	_	I-Claim
347	progression-free	_	_	I-Claim
348	survival	_	_	I-Claim
349	without	_	_	I-Claim
350	compromising	_	_	I-Claim
351	patient	_	_	I-Claim
352	HRQoL	_	_	I-Claim
353	in	_	_	I-Claim
354	comparison	_	_	I-Claim
355	with	_	_	I-Claim
356	placebo	_	_	I-Claim
357	,	_	_	I-Claim
358	with	_	_	I-Claim
359	some	_	_	I-Claim
360	improvement	_	_	I-Claim
361	in	_	_	I-Claim
362	symptoms	_	_	I-Claim
363	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	randomized	_	_	O
3	,	_	_	O
4	multinational	_	_	O
5	phase	_	_	O
6	II/III	_	_	O
7	trial	_	_	O
8	(	_	_	O
9	V325	_	_	O
10	)	_	_	O
11	of	_	_	O
12	untreated	_	_	O
13	advanced	_	_	O
14	gastric	_	_	O
15	cancer	_	_	O
16	patients	_	_	O
17	,	_	_	O
18	the	_	_	O
19	phase	_	_	O
20	II	_	_	O
21	part	_	_	O
22	selected	_	_	O
23	docetaxel	_	_	O
24	,	_	_	O
25	cisplatin	_	_	O
26	,	_	_	O
27	and	_	_	O
28	fluorouracil	_	_	O
29	(	_	_	O
30	DCF	_	_	O
31	)	_	_	O
32	over	_	_	O
33	docetaxel	_	_	O
34	and	_	_	O
35	cisplatin	_	_	O
36	for	_	_	O
37	comparison	_	_	O
38	against	_	_	O
39	cisplatin	_	_	O
40	and	_	_	O
41	fluorouracil	_	_	O
42	(	_	_	O
43	CF	_	_	O
44	;	_	_	O
45	reference	_	_	O
46	regimen	_	_	O
47	)	_	_	O
48	in	_	_	O
49	the	_	_	O
50	phase	_	_	O
51	III	_	_	O
52	part	_	_	O
53	.	_	_	O

54	Advanced	_	_	O
55	gastric	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	docetaxel	_	_	O
63	75	_	_	O
64	mg/m2	_	_	O
65	and	_	_	O
66	cisplatin	_	_	O
67	75	_	_	O
68	mg/m2	_	_	O
69	(	_	_	O
70	day	_	_	O
71	1	_	_	O
72	)	_	_	O
73	plus	_	_	O
74	fluorouracil	_	_	O
75	750	_	_	O
76	mg/m2/d	_	_	O
77	(	_	_	O
78	days	_	_	O
79	1	_	_	O
80	to	_	_	O
81	5	_	_	O
82	)	_	_	O
83	every	_	_	O
84	3	_	_	O
85	weeks	_	_	O
86	or	_	_	O
87	cisplatin	_	_	O
88	100	_	_	O
89	mg/m2	_	_	O
90	(	_	_	O
91	day	_	_	O
92	1	_	_	O
93	)	_	_	O
94	plus	_	_	O
95	fluorouracil	_	_	O
96	1,000	_	_	O
97	mg/m2/d	_	_	O
98	(	_	_	O
99	days	_	_	O
100	1	_	_	O
101	to	_	_	O
102	5	_	_	O
103	)	_	_	O
104	every	_	_	O
105	4	_	_	O
106	weeks	_	_	O
107	.	_	_	O

108	The	_	_	O
109	primary	_	_	O
110	end	_	_	O
111	point	_	_	O
112	was	_	_	O
113	time-to-progression	_	_	O
114	(	_	_	O
115	TTP	_	_	O
116	)	_	_	O
117	.	_	_	O

118	In	_	_	O
119	445	_	_	O
120	randomly	_	_	O
121	assigned	_	_	O
122	and	_	_	O
123	treated	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	DCF	_	_	O
127	=	_	_	O
128	221	_	_	O
129	;	_	_	O
130	CF	_	_	O
131	=	_	_	O
132	224	_	_	O
133	)	_	_	O
134	,	_	_	O
135	TTP	_	_	O
136	was	_	_	O
137	longer	_	_	O
138	with	_	_	O
139	DCF	_	_	O
140	versus	_	_	O
141	CF	_	_	O
142	(	_	_	O
143	32	_	_	O
144	%	_	_	O
145	risk	_	_	O
146	reduction	_	_	O
147	;	_	_	O
148	log-rank	_	_	O
149	P	_	_	O
150	<	_	_	O
151	.001	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Overall	_	_	B-Premise
155	survival	_	_	I-Premise
156	was	_	_	I-Premise
157	longer	_	_	I-Premise
158	with	_	_	I-Premise
159	DCF	_	_	I-Premise
160	versus	_	_	I-Premise
161	CF	_	_	I-Premise
162	(	_	_	I-Premise
163	23	_	_	I-Premise
164	%	_	_	I-Premise
165	risk	_	_	I-Premise
166	reduction	_	_	I-Premise
167	;	_	_	I-Premise
168	log-rank	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	.02	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Two-year	_	_	B-Premise
175	survival	_	_	I-Premise
176	rate	_	_	I-Premise
177	was	_	_	I-Premise
178	18	_	_	I-Premise
179	%	_	_	I-Premise
180	with	_	_	I-Premise
181	DCF	_	_	I-Premise
182	and	_	_	I-Premise
183	9	_	_	I-Premise
184	%	_	_	I-Premise
185	with	_	_	I-Premise
186	CF	_	_	I-Premise
187	.	_	_	I-Premise

188	Overall	_	_	B-Premise
189	response	_	_	I-Premise
190	rate	_	_	I-Premise
191	was	_	_	I-Premise
192	higher	_	_	I-Premise
193	with	_	_	I-Premise
194	DCF	_	_	I-Premise
195	(	_	_	I-Premise
196	chi2	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.01	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Grade	_	_	B-Premise
203	3	_	_	I-Premise
204	to	_	_	I-Premise
205	4	_	_	I-Premise
206	treatment-related	_	_	I-Premise
207	adverse	_	_	I-Premise
208	events	_	_	I-Premise
209	occurred	_	_	I-Premise
210	in	_	_	I-Premise
211	69	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	DCF	_	_	I-Premise
215	)	_	_	I-Premise
216	v	_	_	I-Premise
217	59	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	CF	_	_	I-Premise
221	)	_	_	I-Premise
222	of	_	_	I-Premise
223	patients	_	_	I-Premise
224	.	_	_	I-Premise

225	Frequent	_	_	B-Premise
226	grade	_	_	I-Premise
227	3	_	_	I-Premise
228	to	_	_	I-Premise
229	4	_	_	I-Premise
230	toxicities	_	_	I-Premise
231	for	_	_	I-Premise
232	DCF	_	_	I-Premise
233	v	_	_	I-Premise
234	CF	_	_	I-Premise
235	were	_	_	I-Premise
236	:	_	_	I-Premise
237	neutropenia	_	_	I-Premise
238	(	_	_	I-Premise
239	82	_	_	I-Premise
240	%	_	_	I-Premise
241	v	_	_	I-Premise
242	57	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	stomatitis	_	_	I-Premise
247	(	_	_	I-Premise
248	21	_	_	I-Premise
249	%	_	_	I-Premise
250	v	_	_	I-Premise
251	27	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	diarrhea	_	_	I-Premise
256	(	_	_	I-Premise
257	19	_	_	I-Premise
258	%	_	_	I-Premise
259	v	_	_	I-Premise
260	8	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	lethargy	_	_	I-Premise
265	(	_	_	I-Premise
266	19	_	_	I-Premise
267	%	_	_	I-Premise
268	v	_	_	I-Premise
269	14	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Complicated	_	_	B-Premise
274	neutropenia	_	_	I-Premise
275	was	_	_	I-Premise
276	more	_	_	I-Premise
277	frequent	_	_	I-Premise
278	with	_	_	I-Premise
279	DCF	_	_	I-Premise
280	than	_	_	I-Premise
281	CF	_	_	I-Premise
282	(	_	_	I-Premise
283	29	_	_	I-Premise
284	%	_	_	I-Premise
285	v	_	_	I-Premise
286	12	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Adding	_	_	B-Claim
291	docetaxel	_	_	I-Claim
292	to	_	_	I-Claim
293	CF	_	_	I-Claim
294	significantly	_	_	I-Claim
295	improved	_	_	I-Claim
296	TTP	_	_	I-Claim
297	,	_	_	I-Claim
298	survival	_	_	I-Claim
299	,	_	_	I-Claim
300	and	_	_	I-Claim
301	response	_	_	I-Claim
302	rate	_	_	I-Claim
303	in	_	_	I-Claim
304	gastric	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	,	_	_	I-Claim
308	but	_	_	I-Claim
309	resulted	_	_	I-Claim
310	in	_	_	I-Claim
311	some	_	_	I-Claim
312	increase	_	_	I-Claim
313	in	_	_	I-Claim
314	toxicity	_	_	I-Claim
315	.	_	_	I-Claim

316	Incorporation	_	_	B-Claim
317	of	_	_	I-Claim
318	docetaxel	_	_	I-Claim
319	,	_	_	I-Claim
320	as	_	_	I-Claim
321	in	_	_	I-Claim
322	DCF	_	_	I-Claim
323	or	_	_	I-Claim
324	with	_	_	I-Claim
325	other	_	_	I-Claim
326	active	_	_	I-Claim
327	drug	_	_	I-Claim
328	(	_	_	I-Claim
329	s	_	_	I-Claim
330	)	_	_	I-Claim
331	,	_	_	I-Claim
332	is	_	_	I-Claim
333	a	_	_	I-Claim
334	new	_	_	I-Claim
335	therapy	_	_	I-Claim
336	option	_	_	I-Claim
337	for	_	_	I-Claim
338	patients	_	_	I-Claim
339	with	_	_	I-Claim
340	untreated	_	_	I-Claim
341	advanced	_	_	I-Claim
342	gastric	_	_	I-Claim
343	cancer	_	_	I-Claim
344	.	_	_	I-Claim


0	Hormonal	_	_	B-Claim
1	breast	_	_	I-Claim
2	cancer	_	_	I-Claim
3	treatment	_	_	I-Claim
4	increases	_	_	I-Claim
5	menopausal	_	_	I-Claim
6	symptoms	_	_	I-Claim
7	in	_	_	I-Claim
8	women	_	_	I-Claim
9	.	_	_	I-Claim

10	This	_	_	O
11	study	_	_	O
12	investigated	_	_	O
13	differences	_	_	O
14	between	_	_	O
15	the	_	_	O
16	symptoms	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	either	_	_	O
20	adjuvant	_	_	O
21	tamoxifen	_	_	O
22	or	_	_	O
23	exemestane	_	_	O
24	.	_	_	O

25	Ten	_	_	O
26	common	_	_	O
27	symptoms	_	_	O
28	were	_	_	O
29	assessed	_	_	O
30	by	_	_	O
31	self-report	_	_	O
32	questionnaire	_	_	O
33	administered	_	_	O
34	to	_	_	O
35	1,614	_	_	O
36	consecutive	_	_	O
37	patients	_	_	O
38	at	_	_	O
39	baseline	_	_	O
40	and	_	_	O
41	every	_	_	O
42	3	_	_	O
43	months	_	_	O
44	during	_	_	O
45	the	_	_	O
46	first	_	_	O
47	year	_	_	O
48	of	_	_	O
49	a	_	_	O
50	double-blind	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	trial	_	_	O
54	of	_	_	O
55	postmenopausal	_	_	O
56	women	_	_	O
57	with	_	_	O
58	early	_	_	O
59	hormone	_	_	O
60	receptor-positive	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	.	_	_	O

64	Symptoms	_	_	O
65	were	_	_	O
66	categorized	_	_	O
67	as	_	_	O
68	none	_	_	O
69	,	_	_	O
70	mild	_	_	O
71	,	_	_	O
72	moderate	_	_	O
73	,	_	_	O
74	or	_	_	O
75	severe	_	_	O
76	.	_	_	O

77	A	_	_	O
78	hot	_	_	O
79	flash	_	_	O
80	score	_	_	O
81	was	_	_	O
82	calculated	_	_	O
83	at	_	_	O
84	each	_	_	O
85	time	_	_	O
86	point	_	_	O
87	.	_	_	O

88	Symptoms	_	_	O
89	were	_	_	O
90	analyzed	_	_	O
91	by	_	_	O
92	repeated-measures	_	_	O
93	analysis	_	_	O
94	of	_	_	O
95	variance	_	_	O
96	.	_	_	O

97	Each	_	_	O
98	time	_	_	O
99	period	_	_	O
100	was	_	_	O
101	tested	_	_	O
102	repeatedly	_	_	O
103	against	_	_	O
104	the	_	_	O
105	baseline	_	_	O
106	;	_	_	O
107	an	_	_	O
108	overall	_	_	O
109	P	_	_	O
110	value	_	_	O
111	was	_	_	O
112	assigned	_	_	O
113	for	_	_	O
114	each	_	_	O
115	reported	_	_	O
116	symptom	_	_	O
117	.	_	_	O

118	Compliance	_	_	O
119	was	_	_	O
120	excellent	_	_	O
121	,	_	_	O
122	with	_	_	O
123	7,286	_	_	O
124	questionnaires	_	_	O
125	analyzed	_	_	O
126	.	_	_	O

127	Baseline	_	_	O
128	symptom	_	_	O
129	prevalence	_	_	O
130	ranged	_	_	O
131	from	_	_	O
132	2	_	_	O
133	%	_	_	O
134	(	_	_	O
135	vaginal	_	_	O
136	bleeding	_	_	O
137	)	_	_	O
138	to	_	_	O
139	60	_	_	O
140	%	_	_	O
141	to	_	_	O
142	70	_	_	O
143	%	_	_	O
144	(	_	_	O
145	bone/muscle	_	_	O
146	aches	_	_	O
147	and	_	_	O
148	low	_	_	O
149	energy	_	_	O
150	)	_	_	O
151	.	_	_	O

152	There	_	_	B-Premise
153	were	_	_	I-Premise
154	no	_	_	I-Premise
155	significant	_	_	I-Premise
156	differences	_	_	I-Premise
157	in	_	_	I-Premise
158	vaginal	_	_	I-Premise
159	bleeding	_	_	I-Premise
160	,	_	_	I-Premise
161	mood	_	_	I-Premise
162	alteration	_	_	I-Premise
163	,	_	_	I-Premise
164	or	_	_	I-Premise
165	low	_	_	I-Premise
166	energy	_	_	I-Premise
167	.	_	_	I-Premise

168	Patients	_	_	B-Premise
169	receiving	_	_	I-Premise
170	tamoxifen	_	_	I-Premise
171	had	_	_	I-Premise
172	significantly	_	_	I-Premise
173	more	_	_	I-Premise
174	vaginal	_	_	I-Premise
175	discharge	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	.0001	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Exemestane	_	_	B-Premise
183	patients	_	_	I-Premise
184	reported	_	_	I-Premise
185	more	_	_	I-Premise
186	bone/muscle	_	_	I-Premise
187	aches	_	_	I-Premise
188	(	_	_	I-Premise
189	P	_	_	I-Premise
190	<	_	_	I-Premise
191	.0001	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	vaginal	_	_	I-Premise
195	dryness	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.0004	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	and	_	_	I-Premise
203	difficulty	_	_	I-Premise
204	sleeping	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.03	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	In	_	_	B-Premise
212	both	_	_	I-Premise
213	groups	_	_	I-Premise
214	,	_	_	I-Premise
215	the	_	_	I-Premise
216	hot	_	_	I-Premise
217	flash	_	_	I-Premise
218	score	_	_	I-Premise
219	peaked	_	_	I-Premise
220	at	_	_	I-Premise
221	3	_	_	I-Premise
222	months	_	_	I-Premise
223	and	_	_	I-Premise
224	decreased	_	_	I-Premise
225	thereafter	_	_	I-Premise
226	.	_	_	I-Premise

227	At	_	_	B-Premise
228	12	_	_	I-Premise
229	months	_	_	I-Premise
230	,	_	_	I-Premise
231	patients	_	_	I-Premise
232	receiving	_	_	I-Premise
233	tamoxifen	_	_	I-Premise
234	had	_	_	I-Premise
235	a	_	_	I-Premise
236	significantly	_	_	I-Premise
237	higher	_	_	I-Premise
238	mean	_	_	I-Premise
239	hot	_	_	I-Premise
240	flash	_	_	I-Premise
241	score	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.03	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	with	_	_	I-Premise
249	daily	_	_	I-Premise
250	hot	_	_	I-Premise
251	flashes	_	_	I-Premise
252	increasing	_	_	I-Premise
253	from	_	_	I-Premise
254	baseline	_	_	I-Premise
255	by	_	_	I-Premise
256	33	_	_	I-Premise
257	%	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	a	_	_	I-Premise
261	7	_	_	I-Premise
262	%	_	_	I-Premise
263	increase	_	_	I-Premise
264	from	_	_	I-Premise
265	baseline	_	_	I-Premise
266	with	_	_	I-Premise
267	exemestane	_	_	I-Premise
268	.	_	_	I-Premise

269	At	_	_	B-Premise
270	12	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	exemestane	_	_	I-Premise
274	was	_	_	I-Premise
275	associated	_	_	I-Premise
276	with	_	_	I-Premise
277	fewer	_	_	I-Premise
278	hot	_	_	I-Premise
279	flashes	_	_	I-Premise
280	and	_	_	I-Premise
281	less	_	_	I-Premise
282	vaginal	_	_	I-Premise
283	discharge	_	_	I-Premise
284	than	_	_	I-Premise
285	tamoxifen	_	_	I-Premise
286	,	_	_	I-Premise
287	but	_	_	I-Premise
288	with	_	_	I-Premise
289	more	_	_	I-Premise
290	vaginal	_	_	I-Premise
291	dryness	_	_	I-Premise
292	,	_	_	I-Premise
293	bone/muscle	_	_	I-Premise
294	aches	_	_	I-Premise
295	,	_	_	I-Premise
296	and	_	_	I-Premise
297	difficulty	_	_	I-Premise
298	sleeping	_	_	I-Premise
299	.	_	_	I-Premise

300	Symptoms	_	_	B-Claim
301	were	_	_	I-Claim
302	common	_	_	I-Claim
303	in	_	_	I-Claim
304	both	_	_	I-Claim
305	groups	_	_	I-Claim
306	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	a	_	_	O
8	lay-administered	_	_	O
9	tailored	_	_	O
10	education	_	_	O
11	and	_	_	O
12	coaching	_	_	O
13	(	_	_	O
14	TEC	_	_	O
15	)	_	_	O
16	intervention	_	_	O
17	(	_	_	O
18	aimed	_	_	O
19	at	_	_	O
20	reducing	_	_	O
21	pain	_	_	O
22	misconceptions	_	_	O
23	and	_	_	O
24	enhancing	_	_	O
25	self-efficacy	_	_	O
26	for	_	_	O
27	communicating	_	_	O
28	with	_	_	O
29	physicians	_	_	O
30	)	_	_	O
31	on	_	_	O
32	cancer	_	_	O
33	pain	_	_	O
34	severity	_	_	O
35	,	_	_	O
36	pain-related	_	_	O
37	impairment	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	.	_	_	O

44	Cancer	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	baseline	_	_	O
48	"	_	_	O
49	worst	_	_	O
50	pain	_	_	O
51	"	_	_	O
52	of	_	_	O
53	â‰¥4	_	_	O
54	on	_	_	O
55	a	_	_	O
56	0-10	_	_	O
57	scale	_	_	O
58	or	_	_	O
59	at	_	_	O
60	least	_	_	O
61	moderate	_	_	O
62	functional	_	_	O
63	impairment	_	_	O
64	due	_	_	O
65	to	_	_	O
66	pain	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	TEC	_	_	O
72	or	_	_	O
73	enhanced	_	_	O
74	usual	_	_	O
75	care	_	_	O
76	(	_	_	O
77	EUC	_	_	O
78	)	_	_	O
79	during	_	_	O
80	a	_	_	O
81	telephone	_	_	O
82	interview	_	_	O
83	conducted	_	_	O
84	in	_	_	O
85	advance	_	_	O
86	of	_	_	O
87	a	_	_	O
88	planned	_	_	O
89	oncology	_	_	O
90	office	_	_	O
91	visit	_	_	O
92	(	_	_	O
93	265	_	_	O
94	patients	_	_	O
95	randomized	_	_	O
96	to	_	_	O
97	TEC	_	_	O
98	or	_	_	O
99	EUC	_	_	O
100	;	_	_	O
101	258	_	_	O
102	completed	_	_	O
103	at	_	_	O
104	least	_	_	O
105	one	_	_	O
106	follow-up	_	_	O
107	)	_	_	O
108	.	_	_	O

109	Patients	_	_	O
110	completed	_	_	O
111	questionnaires	_	_	O
112	before	_	_	O
113	and	_	_	O
114	after	_	_	O
115	the	_	_	O
116	visit	_	_	O
117	and	_	_	O
118	were	_	_	O
119	interviewed	_	_	O
120	by	_	_	O
121	telephone	_	_	O
122	at	_	_	O
123	2	_	_	O
124	,	_	_	O
125	6	_	_	O
126	,	_	_	O
127	and	_	_	O
128	12	_	_	O
129	weeks	_	_	O
130	.	_	_	O

131	Mixed	_	_	O
132	effects	_	_	O
133	regressions	_	_	O
134	were	_	_	O
135	used	_	_	O
136	to	_	_	O
137	evaluate	_	_	O
138	the	_	_	O
139	intervention	_	_	O
140	adjusting	_	_	O
141	for	_	_	O
142	patient	_	_	O
143	,	_	_	O
144	practice	_	_	O
145	,	_	_	O
146	and	_	_	O
147	site	_	_	O
148	characteristics	_	_	O
149	.	_	_	O

150	Compared	_	_	B-Premise
151	to	_	_	I-Premise
152	EUC	_	_	I-Premise
153	,	_	_	I-Premise
154	TEC	_	_	I-Premise
155	was	_	_	I-Premise
156	associated	_	_	I-Premise
157	with	_	_	I-Premise
158	increased	_	_	I-Premise
159	pain	_	_	I-Premise
160	communication	_	_	I-Premise
161	self-efficacy	_	_	I-Premise
162	after	_	_	I-Premise
163	the	_	_	I-Premise
164	intervention	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	<	_	_	I-Premise
168	.001	_	_	I-Premise
169	)	_	_	I-Premise
170	;	_	_	I-Premise
171	both	_	_	B-Premise
172	groups	_	_	I-Premise
173	showed	_	_	I-Premise
174	significant	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.0001	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	similar	_	_	I-Premise
182	,	_	_	I-Premise
183	reductions	_	_	I-Premise
184	in	_	_	I-Premise
185	pain	_	_	I-Premise
186	misconceptions	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	B-Premise
189	2	_	_	I-Premise
190	weeks	_	_	I-Premise
191	,	_	_	I-Premise
192	assignment	_	_	I-Premise
193	to	_	_	I-Premise
194	TEC	_	_	I-Premise
195	was	_	_	I-Premise
196	associated	_	_	I-Premise
197	with	_	_	I-Premise
198	improvement	_	_	I-Premise
199	in	_	_	I-Premise
200	pain-related	_	_	I-Premise
201	impairment	_	_	I-Premise
202	(	_	_	I-Premise
203	-0.25	_	_	I-Premise
204	points	_	_	I-Premise
205	on	_	_	I-Premise
206	a	_	_	I-Premise
207	5-point	_	_	I-Premise
208	scale	_	_	I-Premise
209	,	_	_	I-Premise
210	95	_	_	I-Premise
211	%	_	_	I-Premise
212	confidence	_	_	I-Premise
213	interval	_	_	I-Premise
214	-0.43	_	_	I-Premise
215	to	_	_	I-Premise
216	-0.06	_	_	I-Premise
217	,	_	_	I-Premise
218	P=.01	_	_	I-Premise
219	)	_	_	I-Premise
220	but	_	_	B-Premise
221	not	_	_	I-Premise
222	in	_	_	I-Premise
223	pain	_	_	I-Premise
224	severity	_	_	I-Premise
225	(	_	_	I-Premise
226	-0.21	_	_	I-Premise
227	points	_	_	I-Premise
228	on	_	_	I-Premise
229	an	_	_	I-Premise
230	11-point	_	_	I-Premise
231	scale	_	_	I-Premise
232	,	_	_	I-Premise
233	-0.60	_	_	I-Premise
234	to	_	_	I-Premise
235	0.17	_	_	I-Premise
236	,	_	_	I-Premise
237	P=.27	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	B-Premise
241	improvement	_	_	I-Premise
242	in	_	_	I-Premise
243	pain-related	_	_	I-Premise
244	impairment	_	_	I-Premise
245	was	_	_	I-Premise
246	not	_	_	I-Premise
247	sustained	_	_	I-Premise
248	at	_	_	I-Premise
249	6	_	_	I-Premise
250	and	_	_	I-Premise
251	12	_	_	I-Premise
252	weeks	_	_	I-Premise
253	.	_	_	I-Premise

254	There	_	_	B-Premise
255	were	_	_	I-Premise
256	no	_	_	I-Premise
257	significant	_	_	I-Premise
258	intervention	_	_	I-Premise
259	by	_	_	I-Premise
260	subgroup	_	_	I-Premise
261	interactions	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	>	_	_	I-Premise
265	.10	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	We	_	_	B-Claim
269	conclude	_	_	I-Claim
270	that	_	_	I-Claim
271	TEC	_	_	I-Claim
272	,	_	_	I-Claim
273	compared	_	_	I-Claim
274	with	_	_	I-Claim
275	EUC	_	_	I-Claim
276	,	_	_	I-Claim
277	resulted	_	_	I-Claim
278	in	_	_	I-Claim
279	improved	_	_	I-Claim
280	pain	_	_	I-Claim
281	communication	_	_	I-Claim
282	self-efficacy	_	_	I-Claim
283	and	_	_	I-Claim
284	temporary	_	_	I-Claim
285	improvement	_	_	I-Claim
286	in	_	_	I-Claim
287	pain-related	_	_	I-Claim
288	impairment	_	_	I-Claim
289	,	_	_	I-Claim
290	but	_	_	I-Claim
291	no	_	_	I-Claim
292	improvement	_	_	I-Claim
293	in	_	_	I-Claim
294	pain	_	_	I-Claim
295	severity	_	_	I-Claim
296	.	_	_	I-Claim


0	In	_	_	B-Claim
1	phase	_	_	I-Claim
2	II	_	_	I-Claim
3	trials	_	_	I-Claim
4	,	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	has	_	_	I-Claim
7	been	_	_	I-Claim
8	shown	_	_	I-Claim
9	to	_	_	I-Claim
10	have	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	patients	_	_	I-Claim
15	with	_	_	I-Claim
16	advanced	_	_	I-Claim
17	non-small-cell	_	_	I-Claim
18	lung	_	_	I-Claim
19	cancer	_	_	I-Claim
20	(	_	_	I-Claim
21	NSCLC	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	However	_	_	O
25	,	_	_	O
26	the	_	_	O
27	survival	_	_	O
28	and	_	_	O
29	quality-of-life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	benefits	_	_	O
34	of	_	_	O
35	paclitaxel	_	_	O
36	used	_	_	O
37	as	_	_	O
38	a	_	_	O
39	single	_	_	O
40	agent	_	_	O
41	compared	_	_	O
42	with	_	_	O
43	supportive	_	_	O
44	care	_	_	O
45	alone	_	_	O
46	have	_	_	O
47	not	_	_	O
48	been	_	_	O
49	assessed	_	_	O
50	in	_	_	O
51	a	_	_	O
52	randomized	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	.	_	_	O

56	A	_	_	O
57	total	_	_	O
58	of	_	_	O
59	157	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	stage	_	_	O
63	IIIB	_	_	O
64	or	_	_	O
65	IV	_	_	O
66	NSCLC	_	_	O
67	who	_	_	O
68	had	_	_	O
69	received	_	_	O
70	no	_	_	O
71	prior	_	_	O
72	chemotherapy	_	_	O
73	were	_	_	O
74	randomly	_	_	O
75	assigned	_	_	O
76	to	_	_	O
77	receive	_	_	O
78	either	_	_	O
79	best	_	_	O
80	supportive	_	_	O
81	care	_	_	O
82	alone	_	_	O
83	(	_	_	O
84	78	_	_	O
85	patients	_	_	O
86	)	_	_	O
87	or	_	_	O
88	paclitaxel	_	_	O
89	plus	_	_	O
90	supportive	_	_	O
91	care	_	_	O
92	(	_	_	O
93	79	_	_	O
94	patients	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Paclitaxel	_	_	O
98	was	_	_	O
99	administered	_	_	O
100	as	_	_	O
101	a	_	_	O
102	3-hour	_	_	O
103	intravenous	_	_	O
104	infusion	_	_	O
105	every	_	_	O
106	3	_	_	O
107	weeks	_	_	O
108	.	_	_	O

109	Supportive	_	_	O
110	care	_	_	O
111	included	_	_	O
112	palliative	_	_	O
113	radiotherapy	_	_	O
114	and	_	_	O
115	supportive	_	_	O
116	therapy	_	_	O
117	with	_	_	O
118	corticosteroids	_	_	O
119	,	_	_	O
120	antibiotics	_	_	O
121	,	_	_	O
122	analgesics	_	_	O
123	,	_	_	O
124	antiemetics	_	_	O
125	,	_	_	O
126	transfusions	_	_	O
127	,	_	_	O
128	and	_	_	O
129	other	_	_	O
130	symptomatic	_	_	O
131	therapy	_	_	O
132	as	_	_	O
133	required	_	_	O
134	.	_	_	O

135	The	_	_	O
136	primary	_	_	O
137	end	_	_	O
138	point	_	_	O
139	of	_	_	O
140	the	_	_	O
141	study	_	_	O
142	was	_	_	O
143	survival	_	_	O
144	.	_	_	O

145	Time	_	_	O
146	to	_	_	O
147	disease	_	_	O
148	progression	_	_	O
149	,	_	_	O
150	response	_	_	O
151	rate	_	_	O
152	,	_	_	O
153	adverse	_	_	O
154	events	_	_	O
155	,	_	_	O
156	and	_	_	O
157	QOL	_	_	O
158	were	_	_	O
159	secondary	_	_	O
160	end	_	_	O
161	points	_	_	O
162	.	_	_	O

163	Pretreatment	_	_	O
164	characteristics	_	_	O
165	were	_	_	O
166	evenly	_	_	O
167	distributed	_	_	O
168	between	_	_	O
169	the	_	_	O
170	two	_	_	O
171	arms	_	_	O
172	.	_	_	O

173	Survival	_	_	B-Premise
174	was	_	_	I-Premise
175	statistically	_	_	I-Premise
176	significantly	_	_	I-Premise
177	better	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	paclitaxel	_	_	I-Premise
181	plus	_	_	I-Premise
182	supportive	_	_	I-Premise
183	care	_	_	I-Premise
184	arm	_	_	I-Premise
185	than	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	supportive	_	_	I-Premise
189	care	_	_	I-Premise
190	alone	_	_	I-Premise
191	arm	_	_	I-Premise
192	(	_	_	I-Premise
193	two-sided	_	_	I-Premise
194	P	_	_	I-Premise
195	=.037	_	_	I-Premise
196	)	_	_	I-Premise
197	(	_	_	I-Premise
198	median	_	_	I-Premise
199	survival	_	_	I-Premise
200	=	_	_	I-Premise
201	6.8	_	_	I-Premise
202	months	_	_	I-Premise
203	versus	_	_	I-Premise
204	4.8	_	_	I-Premise
205	months	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Cox	_	_	B-Premise
209	multivariate	_	_	I-Premise
210	analysis	_	_	I-Premise
211	showed	_	_	I-Premise
212	paclitaxel	_	_	I-Premise
213	plus	_	_	I-Premise
214	supportive	_	_	I-Premise
215	care	_	_	I-Premise
216	to	_	_	I-Premise
217	be	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significantly	_	_	I-Premise
220	associated	_	_	I-Premise
221	with	_	_	I-Premise
222	improved	_	_	I-Premise
223	survival	_	_	I-Premise
224	(	_	_	I-Premise
225	two-sided	_	_	I-Premise
226	P	_	_	I-Premise
227	=.048	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	QOL	_	_	B-Premise
231	was	_	_	I-Premise
232	similar	_	_	I-Premise
233	for	_	_	I-Premise
234	both	_	_	I-Premise
235	treatment	_	_	I-Premise
236	arms	_	_	I-Premise
237	,	_	_	I-Premise
238	except	_	_	B-Premise
239	for	_	_	I-Premise
240	the	_	_	I-Premise
241	functional	_	_	I-Premise
242	activity	_	_	I-Premise
243	score	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	Rotterdam	_	_	I-Premise
247	Symptom	_	_	I-Premise
248	Checklist	_	_	I-Premise
249	,	_	_	I-Premise
250	where	_	_	I-Premise
251	QOL	_	_	I-Premise
252	data	_	_	I-Premise
253	statistically	_	_	I-Premise
254	significantly	_	_	I-Premise
255	favored	_	_	I-Premise
256	the	_	_	I-Premise
257	paclitaxel	_	_	I-Premise
258	plus	_	_	I-Premise
259	supportive	_	_	I-Premise
260	care	_	_	I-Premise
261	arm	_	_	I-Premise
262	(	_	_	I-Premise
263	two-sided	_	_	I-Premise
264	P	_	_	I-Premise
265	=.043	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Claim
269	addition	_	_	I-Claim
270	of	_	_	I-Claim
271	paclitaxel	_	_	I-Claim
272	to	_	_	I-Claim
273	best	_	_	I-Claim
274	supportive	_	_	I-Claim
275	care	_	_	I-Claim
276	significantly	_	_	I-Claim
277	improved	_	_	I-Claim
278	survival	_	_	I-Claim
279	and	_	_	I-Claim
280	time	_	_	I-Claim
281	to	_	_	I-Claim
282	disease	_	_	I-Claim
283	progression	_	_	I-Claim
284	compared	_	_	I-Claim
285	with	_	_	I-Claim
286	best	_	_	I-Claim
287	supportive	_	_	I-Claim
288	care	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	advanced	_	_	I-Claim
293	NSCLC	_	_	I-Claim
294	and	_	_	I-Claim
295	may	_	_	I-Claim
296	improve	_	_	I-Claim
297	some	_	_	I-Claim
298	aspects	_	_	I-Claim
299	of	_	_	I-Claim
300	QOL	_	_	I-Claim
301	.	_	_	I-Claim


0	National	_	_	O
1	Cancer	_	_	O
2	Institute	_	_	O
3	of	_	_	O
4	Canada	_	_	O
5	Clinical	_	_	O
6	Trials	_	_	O
7	Group	_	_	O
8	CO.17	_	_	O
9	demonstrated	_	_	O
10	the	_	_	O
11	antiepidermal	_	_	O
12	growth	_	_	O
13	factor	_	_	O
14	receptor	_	_	O
15	(	_	_	O
16	anti-EGFR	_	_	O
17	)	_	_	O
18	monoclonal	_	_	O
19	antibody	_	_	O
20	cetuximab	_	_	O
21	improves	_	_	O
22	overall	_	_	O
23	and	_	_	O
24	progression-free	_	_	O
25	survival	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	,	_	_	O
31	chemotherapy-refractory	_	_	O
32	colorectal	_	_	O
33	cancer	_	_	O
34	(	_	_	O
35	CRC	_	_	O
36	)	_	_	O
37	,	_	_	O
38	particularly	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	wild-type	_	_	O
43	KRAS	_	_	O
44	tumors	_	_	O
45	.	_	_	O

46	This	_	_	O
47	article	_	_	O
48	reports	_	_	O
49	the	_	_	O
50	health-related	_	_	O
51	quality-of-life	_	_	O
52	(	_	_	O
53	HRQL	_	_	O
54	)	_	_	O
55	outcomes	_	_	O
56	from	_	_	O
57	CO.17	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	(	_	_	O
61	N	_	_	O
62	=	_	_	O
63	572	_	_	O
64	)	_	_	O
65	with	_	_	O
66	pretreated	_	_	O
67	EGFR-detectable	_	_	O
68	advanced	_	_	O
69	CRC	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	cetuximab	_	_	O
75	and	_	_	O
76	best	_	_	O
77	supportive	_	_	O
78	care	_	_	O
79	(	_	_	O
80	BSC	_	_	O
81	)	_	_	O
82	or	_	_	O
83	to	_	_	O
84	BSC	_	_	O
85	alone	_	_	O
86	.	_	_	O

87	HRQL	_	_	O
88	primary	_	_	O
89	end	_	_	O
90	points	_	_	O
91	assessed	_	_	O
92	by	_	_	O
93	the	_	_	O
94	EORTC	_	_	O
95	QLQ-C30	_	_	O
96	were	_	_	O
97	physical	_	_	O
98	function	_	_	O
99	(	_	_	O
100	PF	_	_	O
101	)	_	_	O
102	and	_	_	O
103	global	_	_	O
104	health	_	_	O
105	status	_	_	O
106	(	_	_	O
107	GHS	_	_	O
108	)	_	_	O
109	;	_	_	O
110	mean	_	_	O
111	changes	_	_	O
112	from	_	_	O
113	baseline	_	_	O
114	to	_	_	O
115	8	_	_	O
116	and	_	_	O
117	16	_	_	O
118	weeks	_	_	O
119	were	_	_	O
120	assessed	_	_	O
121	.	_	_	O

122	Post	_	_	O
123	hoc	_	_	O
124	analysis	_	_	O
125	by	_	_	O
126	KRAS	_	_	O
127	mutation	_	_	O
128	status	_	_	O
129	was	_	_	O
130	performed	_	_	O
131	.	_	_	O

132	Questionnaire	_	_	O
133	compliance	_	_	O
134	was	_	_	O
135	94	_	_	O
136	%	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	but	_	_	O
141	it	_	_	O
142	declined	_	_	O
143	differentially	_	_	O
144	(	_	_	O
145	67	_	_	O
146	%	_	_	O
147	v	_	_	O
148	47	_	_	O
149	%	_	_	O
150	for	_	_	O
151	cetuximab	_	_	O
152	v	_	_	O
153	BSC	_	_	O
154	at	_	_	O
155	16	_	_	O
156	weeks	_	_	O
157	)	_	_	O
158	.	_	_	O

159	PF	_	_	B-Premise
160	change	_	_	I-Premise
161	scores	_	_	I-Premise
162	were	_	_	I-Premise
163	-3.9	_	_	I-Premise
164	for	_	_	I-Premise
165	cetuximab	_	_	I-Premise
166	and	_	_	I-Premise
167	-8.6	_	_	I-Premise
168	for	_	_	I-Premise
169	BSC	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	.046	_	_	I-Premise
174	)	_	_	I-Premise
175	at	_	_	I-Premise
176	8	_	_	I-Premise
177	weeks	_	_	I-Premise
178	and	_	_	I-Premise
179	were	_	_	I-Premise
180	-5.9	_	_	I-Premise
181	and	_	_	I-Premise
182	-12.5	_	_	I-Premise
183	for	_	_	I-Premise
184	cetuximab	_	_	I-Premise
185	and	_	_	I-Premise
186	BSC	_	_	I-Premise
187	,	_	_	I-Premise
188	respectively	_	_	I-Premise
189	,	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	=	_	_	I-Premise
193	.027	_	_	I-Premise
194	)	_	_	I-Premise
195	at	_	_	I-Premise
196	16	_	_	I-Premise
197	weeks	_	_	I-Premise
198	.	_	_	I-Premise

199	GHS	_	_	B-Premise
200	change	_	_	I-Premise
201	scores	_	_	I-Premise
202	were	_	_	I-Premise
203	-0.5	_	_	I-Premise
204	and	_	_	I-Premise
205	-7.1	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.008	_	_	I-Premise
210	)	_	_	I-Premise
211	at	_	_	I-Premise
212	8	_	_	I-Premise
213	weeks	_	_	I-Premise
214	and	_	_	I-Premise
215	were	_	_	I-Premise
216	-3.6	_	_	I-Premise
217	and	_	_	I-Premise
218	-15.2	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	.008	_	_	I-Premise
223	)	_	_	I-Premise
224	at	_	_	I-Premise
225	16	_	_	I-Premise
226	weeks	_	_	I-Premise
227	for	_	_	I-Premise
228	cetuximab	_	_	I-Premise
229	and	_	_	I-Premise
230	BSC	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	.	_	_	I-Premise

234	In	_	_	B-Premise
235	patients	_	_	I-Premise
236	who	_	_	I-Premise
237	had	_	_	I-Premise
238	tumors	_	_	I-Premise
239	with	_	_	I-Premise
240	wild-type	_	_	I-Premise
241	KRAS	_	_	I-Premise
242	status	_	_	I-Premise
243	,	_	_	I-Premise
244	cetuximab	_	_	I-Premise
245	resulted	_	_	I-Premise
246	in	_	_	I-Premise
247	less	_	_	I-Premise
248	PF	_	_	I-Premise
249	deterioration	_	_	I-Premise
250	at	_	_	I-Premise
251	8	_	_	I-Premise
252	weeks	_	_	I-Premise
253	(	_	_	I-Premise
254	-0.7	_	_	I-Premise
255	v	_	_	I-Premise
256	-7.2	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.11	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	16	_	_	I-Premise
264	weeks	_	_	I-Premise
265	(	_	_	I-Premise
266	-3.4	_	_	I-Premise
267	v	_	_	I-Premise
268	-13.8	_	_	I-Premise
269	;	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.008	_	_	I-Premise
273	)	_	_	I-Premise
274	compared	_	_	I-Premise
275	with	_	_	I-Premise
276	BSC	_	_	I-Premise
277	.	_	_	I-Premise

278	Patients	_	_	B-Premise
279	with	_	_	I-Premise
280	wild-type	_	_	I-Premise
281	status	_	_	I-Premise
282	who	_	_	I-Premise
283	received	_	_	I-Premise
284	cetuximab	_	_	I-Premise
285	experienced	_	_	I-Premise
286	improved	_	_	I-Premise
287	GHS	_	_	I-Premise
288	at	_	_	I-Premise
289	8	_	_	I-Premise
290	weeks	_	_	I-Premise
291	,	_	_	I-Premise
292	whereas	_	_	I-Premise
293	patients	_	_	I-Premise
294	who	_	_	I-Premise
295	received	_	_	I-Premise
296	BSC	_	_	I-Premise
297	alone	_	_	I-Premise
298	deteriorated	_	_	I-Premise
299	(	_	_	I-Premise
300	3.2	_	_	I-Premise
301	v	_	_	I-Premise
302	-7.7	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.002	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Cetuximab	_	_	B-Premise
310	preserved	_	_	I-Premise
311	GHS	_	_	I-Premise
312	at	_	_	I-Premise
313	16	_	_	I-Premise
314	weeks	_	_	I-Premise
315	(	_	_	I-Premise
316	-0.2	_	_	I-Premise
317	v	_	_	I-Premise
318	-18.1	_	_	I-Premise
319	;	_	_	I-Premise
320	P	_	_	I-Premise
321	<	_	_	I-Premise
322	.001	_	_	I-Premise
323	)	_	_	I-Premise
324	.	_	_	I-Premise

325	No	_	_	B-Premise
326	significant	_	_	I-Premise
327	differences	_	_	I-Premise
328	were	_	_	I-Premise
329	noted	_	_	I-Premise
330	between	_	_	I-Premise
331	study	_	_	I-Premise
332	arms	_	_	I-Premise
333	for	_	_	I-Premise
334	patients	_	_	I-Premise
335	with	_	_	I-Premise
336	mutated	_	_	I-Premise
337	KRAS	_	_	I-Premise
338	tumors	_	_	I-Premise
339	.	_	_	I-Premise

340	Cetuximab	_	_	B-Claim
341	offers	_	_	I-Claim
342	important	_	_	I-Claim
343	HRQL	_	_	I-Claim
344	and	_	_	I-Claim
345	survival	_	_	I-Claim
346	benefits	_	_	I-Claim
347	for	_	_	I-Claim
348	pretreated	_	_	I-Claim
349	patients	_	_	I-Claim
350	with	_	_	I-Claim
351	advanced	_	_	I-Claim
352	,	_	_	I-Claim
353	wild-type	_	_	I-Claim
354	KRAS	_	_	I-Claim
355	CRC	_	_	I-Claim
356	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	letrozole	_	_	O
6	compared	_	_	O
7	with	_	_	O
8	placebo	_	_	O
9	after	_	_	O
10	adjuvant	_	_	O
11	tamoxifen	_	_	O
12	on	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	the	_	_	O
21	MA.17	_	_	O
22	trial	_	_	O
23	.	_	_	O

24	Patients	_	_	O
25	completed	_	_	O
26	the	_	_	O
27	Short	_	_	O
28	Form	_	_	O
29	36-item	_	_	O
30	Health	_	_	O
31	Survey	_	_	O
32	(	_	_	O
33	SF-36	_	_	O
34	)	_	_	O
35	and	_	_	O
36	the	_	_	O
37	Menopause	_	_	O
38	Specific	_	_	O
39	Quality	_	_	O
40	of	_	_	O
41	Life	_	_	O
42	Questionnaire	_	_	O
43	(	_	_	O
44	MENQOL	_	_	O
45	)	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	,	_	_	O
49	6	_	_	O
50	months	_	_	O
51	,	_	_	O
52	and	_	_	O
53	annually	_	_	O
54	.	_	_	O

55	Mean	_	_	O
56	change	_	_	O
57	scores	_	_	O
58	from	_	_	O
59	baseline	_	_	O
60	were	_	_	O
61	compared	_	_	O
62	between	_	_	O
63	groups	_	_	O
64	for	_	_	O
65	summary	_	_	O
66	measures	_	_	O
67	and	_	_	O
68	domains	_	_	O
69	.	_	_	O

70	A	_	_	O
71	response	_	_	O
72	analysis	_	_	O
73	compared	_	_	O
74	the	_	_	O
75	proportion	_	_	O
76	of	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	demonstrated	_	_	O
80	an	_	_	O
81	important	_	_	O
82	change	_	_	O
83	in	_	_	O
84	QOL	_	_	O
85	.	_	_	O

86	Of	_	_	O
87	5,187	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	women	_	_	O
91	in	_	_	O
92	the	_	_	O
93	trial	_	_	O
94	,	_	_	O
95	3,612	_	_	O
96	(	_	_	O
97	69.9	_	_	O
98	%	_	_	O
99	)	_	_	O
100	participated	_	_	O
101	in	_	_	O
102	the	_	_	O
103	QOL	_	_	O
104	substudy	_	_	O
105	:	_	_	O
106	1,799	_	_	O
107	were	_	_	O
108	allocated	_	_	O
109	to	_	_	O
110	placebo	_	_	O
111	and	_	_	O
112	1,813	_	_	O
113	were	_	_	O
114	allocated	_	_	O
115	to	_	_	O
116	letrozole	_	_	O
117	.	_	_	O

118	No	_	_	B-Premise
119	differences	_	_	I-Premise
120	were	_	_	I-Premise
121	seen	_	_	I-Premise
122	between	_	_	I-Premise
123	groups	_	_	I-Premise
124	in	_	_	I-Premise
125	mean	_	_	I-Premise
126	change	_	_	I-Premise
127	scores	_	_	I-Premise
128	from	_	_	I-Premise
129	baseline	_	_	I-Premise
130	for	_	_	I-Premise
131	the	_	_	I-Premise
132	SF-36	_	_	I-Premise
133	physical	_	_	I-Premise
134	and	_	_	I-Premise
135	mental	_	_	I-Premise
136	component	_	_	I-Premise
137	summary	_	_	I-Premise
138	scores	_	_	I-Premise
139	at	_	_	I-Premise
140	6	_	_	I-Premise
141	,	_	_	I-Premise
142	12	_	_	I-Premise
143	,	_	_	I-Premise
144	24	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	36	_	_	I-Premise
148	months	_	_	I-Premise
149	.	_	_	I-Premise

150	Small	_	_	B-Premise
151	(	_	_	I-Premise
152	<	_	_	I-Premise
153	0.2	_	_	I-Premise
154	standard	_	_	I-Premise
155	deviations	_	_	I-Premise
156	)	_	_	I-Premise
157	but	_	_	I-Premise
158	statistically	_	_	I-Premise
159	significant	_	_	I-Premise
160	differences	_	_	I-Premise
161	in	_	_	I-Premise
162	mean	_	_	I-Premise
163	change	_	_	I-Premise
164	scores	_	_	I-Premise
165	from	_	_	I-Premise
166	baseline	_	_	I-Premise
167	were	_	_	I-Premise
168	seen	_	_	I-Premise
169	for	_	_	I-Premise
170	the	_	_	I-Premise
171	SF-36	_	_	I-Premise
172	domains	_	_	I-Premise
173	of	_	_	I-Premise
174	physical	_	_	I-Premise
175	functioning	_	_	I-Premise
176	(	_	_	I-Premise
177	12	_	_	I-Premise
178	months	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	bodily	_	_	I-Premise
182	pain	_	_	I-Premise
183	(	_	_	I-Premise
184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	vitality	_	_	I-Premise
189	(	_	_	I-Premise
190	6	_	_	I-Premise
191	and	_	_	I-Premise
192	12	_	_	I-Premise
193	months	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	the	_	_	I-Premise
198	MENQOL	_	_	I-Premise
199	vasomotor	_	_	I-Premise
200	(	_	_	I-Premise
201	6	_	_	I-Premise
202	,	_	_	I-Premise
203	12	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	24	_	_	I-Premise
207	months	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	sexual	_	_	I-Premise
211	domains	_	_	I-Premise
212	(	_	_	I-Premise
213	12	_	_	I-Premise
214	and	_	_	I-Premise
215	24	_	_	I-Premise
216	months	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	On	_	_	B-Premise
220	the	_	_	I-Premise
221	response	_	_	I-Premise
222	analysis	_	_	I-Premise
223	,	_	_	I-Premise
224	a	_	_	I-Premise
225	significant	_	_	I-Premise
226	difference	_	_	I-Premise
227	was	_	_	I-Premise
228	seen	_	_	I-Premise
229	between	_	_	I-Premise
230	groups	_	_	I-Premise
231	for	_	_	I-Premise
232	the	_	_	I-Premise
233	bodily	_	_	I-Premise
234	pain	_	_	I-Premise
235	domain	_	_	I-Premise
236	(	_	_	I-Premise
237	percentage	_	_	I-Premise
238	of	_	_	I-Premise
239	patients	_	_	I-Premise
240	reporting	_	_	I-Premise
241	a	_	_	I-Premise
242	worsening	_	_	I-Premise
243	of	_	_	I-Premise
244	QOL	_	_	I-Premise
245	,	_	_	I-Premise
246	47	_	_	I-Premise
247	%	_	_	I-Premise
248	placebo	_	_	I-Premise
249	v	_	_	I-Premise
250	51	_	_	I-Premise
251	%	_	_	I-Premise
252	letrozole	_	_	I-Premise
253	;	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.009	_	_	I-Premise
257	)	_	_	I-Premise
258	and	_	_	I-Premise
259	the	_	_	I-Premise
260	vasomotor	_	_	I-Premise
261	domain	_	_	I-Premise
262	(	_	_	I-Premise
263	22	_	_	I-Premise
264	%	_	_	I-Premise
265	placebo	_	_	I-Premise
266	v	_	_	I-Premise
267	29	_	_	I-Premise
268	%	_	_	I-Premise
269	letrozole	_	_	I-Premise
270	;	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	.001	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Letrozole	_	_	B-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	have	_	_	I-Claim
280	an	_	_	I-Claim
281	adverse	_	_	I-Claim
282	impact	_	_	I-Claim
283	on	_	_	I-Claim
284	overall	_	_	I-Claim
285	QOL	_	_	I-Claim
286	.	_	_	I-Claim

287	Small	_	_	B-Claim
288	effects	_	_	I-Claim
289	were	_	_	I-Claim
290	seen	_	_	I-Claim
291	in	_	_	I-Claim
292	some	_	_	I-Claim
293	domains	_	_	I-Claim
294	consistent	_	_	I-Claim
295	with	_	_	I-Claim
296	a	_	_	I-Claim
297	minority	_	_	I-Claim
298	of	_	_	I-Claim
299	patients	_	_	I-Claim
300	experiencing	_	_	I-Claim
301	changes	_	_	I-Claim
302	in	_	_	I-Claim
303	QOL	_	_	I-Claim
304	compatible	_	_	I-Claim
305	with	_	_	I-Claim
306	a	_	_	I-Claim
307	reduction	_	_	I-Claim
308	in	_	_	I-Claim
309	estrogen	_	_	I-Claim
310	synthesis	_	_	I-Claim
311	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	interferon	_	_	I-Claim
4	alfa	_	_	I-Claim
5	(	_	_	I-Claim
6	IFNalpha	_	_	I-Claim
7	)	_	_	I-Claim
8	and	_	_	I-Claim
9	isotretinoin	_	_	I-Claim
10	has	_	_	I-Claim
11	shown	_	_	I-Claim
12	a	_	_	I-Claim
13	direct	_	_	I-Claim
14	antiproliferative	_	_	I-Claim
15	effect	_	_	I-Claim
16	on	_	_	I-Claim
17	human	_	_	I-Claim
18	melanoma	_	_	I-Claim
19	cell	_	_	I-Claim
20	lines	_	_	I-Claim
21	,	_	_	I-Claim
22	but	_	_	B-Claim
23	it	_	_	I-Claim
24	remained	_	_	I-Claim
25	unclear	_	_	I-Claim
26	whether	_	_	I-Claim
27	this	_	_	I-Claim
28	combination	_	_	I-Claim
29	is	_	_	I-Claim
30	more	_	_	I-Claim
31	effective	_	_	I-Claim
32	than	_	_	I-Claim
33	IFNalpha	_	_	I-Claim
34	alone	_	_	I-Claim
35	in	_	_	I-Claim
36	patients	_	_	I-Claim
37	with	_	_	I-Claim
38	metastatic	_	_	I-Claim
39	melanoma	_	_	I-Claim
40	.	_	_	I-Claim

41	We	_	_	O
42	evaluated	_	_	O
43	safety	_	_	O
44	and	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	IFNalpha	_	_	O
48	and	_	_	O
49	isotretinoin	_	_	O
50	compared	_	_	O
51	with	_	_	O
52	IFNalpha	_	_	O
53	alone	_	_	O
54	as	_	_	O
55	adjuvant	_	_	O
56	treatment	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	primary	_	_	O
61	malignant	_	_	O
62	melanoma	_	_	O
63	stage	_	_	O
64	IIA	_	_	O
65	and	_	_	O
66	IIB	_	_	O
67	.	_	_	O

68	In	_	_	O
69	a	_	_	O
70	prospective	_	_	O
71	,	_	_	O
72	randomized	_	_	O
73	,	_	_	O
74	double-blind	_	_	O
75	,	_	_	O
76	placebo-controlled	_	_	O
77	trial	_	_	O
78	,	_	_	O
79	407	_	_	O
80	melanoma	_	_	O
81	patients	_	_	O
82	in	_	_	O
83	stage	_	_	O
84	IIA	_	_	O
85	(	_	_	O
86	301	_	_	O
87	patients	_	_	O
88	)	_	_	O
89	and	_	_	O
90	IIB	_	_	O
91	(	_	_	O
92	106	_	_	O
93	patients	_	_	O
94	)	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	to	_	_	O
99	either	_	_	O
100	IFNalpha	_	_	O
101	and	_	_	O
102	isotretinoin	_	_	O
103	(	_	_	O
104	isotretinoin	_	_	O
105	group	_	_	O
106	;	_	_	O
107	206	_	_	O
108	patients	_	_	O
109	)	_	_	O
110	or	_	_	O
111	IFNalpha	_	_	O
112	and	_	_	O
113	placebo	_	_	O
114	(	_	_	O
115	placebo	_	_	O
116	group	_	_	O
117	;	_	_	O
118	201	_	_	O
119	patients	_	_	O
120	)	_	_	O
121	after	_	_	O
122	excision	_	_	O
123	of	_	_	O
124	the	_	_	O
125	primary	_	_	O
126	tumor	_	_	O
127	.	_	_	O

128	IFNalpha	_	_	O
129	was	_	_	O
130	administered	_	_	O
131	three	_	_	O
132	times	_	_	O
133	a	_	_	O
134	week	_	_	O
135	at	_	_	O
136	a	_	_	O
137	dose	_	_	O
138	of	_	_	O
139	3	_	_	O
140	million	_	_	O
141	units	_	_	O
142	subcutaneously	_	_	O
143	for	_	_	O
144	24	_	_	O
145	months	_	_	O
146	.	_	_	O

147	Isotretinoin	_	_	O
148	at	_	_	O
149	a	_	_	O
150	dose	_	_	O
151	of	_	_	O
152	20	_	_	O
153	mg	_	_	O
154	for	_	_	O
155	patients	_	_	O
156	<	_	_	O
157	or	_	_	O
158	=	_	_	O
159	73	_	_	O
160	kg	_	_	O
161	,	_	_	O
162	30	_	_	O
163	mg	_	_	O
164	for	_	_	O
165	patients	_	_	O
166	greater	_	_	O
167	than	_	_	O
168	73	_	_	O
169	kg	_	_	O
170	,	_	_	O
171	or	_	_	O
172	placebo	_	_	O
173	daily	_	_	O
174	for	_	_	O
175	24	_	_	O
176	months	_	_	O
177	.	_	_	O

178	A	_	_	B-Premise
179	scheduled	_	_	I-Premise
180	interim	_	_	I-Premise
181	analysis	_	_	I-Premise
182	revealed	_	_	I-Premise
183	no	_	_	I-Premise
184	significant	_	_	I-Premise
185	differences	_	_	I-Premise
186	in	_	_	I-Premise
187	survival	_	_	I-Premise
188	rates	_	_	I-Premise
189	,	_	_	I-Premise
190	with	_	_	I-Premise
191	the	_	_	I-Premise
192	isotretinoin	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	the	_	_	I-Premise
196	placebo	_	_	I-Premise
197	group	_	_	I-Premise
198	showing	_	_	I-Premise
199	5-year	_	_	I-Premise
200	disease-free	_	_	I-Premise
201	survival	_	_	I-Premise
202	rates	_	_	I-Premise
203	of	_	_	I-Premise
204	55	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	,	_	_	I-Premise
211	46	_	_	I-Premise
212	%	_	_	I-Premise
213	to	_	_	I-Premise
214	65	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	67	_	_	I-Premise
219	%	_	_	I-Premise
220	(	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	,	_	_	I-Premise
225	59	_	_	I-Premise
226	%	_	_	I-Premise
227	to	_	_	I-Premise
228	75	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	overall	_	_	I-Premise
236	5-year	_	_	I-Premise
237	survival	_	_	I-Premise
238	rates	_	_	I-Premise
239	of	_	_	I-Premise
240	76	_	_	I-Premise
241	%	_	_	I-Premise
242	(	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	,	_	_	I-Premise
247	67	_	_	I-Premise
248	%	_	_	I-Premise
249	to	_	_	I-Premise
250	84	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	81	_	_	I-Premise
255	%	_	_	I-Premise
256	(	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	,	_	_	I-Premise
261	74	_	_	I-Premise
262	%	_	_	I-Premise
263	to	_	_	I-Premise
264	88	_	_	I-Premise
265	%	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	O
271	trial	_	_	O
272	was	_	_	O
273	stopped	_	_	O
274	for	_	_	O
275	futility	_	_	O
276	.	_	_	O

277	The	_	_	B-Claim
278	addition	_	_	I-Claim
279	of	_	_	I-Claim
280	isotretinoin	_	_	I-Claim
281	to	_	_	I-Claim
282	an	_	_	I-Claim
283	adjuvant	_	_	I-Claim
284	treatment	_	_	I-Claim
285	of	_	_	I-Claim
286	low-dose	_	_	I-Claim
287	IFNalpha	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	stage	_	_	I-Claim
292	IIA	_	_	I-Claim
293	and	_	_	I-Claim
294	IIB	_	_	I-Claim
295	melanoma	_	_	I-Claim
296	had	_	_	I-Claim
297	no	_	_	I-Claim
298	significant	_	_	I-Claim
299	effect	_	_	I-Claim
300	on	_	_	I-Claim
301	disease-free	_	_	I-Claim
302	or	_	_	I-Claim
303	overall	_	_	I-Claim
304	survival	_	_	I-Claim
305	and	_	_	I-Claim
306	is	_	_	I-Claim
307	therefore	_	_	I-Claim
308	not	_	_	I-Claim
309	recommended	_	_	I-Claim
310	.	_	_	I-Claim


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	of	_	_	O
5	radiotherapy	_	_	O
6	alone	_	_	O
7	versus	_	_	O
8	radiotherapy	_	_	O
9	with	_	_	O
10	concomitant	_	_	O
11	and	_	_	O
12	adjuvant	_	_	O
13	temozolomide	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	glioblastoma	_	_	O
18	showed	_	_	O
19	that	_	_	O
20	survival	_	_	O
21	was	_	_	O
22	higher	_	_	O
23	for	_	_	O
24	patients	_	_	O
25	assigned	_	_	O
26	combination	_	_	O
27	treatment	_	_	O
28	compared	_	_	O
29	with	_	_	O
30	those	_	_	O
31	assigned	_	_	O
32	standard	_	_	O
33	radiotherapy	_	_	O
34	alone	_	_	O
35	.	_	_	O

36	This	_	_	O
37	paper	_	_	O
38	reports	_	_	O
39	the	_	_	O
40	health-related	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	HRQOL	_	_	O
46	)	_	_	O
47	of	_	_	O
48	the	_	_	O
49	patients	_	_	O
50	in	_	_	O
51	this	_	_	O
52	trial	_	_	O
53	.	_	_	O

54	573	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	newly	_	_	O
58	diagnosed	_	_	O
59	glioblastoma	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	allocated	_	_	O
63	either	_	_	O
64	radiotherapy	_	_	O
65	alone	_	_	O
66	or	_	_	O
67	radiotherapy	_	_	O
68	and	_	_	O
69	temozolomide	_	_	O
70	.	_	_	O

71	The	_	_	O
72	primary	_	_	O
73	endpoint	_	_	O
74	was	_	_	O
75	survival	_	_	O
76	,	_	_	O
77	and	_	_	O
78	HRQOL	_	_	O
79	was	_	_	O
80	a	_	_	O
81	secondary	_	_	O
82	endpoint	_	_	O
83	.	_	_	O

84	We	_	_	O
85	assessed	_	_	O
86	HRQOL	_	_	O
87	at	_	_	O
88	baseline	_	_	O
89	and	_	_	O
90	at	_	_	O
91	every	_	_	O
92	3	_	_	O
93	months	_	_	O
94	during	_	_	O
95	treatment	_	_	O
96	until	_	_	O
97	progression	_	_	O
98	using	_	_	O
99	the	_	_	O
100	European	_	_	O
101	Organisation	_	_	O
102	for	_	_	O
103	Research	_	_	O
104	and	_	_	O
105	Treatment	_	_	O
106	of	_	_	O
107	Cancer	_	_	O
108	(	_	_	O
109	EORTC	_	_	O
110	)	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	questionnaire	_	_	O
115	core-30	_	_	O
116	(	_	_	O
117	QLQ-C30	_	_	O
118	)	_	_	O
119	and	_	_	O
120	the	_	_	O
121	EORTC	_	_	O
122	brain	_	_	O
123	cancer	_	_	O
124	module	_	_	O
125	(	_	_	O
126	EORTC	_	_	O
127	BN-20	_	_	O
128	)	_	_	O
129	.	_	_	O

130	We	_	_	O
131	calculated	_	_	O
132	changes	_	_	O
133	from	_	_	O
134	baseline	_	_	O
135	score	_	_	O
136	for	_	_	O
137	seven	_	_	O
138	predefined	_	_	O
139	HRQOL	_	_	O
140	measures	_	_	O
141	(	_	_	O
142	fatigue	_	_	O
143	,	_	_	O
144	overall	_	_	O
145	health	_	_	O
146	,	_	_	O
147	social	_	_	O
148	function	_	_	O
149	,	_	_	O
150	emotional	_	_	O
151	function	_	_	O
152	,	_	_	O
153	future	_	_	O
154	uncertainty	_	_	O
155	,	_	_	O
156	insomnia	_	_	O
157	,	_	_	O
158	and	_	_	O
159	communication	_	_	O
160	deficit	_	_	O
161	)	_	_	O
162	and	_	_	O
163	differences	_	_	O
164	between	_	_	O
165	groups	_	_	O
166	for	_	_	O
167	these	_	_	O
168	measures	_	_	O
169	at	_	_	O
170	every	_	_	O
171	time	_	_	O
172	point	_	_	O
173	.	_	_	O

174	The	_	_	O
175	significance	_	_	O
176	of	_	_	O
177	,	_	_	O
178	and	_	_	O
179	proportions	_	_	O
180	of	_	_	O
181	patients	_	_	O
182	with	_	_	O
183	,	_	_	O
184	improved	_	_	O
185	HRQOL	_	_	O
186	scores	_	_	O
187	--	_	_	O
188	defined	_	_	O
189	as	_	_	O
190	a	_	_	O
191	change	_	_	O
192	of	_	_	O
193	10	_	_	O
194	points	_	_	O
195	or	_	_	O
196	more	_	_	O
197	--	_	_	O
198	were	_	_	O
199	recorded	_	_	O
200	.	_	_	O

201	Baseline	_	_	O
202	questionnaires	_	_	O
203	were	_	_	O
204	available	_	_	O
205	for	_	_	O
206	490	_	_	O
207	(	_	_	O
208	86	_	_	O
209	%	_	_	O
210	)	_	_	O
211	patients	_	_	O
212	.	_	_	O

213	Baseline	_	_	O
214	HRQOL	_	_	O
215	scores	_	_	O
216	did	_	_	O
217	not	_	_	O
218	differ	_	_	O
219	between	_	_	O
220	groups	_	_	O
221	.	_	_	O

222	At	_	_	B-Premise
223	first	_	_	I-Premise
224	follow-up	_	_	I-Premise
225	,	_	_	I-Premise
226	groups	_	_	I-Premise
227	differed	_	_	I-Premise
228	only	_	_	I-Premise
229	in	_	_	I-Premise
230	social	_	_	I-Premise
231	functioning	_	_	I-Premise
232	,	_	_	I-Premise
233	favouring	_	_	I-Premise
234	the	_	_	I-Premise
235	radiotherapy-only	_	_	I-Premise
236	group	_	_	I-Premise
237	(	_	_	I-Premise
238	mean	_	_	I-Premise
239	score	_	_	I-Premise
240	79.0	_	_	I-Premise
241	[	_	_	I-Premise
242	SD	_	_	I-Premise
243	3.2	_	_	I-Premise
244	]	_	_	I-Premise
245	for	_	_	I-Premise
246	patients	_	_	I-Premise
247	assigned	_	_	I-Premise
248	radiotherapy	_	_	I-Premise
249	vs	_	_	I-Premise
250	67.4	_	_	I-Premise
251	[	_	_	I-Premise
252	2.7	_	_	I-Premise
253	]	_	_	I-Premise
254	for	_	_	I-Premise
255	those	_	_	I-Premise
256	assigned	_	_	I-Premise
257	radiotherapy	_	_	I-Premise
258	and	_	_	I-Premise
259	temozolomide	_	_	I-Premise
260	;	_	_	I-Premise
261	difference	_	_	I-Premise
262	between	_	_	I-Premise
263	groups	_	_	I-Premise
264	11.6	_	_	I-Premise
265	points	_	_	I-Premise
266	[	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	3.5-19.7	_	_	I-Premise
271	]	_	_	I-Premise
272	,	_	_	I-Premise
273	p=0.0052	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Over	_	_	B-Premise
277	subsequent	_	_	I-Premise
278	assessments	_	_	I-Premise
279	,	_	_	I-Premise
280	HRQOL	_	_	I-Premise
281	was	_	_	I-Premise
282	much	_	_	I-Premise
283	the	_	_	I-Premise
284	same	_	_	I-Premise
285	between	_	_	I-Premise
286	treatment	_	_	I-Premise
287	groups	_	_	I-Premise
288	.	_	_	I-Premise

289	Addition	_	_	B-Claim
290	of	_	_	I-Claim
291	temozolomide	_	_	I-Claim
292	during	_	_	I-Claim
293	and	_	_	I-Claim
294	after	_	_	I-Claim
295	radiotherapy	_	_	I-Claim
296	for	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	newly	_	_	I-Claim
300	diagnosed	_	_	I-Claim
301	glioblastoma	_	_	I-Claim
302	significantly	_	_	I-Claim
303	improved	_	_	I-Claim
304	survival	_	_	I-Claim
305	without	_	_	I-Claim
306	a	_	_	I-Claim
307	negative	_	_	I-Claim
308	effect	_	_	I-Claim
309	on	_	_	I-Claim
310	HRQOL	_	_	I-Claim
311	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	feasibility	_	_	O
4	of	_	_	O
5	administering	_	_	O
6	a	_	_	O
7	flavonoid-rich	_	_	O
8	adjunctive	_	_	O
9	treatment	_	_	O
10	(	_	_	O
11	Concord	_	_	O
12	grape	_	_	O
13	juice	_	_	O
14	)	_	_	O
15	for	_	_	O
16	the	_	_	O
17	management	_	_	O
18	of	_	_	O
19	chemotherapy-induced	_	_	O
20	nausea	_	_	O
21	and	_	_	O
22	vomiting	_	_	O
23	(	_	_	O
24	CINV	_	_	O
25	)	_	_	O
26	;	_	_	O
27	to	_	_	O
28	evaluate	_	_	O
29	the	_	_	O
30	usefulness	_	_	O
31	of	_	_	O
32	existing	_	_	O
33	measures	_	_	O
34	for	_	_	O
35	assessing	_	_	O
36	CINV	_	_	O
37	frequency	_	_	O
38	and	_	_	O
39	severity	_	_	O
40	,	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	,	_	_	O
45	control	_	_	O
46	over	_	_	O
47	life	_	_	O
48	events	_	_	O
49	,	_	_	O
50	and	_	_	O
51	psychological	_	_	O
52	state	_	_	O
53	;	_	_	O
54	to	_	_	O
55	identify	_	_	O
56	any	_	_	O
57	actual	_	_	O
58	or	_	_	O
59	potential	_	_	O
60	adverse	_	_	O
61	events	_	_	O
62	associated	_	_	O
63	with	_	_	O
64	frequent	_	_	O
65	grape	_	_	O
66	juice	_	_	O
67	intake	_	_	O
68	;	_	_	O
69	and	_	_	O
70	to	_	_	O
71	provide	_	_	O
72	preliminary	_	_	O
73	data	_	_	O
74	concerning	_	_	O
75	the	_	_	O
76	effect	_	_	O
77	of	_	_	O
78	Concord	_	_	O
79	grape	_	_	O
80	juice	_	_	O
81	on	_	_	O
82	CINV	_	_	O
83	,	_	_	O
84	quality	_	_	O
85	of	_	_	O
86	life	_	_	O
87	,	_	_	O
88	perceived	_	_	O
89	control	_	_	O
90	over	_	_	O
91	life	_	_	O
92	events	_	_	O
93	,	_	_	O
94	and	_	_	O
95	psychological	_	_	O
96	state	_	_	O
97	.	_	_	O

98	Double-blind	_	_	O
99	,	_	_	O
100	randomized	_	_	O
101	clinical	_	_	O
102	trial	_	_	O
103	.	_	_	O

104	A	_	_	O
105	cancer	_	_	O
106	center	_	_	O
107	in	_	_	O
108	an	_	_	O
109	academic	_	_	O
110	health	_	_	O
111	science	_	_	O
112	center	_	_	O
113	in	_	_	O
114	the	_	_	O
115	northeastern	_	_	O
116	United	_	_	O
117	States	_	_	O
118	.	_	_	O

119	77	_	_	O
120	adult	_	_	O
121	patients	_	_	O
122	with	_	_	O
123	cancer	_	_	O
124	receiving	_	_	O
125	moderately	_	_	O
126	or	_	_	O
127	highly	_	_	O
128	emetogenic	_	_	O
129	chemotherapy	_	_	O
130	agents	_	_	O
131	.	_	_	O

132	Participants	_	_	O
133	drank	_	_	O
134	4	_	_	O
135	oz	_	_	O
136	.	_	_	O

137	of	_	_	O
138	grape	_	_	O
139	juice	_	_	O
140	or	_	_	O
141	placebo	_	_	O
142	prior	_	_	O
143	to	_	_	O
144	meals	_	_	O
145	for	_	_	O
146	one	_	_	O
147	week	_	_	O
148	following	_	_	O
149	each	_	_	O
150	of	_	_	O
151	four	_	_	O
152	chemotherapy	_	_	O
153	treatment	_	_	O
154	cycles	_	_	O
155	.	_	_	O

156	They	_	_	O
157	recorded	_	_	O
158	frequency	_	_	O
159	,	_	_	O
160	duration	_	_	O
161	,	_	_	O
162	and	_	_	O
163	distress	_	_	O
164	of	_	_	O
165	nausea	_	_	O
166	,	_	_	O
167	vomiting	_	_	O
168	,	_	_	O
169	and	_	_	O
170	retching	_	_	O
171	daily	_	_	O
172	,	_	_	O
173	beginning	_	_	O
174	the	_	_	O
175	evening	_	_	O
176	of	_	_	O
177	chemotherapy	_	_	O
178	administration	_	_	O
179	and	_	_	O
180	continuing	_	_	O
181	for	_	_	O
182	seven	_	_	O
183	days	_	_	O
184	.	_	_	O

185	Data	_	_	O
186	were	_	_	O
187	analyzed	_	_	O
188	with	_	_	O
189	generalized	_	_	O
190	estimating	_	_	O
191	equations	_	_	O
192	methodology	_	_	O
193	to	_	_	O
194	model	_	_	O
195	differences	_	_	O
196	between	_	_	O
197	groups	_	_	O
198	over	_	_	O
199	time	_	_	O
200	.	_	_	O

201	Nausea	_	_	B-Premise
202	and	_	_	I-Premise
203	vomiting	_	_	I-Premise
204	frequency	_	_	I-Premise
205	,	_	_	I-Premise
206	duration	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	distress	_	_	I-Premise
210	were	_	_	I-Premise
211	lower	_	_	I-Premise
212	for	_	_	I-Premise
213	experimental	_	_	I-Premise
214	group	_	_	I-Premise
215	members	_	_	I-Premise
216	,	_	_	I-Premise
217	although	_	_	B-Premise
218	a	_	_	I-Premise
219	high	_	_	I-Premise
220	attrition	_	_	I-Premise
221	rate	_	_	I-Premise
222	(	_	_	I-Premise
223	50	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	resulted	_	_	I-Premise
227	in	_	_	I-Premise
228	insufficient	_	_	I-Premise
229	power	_	_	I-Premise
230	to	_	_	I-Premise
231	detect	_	_	I-Premise
232	statistically	_	_	I-Premise
233	significant	_	_	I-Premise
234	differences	_	_	I-Premise
235	over	_	_	I-Premise
236	time	_	_	I-Premise
237	.	_	_	I-Premise

238	Greater	_	_	O
239	levels	_	_	O
240	of	_	_	O
241	anxiety	_	_	O
242	,	_	_	O
243	depression	_	_	O
244	,	_	_	O
245	and	_	_	O
246	hostility	_	_	O
247	at	_	_	O
248	baseline	_	_	O
249	were	_	_	O
250	related	_	_	O
251	to	_	_	O
252	nausea	_	_	O
253	and	_	_	O
254	vomiting	_	_	O
255	,	_	_	O
256	quality	_	_	O
257	of	_	_	O
258	life	_	_	O
259	,	_	_	O
260	and	_	_	O
261	perceived	_	_	O
262	control	_	_	O
263	over	_	_	O
264	decision	_	_	O
265	making	_	_	O
266	.	_	_	O

267	The	_	_	B-Claim
268	effect	_	_	I-Claim
269	of	_	_	I-Claim
270	grape	_	_	I-Claim
271	juice	_	_	I-Claim
272	flavonoids	_	_	I-Claim
273	on	_	_	I-Claim
274	CINV	_	_	I-Claim
275	should	_	_	I-Claim
276	be	_	_	I-Claim
277	investigated	_	_	I-Claim
278	further	_	_	I-Claim
279	with	_	_	I-Claim
280	a	_	_	I-Claim
281	larger	_	_	I-Claim
282	sample	_	_	I-Claim
283	to	_	_	I-Claim
284	determine	_	_	I-Claim
285	whether	_	_	I-Claim
286	preliminary	_	_	I-Claim
287	findings	_	_	I-Claim
288	are	_	_	I-Claim
289	supported	_	_	I-Claim
290	.	_	_	I-Claim

291	Alterations	_	_	O
292	to	_	_	O
293	the	_	_	O
294	study	_	_	O
295	protocol	_	_	O
296	will	_	_	O
297	be	_	_	O
298	necessary	_	_	O
299	to	_	_	O
300	decrease	_	_	O
301	attrition	_	_	O
302	.	_	_	O

303	Flavonoid-rich	_	_	B-Claim
304	fruits	_	_	I-Claim
305	and	_	_	I-Claim
306	vegetables	_	_	I-Claim
307	may	_	_	I-Claim
308	provide	_	_	I-Claim
309	additional	_	_	I-Claim
310	protection	_	_	I-Claim
311	against	_	_	I-Claim
312	CINV	_	_	I-Claim
313	.	_	_	I-Claim

314	If	_	_	O
315	the	_	_	O
316	compounds	_	_	O
317	work	_	_	O
318	,	_	_	O
319	they	_	_	O
320	would	_	_	O
321	offer	_	_	O
322	a	_	_	O
323	low-cost	_	_	O
324	,	_	_	O
325	readily	_	_	O
326	available	_	_	O
327	adjunctive	_	_	O
328	treatment	_	_	O
329	for	_	_	O
330	the	_	_	O
331	management	_	_	O
332	of	_	_	O
333	CINV	_	_	O
334	.	_	_	O


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	in	_	_	I-Claim
6	postmenopausal	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	lymph	_	_	I-Claim
10	node-negative	_	_	I-Claim
11	breast	_	_	I-Claim
12	cancer	_	_	I-Claim
13	is	_	_	I-Claim
14	controversial	_	_	I-Claim
15	.	_	_	I-Claim

16	After	_	_	O
17	demonstrating	_	_	O
18	the	_	_	O
19	efficacy	_	_	O
20	of	_	_	O
21	chemotherapy	_	_	O
22	combined	_	_	O
23	with	_	_	O
24	tamoxifen	_	_	O
25	for	_	_	O
26	postmenopausal	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	lymph	_	_	O
30	node-positive	_	_	O
31	disease	_	_	O
32	,	_	_	O
33	the	_	_	O
34	International	_	_	O
35	Breast	_	_	O
36	Cancer	_	_	O
37	Study	_	_	O
38	Group	_	_	O
39	launched	_	_	O
40	a	_	_	O
41	randomized	_	_	O
42	trial	_	_	O
43	(	_	_	O
44	Trial	_	_	O
45	IX	_	_	O
46	)	_	_	O
47	to	_	_	O
48	evaluate	_	_	O
49	the	_	_	O
50	role	_	_	O
51	of	_	_	O
52	adjuvant	_	_	O
53	chemotherapy	_	_	O
54	preceding	_	_	O
55	treatment	_	_	O
56	with	_	_	O
57	tamoxifen	_	_	O
58	for	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	lymph	_	_	O
62	node-negative	_	_	O
63	disease	_	_	O
64	.	_	_	O

65	After	_	_	O
66	stratification	_	_	O
67	by	_	_	O
68	estrogen	_	_	O
69	receptor	_	_	O
70	(	_	_	O
71	ER	_	_	O
72	)	_	_	O
73	status	_	_	O
74	,	_	_	O
75	patients	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	three	_	_	O
82	28-day	_	_	O
83	courses	_	_	O
84	of	_	_	O
85	"	_	_	O
86	classical	_	_	O
87	"	_	_	O
88	adjuvant	_	_	O
89	CMF	_	_	O
90	chemotherapy	_	_	O
91	(	_	_	O
92	cyclophosphamide	_	_	O
93	at	_	_	O
94	100	_	_	O
95	mg/m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	on	_	_	O
100	days	_	_	O
101	1-14	_	_	O
102	,	_	_	O
103	orally	_	_	O
104	;	_	_	O
105	methotrexate	_	_	O
106	at	_	_	O
107	40	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	on	_	_	O
113	days	_	_	O
114	1	_	_	O
115	and	_	_	O
116	8	_	_	O
117	,	_	_	O
118	intravenously	_	_	O
119	;	_	_	O
120	and	_	_	O
121	5-fluorouracil	_	_	O
122	at	_	_	O
123	600	_	_	O
124	mg/m	_	_	O
125	(	_	_	O
126	2	_	_	O
127	)	_	_	O
128	on	_	_	O
129	days	_	_	O
130	1	_	_	O
131	and	_	_	O
132	8	_	_	O
133	,	_	_	O
134	intravenously	_	_	O
135	)	_	_	O
136	followed	_	_	O
137	by	_	_	O
138	tamoxifen	_	_	O
139	(	_	_	O
140	20	_	_	O
141	mg/day	_	_	O
142	,	_	_	O
143	orally	_	_	O
144	for	_	_	O
145	57	_	_	O
146	months	_	_	O
147	)	_	_	O
148	(	_	_	O
149	CMF	_	_	O
150	--	_	_	O
151	>	_	_	O
152	tamoxifen	_	_	O
153	)	_	_	O
154	or	_	_	O
155	to	_	_	O
156	receive	_	_	O
157	tamoxifen	_	_	O
158	alone	_	_	O
159	(	_	_	O
160	20	_	_	O
161	mg/day	_	_	O
162	,	_	_	O
163	orally	_	_	O
164	for	_	_	O
165	60	_	_	O
166	months	_	_	O
167	)	_	_	O
168	.	_	_	O

169	We	_	_	O
170	enrolled	_	_	O
171	1669	_	_	O
172	eligible	_	_	O
173	patients	_	_	O
174	,	_	_	O
175	382	_	_	O
176	(	_	_	O
177	23	_	_	O
178	%	_	_	O
179	)	_	_	O
180	with	_	_	O
181	ER-negative	_	_	O
182	tumors	_	_	O
183	,	_	_	O
184	1217	_	_	O
185	(	_	_	O
186	73	_	_	O
187	%	_	_	O
188	)	_	_	O
189	with	_	_	O
190	ER-positive	_	_	O
191	tumors	_	_	O
192	,	_	_	O
193	and	_	_	O
194	70	_	_	O
195	(	_	_	O
196	4	_	_	O
197	%	_	_	O
198	)	_	_	O
199	with	_	_	O
200	unknown	_	_	O
201	ER	_	_	O
202	status	_	_	O
203	.	_	_	O

204	The	_	_	O
205	median	_	_	O
206	follow-up	_	_	O
207	was	_	_	O
208	71	_	_	O
209	months	_	_	O
210	.	_	_	O

211	All	_	_	O
212	statistical	_	_	O
213	tests	_	_	O
214	were	_	_	O
215	two-sided	_	_	O
216	.	_	_	O

217	The	_	_	B-Premise
218	added	_	_	I-Premise
219	benefit	_	_	I-Premise
220	of	_	_	I-Premise
221	CMF	_	_	I-Premise
222	followed	_	_	I-Premise
223	by	_	_	I-Premise
224	tamoxifen	_	_	I-Premise
225	over	_	_	I-Premise
226	tamoxifen	_	_	I-Premise
227	alone	_	_	I-Premise
228	was	_	_	I-Premise
229	statistically	_	_	I-Premise
230	significantly	_	_	I-Premise
231	dependent	_	_	I-Premise
232	on	_	_	I-Premise
233	ER	_	_	I-Premise
234	status	_	_	I-Premise
235	(	_	_	I-Premise
236	tests	_	_	I-Premise
237	for	_	_	I-Premise
238	interaction	_	_	I-Premise
239	:	_	_	I-Premise
240	P	_	_	I-Premise
241	=.01	_	_	I-Premise
242	for	_	_	I-Premise
243	disease-free	_	_	I-Premise
244	survival	_	_	I-Premise
245	[	_	_	I-Premise
246	DFS	_	_	I-Premise
247	]	_	_	I-Premise
248	and	_	_	I-Premise
249	P	_	_	I-Premise
250	=.07	_	_	I-Premise
251	for	_	_	I-Premise
252	overall	_	_	I-Premise
253	survival	_	_	I-Premise
254	[	_	_	I-Premise
255	OS	_	_	I-Premise
256	]	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	For	_	_	B-Premise
260	patients	_	_	I-Premise
261	with	_	_	I-Premise
262	ER-negative	_	_	I-Premise
263	tumors	_	_	I-Premise
264	,	_	_	I-Premise
265	the	_	_	I-Premise
266	addition	_	_	I-Premise
267	of	_	_	I-Premise
268	CMF	_	_	I-Premise
269	statistically	_	_	I-Premise
270	significantly	_	_	I-Premise
271	improved	_	_	I-Premise
272	DFS	_	_	I-Premise
273	(	_	_	I-Premise
274	5-year	_	_	I-Premise
275	DFS	_	_	I-Premise
276	=	_	_	I-Premise
277	84	_	_	I-Premise
278	%	_	_	I-Premise
279	for	_	_	I-Premise
280	CMF	_	_	I-Premise
281	--	_	_	I-Premise
282	>	_	_	I-Premise
283	tamoxifen	_	_	I-Premise
284	versus	_	_	I-Premise
285	69	_	_	I-Premise
286	%	_	_	I-Premise
287	for	_	_	I-Premise
288	tamoxifen	_	_	I-Premise
289	alone	_	_	I-Premise
290	;	_	_	I-Premise
291	difference	_	_	I-Premise
292	=	_	_	I-Premise
293	15	_	_	I-Premise
294	%	_	_	I-Premise
295	;	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	confidence	_	_	I-Premise
299	interval	_	_	I-Premise
300	[	_	_	I-Premise
301	CI	_	_	I-Premise
302	]	_	_	I-Premise
303	=	_	_	I-Premise
304	6	_	_	I-Premise
305	%	_	_	I-Premise
306	to	_	_	I-Premise
307	24	_	_	I-Premise
308	%	_	_	I-Premise
309	;	_	_	I-Premise
310	risk	_	_	I-Premise
311	ratio	_	_	I-Premise
312	[	_	_	I-Premise
313	RR	_	_	I-Premise
314	]	_	_	I-Premise
315	=	_	_	I-Premise
316	0.52	_	_	I-Premise
317	;	_	_	I-Premise
318	95	_	_	I-Premise
319	%	_	_	I-Premise
320	CI	_	_	I-Premise
321	=	_	_	I-Premise
322	0.34	_	_	I-Premise
323	to	_	_	I-Premise
324	0.79	_	_	I-Premise
325	;	_	_	I-Premise
326	P	_	_	I-Premise
327	=.003	_	_	I-Premise
328	)	_	_	I-Premise
329	and	_	_	I-Premise
330	OS	_	_	I-Premise
331	(	_	_	I-Premise
332	5-year	_	_	I-Premise
333	OS	_	_	I-Premise
334	=	_	_	I-Premise
335	89	_	_	I-Premise
336	%	_	_	I-Premise
337	for	_	_	I-Premise
338	CMF	_	_	I-Premise
339	--	_	_	I-Premise
340	>	_	_	I-Premise
341	tamoxifen	_	_	I-Premise
342	versus	_	_	I-Premise
343	81	_	_	I-Premise
344	%	_	_	I-Premise
345	for	_	_	I-Premise
346	tamoxifen	_	_	I-Premise
347	alone	_	_	I-Premise
348	;	_	_	I-Premise
349	difference	_	_	I-Premise
350	=	_	_	I-Premise
351	8	_	_	I-Premise
352	%	_	_	I-Premise
353	;	_	_	I-Premise
354	95	_	_	I-Premise
355	%	_	_	I-Premise
356	CI	_	_	I-Premise
357	=	_	_	I-Premise
358	0	_	_	I-Premise
359	%	_	_	I-Premise
360	to	_	_	I-Premise
361	16	_	_	I-Premise
362	%	_	_	I-Premise
363	;	_	_	I-Premise
364	RR	_	_	I-Premise
365	=	_	_	I-Premise
366	0.51	_	_	I-Premise
367	;	_	_	I-Premise
368	95	_	_	I-Premise
369	%	_	_	I-Premise
370	CI	_	_	I-Premise
371	=	_	_	I-Premise
372	0.30	_	_	I-Premise
373	to	_	_	I-Premise
374	0.87	_	_	I-Premise
375	;	_	_	I-Premise
376	P	_	_	I-Premise
377	=.01	_	_	I-Premise
378	)	_	_	I-Premise
379	.	_	_	I-Premise

380	By	_	_	B-Premise
381	contrast	_	_	I-Premise
382	,	_	_	I-Premise
383	for	_	_	I-Premise
384	patients	_	_	I-Premise
385	with	_	_	I-Premise
386	ER-positive	_	_	I-Premise
387	tumors	_	_	I-Premise
388	,	_	_	I-Premise
389	addition	_	_	I-Premise
390	of	_	_	I-Premise
391	CMF	_	_	I-Premise
392	provided	_	_	I-Premise
393	no	_	_	I-Premise
394	benefit	_	_	I-Premise
395	in	_	_	I-Premise
396	terms	_	_	I-Premise
397	of	_	_	I-Premise
398	DFS	_	_	I-Premise
399	(	_	_	I-Premise
400	5-year	_	_	I-Premise
401	DFS	_	_	I-Premise
402	=	_	_	I-Premise
403	84	_	_	I-Premise
404	%	_	_	I-Premise
405	for	_	_	I-Premise
406	CMF	_	_	I-Premise
407	--	_	_	I-Premise
408	>	_	_	I-Premise
409	tamoxifen	_	_	I-Premise
410	versus	_	_	I-Premise
411	85	_	_	I-Premise
412	%	_	_	I-Premise
413	for	_	_	I-Premise
414	tamoxifen	_	_	I-Premise
415	alone	_	_	I-Premise
416	;	_	_	I-Premise
417	difference	_	_	I-Premise
418	=	_	_	I-Premise
419	-1	_	_	I-Premise
420	;	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	=	_	_	I-Premise
425	-6	_	_	I-Premise
426	%	_	_	I-Premise
427	to	_	_	I-Premise
428	4	_	_	I-Premise
429	%	_	_	I-Premise
430	;	_	_	I-Premise
431	RR	_	_	I-Premise
432	=	_	_	I-Premise
433	0.99	_	_	I-Premise
434	;	_	_	I-Premise
435	95	_	_	I-Premise
436	%	_	_	I-Premise
437	CI	_	_	I-Premise
438	=	_	_	I-Premise
439	0.75	_	_	I-Premise
440	to	_	_	I-Premise
441	1.30	_	_	I-Premise
442	;	_	_	I-Premise
443	P	_	_	I-Premise
444	=.92	_	_	I-Premise
445	)	_	_	I-Premise
446	or	_	_	I-Premise
447	OS	_	_	I-Premise
448	(	_	_	I-Premise
449	5-year	_	_	I-Premise
450	OS	_	_	I-Premise
451	=	_	_	I-Premise
452	95	_	_	I-Premise
453	%	_	_	I-Premise
454	for	_	_	I-Premise
455	CMF	_	_	I-Premise
456	--	_	_	I-Premise
457	>	_	_	I-Premise
458	tamoxifen	_	_	I-Premise
459	versus	_	_	I-Premise
460	93	_	_	I-Premise
461	%	_	_	I-Premise
462	for	_	_	I-Premise
463	tamoxifen	_	_	I-Premise
464	alone	_	_	I-Premise
465	;	_	_	I-Premise
466	difference	_	_	I-Premise
467	=	_	_	I-Premise
468	2	_	_	I-Premise
469	%	_	_	I-Premise
470	;	_	_	I-Premise
471	95	_	_	I-Premise
472	%	_	_	I-Premise
473	CI	_	_	I-Premise
474	=	_	_	I-Premise
475	-1	_	_	I-Premise
476	%	_	_	I-Premise
477	to	_	_	I-Premise
478	5	_	_	I-Premise
479	%	_	_	I-Premise
480	;	_	_	I-Premise
481	RR	_	_	I-Premise
482	=	_	_	I-Premise
483	0.95	_	_	I-Premise
484	;	_	_	I-Premise
485	95	_	_	I-Premise
486	%	_	_	I-Premise
487	CI	_	_	I-Premise
488	=	_	_	I-Premise
489	0.64	_	_	I-Premise
490	to	_	_	I-Premise
491	1.40	_	_	I-Premise
492	;	_	_	I-Premise
493	P	_	_	I-Premise
494	=.80	_	_	I-Premise
495	)	_	_	I-Premise
496	.	_	_	I-Premise

497	Postmenopausal	_	_	B-Claim
498	patients	_	_	I-Claim
499	with	_	_	I-Claim
500	lymph	_	_	I-Claim
501	node-negative	_	_	I-Claim
502	breast	_	_	I-Claim
503	cancer	_	_	I-Claim
504	benefited	_	_	I-Claim
505	substantially	_	_	I-Claim
506	from	_	_	I-Claim
507	adjuvant	_	_	I-Claim
508	chemotherapy	_	_	I-Claim
509	if	_	_	I-Claim
510	their	_	_	I-Claim
511	cancer	_	_	I-Claim
512	was	_	_	I-Claim
513	ER-negative	_	_	I-Claim
514	(	_	_	I-Claim
515	i.e.	_	_	I-Claim
516	,	_	_	I-Claim
517	endocrine-nonresponsive	_	_	I-Claim
518	)	_	_	I-Claim
519	.	_	_	I-Claim

520	In	_	_	B-Claim
521	contrast	_	_	I-Claim
522	,	_	_	I-Claim
523	if	_	_	I-Claim
524	their	_	_	I-Claim
525	cancer	_	_	I-Claim
526	was	_	_	I-Claim
527	ER-positive	_	_	I-Claim
528	(	_	_	I-Claim
529	i.e.	_	_	I-Claim
530	,	_	_	I-Claim
531	endocrine-responsive	_	_	I-Claim
532	)	_	_	I-Claim
533	,	_	_	I-Claim
534	they	_	_	I-Claim
535	obtained	_	_	I-Claim
536	no	_	_	I-Claim
537	benefit	_	_	I-Claim
538	from	_	_	I-Claim
539	the	_	_	I-Claim
540	combination	_	_	I-Claim
541	treatment	_	_	I-Claim
542	compared	_	_	I-Claim
543	with	_	_	I-Claim
544	tamoxifen	_	_	I-Claim
545	alone	_	_	I-Claim
546	.	_	_	I-Claim


0	In	_	_	O
1	phase	_	_	O
2	II	_	_	O
3	studies	_	_	O
4	,	_	_	O
5	irinotecan	_	_	O
6	is	_	_	O
7	active	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	colorectal	_	_	O
11	cancer	_	_	O
12	,	_	_	O
13	but	_	_	O
14	the	_	_	O
15	overall	_	_	O
16	benefit	_	_	O
17	has	_	_	O
18	not	_	_	O
19	been	_	_	O
20	assessed	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomised	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Patients	_	_	O
28	with	_	_	O
29	proven	_	_	O
30	metastatic	_	_	O
31	colorectal	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	which	_	_	O
35	had	_	_	O
36	progressed	_	_	O
37	within	_	_	O
38	6	_	_	O
39	months	_	_	O
40	of	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	fluorouracil	_	_	O
44	,	_	_	O
45	were	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	either	_	_	O
49	300-350	_	_	O
50	mg/m2	_	_	O
51	irinotecan	_	_	O
52	every	_	_	O
53	3	_	_	O
54	weeks	_	_	O
55	with	_	_	O
56	supportive	_	_	O
57	care	_	_	O
58	or	_	_	O
59	supportive	_	_	O
60	care	_	_	O
61	alone	_	_	O
62	,	_	_	O
63	in	_	_	O
64	a	_	_	O
65	2:1	_	_	O
66	ratio	_	_	O
67	.	_	_	O

68	189	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	allocated	_	_	O
72	irinotecan	_	_	O
73	and	_	_	O
74	supportive	_	_	O
75	care	_	_	O
76	and	_	_	O
77	90	_	_	O
78	supportive	_	_	O
79	care	_	_	O
80	alone	_	_	O
81	.	_	_	O

82	The	_	_	O
83	mean	_	_	O
84	age	_	_	O
85	of	_	_	O
86	the	_	_	O
87	participants	_	_	O
88	was	_	_	O
89	58.8	_	_	O
90	years	_	_	O
91	;	_	_	O
92	181	_	_	O
93	(	_	_	O
94	65	_	_	O
95	%	_	_	O
96	)	_	_	O
97	were	_	_	O
98	men	_	_	O
99	and	_	_	O
100	98	_	_	O
101	(	_	_	O
102	35	_	_	O
103	%	_	_	O
104	)	_	_	O
105	were	_	_	O
106	women	_	_	O
107	.	_	_	O

108	WHO	_	_	O
109	performance	_	_	O
110	status	_	_	O
111	was	_	_	O
112	0	_	_	O
113	in	_	_	O
114	79	_	_	O
115	(	_	_	O
116	42	_	_	O
117	%	_	_	O
118	)	_	_	O
119	patients	_	_	O
120	,	_	_	O
121	1	_	_	O
122	in	_	_	O
123	77	_	_	O
124	(	_	_	O
125	41	_	_	O
126	%	_	_	O
127	)	_	_	O
128	patients	_	_	O
129	,	_	_	O
130	and	_	_	O
131	2	_	_	O
132	in	_	_	O
133	32	_	_	O
134	(	_	_	O
135	17	_	_	O
136	%	_	_	O
137	)	_	_	O
138	patients	_	_	O
139	.	_	_	O

140	Tumour-related	_	_	O
141	symptoms	_	_	O
142	were	_	_	O
143	present	_	_	O
144	in	_	_	O
145	134	_	_	O
146	(	_	_	O
147	71	_	_	O
148	%	_	_	O
149	)	_	_	O
150	patients	_	_	O
151	and	_	_	O
152	weight	_	_	O
153	loss	_	_	O
154	of	_	_	O
155	more	_	_	O
156	than	_	_	O
157	5	_	_	O
158	%	_	_	O
159	was	_	_	O
160	seen	_	_	O
161	in	_	_	O
162	15	_	_	O
163	(	_	_	O
164	8	_	_	O
165	%	_	_	O
166	)	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	With	_	_	B-Premise
170	a	_	_	I-Premise
171	median	_	_	I-Premise
172	follow-up	_	_	I-Premise
173	of	_	_	I-Premise
174	13	_	_	I-Premise
175	months	_	_	I-Premise
176	,	_	_	I-Premise
177	the	_	_	I-Premise
178	overall	_	_	I-Premise
179	survival	_	_	I-Premise
180	was	_	_	I-Premise
181	significantly	_	_	I-Premise
182	better	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	irinotecan	_	_	I-Premise
186	group	_	_	I-Premise
187	(	_	_	I-Premise
188	p=0.0001	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	with	_	_	I-Premise
192	36.2	_	_	I-Premise
193	%	_	_	I-Premise
194	1-year	_	_	I-Premise
195	survival	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	irinotecan	_	_	I-Premise
199	group	_	_	I-Premise
200	versus	_	_	I-Premise
201	13.8	_	_	I-Premise
202	%	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	supportive-care	_	_	I-Premise
206	group	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	B-Premise
209	survival	_	_	I-Premise
210	benefit	_	_	I-Premise
211	,	_	_	I-Premise
212	adjusted	_	_	I-Premise
213	for	_	_	I-Premise
214	prognostic	_	_	I-Premise
215	factors	_	_	I-Premise
216	in	_	_	I-Premise
217	a	_	_	I-Premise
218	multivariate	_	_	I-Premise
219	analysis	_	_	I-Premise
220	,	_	_	I-Premise
221	remained	_	_	I-Premise
222	significant	_	_	I-Premise
223	(	_	_	I-Premise
224	p=0.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Survival	_	_	B-Premise
228	without	_	_	I-Premise
229	performance-status	_	_	I-Premise
230	deterioration	_	_	I-Premise
231	(	_	_	I-Premise
232	p=0.0001	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	without	_	_	I-Premise
236	weight	_	_	I-Premise
237	loss	_	_	I-Premise
238	of	_	_	I-Premise
239	more	_	_	I-Premise
240	than	_	_	I-Premise
241	5	_	_	I-Premise
242	%	_	_	I-Premise
243	(	_	_	I-Premise
244	p=0.018	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	pain-free	_	_	I-Premise
249	survival	_	_	I-Premise
250	(	_	_	I-Premise
251	p=0.003	_	_	I-Premise
252	)	_	_	I-Premise
253	were	_	_	I-Premise
254	significantly	_	_	I-Premise
255	better	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	patients	_	_	I-Premise
259	given	_	_	I-Premise
260	irinotecan	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	a	_	_	I-Premise
264	quality-of-life	_	_	I-Premise
265	analysis	_	_	I-Premise
266	,	_	_	I-Premise
267	all	_	_	I-Premise
268	significant	_	_	I-Premise
269	differences	_	_	I-Premise
270	,	_	_	I-Premise
271	except	_	_	I-Premise
272	on	_	_	I-Premise
273	diarrhoea	_	_	I-Premise
274	score	_	_	I-Premise
275	,	_	_	I-Premise
276	were	_	_	I-Premise
277	in	_	_	I-Premise
278	favour	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	irinotecan	_	_	I-Premise
282	group	_	_	I-Premise
283	.	_	_	I-Premise

284	Our	_	_	B-Claim
285	study	_	_	I-Claim
286	shows	_	_	I-Claim
287	that	_	_	I-Claim
288	despite	_	_	I-Claim
289	the	_	_	I-Claim
290	side-effects	_	_	I-Claim
291	of	_	_	I-Claim
292	treatment	_	_	I-Claim
293	,	_	_	I-Claim
294	patients	_	_	I-Claim
295	who	_	_	I-Claim
296	have	_	_	I-Claim
297	metastatic	_	_	I-Claim
298	colorectal	_	_	I-Claim
299	cancer	_	_	I-Claim
300	,	_	_	I-Claim
301	and	_	_	I-Claim
302	for	_	_	I-Claim
303	whom	_	_	I-Claim
304	fluorouracil	_	_	I-Claim
305	has	_	_	I-Claim
306	failed	_	_	I-Claim
307	,	_	_	I-Claim
308	have	_	_	I-Claim
309	a	_	_	I-Claim
310	longer	_	_	I-Claim
311	survival	_	_	I-Claim
312	,	_	_	I-Claim
313	fewer	_	_	I-Claim
314	tumour-related	_	_	I-Claim
315	symptoms	_	_	I-Claim
316	,	_	_	I-Claim
317	and	_	_	I-Claim
318	a	_	_	I-Claim
319	better	_	_	I-Claim
320	quality	_	_	I-Claim
321	of	_	_	I-Claim
322	life	_	_	I-Claim
323	when	_	_	I-Claim
324	treated	_	_	I-Claim
325	with	_	_	I-Claim
326	irinotecan	_	_	I-Claim
327	than	_	_	I-Claim
328	with	_	_	I-Claim
329	supportive	_	_	I-Claim
330	care	_	_	I-Claim
331	alone	_	_	I-Claim
332	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	doublet	_	_	O
3	,	_	_	O
4	vinorelbine-cisplatin	_	_	O
5	,	_	_	O
6	was	_	_	O
7	compared	_	_	O
8	with	_	_	O
9	a	_	_	O
10	triplet	_	_	O
11	of	_	_	O
12	vinorelbine-ifosfamide-cisplatin	_	_	O
13	,	_	_	O
14	in	_	_	O
15	terms	_	_	O
16	of	_	_	O
17	survival	_	_	O
18	,	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	advanced	_	_	O
23	non-small-cell	_	_	O
24	lung	_	_	O
25	cancer	_	_	O
26	(	_	_	O
27	NSCLC	_	_	O
28	)	_	_	O
29	.	_	_	O

30	From	_	_	O
31	February	_	_	O
32	1998	_	_	O
33	to	_	_	O
34	June	_	_	O
35	1999	_	_	O
36	,	_	_	O
37	259	_	_	O
38	chemonaÃ¯ve	_	_	O
39	patients	_	_	O
40	entered	_	_	O
41	the	_	_	O
42	study	_	_	O
43	and	_	_	O
44	were	_	_	O
45	randomised	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	either	_	_	O
49	vinorelbine-cisplatin	_	_	O
50	(	_	_	O
51	NP	_	_	O
52	;	_	_	O
53	vinorelbine	_	_	O
54	30	_	_	O
55	mg/m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	on	_	_	O
60	days	_	_	O
61	1	_	_	O
62	,	_	_	O
63	8	_	_	O
64	and	_	_	O
65	15	_	_	O
66	with	_	_	O
67	cisplatin	_	_	O
68	80	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	on	_	_	O
74	day	_	_	O
75	1	_	_	O
76	)	_	_	O
77	or	_	_	O
78	vinorelbine-ifosfamide-cisplatin	_	_	O
79	(	_	_	O
80	NIP	_	_	O
81	;	_	_	O
82	vinorelbine	_	_	O
83	25	_	_	O
84	mg/m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	on	_	_	O
89	days	_	_	O
90	1	_	_	O
91	and	_	_	O
92	8	_	_	O
93	,	_	_	O
94	ifosfamide	_	_	O
95	3	_	_	O
96	g/m	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	on	_	_	O
101	day	_	_	O
102	1	_	_	O
103	and	_	_	O
104	cisplatin	_	_	O
105	75	_	_	O
106	mg/m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	on	_	_	O
111	day	_	_	O
112	1	_	_	O
113	)	_	_	O
114	,	_	_	O
115	with	_	_	O
116	both	_	_	O
117	regimens	_	_	O
118	being	_	_	O
119	repeated	_	_	O
120	every	_	_	O
121	3	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	All	_	_	O
125	patients	_	_	O
126	had	_	_	O
127	stage	_	_	O
128	IV	_	_	O
129	or	_	_	O
130	relapsed	_	_	O
131	disease	_	_	O
132	and	_	_	O
133	a	_	_	O
134	performance	_	_	O
135	score	_	_	O
136	of	_	_	O
137	0	_	_	O
138	or	_	_	O
139	1	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	overall	_	_	I-Premise
143	response	_	_	I-Premise
144	rate	_	_	I-Premise
145	was	_	_	I-Premise
146	34.6	_	_	I-Premise
147	%	_	_	I-Premise
148	for	_	_	I-Premise
149	NP	_	_	I-Premise
150	and	_	_	I-Premise
151	35.7	_	_	I-Premise
152	%	_	_	I-Premise
153	for	_	_	I-Premise
154	NIP	_	_	I-Premise
155	.	_	_	I-Premise

156	Median	_	_	B-Premise
157	and	_	_	I-Premise
158	1-year	_	_	I-Premise
159	survival	_	_	I-Premise
160	rates	_	_	I-Premise
161	were	_	_	I-Premise
162	10.0	_	_	I-Premise
163	months	_	_	I-Premise
164	and	_	_	I-Premise
165	38.4	_	_	I-Premise
166	%	_	_	I-Premise
167	for	_	_	I-Premise
168	NP	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	8.2	_	_	I-Premise
172	months	_	_	I-Premise
173	and	_	_	I-Premise
174	33.7	_	_	I-Premise
175	%	_	_	I-Premise
176	for	_	_	I-Premise
177	NIP	_	_	I-Premise
178	,	_	_	I-Premise
179	respectively	_	_	I-Premise
180	.	_	_	I-Premise

181	A	_	_	O
182	median	_	_	O
183	of	_	_	O
184	four	_	_	O
185	cycles	_	_	O
186	was	_	_	O
187	administered	_	_	O
188	in	_	_	O
189	each	_	_	O
190	arm	_	_	O
191	.	_	_	O

192	The	_	_	B-Premise
193	major	_	_	I-Premise
194	World	_	_	I-Premise
195	Health	_	_	I-Premise
196	Organization	_	_	I-Premise
197	grade	_	_	I-Premise
198	3-4	_	_	I-Premise
199	toxicities	_	_	I-Premise
200	for	_	_	I-Premise
201	NP	_	_	I-Premise
202	and	_	_	I-Premise
203	NIP	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	,	_	_	I-Premise
207	were	_	_	I-Premise
208	:	_	_	I-Premise
209	neutropenia	_	_	I-Premise
210	(	_	_	I-Premise
211	20.3	_	_	I-Premise
212	%	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	9	_	_	I-Premise
216	%	_	_	I-Premise
217	of	_	_	I-Premise
218	cycles	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	anaemia	_	_	I-Premise
222	(	_	_	I-Premise
223	4.1	_	_	I-Premise
224	%	_	_	I-Premise
225	compared	_	_	I-Premise
226	with	_	_	I-Premise
227	5	_	_	I-Premise
228	%	_	_	I-Premise
229	of	_	_	I-Premise
230	cycles	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	nausea	_	_	I-Premise
234	and	_	_	I-Premise
235	vomiting	_	_	I-Premise
236	(	_	_	I-Premise
237	22.2	_	_	I-Premise
238	%	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	19.4	_	_	I-Premise
242	%	_	_	I-Premise
243	of	_	_	I-Premise
244	patients	_	_	I-Premise
245	)	_	_	I-Premise
246	and	_	_	I-Premise
247	alopecia	_	_	I-Premise
248	(	_	_	I-Premise
249	5.6	_	_	I-Premise
250	%	_	_	I-Premise
251	compared	_	_	I-Premise
252	with	_	_	I-Premise
253	29.8	_	_	I-Premise
254	%	_	_	I-Premise
255	of	_	_	I-Premise
256	patients	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Four	_	_	B-Premise
260	toxic	_	_	I-Premise
261	deaths	_	_	I-Premise
262	occurred	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	NP	_	_	I-Premise
266	arm	_	_	I-Premise
267	and	_	_	I-Premise
268	eight	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	NIP	_	_	I-Premise
272	arm	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	different	_	_	I-Premise
276	schedules	_	_	I-Premise
277	of	_	_	I-Premise
278	vinorelbine	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	two	_	_	I-Premise
282	arms	_	_	I-Premise
283	led	_	_	I-Premise
284	to	_	_	I-Premise
285	a	_	_	I-Premise
286	greater	_	_	I-Premise
287	survival	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	NP	_	_	I-Premise
291	arm	_	_	I-Premise
292	without	_	_	I-Premise
293	impairing	_	_	I-Premise
294	the	_	_	I-Premise
295	tolerance	_	_	I-Premise
296	profile	_	_	I-Premise
297	,	_	_	I-Premise
298	although	_	_	B-Premise
299	this	_	_	I-Premise
300	is	_	_	I-Premise
301	not	_	_	I-Premise
302	statistically	_	_	I-Premise
303	significant	_	_	I-Premise
304	.	_	_	I-Premise

305	This	_	_	B-Claim
306	confirms	_	_	I-Claim
307	that	_	_	I-Claim
308	the	_	_	I-Claim
309	two-drug	_	_	I-Claim
310	combination	_	_	I-Claim
311	NP	_	_	I-Claim
312	is	_	_	I-Claim
313	a	_	_	I-Claim
314	reference	_	_	I-Claim
315	treatment	_	_	I-Claim
316	for	_	_	I-Claim
317	metastatic	_	_	I-Claim
318	NSCLC	_	_	I-Claim
319	.	_	_	I-Claim

320	The	_	_	B-Claim
321	role	_	_	I-Claim
322	of	_	_	I-Claim
323	three-drug	_	_	I-Claim
324	combinations	_	_	I-Claim
325	remains	_	_	I-Claim
326	questionable	_	_	I-Claim
327	in	_	_	I-Claim
328	this	_	_	I-Claim
329	subset	_	_	I-Claim
330	of	_	_	I-Claim
331	patients	_	_	I-Claim
332	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	can	_	_	I-Claim
2	profoundly	_	_	I-Claim
3	affect	_	_	I-Claim
4	patients	_	_	I-Claim
5	'	_	_	I-Claim
6	quality	_	_	I-Claim
7	of	_	_	I-Claim
8	life	_	_	I-Claim
9	(	_	_	I-Claim
10	QOL	_	_	I-Claim
11	)	_	_	I-Claim
12	,	_	_	I-Claim
13	yet	_	_	O
14	few	_	_	O
15	clinical	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	cervical	_	_	O
20	cancer	_	_	O
21	have	_	_	O
22	included	_	_	O
23	QOL	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	Our	_	_	O
27	purpose	_	_	O
28	was	_	_	O
29	to	_	_	O
30	assess	_	_	O
31	the	_	_	O
32	impact	_	_	O
33	of	_	_	O
34	cisplatin	_	_	O
35	(	_	_	O
36	C	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	cisplatin	_	_	O
40	plus	_	_	O
41	paclitaxel	_	_	O
42	(	_	_	O
43	CP	_	_	O
44	)	_	_	O
45	on	_	_	O
46	overall	_	_	O
47	QOL	_	_	O
48	and	_	_	O
49	pain	_	_	O
50	in	_	_	O
51	cervical	_	_	O
52	cancer	_	_	O
53	patients	_	_	O
54	.	_	_	O

55	QOL	_	_	O
56	was	_	_	O
57	assessed	_	_	O
58	using	_	_	O
59	FACT-Cx	_	_	O
60	,	_	_	O
61	consisting	_	_	O
62	of	_	_	O
63	the	_	_	O
64	Functional	_	_	O
65	Assessment	_	_	O
66	of	_	_	O
67	Cancer	_	_	O
68	Therapy	_	_	O
69	(	_	_	O
70	FACT-G	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	a	_	_	O
74	cervix	_	_	O
75	cancer-specific	_	_	O
76	subscale	_	_	O
77	,	_	_	O
78	the	_	_	O
79	Brief	_	_	O
80	Pain	_	_	O
81	Inventory-Short	_	_	O
82	Form	_	_	O
83	(	_	_	O
84	BPI-SF	_	_	O
85	)	_	_	O
86	,	_	_	O
87	and	_	_	O
88	a	_	_	O
89	neurotoxicity	_	_	O
90	subscale	_	_	O
91	.	_	_	O

92	Time	_	_	O
93	points	_	_	O
94	were	_	_	O
95	:	_	_	O
96	baseline	_	_	O
97	(	_	_	O
98	prior	_	_	O
99	to	_	_	O
100	randomization	_	_	O
101	)	_	_	O
102	and	_	_	O
103	prior	_	_	O
104	to	_	_	O
105	chemotherapy	_	_	O
106	cycles	_	_	O
107	2	_	_	O
108	,	_	_	O
109	3	_	_	O
110	,	_	_	O
111	and	_	_	O
112	4	_	_	O
113	.	_	_	O

114	Overall	_	_	B-Premise
115	(	_	_	I-Premise
116	FACT-G	_	_	I-Premise
117	)	_	_	I-Premise
118	scores	_	_	I-Premise
119	did	_	_	I-Premise
120	not	_	_	I-Premise
121	differ	_	_	I-Premise
122	significantly	_	_	I-Premise
123	between	_	_	I-Premise
124	arms	_	_	I-Premise
125	at	_	_	I-Premise
126	the	_	_	I-Premise
127	fourth	_	_	I-Premise
128	assessment	_	_	I-Premise
129	(	_	_	I-Premise
130	C	_	_	I-Premise
131	=	_	_	I-Premise
132	70.3	_	_	I-Premise
133	(	_	_	I-Premise
134	19.6	_	_	I-Premise
135	)	_	_	I-Premise
136	;	_	_	I-Premise
137	CP	_	_	I-Premise
138	=	_	_	I-Premise
139	72.8	_	_	I-Premise
140	(	_	_	I-Premise
141	17.4	_	_	I-Premise
142	)	_	_	I-Premise
143	)	_	_	I-Premise
144	.	_	_	I-Premise

145	Scores	_	_	B-Premise
146	were	_	_	I-Premise
147	stable	_	_	I-Premise
148	over	_	_	I-Premise
149	time	_	_	I-Premise
150	and	_	_	I-Premise
151	considerably	_	_	I-Premise
152	lower	_	_	I-Premise
153	than	_	_	I-Premise
154	the	_	_	I-Premise
155	general	_	_	I-Premise
156	population	_	_	I-Premise
157	norms	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	BPI-SF	_	_	I-Premise
161	revealed	_	_	I-Premise
162	a	_	_	I-Premise
163	decline	_	_	I-Premise
164	in	_	_	I-Premise
165	pain	_	_	I-Premise
166	scores	_	_	I-Premise
167	in	_	_	I-Premise
168	both	_	_	I-Premise
169	arms	_	_	I-Premise
170	from	_	_	I-Premise
171	the	_	_	I-Premise
172	first	_	_	I-Premise
173	to	_	_	I-Premise
174	fourth	_	_	I-Premise
175	assessments	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	CP	_	_	I-Premise
179	arm	_	_	I-Premise
180	produced	_	_	I-Premise
181	a	_	_	I-Premise
182	significantly	_	_	I-Premise
183	higher	_	_	I-Premise
184	response	_	_	I-Premise
185	rate	_	_	I-Premise
186	and	_	_	I-Premise
187	progression-free	_	_	I-Premise
188	survival	_	_	I-Premise
189	(	_	_	I-Premise
190	PFS	_	_	I-Premise
191	)	_	_	I-Premise
192	but	_	_	B-Premise
193	not	_	_	I-Premise
194	overall	_	_	I-Premise
195	survival	_	_	I-Premise
196	(	_	_	I-Premise
197	OS	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Greater	_	_	B-Premise
201	myelosuppression	_	_	I-Premise
202	was	_	_	I-Premise
203	reported	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	combination	_	_	I-Premise
207	arm	_	_	I-Premise
208	.	_	_	I-Premise

209	The	_	_	B-Premise
210	rate	_	_	I-Premise
211	of	_	_	I-Premise
212	QOL	_	_	I-Premise
213	drop-out	_	_	I-Premise
214	for	_	_	I-Premise
215	any	_	_	I-Premise
216	reason	_	_	I-Premise
217	was	_	_	I-Premise
218	higher	_	_	I-Premise
219	for	_	_	I-Premise
220	C	_	_	I-Premise
221	(	_	_	I-Premise
222	53	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	compared	_	_	I-Premise
226	to	_	_	I-Premise
227	CP	_	_	I-Premise
228	(	_	_	I-Premise
229	38	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	<	_	_	I-Premise
235	0.05	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	At	_	_	O
239	the	_	_	O
240	fourth	_	_	O
241	time	_	_	O
242	point	_	_	O
243	,	_	_	O
244	60	_	_	O
245	%	_	_	O
246	of	_	_	O
247	living	_	_	O
248	patients	_	_	O
249	in	_	_	O
250	both	_	_	O
251	arms	_	_	O
252	completed	_	_	O
253	a	_	_	O
254	QOL	_	_	O
255	assessment	_	_	O
256	.	_	_	O

257	There	_	_	B-Claim
258	was	_	_	I-Claim
259	no	_	_	I-Claim
260	significant	_	_	I-Claim
261	difference	_	_	I-Claim
262	in	_	_	I-Claim
263	overall	_	_	I-Claim
264	QOL	_	_	I-Claim
265	scores	_	_	I-Claim
266	between	_	_	I-Claim
267	treatment	_	_	I-Claim
268	arms	_	_	I-Claim
269	or	_	_	I-Claim
270	serially	_	_	I-Claim
271	.	_	_	I-Claim

272	Combined	_	_	B-Claim
273	with	_	_	I-Claim
274	QOL	_	_	I-Claim
275	results	_	_	I-Claim
276	,	_	_	I-Claim
277	the	_	_	I-Claim
278	significant	_	_	I-Claim
279	increase	_	_	I-Claim
280	in	_	_	I-Claim
281	response	_	_	I-Claim
282	and	_	_	I-Claim
283	PFS	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	CP	_	_	I-Claim
287	arm	_	_	I-Claim
288	and	_	_	I-Claim
289	the	_	_	I-Claim
290	higher	_	_	I-Claim
291	drop-out	_	_	I-Claim
292	rate	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	C	_	_	I-Claim
296	arm	_	_	I-Claim
297	suggest	_	_	I-Claim
298	a	_	_	I-Claim
299	better	_	_	I-Claim
300	outcome	_	_	I-Claim
301	for	_	_	I-Claim
302	the	_	_	I-Claim
303	combination	_	_	I-Claim
304	regimen	_	_	I-Claim
305	despite	_	_	I-Claim
306	its	_	_	I-Claim
307	increased	_	_	I-Claim
308	myelosuppression	_	_	I-Claim
309	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	cannabis	_	_	O
6	extract	_	_	O
7	(	_	_	O
8	CE	_	_	O
9	)	_	_	O
10	,	_	_	O
11	delta-9-tetrahydrocannabinol	_	_	O
12	(	_	_	O
13	THC	_	_	O
14	)	_	_	O
15	,	_	_	O
16	and	_	_	O
17	placebo	_	_	O
18	(	_	_	O
19	PL	_	_	O
20	)	_	_	O
21	on	_	_	O
22	appetite	_	_	O
23	and	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QOL	_	_	O
29	)	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	cancer-related	_	_	O
34	anorexia-cachexia	_	_	O
35	syndrome	_	_	O
36	(	_	_	O
37	CACS	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Adult	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	advanced	_	_	O
44	cancer	_	_	O
45	,	_	_	O
46	CACS	_	_	O
47	,	_	_	O
48	weight	_	_	O
49	loss	_	_	O
50	(	_	_	O
51	>	_	_	O
52	or	_	_	O
53	=	_	_	O
54	5	_	_	O
55	%	_	_	O
56	over	_	_	O
57	6	_	_	O
58	months	_	_	O
59	)	_	_	O
60	,	_	_	O
61	and	_	_	O
62	Eastern	_	_	O
63	Cooperative	_	_	O
64	Oncology	_	_	O
65	Group	_	_	O
66	(	_	_	O
67	ECOG	_	_	O
68	)	_	_	O
69	performance	_	_	O
70	status	_	_	O
71	(	_	_	O
72	PS	_	_	O
73	)	_	_	O
74	<	_	_	O
75	or	_	_	O
76	=	_	_	O
77	2	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	(	_	_	O
82	2:2:1	_	_	O
83	)	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	CE	_	_	O
87	(	_	_	O
88	standardized	_	_	O
89	for	_	_	O
90	2.5	_	_	O
91	mg	_	_	O
92	THC	_	_	O
93	and	_	_	O
94	1	_	_	O
95	mg	_	_	O
96	cannabidiol	_	_	O
97	)	_	_	O
98	or	_	_	O
99	THC	_	_	O
100	(	_	_	O
101	2.5	_	_	O
102	mg	_	_	O
103	)	_	_	O
104	or	_	_	O
105	PL	_	_	O
106	orally	_	_	O
107	,	_	_	O
108	twice	_	_	O
109	daily	_	_	O
110	for	_	_	O
111	6	_	_	O
112	weeks	_	_	O
113	.	_	_	O

114	Appetite	_	_	O
115	,	_	_	O
116	mood	_	_	O
117	,	_	_	O
118	and	_	_	O
119	nausea	_	_	O
120	were	_	_	O
121	monitored	_	_	O
122	daily	_	_	O
123	with	_	_	O
124	a	_	_	O
125	visual	_	_	O
126	analog	_	_	O
127	scale	_	_	O
128	(	_	_	O
129	VAS	_	_	O
130	)	_	_	O
131	;	_	_	O
132	QOL	_	_	O
133	was	_	_	O
134	assessed	_	_	O
135	with	_	_	O
136	the	_	_	O
137	European	_	_	O
138	Organisation	_	_	O
139	for	_	_	O
140	Research	_	_	O
141	and	_	_	O
142	Treatment	_	_	O
143	of	_	_	O
144	Cancer	_	_	O
145	Quality	_	_	O
146	of	_	_	O
147	Life	_	_	O
148	Questionnaire	_	_	O
149	C30	_	_	O
150	(	_	_	O
151	composite	_	_	O
152	score	_	_	O
153	:	_	_	O
154	questions	_	_	O
155	29	_	_	O
156	and	_	_	O
157	30	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Cannabinoid-related	_	_	O
161	toxicity	_	_	O
162	was	_	_	O
163	assessed	_	_	O
164	every	_	_	O
165	2	_	_	O
166	weeks	_	_	O
167	.	_	_	O

168	Of	_	_	O
169	289	_	_	O
170	patients	_	_	O
171	screened	_	_	O
172	,	_	_	O
173	243	_	_	O
174	were	_	_	O
175	randomly	_	_	O
176	assigned	_	_	O
177	and	_	_	O
178	164	_	_	O
179	(	_	_	O
180	CE	_	_	O
181	,	_	_	O
182	66	_	_	O
183	of	_	_	O
184	95	_	_	O
185	patients	_	_	O
186	;	_	_	O
187	THC	_	_	O
188	,	_	_	O
189	65	_	_	O
190	of	_	_	O
191	100	_	_	O
192	patients	_	_	O
193	;	_	_	O
194	and	_	_	O
195	PL	_	_	O
196	,	_	_	O
197	33	_	_	O
198	of	_	_	O
199	48	_	_	O
200	patients	_	_	O
201	)	_	_	O
202	completed	_	_	O
203	treatment	_	_	O
204	.	_	_	O

205	At	_	_	O
206	baseline	_	_	O
207	,	_	_	O
208	groups	_	_	O
209	were	_	_	O
210	comparable	_	_	O
211	for	_	_	O
212	age	_	_	O
213	(	_	_	O
214	mean	_	_	O
215	,	_	_	O
216	61	_	_	O
217	years	_	_	O
218	)	_	_	O
219	,	_	_	O
220	sex	_	_	O
221	(	_	_	O
222	54	_	_	O
223	%	_	_	O
224	men	_	_	O
225	)	_	_	O
226	,	_	_	O
227	weight	_	_	O
228	loss	_	_	O
229	(	_	_	O
230	32	_	_	O
231	%	_	_	O
232	>	_	_	O
233	or	_	_	O
234	=	_	_	O
235	10	_	_	O
236	%	_	_	O
237	)	_	_	O
238	,	_	_	O
239	PS	_	_	O
240	(	_	_	O
241	13	_	_	O
242	%	_	_	O
243	ECOG	_	_	O
244	=	_	_	O
245	2	_	_	O
246	)	_	_	O
247	,	_	_	O
248	antineoplastic	_	_	O
249	treatment	_	_	O
250	(	_	_	O
251	50	_	_	O
252	%	_	_	O
253	)	_	_	O
254	,	_	_	O
255	appetite	_	_	O
256	(	_	_	O
257	mean	_	_	O
258	VAS	_	_	O
259	score	_	_	O
260	,	_	_	O
261	31/100	_	_	O
262	mm	_	_	O
263	)	_	_	O
264	,	_	_	O
265	and	_	_	O
266	QOL	_	_	O
267	(	_	_	O
268	mean	_	_	O
269	score	_	_	O
270	,	_	_	O
271	30/100	_	_	O
272	)	_	_	O
273	.	_	_	O

274	Intent-to-treat	_	_	B-Premise
275	analysis	_	_	I-Premise
276	showed	_	_	I-Premise
277	no	_	_	I-Premise
278	significant	_	_	I-Premise
279	differences	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	three	_	_	I-Premise
283	arms	_	_	I-Premise
284	for	_	_	I-Premise
285	appetite	_	_	I-Premise
286	,	_	_	I-Premise
287	QOL	_	_	I-Premise
288	,	_	_	I-Premise
289	or	_	_	I-Premise
290	cannabinoid-related	_	_	I-Premise
291	toxicity	_	_	I-Premise
292	.	_	_	I-Premise

293	Increased	_	_	B-Premise
294	appetite	_	_	I-Premise
295	was	_	_	I-Premise
296	reported	_	_	I-Premise
297	by	_	_	I-Premise
298	73	_	_	I-Premise
299	%	_	_	I-Premise
300	,	_	_	I-Premise
301	58	_	_	I-Premise
302	%	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	69	_	_	I-Premise
306	%	_	_	I-Premise
307	of	_	_	I-Premise
308	patients	_	_	I-Premise
309	receiving	_	_	I-Premise
310	CE	_	_	I-Premise
311	,	_	_	I-Premise
312	THC	_	_	I-Premise
313	,	_	_	I-Premise
314	or	_	_	I-Premise
315	PL	_	_	I-Premise
316	,	_	_	I-Premise
317	respectively	_	_	I-Premise
318	.	_	_	I-Premise

319	An	_	_	O
320	independent	_	_	O
321	data	_	_	O
322	review	_	_	O
323	board	_	_	O
324	recommended	_	_	O
325	termination	_	_	O
326	of	_	_	O
327	recruitment	_	_	O
328	because	_	_	O
329	of	_	_	O
330	insufficient	_	_	O
331	differences	_	_	O
332	between	_	_	O
333	study	_	_	O
334	arms	_	_	O
335	.	_	_	O

336	CE	_	_	B-Premise
337	at	_	_	I-Premise
338	the	_	_	I-Premise
339	oral	_	_	I-Premise
340	dose	_	_	I-Premise
341	administered	_	_	I-Premise
342	was	_	_	I-Premise
343	well	_	_	I-Premise
344	tolerated	_	_	I-Premise
345	by	_	_	I-Premise
346	these	_	_	I-Premise
347	patients	_	_	I-Premise
348	with	_	_	I-Premise
349	CACS	_	_	I-Premise
350	.	_	_	I-Premise

351	No	_	_	B-Claim
352	differences	_	_	I-Claim
353	in	_	_	I-Claim
354	patients	_	_	I-Claim
355	'	_	_	I-Claim
356	appetite	_	_	I-Claim
357	or	_	_	I-Claim
358	QOL	_	_	I-Claim
359	were	_	_	I-Claim
360	found	_	_	I-Claim
361	either	_	_	I-Claim
362	between	_	_	I-Claim
363	CE	_	_	I-Claim
364	,	_	_	I-Claim
365	THC	_	_	I-Claim
366	,	_	_	I-Claim
367	and	_	_	I-Claim
368	PL	_	_	I-Claim
369	or	_	_	I-Claim
370	between	_	_	I-Claim
371	CE	_	_	I-Claim
372	and	_	_	I-Claim
373	THC	_	_	I-Claim
374	at	_	_	I-Claim
375	the	_	_	I-Claim
376	dosages	_	_	I-Claim
377	investigated	_	_	I-Claim
378	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	well	_	_	O
3	documented	_	_	O
4	that	_	_	O
5	stress	_	_	O
6	is	_	_	O
7	associated	_	_	O
8	with	_	_	O
9	negative	_	_	O
10	health	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	.	_	_	O

16	The	_	_	O
17	purpose	_	_	O
18	of	_	_	O
19	this	_	_	O
20	study	_	_	O
21	was	_	_	O
22	to	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	effects	_	_	O
26	of	_	_	O
27	a	_	_	O
28	novel	_	_	O
29	mindfulness	_	_	O
30	intervention	_	_	O
31	called	_	_	O
32	mindfulness-based	_	_	O
33	art	_	_	O
34	therapy	_	_	O
35	(	_	_	O
36	MBAT	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	standard	_	_	O
40	educational	_	_	O
41	support	_	_	O
42	,	_	_	O
43	on	_	_	O
44	indices	_	_	O
45	of	_	_	O
46	stress	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	in	_	_	O
52	breast	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	high	_	_	O
57	stress	_	_	O
58	levels	_	_	O
59	.	_	_	O

60	A	_	_	O
61	total	_	_	O
62	of	_	_	O
63	191	_	_	O
64	women	_	_	O
65	were	_	_	O
66	enrolled	_	_	O
67	,	_	_	O
68	stratified	_	_	O
69	by	_	_	O
70	age	_	_	O
71	and	_	_	O
72	stress	_	_	O
73	level	_	_	O
74	,	_	_	O
75	and	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	receive	_	_	O
79	either	_	_	O
80	an	_	_	O
81	8-week	_	_	O
82	MBAT	_	_	O
83	intervention	_	_	O
84	or	_	_	O
85	a	_	_	O
86	breast	_	_	O
87	cancer	_	_	O
88	educational	_	_	O
89	support	_	_	O
90	program	_	_	O
91	of	_	_	O
92	equal	_	_	O
93	time	_	_	O
94	and	_	_	O
95	duration	_	_	O
96	.	_	_	O

97	Psychosocial	_	_	O
98	stress	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	using	_	_	O
102	the	_	_	O
103	Symptoms	_	_	O
104	Checklist-90-Revised	_	_	O
105	,	_	_	O
106	and	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	was	_	_	O
111	measured	_	_	O
112	using	_	_	O
113	the	_	_	O
114	Medical	_	_	O
115	Outcomes	_	_	O
116	Study	_	_	O
117	Short-Form	_	_	O
118	Health	_	_	O
119	Survey	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	,	_	_	O
123	immediately	_	_	O
124	post-intervention	_	_	O
125	,	_	_	O
126	and	_	_	O
127	at	_	_	O
128	6	_	_	O
129	months	_	_	O
130	.	_	_	O

131	Results	_	_	B-Premise
132	showed	_	_	I-Premise
133	overall	_	_	I-Premise
134	significant	_	_	I-Premise
135	improvements	_	_	I-Premise
136	in	_	_	I-Premise
137	psychosocial	_	_	I-Premise
138	stress	_	_	I-Premise
139	and	_	_	I-Premise
140	quality	_	_	I-Premise
141	of	_	_	I-Premise
142	life	_	_	I-Premise
143	in	_	_	I-Premise
144	both	_	_	I-Premise
145	the	_	_	I-Premise
146	MBAT	_	_	I-Premise
147	and	_	_	I-Premise
148	educational	_	_	I-Premise
149	support	_	_	I-Premise
150	groups	_	_	I-Premise
151	immediately	_	_	I-Premise
152	post-intervention	_	_	I-Premise
153	;	_	_	I-Premise
154	however	_	_	B-Premise
155	,	_	_	I-Premise
156	participants	_	_	I-Premise
157	with	_	_	I-Premise
158	high	_	_	I-Premise
159	stress	_	_	I-Premise
160	levels	_	_	I-Premise
161	at	_	_	I-Premise
162	baseline	_	_	I-Premise
163	had	_	_	I-Premise
164	significantly	_	_	I-Premise
165	improved	_	_	I-Premise
166	overall	_	_	I-Premise
167	outcomes	_	_	I-Premise
168	only	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	MBAT	_	_	I-Premise
172	group	_	_	I-Premise
173	,	_	_	I-Premise
174	both	_	_	I-Premise
175	immediately	_	_	I-Premise
176	post-intervention	_	_	I-Premise
177	and	_	_	I-Premise
178	at	_	_	I-Premise
179	6	_	_	I-Premise
180	months	_	_	I-Premise
181	.	_	_	I-Premise

182	In	_	_	O
183	addition	_	_	O
184	,	_	_	O
185	at	_	_	B-Premise
186	6	_	_	I-Premise
187	months	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	,	_	_	I-Premise
190	participants	_	_	I-Premise
191	attending	_	_	I-Premise
192	five	_	_	I-Premise
193	or	_	_	I-Premise
194	more	_	_	I-Premise
195	sessions	_	_	I-Premise
196	trended	_	_	I-Premise
197	toward	_	_	I-Premise
198	retaining	_	_	I-Premise
199	treatment	_	_	I-Premise
200	effects	_	_	I-Premise
201	better	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	MBAT	_	_	I-Premise
205	than	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	control	_	_	I-Premise
209	group	_	_	I-Premise
210	.	_	_	I-Premise

211	Finally	_	_	O
212	,	_	_	O
213	black	_	_	B-Premise
214	women	_	_	I-Premise
215	and	_	_	I-Premise
216	white	_	_	I-Premise
217	women	_	_	I-Premise
218	were	_	_	I-Premise
219	similar	_	_	I-Premise
220	in	_	_	I-Premise
221	terms	_	_	I-Premise
222	of	_	_	I-Premise
223	how	_	_	I-Premise
224	they	_	_	I-Premise
225	benefited	_	_	I-Premise
226	from	_	_	I-Premise
227	the	_	_	I-Premise
228	MBAT	_	_	I-Premise
229	intervention	_	_	I-Premise
230	,	_	_	I-Premise
231	even	_	_	I-Premise
232	though	_	_	I-Premise
233	white	_	_	I-Premise
234	participants	_	_	I-Premise
235	tended	_	_	I-Premise
236	to	_	_	I-Premise
237	have	_	_	I-Premise
238	higher	_	_	I-Premise
239	educational	_	_	I-Premise
240	level	_	_	I-Premise
241	and	_	_	I-Premise
242	marital	_	_	I-Premise
243	status	_	_	I-Premise
244	.	_	_	I-Premise

245	In	_	_	B-Claim
246	conclusion	_	_	I-Claim
247	,	_	_	I-Claim
248	MBAT	_	_	I-Claim
249	is	_	_	I-Claim
250	associated	_	_	I-Claim
251	with	_	_	I-Claim
252	significant	_	_	I-Claim
253	,	_	_	I-Claim
254	sustained	_	_	I-Claim
255	benefits	_	_	I-Claim
256	across	_	_	I-Claim
257	a	_	_	I-Claim
258	diverse	_	_	I-Claim
259	range	_	_	I-Claim
260	of	_	_	I-Claim
261	breast	_	_	I-Claim
262	cancer	_	_	I-Claim
263	patients	_	_	I-Claim
264	,	_	_	I-Claim
265	particularly	_	_	I-Claim
266	those	_	_	I-Claim
267	with	_	_	I-Claim
268	high	_	_	I-Claim
269	stress	_	_	I-Claim
270	levels	_	_	I-Claim
271	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	efficacy	_	_	O
7	,	_	_	O
8	toxicity	_	_	O
9	,	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	combination	_	_	O
15	of	_	_	O
16	chemotherapy	_	_	O
17	drugs	_	_	O
18	and	_	_	O
19	intraperitoneal	_	_	O
20	perfusion	_	_	O
21	of	_	_	O
22	verapamil	_	_	O
23	in	_	_	O
24	the	_	_	O
25	treatment	_	_	O
26	of	_	_	O
27	malignant	_	_	O
28	ascites	_	_	O
29	.	_	_	O

30	Seventy-two	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	malignant	_	_	O
34	ascites	_	_	O
35	were	_	_	O
36	divided	_	_	O
37	into	_	_	O
38	two	_	_	O
39	study	_	_	O
40	groups	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	in	_	_	O
44	control	_	_	O
45	group	_	_	O
46	(	_	_	O
47	31	_	_	O
48	cases	_	_	O
49	)	_	_	O
50	received	_	_	O
51	conventional	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	whereas	_	_	O
55	patients	_	_	O
56	in	_	_	O
57	the	_	_	O
58	combined	_	_	O
59	treatment	_	_	O
60	group	_	_	O
61	(	_	_	O
62	41	_	_	O
63	cases	_	_	O
64	)	_	_	O
65	were	_	_	O
66	given	_	_	O
67	verapamil	_	_	O
68	intraperitoneally	_	_	O
69	in	_	_	O
70	addition	_	_	O
71	to	_	_	O
72	chemotherapy	_	_	O
73	drugs	_	_	O
74	.	_	_	O

75	Thirty	_	_	O
76	days	_	_	O
77	after	_	_	O
78	the	_	_	O
79	treatment	_	_	O
80	,	_	_	O
81	efficacy	_	_	O
82	,	_	_	O
83	toxicity	_	_	O
84	,	_	_	O
85	and	_	_	O
86	adverse	_	_	O
87	effects	_	_	O
88	were	_	_	O
89	assessed	_	_	O
90	in	_	_	O
91	both	_	_	O
92	study	_	_	O
93	groups	_	_	O
94	.	_	_	O

95	The	_	_	B-Premise
96	treatment	_	_	I-Premise
97	of	_	_	I-Premise
98	control	_	_	I-Premise
99	group	_	_	I-Premise
100	led	_	_	I-Premise
101	to	_	_	I-Premise
102	1	_	_	I-Premise
103	case	_	_	I-Premise
104	of	_	_	I-Premise
105	complete	_	_	I-Premise
106	remission	_	_	I-Premise
107	and	_	_	I-Premise
108	2	_	_	I-Premise
109	cases	_	_	I-Premise
110	of	_	_	I-Premise
111	partial	_	_	I-Premise
112	remission	_	_	I-Premise
113	,	_	_	I-Premise
114	making	_	_	I-Premise
115	the	_	_	I-Premise
116	rate	_	_	I-Premise
117	of	_	_	I-Premise
118	efficacy	_	_	I-Premise
119	(	_	_	I-Premise
120	complete	_	_	I-Premise
121	+	_	_	I-Premise
122	partial	_	_	I-Premise
123	remission	_	_	I-Premise
124	)	_	_	I-Premise
125	of	_	_	I-Premise
126	9.7	_	_	I-Premise
127	%	_	_	I-Premise
128	.	_	_	I-Premise

129	The	_	_	B-Premise
130	combined	_	_	I-Premise
131	treatment	_	_	I-Premise
132	group	_	_	I-Premise
133	demonstrated	_	_	I-Premise
134	13	_	_	I-Premise
135	cases	_	_	I-Premise
136	of	_	_	I-Premise
137	complete	_	_	I-Premise
138	remission	_	_	I-Premise
139	and	_	_	I-Premise
140	22	_	_	I-Premise
141	cases	_	_	I-Premise
142	of	_	_	I-Premise
143	partial	_	_	I-Premise
144	remission	_	_	I-Premise
145	.	_	_	I-Premise

146	Thus	_	_	O
147	,	_	_	O
148	the	_	_	B-Premise
149	rate	_	_	I-Premise
150	of	_	_	I-Premise
151	efficacy	_	_	I-Premise
152	was	_	_	I-Premise
153	significantly	_	_	I-Premise
154	higher	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	combined	_	_	I-Premise
158	treatment	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	85.36	_	_	I-Premise
162	%	_	_	I-Premise
163	;	_	_	I-Premise
164	p	_	_	I-Premise
165	<	_	_	I-Premise
166	0.05	_	_	I-Premise
167	vs.	_	_	I-Premise
168	control	_	_	I-Premise
169	group	_	_	I-Premise
170	)	_	_	I-Premise
171	.	_	_	I-Premise

172	Using	_	_	O
173	KPS	_	_	O
174	scores	_	_	O
175	,	_	_	O
176	changes	_	_	O
177	in	_	_	O
178	quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	were	_	_	O
182	compared	_	_	O
183	before	_	_	O
184	and	_	_	O
185	after	_	_	O
186	the	_	_	O
187	treatment	_	_	O
188	.	_	_	O

189	The	_	_	B-Premise
190	quality	_	_	I-Premise
191	of	_	_	I-Premise
192	life	_	_	I-Premise
193	improved	_	_	I-Premise
194	in	_	_	I-Premise
195	control	_	_	I-Premise
196	group	_	_	I-Premise
197	by	_	_	I-Premise
198	13.7	_	_	I-Premise
199	%	_	_	I-Premise
200	,	_	_	I-Premise
201	while	_	_	I-Premise
202	combined	_	_	I-Premise
203	treatment	_	_	I-Premise
204	group	_	_	I-Premise
205	showed	_	_	I-Premise
206	improvement	_	_	I-Premise
207	of	_	_	I-Premise
208	83.5	_	_	I-Premise
209	%	_	_	I-Premise
210	(	_	_	I-Premise
211	p	_	_	I-Premise
212	<	_	_	I-Premise
213	0.05	_	_	I-Premise
214	vs.	_	_	I-Premise
215	control	_	_	I-Premise
216	group	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	Further	_	_	O
220	,	_	_	O
221	cumulative	_	_	B-Premise
222	survival	_	_	I-Premise
223	rate	_	_	I-Premise
224	was	_	_	I-Premise
225	also	_	_	I-Premise
226	significantly	_	_	I-Premise
227	higher	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	combined	_	_	I-Premise
231	treatment	_	_	I-Premise
232	group	_	_	I-Premise
233	.	_	_	I-Premise

234	Treatment	_	_	B-Premise
235	toxicity	_	_	I-Premise
236	and	_	_	I-Premise
237	the	_	_	I-Premise
238	rate	_	_	I-Premise
239	of	_	_	I-Premise
240	adverse	_	_	I-Premise
241	effects	_	_	I-Premise
242	and	_	_	I-Premise
243	intestinal	_	_	I-Premise
244	adhesion	_	_	I-Premise
245	were	_	_	I-Premise
246	not	_	_	I-Premise
247	significantly	_	_	I-Premise
248	different	_	_	I-Premise
249	between	_	_	I-Premise
250	study	_	_	I-Premise
251	groups	_	_	I-Premise
252	.	_	_	I-Premise

253	Intraperitoneal	_	_	B-Claim
254	perfusion	_	_	I-Claim
255	of	_	_	I-Claim
256	verapamil	_	_	I-Claim
257	enhances	_	_	I-Claim
258	the	_	_	I-Claim
259	efficacy	_	_	I-Claim
260	of	_	_	I-Claim
261	chemotherapy	_	_	I-Claim
262	drugs	_	_	I-Claim
263	,	_	_	I-Claim
264	prolongs	_	_	I-Claim
265	survival	_	_	I-Claim
266	,	_	_	I-Claim
267	and	_	_	I-Claim
268	improves	_	_	I-Claim
269	the	_	_	I-Claim
270	quality	_	_	I-Claim
271	of	_	_	I-Claim
272	life	_	_	I-Claim
273	.	_	_	I-Claim

274	Intraperitoneal	_	_	B-Claim
275	administration	_	_	I-Claim
276	limits	_	_	I-Claim
277	cardiotoxicity	_	_	I-Claim
278	of	_	_	I-Claim
279	verapamil	_	_	I-Claim
280	.	_	_	I-Claim


0	Impaired	_	_	B-Claim
1	cognition	_	_	I-Claim
2	,	_	_	I-Claim
3	fatigue	_	_	I-Claim
4	,	_	_	I-Claim
5	and	_	_	I-Claim
6	diminished	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	are	_	_	I-Claim
14	commonly	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	chemotherapy	_	_	I-Claim
20	.	_	_	I-Claim

21	This	_	_	O
22	randomized	_	_	O
23	,	_	_	O
24	double-blind	_	_	O
25	,	_	_	O
26	placebo-controlled	_	_	O
27	pilot	_	_	O
28	trial	_	_	O
29	assessed	_	_	O
30	the	_	_	O
31	feasibility	_	_	O
32	of	_	_	O
33	quantifying	_	_	O
34	the	_	_	O
35	effects	_	_	O
36	of	_	_	O
37	epoetin	_	_	O
38	alfa	_	_	O
39	on	_	_	O
40	cognitive	_	_	O
41	function	_	_	O
42	and	_	_	O
43	mood	_	_	O
44	,	_	_	O
45	and	_	_	O
46	evaluated	_	_	O
47	its	_	_	O
48	effects	_	_	O
49	on	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	QOL	_	_	O
53	in	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	treated	_	_	O
59	with	_	_	O
60	anthracycline-based	_	_	O
61	adjuvant	_	_	O
62	or	_	_	O
63	neoadjuvant	_	_	O
64	chemotherapy	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	receive	_	_	O
71	epoetin	_	_	O
72	alfa	_	_	O
73	40,000	_	_	O
74	U	_	_	O
75	subcutaneously	_	_	O
76	once	_	_	O
77	weekly	_	_	O
78	or	_	_	O
79	placebo	_	_	O
80	at	_	_	O
81	the	_	_	O
82	beginning	_	_	O
83	of	_	_	O
84	4	_	_	O
85	cycles	_	_	O
86	of	_	_	O
87	chemotherapy	_	_	O
88	administered	_	_	O
89	over	_	_	O
90	12	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Cognitive	_	_	O
94	function	_	_	O
95	was	_	_	O
96	assessed	_	_	O
97	by	_	_	O
98	Executive	_	_	O
99	Interview	_	_	O
100	(	_	_	O
101	EXIT25	_	_	O
102	)	_	_	O
103	and	_	_	O
104	Clock	_	_	O
105	Drawing	_	_	O
106	Tasks	_	_	O
107	;	_	_	O
108	mood	_	_	O
109	by	_	_	O
110	Profile	_	_	O
111	of	_	_	O
112	Mood	_	_	O
113	States	_	_	O
114	;	_	_	O
115	anemia-related	_	_	O
116	symptoms	_	_	O
117	,	_	_	O
118	including	_	_	O
119	fatigue	_	_	O
120	,	_	_	O
121	by	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Anemia	_	_	O
128	(	_	_	O
129	FACT-An	_	_	O
130	)	_	_	O
131	subscale	_	_	O
132	;	_	_	O
133	and	_	_	O
134	QOL	_	_	O
135	by	_	_	O
136	Linear	_	_	O
137	Analog	_	_	O
138	Scale	_	_	O
139	Assessment	_	_	O
140	.	_	_	O

141	Ninety-four	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	evaluable	_	_	O
145	for	_	_	O
146	efficacy	_	_	O
147	and	_	_	O
148	safety	_	_	O
149	.	_	_	O

150	Mean	_	_	B-Premise
151	change	_	_	I-Premise
152	in	_	_	I-Premise
153	EXIT25	_	_	I-Premise
154	scores	_	_	I-Premise
155	from	_	_	I-Premise
156	baseline	_	_	I-Premise
157	to	_	_	I-Premise
158	cycle	_	_	I-Premise
159	4	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	epoetin	_	_	I-Premise
163	alfa	_	_	I-Premise
164	group	_	_	I-Premise
165	was	_	_	I-Premise
166	1.3	_	_	I-Premise
167	+/-	_	_	I-Premise
168	3.3	_	_	I-Premise
169	;	_	_	I-Premise
170	the	_	_	B-Premise
171	mean	_	_	I-Premise
172	change	_	_	I-Premise
173	was	_	_	I-Premise
174	0.3	_	_	I-Premise
175	+/-	_	_	I-Premise
176	2.4	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	placebo	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	a	_	_	I-Premise
183	negative	_	_	I-Premise
184	change	_	_	I-Premise
185	indicates	_	_	I-Premise
186	improved	_	_	I-Premise
187	executive	_	_	I-Premise
188	function	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	There	_	_	B-Premise
192	was	_	_	I-Premise
193	no	_	_	I-Premise
194	difference	_	_	I-Premise
195	between	_	_	I-Premise
196	groups	_	_	I-Premise
197	in	_	_	I-Premise
198	mean	_	_	I-Premise
199	change	_	_	I-Premise
200	in	_	_	I-Premise
201	EXIT25	_	_	I-Premise
202	score	_	_	I-Premise
203	from	_	_	I-Premise
204	baseline	_	_	I-Premise
205	to	_	_	I-Premise
206	6-month	_	_	I-Premise
207	follow-up	_	_	I-Premise
208	assessment	_	_	I-Premise
209	.	_	_	I-Premise

210	Mean	_	_	B-Premise
211	hemoglobin	_	_	I-Premise
212	levels	_	_	I-Premise
213	were	_	_	I-Premise
214	higher	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	alfa	_	_	I-Premise
219	group	_	_	I-Premise
220	compared	_	_	I-Premise
221	with	_	_	I-Premise
222	the	_	_	I-Premise
223	placebo	_	_	I-Premise
224	group	_	_	I-Premise
225	after	_	_	I-Premise
226	4	_	_	I-Premise
227	cycles	_	_	I-Premise
228	of	_	_	I-Premise
229	chemotherapy	_	_	I-Premise
230	.	_	_	I-Premise

231	Epoetin	_	_	B-Premise
232	alfa	_	_	I-Premise
233	recipients	_	_	I-Premise
234	had	_	_	I-Premise
235	less	_	_	I-Premise
236	of	_	_	I-Premise
237	a	_	_	I-Premise
238	decrease	_	_	I-Premise
239	in	_	_	I-Premise
240	FACT-An	_	_	I-Premise
241	subscale	_	_	I-Premise
242	scores	_	_	I-Premise
243	from	_	_	I-Premise
244	baseline	_	_	I-Premise
245	to	_	_	I-Premise
246	cycle	_	_	I-Premise
247	4	_	_	I-Premise
248	and	_	_	I-Premise
249	improvement	_	_	I-Premise
250	in	_	_	I-Premise
251	FACT-An	_	_	I-Premise
252	subscale	_	_	I-Premise
253	scores	_	_	I-Premise
254	at	_	_	I-Premise
255	6-month	_	_	I-Premise
256	follow-up	_	_	I-Premise
257	assessment	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	placebo	_	_	I-Premise
261	.	_	_	I-Premise

262	Epoetin	_	_	B-Claim
263	alfa	_	_	I-Claim
264	therapy	_	_	I-Claim
265	was	_	_	I-Claim
266	well	_	_	I-Claim
267	tolerated	_	_	I-Claim
268	.	_	_	I-Claim

269	These	_	_	B-Claim
270	data	_	_	I-Claim
271	suggest	_	_	I-Claim
272	that	_	_	I-Claim
273	epoetin	_	_	I-Claim
274	alfa	_	_	I-Claim
275	may	_	_	I-Claim
276	have	_	_	I-Claim
277	attenuated	_	_	I-Claim
278	the	_	_	I-Claim
279	cognitive	_	_	I-Claim
280	impairment	_	_	I-Claim
281	and	_	_	I-Claim
282	fatigue	_	_	I-Claim
283	that	_	_	I-Claim
284	occurred	_	_	I-Claim
285	during	_	_	I-Claim
286	adjuvant	_	_	I-Claim
287	breast	_	_	I-Claim
288	cancer	_	_	I-Claim
289	chemotherapy	_	_	I-Claim
290	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	Asia-Pacific	_	_	O
3	region	_	_	O
4	and	_	_	O
5	elsewhere	_	_	O
6	,	_	_	O
7	almost	_	_	O
8	85	_	_	O
9	%	_	_	O
10	of	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	hepatocellular	_	_	O
14	carcinoma	_	_	O
15	(	_	_	O
16	HCC	_	_	O
17	)	_	_	O
18	are	_	_	O
19	inoperable	_	_	O
20	at	_	_	O
21	diagnosis	_	_	O
22	and	_	_	O
23	have	_	_	O
24	a	_	_	O
25	dismal	_	_	O
26	prognosis	_	_	O
27	.	_	_	O

28	Tamoxifen	_	_	B-Claim
29	(	_	_	I-Claim
30	TMX	_	_	I-Claim
31	)	_	_	I-Claim
32	is	_	_	I-Claim
33	believed	_	_	I-Claim
34	to	_	_	I-Claim
35	inhibit	_	_	I-Claim
36	HCC	_	_	I-Claim
37	positive	_	_	I-Claim
38	for	_	_	I-Claim
39	estrogen	_	_	I-Claim
40	receptor	_	_	I-Claim
41	(	_	_	I-Claim
42	ER	_	_	I-Claim
43	)	_	_	I-Claim
44	,	_	_	I-Claim
45	but	_	_	I-Claim
46	most	_	_	I-Claim
47	HCCs	_	_	I-Claim
48	are	_	_	I-Claim
49	ER	_	_	I-Claim
50	negative	_	_	I-Claim
51	.	_	_	I-Claim

52	Results	_	_	B-Claim
53	of	_	_	I-Claim
54	previous	_	_	I-Claim
55	phase	_	_	I-Claim
56	3	_	_	I-Claim
57	trials	_	_	I-Claim
58	in	_	_	I-Claim
59	inoperable	_	_	I-Claim
60	HCC	_	_	I-Claim
61	have	_	_	I-Claim
62	been	_	_	I-Claim
63	conflicting	_	_	I-Claim
64	and	_	_	I-Claim
65	inconclusive	_	_	I-Claim
66	.	_	_	I-Claim

67	At	_	_	B-Claim
68	higher	_	_	I-Claim
69	doses	_	_	I-Claim
70	,	_	_	I-Claim
71	however	_	_	I-Claim
72	,	_	_	I-Claim
73	TMX	_	_	I-Claim
74	inhibits	_	_	I-Claim
75	HCC	_	_	I-Claim
76	through	_	_	I-Claim
77	ER-independent	_	_	I-Claim
78	mechanisms	_	_	I-Claim
79	.	_	_	I-Claim

80	A	_	_	O
81	multicenter	_	_	O
82	randomized	_	_	O
83	controlled	_	_	O
84	trial	_	_	O
85	was	_	_	O
86	performed	_	_	O
87	to	_	_	O
88	assess	_	_	O
89	the	_	_	O
90	role	_	_	O
91	of	_	_	O
92	high-dose	_	_	O
93	TMX	_	_	O
94	versus	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	P	_	_	O
98	)	_	_	O
99	in	_	_	O
100	the	_	_	O
101	treatment	_	_	O
102	of	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	inoperable	_	_	O
106	HCC	_	_	O
107	with	_	_	O
108	respect	_	_	O
109	to	_	_	O
110	survival	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	(	_	_	O
116	QoL	_	_	O
117	)	_	_	O
118	.	_	_	O

119	A	_	_	O
120	total	_	_	O
121	of	_	_	O
122	329	_	_	O
123	patients	_	_	O
124	from	_	_	O
125	10	_	_	O
126	centers	_	_	O
127	in	_	_	O
128	9	_	_	O
129	countries	_	_	O
130	in	_	_	O
131	the	_	_	O
132	Asia-Pacific	_	_	O
133	region	_	_	O
134	enrolled	_	_	O
135	in	_	_	O
136	a	_	_	O
137	double-blind	_	_	O
138	randomized	_	_	O
139	controlled	_	_	O
140	trial	_	_	O
141	of	_	_	O
142	TMX	_	_	O
143	120	_	_	O
144	mg/d	_	_	O
145	(	_	_	O
146	TMX120	_	_	O
147	)	_	_	O
148	against	_	_	O
149	P	_	_	O
150	as	_	_	O
151	a	_	_	O
152	control	_	_	O
153	arm	_	_	O
154	with	_	_	O
155	an	_	_	O
156	intermediate	_	_	O
157	dosage	_	_	O
158	of	_	_	O
159	TMX	_	_	O
160	60	_	_	O
161	mg/d	_	_	O
162	(	_	_	O
163	TMX60	_	_	O
164	)	_	_	O
165	to	_	_	O
166	assess	_	_	O
167	possible	_	_	O
168	dose	_	_	O
169	response	_	_	O
170	.	_	_	O

171	An	_	_	O
172	independent	_	_	O
173	data	_	_	O
174	monitoring	_	_	O
175	committee	_	_	O
176	reviewed	_	_	O
177	all	_	_	O
178	aspects	_	_	O
179	of	_	_	O
180	the	_	_	O
181	trial	_	_	O
182	.	_	_	O

183	QoL	_	_	O
184	was	_	_	O
185	assessed	_	_	O
186	using	_	_	O
187	the	_	_	O
188	European	_	_	O
189	Organization	_	_	O
190	for	_	_	O
191	Research	_	_	O
192	and	_	_	O
193	Treatment	_	_	O
194	of	_	_	O
195	Cancer	_	_	O
196	QLQ-C30	_	_	O
197	questionnaire	_	_	O
198	.	_	_	O

199	Three-month	_	_	B-Premise
200	survival	_	_	I-Premise
201	rates	_	_	I-Premise
202	for	_	_	I-Premise
203	the	_	_	I-Premise
204	P	_	_	I-Premise
205	,	_	_	I-Premise
206	TMX60	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	TMX120	_	_	I-Premise
210	groups	_	_	I-Premise
211	were	_	_	I-Premise
212	44	_	_	I-Premise
213	%	_	_	I-Premise
214	,	_	_	I-Premise
215	41	_	_	I-Premise
216	%	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	35	_	_	I-Premise
220	%	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	,	_	_	I-Premise
224	with	_	_	I-Premise
225	a	_	_	I-Premise
226	statistically	_	_	I-Premise
227	significant	_	_	I-Premise
228	trend	_	_	I-Premise
229	difference	_	_	I-Premise
230	in	_	_	I-Premise
231	survival	_	_	I-Premise
232	across	_	_	I-Premise
233	the	_	_	I-Premise
234	3	_	_	I-Premise
235	treatment	_	_	I-Premise
236	regimens	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	=.011	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	There	_	_	B-Premise
243	was	_	_	I-Premise
244	a	_	_	I-Premise
245	significantly	_	_	I-Premise
246	higher	_	_	I-Premise
247	risk	_	_	I-Premise
248	of	_	_	I-Premise
249	death	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	TMX120	_	_	I-Premise
253	group	_	_	I-Premise
254	compared	_	_	I-Premise
255	with	_	_	I-Premise
256	the	_	_	I-Premise
257	P	_	_	I-Premise
258	group	_	_	I-Premise
259	(	_	_	I-Premise
260	hazard	_	_	I-Premise
261	ratio	_	_	I-Premise
262	,	_	_	I-Premise
263	1.39	_	_	I-Premise
264	;	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	confidence	_	_	I-Premise
268	interval	_	_	I-Premise
269	,	_	_	I-Premise
270	1.07-1.81	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Adverse	_	_	B-Premise
274	drug	_	_	I-Premise
275	reactions	_	_	I-Premise
276	were	_	_	I-Premise
277	reported	_	_	I-Premise
278	in	_	_	I-Premise
279	3	_	_	I-Premise
280	%	_	_	I-Premise
281	(	_	_	I-Premise
282	9	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	O
287	8	_	_	B-Premise
288	patients	_	_	I-Premise
289	were	_	_	I-Premise
290	lost	_	_	I-Premise
291	to	_	_	I-Premise
292	follow-up	_	_	I-Premise
293	.	_	_	I-Premise

294	In	_	_	O
295	conclusion	_	_	O
296	,	_	_	O
297	TMX	_	_	B-Claim
298	does	_	_	I-Claim
299	not	_	_	I-Claim
300	prolong	_	_	I-Claim
301	survival	_	_	I-Claim
302	in	_	_	I-Claim
303	patients	_	_	I-Claim
304	with	_	_	I-Claim
305	inoperable	_	_	I-Claim
306	HCC	_	_	I-Claim
307	and	_	_	I-Claim
308	has	_	_	I-Claim
309	an	_	_	I-Claim
310	increasingly	_	_	I-Claim
311	negative	_	_	I-Claim
312	impact	_	_	I-Claim
313	with	_	_	I-Claim
314	increasing	_	_	I-Claim
315	dose	_	_	I-Claim
316	.	_	_	I-Claim

317	No	_	_	B-Claim
318	appreciable	_	_	I-Claim
319	advantage	_	_	I-Claim
320	to	_	_	I-Claim
321	QoL	_	_	I-Claim
322	with	_	_	I-Claim
323	TMX	_	_	I-Claim
324	was	_	_	I-Claim
325	observed	_	_	I-Claim
326	.	_	_	I-Claim


0	This	_	_	O
1	is	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	phase	_	_	O
5	II	_	_	O
6	study	_	_	O
7	designed	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	the	_	_	O
11	toxicity	_	_	O
12	profile	_	_	O
13	of	_	_	O
14	a	_	_	O
15	non-platinum-based	_	_	O
16	with	_	_	O
17	a	_	_	O
18	platinum-based	_	_	O
19	regimen	_	_	O
20	in	_	_	O
21	the	_	_	O
22	treatment	_	_	O
23	of	_	_	O
24	advanced	_	_	O
25	non-small	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Eighty-nine	_	_	O
31	chemotherapy-naÃ¯ve	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomized	_	_	O
35	either	_	_	O
36	to	_	_	O
37	gemcitabine	_	_	O
38	(	_	_	O
39	1,000	_	_	O
40	mg/m2	_	_	O
41	,	_	_	O
42	30-min	_	_	O
43	infusion	_	_	O
44	on	_	_	O
45	days	_	_	O
46	1	_	_	O
47	,	_	_	O
48	8	_	_	O
49	and	_	_	O
50	15	_	_	O
51	)	_	_	O
52	and	_	_	O
53	oral	_	_	O
54	etoposide	_	_	O
55	(	_	_	O
56	50	_	_	O
57	mg	_	_	O
58	,	_	_	O
59	days	_	_	O
60	1-14	_	_	O
61	;	_	_	O
62	GE	_	_	O
63	group	_	_	O
64	)	_	_	O
65	or	_	_	O
66	gemcitabine	_	_	O
67	at	_	_	O
68	the	_	_	O
69	same	_	_	O
70	schedule	_	_	O
71	and	_	_	O
72	cisplatin	_	_	O
73	(	_	_	O
74	75	_	_	O
75	mg/m2	_	_	O
76	on	_	_	O
77	day	_	_	O
78	15	_	_	O
79	;	_	_	O
80	GP	_	_	O
81	group	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	endpoint	_	_	O
87	is	_	_	O
88	toxicity	_	_	O
89	,	_	_	O
90	and	_	_	O
91	secondary	_	_	O
92	endpoints	_	_	O
93	include	_	_	O
94	response	_	_	O
95	rate	_	_	O
96	,	_	_	O
97	survival	_	_	O
98	outcome	_	_	O
99	and	_	_	O
100	quality	_	_	O
101	of	_	_	O
102	life	_	_	O
103	(	_	_	O
104	QOL	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	B-Premise
108	incidence	_	_	I-Premise
109	of	_	_	I-Premise
110	WHO	_	_	I-Premise
111	grade	_	_	I-Premise
112	3	_	_	I-Premise
113	or	_	_	I-Premise
114	4	_	_	I-Premise
115	anemia	_	_	I-Premise
116	,	_	_	I-Premise
117	neutropenia	_	_	I-Premise
118	and	_	_	I-Premise
119	thrombocytopenia	_	_	I-Premise
120	was	_	_	I-Premise
121	29	_	_	I-Premise
122	,	_	_	I-Premise
123	44	_	_	I-Premise
124	and	_	_	I-Premise
125	22	_	_	I-Premise
126	%	_	_	I-Premise
127	(	_	_	I-Premise
128	GE	_	_	I-Premise
129	group	_	_	I-Premise
130	)	_	_	I-Premise
131	,	_	_	I-Premise
132	and	_	_	I-Premise
133	28	_	_	I-Premise
134	,	_	_	I-Premise
135	49	_	_	I-Premise
136	and	_	_	I-Premise
137	23	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	GP	_	_	I-Premise
141	group	_	_	I-Premise
142	)	_	_	I-Premise
143	,	_	_	I-Premise
144	respectively	_	_	I-Premise
145	(	_	_	I-Premise
146	p	_	_	I-Premise
147	=	_	_	I-Premise
148	0.75	_	_	I-Premise
149	,	_	_	I-Premise
150	0.95	_	_	I-Premise
151	and	_	_	I-Premise
152	0.87	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	The	_	_	B-Premise
158	rate	_	_	I-Premise
159	of	_	_	I-Premise
160	grade	_	_	I-Premise
161	2	_	_	I-Premise
162	or	_	_	I-Premise
163	above	_	_	I-Premise
164	nausea	_	_	I-Premise
165	was	_	_	I-Premise
166	numerically	_	_	I-Premise
167	higher	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	GP	_	_	I-Premise
171	arm	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	B-Premise
174	the	_	_	I-Premise
175	difference	_	_	I-Premise
176	was	_	_	I-Premise
177	not	_	_	I-Premise
178	statistically	_	_	I-Premise
179	significant	_	_	I-Premise
180	(	_	_	I-Premise
181	GE	_	_	I-Premise
182	15.5	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	GP	_	_	I-Premise
186	27.7	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.20	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	rate	_	_	I-Premise
196	of	_	_	I-Premise
197	vomiting	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	GE	_	_	I-Premise
201	and	_	_	I-Premise
202	GP	_	_	I-Premise
203	arms	_	_	I-Premise
204	was	_	_	I-Premise
205	20.0	_	_	I-Premise
206	and	_	_	I-Premise
207	20.5	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.96	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	However	_	_	B-Premise
218	,	_	_	I-Premise
219	subjective	_	_	I-Premise
220	changes	_	_	I-Premise
221	in	_	_	I-Premise
222	QOL	_	_	I-Premise
223	scores	_	_	I-Premise
224	on	_	_	I-Premise
225	nausea	_	_	I-Premise
226	and	_	_	I-Premise
227	vomiting	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	higher	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	GP	_	_	I-Premise
234	arm	_	_	I-Premise
235	(	_	_	I-Premise
236	p	_	_	I-Premise
237	=	_	_	I-Premise
238	0.001	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Other	_	_	B-Premise
242	symptoms	_	_	I-Premise
243	including	_	_	I-Premise
244	sore	_	_	I-Premise
245	mouth	_	_	I-Premise
246	and	_	_	I-Premise
247	hair	_	_	I-Premise
248	loss	_	_	I-Premise
249	were	_	_	I-Premise
250	significantly	_	_	I-Premise
251	higher	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	GE	_	_	I-Premise
255	arm	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.003	_	_	I-Premise
260	and	_	_	I-Premise
261	0.007	_	_	I-Premise
262	,	_	_	I-Premise
263	respectively	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	There	_	_	B-Premise
267	were	_	_	I-Premise
268	also	_	_	I-Premise
269	significant	_	_	I-Premise
270	differences	_	_	I-Premise
271	observed	_	_	I-Premise
272	in	_	_	I-Premise
273	emotional	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0.014	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	cognitive	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.028	_	_	I-Premise
285	)	_	_	I-Premise
286	and	_	_	I-Premise
287	social	_	_	I-Premise
288	functioning	_	_	I-Premise
289	(	_	_	I-Premise
290	p	_	_	I-Premise
291	=	_	_	I-Premise
292	0.034	_	_	I-Premise
293	)	_	_	I-Premise
294	in	_	_	I-Premise
295	favor	_	_	I-Premise
296	of	_	_	I-Premise
297	GP	_	_	I-Premise
298	.	_	_	I-Premise

299	The	_	_	B-Premise
300	differences	_	_	I-Premise
301	in	_	_	I-Premise
302	tumor	_	_	I-Premise
303	response	_	_	I-Premise
304	(	_	_	I-Premise
305	35.5	_	_	I-Premise
306	and	_	_	I-Premise
307	46.5	_	_	I-Premise
308	%	_	_	I-Premise
309	for	_	_	I-Premise
310	GE	_	_	I-Premise
311	and	_	_	I-Premise
312	GP	_	_	I-Premise
313	,	_	_	I-Premise
314	respectively	_	_	I-Premise
315	)	_	_	I-Premise
316	were	_	_	I-Premise
317	not	_	_	I-Premise
318	significantly	_	_	I-Premise
319	different	_	_	I-Premise
320	.	_	_	I-Premise

321	Median	_	_	B-Premise
322	time	_	_	I-Premise
323	to	_	_	I-Premise
324	disease	_	_	I-Premise
325	progression	_	_	I-Premise
326	(	_	_	I-Premise
327	33.8	_	_	I-Premise
328	and	_	_	I-Premise
329	40.7	_	_	I-Premise
330	weeks	_	_	I-Premise
331	,	_	_	I-Premise
332	respectively	_	_	I-Premise
333	)	_	_	I-Premise
334	and	_	_	I-Premise
335	overall	_	_	I-Premise
336	survival	_	_	I-Premise
337	(	_	_	I-Premise
338	41.4	_	_	I-Premise
339	and	_	_	I-Premise
340	57.3	_	_	I-Premise
341	weeks	_	_	I-Premise
342	,	_	_	I-Premise
343	respectively	_	_	I-Premise
344	)	_	_	I-Premise
345	were	_	_	I-Premise
346	of	_	_	I-Premise
347	borderline	_	_	I-Premise
348	significance	_	_	I-Premise
349	in	_	_	I-Premise
350	favor	_	_	I-Premise
351	of	_	_	I-Premise
352	the	_	_	I-Premise
353	GP	_	_	I-Premise
354	arm	_	_	I-Premise
355	(	_	_	I-Premise
356	p	_	_	I-Premise
357	=	_	_	I-Premise
358	0.055	_	_	I-Premise
359	)	_	_	I-Premise
360	.	_	_	I-Premise

361	This	_	_	B-Claim
362	toxicity	_	_	I-Claim
363	profile	_	_	I-Claim
364	of	_	_	I-Claim
365	GE	_	_	I-Claim
366	is	_	_	I-Claim
367	similar	_	_	I-Claim
368	to	_	_	I-Claim
369	GP	_	_	I-Claim
370	,	_	_	I-Claim
371	but	_	_	B-Claim
372	the	_	_	I-Claim
373	apparent	_	_	I-Claim
374	inferior	_	_	I-Claim
375	efficacy	_	_	I-Claim
376	may	_	_	I-Claim
377	discourage	_	_	I-Claim
378	further	_	_	I-Claim
379	investigation	_	_	I-Claim
380	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	analgesic	_	_	O
4	effect	_	_	O
5	,	_	_	O
6	safety	_	_	O
7	,	_	_	O
8	and	_	_	O
9	cost-effectiveness	_	_	O
10	of	_	_	O
11	controlled-release	_	_	O
12	oxycodone	_	_	O
13	(	_	_	O
14	CRO	_	_	O
15	)	_	_	O
16	to	_	_	O
17	control	_	_	O
18	postoperative	_	_	O
19	pain	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	liver	_	_	O
24	cancer	_	_	O
25	who	_	_	O
26	are	_	_	O
27	undergoing	_	_	O
28	transarterial	_	_	O
29	chemoembolization	_	_	O
30	.	_	_	O

31	This	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	double-blind	_	_	O
35	,	_	_	O
36	placebo-controlled	_	_	O
37	,	_	_	O
38	prospective	_	_	O
39	clinical	_	_	O
40	study	_	_	O
41	received	_	_	O
42	institutional	_	_	O
43	review	_	_	O
44	board	_	_	O
45	approval	_	_	O
46	.	_	_	O

47	After	_	_	O
48	written	_	_	O
49	informed	_	_	O
50	consent	_	_	O
51	was	_	_	O
52	obtained	_	_	O
53	,	_	_	O
54	210	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	liver	_	_	O
58	cancer	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	into	_	_	O
62	three	_	_	O
63	groups	_	_	O
64	of	_	_	O
65	70	_	_	O
66	patients	_	_	O
67	.	_	_	O

68	Group	_	_	O
69	1	_	_	O
70	received	_	_	O
71	20	_	_	O
72	mg	_	_	O
73	of	_	_	O
74	CRO	_	_	O
75	,	_	_	O
76	group	_	_	O
77	2	_	_	O
78	received	_	_	O
79	10	_	_	O
80	mg	_	_	O
81	of	_	_	O
82	CRO	_	_	O
83	,	_	_	O
84	and	_	_	O
85	group	_	_	O
86	3	_	_	O
87	received	_	_	O
88	a	_	_	O
89	placebo	_	_	O
90	at	_	_	O
91	1	_	_	O
92	hour	_	_	O
93	before	_	_	O
94	transarterial	_	_	O
95	chemoembolization	_	_	O
96	(	_	_	O
97	T	_	_	O
98	(	_	_	O
99	0	_	_	O
100	)	_	_	O
101	)	_	_	O
102	and	_	_	O
103	12	_	_	O
104	(	_	_	O
105	T	_	_	O
106	(	_	_	O
107	12	_	_	O
108	)	_	_	O
109	)	_	_	O
110	and	_	_	O
111	24	_	_	O
112	(	_	_	O
113	T	_	_	O
114	(	_	_	O
115	24	_	_	O
116	)	_	_	O
117	)	_	_	O
118	hours	_	_	O
119	after	_	_	O
120	T	_	_	O
121	(	_	_	O
122	0	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Pain	_	_	O
126	intensity	_	_	O
127	on	_	_	O
128	a	_	_	O
129	numeric	_	_	O
130	rating	_	_	O
131	scale	_	_	O
132	,	_	_	O
133	percentage	_	_	O
134	of	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	each	_	_	O
138	degree	_	_	O
139	of	_	_	O
140	pain	_	_	O
141	,	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	,	_	_	O
146	adverse	_	_	O
147	reactions	_	_	O
148	,	_	_	O
149	analgesic	_	_	O
150	costs	_	_	O
151	,	_	_	O
152	and	_	_	O
153	hospital	_	_	O
154	stays	_	_	O
155	were	_	_	O
156	evaluated	_	_	O
157	and	_	_	O
158	compared	_	_	O
159	among	_	_	O
160	the	_	_	O
161	three	_	_	O
162	groups	_	_	O
163	.	_	_	O

164	Numeric	_	_	B-Premise
165	rating	_	_	I-Premise
166	scale	_	_	I-Premise
167	scores	_	_	I-Premise
168	for	_	_	I-Premise
169	pain	_	_	I-Premise
170	intensity	_	_	I-Premise
171	in	_	_	I-Premise
172	group	_	_	I-Premise
173	1	_	_	I-Premise
174	and	_	_	I-Premise
175	group	_	_	I-Premise
176	2	_	_	I-Premise
177	were	_	_	I-Premise
178	significantly	_	_	I-Premise
179	lower	_	_	I-Premise
180	than	_	_	I-Premise
181	those	_	_	I-Premise
182	in	_	_	I-Premise
183	group	_	_	I-Premise
184	3	_	_	I-Premise
185	at	_	_	I-Premise
186	T	_	_	I-Premise
187	(	_	_	I-Premise
188	0-12	_	_	I-Premise
189	)	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.001	_	_	I-Premise
194	)	_	_	I-Premise
195	;	_	_	I-Premise
196	T	_	_	I-Premise
197	(	_	_	I-Premise
198	12-24	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	.001	_	_	I-Premise
204	)	_	_	I-Premise
205	;	_	_	I-Premise
206	and	_	_	I-Premise
207	T	_	_	I-Premise
208	(	_	_	I-Premise
209	24-48	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	<	_	_	I-Premise
214	.001	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	When	_	_	B-Premise
218	group	_	_	I-Premise
219	1	_	_	I-Premise
220	with	_	_	I-Premise
221	group	_	_	I-Premise
222	2	_	_	I-Premise
223	were	_	_	I-Premise
224	compared	_	_	I-Premise
225	,	_	_	I-Premise
226	numeric	_	_	I-Premise
227	rating	_	_	I-Premise
228	scale	_	_	I-Premise
229	scores	_	_	I-Premise
230	were	_	_	I-Premise
231	significantly	_	_	I-Premise
232	lower	_	_	I-Premise
233	in	_	_	I-Premise
234	group	_	_	I-Premise
235	1	_	_	I-Premise
236	than	_	_	I-Premise
237	in	_	_	I-Premise
238	group	_	_	I-Premise
239	2	_	_	I-Premise
240	during	_	_	I-Premise
241	the	_	_	I-Premise
242	period	_	_	I-Premise
243	of	_	_	I-Premise
244	T	_	_	I-Premise
245	(	_	_	I-Premise
246	0-12	_	_	I-Premise
247	)	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	.001	_	_	I-Premise
252	)	_	_	I-Premise
253	but	_	_	B-Premise
254	were	_	_	I-Premise
255	not	_	_	I-Premise
256	significantly	_	_	I-Premise
257	different	_	_	I-Premise
258	at	_	_	I-Premise
259	T	_	_	I-Premise
260	(	_	_	I-Premise
261	12-24	_	_	I-Premise
262	)	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.68	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	T	_	_	I-Premise
270	(	_	_	I-Premise
271	24-48	_	_	I-Premise
272	)	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.10	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Analgesic	_	_	B-Premise
280	cost	_	_	I-Premise
281	and	_	_	I-Premise
282	hospital	_	_	I-Premise
283	stay	_	_	I-Premise
284	were	_	_	I-Premise
285	significantly	_	_	I-Premise
286	lower	_	_	I-Premise
287	in	_	_	I-Premise
288	treated	_	_	I-Premise
289	groups	_	_	I-Premise
290	than	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	placebo	_	_	I-Premise
294	group	_	_	I-Premise
295	.	_	_	I-Premise

296	No	_	_	B-Premise
297	significant	_	_	I-Premise
298	difference	_	_	I-Premise
299	was	_	_	I-Premise
300	observed	_	_	I-Premise
301	in	_	_	I-Premise
302	quality	_	_	I-Premise
303	of	_	_	I-Premise
304	life	_	_	I-Premise
305	and	_	_	I-Premise
306	adverse	_	_	I-Premise
307	events	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	treated	_	_	I-Premise
311	groups	_	_	I-Premise
312	and	_	_	I-Premise
313	the	_	_	I-Premise
314	placebo	_	_	I-Premise
315	group	_	_	I-Premise
316	.	_	_	I-Premise

317	CRO	_	_	B-Claim
318	is	_	_	I-Claim
319	effective	_	_	I-Claim
320	,	_	_	I-Claim
321	safe	_	_	I-Claim
322	,	_	_	I-Claim
323	and	_	_	I-Claim
324	cost-effective	_	_	I-Claim
325	in	_	_	I-Claim
326	the	_	_	I-Claim
327	control	_	_	I-Claim
328	of	_	_	I-Claim
329	postoperative	_	_	I-Claim
330	pain	_	_	I-Claim
331	after	_	_	I-Claim
332	transarterial	_	_	I-Claim
333	chemoembolization	_	_	I-Claim
334	for	_	_	I-Claim
335	patients	_	_	I-Claim
336	with	_	_	I-Claim
337	inoperable	_	_	I-Claim
338	liver	_	_	I-Claim
339	cancer	_	_	I-Claim
340	.	_	_	I-Claim


0	Health-related	_	_	O
1	quality	_	_	O
2	of	_	_	O
3	life	_	_	O
4	(	_	_	O
5	HRQOL	_	_	O
6	)	_	_	O
7	,	_	_	O
8	symptoms	_	_	O
9	of	_	_	O
10	depression	_	_	O
11	,	_	_	O
12	and	_	_	O
13	adverse	_	_	O
14	events	_	_	O
15	(	_	_	O
16	AEs	_	_	O
17	)	_	_	O
18	were	_	_	O
19	compared	_	_	O
20	between	_	_	O
21	Japanese	_	_	O
22	postmenopausal	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	hormone-sensitive	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	(	_	_	O
29	BC	_	_	O
30	)	_	_	O
31	who	_	_	O
32	received	_	_	O
33	adjuvant	_	_	O
34	tamoxifen	_	_	O
35	,	_	_	O
36	exemestane	_	_	O
37	,	_	_	O
38	or	_	_	O
39	anastrozole	_	_	O
40	in	_	_	O
41	an	_	_	O
42	open-labeled	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	,	_	_	O
46	multicenter	_	_	O
47	trial	_	_	O
48	designated	_	_	O
49	as	_	_	O
50	the	_	_	O
51	National	_	_	O
52	Surgical	_	_	O
53	Adjuvant	_	_	O
54	Study	_	_	O
55	of	_	_	O
56	Breast	_	_	O
57	Cancer	_	_	O
58	(	_	_	O
59	N-SAS	_	_	O
60	BC	_	_	O
61	)	_	_	O
62	04	_	_	O
63	substudy	_	_	O
64	of	_	_	O
65	the	_	_	O
66	Tamoxifen	_	_	O
67	Exemestane	_	_	O
68	Adjuvant	_	_	O
69	Multinational	_	_	O
70	(	_	_	O
71	TEAM	_	_	O
72	)	_	_	O
73	trial	_	_	O
74	.	_	_	O

75	During	_	_	O
76	the	_	_	O
77	first	_	_	O
78	year	_	_	O
79	of	_	_	O
80	treatment	_	_	O
81	,	_	_	O
82	HRQOL	_	_	O
83	and	_	_	O
84	symptoms	_	_	O
85	of	_	_	O
86	depression	_	_	O
87	were	_	_	O
88	analyzed	_	_	O
89	using	_	_	O
90	the	_	_	O
91	Functional	_	_	O
92	Assessment	_	_	O
93	of	_	_	O
94	Cancer	_	_	O
95	Therapy-Breast	_	_	O
96	(	_	_	O
97	FACT-B	_	_	O
98	)	_	_	O
99	and	_	_	O
100	its	_	_	O
101	Endocrine	_	_	O
102	Symptom	_	_	O
103	Subscale	_	_	O
104	(	_	_	O
105	ES	_	_	O
106	)	_	_	O
107	,	_	_	O
108	and	_	_	O
109	the	_	_	O
110	Center	_	_	O
111	for	_	_	O
112	Epidemiologic	_	_	O
113	Studies	_	_	O
114	Depression	_	_	O
115	Scale	_	_	O
116	(	_	_	O
117	CES-D	_	_	O
118	)	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	In	_	_	O
123	addition	_	_	O
124	,	_	_	O
125	predefined	_	_	O
126	AEs	_	_	O
127	were	_	_	O
128	analyzed	_	_	O
129	.	_	_	O

130	A	_	_	O
131	total	_	_	O
132	of	_	_	O
133	166	_	_	O
134	eligible	_	_	O
135	patients	_	_	O
136	were	_	_	O
137	randomly	_	_	O
138	assigned	_	_	O
139	to	_	_	O
140	receive	_	_	O
141	adjuvant	_	_	O
142	tamoxifen	_	_	O
143	,	_	_	O
144	exemestane	_	_	O
145	,	_	_	O
146	or	_	_	O
147	anastrozole	_	_	O
148	.	_	_	O

149	FACT-B	_	_	B-Premise
150	scores	_	_	I-Premise
151	increased	_	_	I-Premise
152	after	_	_	I-Premise
153	treatment	_	_	I-Premise
154	began	_	_	I-Premise
155	and	_	_	I-Premise
156	remained	_	_	I-Premise
157	significantly	_	_	I-Premise
158	higher	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	tamoxifen	_	_	I-Premise
162	group	_	_	I-Premise
163	than	_	_	I-Premise
164	in	_	_	I-Premise
165	the	_	_	I-Premise
166	exemestane	_	_	I-Premise
167	group	_	_	I-Premise
168	or	_	_	I-Premise
169	anastrozole	_	_	I-Premise
170	group	_	_	I-Premise
171	during	_	_	I-Premise
172	the	_	_	I-Premise
173	first	_	_	I-Premise
174	year	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=	_	_	I-Premise
178	0.045	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	FACT-B	_	_	B-Premise
182	scores	_	_	I-Premise
183	were	_	_	I-Premise
184	similar	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	exemestane	_	_	I-Premise
188	group	_	_	I-Premise
189	and	_	_	I-Premise
190	anastrozole	_	_	I-Premise
191	group	_	_	I-Premise
192	.	_	_	I-Premise

193	ES	_	_	B-Premise
194	scores	_	_	I-Premise
195	and	_	_	I-Premise
196	CES-D	_	_	I-Premise
197	scores	_	_	I-Premise
198	were	_	_	I-Premise
199	similar	_	_	I-Premise
200	in	_	_	I-Premise
201	all	_	_	I-Premise
202	treatment	_	_	I-Premise
203	groups	_	_	I-Premise
204	.	_	_	I-Premise

205	Arthralgia	_	_	B-Premise
206	and	_	_	I-Premise
207	fatigue	_	_	I-Premise
208	were	_	_	I-Premise
209	less	_	_	I-Premise
210	frequent	_	_	I-Premise
211	,	_	_	I-Premise
212	but	_	_	I-Premise
213	vaginal	_	_	I-Premise
214	discharge	_	_	I-Premise
215	was	_	_	I-Premise
216	more	_	_	I-Premise
217	frequent	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	tamoxifen	_	_	I-Premise
221	group	_	_	I-Premise
222	than	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	exemestane	_	_	I-Premise
226	group	_	_	I-Premise
227	or	_	_	I-Premise
228	anastrozole	_	_	I-Premise
229	group	_	_	I-Premise
230	.	_	_	I-Premise

231	HRQOL	_	_	B-Claim
232	was	_	_	I-Claim
233	better	_	_	I-Claim
234	in	_	_	I-Claim
235	Japanese	_	_	I-Claim
236	postmenopausal	_	_	I-Claim
237	women	_	_	I-Claim
238	treated	_	_	I-Claim
239	with	_	_	I-Claim
240	tamoxifen	_	_	I-Claim
241	than	_	_	I-Claim
242	those	_	_	I-Claim
243	treated	_	_	I-Claim
244	with	_	_	I-Claim
245	exemestane	_	_	I-Claim
246	or	_	_	I-Claim
247	anastrozole	_	_	I-Claim
248	.	_	_	I-Claim

249	HRQOL	_	_	B-Claim
250	and	_	_	I-Claim
251	AEs	_	_	I-Claim
252	were	_	_	I-Claim
253	similar	_	_	I-Claim
254	with	_	_	I-Claim
255	exemestane	_	_	I-Claim
256	and	_	_	I-Claim
257	anastrozole	_	_	I-Claim
258	.	_	_	I-Claim

259	Given	_	_	B-Claim
260	the	_	_	I-Claim
261	results	_	_	I-Claim
262	of	_	_	I-Claim
263	the	_	_	I-Claim
264	TEAM	_	_	I-Claim
265	trial	_	_	I-Claim
266	,	_	_	I-Claim
267	upfront	_	_	I-Claim
268	use	_	_	I-Claim
269	of	_	_	I-Claim
270	tamoxifen	_	_	I-Claim
271	followed	_	_	I-Claim
272	by	_	_	I-Claim
273	an	_	_	I-Claim
274	aromatase	_	_	I-Claim
275	inhibitor	_	_	I-Claim
276	(	_	_	I-Claim
277	AI	_	_	I-Claim
278	)	_	_	I-Claim
279	may	_	_	I-Claim
280	be	_	_	I-Claim
281	an	_	_	I-Claim
282	important	_	_	I-Claim
283	option	_	_	I-Claim
284	for	_	_	I-Claim
285	adjuvant	_	_	I-Claim
286	endocrine	_	_	I-Claim
287	therapy	_	_	I-Claim
288	in	_	_	I-Claim
289	Japanese	_	_	I-Claim
290	postmenopausal	_	_	I-Claim
291	women	_	_	I-Claim
292	.	_	_	I-Claim


0	We	_	_	O
1	compared	_	_	O
2	fulvestrant	_	_	O
3	500	_	_	O
4	mg	_	_	O
5	regimen	_	_	O
6	with	_	_	O
7	the	_	_	O
8	approved	_	_	O
9	dose	_	_	O
10	of	_	_	O
11	fulvestrant	_	_	O
12	250	_	_	O
13	mg	_	_	O
14	per	_	_	O
15	month	_	_	O
16	for	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	postmenopausal	_	_	O
20	women	_	_	O
21	with	_	_	O
22	estrogen	_	_	O
23	receptor-positive	_	_	O
24	advanced	_	_	O
25	breast	_	_	O
26	cancer	_	_	O
27	who	_	_	O
28	experienced	_	_	O
29	progression	_	_	O
30	after	_	_	O
31	prior	_	_	O
32	endocrine	_	_	O
33	therapy	_	_	O
34	.	_	_	O

35	Comparison	_	_	O
36	of	_	_	O
37	Faslodex	_	_	O
38	in	_	_	O
39	Recurrent	_	_	O
40	or	_	_	O
41	Metastatic	_	_	O
42	Breast	_	_	O
43	Cancer	_	_	O
44	(	_	_	O
45	CONFIRM	_	_	O
46	)	_	_	O
47	is	_	_	O
48	a	_	_	O
49	double-blind	_	_	O
50	,	_	_	O
51	parallel-group	_	_	O
52	,	_	_	O
53	multicenter	_	_	O
54	,	_	_	O
55	phase	_	_	O
56	III	_	_	O
57	study	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	fulvestrant	_	_	O
65	500	_	_	O
66	mg	_	_	O
67	(	_	_	O
68	500	_	_	O
69	mg	_	_	O
70	intramuscularly	_	_	O
71	[	_	_	O
72	IM	_	_	O
73	]	_	_	O
74	on	_	_	O
75	day	_	_	O
76	0	_	_	O
77	,	_	_	O
78	then	_	_	O
79	500	_	_	O
80	mg	_	_	O
81	IM	_	_	O
82	on	_	_	O
83	days	_	_	O
84	14	_	_	O
85	and	_	_	O
86	28	_	_	O
87	and	_	_	O
88	every	_	_	O
89	28	_	_	O
90	days	_	_	O
91	thereafter	_	_	O
92	)	_	_	O
93	or	_	_	O
94	250	_	_	O
95	mg	_	_	O
96	every	_	_	O
97	28	_	_	O
98	days	_	_	O
99	.	_	_	O

100	Primary	_	_	O
101	end	_	_	O
102	point	_	_	O
103	was	_	_	O
104	progression-free	_	_	O
105	survival	_	_	O
106	(	_	_	O
107	PFS	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	included	_	_	O
114	objective	_	_	O
115	response	_	_	O
116	rate	_	_	O
117	,	_	_	O
118	clinical	_	_	O
119	benefit	_	_	O
120	rate	_	_	O
121	(	_	_	O
122	CBR	_	_	O
123	)	_	_	O
124	,	_	_	O
125	duration	_	_	O
126	of	_	_	O
127	clinical	_	_	O
128	benefit	_	_	O
129	(	_	_	O
130	DoCB	_	_	O
131	)	_	_	O
132	,	_	_	O
133	overall	_	_	O
134	survival	_	_	O
135	(	_	_	O
136	OS	_	_	O
137	)	_	_	O
138	,	_	_	O
139	and	_	_	O
140	quality	_	_	O
141	of	_	_	O
142	life	_	_	O
143	(	_	_	O
144	QOL	_	_	O
145	)	_	_	O
146	.	_	_	O

147	PFS	_	_	B-Premise
148	was	_	_	I-Premise
149	significantly	_	_	I-Premise
150	longer	_	_	I-Premise
151	for	_	_	I-Premise
152	fulvestrant	_	_	I-Premise
153	500	_	_	I-Premise
154	mg	_	_	I-Premise
155	(	_	_	I-Premise
156	n	_	_	I-Premise
157	=	_	_	I-Premise
158	362	_	_	I-Premise
159	)	_	_	I-Premise
160	than	_	_	I-Premise
161	250	_	_	I-Premise
162	mg	_	_	I-Premise
163	(	_	_	I-Premise
164	n	_	_	I-Premise
165	=	_	_	I-Premise
166	374	_	_	I-Premise
167	)	_	_	I-Premise
168	(	_	_	I-Premise
169	hazard	_	_	I-Premise
170	ratio	_	_	I-Premise
171	[	_	_	I-Premise
172	HR	_	_	I-Premise
173	]	_	_	I-Premise
174	=	_	_	I-Premise
175	0.80	_	_	I-Premise
176	;	_	_	I-Premise
177	95	_	_	I-Premise
178	%	_	_	I-Premise
179	CI	_	_	I-Premise
180	,	_	_	I-Premise
181	0.68	_	_	I-Premise
182	to	_	_	I-Premise
183	0.94	_	_	I-Premise
184	;	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.006	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	corresponding	_	_	I-Premise
191	to	_	_	I-Premise
192	a	_	_	I-Premise
193	20	_	_	I-Premise
194	%	_	_	I-Premise
195	reduction	_	_	I-Premise
196	in	_	_	I-Premise
197	risk	_	_	I-Premise
198	of	_	_	I-Premise
199	progression	_	_	I-Premise
200	.	_	_	I-Premise

201	Objective	_	_	B-Premise
202	response	_	_	I-Premise
203	rate	_	_	I-Premise
204	was	_	_	I-Premise
205	similar	_	_	I-Premise
206	for	_	_	I-Premise
207	fulvestrant	_	_	I-Premise
208	500	_	_	I-Premise
209	mg	_	_	I-Premise
210	and	_	_	I-Premise
211	250	_	_	I-Premise
212	mg	_	_	I-Premise
213	(	_	_	I-Premise
214	9.1	_	_	I-Premise
215	%	_	_	I-Premise
216	v	_	_	I-Premise
217	10.2	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	respectively	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	CBR	_	_	B-Premise
224	was	_	_	I-Premise
225	45.6	_	_	I-Premise
226	%	_	_	I-Premise
227	for	_	_	I-Premise
228	fulvestrant	_	_	I-Premise
229	500	_	_	I-Premise
230	mg	_	_	I-Premise
231	and	_	_	I-Premise
232	39.6	_	_	I-Premise
233	%	_	_	I-Premise
234	for	_	_	I-Premise
235	fulvestrant	_	_	I-Premise
236	250	_	_	I-Premise
237	mg.	_	_	I-Premise
238	DoCB	_	_	B-Premise
239	and	_	_	I-Premise
240	OS	_	_	I-Premise
241	were	_	_	I-Premise
242	16.6	_	_	I-Premise
243	and	_	_	I-Premise
244	25.1	_	_	I-Premise
245	months	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	,	_	_	I-Premise
249	for	_	_	I-Premise
250	the	_	_	I-Premise
251	500-mg	_	_	I-Premise
252	group	_	_	I-Premise
253	,	_	_	I-Premise
254	whereas	_	_	I-Premise
255	DoCB	_	_	I-Premise
256	and	_	_	I-Premise
257	OS	_	_	I-Premise
258	were	_	_	I-Premise
259	13.9	_	_	I-Premise
260	and	_	_	I-Premise
261	22.8	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	,	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	250-mg	_	_	I-Premise
269	group	_	_	I-Premise
270	.	_	_	I-Premise

271	Fulvestrant	_	_	B-Claim
272	500	_	_	I-Claim
273	mg	_	_	I-Claim
274	was	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	with	_	_	I-Claim
278	no	_	_	I-Claim
279	dose-dependent	_	_	I-Claim
280	adverse	_	_	I-Claim
281	events	_	_	I-Claim
282	.	_	_	I-Claim

283	QOL	_	_	B-Claim
284	was	_	_	I-Claim
285	similar	_	_	I-Claim
286	for	_	_	I-Claim
287	both	_	_	I-Claim
288	arms	_	_	I-Claim
289	.	_	_	I-Claim

290	Fulvestrant	_	_	B-Claim
291	500	_	_	I-Claim
292	mg	_	_	I-Claim
293	was	_	_	I-Claim
294	associated	_	_	I-Claim
295	with	_	_	I-Claim
296	a	_	_	I-Claim
297	statistically	_	_	I-Claim
298	significant	_	_	I-Claim
299	increase	_	_	I-Claim
300	in	_	_	I-Claim
301	PFS	_	_	I-Claim
302	and	_	_	I-Claim
303	not	_	_	I-Claim
304	associated	_	_	I-Claim
305	with	_	_	I-Claim
306	increased	_	_	I-Claim
307	toxicity	_	_	I-Claim
308	,	_	_	I-Claim
309	corresponding	_	_	O
310	to	_	_	O
311	a	_	_	O
312	clinically	_	_	O
313	meaningful	_	_	O
314	improvement	_	_	O
315	in	_	_	O
316	benefit	_	_	O
317	versus	_	_	O
318	risk	_	_	O
319	compared	_	_	O
320	with	_	_	O
321	fulvestrant	_	_	O
322	250	_	_	O
323	mg	_	_	O
324	.	_	_	O


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	previously	_	_	O
5	conducted	_	_	O
6	in	_	_	O
7	radiation	_	_	O
8	oncology	_	_	O
9	patients	_	_	O
10	demonstrated	_	_	O
11	that	_	_	O
12	nutrition	_	_	O
13	intervention	_	_	O
14	had	_	_	O
15	a	_	_	O
16	beneficial	_	_	O
17	impact	_	_	O
18	on	_	_	O
19	body	_	_	O
20	weight	_	_	O
21	,	_	_	O
22	nutritional	_	_	O
23	status	_	_	O
24	,	_	_	O
25	and	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	standard	_	_	O
32	practice	_	_	O
33	,	_	_	O
34	but	_	_	O
35	it	_	_	O
36	did	_	_	O
37	not	_	_	O
38	report	_	_	O
39	on	_	_	O
40	dietary	_	_	O
41	intake	_	_	O
42	data	_	_	O
43	.	_	_	O

44	To	_	_	O
45	determine	_	_	O
46	the	_	_	O
47	impact	_	_	O
48	of	_	_	O
49	nutrition	_	_	O
50	intervention	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	standard	_	_	O
54	practice	_	_	O
55	on	_	_	O
56	dietary	_	_	O
57	intake	_	_	O
58	in	_	_	O
59	outpatients	_	_	O
60	receiving	_	_	O
61	radiotherapy	_	_	O
62	.	_	_	O

63	Prospective	_	_	O
64	,	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	controlled	_	_	O
68	trial	_	_	O
69	.	_	_	O

70	Sixty	_	_	O
71	consecutive	_	_	O
72	radiation	_	_	O
73	oncology	_	_	O
74	outpatients	_	_	O
75	(	_	_	O
76	51	_	_	O
77	men	_	_	O
78	and	_	_	O
79	nine	_	_	O
80	women	_	_	O
81	;	_	_	O
82	age	_	_	O
83	61.9+/-14	_	_	O
84	years	_	_	O
85	[	_	_	O
86	mean+/-standard	_	_	O
87	deviation	_	_	O
88	]	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Australian	_	_	O
92	private	_	_	O
93	radiotherapy	_	_	O
94	facility	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	nutrition	_	_	O
104	intervention	_	_	O
105	(	_	_	O
106	n=29	_	_	O
107	)	_	_	O
108	(	_	_	O
109	nutrition	_	_	O
110	counseling	_	_	O
111	following	_	_	O
112	the	_	_	O
113	American	_	_	O
114	Dietetic	_	_	O
115	Association	_	_	O
116	[	_	_	O
117	ADA	_	_	O
118	]	_	_	O
119	medical	_	_	O
120	nutrition	_	_	O
121	therapy	_	_	O
122	[	_	_	O
123	MNT	_	_	O
124	]	_	_	O
125	protocol	_	_	O
126	for	_	_	O
127	radiation	_	_	O
128	oncology	_	_	O
129	)	_	_	O
130	or	_	_	O
131	standard	_	_	O
132	practice	_	_	O
133	(	_	_	O
134	n=31	_	_	O
135	)	_	_	O
136	(	_	_	O
137	general	_	_	O
138	nutrition	_	_	O
139	talk	_	_	O
140	and	_	_	O
141	booklet	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Dietary	_	_	O
145	intake	_	_	O
146	(	_	_	O
147	protein	_	_	O
148	,	_	_	O
149	energy	_	_	O
150	,	_	_	O
151	fiber	_	_	O
152	)	_	_	O
153	assessed	_	_	O
154	at	_	_	O
155	baseline	_	_	O
156	and	_	_	O
157	at	_	_	O
158	4	_	_	O
159	,	_	_	O
160	8	_	_	O
161	,	_	_	O
162	and	_	_	O
163	12	_	_	O
164	weeks	_	_	O
165	after	_	_	O
166	starting	_	_	O
167	radiotherapy	_	_	O
168	.	_	_	O

169	Repeated-measures	_	_	O
170	analysis	_	_	O
171	of	_	_	O
172	variance	_	_	O
173	done	_	_	O
174	on	_	_	O
175	an	_	_	O
176	intention	_	_	O
177	to	_	_	O
178	treat	_	_	O
179	basis	_	_	O
180	.	_	_	O

181	The	_	_	B-Premise
182	nutrition	_	_	I-Premise
183	intervention	_	_	I-Premise
184	group	_	_	I-Premise
185	had	_	_	I-Premise
186	a	_	_	I-Premise
187	higher	_	_	I-Premise
188	mean	_	_	I-Premise
189	total	_	_	I-Premise
190	energy	_	_	I-Premise
191	(	_	_	I-Premise
192	P=0.029	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	protein	_	_	I-Premise
196	intake	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	<	_	_	I-Premise
200	0.001	_	_	I-Premise
201	)	_	_	I-Premise
202	compared	_	_	I-Premise
203	with	_	_	I-Premise
204	the	_	_	I-Premise
205	standard	_	_	I-Premise
206	practice	_	_	I-Premise
207	group	_	_	I-Premise
208	.	_	_	I-Premise

209	Mean	_	_	B-Premise
210	intake	_	_	I-Premise
211	per	_	_	I-Premise
212	kilogram	_	_	I-Premise
213	of	_	_	I-Premise
214	body	_	_	I-Premise
215	weight	_	_	I-Premise
216	for	_	_	I-Premise
217	the	_	_	I-Premise
218	nutrition	_	_	I-Premise
219	intervention	_	_	I-Premise
220	group	_	_	I-Premise
221	ranged	_	_	I-Premise
222	from	_	_	I-Premise
223	28	_	_	I-Premise
224	to	_	_	I-Premise
225	31	_	_	I-Premise
226	kcal/kg/day	_	_	I-Premise
227	compared	_	_	I-Premise
228	with	_	_	I-Premise
229	25	_	_	I-Premise
230	to	_	_	I-Premise
231	29	_	_	I-Premise
232	kcal/kg/day	_	_	I-Premise
233	for	_	_	I-Premise
234	the	_	_	I-Premise
235	standard	_	_	I-Premise
236	practice	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	P=0.022	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	nutrition	_	_	I-Premise
244	intervention	_	_	I-Premise
245	group	_	_	I-Premise
246	had	_	_	I-Premise
247	a	_	_	I-Premise
248	higher	_	_	I-Premise
249	mean	_	_	I-Premise
250	protein	_	_	I-Premise
251	intake	_	_	I-Premise
252	(	_	_	I-Premise
253	1.1	_	_	I-Premise
254	to	_	_	I-Premise
255	1.3	_	_	I-Premise
256	g/kg/day	_	_	I-Premise
257	)	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	the	_	_	I-Premise
261	standard	_	_	I-Premise
262	practice	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	1.0	_	_	I-Premise
266	to	_	_	I-Premise
267	1.1	_	_	I-Premise
268	g/kg/day	_	_	I-Premise
269	)	_	_	I-Premise
270	(	_	_	I-Premise
271	P=0.001	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Although	_	_	B-Premise
275	the	_	_	I-Premise
276	change	_	_	I-Premise
277	in	_	_	I-Premise
278	fiber	_	_	I-Premise
279	intake	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	groups	_	_	I-Premise
283	was	_	_	I-Premise
284	not	_	_	I-Premise
285	significant	_	_	I-Premise
286	,	_	_	I-Premise
287	there	_	_	B-Premise
288	was	_	_	I-Premise
289	a	_	_	I-Premise
290	trend	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	anticipated	_	_	I-Premise
294	direction	_	_	I-Premise
295	(	_	_	I-Premise
296	P=0.083	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Intensive	_	_	B-Claim
300	nutrition	_	_	I-Claim
301	intervention	_	_	I-Claim
302	following	_	_	I-Claim
303	the	_	_	I-Claim
304	ADA	_	_	I-Claim
305	MNT	_	_	I-Claim
306	protocol	_	_	I-Claim
307	results	_	_	I-Claim
308	in	_	_	I-Claim
309	improved	_	_	I-Claim
310	dietary	_	_	I-Claim
311	intake	_	_	I-Claim
312	compared	_	_	I-Claim
313	with	_	_	I-Claim
314	standard	_	_	I-Claim
315	practice	_	_	I-Claim
316	and	_	_	I-Claim
317	seems	_	_	I-Claim
318	to	_	_	I-Claim
319	beneficially	_	_	I-Claim
320	impact	_	_	I-Claim
321	nutrition-related	_	_	I-Claim
322	outcomes	_	_	I-Claim
323	previously	_	_	I-Claim
324	observed	_	_	I-Claim
325	in	_	_	I-Claim
326	oncology	_	_	I-Claim
327	outpatients	_	_	I-Claim
328	receiving	_	_	I-Claim
329	radiotherapy	_	_	I-Claim
330	.	_	_	I-Claim

331	The	_	_	B-Claim
332	ADA	_	_	I-Claim
333	MNT	_	_	I-Claim
334	protocol	_	_	I-Claim
335	for	_	_	I-Claim
336	radiation	_	_	I-Claim
337	oncology	_	_	I-Claim
338	is	_	_	I-Claim
339	a	_	_	I-Claim
340	useful	_	_	I-Claim
341	guide	_	_	I-Claim
342	to	_	_	I-Claim
343	the	_	_	I-Claim
344	level	_	_	I-Claim
345	of	_	_	I-Claim
346	nutrition	_	_	I-Claim
347	support	_	_	I-Claim
348	required	_	_	I-Claim
349	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	if	_	_	O
3	the	_	_	O
4	type	_	_	O
5	of	_	_	O
6	embolic	_	_	O
7	material	_	_	O
8	used	_	_	O
9	for	_	_	O
10	uterine	_	_	O
11	artery	_	_	O
12	embolization	_	_	O
13	(	_	_	O
14	UAE	_	_	O
15	)	_	_	O
16	for	_	_	O
17	leiomyomas	_	_	O
18	has	_	_	O
19	an	_	_	O
20	impact	_	_	O
21	on	_	_	O
22	short-term	_	_	O
23	recovery	_	_	O
24	or	_	_	O
25	the	_	_	O
26	effectiveness	_	_	O
27	of	_	_	O
28	embolization	_	_	O
29	.	_	_	O

30	One	_	_	O
31	hundred	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	undergo	_	_	O
38	UAE	_	_	O
39	with	_	_	O
40	polyvinyl	_	_	O
41	alcohol	_	_	O
42	(	_	_	O
43	PVA	_	_	O
44	)	_	_	O
45	particles	_	_	O
46	or	_	_	O
47	tris-acryl	_	_	O
48	gelatin	_	_	O
49	microspheres	_	_	O
50	.	_	_	O

51	Short-term	_	_	O
52	,	_	_	O
53	in-hospital	_	_	O
54	medication	_	_	O
55	use	_	_	O
56	and	_	_	O
57	pain	_	_	O
58	levels	_	_	O
59	were	_	_	O
60	recorded	_	_	O
61	.	_	_	O

62	After	_	_	O
63	discharge	_	_	O
64	,	_	_	O
65	symptom	_	_	O
66	severity	_	_	O
67	,	_	_	O
68	temperature	_	_	O
69	,	_	_	O
70	and	_	_	O
71	medications	_	_	O
72	used	_	_	O
73	were	_	_	O
74	recorded	_	_	O
75	daily	_	_	O
76	for	_	_	O
77	1	_	_	O
78	week	_	_	O
79	and	_	_	O
80	symptom	_	_	O
81	levels	_	_	O
82	were	_	_	O
83	measured	_	_	O
84	for	_	_	O
85	weeks	_	_	O
86	2-4	_	_	O
87	.	_	_	O

88	Three	_	_	O
89	months	_	_	O
90	after	_	_	O
91	embolization	_	_	O
92	,	_	_	O
93	contrast	_	_	O
94	material-enhanced	_	_	O
95	magnetic	_	_	O
96	resonance	_	_	O
97	imaging	_	_	O
98	examinations	_	_	O
99	were	_	_	O
100	evaluated	_	_	O
101	blindly	_	_	O
102	to	_	_	O
103	determine	_	_	O
104	the	_	_	O
105	extent	_	_	O
106	of	_	_	O
107	leiomyoma	_	_	O
108	infarction	_	_	O
109	.	_	_	O

110	Symptom	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	(	_	_	O
116	QOL	_	_	O
117	)	_	_	O
118	status	_	_	O
119	was	_	_	O
120	determined	_	_	O
121	with	_	_	O
122	use	_	_	O
123	of	_	_	O
124	questionnaires	_	_	O
125	.	_	_	O

126	Analysis	_	_	O
127	was	_	_	O
128	completed	_	_	O
129	with	_	_	O
130	use	_	_	O
131	of	_	_	O
132	chi	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	analysis	_	_	O
137	,	_	_	O
138	Fisher	_	_	O
139	exact	_	_	O
140	tests	_	_	O
141	,	_	_	O
142	Student	_	_	O
143	t	_	_	O
144	tests	_	_	O
145	,	_	_	O
146	and	_	_	O
147	analysis	_	_	O
148	of	_	_	O
149	variance	_	_	O
150	as	_	_	O
151	appropriate	_	_	O
152	.	_	_	O

153	Regression	_	_	O
154	analysis	_	_	O
155	was	_	_	O
156	used	_	_	O
157	to	_	_	O
158	analyze	_	_	O
159	the	_	_	O
160	impact	_	_	O
161	on	_	_	O
162	outcome	_	_	O
163	of	_	_	O
164	baseline	_	_	O
165	factors	_	_	O
166	(	_	_	O
167	other	_	_	O
168	than	_	_	O
169	type	_	_	O
170	of	_	_	O
171	embolic	_	_	O
172	agent	_	_	O
173	)	_	_	O
174	.	_	_	O

175	No	_	_	O
176	significant	_	_	O
177	differences	_	_	O
178	were	_	_	O
179	noted	_	_	O
180	at	_	_	O
181	baseline	_	_	O
182	between	_	_	O
183	the	_	_	O
184	two	_	_	O
185	treatment	_	_	O
186	groups	_	_	O
187	.	_	_	O

188	On	_	_	B-Premise
189	average	_	_	I-Premise
190	,	_	_	I-Premise
191	there	_	_	I-Premise
192	were	_	_	I-Premise
193	significantly	_	_	I-Premise
194	higher	_	_	I-Premise
195	volumes	_	_	I-Premise
196	of	_	_	I-Premise
197	tris-acryl	_	_	I-Premise
198	microspheres	_	_	I-Premise
199	used	_	_	I-Premise
200	(	_	_	I-Premise
201	9.0	_	_	I-Premise
202	mL	_	_	I-Premise
203	vs	_	_	I-Premise
204	3.0	_	_	I-Premise
205	mL	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	whereas	_	_	O
212	microcatheter	_	_	B-Premise
213	occlusion	_	_	I-Premise
214	was	_	_	I-Premise
215	more	_	_	I-Premise
216	common	_	_	I-Premise
217	with	_	_	I-Premise
218	PVA	_	_	I-Premise
219	(	_	_	I-Premise
220	28	_	_	I-Premise
221	%	_	_	I-Premise
222	vs	_	_	I-Premise
223	4	_	_	I-Premise
224	%	_	_	I-Premise
225	,	_	_	I-Premise
226	P	_	_	I-Premise
227	=.001	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	There	_	_	B-Premise
231	were	_	_	I-Premise
232	no	_	_	I-Premise
233	differences	_	_	I-Premise
234	in	_	_	I-Premise
235	pain	_	_	I-Premise
236	severity	_	_	I-Premise
237	,	_	_	I-Premise
238	other	_	_	I-Premise
239	postprocedural	_	_	I-Premise
240	symptoms	_	_	I-Premise
241	,	_	_	I-Premise
242	or	_	_	I-Premise
243	medication	_	_	I-Premise
244	use	_	_	I-Premise
245	between	_	_	I-Premise
246	the	_	_	I-Premise
247	two	_	_	I-Premise
248	treatment	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	There	_	_	B-Premise
252	were	_	_	I-Premise
253	also	_	_	I-Premise
254	no	_	_	I-Premise
255	differences	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	frequency	_	_	I-Premise
259	of	_	_	I-Premise
260	incompletely	_	_	I-Premise
261	infarcted	_	_	I-Premise
262	leiomyomas	_	_	I-Premise
263	,	_	_	I-Premise
264	degree	_	_	I-Premise
265	of	_	_	I-Premise
266	improvement	_	_	I-Premise
267	in	_	_	I-Premise
268	symptom	_	_	I-Premise
269	score	_	_	I-Premise
270	,	_	_	I-Premise
271	patient	_	_	I-Premise
272	satisfaction	_	_	I-Premise
273	,	_	_	I-Premise
274	or	_	_	I-Premise
275	QOL	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Claim
278	substantive	_	_	I-Claim
279	differences	_	_	I-Claim
280	were	_	_	I-Claim
281	detected	_	_	I-Claim
282	between	_	_	I-Claim
283	outcomes	_	_	I-Claim
284	of	_	_	I-Claim
285	embolization	_	_	I-Claim
286	with	_	_	I-Claim
287	PVA	_	_	I-Claim
288	particles	_	_	I-Claim
289	or	_	_	I-Claim
290	tris-acryl	_	_	I-Claim
291	gelatin	_	_	I-Claim
292	microspheres	_	_	I-Claim
293	.	_	_	I-Claim


0	Previous	_	_	B-Claim
1	trials	_	_	I-Claim
2	have	_	_	I-Claim
3	suggested	_	_	I-Claim
4	a	_	_	I-Claim
5	quality-of-life	_	_	I-Claim
6	(	_	_	I-Claim
7	QOL	_	_	I-Claim
8	)	_	_	I-Claim
9	improvement	_	_	I-Claim
10	for	_	_	I-Claim
11	anemic	_	_	I-Claim
12	cancer	_	_	I-Claim
13	patients	_	_	I-Claim
14	treated	_	_	I-Claim
15	with	_	_	I-Claim
16	erythropoietin	_	_	I-Claim
17	,	_	_	I-Claim
18	but	_	_	I-Claim
19	few	_	_	I-Claim
20	used	_	_	I-Claim
21	QOL	_	_	I-Claim
22	as	_	_	I-Claim
23	the	_	_	I-Claim
24	primary	_	_	I-Claim
25	outcome	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	designed	_	_	O
29	a	_	_	O
30	trial	_	_	O
31	to	_	_	O
32	investigate	_	_	O
33	the	_	_	O
34	effects	_	_	O
35	of	_	_	O
36	epoetin	_	_	O
37	alfa	_	_	O
38	therapy	_	_	O
39	on	_	_	O
40	the	_	_	O
41	QOL	_	_	O
42	of	_	_	O
43	anemic	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	advanced	_	_	O
47	non-small-cell	_	_	O
48	carcinoma	_	_	O
49	of	_	_	O
50	the	_	_	O
51	lung	_	_	O
52	(	_	_	O
53	NSCLC	_	_	O
54	)	_	_	O
55	.	_	_	O

56	A	_	_	O
57	multicenter	_	_	O
58	,	_	_	O
59	randomized	_	_	O
60	,	_	_	O
61	double-blind	_	_	O
62	,	_	_	O
63	placebo-controlled	_	_	O
64	trial	_	_	O
65	was	_	_	O
66	conducted	_	_	O
67	.	_	_	O

68	The	_	_	O
69	proposed	_	_	O
70	sample	_	_	O
71	size	_	_	O
72	was	_	_	O
73	300	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	Eligible	_	_	O
77	patients	_	_	O
78	were	_	_	O
79	required	_	_	O
80	to	_	_	O
81	have	_	_	O
82	NSCLC	_	_	O
83	unsuitable	_	_	O
84	for	_	_	O
85	curative	_	_	O
86	therapy	_	_	O
87	and	_	_	O
88	baseline	_	_	O
89	hemoglobin	_	_	O
90	(	_	_	O
91	Hgb	_	_	O
92	)	_	_	O
93	levels	_	_	O
94	less	_	_	O
95	than	_	_	O
96	121	_	_	O
97	g/L	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	assigned	_	_	O
102	to	_	_	O
103	12	_	_	O
104	weekly	_	_	O
105	injections	_	_	O
106	of	_	_	O
107	subcutaneous	_	_	O
108	epoetin	_	_	O
109	alpha	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	,	_	_	O
113	targeting	_	_	O
114	Hgb	_	_	O
115	levels	_	_	O
116	between	_	_	O
117	120	_	_	O
118	and	_	_	O
119	140	_	_	O
120	g/L	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	outcome	_	_	O
125	was	_	_	O
126	the	_	_	O
127	difference	_	_	O
128	in	_	_	O
129	the	_	_	O
130	change	_	_	O
131	in	_	_	O
132	Functional	_	_	O
133	Assessment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Therapy-Anemia	_	_	O
137	scores	_	_	O
138	between	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	12	_	_	O
142	weeks	_	_	O
143	.	_	_	O

144	Reports	_	_	O
145	of	_	_	O
146	thrombotic	_	_	O
147	events	_	_	O
148	in	_	_	O
149	other	_	_	O
150	epoetin	_	_	O
151	trials	_	_	O
152	prompted	_	_	O
153	an	_	_	O
154	unplanned	_	_	O
155	safety	_	_	O
156	analysis	_	_	O
157	after	_	_	O
158	70	_	_	O
159	patients	_	_	O
160	had	_	_	O
161	been	_	_	O
162	randomly	_	_	O
163	assigned	_	_	O
164	(	_	_	O
165	33	_	_	O
166	to	_	_	O
167	the	_	_	O
168	active	_	_	O
169	arm	_	_	O
170	and	_	_	O
171	37	_	_	O
172	to	_	_	O
173	the	_	_	O
174	placebo	_	_	O
175	arm	_	_	O
176	)	_	_	O
177	.	_	_	O

178	This	_	_	B-Premise
179	revealed	_	_	I-Premise
180	a	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	median	_	_	I-Premise
186	survival	_	_	I-Premise
187	in	_	_	I-Premise
188	favor	_	_	I-Premise
189	of	_	_	I-Premise
190	the	_	_	I-Premise
191	patients	_	_	I-Premise
192	on	_	_	I-Premise
193	the	_	_	I-Premise
194	placebo	_	_	I-Premise
195	arm	_	_	I-Premise
196	of	_	_	I-Premise
197	the	_	_	I-Premise
198	trial	_	_	I-Premise
199	(	_	_	I-Premise
200	63	_	_	I-Premise
201	v	_	_	I-Premise
202	129	_	_	I-Premise
203	days	_	_	I-Premise
204	;	_	_	I-Premise
205	hazard	_	_	I-Premise
206	ratio	_	_	I-Premise
207	,	_	_	I-Premise
208	1.84	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.04	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	O
216	Steering	_	_	O
217	Committee	_	_	O
218	closed	_	_	O
219	the	_	_	O
220	trial	_	_	O
221	.	_	_	O

222	Patient	_	_	B-Premise
223	numbers	_	_	I-Premise
224	compromised	_	_	I-Premise
225	the	_	_	I-Premise
226	interpretation	_	_	I-Premise
227	of	_	_	I-Premise
228	the	_	_	I-Premise
229	QOL	_	_	I-Premise
230	analysis	_	_	I-Premise
231	,	_	_	I-Premise
232	but	_	_	O
233	a	_	_	B-Premise
234	positive	_	_	I-Premise
235	Hgb	_	_	I-Premise
236	response	_	_	I-Premise
237	was	_	_	I-Premise
238	noted	_	_	I-Premise
239	with	_	_	I-Premise
240	epoetin	_	_	I-Premise
241	alfa	_	_	I-Premise
242	treatment	_	_	I-Premise
243	.	_	_	I-Premise

244	An	_	_	B-Claim
245	unplanned	_	_	I-Claim
246	safety	_	_	I-Claim
247	analysis	_	_	I-Claim
248	suggested	_	_	I-Claim
249	decreased	_	_	I-Claim
250	overall	_	_	I-Claim
251	survival	_	_	I-Claim
252	in	_	_	I-Claim
253	patients	_	_	I-Claim
254	with	_	_	I-Claim
255	advanced	_	_	I-Claim
256	NSCLC	_	_	I-Claim
257	treated	_	_	I-Claim
258	with	_	_	I-Claim
259	epoetin	_	_	I-Claim
260	alfa	_	_	I-Claim
261	.	_	_	I-Claim

262	Although	_	_	O
263	infrequent	_	_	O
264	,	_	_	O
265	other	_	_	O
266	similar	_	_	O
267	reports	_	_	O
268	highlight	_	_	O
269	the	_	_	O
270	need	_	_	O
271	for	_	_	O
272	ongoing	_	_	O
273	trials	_	_	O
274	evaluating	_	_	O
275	erythropoietin	_	_	O
276	receptor	_	_	O
277	agonists	_	_	O
278	to	_	_	O
279	ensure	_	_	O
280	that	_	_	O
281	overall	_	_	O
282	survival	_	_	O
283	is	_	_	O
284	monitored	_	_	O
285	closely	_	_	O
286	.	_	_	O


0	We	_	_	O
1	report	_	_	O
2	results	_	_	O
3	of	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	prospective	_	_	O
7	study	_	_	O
8	that	_	_	O
9	compared	_	_	O
10	single	_	_	O
11	agents	_	_	O
12	of	_	_	O
13	low	_	_	O
14	toxicity	_	_	O
15	given	_	_	O
16	both	_	_	O
17	as	_	_	O
18	the	_	_	O
19	first-line	_	_	O
20	and	_	_	O
21	second-line	_	_	O
22	chemotherapy	_	_	O
23	with	_	_	O
24	combination	_	_	O
25	chemotherapy	_	_	O
26	in	_	_	O
27	advanced	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	with	_	_	O
31	distant	_	_	O
32	metastases	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	in	_	_	O
36	the	_	_	O
37	single-agent	_	_	O
38	arm	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	153	_	_	O
43	)	_	_	O
44	received	_	_	O
45	weekly	_	_	O
46	epirubicin	_	_	O
47	(	_	_	O
48	E	_	_	O
49	)	_	_	O
50	20	_	_	O
51	mg/m2	_	_	O
52	until	_	_	O
53	progression	_	_	O
54	or	_	_	O
55	until	_	_	O
56	the	_	_	O
57	cumulative	_	_	O
58	dose	_	_	O
59	of	_	_	O
60	1,000	_	_	O
61	mg/m2	_	_	O
62	,	_	_	O
63	followed	_	_	O
64	by	_	_	O
65	mitomycin	_	_	O
66	(	_	_	O
67	M	_	_	O
68	)	_	_	O
69	8	_	_	O
70	mg/m2	_	_	O
71	every	_	_	O
72	4	_	_	O
73	weeks	_	_	O
74	,	_	_	O
75	and	_	_	O
76	those	_	_	O
77	in	_	_	O
78	the	_	_	O
79	combination	_	_	O
80	chemotherapy	_	_	O
81	arm	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	150	_	_	O
86	)	_	_	O
87	were	_	_	O
88	first	_	_	O
89	given	_	_	O
90	cyclophosphamide	_	_	O
91	500	_	_	O
92	mg/m2	_	_	O
93	,	_	_	O
94	E	_	_	O
95	60	_	_	O
96	mg/m2	_	_	O
97	,	_	_	O
98	and	_	_	O
99	fluorouracil	_	_	O
100	500	_	_	O
101	mg/m2	_	_	O
102	three	_	_	O
103	times	_	_	O
104	per	_	_	O
105	week	_	_	O
106	(	_	_	O
107	CEF	_	_	O
108	)	_	_	O
109	followed	_	_	O
110	by	_	_	O
111	M	_	_	O
112	8	_	_	O
113	mg/m2	_	_	O
114	plus	_	_	O
115	vinblastine	_	_	O
116	(	_	_	O
117	V	_	_	O
118	)	_	_	O
119	6	_	_	O
120	mg/m2	_	_	O
121	every	_	_	O
122	4	_	_	O
123	weeks	_	_	O
124	.	_	_	O

125	Exclusion	_	_	O
126	criteria	_	_	O
127	included	_	_	O
128	age	_	_	O
129	greater	_	_	O
130	than	_	_	O
131	70	_	_	O
132	years	_	_	O
133	,	_	_	O
134	World	_	_	O
135	Health	_	_	O
136	Organization	_	_	O
137	(	_	_	O
138	WHO	_	_	O
139	)	_	_	O
140	performance	_	_	O
141	status	_	_	O
142	greater	_	_	O
143	than	_	_	O
144	2	_	_	O
145	,	_	_	O
146	prior	_	_	O
147	chemotherapy	_	_	O
148	for	_	_	O
149	metastatic	_	_	O
150	disease	_	_	O
151	,	_	_	O
152	and	_	_	O
153	presence	_	_	O
154	of	_	_	O
155	liver	_	_	O
156	metastases	_	_	O
157	in	_	_	O
158	patients	_	_	O
159	younger	_	_	O
160	than	_	_	O
161	50	_	_	O
162	.	_	_	O

163	An	_	_	B-Premise
164	objective	_	_	I-Premise
165	response	_	_	I-Premise
166	(	_	_	I-Premise
167	complete	_	_	I-Premise
168	[	_	_	I-Premise
169	CR	_	_	I-Premise
170	]	_	_	I-Premise
171	or	_	_	I-Premise
172	partial	_	_	I-Premise
173	[	_	_	I-Premise
174	PR	_	_	I-Premise
175	]	_	_	I-Premise
176	)	_	_	I-Premise
177	was	_	_	I-Premise
178	obtained	_	_	I-Premise
179	in	_	_	I-Premise
180	55	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	48	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	16	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	7	_	_	I-Premise
191	%	_	_	I-Premise
192	of	_	_	I-Premise
193	patients	_	_	I-Premise
194	treated	_	_	I-Premise
195	with	_	_	I-Premise
196	CEF	_	_	I-Premise
197	,	_	_	I-Premise
198	E	_	_	I-Premise
199	,	_	_	I-Premise
200	M	_	_	I-Premise
201	,	_	_	I-Premise
202	and	_	_	I-Premise
203	MV	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	A	_	_	B-Premise
208	response	_	_	I-Premise
209	to	_	_	I-Premise
210	CEF	_	_	I-Premise
211	tended	_	_	I-Premise
212	to	_	_	I-Premise
213	last	_	_	I-Premise
214	longer	_	_	I-Premise
215	than	_	_	I-Premise
216	a	_	_	I-Premise
217	response	_	_	I-Premise
218	to	_	_	I-Premise
219	E	_	_	I-Premise
220	(	_	_	I-Premise
221	median	_	_	I-Premise
222	,	_	_	I-Premise
223	12	_	_	I-Premise
224	v	_	_	I-Premise
225	10.5	_	_	I-Premise
226	months	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.07	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Treatment-related	_	_	B-Premise
234	toxicity	_	_	I-Premise
235	was	_	_	I-Premise
236	less	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	single-agent	_	_	I-Premise
240	arm	_	_	I-Premise
241	and	_	_	I-Premise
242	quality-of-life	_	_	I-Premise
243	(	_	_	I-Premise
244	QOL	_	_	I-Premise
245	)	_	_	I-Premise
246	analysis	_	_	I-Premise
247	favored	_	_	I-Premise
248	the	_	_	I-Premise
249	single-agent	_	_	I-Premise
250	arm	_	_	I-Premise
251	.	_	_	I-Premise

252	No	_	_	B-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	time	_	_	I-Premise
257	to	_	_	I-Premise
258	progression	_	_	I-Premise
259	or	_	_	I-Premise
260	survival	_	_	I-Premise
261	was	_	_	I-Premise
262	found	_	_	I-Premise
263	between	_	_	I-Premise
264	the	_	_	I-Premise
265	two	_	_	I-Premise
266	arms	_	_	I-Premise
267	.	_	_	I-Premise

268	Similarly	_	_	B-Premise
269	,	_	_	I-Premise
270	no	_	_	I-Premise
271	difference	_	_	I-Premise
272	in	_	_	I-Premise
273	survival	_	_	I-Premise
274	was	_	_	I-Premise
275	found	_	_	I-Premise
276	when	_	_	I-Premise
277	the	_	_	I-Premise
278	patients	_	_	I-Premise
279	who	_	_	I-Premise
280	received	_	_	I-Premise
281	both	_	_	I-Premise
282	the	_	_	I-Premise
283	planned	_	_	I-Premise
284	first-and	_	_	I-Premise
285	second-line	_	_	I-Premise
286	treatments	_	_	I-Premise
287	were	_	_	I-Premise
288	compared	_	_	I-Premise
289	or	_	_	I-Premise
290	when	_	_	I-Premise
291	survival	_	_	I-Premise
292	was	_	_	I-Premise
293	calculated	_	_	I-Premise
294	from	_	_	I-Premise
295	the	_	_	I-Premise
296	beginning	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	second-line	_	_	I-Premise
300	therapy	_	_	I-Premise
301	.	_	_	I-Premise

302	Patients	_	_	B-Claim
303	treated	_	_	I-Claim
304	with	_	_	I-Claim
305	single-agent	_	_	I-Claim
306	E	_	_	I-Claim
307	followed	_	_	I-Claim
308	by	_	_	I-Claim
309	single-agent	_	_	I-Claim
310	M	_	_	I-Claim
311	had	_	_	I-Claim
312	similar	_	_	I-Claim
313	survival	_	_	I-Claim
314	,	_	_	I-Claim
315	but	_	_	I-Claim
316	less	_	_	I-Claim
317	treatment-related	_	_	I-Claim
318	toxicity	_	_	I-Claim
319	and	_	_	I-Claim
320	better	_	_	I-Claim
321	QOL	_	_	I-Claim
322	as	_	_	I-Claim
323	compared	_	_	I-Claim
324	with	_	_	I-Claim
325	those	_	_	I-Claim
326	treated	_	_	I-Claim
327	with	_	_	I-Claim
328	CEF	_	_	I-Claim
329	followed	_	_	I-Claim
330	by	_	_	I-Claim
331	MV	_	_	I-Claim
332	.	_	_	I-Claim


0	Premenopausal	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	receiving	_	_	O
6	adjuvant	_	_	O
7	chemotherapy	_	_	O
8	are	_	_	O
9	at	_	_	O
10	risk	_	_	O
11	for	_	_	O
12	amenorrhea	_	_	O
13	.	_	_	O

14	The	_	_	O
15	National	_	_	O
16	Surgical	_	_	O
17	Adjuvant	_	_	O
18	Breast	_	_	O
19	and	_	_	O
20	Bowel	_	_	O
21	Project	_	_	O
22	B-30	_	_	O
23	trial	_	_	O
24	included	_	_	O
25	menstrual	_	_	O
26	history	_	_	O
27	(	_	_	O
28	MH	_	_	O
29	)	_	_	O
30	and	_	_	O
31	quality-of-life	_	_	O
32	(	_	_	O
33	QOL	_	_	O
34	)	_	_	O
35	studies	_	_	O
36	to	_	_	O
37	compare	_	_	O
38	treatments	_	_	O
39	on	_	_	O
40	these	_	_	O
41	outcomes	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	sequential	_	_	O
49	doxorubicin	_	_	O
50	(	_	_	O
51	A	_	_	O
52	)	_	_	O
53	and	_	_	O
54	cyclophosphamide	_	_	O
55	(	_	_	O
56	C	_	_	O
57	)	_	_	O
58	followed	_	_	O
59	by	_	_	O
60	docetaxel	_	_	O
61	(	_	_	O
62	T	_	_	O
63	;	_	_	O
64	ACâ†’T	_	_	O
65	)	_	_	O
66	,	_	_	O
67	concurrent	_	_	O
68	TAC	_	_	O
69	,	_	_	O
70	or	_	_	O
71	AT	_	_	O
72	,	_	_	O
73	which	_	_	O
74	varied	_	_	O
75	in	_	_	O
76	duration	_	_	O
77	(	_	_	O
78	24	_	_	O
79	,	_	_	O
80	12	_	_	O
81	,	_	_	O
82	12	_	_	O
83	weeks	_	_	O
84	,	_	_	O
85	respectively	_	_	O
86	)	_	_	O
87	,	_	_	O
88	and	_	_	O
89	use	_	_	O
90	of	_	_	O
91	C.	_	_	O
92	Endocrine	_	_	O
93	therapy	_	_	O
94	was	_	_	O
95	prescribed	_	_	O
96	for	_	_	O
97	women	_	_	O
98	with	_	_	O
99	hormone	_	_	O
100	receptor-positive	_	_	O
101	tumors	_	_	O
102	.	_	_	O

103	MH	_	_	O
104	and	_	_	O
105	QOL	_	_	O
106	were	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	standardized	_	_	O
110	questionnaires	_	_	O
111	at	_	_	O
112	baseline	_	_	O
113	;	_	_	O
114	cycle	_	_	O
115	4	_	_	O
116	,	_	_	O
117	day	_	_	O
118	1	_	_	O
119	;	_	_	O
120	and	_	_	O
121	every	_	_	O
122	6	_	_	O
123	months	_	_	O
124	through	_	_	O
125	24	_	_	O
126	months	_	_	O
127	.	_	_	O

128	Prespecified	_	_	O
129	analyses	_	_	O
130	examined	_	_	O
131	rates	_	_	O
132	of	_	_	O
133	amenorrhea	_	_	O
134	by	_	_	O
135	treatment	_	_	O
136	arm	_	_	O
137	,	_	_	O
138	the	_	_	O
139	relationship	_	_	O
140	between	_	_	O
141	amenorrhea	_	_	O
142	and	_	_	O
143	QOL	_	_	O
144	,	_	_	O
145	and	_	_	O
146	QOL	_	_	O
147	by	_	_	O
148	treatment	_	_	O
149	arm	_	_	O
150	.	_	_	O

151	Amenorrhea	_	_	B-Premise
152	12	_	_	I-Premise
153	months	_	_	I-Premise
154	after	_	_	I-Premise
155	random	_	_	I-Premise
156	assignment	_	_	I-Premise
157	was	_	_	I-Premise
158	significantly	_	_	I-Premise
159	different	_	_	I-Premise
160	between	_	_	I-Premise
161	treatment	_	_	I-Premise
162	groups	_	_	I-Premise
163	:	_	_	I-Premise
164	69.8	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	ACâ†’T	_	_	I-Premise
168	,	_	_	I-Premise
169	57.7	_	_	I-Premise
170	%	_	_	I-Premise
171	for	_	_	I-Premise
172	TAC	_	_	I-Premise
173	,	_	_	I-Premise
174	and	_	_	I-Premise
175	37.9	_	_	I-Premise
176	%	_	_	I-Premise
177	for	_	_	I-Premise
178	AT	_	_	I-Premise
179	(	_	_	I-Premise
180	P	_	_	I-Premise
181	<	_	_	I-Premise
182	.001	_	_	I-Premise
183	)	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	AT	_	_	I-Premise
187	group	_	_	I-Premise
188	without	_	_	I-Premise
189	tamoxifen	_	_	I-Premise
190	had	_	_	I-Premise
191	the	_	_	I-Premise
192	lowest	_	_	I-Premise
193	rate	_	_	I-Premise
194	of	_	_	I-Premise
195	amenorrhea	_	_	I-Premise
196	.	_	_	I-Premise

197	QOL	_	_	B-Premise
198	was	_	_	I-Premise
199	poorer	_	_	I-Premise
200	for	_	_	I-Premise
201	patients	_	_	I-Premise
202	receiving	_	_	I-Premise
203	ACâ†’T	_	_	I-Premise
204	at	_	_	I-Premise
205	6	_	_	I-Premise
206	months	_	_	I-Premise
207	but	_	_	I-Premise
208	similar	_	_	I-Premise
209	to	_	_	I-Premise
210	others	_	_	I-Premise
211	by	_	_	I-Premise
212	12	_	_	I-Premise
213	months	_	_	I-Premise
214	.	_	_	I-Premise

215	Post-treatment	_	_	B-Premise
216	symptoms	_	_	I-Premise
217	were	_	_	I-Premise
218	increased	_	_	I-Premise
219	above	_	_	I-Premise
220	baseline	_	_	I-Premise
221	for	_	_	I-Premise
222	all	_	_	I-Premise
223	treatments	_	_	I-Premise
224	.	_	_	I-Premise

225	Multivariable	_	_	B-Premise
226	repeated	_	_	I-Premise
227	measures	_	_	I-Premise
228	modeling	_	_	I-Premise
229	demonstrated	_	_	I-Premise
230	that	_	_	I-Premise
231	treatment	_	_	I-Premise
232	arm	_	_	I-Premise
233	,	_	_	I-Premise
234	time	_	_	I-Premise
235	point	_	_	I-Premise
236	,	_	_	I-Premise
237	age	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	tamoxifen	_	_	I-Premise
241	use	_	_	I-Premise
242	were	_	_	I-Premise
243	significantly	_	_	I-Premise
244	associated	_	_	I-Premise
245	with	_	_	I-Premise
246	symptom	_	_	I-Premise
247	severity	_	_	I-Premise
248	(	_	_	I-Premise
249	all	_	_	I-Premise
250	P	_	_	I-Premise
251	values	_	_	I-Premise
252	<	_	_	I-Premise
253	.002	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Amenorrhea	_	_	B-Claim
257	rates	_	_	I-Claim
258	differed	_	_	I-Claim
259	significantly	_	_	I-Claim
260	by	_	_	I-Claim
261	treatment	_	_	I-Claim
262	arm	_	_	I-Claim
263	,	_	_	I-Claim
264	with	_	_	I-Claim
265	the	_	_	I-Claim
266	AT	_	_	I-Claim
267	arm	_	_	I-Claim
268	having	_	_	I-Claim
269	the	_	_	I-Claim
270	lowest	_	_	I-Claim
271	rate	_	_	I-Claim
272	.	_	_	I-Claim

273	Patients	_	_	B-Claim
274	treated	_	_	I-Claim
275	with	_	_	I-Claim
276	longer	_	_	I-Claim
277	duration	_	_	I-Claim
278	therapy	_	_	I-Claim
279	(	_	_	I-Claim
280	ACâ†’T	_	_	I-Claim
281	)	_	_	I-Claim
282	had	_	_	I-Claim
283	greater	_	_	I-Claim
284	symptom	_	_	I-Claim
285	severity	_	_	I-Claim
286	and	_	_	I-Claim
287	poorer	_	_	I-Claim
288	QOL	_	_	I-Claim
289	at	_	_	I-Claim
290	6	_	_	I-Claim
291	months	_	_	I-Claim
292	,	_	_	I-Claim
293	but	_	_	I-Claim
294	did	_	_	I-Claim
295	not	_	_	I-Claim
296	differ	_	_	I-Claim
297	from	_	_	I-Claim
298	shorter	_	_	I-Claim
299	duration	_	_	I-Claim
300	treatments	_	_	I-Claim
301	at	_	_	I-Claim
302	12	_	_	I-Claim
303	months	_	_	I-Claim
304	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	frequent	_	_	O
4	hospital	_	_	O
5	follow-up	_	_	O
6	in	_	_	O
7	the	_	_	O
8	first	_	_	O
9	year	_	_	O
10	after	_	_	O
11	breast	_	_	O
12	cancer	_	_	O
13	treatment	_	_	O
14	might	_	_	O
15	partly	_	_	O
16	be	_	_	O
17	replaced	_	_	O
18	by	_	_	O
19	nurse-led	_	_	O
20	telephone	_	_	O
21	follow-up	_	_	O
22	without	_	_	O
23	deteriorating	_	_	O
24	health-related	_	_	O
25	quality	_	_	O
26	of	_	_	O
27	life	_	_	O
28	(	_	_	O
29	HRQoL	_	_	O
30	)	_	_	O
31	,	_	_	O
32	and	_	_	O
33	whether	_	_	O
34	a	_	_	O
35	short	_	_	O
36	educational	_	_	O
37	group	_	_	O
38	programme	_	_	O
39	(	_	_	O
40	EGP	_	_	O
41	)	_	_	O
42	would	_	_	O
43	enhance	_	_	O
44	HRQoL	_	_	O
45	.	_	_	O

46	A	_	_	O
47	multicentre	_	_	O
48	pragmatic	_	_	O
49	randomised	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	(	_	_	O
53	RCT	_	_	O
54	)	_	_	O
55	with	_	_	O
56	a	_	_	O
57	2Ã—2	_	_	O
58	factorial	_	_	O
59	design	_	_	O
60	was	_	_	O
61	performed	_	_	O
62	among	_	_	O
63	320	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	patients	_	_	O
67	who	_	_	O
68	were	_	_	O
69	treated	_	_	O
70	with	_	_	O
71	curative	_	_	O
72	intent	_	_	O
73	.	_	_	O

74	Participants	_	_	O
75	were	_	_	O
76	randomised	_	_	O
77	to	_	_	O
78	follow-up	_	_	O
79	care	_	_	O
80	as	_	_	O
81	usual	_	_	O
82	(	_	_	O
83	3-monthly	_	_	O
84	outpatient	_	_	O
85	clinic	_	_	O
86	visits	_	_	O
87	)	_	_	O
88	,	_	_	O
89	nurse-led	_	_	O
90	telephone	_	_	O
91	follow-up	_	_	O
92	,	_	_	O
93	or	_	_	O
94	the	_	_	O
95	former	_	_	O
96	strategies	_	_	O
97	combined	_	_	O
98	with	_	_	O
99	an	_	_	O
100	educational	_	_	O
101	group	_	_	O
102	programme	_	_	O
103	.	_	_	O

104	The	_	_	O
105	primary	_	_	O
106	outcome	_	_	O
107	for	_	_	O
108	both	_	_	O
109	interventions	_	_	O
110	was	_	_	O
111	HRQoL	_	_	O
112	,	_	_	O
113	measured	_	_	O
114	by	_	_	O
115	EORTC	_	_	O
116	QLQ-C30	_	_	O
117	.	_	_	O

118	Secondary	_	_	O
119	outcomes	_	_	O
120	were	_	_	O
121	role	_	_	O
122	and	_	_	O
123	emotional	_	_	O
124	functioning	_	_	O
125	and	_	_	O
126	feelings	_	_	O
127	of	_	_	O
128	control	_	_	O
129	and	_	_	O
130	anxiety	_	_	O
131	.	_	_	O

132	Data	_	_	O
133	of	_	_	O
134	299	_	_	O
135	patients	_	_	O
136	were	_	_	O
137	available	_	_	O
138	for	_	_	O
139	evaluation	_	_	O
140	.	_	_	O

141	There	_	_	B-Premise
142	was	_	_	I-Premise
143	no	_	_	I-Premise
144	significant	_	_	I-Premise
145	difference	_	_	I-Premise
146	in	_	_	I-Premise
147	HRQoL	_	_	I-Premise
148	between	_	_	I-Premise
149	nurse-led	_	_	I-Premise
150	telephone	_	_	I-Premise
151	and	_	_	I-Premise
152	hospital	_	_	I-Premise
153	follow-up	_	_	I-Premise
154	at	_	_	I-Premise
155	12	_	_	I-Premise
156	months	_	_	I-Premise
157	after	_	_	I-Premise
158	treatment	_	_	I-Premise
159	(	_	_	I-Premise
160	p	_	_	I-Premise
161	=	_	_	I-Premise
162	0.42	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	(	_	_	I-Premise
169	CI	_	_	I-Premise
170	)	_	_	I-Premise
171	for	_	_	I-Premise
172	difference	_	_	I-Premise
173	:	_	_	I-Premise
174	-1.93-4.64	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	neither	_	_	I-Premise
178	between	_	_	I-Premise
179	follow-up	_	_	I-Premise
180	with	_	_	I-Premise
181	or	_	_	I-Premise
182	without	_	_	I-Premise
183	EGP	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	=	_	_	I-Premise
187	0.86	_	_	I-Premise
188	;	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	CI	_	_	I-Premise
192	for	_	_	I-Premise
193	difference	_	_	I-Premise
194	:	_	_	I-Premise
195	-3.59-3.00	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Furthermore	_	_	O
199	,	_	_	O
200	no	_	_	B-Premise
201	differences	_	_	I-Premise
202	between	_	_	I-Premise
203	the	_	_	I-Premise
204	intervention	_	_	I-Premise
205	groups	_	_	I-Premise
206	and	_	_	I-Premise
207	their	_	_	I-Premise
208	corresponding	_	_	I-Premise
209	control	_	_	I-Premise
210	groups	_	_	I-Premise
211	were	_	_	I-Premise
212	found	_	_	I-Premise
213	in	_	_	I-Premise
214	role	_	_	I-Premise
215	and	_	_	I-Premise
216	emotional	_	_	I-Premise
217	functioning	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	feelings	_	_	I-Premise
221	of	_	_	I-Premise
222	control	_	_	I-Premise
223	and	_	_	I-Premise
224	anxiety	_	_	I-Premise
225	(	_	_	I-Premise
226	all	_	_	I-Premise
227	p-values	_	_	I-Premise
228	>	_	_	I-Premise
229	0.05	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Replacement	_	_	B-Claim
233	of	_	_	I-Claim
234	most	_	_	I-Claim
235	hospital	_	_	I-Claim
236	follow-up	_	_	I-Claim
237	visits	_	_	I-Claim
238	in	_	_	I-Claim
239	the	_	_	I-Claim
240	first	_	_	I-Claim
241	year	_	_	I-Claim
242	after	_	_	I-Claim
243	breast	_	_	I-Claim
244	cancer	_	_	I-Claim
245	treatment	_	_	I-Claim
246	by	_	_	I-Claim
247	nurse-led	_	_	I-Claim
248	telephone	_	_	I-Claim
249	follow-up	_	_	I-Claim
250	does	_	_	I-Claim
251	not	_	_	I-Claim
252	impede	_	_	I-Claim
253	patient	_	_	I-Claim
254	outcomes	_	_	I-Claim
255	.	_	_	I-Claim

256	Hence	_	_	O
257	,	_	_	O
258	nurse-led	_	_	B-Claim
259	telephone	_	_	I-Claim
260	follow-up	_	_	I-Claim
261	seems	_	_	I-Claim
262	an	_	_	I-Claim
263	appropriate	_	_	I-Claim
264	way	_	_	I-Claim
265	to	_	_	I-Claim
266	reduce	_	_	I-Claim
267	clinic	_	_	I-Claim
268	visits	_	_	I-Claim
269	and	_	_	I-Claim
270	represents	_	_	I-Claim
271	an	_	_	I-Claim
272	accepted	_	_	I-Claim
273	alternative	_	_	I-Claim
274	strategy	_	_	I-Claim
275	.	_	_	I-Claim

276	An	_	_	O
277	EGP	_	_	O
278	does	_	_	O
279	not	_	_	O
280	unequivocally	_	_	O
281	affect	_	_	O
282	positive	_	_	O
283	HRQoL	_	_	O
284	outcomes	_	_	O
285	.	_	_	O


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	dietary	_	_	O
6	counseling	_	_	O
7	or	_	_	O
8	nutritional	_	_	O
9	supplements	_	_	O
10	on	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	:	_	_	O
16	nutritional	_	_	O
17	,	_	_	O
18	morbidity	_	_	O
19	,	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QoL	_	_	O
26	)	_	_	O
27	during	_	_	O
28	and	_	_	O
29	3	_	_	O
30	months	_	_	O
31	after	_	_	O
32	radiotherapy	_	_	O
33	.	_	_	O

34	A	_	_	O
35	total	_	_	O
36	of	_	_	O
37	111	_	_	O
38	colorectal	_	_	O
39	cancer	_	_	O
40	outpatients	_	_	O
41	referred	_	_	O
42	for	_	_	O
43	radiotherapy	_	_	O
44	,	_	_	O
45	stratified	_	_	O
46	by	_	_	O
47	staging	_	_	O
48	,	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	:	_	_	O
53	group	_	_	O
54	1	_	_	O
55	(	_	_	O
56	G1	_	_	O
57	;	_	_	O
58	n	_	_	O
59	=	_	_	O
60	37	_	_	O
61	)	_	_	O
62	,	_	_	O
63	dietary	_	_	O
64	counseling	_	_	O
65	(	_	_	O
66	regular	_	_	O
67	foods	_	_	O
68	)	_	_	O
69	;	_	_	O
70	group	_	_	O
71	2	_	_	O
72	(	_	_	O
73	G2	_	_	O
74	;	_	_	O
75	n	_	_	O
76	=	_	_	O
77	37	_	_	O
78	)	_	_	O
79	,	_	_	O
80	protein	_	_	O
81	supplements	_	_	O
82	;	_	_	O
83	and	_	_	O
84	group	_	_	O
85	3	_	_	O
86	(	_	_	O
87	G3	_	_	O
88	;	_	_	O
89	n	_	_	O
90	=	_	_	O
91	37	_	_	O
92	)	_	_	O
93	,	_	_	O
94	ad	_	_	O
95	libitum	_	_	O
96	intake	_	_	O
97	.	_	_	O

98	Nutritional	_	_	O
99	intake	_	_	O
100	(	_	_	O
101	diet	_	_	O
102	history	_	_	O
103	)	_	_	O
104	,	_	_	O
105	status	_	_	O
106	(	_	_	O
107	Ottery	_	_	O
108	's	_	_	O
109	Subjective	_	_	O
110	Global	_	_	O
111	Assessment	_	_	O
112	)	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QoL	_	_	O
116	(	_	_	O
117	European	_	_	O
118	Organisation	_	_	O
119	for	_	_	O
120	Research	_	_	O
121	and	_	_	O
122	Treatment	_	_	O
123	of	_	_	O
124	Cancer	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Questionnaire	_	_	O
129	version	_	_	O
130	3.0	_	_	O
131	)	_	_	O
132	were	_	_	O
133	evaluated	_	_	O
134	at	_	_	O
135	baseline	_	_	O
136	,	_	_	O
137	at	_	_	O
138	the	_	_	O
139	end	_	_	O
140	,	_	_	O
141	and	_	_	O
142	3	_	_	O
143	months	_	_	O
144	after	_	_	O
145	radiotherapy	_	_	O
146	.	_	_	O

147	At	_	_	B-Premise
148	radiotherapy	_	_	I-Premise
149	completion	_	_	I-Premise
150	,	_	_	I-Premise
151	energy	_	_	I-Premise
152	intake	_	_	I-Premise
153	increased	_	_	I-Premise
154	in	_	_	I-Premise
155	G1/G2	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	or	_	_	I-Premise
160	=	_	_	I-Premise
161	.04	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	G1	_	_	I-Premise
165	more	_	_	I-Premise
166	than	_	_	I-Premise
167	G2	_	_	I-Premise
168	(	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	.001	_	_	I-Premise
172	)	_	_	I-Premise
173	,	_	_	I-Premise
174	and	_	_	I-Premise
175	decreased	_	_	I-Premise
176	in	_	_	I-Premise
177	G3	_	_	I-Premise
178	(	_	_	I-Premise
179	P	_	_	I-Premise
180	<	_	_	I-Premise
181	.01	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Protein	_	_	B-Premise
185	intake	_	_	I-Premise
186	increased	_	_	I-Premise
187	in	_	_	I-Premise
188	G1/G2	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	or	_	_	I-Premise
193	=	_	_	I-Premise
194	.007	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	G1	_	_	I-Premise
198	less	_	_	I-Premise
199	than	_	_	I-Premise
200	G2	_	_	I-Premise
201	(	_	_	I-Premise
202	not	_	_	I-Premise
203	significant	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	and	_	_	I-Premise
207	decreased	_	_	I-Premise
208	in	_	_	I-Premise
209	G3	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	<	_	_	I-Premise
213	.01	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	At	_	_	B-Premise
217	3	_	_	I-Premise
218	months	_	_	I-Premise
219	,	_	_	I-Premise
220	G1	_	_	I-Premise
221	maintained	_	_	I-Premise
222	nutritional	_	_	I-Premise
223	intake	_	_	I-Premise
224	and	_	_	I-Premise
225	G2/G3	_	_	I-Premise
226	returned	_	_	I-Premise
227	to	_	_	I-Premise
228	baseline	_	_	I-Premise
229	.	_	_	I-Premise

230	After	_	_	B-Premise
231	radiotherapy	_	_	I-Premise
232	and	_	_	I-Premise
233	at	_	_	I-Premise
234	3	_	_	I-Premise
235	months	_	_	I-Premise
236	,	_	_	I-Premise
237	rates	_	_	I-Premise
238	of	_	_	I-Premise
239	anorexia	_	_	I-Premise
240	,	_	_	I-Premise
241	nausea	_	_	I-Premise
242	,	_	_	I-Premise
243	vomiting	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	diarrhea	_	_	I-Premise
247	were	_	_	I-Premise
248	higher	_	_	I-Premise
249	in	_	_	I-Premise
250	G3	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.05	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	At	_	_	B-Premise
258	radiotherapy	_	_	I-Premise
259	completion	_	_	I-Premise
260	,	_	_	I-Premise
261	in	_	_	I-Premise
262	G1	_	_	I-Premise
263	all	_	_	I-Premise
264	QoL	_	_	I-Premise
265	function	_	_	I-Premise
266	scores	_	_	I-Premise
267	improved	_	_	I-Premise
268	proportionally	_	_	I-Premise
269	to	_	_	I-Premise
270	adequate	_	_	I-Premise
271	intake	_	_	I-Premise
272	or	_	_	I-Premise
273	nutritional	_	_	I-Premise
274	status	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	.05	_	_	I-Premise
279	)	_	_	I-Premise
280	;	_	_	I-Premise
281	whereas	_	_	I-Premise
282	in	_	_	I-Premise
283	G2	_	_	I-Premise
284	only	_	_	I-Premise
285	three	_	_	I-Premise
286	of	_	_	I-Premise
287	six	_	_	I-Premise
288	function	_	_	I-Premise
289	scores	_	_	I-Premise
290	improved	_	_	I-Premise
291	proportionally	_	_	I-Premise
292	to	_	_	I-Premise
293	protein	_	_	I-Premise
294	intake	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	=	_	_	I-Premise
298	.04	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	and	_	_	I-Premise
302	in	_	_	I-Premise
303	G3	_	_	I-Premise
304	all	_	_	I-Premise
305	scores	_	_	I-Premise
306	worsened	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	At	_	_	B-Premise
314	3	_	_	I-Premise
315	months	_	_	I-Premise
316	,	_	_	I-Premise
317	G1	_	_	I-Premise
318	patients	_	_	I-Premise
319	maintained/improved	_	_	I-Premise
320	function	_	_	I-Premise
321	,	_	_	I-Premise
322	symptoms	_	_	I-Premise
323	,	_	_	I-Premise
324	and	_	_	I-Premise
325	single-item	_	_	I-Premise
326	scores	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	.02	_	_	I-Premise
331	)	_	_	I-Premise
332	;	_	_	I-Premise
333	in	_	_	I-Premise
334	G2	_	_	I-Premise
335	,	_	_	I-Premise
336	only	_	_	I-Premise
337	few	_	_	I-Premise
338	function	_	_	I-Premise
339	and	_	_	I-Premise
340	symptom	_	_	I-Premise
341	scales	_	_	I-Premise
342	improved	_	_	I-Premise
343	(	_	_	I-Premise
344	P	_	_	I-Premise
345	<	_	_	I-Premise
346	.05	_	_	I-Premise
347	)	_	_	I-Premise
348	;	_	_	I-Premise
349	in	_	_	I-Premise
350	G3	_	_	I-Premise
351	,	_	_	I-Premise
352	QoL	_	_	I-Premise
353	remained	_	_	I-Premise
354	as	_	_	I-Premise
355	poor	_	_	I-Premise
356	as	_	_	I-Premise
357	after	_	_	I-Premise
358	radiotherapy	_	_	I-Premise
359	.	_	_	I-Premise

360	In	_	_	B-Premise
361	G1/G2	_	_	I-Premise
362	,	_	_	I-Premise
363	respectively	_	_	I-Premise
364	,	_	_	I-Premise
365	improvement/deterioration	_	_	I-Premise
366	of	_	_	I-Premise
367	QoL	_	_	I-Premise
368	correlated	_	_	I-Premise
369	with	_	_	I-Premise
370	better	_	_	I-Premise
371	or	_	_	I-Premise
372	poorer	_	_	I-Premise
373	intake	_	_	I-Premise
374	or	_	_	I-Premise
375	nutritional	_	_	I-Premise
376	status	_	_	I-Premise
377	(	_	_	I-Premise
378	P	_	_	I-Premise
379	<	_	_	I-Premise
380	.003	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	During	_	_	B-Claim
384	radiotherapy	_	_	I-Claim
385	,	_	_	I-Claim
386	both	_	_	I-Claim
387	interventions	_	_	I-Claim
388	positively	_	_	I-Claim
389	influenced	_	_	I-Claim
390	outcomes	_	_	I-Claim
391	;	_	_	I-Claim
392	dietary	_	_	B-Claim
393	counseling	_	_	I-Claim
394	was	_	_	I-Claim
395	of	_	_	I-Claim
396	similar	_	_	I-Claim
397	or	_	_	I-Claim
398	higher	_	_	I-Claim
399	benefit	_	_	I-Claim
400	,	_	_	I-Claim
401	whereas	_	_	I-Claim
402	even	_	_	I-Claim
403	3	_	_	I-Claim
404	months	_	_	I-Claim
405	after	_	_	I-Claim
406	RT	_	_	I-Claim
407	,	_	_	I-Claim
408	it	_	_	I-Claim
409	was	_	_	I-Claim
410	the	_	_	I-Claim
411	only	_	_	I-Claim
412	method	_	_	I-Claim
413	to	_	_	I-Claim
414	sustain	_	_	I-Claim
415	a	_	_	I-Claim
416	significant	_	_	I-Claim
417	impact	_	_	I-Claim
418	on	_	_	I-Claim
419	patient	_	_	I-Claim
420	outcomes	_	_	I-Claim
421	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	study	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	determine	_	_	O
8	the	_	_	O
9	superiority	_	_	O
10	of	_	_	O
11	doxorubicin	_	_	O
12	(	_	_	O
13	DOX	_	_	O
14	)	_	_	O
15	and	_	_	O
16	vinorelbine	_	_	O
17	(	_	_	O
18	VNB	_	_	O
19	)	_	_	O
20	(	_	_	O
21	arm	_	_	O
22	1	_	_	O
23	)	_	_	O
24	versus	_	_	O
25	DOX	_	_	O
26	alone	_	_	O
27	(	_	_	O
28	arm	_	_	O
29	2	_	_	O
30	)	_	_	O
31	in	_	_	O
32	metastatic	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	MBC	_	_	O
37	)	_	_	O
38	for	_	_	O
39	overall	_	_	O
40	survival	_	_	O
41	(	_	_	O
42	OS	_	_	O
43	)	_	_	O
44	,	_	_	O
45	time	_	_	O
46	to	_	_	O
47	treatment	_	_	O
48	failure	_	_	O
49	(	_	_	O
50	TTF	_	_	O
51	)	_	_	O
52	,	_	_	O
53	toxicity	_	_	O
54	,	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	.	_	_	O

63	Three	_	_	O
64	hundred	_	_	O
65	three	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	DOX	_	_	O
71	50	_	_	O
72	mg/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	intravenously	_	_	O
77	(	_	_	O
78	IV	_	_	O
79	)	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	VNB	_	_	O
85	25	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	IV	_	_	O
91	on	_	_	O
92	days	_	_	O
93	1	_	_	O
94	and	_	_	O
95	8	_	_	O
96	(	_	_	O
97	arm	_	_	O
98	1	_	_	O
99	)	_	_	O
100	or	_	_	O
101	DOX	_	_	O
102	70	_	_	O
103	mg/m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	IV	_	_	O
108	on	_	_	O
109	day	_	_	O
110	1	_	_	O
111	(	_	_	O
112	arm	_	_	O
113	2	_	_	O
114	)	_	_	O
115	.	_	_	O

116	Both	_	_	O
117	regimens	_	_	O
118	were	_	_	O
119	given	_	_	O
120	every	_	_	O
121	3	_	_	O
122	weeks	_	_	O
123	until	_	_	O
124	a	_	_	O
125	cumulative	_	_	O
126	DOX	_	_	O
127	dose	_	_	O
128	of	_	_	O
129	450	_	_	O
130	mg/m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	.	_	_	O

135	After	_	_	O
136	16	_	_	O
137	of	_	_	O
138	the	_	_	O
139	first	_	_	O
140	65	_	_	O
141	randomized	_	_	O
142	patients	_	_	O
143	experienced	_	_	O
144	febrile	_	_	O
145	neutropenia	_	_	O
146	(	_	_	O
147	FN	_	_	O
148	)	_	_	O
149	,	_	_	O
150	the	_	_	O
151	doses	_	_	O
152	were	_	_	O
153	reduced	_	_	O
154	to	_	_	O
155	DOX	_	_	O
156	40	_	_	O
157	mg/m	_	_	O
158	(	_	_	O
159	2	_	_	O
160	)	_	_	O
161	on	_	_	O
162	day	_	_	O
163	1	_	_	O
164	and	_	_	O
165	VNB	_	_	O
166	20	_	_	O
167	mg/m	_	_	O
168	(	_	_	O
169	2	_	_	O
170	)	_	_	O
171	on	_	_	O
172	days	_	_	O
173	1	_	_	O
174	and	_	_	O
175	8	_	_	O
176	versus	_	_	O
177	DOX	_	_	O
178	60	_	_	O
179	mg/m	_	_	O
180	(	_	_	O
181	2	_	_	O
182	)	_	_	O
183	on	_	_	O
184	day	_	_	O
185	1	_	_	O
186	.	_	_	O

187	Eligible	_	_	O
188	patients	_	_	O
189	were	_	_	O
190	vinca	_	_	O
191	alkaloid	_	_	O
192	and	_	_	O
193	anthracycline	_	_	O
194	naive	_	_	O
195	.	_	_	O

196	Chemotherapy	_	_	O
197	was	_	_	O
198	first-line	_	_	O
199	or	_	_	O
200	second-line	_	_	O
201	for	_	_	O
202	MBC	_	_	O
203	.	_	_	O

204	Three	_	_	O
205	patients	_	_	O
206	were	_	_	O
207	ineligible	_	_	O
208	.	_	_	O

209	Thus	_	_	O
210	,	_	_	O
211	300	_	_	O
212	patients	_	_	O
213	were	_	_	O
214	assessable	_	_	O
215	for	_	_	O
216	toxicity	_	_	O
217	and	_	_	O
218	to	_	_	O
219	determine	_	_	O
220	time	_	_	O
221	to	_	_	O
222	disease	_	_	O
223	progression	_	_	O
224	(	_	_	O
225	TTP	_	_	O
226	)	_	_	O
227	,	_	_	O
228	TTF	_	_	O
229	,	_	_	O
230	and	_	_	O
231	OS	_	_	O
232	.	_	_	O

233	Two	_	_	O
234	hundred	_	_	O
235	eighty-nine	_	_	O
236	patients	_	_	O
237	were	_	_	O
238	assessable	_	_	O
239	for	_	_	O
240	response	_	_	O
241	,	_	_	O
242	and	_	_	O
243	99	_	_	O
244	responders	_	_	O
245	were	_	_	O
246	assessable	_	_	O
247	for	_	_	O
248	response	_	_	O
249	duration	_	_	O
250	(	_	_	O
251	RD	_	_	O
252	)	_	_	O
253	.	_	_	O

254	The	_	_	B-Premise
255	response	_	_	I-Premise
256	rates	_	_	I-Premise
257	,	_	_	I-Premise
258	QOL	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	median	_	_	I-Premise
262	RD	_	_	I-Premise
263	,	_	_	I-Premise
264	TTP	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	TTF	_	_	I-Premise
268	were	_	_	I-Premise
269	not	_	_	I-Premise
270	significantly	_	_	I-Premise
271	different	_	_	I-Premise
272	between	_	_	I-Premise
273	the	_	_	I-Premise
274	arms	_	_	I-Premise
275	.	_	_	I-Premise

276	Median	_	_	B-Premise
277	OS	_	_	I-Premise
278	was	_	_	I-Premise
279	13.8	_	_	I-Premise
280	months	_	_	I-Premise
281	for	_	_	I-Premise
282	arm	_	_	I-Premise
283	1	_	_	I-Premise
284	versus	_	_	I-Premise
285	14.4	_	_	I-Premise
286	months	_	_	I-Premise
287	for	_	_	I-Premise
288	arm	_	_	I-Premise
289	2	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=.4	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Grade	_	_	B-Premise
296	3	_	_	I-Premise
297	or	_	_	I-Premise
298	4	_	_	I-Premise
299	granulocytopenia	_	_	I-Premise
300	was	_	_	I-Premise
301	equivalent	_	_	I-Premise
302	in	_	_	I-Premise
303	both	_	_	I-Premise
304	arms	_	_	I-Premise
305	but	_	_	I-Premise
306	more	_	_	I-Premise
307	grade	_	_	I-Premise
308	3/4	_	_	I-Premise
309	neurotoxicity	_	_	I-Premise
310	,	_	_	I-Premise
311	mild	_	_	I-Premise
312	venous	_	_	I-Premise
313	toxicity	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	FN	_	_	I-Premise
317	were	_	_	I-Premise
318	seen	_	_	I-Premise
319	on	_	_	I-Premise
320	arm	_	_	I-Premise
321	1	_	_	I-Premise
322	.	_	_	I-Premise

323	The	_	_	B-Claim
324	survival	_	_	I-Claim
325	with	_	_	I-Claim
326	DOX	_	_	I-Claim
327	and	_	_	I-Claim
328	VNB	_	_	I-Claim
329	is	_	_	I-Claim
330	not	_	_	I-Claim
331	superior	_	_	I-Claim
332	to	_	_	I-Claim
333	DOX	_	_	I-Claim
334	alone	_	_	I-Claim
335	in	_	_	I-Claim
336	MBC	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	prospectively	_	_	O
4	collected	_	_	O
5	health-related	_	_	O
6	quality-of-life	_	_	O
7	(	_	_	O
8	HRQOL	_	_	O
9	)	_	_	O
10	data	_	_	O
11	from	_	_	O
12	patients	_	_	O
13	enrolled	_	_	O
14	in	_	_	O
15	two	_	_	O
16	Radiation	_	_	O
17	Therapy	_	_	O
18	Oncology	_	_	O
19	Group	_	_	O
20	randomized	_	_	O
21	Phase	_	_	O
22	III	_	_	O
23	head	_	_	O
24	and	_	_	O
25	neck	_	_	O
26	cancer	_	_	O
27	trials	_	_	O
28	(	_	_	O
29	90-03	_	_	O
30	and	_	_	O
31	91-11	_	_	O
32	)	_	_	O
33	to	_	_	O
34	assess	_	_	O
35	their	_	_	O
36	value	_	_	O
37	as	_	_	O
38	an	_	_	O
39	independent	_	_	O
40	prognostic	_	_	O
41	factor	_	_	O
42	for	_	_	O
43	locoregional	_	_	O
44	control	_	_	O
45	(	_	_	O
46	LRC	_	_	O
47	)	_	_	O
48	and/or	_	_	O
49	overall	_	_	O
50	survival	_	_	O
51	(	_	_	O
52	OS	_	_	O
53	)	_	_	O
54	.	_	_	O

55	HRQOL	_	_	O
56	questionnaires	_	_	O
57	,	_	_	O
58	using	_	_	O
59	a	_	_	O
60	validated	_	_	O
61	instrument	_	_	O
62	,	_	_	O
63	the	_	_	O
64	Functional	_	_	O
65	Assessment	_	_	O
66	of	_	_	O
67	Cancer	_	_	O
68	Therapy-Head	_	_	O
69	and	_	_	O
70	Neck	_	_	O
71	(	_	_	O
72	FACT-H	_	_	O
73	&	_	_	O
74	amp	_	_	O
75	;	_	_	O
76	N	_	_	O
77	)	_	_	O
78	,	_	_	O
79	version	_	_	O
80	2	_	_	O
81	,	_	_	O
82	were	_	_	O
83	completed	_	_	O
84	by	_	_	O
85	patients	_	_	O
86	before	_	_	O
87	the	_	_	O
88	start	_	_	O
89	of	_	_	O
90	treatment	_	_	O
91	.	_	_	O

92	OS	_	_	O
93	and	_	_	O
94	LRC	_	_	O
95	were	_	_	O
96	the	_	_	O
97	outcome	_	_	O
98	measures	_	_	O
99	analyzed	_	_	O
100	using	_	_	O
101	a	_	_	O
102	multivariate	_	_	O
103	Cox	_	_	O
104	proportional	_	_	O
105	hazard	_	_	O
106	model	_	_	O
107	.	_	_	O

108	Baseline	_	_	O
109	FACT-H	_	_	O
110	&	_	_	O
111	amp	_	_	O
112	;	_	_	O
113	N	_	_	O
114	data	_	_	O
115	were	_	_	O
116	available	_	_	O
117	for	_	_	O
118	1,093	_	_	O
119	patients	_	_	O
120	and	_	_	O
121	missing	_	_	O
122	for	_	_	O
123	417	_	_	O
124	patients	_	_	O
125	.	_	_	O

126	No	_	_	O
127	significant	_	_	O
128	difference	_	_	O
129	in	_	_	O
130	outcome	_	_	O
131	was	_	_	O
132	found	_	_	O
133	between	_	_	O
134	the	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	and	_	_	O
138	without	_	_	O
139	baseline	_	_	O
140	FACT-H	_	_	O
141	&	_	_	O
142	amp	_	_	O
143	;	_	_	O
144	N	_	_	O
145	data	_	_	O
146	(	_	_	O
147	p	_	_	O
148	=	_	_	O
149	0.58	_	_	O
150	)	_	_	O
151	.	_	_	O

152	The	_	_	O
153	median	_	_	O
154	follow-up	_	_	O
155	time	_	_	O
156	was	_	_	O
157	27.2	_	_	O
158	months	_	_	O
159	for	_	_	O
160	all	_	_	O
161	patients	_	_	O
162	and	_	_	O
163	49	_	_	O
164	months	_	_	O
165	for	_	_	O
166	surviving	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	Multivariate	_	_	O
170	analyses	_	_	O
171	were	_	_	O
172	performed	_	_	O
173	for	_	_	O
174	both	_	_	O
175	OS	_	_	O
176	and	_	_	O
177	LRC	_	_	O
178	.	_	_	O

179	Beyond	_	_	B-Premise
180	tumor	_	_	I-Premise
181	and	_	_	I-Premise
182	nodal	_	_	I-Premise
183	stage	_	_	I-Premise
184	,	_	_	I-Premise
185	Karnofsky	_	_	I-Premise
186	performance	_	_	I-Premise
187	status	_	_	I-Premise
188	,	_	_	I-Premise
189	primary	_	_	I-Premise
190	site	_	_	I-Premise
191	,	_	_	I-Premise
192	cigarette	_	_	I-Premise
193	use	_	_	I-Premise
194	,	_	_	I-Premise
195	use	_	_	I-Premise
196	of	_	_	I-Premise
197	concurrent	_	_	I-Premise
198	chemotherapy	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	altered	_	_	I-Premise
202	fractionation	_	_	I-Premise
203	schedules	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	FACT-H	_	_	I-Premise
207	&	_	_	I-Premise
208	amp	_	_	I-Premise
209	;	_	_	I-Premise
210	N	_	_	I-Premise
211	score	_	_	I-Premise
212	was	_	_	I-Premise
213	independently	_	_	I-Premise
214	predictive	_	_	I-Premise
215	of	_	_	I-Premise
216	LRC	_	_	I-Premise
217	(	_	_	I-Premise
218	but	_	_	I-Premise
219	not	_	_	I-Premise
220	OS	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	with	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.0038	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	functional	_	_	I-Premise
230	well-being	_	_	I-Premise
231	component	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	FACT-H	_	_	I-Premise
235	&	_	_	I-Premise
236	amp	_	_	I-Premise
237	;	_	_	I-Premise
238	N	_	_	I-Premise
239	predicted	_	_	I-Premise
240	most	_	_	I-Premise
241	significantly	_	_	I-Premise
242	for	_	_	I-Premise
243	LRC	_	_	I-Premise
244	(	_	_	I-Premise
245	p	_	_	I-Premise
246	=	_	_	I-Premise
247	0.0004	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	This	_	_	B-Claim
251	study	_	_	I-Claim
252	represents	_	_	I-Claim
253	,	_	_	I-Claim
254	to	_	_	I-Claim
255	our	_	_	I-Claim
256	knowledge	_	_	I-Claim
257	,	_	_	I-Claim
258	the	_	_	I-Claim
259	largest	_	_	I-Claim
260	analysis	_	_	I-Claim
261	of	_	_	I-Claim
262	HRQOL	_	_	I-Claim
263	as	_	_	I-Claim
264	a	_	_	I-Claim
265	prognostic	_	_	I-Claim
266	factor	_	_	I-Claim
267	in	_	_	I-Claim
268	locally	_	_	I-Claim
269	advanced	_	_	I-Claim
270	head	_	_	I-Claim
271	and	_	_	I-Claim
272	neck	_	_	I-Claim
273	cancer	_	_	I-Claim
274	patients	_	_	I-Claim
275	.	_	_	I-Claim

276	The	_	_	B-Claim
277	results	_	_	I-Claim
278	of	_	_	I-Claim
279	this	_	_	I-Claim
280	study	_	_	I-Claim
281	have	_	_	I-Claim
282	demonstrated	_	_	I-Claim
283	the	_	_	I-Claim
284	importance	_	_	I-Claim
285	of	_	_	I-Claim
286	baseline	_	_	I-Claim
287	HRQOL	_	_	I-Claim
288	as	_	_	I-Claim
289	a	_	_	I-Claim
290	significant	_	_	I-Claim
291	and	_	_	I-Claim
292	independent	_	_	I-Claim
293	predictor	_	_	I-Claim
294	of	_	_	I-Claim
295	LRC	_	_	I-Claim
296	in	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	locally	_	_	I-Claim
300	advanced	_	_	I-Claim
301	head	_	_	I-Claim
302	and	_	_	I-Claim
303	neck	_	_	I-Claim
304	cancer	_	_	I-Claim
305	.	_	_	I-Claim


0	Lymphedema	_	_	O
1	is	_	_	O
2	an	_	_	O
3	adverse	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	breast	_	_	O
7	cancer	_	_	O
8	surgery	_	_	O
9	.	_	_	O

10	Aqua	_	_	O
11	lymphatic	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	ALT	_	_	O
15	)	_	_	O
16	is	_	_	O
17	a	_	_	O
18	novel	_	_	O
19	treatment	_	_	O
20	for	_	_	O
21	limb	_	_	O
22	volume	_	_	O
23	reduction	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	was	_	_	O
31	to	_	_	O
32	examine	_	_	O
33	whether	_	_	O
34	ALT	_	_	O
35	is	_	_	O
36	a	_	_	O
37	safe	_	_	O
38	method	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	there	_	_	O
42	are	_	_	O
43	differences	_	_	O
44	in	_	_	O
45	adherence	_	_	O
46	,	_	_	O
47	limb	_	_	O
48	volume	_	_	O
49	,	_	_	O
50	and	_	_	O
51	quality	_	_	O
52	of	_	_	O
53	life	_	_	O
54	between	_	_	O
55	women	_	_	O
56	who	_	_	O
57	perform	_	_	O
58	only	_	_	O
59	self-management	_	_	O
60	treatment	_	_	O
61	and	_	_	O
62	women	_	_	O
63	who	_	_	O
64	participate	_	_	O
65	as	_	_	O
66	well	_	_	O
67	in	_	_	O
68	ALT	_	_	O
69	.	_	_	O

70	Design	_	_	O
71	of	_	_	O
72	the	_	_	O
73	study	_	_	O
74	was	_	_	O
75	single-blind	_	_	O
76	randomized	_	_	O
77	clinical	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	The	_	_	O
81	setting	_	_	O
82	was	_	_	O
83	in	_	_	O
84	a	_	_	O
85	hydrotherapy	_	_	O
86	pool	_	_	O
87	,	_	_	O
88	1.2	_	_	O
89	m	_	_	O
90	depth	_	_	O
91	,	_	_	O
92	and	_	_	O
93	a	_	_	O
94	temperature	_	_	O
95	of	_	_	O
96	32-33	_	_	O
97	degrees	_	_	O
98	capital	_	_	O
99	ES	_	_	O
100	,	_	_	O
101	Cyrillic	_	_	O
102	.	_	_	O

103	Forty-eight	_	_	O
104	women	_	_	O
105	(	_	_	O
106	56	_	_	O
107	+/-	_	_	O
108	10	_	_	O
109	years	_	_	O
110	)	_	_	O
111	,	_	_	O
112	with	_	_	O
113	a	_	_	O
114	12.8	_	_	O
115	%	_	_	O
116	lymphedema	_	_	O
117	relative	_	_	O
118	volume	_	_	O
119	,	_	_	O
120	participated	_	_	O
121	in	_	_	O
122	the	_	_	O
123	study	_	_	O
124	.	_	_	O

125	The	_	_	O
126	control	_	_	O
127	group	_	_	O
128	was	_	_	O
129	instructed	_	_	O
130	to	_	_	O
131	perform	_	_	O
132	the	_	_	O
133	self-management	_	_	O
134	treatment	_	_	O
135	.	_	_	O

136	The	_	_	O
137	study	_	_	O
138	group	_	_	O
139	joined	_	_	O
140	a	_	_	O
141	weekly	_	_	O
142	session	_	_	O
143	of	_	_	O
144	ALT	_	_	O
145	for	_	_	O
146	3	_	_	O
147	months	_	_	O
148	in	_	_	O
149	addition	_	_	O
150	to	_	_	O
151	the	_	_	O
152	self-management	_	_	O
153	therapy	_	_	O
154	.	_	_	O

155	Adherence	_	_	O
156	was	_	_	O
157	assessed	_	_	O
158	by	_	_	O
159	a	_	_	O
160	self-reported	_	_	O
161	diary	_	_	O
162	,	_	_	O
163	limb	_	_	O
164	volume	_	_	O
165	by	_	_	O
166	a	_	_	O
167	water	_	_	O
168	displacement	_	_	O
169	device	_	_	O
170	,	_	_	O
171	quality	_	_	O
172	of	_	_	O
173	life	_	_	O
174	by	_	_	O
175	the	_	_	O
176	Upper	_	_	O
177	Limb	_	_	O
178	Lymphedema	_	_	O
179	Questionnaire	_	_	O
180	(	_	_	O
181	ULL27	_	_	O
182	)	_	_	O
183	,	_	_	O
184	prior	_	_	O
185	to	_	_	O
186	,	_	_	O
187	and	_	_	O
188	after	_	_	O
189	the	_	_	O
190	intervention	_	_	O
191	period	_	_	O
192	.	_	_	O

193	There	_	_	B-Premise
194	was	_	_	I-Premise
195	no	_	_	I-Premise
196	episode	_	_	I-Premise
197	of	_	_	I-Premise
198	arm	_	_	I-Premise
199	infection	_	_	I-Premise
200	or	_	_	I-Premise
201	aggravation	_	_	I-Premise
202	in	_	_	I-Premise
203	limb	_	_	I-Premise
204	volume	_	_	I-Premise
205	during	_	_	I-Premise
206	the	_	_	I-Premise
207	study	_	_	I-Premise
208	period	_	_	I-Premise
209	.	_	_	I-Premise

210	ALT	_	_	B-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	positive	_	_	I-Premise
214	,	_	_	I-Premise
215	statistically	_	_	I-Premise
216	and	_	_	I-Premise
217	clinically	_	_	I-Premise
218	significant	_	_	I-Premise
219	immediate	_	_	I-Premise
220	effect	_	_	I-Premise
221	on	_	_	I-Premise
222	limb	_	_	I-Premise
223	volume	_	_	I-Premise
224	but	_	_	B-Premise
225	no	_	_	I-Premise
226	long-term	_	_	I-Premise
227	effect	_	_	I-Premise
228	was	_	_	I-Premise
229	noted	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	adherence	_	_	I-Premise
233	rate	_	_	I-Premise
234	to	_	_	I-Premise
235	ALT	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	higher	_	_	I-Premise
239	than	_	_	I-Premise
240	the	_	_	I-Premise
241	adherence	_	_	I-Premise
242	to	_	_	I-Premise
243	self-management	_	_	I-Premise
244	therapy	_	_	I-Premise
245	.	_	_	I-Premise

246	QOL	_	_	B-Premise
247	improved	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	study	_	_	I-Premise
251	group	_	_	I-Premise
252	.	_	_	I-Premise

253	ALT	_	_	B-Claim
254	was	_	_	I-Claim
255	found	_	_	I-Claim
256	to	_	_	I-Claim
257	be	_	_	I-Claim
258	a	_	_	I-Claim
259	safe	_	_	I-Claim
260	method	_	_	I-Claim
261	,	_	_	I-Claim
262	with	_	_	I-Claim
263	high	_	_	I-Claim
264	adherence	_	_	I-Claim
265	,	_	_	I-Claim
266	in	_	_	I-Claim
267	treating	_	_	I-Claim
268	women	_	_	I-Claim
269	who	_	_	I-Claim
270	suffer	_	_	I-Claim
271	from	_	_	I-Claim
272	mild	_	_	I-Claim
273	to	_	_	I-Claim
274	moderate	_	_	I-Claim
275	lymphedema	_	_	I-Claim
276	.	_	_	I-Claim

277	A	_	_	B-Claim
278	significant	_	_	I-Claim
279	immediate	_	_	I-Claim
280	and	_	_	I-Claim
281	insignificant	_	_	I-Claim
282	long-term	_	_	I-Claim
283	effect	_	_	I-Claim
284	on	_	_	I-Claim
285	limb	_	_	I-Claim
286	volume	_	_	I-Claim
287	was	_	_	I-Claim
288	noted	_	_	I-Claim
289	.	_	_	I-Claim


0	Recombinant	_	_	O
1	human	_	_	O
2	TSH	_	_	O
3	(	_	_	O
4	rhTSH	_	_	O
5	)	_	_	O
6	has	_	_	O
7	become	_	_	O
8	the	_	_	O
9	modality	_	_	O
10	of	_	_	O
11	choice	_	_	O
12	for	_	_	O
13	radioiodine	_	_	O
14	remnant	_	_	O
15	ablation	_	_	O
16	(	_	_	O
17	RRA	_	_	O
18	)	_	_	O
19	in	_	_	O
20	low-risk	_	_	O
21	thyroid	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aims	_	_	O
27	of	_	_	O
28	the	_	_	O
29	present	_	_	O
30	prospective	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	were	_	_	O
34	to	_	_	O
35	evaluate	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	TSH	_	_	O
40	stimulation	_	_	O
41	procedure	_	_	O
42	(	_	_	O
43	hypothyroidism	_	_	O
44	vs.	_	_	O
45	rhTSH	_	_	O
46	)	_	_	O
47	on	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	(	_	_	O
52	QoL	_	_	O
53	)	_	_	O
54	of	_	_	O
55	thyroid	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	undergoing	_	_	O
59	RRA	_	_	O
60	and	_	_	O
61	to	_	_	O
62	evaluate	_	_	O
63	efficacy	_	_	O
64	of	_	_	O
65	both	_	_	O
66	procedures	_	_	O
67	.	_	_	O

68	L-T4	_	_	O
69	was	_	_	O
70	initiated	_	_	O
71	in	_	_	O
72	both	_	_	O
73	groups	_	_	O
74	after	_	_	O
75	thyroidectomy	_	_	O
76	.	_	_	O

77	After	_	_	O
78	randomization	_	_	O
79	,	_	_	O
80	L-T4	_	_	O
81	was	_	_	O
82	discontinued	_	_	O
83	in	_	_	O
84	hypothyroid	_	_	O
85	(	_	_	O
86	hypo	_	_	O
87	)	_	_	O
88	group	_	_	O
89	and	_	_	O
90	continued	_	_	O
91	in	_	_	O
92	rhTSH	_	_	O
93	group	_	_	O
94	.	_	_	O

95	A	_	_	O
96	measure	_	_	O
97	of	_	_	O
98	3.7	_	_	O
99	GBq	_	_	O
100	of	_	_	O
101	radioiodine	_	_	O
102	was	_	_	O
103	given	_	_	O
104	to	_	_	O
105	both	_	_	O
106	groups	_	_	O
107	.	_	_	O

108	The	_	_	O
109	functional	_	_	O
110	assessment	_	_	O
111	of	_	_	O
112	chronic	_	_	O
113	illness	_	_	O
114	therapy-fatigue	_	_	O
115	(	_	_	O
116	FACIT-F	_	_	O
117	)	_	_	O
118	was	_	_	O
119	administered	_	_	O
120	from	_	_	O
121	the	_	_	O
122	early	_	_	O
123	postoperative	_	_	O
124	period	_	_	O
125	to	_	_	O
126	9	_	_	O
127	months	_	_	O
128	.	_	_	O

129	Socio-demographic	_	_	O
130	parameters	_	_	O
131	,	_	_	O
132	anxiety	_	_	O
133	and	_	_	O
134	depression	_	_	O
135	scales	_	_	O
136	were	_	_	O
137	also	_	_	O
138	evaluated	_	_	O
139	(	_	_	O
140	CES-D	_	_	O
141	,	_	_	O
142	BDI	_	_	O
143	and	_	_	O
144	Spielberger	_	_	O
145	state-trait	_	_	O
146	questionnaires	_	_	O
147	)	_	_	O
148	.	_	_	O

149	At	_	_	O
150	9	_	_	O
151	months	_	_	O
152	,	_	_	O
153	patients	_	_	O
154	underwent	_	_	O
155	an	_	_	O
156	rhTSH	_	_	O
157	stimulation	_	_	O
158	test	_	_	O
159	,	_	_	O
160	diagnostic	_	_	O
161	(	_	_	O
162	131	_	_	O
163	)	_	_	O
164	I	_	_	O
165	whole	_	_	O
166	body	_	_	O
167	scan	_	_	O
168	(	_	_	O
169	dxWBS	_	_	O
170	)	_	_	O
171	and	_	_	O
172	neck	_	_	O
173	ultrasonography	_	_	O
174	.	_	_	O

175	A	_	_	O
176	total	_	_	O
177	of	_	_	O
178	74	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	enrolled	_	_	O
182	for	_	_	O
183	the	_	_	O
184	study	_	_	O
185	.	_	_	O

186	There	_	_	B-Premise
187	was	_	_	I-Premise
188	a	_	_	I-Premise
189	significant	_	_	I-Premise
190	decrease	_	_	I-Premise
191	in	_	_	I-Premise
192	QoL	_	_	I-Premise
193	from	_	_	I-Premise
194	baseline	_	_	I-Premise
195	(	_	_	I-Premise
196	t0	_	_	I-Premise
197	)	_	_	I-Premise
198	to	_	_	I-Premise
199	t1	_	_	I-Premise
200	(	_	_	I-Premise
201	RRA	_	_	I-Premise
202	period	_	_	I-Premise
203	)	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	hypothyroid	_	_	I-Premise
207	group	_	_	I-Premise
208	with	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	in	_	_	I-Premise
212	FACIT-F	_	_	I-Premise
213	TOI	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	10	_	_	I-Premise
218	(	_	_	I-Premise
219	-3	_	_	I-Premise
220	)	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	FACT-G	_	_	I-Premise
224	total	_	_	I-Premise
225	score	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.005	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	FACIT-F	_	_	I-Premise
233	total	_	_	I-Premise
234	score	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0.003	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	By	_	_	B-Premise
242	contrast	_	_	I-Premise
243	,	_	_	I-Premise
244	QoL	_	_	I-Premise
245	was	_	_	I-Premise
246	preserved	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	rhTSH	_	_	I-Premise
250	group	_	_	I-Premise
251	.	_	_	I-Premise

252	In	_	_	O
253	the	_	_	O
254	multivariate	_	_	O
255	analysis	_	_	O
256	,	_	_	O
257	FACIT-TOI	_	_	O
258	changes	_	_	O
259	were	_	_	O
260	only	_	_	O
261	affected	_	_	O
262	by	_	_	O
263	the	_	_	O
264	modality	_	_	O
265	of	_	_	O
266	TSH	_	_	O
267	stimulation	_	_	O
268	performed	_	_	O
269	for	_	_	O
270	RRA	_	_	O
271	.	_	_	O

272	From	_	_	B-Premise
273	3	_	_	I-Premise
274	to	_	_	I-Premise
275	9	_	_	I-Premise
276	months	_	_	I-Premise
277	,	_	_	I-Premise
278	changes	_	_	I-Premise
279	of	_	_	I-Premise
280	QoL	_	_	I-Premise
281	scales	_	_	I-Premise
282	and	_	_	I-Premise
283	subscales	_	_	I-Premise
284	were	_	_	I-Premise
285	no	_	_	I-Premise
286	longer	_	_	I-Premise
287	statistically	_	_	I-Premise
288	different	_	_	I-Premise
289	in	_	_	I-Premise
290	both	_	_	I-Premise
291	groups	_	_	I-Premise
292	of	_	_	I-Premise
293	patients	_	_	I-Premise
294	.	_	_	I-Premise

295	Based	_	_	B-Premise
296	on	_	_	I-Premise
297	serum	_	_	I-Premise
298	rhTSH-stimulated	_	_	I-Premise
299	Tg	_	_	I-Premise
300	alone	_	_	I-Premise
301	(	_	_	I-Premise
302	Tg	_	_	I-Premise
303	<	_	_	I-Premise
304	0.8	_	_	I-Premise
305	microg/l	_	_	I-Premise
306	,	_	_	I-Premise
307	BRAHMS	_	_	I-Premise
308	Tg	_	_	I-Premise
309	Kryptor	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	no	_	_	I-Premise
313	difference	_	_	I-Premise
314	in	_	_	I-Premise
315	ablation	_	_	I-Premise
316	success	_	_	I-Premise
317	was	_	_	I-Premise
318	observed	_	_	I-Premise
319	between	_	_	I-Premise
320	rhTSH	_	_	I-Premise
321	and	_	_	I-Premise
322	hypothyroidism	_	_	I-Premise
323	groups	_	_	I-Premise
324	,	_	_	I-Premise
325	91.7	_	_	I-Premise
326	%	_	_	I-Premise
327	and	_	_	I-Premise
328	97.1	_	_	I-Premise
329	%	_	_	I-Premise
330	,	_	_	I-Premise
331	respectively	_	_	I-Premise
332	.	_	_	I-Premise

333	A	_	_	B-Premise
334	higher	_	_	I-Premise
335	rate	_	_	I-Premise
336	of	_	_	I-Premise
337	persistent	_	_	I-Premise
338	thyroid	_	_	I-Premise
339	remnants	_	_	I-Premise
340	was	_	_	I-Premise
341	observed	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	rhTSH	_	_	I-Premise
345	arm	_	_	I-Premise
346	,	_	_	I-Premise
347	although	_	_	B-Premise
348	in	_	_	I-Premise
349	most	_	_	I-Premise
350	cases	_	_	I-Premise
351	uptake	_	_	I-Premise
352	was	_	_	I-Premise
353	<	_	_	I-Premise
354	0.1	_	_	I-Premise
355	%	_	_	I-Premise
356	and	_	_	I-Premise
357	of	_	_	I-Premise
358	no	_	_	I-Premise
359	clinical	_	_	I-Premise
360	significance	_	_	I-Premise
361	.	_	_	I-Premise

362	rhTSH	_	_	B-Claim
363	preserves	_	_	I-Claim
364	QoL	_	_	I-Claim
365	of	_	_	I-Claim
366	patients	_	_	I-Claim
367	undergoing	_	_	I-Claim
368	RRA	_	_	I-Claim
369	with	_	_	I-Claim
370	similar	_	_	I-Claim
371	rates	_	_	I-Claim
372	of	_	_	I-Claim
373	ablation	_	_	I-Claim
374	success	_	_	I-Claim
375	compared	_	_	I-Claim
376	to	_	_	I-Claim
377	hypothyrodism	_	_	I-Claim
378	.	_	_	I-Claim

379	However	_	_	O
380	,	_	_	O
381	there	_	_	O
382	is	_	_	O
383	a	_	_	O
384	wide	_	_	O
385	heterogeneity	_	_	O
386	in	_	_	O
387	the	_	_	O
388	clinical	_	_	O
389	impact	_	_	O
390	of	_	_	O
391	hypothyroidism	_	_	O
392	.	_	_	O


0	Chemotherapy-induced	_	_	O
1	anemia	_	_	O
2	(	_	_	O
3	CIA	_	_	O
4	)	_	_	O
5	is	_	_	O
6	responsive	_	_	O
7	to	_	_	O
8	treatment	_	_	O
9	with	_	_	O
10	erythropoiesis-stimulating	_	_	O
11	agents	_	_	O
12	(	_	_	O
13	ESAs	_	_	O
14	)	_	_	O
15	such	_	_	O
16	as	_	_	O
17	darbepoetin	_	_	O
18	alfa	_	_	O
19	.	_	_	O

20	Administration	_	_	O
21	of	_	_	O
22	ESAs	_	_	O
23	on	_	_	O
24	a	_	_	O
25	synchronous	_	_	O
26	schedule	_	_	O
27	with	_	_	O
28	chemotherapy	_	_	O
29	administration	_	_	O
30	could	_	_	O
31	benefit	_	_	O
32	patients	_	_	O
33	by	_	_	O
34	reducing	_	_	O
35	clinic	_	_	O
36	visits	_	_	O
37	and	_	_	O
38	potentially	_	_	O
39	enhancing	_	_	O
40	on-time	_	_	O
41	chemotherapy	_	_	O
42	delivery	_	_	O
43	.	_	_	O

44	This	_	_	O
45	phase	_	_	O
46	2	_	_	O
47	,	_	_	O
48	25-week	_	_	O
49	,	_	_	O
50	open-label	_	_	O
51	study	_	_	O
52	evaluated	_	_	O
53	the	_	_	O
54	noninferiority	_	_	O
55	of	_	_	O
56	darbepoetin	_	_	O
57	alfa	_	_	O
58	administered	_	_	O
59	weekly	_	_	O
60	vs.	_	_	O
61	as	_	_	O
62	an	_	_	O
63	extended	_	_	O
64	dosing	_	_	O
65	schedule	_	_	O
66	(	_	_	O
67	every	_	_	O
68	2	_	_	O
69	or	_	_	O
70	3	_	_	O
71	weeks	_	_	O
72	)	_	_	O
73	in	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	CIA	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	1:1	_	_	O
82	to	_	_	O
83	an	_	_	O
84	extended	_	_	O
85	dosing	_	_	O
86	schedule	_	_	O
87	(	_	_	O
88	EDS	_	_	O
89	:	_	_	O
90	darbepoetin	_	_	O
91	alfa	_	_	O
92	300	_	_	O
93	Î¼g	_	_	O
94	Q2W	_	_	O
95	if	_	_	O
96	chemotherapy	_	_	O
97	was	_	_	O
98	QW	_	_	O
99	,	_	_	O
100	Q2W	_	_	O
101	,	_	_	O
102	or	_	_	O
103	Q4W	_	_	O
104	or	_	_	O
105	darbepoetin	_	_	O
106	alfa	_	_	O
107	500	_	_	O
108	Î¼g	_	_	O
109	Q3W	_	_	O
110	if	_	_	O
111	chemotherapy	_	_	O
112	was	_	_	O
113	Q3W	_	_	O
114	)	_	_	O
115	or	_	_	O
116	weekly	_	_	O
117	(	_	_	O
118	150	_	_	O
119	Î¼g	_	_	O
120	QW	_	_	O
121	regardless	_	_	O
122	of	_	_	O
123	chemotherapy	_	_	O
124	schedule	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Stratification	_	_	O
128	factors	_	_	O
129	included	_	_	O
130	chemotherapy	_	_	O
131	cycle	_	_	O
132	length	_	_	O
133	,	_	_	O
134	screening	_	_	O
135	hemoglobin	_	_	O
136	(	_	_	O
137	<	_	_	O
138	10	_	_	O
139	g/dL	_	_	O
140	vs.	_	_	O
141	â‰¥10	_	_	O
142	g/dL	_	_	O
143	)	_	_	O
144	,	_	_	O
145	and	_	_	O
146	tumor	_	_	O
147	type	_	_	O
148	(	_	_	O
149	lung/gynecological	_	_	O
150	vs.	_	_	O
151	other	_	_	O
152	nonmyeloid	_	_	O
153	malignancies	_	_	O
154	)	_	_	O
155	.	_	_	O

156	The	_	_	O
157	primary	_	_	O
158	endpoint	_	_	O
159	was	_	_	O
160	change	_	_	O
161	in	_	_	O
162	hemoglobin	_	_	O
163	from	_	_	O
164	baseline	_	_	O
165	to	_	_	O
166	Week	_	_	O
167	13	_	_	O
168	.	_	_	O

169	Seven	_	_	O
170	hundred	_	_	O
171	fifty-two	_	_	O
172	patients	_	_	O
173	(	_	_	O
174	374	_	_	O
175	QW	_	_	O
176	patients	_	_	O
177	;	_	_	O
178	378	_	_	O
179	EDS	_	_	O
180	patients	_	_	O
181	)	_	_	O
182	received	_	_	O
183	â‰¥1	_	_	O
184	dose	_	_	O
185	of	_	_	O
186	darbepoetin	_	_	O
187	alfa	_	_	O
188	and	_	_	O
189	were	_	_	O
190	included	_	_	O
191	in	_	_	O
192	the	_	_	O
193	analysis	_	_	O
194	.	_	_	O

195	Demographics	_	_	O
196	and	_	_	O
197	disease	_	_	O
198	state	_	_	O
199	were	_	_	O
200	similar	_	_	O
201	between	_	_	O
202	groups	_	_	O
203	.	_	_	O

204	Seventy-one	_	_	B-Premise
205	percent	_	_	I-Premise
206	of	_	_	I-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	EDS	_	_	I-Premise
211	group	_	_	I-Premise
212	and	_	_	I-Premise
213	76	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	QW	_	_	I-Premise
218	group	_	_	I-Premise
219	achieved	_	_	I-Premise
220	the	_	_	I-Premise
221	target	_	_	I-Premise
222	hemoglobin	_	_	I-Premise
223	of	_	_	I-Premise
224	â‰¥11.0	_	_	I-Premise
225	g/dL	_	_	I-Premise
226	.	_	_	I-Premise

227	There	_	_	O
228	was	_	_	O
229	a	_	_	O
230	minimal	_	_	O
231	difference	_	_	O
232	in	_	_	O
233	the	_	_	O
234	primary	_	_	O
235	endpoint	_	_	O
236	of	_	_	O
237	mean	_	_	O
238	change	_	_	O
239	in	_	_	O
240	hemoglobin	_	_	O
241	(	_	_	O
242	baseline	_	_	O
243	to	_	_	O
244	Week	_	_	O
245	13	_	_	O
246	)	_	_	O
247	between	_	_	O
248	the	_	_	O
249	QW	_	_	O
250	and	_	_	O
251	the	_	_	O
252	EDS	_	_	O
253	groups	_	_	O
254	(	_	_	O
255	-0.04	_	_	O
256	g/dL	_	_	O
257	;	_	_	O
258	95	_	_	O
259	%	_	_	O
260	confidence	_	_	O
261	interval	_	_	O
262	:	_	_	O
263	-0.26	_	_	O
264	,	_	_	O
265	0.17	_	_	O
266	g/dL	_	_	O
267	)	_	_	O
268	.	_	_	O

269	The	_	_	O
270	upper	_	_	O
271	limit	_	_	O
272	of	_	_	O
273	the	_	_	O
274	95	_	_	O
275	%	_	_	O
276	confidence	_	_	O
277	interval	_	_	O
278	was	_	_	O
279	less	_	_	O
280	than	_	_	O
281	the	_	_	O
282	prespecified	_	_	O
283	limit	_	_	O
284	of	_	_	O
285	<	_	_	O
286	0.75	_	_	O
287	g/dL	_	_	O
288	,	_	_	O
289	supporting	_	_	O
290	noninferiority	_	_	O
291	of	_	_	O
292	the	_	_	O
293	EDS	_	_	O
294	dosing	_	_	O
295	schedule	_	_	O
296	.	_	_	O

297	Reported	_	_	B-Premise
298	adverse	_	_	I-Premise
299	events	_	_	I-Premise
300	were	_	_	I-Premise
301	similar	_	_	I-Premise
302	between	_	_	I-Premise
303	groups	_	_	I-Premise
304	.	_	_	I-Premise

305	A	_	_	B-Premise
306	slight	_	_	I-Premise
307	increase	_	_	I-Premise
308	in	_	_	I-Premise
309	transfusions	_	_	I-Premise
310	was	_	_	I-Premise
311	reported	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	QW	_	_	I-Premise
315	group	_	_	I-Premise
316	.	_	_	I-Premise

317	Darbepoetin	_	_	B-Claim
318	alfa	_	_	I-Claim
319	,	_	_	I-Claim
320	when	_	_	I-Claim
321	administered	_	_	I-Claim
322	synchronously	_	_	I-Claim
323	with	_	_	I-Claim
324	chemotherapy	_	_	I-Claim
325	,	_	_	I-Claim
326	on	_	_	I-Claim
327	an	_	_	I-Claim
328	EDS	_	_	I-Claim
329	appears	_	_	I-Claim
330	to	_	_	I-Claim
331	be	_	_	I-Claim
332	similarly	_	_	I-Claim
333	efficacious	_	_	I-Claim
334	to	_	_	I-Claim
335	darbepoetin	_	_	I-Claim
336	alfa	_	_	I-Claim
337	weekly	_	_	I-Claim
338	dosing	_	_	I-Claim
339	with	_	_	I-Claim
340	no	_	_	I-Claim
341	unexpected	_	_	I-Claim
342	adverse	_	_	I-Claim
343	events	_	_	I-Claim
344	.	_	_	I-Claim

345	This	_	_	O
346	study	_	_	O
347	provides	_	_	O
348	prospective	_	_	O
349	data	_	_	O
350	on	_	_	O
351	how	_	_	O
352	multiple	_	_	O
353	dosing	_	_	O
354	regimens	_	_	O
355	available	_	_	O
356	with	_	_	O
357	darbepoetin	_	_	O
358	alfa	_	_	O
359	can	_	_	O
360	be	_	_	O
361	synchronized	_	_	O
362	with	_	_	O
363	chemotherapy	_	_	O
364	administered	_	_	O
365	across	_	_	O
366	a	_	_	O
367	range	_	_	O
368	of	_	_	O
369	dosing	_	_	O
370	schedules	_	_	O
371	.	_	_	O


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	trial	_	_	O
5	evaluated	_	_	O
6	two	_	_	O
7	docetaxel-based	_	_	O
8	regimens	_	_	O
9	to	_	_	O
10	see	_	_	O
11	which	_	_	O
12	would	_	_	O
13	be	_	_	O
14	most	_	_	O
15	promising	_	_	O
16	according	_	_	O
17	to	_	_	O
18	overall	_	_	O
19	response	_	_	O
20	rate	_	_	O
21	(	_	_	O
22	ORR	_	_	O
23	)	_	_	O
24	for	_	_	O
25	comparison	_	_	O
26	in	_	_	O
27	a	_	_	O
28	phase	_	_	O
29	III	_	_	O
30	trial	_	_	O
31	with	_	_	O
32	epirubicin-cisplatin-fluorouracil	_	_	O
33	(	_	_	O
34	ECF	_	_	O
35	)	_	_	O
36	as	_	_	O
37	first-line	_	_	O
38	advanced	_	_	O
39	gastric	_	_	O
40	cancer	_	_	O
41	therapy	_	_	O
42	.	_	_	O

43	Chemotherapy-naÃ¯ve	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	measurable	_	_	O
47	unresectable	_	_	O
48	and/or	_	_	O
49	metastatic	_	_	O
50	gastric	_	_	O
51	carcinoma	_	_	O
52	,	_	_	O
53	a	_	_	O
54	performance	_	_	O
55	status	_	_	O
56	<	_	_	O
57	or=	_	_	O
58	1	_	_	O
59	,	_	_	O
60	and	_	_	O
61	adequate	_	_	O
62	hematologic	_	_	O
63	,	_	_	O
64	hepatic	_	_	O
65	,	_	_	O
66	and	_	_	O
67	renal	_	_	O
68	function	_	_	O
69	randomly	_	_	O
70	received	_	_	O
71	<	_	_	O
72	or=	_	_	O
73	eight	_	_	O
74	3-weekly	_	_	O
75	cycles	_	_	O
76	of	_	_	O
77	ECF	_	_	O
78	(	_	_	O
79	epirubicin	_	_	O
80	50	_	_	O
81	mg/m	_	_	O
82	(	_	_	O
83	2	_	_	O
84	)	_	_	O
85	on	_	_	O
86	day	_	_	O
87	1	_	_	O
88	,	_	_	O
89	cisplatin	_	_	O
90	60	_	_	O
91	mg/m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	on	_	_	O
96	day	_	_	O
97	1	_	_	O
98	,	_	_	O
99	and	_	_	O
100	fluorouracil	_	_	O
101	[	_	_	O
102	FU	_	_	O
103	]	_	_	O
104	200	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	/d	_	_	O
110	on	_	_	O
111	days	_	_	O
112	1	_	_	O
113	to	_	_	O
114	21	_	_	O
115	)	_	_	O
116	,	_	_	O
117	TC	_	_	O
118	(	_	_	O
119	docetaxel	_	_	O
120	initially	_	_	O
121	85	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	on	_	_	O
127	day	_	_	O
128	1	_	_	O
129	[	_	_	O
130	later	_	_	O
131	reduced	_	_	O
132	to	_	_	O
133	75	_	_	O
134	mg/m	_	_	O
135	(	_	_	O
136	2	_	_	O
137	)	_	_	O
138	as	_	_	O
139	a	_	_	O
140	result	_	_	O
141	of	_	_	O
142	toxicity	_	_	O
143	]	_	_	O
144	and	_	_	O
145	cisplatin	_	_	O
146	75	_	_	O
147	mg/m	_	_	O
148	(	_	_	O
149	2	_	_	O
150	)	_	_	O
151	on	_	_	O
152	day	_	_	O
153	1	_	_	O
154	)	_	_	O
155	,	_	_	O
156	or	_	_	O
157	TCF	_	_	O
158	(	_	_	O
159	TC	_	_	O
160	plus	_	_	O
161	FU	_	_	O
162	300	_	_	O
163	mg/m	_	_	O
164	(	_	_	O
165	2	_	_	O
166	)	_	_	O
167	/d	_	_	O
168	on	_	_	O
169	days	_	_	O
170	1	_	_	O
171	to	_	_	O
172	14	_	_	O
173	)	_	_	O
174	.	_	_	O

175	Study	_	_	O
176	objectives	_	_	O
177	included	_	_	O
178	response	_	_	O
179	(	_	_	O
180	primary	_	_	O
181	)	_	_	O
182	,	_	_	O
183	survival	_	_	O
184	,	_	_	O
185	toxicity	_	_	O
186	,	_	_	O
187	and	_	_	O
188	quality	_	_	O
189	of	_	_	O
190	life	_	_	O
191	(	_	_	O
192	QOL	_	_	O
193	)	_	_	O
194	.	_	_	O

195	ORR	_	_	B-Premise
196	was	_	_	I-Premise
197	25.0	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	13	_	_	I-Premise
205	%	_	_	I-Premise
206	to	_	_	I-Premise
207	41	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	for	_	_	I-Premise
211	ECF	_	_	I-Premise
212	,	_	_	I-Premise
213	18.5	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	9	_	_	I-Premise
221	%	_	_	I-Premise
222	to	_	_	I-Premise
223	34	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	for	_	_	I-Premise
227	TC	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	36.6	_	_	I-Premise
231	%	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	23	_	_	I-Premise
238	%	_	_	I-Premise
239	to	_	_	I-Premise
240	53	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	for	_	_	I-Premise
244	TCF	_	_	I-Premise
245	(	_	_	I-Premise
246	n	_	_	I-Premise
247	=	_	_	I-Premise
248	119	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Median	_	_	B-Premise
252	overall	_	_	I-Premise
253	survival	_	_	I-Premise
254	times	_	_	I-Premise
255	were	_	_	I-Premise
256	8.3	_	_	I-Premise
257	,	_	_	I-Premise
258	11.0	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	10.4	_	_	I-Premise
262	months	_	_	I-Premise
263	for	_	_	I-Premise
264	ECF	_	_	I-Premise
265	,	_	_	I-Premise
266	TC	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	TCF	_	_	I-Premise
270	,	_	_	I-Premise
271	respectively	_	_	I-Premise
272	.	_	_	I-Premise

273	Toxicity	_	_	B-Premise
274	was	_	_	I-Premise
275	acceptable	_	_	I-Premise
276	,	_	_	I-Premise
277	with	_	_	I-Premise
278	one	_	_	I-Premise
279	toxic	_	_	I-Premise
280	death	_	_	I-Premise
281	(	_	_	I-Premise
282	TC	_	_	I-Premise
283	arm	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	Grade	_	_	B-Premise
287	3	_	_	I-Premise
288	or	_	_	I-Premise
289	4	_	_	I-Premise
290	neutropenia	_	_	I-Premise
291	occurred	_	_	I-Premise
292	in	_	_	I-Premise
293	more	_	_	I-Premise
294	treatment	_	_	I-Premise
295	cycles	_	_	I-Premise
296	with	_	_	I-Premise
297	docetaxel	_	_	I-Premise
298	(	_	_	I-Premise
299	TC	_	_	I-Premise
300	,	_	_	I-Premise
301	49	_	_	I-Premise
302	%	_	_	I-Premise
303	;	_	_	I-Premise
304	TCF	_	_	I-Premise
305	,	_	_	I-Premise
306	57	_	_	I-Premise
307	%	_	_	I-Premise
308	;	_	_	I-Premise
309	ECF	_	_	I-Premise
310	,	_	_	I-Premise
311	34	_	_	I-Premise
312	%	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	Global	_	_	B-Claim
316	health	_	_	I-Claim
317	status/QOL	_	_	I-Claim
318	substantially	_	_	I-Claim
319	improved	_	_	I-Claim
320	with	_	_	I-Claim
321	ECF	_	_	I-Claim
322	and	_	_	I-Claim
323	remained	_	_	I-Claim
324	similar	_	_	I-Claim
325	to	_	_	I-Claim
326	baseline	_	_	I-Claim
327	with	_	_	I-Claim
328	both	_	_	I-Claim
329	docetaxel	_	_	I-Claim
330	regimens	_	_	I-Claim
331	.	_	_	I-Claim

332	Time	_	_	B-Premise
333	to	_	_	I-Premise
334	response	_	_	I-Premise
335	and	_	_	I-Premise
336	ORR	_	_	I-Premise
337	favor	_	_	I-Premise
338	TCF	_	_	I-Premise
339	over	_	_	I-Premise
340	TC	_	_	I-Premise
341	for	_	_	I-Premise
342	further	_	_	I-Premise
343	evaluation	_	_	I-Premise
344	,	_	_	I-Premise
345	particularly	_	_	I-Premise
346	in	_	_	I-Premise
347	the	_	_	I-Premise
348	neoadjuvant	_	_	I-Premise
349	setting	_	_	I-Premise
350	.	_	_	I-Premise

351	A	_	_	B-Premise
352	trend	_	_	I-Premise
353	towards	_	_	I-Premise
354	increased	_	_	I-Premise
355	myelosuppression	_	_	I-Premise
356	and	_	_	I-Premise
357	infectious	_	_	I-Premise
358	complications	_	_	I-Premise
359	with	_	_	I-Premise
360	TCF	_	_	I-Premise
361	versus	_	_	I-Premise
362	TC	_	_	I-Premise
363	or	_	_	I-Premise
364	ECF	_	_	I-Premise
365	was	_	_	I-Premise
366	observed	_	_	I-Premise
367	.	_	_	I-Premise


0	Increased	_	_	O
1	attention	_	_	O
2	has	_	_	O
3	focused	_	_	O
4	on	_	_	O
5	exercise	_	_	O
6	as	_	_	O
7	a	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	intervention	_	_	O
12	for	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	during	_	_	O
17	and	_	_	O
18	after	_	_	O
19	adjuvant	_	_	O
20	therapy	_	_	O
21	.	_	_	O

22	Our	_	_	O
23	objective	_	_	O
24	was	_	_	O
25	to	_	_	O
26	examine	_	_	O
27	the	_	_	O
28	effects	_	_	O
29	of	_	_	O
30	an	_	_	O
31	oncologist	_	_	O
32	's	_	_	O
33	recommendation	_	_	O
34	to	_	_	O
35	exercise	_	_	O
36	on	_	_	O
37	self-reported	_	_	O
38	exercise	_	_	O
39	behavior	_	_	O
40	in	_	_	O
41	newly	_	_	O
42	diagnosed	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	attending	_	_	O
47	their	_	_	O
48	first	_	_	O
49	adjuvant	_	_	O
50	therapy	_	_	O
51	consultation	_	_	O
52	.	_	_	O

53	Using	_	_	O
54	a	_	_	O
55	single-blinded	_	_	O
56	,	_	_	O
57	3-armed	_	_	O
58	,	_	_	O
59	randomized	_	_	O
60	controlled	_	_	O
61	trial	_	_	O
62	,	_	_	O
63	450	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	survivors	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	an	_	_	O
73	oncologist	_	_	O
74	exercise	_	_	O
75	recommendation	_	_	O
76	only	_	_	O
77	,	_	_	O
78	an	_	_	O
79	oncologist	_	_	O
80	exercise	_	_	O
81	recommendation	_	_	O
82	plus	_	_	O
83	referral	_	_	O
84	to	_	_	O
85	an	_	_	O
86	exercise	_	_	O
87	specialist	_	_	O
88	,	_	_	O
89	or	_	_	O
90	usual	_	_	O
91	care	_	_	O
92	.	_	_	O

93	The	_	_	O
94	primary	_	_	O
95	outcome	_	_	O
96	was	_	_	O
97	self-reported	_	_	O
98	total	_	_	O
99	exercise	_	_	O
100	(	_	_	O
101	in	_	_	O
102	metabolic	_	_	O
103	equivalent	_	_	O
104	[	_	_	O
105	MET	_	_	O
106	]	_	_	O
107	hours	_	_	O
108	per	_	_	O
109	week	_	_	O
110	)	_	_	O
111	at	_	_	O
112	5	_	_	O
113	weeks	_	_	O
114	postconsultation	_	_	O
115	.	_	_	O

116	The	_	_	O
117	follow-up	_	_	O
118	assessment	_	_	O
119	rate	_	_	O
120	was	_	_	O
121	73	_	_	O
122	%	_	_	O
123	(	_	_	O
124	329	_	_	O
125	of	_	_	O
126	450	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Intention-to-treat	_	_	B-Premise
130	analysis	_	_	I-Premise
131	based	_	_	I-Premise
132	on	_	_	I-Premise
133	participants	_	_	I-Premise
134	with	_	_	I-Premise
135	follow-up	_	_	I-Premise
136	data	_	_	I-Premise
137	indicated	_	_	I-Premise
138	a	_	_	I-Premise
139	significant	_	_	I-Premise
140	difference	_	_	I-Premise
141	in	_	_	I-Premise
142	total	_	_	I-Premise
143	exercise	_	_	I-Premise
144	in	_	_	I-Premise
145	favor	_	_	I-Premise
146	of	_	_	I-Premise
147	the	_	_	I-Premise
148	recommendation-only	_	_	I-Premise
149	group	_	_	I-Premise
150	over	_	_	I-Premise
151	the	_	_	I-Premise
152	usual	_	_	I-Premise
153	care	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	mean	_	_	I-Premise
157	difference	_	_	I-Premise
158	,	_	_	I-Premise
159	3.4	_	_	I-Premise
160	MET	_	_	I-Premise
161	hr	_	_	I-Premise
162	per	_	_	I-Premise
163	week	_	_	I-Premise
164	;	_	_	I-Premise
165	95	_	_	I-Premise
166	%	_	_	I-Premise
167	confidence	_	_	I-Premise
168	interval	_	_	I-Premise
169	[	_	_	I-Premise
170	CI	_	_	I-Premise
171	]	_	_	I-Premise
172	,	_	_	I-Premise
173	0.7-6.1	_	_	I-Premise
174	MET	_	_	I-Premise
175	hr	_	_	I-Premise
176	per	_	_	I-Premise
177	week	_	_	I-Premise
178	;	_	_	I-Premise
179	p	_	_	I-Premise
180	=	_	_	I-Premise
181	.011	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	There	_	_	B-Premise
185	was	_	_	I-Premise
186	no	_	_	I-Premise
187	significant	_	_	I-Premise
188	difference	_	_	I-Premise
189	between	_	_	I-Premise
190	the	_	_	I-Premise
191	recommendation-plus-referral	_	_	I-Premise
192	group	_	_	I-Premise
193	and	_	_	I-Premise
194	the	_	_	I-Premise
195	usual	_	_	I-Premise
196	care	_	_	I-Premise
197	group	_	_	I-Premise
198	(	_	_	I-Premise
199	mean	_	_	I-Premise
200	difference	_	_	I-Premise
201	,	_	_	I-Premise
202	1.5	_	_	I-Premise
203	MET	_	_	I-Premise
204	hr	_	_	I-Premise
205	per	_	_	I-Premise
206	week	_	_	I-Premise
207	;	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	-1.0	_	_	I-Premise
213	to	_	_	I-Premise
214	4.0	_	_	I-Premise
215	MET	_	_	I-Premise
216	hr	_	_	I-Premise
217	per	_	_	I-Premise
218	week	_	_	I-Premise
219	;	_	_	I-Premise
220	p	_	_	I-Premise
221	=	_	_	I-Premise
222	.244	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Ancillary	_	_	B-Premise
226	"	_	_	I-Premise
227	on-treatment	_	_	I-Premise
228	"	_	_	I-Premise
229	analyzes	_	_	I-Premise
230	showed	_	_	I-Premise
231	that	_	_	I-Premise
232	participants	_	_	I-Premise
233	who	_	_	I-Premise
234	recalled	_	_	I-Premise
235	an	_	_	I-Premise
236	exercise	_	_	I-Premise
237	recommendation	_	_	I-Premise
238	reported	_	_	I-Premise
239	significantly	_	_	I-Premise
240	more	_	_	I-Premise
241	total	_	_	I-Premise
242	exercise	_	_	I-Premise
243	than	_	_	I-Premise
244	participants	_	_	I-Premise
245	who	_	_	I-Premise
246	did	_	_	I-Premise
247	not	_	_	I-Premise
248	recall	_	_	I-Premise
249	an	_	_	I-Premise
250	exercise	_	_	I-Premise
251	recommendation	_	_	I-Premise
252	(	_	_	I-Premise
253	mean	_	_	I-Premise
254	difference	_	_	I-Premise
255	,	_	_	I-Premise
256	4.1	_	_	I-Premise
257	MET	_	_	I-Premise
258	hr	_	_	I-Premise
259	per	_	_	I-Premise
260	week	_	_	I-Premise
261	:	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	,	_	_	I-Premise
266	1.9-6.4	_	_	I-Premise
267	MET	_	_	I-Premise
268	hr	_	_	I-Premise
269	per	_	_	I-Premise
270	week	_	_	I-Premise
271	;	_	_	I-Premise
272	p	_	_	I-Premise
273	<	_	_	I-Premise
274	.001	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Our	_	_	B-Claim
278	findings	_	_	I-Claim
279	suggest	_	_	I-Claim
280	that	_	_	I-Claim
281	an	_	_	I-Claim
282	oncologist	_	_	I-Claim
283	recommendation	_	_	I-Claim
284	may	_	_	I-Claim
285	increase	_	_	I-Claim
286	exercise	_	_	I-Claim
287	behavior	_	_	I-Claim
288	in	_	_	I-Claim
289	newly	_	_	I-Claim
290	diagnosed	_	_	I-Claim
291	breast	_	_	I-Claim
292	cancer	_	_	I-Claim
293	survivors	_	_	I-Claim
294	,	_	_	I-Claim
295	particularly	_	_	I-Claim
296	if	_	_	I-Claim
297	it	_	_	I-Claim
298	is	_	_	I-Claim
299	recalled	_	_	I-Claim
300	1	_	_	I-Claim
301	week	_	_	I-Claim
302	after	_	_	I-Claim
303	the	_	_	I-Claim
304	recommendation	_	_	I-Claim
305	.	_	_	I-Claim


0	Research	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	self-directed	_	_	O
5	stress	_	_	O
6	management	_	_	O
7	training	_	_	O
8	improves	_	_	O
9	mental	_	_	O
10	well-being	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	chemotherapy	_	_	O
15	.	_	_	O

16	The	_	_	O
17	present	_	_	O
18	study	_	_	O
19	extends	_	_	O
20	this	_	_	O
21	work	_	_	O
22	by	_	_	O
23	evaluating	_	_	O
24	separate	_	_	O
25	and	_	_	O
26	combined	_	_	O
27	effects	_	_	O
28	of	_	_	O
29	stress	_	_	O
30	management	_	_	O
31	training	_	_	O
32	and	_	_	O
33	home-based	_	_	O
34	exercise	_	_	O
35	.	_	_	O

36	Following	_	_	O
37	assessment	_	_	O
38	of	_	_	O
39	mental	_	_	O
40	and	_	_	O
41	physical	_	_	O
42	well-being	_	_	O
43	,	_	_	O
44	depression	_	_	O
45	,	_	_	O
46	anxiety	_	_	O
47	,	_	_	O
48	exercise	_	_	O
49	,	_	_	O
50	and	_	_	O
51	stress	_	_	O
52	reduction	_	_	O
53	activity	_	_	O
54	before	_	_	O
55	chemotherapy	_	_	O
56	started	_	_	O
57	,	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	stress	_	_	O
63	management	_	_	O
64	training	_	_	O
65	(	_	_	O
66	SM	_	_	O
67	)	_	_	O
68	,	_	_	O
69	exercise	_	_	O
70	(	_	_	O
71	EX	_	_	O
72	)	_	_	O
73	,	_	_	O
74	combined	_	_	O
75	stress	_	_	O
76	management	_	_	O
77	and	_	_	O
78	exercise	_	_	O
79	(	_	_	O
80	SMEX	_	_	O
81	)	_	_	O
82	,	_	_	O
83	or	_	_	O
84	usual	_	_	O
85	care	_	_	O
86	only	_	_	O
87	(	_	_	O
88	UCO	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Outcomes	_	_	O
92	were	_	_	O
93	reassessed	_	_	O
94	6	_	_	O
95	and	_	_	O
96	12	_	_	O
97	weeks	_	_	O
98	after	_	_	O
99	chemotherapy	_	_	O
100	started	_	_	O
101	.	_	_	O

102	Significance	_	_	O
103	testing	_	_	O
104	of	_	_	O
105	group-by-time	_	_	O
106	interactions	_	_	O
107	in	_	_	O
108	286	_	_	O
109	patients	_	_	O
110	who	_	_	O
111	completed	_	_	O
112	all	_	_	O
113	assessments	_	_	O
114	was	_	_	O
115	used	_	_	O
116	to	_	_	O
117	evaluate	_	_	O
118	intervention	_	_	O
119	efficacy	_	_	O
120	.	_	_	O

121	Interaction	_	_	B-Premise
122	effects	_	_	I-Premise
123	for	_	_	I-Premise
124	mental	_	_	I-Premise
125	and	_	_	I-Premise
126	physical	_	_	I-Premise
127	well-being	_	_	I-Premise
128	scores	_	_	I-Premise
129	were	_	_	I-Premise
130	not	_	_	I-Premise
131	significant	_	_	I-Premise
132	.	_	_	I-Premise

133	Depression	_	_	B-Premise
134	scores	_	_	I-Premise
135	yielded	_	_	I-Premise
136	a	_	_	I-Premise
137	linear	_	_	I-Premise
138	interaction	_	_	I-Premise
139	comparing	_	_	I-Premise
140	UCO	_	_	I-Premise
141	and	_	_	I-Premise
142	SMEX	_	_	I-Premise
143	(	_	_	I-Premise
144	p	_	_	I-Premise
145	=	_	_	I-Premise
146	0.019	_	_	I-Premise
147	)	_	_	I-Premise
148	,	_	_	I-Premise
149	with	_	_	I-Premise
150	decreases	_	_	I-Premise
151	in	_	_	I-Premise
152	SMEX	_	_	I-Premise
153	but	_	_	I-Premise
154	not	_	_	I-Premise
155	UCO	_	_	I-Premise
156	.	_	_	I-Premise

157	Anxiety	_	_	B-Premise
158	scores	_	_	I-Premise
159	yielded	_	_	I-Premise
160	a	_	_	I-Premise
161	quadratic	_	_	I-Premise
162	interaction	_	_	I-Premise
163	comparing	_	_	I-Premise
164	UCO	_	_	I-Premise
165	and	_	_	I-Premise
166	SMEX	_	_	I-Premise
167	(	_	_	I-Premise
168	p	_	_	I-Premise
169	=	_	_	I-Premise
170	0.049	_	_	I-Premise
171	)	_	_	I-Premise
172	,	_	_	I-Premise
173	with	_	_	I-Premise
174	trends	_	_	I-Premise
175	for	_	_	I-Premise
176	changes	_	_	I-Premise
177	in	_	_	I-Premise
178	SMEX	_	_	I-Premise
179	but	_	_	I-Premise
180	not	_	_	I-Premise
181	UCO	_	_	I-Premise
182	.	_	_	I-Premise

183	Additional	_	_	B-Premise
184	analyses	_	_	I-Premise
185	yielded	_	_	I-Premise
186	quadratic	_	_	I-Premise
187	interactions	_	_	I-Premise
188	for	_	_	I-Premise
189	exercise	_	_	I-Premise
190	activity	_	_	I-Premise
191	comparing	_	_	I-Premise
192	UCO	_	_	I-Premise
193	and	_	_	I-Premise
194	SMEX	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	=	_	_	I-Premise
198	0.022	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	with	_	_	I-Premise
202	positive	_	_	I-Premise
203	changes	_	_	I-Premise
204	in	_	_	I-Premise
205	SMEX	_	_	I-Premise
206	but	_	_	I-Premise
207	not	_	_	I-Premise
208	UCO	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	for	_	_	I-Premise
212	stress	_	_	I-Premise
213	management	_	_	I-Premise
214	activity	_	_	I-Premise
215	comparing	_	_	I-Premise
216	UCO	_	_	I-Premise
217	and	_	_	I-Premise
218	SM	_	_	I-Premise
219	(	_	_	I-Premise
220	p	_	_	I-Premise
221	<	_	_	I-Premise
222	0.001	_	_	I-Premise
223	)	_	_	I-Premise
224	and	_	_	I-Premise
225	UCO	_	_	I-Premise
226	and	_	_	I-Premise
227	SMEX	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.013	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	with	_	_	I-Premise
235	positive	_	_	I-Premise
236	changes	_	_	I-Premise
237	in	_	_	I-Premise
238	SM	_	_	I-Premise
239	and	_	_	I-Premise
240	SMEX	_	_	I-Premise
241	but	_	_	I-Premise
242	not	_	_	I-Premise
243	UCO	_	_	I-Premise
244	.	_	_	I-Premise

245	Only	_	_	B-Claim
246	the	_	_	I-Claim
247	combined	_	_	I-Claim
248	intervention	_	_	I-Claim
249	yielded	_	_	I-Claim
250	effects	_	_	I-Claim
251	on	_	_	I-Claim
252	quality	_	_	I-Claim
253	of	_	_	I-Claim
254	life	_	_	I-Claim
255	outcomes	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	these	_	_	I-Claim
259	were	_	_	I-Claim
260	limited	_	_	I-Claim
261	to	_	_	I-Claim
262	anxiety	_	_	I-Claim
263	and	_	_	I-Claim
264	depression	_	_	I-Claim
265	.	_	_	I-Claim

266	These	_	_	B-Premise
267	findings	_	_	I-Premise
268	are	_	_	I-Premise
269	consistent	_	_	I-Premise
270	with	_	_	I-Premise
271	evidence	_	_	I-Premise
272	that	_	_	I-Premise
273	only	_	_	I-Premise
274	the	_	_	I-Premise
275	combined	_	_	I-Premise
276	intervention	_	_	I-Premise
277	yielded	_	_	I-Premise
278	increases	_	_	I-Premise
279	in	_	_	I-Premise
280	both	_	_	I-Premise
281	exercise	_	_	I-Premise
282	and	_	_	I-Premise
283	stress	_	_	I-Premise
284	management	_	_	I-Premise
285	activity	_	_	I-Premise
286	.	_	_	I-Premise

287	Future	_	_	O
288	research	_	_	O
289	should	_	_	O
290	investigate	_	_	O
291	ways	_	_	O
292	to	_	_	O
293	augment	_	_	O
294	this	_	_	O
295	intervention	_	_	O
296	to	_	_	O
297	enhance	_	_	O
298	its	_	_	O
299	benefits	_	_	O
300	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	outcome	_	_	O
5	and	_	_	O
6	health-related	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	(	_	_	O
11	HRQL	_	_	O
12	)	_	_	O
13	of	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	endometrial	_	_	O
17	carcinoma	_	_	O
18	(	_	_	O
19	EC	_	_	O
20	)	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	or	_	_	O
24	without	_	_	O
25	pelvic	_	_	O
26	radiotherapy	_	_	O
27	in	_	_	O
28	the	_	_	O
29	Post	_	_	O
30	Operative	_	_	O
31	Radiation	_	_	O
32	Therapy	_	_	O
33	in	_	_	O
34	Endometrial	_	_	O
35	Carcinoma	_	_	O
36	1	_	_	O
37	(	_	_	O
38	PORTEC-1	_	_	O
39	)	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Between	_	_	O
43	1990	_	_	O
44	and	_	_	O
45	1997	_	_	O
46	,	_	_	O
47	714	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	stage	_	_	O
51	IC	_	_	O
52	grade	_	_	O
53	1	_	_	O
54	to	_	_	O
55	2	_	_	O
56	or	_	_	O
57	IB	_	_	O
58	grade	_	_	O
59	2	_	_	O
60	to	_	_	O
61	3	_	_	O
62	EC	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	allocated	_	_	O
66	to	_	_	O
67	pelvic	_	_	O
68	external-beam	_	_	O
69	radiotherapy	_	_	O
70	(	_	_	O
71	EBRT	_	_	O
72	)	_	_	O
73	or	_	_	O
74	no	_	_	O
75	additional	_	_	O
76	treatment	_	_	O
77	(	_	_	O
78	NAT	_	_	O
79	)	_	_	O
80	.	_	_	O

81	HRQL	_	_	O
82	was	_	_	O
83	evaluated	_	_	O
84	with	_	_	O
85	the	_	_	O
86	Short	_	_	O
87	Form	_	_	O
88	36-Item	_	_	O
89	(	_	_	O
90	SF-36	_	_	O
91	)	_	_	O
92	questionnaire	_	_	O
93	;	_	_	O
94	subscales	_	_	O
95	from	_	_	O
96	the	_	_	O
97	European	_	_	O
98	Organisation	_	_	O
99	for	_	_	O
100	Research	_	_	O
101	and	_	_	O
102	Treatment	_	_	O
103	of	_	_	O
104	Cancer	_	_	O
105	(	_	_	O
106	EORTC	_	_	O
107	)	_	_	O
108	PR25	_	_	O
109	module	_	_	O
110	for	_	_	O
111	bowel	_	_	O
112	and	_	_	O
113	bladder	_	_	O
114	symptoms	_	_	O
115	and	_	_	O
116	the	_	_	O
117	OV28	_	_	O
118	and	_	_	O
119	CX24	_	_	O
120	modules	_	_	O
121	for	_	_	O
122	sexual	_	_	O
123	symptoms	_	_	O
124	;	_	_	O
125	and	_	_	O
126	demographic	_	_	O
127	questions	_	_	O
128	.	_	_	O

129	Analysis	_	_	O
130	was	_	_	O
131	by	_	_	O
132	intention-to-treat	_	_	O
133	.	_	_	O

134	Median	_	_	O
135	follow-up	_	_	O
136	was	_	_	O
137	13.3	_	_	O
138	years	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	15-year	_	_	I-Premise
142	actuarial	_	_	I-Premise
143	locoregional	_	_	I-Premise
144	recurrence	_	_	I-Premise
145	rates	_	_	I-Premise
146	were	_	_	I-Premise
147	5.8	_	_	I-Premise
148	%	_	_	I-Premise
149	for	_	_	I-Premise
150	EBRT	_	_	I-Premise
151	versus	_	_	I-Premise
152	15.5	_	_	I-Premise
153	%	_	_	I-Premise
154	for	_	_	I-Premise
155	NAT	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	.001	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	and	_	_	I-Premise
163	15-year	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	was	_	_	I-Premise
167	52	_	_	I-Premise
168	%	_	_	I-Premise
169	versus	_	_	I-Premise
170	60	_	_	I-Premise
171	%	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.14	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Of	_	_	O
179	the	_	_	O
180	351	_	_	O
181	patients	_	_	O
182	confirmed	_	_	O
183	to	_	_	O
184	be	_	_	O
185	alive	_	_	O
186	with	_	_	O
187	correct	_	_	O
188	address	_	_	O
189	,	_	_	O
190	246	_	_	O
191	(	_	_	O
192	70	_	_	O
193	%	_	_	O
194	)	_	_	O
195	returned	_	_	O
196	the	_	_	O
197	questionnaire	_	_	O
198	.	_	_	O

199	Patients	_	_	B-Premise
200	treated	_	_	I-Premise
201	with	_	_	I-Premise
202	EBRT	_	_	I-Premise
203	reported	_	_	I-Premise
204	significant	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.01	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	clinically	_	_	I-Premise
212	relevant	_	_	I-Premise
213	higher	_	_	I-Premise
214	rates	_	_	I-Premise
215	of	_	_	I-Premise
216	urinary	_	_	I-Premise
217	incontinence	_	_	I-Premise
218	,	_	_	I-Premise
219	diarrhea	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	fecal	_	_	I-Premise
223	leakage	_	_	I-Premise
224	leading	_	_	I-Premise
225	to	_	_	I-Premise
226	more	_	_	I-Premise
227	limitations	_	_	I-Premise
228	in	_	_	I-Premise
229	daily	_	_	I-Premise
230	activities	_	_	I-Premise
231	.	_	_	I-Premise

232	Increased	_	_	B-Premise
233	symptoms	_	_	I-Premise
234	were	_	_	I-Premise
235	reflected	_	_	I-Premise
236	by	_	_	I-Premise
237	the	_	_	I-Premise
238	frequent	_	_	I-Premise
239	use	_	_	I-Premise
240	of	_	_	I-Premise
241	incontinence	_	_	I-Premise
242	materials	_	_	I-Premise
243	after	_	_	I-Premise
244	EBRT	_	_	I-Premise
245	(	_	_	I-Premise
246	day	_	_	I-Premise
247	and	_	_	I-Premise
248	night	_	_	I-Premise
249	use	_	_	I-Premise
250	,	_	_	I-Premise
251	42.9	_	_	I-Premise
252	%	_	_	I-Premise
253	v	_	_	I-Premise
254	15.2	_	_	I-Premise
255	%	_	_	I-Premise
256	for	_	_	I-Premise
257	NAT	_	_	I-Premise
258	;	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	.001	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Patients	_	_	B-Premise
265	treated	_	_	I-Premise
266	with	_	_	I-Premise
267	EBRT	_	_	I-Premise
268	reported	_	_	I-Premise
269	lower	_	_	I-Premise
270	scores	_	_	I-Premise
271	on	_	_	I-Premise
272	the	_	_	I-Premise
273	SF-36	_	_	I-Premise
274	scales	_	_	I-Premise
275	"	_	_	I-Premise
276	physical	_	_	I-Premise
277	functioning	_	_	I-Premise
278	"	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	.004	_	_	I-Premise
283	)	_	_	I-Premise
284	and	_	_	I-Premise
285	"	_	_	I-Premise
286	role-physical	_	_	I-Premise
287	"	_	_	I-Premise
288	(	_	_	I-Premise
289	P	_	_	I-Premise
290	=	_	_	I-Premise
291	.003	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	EBRT	_	_	B-Claim
295	for	_	_	I-Claim
296	endometrial	_	_	I-Claim
297	cancer	_	_	I-Claim
298	is	_	_	I-Claim
299	associated	_	_	I-Claim
300	with	_	_	I-Claim
301	long-term	_	_	I-Claim
302	urinary	_	_	I-Claim
303	and	_	_	I-Claim
304	bowel	_	_	I-Claim
305	symptoms	_	_	I-Claim
306	and	_	_	I-Claim
307	lower	_	_	I-Claim
308	physical	_	_	I-Claim
309	and	_	_	I-Claim
310	role-physical	_	_	I-Claim
311	functioning	_	_	I-Claim
312	,	_	_	I-Claim
313	even	_	_	I-Claim
314	15	_	_	I-Claim
315	years	_	_	I-Claim
316	after	_	_	I-Claim
317	treatment	_	_	I-Claim
318	.	_	_	I-Claim

319	Despite	_	_	B-Claim
320	its	_	_	I-Claim
321	efficacy	_	_	I-Claim
322	in	_	_	I-Claim
323	reducing	_	_	I-Claim
324	locoregional	_	_	I-Claim
325	recurrence	_	_	I-Claim
326	,	_	_	I-Claim
327	EBRT	_	_	I-Claim
328	should	_	_	I-Claim
329	be	_	_	I-Claim
330	avoided	_	_	I-Claim
331	in	_	_	I-Claim
332	patients	_	_	I-Claim
333	with	_	_	I-Claim
334	low-	_	_	I-Claim
335	and	_	_	I-Claim
336	intermediate-risk	_	_	I-Claim
337	EC	_	_	I-Claim
338	.	_	_	I-Claim


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	psychotherapeutic	_	_	O
4	support	_	_	O
5	on	_	_	O
6	survival	_	_	O
7	for	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastrointestinal	_	_	O
11	cancer	_	_	O
12	undergoing	_	_	O
13	surgery	_	_	O
14	was	_	_	O
15	studied	_	_	O
16	.	_	_	O

17	A	_	_	O
18	randomized	_	_	O
19	controlled	_	_	O
20	trial	_	_	O
21	was	_	_	O
22	conducted	_	_	O
23	in	_	_	O
24	cooperation	_	_	O
25	with	_	_	O
26	the	_	_	O
27	Departments	_	_	O
28	of	_	_	O
29	General	_	_	O
30	Surgery	_	_	O
31	and	_	_	O
32	Medical	_	_	O
33	Psychology	_	_	O
34	,	_	_	O
35	University	_	_	O
36	Hospital	_	_	O
37	of	_	_	O
38	Hamburg	_	_	O
39	,	_	_	O
40	Germany	_	_	O
41	,	_	_	O
42	from	_	_	O
43	January	_	_	O
44	1991	_	_	O
45	to	_	_	O
46	January	_	_	O
47	1993	_	_	O
48	.	_	_	O

49	Consenting	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	N	_	_	O
53	=	_	_	O
54	271	_	_	O
55	)	_	_	O
56	with	_	_	O
57	a	_	_	O
58	preliminary	_	_	O
59	diagnosis	_	_	O
60	of	_	_	O
61	cancer	_	_	O
62	of	_	_	O
63	the	_	_	O
64	esophagus	_	_	O
65	,	_	_	O
66	stomach	_	_	O
67	,	_	_	O
68	liver/gallbladder	_	_	O
69	,	_	_	O
70	pancreas	_	_	O
71	,	_	_	O
72	or	_	_	O
73	colon/rectum	_	_	O
74	were	_	_	O
75	stratified	_	_	O
76	by	_	_	O
77	sex	_	_	O
78	and	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	a	_	_	O
83	control	_	_	O
84	group	_	_	O
85	that	_	_	O
86	received	_	_	O
87	standard	_	_	O
88	care	_	_	O
89	as	_	_	O
90	provided	_	_	O
91	on	_	_	O
92	the	_	_	O
93	surgical	_	_	O
94	wards	_	_	O
95	,	_	_	O
96	or	_	_	O
97	to	_	_	O
98	an	_	_	O
99	experimental	_	_	O
100	group	_	_	O
101	that	_	_	O
102	received	_	_	O
103	formal	_	_	O
104	psychotherapeutic	_	_	O
105	support	_	_	O
106	in	_	_	O
107	addition	_	_	O
108	to	_	_	O
109	routine	_	_	O
110	care	_	_	O
111	during	_	_	O
112	the	_	_	O
113	hospital	_	_	O
114	stay	_	_	O
115	.	_	_	O

116	From	_	_	O
117	June	_	_	O
118	2003	_	_	O
119	to	_	_	O
120	December	_	_	O
121	2003	_	_	O
122	,	_	_	O
123	the	_	_	O
124	10-year	_	_	O
125	follow-up	_	_	O
126	was	_	_	O
127	conducted	_	_	O
128	.	_	_	O

129	Survival	_	_	O
130	status	_	_	O
131	for	_	_	O
132	all	_	_	O
133	patients	_	_	O
134	was	_	_	O
135	determined	_	_	O
136	from	_	_	O
137	our	_	_	O
138	own	_	_	O
139	records	_	_	O
140	and	_	_	O
141	from	_	_	O
142	three	_	_	O
143	external	_	_	O
144	sources	_	_	O
145	:	_	_	O
146	the	_	_	O
147	Hamburg	_	_	O
148	cancer	_	_	O
149	registry	_	_	O
150	,	_	_	O
151	family	_	_	O
152	doctors	_	_	O
153	,	_	_	O
154	and	_	_	O
155	the	_	_	O
156	general	_	_	O
157	citizen	_	_	O
158	registration	_	_	O
159	offices	_	_	O
160	.	_	_	O

161	Kaplan-Meier	_	_	B-Premise
162	survival	_	_	I-Premise
163	curves	_	_	I-Premise
164	demonstrated	_	_	I-Premise
165	better	_	_	I-Premise
166	survival	_	_	I-Premise
167	for	_	_	I-Premise
168	the	_	_	I-Premise
169	experimental	_	_	I-Premise
170	group	_	_	I-Premise
171	than	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	.	_	_	I-Premise

176	The	_	_	B-Premise
177	unadjusted	_	_	I-Premise
178	significance	_	_	I-Premise
179	level	_	_	I-Premise
180	for	_	_	I-Premise
181	group	_	_	I-Premise
182	differences	_	_	I-Premise
183	was	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.0006	_	_	I-Premise
187	for	_	_	I-Premise
188	survival	_	_	I-Premise
189	to	_	_	I-Premise
190	10	_	_	I-Premise
191	years	_	_	I-Premise
192	.	_	_	I-Premise

193	Cox	_	_	B-Premise
194	regression	_	_	I-Premise
195	models	_	_	I-Premise
196	that	_	_	I-Premise
197	took	_	_	I-Premise
198	TNM	_	_	I-Premise
199	staging	_	_	I-Premise
200	or	_	_	I-Premise
201	the	_	_	I-Premise
202	residual	_	_	I-Premise
203	tumor	_	_	I-Premise
204	classification	_	_	I-Premise
205	and	_	_	I-Premise
206	tumor	_	_	I-Premise
207	site	_	_	I-Premise
208	into	_	_	I-Premise
209	account	_	_	I-Premise
210	also	_	_	I-Premise
211	found	_	_	I-Premise
212	significant	_	_	I-Premise
213	differences	_	_	I-Premise
214	at	_	_	I-Premise
215	10	_	_	I-Premise
216	years	_	_	I-Premise
217	.	_	_	I-Premise

218	Secondary	_	_	B-Premise
219	analyses	_	_	I-Premise
220	found	_	_	I-Premise
221	that	_	_	I-Premise
222	differences	_	_	I-Premise
223	in	_	_	I-Premise
224	favor	_	_	I-Premise
225	of	_	_	I-Premise
226	the	_	_	I-Premise
227	experimental	_	_	I-Premise
228	group	_	_	I-Premise
229	occurred	_	_	I-Premise
230	in	_	_	I-Premise
231	patients	_	_	I-Premise
232	with	_	_	I-Premise
233	stomach	_	_	I-Premise
234	,	_	_	I-Premise
235	pancreatic	_	_	I-Premise
236	,	_	_	I-Premise
237	primary	_	_	I-Premise
238	liver	_	_	I-Premise
239	,	_	_	I-Premise
240	or	_	_	I-Premise
241	colorectal	_	_	I-Premise
242	cancer	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Claim
245	results	_	_	I-Claim
246	of	_	_	I-Claim
247	this	_	_	I-Claim
248	study	_	_	I-Claim
249	indicate	_	_	I-Claim
250	that	_	_	I-Claim
251	patients	_	_	I-Claim
252	with	_	_	I-Claim
253	gastrointestinal	_	_	I-Claim
254	cancer	_	_	I-Claim
255	,	_	_	I-Claim
256	who	_	_	I-Claim
257	undergo	_	_	I-Claim
258	surgery	_	_	I-Claim
259	for	_	_	I-Claim
260	stomach	_	_	I-Claim
261	,	_	_	I-Claim
262	pancreatic	_	_	I-Claim
263	,	_	_	I-Claim
264	primary	_	_	I-Claim
265	liver	_	_	I-Claim
266	,	_	_	I-Claim
267	or	_	_	I-Claim
268	colorectal	_	_	I-Claim
269	cancer	_	_	I-Claim
270	,	_	_	I-Claim
271	benefit	_	_	I-Claim
272	from	_	_	I-Claim
273	a	_	_	I-Claim
274	formal	_	_	I-Claim
275	program	_	_	I-Claim
276	of	_	_	I-Claim
277	psychotherapeutic	_	_	I-Claim
278	support	_	_	I-Claim
279	during	_	_	I-Claim
280	the	_	_	I-Claim
281	inpatient	_	_	I-Claim
282	hospital	_	_	I-Claim
283	stay	_	_	I-Claim
284	in	_	_	I-Claim
285	terms	_	_	I-Claim
286	of	_	_	I-Claim
287	long-term	_	_	I-Claim
288	survival	_	_	I-Claim
289	.	_	_	I-Claim


0	Compared	_	_	O
1	with	_	_	O
2	placebo	_	_	O
3	,	_	_	O
4	prophylactic	_	_	O
5	treatment	_	_	O
6	with	_	_	O
7	bisphosphonates	_	_	O
8	reduces	_	_	O
9	risk	_	_	O
10	of	_	_	O
11	skeletal	_	_	O
12	events	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	multiple	_	_	O
17	myeloma	_	_	O
18	.	_	_	O

19	However	_	_	O
20	,	_	_	O
21	because	_	_	O
22	of	_	_	O
23	toxicity	_	_	O
24	associated	_	_	O
25	with	_	_	O
26	long-term	_	_	O
27	bisphosphonate	_	_	O
28	treatment	_	_	O
29	,	_	_	O
30	establishing	_	_	O
31	the	_	_	O
32	lowest	_	_	O
33	effective	_	_	O
34	dose	_	_	O
35	is	_	_	O
36	important	_	_	O
37	.	_	_	O

38	This	_	_	O
39	study	_	_	O
40	compared	_	_	O
41	the	_	_	O
42	effect	_	_	O
43	of	_	_	O
44	two	_	_	O
45	doses	_	_	O
46	of	_	_	O
47	pamidronate	_	_	O
48	on	_	_	O
49	health-related	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	and	_	_	O
54	skeletal	_	_	O
55	morbidity	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	newly	_	_	O
60	diagnosed	_	_	O
61	multiple	_	_	O
62	myeloma	_	_	O
63	.	_	_	O

64	This	_	_	O
65	double-blind	_	_	O
66	,	_	_	O
67	randomised	_	_	O
68	,	_	_	O
69	phase	_	_	O
70	3	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	undertaken	_	_	O
74	at	_	_	O
75	37	_	_	O
76	clinics	_	_	O
77	in	_	_	O
78	Denmark	_	_	O
79	,	_	_	O
80	Norway	_	_	O
81	,	_	_	O
82	and	_	_	O
83	Sweden	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	with	_	_	O
87	multiple	_	_	O
88	myeloma	_	_	O
89	who	_	_	O
90	were	_	_	O
91	starting	_	_	O
92	antimyeloma	_	_	O
93	treatment	_	_	O
94	were	_	_	O
95	randomly	_	_	O
96	assigned	_	_	O
97	in	_	_	O
98	a	_	_	O
99	1:1	_	_	O
100	ratio	_	_	O
101	to	_	_	O
102	receive	_	_	O
103	one	_	_	O
104	of	_	_	O
105	two	_	_	O
106	doses	_	_	O
107	of	_	_	O
108	pamidronate	_	_	O
109	(	_	_	O
110	30	_	_	O
111	mg	_	_	O
112	or	_	_	O
113	90	_	_	O
114	mg	_	_	O
115	)	_	_	O
116	given	_	_	O
117	by	_	_	O
118	intravenous	_	_	O
119	infusion	_	_	O
120	once	_	_	O
121	a	_	_	O
122	month	_	_	O
123	for	_	_	O
124	at	_	_	O
125	least	_	_	O
126	3	_	_	O
127	years	_	_	O
128	.	_	_	O

129	Randomisation	_	_	O
130	was	_	_	O
131	done	_	_	O
132	by	_	_	O
133	use	_	_	O
134	of	_	_	O
135	a	_	_	O
136	central	_	_	O
137	,	_	_	O
138	computerised	_	_	O
139	minimisation	_	_	O
140	system	_	_	O
141	.	_	_	O

142	Primary	_	_	O
143	outcome	_	_	O
144	was	_	_	O
145	physical	_	_	O
146	function	_	_	O
147	after	_	_	O
148	12	_	_	O
149	months	_	_	O
150	estimated	_	_	O
151	by	_	_	O
152	the	_	_	O
153	European	_	_	O
154	Organisation	_	_	O
155	for	_	_	O
156	Research	_	_	O
157	and	_	_	O
158	Treatment	_	_	O
159	of	_	_	O
160	Cancer	_	_	O
161	(	_	_	O
162	EORTC	_	_	O
163	)	_	_	O
164	QLQ-C30	_	_	O
165	questionnaire	_	_	O
166	(	_	_	O
167	scale	_	_	O
168	0-100	_	_	O
169	)	_	_	O
170	.	_	_	O

171	All	_	_	O
172	patients	_	_	O
173	who	_	_	O
174	returned	_	_	O
175	questionnaires	_	_	O
176	at	_	_	O
177	12	_	_	O
178	months	_	_	O
179	and	_	_	O
180	were	_	_	O
181	still	_	_	O
182	on	_	_	O
183	study	_	_	O
184	treatment	_	_	O
185	were	_	_	O
186	included	_	_	O
187	in	_	_	O
188	the	_	_	O
189	analysis	_	_	O
190	of	_	_	O
191	the	_	_	O
192	primary	_	_	O
193	endpoint	_	_	O
194	.	_	_	O

195	From	_	_	O
196	January	_	_	O
197	,	_	_	O
198	2001	_	_	O
199	,	_	_	O
200	until	_	_	O
201	August	_	_	O
202	,	_	_	O
203	2005	_	_	O
204	,	_	_	O
205	504	_	_	O
206	patients	_	_	O
207	were	_	_	O
208	randomly	_	_	O
209	assigned	_	_	O
210	to	_	_	O
211	pamidronate	_	_	O
212	30	_	_	O
213	mg	_	_	O
214	or	_	_	O
215	90	_	_	O
216	mg	_	_	O
217	(	_	_	O
218	252	_	_	O
219	in	_	_	O
220	each	_	_	O
221	group	_	_	O
222	)	_	_	O
223	.	_	_	O

224	157	_	_	O
225	patients	_	_	O
226	in	_	_	O
227	the	_	_	O
228	90	_	_	O
229	mg	_	_	O
230	group	_	_	O
231	and	_	_	O
232	156	_	_	O
233	in	_	_	O
234	the	_	_	O
235	30	_	_	O
236	mg	_	_	O
237	group	_	_	O
238	were	_	_	O
239	included	_	_	O
240	in	_	_	O
241	the	_	_	O
242	primary	_	_	O
243	analysis	_	_	O
244	.	_	_	O

245	Mean	_	_	B-Premise
246	physical	_	_	I-Premise
247	function	_	_	I-Premise
248	at	_	_	I-Premise
249	12	_	_	I-Premise
250	months	_	_	I-Premise
251	was	_	_	I-Premise
252	66	_	_	I-Premise
253	points	_	_	I-Premise
254	(	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	62Â·9-70Â·0	_	_	I-Premise
259	)	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	90	_	_	I-Premise
263	mg	_	_	I-Premise
264	group	_	_	I-Premise
265	and	_	_	I-Premise
266	68	_	_	I-Premise
267	points	_	_	I-Premise
268	(	_	_	I-Premise
269	64Â·6-71Â·4	_	_	I-Premise
270	)	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	30	_	_	I-Premise
274	mg	_	_	I-Premise
275	group	_	_	I-Premise
276	(	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	of	_	_	I-Premise
281	difference	_	_	I-Premise
282	-6Â·6	_	_	I-Premise
283	to	_	_	I-Premise
284	3Â·3	_	_	I-Premise
285	;	_	_	I-Premise
286	p=0Â·52	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	Median	_	_	B-Premise
290	time	_	_	I-Premise
291	to	_	_	I-Premise
292	first	_	_	I-Premise
293	skeletal-related	_	_	I-Premise
294	event	_	_	I-Premise
295	in	_	_	I-Premise
296	patients	_	_	I-Premise
297	who	_	_	I-Premise
298	had	_	_	I-Premise
299	such	_	_	I-Premise
300	an	_	_	I-Premise
301	event	_	_	I-Premise
302	was	_	_	I-Premise
303	9Â·2	_	_	I-Premise
304	months	_	_	I-Premise
305	(	_	_	I-Premise
306	8Â·1-10Â·7	_	_	I-Premise
307	)	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	90	_	_	I-Premise
311	mg	_	_	I-Premise
312	group	_	_	I-Premise
313	and	_	_	I-Premise
314	10Â·2	_	_	I-Premise
315	months	_	_	I-Premise
316	(	_	_	I-Premise
317	7Â·3-14Â·0	_	_	I-Premise
318	)	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	30	_	_	I-Premise
322	mg	_	_	I-Premise
323	group	_	_	I-Premise
324	(	_	_	I-Premise
325	p=0Â·63	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	In	_	_	O
329	a	_	_	O
330	retrospective	_	_	O
331	analysis	_	_	O
332	,	_	_	O
333	eight	_	_	B-Premise
334	patients	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	pamidronate	_	_	I-Premise
338	90	_	_	I-Premise
339	mg	_	_	I-Premise
340	group	_	_	I-Premise
341	developed	_	_	I-Premise
342	osteonecrosis	_	_	I-Premise
343	of	_	_	I-Premise
344	the	_	_	I-Premise
345	jaw	_	_	I-Premise
346	compared	_	_	I-Premise
347	with	_	_	I-Premise
348	two	_	_	I-Premise
349	patients	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	30	_	_	I-Premise
353	mg	_	_	I-Premise
354	group	_	_	I-Premise
355	.	_	_	I-Premise

356	Monthly	_	_	B-Claim
357	infusion	_	_	I-Claim
358	of	_	_	I-Claim
359	pamidronate	_	_	I-Claim
360	30	_	_	I-Claim
361	mg	_	_	I-Claim
362	should	_	_	I-Claim
363	be	_	_	I-Claim
364	the	_	_	I-Claim
365	recommended	_	_	I-Claim
366	dose	_	_	I-Claim
367	for	_	_	I-Claim
368	prevention	_	_	I-Claim
369	of	_	_	I-Claim
370	bone	_	_	I-Claim
371	disease	_	_	I-Claim
372	in	_	_	I-Claim
373	patients	_	_	I-Claim
374	with	_	_	I-Claim
375	multiple	_	_	I-Claim
376	myeloma	_	_	I-Claim
377	.	_	_	I-Claim


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	cause	_	_	I-Claim
6	of	_	_	I-Claim
7	morbidity	_	_	I-Claim
8	in	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	prostate	_	_	I-Claim
12	carcinoma	_	_	I-Claim
13	.	_	_	I-Claim

14	We	_	_	O
15	studied	_	_	O
16	the	_	_	O
17	effect	_	_	O
18	of	_	_	O
19	a	_	_	O
20	new	_	_	O
21	bisphosphonate	_	_	O
22	,	_	_	O
23	zoledronic	_	_	O
24	acid	_	_	O
25	,	_	_	O
26	which	_	_	O
27	blocks	_	_	O
28	bone	_	_	O
29	destruction	_	_	O
30	,	_	_	O
31	on	_	_	O
32	skeletal	_	_	O
33	complications	_	_	O
34	in	_	_	O
35	prostate	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	bone	_	_	O
40	metastases	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	with	_	_	O
44	hormone-refractory	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	and	_	_	O
48	a	_	_	O
49	history	_	_	O
50	of	_	_	O
51	bone	_	_	O
52	metastases	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	to	_	_	O
57	a	_	_	O
58	double-blind	_	_	O
59	treatment	_	_	O
60	regimen	_	_	O
61	of	_	_	O
62	intravenous	_	_	O
63	zoledronic	_	_	O
64	acid	_	_	O
65	at	_	_	O
66	4	_	_	O
67	mg	_	_	O
68	(	_	_	O
69	N	_	_	O
70	=	_	_	O
71	214	_	_	O
72	)	_	_	O
73	,	_	_	O
74	zoledronic	_	_	O
75	acid	_	_	O
76	at	_	_	O
77	8	_	_	O
78	mg	_	_	O
79	(	_	_	O
80	subsequently	_	_	O
81	reduced	_	_	O
82	to	_	_	O
83	4	_	_	O
84	mg	_	_	O
85	;	_	_	O
86	8/4	_	_	O
87	)	_	_	O
88	(	_	_	O
89	N	_	_	O
90	=	_	_	O
91	221	_	_	O
92	)	_	_	O
93	,	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	N	_	_	O
98	=	_	_	O
99	208	_	_	O
100	)	_	_	O
101	every	_	_	O
102	3	_	_	O
103	weeks	_	_	O
104	for	_	_	O
105	15	_	_	O
106	months	_	_	O
107	.	_	_	O

108	Proportions	_	_	O
109	of	_	_	O
110	patients	_	_	O
111	with	_	_	O
112	skeletal-related	_	_	O
113	events	_	_	O
114	,	_	_	O
115	time	_	_	O
116	to	_	_	O
117	the	_	_	O
118	first	_	_	O
119	skeletal-related	_	_	O
120	event	_	_	O
121	,	_	_	O
122	skeletal	_	_	O
123	morbidity	_	_	O
124	rate	_	_	O
125	,	_	_	O
126	pain	_	_	O
127	and	_	_	O
128	analgesic	_	_	O
129	scores	_	_	O
130	,	_	_	O
131	disease	_	_	O
132	progression	_	_	O
133	,	_	_	O
134	and	_	_	O
135	safety	_	_	O
136	were	_	_	O
137	assessed	_	_	O
138	.	_	_	O

139	All	_	_	O
140	statistical	_	_	O
141	tests	_	_	O
142	were	_	_	O
143	two-sided	_	_	O
144	.	_	_	O

145	Approximately	_	_	O
146	38	_	_	O
147	%	_	_	O
148	of	_	_	O
149	patients	_	_	O
150	who	_	_	O
151	received	_	_	O
152	zoledronic	_	_	O
153	acid	_	_	O
154	at	_	_	O
155	4	_	_	O
156	mg	_	_	O
157	,	_	_	O
158	28	_	_	O
159	%	_	_	O
160	who	_	_	O
161	received	_	_	O
162	zoledronic	_	_	O
163	acid	_	_	O
164	at	_	_	O
165	8/4	_	_	O
166	mg	_	_	O
167	,	_	_	O
168	and	_	_	O
169	31	_	_	O
170	%	_	_	O
171	who	_	_	O
172	received	_	_	O
173	placebo	_	_	O
174	completed	_	_	O
175	the	_	_	O
176	study	_	_	O
177	.	_	_	O

178	A	_	_	B-Premise
179	greater	_	_	I-Premise
180	proportion	_	_	I-Premise
181	of	_	_	I-Premise
182	patients	_	_	I-Premise
183	who	_	_	I-Premise
184	received	_	_	I-Premise
185	placebo	_	_	I-Premise
186	had	_	_	I-Premise
187	skeletal-related	_	_	I-Premise
188	events	_	_	I-Premise
189	than	_	_	I-Premise
190	those	_	_	I-Premise
191	who	_	_	I-Premise
192	received	_	_	I-Premise
193	zoledronic	_	_	I-Premise
194	acid	_	_	I-Premise
195	at	_	_	I-Premise
196	4	_	_	I-Premise
197	mg	_	_	I-Premise
198	(	_	_	I-Premise
199	44.2	_	_	I-Premise
200	%	_	_	I-Premise
201	versus	_	_	I-Premise
202	33.2	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	difference	_	_	I-Premise
206	=	_	_	I-Premise
207	-11.0	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	95	_	_	I-Premise
211	%	_	_	I-Premise
212	confidence	_	_	I-Premise
213	interval	_	_	I-Premise
214	[	_	_	I-Premise
215	CI	_	_	I-Premise
216	]	_	_	I-Premise
217	=	_	_	I-Premise
218	-20.3	_	_	I-Premise
219	%	_	_	I-Premise
220	to	_	_	I-Premise
221	-1.8	_	_	I-Premise
222	%	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	=.021	_	_	I-Premise
226	)	_	_	I-Premise
227	or	_	_	I-Premise
228	those	_	_	I-Premise
229	who	_	_	I-Premise
230	received	_	_	I-Premise
231	zoledronic	_	_	I-Premise
232	acid	_	_	I-Premise
233	at	_	_	I-Premise
234	8/4	_	_	I-Premise
235	mg	_	_	I-Premise
236	(	_	_	I-Premise
237	38.5	_	_	I-Premise
238	%	_	_	I-Premise
239	;	_	_	I-Premise
240	difference	_	_	I-Premise
241	versus	_	_	I-Premise
242	placebo	_	_	I-Premise
243	=	_	_	I-Premise
244	-5.8	_	_	I-Premise
245	%	_	_	I-Premise
246	,	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	CI	_	_	I-Premise
250	=	_	_	I-Premise
251	-15.1	_	_	I-Premise
252	%	_	_	I-Premise
253	to	_	_	I-Premise
254	3.6	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=.222	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Median	_	_	B-Premise
262	time	_	_	I-Premise
263	to	_	_	I-Premise
264	first	_	_	I-Premise
265	skeletal-related	_	_	I-Premise
266	event	_	_	I-Premise
267	was	_	_	I-Premise
268	321	_	_	I-Premise
269	days	_	_	I-Premise
270	for	_	_	I-Premise
271	patients	_	_	I-Premise
272	who	_	_	I-Premise
273	received	_	_	I-Premise
274	placebo	_	_	I-Premise
275	,	_	_	I-Premise
276	was	_	_	I-Premise
277	not	_	_	I-Premise
278	reached	_	_	I-Premise
279	for	_	_	I-Premise
280	patients	_	_	I-Premise
281	who	_	_	I-Premise
282	received	_	_	I-Premise
283	zoledronic	_	_	I-Premise
284	acid	_	_	I-Premise
285	at	_	_	I-Premise
286	4	_	_	I-Premise
287	mg	_	_	I-Premise
288	(	_	_	I-Premise
289	P	_	_	I-Premise
290	=.011	_	_	I-Premise
291	versus	_	_	I-Premise
292	placebo	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	was	_	_	I-Premise
297	363	_	_	I-Premise
298	days	_	_	I-Premise
299	for	_	_	I-Premise
300	those	_	_	I-Premise
301	who	_	_	I-Premise
302	received	_	_	I-Premise
303	zoledronic	_	_	I-Premise
304	acid	_	_	I-Premise
305	at	_	_	I-Premise
306	8/4	_	_	I-Premise
307	mg	_	_	I-Premise
308	(	_	_	I-Premise
309	P	_	_	I-Premise
310	=.491	_	_	I-Premise
311	versus	_	_	I-Premise
312	placebo	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	Compared	_	_	B-Premise
316	with	_	_	I-Premise
317	urinary	_	_	I-Premise
318	markers	_	_	I-Premise
319	in	_	_	I-Premise
320	patients	_	_	I-Premise
321	who	_	_	I-Premise
322	received	_	_	I-Premise
323	placebo	_	_	I-Premise
324	,	_	_	I-Premise
325	urinary	_	_	I-Premise
326	markers	_	_	I-Premise
327	of	_	_	I-Premise
328	bone	_	_	I-Premise
329	resorption	_	_	I-Premise
330	were	_	_	I-Premise
331	statistically	_	_	I-Premise
332	significantly	_	_	I-Premise
333	decreased	_	_	I-Premise
334	in	_	_	I-Premise
335	patients	_	_	I-Premise
336	who	_	_	I-Premise
337	received	_	_	I-Premise
338	zoledronic	_	_	I-Premise
339	acid	_	_	I-Premise
340	at	_	_	I-Premise
341	either	_	_	I-Premise
342	dose	_	_	I-Premise
343	(	_	_	I-Premise
344	P	_	_	I-Premise
345	=.001	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Pain	_	_	B-Premise
349	and	_	_	I-Premise
350	analgesic	_	_	I-Premise
351	scores	_	_	I-Premise
352	increased	_	_	I-Premise
353	more	_	_	I-Premise
354	in	_	_	I-Premise
355	patients	_	_	I-Premise
356	who	_	_	I-Premise
357	received	_	_	I-Premise
358	placebo	_	_	I-Premise
359	than	_	_	I-Premise
360	in	_	_	I-Premise
361	patients	_	_	I-Premise
362	who	_	_	I-Premise
363	received	_	_	I-Premise
364	zoledronic	_	_	I-Premise
365	acid	_	_	I-Premise
366	,	_	_	I-Premise
367	but	_	_	O
368	there	_	_	B-Premise
369	were	_	_	I-Premise
370	no	_	_	I-Premise
371	differences	_	_	I-Premise
372	in	_	_	I-Premise
373	disease	_	_	I-Premise
374	progression	_	_	I-Premise
375	,	_	_	I-Premise
376	performance	_	_	I-Premise
377	status	_	_	I-Premise
378	,	_	_	I-Premise
379	or	_	_	I-Premise
380	quality-of-life	_	_	I-Premise
381	scores	_	_	I-Premise
382	among	_	_	I-Premise
383	the	_	_	I-Premise
384	groups	_	_	I-Premise
385	.	_	_	I-Premise

386	Zoledronic	_	_	B-Claim
387	acid	_	_	I-Claim
388	at	_	_	I-Claim
389	4	_	_	I-Claim
390	mg	_	_	I-Claim
391	given	_	_	I-Claim
392	as	_	_	I-Claim
393	a	_	_	I-Claim
394	15-minute	_	_	I-Claim
395	infusion	_	_	I-Claim
396	was	_	_	I-Claim
397	well	_	_	I-Claim
398	tolerated	_	_	I-Claim
399	,	_	_	I-Claim
400	but	_	_	O
401	the	_	_	B-Claim
402	8-mg	_	_	I-Claim
403	dose	_	_	I-Claim
404	was	_	_	I-Claim
405	associated	_	_	I-Claim
406	with	_	_	I-Claim
407	renal	_	_	I-Claim
408	function	_	_	I-Claim
409	deterioration	_	_	I-Claim
410	.	_	_	I-Claim

411	Zoledronic	_	_	B-Claim
412	acid	_	_	I-Claim
413	at	_	_	I-Claim
414	4	_	_	I-Claim
415	mg	_	_	I-Claim
416	reduced	_	_	I-Claim
417	skeletal-related	_	_	I-Claim
418	events	_	_	I-Claim
419	in	_	_	I-Claim
420	prostate	_	_	I-Claim
421	cancer	_	_	I-Claim
422	patients	_	_	I-Claim
423	with	_	_	I-Claim
424	bone	_	_	I-Claim
425	metastases	_	_	I-Claim
426	.	_	_	I-Claim


0	For	_	_	O
1	patients	_	_	O
2	undergoing	_	_	O
3	oncologic	_	_	O
4	surgery	_	_	O
5	,	_	_	O
6	the	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	(	_	_	O
11	QoL	_	_	O
12	)	_	_	O
13	is	_	_	O
14	generally	_	_	O
15	accepted	_	_	O
16	as	_	_	O
17	an	_	_	O
18	important	_	_	O
19	outcome	_	_	O
20	parameter	_	_	O
21	in	_	_	O
22	addition	_	_	O
23	to	_	_	O
24	long-term	_	_	O
25	survival	_	_	O
26	,	_	_	O
27	mortality	_	_	O
28	and	_	_	O
29	complication	_	_	O
30	rates	_	_	O
31	.	_	_	O

32	This	_	_	O
33	study	_	_	O
34	focussed	_	_	O
35	on	_	_	O
36	the	_	_	O
37	QoL	_	_	O
38	in	_	_	O
39	patients	_	_	O
40	after	_	_	O
41	oesophagectomy	_	_	O
42	for	_	_	O
43	cancer	_	_	O
44	,	_	_	O
45	comparing	_	_	O
46	the	_	_	O
47	method	_	_	O
48	of	_	_	O
49	reconstruction	_	_	O
50	(	_	_	O
51	narrow	_	_	O
52	gastric	_	_	O
53	tube	_	_	O
54	vs	_	_	O
55	whole	_	_	O
56	stomach	_	_	O
57	)	_	_	O
58	.	_	_	O

59	In	_	_	O
60	a	_	_	O
61	prospective	_	_	O
62	randomised	_	_	O
63	single-centre	_	_	O
64	study	_	_	O
65	from	_	_	O
66	2007	_	_	O
67	to	_	_	O
68	2008	_	_	O
69	,	_	_	O
70	104	_	_	O
71	patients	_	_	O
72	underwent	_	_	O
73	oesophagectomy	_	_	O
74	for	_	_	O
75	cancer	_	_	O
76	.	_	_	O

77	To	_	_	O
78	assess	_	_	O
79	the	_	_	O
80	QoL	_	_	O
81	,	_	_	O
82	a	_	_	O
83	questionnaire	_	_	O
84	in	_	_	O
85	reference	_	_	O
86	to	_	_	O
87	the	_	_	O
88	EORTC-QLQ-C30	_	_	O
89	and	_	_	O
90	the	_	_	O
91	QLQ-OES24	_	_	O
92	was	_	_	O
93	administered	_	_	O
94	at	_	_	O
95	3	_	_	O
96	weeks	_	_	O
97	,	_	_	O
98	6	_	_	O
99	months	_	_	O
100	and	_	_	O
101	1	_	_	O
102	year	_	_	O
103	after	_	_	O
104	surgery	_	_	O
105	.	_	_	O

106	Clinical	_	_	O
107	data	_	_	O
108	were	_	_	O
109	collected	_	_	O
110	prospectively	_	_	O
111	,	_	_	O
112	and	_	_	O
113	follow-up	_	_	O
114	was	_	_	O
115	performed	_	_	O
116	regularly	_	_	O
117	.	_	_	O

118	There	_	_	B-Premise
119	were	_	_	I-Premise
120	no	_	_	I-Premise
121	significant	_	_	I-Premise
122	differences	_	_	I-Premise
123	between	_	_	I-Premise
124	the	_	_	I-Premise
125	narrow	_	_	I-Premise
126	gastric	_	_	I-Premise
127	tube	_	_	I-Premise
128	group	_	_	I-Premise
129	(	_	_	I-Premise
130	NGT	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	n=52	_	_	I-Premise
134	)	_	_	I-Premise
135	and	_	_	I-Premise
136	the	_	_	I-Premise
137	whole-stomach	_	_	I-Premise
138	group	_	_	I-Premise
139	(	_	_	I-Premise
140	WS	_	_	I-Premise
141	group	_	_	I-Premise
142	,	_	_	I-Premise
143	n=52	_	_	I-Premise
144	)	_	_	I-Premise
145	with	_	_	I-Premise
146	regard	_	_	I-Premise
147	to	_	_	I-Premise
148	patient	_	_	I-Premise
149	and	_	_	I-Premise
150	cancer	_	_	I-Premise
151	characteristics	_	_	I-Premise
152	,	_	_	I-Premise
153	operative	_	_	I-Premise
154	procedure	_	_	I-Premise
155	,	_	_	I-Premise
156	postoperative	_	_	I-Premise
157	intensive	_	_	I-Premise
158	care	_	_	I-Premise
159	unit	_	_	I-Premise
160	(	_	_	I-Premise
161	ICU	_	_	I-Premise
162	)	_	_	I-Premise
163	hospitalisation	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	overall	_	_	I-Premise
167	survival	_	_	I-Premise
168	at	_	_	I-Premise
169	1	_	_	I-Premise
170	year	_	_	I-Premise
171	.	_	_	I-Premise

172	Regarding	_	_	B-Premise
173	the	_	_	I-Premise
174	postoperative	_	_	I-Premise
175	complication	_	_	I-Premise
176	,	_	_	I-Premise
177	there	_	_	I-Premise
178	were	_	_	I-Premise
179	more	_	_	I-Premise
180	cases	_	_	I-Premise
181	of	_	_	I-Premise
182	postoperative	_	_	I-Premise
183	reflux	_	_	I-Premise
184	oesophagitis	_	_	I-Premise
185	and	_	_	I-Premise
186	impairment	_	_	I-Premise
187	of	_	_	I-Premise
188	pulmonary	_	_	I-Premise
189	function	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	WS	_	_	I-Premise
193	group	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	<	_	_	I-Premise
197	0.05	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Regarding	_	_	B-Premise
201	the	_	_	I-Premise
202	QoL	_	_	I-Premise
203	investigation	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	scores	_	_	I-Premise
207	of	_	_	I-Premise
208	QoL	_	_	I-Premise
209	dropped	_	_	I-Premise
210	for	_	_	I-Premise
211	all	_	_	I-Premise
212	patients	_	_	I-Premise
213	at	_	_	I-Premise
214	3	_	_	I-Premise
215	weeks	_	_	I-Premise
216	after	_	_	I-Premise
217	surgery	_	_	I-Premise
218	.	_	_	I-Premise

219	Slowly	_	_	O
220	,	_	_	O
221	recovery	_	_	B-Premise
222	was	_	_	I-Premise
223	found	_	_	I-Premise
224	at	_	_	I-Premise
225	both	_	_	I-Premise
226	6	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	1	_	_	I-Premise
230	year	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	groups	_	_	I-Premise
234	.	_	_	I-Premise

235	Patients	_	_	B-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	NGT	_	_	I-Premise
239	group	_	_	I-Premise
240	reported	_	_	I-Premise
241	significantly	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.05	_	_	I-Premise
246	)	_	_	I-Premise
247	better	_	_	I-Premise
248	scores	_	_	I-Premise
249	of	_	_	I-Premise
250	QoL	_	_	I-Premise
251	at	_	_	I-Premise
252	both	_	_	I-Premise
253	6	_	_	I-Premise
254	months	_	_	I-Premise
255	and	_	_	I-Premise
256	1	_	_	I-Premise
257	year	_	_	I-Premise
258	.	_	_	I-Premise

259	Patients	_	_	B-Claim
260	who	_	_	I-Claim
261	underwent	_	_	I-Claim
262	gastric	_	_	I-Claim
263	tube	_	_	I-Claim
264	reconstruction	_	_	I-Claim
265	develop	_	_	I-Claim
266	less	_	_	I-Claim
267	postoperative	_	_	I-Claim
268	digestive	_	_	I-Claim
269	tract	_	_	I-Claim
270	complications	_	_	I-Claim
271	,	_	_	I-Claim
272	and	_	_	I-Claim
273	have	_	_	I-Claim
274	a	_	_	I-Claim
275	quicker	_	_	I-Claim
276	recovery	_	_	I-Claim
277	and	_	_	I-Claim
278	a	_	_	I-Claim
279	better	_	_	I-Claim
280	QoL	_	_	I-Claim
281	during	_	_	I-Claim
282	the	_	_	I-Claim
283	follow-up	_	_	I-Claim
284	period	_	_	I-Claim
285	.	_	_	I-Claim

286	Further	_	_	O
287	investigation	_	_	O
288	and	_	_	O
289	data	_	_	O
290	collection	_	_	O
291	will	_	_	O
292	allow	_	_	O
293	the	_	_	O
294	assessment	_	_	O
295	of	_	_	O
296	this	_	_	O
297	procedure	_	_	O
298	beyond	_	_	O
299	1	_	_	O
300	year	_	_	O
301	after	_	_	O
302	operation	_	_	O
303	.	_	_	O


0	To	_	_	O
1	carry	_	_	O
2	out	_	_	O
3	a	_	_	O
4	preliminary	_	_	O
5	trial	_	_	O
6	evaluating	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	two	_	_	O
11	types	_	_	O
12	of	_	_	O
13	homeopathy	_	_	O
14	for	_	_	O
15	the	_	_	O
16	treatment	_	_	O
17	of	_	_	O
18	menopausal	_	_	O
19	symptoms	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	survivors	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	double-blinded	_	_	O
28	,	_	_	O
29	placebo-controlled	_	_	O
30	.	_	_	O

31	Private	_	_	O
32	medical	_	_	O
33	clinic	_	_	O
34	,	_	_	O
35	Seattle	_	_	O
36	,	_	_	O
37	WA	_	_	O
38	.	_	_	O

39	Women	_	_	O
40	with	_	_	O
41	a	_	_	O
42	history	_	_	O
43	of	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	who	_	_	O
47	had	_	_	O
48	completed	_	_	O
49	all	_	_	O
50	surgery	_	_	O
51	,	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	and	_	_	O
55	radiation	_	_	O
56	treatment	_	_	O
57	and	_	_	O
58	who	_	_	O
59	had	_	_	O
60	an	_	_	O
61	average	_	_	O
62	of	_	_	O
63	at	_	_	O
64	least	_	_	O
65	three	_	_	O
66	hot	_	_	O
67	flashes	_	_	O
68	per	_	_	O
69	day	_	_	O
70	for	_	_	O
71	the	_	_	O
72	previous	_	_	O
73	month	_	_	O
74	.	_	_	O

75	Subjects	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	either	_	_	O
81	an	_	_	O
82	individualized	_	_	O
83	homeopathic	_	_	O
84	single	_	_	O
85	remedy	_	_	O
86	,	_	_	O
87	a	_	_	O
88	homeopathic	_	_	O
89	combination	_	_	O
90	medicine	_	_	O
91	,	_	_	O
92	or	_	_	O
93	placebo	_	_	O
94	.	_	_	O

95	Patients	_	_	O
96	were	_	_	O
97	seen	_	_	O
98	by	_	_	O
99	homeopathic	_	_	O
100	providers	_	_	O
101	every	_	_	O
102	2	_	_	O
103	months	_	_	O
104	for	_	_	O
105	1	_	_	O
106	year	_	_	O
107	.	_	_	O

108	Hot	_	_	O
109	flash	_	_	O
110	frequency	_	_	O
111	and	_	_	O
112	severity	_	_	O
113	,	_	_	O
114	Kupperman	_	_	O
115	Menopausal	_	_	O
116	Index	_	_	O
117	(	_	_	O
118	KMI	_	_	O
119	)	_	_	O
120	,	_	_	O
121	Short	_	_	O
122	Form	_	_	O
123	36	_	_	O
124	(	_	_	O
125	SF-36	_	_	O
126	)	_	_	O
127	.	_	_	O

128	There	_	_	B-Premise
129	was	_	_	I-Premise
130	no	_	_	I-Premise
131	significant	_	_	I-Premise
132	difference	_	_	I-Premise
133	found	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	primary	_	_	I-Premise
137	outcome	_	_	I-Premise
138	measure	_	_	I-Premise
139	,	_	_	I-Premise
140	the	_	_	I-Premise
141	hot	_	_	I-Premise
142	flash	_	_	I-Premise
143	severity	_	_	I-Premise
144	score	_	_	I-Premise
145	,	_	_	I-Premise
146	although	_	_	B-Premise
147	there	_	_	I-Premise
148	was	_	_	I-Premise
149	a	_	_	I-Premise
150	positive	_	_	I-Premise
151	trend	_	_	I-Premise
152	in	_	_	I-Premise
153	the	_	_	I-Premise
154	single	_	_	I-Premise
155	remedy	_	_	I-Premise
156	group	_	_	I-Premise
157	during	_	_	I-Premise
158	the	_	_	I-Premise
159	first	_	_	I-Premise
160	3	_	_	I-Premise
161	months	_	_	I-Premise
162	of	_	_	I-Premise
163	the	_	_	I-Premise
164	study	_	_	I-Premise
165	(	_	_	I-Premise
166	p	_	_	I-Premise
167	=	_	_	I-Premise
168	0.1	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	A	_	_	B-Premise
172	statistically	_	_	I-Premise
173	significant	_	_	I-Premise
174	improvement	_	_	I-Premise
175	in	_	_	I-Premise
176	general	_	_	I-Premise
177	health	_	_	I-Premise
178	score	_	_	I-Premise
179	in	_	_	I-Premise
180	both	_	_	I-Premise
181	homeopathy	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	<	_	_	I-Premise
186	0.05	_	_	I-Premise
187	)	_	_	I-Premise
188	on	_	_	I-Premise
189	the	_	_	I-Premise
190	SF-36	_	_	I-Premise
191	after	_	_	I-Premise
192	1	_	_	I-Premise
193	year	_	_	I-Premise
194	was	_	_	I-Premise
195	found	_	_	I-Premise
196	.	_	_	I-Premise

197	Evidence	_	_	B-Premise
198	of	_	_	I-Premise
199	a	_	_	I-Premise
200	homeopathic	_	_	I-Premise
201	"	_	_	I-Premise
202	drug	_	_	I-Premise
203	proving	_	_	I-Premise
204	"	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	subjects	_	_	I-Premise
208	receiving	_	_	I-Premise
209	the	_	_	I-Premise
210	homeopathic	_	_	I-Premise
211	combination	_	_	I-Premise
212	medicine	_	_	I-Premise
213	who	_	_	I-Premise
214	were	_	_	I-Premise
215	not	_	_	I-Premise
216	taking	_	_	I-Premise
217	tamoxifen	_	_	I-Premise
218	also	_	_	I-Premise
219	was	_	_	I-Premise
220	found	_	_	I-Premise
221	.	_	_	I-Premise

222	Small	_	_	B-Claim
223	sample	_	_	I-Claim
224	size	_	_	I-Claim
225	precludes	_	_	I-Claim
226	definitive	_	_	I-Claim
227	answers	_	_	I-Claim
228	,	_	_	I-Claim
229	but	_	_	B-Claim
230	results	_	_	I-Claim
231	from	_	_	I-Claim
232	this	_	_	I-Claim
233	preliminary	_	_	I-Claim
234	trial	_	_	I-Claim
235	suggest	_	_	I-Claim
236	that	_	_	I-Claim
237	homeopathy	_	_	I-Claim
238	may	_	_	I-Claim
239	be	_	_	I-Claim
240	of	_	_	I-Claim
241	value	_	_	I-Claim
242	in	_	_	I-Claim
243	the	_	_	I-Claim
244	treatment	_	_	I-Claim
245	of	_	_	I-Claim
246	menopausal	_	_	I-Claim
247	symptoms	_	_	I-Claim
248	and	_	_	I-Claim
249	improving	_	_	I-Claim
250	quality	_	_	I-Claim
251	of	_	_	I-Claim
252	life	_	_	I-Claim
253	,	_	_	I-Claim
254	especially	_	_	I-Claim
255	in	_	_	I-Claim
256	those	_	_	I-Claim
257	women	_	_	I-Claim
258	not	_	_	I-Claim
259	on	_	_	I-Claim
260	tamoxifen	_	_	I-Claim
261	.	_	_	I-Claim

262	Larger	_	_	B-Claim
263	studies	_	_	I-Claim
264	should	_	_	I-Claim
265	be	_	_	I-Claim
266	carried	_	_	I-Claim
267	out	_	_	I-Claim
268	that	_	_	I-Claim
269	also	_	_	I-Claim
270	include	_	_	I-Claim
271	healthy	_	_	I-Claim
272	women	_	_	I-Claim
273	who	_	_	I-Claim
274	want	_	_	I-Claim
275	to	_	_	I-Claim
276	avoid	_	_	I-Claim
277	hormone	_	_	I-Claim
278	replacement	_	_	I-Claim
279	therapy	_	_	I-Claim
280	.	_	_	I-Claim


0	Increased	_	_	B-Claim
1	expression	_	_	I-Claim
2	of	_	_	I-Claim
3	metalloproteinases	_	_	I-Claim
4	is	_	_	I-Claim
5	associated	_	_	I-Claim
6	with	_	_	I-Claim
7	poor	_	_	I-Claim
8	prognosis	_	_	I-Claim
9	in	_	_	I-Claim
10	small-cell	_	_	I-Claim
11	lung	_	_	I-Claim
12	cancer	_	_	I-Claim
13	(	_	_	I-Claim
14	SCLC	_	_	I-Claim
15	)	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	trial	_	_	O
19	was	_	_	O
20	undertaken	_	_	O
21	to	_	_	O
22	determine	_	_	O
23	whether	_	_	O
24	adjuvant	_	_	O
25	treatment	_	_	O
26	with	_	_	O
27	the	_	_	O
28	metalloproteinase	_	_	O
29	inhibitor	_	_	O
30	marimastat	_	_	O
31	could	_	_	O
32	prolong	_	_	O
33	survival	_	_	O
34	in	_	_	O
35	responding	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	SCLC	_	_	O
39	after	_	_	O
40	chemotherapy	_	_	O
41	.	_	_	O

42	SCLC	_	_	O
43	patients	_	_	O
44	in	_	_	O
45	complete	_	_	O
46	or	_	_	O
47	partial	_	_	O
48	remission	_	_	O
49	were	_	_	O
50	eligible	_	_	O
51	.	_	_	O

52	They	_	_	O
53	were	_	_	O
54	stratified	_	_	O
55	by	_	_	O
56	radiotherapy	_	_	O
57	(	_	_	O
58	early	_	_	O
59	,	_	_	O
60	late	_	_	O
61	,	_	_	O
62	or	_	_	O
63	none	_	_	O
64	)	_	_	O
65	,	_	_	O
66	stage	_	_	O
67	(	_	_	O
68	extensive	_	_	O
69	or	_	_	O
70	limited	_	_	O
71	)	_	_	O
72	,	_	_	O
73	response	_	_	O
74	(	_	_	O
75	complete	_	_	O
76	or	_	_	O
77	partial	_	_	O
78	)	_	_	O
79	,	_	_	O
80	and	_	_	O
81	cooperative	_	_	O
82	group	_	_	O
83	(	_	_	O
84	National	_	_	O
85	Cancer	_	_	O
86	Institute	_	_	O
87	of	_	_	O
88	Canada-Clinical	_	_	O
89	Trials	_	_	O
90	Group	_	_	O
91	or	_	_	O
92	European	_	_	O
93	Organization	_	_	O
94	for	_	_	O
95	Research	_	_	O
96	and	_	_	O
97	Treatment	_	_	O
98	of	_	_	O
99	Cancer	_	_	O
100	)	_	_	O
101	.	_	_	O

102	They	_	_	O
103	were	_	_	O
104	randomized	_	_	O
105	to	_	_	O
106	receive	_	_	O
107	marimastat	_	_	O
108	10	_	_	O
109	mg	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	orally	_	_	O
113	bid	_	_	O
114	for	_	_	O
115	up	_	_	O
116	to	_	_	O
117	2	_	_	O
118	years	_	_	O
119	.	_	_	O

120	There	_	_	O
121	were	_	_	O
122	532	_	_	O
123	eligible	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	266	_	_	O
127	marimastat	_	_	O
128	and	_	_	O
129	266	_	_	O
130	placebo	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Stage	_	_	O
134	was	_	_	O
135	limited	_	_	O
136	for	_	_	O
137	279	_	_	O
138	patients	_	_	O
139	(	_	_	O
140	52	_	_	O
141	%	_	_	O
142	)	_	_	O
143	and	_	_	O
144	extensive	_	_	O
145	for	_	_	O
146	253	_	_	O
147	(	_	_	O
148	48	_	_	O
149	%	_	_	O
150	)	_	_	O
151	.	_	_	O

152	Best	_	_	B-Premise
153	response	_	_	I-Premise
154	to	_	_	I-Premise
155	induction	_	_	I-Premise
156	therapy	_	_	I-Premise
157	was	_	_	I-Premise
158	complete	_	_	I-Premise
159	remission	_	_	I-Premise
160	for	_	_	I-Premise
161	176	_	_	I-Premise
162	patients	_	_	I-Premise
163	(	_	_	I-Premise
164	33	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	partial	_	_	I-Premise
169	remission	_	_	I-Premise
170	for	_	_	I-Premise
171	341	_	_	I-Premise
172	(	_	_	I-Premise
173	64	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	and	_	_	I-Premise
178	15	_	_	I-Premise
179	patients	_	_	I-Premise
180	(	_	_	I-Premise
181	3	_	_	I-Premise
182	%	_	_	I-Premise
183	)	_	_	I-Premise
184	had	_	_	I-Premise
185	undergone	_	_	I-Premise
186	surgical	_	_	I-Premise
187	resection	_	_	I-Premise
188	.	_	_	I-Premise

189	The	_	_	B-Premise
190	median	_	_	I-Premise
191	time	_	_	I-Premise
192	to	_	_	I-Premise
193	progression	_	_	I-Premise
194	for	_	_	I-Premise
195	marimastat	_	_	I-Premise
196	patients	_	_	I-Premise
197	was	_	_	I-Premise
198	4.3	_	_	I-Premise
199	months	_	_	I-Premise
200	compared	_	_	I-Premise
201	with	_	_	I-Premise
202	4.4	_	_	I-Premise
203	months	_	_	I-Premise
204	for	_	_	I-Premise
205	placebo	_	_	I-Premise
206	patients	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	=.81	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Median	_	_	B-Premise
213	survivals	_	_	I-Premise
214	for	_	_	I-Premise
215	marimastat	_	_	I-Premise
216	and	_	_	I-Premise
217	placebo	_	_	I-Premise
218	patients	_	_	I-Premise
219	were	_	_	I-Premise
220	9.3	_	_	I-Premise
221	months	_	_	I-Premise
222	and	_	_	I-Premise
223	9.7	_	_	I-Premise
224	months	_	_	I-Premise
225	,	_	_	I-Premise
226	respectively	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=.90	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Toxicity	_	_	B-Premise
233	was	_	_	I-Premise
234	generally	_	_	I-Premise
235	limited	_	_	I-Premise
236	to	_	_	I-Premise
237	musculoskeletal	_	_	I-Premise
238	symptoms	_	_	I-Premise
239	(	_	_	I-Premise
240	18	_	_	I-Premise
241	%	_	_	I-Premise
242	grade	_	_	I-Premise
243	3/4	_	_	I-Premise
244	for	_	_	I-Premise
245	marimastat	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Dose	_	_	B-Premise
249	modifications	_	_	I-Premise
250	for	_	_	I-Premise
251	musculoskeletal	_	_	I-Premise
252	toxicity	_	_	I-Premise
253	were	_	_	I-Premise
254	required	_	_	I-Premise
255	in	_	_	I-Premise
256	90	_	_	I-Premise
257	patients	_	_	I-Premise
258	(	_	_	I-Premise
259	33	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	on	_	_	I-Premise
263	the	_	_	I-Premise
264	marimastat	_	_	I-Premise
265	arm	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	87	_	_	I-Premise
269	(	_	_	I-Premise
270	32	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	permanently	_	_	I-Premise
274	stopped	_	_	I-Premise
275	marimastat	_	_	I-Premise
276	because	_	_	I-Premise
277	of	_	_	I-Premise
278	toxicity	_	_	I-Premise
279	.	_	_	I-Premise

280	Patients	_	_	B-Premise
281	on	_	_	I-Premise
282	marimastat	_	_	I-Premise
283	had	_	_	I-Premise
284	significantly	_	_	I-Premise
285	poorer	_	_	I-Premise
286	quality	_	_	I-Premise
287	of	_	_	I-Premise
288	life	_	_	I-Premise
289	at	_	_	I-Premise
290	3	_	_	I-Premise
291	and	_	_	I-Premise
292	6	_	_	I-Premise
293	months	_	_	I-Premise
294	.	_	_	I-Premise

295	Treatment	_	_	B-Claim
296	with	_	_	I-Claim
297	marimastat	_	_	I-Claim
298	after	_	_	I-Claim
299	induction	_	_	I-Claim
300	therapy	_	_	I-Claim
301	for	_	_	I-Claim
302	SCLC	_	_	I-Claim
303	did	_	_	I-Claim
304	not	_	_	I-Claim
305	result	_	_	I-Claim
306	in	_	_	I-Claim
307	improved	_	_	I-Claim
308	survival	_	_	I-Claim
309	and	_	_	I-Claim
310	had	_	_	I-Claim
311	a	_	_	I-Claim
312	negative	_	_	I-Claim
313	impact	_	_	I-Claim
314	on	_	_	I-Claim
315	quality	_	_	I-Claim
316	of	_	_	I-Claim
317	life	_	_	I-Claim
318	.	_	_	I-Claim


0	Morbidity	_	_	B-Claim
1	associated	_	_	I-Claim
2	with	_	_	I-Claim
3	wound	_	_	I-Claim
4	complications	_	_	I-Claim
5	may	_	_	I-Claim
6	translate	_	_	I-Claim
7	into	_	_	I-Claim
8	disability	_	_	I-Claim
9	and	_	_	I-Claim
10	quality-of-life	_	_	I-Claim
11	disadvantages	_	_	I-Claim
12	for	_	_	I-Claim
13	patients	_	_	I-Claim
14	treated	_	_	I-Claim
15	with	_	_	I-Claim
16	radiotherapy	_	_	I-Claim
17	(	_	_	I-Claim
18	RT	_	_	I-Claim
19	)	_	_	I-Claim
20	for	_	_	I-Claim
21	soft	_	_	I-Claim
22	tissue	_	_	I-Claim
23	sarcoma	_	_	I-Claim
24	(	_	_	I-Claim
25	STS	_	_	I-Claim
26	)	_	_	I-Claim
27	of	_	_	I-Claim
28	the	_	_	I-Claim
29	extremities	_	_	I-Claim
30	.	_	_	I-Claim

31	Functional	_	_	O
32	outcome	_	_	O
33	and	_	_	O
34	health	_	_	O
35	status	_	_	O
36	of	_	_	O
37	extremity	_	_	O
38	STS	_	_	O
39	patients	_	_	O
40	randomized	_	_	O
41	in	_	_	O
42	a	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	trial	_	_	O
46	comparing	_	_	O
47	preoperative	_	_	O
48	versus	_	_	O
49	postoperative	_	_	O
50	RT	_	_	O
51	is	_	_	O
52	described	_	_	O
53	.	_	_	O

54	One	_	_	O
55	hundred	_	_	O
56	ninety	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	extremity	_	_	O
60	STS	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	after	_	_	O
64	stratification	_	_	O
65	by	_	_	O
66	tumor	_	_	O
67	size	_	_	O
68	dichotomized	_	_	O
69	at	_	_	O
70	10	_	_	O
71	cm	_	_	O
72	.	_	_	O

73	Function	_	_	O
74	and	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	were	_	_	O
79	measured	_	_	O
80	by	_	_	O
81	the	_	_	O
82	Musculoskeletal	_	_	O
83	Tumor	_	_	O
84	Society	_	_	O
85	Rating	_	_	O
86	Scale	_	_	O
87	(	_	_	O
88	MSTS	_	_	O
89	)	_	_	O
90	,	_	_	O
91	the	_	_	O
92	Toronto	_	_	O
93	Extremity	_	_	O
94	Salvage	_	_	O
95	Score	_	_	O
96	(	_	_	O
97	TESS	_	_	O
98	)	_	_	O
99	,	_	_	O
100	and	_	_	O
101	the	_	_	O
102	Short	_	_	O
103	Form-36	_	_	O
104	(	_	_	O
105	SF-36	_	_	O
106	)	_	_	O
107	at	_	_	O
108	randomization	_	_	O
109	,	_	_	O
110	6	_	_	O
111	weeks	_	_	O
112	,	_	_	O
113	and	_	_	O
114	3	_	_	O
115	,	_	_	O
116	6	_	_	O
117	,	_	_	O
118	12	_	_	O
119	,	_	_	O
120	and	_	_	O
121	24	_	_	O
122	months	_	_	O
123	after	_	_	O
124	surgery	_	_	O
125	.	_	_	O

126	One	_	_	O
127	hundred	_	_	O
128	eighty-five	_	_	O
129	patients	_	_	O
130	had	_	_	O
131	function	_	_	O
132	data	_	_	O
133	.	_	_	O

134	Patients	_	_	B-Premise
135	treated	_	_	I-Premise
136	with	_	_	I-Premise
137	postoperative	_	_	I-Premise
138	RT	_	_	I-Premise
139	had	_	_	I-Premise
140	better	_	_	I-Premise
141	function	_	_	I-Premise
142	with	_	_	I-Premise
143	higher	_	_	I-Premise
144	MSTS	_	_	I-Premise
145	(	_	_	I-Premise
146	25.8	_	_	I-Premise
147	v	_	_	I-Premise
148	21.3	_	_	I-Premise
149	,	_	_	I-Premise
150	P	_	_	I-Premise
151	<	_	_	I-Premise
152	.01	_	_	I-Premise
153	)	_	_	I-Premise
154	,	_	_	I-Premise
155	TESS	_	_	I-Premise
156	(	_	_	I-Premise
157	69.8	_	_	I-Premise
158	v	_	_	I-Premise
159	60.6	_	_	I-Premise
160	,	_	_	I-Premise
161	P	_	_	I-Premise
162	=.01	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	SF-36	_	_	I-Premise
167	bodily	_	_	I-Premise
168	pain	_	_	I-Premise
169	(	_	_	I-Premise
170	67.7	_	_	I-Premise
171	v	_	_	I-Premise
172	58.5	_	_	I-Premise
173	,	_	_	I-Premise
174	P	_	_	I-Premise
175	=.03	_	_	I-Premise
176	)	_	_	I-Premise
177	scores	_	_	I-Premise
178	at	_	_	I-Premise
179	6	_	_	I-Premise
180	weeks	_	_	I-Premise
181	after	_	_	I-Premise
182	surgery	_	_	I-Premise
183	.	_	_	I-Premise

184	There	_	_	O
185	were	_	_	O
186	no	_	_	O
187	differences	_	_	O
188	at	_	_	O
189	later	_	_	O
190	time	_	_	O
191	points	_	_	O
192	.	_	_	O

193	Scores	_	_	B-Premise
194	on	_	_	I-Premise
195	the	_	_	I-Premise
196	physical	_	_	I-Premise
197	function	_	_	I-Premise
198	,	_	_	I-Premise
199	role-physical	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	general	_	_	I-Premise
203	health	_	_	I-Premise
204	subscales	_	_	I-Premise
205	of	_	_	I-Premise
206	the	_	_	I-Premise
207	SF-36	_	_	I-Premise
208	were	_	_	I-Premise
209	significantly	_	_	I-Premise
210	lower	_	_	I-Premise
211	than	_	_	I-Premise
212	Canadian	_	_	I-Premise
213	normative	_	_	I-Premise
214	data	_	_	I-Premise
215	at	_	_	I-Premise
216	all	_	_	I-Premise
217	time	_	_	I-Premise
218	points	_	_	I-Premise
219	.	_	_	I-Premise

220	After	_	_	O
221	treatment	_	_	O
222	arm	_	_	O
223	was	_	_	O
224	controlled	_	_	O
225	for	_	_	O
226	,	_	_	O
227	MSTS	_	_	O
228	change	_	_	O
229	scores	_	_	O
230	were	_	_	O
231	predicted	_	_	O
232	by	_	_	O
233	a	_	_	O
234	lower-extremity	_	_	O
235	tumor	_	_	O
236	,	_	_	O
237	a	_	_	O
238	large	_	_	O
239	resection	_	_	O
240	specimen	_	_	O
241	,	_	_	O
242	and	_	_	O
243	motor	_	_	O
244	nerve	_	_	O
245	sacrifice	_	_	O
246	;	_	_	O
247	TESS	_	_	O
248	change	_	_	O
249	scores	_	_	O
250	were	_	_	O
251	predicted	_	_	O
252	by	_	_	O
253	lower-extremity	_	_	O
254	tumor	_	_	O
255	and	_	_	O
256	prior	_	_	O
257	incomplete	_	_	O
258	excision	_	_	O
259	.	_	_	O

260	When	_	_	B-Premise
261	wound	_	_	I-Premise
262	complication	_	_	I-Premise
263	was	_	_	I-Premise
264	included	_	_	I-Premise
265	in	_	_	I-Premise
266	the	_	_	I-Premise
267	model	_	_	I-Premise
268	,	_	_	I-Premise
269	patients	_	_	I-Premise
270	with	_	_	I-Premise
271	complications	_	_	I-Premise
272	had	_	_	I-Premise
273	lower	_	_	I-Premise
274	MSTS	_	_	I-Premise
275	and	_	_	I-Premise
276	TESS	_	_	I-Premise
277	scores	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	first	_	_	I-Premise
281	2	_	_	I-Premise
282	years	_	_	I-Premise
283	after	_	_	I-Premise
284	treatment	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Claim
287	timing	_	_	I-Claim
288	of	_	_	I-Claim
289	RT	_	_	I-Claim
290	has	_	_	I-Claim
291	minimal	_	_	I-Claim
292	impact	_	_	I-Claim
293	on	_	_	I-Claim
294	the	_	_	I-Claim
295	function	_	_	I-Claim
296	of	_	_	I-Claim
297	STS	_	_	I-Claim
298	patients	_	_	I-Claim
299	in	_	_	I-Claim
300	the	_	_	I-Claim
301	first	_	_	I-Claim
302	year	_	_	I-Claim
303	after	_	_	I-Claim
304	surgery	_	_	I-Claim
305	.	_	_	O

306	Tumor	_	_	B-Claim
307	characteristics	_	_	I-Claim
308	and	_	_	I-Claim
309	wound	_	_	I-Claim
310	complications	_	_	I-Claim
311	have	_	_	I-Claim
312	a	_	_	I-Claim
313	detrimental	_	_	I-Claim
314	effect	_	_	I-Claim
315	on	_	_	I-Claim
316	patient	_	_	I-Claim
317	function	_	_	I-Claim
318	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	assessed	_	_	O
5	the	_	_	O
6	effect	_	_	O
7	of	_	_	O
8	a	_	_	O
9	SMART	_	_	O
10	(	_	_	O
11	Stress	_	_	O
12	Management	_	_	O
13	and	_	_	O
14	Resiliency	_	_	O
15	Training	_	_	O
16	)	_	_	O
17	program	_	_	O
18	among	_	_	O
19	25	_	_	O
20	women	_	_	O
21	diagnosed	_	_	O
22	with	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	Resilience	_	_	O
27	,	_	_	O
28	perceived	_	_	O
29	stress	_	_	O
30	,	_	_	O
31	anxiety	_	_	O
32	,	_	_	O
33	and	_	_	O
34	quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	improved	_	_	O
38	at	_	_	O
39	12	_	_	O
40	weeks	_	_	O
41	in	_	_	O
42	the	_	_	O
43	active	_	_	O
44	but	_	_	O
45	not	_	_	O
46	the	_	_	O
47	control	_	_	O
48	arm	_	_	O
49	.	_	_	O

50	A	_	_	O
51	brief	_	_	O
52	training	_	_	O
53	in	_	_	O
54	the	_	_	O
55	SMART	_	_	O
56	program	_	_	O
57	can	_	_	O
58	enhance	_	_	O
59	resilience	_	_	O
60	and	_	_	O
61	quality	_	_	O
62	of	_	_	O
63	life	_	_	O
64	and	_	_	O
65	decrease	_	_	O
66	stress	_	_	O
67	and	_	_	O
68	anxiety	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	experience	_	_	O
75	stress	_	_	O
76	and	_	_	O
77	anxiety	_	_	O
78	related	_	_	O
79	to	_	_	O
80	their	_	_	O
81	diagnosis	_	_	O
82	,	_	_	O
83	with	_	_	O
84	resulting	_	_	O
85	lower	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	.	_	_	O

90	The	_	_	O
91	purpose	_	_	O
92	of	_	_	O
93	this	_	_	O
94	study	_	_	O
95	was	_	_	O
96	to	_	_	O
97	assess	_	_	O
98	the	_	_	O
99	effect	_	_	O
100	of	_	_	O
101	a	_	_	O
102	SMART	_	_	O
103	(	_	_	O
104	Stress	_	_	O
105	Management	_	_	O
106	and	_	_	O
107	Resiliency	_	_	O
108	Training	_	_	O
109	)	_	_	O
110	program	_	_	O
111	for	_	_	O
112	increasing	_	_	O
113	resiliency	_	_	O
114	and	_	_	O
115	for	_	_	O
116	decreasing	_	_	O
117	stress	_	_	O
118	and	_	_	O
119	anxiety	_	_	O
120	among	_	_	O
121	mentors	_	_	O
122	who	_	_	O
123	themselves	_	_	O
124	were	_	_	O
125	previously	_	_	O
126	diagnosed	_	_	O
127	with	_	_	O
128	breast	_	_	O
129	cancer	_	_	O
130	.	_	_	O

131	The	_	_	O
132	program	_	_	O
133	consisted	_	_	O
134	of	_	_	O
135	two	_	_	O
136	90-minute	_	_	O
137	group	_	_	O
138	training	_	_	O
139	sessions	_	_	O
140	,	_	_	O
141	a	_	_	O
142	brief	_	_	O
143	individual	_	_	O
144	session	_	_	O
145	,	_	_	O
146	and	_	_	O
147	3	_	_	O
148	follow-up	_	_	O
149	telephone	_	_	O
150	calls	_	_	O
151	.	_	_	O

152	Twenty-four	_	_	O
153	mentors	_	_	O
154	at	_	_	O
155	Mayo	_	_	O
156	Clinic	_	_	O
157	in	_	_	O
158	Rochester	_	_	O
159	,	_	_	O
160	Minnesota	_	_	O
161	,	_	_	O
162	were	_	_	O
163	randomized	_	_	O
164	in	_	_	O
165	a	_	_	O
166	single-blind	_	_	O
167	,	_	_	O
168	wait-list	_	_	O
169	controlled	_	_	O
170	clinical	_	_	O
171	trial	_	_	O
172	to	_	_	O
173	either	_	_	O
174	the	_	_	O
175	SMART	_	_	O
176	intervention	_	_	O
177	or	_	_	O
178	a	_	_	O
179	control	_	_	O
180	group	_	_	O
181	for	_	_	O
182	12	_	_	O
183	weeks	_	_	O
184	.	_	_	O

185	Primary	_	_	O
186	outcome	_	_	O
187	measures	_	_	O
188	assessed	_	_	O
189	at	_	_	O
190	baseline	_	_	O
191	and	_	_	O
192	at	_	_	O
193	week	_	_	O
194	12	_	_	O
195	included	_	_	O
196	the	_	_	O
197	Connor	_	_	O
198	Davidson	_	_	O
199	Resilience	_	_	O
200	Scale	_	_	O
201	,	_	_	O
202	Perceived	_	_	O
203	Stress	_	_	O
204	Scale	_	_	O
205	,	_	_	O
206	Smith	_	_	O
207	Anxiety	_	_	O
208	Scale	_	_	O
209	,	_	_	O
210	and	_	_	O
211	Linear	_	_	O
212	Analog	_	_	O
213	Self	_	_	O
214	Assessment	_	_	O
215	Scale	_	_	O
216	.	_	_	O

217	Twenty	_	_	O
218	patients	_	_	O
219	completed	_	_	O
220	the	_	_	O
221	study	_	_	O
222	.	_	_	O

223	A	_	_	B-Premise
224	statistically	_	_	I-Premise
225	significant	_	_	I-Premise
226	improvement	_	_	I-Premise
227	in	_	_	I-Premise
228	resilience	_	_	I-Premise
229	,	_	_	I-Premise
230	perceived	_	_	I-Premise
231	stress	_	_	I-Premise
232	,	_	_	I-Premise
233	anxiety	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	overall	_	_	I-Premise
237	quality	_	_	I-Premise
238	of	_	_	I-Premise
239	life	_	_	I-Premise
240	at	_	_	I-Premise
241	12	_	_	I-Premise
242	weeks	_	_	I-Premise
243	,	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	baseline	_	_	I-Premise
247	was	_	_	I-Premise
248	observed	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	study	_	_	I-Premise
252	arm	_	_	I-Premise
253	.	_	_	I-Premise

254	No	_	_	B-Premise
255	significant	_	_	I-Premise
256	difference	_	_	I-Premise
257	in	_	_	I-Premise
258	any	_	_	I-Premise
259	of	_	_	I-Premise
260	these	_	_	I-Premise
261	measures	_	_	I-Premise
262	was	_	_	I-Premise
263	noted	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	control	_	_	I-Premise
267	group	_	_	I-Premise
268	.	_	_	I-Premise

269	This	_	_	B-Claim
270	study	_	_	I-Claim
271	demonstrates	_	_	I-Claim
272	that	_	_	I-Claim
273	a	_	_	I-Claim
274	brief	_	_	I-Claim
275	,	_	_	I-Claim
276	predominantly	_	_	I-Claim
277	group-based	_	_	I-Claim
278	resilience	_	_	I-Claim
279	training	_	_	I-Claim
280	intervention	_	_	I-Claim
281	is	_	_	I-Claim
282	feasible	_	_	I-Claim
283	in	_	_	I-Claim
284	patients	_	_	I-Claim
285	with	_	_	I-Claim
286	previous	_	_	I-Claim
287	breast	_	_	I-Claim
288	cancer	_	_	I-Claim
289	;	_	_	I-Claim
290	also	_	_	I-Claim
291	,	_	_	I-Claim
292	it	_	_	I-Claim
293	may	_	_	I-Claim
294	be	_	_	I-Claim
295	efficacious	_	_	I-Claim
296	.	_	_	I-Claim


0	Both	_	_	O
1	gemcitabine	_	_	O
2	(	_	_	O
3	GEM	_	_	O
4	)	_	_	O
5	and	_	_	O
6	fluoropyrimidines	_	_	O
7	are	_	_	O
8	valuable	_	_	O
9	treatment	_	_	O
10	for	_	_	O
11	advanced	_	_	O
12	pancreatic	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	This	_	_	O
16	open-label	_	_	O
17	study	_	_	O
18	was	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	compare	_	_	O
22	the	_	_	O
23	overall	_	_	O
24	survival	_	_	O
25	(	_	_	O
26	OS	_	_	O
27	)	_	_	O
28	of	_	_	O
29	patients	_	_	O
30	randomly	_	_	O
31	assigned	_	_	O
32	to	_	_	O
33	GEM	_	_	O
34	alone	_	_	O
35	or	_	_	O
36	GEM	_	_	O
37	plus	_	_	O
38	capecitabine	_	_	O
39	(	_	_	O
40	GEM-CAP	_	_	O
41	)	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	with	_	_	O
45	previously	_	_	O
46	untreated	_	_	O
47	histologically	_	_	O
48	or	_	_	O
49	cytologically	_	_	O
50	proven	_	_	O
51	locally	_	_	O
52	advanced	_	_	O
53	or	_	_	O
54	metastatic	_	_	O
55	carcinoma	_	_	O
56	of	_	_	O
57	the	_	_	O
58	pancreas	_	_	O
59	with	_	_	O
60	a	_	_	O
61	performance	_	_	O
62	status	_	_	O
63	<	_	_	O
64	or=	_	_	O
65	2	_	_	O
66	were	_	_	O
67	recruited	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	GEM	_	_	O
75	or	_	_	O
76	GEM-CAP	_	_	O
77	.	_	_	O

78	The	_	_	O
79	primary	_	_	O
80	outcome	_	_	O
81	measure	_	_	O
82	was	_	_	O
83	survival	_	_	O
84	.	_	_	O

85	Meta-analysis	_	_	O
86	of	_	_	O
87	published	_	_	O
88	studies	_	_	O
89	was	_	_	O
90	also	_	_	O
91	conducted	_	_	O
92	.	_	_	O

93	Between	_	_	O
94	May	_	_	O
95	2002	_	_	O
96	and	_	_	O
97	January	_	_	O
98	2005	_	_	O
99	,	_	_	O
100	533	_	_	O
101	patients	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	assigned	_	_	O
105	to	_	_	O
106	GEM	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	266	_	_	O
111	)	_	_	O
112	and	_	_	O
113	GEM-CAP	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	267	_	_	O
118	)	_	_	O
119	arms	_	_	O
120	.	_	_	O

121	GEM-CAP	_	_	B-Premise
122	significantly	_	_	I-Premise
123	improved	_	_	I-Premise
124	objective	_	_	I-Premise
125	response	_	_	I-Premise
126	rate	_	_	I-Premise
127	(	_	_	I-Premise
128	19.1	_	_	I-Premise
129	%	_	_	I-Premise
130	v	_	_	I-Premise
131	12.4	_	_	I-Premise
132	%	_	_	I-Premise
133	;	_	_	I-Premise
134	P	_	_	I-Premise
135	=	_	_	I-Premise
136	.034	_	_	I-Premise
137	)	_	_	I-Premise
138	and	_	_	I-Premise
139	progression-free	_	_	I-Premise
140	survival	_	_	I-Premise
141	(	_	_	I-Premise
142	hazard	_	_	I-Premise
143	ratio	_	_	I-Premise
144	[	_	_	I-Premise
145	HR	_	_	I-Premise
146	]	_	_	I-Premise
147	,	_	_	I-Premise
148	0.78	_	_	I-Premise
149	;	_	_	I-Premise
150	95	_	_	I-Premise
151	%	_	_	I-Premise
152	CI	_	_	I-Premise
153	,	_	_	I-Premise
154	0.66	_	_	I-Premise
155	to	_	_	I-Premise
156	0.93	_	_	I-Premise
157	;	_	_	I-Premise
158	P	_	_	I-Premise
159	=	_	_	I-Premise
160	.004	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	was	_	_	I-Premise
164	associated	_	_	I-Premise
165	with	_	_	I-Premise
166	a	_	_	I-Premise
167	trend	_	_	I-Premise
168	toward	_	_	I-Premise
169	improved	_	_	I-Premise
170	OS	_	_	I-Premise
171	(	_	_	I-Premise
172	HR	_	_	I-Premise
173	,	_	_	I-Premise
174	0.86	_	_	I-Premise
175	;	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	CI	_	_	I-Premise
179	,	_	_	I-Premise
180	0.72	_	_	I-Premise
181	to	_	_	I-Premise
182	1.02	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.08	_	_	I-Premise
187	)	_	_	I-Premise
188	compared	_	_	I-Premise
189	with	_	_	I-Premise
190	GEM	_	_	I-Premise
191	alone	_	_	I-Premise
192	.	_	_	I-Premise

193	This	_	_	B-Premise
194	trend	_	_	I-Premise
195	for	_	_	I-Premise
196	OS	_	_	I-Premise
197	benefit	_	_	I-Premise
198	for	_	_	I-Premise
199	GEM-CAP	_	_	I-Premise
200	was	_	_	I-Premise
201	consistent	_	_	I-Premise
202	across	_	_	I-Premise
203	different	_	_	I-Premise
204	prognostic	_	_	I-Premise
205	subgroups	_	_	I-Premise
206	according	_	_	I-Premise
207	to	_	_	I-Premise
208	baseline	_	_	I-Premise
209	stratification	_	_	I-Premise
210	factors	_	_	I-Premise
211	(	_	_	I-Premise
212	stage	_	_	I-Premise
213	and	_	_	I-Premise
214	performance	_	_	I-Premise
215	status	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	remained	_	_	I-Premise
219	after	_	_	I-Premise
220	adjusting	_	_	I-Premise
221	for	_	_	I-Premise
222	these	_	_	I-Premise
223	stratification	_	_	I-Premise
224	factors	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.077	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	Moreover	_	_	O
232	,	_	_	O
233	the	_	_	B-Premise
234	meta-analysis	_	_	I-Premise
235	of	_	_	I-Premise
236	two	_	_	I-Premise
237	additional	_	_	I-Premise
238	studies	_	_	I-Premise
239	involving	_	_	I-Premise
240	935	_	_	I-Premise
241	patients	_	_	I-Premise
242	showed	_	_	I-Premise
243	a	_	_	I-Premise
244	significant	_	_	I-Premise
245	survival	_	_	I-Premise
246	benefit	_	_	I-Premise
247	in	_	_	I-Premise
248	favor	_	_	I-Premise
249	of	_	_	I-Premise
250	GEM-CAP	_	_	I-Premise
251	(	_	_	I-Premise
252	HR	_	_	I-Premise
253	,	_	_	I-Premise
254	0.86	_	_	I-Premise
255	;	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.75	_	_	I-Premise
261	to	_	_	I-Premise
262	0.98	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.02	_	_	I-Premise
267	)	_	_	I-Premise
268	with	_	_	I-Premise
269	no	_	_	I-Premise
270	intertrial	_	_	I-Premise
271	heterogeneity	_	_	I-Premise
272	.	_	_	I-Premise

273	On	_	_	B-Claim
274	the	_	_	I-Claim
275	basis	_	_	I-Claim
276	of	_	_	I-Claim
277	our	_	_	I-Claim
278	trial	_	_	I-Claim
279	and	_	_	I-Claim
280	the	_	_	I-Claim
281	meta-analysis	_	_	I-Claim
282	,	_	_	I-Claim
283	GEM-CAP	_	_	I-Claim
284	should	_	_	I-Claim
285	be	_	_	I-Claim
286	considered	_	_	I-Claim
287	as	_	_	I-Claim
288	one	_	_	I-Claim
289	of	_	_	I-Claim
290	the	_	_	I-Claim
291	standard	_	_	I-Claim
292	first-line	_	_	I-Claim
293	options	_	_	I-Claim
294	in	_	_	I-Claim
295	locally	_	_	I-Claim
296	advanced	_	_	I-Claim
297	and	_	_	I-Claim
298	metastatic	_	_	I-Claim
299	pancreatic	_	_	I-Claim
300	cancer	_	_	I-Claim
301	.	_	_	I-Claim


0	The	_	_	O
1	World	_	_	O
2	Health	_	_	O
3	Organization	_	_	O
4	(	_	_	O
5	WHO	_	_	O
6	)	_	_	O
7	guidelines	_	_	O
8	for	_	_	O
9	the	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	cancer	_	_	O
13	pain	_	_	O
14	recommend	_	_	O
15	nonopioid	_	_	O
16	analgesics	_	_	O
17	as	_	_	O
18	first-line	_	_	O
19	therapy	_	_	O
20	,	_	_	O
21	so-called	_	_	O
22	"	_	_	O
23	weak	_	_	O
24	"	_	_	O
25	analgesics	_	_	O
26	combined	_	_	O
27	with	_	_	O
28	nonopioid	_	_	O
29	analgesics	_	_	O
30	as	_	_	O
31	second-line	_	_	O
32	therapy	_	_	O
33	,	_	_	O
34	and	_	_	O
35	so-called	_	_	O
36	"	_	_	O
37	strong	_	_	O
38	"	_	_	O
39	opioids	_	_	O
40	(	_	_	O
41	with	_	_	O
42	nonopioid	_	_	O
43	analgesics	_	_	O
44	)	_	_	O
45	only	_	_	O
46	as	_	_	O
47	third-line	_	_	O
48	therapy	_	_	O
49	.	_	_	O

50	However	_	_	O
51	,	_	_	O
52	these	_	_	O
53	guidelines	_	_	O
54	can	_	_	O
55	be	_	_	O
56	questioned	_	_	O
57	with	_	_	O
58	regard	_	_	O
59	to	_	_	O
60	the	_	_	O
61	extent	_	_	O
62	of	_	_	O
63	efficacy	_	_	O
64	as	_	_	O
65	well	_	_	O
66	as	_	_	O
67	the	_	_	O
68	rationale	_	_	O
69	for	_	_	O
70	not	_	_	O
71	using	_	_	O
72	strong	_	_	O
73	opioids	_	_	O
74	as	_	_	O
75	first-line	_	_	O
76	treatment	_	_	O
77	,	_	_	O
78	especially	_	_	O
79	in	_	_	O
80	terminal	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	.	_	_	O

84	The	_	_	O
85	purpose	_	_	O
86	of	_	_	O
87	this	_	_	O
88	randomized	_	_	O
89	study	_	_	O
90	was	_	_	O
91	to	_	_	O
92	prospectively	_	_	O
93	compare	_	_	O
94	the	_	_	O
95	efficacy	_	_	O
96	and	_	_	O
97	tolerability	_	_	O
98	of	_	_	O
99	strong	_	_	O
100	opioids	_	_	O
101	as	_	_	O
102	first-line	_	_	O
103	agents	_	_	O
104	with	_	_	O
105	the	_	_	O
106	recommendations	_	_	O
107	of	_	_	O
108	the	_	_	O
109	WHO	_	_	O
110	in	_	_	O
111	terminal	_	_	O
112	cancer	_	_	O
113	patients	_	_	O
114	.	_	_	O

115	One	_	_	O
116	hundred	_	_	O
117	patients	_	_	O
118	with	_	_	O
119	mild-moderate	_	_	O
120	pain	_	_	O
121	were	_	_	O
122	randomized	_	_	O
123	to	_	_	O
124	treatment	_	_	O
125	according	_	_	O
126	to	_	_	O
127	WHO	_	_	O
128	guidelines	_	_	O
129	or	_	_	O
130	to	_	_	O
131	treatment	_	_	O
132	with	_	_	O
133	strong	_	_	O
134	opioids	_	_	O
135	.	_	_	O

136	Evaluated	_	_	O
137	outcomes	_	_	O
138	included	_	_	O
139	pain	_	_	O
140	intensity	_	_	O
141	,	_	_	O
142	need	_	_	O
143	for	_	_	O
144	change	_	_	O
145	in	_	_	O
146	therapy	_	_	O
147	,	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	,	_	_	O
152	Karnofsky	_	_	O
153	Performance	_	_	O
154	Status	_	_	O
155	,	_	_	O
156	general	_	_	O
157	condition	_	_	O
158	of	_	_	O
159	the	_	_	O
160	patient	_	_	O
161	,	_	_	O
162	and	_	_	O
163	adverse	_	_	O
164	events	_	_	O
165	.	_	_	O

166	No	_	_	B-Premise
167	between-treatment	_	_	I-Premise
168	differences	_	_	I-Premise
169	were	_	_	I-Premise
170	observed	_	_	I-Premise
171	for	_	_	I-Premise
172	changes	_	_	I-Premise
173	in	_	_	I-Premise
174	quality	_	_	I-Premise
175	of	_	_	I-Premise
176	life	_	_	I-Premise
177	or	_	_	I-Premise
178	performance	_	_	I-Premise
179	status	_	_	I-Premise
180	,	_	_	I-Premise
181	but	_	_	O
182	patients	_	_	B-Premise
183	started	_	_	I-Premise
184	on	_	_	I-Premise
185	strong	_	_	I-Premise
186	opioids	_	_	I-Premise
187	had	_	_	I-Premise
188	significantly	_	_	I-Premise
189	better	_	_	I-Premise
190	pain	_	_	I-Premise
191	relief	_	_	I-Premise
192	than	_	_	I-Premise
193	patients	_	_	I-Premise
194	treated	_	_	I-Premise
195	according	_	_	I-Premise
196	to	_	_	I-Premise
197	WHO	_	_	I-Premise
198	guidelines	_	_	I-Premise
199	(	_	_	I-Premise
200	P=0.041	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	Additionally	_	_	B-Premise
204	,	_	_	I-Premise
205	patients	_	_	I-Premise
206	started	_	_	I-Premise
207	on	_	_	I-Premise
208	strong	_	_	I-Premise
209	opioids	_	_	I-Premise
210	required	_	_	I-Premise
211	significantly	_	_	I-Premise
212	fewer	_	_	I-Premise
213	changes	_	_	I-Premise
214	in	_	_	I-Premise
215	therapy	_	_	I-Premise
216	,	_	_	I-Premise
217	had	_	_	I-Premise
218	greater	_	_	I-Premise
219	reduction	_	_	I-Premise
220	in	_	_	I-Premise
221	pain	_	_	I-Premise
222	when	_	_	I-Premise
223	a	_	_	I-Premise
224	change	_	_	I-Premise
225	was	_	_	I-Premise
226	initiated	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	reported	_	_	I-Premise
230	greater	_	_	I-Premise
231	satisfaction	_	_	I-Premise
232	with	_	_	I-Premise
233	treatment	_	_	I-Premise
234	than	_	_	I-Premise
235	the	_	_	I-Premise
236	comparator	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	P=0.041	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Strong	_	_	B-Claim
243	opioids	_	_	I-Claim
244	were	_	_	I-Claim
245	safe	_	_	I-Claim
246	and	_	_	I-Claim
247	well-tolerated	_	_	I-Claim
248	,	_	_	I-Claim
249	with	_	_	I-Claim
250	no	_	_	I-Claim
251	development	_	_	I-Claim
252	of	_	_	I-Claim
253	tolerance	_	_	I-Claim
254	or	_	_	I-Claim
255	serious	_	_	I-Claim
256	adverse	_	_	I-Claim
257	events	_	_	I-Claim
258	.	_	_	I-Claim

259	These	_	_	B-Claim
260	data	_	_	I-Claim
261	suggest	_	_	I-Claim
262	the	_	_	I-Claim
263	utility	_	_	I-Claim
264	of	_	_	I-Claim
265	strong	_	_	I-Claim
266	opioids	_	_	I-Claim
267	for	_	_	I-Claim
268	first-line	_	_	I-Claim
269	treatment	_	_	I-Claim
270	of	_	_	I-Claim
271	pain	_	_	I-Claim
272	in	_	_	I-Claim
273	patients	_	_	I-Claim
274	with	_	_	I-Claim
275	terminal	_	_	I-Claim
276	cancer	_	_	I-Claim
277	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	clear	_	_	O
4	whether	_	_	O
5	the	_	_	O
6	administration	_	_	O
7	of	_	_	O
8	radioiodine	_	_	O
9	provides	_	_	O
10	any	_	_	O
11	benefit	_	_	O
12	to	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	low-risk	_	_	O
16	thyroid	_	_	O
17	cancer	_	_	O
18	after	_	_	O
19	a	_	_	O
20	complete	_	_	O
21	surgical	_	_	O
22	resection	_	_	O
23	.	_	_	O

24	The	_	_	O
25	administration	_	_	O
26	of	_	_	O
27	the	_	_	O
28	smallest	_	_	O
29	possible	_	_	O
30	amount	_	_	O
31	of	_	_	O
32	radioiodine	_	_	O
33	would	_	_	O
34	improve	_	_	O
35	care	_	_	O
36	.	_	_	O

37	In	_	_	O
38	our	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	phase	_	_	O
42	3	_	_	O
43	trial	_	_	O
44	,	_	_	O
45	we	_	_	O
46	compared	_	_	O
47	two	_	_	O
48	thyrotropin-stimulation	_	_	O
49	methods	_	_	O
50	(	_	_	O
51	thyroid	_	_	O
52	hormone	_	_	O
53	withdrawal	_	_	O
54	and	_	_	O
55	use	_	_	O
56	of	_	_	O
57	recombinant	_	_	O
58	human	_	_	O
59	thyrotropin	_	_	O
60	)	_	_	O
61	and	_	_	O
62	two	_	_	O
63	radioiodine	_	_	O
64	(	_	_	O
65	(	_	_	O
66	131	_	_	O
67	)	_	_	O
68	I	_	_	O
69	)	_	_	O
70	doses	_	_	O
71	(	_	_	O
72	i.e.	_	_	O
73	,	_	_	O
74	administered	_	_	O
75	activities	_	_	O
76	)	_	_	O
77	(	_	_	O
78	1.1	_	_	O
79	GBq	_	_	O
80	and	_	_	O
81	3.7	_	_	O
82	GBq	_	_	O
83	)	_	_	O
84	in	_	_	O
85	a	_	_	O
86	2-by-2	_	_	O
87	design	_	_	O
88	.	_	_	O

89	Inclusion	_	_	O
90	criteria	_	_	O
91	were	_	_	O
92	an	_	_	O
93	age	_	_	O
94	of	_	_	O
95	18	_	_	O
96	years	_	_	O
97	or	_	_	O
98	older	_	_	O
99	;	_	_	O
100	total	_	_	O
101	thyroidectomy	_	_	O
102	for	_	_	O
103	differentiated	_	_	O
104	thyroid	_	_	O
105	carcinoma	_	_	O
106	;	_	_	O
107	tumor-node-metastasis	_	_	O
108	(	_	_	O
109	TNM	_	_	O
110	)	_	_	O
111	stage	_	_	O
112	,	_	_	O
113	ascertained	_	_	O
114	on	_	_	O
115	pathological	_	_	O
116	examination	_	_	O
117	(	_	_	O
118	p	_	_	O
119	)	_	_	O
120	of	_	_	O
121	a	_	_	O
122	surgical	_	_	O
123	specimen	_	_	O
124	,	_	_	O
125	of	_	_	O
126	pT1	_	_	O
127	(	_	_	O
128	with	_	_	O
129	tumor	_	_	O
130	diameter	_	_	O
131	â‰¤1	_	_	O
132	cm	_	_	O
133	)	_	_	O
134	and	_	_	O
135	N1	_	_	O
136	or	_	_	O
137	Nx	_	_	O
138	,	_	_	O
139	pT1	_	_	O
140	(	_	_	O
141	with	_	_	O
142	tumor	_	_	O
143	diameter	_	_	O
144	>	_	_	O
145	1	_	_	O
146	to	_	_	O
147	2	_	_	O
148	cm	_	_	O
149	)	_	_	O
150	and	_	_	O
151	any	_	_	O
152	N	_	_	O
153	stage	_	_	O
154	,	_	_	O
155	or	_	_	O
156	pT2N0	_	_	O
157	;	_	_	O
158	absence	_	_	O
159	of	_	_	O
160	distant	_	_	O
161	metastasis	_	_	O
162	;	_	_	O
163	and	_	_	O
164	no	_	_	O
165	iodine	_	_	O
166	contamination	_	_	O
167	.	_	_	O

168	Thyroid	_	_	O
169	ablation	_	_	O
170	was	_	_	O
171	assessed	_	_	O
172	8	_	_	O
173	months	_	_	O
174	after	_	_	O
175	radioiodine	_	_	O
176	administration	_	_	O
177	by	_	_	O
178	neck	_	_	O
179	ultrasonography	_	_	O
180	and	_	_	O
181	measurement	_	_	O
182	of	_	_	O
183	recombinant	_	_	O
184	human	_	_	O
185	thyrotropin-stimulated	_	_	O
186	thyroglobulin	_	_	O
187	.	_	_	O

188	Comparisons	_	_	O
189	were	_	_	O
190	based	_	_	O
191	on	_	_	O
192	an	_	_	O
193	equivalence	_	_	O
194	framework	_	_	O
195	.	_	_	O

196	There	_	_	O
197	were	_	_	O
198	752	_	_	O
199	patients	_	_	O
200	enrolled	_	_	O
201	between	_	_	O
202	2007	_	_	O
203	and	_	_	O
204	2010	_	_	O
205	;	_	_	O
206	92	_	_	O
207	%	_	_	O
208	had	_	_	O
209	papillary	_	_	O
210	cancer	_	_	O
211	.	_	_	O

212	There	_	_	B-Premise
213	were	_	_	I-Premise
214	no	_	_	I-Premise
215	unexpected	_	_	I-Premise
216	serious	_	_	I-Premise
217	adverse	_	_	I-Premise
218	events	_	_	I-Premise
219	.	_	_	I-Premise

220	In	_	_	B-Premise
221	the	_	_	I-Premise
222	684	_	_	I-Premise
223	patients	_	_	I-Premise
224	with	_	_	I-Premise
225	data	_	_	I-Premise
226	that	_	_	I-Premise
227	could	_	_	I-Premise
228	be	_	_	I-Premise
229	evaluated	_	_	I-Premise
230	,	_	_	I-Premise
231	ultrasonography	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	neck	_	_	I-Premise
235	was	_	_	I-Premise
236	normal	_	_	I-Premise
237	in	_	_	I-Premise
238	652	_	_	I-Premise
239	(	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	and	_	_	I-Premise
245	the	_	_	I-Premise
246	stimulated	_	_	I-Premise
247	thyroglobulin	_	_	I-Premise
248	level	_	_	I-Premise
249	was	_	_	I-Premise
250	1.0	_	_	I-Premise
251	ng	_	_	I-Premise
252	per	_	_	I-Premise
253	milliliter	_	_	I-Premise
254	or	_	_	I-Premise
255	less	_	_	I-Premise
256	in	_	_	I-Premise
257	621	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	652	_	_	I-Premise
261	patients	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	without	_	_	I-Premise
267	detectable	_	_	I-Premise
268	thyroglobulin	_	_	I-Premise
269	antibodies	_	_	I-Premise
270	.	_	_	I-Premise

271	Thyroid	_	_	B-Premise
272	ablation	_	_	I-Premise
273	was	_	_	I-Premise
274	complete	_	_	I-Premise
275	in	_	_	I-Premise
276	631	_	_	I-Premise
277	of	_	_	I-Premise
278	the	_	_	I-Premise
279	684	_	_	I-Premise
280	patients	_	_	I-Premise
281	(	_	_	I-Premise
282	92	_	_	I-Premise
283	%	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	ablation	_	_	I-Premise
288	rate	_	_	I-Premise
289	was	_	_	I-Premise
290	equivalent	_	_	I-Premise
291	between	_	_	I-Premise
292	the	_	_	I-Premise
293	(	_	_	I-Premise
294	131	_	_	I-Premise
295	)	_	_	I-Premise
296	I	_	_	I-Premise
297	doses	_	_	I-Premise
298	and	_	_	I-Premise
299	between	_	_	I-Premise
300	the	_	_	I-Premise
301	thyrotropin-stimulation	_	_	I-Premise
302	methods	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	use	_	_	I-Claim
306	of	_	_	I-Claim
307	recombinant	_	_	I-Claim
308	human	_	_	I-Claim
309	thyrotropin	_	_	I-Claim
310	and	_	_	I-Claim
311	low-dose	_	_	I-Claim
312	(	_	_	I-Claim
313	1.1	_	_	I-Claim
314	GBq	_	_	I-Claim
315	)	_	_	I-Claim
316	postoperative	_	_	I-Claim
317	radioiodine	_	_	I-Claim
318	ablation	_	_	I-Claim
319	may	_	_	I-Claim
320	be	_	_	I-Claim
321	sufficient	_	_	I-Claim
322	for	_	_	I-Claim
323	the	_	_	I-Claim
324	management	_	_	I-Claim
325	of	_	_	I-Claim
326	low-risk	_	_	I-Claim
327	thyroid	_	_	I-Claim
328	cancer	_	_	I-Claim
329	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	toxicity	_	_	O
10	and	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	radiation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	RT	_	_	O
17	)	_	_	O
18	for	_	_	O
19	localized	_	_	O
20	carcinoma	_	_	O
21	of	_	_	O
22	the	_	_	O
23	prostate	_	_	O
24	,	_	_	O
25	using	_	_	O
26	a	_	_	O
27	hypofractionated	_	_	O
28	(	_	_	O
29	55	_	_	O
30	Gy/20	_	_	O
31	fractions/4	_	_	O
32	weeks	_	_	O
33	)	_	_	O
34	vs.	_	_	O
35	a	_	_	O
36	conventionally	_	_	O
37	fractionated	_	_	O
38	(	_	_	O
39	64	_	_	O
40	Gy/32	_	_	O
41	fractions/6.5	_	_	O
42	weeks	_	_	O
43	)	_	_	O
44	dose	_	_	O
45	schedule	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	217	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	either	_	_	O
56	the	_	_	O
57	hypofractionated	_	_	O
58	(	_	_	O
59	108	_	_	O
60	patients	_	_	O
61	)	_	_	O
62	or	_	_	O
63	the	_	_	O
64	conventional	_	_	O
65	(	_	_	O
66	109	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	dose	_	_	O
70	schedule	_	_	O
71	,	_	_	O
72	with	_	_	O
73	planning	_	_	O
74	with	_	_	O
75	two-dimensional	_	_	O
76	(	_	_	O
77	2D	_	_	O
78	)	_	_	O
79	CT	_	_	O
80	scan	_	_	O
81	planning	_	_	O
82	methodology	_	_	O
83	in	_	_	O
84	the	_	_	O
85	majority	_	_	O
86	of	_	_	O
87	cases	_	_	O
88	.	_	_	O

89	All	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	followed	_	_	O
93	for	_	_	O
94	a	_	_	O
95	median	_	_	O
96	of	_	_	O
97	48	_	_	O
98	(	_	_	O
99	6-108	_	_	O
100	)	_	_	O
101	months	_	_	O
102	.	_	_	O

103	Gastrointestinal	_	_	O
104	(	_	_	O
105	GI	_	_	O
106	)	_	_	O
107	and	_	_	O
108	genitourinary	_	_	O
109	(	_	_	O
110	GU	_	_	O
111	)	_	_	O
112	toxicity	_	_	O
113	was	_	_	O
114	evaluated	_	_	O
115	before	_	_	O
116	RT	_	_	O
117	and	_	_	O
118	after	_	_	O
119	its	_	_	O
120	completion	_	_	O
121	using	_	_	O
122	modified	_	_	O
123	late	_	_	O
124	effects	_	_	O
125	of	_	_	O
126	normal	_	_	O
127	tissue-subjective	_	_	O
128	,	_	_	O
129	objective	_	_	O
130	,	_	_	O
131	management	_	_	O
132	,	_	_	O
133	analytic	_	_	O
134	(	_	_	O
135	LENT-SOMA	_	_	O
136	)	_	_	O
137	scales	_	_	O
138	and	_	_	O
139	the	_	_	O
140	European	_	_	O
141	Organization	_	_	O
142	for	_	_	O
143	Research	_	_	O
144	and	_	_	O
145	Treatment	_	_	O
146	of	_	_	O
147	Cancer	_	_	O
148	sexual	_	_	O
149	function	_	_	O
150	questionnaire	_	_	O
151	.	_	_	O

152	Efficacy	_	_	O
153	of	_	_	O
154	RT	_	_	O
155	based	_	_	O
156	on	_	_	O
157	clinical	_	_	O
158	,	_	_	O
159	radiologic	_	_	O
160	,	_	_	O
161	and	_	_	O
162	prostate-specific	_	_	O
163	antigen	_	_	O
164	data	_	_	O
165	were	_	_	O
166	also	_	_	O
167	evaluated	_	_	O
168	at	_	_	O
169	baseline	_	_	O
170	and	_	_	O
171	after	_	_	O
172	RT	_	_	O
173	.	_	_	O

174	Gastrointestinal	_	_	B-Premise
175	and	_	_	I-Premise
176	GU	_	_	I-Premise
177	toxicity	_	_	I-Premise
178	persisted	_	_	I-Premise
179	5	_	_	I-Premise
180	years	_	_	I-Premise
181	after	_	_	I-Premise
182	RT	_	_	I-Premise
183	and	_	_	I-Premise
184	did	_	_	I-Premise
185	not	_	_	I-Premise
186	differ	_	_	I-Premise
187	between	_	_	I-Premise
188	the	_	_	I-Premise
189	two	_	_	I-Premise
190	dose	_	_	I-Premise
191	schedules	_	_	I-Premise
192	other	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	regard	_	_	I-Premise
196	to	_	_	I-Premise
197	urgency	_	_	I-Premise
198	of	_	_	I-Premise
199	defecation	_	_	I-Premise
200	.	_	_	I-Premise

201	However	_	_	B-Premise
202	,	_	_	I-Premise
203	1-month	_	_	I-Premise
204	GI	_	_	I-Premise
205	toxicity	_	_	I-Premise
206	was	_	_	I-Premise
207	not	_	_	I-Premise
208	only	_	_	I-Premise
209	worse	_	_	I-Premise
210	in	_	_	I-Premise
211	patients	_	_	I-Premise
212	with	_	_	I-Premise
213	the	_	_	I-Premise
214	hypofractionated	_	_	I-Premise
215	RT	_	_	I-Premise
216	schedule	_	_	I-Premise
217	but	_	_	I-Premise
218	also	_	_	I-Premise
219	adversely	_	_	I-Premise
220	affected	_	_	I-Premise
221	daily	_	_	I-Premise
222	activities	_	_	I-Premise
223	.	_	_	I-Premise

224	Nadir	_	_	B-Premise
225	prostate-specific	_	_	I-Premise
226	antigen	_	_	I-Premise
227	values	_	_	I-Premise
228	occurred	_	_	I-Premise
229	at	_	_	I-Premise
230	a	_	_	I-Premise
231	median	_	_	I-Premise
232	of	_	_	I-Premise
233	18.0	_	_	I-Premise
234	(	_	_	I-Premise
235	3.0-54.0	_	_	I-Premise
236	)	_	_	I-Premise
237	months	_	_	I-Premise
238	after	_	_	I-Premise
239	RT	_	_	I-Premise
240	.	_	_	I-Premise

241	A	_	_	B-Premise
242	total	_	_	I-Premise
243	of	_	_	I-Premise
244	76	_	_	I-Premise
245	biochemical	_	_	I-Premise
246	relapses	_	_	I-Premise
247	,	_	_	I-Premise
248	with	_	_	I-Premise
249	or	_	_	I-Premise
250	without	_	_	I-Premise
251	clinical	_	_	I-Premise
252	relapses	_	_	I-Premise
253	,	_	_	I-Premise
254	have	_	_	I-Premise
255	occurred	_	_	I-Premise
256	since	_	_	I-Premise
257	;	_	_	I-Premise
258	of	_	_	I-Premise
259	these	_	_	I-Premise
260	,	_	_	I-Premise
261	37	_	_	I-Premise
262	were	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	hypofractionated	_	_	I-Premise
266	and	_	_	I-Premise
267	39	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	conventional	_	_	I-Premise
271	schedule	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	5-year	_	_	I-Premise
275	biochemical	_	_	I-Premise
276	+/-	_	_	I-Premise
277	clinical	_	_	I-Premise
278	relapse-free	_	_	I-Premise
279	and	_	_	I-Premise
280	overall	_	_	I-Premise
281	survival	_	_	I-Premise
282	was	_	_	I-Premise
283	55.9	_	_	I-Premise
284	%	_	_	I-Premise
285	and	_	_	I-Premise
286	85.3	_	_	I-Premise
287	%	_	_	I-Premise
288	respectively	_	_	I-Premise
289	for	_	_	I-Premise
290	all	_	_	I-Premise
291	patients	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	did	_	_	I-Premise
295	not	_	_	I-Premise
296	differ	_	_	I-Premise
297	between	_	_	I-Premise
298	the	_	_	I-Premise
299	two	_	_	I-Premise
300	schedules	_	_	I-Premise
301	.	_	_	I-Premise

302	Radiation	_	_	B-Claim
303	therapy	_	_	I-Claim
304	for	_	_	I-Claim
305	prostate	_	_	I-Claim
306	carcinoma	_	_	I-Claim
307	causes	_	_	I-Claim
308	persistent	_	_	I-Claim
309	GI	_	_	I-Claim
310	toxicity	_	_	I-Claim
311	that	_	_	I-Claim
312	is	_	_	I-Claim
313	largely	_	_	I-Claim
314	independent	_	_	I-Claim
315	of	_	_	I-Claim
316	the	_	_	I-Claim
317	two	_	_	I-Claim
318	dose	_	_	I-Claim
319	schedules	_	_	I-Claim
320	.	_	_	I-Claim

321	The	_	_	B-Claim
322	hypofractionated	_	_	I-Claim
323	schedule	_	_	I-Claim
324	is	_	_	I-Claim
325	equivalent	_	_	I-Claim
326	in	_	_	I-Claim
327	efficacy	_	_	I-Claim
328	to	_	_	I-Claim
329	the	_	_	I-Claim
330	conventional	_	_	I-Claim
331	schedule	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	mindfulness-based	_	_	O
6	stress	_	_	O
7	reduction	_	_	O
8	(	_	_	O
9	MBSR	_	_	O
10	)	_	_	O
11	for	_	_	O
12	mood	_	_	O
13	,	_	_	O
14	breast-	_	_	O
15	and	_	_	O
16	endocrine-specific	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	,	_	_	O
21	and	_	_	O
22	well-being	_	_	O
23	after	_	_	O
24	hospital	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	women	_	_	O
28	with	_	_	O
29	stage	_	_	O
30	0	_	_	O
31	to	_	_	O
32	III	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	.	_	_	O

36	A	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	wait-listed	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	trial	_	_	O
43	was	_	_	O
44	carried	_	_	O
45	out	_	_	O
46	in	_	_	O
47	229	_	_	O
48	women	_	_	O
49	after	_	_	O
50	surgery	_	_	O
51	,	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	and	_	_	O
55	radiotherapy	_	_	O
56	for	_	_	O
57	breast	_	_	O
58	cancer	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	to	_	_	O
65	the	_	_	O
66	8-week	_	_	O
67	MBSR	_	_	O
68	program	_	_	O
69	or	_	_	O
70	standard	_	_	O
71	care	_	_	O
72	.	_	_	O

73	Profile	_	_	O
74	of	_	_	O
75	Mood	_	_	O
76	States	_	_	O
77	(	_	_	O
78	POMS	_	_	O
79	;	_	_	O
80	primary	_	_	O
81	outcome	_	_	O
82	)	_	_	O
83	,	_	_	O
84	Functional	_	_	O
85	Assessment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	Therapy-Breast	_	_	O
89	(	_	_	O
90	FACT-B	_	_	O
91	)	_	_	O
92	,	_	_	O
93	Functional	_	_	O
94	Assessment	_	_	O
95	of	_	_	O
96	Cancer	_	_	O
97	Therapy-Endocrine	_	_	O
98	Symptoms	_	_	O
99	(	_	_	O
100	FACT-ES	_	_	O
101	)	_	_	O
102	scales	_	_	O
103	and	_	_	O
104	the	_	_	O
105	WHO	_	_	O
106	five-item	_	_	O
107	well-being	_	_	O
108	questionnaire	_	_	O
109	(	_	_	O
110	WHO-5	_	_	O
111	)	_	_	O
112	evaluated	_	_	O
113	mood	_	_	O
114	,	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	,	_	_	O
119	and	_	_	O
120	well-being	_	_	O
121	at	_	_	O
122	weeks	_	_	O
123	0	_	_	O
124	,	_	_	O
125	8	_	_	O
126	,	_	_	O
127	and	_	_	O
128	12	_	_	O
129	.	_	_	O

130	For	_	_	O
131	each	_	_	O
132	outcome	_	_	O
133	measure	_	_	O
134	,	_	_	O
135	a	_	_	O
136	repeated-measures	_	_	O
137	analysis	_	_	O
138	of	_	_	O
139	variance	_	_	O
140	model	_	_	O
141	,	_	_	O
142	which	_	_	O
143	incorporated	_	_	O
144	week	_	_	O
145	0	_	_	O
146	measurements	_	_	O
147	as	_	_	O
148	a	_	_	O
149	covariate	_	_	O
150	,	_	_	O
151	was	_	_	O
152	used	_	_	O
153	to	_	_	O
154	compare	_	_	O
155	treatment	_	_	O
156	groups	_	_	O
157	at	_	_	O
158	8	_	_	O
159	and	_	_	O
160	12	_	_	O
161	weeks	_	_	O
162	.	_	_	O

163	There	_	_	B-Premise
164	were	_	_	I-Premise
165	statistically	_	_	I-Premise
166	significant	_	_	I-Premise
167	improvements	_	_	I-Premise
168	in	_	_	I-Premise
169	outcome	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	experimental	_	_	I-Premise
173	group	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	control	_	_	I-Premise
177	group	_	_	I-Premise
178	at	_	_	I-Premise
179	both	_	_	I-Premise
180	8	_	_	I-Premise
181	and	_	_	I-Premise
182	12	_	_	I-Premise
183	weeks	_	_	I-Premise
184	(	_	_	I-Premise
185	except	_	_	I-Premise
186	as	_	_	I-Premise
187	indicated	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	POMS	_	_	I-Premise
191	total	_	_	I-Premise
192	mood	_	_	I-Premise
193	disturbance	_	_	I-Premise
194	(	_	_	I-Premise
195	and	_	_	I-Premise
196	its	_	_	I-Premise
197	subscales	_	_	I-Premise
198	of	_	_	I-Premise
199	anxiety	_	_	I-Premise
200	,	_	_	I-Premise
201	depression	_	_	I-Premise
202	[	_	_	I-Premise
203	8	_	_	I-Premise
204	weeks	_	_	I-Premise
205	only	_	_	I-Premise
206	]	_	_	I-Premise
207	,	_	_	I-Premise
208	anger	_	_	I-Premise
209	[	_	_	I-Premise
210	12	_	_	I-Premise
211	weeks	_	_	I-Premise
212	only	_	_	I-Premise
213	]	_	_	I-Premise
214	,	_	_	I-Premise
215	vigor	_	_	I-Premise
216	,	_	_	I-Premise
217	fatigue	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	confusion	_	_	I-Premise
221	[	_	_	I-Premise
222	8	_	_	I-Premise
223	weeks	_	_	I-Premise
224	only	_	_	I-Premise
225	]	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	FACT-B	_	_	I-Premise
229	,	_	_	I-Premise
230	FACT-ES	_	_	I-Premise
231	,	_	_	I-Premise
232	(	_	_	I-Premise
233	and	_	_	I-Premise
234	Functional	_	_	I-Premise
235	Assessment	_	_	I-Premise
236	of	_	_	I-Premise
237	Cancer	_	_	I-Premise
238	Therapy	_	_	I-Premise
239	subscales	_	_	I-Premise
240	of	_	_	I-Premise
241	physical	_	_	I-Premise
242	,	_	_	I-Premise
243	social	_	_	I-Premise
244	[	_	_	I-Premise
245	8	_	_	I-Premise
246	weeks	_	_	I-Premise
247	only	_	_	I-Premise
248	]	_	_	I-Premise
249	,	_	_	I-Premise
250	emotional	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	functional	_	_	I-Premise
254	well-being	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	WHO-5	_	_	I-Premise
259	.	_	_	I-Premise

260	MSBR	_	_	B-Premise
261	improved	_	_	I-Premise
262	mood	_	_	I-Premise
263	,	_	_	I-Premise
264	breast-	_	_	I-Premise
265	and	_	_	I-Premise
266	endocrine-related	_	_	I-Premise
267	quality	_	_	I-Premise
268	of	_	_	I-Premise
269	life	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	well-being	_	_	I-Premise
273	more	_	_	I-Premise
274	effectively	_	_	I-Premise
275	than	_	_	I-Premise
276	standard	_	_	I-Premise
277	care	_	_	I-Premise
278	in	_	_	I-Premise
279	women	_	_	I-Premise
280	with	_	_	I-Premise
281	stage	_	_	I-Premise
282	0	_	_	I-Premise
283	to	_	_	I-Premise
284	III	_	_	I-Premise
285	breast	_	_	I-Premise
286	cancer	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	these	_	_	I-Premise
290	results	_	_	I-Premise
291	persisted	_	_	I-Premise
292	at	_	_	I-Premise
293	three	_	_	I-Premise
294	months	_	_	I-Premise
295	.	_	_	I-Premise

296	To	_	_	B-Claim
297	our	_	_	I-Claim
298	knowledge	_	_	I-Claim
299	,	_	_	I-Claim
300	this	_	_	I-Claim
301	study	_	_	I-Claim
302	provided	_	_	I-Claim
303	novel	_	_	I-Claim
304	evidence	_	_	I-Claim
305	that	_	_	I-Claim
306	MBSR	_	_	I-Claim
307	can	_	_	I-Claim
308	help	_	_	I-Claim
309	alleviate	_	_	I-Claim
310	long-term	_	_	I-Claim
311	emotional	_	_	I-Claim
312	and	_	_	I-Claim
313	physical	_	_	I-Claim
314	adverse	_	_	I-Claim
315	effects	_	_	I-Claim
316	of	_	_	I-Claim
317	medical	_	_	I-Claim
318	treatments	_	_	I-Claim
319	,	_	_	I-Claim
320	including	_	_	I-Claim
321	endocrine	_	_	I-Claim
322	treatments	_	_	I-Claim
323	.	_	_	I-Claim

324	MBSR	_	_	B-Claim
325	is	_	_	I-Claim
326	recommended	_	_	I-Claim
327	to	_	_	I-Claim
328	support	_	_	I-Claim
329	survivors	_	_	I-Claim
330	of	_	_	I-Claim
331	breast	_	_	I-Claim
332	cancer	_	_	I-Claim
333	.	_	_	I-Claim


0	This	_	_	O
1	trial	_	_	O
2	was	_	_	O
3	conducted	_	_	O
4	to	_	_	O
5	determine	_	_	O
6	whether	_	_	O
7	high-dose	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	FU	_	_	O
11	)	_	_	O
12	given	_	_	O
13	as	_	_	O
14	a	_	_	O
15	weekly	_	_	O
16	24-hour	_	_	O
17	infusion	_	_	O
18	is	_	_	O
19	more	_	_	O
20	active	_	_	O
21	than	_	_	O
22	bolus	_	_	O
23	FU	_	_	O
24	+	_	_	O
25	leucovorin	_	_	O
26	(	_	_	O
27	LV	_	_	O
28	)	_	_	O
29	,	_	_	O
30	and	_	_	O
31	whether	_	_	O
32	high-dose	_	_	O
33	infusional	_	_	O
34	FU	_	_	O
35	can	_	_	O
36	be	_	_	O
37	modulated	_	_	O
38	by	_	_	O
39	LV	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	497	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	previously	_	_	O
48	untreated	_	_	O
49	metastatic	_	_	O
50	colorectal	_	_	O
51	cancer	_	_	O
52	were	_	_	O
53	randomly	_	_	O
54	assigned	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	bolus	_	_	O
58	FU	_	_	O
59	425	_	_	O
60	mg/m2	_	_	O
61	intravenously	_	_	O
62	+	_	_	O
63	LV	_	_	O
64	20	_	_	O
65	mg/m2	_	_	O
66	on	_	_	O
67	days	_	_	O
68	1	_	_	O
69	to	_	_	O
70	5	_	_	O
71	and	_	_	O
72	repeated	_	_	O
73	on	_	_	O
74	day	_	_	O
75	28	_	_	O
76	(	_	_	O
77	FU	_	_	O
78	+	_	_	O
79	LV	_	_	O
80	)	_	_	O
81	,	_	_	O
82	or	_	_	O
83	FU	_	_	O
84	2600	_	_	O
85	mg/m2	_	_	O
86	as	_	_	O
87	a	_	_	O
88	24-hour	_	_	O
89	infusion	_	_	O
90	alone	_	_	O
91	(	_	_	O
92	FU24h	_	_	O
93	)	_	_	O
94	or	_	_	O
95	in	_	_	O
96	combination	_	_	O
97	with	_	_	O
98	500	_	_	O
99	mg/m2	_	_	O
100	LV	_	_	O
101	(	_	_	O
102	FU24h	_	_	O
103	+	_	_	O
104	LV	_	_	O
105	)	_	_	O
106	-all	_	_	O
107	given	_	_	O
108	weekly	_	_	O
109	x6	_	_	O
110	followed	_	_	O
111	by	_	_	O
112	a	_	_	O
113	2-week	_	_	O
114	rest	_	_	O
115	period	_	_	O
116	.	_	_	O

117	Survival	_	_	O
118	was	_	_	O
119	the	_	_	O
120	major	_	_	O
121	study	_	_	O
122	end	_	_	O
123	point	_	_	O
124	.	_	_	O

125	With	_	_	B-Premise
126	a	_	_	I-Premise
127	median	_	_	I-Premise
128	follow-up	_	_	I-Premise
129	of	_	_	I-Premise
130	more	_	_	I-Premise
131	than	_	_	I-Premise
132	3	_	_	I-Premise
133	years	_	_	I-Premise
134	,	_	_	I-Premise
135	survival	_	_	I-Premise
136	did	_	_	I-Premise
137	not	_	_	I-Premise
138	differ	_	_	I-Premise
139	among	_	_	I-Premise
140	the	_	_	I-Premise
141	treatment	_	_	I-Premise
142	groups	_	_	I-Premise
143	(	_	_	I-Premise
144	median	_	_	I-Premise
145	FU	_	_	I-Premise
146	+	_	_	I-Premise
147	LV	_	_	I-Premise
148	,	_	_	I-Premise
149	11.1	_	_	I-Premise
150	months	_	_	I-Premise
151	[	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	CI	_	_	I-Premise
155	,	_	_	I-Premise
156	10.2	_	_	I-Premise
157	to	_	_	I-Premise
158	15.0	_	_	I-Premise
159	months	_	_	I-Premise
160	]	_	_	I-Premise
161	;	_	_	I-Premise
162	FU24h	_	_	I-Premise
163	,	_	_	I-Premise
164	13.0	_	_	I-Premise
165	months	_	_	I-Premise
166	[	_	_	I-Premise
167	95	_	_	I-Premise
168	%	_	_	I-Premise
169	CI	_	_	I-Premise
170	,	_	_	I-Premise
171	10.4	_	_	I-Premise
172	to	_	_	I-Premise
173	15.4	_	_	I-Premise
174	months	_	_	I-Premise
175	]	_	_	I-Premise
176	;	_	_	I-Premise
177	FU24h	_	_	I-Premise
178	+	_	_	I-Premise
179	LV	_	_	I-Premise
180	,	_	_	I-Premise
181	13.7	_	_	I-Premise
182	months	_	_	I-Premise
183	[	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	CI	_	_	I-Premise
187	,	_	_	I-Premise
188	12.0	_	_	I-Premise
189	to	_	_	I-Premise
190	16.4	_	_	I-Premise
191	months	_	_	I-Premise
192	]	_	_	I-Premise
193	;	_	_	I-Premise
194	P	_	_	I-Premise
195	=.724	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Progression-free	_	_	B-Premise
199	survival	_	_	I-Premise
200	(	_	_	I-Premise
201	PFS	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	significantly	_	_	I-Premise
205	longer	_	_	I-Premise
206	for	_	_	I-Premise
207	FU24h	_	_	I-Premise
208	+	_	_	I-Premise
209	LV	_	_	I-Premise
210	(	_	_	I-Premise
211	median	_	_	I-Premise
212	FU	_	_	I-Premise
213	+	_	_	I-Premise
214	LV	_	_	I-Premise
215	,	_	_	I-Premise
216	4.0	_	_	I-Premise
217	months	_	_	I-Premise
218	[	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	3.4	_	_	I-Premise
224	to	_	_	I-Premise
225	4.9	_	_	I-Premise
226	]	_	_	I-Premise
227	;	_	_	I-Premise
228	FU24h	_	_	I-Premise
229	,	_	_	I-Premise
230	4.1	_	_	I-Premise
231	months	_	_	I-Premise
232	[	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	3.4	_	_	I-Premise
238	to	_	_	I-Premise
239	5.0	_	_	I-Premise
240	]	_	_	I-Premise
241	;	_	_	I-Premise
242	FU24h	_	_	I-Premise
243	+	_	_	I-Premise
244	LV	_	_	I-Premise
245	5.6	_	_	I-Premise
246	months	_	_	I-Premise
247	[	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	4.4	_	_	I-Premise
253	to	_	_	I-Premise
254	6.7	_	_	I-Premise
255	]	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=.029	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Premise
262	response	_	_	I-Premise
263	rates	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	subgroup	_	_	I-Premise
267	of	_	_	I-Premise
268	patients	_	_	I-Premise
269	with	_	_	I-Premise
270	measurable	_	_	I-Premise
271	disease	_	_	I-Premise
272	were	_	_	I-Premise
273	12	_	_	I-Premise
274	%	_	_	I-Premise
275	,	_	_	I-Premise
276	10	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	17	_	_	I-Premise
281	%	_	_	I-Premise
282	for	_	_	I-Premise
283	FU	_	_	I-Premise
284	+	_	_	I-Premise
285	LV	_	_	I-Premise
286	,	_	_	I-Premise
287	FU24h	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	FU24h	_	_	I-Premise
291	+	_	_	I-Premise
292	LV	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	(	_	_	I-Premise
296	not	_	_	I-Premise
297	significant	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Occurrence	_	_	B-Premise
301	of	_	_	I-Premise
302	grade	_	_	I-Premise
303	3	_	_	I-Premise
304	and	_	_	I-Premise
305	4	_	_	I-Premise
306	diarrhea	_	_	I-Premise
307	was	_	_	I-Premise
308	higher	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	FU24h	_	_	I-Premise
312	+	_	_	I-Premise
313	LV	_	_	I-Premise
314	arm	_	_	I-Premise
315	(	_	_	I-Premise
316	22	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	compared	_	_	I-Premise
320	with	_	_	I-Premise
321	the	_	_	I-Premise
322	FU24h	_	_	I-Premise
323	(	_	_	I-Premise
324	6	_	_	I-Premise
325	%	_	_	I-Premise
326	)	_	_	I-Premise
327	or	_	_	I-Premise
328	FU	_	_	I-Premise
329	+	_	_	I-Premise
330	LV	_	_	I-Premise
331	(	_	_	I-Premise
332	9	_	_	I-Premise
333	%	_	_	I-Premise
334	)	_	_	I-Premise
335	arms	_	_	I-Premise
336	;	_	_	I-Premise
337	however	_	_	B-Premise
338	,	_	_	I-Premise
339	stomatitis	_	_	I-Premise
340	(	_	_	I-Premise
341	11	_	_	I-Premise
342	%	_	_	I-Premise
343	in	_	_	I-Premise
344	FU	_	_	I-Premise
345	+	_	_	I-Premise
346	LV	_	_	I-Premise
347	v	_	_	I-Premise
348	3	_	_	I-Premise
349	%	_	_	I-Premise
350	in	_	_	I-Premise
351	FU24h	_	_	I-Premise
352	v	_	_	I-Premise
353	5	_	_	I-Premise
354	%	_	_	I-Premise
355	in	_	_	I-Premise
356	FU24h	_	_	I-Premise
357	+	_	_	I-Premise
358	LV	_	_	I-Premise
359	arms	_	_	I-Premise
360	)	_	_	I-Premise
361	and	_	_	I-Premise
362	hematologic	_	_	I-Premise
363	toxicity	_	_	I-Premise
364	were	_	_	I-Premise
365	higher	_	_	I-Premise
366	in	_	_	I-Premise
367	the	_	_	I-Premise
368	bolus	_	_	I-Premise
369	FU	_	_	I-Premise
370	+	_	_	I-Premise
371	LV	_	_	I-Premise
372	arm	_	_	I-Premise
373	.	_	_	I-Premise

374	Global	_	_	B-Claim
375	quality	_	_	I-Claim
376	of	_	_	I-Claim
377	life	_	_	I-Claim
378	did	_	_	I-Claim
379	not	_	_	I-Claim
380	differ	_	_	I-Claim
381	within	_	_	I-Claim
382	the	_	_	I-Claim
383	three	_	_	I-Claim
384	arms	_	_	I-Claim
385	.	_	_	I-Claim

386	Neither	_	_	B-Claim
387	FU24h	_	_	I-Claim
388	+	_	_	I-Claim
389	LV	_	_	I-Claim
390	nor	_	_	I-Claim
391	FU24h	_	_	I-Claim
392	prolong	_	_	I-Claim
393	survival	_	_	I-Claim
394	,	_	_	I-Claim
395	relative	_	_	I-Claim
396	to	_	_	I-Claim
397	bolus	_	_	I-Claim
398	FU	_	_	I-Claim
399	+	_	_	I-Claim
400	LV	_	_	I-Claim
401	.	_	_	I-Claim

402	Leucovorin	_	_	B-Claim
403	increases	_	_	I-Claim
404	PFS	_	_	I-Claim
405	if	_	_	I-Claim
406	added	_	_	I-Claim
407	to	_	_	I-Claim
408	FU24h	_	_	I-Claim
409	,	_	_	I-Claim
410	but	_	_	I-Claim
411	increases	_	_	I-Claim
412	toxicity	_	_	I-Claim
413	.	_	_	I-Claim


0	The	_	_	O
1	European	_	_	O
2	Study	_	_	O
3	Group	_	_	O
4	for	_	_	O
5	Pancreatic	_	_	O
6	Cancer	_	_	O
7	(	_	_	O
8	ESPAC-1	_	_	O
9	)	_	_	O
10	study	_	_	O
11	is	_	_	O
12	the	_	_	O
13	largest	_	_	O
14	study	_	_	O
15	of	_	_	O
16	adjuvant	_	_	O
17	treatment	_	_	O
18	for	_	_	O
19	pancreatic	_	_	O
20	ductal	_	_	O
21	adenocarcinoma	_	_	O
22	to	_	_	O
23	date	_	_	O
24	and	_	_	O
25	confirmed	_	_	O
26	a	_	_	O
27	survival	_	_	O
28	advantage	_	_	O
29	for	_	_	O
30	adjuvant	_	_	O
31	chemotherapy	_	_	O
32	but	_	_	O
33	not	_	_	O
34	for	_	_	O
35	chemoradiation	_	_	O
36	.	_	_	O

37	The	_	_	O
38	importance	_	_	O
39	of	_	_	O
40	parallel	_	_	O
41	evaluation	_	_	O
42	of	_	_	O
43	survival	_	_	O
44	and	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	(	_	_	O
49	QoL	_	_	O
50	)	_	_	O
51	has	_	_	O
52	been	_	_	O
53	recognized	_	_	O
54	as	_	_	O
55	fundamental	_	_	O
56	and	_	_	O
57	the	_	_	O
58	aim	_	_	O
59	was	_	_	O
60	to	_	_	O
61	assess	_	_	O
62	QoL	_	_	O
63	and	_	_	O
64	quality	_	_	O
65	adjusted	_	_	O
66	survival	_	_	O
67	.	_	_	O

68	A	_	_	O
69	longitudinal	_	_	O
70	QoL	_	_	O
71	study	_	_	O
72	on	_	_	O
73	a	_	_	O
74	subset	_	_	O
75	of	_	_	O
76	ESPAC-1	_	_	O
77	patients	_	_	O
78	who	_	_	O
79	prospectively	_	_	O
80	completed	_	_	O
81	the	_	_	O
82	EORTC	_	_	O
83	QLQ	_	_	O
84	C-30	_	_	O
85	questionnaire	_	_	O
86	during	_	_	O
87	treatment	_	_	O
88	and	_	_	O
89	follow-up	_	_	O
90	.	_	_	O

91	An	_	_	O
92	integrated	_	_	O
93	quality-survival	_	_	O
94	product	_	_	O
95	method	_	_	O
96	was	_	_	O
97	used	_	_	O
98	to	_	_	O
99	adjust	_	_	O
100	any	_	_	O
101	treatment	_	_	O
102	effect	_	_	O
103	on	_	_	O
104	survival	_	_	O
105	by	_	_	O
106	a	_	_	O
107	function	_	_	O
108	of	_	_	O
109	measured	_	_	O
110	QoL	_	_	O
111	,	_	_	O
112	calculated	_	_	O
113	over	_	_	O
114	a	_	_	O
115	restricted	_	_	O
116	24-month-period	_	_	O
117	(	_	_	O
118	QALM-24	_	_	O
119	)	_	_	O
120	.	_	_	O

121	Three	_	_	O
122	hundred	_	_	O
123	and	_	_	O
124	sixteen	_	_	O
125	patients	_	_	O
126	completed	_	_	O
127	1,201	_	_	O
128	questionnaires	_	_	O
129	.	_	_	O

130	There	_	_	O
131	were	_	_	O
132	no	_	_	O
133	differences	_	_	O
134	between	_	_	O
135	treatment	_	_	O
136	groups	_	_	O
137	in	_	_	O
138	dimension	_	_	O
139	scores	_	_	O
140	at	_	_	O
141	baseline	_	_	O
142	(	_	_	O
143	randomization	_	_	O
144	)	_	_	O
145	.	_	_	O

146	For	_	_	B-Premise
147	the	_	_	I-Premise
148	chemotherapy	_	_	I-Premise
149	group	_	_	I-Premise
150	,	_	_	I-Premise
151	the	_	_	I-Premise
152	mean	_	_	I-Premise
153	Quality	_	_	I-Premise
154	Adjusted	_	_	I-Premise
155	Life	_	_	I-Premise
156	Months	_	_	I-Premise
157	over	_	_	I-Premise
158	24	_	_	I-Premise
159	months	_	_	I-Premise
160	(	_	_	I-Premise
161	QALM-24	_	_	I-Premise
162	)	_	_	I-Premise
163	was	_	_	I-Premise
164	9.6	_	_	I-Premise
165	(	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	:	_	_	I-Premise
170	8.7	_	_	I-Premise
171	,	_	_	I-Premise
172	11.2	_	_	I-Premise
173	)	_	_	I-Premise
174	months	_	_	I-Premise
175	compared	_	_	I-Premise
176	with	_	_	I-Premise
177	the	_	_	I-Premise
178	mean	_	_	I-Premise
179	QALM-24	_	_	I-Premise
180	of	_	_	I-Premise
181	8.6	_	_	I-Premise
182	(	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	:	_	_	I-Premise
187	7.6	_	_	I-Premise
188	,	_	_	I-Premise
189	10.5	_	_	I-Premise
190	)	_	_	I-Premise
191	months	_	_	I-Premise
192	for	_	_	I-Premise
193	the	_	_	I-Premise
194	no	_	_	I-Premise
195	chemotherapy	_	_	I-Premise
196	group	_	_	I-Premise
197	.	_	_	I-Premise

198	For	_	_	B-Premise
199	the	_	_	I-Premise
200	chemoradiation	_	_	I-Premise
201	group	_	_	I-Premise
202	,	_	_	I-Premise
203	the	_	_	I-Premise
204	mean	_	_	I-Premise
205	QALM-24	_	_	I-Premise
206	was	_	_	I-Premise
207	7.1	_	_	I-Premise
208	(	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	CI	_	_	I-Premise
212	:	_	_	I-Premise
213	6.0	_	_	I-Premise
214	,	_	_	I-Premise
215	9.0	_	_	I-Premise
216	)	_	_	I-Premise
217	months	_	_	I-Premise
218	compared	_	_	I-Premise
219	with	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	QALM-24	_	_	I-Premise
223	of	_	_	I-Premise
224	8.1	_	_	I-Premise
225	(	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	:	_	_	I-Premise
230	7.0	_	_	I-Premise
231	,	_	_	I-Premise
232	10.0	_	_	I-Premise
233	)	_	_	I-Premise
234	months	_	_	I-Premise
235	for	_	_	I-Premise
236	the	_	_	I-Premise
237	no	_	_	I-Premise
238	chemoradiation	_	_	I-Premise
239	group	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Claim
242	previously	_	_	I-Claim
243	reported	_	_	I-Claim
244	survival	_	_	I-Claim
245	advantage	_	_	I-Claim
246	supporting	_	_	I-Claim
247	the	_	_	I-Claim
248	use	_	_	I-Claim
249	of	_	_	I-Claim
250	adjuvant	_	_	I-Claim
251	chemotherapy	_	_	I-Claim
252	is	_	_	I-Claim
253	maintained	_	_	I-Claim
254	when	_	_	I-Claim
255	adjusted	_	_	I-Claim
256	using	_	_	I-Claim
257	quality	_	_	I-Claim
258	adjusted	_	_	I-Claim
259	survival	_	_	I-Claim
260	methodology	_	_	I-Claim
261	.	_	_	I-Claim

262	Chemotherapy	_	_	B-Claim
263	provided	_	_	I-Claim
264	on	_	_	I-Claim
265	average	_	_	I-Claim
266	an	_	_	I-Claim
267	additional	_	_	I-Claim
268	1.0	_	_	I-Claim
269	quality-adjusted	_	_	I-Claim
270	life	_	_	I-Claim
271	months	_	_	I-Claim
272	within	_	_	I-Claim
273	a	_	_	I-Claim
274	restricted	_	_	I-Claim
275	2-year	_	_	I-Claim
276	time	_	_	I-Claim
277	period	_	_	I-Claim
278	from	_	_	I-Claim
279	the	_	_	I-Claim
280	time	_	_	I-Claim
281	of	_	_	I-Claim
282	resection	_	_	I-Claim
283	.	_	_	I-Claim


0	Improvements	_	_	O
1	can	_	_	O
2	be	_	_	O
3	made	_	_	O
4	in	_	_	O
5	the	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	cancer	_	_	O
9	care	_	_	O
10	if	_	_	O
11	supportive	_	_	O
12	care	_	_	O
13	needs	_	_	O
14	are	_	_	O
15	addressed	_	_	O
16	;	_	_	O
17	however	_	_	O
18	,	_	_	O
19	there	_	_	O
20	are	_	_	O
21	few	_	_	O
22	trials	_	_	O
23	of	_	_	O
24	supportive	_	_	O
25	care	_	_	O
26	interventions	_	_	O
27	to	_	_	O
28	guide	_	_	O
29	policy	_	_	O
30	and	_	_	O
31	practice	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	aimed	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	effectiveness	_	_	O
40	of	_	_	O
41	a	_	_	O
42	nurse-delivered	_	_	O
43	telephone	_	_	O
44	supportive	_	_	O
45	intervention	_	_	O
46	(	_	_	O
47	the	_	_	O
48	"	_	_	O
49	CONNECT	_	_	O
50	"	_	_	O
51	intervention	_	_	O
52	)	_	_	O
53	.	_	_	O

54	This	_	_	O
55	study	_	_	O
56	was	_	_	O
57	a	_	_	O
58	pilot	_	_	O
59	randomized	_	_	O
60	controlled	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	Intervention	_	_	O
64	group	_	_	O
65	patients	_	_	O
66	received	_	_	O
67	5	_	_	O
68	calls	_	_	O
69	from	_	_	O
70	a	_	_	O
71	specialist	_	_	O
72	colorectal	_	_	O
73	nurse	_	_	O
74	in	_	_	O
75	the	_	_	O
76	6	_	_	O
77	months	_	_	O
78	after	_	_	O
79	hospital	_	_	O
80	discharge	_	_	O
81	.	_	_	O

82	Each	_	_	O
83	call	_	_	O
84	was	_	_	O
85	standardized	_	_	O
86	,	_	_	O
87	comprising	_	_	O
88	the	_	_	O
89	assessment	_	_	O
90	of	_	_	O
91	unmet	_	_	O
92	need	_	_	O
93	and	_	_	O
94	the	_	_	O
95	provision	_	_	O
96	of	_	_	O
97	information	_	_	O
98	and	_	_	O
99	emotional	_	_	O
100	support	_	_	O
101	.	_	_	O

102	CONNECT	_	_	O
103	was	_	_	O
104	in	_	_	O
105	addition	_	_	O
106	to	_	_	O
107	standard	_	_	O
108	clinical	_	_	O
109	follow-up	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	allocated	_	_	O
113	to	_	_	O
114	the	_	_	O
115	control	_	_	O
116	group	_	_	O
117	received	_	_	O
118	standard	_	_	O
119	follow-up	_	_	O
120	only	_	_	O
121	.	_	_	O

122	This	_	_	O
123	study	_	_	O
124	took	_	_	O
125	place	_	_	O
126	at	_	_	O
127	the	_	_	O
128	Royal	_	_	O
129	Prince	_	_	O
130	Alfred	_	_	O
131	Hospital	_	_	O
132	,	_	_	O
133	Sydney	_	_	O
134	,	_	_	O
135	Australia	_	_	O
136	.	_	_	O

137	Patients	_	_	O
138	(	_	_	O
139	n	_	_	O
140	=	_	_	O
141	75	_	_	O
142	)	_	_	O
143	were	_	_	O
144	included	_	_	O
145	who	_	_	O
146	had	_	_	O
147	been	_	_	O
148	surgically	_	_	O
149	treated	_	_	O
150	for	_	_	O
151	colorectal	_	_	O
152	cancer	_	_	O
153	(	_	_	O
154	any	_	_	O
155	stage	_	_	O
156	)	_	_	O
157	.	_	_	O

158	The	_	_	O
159	main	_	_	O
160	outcome	_	_	O
161	measures	_	_	O
162	were	_	_	O
163	the	_	_	O
164	unmet	_	_	O
165	supportive	_	_	O
166	care	_	_	O
167	needs	_	_	O
168	,	_	_	O
169	health	_	_	O
170	service	_	_	O
171	utilization	_	_	O
172	,	_	_	O
173	and	_	_	O
174	quality	_	_	O
175	of	_	_	O
176	life	_	_	O
177	at	_	_	O
178	1	_	_	O
179	,	_	_	O
180	3	_	_	O
181	,	_	_	O
182	and	_	_	O
183	6	_	_	O
184	months	_	_	O
185	postdischarge	_	_	O
186	.	_	_	O

187	Of	_	_	O
188	87	_	_	O
189	eligible	_	_	O
190	patients	_	_	O
191	,	_	_	O
192	75	_	_	O
193	consented	_	_	O
194	(	_	_	O
195	86	_	_	O
196	%	_	_	O
197	consent	_	_	O
198	rate	_	_	O
199	)	_	_	O
200	.	_	_	O

201	Thirty-nine	_	_	O
202	patients	_	_	O
203	were	_	_	O
204	randomly	_	_	O
205	assigned	_	_	O
206	to	_	_	O
207	CONNECT	_	_	O
208	and	_	_	O
209	36	_	_	O
210	to	_	_	O
211	usual	_	_	O
212	care	_	_	O
213	.	_	_	O

214	At	_	_	B-Premise
215	6	_	_	I-Premise
216	months	_	_	I-Premise
217	,	_	_	I-Premise
218	there	_	_	I-Premise
219	was	_	_	I-Premise
220	a	_	_	I-Premise
221	clinically	_	_	I-Premise
222	relevant	_	_	I-Premise
223	,	_	_	I-Premise
224	but	_	_	I-Premise
225	nonsignificant	_	_	I-Premise
226	reduction	_	_	I-Premise
227	in	_	_	I-Premise
228	presentations	_	_	I-Premise
229	to	_	_	I-Premise
230	emergency	_	_	I-Premise
231	departments	_	_	I-Premise
232	(	_	_	I-Premise
233	21	_	_	I-Premise
234	%	_	_	I-Premise
235	vs	_	_	I-Premise
236	33	_	_	I-Premise
237	%	_	_	I-Premise
238	;	_	_	I-Premise
239	Ï‡1	_	_	I-Premise
240	=	_	_	I-Premise
241	1.41	_	_	I-Premise
242	,	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.23	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	readmission	_	_	I-Premise
249	to	_	_	I-Premise
250	the	_	_	I-Premise
251	hospital	_	_	I-Premise
252	(	_	_	I-Premise
253	37	_	_	I-Premise
254	%	_	_	I-Premise
255	vs	_	_	I-Premise
256	47	_	_	I-Premise
257	%	_	_	I-Premise
258	;	_	_	I-Premise
259	Ï‡1	_	_	I-Premise
260	=	_	_	I-Premise
261	0.82	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.37	_	_	I-Premise
266	)	_	_	I-Premise
267	among	_	_	I-Premise
268	intervention	_	_	I-Premise
269	compared	_	_	I-Premise
270	with	_	_	I-Premise
271	control	_	_	I-Premise
272	group	_	_	I-Premise
273	participants	_	_	I-Premise
274	.	_	_	I-Premise

275	Nonsignificant	_	_	B-Premise
276	differences	_	_	I-Premise
277	between	_	_	I-Premise
278	groups	_	_	I-Premise
279	were	_	_	I-Premise
280	found	_	_	I-Premise
281	for	_	_	I-Premise
282	all	_	_	I-Premise
283	unmet	_	_	I-Premise
284	supportive	_	_	I-Premise
285	care	_	_	I-Premise
286	need	_	_	I-Premise
287	and	_	_	I-Premise
288	quality-of-life	_	_	I-Premise
289	scores	_	_	I-Premise
290	,	_	_	I-Premise
291	change	_	_	I-Premise
292	scores	_	_	I-Premise
293	,	_	_	I-Premise
294	and	_	_	I-Premise
295	trends	_	_	I-Premise
296	.	_	_	I-Premise

297	However	_	_	B-Premise
298	,	_	_	I-Premise
299	at	_	_	I-Premise
300	6	_	_	I-Premise
301	months	_	_	I-Premise
302	,	_	_	I-Premise
303	total	_	_	I-Premise
304	quality-of-life	_	_	I-Premise
305	scores	_	_	I-Premise
306	were	_	_	I-Premise
307	higher	_	_	I-Premise
308	for	_	_	I-Premise
309	intervention	_	_	I-Premise
310	group	_	_	I-Premise
311	patients	_	_	I-Premise
312	than	_	_	I-Premise
313	controls	_	_	I-Premise
314	(	_	_	I-Premise
315	106.0	_	_	I-Premise
316	vs	_	_	I-Premise
317	98.6	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	This	_	_	O
321	difference	_	_	O
322	(	_	_	O
323	7.4	_	_	O
324	)	_	_	O
325	was	_	_	O
326	clinically	_	_	O
327	relevant	_	_	O
328	.	_	_	O

329	Improvements	_	_	B-Claim
330	in	_	_	I-Claim
331	total	_	_	I-Claim
332	quality-of-life	_	_	I-Claim
333	change	_	_	I-Claim
334	scores	_	_	I-Claim
335	demonstrated	_	_	I-Claim
336	that	_	_	I-Claim
337	at	_	_	I-Claim
338	6	_	_	I-Claim
339	months	_	_	I-Claim
340	,	_	_	I-Claim
341	improvements	_	_	I-Claim
342	were	_	_	I-Claim
343	more	_	_	I-Claim
344	than	_	_	I-Claim
345	twice	_	_	I-Claim
346	as	_	_	I-Claim
347	large	_	_	I-Claim
348	and	_	_	I-Claim
349	clinically	_	_	I-Claim
350	significant	_	_	I-Claim
351	in	_	_	I-Claim
352	the	_	_	I-Claim
353	intervention	_	_	I-Claim
354	compared	_	_	I-Claim
355	with	_	_	I-Claim
356	the	_	_	I-Claim
357	control	_	_	I-Claim
358	group	_	_	I-Claim
359	.	_	_	I-Claim

360	CONNECT	_	_	B-Claim
361	has	_	_	I-Claim
362	shown	_	_	I-Claim
363	promising	_	_	I-Claim
364	indications	_	_	I-Claim
365	on	_	_	I-Claim
366	health	_	_	I-Claim
367	system	_	_	I-Claim
368	and	_	_	I-Claim
369	patient	_	_	I-Claim
370	outcomes	_	_	I-Claim
371	that	_	_	I-Claim
372	warrant	_	_	I-Claim
373	a	_	_	I-Claim
374	larger	_	_	I-Claim
375	study	_	_	I-Claim
376	to	_	_	I-Claim
377	further	_	_	I-Claim
378	investigate	_	_	I-Claim
379	the	_	_	I-Claim
380	potential	_	_	I-Claim
381	of	_	_	I-Claim
382	this	_	_	I-Claim
383	intervention	_	_	I-Claim
384	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	progression-free	_	_	O
10	survival	_	_	O
11	(	_	_	O
12	PFS	_	_	O
13	)	_	_	O
14	,	_	_	O
15	overall	_	_	O
16	survival	_	_	O
17	(	_	_	O
18	OS	_	_	O
19	)	_	_	O
20	,	_	_	O
21	and	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	in	_	_	O
26	women	_	_	O
27	with	_	_	O
28	metastatic	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	(	_	_	O
32	MBC	_	_	O
33	)	_	_	O
34	receiving	_	_	O
35	high-dose	_	_	O
36	chemotherapy	_	_	O
37	plus	_	_	O
38	autologous	_	_	O
39	stem-cell	_	_	O
40	transplantation	_	_	O
41	(	_	_	O
42	ASCT	_	_	O
43	;	_	_	O
44	HDCT	_	_	O
45	)	_	_	O
46	compared	_	_	O
47	with	_	_	O
48	standard-dose	_	_	O
49	therapy	_	_	O
50	.	_	_	O

51	Between	_	_	O
52	April	_	_	O
53	1997	_	_	O
54	and	_	_	O
55	December	_	_	O
56	2000	_	_	O
57	,	_	_	O
58	386	_	_	O
59	women	_	_	O
60	with	_	_	O
61	MBC	_	_	O
62	and	_	_	O
63	no	_	_	O
64	prior	_	_	O
65	chemotherapy	_	_	O
66	for	_	_	O
67	metastatic	_	_	O
68	disease	_	_	O
69	were	_	_	O
70	registered	_	_	O
71	.	_	_	O

72	After	_	_	O
73	initial	_	_	O
74	response	_	_	O
75	to	_	_	O
76	anthracycline-	_	_	O
77	or	_	_	O
78	taxane-based	_	_	O
79	induction	_	_	O
80	chemotherapy	_	_	O
81	,	_	_	O
82	224	_	_	O
83	patients	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	:	_	_	O
88	112	_	_	O
89	to	_	_	O
90	high-dose	_	_	O
91	cyclophosphamide	_	_	O
92	,	_	_	O
93	mitoxantrone	_	_	O
94	,	_	_	O
95	and	_	_	O
96	carboplatin	_	_	O
97	chemotherapy	_	_	O
98	and	_	_	O
99	ASCT	_	_	O
100	(	_	_	O
101	HDCT	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	112	_	_	O
106	to	_	_	O
107	standard	_	_	O
108	therapy	_	_	O
109	(	_	_	O
110	ST	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Median	_	_	O
114	age	_	_	O
115	was	_	_	O
116	47	_	_	O
117	years	_	_	O
118	(	_	_	O
119	range	_	_	O
120	,	_	_	O
121	25	_	_	O
122	to	_	_	O
123	67	_	_	O
124	years	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Thirty	_	_	O
128	two	_	_	O
129	percent	_	_	O
130	of	_	_	O
131	women	_	_	O
132	randomly	_	_	O
133	assigned	_	_	O
134	had	_	_	O
135	estrogen	_	_	O
136	and	_	_	O
137	progesterone	_	_	O
138	receptor-negative	_	_	O
139	breast	_	_	O
140	cancer	_	_	O
141	,	_	_	O
142	42	_	_	O
143	%	_	_	O
144	had	_	_	O
145	visceral	_	_	O
146	metastases	_	_	O
147	,	_	_	O
148	and	_	_	O
149	58	_	_	O
150	%	_	_	O
151	had	_	_	O
152	bone	_	_	O
153	metastases	_	_	O
154	.	_	_	O

155	Complete	_	_	O
156	remission	_	_	O
157	rates	_	_	O
158	before	_	_	O
159	random	_	_	O
160	assignment	_	_	O
161	were	_	_	O
162	11	_	_	O
163	%	_	_	O
164	for	_	_	O
165	those	_	_	O
166	receiving	_	_	O
167	HDCT	_	_	O
168	and	_	_	O
169	12	_	_	O
170	%	_	_	O
171	for	_	_	O
172	those	_	_	O
173	receiving	_	_	O
174	ST.	_	_	O
175	After	_	_	B-Premise
176	a	_	_	I-Premise
177	median	_	_	I-Premise
178	follow-up	_	_	I-Premise
179	of	_	_	I-Premise
180	48	_	_	I-Premise
181	months	_	_	I-Premise
182	,	_	_	I-Premise
183	79	_	_	I-Premise
184	deaths	_	_	I-Premise
185	were	_	_	I-Premise
186	observed	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	HDCT	_	_	I-Premise
190	arm	_	_	I-Premise
191	and	_	_	I-Premise
192	77	_	_	I-Premise
193	deaths	_	_	I-Premise
194	were	_	_	I-Premise
195	observed	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	ST	_	_	I-Premise
199	arm	_	_	I-Premise
200	;	_	_	I-Premise
201	seven	_	_	B-Premise
202	patients	_	_	I-Premise
203	(	_	_	I-Premise
204	6	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	HDCT	_	_	I-Premise
210	arm	_	_	I-Premise
211	died	_	_	I-Premise
212	as	_	_	I-Premise
213	a	_	_	I-Premise
214	result	_	_	I-Premise
215	of	_	_	I-Premise
216	toxicity	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	median	_	_	I-Premise
220	OS	_	_	I-Premise
221	was	_	_	I-Premise
222	24	_	_	I-Premise
223	months	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	HDCT	_	_	I-Premise
227	arm	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	,	_	_	I-Premise
233	21	_	_	I-Premise
234	to	_	_	I-Premise
235	35	_	_	I-Premise
236	months	_	_	I-Premise
237	)	_	_	I-Premise
238	and	_	_	I-Premise
239	28	_	_	I-Premise
240	months	_	_	I-Premise
241	for	_	_	I-Premise
242	ST	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	,	_	_	I-Premise
248	22	_	_	I-Premise
249	to	_	_	I-Premise
250	33	_	_	I-Premise
251	months	_	_	I-Premise
252	;	_	_	I-Premise
253	hazard	_	_	I-Premise
254	ratio	_	_	I-Premise
255	[	_	_	I-Premise
256	HR	_	_	I-Premise
257	]	_	_	I-Premise
258	,	_	_	I-Premise
259	0.9	_	_	I-Premise
260	;	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	,	_	_	I-Premise
265	0.6	_	_	I-Premise
266	to	_	_	I-Premise
267	1.2	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.43	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	PFS	_	_	B-Premise
275	was	_	_	I-Premise
276	11	_	_	I-Premise
277	months	_	_	I-Premise
278	for	_	_	I-Premise
279	HDCT	_	_	I-Premise
280	and	_	_	I-Premise
281	9	_	_	I-Premise
282	months	_	_	I-Premise
283	for	_	_	I-Premise
284	ST	_	_	I-Premise
285	(	_	_	I-Premise
286	HR	_	_	I-Premise
287	,	_	_	I-Premise
288	0.6	_	_	I-Premise
289	in	_	_	I-Premise
290	favor	_	_	I-Premise
291	of	_	_	I-Premise
292	HDCT	_	_	I-Premise
293	;	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	,	_	_	I-Premise
298	0.5	_	_	I-Premise
299	to	_	_	I-Premise
300	0.9	_	_	I-Premise
301	;	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	.006	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	HDCT	_	_	B-Claim
308	did	_	_	I-Claim
309	not	_	_	I-Claim
310	improve	_	_	I-Claim
311	OS	_	_	I-Claim
312	in	_	_	I-Claim
313	women	_	_	I-Claim
314	with	_	_	I-Claim
315	MBC	_	_	I-Claim
316	when	_	_	I-Claim
317	used	_	_	I-Claim
318	as	_	_	I-Claim
319	consolidation	_	_	I-Claim
320	after	_	_	I-Claim
321	response	_	_	I-Claim
322	to	_	_	I-Claim
323	induction	_	_	I-Claim
324	chemotherapy	_	_	I-Claim
325	.	_	_	I-Claim


0	Care	_	_	O
1	closer	_	_	O
2	to	_	_	O
3	home	_	_	O
4	is	_	_	O
5	being	_	_	O
6	explored	_	_	O
7	as	_	_	O
8	a	_	_	O
9	means	_	_	O
10	of	_	_	O
11	improving	_	_	O
12	patient	_	_	O
13	experience	_	_	O
14	as	_	_	O
15	well	_	_	O
16	as	_	_	O
17	efficiency	_	_	O
18	in	_	_	O
19	terms	_	_	O
20	of	_	_	O
21	cost	_	_	O
22	savings	_	_	O
23	.	_	_	O

24	Evidence	_	_	O
25	that	_	_	O
26	community	_	_	O
27	cancer	_	_	O
28	services	_	_	O
29	improve	_	_	O
30	care	_	_	O
31	quality	_	_	O
32	and/or	_	_	O
33	generate	_	_	O
34	cost	_	_	O
35	savings	_	_	O
36	is	_	_	O
37	currently	_	_	O
38	limited	_	_	O
39	.	_	_	O

40	A	_	_	O
41	randomised	_	_	O
42	study	_	_	O
43	was	_	_	O
44	undertaken	_	_	O
45	to	_	_	O
46	compare	_	_	O
47	delivery	_	_	O
48	of	_	_	O
49	cancer	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	the	_	_	O
53	hospital	_	_	O
54	with	_	_	O
55	two	_	_	O
56	different	_	_	O
57	community	_	_	O
58	settings	_	_	O
59	.	_	_	O

60	Ninety-seven	_	_	O
61	patients	_	_	O
62	being	_	_	O
63	offered	_	_	O
64	outpatient-based	_	_	O
65	cancer	_	_	O
66	treatment	_	_	O
67	were	_	_	O
68	randomised	_	_	O
69	to	_	_	O
70	treatment	_	_	O
71	delivered	_	_	O
72	in	_	_	O
73	a	_	_	O
74	hospital	_	_	O
75	day	_	_	O
76	unit	_	_	O
77	,	_	_	O
78	at	_	_	O
79	the	_	_	O
80	patient	_	_	O
81	's	_	_	O
82	home	_	_	O
83	or	_	_	O
84	in	_	_	O
85	local	_	_	O
86	general	_	_	O
87	practice	_	_	O
88	(	_	_	O
89	GP	_	_	O
90	)	_	_	O
91	surgeries	_	_	O
92	.	_	_	O

93	The	_	_	O
94	primary	_	_	O
95	outcome	_	_	O
96	was	_	_	O
97	patient-perceived	_	_	O
98	benefits	_	_	O
99	,	_	_	O
100	using	_	_	O
101	the	_	_	O
102	emotional	_	_	O
103	function	_	_	O
104	domain	_	_	O
105	of	_	_	O
106	the	_	_	O
107	EORTC	_	_	O
108	quality	_	_	O
109	of	_	_	O
110	life	_	_	O
111	(	_	_	O
112	QOL	_	_	O
113	)	_	_	O
114	QLQC30	_	_	O
115	questionnaire	_	_	O
116	evaluated	_	_	O
117	after	_	_	O
118	12	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	Secondary	_	_	O
122	outcomes	_	_	O
123	included	_	_	O
124	additional	_	_	O
125	QOL	_	_	O
126	measures	_	_	O
127	,	_	_	O
128	patient	_	_	O
129	satisfaction	_	_	O
130	,	_	_	O
131	safety	_	_	O
132	and	_	_	O
133	health	_	_	O
134	economics	_	_	O
135	.	_	_	O

136	There	_	_	B-Premise
137	was	_	_	I-Premise
138	no	_	_	I-Premise
139	statistically	_	_	I-Premise
140	significant	_	_	I-Premise
141	QOL	_	_	I-Premise
142	difference	_	_	I-Premise
143	between	_	_	I-Premise
144	treatment	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	combined	_	_	I-Premise
148	community	_	_	I-Premise
149	locations	_	_	I-Premise
150	relative	_	_	I-Premise
151	to	_	_	I-Premise
152	hospital	_	_	I-Premise
153	(	_	_	I-Premise
154	difference	_	_	I-Premise
155	of	_	_	I-Premise
156	-7.2	_	_	I-Premise
157	,	_	_	I-Premise
158	95	_	_	I-Premise
159	%	_	_	I-Premise
160	confidence	_	_	I-Premise
161	interval	_	_	I-Premise
162	:	_	_	I-Premise
163	-19Â·5	_	_	I-Premise
164	to	_	_	I-Premise
165	+5Â·2	_	_	I-Premise
166	,	_	_	I-Premise
167	P=0.25	_	_	I-Premise
168	)	_	_	I-Premise
169	.	_	_	I-Premise

170	There	_	_	B-Premise
171	was	_	_	I-Premise
172	a	_	_	I-Premise
173	significant	_	_	I-Premise
174	difference	_	_	I-Premise
175	between	_	_	I-Premise
176	the	_	_	I-Premise
177	two	_	_	I-Premise
178	community	_	_	I-Premise
179	locations	_	_	I-Premise
180	in	_	_	I-Premise
181	favour	_	_	I-Premise
182	of	_	_	I-Premise
183	home	_	_	I-Premise
184	(	_	_	I-Premise
185	+15Â·2	_	_	I-Premise
186	,	_	_	I-Premise
187	1Â·3	_	_	I-Premise
188	to	_	_	I-Premise
189	29Â·1	_	_	I-Premise
190	,	_	_	I-Premise
191	P=0.033	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Hospital	_	_	O
195	anxiety	_	_	O
196	and	_	_	O
197	depression	_	_	O
198	scale	_	_	O
199	scores	_	_	O
200	were	_	_	O
201	consistent	_	_	O
202	with	_	_	O
203	the	_	_	O
204	primary	_	_	O
205	outcome	_	_	O
206	measure	_	_	O
207	.	_	_	O

208	There	_	_	B-Premise
209	was	_	_	I-Premise
210	no	_	_	I-Premise
211	evidence	_	_	I-Premise
212	that	_	_	I-Premise
213	community	_	_	I-Premise
214	treatment	_	_	I-Premise
215	compromised	_	_	I-Premise
216	patient	_	_	I-Premise
217	safety	_	_	I-Premise
218	and	_	_	O
219	no	_	_	B-Premise
220	significant	_	_	I-Premise
221	difference	_	_	I-Premise
222	between	_	_	I-Premise
223	treatment	_	_	I-Premise
224	arms	_	_	I-Premise
225	in	_	_	I-Premise
226	terms	_	_	I-Premise
227	of	_	_	I-Premise
228	overall	_	_	I-Premise
229	costs	_	_	I-Premise
230	or	_	_	I-Premise
231	Quality	_	_	I-Premise
232	Adjusted	_	_	I-Premise
233	Life	_	_	I-Premise
234	Year	_	_	I-Premise
235	.	_	_	I-Premise

236	Seventy-eight	_	_	B-Premise
237	percent	_	_	I-Premise
238	of	_	_	I-Premise
239	patients	_	_	I-Premise
240	expressed	_	_	I-Premise
241	satisfaction	_	_	I-Premise
242	with	_	_	I-Premise
243	their	_	_	I-Premise
244	treatment	_	_	I-Premise
245	whatever	_	_	I-Premise
246	their	_	_	I-Premise
247	location	_	_	I-Premise
248	,	_	_	I-Premise
249	whereas	_	_	I-Premise
250	57	_	_	I-Premise
251	%	_	_	I-Premise
252	of	_	_	I-Premise
253	patients	_	_	I-Premise
254	preferred	_	_	I-Premise
255	future	_	_	I-Premise
256	treatment	_	_	I-Premise
257	to	_	_	I-Premise
258	continue	_	_	I-Premise
259	at	_	_	I-Premise
260	the	_	_	I-Premise
261	hospital	_	_	I-Premise
262	,	_	_	I-Premise
263	81	_	_	I-Premise
264	%	_	_	I-Premise
265	at	_	_	I-Premise
266	GP	_	_	I-Premise
267	surgeries	_	_	I-Premise
268	and	_	_	I-Premise
269	90	_	_	I-Premise
270	%	_	_	I-Premise
271	at	_	_	I-Premise
272	home	_	_	I-Premise
273	.	_	_	I-Premise

274	Although	_	_	O
275	initial	_	_	O
276	pre-trial	_	_	O
277	interviews	_	_	O
278	revealed	_	_	O
279	concerns	_	_	O
280	among	_	_	O
281	health-care	_	_	O
282	professionals	_	_	O
283	and	_	_	O
284	some	_	_	O
285	patients	_	_	O
286	regarding	_	_	O
287	community	_	_	O
288	treatment	_	_	O
289	,	_	_	O
290	opinions	_	_	O
291	were	_	_	O
292	largely	_	_	O
293	more	_	_	O
294	favourable	_	_	O
295	in	_	_	O
296	post-trial	_	_	O
297	interviews	_	_	O
298	.	_	_	O

299	Patient	_	_	B-Claim
300	QOL	_	_	I-Claim
301	favours	_	_	I-Claim
302	delivering	_	_	I-Claim
303	cancer	_	_	I-Claim
304	treatment	_	_	I-Claim
305	in	_	_	I-Claim
306	the	_	_	I-Claim
307	home	_	_	I-Claim
308	rather	_	_	I-Claim
309	than	_	_	I-Claim
310	GP	_	_	I-Claim
311	surgeries	_	_	I-Claim
312	.	_	_	I-Claim

313	Nevertheless	_	_	B-Claim
314	,	_	_	I-Claim
315	both	_	_	I-Claim
316	community	_	_	I-Claim
317	settings	_	_	I-Claim
318	were	_	_	I-Claim
319	acceptable	_	_	I-Claim
320	to	_	_	I-Claim
321	and	_	_	I-Claim
322	preferred	_	_	I-Claim
323	by	_	_	I-Claim
324	patients	_	_	I-Claim
325	compared	_	_	I-Claim
326	with	_	_	I-Claim
327	hospital	_	_	I-Claim
328	,	_	_	I-Claim
329	were	_	_	I-Claim
330	safe	_	_	I-Claim
331	,	_	_	I-Claim
332	with	_	_	I-Claim
333	no	_	_	I-Claim
334	detrimental	_	_	I-Claim
335	impact	_	_	I-Claim
336	on	_	_	I-Claim
337	overall	_	_	I-Claim
338	health-care	_	_	I-Claim
339	costs	_	_	I-Claim
340	.	_	_	I-Claim


0	Docetaxel	_	_	B-Claim
1	has	_	_	I-Claim
2	shown	_	_	I-Claim
3	activity	_	_	I-Claim
4	in	_	_	I-Claim
5	elderly	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non-small-cell	_	_	I-Claim
10	lung	_	_	I-Claim
11	cancer	_	_	I-Claim
12	(	_	_	I-Claim
13	NSCLC	_	_	I-Claim
14	)	_	_	I-Claim
15	.	_	_	I-Claim

16	This	_	_	O
17	randomized	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	trial	_	_	O
21	evaluated	_	_	O
22	the	_	_	O
23	efficacy	_	_	O
24	and	_	_	O
25	safety	_	_	O
26	of	_	_	O
27	docetaxel	_	_	O
28	versus	_	_	O
29	vinorelbine	_	_	O
30	(	_	_	O
31	the	_	_	O
32	current	_	_	O
33	standard	_	_	O
34	treatment	_	_	O
35	)	_	_	O
36	in	_	_	O
37	elderly	_	_	O
38	patients	_	_	O
39	.	_	_	O

40	Chemotherapy-naÃ¯ve	_	_	O
41	patients	_	_	O
42	age	_	_	O
43	70	_	_	O
44	years	_	_	O
45	or	_	_	O
46	older	_	_	O
47	with	_	_	O
48	stage	_	_	O
49	IIIB/IV	_	_	O
50	NSCLC	_	_	O
51	and	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	2	_	_	O
55	or	_	_	O
56	lower	_	_	O
57	were	_	_	O
58	eligible	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	randomly	_	_	O
62	received	_	_	O
63	docetaxel	_	_	O
64	60	_	_	O
65	mg/m2	_	_	O
66	(	_	_	O
67	day	_	_	O
68	1	_	_	O
69	)	_	_	O
70	or	_	_	O
71	vinorelbine	_	_	O
72	25	_	_	O
73	mg/m2	_	_	O
74	(	_	_	O
75	days	_	_	O
76	1	_	_	O
77	and	_	_	O
78	8	_	_	O
79	)	_	_	O
80	every	_	_	O
81	21	_	_	O
82	days	_	_	O
83	for	_	_	O
84	four	_	_	O
85	cycles	_	_	O
86	.	_	_	O

87	The	_	_	O
88	primary	_	_	O
89	end	_	_	O
90	point	_	_	O
91	was	_	_	O
92	overall	_	_	O
93	survival	_	_	O
94	.	_	_	O

95	Overall	_	_	O
96	disease-related	_	_	O
97	symptom	_	_	O
98	improvement	_	_	O
99	was	_	_	O
100	assessed	_	_	O
101	using	_	_	O
102	an	_	_	O
103	eight-item	_	_	O
104	questionnaire	_	_	O
105	.	_	_	O

106	In	_	_	O
107	total	_	_	O
108	,	_	_	O
109	182	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	enrolled	_	_	O
113	.	_	_	O

114	Median	_	_	O
115	age	_	_	O
116	was	_	_	O
117	76	_	_	O
118	years	_	_	O
119	(	_	_	O
120	range	_	_	O
121	,	_	_	O
122	70	_	_	O
123	years	_	_	O
124	to	_	_	O
125	86	_	_	O
126	years	_	_	O
127	)	_	_	O
128	.	_	_	O

129	There	_	_	B-Premise
130	was	_	_	I-Premise
131	no	_	_	I-Premise
132	statistical	_	_	I-Premise
133	difference	_	_	I-Premise
134	in	_	_	I-Premise
135	median	_	_	I-Premise
136	overall	_	_	I-Premise
137	survival	_	_	I-Premise
138	with	_	_	I-Premise
139	docetaxel	_	_	I-Premise
140	versus	_	_	I-Premise
141	vinorelbine	_	_	I-Premise
142	(	_	_	I-Premise
143	14.3	_	_	I-Premise
144	months	_	_	I-Premise
145	v	_	_	I-Premise
146	9.9	_	_	I-Premise
147	months	_	_	I-Premise
148	;	_	_	I-Premise
149	hazard	_	_	I-Premise
150	ratio	_	_	I-Premise
151	,	_	_	I-Premise
152	0.780	_	_	I-Premise
153	;	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	0.561	_	_	I-Premise
159	to	_	_	I-Premise
160	1.085	_	_	I-Premise
161	;	_	_	I-Premise
162	P	_	_	I-Premise
163	=	_	_	I-Premise
164	.138	_	_	I-Premise
165	)	_	_	I-Premise
166	.	_	_	I-Premise

167	There	_	_	B-Premise
168	was	_	_	I-Premise
169	a	_	_	I-Premise
170	significant	_	_	I-Premise
171	difference	_	_	I-Premise
172	in	_	_	I-Premise
173	median	_	_	I-Premise
174	progression-free	_	_	I-Premise
175	survival	_	_	I-Premise
176	(	_	_	I-Premise
177	5.5	_	_	I-Premise
178	months	_	_	I-Premise
179	v	_	_	I-Premise
180	3.1	_	_	I-Premise
181	months	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	.001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	Response	_	_	B-Premise
189	rates	_	_	I-Premise
190	were	_	_	I-Premise
191	also	_	_	I-Premise
192	significantly	_	_	I-Premise
193	improved	_	_	I-Premise
194	with	_	_	I-Premise
195	docetaxel	_	_	I-Premise
196	versus	_	_	I-Premise
197	vinorelbine	_	_	I-Premise
198	(	_	_	I-Premise
199	22.7	_	_	I-Premise
200	%	_	_	I-Premise
201	v	_	_	I-Premise
202	9.9	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.019	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	The	_	_	B-Premise
211	most	_	_	I-Premise
212	common	_	_	I-Premise
213	grade	_	_	I-Premise
214	3	_	_	I-Premise
215	to	_	_	I-Premise
216	4	_	_	I-Premise
217	toxicities	_	_	I-Premise
218	were	_	_	I-Premise
219	neutropenia	_	_	I-Premise
220	(	_	_	I-Premise
221	82.9	_	_	I-Premise
222	%	_	_	I-Premise
223	for	_	_	I-Premise
224	docetaxel	_	_	I-Premise
225	;	_	_	I-Premise
226	69.2	_	_	I-Premise
227	%	_	_	I-Premise
228	for	_	_	I-Premise
229	vinorelbine	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.031	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	leukopenia	_	_	I-Premise
237	(	_	_	I-Premise
238	58.0	_	_	I-Premise
239	%	_	_	I-Premise
240	for	_	_	I-Premise
241	docetaxel	_	_	I-Premise
242	;	_	_	I-Premise
243	51.7	_	_	I-Premise
244	%	_	_	I-Premise
245	for	_	_	I-Premise
246	vinorelbine	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Other	_	_	B-Premise
250	toxicities	_	_	I-Premise
251	were	_	_	I-Premise
252	mild	_	_	I-Premise
253	and	_	_	I-Premise
254	generally	_	_	I-Premise
255	well	_	_	I-Premise
256	tolerated	_	_	I-Premise
257	.	_	_	I-Premise

258	Docetaxel	_	_	B-Premise
259	improved	_	_	I-Premise
260	overall	_	_	I-Premise
261	disease-related	_	_	I-Premise
262	symptoms	_	_	I-Premise
263	over	_	_	I-Premise
264	vinorelbine	_	_	I-Premise
265	(	_	_	I-Premise
266	odds	_	_	I-Premise
267	ratio	_	_	I-Premise
268	,	_	_	I-Premise
269	1.86	_	_	I-Premise
270	;	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	,	_	_	I-Premise
275	1.09	_	_	I-Premise
276	to	_	_	I-Premise
277	3.20	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Docetaxel	_	_	B-Premise
281	improved	_	_	I-Premise
282	progression-free	_	_	I-Premise
283	survival	_	_	I-Premise
284	,	_	_	I-Premise
285	response	_	_	I-Premise
286	rate	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	disease-related	_	_	I-Premise
290	symptoms	_	_	I-Premise
291	versus	_	_	I-Premise
292	vinorelbine	_	_	I-Premise
293	.	_	_	I-Premise

294	Overall	_	_	B-Claim
295	survival	_	_	I-Claim
296	was	_	_	I-Claim
297	not	_	_	I-Claim
298	statistically	_	_	I-Claim
299	significantly	_	_	I-Claim
300	improved	_	_	I-Claim
301	at	_	_	I-Claim
302	this	_	_	I-Claim
303	time	_	_	I-Claim
304	.	_	_	I-Claim

305	Docetaxel	_	_	B-Claim
306	monotherapy	_	_	I-Claim
307	may	_	_	I-Claim
308	be	_	_	I-Claim
309	considered	_	_	I-Claim
310	as	_	_	I-Claim
311	an	_	_	I-Claim
312	option	_	_	I-Claim
313	in	_	_	I-Claim
314	the	_	_	I-Claim
315	standard	_	_	I-Claim
316	treatment	_	_	I-Claim
317	of	_	_	I-Claim
318	elderly	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	advanced	_	_	I-Claim
322	NSCLC	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Alleviating	_	_	O
7	Depression	_	_	O
8	Among	_	_	O
9	Patients	_	_	O
10	With	_	_	O
11	Cancer	_	_	O
12	(	_	_	O
13	ADAPt-C	_	_	O
14	)	_	_	O
15	collaborative	_	_	O
16	care	_	_	O
17	management	_	_	O
18	for	_	_	O
19	major	_	_	O
20	depression	_	_	O
21	or	_	_	O
22	dysthymia	_	_	O
23	.	_	_	O

24	Study	_	_	O
25	patients	_	_	O
26	included	_	_	O
27	472	_	_	O
28	low-income	_	_	O
29	,	_	_	O
30	predominantly	_	_	O
31	female	_	_	O
32	Hispanic	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	cancer	_	_	O
36	age	_	_	O
37	>	_	_	O
38	or=	_	_	O
39	18	_	_	O
40	years	_	_	O
41	with	_	_	O
42	major	_	_	O
43	depression	_	_	O
44	(	_	_	O
45	49	_	_	O
46	%	_	_	O
47	)	_	_	O
48	,	_	_	O
49	dysthymia	_	_	O
50	(	_	_	O
51	5	_	_	O
52	%	_	_	O
53	)	_	_	O
54	,	_	_	O
55	or	_	_	O
56	both	_	_	O
57	(	_	_	O
58	46	_	_	O
59	%	_	_	O
60	)	_	_	O
61	.	_	_	O

62	Patients	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	intervention	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	242	_	_	O
72	)	_	_	O
73	or	_	_	O
74	enhanced	_	_	O
75	usual	_	_	O
76	care	_	_	O
77	(	_	_	O
78	EUC	_	_	O
79	;	_	_	O
80	n	_	_	O
81	=	_	_	O
82	230	_	_	O
83	)	_	_	O
84	.	_	_	O

85	Intervention	_	_	O
86	patients	_	_	O
87	had	_	_	O
88	access	_	_	O
89	for	_	_	O
90	up	_	_	O
91	to	_	_	O
92	12	_	_	O
93	months	_	_	O
94	to	_	_	O
95	a	_	_	O
96	depression	_	_	O
97	clinical	_	_	O
98	specialist	_	_	O
99	(	_	_	O
100	supervised	_	_	O
101	by	_	_	O
102	a	_	_	O
103	psychiatrist	_	_	O
104	)	_	_	O
105	who	_	_	O
106	offered	_	_	O
107	education	_	_	O
108	,	_	_	O
109	structured	_	_	O
110	psychotherapy	_	_	O
111	,	_	_	O
112	and	_	_	O
113	maintenance/relapse	_	_	O
114	prevention	_	_	O
115	support	_	_	O
116	.	_	_	O

117	The	_	_	O
118	psychiatrist	_	_	O
119	prescribed	_	_	O
120	antidepressant	_	_	O
121	medications	_	_	O
122	for	_	_	O
123	patients	_	_	O
124	preferring	_	_	O
125	or	_	_	O
126	assessed	_	_	O
127	to	_	_	O
128	require	_	_	O
129	medication	_	_	O
130	.	_	_	O

131	At	_	_	B-Premise
132	12	_	_	I-Premise
133	months	_	_	I-Premise
134	,	_	_	I-Premise
135	63	_	_	I-Premise
136	%	_	_	I-Premise
137	of	_	_	I-Premise
138	intervention	_	_	I-Premise
139	patients	_	_	I-Premise
140	had	_	_	I-Premise
141	a	_	_	I-Premise
142	50	_	_	I-Premise
143	%	_	_	I-Premise
144	or	_	_	I-Premise
145	greater	_	_	I-Premise
146	reduction	_	_	I-Premise
147	in	_	_	I-Premise
148	depressive	_	_	I-Premise
149	symptoms	_	_	I-Premise
150	from	_	_	I-Premise
151	baseline	_	_	I-Premise
152	as	_	_	I-Premise
153	assessed	_	_	I-Premise
154	by	_	_	I-Premise
155	the	_	_	I-Premise
156	Patient	_	_	I-Premise
157	Health	_	_	I-Premise
158	Questionnaire-9	_	_	I-Premise
159	(	_	_	I-Premise
160	PHQ-9	_	_	I-Premise
161	)	_	_	I-Premise
162	depression	_	_	I-Premise
163	scale	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	50	_	_	I-Premise
167	%	_	_	I-Premise
168	of	_	_	I-Premise
169	EUC	_	_	I-Premise
170	patients	_	_	I-Premise
171	(	_	_	I-Premise
172	odds	_	_	I-Premise
173	ratio	_	_	I-Premise
174	[	_	_	I-Premise
175	OR	_	_	I-Premise
176	]	_	_	I-Premise
177	=	_	_	I-Premise
178	1.98	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	CI	_	_	I-Premise
183	,	_	_	I-Premise
184	1.16	_	_	I-Premise
185	to	_	_	I-Premise
186	3.38	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.01	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Improvement	_	_	B-Premise
194	was	_	_	I-Premise
195	also	_	_	I-Premise
196	found	_	_	I-Premise
197	for	_	_	I-Premise
198	5-point	_	_	I-Premise
199	decrease	_	_	I-Premise
200	in	_	_	I-Premise
201	PHQ-9	_	_	I-Premise
202	score	_	_	I-Premise
203	among	_	_	I-Premise
204	72.2	_	_	I-Premise
205	%	_	_	I-Premise
206	of	_	_	I-Premise
207	intervention	_	_	I-Premise
208	patients	_	_	I-Premise
209	compared	_	_	I-Premise
210	with	_	_	I-Premise
211	59.7	_	_	I-Premise
212	%	_	_	I-Premise
213	of	_	_	I-Premise
214	EUC	_	_	I-Premise
215	patients	_	_	I-Premise
216	(	_	_	I-Premise
217	OR	_	_	I-Premise
218	=	_	_	I-Premise
219	1.99	_	_	I-Premise
220	;	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	,	_	_	I-Premise
225	1.14	_	_	I-Premise
226	to	_	_	I-Premise
227	3.50	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.02	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Intervention	_	_	B-Premise
235	patients	_	_	I-Premise
236	also	_	_	I-Premise
237	experienced	_	_	I-Premise
238	greater	_	_	I-Premise
239	rates	_	_	I-Premise
240	of	_	_	I-Premise
241	depression	_	_	I-Premise
242	treatment	_	_	I-Premise
243	(	_	_	I-Premise
244	72.3	_	_	I-Premise
245	%	_	_	I-Premise
246	v	_	_	I-Premise
247	10.4	_	_	I-Premise
248	%	_	_	I-Premise
249	of	_	_	I-Premise
250	EUC	_	_	I-Premise
251	patients	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	.0001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	significantly	_	_	I-Premise
259	better	_	_	I-Premise
260	quality-of-life	_	_	I-Premise
261	outcomes	_	_	I-Premise
262	,	_	_	I-Premise
263	including	_	_	I-Premise
264	social/family	_	_	I-Premise
265	(	_	_	I-Premise
266	adjusted	_	_	I-Premise
267	mean	_	_	I-Premise
268	difference	_	_	I-Premise
269	between	_	_	I-Premise
270	groups	_	_	I-Premise
271	,	_	_	I-Premise
272	2.7	_	_	I-Premise
273	;	_	_	I-Premise
274	95	_	_	I-Premise
275	%	_	_	I-Premise
276	CI	_	_	I-Premise
277	,	_	_	I-Premise
278	1.22	_	_	I-Premise
279	to	_	_	I-Premise
280	4.17	_	_	I-Premise
281	;	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.001	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	emotional	_	_	I-Premise
288	(	_	_	I-Premise
289	adjusted	_	_	I-Premise
290	mean	_	_	I-Premise
291	difference	_	_	I-Premise
292	,	_	_	I-Premise
293	1.29	_	_	I-Premise
294	;	_	_	I-Premise
295	95	_	_	I-Premise
296	%	_	_	I-Premise
297	CI	_	_	I-Premise
298	,	_	_	I-Premise
299	0.26	_	_	I-Premise
300	to	_	_	I-Premise
301	2.22	_	_	I-Premise
302	;	_	_	I-Premise
303	P	_	_	I-Premise
304	=	_	_	I-Premise
305	.01	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	functional	_	_	I-Premise
309	(	_	_	I-Premise
310	adjusted	_	_	I-Premise
311	mean	_	_	I-Premise
312	difference	_	_	I-Premise
313	,	_	_	I-Premise
314	1.34	_	_	I-Premise
315	;	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	,	_	_	I-Premise
320	0.08	_	_	I-Premise
321	to	_	_	I-Premise
322	2.59	_	_	I-Premise
323	;	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	.04	_	_	I-Premise
327	)	_	_	I-Premise
328	,	_	_	I-Premise
329	and	_	_	I-Premise
330	physical	_	_	I-Premise
331	well-being	_	_	I-Premise
332	(	_	_	I-Premise
333	adjusted	_	_	I-Premise
334	mean	_	_	I-Premise
335	difference	_	_	I-Premise
336	,	_	_	I-Premise
337	2.79	_	_	I-Premise
338	;	_	_	I-Premise
339	95	_	_	I-Premise
340	%	_	_	I-Premise
341	CI	_	_	I-Premise
342	,	_	_	I-Premise
343	0.49	_	_	I-Premise
344	to	_	_	I-Premise
345	5.1	_	_	I-Premise
346	;	_	_	I-Premise
347	P	_	_	I-Premise
348	=	_	_	I-Premise
349	.02	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	ADAPt-C	_	_	B-Claim
353	collaborative	_	_	I-Claim
354	care	_	_	I-Claim
355	is	_	_	I-Claim
356	feasible	_	_	I-Claim
357	and	_	_	I-Claim
358	results	_	_	I-Claim
359	in	_	_	I-Claim
360	significant	_	_	I-Claim
361	reduction	_	_	I-Claim
362	in	_	_	I-Claim
363	depressive	_	_	I-Claim
364	symptoms	_	_	I-Claim
365	,	_	_	I-Claim
366	improvement	_	_	I-Claim
367	in	_	_	I-Claim
368	quality	_	_	I-Claim
369	of	_	_	I-Claim
370	life	_	_	I-Claim
371	,	_	_	I-Claim
372	and	_	_	I-Claim
373	lower	_	_	I-Claim
374	pain	_	_	I-Claim
375	levels	_	_	I-Claim
376	compared	_	_	I-Claim
377	with	_	_	I-Claim
378	EUC	_	_	I-Claim
379	for	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	depressive	_	_	I-Claim
383	disorders	_	_	I-Claim
384	in	_	_	I-Claim
385	a	_	_	I-Claim
386	low-income	_	_	I-Claim
387	,	_	_	I-Claim
388	predominantly	_	_	I-Claim
389	Hispanic	_	_	I-Claim
390	population	_	_	I-Claim
391	in	_	_	I-Claim
392	public	_	_	I-Claim
393	sector	_	_	I-Claim
394	oncology	_	_	I-Claim
395	clinics	_	_	I-Claim
396	.	_	_	I-Claim


0	Depression	_	_	O
1	is	_	_	O
2	common	_	_	O
3	among	_	_	O
4	older	_	_	O
5	cancer	_	_	O
6	patients	_	_	O
7	,	_	_	O
8	but	_	_	O
9	little	_	_	O
10	is	_	_	O
11	known	_	_	O
12	about	_	_	O
13	the	_	_	O
14	optimal	_	_	O
15	approach	_	_	O
16	to	_	_	O
17	caring	_	_	O
18	for	_	_	O
19	this	_	_	O
20	population	_	_	O
21	.	_	_	O

22	This	_	_	O
23	analysis	_	_	O
24	evaluates	_	_	O
25	the	_	_	O
26	effectiveness	_	_	O
27	of	_	_	O
28	the	_	_	O
29	Improving	_	_	O
30	Mood-Promoting	_	_	O
31	Access	_	_	O
32	to	_	_	O
33	Collaborative	_	_	O
34	Treatment	_	_	O
35	(	_	_	O
36	IMPACT	_	_	O
37	)	_	_	O
38	program	_	_	O
39	,	_	_	O
40	a	_	_	O
41	stepped	_	_	O
42	care	_	_	O
43	management	_	_	O
44	program	_	_	O
45	for	_	_	O
46	depression	_	_	O
47	in	_	_	O
48	primary	_	_	O
49	care	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	had	_	_	O
53	an	_	_	O
54	ICD-9	_	_	O
55	cancer	_	_	O
56	diagnosis	_	_	O
57	.	_	_	O

58	Two	_	_	O
59	hundred	_	_	O
60	fifteen	_	_	O
61	cancer	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	identified	_	_	O
65	from	_	_	O
66	the	_	_	O
67	1,801	_	_	O
68	participants	_	_	O
69	in	_	_	O
70	the	_	_	O
71	parent	_	_	O
72	study	_	_	O
73	.	_	_	O

74	Subjects	_	_	O
75	were	_	_	O
76	60	_	_	O
77	years	_	_	O
78	or	_	_	O
79	older	_	_	O
80	with	_	_	O
81	major	_	_	O
82	depression	_	_	O
83	(	_	_	O
84	18	_	_	O
85	%	_	_	O
86	)	_	_	O
87	,	_	_	O
88	dysthymic	_	_	O
89	disorder	_	_	O
90	(	_	_	O
91	33	_	_	O
92	%	_	_	O
93	)	_	_	O
94	,	_	_	O
95	or	_	_	O
96	both	_	_	O
97	(	_	_	O
98	49	_	_	O
99	%	_	_	O
100	)	_	_	O
101	,	_	_	O
102	recruited	_	_	O
103	from	_	_	O
104	18	_	_	O
105	primary	_	_	O
106	care	_	_	O
107	clinics	_	_	O
108	belonging	_	_	O
109	to	_	_	O
110	8	_	_	O
111	health-care	_	_	O
112	organizations	_	_	O
113	in	_	_	O
114	5	_	_	O
115	states	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	were	_	_	O
119	randomly	_	_	O
120	assigned	_	_	O
121	to	_	_	O
122	the	_	_	O
123	IMPACT	_	_	O
124	intervention	_	_	O
125	(	_	_	O
126	n	_	_	O
127	=	_	_	O
128	112	_	_	O
129	)	_	_	O
130	or	_	_	O
131	usual	_	_	O
132	care	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	103	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Intervention	_	_	O
140	patients	_	_	O
141	had	_	_	O
142	access	_	_	O
143	for	_	_	O
144	up	_	_	O
145	to	_	_	O
146	12	_	_	O
147	months	_	_	O
148	to	_	_	O
149	a	_	_	O
150	depression	_	_	O
151	care	_	_	O
152	manager	_	_	O
153	who	_	_	O
154	was	_	_	O
155	supervised	_	_	O
156	by	_	_	O
157	a	_	_	O
158	psychiatrist	_	_	O
159	and	_	_	O
160	a	_	_	O
161	primary	_	_	O
162	care	_	_	O
163	provider	_	_	O
164	and	_	_	O
165	who	_	_	O
166	offered	_	_	O
167	education	_	_	O
168	,	_	_	O
169	care	_	_	O
170	management	_	_	O
171	,	_	_	O
172	support	_	_	O
173	of	_	_	O
174	antidepressant	_	_	O
175	management	_	_	O
176	,	_	_	O
177	and	_	_	O
178	brief	_	_	O
179	,	_	_	O
180	structured	_	_	O
181	psychosocial	_	_	O
182	interventions	_	_	O
183	including	_	_	O
184	behavioral	_	_	O
185	activation	_	_	O
186	and	_	_	O
187	problem-solving	_	_	O
188	treatment	_	_	O
189	.	_	_	O

190	At	_	_	B-Premise
191	6	_	_	I-Premise
192	and	_	_	I-Premise
193	12	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	55	_	_	I-Premise
197	%	_	_	I-Premise
198	and	_	_	I-Premise
199	39	_	_	I-Premise
200	%	_	_	I-Premise
201	of	_	_	I-Premise
202	intervention	_	_	I-Premise
203	patients	_	_	I-Premise
204	had	_	_	I-Premise
205	a	_	_	I-Premise
206	50	_	_	I-Premise
207	%	_	_	I-Premise
208	or	_	_	I-Premise
209	greater	_	_	I-Premise
210	reduction	_	_	I-Premise
211	in	_	_	I-Premise
212	depressive	_	_	I-Premise
213	symptoms	_	_	I-Premise
214	(	_	_	I-Premise
215	SCL-20	_	_	I-Premise
216	)	_	_	I-Premise
217	from	_	_	I-Premise
218	baseline	_	_	I-Premise
219	compared	_	_	I-Premise
220	to	_	_	I-Premise
221	34	_	_	I-Premise
222	%	_	_	I-Premise
223	and	_	_	I-Premise
224	20	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	usual	_	_	I-Premise
228	care	_	_	I-Premise
229	participants	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.003	_	_	I-Premise
234	and	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0.029	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Intervention	_	_	B-Premise
241	patients	_	_	I-Premise
242	also	_	_	I-Premise
243	experienced	_	_	I-Premise
244	greater	_	_	I-Premise
245	remission	_	_	I-Premise
246	rates	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.031	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	more	_	_	I-Premise
254	depression-free	_	_	I-Premise
255	days	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0.001	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	less	_	_	I-Premise
263	functional	_	_	I-Premise
264	impairment	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	0.011	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	greater	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	=	_	_	I-Premise
279	0.039	_	_	I-Premise
280	)	_	_	I-Premise
281	at	_	_	I-Premise
282	12	_	_	I-Premise
283	months	_	_	I-Premise
284	than	_	_	I-Premise
285	usual	_	_	I-Premise
286	care	_	_	I-Premise
287	participants	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Claim
290	IMPACT	_	_	I-Claim
291	collaborative	_	_	I-Claim
292	care	_	_	I-Claim
293	program	_	_	I-Claim
294	appears	_	_	I-Claim
295	to	_	_	I-Claim
296	be	_	_	I-Claim
297	feasible	_	_	I-Claim
298	and	_	_	I-Claim
299	effective	_	_	I-Claim
300	for	_	_	I-Claim
301	depression	_	_	I-Claim
302	among	_	_	I-Claim
303	older	_	_	I-Claim
304	cancer	_	_	I-Claim
305	patients	_	_	I-Claim
306	in	_	_	I-Claim
307	diverse	_	_	I-Claim
308	primary	_	_	I-Claim
309	care	_	_	I-Claim
310	settings	_	_	I-Claim
311	.	_	_	I-Claim


0	Sunitinib	_	_	O
1	has	_	_	O
2	demonstrated	_	_	O
3	antitumor	_	_	O
4	activity	_	_	O
5	in	_	_	O
6	metastatic	_	_	O
7	renal	_	_	O
8	cell	_	_	O
9	carcinoma	_	_	O
10	(	_	_	O
11	mRCC	_	_	O
12	)	_	_	O
13	when	_	_	O
14	given	_	_	O
15	at	_	_	O
16	50	_	_	O
17	mg/d	_	_	O
18	on	_	_	O
19	a	_	_	O
20	4-weeks-on	_	_	O
21	2-weeks-off	_	_	O
22	regimen	_	_	O
23	.	_	_	O

24	Herein	_	_	O
25	,	_	_	O
26	we	_	_	O
27	report	_	_	O
28	results	_	_	O
29	of	_	_	O
30	an	_	_	O
31	open-label	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	phase	_	_	O
35	II	_	_	O
36	mRCC	_	_	O
37	study	_	_	O
38	of	_	_	O
39	sunitinib	_	_	O
40	administered	_	_	O
41	on	_	_	O
42	a	_	_	O
43	continuous	_	_	O
44	once-daily	_	_	O
45	dosing	_	_	O
46	regimen	_	_	O
47	.	_	_	O

48	Eligibility	_	_	O
49	criteria	_	_	O
50	included	_	_	O
51	histologically	_	_	O
52	proven	_	_	O
53	mRCC	_	_	O
54	with	_	_	O
55	measurable	_	_	O
56	disease	_	_	O
57	,	_	_	O
58	failure	_	_	O
59	of	_	_	O
60	one	_	_	O
61	prior	_	_	O
62	cytokine	_	_	O
63	regimen	_	_	O
64	,	_	_	O
65	and	_	_	O
66	good	_	_	O
67	performance	_	_	O
68	status	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	were	_	_	O
72	randomly	_	_	O
73	assigned	_	_	O
74	to	_	_	O
75	a	_	_	O
76	sunitinib	_	_	O
77	starting	_	_	O
78	dose	_	_	O
79	of	_	_	O
80	37.5	_	_	O
81	mg/d	_	_	O
82	in	_	_	O
83	the	_	_	O
84	morning	_	_	O
85	(	_	_	O
86	AM	_	_	O
87	)	_	_	O
88	or	_	_	O
89	evening	_	_	O
90	(	_	_	O
91	PM	_	_	O
92	)	_	_	O
93	.	_	_	O

94	RECIST-defined	_	_	O
95	objective	_	_	O
96	response	_	_	O
97	rate	_	_	O
98	(	_	_	O
99	ORR	_	_	O
100	)	_	_	O
101	was	_	_	O
102	the	_	_	O
103	primary	_	_	O
104	end	_	_	O
105	point	_	_	O
106	.	_	_	O

107	Secondary	_	_	O
108	end	_	_	O
109	points	_	_	O
110	included	_	_	O
111	progression-free	_	_	O
112	survival	_	_	O
113	(	_	_	O
114	PFS	_	_	O
115	)	_	_	O
116	,	_	_	O
117	overall	_	_	O
118	survival	_	_	O
119	(	_	_	O
120	OS	_	_	O
121	)	_	_	O
122	,	_	_	O
123	adverse	_	_	O
124	events	_	_	O
125	(	_	_	O
126	AEs	_	_	O
127	)	_	_	O
128	,	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	measures	_	_	O
132	.	_	_	O

133	One	_	_	O
134	hundred	_	_	O
135	seven	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	randomly	_	_	O
139	assigned	_	_	O
140	to	_	_	O
141	AM	_	_	O
142	(	_	_	O
143	n	_	_	O
144	=	_	_	O
145	54	_	_	O
146	)	_	_	O
147	or	_	_	O
148	PM	_	_	O
149	(	_	_	O
150	n	_	_	O
151	=	_	_	O
152	53	_	_	O
153	)	_	_	O
154	dosing	_	_	O
155	and	_	_	O
156	on	_	_	O
157	study	_	_	O
158	for	_	_	O
159	a	_	_	O
160	median	_	_	O
161	8.3	_	_	O
162	months	_	_	O
163	.	_	_	O

164	Eighty-three	_	_	O
165	patients	_	_	O
166	discontinued	_	_	O
167	,	_	_	O
168	65	_	_	O
169	due	_	_	O
170	to	_	_	O
171	disease	_	_	O
172	progression	_	_	O
173	and	_	_	O
174	16	_	_	O
175	because	_	_	O
176	of	_	_	O
177	AEs	_	_	O
178	;	_	_	O
179	two	_	_	O
180	patients	_	_	O
181	withdrew	_	_	O
182	consent	_	_	O
183	.	_	_	O

184	Dosing	_	_	O
185	was	_	_	O
186	reduced	_	_	O
187	to	_	_	O
188	25	_	_	O
189	mg/d	_	_	O
190	in	_	_	O
191	46	_	_	O
192	patients	_	_	O
193	(	_	_	O
194	43	_	_	O
195	%	_	_	O
196	)	_	_	O
197	due	_	_	O
198	to	_	_	O
199	grade	_	_	O
200	3/4	_	_	O
201	AEs	_	_	O
202	.	_	_	O

203	The	_	_	B-Premise
204	most	_	_	I-Premise
205	common	_	_	I-Premise
206	grade	_	_	I-Premise
207	3	_	_	I-Premise
208	treatment-related	_	_	I-Premise
209	AEs	_	_	I-Premise
210	were	_	_	I-Premise
211	asthenia/fatigue	_	_	I-Premise
212	(	_	_	I-Premise
213	16	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	diarrhea	_	_	I-Premise
218	(	_	_	I-Premise
219	11	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	hypertension	_	_	I-Premise
224	(	_	_	I-Premise
225	11	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	hand-foot	_	_	I-Premise
230	syndrome	_	_	I-Premise
231	(	_	_	I-Premise
232	9	_	_	I-Premise
233	%	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	anorexia	_	_	I-Premise
238	(	_	_	I-Premise
239	8	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	ORR	_	_	O
244	was	_	_	O
245	20	_	_	O
246	%	_	_	O
247	with	_	_	O
248	a	_	_	O
249	7.2-month	_	_	O
250	median	_	_	O
251	response	_	_	O
252	duration	_	_	O
253	.	_	_	O

254	Median	_	_	B-Premise
255	PFS	_	_	I-Premise
256	and	_	_	I-Premise
257	OS	_	_	I-Premise
258	were	_	_	I-Premise
259	8.2	_	_	I-Premise
260	and	_	_	I-Premise
261	19.8	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	,	_	_	I-Premise
266	at	_	_	I-Premise
267	median	_	_	I-Premise
268	follow-up	_	_	I-Premise
269	of	_	_	I-Premise
270	26.4	_	_	I-Premise
271	months	_	_	I-Premise
272	.	_	_	I-Premise

273	Efficacy	_	_	B-Premise
274	,	_	_	I-Premise
275	tolerability	_	_	I-Premise
276	,	_	_	I-Premise
277	and	_	_	I-Premise
278	quality-of-life	_	_	I-Premise
279	results	_	_	I-Premise
280	were	_	_	I-Premise
281	similar	_	_	I-Premise
282	between	_	_	I-Premise
283	patients	_	_	I-Premise
284	dosed	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	AM	_	_	I-Premise
288	or	_	_	I-Premise
289	PM	_	_	I-Premise
290	.	_	_	I-Premise

291	Sunitinib	_	_	B-Claim
292	37.5	_	_	I-Claim
293	mg	_	_	I-Claim
294	,	_	_	I-Claim
295	administered	_	_	I-Claim
296	on	_	_	I-Claim
297	a	_	_	I-Claim
298	continuous	_	_	I-Claim
299	once-daily	_	_	I-Claim
300	dosing	_	_	I-Claim
301	regimen	_	_	I-Claim
302	,	_	_	I-Claim
303	has	_	_	I-Claim
304	a	_	_	I-Claim
305	manageable	_	_	I-Claim
306	safety	_	_	I-Claim
307	profile	_	_	I-Claim
308	as	_	_	I-Claim
309	second-line	_	_	I-Claim
310	mRCC	_	_	I-Claim
311	therapy	_	_	I-Claim
312	,	_	_	I-Claim
313	providing	_	_	I-Claim
314	flexible	_	_	I-Claim
315	dosing	_	_	I-Claim
316	,	_	_	I-Claim
317	which	_	_	I-Claim
318	can	_	_	I-Claim
319	be	_	_	I-Claim
320	explored	_	_	I-Claim
321	in	_	_	I-Claim
322	combination	_	_	I-Claim
323	studies	_	_	I-Claim
324	.	_	_	I-Claim


0	Observational	_	_	O
1	studies	_	_	O
2	demonstrate	_	_	O
3	an	_	_	O
4	association	_	_	O
5	between	_	_	O
6	physical	_	_	O
7	activity	_	_	O
8	and	_	_	O
9	improved	_	_	O
10	outcomes	_	_	O
11	in	_	_	O
12	breast	_	_	O
13	and	_	_	O
14	colon	_	_	O
15	cancer	_	_	O
16	survivors	_	_	O
17	.	_	_	O

18	To	_	_	O
19	test	_	_	O
20	these	_	_	O
21	observations	_	_	O
22	with	_	_	O
23	a	_	_	O
24	large	_	_	O
25	,	_	_	O
26	randomized	_	_	O
27	clinical	_	_	O
28	trial	_	_	O
29	,	_	_	O
30	an	_	_	O
31	intervention	_	_	O
32	that	_	_	O
33	significantly	_	_	O
34	impacts	_	_	O
35	physical	_	_	O
36	activity	_	_	O
37	in	_	_	O
38	these	_	_	O
39	patients	_	_	O
40	is	_	_	O
41	needed	_	_	O
42	.	_	_	O

43	The	_	_	O
44	Active	_	_	O
45	After	_	_	O
46	Cancer	_	_	O
47	Trial	_	_	O
48	(	_	_	O
49	AACT	_	_	O
50	)	_	_	O
51	was	_	_	O
52	a	_	_	O
53	multicenter	_	_	O
54	pilot	_	_	O
55	study	_	_	O
56	evaluating	_	_	O
57	the	_	_	O
58	feasibility	_	_	O
59	of	_	_	O
60	a	_	_	O
61	telephone-based	_	_	O
62	exercise	_	_	O
63	intervention	_	_	O
64	in	_	_	O
65	a	_	_	O
66	cooperative	_	_	O
67	group	_	_	O
68	setting	_	_	O
69	.	_	_	O

70	Sedentary	_	_	O
71	(	_	_	O
72	engaging	_	_	O
73	in	_	_	O
74	<	_	_	O
75	60	_	_	O
76	min	_	_	O
77	of	_	_	O
78	recreational	_	_	O
79	activity/week	_	_	O
80	)	_	_	O
81	breast	_	_	O
82	and	_	_	O
83	colorectal	_	_	O
84	cancer	_	_	O
85	survivors	_	_	O
86	were	_	_	O
87	randomized	_	_	O
88	to	_	_	O
89	a	_	_	O
90	telephone-based	_	_	O
91	exercise	_	_	O
92	intervention	_	_	O
93	or	_	_	O
94	usual	_	_	O
95	care	_	_	O
96	control	_	_	O
97	group	_	_	O
98	.	_	_	O

99	The	_	_	O
100	intervention	_	_	O
101	was	_	_	O
102	delivered	_	_	O
103	through	_	_	O
104	the	_	_	O
105	University	_	_	O
106	of	_	_	O
107	California	_	_	O
108	at	_	_	O
109	San	_	_	O
110	Diego	_	_	O
111	;	_	_	O
112	participants	_	_	O
113	received	_	_	O
114	ten	_	_	O
115	phone	_	_	O
116	calls	_	_	O
117	over	_	_	O
118	the	_	_	O
119	course	_	_	O
120	of	_	_	O
121	the	_	_	O
122	16-week	_	_	O
123	intervention	_	_	O
124	.	_	_	O

125	All	_	_	O
126	participants	_	_	O
127	underwent	_	_	O
128	assessment	_	_	O
129	of	_	_	O
130	physical	_	_	O
131	activity	_	_	O
132	,	_	_	O
133	fitness	_	_	O
134	,	_	_	O
135	physical	_	_	O
136	functioning	_	_	O
137	,	_	_	O
138	fatigue	_	_	O
139	and	_	_	O
140	exercise	_	_	O
141	self-efficacy	_	_	O
142	at	_	_	O
143	baseline	_	_	O
144	and	_	_	O
145	after	_	_	O
146	the	_	_	O
147	16-week	_	_	O
148	intervention	_	_	O
149	.	_	_	O

150	One	_	_	O
151	hundred	_	_	O
152	and	_	_	O
153	twenty-one	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	enrolled	_	_	O
157	through	_	_	O
158	ten	_	_	O
159	Cancer	_	_	O
160	and	_	_	O
161	Leukemia	_	_	O
162	Group	_	_	O
163	B	_	_	O
164	(	_	_	O
165	CALGB	_	_	O
166	)	_	_	O
167	institutions	_	_	O
168	;	_	_	O
169	100	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	breast	_	_	O
173	cancer	_	_	O
174	and	_	_	O
175	21	_	_	O
176	had	_	_	O
177	colorectal	_	_	O
178	cancer	_	_	O
179	.	_	_	O

180	Participants	_	_	B-Premise
181	randomized	_	_	I-Premise
182	to	_	_	I-Premise
183	the	_	_	I-Premise
184	exercise	_	_	I-Premise
185	group	_	_	I-Premise
186	increased	_	_	I-Premise
187	physical	_	_	I-Premise
188	activity	_	_	I-Premise
189	by	_	_	I-Premise
190	more	_	_	I-Premise
191	than	_	_	I-Premise
192	100	_	_	I-Premise
193	versus	_	_	I-Premise
194	22	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	controls	_	_	I-Premise
198	(	_	_	I-Premise
199	54.5	_	_	I-Premise
200	vs.	_	_	I-Premise
201	14.6	_	_	I-Premise
202	min	_	_	I-Premise
203	,	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.13	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	and	_	_	I-Premise
210	experienced	_	_	I-Premise
211	significant	_	_	I-Premise
212	increases	_	_	I-Premise
213	in	_	_	I-Premise
214	fitness	_	_	I-Premise
215	(	_	_	I-Premise
216	increased	_	_	I-Premise
217	6-min	_	_	I-Premise
218	walk	_	_	I-Premise
219	test	_	_	I-Premise
220	distance	_	_	I-Premise
221	by	_	_	I-Premise
222	186.9	_	_	I-Premise
223	vs.	_	_	I-Premise
224	81.9	_	_	I-Premise
225	feet	_	_	I-Premise
226	,	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.006	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	physical	_	_	I-Premise
233	functioning	_	_	I-Premise
234	(	_	_	I-Premise
235	7.1	_	_	I-Premise
236	vs.	_	_	I-Premise
237	2.6	_	_	I-Premise
238	,	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	as	_	_	I-Premise
244	compared	_	_	I-Premise
245	to	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	Breast	_	_	B-Claim
251	and	_	_	I-Claim
252	colorectal	_	_	I-Claim
253	cancer	_	_	I-Claim
254	survivors	_	_	I-Claim
255	enrolled	_	_	I-Claim
256	in	_	_	I-Claim
257	a	_	_	I-Claim
258	multicenter	_	_	I-Claim
259	,	_	_	I-Claim
260	telephone-based	_	_	I-Claim
261	physical	_	_	I-Claim
262	activity	_	_	I-Claim
263	intervention	_	_	I-Claim
264	increased	_	_	I-Claim
265	physical	_	_	I-Claim
266	activity	_	_	I-Claim
267	and	_	_	I-Claim
268	experienced	_	_	I-Claim
269	significant	_	_	I-Claim
270	improvements	_	_	I-Claim
271	in	_	_	I-Claim
272	fitness	_	_	I-Claim
273	and	_	_	I-Claim
274	physical	_	_	I-Claim
275	functioning	_	_	I-Claim
276	.	_	_	I-Claim

277	Lifestyle	_	_	B-Claim
278	intervention	_	_	I-Claim
279	research	_	_	I-Claim
280	is	_	_	I-Claim
281	feasible	_	_	I-Claim
282	in	_	_	I-Claim
283	a	_	_	I-Claim
284	cooperative	_	_	I-Claim
285	group	_	_	I-Claim
286	setting	_	_	I-Claim
287	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	objective	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	the	_	_	O
10	response	_	_	O
11	rates	_	_	O
12	of	_	_	O
13	elderly	_	_	O
14	,	_	_	O
15	chemonaive	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	non-small	_	_	O
20	cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	(	_	_	O
24	NSCLC	_	_	O
25	)	_	_	O
26	treated	_	_	O
27	with	_	_	O
28	daily	_	_	O
29	oral	_	_	O
30	erlotinib	_	_	O
31	versus	_	_	O
32	oral	_	_	O
33	vinorelbine	_	_	O
34	.	_	_	O

35	Chemonaive	_	_	O
36	Taiwanese	_	_	O
37	patients	_	_	O
38	aged	_	_	O
39	70	_	_	O
40	years	_	_	O
41	or	_	_	O
42	older	_	_	O
43	who	_	_	O
44	had	_	_	O
45	advanced	_	_	O
46	NSCLC	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	either	_	_	O
52	oral	_	_	O
53	erlotinib	_	_	O
54	150	_	_	O
55	mg	_	_	O
56	(	_	_	O
57	E	_	_	O
58	)	_	_	O
59	daily	_	_	O
60	or	_	_	O
61	oral	_	_	O
62	vinorelbine	_	_	O
63	60	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	V	_	_	O
67	)	_	_	O
68	on	_	_	O
69	days	_	_	O
70	1	_	_	O
71	and	_	_	O
72	8	_	_	O
73	every	_	_	O
74	3	_	_	O
75	weeks	_	_	O
76	.	_	_	O

77	From	_	_	O
78	February	_	_	O
79	2007	_	_	O
80	to	_	_	O
81	July	_	_	O
82	2008	_	_	O
83	,	_	_	O
84	116	_	_	O
85	patients	_	_	O
86	were	_	_	O
87	enrolled	_	_	O
88	and	_	_	O
89	113	_	_	O
90	were	_	_	O
91	included	_	_	O
92	in	_	_	O
93	the	_	_	O
94	intent-to-treat	_	_	O
95	population	_	_	O
96	:	_	_	O
97	57	_	_	O
98	patients	_	_	O
99	in	_	_	O
100	the	_	_	O
101	E	_	_	O
102	group	_	_	O
103	and	_	_	O
104	56	_	_	O
105	patients	_	_	O
106	in	_	_	O
107	the	_	_	O
108	V	_	_	O
109	group	_	_	O
110	.	_	_	O

111	Objective	_	_	B-Premise
112	response	_	_	I-Premise
113	rates	_	_	I-Premise
114	were	_	_	I-Premise
115	22.8	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	13	_	_	I-Premise
119	of	_	_	I-Premise
120	57	_	_	I-Premise
121	)	_	_	I-Premise
122	in	_	_	I-Premise
123	E	_	_	I-Premise
124	and	_	_	I-Premise
125	8.9	_	_	I-Premise
126	%	_	_	I-Premise
127	(	_	_	I-Premise
128	5	_	_	I-Premise
129	of	_	_	I-Premise
130	56	_	_	I-Premise
131	)	_	_	I-Premise
132	in	_	_	I-Premise
133	V	_	_	I-Premise
134	(	_	_	I-Premise
135	p	_	_	I-Premise
136	=	_	_	I-Premise
137	0.0388	_	_	I-Premise
138	)	_	_	I-Premise
139	.	_	_	I-Premise

140	Median	_	_	B-Premise
141	progression-free	_	_	I-Premise
142	survival	_	_	I-Premise
143	(	_	_	I-Premise
144	PFS	_	_	I-Premise
145	)	_	_	I-Premise
146	was	_	_	I-Premise
147	4.57	_	_	I-Premise
148	months	_	_	I-Premise
149	in	_	_	I-Premise
150	E	_	_	I-Premise
151	and	_	_	I-Premise
152	2.53	_	_	I-Premise
153	months	_	_	I-Premise
154	in	_	_	I-Premise
155	V	_	_	I-Premise
156	(	_	_	I-Premise
157	p	_	_	I-Premise
158	=	_	_	I-Premise
159	0.0287	_	_	I-Premise
160	)	_	_	I-Premise
161	,	_	_	I-Premise
162	with	_	_	I-Premise
163	an	_	_	I-Premise
164	80.6	_	_	I-Premise
165	%	_	_	I-Premise
166	increase	_	_	I-Premise
167	in	_	_	I-Premise
168	median	_	_	I-Premise
169	PFS	_	_	I-Premise
170	for	_	_	I-Premise
171	E	_	_	I-Premise
172	compared	_	_	I-Premise
173	with	_	_	I-Premise
174	V.	_	_	I-Premise
175	Median	_	_	B-Premise
176	survival	_	_	I-Premise
177	time	_	_	I-Premise
178	was	_	_	I-Premise
179	11.67	_	_	I-Premise
180	months	_	_	I-Premise
181	in	_	_	I-Premise
182	E	_	_	I-Premise
183	and	_	_	I-Premise
184	9.3	_	_	I-Premise
185	months	_	_	I-Premise
186	in	_	_	I-Premise
187	V	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.6975	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Toxicities	_	_	B-Premise
195	were	_	_	I-Premise
196	generally	_	_	I-Premise
197	mild	_	_	I-Premise
198	in	_	_	I-Premise
199	both	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	Median	_	_	B-Premise
203	PFS	_	_	I-Premise
204	was	_	_	I-Premise
205	longest	_	_	I-Premise
206	for	_	_	I-Premise
207	epidermal	_	_	I-Premise
208	growth	_	_	I-Premise
209	factor	_	_	I-Premise
210	receptor	_	_	I-Premise
211	gene	_	_	I-Premise
212	(	_	_	I-Premise
213	EGFR	_	_	I-Premise
214	)	_	_	I-Premise
215	-mutated	_	_	I-Premise
216	patients	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	E	_	_	I-Premise
220	group	_	_	I-Premise
221	,	_	_	I-Premise
222	followed	_	_	I-Premise
223	by	_	_	I-Premise
224	EGFR-mutated	_	_	I-Premise
225	patients	_	_	I-Premise
226	in	_	_	I-Premise
227	V	_	_	I-Premise
228	,	_	_	I-Premise
229	EGFR	_	_	I-Premise
230	wild	_	_	I-Premise
231	type	_	_	I-Premise
232	in	_	_	I-Premise
233	E	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	EGFR	_	_	I-Premise
237	wild	_	_	I-Premise
238	type	_	_	I-Premise
239	in	_	_	I-Premise
240	V	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.0034	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Overall	_	_	B-Premise
248	survival	_	_	I-Premise
249	was	_	_	I-Premise
250	longer	_	_	I-Premise
251	for	_	_	I-Premise
252	EGFR-mutated	_	_	I-Premise
253	patients	_	_	I-Premise
254	than	_	_	I-Premise
255	for	_	_	I-Premise
256	EGFR	_	_	I-Premise
257	wild-type	_	_	I-Premise
258	patients	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.0001	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Erlotinib	_	_	B-Claim
266	is	_	_	I-Claim
267	highly	_	_	I-Claim
268	effective	_	_	I-Claim
269	compared	_	_	I-Claim
270	with	_	_	I-Claim
271	oral	_	_	I-Claim
272	vinorelbine	_	_	I-Claim
273	in	_	_	I-Claim
274	elderly	_	_	I-Claim
275	,	_	_	I-Claim
276	chemonaive	_	_	I-Claim
277	,	_	_	I-Claim
278	Taiwanese	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	NSCLC	_	_	I-Claim
282	.	_	_	I-Claim

283	EGFR-mutated	_	_	B-Claim
284	patients	_	_	I-Claim
285	had	_	_	I-Claim
286	better	_	_	I-Claim
287	survival	_	_	I-Claim
288	than	_	_	I-Claim
289	those	_	_	I-Claim
290	with	_	_	I-Claim
291	EGFR	_	_	I-Claim
292	wild-type	_	_	I-Claim
293	disease	_	_	I-Claim
294	,	_	_	I-Claim
295	regardless	_	_	I-Claim
296	of	_	_	I-Claim
297	the	_	_	I-Claim
298	treatment	_	_	I-Claim
299	received	_	_	I-Claim
300	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	and	_	_	O
4	compare	_	_	O
5	health-related	_	_	O
6	quality-of-life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	outcomes	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	head-neck	_	_	O
15	squamous	_	_	O
16	cell	_	_	O
17	carcinoma	_	_	O
18	randomized	_	_	O
19	to	_	_	O
20	either	_	_	O
21	intensity-modulated	_	_	O
22	radiation	_	_	O
23	therapy	_	_	O
24	(	_	_	O
25	IMRT	_	_	O
26	)	_	_	O
27	or	_	_	O
28	three-dimensional	_	_	O
29	conformal	_	_	O
30	radiotherapy	_	_	O
31	(	_	_	O
32	3D-CRT	_	_	O
33	)	_	_	O
34	and	_	_	O
35	assess	_	_	O
36	serial	_	_	O
37	longitudinal	_	_	O
38	change	_	_	O
39	in	_	_	O
40	QOL	_	_	O
41	over	_	_	O
42	time	_	_	O
43	.	_	_	O

44	QOL	_	_	O
45	outcomes	_	_	O
46	were	_	_	O
47	assessed	_	_	O
48	using	_	_	O
49	the	_	_	O
50	European	_	_	O
51	Organization	_	_	O
52	for	_	_	O
53	Research	_	_	O
54	and	_	_	O
55	Treatment	_	_	O
56	of	_	_	O
57	Cancer	_	_	O
58	(	_	_	O
59	EORTC	_	_	O
60	)	_	_	O
61	QOL	_	_	O
62	questionnaire	_	_	O
63	(	_	_	O
64	QLQ-C30	_	_	O
65	)	_	_	O
66	and	_	_	O
67	Head-Neck	_	_	O
68	module	_	_	O
69	(	_	_	O
70	HN-35	_	_	O
71	)	_	_	O
72	at	_	_	O
73	baseline	_	_	O
74	(	_	_	O
75	pre-treatment	_	_	O
76	)	_	_	O
77	and	_	_	O
78	subsequently	_	_	O
79	periodically	_	_	O
80	on	_	_	O
81	follow-up	_	_	O
82	.	_	_	O

83	Mean	_	_	O
84	scores	_	_	O
85	of	_	_	O
86	individual	_	_	O
87	domains/scales	_	_	O
88	of	_	_	O
89	3D-CRT	_	_	O
90	and	_	_	O
91	IMRT	_	_	O
92	were	_	_	O
93	compared	_	_	O
94	using	_	_	O
95	't	_	_	O
96	'	_	_	O
97	test	_	_	O
98	at	_	_	O
99	each	_	_	O
100	time	_	_	O
101	point	_	_	O
102	;	_	_	O
103	while	_	_	O
104	longitudinal	_	_	O
105	change	_	_	O
106	in	_	_	O
107	mean	_	_	O
108	scores	_	_	O
109	of	_	_	O
110	both	_	_	O
111	groups	_	_	O
112	over	_	_	O
113	time	_	_	O
114	was	_	_	O
115	evaluated	_	_	O
116	by	_	_	O
117	repeated	_	_	O
118	measurement	_	_	O
119	analysis	_	_	O
120	of	_	_	O
121	variance	_	_	O
122	.	_	_	O

123	Fifty	_	_	O
124	eight	_	_	O
125	of	_	_	O
126	the	_	_	O
127	60	_	_	O
128	randomized	_	_	O
129	patients	_	_	O
130	who	_	_	O
131	filled	_	_	O
132	the	_	_	O
133	QOL	_	_	O
134	questionnaire	_	_	O
135	at	_	_	O
136	least	_	_	O
137	at	_	_	O
138	one	_	_	O
139	time	_	_	O
140	point	_	_	O
141	were	_	_	O
142	included	_	_	O
143	in	_	_	O
144	the	_	_	O
145	analysis	_	_	O
146	.	_	_	O

147	Several	_	_	O
148	general	_	_	O
149	(	_	_	O
150	emotional	_	_	O
151	functioning	_	_	O
152	,	_	_	O
153	role	_	_	O
154	functioning	_	_	O
155	,	_	_	O
156	social	_	_	O
157	contact	_	_	O
158	)	_	_	O
159	as	_	_	O
160	well	_	_	O
161	as	_	_	O
162	head	_	_	O
163	and	_	_	O
164	neck	_	_	O
165	cancer-specific	_	_	O
166	(	_	_	O
167	dry	_	_	O
168	mouth	_	_	O
169	,	_	_	O
170	opening	_	_	O
171	mouth	_	_	O
172	,	_	_	O
173	sticky	_	_	O
174	saliva	_	_	O
175	,	_	_	O
176	pain	_	_	O
177	,	_	_	O
178	senses	_	_	O
179	)	_	_	O
180	QOL	_	_	O
181	domains	_	_	O
182	were	_	_	O
183	better	_	_	O
184	preserved	_	_	O
185	with	_	_	O
186	IMRT	_	_	O
187	compared	_	_	O
188	to	_	_	O
189	3D-CRT	_	_	O
190	at	_	_	O
191	different	_	_	O
192	time	_	_	O
193	points	_	_	O
194	.	_	_	O

195	Importantly	_	_	O
196	,	_	_	O
197	none	_	_	O
198	of	_	_	O
199	the	_	_	O
200	QOL	_	_	O
201	domains	_	_	O
202	were	_	_	O
203	worse	_	_	O
204	with	_	_	O
205	IMRT	_	_	O
206	at	_	_	O
207	any	_	_	O
208	time	_	_	O
209	point	_	_	O
210	.	_	_	O

211	There	_	_	B-Premise
212	was	_	_	I-Premise
213	substantial	_	_	I-Premise
214	deterioration	_	_	I-Premise
215	in	_	_	I-Premise
216	QOL	_	_	I-Premise
217	scores	_	_	I-Premise
218	immediate	_	_	I-Premise
219	post-treatment	_	_	I-Premise
220	(	_	_	I-Premise
221	3-months	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	both	_	_	I-Premise
225	arms	_	_	I-Premise
226	.	_	_	I-Premise

227	However	_	_	B-Premise
228	,	_	_	I-Premise
229	QOL	_	_	I-Premise
230	scores	_	_	I-Premise
231	gradually	_	_	I-Premise
232	but	_	_	I-Premise
233	definitely	_	_	I-Premise
234	improved	_	_	I-Premise
235	over	_	_	I-Premise
236	time	_	_	I-Premise
237	for	_	_	I-Premise
238	most	_	_	I-Premise
239	domains	_	_	I-Premise
240	.	_	_	I-Premise

241	Global	_	_	B-Premise
242	QOL	_	_	I-Premise
243	,	_	_	I-Premise
244	emotional/role	_	_	I-Premise
245	functioning	_	_	I-Premise
246	,	_	_	I-Premise
247	nausea/vomiting	_	_	I-Premise
248	,	_	_	I-Premise
249	pain	_	_	I-Premise
250	,	_	_	I-Premise
251	swallowing	_	_	I-Premise
252	,	_	_	I-Premise
253	speech	_	_	I-Premise
254	,	_	_	I-Premise
255	social	_	_	I-Premise
256	contact/eating	_	_	I-Premise
257	,	_	_	I-Premise
258	insomnia	_	_	I-Premise
259	showed	_	_	I-Premise
260	rapid	_	_	I-Premise
261	recovery	_	_	I-Premise
262	(	_	_	I-Premise
263	<	_	_	I-Premise
264	6months	_	_	I-Premise
265	)	_	_	I-Premise
266	while	_	_	I-Premise
267	physical/cognitive	_	_	I-Premise
268	functioning	_	_	I-Premise
269	,	_	_	I-Premise
270	dry	_	_	I-Premise
271	mouth	_	_	I-Premise
272	,	_	_	I-Premise
273	sticky	_	_	I-Premise
274	saliva	_	_	I-Premise
275	,	_	_	I-Premise
276	fatigue	_	_	I-Premise
277	,	_	_	I-Premise
278	senses	_	_	I-Premise
279	showed	_	_	I-Premise
280	delayed	_	_	I-Premise
281	recovery	_	_	I-Premise
282	(	_	_	I-Premise
283	>	_	_	I-Premise
284	6months	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	There	_	_	B-Premise
288	were	_	_	I-Premise
289	no	_	_	I-Premise
290	significant	_	_	I-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	loco-regional	_	_	I-Premise
294	or	_	_	I-Premise
295	survival	_	_	I-Premise
296	between	_	_	I-Premise
297	the	_	_	I-Premise
298	two	_	_	I-Premise
299	arms	_	_	I-Premise
300	.	_	_	I-Premise

301	There	_	_	B-Claim
302	is	_	_	I-Claim
303	substantial	_	_	I-Claim
304	deterioration	_	_	I-Claim
305	in	_	_	I-Claim
306	QOL	_	_	I-Claim
307	after	_	_	I-Claim
308	curative-intent	_	_	I-Claim
309	head-neck	_	_	I-Claim
310	irradiation	_	_	I-Claim
311	that	_	_	I-Claim
312	gradually	_	_	I-Claim
313	improves	_	_	I-Claim
314	over	_	_	I-Claim
315	time	_	_	I-Claim
316	.	_	_	I-Claim

317	IMRT	_	_	B-Claim
318	results	_	_	I-Claim
319	in	_	_	I-Claim
320	clinically	_	_	I-Claim
321	meaningful	_	_	I-Claim
322	and	_	_	I-Claim
323	statistically	_	_	I-Claim
324	better	_	_	I-Claim
325	QOL	_	_	I-Claim
326	scores	_	_	I-Claim
327	for	_	_	I-Claim
328	some	_	_	I-Claim
329	domains	_	_	I-Claim
330	compared	_	_	I-Claim
331	to	_	_	I-Claim
332	3D-CRT	_	_	I-Claim
333	at	_	_	I-Claim
334	several	_	_	I-Claim
335	time	_	_	I-Claim
336	points	_	_	I-Claim
337	with	_	_	I-Claim
338	comparable	_	_	I-Claim
339	disease	_	_	I-Claim
340	outcomes	_	_	I-Claim
341	that	_	_	I-Claim
342	could	_	_	I-Claim
343	support	_	_	I-Claim
344	its	_	_	I-Claim
345	widespread	_	_	I-Claim
346	adoption	_	_	I-Claim
347	in	_	_	I-Claim
348	routine	_	_	I-Claim
349	clinical	_	_	I-Claim
350	practice	_	_	I-Claim
351	.	_	_	I-Claim


0	In	_	_	O
1	Lithuania	_	_	O
2	,	_	_	O
3	about	_	_	O
4	400	_	_	O
5	cases	_	_	O
6	of	_	_	O
7	pancreatic	_	_	O
8	cancer	_	_	O
9	are	_	_	O
10	diagnosed	_	_	O
11	each	_	_	O
12	year	_	_	O
13	,	_	_	O
14	and	_	_	O
15	more	_	_	O
16	than	_	_	O
17	50	_	_	O
18	%	_	_	O
19	of	_	_	O
20	patients	_	_	O
21	are	_	_	O
22	diagnosed	_	_	O
23	with	_	_	O
24	stage	_	_	O
25	IV	_	_	O
26	disease	_	_	O
27	.	_	_	O

28	Quality	_	_	B-Claim
29	of	_	_	I-Claim
30	life	_	_	I-Claim
31	is	_	_	I-Claim
32	an	_	_	I-Claim
33	important	_	_	I-Claim
34	issue	_	_	I-Claim
35	in	_	_	I-Claim
36	pancreatic	_	_	I-Claim
37	cancer	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	A	_	_	O
41	prospective	_	_	O
42	randomized	_	_	O
43	clinical	_	_	O
44	study	_	_	O
45	on	_	_	O
46	the	_	_	O
47	treatment	_	_	O
48	of	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	resectable	_	_	O
52	and	_	_	O
53	unresectable	_	_	O
54	pancreatic	_	_	O
55	cancer	_	_	O
56	was	_	_	O
57	conducted	_	_	O
58	at	_	_	O
59	the	_	_	O
60	Department	_	_	O
61	of	_	_	O
62	Oncology	_	_	O
63	of	_	_	O
64	Kaunas	_	_	O
65	University	_	_	O
66	of	_	_	O
67	Medicine	_	_	O
68	Hospital	_	_	O
69	,	_	_	O
70	and	_	_	O
71	in	_	_	O
72	this	_	_	O
73	study	_	_	O
74	,	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	was	_	_	O
79	analyzed	_	_	O
80	.	_	_	O

81	The	_	_	O
82	aim	_	_	O
83	of	_	_	O
84	the	_	_	O
85	study	_	_	O
86	was	_	_	O
87	to	_	_	O
88	analyze	_	_	O
89	the	_	_	O
90	effect	_	_	O
91	of	_	_	O
92	combined	_	_	O
93	treatment	_	_	O
94	methods	_	_	O
95	on	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	in	_	_	O
100	patients	_	_	O
101	diagnosed	_	_	O
102	with	_	_	O
103	pancreatic	_	_	O
104	cancer	_	_	O
105	.	_	_	O

106	During	_	_	O
107	2000-2005	_	_	O
108	,	_	_	O
109	two	_	_	O
110	concomitant	_	_	O
111	chemoradiation	_	_	O
112	treatment	_	_	O
113	methods	_	_	O
114	(	_	_	O
115	radiotherapy	_	_	O
116	with	_	_	O
117	5-fluorouracil	_	_	O
118	and	_	_	O
119	radiotherapy	_	_	O
120	with	_	_	O
121	gemcitabine	_	_	O
122	)	_	_	O
123	were	_	_	O
124	analyzed	_	_	O
125	in	_	_	O
126	the	_	_	O
127	study	_	_	O
128	.	_	_	O

129	A	_	_	O
130	total	_	_	O
131	of	_	_	O
132	60	_	_	O
133	patients	_	_	O
134	were	_	_	O
135	enrolled	_	_	O
136	:	_	_	O
137	41	_	_	O
138	patients	_	_	O
139	diagnosed	_	_	O
140	with	_	_	O
141	resectable	_	_	O
142	and	_	_	O
143	19	_	_	O
144	patients	_	_	O
145	diagnosed	_	_	O
146	with	_	_	O
147	unresectable	_	_	O
148	pancreatic	_	_	O
149	cancer	_	_	O
150	.	_	_	O

151	Quality	_	_	O
152	of	_	_	O
153	life	_	_	O
154	was	_	_	O
155	assessed	_	_	O
156	using	_	_	O
157	European	_	_	O
158	Organization	_	_	O
159	for	_	_	O
160	Research	_	_	O
161	and	_	_	O
162	Treatment	_	_	O
163	of	_	_	O
164	Cancer	_	_	O
165	Quality	_	_	O
166	of	_	_	O
167	Life	_	_	O
168	Core	_	_	O
169	30	_	_	O
170	(	_	_	O
171	EORTC	_	_	O
172	QLQ-C30	_	_	O
173	)	_	_	O
174	questionnaire	_	_	O
175	.	_	_	O

176	Three	_	_	O
177	main	_	_	O
178	quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	scales	_	_	O
182	(	_	_	O
183	general	_	_	O
184	health	_	_	O
185	status	_	_	O
186	,	_	_	O
187	functional	_	_	O
188	,	_	_	O
189	and	_	_	O
190	symptom	_	_	O
191	scales	_	_	O
192	)	_	_	O
193	were	_	_	O
194	assessed	_	_	O
195	and	_	_	O
196	compared	_	_	O
197	between	_	_	O
198	two	_	_	O
199	treatment	_	_	O
200	groups	_	_	O
201	.	_	_	O

202	The	_	_	B-Premise
203	analysis	_	_	I-Premise
204	of	_	_	I-Premise
205	quality	_	_	I-Premise
206	of	_	_	I-Premise
207	live	_	_	I-Premise
208	assessment	_	_	I-Premise
209	showed	_	_	I-Premise
210	a	_	_	I-Premise
211	statistically	_	_	I-Premise
212	significant	_	_	I-Premise
213	decrease	_	_	I-Premise
214	in	_	_	I-Premise
215	quality	_	_	I-Premise
216	of	_	_	I-Premise
217	life	_	_	I-Premise
218	after	_	_	I-Premise
219	treatment	_	_	I-Premise
220	in	_	_	I-Premise
221	patients	_	_	I-Premise
222	with	_	_	I-Premise
223	resectable	_	_	I-Premise
224	pancreatic	_	_	I-Premise
225	cancer	_	_	I-Premise
226	and	_	_	I-Premise
227	treated	_	_	I-Premise
228	with	_	_	I-Premise
229	radiotherapy	_	_	I-Premise
230	and	_	_	I-Premise
231	gemcitabine	_	_	I-Premise
232	.	_	_	I-Premise

233	Decreased	_	_	B-Premise
234	quality	_	_	I-Premise
235	of	_	_	I-Premise
236	life	_	_	I-Premise
237	later	_	_	I-Premise
238	after	_	_	I-Premise
239	treatment	_	_	I-Premise
240	was	_	_	I-Premise
241	also	_	_	I-Premise
242	observed	_	_	I-Premise
243	in	_	_	I-Premise
244	patients	_	_	I-Premise
245	diagnosed	_	_	I-Premise
246	with	_	_	I-Premise
247	unresectable	_	_	I-Premise
248	pancreatic	_	_	I-Premise
249	cancer	_	_	I-Premise
250	and	_	_	I-Premise
251	treated	_	_	I-Premise
252	with	_	_	I-Premise
253	the	_	_	I-Premise
254	same	_	_	I-Premise
255	regimen	_	_	I-Premise
256	.	_	_	I-Premise

257	Treatment	_	_	B-Claim
258	with	_	_	I-Claim
259	radiotherapy	_	_	I-Claim
260	and	_	_	I-Claim
261	5-fluorouracil	_	_	I-Claim
262	changed	_	_	I-Claim
263	only	_	_	I-Claim
264	some	_	_	I-Claim
265	aspects	_	_	I-Claim
266	of	_	_	I-Claim
267	quality	_	_	I-Claim
268	of	_	_	I-Claim
269	life	_	_	I-Claim
270	and	_	_	I-Claim
271	did	_	_	I-Claim
272	not	_	_	I-Claim
273	have	_	_	I-Claim
274	a	_	_	I-Claim
275	significant	_	_	I-Claim
276	impact	_	_	I-Claim
277	on	_	_	I-Claim
278	quality	_	_	I-Claim
279	of	_	_	I-Claim
280	life	_	_	I-Claim
281	.	_	_	I-Claim


0	Therapy	_	_	B-Claim
1	of	_	_	I-Claim
2	patients	_	_	I-Claim
3	with	_	_	I-Claim
4	advanced	_	_	I-Claim
5	gastric	_	_	I-Claim
6	or	_	_	I-Claim
7	gastroesophageal	_	_	I-Claim
8	junction	_	_	I-Claim
9	cancer	_	_	I-Claim
10	should	_	_	I-Claim
11	provide	_	_	I-Claim
12	symptom	_	_	I-Claim
13	relief	_	_	I-Claim
14	and	_	_	I-Claim
15	improve	_	_	I-Claim
16	quality	_	_	I-Claim
17	of	_	_	I-Claim
18	life	_	_	I-Claim
19	(	_	_	I-Claim
20	QOL	_	_	I-Claim
21	)	_	_	I-Claim
22	because	_	_	I-Claim
23	most	_	_	I-Claim
24	patients	_	_	I-Claim
25	are	_	_	I-Claim
26	symptomatic	_	_	I-Claim
27	at	_	_	I-Claim
28	baseline	_	_	I-Claim
29	.	_	_	I-Claim

30	Using	_	_	O
31	validated	_	_	O
32	instruments	_	_	O
33	,	_	_	O
34	we	_	_	O
35	prospectively	_	_	O
36	assessed	_	_	O
37	QOL	_	_	O
38	(	_	_	O
39	even	_	_	O
40	after	_	_	O
41	completion	_	_	O
42	of	_	_	O
43	protocol	_	_	O
44	treatment	_	_	O
45	)	_	_	O
46	as	_	_	O
47	one	_	_	O
48	of	_	_	O
49	the	_	_	O
50	secondary	_	_	O
51	end	_	_	O
52	points	_	_	O
53	of	_	_	O
54	the	_	_	O
55	V325	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Four	_	_	O
61	hundred	_	_	O
62	forty-five	_	_	O
63	patients	_	_	O
64	randomly	_	_	O
65	received	_	_	O
66	either	_	_	O
67	docetaxel	_	_	O
68	75	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	and	_	_	O
74	cisplatin	_	_	O
75	75	_	_	O
76	mg/m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	each	_	_	O
81	on	_	_	O
82	day	_	_	O
83	1	_	_	O
84	plus	_	_	O
85	fluorouracil	_	_	O
86	750	_	_	O
87	mg/m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	/d	_	_	O
92	continuous	_	_	O
93	infusion	_	_	O
94	on	_	_	O
95	days	_	_	O
96	1	_	_	O
97	to	_	_	O
98	5	_	_	O
99	every	_	_	O
100	3	_	_	O
101	weeks	_	_	O
102	(	_	_	O
103	DCF	_	_	O
104	)	_	_	O
105	or	_	_	O
106	cisplatin	_	_	O
107	100	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	on	_	_	O
113	day	_	_	O
114	1	_	_	O
115	plus	_	_	O
116	fluorouracil	_	_	O
117	1,000	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	/d	_	_	O
123	continuous	_	_	O
124	infusion	_	_	O
125	on	_	_	O
126	days	_	_	O
127	1	_	_	O
128	to	_	_	O
129	5	_	_	O
130	every	_	_	O
131	4	_	_	O
132	weeks	_	_	O
133	(	_	_	O
134	CF	_	_	O
135	)	_	_	O
136	.	_	_	O

137	The	_	_	O
138	European	_	_	O
139	Organisation	_	_	O
140	for	_	_	O
141	Research	_	_	O
142	and	_	_	O
143	Treatment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Quality	_	_	O
147	of	_	_	O
148	Life	_	_	O
149	Questionnaire	_	_	O
150	C30	_	_	O
151	(	_	_	O
152	EORTC	_	_	O
153	QLQ-C30	_	_	O
154	)	_	_	O
155	and	_	_	O
156	,	_	_	O
157	where	_	_	O
158	available	_	_	O
159	,	_	_	O
160	the	_	_	O
161	EuroQOL	_	_	O
162	EQ-5D	_	_	O
163	questionnaire	_	_	O
164	were	_	_	O
165	administered	_	_	O
166	every	_	_	O
167	8	_	_	O
168	weeks	_	_	O
169	from	_	_	O
170	baseline	_	_	O
171	until	_	_	O
172	progression	_	_	O
173	and	_	_	O
174	then	_	_	O
175	every	_	_	O
176	3	_	_	O
177	months	_	_	O
178	.	_	_	O

179	Time	_	_	O
180	to	_	_	O
181	definitive	_	_	O
182	deterioration	_	_	O
183	of	_	_	O
184	QOL	_	_	O
185	parameters	_	_	O
186	was	_	_	O
187	analyzed	_	_	O
188	.	_	_	O

189	The	_	_	O
190	proportions	_	_	O
191	of	_	_	O
192	patients	_	_	O
193	having	_	_	O
194	assessable	_	_	O
195	EORTC	_	_	O
196	QLQ-C30	_	_	O
197	and	_	_	O
198	EQ-5D	_	_	O
199	questionnaires	_	_	O
200	at	_	_	O
201	baseline	_	_	O
202	were	_	_	O
203	86.0	_	_	O
204	%	_	_	O
205	and	_	_	O
206	78.7	_	_	O
207	%	_	_	O
208	with	_	_	O
209	DCF	_	_	O
210	,	_	_	O
211	respectively	_	_	O
212	,	_	_	O
213	and	_	_	O
214	89.7	_	_	O
215	%	_	_	O
216	and	_	_	O
217	92.8	_	_	O
218	%	_	_	O
219	with	_	_	O
220	CF	_	_	O
221	,	_	_	O
222	respectively	_	_	O
223	.	_	_	O

224	Time	_	_	B-Premise
225	to	_	_	I-Premise
226	5	_	_	I-Premise
227	%	_	_	I-Premise
228	deterioration	_	_	I-Premise
229	of	_	_	I-Premise
230	global	_	_	I-Premise
231	health	_	_	I-Premise
232	status	_	_	I-Premise
233	(	_	_	I-Premise
234	primary	_	_	I-Premise
235	end	_	_	I-Premise
236	point	_	_	I-Premise
237	)	_	_	I-Premise
238	significantly	_	_	I-Premise
239	favored	_	_	I-Premise
240	DCF	_	_	I-Premise
241	over	_	_	I-Premise
242	CF	_	_	I-Premise
243	(	_	_	I-Premise
244	log-rank	_	_	I-Premise
245	test	_	_	I-Premise
246	,	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	.01	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	QOL	_	_	B-Premise
253	was	_	_	I-Premise
254	preserved	_	_	I-Premise
255	longer	_	_	I-Premise
256	for	_	_	I-Premise
257	patients	_	_	I-Premise
258	on	_	_	I-Premise
259	DCF	_	_	I-Premise
260	than	_	_	I-Premise
261	those	_	_	I-Premise
262	on	_	_	I-Premise
263	CF	_	_	I-Premise
264	for	_	_	I-Premise
265	all	_	_	I-Premise
266	time	_	_	I-Premise
267	to	_	_	I-Premise
268	deterioration	_	_	I-Premise
269	analyses	_	_	I-Premise
270	,	_	_	I-Premise
271	demonstrating	_	_	I-Premise
272	the	_	_	I-Premise
273	statistical	_	_	I-Premise
274	superiority	_	_	I-Premise
275	of	_	_	I-Premise
276	DCF	_	_	I-Premise
277	compared	_	_	I-Premise
278	with	_	_	I-Premise
279	CF	_	_	I-Premise
280	.	_	_	I-Premise

281	V325	_	_	O
282	represents	_	_	O
283	the	_	_	O
284	largest	_	_	O
285	trial	_	_	O
286	with	_	_	O
287	the	_	_	O
288	longest	_	_	O
289	prospectively	_	_	O
290	controlled	_	_	O
291	evaluations	_	_	O
292	of	_	_	O
293	QOL	_	_	O
294	during	_	_	O
295	protocol	_	_	O
296	chemotherapy	_	_	O
297	and	_	_	O
298	follow-up	_	_	O
299	in	_	_	O
300	patients	_	_	O
301	with	_	_	O
302	advanced	_	_	O
303	gastric	_	_	O
304	or	_	_	O
305	gastroesophageal	_	_	O
306	junction	_	_	O
307	cancer	_	_	O
308	.	_	_	O

309	In	_	_	B-Claim
310	V325	_	_	I-Claim
311	,	_	_	I-Claim
312	advanced	_	_	I-Claim
313	gastric	_	_	I-Claim
314	or	_	_	I-Claim
315	gastroesophageal	_	_	I-Claim
316	junction	_	_	I-Claim
317	cancer	_	_	I-Claim
318	patients	_	_	I-Claim
319	receiving	_	_	I-Claim
320	DCF	_	_	I-Claim
321	not	_	_	I-Claim
322	only	_	_	I-Claim
323	had	_	_	I-Claim
324	statistically	_	_	I-Claim
325	improved	_	_	I-Claim
326	overall	_	_	I-Claim
327	survival	_	_	I-Claim
328	and	_	_	I-Claim
329	time	_	_	I-Claim
330	to	_	_	I-Claim
331	tumor-progression	_	_	I-Claim
332	,	_	_	I-Claim
333	but	_	_	I-Claim
334	they	_	_	I-Claim
335	also	_	_	I-Claim
336	had	_	_	I-Claim
337	better	_	_	I-Claim
338	preservation	_	_	I-Claim
339	of	_	_	I-Claim
340	QOL	_	_	I-Claim
341	compared	_	_	I-Claim
342	with	_	_	I-Claim
343	patients	_	_	I-Claim
344	receiving	_	_	I-Claim
345	CF	_	_	I-Claim
346	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	cancer	_	_	O
4	experience	_	_	O
5	depression	_	_	O
6	and	_	_	O
7	anxiety	_	_	O
8	,	_	_	O
9	and	_	_	O
10	an	_	_	O
11	associated	_	_	O
12	decrease	_	_	O
13	in	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	during	_	_	O
21	radiation	_	_	O
22	therapy	_	_	O
23	(	_	_	O
24	RT	_	_	O
25	)	_	_	O
26	.	_	_	O

27	The	_	_	O
28	main	_	_	O
29	objective	_	_	O
30	of	_	_	O
31	the	_	_	O
32	study	_	_	O
33	was	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	benefits	_	_	O
38	of	_	_	O
39	psychosocial	_	_	O
40	interventions	_	_	O
41	for	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	received	_	_	O
46	RT	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	with	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	178	_	_	O
55	)	_	_	O
56	who	_	_	O
57	agreed	_	_	O
58	to	_	_	O
59	participate	_	_	O
60	in	_	_	O
61	the	_	_	O
62	study	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	the	_	_	O
67	intervention	_	_	O
68	arm	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	89	_	_	O
73	)	_	_	O
74	or	_	_	O
75	the	_	_	O
76	control	_	_	O
77	arm	_	_	O
78	(	_	_	O
79	n	_	_	O
80	=	_	_	O
81	89	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	in	_	_	O
86	the	_	_	O
87	intervention	_	_	O
88	group	_	_	O
89	received	_	_	O
90	psychosocial	_	_	O
91	care	_	_	O
92	during	_	_	O
93	RT	_	_	O
94	,	_	_	O
95	whereas	_	_	O
96	the	_	_	O
97	control	_	_	O
98	group	_	_	O
99	received	_	_	O
100	RT	_	_	O
101	only	_	_	O
102	.	_	_	O

103	The	_	_	O
104	benefits	_	_	O
105	of	_	_	O
106	the	_	_	O
107	intervention	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	using	_	_	O
111	the	_	_	O
112	Zung	_	_	O
113	Self-rating	_	_	O
114	Depression	_	_	O
115	Scale	_	_	O
116	(	_	_	O
117	SDS	_	_	O
118	)	_	_	O
119	to	_	_	O
120	measure	_	_	O
121	depression	_	_	O
122	,	_	_	O
123	the	_	_	O
124	Self-rating	_	_	O
125	Anxiety	_	_	O
126	Scale	_	_	O
127	(	_	_	O
128	SAS	_	_	O
129	)	_	_	O
130	to	_	_	O
131	assess	_	_	O
132	anxiety	_	_	O
133	,	_	_	O
134	and	_	_	O
135	the	_	_	O
136	European	_	_	O
137	Organization	_	_	O
138	for	_	_	O
139	Research	_	_	O
140	and	_	_	O
141	Treatment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	Quality	_	_	O
145	of	_	_	O
146	Life	_	_	O
147	Questionnaire-Core	_	_	O
148	30	_	_	O
149	(	_	_	O
150	EORTC	_	_	O
151	QLQ-C30	_	_	O
152	)	_	_	O
153	to	_	_	O
154	survey	_	_	O
155	health-related	_	_	O
156	QOL	_	_	O
157	.	_	_	O

158	The	_	_	O
159	association	_	_	O
160	between	_	_	O
161	intervention	_	_	O
162	and	_	_	O
163	survival	_	_	O
164	was	_	_	O
165	also	_	_	O
166	assessed	_	_	O
167	.	_	_	O

168	Patients	_	_	B-Premise
169	randomly	_	_	I-Premise
170	assigned	_	_	I-Premise
171	to	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	arm	_	_	I-Premise
175	showed	_	_	I-Premise
176	significant	_	_	I-Premise
177	improvements	_	_	I-Premise
178	on	_	_	I-Premise
179	symptoms	_	_	I-Premise
180	of	_	_	I-Premise
181	depression	_	_	I-Premise
182	(	_	_	I-Premise
183	p	_	_	I-Premise
184	<	_	_	I-Premise
185	0.05	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	anxiety	_	_	I-Premise
189	(	_	_	I-Premise
190	p	_	_	I-Premise
191	<	_	_	I-Premise
192	0.05	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	health-related	_	_	I-Premise
196	QOL	_	_	I-Premise
197	(	_	_	I-Premise
198	p	_	_	I-Premise
199	<	_	_	I-Premise
200	0.05	_	_	I-Premise
201	)	_	_	I-Premise
202	(	_	_	I-Premise
203	i.e	_	_	I-Premise
204	.	_	_	I-Premise

205	better	_	_	I-Premise
206	global	_	_	I-Premise
207	health	_	_	I-Premise
208	status	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	physical	_	_	I-Premise
212	and	_	_	I-Premise
213	emotional	_	_	I-Premise
214	functioning	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	less	_	_	I-Premise
218	insomnia	_	_	I-Premise
219	)	_	_	I-Premise
220	when	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	controls	_	_	I-Premise
224	.	_	_	I-Premise

225	In	_	_	B-Claim
226	the	_	_	I-Claim
227	subset	_	_	I-Claim
228	analysis	_	_	I-Claim
229	,	_	_	I-Claim
230	female	_	_	I-Claim
231	patients	_	_	I-Claim
232	,	_	_	I-Claim
233	those	_	_	I-Claim
234	that	_	_	I-Claim
235	received	_	_	I-Claim
236	high	_	_	I-Claim
237	dose	_	_	I-Claim
238	irradiation	_	_	I-Claim
239	,	_	_	I-Claim
240	and	_	_	I-Claim
241	those	_	_	I-Claim
242	that	_	_	I-Claim
243	underwent	_	_	I-Claim
244	adjuvant	_	_	I-Claim
245	chemotherapy	_	_	I-Claim
246	could	_	_	I-Claim
247	benefit	_	_	I-Claim
248	more	_	_	I-Claim
249	from	_	_	I-Claim
250	psychosocial	_	_	I-Claim
251	intervention	_	_	I-Claim
252	.	_	_	I-Claim

253	There	_	_	B-Premise
254	was	_	_	I-Premise
255	no	_	_	I-Premise
256	difference	_	_	I-Premise
257	between	_	_	I-Premise
258	the	_	_	I-Premise
259	two	_	_	I-Premise
260	groups	_	_	I-Premise
261	in	_	_	I-Premise
262	disease-free	_	_	I-Premise
263	survival	_	_	I-Premise
264	(	_	_	I-Premise
265	DFS	_	_	I-Premise
266	)	_	_	I-Premise
267	(	_	_	I-Premise
268	2-year	_	_	I-Premise
269	DFS	_	_	I-Premise
270	79.8	_	_	I-Premise
271	%	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	intervention	_	_	I-Premise
275	arm	_	_	I-Premise
276	and	_	_	I-Premise
277	76.4	_	_	I-Premise
278	%	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	control	_	_	I-Premise
282	arm	_	_	I-Premise
283	;	_	_	I-Premise
284	p	_	_	I-Premise
285	=	_	_	I-Premise
286	0.527	_	_	I-Premise
287	)	_	_	I-Premise
288	and	_	_	I-Premise
289	overall	_	_	I-Premise
290	survival	_	_	I-Premise
291	(	_	_	I-Premise
292	OS	_	_	I-Premise
293	)	_	_	I-Premise
294	(	_	_	I-Premise
295	2-year	_	_	I-Premise
296	OS	_	_	I-Premise
297	83.1	_	_	I-Premise
298	%	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	intervention	_	_	I-Premise
302	arm	_	_	I-Premise
303	and	_	_	I-Premise
304	84.3	_	_	I-Premise
305	%	_	_	I-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	control	_	_	I-Premise
309	arm	_	_	I-Premise
310	;	_	_	I-Premise
311	p	_	_	I-Premise
312	=	_	_	I-Premise
313	0.925	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	Psychosocial	_	_	B-Claim
317	intervention	_	_	I-Claim
318	is	_	_	I-Claim
319	a	_	_	I-Claim
320	cost-effective	_	_	I-Claim
321	approach	_	_	I-Claim
322	that	_	_	I-Claim
323	can	_	_	I-Claim
324	improve	_	_	I-Claim
325	a	_	_	I-Claim
326	patient	_	_	I-Claim
327	's	_	_	I-Claim
328	mood	_	_	I-Claim
329	and	_	_	I-Claim
330	QOL	_	_	I-Claim
331	both	_	_	I-Claim
332	during	_	_	I-Claim
333	and	_	_	I-Claim
334	after	_	_	I-Claim
335	RT	_	_	I-Claim
336	.	_	_	I-Claim

337	However	_	_	B-Claim
338	,	_	_	I-Claim
339	the	_	_	I-Claim
340	intervention	_	_	I-Claim
341	was	_	_	I-Claim
342	not	_	_	I-Claim
343	found	_	_	I-Claim
344	to	_	_	I-Claim
345	reduce	_	_	I-Claim
346	the	_	_	I-Claim
347	risk	_	_	I-Claim
348	of	_	_	I-Claim
349	cancer	_	_	I-Claim
350	recurrence	_	_	I-Claim
351	and	_	_	I-Claim
352	death	_	_	I-Claim
353	.	_	_	I-Claim


0	Dignity	_	_	O
1	therapy	_	_	O
2	is	_	_	O
3	a	_	_	O
4	unique	_	_	O
5	,	_	_	O
6	individualised	_	_	O
7	,	_	_	O
8	short-term	_	_	O
9	psychotherapy	_	_	O
10	that	_	_	O
11	was	_	_	O
12	developed	_	_	O
13	for	_	_	O
14	patients	_	_	O
15	(	_	_	O
16	and	_	_	O
17	their	_	_	O
18	families	_	_	O
19	)	_	_	O
20	living	_	_	O
21	with	_	_	O
22	life-threatening	_	_	O
23	or	_	_	O
24	life-limiting	_	_	O
25	illness	_	_	O
26	.	_	_	O

27	We	_	_	O
28	investigated	_	_	O
29	whether	_	_	O
30	dignity	_	_	O
31	therapy	_	_	O
32	could	_	_	O
33	mitigate	_	_	O
34	distress	_	_	O
35	or	_	_	O
36	bolster	_	_	O
37	the	_	_	O
38	experience	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	nearing	_	_	O
42	the	_	_	O
43	end	_	_	O
44	of	_	_	O
45	their	_	_	O
46	lives	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	(	_	_	O
50	aged	_	_	O
51	â‰¥18	_	_	O
52	years	_	_	O
53	)	_	_	O
54	with	_	_	O
55	a	_	_	O
56	terminal	_	_	O
57	prognosis	_	_	O
58	(	_	_	O
59	life	_	_	O
60	expectancy	_	_	O
61	â‰¤6	_	_	O
62	months	_	_	O
63	)	_	_	O
64	who	_	_	O
65	were	_	_	O
66	receiving	_	_	O
67	palliative	_	_	O
68	care	_	_	O
69	in	_	_	O
70	a	_	_	O
71	hospital	_	_	O
72	or	_	_	O
73	community	_	_	O
74	setting	_	_	O
75	(	_	_	O
76	hospice	_	_	O
77	or	_	_	O
78	home	_	_	O
79	)	_	_	O
80	in	_	_	O
81	Canada	_	_	O
82	,	_	_	O
83	USA	_	_	O
84	,	_	_	O
85	and	_	_	O
86	Australia	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	dignity	_	_	O
92	therapy	_	_	O
93	,	_	_	O
94	client-centred	_	_	O
95	care	_	_	O
96	,	_	_	O
97	or	_	_	O
98	standard	_	_	O
99	palliative	_	_	O
100	care	_	_	O
101	in	_	_	O
102	a	_	_	O
103	1:1:1	_	_	O
104	ratio	_	_	O
105	.	_	_	O

106	Randomisation	_	_	O
107	was	_	_	O
108	by	_	_	O
109	use	_	_	O
110	of	_	_	O
111	a	_	_	O
112	computer-generated	_	_	O
113	table	_	_	O
114	of	_	_	O
115	random	_	_	O
116	numbers	_	_	O
117	in	_	_	O
118	blocks	_	_	O
119	of	_	_	O
120	30	_	_	O
121	.	_	_	O

122	Allocation	_	_	O
123	concealment	_	_	O
124	was	_	_	O
125	by	_	_	O
126	use	_	_	O
127	of	_	_	O
128	opaque	_	_	O
129	sealed	_	_	O
130	envelopes	_	_	O
131	.	_	_	O

132	The	_	_	O
133	primary	_	_	O
134	outcomes	_	_	O
135	--	_	_	O
136	reductions	_	_	O
137	in	_	_	O
138	various	_	_	O
139	dimensions	_	_	O
140	of	_	_	O
141	distress	_	_	O
142	before	_	_	O
143	and	_	_	O
144	after	_	_	O
145	completion	_	_	O
146	of	_	_	O
147	the	_	_	O
148	study	_	_	O
149	--	_	_	O
150	were	_	_	O
151	measured	_	_	O
152	with	_	_	O
153	the	_	_	O
154	Functional	_	_	O
155	Assessment	_	_	O
156	of	_	_	O
157	Chronic	_	_	O
158	Illness	_	_	O
159	Therapy	_	_	O
160	Spiritual	_	_	O
161	Well-Being	_	_	O
162	Scale	_	_	O
163	,	_	_	O
164	Patient	_	_	O
165	Dignity	_	_	O
166	Inventory	_	_	O
167	,	_	_	O
168	Hospital	_	_	O
169	Anxiety	_	_	O
170	and	_	_	O
171	Depression	_	_	O
172	Scale	_	_	O
173	,	_	_	O
174	items	_	_	O
175	from	_	_	O
176	the	_	_	O
177	Structured	_	_	O
178	Interview	_	_	O
179	for	_	_	O
180	Symptoms	_	_	O
181	and	_	_	O
182	Concerns	_	_	O
183	,	_	_	O
184	Quality	_	_	O
185	of	_	_	O
186	Life	_	_	O
187	Scale	_	_	O
188	,	_	_	O
189	and	_	_	O
190	modified	_	_	O
191	Edmonton	_	_	O
192	Symptom	_	_	O
193	Assessment	_	_	O
194	Scale	_	_	O
195	.	_	_	O

196	Secondary	_	_	O
197	outcomes	_	_	O
198	of	_	_	O
199	self-reported	_	_	O
200	end-of-life	_	_	O
201	experiences	_	_	O
202	were	_	_	O
203	assessed	_	_	O
204	in	_	_	O
205	a	_	_	O
206	survey	_	_	O
207	that	_	_	O
208	was	_	_	O
209	undertaken	_	_	O
210	after	_	_	O
211	the	_	_	O
212	completion	_	_	O
213	of	_	_	O
214	the	_	_	O
215	study	_	_	O
216	.	_	_	O

217	Outcomes	_	_	O
218	were	_	_	O
219	assessed	_	_	O
220	by	_	_	O
221	research	_	_	O
222	staff	_	_	O
223	with	_	_	O
224	whom	_	_	O
225	the	_	_	O
226	participant	_	_	O
227	had	_	_	O
228	no	_	_	O
229	previous	_	_	O
230	contact	_	_	O
231	to	_	_	O
232	avoid	_	_	O
233	any	_	_	O
234	possible	_	_	O
235	response	_	_	O
236	bias	_	_	O
237	or	_	_	O
238	contamination	_	_	O
239	.	_	_	O

240	Analyses	_	_	O
241	were	_	_	O
242	done	_	_	O
243	on	_	_	O
244	all	_	_	O
245	patients	_	_	O
246	with	_	_	O
247	available	_	_	O
248	data	_	_	O
249	at	_	_	O
250	baseline	_	_	O
251	and	_	_	O
252	at	_	_	O
253	the	_	_	O
254	end	_	_	O
255	of	_	_	O
256	the	_	_	O
257	study	_	_	O
258	intervention	_	_	O
259	.	_	_	O

260	165	_	_	O
261	of	_	_	O
262	441	_	_	O
263	patients	_	_	O
264	were	_	_	O
265	assigned	_	_	O
266	to	_	_	O
267	dignity	_	_	O
268	therapy	_	_	O
269	,	_	_	O
270	140	_	_	O
271	standard	_	_	O
272	palliative	_	_	O
273	care	_	_	O
274	,	_	_	O
275	and	_	_	O
276	136	_	_	O
277	client-centred	_	_	O
278	care	_	_	O
279	.	_	_	O

280	108	_	_	O
281	,	_	_	O
282	111	_	_	O
283	,	_	_	O
284	and	_	_	O
285	107	_	_	O
286	patients	_	_	O
287	,	_	_	O
288	respectively	_	_	O
289	,	_	_	O
290	were	_	_	O
291	analysed	_	_	O
292	.	_	_	O

293	No	_	_	B-Premise
294	significant	_	_	I-Premise
295	differences	_	_	I-Premise
296	were	_	_	I-Premise
297	noted	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	distress	_	_	I-Premise
301	levels	_	_	I-Premise
302	before	_	_	I-Premise
303	and	_	_	I-Premise
304	after	_	_	I-Premise
305	completion	_	_	I-Premise
306	of	_	_	I-Premise
307	the	_	_	I-Premise
308	study	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	three	_	_	I-Premise
312	groups	_	_	I-Premise
313	.	_	_	I-Premise

314	For	_	_	B-Premise
315	the	_	_	I-Premise
316	secondary	_	_	I-Premise
317	outcomes	_	_	I-Premise
318	,	_	_	I-Premise
319	patients	_	_	I-Premise
320	reported	_	_	I-Premise
321	that	_	_	I-Premise
322	dignity	_	_	I-Premise
323	therapy	_	_	I-Premise
324	was	_	_	I-Premise
325	significantly	_	_	I-Premise
326	more	_	_	I-Premise
327	likely	_	_	I-Premise
328	than	_	_	I-Premise
329	the	_	_	I-Premise
330	other	_	_	I-Premise
331	two	_	_	I-Premise
332	interventions	_	_	I-Premise
333	to	_	_	I-Premise
334	have	_	_	I-Premise
335	been	_	_	I-Premise
336	helpful	_	_	I-Premise
337	(	_	_	I-Premise
338	Ï‡	_	_	I-Premise
339	(	_	_	I-Premise
340	2	_	_	I-Premise
341	)	_	_	I-Premise
342	=35Â·50	_	_	I-Premise
343	,	_	_	I-Premise
344	df=2	_	_	I-Premise
345	;	_	_	I-Premise
346	p	_	_	I-Premise
347	<	_	_	I-Premise
348	0Â·0001	_	_	I-Premise
349	)	_	_	I-Premise
350	,	_	_	I-Premise
351	improve	_	_	I-Premise
352	quality	_	_	I-Premise
353	of	_	_	I-Premise
354	life	_	_	I-Premise
355	(	_	_	I-Premise
356	Ï‡	_	_	I-Premise
357	(	_	_	I-Premise
358	2	_	_	I-Premise
359	)	_	_	I-Premise
360	=14Â·52	_	_	I-Premise
361	;	_	_	I-Premise
362	p=0Â·001	_	_	I-Premise
363	)	_	_	I-Premise
364	,	_	_	I-Premise
365	increase	_	_	I-Premise
366	sense	_	_	I-Premise
367	of	_	_	I-Premise
368	dignity	_	_	I-Premise
369	(	_	_	I-Premise
370	Ï‡	_	_	I-Premise
371	(	_	_	I-Premise
372	2	_	_	I-Premise
373	)	_	_	I-Premise
374	=12Â·66	_	_	I-Premise
375	;	_	_	I-Premise
376	p=0Â·002	_	_	I-Premise
377	)	_	_	I-Premise
378	,	_	_	I-Premise
379	change	_	_	I-Premise
380	how	_	_	I-Premise
381	their	_	_	I-Premise
382	family	_	_	I-Premise
383	saw	_	_	I-Premise
384	and	_	_	I-Premise
385	appreciated	_	_	I-Premise
386	them	_	_	I-Premise
387	(	_	_	I-Premise
388	Ï‡	_	_	I-Premise
389	(	_	_	I-Premise
390	2	_	_	I-Premise
391	)	_	_	I-Premise
392	=33Â·81	_	_	I-Premise
393	;	_	_	I-Premise
394	p	_	_	I-Premise
395	<	_	_	I-Premise
396	0Â·0001	_	_	I-Premise
397	)	_	_	I-Premise
398	,	_	_	I-Premise
399	and	_	_	I-Premise
400	be	_	_	I-Premise
401	helpful	_	_	I-Premise
402	to	_	_	I-Premise
403	their	_	_	I-Premise
404	family	_	_	I-Premise
405	(	_	_	I-Premise
406	Ï‡	_	_	I-Premise
407	(	_	_	I-Premise
408	2	_	_	I-Premise
409	)	_	_	I-Premise
410	=33Â·86	_	_	I-Premise
411	;	_	_	I-Premise
412	p	_	_	I-Premise
413	<	_	_	I-Premise
414	0Â·0001	_	_	I-Premise
415	)	_	_	I-Premise
416	.	_	_	I-Premise

417	Dignity	_	_	B-Premise
418	therapy	_	_	I-Premise
419	was	_	_	I-Premise
420	significantly	_	_	I-Premise
421	better	_	_	I-Premise
422	than	_	_	I-Premise
423	client-centred	_	_	I-Premise
424	care	_	_	I-Premise
425	in	_	_	I-Premise
426	improving	_	_	I-Premise
427	spiritual	_	_	I-Premise
428	wellbeing	_	_	I-Premise
429	(	_	_	I-Premise
430	Ï‡	_	_	I-Premise
431	(	_	_	I-Premise
432	2	_	_	I-Premise
433	)	_	_	I-Premise
434	=10Â·35	_	_	I-Premise
435	;	_	_	I-Premise
436	p=0Â·006	_	_	I-Premise
437	)	_	_	I-Premise
438	,	_	_	I-Premise
439	and	_	_	I-Premise
440	was	_	_	I-Premise
441	significantly	_	_	I-Premise
442	better	_	_	I-Premise
443	than	_	_	I-Premise
444	standard	_	_	I-Premise
445	palliative	_	_	I-Premise
446	care	_	_	I-Premise
447	in	_	_	I-Premise
448	terms	_	_	I-Premise
449	of	_	_	I-Premise
450	lessening	_	_	I-Premise
451	sadness	_	_	I-Premise
452	or	_	_	I-Premise
453	depression	_	_	I-Premise
454	(	_	_	I-Premise
455	Ï‡	_	_	I-Premise
456	(	_	_	I-Premise
457	2	_	_	I-Premise
458	)	_	_	I-Premise
459	=9Â·38	_	_	I-Premise
460	;	_	_	I-Premise
461	p=0Â·009	_	_	I-Premise
462	)	_	_	I-Premise
463	;	_	_	I-Premise
464	significantly	_	_	B-Premise
465	more	_	_	I-Premise
466	patients	_	_	I-Premise
467	who	_	_	I-Premise
468	had	_	_	I-Premise
469	received	_	_	I-Premise
470	dignity	_	_	I-Premise
471	therapy	_	_	I-Premise
472	reported	_	_	I-Premise
473	that	_	_	I-Premise
474	the	_	_	I-Premise
475	study	_	_	I-Premise
476	group	_	_	I-Premise
477	had	_	_	I-Premise
478	been	_	_	I-Premise
479	satisfactory	_	_	I-Premise
480	,	_	_	I-Premise
481	compared	_	_	I-Premise
482	with	_	_	I-Premise
483	those	_	_	I-Premise
484	who	_	_	I-Premise
485	received	_	_	I-Premise
486	standard	_	_	I-Premise
487	palliative	_	_	I-Premise
488	care	_	_	I-Premise
489	(	_	_	I-Premise
490	Ï‡	_	_	I-Premise
491	(	_	_	I-Premise
492	2	_	_	I-Premise
493	)	_	_	I-Premise
494	=29Â·58	_	_	I-Premise
495	;	_	_	I-Premise
496	p	_	_	I-Premise
497	<	_	_	I-Premise
498	0Â·0001	_	_	I-Premise
499	)	_	_	I-Premise
500	.	_	_	I-Premise

501	Although	_	_	B-Claim
502	the	_	_	I-Claim
503	ability	_	_	I-Claim
504	of	_	_	I-Claim
505	dignity	_	_	I-Claim
506	therapy	_	_	I-Claim
507	to	_	_	I-Claim
508	mitigate	_	_	I-Claim
509	outright	_	_	I-Claim
510	distress	_	_	I-Claim
511	,	_	_	I-Claim
512	such	_	_	I-Claim
513	as	_	_	I-Claim
514	depression	_	_	I-Claim
515	,	_	_	I-Claim
516	desire	_	_	I-Claim
517	for	_	_	I-Claim
518	death	_	_	I-Claim
519	or	_	_	I-Claim
520	suicidality	_	_	I-Claim
521	,	_	_	I-Claim
522	has	_	_	I-Claim
523	yet	_	_	I-Claim
524	to	_	_	I-Claim
525	be	_	_	I-Claim
526	proven	_	_	I-Claim
527	,	_	_	I-Claim
528	its	_	_	B-Claim
529	benefits	_	_	I-Claim
530	in	_	_	I-Claim
531	terms	_	_	I-Claim
532	of	_	_	I-Claim
533	self-reported	_	_	I-Claim
534	end-of-life	_	_	I-Claim
535	experiences	_	_	I-Claim
536	support	_	_	I-Claim
537	its	_	_	I-Claim
538	clinical	_	_	I-Claim
539	application	_	_	I-Claim
540	for	_	_	I-Claim
541	patients	_	_	I-Claim
542	nearing	_	_	I-Claim
543	death	_	_	I-Claim
544	.	_	_	I-Claim


0	The	_	_	O
1	finding	_	_	O
2	of	_	_	O
3	a	_	_	O
4	decrease	_	_	O
5	in	_	_	O
6	contralateral	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	incidence	_	_	O
10	following	_	_	O
11	tamoxifen	_	_	O
12	administration	_	_	O
13	for	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	led	_	_	O
17	to	_	_	O
18	the	_	_	O
19	concept	_	_	O
20	that	_	_	O
21	the	_	_	O
22	drug	_	_	O
23	might	_	_	O
24	play	_	_	O
25	a	_	_	O
26	role	_	_	O
27	in	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	prevention	_	_	O
31	.	_	_	O

32	To	_	_	O
33	test	_	_	O
34	this	_	_	O
35	hypothesis	_	_	O
36	,	_	_	O
37	the	_	_	O
38	National	_	_	O
39	Surgical	_	_	O
40	Adjuvant	_	_	O
41	Breast	_	_	O
42	and	_	_	O
43	Bowel	_	_	O
44	Project	_	_	O
45	initiated	_	_	O
46	the	_	_	O
47	Breast	_	_	O
48	Cancer	_	_	O
49	Prevention	_	_	O
50	Trial	_	_	O
51	(	_	_	O
52	P-1	_	_	O
53	)	_	_	O
54	in	_	_	O
55	1992	_	_	O
56	.	_	_	O

57	Women	_	_	O
58	(	_	_	O
59	N=13388	_	_	O
60	)	_	_	O
61	at	_	_	O
62	increased	_	_	O
63	risk	_	_	O
64	for	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	because	_	_	O
68	they	_	_	O
69	1	_	_	O
70	)	_	_	O
71	were	_	_	O
72	60	_	_	O
73	years	_	_	O
74	of	_	_	O
75	age	_	_	O
76	or	_	_	O
77	older	_	_	O
78	,	_	_	O
79	2	_	_	O
80	)	_	_	O
81	were	_	_	O
82	35-59	_	_	O
83	years	_	_	O
84	of	_	_	O
85	age	_	_	O
86	with	_	_	O
87	a	_	_	O
88	5-year	_	_	O
89	predicted	_	_	O
90	risk	_	_	O
91	for	_	_	O
92	breast	_	_	O
93	cancer	_	_	O
94	of	_	_	O
95	at	_	_	O
96	least	_	_	O
97	1.66	_	_	O
98	%	_	_	O
99	,	_	_	O
100	or	_	_	O
101	3	_	_	O
102	)	_	_	O
103	had	_	_	O
104	a	_	_	O
105	history	_	_	O
106	of	_	_	O
107	lobular	_	_	O
108	carcinoma	_	_	O
109	in	_	_	O
110	situ	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	receive	_	_	O
116	placebo	_	_	O
117	(	_	_	O
118	n=6707	_	_	O
119	)	_	_	O
120	or	_	_	O
121	20	_	_	O
122	mg/day	_	_	O
123	tamoxifen	_	_	O
124	(	_	_	O
125	n=6681	_	_	O
126	)	_	_	O
127	for	_	_	O
128	5	_	_	O
129	years	_	_	O
130	.	_	_	O

131	Gail	_	_	O
132	's	_	_	O
133	algorithm	_	_	O
134	,	_	_	O
135	based	_	_	O
136	on	_	_	O
137	a	_	_	O
138	multivariate	_	_	O
139	logistic	_	_	O
140	regression	_	_	O
141	model	_	_	O
142	using	_	_	O
143	combinations	_	_	O
144	of	_	_	O
145	risk	_	_	O
146	factors	_	_	O
147	,	_	_	O
148	was	_	_	O
149	used	_	_	O
150	to	_	_	O
151	estimate	_	_	O
152	the	_	_	O
153	probability	_	_	O
154	(	_	_	O
155	risk	_	_	O
156	)	_	_	O
157	of	_	_	O
158	occurrence	_	_	O
159	of	_	_	O
160	breast	_	_	O
161	cancer	_	_	O
162	over	_	_	O
163	time	_	_	O
164	.	_	_	O

165	Tamoxifen	_	_	B-Premise
166	reduced	_	_	I-Premise
167	the	_	_	I-Premise
168	risk	_	_	I-Premise
169	of	_	_	I-Premise
170	invasive	_	_	I-Premise
171	breast	_	_	I-Premise
172	cancer	_	_	I-Premise
173	by	_	_	I-Premise
174	49	_	_	I-Premise
175	%	_	_	I-Premise
176	(	_	_	I-Premise
177	two-sided	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	.00001	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	with	_	_	I-Premise
184	cumulative	_	_	I-Premise
185	incidence	_	_	I-Premise
186	through	_	_	I-Premise
187	69	_	_	I-Premise
188	months	_	_	I-Premise
189	of	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	of	_	_	I-Premise
192	43.4	_	_	I-Premise
193	versus	_	_	I-Premise
194	22.0	_	_	I-Premise
195	per	_	_	I-Premise
196	1000	_	_	I-Premise
197	women	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	placebo	_	_	I-Premise
201	and	_	_	I-Premise
202	tamoxifen	_	_	I-Premise
203	groups	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	O
208	decreased	_	_	O
209	risk	_	_	O
210	occurred	_	_	O
211	in	_	_	O
212	women	_	_	O
213	aged	_	_	O
214	49	_	_	O
215	years	_	_	O
216	or	_	_	O
217	younger	_	_	O
218	(	_	_	O
219	44	_	_	O
220	%	_	_	O
221	)	_	_	O
222	,	_	_	O
223	50-59	_	_	O
224	years	_	_	O
225	(	_	_	O
226	51	_	_	O
227	%	_	_	O
228	)	_	_	O
229	,	_	_	O
230	and	_	_	O
231	60	_	_	O
232	years	_	_	O
233	or	_	_	O
234	older	_	_	O
235	(	_	_	O
236	55	_	_	O
237	%	_	_	O
238	)	_	_	O
239	;	_	_	O
240	risk	_	_	B-Premise
241	was	_	_	I-Premise
242	also	_	_	I-Premise
243	reduced	_	_	I-Premise
244	in	_	_	I-Premise
245	women	_	_	I-Premise
246	with	_	_	I-Premise
247	a	_	_	I-Premise
248	history	_	_	I-Premise
249	of	_	_	I-Premise
250	lobular	_	_	I-Premise
251	carcinoma	_	_	I-Premise
252	in	_	_	I-Premise
253	situ	_	_	I-Premise
254	(	_	_	I-Premise
255	56	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	or	_	_	I-Premise
259	atypical	_	_	I-Premise
260	hyperplasia	_	_	I-Premise
261	(	_	_	I-Premise
262	86	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	in	_	_	I-Premise
267	those	_	_	I-Premise
268	with	_	_	I-Premise
269	any	_	_	I-Premise
270	category	_	_	I-Premise
271	of	_	_	I-Premise
272	predicted	_	_	I-Premise
273	5-year	_	_	I-Premise
274	risk	_	_	I-Premise
275	.	_	_	I-Premise

276	Tamoxifen	_	_	B-Premise
277	reduced	_	_	I-Premise
278	the	_	_	I-Premise
279	risk	_	_	I-Premise
280	of	_	_	I-Premise
281	noninvasive	_	_	I-Premise
282	breast	_	_	I-Premise
283	cancer	_	_	I-Premise
284	by	_	_	I-Premise
285	50	_	_	I-Premise
286	%	_	_	I-Premise
287	(	_	_	I-Premise
288	two-sided	_	_	I-Premise
289	P	_	_	I-Premise
290	<	_	_	I-Premise
291	.002	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Tamoxifen	_	_	B-Premise
295	reduced	_	_	I-Premise
296	the	_	_	I-Premise
297	occurrence	_	_	I-Premise
298	of	_	_	I-Premise
299	estrogen	_	_	I-Premise
300	receptor-positive	_	_	I-Premise
301	tumors	_	_	I-Premise
302	by	_	_	I-Premise
303	69	_	_	I-Premise
304	%	_	_	I-Premise
305	,	_	_	I-Premise
306	but	_	_	I-Premise
307	no	_	_	I-Premise
308	difference	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	occurrence	_	_	I-Premise
312	of	_	_	I-Premise
313	estrogen	_	_	I-Premise
314	receptor-negative	_	_	I-Premise
315	tumors	_	_	I-Premise
316	was	_	_	I-Premise
317	seen	_	_	I-Premise
318	.	_	_	I-Premise

319	Tamoxifen	_	_	B-Premise
320	administration	_	_	I-Premise
321	did	_	_	I-Premise
322	not	_	_	I-Premise
323	alter	_	_	I-Premise
324	the	_	_	I-Premise
325	average	_	_	I-Premise
326	annual	_	_	I-Premise
327	rate	_	_	I-Premise
328	of	_	_	I-Premise
329	ischemic	_	_	I-Premise
330	heart	_	_	I-Premise
331	disease	_	_	I-Premise
332	;	_	_	I-Premise
333	however	_	_	I-Premise
334	,	_	_	I-Premise
335	a	_	_	I-Premise
336	reduction	_	_	I-Premise
337	in	_	_	I-Premise
338	hip	_	_	I-Premise
339	,	_	_	I-Premise
340	radius	_	_	I-Premise
341	(	_	_	I-Premise
342	Colles	_	_	I-Premise
343	'	_	_	I-Premise
344	)	_	_	I-Premise
345	,	_	_	I-Premise
346	and	_	_	I-Premise
347	spine	_	_	I-Premise
348	fractures	_	_	I-Premise
349	was	_	_	I-Premise
350	observed	_	_	I-Premise
351	.	_	_	I-Premise

352	The	_	_	B-Premise
353	rate	_	_	I-Premise
354	of	_	_	I-Premise
355	endometrial	_	_	I-Premise
356	cancer	_	_	I-Premise
357	was	_	_	I-Premise
358	increased	_	_	I-Premise
359	in	_	_	I-Premise
360	the	_	_	I-Premise
361	tamoxifen	_	_	I-Premise
362	group	_	_	I-Premise
363	(	_	_	I-Premise
364	risk	_	_	I-Premise
365	ratio	_	_	I-Premise
366	=	_	_	I-Premise
367	2.53	_	_	I-Premise
368	;	_	_	I-Premise
369	95	_	_	I-Premise
370	%	_	_	I-Premise
371	confidence	_	_	I-Premise
372	interval	_	_	I-Premise
373	=	_	_	I-Premise
374	1.35-4.97	_	_	I-Premise
375	)	_	_	I-Premise
376	;	_	_	I-Premise
377	this	_	_	I-Premise
378	increased	_	_	I-Premise
379	risk	_	_	I-Premise
380	occurred	_	_	I-Premise
381	predominantly	_	_	I-Premise
382	in	_	_	I-Premise
383	women	_	_	I-Premise
384	aged	_	_	I-Premise
385	50	_	_	I-Premise
386	years	_	_	I-Premise
387	or	_	_	I-Premise
388	older	_	_	I-Premise
389	.	_	_	I-Premise

390	All	_	_	O
391	endometrial	_	_	O
392	cancers	_	_	O
393	in	_	_	O
394	the	_	_	O
395	tamoxifen	_	_	O
396	group	_	_	O
397	were	_	_	O
398	stage	_	_	O
399	I	_	_	O
400	(	_	_	O
401	localized	_	_	O
402	disease	_	_	O
403	)	_	_	O
404	;	_	_	O
405	no	_	_	B-Premise
406	endometrial	_	_	I-Premise
407	cancer	_	_	I-Premise
408	deaths	_	_	I-Premise
409	have	_	_	I-Premise
410	occurred	_	_	I-Premise
411	in	_	_	I-Premise
412	this	_	_	I-Premise
413	group	_	_	I-Premise
414	.	_	_	I-Premise

415	No	_	_	B-Premise
416	liver	_	_	I-Premise
417	cancers	_	_	I-Premise
418	or	_	_	I-Premise
419	increase	_	_	I-Premise
420	in	_	_	I-Premise
421	colon	_	_	I-Premise
422	,	_	_	I-Premise
423	rectal	_	_	I-Premise
424	,	_	_	I-Premise
425	ovarian	_	_	I-Premise
426	,	_	_	I-Premise
427	or	_	_	I-Premise
428	other	_	_	I-Premise
429	tumors	_	_	I-Premise
430	was	_	_	I-Premise
431	observed	_	_	I-Premise
432	in	_	_	I-Premise
433	the	_	_	I-Premise
434	tamoxifen	_	_	I-Premise
435	group	_	_	I-Premise
436	.	_	_	I-Premise

437	The	_	_	B-Premise
438	rates	_	_	I-Premise
439	of	_	_	I-Premise
440	stroke	_	_	I-Premise
441	,	_	_	I-Premise
442	pulmonary	_	_	I-Premise
443	embolism	_	_	I-Premise
444	,	_	_	I-Premise
445	and	_	_	I-Premise
446	deep-vein	_	_	I-Premise
447	thrombosis	_	_	I-Premise
448	were	_	_	I-Premise
449	elevated	_	_	I-Premise
450	in	_	_	I-Premise
451	the	_	_	I-Premise
452	tamoxifen	_	_	I-Premise
453	group	_	_	I-Premise
454	;	_	_	I-Premise
455	these	_	_	I-Premise
456	events	_	_	I-Premise
457	occurred	_	_	I-Premise
458	more	_	_	I-Premise
459	frequently	_	_	I-Premise
460	in	_	_	I-Premise
461	women	_	_	I-Premise
462	aged	_	_	I-Premise
463	50	_	_	I-Premise
464	years	_	_	I-Premise
465	or	_	_	I-Premise
466	older	_	_	I-Premise
467	.	_	_	I-Premise

468	Tamoxifen	_	_	B-Claim
469	decreases	_	_	I-Claim
470	the	_	_	I-Claim
471	incidence	_	_	I-Claim
472	of	_	_	I-Claim
473	invasive	_	_	I-Claim
474	and	_	_	I-Claim
475	noninvasive	_	_	I-Claim
476	breast	_	_	I-Claim
477	cancer	_	_	I-Claim
478	.	_	_	I-Claim

479	Despite	_	_	B-Claim
480	side	_	_	I-Claim
481	effects	_	_	I-Claim
482	resulting	_	_	I-Claim
483	from	_	_	I-Claim
484	administration	_	_	I-Claim
485	of	_	_	I-Claim
486	tamoxifen	_	_	I-Claim
487	,	_	_	I-Claim
488	its	_	_	I-Claim
489	use	_	_	I-Claim
490	as	_	_	I-Claim
491	a	_	_	I-Claim
492	breast	_	_	I-Claim
493	cancer	_	_	I-Claim
494	preventive	_	_	I-Claim
495	agent	_	_	I-Claim
496	is	_	_	I-Claim
497	appropriate	_	_	I-Claim
498	in	_	_	I-Claim
499	many	_	_	I-Claim
500	women	_	_	I-Claim
501	at	_	_	I-Claim
502	increased	_	_	I-Claim
503	risk	_	_	I-Claim
504	for	_	_	I-Claim
505	the	_	_	I-Claim
506	disease	_	_	I-Claim
507	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	standard	_	_	O
7	anthracycline-based	_	_	O
8	regimen	_	_	O
9	to	_	_	O
10	a	_	_	O
11	dose-intensified	_	_	O
12	anthracycline	_	_	O
13	regimen	_	_	O
14	in	_	_	O
15	locally	_	_	O
16	advanced	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	.	_	_	O

20	Locally	_	_	O
21	advanced	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	patients	_	_	O
25	were	_	_	O
26	randomly	_	_	O
27	assigned	_	_	O
28	onto	_	_	O
29	a	_	_	O
30	study	_	_	O
31	comparing	_	_	O
32	cyclophosphamide	_	_	O
33	(	_	_	O
34	C	_	_	O
35	;	_	_	O
36	75	_	_	O
37	mg/m	_	_	O
38	(	_	_	O
39	2	_	_	O
40	)	_	_	O
41	orally	_	_	O
42	days	_	_	O
43	1	_	_	O
44	to	_	_	O
45	14	_	_	O
46	)	_	_	O
47	,	_	_	O
48	epirubicin	_	_	O
49	(	_	_	O
50	E	_	_	O
51	;	_	_	O
52	60	_	_	O
53	mg/m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	intravenously	_	_	O
58	[	_	_	O
59	IV	_	_	O
60	]	_	_	O
61	days	_	_	O
62	1	_	_	O
63	,	_	_	O
64	8	_	_	O
65	)	_	_	O
66	,	_	_	O
67	and	_	_	O
68	fluorouracil	_	_	O
69	(	_	_	O
70	F	_	_	O
71	;	_	_	O
72	500	_	_	O
73	mg/m	_	_	O
74	(	_	_	O
75	2	_	_	O
76	)	_	_	O
77	IV	_	_	O
78	days	_	_	O
79	1	_	_	O
80	,	_	_	O
81	8	_	_	O
82	)	_	_	O
83	six	_	_	O
84	cycles	_	_	O
85	every	_	_	O
86	28	_	_	O
87	days	_	_	O
88	versus	_	_	O
89	E	_	_	O
90	(	_	_	O
91	120	_	_	O
92	mg/m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	IV	_	_	O
97	day	_	_	O
98	1	_	_	O
99	)	_	_	O
100	,	_	_	O
101	C	_	_	O
102	(	_	_	O
103	830	_	_	O
104	mg/m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	IV	_	_	O
109	day	_	_	O
110	1	_	_	O
111	)	_	_	O
112	,	_	_	O
113	and	_	_	O
114	granulocyte	_	_	O
115	colony-stimulating	_	_	O
116	factor	_	_	O
117	(	_	_	O
118	filgrastim	_	_	O
119	;	_	_	O
120	5	_	_	O
121	micro	_	_	O
122	g/kg/d	_	_	O
123	subcutaneously	_	_	O
124	days	_	_	O
125	2	_	_	O
126	to	_	_	O
127	13	_	_	O
128	)	_	_	O
129	six	_	_	O
130	cycles	_	_	O
131	every	_	_	O
132	14	_	_	O
133	days	_	_	O
134	.	_	_	O

135	The	_	_	O
136	study	_	_	O
137	was	_	_	O
138	designed	_	_	O
139	to	_	_	O
140	detect	_	_	O
141	a	_	_	O
142	15	_	_	O
143	%	_	_	O
144	improvement	_	_	O
145	;	_	_	O
146	that	_	_	O
147	is	_	_	O
148	,	_	_	O
149	from	_	_	O
150	50	_	_	O
151	%	_	_	O
152	to	_	_	O
153	65	_	_	O
154	%	_	_	O
155	in	_	_	O
156	median	_	_	O
157	progression-free	_	_	O
158	survival	_	_	O
159	(	_	_	O
160	PFS	_	_	O
161	)	_	_	O
162	in	_	_	O
163	favor	_	_	O
164	of	_	_	O
165	the	_	_	O
166	dose-intensified	_	_	O
167	regimen	_	_	O
168	.	_	_	O

169	A	_	_	O
170	total	_	_	O
171	of	_	_	O
172	448	_	_	O
173	patients	_	_	O
174	were	_	_	O
175	enrolled	_	_	O
176	over	_	_	O
177	a	_	_	O
178	period	_	_	O
179	of	_	_	O
180	3	_	_	O
181	years	_	_	O
182	.	_	_	O

183	The	_	_	O
184	median	_	_	O
185	dose	_	_	O
186	intensity	_	_	O
187	delivered	_	_	O
188	for	_	_	O
189	C	_	_	O
190	and	_	_	O
191	E	_	_	O
192	reached	_	_	O
193	,	_	_	O
194	respectively	_	_	O
195	,	_	_	O
196	85	_	_	O
197	%	_	_	O
198	and	_	_	O
199	87	_	_	O
200	%	_	_	O
201	of	_	_	O
202	that	_	_	O
203	planned	_	_	O
204	in	_	_	O
205	the	_	_	O
206	CEF	_	_	O
207	arm	_	_	O
208	and	_	_	O
209	96	_	_	O
210	%	_	_	O
211	and	_	_	O
212	95	_	_	O
213	%	_	_	O
214	of	_	_	O
215	that	_	_	O
216	planned	_	_	O
217	in	_	_	O
218	the	_	_	O
219	EC	_	_	O
220	arm	_	_	O
221	.	_	_	O

222	The	_	_	B-Premise
223	dose-intensified	_	_	I-Premise
224	arm	_	_	I-Premise
225	was	_	_	I-Premise
226	slightly	_	_	I-Premise
227	more	_	_	I-Premise
228	emetogenic	_	_	I-Premise
229	and	_	_	I-Premise
230	generated	_	_	I-Premise
231	more	_	_	I-Premise
232	grade	_	_	I-Premise
233	3	_	_	I-Premise
234	to	_	_	I-Premise
235	4	_	_	I-Premise
236	anemia	_	_	I-Premise
237	but	_	_	I-Premise
238	less	_	_	I-Premise
239	febrile	_	_	I-Premise
240	neutropenia	_	_	I-Premise
241	episodes	_	_	I-Premise
242	.	_	_	I-Premise

243	After	_	_	O
244	a	_	_	O
245	median	_	_	O
246	follow-up	_	_	O
247	of	_	_	O
248	5.5	_	_	O
249	years	_	_	O
250	,	_	_	O
251	277	_	_	O
252	events	_	_	O
253	have	_	_	O
254	been	_	_	O
255	reported	_	_	O
256	.	_	_	O

257	The	_	_	B-Premise
258	median	_	_	I-Premise
259	PFS	_	_	I-Premise
260	was	_	_	I-Premise
261	34	_	_	I-Premise
262	and	_	_	I-Premise
263	33.7	_	_	I-Premise
264	months	_	_	I-Premise
265	for	_	_	I-Premise
266	CEF	_	_	I-Premise
267	and	_	_	I-Premise
268	EC	_	_	I-Premise
269	,	_	_	I-Premise
270	respectively	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=.68	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	the	_	_	I-Premise
278	5-year	_	_	I-Premise
279	survival	_	_	I-Premise
280	rate	_	_	I-Premise
281	was	_	_	I-Premise
282	53	_	_	I-Premise
283	%	_	_	I-Premise
284	and	_	_	I-Premise
285	51	_	_	I-Premise
286	%	_	_	I-Premise
287	for	_	_	I-Premise
288	CEF	_	_	I-Premise
289	and	_	_	I-Premise
290	EC	_	_	I-Premise
291	,	_	_	I-Premise
292	respectively	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=.94	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Dose-intensified	_	_	B-Claim
299	EC	_	_	I-Claim
300	does	_	_	I-Claim
301	not	_	_	I-Claim
302	provide	_	_	I-Claim
303	a	_	_	I-Claim
304	measurable	_	_	I-Claim
305	therapeutic	_	_	I-Claim
306	benefit	_	_	I-Claim
307	over	_	_	I-Claim
308	CEF	_	_	I-Claim
309	as	_	_	I-Claim
310	neoadjuvant	_	_	I-Claim
311	chemotherapy	_	_	I-Claim
312	for	_	_	I-Claim
313	unselected	_	_	I-Claim
314	locally	_	_	I-Claim
315	advanced	_	_	I-Claim
316	breast	_	_	I-Claim
317	cancer	_	_	I-Claim
318	patients	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	dose-volume	_	_	O
3	histogram	_	_	O
4	variables	_	_	O
5	for	_	_	O
6	the	_	_	O
7	internal	_	_	O
8	and	_	_	O
9	external	_	_	O
10	urinary	_	_	O
11	sphincters	_	_	O
12	(	_	_	O
13	IUS/EUS	_	_	O
14	)	_	_	O
15	with	_	_	O
16	urinary	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	after	_	_	O
21	prostate	_	_	O
22	brachytherapy	_	_	O
23	.	_	_	O

24	Subjects	_	_	O
25	were	_	_	O
26	42	_	_	O
27	consecutive	_	_	O
28	men	_	_	O
29	from	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	study	_	_	O
33	of	_	_	O
34	brachytherapy	_	_	O
35	as	_	_	O
36	monotherapy	_	_	O
37	with	_	_	O
38	(	_	_	O
39	125	_	_	O
40	)	_	_	O
41	I	_	_	O
42	for	_	_	O
43	intermediate-risk	_	_	O
44	localized	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	No	_	_	O
49	patient	_	_	O
50	received	_	_	O
51	hormonal	_	_	O
52	therapy	_	_	O
53	.	_	_	O

54	Preplanning	_	_	O
55	constraints	_	_	O
56	included	_	_	O
57	prostate	_	_	O
58	V100	_	_	O
59	higher	_	_	O
60	than	_	_	O
61	95	_	_	O
62	%	_	_	O
63	,	_	_	O
64	V150	_	_	O
65	lower	_	_	O
66	than	_	_	O
67	60	_	_	O
68	%	_	_	O
69	,	_	_	O
70	and	_	_	O
71	V200	_	_	O
72	lower	_	_	O
73	than	_	_	O
74	20	_	_	O
75	%	_	_	O
76	and	_	_	O
77	rectal	_	_	O
78	R100	_	_	O
79	less	_	_	O
80	than	_	_	O
81	1cm	_	_	O
82	(	_	_	O
83	3	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Patients	_	_	O
87	completed	_	_	O
88	the	_	_	O
89	Expanded	_	_	O
90	Prostate	_	_	O
91	Cancer	_	_	O
92	Index	_	_	O
93	Composite	_	_	O
94	quality-of-life	_	_	O
95	questionnaire	_	_	O
96	before	_	_	O
97	and	_	_	O
98	at	_	_	O
99	1	_	_	O
100	,	_	_	O
101	4	_	_	O
102	,	_	_	O
103	8	_	_	O
104	,	_	_	O
105	and	_	_	O
106	12	_	_	O
107	months	_	_	O
108	after	_	_	O
109	implantation	_	_	O
110	,	_	_	O
111	and	_	_	O
112	urinary	_	_	O
113	domain	_	_	O
114	scores	_	_	O
115	were	_	_	O
116	analyzed	_	_	O
117	.	_	_	O

118	All	_	_	O
119	structures	_	_	O
120	including	_	_	O
121	the	_	_	O
122	IUS	_	_	O
123	and	_	_	O
124	EUS	_	_	O
125	were	_	_	O
126	contoured	_	_	O
127	on	_	_	O
128	T2-weighted	_	_	O
129	MRI	_	_	O
130	at	_	_	O
131	day	_	_	O
132	30	_	_	O
133	,	_	_	O
134	and	_	_	O
135	doses	_	_	O
136	received	_	_	O
137	were	_	_	O
138	calculated	_	_	O
139	from	_	_	O
140	identification	_	_	O
141	of	_	_	O
142	seeds	_	_	O
143	on	_	_	O
144	CT.	_	_	O
145	Spearman	_	_	O
146	's	_	_	O
147	(	_	_	O
148	nonparametric	_	_	O
149	)	_	_	O
150	rank	_	_	O
151	correlation	_	_	O
152	coefficient	_	_	O
153	(	_	_	O
154	Ï	_	_	O
155	)	_	_	O
156	was	_	_	O
157	used	_	_	O
158	for	_	_	O
159	statistical	_	_	O
160	analyses	_	_	O
161	.	_	_	O

162	Overall	_	_	O
163	urinary	_	_	O
164	morbidity	_	_	O
165	was	_	_	O
166	worst	_	_	O
167	at	_	_	O
168	1	_	_	O
169	month	_	_	O
170	after	_	_	O
171	the	_	_	O
172	implant	_	_	O
173	.	_	_	O

174	Urinary	_	_	B-Premise
175	function	_	_	I-Premise
176	declined	_	_	I-Premise
177	when	_	_	I-Premise
178	the	_	_	I-Premise
179	IUS	_	_	I-Premise
180	V285	_	_	I-Premise
181	was	_	_	I-Premise
182	0.4	_	_	I-Premise
183	%	_	_	I-Premise
184	(	_	_	I-Premise
185	Ï=-0.32	_	_	I-Premise
186	,	_	_	I-Premise
187	p=0.04	_	_	I-Premise
188	)	_	_	I-Premise
189	;	_	_	I-Premise
190	bother	_	_	B-Premise
191	worsened	_	_	I-Premise
192	when	_	_	I-Premise
193	the	_	_	I-Premise
194	IUS	_	_	I-Premise
195	V35	_	_	I-Premise
196	was	_	_	I-Premise
197	99	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	Ï=-0.31	_	_	I-Premise
201	,	_	_	I-Premise
202	p=0.05	_	_	I-Premise
203	)	_	_	I-Premise
204	or	_	_	I-Premise
205	the	_	_	I-Premise
206	EUS	_	_	I-Premise
207	V240	_	_	I-Premise
208	was	_	_	I-Premise
209	63	_	_	I-Premise
210	%	_	_	I-Premise
211	(	_	_	I-Premise
212	Ï=-0.31	_	_	I-Premise
213	,	_	_	I-Premise
214	p=0.05	_	_	I-Premise
215	)	_	_	I-Premise
216	;	_	_	I-Premise
217	irritation	_	_	B-Premise
218	increased	_	_	I-Premise
219	when	_	_	I-Premise
220	the	_	_	I-Premise
221	IUS	_	_	I-Premise
222	V35	_	_	I-Premise
223	was	_	_	I-Premise
224	95	_	_	I-Premise
225	%	_	_	I-Premise
226	(	_	_	I-Premise
227	Ï=-0.37	_	_	I-Premise
228	,	_	_	I-Premise
229	p=0.02	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	the	_	_	I-Premise
233	EUS	_	_	I-Premise
234	V265	_	_	I-Premise
235	was	_	_	I-Premise
236	24	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	Ï=-0.32	_	_	I-Premise
240	,	_	_	I-Premise
241	p=0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	;	_	_	I-Premise
244	and	_	_	O
245	urgency	_	_	B-Premise
246	worsened	_	_	I-Premise
247	when	_	_	I-Premise
248	the	_	_	I-Premise
249	IUS	_	_	I-Premise
250	V35	_	_	I-Premise
251	was	_	_	I-Premise
252	99.5	_	_	I-Premise
253	%	_	_	I-Premise
254	(	_	_	I-Premise
255	Ï=-0.38	_	_	I-Premise
256	,	_	_	I-Premise
257	p=0.02	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Incontinence	_	_	B-Premise
261	did	_	_	I-Premise
262	not	_	_	I-Premise
263	correlate	_	_	I-Premise
264	with	_	_	I-Premise
265	EUS	_	_	I-Premise
266	or	_	_	I-Premise
267	IUS	_	_	I-Premise
268	dose	_	_	I-Premise
269	.	_	_	I-Premise

270	Doses	_	_	B-Claim
271	to	_	_	I-Claim
272	the	_	_	I-Claim
273	IUS	_	_	I-Claim
274	and	_	_	I-Claim
275	EUS	_	_	I-Claim
276	on	_	_	I-Claim
277	MRI/CT	_	_	I-Claim
278	predicted	_	_	I-Claim
279	worse	_	_	I-Claim
280	urinary	_	_	I-Claim
281	function	_	_	I-Claim
282	,	_	_	I-Claim
283	with	_	_	I-Claim
284	greater	_	_	I-Claim
285	bother	_	_	I-Claim
286	,	_	_	I-Claim
287	irritative	_	_	I-Claim
288	symptoms	_	_	I-Claim
289	,	_	_	I-Claim
290	and	_	_	I-Claim
291	urgency	_	_	I-Claim
292	.	_	_	I-Claim

293	Incorporating	_	_	B-Claim
294	MRI-based	_	_	I-Claim
295	dose-volume	_	_	I-Claim
296	histogram	_	_	I-Claim
297	analysis	_	_	I-Claim
298	into	_	_	I-Claim
299	the	_	_	I-Claim
300	treatment	_	_	I-Claim
301	planning	_	_	I-Claim
302	process	_	_	I-Claim
303	may	_	_	I-Claim
304	reduce	_	_	I-Claim
305	acute	_	_	I-Claim
306	urinary	_	_	I-Claim
307	morbidity	_	_	I-Claim
308	after	_	_	I-Claim
309	brachytherapy	_	_	I-Claim
310	.	_	_	I-Claim


0	The	_	_	B-Claim
1	incidence	_	_	I-Claim
2	and	_	_	I-Claim
3	development	_	_	I-Claim
4	of	_	_	I-Claim
5	cancer	_	_	I-Claim
6	are	_	_	I-Claim
7	closely	_	_	I-Claim
8	related	_	_	I-Claim
9	to	_	_	I-Claim
10	dysfunction	_	_	I-Claim
11	of	_	_	I-Claim
12	immune	_	_	I-Claim
13	function	_	_	I-Claim
14	.	_	_	I-Claim

15	The	_	_	O
16	immune	_	_	O
17	system	_	_	O
18	can	_	_	O
19	not	_	_	O
20	identify	_	_	O
21	and	_	_	O
22	remove	_	_	O
23	malignant	_	_	O
24	and	_	_	O
25	mutant	_	_	O
26	cells	_	_	O
27	,	_	_	O
28	which	_	_	O
29	cause	_	_	O
30	tumor	_	_	O
31	cells	_	_	O
32	to	_	_	O
33	escape	_	_	O
34	from	_	_	O
35	surveillance	_	_	O
36	and	_	_	O
37	clearance	_	_	O
38	of	_	_	O
39	the	_	_	O
40	immune	_	_	O
41	system	_	_	O
42	.	_	_	O

43	Immunobiological	_	_	O
44	cancer	_	_	O
45	therapy	_	_	O
46	plays	_	_	O
47	an	_	_	O
48	important	_	_	O
49	role	_	_	O
50	in	_	_	O
51	strengthening	_	_	O
52	body	_	_	O
53	immunological	_	_	O
54	surveillance	_	_	O
55	function	_	_	O
56	and	_	_	O
57	killing	_	_	O
58	remaining	_	_	O
59	tumor	_	_	O
60	cells	_	_	O
61	in	_	_	O
62	the	_	_	O
63	body	_	_	O
64	.	_	_	O

65	We	_	_	O
66	investigated	_	_	O
67	the	_	_	O
68	role	_	_	O
69	of	_	_	O
70	DC/CIK	_	_	O
71	(	_	_	O
72	dendritic	_	_	O
73	cell/cytokine-induced	_	_	O
74	killer	_	_	O
75	cells	_	_	O
76	)	_	_	O
77	immunobiological	_	_	O
78	cancer	_	_	O
79	therapy	_	_	O
80	in	_	_	O
81	maintenance	_	_	O
82	therapy	_	_	O
83	of	_	_	O
84	advanced	_	_	O
85	non-small	_	_	O
86	cell	_	_	O
87	lung	_	_	O
88	cancer	_	_	O
89	.	_	_	O

90	When	_	_	O
91	60	_	_	O
92	cases	_	_	O
93	of	_	_	O
94	non-small	_	_	O
95	cell	_	_	O
96	lung	_	_	O
97	cancer	_	_	O
98	patients	_	_	O
99	in	_	_	O
100	stage	_	_	O
101	IIIb	_	_	O
102	and	_	_	O
103	IV	_	_	O
104	reached	_	_	O
105	stable	_	_	O
106	disease	_	_	O
107	after	_	_	O
108	treatment	_	_	O
109	with	_	_	O
110	4	_	_	O
111	cycles	_	_	O
112	of	_	_	O
113	a	_	_	O
114	two-drug	_	_	O
115	regimen	_	_	O
116	with	_	_	O
117	platinum	_	_	O
118	,	_	_	O
119	they	_	_	O
120	were	_	_	O
121	randomly	_	_	O
122	divided	_	_	O
123	into	_	_	O
124	two	_	_	O
125	groups	_	_	O
126	.	_	_	O

127	One	_	_	O
128	group	_	_	O
129	was	_	_	O
130	treated	_	_	O
131	with	_	_	O
132	DC/CIK	_	_	O
133	immunobiological	_	_	O
134	cancer	_	_	O
135	therapy	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	other	_	_	O
140	was	_	_	O
141	taken	_	_	O
142	as	_	_	O
143	a	_	_	O
144	control	_	_	O
145	group	_	_	O
146	.	_	_	O

147	Finally	_	_	O
148	,	_	_	O
149	cancer	_	_	O
150	progression	_	_	O
151	time	_	_	O
152	and	_	_	O
153	toxicity	_	_	O
154	reaction	_	_	O
155	of	_	_	O
156	the	_	_	O
157	two	_	_	O
158	groups	_	_	O
159	were	_	_	O
160	evaluated	_	_	O
161	.	_	_	O

162	DC/CIK	_	_	B-Premise
163	treatment	_	_	I-Premise
164	prolongs	_	_	I-Premise
165	progression-free	_	_	I-Premise
166	survival	_	_	I-Premise
167	(	_	_	I-Premise
168	3.20	_	_	I-Premise
169	months	_	_	I-Premise
170	[	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	,	_	_	I-Premise
175	2.94-3.50	_	_	I-Premise
176	]	_	_	I-Premise
177	vs	_	_	I-Premise
178	2.56	_	_	I-Premise
179	months	_	_	I-Premise
180	[	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	2.39-2.73	_	_	I-Premise
186	]	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	<	_	_	I-Premise
190	0.05	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	In	_	_	B-Premise
194	the	_	_	I-Premise
195	treatment	_	_	I-Premise
196	group	_	_	I-Premise
197	,	_	_	I-Premise
198	the	_	_	I-Premise
199	proportion	_	_	I-Premise
200	of	_	_	I-Premise
201	NK	_	_	I-Premise
202	cells	_	_	I-Premise
203	,	_	_	I-Premise
204	T-cell	_	_	I-Premise
205	subgroups	_	_	I-Premise
206	CD3+	_	_	I-Premise
207	,	_	_	I-Premise
208	CD4+	_	_	I-Premise
209	and	_	_	I-Premise
210	CD8+	_	_	I-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	significant	_	_	I-Premise
214	change	_	_	I-Premise
215	before	_	_	I-Premise
216	and	_	_	I-Premise
217	after	_	_	I-Premise
218	treatment	_	_	I-Premise
219	.	_	_	I-Premise

220	Liver	_	_	B-Premise
221	and	_	_	I-Premise
222	kidney	_	_	I-Premise
223	function	_	_	I-Premise
224	and	_	_	I-Premise
225	blood	_	_	I-Premise
226	tests	_	_	I-Premise
227	of	_	_	I-Premise
228	the	_	_	I-Premise
229	treatment	_	_	I-Premise
230	group	_	_	I-Premise
231	were	_	_	I-Premise
232	within	_	_	I-Premise
233	the	_	_	I-Premise
234	normal	_	_	I-Premise
235	range	_	_	I-Premise
236	before	_	_	I-Premise
237	and	_	_	I-Premise
238	after	_	_	I-Premise
239	treatment	_	_	I-Premise
240	.	_	_	I-Premise

241	In	_	_	B-Premise
242	the	_	_	I-Premise
243	treatment	_	_	I-Premise
244	group	_	_	I-Premise
245	,	_	_	I-Premise
246	1	_	_	I-Premise
247	case	_	_	I-Premise
248	suffered	_	_	I-Premise
249	from	_	_	I-Premise
250	chest	_	_	I-Premise
251	distress	_	_	I-Premise
252	,	_	_	I-Premise
253	3	_	_	I-Premise
254	cases	_	_	I-Premise
255	suffered	_	_	I-Premise
256	from	_	_	I-Premise
257	acratia	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	4	_	_	I-Premise
261	cases	_	_	I-Premise
262	suffered	_	_	I-Premise
263	from	_	_	I-Premise
264	pyrexia	_	_	I-Premise
265	.	_	_	I-Premise

266	DC/CIK	_	_	B-Claim
267	treatment	_	_	I-Claim
268	had	_	_	I-Claim
269	potential	_	_	I-Claim
270	benefit	_	_	I-Claim
271	for	_	_	I-Claim
272	patients	_	_	I-Claim
273	with	_	_	I-Claim
274	advanced	_	_	I-Claim
275	non-small	_	_	I-Claim
276	cell	_	_	I-Claim
277	lung	_	_	I-Claim
278	cancer	_	_	I-Claim
279	compared	_	_	I-Claim
280	with	_	_	I-Claim
281	the	_	_	I-Claim
282	control	_	_	I-Claim
283	group	_	_	I-Claim
284	and	_	_	I-Claim
285	had	_	_	I-Claim
286	no	_	_	I-Claim
287	obvious	_	_	I-Claim
288	side	_	_	I-Claim
289	effects	_	_	I-Claim
290	.	_	_	I-Claim

291	DC/CIK	_	_	B-Claim
292	treatment	_	_	I-Claim
293	is	_	_	I-Claim
294	a	_	_	I-Claim
295	safe	_	_	I-Claim
296	and	_	_	I-Claim
297	effective	_	_	I-Claim
298	method	_	_	I-Claim
299	for	_	_	I-Claim
300	maintenance	_	_	I-Claim
301	therapy	_	_	I-Claim
302	of	_	_	I-Claim
303	advanced	_	_	I-Claim
304	non-small	_	_	I-Claim
305	cell	_	_	I-Claim
306	lung	_	_	I-Claim
307	cancer	_	_	I-Claim
308	.	_	_	I-Claim


0	Many	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	need	_	_	O
6	psychological	_	_	O
7	help	_	_	O
8	to	_	_	O
9	cope	_	_	O
10	more	_	_	O
11	effectively	_	_	O
12	after	_	_	O
13	treatment	_	_	O
14	.	_	_	O

15	Cognitive	_	_	O
16	and	_	_	O
17	behavioural	_	_	O
18	techniques	_	_	O
19	are	_	_	O
20	not	_	_	O
21	yet	_	_	O
22	well	_	_	O
23	established	_	_	O
24	in	_	_	O
25	France	_	_	O
26	.	_	_	O

27	A	_	_	O
28	multi-site	_	_	O
29	randomized	_	_	O
30	study	_	_	O
31	was	_	_	O
32	conducted	_	_	O
33	to	_	_	O
34	evaluate	_	_	O
35	the	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	a	_	_	O
39	psycho-educational	_	_	O
40	group	_	_	O
41	intervention	_	_	O
42	in	_	_	O
43	this	_	_	O
44	population	_	_	O
45	.	_	_	O

46	Two	_	_	O
47	hundred	_	_	O
48	and	_	_	O
49	three	_	_	O
50	patients	_	_	O
51	,	_	_	O
52	recruited	_	_	O
53	after	_	_	O
54	primary	_	_	O
55	treatment	_	_	O
56	,	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	either	_	_	O
61	to	_	_	O
62	a	_	_	O
63	treatment	_	_	O
64	group	_	_	O
65	(	_	_	O
66	psycho-educational	_	_	O
67	intervention	_	_	O
68	)	_	_	O
69	or	_	_	O
70	to	_	_	O
71	a	_	_	O
72	waiting-list	_	_	O
73	control	_	_	O
74	group	_	_	O
75	.	_	_	O

76	The	_	_	O
77	8-week	_	_	O
78	programme	_	_	O
79	of	_	_	O
80	2	_	_	O
81	h	_	_	O
82	sessions	_	_	O
83	comprised	_	_	O
84	of	_	_	O
85	thematic	_	_	O
86	discussions	_	_	O
87	,	_	_	O
88	information	_	_	O
89	and	_	_	O
90	training	_	_	O
91	in	_	_	O
92	stress	_	_	O
93	management	_	_	O
94	techniques	_	_	O
95	.	_	_	O

96	Evaluation	_	_	O
97	at	_	_	O
98	baseline	_	_	O
99	,	_	_	O
100	after	_	_	O
101	8	_	_	O
102	sessions	_	_	O
103	,	_	_	O
104	and	_	_	O
105	1	_	_	O
106	month	_	_	O
107	after	_	_	O
108	programme	_	_	O
109	completion	_	_	O
110	,	_	_	O
111	included	_	_	O
112	evaluations	_	_	O
113	using	_	_	O
114	the	_	_	O
115	STAI	_	_	O
116	,	_	_	O
117	POMS	_	_	O
118	,	_	_	O
119	MAC	_	_	O
120	,	_	_	O
121	EORTC	_	_	O
122	QLQ-C30	_	_	O
123	and	_	_	O
124	EORTC	_	_	O
125	QLQ-BR23	_	_	O
126	breast	_	_	O
127	module	_	_	O
128	scales	_	_	O
129	.	_	_	O

130	We	_	_	B-Premise
131	observed	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	reduction	_	_	I-Premise
135	in	_	_	I-Premise
136	anxiety	_	_	I-Premise
137	(	_	_	I-Premise
138	STAI	_	_	I-Premise
139	,	_	_	I-Premise
140	POMS	_	_	I-Premise
141	)	_	_	I-Premise
142	among	_	_	I-Premise
143	group	_	_	I-Premise
144	participants	_	_	I-Premise
145	,	_	_	I-Premise
146	a	_	_	I-Premise
147	reduction	_	_	I-Premise
148	in	_	_	I-Premise
149	anger	_	_	I-Premise
150	,	_	_	I-Premise
151	depression	_	_	I-Premise
152	and	_	_	I-Premise
153	fatigue	_	_	I-Premise
154	(	_	_	I-Premise
155	POMS	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	a	_	_	I-Premise
159	significant	_	_	I-Premise
160	improvement	_	_	I-Premise
161	in	_	_	I-Premise
162	vigor	_	_	I-Premise
163	and	_	_	I-Premise
164	interpersonal	_	_	I-Premise
165	relationships	_	_	I-Premise
166	(	_	_	I-Premise
167	POMS	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	in	_	_	I-Premise
171	emotional	_	_	I-Premise
172	and	_	_	I-Premise
173	role	_	_	I-Premise
174	functioning	_	_	I-Premise
175	,	_	_	I-Premise
176	in	_	_	I-Premise
177	health	_	_	I-Premise
178	status	_	_	I-Premise
179	and	_	_	I-Premise
180	fatigue	_	_	I-Premise
181	level	_	_	I-Premise
182	(	_	_	I-Premise
183	EORTC	_	_	I-Premise
184	QLQ-C30	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	In	_	_	O
188	contrast	_	_	O
189	,	_	_	O
190	coping	_	_	B-Premise
191	strategies	_	_	I-Premise
192	(	_	_	I-Premise
193	MAC	_	_	I-Premise
194	)	_	_	I-Premise
195	were	_	_	I-Premise
196	not	_	_	I-Premise
197	significantly	_	_	I-Premise
198	different	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	No	_	_	B-Premise
203	group-related	_	_	I-Premise
204	negative	_	_	I-Premise
205	effects	_	_	I-Premise
206	were	_	_	I-Premise
207	observed	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	global	_	_	I-Premise
211	satisfaction	_	_	I-Premise
212	levels	_	_	I-Premise
213	were	_	_	I-Premise
214	very	_	_	I-Premise
215	high	_	_	I-Premise
216	.	_	_	I-Premise

217	This	_	_	B-Claim
218	study	_	_	I-Claim
219	demonstrates	_	_	I-Claim
220	the	_	_	I-Claim
221	feasibility	_	_	I-Claim
222	and	_	_	I-Claim
223	effectiveness	_	_	I-Claim
224	of	_	_	I-Claim
225	a	_	_	I-Claim
226	psycho-educational	_	_	I-Claim
227	intervention	_	_	I-Claim
228	,	_	_	I-Claim
229	which	_	_	I-Claim
230	can	_	_	I-Claim
231	accelerate	_	_	I-Claim
232	the	_	_	I-Claim
233	reduction	_	_	I-Claim
234	of	_	_	I-Claim
235	those	_	_	I-Claim
236	negative	_	_	I-Claim
237	affects	_	_	I-Claim
238	which	_	_	I-Claim
239	are	_	_	I-Claim
240	present	_	_	I-Claim
241	at	_	_	I-Claim
242	the	_	_	I-Claim
243	end	_	_	I-Claim
244	of	_	_	I-Claim
245	treatment	_	_	I-Claim
246	.	_	_	I-Claim

247	It	_	_	B-Claim
248	represents	_	_	I-Claim
249	an	_	_	I-Claim
250	excellent	_	_	I-Claim
251	complement	_	_	I-Claim
252	or	_	_	I-Claim
253	an	_	_	I-Claim
254	alternative	_	_	I-Claim
255	to	_	_	I-Claim
256	individual	_	_	I-Claim
257	psycho-oncologic	_	_	I-Claim
258	therapeutic	_	_	I-Claim
259	support	_	_	I-Claim
260	,	_	_	I-Claim
261	widely	_	_	O
262	proposed	_	_	O
263	in	_	_	O
264	France	_	_	O
265	,	_	_	O
266	and	_	_	O
267	should	_	_	O
268	now	_	_	O
269	be	_	_	O
270	tested	_	_	O
271	in	_	_	O
272	groups	_	_	O
273	with	_	_	O
274	other	_	_	O
275	types	_	_	O
276	of	_	_	O
277	cancer	_	_	O
278	and	_	_	O
279	at	_	_	O
280	other	_	_	O
281	disease	_	_	O
282	phases	_	_	O
283	.	_	_	O


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	scapula-oriented	_	_	O
7	exercise	_	_	O
8	on	_	_	O
9	upper	_	_	O
10	limb	_	_	O
11	dysfunction	_	_	O
12	in	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	.	_	_	O

17	A	_	_	O
18	prospective	_	_	O
19	randomized	_	_	O
20	,	_	_	O
21	controlled	_	_	O
22	pilot	_	_	O
23	trial	_	_	O
24	with	_	_	O
25	historical	_	_	O
26	control	_	_	O
27	.	_	_	O

28	Rehabilitation	_	_	O
29	department	_	_	O
30	at	_	_	O
31	a	_	_	O
32	university	_	_	O
33	hospital	_	_	O
34	.	_	_	O

35	Thirty-two	_	_	O
36	women	_	_	O
37	with	_	_	O
38	breast	_	_	O
39	cancer	_	_	O
40	were	_	_	O
41	randomly	_	_	O
42	assigned	_	_	O
43	to	_	_	O
44	scapula-oriented	_	_	O
45	exercise	_	_	O
46	group	_	_	O
47	(	_	_	O
48	n	_	_	O
49	=	_	_	O
50	16	_	_	O
51	)	_	_	O
52	and	_	_	O
53	general	_	_	O
54	exercise	_	_	O
55	group	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	16	_	_	O
60	)	_	_	O
61	.	_	_	O

62	An	_	_	O
63	historical	_	_	O
64	control	_	_	O
65	group	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	18	_	_	O
70	)	_	_	O
71	without	_	_	O
72	exercise	_	_	O
73	was	_	_	O
74	enrolled	_	_	O
75	from	_	_	O
76	breast	_	_	O
77	cancer	_	_	O
78	survivors	_	_	O
79	.	_	_	O

80	The	_	_	O
81	scapula-oriented	_	_	O
82	exercises	_	_	O
83	were	_	_	O
84	designed	_	_	O
85	focusing	_	_	O
86	on	_	_	O
87	scapulothoracic	_	_	O
88	movement	_	_	O
89	.	_	_	O

90	The	_	_	O
91	general	_	_	O
92	exercise	_	_	O
93	group	_	_	O
94	performed	_	_	O
95	body	_	_	O
96	conditioning	_	_	O
97	exercise	_	_	O
98	.	_	_	O

99	Exercise	_	_	O
100	therapies	_	_	O
101	were	_	_	O
102	performed	_	_	O
103	for	_	_	O
104	one	_	_	O
105	session	_	_	O
106	per	_	_	O
107	week	_	_	O
108	for	_	_	O
109	eight	_	_	O
110	weeks	_	_	O
111	.	_	_	O

112	Pain	_	_	O
113	and	_	_	O
114	physical	_	_	O
115	disabilities	_	_	O
116	related	_	_	O
117	to	_	_	O
118	upper	_	_	O
119	limb	_	_	O
120	dysfunction	_	_	O
121	,	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	and	_	_	O
126	depression	_	_	O
127	were	_	_	O
128	used	_	_	O
129	as	_	_	O
130	subjective	_	_	O
131	outcomes	_	_	O
132	.	_	_	O

133	Objective	_	_	O
134	outcome	_	_	O
135	measures	_	_	O
136	included	_	_	O
137	shoulder	_	_	O
138	range	_	_	O
139	of	_	_	O
140	motion	_	_	O
141	and	_	_	O
142	strength	_	_	O
143	.	_	_	O

144	Outcomes	_	_	O
145	were	_	_	O
146	assessed	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	and	_	_	O
150	post	_	_	O
151	exercise	_	_	O
152	.	_	_	O

153	At	_	_	O
154	baseline	_	_	O
155	,	_	_	O
156	no	_	_	O
157	significant	_	_	O
158	difference	_	_	O
159	was	_	_	O
160	observed	_	_	O
161	among	_	_	O
162	the	_	_	O
163	three	_	_	O
164	groups	_	_	O
165	.	_	_	O

166	The	_	_	B-Premise
167	scapula-oriented	_	_	I-Premise
168	exercise	_	_	I-Premise
169	group	_	_	I-Premise
170	showed	_	_	I-Premise
171	improvements	_	_	I-Premise
172	in	_	_	I-Premise
173	pain	_	_	I-Premise
174	,	_	_	I-Premise
175	physical	_	_	I-Premise
176	function	_	_	I-Premise
177	,	_	_	I-Premise
178	social	_	_	I-Premise
179	function	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	global	_	_	I-Premise
183	quality	_	_	I-Premise
184	of	_	_	I-Premise
185	life	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	baseline	_	_	I-Premise
189	,	_	_	I-Premise
190	whereas	_	_	I-Premise
191	the	_	_	I-Premise
192	general	_	_	I-Premise
193	exercise	_	_	I-Premise
194	group	_	_	I-Premise
195	showed	_	_	I-Premise
196	improved	_	_	I-Premise
197	fatigue	_	_	I-Premise
198	and	_	_	I-Premise
199	range	_	_	I-Premise
200	of	_	_	I-Premise
201	motion	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	change	_	_	I-Premise
205	in	_	_	I-Premise
206	global	_	_	I-Premise
207	quality	_	_	I-Premise
208	of	_	_	I-Premise
209	life	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	0.067	_	_	I-Premise
214	;	_	_	I-Premise
215	effect	_	_	I-Premise
216	size	_	_	I-Premise
217	,	_	_	I-Premise
218	0.33	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	strength	_	_	I-Premise
222	of	_	_	I-Premise
223	external	_	_	I-Premise
224	rotation	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0.001	_	_	I-Premise
229	;	_	_	I-Premise
230	effect	_	_	I-Premise
231	size	_	_	I-Premise
232	,	_	_	I-Premise
233	0.55	_	_	I-Premise
234	)	_	_	I-Premise
235	were	_	_	I-Premise
236	significantly	_	_	I-Premise
237	greater	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	scapula-oriented	_	_	I-Premise
241	exercise	_	_	I-Premise
242	group	_	_	I-Premise
243	than	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	general	_	_	I-Premise
247	exercise	_	_	I-Premise
248	and	_	_	I-Premise
249	control	_	_	I-Premise
250	group	_	_	I-Premise
251	.	_	_	I-Premise

252	Scapula-oriented	_	_	B-Claim
253	exercise	_	_	I-Claim
254	had	_	_	I-Claim
255	beneficial	_	_	I-Claim
256	effects	_	_	I-Claim
257	on	_	_	I-Claim
258	pain	_	_	I-Claim
259	,	_	_	I-Claim
260	quality	_	_	I-Claim
261	of	_	_	I-Claim
262	life	_	_	I-Claim
263	and	_	_	I-Claim
264	aspects	_	_	I-Claim
265	of	_	_	I-Claim
266	strength	_	_	I-Claim
267	.	_	_	I-Claim

268	The	_	_	O
269	sample	_	_	O
270	size	_	_	O
271	required	_	_	O
272	in	_	_	O
273	a	_	_	O
274	larger	_	_	O
275	definitive	_	_	O
276	study	_	_	O
277	is	_	_	O
278	32	_	_	O
279	subjects	_	_	O
280	per	_	_	O
281	group	_	_	O
282	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	project	_	_	O
5	was	_	_	O
6	to	_	_	O
7	identify	_	_	O
8	clinical	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QL	_	_	O
15	)	_	_	O
16	factors	_	_	O
17	that	_	_	O
18	together	_	_	O
19	predict	_	_	O
20	survival	_	_	O
21	and	_	_	O
22	response	_	_	O
23	to	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	advanced	_	_	O
27	breast	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Potential	_	_	O
31	prognostic	_	_	O
32	factors	_	_	O
33	were	_	_	O
34	studied	_	_	O
35	in	_	_	O
36	187	_	_	O
37	women	_	_	O
38	with	_	_	O
39	baseline	_	_	O
40	QL	_	_	O
41	data	_	_	O
42	from	_	_	O
43	a	_	_	O
44	trial	_	_	O
45	of	_	_	O
46	paclitaxel	_	_	O
47	versus	_	_	O
48	doxorubicin	_	_	O
49	as	_	_	O
50	first-line	_	_	O
51	chemotherapy	_	_	O
52	.	_	_	O

53	Demographic	_	_	O
54	and	_	_	O
55	clinical	_	_	O
56	factors	_	_	O
57	studied	_	_	O
58	were	_	_	O
59	age	_	_	O
60	,	_	_	O
61	performance	_	_	O
62	status	_	_	O
63	,	_	_	O
64	dominant	_	_	O
65	site	_	_	O
66	of	_	_	O
67	disease	_	_	O
68	and	_	_	O
69	preceding	_	_	O
70	disease-free	_	_	O
71	interval	_	_	O
72	(	_	_	O
73	DFI	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Factors	_	_	O
77	from	_	_	O
78	the	_	_	O
79	EORTC	_	_	O
80	QLQ-C30	_	_	O
81	were	_	_	O
82	all	_	_	O
83	function	_	_	O
84	scales	_	_	O
85	,	_	_	O
86	fatigue	_	_	O
87	,	_	_	O
88	nausea/vomiting	_	_	O
89	,	_	_	O
90	pain	_	_	O
91	,	_	_	O
92	dyspnoea	_	_	O
93	,	_	_	O
94	insomnia	_	_	O
95	,	_	_	O
96	loss	_	_	O
97	of	_	_	O
98	appetite	_	_	O
99	and	_	_	O
100	global	_	_	O
101	QL	_	_	O
102	.	_	_	O

103	The	_	_	O
104	proportional	_	_	O
105	hazards	_	_	O
106	regression	_	_	O
107	model	_	_	O
108	with	_	_	O
109	stratification	_	_	O
110	for	_	_	O
111	treatment	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	logistic	_	_	O
116	regression	_	_	O
117	model	_	_	O
118	adjusting	_	_	O
119	for	_	_	O
120	treatment	_	_	O
121	arm	_	_	O
122	were	_	_	O
123	used	_	_	O
124	for	_	_	O
125	univariate	_	_	O
126	and	_	_	O
127	multivariate	_	_	O
128	analyses	_	_	O
129	of	_	_	O
130	survival	_	_	O
131	and	_	_	O
132	response	_	_	O
133	to	_	_	O
134	treatment	_	_	O
135	,	_	_	O
136	respectively	_	_	O
137	.	_	_	O

138	For	_	_	B-Premise
139	survival	_	_	I-Premise
140	,	_	_	I-Premise
141	multiple	_	_	I-Premise
142	sites	_	_	I-Premise
143	of	_	_	I-Premise
144	visceral	_	_	I-Premise
145	disease	_	_	I-Premise
146	,	_	_	I-Premise
147	pain	_	_	I-Premise
148	,	_	_	I-Premise
149	global	_	_	I-Premise
150	QL	_	_	I-Premise
151	and	_	_	I-Premise
152	fatigue	_	_	I-Premise
153	were	_	_	I-Premise
154	significant	_	_	I-Premise
155	prognostic	_	_	I-Premise
156	factors	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	univariate	_	_	I-Premise
160	analysis	_	_	I-Premise
161	.	_	_	I-Premise

162	The	_	_	B-Premise
163	final	_	_	I-Premise
164	multivariate	_	_	I-Premise
165	model	_	_	I-Premise
166	predicted	_	_	I-Premise
167	poor	_	_	I-Premise
168	survival	_	_	I-Premise
169	with	_	_	I-Premise
170	multiple	_	_	I-Premise
171	sites	_	_	I-Premise
172	of	_	_	I-Premise
173	visceral	_	_	I-Premise
174	disease	_	_	I-Premise
175	(	_	_	I-Premise
176	P=0.003	_	_	I-Premise
177	)	_	_	I-Premise
178	,	_	_	I-Premise
179	DFI	_	_	I-Premise
180	<	_	_	I-Premise
181	/=2	_	_	I-Premise
182	years	_	_	I-Premise
183	(	_	_	I-Premise
184	P=0.026	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	pain	_	_	I-Premise
188	(	_	_	I-Premise
189	P=0.003	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	For	_	_	B-Premise
193	response	_	_	I-Premise
194	,	_	_	I-Premise
195	age	_	_	I-Premise
196	,	_	_	I-Premise
197	dyspnoea	_	_	I-Premise
198	,	_	_	I-Premise
199	fatigue	_	_	I-Premise
200	and	_	_	I-Premise
201	global	_	_	I-Premise
202	QL	_	_	I-Premise
203	were	_	_	I-Premise
204	significant	_	_	I-Premise
205	predictive	_	_	I-Premise
206	factors	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	univariate	_	_	I-Premise
210	analysis	_	_	I-Premise
211	.	_	_	I-Premise

212	The	_	_	B-Premise
213	final	_	_	I-Premise
214	multivariate	_	_	I-Premise
215	model	_	_	I-Premise
216	for	_	_	I-Premise
217	response	_	_	I-Premise
218	selected	_	_	I-Premise
219	DFI	_	_	I-Premise
220	(	_	_	I-Premise
221	P=0.009	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	multiple	_	_	I-Premise
225	sites	_	_	I-Premise
226	of	_	_	I-Premise
227	visceral	_	_	I-Premise
228	disease	_	_	I-Premise
229	(	_	_	I-Premise
230	P=0.037	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	dyspnoea	_	_	I-Premise
234	(	_	_	I-Premise
235	P=	_	_	I-Premise
236	<	_	_	I-Premise
237	0.001	_	_	I-Premise
238	)	_	_	I-Premise
239	using	_	_	I-Premise
240	forward	_	_	I-Premise
241	selection	_	_	I-Premise
242	,	_	_	I-Premise
243	but	_	_	B-Premise
244	model	_	_	I-Premise
245	instability	_	_	I-Premise
246	was	_	_	I-Premise
247	indicated	_	_	I-Premise
248	by	_	_	I-Premise
249	the	_	_	I-Premise
250	inclusion	_	_	I-Premise
251	of	_	_	I-Premise
252	fatigue	_	_	I-Premise
253	and	_	_	I-Premise
254	emotional	_	_	I-Premise
255	function	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	final	_	_	I-Premise
259	model	_	_	I-Premise
260	when	_	_	I-Premise
261	backward	_	_	I-Premise
262	selection	_	_	I-Premise
263	was	_	_	I-Premise
264	used	_	_	I-Premise
265	.	_	_	I-Premise

266	In	_	_	O
267	addition	_	_	O
268	to	_	_	O
269	known	_	_	O
270	clinical	_	_	O
271	factors	_	_	O
272	,	_	_	O
273	patient-assessed	_	_	B-Claim
274	QL	_	_	I-Claim
275	variables	_	_	I-Claim
276	appear	_	_	I-Claim
277	to	_	_	I-Claim
278	be	_	_	I-Claim
279	prognostic	_	_	I-Claim
280	for	_	_	I-Claim
281	survival	_	_	I-Claim
282	and	_	_	I-Claim
283	response	_	_	I-Claim
284	to	_	_	I-Claim
285	chemotherapy	_	_	I-Claim
286	in	_	_	I-Claim
287	women	_	_	I-Claim
288	with	_	_	I-Claim
289	advanced	_	_	I-Claim
290	breast	_	_	I-Claim
291	cancer	_	_	I-Claim
292	.	_	_	I-Claim

293	However	_	_	B-Claim
294	,	_	_	I-Claim
295	identification	_	_	I-Claim
296	of	_	_	I-Claim
297	prognostic	_	_	I-Claim
298	factors	_	_	I-Claim
299	from	_	_	I-Claim
300	responses	_	_	I-Claim
301	to	_	_	I-Claim
302	questionnaires	_	_	I-Claim
303	may	_	_	I-Claim
304	be	_	_	I-Claim
305	unstable	_	_	I-Claim
306	,	_	_	I-Claim
307	and	_	_	I-Claim
308	their	_	_	I-Claim
309	reliability	_	_	I-Claim
310	and	_	_	I-Claim
311	clinical	_	_	I-Claim
312	utility	_	_	I-Claim
313	should	_	_	I-Claim
314	be	_	_	I-Claim
315	tested	_	_	I-Claim
316	prospectively	_	_	I-Claim
317	.	_	_	I-Claim


0	Everolimus	_	_	O
1	(	_	_	O
2	EVE	_	_	O
3	)	_	_	O
4	+exemestane	_	_	O
5	(	_	_	O
6	EXE	_	_	O
7	;	_	_	O
8	n	_	_	O
9	=	_	_	O
10	485	_	_	O
11	)	_	_	O
12	more	_	_	O
13	than	_	_	O
14	doubled	_	_	O
15	median	_	_	O
16	progression-free	_	_	O
17	survival	_	_	O
18	versus	_	_	O
19	placebo	_	_	O
20	(	_	_	O
21	PBO	_	_	O
22	)	_	_	O
23	+	_	_	O
24	EXE	_	_	O
25	(	_	_	O
26	n	_	_	O
27	=	_	_	O
28	239	_	_	O
29	)	_	_	O
30	,	_	_	O
31	with	_	_	O
32	a	_	_	O
33	manageable	_	_	O
34	safety	_	_	O
35	profile	_	_	O
36	and	_	_	O
37	no	_	_	O
38	deterioration	_	_	O
39	in	_	_	O
40	health-related	_	_	O
41	quality-of-life	_	_	O
42	(	_	_	O
43	HRQOL	_	_	O
44	)	_	_	O
45	in	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	hormone-receptor-positive	_	_	O
49	(	_	_	O
50	HR	_	_	O
51	(	_	_	O
52	+	_	_	O
53	)	_	_	O
54	)	_	_	O
55	advanced	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	(	_	_	O
59	ABC	_	_	O
60	)	_	_	O
61	who	_	_	O
62	recurred	_	_	O
63	or	_	_	O
64	progressed	_	_	O
65	on/after	_	_	O
66	nonsteroidal	_	_	O
67	aromatase	_	_	O
68	inhibitor	_	_	O
69	(	_	_	O
70	NSAI	_	_	O
71	)	_	_	O
72	therapy	_	_	O
73	.	_	_	O

74	To	_	_	O
75	further	_	_	O
76	evaluate	_	_	O
77	EVE	_	_	O
78	+	_	_	O
79	EXE	_	_	O
80	impact	_	_	O
81	on	_	_	O
82	disease	_	_	O
83	burden	_	_	O
84	,	_	_	O
85	we	_	_	O
86	conducted	_	_	O
87	additional	_	_	O
88	post-hoc	_	_	O
89	analyses	_	_	O
90	of	_	_	O
91	patient-reported	_	_	O
92	HRQOL	_	_	O
93	.	_	_	O

94	HRQOL	_	_	O
95	was	_	_	O
96	assessed	_	_	O
97	using	_	_	O
98	EORTC	_	_	O
99	QLQ-C30	_	_	O
100	and	_	_	O
101	QLQ-BR23	_	_	O
102	questionnaires	_	_	O
103	at	_	_	O
104	baseline	_	_	O
105	and	_	_	O
106	every	_	_	O
107	6	_	_	O
108	weeks	_	_	O
109	thereafter	_	_	O
110	until	_	_	O
111	treatment	_	_	O
112	discontinuation	_	_	O
113	because	_	_	O
114	of	_	_	O
115	disease	_	_	O
116	progression	_	_	O
117	,	_	_	O
118	toxicity	_	_	O
119	,	_	_	O
120	or	_	_	O
121	consent	_	_	O
122	withdrawal	_	_	O
123	.	_	_	O

124	Endpoints	_	_	O
125	included	_	_	O
126	the	_	_	O
127	QLQ-C30	_	_	O
128	Global	_	_	O
129	Health	_	_	O
130	Status	_	_	O
131	(	_	_	O
132	QL2	_	_	O
133	)	_	_	O
134	scale	_	_	O
135	,	_	_	O
136	the	_	_	O
137	QLQ-BR23	_	_	O
138	breast	_	_	O
139	symptom	_	_	O
140	(	_	_	O
141	BRBS	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	arm	_	_	O
146	symptom	_	_	O
147	(	_	_	O
148	BRAS	_	_	O
149	)	_	_	O
150	scales	_	_	O
151	.	_	_	O

152	Between-group	_	_	O
153	differences	_	_	O
154	in	_	_	O
155	change	_	_	O
156	from	_	_	O
157	baseline	_	_	O
158	were	_	_	O
159	assessed	_	_	O
160	using	_	_	O
161	linear	_	_	O
162	mixed	_	_	O
163	models	_	_	O
164	with	_	_	O
165	selected	_	_	O
166	covariates	_	_	O
167	.	_	_	O

168	Sensitivity	_	_	O
169	analysis	_	_	O
170	using	_	_	O
171	pattern-mixture	_	_	O
172	models	_	_	O
173	determined	_	_	O
174	the	_	_	O
175	effect	_	_	O
176	of	_	_	O
177	study	_	_	O
178	discontinuation	_	_	O
179	on/before	_	_	O
180	week	_	_	O
181	24	_	_	O
182	.	_	_	O

183	Treatment	_	_	O
184	arms	_	_	O
185	were	_	_	O
186	compared	_	_	O
187	using	_	_	O
188	differences	_	_	O
189	of	_	_	O
190	least	_	_	O
191	squares	_	_	O
192	mean	_	_	O
193	(	_	_	O
194	LSM	_	_	O
195	)	_	_	O
196	changes	_	_	O
197	from	_	_	O
198	baseline	_	_	O
199	and	_	_	O
200	95	_	_	O
201	%	_	_	O
202	confidence	_	_	O
203	intervals	_	_	O
204	(	_	_	O
205	CIs	_	_	O
206	)	_	_	O
207	at	_	_	O
208	each	_	_	O
209	timepoint	_	_	O
210	and	_	_	O
211	overall	_	_	O
212	.	_	_	O

213	Progression-free	_	_	O
214	survival	_	_	O
215	,	_	_	O
216	survival	_	_	O
217	,	_	_	O
218	response	_	_	O
219	rate	_	_	O
220	,	_	_	O
221	safety	_	_	O
222	,	_	_	O
223	and	_	_	O
224	HRQOL	_	_	O
225	.	_	_	O

226	Linear	_	_	B-Premise
227	mixed	_	_	I-Premise
228	models	_	_	I-Premise
229	(	_	_	I-Premise
230	primary	_	_	I-Premise
231	model	_	_	I-Premise
232	)	_	_	I-Premise
233	demonstrated	_	_	I-Premise
234	no	_	_	I-Premise
235	statistically	_	_	I-Premise
236	significant	_	_	I-Premise
237	overall	_	_	I-Premise
238	difference	_	_	I-Premise
239	between	_	_	I-Premise
240	EVE	_	_	I-Premise
241	+	_	_	I-Premise
242	EXE	_	_	I-Premise
243	and	_	_	I-Premise
244	PBO	_	_	I-Premise
245	+	_	_	I-Premise
246	EXE	_	_	I-Premise
247	for	_	_	I-Premise
248	QL2	_	_	I-Premise
249	(	_	_	I-Premise
250	LSM	_	_	I-Premise
251	difference	_	_	I-Premise
252	=	_	_	I-Premise
253	-1.91	_	_	I-Premise
254	;	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	=	_	_	I-Premise
259	-4.61	_	_	I-Premise
260	,	_	_	I-Premise
261	0.78	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	BRBS	_	_	I-Premise
265	(	_	_	I-Premise
266	LSM	_	_	I-Premise
267	difference	_	_	I-Premise
268	=	_	_	I-Premise
269	-0.18	_	_	I-Premise
270	;	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	=	_	_	I-Premise
275	-1.98	_	_	I-Premise
276	,	_	_	I-Premise
277	1.62	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	or	_	_	I-Premise
281	BRAS	_	_	I-Premise
282	(	_	_	I-Premise
283	LSM	_	_	I-Premise
284	difference	_	_	I-Premise
285	=	_	_	I-Premise
286	-0.42	_	_	I-Premise
287	;	_	_	I-Premise
288	95	_	_	I-Premise
289	%	_	_	I-Premise
290	CI	_	_	I-Premise
291	=	_	_	I-Premise
292	-2.94	_	_	I-Premise
293	,	_	_	I-Premise
294	2.10	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	Based	_	_	O
298	on	_	_	O
299	pattern-mixture	_	_	O
300	models	_	_	O
301	,	_	_	O
302	patients	_	_	O
303	who	_	_	O
304	dropped	_	_	O
305	out	_	_	O
306	early	_	_	O
307	had	_	_	O
308	worse	_	_	O
309	QL2	_	_	O
310	decline	_	_	O
311	on	_	_	O
312	both	_	_	O
313	treatments	_	_	O
314	.	_	_	O

315	In	_	_	B-Premise
316	the	_	_	I-Premise
317	expanded	_	_	I-Premise
318	pattern-mixture	_	_	I-Premise
319	model	_	_	I-Premise
320	,	_	_	I-Premise
321	EVE	_	_	I-Premise
322	+	_	_	I-Premise
323	EXE-treated	_	_	I-Premise
324	patients	_	_	I-Premise
325	who	_	_	I-Premise
326	did	_	_	I-Premise
327	not	_	_	I-Premise
328	drop	_	_	I-Premise
329	out	_	_	I-Premise
330	early	_	_	I-Premise
331	had	_	_	I-Premise
332	stable	_	_	I-Premise
333	BRBS	_	_	I-Premise
334	and	_	_	I-Premise
335	BRAS	_	_	I-Premise
336	relative	_	_	I-Premise
337	to	_	_	I-Premise
338	PBO	_	_	I-Premise
339	+	_	_	I-Premise
340	EXE	_	_	I-Premise
341	.	_	_	I-Premise

342	HRQOL	_	_	O
343	data	_	_	O
344	were	_	_	O
345	not	_	_	O
346	collected	_	_	O
347	after	_	_	O
348	disease	_	_	O
349	progression	_	_	O
350	.	_	_	O

351	These	_	_	B-Claim
352	analyses	_	_	I-Claim
353	confirm	_	_	I-Claim
354	that	_	_	I-Claim
355	EVE	_	_	I-Claim
356	+	_	_	I-Claim
357	EXE	_	_	I-Claim
358	provides	_	_	I-Claim
359	clinical	_	_	I-Claim
360	benefit	_	_	I-Claim
361	without	_	_	I-Claim
362	adversely	_	_	I-Claim
363	impacting	_	_	I-Claim
364	HRQOL	_	_	I-Claim
365	in	_	_	I-Claim
366	patients	_	_	I-Claim
367	with	_	_	I-Claim
368	HR	_	_	I-Claim
369	(	_	_	I-Claim
370	+	_	_	I-Claim
371	)	_	_	I-Claim
372	ABC	_	_	I-Claim
373	who	_	_	I-Claim
374	recurred/progressed	_	_	I-Claim
375	on	_	_	I-Claim
376	prior	_	_	I-Claim
377	NSAIs	_	_	I-Claim
378	versus	_	_	I-Claim
379	endocrine	_	_	I-Claim
380	therapy	_	_	I-Claim
381	alone	_	_	I-Claim
382	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	progressive	_	_	O
7	upper-body	_	_	O
8	exercise	_	_	O
9	program	_	_	O
10	on	_	_	O
11	lymphedema	_	_	O
12	secondary	_	_	O
13	to	_	_	O
14	breast	_	_	O
15	cancer	_	_	O
16	treatment	_	_	O
17	.	_	_	O

18	Fourteen	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	with	_	_	O
23	unilateral	_	_	O
24	upper	_	_	O
25	extremity	_	_	O
26	lymphedema	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	an	_	_	O
32	exercise	_	_	O
33	(	_	_	O
34	n	_	_	O
35	=	_	_	O
36	7	_	_	O
37	)	_	_	O
38	or	_	_	O
39	control	_	_	O
40	group	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	7	_	_	O
45	)	_	_	O
46	.	_	_	O

47	The	_	_	O
48	exercise	_	_	O
49	group	_	_	O
50	followed	_	_	O
51	a	_	_	O
52	progressive	_	_	O
53	,	_	_	O
54	8-week	_	_	O
55	upper-body	_	_	O
56	exercise	_	_	O
57	program	_	_	O
58	consisting	_	_	O
59	of	_	_	O
60	resistance	_	_	O
61	training	_	_	O
62	plus	_	_	O
63	aerobic	_	_	O
64	exercise	_	_	O
65	using	_	_	O
66	a	_	_	O
67	Monark	_	_	O
68	Rehab	_	_	O
69	Trainer	_	_	O
70	arm	_	_	O
71	ergometer	_	_	O
72	.	_	_	O

73	Lymphedema	_	_	O
74	was	_	_	O
75	assessed	_	_	O
76	by	_	_	O
77	arm	_	_	O
78	circumference	_	_	O
79	and	_	_	O
80	measurement	_	_	O
81	of	_	_	O
82	arm	_	_	O
83	volume	_	_	O
84	by	_	_	O
85	water	_	_	O
86	displacement	_	_	O
87	.	_	_	O

88	Patients	_	_	O
89	were	_	_	O
90	evaluated	_	_	O
91	on	_	_	O
92	five	_	_	O
93	occasions	_	_	O
94	over	_	_	O
95	the	_	_	O
96	experimental	_	_	O
97	period	_	_	O
98	.	_	_	O

99	The	_	_	O
100	Medical	_	_	O
101	Outcomes	_	_	O
102	Trust	_	_	O
103	Short-Form	_	_	O
104	36	_	_	O
105	Survey	_	_	O
106	was	_	_	O
107	used	_	_	O
108	to	_	_	O
109	measure	_	_	O
110	quality	_	_	O
111	of	_	_	O
112	life	_	_	O
113	before	_	_	O
114	and	_	_	O
115	after	_	_	O
116	the	_	_	O
117	intervention	_	_	O
118	.	_	_	O

119	Significance	_	_	O
120	was	_	_	O
121	set	_	_	O
122	at	_	_	O
123	alpha	_	_	O
124	<	_	_	O
125	or	_	_	O
126	=	_	_	O
127	0.01	_	_	O
128	.	_	_	O

129	No	_	_	B-Premise
130	changes	_	_	I-Premise
131	were	_	_	I-Premise
132	found	_	_	I-Premise
133	in	_	_	I-Premise
134	arm	_	_	I-Premise
135	circumference	_	_	I-Premise
136	or	_	_	I-Premise
137	arm	_	_	I-Premise
138	volume	_	_	I-Premise
139	as	_	_	I-Premise
140	a	_	_	I-Premise
141	result	_	_	I-Premise
142	of	_	_	I-Premise
143	the	_	_	I-Premise
144	exercise	_	_	I-Premise
145	program	_	_	I-Premise
146	.	_	_	I-Premise

147	Three	_	_	B-Premise
148	of	_	_	I-Premise
149	the	_	_	I-Premise
150	quality-of-life	_	_	I-Premise
151	domains	_	_	I-Premise
152	showed	_	_	I-Premise
153	trends	_	_	I-Premise
154	toward	_	_	I-Premise
155	increases	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	exercise	_	_	I-Premise
159	group	_	_	I-Premise
160	:	_	_	I-Premise
161	physical	_	_	I-Premise
162	functioning	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=.050	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	general	_	_	I-Premise
169	health	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=.048	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	vitality	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=.023	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Mental	_	_	B-Premise
183	health	_	_	I-Premise
184	increased	_	_	I-Premise
185	,	_	_	I-Premise
186	although	_	_	I-Premise
187	not	_	_	I-Premise
188	significantly	_	_	I-Premise
189	,	_	_	I-Premise
190	for	_	_	I-Premise
191	all	_	_	I-Premise
192	subjects	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=.019	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Arm	_	_	B-Premise
199	volume	_	_	I-Premise
200	measured	_	_	I-Premise
201	by	_	_	I-Premise
202	water	_	_	I-Premise
203	displacement	_	_	I-Premise
204	was	_	_	I-Premise
205	correlated	_	_	I-Premise
206	with	_	_	I-Premise
207	calculated	_	_	I-Premise
208	arm	_	_	I-Premise
209	volume	_	_	I-Premise
210	(	_	_	I-Premise
211	r	_	_	I-Premise
212	=.973	_	_	I-Premise
213	,	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	.001	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	although	_	_	B-Premise
220	the	_	_	I-Premise
221	exercise	_	_	I-Premise
222	and	_	_	I-Premise
223	control	_	_	I-Premise
224	group	_	_	I-Premise
225	means	_	_	I-Premise
226	were	_	_	I-Premise
227	significantly	_	_	I-Premise
228	different	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.001	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Participation	_	_	B-Claim
236	in	_	_	I-Claim
237	an	_	_	I-Claim
238	upper-body	_	_	I-Claim
239	exercise	_	_	I-Claim
240	program	_	_	I-Claim
241	caused	_	_	I-Claim
242	no	_	_	I-Claim
243	changes	_	_	I-Claim
244	in	_	_	I-Claim
245	arm	_	_	I-Claim
246	circumference	_	_	I-Claim
247	or	_	_	I-Claim
248	arm	_	_	I-Claim
249	volume	_	_	I-Claim
250	in	_	_	I-Claim
251	women	_	_	I-Claim
252	with	_	_	I-Claim
253	lymphedema	_	_	I-Claim
254	after	_	_	I-Claim
255	breast	_	_	I-Claim
256	cancer	_	_	I-Claim
257	,	_	_	I-Claim
258	and	_	_	I-Claim
259	they	_	_	I-Claim
260	may	_	_	I-Claim
261	have	_	_	I-Claim
262	experienced	_	_	I-Claim
263	an	_	_	I-Claim
264	increase	_	_	I-Claim
265	in	_	_	I-Claim
266	quality	_	_	I-Claim
267	of	_	_	I-Claim
268	life	_	_	I-Claim
269	.	_	_	I-Claim

270	Additional	_	_	B-Claim
271	studies	_	_	I-Claim
272	should	_	_	I-Claim
273	be	_	_	I-Claim
274	done	_	_	I-Claim
275	in	_	_	I-Claim
276	this	_	_	I-Claim
277	area	_	_	I-Claim
278	to	_	_	I-Claim
279	determine	_	_	I-Claim
280	the	_	_	I-Claim
281	optimum	_	_	I-Claim
282	training	_	_	I-Claim
283	program	_	_	I-Claim
284	.	_	_	I-Claim


0	Studies	_	_	O
1	have	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	there	_	_	O
5	is	_	_	O
6	a	_	_	O
7	high	_	_	O
8	prevalence	_	_	O
9	of	_	_	O
10	depression	_	_	O
11	in	_	_	O
12	cancer	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	Women	_	_	B-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	may	_	_	I-Claim
20	have	_	_	I-Claim
21	an	_	_	I-Claim
22	even	_	_	I-Claim
23	higher	_	_	I-Claim
24	risk	_	_	I-Claim
25	of	_	_	I-Claim
26	depression	_	_	I-Claim
27	particularly	_	_	I-Claim
28	in	_	_	I-Claim
29	a	_	_	I-Claim
30	postmenopausal	_	_	I-Claim
31	or	_	_	I-Claim
32	estrogen	_	_	I-Claim
33	deficiency	_	_	I-Claim
34	state	_	_	I-Claim
35	.	_	_	I-Claim

36	A	_	_	O
37	small	_	_	O
38	number	_	_	O
39	of	_	_	O
40	randomized	_	_	O
41	controlled	_	_	O
42	trials	_	_	O
43	have	_	_	O
44	examined	_	_	O
45	the	_	_	O
46	efficacy	_	_	O
47	of	_	_	O
48	antidepressants	_	_	O
49	compared	_	_	O
50	to	_	_	O
51	that	_	_	O
52	of	_	_	O
53	a	_	_	O
54	placebo	_	_	O
55	in	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	,	_	_	O
59	but	_	_	O
60	some	_	_	O
61	results	_	_	O
62	have	_	_	O
63	been	_	_	O
64	difficult	_	_	O
65	to	_	_	O
66	interpret	_	_	O
67	due	_	_	O
68	to	_	_	O
69	a	_	_	O
70	heterogeneous	_	_	O
71	patient	_	_	O
72	group	_	_	O
73	.	_	_	O

74	In	_	_	O
75	the	_	_	O
76	current	_	_	O
77	investigation	_	_	O
78	,	_	_	O
79	we	_	_	O
80	screened	_	_	O
81	newly	_	_	O
82	diagnosed	_	_	O
83	early	_	_	O
84	stage	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	patients	_	_	O
88	for	_	_	O
89	depressive	_	_	O
90	symptoms	_	_	O
91	prior	_	_	O
92	to	_	_	O
93	the	_	_	O
94	initiation	_	_	O
95	of	_	_	O
96	adjuvant	_	_	O
97	therapy	_	_	O
98	and	_	_	O
99	investigated	_	_	O
100	whether	_	_	O
101	the	_	_	O
102	oral	_	_	O
103	antidepressant	_	_	O
104	fluoxetine	_	_	O
105	affected	_	_	O
106	depressive	_	_	O
107	symptoms	_	_	O
108	,	_	_	O
109	completion	_	_	O
110	of	_	_	O
111	adjuvant	_	_	O
112	treatment	_	_	O
113	,	_	_	O
114	and	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	with	_	_	O
121	newly	_	_	O
122	diagnosed	_	_	O
123	early	_	_	O
124	stage	_	_	O
125	breast	_	_	O
126	cancer	_	_	O
127	were	_	_	O
128	screened	_	_	O
129	for	_	_	O
130	depressive	_	_	O
131	symptoms	_	_	O
132	prior	_	_	O
133	to	_	_	O
134	the	_	_	O
135	initiation	_	_	O
136	of	_	_	O
137	adjuvant	_	_	O
138	therapy	_	_	O
139	.	_	_	O

140	Patients	_	_	O
141	with	_	_	O
142	depressive	_	_	O
143	symptoms	_	_	O
144	were	_	_	O
145	randomized	_	_	O
146	to	_	_	O
147	a	_	_	O
148	daily	_	_	O
149	oral	_	_	O
150	fluoxetine	_	_	O
151	or	_	_	O
152	a	_	_	O
153	placebo	_	_	O
154	.	_	_	O

155	Patients	_	_	O
156	were	_	_	O
157	then	_	_	O
158	followed	_	_	O
159	for	_	_	O
160	6	_	_	O
161	months	_	_	O
162	and	_	_	O
163	evaluated	_	_	O
164	for	_	_	O
165	quality	_	_	O
166	of	_	_	O
167	life	_	_	O
168	,	_	_	O
169	completion	_	_	O
170	of	_	_	O
171	adjuvant	_	_	O
172	treatment	_	_	O
173	,	_	_	O
174	and	_	_	O
175	depressive	_	_	O
176	symptoms	_	_	O
177	.	_	_	O

178	A	_	_	O
179	high	_	_	O
180	percentage	_	_	O
181	of	_	_	O
182	patients	_	_	O
183	with	_	_	O
184	newly	_	_	O
185	diagnosed	_	_	O
186	early	_	_	O
187	stage	_	_	O
188	breast	_	_	O
189	cancer	_	_	O
190	were	_	_	O
191	found	_	_	O
192	to	_	_	O
193	have	_	_	O
194	depressive	_	_	O
195	symptoms	_	_	O
196	prior	_	_	O
197	to	_	_	O
198	the	_	_	O
199	initiation	_	_	O
200	of	_	_	O
201	adjuvant	_	_	O
202	therapy	_	_	O
203	.	_	_	O

204	The	_	_	B-Premise
205	use	_	_	I-Premise
206	of	_	_	I-Premise
207	fluoxetine	_	_	I-Premise
208	for	_	_	I-Premise
209	6	_	_	I-Premise
210	months	_	_	I-Premise
211	resulted	_	_	I-Premise
212	in	_	_	I-Premise
213	an	_	_	I-Premise
214	improvement	_	_	I-Premise
215	in	_	_	I-Premise
216	quality	_	_	I-Premise
217	of	_	_	I-Premise
218	life	_	_	I-Premise
219	,	_	_	I-Premise
220	a	_	_	I-Premise
221	higher	_	_	I-Premise
222	completion	_	_	I-Premise
223	of	_	_	I-Premise
224	adjuvant	_	_	I-Premise
225	treatment	_	_	I-Premise
226	(	_	_	I-Premise
227	chemotherapy	_	_	I-Premise
228	,	_	_	I-Premise
229	hormonal	_	_	I-Premise
230	therapy	_	_	I-Premise
231	,	_	_	I-Premise
232	chemotherapy	_	_	I-Premise
233	plus	_	_	I-Premise
234	hormonal	_	_	I-Premise
235	therapy	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	and	_	_	I-Premise
239	a	_	_	I-Premise
240	reduction	_	_	I-Premise
241	in	_	_	I-Premise
242	depressive	_	_	I-Premise
243	symptoms	_	_	I-Premise
244	compared	_	_	I-Premise
245	to	_	_	I-Premise
246	patients	_	_	I-Premise
247	who	_	_	I-Premise
248	received	_	_	I-Premise
249	placebo	_	_	I-Premise
250	.	_	_	I-Premise

251	An	_	_	B-Claim
252	antidepressant	_	_	I-Claim
253	should	_	_	I-Claim
254	be	_	_	I-Claim
255	considered	_	_	I-Claim
256	for	_	_	I-Claim
257	early	_	_	I-Claim
258	stage	_	_	I-Claim
259	breast	_	_	I-Claim
260	cancer	_	_	I-Claim
261	patients	_	_	I-Claim
262	with	_	_	I-Claim
263	depressive	_	_	I-Claim
264	symptoms	_	_	I-Claim
265	who	_	_	I-Claim
266	are	_	_	I-Claim
267	receiving	_	_	I-Claim
268	adjuvant	_	_	I-Claim
269	treatment	_	_	I-Claim
270	.	_	_	I-Claim


0	The	_	_	O
1	second	_	_	O
2	International	_	_	O
3	Society	_	_	O
4	of	_	_	O
5	Paediatric	_	_	O
6	Oncology	_	_	O
7	(	_	_	O
8	SIOP	_	_	O
9	)	_	_	O
10	study	_	_	O
11	for	_	_	O
12	rhabdomyosarcoma	_	_	O
13	(	_	_	O
14	MMT84	_	_	O
15	)	_	_	O
16	had	_	_	O
17	several	_	_	O
18	goals	_	_	O
19	.	_	_	O

20	The	_	_	O
21	two	_	_	O
22	principal	_	_	O
23	aims	_	_	O
24	were	_	_	O
25	:	_	_	O
26	(	_	_	O
27	1	_	_	O
28	)	_	_	O
29	to	_	_	O
30	improve	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	of	_	_	O
34	children	_	_	O
35	with	_	_	O
36	rhabdomyosarcoma	_	_	O
37	;	_	_	O
38	and	_	_	O
39	(	_	_	O
40	2	_	_	O
41	)	_	_	O
42	to	_	_	O
43	reduce	_	_	O
44	the	_	_	O
45	late	_	_	O
46	effects	_	_	O
47	from	_	_	O
48	therapy	_	_	O
49	by	_	_	O
50	restricting	_	_	O
51	the	_	_	O
52	indications	_	_	O
53	for	_	_	O
54	surgery	_	_	O
55	and/or	_	_	O
56	radiotherapy	_	_	O
57	after	_	_	O
58	good	_	_	O
59	response	_	_	O
60	to	_	_	O
61	initial	_	_	O
62	chemotherapy	_	_	O
63	.	_	_	O

64	A	_	_	O
65	further	_	_	O
66	aim	_	_	O
67	was	_	_	O
68	to	_	_	O
69	investigate	_	_	O
70	the	_	_	O
71	role	_	_	O
72	of	_	_	O
73	high-dose	_	_	O
74	chemotherapy	_	_	O
75	in	_	_	O
76	young	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	parameningeal	_	_	O
80	primary	_	_	O
81	tumours	_	_	O
82	.	_	_	O

83	186	_	_	O
84	previously	_	_	O
85	untreated	_	_	O
86	eligible	_	_	O
87	patients	_	_	O
88	entered	_	_	O
89	the	_	_	O
90	study	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	with	_	_	O
94	completely	_	_	O
95	resected	_	_	O
96	primary	_	_	O
97	tumour	_	_	O
98	received	_	_	O
99	three	_	_	O
100	courses	_	_	O
101	of	_	_	O
102	IVA	_	_	O
103	(	_	_	O
104	ifosfamide	_	_	O
105	,	_	_	O
106	vincristine	_	_	O
107	and	_	_	O
108	actinomycin	_	_	O
109	D	_	_	O
110	)	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	with	_	_	O
114	incompletely	_	_	O
115	resected	_	_	O
116	tumour	_	_	O
117	received	_	_	O
118	six	_	_	O
119	to	_	_	O
120	10	_	_	O
121	courses	_	_	O
122	of	_	_	O
123	IVA	_	_	O
124	according	_	_	O
125	to	_	_	O
126	stage	_	_	O
127	.	_	_	O

128	Patients	_	_	O
129	achieving	_	_	O
130	complete	_	_	O
131	remission	_	_	O
132	with	_	_	O
133	chemotherapy	_	_	O
134	alone	_	_	O
135	did	_	_	O
136	not	_	_	O
137	usually	_	_	O
138	receive	_	_	O
139	radiotherapy	_	_	O
140	or	_	_	O
141	undergo	_	_	O
142	extensive	_	_	O
143	surgery	_	_	O
144	,	_	_	O
145	but	_	_	O
146	patients	_	_	O
147	remaining	_	_	O
148	in	_	_	O
149	partial	_	_	O
150	remission	_	_	O
151	received	_	_	O
152	local	_	_	O
153	therapy	_	_	O
154	with	_	_	O
155	surgery	_	_	O
156	and/or	_	_	O
157	radiotherapy	_	_	O
158	.	_	_	O

159	Only	_	_	O
160	patients	_	_	O
161	over	_	_	O
162	5	_	_	O
163	years	_	_	O
164	of	_	_	O
165	age	_	_	O
166	with	_	_	O
167	parameningeal	_	_	O
168	disease	_	_	O
169	and	_	_	O
170	patients	_	_	O
171	over	_	_	O
172	12	_	_	O
173	years	_	_	O
174	with	_	_	O
175	tumours	_	_	O
176	at	_	_	O
177	any	_	_	O
178	site	_	_	O
179	were	_	_	O
180	given	_	_	O
181	systematic	_	_	O
182	irradiation	_	_	O
183	.	_	_	O

184	Complete	_	_	B-Premise
185	remission	_	_	I-Premise
186	was	_	_	I-Premise
187	achieved	_	_	I-Premise
188	in	_	_	I-Premise
189	91	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	170/186	_	_	I-Premise
193	)	_	_	I-Premise
194	of	_	_	I-Premise
195	all	_	_	I-Premise
196	patients	_	_	I-Premise
197	.	_	_	I-Premise

198	With	_	_	B-Premise
199	a	_	_	I-Premise
200	median	_	_	I-Premise
201	follow-up	_	_	I-Premise
202	of	_	_	I-Premise
203	8	_	_	I-Premise
204	years	_	_	I-Premise
205	,	_	_	I-Premise
206	the	_	_	I-Premise
207	5-year	_	_	I-Premise
208	overall	_	_	I-Premise
209	survival	_	_	I-Premise
210	was	_	_	I-Premise
211	68	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	+/-	_	_	I-Premise
215	3	_	_	I-Premise
216	%	_	_	I-Premise
217	standard	_	_	I-Premise
218	error	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	(	_	_	I-Premise
223	SEM	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	the	_	_	I-Premise
227	5-year	_	_	I-Premise
228	event-free	_	_	I-Premise
229	survival	_	_	I-Premise
230	53	_	_	I-Premise
231	%	_	_	I-Premise
232	(	_	_	I-Premise
233	+/-	_	_	I-Premise
234	4	_	_	I-Premise
235	%	_	_	I-Premise
236	SEM	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	These	_	_	B-Premise
240	results	_	_	I-Premise
241	show	_	_	I-Premise
242	an	_	_	I-Premise
243	improvement	_	_	I-Premise
244	over	_	_	I-Premise
245	previous	_	_	I-Premise
246	SIOP	_	_	I-Premise
247	study	_	_	I-Premise
248	(	_	_	I-Premise
249	RMS75	_	_	I-Premise
250	)	_	_	I-Premise
251	in	_	_	I-Premise
252	which	_	_	I-Premise
253	survival	_	_	I-Premise
254	was	_	_	I-Premise
255	52	_	_	I-Premise
256	%	_	_	I-Premise
257	and	_	_	I-Premise
258	event-free	_	_	I-Premise
259	survival	_	_	I-Premise
260	was	_	_	I-Premise
261	47	_	_	I-Premise
262	%	_	_	I-Premise
263	.	_	_	I-Premise

264	Among	_	_	B-Premise
265	the	_	_	I-Premise
266	54	_	_	I-Premise
267	patients	_	_	I-Premise
268	who	_	_	I-Premise
269	exhibited	_	_	I-Premise
270	isolated	_	_	I-Premise
271	local	_	_	I-Premise
272	relapse	_	_	I-Premise
273	,	_	_	I-Premise
274	35	_	_	I-Premise
275	%	_	_	I-Premise
276	(	_	_	I-Premise
277	19/54	_	_	I-Premise
278	)	_	_	I-Premise
279	survived	_	_	I-Premise
280	in	_	_	I-Premise
281	further	_	_	I-Premise
282	remission	_	_	I-Premise
283	longer	_	_	I-Premise
284	than	_	_	I-Premise
285	2	_	_	I-Premise
286	years	_	_	I-Premise
287	after	_	_	I-Premise
288	retreatment	_	_	I-Premise
289	,	_	_	I-Premise
290	including	_	_	I-Premise
291	local	_	_	I-Premise
292	therapy	_	_	I-Premise
293	(	_	_	I-Premise
294	surgery	_	_	I-Premise
295	+/-	_	_	I-Premise
296	radiotherapy	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Analysis	_	_	O
300	of	_	_	O
301	the	_	_	O
302	overall	_	_	O
303	burden	_	_	O
304	of	_	_	O
305	therapy	_	_	O
306	received	_	_	O
307	by	_	_	O
308	all	_	_	O
309	surviving	_	_	O
310	children	_	_	O
311	(	_	_	O
312	including	_	_	O
313	primary	_	_	O
314	treatment	_	_	O
315	and	_	_	O
316	treatment	_	_	O
317	for	_	_	O
318	relapse	_	_	O
319	if	_	_	O
320	required	_	_	O
321	)	_	_	O
322	showed	_	_	O
323	that	_	_	O
324	24	_	_	O
325	%	_	_	O
326	(	_	_	O
327	28/116	_	_	O
328	)	_	_	O
329	were	_	_	O
330	treated	_	_	O
331	by	_	_	O
332	limited	_	_	O
333	surgery	_	_	O
334	followed	_	_	O
335	by	_	_	O
336	three	_	_	O
337	courses	_	_	O
338	of	_	_	O
339	IVA	_	_	O
340	,	_	_	O
341	29	_	_	O
342	%	_	_	O
343	(	_	_	O
344	34/116	_	_	O
345	)	_	_	O
346	were	_	_	O
347	treated	_	_	O
348	by	_	_	O
349	chemotherapy	_	_	O
350	alone	_	_	O
351	(	_	_	O
352	after	_	_	O
353	initial	_	_	O
354	biopsy	_	_	O
355	)	_	_	O
356	and	_	_	O
357	13	_	_	O
358	%	_	_	O
359	(	_	_	O
360	15/116	_	_	O
361	)	_	_	O
362	received	_	_	O
363	chemotherapy	_	_	O
364	plus	_	_	O
365	conservative	_	_	O
366	local	_	_	O
367	treatment	_	_	O
368	(	_	_	O
369	limited	_	_	O
370	surgery	_	_	O
371	or	_	_	O
372	radiotherapy	_	_	O
373	for	_	_	O
374	residual	_	_	O
375	disease	_	_	O
376	)	_	_	O
377	.	_	_	O

378	Only	_	_	O
379	34	_	_	O
380	%	_	_	O
381	(	_	_	O
382	39/116	_	_	O
383	)	_	_	O
384	received	_	_	O
385	intensive	_	_	O
386	local	_	_	O
387	therapy	_	_	O
388	defined	_	_	O
389	as	_	_	O
390	radical	_	_	O
391	wide	_	_	O
392	field	_	_	O
393	radiotherapy	_	_	O
394	or	_	_	O
395	radical	_	_	O
396	surgery	_	_	O
397	or	_	_	O
398	both	_	_	O
399	.	_	_	O

400	Compared	_	_	B-Claim
401	with	_	_	I-Claim
402	the	_	_	I-Claim
403	results	_	_	I-Claim
404	obtained	_	_	I-Claim
405	in	_	_	I-Claim
406	the	_	_	I-Claim
407	previous	_	_	I-Claim
408	SIOP	_	_	I-Claim
409	study	_	_	I-Claim
410	,	_	_	I-Claim
411	treatment	_	_	I-Claim
412	in	_	_	I-Claim
413	MMT84	_	_	I-Claim
414	was	_	_	I-Claim
415	based	_	_	I-Claim
416	on	_	_	I-Claim
417	response	_	_	I-Claim
418	to	_	_	I-Claim
419	initial	_	_	I-Claim
420	chemotherapy	_	_	I-Claim
421	and	_	_	I-Claim
422	,	_	_	I-Claim
423	despite	_	_	I-Claim
424	an	_	_	I-Claim
425	overall	_	_	I-Claim
426	reduction	_	_	I-Claim
427	of	_	_	I-Claim
428	the	_	_	I-Claim
429	use	_	_	I-Claim
430	of	_	_	I-Claim
431	local	_	_	I-Claim
432	therapy	_	_	I-Claim
433	,	_	_	I-Claim
434	significantly	_	_	I-Claim
435	improved	_	_	I-Claim
436	survival	_	_	I-Claim
437	for	_	_	I-Claim
438	patients	_	_	I-Claim
439	with	_	_	I-Claim
440	non-metastatic	_	_	I-Claim
441	disease	_	_	I-Claim
442	.	_	_	I-Claim

443	This	_	_	B-Claim
444	trial	_	_	I-Claim
445	,	_	_	I-Claim
446	also	_	_	I-Claim
447	for	_	_	I-Claim
448	the	_	_	I-Claim
449	first	_	_	I-Claim
450	time	_	_	I-Claim
451	,	_	_	I-Claim
452	provides	_	_	I-Claim
453	evidence	_	_	I-Claim
454	that	_	_	I-Claim
455	retreatment	_	_	I-Claim
456	after	_	_	I-Claim
457	local	_	_	I-Claim
458	relapse	_	_	I-Claim
459	can	_	_	I-Claim
460	achieve	_	_	I-Claim
461	long-term	_	_	I-Claim
462	second	_	_	I-Claim
463	remissions	_	_	I-Claim
464	.	_	_	I-Claim


0	DPPE	_	_	B-Claim
1	(	_	_	I-Claim
2	tesmilifene	_	_	I-Claim
3	)	_	_	I-Claim
4	plus	_	_	I-Claim
5	doxorubicin	_	_	I-Claim
6	(	_	_	I-Claim
7	DOX	_	_	I-Claim
8	)	_	_	I-Claim
9	demonstrated	_	_	I-Claim
10	a	_	_	I-Claim
11	significant	_	_	I-Claim
12	improvement	_	_	I-Claim
13	in	_	_	I-Claim
14	survival	_	_	I-Claim
15	versus	_	_	I-Claim
16	DOX	_	_	I-Claim
17	in	_	_	I-Claim
18	a	_	_	I-Claim
19	phase	_	_	I-Claim
20	III	_	_	I-Claim
21	clinical	_	_	I-Claim
22	trial	_	_	I-Claim
23	in	_	_	I-Claim
24	advanced	_	_	I-Claim
25	breast	_	_	I-Claim
26	cancer	_	_	I-Claim
27	.	_	_	I-Claim

28	However	_	_	B-Premise
29	,	_	_	I-Premise
30	DPPE	_	_	I-Premise
31	is	_	_	I-Premise
32	associated	_	_	I-Premise
33	with	_	_	I-Premise
34	unusual	_	_	I-Premise
35	toxicity	_	_	I-Premise
36	in	_	_	I-Premise
37	the	_	_	I-Premise
38	form	_	_	I-Premise
39	of	_	_	I-Premise
40	hallucinations	_	_	I-Premise
41	,	_	_	I-Premise
42	nausea	_	_	I-Premise
43	and	_	_	I-Premise
44	vomiting	_	_	I-Premise
45	which	_	_	I-Premise
46	were	_	_	I-Premise
47	anticipated	_	_	I-Premise
48	to	_	_	I-Premise
49	impact	_	_	I-Premise
50	on	_	_	I-Premise
51	short-term	_	_	I-Premise
52	quality	_	_	I-Premise
53	of	_	_	I-Premise
54	life	_	_	I-Premise
55	(	_	_	I-Premise
56	QOL	_	_	I-Premise
57	)	_	_	I-Premise
58	.	_	_	I-Premise

59	Standard	_	_	O
60	National	_	_	O
61	Cancer	_	_	O
62	Institute	_	_	O
63	of	_	_	O
64	Canada	_	_	O
65	Clinical	_	_	O
66	Trials	_	_	O
67	Group	_	_	O
68	(	_	_	O
69	NCIC	_	_	O
70	CTG	_	_	O
71	)	_	_	O
72	approaches	_	_	O
73	were	_	_	O
74	applied	_	_	O
75	as	_	_	O
76	the	_	_	O
77	primary	_	_	O
78	method	_	_	O
79	to	_	_	O
80	analyze	_	_	O
81	the	_	_	O
82	QOL	_	_	O
83	data	_	_	O
84	from	_	_	O
85	this	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	This	_	_	O
89	includes	_	_	O
90	cross-sectional	_	_	O
91	comparisons	_	_	O
92	,	_	_	O
93	together	_	_	O
94	with	_	_	O
95	a	_	_	O
96	global	_	_	O
97	test	_	_	O
98	for	_	_	O
99	the	_	_	O
100	QOL	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	.	_	_	O

104	Sensitivity	_	_	O
105	analyses	_	_	O
106	were	_	_	O
107	also	_	_	O
108	performed	_	_	O
109	for	_	_	O
110	selected	_	_	O
111	QOL	_	_	O
112	domains	_	_	O
113	and	_	_	O
114	items	_	_	O
115	,	_	_	O
116	using	_	_	O
117	other	_	_	O
118	types	_	_	O
119	of	_	_	O
120	summary	_	_	O
121	measures	_	_	O
122	and	_	_	O
123	statistics	_	_	O
124	.	_	_	O

125	Two	_	_	O
126	hundred	_	_	O
127	seventy	_	_	O
128	one	_	_	O
129	patients	_	_	O
130	(	_	_	O
131	89	_	_	O
132	%	_	_	O
133	of	_	_	O
134	randomized	_	_	O
135	)	_	_	O
136	submitted	_	_	O
137	the	_	_	O
138	baseline	_	_	O
139	QOL	_	_	O
140	questionnaires	_	_	O
141	and	_	_	O
142	were	_	_	O
143	included	_	_	O
144	in	_	_	O
145	the	_	_	O
146	QOL	_	_	O
147	analysis	_	_	O
148	.	_	_	O

149	No	_	_	B-Premise
150	statistically	_	_	I-Premise
151	significant	_	_	I-Premise
152	difference	_	_	I-Premise
153	in	_	_	I-Premise
154	QOL	_	_	I-Premise
155	response	_	_	I-Premise
156	between	_	_	I-Premise
157	treatment	_	_	I-Premise
158	arms	_	_	I-Premise
159	was	_	_	I-Premise
160	found	_	_	I-Premise
161	for	_	_	I-Premise
162	any	_	_	I-Premise
163	domain	_	_	I-Premise
164	or	_	_	I-Premise
165	item	_	_	I-Premise
166	except	_	_	I-Premise
167	nausea	_	_	I-Premise
168	and	_	_	I-Premise
169	vomiting	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	0.04	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Cross-sectional	_	_	B-Premise
177	comparisons	_	_	I-Premise
178	showed	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	differences	_	_	I-Premise
182	for	_	_	I-Premise
183	some	_	_	I-Premise
184	domains/items	_	_	I-Premise
185	at	_	_	I-Premise
186	specific	_	_	I-Premise
187	assessment	_	_	I-Premise
188	times	_	_	I-Premise
189	with	_	_	I-Premise
190	all	_	_	I-Premise
191	differences	_	_	I-Premise
192	favoring	_	_	I-Premise
193	the	_	_	I-Premise
194	DOX	_	_	I-Premise
195	alone	_	_	I-Premise
196	arm	_	_	I-Premise
197	.	_	_	I-Premise

198	Patients	_	_	B-Premise
199	on	_	_	I-Premise
200	DPPE/DOX	_	_	I-Premise
201	arm	_	_	I-Premise
202	were	_	_	I-Premise
203	significantly	_	_	I-Premise
204	worse	_	_	I-Premise
205	in	_	_	I-Premise
206	terms	_	_	I-Premise
207	of	_	_	I-Premise
208	average	_	_	I-Premise
209	and	_	_	I-Premise
210	median	_	_	I-Premise
211	pain	_	_	I-Premise
212	change	_	_	I-Premise
213	scores	_	_	I-Premise
214	.	_	_	I-Premise

215	Different	_	_	B-Claim
216	analyses	_	_	I-Claim
217	yielded	_	_	I-Claim
218	slightly	_	_	I-Claim
219	different	_	_	I-Claim
220	conclusions	_	_	I-Claim
221	but	_	_	O
222	,	_	_	O
223	in	_	_	B-Claim
224	general	_	_	I-Claim
225	,	_	_	I-Claim
226	the	_	_	I-Claim
227	QOL	_	_	I-Claim
228	analyses	_	_	I-Claim
229	were	_	_	I-Claim
230	concordant	_	_	I-Claim
231	and	_	_	I-Claim
232	showed	_	_	I-Claim
233	that	_	_	I-Claim
234	patients	_	_	I-Claim
235	on	_	_	I-Claim
236	DOX	_	_	I-Claim
237	alone	_	_	I-Claim
238	had	_	_	I-Claim
239	fewer	_	_	I-Claim
240	disease	_	_	I-Claim
241	and	_	_	I-Claim
242	treatment	_	_	I-Claim
243	related	_	_	I-Claim
244	adverse	_	_	I-Claim
245	events	_	_	I-Claim
246	and	_	_	I-Claim
247	better	_	_	I-Claim
248	QOL	_	_	I-Claim
249	.	_	_	I-Claim

250	Interestingly	_	_	B-Claim
251	,	_	_	I-Claim
252	the	_	_	I-Claim
253	QOL	_	_	I-Claim
254	response	_	_	I-Claim
255	analysis	_	_	I-Claim
256	also	_	_	I-Claim
257	showed	_	_	I-Claim
258	that	_	_	I-Claim
259	aggressive	_	_	I-Claim
260	premedication	_	_	I-Claim
261	regimens	_	_	I-Claim
262	appear	_	_	I-Claim
263	to	_	_	I-Claim
264	ameliorate	_	_	I-Claim
265	potential	_	_	I-Claim
266	negative	_	_	I-Claim
267	effects	_	_	I-Claim
268	of	_	_	I-Claim
269	DPPE	_	_	I-Claim
270	on	_	_	I-Claim
271	emesis	_	_	I-Claim
272	and	_	_	I-Claim
273	nausea	_	_	I-Claim
274	as	_	_	I-Claim
275	measured	_	_	I-Claim
276	by	_	_	I-Claim
277	patient	_	_	I-Claim
278	assessed	_	_	I-Claim
279	QOL	_	_	I-Claim
280	.	_	_	I-Claim


0	Numerous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	comorbidity	_	_	O
6	of	_	_	O
7	depression	_	_	O
8	with	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	and	_	_	O
12	some	_	_	O
13	have	_	_	O
14	indicated	_	_	O
15	that	_	_	O
16	depression	_	_	O
17	may	_	_	O
18	be	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	cancer	_	_	O
22	progression	_	_	O
23	or	_	_	O
24	survival	_	_	O
25	.	_	_	O

26	However	_	_	O
27	,	_	_	O
28	few	_	_	O
29	studies	_	_	O
30	have	_	_	O
31	assessed	_	_	O
32	whether	_	_	O
33	changes	_	_	O
34	in	_	_	O
35	depression	_	_	O
36	symptoms	_	_	O
37	are	_	_	O
38	associated	_	_	O
39	with	_	_	O
40	survival	_	_	O
41	.	_	_	O

42	In	_	_	O
43	a	_	_	O
44	secondary	_	_	O
45	analysis	_	_	O
46	of	_	_	O
47	a	_	_	O
48	randomized	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	supportive-expressive	_	_	O
52	group	_	_	O
53	therapy	_	_	O
54	,	_	_	O
55	125	_	_	O
56	women	_	_	O
57	with	_	_	O
58	metastatic	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	MBC	_	_	O
63	)	_	_	O
64	completed	_	_	O
65	a	_	_	O
66	depression	_	_	O
67	symptom	_	_	O
68	measure	_	_	O
69	(	_	_	O
70	Center	_	_	O
71	for	_	_	O
72	Epidemiologic	_	_	O
73	Studies-Depression	_	_	O
74	Scale	_	_	O
75	[	_	_	O
76	CES-D	_	_	O
77	]	_	_	O
78	)	_	_	O
79	at	_	_	O
80	baseline	_	_	O
81	and	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	a	_	_	O
87	treatment	_	_	O
88	group	_	_	O
89	or	_	_	O
90	to	_	_	O
91	a	_	_	O
92	control	_	_	O
93	group	_	_	O
94	that	_	_	O
95	received	_	_	O
96	educational	_	_	O
97	materials	_	_	O
98	.	_	_	O

99	At	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	three	_	_	O
103	follow-up	_	_	O
104	points	_	_	O
105	,	_	_	O
106	101	_	_	O
107	of	_	_	O
108	125	_	_	O
109	women	_	_	O
110	completed	_	_	O
111	a	_	_	O
112	depression	_	_	O
113	symptom	_	_	O
114	measure	_	_	O
115	.	_	_	O

116	We	_	_	O
117	used	_	_	O
118	these	_	_	O
119	data	_	_	O
120	in	_	_	O
121	a	_	_	O
122	Cox	_	_	O
123	proportional	_	_	O
124	hazards	_	_	O
125	analysis	_	_	O
126	to	_	_	O
127	examine	_	_	O
128	whether	_	_	O
129	decreasing	_	_	O
130	depression	_	_	O
131	symptoms	_	_	O
132	over	_	_	O
133	the	_	_	O
134	first	_	_	O
135	year	_	_	O
136	of	_	_	O
137	the	_	_	O
138	study	_	_	O
139	(	_	_	O
140	the	_	_	O
141	length	_	_	O
142	of	_	_	O
143	the	_	_	O
144	intervention	_	_	O
145	)	_	_	O
146	would	_	_	O
147	be	_	_	O
148	associated	_	_	O
149	with	_	_	O
150	longer	_	_	O
151	survival	_	_	O
152	.	_	_	O

153	Median	_	_	B-Premise
154	survival	_	_	I-Premise
155	time	_	_	I-Premise
156	was	_	_	I-Premise
157	53.6	_	_	I-Premise
158	months	_	_	I-Premise
159	for	_	_	I-Premise
160	women	_	_	I-Premise
161	with	_	_	I-Premise
162	decreasing	_	_	I-Premise
163	CES-D	_	_	I-Premise
164	scores	_	_	I-Premise
165	over	_	_	I-Premise
166	1	_	_	I-Premise
167	year	_	_	I-Premise
168	and	_	_	I-Premise
169	25.1	_	_	I-Premise
170	months	_	_	I-Premise
171	for	_	_	I-Premise
172	women	_	_	I-Premise
173	with	_	_	I-Premise
174	increasing	_	_	I-Premise
175	CES-D	_	_	I-Premise
176	scores	_	_	I-Premise
177	.	_	_	I-Premise

178	There	_	_	B-Premise
179	was	_	_	I-Premise
180	a	_	_	I-Premise
181	significant	_	_	I-Premise
182	effect	_	_	I-Premise
183	of	_	_	I-Premise
184	change	_	_	I-Premise
185	in	_	_	I-Premise
186	CES-D	_	_	I-Premise
187	over	_	_	I-Premise
188	the	_	_	I-Premise
189	first	_	_	I-Premise
190	year	_	_	I-Premise
191	on	_	_	I-Premise
192	survival	_	_	I-Premise
193	out	_	_	I-Premise
194	to	_	_	I-Premise
195	14	_	_	I-Premise
196	years	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.007	_	_	I-Premise
201	)	_	_	I-Premise
202	but	_	_	B-Premise
203	no	_	_	I-Premise
204	significant	_	_	I-Premise
205	interaction	_	_	I-Premise
206	between	_	_	I-Premise
207	treatment	_	_	I-Premise
208	condition	_	_	I-Premise
209	and	_	_	I-Premise
210	CES-D	_	_	I-Premise
211	change	_	_	I-Premise
212	on	_	_	I-Premise
213	survival	_	_	I-Premise
214	.	_	_	I-Premise

215	Neither	_	_	O
216	demographic	_	_	O
217	nor	_	_	O
218	medical	_	_	O
219	variables	_	_	O
220	explained	_	_	O
221	this	_	_	O
222	association	_	_	O
223	.	_	_	O

224	Decreasing	_	_	B-Claim
225	depression	_	_	I-Claim
226	symptoms	_	_	I-Claim
227	over	_	_	I-Claim
228	the	_	_	I-Claim
229	first	_	_	I-Claim
230	year	_	_	I-Claim
231	were	_	_	I-Claim
232	associated	_	_	I-Claim
233	with	_	_	I-Claim
234	longer	_	_	I-Claim
235	subsequent	_	_	I-Claim
236	survival	_	_	I-Claim
237	for	_	_	I-Claim
238	women	_	_	I-Claim
239	with	_	_	I-Claim
240	MBC	_	_	I-Claim
241	in	_	_	I-Claim
242	this	_	_	I-Claim
243	sample	_	_	I-Claim
244	.	_	_	I-Claim

245	Further	_	_	B-Claim
246	research	_	_	I-Claim
247	is	_	_	I-Claim
248	necessary	_	_	I-Claim
249	to	_	_	I-Claim
250	confirm	_	_	I-Claim
251	this	_	_	I-Claim
252	hypothesis	_	_	I-Claim
253	in	_	_	I-Claim
254	other	_	_	I-Claim
255	samples	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	causation	_	_	I-Claim
259	can	_	_	I-Claim
260	not	_	_	I-Claim
261	be	_	_	I-Claim
262	assumed	_	_	I-Claim
263	based	_	_	I-Claim
264	on	_	_	I-Claim
265	this	_	_	I-Claim
266	analysis	_	_	I-Claim
267	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	dietary	_	_	O
8	counseling	_	_	O
9	or	_	_	O
10	oral	_	_	O
11	supplements	_	_	O
12	on	_	_	O
13	outcome	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	cancer	_	_	O
18	,	_	_	O
19	specifically	_	_	O
20	,	_	_	O
21	nutritional	_	_	O
22	outcome	_	_	O
23	,	_	_	O
24	morbidity	_	_	O
25	,	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	,	_	_	O
34	during	_	_	O
35	and	_	_	O
36	3	_	_	O
37	months	_	_	O
38	after	_	_	O
39	radiotherapy	_	_	O
40	.	_	_	O

41	Seventy-five	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	head	_	_	O
45	and	_	_	O
46	neck	_	_	O
47	cancer	_	_	O
48	who	_	_	O
49	were	_	_	O
50	referred	_	_	O
51	for	_	_	O
52	radiotherapy	_	_	O
53	(	_	_	O
54	RT	_	_	O
55	)	_	_	O
56	were	_	_	O
57	randomized	_	_	O
58	to	_	_	O
59	the	_	_	O
60	following	_	_	O
61	groups	_	_	O
62	:	_	_	O
63	group	_	_	O
64	1	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	25	_	_	O
69	)	_	_	O
70	,	_	_	O
71	patients	_	_	O
72	who	_	_	O
73	received	_	_	O
74	dietary	_	_	O
75	counseling	_	_	O
76	with	_	_	O
77	regular	_	_	O
78	foods	_	_	O
79	;	_	_	O
80	group	_	_	O
81	2	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	25	_	_	O
86	)	_	_	O
87	,	_	_	O
88	patients	_	_	O
89	who	_	_	O
90	maintained	_	_	O
91	usual	_	_	O
92	diet	_	_	O
93	plus	_	_	O
94	supplements	_	_	O
95	;	_	_	O
96	and	_	_	O
97	group	_	_	O
98	3	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	25	_	_	O
103	)	_	_	O
104	,	_	_	O
105	patients	_	_	O
106	who	_	_	O
107	maintained	_	_	O
108	intake	_	_	O
109	ad	_	_	O
110	lib	_	_	O
111	.	_	_	O

112	Nutritional	_	_	O
113	intake	_	_	O
114	(	_	_	O
115	determined	_	_	O
116	by	_	_	O
117	diet	_	_	O
118	history	_	_	O
119	)	_	_	O
120	and	_	_	O
121	status	_	_	O
122	(	_	_	O
123	determined	_	_	O
124	by	_	_	O
125	Ottery	_	_	O
126	's	_	_	O
127	Subjective	_	_	O
128	Global	_	_	O
129	Assessment	_	_	O
130	)	_	_	O
131	,	_	_	O
132	and	_	_	O
133	QOL	_	_	O
134	(	_	_	O
135	determined	_	_	O
136	by	_	_	O
137	the	_	_	O
138	European	_	_	O
139	Organization	_	_	O
140	for	_	_	O
141	the	_	_	O
142	Research	_	_	O
143	and	_	_	O
144	Treatment	_	_	O
145	of	_	_	O
146	Cancer	_	_	O
147	Quality	_	_	O
148	of	_	_	O
149	Life	_	_	O
150	Questionnaire	_	_	O
151	version	_	_	O
152	3.0	_	_	O
153	[	_	_	O
154	EORTC	_	_	O
155	QLQ-C30	_	_	O
156	]	_	_	O
157	)	_	_	O
158	were	_	_	O
159	evaluated	_	_	O
160	at	_	_	O
161	baseline	_	_	O
162	,	_	_	O
163	at	_	_	O
164	the	_	_	O
165	end	_	_	O
166	of	_	_	O
167	RT	_	_	O
168	,	_	_	O
169	and	_	_	O
170	at	_	_	O
171	3	_	_	O
172	months	_	_	O
173	.	_	_	O

174	Energy	_	_	B-Premise
175	intake	_	_	I-Premise
176	after	_	_	I-Premise
177	RT	_	_	I-Premise
178	increased	_	_	I-Premise
179	in	_	_	I-Premise
180	both	_	_	I-Premise
181	groups	_	_	I-Premise
182	1	_	_	I-Premise
183	and	_	_	I-Premise
184	2	_	_	I-Premise
185	(	_	_	I-Premise
186	p	_	_	I-Premise
187	<	_	_	I-Premise
188	or	_	_	I-Premise
189	=	_	_	I-Premise
190	.05	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Protein	_	_	B-Premise
194	intake	_	_	I-Premise
195	also	_	_	I-Premise
196	increased	_	_	I-Premise
197	in	_	_	I-Premise
198	both	_	_	I-Premise
199	groups	_	_	I-Premise
200	1	_	_	I-Premise
201	and	_	_	I-Premise
202	2	_	_	I-Premise
203	(	_	_	I-Premise
204	p	_	_	I-Premise
205	<	_	_	I-Premise
206	or	_	_	I-Premise
207	=	_	_	I-Premise
208	.006	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Both	_	_	B-Premise
212	energy	_	_	I-Premise
213	and	_	_	I-Premise
214	protein	_	_	I-Premise
215	intake	_	_	I-Premise
216	decreased	_	_	I-Premise
217	significantly	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	3	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	<	_	_	I-Premise
224	.01	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	At	_	_	B-Premise
228	3	_	_	I-Premise
229	months	_	_	I-Premise
230	,	_	_	I-Premise
231	group	_	_	I-Premise
232	1	_	_	I-Premise
233	maintained	_	_	I-Premise
234	intakes	_	_	I-Premise
235	,	_	_	I-Premise
236	whereas	_	_	I-Premise
237	groups	_	_	I-Premise
238	2	_	_	I-Premise
239	and	_	_	I-Premise
240	3	_	_	I-Premise
241	returned	_	_	I-Premise
242	to	_	_	I-Premise
243	or	_	_	I-Premise
244	below	_	_	I-Premise
245	baseline	_	_	I-Premise
246	levels	_	_	I-Premise
247	.	_	_	I-Premise

248	After	_	_	B-Premise
249	RT	_	_	I-Premise
250	,	_	_	I-Premise
251	>	_	_	I-Premise
252	90	_	_	I-Premise
253	%	_	_	I-Premise
254	of	_	_	I-Premise
255	patients	_	_	I-Premise
256	experienced	_	_	I-Premise
257	RT	_	_	I-Premise
258	toxicity	_	_	I-Premise
259	;	_	_	I-Premise
260	this	_	_	B-Premise
261	was	_	_	I-Premise
262	not	_	_	I-Premise
263	significantly	_	_	I-Premise
264	different	_	_	I-Premise
265	between	_	_	I-Premise
266	groups	_	_	I-Premise
267	,	_	_	I-Premise
268	with	_	_	I-Premise
269	a	_	_	I-Premise
270	trend	_	_	I-Premise
271	for	_	_	I-Premise
272	reduced	_	_	I-Premise
273	symptomatology	_	_	I-Premise
274	in	_	_	I-Premise
275	group	_	_	I-Premise
276	1	_	_	I-Premise
277	versus	_	_	I-Premise
278	group	_	_	I-Premise
279	2/group	_	_	I-Premise
280	3	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	<	_	_	I-Premise
284	.07	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	At	_	_	B-Premise
288	3	_	_	I-Premise
289	months	_	_	I-Premise
290	,	_	_	I-Premise
291	the	_	_	I-Premise
292	reduction	_	_	I-Premise
293	of	_	_	I-Premise
294	incidence/severity	_	_	I-Premise
295	of	_	_	I-Premise
296	grade	_	_	I-Premise
297	1+2	_	_	I-Premise
298	anorexia	_	_	I-Premise
299	,	_	_	I-Premise
300	nausea/vomiting	_	_	I-Premise
301	,	_	_	I-Premise
302	xerostomia	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	dysgeusia	_	_	I-Premise
306	was	_	_	I-Premise
307	different	_	_	I-Premise
308	:	_	_	I-Premise
309	90	_	_	I-Premise
310	%	_	_	I-Premise
311	of	_	_	I-Premise
312	the	_	_	I-Premise
313	patients	_	_	I-Premise
314	improved	_	_	I-Premise
315	in	_	_	I-Premise
316	group	_	_	I-Premise
317	1	_	_	I-Premise
318	versus	_	_	I-Premise
319	67	_	_	I-Premise
320	%	_	_	I-Premise
321	in	_	_	I-Premise
322	group	_	_	I-Premise
323	2	_	_	I-Premise
324	versus	_	_	I-Premise
325	51	_	_	I-Premise
326	%	_	_	I-Premise
327	in	_	_	I-Premise
328	group	_	_	I-Premise
329	3	_	_	I-Premise
330	(	_	_	I-Premise
331	p	_	_	I-Premise
332	<	_	_	I-Premise
333	.0001	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	After	_	_	B-Premise
337	RT	_	_	I-Premise
338	,	_	_	I-Premise
339	QOL	_	_	I-Premise
340	function	_	_	I-Premise
341	scores	_	_	I-Premise
342	improved	_	_	I-Premise
343	(	_	_	I-Premise
344	p	_	_	I-Premise
345	<	_	_	I-Premise
346	.003	_	_	I-Premise
347	)	_	_	I-Premise
348	proportionally	_	_	I-Premise
349	with	_	_	I-Premise
350	improved	_	_	I-Premise
351	nutritional	_	_	I-Premise
352	intake	_	_	I-Premise
353	and	_	_	I-Premise
354	status	_	_	I-Premise
355	in	_	_	I-Premise
356	group	_	_	I-Premise
357	1/group	_	_	I-Premise
358	2	_	_	I-Premise
359	(	_	_	I-Premise
360	p	_	_	I-Premise
361	<	_	_	I-Premise
362	.05	_	_	I-Premise
363	)	_	_	I-Premise
364	and	_	_	I-Premise
365	worsened	_	_	I-Premise
366	in	_	_	I-Premise
367	group	_	_	I-Premise
368	3	_	_	I-Premise
369	(	_	_	I-Premise
370	p	_	_	I-Premise
371	<	_	_	I-Premise
372	.05	_	_	I-Premise
373	)	_	_	I-Premise
374	;	_	_	I-Premise
375	at	_	_	B-Premise
376	3	_	_	I-Premise
377	months	_	_	I-Premise
378	,	_	_	I-Premise
379	patients	_	_	I-Premise
380	in	_	_	I-Premise
381	group	_	_	I-Premise
382	1	_	_	I-Premise
383	maintained	_	_	I-Premise
384	or	_	_	I-Premise
385	improved	_	_	I-Premise
386	overall	_	_	I-Premise
387	QOL	_	_	I-Premise
388	,	_	_	I-Premise
389	whereas	_	_	I-Premise
390	patients	_	_	I-Premise
391	in	_	_	I-Premise
392	groups	_	_	I-Premise
393	2	_	_	I-Premise
394	and	_	_	I-Premise
395	3	_	_	I-Premise
396	maintained	_	_	I-Premise
397	or	_	_	I-Premise
398	worsened	_	_	I-Premise
399	overall	_	_	I-Premise
400	QOL	_	_	I-Premise
401	.	_	_	I-Premise

402	During	_	_	B-Claim
403	RT	_	_	I-Claim
404	,	_	_	I-Claim
405	nutritional	_	_	I-Claim
406	interventions	_	_	I-Claim
407	positively	_	_	I-Claim
408	influenced	_	_	I-Claim
409	outcomes	_	_	I-Claim
410	,	_	_	I-Claim
411	and	_	_	I-Claim
412	counseling	_	_	I-Claim
413	was	_	_	I-Claim
414	of	_	_	I-Claim
415	similar/higher	_	_	I-Claim
416	benefit	_	_	I-Claim
417	;	_	_	I-Claim
418	in	_	_	B-Claim
419	the	_	_	I-Claim
420	medium	_	_	I-Claim
421	term	_	_	I-Claim
422	,	_	_	I-Claim
423	only	_	_	I-Claim
424	counseling	_	_	I-Claim
425	exerted	_	_	I-Claim
426	a	_	_	I-Claim
427	significant	_	_	I-Claim
428	impact	_	_	I-Claim
429	on	_	_	I-Claim
430	patient	_	_	I-Claim
431	outcomes	_	_	I-Claim
432	.	_	_	I-Claim


0	Pemetrexed	_	_	O
1	maintenance	_	_	O
2	therapy	_	_	O
3	significantly	_	_	O
4	improved	_	_	O
5	overall	_	_	O
6	survival	_	_	O
7	and	_	_	O
8	progression-free	_	_	O
9	survival	_	_	O
10	compared	_	_	O
11	with	_	_	O
12	placebo	_	_	O
13	,	_	_	O
14	and	_	_	O
15	had	_	_	O
16	a	_	_	O
17	good	_	_	O
18	safety	_	_	O
19	profile	_	_	O
20	in	_	_	O
21	a	_	_	O
22	phase	_	_	O
23	3	_	_	O
24	placebo-controlled	_	_	O
25	study	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	non-small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	(	_	_	O
34	NSCLC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	Results	_	_	O
38	for	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	,	_	_	O
43	symptom	_	_	O
44	palliation	_	_	O
45	,	_	_	O
46	and	_	_	O
47	tolerability	_	_	O
48	are	_	_	O
49	presented	_	_	O
50	here	_	_	O
51	.	_	_	O

52	After	_	_	O
53	four	_	_	O
54	cycles	_	_	O
55	of	_	_	O
56	platinum-based	_	_	O
57	induction	_	_	O
58	therapy	_	_	O
59	,	_	_	O
60	663	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	stage	_	_	O
64	IIIB	_	_	O
65	or	_	_	O
66	stage	_	_	O
67	IV	_	_	O
68	NSCLC	_	_	O
69	and	_	_	O
70	Eastern	_	_	O
71	Cooperative	_	_	O
72	Oncology	_	_	O
73	Group	_	_	O
74	performance	_	_	O
75	status	_	_	O
76	of	_	_	O
77	0	_	_	O
78	or	_	_	O
79	1	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	(	_	_	O
84	in	_	_	O
85	a	_	_	O
86	2:1	_	_	O
87	ratio	_	_	O
88	)	_	_	O
89	from	_	_	O
90	March	_	_	O
91	15	_	_	O
92	,	_	_	O
93	2005	_	_	O
94	,	_	_	O
95	to	_	_	O
96	July	_	_	O
97	20	_	_	O
98	,	_	_	O
99	2007	_	_	O
100	,	_	_	O
101	using	_	_	O
102	the	_	_	O
103	Pocock	_	_	O
104	and	_	_	O
105	Simon	_	_	O
106	minimisation	_	_	O
107	method	_	_	O
108	to	_	_	O
109	receive	_	_	O
110	pemetrexed	_	_	O
111	(	_	_	O
112	500	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	every	_	_	O
118	21	_	_	O
119	days	_	_	O
120	;	_	_	O
121	n=441	_	_	O
122	)	_	_	O
123	or	_	_	O
124	placebo	_	_	O
125	(	_	_	O
126	n=222	_	_	O
127	)	_	_	O
128	plus	_	_	O
129	best	_	_	O
130	supportive	_	_	O
131	care	_	_	O
132	until	_	_	O
133	disease	_	_	O
134	progression	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	efficacy	_	_	O
139	data	_	_	O
140	have	_	_	O
141	been	_	_	O
142	reported	_	_	O
143	previously	_	_	O
144	.	_	_	O

145	Patients	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	Lung	_	_	O
149	Cancer	_	_	O
150	Symptom	_	_	O
151	Scale	_	_	O
152	(	_	_	O
153	LCSS	_	_	O
154	)	_	_	O
155	at	_	_	O
156	baseline	_	_	O
157	,	_	_	O
158	after	_	_	O
159	each	_	_	O
160	cycle	_	_	O
161	,	_	_	O
162	and	_	_	O
163	post-discontinuation	_	_	O
164	.	_	_	O

165	Worsening	_	_	O
166	of	_	_	O
167	symptoms	_	_	O
168	was	_	_	O
169	defined	_	_	O
170	as	_	_	O
171	an	_	_	O
172	increase	_	_	O
173	of	_	_	O
174	15	_	_	O
175	mm	_	_	O
176	or	_	_	O
177	more	_	_	O
178	from	_	_	O
179	baseline	_	_	O
180	on	_	_	O
181	a	_	_	O
182	100	_	_	O
183	mm	_	_	O
184	scale	_	_	O
185	for	_	_	O
186	each	_	_	O
187	LCSS	_	_	O
188	item	_	_	O
189	.	_	_	O

190	The	_	_	O
191	primary	_	_	O
192	outcome	_	_	O
193	for	_	_	O
194	these	_	_	O
195	quality-of-life	_	_	O
196	analyses	_	_	O
197	was	_	_	O
198	time	_	_	O
199	to	_	_	O
200	worsening	_	_	O
201	of	_	_	O
202	symptoms	_	_	O
203	,	_	_	O
204	analysed	_	_	O
205	for	_	_	O
206	all	_	_	O
207	randomised	_	_	O
208	patients	_	_	O
209	.	_	_	O

210	Baseline	_	_	O
211	characteristics	_	_	O
212	,	_	_	O
213	including	_	_	O
214	LCSS	_	_	O
215	scores	_	_	O
216	,	_	_	O
217	were	_	_	O
218	well	_	_	O
219	balanced	_	_	O
220	between	_	_	O
221	groups	_	_	O
222	.	_	_	O

223	Baseline	_	_	O
224	LCSS	_	_	O
225	scores	_	_	O
226	were	_	_	O
227	low	_	_	O
228	,	_	_	O
229	indicating	_	_	O
230	low	_	_	O
231	symptom	_	_	O
232	burden	_	_	O
233	for	_	_	O
234	patients	_	_	O
235	without	_	_	O
236	disease	_	_	O
237	progression	_	_	O
238	after	_	_	O
239	completion	_	_	O
240	of	_	_	O
241	first-line	_	_	O
242	treatment	_	_	O
243	.	_	_	O

244	Longer	_	_	B-Premise
245	time	_	_	I-Premise
246	to	_	_	I-Premise
247	worsening	_	_	I-Premise
248	was	_	_	I-Premise
249	recorded	_	_	I-Premise
250	for	_	_	I-Premise
251	pain	_	_	I-Premise
252	(	_	_	I-Premise
253	hazard	_	_	I-Premise
254	ratio	_	_	I-Premise
255	[	_	_	I-Premise
256	HR	_	_	I-Premise
257	]	_	_	I-Premise
258	0Â·76	_	_	I-Premise
259	,	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	0Â·59-0Â·99	_	_	I-Premise
264	;	_	_	I-Premise
265	p=0Â·041	_	_	I-Premise
266	)	_	_	I-Premise
267	and	_	_	I-Premise
268	haemoptysis	_	_	I-Premise
269	(	_	_	I-Premise
270	HR	_	_	I-Premise
271	0Â·58	_	_	I-Premise
272	,	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	0Â·34-0Â·97	_	_	I-Premise
277	;	_	_	I-Premise
278	p=0Â·038	_	_	I-Premise
279	)	_	_	I-Premise
280	with	_	_	I-Premise
281	pemetrexed	_	_	I-Premise
282	than	_	_	I-Premise
283	with	_	_	I-Premise
284	placebo	_	_	I-Premise
285	;	_	_	I-Premise
286	no	_	_	B-Premise
287	other	_	_	I-Premise
288	significant	_	_	I-Premise
289	differences	_	_	I-Premise
290	in	_	_	I-Premise
291	analyses	_	_	I-Premise
292	of	_	_	I-Premise
293	time	_	_	I-Premise
294	to	_	_	I-Premise
295	worsening	_	_	I-Premise
296	were	_	_	I-Premise
297	noted	_	_	I-Premise
298	.	_	_	I-Premise

299	Additional	_	_	B-Premise
300	longitudinal	_	_	I-Premise
301	analyses	_	_	I-Premise
302	showed	_	_	I-Premise
303	a	_	_	I-Premise
304	greater	_	_	I-Premise
305	increase	_	_	I-Premise
306	in	_	_	I-Premise
307	loss	_	_	I-Premise
308	of	_	_	I-Premise
309	appetite	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	pemetrexed	_	_	I-Premise
313	group	_	_	I-Premise
314	than	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	placebo	_	_	I-Premise
318	group	_	_	I-Premise
319	(	_	_	I-Premise
320	4Â·3	_	_	I-Premise
321	mm	_	_	I-Premise
322	vs	_	_	I-Premise
323	0Â·2	_	_	I-Premise
324	mm	_	_	I-Premise
325	;	_	_	I-Premise
326	p=0Â·028	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	Rates	_	_	B-Premise
330	of	_	_	I-Premise
331	resource	_	_	I-Premise
332	use	_	_	I-Premise
333	were	_	_	I-Premise
334	statistically	_	_	I-Premise
335	higher	_	_	I-Premise
336	for	_	_	I-Premise
337	pemetrexed	_	_	I-Premise
338	than	_	_	I-Premise
339	for	_	_	I-Premise
340	placebo	_	_	I-Premise
341	:	_	_	I-Premise
342	admissions	_	_	I-Premise
343	to	_	_	I-Premise
344	hospital	_	_	I-Premise
345	for	_	_	I-Premise
346	drug-related	_	_	I-Premise
347	adverse	_	_	I-Premise
348	events	_	_	I-Premise
349	(	_	_	I-Premise
350	19	_	_	I-Premise
351	[	_	_	I-Premise
352	4	_	_	I-Premise
353	%	_	_	I-Premise
354	]	_	_	I-Premise
355	vs	_	_	I-Premise
356	none	_	_	I-Premise
357	;	_	_	I-Premise
358	p=0Â·001	_	_	I-Premise
359	)	_	_	I-Premise
360	,	_	_	I-Premise
361	transfusions	_	_	I-Premise
362	(	_	_	I-Premise
363	42	_	_	I-Premise
364	[	_	_	I-Premise
365	10	_	_	I-Premise
366	%	_	_	I-Premise
367	]	_	_	I-Premise
368	vs	_	_	I-Premise
369	seven	_	_	I-Premise
370	[	_	_	I-Premise
371	3	_	_	I-Premise
372	%	_	_	I-Premise
373	]	_	_	I-Premise
374	;	_	_	I-Premise
375	p=0Â·003	_	_	I-Premise
376	)	_	_	I-Premise
377	,	_	_	I-Premise
378	and	_	_	I-Premise
379	erythropoiesis-stimulating	_	_	I-Premise
380	agents	_	_	I-Premise
381	(	_	_	I-Premise
382	26	_	_	I-Premise
383	[	_	_	I-Premise
384	6	_	_	I-Premise
385	%	_	_	I-Premise
386	]	_	_	I-Premise
387	vs	_	_	I-Premise
388	four	_	_	I-Premise
389	[	_	_	I-Premise
390	2	_	_	I-Premise
391	%	_	_	I-Premise
392	]	_	_	I-Premise
393	;	_	_	I-Premise
394	p=0Â·017	_	_	I-Premise
395	)	_	_	I-Premise
396	.	_	_	I-Premise

397	Quality	_	_	B-Claim
398	of	_	_	I-Claim
399	life	_	_	I-Claim
400	during	_	_	I-Claim
401	maintenance	_	_	I-Claim
402	therapy	_	_	I-Claim
403	with	_	_	I-Claim
404	pemetrexed	_	_	I-Claim
405	is	_	_	I-Claim
406	similar	_	_	I-Claim
407	to	_	_	I-Claim
408	placebo	_	_	I-Claim
409	,	_	_	I-Claim
410	except	_	_	B-Claim
411	for	_	_	I-Claim
412	a	_	_	I-Claim
413	small	_	_	I-Claim
414	increase	_	_	I-Claim
415	in	_	_	I-Claim
416	loss	_	_	I-Claim
417	of	_	_	I-Claim
418	appetite	_	_	I-Claim
419	,	_	_	I-Claim
420	and	_	_	I-Claim
421	significantly	_	_	I-Claim
422	delayed	_	_	I-Claim
423	worsening	_	_	I-Claim
424	of	_	_	I-Claim
425	pain	_	_	I-Claim
426	and	_	_	I-Claim
427	haemoptysis	_	_	I-Claim
428	.	_	_	I-Claim

429	In	_	_	O
430	view	_	_	O
431	of	_	_	O
432	the	_	_	O
433	improvements	_	_	O
434	in	_	_	O
435	overall	_	_	O
436	and	_	_	O
437	progression-free	_	_	O
438	survival	_	_	O
439	noted	_	_	O
440	with	_	_	O
441	pemetrexed	_	_	O
442	maintenance	_	_	O
443	therapy	_	_	O
444	,	_	_	O
445	such	_	_	B-Claim
446	treatment	_	_	I-Claim
447	is	_	_	I-Claim
448	an	_	_	I-Claim
449	option	_	_	I-Claim
450	for	_	_	I-Claim
451	patients	_	_	I-Claim
452	with	_	_	I-Claim
453	advanced	_	_	I-Claim
454	non-squamous	_	_	I-Claim
455	NSCLC	_	_	I-Claim
456	who	_	_	I-Claim
457	have	_	_	I-Claim
458	not	_	_	I-Claim
459	progressed	_	_	I-Claim
460	after	_	_	I-Claim
461	platinum-based	_	_	I-Claim
462	induction	_	_	I-Claim
463	therapy	_	_	I-Claim
464	.	_	_	I-Claim


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	high-dose	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	(	_	_	I-Claim
6	HDCT	_	_	I-Claim
7	)	_	_	I-Claim
8	in	_	_	I-Claim
9	metastatic	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	remains	_	_	I-Claim
13	controversial	_	_	I-Claim
14	.	_	_	I-Claim

15	Trials	_	_	B-Claim
16	with	_	_	I-Claim
17	late	_	_	I-Claim
18	intensification	_	_	I-Claim
19	HDCT	_	_	I-Claim
20	have	_	_	I-Claim
21	failed	_	_	I-Claim
22	to	_	_	I-Claim
23	show	_	_	I-Claim
24	an	_	_	I-Claim
25	advantage	_	_	I-Claim
26	in	_	_	I-Claim
27	overall	_	_	I-Claim
28	survival	_	_	I-Claim
29	.	_	_	I-Claim

30	This	_	_	O
31	study	_	_	O
32	was	_	_	O
33	initiated	_	_	O
34	to	_	_	O
35	compare	_	_	O
36	up-front	_	_	O
37	tandem	_	_	O
38	HDCT	_	_	O
39	and	_	_	O
40	standard	_	_	O
41	combination	_	_	O
42	therapy	_	_	O
43	in	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	metastatic	_	_	O
47	breast	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	without	_	_	O
52	prior	_	_	O
53	chemotherapy	_	_	O
54	for	_	_	O
55	metastatic	_	_	O
56	disease	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	standard	_	_	O
62	combination	_	_	O
63	therapy	_	_	O
64	with	_	_	O
65	doxorubicin	_	_	O
66	and	_	_	O
67	paclitaxel	_	_	O
68	(	_	_	O
69	AT	_	_	O
70	)	_	_	O
71	or	_	_	O
72	double	_	_	O
73	HDCT	_	_	O
74	with	_	_	O
75	cyclophosphamide	_	_	O
76	,	_	_	O
77	mitoxantrone	_	_	O
78	,	_	_	O
79	and	_	_	O
80	etoposide	_	_	O
81	followed	_	_	O
82	by	_	_	O
83	peripheral-blood	_	_	O
84	stem-cell	_	_	O
85	transplantation	_	_	O
86	.	_	_	O

87	HDCT	_	_	O
88	was	_	_	O
89	repeated	_	_	O
90	after	_	_	O
91	6	_	_	O
92	weeks	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	stratified	_	_	O
97	by	_	_	O
98	menopausal	_	_	O
99	and	_	_	O
100	hormone-receptor	_	_	O
101	status	_	_	O
102	.	_	_	O

103	The	_	_	O
104	primary	_	_	O
105	objective	_	_	O
106	was	_	_	O
107	to	_	_	O
108	compare	_	_	O
109	complete	_	_	O
110	response	_	_	O
111	(	_	_	O
112	CR	_	_	O
113	)	_	_	O
114	rates	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	93	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	enrolled	_	_	O
123	onto	_	_	O
124	the	_	_	O
125	trial	_	_	O
126	.	_	_	O

127	Intent-to-treat	_	_	B-Premise
128	CR	_	_	I-Premise
129	rates	_	_	I-Premise
130	for	_	_	I-Premise
131	patients	_	_	I-Premise
132	randomized	_	_	I-Premise
133	to	_	_	I-Premise
134	HDCT	_	_	I-Premise
135	and	_	_	I-Premise
136	AT	_	_	I-Premise
137	were	_	_	I-Premise
138	12.5	_	_	I-Premise
139	%	_	_	I-Premise
140	and	_	_	I-Premise
141	11.1	_	_	I-Premise
142	%	_	_	I-Premise
143	,	_	_	I-Premise
144	respectively	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	=	_	_	I-Premise
148	.84	_	_	I-Premise
149	)	_	_	I-Premise
150	.	_	_	I-Premise

151	Objective	_	_	B-Premise
152	response	_	_	I-Premise
153	rates	_	_	I-Premise
154	were	_	_	I-Premise
155	66.7	_	_	I-Premise
156	%	_	_	I-Premise
157	for	_	_	I-Premise
158	patients	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	high-dose	_	_	I-Premise
162	group	_	_	I-Premise
163	and	_	_	I-Premise
164	64.4	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	AT	_	_	I-Premise
171	arm	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.82	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	In	_	_	B-Premise
179	an	_	_	I-Premise
180	intent-to-treat	_	_	I-Premise
181	analysis	_	_	I-Premise
182	,	_	_	I-Premise
183	there	_	_	I-Premise
184	were	_	_	I-Premise
185	no	_	_	I-Premise
186	significant	_	_	I-Premise
187	differences	_	_	I-Premise
188	between	_	_	I-Premise
189	the	_	_	I-Premise
190	two	_	_	I-Premise
191	treatments	_	_	I-Premise
192	in	_	_	I-Premise
193	median	_	_	I-Premise
194	time	_	_	I-Premise
195	to	_	_	I-Premise
196	progression	_	_	I-Premise
197	(	_	_	I-Premise
198	HDCT	_	_	I-Premise
199	,	_	_	I-Premise
200	11.1	_	_	I-Premise
201	months	_	_	I-Premise
202	;	_	_	I-Premise
203	AT	_	_	I-Premise
204	,	_	_	I-Premise
205	10.6	_	_	I-Premise
206	months	_	_	I-Premise
207	;	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.67	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	duration	_	_	I-Premise
214	of	_	_	I-Premise
215	response	_	_	I-Premise
216	(	_	_	I-Premise
217	HDCT	_	_	I-Premise
218	,	_	_	I-Premise
219	13.9	_	_	I-Premise
220	months	_	_	I-Premise
221	;	_	_	I-Premise
222	AT	_	_	I-Premise
223	,	_	_	I-Premise
224	14.3	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.98	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	overall	_	_	I-Premise
234	survival	_	_	I-Premise
235	(	_	_	I-Premise
236	HDCT	_	_	I-Premise
237	,	_	_	I-Premise
238	26.9	_	_	I-Premise
239	months	_	_	I-Premise
240	;	_	_	I-Premise
241	AT	_	_	I-Premise
242	,	_	_	I-Premise
243	23.4	_	_	I-Premise
244	months	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.60	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	HDCT	_	_	B-Premise
252	was	_	_	I-Premise
253	associated	_	_	I-Premise
254	with	_	_	I-Premise
255	significantly	_	_	I-Premise
256	more	_	_	I-Premise
257	myelosuppression	_	_	I-Premise
258	,	_	_	I-Premise
259	infection	_	_	I-Premise
260	,	_	_	I-Premise
261	diarrhea	_	_	I-Premise
262	,	_	_	I-Premise
263	stomatitis	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	nausea	_	_	I-Premise
267	and	_	_	I-Premise
268	vomiting	_	_	I-Premise
269	,	_	_	I-Premise
270	whereas	_	_	I-Premise
271	patients	_	_	I-Premise
272	treated	_	_	I-Premise
273	with	_	_	I-Premise
274	AT	_	_	I-Premise
275	developed	_	_	I-Premise
276	more	_	_	I-Premise
277	neurotoxicity	_	_	I-Premise
278	.	_	_	I-Premise

279	This	_	_	B-Claim
280	trial	_	_	I-Claim
281	failed	_	_	I-Claim
282	to	_	_	I-Claim
283	show	_	_	I-Claim
284	a	_	_	I-Claim
285	benefit	_	_	I-Claim
286	for	_	_	I-Claim
287	up-front	_	_	I-Claim
288	tandem	_	_	I-Claim
289	HDCT	_	_	I-Claim
290	compared	_	_	I-Claim
291	with	_	_	I-Claim
292	standard	_	_	I-Claim
293	combination	_	_	I-Claim
294	therapy	_	_	I-Claim
295	.	_	_	I-Claim

296	HDCT	_	_	B-Claim
297	was	_	_	I-Claim
298	associated	_	_	I-Claim
299	with	_	_	I-Claim
300	more	_	_	I-Claim
301	acute	_	_	I-Claim
302	adverse	_	_	I-Claim
303	effects	_	_	I-Claim
304	.	_	_	I-Claim


0	Standard	_	_	O
1	guidelines	_	_	O
2	for	_	_	O
3	cancer	_	_	O
4	pain	_	_	O
5	treatment	_	_	O
6	routinely	_	_	O
7	recommend	_	_	O
8	training	_	_	O
9	patients	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	barriers	_	_	O
13	to	_	_	O
14	pain	_	_	O
15	relief	_	_	O
16	,	_	_	O
17	use	_	_	O
18	medications	_	_	O
19	appropriately	_	_	O
20	,	_	_	O
21	and	_	_	O
22	communicate	_	_	O
23	their	_	_	O
24	pain-related	_	_	O
25	needs	_	_	O
26	.	_	_	O

27	Methods	_	_	B-Claim
28	are	_	_	I-Claim
29	needed	_	_	I-Claim
30	to	_	_	I-Claim
31	reduce	_	_	I-Claim
32	professional	_	_	I-Claim
33	time	_	_	I-Claim
34	required	_	_	I-Claim
35	while	_	_	I-Claim
36	achieving	_	_	I-Claim
37	sustained	_	_	I-Claim
38	intervention	_	_	I-Claim
39	effectiveness	_	_	I-Claim
40	.	_	_	I-Claim

41	In	_	_	O
42	a	_	_	O
43	multisite	_	_	O
44	,	_	_	O
45	randomized	_	_	O
46	controlled	_	_	O
47	trial	_	_	O
48	,	_	_	O
49	this	_	_	O
50	study	_	_	O
51	tested	_	_	O
52	a	_	_	O
53	pain	_	_	O
54	training	_	_	O
55	method	_	_	O
56	versus	_	_	O
57	a	_	_	O
58	nutrition	_	_	O
59	control	_	_	O
60	.	_	_	O

61	At	_	_	O
62	six	_	_	O
63	oncology	_	_	O
64	clinics	_	_	O
65	,	_	_	O
66	physicians	_	_	O
67	(	_	_	O
68	N=22	_	_	O
69	)	_	_	O
70	and	_	_	O
71	nurses	_	_	O
72	(	_	_	O
73	N=23	_	_	O
74	)	_	_	O
75	enrolled	_	_	O
76	patients	_	_	O
77	(	_	_	O
78	N=93	_	_	O
79	)	_	_	O
80	who	_	_	O
81	were	_	_	O
82	over	_	_	O
83	18	_	_	O
84	years	_	_	O
85	of	_	_	O
86	age	_	_	O
87	,	_	_	O
88	with	_	_	O
89	cancer	_	_	O
90	diagnoses	_	_	O
91	,	_	_	O
92	pain	_	_	O
93	,	_	_	O
94	and	_	_	O
95	a	_	_	O
96	life	_	_	O
97	expectancy	_	_	O
98	of	_	_	O
99	at	_	_	O
100	least	_	_	O
101	6	_	_	O
102	months	_	_	O
103	.	_	_	O

104	Pain	_	_	O
105	training	_	_	O
106	and	_	_	O
107	control	_	_	O
108	interventions	_	_	O
109	were	_	_	O
110	matched	_	_	O
111	for	_	_	O
112	materials	_	_	O
113	and	_	_	O
114	method	_	_	O
115	.	_	_	O

116	Patients	_	_	O
117	watched	_	_	O
118	a	_	_	O
119	video	_	_	O
120	followed	_	_	O
121	by	_	_	O
122	about	_	_	O
123	20	_	_	O
124	min	_	_	O
125	of	_	_	O
126	manual-standardized	_	_	O
127	training	_	_	O
128	with	_	_	O
129	an	_	_	O
130	oncology	_	_	O
131	nurse	_	_	O
132	focused	_	_	O
133	on	_	_	O
134	reviewing	_	_	O
135	the	_	_	O
136	printed	_	_	O
137	material	_	_	O
138	and	_	_	O
139	adapted	_	_	O
140	to	_	_	O
141	individual	_	_	O
142	concerns	_	_	O
143	of	_	_	O
144	patients	_	_	O
145	.	_	_	O

146	A	_	_	O
147	follow-up	_	_	O
148	phone	_	_	O
149	call	_	_	O
150	after	_	_	O
151	72	_	_	O
152	h	_	_	O
153	addressed	_	_	O
154	individualized	_	_	O
155	treatment	_	_	O
156	content	_	_	O
157	and	_	_	O
158	pain	_	_	O
159	communication	_	_	O
160	.	_	_	O

161	Assessments	_	_	O
162	at	_	_	O
163	baseline	_	_	O
164	,	_	_	O
165	one	_	_	O
166	,	_	_	O
167	three	_	_	O
168	,	_	_	O
169	and	_	_	O
170	6	_	_	O
171	months	_	_	O
172	included	_	_	O
173	barriers	_	_	O
174	,	_	_	O
175	the	_	_	O
176	Brief	_	_	O
177	Pain	_	_	O
178	Inventory	_	_	O
179	,	_	_	O
180	opioid	_	_	O
181	use	_	_	O
182	,	_	_	O
183	and	_	_	O
184	physician	_	_	O
185	and	_	_	O
186	nurse	_	_	O
187	ratings	_	_	O
188	of	_	_	O
189	their	_	_	O
190	patients	_	_	O
191	'	_	_	O
192	pain	_	_	O
193	.	_	_	O

194	Trained	_	_	B-Premise
195	versus	_	_	I-Premise
196	control	_	_	I-Premise
197	patients	_	_	I-Premise
198	reported	_	_	I-Premise
199	reduced	_	_	I-Premise
200	barriers	_	_	I-Premise
201	to	_	_	I-Premise
202	pain	_	_	I-Premise
203	relief	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	.001	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	lower	_	_	I-Premise
211	usual	_	_	I-Premise
212	pain	_	_	I-Premise
213	(	_	_	I-Premise
214	P=.03	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	greater	_	_	I-Premise
219	opioid	_	_	I-Premise
220	use	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	No	_	_	B-Premise
228	pain	_	_	I-Premise
229	training	_	_	I-Premise
230	patients	_	_	I-Premise
231	reported	_	_	I-Premise
232	severe	_	_	I-Premise
233	pain	_	_	I-Premise
234	(	_	_	I-Premise
235	>	_	_	I-Premise
236	6	_	_	I-Premise
237	on	_	_	I-Premise
238	a	_	_	I-Premise
239	0-10	_	_	I-Premise
240	scale	_	_	I-Premise
241	)	_	_	I-Premise
242	at	_	_	I-Premise
243	1-month	_	_	I-Premise
244	outcomes	_	_	I-Premise
245	(	_	_	I-Premise
246	P=.03	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Physician	_	_	O
250	and	_	_	O
251	nurse	_	_	O
252	ratings	_	_	O
253	were	_	_	O
254	closer	_	_	O
255	to	_	_	O
256	patients	_	_	O
257	'	_	_	O
258	ratings	_	_	O
259	of	_	_	O
260	pain	_	_	O
261	for	_	_	O
262	trained	_	_	O
263	versus	_	_	O
264	nutrition	_	_	O
265	groups	_	_	O
266	(	_	_	O
267	P=.04	_	_	O
268	and	_	_	O
269	<	_	_	O
270	.001	_	_	O
271	,	_	_	O
272	respectively	_	_	O
273	)	_	_	O
274	.	_	_	O

275	Training	_	_	O
276	efficacy	_	_	O
277	was	_	_	O
278	not	_	_	O
279	modified	_	_	O
280	by	_	_	O
281	patient	_	_	O
282	characteristics	_	_	O
283	.	_	_	O

284	Using	_	_	B-Claim
285	video	_	_	I-Claim
286	and	_	_	I-Claim
287	print	_	_	I-Claim
288	materials	_	_	I-Claim
289	,	_	_	I-Claim
290	with	_	_	I-Claim
291	brief	_	_	I-Claim
292	individualized	_	_	I-Claim
293	training	_	_	I-Claim
294	,	_	_	I-Claim
295	effectively	_	_	I-Claim
296	improved	_	_	I-Claim
297	pain	_	_	I-Claim
298	management	_	_	I-Claim
299	over	_	_	I-Claim
300	time	_	_	I-Claim
301	for	_	_	I-Claim
302	cancer	_	_	I-Claim
303	patients	_	_	I-Claim
304	of	_	_	I-Claim
305	varying	_	_	I-Claim
306	diagnostic	_	_	I-Claim
307	and	_	_	I-Claim
308	demographic	_	_	I-Claim
309	groups	_	_	I-Claim
310	.	_	_	I-Claim


0	Sexual	_	_	O
1	dysfunction	_	_	O
2	represents	_	_	O
3	a	_	_	O
4	complex	_	_	O
5	and	_	_	O
6	multifactorial	_	_	O
7	construct	_	_	O
8	that	_	_	O
9	can	_	_	O
10	affect	_	_	O
11	both	_	_	O
12	men	_	_	O
13	and	_	_	O
14	women	_	_	O
15	and	_	_	O
16	has	_	_	O
17	been	_	_	O
18	noted	_	_	O
19	to	_	_	O
20	often	_	_	O
21	deteriorate	_	_	O
22	significantly	_	_	O
23	after	_	_	O
24	treatment	_	_	O
25	for	_	_	O
26	rectal	_	_	O
27	and	_	_	O
28	anal	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	Despite	_	_	O
32	this	_	_	O
33	,	_	_	O
34	it	_	_	O
35	remains	_	_	O
36	an	_	_	O
37	understudied	_	_	O
38	,	_	_	O
39	underreported	_	_	O
40	,	_	_	O
41	and	_	_	O
42	undertreated	_	_	O
43	issue	_	_	O
44	in	_	_	O
45	the	_	_	O
46	field	_	_	O
47	of	_	_	O
48	cancer	_	_	O
49	survivorship	_	_	O
50	.	_	_	O

51	This	_	_	O
52	study	_	_	O
53	examined	_	_	O
54	the	_	_	O
55	characteristics	_	_	O
56	of	_	_	O
57	women	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	an	_	_	O
61	intervention	_	_	O
62	trial	_	_	O
63	to	_	_	O
64	treat	_	_	O
65	sexual	_	_	O
66	dysfunction	_	_	O
67	,	_	_	O
68	and	_	_	O
69	explored	_	_	O
70	the	_	_	O
71	relationship	_	_	O
72	between	_	_	O
73	sexual	_	_	O
74	functioning	_	_	O
75	and	_	_	O
76	psychological	_	_	O
77	well-being	_	_	O
78	.	_	_	O

79	There	_	_	O
80	were	_	_	O
81	70	_	_	O
82	female	_	_	O
83	posttreatment	_	_	O
84	anal	_	_	O
85	or	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	survivors	_	_	O
89	assessed	_	_	O
90	as	_	_	O
91	part	_	_	O
92	of	_	_	O
93	the	_	_	O
94	current	_	_	O
95	study	_	_	O
96	.	_	_	O

97	Participants	_	_	O
98	were	_	_	O
99	enrolled	_	_	O
100	in	_	_	O
101	a	_	_	O
102	randomized	_	_	O
103	intervention	_	_	O
104	trial	_	_	O
105	to	_	_	O
106	treat	_	_	O
107	sexual	_	_	O
108	dysfunction	_	_	O
109	and	_	_	O
110	completed	_	_	O
111	outcome	_	_	O
112	measures	_	_	O
113	prior	_	_	O
114	to	_	_	O
115	randomization	_	_	O
116	.	_	_	O

117	The	_	_	O
118	main	_	_	O
119	outcome	_	_	O
120	measures	_	_	O
121	are	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	(	_	_	O
126	QOL	_	_	O
127	)	_	_	O
128	(	_	_	O
129	European	_	_	O
130	Organization	_	_	O
131	for	_	_	O
132	Research	_	_	O
133	and	_	_	O
134	Treatment	_	_	O
135	of	_	_	O
136	Cancer	_	_	O
137	Core	_	_	O
138	Quality	_	_	O
139	of	_	_	O
140	Life	_	_	O
141	Questionnaire	_	_	O
142	[	_	_	O
143	EORTC-QLQ-C30	_	_	O
144	]	_	_	O
145	and	_	_	O
146	Colorectal	_	_	O
147	Cancer-Specific	_	_	O
148	Module	_	_	O
149	[	_	_	O
150	QLQ-CR38	_	_	O
151	]	_	_	O
152	)	_	_	O
153	,	_	_	O
154	sexual	_	_	O
155	functioning	_	_	O
156	(	_	_	O
157	Female	_	_	O
158	Sexual	_	_	O
159	Functioning	_	_	O
160	Index	_	_	O
161	)	_	_	O
162	,	_	_	O
163	and	_	_	O
164	psychological	_	_	O
165	well-being	_	_	O
166	(	_	_	O
167	Brief	_	_	O
168	Symptom	_	_	O
169	Inventory	_	_	O
170	Depression/Anxiety	_	_	O
171	,	_	_	O
172	Impact	_	_	O
173	of	_	_	O
174	Events	_	_	O
175	Scale-Revised	_	_	O
176	,	_	_	O
177	CR-38	_	_	O
178	Body	_	_	O
179	Image	_	_	O
180	)	_	_	O
181	.	_	_	O

182	Women	_	_	O
183	enrolled	_	_	O
184	in	_	_	O
185	the	_	_	O
186	study	_	_	O
187	intervention	_	_	O
188	were	_	_	O
189	on	_	_	O
190	average	_	_	O
191	55	_	_	O
192	years	_	_	O
193	old	_	_	O
194	,	_	_	O
195	predominantly	_	_	O
196	Caucasian	_	_	O
197	(	_	_	O
198	79	_	_	O
199	%	_	_	O
200	)	_	_	O
201	,	_	_	O
202	married	_	_	O
203	(	_	_	O
204	57	_	_	O
205	%	_	_	O
206	)	_	_	O
207	,	_	_	O
208	and	_	_	O
209	a	_	_	O
210	median	_	_	O
211	of	_	_	O
212	4	_	_	O
213	years	_	_	O
214	postprimary	_	_	O
215	treatment	_	_	O
216	.	_	_	O

217	For	_	_	O
218	those	_	_	O
219	reporting	_	_	O
220	sexual	_	_	O
221	activity	_	_	O
222	at	_	_	O
223	baseline	_	_	O
224	(	_	_	O
225	N=41	_	_	O
226	)	_	_	O
227	,	_	_	O
228	sexual	_	_	O
229	dysfunction	_	_	O
230	was	_	_	O
231	associated	_	_	O
232	with	_	_	O
233	a	_	_	O
234	range	_	_	O
235	of	_	_	O
236	specific	_	_	O
237	measures	_	_	O
238	of	_	_	O
239	psychological	_	_	O
240	well-being	_	_	O
241	,	_	_	O
242	all	_	_	O
243	in	_	_	O
244	the	_	_	O
245	hypothesized	_	_	O
246	direction	_	_	O
247	.	_	_	O

248	The	_	_	B-Premise
249	Sexual/Relationship	_	_	I-Premise
250	Satisfaction	_	_	I-Premise
251	subscale	_	_	I-Premise
252	was	_	_	I-Premise
253	associated	_	_	I-Premise
254	with	_	_	I-Premise
255	all	_	_	I-Premise
256	measures	_	_	I-Premise
257	of	_	_	I-Premise
258	psychological	_	_	I-Premise
259	well-being	_	_	I-Premise
260	(	_	_	I-Premise
261	r=-0.45	_	_	I-Premise
262	to	_	_	I-Premise
263	-0.70	_	_	I-Premise
264	,	_	_	I-Premise
265	all	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	0.01	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Body	_	_	B-Premise
272	image	_	_	I-Premise
273	,	_	_	I-Premise
274	anxiety	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	cancer-specific	_	_	I-Premise
278	posttraumatic	_	_	I-Premise
279	distress	_	_	I-Premise
280	were	_	_	I-Premise
281	notable	_	_	I-Premise
282	in	_	_	I-Premise
283	their	_	_	I-Premise
284	association	_	_	I-Premise
285	with	_	_	I-Premise
286	subscales	_	_	I-Premise
287	of	_	_	I-Premise
288	sexual	_	_	I-Premise
289	functioning	_	_	I-Premise
290	,	_	_	I-Premise
291	while	_	_	I-Premise
292	a	_	_	I-Premise
293	global	_	_	I-Premise
294	QOL	_	_	I-Premise
295	measure	_	_	I-Premise
296	was	_	_	I-Premise
297	largely	_	_	I-Premise
298	unrelated	_	_	I-Premise
299	.	_	_	I-Premise

300	For	_	_	B-Premise
301	sexually	_	_	I-Premise
302	active	_	_	I-Premise
303	female	_	_	I-Premise
304	rectal	_	_	I-Premise
305	and	_	_	I-Premise
306	anal	_	_	I-Premise
307	cancer	_	_	I-Premise
308	survivors	_	_	I-Premise
309	enrolled	_	_	I-Premise
310	in	_	_	I-Premise
311	a	_	_	I-Premise
312	sexual	_	_	I-Premise
313	health	_	_	I-Premise
314	intervention	_	_	I-Premise
315	,	_	_	I-Premise
316	sexual	_	_	I-Premise
317	dysfunction	_	_	I-Premise
318	was	_	_	I-Premise
319	significantly	_	_	I-Premise
320	and	_	_	I-Premise
321	consistently	_	_	I-Premise
322	associated	_	_	I-Premise
323	with	_	_	I-Premise
324	specific	_	_	I-Premise
325	measures	_	_	I-Premise
326	of	_	_	I-Premise
327	psychological	_	_	I-Premise
328	well-being	_	_	I-Premise
329	,	_	_	I-Premise
330	most	_	_	I-Premise
331	notably	_	_	I-Premise
332	Sexual/Relationship	_	_	I-Premise
333	Satisfaction	_	_	I-Premise
334	.	_	_	I-Premise

335	These	_	_	B-Claim
336	results	_	_	I-Claim
337	suggest	_	_	I-Claim
338	that	_	_	I-Claim
339	sexual	_	_	I-Claim
340	functioning	_	_	I-Claim
341	may	_	_	I-Claim
342	require	_	_	I-Claim
343	focused	_	_	I-Claim
344	assessment	_	_	I-Claim
345	by	_	_	I-Claim
346	providers	_	_	I-Claim
347	,	_	_	I-Claim
348	beyond	_	_	I-Claim
349	broad	_	_	I-Claim
350	QOL	_	_	I-Claim
351	assessments	_	_	I-Claim
352	,	_	_	I-Claim
353	and	_	_	O
354	that	_	_	O
355	attention	_	_	B-Claim
356	to	_	_	I-Claim
357	Sexual/Relationship	_	_	I-Claim
358	Satisfaction	_	_	I-Claim
359	may	_	_	I-Claim
360	be	_	_	I-Claim
361	critical	_	_	I-Claim
362	in	_	_	I-Claim
363	the	_	_	I-Claim
364	development	_	_	I-Claim
365	and	_	_	I-Claim
366	implementation	_	_	I-Claim
367	of	_	_	I-Claim
368	interventions	_	_	I-Claim
369	for	_	_	I-Claim
370	this	_	_	I-Claim
371	cohort	_	_	I-Claim
372	of	_	_	I-Claim
373	patients	_	_	I-Claim
374	.	_	_	I-Claim


0	We	_	_	O
1	have	_	_	O
2	recently	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	bolus	_	_	O
6	5-fluorouracil	_	_	O
7	(	_	_	O
8	5-FU	_	_	O
9	)	_	_	O
10	may	_	_	O
11	work	_	_	O
12	via	_	_	O
13	a	_	_	O
14	RNA	_	_	O
15	directed	_	_	O
16	mechanism	_	_	O
17	while	_	_	O
18	continuous	_	_	O
19	infusion	_	_	O
20	5-FU	_	_	O
21	may	_	_	O
22	kill	_	_	O
23	cells	_	_	O
24	via	_	_	O
25	a	_	_	O
26	thymidylate	_	_	O
27	synthase	_	_	O
28	related	_	_	O
29	pathway	_	_	O
30	.	_	_	O

31	It	_	_	O
32	may	_	_	O
33	thus	_	_	O
34	be	_	_	O
35	possible	_	_	O
36	to	_	_	O
37	selectively	_	_	O
38	modulate	_	_	O
39	each	_	_	O
40	schedule	_	_	O
41	biochemically	_	_	O
42	.	_	_	O

43	We	_	_	O
44	have	_	_	O
45	compared	_	_	O
46	an	_	_	O
47	alternating	_	_	O
48	regimen	_	_	O
49	of	_	_	O
50	bolus	_	_	O
51	and	_	_	O
52	continuous	_	_	O
53	infusion	_	_	O
54	5-FU	_	_	O
55	,	_	_	O
56	selectively	_	_	O
57	modulated	_	_	O
58	for	_	_	O
59	the	_	_	O
60	schedule	_	_	O
61	of	_	_	O
62	administration	_	_	O
63	,	_	_	O
64	with	_	_	O
65	modulated	_	_	O
66	bolus	_	_	O
67	5-FU	_	_	O
68	in	_	_	O
69	advanced	_	_	O
70	colorectal	_	_	O
71	cancer	_	_	O
72	patients	_	_	O
73	.	_	_	O

74	Two	_	_	O
75	hundred	_	_	O
76	fourteen	_	_	O
77	patients	_	_	O
78	from	_	_	O
79	nineteen	_	_	O
80	Italian	_	_	O
81	centers	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	the	_	_	O
86	control	_	_	O
87	arm	_	_	O
88	consisting	_	_	O
89	of	_	_	O
90	biweekly	_	_	O
91	cycles	_	_	O
92	of	_	_	O
93	MTX	_	_	O
94	,	_	_	O
95	200	_	_	O
96	mg/m2	_	_	O
97	on	_	_	O
98	day	_	_	O
99	1	_	_	O
100	,	_	_	O
101	followed	_	_	O
102	by	_	_	O
103	bolus	_	_	O
104	5-FU	_	_	O
105	600	_	_	O
106	mg/m2	_	_	O
107	on	_	_	O
108	day	_	_	O
109	2	_	_	O
110	and	_	_	O
111	6-S-leucovorin	_	_	O
112	rescue	_	_	O
113	,	_	_	O
114	or	_	_	O
115	to	_	_	O
116	the	_	_	O
117	experimental	_	_	O
118	arm	_	_	O
119	consisting	_	_	O
120	of	_	_	O
121	two	_	_	O
122	biweekly	_	_	O
123	cycles	_	_	O
124	of	_	_	O
125	the	_	_	O
126	same	_	_	O
127	regimen	_	_	O
128	as	_	_	O
129	in	_	_	O
130	the	_	_	O
131	control	_	_	O
132	arm	_	_	O
133	alternated	_	_	O
134	to	_	_	O
135	three	_	_	O
136	weeks	_	_	O
137	of	_	_	O
138	continuous	_	_	O
139	infusion	_	_	O
140	5-FU	_	_	O
141	(	_	_	O
142	200	_	_	O
143	mg/m2	_	_	O
144	day	_	_	O
145	)	_	_	O
146	+	_	_	O
147	weekly	_	_	O
148	bolus	_	_	O
149	6-S-leucovorin	_	_	O
150	,	_	_	O
151	20	_	_	O
152	mg/m2	_	_	O
153	.	_	_	O

154	Nine	_	_	B-Premise
155	CR	_	_	I-Premise
156	and	_	_	I-Premise
157	twenty-seven	_	_	I-Premise
158	PR	_	_	I-Premise
159	were	_	_	I-Premise
160	obtained	_	_	I-Premise
161	on	_	_	I-Premise
162	one	_	_	I-Premise
163	hundred	_	_	I-Premise
164	eleven	_	_	I-Premise
165	evaluable	_	_	I-Premise
166	patients	_	_	I-Premise
167	treated	_	_	I-Premise
168	in	_	_	I-Premise
169	experimental	_	_	I-Premise
170	arm	_	_	I-Premise
171	(	_	_	I-Premise
172	RR	_	_	I-Premise
173	=	_	_	I-Premise
174	32	_	_	I-Premise
175	%	_	_	I-Premise
176	,	_	_	I-Premise
177	95	_	_	I-Premise
178	%	_	_	I-Premise
179	confidence	_	_	I-Premise
180	interval	_	_	I-Premise
181	(	_	_	I-Premise
182	95	_	_	I-Premise
183	%	_	_	I-Premise
184	CI	_	_	I-Premise
185	)	_	_	I-Premise
186	:	_	_	I-Premise
187	24	_	_	I-Premise
188	%	_	_	I-Premise
189	-42	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	while	_	_	I-Premise
194	two	_	_	I-Premise
195	CR	_	_	I-Premise
196	and	_	_	I-Premise
197	eleven	_	_	I-Premise
198	PR	_	_	I-Premise
199	were	_	_	I-Premise
200	observed	_	_	I-Premise
201	among	_	_	I-Premise
202	one	_	_	I-Premise
203	hundred	_	_	I-Premise
204	three	_	_	I-Premise
205	evaluable	_	_	I-Premise
206	patients	_	_	I-Premise
207	in	_	_	I-Premise
208	control	_	_	I-Premise
209	arm	_	_	I-Premise
210	(	_	_	I-Premise
211	RR	_	_	I-Premise
212	=	_	_	I-Premise
213	13	_	_	I-Premise
214	%	_	_	I-Premise
215	,	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	:	_	_	I-Premise
220	7	_	_	I-Premise
221	%	_	_	I-Premise
222	-21	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	WHO	_	_	B-Premise
227	grade	_	_	I-Premise
228	3-4	_	_	I-Premise
229	toxicity	_	_	I-Premise
230	occurred	_	_	I-Premise
231	in	_	_	I-Premise
232	13	_	_	I-Premise
233	%	_	_	I-Premise
234	of	_	_	I-Premise
235	cycles	_	_	I-Premise
236	of	_	_	I-Premise
237	experimental	_	_	I-Premise
238	arm	_	_	I-Premise
239	and	_	_	I-Premise
240	in	_	_	I-Premise
241	8	_	_	I-Premise
242	%	_	_	I-Premise
243	of	_	_	I-Premise
244	cycles	_	_	I-Premise
245	in	_	_	I-Premise
246	control	_	_	I-Premise
247	arm	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	PFS	_	_	I-Premise
251	was	_	_	I-Premise
252	significantly	_	_	I-Premise
253	longer	_	_	I-Premise
254	in	_	_	I-Premise
255	experimental	_	_	I-Premise
256	arm	_	_	I-Premise
257	(	_	_	I-Premise
258	6.2	_	_	I-Premise
259	vs.	_	_	I-Premise
260	4.3	_	_	I-Premise
261	months	_	_	I-Premise
262	,	_	_	I-Premise
263	odds	_	_	I-Premise
264	ratio	_	_	I-Premise
265	0.66	_	_	I-Premise
266	,	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	0.003	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	while	_	_	O
273	the	_	_	B-Premise
274	overall	_	_	I-Premise
275	survival	_	_	I-Premise
276	was	_	_	I-Premise
277	similar	_	_	I-Premise
278	in	_	_	I-Premise
279	both	_	_	I-Premise
280	arms	_	_	I-Premise
281	(	_	_	I-Premise
282	14.8	_	_	I-Premise
283	months	_	_	I-Premise
284	in	_	_	I-Premise
285	experimental	_	_	I-Premise
286	arm	_	_	I-Premise
287	vs.	_	_	I-Premise
288	14.1	_	_	I-Premise
289	months	_	_	I-Premise
290	in	_	_	I-Premise
291	control	_	_	I-Premise
292	arm	_	_	I-Premise
293	)	_	_	I-Premise
294	;	_	_	I-Premise
295	quality	_	_	B-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	was	_	_	I-Claim
299	similar	_	_	I-Claim
300	as	_	_	I-Claim
301	well	_	_	I-Claim
302	.	_	_	I-Claim

303	Eighty	_	_	B-Premise
304	percent	_	_	I-Premise
305	of	_	_	I-Premise
306	patients	_	_	I-Premise
307	receiving	_	_	I-Premise
308	second-line	_	_	I-Premise
309	chemotherapy	_	_	I-Premise
310	in	_	_	I-Premise
311	control	_	_	I-Premise
312	arm	_	_	I-Premise
313	were	_	_	I-Premise
314	treated	_	_	I-Premise
315	with	_	_	I-Premise
316	continuous	_	_	I-Premise
317	infusion	_	_	I-Premise
318	5-FU	_	_	I-Premise
319	.	_	_	I-Premise

320	Alternating	_	_	O
321	,	_	_	O
322	schedule-specific	_	_	B-Claim
323	biochemical	_	_	I-Claim
324	modulation	_	_	I-Claim
325	of	_	_	I-Claim
326	FU	_	_	I-Claim
327	is	_	_	I-Claim
328	more	_	_	I-Claim
329	active	_	_	I-Claim
330	than	_	_	I-Claim
331	MTX	_	_	I-Claim
332	--	_	_	I-Claim
333	>	_	_	I-Claim
334	5-FU	_	_	I-Claim
335	as	_	_	I-Claim
336	first-line	_	_	I-Claim
337	treatment	_	_	I-Claim
338	of	_	_	I-Claim
339	advanced	_	_	I-Claim
340	colorectal	_	_	I-Claim
341	cancer	_	_	I-Claim
342	.	_	_	I-Claim

343	However	_	_	B-Claim
344	,	_	_	I-Claim
345	the	_	_	I-Claim
346	overall	_	_	I-Claim
347	survival	_	_	I-Claim
348	was	_	_	I-Claim
349	similar	_	_	I-Claim
350	suggesting	_	_	I-Claim
351	that	_	_	I-Claim
352	alternating	_	_	I-Claim
353	bolus	_	_	I-Claim
354	and	_	_	I-Claim
355	infusional	_	_	I-Claim
356	5-FU	_	_	I-Claim
357	upfront	_	_	I-Claim
358	may	_	_	I-Claim
359	be	_	_	I-Claim
360	as	_	_	I-Claim
361	effective	_	_	I-Claim
362	as	_	_	I-Claim
363	giving	_	_	I-Claim
364	them	_	_	I-Claim
365	in	_	_	I-Claim
366	sequence	_	_	I-Claim
367	as	_	_	I-Claim
368	first-	_	_	I-Claim
369	and	_	_	I-Claim
370	second-line	_	_	I-Claim
371	treatment	_	_	I-Claim
372	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	high	_	_	O
4	response	_	_	O
5	rate	_	_	O
6	and	_	_	O
7	improved	_	_	O
8	progression-free	_	_	O
9	survival	_	_	O
10	(	_	_	O
11	PFS	_	_	O
12	)	_	_	O
13	in	_	_	O
14	never-smokers	_	_	O
15	with	_	_	O
16	lung	_	_	O
17	adenocarcinoma	_	_	O
18	(	_	_	O
19	NSLAs	_	_	O
20	)	_	_	O
21	.	_	_	O

22	We	_	_	O
23	compared	_	_	O
24	efficacy	_	_	O
25	of	_	_	O
26	gefitinib	_	_	O
27	with	_	_	O
28	gemcitabine	_	_	O
29	and	_	_	O
30	cisplatin	_	_	O
31	(	_	_	O
32	GP	_	_	O
33	)	_	_	O
34	chemotherapy	_	_	O
35	in	_	_	O
36	this	_	_	O
37	group	_	_	O
38	of	_	_	O
39	patients	_	_	O
40	as	_	_	O
41	first-line	_	_	O
42	therapy	_	_	O
43	.	_	_	O

44	In	_	_	O
45	this	_	_	O
46	randomized	_	_	O
47	phase	_	_	O
48	III	_	_	O
49	trial	_	_	O
50	,	_	_	O
51	a	_	_	O
52	total	_	_	O
53	of	_	_	O
54	313	_	_	O
55	Korean	_	_	O
56	never-smokers	_	_	O
57	with	_	_	O
58	stage	_	_	O
59	IIIB	_	_	O
60	or	_	_	O
61	IV	_	_	O
62	lung	_	_	O
63	adenocarcinoma	_	_	O
64	,	_	_	O
65	Eastern	_	_	O
66	Cooperative	_	_	O
67	Oncology	_	_	O
68	Group	_	_	O
69	performance	_	_	O
70	status	_	_	O
71	0	_	_	O
72	to	_	_	O
73	2	_	_	O
74	,	_	_	O
75	and	_	_	O
76	adequate	_	_	O
77	organ	_	_	O
78	function	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	either	_	_	O
85	gefitinib	_	_	O
86	(	_	_	O
87	250	_	_	O
88	mg	_	_	O
89	daily	_	_	O
90	)	_	_	O
91	or	_	_	O
92	GP	_	_	O
93	chemotherapy	_	_	O
94	(	_	_	O
95	gemcitabine	_	_	O
96	1,250	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	;	_	_	O
107	cisplatin	_	_	O
108	80	_	_	O
109	mg/m	_	_	O
110	(	_	_	O
111	2	_	_	O
112	)	_	_	O
113	on	_	_	O
114	day	_	_	O
115	1	_	_	O
116	every	_	_	O
117	3	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	for	_	_	O
121	up	_	_	O
122	to	_	_	O
123	nine	_	_	O
124	courses	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	primary	_	_	O
129	objective	_	_	O
130	was	_	_	O
131	to	_	_	O
132	demonstrate	_	_	O
133	better	_	_	O
134	overall	_	_	O
135	survival	_	_	O
136	(	_	_	O
137	OS	_	_	O
138	)	_	_	O
139	for	_	_	O
140	gefitinib	_	_	O
141	compared	_	_	O
142	with	_	_	O
143	GP	_	_	O
144	in	_	_	O
145	chemotherapy-naive	_	_	O
146	NSLAs	_	_	O
147	.	_	_	O

148	Three	_	_	O
149	hundred	_	_	O
150	nine	_	_	O
151	patients	_	_	O
152	were	_	_	O
153	analyzed	_	_	O
154	per	_	_	O
155	protocol	_	_	O
156	(	_	_	O
157	gefitinib	_	_	O
158	arm	_	_	O
159	,	_	_	O
160	n	_	_	O
161	=	_	_	O
162	159	_	_	O
163	;	_	_	O
164	GP	_	_	O
165	arm	_	_	O
166	,	_	_	O
167	n	_	_	O
168	=	_	_	O
169	150	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Gefitinib	_	_	B-Premise
173	did	_	_	I-Premise
174	not	_	_	I-Premise
175	show	_	_	I-Premise
176	better	_	_	I-Premise
177	OS	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	GP	_	_	I-Premise
181	(	_	_	I-Premise
182	hazard	_	_	I-Premise
183	ratio	_	_	I-Premise
184	[	_	_	I-Premise
185	HR	_	_	I-Premise
186	]	_	_	I-Premise
187	,	_	_	I-Premise
188	0.932	_	_	I-Premise
189	;	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	,	_	_	I-Premise
194	0.716	_	_	I-Premise
195	to	_	_	I-Premise
196	1.213	_	_	I-Premise
197	;	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.604	_	_	I-Premise
201	;	_	_	I-Premise
202	median	_	_	I-Premise
203	OS	_	_	I-Premise
204	,	_	_	I-Premise
205	22.3	_	_	I-Premise
206	v	_	_	I-Premise
207	22.9	_	_	I-Premise
208	months	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	1-year	_	_	I-Premise
215	PFS	_	_	I-Premise
216	rates	_	_	I-Premise
217	were	_	_	I-Premise
218	16.7	_	_	I-Premise
219	%	_	_	I-Premise
220	with	_	_	I-Premise
221	gefitinib	_	_	I-Premise
222	and	_	_	I-Premise
223	2.8	_	_	I-Premise
224	%	_	_	I-Premise
225	with	_	_	I-Premise
226	GP	_	_	I-Premise
227	(	_	_	I-Premise
228	HR	_	_	I-Premise
229	,	_	_	I-Premise
230	1.198	_	_	I-Premise
231	;	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	0.944	_	_	I-Premise
237	to	_	_	I-Premise
238	1.520	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Response	_	_	B-Premise
242	rates	_	_	I-Premise
243	were	_	_	I-Premise
244	55	_	_	I-Premise
245	%	_	_	I-Premise
246	with	_	_	I-Premise
247	gefitinib	_	_	I-Premise
248	and	_	_	I-Premise
249	46	_	_	I-Premise
250	%	_	_	I-Premise
251	with	_	_	I-Premise
252	GP	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.101	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Myelosuppression	_	_	B-Premise
260	,	_	_	I-Premise
261	renal	_	_	I-Premise
262	insufficiency	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	fatigue	_	_	I-Premise
266	were	_	_	I-Premise
267	more	_	_	I-Premise
268	common	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	GP	_	_	I-Premise
272	arm	_	_	I-Premise
273	,	_	_	I-Premise
274	but	_	_	O
275	skin	_	_	B-Premise
276	toxicities	_	_	I-Premise
277	and	_	_	I-Premise
278	liver	_	_	I-Premise
279	dysfunction	_	_	I-Premise
280	were	_	_	I-Premise
281	more	_	_	I-Premise
282	common	_	_	I-Premise
283	in	_	_	I-Premise
284	the	_	_	I-Premise
285	gefitinib	_	_	I-Premise
286	arm	_	_	I-Premise
287	.	_	_	I-Premise

288	Two	_	_	B-Premise
289	patients	_	_	I-Premise
290	(	_	_	I-Premise
291	1.3	_	_	I-Premise
292	%	_	_	I-Premise
293	)	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	gefitinib	_	_	I-Premise
297	arm	_	_	I-Premise
298	developed	_	_	I-Premise
299	interstitial	_	_	I-Premise
300	lung	_	_	I-Premise
301	disease	_	_	I-Premise
302	and	_	_	I-Premise
303	died	_	_	I-Premise
304	.	_	_	I-Premise

305	Gefitinib	_	_	B-Claim
306	failed	_	_	I-Claim
307	to	_	_	I-Claim
308	demonstrate	_	_	I-Claim
309	superior	_	_	I-Claim
310	OS	_	_	I-Claim
311	compared	_	_	I-Claim
312	with	_	_	I-Claim
313	GP	_	_	I-Claim
314	as	_	_	I-Claim
315	first-line	_	_	I-Claim
316	therapy	_	_	I-Claim
317	for	_	_	I-Claim
318	NSLAs	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	survival	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	recurrent	_	_	O
7	or	_	_	O
8	metastatic	_	_	O
9	squamous	_	_	O
10	cell	_	_	O
11	carcinoma	_	_	O
12	of	_	_	O
13	the	_	_	O
14	head	_	_	O
15	and	_	_	O
16	neck	_	_	O
17	(	_	_	O
18	SCCHN	_	_	O
19	)	_	_	O
20	treated	_	_	O
21	with	_	_	O
22	gefitinib	_	_	O
23	250	_	_	O
24	or	_	_	O
25	500	_	_	O
26	mg/day	_	_	O
27	or	_	_	O
28	standard	_	_	O
29	methotrexate	_	_	O
30	.	_	_	O

31	Four	_	_	O
32	hundred	_	_	O
33	eighty-six	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	recurrent	_	_	O
37	SCCHN	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	to	_	_	O
42	oral	_	_	O
43	gefitinib	_	_	O
44	250	_	_	O
45	mg/day	_	_	O
46	,	_	_	O
47	gefitinib	_	_	O
48	500	_	_	O
49	mg/day	_	_	O
50	,	_	_	O
51	or	_	_	O
52	methotrexate	_	_	O
53	40	_	_	O
54	mg/m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	intravenously	_	_	O
59	weekly	_	_	O
60	.	_	_	O

61	Primary	_	_	O
62	end	_	_	O
63	point	_	_	O
64	was	_	_	O
65	overall	_	_	O
66	survival	_	_	O
67	,	_	_	O
68	secondary	_	_	O
69	end	_	_	O
70	points	_	_	O
71	were	_	_	O
72	objective	_	_	O
73	response	_	_	O
74	rate	_	_	O
75	(	_	_	O
76	ORR	_	_	O
77	)	_	_	O
78	,	_	_	O
79	safety	_	_	O
80	,	_	_	O
81	symptom	_	_	O
82	improvement	_	_	O
83	,	_	_	O
84	and	_	_	O
85	quality	_	_	O
86	of	_	_	O
87	life	_	_	O
88	(	_	_	O
89	QOL	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Exploratory	_	_	O
93	end	_	_	O
94	points	_	_	O
95	included	_	_	O
96	association	_	_	O
97	of	_	_	O
98	efficacy	_	_	O
99	with	_	_	O
100	epidermal	_	_	O
101	growth	_	_	O
102	factor	_	_	O
103	receptor	_	_	O
104	gene	_	_	O
105	copy	_	_	O
106	number	_	_	O
107	and	_	_	O
108	other	_	_	O
109	biomarkers	_	_	O
110	.	_	_	O

111	Neither	_	_	B-Premise
112	gefitinib	_	_	I-Premise
113	250	_	_	I-Premise
114	nor	_	_	I-Premise
115	500	_	_	I-Premise
116	mg/day	_	_	I-Premise
117	improved	_	_	I-Premise
118	overall	_	_	I-Premise
119	survival	_	_	I-Premise
120	compared	_	_	I-Premise
121	with	_	_	I-Premise
122	methotrexate	_	_	I-Premise
123	(	_	_	I-Premise
124	hazard	_	_	I-Premise
125	ratio	_	_	I-Premise
126	[	_	_	I-Premise
127	HR	_	_	I-Premise
128	]	_	_	I-Premise
129	,	_	_	I-Premise
130	1.22	_	_	I-Premise
131	;	_	_	I-Premise
132	95	_	_	I-Premise
133	%	_	_	I-Premise
134	CI	_	_	I-Premise
135	,	_	_	I-Premise
136	0.95	_	_	I-Premise
137	to	_	_	I-Premise
138	1.57	_	_	I-Premise
139	;	_	_	I-Premise
140	P	_	_	I-Premise
141	=	_	_	I-Premise
142	.12	_	_	I-Premise
143	;	_	_	I-Premise
144	and	_	_	I-Premise
145	HR	_	_	I-Premise
146	,	_	_	I-Premise
147	1.12	_	_	I-Premise
148	;	_	_	I-Premise
149	95	_	_	I-Premise
150	%	_	_	I-Premise
151	CI	_	_	I-Premise
152	,	_	_	I-Premise
153	0.87	_	_	I-Premise
154	to	_	_	I-Premise
155	1.43	_	_	I-Premise
156	;	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	.39	_	_	I-Premise
160	,	_	_	I-Premise
161	respectively	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	In	_	_	B-Premise
165	the	_	_	I-Premise
166	gefitinib	_	_	I-Premise
167	250	_	_	I-Premise
168	mg/day	_	_	I-Premise
169	,	_	_	I-Premise
170	500	_	_	I-Premise
171	mg/day	_	_	I-Premise
172	,	_	_	I-Premise
173	and	_	_	I-Premise
174	methotrexate	_	_	I-Premise
175	groups	_	_	I-Premise
176	,	_	_	I-Premise
177	respectively	_	_	I-Premise
178	,	_	_	I-Premise
179	median	_	_	I-Premise
180	overall	_	_	I-Premise
181	survival	_	_	I-Premise
182	was	_	_	I-Premise
183	5.6	_	_	I-Premise
184	,	_	_	I-Premise
185	6.0	_	_	I-Premise
186	,	_	_	I-Premise
187	and	_	_	I-Premise
188	6.7	_	_	I-Premise
189	months	_	_	I-Premise
190	;	_	_	I-Premise
191	ORRs	_	_	I-Premise
192	(	_	_	I-Premise
193	Response	_	_	I-Premise
194	Evaluation	_	_	I-Premise
195	Criteria	_	_	I-Premise
196	in	_	_	I-Premise
197	Solid	_	_	I-Premise
198	Tumors	_	_	I-Premise
199	)	_	_	I-Premise
200	were	_	_	I-Premise
201	2.7	_	_	I-Premise
202	%	_	_	I-Premise
203	,	_	_	I-Premise
204	7.6	_	_	I-Premise
205	%	_	_	I-Premise
206	and	_	_	I-Premise
207	3.9	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	with	_	_	I-Premise
211	no	_	_	I-Premise
212	statistically	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	between	_	_	I-Premise
216	either	_	_	I-Premise
217	gefitinib	_	_	I-Premise
218	arm	_	_	I-Premise
219	and	_	_	I-Premise
220	methotrexate	_	_	I-Premise
221	.	_	_	I-Premise

222	No	_	_	B-Premise
223	unexpected	_	_	I-Premise
224	adverse	_	_	I-Premise
225	events	_	_	I-Premise
226	were	_	_	I-Premise
227	observed	_	_	I-Premise
228	,	_	_	I-Premise
229	except	_	_	B-Premise
230	for	_	_	I-Premise
231	tumor	_	_	I-Premise
232	hemorrhage-type	_	_	I-Premise
233	events	_	_	I-Premise
234	with	_	_	I-Premise
235	gefitinib	_	_	I-Premise
236	(	_	_	I-Premise
237	8.9	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	gefitinib	_	_	I-Premise
241	250	_	_	I-Premise
242	mg/day	_	_	I-Premise
243	;	_	_	I-Premise
244	11.4	_	_	I-Premise
245	%	_	_	I-Premise
246	,	_	_	I-Premise
247	gefitinib	_	_	I-Premise
248	500	_	_	I-Premise
249	mg/day	_	_	I-Premise
250	;	_	_	I-Premise
251	1.9	_	_	I-Premise
252	%	_	_	I-Premise
253	,	_	_	I-Premise
254	methotrexate	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	QOL	_	_	B-Premise
258	improvement	_	_	I-Premise
259	rates	_	_	I-Premise
260	(	_	_	I-Premise
261	Functional	_	_	I-Premise
262	Assessment	_	_	I-Premise
263	of	_	_	I-Premise
264	Cancer	_	_	I-Premise
265	Therapy-Head	_	_	I-Premise
266	&	_	_	I-Premise
267	amp	_	_	I-Premise
268	;	_	_	I-Premise
269	Neck	_	_	I-Premise
270	total	_	_	I-Premise
271	score	_	_	I-Premise
272	)	_	_	I-Premise
273	were	_	_	I-Premise
274	13.4	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	18.0	_	_	I-Premise
278	%	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	6.0	_	_	I-Premise
282	%	_	_	I-Premise
283	for	_	_	I-Premise
284	gefitinib	_	_	I-Premise
285	250	_	_	I-Premise
286	mg/day	_	_	I-Premise
287	,	_	_	I-Premise
288	500	_	_	I-Premise
289	mg/day	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	methotrexate	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	.	_	_	I-Premise

296	In	_	_	B-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	recurrent	_	_	I-Claim
300	or	_	_	I-Claim
301	metastatic	_	_	I-Claim
302	SCCHN	_	_	I-Claim
303	,	_	_	I-Claim
304	while	_	_	I-Claim
305	responses	_	_	I-Claim
306	with	_	_	I-Claim
307	gefitinib	_	_	I-Claim
308	were	_	_	I-Claim
309	seen	_	_	I-Claim
310	,	_	_	I-Claim
311	neither	_	_	I-Claim
312	gefitinib	_	_	I-Claim
313	250	_	_	I-Claim
314	nor	_	_	I-Claim
315	500	_	_	I-Claim
316	mg/day	_	_	I-Claim
317	improved	_	_	I-Claim
318	overall	_	_	I-Claim
319	survival	_	_	I-Claim
320	compared	_	_	I-Claim
321	with	_	_	I-Claim
322	methotrexate	_	_	I-Claim
323	.	_	_	I-Claim

324	With	_	_	B-Claim
325	the	_	_	I-Claim
326	exception	_	_	I-Claim
327	of	_	_	I-Claim
328	tumor	_	_	I-Claim
329	hemorrhage-type	_	_	I-Claim
330	events	_	_	I-Claim
331	with	_	_	I-Claim
332	gefitinib	_	_	I-Claim
333	,	_	_	I-Claim
334	the	_	_	I-Claim
335	adverse	_	_	I-Claim
336	event	_	_	I-Claim
337	profiles	_	_	I-Claim
338	were	_	_	I-Claim
339	generally	_	_	I-Claim
340	consistent	_	_	I-Claim
341	with	_	_	I-Claim
342	those	_	_	I-Claim
343	previously	_	_	I-Claim
344	observed	_	_	I-Claim
345	.	_	_	I-Claim


0	Gemcitabine	_	_	O
1	(	_	_	O
2	G	_	_	O
3	)	_	_	O
4	is	_	_	O
5	standard	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	pancreatic	_	_	O
9	cancer	_	_	O
10	.	_	_	O

11	Enzastaurin	_	_	O
12	(	_	_	O
13	E	_	_	O
14	)	_	_	O
15	inhibits	_	_	O
16	PKCÎ²	_	_	O
17	and	_	_	O
18	PI3K/AKT	_	_	O
19	signaling	_	_	O
20	pathways	_	_	O
21	with	_	_	O
22	a	_	_	O
23	dose-dependent	_	_	O
24	effect	_	_	O
25	on	_	_	O
26	growth	_	_	O
27	of	_	_	O
28	pancreatic	_	_	O
29	carcinoma	_	_	O
30	xenografts	_	_	O
31	.	_	_	O

32	Data	_	_	B-Claim
33	suggest	_	_	I-Claim
34	that	_	_	I-Claim
35	the	_	_	I-Claim
36	GE	_	_	I-Claim
37	combination	_	_	I-Claim
38	may	_	_	I-Claim
39	improve	_	_	I-Claim
40	clinical	_	_	I-Claim
41	outcomes	_	_	I-Claim
42	.	_	_	I-Claim

43	Primary	_	_	O
44	objective	_	_	O
45	was	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	(	_	_	O
49	OS	_	_	O
50	)	_	_	O
51	;	_	_	O
52	secondary	_	_	O
53	objectives	_	_	O
54	assessed	_	_	O
55	progression-free	_	_	O
56	survival	_	_	O
57	(	_	_	O
58	PFS	_	_	O
59	)	_	_	O
60	,	_	_	O
61	response	_	_	O
62	rate	_	_	O
63	(	_	_	O
64	RR	_	_	O
65	)	_	_	O
66	,	_	_	O
67	quality	_	_	O
68	of	_	_	O
69	life	_	_	O
70	(	_	_	O
71	QOL	_	_	O
72	)	_	_	O
73	,	_	_	O
74	toxicity	_	_	O
75	,	_	_	O
76	and	_	_	O
77	relationships	_	_	O
78	between	_	_	O
79	biomarker	_	_	O
80	expression	_	_	O
81	and	_	_	O
82	clinical	_	_	O
83	outcomes	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	(	_	_	O
90	2:1	_	_	O
91	)	_	_	O
92	to	_	_	O
93	GE	_	_	O
94	or	_	_	O
95	G	_	_	O
96	treatment	_	_	O
97	;	_	_	O
98	GE	_	_	O
99	arm	_	_	O
100	:	_	_	O
101	E	_	_	O
102	500	_	_	O
103	mg	_	_	O
104	p.o	_	_	O
105	.	_	_	O

106	daily	_	_	O
107	;	_	_	O
108	loading-dose	_	_	O
109	(	_	_	O
110	1200	_	_	O
111	mg	_	_	O
112	;	_	_	O
113	Day	_	_	O
114	1	_	_	O
115	Cycle	_	_	O
116	1	_	_	O
117	only	_	_	O
118	)	_	_	O
119	and	_	_	O
120	G	_	_	O
121	1000	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	i.v	_	_	O
127	.	_	_	O

128	Days	_	_	O
129	1	_	_	O
130	,	_	_	O
131	8	_	_	O
132	,	_	_	O
133	and	_	_	O
134	15	_	_	O
135	in	_	_	O
136	28-day	_	_	O
137	cycles	_	_	O
138	;	_	_	O
139	G	_	_	O
140	arm	_	_	O
141	:	_	_	O
142	G	_	_	O
143	as	_	_	O
144	in	_	_	O
145	GE	_	_	O
146	.	_	_	O

147	Biomarker	_	_	O
148	expression	_	_	O
149	was	_	_	O
150	assessed	_	_	O
151	by	_	_	O
152	immunohistochemistry	_	_	O
153	.	_	_	O

154	Randomization	_	_	O
155	totaled	_	_	O
156	130	_	_	O
157	patients	_	_	O
158	(	_	_	O
159	GE	_	_	O
160	=	_	_	O
161	86	_	_	O
162	,	_	_	O
163	G	_	_	O
164	=	_	_	O
165	44	_	_	O
166	)	_	_	O
167	;	_	_	O
168	121	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	treated	_	_	O
172	(	_	_	O
173	GE	_	_	O
174	=	_	_	O
175	82	_	_	O
176	,	_	_	O
177	G	_	_	O
178	=	_	_	O
179	39	_	_	O
180	)	_	_	O
181	.	_	_	O

182	GE/G	_	_	O
183	median	_	_	O
184	OS	_	_	O
185	was	_	_	O
186	5.6/5.1	_	_	O
187	months	_	_	O
188	;	_	_	O
189	median	_	_	O
190	PFS	_	_	O
191	was	_	_	O
192	3.4/3.0	_	_	O
193	months	_	_	O
194	.	_	_	O

195	GE	_	_	O
196	responses	_	_	O
197	:	_	_	O
198	1	_	_	O
199	complete	_	_	O
200	response	_	_	O
201	(	_	_	O
202	CR	_	_	O
203	,	_	_	O
204	1.2	_	_	O
205	%	_	_	O
206	)	_	_	O
207	,	_	_	O
208	6	_	_	O
209	partial	_	_	O
210	response	_	_	O
211	(	_	_	O
212	PR	_	_	O
213	,	_	_	O
214	7.4	_	_	O
215	%	_	_	O
216	)	_	_	O
217	,	_	_	O
218	and	_	_	O
219	33	_	_	O
220	stable	_	_	O
221	disease	_	_	O
222	(	_	_	O
223	SD	_	_	O
224	,	_	_	O
225	40.7	_	_	O
226	%	_	_	O
227	)	_	_	O
228	;	_	_	O
229	disease	_	_	O
230	control	_	_	O
231	rate	_	_	O
232	(	_	_	O
233	DCR=CR+PR+SD	_	_	O
234	,	_	_	O
235	49.4	_	_	O
236	%	_	_	O
237	)	_	_	O
238	.	_	_	O

239	G	_	_	O
240	responses	_	_	O
241	:	_	_	O
242	2	_	_	O
243	PR	_	_	O
244	(	_	_	O
245	5.3	_	_	O
246	%	_	_	O
247	)	_	_	O
248	and	_	_	O
249	16	_	_	O
250	SD	_	_	O
251	(	_	_	O
252	42.1	_	_	O
253	%	_	_	O
254	)	_	_	O
255	;	_	_	O
256	DCR	_	_	O
257	(	_	_	O
258	47.4	_	_	O
259	%	_	_	O
260	)	_	_	O
261	.	_	_	O

262	No	_	_	B-Premise
263	QOL	_	_	I-Premise
264	differences	_	_	I-Premise
265	were	_	_	I-Premise
266	noted	_	_	I-Premise
267	between	_	_	I-Premise
268	arms	_	_	I-Premise
269	.	_	_	I-Premise

270	GE/G	_	_	B-Premise
271	Grade	_	_	I-Premise
272	3-4	_	_	I-Premise
273	toxicities	_	_	I-Premise
274	included	_	_	I-Premise
275	:	_	_	I-Premise
276	neutropenia	_	_	I-Premise
277	(	_	_	I-Premise
278	18.3	_	_	I-Premise
279	%	_	_	I-Premise
280	/28.2	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	;	_	_	I-Premise
284	thrombocytopenia	_	_	I-Premise
285	(	_	_	I-Premise
286	14.6	_	_	I-Premise
287	%	_	_	I-Premise
288	/25.6	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	;	_	_	I-Premise
292	and	_	_	I-Premise
293	fatigue	_	_	I-Premise
294	(	_	_	I-Premise
295	11.0	_	_	I-Premise
296	%	_	_	I-Premise
297	/7.7	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	No	_	_	B-Premise
302	statistically	_	_	I-Premise
303	significant	_	_	I-Premise
304	relationships	_	_	I-Premise
305	between	_	_	I-Premise
306	biomarker	_	_	I-Premise
307	expression	_	_	I-Premise
308	and	_	_	I-Premise
309	outcomes	_	_	I-Premise
310	were	_	_	I-Premise
311	observed	_	_	I-Premise
312	.	_	_	I-Premise

313	However	_	_	O
314	,	_	_	O
315	patients	_	_	B-Premise
316	with	_	_	I-Premise
317	low	_	_	I-Premise
318	expression	_	_	I-Premise
319	of	_	_	I-Premise
320	cytoplasmic	_	_	I-Premise
321	pGSK-3Î²	_	_	I-Premise
322	trended	_	_	I-Premise
323	toward	_	_	I-Premise
324	greater	_	_	I-Premise
325	OS	_	_	I-Premise
326	with	_	_	I-Premise
327	GE	_	_	I-Premise
328	treatment	_	_	I-Premise
329	.	_	_	I-Premise

330	OS	_	_	B-Premise
331	,	_	_	I-Premise
332	PFS	_	_	I-Premise
333	,	_	_	I-Premise
334	QOL	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	RR	_	_	I-Premise
338	were	_	_	I-Premise
339	comparable	_	_	I-Premise
340	between	_	_	I-Premise
341	arms	_	_	I-Premise
342	.	_	_	I-Premise

343	Adding	_	_	B-Claim
344	E	_	_	I-Claim
345	to	_	_	I-Claim
346	G	_	_	I-Claim
347	did	_	_	I-Claim
348	not	_	_	I-Claim
349	increase	_	_	I-Claim
350	hematologic	_	_	I-Claim
351	toxicities	_	_	I-Claim
352	.	_	_	I-Claim

353	GE	_	_	O
354	does	_	_	O
355	not	_	_	O
356	warrant	_	_	O
357	further	_	_	O
358	investigation	_	_	O
359	in	_	_	O
360	unselected	_	_	O
361	pancreatic	_	_	O
362	cancer	_	_	O
363	patients	_	_	O
364	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	impact	_	_	O
5	of	_	_	O
6	"	_	_	O
7	laying	_	_	O
8	on	_	_	O
9	of	_	_	O
10	hands	_	_	O
11	"	_	_	O
12	on	_	_	O
13	the	_	_	O
14	well-being	_	_	O
15	of	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	cancer	_	_	O
20	is	_	_	O
21	more	_	_	O
22	efficient	_	_	O
23	when	_	_	O
24	performed	_	_	O
25	by	_	_	O
26	a	_	_	O
27	person	_	_	O
28	with	_	_	O
29	self-declared	_	_	O
30	"	_	_	O
31	healing	_	_	O
32	powers	_	_	O
33	"	_	_	O
34	as	_	_	O
35	compared	_	_	O
36	to	_	_	O
37	an	_	_	O
38	actor	_	_	O
39	mimicking	_	_	O
40	the	_	_	O
41	healer	_	_	O
42	in	_	_	O
43	close	_	_	O
44	detail	_	_	O
45	.	_	_	O

46	A	_	_	O
47	total	_	_	O
48	of	_	_	O
49	80	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	registered	_	_	O
53	to	_	_	O
54	participate	_	_	O
55	in	_	_	O
56	a	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	single-blind	_	_	O
60	phase	_	_	O
61	III	_	_	O
62	trial	_	_	O
63	to	_	_	O
64	evaluate	_	_	O
65	the	_	_	O
66	difference	_	_	O
67	in	_	_	O
68	efficacy	_	_	O
69	of	_	_	O
70	"	_	_	O
71	laying	_	_	O
72	on	_	_	O
73	of	_	_	O
74	hands	_	_	O
75	"	_	_	O
76	by	_	_	O
77	either	_	_	O
78	a	_	_	O
79	"	_	_	O
80	healer	_	_	O
81	"	_	_	O
82	or	_	_	O
83	an	_	_	O
84	actor	_	_	O
85	.	_	_	O

86	Each	_	_	O
87	group	_	_	O
88	consisted	_	_	O
89	of	_	_	O
90	40	_	_	O
91	patients	_	_	O
92	,	_	_	O
93	scheduled	_	_	O
94	to	_	_	O
95	receive	_	_	O
96	treatment	_	_	O
97	for	_	_	O
98	5	_	_	O
99	min	_	_	O
100	,	_	_	O
101	three	_	_	O
102	times	_	_	O
103	a	_	_	O
104	week	_	_	O
105	.	_	_	O

106	The	_	_	O
107	effect	_	_	O
108	of	_	_	O
109	treatment	_	_	O
110	was	_	_	O
111	measured	_	_	O
112	using	_	_	O
113	a	_	_	O
114	"	_	_	O
115	Well-Being	_	_	O
116	scale	_	_	O
117	"	_	_	O
118	,	_	_	O
119	with	_	_	O
120	the	_	_	O
121	difference	_	_	O
122	of	_	_	O
123	the	_	_	O
124	average	_	_	O
125	score	_	_	O
126	of	_	_	O
127	the	_	_	O
128	"	_	_	O
129	Well-Being	_	_	O
130	scale	_	_	O
131	"	_	_	O
132	on	_	_	O
133	day	_	_	O
134	10	_	_	O
135	being	_	_	O
136	defined	_	_	O
137	as	_	_	O
138	primary	_	_	O
139	and	_	_	O
140	that	_	_	O
141	on	_	_	O
142	day	_	_	O
143	5	_	_	O
144	as	_	_	O
145	secondary	_	_	O
146	endpoint	_	_	O
147	.	_	_	O

148	There	_	_	B-Premise
149	was	_	_	I-Premise
150	no	_	_	I-Premise
151	significant	_	_	I-Premise
152	difference	_	_	I-Premise
153	in	_	_	I-Premise
154	average	_	_	I-Premise
155	score	_	_	I-Premise
156	values	_	_	I-Premise
157	between	_	_	I-Premise
158	the	_	_	I-Premise
159	"	_	_	I-Premise
160	healer	_	_	I-Premise
161	"	_	_	I-Premise
162	and	_	_	I-Premise
163	the	_	_	I-Premise
164	actor	_	_	I-Premise
165	with	_	_	I-Premise
166	regard	_	_	I-Premise
167	to	_	_	I-Premise
168	the	_	_	I-Premise
169	primary	_	_	I-Premise
170	(	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.34	_	_	I-Premise
174	)	_	_	I-Premise
175	or	_	_	I-Premise
176	the	_	_	I-Premise
177	secondary	_	_	I-Premise
178	endpoint	_	_	I-Premise
179	(	_	_	I-Premise
180	p	_	_	I-Premise
181	=	_	_	I-Premise
182	0.94	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	but	_	_	B-Premise
186	the	_	_	I-Premise
187	comparison	_	_	I-Premise
188	was	_	_	I-Premise
189	limited	_	_	I-Premise
190	due	_	_	I-Premise
191	to	_	_	I-Premise
192	major	_	_	I-Premise
193	protocol	_	_	I-Premise
194	violations	_	_	I-Premise
195	by	_	_	I-Premise
196	the	_	_	I-Premise
197	"	_	_	I-Premise
198	healer	_	_	I-Premise
199	"	_	_	I-Premise
200	who	_	_	I-Premise
201	unblinded	_	_	I-Premise
202	his	_	_	I-Premise
203	status	_	_	I-Premise
204	after	_	_	I-Premise
205	the	_	_	I-Premise
206	first	_	_	I-Premise
207	run	_	_	I-Premise
208	and	_	_	I-Premise
209	quit	_	_	I-Premise
210	the	_	_	I-Premise
211	study	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	O
214	study	_	_	O
215	was	_	_	O
216	completed	_	_	O
217	by	_	_	O
218	the	_	_	O
219	actor	_	_	O
220	as	_	_	O
221	a	_	_	O
222	descriptive	_	_	O
223	,	_	_	O
224	explorative	_	_	O
225	study	_	_	O
226	on	_	_	O
227	the	_	_	O
228	impact	_	_	O
229	of	_	_	O
230	"	_	_	O
231	laying	_	_	O
232	on	_	_	O
233	of	_	_	O
234	hands	_	_	O
235	"	_	_	O
236	.	_	_	O

237	A	_	_	B-Premise
238	significant	_	_	I-Premise
239	improvement	_	_	I-Premise
240	in	_	_	I-Premise
241	symptoms	_	_	I-Premise
242	after	_	_	I-Premise
243	treatment	_	_	I-Premise
244	was	_	_	I-Premise
245	found	_	_	I-Premise
246	on	_	_	I-Premise
247	day	_	_	I-Premise
248	5	_	_	I-Premise
249	(	_	_	I-Premise
250	p	_	_	I-Premise
251	<	_	_	I-Premise
252	0.001	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	on	_	_	I-Premise
256	day	_	_	I-Premise
257	10	_	_	I-Premise
258	(	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	0.0002	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	"	_	_	B-Claim
265	Laying	_	_	I-Claim
266	on	_	_	I-Claim
267	of	_	_	I-Claim
268	hands	_	_	I-Claim
269	"	_	_	I-Claim
270	resulted	_	_	I-Claim
271	in	_	_	I-Claim
272	a	_	_	I-Claim
273	significant	_	_	I-Claim
274	improvement	_	_	I-Claim
275	of	_	_	I-Claim
276	cancer-	_	_	I-Claim
277	or	_	_	I-Claim
278	cancer-therapy-associated	_	_	I-Claim
279	symptoms	_	_	I-Claim
280	.	_	_	I-Claim

281	The	_	_	B-Claim
282	magnitude	_	_	I-Claim
283	of	_	_	I-Claim
284	improvement	_	_	I-Claim
285	obtained	_	_	I-Claim
286	was	_	_	I-Claim
287	similar	_	_	I-Claim
288	whether	_	_	I-Claim
289	on	_	_	I-Claim
290	a	_	_	I-Claim
291	self-declared-healer-	_	_	I-Claim
292	or	_	_	I-Claim
293	an	_	_	I-Claim
294	actor-provided	_	_	I-Claim
295	"	_	_	I-Claim
296	treatment	_	_	I-Claim
297	"	_	_	I-Claim
298	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	multimodal	_	_	O
7	group	_	_	O
8	exercise	_	_	O
9	intervention	_	_	O
10	,	_	_	O
11	as	_	_	O
12	an	_	_	O
13	adjunct	_	_	O
14	to	_	_	O
15	conventional	_	_	O
16	care	_	_	O
17	,	_	_	O
18	on	_	_	O
19	fatigue	_	_	O
20	,	_	_	O
21	physical	_	_	O
22	capacity	_	_	O
23	,	_	_	O
24	general	_	_	O
25	wellbeing	_	_	O
26	,	_	_	O
27	physical	_	_	O
28	activity	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	who	_	_	O
39	were	_	_	O
40	undergoing	_	_	O
41	adjuvant	_	_	O
42	chemotherapy	_	_	O
43	or	_	_	O
44	treatment	_	_	O
45	for	_	_	O
46	advanced	_	_	O
47	disease	_	_	O
48	.	_	_	O

49	Randomised	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	Two	_	_	O
54	university	_	_	O
55	hospitals	_	_	O
56	in	_	_	O
57	Copenhagen	_	_	O
58	,	_	_	O
59	Denmark	_	_	O
60	.	_	_	O

61	269	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	cancer	_	_	O
65	;	_	_	O
66	73	_	_	O
67	men	_	_	O
68	,	_	_	O
69	196	_	_	O
70	women	_	_	O
71	,	_	_	O
72	mean	_	_	O
73	age	_	_	O
74	47	_	_	O
75	years	_	_	O
76	(	_	_	O
77	range	_	_	O
78	20-65	_	_	O
79	)	_	_	O
80	representing	_	_	O
81	21	_	_	O
82	diagnoses	_	_	O
83	.	_	_	O

84	Main	_	_	O
85	exclusion	_	_	O
86	criteria	_	_	O
87	were	_	_	O
88	brain	_	_	O
89	or	_	_	O
90	bone	_	_	O
91	metastases	_	_	O
92	.	_	_	O

93	235	_	_	O
94	patients	_	_	O
95	completed	_	_	O
96	follow-up	_	_	O
97	.	_	_	O

98	Supervised	_	_	O
99	exercise	_	_	O
100	comprising	_	_	O
101	high	_	_	O
102	intensity	_	_	O
103	cardiovascular	_	_	O
104	and	_	_	O
105	resistance	_	_	O
106	training	_	_	O
107	,	_	_	O
108	relaxation	_	_	O
109	and	_	_	O
110	body	_	_	O
111	awareness	_	_	O
112	training	_	_	O
113	,	_	_	O
114	massage	_	_	O
115	,	_	_	O
116	nine	_	_	O
117	hours	_	_	O
118	weekly	_	_	O
119	for	_	_	O
120	six	_	_	O
121	weeks	_	_	O
122	in	_	_	O
123	addition	_	_	O
124	to	_	_	O
125	conventional	_	_	O
126	care	_	_	O
127	,	_	_	O
128	compared	_	_	O
129	with	_	_	O
130	conventional	_	_	O
131	care	_	_	O
132	.	_	_	O

133	The	_	_	O
134	general	_	_	O
135	linear	_	_	O
136	model	_	_	O
137	was	_	_	O
138	used	_	_	O
139	for	_	_	O
140	continuous	_	_	O
141	outcome	_	_	O
142	while	_	_	O
143	analysis	_	_	O
144	of	_	_	O
145	associates	_	_	O
146	between	_	_	O
147	categorical	_	_	O
148	outcomes	_	_	O
149	was	_	_	O
150	performed	_	_	O
151	as	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	marginal	_	_	O
155	homogeneity	_	_	O
156	in	_	_	O
157	contingency	_	_	O
158	tables	_	_	O
159	.	_	_	O

160	Adjusted	_	_	B-Premise
161	for	_	_	I-Premise
162	baseline	_	_	I-Premise
163	score	_	_	I-Premise
164	,	_	_	I-Premise
165	disease	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	demographic	_	_	I-Premise
169	covariates	_	_	I-Premise
170	,	_	_	I-Premise
171	the	_	_	I-Premise
172	intervention	_	_	I-Premise
173	group	_	_	I-Premise
174	showed	_	_	I-Premise
175	an	_	_	I-Premise
176	estimated	_	_	I-Premise
177	improvement	_	_	I-Premise
178	at	_	_	I-Premise
179	six	_	_	I-Premise
180	weeks	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	primary	_	_	I-Premise
184	outcome	_	_	I-Premise
185	,	_	_	I-Premise
186	fatigue	_	_	I-Premise
187	,	_	_	I-Premise
188	of	_	_	I-Premise
189	-6.6	_	_	I-Premise
190	points	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	confidence	_	_	I-Premise
195	interval	_	_	I-Premise
196	-12.3	_	_	I-Premise
197	to	_	_	I-Premise
198	-0.9	_	_	I-Premise
199	,	_	_	I-Premise
200	P=0.02	_	_	I-Premise
201	;	_	_	I-Premise
202	effect	_	_	I-Premise
203	size=0.33	_	_	I-Premise
204	,	_	_	I-Premise
205	0.04	_	_	I-Premise
206	to	_	_	I-Premise
207	0.61	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Significant	_	_	B-Premise
211	effects	_	_	I-Premise
212	were	_	_	I-Premise
213	seen	_	_	I-Premise
214	on	_	_	I-Premise
215	vitality	_	_	I-Premise
216	(	_	_	I-Premise
217	effect	_	_	I-Premise
218	size	_	_	I-Premise
219	0.55	_	_	I-Premise
220	,	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	0.27	_	_	I-Premise
225	to	_	_	I-Premise
226	0.82	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	physical	_	_	I-Premise
230	functioning	_	_	I-Premise
231	(	_	_	I-Premise
232	0.37	_	_	I-Premise
233	,	_	_	I-Premise
234	0.09	_	_	I-Premise
235	to	_	_	I-Premise
236	0.65	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	role	_	_	I-Premise
240	physical	_	_	I-Premise
241	(	_	_	I-Premise
242	0.37	_	_	I-Premise
243	,	_	_	I-Premise
244	0.10	_	_	I-Premise
245	to	_	_	I-Premise
246	0.64	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	role	_	_	I-Premise
250	emotional	_	_	I-Premise
251	(	_	_	I-Premise
252	0.32	_	_	I-Premise
253	,	_	_	I-Premise
254	0.05	_	_	I-Premise
255	to	_	_	I-Premise
256	0.59	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	mental	_	_	I-Premise
261	health	_	_	I-Premise
262	(	_	_	I-Premise
263	0.28	_	_	I-Premise
264	,	_	_	I-Premise
265	0.02	_	_	I-Premise
266	to	_	_	I-Premise
267	0.56	_	_	I-Premise
268	)	_	_	I-Premise
269	scores	_	_	I-Premise
270	.	_	_	I-Premise

271	Improvement	_	_	B-Premise
272	was	_	_	I-Premise
273	noted	_	_	I-Premise
274	in	_	_	I-Premise
275	physical	_	_	I-Premise
276	capacity	_	_	I-Premise
277	:	_	_	I-Premise
278	estimated	_	_	I-Premise
279	mean	_	_	I-Premise
280	difference	_	_	I-Premise
281	between	_	_	I-Premise
282	groups	_	_	I-Premise
283	for	_	_	I-Premise
284	maximum	_	_	I-Premise
285	oxygen	_	_	I-Premise
286	consumption	_	_	I-Premise
287	was	_	_	I-Premise
288	0.16	_	_	I-Premise
289	l/min	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	0.1	_	_	I-Premise
295	to	_	_	I-Premise
296	0.2	_	_	I-Premise
297	,	_	_	I-Premise
298	P	_	_	I-Premise
299	<	_	_	I-Premise
300	0.0001	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	for	_	_	I-Premise
304	muscular	_	_	I-Premise
305	strength	_	_	I-Premise
306	(	_	_	I-Premise
307	leg	_	_	I-Premise
308	press	_	_	I-Premise
309	)	_	_	I-Premise
310	was	_	_	I-Premise
311	29.7	_	_	I-Premise
312	kg	_	_	I-Premise
313	(	_	_	I-Premise
314	23.4	_	_	I-Premise
315	to	_	_	I-Premise
316	34.9	_	_	I-Premise
317	,	_	_	I-Premise
318	P	_	_	I-Premise
319	<	_	_	I-Premise
320	0.0001	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	No	_	_	B-Premise
324	significant	_	_	I-Premise
325	effect	_	_	I-Premise
326	was	_	_	I-Premise
327	seen	_	_	I-Premise
328	on	_	_	I-Premise
329	global	_	_	I-Premise
330	health	_	_	I-Premise
331	status/quality	_	_	I-Premise
332	of	_	_	I-Premise
333	life	_	_	I-Premise
334	.	_	_	I-Premise

335	A	_	_	B-Claim
336	supervised	_	_	I-Claim
337	multimodal	_	_	I-Claim
338	exercise	_	_	I-Claim
339	intervention	_	_	I-Claim
340	including	_	_	I-Claim
341	high	_	_	I-Claim
342	and	_	_	I-Claim
343	low	_	_	I-Claim
344	intensity	_	_	I-Claim
345	components	_	_	I-Claim
346	was	_	_	I-Claim
347	feasible	_	_	I-Claim
348	and	_	_	I-Claim
349	could	_	_	I-Claim
350	safely	_	_	I-Claim
351	be	_	_	I-Claim
352	used	_	_	I-Claim
353	in	_	_	I-Claim
354	patients	_	_	I-Claim
355	with	_	_	I-Claim
356	various	_	_	I-Claim
357	cancers	_	_	I-Claim
358	who	_	_	I-Claim
359	were	_	_	I-Claim
360	receiving	_	_	I-Claim
361	adjuvant	_	_	I-Claim
362	chemotherapy	_	_	I-Claim
363	or	_	_	I-Claim
364	treatment	_	_	I-Claim
365	for	_	_	I-Claim
366	advanced	_	_	I-Claim
367	disease	_	_	I-Claim
368	.	_	_	I-Claim

369	The	_	_	B-Claim
370	intervention	_	_	I-Claim
371	reduced	_	_	I-Claim
372	fatigue	_	_	I-Claim
373	and	_	_	I-Claim
374	improved	_	_	I-Claim
375	vitality	_	_	I-Claim
376	,	_	_	I-Claim
377	aerobic	_	_	I-Claim
378	capacity	_	_	I-Claim
379	,	_	_	I-Claim
380	muscular	_	_	I-Claim
381	strength	_	_	I-Claim
382	,	_	_	I-Claim
383	and	_	_	I-Claim
384	physical	_	_	I-Claim
385	and	_	_	I-Claim
386	functional	_	_	I-Claim
387	activity	_	_	I-Claim
388	,	_	_	I-Claim
389	and	_	_	I-Claim
390	emotional	_	_	I-Claim
391	wellbeing	_	_	I-Claim
392	,	_	_	I-Claim
393	but	_	_	B-Claim
394	not	_	_	I-Claim
395	quality	_	_	I-Claim
396	of	_	_	I-Claim
397	life	_	_	I-Claim
398	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	weekly	_	_	O
4	epoetin	_	_	O
5	alfa	_	_	O
6	could	_	_	O
7	improve	_	_	O
8	hemoglobin	_	_	O
9	(	_	_	O
10	HgB	_	_	O
11	)	_	_	O
12	levels	_	_	O
13	,	_	_	O
14	reduce	_	_	O
15	RBC	_	_	O
16	transfusions	_	_	O
17	,	_	_	O
18	and	_	_	O
19	improve	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	QOL	_	_	O
25	)	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	cancer	_	_	O
31	and	_	_	O
32	with	_	_	O
33	anemia	_	_	O
34	after	_	_	O
35	receiving	_	_	O
36	myelosuppressive	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	This	_	_	O
40	double-blind	_	_	O
41	,	_	_	O
42	placebo-controlled	_	_	O
43	study	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	patients	_	_	O
47	to	_	_	O
48	placebo	_	_	O
49	or	_	_	O
50	epoetin	_	_	O
51	alfa	_	_	O
52	(	_	_	O
53	Ortho	_	_	O
54	Biotech	_	_	O
55	,	_	_	O
56	Bridgewater	_	_	O
57	,	_	_	O
58	NJ	_	_	O
59	)	_	_	O
60	40,000	_	_	O
61	U	_	_	O
62	subcutaneous	_	_	O
63	weekly	_	_	O
64	for	_	_	O
65	16	_	_	O
66	weeks	_	_	O
67	.	_	_	O

68	QOL	_	_	O
69	,	_	_	O
70	HgB	_	_	O
71	,	_	_	O
72	and	_	_	O
73	RBC	_	_	O
74	transfusions	_	_	O
75	were	_	_	O
76	measured	_	_	O
77	pretreatment	_	_	O
78	and	_	_	O
79	monthly	_	_	O
80	.	_	_	O

81	The	_	_	O
82	study	_	_	O
83	accrued	_	_	O
84	344	_	_	O
85	patients	_	_	O
86	;	_	_	O
87	330	_	_	O
88	were	_	_	O
89	assessable	_	_	O
90	for	_	_	O
91	efficacy	_	_	O
92	and	_	_	O
93	305	_	_	O
94	were	_	_	O
95	assessable	_	_	O
96	for	_	_	O
97	QOL	_	_	O
98	.	_	_	O

99	Placebo-treated	_	_	B-Premise
100	patients	_	_	I-Premise
101	had	_	_	I-Premise
102	a	_	_	I-Premise
103	mean	_	_	I-Premise
104	increase	_	_	I-Premise
105	in	_	_	I-Premise
106	HgB	_	_	I-Premise
107	of	_	_	I-Premise
108	0.9	_	_	I-Premise
109	g/dL	_	_	I-Premise
110	(	_	_	I-Premise
111	range	_	_	I-Premise
112	,	_	_	I-Premise
113	-3.8	_	_	I-Premise
114	to	_	_	I-Premise
115	+5.3	_	_	I-Premise
116	)	_	_	I-Premise
117	compared	_	_	I-Premise
118	with	_	_	I-Premise
119	2.8	_	_	I-Premise
120	g/dL	_	_	I-Premise
121	(	_	_	I-Premise
122	range	_	_	I-Premise
123	,	_	_	I-Premise
124	-2.2	_	_	I-Premise
125	to	_	_	I-Premise
126	+7.5	_	_	I-Premise
127	)	_	_	I-Premise
128	for	_	_	I-Premise
129	epoetin-treated	_	_	I-Premise
130	patients	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	.0001	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	During	_	_	B-Premise
138	the	_	_	I-Premise
139	study	_	_	I-Premise
140	,	_	_	I-Premise
141	31.7	_	_	I-Premise
142	%	_	_	I-Premise
143	of	_	_	I-Premise
144	placebo-treated	_	_	I-Premise
145	patients	_	_	I-Premise
146	achieved	_	_	I-Premise
147	a	_	_	I-Premise
148	>	_	_	I-Premise
149	or	_	_	I-Premise
150	=	_	_	I-Premise
151	2	_	_	I-Premise
152	g/dL	_	_	I-Premise
153	HgB	_	_	I-Premise
154	increase	_	_	I-Premise
155	compared	_	_	I-Premise
156	with	_	_	I-Premise
157	72.7	_	_	I-Premise
158	%	_	_	I-Premise
159	of	_	_	I-Premise
160	epoetin-treated	_	_	I-Premise
161	patients	_	_	I-Premise
162	(	_	_	I-Premise
163	P	_	_	I-Premise
164	<	_	_	I-Premise
165	.0001	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	The	_	_	B-Premise
169	incidence	_	_	I-Premise
170	of	_	_	I-Premise
171	RBC	_	_	I-Premise
172	transfusion	_	_	I-Premise
173	for	_	_	I-Premise
174	placebo	_	_	I-Premise
175	and	_	_	I-Premise
176	epoetin	_	_	I-Premise
177	treatment	_	_	I-Premise
178	arms	_	_	I-Premise
179	was	_	_	I-Premise
180	39.6	_	_	I-Premise
181	%	_	_	I-Premise
182	and	_	_	I-Premise
183	25.3	_	_	I-Premise
184	%	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.005	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	.	_	_	I-Premise

193	The	_	_	O
194	placebo	_	_	O
195	group	_	_	O
196	received	_	_	O
197	256	_	_	O
198	units	_	_	O
199	of	_	_	O
200	RBCs	_	_	O
201	compared	_	_	O
202	with	_	_	O
203	127	_	_	O
204	units	_	_	O
205	in	_	_	O
206	the	_	_	O
207	epoetin	_	_	O
208	group	_	_	O
209	(	_	_	O
210	P	_	_	O
211	<	_	_	O
212	.0001	_	_	O
213	)	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	incidence	_	_	I-Premise
217	of	_	_	I-Premise
218	toxicity	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	groups	_	_	I-Premise
222	was	_	_	I-Premise
223	similar	_	_	I-Premise
224	.	_	_	I-Premise

225	Changes	_	_	B-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	average	_	_	I-Premise
229	QOL	_	_	I-Premise
230	scores	_	_	I-Premise
231	from	_	_	I-Premise
232	baseline	_	_	I-Premise
233	to	_	_	I-Premise
234	the	_	_	I-Premise
235	end	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	study	_	_	I-Premise
239	were	_	_	I-Premise
240	similar	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	two	_	_	I-Premise
244	groups	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	not	_	_	I-Premise
249	significant	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	The	_	_	B-Premise
253	HgB	_	_	I-Premise
254	responders	_	_	I-Premise
255	(	_	_	I-Premise
256	irrespective	_	_	I-Premise
257	of	_	_	I-Premise
258	treatment	_	_	I-Premise
259	arm	_	_	I-Premise
260	)	_	_	I-Premise
261	had	_	_	I-Premise
262	a	_	_	I-Premise
263	mean	_	_	I-Premise
264	change	_	_	I-Premise
265	in	_	_	I-Premise
266	Functional	_	_	I-Premise
267	Assessment	_	_	I-Premise
268	of	_	_	I-Premise
269	Cancer	_	_	I-Premise
270	Therapy	_	_	I-Premise
271	(	_	_	I-Premise
272	FACT	_	_	I-Premise
273	)	_	_	I-Premise
274	fatigue	_	_	I-Premise
275	score	_	_	I-Premise
276	from	_	_	I-Premise
277	a	_	_	I-Premise
278	baseline	_	_	I-Premise
279	of	_	_	I-Premise
280	+5.1	_	_	I-Premise
281	compared	_	_	I-Premise
282	with	_	_	I-Premise
283	-2.1	_	_	I-Premise
284	for	_	_	I-Premise
285	the	_	_	I-Premise
286	nonresponders	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.006	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Epoetin	_	_	B-Claim
294	alfa	_	_	I-Claim
295	significantly	_	_	I-Claim
296	improved	_	_	I-Claim
297	HgB	_	_	I-Claim
298	and	_	_	I-Claim
299	reduced	_	_	I-Claim
300	transfusions	_	_	I-Claim
301	in	_	_	I-Claim
302	this	_	_	I-Claim
303	patient	_	_	I-Claim
304	population	_	_	I-Claim
305	.	_	_	I-Claim

306	These	_	_	B-Claim
307	results	_	_	I-Claim
308	support	_	_	I-Claim
309	the	_	_	I-Claim
310	use	_	_	I-Claim
311	of	_	_	I-Claim
312	weekly	_	_	I-Claim
313	epoetin	_	_	I-Claim
314	alfa	_	_	I-Claim
315	as	_	_	I-Claim
316	an	_	_	I-Claim
317	ameliorative	_	_	I-Claim
318	agent	_	_	I-Claim
319	for	_	_	I-Claim
320	cancer-related	_	_	I-Claim
321	anemia	_	_	I-Claim
322	.	_	_	I-Claim


0	Temozolomide	_	_	O
1	(	_	_	O
2	TMZ	_	_	O
3	)	_	_	O
4	is	_	_	O
5	an	_	_	O
6	alkylating	_	_	O
7	agent	_	_	O
8	licensed	_	_	O
9	for	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	high-grade	_	_	O
13	glioma	_	_	O
14	(	_	_	O
15	HGG	_	_	O
16	)	_	_	O
17	.	_	_	O

18	No	_	_	O
19	prospective	_	_	O
20	comparison	_	_	O
21	with	_	_	O
22	nitrosourea-based	_	_	O
23	chemotherapy	_	_	O
24	exists	_	_	O
25	.	_	_	O

26	We	_	_	O
27	report	_	_	O
28	,	_	_	O
29	to	_	_	O
30	our	_	_	O
31	knowledge	_	_	O
32	,	_	_	O
33	the	_	_	O
34	first	_	_	O
35	randomized	_	_	O
36	trial	_	_	O
37	of	_	_	O
38	procarbazine	_	_	O
39	,	_	_	O
40	lomustine	_	_	O
41	,	_	_	O
42	and	_	_	O
43	vincristine	_	_	O
44	(	_	_	O
45	PCV	_	_	O
46	)	_	_	O
47	versus	_	_	O
48	TMZ	_	_	O
49	in	_	_	O
50	chemotherapy-naive	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	recurrent	_	_	O
54	HGG	_	_	O
55	.	_	_	O

56	Four	_	_	O
57	hundred	_	_	O
58	forty-seven	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	PCV	_	_	O
65	(	_	_	O
66	224	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	or	_	_	O
70	TMZ	_	_	O
71	(	_	_	O
72	sub-random	_	_	O
73	assignment	_	_	O
74	:	_	_	O
75	TMZ-5	_	_	O
76	[	_	_	O
77	200	_	_	O
78	mg/m	_	_	O
79	(	_	_	O
80	2	_	_	O
81	)	_	_	O
82	for	_	_	O
83	5	_	_	O
84	days	_	_	O
85	,	_	_	O
86	112	_	_	O
87	patients	_	_	O
88	]	_	_	O
89	or	_	_	O
90	TMZ-21	_	_	O
91	[	_	_	O
92	100	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	for	_	_	O
98	21	_	_	O
99	days	_	_	O
100	,	_	_	O
101	111	_	_	O
102	patients	_	_	O
103	]	_	_	O
104	)	_	_	O
105	for	_	_	O
106	up	_	_	O
107	to	_	_	O
108	9	_	_	O
109	months	_	_	O
110	or	_	_	O
111	until	_	_	O
112	progression	_	_	O
113	.	_	_	O

114	The	_	_	O
115	primary	_	_	O
116	outcomes	_	_	O
117	were	_	_	O
118	survival	_	_	O
119	(	_	_	O
120	PCV	_	_	O
121	v	_	_	O
122	TMZ	_	_	O
123	)	_	_	O
124	and	_	_	O
125	12-week	_	_	O
126	progression-free	_	_	O
127	survival	_	_	O
128	(	_	_	O
129	PFS	_	_	O
130	;	_	_	O
131	TMZ-5	_	_	O
132	v	_	_	O
133	TMZ-21	_	_	O
134	)	_	_	O
135	.	_	_	O

136	This	_	_	O
137	study	_	_	O
138	is	_	_	O
139	registered	_	_	O
140	as	_	_	O
141	ISRCTN83176944	_	_	O
142	.	_	_	O

143	Percentages	_	_	O
144	of	_	_	O
145	patients	_	_	O
146	completing	_	_	O
147	9	_	_	O
148	months	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	in	_	_	O
152	the	_	_	O
153	PCV	_	_	O
154	,	_	_	O
155	TMZ-5	_	_	O
156	,	_	_	O
157	and	_	_	O
158	TMZ-21	_	_	O
159	arms	_	_	O
160	were	_	_	O
161	17	_	_	O
162	%	_	_	O
163	,	_	_	O
164	26	_	_	O
165	%	_	_	O
166	,	_	_	O
167	and	_	_	O
168	13	_	_	O
169	%	_	_	O
170	,	_	_	O
171	respectively	_	_	O
172	.	_	_	O

173	Major	_	_	B-Premise
174	toxicity	_	_	I-Premise
175	was	_	_	I-Premise
176	similar	_	_	I-Premise
177	across	_	_	I-Premise
178	all	_	_	I-Premise
179	three	_	_	I-Premise
180	groups	_	_	I-Premise
181	.	_	_	I-Premise

182	With	_	_	B-Premise
183	a	_	_	I-Premise
184	median	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	time	_	_	I-Premise
187	of	_	_	I-Premise
188	12	_	_	I-Premise
189	months	_	_	I-Premise
190	and	_	_	I-Premise
191	382	_	_	I-Premise
192	deaths	_	_	I-Premise
193	,	_	_	I-Premise
194	there	_	_	I-Premise
195	was	_	_	I-Premise
196	no	_	_	I-Premise
197	clear	_	_	I-Premise
198	survival	_	_	I-Premise
199	benefit	_	_	I-Premise
200	when	_	_	I-Premise
201	comparing	_	_	I-Premise
202	PCV	_	_	I-Premise
203	with	_	_	I-Premise
204	TMZ	_	_	I-Premise
205	(	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	[	_	_	I-Premise
209	HR	_	_	I-Premise
210	]	_	_	I-Premise
211	,	_	_	I-Premise
212	0.91	_	_	I-Premise
213	;	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	0.74	_	_	I-Premise
219	to	_	_	I-Premise
220	1.11	_	_	I-Premise
221	;	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.350	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	For	_	_	B-Premise
228	TMZ-5	_	_	I-Premise
229	versus	_	_	I-Premise
230	TMZ-21	_	_	I-Premise
231	,	_	_	I-Premise
232	12-week	_	_	I-Premise
233	PFS	_	_	I-Premise
234	rates	_	_	I-Premise
235	were	_	_	I-Premise
236	similar	_	_	I-Premise
237	(	_	_	I-Premise
238	63.6	_	_	I-Premise
239	%	_	_	I-Premise
240	and	_	_	I-Premise
241	65.7	_	_	I-Premise
242	%	_	_	I-Premise
243	,	_	_	I-Premise
244	respectively	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.745	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	but	_	_	B-Premise
252	TMZ-5	_	_	I-Premise
253	improved	_	_	I-Premise
254	overall	_	_	I-Premise
255	PFS	_	_	I-Premise
256	(	_	_	I-Premise
257	HR	_	_	I-Premise
258	,	_	_	I-Premise
259	1.38	_	_	I-Premise
260	;	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	,	_	_	I-Premise
265	1.05	_	_	I-Premise
266	to	_	_	I-Premise
267	1.82	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.023	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	survival	_	_	I-Premise
275	(	_	_	I-Premise
276	HR	_	_	I-Premise
277	,	_	_	I-Premise
278	1.32	_	_	I-Premise
279	;	_	_	I-Premise
280	95	_	_	I-Premise
281	%	_	_	I-Premise
282	CI	_	_	I-Premise
283	,	_	_	I-Premise
284	0.99	_	_	I-Premise
285	to	_	_	I-Premise
286	1.75	_	_	I-Premise
287	;	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.056	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	global	_	_	I-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	(	_	_	I-Premise
299	49	_	_	I-Premise
300	%	_	_	I-Premise
301	v	_	_	I-Premise
302	19	_	_	I-Premise
303	%	_	_	I-Premise
304	improved	_	_	I-Premise
305	>	_	_	I-Premise
306	10	_	_	I-Premise
307	points	_	_	I-Premise
308	at	_	_	I-Premise
309	6	_	_	I-Premise
310	months	_	_	I-Premise
311	,	_	_	I-Premise
312	respectively	_	_	I-Premise
313	;	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	.005	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Although	_	_	B-Claim
320	TMZ	_	_	I-Claim
321	(	_	_	I-Claim
322	both	_	_	I-Claim
323	arms	_	_	I-Claim
324	combined	_	_	I-Claim
325	)	_	_	I-Claim
326	did	_	_	I-Claim
327	not	_	_	I-Claim
328	show	_	_	I-Claim
329	a	_	_	I-Claim
330	clear	_	_	I-Claim
331	benefit	_	_	I-Claim
332	compared	_	_	I-Claim
333	with	_	_	I-Claim
334	PCV	_	_	I-Claim
335	,	_	_	I-Claim
336	comparison	_	_	I-Claim
337	of	_	_	I-Claim
338	the	_	_	I-Claim
339	TMZ	_	_	I-Claim
340	schedules	_	_	I-Claim
341	demonstrated	_	_	I-Claim
342	that	_	_	I-Claim
343	the	_	_	I-Claim
344	21-day	_	_	I-Claim
345	schedule	_	_	I-Claim
346	was	_	_	I-Claim
347	inferior	_	_	I-Claim
348	to	_	_	I-Claim
349	the	_	_	I-Claim
350	5-day	_	_	I-Claim
351	schedule	_	_	I-Claim
352	in	_	_	I-Claim
353	this	_	_	I-Claim
354	setting	_	_	I-Claim
355	.	_	_	I-Claim

356	This	_	_	B-Claim
357	challenges	_	_	I-Claim
358	the	_	_	I-Claim
359	current	_	_	I-Claim
360	understanding	_	_	I-Claim
361	of	_	_	I-Claim
362	increasing	_	_	I-Claim
363	TMZ	_	_	I-Claim
364	dose-intensity	_	_	I-Claim
365	by	_	_	I-Claim
366	prolonged	_	_	I-Claim
367	scheduling	_	_	I-Claim
368	.	_	_	I-Claim


0	Radiation-induced	_	_	O
1	mucositis	_	_	O
2	is	_	_	O
3	an	_	_	O
4	acute	_	_	O
5	reaction	_	_	O
6	of	_	_	O
7	the	_	_	O
8	mucosa	_	_	O
9	of	_	_	O
10	patients	_	_	O
11	undergoing	_	_	O
12	head	_	_	O
13	and	_	_	O
14	neck	_	_	O
15	radiotherapy	_	_	O
16	.	_	_	O

17	It	_	_	O
18	can	_	_	O
19	have	_	_	O
20	debilitating	_	_	O
21	and	_	_	O
22	dose-limiting	_	_	O
23	consequences	_	_	O
24	.	_	_	O

25	There	_	_	B-Claim
26	is	_	_	I-Claim
27	no	_	_	I-Claim
28	consensus	_	_	I-Claim
29	on	_	_	I-Claim
30	an	_	_	I-Claim
31	accepted	_	_	I-Claim
32	intervention	_	_	I-Claim
33	that	_	_	I-Claim
34	significantly	_	_	I-Claim
35	reduces	_	_	I-Claim
36	its	_	_	I-Claim
37	severity	_	_	I-Claim
38	.	_	_	I-Claim

39	Misoprostol	_	_	O
40	is	_	_	O
41	a	_	_	O
42	synthetic	_	_	O
43	prostaglandin	_	_	O
44	E1	_	_	O
45	analogue	_	_	O
46	,	_	_	O
47	with	_	_	O
48	properties	_	_	O
49	of	_	_	O
50	a	_	_	O
51	mucosal	_	_	O
52	cytoprotectant	_	_	O
53	.	_	_	O

54	We	_	_	O
55	designed	_	_	O
56	a	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	double-blind	_	_	O
60	,	_	_	O
61	placebo-controlled	_	_	O
62	trial	_	_	O
63	of	_	_	O
64	misoprostol	_	_	O
65	in	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	head	_	_	O
69	and	_	_	O
70	neck	_	_	O
71	cancer	_	_	O
72	.	_	_	O

73	The	_	_	O
74	aim	_	_	O
75	of	_	_	O
76	this	_	_	O
77	study	_	_	O
78	was	_	_	O
79	to	_	_	O
80	determine	_	_	O
81	if	_	_	O
82	topical	_	_	O
83	misoprostol	_	_	O
84	was	_	_	O
85	effective	_	_	O
86	in	_	_	O
87	reducing	_	_	O
88	the	_	_	O
89	severity	_	_	O
90	of	_	_	O
91	radiation-induced	_	_	O
92	mucositis	_	_	O
93	in	_	_	O
94	patients	_	_	O
95	receiving	_	_	O
96	radical	_	_	O
97	dose	_	_	O
98	radiotherapy	_	_	O
99	.	_	_	O

100	The	_	_	O
101	effect	_	_	O
102	of	_	_	O
103	this	_	_	O
104	intervention	_	_	O
105	on	_	_	O
106	a	_	_	O
107	patient	_	_	O
108	's	_	_	O
109	general	_	_	O
110	well-being	_	_	O
111	was	_	_	O
112	also	_	_	O
113	investigated	_	_	O
114	.	_	_	O

115	The	_	_	O
116	primary	_	_	O
117	end-point	_	_	O
118	of	_	_	O
119	the	_	_	O
120	study	_	_	O
121	was	_	_	O
122	the	_	_	O
123	incidence	_	_	O
124	of	_	_	O
125	Radiation	_	_	O
126	Therapy	_	_	O
127	Oncology	_	_	O
128	Group	_	_	O
129	grade	_	_	O
130	3	_	_	O
131	mucositis	_	_	O
132	.	_	_	O

133	Between	_	_	O
134	1999	_	_	O
135	and	_	_	O
136	2002	_	_	O
137	,	_	_	O
138	83	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	recruited	_	_	O
142	into	_	_	O
143	the	_	_	O
144	study	_	_	O
145	at	_	_	O
146	Westmead	_	_	O
147	and	_	_	O
148	Nepean	_	_	O
149	Hospitals	_	_	O
150	,	_	_	O
151	Sydney	_	_	O
152	.	_	_	O

153	Forty-two	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	receive	_	_	O
159	misoprostol	_	_	O
160	and	_	_	O
161	41	_	_	O
162	to	_	_	O
163	receive	_	_	O
164	a	_	_	O
165	placebo	_	_	O
166	.	_	_	O

167	Most	_	_	O
168	patients	_	_	O
169	received	_	_	O
170	radiotherapy	_	_	O
171	in	_	_	O
172	the	_	_	O
173	adjuvant	_	_	O
174	setting	_	_	O
175	(	_	_	O
176	52	_	_	O
177	of	_	_	O
178	the	_	_	O
179	83	_	_	O
180	)	_	_	O
181	and	_	_	O
182	had	_	_	O
183	either	_	_	O
184	an	_	_	O
185	oral	_	_	O
186	cavity	_	_	O
187	(	_	_	O
188	42	_	_	O
189	of	_	_	O
190	the	_	_	O
191	83	_	_	O
192	)	_	_	O
193	or	_	_	O
194	an	_	_	O
195	oropharyngeal	_	_	O
196	(	_	_	O
197	16	_	_	O
198	of	_	_	O
199	the	_	_	O
200	83	_	_	O
201	)	_	_	O
202	cancer	_	_	O
203	.	_	_	O

204	We	_	_	B-Claim
205	could	_	_	I-Claim
206	not	_	_	I-Claim
207	identify	_	_	I-Claim
208	any	_	_	I-Claim
209	significant	_	_	I-Claim
210	difference	_	_	I-Claim
211	in	_	_	I-Claim
212	the	_	_	I-Claim
213	incidence	_	_	I-Claim
214	of	_	_	I-Claim
215	severe	_	_	I-Claim
216	mucositis	_	_	I-Claim
217	based	_	_	I-Claim
218	on	_	_	I-Claim
219	whether	_	_	I-Claim
220	patients	_	_	I-Claim
221	were	_	_	I-Claim
222	allocated	_	_	I-Claim
223	to	_	_	I-Claim
224	receive	_	_	I-Claim
225	misoprostol	_	_	I-Claim
226	or	_	_	I-Claim
227	placebo	_	_	I-Claim
228	.	_	_	I-Claim

229	There	_	_	B-Premise
230	was	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	mean	_	_	I-Premise
237	area	_	_	I-Premise
238	under	_	_	I-Premise
239	the	_	_	I-Premise
240	mucositis	_	_	I-Premise
241	curve	_	_	I-Premise
242	(	_	_	I-Premise
243	13.2	_	_	I-Premise
244	vs	_	_	I-Premise
245	16.6	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.1	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Patients	_	_	B-Premise
253	allocated	_	_	I-Premise
254	to	_	_	I-Premise
255	misoprostol	_	_	I-Premise
256	did	_	_	I-Premise
257	report	_	_	I-Premise
258	slightly	_	_	I-Premise
259	increased	_	_	I-Premise
260	soreness	_	_	I-Premise
261	(	_	_	I-Premise
262	7.6	_	_	I-Premise
263	vs	_	_	I-Premise
264	6.9	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	0.04	_	_	I-Premise
269	)	_	_	I-Premise
270	and	_	_	I-Premise
271	a	_	_	I-Premise
272	greater	_	_	I-Premise
273	use	_	_	I-Premise
274	of	_	_	I-Premise
275	analgesics	_	_	I-Premise
276	.	_	_	I-Premise

277	However	_	_	B-Premise
278	,	_	_	I-Premise
279	this	_	_	I-Premise
280	difference	_	_	I-Premise
281	did	_	_	I-Premise
282	not	_	_	I-Premise
283	translate	_	_	I-Premise
284	into	_	_	I-Premise
285	a	_	_	I-Premise
286	worse	_	_	I-Premise
287	feeling	_	_	I-Premise
288	of	_	_	I-Premise
289	general	_	_	I-Premise
290	well-being	_	_	I-Premise
291	as	_	_	I-Premise
292	measured	_	_	I-Premise
293	by	_	_	I-Premise
294	a	_	_	I-Premise
295	simple	_	_	I-Premise
296	visual	_	_	I-Premise
297	analogue	_	_	I-Premise
298	scale	_	_	I-Premise
299	(	_	_	I-Premise
300	5.8	_	_	I-Premise
301	vs	_	_	I-Premise
302	5.2	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0.3	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	In	_	_	B-Claim
310	conclusion	_	_	I-Claim
311	,	_	_	I-Claim
312	we	_	_	I-Claim
313	were	_	_	I-Claim
314	unable	_	_	I-Claim
315	to	_	_	I-Claim
316	identify	_	_	I-Claim
317	a	_	_	I-Claim
318	reduction	_	_	I-Claim
319	in	_	_	I-Claim
320	radiation-induced	_	_	I-Claim
321	mucositis	_	_	I-Claim
322	in	_	_	I-Claim
323	patients	_	_	I-Claim
324	receiving	_	_	I-Claim
325	misoprostol	_	_	I-Claim
326	.	_	_	I-Claim

327	There	_	_	B-Claim
328	is	_	_	I-Claim
329	a	_	_	I-Claim
330	paucity	_	_	I-Claim
331	of	_	_	I-Claim
332	high-level	_	_	I-Claim
333	evidence	_	_	I-Claim
334	on	_	_	I-Claim
335	potentially	_	_	I-Claim
336	useful	_	_	I-Claim
337	interventions	_	_	I-Claim
338	and	_	_	I-Claim
339	a	_	_	I-Claim
340	continued	_	_	I-Claim
341	need	_	_	I-Claim
342	for	_	_	I-Claim
343	new	_	_	I-Claim
344	and	_	_	I-Claim
345	innovative	_	_	I-Claim
346	research	_	_	I-Claim
347	,	_	_	I-Claim
348	incorporating	_	_	I-Claim
349	quality-of-life	_	_	I-Claim
350	measurements	_	_	I-Claim
351	,	_	_	I-Claim
352	in	_	_	I-Claim
353	patients	_	_	I-Claim
354	experiencing	_	_	I-Claim
355	radiation-induced	_	_	I-Claim
356	mucositis	_	_	I-Claim
357	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	study	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	treatment	_	_	O
8	schedules	_	_	O
9	of	_	_	O
10	gemcitabine	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	non-small-cell	_	_	O
15	lung	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NSCLC	_	_	O
19	)	_	_	O
20	and	_	_	O
21	impaired	_	_	O
22	Karnofsky	_	_	O
23	performance	_	_	O
24	status	_	_	O
25	(	_	_	O
26	KP	_	_	O
27	)	_	_	O
28	.	_	_	O

29	Primary	_	_	O
30	objectives	_	_	O
31	were	_	_	O
32	to	_	_	O
33	record	_	_	O
34	changes	_	_	O
35	from	_	_	O
36	baseline	_	_	O
37	KP	_	_	O
38	and	_	_	O
39	to	_	_	O
40	assess	_	_	O
41	symptom	_	_	O
42	palliation	_	_	O
43	.	_	_	O

44	Secondary	_	_	O
45	objectives	_	_	O
46	were	_	_	O
47	overall	_	_	O
48	survival	_	_	O
49	,	_	_	O
50	tumor	_	_	O
51	response	_	_	O
52	,	_	_	O
53	and	_	_	O
54	toxicity	_	_	O
55	.	_	_	O

56	Patients	_	_	O
57	with	_	_	O
58	stage	_	_	O
59	IIIb	_	_	O
60	and	_	_	O
61	IV	_	_	O
62	NSCLC	_	_	O
63	and	_	_	O
64	KP	_	_	O
65	<	_	_	O
66	/=	_	_	O
67	70	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	gemcitabine	_	_	O
74	1,000	_	_	O
75	mg/m	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	on	_	_	O
80	days	_	_	O
81	1	_	_	O
82	,	_	_	O
83	8	_	_	O
84	,	_	_	O
85	and	_	_	O
86	15	_	_	O
87	of	_	_	O
88	each	_	_	O
89	28-day	_	_	O
90	cycle	_	_	O
91	(	_	_	O
92	3w4	_	_	O
93	)	_	_	O
94	or	_	_	O
95	gemcitabine	_	_	O
96	1,500	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	of	_	_	O
107	each	_	_	O
108	21-day	_	_	O
109	cycle	_	_	O
110	(	_	_	O
111	2w3	_	_	O
112	)	_	_	O
113	,	_	_	O
114	both	_	_	O
115	for	_	_	O
116	up	_	_	O
117	to	_	_	O
118	six	_	_	O
119	cycles	_	_	O
120	.	_	_	O

121	KP	_	_	O
122	,	_	_	O
123	toxicity	_	_	O
124	,	_	_	O
125	and	_	_	O
126	SS14	_	_	O
127	lung	_	_	O
128	cancer	_	_	O
129	specific	_	_	O
130	questions	_	_	O
131	were	_	_	O
132	recorded	_	_	O
133	before	_	_	O
134	each	_	_	O
135	cycle	_	_	O
136	of	_	_	O
137	treatment	_	_	O
138	.	_	_	O

139	Response	_	_	O
140	was	_	_	O
141	evaluated	_	_	O
142	4	_	_	O
143	weeks	_	_	O
144	after	_	_	O
145	the	_	_	O
146	last	_	_	O
147	cycle	_	_	O
148	.	_	_	O

149	One	_	_	O
150	hundred	_	_	O
151	seventy-four	_	_	O
152	patients	_	_	O
153	were	_	_	O
154	enrolled	_	_	O
155	.	_	_	O

156	There	_	_	B-Premise
157	was	_	_	I-Premise
158	significant	_	_	I-Premise
159	early	_	_	I-Premise
160	attrition	_	_	I-Premise
161	due	_	_	I-Premise
162	to	_	_	I-Premise
163	disease	_	_	I-Premise
164	progression	_	_	I-Premise
165	;	_	_	I-Premise
166	only	_	_	I-Premise
167	61.5	_	_	I-Premise
168	%	_	_	I-Premise
169	of	_	_	I-Premise
170	patients	_	_	I-Premise
171	were	_	_	I-Premise
172	alive	_	_	I-Premise
173	at	_	_	I-Premise
174	2	_	_	I-Premise
175	months	_	_	I-Premise
176	.	_	_	I-Premise

177	There	_	_	B-Premise
178	was	_	_	I-Premise
179	a	_	_	I-Premise
180	significant	_	_	I-Premise
181	improvement	_	_	I-Premise
182	in	_	_	I-Premise
183	KP	_	_	I-Premise
184	from	_	_	I-Premise
185	baseline	_	_	I-Premise
186	to	_	_	I-Premise
187	pre-cycle	_	_	I-Premise
188	3	_	_	I-Premise
189	in	_	_	I-Premise
190	both	_	_	I-Premise
191	arms	_	_	I-Premise
192	,	_	_	I-Premise
193	with	_	_	I-Premise
194	a	_	_	I-Premise
195	trend	_	_	I-Premise
196	in	_	_	I-Premise
197	favor	_	_	I-Premise
198	of	_	_	I-Premise
199	the	_	_	I-Premise
200	3w4	_	_	I-Premise
201	regimen	_	_	I-Premise
202	for	_	_	I-Premise
203	duration	_	_	I-Premise
204	and	_	_	I-Premise
205	faster	_	_	I-Premise
206	onset	_	_	I-Premise
207	of	_	_	I-Premise
208	improvement	_	_	I-Premise
209	.	_	_	I-Premise

210	Eight	_	_	B-Premise
211	of	_	_	I-Premise
212	the	_	_	I-Premise
213	17	_	_	I-Premise
214	quality-of-life	_	_	I-Premise
215	(	_	_	I-Premise
216	QOL	_	_	I-Premise
217	)	_	_	I-Premise
218	variables	_	_	I-Premise
219	assessed	_	_	I-Premise
220	showed	_	_	I-Premise
221	an	_	_	I-Premise
222	improvement	_	_	I-Premise
223	of	_	_	I-Premise
224	more	_	_	I-Premise
225	than	_	_	I-Premise
226	10	_	_	I-Premise
227	%	_	_	I-Premise
228	between	_	_	I-Premise
229	baseline	_	_	I-Premise
230	and	_	_	I-Premise
231	the	_	_	I-Premise
232	start	_	_	I-Premise
233	of	_	_	I-Premise
234	the	_	_	I-Premise
235	third	_	_	I-Premise
236	cycle	_	_	I-Premise
237	of	_	_	I-Premise
238	treatment	_	_	I-Premise
239	.	_	_	I-Premise

240	Response	_	_	B-Premise
241	rate	_	_	I-Premise
242	,	_	_	I-Premise
243	survival	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	duration	_	_	I-Premise
247	were	_	_	I-Premise
248	similar	_	_	I-Premise
249	in	_	_	I-Premise
250	both	_	_	I-Premise
251	arms	_	_	I-Premise
252	.	_	_	I-Premise

253	There	_	_	B-Claim
254	was	_	_	I-Claim
255	no	_	_	I-Claim
256	significant	_	_	I-Claim
257	difference	_	_	I-Claim
258	between	_	_	I-Claim
259	the	_	_	I-Claim
260	two	_	_	I-Claim
261	schedules	_	_	I-Claim
262	examined	_	_	I-Claim
263	in	_	_	I-Claim
264	terms	_	_	I-Claim
265	of	_	_	I-Claim
266	improvement	_	_	I-Claim
267	in	_	_	I-Claim
268	KP	_	_	I-Claim
269	or	_	_	I-Claim
270	QOL	_	_	I-Claim
271	,	_	_	I-Claim
272	but	_	_	I-Claim
273	there	_	_	I-Claim
274	seemed	_	_	I-Claim
275	to	_	_	I-Claim
276	be	_	_	I-Claim
277	a	_	_	I-Claim
278	trend	_	_	I-Claim
279	in	_	_	I-Claim
280	favor	_	_	I-Claim
281	of	_	_	I-Claim
282	the	_	_	I-Claim
283	3w4	_	_	I-Claim
284	schedule	_	_	I-Claim
285	.	_	_	I-Claim


0	Behavioral	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	in	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	survivors	_	_	O
8	,	_	_	O
9	including	_	_	O
10	disturbances	_	_	O
11	in	_	_	O
12	energy	_	_	O
13	,	_	_	O
14	sleep	_	_	O
15	,	_	_	O
16	and	_	_	O
17	mood	_	_	O
18	,	_	_	O
19	though	_	_	O
20	few	_	_	O
21	risk	_	_	O
22	factors	_	_	O
23	for	_	_	O
24	these	_	_	O
25	negative	_	_	O
26	outcomes	_	_	O
27	have	_	_	O
28	been	_	_	O
29	identified	_	_	O
30	.	_	_	O

31	Our	_	_	O
32	study	_	_	O
33	examined	_	_	O
34	intrusive	_	_	O
35	thoughts	_	_	O
36	as	_	_	O
37	a	_	_	O
38	predictor	_	_	O
39	of	_	_	O
40	lingering	_	_	O
41	symptoms	_	_	O
42	in	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	in	_	_	O
47	the	_	_	O
48	year	_	_	O
49	following	_	_	O
50	treatment	_	_	O
51	.	_	_	O

52	Data	_	_	O
53	come	_	_	O
54	from	_	_	O
55	the	_	_	O
56	Moving	_	_	O
57	Beyond	_	_	O
58	Cancer	_	_	O
59	psychoeducational	_	_	O
60	intervention	_	_	O
61	trial	_	_	O
62	,	_	_	O
63	aimed	_	_	O
64	at	_	_	O
65	easing	_	_	O
66	the	_	_	O
67	transition	_	_	O
68	from	_	_	O
69	patient	_	_	O
70	to	_	_	O
71	survivor	_	_	O
72	.	_	_	O

73	Women	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	558	_	_	O
78	)	_	_	O
79	completed	_	_	O
80	psychosocial	_	_	O
81	questionnaires	_	_	O
82	within	_	_	O
83	4	_	_	O
84	weeks	_	_	O
85	posttreatment	_	_	O
86	and	_	_	O
87	again	_	_	O
88	2	_	_	O
89	,	_	_	O
90	6	_	_	O
91	,	_	_	O
92	and	_	_	O
93	12	_	_	O
94	months	_	_	O
95	later	_	_	O
96	.	_	_	O

97	We	_	_	O
98	examined	_	_	O
99	intrusive	_	_	O
100	thoughts	_	_	O
101	about	_	_	O
102	cancer	_	_	O
103	at	_	_	O
104	the	_	_	O
105	baseline	_	_	O
106	assessment	_	_	O
107	as	_	_	O
108	a	_	_	O
109	predictor	_	_	O
110	of	_	_	O
111	fatigue	_	_	O
112	,	_	_	O
113	sleep	_	_	O
114	problems	_	_	O
115	,	_	_	O
116	pain	_	_	O
117	,	_	_	O
118	breast	_	_	O
119	cancer-specific	_	_	O
120	symptoms	_	_	O
121	,	_	_	O
122	depressive	_	_	O
123	symptoms	_	_	O
124	,	_	_	O
125	negative	_	_	O
126	affect	_	_	O
127	,	_	_	O
128	and	_	_	O
129	quality	_	_	O
130	of	_	_	O
131	life	_	_	O
132	using	_	_	O
133	growth	_	_	O
134	curve	_	_	O
135	modeling	_	_	O
136	,	_	_	O
137	controlling	_	_	O
138	for	_	_	O
139	study	_	_	O
140	condition	_	_	O
141	and	_	_	O
142	other	_	_	O
143	covariates	_	_	O
144	.	_	_	O

145	Intrusive	_	_	B-Premise
146	thoughts	_	_	I-Premise
147	were	_	_	I-Premise
148	associated	_	_	I-Premise
149	with	_	_	I-Premise
150	higher	_	_	I-Premise
151	levels	_	_	I-Premise
152	of	_	_	I-Premise
153	all	_	_	I-Premise
154	symptoms	_	_	I-Premise
155	at	_	_	I-Premise
156	baseline	_	_	I-Premise
157	and	_	_	I-Premise
158	at	_	_	I-Premise
159	the	_	_	I-Premise
160	12-month	_	_	I-Premise
161	assessment	_	_	I-Premise
162	.	_	_	I-Premise

163	Intrusive	_	_	B-Premise
164	thoughts	_	_	I-Premise
165	also	_	_	I-Premise
166	influenced	_	_	I-Premise
167	the	_	_	I-Premise
168	trajectory	_	_	I-Premise
169	of	_	_	I-Premise
170	pain	_	_	I-Premise
171	,	_	_	I-Premise
172	depressive	_	_	I-Premise
173	symptoms	_	_	I-Premise
174	,	_	_	I-Premise
175	negative	_	_	I-Premise
176	affect	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	physical	_	_	I-Premise
180	functioning	_	_	I-Premise
181	over	_	_	I-Premise
182	time	_	_	I-Premise
183	;	_	_	I-Premise
184	women	_	_	B-Premise
185	with	_	_	I-Premise
186	higher	_	_	I-Premise
187	intrusions	_	_	I-Premise
188	at	_	_	I-Premise
189	baseline	_	_	I-Premise
190	started	_	_	I-Premise
191	worse	_	_	I-Premise
192	and	_	_	I-Premise
193	improved	_	_	I-Premise
194	over	_	_	I-Premise
195	time	_	_	I-Premise
196	,	_	_	I-Premise
197	whereas	_	_	I-Premise
198	those	_	_	I-Premise
199	with	_	_	I-Premise
200	lower	_	_	I-Premise
201	intrusions	_	_	I-Premise
202	remained	_	_	I-Premise
203	at	_	_	I-Premise
204	a	_	_	I-Premise
205	constant	_	_	I-Premise
206	,	_	_	I-Premise
207	lower	_	_	I-Premise
208	level	_	_	I-Premise
209	over	_	_	I-Premise
210	time	_	_	I-Premise
211	.	_	_	I-Premise

212	Intrusions	_	_	B-Premise
213	were	_	_	I-Premise
214	not	_	_	I-Premise
215	associated	_	_	I-Premise
216	with	_	_	I-Premise
217	the	_	_	I-Premise
218	trajectory	_	_	I-Premise
219	of	_	_	I-Premise
220	fatigue	_	_	I-Premise
221	,	_	_	I-Premise
222	sleep	_	_	I-Premise
223	,	_	_	I-Premise
224	breast	_	_	I-Premise
225	cancer-specific	_	_	I-Premise
226	symptoms	_	_	I-Premise
227	,	_	_	I-Premise
228	or	_	_	I-Premise
229	mental	_	_	I-Premise
230	functioning	_	_	I-Premise
231	;	_	_	I-Premise
232	women	_	_	B-Premise
233	with	_	_	I-Premise
234	higher	_	_	I-Premise
235	intrusions	_	_	I-Premise
236	at	_	_	I-Premise
237	baseline	_	_	I-Premise
238	started	_	_	I-Premise
239	worse	_	_	I-Premise
240	and	_	_	I-Premise
241	remained	_	_	I-Premise
242	worse	_	_	I-Premise
243	over	_	_	I-Premise
244	time	_	_	I-Premise
245	.	_	_	I-Premise

246	Intrusive	_	_	B-Claim
247	thoughts	_	_	I-Claim
248	are	_	_	I-Claim
249	associated	_	_	I-Claim
250	with	_	_	I-Claim
251	enduring	_	_	I-Claim
252	elevations	_	_	I-Claim
253	in	_	_	I-Claim
254	behavioral	_	_	I-Claim
255	symptoms	_	_	I-Claim
256	and	_	_	I-Claim
257	impaired	_	_	I-Claim
258	quality	_	_	I-Claim
259	of	_	_	I-Claim
260	life	_	_	I-Claim
261	in	_	_	I-Claim
262	the	_	_	I-Claim
263	year	_	_	I-Claim
264	after	_	_	I-Claim
265	breast	_	_	I-Claim
266	cancer	_	_	I-Claim
267	treatment	_	_	I-Claim
268	and	_	_	I-Claim
269	may	_	_	I-Claim
270	be	_	_	I-Claim
271	a	_	_	I-Claim
272	risk	_	_	I-Claim
273	factor	_	_	I-Claim
274	for	_	_	I-Claim
275	poor	_	_	I-Claim
276	outcomes	_	_	I-Claim
277	.	_	_	I-Claim


0	On	_	_	O
1	March	_	_	O
2	15	_	_	O
3	,	_	_	O
4	2005	_	_	O
5	,	_	_	O
6	the	_	_	O
7	US	_	_	O
8	Food	_	_	O
9	and	_	_	O
10	Drug	_	_	O
11	Administration	_	_	O
12	approved	_	_	O
13	temozolomide	_	_	O
14	(	_	_	O
15	Temodar	_	_	O
16	capsules	_	_	O
17	,	_	_	O
18	Schering-Plough	_	_	O
19	Research	_	_	O
20	Institute	_	_	O
21	)	_	_	O
22	for	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	adult	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	newly	_	_	O
30	diagnosed	_	_	O
31	glioblastoma	_	_	O
32	multiforme	_	_	O
33	concomitantly	_	_	O
34	with	_	_	O
35	radiotherapy	_	_	O
36	and	_	_	O
37	then	_	_	O
38	as	_	_	O
39	maintenance	_	_	O
40	treatment	_	_	O
41	.	_	_	O

42	Five	_	_	O
43	hundred	_	_	O
44	seventy-three	_	_	O
45	glioblastoma	_	_	O
46	multiforme	_	_	O
47	patients	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	to	_	_	O
51	receive	_	_	O
52	either	_	_	O
53	temozolomide	_	_	O
54	+	_	_	O
55	radiotherapy	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	287	_	_	O
60	)	_	_	O
61	or	_	_	O
62	radiotherapy	_	_	O
63	alone	_	_	O
64	(	_	_	O
65	n	_	_	O
66	=	_	_	O
67	286	_	_	O
68	)	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	in	_	_	O
72	the	_	_	O
73	temozolomide	_	_	O
74	+	_	_	O
75	radiotherapy	_	_	O
76	arm	_	_	O
77	received	_	_	O
78	concomitant	_	_	O
79	temozolomide	_	_	O
80	(	_	_	O
81	75	_	_	O
82	mg/m2	_	_	O
83	)	_	_	O
84	once	_	_	O
85	daily	_	_	O
86	for	_	_	O
87	the	_	_	O
88	duration	_	_	O
89	of	_	_	O
90	radiation	_	_	O
91	therapy	_	_	O
92	(	_	_	O
93	42-49	_	_	O
94	days	_	_	O
95	)	_	_	O
96	.	_	_	O

97	This	_	_	O
98	was	_	_	O
99	followed	_	_	O
100	,	_	_	O
101	4	_	_	O
102	weeks	_	_	O
103	later	_	_	O
104	,	_	_	O
105	by	_	_	O
106	six	_	_	O
107	cycles	_	_	O
108	of	_	_	O
109	temozolomide	_	_	O
110	,	_	_	O
111	150	_	_	O
112	or	_	_	O
113	200	_	_	O
114	mg/m2	_	_	O
115	daily	_	_	O
116	for	_	_	O
117	5	_	_	O
118	days	_	_	O
119	,	_	_	O
120	every	_	_	O
121	4	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	Patients	_	_	O
125	in	_	_	O
126	the	_	_	O
127	control	_	_	O
128	arm	_	_	O
129	received	_	_	O
130	radiotherapy	_	_	O
131	only	_	_	O
132	.	_	_	O

133	In	_	_	O
134	both	_	_	O
135	arms	_	_	O
136	,	_	_	O
137	radiotherapy	_	_	O
138	was	_	_	O
139	delivered	_	_	O
140	as	_	_	O
141	60	_	_	O
142	Gy/30	_	_	O
143	fractions	_	_	O
144	to	_	_	O
145	the	_	_	O
146	tumor	_	_	O
147	site	_	_	O
148	with	_	_	O
149	a	_	_	O
150	2	_	_	O
151	to	_	_	O
152	3	_	_	O
153	cm	_	_	O
154	margin	_	_	O
155	.	_	_	O

156	Pneumocystis	_	_	O
157	carinii	_	_	O
158	pneumonia	_	_	O
159	prophylaxis	_	_	O
160	was	_	_	O
161	required	_	_	O
162	during	_	_	O
163	temozolomide	_	_	O
164	+	_	_	O
165	radiotherapy	_	_	O
166	treatment	_	_	O
167	and	_	_	O
168	was	_	_	O
169	continued	_	_	O
170	until	_	_	O
171	recovery	_	_	O
172	of	_	_	O
173	lymphocytopenia	_	_	O
174	(	_	_	O
175	Common	_	_	O
176	Toxicity	_	_	O
177	Criteria	_	_	O
178	grade	_	_	O
179	<	_	_	O
180	1	_	_	O
181	)	_	_	O
182	.	_	_	O

183	At	_	_	O
184	disease	_	_	O
185	progression	_	_	O
186	,	_	_	O
187	temozolomide	_	_	O
188	salvage	_	_	O
189	treatment	_	_	O
190	was	_	_	O
191	given	_	_	O
192	to	_	_	O
193	161	_	_	O
194	of	_	_	O
195	282	_	_	O
196	patients	_	_	O
197	(	_	_	O
198	57	_	_	O
199	%	_	_	O
200	)	_	_	O
201	in	_	_	O
202	the	_	_	O
203	radiotherapy	_	_	O
204	alone	_	_	O
205	arm	_	_	O
206	,	_	_	O
207	and	_	_	O
208	to	_	_	O
209	62	_	_	O
210	of	_	_	O
211	277	_	_	O
212	patients	_	_	O
213	(	_	_	O
214	22	_	_	O
215	%	_	_	O
216	)	_	_	O
217	in	_	_	O
218	the	_	_	O
219	temozolomide	_	_	O
220	+	_	_	O
221	radiotherapy	_	_	O
222	arm	_	_	O
223	.	_	_	O

224	Patients	_	_	B-Claim
225	receiving	_	_	I-Claim
226	concomitant	_	_	I-Claim
227	and	_	_	I-Claim
228	maintenance	_	_	I-Claim
229	temozolomide	_	_	I-Claim
230	+	_	_	I-Claim
231	radiotherapy	_	_	I-Claim
232	had	_	_	I-Claim
233	significantly	_	_	I-Claim
234	improved	_	_	I-Claim
235	overall	_	_	I-Claim
236	survival	_	_	I-Claim
237	.	_	_	I-Claim

238	The	_	_	B-Premise
239	hazard	_	_	I-Premise
240	ratio	_	_	I-Premise
241	was	_	_	I-Premise
242	0.63	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	confidence	_	_	I-Premise
247	interval	_	_	I-Premise
248	,	_	_	I-Premise
249	0.52-0.75	_	_	I-Premise
250	;	_	_	I-Premise
251	log-rank	_	_	I-Premise
252	,	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	0.0001	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Median	_	_	B-Premise
259	survival	_	_	I-Premise
260	was	_	_	I-Premise
261	14.6	_	_	I-Premise
262	months	_	_	I-Premise
263	(	_	_	I-Premise
264	temozolomide	_	_	I-Premise
265	+	_	_	I-Premise
266	radiotherapy	_	_	I-Premise
267	)	_	_	I-Premise
268	versus	_	_	I-Premise
269	12.1	_	_	I-Premise
270	months	_	_	I-Premise
271	(	_	_	I-Premise
272	radiotherapy	_	_	I-Premise
273	alone	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Adverse	_	_	B-Claim
277	events	_	_	I-Claim
278	during	_	_	I-Claim
279	temozolomide	_	_	I-Claim
280	treatment	_	_	I-Claim
281	included	_	_	I-Claim
282	thrombocytopenia	_	_	I-Claim
283	,	_	_	I-Claim
284	nausea	_	_	I-Claim
285	,	_	_	I-Claim
286	vomiting	_	_	I-Claim
287	,	_	_	I-Claim
288	anorexia	_	_	I-Claim
289	,	_	_	I-Claim
290	constipation	_	_	I-Claim
291	,	_	_	I-Claim
292	alopecia	_	_	I-Claim
293	,	_	_	I-Claim
294	headache	_	_	I-Claim
295	,	_	_	I-Claim
296	fatigue	_	_	I-Claim
297	,	_	_	I-Claim
298	and	_	_	I-Claim
299	convulsions	_	_	I-Claim
300	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	the	_	_	O
4	feasibility	_	_	O
5	and	_	_	O
6	acceptability	_	_	O
7	of	_	_	O
8	an	_	_	O
9	Individual	_	_	O
10	Internet	_	_	O
11	Intervention	_	_	O
12	(	_	_	O
13	III	_	_	O
14	)	_	_	O
15	embedded	_	_	O
16	and	_	_	O
17	integrated	_	_	O
18	into	_	_	O
19	an	_	_	O
20	Internet	_	_	O
21	Support	_	_	O
22	Group	_	_	O
23	(	_	_	O
24	ISG	_	_	O
25	)	_	_	O
26	with	_	_	O
27	the	_	_	O
28	ultimate	_	_	O
29	goal	_	_	O
30	of	_	_	O
31	enhancing	_	_	O
32	adherence	_	_	O
33	and	_	_	O
34	learning	_	_	O
35	,	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	an	_	_	O
39	individual	_	_	O
40	internet	_	_	O
41	invention	_	_	O
42	alone	_	_	O
43	.	_	_	O

44	Thirty-one	_	_	O
45	posttreatment	_	_	O
46	cancer	_	_	O
47	survivors	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	in	_	_	O
51	groups	_	_	O
52	of	_	_	O
53	seven	_	_	O
54	to	_	_	O
55	nine	_	_	O
56	to	_	_	O
57	either	_	_	O
58	the	_	_	O
59	8-week	_	_	O
60	III	_	_	O
61	+	_	_	O
62	ISG	_	_	O
63	intervention	_	_	O
64	or	_	_	O
65	the	_	_	O
66	8-week	_	_	O
67	III	_	_	O
68	condition	_	_	O
69	.	_	_	O

70	Seventeen	_	_	O
71	participants	_	_	O
72	met	_	_	O
73	the	_	_	O
74	Hospital	_	_	O
75	Anxiety	_	_	O
76	and	_	_	O
77	Depression	_	_	O
78	Scale	_	_	O
79	(	_	_	O
80	HADS	_	_	O
81	)	_	_	O
82	criteria	_	_	O
83	for	_	_	O
84	depressive	_	_	O
85	symptoms	_	_	O
86	(	_	_	O
87	HADS	_	_	O
88	â‰¥	_	_	O
89	8	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Among	_	_	O
93	all	_	_	O
94	participants	_	_	O
95	,	_	_	O
96	the	_	_	O
97	mean	_	_	O
98	number	_	_	O
99	of	_	_	O
100	logins	_	_	O
101	over	_	_	O
102	8	_	_	O
103	weeks	_	_	O
104	was	_	_	O
105	20.8	_	_	O
106	Â±	_	_	O
107	17.7	_	_	O
108	logins	_	_	O
109	for	_	_	O
110	the	_	_	O
111	III	_	_	O
112	+	_	_	O
113	ISG	_	_	O
114	compared	_	_	O
115	with	_	_	O
116	12.5	_	_	O
117	Â±	_	_	O
118	12.5	_	_	O
119	in	_	_	O
120	III-only	_	_	O
121	(	_	_	O
122	p	_	_	O
123	=	_	_	O
124	0.15	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Two	_	_	O
128	participants	_	_	O
129	in	_	_	O
130	the	_	_	O
131	III	_	_	O
132	+	_	_	O
133	ISG	_	_	O
134	dropped	_	_	O
135	out	_	_	O
136	,	_	_	O
137	compared	_	_	O
138	with	_	_	O
139	five	_	_	O
140	in	_	_	O
141	III	_	_	O
142	(	_	_	O
143	p	_	_	O
144	=	_	_	O
145	0.39	_	_	O
146	)	_	_	O
147	.	_	_	O

148	Among	_	_	B-Premise
149	the	_	_	I-Premise
150	17	_	_	I-Premise
151	participants	_	_	I-Premise
152	with	_	_	I-Premise
153	depressive	_	_	I-Premise
154	symptoms	_	_	I-Premise
155	at	_	_	I-Premise
156	baseline	_	_	I-Premise
157	,	_	_	I-Premise
158	both	_	_	I-Premise
159	the	_	_	I-Premise
160	Onward	_	_	I-Premise
161	and	_	_	I-Premise
162	the	_	_	I-Premise
163	III-only	_	_	I-Premise
164	condition	_	_	I-Premise
165	showed	_	_	I-Premise
166	large	_	_	I-Premise
167	reductions	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	depression	_	_	I-Premise
171	scale	_	_	I-Premise
172	of	_	_	I-Premise
173	HADS	_	_	I-Premise
174	(	_	_	I-Premise
175	d	_	_	I-Premise
176	=	_	_	I-Premise
177	1.27	_	_	I-Premise
178	and	_	_	I-Premise
179	0.89	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Improvement	_	_	B-Premise
185	over	_	_	I-Premise
186	time	_	_	I-Premise
187	and	_	_	I-Premise
188	time	_	_	I-Premise
189	x	_	_	I-Premise
190	treatment	_	_	I-Premise
191	effects	_	_	I-Premise
192	only	_	_	I-Premise
193	reached	_	_	I-Premise
194	trend	_	_	I-Premise
195	significance	_	_	I-Premise
196	levels	_	_	I-Premise
197	(	_	_	I-Premise
198	ps	_	_	I-Premise
199	=	_	_	I-Premise
200	0.07	_	_	I-Premise
201	&	_	_	I-Premise
202	amp	_	_	I-Premise
203	;	_	_	I-Premise
204	0.12	_	_	I-Premise
205	)	_	_	I-Premise
206	as	_	_	I-Premise
207	this	_	_	I-Premise
208	pilot	_	_	I-Premise
209	was	_	_	I-Premise
210	not	_	_	I-Premise
211	powered	_	_	I-Premise
212	to	_	_	I-Premise
213	detect	_	_	I-Premise
214	these	_	_	I-Premise
215	differences	_	_	I-Premise
216	.	_	_	I-Premise

217	Both	_	_	B-Claim
218	the	_	_	I-Claim
219	III	_	_	I-Claim
220	+	_	_	I-Claim
221	ISG	_	_	I-Claim
222	and	_	_	I-Claim
223	III-only	_	_	I-Claim
224	demonstrated	_	_	I-Claim
225	pre-post	_	_	I-Claim
226	reductions	_	_	I-Claim
227	in	_	_	I-Claim
228	depressive	_	_	I-Claim
229	symptoms	_	_	I-Claim
230	and	_	_	I-Claim
231	high	_	_	I-Claim
232	rates	_	_	I-Claim
233	of	_	_	I-Claim
234	utilization	_	_	I-Claim
235	compared	_	_	I-Claim
236	with	_	_	I-Claim
237	other	_	_	I-Claim
238	web-based	_	_	I-Claim
239	treatments	_	_	I-Claim
240	for	_	_	I-Claim
241	depression	_	_	I-Claim
242	.	_	_	I-Claim

243	Although	_	_	B-Claim
244	it	_	_	I-Claim
245	is	_	_	I-Claim
246	premature	_	_	I-Claim
247	to	_	_	I-Claim
248	make	_	_	I-Claim
249	any	_	_	I-Claim
250	determination	_	_	I-Claim
251	as	_	_	I-Claim
252	to	_	_	I-Claim
253	the	_	_	I-Claim
254	efficacy	_	_	I-Claim
255	of	_	_	I-Claim
256	the	_	_	I-Claim
257	interventions	_	_	I-Claim
258	tested	_	_	I-Claim
259	in	_	_	I-Claim
260	this	_	_	I-Claim
261	feasibility	_	_	I-Claim
262	study	_	_	I-Claim
263	,	_	_	I-Claim
264	these	_	_	B-Claim
265	results	_	_	I-Claim
266	indicate	_	_	I-Claim
267	that	_	_	I-Claim
268	pursuing	_	_	I-Claim
269	the	_	_	I-Claim
270	III	_	_	I-Claim
271	+	_	_	I-Claim
272	ISG	_	_	I-Claim
273	model	_	_	I-Claim
274	,	_	_	I-Claim
275	as	_	_	I-Claim
276	well	_	_	I-Claim
277	as	_	_	I-Claim
278	standard	_	_	I-Claim
279	IIIs	_	_	I-Claim
280	,	_	_	I-Claim
281	may	_	_	I-Claim
282	be	_	_	I-Claim
283	fruitful	_	_	I-Claim
284	areas	_	_	I-Claim
285	of	_	_	I-Claim
286	future	_	_	I-Claim
287	research	_	_	I-Claim
288	.	_	_	I-Claim


0	The	_	_	O
1	optimal	_	_	O
2	duration	_	_	O
3	over	_	_	O
4	which	_	_	O
5	lung	_	_	O
6	SBRT	_	_	O
7	should	_	_	O
8	be	_	_	O
9	delivered	_	_	O
10	is	_	_	O
11	unknown	_	_	O
12	.	_	_	O

13	We	_	_	O
14	conducted	_	_	O
15	a	_	_	O
16	randomized	_	_	O
17	pilot	_	_	O
18	study	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	four	_	_	O
24	fractions	_	_	O
25	of	_	_	O
26	lung	_	_	O
27	SBRT	_	_	O
28	delivered	_	_	O
29	over	_	_	O
30	4	_	_	O
31	or	_	_	O
32	over	_	_	O
33	11	_	_	O
34	days	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	peripheral	_	_	O
40	solitary	_	_	O
41	lung	_	_	O
42	tumor	_	_	O
43	(	_	_	O
44	NSCLC	_	_	O
45	or	_	_	O
46	pulmonary	_	_	O
47	metastasis	_	_	O
48	)	_	_	O
49	â‰¤	_	_	O
50	5	_	_	O
51	cm	_	_	O
52	were	_	_	O
53	eligible	_	_	O
54	.	_	_	O

55	For	_	_	O
56	NSCLC	_	_	O
57	lung	_	_	O
58	tumors	_	_	O
59	â‰¤	_	_	O
60	3	_	_	O
61	cm	_	_	O
62	,	_	_	O
63	a	_	_	O
64	dose	_	_	O
65	of	_	_	O
66	48	_	_	O
67	Gy	_	_	O
68	in	_	_	O
69	4	_	_	O
70	fractions	_	_	O
71	was	_	_	O
72	used	_	_	O
73	,	_	_	O
74	otherwise	_	_	O
75	52	_	_	O
76	Gy	_	_	O
77	in	_	_	O
78	4	_	_	O
79	fractions	_	_	O
80	was	_	_	O
81	delivered	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	treatment	_	_	O
89	over	_	_	O
90	4	_	_	O
91	consecutive	_	_	O
92	days	_	_	O
93	or	_	_	O
94	over	_	_	O
95	11	_	_	O
96	days	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	end-point	_	_	O
101	was	_	_	O
102	acute	_	_	O
103	grade	_	_	O
104	â‰¥	_	_	O
105	2	_	_	O
106	toxicity	_	_	O
107	.	_	_	O

108	Secondary	_	_	O
109	end-points	_	_	O
110	included	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	(	_	_	O
115	QOL	_	_	O
116	)	_	_	O
117	assessed	_	_	O
118	using	_	_	O
119	the	_	_	O
120	EORTC	_	_	O
121	QLQ-C30	_	_	O
122	and	_	_	O
123	QLQ-LC13	_	_	O
124	questionnaires	_	_	O
125	.	_	_	O

126	Fifty	_	_	O
127	four	_	_	O
128	patients	_	_	O
129	were	_	_	O
130	enrolled	_	_	O
131	.	_	_	O

132	More	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	the	_	_	O
136	11	_	_	O
137	day	_	_	O
138	group	_	_	O
139	had	_	_	O
140	respiratory	_	_	O
141	symptoms	_	_	O
142	at	_	_	O
143	baseline	_	_	O
144	.	_	_	O

145	55.6	_	_	B-Premise
146	%	_	_	I-Premise
147	patients	_	_	I-Premise
148	treated	_	_	I-Premise
149	over	_	_	I-Premise
150	4	_	_	I-Premise
151	days	_	_	I-Premise
152	and	_	_	I-Premise
153	33.3	_	_	I-Premise
154	%	_	_	I-Premise
155	of	_	_	I-Premise
156	patients	_	_	I-Premise
157	treated	_	_	I-Premise
158	over	_	_	I-Premise
159	11	_	_	I-Premise
160	days	_	_	I-Premise
161	experienced	_	_	I-Premise
162	acute	_	_	I-Premise
163	grade	_	_	I-Premise
164	â‰¥	_	_	I-Premise
165	2	_	_	I-Premise
166	toxicity	_	_	I-Premise
167	(	_	_	I-Premise
168	p=0.085	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Dyspnea	_	_	B-Premise
172	,	_	_	I-Premise
173	fatigue	_	_	I-Premise
174	and	_	_	I-Premise
175	coughing	_	_	I-Premise
176	domains	_	_	I-Premise
177	were	_	_	I-Premise
178	worse	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	11	_	_	I-Premise
182	day	_	_	I-Premise
183	group	_	_	I-Premise
184	at	_	_	I-Premise
185	baseline	_	_	I-Premise
186	.	_	_	I-Premise

187	At	_	_	B-Premise
188	1	_	_	I-Premise
189	and	_	_	I-Premise
190	4	_	_	I-Premise
191	months	_	_	I-Premise
192	,	_	_	I-Premise
193	more	_	_	I-Premise
194	patients	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	4	_	_	I-Premise
198	day	_	_	I-Premise
199	group	_	_	I-Premise
200	experienced	_	_	I-Premise
201	a	_	_	I-Premise
202	clinically	_	_	I-Premise
203	meaningful	_	_	I-Premise
204	worsening	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	dyspnea	_	_	I-Premise
208	QOL	_	_	I-Premise
209	domain	_	_	I-Premise
210	compared	_	_	I-Premise
211	to	_	_	I-Premise
212	the	_	_	I-Premise
213	11	_	_	I-Premise
214	day	_	_	I-Premise
215	group	_	_	I-Premise
216	(	_	_	I-Premise
217	44.5	_	_	I-Premise
218	%	_	_	I-Premise
219	vs	_	_	I-Premise
220	15.4	_	_	I-Premise
221	%	_	_	I-Premise
222	,	_	_	I-Premise
223	p=0.02	_	_	I-Premise
224	;	_	_	I-Premise
225	38.5	_	_	I-Premise
226	%	_	_	I-Premise
227	vs	_	_	I-Premise
228	12.0	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	p=0.03	_	_	I-Premise
232	,	_	_	I-Premise
233	respectively	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	However	_	_	B-Premise
237	,	_	_	I-Premise
238	raw	_	_	I-Premise
239	QOL	_	_	I-Premise
240	scores	_	_	I-Premise
241	were	_	_	I-Premise
242	not	_	_	I-Premise
243	different	_	_	I-Premise
244	at	_	_	I-Premise
245	these	_	_	I-Premise
246	time-points	_	_	I-Premise
247	between	_	_	I-Premise
248	treatment	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	Grade	_	_	B-Claim
252	2	_	_	I-Claim
253	or	_	_	I-Claim
254	higher	_	_	I-Claim
255	acute	_	_	I-Claim
256	toxicity	_	_	I-Claim
257	was	_	_	I-Claim
258	more	_	_	I-Claim
259	common	_	_	I-Claim
260	in	_	_	I-Claim
261	the	_	_	I-Claim
262	4	_	_	I-Claim
263	day	_	_	I-Claim
264	group	_	_	I-Claim
265	,	_	_	I-Claim
266	approaching	_	_	I-Claim
267	statistical	_	_	I-Claim
268	significance	_	_	I-Claim
269	.	_	_	I-Claim

270	More	_	_	B-Claim
271	patients	_	_	I-Claim
272	treated	_	_	I-Claim
273	on	_	_	I-Claim
274	4	_	_	I-Claim
275	consecutive	_	_	I-Claim
276	days	_	_	I-Claim
277	reported	_	_	I-Claim
278	a	_	_	I-Claim
279	clinically	_	_	I-Claim
280	meaningful	_	_	I-Claim
281	increase	_	_	I-Claim
282	in	_	_	I-Claim
283	dyspnea	_	_	I-Claim
284	,	_	_	I-Claim
285	although	_	_	B-Claim
286	interpretation	_	_	I-Claim
287	of	_	_	I-Claim
288	these	_	_	I-Claim
289	results	_	_	I-Claim
290	is	_	_	I-Claim
291	challenging	_	_	I-Claim
292	due	_	_	I-Claim
293	to	_	_	I-Claim
294	baseline	_	_	I-Claim
295	imbalance	_	_	I-Claim
296	between	_	_	I-Claim
297	treatment	_	_	I-Claim
298	groups	_	_	I-Claim
299	.	_	_	I-Claim

300	Larger	_	_	B-Claim
301	studies	_	_	I-Claim
302	are	_	_	I-Claim
303	required	_	_	I-Claim
304	to	_	_	I-Claim
305	validate	_	_	I-Claim
306	these	_	_	I-Claim
307	results	_	_	I-Claim
308	.	_	_	I-Claim


0	Several	_	_	O
1	guidelines	_	_	O
2	on	_	_	O
3	the	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	cancer-related	_	_	O
7	fatigue	_	_	O
8	recommend	_	_	O
9	optimizing	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	accompanying	_	_	O
13	symptoms	_	_	O
14	.	_	_	O

15	However	_	_	O
16	,	_	_	O
17	evidence	_	_	O
18	for	_	_	O
19	this	_	_	O
20	recommendation	_	_	O
21	from	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trials	_	_	O
25	is	_	_	O
26	lacking	_	_	O
27	.	_	_	O

28	We	_	_	O
29	investigated	_	_	O
30	whether	_	_	O
31	monitoring	_	_	O
32	and	_	_	O
33	protocolized	_	_	O
34	treatment	_	_	O
35	of	_	_	O
36	physical	_	_	O
37	symptoms	_	_	O
38	alleviates	_	_	O
39	fatigue	_	_	O
40	.	_	_	O

41	In	_	_	O
42	all	_	_	O
43	,	_	_	O
44	152	_	_	O
45	fatigued	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	advanced	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	protocolized	_	_	O
55	patient-tailored	_	_	O
56	treatment	_	_	O
57	(	_	_	O
58	PPT	_	_	O
59	)	_	_	O
60	of	_	_	O
61	symptoms	_	_	O
62	or	_	_	O
63	care	_	_	O
64	as	_	_	O
65	usual	_	_	O
66	.	_	_	O

67	The	_	_	O
68	PPT	_	_	O
69	group	_	_	O
70	had	_	_	O
71	four	_	_	O
72	appointments	_	_	O
73	with	_	_	O
74	a	_	_	O
75	nurse	_	_	O
76	who	_	_	O
77	assessed	_	_	O
78	nine	_	_	O
79	symptoms	_	_	O
80	on	_	_	O
81	a	_	_	O
82	0	_	_	O
83	to	_	_	O
84	10	_	_	O
85	numeric	_	_	O
86	rating	_	_	O
87	scale	_	_	O
88	(	_	_	O
89	NRS	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	received	_	_	O
94	a	_	_	O
95	nonpharmacologic	_	_	O
96	intervention	_	_	O
97	for	_	_	O
98	symptoms	_	_	O
99	with	_	_	O
100	a	_	_	O
101	score	_	_	O
102	â‰¥	_	_	O
103	1	_	_	O
104	and	_	_	O
105	a	_	_	O
106	medical	_	_	O
107	intervention	_	_	O
108	for	_	_	O
109	symptoms	_	_	O
110	with	_	_	O
111	a	_	_	O
112	score	_	_	O
113	â‰¥	_	_	O
114	4	_	_	O
115	.	_	_	O

116	Fatigue	_	_	O
117	dimensions	_	_	O
118	,	_	_	O
119	fatigue	_	_	O
120	NRS	_	_	O
121	score	_	_	O
122	,	_	_	O
123	interference	_	_	O
124	of	_	_	O
125	fatigue	_	_	O
126	with	_	_	O
127	daily	_	_	O
128	life	_	_	O
129	,	_	_	O
130	symptom	_	_	O
131	burden	_	_	O
132	,	_	_	O
133	quality	_	_	O
134	of	_	_	O
135	life	_	_	O
136	,	_	_	O
137	anxiety	_	_	O
138	,	_	_	O
139	and	_	_	O
140	depression	_	_	O
141	were	_	_	O
142	measured	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	and	_	_	O
146	after	_	_	O
147	1	_	_	O
148	,	_	_	O
149	2	_	_	O
150	,	_	_	O
151	and	_	_	O
152	3	_	_	O
153	months	_	_	O
154	.	_	_	O

155	Differences	_	_	O
156	between	_	_	O
157	the	_	_	O
158	groups	_	_	O
159	over	_	_	O
160	time	_	_	O
161	were	_	_	O
162	assessed	_	_	O
163	by	_	_	O
164	using	_	_	O
165	mixed	_	_	O
166	modeling	_	_	O
167	.	_	_	O

168	Seventy-six	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	randomly	_	_	O
172	assigned	_	_	O
173	to	_	_	O
174	each	_	_	O
175	study	_	_	O
176	arm	_	_	O
177	.	_	_	O

178	Mean	_	_	O
179	age	_	_	O
180	was	_	_	O
181	58	_	_	O
182	Â±	_	_	O
183	10	_	_	O
184	years	_	_	O
185	,	_	_	O
186	57	_	_	O
187	%	_	_	O
188	were	_	_	O
189	female	_	_	O
190	,	_	_	O
191	and	_	_	O
192	65	_	_	O
193	%	_	_	O
194	were	_	_	O
195	given	_	_	O
196	palliative	_	_	O
197	chemotherapy	_	_	O
198	.	_	_	O

199	We	_	_	B-Premise
200	found	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvements	_	_	I-Premise
203	over	_	_	I-Premise
204	time	_	_	I-Premise
205	in	_	_	I-Premise
206	favor	_	_	I-Premise
207	of	_	_	I-Premise
208	PPT	_	_	I-Premise
209	for	_	_	I-Premise
210	the	_	_	I-Premise
211	primary	_	_	I-Premise
212	outcome	_	_	I-Premise
213	general	_	_	I-Premise
214	fatigue	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.01	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	with	_	_	I-Premise
222	significant	_	_	I-Premise
223	group	_	_	I-Premise
224	differences	_	_	I-Premise
225	at	_	_	I-Premise
226	month	_	_	I-Premise
227	1	_	_	I-Premise
228	(	_	_	I-Premise
229	effect	_	_	I-Premise
230	size	_	_	I-Premise
231	,	_	_	I-Premise
232	0.26	_	_	I-Premise
233	;	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.007	_	_	I-Premise
237	)	_	_	I-Premise
238	and	_	_	I-Premise
239	month	_	_	I-Premise
240	2	_	_	I-Premise
241	(	_	_	I-Premise
242	effect	_	_	I-Premise
243	size	_	_	I-Premise
244	,	_	_	I-Premise
245	0.35	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	.005	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Improvements	_	_	B-Premise
253	in	_	_	I-Premise
254	favor	_	_	I-Premise
255	of	_	_	I-Premise
256	PPT	_	_	I-Premise
257	were	_	_	I-Premise
258	also	_	_	I-Premise
259	found	_	_	I-Premise
260	for	_	_	I-Premise
261	the	_	_	I-Premise
262	following	_	_	I-Premise
263	secondary	_	_	I-Premise
264	outcomes	_	_	I-Premise
265	:	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	dimensions	_	_	I-Premise
268	"	_	_	I-Premise
269	reduced	_	_	I-Premise
270	activity	_	_	I-Premise
271	"	_	_	I-Premise
272	and	_	_	I-Premise
273	"	_	_	I-Premise
274	reduced	_	_	I-Premise
275	motivation	_	_	I-Premise
276	,	_	_	I-Premise
277	"	_	_	I-Premise
278	fatigue	_	_	I-Premise
279	NRS	_	_	I-Premise
280	,	_	_	I-Premise
281	symptom	_	_	I-Premise
282	burden	_	_	I-Premise
283	,	_	_	I-Premise
284	interference	_	_	I-Premise
285	of	_	_	I-Premise
286	fatigue	_	_	I-Premise
287	with	_	_	I-Premise
288	daily	_	_	I-Premise
289	life	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	anxiety	_	_	I-Premise
293	(	_	_	I-Premise
294	all	_	_	I-Premise
295	P	_	_	I-Premise
296	â‰¤	_	_	I-Premise
297	.03	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	In	_	_	B-Claim
301	fatigued	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	advanced	_	_	I-Claim
305	cancer	_	_	I-Claim
306	,	_	_	I-Claim
307	nurse-led	_	_	I-Claim
308	monitoring	_	_	I-Claim
309	and	_	_	I-Claim
310	protocolized	_	_	I-Claim
311	treatment	_	_	I-Claim
312	of	_	_	I-Claim
313	physical	_	_	I-Claim
314	symptoms	_	_	I-Claim
315	is	_	_	I-Claim
316	effective	_	_	I-Claim
317	in	_	_	I-Claim
318	alleviating	_	_	I-Claim
319	fatigue	_	_	I-Claim
320	.	_	_	I-Claim


0	Bevacizumab	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	monoclonal	_	_	I-Claim
4	antibody	_	_	I-Claim
5	against	_	_	I-Claim
6	vascular	_	_	I-Claim
7	endothelial	_	_	I-Claim
8	growth	_	_	I-Claim
9	factor	_	_	I-Claim
10	,	_	_	I-Claim
11	increases	_	_	I-Claim
12	survival	_	_	I-Claim
13	when	_	_	I-Claim
14	combined	_	_	I-Claim
15	with	_	_	I-Claim
16	irinotecan-based	_	_	I-Claim
17	chemotherapy	_	_	I-Claim
18	in	_	_	I-Claim
19	first-line	_	_	I-Claim
20	treatment	_	_	I-Claim
21	of	_	_	I-Claim
22	metastatic	_	_	I-Claim
23	colorectal	_	_	I-Claim
24	cancer	_	_	I-Claim
25	(	_	_	I-Claim
26	CRC	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	This	_	_	O
30	randomized	_	_	O
31	,	_	_	O
32	phase	_	_	O
33	II	_	_	O
34	trial	_	_	O
35	compared	_	_	O
36	bevacizumab	_	_	O
37	plus	_	_	O
38	fluorouracil	_	_	O
39	and	_	_	O
40	leucovorin	_	_	O
41	(	_	_	O
42	FU/LV	_	_	O
43	)	_	_	O
44	versus	_	_	O
45	placebo	_	_	O
46	plus	_	_	O
47	FU/LV	_	_	O
48	as	_	_	O
49	first-line	_	_	O
50	therapy	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	considered	_	_	O
54	nonoptimal	_	_	O
55	candidates	_	_	O
56	for	_	_	O
57	first-line	_	_	O
58	irinotecan	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	had	_	_	O
62	metastatic	_	_	O
63	CRC	_	_	O
64	and	_	_	O
65	one	_	_	O
66	of	_	_	O
67	the	_	_	O
68	following	_	_	O
69	characteristics	_	_	O
70	:	_	_	O
71	age	_	_	O
72	>	_	_	O
73	or	_	_	O
74	=	_	_	O
75	65	_	_	O
76	years	_	_	O
77	,	_	_	O
78	Eastern	_	_	O
79	Cooperative	_	_	O
80	Oncology	_	_	O
81	Group	_	_	O
82	performance	_	_	O
83	status	_	_	O
84	1	_	_	O
85	or	_	_	O
86	2	_	_	O
87	,	_	_	O
88	serum	_	_	O
89	albumin	_	_	O
90	<	_	_	O
91	or	_	_	O
92	=	_	_	O
93	3.5	_	_	O
94	g/dL	_	_	O
95	,	_	_	O
96	or	_	_	O
97	prior	_	_	O
98	abdominal/pelvic	_	_	O
99	radiotherapy	_	_	O
100	.	_	_	O

101	Patients	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	assigned	_	_	O
105	to	_	_	O
106	FU/LV/placebo	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	105	_	_	O
111	)	_	_	O
112	or	_	_	O
113	FU/LV/bevacizumab	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	104	_	_	O
118	)	_	_	O
119	.	_	_	O

120	The	_	_	O
121	primary	_	_	O
122	end	_	_	O
123	point	_	_	O
124	was	_	_	O
125	overall	_	_	O
126	survival	_	_	O
127	.	_	_	O

128	Secondary	_	_	O
129	end	_	_	O
130	points	_	_	O
131	were	_	_	O
132	progression-free	_	_	O
133	survival	_	_	O
134	,	_	_	O
135	response	_	_	O
136	rate	_	_	O
137	,	_	_	O
138	response	_	_	O
139	duration	_	_	O
140	,	_	_	O
141	and	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	.	_	_	O

146	Safety	_	_	O
147	was	_	_	O
148	also	_	_	O
149	assessed	_	_	O
150	.	_	_	O

151	Median	_	_	B-Premise
152	survival	_	_	I-Premise
153	was	_	_	I-Premise
154	16.6	_	_	I-Premise
155	months	_	_	I-Premise
156	for	_	_	I-Premise
157	the	_	_	I-Premise
158	FU/LV/bevacizumab	_	_	I-Premise
159	group	_	_	I-Premise
160	and	_	_	I-Premise
161	12.9	_	_	I-Premise
162	months	_	_	I-Premise
163	for	_	_	I-Premise
164	the	_	_	I-Premise
165	FU/LV/placebo	_	_	I-Premise
166	group	_	_	I-Premise
167	(	_	_	I-Premise
168	hazard	_	_	I-Premise
169	ratio	_	_	I-Premise
170	,	_	_	I-Premise
171	0.79	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.16	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Median	_	_	B-Premise
179	progression-free	_	_	I-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	9.2	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	FU/LV/bevacizumab	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	5.5	_	_	I-Premise
189	months	_	_	I-Premise
190	(	_	_	I-Premise
191	FU/LV/placebo	_	_	I-Premise
192	)	_	_	I-Premise
193	;	_	_	I-Premise
194	hazard	_	_	B-Premise
195	ratio	_	_	I-Premise
196	was	_	_	I-Premise
197	0.50	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	.0002	_	_	I-Premise
202	.	_	_	O

203	Response	_	_	B-Premise
204	rates	_	_	I-Premise
205	were	_	_	I-Premise
206	26.0	_	_	I-Premise
207	%	_	_	I-Premise
208	(	_	_	I-Premise
209	FU/LV/bevacizumab	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	15.2	_	_	I-Premise
213	%	_	_	I-Premise
214	(	_	_	I-Premise
215	FU/LV/placebo	_	_	I-Premise
216	)	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.055	_	_	I-Premise
221	)	_	_	I-Premise
222	;	_	_	I-Premise
223	duration	_	_	B-Premise
224	of	_	_	I-Premise
225	response	_	_	I-Premise
226	was	_	_	I-Premise
227	9.2	_	_	I-Premise
228	months	_	_	I-Premise
229	(	_	_	I-Premise
230	FU/LV/bevacizumab	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	6.8	_	_	I-Premise
234	months	_	_	I-Premise
235	(	_	_	I-Premise
236	FU/LV/placebo	_	_	I-Premise
237	)	_	_	I-Premise
238	;	_	_	I-Premise
239	hazard	_	_	B-Premise
240	ratio	_	_	I-Premise
241	was	_	_	I-Premise
242	0.42	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.088	_	_	I-Premise
247	.	_	_	I-Premise

248	Grade	_	_	B-Premise
249	3	_	_	I-Premise
250	hypertension	_	_	I-Premise
251	was	_	_	I-Premise
252	more	_	_	I-Premise
253	common	_	_	I-Premise
254	with	_	_	I-Premise
255	bevacizumab	_	_	I-Premise
256	treatment	_	_	I-Premise
257	(	_	_	I-Premise
258	16	_	_	I-Premise
259	%	_	_	I-Premise
260	v	_	_	I-Premise
261	3	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	but	_	_	B-Premise
265	was	_	_	I-Premise
266	controlled	_	_	I-Premise
267	with	_	_	I-Premise
268	oral	_	_	I-Premise
269	medication	_	_	I-Premise
270	and	_	_	I-Premise
271	did	_	_	I-Premise
272	not	_	_	I-Premise
273	cause	_	_	I-Premise
274	study	_	_	I-Premise
275	drug	_	_	I-Premise
276	discontinuation	_	_	I-Premise
277	.	_	_	I-Premise

278	Addition	_	_	B-Claim
279	of	_	_	I-Claim
280	bevacizumab	_	_	I-Claim
281	to	_	_	I-Claim
282	FU/LV	_	_	I-Claim
283	as	_	_	I-Claim
284	first-line	_	_	I-Claim
285	therapy	_	_	I-Claim
286	in	_	_	I-Claim
287	CRC	_	_	I-Claim
288	patients	_	_	I-Claim
289	who	_	_	I-Claim
290	were	_	_	I-Claim
291	not	_	_	I-Claim
292	considered	_	_	I-Claim
293	optimal	_	_	I-Claim
294	candidates	_	_	I-Claim
295	for	_	_	I-Claim
296	first-line	_	_	I-Claim
297	irinotecan	_	_	I-Claim
298	treatment	_	_	I-Claim
299	provided	_	_	I-Claim
300	clinically	_	_	I-Claim
301	significant	_	_	I-Claim
302	patient	_	_	I-Claim
303	benefit	_	_	I-Claim
304	,	_	_	I-Claim
305	including	_	_	I-Claim
306	statistically	_	_	I-Claim
307	significant	_	_	I-Claim
308	improvement	_	_	I-Claim
309	in	_	_	I-Claim
310	progression-free	_	_	I-Claim
311	survival	_	_	I-Claim
312	.	_	_	I-Claim


0	The	_	_	B-Claim
1	generalizability	_	_	I-Claim
2	of	_	_	I-Claim
3	palliative	_	_	I-Claim
4	care	_	_	I-Claim
5	intervention	_	_	I-Claim
6	research	_	_	I-Claim
7	is	_	_	I-Claim
8	often	_	_	I-Claim
9	limited	_	_	I-Claim
10	by	_	_	I-Claim
11	high	_	_	I-Claim
12	rates	_	_	I-Claim
13	of	_	_	I-Claim
14	study	_	_	I-Claim
15	attrition	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	study	_	_	O
19	examined	_	_	O
20	factors	_	_	O
21	associated	_	_	O
22	with	_	_	O
23	attrition	_	_	O
24	from	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	comparing	_	_	O
30	meaning-centered	_	_	O
31	group	_	_	O
32	psychotherapy	_	_	O
33	(	_	_	O
34	MCGP	_	_	O
35	)	_	_	O
36	,	_	_	O
37	an	_	_	O
38	intervention	_	_	O
39	designed	_	_	O
40	to	_	_	O
41	help	_	_	O
42	advanced	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	sustain	_	_	O
46	or	_	_	O
47	enhance	_	_	O
48	their	_	_	O
49	sense	_	_	O
50	of	_	_	O
51	meaning	_	_	O
52	to	_	_	O
53	the	_	_	O
54	supportive	_	_	O
55	group	_	_	O
56	psychotherapy	_	_	O
57	(	_	_	O
58	SGP	_	_	O
59	)	_	_	O
60	,	_	_	O
61	a	_	_	O
62	standardized	_	_	O
63	support	_	_	O
64	group	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	with	_	_	O
68	advanced	_	_	O
69	solid	_	_	O
70	tumor	_	_	O
71	cancers	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	153	_	_	O
76	)	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	eight	_	_	O
81	sessions	_	_	O
82	of	_	_	O
83	either	_	_	O
84	the	_	_	O
85	MCGP	_	_	O
86	or	_	_	O
87	SGP	_	_	O
88	.	_	_	O

89	They	_	_	O
90	completed	_	_	O
91	assessments	_	_	O
92	of	_	_	O
93	psychosocial	_	_	O
94	,	_	_	O
95	spiritual	_	_	O
96	,	_	_	O
97	and	_	_	O
98	physical	_	_	O
99	well-being	_	_	O
100	pretreatment	_	_	O
101	,	_	_	O
102	midtreatment	_	_	O
103	,	_	_	O
104	and	_	_	O
105	2	_	_	O
106	months	_	_	O
107	post-treatment	_	_	O
108	.	_	_	O

109	Attrition	_	_	O
110	was	_	_	O
111	assessed	_	_	O
112	in	_	_	O
113	terms	_	_	O
114	of	_	_	O
115	the	_	_	O
116	percent	_	_	O
117	of	_	_	O
118	participants	_	_	O
119	who	_	_	O
120	failed	_	_	O
121	to	_	_	O
122	complete	_	_	O
123	these	_	_	O
124	assessments	_	_	O
125	,	_	_	O
126	and	_	_	O
127	demographic	_	_	O
128	,	_	_	O
129	psychiatric	_	_	O
130	,	_	_	O
131	medical	_	_	O
132	,	_	_	O
133	and	_	_	O
134	study-related	_	_	O
135	correlates	_	_	O
136	of	_	_	O
137	attrition	_	_	O
138	were	_	_	O
139	examined	_	_	O
140	for	_	_	O
141	the	_	_	O
142	participants	_	_	O
143	in	_	_	O
144	each	_	_	O
145	of	_	_	O
146	these	_	_	O
147	categories	_	_	O
148	.	_	_	O

149	The	_	_	B-Premise
150	rates	_	_	I-Premise
151	of	_	_	I-Premise
152	attrition	_	_	I-Premise
153	at	_	_	I-Premise
154	these	_	_	I-Premise
155	time	_	_	I-Premise
156	points	_	_	I-Premise
157	were	_	_	I-Premise
158	28.1	_	_	I-Premise
159	%	_	_	I-Premise
160	,	_	_	I-Premise
161	17.7	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	and	_	_	I-Premise
165	11.1	_	_	I-Premise
166	%	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	43.1	_	_	I-Premise
171	%	_	_	I-Premise
172	of	_	_	I-Premise
173	the	_	_	I-Premise
174	participants	_	_	I-Premise
175	(	_	_	I-Premise
176	66	_	_	I-Premise
177	of	_	_	I-Premise
178	153	_	_	I-Premise
179	)	_	_	I-Premise
180	completed	_	_	I-Premise
181	the	_	_	I-Premise
182	entire	_	_	I-Premise
183	study	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	most	_	_	I-Premise
187	common	_	_	I-Premise
188	reason	_	_	I-Premise
189	for	_	_	I-Premise
190	dropout	_	_	I-Premise
191	was	_	_	I-Premise
192	patients	_	_	I-Premise
193	feeling	_	_	I-Premise
194	too	_	_	I-Premise
195	ill	_	_	I-Premise
196	.	_	_	I-Premise

197	Attrition	_	_	B-Premise
198	rates	_	_	I-Premise
199	did	_	_	I-Premise
200	not	_	_	I-Premise
201	vary	_	_	I-Premise
202	significantly	_	_	I-Premise
203	between	_	_	I-Premise
204	study	_	_	I-Premise
205	arms	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	O
208	participants	_	_	O
209	who	_	_	O
210	dropped	_	_	O
211	out	_	_	O
212	pretreatment	_	_	O
213	reported	_	_	O
214	less	_	_	O
215	financial	_	_	O
216	concerns	_	_	O
217	than	_	_	O
218	post-treatment	_	_	O
219	dropouts	_	_	O
220	,	_	_	O
221	and	_	_	O
222	the	_	_	O
223	participants	_	_	O
224	who	_	_	O
225	dropped	_	_	O
226	out	_	_	O
227	of	_	_	O
228	the	_	_	O
229	study	_	_	O
230	midtreatment	_	_	O
231	had	_	_	O
232	poorer	_	_	O
233	physical	_	_	O
234	health	_	_	O
235	than	_	_	O
236	treatment	_	_	O
237	completers	_	_	O
238	.	_	_	O

239	There	_	_	B-Premise
240	were	_	_	I-Premise
241	no	_	_	I-Premise
242	other	_	_	I-Premise
243	significant	_	_	I-Premise
244	associations	_	_	I-Premise
245	between	_	_	I-Premise
246	attrition	_	_	I-Premise
247	and	_	_	I-Premise
248	any	_	_	I-Premise
249	demographic	_	_	I-Premise
250	,	_	_	I-Premise
251	medical	_	_	I-Premise
252	,	_	_	I-Premise
253	psychiatric	_	_	I-Premise
254	,	_	_	I-Premise
255	or	_	_	I-Premise
256	study-related	_	_	I-Premise
257	variables	_	_	I-Premise
258	.	_	_	I-Premise

259	These	_	_	B-Claim
260	findings	_	_	I-Claim
261	highlight	_	_	I-Claim
262	the	_	_	I-Claim
263	challenge	_	_	I-Claim
264	of	_	_	I-Claim
265	maintaining	_	_	I-Claim
266	advanced	_	_	I-Claim
267	cancer	_	_	I-Claim
268	patients	_	_	I-Claim
269	in	_	_	I-Claim
270	longitudinal	_	_	I-Claim
271	research	_	_	I-Claim
272	and	_	_	I-Claim
273	suggest	_	_	I-Claim
274	the	_	_	I-Claim
275	need	_	_	I-Claim
276	to	_	_	I-Claim
277	consider	_	_	I-Claim
278	alternative	_	_	I-Claim
279	approaches	_	_	I-Claim
280	(	_	_	I-Claim
281	e.g.	_	_	I-Claim
282	,	_	_	I-Claim
283	telemedicine	_	_	I-Claim
284	)	_	_	I-Claim
285	for	_	_	I-Claim
286	patients	_	_	I-Claim
287	who	_	_	I-Claim
288	might	_	_	I-Claim
289	benefit	_	_	I-Claim
290	from	_	_	I-Claim
291	group	_	_	I-Claim
292	interventions	_	_	I-Claim
293	but	_	_	I-Claim
294	are	_	_	I-Claim
295	too	_	_	I-Claim
296	ill	_	_	I-Claim
297	to	_	_	I-Claim
298	travel	_	_	I-Claim
299	.	_	_	I-Claim


0	We	_	_	O
1	evaluated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	glutathione-related	_	_	O
6	genotypes	_	_	O
7	on	_	_	O
8	overall	_	_	O
9	survival	_	_	O
10	,	_	_	O
11	time	_	_	O
12	to	_	_	O
13	progression	_	_	O
14	,	_	_	O
15	adverse	_	_	O
16	events	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	stage	_	_	O
27	IIIB/IV	_	_	O
28	non-small	_	_	O
29	cell	_	_	O
30	lung	_	_	O
31	cancer	_	_	O
32	patients	_	_	O
33	who	_	_	O
34	were	_	_	O
35	stable	_	_	O
36	or	_	_	O
37	responding	_	_	O
38	from	_	_	O
39	initial	_	_	O
40	treatment	_	_	O
41	with	_	_	O
42	platinum-based	_	_	O
43	chemotherapy	_	_	O
44	and	_	_	O
45	subsequently	_	_	O
46	randomized	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	daily	_	_	O
50	oral	_	_	O
51	carboxyaminoimidazole	_	_	O
52	or	_	_	O
53	a	_	_	O
54	placebo	_	_	O
55	.	_	_	O

56	Of	_	_	O
57	the	_	_	O
58	186	_	_	O
59	total	_	_	O
60	patients	_	_	O
61	,	_	_	O
62	113	_	_	O
63	had	_	_	O
64	initial	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	platinum	_	_	O
68	therapy	_	_	O
69	and	_	_	O
70	DNA	_	_	O
71	samples	_	_	O
72	of	_	_	O
73	whom	_	_	O
74	46	_	_	O
75	also	_	_	O
76	had	_	_	O
77	QOL	_	_	O
78	data	_	_	O
79	.	_	_	O

80	These	_	_	O
81	samples	_	_	O
82	were	_	_	O
83	analyzed	_	_	O
84	using	_	_	O
85	six	_	_	O
86	polymorphic	_	_	O
87	DNA	_	_	O
88	markers	_	_	O
89	that	_	_	O
90	encode	_	_	O
91	five	_	_	O
92	important	_	_	O
93	enzymes	_	_	O
94	in	_	_	O
95	the	_	_	O
96	glutathione	_	_	O
97	metabolic	_	_	O
98	pathway	_	_	O
99	.	_	_	O

100	Patient	_	_	O
101	QOL	_	_	O
102	was	_	_	O
103	assessed	_	_	O
104	using	_	_	O
105	the	_	_	O
106	Functional	_	_	O
107	Assessment	_	_	O
108	of	_	_	O
109	Cancer	_	_	O
110	Therapy-Lung	_	_	O
111	and	_	_	O
112	the	_	_	O
113	UNISCALE	_	_	O
114	QOL	_	_	O
115	questionnaires	_	_	O
116	.	_	_	O

117	A	_	_	O
118	clinically	_	_	O
119	significant	_	_	O
120	decline	_	_	O
121	in	_	_	O
122	QOL	_	_	O
123	was	_	_	O
124	defined	_	_	O
125	as	_	_	O
126	a	_	_	O
127	10	_	_	O
128	%	_	_	O
129	decrease	_	_	O
130	from	_	_	O
131	baseline	_	_	O
132	to	_	_	O
133	week-8	_	_	O
134	.	_	_	O

135	Multivariate	_	_	O
136	analyses	_	_	O
137	were	_	_	O
138	used	_	_	O
139	to	_	_	O
140	evaluate	_	_	O
141	the	_	_	O
142	association	_	_	O
143	of	_	_	O
144	the	_	_	O
145	genotypes	_	_	O
146	on	_	_	O
147	the	_	_	O
148	four	_	_	O
149	endpoints	_	_	O
150	.	_	_	O

151	Patients	_	_	B-Premise
152	carrying	_	_	I-Premise
153	a	_	_	I-Premise
154	GCLC	_	_	I-Premise
155	77	_	_	I-Premise
156	genotype	_	_	I-Premise
157	had	_	_	I-Premise
158	a	_	_	I-Premise
159	worse	_	_	I-Premise
160	overall	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	hazard	_	_	I-Premise
164	ratio	_	_	I-Premise
165	(	_	_	I-Premise
166	HR	_	_	I-Premise
167	)	_	_	I-Premise
168	=	_	_	I-Premise
169	1.5	_	_	I-Premise
170	,	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.05	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Patients	_	_	B-Premise
177	carrying	_	_	I-Premise
178	the	_	_	I-Premise
179	GPX1-CC	_	_	I-Premise
180	genotype	_	_	I-Premise
181	had	_	_	I-Premise
182	a	_	_	I-Premise
183	clinically	_	_	I-Premise
184	significant	_	_	I-Premise
185	decline	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	UNISCALE	_	_	I-Premise
189	(	_	_	I-Premise
190	odds	_	_	I-Premise
191	ratio	_	_	I-Premise
192	(	_	_	I-Premise
193	OR	_	_	I-Premise
194	)	_	_	I-Premise
195	:	_	_	I-Premise
196	7.5	_	_	I-Premise
197	;	_	_	I-Premise
198	p	_	_	I-Premise
199	=	_	_	I-Premise
200	0.04	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	total	_	_	I-Premise
204	Functional	_	_	I-Premise
205	Assessment	_	_	I-Premise
206	of	_	_	I-Premise
207	Cancer	_	_	I-Premise
208	Therapy-Lung	_	_	I-Premise
209	score	_	_	I-Premise
210	(	_	_	I-Premise
211	OR	_	_	I-Premise
212	:	_	_	I-Premise
213	11.0	_	_	I-Premise
214	;	_	_	I-Premise
215	p	_	_	I-Premise
216	=	_	_	I-Premise
217	0.04	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	physical	_	_	I-Premise
221	(	_	_	I-Premise
222	OR	_	_	I-Premise
223	:	_	_	I-Premise
224	7.1	_	_	I-Premise
225	;	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0.03	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	functional	_	_	I-Premise
232	(	_	_	I-Premise
233	OR	_	_	I-Premise
234	:	_	_	I-Premise
235	5.2	_	_	I-Premise
236	;	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.04	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	emotional	_	_	I-Premise
244	well-being	_	_	I-Premise
245	constructs	_	_	I-Premise
246	(	_	_	I-Premise
247	OR	_	_	I-Premise
248	:	_	_	I-Premise
249	23.8	_	_	I-Premise
250	;	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Genotypes	_	_	B-Claim
257	of	_	_	I-Claim
258	glutathione-related	_	_	I-Claim
259	enzymes	_	_	I-Claim
260	,	_	_	I-Claim
261	especially	_	_	I-Claim
262	GCLC	_	_	I-Claim
263	,	_	_	I-Claim
264	may	_	_	I-Claim
265	be	_	_	I-Claim
266	used	_	_	I-Claim
267	as	_	_	I-Claim
268	host	_	_	I-Claim
269	factors	_	_	I-Claim
270	in	_	_	I-Claim
271	predicting	_	_	I-Claim
272	patients	_	_	I-Claim
273	'	_	_	I-Claim
274	survival	_	_	I-Claim
275	after	_	_	I-Claim
276	platinum-based	_	_	I-Claim
277	chemotherapy	_	_	I-Claim
278	.	_	_	I-Claim

279	GPX1	_	_	B-Claim
280	may	_	_	I-Claim
281	be	_	_	I-Claim
282	an	_	_	I-Claim
283	inherited	_	_	I-Claim
284	factor	_	_	I-Claim
285	in	_	_	I-Claim
286	predicting	_	_	I-Claim
287	patients	_	_	I-Claim
288	'	_	_	I-Claim
289	QOL	_	_	I-Claim
290	.	_	_	I-Claim

291	Further	_	_	B-Claim
292	investigation	_	_	I-Claim
293	to	_	_	I-Claim
294	define	_	_	I-Claim
295	and	_	_	I-Claim
296	measure	_	_	I-Claim
297	the	_	_	I-Claim
298	effects	_	_	I-Claim
299	of	_	_	I-Claim
300	these	_	_	I-Claim
301	genes	_	_	I-Claim
302	in	_	_	I-Claim
303	chemotherapeutic	_	_	I-Claim
304	regimens	_	_	I-Claim
305	,	_	_	I-Claim
306	drug	_	_	I-Claim
307	toxicities	_	_	I-Claim
308	,	_	_	I-Claim
309	disease	_	_	I-Claim
310	progression	_	_	I-Claim
311	,	_	_	I-Claim
312	and	_	_	I-Claim
313	QOL	_	_	I-Claim
314	are	_	_	I-Claim
315	critical	_	_	I-Claim
316	.	_	_	I-Claim


0	Serum	_	_	O
1	CA125	_	_	O
2	concentration	_	_	O
3	often	_	_	O
4	rises	_	_	O
5	several	_	_	O
6	months	_	_	O
7	before	_	_	O
8	clinical	_	_	O
9	or	_	_	O
10	symptomatic	_	_	O
11	relapse	_	_	O
12	in	_	_	O
13	women	_	_	O
14	with	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	In	_	_	O
19	the	_	_	O
20	MRC	_	_	O
21	OV05/EORTC	_	_	O
22	55955	_	_	O
23	collaborative	_	_	O
24	trial	_	_	O
25	,	_	_	O
26	we	_	_	O
27	aimed	_	_	O
28	to	_	_	O
29	establish	_	_	O
30	the	_	_	O
31	benefits	_	_	O
32	of	_	_	O
33	early	_	_	O
34	treatment	_	_	O
35	on	_	_	O
36	the	_	_	O
37	basis	_	_	O
38	of	_	_	O
39	increased	_	_	O
40	CA125	_	_	O
41	concentrations	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	delayed	_	_	O
45	treatment	_	_	O
46	on	_	_	O
47	the	_	_	O
48	basis	_	_	O
49	of	_	_	O
50	clinical	_	_	O
51	recurrence	_	_	O
52	.	_	_	O

53	Women	_	_	O
54	with	_	_	O
55	ovarian	_	_	O
56	cancer	_	_	O
57	in	_	_	O
58	complete	_	_	O
59	remission	_	_	O
60	after	_	_	O
61	first-line	_	_	O
62	platinum-based	_	_	O
63	chemotherapy	_	_	O
64	and	_	_	O
65	a	_	_	O
66	normal	_	_	O
67	CA125	_	_	O
68	concentration	_	_	O
69	were	_	_	O
70	registered	_	_	O
71	for	_	_	O
72	this	_	_	O
73	randomised	_	_	O
74	controlled	_	_	O
75	trial	_	_	O
76	.	_	_	O

77	Clinical	_	_	O
78	examination	_	_	O
79	and	_	_	O
80	CA125	_	_	O
81	measurement	_	_	O
82	were	_	_	O
83	done	_	_	O
84	every	_	_	O
85	3	_	_	O
86	months	_	_	O
87	.	_	_	O

88	Patients	_	_	O
89	and	_	_	O
90	investigators	_	_	O
91	were	_	_	O
92	masked	_	_	O
93	to	_	_	O
94	CA125	_	_	O
95	results	_	_	O
96	,	_	_	O
97	which	_	_	O
98	were	_	_	O
99	monitored	_	_	O
100	by	_	_	O
101	coordinating	_	_	O
102	centres	_	_	O
103	.	_	_	O

104	If	_	_	O
105	CA125	_	_	O
106	concentration	_	_	O
107	exceeded	_	_	O
108	twice	_	_	O
109	the	_	_	O
110	upper	_	_	O
111	limit	_	_	O
112	of	_	_	O
113	normal	_	_	O
114	,	_	_	O
115	patients	_	_	O
116	were	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	(	_	_	O
120	1:1	_	_	O
121	)	_	_	O
122	by	_	_	O
123	minimisation	_	_	O
124	to	_	_	O
125	early	_	_	O
126	or	_	_	O
127	delayed	_	_	O
128	chemotherapy	_	_	O
129	.	_	_	O

130	Patients	_	_	O
131	and	_	_	O
132	clinical	_	_	O
133	sites	_	_	O
134	were	_	_	O
135	informed	_	_	O
136	of	_	_	O
137	allocation	_	_	O
138	to	_	_	O
139	early	_	_	O
140	treatment	_	_	O
141	,	_	_	O
142	and	_	_	O
143	treatment	_	_	O
144	was	_	_	O
145	started	_	_	O
146	as	_	_	O
147	soon	_	_	O
148	as	_	_	O
149	possible	_	_	O
150	within	_	_	O
151	28	_	_	O
152	days	_	_	O
153	of	_	_	O
154	the	_	_	O
155	increased	_	_	O
156	CA125	_	_	O
157	measurement	_	_	O
158	.	_	_	O

159	Patients	_	_	O
160	assigned	_	_	O
161	to	_	_	O
162	delayed	_	_	O
163	treatment	_	_	O
164	continued	_	_	O
165	masked	_	_	O
166	CA125	_	_	O
167	measurements	_	_	O
168	,	_	_	O
169	with	_	_	O
170	treatment	_	_	O
171	commencing	_	_	O
172	at	_	_	O
173	clinical	_	_	O
174	or	_	_	O
175	symptomatic	_	_	O
176	relapse	_	_	O
177	.	_	_	O

178	All	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	treated	_	_	O
182	according	_	_	O
183	to	_	_	O
184	standard	_	_	O
185	local	_	_	O
186	practice	_	_	O
187	.	_	_	O

188	The	_	_	O
189	primary	_	_	O
190	outcome	_	_	O
191	was	_	_	O
192	overall	_	_	O
193	survival	_	_	O
194	.	_	_	O

195	Analysis	_	_	O
196	was	_	_	O
197	by	_	_	O
198	intention	_	_	O
199	to	_	_	O
200	treat	_	_	O
201	.	_	_	O

202	This	_	_	O
203	study	_	_	O
204	is	_	_	O
205	registered	_	_	O
206	,	_	_	O
207	ISRCTN87786644	_	_	O
208	.	_	_	O

209	1442	_	_	O
210	patients	_	_	O
211	were	_	_	O
212	registered	_	_	O
213	for	_	_	O
214	the	_	_	O
215	trial	_	_	O
216	,	_	_	O
217	of	_	_	O
218	whom	_	_	O
219	529	_	_	O
220	were	_	_	O
221	randomly	_	_	O
222	assigned	_	_	O
223	to	_	_	O
224	treatment	_	_	O
225	groups	_	_	O
226	and	_	_	O
227	were	_	_	O
228	included	_	_	O
229	in	_	_	O
230	our	_	_	O
231	analysis	_	_	O
232	(	_	_	O
233	265	_	_	O
234	early	_	_	O
235	,	_	_	O
236	264	_	_	O
237	delayed	_	_	O
238	)	_	_	O
239	.	_	_	O

240	With	_	_	B-Premise
241	a	_	_	I-Premise
242	median	_	_	I-Premise
243	follow-up	_	_	I-Premise
244	of	_	_	I-Premise
245	56Â·9	_	_	I-Premise
246	months	_	_	I-Premise
247	(	_	_	I-Premise
248	IQR	_	_	I-Premise
249	37Â·4-81Â·8	_	_	I-Premise
250	)	_	_	I-Premise
251	from	_	_	I-Premise
252	randomisation	_	_	I-Premise
253	and	_	_	I-Premise
254	370	_	_	I-Premise
255	deaths	_	_	I-Premise
256	(	_	_	I-Premise
257	186	_	_	I-Premise
258	early	_	_	I-Premise
259	,	_	_	I-Premise
260	184	_	_	I-Premise
261	delayed	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	there	_	_	I-Premise
265	was	_	_	I-Premise
266	no	_	_	I-Premise
267	evidence	_	_	I-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	overall	_	_	I-Premise
273	survival	_	_	I-Premise
274	between	_	_	I-Premise
275	early	_	_	I-Premise
276	and	_	_	I-Premise
277	delayed	_	_	I-Premise
278	treatment	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	0Â·98	_	_	I-Premise
282	,	_	_	I-Premise
283	95	_	_	I-Premise
284	%	_	_	I-Premise
285	CI	_	_	I-Premise
286	0Â·80-1Â·20	_	_	I-Premise
287	,	_	_	I-Premise
288	p=0Â·85	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Median	_	_	B-Premise
292	survival	_	_	I-Premise
293	from	_	_	I-Premise
294	randomisation	_	_	I-Premise
295	was	_	_	I-Premise
296	25Â·7	_	_	I-Premise
297	months	_	_	I-Premise
298	(	_	_	I-Premise
299	95	_	_	I-Premise
300	%	_	_	I-Premise
301	CI	_	_	I-Premise
302	23Â·0-27Â·9	_	_	I-Premise
303	)	_	_	I-Premise
304	for	_	_	I-Premise
305	patients	_	_	I-Premise
306	on	_	_	I-Premise
307	early	_	_	I-Premise
308	treatment	_	_	I-Premise
309	and	_	_	I-Premise
310	27Â·1	_	_	I-Premise
311	months	_	_	I-Premise
312	(	_	_	I-Premise
313	22Â·8-30Â·9	_	_	I-Premise
314	)	_	_	I-Premise
315	for	_	_	I-Premise
316	those	_	_	I-Premise
317	on	_	_	I-Premise
318	delayed	_	_	I-Premise
319	treatment	_	_	I-Premise
320	.	_	_	I-Premise

321	Our	_	_	B-Claim
322	findings	_	_	I-Claim
323	showed	_	_	I-Claim
324	no	_	_	I-Claim
325	evidence	_	_	I-Claim
326	of	_	_	I-Claim
327	a	_	_	I-Claim
328	survival	_	_	I-Claim
329	benefit	_	_	I-Claim
330	with	_	_	I-Claim
331	early	_	_	I-Claim
332	treatment	_	_	I-Claim
333	of	_	_	I-Claim
334	relapse	_	_	I-Claim
335	on	_	_	I-Claim
336	the	_	_	I-Claim
337	basis	_	_	I-Claim
338	of	_	_	I-Claim
339	a	_	_	I-Claim
340	raised	_	_	I-Claim
341	CA125	_	_	I-Claim
342	concentration	_	_	I-Claim
343	alone	_	_	I-Claim
344	,	_	_	I-Claim
345	and	_	_	B-Claim
346	therefore	_	_	I-Claim
347	the	_	_	I-Claim
348	value	_	_	I-Claim
349	of	_	_	I-Claim
350	routine	_	_	I-Claim
351	measurement	_	_	I-Claim
352	of	_	_	I-Claim
353	CA125	_	_	I-Claim
354	in	_	_	I-Claim
355	the	_	_	I-Claim
356	follow-up	_	_	I-Claim
357	of	_	_	I-Claim
358	patients	_	_	I-Claim
359	with	_	_	I-Claim
360	ovarian	_	_	I-Claim
361	cancer	_	_	I-Claim
362	who	_	_	I-Claim
363	attain	_	_	I-Claim
364	a	_	_	I-Claim
365	complete	_	_	I-Claim
366	response	_	_	I-Claim
367	after	_	_	I-Claim
368	first-line	_	_	I-Claim
369	treatment	_	_	I-Claim
370	is	_	_	I-Claim
371	not	_	_	I-Claim
372	proven	_	_	I-Claim
373	.	_	_	I-Claim


0	Kaposi	_	_	O
1	's	_	_	O
2	sarcoma	_	_	O
3	is	_	_	O
4	currently	_	_	O
5	the	_	_	O
6	most	_	_	O
7	common	_	_	O
8	tumor	_	_	O
9	in	_	_	O
10	Zimbabwe	_	_	O
11	.	_	_	O

12	The	_	_	O
13	purpose	_	_	O
14	of	_	_	O
15	our	_	_	O
16	study	_	_	O
17	is	_	_	O
18	to	_	_	O
19	compare	_	_	O
20	the	_	_	O
21	effectiveness	_	_	O
22	of	_	_	O
23	supportive	_	_	O
24	care	_	_	O
25	vs.	_	_	O
26	3	_	_	O
27	intervention	_	_	O
28	approaches	_	_	O
29	,	_	_	O
30	namely	_	_	O
31	oral	_	_	O
32	Etoposide	_	_	O
33	,	_	_	O
34	a	_	_	O
35	3-drug	_	_	O
36	combination	_	_	O
37	,	_	_	O
38	and	_	_	O
39	radiotherapy	_	_	O
40	using	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	QOL	_	_	O
46	)	_	_	O
47	as	_	_	O
48	the	_	_	O
49	primary	_	_	O
50	measure	_	_	O
51	of	_	_	O
52	success	_	_	O
53	.	_	_	O

54	In	_	_	O
55	addition	_	_	O
56	,	_	_	O
57	our	_	_	O
58	study	_	_	O
59	was	_	_	O
60	to	_	_	O
61	determine	_	_	O
62	whether	_	_	O
63	a	_	_	O
64	disease-specific	_	_	O
65	module	_	_	O
66	has	_	_	O
67	greater	_	_	O
68	sensitivity	_	_	O
69	to	_	_	O
70	group	_	_	O
71	differences	_	_	O
72	than	_	_	O
73	a	_	_	O
74	generic	_	_	O
75	QOL	_	_	O
76	questionnaire	_	_	O
77	and	_	_	O
78	to	_	_	O
79	determine	_	_	O
80	the	_	_	O
81	most	_	_	O
82	pragmatic	_	_	O
83	approach	_	_	O
84	to	_	_	O
85	treating	_	_	O
86	epidemic	_	_	O
87	Kaposi	_	_	O
88	's	_	_	O
89	sarcoma	_	_	O
90	(	_	_	O
91	EKS	_	_	O
92	)	_	_	O
93	in	_	_	O
94	Zimbabwe	_	_	O
95	.	_	_	O

96	Histologically	_	_	O
97	confirmed	_	_	O
98	HIV-positive	_	_	O
99	patients	_	_	O
100	with	_	_	O
101	Kaposi	_	_	O
102	's	_	_	O
103	sarcoma	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	receive	_	_	O
108	supportive	_	_	O
109	care	_	_	O
110	only	_	_	O
111	or	_	_	O
112	supportive	_	_	O
113	care	_	_	O
114	plus	_	_	O
115	either	_	_	O
116	radiotherapy	_	_	O
117	,	_	_	O
118	oral	_	_	O
119	Etoposide	_	_	O
120	or	_	_	O
121	a	_	_	O
122	3-drug	_	_	O
123	combination	_	_	O
124	consisting	_	_	O
125	of	_	_	O
126	actinomycin-D	_	_	O
127	,	_	_	O
128	vincristine	_	_	O
129	and	_	_	O
130	bleomycin	_	_	O
131	.	_	_	O

132	No	_	_	O
133	patient	_	_	O
134	received	_	_	O
135	antiretroviral	_	_	O
136	therapy	_	_	O
137	.	_	_	O

138	The	_	_	O
139	primary	_	_	O
140	outcome	_	_	O
141	was	_	_	O
142	QOL	_	_	O
143	measured	_	_	O
144	by	_	_	O
145	the	_	_	O
146	functional	_	_	O
147	living	_	_	O
148	index-cancer	_	_	O
149	(	_	_	O
150	FLI-C	_	_	O
151	)	_	_	O
152	and	_	_	O
153	supplemented	_	_	O
154	by	_	_	O
155	the	_	_	O
156	Kaposi	_	_	O
157	's	_	_	O
158	sarcoma	_	_	O
159	module	_	_	O
160	(	_	_	O
161	KSM	_	_	O
162	)	_	_	O
163	.	_	_	O

164	From	_	_	O
165	1994-1999	_	_	O
166	,	_	_	O
167	495	_	_	O
168	EKS	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	accrued	_	_	O
172	,	_	_	O
173	and	_	_	O
174	470	_	_	O
175	were	_	_	O
176	evaluable	_	_	O
177	.	_	_	O

178	Of	_	_	O
179	these	_	_	O
180	,	_	_	O
181	433	_	_	O
182	are	_	_	O
183	known	_	_	O
184	to	_	_	O
185	be	_	_	O
186	dead	_	_	O
187	,	_	_	O
188	26	_	_	O
189	are	_	_	O
190	lost	_	_	O
191	to	_	_	O
192	follow-up	_	_	O
193	and	_	_	O
194	11	_	_	O
195	are	_	_	O
196	still	_	_	O
197	alive	_	_	O
198	.	_	_	O

199	The	_	_	B-Premise
200	group	_	_	I-Premise
201	treated	_	_	I-Premise
202	with	_	_	I-Premise
203	oral	_	_	I-Premise
204	Etoposide	_	_	I-Premise
205	had	_	_	I-Premise
206	a	_	_	I-Premise
207	significantly	_	_	I-Premise
208	better	_	_	I-Premise
209	QOL	_	_	I-Premise
210	than	_	_	I-Premise
211	the	_	_	I-Premise
212	radiotherapy	_	_	I-Premise
213	group	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	total	_	_	I-Premise
217	FLI-C	_	_	I-Premise
218	score	_	_	I-Premise
219	(	_	_	I-Premise
220	adjusted	_	_	I-Premise
221	mean	_	_	I-Premise
222	plus	_	_	I-Premise
223	standard	_	_	I-Premise
224	error	_	_	I-Premise
225	at	_	_	I-Premise
226	3-months	_	_	I-Premise
227	89	_	_	I-Premise
228	+/-	_	_	I-Premise
229	3	_	_	I-Premise
230	vs.	_	_	I-Premise
231	76	_	_	I-Premise
232	+/-	_	_	I-Premise
233	3	_	_	I-Premise
234	;	_	_	I-Premise
235	p	_	_	I-Premise
236	=	_	_	I-Premise
237	0.004	_	_	I-Premise
238	)	_	_	I-Premise
239	and	_	_	I-Premise
240	for	_	_	I-Premise
241	the	_	_	I-Premise
242	hardship	_	_	I-Premise
243	(	_	_	I-Premise
244	11	_	_	I-Premise
245	+/-	_	_	I-Premise
246	0.4	_	_	I-Premise
247	vs.	_	_	I-Premise
248	9	_	_	I-Premise
249	+/-	_	_	I-Premise
250	0.4	_	_	I-Premise
251	;	_	_	I-Premise
252	p	_	_	I-Premise
253	=	_	_	I-Premise
254	0.001	_	_	I-Premise
255	)	_	_	I-Premise
256	;	_	_	I-Premise
257	social	_	_	I-Premise
258	(	_	_	I-Premise
259	10	_	_	I-Premise
260	+/-	_	_	I-Premise
261	0.4	_	_	I-Premise
262	vs.	_	_	I-Premise
263	8	_	_	I-Premise
264	+/-	_	_	I-Premise
265	0.4	_	_	I-Premise
266	;	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0.001	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	nausea	_	_	I-Premise
273	(	_	_	I-Premise
274	9	_	_	I-Premise
275	+/-	_	_	I-Premise
276	0.4	_	_	I-Premise
277	vs.	_	_	I-Premise
278	8	_	_	I-Premise
279	+/-	_	_	I-Premise
280	0.4	_	_	I-Premise
281	;	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.002	_	_	I-Premise
285	)	_	_	I-Premise
286	subscales	_	_	I-Premise
287	.	_	_	I-Premise

288	In	_	_	B-Premise
289	addition	_	_	I-Premise
290	,	_	_	I-Premise
291	on	_	_	I-Premise
292	the	_	_	I-Premise
293	physical	_	_	I-Premise
294	and	_	_	I-Premise
295	psychological	_	_	I-Premise
296	subscales	_	_	I-Premise
297	,	_	_	I-Premise
298	the	_	_	I-Premise
299	Etoposide	_	_	I-Premise
300	group	_	_	I-Premise
301	had	_	_	I-Premise
302	a	_	_	I-Premise
303	significantly	_	_	I-Premise
304	better	_	_	I-Premise
305	QOL	_	_	I-Premise
306	than	_	_	I-Premise
307	the	_	_	I-Premise
308	other	_	_	I-Premise
309	3	_	_	I-Premise
310	treatment	_	_	I-Premise
311	groups	_	_	I-Premise
312	(	_	_	I-Premise
313	p	_	_	I-Premise
314	<	_	_	I-Premise
315	0.04	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	The	_	_	B-Premise
319	3-drug	_	_	I-Premise
320	combination	_	_	I-Premise
321	,	_	_	I-Premise
322	supportive	_	_	I-Premise
323	care	_	_	I-Premise
324	and	_	_	I-Premise
325	radiotherapy	_	_	I-Premise
326	groups	_	_	I-Premise
327	did	_	_	I-Premise
328	not	_	_	I-Premise
329	differ	_	_	I-Premise
330	significantly	_	_	I-Premise
331	from	_	_	I-Premise
332	each	_	_	I-Premise
333	other	_	_	I-Premise
334	with	_	_	I-Premise
335	respect	_	_	I-Premise
336	to	_	_	I-Premise
337	the	_	_	I-Premise
338	total	_	_	I-Premise
339	FLI-C	_	_	I-Premise
340	score	_	_	I-Premise
341	or	_	_	I-Premise
342	its	_	_	I-Premise
343	subscales	_	_	I-Premise
344	.	_	_	I-Premise

345	There	_	_	B-Premise
346	were	_	_	I-Premise
347	no	_	_	I-Premise
348	group	_	_	I-Premise
349	differences	_	_	I-Premise
350	with	_	_	I-Premise
351	respect	_	_	I-Premise
352	to	_	_	I-Premise
353	survival	_	_	I-Premise
354	.	_	_	I-Premise

355	Oral	_	_	B-Claim
356	Etoposide	_	_	I-Claim
357	therapy	_	_	I-Claim
358	resulted	_	_	I-Claim
359	in	_	_	I-Claim
360	better	_	_	I-Claim
361	total	_	_	I-Claim
362	FLI-C	_	_	I-Claim
363	QOL	_	_	I-Claim
364	score	_	_	I-Claim
365	than	_	_	I-Claim
366	radiotherapy	_	_	I-Claim
367	.	_	_	I-Claim

368	As	_	_	O
369	well	_	_	O
370	,	_	_	O
371	Etoposide	_	_	B-Claim
372	resulted	_	_	I-Claim
373	in	_	_	I-Claim
374	better	_	_	I-Claim
375	physical	_	_	I-Claim
376	and	_	_	I-Claim
377	psychological	_	_	I-Claim
378	subscale	_	_	I-Claim
379	scores	_	_	I-Claim
380	than	_	_	I-Claim
381	radiotherapy	_	_	I-Claim
382	,	_	_	I-Claim
383	3-drugs	_	_	I-Claim
384	and	_	_	I-Claim
385	supportive	_	_	I-Claim
386	care	_	_	I-Claim
387	.	_	_	I-Claim

388	Thus	_	_	B-Claim
389	,	_	_	I-Claim
390	funds	_	_	I-Claim
391	permitting	_	_	I-Claim
392	,	_	_	I-Claim
393	oral	_	_	I-Claim
394	Etoposide	_	_	I-Claim
395	is	_	_	I-Claim
396	a	_	_	I-Claim
397	pragmatic	_	_	I-Claim
398	approach	_	_	I-Claim
399	to	_	_	I-Claim
400	treating	_	_	I-Claim
401	EKS	_	_	I-Claim
402	in	_	_	I-Claim
403	an	_	_	I-Claim
404	environment	_	_	I-Claim
405	where	_	_	I-Claim
406	antiretroviral	_	_	I-Claim
407	drugs	_	_	I-Claim
408	are	_	_	I-Claim
409	not	_	_	I-Claim
410	universally	_	_	I-Claim
411	available	_	_	I-Claim
412	.	_	_	I-Claim

413	The	_	_	B-Claim
414	study	_	_	I-Claim
415	underscores	_	_	I-Claim
416	the	_	_	I-Claim
417	value	_	_	I-Claim
418	of	_	_	I-Claim
419	undertaking	_	_	I-Claim
420	studies	_	_	I-Claim
421	in	_	_	I-Claim
422	areas	_	_	I-Claim
423	of	_	_	I-Claim
424	disease	_	_	I-Claim
425	prevalence	_	_	I-Claim
426	and	_	_	I-Claim
427	the	_	_	I-Claim
428	necessity	_	_	I-Claim
429	of	_	_	I-Claim
430	selecting	_	_	I-Claim
431	appropriate	_	_	I-Claim
432	outcome	_	_	I-Claim
433	measures	_	_	I-Claim
434	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	functional	_	_	O
3	and	_	_	O
4	psychological	_	_	O
5	benefits	_	_	O
6	of	_	_	O
7	a	_	_	O
8	12	_	_	O
9	week	_	_	O
10	supervised	_	_	O
11	group	_	_	O
12	exercise	_	_	O
13	programme	_	_	O
14	during	_	_	O
15	treatment	_	_	O
16	for	_	_	O
17	early	_	_	O
18	stage	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	,	_	_	O
22	with	_	_	O
23	six	_	_	O
24	month	_	_	O
25	follow-up	_	_	O
26	.	_	_	O

27	Pragmatic	_	_	O
28	randomised	_	_	O
29	controlled	_	_	O
30	prospective	_	_	O
31	open	_	_	O
32	trial	_	_	O
33	.	_	_	O

34	Three	_	_	O
35	National	_	_	O
36	Health	_	_	O
37	Service	_	_	O
38	oncology	_	_	O
39	clinics	_	_	O
40	in	_	_	O
41	Scotland	_	_	O
42	and	_	_	O
43	community	_	_	O
44	exercise	_	_	O
45	facilities	_	_	O
46	.	_	_	O

47	203	_	_	O
48	women	_	_	O
49	entered	_	_	O
50	the	_	_	O
51	study	_	_	O
52	;	_	_	O
53	177	_	_	O
54	completed	_	_	O
55	the	_	_	O
56	six	_	_	O
57	month	_	_	O
58	follow-up	_	_	O
59	.	_	_	O

60	Supervised	_	_	O
61	12	_	_	O
62	week	_	_	O
63	group	_	_	O
64	exercise	_	_	O
65	programme	_	_	O
66	in	_	_	O
67	addition	_	_	O
68	to	_	_	O
69	usual	_	_	O
70	care	_	_	O
71	,	_	_	O
72	compared	_	_	O
73	with	_	_	O
74	usual	_	_	O
75	care	_	_	O
76	.	_	_	O

77	Functional	_	_	O
78	assessment	_	_	O
79	of	_	_	O
80	cancer	_	_	O
81	therapy	_	_	O
82	(	_	_	O
83	FACT	_	_	O
84	)	_	_	O
85	questionnaire	_	_	O
86	,	_	_	O
87	Beck	_	_	O
88	depression	_	_	O
89	inventory	_	_	O
90	,	_	_	O
91	positive	_	_	O
92	and	_	_	O
93	negative	_	_	O
94	affect	_	_	O
95	scale	_	_	O
96	,	_	_	O
97	body	_	_	O
98	mass	_	_	O
99	index	_	_	O
100	,	_	_	O
101	seven	_	_	O
102	day	_	_	O
103	recall	_	_	O
104	of	_	_	O
105	physical	_	_	O
106	activity	_	_	O
107	,	_	_	O
108	12	_	_	O
109	minute	_	_	O
110	walk	_	_	O
111	test	_	_	O
112	,	_	_	O
113	and	_	_	O
114	assessment	_	_	O
115	of	_	_	O
116	shoulder	_	_	O
117	mobility	_	_	O
118	.	_	_	O

119	Mixed	_	_	B-Premise
120	effects	_	_	I-Premise
121	models	_	_	I-Premise
122	with	_	_	I-Premise
123	adjustment	_	_	I-Premise
124	for	_	_	I-Premise
125	baseline	_	_	I-Premise
126	values	_	_	I-Premise
127	,	_	_	I-Premise
128	study	_	_	I-Premise
129	site	_	_	I-Premise
130	,	_	_	I-Premise
131	treatment	_	_	I-Premise
132	at	_	_	I-Premise
133	baseline	_	_	I-Premise
134	,	_	_	I-Premise
135	and	_	_	I-Premise
136	age	_	_	I-Premise
137	gave	_	_	I-Premise
138	intervention	_	_	I-Premise
139	effect	_	_	I-Premise
140	estimates	_	_	I-Premise
141	(	_	_	I-Premise
142	intervention	_	_	I-Premise
143	minus	_	_	I-Premise
144	control	_	_	I-Premise
145	)	_	_	I-Premise
146	at	_	_	I-Premise
147	12	_	_	I-Premise
148	weeks	_	_	I-Premise
149	of	_	_	I-Premise
150	129	_	_	I-Premise
151	(	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	confidence	_	_	I-Premise
155	interval	_	_	I-Premise
156	83	_	_	I-Premise
157	to	_	_	I-Premise
158	176	_	_	I-Premise
159	)	_	_	I-Premise
160	for	_	_	I-Premise
161	metres	_	_	I-Premise
162	walked	_	_	I-Premise
163	in	_	_	I-Premise
164	12	_	_	I-Premise
165	minutes	_	_	I-Premise
166	,	_	_	I-Premise
167	182	_	_	I-Premise
168	(	_	_	I-Premise
169	75	_	_	I-Premise
170	to	_	_	I-Premise
171	289	_	_	I-Premise
172	)	_	_	I-Premise
173	for	_	_	I-Premise
174	minutes	_	_	I-Premise
175	of	_	_	I-Premise
176	moderate	_	_	I-Premise
177	intensity	_	_	I-Premise
178	activity	_	_	I-Premise
179	reported	_	_	I-Premise
180	in	_	_	I-Premise
181	a	_	_	I-Premise
182	week	_	_	I-Premise
183	,	_	_	I-Premise
184	2.6	_	_	I-Premise
185	(	_	_	I-Premise
186	1.6	_	_	I-Premise
187	to	_	_	I-Premise
188	3.7	_	_	I-Premise
189	)	_	_	I-Premise
190	for	_	_	I-Premise
191	shoulder	_	_	I-Premise
192	mobility	_	_	I-Premise
193	,	_	_	I-Premise
194	2.5	_	_	I-Premise
195	(	_	_	I-Premise
196	1.0	_	_	I-Premise
197	to	_	_	I-Premise
198	3.9	_	_	I-Premise
199	)	_	_	I-Premise
200	for	_	_	I-Premise
201	breast	_	_	I-Premise
202	cancer	_	_	I-Premise
203	specific	_	_	I-Premise
204	subscale	_	_	I-Premise
205	of	_	_	I-Premise
206	quality	_	_	I-Premise
207	of	_	_	I-Premise
208	life	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	4.0	_	_	I-Premise
212	(	_	_	I-Premise
213	1.8	_	_	I-Premise
214	to	_	_	I-Premise
215	6.3	_	_	I-Premise
216	)	_	_	I-Premise
217	for	_	_	I-Premise
218	positive	_	_	I-Premise
219	mood	_	_	I-Premise
220	.	_	_	I-Premise

221	No	_	_	B-Premise
222	significant	_	_	I-Premise
223	effect	_	_	I-Premise
224	was	_	_	I-Premise
225	seen	_	_	I-Premise
226	for	_	_	I-Premise
227	general	_	_	I-Premise
228	quality	_	_	I-Premise
229	of	_	_	I-Premise
230	life	_	_	I-Premise
231	(	_	_	I-Premise
232	FACT-G	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	which	_	_	I-Premise
236	was	_	_	I-Premise
237	the	_	_	I-Premise
238	primary	_	_	I-Premise
239	outcome	_	_	I-Premise
240	.	_	_	I-Premise

241	At	_	_	B-Premise
242	the	_	_	I-Premise
243	six	_	_	I-Premise
244	month	_	_	I-Premise
245	follow-up	_	_	I-Premise
246	,	_	_	I-Premise
247	most	_	_	I-Premise
248	of	_	_	I-Premise
249	these	_	_	I-Premise
250	effects	_	_	I-Premise
251	were	_	_	I-Premise
252	maintained	_	_	I-Premise
253	and	_	_	I-Premise
254	an	_	_	I-Premise
255	intervention	_	_	I-Premise
256	effect	_	_	I-Premise
257	for	_	_	I-Premise
258	breast	_	_	I-Premise
259	cancer	_	_	I-Premise
260	specific	_	_	I-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	emerged	_	_	I-Premise
265	.	_	_	I-Premise

266	No	_	_	B-Premise
267	adverse	_	_	I-Premise
268	effects	_	_	I-Premise
269	were	_	_	I-Premise
270	noted	_	_	I-Premise
271	.	_	_	I-Premise

272	Supervised	_	_	B-Claim
273	group	_	_	I-Claim
274	exercise	_	_	I-Claim
275	provided	_	_	I-Claim
276	functional	_	_	I-Claim
277	and	_	_	I-Claim
278	psychological	_	_	I-Claim
279	benefit	_	_	I-Claim
280	after	_	_	I-Claim
281	a	_	_	I-Claim
282	12	_	_	I-Claim
283	week	_	_	I-Claim
284	intervention	_	_	I-Claim
285	and	_	_	I-Claim
286	six	_	_	I-Claim
287	months	_	_	I-Claim
288	later	_	_	I-Claim
289	.	_	_	I-Claim

290	Clinicians	_	_	B-Claim
291	should	_	_	I-Claim
292	encourage	_	_	I-Claim
293	activity	_	_	I-Claim
294	for	_	_	I-Claim
295	their	_	_	I-Claim
296	patients	_	_	I-Claim
297	.	_	_	I-Claim

298	Policy	_	_	B-Claim
299	makers	_	_	I-Claim
300	should	_	_	I-Claim
301	consider	_	_	I-Claim
302	the	_	_	I-Claim
303	inclusion	_	_	I-Claim
304	of	_	_	I-Claim
305	exercise	_	_	I-Claim
306	opportunities	_	_	I-Claim
307	in	_	_	I-Claim
308	cancer	_	_	I-Claim
309	rehabilitation	_	_	I-Claim
310	services	_	_	I-Claim
311	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	treatment	_	_	O
10	and	_	_	O
11	retention	_	_	O
12	effects	_	_	O
13	between	_	_	O
14	standard	_	_	O
15	decongestive	_	_	O
16	lymphatic	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	DLT	_	_	O
20	)	_	_	O
21	combined	_	_	O
22	with	_	_	O
23	pneumatic	_	_	O
24	compression	_	_	O
25	(	_	_	O
26	PC	_	_	O
27	)	_	_	O
28	and	_	_	O
29	modified	_	_	O
30	DLT	_	_	O
31	,	_	_	O
32	in	_	_	O
33	which	_	_	O
34	the	_	_	O
35	use	_	_	O
36	of	_	_	O
37	a	_	_	O
38	short-stretch	_	_	O
39	bandage	_	_	O
40	is	_	_	O
41	replaced	_	_	O
42	with	_	_	O
43	the	_	_	O
44	use	_	_	O
45	of	_	_	O
46	Kinesio	_	_	O
47	tape	_	_	O
48	(	_	_	O
49	K-tape	_	_	O
50	)	_	_	O
51	combined	_	_	O
52	with	_	_	O
53	PC	_	_	O
54	.	_	_	O

55	Forty-one	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	unilateral	_	_	O
59	breast-cancer-related	_	_	O
60	lymphedema	_	_	O
61	for	_	_	O
62	at	_	_	O
63	least	_	_	O
64	3	_	_	O
65	months	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	grouped	_	_	O
69	into	_	_	O
70	the	_	_	O
71	DLT	_	_	O
72	group	_	_	O
73	(	_	_	O
74	bandage	_	_	O
75	group	_	_	O
76	,	_	_	O
77	N	_	_	O
78	=	_	_	O
79	21	_	_	O
80	)	_	_	O
81	or	_	_	O
82	the	_	_	O
83	modified	_	_	O
84	DLT	_	_	O
85	group	_	_	O
86	(	_	_	O
87	K-tape	_	_	O
88	group	_	_	O
89	,	_	_	O
90	N	_	_	O
91	=	_	_	O
92	20	_	_	O
93	)	_	_	O
94	.	_	_	O

95	Skin	_	_	O
96	care	_	_	O
97	,	_	_	O
98	30-min	_	_	O
99	manual	_	_	O
100	lymphatic	_	_	O
101	drainage	_	_	O
102	,	_	_	O
103	1-h	_	_	O
104	pneumatic	_	_	O
105	compression	_	_	O
106	therapy	_	_	O
107	,	_	_	O
108	application	_	_	O
109	of	_	_	O
110	a	_	_	O
111	short-stretch	_	_	O
112	bandage	_	_	O
113	or	_	_	O
114	K-tape	_	_	O
115	for	_	_	O
116	each	_	_	O
117	group	_	_	O
118	,	_	_	O
119	and	_	_	O
120	a	_	_	O
121	20-min	_	_	O
122	physical	_	_	O
123	therapy	_	_	O
124	exercise	_	_	O
125	were	_	_	O
126	given	_	_	O
127	during	_	_	O
128	every	_	_	O
129	treatment	_	_	O
130	session	_	_	O
131	.	_	_	O

132	Patient	_	_	O
133	evaluation	_	_	O
134	items	_	_	O
135	included	_	_	O
136	physical	_	_	O
137	therapy	_	_	O
138	assessment	_	_	O
139	,	_	_	O
140	limb	_	_	O
141	size	_	_	O
142	,	_	_	O
143	water	_	_	O
144	composition	_	_	O
145	of	_	_	O
146	the	_	_	O
147	upper	_	_	O
148	extremity	_	_	O
149	,	_	_	O
150	lymphedema-related	_	_	O
151	symptoms	_	_	O
152	,	_	_	O
153	quality	_	_	O
154	of	_	_	O
155	life	_	_	O
156	,	_	_	O
157	and	_	_	O
158	patients	_	_	O
159	'	_	_	O
160	acceptance	_	_	O
161	to	_	_	O
162	the	_	_	O
163	bandage	_	_	O
164	or	_	_	O
165	tape	_	_	O
166	.	_	_	O

167	There	_	_	B-Premise
168	was	_	_	I-Premise
169	no	_	_	I-Premise
170	significant	_	_	I-Premise
171	difference	_	_	I-Premise
172	between	_	_	I-Premise
173	groups	_	_	I-Premise
174	in	_	_	I-Premise
175	all	_	_	I-Premise
176	outcome	_	_	I-Premise
177	variables	_	_	I-Premise
178	(	_	_	I-Premise
179	P	_	_	I-Premise
180	>	_	_	I-Premise
181	0.05	_	_	I-Premise
182	)	_	_	I-Premise
183	through	_	_	I-Premise
184	the	_	_	I-Premise
185	whole	_	_	I-Premise
186	study	_	_	I-Premise
187	period	_	_	I-Premise
188	.	_	_	I-Premise

189	Excess	_	_	B-Premise
190	limb	_	_	I-Premise
191	size	_	_	I-Premise
192	(	_	_	I-Premise
193	circumference	_	_	I-Premise
194	and	_	_	I-Premise
195	water	_	_	I-Premise
196	displacement	_	_	I-Premise
197	)	_	_	I-Premise
198	and	_	_	I-Premise
199	excess	_	_	I-Premise
200	water	_	_	I-Premise
201	composition	_	_	I-Premise
202	were	_	_	I-Premise
203	reduced	_	_	I-Premise
204	significantly	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	bandage	_	_	I-Premise
208	group	_	_	I-Premise
209	;	_	_	I-Premise
210	excess	_	_	B-Premise
211	circumference	_	_	I-Premise
212	and	_	_	I-Premise
213	excess	_	_	I-Premise
214	water	_	_	I-Premise
215	composition	_	_	I-Premise
216	were	_	_	I-Premise
217	reduced	_	_	I-Premise
218	significantly	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	tape	_	_	I-Premise
222	group	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	acceptance	_	_	I-Premise
226	of	_	_	I-Premise
227	K-tape	_	_	I-Premise
228	was	_	_	I-Premise
229	better	_	_	I-Premise
230	than	_	_	I-Premise
231	the	_	_	I-Premise
232	bandage	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	benefits	_	_	I-Premise
236	included	_	_	I-Premise
237	longer	_	_	I-Premise
238	wearing	_	_	I-Premise
239	time	_	_	I-Premise
240	,	_	_	I-Premise
241	less	_	_	I-Premise
242	difficulty	_	_	I-Premise
243	in	_	_	I-Premise
244	usage	_	_	I-Premise
245	,	_	_	I-Premise
246	and	_	_	I-Premise
247	increased	_	_	I-Premise
248	comfort	_	_	I-Premise
249	and	_	_	I-Premise
250	convenience	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	0.05	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	The	_	_	B-Claim
258	study	_	_	I-Claim
259	results	_	_	I-Claim
260	suggest	_	_	I-Claim
261	that	_	_	I-Claim
262	K-tape	_	_	I-Claim
263	could	_	_	I-Claim
264	replace	_	_	I-Claim
265	the	_	_	I-Claim
266	bandage	_	_	I-Claim
267	in	_	_	I-Claim
268	DLT	_	_	I-Claim
269	,	_	_	I-Claim
270	and	_	_	I-Claim
271	it	_	_	I-Claim
272	could	_	_	I-Claim
273	be	_	_	I-Claim
274	an	_	_	I-Claim
275	alternative	_	_	I-Claim
276	choice	_	_	I-Claim
277	for	_	_	I-Claim
278	the	_	_	I-Claim
279	breast-cancer-related	_	_	I-Claim
280	lymphedema	_	_	I-Claim
281	patient	_	_	I-Claim
282	with	_	_	I-Claim
283	poor	_	_	I-Claim
284	short-stretch	_	_	I-Claim
285	bandage	_	_	I-Claim
286	compliance	_	_	I-Claim
287	after	_	_	I-Claim
288	1-month	_	_	I-Claim
289	intervention	_	_	I-Claim
290	.	_	_	I-Claim

291	If	_	_	O
292	the	_	_	O
293	intervention	_	_	O
294	period	_	_	O
295	was	_	_	O
296	prolonged	_	_	O
297	,	_	_	O
298	we	_	_	O
299	might	_	_	O
300	get	_	_	O
301	different	_	_	O
302	conclusion	_	_	O
303	.	_	_	O

304	Moreover	_	_	O
305	,	_	_	O
306	these	_	_	B-Claim
307	two	_	_	I-Claim
308	treatment	_	_	I-Claim
309	protocols	_	_	I-Claim
310	are	_	_	I-Claim
311	inefficient	_	_	I-Claim
312	and	_	_	I-Claim
313	cost	_	_	I-Claim
314	time	_	_	I-Claim
315	in	_	_	I-Claim
316	application	_	_	I-Claim
317	.	_	_	I-Claim

318	More	_	_	B-Claim
319	efficient	_	_	I-Claim
320	treatment	_	_	I-Claim
321	protocol	_	_	I-Claim
322	is	_	_	I-Claim
323	needed	_	_	I-Claim
324	for	_	_	I-Claim
325	clinical	_	_	I-Claim
326	practice	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	study	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	Fuzheng	_	_	O
6	Jianpi	_	_	O
7	Decoction	_	_	O
8	(	_	_	O
9	FJD	_	_	O
10	)	_	_	O
11	combined	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	and	_	_	O
22	the	_	_	O
23	survival	_	_	O
24	time	_	_	O
25	of	_	_	O
26	children	_	_	O
27	with	_	_	O
28	solid	_	_	O
29	tumor	_	_	O
30	.	_	_	O

31	Recruited	_	_	O
32	were	_	_	O
33	167	_	_	O
34	solid	_	_	O
35	tumor	_	_	O
36	children	_	_	O
37	patients	_	_	O
38	at	_	_	O
39	Department	_	_	O
40	of	_	_	O
41	Tumor	_	_	O
42	,	_	_	O
43	Beijing	_	_	O
44	Children	_	_	O
45	's	_	_	O
46	Hospital	_	_	O
47	.	_	_	O

48	They	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	the	_	_	O
54	treatment	_	_	O
55	group	_	_	O
56	(	_	_	O
57	83	_	_	O
58	cases	_	_	O
59	)	_	_	O
60	and	_	_	O
61	the	_	_	O
62	control	_	_	O
63	group	_	_	O
64	(	_	_	O
65	84	_	_	O
66	cases	_	_	O
67	)	_	_	O
68	according	_	_	O
69	to	_	_	O
70	the	_	_	O
71	random	_	_	O
72	digit	_	_	O
73	table	_	_	O
74	.	_	_	O

75	All	_	_	O
76	had	_	_	O
77	chemotherapy	_	_	O
78	.	_	_	O

79	Those	_	_	O
80	in	_	_	O
81	the	_	_	O
82	treatment	_	_	O
83	group	_	_	O
84	additionally	_	_	O
85	took	_	_	O
86	FJD	_	_	O
87	,	_	_	O
88	50	_	_	O
89	-100	_	_	O
90	mL	_	_	O
91	each	_	_	O
92	time	_	_	O
93	,	_	_	O
94	twice	_	_	O
95	daily	_	_	O
96	.	_	_	O

97	After	_	_	O
98	chemotherapy	_	_	O
99	those	_	_	O
100	in	_	_	O
101	the	_	_	O
102	treatment	_	_	O
103	group	_	_	O
104	took	_	_	O
105	modified	_	_	O
106	FJD	_	_	O
107	.	_	_	O

108	The	_	_	O
109	WBC	_	_	O
110	,	_	_	O
111	Hb	_	_	O
112	,	_	_	O
113	and	_	_	O
114	PLT	_	_	O
115	were	_	_	O
116	detected	_	_	O
117	in	_	_	O
118	all	_	_	O
119	patients	_	_	O
120	before	_	_	O
121	treatment	_	_	O
122	,	_	_	O
123	6	_	_	O
124	months	_	_	O
125	after	_	_	O
126	treatment	_	_	O
127	,	_	_	O
128	and	_	_	O
129	1	_	_	O
130	year	_	_	O
131	after	_	_	O
132	treatment	_	_	O
133	.	_	_	O

134	The	_	_	O
135	1-	_	_	O
136	,	_	_	O
137	2-	_	_	O
138	,	_	_	O
139	and	_	_	O
140	3-year	_	_	O
141	QOL	_	_	O
142	,	_	_	O
143	3-year	_	_	O
144	survival	_	_	O
145	rate	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	survival	_	_	O
150	life	_	_	O
151	of	_	_	O
152	dead	_	_	O
153	children	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	observed	_	_	O
157	.	_	_	O

158	Compared	_	_	B-Premise
159	with	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	of	_	_	I-Premise
164	the	_	_	I-Premise
165	same	_	_	I-Premise
166	period	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	6-month	_	_	I-Premise
170	and	_	_	I-Premise
171	1-year	_	_	I-Premise
172	WBC	_	_	I-Premise
173	and	_	_	I-Premise
174	Hb	_	_	I-Premise
175	increased	_	_	I-Premise
176	,	_	_	I-Premise
177	the	_	_	I-Premise
178	1-year	_	_	I-Premise
179	PLT	_	_	I-Premise
180	increased	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	,	_	_	I-Premise
186	showing	_	_	I-Premise
187	statistical	_	_	I-Premise
188	difference	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.05	_	_	I-Premise
193	,	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	0.01	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	Compared	_	_	B-Premise
200	with	_	_	I-Premise
201	1-year	_	_	I-Premise
202	treatment	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	treatment	_	_	I-Premise
206	group	_	_	I-Premise
207	,	_	_	I-Premise
208	the	_	_	I-Premise
209	2-and	_	_	I-Premise
210	3-year	_	_	I-Premise
211	psychological	_	_	I-Premise
212	functions	_	_	I-Premise
213	and	_	_	I-Premise
214	the	_	_	I-Premise
215	general	_	_	I-Premise
216	symptoms	_	_	I-Premise
217	scores	_	_	I-Premise
218	decreased	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	0.05	_	_	I-Premise
223	,	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Compared	_	_	B-Premise
230	with	_	_	I-Premise
231	the	_	_	I-Premise
232	control	_	_	I-Premise
233	group	_	_	I-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	same	_	_	I-Premise
237	period	_	_	I-Premise
238	,	_	_	I-Premise
239	the	_	_	I-Premise
240	2-and	_	_	I-Premise
241	3-year	_	_	I-Premise
242	somatic	_	_	I-Premise
243	functions	_	_	I-Premise
244	,	_	_	I-Premise
245	psychological	_	_	I-Premise
246	functions	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	the	_	_	I-Premise
250	general	_	_	I-Premise
251	symptoms	_	_	I-Premise
252	scores	_	_	I-Premise
253	decreased	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	treatment	_	_	I-Premise
257	group	_	_	I-Premise
258	;	_	_	I-Premise
259	the	_	_	B-Premise
260	2-year	_	_	I-Premise
261	somatic	_	_	I-Premise
262	functions	_	_	I-Premise
263	and	_	_	I-Premise
264	psychological	_	_	I-Premise
265	functions	_	_	I-Premise
266	decreased	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	treatment	_	_	I-Premise
270	group	_	_	I-Premise
271	;	_	_	I-Premise
272	the	_	_	B-Premise
273	3-year	_	_	I-Premise
274	psychological	_	_	I-Premise
275	functions	_	_	I-Premise
276	and	_	_	I-Premise
277	the	_	_	I-Premise
278	general	_	_	I-Premise
279	symptoms	_	_	I-Premise
280	scores	_	_	I-Premise
281	decreased	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	treatment	_	_	I-Premise
285	group	_	_	I-Premise
286	,	_	_	I-Premise
287	all	_	_	I-Premise
288	with	_	_	I-Premise
289	statistical	_	_	I-Premise
290	difference	_	_	I-Premise
291	(	_	_	I-Premise
292	all	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	0.05	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Compared	_	_	B-Premise
299	with	_	_	I-Premise
300	the	_	_	I-Premise
301	control	_	_	I-Premise
302	group	_	_	I-Premise
303	,	_	_	I-Premise
304	the	_	_	I-Premise
305	death	_	_	I-Premise
306	number	_	_	I-Premise
307	decreased	_	_	I-Premise
308	,	_	_	I-Premise
309	the	_	_	I-Premise
310	survival	_	_	I-Premise
311	rate	_	_	I-Premise
312	increased	_	_	I-Premise
313	,	_	_	I-Premise
314	the	_	_	I-Premise
315	life	_	_	I-Premise
316	span	_	_	I-Premise
317	of	_	_	I-Premise
318	dead	_	_	I-Premise
319	children	_	_	I-Premise
320	was	_	_	I-Premise
321	prolonged	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	treatment	_	_	I-Premise
325	group	_	_	I-Premise
326	,	_	_	I-Premise
327	showing	_	_	I-Premise
328	statistical	_	_	I-Premise
329	difference	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	0.05	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	FJD	_	_	B-Claim
337	combined	_	_	I-Claim
338	chemotherapy	_	_	I-Claim
339	could	_	_	I-Claim
340	effectively	_	_	I-Claim
341	improve	_	_	I-Claim
342	the	_	_	I-Claim
343	QOL	_	_	I-Claim
344	of	_	_	I-Claim
345	solid	_	_	I-Claim
346	tumor	_	_	I-Claim
347	children	_	_	I-Claim
348	patients	_	_	I-Claim
349	,	_	_	I-Claim
350	elevate	_	_	I-Claim
351	their	_	_	I-Claim
352	survival	_	_	I-Claim
353	rate	_	_	I-Claim
354	,	_	_	I-Claim
355	and	_	_	I-Claim
356	prolong	_	_	I-Claim
357	their	_	_	I-Claim
358	life	_	_	I-Claim
359	spans	_	_	I-Claim
360	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	whether	_	_	O
4	changes	_	_	O
5	in	_	_	O
6	self-efficacy	_	_	O
7	explain	_	_	O
8	the	_	_	O
9	effects	_	_	O
10	of	_	_	O
11	a	_	_	O
12	mailed	_	_	O
13	print	_	_	O
14	intervention	_	_	O
15	on	_	_	O
16	long-term	_	_	O
17	dietary	_	_	O
18	practices	_	_	O
19	of	_	_	O
20	breast	_	_	O
21	and	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	survivors	_	_	O
25	.	_	_	O

26	The	_	_	O
27	relationship	_	_	O
28	between	_	_	O
29	change	_	_	O
30	in	_	_	O
31	self-efficacy	_	_	O
32	and	_	_	O
33	long-term	_	_	O
34	physical	_	_	O
35	activity	_	_	O
36	(	_	_	O
37	PA	_	_	O
38	)	_	_	O
39	also	_	_	O
40	was	_	_	O
41	examined	_	_	O
42	.	_	_	O

43	Breast	_	_	O
44	and	_	_	O
45	prostate	_	_	O
46	cancer	_	_	O
47	survivors	_	_	O
48	(	_	_	O
49	N	_	_	O
50	=	_	_	O
51	543	_	_	O
52	)	_	_	O
53	from	_	_	O
54	39	_	_	O
55	US	_	_	O
56	states	_	_	O
57	and	_	_	O
58	two	_	_	O
59	Canadian	_	_	O
60	provinces	_	_	O
61	participated	_	_	O
62	in	_	_	O
63	the	_	_	O
64	FRESH	_	_	O
65	START	_	_	O
66	intervention	_	_	O
67	trial	_	_	O
68	.	_	_	O

69	Participants	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	a	_	_	O
76	10-month	_	_	O
77	program	_	_	O
78	of	_	_	O
79	mailed	_	_	O
80	print	_	_	O
81	materials	_	_	O
82	on	_	_	O
83	diet	_	_	O
84	and	_	_	O
85	PA	_	_	O
86	available	_	_	O
87	in	_	_	O
88	the	_	_	O
89	public	_	_	O
90	domain	_	_	O
91	or	_	_	O
92	a	_	_	O
93	10-month	_	_	O
94	program	_	_	O
95	of	_	_	O
96	tailored	_	_	O
97	materials	_	_	O
98	designed	_	_	O
99	to	_	_	O
100	increase	_	_	O
101	fruit	_	_	O
102	and	_	_	O
103	vegetable	_	_	O
104	(	_	_	O
105	F	_	_	O
106	&	_	_	O
107	V	_	_	O
108	)	_	_	O
109	intake	_	_	O
110	,	_	_	O
111	decrease	_	_	O
112	fat	_	_	O
113	intake	_	_	O
114	,	_	_	O
115	and/or	_	_	O
116	increase	_	_	O
117	PA.	_	_	O
118	Changes	_	_	O
119	in	_	_	O
120	self-efficacy	_	_	O
121	for	_	_	O
122	F	_	_	O
123	&	_	_	O
124	V	_	_	O
125	intake	_	_	O
126	and	_	_	O
127	fat	_	_	O
128	restriction	_	_	O
129	were	_	_	O
130	analyzed	_	_	O
131	as	_	_	O
132	potential	_	_	O
133	mediators	_	_	O
134	of	_	_	O
135	the	_	_	O
136	intervention	_	_	O
137	's	_	_	O
138	effects	_	_	O
139	on	_	_	O
140	diet	_	_	O
141	at	_	_	O
142	2-year	_	_	O
143	follow-up	_	_	O
144	.	_	_	O

145	Because	_	_	O
146	we	_	_	O
147	previously	_	_	O
148	found	_	_	O
149	that	_	_	O
150	change	_	_	O
151	in	_	_	O
152	self-efficacy	_	_	O
153	for	_	_	O
154	PA	_	_	O
155	did	_	_	O
156	not	_	_	O
157	vary	_	_	O
158	by	_	_	O
159	group	_	_	O
160	assignment	_	_	O
161	,	_	_	O
162	the	_	_	O
163	relationship	_	_	O
164	between	_	_	O
165	change	_	_	O
166	in	_	_	O
167	self-efficacy	_	_	O
168	and	_	_	O
169	PA	_	_	O
170	at	_	_	O
171	2-year	_	_	O
172	follow-up	_	_	O
173	was	_	_	O
174	examined	_	_	O
175	across	_	_	O
176	study	_	_	O
177	conditions	_	_	O
178	.	_	_	O

179	Results	_	_	B-Claim
180	suggest	_	_	I-Claim
181	that	_	_	I-Claim
182	change	_	_	I-Claim
183	in	_	_	I-Claim
184	self-efficacy	_	_	I-Claim
185	for	_	_	I-Claim
186	fat	_	_	I-Claim
187	restriction	_	_	I-Claim
188	partially	_	_	I-Claim
189	explained	_	_	I-Claim
190	the	_	_	I-Claim
191	intervention	_	_	I-Claim
192	's	_	_	I-Claim
193	effect	_	_	I-Claim
194	on	_	_	I-Claim
195	fat	_	_	I-Claim
196	intake	_	_	I-Claim
197	(	_	_	I-Claim
198	mean	_	_	I-Claim
199	indirect	_	_	I-Claim
200	effect	_	_	I-Claim
201	=	_	_	I-Claim
202	-0.28	_	_	I-Claim
203	)	_	_	I-Claim
204	,	_	_	I-Claim
205	and	_	_	I-Claim
206	change	_	_	I-Claim
207	in	_	_	I-Claim
208	self-efficacy	_	_	I-Claim
209	for	_	_	I-Claim
210	F	_	_	I-Claim
211	&	_	_	I-Claim
212	V	_	_	I-Claim
213	consumption	_	_	I-Claim
214	partially	_	_	I-Claim
215	explained	_	_	I-Claim
216	the	_	_	I-Claim
217	intervention	_	_	I-Claim
218	's	_	_	I-Claim
219	effect	_	_	I-Claim
220	on	_	_	I-Claim
221	daily	_	_	I-Claim
222	F	_	_	I-Claim
223	&	_	_	I-Claim
224	V	_	_	I-Claim
225	intake	_	_	I-Claim
226	(	_	_	I-Claim
227	mean	_	_	I-Claim
228	indirect	_	_	I-Claim
229	effect	_	_	I-Claim
230	=	_	_	I-Claim
231	.11	_	_	I-Claim
232	)	_	_	I-Claim
233	.	_	_	I-Claim

234	Change	_	_	B-Premise
235	in	_	_	I-Premise
236	self-efficacy	_	_	I-Premise
237	for	_	_	I-Premise
238	fat	_	_	I-Premise
239	restriction	_	_	I-Premise
240	partially	_	_	I-Premise
241	accounted	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	intervention	_	_	I-Premise
245	's	_	_	I-Premise
246	impact	_	_	I-Premise
247	on	_	_	I-Premise
248	overall	_	_	I-Premise
249	diet	_	_	I-Premise
250	quality	_	_	I-Premise
251	among	_	_	I-Premise
252	men	_	_	I-Premise
253	only	_	_	I-Premise
254	(	_	_	I-Premise
255	mean	_	_	I-Premise
256	indirect	_	_	I-Premise
257	effect	_	_	I-Premise
258	=	_	_	I-Premise
259	0.60	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Finally	_	_	O
263	,	_	_	O
264	change	_	_	O
265	in	_	_	O
266	self-efficacy	_	_	O
267	for	_	_	O
268	PA	_	_	O
269	predicted	_	_	O
270	PA	_	_	O
271	at	_	_	O
272	2-year	_	_	O
273	follow-up	_	_	O
274	.	_	_	O

275	Findings	_	_	B-Claim
276	suggest	_	_	I-Claim
277	that	_	_	I-Claim
278	self-efficacy	_	_	I-Claim
279	may	_	_	I-Claim
280	influence	_	_	I-Claim
281	long-term	_	_	I-Claim
282	maintenance	_	_	I-Claim
283	of	_	_	I-Claim
284	healthy	_	_	I-Claim
285	lifestyle	_	_	I-Claim
286	practices	_	_	I-Claim
287	among	_	_	I-Claim
288	cancer	_	_	I-Claim
289	survivors	_	_	I-Claim
290	.	_	_	I-Claim


0	Patients	_	_	O
1	experience	_	_	O
2	reductions	_	_	O
3	in	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	while	_	_	O
11	receiving	_	_	O
12	cancer	_	_	O
13	treatment	_	_	O
14	and	_	_	O
15	several	_	_	O
16	approaches	_	_	O
17	have	_	_	O
18	been	_	_	O
19	proposed	_	_	O
20	to	_	_	O
21	address	_	_	O
22	QOL	_	_	O
23	issues	_	_	O
24	.	_	_	O

25	In	_	_	O
26	this	_	_	O
27	project	_	_	O
28	,	_	_	O
29	the	_	_	O
30	QOL	_	_	O
31	differences	_	_	O
32	between	_	_	O
33	older	_	_	O
34	adult	_	_	O
35	(	_	_	O
36	age	_	_	O
37	65+	_	_	O
38	)	_	_	O
39	and	_	_	O
40	younger	_	_	O
41	adult	_	_	O
42	(	_	_	O
43	age	_	_	O
44	18-64	_	_	O
45	)	_	_	O
46	advanced	_	_	O
47	cancer	_	_	O
48	patients	_	_	O
49	in	_	_	O
50	response	_	_	O
51	to	_	_	O
52	a	_	_	O
53	multidisciplinary	_	_	O
54	intervention	_	_	O
55	designed	_	_	O
56	to	_	_	O
57	improve	_	_	O
58	QOL	_	_	O
59	were	_	_	O
60	examined	_	_	O
61	.	_	_	O

62	This	_	_	O
63	study	_	_	O
64	was	_	_	O
65	registered	_	_	O
66	on	_	_	O
67	ClinicalTrials.gov	_	_	O
68	.	_	_	O

69	Newly	_	_	O
70	diagnosed	_	_	O
71	advanced	_	_	O
72	cancer	_	_	O
73	patients	_	_	O
74	undergoing	_	_	O
75	radiation	_	_	O
76	therapy	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	active	_	_	O
81	QOL	_	_	O
82	intervention	_	_	O
83	or	_	_	O
84	control	_	_	O
85	groups	_	_	O
86	.	_	_	O

87	Those	_	_	O
88	in	_	_	O
89	the	_	_	O
90	intervention	_	_	O
91	group	_	_	O
92	received	_	_	O
93	six	_	_	O
94	multidisciplinary	_	_	O
95	90-minute	_	_	O
96	sessions	_	_	O
97	designed	_	_	O
98	to	_	_	O
99	address	_	_	O
100	the	_	_	O
101	five	_	_	O
102	major	_	_	O
103	domains	_	_	O
104	of	_	_	O
105	QOL	_	_	O
106	.	_	_	O

107	Outcomes	_	_	O
108	measured	_	_	O
109	at	_	_	O
110	baseline	_	_	O
111	and	_	_	O
112	weeks	_	_	O
113	4	_	_	O
114	,	_	_	O
115	27	_	_	O
116	,	_	_	O
117	and	_	_	O
118	52	_	_	O
119	included	_	_	O
120	QOL	_	_	O
121	(	_	_	O
122	Linear	_	_	O
123	Analogue	_	_	O
124	Self-Assessment	_	_	O
125	(	_	_	O
126	LASA	_	_	O
127	)	_	_	O
128	,	_	_	O
129	Functional	_	_	O
130	Assessment	_	_	O
131	of	_	_	O
132	Cancer	_	_	O
133	Therapy-General	_	_	O
134	(	_	_	O
135	FACT-G	_	_	O
136	)	_	_	O
137	)	_	_	O
138	and	_	_	O
139	mood	_	_	O
140	(	_	_	O
141	Profile	_	_	O
142	of	_	_	O
143	Mood	_	_	O
144	States	_	_	O
145	(	_	_	O
146	POMS	_	_	O
147	)	_	_	O
148	)	_	_	O
149	.	_	_	O

150	Kruskall-Wallis	_	_	O
151	methodology	_	_	O
152	was	_	_	O
153	used	_	_	O
154	to	_	_	O
155	compare	_	_	O
156	scores	_	_	O
157	between	_	_	O
158	older	_	_	O
159	and	_	_	O
160	younger	_	_	O
161	adult	_	_	O
162	patients	_	_	O
163	randomized	_	_	O
164	to	_	_	O
165	the	_	_	O
166	intervention	_	_	O
167	.	_	_	O

168	Of	_	_	O
169	131	_	_	O
170	patients	_	_	O
171	in	_	_	O
172	the	_	_	O
173	larger	_	_	O
174	randomized	_	_	O
175	controlled	_	_	O
176	study	_	_	O
177	,	_	_	O
178	we	_	_	O
179	report	_	_	O
180	data	_	_	O
181	on	_	_	O
182	54	_	_	O
183	evaluable	_	_	O
184	patients	_	_	O
185	(	_	_	O
186	16	_	_	O
187	older	_	_	O
188	adults	_	_	O
189	and	_	_	O
190	38	_	_	O
191	younger	_	_	O
192	adults	_	_	O
193	)	_	_	O
194	randomized	_	_	O
195	to	_	_	O
196	the	_	_	O
197	intervention	_	_	O
198	.	_	_	O

199	Older	_	_	B-Premise
200	adult	_	_	I-Premise
201	patients	_	_	I-Premise
202	reported	_	_	I-Premise
203	better	_	_	I-Premise
204	overall	_	_	I-Premise
205	QOL	_	_	I-Premise
206	(	_	_	I-Premise
207	LASA	_	_	I-Premise
208	74.4	_	_	I-Premise
209	vs.	_	_	I-Premise
210	62.9	_	_	I-Premise
211	,	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.040	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	higher	_	_	I-Premise
218	social	_	_	I-Premise
219	well-being	_	_	I-Premise
220	(	_	_	I-Premise
221	FACT-G	_	_	I-Premise
222	91.1	_	_	I-Premise
223	vs.	_	_	I-Premise
224	83.3	_	_	I-Premise
225	,	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0.045	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	fewer	_	_	I-Premise
233	problems	_	_	I-Premise
234	with	_	_	I-Premise
235	anger	_	_	I-Premise
236	(	_	_	I-Premise
237	POMS	_	_	I-Premise
238	anger-hostility	_	_	I-Premise
239	95.0	_	_	I-Premise
240	vs.	_	_	I-Premise
241	86.4	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.028	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Long-term	_	_	B-Premise
249	benefits	_	_	I-Premise
250	for	_	_	I-Premise
251	older	_	_	I-Premise
252	patients	_	_	I-Premise
253	were	_	_	I-Premise
254	seen	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	anger-hostility	_	_	I-Premise
258	scale	_	_	I-Premise
259	at	_	_	I-Premise
260	week	_	_	I-Premise
261	27	_	_	I-Premise
262	(	_	_	I-Premise
263	92.2	_	_	I-Premise
264	vs.	_	_	I-Premise
265	84.2	_	_	I-Premise
266	,	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0.027	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	week	_	_	I-Premise
273	52	_	_	I-Premise
274	(	_	_	I-Premise
275	96.3	_	_	I-Premise
276	vs.	_	_	I-Premise
277	85.9	_	_	I-Premise
278	,	_	_	I-Premise
279	p	_	_	I-Premise
280	=	_	_	I-Premise
281	0.005	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Older	_	_	B-Claim
285	adult	_	_	I-Claim
286	patients	_	_	I-Claim
287	who	_	_	I-Claim
288	received	_	_	I-Claim
289	a	_	_	I-Claim
290	multidisciplinary	_	_	I-Claim
291	intervention	_	_	I-Claim
292	to	_	_	I-Claim
293	improve	_	_	I-Claim
294	QOL	_	_	I-Claim
295	while	_	_	I-Claim
296	undergoing	_	_	I-Claim
297	advanced	_	_	I-Claim
298	cancer	_	_	I-Claim
299	treatments	_	_	I-Claim
300	benefited	_	_	I-Claim
301	differently	_	_	I-Claim
302	in	_	_	I-Claim
303	some	_	_	I-Claim
304	QOL	_	_	I-Claim
305	domains	_	_	I-Claim
306	,	_	_	I-Claim
307	compared	_	_	I-Claim
308	to	_	_	I-Claim
309	younger	_	_	I-Claim
310	adult	_	_	I-Claim
311	patients	_	_	I-Claim
312	.	_	_	I-Claim

313	Future	_	_	O
314	studies	_	_	O
315	can	_	_	O
316	provide	_	_	O
317	further	_	_	O
318	insight	_	_	O
319	on	_	_	O
320	how	_	_	O
321	to	_	_	O
322	tailor	_	_	O
323	QOL	_	_	O
324	interventions	_	_	O
325	for	_	_	O
326	these	_	_	O
327	age	_	_	O
328	groups	_	_	O
329	.	_	_	O


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	explore	_	_	O
8	the	_	_	O
9	inflammatory	_	_	O
10	modulation	_	_	O
11	effect	_	_	O
12	of	_	_	O
13	glutamine-enriched	_	_	O
14	total	_	_	O
15	parenteral	_	_	O
16	nutrition	_	_	O
17	(	_	_	O
18	TPN	_	_	O
19	)	_	_	O
20	by	_	_	O
21	investigating	_	_	O
22	the	_	_	O
23	alterations	_	_	O
24	of	_	_	O
25	inflammation-related	_	_	O
26	cytokines	_	_	O
27	in	_	_	O
28	gastrointestinal	_	_	O
29	(	_	_	O
30	GI	_	_	O
31	)	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	postoperatively	_	_	O
35	.	_	_	O

36	Fifty	_	_	O
37	GI	_	_	O
38	cancer	_	_	O
39	patients	_	_	O
40	received	_	_	O
41	postoperative	_	_	O
42	7	_	_	O
43	days	_	_	O
44	of	_	_	O
45	isocaloric	_	_	O
46	and	_	_	O
47	isonitrogenous	_	_	O
48	TPN	_	_	O
49	after	_	_	O
50	operation	_	_	O
51	.	_	_	O

52	They	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	divided	_	_	O
56	to	_	_	O
57	receive	_	_	O
58	either	_	_	O
59	glutamine-enriched	_	_	O
60	TPN	_	_	O
61	or	_	_	O
62	standard	_	_	O
63	TPN	_	_	O
64	.	_	_	O

65	The	_	_	O
66	inflammation-related	_	_	O
67	cytokines	_	_	O
68	including	_	_	O
69	interleukin-6	_	_	O
70	,	_	_	O
71	interleukin-10	_	_	O
72	,	_	_	O
73	and	_	_	O
74	tumor	_	_	O
75	necrosis	_	_	O
76	factor-Î±	_	_	O
77	were	_	_	O
78	also	_	_	O
79	determined	_	_	O
80	.	_	_	O

81	Records	_	_	O
82	of	_	_	O
83	nutritional	_	_	O
84	assessments	_	_	O
85	,	_	_	O
86	inflammatory	_	_	O
87	status	_	_	O
88	,	_	_	O
89	and	_	_	O
90	postoperative	_	_	O
91	complications	_	_	O
92	were	_	_	O
93	compared	_	_	O
94	between	_	_	O
95	the	_	_	O
96	two	_	_	O
97	groups	_	_	O
98	.	_	_	O

99	Of	_	_	O
100	50	_	_	O
101	enrolled	_	_	O
102	patients	_	_	O
103	,	_	_	O
104	25	_	_	O
105	patients	_	_	O
106	were	_	_	O
107	classified	_	_	O
108	as	_	_	O
109	the	_	_	O
110	intervention	_	_	O
111	group	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	control	_	_	O
116	group	_	_	O
117	also	_	_	O
118	comprised	_	_	O
119	25	_	_	O
120	patients	_	_	O
121	.	_	_	O

122	The	_	_	O
123	differences	_	_	O
124	of	_	_	O
125	gender	_	_	O
126	,	_	_	O
127	age	_	_	O
128	,	_	_	O
129	primary	_	_	O
130	GI	_	_	O
131	malignancies	_	_	O
132	,	_	_	O
133	and	_	_	O
134	hematological	_	_	O
135	and	_	_	O
136	biochemical	_	_	O
137	data	_	_	O
138	between	_	_	O
139	the	_	_	O
140	two	_	_	O
141	compared	_	_	O
142	groups	_	_	O
143	were	_	_	O
144	not	_	_	O
145	statistically	_	_	O
146	significant	_	_	O
147	(	_	_	O
148	all	_	_	O
149	P	_	_	O
150	>	_	_	O
151	0.05	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Compared	_	_	B-Premise
155	with	_	_	I-Premise
156	standard	_	_	I-Premise
157	TPN	_	_	I-Premise
158	,	_	_	I-Premise
159	a	_	_	I-Premise
160	higher	_	_	I-Premise
161	serum	_	_	I-Premise
162	prealbumin	_	_	I-Premise
163	level	_	_	I-Premise
164	and	_	_	I-Premise
165	better	_	_	I-Premise
166	nitrogen	_	_	I-Premise
167	balance	_	_	I-Premise
168	were	_	_	I-Premise
169	observed	_	_	I-Premise
170	in	_	_	I-Premise
171	glutamine-enriched	_	_	I-Premise
172	TPN	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	=	_	_	I-Premise
176	0.039	_	_	I-Premise
177	and	_	_	I-Premise
178	0.048	_	_	I-Premise
179	respectively	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	A	_	_	B-Premise
183	significantly	_	_	I-Premise
184	lower	_	_	I-Premise
185	serum	_	_	I-Premise
186	interleukin-6	_	_	I-Premise
187	level	_	_	I-Premise
188	was	_	_	I-Premise
189	found	_	_	I-Premise
190	in	_	_	I-Premise
191	comparing	_	_	I-Premise
192	glutamine-enriched	_	_	I-Premise
193	with	_	_	I-Premise
194	standard	_	_	I-Premise
195	TPN	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	0.01	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	but	_	_	B-Premise
203	not	_	_	I-Premise
204	in	_	_	I-Premise
205	interleukin-10	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.374	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	tumor	_	_	I-Premise
213	necrosis	_	_	I-Premise
214	factor-Î±	_	_	I-Premise
215	levels	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	0.653	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Moreover	_	_	O
223	,	_	_	O
224	a	_	_	B-Premise
225	significant	_	_	I-Premise
226	lower	_	_	I-Premise
227	serum	_	_	I-Premise
228	C-reactive	_	_	I-Premise
229	protein	_	_	I-Premise
230	level	_	_	I-Premise
231	was	_	_	I-Premise
232	detected	_	_	I-Premise
233	in	_	_	I-Premise
234	glutamine-enriched	_	_	I-Premise
235	TPN	_	_	I-Premise
236	compared	_	_	I-Premise
237	with	_	_	I-Premise
238	standard	_	_	I-Premise
239	TPN	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.013	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Indeed	_	_	O
247	,	_	_	O
248	four	_	_	B-Premise
249	cases	_	_	I-Premise
250	of	_	_	I-Premise
251	postoperative	_	_	I-Premise
252	infectious	_	_	I-Premise
253	complications	_	_	I-Premise
254	were	_	_	I-Premise
255	noted	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	control	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	but	_	_	I-Premise
262	no	_	_	I-Premise
263	postoperative	_	_	I-Premise
264	infectious	_	_	I-Premise
265	complications	_	_	I-Premise
266	were	_	_	I-Premise
267	observed	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	interventional	_	_	I-Premise
271	group	_	_	I-Premise
272	(	_	_	I-Premise
273	P	_	_	I-Premise
274	=	_	_	I-Premise
275	0.037	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	Our	_	_	B-Claim
279	present	_	_	I-Claim
280	study	_	_	I-Claim
281	shows	_	_	I-Claim
282	that	_	_	I-Claim
283	glutamine-enriched	_	_	I-Claim
284	TPN	_	_	I-Claim
285	may	_	_	I-Claim
286	be	_	_	I-Claim
287	beneficial	_	_	I-Claim
288	in	_	_	I-Claim
289	improving	_	_	I-Claim
290	the	_	_	I-Claim
291	inflammatory	_	_	I-Claim
292	status	_	_	I-Claim
293	and	_	_	I-Claim
294	decreasing	_	_	I-Claim
295	the	_	_	I-Claim
296	infectious	_	_	I-Claim
297	morbidity	_	_	I-Claim
298	in	_	_	I-Claim
299	postoperative	_	_	I-Claim
300	GI	_	_	I-Claim
301	cancer	_	_	I-Claim
302	patients	_	_	I-Claim
303	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	the	_	_	O
7	impact	_	_	O
8	of	_	_	O
9	laparoscopic	_	_	O
10	rectal	_	_	O
11	resection	_	_	O
12	on	_	_	O
13	short-term	_	_	O
14	postoperative	_	_	O
15	morbidity	_	_	O
16	and	_	_	O
17	costs	_	_	O
18	.	_	_	O

19	A	_	_	O
20	total	_	_	O
21	of	_	_	O
22	168	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	rectal	_	_	O
26	cancer	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	laparoscopic	_	_	O
32	(	_	_	O
33	n	_	_	O
34	=	_	_	O
35	83	_	_	O
36	)	_	_	O
37	or	_	_	O
38	open	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	85	_	_	O
43	)	_	_	O
44	resection	_	_	O
45	.	_	_	O

46	Outcome	_	_	O
47	parameters	_	_	O
48	were	_	_	O
49	:	_	_	O
50	postoperative	_	_	O
51	morbidity	_	_	O
52	,	_	_	O
53	length	_	_	O
54	of	_	_	O
55	hospital	_	_	O
56	stay	_	_	O
57	,	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	,	_	_	O
62	long-term	_	_	O
63	survival	_	_	O
64	,	_	_	O
65	and	_	_	O
66	local	_	_	O
67	recurrences	_	_	O
68	.	_	_	O

69	The	_	_	O
70	mean	_	_	O
71	follow-up	_	_	O
72	period	_	_	O
73	was	_	_	O
74	53.6	_	_	O
75	months	_	_	O
76	.	_	_	O

77	Cost-benefit	_	_	O
78	analysis	_	_	O
79	was	_	_	O
80	based	_	_	O
81	on	_	_	O
82	hospital	_	_	O
83	costs	_	_	O
84	.	_	_	O

85	Operative	_	_	B-Premise
86	time	_	_	I-Premise
87	was	_	_	I-Premise
88	53	_	_	I-Premise
89	minutes	_	_	I-Premise
90	longer	_	_	I-Premise
91	in	_	_	I-Premise
92	the	_	_	I-Premise
93	laparoscopic	_	_	I-Premise
94	group	_	_	I-Premise
95	(	_	_	I-Premise
96	P	_	_	I-Premise
97	<	_	_	I-Premise
98	0.0001	_	_	I-Premise
99	)	_	_	I-Premise
100	.	_	_	I-Premise

101	Postoperative	_	_	B-Premise
102	morbidity	_	_	I-Premise
103	rate	_	_	I-Premise
104	was	_	_	I-Premise
105	28.9	_	_	I-Premise
106	percent	_	_	I-Premise
107	in	_	_	I-Premise
108	the	_	_	I-Premise
109	laparoscopic	_	_	I-Premise
110	vs.	_	_	I-Premise
111	40	_	_	I-Premise
112	percent	_	_	I-Premise
113	in	_	_	I-Premise
114	the	_	_	I-Premise
115	open	_	_	I-Premise
116	group	_	_	I-Premise
117	(	_	_	I-Premise
118	P	_	_	I-Premise
119	=	_	_	I-Premise
120	0.18	_	_	I-Premise
121	)	_	_	I-Premise
122	.	_	_	I-Premise

123	The	_	_	B-Premise
124	mean	_	_	I-Premise
125	length	_	_	I-Premise
126	of	_	_	I-Premise
127	hospital	_	_	I-Premise
128	stay	_	_	I-Premise
129	was	_	_	I-Premise
130	10	_	_	I-Premise
131	(	_	_	I-Premise
132	4.9	_	_	I-Premise
133	)	_	_	I-Premise
134	days	_	_	I-Premise
135	in	_	_	I-Premise
136	the	_	_	I-Premise
137	laparoscopic	_	_	I-Premise
138	group	_	_	I-Premise
139	and	_	_	I-Premise
140	13.6	_	_	I-Premise
141	(	_	_	I-Premise
142	10	_	_	I-Premise
143	)	_	_	I-Premise
144	days	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	open	_	_	I-Premise
148	group	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	=	_	_	I-Premise
152	0.004	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Local	_	_	B-Premise
156	recurrence	_	_	I-Premise
157	rate	_	_	I-Premise
158	and	_	_	I-Premise
159	five-year	_	_	I-Premise
160	survival	_	_	I-Premise
161	were	_	_	I-Premise
162	similar	_	_	I-Premise
163	in	_	_	I-Premise
164	both	_	_	I-Premise
165	groups	_	_	I-Premise
166	;	_	_	I-Premise
167	however	_	_	B-Claim
168	,	_	_	I-Claim
169	the	_	_	I-Claim
170	limited	_	_	I-Claim
171	number	_	_	I-Claim
172	of	_	_	I-Claim
173	patients	_	_	I-Claim
174	does	_	_	I-Claim
175	not	_	_	I-Claim
176	allow	_	_	I-Claim
177	firm	_	_	I-Claim
178	conclusions	_	_	I-Claim
179	.	_	_	I-Claim

180	Quality	_	_	B-Premise
181	of	_	_	I-Premise
182	life	_	_	I-Premise
183	was	_	_	I-Premise
184	better	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	laparoscopic	_	_	I-Premise
188	group	_	_	I-Premise
189	only	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	first	_	_	I-Premise
193	year	_	_	I-Premise
194	after	_	_	I-Premise
195	surgery	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	0.0001	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	additional	_	_	I-Premise
204	charge	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	laparoscopic	_	_	I-Premise
208	group	_	_	I-Premise
209	was	_	_	I-Premise
210	$	_	_	I-Premise
211	1,748	_	_	I-Premise
212	per	_	_	I-Premise
213	patient	_	_	I-Premise
214	randomized	_	_	I-Premise
215	(	_	_	I-Premise
216	$	_	_	I-Premise
217	1,194	_	_	I-Premise
218	the	_	_	I-Premise
219	result	_	_	I-Premise
220	of	_	_	I-Premise
221	surgical	_	_	I-Premise
222	instruments	_	_	I-Premise
223	and	_	_	I-Premise
224	$	_	_	I-Premise
225	554	_	_	I-Premise
226	the	_	_	I-Premise
227	result	_	_	I-Premise
228	of	_	_	I-Premise
229	longer	_	_	I-Premise
230	operative	_	_	I-Premise
231	time	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	saving	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	laparoscopic	_	_	I-Premise
239	group	_	_	I-Premise
240	was	_	_	I-Premise
241	$	_	_	I-Premise
242	1,396	_	_	I-Premise
243	per	_	_	I-Premise
244	patient	_	_	I-Premise
245	randomized	_	_	I-Premise
246	(	_	_	I-Premise
247	$	_	_	I-Premise
248	647	_	_	I-Premise
249	the	_	_	I-Premise
250	result	_	_	I-Premise
251	of	_	_	I-Premise
252	shorter	_	_	I-Premise
253	length	_	_	I-Premise
254	of	_	_	I-Premise
255	hospital	_	_	I-Premise
256	stay	_	_	I-Premise
257	and	_	_	I-Premise
258	$	_	_	I-Premise
259	749	_	_	I-Premise
260	the	_	_	I-Premise
261	result	_	_	I-Premise
262	of	_	_	I-Premise
263	the	_	_	I-Premise
264	lower	_	_	I-Premise
265	cost	_	_	I-Premise
266	of	_	_	I-Premise
267	postoperative	_	_	I-Premise
268	complications	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Premise
272	net	_	_	I-Premise
273	balance	_	_	I-Premise
274	resulted	_	_	I-Premise
275	in	_	_	I-Premise
276	$	_	_	I-Premise
277	351	_	_	I-Premise
278	extra	_	_	I-Premise
279	cost	_	_	I-Premise
280	per	_	_	I-Premise
281	patient	_	_	I-Premise
282	randomly	_	_	I-Premise
283	allocated	_	_	I-Premise
284	to	_	_	I-Premise
285	the	_	_	I-Premise
286	laparoscopic	_	_	I-Premise
287	group	_	_	I-Premise
288	.	_	_	I-Premise

289	Short-term	_	_	B-Claim
290	postoperative	_	_	I-Claim
291	morbidity	_	_	I-Claim
292	was	_	_	I-Claim
293	similar	_	_	I-Claim
294	in	_	_	I-Claim
295	the	_	_	I-Claim
296	two	_	_	I-Claim
297	groups	_	_	I-Claim
298	.	_	_	I-Claim

299	Laparoscopic	_	_	B-Claim
300	resection	_	_	I-Claim
301	reduced	_	_	I-Claim
302	length	_	_	I-Claim
303	of	_	_	I-Claim
304	hospital	_	_	I-Claim
305	stay	_	_	I-Claim
306	,	_	_	I-Claim
307	improved	_	_	I-Claim
308	first-year	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	slightly	_	_	I-Claim
315	increased	_	_	I-Claim
316	hospital	_	_	I-Claim
317	costs	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	investigate	_	_	O
8	whether	_	_	O
9	specialized	_	_	O
10	supportive	_	_	O
11	enteral	_	_	O
12	and	_	_	O
13	parenteral	_	_	O
14	feeding	_	_	O
15	have	_	_	O
16	superior	_	_	O
17	effects	_	_	O
18	compared	_	_	O
19	to	_	_	O
20	oral	_	_	O
21	nutrition	_	_	O
22	on	_	_	O
23	recovery	_	_	O
24	during	_	_	O
25	long-term	_	_	O
26	postoperative	_	_	O
27	treatment	_	_	O
28	of	_	_	O
29	cancer	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	preoperative	_	_	O
33	weight	_	_	O
34	loss	_	_	O
35	and	_	_	O
36	reduced	_	_	O
37	maximum	_	_	O
38	exercise	_	_	O
39	capacity	_	_	O
40	.	_	_	O

41	One	_	_	O
42	hundred	_	_	O
43	twenty-six	_	_	O
44	patients	_	_	O
45	referred	_	_	O
46	for	_	_	O
47	resection	_	_	O
48	of	_	_	O
49	the	_	_	O
50	esophagus	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	48	_	_	O
55	)	_	_	O
56	,	_	_	O
57	stomach	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	28	_	_	O
62	)	_	_	O
63	,	_	_	O
64	or	_	_	O
65	pancreas	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	50	_	_	O
70	)	_	_	O
71	were	_	_	O
72	considered	_	_	O
73	to	_	_	O
74	be	_	_	O
75	included	_	_	O
76	before	_	_	O
77	operation	_	_	O
78	.	_	_	O

79	Included	_	_	O
80	patients	_	_	O
81	(	_	_	O
82	n	_	_	O
83	=	_	_	O
84	80	_	_	O
85	)	_	_	O
86	received	_	_	O
87	supportive	_	_	O
88	enteral	_	_	O
89	or	_	_	O
90	parenteral	_	_	O
91	nutrition	_	_	O
92	postoperatively	_	_	O
93	at	_	_	O
94	home	_	_	O
95	corresponding	_	_	O
96	to	_	_	O
97	1000	_	_	O
98	kcal/d	_	_	O
99	until	_	_	O
100	the	_	_	O
101	patients	_	_	O
102	did	_	_	O
103	not	_	_	O
104	wish	_	_	O
105	to	_	_	O
106	continue	_	_	O
107	with	_	_	O
108	artificial	_	_	O
109	nutrition	_	_	O
110	for	_	_	O
111	any	_	_	O
112	reason	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	randomized	_	_	O
116	to	_	_	O
117	oral	_	_	O
118	nutrition	_	_	O
119	only	_	_	O
120	served	_	_	O
121	as	_	_	O
122	control	_	_	O
123	subjects	_	_	O
124	.	_	_	O

125	Caloric	_	_	O
126	intake	_	_	O
127	,	_	_	O
128	body	_	_	O
129	composition	_	_	O
130	(	_	_	O
131	dual-energy	_	_	O
132	x-ray	_	_	O
133	absorptiometry	_	_	O
134	)	_	_	O
135	,	_	_	O
136	and	_	_	O
137	respiratory	_	_	O
138	gas	_	_	O
139	exchanges	_	_	O
140	at	_	_	O
141	rest	_	_	O
142	and	_	_	O
143	during	_	_	O
144	exercise	_	_	O
145	were	_	_	O
146	measured	_	_	O
147	including	_	_	O
148	health-related	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	.	_	_	O

153	Survival	_	_	B-Premise
154	and	_	_	I-Premise
155	hospital	_	_	I-Premise
156	stay	_	_	I-Premise
157	did	_	_	I-Premise
158	not	_	_	I-Premise
159	differ	_	_	I-Premise
160	among	_	_	I-Premise
161	the	_	_	I-Premise
162	groups	_	_	I-Premise
163	,	_	_	I-Premise
164	whereas	_	_	I-Premise
165	overall	_	_	I-Premise
166	complications	_	_	I-Premise
167	were	_	_	I-Premise
168	higher	_	_	I-Premise
169	on	_	_	I-Premise
170	artificial	_	_	I-Premise
171	nutrition	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.05	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Changes	_	_	B-Premise
179	in	_	_	I-Premise
180	resting	_	_	I-Premise
181	energy	_	_	I-Premise
182	expenditure	_	_	I-Premise
183	and	_	_	I-Premise
184	biochemical	_	_	I-Premise
185	tests	_	_	I-Premise
186	did	_	_	I-Premise
187	not	_	_	I-Premise
188	differ	_	_	I-Premise
189	during	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	among	_	_	I-Premise
192	the	_	_	I-Premise
193	groups	_	_	I-Premise
194	.	_	_	I-Premise

195	Body	_	_	B-Premise
196	weight	_	_	I-Premise
197	and	_	_	I-Premise
198	whole	_	_	I-Premise
199	body	_	_	I-Premise
200	fat	_	_	I-Premise
201	declined	_	_	I-Premise
202	similarly	_	_	I-Premise
203	over	_	_	I-Premise
204	time	_	_	I-Premise
205	in	_	_	I-Premise
206	all	_	_	I-Premise
207	groups	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	.005	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	whereas	_	_	O
215	lean	_	_	B-Premise
216	body	_	_	I-Premise
217	mass	_	_	I-Premise
218	was	_	_	I-Premise
219	unchanged	_	_	I-Premise
220	during	_	_	I-Premise
221	follow-up	_	_	I-Premise
222	compared	_	_	I-Premise
223	to	_	_	I-Premise
224	preoperative	_	_	I-Premise
225	values	_	_	I-Premise
226	.	_	_	I-Premise

227	Maximum	_	_	B-Premise
228	exercise	_	_	I-Premise
229	capacity	_	_	I-Premise
230	and	_	_	I-Premise
231	maximum	_	_	I-Premise
232	oxygen	_	_	I-Premise
233	consumption	_	_	I-Premise
234	were	_	_	I-Premise
235	normalized	_	_	I-Premise
236	within	_	_	I-Premise
237	6	_	_	I-Premise
238	months	_	_	I-Premise
239	postoperatively	_	_	I-Premise
240	in	_	_	I-Premise
241	all	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	There	_	_	B-Premise
245	was	_	_	I-Premise
246	no	_	_	I-Premise
247	difference	_	_	I-Premise
248	in	_	_	I-Premise
249	recovery	_	_	I-Premise
250	of	_	_	I-Premise
251	food	_	_	I-Premise
252	intake	_	_	I-Premise
253	among	_	_	I-Premise
254	the	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Parenteral	_	_	B-Claim
258	feeding	_	_	I-Claim
259	was	_	_	I-Claim
260	associated	_	_	I-Claim
261	with	_	_	I-Claim
262	the	_	_	I-Claim
263	highest	_	_	I-Claim
264	rate	_	_	I-Claim
265	of	_	_	I-Claim
266	nutrition-related	_	_	I-Claim
267	complications	_	_	I-Claim
268	,	_	_	I-Claim
269	whereas	_	_	O
270	enteral	_	_	B-Claim
271	feeding	_	_	I-Claim
272	reduced	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	most	_	_	I-Claim
277	extensively	_	_	I-Claim
278	.	_	_	I-Claim

279	After	_	_	B-Claim
280	major	_	_	I-Claim
281	surgery	_	_	I-Claim
282	,	_	_	I-Claim
283	specialized	_	_	I-Claim
284	supportive	_	_	I-Claim
285	enteral	_	_	I-Claim
286	and	_	_	I-Claim
287	parenteral	_	_	I-Claim
288	nutrition	_	_	I-Claim
289	are	_	_	I-Claim
290	not	_	_	I-Claim
291	superior	_	_	I-Claim
292	to	_	_	I-Claim
293	oral	_	_	I-Claim
294	nutrition	_	_	I-Claim
295	only	_	_	I-Claim
296	when	_	_	I-Claim
297	guided	_	_	I-Claim
298	by	_	_	I-Claim
299	a	_	_	I-Claim
300	dietitian	_	_	I-Claim
301	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	and	_	_	O
3	compare	_	_	O
4	radiologic	_	_	O
5	lung	_	_	O
6	expansion	_	_	O
7	after	_	_	O
8	talc	_	_	O
9	pleurodesis	_	_	O
10	performed	_	_	O
11	either	_	_	O
12	by	_	_	O
13	videothoracoscopy	_	_	O
14	or	_	_	O
15	chest	_	_	O
16	tube	_	_	O
17	and	_	_	O
18	correlate	_	_	O
19	it	_	_	O
20	with	_	_	O
21	clinical	_	_	O
22	outcome	_	_	O
23	.	_	_	O

24	Secondary	_	_	O
25	end	_	_	O
26	points	_	_	O
27	evaluated	_	_	O
28	were	_	_	O
29	as	_	_	O
30	follows	_	_	O
31	:	_	_	O
32	clinical	_	_	O
33	efficacy	_	_	O
34	;	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	;	_	_	O
39	safety	_	_	O
40	;	_	_	O
41	and	_	_	O
42	survival	_	_	O
43	.	_	_	O

44	Prospective	_	_	O
45	randomized	_	_	O
46	study	_	_	O
47	that	_	_	O
48	included	_	_	O
49	60	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	45	_	_	O
53	women	_	_	O
54	,	_	_	O
55	15	_	_	O
56	men	_	_	O
57	;	_	_	O
58	mean	_	_	O
59	age	_	_	O
60	,	_	_	O
61	55.2	_	_	O
62	years	_	_	O
63	)	_	_	O
64	with	_	_	O
65	recurrent	_	_	O
66	malignant	_	_	O
67	pleural	_	_	O
68	effusion	_	_	O
69	between	_	_	O
70	January	_	_	O
71	2005	_	_	O
72	and	_	_	O
73	January	_	_	O
74	2008	_	_	O
75	.	_	_	O

76	They	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	into	_	_	O
80	the	_	_	O
81	following	_	_	O
82	two	_	_	O
83	groups	_	_	O
84	:	_	_	O
85	video-assisted	_	_	O
86	thoracic	_	_	O
87	surgery	_	_	O
88	(	_	_	O
89	VATS	_	_	O
90	)	_	_	O
91	talc	_	_	O
92	poudrage	_	_	O
93	;	_	_	O
94	and	_	_	O
95	talc	_	_	O
96	slurry	_	_	O
97	(	_	_	O
98	TS	_	_	O
99	)	_	_	O
100	administered	_	_	O
101	through	_	_	O
102	a	_	_	O
103	chest	_	_	O
104	tube	_	_	O
105	.	_	_	O

106	Lung	_	_	O
107	expansion	_	_	O
108	was	_	_	O
109	evaluated	_	_	O
110	through	_	_	O
111	chest	_	_	O
112	CT	_	_	O
113	scans	_	_	O
114	obtained	_	_	O
115	0	_	_	O
116	,	_	_	O
117	1	_	_	O
118	,	_	_	O
119	3	_	_	O
120	and	_	_	O
121	6	_	_	O
122	months	_	_	O
123	after	_	_	O
124	pleurodesis	_	_	O
125	.	_	_	O

126	Complications	_	_	O
127	,	_	_	O
128	drainage	_	_	O
129	time	_	_	O
130	,	_	_	O
131	hospital	_	_	O
132	stay	_	_	O
133	,	_	_	O
134	and	_	_	O
135	quality	_	_	O
136	of	_	_	O
137	life	_	_	O
138	(	_	_	O
139	Medical	_	_	O
140	Outcomes	_	_	O
141	Study	_	_	O
142	36-item	_	_	O
143	short	_	_	O
144	form	_	_	O
145	and	_	_	O
146	World	_	_	O
147	Health	_	_	O
148	Organization	_	_	O
149	quality-of-life	_	_	O
150	questionnaires	_	_	O
151	)	_	_	O
152	were	_	_	O
153	also	_	_	O
154	analyzed	_	_	O
155	.	_	_	O

156	There	_	_	O
157	were	_	_	O
158	no	_	_	O
159	significant	_	_	O
160	differences	_	_	O
161	in	_	_	O
162	preprocedure	_	_	O
163	clinical	_	_	O
164	and	_	_	O
165	pathologic	_	_	O
166	variables	_	_	O
167	between	_	_	O
168	groups	_	_	O
169	.	_	_	O

170	The	_	_	O
171	immediate	_	_	O
172	total	_	_	O
173	(	_	_	O
174	ie	_	_	O
175	,	_	_	O
176	>	_	_	O
177	90	_	_	O
178	%	_	_	O
179	)	_	_	O
180	lung	_	_	O
181	expansion	_	_	O
182	was	_	_	O
183	observed	_	_	O
184	in	_	_	O
185	27	_	_	O
186	patients	_	_	O
187	(	_	_	O
188	45	_	_	O
189	%	_	_	O
190	)	_	_	O
191	and	_	_	O
192	was	_	_	O
193	more	_	_	O
194	frequent	_	_	O
195	in	_	_	O
196	the	_	_	O
197	VATS	_	_	O
198	group	_	_	O
199	(	_	_	O
200	60	_	_	O
201	%	_	_	O
202	vs	_	_	O
203	30	_	_	O
204	%	_	_	O
205	,	_	_	O
206	respectively	_	_	O
207	;	_	_	O
208	p	_	_	O
209	=	_	_	O
210	0.027	_	_	O
211	)	_	_	O
212	.	_	_	O

213	During	_	_	B-Premise
214	follow-up	_	_	I-Premise
215	,	_	_	I-Premise
216	71	_	_	I-Premise
217	%	_	_	I-Premise
218	of	_	_	I-Premise
219	the	_	_	I-Premise
220	patients	_	_	I-Premise
221	showed	_	_	I-Premise
222	unaltered	_	_	I-Premise
223	or	_	_	I-Premise
224	improved	_	_	I-Premise
225	lung	_	_	I-Premise
226	expansion	_	_	I-Premise
227	and	_	_	I-Premise
228	9	_	_	I-Premise
229	patients	_	_	I-Premise
230	(	_	_	I-Premise
231	15	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	needed	_	_	I-Premise
235	new	_	_	I-Premise
236	pleural	_	_	I-Premise
237	procedures	_	_	I-Premise
238	(	_	_	I-Premise
239	VATS	_	_	I-Premise
240	group	_	_	I-Premise
241	,	_	_	I-Premise
242	5	_	_	I-Premise
243	recurrences	_	_	I-Premise
244	;	_	_	I-Premise
245	TS	_	_	I-Premise
246	group	_	_	I-Premise
247	,	_	_	I-Premise
248	4	_	_	I-Premise
249	recurrences	_	_	I-Premise
250	;	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.999	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	No	_	_	B-Premise
257	differences	_	_	I-Premise
258	were	_	_	I-Premise
259	found	_	_	I-Premise
260	between	_	_	I-Premise
261	groups	_	_	I-Premise
262	regarding	_	_	I-Premise
263	quality	_	_	I-Premise
264	of	_	_	I-Premise
265	life	_	_	I-Premise
266	,	_	_	I-Premise
267	complications	_	_	I-Premise
268	,	_	_	I-Premise
269	drainage	_	_	I-Premise
270	time	_	_	I-Premise
271	,	_	_	I-Premise
272	hospital	_	_	I-Premise
273	stay	_	_	I-Premise
274	,	_	_	I-Premise
275	and	_	_	I-Premise
276	survival	_	_	I-Premise
277	.	_	_	I-Premise

278	Immediate	_	_	B-Premise
279	lung	_	_	I-Premise
280	expansion	_	_	I-Premise
281	did	_	_	I-Premise
282	not	_	_	I-Premise
283	correlate	_	_	I-Premise
284	with	_	_	I-Premise
285	radiologic	_	_	I-Premise
286	recurrence	_	_	I-Premise
287	,	_	_	I-Premise
288	clinical	_	_	I-Premise
289	recurrence	_	_	I-Premise
290	,	_	_	I-Premise
291	or	_	_	I-Premise
292	complications	_	_	I-Premise
293	(	_	_	I-Premise
294	p	_	_	I-Premise
295	=	_	_	I-Premise
296	0.60	_	_	I-Premise
297	,	_	_	I-Premise
298	0.15	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	0.20	_	_	I-Premise
302	,	_	_	I-Premise
303	respectively	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Immediate	_	_	B-Premise
307	partial	_	_	I-Premise
308	lung	_	_	I-Premise
309	expansion	_	_	I-Premise
310	was	_	_	I-Premise
311	a	_	_	I-Premise
312	frequent	_	_	I-Premise
313	finding	_	_	I-Premise
314	and	_	_	I-Premise
315	was	_	_	I-Premise
316	more	_	_	I-Premise
317	frequent	_	_	I-Premise
318	after	_	_	I-Premise
319	TS	_	_	I-Premise
320	.	_	_	I-Premise

321	Nonetheless	_	_	O
322	,	_	_	O
323	no	_	_	B-Claim
324	correlation	_	_	I-Claim
325	between	_	_	I-Claim
326	immediate	_	_	I-Claim
327	lung	_	_	I-Claim
328	expansion	_	_	I-Claim
329	and	_	_	I-Claim
330	clinical	_	_	I-Claim
331	outcome	_	_	I-Claim
332	was	_	_	I-Claim
333	found	_	_	I-Claim
334	in	_	_	I-Claim
335	this	_	_	I-Claim
336	study	_	_	I-Claim
337	.	_	_	I-Claim


0	Psychological	_	_	B-Claim
1	interventions	_	_	I-Claim
2	are	_	_	I-Claim
3	efficacious	_	_	I-Claim
4	in	_	_	I-Claim
5	reducing	_	_	I-Claim
6	emotional	_	_	I-Claim
7	distress	_	_	I-Claim
8	for	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	.	_	_	I-Claim

12	However	_	_	B-Claim
13	,	_	_	I-Claim
14	it	_	_	I-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	clear	_	_	I-Claim
18	whether	_	_	I-Claim
19	psychological	_	_	I-Claim
20	improvements	_	_	I-Claim
21	are	_	_	I-Claim
22	,	_	_	I-Claim
23	in	_	_	I-Claim
24	turn	_	_	I-Claim
25	,	_	_	I-Claim
26	related	_	_	I-Claim
27	to	_	_	I-Claim
28	improved	_	_	I-Claim
29	health	_	_	I-Claim
30	.	_	_	I-Claim

31	A	_	_	O
32	clinical	_	_	O
33	trial	_	_	O
34	tests	_	_	O
35	whether	_	_	O
36	a	_	_	O
37	psychological	_	_	O
38	intervention	_	_	O
39	for	_	_	O
40	cancer	_	_	O
41	patients	_	_	O
42	can	_	_	O
43	do	_	_	O
44	so	_	_	O
45	,	_	_	O
46	and	_	_	O
47	also	_	_	O
48	tests	_	_	O
49	two	_	_	O
50	routes	_	_	O
51	to	_	_	O
52	achieve	_	_	O
53	better	_	_	O
54	health	_	_	O
55	:	_	_	O
56	(	_	_	O
57	a	_	_	O
58	)	_	_	O
59	reducing	_	_	O
60	patients	_	_	O
61	'	_	_	O
62	Emotional	_	_	O
63	Distress	_	_	O
64	,	_	_	O
65	and/or	_	_	O
66	(	_	_	O
67	b	_	_	O
68	)	_	_	O
69	enhancing	_	_	O
70	their	_	_	O
71	functional	_	_	O
72	immunity	_	_	O
73	.	_	_	O

74	Post-surgery	_	_	O
75	,	_	_	O
76	227	_	_	O
77	breast	_	_	O
78	cancer	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	intervention	_	_	O
84	or	_	_	O
85	assessment	_	_	O
86	only	_	_	O
87	Study	_	_	O
88	Arms	_	_	O
89	.	_	_	O

90	Conducted	_	_	O
91	in	_	_	O
92	small	_	_	O
93	groups	_	_	O
94	,	_	_	O
95	intervention	_	_	O
96	sessions	_	_	O
97	were	_	_	O
98	offered	_	_	O
99	weekly	_	_	O
100	for	_	_	O
101	4	_	_	O
102	months	_	_	O
103	and	_	_	O
104	followed	_	_	O
105	by	_	_	O
106	monthly	_	_	O
107	sessions	_	_	O
108	for	_	_	O
109	8	_	_	O
110	months	_	_	O
111	.	_	_	O

112	Measures	_	_	O
113	included	_	_	O
114	psychological	_	_	O
115	(	_	_	O
116	distress	_	_	O
117	)	_	_	O
118	,	_	_	O
119	biological	_	_	O
120	(	_	_	O
121	immune	_	_	O
122	)	_	_	O
123	,	_	_	O
124	and	_	_	O
125	health	_	_	O
126	outcomes	_	_	O
127	(	_	_	O
128	performance	_	_	O
129	status	_	_	O
130	and	_	_	O
131	evaluations	_	_	O
132	of	_	_	O
133	patient	_	_	O
134	's	_	_	O
135	symptomatology	_	_	O
136	,	_	_	O
137	including	_	_	O
138	toxicity	_	_	O
139	from	_	_	O
140	cancer	_	_	O
141	treatment	_	_	O
142	,	_	_	O
143	lab	_	_	O
144	values	_	_	O
145	)	_	_	O
146	collected	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	,	_	_	O
150	4	_	_	O
151	months	_	_	O
152	,	_	_	O
153	and	_	_	O
154	12	_	_	O
155	months	_	_	O
156	.	_	_	O

157	A	_	_	B-Premise
158	path	_	_	I-Premise
159	model	_	_	I-Premise
160	revealed	_	_	I-Premise
161	that	_	_	I-Premise
162	intervention	_	_	I-Premise
163	participation	_	_	I-Premise
164	directly	_	_	I-Premise
165	improved	_	_	I-Premise
166	health	_	_	I-Premise
167	(	_	_	I-Premise
168	p	_	_	I-Premise
169	<	_	_	I-Premise
170	.05	_	_	I-Premise
171	)	_	_	I-Premise
172	at	_	_	I-Premise
173	12	_	_	I-Premise
174	months	_	_	I-Premise
175	.	_	_	I-Premise

176	These	_	_	B-Premise
177	effects	_	_	I-Premise
178	remained	_	_	I-Premise
179	when	_	_	I-Premise
180	statistically	_	_	I-Premise
181	controlling	_	_	I-Premise
182	for	_	_	I-Premise
183	baseline	_	_	I-Premise
184	levels	_	_	I-Premise
185	of	_	_	I-Premise
186	distress	_	_	I-Premise
187	,	_	_	I-Premise
188	immunity	_	_	I-Premise
189	,	_	_	I-Premise
190	and	_	_	I-Premise
191	health	_	_	I-Premise
192	as	_	_	I-Premise
193	well	_	_	I-Premise
194	as	_	_	I-Premise
195	sociodemographic	_	_	I-Premise
196	,	_	_	I-Premise
197	disease	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	cancer	_	_	I-Premise
201	treatment	_	_	I-Premise
202	variables	_	_	I-Premise
203	.	_	_	I-Premise

204	Regarding	_	_	B-Premise
205	the	_	_	I-Premise
206	mechanisms	_	_	I-Premise
207	for	_	_	I-Premise
208	achieving	_	_	I-Premise
209	better	_	_	I-Premise
210	health	_	_	I-Premise
211	,	_	_	I-Premise
212	support	_	_	I-Premise
213	was	_	_	I-Premise
214	found	_	_	I-Premise
215	for	_	_	I-Premise
216	an	_	_	I-Premise
217	indirect	_	_	I-Premise
218	effect	_	_	I-Premise
219	of	_	_	I-Premise
220	distress	_	_	I-Premise
221	reduction	_	_	I-Premise
222	.	_	_	I-Premise

223	That	_	_	B-Premise
224	is	_	_	I-Premise
225	,	_	_	I-Premise
226	by	_	_	I-Premise
227	specifically	_	_	I-Premise
228	lowering	_	_	I-Premise
229	intervention	_	_	I-Premise
230	patients	_	_	I-Premise
231	'	_	_	I-Premise
232	distress	_	_	I-Premise
233	at	_	_	I-Premise
234	4	_	_	I-Premise
235	months	_	_	I-Premise
236	,	_	_	I-Premise
237	their	_	_	I-Premise
238	health	_	_	I-Premise
239	was	_	_	I-Premise
240	improved	_	_	I-Premise
241	at	_	_	I-Premise
242	12	_	_	I-Premise
243	months	_	_	I-Premise
244	(	_	_	I-Premise
245	p	_	_	I-Premise
246	<	_	_	I-Premise
247	.05	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	Although	_	_	B-Premise
251	the	_	_	I-Premise
252	intervention	_	_	I-Premise
253	simultaneously	_	_	I-Premise
254	improved	_	_	I-Premise
255	patients	_	_	I-Premise
256	'	_	_	I-Premise
257	T-cell	_	_	I-Premise
258	blastogenesis	_	_	I-Premise
259	in	_	_	I-Premise
260	response	_	_	I-Premise
261	to	_	_	I-Premise
262	phytohemagglutinin	_	_	I-Premise
263	(	_	_	I-Premise
264	PHA	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	the	_	_	B-Premise
268	latter	_	_	I-Premise
269	increases	_	_	I-Premise
270	were	_	_	I-Premise
271	unrelated	_	_	I-Premise
272	to	_	_	I-Premise
273	improved	_	_	I-Premise
274	health	_	_	I-Premise
275	.	_	_	I-Premise

276	A	_	_	B-Premise
277	convergence	_	_	I-Premise
278	of	_	_	I-Premise
279	biobehavioral	_	_	I-Premise
280	effects	_	_	I-Premise
281	and	_	_	I-Premise
282	health	_	_	I-Premise
283	improvements	_	_	I-Premise
284	were	_	_	I-Premise
285	observed	_	_	I-Premise
286	.	_	_	I-Premise

287	Behavioral	_	_	B-Claim
288	change	_	_	I-Claim
289	,	_	_	I-Claim
290	rather	_	_	I-Claim
291	than	_	_	I-Claim
292	immunity	_	_	I-Claim
293	change	_	_	I-Claim
294	,	_	_	I-Claim
295	was	_	_	I-Claim
296	influential	_	_	I-Claim
297	in	_	_	I-Claim
298	achieving	_	_	I-Claim
299	lower	_	_	I-Claim
300	levels	_	_	I-Claim
301	of	_	_	I-Claim
302	symptomatology	_	_	I-Claim
303	and	_	_	I-Claim
304	higher	_	_	I-Claim
305	functional	_	_	I-Claim
306	status	_	_	I-Claim
307	.	_	_	I-Claim

308	Distress	_	_	B-Claim
309	reduction	_	_	I-Claim
310	is	_	_	I-Claim
311	highlighted	_	_	I-Claim
312	as	_	_	I-Claim
313	an	_	_	I-Claim
314	important	_	_	I-Claim
315	mechanism	_	_	I-Claim
316	by	_	_	I-Claim
317	which	_	_	I-Claim
318	health	_	_	I-Claim
319	can	_	_	I-Claim
320	be	_	_	I-Claim
321	improved	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	directly	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	intensity-modulated	_	_	O
7	radiotherapy	_	_	O
8	(	_	_	O
9	IMRT	_	_	O
10	)	_	_	O
11	vs.	_	_	O
12	conventional	_	_	O
13	radiotherapy	_	_	O
14	(	_	_	O
15	CRT	_	_	O
16	)	_	_	O
17	on	_	_	O
18	salivary	_	_	O
19	flow	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QoL	_	_	O
26	)	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	early-stage	_	_	O
31	nasopharyngeal	_	_	O
32	carcinoma	_	_	O
33	(	_	_	O
34	NPC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	Fifty-one	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	T2	_	_	O
41	,	_	_	O
42	N0/N1	_	_	O
43	,	_	_	O
44	M0	_	_	O
45	NPC	_	_	O
46	took	_	_	O
47	part	_	_	O
48	in	_	_	O
49	a	_	_	O
50	randomized	_	_	O
51	controlled	_	_	O
52	clinical	_	_	O
53	study	_	_	O
54	and	_	_	O
55	received	_	_	O
56	IMRT	_	_	O
57	or	_	_	O
58	CRT	_	_	O
59	.	_	_	O

60	Stimulated	_	_	O
61	whole	_	_	O
62	(	_	_	O
63	SWS	_	_	O
64	)	_	_	O
65	and	_	_	O
66	parotid	_	_	O
67	(	_	_	O
68	SPS	_	_	O
69	)	_	_	O
70	saliva	_	_	O
71	flow	_	_	O
72	were	_	_	O
73	measured	_	_	O
74	and	_	_	O
75	Medical	_	_	O
76	Outcomes	_	_	O
77	Short	_	_	O
78	Form	_	_	O
79	36	_	_	O
80	(	_	_	O
81	SF-36	_	_	O
82	)	_	_	O
83	,	_	_	O
84	European	_	_	O
85	Organization	_	_	O
86	for	_	_	O
87	Research	_	_	O
88	and	_	_	O
89	Treatment	_	_	O
90	of	_	_	O
91	Cancer	_	_	O
92	(	_	_	O
93	EORTC	_	_	O
94	)	_	_	O
95	core	_	_	O
96	quetionnaire	_	_	O
97	,	_	_	O
98	and	_	_	O
99	EORTC	_	_	O
100	head-and-neck	_	_	O
101	module	_	_	O
102	(	_	_	O
103	QLQ-H	_	_	O
104	&	_	_	O
105	amp	_	_	O
106	;	_	_	O
107	N35	_	_	O
108	)	_	_	O
109	were	_	_	O
110	completed	_	_	O
111	at	_	_	O
112	baseline	_	_	O
113	and	_	_	O
114	2	_	_	O
115	,	_	_	O
116	6	_	_	O
117	,	_	_	O
118	and	_	_	O
119	12	_	_	O
120	months	_	_	O
121	after	_	_	O
122	radiotherapy	_	_	O
123	.	_	_	O

124	Forty-six	_	_	B-Premise
125	patients	_	_	I-Premise
126	(	_	_	I-Premise
127	88	_	_	I-Premise
128	%	_	_	I-Premise
129	)	_	_	I-Premise
130	were	_	_	I-Premise
131	in	_	_	I-Premise
132	disease	_	_	I-Premise
133	remission	_	_	I-Premise
134	12	_	_	I-Premise
135	months	_	_	I-Premise
136	after	_	_	I-Premise
137	radiotherapy	_	_	I-Premise
138	.	_	_	I-Premise

139	At	_	_	B-Premise
140	12	_	_	I-Premise
141	months	_	_	I-Premise
142	postradiotherapy	_	_	I-Premise
143	,	_	_	I-Premise
144	12	_	_	I-Premise
145	(	_	_	I-Premise
146	50.0	_	_	I-Premise
147	%	_	_	I-Premise
148	)	_	_	I-Premise
149	and	_	_	I-Premise
150	20	_	_	I-Premise
151	patients	_	_	I-Premise
152	(	_	_	I-Premise
153	83.3	_	_	I-Premise
154	%	_	_	I-Premise
155	)	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	IMRT	_	_	I-Premise
159	group	_	_	I-Premise
160	had	_	_	I-Premise
161	recovered	_	_	I-Premise
162	at	_	_	I-Premise
163	least	_	_	I-Premise
164	25	_	_	I-Premise
165	%	_	_	I-Premise
166	of	_	_	I-Premise
167	preradiotherapy	_	_	I-Premise
168	SWS	_	_	I-Premise
169	and	_	_	I-Premise
170	SPS	_	_	I-Premise
171	flow	_	_	I-Premise
172	respectively	_	_	I-Premise
173	,	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	1	_	_	I-Premise
177	(	_	_	I-Premise
178	4.8	_	_	I-Premise
179	%	_	_	I-Premise
180	)	_	_	I-Premise
181	and	_	_	I-Premise
182	2	_	_	I-Premise
183	patients	_	_	I-Premise
184	(	_	_	I-Premise
185	9.5	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	respectively	_	_	I-Premise
190	,	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	CRT	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	Global	_	_	B-Premise
197	health	_	_	I-Premise
198	scores	_	_	I-Premise
199	showed	_	_	I-Premise
200	continuous	_	_	I-Premise
201	improvement	_	_	I-Premise
202	in	_	_	I-Premise
203	QoL	_	_	I-Premise
204	after	_	_	I-Premise
205	both	_	_	I-Premise
206	treatments	_	_	I-Premise
207	(	_	_	I-Premise
208	p	_	_	I-Premise
209	<	_	_	I-Premise
210	0.001	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	However	_	_	B-Premise
214	,	_	_	I-Premise
215	after	_	_	I-Premise
216	12	_	_	I-Premise
217	months	_	_	I-Premise
218	subscale	_	_	I-Premise
219	scores	_	_	I-Premise
220	for	_	_	I-Premise
221	role-physical	_	_	I-Premise
222	,	_	_	I-Premise
223	bodily	_	_	I-Premise
224	pain	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	physical	_	_	I-Premise
228	function	_	_	I-Premise
229	were	_	_	I-Premise
230	significantly	_	_	I-Premise
231	higher	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	IMRT	_	_	I-Premise
235	group	_	_	I-Premise
236	,	_	_	I-Premise
237	indicating	_	_	I-Premise
238	a	_	_	I-Premise
239	better	_	_	I-Premise
240	condition	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	<	_	_	I-Premise
244	0.05	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Dry	_	_	B-Premise
248	mouth	_	_	I-Premise
249	and	_	_	I-Premise
250	sticky	_	_	I-Premise
251	saliva	_	_	I-Premise
252	were	_	_	I-Premise
253	problems	_	_	I-Premise
254	in	_	_	I-Premise
255	both	_	_	I-Premise
256	groups	_	_	I-Premise
257	2	_	_	I-Premise
258	months	_	_	I-Premise
259	after	_	_	I-Premise
260	treatment	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	the	_	_	I-Premise
264	IMRT	_	_	I-Premise
265	group	_	_	I-Premise
266	,	_	_	I-Premise
267	there	_	_	I-Premise
268	was	_	_	I-Premise
269	consistent	_	_	I-Premise
270	improvement	_	_	I-Premise
271	over	_	_	I-Premise
272	time	_	_	I-Premise
273	with	_	_	I-Premise
274	xerostomia-related	_	_	I-Premise
275	symptoms	_	_	I-Premise
276	significantly	_	_	I-Premise
277	less	_	_	I-Premise
278	common	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	CRT	_	_	I-Premise
283	group	_	_	I-Premise
284	at	_	_	I-Premise
285	12	_	_	I-Premise
286	months	_	_	I-Premise
287	postradiotherapy	_	_	I-Premise
288	.	_	_	I-Premise

289	IMRT	_	_	B-Claim
290	was	_	_	I-Claim
291	significantly	_	_	I-Claim
292	better	_	_	I-Claim
293	than	_	_	I-Claim
294	CRT	_	_	I-Claim
295	in	_	_	I-Claim
296	terms	_	_	I-Claim
297	of	_	_	I-Claim
298	parotid	_	_	I-Claim
299	sparing	_	_	I-Claim
300	and	_	_	I-Claim
301	improved	_	_	I-Claim
302	QoL	_	_	I-Claim
303	for	_	_	I-Claim
304	early-stage	_	_	I-Claim
305	disease	_	_	I-Claim
306	.	_	_	I-Claim

307	The	_	_	B-Claim
308	findings	_	_	I-Claim
309	support	_	_	I-Claim
310	the	_	_	I-Claim
311	case	_	_	I-Claim
312	for	_	_	I-Claim
313	assessment	_	_	I-Claim
314	of	_	_	I-Claim
315	health-related	_	_	I-Claim
316	QoL	_	_	I-Claim
317	in	_	_	I-Claim
318	relation	_	_	I-Claim
319	to	_	_	I-Claim
320	head-and-neck	_	_	I-Claim
321	cancer	_	_	I-Claim
322	using	_	_	I-Claim
323	a	_	_	I-Claim
324	site-specific	_	_	I-Claim
325	approach	_	_	I-Claim
326	.	_	_	O


0	A	_	_	O
1	dramatic	_	_	O
2	rise	_	_	O
3	in	_	_	O
4	incidence	_	_	O
5	,	_	_	O
6	an	_	_	O
7	aging	_	_	O
8	population	_	_	O
9	,	_	_	O
10	and	_	_	O
11	expensive	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	have	_	_	O
15	led	_	_	O
16	to	_	_	O
17	an	_	_	O
18	escalating	_	_	O
19	burden	_	_	O
20	on	_	_	O
21	clinicians	_	_	O
22	managing	_	_	O
23	inoperable	_	_	O
24	esophageal	_	_	O
25	cancer	_	_	O
26	with	_	_	O
27	only	_	_	O
28	limited	_	_	O
29	evidence	_	_	O
30	of	_	_	O
31	effectiveness	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	compares	_	_	O
36	the	_	_	O
37	clinical	_	_	O
38	effectiveness	_	_	O
39	and	_	_	O
40	cost-effectiveness	_	_	O
41	of	_	_	O
42	self-expanding	_	_	O
43	metal	_	_	O
44	stents	_	_	O
45	(	_	_	O
46	SEMSs	_	_	O
47	)	_	_	O
48	with	_	_	O
49	other	_	_	O
50	palliative	_	_	O
51	therapies	_	_	O
52	to	_	_	O
53	aid	_	_	O
54	clinicians	_	_	O
55	in	_	_	O
56	making	_	_	O
57	an	_	_	O
58	evidence-based	_	_	O
59	treatment	_	_	O
60	choice	_	_	O
61	.	_	_	O

62	We	_	_	O
63	conducted	_	_	O
64	a	_	_	O
65	prospective	_	_	O
66	,	_	_	O
67	multicenter	_	_	O
68	,	_	_	O
69	randomized	_	_	O
70	,	_	_	O
71	controlled	_	_	O
72	,	_	_	O
73	clinical	_	_	O
74	trial	_	_	O
75	with	_	_	O
76	215	_	_	O
77	patients	_	_	O
78	followed	_	_	O
79	until	_	_	O
80	death	_	_	O
81	or	_	_	O
82	study	_	_	O
83	closure	_	_	O
84	.	_	_	O

85	The	_	_	O
86	primary	_	_	O
87	outcome	_	_	O
88	measures	_	_	O
89	were	_	_	O
90	dysphagia	_	_	O
91	,	_	_	O
92	quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	(	_	_	O
96	QL	_	_	O
97	)	_	_	O
98	6	_	_	O
99	weeks	_	_	O
100	following	_	_	O
101	treatment	_	_	O
102	,	_	_	O
103	and	_	_	O
104	total	_	_	O
105	cost	_	_	O
106	of	_	_	O
107	treatment	_	_	O
108	.	_	_	O

109	Secondary	_	_	O
110	outcome	_	_	O
111	measures	_	_	O
112	included	_	_	O
113	treatment-associated	_	_	O
114	morbidity	_	_	O
115	,	_	_	O
116	mortality	_	_	O
117	,	_	_	O
118	survival	_	_	O
119	,	_	_	O
120	and	_	_	O
121	cost-effectiveness	_	_	O
122	.	_	_	O

123	An	_	_	O
124	intention-to-treat	_	_	O
125	analysis	_	_	O
126	was	_	_	O
127	carried	_	_	O
128	out	_	_	O
129	.	_	_	O

130	There	_	_	B-Premise
131	was	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	difference	_	_	I-Premise
135	in	_	_	I-Premise
136	mean	_	_	I-Premise
137	dysphagia	_	_	I-Premise
138	grade	_	_	I-Premise
139	between	_	_	I-Premise
140	treatment	_	_	I-Premise
141	arms	_	_	I-Premise
142	6	_	_	I-Premise
143	weeks	_	_	I-Premise
144	following	_	_	I-Premise
145	treatment	_	_	I-Premise
146	(	_	_	I-Premise
147	P=0.046	_	_	I-Premise
148	)	_	_	I-Premise
149	,	_	_	I-Premise
150	with	_	_	I-Premise
151	worse	_	_	I-Premise
152	swallowing	_	_	I-Premise
153	reported	_	_	I-Premise
154	by	_	_	I-Premise
155	rigid	_	_	I-Premise
156	stent-treated	_	_	I-Premise
157	patients	_	_	I-Premise
158	(	_	_	I-Premise
159	mean	_	_	I-Premise
160	dysphagia	_	_	I-Premise
161	score	_	_	I-Premise
162	difference=-0.49	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	(	_	_	I-Premise
169	CI	_	_	I-Premise
170	)	_	_	I-Premise
171	-0.10	_	_	I-Premise
172	to	_	_	I-Premise
173	-0.89	_	_	I-Premise
174	,	_	_	I-Premise
175	P=0.014	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Global	_	_	B-Premise
179	QL	_	_	I-Premise
180	scores	_	_	I-Premise
181	were	_	_	I-Premise
182	lower	_	_	I-Premise
183	at	_	_	I-Premise
184	both	_	_	I-Premise
185	1	_	_	I-Premise
186	and	_	_	I-Premise
187	6	_	_	I-Premise
188	weeks	_	_	I-Premise
189	following	_	_	I-Premise
190	treatment	_	_	I-Premise
191	for	_	_	I-Premise
192	patients	_	_	I-Premise
193	treated	_	_	I-Premise
194	by	_	_	I-Premise
195	SEMSs	_	_	I-Premise
196	(	_	_	I-Premise
197	mean	_	_	I-Premise
198	difference	_	_	I-Premise
199	QL	_	_	I-Premise
200	index	_	_	I-Premise
201	week	_	_	I-Premise
202	1=-0.66	_	_	I-Premise
203	;	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	CI	_	_	I-Premise
207	:	_	_	I-Premise
208	-0.02	_	_	I-Premise
209	to	_	_	I-Premise
210	-1.30	_	_	I-Premise
211	,	_	_	I-Premise
212	P=0.04	_	_	I-Premise
213	;	_	_	I-Premise
214	mean	_	_	I-Premise
215	difference	_	_	I-Premise
216	QL	_	_	I-Premise
217	index	_	_	I-Premise
218	week	_	_	I-Premise
219	6=-1.01	_	_	I-Premise
220	;	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	-0.30	_	_	I-Premise
225	to	_	_	I-Premise
226	-1.72	_	_	I-Premise
227	,	_	_	I-Premise
228	P=0.006	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	These	_	_	B-Premise
232	findings	_	_	I-Premise
233	were	_	_	I-Premise
234	associated	_	_	I-Premise
235	with	_	_	I-Premise
236	higher	_	_	I-Premise
237	post-procedure	_	_	I-Premise
238	pain	_	_	I-Premise
239	scores	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	SEMS	_	_	I-Premise
243	patient	_	_	I-Premise
244	group	_	_	I-Premise
245	(	_	_	I-Premise
246	mean	_	_	I-Premise
247	difference	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	European	_	_	I-Premise
251	Organisation	_	_	I-Premise
252	for	_	_	I-Premise
253	Research	_	_	I-Premise
254	and	_	_	I-Premise
255	Treatment	_	_	I-Premise
256	of	_	_	I-Premise
257	Cancer	_	_	I-Premise
258	QLQ	_	_	I-Premise
259	C-30	_	_	I-Premise
260	pain	_	_	I-Premise
261	symptom	_	_	I-Premise
262	score	_	_	I-Premise
263	at	_	_	I-Premise
264	week	_	_	I-Premise
265	1=11.13	_	_	I-Premise
266	;	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	:	_	_	I-Premise
271	2.89-19.4	_	_	I-Premise
272	;	_	_	I-Premise
273	P=0.01	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Although	_	_	B-Premise
277	mean	_	_	I-Premise
278	EQ-5D	_	_	I-Premise
279	QL	_	_	I-Premise
280	values	_	_	I-Premise
281	differed	_	_	I-Premise
282	between	_	_	I-Premise
283	the	_	_	I-Premise
284	treatments	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	0.001	_	_	I-Premise
289	)	_	_	I-Premise
290	,	_	_	I-Premise
291	this	_	_	I-Premise
292	difference	_	_	I-Premise
293	dissipated	_	_	I-Premise
294	following	_	_	I-Premise
295	generation	_	_	I-Premise
296	of	_	_	I-Premise
297	quality-adjusted	_	_	I-Premise
298	life	_	_	I-Premise
299	year	_	_	I-Premise
300	values	_	_	I-Premise
301	.	_	_	I-Premise

302	Total	_	_	O
303	costs	_	_	O
304	varied	_	_	O
305	between	_	_	O
306	treatment	_	_	O
307	arms	_	_	O
308	but	_	_	O
309	these	_	_	O
310	findings	_	_	O
311	canceled	_	_	O
312	out	_	_	O
313	when	_	_	O
314	SEMSs	_	_	O
315	were	_	_	O
316	compared	_	_	O
317	with	_	_	O
318	non-SEMS	_	_	O
319	therapies	_	_	O
320	(	_	_	O
321	95	_	_	O
322	%	_	_	O
323	CI	_	_	O
324	-845.15-1,332.62	_	_	O
325	)	_	_	O
326	.	_	_	O

327	These	_	_	O
328	results	_	_	O
329	were	_	_	O
330	robust	_	_	O
331	to	_	_	O
332	sensitivity	_	_	O
333	analysis	_	_	O
334	.	_	_	O

335	There	_	_	B-Premise
336	were	_	_	I-Premise
337	no	_	_	I-Premise
338	differences	_	_	I-Premise
339	in	_	_	I-Premise
340	the	_	_	I-Premise
341	in-hospital	_	_	I-Premise
342	mortality	_	_	I-Premise
343	or	_	_	I-Premise
344	early	_	_	I-Premise
345	complication	_	_	I-Premise
346	rates	_	_	I-Premise
347	,	_	_	I-Premise
348	but	_	_	B-Premise
349	late	_	_	I-Premise
350	complications	_	_	I-Premise
351	were	_	_	I-Premise
352	more	_	_	I-Premise
353	frequent	_	_	I-Premise
354	after	_	_	I-Premise
355	rigid	_	_	I-Premise
356	stenting	_	_	I-Premise
357	(	_	_	I-Premise
358	risk	_	_	I-Premise
359	ratio=2.47	_	_	I-Premise
360	;	_	_	I-Premise
361	95	_	_	I-Premise
362	%	_	_	I-Premise
363	CI	_	_	I-Premise
364	1.88-3.04	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	There	_	_	B-Premise
368	was	_	_	I-Premise
369	a	_	_	I-Premise
370	survival	_	_	I-Premise
371	advantage	_	_	I-Premise
372	for	_	_	I-Premise
373	non-stent-treated	_	_	I-Premise
374	patients	_	_	I-Premise
375	(	_	_	I-Premise
376	log-rank	_	_	I-Premise
377	statistic=4.21	_	_	I-Premise
378	,	_	_	I-Premise
379	P=0.04	_	_	I-Premise
380	)	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Claim
383	treatment	_	_	I-Claim
384	choice	_	_	I-Claim
385	for	_	_	I-Claim
386	patients	_	_	I-Claim
387	with	_	_	I-Claim
388	inoperable	_	_	I-Claim
389	esophageal	_	_	I-Claim
390	cancer	_	_	I-Claim
391	should	_	_	I-Claim
392	be	_	_	I-Claim
393	between	_	_	I-Claim
394	a	_	_	I-Claim
395	SEMS	_	_	I-Claim
396	or	_	_	I-Claim
397	a	_	_	I-Claim
398	non-stent	_	_	I-Claim
399	treatment	_	_	I-Claim
400	after	_	_	I-Claim
401	consideration	_	_	I-Claim
402	has	_	_	I-Claim
403	been	_	_	I-Claim
404	given	_	_	I-Claim
405	to	_	_	I-Claim
406	both	_	_	I-Claim
407	patient	_	_	I-Claim
408	and	_	_	I-Claim
409	tumor	_	_	I-Claim
410	characteristics	_	_	I-Claim
411	and	_	_	I-Claim
412	clinician	_	_	I-Claim
413	and	_	_	I-Claim
414	patient	_	_	I-Claim
415	preferences	_	_	I-Claim
416	.	_	_	I-Claim


0	The	_	_	B-Claim
1	efficacy	_	_	I-Claim
2	and	_	_	I-Claim
3	safety	_	_	I-Claim
4	of	_	_	I-Claim
5	uterine-artery	_	_	I-Claim
6	embolization	_	_	I-Claim
7	,	_	_	I-Claim
8	as	_	_	I-Claim
9	compared	_	_	I-Claim
10	with	_	_	I-Claim
11	standard	_	_	I-Claim
12	surgical	_	_	I-Claim
13	methods	_	_	I-Claim
14	,	_	_	I-Claim
15	for	_	_	I-Claim
16	the	_	_	I-Claim
17	treatment	_	_	I-Claim
18	of	_	_	I-Claim
19	symptomatic	_	_	I-Claim
20	uterine	_	_	I-Claim
21	fibroids	_	_	I-Claim
22	remain	_	_	I-Claim
23	uncertain	_	_	I-Claim
24	.	_	_	I-Claim

25	We	_	_	O
26	conducted	_	_	O
27	a	_	_	O
28	randomized	_	_	O
29	trial	_	_	O
30	comparing	_	_	O
31	uterine-artery	_	_	O
32	embolization	_	_	O
33	and	_	_	O
34	surgery	_	_	O
35	in	_	_	O
36	women	_	_	O
37	with	_	_	O
38	symptomatic	_	_	O
39	uterine	_	_	O
40	fibroids	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	outcome	_	_	O
45	was	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	at	_	_	O
50	1	_	_	O
51	year	_	_	O
52	of	_	_	O
53	follow-up	_	_	O
54	,	_	_	O
55	as	_	_	O
56	measured	_	_	O
57	by	_	_	O
58	the	_	_	O
59	Medical	_	_	O
60	Outcomes	_	_	O
61	Study	_	_	O
62	36-Item	_	_	O
63	Short-Form	_	_	O
64	General	_	_	O
65	Health	_	_	O
66	Survey	_	_	O
67	(	_	_	O
68	SF-36	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	in	_	_	O
76	a	_	_	O
77	2:1	_	_	O
78	ratio	_	_	O
79	to	_	_	O
80	undergo	_	_	O
81	either	_	_	O
82	uterine-artery	_	_	O
83	embolization	_	_	O
84	or	_	_	O
85	surgery	_	_	O
86	,	_	_	O
87	with	_	_	O
88	106	_	_	O
89	patients	_	_	O
90	undergoing	_	_	O
91	embolization	_	_	O
92	and	_	_	O
93	51	_	_	O
94	undergoing	_	_	O
95	surgery	_	_	O
96	(	_	_	O
97	43	_	_	O
98	hysterectomies	_	_	O
99	and	_	_	O
100	8	_	_	O
101	myomectomies	_	_	O
102	)	_	_	O
103	.	_	_	O

104	There	_	_	B-Premise
105	were	_	_	I-Premise
106	no	_	_	I-Premise
107	significant	_	_	I-Premise
108	differences	_	_	I-Premise
109	between	_	_	I-Premise
110	groups	_	_	I-Premise
111	in	_	_	I-Premise
112	any	_	_	I-Premise
113	of	_	_	I-Premise
114	the	_	_	I-Premise
115	eight	_	_	I-Premise
116	components	_	_	I-Premise
117	of	_	_	I-Premise
118	the	_	_	I-Premise
119	SF-36	_	_	I-Premise
120	scores	_	_	I-Premise
121	at	_	_	I-Premise
122	1	_	_	I-Premise
123	year	_	_	I-Premise
124	.	_	_	I-Premise

125	The	_	_	B-Premise
126	embolization	_	_	I-Premise
127	group	_	_	I-Premise
128	had	_	_	I-Premise
129	a	_	_	I-Premise
130	shorter	_	_	I-Premise
131	median	_	_	I-Premise
132	duration	_	_	I-Premise
133	of	_	_	I-Premise
134	hospitalization	_	_	I-Premise
135	than	_	_	I-Premise
136	the	_	_	I-Premise
137	surgical	_	_	I-Premise
138	group	_	_	I-Premise
139	(	_	_	I-Premise
140	1	_	_	I-Premise
141	day	_	_	I-Premise
142	vs.	_	_	I-Premise
143	5	_	_	I-Premise
144	days	_	_	I-Premise
145	,	_	_	I-Premise
146	P	_	_	I-Premise
147	<	_	_	I-Premise
148	0.001	_	_	I-Premise
149	)	_	_	I-Premise
150	and	_	_	I-Premise
151	a	_	_	I-Premise
152	shorter	_	_	I-Premise
153	time	_	_	I-Premise
154	before	_	_	I-Premise
155	returning	_	_	I-Premise
156	to	_	_	I-Premise
157	work	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	<	_	_	I-Premise
161	0.001	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	At	_	_	B-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	,	_	_	I-Premise
168	symptom	_	_	I-Premise
169	scores	_	_	I-Premise
170	were	_	_	I-Premise
171	better	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	surgical	_	_	I-Premise
175	group	_	_	I-Premise
176	(	_	_	I-Premise
177	P=0.03	_	_	I-Premise
178	)	_	_	I-Premise
179	.	_	_	I-Premise

180	During	_	_	B-Premise
181	the	_	_	I-Premise
182	first	_	_	I-Premise
183	year	_	_	I-Premise
184	of	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	,	_	_	I-Premise
187	there	_	_	I-Premise
188	were	_	_	I-Premise
189	13	_	_	I-Premise
190	major	_	_	I-Premise
191	adverse	_	_	I-Premise
192	events	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	embolization	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	12	_	_	I-Premise
199	%	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	10	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	surgical	_	_	I-Premise
206	group	_	_	I-Premise
207	(	_	_	I-Premise
208	20	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	P=0.22	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	mostly	_	_	I-Premise
216	related	_	_	I-Premise
217	to	_	_	I-Premise
218	the	_	_	I-Premise
219	intervention	_	_	I-Premise
220	.	_	_	I-Premise

221	Ten	_	_	B-Premise
222	patients	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	embolization	_	_	I-Premise
226	group	_	_	I-Premise
227	(	_	_	I-Premise
228	9	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	required	_	_	I-Premise
232	repeated	_	_	I-Premise
233	embolization	_	_	I-Premise
234	or	_	_	I-Premise
235	hysterectomy	_	_	I-Premise
236	for	_	_	I-Premise
237	inadequate	_	_	I-Premise
238	symptom	_	_	I-Premise
239	control	_	_	I-Premise
240	.	_	_	I-Premise

241	After	_	_	B-Premise
242	the	_	_	I-Premise
243	first	_	_	I-Premise
244	year	_	_	I-Premise
245	of	_	_	I-Premise
246	follow-up	_	_	I-Premise
247	,	_	_	I-Premise
248	14	_	_	I-Premise
249	women	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	embolization	_	_	I-Premise
253	group	_	_	I-Premise
254	(	_	_	I-Premise
255	13	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	required	_	_	I-Premise
259	hospitalization	_	_	I-Premise
260	,	_	_	I-Premise
261	3	_	_	I-Premise
262	of	_	_	I-Premise
263	them	_	_	I-Premise
264	for	_	_	I-Premise
265	major	_	_	I-Premise
266	adverse	_	_	I-Premise
267	events	_	_	I-Premise
268	and	_	_	I-Premise
269	11	_	_	I-Premise
270	for	_	_	I-Premise
271	reintervention	_	_	I-Premise
272	for	_	_	I-Premise
273	treatment	_	_	I-Premise
274	failure	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	women	_	_	I-Claim
278	with	_	_	I-Claim
279	symptomatic	_	_	I-Claim
280	fibroids	_	_	I-Claim
281	,	_	_	I-Claim
282	the	_	_	I-Claim
283	faster	_	_	I-Claim
284	recovery	_	_	I-Claim
285	after	_	_	I-Claim
286	embolization	_	_	I-Claim
287	must	_	_	I-Claim
288	be	_	_	I-Claim
289	weighed	_	_	I-Claim
290	against	_	_	I-Claim
291	the	_	_	I-Claim
292	need	_	_	I-Claim
293	for	_	_	I-Claim
294	further	_	_	I-Claim
295	treatment	_	_	I-Claim
296	in	_	_	I-Claim
297	a	_	_	I-Claim
298	minority	_	_	I-Claim
299	of	_	_	I-Claim
300	patients	_	_	I-Claim
301	.	_	_	I-Claim


0	Pain	_	_	O
1	is	_	_	O
2	1	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	that	_	_	O
9	a	_	_	O
10	cancer	_	_	O
11	patient	_	_	O
12	would	_	_	O
13	experience	_	_	O
14	.	_	_	O

15	A	_	_	O
16	significant	_	_	O
17	barrier	_	_	O
18	to	_	_	O
19	positive	_	_	O
20	pain	_	_	O
21	management	_	_	O
22	is	_	_	O
23	patients	_	_	O
24	'	_	_	O
25	misconceptions	_	_	O
26	regarding	_	_	O
27	analgesics	_	_	O
28	and	_	_	O
29	inadequate	_	_	O
30	use	_	_	O
31	of	_	_	O
32	nonpharmacological	_	_	O
33	strategies	_	_	O
34	as	_	_	O
35	pain	_	_	O
36	relief	_	_	O
37	.	_	_	O

38	The	_	_	O
39	purpose	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	investigate	_	_	O
46	the	_	_	O
47	effectiveness	_	_	O
48	of	_	_	O
49	a	_	_	O
50	pain	_	_	O
51	management	_	_	O
52	program	_	_	O
53	(	_	_	O
54	PMP	_	_	O
55	)	_	_	O
56	on	_	_	O
57	pain	_	_	O
58	intensity	_	_	O
59	,	_	_	O
60	use	_	_	O
61	of	_	_	O
62	PRN	_	_	O
63	drugs	_	_	O
64	and	_	_	O
65	nonpharmacological	_	_	O
66	strategies	_	_	O
67	as	_	_	O
68	pain	_	_	O
69	relief	_	_	O
70	,	_	_	O
71	and	_	_	O
72	barriers	_	_	O
73	to	_	_	O
74	managing	_	_	O
75	pain	_	_	O
76	in	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	.	_	_	O

80	The	_	_	O
81	study	_	_	O
82	was	_	_	O
83	conducted	_	_	O
84	in	_	_	O
85	the	_	_	O
86	palliative	_	_	O
87	care	_	_	O
88	and	_	_	O
89	hospice	_	_	O
90	ward	_	_	O
91	of	_	_	O
92	a	_	_	O
93	public	_	_	O
94	hospital	_	_	O
95	in	_	_	O
96	Hong	_	_	O
97	Kong	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	randomized	_	_	O
102	to	_	_	O
103	either	_	_	O
104	an	_	_	O
105	experimental	_	_	O
106	group	_	_	O
107	(	_	_	O
108	receiving	_	_	O
109	the	_	_	O
110	PMP	_	_	O
111	)	_	_	O
112	or	_	_	O
113	a	_	_	O
114	control	_	_	O
115	group	_	_	O
116	(	_	_	O
117	routine	_	_	O
118	care	_	_	O
119	)	_	_	O
120	.	_	_	O

121	There	_	_	O
122	were	_	_	O
123	38	_	_	O
124	hospitalized	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	with	_	_	O
128	20	_	_	O
129	(	_	_	O
130	13	_	_	O
131	males	_	_	O
132	and	_	_	O
133	7	_	_	O
134	females	_	_	O
135	)	_	_	O
136	in	_	_	O
137	the	_	_	O
138	experimental	_	_	O
139	group	_	_	O
140	and	_	_	O
141	18	_	_	O
142	(	_	_	O
143	11	_	_	O
144	males	_	_	O
145	and	_	_	O
146	7	_	_	O
147	females	_	_	O
148	)	_	_	O
149	in	_	_	O
150	the	_	_	O
151	control	_	_	O
152	group	_	_	O
153	;	_	_	O
154	mean	_	_	O
155	age	_	_	O
156	was	_	_	O
157	61.95	_	_	O
158	years	_	_	O
159	(	_	_	O
160	experimental	_	_	O
161	group	_	_	O
162	)	_	_	O
163	to	_	_	O
164	63.94	_	_	O
165	years	_	_	O
166	(	_	_	O
167	control	_	_	O
168	group	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Upon	_	_	B-Premise
172	the	_	_	I-Premise
173	completion	_	_	I-Premise
174	of	_	_	I-Premise
175	PMP	_	_	I-Premise
176	,	_	_	I-Premise
177	pain	_	_	I-Premise
178	scores	_	_	I-Premise
179	were	_	_	I-Premise
180	significantly	_	_	I-Premise
181	reduced	_	_	I-Premise
182	in	_	_	I-Premise
183	both	_	_	I-Premise
184	groups	_	_	I-Premise
185	,	_	_	I-Premise
186	yet	_	_	B-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	experimental	_	_	I-Premise
191	group	_	_	I-Premise
192	showed	_	_	I-Premise
193	a	_	_	I-Premise
194	significant	_	_	I-Premise
195	increase	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	use	_	_	I-Premise
199	of	_	_	I-Premise
200	PRN	_	_	I-Premise
201	analgesics	_	_	I-Premise
202	and	_	_	I-Premise
203	nonpharmacological	_	_	I-Premise
204	strategies	_	_	I-Premise
205	to	_	_	I-Premise
206	relieve	_	_	I-Premise
207	pain	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	.05	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	significantly	_	_	I-Premise
215	reduce	_	_	I-Premise
216	barriers	_	_	I-Premise
217	to	_	_	I-Premise
218	managing	_	_	I-Premise
219	their	_	_	I-Premise
220	cancer	_	_	I-Premise
221	pain	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.05	_	_	I-Premise
226	)	_	_	I-Premise
227	compared	_	_	I-Premise
228	with	_	_	I-Premise
229	the	_	_	I-Premise
230	control	_	_	I-Premise
231	group	_	_	I-Premise
232	.	_	_	I-Premise

233	Cancer	_	_	B-Claim
234	patients	_	_	I-Claim
235	should	_	_	I-Claim
236	be	_	_	I-Claim
237	empowered	_	_	I-Claim
238	with	_	_	I-Claim
239	pain	_	_	I-Claim
240	management	_	_	I-Claim
241	education	_	_	I-Claim
242	to	_	_	I-Claim
243	gain	_	_	I-Claim
244	knowledge	_	_	I-Claim
245	and	_	_	I-Claim
246	correct	_	_	I-Claim
247	misconceptions	_	_	I-Claim
248	in	_	_	I-Claim
249	managing	_	_	I-Claim
250	their	_	_	I-Claim
251	cancer	_	_	I-Claim
252	pain	_	_	I-Claim
253	.	_	_	I-Claim

254	Integration	_	_	B-Claim
255	of	_	_	I-Claim
256	the	_	_	I-Claim
257	PMP	_	_	I-Claim
258	into	_	_	I-Claim
259	routine	_	_	I-Claim
260	clinical	_	_	I-Claim
261	work	_	_	I-Claim
262	may	_	_	I-Claim
263	help	_	_	I-Claim
264	to	_	_	I-Claim
265	improve	_	_	I-Claim
266	the	_	_	I-Claim
267	standard	_	_	I-Claim
268	of	_	_	I-Claim
269	care	_	_	I-Claim
270	for	_	_	I-Claim
271	cancer	_	_	I-Claim
272	patients	_	_	I-Claim
273	.	_	_	I-Claim

274	It	_	_	O
275	is	_	_	O
276	recommended	_	_	O
277	to	_	_	O
278	provide	_	_	O
279	pain	_	_	O
280	management	_	_	O
281	education	_	_	O
282	to	_	_	O
283	all	_	_	O
284	cancer	_	_	O
285	patients	_	_	O
286	.	_	_	O


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	test	_	_	O
8	whether	_	_	O
9	the	_	_	O
10	novel	_	_	O
11	vascular	_	_	O
12	disrupting	_	_	O
13	agent	_	_	O
14	ASA404	_	_	O
15	(	_	_	O
16	vadimezan	_	_	O
17	)	_	_	O
18	,	_	_	O
19	when	_	_	O
20	combined	_	_	O
21	with	_	_	O
22	first-line	_	_	O
23	platinum-based	_	_	O
24	chemotherapy	_	_	O
25	,	_	_	O
26	improves	_	_	O
27	survival	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	advanced	_	_	O
32	non-small-cell	_	_	O
33	lung	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	NSCLC	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	chemotherapy	_	_	O
40	alone	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	with	_	_	O
44	advanced	_	_	O
45	stage	_	_	O
46	IIIB	_	_	O
47	or	_	_	O
48	IV	_	_	O
49	NSCLC	_	_	O
50	,	_	_	O
51	stratified	_	_	O
52	by	_	_	O
53	sex	_	_	O
54	and	_	_	O
55	tumor	_	_	O
56	histology	_	_	O
57	,	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	1:1	_	_	O
62	to	_	_	O
63	paclitaxel	_	_	O
64	(	_	_	O
65	200	_	_	O
66	mg/m	_	_	O
67	(	_	_	O
68	2	_	_	O
69	)	_	_	O
70	)	_	_	O
71	and	_	_	O
72	carboplatin	_	_	O
73	(	_	_	O
74	area	_	_	O
75	under	_	_	O
76	the	_	_	O
77	curve	_	_	O
78	,	_	_	O
79	6.0	_	_	O
80	)	_	_	O
81	with	_	_	O
82	or	_	_	O
83	without	_	_	O
84	ASA404	_	_	O
85	(	_	_	O
86	1,800	_	_	O
87	mg	_	_	O
88	m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	)	_	_	O
93	,	_	_	O
94	given	_	_	O
95	intravenously	_	_	O
96	once	_	_	O
97	every	_	_	O
98	3	_	_	O
99	weeks	_	_	O
100	for	_	_	O
101	six	_	_	O
102	cycles	_	_	O
103	followed	_	_	O
104	by	_	_	O
105	maintenance	_	_	O
106	ASA404	_	_	O
107	or	_	_	O
108	placebo	_	_	O
109	.	_	_	O

110	Primary	_	_	O
111	end	_	_	O
112	point	_	_	O
113	was	_	_	O
114	overall	_	_	O
115	survival	_	_	O
116	(	_	_	O
117	OS	_	_	O
118	)	_	_	O
119	;	_	_	O
120	secondary	_	_	O
121	end	_	_	O
122	points	_	_	O
123	included	_	_	O
124	overall	_	_	O
125	response	_	_	O
126	rate	_	_	O
127	(	_	_	O
128	ORR	_	_	O
129	)	_	_	O
130	and	_	_	O
131	progression-free	_	_	O
132	survival	_	_	O
133	(	_	_	O
134	PFS	_	_	O
135	)	_	_	O
136	.	_	_	O

137	One	_	_	O
138	thousand	_	_	O
139	two	_	_	O
140	hundred	_	_	O
141	ninety-nine	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomly	_	_	O
145	assigned	_	_	O
146	.	_	_	O

147	The	_	_	O
148	trial	_	_	O
149	was	_	_	O
150	stopped	_	_	O
151	for	_	_	O
152	futility	_	_	O
153	at	_	_	O
154	interim	_	_	O
155	analysis	_	_	O
156	.	_	_	O

157	At	_	_	O
158	final	_	_	O
159	analysis	_	_	O
160	,	_	_	O
161	there	_	_	B-Premise
162	was	_	_	I-Premise
163	no	_	_	I-Premise
164	difference	_	_	I-Premise
165	in	_	_	I-Premise
166	OS	_	_	I-Premise
167	seen	_	_	I-Premise
168	between	_	_	I-Premise
169	ASA404	_	_	I-Premise
170	(	_	_	I-Premise
171	n	_	_	I-Premise
172	=	_	_	I-Premise
173	649	_	_	I-Premise
174	)	_	_	I-Premise
175	and	_	_	I-Premise
176	placebo	_	_	I-Premise
177	(	_	_	I-Premise
178	n	_	_	I-Premise
179	=	_	_	I-Premise
180	650	_	_	I-Premise
181	)	_	_	I-Premise
182	arms	_	_	I-Premise
183	:	_	_	I-Premise
184	median	_	_	I-Premise
185	OS	_	_	I-Premise
186	was	_	_	I-Premise
187	13.4	_	_	I-Premise
188	and	_	_	I-Premise
189	12.7	_	_	I-Premise
190	months	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	hazard	_	_	I-Premise
194	ratio	_	_	I-Premise
195	[	_	_	I-Premise
196	HR	_	_	I-Premise
197	]	_	_	I-Premise
198	,	_	_	I-Premise
199	1.01	_	_	I-Premise
200	;	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	,	_	_	I-Premise
205	0.85	_	_	I-Premise
206	to	_	_	I-Premise
207	1.19	_	_	I-Premise
208	;	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.535	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	Similarly	_	_	O
215	,	_	_	O
216	no	_	_	B-Premise
217	OS	_	_	I-Premise
218	difference	_	_	I-Premise
219	was	_	_	I-Premise
220	seen	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	histologic	_	_	I-Premise
224	(	_	_	I-Premise
225	squamous	_	_	I-Premise
226	or	_	_	I-Premise
227	nonsquamous	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	sex	_	_	I-Premise
231	(	_	_	I-Premise
232	male	_	_	I-Premise
233	or	_	_	I-Premise
234	female	_	_	I-Premise
235	)	_	_	I-Premise
236	strata	_	_	I-Premise
237	.	_	_	I-Premise

238	Median	_	_	B-Premise
239	PFS	_	_	I-Premise
240	was	_	_	I-Premise
241	5.5	_	_	I-Premise
242	months	_	_	I-Premise
243	in	_	_	I-Premise
244	both	_	_	I-Premise
245	arms	_	_	I-Premise
246	(	_	_	I-Premise
247	HR	_	_	I-Premise
248	,	_	_	I-Premise
249	1.04	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	.727	_	_	I-Premise
254	)	_	_	I-Premise
255	,	_	_	I-Premise
256	while	_	_	I-Premise
257	ORR	_	_	I-Premise
258	was	_	_	I-Premise
259	25	_	_	I-Premise
260	%	_	_	I-Premise
261	in	_	_	I-Premise
262	both	_	_	I-Premise
263	arms	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	1.0	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Overall	_	_	B-Premise
271	rate	_	_	I-Premise
272	of	_	_	I-Premise
273	adverse	_	_	I-Premise
274	events	_	_	I-Premise
275	(	_	_	I-Premise
276	AEs	_	_	I-Premise
277	)	_	_	I-Premise
278	was	_	_	I-Premise
279	comparable	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	ASA404	_	_	I-Premise
283	and	_	_	I-Premise
284	placebo	_	_	I-Premise
285	arms	_	_	I-Premise
286	.	_	_	I-Premise

287	Grade	_	_	B-Premise
288	4	_	_	I-Premise
289	neutropenia	_	_	I-Premise
290	(	_	_	I-Premise
291	27	_	_	I-Premise
292	%	_	_	I-Premise
293	v	_	_	I-Premise
294	19	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	and	_	_	I-Premise
298	infusion	_	_	I-Premise
299	site	_	_	I-Premise
300	pain	_	_	I-Premise
301	(	_	_	I-Premise
302	10	_	_	I-Premise
303	%	_	_	I-Premise
304	v	_	_	I-Premise
305	0.5	_	_	I-Premise
306	%	_	_	I-Premise
307	)	_	_	I-Premise
308	were	_	_	I-Premise
309	reported	_	_	I-Premise
310	more	_	_	I-Premise
311	frequently	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	ASA404	_	_	I-Premise
315	arm	_	_	I-Premise
316	.	_	_	I-Premise

317	The	_	_	B-Claim
318	addition	_	_	I-Claim
319	of	_	_	I-Claim
320	ASA404	_	_	I-Claim
321	to	_	_	I-Claim
322	carboplatin	_	_	I-Claim
323	and	_	_	I-Claim
324	paclitaxel	_	_	I-Claim
325	,	_	_	I-Claim
326	although	_	_	I-Claim
327	generally	_	_	I-Claim
328	well	_	_	I-Claim
329	tolerated	_	_	I-Claim
330	,	_	_	I-Claim
331	failed	_	_	I-Claim
332	to	_	_	I-Claim
333	improve	_	_	I-Claim
334	frontline	_	_	I-Claim
335	efficacy	_	_	I-Claim
336	in	_	_	I-Claim
337	advanced	_	_	I-Claim
338	NSCLC	_	_	I-Claim
339	.	_	_	I-Claim


0	The	_	_	B-Claim
1	postoperative	_	_	I-Claim
2	clinical	_	_	I-Claim
3	superiority	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	interposition	_	_	I-Claim
7	of	_	_	I-Claim
8	jejunum	_	_	I-Claim
9	reconstruction	_	_	I-Claim
10	(	_	_	I-Claim
11	INT	_	_	I-Claim
12	)	_	_	I-Claim
13	to	_	_	I-Claim
14	Roux-en-Y	_	_	I-Claim
15	reconstruction	_	_	I-Claim
16	(	_	_	I-Claim
17	RY	_	_	I-Claim
18	)	_	_	I-Claim
19	after	_	_	I-Claim
20	total	_	_	I-Claim
21	gastrectomy	_	_	I-Claim
22	has	_	_	I-Claim
23	not	_	_	I-Claim
24	been	_	_	I-Claim
25	clarified	_	_	I-Claim
26	.	_	_	I-Claim

27	Postoperative	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	(	_	_	O
32	QOL	_	_	O
33	)	_	_	O
34	was	_	_	O
35	evaluated	_	_	O
36	between	_	_	O
37	the	_	_	O
38	2	_	_	O
39	methods	_	_	O
40	by	_	_	O
41	a	_	_	O
42	multi-institutional	_	_	O
43	prospective	_	_	O
44	randomized	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	103	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	gastric	_	_	O
54	cancer	_	_	O
55	were	_	_	O
56	prospectively	_	_	O
57	randomly	_	_	O
58	divided	_	_	O
59	into	_	_	O
60	groups	_	_	O
61	for	_	_	O
62	RY	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	51	_	_	O
67	)	_	_	O
68	or	_	_	O
69	INT	_	_	O
70	reconstruction	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	52	_	_	O
75	)	_	_	O
76	after	_	_	O
77	total	_	_	O
78	gastrectomy	_	_	O
79	.	_	_	O

80	They	_	_	O
81	were	_	_	O
82	stratified	_	_	O
83	by	_	_	O
84	sex	_	_	O
85	,	_	_	O
86	age	_	_	O
87	,	_	_	O
88	institute	_	_	O
89	,	_	_	O
90	histology	_	_	O
91	,	_	_	O
92	and	_	_	O
93	degree	_	_	O
94	of	_	_	O
95	lymph	_	_	O
96	node	_	_	O
97	dissection	_	_	O
98	.	_	_	O

99	Postoperatively	_	_	O
100	,	_	_	O
101	body	_	_	O
102	mass	_	_	O
103	index	_	_	O
104	(	_	_	O
105	BMI	_	_	O
106	)	_	_	O
107	and	_	_	O
108	nutritional	_	_	O
109	conditions	_	_	O
110	were	_	_	O
111	measured	_	_	O
112	serially	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QOL	_	_	O
116	and	_	_	O
117	postoperative	_	_	O
118	squalor	_	_	O
119	scores	_	_	O
120	were	_	_	O
121	evaluated	_	_	O
122	at	_	_	O
123	3	_	_	O
124	,	_	_	O
125	12	_	_	O
126	,	_	_	O
127	and	_	_	O
128	60	_	_	O
129	months	_	_	O
130	and	_	_	O
131	compared	_	_	O
132	between	_	_	O
133	the	_	_	O
134	2	_	_	O
135	groups	_	_	O
136	.	_	_	O

137	After	_	_	O
138	removing	_	_	O
139	patients	_	_	O
140	who	_	_	O
141	did	_	_	O
142	not	_	_	O
143	complete	_	_	O
144	the	_	_	O
145	follow-up	_	_	O
146	survey	_	_	O
147	or	_	_	O
148	censured	_	_	O
149	cases	_	_	O
150	,	_	_	O
151	24	_	_	O
152	patients	_	_	O
153	in	_	_	O
154	the	_	_	O
155	RY	_	_	O
156	group	_	_	O
157	and	_	_	O
158	18	_	_	O
159	patients	_	_	O
160	in	_	_	O
161	the	_	_	O
162	INT	_	_	O
163	group	_	_	O
164	were	_	_	O
165	clinically	_	_	O
166	available	_	_	O
167	and	_	_	O
168	their	_	_	O
169	postoperative	_	_	O
170	status	_	_	O
171	was	_	_	O
172	assessed	_	_	O
173	.	_	_	O

174	QOL	_	_	B-Premise
175	scores	_	_	I-Premise
176	were	_	_	I-Premise
177	increased	_	_	I-Premise
178	and	_	_	I-Premise
179	complication	_	_	I-Premise
180	scores	_	_	I-Premise
181	were	_	_	I-Premise
182	improved	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	postoperative	_	_	I-Premise
186	periods	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	<	_	_	I-Premise
190	.01	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Postoperative	_	_	B-Premise
194	BMI	_	_	I-Premise
195	significantly	_	_	I-Premise
196	deteriorated	_	_	I-Premise
197	compared	_	_	I-Premise
198	with	_	_	I-Premise
199	preoperative	_	_	I-Premise
200	BMI	_	_	I-Premise
201	in	_	_	I-Premise
202	each	_	_	I-Premise
203	group	_	_	I-Premise
204	.	_	_	I-Premise

205	The	_	_	B-Premise
206	postoperative	_	_	I-Premise
207	QOL	_	_	I-Premise
208	and	_	_	I-Premise
209	complication	_	_	I-Premise
210	scores	_	_	I-Premise
211	at	_	_	I-Premise
212	60	_	_	I-Premise
213	months	_	_	I-Premise
214	after	_	_	I-Premise
215	surgery	_	_	I-Premise
216	were	_	_	I-Premise
217	significantly	_	_	I-Premise
218	better	_	_	I-Premise
219	than	_	_	I-Premise
220	those	_	_	I-Premise
221	at	_	_	I-Premise
222	3	_	_	I-Premise
223	months	_	_	I-Premise
224	after	_	_	I-Premise
225	surgery	_	_	I-Premise
226	in	_	_	I-Premise
227	each	_	_	I-Premise
228	group	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.01	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	O
236	,	_	_	O
237	there	_	_	B-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	significant	_	_	I-Premise
241	difference	_	_	I-Premise
242	of	_	_	I-Premise
243	QOL	_	_	I-Premise
244	scores	_	_	I-Premise
245	and	_	_	I-Premise
246	postoperative	_	_	I-Premise
247	complication	_	_	I-Premise
248	scores	_	_	I-Premise
249	between	_	_	I-Premise
250	the	_	_	I-Premise
251	2	_	_	I-Premise
252	reconstruction	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	nutritional	_	_	I-Premise
257	condition	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	INT	_	_	I-Premise
261	group	_	_	I-Premise
262	was	_	_	I-Premise
263	nearly	_	_	I-Premise
264	the	_	_	I-Premise
265	same	_	_	I-Premise
266	as	_	_	I-Premise
267	that	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	RY	_	_	I-Premise
271	group	_	_	I-Premise
272	.	_	_	I-Premise

273	Although	_	_	B-Premise
274	our	_	_	I-Premise
275	patient	_	_	I-Premise
276	sample	_	_	I-Premise
277	was	_	_	I-Premise
278	small	_	_	I-Premise
279	and	_	_	I-Premise
280	patients	_	_	I-Premise
281	who	_	_	I-Premise
282	did	_	_	I-Premise
283	not	_	_	I-Premise
284	complete	_	_	I-Premise
285	the	_	_	I-Premise
286	follow-up	_	_	I-Premise
287	survey	_	_	I-Premise
288	were	_	_	I-Premise
289	present	_	_	I-Premise
290	,	_	_	I-Premise
291	we	_	_	B-Claim
292	could	_	_	I-Claim
293	not	_	_	I-Claim
294	identify	_	_	I-Claim
295	any	_	_	I-Claim
296	clinical	_	_	I-Claim
297	difference	_	_	I-Claim
298	between	_	_	I-Claim
299	INT	_	_	I-Claim
300	and	_	_	I-Claim
301	RY	_	_	I-Claim
302	after	_	_	I-Claim
303	total	_	_	I-Claim
304	gastrectomy	_	_	I-Claim
305	60	_	_	I-Claim
306	months	_	_	I-Claim
307	after	_	_	I-Claim
308	surgery	_	_	I-Claim
309	.	_	_	I-Claim

310	The	_	_	B-Claim
311	safer	_	_	I-Claim
312	and	_	_	I-Claim
313	simpler	_	_	I-Claim
314	RY	_	_	I-Claim
315	method	_	_	I-Claim
316	may	_	_	I-Claim
317	be	_	_	I-Claim
318	a	_	_	I-Claim
319	more	_	_	I-Claim
320	suitable	_	_	I-Claim
321	reconstruction	_	_	I-Claim
322	method	_	_	I-Claim
323	than	_	_	I-Claim
324	INT	_	_	I-Claim
325	after	_	_	I-Claim
326	total	_	_	I-Claim
327	gastrectomy	_	_	I-Claim
328	.	_	_	I-Claim


0	Approximately	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	lung	_	_	O
5	cancer	_	_	O
6	cases	_	_	O
7	are	_	_	O
8	diagnosed	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	>	_	_	O
12	70	_	_	O
13	years	_	_	O
14	of	_	_	O
15	age	_	_	O
16	.	_	_	O

17	Standard	_	_	B-Claim
18	chemotherapy	_	_	I-Claim
19	regimens	_	_	I-Claim
20	are	_	_	I-Claim
21	generally	_	_	I-Claim
22	considered	_	_	I-Claim
23	too	_	_	I-Claim
24	toxic	_	_	I-Claim
25	for	_	_	I-Claim
26	elderly	_	_	I-Claim
27	patients	_	_	I-Claim
28	.	_	_	I-Claim

29	We	_	_	O
30	conducted	_	_	O
31	a	_	_	O
32	multicenter	_	_	O
33	phase	_	_	O
34	II	_	_	O
35	trial	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	efficacy	_	_	O
40	and	_	_	O
41	safety	_	_	O
42	of	_	_	O
43	carboplatin	_	_	O
44	combined	_	_	O
45	with	_	_	O
46	vinorelbine	_	_	O
47	every	_	_	O
48	4	_	_	O
49	weeks	_	_	O
50	as	_	_	O
51	first-line	_	_	O
52	treatment	_	_	O
53	for	_	_	O
54	advanced	_	_	O
55	non-small-cell	_	_	O
56	lung	_	_	O
57	cancer	_	_	O
58	(	_	_	O
59	NSCLC	_	_	O
60	)	_	_	O
61	in	_	_	O
62	elderly	_	_	O
63	patients	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	eligible	_	_	O
68	if	_	_	O
69	they	_	_	O
70	were	_	_	O
71	aged	_	_	O
72	>	_	_	O
73	OR=	_	_	O
74	70	_	_	O
75	years	_	_	O
76	,	_	_	O
77	had	_	_	O
78	stage	_	_	O
79	IIIB	_	_	O
80	(	_	_	O
81	with	_	_	O
82	pleural	_	_	O
83	effusion	_	_	O
84	)	_	_	O
85	or	_	_	O
86	stage	_	_	O
87	IV	_	_	O
88	NSCLC	_	_	O
89	,	_	_	O
90	had	_	_	O
91	a	_	_	O
92	performance	_	_	O
93	status	_	_	O
94	of	_	_	O
95	0/1	_	_	O
96	,	_	_	O
97	had	_	_	O
98	not	_	_	O
99	previously	_	_	O
100	received	_	_	O
101	chemotherapy	_	_	O
102	,	_	_	O
103	and	_	_	O
104	had	_	_	O
105	normal	_	_	O
106	organ	_	_	O
107	function	_	_	O
108	.	_	_	O

109	Forty	_	_	O
110	patients	_	_	O
111	(	_	_	O
112	31	_	_	O
113	men	_	_	O
114	and	_	_	O
115	9	_	_	O
116	women	_	_	O
117	)	_	_	O
118	were	_	_	O
119	enrolled	_	_	O
120	and	_	_	O
121	received	_	_	O
122	3-5	_	_	O
123	courses	_	_	O
124	of	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	Median	_	_	O
128	age	_	_	O
129	was	_	_	O
130	72	_	_	O
131	years	_	_	O
132	(	_	_	O
133	range	_	_	O
134	,	_	_	O
135	70-82	_	_	O
136	years	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Eighty	_	_	O
140	percent	_	_	O
141	of	_	_	O
142	patients	_	_	O
143	had	_	_	O
144	stage	_	_	O
145	IV	_	_	O
146	NSCLC	_	_	O
147	,	_	_	O
148	with	_	_	O
149	squamous	_	_	O
150	cell	_	_	O
151	(	_	_	O
152	n=21	_	_	O
153	)	_	_	O
154	,	_	_	O
155	adenocarcinoma	_	_	O
156	(	_	_	O
157	n=12	_	_	O
158	)	_	_	O
159	,	_	_	O
160	and	_	_	O
161	undifferentiated	_	_	O
162	(	_	_	O
163	n=7	_	_	O
164	)	_	_	O
165	histologies	_	_	O
166	.	_	_	O

167	Forty	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	assessable	_	_	O
171	for	_	_	O
172	toxicity	_	_	O
173	and	_	_	O
174	32	_	_	O
175	for	_	_	O
176	treatment	_	_	O
177	response	_	_	O
178	.	_	_	O

179	Among	_	_	B-Premise
180	these	_	_	I-Premise
181	32	_	_	I-Premise
182	patients	_	_	I-Premise
183	,	_	_	I-Premise
184	8	_	_	I-Premise
185	had	_	_	I-Premise
186	a	_	_	I-Premise
187	partial	_	_	I-Premise
188	response	_	_	I-Premise
189	(	_	_	I-Premise
190	intent-to-treat	_	_	I-Premise
191	response	_	_	I-Premise
192	rate	_	_	I-Premise
193	,	_	_	I-Premise
194	20	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	10	_	_	I-Premise
200	(	_	_	I-Premise
201	25	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	had	_	_	I-Premise
205	stable	_	_	I-Premise
206	disease	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	B-Premise
209	median	_	_	I-Premise
210	survival	_	_	I-Premise
211	was	_	_	I-Premise
212	7.8	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	range	_	_	I-Premise
216	,	_	_	I-Premise
217	4-11.6	_	_	I-Premise
218	months	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	1-	_	_	I-Premise
223	and	_	_	I-Premise
224	2-year	_	_	I-Premise
225	survival	_	_	I-Premise
226	rates	_	_	I-Premise
227	were	_	_	I-Premise
228	25	_	_	I-Premise
229	%	_	_	I-Premise
230	and	_	_	I-Premise
231	7	_	_	I-Premise
232	%	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	;	_	_	I-Premise
236	median	_	_	B-Premise
237	time	_	_	I-Premise
238	to	_	_	I-Premise
239	progression	_	_	I-Premise
240	was	_	_	I-Premise
241	4.3	_	_	I-Premise
242	months	_	_	I-Premise
243	(	_	_	I-Premise
244	range	_	_	I-Premise
245	,	_	_	I-Premise
246	0.2-13.8	_	_	I-Premise
247	months	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	Grade	_	_	B-Premise
251	3/4	_	_	I-Premise
252	neutropenia	_	_	I-Premise
253	was	_	_	I-Premise
254	seen	_	_	I-Premise
255	in	_	_	I-Premise
256	27	_	_	I-Premise
257	patients	_	_	I-Premise
258	(	_	_	I-Premise
259	68	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	grade	_	_	I-Premise
265	3/4	_	_	I-Premise
266	anemia	_	_	I-Premise
267	was	_	_	I-Premise
268	seen	_	_	I-Premise
269	in	_	_	I-Premise
270	5	_	_	I-Premise
271	patients	_	_	I-Premise
272	(	_	_	I-Premise
273	13	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	One	_	_	B-Premise
278	patient	_	_	I-Premise
279	died	_	_	I-Premise
280	of	_	_	I-Premise
281	febrile	_	_	I-Premise
282	neutropenia	_	_	I-Premise
283	during	_	_	I-Premise
284	treatment	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	main	_	_	I-Premise
288	nonhematologic	_	_	I-Premise
289	adverse	_	_	I-Premise
290	effect	_	_	I-Premise
291	was	_	_	I-Premise
292	fatigue	_	_	I-Premise
293	(	_	_	I-Premise
294	grade	_	_	I-Premise
295	3/4	_	_	I-Premise
296	in	_	_	I-Premise
297	18	_	_	I-Premise
298	%	_	_	I-Premise
299	of	_	_	I-Premise
300	patients	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Carboplatin/vinorelbine	_	_	B-Claim
304	is	_	_	I-Claim
305	well	_	_	I-Claim
306	tolerated	_	_	I-Claim
307	by	_	_	I-Claim
308	elderly	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	extensive-stage	_	_	I-Claim
312	NSCLC	_	_	I-Claim
313	.	_	_	I-Claim

314	Efficacy	_	_	B-Claim
315	is	_	_	I-Claim
316	low	_	_	I-Claim
317	but	_	_	I-Claim
318	similar	_	_	I-Claim
319	to	_	_	I-Claim
320	that	_	_	I-Claim
321	of	_	_	I-Claim
322	other	_	_	I-Claim
323	treatments	_	_	I-Claim
324	used	_	_	I-Claim
325	in	_	_	I-Claim
326	this	_	_	I-Claim
327	setting	_	_	I-Claim
328	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	pilot	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	examine	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	a	_	_	O
13	combined	_	_	O
14	cardiorespiratory	_	_	O
15	and	_	_	O
16	resistance	_	_	O
17	exercise	_	_	O
18	training	_	_	O
19	program	_	_	O
20	of	_	_	O
21	short	_	_	O
22	duration	_	_	O
23	on	_	_	O
24	the	_	_	O
25	cardiorespiratory	_	_	O
26	fitness	_	_	O
27	,	_	_	O
28	strength	_	_	O
29	endurance	_	_	O
30	,	_	_	O
31	task	_	_	O
32	specific	_	_	O
33	functional	_	_	O
34	muscle	_	_	O
35	capacity	_	_	O
36	,	_	_	O
37	body	_	_	O
38	composition	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	in	_	_	O
47	women	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	survivors	_	_	O
51	.	_	_	O

52	Sixteen	_	_	O
53	subjects	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	either	_	_	O
59	a	_	_	O
60	training	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	8	_	_	O
65	;	_	_	O
66	age	_	_	O
67	:	_	_	O
68	50	_	_	O
69	+/-	_	_	O
70	5	_	_	O
71	yrs	_	_	O
72	)	_	_	O
73	or	_	_	O
74	control	_	_	O
75	non-exercising	_	_	O
76	group	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	8	_	_	O
81	;	_	_	O
82	age	_	_	O
83	:	_	_	O
84	51	_	_	O
85	+/-	_	_	O
86	10	_	_	O
87	yrs	_	_	O
88	)	_	_	O
89	.	_	_	O

90	The	_	_	O
91	training	_	_	O
92	group	_	_	O
93	followed	_	_	O
94	an	_	_	O
95	8-week	_	_	O
96	exercise	_	_	O
97	program	_	_	O
98	consisting	_	_	O
99	of	_	_	O
100	3	_	_	O
101	weekly	_	_	O
102	sessions	_	_	O
103	of	_	_	O
104	90-min	_	_	O
105	duration	_	_	O
106	,	_	_	O
107	supervised	_	_	O
108	by	_	_	O
109	an	_	_	O
110	experienced	_	_	O
111	investigator	_	_	O
112	and	_	_	O
113	divided	_	_	O
114	into	_	_	O
115	resistance	_	_	O
116	exercises	_	_	O
117	and	_	_	O
118	aerobic	_	_	O
119	training	_	_	O
120	.	_	_	O

121	Before	_	_	O
122	and	_	_	O
123	after	_	_	O
124	the	_	_	O
125	intervention	_	_	O
126	period	_	_	O
127	,	_	_	O
128	all	_	_	O
129	of	_	_	O
130	the	_	_	O
131	subjects	_	_	O
132	performed	_	_	O
133	a	_	_	O
134	cardiorespiratory	_	_	O
135	test	_	_	O
136	to	_	_	O
137	measure	_	_	O
138	peak	_	_	O
139	oxygen	_	_	O
140	uptake	_	_	O
141	(	_	_	O
142	VO2peak	_	_	O
143	)	_	_	O
144	,	_	_	O
145	a	_	_	O
146	dynamic	_	_	O
147	strength	_	_	O
148	endurance	_	_	O
149	test	_	_	O
150	(	_	_	O
151	maximum	_	_	O
152	number	_	_	O
153	of	_	_	O
154	repetitions	_	_	O
155	for	_	_	O
156	chest	_	_	O
157	and	_	_	O
158	leg	_	_	O
159	press	_	_	O
160	exercise	_	_	O
161	at	_	_	O
162	30	_	_	O
163	-	_	_	O
164	35	_	_	O
165	%	_	_	O
166	and	_	_	O
167	100	_	_	O
168	-	_	_	O
169	110	_	_	O
170	%	_	_	O
171	of	_	_	O
172	body	_	_	O
173	mass	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	)	_	_	O
177	and	_	_	O
178	a	_	_	O
179	sit-stand	_	_	O
180	test	_	_	O
181	.	_	_	O

182	Quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	was	_	_	O
186	assessed	_	_	O
187	using	_	_	O
188	the	_	_	O
189	European	_	_	O
190	Organization	_	_	O
191	for	_	_	O
192	Research	_	_	O
193	and	_	_	O
194	Treatment	_	_	O
195	of	_	_	O
196	Cancer	_	_	O
197	QLQ-C30	_	_	O
198	(	_	_	O
199	EORTC-C30	_	_	O
200	)	_	_	O
201	questionnaire	_	_	O
202	.	_	_	O

203	In	_	_	B-Premise
204	response	_	_	I-Premise
205	to	_	_	I-Premise
206	training	_	_	I-Premise
207	,	_	_	I-Premise
208	QOL	_	_	I-Premise
209	,	_	_	I-Premise
210	VO2peak	_	_	I-Premise
211	(	_	_	I-Premise
212	mean	_	_	I-Premise
213	3.9	_	_	I-Premise
214	ml/kg/min	_	_	I-Premise
215	;	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	0.93	_	_	I-Premise
221	,	_	_	I-Premise
222	6.90	_	_	I-Premise
223	)	_	_	I-Premise
224	performance	_	_	I-Premise
225	in	_	_	I-Premise
226	leg	_	_	I-Premise
227	press	_	_	I-Premise
228	(	_	_	I-Premise
229	17.9	_	_	I-Premise
230	kg	_	_	I-Premise
231	;	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	12.8	_	_	I-Premise
237	,	_	_	I-Premise
238	22.4	_	_	I-Premise
239	)	_	_	I-Premise
240	and	_	_	I-Premise
241	sit-stand	_	_	I-Premise
242	test	_	_	I-Premise
243	(	_	_	I-Premise
244	-	_	_	I-Premise
245	0.67	_	_	I-Premise
246	s	_	_	I-Premise
247	;	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	-	_	_	I-Premise
253	0.52	_	_	I-Premise
254	,	_	_	I-Premise
255	-	_	_	I-Premise
256	1.2	_	_	I-Premise
257	)	_	_	I-Premise
258	improved	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	or	_	_	I-Premise
263	=	_	_	I-Premise
264	0.05	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	We	_	_	B-Premise
268	observed	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	changes	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	control	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Combined	_	_	B-Claim
278	cardiorespiratory	_	_	I-Claim
279	and	_	_	I-Claim
280	resistance	_	_	I-Claim
281	training	_	_	I-Claim
282	,	_	_	I-Claim
283	even	_	_	I-Claim
284	of	_	_	I-Claim
285	very	_	_	I-Claim
286	brief	_	_	I-Claim
287	duration	_	_	I-Claim
288	,	_	_	I-Claim
289	improves	_	_	I-Claim
290	the	_	_	I-Claim
291	QOL	_	_	I-Claim
292	and	_	_	I-Claim
293	the	_	_	I-Claim
294	overall	_	_	I-Claim
295	physical	_	_	I-Claim
296	fitness	_	_	I-Claim
297	of	_	_	I-Claim
298	women	_	_	I-Claim
299	breast	_	_	I-Claim
300	cancer	_	_	I-Claim
301	survivors	_	_	I-Claim
302	.	_	_	I-Claim


0	Phase	_	_	O
1	III	_	_	O
2	EGF104900	_	_	O
3	data	_	_	O
4	demonstrated	_	_	O
5	that	_	_	O
6	lapatinib	_	_	O
7	plus	_	_	O
8	trastuzumab	_	_	O
9	significantly	_	_	O
10	improved	_	_	O
11	progression-free	_	_	O
12	survival	_	_	O
13	(	_	_	O
14	PFS	_	_	O
15	)	_	_	O
16	and	_	_	O
17	clinical	_	_	O
18	benefit	_	_	O
19	rate	_	_	O
20	versus	_	_	O
21	lapatinib	_	_	O
22	monotherapy	_	_	O
23	,	_	_	O
24	offering	_	_	O
25	a	_	_	O
26	chemotherapy-free	_	_	O
27	option	_	_	O
28	for	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	heavily	_	_	O
32	pretreated	_	_	O
33	human	_	_	O
34	epidermal	_	_	O
35	growth	_	_	O
36	factor	_	_	O
37	receptor	_	_	O
38	2	_	_	O
39	(	_	_	O
40	HER2	_	_	O
41	)	_	_	O
42	-positive	_	_	O
43	metastatic	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	MBC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	Final	_	_	O
51	planned	_	_	O
52	overall	_	_	O
53	survival	_	_	O
54	(	_	_	O
55	OS	_	_	O
56	)	_	_	O
57	analysis	_	_	O
58	from	_	_	O
59	EGF104900	_	_	O
60	is	_	_	O
61	reported	_	_	O
62	here	_	_	O
63	.	_	_	O

64	Patients	_	_	O
65	with	_	_	O
66	HER2-positive	_	_	O
67	MBC	_	_	O
68	whose	_	_	O
69	disease	_	_	O
70	progressed	_	_	O
71	during	_	_	O
72	prior	_	_	O
73	trastuzumab-based	_	_	O
74	therapies	_	_	O
75	were	_	_	O
76	randomly	_	_	O
77	assigned	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	lapatinib	_	_	O
81	monotherapy	_	_	O
82	or	_	_	O
83	lapatinib	_	_	O
84	in	_	_	O
85	combination	_	_	O
86	with	_	_	O
87	trastuzumab	_	_	O
88	.	_	_	O

89	OS	_	_	O
90	and	_	_	O
91	updated	_	_	O
92	PFS	_	_	O
93	data	_	_	O
94	are	_	_	O
95	presented	_	_	O
96	using	_	_	O
97	Kaplan-Meier	_	_	O
98	curves	_	_	O
99	and	_	_	O
100	log-rank	_	_	O
101	tests	_	_	O
102	stratified	_	_	O
103	for	_	_	O
104	hormone	_	_	O
105	receptor	_	_	O
106	and	_	_	O
107	visceral	_	_	O
108	disease	_	_	O
109	status	_	_	O
110	.	_	_	O

111	Subgroup	_	_	O
112	analyses	_	_	O
113	were	_	_	O
114	conducted	_	_	O
115	to	_	_	O
116	identify	_	_	O
117	characteristics	_	_	O
118	of	_	_	O
119	patients	_	_	O
120	deriving	_	_	O
121	the	_	_	O
122	greatest	_	_	O
123	clinical	_	_	O
124	benefit	_	_	O
125	.	_	_	O

126	In	_	_	B-Premise
127	this	_	_	I-Premise
128	updated	_	_	I-Premise
129	final	_	_	I-Premise
130	analysis	_	_	I-Premise
131	of	_	_	I-Premise
132	all	_	_	I-Premise
133	patients	_	_	I-Premise
134	randomly	_	_	I-Premise
135	assigned	_	_	I-Premise
136	with	_	_	I-Premise
137	strata	_	_	I-Premise
138	(	_	_	I-Premise
139	n	_	_	I-Premise
140	=	_	_	I-Premise
141	291	_	_	I-Premise
142	)	_	_	I-Premise
143	,	_	_	I-Premise
144	lapatinib	_	_	I-Premise
145	plus	_	_	I-Premise
146	trastuzumab	_	_	I-Premise
147	continued	_	_	I-Premise
148	to	_	_	I-Premise
149	show	_	_	I-Premise
150	superiority	_	_	I-Premise
151	to	_	_	I-Premise
152	lapatinib	_	_	I-Premise
153	monotherapy	_	_	I-Premise
154	in	_	_	I-Premise
155	PFS	_	_	I-Premise
156	(	_	_	I-Premise
157	hazard	_	_	I-Premise
158	ratio	_	_	I-Premise
159	[	_	_	I-Premise
160	HR	_	_	I-Premise
161	]	_	_	I-Premise
162	,	_	_	I-Premise
163	0.74	_	_	I-Premise
164	;	_	_	I-Premise
165	95	_	_	I-Premise
166	%	_	_	I-Premise
167	CI	_	_	I-Premise
168	,	_	_	I-Premise
169	0.58	_	_	I-Premise
170	to	_	_	I-Premise
171	0.94	_	_	I-Premise
172	;	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.011	_	_	I-Premise
176	)	_	_	I-Premise
177	and	_	_	I-Premise
178	offered	_	_	I-Premise
179	significant	_	_	I-Premise
180	OS	_	_	I-Premise
181	benefit	_	_	I-Premise
182	(	_	_	I-Premise
183	HR	_	_	I-Premise
184	,	_	_	I-Premise
185	0.74	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	,	_	_	I-Premise
191	0.57	_	_	I-Premise
192	to	_	_	I-Premise
193	0.97	_	_	I-Premise
194	;	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.026	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Improvements	_	_	B-Premise
201	in	_	_	I-Premise
202	absolute	_	_	I-Premise
203	OS	_	_	I-Premise
204	rates	_	_	I-Premise
205	were	_	_	I-Premise
206	10	_	_	I-Premise
207	%	_	_	I-Premise
208	at	_	_	I-Premise
209	6	_	_	I-Premise
210	months	_	_	I-Premise
211	and	_	_	I-Premise
212	15	_	_	I-Premise
213	%	_	_	I-Premise
214	at	_	_	I-Premise
215	12	_	_	I-Premise
216	months	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	combination	_	_	I-Premise
220	arm	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	the	_	_	I-Premise
224	monotherapy	_	_	I-Premise
225	arm	_	_	I-Premise
226	.	_	_	I-Premise

227	Multiple	_	_	B-Premise
228	baseline	_	_	I-Premise
229	factors	_	_	I-Premise
230	,	_	_	I-Premise
231	including	_	_	I-Premise
232	Eastern	_	_	I-Premise
233	Cooperative	_	_	I-Premise
234	Oncology	_	_	I-Premise
235	Group	_	_	I-Premise
236	performance	_	_	I-Premise
237	status	_	_	I-Premise
238	of	_	_	I-Premise
239	0	_	_	I-Premise
240	,	_	_	I-Premise
241	nonvisceral	_	_	I-Premise
242	disease	_	_	I-Premise
243	,	_	_	I-Premise
244	<	_	_	I-Premise
245	three	_	_	I-Premise
246	metastatic	_	_	I-Premise
247	sites	_	_	I-Premise
248	,	_	_	I-Premise
249	and	_	_	I-Premise
250	less	_	_	I-Premise
251	time	_	_	I-Premise
252	from	_	_	I-Premise
253	initial	_	_	I-Premise
254	diagnosis	_	_	I-Premise
255	until	_	_	I-Premise
256	random	_	_	I-Premise
257	assignment	_	_	I-Premise
258	,	_	_	I-Premise
259	were	_	_	I-Premise
260	associated	_	_	I-Premise
261	with	_	_	I-Premise
262	improved	_	_	I-Premise
263	OS	_	_	I-Premise
264	.	_	_	I-Premise

265	Incidence	_	_	B-Premise
266	of	_	_	I-Premise
267	adverse	_	_	I-Premise
268	events	_	_	I-Premise
269	was	_	_	I-Premise
270	consistent	_	_	I-Premise
271	with	_	_	I-Premise
272	previously	_	_	I-Premise
273	reported	_	_	I-Premise
274	rates	_	_	I-Premise
275	.	_	_	I-Premise

276	These	_	_	B-Claim
277	data	_	_	I-Claim
278	demonstrated	_	_	I-Claim
279	a	_	_	I-Claim
280	significant	_	_	I-Claim
281	4.5-month	_	_	I-Claim
282	median	_	_	I-Claim
283	OS	_	_	I-Claim
284	advantage	_	_	I-Claim
285	with	_	_	I-Claim
286	the	_	_	I-Claim
287	lapatinib	_	_	I-Claim
288	and	_	_	I-Claim
289	trastuzumab	_	_	I-Claim
290	combination	_	_	I-Claim
291	and	_	_	I-Claim
292	support	_	_	I-Claim
293	dual	_	_	I-Claim
294	HER2	_	_	I-Claim
295	blockade	_	_	I-Claim
296	in	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	heavily	_	_	I-Claim
300	pretreated	_	_	I-Claim
301	HER2-positive	_	_	I-Claim
302	MBC	_	_	I-Claim
303	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	present	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	and	_	_	O
19	survival	_	_	O
20	of	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	non-small	_	_	O
25	cell	_	_	O
26	lung	_	_	O
27	cancer	_	_	O
28	(	_	_	O
29	NSCLC	_	_	O
30	)	_	_	O
31	(	_	_	O
32	stage	_	_	O
33	IIIB	_	_	O
34	or	_	_	O
35	IV	_	_	O
36	)	_	_	O
37	.	_	_	O

38	In	_	_	O
39	a	_	_	O
40	controlled	_	_	O
41	multicentre	_	_	O
42	trial	_	_	O
43	,	_	_	O
44	patients	_	_	O
45	were	_	_	O
46	randomised	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	supportive	_	_	O
50	care	_	_	O
51	only	_	_	O
52	or	_	_	O
53	supportive	_	_	O
54	care	_	_	O
55	plus	_	_	O
56	chemotherapy	_	_	O
57	.	_	_	O

58	Chemotherapy	_	_	O
59	consisted	_	_	O
60	of	_	_	O
61	intravenous	_	_	O
62	(	_	_	O
63	i.v	_	_	O
64	.	_	_	O
65	)	_	_	O

66	carboplatin	_	_	O
67	300	_	_	O
68	mg/m2	_	_	O
69	on	_	_	O
70	day	_	_	O
71	1	_	_	O
72	and	_	_	O
73	etoposide	_	_	O
74	120	_	_	O
75	mg/m2	_	_	O
76	orally	_	_	O
77	on	_	_	O
78	days	_	_	O
79	1-5	_	_	O
80	every	_	_	O
81	4	_	_	O
82	weeks	_	_	O
83	for	_	_	O
84	a	_	_	O
85	maximum	_	_	O
86	of	_	_	O
87	eight	_	_	O
88	courses	_	_	O
89	.	_	_	O

90	Quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	was	_	_	O
94	measured	_	_	O
95	at	_	_	O
96	randomisation	_	_	O
97	and	_	_	O
98	prior	_	_	O
99	to	_	_	O
100	each	_	_	O
101	treatment	_	_	O
102	course	_	_	O
103	and	_	_	O
104	at	_	_	O
105	corresponding	_	_	O
106	4-week	_	_	O
107	intervals	_	_	O
108	in	_	_	O
109	the	_	_	O
110	control	_	_	O
111	arm	_	_	O
112	,	_	_	O
113	using	_	_	O
114	the	_	_	O
115	EORTC	_	_	O
116	QLQ-C30	_	_	O
117	+	_	_	O
118	LC13	_	_	O
119	questionnaire	_	_	O
120	.	_	_	O

121	48	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	randomised	_	_	O
125	(	_	_	O
126	supportive	_	_	O
127	care	_	_	O
128	26	_	_	O
129	,	_	_	O
130	chemotherapy	_	_	O
131	22	_	_	O
132	)	_	_	O
133	,	_	_	O
134	being	_	_	O
135	eligible	_	_	O
136	for	_	_	O
137	comparative	_	_	O
138	analyses	_	_	O
139	.	_	_	O

140	Another	_	_	O
141	102	_	_	O
142	patients	_	_	O
143	,	_	_	O
144	97	_	_	O
145	of	_	_	O
146	which	_	_	O
147	received	_	_	O
148	chemotherapy	_	_	O
149	,	_	_	O
150	were	_	_	O
151	subsequently	_	_	O
152	included	_	_	O
153	in	_	_	O
154	the	_	_	O
155	study	_	_	O
156	on	_	_	O
157	an	_	_	O
158	individual	_	_	O
159	treatment	_	_	O
160	preference	_	_	O
161	basis	_	_	O
162	.	_	_	O

163	Data	_	_	O
164	from	_	_	O
165	these	_	_	O
166	patients	_	_	O
167	were	_	_	O
168	used	_	_	O
169	for	_	_	O
170	confirmative	_	_	O
171	purposes	_	_	O
172	.	_	_	O

173	Patients	_	_	B-Premise
174	in	_	_	I-Premise
175	the	_	_	I-Premise
176	chemotherapy	_	_	I-Premise
177	group	_	_	I-Premise
178	reported	_	_	I-Premise
179	better	_	_	I-Premise
180	overall	_	_	I-Premise
181	physical	_	_	I-Premise
182	functioning	_	_	I-Premise
183	and	_	_	I-Premise
184	symptom	_	_	I-Premise
185	control	_	_	I-Premise
186	compared	_	_	I-Premise
187	with	_	_	I-Premise
188	the	_	_	I-Premise
189	supportive	_	_	I-Premise
190	care	_	_	I-Premise
191	group	_	_	I-Premise
192	.	_	_	I-Premise

193	Group	_	_	B-Premise
194	differences	_	_	I-Premise
195	were	_	_	I-Premise
196	smaller	_	_	I-Premise
197	within	_	_	I-Premise
198	the	_	_	I-Premise
199	psychosocial	_	_	I-Premise
200	domain	_	_	I-Premise
201	,	_	_	I-Premise
202	although	_	_	B-Premise
203	trends	_	_	I-Premise
204	were	_	_	I-Premise
205	seen	_	_	I-Premise
206	in	_	_	I-Premise
207	favour	_	_	I-Premise
208	of	_	_	I-Premise
209	the	_	_	I-Premise
210	chemotherapy	_	_	I-Premise
211	group	_	_	I-Premise
212	.	_	_	I-Premise

213	No	_	_	B-Premise
214	significant	_	_	I-Premise
215	differences	_	_	I-Premise
216	were	_	_	I-Premise
217	seen	_	_	I-Premise
218	in	_	_	I-Premise
219	favour	_	_	I-Premise
220	of	_	_	I-Premise
221	the	_	_	I-Premise
222	supportive	_	_	I-Premise
223	care	_	_	I-Premise
224	group	_	_	I-Premise
225	,	_	_	I-Premise
226	except	_	_	B-Premise
227	for	_	_	I-Premise
228	hair	_	_	I-Premise
229	loss	_	_	I-Premise
230	.	_	_	I-Premise

231	Median	_	_	B-Premise
232	survival	_	_	I-Premise
233	times	_	_	I-Premise
234	were	_	_	I-Premise
235	29	_	_	I-Premise
236	weeks	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	chemotherapy	_	_	I-Premise
240	group	_	_	I-Premise
241	versus	_	_	I-Premise
242	11	_	_	I-Premise
243	weeks	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	supportive	_	_	I-Premise
247	care	_	_	I-Premise
248	group	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	1-year	_	_	I-Premise
252	survival	_	_	I-Premise
253	rates	_	_	I-Premise
254	were	_	_	I-Premise
255	28	_	_	I-Premise
256	%	_	_	I-Premise
257	versus	_	_	I-Premise
258	8	_	_	I-Premise
259	%	_	_	I-Premise
260	.	_	_	I-Premise

261	Quality	_	_	B-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	and	_	_	I-Premise
265	survival	_	_	I-Premise
266	outcomes	_	_	I-Premise
267	were	_	_	I-Premise
268	similar	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	randomised	_	_	I-Premise
272	and	_	_	I-Premise
273	non-randomised	_	_	I-Premise
274	patients	_	_	I-Premise
275	receiving	_	_	I-Premise
276	chemotherapy	_	_	I-Premise
277	.	_	_	I-Premise

278	No	_	_	B-Premise
279	treatment-related	_	_	I-Premise
280	deaths	_	_	I-Premise
281	occurred	_	_	I-Premise
282	.	_	_	I-Premise

283	In	_	_	B-Claim
284	conclusion	_	_	I-Claim
285	,	_	_	I-Claim
286	treatment	_	_	I-Claim
287	with	_	_	I-Claim
288	carboplatin	_	_	I-Claim
289	and	_	_	I-Claim
290	etoposide	_	_	I-Claim
291	can	_	_	I-Claim
292	improve	_	_	I-Claim
293	both	_	_	I-Claim
294	the	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	and	_	_	I-Claim
299	the	_	_	I-Claim
300	survival	_	_	I-Claim
301	of	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	advanced	_	_	I-Claim
305	NSCLC	_	_	I-Claim
306	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	prophylactic	_	_	O
6	swallowing	_	_	O
7	exercises	_	_	O
8	on	_	_	O
9	swallowing	_	_	O
10	function	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	chemoradiation	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	CRT	_	_	O
18	)	_	_	O
19	for	_	_	O
20	head	_	_	O
21	and	_	_	O
22	neck	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	controlled	_	_	O
27	trial	_	_	O
28	.	_	_	O

29	Tertiary	_	_	O
30	care	_	_	O
31	,	_	_	O
32	academic	_	_	O
33	medical	_	_	O
34	center	_	_	O
35	.	_	_	O

36	Twenty-six	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	head	_	_	O
40	and	_	_	O
41	neck	_	_	O
42	cancer	_	_	O
43	receiving	_	_	O
44	CRT	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	performed	_	_	O
48	5	_	_	O
49	targeted	_	_	O
50	swallowing	_	_	O
51	exercises	_	_	O
52	throughout	_	_	O
53	their	_	_	O
54	CRT	_	_	O
55	and	_	_	O
56	participated	_	_	O
57	in	_	_	O
58	weekly	_	_	O
59	swallowing	_	_	O
60	therapy	_	_	O
61	sessions	_	_	O
62	to	_	_	O
63	promote	_	_	O
64	adherence	_	_	O
65	and	_	_	O
66	accurate	_	_	O
67	technique	_	_	O
68	.	_	_	O

69	Controls	_	_	O
70	had	_	_	O
71	no	_	_	O
72	prophylactic	_	_	O
73	exercises	_	_	O
74	and	_	_	O
75	were	_	_	O
76	referred	_	_	O
77	for	_	_	O
78	swallowing	_	_	O
79	treatment	_	_	O
80	after	_	_	O
81	completion	_	_	O
82	of	_	_	O
83	CRT	_	_	O
84	if	_	_	O
85	indicated	_	_	O
86	.	_	_	O

87	Swallowing	_	_	O
88	function	_	_	O
89	was	_	_	O
90	assessed	_	_	O
91	with	_	_	O
92	the	_	_	O
93	Functional	_	_	O
94	Oral	_	_	O
95	Intake	_	_	O
96	Scale	_	_	O
97	(	_	_	O
98	FOIS	_	_	O
99	)	_	_	O
100	and	_	_	O
101	the	_	_	O
102	Performance	_	_	O
103	Status	_	_	O
104	Scale	_	_	O
105	for	_	_	O
106	Head	_	_	O
107	and	_	_	O
108	Neck	_	_	O
109	Cancer	_	_	O
110	Patients	_	_	O
111	(	_	_	O
112	PSS-H	_	_	O
113	&	_	_	O
114	N	_	_	O
115	)	_	_	O
116	at	_	_	O
117	baseline	_	_	O
118	,	_	_	O
119	immediately	_	_	O
120	after	_	_	O
121	CRT	_	_	O
122	,	_	_	O
123	and	_	_	O
124	at	_	_	O
125	3	_	_	O
126	,	_	_	O
127	6	_	_	O
128	,	_	_	O
129	9	_	_	O
130	,	_	_	O
131	and	_	_	O
132	12	_	_	O
133	months	_	_	O
134	after	_	_	O
135	CRT	_	_	O
136	.	_	_	O

137	There	_	_	B-Premise
138	were	_	_	I-Premise
139	no	_	_	I-Premise
140	statistically	_	_	I-Premise
141	significant	_	_	I-Premise
142	differences	_	_	I-Premise
143	in	_	_	I-Premise
144	FOIS	_	_	I-Premise
145	scores	_	_	I-Premise
146	between	_	_	I-Premise
147	intervention	_	_	I-Premise
148	and	_	_	I-Premise
149	control	_	_	I-Premise
150	patients	_	_	I-Premise
151	immediately	_	_	I-Premise
152	after	_	_	I-Premise
153	CRT	_	_	I-Premise
154	(	_	_	I-Premise
155	immediately	_	_	I-Premise
156	after	_	_	I-Premise
157	CRT	_	_	I-Premise
158	:	_	_	I-Premise
159	intervention	_	_	I-Premise
160	group	_	_	I-Premise
161	median	_	_	I-Premise
162	score	_	_	I-Premise
163	,	_	_	I-Premise
164	3	_	_	I-Premise
165	[	_	_	I-Premise
166	range	_	_	I-Premise
167	,	_	_	I-Premise
168	1-7	_	_	I-Premise
169	]	_	_	I-Premise
170	,	_	_	I-Premise
171	vs	_	_	I-Premise
172	median	_	_	I-Premise
173	control	_	_	I-Premise
174	score	_	_	I-Premise
175	,	_	_	I-Premise
176	4	_	_	I-Premise
177	[	_	_	I-Premise
178	range	_	_	I-Premise
179	,	_	_	I-Premise
180	1-6	_	_	I-Premise
181	]	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	.88	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	However	_	_	O
189	,	_	_	O
190	intervention	_	_	B-Premise
191	patients	_	_	I-Premise
192	had	_	_	I-Premise
193	significantly	_	_	I-Premise
194	better	_	_	I-Premise
195	scores	_	_	I-Premise
196	at	_	_	I-Premise
197	months	_	_	I-Premise
198	3	_	_	I-Premise
199	and	_	_	I-Premise
200	6	_	_	I-Premise
201	(	_	_	I-Premise
202	median	_	_	I-Premise
203	3-month	_	_	I-Premise
204	intervention	_	_	I-Premise
205	score	_	_	I-Premise
206	,	_	_	I-Premise
207	7	_	_	I-Premise
208	[	_	_	I-Premise
209	range	_	_	I-Premise
210	,	_	_	I-Premise
211	5-7	_	_	I-Premise
212	]	_	_	I-Premise
213	,	_	_	I-Premise
214	vs	_	_	I-Premise
215	median	_	_	I-Premise
216	control	_	_	I-Premise
217	score	_	_	I-Premise
218	,	_	_	I-Premise
219	5	_	_	I-Premise
220	[	_	_	I-Premise
221	range	_	_	I-Premise
222	,	_	_	I-Premise
223	3-7	_	_	I-Premise
224	]	_	_	I-Premise
225	[	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.03	_	_	I-Premise
229	]	_	_	I-Premise
230	;	_	_	I-Premise
231	median	_	_	I-Premise
232	6-month	_	_	I-Premise
233	intervention	_	_	I-Premise
234	score	_	_	I-Premise
235	,	_	_	I-Premise
236	7	_	_	I-Premise
237	[	_	_	I-Premise
238	range	_	_	I-Premise
239	,	_	_	I-Premise
240	6-7	_	_	I-Premise
241	]	_	_	I-Premise
242	,	_	_	I-Premise
243	vs	_	_	I-Premise
244	median	_	_	I-Premise
245	control	_	_	I-Premise
246	score	_	_	I-Premise
247	,	_	_	I-Premise
248	6	_	_	I-Premise
249	[	_	_	I-Premise
250	range	_	_	I-Premise
251	,	_	_	I-Premise
252	3-7	_	_	I-Premise
253	]	_	_	I-Premise
254	[	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.009	_	_	I-Premise
258	]	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	There	_	_	B-Premise
262	was	_	_	I-Premise
263	no	_	_	I-Premise
264	significant	_	_	I-Premise
265	difference	_	_	I-Premise
266	in	_	_	I-Premise
267	scores	_	_	I-Premise
268	at	_	_	I-Premise
269	months	_	_	I-Premise
270	9	_	_	I-Premise
271	and	_	_	I-Premise
272	12	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.24	_	_	I-Premise
277	and	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.93	_	_	I-Premise
281	,	_	_	I-Premise
282	respectively	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	The	_	_	B-Premise
286	same	_	_	I-Premise
287	pattern	_	_	I-Premise
288	between	_	_	I-Premise
289	intervention	_	_	I-Premise
290	and	_	_	I-Premise
291	control	_	_	I-Premise
292	patients	_	_	I-Premise
293	was	_	_	I-Premise
294	observed	_	_	I-Premise
295	for	_	_	I-Premise
296	scores	_	_	I-Premise
297	on	_	_	I-Premise
298	the	_	_	I-Premise
299	PSS-H	_	_	I-Premise
300	&	_	_	I-Premise
301	N	_	_	I-Premise
302	.	_	_	I-Premise

303	Patients	_	_	B-Claim
304	who	_	_	I-Claim
305	performed	_	_	I-Claim
306	prophylactic	_	_	I-Claim
307	swallowing	_	_	I-Claim
308	exercises	_	_	I-Claim
309	had	_	_	I-Claim
310	improved	_	_	I-Claim
311	swallowing	_	_	I-Claim
312	function	_	_	I-Claim
313	at	_	_	I-Claim
314	3	_	_	I-Claim
315	and	_	_	I-Claim
316	6	_	_	I-Claim
317	months	_	_	I-Claim
318	after	_	_	I-Claim
319	CRT	_	_	I-Claim
320	but	_	_	I-Claim
321	not	_	_	I-Claim
322	immediately	_	_	I-Claim
323	after	_	_	I-Claim
324	CRT	_	_	I-Claim
325	or	_	_	I-Claim
326	at	_	_	I-Claim
327	9	_	_	I-Claim
328	and	_	_	I-Claim
329	12	_	_	I-Claim
330	months	_	_	I-Claim
331	after	_	_	I-Claim
332	CRT	_	_	I-Claim
333	.	_	_	I-Claim

334	The	_	_	B-Claim
335	small	_	_	I-Claim
336	sample	_	_	I-Claim
337	size	_	_	I-Claim
338	may	_	_	I-Claim
339	have	_	_	I-Claim
340	limited	_	_	I-Claim
341	our	_	_	I-Claim
342	ability	_	_	I-Claim
343	to	_	_	I-Claim
344	detect	_	_	I-Claim
345	significant	_	_	I-Claim
346	differences	_	_	I-Claim
347	beyond	_	_	I-Claim
348	6	_	_	I-Claim
349	months	_	_	I-Claim
350	of	_	_	I-Claim
351	observation	_	_	I-Claim
352	as	_	_	I-Claim
353	well	_	_	I-Claim
354	as	_	_	I-Claim
355	additional	_	_	I-Claim
356	significant	_	_	I-Claim
357	differences	_	_	I-Claim
358	in	_	_	I-Claim
359	our	_	_	I-Claim
360	study	_	_	I-Claim
361	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	HRQOL	_	_	O
9	)	_	_	O
10	outcomes	_	_	O
11	for	_	_	O
12	uterine	_	_	O
13	artery	_	_	O
14	embolization	_	_	O
15	(	_	_	O
16	UAE	_	_	O
17	)	_	_	O
18	and	_	_	O
19	hysterectomy	_	_	O
20	up	_	_	O
21	to	_	_	O
22	24	_	_	O
23	months	_	_	O
24	after	_	_	O
25	the	_	_	O
26	intervention	_	_	O
27	in	_	_	O
28	terms	_	_	O
29	of	_	_	O
30	mental	_	_	O
31	and	_	_	O
32	physical	_	_	O
33	health	_	_	O
34	,	_	_	O
35	urinary	_	_	O
36	and	_	_	O
37	defecatory	_	_	O
38	function	_	_	O
39	,	_	_	O
40	and	_	_	O
41	overall	_	_	O
42	patient	_	_	O
43	satisfaction	_	_	O
44	.	_	_	O

45	Ethics	_	_	O
46	committee	_	_	O
47	approval	_	_	O
48	and	_	_	O
49	informed	_	_	O
50	consent	_	_	O
51	were	_	_	O
52	obtained	_	_	O
53	for	_	_	O
54	the	_	_	O
55	Embolisation	_	_	O
56	versus	_	_	O
57	Hysterectomy	_	_	O
58	Trial	_	_	O
59	.	_	_	O

60	Women	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	177	_	_	O
65	)	_	_	O
66	with	_	_	O
67	uterine	_	_	O
68	fibroids	_	_	O
69	and	_	_	O
70	heavy	_	_	O
71	menstrual	_	_	O
72	bleeding	_	_	O
73	who	_	_	O
74	were	_	_	O
75	scheduled	_	_	O
76	to	_	_	O
77	undergo	_	_	O
78	hysterectomy	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	undergo	_	_	O
84	UAE	_	_	O
85	(	_	_	O
86	n	_	_	O
87	=	_	_	O
88	88	_	_	O
89	)	_	_	O
90	or	_	_	O
91	hysterectomy	_	_	O
92	(	_	_	O
93	n	_	_	O
94	=	_	_	O
95	89	_	_	O
96	)	_	_	O
97	.	_	_	O

98	HRQOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	six	_	_	O
102	times	_	_	O
103	during	_	_	O
104	a	_	_	O
105	24-month	_	_	O
106	follow-up	_	_	O
107	period	_	_	O
108	with	_	_	O
109	the	_	_	O
110	following	_	_	O
111	validated	_	_	O
112	questionnaires	_	_	O
113	:	_	_	O
114	Medical	_	_	O
115	Outcome	_	_	O
116	Study	_	_	O
117	Short	_	_	O
118	Form	_	_	O
119	36	_	_	O
120	(	_	_	O
121	SF-36	_	_	O
122	)	_	_	O
123	mental	_	_	O
124	component	_	_	O
125	summary	_	_	O
126	(	_	_	O
127	MCS	_	_	O
128	)	_	_	O
129	and	_	_	O
130	physical	_	_	O
131	component	_	_	O
132	summary	_	_	O
133	(	_	_	O
134	PCS	_	_	O
135	)	_	_	O
136	,	_	_	O
137	Health	_	_	O
138	Utilities	_	_	O
139	Index	_	_	O
140	Mark	_	_	O
141	3	_	_	O
142	,	_	_	O
143	EuroQol	_	_	O
144	5D	_	_	O
145	,	_	_	O
146	urogenital	_	_	O
147	distress	_	_	O
148	inventory	_	_	O
149	(	_	_	O
150	UDI	_	_	O
151	)	_	_	O
152	,	_	_	O
153	incontinence	_	_	O
154	impact	_	_	O
155	questionnaire	_	_	O
156	,	_	_	O
157	and	_	_	O
158	defecation	_	_	O
159	distress	_	_	O
160	inventory	_	_	O
161	(	_	_	O
162	DDI	_	_	O
163	)	_	_	O
164	.	_	_	O

165	Satisfaction	_	_	O
166	was	_	_	O
167	assessed	_	_	O
168	with	_	_	O
169	a	_	_	O
170	seven-point	_	_	O
171	Likert	_	_	O
172	scale	_	_	O
173	.	_	_	O

174	Repeated	_	_	O
175	measurement	_	_	O
176	analysis	_	_	O
177	was	_	_	O
178	performed	_	_	O
179	for	_	_	O
180	between-group	_	_	O
181	analysis	_	_	O
182	.	_	_	O

183	Paired	_	_	O
184	t	_	_	O
185	tests	_	_	O
186	were	_	_	O
187	performed	_	_	O
188	for	_	_	O
189	within-group	_	_	O
190	analysis	_	_	O
191	.	_	_	O

192	Satisfaction	_	_	O
193	was	_	_	O
194	analyzed	_	_	O
195	with	_	_	O
196	the	_	_	O
197	Fisher	_	_	O
198	exact	_	_	O
199	test	_	_	O
200	.	_	_	O

201	The	_	_	B-Premise
202	SF-36	_	_	I-Premise
203	MCS	_	_	I-Premise
204	and	_	_	I-Premise
205	PCS	_	_	I-Premise
206	,	_	_	I-Premise
207	Health	_	_	I-Premise
208	Utilities	_	_	I-Premise
209	Index	_	_	I-Premise
210	Mark	_	_	I-Premise
211	3	_	_	I-Premise
212	,	_	_	I-Premise
213	EuroQol	_	_	I-Premise
214	5D	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	UDI	_	_	I-Premise
218	scores	_	_	I-Premise
219	were	_	_	I-Premise
220	improved	_	_	I-Premise
221	significantly	_	_	I-Premise
222	in	_	_	I-Premise
223	both	_	_	I-Premise
224	groups	_	_	I-Premise
225	at	_	_	I-Premise
226	6	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	afterward	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	.05	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	O
237	DDI	_	_	O
238	score	_	_	O
239	was	_	_	O
240	improved	_	_	O
241	significantly	_	_	O
242	in	_	_	O
243	only	_	_	O
244	the	_	_	O
245	UAE	_	_	O
246	group	_	_	O
247	at	_	_	O
248	6	_	_	O
249	months	_	_	O
250	and	_	_	O
251	afterward	_	_	O
252	(	_	_	O
253	P	_	_	O
254	<	_	_	O
255	.05	_	_	O
256	)	_	_	O
257	.	_	_	O

258	No	_	_	O
259	differences	_	_	O
260	between	_	_	O
261	groups	_	_	O
262	were	_	_	O
263	observed	_	_	O
264	,	_	_	O
265	with	_	_	O
266	the	_	_	O
267	exception	_	_	O
268	of	_	_	O
269	PCS	_	_	O
270	scores	_	_	O
271	at	_	_	O
272	6-week	_	_	O
273	follow-up	_	_	O
274	:	_	_	O
275	Patients	_	_	O
276	in	_	_	O
277	the	_	_	O
278	UAE	_	_	O
279	group	_	_	O
280	had	_	_	O
281	significantly	_	_	O
282	better	_	_	O
283	scores	_	_	O
284	than	_	_	O
285	did	_	_	O
286	patients	_	_	O
287	in	_	_	O
288	the	_	_	O
289	hysterectomy	_	_	O
290	group	_	_	O
291	(	_	_	O
292	P	_	_	O
293	<	_	_	O
294	.001	_	_	O
295	)	_	_	O
296	.	_	_	O

297	Improvement	_	_	O
298	in	_	_	O
299	PCS	_	_	O
300	score	_	_	O
301	at	_	_	O
302	24-month	_	_	O
303	follow-up	_	_	O
304	was	_	_	O
305	significantly	_	_	O
306	higher	_	_	O
307	for	_	_	O
308	patients	_	_	O
309	who	_	_	O
310	were	_	_	O
311	employed	_	_	O
312	at	_	_	O
313	baseline	_	_	O
314	(	_	_	O
315	P	_	_	O
316	=	_	_	O
317	.035	_	_	O
318	)	_	_	O
319	.	_	_	O

320	At	_	_	B-Premise
321	24-month	_	_	I-Premise
322	follow-up	_	_	I-Premise
323	,	_	_	I-Premise
324	patients	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	hysterectomy	_	_	I-Premise
328	group	_	_	I-Premise
329	were	_	_	I-Premise
330	significantly	_	_	I-Premise
331	more	_	_	I-Premise
332	satisfied	_	_	I-Premise
333	than	_	_	I-Premise
334	those	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	UAE	_	_	I-Premise
338	group	_	_	I-Premise
339	(	_	_	I-Premise
340	P	_	_	I-Premise
341	=	_	_	I-Premise
342	.02	_	_	I-Premise
343	)	_	_	I-Premise
344	.	_	_	I-Premise

345	Both	_	_	B-Claim
346	UAE	_	_	I-Claim
347	and	_	_	I-Claim
348	hysterectomy	_	_	I-Claim
349	improved	_	_	I-Claim
350	HRQOL	_	_	I-Claim
351	.	_	_	I-Claim

352	No	_	_	B-Claim
353	differences	_	_	I-Claim
354	were	_	_	I-Claim
355	observed	_	_	I-Claim
356	between	_	_	I-Claim
357	groups	_	_	I-Claim
358	regarding	_	_	I-Claim
359	HRQOL	_	_	I-Claim
360	at	_	_	I-Claim
361	24-month	_	_	I-Claim
362	follow-up	_	_	I-Claim
363	.	_	_	I-Claim

364	On	_	_	B-Claim
365	the	_	_	I-Claim
366	basis	_	_	I-Claim
367	of	_	_	I-Claim
368	HRQOL	_	_	I-Claim
369	results	_	_	I-Claim
370	,	_	_	I-Claim
371	the	_	_	I-Claim
372	authors	_	_	I-Claim
373	determined	_	_	I-Claim
374	that	_	_	I-Claim
375	UAE	_	_	I-Claim
376	is	_	_	I-Claim
377	a	_	_	I-Claim
378	good	_	_	I-Claim
379	alternative	_	_	I-Claim
380	to	_	_	I-Claim
381	hysterectomy	_	_	I-Claim
382	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	no	_	_	O
3	known	_	_	O
4	effective	_	_	O
5	treatments	_	_	O
6	for	_	_	O
7	painful	_	_	O
8	chemotherapy-induced	_	_	O
9	peripheral	_	_	O
10	neuropathy	_	_	O
11	.	_	_	O

12	To	_	_	O
13	determine	_	_	O
14	the	_	_	O
15	effect	_	_	O
16	of	_	_	O
17	duloxetine	_	_	O
18	,	_	_	O
19	60	_	_	O
20	mg	_	_	O
21	daily	_	_	O
22	,	_	_	O
23	on	_	_	O
24	average	_	_	O
25	pain	_	_	O
26	severity	_	_	O
27	.	_	_	O

28	Randomized	_	_	O
29	,	_	_	O
30	double-blind	_	_	O
31	,	_	_	O
32	placebo-controlled	_	_	O
33	crossover	_	_	O
34	trial	_	_	O
35	at	_	_	O
36	8	_	_	O
37	National	_	_	O
38	Cancer	_	_	O
39	Institute	_	_	O
40	(	_	_	O
41	NCI	_	_	O
42	)	_	_	O
43	-funded	_	_	O
44	cooperative	_	_	O
45	research	_	_	O
46	networks	_	_	O
47	that	_	_	O
48	enrolled	_	_	O
49	231	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	were	_	_	O
53	25	_	_	O
54	years	_	_	O
55	or	_	_	O
56	older	_	_	O
57	being	_	_	O
58	treated	_	_	O
59	at	_	_	O
60	community	_	_	O
61	and	_	_	O
62	academic	_	_	O
63	settings	_	_	O
64	between	_	_	O
65	April	_	_	O
66	2008	_	_	O
67	and	_	_	O
68	March	_	_	O
69	2011	_	_	O
70	.	_	_	O

71	Study	_	_	O
72	follow-up	_	_	O
73	was	_	_	O
74	completed	_	_	O
75	July	_	_	O
76	2012	_	_	O
77	.	_	_	O

78	Stratified	_	_	O
79	by	_	_	O
80	chemotherapeutic	_	_	O
81	drug	_	_	O
82	and	_	_	O
83	comorbid	_	_	O
84	pain	_	_	O
85	risk	_	_	O
86	,	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	either	_	_	O
93	duloxetine	_	_	O
94	followed	_	_	O
95	by	_	_	O
96	placebo	_	_	O
97	or	_	_	O
98	placebo	_	_	O
99	followed	_	_	O
100	by	_	_	O
101	duloxetine	_	_	O
102	.	_	_	O

103	Eligibility	_	_	O
104	required	_	_	O
105	that	_	_	O
106	patients	_	_	O
107	have	_	_	O
108	grade	_	_	O
109	1	_	_	O
110	or	_	_	O
111	higher	_	_	O
112	sensory	_	_	O
113	neuropathy	_	_	O
114	according	_	_	O
115	to	_	_	O
116	the	_	_	O
117	NCI	_	_	O
118	Common	_	_	O
119	Terminology	_	_	O
120	Criteria	_	_	O
121	for	_	_	O
122	Adverse	_	_	O
123	Events	_	_	O
124	and	_	_	O
125	at	_	_	O
126	least	_	_	O
127	4	_	_	O
128	on	_	_	O
129	a	_	_	O
130	scale	_	_	O
131	of	_	_	O
132	0	_	_	O
133	to	_	_	O
134	10	_	_	O
135	,	_	_	O
136	representing	_	_	O
137	average	_	_	O
138	chemotherapy-induced	_	_	O
139	pain	_	_	O
140	,	_	_	O
141	after	_	_	O
142	paclitaxel	_	_	O
143	,	_	_	O
144	other	_	_	O
145	taxane	_	_	O
146	,	_	_	O
147	or	_	_	O
148	oxaliplatin	_	_	O
149	treatment	_	_	O
150	.	_	_	O

151	The	_	_	O
152	initial	_	_	O
153	treatment	_	_	O
154	consisted	_	_	O
155	of	_	_	O
156	taking	_	_	O
157	1	_	_	O
158	capsule	_	_	O
159	daily	_	_	O
160	of	_	_	O
161	either	_	_	O
162	30	_	_	O
163	mg	_	_	O
164	of	_	_	O
165	duloxetine	_	_	O
166	or	_	_	O
167	placebo	_	_	O
168	for	_	_	O
169	the	_	_	O
170	first	_	_	O
171	week	_	_	O
172	and	_	_	O
173	2	_	_	O
174	capsules	_	_	O
175	of	_	_	O
176	either	_	_	O
177	30	_	_	O
178	mg	_	_	O
179	of	_	_	O
180	duloxetine	_	_	O
181	or	_	_	O
182	placebo	_	_	O
183	daily	_	_	O
184	for	_	_	O
185	4	_	_	O
186	additional	_	_	O
187	weeks	_	_	O
188	.	_	_	O

189	The	_	_	O
190	primary	_	_	O
191	hypothesis	_	_	O
192	was	_	_	O
193	that	_	_	O
194	duloxetine	_	_	O
195	would	_	_	O
196	be	_	_	O
197	more	_	_	O
198	effective	_	_	O
199	than	_	_	O
200	placebo	_	_	O
201	in	_	_	O
202	decreasing	_	_	O
203	chemotherapy-induced	_	_	O
204	peripheral	_	_	O
205	neuropathic	_	_	O
206	pain	_	_	O
207	.	_	_	O

208	Pain	_	_	O
209	severity	_	_	O
210	was	_	_	O
211	assessed	_	_	O
212	using	_	_	O
213	the	_	_	O
214	Brief	_	_	O
215	Pain	_	_	O
216	Inventory-Short	_	_	O
217	Form	_	_	O
218	"	_	_	O
219	average	_	_	O
220	pain	_	_	O
221	"	_	_	O
222	item	_	_	O
223	with	_	_	O
224	0	_	_	O
225	representing	_	_	O
226	no	_	_	O
227	pain	_	_	O
228	and	_	_	O
229	10	_	_	O
230	representing	_	_	O
231	as	_	_	O
232	bad	_	_	O
233	as	_	_	O
234	can	_	_	O
235	be	_	_	O
236	imagined	_	_	O
237	.	_	_	O

238	Individuals	_	_	B-Premise
239	receiving	_	_	I-Premise
240	duloxetine	_	_	I-Premise
241	as	_	_	I-Premise
242	their	_	_	I-Premise
243	initial	_	_	I-Premise
244	5-week	_	_	I-Premise
245	treatment	_	_	I-Premise
246	reported	_	_	I-Premise
247	a	_	_	I-Premise
248	mean	_	_	I-Premise
249	decrease	_	_	I-Premise
250	in	_	_	I-Premise
251	average	_	_	I-Premise
252	pain	_	_	I-Premise
253	of	_	_	I-Premise
254	1.06	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.72-1.40	_	_	I-Premise
261	)	_	_	I-Premise
262	vs	_	_	I-Premise
263	0.34	_	_	I-Premise
264	(	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	CI	_	_	I-Premise
268	,	_	_	I-Premise
269	0.01-0.66	_	_	I-Premise
270	)	_	_	I-Premise
271	among	_	_	I-Premise
272	those	_	_	I-Premise
273	who	_	_	I-Premise
274	received	_	_	I-Premise
275	placebo	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	=	_	_	I-Premise
279	.003	_	_	I-Premise
280	;	_	_	I-Premise
281	effect	_	_	I-Premise
282	size	_	_	I-Premise
283	,	_	_	I-Premise
284	0.513	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Premise
288	observed	_	_	I-Premise
289	mean	_	_	I-Premise
290	difference	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	average	_	_	I-Premise
294	pain	_	_	I-Premise
295	score	_	_	I-Premise
296	between	_	_	I-Premise
297	duloxetine	_	_	I-Premise
298	and	_	_	I-Premise
299	placebo	_	_	I-Premise
300	was	_	_	I-Premise
301	0.73	_	_	I-Premise
302	(	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	CI	_	_	I-Premise
306	,	_	_	I-Premise
307	0.26-1.20	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	Fifty-nine	_	_	B-Premise
311	percent	_	_	I-Premise
312	of	_	_	I-Premise
313	those	_	_	I-Premise
314	initially	_	_	I-Premise
315	receiving	_	_	I-Premise
316	duloxetine	_	_	I-Premise
317	vs	_	_	I-Premise
318	38	_	_	I-Premise
319	%	_	_	I-Premise
320	of	_	_	I-Premise
321	those	_	_	I-Premise
322	initially	_	_	I-Premise
323	receiving	_	_	I-Premise
324	placebo	_	_	I-Premise
325	reported	_	_	I-Premise
326	decreased	_	_	I-Premise
327	pain	_	_	I-Premise
328	of	_	_	I-Premise
329	any	_	_	I-Premise
330	amount	_	_	I-Premise
331	.	_	_	I-Premise

332	Among	_	_	B-Claim
333	patients	_	_	I-Claim
334	with	_	_	I-Claim
335	painful	_	_	I-Claim
336	chemotherapy-induced	_	_	I-Claim
337	peripheral	_	_	I-Claim
338	neuropathy	_	_	I-Claim
339	,	_	_	I-Claim
340	the	_	_	I-Claim
341	use	_	_	I-Claim
342	of	_	_	I-Claim
343	duloxetine	_	_	I-Claim
344	compared	_	_	I-Claim
345	with	_	_	I-Claim
346	placebo	_	_	I-Claim
347	for	_	_	I-Claim
348	5	_	_	I-Claim
349	weeks	_	_	I-Claim
350	resulted	_	_	I-Claim
351	in	_	_	I-Claim
352	a	_	_	I-Claim
353	greater	_	_	I-Claim
354	reduction	_	_	I-Claim
355	in	_	_	I-Claim
356	pain	_	_	I-Claim
357	.	_	_	I-Claim


0	The	_	_	O
1	majority	_	_	O
2	of	_	_	O
3	prostate	_	_	O
4	carcinoma	_	_	O
5	survivors	_	_	O
6	experience	_	_	O
7	enduring	_	_	O
8	sexual	_	_	O
9	difficulties	_	_	O
10	and	_	_	O
11	associated	_	_	O
12	distress	_	_	O
13	in	_	_	O
14	the	_	_	O
15	years	_	_	O
16	after	_	_	O
17	definitive	_	_	O
18	treatment	_	_	O
19	.	_	_	O

20	A	_	_	O
21	counseling	_	_	O
22	intervention	_	_	O
23	aimed	_	_	O
24	at	_	_	O
25	improving	_	_	O
26	levels	_	_	O
27	of	_	_	O
28	sexual	_	_	O
29	satisfaction	_	_	O
30	and	_	_	O
31	increasing	_	_	O
32	successful	_	_	O
33	utilization	_	_	O
34	of	_	_	O
35	medical	_	_	O
36	treatment	_	_	O
37	for	_	_	O
38	erectile	_	_	O
39	dysfunction	_	_	O
40	(	_	_	O
41	ED	_	_	O
42	)	_	_	O
43	was	_	_	O
44	developed	_	_	O
45	and	_	_	O
46	pilot-tested	_	_	O
47	for	_	_	O
48	both	_	_	O
49	the	_	_	O
50	survivor	_	_	O
51	of	_	_	O
52	prostate	_	_	O
53	carcinoma	_	_	O
54	and	_	_	O
55	his	_	_	O
56	partner	_	_	O
57	.	_	_	O

58	All	_	_	O
59	male	_	_	O
60	participants	_	_	O
61	were	_	_	O
62	3-month	_	_	O
63	to	_	_	O
64	5-year	_	_	O
65	survivors	_	_	O
66	of	_	_	O
67	localized	_	_	O
68	prostate	_	_	O
69	carcinoma	_	_	O
70	who	_	_	O
71	had	_	_	O
72	been	_	_	O
73	treated	_	_	O
74	with	_	_	O
75	radical	_	_	O
76	prostatectomy	_	_	O
77	or	_	_	O
78	radiation	_	_	O
79	therapy	_	_	O
80	,	_	_	O
81	and	_	_	O
82	were	_	_	O
83	married	_	_	O
84	or	_	_	O
85	in	_	_	O
86	a	_	_	O
87	committed	_	_	O
88	relationship	_	_	O
89	.	_	_	O

90	Couples	_	_	O
91	were	_	_	O
92	randomized	_	_	O
93	to	_	_	O
94	attend	_	_	O
95	four	_	_	O
96	sessions	_	_	O
97	of	_	_	O
98	counseling	_	_	O
99	together	_	_	O
100	or	_	_	O
101	to	_	_	O
102	have	_	_	O
103	the	_	_	O
104	man	_	_	O
105	attend	_	_	O
106	alone	_	_	O
107	.	_	_	O

108	In	_	_	O
109	both	_	_	O
110	groups	_	_	O
111	,	_	_	O
112	partners	_	_	O
113	completed	_	_	O
114	behavioral	_	_	O
115	homework	_	_	O
116	.	_	_	O

117	The	_	_	O
118	sessions	_	_	O
119	included	_	_	O
120	education	_	_	O
121	on	_	_	O
122	prostate	_	_	O
123	carcinoma	_	_	O
124	and	_	_	O
125	sexual	_	_	O
126	function	_	_	O
127	and	_	_	O
128	options	_	_	O
129	to	_	_	O
130	treat	_	_	O
131	ED	_	_	O
132	as	_	_	O
133	well	_	_	O
134	as	_	_	O
135	sexual	_	_	O
136	communication	_	_	O
137	and	_	_	O
138	stimulation	_	_	O
139	skills	_	_	O
140	.	_	_	O

141	Standardized	_	_	O
142	questionnaires	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	,	_	_	O
146	posttreatment	_	_	O
147	,	_	_	O
148	and	_	_	O
149	at	_	_	O
150	3-month	_	_	O
151	and	_	_	O
152	6-month	_	_	O
153	follow-up	_	_	O
154	assessed	_	_	O
155	sexual	_	_	O
156	function	_	_	O
157	,	_	_	O
158	marital	_	_	O
159	adjustment	_	_	O
160	,	_	_	O
161	psychologic	_	_	O
162	distress	_	_	O
163	,	_	_	O
164	and	_	_	O
165	utilization	_	_	O
166	of	_	_	O
167	treatments	_	_	O
168	for	_	_	O
169	ED	_	_	O
170	.	_	_	O

171	Fifty-one	_	_	O
172	of	_	_	O
173	84	_	_	O
174	couples	_	_	O
175	randomized	_	_	O
176	to	_	_	O
177	treatment	_	_	O
178	completed	_	_	O
179	the	_	_	O
180	intervention	_	_	O
181	(	_	_	O
182	61	_	_	O
183	%	_	_	O
184	)	_	_	O
185	.	_	_	O

186	Attendance	_	_	O
187	by	_	_	O
188	the	_	_	O
189	partner	_	_	O
190	did	_	_	O
191	not	_	_	O
192	affect	_	_	O
193	outcomes	_	_	O
194	.	_	_	O

195	Participants	_	_	B-Premise
196	completing	_	_	I-Premise
197	the	_	_	I-Premise
198	intervention	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	improvement	_	_	I-Premise
201	in	_	_	I-Premise
202	male	_	_	I-Premise
203	overall	_	_	I-Premise
204	distress	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	0.01	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	male	_	_	I-Premise
212	global	_	_	I-Premise
213	sexual	_	_	I-Premise
214	function	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	<	_	_	I-Premise
218	0.0001	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	female	_	_	I-Premise
223	global	_	_	I-Premise
224	sexual	_	_	I-Premise
225	function	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.05	_	_	I-Premise
230	)	_	_	I-Premise
231	at	_	_	I-Premise
232	3-month	_	_	I-Premise
233	follow-up	_	_	I-Premise
234	,	_	_	I-Premise
235	but	_	_	B-Premise
236	regression	_	_	I-Premise
237	toward	_	_	I-Premise
238	baseline	_	_	I-Premise
239	was	_	_	I-Premise
240	noted	_	_	I-Premise
241	at	_	_	I-Premise
242	6-month	_	_	I-Premise
243	follow-up	_	_	I-Premise
244	.	_	_	I-Premise

245	However	_	_	B-Premise
246	,	_	_	I-Premise
247	utilization	_	_	I-Premise
248	of	_	_	I-Premise
249	ED	_	_	I-Premise
250	treatments	_	_	I-Premise
251	increased	_	_	I-Premise
252	from	_	_	I-Premise
253	31	_	_	I-Premise
254	%	_	_	I-Premise
255	at	_	_	I-Premise
256	the	_	_	I-Premise
257	time	_	_	I-Premise
258	of	_	_	I-Premise
259	study	_	_	I-Premise
260	entry	_	_	I-Premise
261	to	_	_	I-Premise
262	49	_	_	I-Premise
263	%	_	_	I-Premise
264	at	_	_	I-Premise
265	the	_	_	I-Premise
266	6-month	_	_	I-Premise
267	follow-up	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.003	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Claim
275	results	_	_	I-Claim
276	of	_	_	I-Claim
277	this	_	_	I-Claim
278	brief	_	_	I-Claim
279	pilot	_	_	I-Claim
280	counseling	_	_	I-Claim
281	intervention	_	_	I-Claim
282	demonstrated	_	_	I-Claim
283	significant	_	_	I-Claim
284	gains	_	_	I-Claim
285	in	_	_	I-Claim
286	sexual	_	_	I-Claim
287	function	_	_	I-Claim
288	and	_	_	I-Claim
289	satisfaction	_	_	I-Claim
290	and	_	_	I-Claim
291	increased	_	_	I-Claim
292	utilization	_	_	I-Claim
293	of	_	_	I-Claim
294	treatments	_	_	I-Claim
295	for	_	_	I-Claim
296	ED	_	_	I-Claim
297	.	_	_	I-Claim

298	However	_	_	B-Claim
299	,	_	_	I-Claim
300	modifications	_	_	I-Claim
301	are	_	_	I-Claim
302	needed	_	_	I-Claim
303	in	_	_	I-Claim
304	future	_	_	I-Claim
305	randomized	_	_	I-Claim
306	trials	_	_	I-Claim
307	to	_	_	I-Claim
308	reduce	_	_	I-Claim
309	the	_	_	I-Claim
310	rate	_	_	I-Claim
311	of	_	_	I-Claim
312	premature	_	_	I-Claim
313	termination	_	_	I-Claim
314	and	_	_	I-Claim
315	to	_	_	I-Claim
316	improve	_	_	I-Claim
317	long-term	_	_	I-Claim
318	maintenance	_	_	I-Claim
319	of	_	_	I-Claim
320	gains	_	_	I-Claim
321	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	prospective	_	_	O
5	controlled	_	_	O
6	study	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	two	_	_	O
14	different	_	_	O
15	combination	_	_	O
16	treatment	_	_	O
17	modalities	_	_	O
18	of	_	_	O
19	lymphedema	_	_	O
20	(	_	_	O
21	LE	_	_	O
22	)	_	_	O
23	.	_	_	O

24	Manual	_	_	O
25	lymphatic	_	_	O
26	drainage	_	_	O
27	(	_	_	O
28	MLD	_	_	O
29	)	_	_	O
30	and	_	_	O
31	compression	_	_	O
32	bandage	_	_	O
33	combination	_	_	O
34	(	_	_	O
35	complex	_	_	O
36	decongestive	_	_	O
37	therapy	_	_	O
38	)	_	_	O
39	have	_	_	O
40	been	_	_	O
41	compared	_	_	O
42	with	_	_	O
43	intermittent	_	_	O
44	pneumatic	_	_	O
45	compression	_	_	O
46	(	_	_	O
47	IPC	_	_	O
48	)	_	_	O
49	plus	_	_	O
50	self-lymphatic	_	_	O
51	drainage	_	_	O
52	(	_	_	O
53	SLD	_	_	O
54	)	_	_	O
55	.	_	_	O

56	Both	_	_	O
57	MLD	_	_	O
58	with	_	_	O
59	compression	_	_	O
60	bandage	_	_	O
61	(	_	_	O
62	complex	_	_	O
63	decongestive	_	_	O
64	therapy	_	_	O
65	)	_	_	O
66	group	_	_	O
67	(	_	_	O
68	Group	_	_	O
69	I	_	_	O
70	,	_	_	O
71	n=15	_	_	O
72	)	_	_	O
73	and	_	_	O
74	IPC	_	_	O
75	with	_	_	O
76	SLD	_	_	O
77	group	_	_	O
78	(	_	_	O
79	Group	_	_	O
80	II	_	_	O
81	,	_	_	O
82	n=15	_	_	O
83	)	_	_	O
84	received	_	_	O
85	treatment	_	_	O
86	for	_	_	O
87	LE	_	_	O
88	3	_	_	O
89	days	_	_	O
90	in	_	_	O
91	a	_	_	O
92	week	_	_	O
93	and	_	_	O
94	every	_	_	O
95	other	_	_	O
96	day	_	_	O
97	for	_	_	O
98	6	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Arm	_	_	O
102	circumferences	_	_	O
103	were	_	_	O
104	measured	_	_	O
105	before	_	_	O
106	and	_	_	O
107	the	_	_	O
108	1st	_	_	O
109	,	_	_	O
110	3rd	_	_	O
111	,	_	_	O
112	and	_	_	O
113	6th	_	_	O
114	weeks	_	_	O
115	of	_	_	O
116	the	_	_	O
117	treatment	_	_	O
118	.	_	_	O

119	EORTC-QLQ	_	_	O
120	and	_	_	O
121	ASES-tests	_	_	O
122	were	_	_	O
123	performed	_	_	O
124	to	_	_	O
125	assess	_	_	O
126	the	_	_	O
127	quality	_	_	O
128	of	_	_	O
129	life	_	_	O
130	before	_	_	O
131	and	_	_	O
132	after	_	_	O
133	6	_	_	O
134	week-treatment	_	_	O
135	.	_	_	O

136	Patients	_	_	O
137	in	_	_	O
138	both	_	_	O
139	groups	_	_	O
140	had	_	_	O
141	similar	_	_	O
142	demographic	_	_	O
143	and	_	_	O
144	clinical	_	_	O
145	characteristics	_	_	O
146	.	_	_	O

147	Even	_	_	O
148	though	_	_	O
149	both	_	_	B-Premise
150	treatment	_	_	I-Premise
151	modalities	_	_	I-Premise
152	resulted	_	_	I-Premise
153	in	_	_	I-Premise
154	significant	_	_	I-Premise
155	decrease	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	total	_	_	I-Premise
159	arm	_	_	I-Premise
160	volume	_	_	I-Premise
161	(	_	_	I-Premise
162	12.2	_	_	I-Premise
163	%	_	_	I-Premise
164	decrease	_	_	I-Premise
165	in	_	_	I-Premise
166	Group	_	_	I-Premise
167	II	_	_	I-Premise
168	and	_	_	I-Premise
169	14.9	_	_	I-Premise
170	%	_	_	I-Premise
171	decrease	_	_	I-Premise
172	in	_	_	I-Premise
173	Group	_	_	I-Premise
174	I	_	_	I-Premise
175	)	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	<	_	_	I-Premise
179	0.001	_	_	I-Premise
180	)	_	_	I-Premise
181	,	_	_	I-Premise
182	no	_	_	B-Premise
183	significant	_	_	I-Premise
184	difference	_	_	I-Premise
185	(	_	_	I-Premise
186	p=0.582	_	_	I-Premise
187	)	_	_	I-Premise
188	was	_	_	I-Premise
189	found	_	_	I-Premise
190	between	_	_	I-Premise
191	those	_	_	I-Premise
192	two	_	_	I-Premise
193	groups	_	_	I-Premise
194	.	_	_	I-Premise

195	Similarly	_	_	B-Premise
196	,	_	_	I-Premise
197	ASES	_	_	I-Premise
198	scores	_	_	I-Premise
199	were	_	_	I-Premise
200	significantly	_	_	I-Premise
201	(	_	_	I-Premise
202	p=0.001	_	_	I-Premise
203	)	_	_	I-Premise
204	improved	_	_	I-Premise
205	in	_	_	I-Premise
206	both	_	_	I-Premise
207	Group	_	_	I-Premise
208	I	_	_	I-Premise
209	and	_	_	I-Premise
210	II	_	_	I-Premise
211	without	_	_	I-Premise
212	any	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	between	_	_	I-Premise
216	the	_	_	I-Premise
217	groups	_	_	I-Premise
218	.	_	_	I-Premise

219	While	_	_	B-Premise
220	emotional	_	_	I-Premise
221	functioning	_	_	I-Premise
222	,	_	_	I-Premise
223	fatigue	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	pain	_	_	I-Premise
227	scores	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	improved	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	groups	_	_	I-Premise
234	,	_	_	I-Premise
235	global	_	_	I-Premise
236	health	_	_	I-Premise
237	status	_	_	I-Premise
238	,	_	_	I-Premise
239	functional	_	_	I-Premise
240	and	_	_	I-Premise
241	cognitive	_	_	I-Premise
242	functioning	_	_	I-Premise
243	scores	_	_	I-Premise
244	appeared	_	_	I-Premise
245	to	_	_	I-Premise
246	be	_	_	I-Premise
247	improved	_	_	I-Premise
248	only	_	_	I-Premise
249	in	_	_	I-Premise
250	patients	_	_	I-Premise
251	of	_	_	I-Premise
252	group	_	_	I-Premise
253	I	_	_	I-Premise
254	.	_	_	I-Premise

255	Different	_	_	B-Claim
256	treatment	_	_	I-Claim
257	modalities	_	_	I-Claim
258	consisting	_	_	I-Claim
259	of	_	_	I-Claim
260	MLD	_	_	I-Claim
261	and	_	_	I-Claim
262	compression	_	_	I-Claim
263	bandage	_	_	I-Claim
264	(	_	_	I-Claim
265	complex	_	_	I-Claim
266	decongestive	_	_	I-Claim
267	therapy	_	_	I-Claim
268	)	_	_	I-Claim
269	or	_	_	I-Claim
270	IPC	_	_	I-Claim
271	and	_	_	I-Claim
272	SLD	_	_	I-Claim
273	appear	_	_	I-Claim
274	to	_	_	I-Claim
275	be	_	_	I-Claim
276	effective	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	treatment	_	_	I-Claim
280	of	_	_	I-Claim
281	LE	_	_	I-Claim
282	with	_	_	I-Claim
283	similar	_	_	I-Claim
284	therapeutic	_	_	I-Claim
285	efficacy	_	_	I-Claim
286	in	_	_	I-Claim
287	patients	_	_	I-Claim
288	with	_	_	I-Claim
289	breast	_	_	I-Claim
290	cancer	_	_	I-Claim
291	.	_	_	I-Claim

292	However	_	_	B-Claim
293	,	_	_	I-Claim
294	combination	_	_	I-Claim
295	modalities	_	_	I-Claim
296	including	_	_	I-Claim
297	IPC	_	_	I-Claim
298	and	_	_	I-Claim
299	SLD	_	_	I-Claim
300	may	_	_	I-Claim
301	be	_	_	I-Claim
302	the	_	_	I-Claim
303	preferred	_	_	I-Claim
304	choices	_	_	I-Claim
305	for	_	_	I-Claim
306	their	_	_	I-Claim
307	applicability	_	_	I-Claim
308	at	_	_	I-Claim
309	home	_	_	I-Claim
310	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	study	_	_	O
8	compared	_	_	O
9	doxorubicin	_	_	O
10	and	_	_	O
11	docetaxel	_	_	O
12	(	_	_	O
13	AT	_	_	O
14	)	_	_	O
15	with	_	_	O
16	doxorubicin	_	_	O
17	and	_	_	O
18	cyclophosphamide	_	_	O
19	(	_	_	O
20	AC	_	_	O
21	)	_	_	O
22	as	_	_	O
23	first-line	_	_	O
24	chemotherapy	_	_	O
25	(	_	_	O
26	CT	_	_	O
27	)	_	_	O
28	in	_	_	O
29	metastatic	_	_	O
30	breast	_	_	O
31	cancer	_	_	O
32	(	_	_	O
33	MBC	_	_	O
34	)	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	(	_	_	O
38	n	_	_	O
39	=	_	_	O
40	429	_	_	O
41	)	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	doxorubicin	_	_	O
48	50	_	_	O
49	mg/m	_	_	O
50	(	_	_	O
51	2	_	_	O
52	)	_	_	O
53	plus	_	_	O
54	docetaxel	_	_	O
55	75	_	_	O
56	mg/m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	214	_	_	O
64	)	_	_	O
65	or	_	_	O
66	doxorubicin	_	_	O
67	60	_	_	O
68	mg/m	_	_	O
69	(	_	_	O
70	2	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	cyclophosphamide	_	_	O
74	600	_	_	O
75	mg/m	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	(	_	_	O
80	n	_	_	O
81	=	_	_	O
82	215	_	_	O
83	)	_	_	O
84	on	_	_	O
85	day	_	_	O
86	1	_	_	O
87	,	_	_	O
88	every	_	_	O
89	3	_	_	O
90	weeks	_	_	O
91	for	_	_	O
92	up	_	_	O
93	to	_	_	O
94	eight	_	_	O
95	cycles	_	_	O
96	.	_	_	O

97	Time	_	_	B-Premise
98	to	_	_	I-Premise
99	progression	_	_	I-Premise
100	(	_	_	I-Premise
101	TTP	_	_	I-Premise
102	;	_	_	I-Premise
103	primary	_	_	I-Premise
104	end	_	_	I-Premise
105	point	_	_	I-Premise
106	)	_	_	I-Premise
107	and	_	_	I-Premise
108	time	_	_	I-Premise
109	to	_	_	I-Premise
110	treatment	_	_	I-Premise
111	failure	_	_	I-Premise
112	(	_	_	I-Premise
113	TTF	_	_	I-Premise
114	)	_	_	I-Premise
115	were	_	_	I-Premise
116	significantly	_	_	I-Premise
117	longer	_	_	I-Premise
118	with	_	_	I-Premise
119	AT	_	_	I-Premise
120	than	_	_	I-Premise
121	AC	_	_	I-Premise
122	(	_	_	I-Premise
123	median	_	_	I-Premise
124	TTP	_	_	I-Premise
125	,	_	_	I-Premise
126	37.3	_	_	I-Premise
127	v	_	_	I-Premise
128	31.9	_	_	I-Premise
129	weeks	_	_	I-Premise
130	;	_	_	I-Premise
131	log-rank	_	_	I-Premise
132	P	_	_	I-Premise
133	=.014	_	_	I-Premise
134	;	_	_	I-Premise
135	median	_	_	I-Premise
136	TTF	_	_	I-Premise
137	,	_	_	I-Premise
138	25.6	_	_	I-Premise
139	v	_	_	I-Premise
140	23.7	_	_	I-Premise
141	weeks	_	_	I-Premise
142	;	_	_	I-Premise
143	log-rank	_	_	I-Premise
144	P	_	_	I-Premise
145	=.048	_	_	I-Premise
146	)	_	_	I-Premise
147	.	_	_	I-Premise

148	The	_	_	B-Premise
149	overall	_	_	I-Premise
150	response	_	_	I-Premise
151	rate	_	_	I-Premise
152	(	_	_	I-Premise
153	ORR	_	_	I-Premise
154	)	_	_	I-Premise
155	was	_	_	I-Premise
156	significantly	_	_	I-Premise
157	greater	_	_	I-Premise
158	for	_	_	I-Premise
159	patients	_	_	I-Premise
160	taking	_	_	I-Premise
161	AT	_	_	I-Premise
162	(	_	_	I-Premise
163	59	_	_	I-Premise
164	%	_	_	I-Premise
165	,	_	_	I-Premise
166	with	_	_	I-Premise
167	10	_	_	I-Premise
168	%	_	_	I-Premise
169	complete	_	_	I-Premise
170	response	_	_	I-Premise
171	[	_	_	I-Premise
172	CR	_	_	I-Premise
173	]	_	_	I-Premise
174	,	_	_	I-Premise
175	49	_	_	I-Premise
176	%	_	_	I-Premise
177	partial	_	_	I-Premise
178	response	_	_	I-Premise
179	[	_	_	I-Premise
180	PR	_	_	I-Premise
181	]	_	_	I-Premise
182	)	_	_	I-Premise
183	than	_	_	I-Premise
184	for	_	_	I-Premise
185	those	_	_	I-Premise
186	taking	_	_	I-Premise
187	AC	_	_	I-Premise
188	(	_	_	I-Premise
189	47	_	_	I-Premise
190	%	_	_	I-Premise
191	,	_	_	I-Premise
192	with	_	_	I-Premise
193	7	_	_	I-Premise
194	%	_	_	I-Premise
195	CR	_	_	I-Premise
196	,	_	_	I-Premise
197	39	_	_	I-Premise
198	%	_	_	I-Premise
199	PR	_	_	I-Premise
200	)	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=.009	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	B-Premise
207	ORR	_	_	I-Premise
208	was	_	_	I-Premise
209	also	_	_	I-Premise
210	higher	_	_	I-Premise
211	with	_	_	I-Premise
212	AT	_	_	I-Premise
213	in	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	visceral	_	_	I-Premise
217	involvement	_	_	I-Premise
218	(	_	_	I-Premise
219	58	_	_	I-Premise
220	%	_	_	I-Premise
221	v	_	_	I-Premise
222	41	_	_	I-Premise
223	%	_	_	I-Premise
224	;	_	_	I-Premise
225	liver	_	_	I-Premise
226	,	_	_	I-Premise
227	62	_	_	I-Premise
228	%	_	_	I-Premise
229	v	_	_	I-Premise
230	42	_	_	I-Premise
231	%	_	_	I-Premise
232	;	_	_	I-Premise
233	lung	_	_	I-Premise
234	,	_	_	I-Premise
235	58	_	_	I-Premise
236	%	_	_	I-Premise
237	v	_	_	I-Premise
238	35	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	three	_	_	I-Premise
243	or	_	_	I-Premise
244	more	_	_	I-Premise
245	organs	_	_	I-Premise
246	involved	_	_	I-Premise
247	(	_	_	I-Premise
248	59	_	_	I-Premise
249	%	_	_	I-Premise
250	v	_	_	I-Premise
251	40	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	or	_	_	I-Premise
256	prior	_	_	I-Premise
257	adjuvant	_	_	I-Premise
258	CT	_	_	I-Premise
259	(	_	_	I-Premise
260	53	_	_	I-Premise
261	%	_	_	I-Premise
262	v	_	_	I-Premise
263	41	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Overall	_	_	B-Premise
268	survival	_	_	I-Premise
269	(	_	_	I-Premise
270	OS	_	_	I-Premise
271	)	_	_	I-Premise
272	was	_	_	I-Premise
273	comparable	_	_	I-Premise
274	in	_	_	I-Premise
275	both	_	_	I-Premise
276	arms	_	_	I-Premise
277	.	_	_	I-Premise

278	Grade	_	_	B-Premise
279	3/4	_	_	I-Premise
280	neutropenia	_	_	I-Premise
281	was	_	_	I-Premise
282	frequent	_	_	I-Premise
283	in	_	_	I-Premise
284	both	_	_	I-Premise
285	groups	_	_	I-Premise
286	,	_	_	I-Premise
287	although	_	_	B-Premise
288	febrile	_	_	I-Premise
289	neutropenia	_	_	I-Premise
290	and	_	_	I-Premise
291	infections	_	_	I-Premise
292	were	_	_	I-Premise
293	more	_	_	I-Premise
294	frequent	_	_	I-Premise
295	for	_	_	I-Premise
296	patients	_	_	I-Premise
297	taking	_	_	I-Premise
298	AT	_	_	I-Premise
299	(	_	_	I-Premise
300	respectively	_	_	I-Premise
301	,	_	_	I-Premise
302	33	_	_	I-Premise
303	%	_	_	I-Premise
304	v	_	_	I-Premise
305	10	_	_	I-Premise
306	%	_	_	I-Premise
307	,	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.001	_	_	I-Premise
311	;	_	_	I-Premise
312	8	_	_	I-Premise
313	%	_	_	I-Premise
314	v	_	_	I-Premise
315	2	_	_	I-Premise
316	%	_	_	I-Premise
317	,	_	_	I-Premise
318	P	_	_	I-Premise
319	=.01	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	Severe	_	_	B-Premise
323	nonhematologic	_	_	I-Premise
324	toxicity	_	_	I-Premise
325	was	_	_	I-Premise
326	infrequent	_	_	I-Premise
327	in	_	_	I-Premise
328	both	_	_	I-Premise
329	groups	_	_	I-Premise
330	,	_	_	I-Premise
331	including	_	_	I-Premise
332	grade	_	_	I-Premise
333	3/4	_	_	I-Premise
334	cardiac	_	_	I-Premise
335	events	_	_	I-Premise
336	(	_	_	I-Premise
337	AT	_	_	I-Premise
338	,	_	_	I-Premise
339	3	_	_	I-Premise
340	%	_	_	I-Premise
341	;	_	_	I-Premise
342	AC	_	_	I-Premise
343	,	_	_	I-Premise
344	4	_	_	I-Premise
345	%	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	AT	_	_	B-Claim
349	significantly	_	_	I-Claim
350	improves	_	_	I-Claim
351	TTP	_	_	I-Claim
352	and	_	_	I-Claim
353	ORR	_	_	I-Claim
354	compared	_	_	I-Claim
355	with	_	_	I-Claim
356	AC	_	_	I-Claim
357	in	_	_	I-Claim
358	patients	_	_	I-Claim
359	with	_	_	I-Claim
360	MBC	_	_	I-Claim
361	,	_	_	I-Claim
362	but	_	_	B-Claim
363	there	_	_	I-Claim
364	is	_	_	I-Claim
365	no	_	_	I-Claim
366	difference	_	_	I-Claim
367	in	_	_	I-Claim
368	OS	_	_	I-Claim
369	.	_	_	I-Claim

370	AT	_	_	B-Claim
371	represents	_	_	I-Claim
372	a	_	_	I-Claim
373	valid	_	_	I-Claim
374	option	_	_	I-Claim
375	for	_	_	I-Claim
376	the	_	_	I-Claim
377	treatment	_	_	I-Claim
378	of	_	_	I-Claim
379	MBC	_	_	I-Claim
380	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	studies	_	_	O
3	have	_	_	O
4	been	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	help	_	_	O
8	couples	_	_	O
9	manage	_	_	O
10	the	_	_	O
11	effects	_	_	O
12	of	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	and	_	_	O
16	maintain	_	_	O
17	their	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	.	_	_	O

22	The	_	_	O
23	objective	_	_	O
24	of	_	_	O
25	this	_	_	O
26	study	_	_	O
27	was	_	_	O
28	to	_	_	O
29	determine	_	_	O
30	whether	_	_	O
31	a	_	_	O
32	family-based	_	_	O
33	intervention	_	_	O
34	could	_	_	O
35	improve	_	_	O
36	appraisal	_	_	O
37	variables	_	_	O
38	(	_	_	O
39	appraisal	_	_	O
40	of	_	_	O
41	illness	_	_	O
42	or	_	_	O
43	caregiving	_	_	O
44	,	_	_	O
45	uncertainty	_	_	O
46	,	_	_	O
47	hopelessness	_	_	O
48	)	_	_	O
49	,	_	_	O
50	coping	_	_	O
51	resources	_	_	O
52	(	_	_	O
53	coping	_	_	O
54	strategies	_	_	O
55	,	_	_	O
56	self-efficacy	_	_	O
57	,	_	_	O
58	communication	_	_	O
59	)	_	_	O
60	,	_	_	O
61	symptom	_	_	O
62	distress	_	_	O
63	,	_	_	O
64	and	_	_	O
65	quality	_	_	O
66	of	_	_	O
67	life	_	_	O
68	in	_	_	O
69	men	_	_	O
70	with	_	_	O
71	prostate	_	_	O
72	cancer	_	_	O
73	and	_	_	O
74	their	_	_	O
75	spouses	_	_	O
76	.	_	_	O

77	For	_	_	O
78	this	_	_	O
79	clinical	_	_	O
80	trial	_	_	O
81	,	_	_	O
82	263	_	_	O
83	patient-spouse	_	_	O
84	dyads	_	_	O
85	were	_	_	O
86	stratified	_	_	O
87	by	_	_	O
88	research	_	_	O
89	site	_	_	O
90	,	_	_	O
91	phase	_	_	O
92	of	_	_	O
93	illness	_	_	O
94	,	_	_	O
95	and	_	_	O
96	treatment	_	_	O
97	;	_	_	O
98	then	_	_	O
99	,	_	_	O
100	they	_	_	O
101	were	_	_	O
102	randomized	_	_	O
103	to	_	_	O
104	the	_	_	O
105	control	_	_	O
106	group	_	_	O
107	(	_	_	O
108	standard	_	_	O
109	care	_	_	O
110	)	_	_	O
111	or	_	_	O
112	the	_	_	O
113	experimental	_	_	O
114	group	_	_	O
115	(	_	_	O
116	standard	_	_	O
117	care	_	_	O
118	plus	_	_	O
119	a	_	_	O
120	5-session	_	_	O
121	family	_	_	O
122	intervention	_	_	O
123	)	_	_	O
124	.	_	_	O

125	The	_	_	O
126	intervention	_	_	O
127	targeted	_	_	O
128	couples	_	_	O
129	'	_	_	O
130	communication	_	_	O
131	,	_	_	O
132	hope	_	_	O
133	,	_	_	O
134	coping	_	_	O
135	,	_	_	O
136	uncertainty	_	_	O
137	,	_	_	O
138	and	_	_	O
139	symptom	_	_	O
140	management	_	_	O
141	.	_	_	O

142	The	_	_	O
143	final	_	_	O
144	sample	_	_	O
145	consisted	_	_	O
146	of	_	_	O
147	235	_	_	O
148	couples	_	_	O
149	:	_	_	O
150	123	_	_	O
151	couples	_	_	O
152	in	_	_	O
153	the	_	_	O
154	control	_	_	O
155	group	_	_	O
156	and	_	_	O
157	112	_	_	O
158	couples	_	_	O
159	in	_	_	O
160	the	_	_	O
161	experimental	_	_	O
162	group	_	_	O
163	.	_	_	O

164	Data	_	_	O
165	collection	_	_	O
166	occurred	_	_	O
167	at	_	_	O
168	baseline	_	_	O
169	before	_	_	O
170	randomization	_	_	O
171	and	_	_	O
172	at	_	_	O
173	4	_	_	O
174	months	_	_	O
175	,	_	_	O
176	8	_	_	O
177	months	_	_	O
178	,	_	_	O
179	and	_	_	O
180	12	_	_	O
181	months	_	_	O
182	.	_	_	O

183	At	_	_	B-Premise
184	4-month	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	,	_	_	I-Premise
187	intervention	_	_	I-Premise
188	patients	_	_	I-Premise
189	reported	_	_	I-Premise
190	less	_	_	I-Premise
191	uncertainty	_	_	I-Premise
192	and	_	_	I-Premise
193	better	_	_	I-Premise
194	communication	_	_	I-Premise
195	with	_	_	I-Premise
196	spouses	_	_	I-Premise
197	than	_	_	I-Premise
198	control	_	_	I-Premise
199	patients	_	_	I-Premise
200	,	_	_	I-Premise
201	but	_	_	B-Premise
202	they	_	_	I-Premise
203	reported	_	_	I-Premise
204	no	_	_	I-Premise
205	other	_	_	I-Premise
206	effects	_	_	I-Premise
207	.	_	_	I-Premise

208	Intervention	_	_	B-Premise
209	spouses	_	_	I-Premise
210	reported	_	_	I-Premise
211	higher	_	_	I-Premise
212	quality	_	_	I-Premise
213	of	_	_	I-Premise
214	life	_	_	I-Premise
215	,	_	_	I-Premise
216	more	_	_	I-Premise
217	self-efficacy	_	_	I-Premise
218	,	_	_	I-Premise
219	better	_	_	I-Premise
220	communication	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	less	_	_	I-Premise
224	negative	_	_	I-Premise
225	appraisal	_	_	I-Premise
226	of	_	_	I-Premise
227	caregiving	_	_	I-Premise
228	,	_	_	I-Premise
229	uncertainty	_	_	I-Premise
230	,	_	_	I-Premise
231	hopelessness	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	symptom	_	_	I-Premise
235	distress	_	_	I-Premise
236	at	_	_	I-Premise
237	4	_	_	I-Premise
238	months	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	controls	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	some	_	_	I-Premise
245	effects	_	_	I-Premise
246	were	_	_	I-Premise
247	sustained	_	_	I-Premise
248	to	_	_	I-Premise
249	8	_	_	I-Premise
250	months	_	_	I-Premise
251	and	_	_	I-Premise
252	12	_	_	I-Premise
253	months	_	_	I-Premise
254	.	_	_	I-Premise

255	Men	_	_	B-Premise
256	with	_	_	I-Premise
257	prostate	_	_	I-Premise
258	cancer	_	_	I-Premise
259	and	_	_	I-Premise
260	their	_	_	I-Premise
261	spouses	_	_	I-Premise
262	reported	_	_	I-Premise
263	positive	_	_	I-Premise
264	outcomes	_	_	I-Premise
265	from	_	_	I-Premise
266	a	_	_	I-Premise
267	family	_	_	I-Premise
268	intervention	_	_	I-Premise
269	that	_	_	I-Premise
270	offered	_	_	I-Premise
271	them	_	_	I-Premise
272	information	_	_	I-Premise
273	and	_	_	I-Premise
274	support	_	_	I-Premise
275	.	_	_	I-Premise

276	Programs	_	_	B-Claim
277	of	_	_	I-Claim
278	care	_	_	I-Claim
279	need	_	_	I-Claim
280	to	_	_	I-Claim
281	be	_	_	I-Claim
282	extended	_	_	I-Claim
283	to	_	_	I-Claim
284	spouses	_	_	I-Claim
285	who	_	_	I-Claim
286	likely	_	_	I-Claim
287	will	_	_	I-Claim
288	experience	_	_	I-Claim
289	multiple	_	_	I-Claim
290	benefits	_	_	I-Claim
291	from	_	_	I-Claim
292	intervention	_	_	I-Claim
293	.	_	_	I-Claim


0	Exercise	_	_	O
1	training	_	_	O
2	improves	_	_	O
3	supportive	_	_	O
4	care	_	_	O
5	outcomes	_	_	O
6	in	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	breast	_	_	O
10	cancer	_	_	O
11	who	_	_	O
12	are	_	_	O
13	receiving	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	,	_	_	O
17	but	_	_	O
18	the	_	_	O
19	responses	_	_	O
20	are	_	_	O
21	heterogeneous	_	_	O
22	.	_	_	O

23	In	_	_	O
24	this	_	_	O
25	study	_	_	O
26	,	_	_	O
27	the	_	_	O
28	authors	_	_	O
29	examined	_	_	O
30	personal	_	_	O
31	and	_	_	O
32	clinical	_	_	O
33	factors	_	_	O
34	that	_	_	O
35	may	_	_	O
36	predict	_	_	O
37	exercise	_	_	O
38	training	_	_	O
39	responses	_	_	O
40	.	_	_	O

41	Breast	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	were	_	_	O
46	initiating	_	_	O
47	adjuvant	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	N=242	_	_	O
51	)	_	_	O
52	were	_	_	O
53	assigned	_	_	O
54	randomly	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	(	_	_	O
60	UC	_	_	O
61	)	_	_	O
62	(	_	_	O
63	n=82	_	_	O
64	)	_	_	O
65	,	_	_	O
66	resistance	_	_	O
67	exercise	_	_	O
68	training	_	_	O
69	(	_	_	O
70	RET	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n=82	_	_	O
74	)	_	_	O
75	,	_	_	O
76	or	_	_	O
77	aerobic	_	_	O
78	exercise	_	_	O
79	training	_	_	O
80	(	_	_	O
81	AET	_	_	O
82	)	_	_	O
83	(	_	_	O
84	n=78	_	_	O
85	)	_	_	O
86	for	_	_	O
87	the	_	_	O
88	duration	_	_	O
89	of	_	_	O
90	chemotherapy	_	_	O
91	.	_	_	O

92	Endpoints	_	_	O
93	were	_	_	O
94	quality	_	_	O
95	of	_	_	O
96	life	_	_	O
97	(	_	_	O
98	QoL	_	_	O
99	)	_	_	O
100	,	_	_	O
101	aerobic	_	_	O
102	fitness	_	_	O
103	,	_	_	O
104	muscular	_	_	O
105	strength	_	_	O
106	,	_	_	O
107	lean	_	_	O
108	body	_	_	O
109	mass	_	_	O
110	,	_	_	O
111	and	_	_	O
112	body	_	_	O
113	fat	_	_	O
114	.	_	_	O

115	Moderators	_	_	O
116	were	_	_	O
117	patient	_	_	O
118	preference	_	_	O
119	for	_	_	O
120	group	_	_	O
121	assignment	_	_	O
122	,	_	_	O
123	marital	_	_	O
124	status	_	_	O
125	,	_	_	O
126	age	_	_	O
127	,	_	_	O
128	disease	_	_	O
129	stage	_	_	O
130	,	_	_	O
131	and	_	_	O
132	chemotherapy	_	_	O
133	regimen	_	_	O
134	.	_	_	O

135	Adjusted	_	_	O
136	linear	_	_	O
137	mixed-model	_	_	O
138	analyses	_	_	O
139	demonstrated	_	_	O
140	that	_	_	O
141	patient	_	_	O
142	preference	_	_	O
143	moderated	_	_	O
144	QoL	_	_	O
145	response	_	_	O
146	(	_	_	O
147	P=	_	_	O
148	.005	_	_	O
149	)	_	_	O
150	.	_	_	O

151	Patients	_	_	B-Premise
152	who	_	_	I-Premise
153	preferred	_	_	I-Premise
154	RET	_	_	I-Premise
155	improved	_	_	I-Premise
156	QoL	_	_	I-Premise
157	when	_	_	I-Premise
158	they	_	_	I-Premise
159	were	_	_	I-Premise
160	assigned	_	_	I-Premise
161	to	_	_	I-Premise
162	receive	_	_	I-Premise
163	RET	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	UC	_	_	I-Premise
167	(	_	_	I-Premise
168	mean	_	_	I-Premise
169	difference	_	_	I-Premise
170	,	_	_	I-Premise
171	16.5	_	_	I-Premise
172	;	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	confidence	_	_	I-Premise
176	interval	_	_	I-Premise
177	[	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	]	_	_	I-Premise
182	,	_	_	I-Premise
183	4.3-28.7	_	_	I-Premise
184	;	_	_	I-Premise
185	P=	_	_	I-Premise
186	.008	_	_	I-Premise
187	)	_	_	I-Premise
188	or	_	_	I-Premise
189	AET	_	_	I-Premise
190	(	_	_	I-Premise
191	mean	_	_	I-Premise
192	difference	_	_	I-Premise
193	,	_	_	I-Premise
194	11	_	_	I-Premise
195	;	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	CI	_	_	I-Premise
199	,	_	_	I-Premise
200	-1.1-23.4	_	_	I-Premise
201	;	_	_	I-Premise
202	P=	_	_	I-Premise
203	.076	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Patients	_	_	B-Premise
207	who	_	_	I-Premise
208	had	_	_	I-Premise
209	no	_	_	I-Premise
210	preference	_	_	I-Premise
211	had	_	_	I-Premise
212	improved	_	_	I-Premise
213	QoL	_	_	I-Premise
214	when	_	_	I-Premise
215	they	_	_	I-Premise
216	were	_	_	I-Premise
217	assigned	_	_	I-Premise
218	to	_	_	I-Premise
219	receive	_	_	I-Premise
220	AET	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	RET	_	_	I-Premise
224	(	_	_	I-Premise
225	mean	_	_	I-Premise
226	difference	_	_	I-Premise
227	,	_	_	I-Premise
228	23	_	_	I-Premise
229	;	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	4.9-41	_	_	I-Premise
235	;	_	_	I-Premise
236	P=	_	_	I-Premise
237	.014	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Marital	_	_	B-Premise
241	status	_	_	I-Premise
242	also	_	_	I-Premise
243	moderated	_	_	I-Premise
244	QoL	_	_	I-Premise
245	response	_	_	I-Premise
246	(	_	_	I-Premise
247	P=	_	_	I-Premise
248	.026	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	age	_	_	I-Premise
252	moderated	_	_	I-Premise
253	aerobic	_	_	I-Premise
254	fitness	_	_	I-Premise
255	response	_	_	I-Premise
256	(	_	_	I-Premise
257	P=	_	_	I-Premise
258	.029	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	chemotherapy	_	_	I-Premise
262	regimen	_	_	I-Premise
263	moderated	_	_	I-Premise
264	strength	_	_	I-Premise
265	gain	_	_	I-Premise
266	(	_	_	I-Premise
267	P=	_	_	I-Premise
268	.009	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	disease	_	_	I-Premise
273	stage	_	_	I-Premise
274	moderated	_	_	I-Premise
275	both	_	_	I-Premise
276	lean	_	_	I-Premise
277	body	_	_	I-Premise
278	mass	_	_	I-Premise
279	gain	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	<	_	_	I-Premise
283	.001	_	_	I-Premise
284	)	_	_	I-Premise
285	and	_	_	I-Premise
286	fat	_	_	I-Premise
287	loss	_	_	I-Premise
288	(	_	_	I-Premise
289	P=	_	_	I-Premise
290	.059	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Unmarried	_	_	B-Premise
294	,	_	_	I-Premise
295	younger	_	_	I-Premise
296	patients	_	_	I-Premise
297	who	_	_	I-Premise
298	were	_	_	I-Premise
299	receiving	_	_	I-Premise
300	nontaxane-based	_	_	I-Premise
301	therapies	_	_	I-Premise
302	and	_	_	I-Premise
303	had	_	_	I-Premise
304	more	_	_	I-Premise
305	advanced	_	_	I-Premise
306	disease	_	_	I-Premise
307	stage	_	_	I-Premise
308	experienced	_	_	I-Premise
309	better	_	_	I-Premise
310	outcomes	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	O
313	findings	_	_	O
314	were	_	_	O
315	not	_	_	O
316	explained	_	_	O
317	by	_	_	O
318	differences	_	_	O
319	in	_	_	O
320	adherence	_	_	O
321	.	_	_	O

322	Patient	_	_	B-Claim
323	preference	_	_	I-Claim
324	,	_	_	I-Claim
325	demographic	_	_	I-Claim
326	variables	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	medical	_	_	I-Claim
330	variables	_	_	I-Claim
331	moderated	_	_	I-Claim
332	the	_	_	I-Claim
333	effects	_	_	I-Claim
334	of	_	_	I-Claim
335	exercise	_	_	I-Claim
336	training	_	_	I-Claim
337	in	_	_	I-Claim
338	breast	_	_	I-Claim
339	cancer	_	_	I-Claim
340	patients	_	_	I-Claim
341	who	_	_	I-Claim
342	were	_	_	I-Claim
343	receiving	_	_	I-Claim
344	chemotherapy	_	_	I-Claim
345	.	_	_	I-Claim

346	If	_	_	O
347	replicated	_	_	O
348	,	_	_	O
349	these	_	_	O
350	results	_	_	O
351	may	_	_	O
352	inform	_	_	O
353	clinical	_	_	O
354	practice	_	_	O
355	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	short-	_	_	O
3	and	_	_	O
4	long-term	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	adjuvant	_	_	O
8	treatment	_	_	O
9	versus	_	_	O
10	observation	_	_	O
11	after	_	_	O
12	surgery	_	_	O
13	on	_	_	O
14	health-related	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	HRQL	_	_	O
20	)	_	_	O
21	of	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	patients	_	_	O
25	.	_	_	O

26	The	_	_	O
27	Southwest	_	_	O
28	Oncology	_	_	O
29	Group	_	_	O
30	(	_	_	O
31	SWOG	_	_	O
32	)	_	_	O
33	intergroup	_	_	O
34	trial	_	_	O
35	compared	_	_	O
36	radical	_	_	O
37	prostatectomy	_	_	O
38	(	_	_	O
39	RP	_	_	O
40	)	_	_	O
41	plus	_	_	O
42	observation	_	_	O
43	versus	_	_	O
44	RP	_	_	O
45	plus	_	_	O
46	adjuvant	_	_	O
47	radiation	_	_	O
48	therapy	_	_	O
49	(	_	_	O
50	RT	_	_	O
51	)	_	_	O
52	.	_	_	O

53	Two-hundred	_	_	O
54	seventeen	_	_	O
55	of	_	_	O
56	425	_	_	O
57	therapeutic	_	_	O
58	trial	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	eligible	_	_	O
62	and	_	_	O
63	registered	_	_	O
64	to	_	_	O
65	the	_	_	O
66	HRQL	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	completed	_	_	O
71	the	_	_	O
72	SWOG	_	_	O
73	Quality	_	_	O
74	of	_	_	O
75	Life	_	_	O
76	Questionnaire	_	_	O
77	(	_	_	O
78	emotional	_	_	O
79	,	_	_	O
80	physical	_	_	O
81	,	_	_	O
82	social	_	_	O
83	,	_	_	O
84	and	_	_	O
85	role	_	_	O
86	function	_	_	O
87	;	_	_	O
88	general	_	_	O
89	symptom	_	_	O
90	status	_	_	O
91	;	_	_	O
92	treatment/disease-specific	_	_	O
93	symptoms	_	_	O
94	;	_	_	O
95	and	_	_	O
96	global	_	_	O
97	HRQL	_	_	O
98	[	_	_	O
99	GHRQL	_	_	O
100	]	_	_	O
101	)	_	_	O
102	at	_	_	O
103	baseline	_	_	O
104	,	_	_	O
105	6	_	_	O
106	weeks	_	_	O
107	,	_	_	O
108	6	_	_	O
109	months	_	_	O
110	,	_	_	O
111	and	_	_	O
112	annually	_	_	O
113	for	_	_	O
114	5	_	_	O
115	years	_	_	O
116	.	_	_	O

117	Prespecified	_	_	O
118	outcomes	_	_	O
119	were	_	_	O
120	three	_	_	O
121	genitourinary	_	_	O
122	symptoms	_	_	O
123	(	_	_	O
124	bowel	_	_	O
125	function	_	_	O
126	tenderness	_	_	O
127	,	_	_	O
128	frequent	_	_	O
129	urination	_	_	O
130	,	_	_	O
131	and	_	_	O
132	erectile	_	_	O
133	dysfunction	_	_	O
134	[	_	_	O
135	ED	_	_	O
136	]	_	_	O
137	)	_	_	O
138	and	_	_	O
139	measures	_	_	O
140	of	_	_	O
141	physical	_	_	O
142	and	_	_	O
143	emotional	_	_	O
144	function	_	_	O
145	.	_	_	O

146	Adjustments	_	_	O
147	were	_	_	O
148	made	_	_	O
149	for	_	_	O
150	the	_	_	O
151	baseline	_	_	O
152	score	_	_	O
153	.	_	_	O

154	Patients	_	_	O
155	receiving	_	_	O
156	adjuvant	_	_	O
157	RT	_	_	O
158	reported	_	_	O
159	worse	_	_	O
160	bowel	_	_	O
161	function	_	_	O
162	(	_	_	O
163	through	_	_	O
164	approximately	_	_	O
165	2	_	_	O
166	years	_	_	O
167	)	_	_	O
168	and	_	_	O
169	worse	_	_	O
170	urinary	_	_	O
171	function	_	_	O
172	.	_	_	O

173	There	_	_	O
174	were	_	_	O
175	no	_	_	O
176	statistically	_	_	O
177	significant	_	_	O
178	differences	_	_	O
179	for	_	_	O
180	ED	_	_	O
181	.	_	_	O

182	GHRQL	_	_	B-Premise
183	was	_	_	I-Premise
184	initially	_	_	I-Premise
185	worse	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	RP+RT	_	_	I-Premise
189	arm	_	_	I-Premise
190	but	_	_	I-Premise
191	improved	_	_	I-Premise
192	over	_	_	I-Premise
193	time	_	_	I-Premise
194	and	_	_	I-Premise
195	was	_	_	I-Premise
196	better	_	_	I-Premise
197	at	_	_	I-Premise
198	the	_	_	I-Premise
199	end	_	_	I-Premise
200	of	_	_	I-Premise
201	the	_	_	I-Premise
202	period	_	_	I-Premise
203	than	_	_	I-Premise
204	the	_	_	I-Premise
205	GHRQL	_	_	I-Premise
206	reported	_	_	I-Premise
207	for	_	_	I-Premise
208	RP	_	_	I-Premise
209	alone	_	_	I-Premise
210	(	_	_	I-Premise
211	treatment	_	_	I-Premise
212	arm	_	_	I-Premise
213	x	_	_	I-Premise
214	time	_	_	I-Premise
215	interaction	_	_	I-Premise
216	,	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.0004	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Symptom	_	_	B-Premise
223	distress	_	_	I-Premise
224	was	_	_	I-Premise
225	significantly	_	_	I-Premise
226	worse	_	_	I-Premise
227	for	_	_	I-Premise
228	the	_	_	I-Premise
229	RP+RT	_	_	I-Premise
230	arm	_	_	I-Premise
231	compared	_	_	I-Premise
232	with	_	_	I-Premise
233	the	_	_	I-Premise
234	RP	_	_	I-Premise
235	alone	_	_	I-Premise
236	arm	_	_	I-Premise
237	,	_	_	O
238	but	_	_	B-Premise
239	the	_	_	I-Premise
240	treatment	_	_	I-Premise
241	arms	_	_	I-Premise
242	did	_	_	I-Premise
243	not	_	_	I-Premise
244	differ	_	_	I-Premise
245	with	_	_	I-Premise
246	respect	_	_	I-Premise
247	to	_	_	I-Premise
248	other	_	_	I-Premise
249	general	_	_	I-Premise
250	measures	_	_	I-Premise
251	of	_	_	I-Premise
252	HRQL	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	addition	_	_	I-Premise
256	of	_	_	I-Premise
257	RT	_	_	I-Premise
258	to	_	_	I-Premise
259	surgery	_	_	I-Premise
260	resulted	_	_	I-Premise
261	in	_	_	I-Premise
262	more	_	_	I-Premise
263	frequent	_	_	I-Premise
264	urination	_	_	I-Premise
265	,	_	_	I-Premise
266	as	_	_	I-Premise
267	well	_	_	I-Premise
268	as	_	_	I-Premise
269	early	_	_	I-Premise
270	report	_	_	I-Premise
271	of	_	_	I-Premise
272	more	_	_	I-Premise
273	bowel	_	_	I-Premise
274	dysfunction	_	_	I-Premise
275	,	_	_	O
276	although	_	_	B-Premise
277	bowel	_	_	I-Premise
278	function	_	_	I-Premise
279	differences	_	_	I-Premise
280	disappeared	_	_	I-Premise
281	over	_	_	I-Premise
282	the	_	_	I-Premise
283	5-year	_	_	I-Premise
284	period	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Claim
287	addition	_	_	I-Claim
288	of	_	_	I-Claim
289	RT	_	_	I-Claim
290	did	_	_	I-Claim
291	not	_	_	I-Claim
292	negatively	_	_	I-Claim
293	impact	_	_	I-Claim
294	ED	_	_	I-Claim
295	.	_	_	I-Claim


0	Evidence	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	the	_	_	I-Claim
4	re-entry	_	_	I-Claim
5	phase	_	_	I-Claim
6	(	_	_	I-Claim
7	ie	_	_	I-Claim
8	,	_	_	I-Claim
9	early	_	_	I-Claim
10	period	_	_	I-Claim
11	after	_	_	I-Claim
12	medical	_	_	I-Claim
13	treatment	_	_	I-Claim
14	completion	_	_	I-Claim
15	)	_	_	I-Claim
16	presents	_	_	I-Claim
17	distinct	_	_	I-Claim
18	challenges	_	_	I-Claim
19	for	_	_	I-Claim
20	cancer	_	_	I-Claim
21	patients	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	facilitate	_	_	O
25	the	_	_	O
26	transition	_	_	O
27	to	_	_	O
28	recovery	_	_	O
29	,	_	_	O
30	we	_	_	O
31	conducted	_	_	O
32	the	_	_	O
33	Moving	_	_	O
34	Beyond	_	_	O
35	Cancer	_	_	O
36	(	_	_	O
37	MBC	_	_	O
38	)	_	_	O
39	trial	_	_	O
40	,	_	_	O
41	a	_	_	O
42	multisite	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	,	_	_	O
46	controlled	_	_	O
47	trial	_	_	O
48	of	_	_	O
49	psychoeducational	_	_	O
50	interventions	_	_	O
51	for	_	_	O
52	breast	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	Breast	_	_	O
57	cancer	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	registered	_	_	O
61	within	_	_	O
62	6	_	_	O
63	weeks	_	_	O
64	after	_	_	O
65	surgery	_	_	O
66	.	_	_	O

67	After	_	_	O
68	medical	_	_	O
69	treatment	_	_	O
70	,	_	_	O
71	they	_	_	O
72	completed	_	_	O
73	baseline	_	_	O
74	measures	_	_	O
75	and	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	standard	_	_	O
81	National	_	_	O
82	Cancer	_	_	O
83	Institute	_	_	O
84	print	_	_	O
85	material	_	_	O
86	(	_	_	O
87	CTL	_	_	O
88	)	_	_	O
89	;	_	_	O
90	standard	_	_	O
91	print	_	_	O
92	material	_	_	O
93	and	_	_	O
94	peer-modeling	_	_	O
95	videotape	_	_	O
96	(	_	_	O
97	VID	_	_	O
98	)	_	_	O
99	;	_	_	O
100	or	_	_	O
101	standard	_	_	O
102	print	_	_	O
103	material	_	_	O
104	,	_	_	O
105	videotape	_	_	O
106	,	_	_	O
107	two	_	_	O
108	sessions	_	_	O
109	with	_	_	O
110	a	_	_	O
111	trained	_	_	O
112	cancer	_	_	O
113	educator	_	_	O
114	,	_	_	O
115	and	_	_	O
116	informational	_	_	O
117	workbook	_	_	O
118	(	_	_	O
119	EDU	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Two	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	points	_	_	O
126	were	_	_	O
127	examined	_	_	O
128	:	_	_	O
129	energy/fatigue	_	_	O
130	and	_	_	O
131	cancer-specific	_	_	O
132	distress	_	_	O
133	.	_	_	O

134	Secondary	_	_	O
135	end	_	_	O
136	points	_	_	O
137	were	_	_	O
138	depressive	_	_	O
139	symptoms	_	_	O
140	and	_	_	O
141	post-traumatic	_	_	O
142	growth	_	_	O
143	.	_	_	O

144	Perceived	_	_	O
145	preparedness	_	_	O
146	for	_	_	O
147	re-entry	_	_	O
148	was	_	_	O
149	analyzed	_	_	O
150	as	_	_	O
151	a	_	_	O
152	moderator	_	_	O
153	of	_	_	O
154	effects	_	_	O
155	.	_	_	O

156	Of	_	_	O
157	558	_	_	O
158	women	_	_	O
159	randomly	_	_	O
160	assigned	_	_	O
161	to	_	_	O
162	treatment	_	_	O
163	,	_	_	O
164	418	_	_	O
165	completed	_	_	O
166	the	_	_	O
167	6-month	_	_	O
168	assessment	_	_	O
169	and	_	_	O
170	399	_	_	O
171	completed	_	_	O
172	the	_	_	O
173	12-month	_	_	O
174	assessment	_	_	O
175	.	_	_	O

176	In	_	_	B-Premise
177	analyses	_	_	I-Premise
178	controlling	_	_	I-Premise
179	for	_	_	I-Premise
180	study	_	_	I-Premise
181	site	_	_	I-Premise
182	and	_	_	I-Premise
183	baseline	_	_	I-Premise
184	depressive	_	_	I-Premise
185	symptoms	_	_	I-Premise
186	,	_	_	I-Premise
187	VID	_	_	I-Premise
188	produced	_	_	I-Premise
189	significant	_	_	I-Premise
190	improvement	_	_	I-Premise
191	in	_	_	I-Premise
192	energy/fatigue	_	_	I-Premise
193	at	_	_	I-Premise
194	6	_	_	I-Premise
195	months	_	_	I-Premise
196	relative	_	_	I-Premise
197	to	_	_	I-Premise
198	CTL	_	_	I-Premise
199	,	_	_	I-Premise
200	particularly	_	_	I-Premise
201	among	_	_	I-Premise
202	women	_	_	I-Premise
203	who	_	_	I-Premise
204	felt	_	_	I-Premise
205	less	_	_	I-Premise
206	prepared	_	_	I-Premise
207	for	_	_	I-Premise
208	re-entry	_	_	I-Premise
209	at	_	_	I-Premise
210	baseline	_	_	I-Premise
211	.	_	_	I-Premise

212	No	_	_	B-Premise
213	significant	_	_	I-Premise
214	main	_	_	I-Premise
215	effect	_	_	I-Premise
216	of	_	_	I-Premise
217	the	_	_	I-Premise
218	interventions	_	_	I-Premise
219	emerged	_	_	I-Premise
220	on	_	_	I-Premise
221	cancer-specific	_	_	I-Premise
222	distress	_	_	I-Premise
223	,	_	_	I-Premise
224	but	_	_	B-Premise
225	EDU	_	_	I-Premise
226	prompted	_	_	I-Premise
227	greater	_	_	I-Premise
228	reduction	_	_	I-Premise
229	in	_	_	I-Premise
230	this	_	_	I-Premise
231	outcome	_	_	I-Premise
232	relative	_	_	I-Premise
233	to	_	_	I-Premise
234	CTL	_	_	I-Premise
235	at	_	_	I-Premise
236	6	_	_	I-Premise
237	months	_	_	I-Premise
238	for	_	_	I-Premise
239	patients	_	_	I-Premise
240	who	_	_	I-Premise
241	felt	_	_	I-Premise
242	more	_	_	I-Premise
243	prepared	_	_	I-Premise
244	for	_	_	I-Premise
245	re-entry	_	_	I-Premise
246	.	_	_	I-Premise

247	Between-group	_	_	B-Premise
248	differences	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	primary	_	_	I-Premise
252	outcomes	_	_	I-Premise
253	were	_	_	I-Premise
254	not	_	_	I-Premise
255	significant	_	_	I-Premise
256	at	_	_	I-Premise
257	12	_	_	I-Premise
258	months	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	B-Premise
261	no	_	_	I-Premise
262	significant	_	_	I-Premise
263	effects	_	_	I-Premise
264	emerged	_	_	I-Premise
265	on	_	_	I-Premise
266	the	_	_	I-Premise
267	secondary	_	_	I-Premise
268	end	_	_	I-Premise
269	points	_	_	I-Premise
270	.	_	_	I-Premise

271	A	_	_	B-Claim
272	peer-modeling	_	_	I-Claim
273	videotape	_	_	I-Claim
274	can	_	_	I-Claim
275	accelerate	_	_	I-Claim
276	the	_	_	I-Claim
277	recovery	_	_	I-Claim
278	of	_	_	I-Claim
279	energy	_	_	I-Claim
280	during	_	_	I-Claim
281	the	_	_	I-Claim
282	re-entry	_	_	I-Claim
283	phase	_	_	I-Claim
284	in	_	_	I-Claim
285	women	_	_	I-Claim
286	treated	_	_	I-Claim
287	for	_	_	I-Claim
288	breast	_	_	I-Claim
289	cancer	_	_	I-Claim
290	,	_	_	I-Claim
291	particularly	_	_	I-Claim
292	among	_	_	I-Claim
293	those	_	_	I-Claim
294	who	_	_	I-Claim
295	feel	_	_	I-Claim
296	less	_	_	I-Claim
297	prepared	_	_	I-Claim
298	for	_	_	I-Claim
299	re-entry	_	_	I-Claim
300	.	_	_	I-Claim


0	Sentinel	_	_	B-Claim
1	lymph	_	_	I-Claim
2	node	_	_	I-Claim
3	biopsy	_	_	I-Claim
4	in	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	operable	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	is	_	_	I-Claim
11	routinely	_	_	I-Claim
12	used	_	_	I-Claim
13	in	_	_	I-Claim
14	some	_	_	I-Claim
15	countries	_	_	I-Claim
16	for	_	_	I-Claim
17	staging	_	_	I-Claim
18	the	_	_	I-Claim
19	axilla	_	_	I-Claim
20	despite	_	_	I-Claim
21	limited	_	_	I-Claim
22	data	_	_	I-Claim
23	from	_	_	I-Claim
24	randomized	_	_	I-Claim
25	trials	_	_	I-Claim
26	on	_	_	I-Claim
27	morbidity	_	_	I-Claim
28	and	_	_	I-Claim
29	mortality	_	_	I-Claim
30	outcomes	_	_	I-Claim
31	.	_	_	I-Claim

32	We	_	_	O
33	conducted	_	_	O
34	a	_	_	O
35	multicenter	_	_	O
36	randomized	_	_	O
37	trial	_	_	O
38	to	_	_	O
39	compare	_	_	O
40	quality-of-life	_	_	O
41	outcomes	_	_	O
42	between	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	clinically	_	_	O
46	node-negative	_	_	O
47	invasive	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	who	_	_	O
51	received	_	_	O
52	sentinel	_	_	O
53	lymph	_	_	O
54	node	_	_	O
55	biopsy	_	_	O
56	and	_	_	O
57	patients	_	_	O
58	who	_	_	O
59	received	_	_	O
60	standard	_	_	O
61	axillary	_	_	O
62	treatment	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	outcome	_	_	O
67	measures	_	_	O
68	were	_	_	O
69	arm	_	_	O
70	and	_	_	O
71	shoulder	_	_	O
72	morbidity	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	.	_	_	O

78	From	_	_	O
79	November	_	_	O
80	1999	_	_	O
81	to	_	_	O
82	October	_	_	O
83	2003	_	_	O
84	,	_	_	O
85	1031	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	undergo	_	_	O
92	sentinel	_	_	O
93	lymph	_	_	O
94	node	_	_	O
95	biopsy	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	515	_	_	O
100	)	_	_	O
101	or	_	_	O
102	standard	_	_	O
103	axillary	_	_	O
104	surgery	_	_	O
105	(	_	_	O
106	n	_	_	O
107	=	_	_	O
108	516	_	_	O
109	)	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	with	_	_	O
113	sentinel	_	_	O
114	lymph	_	_	O
115	node	_	_	O
116	metastases	_	_	O
117	proceeded	_	_	O
118	to	_	_	O
119	delayed	_	_	O
120	axillary	_	_	O
121	clearance	_	_	O
122	or	_	_	O
123	received	_	_	O
124	axillary	_	_	O
125	radiotherapy	_	_	O
126	(	_	_	O
127	depending	_	_	O
128	on	_	_	O
129	the	_	_	O
130	protocol	_	_	O
131	at	_	_	O
132	the	_	_	O
133	treating	_	_	O
134	institution	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Intention-to-treat	_	_	O
138	analyses	_	_	O
139	of	_	_	O
140	data	_	_	O
141	at	_	_	O
142	1	_	_	O
143	,	_	_	O
144	3	_	_	O
145	,	_	_	O
146	6	_	_	O
147	,	_	_	O
148	and	_	_	O
149	12	_	_	O
150	months	_	_	O
151	after	_	_	O
152	surgery	_	_	O
153	are	_	_	O
154	presented	_	_	O
155	.	_	_	O

156	All	_	_	O
157	statistical	_	_	O
158	tests	_	_	O
159	were	_	_	O
160	two-sided	_	_	O
161	.	_	_	O

162	The	_	_	B-Premise
163	relative	_	_	I-Premise
164	risks	_	_	I-Premise
165	of	_	_	I-Premise
166	any	_	_	I-Premise
167	lymphedema	_	_	I-Premise
168	and	_	_	I-Premise
169	sensory	_	_	I-Premise
170	loss	_	_	I-Premise
171	for	_	_	I-Premise
172	the	_	_	I-Premise
173	sentinel	_	_	I-Premise
174	lymph	_	_	I-Premise
175	node	_	_	I-Premise
176	biopsy	_	_	I-Premise
177	group	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	the	_	_	I-Premise
181	standard	_	_	I-Premise
182	axillary	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	at	_	_	I-Premise
186	12	_	_	I-Premise
187	months	_	_	I-Premise
188	were	_	_	I-Premise
189	0.37	_	_	I-Premise
190	(	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	confidence	_	_	I-Premise
194	interval	_	_	I-Premise
195	[	_	_	I-Premise
196	CI	_	_	I-Premise
197	]	_	_	I-Premise
198	=	_	_	I-Premise
199	0.23	_	_	I-Premise
200	to	_	_	I-Premise
201	0.60	_	_	I-Premise
202	;	_	_	I-Premise
203	absolute	_	_	I-Premise
204	rates	_	_	I-Premise
205	:	_	_	I-Premise
206	5	_	_	I-Premise
207	%	_	_	I-Premise
208	versus	_	_	I-Premise
209	13	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	and	_	_	I-Premise
213	0.37	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	=	_	_	I-Premise
219	0.27	_	_	I-Premise
220	to	_	_	I-Premise
221	0.50	_	_	I-Premise
222	;	_	_	I-Premise
223	absolute	_	_	I-Premise
224	rates	_	_	I-Premise
225	:	_	_	I-Premise
226	11	_	_	I-Premise
227	%	_	_	I-Premise
228	versus	_	_	I-Premise
229	31	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	respectively	_	_	I-Premise
234	.	_	_	I-Premise

235	Drain	_	_	B-Premise
236	usage	_	_	I-Premise
237	,	_	_	I-Premise
238	length	_	_	I-Premise
239	of	_	_	I-Premise
240	hospital	_	_	I-Premise
241	stay	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	time	_	_	I-Premise
245	to	_	_	I-Premise
246	resumption	_	_	I-Premise
247	of	_	_	I-Premise
248	normal	_	_	I-Premise
249	day-to-day	_	_	I-Premise
250	activities	_	_	I-Premise
251	after	_	_	I-Premise
252	surgery	_	_	I-Premise
253	were	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significantly	_	_	I-Premise
256	lower	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	sentinel	_	_	I-Premise
260	lymph	_	_	I-Premise
261	node	_	_	I-Premise
262	biopsy	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	all	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	.001	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	axillary	_	_	I-Premise
273	operative	_	_	I-Premise
274	time	_	_	I-Premise
275	was	_	_	I-Premise
276	reduced	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.055	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	Overall	_	_	B-Premise
284	patient-recorded	_	_	I-Premise
285	quality	_	_	I-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	and	_	_	I-Premise
289	arm	_	_	I-Premise
290	functioning	_	_	I-Premise
291	scores	_	_	I-Premise
292	were	_	_	I-Premise
293	statistically	_	_	I-Premise
294	significantly	_	_	I-Premise
295	better	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	sentinel	_	_	I-Premise
299	lymph	_	_	I-Premise
300	node	_	_	I-Premise
301	biopsy	_	_	I-Premise
302	group	_	_	I-Premise
303	throughout	_	_	I-Premise
304	(	_	_	I-Premise
305	all	_	_	I-Premise
306	P	_	_	I-Premise
307	<	_	_	I-Premise
308	or	_	_	I-Premise
309	=	_	_	I-Premise
310	.003	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	These	_	_	B-Premise
314	benefits	_	_	I-Premise
315	were	_	_	I-Premise
316	seen	_	_	I-Premise
317	with	_	_	I-Premise
318	no	_	_	I-Premise
319	increase	_	_	I-Premise
320	in	_	_	I-Premise
321	anxiety	_	_	I-Premise
322	levels	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	sentinel	_	_	I-Premise
326	lymph	_	_	I-Premise
327	node	_	_	I-Premise
328	biopsy	_	_	I-Premise
329	group	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	>	_	_	I-Premise
333	.05	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Sentinel	_	_	B-Claim
337	lymph	_	_	I-Claim
338	node	_	_	I-Claim
339	biopsy	_	_	I-Claim
340	is	_	_	I-Claim
341	associated	_	_	I-Claim
342	with	_	_	I-Claim
343	reduced	_	_	I-Claim
344	arm	_	_	I-Claim
345	morbidity	_	_	I-Claim
346	and	_	_	I-Claim
347	better	_	_	I-Claim
348	quality	_	_	I-Claim
349	of	_	_	I-Claim
350	life	_	_	I-Claim
351	than	_	_	I-Claim
352	standard	_	_	I-Claim
353	axillary	_	_	I-Claim
354	treatment	_	_	I-Claim
355	and	_	_	I-Claim
356	should	_	_	I-Claim
357	be	_	_	I-Claim
358	the	_	_	I-Claim
359	treatment	_	_	I-Claim
360	of	_	_	I-Claim
361	choice	_	_	I-Claim
362	for	_	_	I-Claim
363	patients	_	_	I-Claim
364	who	_	_	I-Claim
365	have	_	_	I-Claim
366	early-stage	_	_	I-Claim
367	breast	_	_	I-Claim
368	cancer	_	_	I-Claim
369	with	_	_	I-Claim
370	clinically	_	_	I-Claim
371	negative	_	_	I-Claim
372	nodes	_	_	I-Claim
373	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	immediate	_	_	O
4	and	_	_	O
5	long-term	_	_	O
6	effects	_	_	O
7	of	_	_	O
8	true	_	_	O
9	acupuncture	_	_	O
10	versus	_	_	O
11	sham	_	_	O
12	acupuncture	_	_	O
13	on	_	_	O
14	hot	_	_	O
15	flash	_	_	O
16	frequency	_	_	O
17	in	_	_	O
18	women	_	_	O
19	with	_	_	O
20	breast	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	Seventy-two	_	_	O
24	women	_	_	O
25	with	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	experiencing	_	_	O
29	three	_	_	O
30	or	_	_	O
31	more	_	_	O
32	hot	_	_	O
33	flashes	_	_	O
34	per	_	_	O
35	day	_	_	O
36	were	_	_	O
37	randomly	_	_	O
38	assigned	_	_	O
39	to	_	_	O
40	receive	_	_	O
41	either	_	_	O
42	true	_	_	O
43	or	_	_	O
44	sham	_	_	O
45	acupuncture	_	_	O
46	.	_	_	O

47	Interventions	_	_	O
48	were	_	_	O
49	given	_	_	O
50	twice	_	_	O
51	weekly	_	_	O
52	for	_	_	O
53	4	_	_	O
54	consecutive	_	_	O
55	weeks	_	_	O
56	.	_	_	O

57	Hot	_	_	O
58	flash	_	_	O
59	frequency	_	_	O
60	was	_	_	O
61	evaluated	_	_	O
62	at	_	_	O
63	baseline	_	_	O
64	,	_	_	O
65	at	_	_	O
66	6	_	_	O
67	weeks	_	_	O
68	,	_	_	O
69	and	_	_	O
70	at	_	_	O
71	6	_	_	O
72	months	_	_	O
73	after	_	_	O
74	initiation	_	_	O
75	of	_	_	O
76	treatment	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	initially	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	the	_	_	O
84	sham	_	_	O
85	group	_	_	O
86	were	_	_	O
87	crossed	_	_	O
88	over	_	_	O
89	to	_	_	O
90	true	_	_	O
91	acupuncture	_	_	O
92	starting	_	_	O
93	at	_	_	O
94	week	_	_	O
95	7	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	number	_	_	O
100	of	_	_	O
101	hot	_	_	O
102	flashes	_	_	O
103	per	_	_	O
104	day	_	_	O
105	was	_	_	O
106	reduced	_	_	O
107	from	_	_	O
108	8.7	_	_	O
109	(	_	_	O
110	standard	_	_	O
111	deviation	_	_	O
112	[	_	_	O
113	SD	_	_	O
114	]	_	_	O
115	,	_	_	O
116	3.9	_	_	O
117	)	_	_	O
118	to	_	_	O
119	6.2	_	_	O
120	(	_	_	O
121	SD	_	_	O
122	,	_	_	O
123	4.2	_	_	O
124	)	_	_	O
125	in	_	_	O
126	the	_	_	O
127	true	_	_	O
128	acupuncture	_	_	O
129	group	_	_	O
130	and	_	_	O
131	from	_	_	O
132	10.0	_	_	O
133	(	_	_	O
134	SD	_	_	O
135	,	_	_	O
136	6.1	_	_	O
137	)	_	_	O
138	to	_	_	O
139	7.6	_	_	O
140	(	_	_	O
141	SD	_	_	O
142	,	_	_	O
143	5.7	_	_	O
144	)	_	_	O
145	in	_	_	O
146	the	_	_	O
147	sham	_	_	O
148	group	_	_	O
149	.	_	_	O

150	True	_	_	B-Premise
151	acupuncture	_	_	I-Premise
152	was	_	_	I-Premise
153	associated	_	_	I-Premise
154	with	_	_	I-Premise
155	0.8	_	_	I-Premise
156	fewer	_	_	I-Premise
157	hot	_	_	I-Premise
158	flashes	_	_	I-Premise
159	per	_	_	I-Premise
160	day	_	_	I-Premise
161	than	_	_	I-Premise
162	sham	_	_	I-Premise
163	at	_	_	I-Premise
164	6	_	_	I-Premise
165	weeks	_	_	I-Premise
166	,	_	_	O
167	but	_	_	B-Premise
168	the	_	_	I-Premise
169	difference	_	_	I-Premise
170	did	_	_	I-Premise
171	not	_	_	I-Premise
172	reach	_	_	I-Premise
173	statistical	_	_	I-Premise
174	significance	_	_	I-Premise
175	(	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	CI	_	_	I-Premise
179	,	_	_	I-Premise
180	-0.7	_	_	I-Premise
181	to	_	_	I-Premise
182	2.4	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.3	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	When	_	_	B-Premise
190	participants	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	sham	_	_	I-Premise
194	acupuncture	_	_	I-Premise
195	group	_	_	I-Premise
196	were	_	_	I-Premise
197	crossed	_	_	I-Premise
198	over	_	_	I-Premise
199	to	_	_	I-Premise
200	true	_	_	I-Premise
201	acupuncture	_	_	I-Premise
202	,	_	_	I-Premise
203	a	_	_	I-Premise
204	further	_	_	I-Premise
205	reduction	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	frequency	_	_	I-Premise
209	of	_	_	I-Premise
210	hot	_	_	I-Premise
211	flashes	_	_	I-Premise
212	was	_	_	I-Premise
213	seen	_	_	I-Premise
214	.	_	_	I-Premise

215	This	_	_	O
216	reduction	_	_	O
217	in	_	_	O
218	hot	_	_	O
219	flash	_	_	O
220	frequency	_	_	O
221	persisted	_	_	O
222	for	_	_	O
223	up	_	_	O
224	to	_	_	O
225	6	_	_	O
226	months	_	_	O
227	after	_	_	O
228	the	_	_	O
229	completion	_	_	O
230	of	_	_	O
231	treatment	_	_	O
232	.	_	_	O

233	Hot	_	_	B-Claim
234	flash	_	_	I-Claim
235	frequency	_	_	I-Claim
236	in	_	_	I-Claim
237	breast	_	_	I-Claim
238	cancer	_	_	I-Claim
239	patients	_	_	I-Claim
240	was	_	_	I-Claim
241	reduced	_	_	I-Claim
242	following	_	_	I-Claim
243	acupuncture	_	_	I-Claim
244	.	_	_	I-Claim

245	However	_	_	O
246	,	_	_	O
247	when	_	_	B-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	sham	_	_	I-Premise
251	acupuncture	_	_	I-Premise
252	,	_	_	I-Premise
253	the	_	_	I-Premise
254	reduction	_	_	I-Premise
255	by	_	_	I-Premise
256	the	_	_	I-Premise
257	acupuncture	_	_	I-Premise
258	regimen	_	_	I-Premise
259	as	_	_	I-Premise
260	provided	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	current	_	_	I-Premise
264	study	_	_	I-Premise
265	did	_	_	I-Premise
266	not	_	_	I-Premise
267	reach	_	_	I-Premise
268	statistical	_	_	I-Premise
269	significance	_	_	I-Premise
270	.	_	_	I-Premise

271	We	_	_	B-Claim
272	can	_	_	I-Claim
273	not	_	_	I-Claim
274	exclude	_	_	I-Claim
275	the	_	_	I-Claim
276	possibility	_	_	I-Claim
277	that	_	_	I-Claim
278	a	_	_	I-Claim
279	longer	_	_	I-Claim
280	and	_	_	I-Claim
281	more	_	_	I-Claim
282	intense	_	_	I-Claim
283	acupuncture	_	_	I-Claim
284	intervention	_	_	I-Claim
285	could	_	_	I-Claim
286	produce	_	_	I-Claim
287	a	_	_	I-Claim
288	larger	_	_	I-Claim
289	reduction	_	_	I-Claim
290	of	_	_	I-Claim
291	these	_	_	I-Claim
292	symptoms	_	_	I-Claim
293	.	_	_	I-Claim


0	Single-agent	_	_	O
1	therapy	_	_	O
2	with	_	_	O
3	bicalutamide	_	_	O
4	,	_	_	O
5	a	_	_	O
6	nonsteroidal	_	_	O
7	antiandrogen	_	_	O
8	,	_	_	O
9	was	_	_	O
10	compared	_	_	O
11	with	_	_	O
12	castration	_	_	O
13	,	_	_	O
14	either	_	_	O
15	surgical	_	_	O
16	or	_	_	O
17	medical	_	_	O
18	,	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	untreated	_	_	O
23	Stage	_	_	O
24	D2	_	_	O
25	prostate	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	In	_	_	O
29	an	_	_	O
30	open	_	_	O
31	,	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	multicenter	_	_	O
35	trial	_	_	O
36	,	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	50	_	_	O
44	mg	_	_	O
45	bicalutamide	_	_	O
46	(	_	_	O
47	n	_	_	O
48	=	_	_	O
49	243	_	_	O
50	)	_	_	O
51	once	_	_	O
52	daily	_	_	O
53	or	_	_	O
54	to	_	_	O
55	castration	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	243	_	_	O
60	)	_	_	O
61	,	_	_	O
62	either	_	_	O
63	orchiectomy	_	_	O
64	or	_	_	O
65	depot	_	_	O
66	injection	_	_	O
67	of	_	_	O
68	goserelin	_	_	O
69	acetate	_	_	O
70	every	_	_	O
71	28	_	_	O
72	days	_	_	O
73	.	_	_	O

74	Primary	_	_	O
75	efficacy	_	_	O
76	endpoints	_	_	O
77	were	_	_	O
78	times	_	_	O
79	to	_	_	O
80	treatment	_	_	O
81	failure	_	_	O
82	and	_	_	O
83	objective	_	_	O
84	disease	_	_	O
85	progression	_	_	O
86	and	_	_	O
87	survival	_	_	O
88	.	_	_	O

89	Assessments	_	_	O
90	included	_	_	O
91	review	_	_	O
92	of	_	_	O
93	measurable	_	_	O
94	metastases	_	_	O
95	,	_	_	O
96	prostate	_	_	O
97	dimensions	_	_	O
98	,	_	_	O
99	Eastern	_	_	O
100	Cooperative	_	_	O
101	Oncology	_	_	O
102	Group	_	_	O
103	performance	_	_	O
104	status	_	_	O
105	,	_	_	O
106	pain	_	_	O
107	,	_	_	O
108	analgesic	_	_	O
109	requirements	_	_	O
110	,	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	responses	_	_	O
116	.	_	_	O

117	The	_	_	O
118	median	_	_	O
119	duration	_	_	O
120	of	_	_	O
121	therapy	_	_	O
122	was	_	_	O
123	39	_	_	O
124	weeks	_	_	O
125	for	_	_	O
126	bicalutamide-treated	_	_	O
127	patients	_	_	O
128	and	_	_	O
129	42	_	_	O
130	weeks	_	_	O
131	for	_	_	O
132	castrated	_	_	O
133	patients	_	_	O
134	;	_	_	O
135	treatment	_	_	O
136	failure	_	_	O
137	occurred	_	_	O
138	in	_	_	O
139	53	_	_	O
140	%	_	_	O
141	and	_	_	O
142	42	_	_	O
143	%	_	_	O
144	and	_	_	O
145	disease	_	_	O
146	progression	_	_	O
147	in	_	_	O
148	43	_	_	O
149	%	_	_	O
150	and	_	_	O
151	33	_	_	O
152	%	_	_	O
153	,	_	_	O
154	respectively	_	_	O
155	.	_	_	O

156	Treatment	_	_	B-Premise
157	effects	_	_	I-Premise
158	favored	_	_	I-Premise
159	castration	_	_	I-Premise
160	for	_	_	I-Premise
161	both	_	_	I-Premise
162	endpoints	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	or	_	_	I-Premise
167	=	_	_	I-Premise
168	0.002	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	with	_	_	I-Premise
172	hazard	_	_	I-Premise
173	ratios	_	_	I-Premise
174	(	_	_	I-Premise
175	bicalutamide	_	_	I-Premise
176	:	_	_	I-Premise
177	castration	_	_	I-Premise
178	)	_	_	I-Premise
179	of	_	_	I-Premise
180	1.54	_	_	I-Premise
181	(	_	_	I-Premise
182	95	_	_	I-Premise
183	%	_	_	I-Premise
184	confidence	_	_	I-Premise
185	interval	_	_	I-Premise
186	[	_	_	I-Premise
187	CI	_	_	I-Premise
188	]	_	_	I-Premise
189	,	_	_	I-Premise
190	1.18	_	_	I-Premise
191	to	_	_	I-Premise
192	2.00	_	_	I-Premise
193	)	_	_	I-Premise
194	for	_	_	I-Premise
195	time	_	_	I-Premise
196	to	_	_	I-Premise
197	treatment	_	_	I-Premise
198	failure	_	_	I-Premise
199	and	_	_	I-Premise
200	1.6	_	_	I-Premise
201	(	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	,	_	_	I-Premise
206	1.19	_	_	I-Premise
207	to	_	_	I-Premise
208	2.15	_	_	I-Premise
209	)	_	_	I-Premise
210	for	_	_	I-Premise
211	time	_	_	I-Premise
212	to	_	_	I-Premise
213	disease	_	_	I-Premise
214	progression	_	_	I-Premise
215	.	_	_	I-Premise

216	From	_	_	B-Premise
217	the	_	_	I-Premise
218	1-year	_	_	I-Premise
219	survival	_	_	I-Premise
220	analysis	_	_	I-Premise
221	,	_	_	I-Premise
222	the	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	for	_	_	I-Premise
226	probability	_	_	I-Premise
227	of	_	_	I-Premise
228	death	_	_	I-Premise
229	was	_	_	I-Premise
230	1.29	_	_	I-Premise
231	(	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	0.96	_	_	I-Premise
237	to	_	_	I-Premise
238	1.72	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Thus	_	_	B-Premise
242	far	_	_	I-Premise
243	,	_	_	I-Premise
244	with	_	_	I-Premise
245	a	_	_	I-Premise
246	median	_	_	I-Premise
247	follow-up	_	_	I-Premise
248	of	_	_	I-Premise
249	86	_	_	I-Premise
250	weeks	_	_	I-Premise
251	,	_	_	I-Premise
252	median	_	_	I-Premise
253	survival	_	_	I-Premise
254	has	_	_	I-Premise
255	not	_	_	I-Premise
256	been	_	_	I-Premise
257	reached	_	_	I-Premise
258	in	_	_	I-Premise
259	either	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	Changes	_	_	B-Premise
263	from	_	_	I-Premise
264	baseline	_	_	I-Premise
265	in	_	_	I-Premise
266	several	_	_	I-Premise
267	quality	_	_	I-Premise
268	of	_	_	I-Premise
269	life	_	_	I-Premise
270	variables	_	_	I-Premise
271	were	_	_	I-Premise
272	significantly	_	_	I-Premise
273	different	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	<	_	_	I-Premise
277	or	_	_	I-Premise
278	=	_	_	I-Premise
279	0.01	_	_	I-Premise
280	)	_	_	I-Premise
281	between	_	_	I-Premise
282	treatment	_	_	I-Premise
283	groups	_	_	I-Premise
284	periodically	_	_	I-Premise
285	from	_	_	I-Premise
286	months	_	_	I-Premise
287	1	_	_	I-Premise
288	to	_	_	I-Premise
289	6	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	all	_	_	I-Premise
293	favored	_	_	I-Premise
294	bicalutamide	_	_	I-Premise
295	.	_	_	I-Premise

296	Overall	_	_	B-Premise
297	,	_	_	I-Premise
298	the	_	_	I-Premise
299	antiandrogen	_	_	I-Premise
300	was	_	_	I-Premise
301	well	_	_	I-Premise
302	tolerated	_	_	I-Premise
303	compared	_	_	I-Premise
304	with	_	_	I-Premise
305	castration	_	_	I-Premise
306	;	_	_	I-Premise
307	with	_	_	B-Premise
308	bicalutamide	_	_	I-Premise
309	,	_	_	I-Premise
310	hot	_	_	I-Premise
311	flushes	_	_	I-Premise
312	occurred	_	_	I-Premise
313	less	_	_	I-Premise
314	often	_	_	I-Premise
315	and	_	_	I-Premise
316	breast	_	_	I-Premise
317	tenderness	_	_	I-Premise
318	and	_	_	I-Premise
319	gynecomastia	_	_	I-Premise
320	more	_	_	I-Premise
321	often	_	_	I-Premise
322	.	_	_	I-Premise

323	Although	_	_	B-Premise
324	a	_	_	I-Premise
325	dosage	_	_	I-Premise
326	of	_	_	I-Premise
327	50	_	_	I-Premise
328	mg	_	_	I-Premise
329	of	_	_	I-Premise
330	bicalutamide	_	_	I-Premise
331	once	_	_	I-Premise
332	daily	_	_	I-Premise
333	was	_	_	I-Premise
334	not	_	_	I-Premise
335	as	_	_	I-Premise
336	effective	_	_	I-Premise
337	as	_	_	I-Premise
338	castration	_	_	I-Premise
339	,	_	_	I-Premise
340	the	_	_	B-Claim
341	favorable	_	_	I-Claim
342	quality	_	_	I-Claim
343	of	_	_	I-Claim
344	life	_	_	I-Claim
345	outcomes	_	_	I-Claim
346	and	_	_	I-Claim
347	the	_	_	I-Claim
348	low	_	_	I-Claim
349	incidence	_	_	I-Claim
350	of	_	_	I-Claim
351	nonhormonal	_	_	I-Claim
352	adverse	_	_	I-Claim
353	events	_	_	I-Claim
354	provide	_	_	I-Claim
355	reasons	_	_	I-Claim
356	to	_	_	I-Claim
357	evaluate	_	_	I-Claim
358	bicalutamide	_	_	I-Claim
359	,	_	_	I-Claim
360	as	_	_	I-Claim
361	a	_	_	I-Claim
362	single	_	_	I-Claim
363	therapeutic	_	_	I-Claim
364	agent	_	_	I-Claim
365	,	_	_	I-Claim
366	at	_	_	I-Claim
367	higher	_	_	I-Claim
368	doses	_	_	I-Claim
369	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	equivalence	_	_	O
4	of	_	_	O
5	three	_	_	O
6	versus	_	_	O
7	four	_	_	O
8	cycles	_	_	O
9	of	_	_	O
10	bleomycin	_	_	O
11	,	_	_	O
12	etoposide	_	_	O
13	,	_	_	O
14	and	_	_	O
15	cisplatin	_	_	O
16	(	_	_	O
17	BEP	_	_	O
18	)	_	_	O
19	and	_	_	O
20	of	_	_	O
21	the	_	_	O
22	5-day	_	_	O
23	schedule	_	_	O
24	versus	_	_	O
25	3	_	_	O
26	days	_	_	O
27	per	_	_	O
28	cycle	_	_	O
29	in	_	_	O
30	good-prognosis	_	_	O
31	germ	_	_	O
32	cell	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	The	_	_	O
36	study	_	_	O
37	was	_	_	O
38	designed	_	_	O
39	as	_	_	O
40	a	_	_	O
41	2	_	_	O
42	x	_	_	O
43	2	_	_	O
44	factorial	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	The	_	_	O
48	aim	_	_	O
49	was	_	_	O
50	to	_	_	O
51	rule	_	_	O
52	out	_	_	O
53	a	_	_	O
54	5	_	_	O
55	%	_	_	O
56	decrease	_	_	O
57	in	_	_	O
58	the	_	_	O
59	2-year	_	_	O
60	progression-free	_	_	O
61	survival	_	_	O
62	(	_	_	O
63	PFS	_	_	O
64	)	_	_	O
65	rate	_	_	O
66	.	_	_	O

67	The	_	_	O
68	study	_	_	O
69	included	_	_	O
70	the	_	_	O
71	assessment	_	_	O
72	of	_	_	O
73	patient	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	.	_	_	O

78	A	_	_	O
79	cycle	_	_	O
80	of	_	_	O
81	BEP	_	_	O
82	consisted	_	_	O
83	of	_	_	O
84	etoposide	_	_	O
85	500	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	,	_	_	O
91	administered	_	_	O
92	at	_	_	O
93	either	_	_	O
94	100	_	_	O
95	mg/m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	days	_	_	O
100	1	_	_	O
101	through	_	_	O
102	5	_	_	O
103	or	_	_	O
104	165	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	days	_	_	O
110	1	_	_	O
111	through	_	_	O
112	3	_	_	O
113	,	_	_	O
114	cisplatin	_	_	O
115	100	_	_	O
116	mg/m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	,	_	_	O
121	administered	_	_	O
122	at	_	_	O
123	either	_	_	O
124	20	_	_	O
125	mg/m	_	_	O
126	(	_	_	O
127	2	_	_	O
128	)	_	_	O
129	days	_	_	O
130	1	_	_	O
131	through	_	_	O
132	5	_	_	O
133	or	_	_	O
134	50	_	_	O
135	mg/m	_	_	O
136	(	_	_	O
137	2	_	_	O
138	)	_	_	O
139	days	_	_	O
140	1	_	_	O
141	and	_	_	O
142	2	_	_	O
143	.	_	_	O

144	Bleomycin	_	_	O
145	30	_	_	O
146	mg	_	_	O
147	was	_	_	O
148	administered	_	_	O
149	on	_	_	O
150	days	_	_	O
151	1	_	_	O
152	,	_	_	O
153	8	_	_	O
154	,	_	_	O
155	and	_	_	O
156	15	_	_	O
157	during	_	_	O
158	cycles	_	_	O
159	1	_	_	O
160	through	_	_	O
161	3	_	_	O
162	.	_	_	O

163	The	_	_	O
164	randomization	_	_	O
165	procedure	_	_	O
166	allowed	_	_	O
167	some	_	_	O
168	investigators	_	_	O
169	to	_	_	O
170	participate	_	_	O
171	only	_	_	O
172	in	_	_	O
173	the	_	_	O
174	comparison	_	_	O
175	of	_	_	O
176	three	_	_	O
177	versus	_	_	O
178	four	_	_	O
179	cycles	_	_	O
180	.	_	_	O

181	From	_	_	O
182	March	_	_	O
183	1995	_	_	O
184	until	_	_	O
185	April	_	_	O
186	1998	_	_	O
187	,	_	_	O
188	812	_	_	O
189	patients	_	_	O
190	were	_	_	O
191	randomly	_	_	O
192	assigned	_	_	O
193	to	_	_	O
194	receive	_	_	O
195	three	_	_	O
196	or	_	_	O
197	four	_	_	O
198	cycles	_	_	O
199	:	_	_	O
200	of	_	_	O
201	these	_	_	O
202	,	_	_	O
203	681	_	_	O
204	were	_	_	O
205	also	_	_	O
206	randomly	_	_	O
207	assigned	_	_	O
208	to	_	_	O
209	the	_	_	O
210	5-day	_	_	O
211	or	_	_	O
212	the	_	_	O
213	3-day	_	_	O
214	schedule	_	_	O
215	.	_	_	O

216	Histology	_	_	O
217	,	_	_	O
218	marker	_	_	O
219	values	_	_	O
220	,	_	_	O
221	and	_	_	O
222	disease	_	_	O
223	extent	_	_	O
224	are	_	_	O
225	well	_	_	O
226	balanced	_	_	O
227	in	_	_	O
228	the	_	_	O
229	treatment	_	_	O
230	arms	_	_	O
231	of	_	_	O
232	the	_	_	O
233	two	_	_	O
234	comparisons	_	_	O
235	.	_	_	O

236	The	_	_	B-Premise
237	projected	_	_	I-Premise
238	2-year	_	_	I-Premise
239	PFS	_	_	I-Premise
240	is	_	_	I-Premise
241	90.4	_	_	I-Premise
242	%	_	_	I-Premise
243	on	_	_	I-Premise
244	three	_	_	I-Premise
245	cycles	_	_	I-Premise
246	and	_	_	I-Premise
247	89.4	_	_	I-Premise
248	%	_	_	I-Premise
249	on	_	_	I-Premise
250	four	_	_	I-Premise
251	cycles	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	PFS	_	_	I-Premise
257	between	_	_	I-Premise
258	three	_	_	I-Premise
259	and	_	_	I-Premise
260	four	_	_	I-Premise
261	cycles	_	_	I-Premise
262	is	_	_	I-Premise
263	-1.0	_	_	I-Premise
264	%	_	_	I-Premise
265	(	_	_	I-Premise
266	80	_	_	I-Premise
267	%	_	_	I-Premise
268	confidence	_	_	I-Premise
269	limit	_	_	I-Premise
270	[	_	_	I-Premise
271	CL	_	_	I-Premise
272	]	_	_	I-Premise
273	,	_	_	I-Premise
274	-3.8	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	+1.8	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Equivalence	_	_	B-Claim
282	for	_	_	I-Claim
283	three	_	_	I-Claim
284	versus	_	_	I-Claim
285	four	_	_	I-Claim
286	cycles	_	_	I-Claim
287	is	_	_	I-Claim
288	claimed	_	_	I-Claim
289	because	_	_	I-Claim
290	both	_	_	I-Claim
291	the	_	_	I-Claim
292	upper	_	_	I-Claim
293	and	_	_	I-Claim
294	lower	_	_	I-Claim
295	bounds	_	_	I-Claim
296	of	_	_	I-Claim
297	the	_	_	I-Claim
298	80	_	_	I-Claim
299	%	_	_	I-Claim
300	CL	_	_	I-Claim
301	are	_	_	I-Claim
302	less	_	_	I-Claim
303	than	_	_	I-Claim
304	5	_	_	I-Claim
305	%	_	_	I-Claim
306	.	_	_	I-Claim

307	In	_	_	B-Premise
308	the	_	_	I-Premise
309	5-	_	_	I-Premise
310	versus	_	_	I-Premise
311	3-day	_	_	I-Premise
312	comparison	_	_	I-Premise
313	,	_	_	I-Premise
314	the	_	_	I-Premise
315	projected	_	_	I-Premise
316	2-year	_	_	I-Premise
317	PFS	_	_	I-Premise
318	is	_	_	I-Premise
319	88.8	_	_	I-Premise
320	%	_	_	I-Premise
321	and	_	_	I-Premise
322	89.7	_	_	I-Premise
323	%	_	_	I-Premise
324	,	_	_	I-Premise
325	respectively	_	_	I-Premise
326	(	_	_	I-Premise
327	difference	_	_	I-Premise
328	,	_	_	I-Premise
329	-0.9	_	_	I-Premise
330	%	_	_	I-Premise
331	,	_	_	I-Premise
332	(	_	_	I-Premise
333	80	_	_	I-Premise
334	%	_	_	I-Premise
335	CL	_	_	I-Premise
336	,	_	_	I-Premise
337	-4.1	_	_	I-Premise
338	%	_	_	I-Premise
339	,	_	_	I-Premise
340	+2.2	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	Hence	_	_	O
345	,	_	_	O
346	equivalence	_	_	B-Claim
347	is	_	_	I-Claim
348	claimed	_	_	I-Claim
349	in	_	_	I-Claim
350	this	_	_	I-Claim
351	comparison	_	_	I-Claim
352	also	_	_	I-Claim
353	.	_	_	I-Claim

354	Frequencies	_	_	B-Premise
355	of	_	_	I-Premise
356	hematologic	_	_	I-Premise
357	and	_	_	I-Premise
358	nonhematologic	_	_	I-Premise
359	toxicities	_	_	I-Premise
360	were	_	_	I-Premise
361	essentially	_	_	I-Premise
362	similar	_	_	I-Premise
363	.	_	_	I-Premise

364	Quality	_	_	B-Premise
365	of	_	_	I-Premise
366	life	_	_	I-Premise
367	was	_	_	I-Premise
368	maintained	_	_	I-Premise
369	better	_	_	I-Premise
370	in	_	_	I-Premise
371	patients	_	_	I-Premise
372	receiving	_	_	I-Premise
373	three	_	_	I-Premise
374	cycles	_	_	I-Premise
375	;	_	_	I-Premise
376	no	_	_	B-Premise
377	differences	_	_	I-Premise
378	were	_	_	I-Premise
379	detected	_	_	I-Premise
380	between	_	_	I-Premise
381	3	_	_	I-Premise
382	and	_	_	I-Premise
383	5	_	_	I-Premise
384	days	_	_	I-Premise
385	of	_	_	I-Premise
386	treatment	_	_	I-Premise
387	.	_	_	I-Premise

388	We	_	_	O
389	conclude	_	_	O
390	that	_	_	O
391	three	_	_	B-Claim
392	cycles	_	_	I-Claim
393	of	_	_	I-Claim
394	BEP	_	_	I-Claim
395	,	_	_	I-Claim
396	with	_	_	I-Claim
397	etoposide	_	_	I-Claim
398	at	_	_	I-Claim
399	500	_	_	I-Claim
400	mg/m	_	_	I-Claim
401	(	_	_	I-Claim
402	2	_	_	I-Claim
403	)	_	_	I-Claim
404	,	_	_	I-Claim
405	is	_	_	I-Claim
406	sufficient	_	_	I-Claim
407	therapy	_	_	I-Claim
408	in	_	_	I-Claim
409	good-prognosis	_	_	I-Claim
410	germ	_	_	I-Claim
411	cell	_	_	I-Claim
412	cancer	_	_	I-Claim
413	and	_	_	O
414	that	_	_	O
415	the	_	_	B-Claim
416	administration	_	_	I-Claim
417	of	_	_	I-Claim
418	the	_	_	I-Claim
419	chemotherapy	_	_	I-Claim
420	in	_	_	I-Claim
421	3	_	_	I-Claim
422	days	_	_	I-Claim
423	has	_	_	I-Claim
424	no	_	_	I-Claim
425	detrimental	_	_	I-Claim
426	effect	_	_	I-Claim
427	on	_	_	I-Claim
428	the	_	_	I-Claim
429	effectiveness	_	_	I-Claim
430	of	_	_	I-Claim
431	the	_	_	I-Claim
432	BEP	_	_	I-Claim
433	regimen	_	_	I-Claim
434	.	_	_	I-Claim


0	The	_	_	O
1	effectiveness	_	_	O
2	of	_	_	O
3	a	_	_	O
4	Pain	_	_	O
5	Education	_	_	O
6	Program	_	_	O
7	in	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	chronic	_	_	O
12	pain	_	_	O
13	offered	_	_	O
14	by	_	_	O
15	nurses	_	_	O
16	was	_	_	O
17	investigated	_	_	O
18	in	_	_	O
19	a	_	_	O
20	randomized	_	_	O
21	controlled	_	_	O
22	clinical	_	_	O
23	trial	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multi-method	_	_	O
27	approach	_	_	O
28	was	_	_	O
29	used	_	_	O
30	in	_	_	O
31	which	_	_	O
32	verbal	_	_	O
33	instruction	_	_	O
34	,	_	_	O
35	written	_	_	O
36	material	_	_	O
37	,	_	_	O
38	an	_	_	O
39	audio	_	_	O
40	cassette	_	_	O
41	tape	_	_	O
42	,	_	_	O
43	and	_	_	O
44	the	_	_	O
45	use	_	_	O
46	of	_	_	O
47	a	_	_	O
48	pain	_	_	O
49	diary	_	_	O
50	were	_	_	O
51	combined	_	_	O
52	to	_	_	O
53	inform	_	_	O
54	and	_	_	O
55	instruct	_	_	O
56	patients	_	_	O
57	about	_	_	O
58	pain	_	_	O
59	and	_	_	O
60	pain	_	_	O
61	management	_	_	O
62	.	_	_	O

63	The	_	_	O
64	Pain	_	_	O
65	Education	_	_	O
66	Program	_	_	O
67	was	_	_	O
68	tailored	_	_	O
69	to	_	_	O
70	the	_	_	O
71	needs	_	_	O
72	of	_	_	O
73	the	_	_	O
74	individual	_	_	O
75	patient	_	_	O
76	and	_	_	O
77	consisted	_	_	O
78	of	_	_	O
79	three	_	_	O
80	elements	_	_	O
81	:	_	_	O
82	(	_	_	O
83	1	_	_	O
84	)	_	_	O
85	educating	_	_	O
86	patients	_	_	O
87	about	_	_	O
88	the	_	_	O
89	basic	_	_	O
90	principles	_	_	O
91	regarding	_	_	O
92	pain	_	_	O
93	and	_	_	O
94	pain	_	_	O
95	management	_	_	O
96	;	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	instructing	_	_	O
101	patients	_	_	O
102	how	_	_	O
103	to	_	_	O
104	report	_	_	O
105	their	_	_	O
106	pain	_	_	O
107	in	_	_	O
108	a	_	_	O
109	pain	_	_	O
110	diary	_	_	O
111	;	_	_	O
112	and	_	_	O
113	(	_	_	O
114	3	_	_	O
115	)	_	_	O
116	instructing	_	_	O
117	patients	_	_	O
118	how	_	_	O
119	to	_	_	O
120	communicate	_	_	O
121	about	_	_	O
122	pain	_	_	O
123	and	_	_	O
124	how	_	_	O
125	to	_	_	O
126	contact	_	_	O
127	health	_	_	O
128	care	_	_	O
129	providers	_	_	O
130	.	_	_	O

131	Following	_	_	O
132	pretesting	_	_	O
133	in	_	_	O
134	313	_	_	O
135	patients	_	_	O
136	,	_	_	O
137	patients	_	_	O
138	who	_	_	O
139	needed	_	_	O
140	district	_	_	O
141	nursing	_	_	O
142	and	_	_	O
143	who	_	_	O
144	did	_	_	O
145	not	_	_	O
146	need	_	_	O
147	district	_	_	O
148	nursing	_	_	O
149	at	_	_	O
150	home	_	_	O
151	were	_	_	O
152	randomly	_	_	O
153	assigned	_	_	O
154	to	_	_	O
155	a	_	_	O
156	control	_	_	O
157	or	_	_	O
158	intervention	_	_	O
159	group	_	_	O
160	.	_	_	O

161	Intervention	_	_	O
162	group	_	_	O
163	patients	_	_	O
164	received	_	_	O
165	the	_	_	O
166	Pain	_	_	O
167	Education	_	_	O
168	Program	_	_	O
169	in	_	_	O
170	the	_	_	O
171	hospital	_	_	O
172	,	_	_	O
173	and	_	_	O
174	3	_	_	O
175	and	_	_	O
176	7	_	_	O
177	days	_	_	O
178	postdischarge	_	_	O
179	by	_	_	O
180	telephone	_	_	O
181	;	_	_	O
182	this	_	_	O
183	was	_	_	O
184	done	_	_	O
185	by	_	_	O
186	nurses	_	_	O
187	who	_	_	O
188	were	_	_	O
189	specially	_	_	O
190	trained	_	_	O
191	as	_	_	O
192	pain	_	_	O
193	counselors	_	_	O
194	.	_	_	O

195	Follow-up	_	_	O
196	assessments	_	_	O
197	were	_	_	O
198	at	_	_	O
199	2	_	_	O
200	,	_	_	O
201	4	_	_	O
202	and	_	_	O
203	8	_	_	O
204	weeks	_	_	O
205	postdischarge	_	_	O
206	.	_	_	O

207	Results	_	_	O
208	of	_	_	O
209	the	_	_	O
210	pretest	_	_	O
211	showed	_	_	O
212	that	_	_	O
213	many	_	_	O
214	patients	_	_	O
215	lacked	_	_	O
216	knowledge	_	_	O
217	about	_	_	O
218	pain	_	_	O
219	and	_	_	O
220	pain	_	_	O
221	management	_	_	O
222	.	_	_	O

223	The	_	_	O
224	majority	_	_	O
225	of	_	_	O
226	pain	_	_	O
227	topics	_	_	O
228	had	_	_	O
229	to	_	_	O
230	be	_	_	O
231	discussed	_	_	O
232	.	_	_	O

233	The	_	_	B-Claim
234	Pain	_	_	I-Claim
235	Education	_	_	I-Claim
236	Program	_	_	I-Claim
237	proved	_	_	I-Claim
238	to	_	_	I-Claim
239	be	_	_	I-Claim
240	feasible	_	_	I-Claim
241	:	_	_	I-Claim
242	75.0	_	_	B-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	patients	_	_	I-Premise
247	had	_	_	I-Premise
248	read	_	_	I-Premise
249	the	_	_	I-Premise
250	entire	_	_	I-Premise
251	pain	_	_	I-Premise
252	brochure	_	_	I-Premise
253	,	_	_	I-Premise
254	55.7	_	_	I-Premise
255	%	_	_	I-Premise
256	had	_	_	I-Premise
257	listened	_	_	I-Premise
258	to	_	_	I-Premise
259	the	_	_	I-Premise
260	audio	_	_	I-Premise
261	cassette	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	85.6	_	_	I-Premise
265	%	_	_	I-Premise
266	of	_	_	I-Premise
267	pain	_	_	I-Premise
268	scores	_	_	I-Premise
269	were	_	_	I-Premise
270	completed	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	pain	_	_	I-Premise
274	diary	_	_	I-Premise
275	.	_	_	I-Premise

276	Results	_	_	B-Claim
277	showed	_	_	I-Claim
278	a	_	_	I-Claim
279	significant	_	_	I-Claim
280	increase	_	_	I-Claim
281	in	_	_	I-Claim
282	pain	_	_	I-Claim
283	knowledge	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	who	_	_	I-Claim
287	received	_	_	I-Claim
288	the	_	_	I-Claim
289	Pain	_	_	I-Claim
290	Education	_	_	I-Claim
291	Program	_	_	I-Claim
292	and	_	_	I-Claim
293	a	_	_	I-Claim
294	significant	_	_	I-Claim
295	decrease	_	_	I-Claim
296	in	_	_	I-Claim
297	pain	_	_	I-Claim
298	intensity	_	_	I-Claim
299	.	_	_	I-Claim

300	However	_	_	B-Premise
301	,	_	_	I-Premise
302	pain	_	_	I-Premise
303	relief	_	_	I-Premise
304	was	_	_	I-Premise
305	mainly	_	_	I-Premise
306	found	_	_	I-Premise
307	in	_	_	I-Premise
308	the	_	_	I-Premise
309	intervention	_	_	I-Premise
310	group	_	_	I-Premise
311	patients	_	_	I-Premise
312	without	_	_	I-Premise
313	district	_	_	I-Premise
314	nursing	_	_	I-Premise
315	.	_	_	I-Premise

316	It	_	_	B-Claim
317	can	_	_	I-Claim
318	be	_	_	I-Claim
319	concluded	_	_	I-Claim
320	that	_	_	I-Claim
321	the	_	_	I-Claim
322	tailored	_	_	I-Claim
323	Pain	_	_	I-Claim
324	Education	_	_	I-Claim
325	Program	_	_	I-Claim
326	is	_	_	I-Claim
327	effective	_	_	I-Claim
328	for	_	_	I-Claim
329	cancer	_	_	I-Claim
330	patients	_	_	I-Claim
331	in	_	_	I-Claim
332	chronic	_	_	I-Claim
333	pain	_	_	I-Claim
334	.	_	_	I-Claim

335	The	_	_	B-Claim
336	use	_	_	I-Claim
337	of	_	_	I-Claim
338	the	_	_	I-Claim
339	Pain	_	_	I-Claim
340	Education	_	_	I-Claim
341	Program	_	_	I-Claim
342	by	_	_	I-Claim
343	nurses	_	_	I-Claim
344	should	_	_	I-Claim
345	be	_	_	I-Claim
346	seriously	_	_	I-Claim
347	considered	_	_	I-Claim
348	on	_	_	I-Claim
349	oncology	_	_	I-Claim
350	units	_	_	I-Claim
351	.	_	_	I-Claim


0	Proinflammatory	_	_	O
1	cytokines	_	_	O
2	,	_	_	O
3	especially	_	_	O
4	tumour	_	_	O
5	necrosis	_	_	O
6	factor	_	_	O
7	alpha	_	_	O
8	(	_	_	O
9	TNF-alpha	_	_	O
10	)	_	_	O
11	,	_	_	O
12	play	_	_	O
13	a	_	_	O
14	prominent	_	_	O
15	role	_	_	O
16	in	_	_	O
17	the	_	_	O
18	pathogenesis	_	_	O
19	of	_	_	O
20	cancer	_	_	O
21	cachexia	_	_	O
22	.	_	_	O

23	Thalidomide	_	_	B-Claim
24	,	_	_	I-Claim
25	which	_	_	I-Claim
26	is	_	_	I-Claim
27	an	_	_	I-Claim
28	inhibitor	_	_	I-Claim
29	of	_	_	I-Claim
30	TNF-alpha	_	_	I-Claim
31	synthesis	_	_	I-Claim
32	,	_	_	I-Claim
33	may	_	_	I-Claim
34	represent	_	_	I-Claim
35	a	_	_	I-Claim
36	novel	_	_	I-Claim
37	and	_	_	I-Claim
38	rational	_	_	I-Claim
39	approach	_	_	I-Claim
40	to	_	_	I-Claim
41	the	_	_	I-Claim
42	treatment	_	_	I-Claim
43	of	_	_	I-Claim
44	cancer	_	_	I-Claim
45	cachexia	_	_	I-Claim
46	.	_	_	I-Claim

47	To	_	_	O
48	assess	_	_	O
49	the	_	_	O
50	safety	_	_	O
51	and	_	_	O
52	efficacy	_	_	O
53	of	_	_	O
54	thalidomide	_	_	O
55	in	_	_	O
56	attenuating	_	_	O
57	weight	_	_	O
58	loss	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	cachexia	_	_	O
63	secondary	_	_	O
64	to	_	_	O
65	advanced	_	_	O
66	pancreatic	_	_	O
67	cancer	_	_	O
68	.	_	_	O

69	Fifty	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	advanced	_	_	O
73	pancreatic	_	_	O
74	cancer	_	_	O
75	who	_	_	O
76	had	_	_	O
77	lost	_	_	O
78	at	_	_	O
79	least	_	_	O
80	10	_	_	O
81	%	_	_	O
82	of	_	_	O
83	their	_	_	O
84	body	_	_	O
85	weight	_	_	O
86	were	_	_	O
87	randomised	_	_	O
88	to	_	_	O
89	receive	_	_	O
90	thalidomide	_	_	O
91	200	_	_	O
92	mg	_	_	O
93	daily	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	for	_	_	O
97	24	_	_	O
98	weeks	_	_	O
99	in	_	_	O
100	a	_	_	O
101	single	_	_	O
102	centre	_	_	O
103	,	_	_	O
104	double	_	_	O
105	blind	_	_	O
106	,	_	_	O
107	randomised	_	_	O
108	controlled	_	_	O
109	trial	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	outcome	_	_	O
114	was	_	_	O
115	change	_	_	O
116	in	_	_	O
117	weight	_	_	O
118	and	_	_	O
119	nutritional	_	_	O
120	status	_	_	O
121	.	_	_	O

122	Thirty	_	_	O
123	three	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	16	_	_	O
127	control	_	_	O
128	,	_	_	O
129	17	_	_	O
130	thalidomide	_	_	O
131	)	_	_	O
132	were	_	_	O
133	evaluated	_	_	O
134	at	_	_	O
135	four	_	_	O
136	weeks	_	_	O
137	,	_	_	O
138	and	_	_	O
139	20	_	_	O
140	patients	_	_	O
141	(	_	_	O
142	eight	_	_	O
143	control	_	_	O
144	,	_	_	O
145	12	_	_	O
146	thalidomide	_	_	O
147	)	_	_	O
148	at	_	_	O
149	eight	_	_	O
150	weeks	_	_	O
151	.	_	_	O

152	At	_	_	B-Premise
153	four	_	_	I-Premise
154	weeks	_	_	I-Premise
155	,	_	_	I-Premise
156	patients	_	_	I-Premise
157	who	_	_	I-Premise
158	received	_	_	I-Premise
159	thalidomide	_	_	I-Premise
160	had	_	_	I-Premise
161	gained	_	_	I-Premise
162	on	_	_	I-Premise
163	average	_	_	I-Premise
164	0.37	_	_	I-Premise
165	kg	_	_	I-Premise
166	in	_	_	I-Premise
167	weight	_	_	I-Premise
168	and	_	_	I-Premise
169	1.0	_	_	I-Premise
170	cm	_	_	I-Premise
171	(	_	_	I-Premise
172	3	_	_	I-Premise
173	)	_	_	I-Premise
174	in	_	_	I-Premise
175	arm	_	_	I-Premise
176	muscle	_	_	I-Premise
177	mass	_	_	I-Premise
178	(	_	_	I-Premise
179	AMA	_	_	I-Premise
180	)	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	a	_	_	I-Premise
184	loss	_	_	I-Premise
185	of	_	_	I-Premise
186	2.21	_	_	I-Premise
187	kg	_	_	I-Premise
188	(	_	_	I-Premise
189	absolute	_	_	I-Premise
190	difference	_	_	I-Premise
191	-2.59	_	_	I-Premise
192	kg	_	_	I-Premise
193	(	_	_	I-Premise
194	95	_	_	I-Premise
195	%	_	_	I-Premise
196	confidence	_	_	I-Premise
197	interval	_	_	I-Premise
198	(	_	_	I-Premise
199	CI	_	_	I-Premise
200	)	_	_	I-Premise
201	-4.3	_	_	I-Premise
202	to	_	_	I-Premise
203	-0.8	_	_	I-Premise
204	)	_	_	I-Premise
205	;	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.005	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	4.46	_	_	I-Premise
212	cm	_	_	I-Premise
213	(	_	_	I-Premise
214	3	_	_	I-Premise
215	)	_	_	I-Premise
216	(	_	_	I-Premise
217	absolute	_	_	I-Premise
218	difference	_	_	I-Premise
219	-5.6	_	_	I-Premise
220	cm	_	_	I-Premise
221	(	_	_	I-Premise
222	3	_	_	I-Premise
223	)	_	_	I-Premise
224	(	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	CI	_	_	I-Premise
228	-8.9	_	_	I-Premise
229	to	_	_	I-Premise
230	-2.2	_	_	I-Premise
231	)	_	_	I-Premise
232	;	_	_	I-Premise
233	p	_	_	I-Premise
234	=	_	_	I-Premise
235	0.002	_	_	I-Premise
236	)	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	placebo	_	_	I-Premise
240	group	_	_	I-Premise
241	.	_	_	I-Premise

242	At	_	_	B-Premise
243	eight	_	_	I-Premise
244	weeks	_	_	I-Premise
245	,	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	thalidomide	_	_	I-Premise
250	group	_	_	I-Premise
251	had	_	_	I-Premise
252	lost	_	_	I-Premise
253	0.06	_	_	I-Premise
254	kg	_	_	I-Premise
255	in	_	_	I-Premise
256	weight	_	_	I-Premise
257	and	_	_	I-Premise
258	0.5	_	_	I-Premise
259	cm	_	_	I-Premise
260	(	_	_	I-Premise
261	3	_	_	I-Premise
262	)	_	_	I-Premise
263	in	_	_	I-Premise
264	AMA	_	_	I-Premise
265	compared	_	_	I-Premise
266	with	_	_	I-Premise
267	a	_	_	I-Premise
268	loss	_	_	I-Premise
269	of	_	_	I-Premise
270	3.62	_	_	I-Premise
271	kg	_	_	I-Premise
272	(	_	_	I-Premise
273	absolute	_	_	I-Premise
274	difference	_	_	I-Premise
275	-3.57	_	_	I-Premise
276	kg	_	_	I-Premise
277	(	_	_	I-Premise
278	95	_	_	I-Premise
279	%	_	_	I-Premise
280	CI	_	_	I-Premise
281	-6.8	_	_	I-Premise
282	to	_	_	I-Premise
283	-0.3	_	_	I-Premise
284	)	_	_	I-Premise
285	;	_	_	I-Premise
286	p	_	_	I-Premise
287	=	_	_	I-Premise
288	0.034	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	8.4	_	_	I-Premise
292	cm	_	_	I-Premise
293	(	_	_	I-Premise
294	3	_	_	I-Premise
295	)	_	_	I-Premise
296	(	_	_	I-Premise
297	absolute	_	_	I-Premise
298	difference	_	_	I-Premise
299	-7.9	_	_	I-Premise
300	cm	_	_	I-Premise
301	(	_	_	I-Premise
302	3	_	_	I-Premise
303	)	_	_	I-Premise
304	(	_	_	I-Premise
305	95	_	_	I-Premise
306	%	_	_	I-Premise
307	CI	_	_	I-Premise
308	-14.0	_	_	I-Premise
309	to	_	_	I-Premise
310	-1.8	_	_	I-Premise
311	)	_	_	I-Premise
312	;	_	_	I-Premise
313	p	_	_	I-Premise
314	=	_	_	I-Premise
315	0.014	_	_	I-Premise
316	)	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	placebo	_	_	I-Premise
320	group	_	_	I-Premise
321	.	_	_	I-Premise

322	Improvement	_	_	B-Premise
323	in	_	_	I-Premise
324	physical	_	_	I-Premise
325	functioning	_	_	I-Premise
326	correlated	_	_	I-Premise
327	positively	_	_	I-Premise
328	with	_	_	I-Premise
329	weight	_	_	I-Premise
330	gain	_	_	I-Premise
331	(	_	_	I-Premise
332	r	_	_	I-Premise
333	=	_	_	I-Premise
334	0.56	_	_	I-Premise
335	,	_	_	I-Premise
336	p	_	_	I-Premise
337	=	_	_	I-Premise
338	0.001	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	Thalidomide	_	_	B-Claim
342	was	_	_	I-Claim
343	well	_	_	I-Claim
344	tolerated	_	_	I-Claim
345	and	_	_	I-Claim
346	effective	_	_	I-Claim
347	at	_	_	I-Claim
348	attenuating	_	_	I-Claim
349	loss	_	_	I-Claim
350	of	_	_	I-Claim
351	weight	_	_	I-Claim
352	and	_	_	I-Claim
353	lean	_	_	I-Claim
354	body	_	_	I-Claim
355	mass	_	_	I-Claim
356	in	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	cachexia	_	_	I-Claim
360	due	_	_	I-Claim
361	to	_	_	I-Claim
362	advanced	_	_	I-Claim
363	pancreatic	_	_	I-Claim
364	cancer	_	_	I-Claim
365	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	our	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	the	_	_	O
9	effect	_	_	O
10	of	_	_	O
11	cognitive	_	_	O
12	behavioral	_	_	O
13	therapy	_	_	O
14	(	_	_	O
15	CBT	_	_	O
16	)	_	_	O
17	,	_	_	O
18	physical	_	_	O
19	exercise	_	_	O
20	(	_	_	O
21	PE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	and	_	_	O
25	of	_	_	O
26	these	_	_	O
27	two	_	_	O
28	interventions	_	_	O
29	combined	_	_	O
30	(	_	_	O
31	CBT/PE	_	_	O
32	)	_	_	O
33	on	_	_	O
34	menopausal	_	_	O
35	symptoms	_	_	O
36	(	_	_	O
37	primary	_	_	O
38	outcome	_	_	O
39	)	_	_	O
40	,	_	_	O
41	body	_	_	O
42	image	_	_	O
43	,	_	_	O
44	sexual	_	_	O
45	functioning	_	_	O
46	,	_	_	O
47	psychological	_	_	O
48	well-being	_	_	O
49	,	_	_	O
50	and	_	_	O
51	health-related	_	_	O
52	quality	_	_	O
53	of	_	_	O
54	life	_	_	O
55	(	_	_	O
56	secondary	_	_	O
57	outcomes	_	_	O
58	)	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	breast	_	_	O
63	cancer	_	_	O
64	experiencing	_	_	O
65	treatment-induced	_	_	O
66	menopause	_	_	O
67	.	_	_	O

68	Patients	_	_	O
69	with	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	reporting	_	_	O
73	treatment-induced	_	_	O
74	menopausal	_	_	O
75	symptoms	_	_	O
76	(	_	_	O
77	N=422	_	_	O
78	)	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	CBT	_	_	O
84	(	_	_	O
85	n=109	_	_	O
86	)	_	_	O
87	,	_	_	O
88	PE	_	_	O
89	(	_	_	O
90	n=104	_	_	O
91	)	_	_	O
92	,	_	_	O
93	CBT/PE	_	_	O
94	(	_	_	O
95	n=106	_	_	O
96	)	_	_	O
97	,	_	_	O
98	or	_	_	O
99	to	_	_	O
100	a	_	_	O
101	waiting	_	_	O
102	list	_	_	O
103	control	_	_	O
104	group	_	_	O
105	(	_	_	O
106	n=103	_	_	O
107	)	_	_	O
108	.	_	_	O

109	Self-report	_	_	O
110	questionnaires	_	_	O
111	were	_	_	O
112	completed	_	_	O
113	at	_	_	O
114	baseline	_	_	O
115	,	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	,	_	_	O
119	and	_	_	O
120	6	_	_	O
121	months	_	_	O
122	.	_	_	O

123	Multilevel	_	_	O
124	procedures	_	_	O
125	were	_	_	O
126	used	_	_	O
127	to	_	_	O
128	compare	_	_	O
129	the	_	_	O
130	intervention	_	_	O
131	groups	_	_	O
132	with	_	_	O
133	the	_	_	O
134	control	_	_	O
135	group	_	_	O
136	over	_	_	O
137	time	_	_	O
138	.	_	_	O

139	Compared	_	_	B-Premise
140	with	_	_	I-Premise
141	the	_	_	I-Premise
142	control	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	the	_	_	I-Premise
146	intervention	_	_	I-Premise
147	groups	_	_	I-Premise
148	had	_	_	I-Premise
149	a	_	_	I-Premise
150	significant	_	_	I-Premise
151	decrease	_	_	I-Premise
152	in	_	_	I-Premise
153	levels	_	_	I-Premise
154	of	_	_	I-Premise
155	endocrine	_	_	I-Premise
156	symptoms	_	_	I-Premise
157	(	_	_	I-Premise
158	Functional	_	_	I-Premise
159	Assessment	_	_	I-Premise
160	of	_	_	I-Premise
161	Cancer	_	_	I-Premise
162	Therapy-Endocrine	_	_	I-Premise
163	Symptoms	_	_	I-Premise
164	;	_	_	I-Premise
165	P	_	_	I-Premise
166	<	_	_	I-Premise
167	.001	_	_	I-Premise
168	;	_	_	I-Premise
169	effect	_	_	I-Premise
170	size	_	_	I-Premise
171	,	_	_	I-Premise
172	0.31-0.52	_	_	I-Premise
173	)	_	_	I-Premise
174	and	_	_	I-Premise
175	urinary	_	_	I-Premise
176	symptoms	_	_	I-Premise
177	(	_	_	I-Premise
178	Bristol	_	_	I-Premise
179	Female	_	_	I-Premise
180	Lower	_	_	I-Premise
181	Urinary	_	_	I-Premise
182	Tract	_	_	I-Premise
183	Symptoms	_	_	I-Premise
184	Questionnaire	_	_	I-Premise
185	;	_	_	I-Premise
186	P=.002	_	_	I-Premise
187	;	_	_	I-Premise
188	effect	_	_	I-Premise
189	size	_	_	I-Premise
190	,	_	_	I-Premise
191	0.29-0.33	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	they	_	_	I-Premise
196	showed	_	_	I-Premise
197	an	_	_	I-Premise
198	improvement	_	_	I-Premise
199	in	_	_	I-Premise
200	physical	_	_	I-Premise
201	functioning	_	_	I-Premise
202	(	_	_	I-Premise
203	36-Item	_	_	I-Premise
204	Short	_	_	I-Premise
205	Form	_	_	I-Premise
206	Health	_	_	I-Premise
207	Survey	_	_	I-Premise
208	physical	_	_	I-Premise
209	functioning	_	_	I-Premise
210	subscale	_	_	I-Premise
211	;	_	_	I-Premise
212	P=.002	_	_	I-Premise
213	;	_	_	I-Premise
214	effect	_	_	I-Premise
215	size	_	_	I-Premise
216	,	_	_	I-Premise
217	0.37-0.46	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	The	_	_	B-Premise
221	groups	_	_	I-Premise
222	that	_	_	I-Premise
223	included	_	_	I-Premise
224	CBT	_	_	I-Premise
225	also	_	_	I-Premise
226	showed	_	_	I-Premise
227	a	_	_	I-Premise
228	significant	_	_	I-Premise
229	decrease	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	perceived	_	_	I-Premise
233	burden	_	_	I-Premise
234	of	_	_	I-Premise
235	hot	_	_	I-Premise
236	flashes	_	_	I-Premise
237	and	_	_	I-Premise
238	night	_	_	I-Premise
239	sweats	_	_	I-Premise
240	(	_	_	I-Premise
241	problem	_	_	I-Premise
242	rating	_	_	I-Premise
243	scale	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	Hot	_	_	I-Premise
247	Flush	_	_	I-Premise
248	Rating	_	_	I-Premise
249	Scale	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	.001	_	_	I-Premise
254	;	_	_	I-Premise
255	effect	_	_	I-Premise
256	size	_	_	I-Premise
257	,	_	_	I-Premise
258	0.39-0.56	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	an	_	_	I-Premise
262	increase	_	_	I-Premise
263	in	_	_	I-Premise
264	sexual	_	_	I-Premise
265	activity	_	_	I-Premise
266	(	_	_	I-Premise
267	Sexual	_	_	I-Premise
268	Activity	_	_	I-Premise
269	Questionnaire	_	_	I-Premise
270	habit	_	_	I-Premise
271	subscale	_	_	I-Premise
272	;	_	_	I-Premise
273	P=.027	_	_	I-Premise
274	;	_	_	I-Premise
275	effect	_	_	I-Premise
276	size	_	_	I-Premise
277	,	_	_	I-Premise
278	0.65	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Most	_	_	O
282	of	_	_	O
283	these	_	_	O
284	effects	_	_	O
285	were	_	_	O
286	observed	_	_	O
287	at	_	_	O
288	both	_	_	O
289	the	_	_	O
290	12-week	_	_	O
291	and	_	_	O
292	6-month	_	_	O
293	follow-ups	_	_	O
294	.	_	_	O

295	CBT	_	_	B-Claim
296	and	_	_	I-Claim
297	PE	_	_	I-Claim
298	can	_	_	I-Claim
299	have	_	_	I-Claim
300	salutary	_	_	I-Claim
301	effects	_	_	I-Claim
302	on	_	_	I-Claim
303	endocrine	_	_	I-Claim
304	symptoms	_	_	I-Claim
305	and	_	_	I-Claim
306	,	_	_	I-Claim
307	to	_	_	I-Claim
308	a	_	_	I-Claim
309	lesser	_	_	I-Claim
310	degree	_	_	I-Claim
311	,	_	_	I-Claim
312	on	_	_	I-Claim
313	sexuality	_	_	I-Claim
314	and	_	_	I-Claim
315	physical	_	_	I-Claim
316	functioning	_	_	I-Claim
317	of	_	_	I-Claim
318	patients	_	_	I-Claim
319	with	_	_	I-Claim
320	breast	_	_	I-Claim
321	cancer	_	_	I-Claim
322	experiencing	_	_	I-Claim
323	treatment-induced	_	_	I-Claim
324	menopause	_	_	I-Claim
325	.	_	_	I-Claim

326	Future	_	_	B-Claim
327	work	_	_	I-Claim
328	is	_	_	I-Claim
329	needed	_	_	I-Claim
330	to	_	_	I-Claim
331	improve	_	_	I-Claim
332	the	_	_	I-Claim
333	design	_	_	I-Claim
334	and	_	_	I-Claim
335	the	_	_	I-Claim
336	planning	_	_	I-Claim
337	of	_	_	I-Claim
338	these	_	_	I-Claim
339	interventions	_	_	I-Claim
340	to	_	_	I-Claim
341	improve	_	_	I-Claim
342	program	_	_	I-Claim
343	adherence	_	_	I-Claim
344	.	_	_	I-Claim


0	Randomized	_	_	B-Claim
1	trials	_	_	I-Claim
2	in	_	_	I-Claim
3	fluorouracil	_	_	I-Claim
4	(	_	_	I-Claim
5	FU	_	_	I-Claim
6	)	_	_	I-Claim
7	-refractory	_	_	I-Claim
8	colorectal	_	_	I-Claim
9	cancer	_	_	I-Claim
10	demonstrate	_	_	I-Claim
11	significant	_	_	I-Claim
12	survival	_	_	I-Claim
13	advantages	_	_	I-Claim
14	for	_	_	I-Claim
15	patients	_	_	I-Claim
16	receiving	_	_	I-Claim
17	irinotecan	_	_	I-Claim
18	.	_	_	I-Claim

19	We	_	_	O
20	prospectively	_	_	O
21	compared	_	_	O
22	the	_	_	O
23	efficacy	_	_	O
24	and	_	_	O
25	tolerability	_	_	O
26	of	_	_	O
27	two	_	_	O
28	irinotecan	_	_	O
29	regimens	_	_	O
30	(	_	_	O
31	once	_	_	O
32	a	_	_	O
33	week	_	_	O
34	for	_	_	O
35	4	_	_	O
36	weeks	_	_	O
37	followed	_	_	O
38	by	_	_	O
39	a	_	_	O
40	2-week	_	_	O
41	rest	_	_	O
42	period	_	_	O
43	[	_	_	O
44	weekly	_	_	O
45	]	_	_	O
46	v	_	_	O
47	once	_	_	O
48	every	_	_	O
49	3	_	_	O
50	weeks	_	_	O
51	)	_	_	O
52	in	_	_	O
53	such	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	This	_	_	O
57	multicenter	_	_	O
58	,	_	_	O
59	open-label	_	_	O
60	,	_	_	O
61	phase	_	_	O
62	III	_	_	O
63	study	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	patients	_	_	O
67	in	_	_	O
68	a	_	_	O
69	1:2	_	_	O
70	ratio	_	_	O
71	to	_	_	O
72	irinotecan	_	_	O
73	given	_	_	O
74	either	_	_	O
75	weekly	_	_	O
76	(	_	_	O
77	125	_	_	O
78	mg/m	_	_	O
79	(	_	_	O
80	2	_	_	O
81	)	_	_	O
82	)	_	_	O
83	or	_	_	O
84	once	_	_	O
85	every	_	_	O
86	3	_	_	O
87	weeks	_	_	O
88	(	_	_	O
89	350	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	,	_	_	O
95	or	_	_	O
96	300	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	in	_	_	O
102	patients	_	_	O
103	who	_	_	O
104	were	_	_	O
105	>	_	_	O
106	/=	_	_	O
107	70	_	_	O
108	years	_	_	O
109	of	_	_	O
110	age	_	_	O
111	,	_	_	O
112	who	_	_	O
113	had	_	_	O
114	Eastern	_	_	O
115	Cooperative	_	_	O
116	Oncology	_	_	O
117	Group	_	_	O
118	performance	_	_	O
119	status	_	_	O
120	equal	_	_	O
121	to	_	_	O
122	2	_	_	O
123	,	_	_	O
124	or	_	_	O
125	who	_	_	O
126	had	_	_	O
127	prior	_	_	O
128	pelvic	_	_	O
129	irradiation	_	_	O
130	)	_	_	O
131	.	_	_	O

132	With	_	_	B-Premise
133	median	_	_	I-Premise
134	follow-up	_	_	I-Premise
135	of	_	_	I-Premise
136	15.8	_	_	I-Premise
137	months	_	_	I-Premise
138	,	_	_	I-Premise
139	there	_	_	I-Premise
140	was	_	_	I-Premise
141	no	_	_	I-Premise
142	significant	_	_	I-Premise
143	difference	_	_	I-Premise
144	in	_	_	I-Premise
145	1-year	_	_	I-Premise
146	survival	_	_	I-Premise
147	(	_	_	I-Premise
148	46	_	_	I-Premise
149	%	_	_	I-Premise
150	v	_	_	I-Premise
151	41	_	_	I-Premise
152	%	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	;	_	_	I-Premise
156	P	_	_	I-Premise
157	=.42	_	_	I-Premise
158	)	_	_	I-Premise
159	,	_	_	I-Premise
160	median	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	9.9	_	_	I-Premise
164	v	_	_	I-Premise
165	9.9	_	_	I-Premise
166	months	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	P	_	_	I-Premise
171	=.43	_	_	I-Premise
172	)	_	_	I-Premise
173	,	_	_	I-Premise
174	or	_	_	I-Premise
175	median	_	_	I-Premise
176	time	_	_	I-Premise
177	to	_	_	I-Premise
178	progression	_	_	I-Premise
179	(	_	_	I-Premise
180	4.0	_	_	I-Premise
181	v	_	_	I-Premise
182	3.0	_	_	I-Premise
183	months	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=.54	_	_	I-Premise
189	)	_	_	I-Premise
190	between	_	_	I-Premise
191	the	_	_	I-Premise
192	two	_	_	I-Premise
193	regimens	_	_	I-Premise
194	.	_	_	I-Premise

195	Grade	_	_	B-Premise
196	3/4	_	_	I-Premise
197	diarrhea	_	_	I-Premise
198	occurred	_	_	I-Premise
199	in	_	_	I-Premise
200	36	_	_	I-Premise
201	%	_	_	I-Premise
202	of	_	_	I-Premise
203	patients	_	_	I-Premise
204	treated	_	_	I-Premise
205	weekly	_	_	I-Premise
206	and	_	_	I-Premise
207	in	_	_	I-Premise
208	19	_	_	I-Premise
209	%	_	_	I-Premise
210	of	_	_	I-Premise
211	those	_	_	I-Premise
212	treated	_	_	I-Premise
213	once	_	_	I-Premise
214	every	_	_	I-Premise
215	3	_	_	I-Premise
216	weeks	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=.002	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Grade	_	_	B-Premise
223	3/4	_	_	I-Premise
224	neutropenia	_	_	I-Premise
225	occurred	_	_	I-Premise
226	in	_	_	I-Premise
227	29	_	_	I-Premise
228	%	_	_	I-Premise
229	of	_	_	I-Premise
230	patients	_	_	I-Premise
231	treated	_	_	I-Premise
232	weekly	_	_	I-Premise
233	and	_	_	I-Premise
234	34	_	_	I-Premise
235	%	_	_	I-Premise
236	of	_	_	I-Premise
237	those	_	_	I-Premise
238	treated	_	_	I-Premise
239	once	_	_	I-Premise
240	every	_	_	I-Premise
241	3	_	_	I-Premise
242	weeks	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	=.35	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Treatment-related	_	_	B-Premise
249	mortality	_	_	I-Premise
250	occurred	_	_	I-Premise
251	in	_	_	I-Premise
252	five	_	_	I-Premise
253	patients	_	_	I-Premise
254	(	_	_	I-Premise
255	5.3	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	receiving	_	_	I-Premise
259	irinotecan	_	_	I-Premise
260	weekly	_	_	I-Premise
261	and	_	_	I-Premise
262	three	_	_	I-Premise
263	patients	_	_	I-Premise
264	(	_	_	I-Premise
265	1.6	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	given	_	_	I-Premise
269	therapy	_	_	I-Premise
270	once	_	_	I-Premise
271	every	_	_	I-Premise
272	3	_	_	I-Premise
273	weeks	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=.12	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Global	_	_	B-Premise
280	quality	_	_	I-Premise
281	of	_	_	I-Premise
282	life	_	_	I-Premise
283	was	_	_	I-Premise
284	not	_	_	I-Premise
285	statistically	_	_	I-Premise
286	different	_	_	I-Premise
287	between	_	_	I-Premise
288	treatment	_	_	I-Premise
289	groups	_	_	I-Premise
290	.	_	_	I-Premise

291	Irinotecan	_	_	B-Claim
292	schedules	_	_	I-Claim
293	of	_	_	I-Claim
294	weekly	_	_	I-Claim
295	and	_	_	I-Claim
296	of	_	_	I-Claim
297	once	_	_	I-Claim
298	every	_	_	I-Claim
299	3	_	_	I-Claim
300	weeks	_	_	I-Claim
301	demonstrated	_	_	I-Claim
302	similar	_	_	I-Claim
303	efficacy	_	_	I-Claim
304	and	_	_	I-Claim
305	quality	_	_	I-Claim
306	of	_	_	I-Claim
307	life	_	_	I-Claim
308	in	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	FU-refractory	_	_	I-Claim
312	,	_	_	I-Claim
313	metastatic	_	_	I-Claim
314	colorectal	_	_	I-Claim
315	cancer	_	_	I-Claim
316	.	_	_	I-Claim

317	The	_	_	B-Claim
318	regimen	_	_	I-Claim
319	of	_	_	I-Claim
320	once	_	_	I-Claim
321	every	_	_	I-Claim
322	3	_	_	I-Claim
323	weeks	_	_	I-Claim
324	was	_	_	I-Claim
325	associated	_	_	I-Claim
326	with	_	_	I-Claim
327	a	_	_	I-Claim
328	significantly	_	_	I-Claim
329	lower	_	_	I-Claim
330	incidence	_	_	I-Claim
331	of	_	_	I-Claim
332	severe	_	_	I-Claim
333	diarrhea	_	_	I-Claim
334	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	and	_	_	O
2	Pemetrexed	_	_	O
3	are	_	_	O
4	drugs	_	_	O
5	used	_	_	O
6	as	_	_	O
7	second-line	_	_	O
8	therapy	_	_	O
9	for	_	_	O
10	advanced	_	_	O
11	non-small	_	_	O
12	cell	_	_	O
13	lung	_	_	O
14	cancer	_	_	O
15	(	_	_	O
16	NSCLC	_	_	O
17	)	_	_	O
18	,	_	_	O
19	although	_	_	O
20	studies	_	_	O
21	comparing	_	_	O
22	the	_	_	O
23	two	_	_	O
24	drugs	_	_	O
25	are	_	_	O
26	limited	_	_	O
27	.	_	_	O

28	The	_	_	O
29	aim	_	_	O
30	of	_	_	O
31	this	_	_	O
32	study	_	_	O
33	is	_	_	O
34	to	_	_	O
35	explore	_	_	O
36	the	_	_	O
37	effects	_	_	O
38	,	_	_	O
39	safety	_	_	O
40	,	_	_	O
41	and	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	of	_	_	O
49	Gefitinib	_	_	O
50	and	_	_	O
51	Pemetrexed	_	_	O
52	on	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	advanced	_	_	O
56	non-squamous	_	_	O
57	NSCLC	_	_	O
58	.	_	_	O

59	Forty-six	_	_	O
60	advanced	_	_	O
61	non-squamous	_	_	O
62	NSCLC	_	_	O
63	patients	_	_	O
64	who	_	_	O
65	failed	_	_	O
66	to	_	_	O
67	first-line	_	_	O
68	therapy	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	divided	_	_	O
72	into	_	_	O
73	two	_	_	O
74	groups	_	_	O
75	with	_	_	O
76	23	_	_	O
77	patients	_	_	O
78	each	_	_	O
79	,	_	_	O
80	one	_	_	O
81	using	_	_	O
82	oral	_	_	O
83	Gefitinib	_	_	O
84	(	_	_	O
85	Gefitinib	_	_	O
86	group	_	_	O
87	)	_	_	O
88	and	_	_	O
89	the	_	_	O
90	other	_	_	O
91	using	_	_	O
92	intravenous	_	_	O
93	injection	_	_	O
94	Pemetrexed	_	_	O
95	(	_	_	O
96	Pemetrexed	_	_	O
97	group	_	_	O
98	)	_	_	O
99	.	_	_	O

100	The	_	_	O
101	effects	_	_	O
102	,	_	_	O
103	safety	_	_	O
104	,	_	_	O
105	and	_	_	O
106	QoL	_	_	O
107	were	_	_	O
108	determined	_	_	O
109	and	_	_	O
110	analyzed	_	_	O
111	.	_	_	O

112	For	_	_	B-Premise
113	the	_	_	I-Premise
114	Pemetrexed	_	_	I-Premise
115	group	_	_	I-Premise
116	,	_	_	I-Premise
117	objective	_	_	I-Premise
118	response	_	_	I-Premise
119	rate	_	_	I-Premise
120	(	_	_	I-Premise
121	ORR	_	_	I-Premise
122	)	_	_	I-Premise
123	was	_	_	I-Premise
124	13.0	_	_	I-Premise
125	%	_	_	I-Premise
126	(	_	_	I-Premise
127	3/23	_	_	I-Premise
128	)	_	_	I-Premise
129	,	_	_	I-Premise
130	disease	_	_	I-Premise
131	control	_	_	I-Premise
132	rate	_	_	I-Premise
133	(	_	_	I-Premise
134	DCR	_	_	I-Premise
135	)	_	_	I-Premise
136	was	_	_	I-Premise
137	30.4	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	7/23	_	_	I-Premise
141	)	_	_	I-Premise
142	,	_	_	I-Premise
143	and	_	_	I-Premise
144	median	_	_	I-Premise
145	progression-free	_	_	I-Premise
146	survival	_	_	I-Premise
147	(	_	_	I-Premise
148	mPFS	_	_	I-Premise
149	)	_	_	I-Premise
150	was	_	_	I-Premise
151	3.1	_	_	I-Premise
152	months	_	_	I-Premise
153	.	_	_	I-Premise

154	In	_	_	B-Premise
155	the	_	_	I-Premise
156	Gefitinib	_	_	I-Premise
157	group	_	_	I-Premise
158	,	_	_	I-Premise
159	ORR	_	_	I-Premise
160	was	_	_	I-Premise
161	17.3	_	_	I-Premise
162	%	_	_	I-Premise
163	(	_	_	I-Premise
164	4/23	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	DCR	_	_	I-Premise
168	was	_	_	I-Premise
169	39.1	_	_	I-Premise
170	%	_	_	I-Premise
171	(	_	_	I-Premise
172	9/23	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	mPFS	_	_	I-Premise
177	was	_	_	I-Premise
178	4.4	_	_	I-Premise
179	months	_	_	I-Premise
180	.	_	_	I-Premise

181	Compared	_	_	B-Premise
182	with	_	_	I-Premise
183	the	_	_	I-Premise
184	Pemetrexed	_	_	I-Premise
185	group	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	ORR	_	_	I-Premise
189	,	_	_	I-Premise
190	DCR	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	mPFS	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	Gefitinib	_	_	I-Premise
197	group	_	_	I-Premise
198	exhibited	_	_	I-Premise
199	no	_	_	I-Premise
200	statistical	_	_	I-Premise
201	significance	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	>	_	_	I-Premise
205	0.05	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Furthermore	_	_	O
209	,	_	_	O
210	the	_	_	B-Premise
211	most	_	_	I-Premise
212	common	_	_	I-Premise
213	toxicities	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	Pemetrexed	_	_	I-Premise
217	group	_	_	I-Premise
218	were	_	_	I-Premise
219	neutropenia	_	_	I-Premise
220	(	_	_	I-Premise
221	n=9	_	_	I-Premise
222	,	_	_	I-Premise
223	39.13	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	and	_	_	I-Premise
227	fatigue	_	_	I-Premise
228	(	_	_	I-Premise
229	n=8	_	_	I-Premise
230	,	_	_	I-Premise
231	34.78	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	whereas	_	_	I-Premise
236	those	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	in	_	_	I-Premise
240	Gefitinib	_	_	I-Premise
241	group	_	_	I-Premise
242	were	_	_	I-Premise
243	skin	_	_	I-Premise
244	rash	_	_	I-Premise
245	(	_	_	I-Premise
246	n=8	_	_	I-Premise
247	,	_	_	I-Premise
248	34.78	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	diarrhea	_	_	I-Premise
253	(	_	_	I-Premise
254	n=4	_	_	I-Premise
255	,	_	_	I-Premise
256	17.39	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Compared	_	_	B-Premise
261	with	_	_	I-Premise
262	baseline	_	_	I-Premise
263	,	_	_	I-Premise
264	the	_	_	I-Premise
265	QoL	_	_	I-Premise
266	improved	_	_	I-Premise
267	in	_	_	I-Premise
268	both	_	_	I-Premise
269	groups	_	_	I-Premise
270	but	_	_	I-Premise
271	to	_	_	I-Premise
272	different	_	_	I-Premise
273	degrees	_	_	I-Premise
274	.	_	_	I-Premise

275	Likewise	_	_	O
276	,	_	_	O
277	emotional	_	_	B-Premise
278	,	_	_	I-Premise
279	functional	_	_	I-Premise
280	well-being	_	_	I-Premise
281	,	_	_	I-Premise
282	and	_	_	I-Premise
283	QoL	_	_	I-Premise
284	aspects	_	_	I-Premise
285	specifically	_	_	I-Premise
286	related	_	_	I-Premise
287	to	_	_	I-Premise
288	lung	_	_	I-Premise
289	cancer	_	_	I-Premise
290	were	_	_	I-Premise
291	better	_	_	I-Premise
292	improved	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	Gefitinib	_	_	I-Premise
296	group	_	_	I-Premise
297	than	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	Pemetrexed	_	_	I-Premise
301	group	_	_	I-Premise
302	(	_	_	I-Premise
303	P	_	_	I-Premise
304	<	_	_	I-Premise
305	0.05	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Claim
309	effects	_	_	I-Claim
310	of	_	_	I-Claim
311	Pemetrexed	_	_	I-Claim
312	and	_	_	I-Claim
313	Gefitinib	_	_	I-Claim
314	as	_	_	I-Claim
315	second	_	_	I-Claim
316	line	_	_	I-Claim
317	therapy	_	_	I-Claim
318	were	_	_	I-Claim
319	similar	_	_	I-Claim
320	,	_	_	I-Claim
321	although	_	_	B-Premise
322	with	_	_	I-Premise
323	different	_	_	I-Premise
324	AEs	_	_	I-Premise
325	.	_	_	I-Premise

326	Both	_	_	B-Claim
327	drugs	_	_	I-Claim
328	could	_	_	I-Claim
329	improve	_	_	I-Claim
330	the	_	_	I-Claim
331	QoL	_	_	I-Claim
332	,	_	_	I-Claim
333	but	_	_	O
334	Gefitinib	_	_	B-Claim
335	showed	_	_	I-Claim
336	better	_	_	I-Claim
337	overall	_	_	I-Claim
338	results	_	_	I-Claim
339	than	_	_	I-Claim
340	Pemetrexed	_	_	I-Claim
341	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	with	_	_	I-Claim
2	advanced	_	_	I-Claim
3	non-small	_	_	I-Claim
4	cell	_	_	I-Claim
5	lung	_	_	I-Claim
6	cancer	_	_	I-Claim
7	(	_	_	I-Claim
8	NSCLC	_	_	I-Claim
9	)	_	_	I-Claim
10	do	_	_	I-Claim
11	not	_	_	I-Claim
12	have	_	_	I-Claim
13	curative	_	_	I-Claim
14	treatment	_	_	I-Claim
15	options	_	_	I-Claim
16	;	_	_	I-Claim
17	therefore	_	_	O
18	,	_	_	O
19	treatments	_	_	O
20	should	_	_	O
21	prolong	_	_	O
22	survival	_	_	O
23	and	_	_	O
24	improve	_	_	O
25	quality	_	_	O
26	of	_	_	O
27	life	_	_	O
28	(	_	_	O
29	QoL	_	_	O
30	)	_	_	O
31	.	_	_	O

32	We	_	_	O
33	compared	_	_	O
34	the	_	_	O
35	effect	_	_	O
36	on	_	_	O
37	QoL	_	_	O
38	of	_	_	O
39	two	_	_	O
40	docetaxel-platinum	_	_	O
41	regimens	_	_	O
42	with	_	_	O
43	vinorelbine-cisplatin	_	_	O
44	.	_	_	O

45	QoL	_	_	O
46	was	_	_	O
47	assessed	_	_	O
48	by	_	_	O
49	the	_	_	O
50	Lung	_	_	O
51	Cancer	_	_	O
52	Symptom	_	_	O
53	Scale	_	_	O
54	(	_	_	O
55	LCSS	_	_	O
56	)	_	_	O
57	and	_	_	O
58	the	_	_	O
59	general	_	_	O
60	EuroQol	_	_	O
61	five-dimensional	_	_	O
62	questionnaire	_	_	O
63	(	_	_	O
64	EQ-5D	_	_	O
65	)	_	_	O
66	in	_	_	O
67	926	_	_	O
68	chemotherapy-naÃ¯ve	_	_	O
69	patients	_	_	O
70	with	_	_	O
71	stages	_	_	O
72	IIIB	_	_	O
73	to	_	_	O
74	IV	_	_	O
75	NSCLC	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	:	_	_	O
84	docetaxel	_	_	O
85	75	_	_	O
86	mg/m2	_	_	O
87	plus	_	_	O
88	cisplatin	_	_	O
89	75	_	_	O
90	mg/m2	_	_	O
91	,	_	_	O
92	every	_	_	O
93	3	_	_	O
94	weeks	_	_	O
95	(	_	_	O
96	DC	_	_	O
97	)	_	_	O
98	;	_	_	O
99	docetaxel	_	_	O
100	75	_	_	O
101	mg/m2	_	_	O
102	and	_	_	O
103	carboplatin	_	_	O
104	6	_	_	O
105	mg/ml	_	_	O
106	min	_	_	O
107	,	_	_	O
108	every	_	_	O
109	3	_	_	O
110	weeks	_	_	O
111	(	_	_	O
112	DCb	_	_	O
113	)	_	_	O
114	;	_	_	O
115	or	_	_	O
116	vinorelbine	_	_	O
117	25	_	_	O
118	mg/m2/week	_	_	O
119	plus	_	_	O
120	cisplatin	_	_	O
121	100	_	_	O
122	mg/m2	_	_	O
123	,	_	_	O
124	every	_	_	O
125	4	_	_	O
126	weeks	_	_	O
127	(	_	_	O
128	VC	_	_	O
129	)	_	_	O
130	.	_	_	O

131	Overall	_	_	B-Premise
132	,	_	_	I-Premise
133	patients	_	_	I-Premise
134	treated	_	_	I-Premise
135	with	_	_	I-Premise
136	either	_	_	I-Premise
137	docetaxel-containing	_	_	I-Premise
138	regimen	_	_	I-Premise
139	had	_	_	I-Premise
140	better	_	_	I-Premise
141	QoL	_	_	I-Premise
142	than	_	_	I-Premise
143	VC-treated	_	_	I-Premise
144	patients	_	_	I-Premise
145	(	_	_	I-Premise
146	LCSS	_	_	I-Premise
147	global	_	_	I-Premise
148	item	_	_	I-Premise
149	"	_	_	I-Premise
150	QoL	_	_	I-Premise
151	today	_	_	I-Premise
152	"	_	_	I-Premise
153	:	_	_	I-Premise
154	P=0.064	_	_	I-Premise
155	for	_	_	I-Premise
156	DC	_	_	I-Premise
157	and	_	_	I-Premise
158	P=0.016	_	_	I-Premise
159	for	_	_	I-Premise
160	DCb	_	_	I-Premise
161	versus	_	_	I-Premise
162	VC	_	_	I-Premise
163	;	_	_	I-Premise
164	EQ-5D	_	_	I-Premise
165	global	_	_	I-Premise
166	item	_	_	I-Premise
167	"	_	_	I-Premise
168	health	_	_	I-Premise
169	state	_	_	I-Premise
170	today	_	_	I-Premise
171	"	_	_	I-Premise
172	:	_	_	I-Premise
173	P=0.016	_	_	I-Premise
174	for	_	_	I-Premise
175	DC	_	_	I-Premise
176	and	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	0.001	_	_	I-Premise
180	for	_	_	I-Premise
181	DCb	_	_	I-Premise
182	versus	_	_	I-Premise
183	VC	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	DC-treated	_	_	B-Premise
187	patients	_	_	I-Premise
188	experienced	_	_	I-Premise
189	improved	_	_	I-Premise
190	pain	_	_	I-Premise
191	relief	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	VC	_	_	I-Premise
195	(	_	_	I-Premise
196	P=0.033	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	whereas	_	_	O
200	pain	_	_	B-Premise
201	relief	_	_	I-Premise
202	with	_	_	I-Premise
203	DCb	_	_	I-Premise
204	and	_	_	I-Premise
205	VC	_	_	I-Premise
206	was	_	_	I-Premise
207	similar	_	_	I-Premise
208	.	_	_	I-Premise

209	Patients	_	_	B-Premise
210	treated	_	_	I-Premise
211	with	_	_	I-Premise
212	either	_	_	I-Premise
213	docetaxel	_	_	I-Premise
214	regimen	_	_	I-Premise
215	had	_	_	I-Premise
216	more	_	_	I-Premise
217	favorable	_	_	I-Premise
218	changes	_	_	I-Premise
219	in	_	_	I-Premise
220	performance	_	_	I-Premise
221	status	_	_	I-Premise
222	(	_	_	I-Premise
223	P=0.065	_	_	I-Premise
224	for	_	_	I-Premise
225	DC	_	_	I-Premise
226	and	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	for	_	_	I-Premise
231	DCb	_	_	I-Premise
232	versus	_	_	I-Premise
233	VC	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	mean	_	_	I-Premise
237	weight	_	_	I-Premise
238	loss	_	_	I-Premise
239	(	_	_	I-Premise
240	0.06	_	_	I-Premise
241	kg	_	_	I-Premise
242	,	_	_	I-Premise
243	gain	_	_	I-Premise
244	of	_	_	I-Premise
245	0.08	_	_	I-Premise
246	kg	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	2.27	_	_	I-Premise
250	kg	_	_	I-Premise
251	for	_	_	I-Premise
252	DC	_	_	I-Premise
253	,	_	_	I-Premise
254	DCb	_	_	I-Premise
255	,	_	_	I-Premise
256	and	_	_	I-Premise
257	VC	_	_	I-Premise
258	,	_	_	I-Premise
259	respectively	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	<	_	_	I-Premise
263	0.001	_	_	I-Premise
264	for	_	_	I-Premise
265	both	_	_	I-Premise
266	DC	_	_	I-Premise
267	versus	_	_	I-Premise
268	VC	_	_	I-Premise
269	and	_	_	I-Premise
270	DCb	_	_	I-Premise
271	versus	_	_	I-Premise
272	VC	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Claim
276	TAX	_	_	I-Claim
277	326	_	_	I-Claim
278	study	_	_	I-Claim
279	shows	_	_	I-Claim
280	that	_	_	I-Claim
281	docetaxel-platinum	_	_	I-Claim
282	regimens	_	_	I-Claim
283	relieve	_	_	I-Claim
284	symptoms	_	_	I-Claim
285	and	_	_	I-Claim
286	improve	_	_	I-Claim
287	QoL	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	advanced	_	_	I-Claim
292	NSCLC	_	_	I-Claim
293	.	_	_	I-Claim

294	DCb	_	_	B-Claim
295	and	_	_	I-Claim
296	DC	_	_	I-Claim
297	were	_	_	I-Claim
298	superior	_	_	I-Claim
299	to	_	_	I-Claim
300	VC	_	_	I-Claim
301	in	_	_	I-Claim
302	all	_	_	I-Claim
303	QoL	_	_	I-Claim
304	outcomes	_	_	I-Claim
305	assessed	_	_	I-Claim
306	except	_	_	I-Claim
307	for	_	_	I-Claim
308	the	_	_	I-Claim
309	difference	_	_	I-Claim
310	between	_	_	I-Claim
311	DC	_	_	I-Claim
312	and	_	_	I-Claim
313	VC	_	_	I-Claim
314	in	_	_	I-Claim
315	LCSS	_	_	I-Claim
316	"	_	_	I-Claim
317	QoL	_	_	I-Claim
318	today	_	_	I-Claim
319	"	_	_	I-Claim
320	,	_	_	I-Claim
321	which	_	_	I-Claim
322	was	_	_	I-Claim
323	not	_	_	I-Claim
324	significant	_	_	I-Claim
325	.	_	_	I-Claim


0	Relapse	_	_	B-Claim
1	after	_	_	I-Claim
2	completing	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	tamoxifen	_	_	I-Claim
5	therapy	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	persistent	_	_	I-Claim
9	threat	_	_	I-Claim
10	for	_	_	I-Claim
11	women	_	_	I-Claim
12	with	_	_	I-Claim
13	hormone-responsive	_	_	I-Claim
14	breast	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	Third-generation	_	_	O
18	aromatase	_	_	O
19	inhibitors	_	_	O
20	,	_	_	O
21	such	_	_	O
22	as	_	_	O
23	letrozole	_	_	O
24	,	_	_	O
25	provide	_	_	O
26	a	_	_	O
27	new	_	_	O
28	option	_	_	O
29	for	_	_	O
30	extended	_	_	O
31	adjuvant	_	_	O
32	hormonal	_	_	O
33	therapy	_	_	O
34	after	_	_	O
35	5	_	_	O
36	years	_	_	O
37	of	_	_	O
38	tamoxifen	_	_	O
39	.	_	_	O

40	MA.17	_	_	O
41	was	_	_	O
42	conducted	_	_	O
43	to	_	_	O
44	determine	_	_	O
45	whether	_	_	O
46	letrozole	_	_	O
47	improves	_	_	O
48	outcome	_	_	O
49	after	_	_	O
50	discontinuation	_	_	O
51	of	_	_	O
52	tamoxifen	_	_	O
53	.	_	_	O

54	Postmenopausal	_	_	O
55	women	_	_	O
56	with	_	_	O
57	hormone	_	_	O
58	receptor-positive	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	N=5,187	_	_	O
63	)	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	letrozole	_	_	O
68	2.5	_	_	O
69	mg	_	_	O
70	or	_	_	O
71	placebo	_	_	O
72	once	_	_	O
73	daily	_	_	O
74	for	_	_	O
75	5	_	_	O
76	years	_	_	O
77	.	_	_	O

78	At	_	_	B-Premise
79	a	_	_	I-Premise
80	median	_	_	I-Premise
81	follow-up	_	_	I-Premise
82	of	_	_	I-Premise
83	30	_	_	I-Premise
84	months	_	_	I-Premise
85	,	_	_	I-Premise
86	letrozole	_	_	I-Premise
87	significantly	_	_	I-Premise
88	improved	_	_	I-Premise
89	disease-free	_	_	I-Premise
90	survival	_	_	I-Premise
91	(	_	_	I-Premise
92	DFS	_	_	I-Premise
93	;	_	_	I-Premise
94	P	_	_	I-Premise
95	<	_	_	I-Premise
96	0.001	_	_	I-Premise
97	)	_	_	I-Premise
98	,	_	_	I-Premise
99	the	_	_	I-Premise
100	primary	_	_	I-Premise
101	end	_	_	I-Premise
102	point	_	_	I-Premise
103	,	_	_	I-Premise
104	compared	_	_	I-Premise
105	with	_	_	I-Premise
106	placebo	_	_	I-Premise
107	(	_	_	I-Premise
108	hazard	_	_	I-Premise
109	ratio	_	_	I-Premise
110	[	_	_	I-Premise
111	HR	_	_	I-Premise
112	]	_	_	I-Premise
113	for	_	_	I-Premise
114	recurrence	_	_	I-Premise
115	or	_	_	I-Premise
116	contralateral	_	_	I-Premise
117	breast	_	_	I-Premise
118	cancer	_	_	I-Premise
119	0.58	_	_	I-Premise
120	;	_	_	I-Premise
121	95	_	_	I-Premise
122	%	_	_	I-Premise
123	confidence	_	_	I-Premise
124	interval	_	_	I-Premise
125	[	_	_	I-Premise
126	CI	_	_	I-Premise
127	]	_	_	I-Premise
128	0.45	_	_	I-Premise
129	,	_	_	I-Premise
130	0.76	_	_	I-Premise
131	]	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	0.001	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Furthermore	_	_	B-Premise
138	,	_	_	I-Premise
139	letrozole	_	_	I-Premise
140	significantly	_	_	I-Premise
141	improved	_	_	I-Premise
142	distant	_	_	I-Premise
143	DFS	_	_	I-Premise
144	(	_	_	I-Premise
145	HR=0.60	_	_	I-Premise
146	;	_	_	I-Premise
147	95	_	_	I-Premise
148	%	_	_	I-Premise
149	CI	_	_	I-Premise
150	0.43	_	_	I-Premise
151	,	_	_	I-Premise
152	0.84	_	_	I-Premise
153	;	_	_	I-Premise
154	P=0.002	_	_	I-Premise
155	)	_	_	I-Premise
156	and	_	_	I-Premise
157	,	_	_	I-Premise
158	in	_	_	I-Premise
159	women	_	_	I-Premise
160	with	_	_	I-Premise
161	node-positive	_	_	I-Premise
162	tumors	_	_	I-Premise
163	,	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	(	_	_	I-Premise
167	HR=0.61	_	_	I-Premise
168	;	_	_	I-Premise
169	95	_	_	I-Premise
170	%	_	_	I-Premise
171	CI	_	_	I-Premise
172	0.38	_	_	I-Premise
173	,	_	_	I-Premise
174	0.98	_	_	I-Premise
175	;	_	_	I-Premise
176	P=0.04	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Clinical	_	_	B-Premise
180	benefits	_	_	I-Premise
181	,	_	_	I-Premise
182	including	_	_	I-Premise
183	an	_	_	I-Premise
184	overall	_	_	I-Premise
185	survival	_	_	I-Premise
186	advantage	_	_	I-Premise
187	,	_	_	I-Premise
188	were	_	_	I-Premise
189	also	_	_	I-Premise
190	seen	_	_	I-Premise
191	in	_	_	I-Premise
192	women	_	_	I-Premise
193	who	_	_	I-Premise
194	crossed	_	_	I-Premise
195	over	_	_	I-Premise
196	from	_	_	I-Premise
197	placebo	_	_	I-Premise
198	to	_	_	I-Premise
199	letrozole	_	_	I-Premise
200	after	_	_	I-Premise
201	unblinding	_	_	I-Premise
202	,	_	_	I-Premise
203	indicating	_	_	I-Premise
204	that	_	_	I-Premise
205	tumors	_	_	I-Premise
206	remain	_	_	I-Premise
207	sensitive	_	_	I-Premise
208	to	_	_	I-Premise
209	hormone	_	_	I-Premise
210	therapy	_	_	I-Premise
211	despite	_	_	I-Premise
212	a	_	_	I-Premise
213	prolonged	_	_	I-Premise
214	period	_	_	I-Premise
215	since	_	_	I-Premise
216	discontinuation	_	_	I-Premise
217	of	_	_	I-Premise
218	tamoxifen	_	_	I-Premise
219	.	_	_	I-Premise

220	The	_	_	O
221	efficacy	_	_	O
222	and	_	_	O
223	safety	_	_	O
224	of	_	_	O
225	letrozole	_	_	O
226	therapy	_	_	O
227	beyond	_	_	O
228	5	_	_	O
229	years	_	_	O
230	is	_	_	O
231	being	_	_	O
232	assessed	_	_	O
233	in	_	_	O
234	a	_	_	O
235	re-randomization	_	_	O
236	study	_	_	O
237	,	_	_	O
238	following	_	_	O
239	the	_	_	O
240	emergence	_	_	O
241	of	_	_	O
242	new	_	_	O
243	data	_	_	O
244	suggesting	_	_	O
245	that	_	_	O
246	clinical	_	_	O
247	benefit	_	_	O
248	correlates	_	_	O
249	with	_	_	O
250	the	_	_	O
251	duration	_	_	O
252	of	_	_	O
253	letrozole	_	_	O
254	.	_	_	O

255	MA.17	_	_	B-Claim
256	showed	_	_	I-Claim
257	that	_	_	I-Claim
258	letrozole	_	_	I-Claim
259	is	_	_	I-Claim
260	extremely	_	_	I-Claim
261	well-tolerated	_	_	I-Claim
262	relative	_	_	I-Claim
263	to	_	_	I-Claim
264	placebo	_	_	I-Claim
265	.	_	_	I-Claim

266	Letrozole	_	_	B-Claim
267	should	_	_	I-Claim
268	be	_	_	I-Claim
269	considered	_	_	I-Claim
270	for	_	_	I-Claim
271	all	_	_	I-Claim
272	women	_	_	I-Claim
273	completing	_	_	I-Claim
274	tamoxifen	_	_	I-Claim
275	;	_	_	I-Claim
276	new	_	_	B-Claim
277	results	_	_	I-Claim
278	from	_	_	I-Claim
279	the	_	_	I-Claim
280	post-unblinding	_	_	I-Claim
281	analysis	_	_	I-Claim
282	suggest	_	_	I-Claim
283	that	_	_	I-Claim
284	letrozole	_	_	I-Claim
285	treatment	_	_	I-Claim
286	should	_	_	I-Claim
287	also	_	_	I-Claim
288	be	_	_	I-Claim
289	considered	_	_	I-Claim
290	for	_	_	I-Claim
291	all	_	_	I-Claim
292	disease-free	_	_	I-Claim
293	women	_	_	I-Claim
294	for	_	_	I-Claim
295	periods	_	_	I-Claim
296	up	_	_	I-Claim
297	to	_	_	I-Claim
298	5	_	_	I-Claim
299	years	_	_	I-Claim
300	following	_	_	I-Claim
301	completion	_	_	I-Claim
302	of	_	_	I-Claim
303	adjuvant	_	_	I-Claim
304	tamoxifen	_	_	I-Claim
305	.	_	_	I-Claim


0	Lung	_	_	O
1	cancer	_	_	O
2	is	_	_	O
3	one	_	_	O
4	of	_	_	O
5	the	_	_	O
6	most	_	_	O
7	common	_	_	O
8	cancers	_	_	O
9	in	_	_	O
10	the	_	_	O
11	United	_	_	O
12	States	_	_	O
13	and	_	_	O
14	is	_	_	O
15	associated	_	_	O
16	with	_	_	O
17	high	_	_	O
18	levels	_	_	O
19	of	_	_	O
20	symptoms	_	_	O
21	,	_	_	O
22	including	_	_	O
23	pain	_	_	O
24	,	_	_	O
25	fatigue	_	_	O
26	,	_	_	O
27	shortness	_	_	O
28	of	_	_	O
29	breath	_	_	O
30	,	_	_	O
31	and	_	_	O
32	psychological	_	_	O
33	distress	_	_	O
34	.	_	_	O

35	Caregivers	_	_	O
36	and	_	_	O
37	patients	_	_	O
38	are	_	_	O
39	adversely	_	_	O
40	affected	_	_	O
41	.	_	_	O

42	However	_	_	O
43	,	_	_	O
44	previous	_	_	O
45	studies	_	_	O
46	of	_	_	O
47	coping	_	_	O
48	skills	_	_	O
49	training	_	_	O
50	(	_	_	O
51	CST	_	_	O
52	)	_	_	O
53	interventions	_	_	O
54	have	_	_	O
55	not	_	_	O
56	been	_	_	O
57	tested	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	lung	_	_	O
62	cancer	_	_	O
63	nor	_	_	O
64	have	_	_	O
65	systematically	_	_	O
66	included	_	_	O
67	caregivers	_	_	O
68	.	_	_	O

69	This	_	_	O
70	study	_	_	O
71	tested	_	_	O
72	the	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	a	_	_	O
76	caregiver-assisted	_	_	O
77	CST	_	_	O
78	protocol	_	_	O
79	in	_	_	O
80	a	_	_	O
81	sample	_	_	O
82	of	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	.	_	_	O

88	Two	_	_	O
89	hundred	_	_	O
90	thirty-three	_	_	O
91	lung	_	_	O
92	cancer	_	_	O
93	patients	_	_	O
94	and	_	_	O
95	their	_	_	O
96	caregivers	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	14	_	_	O
103	telephone-based	_	_	O
104	sessions	_	_	O
105	of	_	_	O
106	either	_	_	O
107	caregiver-assisted	_	_	O
108	CST	_	_	O
109	or	_	_	O
110	education/support	_	_	O
111	involving	_	_	O
112	the	_	_	O
113	caregiver	_	_	O
114	.	_	_	O

115	Patients	_	_	O
116	completed	_	_	O
117	measures	_	_	O
118	assessing	_	_	O
119	pain	_	_	O
120	,	_	_	O
121	psychological	_	_	O
122	distress	_	_	O
123	,	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	,	_	_	O
131	and	_	_	O
132	self-efficacy	_	_	O
133	for	_	_	O
134	symptom	_	_	O
135	management	_	_	O
136	;	_	_	O
137	caregivers	_	_	O
138	completed	_	_	O
139	measures	_	_	O
140	assessing	_	_	O
141	psychological	_	_	O
142	distress	_	_	O
143	,	_	_	O
144	caregiver	_	_	O
145	strain	_	_	O
146	,	_	_	O
147	and	_	_	O
148	self-efficacy	_	_	O
149	for	_	_	O
150	helping	_	_	O
151	the	_	_	O
152	patient	_	_	O
153	manage	_	_	O
154	symptoms	_	_	O
155	.	_	_	O

156	Patients	_	_	B-Premise
157	in	_	_	I-Premise
158	both	_	_	I-Premise
159	treatment	_	_	I-Premise
160	conditions	_	_	I-Premise
161	showed	_	_	I-Premise
162	improvements	_	_	I-Premise
163	in	_	_	I-Premise
164	pain	_	_	I-Premise
165	,	_	_	I-Premise
166	depression	_	_	I-Premise
167	,	_	_	I-Premise
168	QOL	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	self-efficacy	_	_	I-Premise
172	,	_	_	I-Premise
173	and	_	_	I-Premise
174	caregivers	_	_	I-Premise
175	in	_	_	I-Premise
176	both	_	_	I-Premise
177	conditions	_	_	I-Premise
178	showed	_	_	I-Premise
179	improvements	_	_	I-Premise
180	in	_	_	I-Premise
181	anxiety	_	_	I-Premise
182	and	_	_	I-Premise
183	self-efficacy	_	_	I-Premise
184	from	_	_	I-Premise
185	baseline	_	_	I-Premise
186	to	_	_	I-Premise
187	four-month	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	.	_	_	I-Premise

190	Results	_	_	B-Premise
191	of	_	_	I-Premise
192	exploratory	_	_	I-Premise
193	analyses	_	_	I-Premise
194	suggested	_	_	I-Premise
195	that	_	_	I-Premise
196	the	_	_	I-Premise
197	CST	_	_	I-Premise
198	intervention	_	_	I-Premise
199	was	_	_	I-Premise
200	more	_	_	I-Premise
201	beneficial	_	_	I-Premise
202	to	_	_	I-Premise
203	patients/caregivers	_	_	I-Premise
204	with	_	_	I-Premise
205	Stage	_	_	I-Premise
206	II	_	_	I-Premise
207	and	_	_	I-Premise
208	III	_	_	I-Premise
209	cancers	_	_	I-Premise
210	,	_	_	I-Premise
211	whereas	_	_	O
212	the	_	_	B-Premise
213	education/support	_	_	I-Premise
214	intervention	_	_	I-Premise
215	was	_	_	I-Premise
216	more	_	_	I-Premise
217	beneficial	_	_	I-Premise
218	to	_	_	I-Premise
219	patients/caregivers	_	_	I-Premise
220	with	_	_	I-Premise
221	Stage	_	_	I-Premise
222	I	_	_	I-Premise
223	cancer	_	_	I-Premise
224	.	_	_	I-Premise

225	Taken	_	_	B-Premise
226	together	_	_	I-Premise
227	with	_	_	I-Premise
228	the	_	_	I-Premise
229	broader	_	_	I-Premise
230	literature	_	_	I-Premise
231	in	_	_	I-Premise
232	this	_	_	I-Premise
233	area	_	_	I-Premise
234	,	_	_	I-Premise
235	results	_	_	B-Claim
236	from	_	_	I-Claim
237	this	_	_	I-Claim
238	study	_	_	I-Claim
239	suggest	_	_	I-Claim
240	that	_	_	I-Claim
241	psychosocial	_	_	I-Claim
242	interventions	_	_	I-Claim
243	can	_	_	I-Claim
244	lead	_	_	I-Claim
245	to	_	_	I-Claim
246	improvements	_	_	I-Claim
247	in	_	_	I-Claim
248	a	_	_	I-Claim
249	range	_	_	I-Claim
250	of	_	_	I-Claim
251	outcomes	_	_	I-Claim
252	for	_	_	I-Claim
253	cancer	_	_	I-Claim
254	patients	_	_	I-Claim
255	.	_	_	I-Claim

256	Suggestions	_	_	O
257	for	_	_	O
258	future	_	_	O
259	studies	_	_	O
260	include	_	_	O
261	the	_	_	O
262	use	_	_	O
263	of	_	_	O
264	three-group	_	_	O
265	designs	_	_	O
266	(	_	_	O
267	e.g.	_	_	O
268	,	_	_	O
269	comparing	_	_	O
270	two	_	_	O
271	active	_	_	O
272	interventions	_	_	O
273	with	_	_	O
274	a	_	_	O
275	standard-care	_	_	O
276	control	_	_	O
277	)	_	_	O
278	and	_	_	O
279	examining	_	_	O
280	mechanisms	_	_	O
281	of	_	_	O
282	change	_	_	O
283	.	_	_	O

